PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Dayan, A; Fleminger, G; Ashur-Fabian, O				Dayan, Avraham; Fleminger, Gideon; Ashur-Fabian, Osnat			Targeting the Achilles' heel of cancer cells via integrin-mediated delivery of ROS-generating dihydrolipoamide dehydrogenase	ONCOGENE			English	Article							ALPHA-KETOGLUTARATE DEHYDROGENASE; LIPOAMIDE DEHYDROGENASE; COMPLEX; STRATEGIES; SUBSTRATE; SEQUENCE; SUBUNIT; IMPORT; STRAIN	Cancer cells frequently exhibit higher levels of reactive oxygen species (ROS) than normal cells and when ROS levels increase beyond a cellular tolerability threshold, cancer cell death is enhanced. The mitochondrial dihydrolipoamide dehydrogenase (DLDH) is an enzyme which produces ROS in association with its oxidoreductive activity and may be thus utilized as an exogenous anticancer agent. As cancer cells often overexpress integrins that recognize RGD-containing proteins, we have bioengineered the human DLDH with RGD motifs (DLDHRGD) for integrin-mediated drug delivery. The modified protein fully retained its enzyme activity and ROS-production capability. DLDHRGD uptake by cells was shown to depend on the presence of cell-associated integrin alpha v beta 3, as comparatively demonstrated with normal kidney cells (HEK293) transfected with either beta 1 (alpha v beta 1 positive) or beta 3 integrins (alpha v beta 3 positive). The interaction with beta 3 integrins was shown to be competitively inhibited by an RGD peptide. In mice melanoma cells (B16F10), which highly express an endogenous alpha v beta 3 integrin, fast cellular uptake of DLDHRGD which resulted in cell number reduction, apoptosis induction, and a parallel intracellular ROS production was shown. Similar results were obtained with additional human melanoma cell models (A375, WM3314, and WM3682). In contrast, HEK293 beta 3 cells remained intact following DLDHRGD uptake. The high pharmacological safety profile of DLDHRGD has been observed by several modes of administrations in BALB/C or C57B1/6 mouse strains. Treatments with DLDHRGD in a subcutaneous melanoma mice model resulted in significant tumor inhibition. Our study demonstrated, in vitro and in vivo, the development of a unique platform, which targets cancer cells via integrin-mediated drug delivery of an exogenous ROS-generating drug.	[Dayan, Avraham; Fleminger, Gideon] Tel Aviv Univ, George S Wise Fac Life Sci, Sch Mol Cell Biol & Biotechnol, Tel Aviv, Israel; [Ashur-Fabian, Osnat] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Ashur-Fabian, O (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, Tel Aviv, Israel.	osnataf@gmail.com	Ashur, Osnat/AAC-1417-2020	Ashur-Fabian, Osnat/0000-0001-8624-3182	Israeli Ministry of Economics [52679, 55869]	Israeli Ministry of Economics	The authors wish to thank Mrs. Ronit Hollander for the graphics assistance and the table of contents illustration. This research was supported by the Israeli Ministry of Economics (Projects 52679 and 55869).	Ambrus A, 2018, NEUROCHEM INT, V117, P5, DOI 10.1016/j.neuint.2017.05.018; Ambrus A, 2013, ARCH BIOCHEM BIOPHYS, V538, P145, DOI 10.1016/j.abb.2013.08.015; Babu A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15012-5; Bender T, 2016, BBA-MOL CELL RES, V1863, P2436, DOI 10.1016/j.bbamcr.2016.01.017; Bolley J, 2013, NANOSCALE, V5, P11478, DOI 10.1039/c3nr03763k; Bui T, 2006, CANCER CELL, V9, P419, DOI 10.1016/j.ccr.2006.05.012; Caswell P, 2008, TRENDS CELL BIOL, V18, P257, DOI 10.1016/j.tcb.2008.03.004; Chen W, 2017, SMALL, V13, DOI 10.1002/smll.201601997; Chiarugi A, 2012, NAT REV CANCER, V12, P741, DOI 10.1038/nrc3340; CUNNINGHAM ML, 1985, PHOTOCHEM PHOTOBIOL, V42, P125, DOI 10.1111/j.1751-1097.1985.tb01549.x; DAHL HHM, 1987, J BIOL CHEM, V262, P7398; Danhier F, 2012, MOL PHARMACEUT, V9, P2961, DOI 10.1021/mp3002733; Dayan A, 2018, RSC ADV, V8, P9112, DOI 10.1039/c7ra13777j; Dayan A, 2017, J MOL RECOGNIT, V30, DOI 10.1002/jmr.2617; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Diebold L, 2016, FREE RADICAL BIO MED, V100, P86, DOI 10.1016/j.freeradbiomed.2016.04.198; FLEMINGER G, 1995, APPL ENVIRON MICROB, V61, P4357, DOI 10.1128/AEM.61.12.4357-4361.1995; Fu Q, 2016, INT J EXP PATHOL, V97, P351, DOI 10.1111/iep.12192; Galadari S, 2017, FREE RADICAL BIO MED, V104, P144, DOI 10.1016/j.freeradbiomed.2017.01.004; Gandioso A, 2016, J ORG CHEM, V81, P11556, DOI 10.1021/acs.joc.6b02415; Hu ZW, 2000, P NATL ACAD SCI USA, V97, P9221, DOI 10.1073/pnas.97.16.9221; Jezek J, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7010013; Kapp TG, 2017, SCI REP-UK, V7, DOI 10.1038/srep39805; Klyachko NL, 2005, J BIOL CHEM, V280, P16106, DOI 10.1074/jbc.M414285200; Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007; McCartney RG, 1998, J BIOL CHEM, V273, P24158, DOI 10.1074/jbc.273.37.24158; Nicco C, 2018, MOLECULES, V23, DOI 10.3390/molecules23010084; Nogueira V, 2013, CLIN CANCER RES, V19, P4309, DOI 10.1158/1078-0432.CCR-12-1424; Omura T, 1998, J BIOCHEM-TOKYO, V123, P1010; Poprac P, 2017, TRENDS PHARMACOL SCI, V38, P592, DOI 10.1016/j.tips.2017.04.005; Ralph SJ, 2011, PHARM RES-DORDR, V28, P2695, DOI 10.1007/s11095-011-0566-7; Raza MH, 2017, J CANCER RES CLIN, V143, P1789, DOI 10.1007/s00432-017-2464-9; Schaffner P, 2003, CELL MOL LIFE SCI, V60, P119, DOI 10.1007/s000180300008; Schiffelers RM, 2003, J CONTROL RELEASE, V91, P115, DOI 10.1016/S0168-3659(03)00240-2; Schito L, 2016, TRENDS CANCER, V2, P758, DOI 10.1016/j.trecan.2016.10.016; Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015; Sheldrake HM, 2014, J MED CHEM, V57, P6301, DOI 10.1021/jm5000547; STAMBAUGH R, 1966, J BIOL CHEM, V241, P1462; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; Sun Y, 2017, DRUG DEVELOP RES, V78, P283, DOI 10.1002/ddr.21399; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Tretter L, 2004, J NEUROSCI, V24, P7771, DOI 10.1523/JNEUROSCI.1842-04.2004; TSAI CS, 1981, ARCH BIOCHEM BIOPHYS, V206, P77, DOI 10.1016/0003-9861(81)90068-0; Vanderperre B, 2015, CURR OPIN CELL BIOL, V33, P35, DOI 10.1016/j.ceb.2014.10.008; Wang J, 2008, CANCER BIOL THER, V7, P1875, DOI 10.4161/cbt.7.12.7067; Wang YC, 2007, J BIOMED SCI, V14, P203, DOI 10.1007/s11373-006-9136-0; Yu YP, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-78; Zhou ZH, 2001, P NATL ACAD SCI USA, V98, P14802, DOI 10.1073/pnas.011597698; Zundorf G, 2009, NEUROSCIENCE, V158, P610, DOI 10.1016/j.neuroscience.2008.10.015	49	23	23	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					5050	5061		10.1038/s41388-019-0775-9	http://dx.doi.org/10.1038/s41388-019-0775-9			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30872792				2023-01-03	WOS:000472145900012
J	Alessandrini, F; Menotti, L; Avitabile, E; Appolloni, I; Ceresa, D; Marubbi, D; Campadelli-Fiume, G; Malatesta, P				Alessandrini, Francesco; Menotti, Laura; Avitabile, Elisa; Appolloni, Irene; Ceresa, Davide; Marubbi, Daniela; Campadelli-Fiume, Gabriella; Malatesta, Paolo			Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model	ONCOGENE			English	Article							HERPES-SIMPLEX-VIRUS; PHASE-I; EXPRESSING IL-12; VIRAL THERAPY; STEM-CELLS; GLIOMA; GROWTH; MUTANT; EFFICACY; TUMOR	Oncolytic herpes simplex viruses are proving to be effective in clinical trials against a number of cancers. Here, R-115, an oncolytic herpes simplex virus retargeted to human erbB-2, fully virulent in its target cells, and armed with murine interleukin-12 was evaluated in a murine model of glioblastoma. We show that a single R-115 injection in established tumors resulted, in about 30% of animals, in the complete eradication of the tumor, otherwise invariably lethal. The treatment also induced a significant improvement in the overall median survival time of mice and a resistance to recurrence from the same neoplasia. Such a high degree of protection was unprecedented; it was not observed before following treatments with the commonly used, mutated/attenuated oncolytic viruses. This is the first study providing the evidence of benefits offered by a fully virulent, retargeted, and armed herpes simplex virus in the treatment of glioblastoma and paves the way for clinical translation.	[Alessandrini, Francesco; Appolloni, Irene; Ceresa, Davide; Marubbi, Daniela; Malatesta, Paolo] Univ Genoa, Dept Expt Med, Genoa, Italy; [Menotti, Laura; Avitabile, Elisa] Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy; [Marubbi, Daniela; Malatesta, Paolo] Osped Policlin San Martino, IRCCS Oncol, Genoa, Italy; [Campadelli-Fiume, Gabriella] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy	University of Genoa; University of Bologna; University of Bologna	Malatesta, P (corresponding author), Univ Genoa, Dept Expt Med, Genoa, Italy.; Malatesta, P (corresponding author), Osped Policlin San Martino, IRCCS Oncol, Genoa, Italy.	paolo.malatesta@unige.it	Malatesta, Paolo/J-3570-2012; Ceresa, Davide/AAB-8518-2019; Appolloni, Irene/AAC-1629-2019	Malatesta, Paolo/0000-0003-3045-3361; AVITABILE, ELISA/0000-0003-0328-2544; Alessandrini, Francesco/0000-0002-8450-848X; MENOTTI, LAURA/0000-0003-3277-5399	European Research Council (ERC) [340060]; Compagnia di San Paolo, Turin, Italy [2015.9834]; RFO (University of Bologna)	European Research Council (ERC)(European Research Council (ERC)); Compagnia di San Paolo, Turin, Italy(Compagnia di San Paolo); RFO (University of Bologna)	This work was supported by European Research Council (ERC) advanced grant number 340060 to GCF and PM; by Compagnia di San Paolo, Turin, Italy (grant no 2015.9834) "Terapie innovative per il glioblastoma" to PM; by RFO (University of Bologna) to LM and EA. We would like to thank Dr. Antonio Daga for providing human glioma-initiating cells.	Ahmed N, 2010, CLIN CANCER RES, V16, P474, DOI 10.1158/1078-0432.CCR-09-1322; Alessandrini F, 2016, J CANCER, V7, P1791, DOI 10.7150/jca.15564; Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; [Anonymous], R LANG ENV STAT COMP; Appolloni I, 2019, CANCER LETT, V442, P213, DOI 10.1016/j.canlet.2018.10.006; Banelli B, 2015, CELL CYCLE, V14, P3418, DOI 10.1080/15384101.2015.1090063; BYSTRYN JC, 1978, J IMMUNOL, V120, P96; Campadelli-Fiume G, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8030063; Campadelli-Fiume G, 2011, REV MED VIROL, V21, P213, DOI 10.1002/rmv.691; Cheema TA, 2013, P NATL ACAD SCI USA, V110, P12006, DOI 10.1073/pnas.1307935110; Cody JJ, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/628697; Coffin RS, 2015, CURR OPIN VIROL, V13, P93, DOI 10.1016/j.coviro.2015.06.005; Delman KA, 2000, HUM GENE THER, V11, P2465, DOI 10.1089/10430340050207957; Dobin Alexander, 2015, Curr Protoc Bioinformatics, V51, DOI 10.1002/0471250953.bi1114s51; Duhem-Tonnelle V, 2010, J NEUROPATH EXP NEUR, V69, P606, DOI 10.1097/NEN.0b013e3181e00579; Edelstein Arthur, 2010, Curr Protoc Mol Biol, VChapter 14, DOI 10.1002/0471142727.mb1420s92; Favaro R, 2014, CANCER RES, V74, P1833, DOI 10.1158/0008-5472.CAN-13-1942; Gambini E, 2012, MOL THER, V20, P994, DOI 10.1038/mt.2012.22; Gulati S, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-18; Guo HY, 2015, MED MICROBIOL IMMUN, V204, P439, DOI 10.1007/s00430-015-0410-5; Hausler SFM, 2011, CANCER IMMUNOL IMMUN, V60, P1405, DOI 10.1007/s00262-011-1040-4; Hellums EK, 2005, NEURO-ONCOLOGY, V7, P213, DOI 10.1215/S1152851705000074; HIESIGER EM, 1993, J NEURO-ONCOL, V16, P93, DOI 10.1007/BF01324695; Hunter WD, 1999, J VIROL, V73, P6319, DOI 10.1128/JVI.73.8.6319-6326.1999; Kambara H, 2005, CANCER RES, V65, P2832, DOI 10.1158/0008-5472.CAN-04-3227; Kemeny N, 2006, HUM GENE THER, V17, P1214, DOI 10.1089/hum.2006.17.1214; Kimata H, 2006, ANN SURG ONCOL, V13, P1078, DOI 10.1245/ASO.2006.08.035; Korn T, 2017, NAT REV IMMUNOL, V17, P179, DOI 10.1038/nri.2016.144; Lambright ES, 2000, MOL THER, V2, P387, DOI 10.1006/mthe.2000.0133; Leoni V, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007209; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liu BL, 2003, GENE THER, V10, P292, DOI 10.1038/sj.gt.3301885; Louis DN., 2016, WHO CLASSIFICATION T; Louyeau A, 2015, TRENDS IMMUNOL, V36, P569, DOI 10.1016/j.it.2015.08.006; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; Menotti L, 2008, J VIROL, V82, P10153, DOI 10.1128/JVI.01133-08; Menotti L, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10070352; Mineo JF, 2007, J NEURO-ONCOL, V85, P281, DOI 10.1007/s11060-007-9424-1; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; Nabika Shinya, 2010, Hiroshima Journal of Medical Sciences, V59, P65; Nakao A, 2011, CANCER GENE THER, V18, P167, DOI 10.1038/cgt.2010.65; Parker JN, 2000, P NATL ACAD SCI USA, V97, P2208, DOI 10.1073/pnas.040557897; Patel DM, 2016, HUM GENE THER CL DEV, V27, P69, DOI 10.1089/humc.2016.031; Pritchard CC, 2001, P NATL ACAD SCI USA, V98, P13266, DOI 10.1073/pnas.221465998; Reisoli E, 2012, CANCER GENE THER, V19, P788, DOI 10.1038/cgt.2012.62; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Saha D, 2017, CANCER CELL, V32, P253, DOI 10.1016/j.ccell.2017.07.006; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Thomas ED, 2016, J OVARIAN RES, V9, DOI 10.1186/s13048-016-0282-3; Toda M, 1998, J IMMUNOL, V160, P4457; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Uchida H, 2013, MOL THER, V21, P561, DOI 10.1038/mt.2012.211; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; van der Woude LL, 2017, TRENDS CANCER, V3, P797, DOI 10.1016/j.trecan.2017.09.006; Veinalde R, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1285992	58	37	37	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4467	4479		10.1038/s41388-019-0737-2	http://dx.doi.org/10.1038/s41388-019-0737-2			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30755732				2023-01-03	WOS:000470240300003
J	Liu, YJ; Aguzzi, A				Liu, Yingjun; Aguzzi, Adriano			Immunotherapy for neurodegeneration?	SCIENCE			English	Editorial Material							IMMUNE-CHECKPOINT BLOCKADE; AMYLOID-BETA; PATHOLOGY; NLRP3		[Liu, Yingjun; Aguzzi, Adriano] Univ Zurich, Inst Neuropathol, CH-8091 Zurich, Switzerland	University of Zurich	Liu, YJ (corresponding author), Univ Zurich, Inst Neuropathol, CH-8091 Zurich, Switzerland.	yingjun.liu@usz.ch; adriano.aguzzi@usz.ch	Liu, Yingjun/AAW-5353-2020	Liu, Yingjun/0000-0003-1543-1965; Aguzzi, Adriano/0000-0002-0344-6708	European Research Council; Swiss National Research Foundation; Nomis Foundation	European Research Council(European Research Council (ERC)European Commission); Swiss National Research Foundation(Swiss National Science Foundation (SNSF)); Nomis Foundation	A.A. is supported by the European Research Council, the Swiss National Research Foundation, and the Nomis Foundation.	Baruch K, 2016, NAT MED, V22, P135, DOI 10.1038/nm.4022; Boulanger LM, 2009, NEURON, V64, P93, DOI 10.1016/j.neuron.2009.09.001; Daniels MJD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12504; Gordon R, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aah4066; Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729; Johann S, 2015, GLIA, V63, P2260, DOI 10.1002/glia.22891; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; Latta-Mahieu M, 2018, GLIA, V66, P492, DOI 10.1002/glia.23260; Liu YJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32712-8; Mao XB, 2016, SCIENCE, V353, DOI 10.1126/science.aah3374; McGinnis GJ, 2017, ONCOTARGET, V8, P9155, DOI 10.18632/oncotarget.13551; Obst J, 2018, BRAIN BEHAV IMMUN, V73, P708, DOI 10.1016/j.bbi.2018.08.006; Schwartz M, 2017, SCIENCE, V357, P254, DOI 10.1126/science.aai8231; Sims R, 2017, NAT GENET, V49, P1373, DOI 10.1038/ng.3916; Venegas C, 2017, NATURE, V552, P355, DOI 10.1038/nature25158	15	12	13	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	2019	364	6436					130	131		10.1126/science.aaw0685	http://dx.doi.org/10.1126/science.aaw0685			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HT5RC	30975878	Green Published			2023-01-03	WOS:000464620000024
J	Dhillon-Smith, RK; Middleton, LJ; Sunner, KK; Cheed, V; Baker, K; Farrell-Carver, S; Bender-Atik, R; Agrawal, R; Bhatia, K; Edi-Osagie, E; Ghobara, T; Gupta, P; Jurkovic, D; Khalaf, Y; MacLean, M; McCabe, C; Mulbagal, K; Nunes, N; Overton, C; Quenby, S; Rai, R; Raine-Fenning, N; Robinson, L; Ross, J; Sizer, A; Small, R; Tan, A; Underwood, M; Kilby, MD; Boelaert, K; Daniels, J; Thangaratinam, S; Chan, SY; Coomarasamy, A				Dhillon-Smith, Rima K.; Middleton, Lee J.; Sunner, Kirandeep K.; Cheed, Versha; Baker, Krys; Farrell-Carver, Samantha; Bender-Atik, Ruth; Agrawal, Rina; Bhatia, Kalsang; Edi-Osagie, Edmond; Ghobara, Tarek; Gupta, Pratima; Jurkovic, Davor; Khalaf, Yacoub; MacLean, Marjory; McCabe, Christopher; Mulbagal, Khashia; Nunes, Natalie; Overton, Caroline; Quenby, Siobhan; Rai, Raj; Raine-Fenning, Nick; Robinson, Lynne; Ross, Jackie; Sizer, Andrew; Small, Rachel; Tan, Alex; Underwood, Martyn; Kilby, Mark D.; Boelaert, Kristien; Daniels, Jane; Thangaratinam, Shakila; Chan, Shiao Y.; Coomarasamy, Arri			Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISEASE	Background Thyroid peroxidase antibodies are associated with an increased risk of miscarriage and preterm birth, even when thyroid function is normal. Small trials indicate that the use of levothyroxine could reduce the incidence of such adverse outcomes. Methods We conducted a double-blind, placebo-controlled trial to investigate whether levothyroxine treatment would increase live-birth rates among euthyroid women who had thyroid peroxidase antibodies and a history of miscarriage or infertility. A total of 19,585 women from 49 hospitals in the United Kingdom underwent testing for thyroid peroxidase antibodies and thyroid function. We randomly assigned 952 women to receive either 50 mu g once daily of levothyroxine (476 women) or placebo (476 women) before conception through the end of pregnancy. The primary outcome was live birth after at least 34 weeks of gestation. Results The follow-up rate for the primary outcome was 98.7% (940 of 952 women). A total of 266 of 470 women in the levothyroxine group (56.6%) and 274 of 470 women in the placebo group (58.3%) became pregnant. The live-birth rate was 37.4% (176 of 470 women) in the levothyroxine group and 37.9% (178 of 470 women) in the placebo group (relative risk, 0.97; 95% confidence interval [CI], 0.83 to 1.14, P=0.74; absolute difference, -0.4 percentage points; 95% CI, -6.6 to 5.8). There were no significant between-group differences in other pregnancy outcomes, including pregnancy loss or preterm birth, or in neonatal outcomes. Serious adverse events occurred in 5.9% of women in the levothyroxine group and 3.8% in the placebo group (P=0.14). Conclusions The use of levothyroxine in euthyroid women with thyroid peroxidase antibodies did not result in a higher rate of live births than placebo. (Funded by the United Kingdom National Institute for Health Research; TABLET Current Controlled Trials number, .) Thyroid peroxidase antibodies may increase the risk of miscarriage and preterm birth. In this controlled trial, the use of levothyroxine before conception and through birth did not improve live-birth rates among euthyroid women with such antibodies and a history of miscarriage or infertility.	[Dhillon-Smith, Rima K.; McCabe, Christopher; Kilby, Mark D.; Boelaert, Kristien; Coomarasamy, Arri] Univ Birmingham, Coll Med & Dent Sci, Inst Metab & Syst Res, Birmingham B15 2TT, W Midlands, England; [Dhillon-Smith, Rima K.; Coomarasamy, Arri] Univ Birmingham, Coll Med & Dent Sci, Tommys Natl Ctr Miscarriage Res, Birmingham E15 2TT, W Midlands, England; [Middleton, Lee J.; Sunner, Kirandeep K.; Cheed, Versha; Farrell-Carver, Samantha; Robinson, Lynne] Univ Birmingham, Coll Med & Dent Sci, Birmingham Clin Trials Unit, Inst Appl Hlth Res, Birmingham, W Midlands, England; [Dhillon-Smith, Rima K.; Middleton, Lee J.; Robinson, Lynne; Kilby, Mark D.; Coomarasamy, Arri] Univ Hosp Birmingham, Womens & Childrens NHS Fdn Trust, Birmingham, W Midlands, England; [Gupta, Pratima; Small, Rachel] Univ Hosp Birmingham, Birmingham, W Midlands, England; [Baker, Krys] Univ Oxford, Nuffield Dept Populat Hlth, Canc Epidemiol Unit, Oxford, England; [Bender-Atik, Ruth] Miscarriage Assoc, Wakefield, England; [Agrawal, Rina; Ghobara, Tarek; Quenby, Siobhan] Univ Hosp Coventry & Warwickshire NHS Trust, Univ Hosp Coventry, Coventry, W Midlands, England; [Bhatia, Kalsang] East Lancashire Hosp NHS Trust, Burnley Gen Teaching Hosp, Burnley, Lancs, England; [Edi-Osagie, Edmond] Cent Manchester Univ Hosp NHS Fdn Trust, St Marys Hosp, Manchester, Lancs, England; [Jurkovic, Davor] Univ Coll London Hosp NHS Fdn Trust, Univ Coll Hosp, London, England; [Khalaf, Yacoub] Guys & St Thomas NHS Fdn Trust, Assisted Concept Unit, London, England; [Rai, Raj] Imperial Coll Healthcare NHS Trust, St Marys Hosp, London, England; [Ross, Jackie] Kings Coll Hosp NHS Fdn Trust, London, England; [Tan, Alex; Thangaratinam, Shakila] Queen Mary Univ London, Barts & London Sch Med & Dent, Barts Res Ctr Womens Hlth, London, England; [MacLean, Marjory] Univ Hosp Crosshouse, Ayrshire Matern Unit, Kilmarnock, Scotland; [Mulbagal, Khashia] Royal Bolton Hosp, Bolton NHS Fdn Trust, Bolton, England; [Nunes, Natalie] West Middlesex Univ Hosp, Chelsea & Westminster Hosp NHS Fdn Trust, Chelsea, England; [Overton, Caroline] Univ Hosp Bristol NHS Fdn Trust, St Michaels Hosp, Bristol, Avon, England; [Raine-Fenning, Nick] Nottingham Univ Hosp NHS Trust, Queens Med Ctr, Nottingham, England; [Daniels, Jane] Univ Nottingham, Nottingham Clin Trials Unit, Sch Med, Nottingham Hlth Sci Partners,Queens Med Ctr, Nottingham, England; [Sizer, Andrew; Underwood, Martyn] Shrewsbury & Telford Hosp NHS Trust, Princess Royal Hosp, Shrewsbury, Salop, England; [Chan, Shiao Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Obstet & Gynecol, Singapore, Singapore	University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Oxford; University of Warwick; University of Manchester; University College London Hospitals NHS Foundation Trust; University of London; University College London; Guy's & St Thomas' NHS Foundation Trust; Imperial College London; King's College Hospital NHS Foundation Trust; University of London; Queen Mary University London; Royal Bolton Hospital; University of Bristol; Nottingham University Hospital NHS Trust; University of Nottingham; University of Nottingham; National University of Singapore	Dhillon-Smith, RK; Coomarasamy, A (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Tommys Natl Ctr Miscarriage Res, Birmingham E15 2TT, W Midlands, England.	a.coomarasamy@bham.ac.uk; a.coomarasamy@bham.ac.uk	Ghobara, Tarek/AAU-9317-2021; FRCPI, Mark D Kilby MB BS DSc MD FRCOG/AAW-9704-2020; Raine-Fenning, Nicholas J/C-3005-2008; Ross, Jackie A/H-2113-2013; Thangaratinam, Shakila/AAP-3724-2021; McCabe, Christopher/G-5705-2014	FRCPI, Mark D Kilby MB BS DSc MD FRCOG/0000-0001-9987-4223; Raine-Fenning, Nicholas J/0000-0001-5521-9059; Ross, Jackie A/0000-0003-4168-6910; Thangaratinam, Shakila/0000-0002-4254-460X; Quenby, Siobhan/0000-0003-3221-5471; Baker, Krys/0000-0003-4451-2502; Middleton, Lee/0000-0003-4621-1922; Robinson, Lauren/0000-0001-9550-2940; Cheed, Versha/0000-0002-6713-0913; Chan, Shiao-Yng/0000-0002-3530-3023; McCabe, Christopher/0000-0002-4767-821X	United Kingdom National Institute for Health Research; MRC [MR/P000509/1, MC_G1002674] Funding Source: UKRI	United Kingdom National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Funded by the United Kingdom National Institute for Health Research; TABLET Current Controlled Trials number, ISRCTN15948785.	Alexander EK, 2017, THYROID, V27, P315, DOI 10.1089/thy.2016.0457; [Anonymous], IMM ALL; [Anonymous], MISC STAT; eMC, LEV 25 MICR TABL SUM; National Institute for Health and Care Excellence, 2013, FERT PROBL ASS TREAT; Negro R, 2005, HUM REPROD, V20, P1529, DOI 10.1093/humrep/deh843; Negro R, 2006, J CLIN ENDOCR METAB, V91, P2587, DOI 10.1210/jc.2005-1603; NICE, 2015, S3 GUID NAT HLTH CAR; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Thangaratinam S, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2616; Wang HN, 2017, JAMA-J AM MED ASSOC, V318, P2190, DOI 10.1001/jama.2017.18249	11	122	131	3	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 4	2019	380	14					1316	1325		10.1056/NEJMoa1812537	http://dx.doi.org/10.1056/NEJMoa1812537			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR8DR	30907987	Green Published, Bronze			2023-01-03	WOS:000463386900008
J	Singer, N; Kreuzpointner, L; Sommer, M; Wust, S; Kudielka, BM				Singer, Nina; Kreuzpointner, Ludwig; Sommer, Monika; Wuest, Stefan; Kudielka, Brigitte M.			Decision-making in everyday moral conflict situations: Development and validation of a new measure	PLOS ONE			English	Article							GENDER-DIFFERENCES; ALTRUISM; STRESS; DILEMMAS; NEUROSCIENCE; RESPONSES; VALIDITY; ROLES; BASES; MEN	In everyday life, we are often confronted with morally conflicting social interaction situations. Therefore, the main objective of the present set of studies was the development and validation of a new measure to assess decision-making in everyday moral conflict situations. All vignettes required a decision between an altruistic versus an egoistic behavioral response alternative. In three independent surveys (N = 200), we developed a 40-items measure with preferable mean rates of altruistic decisions (Study 1), clear representation of altruistic and egoistic response classes (Study 2), unambiguousness of social closeness classifications (socially close vs. socially distant protagonists; Studies 1 and 2), and high similarity to reality ratings (Studies 1 and 2). Additionally, we developed two parallelized item sets for future use in within-subjects design studies and investigated the measurement properties of our new scale (Studies 1 and 3). Results of Rasch model analyses and classical test theory fit indices showed unidimensionality and confirmed the appropriateness of the fragmentation into two parallelized item sets. Notably, in our data, there were neither effects of social closeness nor gender on the percentage of altruistic decisions. In sum, we propose the Everyday Moral Conflict Situations (EMCS) Scale as a promising new measurement tool that may facilitate further research in different research areas due to its broad applicability.	[Singer, Nina; Kreuzpointner, Ludwig; Kudielka, Brigitte M.] Univ Regensburg, Dept Med Psychol Psychol Diagnost & Res Methodol, Regensburg, Germany; [Sommer, Monika] Univ Regensburg, Dept Psychiat & Psychotherapy, Regensburg, Germany; [Sommer, Monika] Ludwig Maximilians Univ Munchen, Dept Psychol, Munich, Germany; [Wuest, Stefan] Univ Regensburg, Inst Expt Psychol, Regensburg, Germany	University of Regensburg; University of Regensburg; University of Munich; University of Regensburg	Singer, N (corresponding author), Univ Regensburg, Dept Med Psychol Psychol Diagnost & Res Methodol, Regensburg, Germany.	Nina.Singer@psychologie.uni-regensburg.de	; Kreuzpointner, Ludwig/K-1741-2013	Wust, Stefan/0000-0002-2315-8949; Singer, Nina/0000-0003-2725-6498; Kudielka, Brigitte M/0000-0002-8349-926X; Kreuzpointner, Ludwig/0000-0003-1391-0807	German Research Foundation (DFG) [DFG-KU 1401/10-1]	German Research Foundation (DFG)(German Research Foundation (DFG))	This work was supported by the German Research Foundation (DFG) within the funding programme Open Access Publishing and by grant number DFG-KU 1401/10-1 assigned to BMK, MS, and SW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abeler J, ECONOMETRICA; ANDERSEN EB, 1973, PSYCHOMETRIKA, V38, P123, DOI 10.1007/BF02291180; [Anonymous], 2018, PSYCH PROCEDURES PER; [Anonymous], 2018, R LANG ENV STAT COMP; [Anonymous], 1980, APPL ITEM RESPONSE T; Armstrong J, 2019, SOC PSYCHOL PERS SCI, V10, P353, DOI 10.1177/1948550618755873; Bauman CW, 2014, SOC PERSONAL PSYCHOL, V8, P536, DOI 10.1111/spc3.12131; Bostyn DH, 2018, PSYCHOL SCI, V29, P1084, DOI 10.1177/0956797617752640; Branas-Garza P, 2018, ECON LETT, V170, P19, DOI 10.1016/j.econlet.2018.05.022; Capraro V, 2019, PRIMING INTUITION DE; Capraro V, 2018, JUDGM DECIS MAK, V13, P345; Capraro V, 2017, COGN PROCESS, V18, P399, DOI 10.1007/s10339-017-0822-9; Ceccato S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199528; Charness G, 2012, J ECON BEHAV ORGAN, V81, P1, DOI 10.1016/j.jebo.2011.08.009; Christensen JF, 2012, NEUROSCI BIOBEHAV R, V36, P1249, DOI 10.1016/j.neubiorev.2012.02.008; Christensen KB, 2002, PSYCHOMETRIKA, V67, P563, DOI 10.1007/BF02295131; Clifford S, 2015, BEHAV RES METHODS, V47, P1178, DOI 10.3758/s13428-014-0551-2; Embretson S.E., 2000, ITEM RESPONSE THEORY; FeldmanHall O, 2012, COGNITION, V123, P434, DOI 10.1016/j.cognition.2012.02.001; Fletcher T. D., 2010, PSYCHOMETRIC APPL PS; Friesdorf R, 2015, PERS SOC PSYCHOL B, V41, P696, DOI 10.1177/0146167215575731; Frith CD, 2007, CURR BIOL, V17, pR724, DOI 10.1016/j.cub.2007.05.068; Fumagalli M, 2010, COGN PROCESS, V11, P219, DOI 10.1007/s10339-009-0335-2; Giammarco EA, 2016, PERS INDIV DIFFER, V88, P26, DOI 10.1016/j.paid.2015.08.039; GILLIGAN C, 1982, AM J ORTHOPSYCHIAT, V52, P199, DOI 10.1111/j.1939-0025.1982.tb02682.x; Graham J, 2011, J PERS SOC PSYCHOL, V101, P366, DOI 10.1037/a0021847; Graham J, 2013, ADV EXP SOC PSYCHOL, V47, P55, DOI 10.1016/B978-0-12-407236-7.00002-4; Greene JD, 2004, NEURON, V44, P389, DOI 10.1016/j.neuron.2004.09.027; Greene JD, 2001, SCIENCE, V293, P2105, DOI 10.1126/science.1062872; Greene JD, 2015, COGNITION, V135, P39, DOI 10.1016/j.cognition.2014.11.018; Haidt J., 2007, SOC JUSTICE RES, V20, P98, DOI [10.1007/s11211-007-0034-z, DOI 10.1007/S11211-007-0034-Z]; Haidt J, 2007, SCIENCE, V316, P998, DOI 10.1126/science.1137651; Hofmann W, 2018, PERS SOC PSYCHOL B, V44, P1697, DOI 10.1177/0146167218775075; Hofmann W, 2014, SCIENCE, V345, P1340, DOI 10.1126/science.1251560; Jones B, 2006, PSYCHOL SCI, V17, P283, DOI 10.1111/j.1467-9280.2006.01699.x; Kahane G, 2018, PSYCHOL REV, V125, P131, DOI 10.1037/rev0000093; Kahane G, 2015, SOC NEUROSCI-UK, V10, P551, DOI 10.1080/17470919.2015.1023400; Kahane G, 2015, COGNITION, V134, P193, DOI 10.1016/j.cognition.2014.10.005; Kossowska M, 2016, PERS INDIV DIFFER, V101, P249, DOI 10.1016/j.paid.2016.06.017; Kurzban R, 2012, EVOL HUM BEHAV, V33, P323, DOI 10.1016/j.evolhumbehav.2011.11.002; Linacre J., 2002, RASCH MEAS T, V16; Linke LH, 2012, CURR PSYCHOL, V31, P291, DOI 10.1007/s12144-012-9146-1; Mair P, 2018, EXTENDED RASCH MODEL; Margittai Z, 2015, HORM BEHAV, V73, P75, DOI 10.1016/j.yhbeh.2015.05.019; Margittai Z, 2018, PSYCHONEUROENDOCRINO, V90, P22, DOI 10.1016/j.psyneuen.2018.01.015; Oda R, 2014, PERS INDIV DIFFER, V56, P206, DOI 10.1016/j.paid.2013.09.017; Oda R, 2013, BRIT J PSYCHOL, V104, P577, DOI 10.1111/bjop.12021; R Core Team, 2018, FOR READ DAT STOR MI; Rand DG, 2016, J EXP PSYCHOL GEN, V145, P389, DOI 10.1037/xge0000154; Rasch D, 2011, STAT PAP, V52, P219, DOI 10.1007/s00362-009-0224-x; Reise SP, 2000, PSYCHOL ASSESSMENT, V12, P287, DOI 10.1037//1040-3590.12.3.287; Rilling JK, 2011, ANNU REV PSYCHOL, V62, P23, DOI 10.1146/annurev.psych.121208.131647; Rosen JB, 2015, PARKINSONISM RELAT D, V21, P1191, DOI 10.1016/j.parkreldis.2015.08.016; Singer N, 2017, HORM BEHAV, V93, P72, DOI 10.1016/j.yhbeh.2017.05.002; Sinnott-Armstrong W, 2008, PHENOMENOL COGN SCI, V7, P85, DOI 10.1007/s11097-007-9065-z; Sommer M, 2014, SOC NEUROSCI-UK, V9, P452, DOI 10.1080/17470919.2014.933714; Sommer M, 2010, NEUROPSYCHOLOGIA, V48, P2018, DOI 10.1016/j.neuropsychologia.2010.03.023; Starcke K, 2012, JUDGM DECIS MAK, V7, P61; Starcke K, 2011, PSYCHONEUROENDOCRINO, V36, P210, DOI 10.1016/j.psyneuen.2010.07.010; Strombach T, 2015, P NATL ACAD SCI USA, V112, P1619, DOI 10.1073/pnas.1414715112; Strombach T, 2014, J BEHAV DECIS MAKING, V27, P235, DOI 10.1002/bdm.1802; Takahashi T, 2007, MED HYPOTHESES, V68, P184, DOI 10.1016/j.mehy.2006.05.057; Tassy S, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00250; Taylor SE, 2006, CURR DIR PSYCHOL SCI, V15, P273, DOI 10.1111/j.1467-8721.2006.00451.x; Urbaniak GC, 2019, RES RANDOMIZER VERSI; von Davier M, 2016, CH CRC STAT SOC BEHA, P31; WILKS SS, 1946, ANN MATH STAT, V17, P257, DOI 10.1214/aoms/1177730940; Youssef FF, 2012, PSYCHONEUROENDOCRINO, V37, P491, DOI 10.1016/j.psyneuen.2011.07.017; Zhan YL, 2018, NEUROSCI LETT, V672, P15, DOI 10.1016/j.neulet.2018.02.039	69	8	8	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2019	14	4							e0214747	10.1371/journal.pone.0214747	http://dx.doi.org/10.1371/journal.pone.0214747			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HR1CY	30934016	Green Published, gold, Green Submitted			2023-01-03	WOS:000462867000039
J	Grice, PM; Kemp, CC				Grice, Phillip M.; Kemp, Charles C.			In-home and remote use of robotic body surrogates by people with profound motor deficits	PLOS ONE			English	Article							ARM; ACCEPTANCE; GRASP; TETRAPLEGIA; AUTONOMY; REACH	By controlling robots comparable to the human body, people with profound motor deficits could potentially perform a variety of physical tasks for themselves, improving their quality of life. The extent to which this is achievable has been unclear due to the lack of suitable interfaces by which to control robotic body surrogates and a dearth of studies involving substantial numbers of people with profound motor deficits. We developed a novel, web-based augmented reality interface that enables people with profound motor deficits to remotely control a PR2 mobile manipulator from Willow Garage, which is a human-scale, wheeled robot with two arms. We then conducted two studies to investigate the use of robotic body surrogates. In the first study, 15 novice users with profound motor deficits from across the United States controlled a PR2 in Atlanta, GA to perform a modified Action Research Arm Test (ARAT) and a simulated self-care task. Participants achieved clinically meaningful improvements on the ARAT and 12 of 15 participants (80%) successfully completed the simulated self-care task. Participants agreed that the robotic system was easy to use, was useful, and would provide a meaningful improvement in their lives. In the second study, one expert user with profound motor deficits had free use of a PR2 in his home for seven days. He performed a variety of self-care and household tasks, and also used the robot in novel ways. Taking both studies together, our results suggest that people with profound motor deficits can improve their quality of life using robotic body surrogates, and that they can gain benefit with only low-level robot autonomy and without invasive interfaces. However, methods to reduce the rate of errors and increase operational speed merit further investigation.	[Grice, Phillip M.; Kemp, Charles C.] Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology	Grice, PM (corresponding author), Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30332 USA.	phillip.grice@gatech.edu			National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) via RERC TechSAge [90RE5016-01-00]; National Science Foundation Award [IIS-1150157]; National Science Foundation Graduate Research Fellowship Program Award; Residential Care Facilities for the Elderly of Fulton County Scholar Award	National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) via RERC TechSAge(United States Department of Health & Human Services); National Science Foundation Award(National Science Foundation (NSF)); National Science Foundation Graduate Research Fellowship Program Award; Residential Care Facilities for the Elderly of Fulton County Scholar Award	This work was supported by the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR), grant 90RE5016-01-00 via RERC TechSAge (https://www.acl.gov/about-acl/about-national-institute-disability-independent-living-and-rehabilitation-research, CK), National Science Foundation Award IIS-1150157 (https://www.nsf.gov/div/index.jsp?div=IIS, CK), by a National Science Foundation Graduate Research Fellowship Program Award (https://www.nsfgrfp.org, PG), and the Residential Care Facilities for the Elderly of Fulton County Scholar Award (http://www.fultoncountyga.gov/appointed-boards-a-athorities/3255-residential-care-facilities-for-the-elderly-authority-of-fulton-county, PG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ajemian R, 2017, NATURE, V544, P416, DOI 10.1038/544416c; Ajiboye AB, 2017, LANCET, V389, P1821, DOI 10.1016/S0140-6736(17)30601-3; Alaiad A, 2014, INT J HEALTHC INF SY, V9, P44, DOI 10.4018/ijhisi.2014100104; Annett J, 2003, HUM FAC ER, P17; [Anonymous], 2017, ROBOTNIK RB 1 DATASH; Bien Z, 2004, AUTON ROBOT, V16, P165, DOI 10.1023/B:AURO.0000016864.12513.77; Cargo M, 2008, ANNU REV PUBL HEALTH, V29, P325, DOI 10.1146/annurev.publhealth.29.091307.083824; Chen TL, 2013, IEEE ROBOT AUTOM MAG, V20, P30, DOI 10.1109/MRA.2012.2229950; Ciocarlie M, 2012, IEEE INT C INT ROBOT, P5313, DOI 10.1109/IROS.2012.6385907; Cohen O, 2012, P IEEE RAS-EMBS INT, P314, DOI 10.1109/BioRob.2012.6290866; Collinger JL, 2013, LANCET, V381, P557, DOI 10.1016/S0140-6736(12)61816-9; Cornwall A, 1995, SOC SCI MED, V41, P1667, DOI 10.1016/0277-9536(95)00127-S; DAVIS FD, 1989, MIS QUART, V13, P319, DOI 10.2307/249008; Ezer N, 2009, LECT NOTES COMPUT SC, V5615, P39, DOI 10.1007/978-3-642-02710-9_5; Felipe S.K., 2010, P HUM FACT ERG SOC A, V54, P2005, DOI [10.1177/154193121005402321, DOI 10.1177/154193121005402321]; Gopinath D, 2017, IEEE ROBOT AUTOM LET, V2, P247, DOI 10.1109/LRA.2016.2593928; Green A, 2000, IEEE RO-MAN 2000: 9TH IEEE INTERNATIONAL WORKSHOP ON ROBOT AND HUMAN INTERACTIVE COMMUNICATION, PROCEEDINGS, P161, DOI 10.1109/ROMAN.2000.892488; Grice P. M., 2013, REH ROB ICORR 2013 I, P1; Grice Phillip M, 2016, RSS 2016 WORKSH SOC; Hawkins Kelsey P., 2014, 2014 IEEE Symposium on Computational Intelligence in Robotic Rehabilitation and Assistive Technologies (CIR2AT), P16, DOI 10.1109/CIRAT.2014.7009736; Herlant L, 2016, HUMAN ROBOT INTERACT; Hochberg LR, 2006, NATURE, V442, P164, DOI 10.1038/nature04970; Hochberg LR, 2012, NATURE, V485, P372, DOI 10.1038/nature11076; Hutchins E. L., 1985, HUMAN COMPUTER INTER, V1, P311, DOI [DOI 10.1207/S15327051HCI0104_2, 10.1207/s15327051hci0104_2]; Inc K, 2018, KIN MOVO DAT; Iwarsson S, 2003, DISABIL REHABIL, V25, P57, DOI 10.1080/0963828021000007969; Jain A, 2013, INT J ROBOT RES, V32, P458, DOI 10.1177/0278364912471865; Jain S, 2015, INT C REHAB ROBOT, P526, DOI 10.1109/ICORR.2015.7281253; Kajita S, 2016, SPRINGER HDB ROBOTIC; Kintsch A., 2002, P STATEWIDE ASSISTIV; Lang CE, 2008, ARCH PHYS MED REHAB, V89, P1693, DOI 10.1016/j.apmr.2008.02.022; Leeper A, 2012, ACMIEEE INT CONF HUM, P1; Mankoff J., 2002, ASSETS 2002. Proceedings of the Fifth International ACM SIGCAPH Conference on Assistive Technologies, P17, DOI 10.1145/638249.638255; Marion P, 2017, J FIELD ROBOT, V34, P262, DOI 10.1002/rob.21681; Meng JJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep38565; Murphy RR, 2015, J FIELD ROBOT, V32, P189, DOI 10.1002/rob.21578; Norman D., 2013, DESIGN EVERYDAY THIN; Pages J., 2016, INT WORK ROBOT MODUL; Pandarinath C, 2017, ELIFE, V6, DOI 10.7554/eLife.18554; Park D, 2017, IEEE INT C INT ROBOT, P5406; Robinson-Smith G, 2000, ARCH PHYS MED REHAB, V81, P460, DOI 10.1053/mr.2000.3863; Romano JM, 2011, IEEE T ROBOT, V27, P1067, DOI 10.1109/TRO.2011.2162271; Rosenholtz R, 2007, J VISION, V7, DOI 10.1167/7.2.17; Sanders EBN, 2002, DESIGN AND THE SOCIAL SCIENCES: MAKING CONNECTIONS, P1; Schuler Douglas, 1993, PARTICIPATORY DESIGN; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Simpson Richard, 2010, Phys Med Rehabil Clin N Am, V21, P15, DOI 10.1016/j.pmr.2009.07.006; Soekadar SR, 2016, SCI ROBOT, V1, DOI 10.1126/scirobotics.aag3296; Soukoreff RW, 2004, INT J HUM-COMPUT ST, V61, P751, DOI 10.1016/j.ijhcs.2004.09.001; Spenko M., 2018, DARPA ROBOTICS CHALL, V121; Sung J, 2010, INT J SOC ROBOT, V2, P417, DOI 10.1007/s12369-010-0065-8; Tidoni E, 2017, IEEE T NEUR SYS REH, V25, P772, DOI 10.1109/TNSRE.2016.2597863; Toris R, 2015, IEEE RSJ INT C INT R; Townsend G, 2010, CLIN NEUROPHYSIOL, V121, P1109, DOI 10.1016/j.clinph.2010.01.030; Tsui K, 2015, PALADYN J BEHAV ROBO, V6; Van der Lee JH, 2001, ARCH PHYS MED REHAB, V82, P14, DOI 10.1053/apmr.2001.18668; Venkatesh V, 2000, MANAGE SCI, V46, P186, DOI 10.1287/mnsc.46.2.186.11926; Viswanathan M, 2004, Evid Rep Technol Assess (Summ), P1; Wagner J, 1999, P ICORR, V99, P250; Wang HW, 2013, J SPINAL CORD MED, V36, P333, DOI 10.1179/2045772313Y.0000000094; Wilkinson CR, 2014, DESIGN STUD, V35, P614, DOI 10.1016/j.destud.2014.06.001; Wise M., 2016, FETCH FREIGHT STANDA; Wodlinger B, 2015, J NEURAL ENG, V12, DOI 10.1088/1741-2560/12/1/016011; Wusheng Chou, 2001, 2001 IEEE International Conference on Systems, Man and Cybernetics. e-Systems and e-Man for Cybernetics in Cyberspace (Cat.No.01CH37236), P3187, DOI 10.1109/ICSMC.2001.972009; Yamamoto T, 2018, SIGGRAPH'18: ACM SIGGRAPH 2018 EMERGING TECHNOLOGIES, DOI 10.1145/3214907.3233972; Yanco HA, 2015, J FIELD ROBOT, V32, P420, DOI 10.1002/rob.21568; Yozbatiran N, 2008, NEUROREHAB NEURAL RE, V22, P78, DOI 10.1177/1545968307305353; Zalud L, 2006, 2006 IEEE/RSJ INTERNATIONAL CONFERENCE ON INTELLIGENT ROBOTS AND SYSTEMS, VOLS 1-12, P211, DOI 10.1109/IROS.2006.282495	69	7	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2019	14	3							e0212904	10.1371/journal.pone.0212904	http://dx.doi.org/10.1371/journal.pone.0212904			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HO9WM	30875377	Green Published, gold, Green Submitted			2023-01-03	WOS:000461316400007
J	Mayor, E; Daehne, M; Bianchi, R				Mayor, Eric; Daehne, Maxime; Bianchi, Renzo			How perceived substance characteristics affect ethical judgement towards cognitive enhancement	PLOS ONE			English	Article							PRESCRIPTION STIMULANTS; DECISION-MAKING; MORAL JUDGMENT; COMMUNICATION; KNOWLEDGE; ATTITUDES; VIGNETTE; COLLEGE; UTILITY; VALUES	Some individuals seek to enhance their cognitive capabilities through the use of pharmacology. Such behavior entails potential health risks and raises ethical concerns. The aim of this study was to examine whether a precursor of behavior, ethical judgement towards the use of existing biological cognitive enhancers (e.g., coffee, legal and illegal drugs), is shaped by the perceived characteristics of these cognitive enhancers. Students and employees completed an online questionnaire which measured perceived characteristics of 15 substances presented as potential cognitive enhancers and a measure of ethical judgement towards these cognitive enhancers. Results of mixed model regression analyzes show that ethical judgement is more favourable when cognitive enhancers are perceived as being legal, familiar, efficient, and safe for users' health, supporting all hypotheses. Results further show that 36% of variance (in the null model) lies at the level of cognitive enhancers and 21% at the level of participants. In conclusion, cognitive enhancers vary widely in terms of ethical judgement, which is explained by the perception of the mentioned characteristics. Implications regarding prevention and policy-making are discussed.	[Mayor, Eric; Daehne, Maxime; Bianchi, Renzo] Univ Neuchatel, Fac Sci, Inst Work & Org Psychol, Neuchatel, Switzerland	University of Neuchatel	Mayor, E (corresponding author), Univ Neuchatel, Fac Sci, Inst Work & Org Psychol, Neuchatel, Switzerland.	eric.mayor@unine.ch	Bianchi, Renzo/U-9777-2017; Mayor, eric/AFT-8486-2022	Bianchi, Renzo/0000-0003-2336-0407; Mayor, eric/0000-0001-9441-7592				Aguinis H, 2014, ORGAN RES METHODS, V17, P351, DOI 10.1177/1094428114547952; Ajzen I, 2001, ANNU REV PSYCHOL, V52, P27, DOI 10.1146/annurev.psych.52.1.27; Amonini C, 2006, HEALTH EDUC RES, V21, P276, DOI 10.1093/her/cyh064; Bates D., 2014, R PACKAGE VERSION, DOI 10.18637/jss.v067.i01; Bedzow I., 2018, J CLIN PSYCHIAT NEUR, V1, P12; Bergkvist L, 2007, J MARKETING RES, V44, P175, DOI 10.1509/jmkr.44.2.175; Bilz K, 2009, PSYCHOL LEARN MOTIV, V50, P101, DOI 10.1016/S0079-7421(08)00403-9; Bohrn IC, 2013, BRAIN LANG, V124, P1, DOI 10.1016/j.bandl.2012.10.003; Bostrom N, 2009, SCI ENG ETHICS, V15, P311, DOI 10.1007/s11948-009-9142-5; Cakic V, 2009, J MED ETHICS, V35, P611, DOI 10.1136/jme.2009.030882; CARLSON JS, 1988, INT J INTERCULT REL, V12, P1, DOI 10.1016/0147-1767(88)90003-X; Clark, 2007, BLACKWELL HDB SOCIAL, P308, DOI [10.1002/9780470998557.ch12, DOI 10.1002/9780470998557.CH12]; CONRAD P, 1994, CULT MED PSYCHIAT, V18, P385, DOI 10.1007/BF01379232; Coupey E, 1998, J CONSUM RES, V24, P459, DOI 10.1086/209521; Dubljevi V., 2015, NEUROL NEUROSCI, V4, P25, DOI DOI 10.2147/NAN.S61925; Eisenberg A.E., 1998, PSYCHOL BULL, V87, P245; Faber NS, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00232; Fisher GG, 2016, J OCCUP HEALTH PSYCH, V21, P3, DOI 10.1037/a0039139; Fitz NS, 2014, NEUROETHICS-NETH, V7, P173, DOI 10.1007/s12152-013-9190-z; Forlini C, 2009, NEUROETHICS-NETH, V2, P163, DOI 10.1007/s12152-009-9043-y; Franke A. G., 2013, COGNITIVE ENHANCEMEN, P17; Franke AG, 2014, EUR ARCH PSY CLIN N, V264, pS83, DOI 10.1007/s00406-014-0537-1; Gibson BM, 2007, J EXP PSYCHOL ANIM B, V33, P244, DOI 10.1037/0097-7403.33.3.244; Glannon W, 2008, NEUROETHICS-NETH, V1, P45, DOI 10.1007/s12152-008-9005-9; Greene J, 2002, TRENDS COGN SCI, V6, P517, DOI 10.1016/S1364-6613(02)02011-9; Hainmueller J, 2015, P NATL ACAD SCI USA, V112, P2395, DOI 10.1073/pnas.1416587112; Hall W., 2012, AJOB PRIMARY RES, V3, P81, DOI [DOI 10.1080/21507716.2012.720639, 10.1080/21507716.2012.720639]; HECHTER M, 1994, RATION SOC, V6, P318, DOI 10.1177/1043463194006003003; Helman CG, 2007, CULTURE HLTH ILLNESS; HOGAN R, 1973, PSYCHOL BULL, V79, P217, DOI 10.1037/h0033956; Illies C., 2003, GROUNDS ETHICAL JUDG; Judson R, 2009, PSYCHOL HEALTH MED, V14, P97, DOI 10.1080/13548500802126723; Jung N, 2011, MASS COMMUN SOC, V14, P407, DOI 10.1080/15205436.2010.496135; KAHNEMAN D, 1984, AM PSYCHOL, V39, P341, DOI 10.1037/0003-066X.39.4.341; LOEWENSTEIN GF, 1989, J PERS SOC PSYCHOL, V57, P426, DOI 10.1037/0022-3514.57.3.426; Maslen H, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00107; MASSEY JL, 1986, SOC FORCES, V65, P106, DOI 10.2307/2578938; Mazanov J., 2013, PERFORM ENHANC HLTH, V2, P110, DOI [10.1016/j.peh.2013.08.017, DOI 10.1016/J.PEH.2013.08.017]; Moll J, 2005, NAT REV NEUROSCI, V6, P799, DOI 10.1038/nrn1768; Nutbeam D, 2000, HEALTH PROMOT INT, V15, P259, DOI 10.1093/heapro/15.3.259; Partridge BJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028416; Pettigrew TF, 2006, J PERS SOC PSYCHOL, V90, P751, DOI 10.1037/0022-3514.90.5.751; Pickett JT, 2017, J EXP CRIMINOL, V13, P217, DOI 10.1007/s11292-017-9287-1; Podsakoff PM, 2003, J APPL PSYCHOL, V88, P879, DOI 10.1037/0021-9010.88.5.879; Pohl S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01451; PRENTICE DA, 1993, J PERS SOC PSYCHOL, V64, P243, DOI 10.1037/0022-3514.64.2.243; Raz Joseph, 2009, AUTHORITY LAW ESSAYS, V2nd; Riis J, 2008, J CONSUM RES, V35, P495, DOI 10.1086/588746; Rozin P., 1999, J CONSUM PSYCHOL, V8, P321, DOI [10.1207/s15327663jcp0803_07, DOI 10.1207/S15327663JCP0803_07]; Sattler S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071452; Sattler S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068821; Simmonds, 2007, LAW AS A MORAL IDEA; Smith ME, 2011, PSYCHOL BULL, V137, P717, DOI 10.1037/a0023825; Snijders T.A.B., 2012, MULTILEVEL ANAL INTR, Vsecond; Spector PE, 2006, ORGAN RES METHODS, V9, P221, DOI 10.1177/1094428105284955; Tangney JP, 2007, ANNU REV PSYCHOL, V58, P345, DOI 10.1146/annurev.psych.56.091103.070145; Tobler PN, 2008, COGN AFFECT BEHAV NE, V8, P390, DOI 10.3758/CABN.8.4.390; TVERSKY A, 1992, J RISK UNCERTAINTY, V5, P297, DOI 10.1007/BF00122574; Tyler T. R., 2006, CONTEMP SOCIOL, DOI [10.1515/9781400828609, DOI 10.2307/2076193]; WALKER N, 1964, BRIT J CRIMINOL, V4, P570, DOI 10.1093/oxfordjournals.bjc.a048782; Wanous JP, 2001, ORGAN RES METHODS, V4, P361, DOI 10.1177/109442810144003; Williams B., 1973, UTILITARIANISM; ZAJONC RB, 1968, J PERS SOC PSYCHOL, V9, P1, DOI 10.1037/h0025848; Zhao JL, 2016, PERS INDIV DIFFER, V95, P29, DOI 10.1016/j.paid.2016.02.024	64	6	6	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2019	14	3							e0213619	10.1371/journal.pone.0213619	http://dx.doi.org/10.1371/journal.pone.0213619			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HO7YP	30870469	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000461166300050
J	Park, SB; Sung, DJ; Kim, B; Kim, S; Han, JK				Park, Seung-Bo; Sung, Dong Jun; Kim, Bokyung; Kim, SoJung; Han, Joung-Kyue			Transcranial Direct Current Stimulation of motor cortex enhances running performance	PLOS ONE			English	Article							DORSOLATERAL PREFRONTAL CORTEX; EXERCISE PERFORMANCE; BRAIN-STIMULATION; COGNITIVE CONTROL; MUSCLE AFFERENTS; DC-STIMULATION; PERCEPTION; PAIN; MODULATION; ENDURANCE	Transcranial direct current stimulation (tDCS) is a technique used to modulate neuronal excitability through non-invasive brain stimulation that can enhance exercise performance. We hypothesize that tDCS would improve submaximal running time to exhaustion (TTE) and delay the increase in the rating of perceived exertion (RPE) over time. We also hypothesize that tDCS would not lead to difference in cardiorespiratory responses. We employed a randomized, single-blinded, and counterbalanced design in which 10 trained men participated. After receiving either 20 min of 1.98 mA anodal tDCS applied over the primary motor cortex (M1) or sham-operated control on separate days, participants completed a constant-load test involving running at a speed equivalent to 80% of their own maximum oxygen consumption (VO(2)max). During this constant-load test, RPE, heart rate (HR), VO2, pulmonary ventilation (VE), respiratory exchange ratio (RER), and ventilatory threshold (VT) were continuously monitored. TTE was recorded at the end of the test. TTEs were significantly longer in the tDCS than in the sham conditions (21.18 +/- 7.13 min; 18.44 +/- 6.32 min; p = 0.011). For TTE, no significant differences were found in RPE between conditions at isotime. In addition, no significant differences in HR, VO2, VE, RER, and VT were found during TTE between the two stimulation conditions at any time point. These results indicate that the application of tDCS does not induce a change of the exercise performance-related index; however, it can affect the increase of the exercise duration due to the stimuli in the M1 area.	[Park, Seung-Bo; Kim, Bokyung] Konkuk Univ, Dept Physiol, KU Open Innovat Ctr, Res Inst Med Sci,Sch Med, Chungju, Chungbuk, South Korea; [Sung, Dong Jun] Konkuk Univ, Div Sport & Hlth Sci, Coll Biomed & Hlth Sci, Chungju, Chungbuk, South Korea; [Kim, SoJung] Univ Massachusetts, Dept Phys Therapy & Kinesiol, Coll Hlth Sci, Lowell, MA USA; [Han, Joung-Kyue] Chung Ang Univ, Coll Sport Sci, Anseong, Gyoenggi, South Korea	Konkuk University; Konkuk University Medical Center; Konkuk University; University of Massachusetts System; University of Massachusetts Lowell; Chung Ang University	Han, JK (corresponding author), Chung Ang Univ, Coll Sport Sci, Anseong, Gyoenggi, South Korea.	jkhan@cau.ac.kr		sung, dongjun/0000-0001-6390-454X				Abdelmoula A, 2016, NEUROSCIENCE, V322, P94, DOI 10.1016/j.neuroscience.2016.02.025; Amann M, 2011, J PHYSIOL-LONDON, V589, P5299, DOI 10.1113/jphysiol.2011.213769; Amann M, 2009, J PHYSIOL-LONDON, V587, P271, DOI 10.1113/jphysiol.2008.163303; American College of Sports Medicine, 2017, ACSMS EX TEST PRESCR, V10th; Angius L., 2016, P PHYSL SOC, V35, pC03, DOI DOI 10.1016/J.BRS.2017.09.017; Angius L, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00090; Angius L, 2015, EUR J APPL PHYSIOL, V115, P2311, DOI 10.1007/s00421-015-3212-y; Barwood MJ, 2016, BRAIN STIMUL, V9, P842, DOI 10.1016/j.brs.2016.07.006; Boggio PS, 2008, EUR J NEUROL, V15, P1124, DOI 10.1111/j.1468-1331.2008.02270.x; Boggio PS, 2009, J NEUROL NEUROSUR PS, V80, P444, DOI 10.1136/jnnp.2007.141853; Boggio PS, 2008, INT J NEUROPSYCHOPH, V11, P249, DOI 10.1017/S1461145707007833; Boggio PS, 2009, NEUROPSYCHOLOGIA, V47, P212, DOI 10.1016/j.neuropsychologia.2008.07.022; Cogiamanian F, 2007, EUR J NEUROSCI, V26, P242, DOI 10.1111/j.1460-9568.2007.05633.x; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; de Morree HM, 2014, J APPL PHYSIOL, V117, P1514, DOI 10.1152/japplphysiol.00898.2013; de Morree HM, 2012, PSYCHOPHYSIOLOGY, V49, P1242, DOI 10.1111/j.1469-8986.2012.01399.x; Edwards DJ, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00243; Feeser M, 2014, BRAIN STIMUL, V7, P105, DOI 10.1016/j.brs.2013.08.006; Gandevia SC, 2001, PHYSIOL REV, V81, P1725, DOI 10.1152/physrev.2001.81.4.1725; George MS, 2010, NEUROPSYCHOPHARMACOL, V35, P301, DOI 10.1038/npp.2009.87; Glass S., 2007, ACSMS METABOLIC CALC, P111; Hopkins WG, 2002, SCALE MAGNITUDE EFFE; Jatupaiboon N, 2013, SCI WORLD J, DOI 10.1155/2013/618649; Jurcak V, 2007, NEUROIMAGE, V34, P1600, DOI 10.1016/j.neuroimage.2006.09.024; Lang N, 2005, EUR J NEUROSCI, V22, P495, DOI 10.1111/j.1460-9568.2005.04233.x; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Lorenz J, 2003, BRAIN, V126, P1079, DOI 10.1093/brain/awg102; Mauger AR, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00104; McMorris T, 2018, NEUROSCI BIOBEHAV R, V93, P93, DOI 10.1016/j.neubiorev.2018.03.024; Meinzer M, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00253; Montenegro RA, 2011, NEUROSCI LETT, V497, P32, DOI 10.1016/j.neulet.2011.04.019; Nitsche M A, 2012, Front Psychiatry, V3, P58, DOI 10.3389/fpsyt.2012.00058; Nitsche MA, 2003, SUPPL CLIN NEUROPHYS, V56, P255; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Ohuchi H, 1996, PEDIATR CARDIOL, V17, P7, DOI 10.1007/s002469900002; Okano AH, 2017, INT J SPORTS MED, V38, P493, DOI 10.1055/s-0042-121897; Okano AH, 2015, BRIT J SPORT MED, V49, P1213, DOI 10.1136/bjsports-2012-091658; Pena-Gomez C, 2012, BRAIN STIMUL, V5, P252, DOI 10.1016/j.brs.2011.08.006; Polania R, 2012, HUM BRAIN MAPP, V33, P2499, DOI 10.1002/hbm.21380; Reardon S, 2016, NATURE, V531, P283, DOI 10.1038/nature.2016.19534; Rosenkranz K, 2000, NEUROSCI LETT, V296, P61, DOI 10.1016/S0304-3940(00)01621-9; Rosenthal R, 1994, HDB RES SYNTHESIS, P231; Salehinejad MA, 2017, J AFFECT DISORDERS, V210, P241, DOI 10.1016/j.jad.2016.12.036; Tanaka S, 2011, NEUROREHAB NEURAL RE, V25, P565, DOI 10.1177/1545968311402091; Tanaka S, 2009, EXP BRAIN RES, V196, P459, DOI 10.1007/s00221-009-1863-9; Vitor-Costa M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144916; Williams PS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081418; Zandieh A, 2013, NEUROMODULATION, V16, P345, DOI 10.1111/ner.12009	48	22	23	2	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2019	14	2							e0211902	10.1371/journal.pone.0211902	http://dx.doi.org/10.1371/journal.pone.0211902			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM8DR	30794568	Green Published, gold, Green Submitted			2023-01-03	WOS:000459709100026
J	Ramazzotti, D; Clardy, P; Celi, LA; Stone, DJ; Rudin, RS				Ramazzotti, Daniele; Clardy, Peter; Celi, Leo Anthony; Stone, David J.; Rudin, Robert S.			Withholding or withdrawing invasive interventions may not accelerate time to death among dying ICU patients	PLOS ONE			English	Article							INTENSIVE-CARE; LIFE-SUPPORT; END	Background Critically ill patients may die despite invasive intervention. In this study, we examine trends in the application of two such treatments over a decade, namely, endotracheal ventilation and vasopressors and inotropes administration, as well as the impact of these trends on survival durations in patients who die within a month of ICU admission. Methods We considered observational data available from the MIMIC-III open-access ICU database and collected within a study period between year 2002 up to 2011. If a patient had multiple admissions to the ICU during the 30 days before death, only the first stay was analyzed, leading to a final set of 6,436 unique ICU admissions during the study period. We tested two hypotheses: (i) administration of invasive intervention during the ICU stay immediately preceding end-of-life would decrease over the study time period and (ii) time-to-death from ICU admission would also decrease, due to the decrease in invasive intervention administration. To investigate the latter hypothesis, we performed a subgroups analysis by considering patients with lowest and highest severity. To do so, we stratified the patients based on their SAPS I scores, and we considered patients within the first and the third tertiles of the score. We then assessed differences in trends within these groups between years 2002-05 vs. 2008-11. Results Comparing the period 2002-2005 vs. 2008-2011, we found a reduction in endotracheal ventilation among patients who died within 30 days of ICU admission (120.8 vs. 68.5 hours for the lowest severity patients, p<0.001; 47.7 vs. 46.0 hours for the highest severity patients, p = 0.004). This is explained in part by an increase in the use of non-invasive ventilation. Comparing the period 2002-2005 vs. 2008-2011, we found a reduction in the use of vasopressors and inotropes among patients with the lowest severity who died within 30 days of ICU admission (41.8 vs. 36.2 hours, p<0.001) but not among those with the highest severity. Despite a reduction in the use of invasive interventions, we did not find a reduction in the time to death between 2002-2005 vs. 2008-2011 (7.8 days vs. 8.2 days for the lowest severity patients, p = 0.32; 2.1 days vs. 2.0 days for the highest severity patients, p = 0.74). Conclusion We found that the reduction in the use of invasive treatments over time in patients with very poor prognosis did not shorten the time-to-death. These findings may be useful for goals of care discussions.	[Ramazzotti, Daniele] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; [Clardy, Peter] Mt Auburn Hosp, Dept Med, Div Pulm & Crit Care, Cambridge, MA USA; [Clardy, Peter] Mt Auburn Hosp, Dept Med Educ, Div Pulm & Crit Care, Cambridge, MA USA; [Clardy, Peter] Harvard Med Sch, Boston, MA USA; [Celi, Leo Anthony] MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Stone, David J.] Univ Virginia, Sch Med, Dept Anesthesiol, Charlottesville, VA 22908 USA; [Stone, David J.] Univ Virginia, Sch Med, Dept Neurol Surg, Charlottesville, VA 22908 USA; [Rudin, Robert S.] RAND Corp, Boston, MA USA	Stanford University; Harvard University; Mount Auburn Hospital; Harvard University; Mount Auburn Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); University of Virginia; University of Virginia; RAND Corporation	Celi, LA (corresponding author), MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	lceli@mit.edu		RAMAZZOTTI, DANIELE/0000-0002-6087-2666; Clardy, Peter/0000-0003-4347-4372	National Institutes of Health through NIBIB [EB017205-01A1]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB017205] Funding Source: NIH RePORTER	National Institutes of Health through NIBIB(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This work was supported by the National Institutes of Health through NIBIB R01 grant EB017205-01A1 to LAC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angus DC, 2004, CRIT CARE MED, V32, P638, DOI 10.1097/01.CCM.0000114816.62331.08; Box Fisher, 1987, STAT SCI, V2, P45, DOI [10.1214/ss/1177013437, DOI 10.1214/SS/1177013437]; Cook D, 2003, NEW ENGL J MED, V349, P1123, DOI 10.1056/NEJMoa030083; Digwood G, 2011, PALLIAT SUPPORT CARE, V9, P387, DOI 10.1017/S147895151100040X; Gilmer T, 2005, HEALTH AFFAIR, V24, P961, DOI 10.1377/hlthaff.24.4.961; Johnson AEW, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.35; LEGALL JR, 1984, CRIT CARE MED, V12, P975; Lesieur O., 2018, J CRITICAL CARE; Moore BJ, 2017, MED CARE, V55, P698, DOI 10.1097/MLR.0000000000000735; Pearson K, 1900, PHILOS MAG, V50, P157, DOI 10.1080/14786440009463897; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Wilson ME, 2018, CRIT CARE MED, V46, P1209, DOI 10.1097/CCM.0000000000003082	15	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2019	14	2							e0212439	10.1371/journal.pone.0212439	http://dx.doi.org/10.1371/journal.pone.0212439			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL5JX	30763372	Green Published, gold, Green Submitted			2023-01-03	WOS:000458763900081
J	Weber, T; Green, DA; Attias, J; Sies, W; Frechette, A; Braunstein, B; Rittweger, J				Weber, Tobias; Green, David A.; Attias, Julia; Sies, Wolfram; Frechette, Alexandre; Braunstein, Bjoern; Rittweger, Joern			Hopping in hypogravity - A rationale for a plyometric exercise countermeasure in planetary exploration missions	PLOS ONE			English	Article							BED-REST; BONE LOSS; GRAVITY; ADAPTATIONS; PRESSURE; SPACE; MOON; JUMP	Moon and Mars are considered to be future targets for human space explorations. The gravity level on the Moon and Mars amount to 16% and 38%, respectively, of Earth's gravity. Mechanical loading during the anticipated habitual activities in these hypogravity environments will most likely not be sufficient to maintain physiological integrity of astronauts unless additional exercise countermeasures are performed. Current microgravity exercise countermeasures appear to attenuate but not prevent 'space deconditioning'. However, plyometric exercises (hopping and whole body vibration) have shown promise in recent analogue bed rest studies and may be options for space exploration missions where resources will be limited compared to the ISS. This paper therefore tests the hypothesis that plyometric hop exercise in hypogravity can generate sufficient mechanical stimuli to prevent musculoskeletal deconditioning. It has been suggested that hypogravity-induced reductions in peak ground reaction force (peak vertical GRF) can be offset by increases in hopping height. Therefore, this study investigated the effects of simulated hypogravity (0.16G, 0.27G, 0.38G, and 0.7G) upon sub-maximal plyometric hopping on the Verticalised Treadmill Facility, simulating different hypogravity levels. Results show that peak vertical GRF are negatively related to simulated gravity level, but positively to hopping height. Contact times decreased with increasing gravity level but were not influenced through hopping height. In contrast, flight time increased with decreasing gravity levels and increasing hopping height (P < 0.001). The present data suggest that the anticipated hypogravity-related reductions of musculoskeletal forces during normal walking can be compensated by performing hops and therefore support the idea of plyometric hopping as a robust and resourceful exercise countermeasure in hypogravity. As maximal hop height was constrained on the VTF further research is needed to determine whether similar relationships are evident during maximal hops and other forms of jumping.	[Weber, Tobias; Green, David A.; Frechette, Alexandre] European Space Agcy, European Astronaut Ctr, Space Med Team HRE, Cologne, Germany; [Weber, Tobias; Green, David A.; Frechette, Alexandre] KBRwyle GmbH, Cologne, Germany; [Attias, Julia] Kings Coll London, Ctr Appl Physiol Sci CHAPS, London, England; [Sies, Wolfram; Rittweger, Joern] German Aerosp Ctr DLR, Inst Aerosp Med, Cologne, Germany; [Braunstein, Bjoern] German Sport Univ Cologne, Inst Biomech & Orthopaed, Cologne, Germany; [Braunstein, Bjoern] Ctr Hlth & Integrat Physiol Space CHIPS, Cologne, Germany; [Rittweger, Joern] Univ Cologne, Dept Pediat & Adolescent Med, Cologne, Germany	European Space Agency; University of London; King's College London; Helmholtz Association; German Aerospace Centre (DLR); German Sport University Cologne; University of Cologne	Weber, T (corresponding author), European Space Agcy, European Astronaut Ctr, Space Med Team HRE, Cologne, Germany.; Weber, T (corresponding author), KBRwyle GmbH, Cologne, Germany.	tobias.weber@esa.int	Rittweger, Jörn/A-4308-2009; Braunstein, Bjoern/D-7142-2013	Rittweger, Jörn/0000-0002-2223-8963; Braunstein, Bjoern/0000-0002-5173-8916; Weber, Tobias/0000-0002-3015-3468	ESA's Space Medicine Team (HRE-OM)	ESA's Space Medicine Team (HRE-OM)	The study has been funded by ESA's Space Medicine Team (HRE-OM) and is part of the 'Moon Gym Project'.	Astrobotic, PER LUN LAND PAYL US; Belavy DL, 2011, J MUSCULOSKEL NEURON, V11, P215; Belavy DL, 2011, OSTEOPOROSIS INT, V22, P1581, DOI 10.1007/s00198-010-1371-6; CAVAGNA GA, 1972, AEROSPACE MED, V43, P408; Clement G, 2011, SPACE TECHNOL LIB, V23, P1, DOI 10.1007/978-1-4419-9905-4; Cochrane DJ, 2011, J SPORT SCI MED, V10, P19; Cutuk A, 2006, J APPL PHYSIOL, V101, P771, DOI 10.1152/japplphysiol.00644.2005; Frost HM, 2003, ANAT REC PART A, V275A, P1081, DOI 10.1002/ar.a.10119; Genc KO, 2010, J BIOMECH, V43, P3020, DOI 10.1016/j.jbiomech.2010.06.028; Goodman CA, 2015, BONE, V80, P24, DOI 10.1016/j.bone.2015.04.014; Gosseye TP, 2010, EUR J APPL PHYSIOL, V110, P709, DOI 10.1007/s00421-010-1549-9; Jones H., 2017, 47 INT C ENV SYST, P16; Korth DW, 2015, AEROSP MED HUM PERF, V86, pA7, DOI 10.3357/AMHP.EC02.2015; Kramer A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13659-8; Larson WJ, 1999, HUMAN SPACEFLIGHT MI, DOI [10.1016/j.bone.2009.08.051, DOI 10.1016/J.BONE.2009.08.051]; Markovic G, 2010, SPORTS MED, V40, P859, DOI 10.2165/11318370-000000000-00000; Mosley JR, 1998, BONE, V23, P313, DOI 10.1016/S8756-3282(98)00113-6; Petersen N, 2016, EXTREME PHYSIOL MED, V5, DOI 10.1186/s13728-016-0050-4; Richter K, 2017, FRONT PSYCHOL, V8, DOI [10.3389/fpsyg.2017.00575, 10.3389/fphys.2017.00583]; Rittweger J, 2010, BONE, V46, P137, DOI 10.1016/j.bone.2009.08.051; Ritzmann R, 2016, J APPL PHYSIOL, V121, P1187, DOI 10.1152/japplphysiol.00692.2016; Salles AS, 2011, EUR J APPL PHYSIOL, V111, P441, DOI 10.1007/s00421-010-1665-6; Smith SM, 2008, BONE, V42, P572, DOI 10.1016/j.bone.2007.11.015; Vanrenterghem J, 2004, HUM MOVEMENT SCI, V22, P713, DOI 10.1016/j.humov.2003.11.001; Whitley R, 2017, GLOBAL EXPLORATION R; Witzke KA, 2000, MED SCI SPORT EXER, V32, P1051, DOI 10.1097/00005768-200006000-00003; Woerner J., 2016, MOON VILLAGE VISION; Yang PF, 2014, MED ENG PHYS, V36, P1041, DOI 10.1016/j.medengphy.2014.05.005; Yang PF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094525	29	11	11	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2019	14	2							e0211263	10.1371/journal.pone.0211263	http://dx.doi.org/10.1371/journal.pone.0211263			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL5IX	30759113	Green Accepted, gold, Green Published, Green Submitted			2023-01-03	WOS:000458761300035
J	Hellmann, MD; Snyder, A				Hellmann, Matthew D.; Snyder, Alexandra			Adding to the checkpoint blockade armamentarium	NATURE MEDICINE			English	Editorial Material							EXPRESSION; RECEPTORS; CANCER		[Hellmann, Matthew D.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Hellmann, Matthew D.] Weill Cornell Med Coll, New York, NY USA; [Snyder, Alexandra] Merck, Rahway, NJ 07065 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Merck & Company	Snyder, A (corresponding author), Merck, Rahway, NJ 07065 USA.	alex.snyder@merck.com						Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014; Bastidas-Legarda LY, 2019, IMMUNOLOGY, V156, P319, DOI 10.1111/imm.13039; Bossard C, 2012, INT J CANCER, V131, P855, DOI 10.1002/ijc.26453; Gooden M, 2011, P NATL ACAD SCI USA, V108, P10656, DOI 10.1073/pnas.1100354108; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Gunturi A, 2005, EUR J IMMUNOL, V35, P766, DOI 10.1002/eji.200425735; Kim N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02041; Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426; Massarelli E, 2019, JAMA ONCOL, V5, P67, DOI 10.1001/jamaoncol.2018.4051; van Montfoort N, 2018, CELL, V175, P1744, DOI 10.1016/j.cell.2018.10.028; Vermorken JB, 2007, J CLIN ONCOL, V25, P2171, DOI 10.1200/JCO.2006.06.7447	11	4	4	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2019	25	2					203	205		10.1038/s41591-019-0350-5	http://dx.doi.org/10.1038/s41591-019-0350-5			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	HK3TW	30728540				2023-01-03	WOS:000457842100013
J	Chitapanarux, I; Nobnop, W; Tippanya, D; Sripan, P; Chakrabandhu, S; Klunklin, P; Onchan, W; Jia-Mahasap, B; Tharavichitkul, E				Chitapanarux, Imjai; Nobnop, Wannapha; Tippanya, Damrongsak; Sripan, Patumrat; Chakrabandhu, Somvilai; Klunklin, Pitchayaponne; Onchan, Wimrak; Jia-Mahasap, Bongkot; Tharavichitkul, Ekkasit			Clinical outcomes and dosimetric study of hypofractionated Helical TomoTherapy in breast cancer patients	PLOS ONE			English	Article							RADIOTHERAPY; TOXICITY; THERAPY	We present a single center's experience of treatment outcomes and dosimetric parameters for breast cancer patients treated with hypofractionated Helical TomoTherapy (HT). This is a retrospective study of one hundred and thirty-six patients with invasive breast cancer treated between March 2012 and October 2016. Dosimetric parameters and 3-year loco-regional failure free survival (LRFFS) were analyzed. Dose to ipsilateral lung, heart and contralateral breast as well as acute and late toxicities were recorded. The median follow-up time is 45 months (range: 5-83). Two patients had loco-regional failure. The 3-year LRFFS was 99%. Acute grade 1 and 2 skin toxicities occurred in 95% and 1%, respectively. Coverage of the target volumes was achieved with the mean +/- standard deviation (SD) of homogeneity and conformity index being 0.1 +/- 0.04, and 0.8 +/- 0.07, respectively. Dose to ipsilateral lung, contralateral breast, and heart was also within the limited constraints regardless of the complexity of target volumes. Only two percent of patients experienced late grade 2 skin toxicity. No late grade 2 subcutaneous tissue toxicity was found. Nine percent of patients developed late grade 1 lung toxicity. Hypofractionated radiotherapy using Helical TomoTherapy in breast irradiation provides excellent 3-year LRFFS and minimal acute and late toxicities. A careful, longer follow-up of healthy tissue effects to lung, heart, and contralateral breast is warranted.	[Chitapanarux, Imjai; Nobnop, Wannapha; Tippanya, Damrongsak; Chakrabandhu, Somvilai; Klunklin, Pitchayaponne; Onchan, Wimrak; Jia-Mahasap, Bongkot; Tharavichitkul, Ekkasit] Chiang Mai Univ, Fac Med, Dept Radiol, Div Radiat Oncol, Chiang Mai, Thailand; [Chitapanarux, Imjai; Sripan, Patumrat] Chiang Mai Univ, Fac Med, NTRG RO, Chiang Mai, Thailand; [Chitapanarux, Imjai] Chiang Mai Univ, Fac Med, Maharaj Nakorn Chiang Mai Hosp, Chiang Mai Canc Registry, Chiang Mai, Thailand	Chiang Mai University; Chiang Mai University; Chiang Mai University	Chitapanarux, I (corresponding author), Chiang Mai Univ, Fac Med, Dept Radiol, Div Radiat Oncol, Chiang Mai, Thailand.; Chitapanarux, I (corresponding author), Chiang Mai Univ, Fac Med, NTRG RO, Chiang Mai, Thailand.; Chitapanarux, I (corresponding author), Chiang Mai Univ, Fac Med, Maharaj Nakorn Chiang Mai Hosp, Chiang Mai Canc Registry, Chiang Mai, Thailand.	imjai@hotmail.com	Onchan, Wimrak/N-7072-2018; Sripan, Patumrat/HDS-9297-2022	Onchan, Wimrak/0000-0001-5174-4403; Sripan, Patumrat/0000-0002-8337-9524; , Ekkasit/0000-0002-5495-1421				Cammarota F, 2014, ANTICANCER RES, V34, P1233; Cendales R, 2011, CLIN TRANSL ONCOL, V13, P268, DOI 10.1007/s12094-011-0652-7; Chargari C, 2011, CANCER TREAT REV, V37, P321, DOI 10.1016/j.ctrv.2010.08.007; Chira C, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/264306; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; Duma MN, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-016-0736-1; Early Breast Canc Trialists Collaborat, 2000, LANCET, V355, P1757, DOI 10.1016/S0140-6736(00)02263-7; Forrest LJ, 2004, INT J RADIAT ONCOL, V60, P1639, DOI 10.1016/j.ijrobp.2004.08.016; Giordano SH, 2005, JNCI-J NATL CANCER I, V97, P419, DOI 10.1093/jnci/dji067; Goddu SM, 2009, RADIOTHER ONCOL, V93, P64, DOI 10.1016/j.radonc.2009.07.013; Goddu SM, 2009, INT J RADIAT ONCOL, V73, P1243, DOI 10.1016/j.ijrobp.2008.11.004; Haciislamoglu E, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2314-2; Haciislamoglu E, 2015, PHYS MEDICA, V31, P360, DOI 10.1016/j.ejmp.2015.02.005; Hijal T, 2010, RADIOTHER ONCOL, V94, P300, DOI 10.1016/j.radonc.2009.12.043; Kestin LL, 2000, INT J RADIAT ONCOL, V48, P1559, DOI 10.1016/S0360-3016(00)01396-1; MACKIE TR, 1993, MED PHYS, V20, P1709, DOI 10.1118/1.596958; Mahan SL, 2005, INT J RADIAT ONCOL, V63, P1576, DOI 10.1016/j.ijrobp.2005.05.015; Nagai A, 2017, J RADIAT RES, V58, P529, DOI 10.1093/jrr/rrw132; Qiu J, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/513708; RTOG, 2018, BREAST CANC ATL RAD; Taylor CW, 2009, INT J RADIAT ONCOL, V73, P1061, DOI 10.1016/j.ijrobp.2008.05.066; Zhou GX, 2011, TECHNOL CANCER RES T, V10, P15, DOI 10.7785/tcrt.2012.500174	23	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2019	14	1							e0211578	10.1371/journal.pone.0211578	http://dx.doi.org/10.1371/journal.pone.0211578			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ6LR	30703145	Green Submitted, gold, Green Published			2023-01-03	WOS:000457301600060
J	Masomi-Bornwasser, J; Winter, P; Neulen, A; Kantelhardt, SR; Konig, J; Kempski, O; Ringel, F; Keric, N				Masomi-Bornwasser, Julia; Winter, Philipp; Neulen, Axel; Kantelhardt, Sven R.; Koenig, Jochem; Kempski, Oliver; Ringel, Florian; Keric, Naureen			Doppler sonography enhances rtPA-induced fibrinolysis in an in vitro clot model of spontaneous intracerebral hemorrhages	PLOS ONE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; INITIAL CONSERVATIVE TREATMENT; INDEPENDENT ULTRASOUND DEVICE; MINIMALLY INVASIVE EVACUATION; EARLY SURGERY; THROMBOLYSIS; SAFETY; SONOTHROMBOLYSIS; ASPIRATION; HEMATOMA	Background Transcranial Doppler (TCD) was shown to enhance intravascular fibrinolysis by rtPA in ischemic stroke. Studies revealed that catheter- based administration of rtPA induces lysis of intracerebral hemorrhages (ICH). However, it is unknown whether TCD would be suitable to enhance rtPA-induced fibrinolysis in patients with ICH. The aim of this study was to assess the potential of TCD to enhance rtPA-induced fibrinolysis in an in vitro clot system. Methods Reproducible human blood clots of 25 ml were incubated in a water bath at 37 degrees C during treatments. They were weighed before and after 6 different treatments: (I) control (incubation only), (II) rtPA only, (III) one Doppler probe, (IV) two Doppler probes placed vis-a-vis, (V) one probe and rtPA and (VI) two probes and rtPA. To quantify lysis of the blood clots and attenuation of the Doppler through a temporal squama acoustic peak rarefaction pressure (APRP) was measured in the field of the probes. Temperature was assessed to evaluate possible side effects. Results Clot weight was reduced in all groups. The control group had the highest relative end weight of 70.2%+/- 7.2% compared to all other groups (p<0,0001). Most efficient lysis was achieved using (VI) 2 probes and rtPA 36.3%+/- 4.4% compared to (II, III, IV) (p<0.0001; p = 0.0002; p = 0.048). APRP was above lysis threshold (535.5 +/- 7.2 kPa) using 2 probes even through the temporal squama (731.6 +/- 32.5 kPa) (p = 0.0043). There was a maximal temperature elevation of 0.17 +/- 0.07 degrees C using both probes. Conclusions TCD significantly enhances rtPA-induced lysis of blood clots, and the effect is amplified by using multiple probes. Our results indicate that bitemporal TCD insonation of hematomas could be a new and safe approach to enhance fibrinolysis of ICH's treated with intralesional catheter and rtPA.	[Masomi-Bornwasser, Julia; Winter, Philipp; Neulen, Axel; Kantelhardt, Sven R.; Ringel, Florian; Keric, Naureen] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Neurosurg, Mainz, Germany; [Koenig, Jochem] Johannes Gutenberg Univ Mainz, Univ Med Ctr, IMBEI, Mainz, Germany; [Kempski, Oliver] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Neurosurg Pathophysiol, Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Masomi-Bornwasser, J (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Neurosurg, Mainz, Germany.	Julia.Masomi@unimedizin-mainz.de	Ringel, Florian/E-4933-2014; König, Jochem/T-3500-2019	König, Jochem/0000-0003-4683-0360; Masomi-Bornwasser, Julia/0000-0003-1955-9827; Neulen, Axel/0000-0003-3547-1630				Abdu E, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS11362; Alexandrov AV, 2000, STROKE, V31, P610, DOI 10.1161/01.STR.31.3.610; Alexandrov AV, 2004, NEW ENGL J MED, V351, P2170, DOI 10.1056/NEJMoa041175; Ammi AY, 2008, ULTRASOUND MED BIOL, V34, P1578, DOI 10.1016/j.ultrasmedbio.2008.02.012; Bardon P, 2014, BIOMED PAP, V158, P233, DOI 10.5507/bp.2012.064; Barlinn K, 2013, STROKE, V44, P1641, DOI 10.1161/STROKEAHA.113.001122; Barlinn K, 2013, J CLIN ULTRASOUND, V41, P354, DOI 10.1002/jcu.21978; Barreto AD, 2013, STROKE, V44, P3376, DOI 10.1161/STROKEAHA.113.002713; Braaten JV, 1997, THROMB HAEMOSTASIS, V78, P1063; Cintas P, 2002, STROKE, V33, P626, DOI 10.1161/hs0202.103073; Culjat MO, 2010, ULTRASOUND MED BIOL, V36, P861, DOI 10.1016/j.ultrasmedbio.2010.02.012; Daffertshofer M, 2005, STROKE, V36, P1441, DOI 10.1161/01.STR.0000170707.86793.1a; Eggers J, 2003, ANN NEUROL, V53, P797, DOI 10.1002/ana.10590; Fernandes HM, 2000, ACT NEUR S, V76, P463; Fiorella D, 2015, J NEUROINTERV SURG, V7, P752, DOI 10.1136/neurintsurg-2014-011358; FRANCIS CW, 1995, ULTRASOUND MED BIOL, V21, P419, DOI 10.1016/0301-5629(94)00119-X; Gregson BA, 2012, STROKE, V43, P1496, DOI 10.1161/STROKEAHA.111.640284; Hanley DF, 2016, LANCET NEUROL, V15, P1226, DOI 10.1016/S1474-4422(16)30234-4; Heit JJ, 2017, J STROKE, V19, P11, DOI 10.5853/jos.2016.00563; Huda W, 2010, REV RADIOLOGIC PHYS; Keric N, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5472936; LIPPITZ BE, 1994, ACTA NEUROCHIR, V127, P157, DOI 10.1007/BF01808759; Masomi-Bornwasser J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188131; Mendelow AD, 2013, LANCET, V382, P397, DOI 10.1016/S0140-6736(13)60986-1; Mendelow AD, 2005, LANCET, V365, P387; Meunier JM, 2011, CURR NEUROVASC RES, V8, P305; Morgan T, 2008, ACTA NEUROCHIR SUPPL, V105, P147; Nedelmann M, 2008, ULTRASOUND MED BIOL, V34, P2019, DOI 10.1016/j.ultrasmedbio.2008.06.003; Neulen A, 2016, CLIN NEUROL NEUROSUR, V145, P14, DOI 10.1016/j.clineuro.2016.03.012; Newell DW, 2011, J NEUROSURG, V115, P592, DOI 10.3171/2011.5.JNS10505; Pfaffenberger S, 2005, STROKE, V36, P124, DOI 10.1161/01.STR.0000150503.10480.a7; Pieters M, 2004, ULTRASOUND MED BIOL, V30, P1545, DOI 10.1016/j.ultrasmedbio.2004.08.028; Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8; Rohde V, 2002, J NEUROSURG, V97, P954, DOI 10.3171/jns.2002.97.4.0954; Soltani A, 2011, J THROMB THROMBOLYS, V31, P71, DOI 10.1007/s11239-010-0483-3; Thiex R, 2004, J NEUROL, V251, P1443, DOI 10.1007/s00415-004-0554-5; Wagner KR, 1999, J NEUROSURG, V90, P491, DOI 10.3171/jns.1999.90.3.0491; Wilhelm-Schwenkmezger T, 2007, STROKE, V38, P1031, DOI 10.1161/01.STR.0000257966.32242.0b; Xiao Fang, 2015, Zhonghua Yi Xue Za Zhi, V95, P1135	39	3	3	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2019	14	1							e0210810	10.1371/journal.pone.0210810	http://dx.doi.org/10.1371/journal.pone.0210810			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH8WT	30653589	Green Published, Green Submitted, gold			2023-01-03	WOS:000456015500075
J	Saygin, C; Matei, D; Majeti, R; Reizes, O; Lathia, JD				Saygin, Caner; Matei, Daniela; Majeti, Ravindra; Reizes, Ofer; Lathia, Justin D.			Targeting Cancer Stemness in the Clinic: From Hype to Hope	CELL STEM CELL			English	Review							GAMMA-SECRETASE INHIBITOR; ACUTE MYELOID-LEUKEMIA; PHASE-I TRIAL; TUMOR-INITIATING CELLS; OVARIAN-CANCER; THERAPEUTIC TARGET; HEDGEHOG INHIBITOR; CLONAL EVOLUTION; DOSE-ESCALATION; BREAST CANCERS	Tumors are composed of non-homogeneous cell populations exhibiting varying degrees of genetic and functional heterogeneity. Cancer stem cells (CSCs) are capable of sustaining tumors by manipulating genetic and non-genetic factors to metastasize, resist treatment, and maintain the tumor microenvironment. Understanding the key traits and mechanisms of CSC survival provides opportunities to improve patient outcomes via improved prognostic models and therapeutics. Here, we review the clinical significance of CSCs and results of potential CSC-targeting therapies in various cancers. We discuss barriers to translating cues from pre-clinical models into clinical applications and propose new strategies for rational design of future anti-CSC trials.	[Saygin, Caner] Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; [Matei, Daniela] Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA; [Majeti, Ravindra] Stanford Univ, Sch Med, Dept Med, Canc Inst,Div Hematol, Stanford, CA 94305 USA; [Majeti, Ravindra] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA; [Reizes, Ofer; Lathia, Justin D.] Cleveland Clin, Dept Cellular & Mol Med, Cleveland, OH 44192 USA	University System of Ohio; Ohio State University; Northwestern University; Feinberg School of Medicine; Stanford University; Stanford University; Cleveland Clinic Foundation	Lathia, JD (corresponding author), Cleveland Clin, Dept Cellular & Mol Med, Cleveland, OH 44192 USA.	lathiaj@ccf.org	Reizes, Ofer/ABA-4179-2021; Lathia, Justin/AHB-8296-2022	Reizes, Ofer/0000-0003-0075-6871; Matei, Daniela/0000-0003-2169-5035; Majeti, Ravindra/0000-0002-5814-0984	NIH [CA 191263]; NCI [CA198409]; Leukemia and Lymphoma Society; Cleveland Clinic Foundation; Laura J. Fogarty Endowed Chair for Uterine Cancer Research; Lurie Cancer Center's Diana Princess of Wales Endowed Chair for Cancer Research; Cleveland Clinic VeloSano Bike Race;  [R01 CA188055]; NATIONAL CANCER INSTITUTE [R01CA188055] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000792] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Cleveland Clinic Foundation; Laura J. Fogarty Endowed Chair for Uterine Cancer Research; Lurie Cancer Center's Diana Princess of Wales Endowed Chair for Cancer Research; Cleveland Clinic VeloSano Bike Race; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	We regret omitting many reports due to space constraints. We would like to thank Amanda Mendelsohn from Cleveland Clinic Center for Medical Art and Photography for her exceptional help with the figures of this manuscript. This work was funded by NIH grant CA 191263 (O.R. and J.D.L.), NCI CA198409 (D.M.), R01 CA188055 (R.M.), Scholar Award from the Leukemia and Lymphoma Society (R.M.), Cleveland Clinic Foundation, Cleveland Clinic VeloSano Bike Race, the Laura J. Fogarty Endowed Chair for Uterine Cancer Research (O.R.), and the Lurie Cancer Center's Diana Princess of Wales Endowed Chair for Cancer Research (D.M.).	Abelson S, 2018, NATURE, V559, P400, DOI 10.1038/s41586-018-0317-6; ANDREEFF M, 2014, J CLIN ONCOL S, V32; Ayub TH, 2015, ONCOTARGET, V6, P16437, DOI 10.18632/oncotarget.4103; Berlin J, 2013, CLIN CANCER RES, V19, P258, DOI 10.1158/1078-0432.CCR-12-1800; Bogdahn U, 2011, NEURO-ONCOLOGY, V13, P132, DOI 10.1093/neuonc/noq142; Brana I, 2014, BRIT J CANCER, V111, P1932, DOI 10.1038/bjc.2014.497; Brandes AA, 2016, NEURO-ONCOLOGY, V18, P1146, DOI 10.1093/neuonc/now009; Brooks MD, 2015, CELL STEM CELL, V17, P260, DOI 10.1016/j.stem.2015.08.014; Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625; Catenacci DVT, 2015, J CLIN ONCOL, V33, P4284, DOI 10.1200/JCO.2015.62.8719; Chaffer CL, 2015, CANCER DISCOV, V5, P22, DOI 10.1158/2159-8290.CD-14-0788; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chao MP, 2012, CURR OPIN IMMUNOL, V24, P225, DOI 10.1016/j.coi.2012.01.010; Choi MY, 2018, CELL STEM CELL, V22, P951, DOI 10.1016/j.stem.2018.05.018; Cook N, 2014, J CLIN ONCOL S, V32; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Cremona CA, 2016, SEMIN CANCER BIOL, V36, P52, DOI 10.1016/j.semcancer.2015.09.006; De Jesus-Acosta A, 2014, INVEST NEW DRUG, V32, P739, DOI 10.1007/s10637-014-0083-8; Deangelo D., 2006, J CLIN ONCOL, V24, P6585; Deng S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010277; Dhodapkar MV, 2015, BLOOD, V126, P2475, DOI 10.1182/blood-2015-03-632919; Diaz-Padilla I, 2015, GYNECOL ONCOL, V137, P216, DOI 10.1016/j.ygyno.2015.03.005; Dummer R, 2016, J AM ACAD DERMATOL, V75, P113, DOI 10.1016/j.jaad.2016.02.1226; FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301; Fouladi M, 2011, J CLIN ONCOL, V29, P3529, DOI 10.1200/JCO.2011.35.7806; Ge YJ, 2017, CELL, V169, P636, DOI 10.1016/j.cell.2017.03.042; Gentles AJ, 2010, JAMA-J AM MED ASSOC, V304, P2706, DOI 10.1001/jama.2010.1862; Geoerger B, 2012, ASCO ANN M ABSTRACTS, V30, P9519; GILMAN A, 1963, AM J SURG, V105, P574, DOI 10.1016/0002-9610(63)90232-0; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; GOUNDER MM, 2012, J CLIN ONCOL, V30; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Harless WW, 2011, CANCER CELL INT, V11, DOI 10.1186/1475-2867-11-1; Heiss MM, 2010, INT J CANCER, V127, P2209, DOI 10.1002/ijc.25423; Heuser M, 2009, BLOOD, V114, P3983, DOI 10.1182/blood-2009-06-227603; Ho TC, 2016, BLOOD, V128, P1671, DOI 10.1182/blood-2016-02-695312; Holyoake TL, 2017, BLOOD, V129, P1595, DOI 10.1182/blood-2016-09-696013; Houot R, 2016, ANN ONCOL, V27, P1349, DOI 10.1093/annonc/mdw138; Ishizawa K, 2010, CELL STEM CELL, V7, P279, DOI 10.1016/j.stem.2010.08.009; Jan M, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004315; Jimeno A, 2017, CLIN CANCER RES, V23, P7490, DOI 10.1158/1078-0432.CCR-17-2157; Jones CL, 2018, CANCER CELL, V34, P724, DOI 10.1016/j.ccell.2018.10.005; Jonker DJ, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.tps3660; Jung N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9489; Kaye SB, 2012, CLIN CANCER RES, V18, P6509, DOI 10.1158/1078-0432.CCR-12-1796; Kim EJ, 2014, CLIN CANCER RES, V20, P5937, DOI 10.1158/1078-0432.CCR-14-1269; Ko AH, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.e15721; Konopleva M, 2016, CANCER DISCOV, V6, P1106, DOI 10.1158/2159-8290.CD-16-0313; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Krop I, 2012, J CLIN ONCOL, V30, P2307, DOI 10.1200/JCO.2011.39.1540; Kummar S, 2017, J CLIN ONCOL, V35, P1561, DOI 10.1200/JCO.2016.71.1994; Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; LAURIE SA, 2014, J CLIN ONCOL S, V32; Lechman ER, 2016, CANCER CELL, V29, P214, DOI 10.1016/j.ccell.2015.12.011; Li JJ, 2017, CELL STEM CELL, V20, P303, DOI 10.1016/j.stem.2016.11.004; Liau BB, 2017, CELL STEM CELL, V20, P233, DOI 10.1016/j.stem.2016.11.003; Lindhofer H, 2009, J CLIN ONCOL, V27; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Magnani L, 2013, P NATL ACAD SCI USA, V110, pE1490, DOI 10.1073/pnas.1219992110; MATSUI WH, 2016, MEDICINE S1, V95, DOI DOI 10.1097/MD.0000000000004765; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Messersmith WA, 2015, CLIN CANCER RES, V21, P60, DOI 10.1158/1078-0432.CCR-14-0607; Mustjoki S, 2013, LEUKEMIA, V27, P1520, DOI 10.1038/leu.2013.19; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Ng SWK, 2016, NATURE, V540, P433, DOI 10.1038/nature20598; Niedzwiecki D, 2011, J CLIN ONCOL, V29, P3146, DOI 10.1200/JCO.2010.32.5357; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Pan E, 2016, J NEURO-ONCOL, V130, P571, DOI 10.1007/s11060-016-2263-1; Pan Q, 2015, STEM CELLS, V33, P2085, DOI 10.1002/stem.2039; Papayannidis C, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.80; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; PEMMARAJU N, 2016, BLOOD, V128; Peng DJ, 2016, CANCER RES, V76, P3156, DOI 10.1158/0008-5472.CAN-15-2528; Pietanza MC, 2016, LUNG CANCER, V99, P23, DOI 10.1016/j.lungcan.2016.04.014; Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015; Pollyea DA, 2018, NAT MED, V24, P1859, DOI 10.1038/s41591-018-0233-1; Pollyea DA, 2017, BLOOD, V129, P1627, DOI 10.1182/blood-2016-10-696039; Rich JN, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004764; Richardet M, 2015, J CLIN ONCOL, V33; Robinson GW, 2015, J CLIN ONCOL, V33, P2646, DOI 10.1200/JCO.2014.60.1591; Roudi R, 2014, CANCER BIOMARK, V14, P457, DOI 10.3233/CBM-140424; Sahebjam S, 2013, BRIT J CANCER, V109, P943, DOI 10.1038/bjc.2013.380; Saygin C, 2016, METHODS MOL BIOL, V1516, P319, DOI 10.1007/7651_2016_360; Schepers K, 2015, CELL STEM CELL, V16, P254, DOI 10.1016/j.stem.2015.02.014; Schmidt M, 2010, ANN ONCOL, V21, P275, DOI 10.1093/annonc/mdp314; Schott AF, 2017, CLIN CANCER RES, V23, P5358, DOI 10.1158/1078-0432.CCR-16-2748; Schott AF, 2013, CLIN CANCER RES, V19, P1512, DOI 10.1158/1078-0432.CCR-11-3326; Schulenburg A, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0113-9; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shih KC, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.tps2109; Shou Y, 2015, CLIN CANCER RES, V21, P585, DOI 10.1158/1078-0432.CCR-13-1711; Siu MKY, 2013, ONCOGENE, V32, P3500, DOI 10.1038/onc.2012.363; Skvortsova I, 2015, SEMIN CANCER BIOL, V35, P39, DOI 10.1016/j.semcancer.2015.09.009; Sloan AE, 2014, NEURO-ONCOLOGY, V16, DOI 10.1093/neuonc/nou209.17; Smith DC, 2014, CLIN CANCER RES, V20, P6295, DOI 10.1158/1078-0432.CCR-14-1373; Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015; Sprenger T, 2013, CANCER-AM CANCER SOC, V119, P26, DOI 10.1002/cncr.27703; Strosberg JR, 2012, EUR J CANCER, V48, P997, DOI 10.1016/j.ejca.2012.02.056; Takeishi S, 2016, CANCER SCI, V107, P875, DOI 10.1111/cas.12958; Thomas D, 2017, BLOOD, V129, P1577, DOI 10.1182/blood-2016-10-696054; Tijink BM, 2006, CLIN CANCER RES, V12, P6064, DOI 10.1158/1078-0432.CCR-06-0910; Toi M, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2006.08.1646; Uy GL, 2012, BLOOD, V119, P3917, DOI 10.1182/blood-2011-10-383406; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; van Galen P, 2014, CELL STEM CELL, V14, P94, DOI 10.1016/j.stem.2013.11.021; van Rhenen A, 2005, CLIN CANCER RES, V11, P6520, DOI 10.1158/1078-0432.CCR-05-0468; Vey N, 2016, ONCOTARGET, V7, P32532, DOI 10.18632/oncotarget.8687; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wang Y, 2011, CELL STEM CELL, V8, P399, DOI 10.1016/j.stem.2011.02.006; Westphalen CB, 2014, J CLIN INVEST, V124, P1283, DOI 10.1172/JCI73434; Wiechert A, 2016, ONCOTARGET, V7, P30511, DOI 10.18632/oncotarget.8852; Willingham SB, 2012, P NATL ACAD SCI USA, V109, P6662, DOI 10.1073/pnas.1121623109; Yin ZQ, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-49; Zeuner A, 2014, CELL STEM CELL, V15, P692, DOI 10.1016/j.stem.2014.11.012; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137	126	243	247	8	76	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1934-5909	1875-9777		CELL STEM CELL	Cell Stem Cell	JAN 3	2019	24	1					25	40		10.1016/j.stem.2018.11.017	http://dx.doi.org/10.1016/j.stem.2018.11.017			16	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	HG2ZF	30595497	Bronze			2023-01-03	WOS:000454836900007
J	Martin-Gill, C; Doyle, TJ; Yealy, DM				Martin-Gill, Christian; Doyle, Thomas J.; Yealy, Donald M.			In-Flight Medical Emergencies A Review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							OBSTRUCTIVE PULMONARY-DISEASE; COMMERCIAL AIRLINE FLIGHTS; AIR-TRAVEL; OXYGEN SUPPLEMENTATION; VENOUS THROMBOEMBOLISM; RISK; THROMBOSIS; KIT; RESUSCITATION; TRANSMISSION	IMPORTANCE In-flight medical emergencies (IMEs) are common and occur in a complex environment with limited medical resources. Health care personnel are often asked to assist affected passengers and the flight team, and many have limited experience in this environment. OBSERVATIONS In-flight medical emergencies are estimated to occur in approximately 1 per 604 flights, or 24 to 130 IMEs per 1 million passengers. These events happen in a unique environment, with airplane cabin pressurization equivalent to an altitude of 5000 to 8000 ft during flight, exposing patients to a low partial pressure of oxygen and low humidity. Minimum requirements for emergency medical kit equipment in the United States include an automated external defibrillator; equipment to obtain a basic assessment, hemorrhage control, and initiation of an intravenous line; and medications to treat basic conditions. Other countries have different minimum medical kit standards, and individual airlines have expanded the contents of their medical kit. The most common IMEs involve syncope or near-syncope (32.7%) and gastrointestinal (14.8%), respiratory (10.1%), and cardiovascular (7.0%) symptoms. Diversion of the aircraft from landing at the scheduled destination to a different airport because of a medical emergency occurs in an estimated 4.4%(95% CI, 4.3%-4.6%) of IMEs. Protections for medical volunteers who respond to IMEs in the United States include a Good Samaritan provision of the Aviation Medical Assistance Act and components of the Montreal Convention, although the duty to respond and legal protections vary across countries. Medical volunteers should identify their background and skills, perform an assessment, and report findings to ground-based medical support personnel through the flight crew. Ground-based recommendations ultimately guide interventions on board. CONCLUSIONS AND RELEVANCE In-flight medical emergencies most commonly involve near-syncope and gastrointestinal, respiratory, and cardiovascular symptoms. Health care professionals can assist during these emergencies as part of a collaborative team involving the flight crew and ground-based physicians.	[Martin-Gill, Christian] Univ Pittsburgh, Dept Emergency Med, 3600 Forbes Ave,Iroquois Bldg,Ste 400A, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Martin-Gill, C (corresponding author), Univ Pittsburgh, Dept Emergency Med, 3600 Forbes Ave,Iroquois Bldg,Ste 400A, Pittsburgh, PA 15261 USA.	martingillc2@upmc.edu						Adi Yaser, 2004, BMC Cardiovasc Disord, V4, P7; Adwani SH, 2018, J AM ACAD DERMATOL, V79, P387, DOI 10.1016/j.jaad.2017.12.066; Aerosp Med Assoc, 1998, AVIAT SPACE ENVIR MD, V69, P427; Akero A, 2011, CHEST, V140, P84, DOI 10.1378/chest.10-0965; Aryal KR, 2006, EUR J VASC ENDOVASC, V31, P187, DOI 10.1016/j.ejvs.2005.08.025; Badawy SM, 2016, J PAEDIATR CHILD H, V52, P363, DOI 10.1111/jpc.13118; Bagshaw M, 2001, AVIAT SPACE ENVIR MD, V72, P848; Baltsezak S, 2008, J TRAVEL MED, V15, P391, DOI 10.1111/j.1708-8305.2008.00233.x; Bar-Oz B, 2003, EMERG INFECT DIS, V9, P757; BERG BW, 1991, POSTGRAD MED, V90, P39; BERG BW, 1992, CHEST, V101, P638, DOI 10.1378/chest.101.3.638; Bertrand C, 2004, RESUSCITATION, V63, P175, DOI 10.1016/j.resuscitation.2004.05.011; BLUMEN IJ, 1992, CRIT CARE CLIN, V8, P597, DOI 10.1016/S0749-0704(18)30243-4; Bor Robert, 2007, Travel Med Infect Dis, V5, P207, DOI 10.1016/j.tmaid.2007.03.003; Bor Robert, 2003, Travel Med Infect Dis, V1, P153, DOI 10.1016/j.tmaid.2003.09.006; BYRNE NJ, 1995, AVIAT SPACE ENVIR MD, V66, P780; Campbell CD, 2018, RESP CARE, V63, P326, DOI 10.4187/respcare.05522; Chan SB, 2002, AVIAT SPACE ENVIR MD, V73, P1021; Chatfield E, 2017, AEROSP MED HUM PERF, V88, P876, DOI 10.3357/AMHP.4865.2017; Chee YL, 2005, BRIT J HAEMATOL, V130, P671, DOI 10.1111/j.1365-2141.2005.05617.x; Coker RK, 2007, EUR RESPIR J, V30, P1057, DOI 10.1183/09031936.00024707; Coker RK, 2002, THORAX, V57, P289; Cramer D, 1996, THORAX, V51, P202, DOI 10.1136/thx.51.2.202; CUMMINS RO, 1989, JAMA-J AM MED ASSOC, V261, P1295, DOI 10.1001/jama.261.9.1295; DeJohn C, 2000, EVALUATION FLIGHT ME; DeJohn CA, 2002, AVIAT SPACE ENVIR MD, V73, P496; Delaune EF, 2003, AVIAT SPACE ENVIR MD, V74, P62; Drennan IR, 2017, RESUSCITATION, V111, P96, DOI 10.1016/j.resuscitation.2016.11.021; Edvardsen A, 2012, THORAX, V67, P964, DOI 10.1136/thoraxjnl-2012-201855; Federal Aviation Administration, 2006, POL AC121 33B EM MED; Gavish I, 2011, INTERN EMERG MED, V6, P113, DOI 10.1007/s11739-010-0474-6; Geroulakos G, 2001, BRIT MED J, V322, P188, DOI 10.1136/bmj.322.7280.188; Graf J, 2012, DTSCH ARZTEBL INT, V109, P591, DOI 10.3238/arztebl.2012.0591; Hampson NB, 2013, AVIAT SPACE ENVIR MD, V84, P27, DOI 10.3357/ASEM.3438.2013; Hedouin V, 1998, Med Law, V17, P503; Hinkelbein J, 2018, INTERN EMERG MED, V13, P1305, DOI 10.1007/s11739-018-1856-4; Humphreys S, 2005, ANAESTHESIA, V60, P458, DOI 10.1111/j.1365-2044.2005.04124.x; Hung KKC, 2013, AVIAT SPACE ENVIR MD, V84, P491, DOI 10.3357/ASEM.3452.2013; *INT AIR TRANSP AS, 2018, ANN REV; International Air Transport Association, 2018, IATA MED MAN; James JM, 1999, J ALLERGY CLIN IMMUN, V104, P25, DOI 10.1016/S0091-6749(99)70109-0; Kay RS., 1994, NURSE PRACT, V19, DOI DOI 10.1097/00006205-199405000-00014; Kelly PT, 2007, RESPIROLOGY, V12, P511, DOI 10.1111/j.1440-1843.2007.01104.x; Kennedy M G, 1991, J Emerg Nurs, V17, P295; Kesapli M, 2015, J TRAVEL MED, V22, P361, DOI 10.1111/jtm.12230; Kesteven PJL, 2001, AVIAT SPACE ENVIR MD, V72, P125; Kim JH, 2017, J TRAVEL MED, V24, DOI [10.5953/JMJH.2017.24.1.1, 10.1093/jtm/taw091]; Lee JM, 2017, AEROSP MED HUM PERF, V88, P651, DOI 10.3357/AMHP.4366.2017; Lopman B, 2011, CLIN INFECT DIS, V53, P521, DOI 10.1093/cid/cir486; Lyznicki JM, 2000, AVIAT SPACE ENVIR MD, V71, P827; Lyznicki JM, 2000, AVIAT SPACE ENVIR MD, V71, P832; Macleod S, 2008, AUSTRALAS PSYCHIATRY, V16, P233, DOI 10.1080/10398560701882211; Mahony PH, 2011, AVIAT SPACE ENVIR MD, V82, P1131, DOI 10.3357/ASEM.3099.2011; Mangili A, 2005, LANCET, V365, P989, DOI 10.1016/S0140-6736(05)71089-8; Matsumoto K, 2001, AVIAT SPACE ENVIR MD, V72, P919; Mattison MLP, 2011, JAMA-J AM MED ASSOC, V305, P2003, DOI 10.1001/jama.2011.618; McIntosh IB, 1998, J TRAVEL MED, V5, P198, DOI 10.1111/j.1708-8305.1998.tb00507.x; Mohrenschlager M, 2010, ALLERGY, V65, P1496, DOI 10.1111/j.1398-9995.2010.02400.x; Muhm JM, 2004, AVIAT SPACE ENVIR MD, V75, P905; Nable JV, 2015, NEW ENGL J MED, V373, P939, DOI 10.1056/NEJMra1409213; Nable JV, 2018, FLIGHT MED EMERGENCI, DOI [10.1007/978-3-319-74234-2, DOI 10.1007/978-3-319-74234-2]; NewsonSmith MS, 1997, AVIAT SPACE ENVIR MD, V68, P1134; Nicholson Trevor T, 2014, Ann Am Thorac Soc, V11, P1614, DOI 10.1513/AnnalsATS.201406-234PS; Peterson DC, 2013, NEW ENGL J MED, V368, P2075, DOI 10.1056/NEJMoa1212052; Pierson K, 2007, AVIAT SPACE ENVIR MD, V78, P361; Qureshi A, 2005, EMERG MED J, V22, P658, DOI 10.1136/emj.2005.024505; Rayman RB, 2002, AVIAT SPACE ENVIR MD, V73, P501; Rayman RB, 1998, AVIAT SPACE ENVIR MD, V69, P1007; Rotta AT, 2014, PEDIATR CRIT CARE ME, V15, pE360, DOI 10.1097/PCC.0000000000000220; Sanchez-Borges M, 2017, WORLD ALLERGY ORGAN, V10, DOI 10.1186/s40413-017-0148-1; Sand M, 2010, TRAVEL MED INFECT DI, V8, P388, DOI 10.1016/j.tmaid.2010.10.008; Sand M, 2009, CRIT CARE, V13, DOI 10.1186/cc7690; Schreijer AJM, 2010, J THROMB HAEMOST, V8, P971, DOI 10.1111/j.1538-7836.2010.03819.x; Scurr JH, 2001, LANCET, V357, P1485, DOI 10.1016/S0140-6736(00)04645-6; Seccombe LM, 2006, CURR OPIN PULM MED, V12, P140, DOI 10.1097/01.mcp.0000208454.03597.bb; Shepherd B, 2006, J ROY SOC MED, V99, P628, DOI 10.1258/jrsm.99.12.628; Sirven JI, 2002, NEUROLOGY, V58, P1739, DOI 10.1212/WNL.58.12.1739; Spoorenberg ME, 2016, AEROSP MED HUM PERF, V87, P54, DOI 10.3357/AMHP.4408.2016; Stojanovic S, 2016, MED J AUSTRALIA, V205, P270, DOI 10.5694/mja16.00384; Szmajer M, 2001, RESUSCITATION, V50, P147, DOI 10.1016/S0300-9572(01)00347-1; Thibeault C, 2002, AVIAT SPACE ENVIR MD, V73, P612; Thibeault C, 1998, AVIAT SPACE ENVIR MD, V69, P1112; Thibeault C, 2007, AVIAT SPACE ENVIR MD, V78, P1170, DOI 10.3357/ASEM.2188.2007; Toff WD, 2006, JAMA-J AM MED ASSOC, V295, P2251, DOI 10.1001/jama.295.19.2251; Valani R, 2010, AVIAT SPACE ENVIR MD, V81, P1037, DOI 10.3357/ASEM.2789.2010; Verjee MA, 2018, OPEN ACCESS EMERG M, V10, P47, DOI 10.2147/OAEM.S152777; Weinlich M, 2009, J TELEMED TELECARE, V15, P409, DOI 10.1258/jtt.2009.090501; Weir E, 2001, CAN MED ASSOC J, V164, P1037; Wong M., 2017, MED LAW INT, V17, P65	90	36	36	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	2018	320	24					2580	2590		10.1001/jama.2018.19842	http://dx.doi.org/10.1001/jama.2018.19842			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG1EK	30575886	Bronze			2023-01-03	WOS:000454693000018
J	Benatar, JR; Stewart, RAH				Benatar, Jocelyne R.; Stewart, Ralph A. H.			Cardiometabolic risk factors in vegans; A meta-analysis of observational studies	PLOS ONE			English	Article							FATTY-ACID-COMPOSITION; FOOD-FREQUENCY QUESTIONNAIRE; BLOOD-PRESSURE; MEAT-EATERS; VEGETARIAN DIETS; FISH-EATERS; CARDIOVASCULAR-DISEASE; MEDITERRANEAN DIET; INSULIN-RESISTANCE; ADVENTIST HEALTH	Background There is increasing evidence that plant based diets are associated with lower cardiovascular risk. Objective To evaluate effects of a vegan compared to an omnivorous diet on cardio-metabolic risk factors. Methods Meta-analysis of observational studies published between 1960 and June 2018 that reported one or more cardio-metabolic risk factors in vegans and controls eating an omnivorous diet were undertaken. Macro-nutrient intake and cardio-metabolic risk factors were compared by dietary pattern. The Newcastle Ottawa Scale (NOS) was used to assess the quality of each study. The inverse-variance method was used to pool mean differences. Statistical analyses were performed using RevMan software version 5.2 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen. Results 40 studies with 12 619 vegans and 179 630 omnivores were included. From food frequency questionnaires in 28 studies, vegans compared to omnivores consumed less energy (-11%, 95% confidence interval -14 to -8) and less saturated fat (- 51%, CI -57 to -45). Compared to controls vegans had a lower body mass index (-1.72 kg/m(2), CI -2.30 to -1.16), waist circumference (-2.35 cm, CI -3.93 to -0.76), low density lipoprotein cholesterol (-0.49 mmol/L CI -0.62 to -0.36), triglycerides (-0.14 mmol/L, CI -0.24 to -0.05), fasting blood glucose (-0.23 mmol/, CI -0.35 to -0.10), and systolic (-2.56 mmHg, CI -4.66 to -0.45) and diastolic blood pressure (-1.33 mmHg, CI -2.67 to -0.02), p<0.0001 for all. Results were consistent for studies with < and >= 50 vegans, and published before and after 2010. However in several large studies from Taiwan a vegan diet was not associated with favourable cardio-metabolic risk factors compared to the control diets. Conclusion In most countries a vegan diet is associated with a more favourable cardio- metabolic profile compared to an omnivorous diet.	[Benatar, Jocelyne R.; Stewart, Ralph A. H.] Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand	Auckland City Hospital	Benatar, JR (corresponding author), Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand.	Jbenatar@adhb.govt.nz		benatar, jocelyne/0000-0002-6724-8997				AGREN JJ, 1995, LIPIDS, V30, P365, DOI 10.1007/BF02536047; Al-Khudairy L, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011094.pub2; [Anonymous], 2015, 2015 2020 DIET GUID; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Appleby PN, 2002, PUBLIC HEALTH NUTR, V5, P645, DOI 10.1079/PHN2002332; Barnard ND, 2006, DIABETES CARE, V29, P1777, DOI 10.2337/dc06-0606; Benatar J, 2017, HEART LUNG CIRCULATI, V26, pS344; Bradbury KE, 2014, EUR J CLIN NUTR, V68, P178, DOI 10.1038/ejcn.2013.248; Brouwer IA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009434; Burkert NT, 2014, WIEN KLIN WOCHENSCHR, V126, P113, DOI 10.1007/s00508-013-0483-3; Cannon Christopher P, 2007, Clin Cornerstone, V8, P11, DOI 10.1016/S1098-3597(07)80025-1; Chiu S, 2016, AM J CLIN NUTR, V103, P341, DOI 10.3945/ajcn.115.123281; Chiu YF, 2015, BRIT J NUTR, V114, P1313, DOI 10.1017/S0007114515002937; Craig WJ, 2009, AM J CLIN NUTR, V89, pS1627, DOI 10.3945/ajcn.2009.26736N; De Biase SG, 2007, ARQ BRAS CARDIOL, V88, P35, DOI 10.1590/S0066-782X2007000100006; Dehghan M, LANCET; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Elorinne AL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148235; Esposito K, 2014, DIABETES-METAB RES, V30, P34, DOI 10.1002/dmrr.2516; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Ettehad D, 2016, LANCET, V387, P957, DOI 10.1016/S0140-6736(15)01225-8; Famodu AA, 1998, CLIN BIOCHEM, V31, P545, DOI 10.1016/S0009-9120(98)00067-8; FISHER M, 1986, ARCH INTERN MED, V146, P1193, DOI 10.1001/archinte.146.6.1193; Flint AJ, 2010, OBES RES CLIN PRACT, V4, pE171, DOI 10.1016/j.orcp.2010.01.001; Fokkema MR, 2000, PROSTAG LEUKOTR ESS, V63, P279, DOI 10.1054/plef.2000.0215; Fontana L, 2007, REJUV RES, V10, P225, DOI 10.1089/rej.2006.0529; Fraser G, 2015, PUBLIC HEALTH NUTR, V18, P537, DOI 10.1017/S1368980014000263; Goff LM, 2005, EUR J CLIN NUTR, V59, P291, DOI 10.1038/sj.ejcn.1602076; Gojda J, 2013, EUR J CLIN NUTR, V67, P1310, DOI 10.1038/ejcn.2013.202; Haddad EH, 1999, AM J CLIN NUTR, V70, p586S, DOI 10.1093/ajcn/70.3.586s; Hammad S, 2016, LIPIDS, V51, P507, DOI 10.1007/s11745-015-4113-x; HARDINGE MG, 1954, J CLIN NUTR, V2, P83; Hooper L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002137.pub3; Huang CJ, 2011, BRIT J NUTR, V106, P451, DOI 10.1017/S0007114511000195; Huang YW, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-55; Jian ZH, 2015, PUBLIC HEALTH NUTR, V18, P721, DOI 10.1017/S1368980014000883; Kennedy ET, 2001, J AM DIET ASSOC, V101, P411, DOI 10.1016/S0002-8223(01)00108-0; Key TJ, 2014, AM J CLIN NUTR, V100, p378S, DOI 10.3945/ajcn.113.071266; Krajcovicova-Kudlackova M, 2000, SCAND J CLIN LAB INV, V60, P657, DOI 10.1080/00365510050216385; Kris-Etherton P, 2001, CIRCULATION, V103, P1823, DOI 10.1161/01.CIR.103.13.1823; Kristal AR, 2005, CANCER EPIDEM BIOMAR, V14, P2826, DOI 10.1158/1055-9965.EPI-12-ED1; KRITCHEVSKY D, 1984, American Journal of Clinical Nutrition, V40, P921, DOI 10.1093/ajcn/40.4.921; Kuchta A, 2016, CARDIOL J, V23, P141, DOI 10.5603/CJ.a2016.0002; Lee YM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155918; Li D, 1999, EUR J CLIN NUTR, V53, P612, DOI 10.1038/sj.ejcn.1600817; Liese AD, 2009, DIABETES CARE, V32, P1434, DOI 10.2337/dc09-0228; Lin CK, 2010, J HEALTH POPUL NUTR, V28, P470; Mann N, 2006, LIPIDS, V41, P637, DOI 10.1007/s11745-006-5014-9; Navarro A, 2001, J EXP CLIN CANC RES, V20, P365; Neter JE, 2003, HYPERTENSION, V42, P878, DOI 10.1161/01.HYP.0000094221.86888.AE; Newby PK, 2005, AM J CLIN NUTR, V81, P1267; Newby PK, 2004, AM J CLIN NUTR, V80, P504, DOI 10.1093/ajcn/80.2.504; Orlich MJ, 2013, JAMA INTERN MED, V173, P1230, DOI 10.1001/jamainternmed.2013.6473; Orlov S N, 1994, J Cardiovasc Risk, V1, P249; Pan WH, 2011, ASIA PAC J CLIN NUTR, V20, P238; Perez-Martinez P, 2011, CURR PHARM DESIGN, V17, P769, DOI 10.2174/138161211795428948; Perk Joep, 2012, Int J Behav Med, V19, P403, DOI [10.1016/j.atherosclerosis.2012.05.007, 10.1093/eurheartj/ehs092, 10.1007/s12529-012-9242-5]; Pettersen BJ, 2012, PUBLIC HEALTH NUTR, V15, P1909, DOI 10.1017/S1368980011003454; Radnitz C, 2015, APPETITE, V90, P31, DOI 10.1016/j.appet.2015.02.026; Ramage S, 2014, APPL PHYSIOL NUTR ME, V39, P1, DOI 10.1139/apnm-2013-0026; Rosenthal R L, 2000, Proc (Bayl Univ Med Cent), V13, P351; ROSHANAI F, 1984, HUM NUTR-APPL NUTR, V38A, P345; Sambol SZ, 2009, W INDIAN MED J, V58, P512; SANDERS TAB, 1978, AM J CLIN NUTR, V31, P805, DOI 10.1093/ajcn/31.5.805; SANDERS TAB, 1992, EUR J CLIN NUTR, V46, P823; SANDERS TAB, 1987, HUM NUTR-APPL NUTR, V41A, P204; Schaefer EJ, 2000, AM J CLIN NUTR, V71, P746, DOI 10.1093/ajcn/71.3.746; Schupbach R, 2017, EUR J NUTR, V56, P283, DOI 10.1007/s00394-015-1079-7; Silverman MG, 2016, JAMA-J AM MED ASSOC, V316, P1289, DOI 10.1001/jama.2016.13985; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Thomas HV, 1999, BRIT J CANCER, V80, P1470, DOI 10.1038/sj.bjc.6690546; THOROGOOD M, 1990, BRIT MED J, V300, P1297, DOI 10.1136/bmj.300.6735.1297; Timko CA, 2012, APPETITE, V58, P982, DOI 10.1016/j.appet.2012.02.005; Toohey ML, 1998, J AM COLL NUTR, V17, P425, DOI 10.1080/07315724.1998.10718789; Tufanaru C, 2015, INT J EVID-BASED HEA, V13, P196, DOI 10.1097/XEB.0000000000000065; Vinagre JC, 2013, NUTR METAB CARDIOVAS, V23, P61, DOI 10.1016/j.numecd.2011.02.011; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; Wells GA, NEWCASTLE OTTAWA SCA; Wing RR, 2011, DIABETES CARE, V34, P1481, DOI 10.2337/dc10-2415; Yokoyama Y, 2014, JAMA INTERN MED, V174, P577, DOI 10.1001/jamainternmed.2013.14547	80	44	45	2	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2018	13	12							e0209086	10.1371/journal.pone.0209086	http://dx.doi.org/10.1371/journal.pone.0209086			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF0HP	30571724	gold, Green Submitted, Green Published			2023-01-03	WOS:000453841700035
J	Djebbari, F; Srinivasan, A; Valiance, G; Moore, S; Kothari, J; Ramasamy, K				Djebbari, Faouzi; Srinivasan, Anandagopal; Valiance, Grant; Moore, Sally; Kothari, Jaime; Ramasamy, Karthik			Clinical outcomes of bortezomib-based therapy in myeloma	PLOS ONE			English	Article							MULTIPLE-MYELOMA; DEXAMETHASONE; PREDNISONE; MELPHALAN; SURVIVAL	Bortezomib, a first generation proteasome inhibitor, is used in both newly diagnosed and relapsed myeloma settings. Considerable differences exist in the usage of bortezomib therapy in the clinical practice setting in comparison to clinical trial setting as well manufacturer's recommendations. These differences include route of administration (intravenous (iv) vs. subcutaneous (sc)), frequency from twice to once weekly, choice of alkylating agent used in combination with bortezomib (melphalan or cyclophosphamide), and choice of glucocorticoids (dexamethasone or prednisolone). We reviewed data from 272 consecutive bortezomib-treated myeloma patients, who received therapy within the regional Thames Valley Cancer Network for both newly diagnosed myeloma (NDMM, n = 120) and relapsed MM (RMM, n = 152). We investigated the influence of age, sex, transplant, bortezomib combinations (doublet vs. triplet), cumulative bortezomib dose per treatment line (<50mg vs. >= 50mg), and route of administration (iv vs. sc) on time to next treatment (TTNT) and on overall survival (OS). Route of bortezomib administration (iv vs. sc) influenced neither OS (41 vs 35 months, p = 0.5), nor TTNT (14 vs. 19 months, p = 0.052). Our study showed a statistically significant improvement in median OS in patients receiving a cumulative dose >= 50mg compared to <50mg (42 vs. 33months, p = 0.003), although presence of confounders need to be taken into account, such as disease stage, performance status, genetic changes and prior therapies. Median OS was longer using triplet therapies compared to a doublet in the RMM cohort (37 vs. 29 months, p = 0.06), although this did not reach statistical significance. Multivariate Cox Regression analysis showed that cumulative bortezomib dose >50mg (p = 0.002, HR = 1.83, 95% CI 1.25-2.67) and autologous transplant (p = 0.002, HR = 2.6, 95% CI 1.41-3.98) were both significant factors associated with improved OS. Our data argues in favour of continuing bortezomib for the recommended duration as per Summary of Product Characteristics (SPC), subject to good tolerability, in order to deepen response or extend the duration of best response.	[Djebbari, Faouzi; Srinivasan, Anandagopal; Valiance, Grant; Moore, Sally; Kothari, Jaime; Ramasamy, Karthik] Oxford Univ Hosp NHS Fdn Trust, Dept Clin Haematol, Oxford, England; [Kothari, Jaime; Ramasamy, Karthik] NIHR BRC Blood Theme, Oxford, England; [Kothari, Jaime; Ramasamy, Karthik] Oxford Myeloma Ctr Translat Res, Oxford, England	Oxford University Hospitals NHS Foundation Trust	Djebbari, F (corresponding author), Oxford Univ Hosp NHS Fdn Trust, Dept Clin Haematol, Oxford, England.	faouzi.djebbari@ouh.nhs.uk		DJEBBARI, Faouzi/0000-0001-9578-7632; Ramasamy, Karthik/0000-0003-3385-3707				[Anonymous], 2016, INTRO MYELOMA; Bianchi G, 2014, CA-CANCER J CLIN, V64, P422, DOI 10.3322/caac.21252; Bringhen S, 2010, BLOOD, V116, P4745, DOI 10.1182/blood-2010-07-294983; Cancer Research UK, MYEL STAT; Larocca A, 2016, LEUKEMIA, V30, P1320, DOI 10.1038/leu.2016.36; Mangiacavalli S, 2018, LEUKEMIA LYMPHOMA, V59, P1505, DOI 10.1080/10428194.2017.1382695; Minarik J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123866; Moreau P, 2011, LANCET ONCOL, V12, P431, DOI 10.1016/S1470-2045(11)70081-X; National Institute for Care and Clinical Excellence, BORT THAL 1 LIN TREA; National Institute for Care and Clinical Excellence, BORT IND THER MULT M; National Institute for Care and Clinical Excellence, BORT MON REL MULT MY; Niesvizky R, 2015, J CLIN ONCOL, V33, P3921, DOI 10.1200/JCO.2014.58.7618; Palumbo A, 2015, BLOOD, V125, P2068, DOI 10.1182/blood-2014-12-615187; Ramasamy K, 2015, FAST FACTS MULTIPLE; Richardson PG, 2010, BLOOD, V116, P679, DOI 10.1182/blood-2010-02-268862; Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445; San Miguel JF, 2008, NEW ENGL J MED, V359, P906, DOI 10.1056/NEJMoa0801479; Mateos MV, 2015, AM J HEMATOL, V90, P314, DOI 10.1002/ajh.23933	18	3	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2018	13	12							e0208920	10.1371/journal.pone.0208920	http://dx.doi.org/10.1371/journal.pone.0208920			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD9QX	30540831	Green Published, Green Submitted, gold			2023-01-03	WOS:000452898600099
J	Tang, HW; Xiang, S; Li, XZ; Zhou, J; Kuang, CT				Tang, Hongwei; Xiang, Shu; Li, Xiangzhou; Zhou, Jun; Kuang, Chuntao			Preparation and in vitro performance evaluation of resveratrol for oral self-microemulsion	PLOS ONE			English	Article							DRUG-DELIVERY SYSTEMS; ANTIOXIDANT ACTIVITY; BIOAVAILABILITY; DISSOLUTION; SMEDDS; STABILITY; OPTIMIZATION; FORMULATION; EFFICIENCY; TOXICITY	The purpose of this study was to improve the solubility of resveratrol (Res) by a self-microemulsifying drug-delivery system (SMEDDS). Through a solubility experiment, the pseudo ternary phase diagram and ternary phase diagram were used to optimize the Res SMEDDS formula. The optimum formulation consisted of 5% IPM, 20% PEG400, and 65% Cremophor RH40. The water solubility, stability, in vitro release and antioxidant activity of the Res SMEDDS were characterized. The Res solubility in the SMEDDS was at least 1,000 times compared to that in water. The average droplet size of the microemulsion was 28.00 +/- 1.67 nm and uniform distribution. The Res SMEDDS should be stored at low temperature and in the dark to avoid light conditions. Res SMEDDS was able to improve the in vitro release rate of Res, and the in vitro release of Res from Res SMEDDS was significantly faster that of Res powder and unaffected by pH value of media. Antioxidant assays showed that antioxidant activities of Res in Res SMEDDS were unaffected compared to Res powder. Cytotoxicity study indicated that Res SMEDDS at the concentration of less than 100 mu M was safe. These results demonstrated the potential use of Res SMEDDS for oral administration of Res.	[Tang, Hongwei; Xiang, Shu; Li, Xiangzhou; Zhou, Jun; Kuang, Chuntao] Cent South Univ Forestry & Technol, Coll Mat Sci & Engn, Changsha, Hunan, Peoples R China; [Li, Xiangzhou] State Key Lab Ecol Appl Technol Forest Area South, Changsha, Hunan, Peoples R China	Central South University of Forestry & Technology	Kuang, CT (corresponding author), Cent South Univ Forestry & Technol, Coll Mat Sci & Engn, Changsha, Hunan, Peoples R China.	hnkct@163.com			National Key R&D Program of China [2016YFD0600805]	National Key R&D Program of China	This work was financially supported by the National Key R&D Program of China (2016YFD0600805).	Bumajdad A, 2003, LANGMUIR, V19, P2560, DOI 10.1021/la026586f; Caruso F, 2004, J AGR FOOD CHEM, V52, P7279, DOI 10.1021/jf048794e; Chen Y, 2015, MOLECULES, V20, P21167, DOI 10.3390/molecules201219750; Cui SM, 2005, DRUG DEV IND PHARM, V31, P349, DOI 10.1081/DDC-200054309; Donini C, 2002, INT J PHARMACEUT, V245, P83, DOI 10.1016/S0378-5173(02)00335-6; Garti N, 1999, J MOL LIQ, V80, P253, DOI 10.1016/S0167-7322(99)00026-4; Gong YJ, 2010, J CENTRAL S U FOREST, V30, P180; Guan QX, 2016, BIOL PHARM BULL, V39, P762, DOI 10.1248/bpb.b15-00854; Guo RX, 2017, J FOOD SCI, V82, P2901, DOI 10.1111/1750-3841.13944; He H, 2013, J AGR FOOD CHEM, V61, P8110, DOI 10.1021/jf4019323; Hung CF, 2006, J NANOSCI NANOTECHNO, V6, P2950, DOI 10.1166/jnn.2006.420; Khoo SM, 1998, INT J PHARM, V167, P155, DOI 10.1016/S0378-5173(98)00054-4; Kiss L, 2013, J PHARM SCI-US, V102, P1173, DOI 10.1002/jps.23458; Lawrence MJ, 2012, ADV DRUG DELIVER REV, V64, P175, DOI 10.1016/j.addr.2012.09.018; Liu QY, 2009, POLYM DEGRAD STABIL, V94, P1427, DOI 10.1016/j.polymdegradstab.2009.05.023; Ma LJ, 2015, INT J ONCOL, V47, P1460, DOI 10.3892/ijo.2015.3124; Mattarei A, 2013, MOL PHARMACEUT, V10, P2781, DOI 10.1021/mp400226p; Moghimipour E, 2013, ADV PHARM BULL, V3, P63, DOI 10.5681/apb.2013.011; Papay ZE, 2017, J AEROSOL MED PULM D, V30, P274, DOI 10.1089/jamp.2016.1316; Pineros I, 2017, EUR J PHARM SCI, V101, P220, DOI 10.1016/j.ejps.2016.12.030; POUTON CW, 1985, INT J PHARM, V27, P335, DOI 10.1016/0378-5173(85)90081-X; Pujara N, 2017, J COLLOID INTERF SCI, V488, P303, DOI 10.1016/j.jcis.2016.11.015; Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3; Seljak KB, 2014, J PHARM SCI-US, V103, P3491, DOI 10.1002/jps.24114; Selvaraj S, 2013, J MED CHEM, V56, P970, DOI 10.1021/jm3014579; Sessa M, 2011, J AGR FOOD CHEM, V59, P12352, DOI 10.1021/jf2031346; Shen HR, 2006, J PHARM PHARMACOL, V58, P1183, DOI 10.1211/jpp.58.9.0004; Shi Xian-min, 2011, China Surfactant Detergent & Cosmetics, V41, P204; Surguladze M. A., 2017, Annals of Agrarian Science, V15, P137, DOI 10.1016/j.aasci.2016.10.002; TOGUCHI H, 1990, CHEM PHARM BULL, V38, P2797, DOI 10.1248/cpb.38.2797; Trotta M, 1998, INT J PHARM, V174, P253, DOI 10.1016/S0378-5173(98)00273-7; Udenigwe CC, 2008, NUTR REV, V66, P445, DOI 10.1111/j.1753-4887.2008.00076.x; Vancauwenberghe E, 2017, MOL CARCINOGEN, V56, P1851, DOI 10.1002/mc.22642; Wu XM, 2011, DRUG DEV IND PHARM, V37, P15, DOI 10.3109/03639045.2010.489560; Xu Y, 2016, J FUNCT FOODS, V27, P703, DOI 10.1016/j.jff.2016.10.007; [严建业 Yan Jianye], 2015, [中成药, Chinese Traditional Patent Medicine], V37, P2628; Yang YJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0550-6; Zhang JB, 2014, AAPS PHARMSCITECH, V15, P731, DOI 10.1208/s12249-014-0096-9; Zhang QH, 2015, FOOD CHEM, V179, P15, DOI 10.1016/j.foodchem.2015.01.113; Zhang QZ, 2004, INT J PHARMACEUT, V275, P85, DOI 10.1016/j.ijpharm.2004.01.039; Zhang XP, 2013, LWT-FOOD SCI TECHNOL, V50, P622, DOI 10.1016/j.lwt.2012.07.041	41	13	13	4	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2019	14	4							e0214544	10.1371/journal.pone.0214544	http://dx.doi.org/10.1371/journal.pone.0214544			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT6TE	30990813	Green Submitted, Green Published, gold			2023-01-03	WOS:000464696100010
J	Boden, S; Myte, R; Wennberg, M; Harlid, S; Johansson, I; Shivappa, N; Hebert, JR; Van Guelpen, B; Nilsson, LM				Boden, Stina; Myte, Robin; Wennberg, Maria; Harlid, Sophia; Johansson, Ingegerd; Shivappa, Nitin; Hebert, James R.; Van Guelpen, Bethany; Nilsson, Lena Maria			The inflammatory potential of diet in determining cancer risk; A prospective investigation of two dietary pattern scores	PLOS ONE			English	Article							MEDITERRANEAN DIET; CARDIOVASCULAR-DISEASE; PROSTATE-CANCER; GASTRIC-CANCER; ENERGY-INTAKE; LUNG-CANCER; INDEX; ASSOCIATION; MORTALITY; BREAST	Purpose Inflammation-related mechanisms may contribute to the link between diet and cancer. We sought to investigate the inflammatory impact of diet on cancer risk using the Dietary inflammatory index (DII) and an adapted Mediterranean diet score (MDS). Methods This population-based, prospective cohort study used self-reported dietary data from the Vasterbotten Intervention Programme, including 100,881 participants, of whom 35,393 had repeated measures. Associations between dietary patterns and cancer risk were evaluated using Cox proportional hazards regression. We also used restricted cubic splines to test for potential non-linear associations. Results A total of 9,250 incident cancer cases were diagnosed during a median follow-up of 15 years. The two dietary patterns were moderately correlated to each other and had similar associations with cancer risk, predominantly lung cancer in men (DII per tertile decrease: Hazard ratio (HR) 0.81 (0.66-0.99), MDS per tertile increase: HR 0.86 (0.72-1.03)), and gastric cancer in men (DII: 0.73 (0.53-0.99), MDS: 0.73 (0.56-0.96)). Associations were, in general, found to be linear. We found no longitudinal association between 10-year change in diet and cancer risk. Conclusion We confirm small, but consistent and statistically significant associations between a more anti-inflammatory or healthier diet and reduced risk of cancer, including a lower risk of lung and gastric cancer in men. The dietary indexes produced similar associations with respect to the risk of cancer.	[Boden, Stina; Myte, Robin; Harlid, Sophia; Van Guelpen, Bethany] Umea Univ, Dept Radiat Sci, Oncol, Umea, Sweden; [Wennberg, Maria; Johansson, Ingegerd; Nilsson, Lena Maria] Umea Univ, Dept Publ Hlth & Clin Med, Sustainable Hlth Nutr Res, Umea, Sweden; [Shivappa, Nitin; Hebert, James R.] Univ South Carolina, Canc Prevent & Control Program, Columbia, SC 29208 USA; [Shivappa, Nitin; Hebert, James R.] Univ South Carolina, Arnold Sch Publ Hlth, Dept Epidemiol & Biostat, Columbia, SC 29208 USA; [Shivappa, Nitin; Hebert, James R.] Connecting Hlth Innovat LLC, Columbia, SC USA; [Van Guelpen, Bethany] Umea Univ, Wallenberg Ctr Mol Med, Umea, Sweden; [Nilsson, Lena Maria] Umea Univ, Arctic Res Ctr, Arcum, Umea, Sweden	Umea University; Umea University; University of South Carolina System; University of South Carolina Columbia; University of South Carolina System; University of South Carolina Columbia; Umea University; Umea University	Boden, S (corresponding author), Umea Univ, Dept Radiat Sci, Oncol, Umea, Sweden.	stina.boden@umu.se	Harlid, Sophia/AAJ-5809-2021; Shivappa, Nitin/X-2215-2018; Van Guelpen, Bethany/J-8159-2015	Harlid, Sophia/0000-0001-8540-6891; Shivappa, Nitin/0000-0003-0441-8896; Van Guelpen, Bethany/0000-0002-9692-101X; Nilsson, Lena Maria/0000-0002-2354-7258	Cancer Research Fund in Northern Sweden [LP18-2175]; Arctic Research Center (Arcum) at Umea University; Unit of Research, Education and Development, Ostersunds Hospital, Region Jamtland Harjedalen; Swedish Cancer Society [CAN 2014/780, CAN 2017/581]; Region Vaterbotten, Sweden [VLL-761731, VLL-680921, VLL-582691, VLL-547711, RV-865561]; Swedish Research Council for Health, Working Life and Welfare (Forte); Swedish Research Council (VR)	Cancer Research Fund in Northern Sweden; Arctic Research Center (Arcum) at Umea University; Unit of Research, Education and Development, Ostersunds Hospital, Region Jamtland Harjedalen; Swedish Cancer Society(Swedish Cancer Society); Region Vaterbotten, Sweden; Swedish Research Council for Health, Working Life and Welfare (Forte); Swedish Research Council (VR)(Swedish Research Council)	SB was supported from The Cancer Research Fund in Northern Sweden (grant LP18-2175) and smaller funding from the Arctic Research Center (Arcum) at Umea University (no grant-nr). Acknowledgement also to the Unit of Research, Education and Development, Ostersunds Hospital, Region Jamtland Harjedalen for supporting SB in this project (no grant-nr). BVG was supported by the Swedish Cancer Society (grant CAN 2014/780 and CAN 2017/581) and from Region Vaterbotten, Sweden (bas-ALF 2016-2019: VLL-761731, VLL-680921, VLL-582691, VLL-547711, RV-865561) and smaller annual grants (VLL-761731, VLL-680921, VLL-582691, RV-865561). The Northern Sweden Diet Database has been supported by the Swedish Research Council for Health, Working Life and Welfare (Forte) and The Swedish Research Council (VR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrams JA, 2013, J CLIN GASTROENTEROL, V47, P322, DOI 10.1097/MCG.0b013e318260177a; Agudo A, 2018, AM J CLIN NUTR, V107, P607, DOI 10.1093/ajcn/nqy002; Ax E, 2014, NUTR CANCER, V66, P77, DOI 10.1080/01635581.2014.851712; Boden S, 2017, NUTR J, V16, DOI 10.1186/s12937-017-0243-8; Brenner DR, 2017, AM J EPIDEMIOL, V185, P86, DOI 10.1093/aje/kww159; Casas R, 2014, ENDOCR METAB IMMUNE, V14, P245, DOI 10.2174/1871530314666140922153350; Deng FE, 2017, EUR J NUTR, V56, P1085, DOI 10.1007/s00394-016-1158-4; Fowler ME, 2017, INT J CANCER, V141, P2215, DOI 10.1002/ijc.30922; Grosso G, 2017, NUTR REV, V75, P405, DOI 10.1093/nutrit/nux012; Grosso G, 2013, BMC SURG, V13, DOI 10.1186/1471-2482-13-S2-S14; Hebert JR, 2002, ANN EPIDEMIOL, V12, P577, DOI 10.1016/S1047-2797(01)00297-6; Hodge AM, 2016, CANCER CAUSE CONTROL, V27, P907, DOI 10.1007/s10552-016-0770-1; Hornell A, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-48; Johansson G, 2001, PUBLIC HEALTH NUTR, V4, P919, DOI 10.1079/PHN2001124; Johansson I, 2010, EUR J CLIN NUTR, V64, P905, DOI 10.1038/ejcn.2010.80; Johansson I, 2002, PUBLIC HEALTH NUTR, V5, P487, DOI 10.1079/PHN2001315; Lauby-Secretan B, 2016, NEW ENGL J MED, V375, P794, DOI 10.1056/NEJMsr1606602; Li YJ, 2015, CANCER CAUSE CONTROL, V26, P893, DOI 10.1007/s10552-015-0564-x; Lundqvist Adam, 2016, Eur J Public Health, V26, P804, DOI 10.1093/eurpub/ckw070; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Moradi S, 2018, NUTRITION, V55-56, P168, DOI 10.1016/j.nut.2018.04.018; Norat T, 2015, CANCER EPIDEMIOL, V39, pS56, DOI 10.1016/j.canep.2014.12.016; Norberg M, 2010, GLOBAL HEALTH ACTION, V3, DOI 10.3402/gha.v3i0.4643; Ostan R, 2015, NUTRIENTS, V7, P2589, DOI 10.3390/nu7042589; Pan P, 2019, CURR OPIN GASTROEN, V35, P101, DOI 10.1097/MOG.0000000000000501; Park YM, 2017, J NUTR, V147, P563, DOI 10.3945/jn.116.243543; Pukkala E, 2007, ACTA ONCOL, V46, P286, DOI 10.1080/02841860701203545; Russo GI, 2019, INT J IMPOT RES, V31, P269, DOI 10.1038/s41443-018-0088-5; Schwingshackl L, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101063; Secretan B, 2009, LANCET ONCOL, V10, P1033, DOI 10.1016/S1470-2045(09)70326-2; Shivappa N, 2019, EUR J NUTR, V58, P2755, DOI 10.1007/s00394-018-1825-8; Shivappa N, 2017, NUTRIENTS, V9, DOI 10.3390/nu9091043; Shivappa N, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600592; Shivappa N, 2016, NUTR CANCER, V68, P1262, DOI 10.1080/01635581.2016.1224367; Shivappa N, 2015, BRIT J NUTR, V114, P152, DOI 10.1017/S0007114515001828; Shivappa N, 2014, PUBLIC HEALTH NUTR, V17, P1825, DOI 10.1017/S1368980013002565; Shivappa N, 2014, PUBLIC HEALTH NUTR, V17, P1689, DOI 10.1017/S1368980013002115; Sofi F, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1344; Tabung FK, 2016, EUR J CLIN NUTR, V70, P1374, DOI 10.1038/ejcn.2016.116; Tabung FK, 2015, ANN EPIDEMIOL, V25, P398, DOI 10.1016/j.annepidem.2015.03.009; Tognon G, 2012, J NUTR, V142, P1547, DOI 10.3945/jn.112.160499; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Weinehall L, 1998, SCAND J PRIM HEALTH, V16, P171; Wennberg M, 2009, PUBLIC HEALTH NUTR, V12, P1477, DOI 10.1017/S1368980008004503; Zaidi SF, 2017, NUTR CANC, P1	45	25	25	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2019	14	4							e0214551	10.1371/journal.pone.0214551	http://dx.doi.org/10.1371/journal.pone.0214551			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT1UC	30978193	Green Published, Green Submitted, gold			2023-01-03	WOS:000464349000016
J	de Sena, DP; Fabricio, DD; da Silva, VD; Bodanese, LC; Franco, AR				de Sena, David P.; Fabricio, Daniela D.; da Silva, Vinicius D.; Bodanese, Luiz Carlos; Franco, Alexandre R.			Comparative evaluation of video-based on-line course versus serious game for training medical students in cardiopulmonary resuscitation: A randomised trial	PLOS ONE			English	Article							BASIC LIFE-SUPPORT; ASSOCIATION GUIDELINES UPDATE; EUROPEAN RESUSCITATION; COUNCIL GUIDELINES; CARDIAC-ARREST; SIMULATION; PERFORMANCE; SURVIVAL; TECHNOLOGY; EDUCATION	Purpose To estimate the effect size of a serious game for cardiopulmonary resuscitation (CPR) training in comparison with a video-based on-line course in terms of learning outcomes among medical students before simulation-based CPR using a manikin. Methods Participants were 45 first-year medical students randomly assigned to CPR self-training using either a video-based Apple Keynote presentation (n = 22) or a serious game developed in a 3D learning environment (n = 23) for up to 20 min. Each participant was evaluated on a written, multiple-choice test (theoretical test) and then on a scenario of cardiac arrest (practical test) before and after exposure to the self-learning methods. The primary endpoint was change in theoretical and practical baseline scores during simulated CPR. This study was conducted in 2017. Results Both groups improved scores after exposure. The video group had superior performance in both the theoretical test (7.56 +/- 0.21 vs 6.51 +/- 0.21 for the game group; p = 0.001) and the practical test (9.67 +/- 0.21 vs 8.40 +/- 0.21 for the game group; p < 0.001). However, students showed a preference for using games, as suggested by the longer time they remained interested in the method (18.57 +/- 0.66 min for the game group vs 7.41 +/- 0.43 for the video group; p <0.001). Conclusions The self-training modality using a serious game, after a short period of exposure, resulted in inferior students' performance in both theoretical and practical CPR tests compared to the video-based self-training modality. However, students showed a clear preference for using games rather than videos as a form of self-training.	[de Sena, David P.] Pontificia Univ Catolica Rio Grande do Sul PUCRS, Sch Hlth Sci, Postgrad Program Hlth Sci, Porto Alegre, RS, Brazil; [Fabricio, Daniela D.] Pontificia Univ Catolica Rio Grande do Sul, Dept Otolaryngol, Porto Alegre, RS, Brazil; [da Silva, Vinicius D.] Hosp Canc Barretos, Dept Pathol Anat, Sao Paulo, Brazil; [Bodanese, Luiz Carlos] Pontificia Univ Catolica Rio Grande do Sul, Dept Cardiol, Porto Alegre, RS, Brazil; [Franco, Alexandre R.] Pontificia Univ Catolica Rio Grande do Sul, Brain Inst Rio Grande do Sul, Porto Alegre, RS, Brazil	Pontificia Universidade Catolica Do Rio Grande Do Sul; Pontificia Universidade Catolica Do Rio Grande Do Sul; Hospital de Cancer de Barretos; Pontificia Universidade Catolica Do Rio Grande Do Sul; Pontificia Universidade Catolica Do Rio Grande Do Sul	de Sena, DP (corresponding author), Pontificia Univ Catolica Rio Grande do Sul PUCRS, Sch Hlth Sci, Postgrad Program Hlth Sci, Porto Alegre, RS, Brazil.	dublesena@hotmail.com	Rosa Franco, Alexandre/D-1706-2015	Rosa Franco, Alexandre/0000-0002-1552-1090				Alam F, 2016, ADV HEALTH SCI EDUC, V21, P789, DOI 10.1007/s10459-016-9666-9; American Heart Association, 2016, AD CPR AED SKILLS TE; Berdowski J, 2010, RESUSCITATION, V81, P1479, DOI 10.1016/j.resuscitation.2010.08.006; Bhanji F, 2015, CIRCULATION, V132, pS561, DOI 10.1161/CIR.0000000000000268; Bhatti I, 2011, COLORECTAL DIS, V13, P459, DOI 10.1111/j.1463-1318.2009.02173.x; Boada I, 2015, COMPUT METH PROG BIO, V122, P282, DOI 10.1016/j.cmpb.2015.08.006; Buttussi F, 2013, INT J MED INFORM, V82, P798, DOI 10.1016/j.ijmedinf.2013.05.007; Cook DA, 2013, ACAD MED, V88, P1178, DOI 10.1097/ACM.0b013e31829a365d; Cook NF, 2012, NURS EDUC TODAY, V32, P714, DOI 10.1016/j.nedt.2011.09.013; Cortegiani A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169591; Creutzfeldt J, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-79; Dankbaar M, 2017, PERSPECT MED EDUC, V6, P58, DOI 10.1007/s40037-016-0320-2; Dankbaar MEW, 2017, BMC MED EDUC, V17, DOI 10.1186/s12909-016-0836-5; de Sena DP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065833; de Vries W, 2008, RESUSCITATION, V76, P76, DOI 10.1016/j.resuscitation.2007.06.030; Doughty CB, 2015, PEDIATRICS, V136, pE152, DOI 10.1542/peds.2014-4158; Drummond D, 2017, EUR J ANAESTH, V34, P836, DOI 10.1097/EJA.0000000000000675; Ericsson KA, 2004, ACAD MED, V79, pS70, DOI 10.1097/00001888-200410001-00022; Grasner JT, 2011, RESUSCITATION, V82, P989, DOI 10.1016/j.resuscitation.2011.02.047; Greif R, 2015, RESUSCITATION, V95, P288, DOI 10.1016/j.resuscitation.2015.07.032; Miotto HC, 2010, ARQ BRAS CARDIOL, V95, P328, DOI 10.1590/S0066-782X2010005000104; Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350; O'Leary FM, 2010, EMERG MED AUSTRALAS, V22, P324, DOI 10.1111/j.1742-6723.2010.01302.x; Roppolo LP, 2011, RESUSCITATION, V82, P319, DOI 10.1016/j.resuscitation.2010.10.025; Ruiz JG, 2006, ACAD MED, V81, P207, DOI 10.1097/00001888-200603000-00002; Thorne CJ, 2015, RESUSCITATION, V90, P79, DOI 10.1016/j.resuscitation.2015.02.026; Tobase L, 2017, INT J MED EDUC, V8, P309, DOI 10.5116/ijme.5985.cbce; Vadeboncoeur T, 2014, RESUSCITATION, V85, P182, DOI 10.1016/j.resuscitation.2013.10.002; Wattanasoontorn V, 2014, RESUSCITATION, V85, pS72, DOI [10.1016/j.resuscitation.2014.03.182, DOI 10.1016/J.RESUSCITATION.2014.03.182]; Wayne DB, 2006, J GEN INTERN MED, V21, P251, DOI 10.1111/j.1525-1497.2006.00341.x	33	8	8	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2019	14	4							e0214722	10.1371/journal.pone.0214722	http://dx.doi.org/10.1371/journal.pone.0214722			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HS2MY	30958836	Green Published, Green Submitted, gold			2023-01-03	WOS:000463695900018
J	Xu, CH; Li, RZ; Shewade, HD; Jeyashree, K; Ruan, YZ; Zhang, CY; Wang, LX; Zhang, H				Xu, Caihong; Li, Renzhong; Shewade, Hemant Deepak; Jeyashree, Kathiresan; Ruan, Yunzhou; Zhang, Canyou; Wang, Lixia; Zhang, Hui			Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors	PLOS ONE			English	Article							RESISTANT TUBERCULOSIS; DIAGNOSIS; TIME	Background China's national tuberculosis programme does not have cohort wise information regarding attrition and delays in the multidrug resistant tuberculosis (MDR-TB) diagnosis and treatment pathway. Objective Under the Global Fund programmatic management of drug-resistant TB (2006-13), we assessed the attrition and delay in the pathway and the factors associated. Methods Cohort study involving secondary programme data. All patients identified as presumptive MDR-TB (defined as i) previously treated TB patients which included recurrent TB, return after loss to follow up, treatment after failure and ii) new TB patients that were non-converters at three months of treatment or in close contact with a known MDR-TB patient) during October 2006 to June 2013 were eligible for phenotypic drug susceptibility testing (DST). Pre-diagnosis attrition (presumptive MDR-TB not undergoing culture and DST) and pretreatment attrition (confirmed MDR-TB patients not initiated on treatment) was calculated. Diagnosis delay was the time interval from DST eligibility to DST result, treatment initiation delay was fom DST result to treatment initiation and total delay was from DST eligbility to treatment initiation. Factors associated with attrition and delay were identified using log binomial regression and linear regression, respectively. Results Of 78 564 presumptive MDR-TB patients, 2 470 (3.1%) underwent pre-diagnosis attrition. Of 9 283 MDR-TB patients, 3 361 (36.2%) underwent pre-treatment attrition. Median(IQR) diagnosis delay was 84 (64, 114) days; treatment initation delay was 23(6,68) days and total delay was 117(77,187) days. Long diagnosis delay was an independent predictor of pretreatment attrition in a dose response relationship. While pre-treatment attrition was less likely among presumptive criterion 'previously treated' and with increasing time period, it was more likey among elderly and in east and west region. While the diagnosis delay increased with time period, treatment initiation delay and total delay reduced with time period. Short diagnosis delay was associated with west region, smear negative patients and presumptive criterion 'treatment after lost to follow up'. Short treatment initiation delay was associatied with east and west regions while long treatment initiation delay was associated with elderly and presumptive criterion 'recurrent TB'. Total delay predictors were similar to treatment initiation delay. In addition, short total delay was associated with presumptive criterion 'treatment after failure'. Conclusion The diagnosis and treatment delay were long and the pre-treatment attrition was considerable high. Long diagnosis delay is likely to predict pre-treatment attrition.	[Xu, Caihong; Li, Renzhong; Ruan, Yunzhou; Zhang, Canyou; Wang, Lixia; Zhang, Hui] China Ctr Dis Control CDC, Natl Ctr TB Control & Prevent, Beijing, Peoples R China; [Shewade, Hemant Deepak] Int Union TB & Lung Dis, South East Asia Off, New Delhi, India; [Shewade, Hemant Deepak] Int Union TB & Lung Dis, Paris, France; [Shewade, Hemant Deepak] Karuna Trust, Bengaluru, India; [Jeyashree, Kathiresan] Velammal Med Coll Hosp & Res Inst, Madurai, Tamil Nadu, India		Zhang, H (corresponding author), China Ctr Dis Control CDC, Natl Ctr TB Control & Prevent, Beijing, Peoples R China.	zhanghui@chinacdc.cn	Jeyashree, Kathiresan/A-9496-2016; Shewade MD PhD, Hemant Deepak/J-3907-2019	Jeyashree, Kathiresan/0000-0001-6459-3659; Shewade MD PhD, Hemant Deepak/0000-0002-8242-1911; Zhang, Canyou/0000-0003-1819-5347	Department for International Development (DFID), UK; FIDELIS project	Department for International Development (DFID), UK; FIDELIS project	The author(s) received no specific funding for this work. The training programmes were funded by the Department for International Development (DFID), UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The open access costs were covered with support from FIDELIS project.; This research was conducted through the Structured Operational Research and Training Initiative (SORT IT), a global partnership led by the Special Program for Research and Training in Tropical Diseases at the World Health Organization (WHO/TDR). The model is based on a course developed jointly by the International Union Against Tuberculosis and Lung Disease (The Union) and Medecins sans Frontieres (MSF/Doctors Without Borders). The specific SORT IT program which resulted in this publication was jointly developed and implemented by: The Union South-East Asia Office, New Delhi, India; the Center for Operational Research, The Union, Paris, France; The Union, Mandalay, Myanmar; The Union, Harare, Zimbabwe; MSF Luxembourg Operational Research (LuxOR); MSF Operational Center Brussels (MSF OCB); Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India; Velammal Medical College Hospital and Research Institute, Madurai, India; National Center for Tuberculosis Control and Prevention, China CDC, Beijing, China and Khesar Gyalpo University Medical Sciences, Thimpu, Bhutan.	Abeygunawardena SC, 2014, PUBLIC HEALTH ACTION, V4, P105, DOI 10.5588/pha.13.0111; [Anonymous], 2011, AUT REAL TIM NUCL AC; Boyd R, 2017, INT J TUBERC LUNG D, V21, P1173, DOI 10.5588/ijtld.17.0230; Chadha SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026659; Chen Y, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.02259-17, 10.1128/aac.02259-17]; China National Center for Tuberculosis Control and Prevention, 2012, MULT RES TUB PREV MA; Cox H, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002238; Harris RC, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1524-0; Hossain ST, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129155; HSE National Drug Treatment Centre, 2016, CERV SMEAR GUID; Khann S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059903; Kibret KT, 2017, INFECT DIS POVERTY, V6, DOI 10.1186/s40249-016-0214-x; Kilale AM, 2013, PUBLIC HEALTH ACTION, V3, P156, DOI 10.5588/pha.12.0103; Li Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088330; Qi W, 2011, INT J TUBERC LUNG D, V15, P137; Shewade D, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2191-6; Shewade HD, 2018, PUBLIC HEALTH ACTION, V8, P59, DOI 10.5588/pha.18.0003; Shewade HD, 2016, PUBLIC HEALTH ACTION, V6, P242, DOI 10.5588/pha.16.0075; Shewade HD, 2015, PUBLIC HEALTH ACTION, V5, P132, DOI 10.5588/pha.14.0098; Shewade HD, 2017, J TUBERC RES, V5, P237, DOI [10.4236/jtr.2017.54025, DOI 10.4236/JTR.2017.54025]; Shewade HD, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196162; Shewade HD, 2017, J EPIDEMIOL GLOB HEA, V7, P227, DOI 10.1016/j.jegh.2017.07.001; Wai PP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194087; Wang LX, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177536; Wang LX, 2014, LANCET, V383, P2057, DOI 10.1016/S0140-6736(13)62639-2; World Health Organization, 2021, B WORLD HEALTH ORGAN, DOI DOI 10.2471/BLT.21.286807; World Health Organization, 2015, CHIN WHO STAT PROF; World Health Organization, 2014, WHOHTMTB201408; World Health Organization, 2018, END TB STRAT GLOB ST	29	11	12	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2019	14	4							e0214943	10.1371/journal.pone.0214943	http://dx.doi.org/10.1371/journal.pone.0214943			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HS2MY	30958841	Green Published, Green Submitted, gold			2023-01-03	WOS:000463695900028
J	Maley, MJ; Hunt, AP; Stewart, IB; Faulkner, SH; Minett, GM				Maley, Matthew J.; Hunt, Andrew P.; Stewart, Ian B.; Faulkner, Steve H.; Minett, Geoffrey M.			Passive heating and glycaemic control in non-diabetic and diabetic individuals: A systematic review and meta-analysis	PLOS ONE			English	Review							INDUCED INSULIN-RESISTANCE; REPEATED THERMAL THERAPY; ORAL GLUCOSE-TOLERANCE; HOT-TUB THERAPY; SHOCK PROTEINS; AMBIENT-TEMPERATURE; SKELETAL-MUSCLE; NITRIC-OXIDE; ENDOTHELIAL FUNCTION; STRESS-RESPONSE	Objective Passive heating (PH) has begun to gain research attention as an alternative therapy for cardio-metabolic diseases. Whether PH improves glycaemic control in diabetic and non-diabetic individuals is unknown. This study aims to review and conduct a meta-analysis of published literature relating to PH and glycaemic control. Methods Electronic data sources, PubMed, Embase and Web of Science from inception to July 2018 were searched for randomised controlled trials (RCT) studying the effect of PH on glycaemic control in diabetic or non-diabetic individuals. To measure the treatment effect, standardised mean differences (SMD) with 95% confidence intervals (CI) were calculated. Results Fourteen articles were included in the meta-analysis. Following a glucose load, glucose concentration was greater during PH in non-diabetic (SMD 0.75, 95% CI 1.02 to 0.48, P < 0.001) and diabetic individuals (SMD 0.27, 95% CI 0.52 to 0.02, P = 0.030). In non-diabetic individuals, glycaemic control did not differ between PH and control only (SMD 0.11, 95% CI 0.44 to -0.22, P > 0.050) and a glucose challenge given within 24 hours post-heating (SMD 0.30, 95% CI 0.62 to -0.02, P > 0.050). Conclusion PH preceded by a glucose load results in acute glucose intolerance in non-diabetic and diabetic individuals. However, heating a non-diabetic individual without a glucose load appears not to affect glycaemic control. Likewise, a glucose challenge given within 24 hours of a single-bout of heating does not affect glucose tolerance in non-diabetic individuals. Despite the promise PH may hold, no short-term benefit to glucose tolerance is observed in non-diabetic individuals. More research is needed to elucidate whether this alternative therapy benefits diabetic individuals.	[Maley, Matthew J.; Hunt, Andrew P.; Stewart, Ian B.; Minett, Geoffrey M.] Queensland Univ Technol, Sch Exercise & Nutr Sci, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia; [Maley, Matthew J.] Univ Portsmouth, Dept Sport & Exercise Sci, Portsmouth, Hants, England; [Faulkner, Steve H.] Nottingham Trent Univ, Sch Sci & Technol, Dept Engn, Nottingham, England	Queensland University of Technology (QUT); University of Portsmouth; Nottingham Trent University	Maley, MJ (corresponding author), Queensland Univ Technol, Sch Exercise & Nutr Sci, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia.; Maley, MJ (corresponding author), Univ Portsmouth, Dept Sport & Exercise Sci, Portsmouth, Hants, England.	matthew.maley@port.ac.uk	Hunt, Andrew/ABF-9558-2020; Stewart, Ian B/I-9927-2012; Minett, Geoffrey/L-5757-2017; Maley, Matthew J/AAC-7041-2020; Faulkner, Steve/AAA-2262-2020	Minett, Geoffrey/0000-0003-4617-2820; Maley, Matthew J/0000-0001-5200-7640; Faulkner, Steve/0000-0003-4688-7252; Hunt, Andrew/0000-0002-2753-7567; Stewart, Ian/0000-0003-1741-718X				AKANJI AO, 1987, DIABETOLOGIA, V30, P431, DOI 10.1007/BF00292547; AKANJI AO, 1991, TROP GEOGR MED, V43, P283; Al-Qaissi A, 2019, DIABETES OBES METAB, V21, P569, DOI 10.1111/dom.13555; American Diabetes Association, 2017, Diabetes Care, V40, pS88; Archer AE, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0529; Atalay M, 2004, J APPL PHYSIOL, V97, P605, DOI 10.1152/japplphysiol.01183.2003; Atalay M, 2009, CURR PROTEIN PEPT SC, V10, P85, DOI 10.2174/138920309787315202; BARON AD, 1994, AM J PHYSIOL, V266, pE248, DOI 10.1152/ajpendo.1994.266.2.E248; Bathaie SZ, 2010, INT J HYPERTHER, V26, P577, DOI 10.3109/02656736.2010.485594; Beever R, 2010, J ALTERN COMPLEM MED, V16, P677, DOI 10.1089/acm.2009.0358; BLAAK EE, 1992, J APPL PHYSIOL, V72, P2364, DOI 10.1152/jappl.1992.72.6.2364; Brenner I, 1998, INT J SPORTS MED, V19, P130, DOI 10.1055/s-2007-971895; Bruce CR, 2003, DIABETES, V52, P2338, DOI 10.2337/diabetes.52.9.2338; Brunt VE, 2016, J PHYSIOL-LONDON, V594, P5329, DOI 10.1113/JP272453; Brunt VE, 2016, J APPL PHYSIOL, V121, P716, DOI 10.1152/japplphysiol.00424.2016; Chung J, 2008, P NATL ACAD SCI USA, V105, P1739, DOI 10.1073/pnas.0705799105; Dumke CL, 2015, WILD ENVIRON MED, V26, P335, DOI 10.1016/j.wem.2015.03.002; Edkins AL, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0521; Ely Brett R, 2018, Temperature (Austin), V5, P9, DOI 10.1080/23328940.2017.1384089; Faure C, 2016, CLIN SCI, V130, P1017, DOI 10.1042/CS20150461; FRAYN KN, 1989, CLIN SCI, V76, P323, DOI 10.1042/cs0760323; Geiger PC, 2011, EXERC SPORT SCI REV, V39, P34, DOI 10.1097/JES.0b013e318201f236; Gibson OR, 2014, CELL STRESS CHAPERON, V19, P389, DOI 10.1007/s12192-013-0468-1; Gryka D, 2014, INT J OCCUP MED ENV, V27, P608, DOI 10.2478/s13382-014-0281-9; Gupte AA, 2011, J APPL PHYSIOL, V110, P451, DOI 10.1152/japplphysiol.00849.2010; Gupte AA, 2009, DIABETES, V58, P567, DOI 10.2337/db08-1070; Habich Christiane, 2017, Current Immunology Reviews, V13, P82, DOI 10.2174/1573395513666170606121625; Hannuksela ML, 2001, AM J MED, V110, P118, DOI 10.1016/S0002-9343(00)00671-9; Hawley JA, 2008, ACTA PHYSIOL, V192, P127, DOI 10.1111/j.1748-1716.2007.01783.x; Heinonen I, 2018, AM J PHYSIOL-REG I, V314, pR629, DOI 10.1152/ajpregu.00115.2017; Heinonen I, 2011, J APPL PHYSIOL, V111, P818, DOI 10.1152/japplphysiol.00269.2011; Henstridge DC, 2014, MOL METAB, V3, P781, DOI 10.1016/j.molmet.2014.08.003; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hooper PL, 2014, CELL STRESS CHAPERON, V19, P447, DOI 10.1007/s12192-014-0493-8; Hooper PL, 2009, CELL STRESS CHAPERON, V14, P113, DOI 10.1007/s12192-008-0073-x; Hooper PL, 1999, NEW ENGL J MED, V341, P924, DOI 10.1056/NEJM199909163411216; Hussain J, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/1857413; Iguchi M, 2012, J ATHL TRAINING, V47, P184; Imamura M, 2001, J AM COLL CARDIOL, V38, P1083, DOI 10.1016/S0735-1097(01)01467-X; Jezova D, 1998, J ENDOCRINOL INVEST, V21, P412; JURCOVICOVA J, 1980, ENDOCRINOL EXP, V14, P221; Kenny Glen P, 2016, Temperature (Austin), V3, P119, DOI 10.1080/23328940.2015.1131506; Kihara T, 2002, J AM COLL CARDIOL, V39, P754, DOI 10.1016/S0735-1097(01)01824-1; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; KOIVISTO VA, 1980, BRIT MED J, V280, P1411, DOI 10.1136/bmj.280.6229.1411; KOIVISTO VA, 1983, ACTA DIABETOL LAT, V20, P175; KOIVISTO VA, 1981, METABOLISM, V30, P402, DOI 10.1016/0026-0495(81)90122-0; Kokura S, 2007, INT J HYPERTHER, V23, P259, DOI 10.1080/02656730601176824; Koshinaka K, 2013, J PHYSIOL SCI, V63, P409, DOI 10.1007/s12576-013-0278-3; Kramer HH, 2004, DIABETES CARE, V27, P2386, DOI 10.2337/diacare.27.10.2386; Krause M, 2015, CURR OPIN CLIN NUTR, V18, P374, DOI 10.1097/MCO.0000000000000183; Krause M, 2015, CLIN SCI, V128, P789, DOI 10.1042/CS20140695; Krause M, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/249205; Kunutsor SK, 2017, EUR J EPIDEMIOL, V32, P1107, DOI 10.1007/s10654-017-0311-6; Kunutsor SK, 2018, NEUROLOGY; Kurucz I, 2002, DIABETES, V51, P1102, DOI 10.2337/diabetes.51.4.1102; LAATIKAINEN T, 1988, EUR J APPL PHYSIOL O, V57, P98, DOI 10.1007/BF00691246; Laukkanen T, 2017, AGE AGEING, V46, P245, DOI 10.1093/ageing/afw212; Laukkanen T, 2015, JAMA INTERN MED, V175, P542, DOI 10.1001/jamainternmed.2014.8187; LEPPALUOTO J, 1986, ACTA PHYSIOL SCAND, V128, P77, DOI 10.1111/j.1748-1716.1986.tb07952.x; Linnane DM, 2004, EUR J APPL PHYSIOL, V93, P159, DOI 10.1007/s00421-004-1191-5; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Malyshev IY, 2000, PHYSIOL RES, V49, P99; Masuda A, 2004, JPN HEART J, V45, P297, DOI 10.1536/jhj.45.297; McCarty MF, 2009, MED HYPOTHESES, V73, P103, DOI 10.1016/j.mehy.2008.12.020; MCGUIRE EAH, 1976, J APPL PHYSIOL, V41, P565, DOI 10.1152/jappl.1976.41.4.565; Miova B, 2016, CURR PHARM DESIGN, V22, P2619, DOI 10.2174/1381612822666160203114738; Moses RG, 1997, DIABETES RES CLIN PR, V36, P35, DOI 10.1016/S0168-8227(97)01391-0; Molina MN, 2016, CURR HYPERTENS REP, V18, DOI 10.1007/s11906-015-0615-4; Norris SL, 2002, DIABETES CARE, V25, P1159, DOI 10.2337/diacare.25.7.1159; Padmalayam I, 2014, DISCOV MED, V18, P29; Pilch W, 2010, INT J OCCUP MED ENV, V23, P167, DOI 10.2478/v10001-010-0020-9; Restaino RM, 2016, AM J PHYSIOL-HEART C, V310, pH648, DOI 10.1152/ajpheart.00943.2015; Rivas E, 2016, J THERM BIOL, V59, P26, DOI 10.1016/j.jtherbio.2016.04.010; Rodrigues-Krause J, 2012, CELL STRESS CHAPERON, V17, P293, DOI 10.1007/s12192-011-0319-x; Rohatgi A., 2018, WEBPLOTDIGITIZER 4 1; Simar D, 2012, CELL STRESS CHAPERON, V17, P615, DOI 10.1007/s12192-012-0336-4; Soti C, 2005, BRIT J PHARMACOL, V146, P769, DOI 10.1038/sj.bjp.0706396; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; STRBAK V, 1987, METABOLISM, V36, P426, DOI 10.1016/0026-0495(87)90038-2; Strokov IA, 2000, B EXP BIOL MED+, V130, P986, DOI 10.1007/BF02682046; TATAR P, 1985, ENDOCRINOL EXP, V19, P277; Thomas KN, 2017, AM J PHYSIOL-REG I, V312, pR281, DOI 10.1152/ajpregu.00404.2016; Thomas Kate Nicole, 2017, Temperature (Austin), V4, P208, DOI 10.1080/23328940.2017.1317379; Whitham M, 2007, J APPL PHYSIOL, V103, P1251, DOI 10.1152/japplphysiol.00484.2007; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zaccardi F, 2017, AM J HYPERTENS, V30, P1120, DOI 10.1093/ajh/hpx102; Zaccardi F, 2016, POSTGRAD MED J, V92, P63, DOI 10.1136/postgradmedj-2015-133281; Zhou B, 2016, LANCET, V387, P1513, DOI 10.1016/S0140-6736(16)00618-8	89	7	7	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2019	14	3							e0214223	10.1371/journal.pone.0214223	http://dx.doi.org/10.1371/journal.pone.0214223			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP9GF	30901372	Green Accepted, Green Published, Green Submitted, gold			2023-01-03	WOS:000462000400043
J	Block, GA; Chertow, GM; Sullivan, JT; Deng, HJ; Mather, O; Tomlin, H; Serenko, M				Block, Geoffrey A.; Chertow, Glenn M.; Sullivan, John T.; Deng, Hongjie; Mather, Omar; Tomlin, Holly; Serenko, Michael			An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; SERUM PARATHYROID-HORMONE; CALCIUM-SENSING RECEPTOR; AMG 416 VELCALCETIDE; CARDIOVASCULAR-DISEASE; PEPTIDE AGONIST; CINACALCET; PHARMACOKINETICS; PROGRESSION; FRACTURE	Background Calcimimetics have been shown to be effective and safe therapies for the treatment of secondary hyperparathyroidism (sHPT), a serious complication of disordered mineral metabolism associated with dialysis-dependent chronic kidney disease. Etelcalcetide, a recently approved intravenous calcimimetic, reduces serum parathyroid hormone (PTH), calcium, phosphorus, and fibroblast growth factor-23 concentrations. Here we report the first integrated safety profile of etelcalcetide using pooled data from five pivotal clinical trials. Methods This analysis included data from patients receiving hemodialysis with moderate to severe sHPT enrolled in two randomized, placebo-controlled trials; a randomized active-controlled (with cinacalcet) trial; and two single-arm, open-label extension trials. Patients initially received etelcalcetide intravenously 5 mg three times weekly (TIW) after hemodialysis; with potential dose increases of 2.5 or 5 mg at 4-week intervals to a maximum dose of 15 mg TIW, depending on serum PTH and calcium levels. The nature, frequency, and severity of treatment-emergent adverse events (AEs) and changes in laboratory parameters were assessed. Results Overall, we evaluated 1023 patients from the placebo-controlled trials, 683 from the active controlled trial, and 1299 from open-label extensions. The frequency and nature of common treatment-emergent AEs reported for the etelcalcetide arm were consistent among the placebo-controlled and active-controlled trials. The most common AEs were those related to mineral metabolism (decreased blood calcium, hypophosphatemia, muscle spasms) or gastrointestinal abnormalities (diarrhea, nausea, vomiting). Hypocalcemia leading to discontinuation of either calcimimetic was experienced in <= 1% of patients. Conclusions This integrated safety assessment of etelcalcetide across placebo- and active-controlled trials showed an overall favorable risk/benefit profile, with safety similar to that of cinacalcet. Consistent with its mechanism of action, the most important risks associated with etelcalcetide were serum calcium reductions and hypocalcemia-related AEs; no new safety findings were identified in the pooled long-term extension trials.	[Block, Geoffrey A.] Denver Nephrol, Denver, CO USA; [Chertow, Glenn M.] Stanford Univ, Stanford, CA 94305 USA; [Sullivan, John T.; Deng, Hongjie; Mather, Omar; Tomlin, Holly; Serenko, Michael] Amgen Inc, Thousand Oaks, CA 91320 USA	Stanford University; Amgen	Mather, O (corresponding author), Amgen Inc, Thousand Oaks, CA 91320 USA.	omather@amgen.com	Block, Geoffrey/AAV-8070-2021	Block, Geoffrey/0000-0002-4646-7074; Chertow, Glenn/0000-0002-7599-0534	Amgen Inc.	Amgen Inc.(Amgen)	This trial was sponsored by Amgen Inc. The funder provided support in the form of salaries for authors JTS, OM, HD, HT, and MS. The funder was involved in the study design, data collection and analysis, decision to publish, and preparation of the manuscript. They also provided funding for medical writing assistance and for the journal publication fee. The specific roles of these authors are articulated in the 'author contributions' section.; The authors acknowledge Miranda Tradewell, PhD, Meghan Johnson, PhD, and James Balwit, MS, CMPP (Complete Healthcare Communications, LLC, North Wales, PA, a CHC Group company), whose work was funded by Amgen Inc., and William W. Stark, Jr, PhD (Amgen employee and stockholder), for assistance in writing this manuscript.	AKIYAMA T, 1989, J ELECTROCARDIOL, V22, P89, DOI 10.1016/0022-0736(89)90026-5; Amgen Inc, 2017, SWISS SUMM RISK MAN; [Anonymous], 2017, PARS PACK INS; [Anonymous], 2017, SENS PACK INS; Behets GJ, 2015, KIDNEY INT, V87, P846, DOI 10.1038/ki.2014.349; Block GA, 2017, JAMA-J AM MED ASSOC, V317, P146, DOI 10.1001/jama.2016.19456; Block GA, 2017, JAMA-J AM MED ASSOC, V317, P156, DOI 10.1001/jama.2016.19468; Brunelli SM, 2015, PHARMACOEPIDEM DR S, V24, P1058, DOI 10.1002/pds.3845; Center for Drug Evaluation and Research, SUMM REV CLASS 2 RES; Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624; Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523-1755.2005.00596.x; Cunningham J, 2011, CLIN J AM SOC NEPHRO, V6, P913, DOI 10.2215/CJN.06040710; Fielden MR, 2016, INT J TOXICOL, V35, P294, DOI 10.1177/1091581816633407; FOLEY RN, 1995, KIDNEY INT, V47, P186, DOI 10.1038/ki.1995.22; Goodman WG, 2008, KIDNEY INT, V74, P276, DOI 10.1038/sj.ki.5002287; Huang TC, 2000, J PEDIATR-US, V136, P404, DOI 10.1067/mpd.2000.103447; KDIGO Workgroup, 2017, KDIGO 2017 CLIN PRAC; Kroenke MA, 2017, J IMMUNOL METHODS, V445, P37, DOI 10.1016/j.jim.2017.03.005; Levin A, 2007, KIDNEY INT, V71, P31, DOI 10.1038/sj.ki.5002009; Martin KJ, 2014, KIDNEY INT, V85, P191, DOI 10.1038/ki.2013.289; Moe SM, 2015, J AM SOC NEPHROL, V26, P1466, DOI 10.1681/ASN.2014040414; Romagnani P, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.88; Subramanian R, 2017, CLIN PHARMACOKINET, V56, P179, DOI 10.1007/s40262-016-0433-0; Subramanian R, 2016, DRUG METAB DISPOS, V44, P1319, DOI 10.1124/dmd.115.068007; Walter S, 2013, J PHARMACOL EXP THER, V346, P229, DOI 10.1124/jpet.113.204834; Wanner C, 2016, LANCET, V388, P276, DOI 10.1016/S0140-6736(16)30508-6	26	8	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2019	14	3							e0213774	10.1371/journal.pone.0213774	http://dx.doi.org/10.1371/journal.pone.0213774			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO9WM	30875390	gold, Green Published, Green Submitted			2023-01-03	WOS:000461316400029
J	Ddungu, H; Krantz, EM; Kajja, I; Naluzze, S; Nabbanja, H; Nalubwama, F; Phipps, W; Orem, J; Kiwanuka, N; Wald, A				Ddungu, Henry; Krantz, Elizabeth M.; Kajja, Isaac; Naluzze, Sandra; Nabbanja, Hanifah; Nalubwama, Flavia; Phipps, Warren; Orem, Jackson; Kiwanuka, Noah; Wald, Anna			How low can you go: What is the safe threshold for platelet transfusions in patients with hematologic malignancy in sub-Saharan Africa	PLOS ONE			English	Article							PROSPECTIVE RANDOMIZED-TRIAL; ACUTE-LEUKEMIA; AUDIT; BLOOD; CANCER; ADULTS; COMPLICATIONS; CHALLENGES; CHILDREN; RISKS	Background Despite the importance of platelet transfusions in treatment of hematologic cancer patients, the optimal platelet count threshold for prophylactic transfusion is unknown in sub-Saharan Africa. Methods We followed patients admitted to the Uganda Cancer Institute with a hematological malignancy in 3 sequential 4-month time-periods using incrementally lower thresholds for prophylactic platelet transfusion: platelet counts <= 30 x 10(9)/L in period 1, <= 20 x 10(9)/L in period 2, and <= 10 x 10(9)/L in period 3. Clinically significant bleeding was defined as WHO grade >= 2 bleeding. We used generalized estimating equations (GEE) to compare the frequency of clinically significant bleeding and platelet transfusions by study period, adjusting for age, sex, cancer type, chemotherapy, baseline platelet count, and baseline hemoglobin. Results Overall, 188 patients were enrolled. The median age was 22 years (range 1-80). Platelet transfusions were given to 42% of patients in period 1, 55% in period 2, and 45% in period 3. These transfusions occurred on 8% of days in period 1, 12% in period 2, and 8% in period 3. In adjusted models, period 3 had significantly fewer transfusions than period 1 (RR = 0.6, 95% CI 0.4-0.9; p = 0.01) and period 2 (RR = 0.5, 95% CI 0.4-0.7; p< 0.001). Eighteen patients (30%) had clinically significant bleeding on at least one day in period 1, 23 (30%) in period 2, and 15 (23%) in period 3. Clinically significant bleeding occurred on 8% of patientdays in period 1, 9% in period 2, and 5% in period 3 (adjusted p = 0.41). Thirteen (21%) patients died in period 1, 15 (22%) in period 2, and 11 (19%) in period 3 (adjusted p = 0.96). Conclusion Lowering the threshold for platelet transfusion led to fewer transfusions and did not change the incidence of clinically significant bleeding or mortality, suggesting that a threshold of 10 x 10(9) /L platelets, used in resource-rich countries, may be implemented as a safe level for transfusions in sub-Saharan Africa.	[Ddungu, Henry; Naluzze, Sandra; Nabbanja, Hanifah; Nalubwama, Flavia; Orem, Jackson] Uganda Canc Inst, Upper Mulago Hill Rd, Kampala, Uganda; [Krantz, Elizabeth M.; Phipps, Warren; Wald, Anna] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA; [Kajja, Isaac] Makerere Univ, Coll Hlth Sci, Sch Med, Kampala, Uganda; [Phipps, Warren; Wald, Anna] Univ Washington, Dept Med, Seattle, WA USA; [Kiwanuka, Noah] Makerere Univ, Coll Hlth Sci, Sch Publ Hlth, Kampala, Uganda; [Wald, Anna] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Wald, Anna] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; Makerere University; University of Washington; University of Washington Seattle; Makerere University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Ddungu, H (corresponding author), Uganda Canc Inst, Upper Mulago Hill Rd, Kampala, Uganda.	hddungu@fredhutch.org		Ddungu, Henry/0000-0001-9227-4030	Fogarty/NCI D43 Training Grants [D43 CA153720, D43 TW009759]; FOGARTY INTERNATIONAL CENTER [D43TW009759] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [U54CA190146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027757] Funding Source: NIH RePORTER	Fogarty/NCI D43 Training Grants; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	sThis study was supported by the Fogarty/NCI D43 Training Grants (D43 CA153720; D43 TW009759).	BELT RJ, 1978, JAMA-J AM MED ASSOC, V239, P2571, DOI 10.1001/jama.239.24.2571; Buhrkuhl DC, 2012, INTERN MED J, V42, P65, DOI 10.1111/j.1445-5994.2010.02358.x; Callow CR, 2002, BRIT J HAEMATOL, V118, P677, DOI 10.1046/j.1365-2141.2002.03616.x; Dhingra N, 2012, VOX SANG, V103, P337, DOI 10.1111/j.1423-0410.2012.01630.x; Diedrich B, 2005, TRANSFUSION, V45, P1064, DOI 10.1111/j.1537-2995.2005.04157.x; Estcourt LJ, 2016, JAMA ONCOL, V2, P1091, DOI 10.1001/jamaoncol.2016.2466; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; GAYDOS LA, 1962, NEW ENGL J MED, V266, P905, DOI 10.1056/NEJM196205032661802; Gopal S, 2012, BLOOD, V119, P5078, DOI 10.1182/blood-2012-02-387092; HAN T, 1966, CANCER, V19, P1937, DOI 10.1002/1097-0142(196612)19:12<1937::AID-CNCR2820191221>3.0.CO;2-G; Heckman KD, 1997, J CLIN ONCOL, V15, P1143, DOI 10.1200/JCO.1997.15.3.1143; Josephson CD, 2012, BLOOD, V120, P748, DOI 10.1182/blood-2011-11-389569; Kaufman RM, 2015, ANN INTERN MED, V162, P205, DOI 10.7326/M14-1589; Kelsey P, 2003, BRIT J HAEMATOL, V122, P10; Lund TC, 2013, TRANSFUS APHER SCI, V49, P416, DOI 10.1016/j.transci.2013.06.014; MURPHY S, 1982, AM J HEMATOL, V12, P347, DOI 10.1002/ajh.2830120406; Orem J, 2009, ONCOLOGY-BASEL, V77, P272, DOI 10.1159/000259258; Osaro E, 2011, J BLOOD MED, V2, P7, DOI 10.2147/JBM.S17194; Politsmakher A, 2013, AM J MED, V126, P894, DOI 10.1016/j.amjmed.2013.06.013; Qureshi H, 2007, TRANSFUS CLIN BIOL, V14, P509, DOI 10.1016/j.tracli.2008.01.002; Rebulla P, 1997, NEW ENGL J MED, V337, P1870, DOI 10.1056/NEJM199712253372602; Schiffer CA, 2001, J CLIN ONCOL, V19, P1519, DOI 10.1200/JCO.2001.19.5.1519; Slichter Sherrill J, 2007, Hematology Am Soc Hematol Educ Program, P172, DOI 10.1182/asheducation-2007.1.172; SLICHTER SJ, 1976, BRIT J HAEMATOL, V34, P403, DOI 10.1111/j.1365-2141.1976.tb03587.x; Solves P, 2014, TRANSFUS APHER SCI, V50, P228, DOI 10.1016/j.transci.2013.11.009; Sonnekus PH, 2014, TRANSFUS APHER SCI, V51, P44, DOI 10.1016/j.transci.2014.10.011; Stanworth SJ, 2005, BRIT J HAEMATOL, V131, P588, DOI 10.1111/j.1365-2141.2005.05769.x; van Veen JJ, 2010, BRIT J HAEMATOL, V148, P15, DOI 10.1111/j.1365-2141.2009.07899.x; Vavricka SR, 2003, ANN HEMATOL, V82, P570, DOI 10.1007/s00277-003-0707-0; Yelland LN, 2011, AM J EPIDEMIOL, V174, P984, DOI 10.1093/aje/kwr183; Zumberg MS, 2002, BIOL BLOOD MARROW TR, V8, P569, DOI 10.1053/bbmt.2002.v8.pm12434952	31	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2019	14	2							e0211648	10.1371/journal.pone.0211648	http://dx.doi.org/10.1371/journal.pone.0211648			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK4EL	30726290	Green Published, gold, Green Submitted			2023-01-03	WOS:000457874000070
J	Bleakley, T; Smith, R; Taylor, R				Bleakley, Tracey; Smith, Richard; Taylor, Ros			Has the NHS Long Term Plan forgotten we are all going to die?	LANCET			English	Editorial Material							COMPRESSION		[Bleakley, Tracey] Hosp UK, London, England; [Smith, Richard] The Lancet, London EC2Y 5AS, England; [Taylor, Ros] Royal Marsden, London, England	Royal Marsden NHS Foundation Trust	Smith, R (corresponding author), The Lancet, London EC2Y 5AS, England.	richardswsmith@yahoo.co.uk						Crimmins EM, 2011, J GERONTOL B-PSYCHOL, V66, P75, DOI 10.1093/geronb/gbq088; Disabled Living Foundation, 2009, LOS IND IS BIGG AG W; Durant William, 2005, STORY PHILOS; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; Hunter J., 2018, END LIFE CARE ENGLAN; Institute of Medicine of the National Academies, 2015, DYING AM IMPR QUAL H; National Council for Palliative Care, 2015, TIM ACT WHY END LIF; O'Mahony S., 2017, THE WAY WE DIE NOW; Public Health England, 2018, REV REC TRENDS MORT; Triggle N, 2019, BBC NEWS	10	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 2	2019	393	10170					387	389		10.1016/S0140-6736(19)30201-6	http://dx.doi.org/10.1016/S0140-6736(19)30201-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HK1AM	30712890				2023-01-03	WOS:000457636900010
J	Olagaray, KE; Brouk, MJ; Mamedova, LK; Sivinski, SE; Liu, H; Robert, F; Dupuis, E; Zachut, M; Bradford, J				Olagaray, K. E.; Brouk, M. J.; Mamedova, L. K.; Sivinski, S. E.; Liu, H.; Robert, F.; Dupuis, E.; Zachut, M.; Bradford, J.			Dietary supplementation of Scutellaria baicalensis extract during early lactation decreases milk somatic cells and increases whole lactation milk yield in dairy cattle	PLOS ONE			English	Article							COWS; PERFORMANCE; INFLAMMATION; INDICATORS; QUERCETIN; BIOAVAILABILITY; BAICALIN; STRESS; GLUCOSE-6-PHOSPHATE; LIPOPOLYSACCHARIDE	Systemic inflammation is common in early lactation dairy cows and is associated with decreased milk production. The Scutellaria baicalensis plant contains flavonoids with anti-inflammatory and anti-oxidative properties, which may counteract the inflammatory state in early lactation dairy cows. The objective of this experiment was to determine whether Scutellaria baicalensis extract (SBE), a source of bioactive flavonoids, would alter the adaptation to lactation. Multiparous Holstein cows (n = 122) were used in a randomized block design to determine the effect of short-term and long-term postpartum administration of SBE on 305-d milk yield, 120-d milk component yield, and early lactation milk markers of inflammation and metabolic function. Treatments were 1) control, 2) short term (5-d) administration of the SBE (SBE5), and 3) long term (60-d) administration of the SBE (SBE60). Treatments were included in a treatment pellet that was identical to a control pellet in ingredient source and composition except for the extract (10 g/d SBE providing 3.3 g/d of the flavonoid baicalin), both provided via an automated milking system beginning on d 1 of lactation. Milk samples were collected on d 1, 3, and once during d 5-12 of lactation, followed by weekly sampling until 120 days in milk (DIM). Milk samples collected in the first 2 wk were used for biomarker analysis (haptoglobin, P-hydroxybutyrate [BHB], and glucose-6-phosphate [G6P]), and all samples were used for composition analysis. Cows were body condition scored every 2 wk prepartum and postpartum. Milk production, programmed pellet allocation, and actual provision of both pelleted feeds were recorded daily. Treatment effects were evaluated by contrasts between control and SBE5 and control and SBE60 for both the treatment (TP; wk 1-9) and carryover periods (CP; wk 10-37). Total pellet offered was greater for SBE60 in both the TP (P < 0.01) and CP (P = 0.02) but was not different for SBE5 during either period (P >= 0.13). No treatment effects were observed for body condition score (BCS), milk haptoglobin, BHB, or G6P. SBE5 did not alter milk yield or milk components. SBE60 increased whole-lactation milk yield by 1,419 kg (13%; P=0.03). SBE60 increased milk lactose and fat yields (P <= 0.04) and tended to increase milk protein yield (P=0.09) during TP, and each increased during CP (P <= 0.04). Somatic cell count decreased by 10% in SBE60 during TP (P=0.02) but not CP (P=0.13). Mastitis incidence tended to differ by treatment, being lesser for both SBE5 and SBE60 vs. control (14 and 15% vs. 33%). SBE supplementation did not impact time to pregnancy or hazard of leaving the herd. In conclusion, despite no detected treatment effects on BCS or milk biomarkers of inflammation and metabolic status, supplementation of postpartum dairy cows with Scutellaria baicalensis extract for 60 d was effective at increasing whole lactation milk yield.	[Olagaray, K. E.; Brouk, M. J.; Mamedova, L. K.; Sivinski, S. E.; Liu, H.; Bradford, J.] Kansas State Univ, Dept Anim Sci & Ind, Manhattan, KS 66506 USA; [Robert, F.; Dupuis, E.] CCPA Grp, Janze, France; [Zachut, M.] Agr Res Org, Volcani Ctr, Rishon Leziyyon, Israel	Kansas State University; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH	Bradford, J (corresponding author), Kansas State Univ, Dept Anim Sci & Ind, Manhattan, KS 66506 USA.	bbradfor@ksu.edu	Bradford, Barry/B-7870-2010	Bradford, Barry/0000-0002-6775-4961; Mamedova, Laman/0000-0003-3612-0381	CCPA Group (Janze, France)	CCPA Group (Janze, France)	Contribution no. 18-364-J from the Kansas Agricultural Experiment Station. This work was funded in part by CCPA Group (Janze, France). The funder provided support in the form of salaries for authors FR and EDP, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	[Anonymous], 2001, NUTR REQ DAIR CATTL, DOI DOI 10.17226/9825; Balcells J, 2012, J ANIM SCI, V90, P4975, DOI 10.2527/jas.2011-4955; Ballou MA, 2013, FLOR RUM NUTR S, P50; Bauman DE, 2003, ANNU REV NUTR, V23, P203, DOI 10.1146/annurev.nutr.23.011702.073408; Berger LM, 2012, J DAIRY SCI, V95, P5047, DOI 10.3168/jds.2012-5439; Bertoni G, 2008, J DAIRY SCI, V91, P3300, DOI 10.3168/jds.2008-0995; Besle JM, 2010, J DAIRY SCI, V93, P2846, DOI 10.3168/jds.2009-2939; Bjerre-Harpoth V, 2016, J DAIRY RES, V83, P156, DOI 10.1017/S0022029916000145; Bradford BJ, 2015, J DAIRY SCI, V98, P6631, DOI 10.3168/jds.2015-9683; Carpenter AJ, 2016, J DAIRY SCI, V99, P672, DOI 10.3168/jds.2015-10048; Cermak R, 2003, J NUTR, V133, P2802, DOI 10.1093/jn/133.9.2802; De Nardi R, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0653-4; Dematawewa CMB, 1997, J DAIRY SCI, V80, P754, DOI 10.3168/jds.S0022-0302(97)75995-2; Drackley JK, 1999, J DAIRY SCI, V82, P2259, DOI 10.3168/jds.S0022-0302(99)75474-3; Enjalbert F, 2001, J DAIRY SCI, V84, P583, DOI 10.3168/jds.S0022-0302(01)74511-0; Farney JK, 2013, AM J PHYSIOL-REG I, V305, pR110, DOI 10.1152/ajpregu.00152.2013; Ferruzzi MG, 2006, FOOD CHEM, V99, P484, DOI 10.1016/j.foodchem.2005.08.010; FOX LK, 1985, J DAIRY SCI, V68, P2100, DOI 10.3168/jds.S0022-0302(85)81074-2; Gao J, 2008, J PHARM PHARM SCI, V11, P77; Garavaglia L, 2015, NEW ZEAL VET J, V63, P313, DOI 10.1080/00480169.2015.1047911; Gessner DK, 2017, J ANIM PHYSIOL AN N, V101, P605, DOI 10.1111/jpn.12579; Gessner DK, 2015, J DAIRY SCI, V98, P8856, DOI 10.3168/jds.2015-9478; Gohlke A, 2013, J DAIRY SCI, V96, P2303, DOI 10.3168/jds.2012-6234; HARMON RJ, 1994, J DAIRY SCI, V77, P2103, DOI 10.3168/jds.S0022-0302(94)77153-8; He X, 2015, INT IMMUNOPHARMACOL, V28, P470, DOI DOI 10.1016/J.INTIMP.2015.07.012; Hiss S, 2004, J DAIRY SCI, V87, P3778, DOI 10.3168/jds.S0022-0302(04)73516-X; Hiss S, 2009, J DAIRY SCI, V92, P4439, DOI 10.3168/jds.2008-1632; Huzzey JM, 2015, PREV VET MED, V120, P291, DOI 10.1016/j.prevetmed.2015.04.011; Klein MS, 2010, J DAIRY SCI, V93, P1539, DOI 10.3168/jds.2009-2563; Lai MY, 2003, J PHARM PHARMACOL, V55, P205, DOI 10.1211/002235702522; Larsen T, 2015, ANIMAL, V9, P86, DOI 10.1017/S1751731114002043; Li CR, 2011, BIOPHARM DRUG DISPOS, V32, P427, DOI 10.1002/bdd.771; Li-Weber M, 2009, CANCER TREAT REV, V35, P57, DOI 10.1016/j.ctrv.2008.09.005; Lin M, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-19; Liu LL, 2008, BIOCHEM PHARMACOL, V75, P914, DOI 10.1016/j.bcp.2007.10.009; McCarthy MM, 2016, J DAIRY SCI, V99, P680, DOI 10.3168/jds.2015-9694; Robert F, 2014, 5 ANN M EAAP COP, P372; Robert F, 2016, United States patent, Patent No. [US 14/ 910,707, 14910707]; Shabtay A, 2012, ANIM FEED SCI TECH, V175, P24, DOI 10.1016/j.anifeedsci.2012.04.004; Silanikove N, 2014, J DAIRY RES, V81, P358, DOI 10.1017/S0022029914000260; Stoldt AK, 2015, J DAIRY SCI, V98, P4509, DOI 10.3168/jds.2014-9053; Tedesco D, 2004, J DAIRY SCI, V87, P2239, DOI 10.3168/jds.S0022-0302(04)70044-2; Thomas FC, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0533-3; Wakabayashi I, 1999, PHARMACOL TOXICOL, V84, P288, DOI 10.1111/j.1600-0773.1999.tb01496.x; Wang Hong-zhi, 2007, Zhongguo Zhong Yao Za Zhi, V32, P1637; Wang QH, 2013, J ETHNOPHARMACOL, V146, P9, DOI 10.1016/j.jep.2012.12.013; WILDMAN EE, 1982, J DAIRY SCI, V65, P495, DOI 10.3168/jds.S0022-0302(82)82223-6; Winkler A, 2015, ARCH ANIM NUTR, V69, P425, DOI 10.1080/1745039X.2015.1093873; Ylioja CM, 2018, J DAIRY SCI, V101, P6066, DOI 10.3168/jds.2017-13991; Zachut M, 2016, RSC ADV, V6, P65412, DOI 10.1039/c6ra11924g	50	9	15	3	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2019	14	1							e0210744	10.1371/journal.pone.0210744	http://dx.doi.org/10.1371/journal.pone.0210744			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HI4TC	30673736	Green Published, gold, Green Submitted			2023-01-03	WOS:000456442800052
J	Kim, JH; Park, EC				Kim, Jae-Hyun; Park, Eun-Cheol			Can diabetes patients seeking a second hospital get better care? Results from nested case-control study	PLOS ONE			English	Article							DOCTOR-SHOPPING BEHAVIOR; HEALTH-CARE; NATIONAL-HEALTH; COMMUNICATION; ASSOCIATION; COMPLICATIONS; CONTINUITY; OUTCOMES; SYSTEM; USERS	This study investigates the effects of the number of medical institutions visited on risk of death. This study conducted a nested case-control design using the National Health Insurance Service-Senior database from 2002 to 2013. Cases were defined as those with death among outpatients who had first diagnosis of diabetes mellitus (E10-E14) after entry into the base cohort and controls were selected by incidence density sampling and matched to cases based on age, and sex. Our main results were presented by conditional logistic regression for nested case-controls design. Of total 55,558 final study samples, there were 9,313 (16.8%) cases and 46,245 (83.2%) controls. With an increase by one point in the number of hospitals per medical utilization, risk of death significantly increased by 4.1% (odds ratio (OR): 1.041, 95% confidence interval [CI]: 1.039-1.043). In both medical utilization and number of hospitals, those with high medical utilization (OR: 1.065, 95% CI: 1.059-1.070) and number of hospitals (OR: 1.049, 95% CI: 1.041-1.058) for risk of death were significantly higher than those with low medical utilization (OR: 1.040, 95% CI: 1.037-1.043) and number of hospitals (OR: 1.029, 95% CI: 1.027-1.032), respectively. The number of medical institution visited was significantly associated with risk of death. Therefore, diabetics should be warned about the potential of risk of death incurred from excessive access to medical utilizations.	[Kim, Jae-Hyun] Dankook Univ, Dept Hlth Adm, Coll Hlth Sci, Cheonan, South Korea; [Kim, Jae-Hyun] Dankook Univ, Inst Hlth Promot & Policy, Cheonan, South Korea; [Park, Eun-Cheol] Yonsei Univ, Inst Hlth Serv Res, Seoul, South Korea; [Park, Eun-Cheol] Yonsei Univ, Coll Med, Dept Prevent Med, Seoul, South Korea	Dankook University; Dankook University; Yonsei University; Yonsei University; Yonsei University Health System	Park, EC (corresponding author), Yonsei Univ, Inst Hlth Serv Res, Seoul, South Korea.; Park, EC (corresponding author), Yonsei Univ, Coll Med, Dept Prevent Med, Seoul, South Korea.	ecpark@yuhs.ac	Park, Eun-Cheol/O-5644-2019	Park, Eun-Cheol/0000-0002-2306-5398				Asai A, 1998, BIOETHICS, V12, P162, DOI 10.1111/1467-8519.00102; Chu HY, 2012, MED CARE, V50, P1002, DOI 10.1097/MLR.0b013e31826c870f; DEMERS M, 1995, CAN MED ASSOC J, V153, P37; Fox CS, 2004, JAMA-J AM MED ASSOC, V292, P2495, DOI 10.1001/jama.292.20.2495; GREENE MG, 1994, SOC SCI MED, V38, P1279, DOI 10.1016/0277-9536(94)90191-0; Hagihara A, 2005, J EVAL CLIN PRACT, V11, P556, DOI 10.1111/j.1365-2753.2005.00581.x; Hariman KW, 2013, FEVER PREDICTOR DOCT, V1; Hsieh CI, 2013, PATIENT PREFER ADHER, V7, P693, DOI 10.2147/PPA.S43631; Hsu MH, 2011, INT J MED INFORM, V80, P181, DOI 10.1016/j.ijmedinf.2010.11.003; Kim DJ, 2011, DIABETES METAB J, V35, P303, DOI 10.4093/dmj.2011.35.4.303; Klienschmidt R, 1995, Aust Fam Physician, V24, P1037; Kwon S, 2009, HEALTH POLICY PLANN, V24, P63, DOI 10.1093/heapol/czn037; Lee HK, 2014, IRAN J PUBLIC HEALTH, V43, P6; Lee J, 2016, BOUND VALUE PROBL, DOI 10.1186/s13661-016-0603-x; Lin CC, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-318; Lo A Y, 1994, Int J Qual Health Care, V6, P371; Mercer SW, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-46; National Statistical Office, 2014, ANN REP VIT STAT KOR; ONG LML, 1995, SOC SCI MED, V40, P903, DOI 10.1016/0277-9536(94)00155-M; Resnick HE, 2000, DIABETES CARE, V23, P176, DOI 10.2337/diacare.23.2.176; Retnakaran R, 2006, DIABETES, V55, P1832, DOI 10.2337/db05-1620; Richardson DB, 2004, OCCUP ENVIRON MED, V61, DOI 10.1136/oem.2004.014472; SATO T, 1995, GEN HOSP PSYCHIAT, V17, P115, DOI 10.1016/0163-8343(94)00094-T; Schoen C, 2006, HEALTH AFFAIR, V25, pW457, DOI 10.1377/hlthaff.25.w457; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Van Walraven C, 2006, CLIN CHEM, V52, P2219, DOI 10.1373/clinchem.2006.072934; Wang MJ, 2010, HEALTH POLICY, V94, P61, DOI 10.1016/j.healthpol.2009.08.009; Yang JH, 2015, INT J MED INFORM, V84, P912, DOI 10.1016/j.ijmedinf.2015.08.007	28	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2019	14	1							e0210809	10.1371/journal.pone.0210809	http://dx.doi.org/10.1371/journal.pone.0210809			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HI2WF	30668580	Green Published, Green Submitted, gold			2023-01-03	WOS:000456306400015
J	Dickey, J; Perrot, V				Dickey, James; Perrot, Veronique			Adjunct phage treatment enhances the effectiveness of low antibiotic concentration against Staphylococcus aureus biofilms in vitro	PLOS ONE			English	Article							BACTERIOPHAGE THERAPY; PSEUDOMONAS; RESISTANCE; INFECTIONS	Phage therapy is drawing more interest as antibiotic resistance becomes an ever more serious threat to public health. Bacterial biofilms represent a major obstacle in the fight against bacterial infections as they are inherently refractory to many types of antibiotics. Treating biofilms with phage has shown promise in a handful of experimental and case studies. However, quantification of the effect of phage combined with antibiotics is needed to pave the way for larger clinical trials. Here we explore the effect of using phage in combination with a total of nine antibiotics, applied simultaneously or as a pretreatment before antibiotics are applied to in vitro biofilms of Staphylococcus aureus. Most antibiotics alone were ineffective at low concentration (2xMIC), but the addition of phage to treatment regimens led to substantial improvements in efficacy. At high concentration (10xMIC), antibiotics alone were effective, and in most cases the addition of phage to treatment regimens did not improve efficacy. Using phage with rifampin was also very effective at reducing the outgrowth of resistant strains during the course of treatment.	[Dickey, James; Perrot, Veronique] Emory Univ, Dept Biol, Atlanta, GA 30322 USA; [Dickey, James] Med Coll Georgia, Augusta, GA 30912 USA	Emory University; University System of Georgia; Augusta University	Perrot, V (corresponding author), Emory Univ, Dept Biol, Atlanta, GA 30322 USA.	vperrot@emory.edu			NIH-NIGMS grant [GM091875]; Emory College of Arts and Sciences; Emory University School of Medicine; NIH [S10 RR025679]	NIH-NIGMS grant; Emory College of Arts and Sciences; Emory University School of Medicine; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was funded by NIH-NIGMS grant GM091875. The Robert P. Apkarian Integrated Electron Microscopy Core is subsidized by the Emory College of Arts and Sciences and the Emory University School of Medicine and is one of the Emory Integrated Core Facilities, and the JEOL JEM-1400 120kV TEM is supported by NIH grant S10 RR025679. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abedon ST, 2015, PHARMACEUTICALS-BASE, V8, P525, DOI 10.3390/ph8030525; Abedon Stephen T, 2011, Bacteriophage, V1, P66; Alemayehu D, 2012, MBIO, V3, DOI 10.1128/mBio.00029-12; [Anonymous], 2015, RSTUDIO INT DEV ENV; Bhattacharya M, 2015, EXPERT REV ANTI-INFE, V13, P1499, DOI 10.1586/14787210.2015.1100533; Biswas B, 2002, INFECT IMMUN, V70, P204, DOI 10.1128/IAI.70.1.204-210.2002; Bull JJ, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-35; Chan BK, 2016, SCI REP-UK, V6, DOI 10.1038/srep26717; Chaudhry WN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168615; Colvin KM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001264; d'Herelle F, 1917, CR HEBD ACAD SCI, V165, P373; D'Herelle F., 1926, NATURE, V118, P183, DOI [10.1038/118183a0, DOI 10.1038/118183A0]; Danis-Wlodarczyk K, 2016, SCI REP-UK, V6, DOI 10.1038/srep28115; Davies D, 2003, NAT REV DRUG DISCOV, V2, P114, DOI 10.1038/nrd1008; de Kraker MEA, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002184; Debarbieux L, 2016, FEMS MICROBIOL LETT, V363, DOI 10.1093/femsle/fnv225; DESRANLEAU J M, 1948, Can J Public Health, V39, P317; Ferreira FA, 2012, J MICROBIOL METH, V88, P393, DOI 10.1016/j.mimet.2012.01.007; Forrest GN, 2010, CLIN MICROBIOL REV, V23, P14, DOI 10.1128/CMR.00034-09; Galtier M, 2016, ENVIRON MICROBIOL, V18, P2237, DOI 10.1111/1462-2920.13284; Gorski A, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01515; Hall-Stoodley L, 2004, NAT REV MICROBIOL, V2, P95, DOI 10.1038/nrmicro821; Harper DR, 2014, ANTIBIOTICS-BASEL, V3, P270, DOI 10.3390/antibiotics3030270; Hawkins C, 2010, VET MICROBIOL, V146, P309, DOI 10.1016/j.vetmic.2010.05.014; Henein Alexandra, 2013, Bacteriophage, V3, pe24872; Jennes S, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1709-y; Johnson PJT, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003123; Jorgensen JH, 2009, CLIN INFECT DIS, V49, P1749, DOI 10.1086/647952; Khan W, 2010, INT MICROBIOL, V13, P207, DOI 10.2436/20.1501.01.127; Kim S, 2012, APPL ENVIRON MICROB, V78, P6380, DOI 10.1128/AEM.00648-12; Kirby AE, 2012, ANTIMICROB AGENTS CH, V56, P2967, DOI 10.1128/AAC.06480-11; KNOUF EG, 1946, JAMA-J AM MED ASSOC, V132, P134, DOI 10.1001/jama.1946.02870380016006; Kumaran D, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00127; Kwan T, 2005, P NATL ACAD SCI USA, V102, P5174, DOI 10.1073/pnas.0501140102; LANG G, 1979, REV CHIR ORTHOP, V65, P33; Mah TFC, 2001, TRENDS MICROBIOL, V9, P34, DOI 10.1016/S0966-842X(00)01913-2; ONeill J., 2016, TACKLING DRUG RESIST; Pirnay JP, 2011, PHARM RES-DORDR, V28, P934, DOI 10.1007/s11095-010-0313-5; Rahman M, 2011, BIOFOULING, V27, P1087, DOI 10.1080/08927014.2011.631169; Roach DR, 2017, CELL HOST MICROBE, V22, P38, DOI 10.1016/j.chom.2017.06.018; Rose T, 2014, INT J BURNS TRAUMA, V4, P66; Schooley RT, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00954-17; Shen Y, 2016, ELIFE, V5; SMITH HW, 1982, J GEN MICROBIOL, V128, P307; Stewart PS, 2008, NAT REV MICROBIOL, V6, P199, DOI 10.1038/nrmicro1838; Thandar M, 2016, ANTIMICROB AGENTS CH, V60, P2671, DOI 10.1128/AAC.02972-15; Torres-Barcelo C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106628; Twort FW, 1915, LANCET, V2, P1241, DOI 10.1016/s0140-6736(01)20383-3; Verma V, 2010, BIOFOULING, V26, P729, DOI 10.1080/08927014.2010.511196; Waters EM, 2017, THORAX, V72, P666, DOI 10.1136/thoraxjnl-2016-209265	50	57	59	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2019	14	1							e0209390	10.1371/journal.pone.0209390	http://dx.doi.org/10.1371/journal.pone.0209390			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH6BK	30650088	Green Submitted, gold, Green Published			2023-01-03	WOS:000455813300013
J	DeFilippis, EM; Nohria, A; Burstein, HJ; Doyle, LA; Miller, AL; Loscalzo, J				DeFilippis, Ersilia M.; Nohria, Anju; Burstein, Harold J.; Doyle, Leona A.; Miller, Amy L.; Loscalzo, Joseph			A Breath-Taking Diagnosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SARCOMAS		[DeFilippis, Ersilia M.; Nohria, Anju; Burstein, Harold J.; Doyle, Leona A.; Miller, Amy L.; Loscalzo, Joseph] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Miller, AL (corresponding author), 75 Francis St, Boston, MA 02115 USA.	almiller@bwh.harvard.edu	Loscalzo, Joseph/ABD-8980-2021; Nohria, Anju/AAD-4925-2022	DeFilippis, Ersilia/0000-0002-0493-1326				Bussani R, 2007, J CLIN PATHOL, V60, P27, DOI 10.1136/jcp.2005.035105; Cha C, 2004, ANN SURG, V239, P903, DOI 10.1097/01.sla.0000128686.51815.8b; Gladdy RA, 2010, J CLIN ONCOL, V28, P2064, DOI 10.1200/JCO.2009.25.1728; Gopal AS, 2000, NEW ENGL J MED, V342, P295, DOI 10.1056/NEJM200001273420418; Kacker C, 2013, GENE CHROMOSOME CANC, V52, P93, DOI 10.1002/gcc.22009; Kassop D, 2014, CURR CARDIOVASC IMAG, V7, DOI 10.1007/s12410-014-9281-1; Maleszewski JJ, 2018, J AM COLL CARDIOL, V72, P202, DOI 10.1016/j.jacc.2018.05.026; Murray EM, 1999, INT J RADIAT ONCOL, V45, P951, DOI 10.1016/S0360-3016(99)00279-5; Neuville A, 2014, AM J SURG PATHOL, V38, P461, DOI 10.1097/PAS.0000000000000184; Ognjanovic S, 2012, CANCER-AM CANCER SOC, V118, P1387, DOI 10.1002/cncr.26390; Palaskas Nicolas, 2018, Curr Treat Options Cardiovasc Med, V20, P29, DOI 10.1007/s11936-018-0625-z; Paoluzzi L, 2016, CLIN SARCOMA RES, V6, DOI 10.1186/s13569-016-0064-0; Ramlawi B, 2016, ANN THORAC SURG, V101, P698, DOI 10.1016/j.athoracsur.2015.07.087; Randhawa JS, 2016, AM J CLIN ONCOL-CANC, V39, P593, DOI 10.1097/COC.0000000000000106; Zhu D, 2016, INT J CARDIOL, V203, P474, DOI 10.1016/j.ijcard.2015.09.021	15	2	2	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 3	2019	380	1					81	87		10.1056/NEJMcps1807721	http://dx.doi.org/10.1056/NEJMcps1807721			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HG1PP	30601740				2023-01-03	WOS:000454731200013
J	Yokoyama, S; Nakagawa, I; Ogawa, Y; Morisaki, Y; Motoyama, Y; Park, YS; Saito, Y; Nakase, H				Yokoyama, Shohei; Nakagawa, Ichiro; Ogawa, Yoichi; Morisaki, Yudai; Motoyama, Yasushi; Park, Young Su; Saito, Yasuhiko; Nakase, Hiroyuki			Ischemic postconditioning prevents surge of presynaptic glutamate release by activating mitochondrial ATP-dependent potassium channels in the mouse hippocampus	PLOS ONE			English	Article							BRAIN-INJURY; NEURONAL DAMAGE; RAT MODEL; DIAZOXIDE; REPERFUSION; PROTECTS; INHIBITION; TOLERANCE; 5-HYDROXYDECANOATE; ASPARTATE	A mild ischemic load applied after a lethal ischemic insult reduces the subsequent ischemia-reperfusion injury, and is called ischemic postconditioning (PostC). We studied the effect of ischemic PostC on synaptic glutamate release using a whole-cell patch-clamp technique. We recorded spontaneous excitatory post-synaptic currents (sEPSCs) from CA1 pyramidal cells in mouse hippocampal slices. The ischemic load was perfusion of artificial cerebrospinal fluid (ACSF) equilibrated with mixed gas (95% N-2 and 5% CO2). The ischemic load was applied for 7.5 min, followed by ischemic PostC 30 s later, consisting of three cycles of 15 s of reperfusion and 15 s of re-ischemia. We found that a surging increase in sEPSCs frequency occurred during the immediate-early reperfusion period after the ischemic insult. We found a significant positive correlation between cumulative sEPSCs and the number of dead CA1 neurons (r = 0.70; p = 0.02). Ischemic PostC significantly suppressed this surge of sEPSCs. The mitochondrial K-ATP (mito-K-ATP) channel opener, diazoxide, also suppressed the surge of sEPSCs when applied for 15 min immediately after the ischemic load. The mito-K-ATP channel blocker, 5-hydroxydecanoate (5-HD), significantly attenuated the suppressive effect of both ischemic PostC and diazoxide application on the surge of sEPSCs. These results suggest that the opening of mito-K-ATP channels is involved in the suppressive effect of ischemic PostC on synaptic glutamate release and protection against neuronal death. We hypothesize that activation of mito-K-ATP channels prevents mitochondrial malfunction and breaks mutual facilitatory coupling between glutamate release and Ca2+ entry at presynaptic sites.	[Yokoyama, Shohei; Nakagawa, Ichiro; Morisaki, Yudai; Motoyama, Yasushi; Park, Young Su; Nakase, Hiroyuki] Nara Med Univ, Dept Neurosurg, Kashihara, Nara, Japan; [Ogawa, Yoichi; Saito, Yasuhiko] Nara Med Univ, Dept Neurophysiol, Kashihara, Nara, Japan	Nara Medical University; Nara Medical University	Nakagawa, I (corresponding author), Nara Med Univ, Dept Neurosurg, Kashihara, Nara, Japan.	nakagawa@nmu-gw.naramed-u.ac.jp						Adamczyk S, 2010, BRIT J ANAESTH, V104, P191, DOI 10.1093/bja/aep365; Anastacio MM, 2013, ANN THORAC SURG, V95, P2042, DOI 10.1016/j.athoracsur.2013.03.035; Ballanyi K, 2004, J EXP BIOL, V207, P3201, DOI 10.1242/jeb.01106; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bonova P, 2013, NEUROCHEM INT, V62, P854, DOI 10.1016/j.neuint.2013.02.019; Chen J, 1996, J CEREBR BLOOD F MET, V16, P566, DOI 10.1097/00004647-199607000-00006; Davalos A, 1997, STROKE, V28, P708, DOI 10.1161/01.STR.28.4.708; Drose S, 2006, J BIOL CHEM, V281, P23733, DOI 10.1074/jbc.M602570200; Dzeja PP, 2003, AM J PHYSIOL-HEART C, V284, pH1048, DOI 10.1152/ajpheart.00847.2002; Evanko DS, 2004, GLIA, V47, P233, DOI 10.1002/glia.20050; Gao XW, 2008, J NEUROSCI RES, V86, P2505, DOI 10.1002/jnr.21703; Glantz L, 2005, EXP NEUROL, V192, P117, DOI 10.1016/j.expneurol.2004.11.012; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; Han D, 2014, J MOL NEUROSCI, V53, P50, DOI 10.1007/s12031-013-0196-0; Hanley PJ, 2002, J PHYSIOL-LONDON, V542, P735, DOI 10.1113/jphysiol.2002.023960; Jiang X, 2006, ANN SURG, V244, P148, DOI 10.1097/01.sla.0000217608.08582.35; Kis B, 2003, J NEUROCHEM, V87, P969, DOI 10.1046/j.1471-4159.2003.02072.x; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Lee JJ, 2008, ANESTHESIOLOGY, V108, P1055, DOI 10.1097/ALN.0b013e3181730257; Li ZY, 2012, J INT MED RES, V40, P954, DOI 10.1177/147323001204000314; Lim KHH, 2002, J PHYSIOL-LONDON, V545, P961, DOI 10.1113/jphysiol.2002.031484; Liu HT, 2006, GLIA, V54, P343, DOI 10.1002/glia.20400; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nakagawa I, 2005, NEUROSURGERY, V57, P334, DOI 10.1227/01.NEU.0000166681.88736.86; Nakagawa I, 2003, EXP NEUROL, V183, P180, DOI 10.1016/S0014-4886(03)00158-4; Nakagawa I, 2002, NEUROSCI LETT, V320, P33, DOI 10.1016/S0304-3940(02)00017-4; Nakagawa I, 2013, J CLIN NEUROSCI, V20, P144, DOI 10.1016/j.jocn.2012.03.027; Nishizawa Y, 2001, LIFE SCI, V69, P369, DOI 10.1016/S0024-3205(01)01142-0; Perez-Pinzon MA, 2005, ANTIOXID REDOX SIGN, V7, P1150, DOI 10.1089/ars.2005.7.1150; Robin E, 2011, BRAIN RES, V1375, P137, DOI 10.1016/j.brainres.2010.12.054; Rossi DJ, 2007, NAT NEUROSCI, V10, P1377, DOI 10.1038/nn2004; Shimizu K, 2002, AM J PHYSIOL-HEART C, V283, pH1005, DOI 10.1152/ajpheart.00054.2002; Simerabet M, 2008, BRAIN RES, V1240, P177, DOI 10.1016/j.brainres.2008.08.070; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; Wang JY, 2008, STROKE, V39, P983, DOI 10.1161/STROKEAHA.107.499079; Xing BZ, 2008, J NEUROCHEM, V105, P1737, DOI 10.1111/j.1471-4159.2008.05276.x; Yamada K, 2002, NEWS PHYSIOL SCI, V17, P127, DOI 10.1152/nips.01384.2001; Yin XH, 2005, J NEUROCHEM, V93, P1021, DOI 10.1111/j.1471-4159.2005.03096.x; Zhang WQ, 2011, J CLIN NEUROSCI, V18, P685, DOI 10.1016/j.jocn.2010.08.027; Zhang WQ, 2010, INT J MOL SCI, V11, P4407, DOI 10.3390/ijms11114407; Zhao H, 2006, J CEREBR BLOOD F MET, V26, P1114, DOI 10.1038/sj.jcbfm.9600348; Zhao ZQ, 2003, AM J PHYSIOL-HEART C, V285, pH579, DOI 10.1152/ajpheart.01064.2002	43	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2019	14	4							e0215104	10.1371/journal.pone.0215104	http://dx.doi.org/10.1371/journal.pone.0215104			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT1UC	30978206	Green Submitted, Green Published, gold			2023-01-03	WOS:000464349000035
J	Freeman, TP; Hindocha, C; Green, SF; Bloomfield, MAP				Freeman, Tom P.; Hindocha, Chandni; Green, Sebastian F.; Bloomfield, Michael A. P.			CLINICAL UPDATE Medicinal use of cannabis based products and cannabinoids	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Freeman, Tom P.] Univ Bath, Dept Psychol, Addict & Mental Hlth Grp AIM, Bath, Avon, England; [Freeman, Tom P.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Natl Addict Ctr, London, England; [Freeman, Tom P.; Hindocha, Chandni; Bloomfield, Michael A. P.] UCL, Res Dept Clin Educ & Hlth Psychol, Clin Psychopharmacol Unit, London, England; [Freeman, Tom P.; Hindocha, Chandni; Green, Sebastian F.; Bloomfield, Michael A. P.] UCL, Fac Brain Sci, Div Psychiat, Translat Psychiat Res Grp,Res Dept Mental Hlth Ne, London, England; [Hindocha, Chandni; Bloomfield, Michael A. P.] Univ Coll Hosp, NIHR Univ Coll London Hosp, Biomed Res Ctr, London, England; [Bloomfield, Michael A. P.] Imperial Coll London, Psychiat Imaging Grp, MRC London Inst Med Sci, London, England; [Bloomfield, Michael A. P.] Camden & Islington NHS Fdn Trust, St Pancras Hosp, Traumat Stress Clin, London, England	University of Bath; University of London; King's College London; University of London; University College London; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; Imperial College London; University of London; University College London	Freeman, TP (corresponding author), Univ Bath, Dept Psychol, Addict & Mental Hlth Grp AIM, Bath, Avon, England.; Freeman, TP (corresponding author), Kings Coll London, Inst Psychiat Psychol & Neurosci, Natl Addict Ctr, London, England.; Freeman, TP (corresponding author), UCL, Res Dept Clin Educ & Hlth Psychol, Clin Psychopharmacol Unit, London, England.; Freeman, TP (corresponding author), UCL, Fac Brain Sci, Div Psychiat, Translat Psychiat Res Grp,Res Dept Mental Hlth Ne, London, England.	t.p.freeman@bath.ac.uk		Freeman, Tom/0000-0002-5667-507X				Abrams DI, 2007, CLIN PHARMACOL THER, V82, P572, DOI 10.1038/sj.clpt.6100200; [Anonymous], 2018, HIGHLIGHTS PRESCRIBI; [Anonymous], 2017, HLTH EFF CANN CANN C; [Anonymous], 2018, MED US CANN CANN QUE; Curran HV, 2016, NAT REV NEUROSCI, V17, P293, DOI 10.1038/nrn.2016.28; Department of Health & Social Care, 2018, CANN BAS PROD MED US; Devinsky O, 2018, NEUROLOGY, V90, pE1204, DOI 10.1212/WNL.0000000000005254; emc, 2014, NAB 1MG CAPS; Englund A, 2013, J PSYCHOPHARMACOL, V27, P19, DOI 10.1177/0269881112460109; European Monitoring Centre for Drugs and Drug Addiction, 2018, CANN LEG EUR OV; Freeman TP, 2018, J PSYCHOPHARMACOL, V32, P1053, DOI 10.1177/0269881118798609; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Hanus LO, 2016, NAT PROD REP, V33, P1357, DOI 10.1039/c6np00074f; Hazekamp Arno, 2018, Med Cannabis Cannabinoids, V1, P65, DOI 10.1159/000489287; Kalk NJ, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5639; Leweke FM, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.15; Mayor S., 2019, BMJ; Morgan CJA, 2010, BRIT J PSYCHIAT, V197, P285, DOI 10.1192/bjp.bp.110.077503; National Institute for Health and Care Excellence, 2014, DO NOT DO REC SAT TR; NHS England, CANN BAS PROD MED US; Niesink RJM, 2015, ADDICTION, V110, P1941, DOI 10.1111/add.13082; Pavlovic R, 2018, MOLECULES, V23, DOI 10.3390/molecules23051230; Pertwee RG, 2008, BRIT J PHARMACOL, V153, P199, DOI 10.1038/sj.bjp.0707442; Royal College of General Practitioners, 2018, CANN BAS MED INT DES; Schoedel KA, 2018, EPILEPSY BEHAV, V88, P162, DOI 10.1016/j.yebeh.2018.07.027; Shannon S, 2016, PERM J, V20; Shannon Scott, 2015, Integr Med (Encinitas), V14, P31; Stockings E, 2018, J NEUROL NEUROSUR PS, V89, P741, DOI 10.1136/jnnp-2017-317168; Stockings E, 2018, PAIN, V159, P1932, DOI 10.1097/j.pain.0000000000001293; Taylor L, 2018, CNS DRUGS, V32, P1053, DOI 10.1007/s40263-018-0578-5; Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456, DOI 10.1001/jama.2015.6358	31	87	87	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 4	2019	365								l1141	10.1136/bmj.l1141	http://dx.doi.org/10.1136/bmj.l1141			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HS6UA	30948383	Green Published, hybrid			2023-01-03	WOS:000464005600001
J	Restrepo, C; Gutierrez-Rivas, M; Pacheco, YM; Garcia, M; Blanco, J; Medrano, LM; Navarrete-Munoz, MA; Gutierrez, F; Miralles, P; Dalmau, D; Gomez, JL; Gorgolas, M; Cabello, A; Resino, S; Benito, JM; Rallon, N; Munoz-Fernandez, MA				Restrepo, Clara; Gutierrez-Rivas, Monica; Pacheco, Yolanda M.; Garcia, Marcial; Blanco, Julia; Medrano, Luz M.; Navarrete-Munoz, Maria A.; Gutierrez, Felix; Miralles, Pilar; Dalmau, David; Luis Gomez, Juan; Gorgolas, Miguel; Cabello, Alfonso; Resino, Salvador; Benito, Jose M.; Rallon, Norma; Munoz-Fernandez, M. A.		Spanish AIDS Res Network Project	Genetic variation in CCR2 and CXCL12 genes impacts on CD4 restoration in patients initiating cART with advanced immunesupression	PLOS ONE			English	Article							HIV-INFECTED PATIENTS; ACTIVE ANTIRETROVIRAL THERAPY; T-CELL RECOVERY; DISEASE PROGRESSION; COUNT RECOVERY; POLYMORPHISMS; VIRUS; GENOTYPE; HAART; EXPRESSION	Objective We investigated the association of genetic polymorphisms in chemokine and chemokine receptor genes with poor immunological recovery in HIV patients starting combined antiretroviral therapy (cART) with low CD4 T-cell counts. Methods A case-control study was conducted in 412 HIV-infected patients starting cART with CD4 T-cell count <200 cells/mu L and successful viral control for two years. CD4 count increase below 200 cells/mu L after two years on cART was used to define INR (immunological nonresponder) patients. Polymorphisms in CXCL12, CCL5 and CCR2 genes were genotyped using sequenom's MassARRAY platform. Results Thirty two percent (134/412) of patients were classified as INR. After adjusting by age, route of HIV infection, length of infection before cART and viral hepatitis coinfection, CCR2 rs1799864-AG genotype was significantly associated with INR status (OR [95% CI]: 1.80 [1.04-3.11]; p = 0.04), and CXCL1 2 rs1801157-TT genotype showed a trend (OR [95% CI]: 2.47 [0.96-6.35]; p = 0.06). Conclusions CCR2 rs1799864-AG or CXCL12 rs1801157-TT genotypes influence on the probability of poor CD4 recovery in the population of HIV patients starting cART with low CD4 counts. Genotyping of these polymorphisms could be used to estimate the risk of poor CD4 restoration, mainly in patients who are diagnosed late in the course of infection.	[Restrepo, Clara; Garcia, Marcial; Navarrete-Munoz, Maria A.; Benito, Jose M.; Rallon, Norma] UAM, FJD, IIS, HIV & Viral Hepatitis Res Lab, Madrid, Spain; [Restrepo, Clara; Garcia, Marcial; Navarrete-Munoz, Maria A.; Benito, Jose M.; Rallon, Norma] Hosp Univ Rey Juan Carlos, Mostoles, Madrid, Spain; [Gutierrez-Rivas, Monica; Medrano, Luz M.; Resino, Salvador] Inst Salud Carlos III, Madrid, Spain; [Pacheco, Yolanda M.] Hosp Univ Virgen del Rocio, UGC Clin Labs, Inst Biomed Sevilla IBiS, Immunol Lab, Seville, Spain; [Blanco, Julia] IrsiCaixa AIDS Res Inst, Badalona, Spain; [Gutierrez, Felix] Hosp Gen Univ Elche, Alicante, Spain; [Gutierrez, Felix] Univ Miguel Hernandez, Alicante, Spain; [Miralles, Pilar] Hosp Gen Univ Gregorio Maranon, Madrid, Spain; [Dalmau, David] Hosp Univ Mutua Terrasa, Terrassa, Spain; [Luis Gomez, Juan] Hosp Univ Canarias, Santa Cruz De Tenerife, Spain; [Gorgolas, Miguel; Cabello, Alfonso] Fdn Jimenez Diaz, Univ Hosp, Madrid, Spain; [Munoz-Fernandez, M. A.] Hosp Gen Univ Gregorio Maranon, Lab Mol Immunobiol, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain	Autonomous University of Madrid; Fundacion Jimenez Diaz; Instituto de Salud Carlos III; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; Institut de Recerca de la Sida - IrsiCaixa; Universidad Miguel Hernandez de Elche; General University Gregorio Maranon Hospital; Hospital Universitario Mutua Terrassa; Universidad de la Laguna; Fundacion Jimenez Diaz; General University Gregorio Maranon Hospital	Benito, JM (corresponding author), UAM, FJD, IIS, HIV & Viral Hepatitis Res Lab, Madrid, Spain.; Benito, JM (corresponding author), Hosp Univ Rey Juan Carlos, Mostoles, Madrid, Spain.; Resino, S (corresponding author), Inst Salud Carlos III, Madrid, Spain.	mmunoz.hgugm@gmail.com; Sresino@isciii.es; jbenito1@hotmail.com	Rivas, Mónica Gutiérrez/G-9713-2016; Pacheco, Yolanda M/C-8457-2015; Fernández-González, Marta/U-7492-2017; Resino, Salvador/B-2430-2008; Cabello, Alfonso/ABH-3203-2021; Benito, Jose/AAC-4554-2020; Blanco, Julià/A-5347-2008; Rodero, Félix Gutiérrez/Q-7880-2018; de dios, luz maria medrano/K-1946-2016	Rivas, Mónica Gutiérrez/0000-0001-9752-7498; Pacheco, Yolanda M/0000-0002-9451-8083; Fernández-González, Marta/0000-0001-9949-8504; Resino, Salvador/0000-0001-8783-0450; Blanco, Julià/0000-0002-2225-0217; Rodero, Félix Gutiérrez/0000-0002-9485-6867; de dios, luz maria medrano/0000-0003-3717-5384; Garcia, Marcial/0000-0001-7462-1836; Benito, Jose/0000-0002-7172-049X; GARCIA GOMEZ, JOSE ALBERTO/0000-0002-1203-7260; Cabello-Ubeda, Alfonso/0000-0001-8429-8358; Rallon, Norma/0000-0002-4643-247X	Spanish AIDS Research Network as part of the Health Research and Development Strategy, State Plan for Scientific and Technical Research and Innovation [RD12/0017/0031, RD16/0025/0013, RD16CIII/0002/0002, PI14CIII/00011]; Institute of Health Carlos III, ISCIII-Sub-Directorate General for Research Assessment and Promotion; European Regional Development Fund (ERDF); IISCIII [CD14/00002, PI08/893, PI13/02256, PI16/01740]; FISABIO [UGP-14-197, UGP-15232, RD16/0025/0038]; ISCIII, Madrid, Spain [CP14/00198]; IIS-FJD	Spanish AIDS Research Network as part of the Health Research and Development Strategy, State Plan for Scientific and Technical Research and Innovation; Institute of Health Carlos III, ISCIII-Sub-Directorate General for Research Assessment and Promotion; European Regional Development Fund (ERDF)(European Commission); IISCIII; FISABIO; ISCIII, Madrid, Spain(Instituto de Salud Carlos III); IIS-FJD	This work has been (partially) funded by the Spanish AIDS Research Network RD12/0017/0031, RD16/0025/0013, RD16CIII/0002/0002, and PI14CIII/00011 projects as part of the Health Research and Development Strategy, State Plan for Scientific and Technical Research and Innovation (2008-2011, 2013-2016) and co-financed by Institute of Health Carlos III, ISCIII-Sub-Directorate General for Research Assessment and Promotion and European Regional Development Fund (ERDF). M Gutierrez-Rivas is funded by project RD16CIII/0002/0002. LM Medrano is supported by IISCIII, grant CD14/00002. F. Gutierrez is supported by ISCIII, grants PI08/893, PI13/02256 and PI16/01740; FISABIO, grants UGP-14-197 and UGP-15232, and RD16/0025/0038. N Rallon is a Miguel Servet investigator from the ISCIII (grant CP14/00198), Madrid, Spain. MA Navarrete-Munoz is co-funded by RD16/0025/0013 project and Intramural Research Scholarship from IIS-FJD. M Garcia is co-funded by CP14/00198 project and Intramural Research Scholarship from IIS-FJD. C Restrepo was funded by project RD12/0017/0031 and currently is funded by project RD16/0025/0013.	Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393; An P, 2002, P NATL ACAD SCI USA, V99, P10002, DOI 10.1073/pnas.142313799; Appay V, 2011, AIDS, V25, P1813, DOI 10.1097/QAD.0b013e32834640e6; Arenzana-Seisdedos F, 2006, SEMIN IMMUNOL, V18, P387, DOI 10.1016/j.smim.2006.07.007; Brambilla A, 2000, J INFECT DIS, V182, P311, DOI 10.1086/315650; Caro-Murillo AM, 2007, ENFERM INFEC MICR CL, V25, P23, DOI 10.1157/13096749; Chan DPC, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010998; Daar ES, 2005, J INFECT DIS, V192, P1597, DOI 10.1086/496893; de Oliveira KB, 2013, CLIN EXP MED, V13, P211, DOI 10.1007/s10238-012-0194-5; Fernandez S, 2006, JAIDS-J ACQ IMM DEF, V41, P1, DOI 10.1097/01.qai.0000188990.57760.e3; Gaardbo JC, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/670957; Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27; Gazzola L, 2009, CLIN INFECT DIS, V48, P328, DOI 10.1086/595851; Guzman-Fulgencio M, 2015, EUR J CLIN INVEST, V45, P1192, DOI 10.1111/eci.12539; Haas DW, 2006, J INFECT DIS, V194, P1098, DOI 10.1086/507313; Ioannidis JPA, 2001, ANN INTERN MED, V135, P782, DOI 10.7326/0003-4819-135-9-200111060-00008; Kelley CF, 2009, CLIN INFECT DIS, V48, P787, DOI 10.1086/597093; Kostrikis LG, 1998, NAT MED, V4, P350, DOI 10.1038/nm0398-350; Lee B, 1998, J VIROL, V72, P7450, DOI 10.1128/JVI.72.9.7450-7458.1998; Li TS, 2011, CLIN INFECT DIS, V53, P944, DOI 10.1093/cid/cir552; Mahajan SD, 2010, BIOCHEM BIOPH RES CO, V396, P348, DOI 10.1016/j.bbrc.2010.04.095; Massanella M, 2010, AIDS, V24, P959, DOI 10.1097/QAD.0b013e328337b957; Miller MF, 2005, CLIN INFECT DIS, V41, P713, DOI 10.1086/432618; Mocroft A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001510; Moore RD, 2007, CLIN INFECT DIS, V44, P441, DOI 10.1086/510746; Nakanjako D, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-43; Negredo E, 2010, CLIN INFECT DIS, V50, P1300, DOI 10.1086/651689; O'Brien TR, 2000, AIDS, V14, P821, DOI 10.1097/00002030-200005050-00008; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Passam AM, 2005, J CLIN VIROL, V34, P302, DOI 10.1016/j.jcv.2004.05.021; Philpott S, 2004, CLIN INFECT DIS, V39, P861, DOI 10.1086/423386; Puissant B, 2006, AIDS RES HUM RETROV, V22, P153, DOI 10.1089/aid.2006.22.153; Rigato PO, 2008, CURR HIV RES, V6, P466, DOI 10.2174/157016208785861131; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Sobrino-Vegas P, 2011, ENFERM INFEC MICR CL, V29, P645, DOI 10.1016/j.eimc.2011.06.002; Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268; Soria A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027349; Soriano A, 2002, J INFECT DIS, V186, P922, DOI 10.1086/343741; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389; Zoufaly A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087160	40	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2019	14	3							e0214421	10.1371/journal.pone.0214421	http://dx.doi.org/10.1371/journal.pone.0214421			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ7IR	30921390	Green Published, gold, Green Submitted			2023-01-03	WOS:000462594000067
J	Yahya, N; Sukiman, NK; Suhaimi, NA; Azmi, NA; Manan, HA				Yahya, Noorazrul; Sukiman, Nur Khalis; Suhaimi, Nani Adilah; Azmi, Nor Aniza; Manan, Hanani A.			How many roads must a Malaysian walk down? Mapping the accessibility of radiotherapy facilities in Malaysia	PLOS ONE			English	Article							RADIATION-THERAPY; TRAVEL DISTANCE; CANCER-PATIENTS; EXPERIENCE; COUNTRIES; RECEIPT; ACCESS	Background The accessibility to radiotherapy facilities may affect the willingness to undergo treatment. We sought to quantify the distance and travel time of Malaysian population to the closest radiotherapy centre and to estimate the megavoltage unit (MV)/million population based on the regions. Materials & methods Data for subdistricts in Malaysia and radiotherapy services were extracted from Department of Statistics Malaysia and Directory of Radiotherapy Centres (DIRAC). Data from DIRAC were validated by direct communication with centres. Locations of radiotherapy centres, distance and travel time to the nearest radiotherapy were estimated using web mapping service, Google Map. Results The average distance and travel time from Malaysian population to the closest radiotherapy centre were 82.5km and 83.4mins, respectively. The average distance and travel were not homogenous; East Malaysia (228.1km, 236.1mins), Central (14.4km, 20.1mins), East Coast (124.2km, 108.8mins), Northern (42.9km, 42.8mins) and Southern (36.0km, 39.8mins). The MV/million population for the country is 2.47, East Malaysia (1.76), Central (4.19), East Coast (0.54), Northern (2.40), Southern (2.36). About 25% of the population needs to travel > 100 km to get to the closest radiotherapy facility. Conclusion On average, Malaysians need to travel far and long to reach radiotherapy facilities. The accessibility to radiotherapy facilities is not equitable. The disparity may be reduced by adding centres in East Malaysia and the East Coast.	[Yahya, Noorazrul; Sukiman, Nur Khalis; Suhaimi, Nani Adilah; Azmi, Nor Aniza] Natl Univ Malaysia, Fac Hlth Sci, Diagnost Imaging & Radiotherapy Programme, Kuala Lumpur, Malaysia; [Manan, Hanani A.] Natl Univ Malaysia, Dept Radiol, Fac Med, Kuala Lumpur, Malaysia	Universiti Kebangsaan Malaysia; Universiti Kebangsaan Malaysia	Yahya, N (corresponding author), Natl Univ Malaysia, Fac Hlth Sci, Diagnost Imaging & Radiotherapy Programme, Kuala Lumpur, Malaysia.	azrulyahya@ukm.edu.my	Yahya, Noorazrul/N-9436-2016	Yahya, Noorazrul/0000-0002-2736-6489; AZMI, NOR ANIZA/0000-0002-6825-2381	National University of Malaysia [GGPM-2017-095]	National University of Malaysia	This work was supported by the National University of Malaysia, GGPM-2017-095 (ukm.edu.my) to NY. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdullah MFIL, 2015, PSYCHO-ONCOLOGY, V24, P894, DOI 10.1002/pon.3740; Ambroggi M, 2015, ONCOLOGIST, V20, P1378, DOI 10.1634/theoncologist.2015-0110; Arenas M, 2015, REP PRACT ONCOL RADI, V20, P141, DOI 10.1016/j.rpor.2014.10.008; Athas WF, 2000, J NATL CANCER I, V92, P269, DOI 10.1093/jnci/92.3.269; Birch EM, 2018, ASIA-PAC J CLIN ONCO, V14, pe505, DOI 10.1111/ajco.12873; Bishr MK, 2018, INT J RADIAT ONCOL, V102, P490, DOI 10.1016/j.ijrobp.2018.06.046; Chan CMH, 2018, CANCER-AM CANCER SOC, V124, P406, DOI 10.1002/cncr.30980; Chen Z, 2008, RADIOTHER ONCOL, V87, P3, DOI 10.1016/j.radonc.2007.11.016; Collins IM, 2018, ASIA-PAC J CLIN ONCO, V14, pe224, DOI 10.1111/ajco.12828; Department of Statistics Malaysia, REP HOUS INC BAS AM; Edib Z, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0428-4; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gabriel G, 2015, RADIOTHER ONCOL, V117, P386, DOI 10.1016/j.radonc.2015.07.031; Grau C, 2014, RADIOTHER ONCOL, V112, P155, DOI 10.1016/j.radonc.2014.08.029; Hegney D, 2005, EUR J CANCER CARE, V14, P75, DOI 10.1111/j.1365-2354.2005.00525.x; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Ke KM, 2012, EUR J CANCER CARE, V21, P158, DOI 10.1111/j.1365-2354.2011.01323.x; Lim GCC, 2002, JPN J CLIN ONCOL, V32, pS37, DOI 10.1093/jjco/hye132; Lin CC, 2015, J CLIN ONCOL, V33, P3177, DOI 10.1200/JCO.2015.61.1558; Mackillop WJ, 1997, J CLIN ONCOL, V15, P1261, DOI 10.1200/JCO.1997.15.3.1261; Rasid N, 2018, ADV SCI LETT, V24, P1562, DOI 10.1166/asl.2018.11109; Rosenblatt E, 2015, RADIOTHER ONCOL, V116, P35, DOI 10.1016/j.radonc.2015.06.012; Santibanez P, 2014, INT J RADIAT ONCOL, V89, P745, DOI 10.1016/j.ijrobp.2014.04.011; Sharma DK, 2016, RURAL REMOTE HEALTH, V16; Soo J, 2011, J RADIOTHER PRACT, V10, P159, DOI 10.1017/S1460396910000348; Stoker SD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085959; Sundaresan P, 2017, ASIA-PAC J CLIN ONCO, V13, pE489, DOI 10.1111/ajco.12579; Tin ST, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153206; Wong LC, 2010, ASIA-PAC J CLIN ONCO, V6, P357, DOI 10.1111/j.1743-7563.2010.01296.x; Yahya N, 2018, ASIA-PAC J CLIN ONCO, V14, pe543, DOI 10.1111/ajco.12831; Yap ML, 2017, CLIN ONCOL-UK, V29, P72, DOI 10.1016/j.clon.2016.11.003	31	9	9	3	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2019	14	3							e0213583	10.1371/journal.pone.0213583	http://dx.doi.org/10.1371/journal.pone.0213583			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP7SO	30897166	gold, Green Published, Green Submitted			2023-01-03	WOS:000461889700026
J	Eriksen, VR; Trautner, S; Hahn, GH; Greisen, G				Eriksen, Vibeke Ramsgaard; Trautner, Simon; Hahn, Gitte Holst; Greisen, Gorm			Lactate acidosis and cardiac output during initial therapeutic cooling in asphyxiated newborn infants	PLOS ONE			English	Article							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; WHOLE-BODY HYPOTHERMIA; ELECTRICAL VELOCIMETRY; BLOOD LACTATE; HEMODYNAMICS; BIRTH; DYSFUNCTION; CONSENT; FLOW	Aim We hypothesized that compromised cardiac output in asphyxiated infants may influence on the rate of disappearance of lactate due to insufficient perfusion. Methods The study was a prospective, observational study, where infants with perinatal asphyxia who met the criteria for therapeutic hypothermia were included. Cardiac output, stroke volume and heart rate were measured by electrical velocimetry in 15 newborn infants with perinatal asphyxia during the first six hours of active therapeutic hypothermia. Results from routine blood samples were collected retrospectively. Cardiac parameters were also measured in 10 healthy, term infants after caesarian section. Cardiac parameters were compared between the asphyxiated group and the control group prior to and during hypothermia. Rate of disappearance of lactate was correlated to cardiac output in the asphyxiated infants. Results Cardiac output was stable in the healthy infants from 0.5 to 6 hours postnatally. The infants with perinatal asphyxia had lower cardiac output prior to and during therapeutic hypothermia compared to the control group. Rate of disappearance of lactate was not related to cardiac output. Conclusion An association between disappearance of lactate acidosis and low cardiac output was not confirmed. A low rate of disappearance of lactate may rather be an indicator of organ injury due to asphyxia.	[Eriksen, Vibeke Ramsgaard; Trautner, Simon; Hahn, Gitte Holst; Greisen, Gorm] Copenhagen Univ Hosp, Rigshosp, Dept Neonatol, Copenhagen, Denmark	Rigshospitalet; University of Copenhagen	Eriksen, VR (corresponding author), Copenhagen Univ Hosp, Rigshosp, Dept Neonatol, Copenhagen, Denmark.	vibeke.eriksen@dadlnet.dk	Greisen, Gorm/AAA-6463-2022; Hahn, Gitte/AAN-4967-2020	Greisen, Gorm/0000-0001-8042-3262; Eriksen, Vibeke/0000-0002-8544-8626	University of Copenhagen; Augustinus Foundation, Denmark	University of Copenhagen; Augustinus Foundation, Denmark	The study was financially supported by University of Copenhagen (VRE) and The Augustinus Foundation, Denmark (GHH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al Balushi A, 2016, AJP REP, V6, pE48, DOI 10.1055/s-0035-1565921; Azzopardi D, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-17; Battin MR, 2009, PEDIATRICS, V123, P1031, DOI 10.1542/peds.2008-1610; BECA JP, 1972, ARCH DIS CHILD, V47, P550, DOI 10.1136/adc.47.254.550; Deshpande SA, 1997, ARCH DIS CHILD-FETAL, V76, pF15, DOI 10.1136/fn.76.1.F15; Freidl T, 2017, NEONATOLOGY, V111, P55, DOI 10.1159/000446468; Fugelseth D, 2003, ARCH DIS CHILD-FETAL, V88, P223; Gebauer CM, 2006, PEDIATRICS, V117, P843, DOI 10.1542/peds.2004-1587; Hochwald O, 2014, J PEDIATR-US, V164, P999, DOI 10.1016/j.jpeds.2014.01.028; Kraut JA, 2014, NEW ENGL J MED, V371, P2309, DOI 10.1056/NEJMra1309483; Liu J, 2007, J TROP PEDIATRICS, V53, P44, DOI 10.1093/tropej/fml053; Manning DJ, 2000, J MED ETHICS, V26, P249, DOI 10.1136/jme.26.4.249; MARTINANCEL A, 1995, J PEDIATR-US, V127, P786, DOI 10.1016/S0022-3476(95)70174-5; Mason SA, 2000, LANCET, V356, P2045, DOI 10.1016/S0140-6736(00)03401-2; Murray DM, 2008, ARCH DIS CHILD-FETAL, V93, pF183, DOI 10.1136/adc.2006.100800; Noori S, 2012, ARCH DIS CHILD-FETAL, V97, pF340, DOI 10.1136/fetalneonatal-2011-301090; Post H, 2010, ACTA PHYSIOL, V199, P43, DOI 10.1111/j.1748-1716.2010.02083.x; Sehgal A, 2013, CARDIOVASC ULTRASOUN, V11, DOI 10.1186/1476-7120-11-34; Sehgal A, 2012, EUR J PEDIATR, V171, P1511, DOI 10.1007/s00431-012-1764-y; Shah P, 2004, ARCH DIS CHILD-FETAL, V89, P152, DOI 10.1136/adc.2002.023093; Shankaran S, 2008, PEDIATRICS, V122, pE791, DOI 10.1542/peds.2008-0456; Thompson CM, 1997, ACTA PAEDIATR, V86, P757, DOI 10.1111/j.1651-2227.1997.tb08581.x; Thoresen M, 2000, PEDIATRICS, V106, P92, DOI 10.1542/peds.106.1.92; Torigoe T, 2015, J PERINATOL, V35, P485, DOI 10.1038/jp.2014.245; VANBEL F, 1990, ACTA PAEDIATR SCAND, V79, P756; Vrancken SL, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00087; Wei Y, 2009, PEDIATR CARDIOL, V30, P741, DOI 10.1007/s00246-009-9421-6; Wu TW, 2018, J PEDIATR-US, V197, P68, DOI 10.1016/j.jpeds.2018.01.067; Yoon JH, 2018, J MATERN-FETAL NEO M, V31, P2175, DOI 10.1080/14767058.2017.1338256	29	11	11	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2019	14	3							e0213537	10.1371/journal.pone.0213537	http://dx.doi.org/10.1371/journal.pone.0213537			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO7YP	30870445	Green Published, Green Submitted, gold			2023-01-03	WOS:000461166300040
J	Kowaleski, JM				Kowaleski, Jeffrey Michael			Wearing Two Hats	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Kowaleski, Jeffrey Michael] Penn State Milton S Hershey Med Ctr, Div Gen Internal Med, Sect Palliat Care, Dept Med, 500 Univ Dr,POB 850,Mail Code H106, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Kowaleski, JM (corresponding author), Penn State Milton S Hershey Med Ctr, Div Gen Internal Med, Sect Palliat Care, Dept Med, 500 Univ Dr,POB 850,Mail Code H106, Hershey, PA 17033 USA.	jkowaleski@pennstatehealth.psu.edu		Kowaleski, Jeffrey/0000-0002-7139-6335					0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 12	2019	321	10					941	942		10.1001/jama.2019.1323	http://dx.doi.org/10.1001/jama.2019.1323			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HO5JE	30860563				2023-01-03	WOS:000460961000010
J	Chen, PH; Kao, YW; Shia, BC; Lin, HC; Kang, JH				Chen, Pao-Huan; Kao, Yi-Wei; Shia, Ben-Chang; Lin, Herng-Ching; Kang, Jiunn-Horng			Adverse stroke outcomes among patients with bipolar disorder	PLOS ONE			English	Article							HEALTH-CARE PROFESSIONALS; MENTAL-DISORDERS; CARDIOVASCULAR-DISEASE; ISCHEMIC-STROKE; FOLLOW-UP; MORTALITY; RISK; COMORBIDITIES; PREVALENCE; GUIDELINES	Failure to deliver the standard stroke care is suspected to be a potential reason for disproportionately high mortality among patients with co-morbid bipolar disorder (BD). Few studies have explored adverse outcomes and medical care costs concurrently (as a proxy for care intensity) among patients with BD admitted for stroke. Data for this nationwide population-based study were extracted from the Taiwan National Health Insurance Research Database, on 580 patients with BD hospitalized for stroke (the study group) and a comparison group consisting of randomly selected 1740 stroke patients without BD matched by propensity scores. Conditional logistic regression was used to estimate odds ratios (OR) for adverse in-hospital outcomes between study group and comparison group. We found that stroke patients with BD had significantly lower in-hospital mortality (3.28% vs. 5.63%), acute respiratory failure (2.59% vs. 5.57%), and use of mechanical ventilation (6.55% vs. 10.23%) than the comparison group. After adjusting for geographical location, urbanization level, monthly income, hypertension, diabetes, hyperlipidemia, and coronary heart disease, the odds of in-hospital mortality, acute respiratory failure, and use of mechanical ventilation in the BD group were 0.56 (95% CI: 0.34-0.92), 0.46 (95% CI: 0.26-0.80), and 0.63 (95% CI: 0.44-0.91), respectively. No differences were found in hospitalization costs and the length of hospital stay. With comparable hospitalization costs and length of hospital stay, we concluded that stroke patients with BD had lower in-hospital mortality and serious adverse events compared to stroke patients without BD.	[Chen, Pao-Huan] Taipei Med Univ Hosp, Dept Psychiat, Taipei, Taiwan; [Chen, Pao-Huan] Taipei Med Univ, Sch Med, Dept Psychiat, Coll Med, Taipei, Taiwan; [Chen, Pao-Huan] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan; [Kao, Yi-Wei; Shia, Ben-Chang] Taipei Med Univ, Big Data Res Ctr, Taipei, Taiwan; [Lin, Herng-Ching] Taipei Med Univ, Sch Hlth Care Adm, Taipei, Taiwan; [Lin, Herng-Ching] Taipei Med Univ Hosp, Sleep Res Ctr, Taipei, Taiwan; [Kang, Jiunn-Horng] Taipei Med Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Kang, Jiunn-Horng] Taipei Med Univ, Sch Med, Dept Phys Med & Rehabil, Coll Med, Taipei, Taiwan	Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University	Kang, JH (corresponding author), Taipei Med Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan.; Kang, JH (corresponding author), Taipei Med Univ, Sch Med, Dept Phys Med & Rehabil, Coll Med, Taipei, Taiwan.	jhk@tmu.edu.tw	Chen, Pao-Huan/ABG-5963-2020					Angst F, 2002, J AFFECT DISORDERS, V68, P167, DOI 10.1016/S0165-0327(01)00377-9; Bai YM, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-1143-8; Chang HH, 2009, J AFFECT DISORDERS, V117, P124, DOI 10.1016/j.jad.2008.12.018; Chang KC, 2003, STROKE, V34, pE219, DOI 10.1161/01.STR.0000095565.12945.18; Chang KC, 2002, STROKE, V33, P2670, DOI 10.1161/01.STR.0000034396.68980.39; Chen PH, 2017, KAOHSIUNG J MED SCI, V33, P630, DOI 10.1016/j.kjms.2017.07.005; Correll CU, 2017, WORLD PSYCHIATRY, V16, P163, DOI 10.1002/wps.20420; Correll CU, 2015, WORLD PSYCHIATRY, V14, P119, DOI 10.1002/wps.20204; Crump C, 2013, JAMA PSYCHIAT, V70, P931, DOI 10.1001/jamapsychiatry.2013.1394; Druss BG, 2000, JAMA-J AM MED ASSOC, V283, P506, DOI 10.1001/jama.283.4.506; Goldstein BI, 2009, BIPOLAR DISORD, V11, P657, DOI 10.1111/j.1399-5618.2009.00735.x; Hsieh MH, 2012, J AFFECT DISORDERS, V141, P449, DOI 10.1016/j.jad.2012.02.038; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Jones LE, 2005, PSYCHOSOM MED, V67, P568, DOI 10.1097/01.psy.0000170336.87544.74; Kim JS, 2014, INT J STROKE, V9, P856, DOI 10.1111/ijs.12317; Krishnan KRR, 2005, PSYCHOSOM MED, V67, P1, DOI 10.1097/01.psy.0000151489.36347.18; Lawrence D, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2539; Lin HC, 2007, J AFFECT DISORDERS, V100, P49, DOI 10.1016/j.jad.2006.09.016; Liu NH, 2017, WORLD PSYCHIATRY, V16, P30, DOI 10.1002/wps.20384; McClure LA, 2014, STROKE, V45, P1716, DOI 10.1161/STROKEAHA.114.004915; Meschia JF, 2014, STROKE, V45, P3754, DOI 10.1161/STR.0000000000000046; Prieto ML, 2014, ACTA PSYCHIAT SCAND, V130, P342, DOI 10.1111/acps.12293; Sajatovic M, 2015, BIPOLAR DISORD, V17, P689, DOI 10.1111/bdi.12331; Schoepf D, 2014, J AFFECT DISORDERS, V169, P170, DOI 10.1016/j.jad.2014.08.025; Strong K, 2007, LANCET NEUROL, V6, P182, DOI 10.1016/S1474-4422(07)70031-5; Tsai SY, 2017, PSYCHIAT CLIN NEUROS, V71, P716, DOI 10.1111/pcn.12538; Tsai SY, 2005, J CLIN PSYCHIAT, V66, P1586, DOI 10.4088/JCP.v66n1215; Weiner M, 2011, ANN CLIN PSYCHIATRY, V23, P40; Westman J, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002373; Wu HC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073037; Zimmerman M, 2014, PSYCHOTHER PSYCHOSOM, V83, P259, DOI 10.1159/000362564	31	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2019	14	3							e0213072	10.1371/journal.pone.0213072	http://dx.doi.org/10.1371/journal.pone.0213072			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HN7LU	30830937	Green Published, gold, Green Submitted			2023-01-03	WOS:000460371700024
J	Schutgens, F; Rookmaaker, MB; Margaritis, T; Rios, A; Ammerlaan, C; Jansen, J; Gijzen, L; Vormann, M; Vonk, A; Viveen, M; Yengej, FY; Derakhshan, S; de Winter-de Groot, KM; Artegiani, B; van Boxtel, R; Cuppen, E; Hendrickx, APA; Van Den Heuvel-Eibrink, MM; Heitzer, E; Lanz, H; Beekman, J; Murk, JL; Masereeuw, R; Holstege, F; Drost, J; Verhaar, MC; Clevers, H				Schutgens, Frans; Rookmaaker, Maarten B.; Margaritis, Thanasis; Rios, Anne; Ammerlaan, Carola; Jansen, Jitske; Gijzen, Linda; Vormann, Marianne; Vonk, Annelotte; Viveen, Marco; Yengej, Fjodor Yousef; Derakhshan, Sepide; de Winter-de Groot, Karin M.; Artegiani, Benedetta; van Boxtel, Ruben; Cuppen, Edwin; Hendrickx, Antoni P. A.; Van Den Heuvel-Eibrink, Marry M.; Heitzer, Ellen; Lanz, Henriette; Beekman, Jeffrey; Murk, Jean-Luc; Masereeuw, Rosalinde; Holstege, Frank; Drost, Jarno; Verhaar, Marianne C.; Clevers, Hans			Tubuloids derived from human adult kidney and urine for personalized disease modeling	NATURE BIOTECHNOLOGY			English	Article							PLURIPOTENT STEM-CELLS; TUBULAR EPITHELIAL-CELLS; BK-VIRUS NEPHROPATHY; GENE-EXPRESSION; WILMS-TUMOR; INTESTINAL CRYPT; IN-VITRO; MUTATIONS; ORGANOIDS; WNT	Adult stem cell-derived organoids are three-dimensional epithelial structures that recapitulate fundamental aspects of their organ of origin. We describe conditions for the long-term growth of primary kidney tubular epithelial organoids, or 'tubuloids'. The cultures are established from human and mouse kidney tissue and can be expanded for at least 20 passages (>6 months) while retaining a normal number of chromosomes. In addition, cultures can be established from human urine. Human tubuloids represent proximal as well as distal nephron segments, as evidenced by gene expression, immunofluorescence and tubular functional analyses. We apply tubuloids to model infectious, malignant and hereditary kidney diseases in a personalized fashion. BK virus infection of tubuloids recapitulates in vivo phenomena. Tubuloids are established from Wilms tumors. Kidney tubuloids derived from the urine of a subject with cystic fibrosis allow ex vivo assessment of treatment efficacy. Finally, tubuloids cultured on microfluidic organ-on-a-chip plates adopt a tubular conformation and display active (trans-)epithelial transport function.	[Schutgens, Frans; Ammerlaan, Carola; Yengej, Fjodor Yousef; Artegiani, Benedetta; Clevers, Hans] Royal Netherlands Acad Arts & Sci, Hubrecht Inst, Utrecht, Netherlands; [Schutgens, Frans; Rookmaaker, Maarten B.; Ammerlaan, Carola; Yengej, Fjodor Yousef; Verhaar, Marianne C.] Univ Med Ctr Utrecht, Dept Nephrol & Hypertens, Utrecht, Netherlands; [Margaritis, Thanasis; Rios, Anne; Derakhshan, Sepide; van Boxtel, Ruben; Van Den Heuvel-Eibrink, Marry M.; Holstege, Frank; Drost, Jarno; Clevers, Hans] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands; [Jansen, Jitske; Murk, Jean-Luc; Masereeuw, Rosalinde] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacol, Utrecht, Netherlands; [Gijzen, Linda; Vormann, Marianne; Lanz, Henriette] Mimetas, Organ On A Chip Co, Leiden, Netherlands; [Vonk, Annelotte; Beekman, Jeffrey] Regenerat Med Ctr Utrecht, Utrecht, Netherlands; [Viveen, Marco; Hendrickx, Antoni P. A.] Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands; [de Winter-de Groot, Karin M.] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Utrecht, Netherlands; [Cuppen, Edwin] Univ Med Ctr Utrecht, Ctr Mol Med, Dept Genet, Canc Genom Netherlands, Utrecht, Netherlands; [Heitzer, Ellen] Med Univ Graz, Inst Human Genet, Graz, Austria; [Murk, Jean-Luc] St Elisabeth TweeSteden Ziekenhuis, Lab Med Microbiol & Immunol, Tilburg, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Utrecht University; Utrecht University Medical Center; Medical University of Graz; Elisabeth-TweeSteden Ziekenhuis (ETZ)	Clevers, H (corresponding author), Royal Netherlands Acad Arts & Sci, Hubrecht Inst, Utrecht, Netherlands.; Clevers, H (corresponding author), Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands.	h.clevers@hubrecht.eu	Beekman, Jeffrey M/I-7781-2014; Cuppen, Edwin/H-2389-2016; Hendrickx, Antoni/AAN-1789-2021; Cuppen, Edwin/F-5696-2011; Holstege, Frank/AAM-9944-2021; Jansen, Jitske/AAB-2866-2021; Masereeuw, Roos/I-5276-2016	Beekman, Jeffrey M/0000-0003-4886-3756; Cuppen, Edwin/0000-0002-0400-9542; Cuppen, Edwin/0000-0002-0400-9542; Masereeuw, Roos/0000-0002-1560-1074; Hendrickx, Antoni P.A./0000-0003-4431-9323; Drost, Jarno/0000-0002-2941-6179; van Boxtel, Ruben/0000-0003-1285-2836	Dutch Kidney Foundation [DKF14OP04]; Zwaartekracht (NWO)	Dutch Kidney Foundation; Zwaartekracht (NWO)	We thank the Hubrecht Imaging Center for assistance with (confocal) microscopy. We thank H. Begthel and J. Korving (both Hubrecht Institute) for preparation of histological and immunohistochemical specimens. We thank T. Nguyen (UMC Utrecht, the Netherlands) and R. de Krijger (Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands) for help with the analysis of histological specimens. We thank the Hubrecht FACS facility for help with the sort of single (EPCAM+) cells and G. Posthuma (Department of Cell Biology and Institute of Biomembranes, UMC Utrecht, the Netherlands) for excellent support with transmission electron microscopy. We thank E. Driehuis for the photography of the VP-1 staining and for help with finalizing the manuscript. We thank J. Hoenderop (Radboud UMC, the Netherlands) for kindly providing UMOD and SLC12A1 antibodies, and NC3Rs for development of the kidney-on-a-chip assays (Nephrotube, CRACK-IT challenge). This work was supported by a grant from the Dutch Kidney Foundation (grant no. DKF14OP04), and Zwaartekracht (NWO). This work was supported by the partners of Regenerative Medicine Crossing Borders (www.regmedxb.com).Powered by Health similar to Holland, Top Sector Life Sciences & Health.	Adams DC, 2010, AM J PHYSIOL-RENAL, V299, pF1320, DOI 10.1152/ajprenal.00325.2010; Baker DEC, 2007, NAT BIOTECHNOL, V25, P207, DOI 10.1038/nbt1285; Barker N, 2012, CELL STEM CELL, V11, P452, DOI 10.1016/j.stem.2012.09.009; Barker N, 2012, CELL REP, V2, P540, DOI 10.1016/j.celrep.2012.08.018; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; BIRUKOV KG, 1995, MOL CELL BIOCHEM, V144, P131, DOI 10.1007/BF00944392; Bohl DL, 2007, CLIN J AM SOC NEPHRO, V2, pS36, DOI 10.2215/CJN.00920207; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Breiderhoff T, 2012, P NATL ACAD SCI USA, V109, P14241, DOI 10.1073/pnas.1203834109; Brunskill EW, 2008, DEV CELL, V15, P781, DOI 10.1016/j.devcel.2008.09.007; Bussolati B, 2005, AM J PATHOL, V166, P545, DOI 10.1016/S0002-9440(10)62276-6; Cakalagaoglu F, 2007, DIALYSIS TRANSPLANT, V36, P122, DOI 10.1002/dat.20101; Cancilla B, 2001, KIDNEY INT, V60, P147, DOI 10.1046/j.1523-1755.2001.00781.x; Cassio Doris, 2013, BMC Res Notes, V6, P162, DOI 10.1186/1756-0500-6-162; Chen GP, 2013, INT J MOL SCI, V14, P10674, DOI 10.3390/ijms140510674; Cheng LZ, 2012, CELL STEM CELL, V10, P337, DOI 10.1016/j.stem.2012.01.005; Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082; Clevers H, 2013, CELL, V154, P274, DOI 10.1016/j.cell.2013.07.004; COPPES MJ, 1993, P NATL ACAD SCI USA, V90, P1416, DOI 10.1073/pnas.90.4.1416; CUNDY KC, 1995, ANTIMICROB AGENTS CH, V39, P1247, DOI 10.1128/AAC.39.6.1247; de Baaij JHF, 2016, SCI REP-UK, V6, DOI 10.1038/srep28565; de Kort H, 2017, TRANSPLANTATION, V101, P1820, DOI 10.1097/TP.0000000000001521; Dekkers JF, 2016, J CYST FIBROS, V15, P568, DOI 10.1016/j.jcf.2016.04.007; Dekkers JF, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8278; Dekkers JF, 2013, NAT MED, V19, P939, DOI 10.1038/nm.3201; Dimke H, 2013, AM J PHYSIOL-RENAL, V304, pF761, DOI 10.1152/ajprenal.00263.2012; Drost J, 2018, NAT REV CANCER, V18, P407, DOI 10.1038/s41568-018-0007-6; Drost J, 2017, SCIENCE, V358, P234, DOI 10.1126/science.aao3130; Ferre S, 2014, J AM SOC NEPHROL, V25, P574, DOI 10.1681/ASN.2013040337; Freedman BS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9715; Galmes R, 2015, TRAFFIC, V16, P1288, DOI 10.1111/tra.12334; Ganguly N, 2010, TRANSPL INFECT DIS, V12, P406, DOI 10.1111/j.1399-3062.2010.00513.x; Gutierrez-Aranda I, 2010, STEM CELLS, V28, P1568, DOI 10.1002/stem.471; Hashimshony T, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0938-8; Hawthorn L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018941; Heitzer E, 2013, GENOME MED, V5, DOI 10.1186/gm434; Hing S, 2001, AM J PATHOL, V158, P393, DOI 10.1016/S0002-9440(10)63982-X; Hirsch HH, 2005, TRANSPLANTATION, V79, P1277, DOI 10.1097/01.TP.0000156165.83160.09; Hohenstein P, 2015, GENE DEV, V29, P467, DOI 10.1101/gad.256396.114; Homan KA, 2016, SCI REP-UK, V6, DOI 10.1038/srep34845; Huch M, 2015, CELL, V160, P299, DOI 10.1016/j.cell.2014.11.050; Huch M, 2013, NATURE, V494, P247, DOI 10.1038/nature11826; Janda CY, 2017, NATURE, V545, P234, DOI 10.1038/nature22306; Jansen J, 2014, EXP CELL RES, V323, P87, DOI 10.1016/j.yexcr.2014.02.011; Jouan E, 2014, FUND CLIN PHARMACOL, V28, P65, DOI 10.1111/j.1472-8206.2012.01071.x; Kalapurakal JA, 2004, LANCET ONCOL, V5, P37, DOI 10.1016/S1470-2045(03)01322-6; Kang HM, 2016, CELL REP, V14, P861, DOI 10.1016/j.celrep.2015.12.071; Karafin M, 2011, AM J SURG PATHOL, V35, P1264, DOI 10.1097/PAS.0b013e31822539a1; Kim KA, 2005, SCIENCE, V309, P1256, DOI 10.1126/science.1112521; Kirk A, 2010, NEPHROL DIAL TRANSPL, V25, P2107, DOI 10.1093/ndt/gfq006; Kobayashi A, 2008, CELL STEM CELL, V3, P169, DOI 10.1016/j.stem.2008.05.020; Kriz W, 2005, KIDNEY INT, V67, P404, DOI 10.1111/j.1523-1755.2005.67097.x; Lam AQ, 2014, J AM SOC NEPHROL, V25, P1211, DOI 10.1681/ASN.2013080831; Lancaster MA, 2009, NAT MED, V15, P1046, DOI 10.1038/nm.2010; LeBleu VS, 2013, NAT MED, V19, P1047, DOI 10.1038/nm.3218; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mengelbier LH, 2010, AM J PATHOL, V177, P2609, DOI 10.2353/ajpath.2010.100130; Muraro MJ, 2016, CELL SYST, V3, P385, DOI 10.1016/j.cels.2016.09.002; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; Ozcan A, 2011, MODERN PATHOL, V24, P751, DOI 10.1038/modpathol.2011.3; Poladia DP, 2006, DEV BIOL, V291, P325, DOI 10.1016/j.ydbio.2005.12.034; Rivera MN, 2005, NAT REV CANCER, V5, P699, DOI 10.1038/nrc1696; Royer-Pokora B, 2010, HUM MOL GENET, V19, P1651, DOI 10.1093/hmg/ddq042; Rudnicki M, 2009, LAB INVEST, V89, P337, DOI 10.1038/labinvest.2008.158; Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Scialdone A, 2015, METHODS, V85, P54, DOI 10.1016/j.ymeth.2015.06.021; Takasato M, 2014, NAT CELL BIOL, V16, P118, DOI 10.1038/ncb2894; Takasato M, 2015, NATURE, V526, P564, DOI 10.1038/nature15695; Tan L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051439; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Trietsch SJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00259-3; Trietsch SJ, 2013, LAB CHIP, V13, P3548, DOI 10.1039/c3lc50210d; van den Brink SC, 2017, NAT METHODS, V14, P935, DOI 10.1038/nmeth.4437; Watanabe K, 2007, NAT BIOTECHNOL, V25, P681, DOI 10.1038/nbt1310; Wegert J, 2015, CANCER CELL, V27, P298, DOI 10.1016/j.ccell.2015.01.002; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yumoto R, 1999, J PHARMACOL EXP THER, V289, P149; Zhou T, 2012, NAT PROTOC, V7, P2080, DOI 10.1038/nprot.2012.115	81	171	178	12	137	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2019	37	3					303	+		10.1038/s41587-019-0048-8	http://dx.doi.org/10.1038/s41587-019-0048-8			15	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	HN4LR	30833775				2023-01-03	WOS:000460155900022
J	Izawa, J; Komukai, S; Gibo, K; Okubo, M; Kiyohara, K; Nishiyama, C; Kiguchi, T; Matsuyama, T; Kawamura, T; Iwami, T; Callaway, CW; Kitamura, T				Izawa, Junichi; Komukai, Sho; Gibo, Koichiro; Okubo, Masashi; Kiyohara, Kosuke; Nishiyama, Chika; Kiguchi, Takeyuki; Matsuyama, Tasuku; Kawamura, Takashi; Iwami, Taku; Callaway, Clifton W.; Kitamura, Tetsuhisa			Pre-hospital advanced airway management for adults with out-of-hospital cardiac arrest: nationwide cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EUROPEAN RESUSCITATION COUNCIL; PULSELESS ELECTRICAL-ACTIVITY; PUBLIC-ACCESS DEFIBRILLATION; AMERICAN-HEART-ASSOCIATION; CARDIOPULMONARY-RESUSCITATION; TRACHEAL INTUBATION; ENDOTRACHEAL INTUBATION; SURVIVAL; GUIDELINES; STRATEGY	OBJECTIVE To determine survival associated with advanced airway management (AAM) compared with no AAM for adults with out-of-hospital cardiac arrest. DESIGN Cohort study between January 2014 and December 2016. SETTING Nationwide, population based registry in Japan (All-Japan Utstein Registry). PARTICIPANTS Consecutive adult patients with out-of-hospital cardiac arrest, separated into two sub-cohorts by their first documented electrocardiographic rhythm: shockable (ventricular fibrillation or pulseless ventricular tachycardia) and non-shockable (pulseless electrical activity or asystole). Patients who received AAM during cardiopulmonary resuscitation were sequentially matched with patients at risk of AAM within the same minute on the basis of time dependent propensity scores. MAIN OUTCOME MEASURES Survival at one month or at hospital discharge within one month. RESULTS Of the 310 620 patients eligible, 8459 (41.2%) of 20 516 in the shockable cohort and 121 890 (42.0%) of 290 104 in the non-shockable cohort received AAM during cardiopulmonary resuscitation. After time dependent propensity score sequential matching, 16 114 patients in the shockable cohort and 236 042 in the non-shockable cohort were matched at the same minute. In the shockable cohort, survival did not differ between patients with AAM and those with no AAM: 1546/8057 (19.2%) versus 1500/8057 (18.6%) (adjusted risk ratio 1.00, 95% confidence interval 0.93 to 1.07). In the non-shockable cohort, patients with AAM had better survival than those with no AAM: 2696/118 021 (2.3%) versus 2127/118 021 (1.8%) (adjusted risk ratio 1.27, 1.20 to 1.35). CONCLUSIONS In the time dependent propensity score sequential matching for out-of-hospital cardiac arrest in adults, AAM was not associated with survival among patients with shockable rhythm, whereas AAM was associated with better survival among patients with non-shockable rhythm.	[Izawa, Junichi] Jikei Univ, Dept Anesthesiol, Sch Med, Tokyo 1058491, Japan; [Izawa, Junichi] Univ Pittsburgh, Ctr Crit Care Nephrol, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Komukai, Sho] Osaka Univ, Grad Sch Med, Div Biomed Stat, Dept Integrated Med, Osaka, Japan; [Gibo, Koichiro] Okinawa Chubu Hosp, Dept Emergency Med, Uruma, Okinawa, Japan; [Okubo, Masashi; Callaway, Clifton W.] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA USA; [Kiyohara, Kosuke] Otsuma Womens Univ, Dept Food Sci, Tokyo, Japan; [Nishiyama, Chika] Kyoto Univ, Dept Crit Care Nursing, Grad Sch Human Hlth Sci, Kyoto, Japan; [Kiguchi, Takeyuki; Kawamura, Takashi; Iwami, Taku] Kyoto Univ, Hlth Serv, Kyoto, Japan; [Matsuyama, Tasuku] Kyoto Prefectural Univ Med, Dept Emergency Med, Kyoto, Japan; [Kitamura, Tetsuhisa] Osaka Univ, Grad Sch Med, Dept Social & Environm Med, Div Environm Med & Populat Sci, Osaka, Japan	Jikei University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Osaka University; Okinawa Chubu Central Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kyoto University; Kyoto University; Kyoto Prefectural University of Medicine; Osaka University	Izawa, J (corresponding author), Jikei Univ, Dept Anesthesiol, Sch Med, Tokyo 1058491, Japan.; Izawa, J (corresponding author), Univ Pittsburgh, Ctr Crit Care Nephrol, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	izawa.junichi.87r@st.kyoto-u.ac.jp	IWAMI, Taku/HCH-0599-2022; Izawa, Junichi/L-2308-2019; Kiyohara, Kosuke/ABD-5652-2020; Kitamura, Tetsuhisa/AAA-2555-2020	IWAMI, Taku/0000-0002-4150-7065; Izawa, Junichi/0000-0003-1920-8218; Kiyohara, Kosuke/0000-0003-0644-6129; Kitamura, Tetsuhisa/0000-0003-0107-0580; Okubo, Masashi/0000-0002-1447-8908	Clinical Investigator's Research Project at Osaka University Graduate School of Medicine; Ministry of Education, Culture, Sports, Science and Technology of Japan [16K09034, 15H05006]	Clinical Investigator's Research Project at Osaka University Graduate School of Medicine; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was an investigator initiated study supported by the Clinical Investigator's Research Project at Osaka University Graduate School of Medicine and scientific research grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (16K09034 and 15H05006). This paper presents independent research supported by the funds.	Andersen LW, 2018, JAMA-J AM MED ASSOC, V320, P761, DOI 10.1001/jama.2018.10824; Andersen LW, 2018, RESUSCITATION, V131, pE1, DOI 10.1016/j.resuscitation.2018.07.028; Andersen LW, 2018, RESUSCITATION, V125, P79, DOI 10.1016/j.resuscitation.2018.02.006; Andersen LW, 2017, JAMA-J AM MED ASSOC, V317, P494, DOI 10.1001/jama.2016.20165; Andersen LW, 2016, JAMA-J AM MED ASSOC, V316, P1786, DOI 10.1001/jama.2016.14486; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Benger JR, 2018, JAMA-J AM MED ASSOC, V320, P779, DOI 10.1001/jama.2018.11597; Beyersmann J, 2008, BIOSTATISTICS, V9, P765, DOI 10.1093/biostatistics/kxn009; Fouche PF, 2014, PREHOSP EMERG CARE, V18, P244, DOI 10.3109/10903127.2013.831509; Hagihara A, 2012, JAMA-J AM MED ASSOC, V307, P1161, DOI 10.1001/jama.2012.294; Hasegawa K, 2013, JAMA-J AM MED ASSOC, V309, P257, DOI 10.1001/jama.2012.187612; Iwami T, 2015, CIRCULATION, V132, P415, DOI 10.1161/CIRCULATIONAHA.114.014905; Jabre P, 2018, JAMA-J AM MED ASSOC, V319, P779, DOI 10.1001/jama.2018.0156; Jacobs I, 2004, RESUSCITATION, V63, P233, DOI 10.1016/j.resuscitation.2004.09.008; Japan Resuscitation Council, 2011, 2010 JAP GUID EM CAR; Jeong S, 2016, AM J EMERG MED, V34, P2101, DOI 10.1016/j.ajem.2016.07.025; Kalbfleisch J.D., 2011, STAT ANAL FAILURE TI, DOI DOI 10.1016/0197-2456(81)90009-X; Kim J, 2014, RESUSCITATION, V85, P623, DOI 10.1016/j.resuscitation.2014.01.017; Kitamura T, 2016, NEW ENGL J MED, V375, P1649, DOI 10.1056/NEJMsa1600011; Kitamura T, 2010, NEW ENGL J MED, V362, P994, DOI 10.1056/NEJMoa0906644; Li YFP, 2001, J AM STAT ASSOC, V96, P870, DOI 10.1198/016214501753208573; Link MS, 2015, CIRCULATION, V132, pS444, DOI 10.1161/CIR.0000000000000261; Lu B, 2005, BIOMETRICS, V61, P721, DOI 10.1111/j.1541-0420.2005.00356.x; McMullan J, 2014, RESUSCITATION, V85, P617, DOI 10.1016/j.resuscitation.2014.02.007; Mehta C, 2012, AM J EMERG MED, V30, P236, DOI 10.1016/j.ajem.2010.08.017; Myat A, 2018, LANCET, V391, P970, DOI 10.1016/S0140-6736(18)30472-0; Nakahara S, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6829; Niemann JT, 2001, CRIT CARE MED, V29, P2366, DOI 10.1097/00003246-200112000-00020; Nolan JP, 2010, RESUSCITATION, V81, pE1, DOI 10.1016/j.resuscitation.2010.08.002; Ong MEH, 2018, LANCET, V391, P980, DOI 10.1016/S0140-6736(18)30316-7; Perkins GD, 2018, NEW ENGL J MED, V379, P711, DOI 10.1056/NEJMoa1806842; Perkins GD, 2015, RESUSCITATION, V96, P328, DOI 10.1016/j.resuscitation.2014.11.002; Soar J, 2015, RESUSCITATION, V95, P100, DOI 10.1016/j.resuscitation.2015.07.016; Stuart EA, 2010, STAT SCI, V25, P1, DOI 10.1214/09-STS313; Wang HE, 2018, JAMA-J AM MED ASSOC, V320, P769, DOI 10.1001/jama.2018.7044	35	39	39	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 28	2019	364								l430	10.1136/bmj.l430	http://dx.doi.org/10.1136/bmj.l430			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN7SE	30819685	Green Published, hybrid			2023-01-03	WOS:000460391200002
J	Walley, AY; Wakeman, SE; Eng, G				Walley, Alexander Y.; Wakeman, Sarah E.; Eng, George			Case 6-2019: A 29-Year-Old Woman with Nausea, Vomiting, and Diarrhea	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OPIOID USE DISORDER; URINE; ABUSE		[Walley, Alexander Y.] Boston Med Ctr, Dept Med, Boston, MA 02118 USA; [Walley, Alexander Y.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Wakeman, Sarah E.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Eng, George] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Wakeman, Sarah E.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Eng, George] Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA	Boston Medical Center; Boston University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Walley, AY (corresponding author), Boston Med Ctr, Dept Med, Boston, MA 02118 USA.; Walley, AY (corresponding author), Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.							Cicero TJ, 2018, DRUG ALCOHOL DEPEN, V193, P117, DOI 10.1016/j.drugalcdep.2018.09.007; Cunningham CO, 2013, J ADDICT MED, V7, P287, DOI 10.1097/ADM.0b013e31829727b2; Cunningham CO, 2011, J SUBST ABUSE TREAT, V40, P349, DOI 10.1016/j.jsat.2010.12.002; Department of Health and Human Services, 2008, HHS REC PRESCR COPR; Hadland SE, 2018, ADDICT SCI CLIN PRAC, V13, DOI 10.1186/s13722-018-0116-2; Hasin DS, 2013, AM J PSYCHIAT, V170, P834, DOI 10.1176/appi.ajp.2013.12060782; Jack HE, 2017, SUBST ABUS; Jaffee WB, 2007, J SUBST ABUSE TREAT, V33, P33, DOI 10.1016/j.jsat.2006.11.008; Lanier D., 2008, SCREENING PRIMARY CA; Larochelle MR, 2018, ANN INTERN MED, V169, P137, DOI 10.7326/M17-3107; Mattick RP, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub3; Minozzi S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001333.pub3; Moeller KE, 2008, MAYO CLIN PROC, V83, P66, DOI 10.4065/83.1.66; Morgan JR, 2018, J SUBST ABUSE TREAT, V85, P90, DOI 10.1016/j.jsat.2017.07.001; Noska A, 2015, J ADDICT BEHAV THER, V4; Petrides AK, 2018, CLIN CHIM ACTA, V481, P75, DOI 10.1016/j.cca.2018.02.034; Smith PC, 2010, ARCH INTERN MED, V170, P1155, DOI 10.1001/archinternmed.2010.140; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550; Weiss RD, 2015, DRUG ALCOHOL DEPEN, V150, P112, DOI 10.1016/j.drugalcdep.2015.02.030; Wilson FA, 2014, PUBLIC HEALTH REP, V129, P342, DOI 10.1177/003335491412900409	20	0	0	2	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 21	2019	380	8					772	779		10.1056/NEJMcpc1816407	http://dx.doi.org/10.1056/NEJMcpc1816407			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HM0PM	30786192	Bronze			2023-01-03	WOS:000459149500012
J	Huang, CH; Umegaki, H; Watanabe, Y; Kamitani, H; Asai, A; Kanda, S; Nomura, H; Kuzuya, M				Huang, Chi-Hsien; Umegaki, Hiroyuki; Watanabe, Yuuki; Kamitani, Hiroko; Asai, Atushi; Kanda, Shigeru; Nomura, Hideki; Kuzuya, Masafumi			Potentially inappropriate medications according to STOPP-J criteria and risks of hospitalization and mortality in elderly patients receiving home-based medical services	PLOS ONE			English	Article							MINI-NUTRITIONAL ASSESSMENT; BEERS CRITERIA; HEALTH-CARE; GUIDELINES; OUTCOMES; IMPACT; POLYPHARMACY; METAANALYSIS; ASSOCIATION; PREVALENCE	Background Although potentially inappropriate medications (PIMs) have been linked to poor health outcomes, country-specific PIM criteria have not been compared. Thus, we compared the identification of PIMs between the Screening Tool for Older Person's Appropriate Prescriptions for Japanese (STOPP-J) and the 2015 American Geriatrics Society Beers Criteria in elderly patients receiving home-based medical services. Methods A 5-year prospective cohort study was conducted with 196 patients receiving home-based medical services. Data were collected using questionnaires and chart reviews and included detailed information on prescription medication. STOPP-J and the Beers Criteria were used to categorize PIM and non-PIM recipients. All-cause mortality and first hospitalization were compared using a multivariate Cox regression model. Results PIMs were detected in 132 patients (67.3%) by STOPP-J and in 141 patients (71.9%) by the Beers Criteria, and the mean numbers of PIMs were 1.3 +/- 1.3 and 1.2 +/- 1.1, respectively. The three most frequently prescribed STOPP-J PIMs were hypnotics (26.8%), diuretics (25.6%), and NSAIDs (12.6%), compared with proton pump inhibitors (PPIs) (29.8%), hypnotics (26%), and NSAIDs (8.1%) according to the Beers Criteria. STOPP-J PIMs were associated with all-cause mortality (HR 3.01, 95% CI 1.37-6.64) and hospitalization (HR 1.91, 95% CI 1.17-3.09); neither was associated with Beers Criteria PIMs. Using a modified Beers Criteria (excluding PPIs), PIMs were correlated with first hospitalization (HR 1.91, 95% CI 1.17-3.09). Conclusions PIMs categorized by STOPP-J are associated with hospitalization and mortality in Japanese patients receiving home-based medical services. PPIs, commonly used for acid-related diseases, do not seem to have deleterious effects on health outcomes. Country-oriented, medication-specific criteria would be of considerable clinical utility.	[Huang, Chi-Hsien; Umegaki, Hiroyuki; Kamitani, Hiroko; Kuzuya, Masafumi] Nagoya Univ, Grad Sch Med, Dept Community Healthcare & Geriatr, Showa Ku, Nagoya, Aichi, Japan; [Huang, Chi-Hsien] E Da Hosp, Dept Family Med, Kaohsiung, Taiwan; [Huang, Chi-Hsien] I Shou Univ, Sch Med Int Students, Kaohsiung, Taiwan; [Watanabe, Yuuki] Nagoya Univ Hosp, Dept Hosp Pharm, Showa Ku, Nagoya, Aichi, Japan; [Asai, Atushi] Sanei Clin, Komaki, Aichi, Japan; [Kanda, Shigeru] Minami Hlth Med Cooperat Kaname Hosp, Minami Ku, Nagoya, Aichi, Japan; [Nomura, Hideki] Aichi Clin, Tenpa Ku, Nagoya, Aichi, Japan	Nagoya University; E-Da Hospital; I Shou University; Nagoya University	Umegaki, H (corresponding author), Nagoya Univ, Grad Sch Med, Dept Community Healthcare & Geriatr, Showa Ku, Nagoya, Aichi, Japan.	umegaki@med.nagoya-u.ac.jp		HUANG, CHI HSIEN/0000-0002-4619-5144	Health Labour Sciences Research [H24YA003]; Ministry of Health Labour and Welfare, Japan	Health Labour Sciences Research; Ministry of Health Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan)	Dr. Hiroyuki Umegaki was funded by a grant from the Health Labour Sciences Research (#H24YA003) of the Ministry of Health Labour and Welfare, Japan. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Caughey GE, 2017, DIABETIC MED, V34, P432, DOI 10.1111/dme.13148; Chang CM, 2005, PHARMACOTHERAPY, V25, P831, DOI 10.1592/phco.2005.25.6.831; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cross AJ, 2017, J ALZHEIMERS DIS, V60, P349, DOI 10.3233/JAD-170265; Dosa D, 2013, J AM GERIATR SOC, V61, P1994, DOI 10.1111/jgs.12516; Fei Y, 2018, INT J CARDIOL, V254, P291, DOI 10.1016/j.ijcard.2017.12.039; Ferrah N, 2017, J AM GERIATR SOC, V65, P433, DOI 10.1111/jgs.14683; Forsetlund L, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-16; Gheewala PA, 2014, DRUG AGING, V31, P825, DOI 10.1007/s40266-014-0208-y; Giovannini S, 2018, DRUG AGING, V35, P145, DOI 10.1007/s40266-018-0521-y; Grace AR, 2014, J AM MED DIR ASSOC, V15, P830, DOI 10.1016/j.jamda.2014.08.008; Gutierrez-Valencia M, 2017, GERIATR GERONTOL INT, V17, P2354, DOI 10.1111/ggi.13073; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Harrison SL, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0704-8; Hawley S, 2016, AGE AGEING, V45, P236, DOI 10.1093/ageing/afv204; Holmes HM, 2008, J AM GERIATR SOC, V56, P1306, DOI 10.1111/j.1532-5415.2008.01741.x; Hyttinen V, 2019, EUR J HEALTH ECON, V20, P233, DOI 10.1007/s10198-018-0992-0; Hyttinen V, 2016, MED CARE, V54, P950, DOI 10.1097/MLR.0000000000000587; Jeon HL, 2018, INT J QUAL HEALTH C, V30, P50, DOI 10.1093/intqhc/mzx171; Juola AL, 2016, J AM MED DIR ASSOC, V17, DOI 10.1016/j.jamda.2015.12.011; Juurlink DN, 2004, NEW ENGL J MED, V351, P543, DOI 10.1056/NEJMoa040135; Katz PO, 2013, AM J GASTROENTEROL, V108, P308, DOI 10.1038/ajg.2012.444; Khow KSF, 2014, CURR DRUG SAF, V9, P2, DOI 10.2174/1574886308666140109112730; Kojima T, 2016, GERIATR GERONTOL INT, V16, P983, DOI 10.1111/ggi.12890; Komagamine J, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2228-3; Kose E, 2018, GERIATR GERONTOL INT, V18, P321, DOI 10.1111/ggi.13187; Kristensen RU, 2018, J ALZHEIMERS DIS, V63, P383, DOI 10.3233/JAD-170905; Kuzuya M, 2005, NUTRITION, V21, P498, DOI 10.1016/j.nut.2004.08.023; Lim LS, 2009, J AM GERIATR SOC, V57, P855, DOI 10.1111/j.1532-5415.2009.02195.x; Menditto E, 2018, PATIENT PREFER ADHER, V12, P1975, DOI 10.2147/PPA.S164819; Motter FR, 2018, EUR J CLIN PHARMACOL, V74, P679, DOI 10.1007/s00228-018-2446-0; Muhlack DC, 2017, J AM MED DIR ASSOC, V18, P211, DOI 10.1016/j.jamda.2016.11.025; Nakae H, 2018, FRONT NUTR, V5, DOI 10.3389/fnut.2018.00031; Nam YS, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0285-3; Nothelle SK, 2017, J AM MED DIR ASSOC, V18, DOI 10.1016/j.jamda.2017.06.005; O'Mahony D, 2015, AGE AGEING, V44, P213, DOI 10.1093/ageing/afu145; Ozalas SM, 2017, CONSULT PHARM, V32, P752, DOI 10.4140/TCP.n.2017.752; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Quilliam BJ, 2013, DIABETIC MED, V30, P1305, DOI 10.1111/dme.12217; Radcliff S, 2015, J AM GERIATR SOC, V63, P2227, DOI 10.1111/jgs.13702; Reboussin DM, 2018, CIRCULATION, V138, pE595, DOI 10.1161/CIR.0000000000000601; Redston MR, 2018, J ALZHEIMERS DIS, V61, P1639, DOI 10.3233/JAD-170842; Renom-Guiteras A, 2015, EUR J CLIN PHARMACOL, V71, P861, DOI 10.1007/s00228-015-1860-9; Rubenstein LZ, 2001, J GERONTOL A-BIOL, V56, pM366, DOI 10.1093/gerona/56.6.M366; Sato I, 2018, DRUG SAFETY, V41, P959, DOI 10.1007/s40264-018-0676-9; Sato Susumu, 2002, Journal of Physiological Anthropology and Applied Human Science, V21, P179, DOI 10.2114/jpa.21.179; Savarese G, 2013, J AM COLL CARDIOL, V62, P2090, DOI 10.1016/j.jacc.2013.07.069; Schoenfeld AJ, 2016, JAMA INTERN MED, V176, P172, DOI 10.1001/jamainternmed.2015.7927; Sevilla-Sanchez D, 2017, INT J CLIN PHARM-NET, V39, P1018, DOI 10.1007/s11096-017-0518-3; Stevenson DG, 2010, AM J GERIAT PSYCHIAT, V18, P1078, DOI 10.1097/JGP.0b013e3181d6c0c6; Tamiya N, 2011, LANCET, V378, P1183, DOI 10.1016/S0140-6736(11)61176-8; Tirmizi Samad, 2015, Consult Pharm, V30, P116, DOI 10.4140/TCP.n.2015.116.; Tokuda Y, 2016, J GEN FAM MED, V17, P3, DOI 10.14442/jgfm.17.1_3; Umegaki H, 2017, GERIATR GERONTOL INT, V17, P1623, DOI 10.1111/ggi.12943; de Lima TJV, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-52; Wang KN, 2018, DRUG AGING, V35, P423, DOI 10.1007/s40266-018-0537-3; Wilhelm SM, 2013, EXPERT REV CLIN PHAR, V6, P443, DOI 10.1586/17512433.2013.811206	57	19	19	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2019	14	2							e0211947	10.1371/journal.pone.0211947	http://dx.doi.org/10.1371/journal.pone.0211947			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HK7PK	30735544	Green Published, Green Submitted, gold			2023-01-03	WOS:000458181200049
J	Coulthard, MG; Varghese, V; Harvey, LP; Gillen, TC; Kimble, RM; Ware, RS				Coulthard, Mark G.; Varghese, Vanil; Harvey, Lauren P.; Gillen, Tona C.; Kimble, Roy M.; Ware, Robert S.			A review of children with severe trauma admitted to pediatric intensive care in Queensland, Australia	PLOS ONE			English	Review							GLOBAL BURDEN; BRAIN-INJURY; MORTALITY; DISEASE	Background The aim of this study is to review patient characteristics, injury patterns, and outcomes of trauma cases admitted to pediatric intensive care in Children's Health Queensland, Brisbane, Queensland, Australia. Methods Routinely recorded data collected prospectively from the Children's Health Queensland Trauma Service registry from November 2008 to October 2015 were reviewed. Demographic and clinical characteristics of trauma cases in children under 16 years of age are described, and their association with age and mortality analyzed. Results There were 542 cases of pediatric trauma identified and 66.4% were male. The overall mortality since January 2012 was 11.1%. The median injury severity score (ISS) was 11 (IQR = 9-22), 48.2% (n = 261) had an ISS > 12 and 41.7% (n = 226) patients had an ISS > 15. The most common injury patterns were isolated head injury (29.7%; n = 161) and multiple trauma (31.2%; n = 169). In 28.4% of cases (n = 154) surgery was required. The home was reported to be the most common place of injury (37.6%; n = 204). Children aged 0-4 years were least likely to survive their injury (15.3% mortality) compared with the 5-9 (5.6% mortality) and 10-15 (9.0% mortality) age groups. Higher mortality was associated with more severe injuries, abdomen/spine/thorax injuries, inflicted injuries, drowning and hanging. Conclusion This description of major pediatric trauma cases admitted to pediatric intensive care in Children's Health Queensland, Australia, will inform future pediatric major trauma service requirements as it identifies injury patterns and profiles, injury severity, management and mortality across different age groups.	[Coulthard, Mark G.; Varghese, Vanil] Queensland Childrens Hosp, Paediat Intens Care Unit, Brisbane, Qld, Australia; [Coulthard, Mark G.; Kimble, Roy M.] Univ Queensland, Queensland Childrens Hosp, Sch Clin Med, Acad Discipline Paediat & Child Hlth, South Brisbane, Australia; [Harvey, Lauren P.; Gillen, Tona C.; Kimble, Roy M.] Queensland Childrens Hosp, Paediat Trauma Serv, Brisbane, Qld, Australia; [Harvey, Lauren P.; Kimble, Roy M.] Childrens Hlth Queensland, Ctr Childrens Burns & Trauma Res, Brisbane, Qld, Australia; [Ware, Robert S.] Griffith Univ, Menzies Hlth Inst Queensland, Brisbane, Qld, Australia	University of Queensland; Griffith University; Menzies Health Institute Queensland	Coulthard, MG (corresponding author), Queensland Childrens Hosp, Paediat Intens Care Unit, Brisbane, Qld, Australia.; Coulthard, MG (corresponding author), Univ Queensland, Queensland Childrens Hosp, Sch Clin Med, Acad Discipline Paediat & Child Hlth, South Brisbane, Australia.	Mark.Coulthard@health.qld.gov.au	Coulthard, Mark G/AAT-7735-2021; Coulthard, Mark Graeme/E-9444-2010; Ware, Robert/B-2024-2014	Coulthard, Mark G/0000-0001-7400-5582; Coulthard, Mark Graeme/0000-0001-7400-5582; Ware, Robert/0000-0002-6129-6736				Adamo MA, 2009, J NEUROSURG-PEDIATR, V4, P414, DOI 10.3171/2009.6.PEDS0939; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bayreuther J, 2009, ARCH DIS CHILDHOOD-E, V94, P37, DOI 10.1136/adc.2007.132787; COMMITTEE ON PEDIATRIC EMERGENCY MEDICINE COUNCIL ON INJURY, 2016, Pediatrics, V138, DOI 10.1542/peds.2016-1569; Davies FC, 2015, EMERG MED J, V32, P921, DOI 10.1136/emermed-2015-205285; Deans KJ, 2013, J TRAUMA ACUTE CARE, V75, P157, DOI 10.1097/TA.0b013e3182984acb; Deasy C, 2012, INJURY, V43, P2006, DOI 10.1016/j.injury.2011.08.032; Densmore JC, 2006, J PEDIATR SURG, V41, P92, DOI 10.1016/j.jpedsurg.2005.10.013; Foster K, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0693-8; Franzen L, 2007, INJURY, V38, P91, DOI 10.1016/j.injury.2006.07.042; Haagsma JA, 2016, INJURY PREV, V22, P3, DOI 10.1136/injuryprev-2015-041616; Herman BE, 2011, PEDIATR EMERG CARE, V27, P65, DOI 10.1097/PEC.0b013e31820349db; Holland AJA, 2005, ANZ J SURG, V75, P878, DOI 10.1111/j.1445-2197.2005.03553.x; Holland AJA, 2002, J PAEDIATR CHILD H, V38, P487, DOI 10.1046/j.1440-1754.2002.00034.x; Kelly P, 2015, ARCH DIS CHILD, V100, P1123, DOI 10.1136/archdischild-2014-306960; KLEM SA, 1990, J TRAUMA, V30, P32, DOI 10.1097/00005373-199001000-00005; Kristiansen T, 2012, INJURY, V43, P1865, DOI 10.1016/j.injury.2011.08.011; Kyu HH, 2016, JAMA PEDIATR, V170, P267, DOI 10.1001/jamapediatrics.2015.4276; Lee KJ, 2015, AM J CRIT CARE, V24, P422, DOI 10.4037/ajcc2015720; Miller TR, 2000, FUTURE CHILD, V10, P137, DOI 10.2307/1602828; Osterman MJK, 2015, PEDIATRICS, V135, P1115, DOI 10.1542/peds.2015-0434; Patel N, 2017, PEDIATR SURG INT, V33, P1013, DOI 10.1007/s00383-017-4125-0; Powell EC, 2002, PEDIATRICS, V110, P792, DOI 10.1542/peds.110.4.792; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Sharar Sam R, 2012, Int J Crit Illn Inj Sci, V2, P111, DOI 10.4103/2229-5151.100886; Shudy M, 2006, PEDIATRICS, V118, pS203, DOI 10.1542/peds.2006-0951B; Stelfox HT, 2008, J TRAUMA, V65, P1488, DOI 10.1097/TA.0b013e3181568cfc; Tracy ET, 2013, J PEDIATR SURG, V48, P1384, DOI 10.1016/j.jpedsurg.2013.03.041; Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; Wohlgemut JM, 2013, J PEDIATR SURG, V48, P1593, DOI 10.1016/j.jpedsurg.2013.03.060	30	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2019	14	2							e0211530	10.1371/journal.pone.0211530	http://dx.doi.org/10.1371/journal.pone.0211530			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK5RX	30730910	gold, Green Submitted, Green Published			2023-01-03	WOS:000458026000032
J	Li, HK; Rombach, I; Zambellas, R; Walker, AS; McNally, MA; Atkins, BL; Lipsky, BA; Hughes, HC; Bose, D; Kumin, M; Scarborough, C; Matthews, PC; Brent, AJ; Lomas, J; Gundle, R; Rogers, M; Taylor, A; Angus, B; Byren, I; Berendt, AR; Warren, S; Fitzgerald, FE; Mack, DJF; Hopkins, S; Folb, J; Reynolds, HE; Moore, E; Marshall, J; Jenkins, N; Moran, CE; Woodhouse, AF; Stafford, S; Seaton, RA; Vallance, C; Hemsley, CJ; Bisnauthsing, K; Sandoe, JAT; Aggarwal, I; Ellis, SC; Bunn, DJ; Sutherland, RK; Barlow, G; Cooper, C; Geue, C; McMeekin, N; Briggs, AH; Sendi, P; Khatamzas, E; Wangrangsimakul, T; Wong, THN; Barrett, LK; Alvand, A; Old, CF; Bostock, J; Paul, J; Cooke, G; Thwaites, GE; Bejon, P; Scarborough, M				Li, H. -K.; Rombach, I.; Zambellas, R.; Walker, A. S.; McNally, M. A.; Atkins, B. L.; Lipsky, B. A.; Hughes, H. C.; Bose, D.; Kumin, M.; Scarborough, C.; Matthews, P. C.; Brent, A. J.; Lomas, J.; Gundle, R.; Rogers, M.; Taylor, A.; Angus, B.; Byren, I.; Berendt, A. R.; Warren, S.; Fitzgerald, F. E.; Mack, D. J. F.; Hopkins, S.; Folb, J.; Reynolds, H. E.; Moore, E.; Marshall, J.; Jenkins, N.; Moran, C. E.; Woodhouse, A. F.; Stafford, S.; Seaton, R. A.; Vallance, C.; Hemsley, C. J.; Bisnauthsing, K.; Sandoe, J. A. T.; Aggarwal, I.; Ellis, S. C.; Bunn, D. J.; Sutherland, R. K.; Barlow, G.; Cooper, C.; Geue, C.; McMeekin, N.; Briggs, A. H.; Sendi, P.; Khatamzas, E.; Wangrangsimakul, T.; Wong, T. H. N.; Barrett, L. K.; Alvand, A.; Old, C. F.; Bostock, J.; Paul, J.; Cooke, G.; Thwaites, G. E.; Bejon, P.; Scarborough, M.		OVIVA Trial Collaborators	Oral versus Intravenous Antibiotics for Bone and Joint Infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OSTEOMYELITIS; MANAGEMENT	BACKGROUND The management of complex orthopedic infections usually includes a prolonged course of intravenous antibiotic agents. We investigated whether oral antibiotic therapy is noninferior to intravenous antibiotic therapy for this indication. METHODS We enrolled adults who were being treated for bone or joint infection at 26 U.K. centers. Within 7 days after surgery (or, if the infection was being managed without surgery, within 7 days after the start of antibiotic treatment), participants were randomly assigned to receive either intravenous or oral antibiotics to complete the first 6 weeks of therapy. Follow-on oral antibiotics were permitted in both groups. The primary end point was definitive treatment failure within 1 year after randomization. In the analysis of the risk of the primary end point, the noninferiority margin was 7.5 percentage points. RESULTS Among the 1054 participants (527 in each group), end-point data were available for 1015 (96.3%). Treatment failure occurred in 74 of 506 participants (14.6%) in the intravenous group and 67 of 509 participants (13.2%) in the oral group. Missing end-point data (39 participants, 3.7%) were imputed. The intention-to-treat analysis showed a difference in the risk of definitive treatment failure (oral group vs. intravenous group) of -1.4 percentage points (90% confidence interval [CI], -4.9 to 2.2; 95% CI, -5.6 to 2.9), indicating noninferiority. Complete-case, per-protocol, and sensitivity analyses supported this result. The between-group difference in the incidence of serious adverse events was not significant (146 of 527 participants [27.7%] in the intravenous group and 138 of 527 [26.2%] in the oral group; P=0.58). Catheter complications, analyzed as a secondary end point, were more common in the intravenous group (9.4% vs. 1.0%). CONCLUSIONS Oral antibiotic therapy was noninferior to intravenous antibiotic therapy when used during the first 6 weeks for complex orthopedic infection, as assessed by treatment failure at 1 year.	[Li, H. -K.; McNally, M. A.; Atkins, B. L.; Matthews, P. C.; Brent, A. J.; Lomas, J.; Gundle, R.; Rogers, M.; Taylor, A.; Angus, B.; Byren, I.; Berendt, A. R.; Khatamzas, E.; Wangrangsimakul, T.; Wong, T. H. N.; Barrett, L. K.; Alvand, A.; Bejon, P.; Scarborough, M.] Oxford Univ Hosp NHS Fdn Trust, Oxford, England; [Rombach, I.; Zambellas, R.; Cooper, C.; Alvand, A.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England; [Kumin, M.; Scarborough, C.; Matthews, P. C.; Brent, A. J.; Angus, B.; Thwaites, G. E.; Bejon, P.; Scarborough, M.] Univ Oxford, Dept Med, Oxford, England; [Lipsky, B. A.] Univ Oxford, Div Med Sci, Oxford, England; [Li, H. -K.; Cooke, G.] Imperial Coll London, Div Infect Dis, London, England; [Walker, A. S.] UCL, Med Res Council Clin Trials Unit, London, England; [Warren, S.; Mack, D. J. F.; Hopkins, S.] Royal Free London NHS Fdn Trust, London, England; [Hemsley, C. J.; Bisnauthsing, K.] Guys & St Thomas NHS Fdn Trust, London, England; [Paul, J.] Publ Hlth England, London, England; [Hughes, H. C.] Univ Wales Hosp, Cardiff, S Glam, Wales; [Bose, D.] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England; [Jenkins, N.; Moran, C. E.; Woodhouse, A. F.; Stafford, S.] Heart England NHS Fdn Trust, Birmingham, W Midlands, England; [Warren, S.; Fitzgerald, F. E.; Mack, D. J. F.] Royal Natl Orthopaed Hosp NHS Trust, Stanmore, Middx, England; [Folb, J.; Reynolds, H. E.] Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Liverpool, Merseyside, England; [Moore, E.; Marshall, J.] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England; [Seaton, R. A.; Vallance, C.] Queen Elizabeth Univ Hosp, NHS Greater Glasgow & Clyde, Glasgow, Lanark, Scotland; [Geue, C.; McMeekin, N.; Briggs, A. H.] Univ Glasgow, Hlth Econ & Hlth Technol Assessment, Glasgow, Lanark, Scotland; [Sandoe, J. A. T.] Univ Leeds, Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England; [Aggarwal, I.] Ninewells Hosp, NHS Tayside, Dundee, Scotland; [Ellis, S. C.; Bunn, D. J.] Northumbria Healthcare NHS Fdn Trust, Northumberland, England; [Sutherland, R. K.] Western Gen Hosp, NHS Lothian, Edinburgh, Midlothian, Scotland; [Barlow, G.] Hull & East Yorkshire Hosp NHS Trust, Kingston Upon Hull, N Humberside, England; [Sendi, P.] Univ Bern, Bern, Switzerland; [Thwaites, G. E.] Univ Oxford, Clin Res Unit, Wellcome Trust, Ho Chi Minh City, Vietnam; [Bejon, P.] Kenya Med Res Inst KEMRI, Wellcome Trust Res Programme, Kilifi, Kenya	Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Oxford; University of Oxford; Imperial College London; Medical Research Council Clinical Trials Unit; University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; Public Health England; Cardiff University; University of Birmingham; Heart of England NHS Foundation Trust; University of London; University College London; Royal National Orthopaedic Hospital NHS Trust; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Cambridge; Queen Elizabeth University Hospital (QEUH); University of Glasgow; University of Leeds; University of Edinburgh; University of Bern; University of Oxford; Kenya Medical Research Institute	Scarborough, M (corresponding author), John Radcliffe Hosp, Microbiol Level 6, Oxford OX3 9DL, England.		Briggs, Andrew/ABA-9009-2020; Matthews, Philippa/P-7810-2019; Thwaites, Guy E/R-4993-2019; Sendi, Parham/R-3286-2018; Walker, Sarah/HDM-8717-2022; Sandoe, Jonathan/AAL-2117-2020; Wangrangsimakul, Tri/AAW-6224-2020; Llewelyn, Martin/A-7194-2011; Llewelyn, Martin/Y-1472-2019; Reynolds, Helen/H-1697-2014	Briggs, Andrew/0000-0002-0777-1997; Matthews, Philippa/0000-0002-4036-4269; Thwaites, Guy E/0000-0002-2858-2087; Sendi, Parham/0000-0002-7347-6312; Sandoe, Jonathan/0000-0003-0193-8677; Llewelyn, Martin/0000-0002-6811-1124; Reynolds, Helen/0000-0001-7443-4520; Alvand, Abtin/0000-0001-6069-978X; Pandit, Hemant/0000-0001-7392-8561; Hughes, Harriet/0000-0002-6405-0731; Li, Ho Kwong/0000-0002-8149-5943; Hopkins, Susan/0000-0001-5179-5702	National Institute for Health Research Health Technology Assessment program [11/36/29]; NIHR Imperial College Biomedical Research Centre; NIHR Oxford Biomedical Research Centre; MRC [MC_UU_12023/22] Funding Source: UKRI	National Institute for Health Research Health Technology Assessment program; NIHR Imperial College Biomedical Research Centre; NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the National Institute for Health Research Health Technology Assessment program (project number 11/36/29), the NIHR Imperial College Biomedical Research Centre (to Dr. Cooke), and the NIHR Oxford Biomedical Research Centre (to Drs. Walker, M. Scarborough, and Bejon).	Berendt AR, 2010, OXFORD TXB MED, P3788; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Conterno LO, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004439.pub3; Lew DP, 2004, LANCET, V364, P369, DOI 10.1016/S0140-6736(04)16727-5; Li HK, 2015, TRIALS, V16, DOI 10.1186/s13063-015-1098-y; Li HK, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001825; Mader JT, 1995, DOUGLAS BENNETTS PRI, P1039; Morisky DE, 2008, J CLIN HYPERTENS, V10, P348, DOI 10.1111/j.1751-7176.2008.07572.x; Murray DW, 2007, J BONE JOINT SURG BR, V89B, P1010, DOI 10.1302/0301-620X.89B8; Osmon DR, 2013, CLIN INFECT DIS, V56, P1, DOI [10.1093/cid/cis803, 10.1093/cid/cis966]; Rangel SJ, 2017, ANN SURG, V266, P361, DOI 10.1097/SLA.0000000000001923; Sheehy SH, 2010, J INFECTION, V60, P338, DOI 10.1016/j.jinf.2010.03.006; Spellberg B, 2012, CLIN INFECT DIS, V54, P393, DOI 10.1093/cid/cir842; Titecat M, 2013, ORTHOP TRAUMATOL-SUR, V99, P653, DOI 10.1016/j.otsr.2013.02.011; WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P198, DOI 10.1056/NEJM197001222820406; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Zimmerli W, 2003, INFECTION, V31, P99, DOI 10.1007/s15010-002-3079-9	17	300	306	5	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 31	2019	380	5					425	436		10.1056/NEJMoa1710926	http://dx.doi.org/10.1056/NEJMoa1710926			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ4HS	30699315	Green Accepted, Green Published, Bronze, Green Submitted			2023-01-03	WOS:000457135700006
J	Hwang, JK; Gwag, HB; Park, KM; On, YK; Kim, JS; Park, SJ				Hwang, Jin Kyung; Gwag, Hye Bin; Park, Kyoung-min; On, Young Keun; Kim, June Soo; Park, Seung-Jung			Outcomes of cardiac resynchronization therapy in patients with atrial fibrillation accompanied by slow ventricular response	PLOS ONE			English	Article							PACED HEART-RATE; FAILURE; MORTALITY; INCREASE; RHYTHM	It remains unclear as to whether cardiac resynchronization therapy (CRT) would be as effective in patients with atrial fibrillation (AF) accompanied by slow ventricular response (AFSVR, < 60 beats/min) as in those with sinus rhythm (SR). Echocardiographic reverse remodeling was compared between AF-SVR patients (n = 17) and those with SR (n = 88) at six months and 12 months after CRT treatment. We also evaluated the changes in QRS duration; New York Heart Association (NYHA) functional class; and long-term composite clinical outcomes including cardiac death, heart transplantation, and heart failure (HF)-related hospitalization. Left ventricular pacing sites and biventricular pacing percentages were not significantly different between the AF-SVR and SR groups. However, heart rate increase after CRT was significantly greater in the AF-SVR group than in the SR group (P < 0.001). At six and 12 months postoperation, both groups showed a comparable improvement in NYHA class; QRS narrowing; and echocardiographic variables including left ventricular end-systolic volume, left ventricular ejection fraction, and left atrial volume index. Over the median follow-up duration of 1.6 (interquartile range: 0.8-2.2) years, no significant between-group differences were observed regarding the rates of long-term composite clinical events (35% versus 24%; hazard ratio: 1.71; 95% confidence interval: 0.23-12.48; P = 0.60). CRT implantation provided comparable beneficial effects for patients with AF-SVR as compared with those with SR, by correcting electrical dyssynchrony and increasing biventricular pacing rate, in terms of QRS narrowing, symptom improvement, ventricular reverse remodeling, and long-term clinical outcomes.	[Hwang, Jin Kyung] Vet Hlth Serv Med Ctr, Div Cardiol, Dept Med, Seoul, South Korea; [Gwag, Hye Bin; Park, Kyoung-min; On, Young Keun; Kim, June Soo; Park, Seung-Jung] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Cardiol,Dept Med, Seoul, South Korea	Veterans Health Service Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center	Park, SJ (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Cardiol,Dept Med, Seoul, South Korea.	orthovics@skku.edu		Park, Seung-Jung/0000-0003-3288-0594				Brignole M, 2013, EUR HEART J, V34, P2281, DOI 10.1093/eurheartj/eht150; Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496; Delnoy PPHM, 2007, AM J CARDIOL, V99, P1252, DOI 10.1016/j.amjcard.2006.12.040; Gasparini M, 2006, J AM COLL CARDIOL, V48, P734, DOI 10.1016/j.jacc.2006.03.056; Gasparini M, 2013, JACC-HEART FAIL, V1, P500, DOI 10.1016/j.jchf.2013.06.003; Gwag HB, 2017, YONSEI MED J, V58, P703, DOI 10.3349/ymj.2017.58.4.703; Jeon DS, 2017, KOREAN CIRC J, V47, P523, DOI 10.4070/kcj.2016.0361; Khand AU, 2000, EUR HEART J, V21, P614, DOI 10.1053/euhj.1999.1767; Lim K, 2017, KOREAN CIRC J, V47, P132, DOI 10.4070/kcj.2016.0176; Maisel WH, 2003, AM J CARDIOL, V91, p2D, DOI 10.1016/S0002-9149(02)03373-8; MUKHARJI J, 1990, CLIN CARDIOL, V13, P639, DOI 10.1002/clc.4960130910; NISHIMURA RA, 1995, J AM COLL CARDIOL, V25, P281, DOI 10.1016/0735-1097(94)00419-Q; Stahlberg M, 2015, EUROPACE, V17, P439, DOI 10.1093/europace/euu289; Stahlberg M, 2011, EUROPACE, V13, P237, DOI 10.1093/europace/euq354; Strauss DG, 2011, AM J CARDIOL, V107, P927, DOI 10.1016/j.amjcard.2010.11.010; Sutton MGS, 2003, CIRCULATION, V107, P1985, DOI 10.1161/01.CIR.0000065226.24159.E9; Tang ASL, 2010, NEW ENGL J MED, V363, P2385, DOI 10.1056/NEJMoa1009540; Wang TJ, 2003, CIRCULATION, V107, P2920, DOI 10.1161/01.CIR.0000072767.89944.6E; Wilton SB, 2011, HEART RHYTHM, V8, P1088, DOI 10.1016/j.hrthm.2011.02.014	20	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2019	14	1							e0210603	10.1371/journal.pone.0210603	http://dx.doi.org/10.1371/journal.pone.0210603			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH1MW	30633768	Green Published, gold, Green Submitted			2023-01-03	WOS:000455485100031
J	O'Neill, B; Kalia, S; Aliarzadeh, B; Moineddin, R; Fung, WLA; Sullivan, F; Maloul, A; Bernard, S; Greiver, M				O'Neill, Braden; Kalia, Sumeet; Aliarzadeh, Babak; Moineddin, Rahim; Fung, Wai Lun Alan; Sullivan, Frank; Maloul, Asmaa; Bernard, Steven; Greiver, Michelle			Agreement between primary care and hospital diagnosis of schizophrenia and bipolar disorder: A cross-sectional, observational study using record linkage	PLOS ONE			English	Article							SURVEILLANCE; MORTALITY; ILLNESS; COHORT	People with serious mental illness die 10-25 years sooner than people without these conditions. Multiple challenges to accessing and benefitting from healthcare have been identified amongst this population, including a lack of coordination between mental health services and general health services. It has been identified in other conditions such as diabetes that accurate documentation of diagnosis in the primary care chart is associated with better quality of care. It is suspected that if a patient admitted to the hospital with serious mental illness is then discharged without adequate identification of their diagnosis in the primary care setting, follow up (such as medication management and care coordination) may be more difficult. We identified cohorts of patients with schizophrenia and bipolar disorder who accessed care through the North York Family Health Team (a group of 77 family physicians in Toronto, Canada) and North York General Hospital (a large community hospital) between January 1, 2012 and December 31, 2014. We identified whether labeling for these conditions was concordant between the two settings and explored predictors of concordant labeling. This was a retrospective cross-sectional study using de-identified data from the Health Databank Collaborative, a linked primary care-hospital database. We identified 168 patients with schizophrenia and 370 patients with bipolar disorder. Overall diagnostic concordance between primary care and hospital records was 23.2% for schizophrenia and 15.7% for bipolar disorder. Concordance was higher for those with multiple (2+) inpatient visits (for schizophrenia: OR 2.42; 95% CI 0.64-9.20 and for bipolar disorder: OR 8.38; 95% CI 3.16-22.22). Capture-recapture modeling estimated that 37.4% of patients with schizophrenia (95% CI 20.7-54.1) and 39.6% with bipolar disorder (95% CI 25.7-53.6) had missing labels in both settings when adjusting for patients' age, sex, income quintiles and co-morbidities. In this sample of patients accessing care at a large family health team and community hospital, concordance of diagnostic information about serious mental illness was low. Interventions should be developed to improve diagnosis and continuity of care across multiple settings.	[O'Neill, Braden; Sullivan, Frank; Greiver, Michelle] North York Gen Hosp, Dept Family & Community Med, Toronto, ON, Canada; [O'Neill, Braden; Moineddin, Rahim; Greiver, Michelle] Univ Toronto, Dept Family & Community Med, Fac Med, Toronto, ON, Canada; [O'Neill, Braden; Kalia, Sumeet; Aliarzadeh, Babak; Sullivan, Frank; Greiver, Michelle] Univ Toronto, Practice Based Res Network, Toronto, ON, Canada; [Kalia, Sumeet; Aliarzadeh, Babak] North York Gen Hosp, Res & Innovat, Toronto, ON, Canada; [Fung, Wai Lun Alan] North York Gen Hosp, Dept Psychiat, Toronto, ON, Canada; [Fung, Wai Lun Alan] Univ Toronto, Dept Psychiat, Fac Med, Toronto, ON, Canada; [Sullivan, Frank] Univ St Andrews, Sch Med, St Andrews, Scotland; [Maloul, Asmaa; Bernard, Steven] North York Gen Hosp, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; North York General Hospital; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; North York General Hospital; University of Toronto; University Toronto Affiliates; North York General Hospital; University of Toronto; University of St Andrews; University of Toronto; University Toronto Affiliates; North York General Hospital	O'Neill, B (corresponding author), North York Gen Hosp, Dept Family & Community Med, Toronto, ON, Canada.; O'Neill, B (corresponding author), Univ Toronto, Dept Family & Community Med, Fac Med, Toronto, ON, Canada.; O'Neill, B (corresponding author), Univ Toronto, Practice Based Res Network, Toronto, ON, Canada.	braden.oneill@nygh.on.ca	Sullivan, Frank/L-8286-2019	Sullivan, Frank/0000-0002-6623-4964	North York General Hospital; North York General Hospital, as part of the development and implementation of the Health Databank Collaborative; Department of Family and Community Medicine, Faculty of Medicine, University of Toronto	North York General Hospital(University of Toronto); North York General Hospital, as part of the development and implementation of the Health Databank Collaborative; Department of Family and Community Medicine, Faculty of Medicine, University of Toronto	Support for this project was provided by North York General Hospital. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study was reviewed and approved by the Research Ethics Board of North York General Hospital, Toronto, Ontario. It was funded by North York General Hospital, as part of the development and implementation of the Health Databank Collaborative. Drs. O'Neill and Greiver hold Investigator awards from the Department of Family and Community Medicine, Faculty of Medicine, University of Toronto. Dr. Greiver is supported by a research stipend from North York General Hospital. All authors declare that they have no conflicts of interest to disclose with respect to this study.	Agency for Healthcare Research and Quality, 2014, TOOLK IMPL CHRON CAR; An J, 2015, STUD HEALTH TECHNOL, V208, P45, DOI 10.3233/978-1-61499-488-6-45; Birtwhistle R, 2009, J AM BOARD FAM MED, V22, P412, DOI 10.3122/jabfm.2009.04.090081; Birtwhistle RV, 2011, CAN FAM PHYSICIAN, V57, P1219; Canadian Institute for Health Information, 2017, NAT AMB CAR REP SYST; Canadian Institute for Health Information, 2017, ONT MENT HLTH REP SY; College of Physicians and Surgeons of Ontario, 2012, MED REC POL STAT 4 1, P4; Davydow DS, 2016, MED CARE, V54, P90, DOI 10.1097/MLR.0000000000000448; De Hert M, 2011, WORLD PSYCHIATRY, V10, P52, DOI 10.1002/j.2051-5545.2011.tb00014.x; Gatov E, 2017, CAN MED ASSOC J, V189, pE1177, DOI 10.1503/cmaj.161351; Greiver M, 2018, NPJ PRIM CARE RESP M, V28, DOI 10.1038/s41533-018-0076-8; Hayes JF, 2017, BRIT J PSYCHIAT, V211, P175, DOI 10.1192/bjp.bp.117.202606; Health Canada, 2012, SCHIZ REP MENT ILLN; Health Canada, 2012, REPORT MENTAL ILLNES; Healthcare Information and Management Systems Society, 2016, NON TRADITIONAL REF; Jacobs R, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1107-6; Kurdyak P, 2015, CAN J PSYCHIAT, V60, P362, DOI 10.1177/070674371506000805; MCGUFFIN P, 1991, ARCH GEN PSYCHIAT, V48, P764; Molina-Ortiz EI, 2012, MT SINAI J MED, V79, P475, DOI 10.1002/msj.21328; Pampalon R, 2009, CHRONIC DIS CAN, V29, P178; Payne RA, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000723; Queenan JA, 2016, CMAJ OPEN, V4, pE2; Revilla-Lopez C, 2016, ATEN PRIM, V48, P244, DOI 10.1016/j.aprim.2015.06.002; Rhodes A, 2006, PRIMARY CARE ONTARIO; Schoepf D, 2014, EUR ARCH PSY CLIN N, V264, P3, DOI 10.1007/s00406-013-0436-x; Slomp M, 2009, CAN J PSYCHIAT, V54, P199, DOI 10.1177/070674370905400308; Stukel Therese A, 2013, Open Med, V7, pe40; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013; Wilkins R, 1993, Health Rep, V5, P157; Williamson T, 2014, ANN FAM MED, V12, P367, DOI 10.1370/afm.1644	31	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2019	14	1							e0210214	10.1371/journal.pone.0210214	http://dx.doi.org/10.1371/journal.pone.0210214			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG5UW	30615653	Green Published, gold			2023-01-03	WOS:000455045900053
J	Abbing, A; Ponstein, A; van Hooren, S; de Sonneville, L; Swaab, H; Baars, E				Abbing, Annemarie; Ponstein, Anne; van Hooren, Susan; de Sonneville, Leo; Swaab, Hanna; Baars, Erik			The effectiveness of art therapy for anxiety in adults: A systematic review of randomised and non-randomised controlled trials	PLOS ONE			English	Review							COGNITIVE-BEHAVIORAL THERAPY; POSTTRAUMATIC-STRESS-DISORDER; PSYCHODYNAMIC THERAPY; COST-EFFECTIVENESS; MENTAL-DISORDERS; QUALITY; PSYCHOTHERAPY; INTERVENTION; PERSONALITY; IMPAIRMENT	Background Anxiety disorders are one of the most diagnosed mental health disorders. Common treatment consists of cognitive behavioral therapy and pharmacotherapy. In clinical practice, also art therapy is additionally provided to patients with anxiety (disorders), among others because treatment as usual is not sufficiently effective for a large group of patients. There is no clarity on the effectiveness of art therapy (AT) on the reduction of anxiety symptoms in adults and there is no overview of the intervention characteristics and working mechanisms. Methods A systematic review of (non-) randomised controlled trials on AT for anxiety in adults to evaluate the effects on anxiety symptom severity and to explore intervention characteristics, benefitting populations and working mechanisms. Thirteen databases and two journals were searched for the period 1997-October 2017. The study was registered at PROSPERO (CRD42017080733) and performed according to the Cochrane recommendations. PRISMA Guidelines were used for reporting. Results Only three publications out of 776 hits from the search fulfilled the inclusion criteria: three RCTs with 162 patients in total. All studies have a high risk of bias. Study populations were: students with PTSD symptoms, students with exam anxiety and prisoners with prelease anxiety. Visual art techniques varied: trauma-related mandala design, collage making, free painting, clay work, still life drawing and house-tree-person drawing. There is some evidence of effectiveness of AT for pre-exam anxiety in undergraduate students. AT is possibly effective in reducing pre-release anxiety in prisoners. The AT characteristics varied and narrative synthesis led to hypothesized working mechanisms of AT: induce relaxation; gain access to unconscious traumatic memories, thereby creating possibilities to investigate cognitions; and improve emotion regulation. Conclusions Effectiveness of AT on anxiety has hardly been studied, so no strong conclusions can be drawn. This emphasizes the need for high quality trials studying the effectiveness of AT on anxiety.	[Abbing, Annemarie; Ponstein, Anne; Baars, Erik] Univ Appl Sci Leiden, Fac Hlth, Leiden, Netherlands; [Abbing, Annemarie; de Sonneville, Leo; Swaab, Hanna] Leiden Univ, Clin Neurodev Sci, Fac Social Sci, Leiden, Netherlands; [Ponstein, Anne; van Hooren, Susan] KenVak, Res Ctr Arts Therapies, Heerlen, Netherlands; [van Hooren, Susan] Zuyd Univ Appl Sci, Ctr Arts Therapies, Heerlen, Netherlands; [van Hooren, Susan] Open Univ, Fac Psychol & Educ Sci, Heerlen, Netherlands	Leiden University; Leiden University - Excl LUMC; Open University Netherlands	Abbing, A (corresponding author), Univ Appl Sci Leiden, Fac Hlth, Leiden, Netherlands.; Abbing, A (corresponding author), Leiden Univ, Clin Neurodev Sci, Fac Social Sci, Leiden, Netherlands.	abbing.a@hsleiden.nl	Shvarzblat, Chayim/C-8233-2019; Swaab, Hanna/AAD-2555-2019; Chicago, David Berkowitz/B-7239-2019	Shvarzblat, Chayim/0000-0003-0968-1167; Chicago, David Berkowitz/0000-0001-6519-1061; Baars, Erik/0000-0003-4428-5135; Abbing, Annemarie/0000-0002-8096-3530				Abbing A, 2017, CRD20170807332017 RC; Aderka IM, 2012, J ANXIETY DISORD, V26, P393, DOI 10.1016/j.janxdis.2012.01.003; Allen KN, 2010, SOC WORK MENT HEALTH, V9, P37, DOI 10.1080/15332985.2010.494540; Andersson G, 2012, PSYCHOTHER PSYCHOSOM, V81, P344, DOI 10.1159/000339371; Asawa P., 2003, THESIS; Balkom ALJM van VIv, 2013, MULTIDISCIPLINARY GU; Bandelow B, 2012, INT J PSYCHIAT CLIN, V16, P77, DOI 10.3109/13651501.2012.667114; Bateman A., 2004, PSYCHOTHERAPY BORDER; Baumeister RF, 2006, J PERS, V74, P1773, DOI 10.1111/j.1467-6494.2006.00428.x; Baxter AJ, 2014, PSYCHOL MED, V44, P2363, DOI 10.1017/S0033291713003243; Bell CE, 2007, ART THER, V24, P71, DOI 10.1080/07421656.2007.10129589; Blanco C, 2010, ARCH GEN PSYCHIAT, V67, P286, DOI 10.1001/archgenpsychiatry.2010.11; Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822; Campbell M, 2016, ART THER, V33, P169, DOI 10.1080/07421656.2016.1226643; Cascone S., EXPERTS WARN ADULT C; Csikszentimihalyi M., 1997, CREATIVITY FLOW PSYC; Curry NA, 2005, ART THER, V22, P81, DOI 10.1080/07421656.2005.10129441; Davidson JRT, 2004, ARCH GEN PSYCHIAT, V61, P1005, DOI 10.1001/archpsyc.61.10.1005; de Graaf R, 2012, SOC PSYCH PSYCH EPID, V47, P203, DOI 10.1007/s00127-010-0334-8; de Morais AH, 2014, ART PSYCHOTHER, V41, P205, DOI 10.1016/j.aip.2014.02.002; Drozdek B, 2010, TRAUMATOLOGY, V16, P117, DOI DOI 10.1177/1534765610388298; Drozdek B, 2012, J NERV MENT DIS, V200, P758, DOI 10.1097/NMD.0b013e318266f860; Eaton J, 2017, ART THER, V34, P42, DOI 10.1080/07421656.2016.1277113; Egger N, 2015, J AFFECT DISORDERS, V180, P21, DOI 10.1016/j.jad.2015.03.037; Eren N, 2014, ART PSYCHOTHER, V41, P375, DOI 10.1016/j.aip.2014.06.004; Fenner P, 2017, CURR OPIN PSYCHIATR, V30, P306, DOI 10.1097/YCO.0000000000000338; Fonagy P, 2015, WORLD PSYCHIATRY, V14, P137, DOI 10.1002/wps.20235; Frances A, 2000, TASK FORCE D I DIAGN; Grant S, 2016, ADDICTION, V111, P1533, DOI 10.1111/add.13380; Gruber H, 2018, ART PSYCHOTHER, V59, P65, DOI 10.1016/j.aip.2017.12.006; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012; Haeyen S., 2005, PANEL DISCUSSION EXP; Haeyen S, 2015, ART PSYCHOTHER, V45, P1, DOI 10.1016/j.aip.2015.04.005; Hassink-Franke LT, 2012, DUTCH PRIMARY CARE S; Henderson P., 2007, PSYCHOL AESTHET CREA, V1, P148, DOI [https://doi.org/10.1037/1931-3896.1.3.148, DOI 10.1037/1931-3896.1.3.148, 10.1037/1931-3896.1.3.148]; Heynen E, 2017, ART PSYCHOTHER, V55, P111, DOI 10.1016/j.aip.2017.05.006; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Holmqvist G, 2012, SCAND J PSYCHOL, V53, P47, DOI 10.1111/j.1467-9450.2011.00923.x; Huijbregts SCJ, 2015, KLINISCHE KINDERNEUR; Hyman SE, 2010, ANNU REV CLIN PSYCHO, V6, P155, DOI 10.1146/annurev.clinpsy.3.022806.091532; Kaimal G, 2016, ART THER, V33, P74, DOI 10.1080/07421656.2016.1166832; Kessler RC, 1999, AM J PSYCHIAT, V156, P1915; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kim SK, 2013, ART PSYCHOTHER, V40, P158, DOI 10.1016/j.aip.2012.11.002; Kimport ER, 2015, ART THER, V32, P184, DOI 10.1080/07421656.2015.1092802; Knijnik DZ, 2009, J NERV MENT DIS, V197, P547, DOI 10.1097/NMD.0b013e3181aac833; Konnopka A, 2009, J AFFECT DISORDERS, V114, P14, DOI 10.1016/j.jad.2008.07.014; Kramer E., 1975, STUDIES ART ED, V16, P68; Lande RG, 2011, J AGGRESS MALTREAT T, V20, P530, DOI DOI 10.1080/10926771.2011.588149; Lankston L, 2010, J ROY SOC MED, V103, P490, DOI 10.1258/jrsm.2010.100256; Leichsenring F, 2014, AM J PSYCHIAT, V171, P1074, DOI 10.1176/appi.ajp.2014.13111514; Leichsenring F, 2013, AM J PSYCHIAT, V170, P759, DOI [10.1176/appi.ajp.2013.13060744r, 10.1176/appi.ajp.2013.12081125]; Leichsenring F, 2009, AM J PSYCHIAT, V166, P875, DOI 10.1176/appi.ajp.2009.09030441; Lydiard RB, 1996, J CONSULT CLIN PSYCH, V64, P660; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Malchiodi Cathy A, 2003, HDB ART THERAPY; McGrath CE, 2012, THESIS; McNeilly G, 2011, CHANGING SHAPE ART T; Mendlowicz MV, 2000, AM J PSYCHIAT, V157, P669, DOI 10.1176/appi.ajp.157.5.669; Moher D., 2009, BMJ-BRIT MED J, V6, DOI [DOI 10.1023/B:MEDI.0000005484.26741.79, 10.1371/journal.pmed1000097.]; Morgan L., 2012, INT J ART THERAPY, V17, P91, DOI [10.1080/17454832.2012.734836, DOI 10.1080/17454832.2012.734836]; Munder T, 2018, PSYCHOTHER RES, V28, P347, DOI 10.1080/10503307.2017.1411628; Nanda U, 2010, ENVIRON BEHAV, V42, P376, DOI 10.1177/0013916510361874; Naragon-Gainey K, 2014, PSYCHOL MED, V44, P1691, DOI 10.1017/S0033291713001967; Naumburg M., 1966, ILLUSTRATED 3 CASE S; Nederland FeG. GZ Vaktherapeut, 2012, BER; Nielsen S. K. K., 2018, PSYCHOTHER RES, P1; Oster Inger, 2006, Palliat Support Care, V4, P57, DOI 10.1017/S147895150606007X; Ouwens M, 2007, TIJDSCHRIFT VAKTHERA, V2007, P17; Ramirez J., 2016, J MILITARY VETERANS, V24; Ryan R, 2016, GRADE QUALITY EVIDEN; Sandmire DA, 2012, ART THER, V29, P68, DOI 10.1080/07421656.2012.683748; Sarid O, 2010, ART PSYCHOTHER, V37, P8, DOI 10.1016/j.aip.2009.11.004; Schouten K. A., 2014, VIOLENCE ABUSE, V16, P220, DOI DOI 10.1177/1524838014555032; Schweizer C, 2009, ART THERAPY HDB ART, P25; Selders M, 2015, PSYCHOANAL PSYCHOTHE, V29, P182, DOI 10.1080/02668734.2015.1036106; Shea BJ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j4008; Slayton SC, 2010, ART THER, V27, P108, DOI 10.1080/07421656.2010.10129660; Swami V, 2017, BODY IMAGE, V20, P65, DOI 10.1016/j.bodyim.2016.12.001; TOROGHI LM, 2015, EUR PSYCHIAT S1, V30; Twenge JM, 2000, J PERS SOC PSYCHOL, V79, P1007, DOI 10.1037//0022-3514.79.6.1007; Uttley L, 2015, BMC PSYCHIATRY, V15, DOI 10.1186/s12888-015-0528-4; Van Lith T, 2016, ART PSYCHOTHER, V47, P9, DOI 10.1016/j.aip.2015.09.003; Williams ME, 2010, J IMMIGR MINOR HEALT, V13, P780; Wittchen HU, 2011, EUR NEUROPSYCHOPHARM, V21, P655, DOI 10.1016/j.euroneuro.2011.07.018; Yan H., 2011, MED PHILOS, V10, P56; Yu YZ, 2016, SOC BEHAV PERSONAL, V44, P987, DOI 10.2224/sbp.2016.44.6.987	87	24	25	13	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2018	13	12							e0208716	10.1371/journal.pone.0208716	http://dx.doi.org/10.1371/journal.pone.0208716			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HE5TK	30557381	Green Published, Green Submitted, gold			2023-01-03	WOS:000453451000039
J	Hirshberg, MJ; Goldberg, SB; Schaefer, SM; Flook, L; Findley, D; Davidson, RJ				Hirshberg, Matthew J.; Goldberg, Simon B.; Schaefer, Stacey M.; Flook, Lisa; Findley, David; Davidson, Richard J.			Divergent effects of brief contemplative practices in response to an acute stressor: A randomized controlled trial of brief breath awareness, loving-kindness, gratitude or an attention control practice	PLOS ONE			English	Article							MINDFULNESS MEDITATION; NEGATIVE AFFECT; ACTIVATION	Mindfulness practices are increasingly being utilized as a method for cultivating well-being. The term mindfulness is often used as an umbrella for a variety of different practices and many mindfulness-based interventions (MBIs) contain multiple styles of practice. Despite the diversity of practices within MBIs, few studies have investigated whether constituent practices produce specific effects. We randomized 156 undergraduates to one of four brief practices: breath awareness, loving-kindness, gratitude, or to an attention control condition. We assessed practice effects on affect following brief training, and effects on affect and behavior after provocation with a stressor (i.e., Cold pressor test). Results indicate that gratitude training significantly improved positive affect compared to breath awareness (d=0.58) and loving-kindness led to significantly greater reductions in implicit negative affect compared to the control condition (d= 0.59) immediately after brief practice. In spite of gains in positive affect, the gratitude group demonstrated increased reactivity to the stressor, reporting the CPT as significantly more aversive than the control condition (d=0.46) and showing significantly greater increases in negative affect compared to the breath awareness, loving-kindness, and control groups (ds =0.55, 0.60, 0.65, respectively). Greater gains in implicit positive affect following gratitude training predicted decreased post-stressor likability ratings of novel neutral faces compared to breath awareness, loving-kindness, and control groups (ds =- 0.39,-0.40,-0.33, respectively) as well. Moreover, the gratitude group was significantly less likely to donate time than the loving-kindness group in an ecologically valid opportunity to provide unrewarded support. These data suggest that different styles of contemplative practice may produce different effects in the context of brief, introductory practice and these differences may be heightened by stress. Implications for the study of contemplative practices are discussed.	[Hirshberg, Matthew J.; Goldberg, Simon B.; Schaefer, Stacey M.; Flook, Lisa; Findley, David; Davidson, Richard J.] Univ Wisconsin, Ctr Hlth Minds, Madison, WI 53706 USA; [Hirshberg, Matthew J.] Univ Wisconsin, Dept Educ Psychol, Madison, WI 53706 USA; [Goldberg, Simon B.] Univ Wisconsin, Dept Counseling Psychol, Madison, WI USA; [Goldberg, Simon B.] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA; [Davidson, Richard J.] Univ Wisconsin, Dept Psychol, 1202 W Johnson St, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Wisconsin System; University of Wisconsin Madison	Hirshberg, MJ (corresponding author), Univ Wisconsin, Ctr Hlth Minds, Madison, WI 53706 USA.; Hirshberg, MJ (corresponding author), Univ Wisconsin, Dept Educ Psychol, Madison, WI 53706 USA.	Hirshberg@wisc.edu	Goldberg, Simon/AAQ-5173-2021; Hirshberg, Matthew/AAM-7317-2021	Goldberg, Simon/0000-0002-6888-0126; Hirshberg, Matthew/0000-0001-9070-1270; Davidson, Richard/0000-0002-8506-4964	National Center for Complementary and Alternative Medicine (NCCAM) [P01AT004952]; Institute of Educational Sciences (IES) [R305A140479]; National Center for Complementary & Integrative Health [P01AT004952] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine (NCCAM)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Institute of Educational Sciences (IES); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Center for Complementary and Alternative Medicine (NCCAM) P01AT004952 to RJD (https://projectreporter.nih.gov/reporter_searchresults.cfm) and by generous donations from individuals to the Center for Investigating Healthy Minds. MJH was supported by an Institute of Educational Sciences (IES) grant R305A140479 to LF and RJD (https://ies.ed.gov/funding/grantsearch/details.asp? ID=1530). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beaupre M.G., 2000, MONTREAL SET FACIAL; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brown CC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14846-3; Chiesa A, 2013, CLIN PSYCHOL REV, V33, P82, DOI 10.1016/j.cpr.2012.10.006; Condon P, 2013, PSYCHOL SCI, V24, P2125, DOI 10.1177/0956797613485603; Creswell JD, 2017, ANNU REV PSYCHOL, V68, P491, DOI 10.1146/annurev-psych-042716-051139; Dahl CJ, 2015, TRENDS COGN SCI, V19, P515, DOI 10.1016/j.tics.2015.07.001; Emmons RA, 2003, J PERS SOC PSYCHOL, V84, P377, DOI 10.1037/0022-3514.84.2.377; Engert V, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1700495; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Forgas JP, 2011, J EXP SOC PSYCHOL, V47, P425, DOI 10.1016/j.jesp.2010.11.005; Fredrickson BL, 2008, J PERS SOC PSYCHOL, V95, P1045, DOI 10.1037/a0013262; Goldberg SB, 2018, CLIN PSYCHOL REV, V59, P52, DOI 10.1016/j.cpr.2017.10.011; Goldberg SB, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01367; Grupe DW, 2018, SOC COGN AFFECT NEUR, V13, P310, DOI 10.1093/scan/nsy011; Hofmann SG, 2011, CLIN PSYCHOL REV, V31, P1126, DOI 10.1016/j.cpr.2011.07.003; Hutcherson CA, 2008, EMOTION, V8, P720, DOI 10.1037/a0013237; Kabat-Zinn J, 2009, LIBR J; KABATZINN J, 1982, GEN HOSP PSYCHIAT, V4, P33, DOI 10.1016/0163-8343(82)90026-3; Lakens D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00863; Lapate RC, 2014, PSYCHOL SCI, V25, P349, DOI 10.1177/0956797613503175; Law RW, 2011, ANALOGUE STUDY LOVIN; LOVALLO W, 1975, PSYCHOPHYSIOLOGY, V12, P268, DOI 10.1111/j.1469-8986.1975.tb01289.x; Lumma AL, 2015, INT J PSYCHOPHYSIOL, V97, P38, DOI 10.1016/j.ijpsycho.2015.04.017; Lutz A, 2013, NEUROIMAGE, V64, P538, DOI 10.1016/j.neuroimage.2012.09.030; McCullough ME, 2002, J PERS SOC PSYCHOL, V82, P112, DOI 10.1037//0022-3514.82.1.112; Messer K., 1999, PROC INT C AUDIO VID, V964, P965; Muraven M, 1998, J PERS SOC PSYCHOL, V74, P774, DOI 10.1037/0022-3514.74.3.774; Przyrembel M, 2018, CONSCIOUS COGN, V62, P82, DOI 10.1016/j.concog.2018.04.004; Quirin M, 2009, J PERS SOC PSYCHOL, V97, P500, DOI 10.1037/a0016063; Raio CM, 2013, P NATL ACAD SCI USA, V110, P15139, DOI 10.1073/pnas.1305706110; REISS S, 1986, BEHAV RES THER, V24, P1, DOI 10.1016/0005-7967(86)90143-9; RStudio Team, 2015, RSTUDIO INTEGRATED D; Salzberg S., 2009, GUIDED MEDITATIONS L; Schwabe L, 2008, PSYCHONEUROENDOCRINO, V33, P890, DOI 10.1016/j.psyneuen.2008.03.001; Stahl B., 2010, MINDFULNESS BASED ST; Steinbeis N, 2015, PSYCHONEUROENDOCRINO, V62, P138, DOI 10.1016/j.psyneuen.2015.08.003; Tottenham N, 2009, PSYCHIAT RES, V168, P242, DOI 10.1016/j.psychres.2008.05.006; Unsworth N, 2005, BEHAV RES METHODS, V37, P498, DOI 10.3758/BF03192720; Vago DR, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00296; Wallace BA, 2002, THE SPECTRUM OF BUDD, P34; Watkins PC, 2003, SOC BEHAV PERSONAL, V31, P431, DOI 10.2224/sbp.2003.31.5.431; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Wood AM, 2008, J RES PERS, V42, P854, DOI 10.1016/j.jrp.2007.11.003; Wood AM, 2010, CLIN PSYCHOL REV, V30, P890, DOI 10.1016/j.cpr.2010.03.005; Zeidan F, 2010, J ALTERN COMPLEM MED, V16, P867, DOI 10.1089/acm.2009.0321	46	11	11	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2018	13	12							e0207765	10.1371/journal.pone.0207765	http://dx.doi.org/10.1371/journal.pone.0207765			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HD9QX	30540772	Green Submitted, Green Published, gold			2023-01-03	WOS:000452898600033
J	Higashi, H; Takaku, R; Yamaoka, A; Lefor, AK; Shiga, T				Higashi, Hidenori; Takaku, Reo; Yamaoka, Atsushi; Lefor, Alan Kawarai; Shiga, Takashi			The Dedicated Emergency Physician Model of emergency care is associated with reduced pre-hospital transportation time: A retrospective study with a nationwide database in Japan	PLOS ONE			English	Article							AMBULANCE SERVICES; DEMAND	In Japan, the increasing number of patients needing emergency medical care due to population aging is a major public health problem. Recently, emergency medicine in Japan has seen a growth in the number of Dedicated Emergency Physician Model style departments. We aimed to determine whether there is an association between Dedicated Emergency Physician Model emergency care and pre-hospital transportation time. We conducted a secondary analysis of a Japanese national pre-hospital database from 2010 to 2014. Three regions (group 1: Urayasu city and Ichikawa city in Chiba prefecture, group 2: Kamakura city, Chigasaki city, Fujisawa city and Zushi city in Kanagawa prefecture, and group 3: Fukui city in Fukui prefecture) were evaluated as Dedicated Emergency Physician Model emergency medicine areas. We compared transportation times in these areas with all municipalities in the same prefectures, and with a nearby area using multivariate linear regression with cluster adjustment. The variables used for adjustment are the time from Emergency Medical Services activation to the scene, month, day of the month, day of the week, time of day, age, gender, type of injury, severity, and location of call. Compared with all municipalities in each prefecture there were significant reductions in pre-hospital transportation time: 4.2 minutes (95% confidence interval, 0.9 to 7.5, p<0.05) in Group 1, 6.2 minutes (95%CI, 2.9 to 9.6, p<0.01) fin Group 2 and 7.5 minutes (95%CI, 6.0 to 9.0, p<0.01) in Group 3. Compared with nearby areas, there were statistically significant reductions in transportation time in Group 1, 6.8 minutes (95%CI, 0.7 to 12.8, p<0.05) and in Group 2, 6.8 minutes (95%CI, 3.7 to 9.9, p<0.05). There was a trend for reduced transportation time in Group 3, 2.3 minutes, (5.3 to -0.6, p<0.1). Areas with a Dedicated Emergency Physician Model are associated with reduced pre-hospital transportation time.	[Higashi, Hidenori] Japanese Red Cross Wakayama Med Ctr, Dept Emergency & Crit Care Med, Wakayama, Wakayama, Japan; [Takaku, Reo] Inst Hlth Econ & Policy, Minato Ku, Tokyo, Japan; [Yamaoka, Atsushi] Kobe Univ, Fac Econ, Nada Ku, Kobe, Hyogo, Japan; [Lefor, Alan Kawarai] Jichi Med Univ, Dept Surg, Shimotsuke, Tochigi, Japan; [Shiga, Takashi] Int Univ Hlth & Welf, Dept Emergency Med, Minato Ku, Tokyo, Japan	Kobe University; Jichi Medical University; International University of Health & Welfare	Higashi, H (corresponding author), Japanese Red Cross Wakayama Med Ctr, Dept Emergency & Crit Care Med, Wakayama, Wakayama, Japan.	higashihidenori@yahoo.co.jp	; Lefor, Alan/E-9979-2012	Takaku, Reo/0000-0001-6091-9199; Lefor, Alan/0000-0001-6673-5630				Clark MJ, 1999, J ACCID EMERG MED, V16, P108; Hasegawa K, 2013, RESUSCITATION, V84, P1099, DOI 10.1016/j.resuscitation.2013.03.007; Hori Shingo, 2010, Keio Journal of Medicine, V59, P131, DOI 10.2302/kjm.59.131; Katayama Y, 2017, ACUTE MED SURG, V4, P401, DOI 10.1002/ams2.291; Katayama Y, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-013849; Lowthian JA, 2011, MED J AUSTRALIA, V194, P574, DOI 10.5694/j.1326-5377.2011.tb03107.x; Markham D, 2011, BMC EMERG MED, V11, DOI 10.1186/1471-227X-11-21; Matsuyama T, 2017, GERIATR GERONTOL INT, V17, P2441, DOI 10.1111/ggi.13098; Platts-Mills TF, 2010, PREHOSP EMERG CARE, V14, P329, DOI 10.3109/10903127.2010.481759; Sandoval E, 2010, J EMERG MED, V38, P115, DOI 10.1016/j.jemermed.2007.09.042; Seikei Hibino SH, 2010, JJAAM, V21, P925; Takaku R, 2018, INT J HLTH EC MANAG; Wrigley H, 2002, BRIT MED J, V324, P646, DOI 10.1136/bmj.324.7338.646; Yamada KC, 2015, JMIR MHEALTH UHEALTH, V3, DOI 10.2196/mhealth.3293	14	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2019	14	4							e0215231	10.1371/journal.pone.0215231	http://dx.doi.org/10.1371/journal.pone.0215231			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT6TE	30990824	gold, Green Published, Green Submitted			2023-01-03	WOS:000464696100025
J	Huang, SS; Septimus, E; Kleinman, K; Moody, J; Hickok, J; Heim, L; Gombosev, A; Avery, TR; Haffenreffer, K; Shimelman, L; Hayden, MK; Weinstein, RA; Spencer-Smith, C; Kaganov, RE; Murphy, MV; Forehand, T; Lankiewicz, J; Coady, MH; Portillo, L; Sarup-Patel, J; Jernigan, JA; Perlin, JB; Platt, R				Huang, Susan S.; Septimus, Edward; Kleinman, Ken; Moody, Julia; Hickok, Jason; Heim, Lauren; Gombosev, Adrijana; Avery, Taliser R.; Haffenreffer, Katherine; Shimelman, Lauren; Hayden, Mary K.; Weinstein, Robert A.; Spencer-Smith, Caren; Kaganov, Rebecca E.; Murphy, Michael V.; Forehand, Tyler; Lankiewicz, Julie; Coady, Micaela H.; Portillo, Lena; Sarup-Patel, Jalpa; Jernigan, John A.; Perlin, Jonathan B.; Platt, Richard		ABATE Infect Trial Team	Chlorhexidine versus routine bathing to prevent multidrug-resistant organisms and all-cause bloodstream infections in general medical and surgical units (ABATE Infection trial): a cluster-randomised trial	LANCET			English	Article							INTENSIVE-CARE UNITS; STAPHYLOCOCCUS-AUREUS; UNIVERSAL DECOLONIZATION; POVIDONE-IODINE; GLUCONATE; REDUCE; ENTEROCOCCUS; MULTICENTER; ICU; INTERVENTIONS	Background Universal skin and nasal decolonisation reduces multidrug-resistant pathogens and bloodstream infections in intensive care units. The effect of universal decolonisation on pathogens and infections in non-criticalcare units is unknown. The aim of the ABATE Infection trial was to evaluate the use of chlorhexidine bathing in non-critical-care units, with an intervention similar to one that was found to reduce multidrug-resistant organisms and bacteraemia in intensive care units. Methods The ABATE Infection (active bathing to eliminate infection) trial was a cluster-randomised trial of 53 hospitals comparing routine bathing to decolonisation with universal chlorhexidine and targeted nasal mupirocin in non-critical-care units. The trial was done in hospitals affiliated with HCA Healthcare and consisted of a 12-month baseline period from March 1, 2013, to Feb 28, 2014, a 2-month phase-in period from April 1, 2014, to May 31, 2014, and a 21-month intervention period from June 1, 2014, to Feb 29, 2016. Hospitals were randomised and their participating non-critical-care units assigned to either routine care or daily chlorhexidine bathing for all patients plus mupirocin for known methicillin-resistant Staphylococcus aureus (MRSA) carriers. The primary outcome was MRSA or vancomycin-resistant enterococcus clinical cultures attributed to participating units, measured in the unadjusted, intention-to-treat population as the HR for the intervention period versus the baseline period in the decolonisation group versus the HR in the routine care group. Proportional hazards models assessed differences in outcome reductions across groups, accounting for clustering within hospitals. This trial is registered with ClinicalTrials. gov, number NCT02063867. Findings There were 189 081 patients in the baseline period and 339 902 patients (156 889 patients in the routine care group and 183 013 patients in the decolonisation group) in the intervention period across 194 non-critical-care units in 53 hospitals. For the primary outcome of unit-attributable MRSA-positive or VRE-positive clinical cultures (figure 2), the HR for the intervention period versus the baseline period was 0.79 (0.73-0.87) in the decolonisation group versus 0.87 (95% CI 0.79-0.95) in the routine care group. No difference was seen in the relative HRs (p= 0.17). There were 25 (< 1%) adverse events, all involving chlorhexidine, among 183 013 patients in units assigned to chlorhexidine, and none were reported for mupirocin. Interpretation Decolonisation with universal chlorhexidine bathing and targeted mupirocin for MRSA carriers did not significantly reduce multidrug-resistant organisms in non-critical-care patients. Copyright (c) 2019 Elsevier Ltd. All rights reserved.	[Huang, Susan S.; Heim, Lauren; Gombosev, Adrijana] Univ Calif Irvine, Div Infect Dis, Sch Med, Irvine, CA 92697 USA; [Septimus, Edward] HCA Healthcare, Clin Serv Grp, Houston, TX USA; [Moody, Julia; Hickok, Jason; Spencer-Smith, Caren; Forehand, Tyler; Perlin, Jonathan B.] HCA Healthcare, Clin Serv Grp, Nashville, TN USA; [Septimus, Edward] Texas A&M Coll Med, Div Infect Dis, Houston, TX USA; [Septimus, Edward; Avery, Taliser R.; Haffenreffer, Katherine; Shimelman, Lauren; Kaganov, Rebecca E.; Murphy, Michael V.; Lankiewicz, Julie; Coady, Micaela H.; Platt, Richard] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA; [Septimus, Edward; Avery, Taliser R.; Haffenreffer, Katherine; Shimelman, Lauren; Kaganov, Rebecca E.; Murphy, Michael V.; Lankiewicz, Julie; Coady, Micaela H.; Platt, Richard] Harvard Med Sch, Boston, MA 02115 USA; [Kleinman, Ken] Univ Massachusetts, Dept Biostat & Epidemiol, Sch Publ Hlth & Hlth Sci, Amherst, MA 01003 USA; [Hayden, Mary K.; Weinstein, Robert A.; Portillo, Lena; Sarup-Patel, Jalpa] Rush Med Coll, Div Infect Dis, Chicago, IL 60612 USA; [Weinstein, Robert A.] Cook Cty Hlth & Hosp Syst, Dept Med, Chicago, IL USA; [Jernigan, John A.] Ctr Dis Control & Prevent, Off HAI Prevent Res & Evaluat, Atlanta, GA USA	University of California System; University of California Irvine; Hospital Corporation of America; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Amherst; Rush University; John H Stroger Junior Hospital Cook County; Centers for Disease Control & Prevention - USA	Huang, SS (corresponding author), Univ Calif Irvine, Div Infect Dis, Sch Med, Irvine, CA 92697 USA.	sshuang@uci.edu		Hayden, Mary/0000-0002-4603-8501; Kleinman, Ken/0000-0002-5600-5834; Jernigan, John/0000-0001-8163-925X	National Institutes of Health; National Institutes of Health Common Fund; National Institute of Allergy and Infectious Diseases [UH2/UH3 AT007769-0]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UH3AI113337] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health Common Fund(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	National Institutes of Health.; This project was funded by the National Institutes of Health Common Fund and administered by the National Institute of Allergy and Infectious Diseases (UH2/UH3 AT007769-0 to SSH). The findings and conclusions expressed in this Article are those of the authors and do not necessarily represent the official position of the National Institutes of Health or the CDC. We thank the following individuals for their invaluable contribution: Laurie Brewer, Jane Englebright, Andrew Ko, Deborah Lilly, Bradley Ninness, Russell Poland, Lorraine Rognstad, Deepak Sharma, and David Vulcano; Dottie White from HCA; and Grace Lee from the Harvard Pilgrim Health Care Institute and Harvard Medical School. We also thank Sage Products for providing bathing demonstrations to the decolonisation group. We especially recognise and thank the unit staff and leadership, infection prevention programmes, nurse educators, microbiology laboratories, and administrative leadership at all of the participating hospitals for their commitment and dedication to this trial: Blake Medical Center (Bradenton, FL), Chippenham Johnston Willis Medical Center (Richmond, VA), Cartersville Medical Center (Cartersville, GA), Clear Lake Regional Medical Center (Webster, TX), Coliseum Northside Hospital (Macon, GA), Colleton Medical Center (Walterboro, SC), Conroe Regional Medical Center (Conroe, TX), Corpus Christi Medical Center (Corpus Christi, TX), Eastside Medical Center (Snellville, GA), Garden Park Medical Center (Gulfport, MS), Hendersonville Medical Center (Hendersonville, TN), Henrico Doctors' Hospital (Richmond, VA), John Randolph Medical Center (Hopewell, VA), Kingwood Medical Center (Kingwood, TX), Las Colinas Medical Center (Irving, TX), Las Palmas Medical Center (El Paso, TX), Lee's Summit Medical Center (Lee's Summit, MO), LewisGale Hospital Alleghany (Low Moor, VA), Medical Center of Plano (Plano, TX), Methodist Hospital (San Antonio, TX), Methodist Specialty and Transplant Hospital (San Antonio, TX), Methodist Stone Oak Hospital (San Antonio, TX), Methodist Texsan Hospital (San Antonio, TX), MountainView Hospital (Las Vegas, NV), North Hills Hospital (North Richland Hills, TX), Northside Hospital (St Petersburg, FL), North Suburban Medical Center (Thornton, CO), Northeast Methodist Hospital (Live Oak, TX), Orange Park Medical Center (Orange Park, FL), Osceola Regional Medical Center (Kissimmee, FL), Overland Park Regional Medical Center (Overland Park, KS), Palms West Hospital (Loxahatchee, FL), Parkland Medical Center (Derry, NH), Parkridge East Hospital (Chattanooga, TN), Parkridge Medical Center (Chattanooga, TN), Plaza Medical Center of Fort Worth (Fort Worth, TX), Portsmouth Regional Hospital (Portsmouth, NH), Regional Medical Center of Acadiana (Lafayette, LA), Research Medical Center (Kansas City, MO), Reston Hospital Center (Reston, VA), Rio Grande Regional Hospital (McAllen, TX), South Bay Hospital (Sun City Center, FL), St David's Medical Center (Austin, TX), St Petersburg General Hospital (St Petersburg, FL), Summit Medical Center (Hermitage, TN), Sunrise Hospital and Medical Center (Las Vegas, NV), Timpanogos Regional Hospital (Orem, UT), TriStar Horizon Medical Center (Dickson, TN), TriStar Southern Hills Medical Center (Nashville, TN), Valley Regional Medical Center (Brownsville, TX), West Florida Hospital (Pensacola, FL), West Hills Hospital & Medical Center (West Hills, CA), and West Palm Hospital (West Palm Beach, FL).	Calfee DP, 2014, INFECT CONT HOSP EP, V35, P772, DOI [10.1086/676534, 10.1017/S0899823X00193882]; Centers for Disease Control and Prevention, 2016, 2014 NAT STAT HEALTH; Climo MW, 2013, NEW ENGL J MED, V368, P533, DOI 10.1056/NEJMoa1113849; Climo MW, 2009, CRIT CARE MED, V37, P1858, DOI 10.1097/CCM.0b013e31819ffe6d; de Smet AMGA, 2009, NEW ENGL J MED, V360, P20, DOI 10.1056/NEJMoa0800394; Derde LPG, 2014, LANCET INFECT DIS, V14, P31, DOI 10.1016/S1473-3099(13)70295-0; DIEHR P, 1995, STAT MED, V14, P1491, DOI 10.1002/sim.4780141309; Edgeworth JD, 2011, J ANTIMICROB CHEMOTH, V66, pII41, DOI 10.1093/jac/dkq325; Edmiston CE, 2008, J AM COLL SURGEONS, V207, P233, DOI 10.1016/j.jamcollsurg.2007.12.054; Edmiston CE, 2007, AM J INFECT CONTROL, V35, P89, DOI 10.1016/j.ajic.2006.06.012; Harris AD, 2013, JAMA-J AM MED ASSOC, V310, P1571, DOI 10.1001/jama.2013.277815; Hayes RJ, 2009, INTERD STAT, P3; Huang SS, 2016, LANCET INFECT DIS, V16, P70, DOI 10.1016/S1473-3099(15)00238-8; Huang SS, 2014, INFECT CONT HOSP EP, V35, pS23, DOI 10.1086/677819; Huang SS, 2013, NEW ENGL J MED, V368, P2255, DOI 10.1056/NEJMoa1207290; Kassakian SZ, 2011, INFECT CONT HOSP EP, V32, P238, DOI 10.1086/658334; Kleinman Ken, 2016, EGEMS (Wash DC), V4, P1202, DOI 10.13063/2327-9214.1202; Lin MY, 2014, INFECT CONT HOSP EP, V35, P440, DOI 10.1086/675613; Liu C, 2011, CLIN INFECT DIS, V53, P319, DOI [10.1093/cid/ciq146, 10.1093/cid/cir353]; Lowe CF, 2017, AM J INFECT CONTROL, V45, P255, DOI 10.1016/j.ajic.2016.09.019; Mahalanobis P., 1936, P NATL I SCI INDIA, P49; MAKI DG, 1991, LANCET, V338, P339, DOI 10.1016/0140-6736(91)90479-9; Marschall J, 2014, INFECT CONT HOSP EP, V35, P753, DOI [10.1086/676533, 10.1017/S0899823X00193870]; Milstone AM, 2013, LANCET, V381, P1099, DOI 10.1016/S0140-6736(12)61687-0; Mimoz O, 2015, LANCET, V386, P2069, DOI 10.1016/S0140-6736(15)00244-5; Platt R, 2018, JAMA-J AM MED ASSOC, V320, P753, DOI 10.1001/jama.2018.9342; Raad I, 1997, ANN INTERN MED, V127, P267, DOI 10.7326/0003-4819-127-4-199708150-00002; Rhee Y, 2018, INFECT CONT HOSP EP, V39, P405, DOI 10.1017/ice.2017.312; Ripatti S, 2000, BIOMETRICS, V56, P1016, DOI 10.1111/j.0006-341X.2000.01016.x; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; Rupp ME, 2012, INFECT CONT HOSP EP, V33, P1094, DOI 10.1086/668024; Russell D, 2016, INFECT CONT HOSP EP, V37, P36, DOI 10.1017/ice.2015.246; Septimus E, 2016, CLIN INFECT DIS, V63, P172, DOI 10.1093/cid/ciw282; Shuman EK, IDWEEK 2014; Vernon MO, 2006, ARCH INTERN MED, V166, P306, DOI 10.1001/archinte.166.3.306; Weiner LM, 2016, INFECT CONT HOSP EP, V37, P1105, DOI 10.1017/ice.2016.139	36	46	48	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 23	2019	393	10177					1205	1215		10.1016/S0140-6736(18)32593-5	http://dx.doi.org/10.1016/S0140-6736(18)32593-5			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP9UL	30850112	Green Submitted, Green Accepted			2023-01-03	WOS:000462038400027
J	Kondo, Y; Ishitsuka, Y; Kawabata, N; Iwamoto, N; Takahashi, R; Narita, Y; Kadowaki, D; Hirata, S; Uchino, S; Irie, T				Kondo, Yuki; Ishitsuka, Yoichi; Kawabata, Nobuhiro; Iwamoto, Nobuhide; Takahashi, Risa; Narita, Yuki; Kadowaki, Daisuke; Hirata, Sumio; Uchino, Satoru; Irie, Tetsumi			Knowledge and awareness of nonpharmacist salespersons regarding over-the-counter drug use in patients with chronic kidney disease in Japan	PLOS ONE			English	Article							PHARMACISTS; ADJUSTMENT; MEDICATION; RISK; SAFE	Introduction Patients with chronic kidney disease (CKD) depend on advice from healthcare professionals to avoid using unsuitable over-the-counter (OTC) drugs. Recently, qualified, registered non-pharmacist salespersons became licensed to sell OTC drugs in Japan. However, registered salespersons' knowledge and awareness of precautions regarding unsuitable OTC drugs for use in patients with CKD are unclear. Objectives This study aimed to clarify the awareness, knowledge, and implementation of precautions by registered salespersons regarding OTC drugs used by patients with CKD. Additionally, we evaluated the change of registered salespersons' knowledge and awareness of this topic generated by a pharmacist intervention. Methods A questionnaire survey and pharmacist intervention were applied to 175 registered salespersons. The intervention comprised a 50-minute lecture imparted by a pharmacist who was trained in nephrology. The knowledge, awareness, and implementation of precautions by participants with respect to nonsteroidal anti-inflammatory drugs (NSAIDs) and antacids were evaluated before and after the intervention. Results Approximately half of the registered salespersons reported previous experience with selling OTC drugs that were inappropriate for patients with CKD (NSAIDs, 48.0%; antacids, 39.7%). Few participants recognized the need to check renal function when selling those drugs to such patients (NSAIDs, 25.7%; antacids, 47.5%). The registered salespersons' awareness and knowledge were significantly higher after the intervention than before it. Conclusion The results indicate that before the intervention, the registered salespersons had low levels of awareness and knowledge regarding OTC drug use in patients with CKD despite having prior experience selling unsuitable OTC drugs. However, the pharmacist intervention improved the registered salespersons' awareness and knowledge. The educational program for registered salespersons might be necessary to prevent inappropriate OTC drug use by patients with CKD.	[Kondo, Yuki; Ishitsuka, Yoichi; Takahashi, Risa; Irie, Tetsumi] Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Clin Chem & Informat, Chuo Ku, 5-1 Oe Honmachi, Kumamoto, Japan; [Kawabata, Nobuhiro; Iwamoto, Nobuhide; Uchino, Satoru] Kagoshima Pharmaceut Assoc, 2-8-15 Yojiro, Kagoshima, Japan; [Narita, Yuki; Hirata, Sumio] Kumamoto Univ, Fac Pharmaceut Sci, Dept Clin Pharmacol, Chuo Ku, 5-1 Oe Honmachi, Kumamoto, Japan; [Kadowaki, Daisuke] Sojo Univ, Fac Pharmaceut Sci, Lab Clin Pharmaceut, 4-22-1 Ikeda, Kumamoto, Japan; [Hirata, Sumio; Irie, Tetsumi] Kumamoto Univ, Fac Pharmaceut Sci, Ctr Clin Pharmaceut Sci, Chuo Ku, 5-1 Oe Honmachi, Kumamoto, Japan	Kumamoto University; Kumamoto University; Sojo University; Kumamoto University	Kondo, Y (corresponding author), Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Clin Chem & Informat, Chuo Ku, 5-1 Oe Honmachi, Kumamoto, Japan.	ykondo@kumamoto-u.ac.jp	KONDO, Yuki/ABB-9085-2020	KONDO, Yuki/0000-0003-1456-7721; Kadowaki, Daisuke/0000-0001-5166-7145; Irie, Tetsumi/0000-0001-8664-7048	OTC Self-Medication Promotion Foundation	OTC Self-Medication Promotion Foundation	This work was supported in Grants-in-Aid for Research from the OTC Self-Medication Promotion Foundation (http://www.otc-spf.jp/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams OP, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-135; Annual Health, LAB WELF REP 2007 20; Brata C, 2015, RES SOC ADMIN PHARM, V11, P136, DOI 10.1016/j.sapharm.2014.07.003; Driesen A, 2007, AM J PHARM EDUC, V71, DOI 10.5688/aj710352; Duffy RM, 2015, ACAD PSYCHIATR, V39, P615, DOI 10.1007/s40596-014-0204-x; Gooch K, 2007, AM J MED, V120, DOI 10.1016/j.amjmed.2006.02.015; Guan F, 2010, CHINESE MED J-PEKING, V123, P884, DOI 10.3760/cma.j.issn.0366-6999.2010.07.022; Hassan Y, 2009, ANN PHARMACOTHER, V43, P1598, DOI 10.1345/aph.1M187; HERZOG P, 1982, SCAND J GASTROENTERO, V17, P56; Houle C. O., 1981, MOBIUS J CONTIN ED P, V1, P76, DOI [DOI 10.1002/CHP.4760010112, 10.1002/chp.4760010112]; Huerta C, 2005, AM J KIDNEY DIS, V45, P531, DOI 10.1053/j.ajkd.2004.12.005; Imai Enyu, 2007, Clin Exp Nephrol, V11, P156, DOI 10.1007/s10157-007-0463-x; Kappel J, 2002, CAN MED ASSOC J, V166, P473; Kondo Y, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0615-0; LaCivita C, 2009, J AM PHARM ASSOC, V49, pE110, DOI 10.1331/JAPhA.2009.09005; Lenz PH, 2015, ANN AM THORAC SOC, V12, P561, DOI 10.1513/AnnalsATS.201501-024AR; Manley Harold J, 2003, BMC Nephrol, V4, P10, DOI 10.1186/1471-2369-4-10; Manley HJ, 2005, AM J KIDNEY DIS, V46, P669, DOI 10.1053/j.ajkd.2005.07.001; Pai AB, 2015, J AM PHARM ASSOC, V55, pE15, DOI 10.1331/JAPhA.2015.15506; Paige NM, 2009, MAYO CLIN PROC, V84, P180, DOI 10.1016/S0025-6196(11)60826-4; Puspitasari HP, 2013, INT J CLIN PHARM-NET, V35, P1218, DOI 10.1007/s11096-013-9854-0; RANDALL RE, 1964, ANN INTERN MED, V61, P73, DOI 10.7326/0003-4819-61-1-73; Tuot DS, 2016, CLIN J AM SOC NEPHRO, V11, P1566, DOI 10.2215/CJN.00490116; World Health Organization, 1998, ROL PHARM SELF CAR S	24	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2019	14	3							e0213763	10.1371/journal.pone.0213763	http://dx.doi.org/10.1371/journal.pone.0213763			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP6AW	30893364	Green Published, Green Submitted, gold			2023-01-03	WOS:000461765900050
J	Vieira, SE; Bando, SY; de Paulis, M; Oliveira, DBL; Thomazelli, LM; Durigon, EL; Martinez, MB; Moreira, CA				Vieira, Sandra E.; Bando, Silvia Y.; de Paulis, Milena; Oliveira, Danielle B. L.; Thomazelli, Luciano M.; Durigon, Edison L.; Martinez, Marina B.; Moreira-Filho, Carlos Alberto			Distinct transcriptional modules in the peripheral blood mononuclear cells response to human respiratory syncytial virus or to human rhinovirus in hospitalized infants with bronchiolitis	PLOS ONE			English	Article							IMMUNE-RESPONSES; INFECTION; PREDNISOLONE; ACTIVATION; INTERACTS; MEDICINE; PROTEIN; RISK	Human respiratory syncytial virus (HRSV) is the main cause of bronchiolitis during the first year of life, when infections by other viruses, such as rhinovirus, also occur and are clinically indistinguishable from those caused by HRSV. In hospitalized infants with bronchiolitis, the analysis of gene expression profiles from peripheral blood mononuclear cells (PBMC) may be useful for the rapid identification of etiological factors, as well as for developing diagnostic tests, and elucidating pathogenic mechanisms triggered by different viral agents. In this study we conducted a comparative global gene expression analysis of PBMC obtained from two groups of infants with acute viral bronchiolitis who were infected by HRSV (HRSV group) or by HRV (HRV group). We employed a weighted gene co-expression network analysis (WGCNA) which allows the identification of transcriptional modules and their correlations with HRSV or HRV groups. This approach permitted the identification of distinct transcription modules for the HRSV and HRV groups. According to these data, the immune response to HRSV infection comparatively to HRV infection was more associated to the activation of the interferon gamma signaling pathways and less related to neutrophil activation mechanisms. Moreover, we also identified host-response molecular markers that could be used for etiopathogenic diagnosis. These results may contribute to the development of new tests for respiratory virus identification. The finding that distinct transcriptional profiles are associated to specific host responses to HRSV or to HRV may also contribute to the elucidation of the pathogenic mechanisms triggered by different respiratory viruses, paving the way for new therapeutic strategies.	[Vieira, Sandra E.; Bando, Silvia Y.; Moreira-Filho, Carlos Alberto] Univ Sao Paulo, Dept Pediat, Fac Med, Sao Paulo, SP, Brazil; [de Paulis, Milena; Martinez, Marina B.] Univ Sao Paulo, Univ Hosp, Sao Paulo, SP, Brazil; [Oliveira, Danielle B. L.; Thomazelli, Luciano M.; Durigon, Edison L.] Univ Sao Paulo, Dept Microbiol, Inst Ciencias Biomed, Sao Paulo, SP, Brazil	Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Universidade de Sao Paulo; Universidade de Sao Paulo	Vieira, SE; Moreira, CA (corresponding author), Univ Sao Paulo, Dept Pediat, Fac Med, Sao Paulo, SP, Brazil.	sandra.vieira@fm.usp.br; carlos.moreira@hc.fm.usp.br	Martínez Filgueira, Marina/GZG-8145-2022; Oliveira, Danielle BL/H-8030-2015; moreira-filho, carlos alberto/J-2551-2014; Thomazelli, Luciano Matsumiya/Q-6119-2017	Oliveira, Danielle BL/0000-0002-3452-1336; moreira-filho, carlos alberto/0000-0003-3433-4714; Thomazelli, Luciano Matsumiya/0000-0002-9157-6122; Oliveira, Danielle/0000-0002-0534-0886; vieira, sandra/0000-0001-5100-8713; Bando, Silvia Yumi/0000-0003-3794-2440	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [12/22854-9]; FAPESP [2015/22308-2]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [307626/2014-8]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) grant no. 12/22854-9 to SEV, by FAPESP grant no. 2015/22308-2 and by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) grant no. 307626/2014-8 to CAM-F. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andika IB, 2017, P NATL ACAD SCI USA, V114, pE3499, DOI 10.1073/pnas.1701196114; Bando SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079913; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918; Brady MT, 2014, PEDIATRICS, V134, pE620, DOI [10.1542/peds.2014-1666, 10.1542/peds.2014-1665]; Breese C, 2013, PEDIATRICS, V132, pE341, DOI 10.1542/peds.2013-0303; Burana D, 2016, J BIOL CHEM, V291, P6218, DOI 10.1074/jbc.M115.710707; Chaussabel D, 2014, NAT REV IMMUNOL, V14, P271, DOI 10.1038/nri3642; Choi Eunjin, 2018, Korean J Pediatr, V61, P180, DOI 10.3345/kjp.2018.61.6.180; Chung HL, 2007, PEDIAT ALLERG IMM-UK, V18, P94, DOI 10.1111/j.1399-3038.2006.00501.x; De Paulis M, 2011, J PEDIAT-BRAZIL, V87, P307, DOI [10.2223/JPED.2100, 10.1590/S0021-75572011000400006]; Dikeakos JD, 2012, MOL BIOL CELL, V23, P2184, DOI 10.1091/mbc.E11-11-0928; EVERARD ML, 1994, ARCH DIS CHILD, V71, P428, DOI 10.1136/adc.71.5.428; Ferronato AE, 2012, CLINICS, V67, P1001, DOI 10.6061/clinics/2012(09)03; Fleming EH, 2018, J MED VIROL, V90, P26, DOI 10.1002/jmv.24917; Gaelings L, 2017, FEBS J, V284, P222, DOI 10.1111/febs.13966; Gardeux V, 2017, J AM MED INFORM ASSN, V24, P1116, DOI 10.1093/jamia/ocx069; Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877; Huang JB, 2018, CANCER MED-US, V7, P3157, DOI 10.1002/cam4.1524; Jansen BJH, 2009, MOL IMMUNOL, V46, P505, DOI 10.1016/j.molimm.2008.06.032; Kamijuku H, 2008, MUCOSAL IMMUNOL, V1, P208, DOI 10.1038/mi.2008.2; Koistinen A, 2017, PEDIAT ALLERG IMM-UK, V28, P557, DOI 10.1111/pai.12749; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Liu ZH, 2005, MOL CANCER RES, V3, P21; Lodermeyer V, 2018, J VIROL, V92, DOI 10.1128/JVI.00226-18; Lukkarinen M, 2013, PEDIAT ALLERG IMM-UK, V24, P237, DOI 10.1111/pai.12046; Luo HY, 2011, J BIOL CHEM, V286, P41135, DOI 10.1074/jbc.M111.302596; Mejias A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001549; Miller EK, 2013, PEDIATR INFECT DIS J, V32, P950, DOI 10.1097/INF.0b013e31829b7e43; Pinto RA, 2006, PEDIATRICS, V117, pE878, DOI 10.1542/peds.2005-2119; Raniga K, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10010036; Rodriguez-Fernandez R, 2018, J INFECT DIS, V217, P24, DOI 10.1093/infdis/jix543; Russell CD, 2017, CLIN MICROBIOL REV, V30, P481, DOI 10.1128/CMR.00090-16; Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Song YJ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14654; Taylor HE, 2014, J VIROL, V88, P592, DOI 10.1128/JVI.02828-13; Turner R, 2017, RHINOVIRUS; Vieira SE, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3459785; Zaas AK, 2009, CELL HOST MICROBE, V6, P207, DOI 10.1016/j.chom.2009.07.006	42	6	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2019	14	3							e0213501	10.1371/journal.pone.0213501	http://dx.doi.org/10.1371/journal.pone.0213501			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO1AY	30845274	gold, Green Published, Green Submitted			2023-01-03	WOS:000460638800096
J	Zilahi, G; O'Connor, E				Zilahi, Gabor; O'Connor, Enda			Information sharing between intensive care and primary care after an episode of critical illness; A mixed methods analysis\	PLOS ONE			English	Article							FUNCTIONAL DISABILITY; COMMUNICATION; DISCHARGE; SURVIVORS; PHYSICIANS; OUTCOMES; QUALITY	Introduction Poor quality communication between hospital doctors and GPs at the time of hospital discharge is associated with adverse patient outcomes. This may be more marked after an episode of critical illness, the complications of which can persist long after hospital discharge. Aims 1. to evaluate information sharing between ICU staff and GPs after a critical illness 2. to identify factors influencing the flow and utilisation of this information. Methods Parallel mixed methods observational study in an Irish setting, with equal emphasis on quantitative and qualitative data. Descriptive analysis was performed on quantitative data derived from GP and ICU consultant questionnaires. Qualitative data came from semi-structured interviews with GPs and consultants, and were analysed using directed content analysis. Mixing of data occurred at the stage of interpretation. Results GPs rarely received information about an episode of critical illness directly from ICU staff, with most coming from patients and relatives. Information received from hospital sources was frequently brief and incomplete. Common communication barriers reported by consultants were insufficient time, low perceived importance and difficulty establishing GP contact. When provided information, GPs seldom actioned specific interventions, citing insufficient guidance in hospital correspondence and poor knowledge about critical illness complications and their management. A majority of all respondents thought that improved information sharing would benefit patients. Cultural influences on practice were identified in qualitative data. A priori qualitative themes were: (1) perceived benefits of information sharing, (2) factors influencing current practice and (3) strategies for optimal information sharing. Emergent themes were: (4) the central role of the GP in patient care, (5) the concept of the "whole patient journey" and (6) a culture of expectation around a GP's knowledge of hospital care. Conclusions Practical and cultural factors contribute to suboptimal information sharing between ICU and primary care doctors around an episode of critical illness in ICU. We propose a three-milestone strategy to improve the flow and utilisation of information when patients are admitted, discharged or die within the ICU.	[Zilahi, Gabor; O'Connor, Enda] St James Hosp, Dept Intens Care & Anaesthesia, Dublin, Ireland; [O'Connor, Enda] Trinity Coll Dublin, Sch Med, Dublin, Ireland	Trinity College Dublin; Trinity College Dublin	O'Connor, E (corresponding author), St James Hosp, Dept Intens Care & Anaesthesia, Dublin, Ireland.; O'Connor, E (corresponding author), Trinity Coll Dublin, Sch Med, Dublin, Ireland.	oconnoen@tcd.ie			Multidisciplinary Intensive Care Research Organisation	Multidisciplinary Intensive Care Research Organisation	Funding was provided by the Multidisciplinary Intensive Care Research Organisation to EO. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allum L, 2018, NURS CRIT CARE, V23, P316, DOI 10.1111/nicc.12305; [Anonymous], 2009, REHABILITATION CRITI; Bench S, 2016, BRIT J GEN PRACT, V66, pE904, DOI 10.3399/bjgp16X688045; Braet A, 2016, INT J CARE COORD, V19, P29, DOI 10.1177/2053434516656149; Connolly B, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004963; Creswell J. W., 2018, DESIGNING CONDUCTING, V3rd; Creswell JW, 2017, DESIGNING CONDUCTING; Czerwonka AI, 2015, J CRIT CARE, V30, P242, DOI 10.1016/j.jcrc.2014.10.017; Daruwalla F., 2012, CRIT CARE, V16, pP520, DOI [10.1186/cc11127, DOI 10.1186/CC11127]; DePoy E, 2019, INTRO RES UNDERSTAND, V6; Ellis KA, 2015, AM J CRIT CARE, V24, P496, DOI 10.4037/ajcc2015332; Etesse B, 2010, CRIT CARE, V14, DOI 10.1186/cc9061; Fetters MD, 2013, HEALTH SERV RES, V48, P2134, DOI 10.1111/1475-6773.12117; Foy R, 2010, ANN INTERN MED, V152, P247, DOI 10.7326/0003-4819-152-4-201002160-00010; Griffiths J, 2013, CRIT CARE, V17, DOI 10.1186/cc12745; Herridge MS, 2016, INTENS CARE MED, V42, P725, DOI 10.1007/s00134-016-4321-8; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Hua M, 2015, CRIT CARE MED, V43, P430, DOI 10.1097/CCM.0000000000000717; Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Malterud K, 2016, QUAL HEALTH RES, V26, P1753, DOI 10.1177/1049732315617444; Mayr FB, 2017, JAMA-J AM MED ASSOC, V317, P530, DOI 10.1001/jama.2016.20468; Mays N, 2000, BMJ-BRIT MED J, V320, P50, DOI 10.1136/bmj.320.7226.50; Moore C, 2003, J GEN INTERN MED, V18, P646, DOI 10.1046/j.1525-1497.2003.20722.x; MORSE JM, 1991, NURS RES, V40, P120; Office CS, 2017, CENS 2016 SUMM RES 1; Philibert I, 2012, BMJ QUAL SAF, V21, P1, DOI 10.1136/bmjqs-2012-001598; Pronovost PJ, 2006, CURR OPIN CRIT CARE, V12, P604, DOI 10.1097/MCC.0b013e32800ff3da; Stelfox HT, 2018, JAMA INTERN MED, V178, P1390, DOI 10.1001/jamainternmed.2018.3675; Tashakkori A., 2002, HDB MIXED METHODS SO; Toccafondi G, 2012, BMJ QUAL SAF, V21, P58, DOI 10.1136/bmjqs-2012-001178; van Sluisveld N, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2139-x; van Sluisveld N, 2015, INTENS CARE MED, V41, P589, DOI 10.1007/s00134-015-3666-8; Weissman GE, 2016, ANN AM THORAC SOC, V13, P1538, DOI 10.1513/AnnalsATS.201602-131OC; Williams H, 2015, BRIT J GEN PRACT, V65, pE829, DOI 10.3399/bjgp15X687877; Williams TA, 2008, CRIT CARE MED, V36, P1523, DOI 10.1097/CCM.0b013e318170a405; Wunsch H, 2014, JAMA-J AM MED ASSOC, V311, P1133, DOI 10.1001/jama.2014.2137; Wunsch H, 2010, JAMA-J AM MED ASSOC, V303, P849, DOI 10.1001/jama.2010.216	39	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2019	14	2							e0212438	10.1371/journal.pone.0212438	http://dx.doi.org/10.1371/journal.pone.0212438			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HN7LS	30818372	Green Submitted, gold, Green Published			2023-01-03	WOS:000460371500021
J	Riley, CM; Sciurba, FC				Riley, Craig M.; Sciurba, Frank C.			Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease A Review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							INSPIRATORY FLOW-RATE; POST-HOC ANALYSIS; INHALED CORTICOSTEROIDS; UNITED-STATES; LUNG-FUNCTION; RANDOMIZED-TRIAL; COPD; EXACERBATIONS; THERAPY; ADULTS	IMPORTANCE There are 30 million adults (12%) in the United States who have chronic obstructive pulmonary disease (COPD). Chronic obstructive pulmonary disease accounts for 3.2% of all physician office visits annually and is the fourth leading cause of death (126 000 deaths per year). Most patients are diagnosed by their primary care clinicians who must address the highly variable clinical features and responses to therapy. The diagnosis and treatment of COPD is rapidly changing, so understanding recent advances is important for the delivery of optimal patient care. OBSERVATIONS Chronic obstructive pulmonary disease is characterized by incompletely reversible expiratory airflow limitation. Spirometry is the reference standard for diagnosing and assessing the severity of COPD. All patients should be counseled about and receive preventive measures such as smoking cessation and vaccination. Treatment should be guided by the severity of lung impairment, symptoms such as dyspnea, the amount of cough and sputum production, and how often a patient experiences an exacerbation. When dyspnea limits activity or quality of life, COPD should be treated with once- or twice-daily maintenance long-acting anticholinergic and beta-agonist bronchodilators. Patients with acute exacerbations may benefit from the addition of inhaled corticosteroids, particularly those with elevated peripheral eosinophil levels. Pulmonary rehabilitation, which includes strength and endurance training and educational, nutritional, and psychosocial support, improves symptoms and exercise tolerance but is underutilized. Supplemental oxygen for patients with resting hypoxemia (defined as SpO(2) <89%) improves survival. CONCLUSIONS AND RELEVANCE Chronic obstructive pulmonary disease is a complicated disease requiring intensive treatment. Appropriate use of long-acting maintenance bronchodilators, inhaled corticosteroids, and pulmonary rehabilitation decreases symptoms, optimizes functional performance, and reduces exacerbation frequency. Supplemental oxygen in patients with resting hypoxemia prolongs life, and other advanced treatments are available based on specific patient characteristics.	[Riley, Craig M.; Sciurba, Frank C.] Univ Pittsburgh, Dept Med Allergy & Crit Care Med, Div Pulm, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sciurba, FC (corresponding author), Kaufmann Bldg,Ste 1211,3471 Fifth Ave, Pittsburgh, PA 15213 USA.	sciurbafc@upmc.edu	Sciurba, Frank/AAZ-9339-2021	sciurba, frank/0000-0001-7468-2225				Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873; Agusti A., 2018, GLOBAL STRATEGY DIAG; Agusti A, 2017, LANCET RESP MED, V5, P935, DOI 10.1016/S2213-2600(17)30434-4; Agusti A, 2016, EUR RESPIR J, V47, P410, DOI 10.1183/13993003.01359-2015; Albert RK, 2016, NEW ENGL J MED, V375, P1617, DOI 10.1056/NEJMoa1604344; Albert RK, 2011, NEW ENGL J MED, V365, P689, DOI 10.1056/NEJMoa1104623; [Anonymous], 1980, ANN INTERN MED, V93, P391; Aziz MIA, 2018, INT J CHRONIC OBSTR, V13, P3203, DOI 10.2147/COPD.S173472; Bafadhel M, 2018, LANCET RESP MED, V6, P117, DOI 10.1016/S2213-2600(18)30006-7; Bon J, 2011, AM J RESP CRIT CARE, V183, P885, DOI 10.1164/rccm.201004-0666OC; BONE R, 1994, CHEST, V105, P1411; Budhiraja R, 2015, J CLIN SLEEP MED, V11, P259, DOI 10.5664/jcsm.4540; Calzetta L, 2016, CHEST, V149, P1181, DOI 10.1016/j.chest.2016.02.646; Cantoli M, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00451-2017; Carr LL, 2018, CHEST, V153, P1326, DOI 10.1016/j.chest.2018.01.049; Chapman KR, 2018, AM J RESP CRIT CARE, V198, P329, DOI 10.1164/rccm.201803-0405OC; Chong J, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002309.pub5; Chong J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009157.pub2; Chrystyn H, 2017, NPJ PRIM CARE RESP M, V27, DOI 10.1038/s41533-017-0016-z; Criner GJ, 2018, AM J RESP CRIT CARE, V198, P1151, DOI 10.1164/rccm.201803-0590OC; de Torres JP, 2007, CHEST, V132, P1932, DOI 10.1378/chest.07-1490; Devereux G, 2018, JAMA-J AM MED ASSOC, V320, P1548, DOI 10.1001/jama.2018.14432; Emtner M, 2003, AM J RESP CRIT CARE, V168, P1034, DOI 10.1164/rccm.200212-1525OC; Feldman GJ, 2017, ADV THER, V34, P2518, DOI 10.1007/s12325-017-0626-4; Ferguson GT, 2018, LANCET RESP MED, V6, P747, DOI 10.1016/S2213-2600(18)30327-8; Fishman A, 2003, NEW ENGL J MED, V348, P2059; FLENLEY DC, 1981, LANCET, V1, P681; Ford ES, 2013, CHEST, V143, P1395, DOI 10.1378/chest.12-1135; Goto T, 2018, J GEN INTERN MED, V33, P1461, DOI 10.1007/s11606-018-4518-3; Gotzsche PC, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007851.pub3; Grenard JL, 2011, J GEN INTERN MED, V26, P1175, DOI 10.1007/s11606-011-1704-y; Guerra B, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1013-y; Gupta N, 2014, EUR RESPIR J, V44, P873, DOI 10.1183/09031936.00025214; Hurley K, 2018, JAMA-J AM MED ASSOC, V319, P2034, DOI 10.1001/jama.2018.3888; Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883; Nannini LJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003794.pub4; Jones PW, 2009, EUR RESPIR J, V34, P648, DOI 10.1183/09031936.00102509; Karner C, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009285.pub3; Kew KM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010844.pub2; Kew KM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010177.pub2; Kochanek Kenneth D, 2017, NCHS Data Brief, P1; Kohnlein T, 2014, LANCET RESP MED, V2, P698, DOI 10.1016/S2213-2600(14)70153-5; Kopsaftis Z, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002733.pub3; Krishnan JK, 2018, CURR OPIN PULM MED, V24, P124, DOI 10.1097/MCP.0000000000000456; LAL S, 1964, BRIT MED J, V1, P814, DOI 10.1136/bmj.1.5386.814; Lipson DA, 2018, NEW ENGL J MED, V378, P1671, DOI 10.1056/NEJMoa1713901; Magnussen H, 2014, NEW ENGL J MED, V371, P1285, DOI 10.1056/NEJMoa1407154; MAHLER DA, 1988, CHEST, V93, P580, DOI 10.1378/chest.93.3.580; Mahler DA, 2017, ANN AM THORAC SOC, V14, P1103, DOI 10.1513/AnnalsATS.201702-156PS; Maltais F, 2014, AM J RESP CRIT CARE, V189, P1121, DOI 10.1164/rccrn.201402-0373ST; Mannino DM, 2007, THORAX, V62, P237, DOI 10.1136/thx.2006.068379; McCarthy B, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub3; Melani AS, 2017, RESP CARE, V62, P409, DOI 10.4187/respcare.05117; Miravitlles M, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00610-2017; Munoz-Esquerre M, 2015, PULM PHARMACOL THER, V30, P16, DOI 10.1016/j.pupt.2014.10.002; Murphy PB, 2017, JAMA-J AM MED ASSOC, V317, P2177, DOI 10.1001/jama.2017.4451; Nishi SPE, 2016, J CARDIOPULM REHABIL, V36, P375, DOI 10.1097/HCR.0000000000000194; Oba Y, 2016, THORAX, V71, P15, DOI 10.1136/thoraxjnl-2014-206732; Papi A, 2018, LANCET, V391, P783, DOI 10.1016/S0140-6736(17)33311-1; Poole P, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001287.pub5; Puhan MA, 2009, LANCET, V374, P704, DOI 10.1016/S0140-6736(09)61301-5; Qaseem A, 2011, ANN INTERN MED, V155, P179, DOI 10.7326/0003-4819-155-3-201108020-00008; Rennard SI, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-18; Rocha A, 2017, AM J RESP CRIT CARE, V196, P1264, DOI 10.1164/rccm.201704-0675OC; Rochester CL, 2015, AM J RESP CRIT CARE, V192, P1373, DOI 10.1164/rccm.201510-1966ST; Rodrigo GJ, 2017, INT J CHRONIC OBSTR, V12, P907, DOI 10.2147/COPD.S130482; Rothnie KJ, 2018, AM J RESP CRIT CARE, V198, P464, DOI 10.1164/rccm.201710-2029OC; Ryrso CK, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0718-1; Salvi SS, 2009, LANCET, V374, P733, DOI 10.1016/S0140-6736(09)61303-9; Sharma G, 2017, COPD-J COPD FDN, V4, P217, DOI 10.15326/jcopdf.4.3.2017.0183; Singh S, 2010, CURR OPIN PULM MED, V16, P118, DOI 10.1097/MCP.0b013e328334c085; Siu AL, 2016, JAMA-J AM MED ASSOC, V315, P1372, DOI 10.1001/jama.2016.2638; Suissa S, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02245-2016; Sulaiman I, 2017, AM J RESP CRIT CARE, V195, P1333, DOI 10.1164/rccm.201604-0733OC; Tomczyk S, 2014, MMWR-MORBID MORTAL W, V63, P822; Uzun S, 2014, LANCET RESP MED, V2, P361, DOI 10.1016/S2213-2600(14)70019-0; van Eerd EAM, 2015, BMC FAM PRACT, V16, DOI 10.1186/s12875-015-0382-y; Vestbo J, 2009, THORAX, V64, P939, DOI 10.1136/thx.2009.113662; Vollenweider DJ, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010257.pub2; Walters JA, 2018, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD006897.PUB4; Wang MT, 2018, JAMA INTERN MED, V178, P229, DOI 10.1001/jamainternmed.2017.7720; Watz H, 2018, INT J CHRONIC OBSTR, V13, P813, DOI 10.2147/COPD.S154012; Watz H, 2016, LANCET RESP MED, V4, P390, DOI 10.1016/S2213-2600(16)00100-4; Wedzicha JA, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00791-2016; Wheaton AG, 2015, MMWR-MORBID MORTAL W, V64, P289; Yawn B, 2018, J FAM PRACTICE, V67, pS28, DOI 10.3949/ccjm.85.s1.05; Yawn BP, 2017, COPD-J COPD FDN, V4, P177, DOI 10.15326/jcopdf.4.3.2017.0136; Yohannes AM, 2018, J FAM PRACTICE, V67, pS11; Zheng YY, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4388; ZuWallack Richard, 2007, COPD, V4, P293, DOI 10.1080/15412550701480620	90	99	111	4	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	2019	321	8					786	797		10.1001/jama.2019.0131	http://dx.doi.org/10.1001/jama.2019.0131			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN4ZE	30806700				2023-01-03	WOS:000460191400020
J	Saari, H; Wahlgren, M; Rayner, M; Sjoo, M; Matos, M				Saari, Hisfazilah; Wahlgren, Marie; Rayner, Marilyn; Sjoo, Malin; Matos, Maria			A comparison of emulsion stability for different OSA-modified waxy maize emulsifiers: Granules, dissolved starch, and non-solvent precipitates	PLOS ONE			English	Article							HYDROPHOBICALLY-MODIFIED STARCH; PICKERING-TYPE EMULSIONS; PARTICLES; NANOPARTICLES; FOOD; RETROGRADATION; SIZE; EMULSIFICATION; STABILIZATION; DISSOLUTION	This work investigates the stability of emulsions prepared by using octenyl succinic anhydride (OSA)-modified waxy maize starch in the form of granules, dissolved starch, and non-solvent precipitated starch as Pickering emulsion stabilisers. The aim of this study was to investigate the effects of different forms of starches on the stability of emulsion using light microscopy, light scattering, and static multiple light scattering. All starch samples were hydrophobically modified with 3% (w/w) n-octenyl succinyl anhydride (OSA). Starch polymer solutions were prepared by dissolving OSA-modified starch in water in an autoclave at 140 degrees C. Non-solvent precipitates were obtained through ethanol precipitation of dissolved waxy maize. The stability of the oil/water emulsions were different for the three forms of starches used. The granule-based emulsions were unstable, with only a small proportion of the granules adsorbed onto oil droplets, as viewed under a light microscope. The emulsions were observed to cream after 2 hours. The dissolved starch and non-solvent precipitate-based emulsions were stable towards creaming for months, and they had almost 100% emulsifying index (EI = 1) by visual observation and EI similar to 0.9 by multiple light scattering measurements. The results from light microscopy and multiple light scattering measurements indicated the occurrence of coalescence for all three types of emulsions. The coalescence was fastest within days for the granule stabilised system while it was slower both for the dissolved starch and non-solvent precipitate-based emulsions. The latter demonstrated the least degree of coalescence over time. Thus, it was concluded that differences in starch particle size and molecular structure influenced the emulsion droplet size and stability. A decreased particle size correlates to a decrease in droplet size, thus increasing stabilisation against creaming. However, stability towards coalescence was low for the large granules but was best for the non-solvent precipitate starch indicating that there is a window of optimal particle size for stability. Thus, best emulsifying properties were obtained with the non-solvent precipitates (similar to 120 nm particle size) where the emulsions remained stable after one year of storage. In conclusion, this study illustrated the potentiality of non-solvent precipitated starch as emulsion stabilizers.	[Saari, Hisfazilah; Wahlgren, Marie; Rayner, Marilyn; Sjoo, Malin] Lund Univ, Dept Food Technol Engn & Nutr, Lund, Sweden; [Matos, Maria] Univ Oviedo, Dept Chem & Environm Engn, Julian Claveria 8, Oviedo, Spain	Lund University; University of Oviedo	Saari, H (corresponding author), Lund Univ, Dept Food Technol Engn & Nutr, Lund, Sweden.	hisfazilah@gmail.com	Rayner, Marilyn D/B-2679-2017	Rayner, Marilyn D/0000-0001-6338-7124; Wahlgren, Marie/0000-0002-1705-3964	Vetenskapsradet (Swedish research council) [2010-5393]	Vetenskapsradet (Swedish research council)(Swedish Research Council)	This work was supported by grant number: 2010-5393, http://www.vr.se/, Vetenskapsradet (Swedish research council). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berton-Carabin CC, 2015, ANNU REV FOOD SCI T, V6, P263, DOI 10.1146/annurev-food-081114-110822; Bromley EHC, 2002, J COLLOID INTERF SCI, V245, P75, DOI 10.1006/jcis.2001.8005; Chin SF, 2011, CARBOHYD POLYM, V86, P1817, DOI 10.1016/j.carbpol.2011.07.012; Dickinson E, 2017, FOOD HYDROCOLLOID, V68, P219, DOI 10.1016/j.foodhyd.2016.06.024; Dickinson E, 2010, CURR OPIN COLLOID IN, V15, P40, DOI 10.1016/j.cocis.2009.11.001; Dokic L, 2012, FOOD HYDROCOLLOID, V29, P185, DOI 10.1016/j.foodhyd.2012.02.008; Eliasson A-C., 2006, CARBOHYDRATES FOOD, V159, P391; Fredriksson H, 1998, CARBOHYD POLYM, V35, P119, DOI 10.1016/S0144-8617(97)00247-6; GUDMUNDSSON M, 1994, THERMOCHIM ACTA, V246, P329, DOI 10.1016/0040-6031(94)80100-2; HALL DM, 1971, TEXT RES J, V41, P880, DOI 10.1177/004051757104101102; Hoover R, 2010, FOOD RES INT, V43, P399, DOI 10.1016/j.foodres.2009.09.001; JANE JL, 1994, STARCH-STARKE, V46, P121, DOI 10.1002/star.19940460402; Kim HY, 2015, COLLOID SURFACE B, V126, P607, DOI 10.1016/j.colsurfb.2014.11.011; Li C, 2012, STARCH-STARKE, V64, P497, DOI 10.1002/star.201100178; Liu HS, 2007, CARBOHYD POLYM, V69, P756, DOI 10.1016/j.carbpol.2007.02.011; Lyklema J, 2005, FUND INTERFACE COLL, V5, P1; Magnusson E, 2011, FOOD HYDROCOLLOID, V25, P764, DOI 10.1016/j.foodhyd.2010.09.006; Marku D, 2012, INT J PHARMACEUT, V428, P1, DOI 10.1016/j.ijpharm.2012.01.031; Matos M, 2017, CARBOHYD POLYM, V169, P127, DOI 10.1016/j.carbpol.2017.04.006; Matos M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160140; Matos M, 2013, COLLOID SURFACE A, V423, P147, DOI 10.1016/j.colsurfa.2013.01.060; Modig G, 2006, FOOD HYDROCOLLOID, V20, P1087, DOI 10.1016/j.foodhyd.2005.12.011; Nilsson L, 2007, LANGMUIR, V23, P2346, DOI 10.1021/la062483b; Nilsson L, 2007, J AGR FOOD CHEM, V55, P1469, DOI 10.1021/jf062087z; Perez-Rea D, 2015, ANAL BIOANAL CHEM, V407, P4315, DOI 10.1007/s00216-015-8611-8; Pickering SU, 1907, J CHEM SOC, V91, P2001, DOI 10.1039/ct9079102001; Qin Y, 2016, IND CROP PROD, V87, P182, DOI 10.1016/j.indcrop.2016.04.038; Ramsden W, 1903, P R SOC LONDON, V72, P156, DOI 10.1098/rspl.1903.0034; Rayner M, 2014, COLLOID SURFACE A, V458, P48, DOI 10.1016/j.colsurfa.2014.03.053; Rayner M, 2012, FARADAY DISCUSS, V158, P139, DOI 10.1039/c2fd20038d; Saari H., 2017, STARCH STABILIZED PI; Saari H, 2017, CARBOHYD POLYM, V157, P558, DOI 10.1016/j.carbpol.2016.10.003; Saari H, 2016, CEREAL CHEM, V93, P116, DOI 10.1094/CCHEM-05-15-0107-R; Singh N., 2014, MAIZE NUTR DYNAMICS, P65, DOI DOI 10.1007/978-81-322-1623-0_5; Sjoo M, 2015, J COLLOID INTERF SCI, V450, P182, DOI 10.1016/j.jcis.2015.03.004; Sweedman MC, 2014, CARBOHYD POLYM, V112, P85, DOI 10.1016/j.carbpol.2014.05.067; Sweedman MC, 2013, CARBOHYD POLYM, V92, P905, DOI 10.1016/j.carbpol.2012.09.040; Tan Y, 2009, ACS APPL MATER INTER, V1, P956, DOI 10.1021/am900054f; Tang JT, 2015, SOFT MATTER, V11, P3512, DOI 10.1039/c5sm00247h; Tcholakova S, 2008, PHYS CHEM CHEM PHYS, V10, P1608, DOI 10.1039/b715933c; Tesch S, 2002, J FOOD ENG, V54, P167, DOI 10.1016/S0260-8774(01)00206-0; Timgren A, 2013, FOOD SCI NUTR, V1, P157, DOI 10.1002/fsn3.17; Timgren A, 2011, PROC FOOD SCI, V1, P95, DOI 10.1016/j.profoo.2011.09.016; Viswanathan A, 1999, J ENVIRON POLYM DEGR, V7, P191, DOI 10.1023/A:1022830715565; Wahlgren M, 2013, CURR PHARM BIOTECHNO, V14, P1222; WALSTRA P, 1993, CHEM ENG SCI, V48, P333, DOI 10.1016/0009-2509(93)80021-H; Yusoff A, 2011, FOOD HYDROCOLLOID, V25, P42, DOI 10.1016/j.foodhyd.2010.05.004	47	17	18	4	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2019	14	2							e0210690	10.1371/journal.pone.0210690	http://dx.doi.org/10.1371/journal.pone.0210690			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK4EL	30726246	Green Published, Green Submitted, gold			2023-01-03	WOS:000457874000023
J	Martyn, JAJ; Mao, JR; Bittner, EA				Martyn, J. A. Jeevendra; Mao, Jianren; Bittner, Edward A.			Opioid Tolerance in Critical Illness	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INTENSIVE-CARE-UNIT; PAIN MANAGEMENT; INDUCED HYPERALGESIA; ILL PATIENTS; MORPHINE-TOLERANCE; DRUG-INTERACTIONS; STRESS; METHADONE; ANALGESIA; MECHANISMS		Massachusetts Gen Hosp, Shriners Hosp Children, Dept Anesthesiol Crit Care & Pain Med, Boston, MA 02114 USA; Harvard Med Sch, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Martyn, JAJ (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 51 Blossom St,Rm 206, Boston, MA 02114 USA.	jmartyn@mgh.harvard.edu	Bittner, Edward/ABB-3519-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM118947] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM118947] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbas M, 2016, EUR J PHARMACOL, V783, P85, DOI 10.1016/j.ejphar.2016.05.003; Anand KJS, 2010, PEDIATRICS, V125, pE1208, DOI 10.1542/peds.2009-0489; Anderson BJ, 2017, ANN AM THORAC SOC, V14, P839, DOI 10.1513/AnnalsATS.201703-203ED; Bagdas D, 2018, CURR NEUROPHARMACOL, V16, P415, DOI 10.2174/1570159X15666170818102108; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Bauer B, 2007, MOL PHARMACOL, V71, P667, DOI 10.1124/mol.106.029512; Baumbach P, 2016, CRIT CARE MED, V44, P1129, DOI 10.1097/CCM.0000000000001635; Bista SR, 2015, XENOBIOTICA, V45, P207, DOI 10.3109/00498254.2014.971093; Bittner EA, 2015, ANESTHESIOLOGY, V122, P448, DOI 10.1097/ALN.0000000000000559; Boriushkin E, 2016, SCI REP-UK, V6, DOI 10.1038/srep25013; Cahill CM, 2016, TRENDS PHARMACOL SCI, V37, P963, DOI 10.1016/j.tips.2016.08.002; Capdevila M, 2017, CURR OPIN CRIT CARE, V23, P430, DOI 10.1097/MCC.0000000000000440; Carmona-Bayonas A, 2017, CLIN TRANSL ONCOL, V19, P236, DOI 10.1007/s12094-016-1529-6; Chanques G, 2007, ANESTHESIOLOGY, V107, P858, DOI 10.1097/01.anes.0000287211.98642.51; Chanques G, 2014, CRIT CARE, V18, DOI 10.1186/cc14000; Chapman CR, 2008, J PAIN, V9, P122, DOI 10.1016/j.jpain.2007.09.006; Chavan SS, 2017, IMMUNITY, V46, P927, DOI 10.1016/j.immuni.2017.06.008; Chavan SS, 2017, J IMMUNOL, V198, P3389, DOI 10.4049/jimmunol.1601613; Chen KY, 2014, ANESTHESIOLOGY, V120, P1262, DOI 10.1097/ALN.0000000000000170; Chiu IM, 2013, NATURE, V501, P52, DOI 10.1038/nature12479; Choi L, 2016, CRIT CARE MED, V44, P64, DOI 10.1097/CCM.0000000000001347; Chu LF, 2008, CLIN J PAIN, V24, P479, DOI 10.1097/AJP.0b013e31816b2f43; Compton P, 2001, DRUG ALCOHOL DEPEN, V63, P139, DOI 10.1016/S0376-8716(00)00200-3; Costantino CM, 2012, EXPERT REV MOL MED, V14, DOI 10.1017/erm.2012.5; Costi Sara, 2015, Curr Behav Neurosci Rep, V2, P216; Cullen DJ, 1997, CRIT CARE MED, V25, P1289, DOI 10.1097/00003246-199708000-00014; Davis Mellar P, 2012, J Support Oncol, V10, P209, DOI 10.1016/j.suponc.2012.05.002; de Goeij M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084159; De Pinto Mario, 2015, Int J Crit Illn Inj Sci, V5, P138, DOI 10.4103/2229-5151.164917; Devabhakthuni S, 2012, ANN PHARMACOTHER, V46, P530, DOI 10.1345/aph.1Q525; Donello JE, 2011, ANESTHESIOLOGY, V114, P1403, DOI 10.1097/ALN.0b013e31821c3878; Dumas EO, 2008, AAPS J, V10, P537, DOI 10.1208/s12248-008-9056-1; Elefritz JL, 2016, J CRIT CARE, V34, P84, DOI 10.1016/j.jcrc.2016.03.023; Faust AC, 2016, ANESTH ANALG, V123, P903, DOI 10.1213/ANE.0000000000001393; Feng XQ, 2017, J PAIN RES, V10, P1225, DOI 10.2147/JPR.S138698; Finan PH, 2013, J PAIN, V14, P1539, DOI 10.1016/j.jpain.2013.08.007; Finnerty CC, 2013, JPEN-PARENTER ENTER, V37, p21S, DOI 10.1177/0148607113496117; Fonken LK, 2016, PSYCHONEUROENDOCRINO, V66, P82, DOI 10.1016/j.psyneuen.2016.01.006; Frank MG, 2013, BRAIN BEHAV IMMUN, V33, P1, DOI 10.1016/j.bbi.2013.02.004; Fusco M, 2017, PAIN PRACT, V17, P522, DOI 10.1111/papr.12551; Gatson JW, 2015, J BURN CARE RES, V36, P545, DOI 10.1097/BCR.0000000000000176; Ghassemi M, 2014, CHEST, V145, P745, DOI 10.1378/chest.13-1722; Gudin JA, 2015, PAIN MED, V16, pS9, DOI 10.1111/pme.12926; Han TH, 2007, J CLIN PHARMACOL, V47, P674, DOI 10.1177/0091270007299756; Hayhurst CJ, 2016, ANESTHESIOLOGY, V124, P483, DOI 10.1097/ALN.0000000000000963; HORAN P, 1992, J PHARMACOL EXP THER, V260, P1237; Hutchinson MR, 2011, PHARMACOL REV, V63, P772, DOI 10.1124/pr.110.004135; Huxtable CA, 2011, ANAESTH INTENS CARE, V39, P804, DOI 10.1177/0310057X1103900505; Ji RR, 2016, SCIENCE, V354, P572, DOI 10.1126/science.aaf8924; Jiang XY, 2017, ANN SURG, V265, P722, DOI 10.1097/SLA.0000000000001780; Juneja R, 2014, CURR OPIN SUPPORT PA, V8, P91, DOI 10.1097/SPC.0000000000000056; Kharasch ED, 2017, CLIN PHARM DRUG DEV, V6, P125, DOI 10.1002/cpdd.326; Knezevic NN, 2017, ANESTH ANALG, V125, P1714, DOI 10.1213/ANE.0000000000002442; Kohler M, 2016, PAIN MANAG, V6, P591, DOI 10.2217/pmt-2016-0002; Krantz MJ, 2009, ANN INTERN MED, V150, P387, DOI 10.7326/0003-4819-150-6-200903170-00103; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kress JP, 2003, AM J RESP CRIT CARE, V168, P1457, DOI 10.1164/rccm.200303-455OC; Kumar K, 2017, ANESTH ANALG, V125, P1749, DOI 10.1213/ANE.0000000000002497; McCance-Katz EF, 2010, AM J ADDICTION, V19, P4, DOI 10.1111/j.1521-0391.2009.00005.x; McDaid C, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14170; Meisner JG, 2010, J NEUROTRAUM, V27, P729, DOI 10.1089/neu.2009.1166; Mendell JR, 2003, NEW ENGL J MED, V348, P1243, DOI 10.1056/NEJMcp022282; Mion G, 2013, CNS NEUROSCI THER, V19, P370, DOI 10.1111/cns.12099; Moody DE, 2013, EXPERT OPIN DRUG MET, V9, P675, DOI 10.1517/17425255.2013.783567; Nassar Junior Antonio Paulo, 2016, Rev. bras. ter. intensiva, V28, P444, DOI [10.5935/0103-507X.20160078, 10.5935/0103-507x.20160078]; Novaes MAFP, 1999, INTENS CARE MED, V25, P1421, DOI 10.1007/s001340051091; Nyland JE, 2015, BURNS, V41, P1796, DOI 10.1016/j.burns.2015.09.007; Pandharipande P, 2008, J TRAUMA, V65, P34, DOI 10.1097/TA.0b013e31814b2c4d; Pisani MA, 2010, J CRIT CARE, V25, DOI 10.1016/j.jcrc.2010.02.009; PORRECA F, 1982, LIFE SCI, V31, P2355, DOI 10.1016/0024-3205(82)90155-2; Puntillo KA, 2014, AM J RESP CRIT CARE, V189, P39, DOI 10.1164/rccm.201306-1174OC; Puntillo KA, 2016, CURR OPIN CRIT CARE, V22, P506, DOI 10.1097/MCC.0000000000000343; Quintero Gabriel C, 2017, J Exp Pharmacol, V9, P13, DOI 10.2147/JEP.S124391; Ren C, 2017, INT J BIOL SCI, V13, P46, DOI 10.7150/ijbs.16404; Roeckel LA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11120-4; Roeckel LA, 2016, NEUROSCIENCE, V338, P160, DOI 10.1016/j.neuroscience.2016.06.029; Schaller SJ, 2017, J PHARM PHARMACOL, V69, P82, DOI 10.1111/jphp.12663; Shehabi Y, 2018, CRIT CARE MED, V46, P490, DOI 10.1097/CCM.0000000000002902; Smith MT, 2000, CLIN EXP PHARMACOL P, V27, P524, DOI 10.1046/j.1440-1681.2000.03290.x; Song L, 2014, BRAIN RES, V1564, P52, DOI 10.1016/j.brainres.2014.03.047; Stein C, 2016, ANNU REV MED, V67, P433, DOI 10.1146/annurev-med-062613-093100; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; Tennant F, 2013, PAIN THER, V2, P75, DOI 10.1007/s40122-013-0015-x; Ueda M, 2014, ANESTHESIOLOGY, V121, P1311, DOI 10.1097/ALN.0000000000000422; Vanderah TW, 2000, J NEUROSCI, V20, P7074, DOI 10.1523/JNEUROSCI.20-18-07074.2000; Verriotis M, 2016, NEUROSCIENCE, V338, P207, DOI 10.1016/j.neuroscience.2016.07.026; Wang JG, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1610-8; Wang Y, 2005, ANESTH ANALG, V100, P1733, DOI 10.1213/01.ANE.0000152192.23851.40; Waxman AR, 2009, NEUROSCI LETT, V462, P68, DOI 10.1016/j.neulet.2009.06.061; Webster LR, 2012, PAIN MED, V13, P562, DOI 10.1111/j.1526-4637.2012.01357.x; Wibbenmeyer L, 2010, J BURN CARE RES, V31, P48, DOI 10.1097/BCR.0b013e3181c7ed30; Wick EC, 2017, JAMA SURG, V152, P691, DOI 10.1001/jamasurg.2017.0898; Wiebalck A, 2007, CRIT CARE MED, V35, pS268, DOI 10.1097/01.CCM.0000260676.90475.00; Wohleb ES, 2015, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00447; Woodhams SG, 2017, NEUROPHARMACOLOGY, V124, P105, DOI 10.1016/j.neuropharm.2017.06.015	95	81	82	2	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 24	2019	380	4					365	378		10.1056/NEJMra1800222	http://dx.doi.org/10.1056/NEJMra1800222			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HI4YT	30673555	Green Accepted			2023-01-03	WOS:000456459400010
J	Kline, JA; Fisher, MA; Pettit, KL; Linville, CT; Beck, AM				Kline, Jeffrey A.; Fisher, Michelle A.; Pettit, Katherine L.; Linville, Courtney T.; Beck, Alan M.			Controlled clinical trial of canine therapy versus usual care to reduce patient anxiety in the emergency department	PLOS ONE			English	Article							ANIMAL-ASSISTED THERAPY; PAIN; STRESS; DOGS	Objective Test if therapy dogs reduce anxiety in emergency department (ED) patients. Methods In this controlled clinical trial (NCT03471429), medically stable, adult patients were approached if the physician believed that the patient had "moderate or greater anxiety." Patients were allocated on a 1: 1 ratio to either 15 min exposure to a certified therapy dog and handler (dog), or usual care (control). Patient reported anxiety, pain and depression were assessed using a 0-10 scale (10 = worst). Primary outcome was change in anxiety from baseline (T0) to 30 min and 90 min after exposure to dog or control (T1 and T2 respectively); secondary outcomes were pain, depression and frequency of pain medication. Results Among 93 patients willing to participate in research, 7 had aversions to dogs, leaving 86 (92%) were willing to see a dog six others met exclusion criteria, leaving 40 patients allocated to each group (dog or control). Median and mean baseline anxiety, pain and depression scores were similar between groups. With dog exposure, median anxiety decreased significantly from T0 to T1: 6 (IQR 4-9.75) to T1: 2 (0-6) compared with 6 (4-8) to 6 (2.5-8) in controls (P<0.001, for T1, Mann-Whitney U and unpaired t-test). Dog exposure was associated with significantly lower anxiety at T2 and a significant overall treatment effect on two-way repeated measures ANOVA for anxiety, pain and depression. After exposure, 1/40 in the dog group needed pain medication, versus 7/40 in controls (P = 0.056, Fisher's exact test). Conclusions Exposure to therapy dogs plus handlers significantly reduced anxiety in ED patients.	[Kline, Jeffrey A.; Pettit, Katherine L.; Linville, Courtney T.] Indiana Univ Sch Med, Dept Emergency Med, Indianapolis, IN 46202 USA; [Fisher, Michelle A.] Eskenazi Hlth, Indianapolis, IN USA; [Beck, Alan M.] Purdue Univ, Dept Comparat Pathobiol, Lafayette, IN USA	Indiana University System; Indiana University Bloomington; Eskenazi Health; Purdue University System; Purdue University	Kline, JA (corresponding author), Indiana Univ Sch Med, Dept Emergency Med, Indianapolis, IN 46202 USA.	jefkline@iupui.edu		Beck, Alan/0000-0002-0661-7672	Lilly Physician Scientist Initiative	Lilly Physician Scientist Initiative	This work was supported by the Lilly Physician Scientist Initiative to JAK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1984, BIOPHILIA HUMAN BOND; Antonioli C, 2005, BMJ-BRIT MED J, V331, P1231, DOI 10.1136/bmj.331.7527.1231; Barker SB, 1998, PSYCHIATR SERV, V49, P797, DOI 10.1176/ps.49.6.797; Beck A. M., 2014, Animal Frontiers, V4, P32, DOI 10.2527/af.2014-0019; Braun Carie, 2009, Complement Ther Clin Pract, V15, P105, DOI 10.1016/j.ctcp.2009.02.008; Brucker K, 2018, ACAD EMERG MED, V28; Burt R. S., 2005, BROKERAGE CLOSURE IN; Epstein RM, 2007, J GEN INTERN MED, V22, P1731, DOI 10.1007/s11606-007-0416-9; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Havener L, 2001, Issues Compr Pediatr Nurs, V24, P137, DOI 10.1080/01460860118472; Havey J, 2014, ANTHROZOOS, V27, P361, DOI 10.2752/175303714X13903827487962; Kertes DA, 2017, SOC DEV, V26, P382, DOI 10.1111/sode.12203; Lin MP, 2017, PATIENT ED COUNS; Marcus DA, 2013, PAIN MED, V14, P43, DOI 10.1111/j.1526-4637.2012.01522.x; McCullough A, 2018, J PEDIATR ONCOL NURS, V35, P159, DOI 10.1177/1043454217748586; McKinley S, 2004, AM J CRIT CARE, V13, P146, DOI 10.4037/ajcc2004.13.2.146; McKinley S, 2008, J PSYCHOSOM RES, V64, P503, DOI 10.1016/j.jpsychores.2008.02.002; Lasa SM, 2015, NEUROLOGIA, V30, P1, DOI 10.1016/j.nrl.2013.01.012; Musey P, 2018, AM J CARDIOL; Musey PI, 2018, BMC EMERG MED, V18, DOI 10.1186/s12873-018-0161-x; Musey PI, 2017, J EMERG MED, V52, P273, DOI 10.1016/j.jemermed.2016.11.022; Nahm N, 2012, WEST J EMERG MED, V13, P363, DOI 10.5811/westjem.2011.5.6574; Patel R, 2014, ACAD EMERG MED, V21, P1478, DOI 10.1111/acem.12543; Perpina-Galvan J, 2009, AM J CRIT CARE, V18, P571, DOI 10.4037/ajcc2009682; POULIN PA, 2016, PAIN RES MANAG, pNIL1, DOI DOI 10.1155/2016/3092391; Sobo EJ, 2006, J HOLIST NURS, V24, P51, DOI 10.1177/0898010105280112; Tanabe P, 2008, ANN EMERG MED, V51, P221, DOI 10.1016/j.annemergmed.2007.10.017; ULRICH RS, 1984, SCIENCE, V224, P420, DOI 10.1126/science.6143402	28	18	18	2	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2019	14	1							e0209232	10.1371/journal.pone.0209232	http://dx.doi.org/10.1371/journal.pone.0209232			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HG9VK	30625184	Green Submitted, gold, Green Published			2023-01-03	WOS:000455359400030
J	Norgaard, CH; Sogaard, NB; Biccler, JL; Pilgaard, L; Eskesen, MH; Kjartansdottir, TH; Bogsted, M; El-Galaly, TC				Norgaard, Caroline Holm; Sogaard, Nikoline Buus; Biccler, Jorne Lionel; Pilgaard, Laura; Eskesen, Mathias Holmsgaard; Kjartansdottir, Thordis Helga; Bogsted, Martin; El-Galaly, Tarec Christoffer			Limited value of routine follow-up visits in chronic lymphocytic leukemia managed initially by watch and wait: A North Denmark population-based study	PLOS ONE			English	Article							INTERNATIONAL PROGNOSTIC INDEX; QUALITY-OF-LIFE; DIAGNOSIS; GUIDELINES; SURVIVAL; STAGE	Introduction The majority of newly diagnosed chronic lymphocytic leukemia (CLL) patients are followed initially by watch and wait (WAW). Clinical practice varies and the value of frequent follow-up visits remains unclear. Thus, in this study we investigated the clinical value of follow-up visits for patients with CLL. Methods We collected data from diagnosis and follow-up visits for patients diagnosed with CLL and managed by WAW in the North Denmark Region between 2007-2014. High-and low-risk group patients were determined by Binet stage, IgVH status, and cytogenetics at diagnosis. The effect of risk group allocation on the probability of receiving CLL-directed treatment within two years was included in a multivariable logistic regression model adjusted for age and blood test results. Results 273 patients were included in the study with a median follow-up of 3 years (IQR: 1.6-5.4). Overall, the median interval between follow-up visits was 98 days (95% CI: 96-100) (high-risk patients: 91 days [ 95% CI: 86-95] vs. low-risk patients: 105 days [ 95% CI: 100-110]). Among 2,312 follow-up visits, only 387 (17%) were associated with interventions. At the following time points: 6 months, 1 year, and 1.5 years, patients with low-risk CLL had significantly lower odds of initiating treatment compared to patients with high-risk CLL. Conclusion WAWplays an important role in managing CLL. Interventions at follow-up visits were infrequent and low-risk patients had significantly lower risk of treatment initiation. We question the value of routine follow-up in CLL in the absence of changes in symptoms and/or blood test results.	[Norgaard, Caroline Holm; Sogaard, Nikoline Buus; Biccler, Jorne Lionel; Pilgaard, Laura; Eskesen, Mathias Holmsgaard; Kjartansdottir, Thordis Helga; Bogsted, Martin; El-Galaly, Tarec Christoffer] Aalborg Univ Hosp, Dept Haematol, Aalborg, Denmark; [Norgaard, Caroline Holm] Aalborg Univ Hosp, Unit Epidemiol & Biostat, Aalborg, Denmark; [Biccler, Jorne Lionel; Bogsted, Martin; El-Galaly, Tarec Christoffer] Aalborg Univ, Dept Clin Med, Aalborg, Denmark; [Biccler, Jorne Lionel; Bogsted, Martin; El-Galaly, Tarec Christoffer] Aalborg Univ Hosp, Clin Canc Res Ctr, Aalborg, Denmark	Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University; Aalborg University Hospital	Norgaard, CH (corresponding author), Aalborg Univ Hosp, Dept Haematol, Aalborg, Denmark.; Norgaard, CH (corresponding author), Aalborg Univ Hosp, Unit Epidemiol & Biostat, Aalborg, Denmark.	caroline.noergaard@rn.dk	Noergaard, Caroline Holm/I-4852-2018	Noergaard, Caroline Holm/0000-0003-3279-4872; Bogsted, Martin/0000-0001-9192-1814				ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Baliakas P, 2016, J INTERN MED, V279, P347, DOI 10.1111/joim.12455; BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V; Christensen I, 2018, NATL RETNINGSLINJER; da Cunha-Bang C, 2016, CLIN EPIDEMIOL, V8, P561, DOI 10.2147/CLEP.S99486; Del Giudice I, 2011, HAEMATOL-HEMATOL J, V96, P626, DOI 10.3324/haematol.2010.028779; Dickinson R, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-311; Eichhorst B, 2015, ANN ONCOL, V26, pV78, DOI 10.1093/annonc/mdv303; Ghia P, 2014, HAEMATOLOGICA, V99, P965, DOI 10.3324/haematol.2013.096107; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Hallek M, 2018, BLOOD, V131, P2745, DOI 10.1182/blood-2017-09-806398; Hallek M, 2016, LANCET ONCOL, V17, P779, DOI 10.1016/S1470-2045(16)30029-8; Hallek M, 2010, ANN ONCOL, V21, P154, DOI 10.1093/annonc/mdq373; Levin TT, 2007, GEN HOSP PSYCHIAT, V29, P251, DOI 10.1016/j.genhosppsych.2007.01.014; Molica S, 2016, AM J HEMATOL, V91, P1090, DOI 10.1002/ajh.24493; Oscier D, 2012, BRIT J HAEMATOL, V159, P541, DOI 10.1111/bjh.12067; Overend Aldyn, 2008, Can Oncol Nurs J, V18, P64; Pepper C, 2012, BRIT J HAEMATOL, V156, P499, DOI 10.1111/j.1365-2141.2011.08974.x; Scheike TH, 2008, BIOMETRIKA, V95, P205, DOI 10.1093/biomet/asm096; Shanafelt TD, 2007, BRIT J HAEMATOL, V139, P255, DOI 10.1111/j.1365-2141.2007.06791.x; Shanafelt Tait D, 2009, Hematology Am Soc Hematol Educ Program, P421, DOI 10.1182/asheducation-2009.1.421; Trial C, 1999, CHEMOTHERAPEUTIC OPT, P861; VERHEUL HA, 1993, LANCET, V341, P872, DOI 10.1016/0140-6736(93)93073-A; Wang MC, 1999, J AM STAT ASSOC, V94, P146, DOI 10.2307/2669690	24	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2018	13	12							e0208180	10.1371/journal.pone.0208180	http://dx.doi.org/10.1371/journal.pone.0208180			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF7KM	30589850	Green Submitted, Green Published, gold			2023-01-03	WOS:000454418200004
J	Shukla, AM; Hinkamp, C; Segal, E; Baslanti, TO; Martinez, T; Thomas, M; Ramamoorthy, R; Bozorgmehri, S				Shukla, Ashutosh M.; Hinkamp, Colin; Segal, Emma; Baslanti, Tezcan Ozrazgat; Martinez, Teri; Thomas, Michelle; Ramamoorthy, Ramya; Bozorgmehri, Shahab			What do the US advanced kidney disease patients want? Comprehensive pre-ESRD Patient Education (CPE) and choice of dialysis modality	PLOS ONE			English	Article							STAGE RENAL-DISEASE; PERITONEAL-DIALYSIS; HOME DIALYSIS; PROGRAM; AWARENESS; NEPHROLOGISTS; INITIATION; SELECTION	Improvement in Home Dialysis (HoD) utilizations as a mean to improve the patient reported and health services outcomes, has been a long-held goal of the providers and healthcare system in United States. However, measures to improve HoD rates have yielded limited success so far. Lack of patient awareness of chronic kidney disease (CKD) and its management options, is one of the important barriers against patient adoption of HoD. Despite ample evidence that Comprehensive pre-ESERD Patient Education (CPE) improves patient awareness and informed HoD choice, use of CPE among US advanced CKD patients is low. Need for significant resources, lack of validated data showing unequivocal and reproducible benefits, and the lack of validated CPE protocols proven to have consistent efficacy in improving not only patient awareness but also HoD rates in US population, are major limitations deterring adoption of CPE in routine clinical practice. We recently demonstrated that if a structured, protocol based CPE is integrated within the routine nephrology care for patients with advanced CKD, it substantially improves informed HoD choice and utilizations. However, this requires establishing CPE resources within each nephrology practice. Efficacy of a stand-alone CPE model, independent of clinical care, has not been examined till date. In this report we report the efficacy of our structured CPE protocol, delivered outside the realm of routine nephrology care-as a stand-alone patient education program, in a geo-graphically distant region, and show that: when provided opportunity for informed dialysis choice, a majority of advanced CKD patients in US would prefer HoD. We also show that initiating CPE leads to accelerated growth in HoD utilizations and reduces disparities in HoD utilizations, goals for system improvements. Finally, the reproducibility of our structured CPE protocol with consistent efficacy data suggest that initiating such programs at institutional levels has the potential to improve informed dialysis selection and HoD rates across any similar large healthcare institute within US.	[Shukla, Ashutosh M.] North Florida South Georgia Vet Healthcare Syst, Dept Med, Gainesville, FL 32608 USA; [Shukla, Ashutosh M.; Hinkamp, Colin; Segal, Emma; Baslanti, Tezcan Ozrazgat; Martinez, Teri; Bozorgmehri, Shahab] Univ Florida, Dept Med, Div Nephrol Hypertens & Transplantat, Gainesville, FL 32610 USA; [Thomas, Michelle] DCI, Gainesville, FL USA; [Ramamoorthy, Ramya] UF Hlth, Dept Med Socidal Worker, Gainesville, FL USA	State University System of Florida; University of Florida	Shukla, AM (corresponding author), North Florida South Georgia Vet Healthcare Syst, Dept Med, Gainesville, FL 32608 USA.; Shukla, AM (corresponding author), Univ Florida, Dept Med, Div Nephrol Hypertens & Transplantat, Gainesville, FL 32610 USA.	Ashutosh.shukla@medicine.ufl.edu		Hinkamp, Colin/0000-0001-6047-883X				[Anonymous], 2017, AM J KIDNEY DIS, V69, pS261, DOI DOI 10.1053/J.AJKD.2017.01.020; [Anonymous], 2017, KIDNEY NEWS ONLINE; Blake P, 2009, AM J KIDNEY DIS, V54, P194, DOI 10.1053/j.ajkd.2009.04.003; Covic A, 2010, CLIN KIDNEY J, V3, P225, DOI 10.1093/ndtplus/sfq059; Fadem SZ, 2011, CLIN J AM SOC NEPHRO, V6, P605, DOI 10.2215/CJN.06970810; Finkelstein FO, 2008, KIDNEY INT, V74, P1178, DOI 10.1038/ki.2008.376; Fluck RJ, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-16; Ghafari A, 2010, SAUDI J KIDNEY DIS T, V21, P636; Goovaerts T, 2005, NEPHROL DIAL TRANSPL, V20, P1842, DOI 10.1093/ndt/gfh905; Introduction to Volume Two: Atlas of End-Stage Renal Disease in the United States, 2014, AM J KIDNEY DIS, V63, pe151, DOI [10.1053/j.ajkd.2013.10.025, DOI 10.1053/J.AJKD.2013.10.025]; Kutner NG, 2011, ARCH INTERN MED, V171, P119, DOI 10.1001/archinternmed.2010.361; Lacson E, 2011, AM J KIDNEY DIS, V58, P235, DOI 10.1053/j.ajkd.2011.04.015; Liebman SE, 2012, AM J KIDNEY DIS, V59, P550, DOI 10.1053/j.ajkd.2011.11.040; Manns BJ, 2005, KIDNEY INT, V68, P1777, DOI 10.1111/j.1523-1755.2005.00594.x; Mehrotra R, 2016, J AM SOC NEPHROL, V27, P2123, DOI 10.1681/ASN.2015050472; Mehrotra R, 2011, AM J KIDNEY DIS, V58, P160, DOI 10.1053/j.ajkd.2011.06.002; Mendelssohn DC, 2001, AM J KIDNEY DIS, V37, P22, DOI 10.1053/ajkd.2001.20573; Moss AH, 2011, CLIN J AM SOC NEPHRO, V6, P2313, DOI 10.2215/CJN.03960411; Prieto-Velasco M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138811; Ribitsch W, 2013, PERITON DIALYSIS INT, V33, P367, DOI 10.3747/pdi.2011.00255; Saran R, 2018, AM J KIDNEY DIS, V71, pS1, DOI 10.1053/j.ajkd.2018.01.002; Schiller B, 2011, CLIN KIDNEY J, V4, P11, DOI 10.1093/ndtplus/sfr123; Shukla AM, 2017, PERITON DIALYSIS INT, V37, P542, DOI 10.3747/pdi.2016.00270; Tuso Phillip, 2013, Perm J, V17, P75, DOI 10.7812/TPP/13-006; Whaley-Connell A, 2012, AM J MED, V125, P661, DOI 10.1016/j.amjmed.2011.11.026; Wu IW, 2009, NEPHROL DIAL TRANSPL, V24, P3426, DOI 10.1093/ndt/gfp259; Young HN, 2011, AM J KIDNEY DIS, V57, P381, DOI 10.1053/j.ajkd.2010.10.056	27	12	12	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2019	14	4							e0215091	10.1371/journal.pone.0215091	http://dx.doi.org/10.1371/journal.pone.0215091			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HS4YI	30964936	Green Submitted, Green Published, gold			2023-01-03	WOS:000463876300059
J	Hernandez-Izquierdo, C; Lopez-Valcarcel, BG; Morris, S; Melnychuk, M; Alesson, IA				Hernandez-Izquierdo, Cristina; Gonzalez Lopez-Valcarcel, Beatriz; Morris, Stephen; Melnychuk, Mariya; Abasolo Alesson, Ignacio			The effect of a change in co-payment on prescription drug demand in a National Health System: The case of 15 drug families by price elasticity of demand	PLOS ONE			English	Article							CARE UTILIZATION; FREE MEDICINES; IMPACT; EXPENDITURES; NUMBER	Objectives To test the heterogeneity of the effect of a change in pharmaceutical cost-sharing by therapeutic groups in a Spanish region. Methods Data: random sample (provided by the Canary Islands Health Service) of 40,471 people covered by the Spanish National Health System (SNHS) in the Canary Islands. The database includes individualised monthly-dispensed medications (prescribed by the SNHS) from one year before (August 2011) to one year after (June 2013) the Royal Decree Law 16/2012 (RDL 16/2012). Sample: two intervention groups (low-income pensioners and middle-income working population) and one control group (low-income working population). Empirical model: quasi-experimental difference-in-differences design to study the change in consumption (measured in number of monthly Defined Daily Dose (DDDs) per individual) among 13 therapeutic groups. The policy break indicator (three-level categorical variable) tested the existence of stockpiling between the reform's announcement and its implementation. We ran 16 linear regression models (general, by therapeutic groups and by comorbidities) that considered whether the exclusion of some drugs from public provision impacted on consumption more than the co-payment increase. Results General: Reduction (-13.04) in consumption after the reform's implementation, which was fully compensated by a previous increase (16.60 i.e., stockpiling) among low-income pensioners. The middle-income working population maintained its trend of increasing consumption. Therapeutic groups: Reductions in consumption after the reform's implementation among low-income pensioners in 7 of the 13 groups, which were fully compensated for by a previous increase (i.e., stockpiling) in 4 groups and partially compensated for in the remaining 3. The analysis without the excluded medicines provided fewer negative coefficients. Comorbidities: Reduction in consumption that was only slightly compensated for by a previous increase (i.e., stockpiling). Conclusions The negative impact of cost-sharing produced, among low-income pensioners, a risk of loss of adherence to treatments, which could deteriorate the health status of individuals, especially among pensioners within the most inelastic therapeutic groups (associated with chronic diseases) and patients with comorbidities (also, associated with chronic diseases). Notwithstanding the above, this risk was more related to the exclusion of some drugs from provision than to the cost-sharing increase.	[Hernandez-Izquierdo, Cristina; Abasolo Alesson, Ignacio] ULL, Fac Econ Empresa & Turismo, Dept Econ Aplicada & Metodos Cuantitat, San Cristobal De La Lagu, Spain; [Gonzalez Lopez-Valcarcel, Beatriz] ULPGC, Fac Econ Empresa & Turismo, Dept Metodos Cuantitat Econ & Gest, Las Palmas Gran Canaria, Spain; [Morris, Stephen; Melnychuk, Mariya] UCL, Dept Appl Hlth Res, London, England; [Melnychuk, Mariya] URJC, Dept Econ Empresa ADO Econ Aplicada & Fundamentos, Madrid, Spain; [Abasolo Alesson, Ignacio] ULL, Fac Econ Empresa & Turismo, Inst Univ Desarrollo Reg, San Cristobal De La Lagu, Spain	Universidad de Las Palmas de Gran Canaria; University of London; University College London; Universidad Rey Juan Carlos	Hernandez-Izquierdo, C (corresponding author), ULL, Fac Econ Empresa & Turismo, Dept Econ Aplicada & Metodos Cuantitat, San Cristobal De La Lagu, Spain.	chernani@ull.edu.es		Hernandez-Izquierdo, Cristina/0000-0003-3188-1085; Abasolo, Ignacio/0000-0002-9297-232X; Morris, Stephen/0000-0002-5828-3563	Ministry of Science, Innovation and Universities [ECO2016-79588-R]	Ministry of Science, Innovation and Universities	IAA received an award from the national grant ECO2016-79588-R aimed at Research, Development and Innovation oriented to the challenges of society (Ministry of Science, Innovation and Universities) and this study is part of the works developed in this national grant. http://www.ciencia.gob.es/portal/site/MICINN/menuitem.dbc68b34d11ccbd5d52ffeb801432ea0/? vgnextoid=	Villar FA, 2014, REV ESP SALUD PUBLIC, V88, P233, DOI 10.4321/S1135-57272014000200006; Baixauli Fernandez VJ, 2015, SOC ESPANOLA FARMACI, P22; Chen SY, 2014, J MANAGE CARE PHARM, V20, P34, DOI 10.18553/jmcp.2014.20.1.34; Contoyannis P, 2005, HEALTH ECON, V14, P909, DOI 10.1002/hec.1041; Damiani G, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-6; Fraeyman J, 2013, APPL HEALTH ECON HEA, V11, P543, DOI 10.1007/s40258-013-0054-9; Gallo P, 2013, HEALTH POLICY, V113, P1, DOI 10.1016/j.healthpol.2013.06.016; Garcia-Gomez P, 2018, APPL HEALTH ECON HEA, V16, P407, DOI 10.1007/s40258-018-0382-x; Gobierno de Espana, 2013, PROGR NAC REF; Gobierno de Espana, 2012, INF AN SIST NAC SAL; Gonzalez B, 2016, VALUE HEALTH, V19, pA659, DOI 10.1016/j.jval.2016.09.1800; Gonzalez Lopez-Valcarcel B, 2004, CUAD EC ICE, P161; Gonzalez Lopez-Valcarcel B, 2016, COPAGOS SANITARIOS R; Grootendorst P, 2002, DO DRUG PLANS MATTER; IMS, 2012, EV MERC FARM IMPL CO; Jimenez-Martin S, 2016, CONSUMO MEDICAMENTOS; Kiil A, 2014, EUR J HEALTH ECON, V15, P813, DOI 10.1007/s10198-013-0526-8; Lesen E, 2014, EUR J PUBLIC HEALTH, V24, P85, DOI 10.1093/eurpub/ckt062; Li X, 2013, APPL ECON LETT, V20, P23, DOI 10.1080/13504851.2012.669456; Li X, 2007, HEALTH POLICY, V82, P340, DOI 10.1016/j.healthpol.2006.11.002; Lopez Navarro AT, 2015, REV HOSP U GRAN CANA; Malani A, 2010, ACCOUNTING ANTICIPAT; Margolles Martins M, 2015, 3 ENCUESTA SALUD AST; Lesende IM, 2014, ATEN PRIM, V46, P55, DOI 10.1016/j.aprim.2013.11.001; Mas N., 2011, SISTEMAS COPAGO EURO; McManus P, 1996, Pharmacoepidemiol Drug Saf, V5, P385, DOI 10.1002/(SICI)1099-1557(199611)5:6<385::AID-PDS246>3.0.CO;2-8; Puig-Junoy J, 2016, REV ESPANOLA SALUD P, V90; Puig-Junoy J, 2011, FREE MED THANKS RETI, V07, DOI [10.2139/ssrn.1912438, DOI 10.2139/SSRN.1912438]; Puig-Junoy J, 2014, ESTIMATION PRICE ELA; Puig-Junoy J, 1999, CUADERNOS INFORM EC, V143, P77; Puig-Junoy J, 2001, HACIENDA PUBLICA ESP, V158, P105; Puig-Junoy J, 2016, HEALTH ECON, V25, P750, DOI 10.1002/hec.3182; Puig-Junoy J, 2014, APPL HEALTH ECON HEA, V12, P279, DOI 10.1007/s40258-014-0097-6; Robert BH, 2006, HLTH INSURANCE EXPT; Rodriguez M, 2012, GAC SANIT, V26, P78, DOI 10.1016/j.gaceta.2011.09.026; Sanchez DP, 2015, ATEN PRIM, V47, P411, DOI 10.1016/j.aprim.2014.10.005; Siles Gutierrez M, 2001, SISTEMA CODIFICACION; Minana JS, 2015, ATEN PRIM, V47, P669, DOI 10.1016/j.aprim.2015.06.010; Simonsen M, 2016, J APPL ECONOMET, V31, P320, DOI 10.1002/jae.2436; Skipper N, 2010, UTILIZATION STOCKPIL; Skipper N, 2013, HEALTH ECON, V22, P857, DOI 10.1002/hec.2864; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; WHO Collaborating Centre for Drug Statistics Methodology, 2018, ATC DDD IND 2018	43	10	10	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2019	14	3							e0213403	10.1371/journal.pone.0213403	http://dx.doi.org/10.1371/journal.pone.0213403			39	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HQ5PT	30917142	Green Published, Green Submitted, gold			2023-01-03	WOS:000462465800032
J	Wang, CJ; Lin, SY; Tsai, SH; Shan, YS				Wang, Chih Jung; Lin, Su Yueh; Tsai, Sheng Han; Shan, Yan Shen			Implications of long-term low-fidelity in situ simulation in acute care and association with a reduction in unexpected cardiac arrests: A retrospective research study	PLOS ONE			English	Article							CRISIS-RESOURCE-MANAGEMENT; RESUSCITATION; TEAMWORK; MULTIDISCIPLINARY; EDUCATION; TRAUMA; PROFESSIONS; PERFORMANCE; QUALITY; SAFETY	In situ simulation is a new tool for building teamwork during crisis. However, only a few studies have discussed the long-term effects of regular in situ simulations. To better understand these effects, this study retrospectively analyzed the effect of regular (twice a month over a four-year period) in situ simulations in the National Cheng Kung University Hospital acute care ward, which provides care for patients with acute illnesses and requires admission during an emergency room visit. The simulations were held in a real clinical environment using a low-fidelity mannequin and the trainees involved in the simulations were the medical staff of the acute care ward. In this study, we review the effects of such long-term simulations with respect to team performance based on the Ottawa global rating scale (GRS) and incidences of urgent intubation and unexpected cardiac arrest. Our results revealed that among the 84 simulations that were conducted during the study period, 42 could be categorized as "high performance" and the remaining 42 as "low performance" based on the team's Ottawa GRS. Further, the seniority of nurse leaders and exposure of nurses to repeated simulations did not have any effect on performance. However, although regular simulations did not have any effect on the number of urgent intubations, they caused a marked decrease in the number of unexpected cardiac arrests. The current study did not show that repeated, low-fidelity, regular in situ simulations improve team performance in simulations based on Ottawa GRS, but it was associated with a reduction in the unexpected cardiac arrest rate in the acute care ward. Our results support the use of in situ simulations in acute care wards as an educational tool for first-line caregivers.	[Wang, Chih Jung] Natl Cheng Kung Univ Hosp, Div Trauma, Dept Surg, Tainan, Taiwan; [Lin, Su Yueh] Natl Cheng Kung Univ Hosp, Dept Nursing, Tainan, Taiwan; [Tsai, Sheng Han] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan; [Shan, Yan Shen] Natl Cheng Kung Univ Hosp, Div Gen Surg, Dept Surg, Tainan, Taiwan; [Shan, Yan Shen] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan, Taiwan	National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University	Wang, CJ (corresponding author), Natl Cheng Kung Univ Hosp, Div Trauma, Dept Surg, Tainan, Taiwan.	poemcage@gmail.com		Wang, Chih Jung/0000-0002-7625-2891				Berwick DM, 2006, JAMA-J AM MED ASSOC, V295, P324, DOI 10.1001/jama.295.3.324; Bethards ML, 2014, CLIN SIMUL NURS, V10, pE65, DOI 10.1016/j.ecns.2013.08.002; Bittencourt T, 2015, SIMUL HEALTHC, V10, P76, DOI 10.1097/SIH.0000000000000081; Boet S, 2014, CAN J ANESTH, V61, P571, DOI 10.1007/s12630-014-0143-8; Clapper TC, 2013, CLIN SIMUL NURS, V9, pE551, DOI 10.1016/j.ecns.2012.12.005; Cook DA, 2011, JAMA-J AM MED ASSOC, V306, P978, DOI 10.1001/jama.2011.1234; Doumouras AG, 2014, CAN J SURG, V57, P354, DOI 10.1503/cjs.000814; Edler AA, 2010, SIMUL HEALTHC, V5, P112, DOI 10.1097/SIH.0b013e3181c76332; Gilligan P, 2005, EMERG MED J, V22, P628, DOI 10.1136/emj.2004.015321; Gillman LM, 2016, AM J SURG, V212, P188, DOI 10.1016/j.amjsurg.2015.07.024; Hillman K, 2005, LANCET, V365, P2091; Hunziker S, 2011, J AM COLL CARDIOL, V57, P2381, DOI 10.1016/j.jacc.2011.03.017; Kim J, 2006, CRIT CARE MED, V34, P2167, DOI 10.1097/01.CCM.0000229877.45125.CC; Lai A, 2016, ANAESTH CRIT CARE PA, V35, P275, DOI 10.1016/j.accpm.2015.10.010; Maran NJ, 2003, MED EDUC, V37, P22, DOI 10.1046/j.1365-2923.37.s1.9.x; Marsch SCU, 2004, RESUSCITATION, V60, P51, DOI 10.1016/j.resuscitation.2003.08.004; Meurling L, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-221; Miller K, 2009, J NURS MANAGE, V17, P247, DOI 10.1111/j.1365-2834.2009.00978.x; Miller KK, 2008, J PERINAT NEONAT NUR, V22, P105, DOI 10.1097/01.JPN.0000319096.97790.f7; Moon A, 2011, RESUSCITATION, V82, P150, DOI 10.1016/j.resuscitation.2010.09.480; Murray WB, 2000, J CLIN ANESTH, V12, P633, DOI 10.1016/S0952-8180(00)00223-3; Patterson MD, 2013, BMJ QUAL SAF, V22, P468, DOI 10.1136/bmjqs-2012-000942; Riley W, 2009, J NURS MANAGE, V17, P238, DOI 10.1111/j.1365-2834.2009.00971.x; Rosen MA, 2012, J CONTIN EDUC HEALTH, V32, P243, DOI 10.1002/chp.21152; Rubio-Gurung S, 2014, PEDIATRICS, V134, pE790, DOI 10.1542/peds.2013-3988; Sorensen JL, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008345; Steinemann S, 2011, J SURG EDUC, V68, P472, DOI 10.1016/j.jsurg.2011.05.009; Theilen U, 2013, RESUSCITATION, V84, P218, DOI 10.1016/j.resuscitation.2012.06.027; van Schaik SM, 2011, CLIN PEDIATR, V50, P807, DOI 10.1177/0009922811405518; Wayne DB, 2008, CHEST, V133, P56, DOI 10.1378/chest.07-0131; Weinstock PH, 2009, PEDIATR CRIT CARE ME, V10, P176, DOI 10.1097/PCC.0b013e3181956c6f; Winters BD, 2006, JAMA-J AM MED ASSOC, V296, P1645, DOI 10.1001/jama.296.13.1645; Yee B, 2005, ANESTHESIOLOGY, V103, P241, DOI 10.1097/00000542-200508000-00006	33	5	6	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2019	14	3							e0213789	10.1371/journal.pone.0213789	http://dx.doi.org/10.1371/journal.pone.0213789			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO6JJ	30861053	gold, Green Submitted, Green Published			2023-01-03	WOS:000461035600059
J	Gomides, APM; de Albuquerque, CP; Santos, ABV; Amorim, RBC; Bertolo, MB; Louzada, P; Santos, IA; Giorgi, RDN; Sacilotto, ND; Radominski, SC; Borghi, FM; Guimaraes, MFBR; Pinto, MRD; Resende, GG; Bonfiglioli, KR; da Silva, HC; Sauma, MDLD; Sauma, ML; de Medeiros, JB; Pereira, IA; de Castro, GRW; Brenol, CV; Xavier, RM; da Mota, LMH; Pinheiro, GDC				Monteiro Gomides, Ana Paula; de Albuquerque, Cleandro Pires; Vargas Santos, Ana Beatriz; Chaves Amorim, Rodrigo Balbino; Bertolo, Manoel Barros; Louzada Junior, Paulo; Santos, Isabela Araujo; Neubarth Giorgi, Rina Dalva; Sacilotto, Nathalia de Carvalho; Radominski, Sebastiao Cezar; Borghi, Fernanda Maria; Resende Guimaraes, Maria Fernanda B.; da Costa Pinto, Maria Raquel; Resende, Gustavo Gomes; Bonfiglioli, Karina Rossi; da Silva, Henrique Carrico; Lobato da Cunha Sauma, Maria de Fatima; Sauma, Marcel Lobato; de Medeiros, Julia Brito; Pereira, Ivanio Alves; Wernwer de Castro, Glaucio Ricardo; Brenol, Claiton Viegas; Xavier, Ricardo Machado; Henrique da Mota, Licia Maria; Castelar Pinheiro, Geraldo da Rocha			Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis: Data from a large real-life cohort	PLOS ONE			English	Article							METHOTREXATE; COMBINATION; THERAPY	The treatment of rheumatoid arthritis (RA) has evolved rapidly in recent years. Nonetheless, conventional synthetic disease-modifying drugs (csDMARDs) remain the gold standard for RA treatment. The treatment for RA is expensive and this has a negative impact on public health. Given the low cost of csDMARDs compared to those of other treatment strategies, it is important to manage this type of treatment properly. Information on the duration of use of each drug and the reasons for their discontinuation is relevant to medical practitioners as it could improve the information available regarding side effects and their proper management. Moreover, data from clinical practice in the population can provide health care managers with information for resource allocation and optimization of csDMARD use with a consequent cost reduction in the treatment of RA. In this cross-sectional study, we aimed to describe the use of csDMARDs in public health services in Brazil, emphasizing on the duration of use and reasons for discontinuation of each drug. This study is a part of the REAL, a multicenter project that evaluated Brazilian patients with RA from eleven rheumatology services from August to October 2015. Patients were examined clinically, and an analysis of complementary exams and medical records was performed. A total of 1125 patients were included. 98.5% were women with a median age of 55.6 years. 36% and 90.84% patients were using biological disease-modifying drugs (bDMARDs) and csDMARDs, respectively. The duration of use and doses of each medication and the causes of suspension were analyzed. Most of the patients analyzed in this study were using csDMARDs for prolonged periods and methotrexate showed the longest duration of use. Interruption indexes due to ineffectiveness and side effects were analyzed. The knowledge of common adverse effects may alert attending physicians to the proper management of effective and low-cost therapeutic groups.	[Monteiro Gomides, Ana Paula; de Albuquerque, Cleandro Pires; Henrique da Mota, Licia Maria] Univ Brasilia, Dept Reumatol, Brasilia, DF, Brazil; [Monteiro Gomides, Ana Paula] Ctr Univ Brasilia Uniceub, Dept Curso Med, Brasilia, DF, Brazil; [Vargas Santos, Ana Beatriz; Chaves Amorim, Rodrigo Balbino; Castelar Pinheiro, Geraldo da Rocha] Univ Estado Rio de Janeiro, Dept Reumatol, Rio De Janeiro, RJ, Brazil; [Bertolo, Manoel Barros] Univ Estadual Campinas, Dept Reumatol, Sao Paulo, Brazil; [Louzada Junior, Paulo; Santos, Isabela Araujo] Univ Sao Paulo, Fac Med, Dept Reumatol, Sao Paulo, Brazil; [Neubarth Giorgi, Rina Dalva; Sacilotto, Nathalia de Carvalho] Hosp Serv Publ Estadual Sao Paulo, Dept Reumatol, Inst Assistencia Med Serv Publ Estadual, Sao Paulo, SP, Brazil; [Radominski, Sebastiao Cezar] Univ Fed Parana, Dept Reumatol, Curitiba, Parana, Brazil; [Borghi, Fernanda Maria] Univ Estadual Maringa, Dept Reumatol, Maringa, Parana, Brazil; [Resende Guimaraes, Maria Fernanda B.; da Costa Pinto, Maria Raquel; Resende, Gustavo Gomes] Univ Fed Minas Gerais, Dept Reumatol, Belo Horizonte, MG, Brazil; [Bonfiglioli, Karina Rossi; da Silva, Henrique Carrico] Univ Sao Paulo, Dept Reumatol, Sao Paulo, SP, Brazil; [Lobato da Cunha Sauma, Maria de Fatima; Sauma, Marcel Lobato; de Medeiros, Julia Brito] Univ Fed Para, Dept Reumatol, Belem, Para, Brazil; [Pereira, Ivanio Alves] Univ Fed Santa Catarina, Dept Reumatol, Florianopolis, SC, Brazil; [Wernwer de Castro, Glaucio Ricardo] Univ Sul Santa Catarina Unisul, Dept Reumatol, Florianopolis, SC, Brazil; [Brenol, Claiton Viegas; Xavier, Ricardo Machado] Univ Fed Rio Grande do Sul, Dept Reumatol, Porto Alegre, RS, Brazil	Universidade de Brasilia; Centro Universitario de Brasilia (UniCEUB); Universidade do Estado do Rio de Janeiro; Universidade Estadual de Campinas; Universidade de Sao Paulo; Instituto de Assistencia Medica ao Servidor Publico Estadual (IAMSPE); Universidade Federal do Parana; Universidade Estadual de Maringa; Universidade Federal de Minas Gerais; Universidade de Sao Paulo; Universidade Federal do Para; Universidade Federal de Santa Catarina (UFSC); Universidade do Sul de Santa Catarina; Universidade Federal do Rio Grande do Sul	Gomides, APM (corresponding author), Univ Brasilia, Dept Reumatol, Brasilia, DF, Brazil.; Gomides, APM (corresponding author), Ctr Univ Brasilia Uniceub, Dept Curso Med, Brasilia, DF, Brazil.	anapmgomides@gmail.com	Xavier, Ricardo Machado/G-4426-2012; Louzada-Junior, Paulo/E-4132-2012; dos Santos, Ana Beatriz Vargas/S-4908-2019; RESENDE, GUSTAVO GOMES/AAE-4671-2020	Xavier, Ricardo Machado/0000-0001-6570-4533; Louzada-Junior, Paulo/0000-0003-2585-3870; dos Santos, Ana Beatriz Vargas/0000-0001-5307-0254; Rossi Bonfiglioli, Karina/0000-0003-3547-5674; Pinheiro, Geraldo/0000-0002-7778-569X	Brazilian Society of Rheumatology (BSR); Bristol-Myers Squibb Farmaceutica Ltda; Eli Lilly do Brasil Ltda; Janssen-Cilag Farmaceuticos Ltda; Laboratorios Pfizer Ltda; Produtos Roche Quimicos e Farmaceuticos S.A.; UCB Biopharma Ltda; Brazilian Society of Rheumatology; University Hospital of Brasilia-HUB-UnB	Brazilian Society of Rheumatology (BSR); Bristol-Myers Squibb Farmaceutica Ltda; Eli Lilly do Brasil Ltda; Janssen-Cilag Farmaceuticos Ltda; Laboratorios Pfizer Ltda; Produtos Roche Quimicos e Farmaceuticos S.A.; UCB Biopharma Ltda; Brazilian Society of Rheumatology; University Hospital of Brasilia-HUB-UnB	This work was supported by the Brazilian Society of Rheumatology (BSR). For this project, BSR received specific grant support from the following companies: Bristol-Myers Squibb Farmaceutica Ltda; Eli Lilly do Brasil Ltda; Janssen-Cilag Farmaceuticos Ltda; Laboratorios Pfizer Ltda; Produtos Roche Quimicos e Farmaceuticos S.A. and UCB Biopharma Ltda. The funding body or the companies had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.; We thank the Brazilian Society of Rheumatology and the Rheumatology team of the University Hospital of Brasilia-HUB-UnB for support of this project.	Agresti A., 2007, INTRO CATEGORICAL DA, V2nd; Anvari B, 2016, EGYPT RHEUMATOL, V38, P147, DOI 10.1016/j.ejr.2015.12.003; Bettembourg-Brault I, 2006, CLIN EXP RHEUMATOL, V24, P168; Bird P, 2013, J RHEUMATOL, V40, P228, DOI 10.3899/jrheum.120922; Cardiel MH, 2012, JCR-J CLIN RHEUMATOL, V18, P327, DOI 10.1097/RHU.0b013e31826d6610; Castelar-Pinheiro GD, 2018, ADV RHEUMATOL, V58, DOI 10.1186/s42358-018-0017-9; Cipriani P, 2014, CLIN THER, V36, P427, DOI 10.1016/j.clinthera.2014.01.014; de Azevedo ABC, 2008, VALUE HEALTH, V11, P869, DOI 10.1111/j.1524-4733.2008.00332.x; da Mota LMH, 2018, ADV RHEUMATOL, V58, DOI 10.1186/s42358-018-0005-0; Kahlenberg JM, 2011, HAND CLIN, V27, P11, DOI 10.1016/j.hcl.2010.09.002; Kapral T, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1902; Kern DM, 2018, RHEUMATOL THER, V5, P355, DOI 10.1007/s40744-018-0114-6; Mittal N, 2012, RHEUMATOL INT, V32, P743, DOI 10.1007/s00296-010-1646-4; Rein P, 2017, RHEUMATOL THER, V4, P247, DOI 10.1007/s40744-017-0073-3; Singh JA, 2016, ARTHRIT CARE RES, V68, P1, DOI 10.1002/acr.22783; Smolen JS, 2017, ANN RHEUM DIS, V76, P960, DOI 10.1136/annrheumdis-2016-210715; Solomon DH, 2012, ARTHRIT CARE RES, V64, P184, DOI 10.1002/acr.20674; Tornero-Molina J, 2019, REUMATOL CLIN, V15, P338, DOI 10.1016/j.reuma.2017.11.007; Wabe N, 2017, RHEUMATOL INT, V37, P897, DOI 10.1007/s00296-017-3655-z	19	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2019	14	3							e0213219	10.1371/journal.pone.0213219	http://dx.doi.org/10.1371/journal.pone.0213219			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN7LT	30822348	Green Published, Green Submitted, gold			2023-01-03	WOS:000460371600037
J	Garcia-Ramos, A; Ulloa-Diaz, D; Barboza-Gonzalez, P; Rodriguez-Perea, A; Martinez-Garcia, D; Quidel-Catrilelbun, M; Guede-Rojas, F; Cuevas-Aburto, J; Janicijevic, D; Weakley, J				Garcia-Ramos, Amador; Ulloa-Diaz, David; Barboza-Gonzalez, Paola; Rodriguez-Perea, Angela; Martinez-Garcia, Dario; Quidel-Catrilelbun, Mauricio; Guede-Rojas, Francisco; Cuevas-Aburto, Jesualdo; Janicijevic, Danica; Weakley, Jonathon			Assessment of the load-velocity profile in the free-weight prone bench pull exercise through different velocity variables and regression models	PLOS ONE			English	Article							MOVEMENT VELOCITY; PERFORMANCE; INTENSITY; STRENGTH; PRESS	This aims of this study were (I) to determine the velocity variable and regression model which best fit the load-velocity relationship during the free-weight prone bench pull exercise, (II) to compare the reliability of the velocity attained at each percentage of the one-repetition maximum (1RM) between different velocity variables and regression models, and (III) to compare the within-and between-subject variability of the velocity attained at each %1RM. Eighteen men (14 rowers and four weightlifters) performed an incremental test during the free-weight prone bench pull exercise in two different sessions. General and individual load-velocity relationships were modelled through three velocity variables (mean velocity [MV], mean propulsive velocity [MPV] and peak velocity [PV]) and two regression models (linear and second-order polynomial). The main findings revealed that (I) the general (Pearson's correlation coefficient [r] range = 0.964-0.973) and individual (median r = 0.986 for MV, 0.989 for MPV, and 0.984 for PV) load-velocity relationships were highly linear, (II) the reliability of the velocity attained at each %1RM did not meaningfully differ between the velocity variables (coefficient of variation [ CV] range = 2.55-7.61% for MV, 2.84-7.72% for MPV and 3.50-6.03% for PV) neither between the regression models (CV range = 2.55-7.72% and 2.73-5.25% for the linear and polynomial regressions, respectively), and (III) the within-subject variability of the velocity attained at each % 1RM was lower than the between-subject variability for the light-moderate loads. No meaningful differences between the within-and between-subject CVs were observed for the MV of the 1RM trial (6.02% vs. 6.60%; CVratio = 1.10), while the within-subject CV was lower for PV (6.36% vs. 7.56%; CVratio = 1.19). These results suggest that the individual load-MV relationship should be determined with a linear regression model to obtain the most accurate prescription of the relative load during the free-weight prone bench pull exercise.	[Garcia-Ramos, Amador; Rodriguez-Perea, Angela; Martinez-Garcia, Dario] Univ Granada, Fac Sport Sci, Dept Phys Educ & Sport, Granada, Spain; [Garcia-Ramos, Amador; Ulloa-Diaz, David; Quidel-Catrilelbun, Mauricio; Cuevas-Aburto, Jesualdo] Catholic Univ Most Holy Concepcion, Dept Sports Sci & Phys Conditioning, Fac Educ, CIEDE, Concepcion, Chile; [Barboza-Gonzalez, Paola] Univ Andres Bello, Fac Educ, Concepcion, Chile; [Guede-Rojas, Francisco] Univ Andres Bello, Fac Rehabil Sci, Concepcion, Chile; [Janicijevic, Danica] Univ Belgrade, Res Ctr, Fac Sport & Phys Educ, Belgrade, Serbia; [Weakley, Jonathon] Leeds Beckett Univ, Inst Sport Phys Act & Leisure, Leeds, W Yorkshire, England	University of Granada; Universidad Catolica de la Santisima Concepcion; Universidad Andres Bello; Universidad Andres Bello; University of Belgrade; Leeds Beckett University	Garcia-Ramos, A (corresponding author), Univ Granada, Fac Sport Sci, Dept Phys Educ & Sport, Granada, Spain.; Garcia-Ramos, A (corresponding author), Catholic Univ Most Holy Concepcion, Dept Sports Sci & Phys Conditioning, Fac Educ, CIEDE, Concepcion, Chile.	amagr@ugr.es	RODRIGUEZ PEREA, ANGELA/B-6638-2019; Guede, Francisco/AAD-3561-2019; Weakley, Jonathon/AAJ-2182-2020; Martínez-García, Darío/O-4742-2019; Ramos, Amador Garcia/S-6982-2016; Garcia, Dario Martinez/Q-2872-2016; Janićijević, Danica/AAA-9861-2020	RODRIGUEZ PEREA, ANGELA/0000-0001-5155-1337; Guede, Francisco/0000-0002-1870-1396; Weakley, Jonathon/0000-0001-7892-4885; Martínez-García, Darío/0000-0003-0077-6813; Ramos, Amador Garcia/0000-0003-0608-8755; Janićijević, Danica/0000-0001-9925-7751; Ulloa-Diaz, David/0000-0003-1288-1397				Banyard HG, 2018, INT J SPORT PHYSIOL, V13, P763, DOI 10.1123/ijspp.2017-0610; Conceicao F, 2016, J SPORT SCI, V34, P1099, DOI 10.1080/02640414.2015.1090010; Cormack SJ, 2008, INTJ SPORT PHYSIOL, V3, P131, DOI 10.1123/ijspp.3.2.131; Dong JG, 2016, EXP THER MED, V11, P1531, DOI 10.3892/etm.2016.3104; Fernandes JFT, 2021, J STRENGTH COND RES, V35, P1760, DOI 10.1519/JSC.0000000000002952; Fulton SK, 2009, J SPORT SCI, V27, P535, DOI 10.1080/02640410802641418; Garcia- Ramos A, 2018, INT J SPORTS SCI COA, DOI [10.1177/1747954118791525b, DOI 10.1177/1747954118791525B]; Garcia-Ramos A, 2018, STRENGTH COND J, V40, P54, DOI 10.1519/SSC.0000000000000359; Garcia-Ramos A, 2018, J STRENGTH COND RES, V32, P1273, DOI 10.1519/JSC.0000000000001998; Garcia-Ramos A, 2018, INT J SPORT PHYSIOL, V13, P326, DOI 10.1123/ijspp.2017-0158; Garcia-Ramos A, 2018, INT J SPORT PHYSIOL, V13, P474, DOI 10.1123/ijspp.2017-0374; Gonzalez-Badillo JJ, 2010, INT J SPORTS MED, V31, P347, DOI 10.1055/s-0030-1248333; Gonzalez-Hernandez JM, 2020, J STRENGTH COND RES, V34, P1581, DOI 10.1519/JSC.0000000000002117; Harris NK, 2010, STRENGTH COND J, V32, P66, DOI 10.1519/SSC.0b013e3181eb341b; Helms ER, 2017, J STRENGTH COND RES, V31, P292, DOI 10.1519/JSC.0000000000001517; Hopkins W., NEW VIEW STAT 2000; Jidovtseff B, 2011, J STRENGTH COND RES, V25, P267, DOI 10.1519/JSC.0b013e3181b62c5f; Jovanovic M., 2014, J AUST STRENGTH COND, V22, P58; Loturco I, 2021, J STRENGTH COND RES, V35, P300, DOI 10.1519/JSC.0000000000002543; Pestana-Melero FL, 2018, J APPL BIOMECH, V34, P184, DOI 10.1123/jab.2017-0266; Mann JB, 2015, STRENGTH COND J, V37, P52, DOI 10.1519/SSC.0000000000000177; Peart DJ, 2019, J STRENGTH COND RES, V33, P1167, DOI 10.1519/JSC.0000000000002344; Perez-Castilla A, 2020, J STRENGTH COND RES, V34, P1024, DOI 10.1519/JSC.0000000000002072; Picerno P, 2016, EUR J APPL PHYSIOL, V116, P2035, DOI 10.1007/s00421-016-3457-0; Randell AD, 2011, J STRENGTH COND RES, V25, P87, DOI 10.1519/JSC.0b013e3181fee634; Sanchez-Medina L, 2014, INT J SPORTS MED, V35, P209, DOI 10.1055/s-0033-1351252; Sanchez-Medina L, 2010, INT J SPORTS MED, V31, P123, DOI 10.1055/s-0029-1242815; Sanchez-Medina L, 2011, MED SCI SPORT EXER, V43, P1725, DOI 10.1249/MSS.0b013e318213f880; Weakley JJS, 2019, J STRENGTH COND RES, V33, P2420, DOI 10.1519/JSC.0000000000002133	29	24	24	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2019	14	2							e0212085	10.1371/journal.pone.0212085	http://dx.doi.org/10.1371/journal.pone.0212085			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM9LQ	30811432	Green Published, Green Accepted, gold			2023-01-03	WOS:000459806400052
J	King, DR				King, David R.			Initial Care of the Severely Injured Patient	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ENDOVASCULAR BALLOON OCCLUSION; RECEIVING MASSIVE TRANSFUSIONS; PRIMARY FASCIAL CLOSURE; DAMAGE-CONTROL; TRAUMA PATIENTS; GOLDEN HOUR; FLUID RESUSCITATION; IMPROVED SURVIVAL; TRANEXAMIC ACID; TOURNIQUET USE		[King, David R.] Massachusetts Gen Hosp, Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA; [King, David R.] Harvard Med Sch, Dept Surg, Boston, MA 02115 USA; [King, David R.] US Army Special Operat Command, Ft Bragg, NC USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; United States Department of Defense; United States Army	King, DR (corresponding author), Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Suite 810, Boston, MA 02114 USA.	dking3@mgh.harvard.edu						Abe T, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1577-x; Abouassaly CT, 2010, J TRAUMA, V69, P557, DOI 10.1097/TA.0b013e3181e77ca4; Alarhayem AQ, 2016, AM J SURG, V212, P1101, DOI 10.1016/j.amjsurg.2016.08.018; [Anonymous], 1817, APHORISMS HIPPOCRATE; Ballard RB, 1999, J AM COLL SURGEONS, V189, P145, DOI 10.1016/S1072-7515(99)00121-0; Barbosa RR, 2013, J TRAUMA ACUTE CARE, V75, pS48, DOI 10.1097/TA.0b013e31828fa54e; Bennett Brad L, 2014, J Spec Oper Med, V14, P40, DOI 10.55460/03VO-8FLO; Bhangu A, 2013, INJURY, V44, P1693, DOI 10.1016/j.injury.2012.07.193; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Bulger EM, 2014, PREHOSP EMERG CARE, V18, P163, DOI 10.3109/10903127.2014.896962; Butler FK, 1996, MIL MED, V161, P3, DOI 10.1093/milmed/161.suppl_1.3; Carter JW, 2015, INJURY, V46, P817, DOI 10.1016/j.injury.2014.11.023; Clarke JR, 2002, J TRAUMA, V52, P420, DOI 10.1097/00005373-200203000-00002; Cotton BA, 2009, J TRAUMA, V67, P389, DOI 10.1097/TA.0b013e3181a8b26f; del Junco DJ, 2013, J TRAUMA ACUTE CARE, V75, pS24, DOI 10.1097/TA.0b013e31828fa3b9; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Fortuna G, 2016, J TRAUMA ACUTE CARE, V81, P63, DOI 10.1097/TA.0000000000000996; Gayet-Ageron A, 2018, LANCET, V391, P125, DOI 10.1016/S0140-6736(17)32455-8; Haider AH, 2015, SURGERY, V158, P1687, DOI 10.1016/j.surg.2015.06.026; Harvin JA, 2017, J AM COLL SURGEONS, V225, P200, DOI 10.1016/j.jamcollsurg.2017.04.010; Hatch QM, 2011, J TRAUMA, V70, P1429, DOI 10.1097/TA.0b013e31821b245a; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Holcomb JB, 2011, J TRAUMA, V71, pS318, DOI 10.1097/TA.0b013e318227edbb; Howard JT, 2018, J TRAUMA ACUTE CARE, V84, P11, DOI 10.1097/TA.0000000000001727; Ives C, 2012, J AM COLL SURGEONS, V215, P496, DOI 10.1016/j.jamcollsurg.2012.06.005; Jacobs Lenworth M, 2013, Bull Am Coll Surg, V98, P14; Kasotakis G, 2013, J TRAUMA ACUTE CARE, V74, P1215, DOI 10.1097/TA.0b013e3182826e13; King DR, 2015, J TRAUMA ACUTE CARE, V78, P594, DOI 10.1097/TA.0000000000000561; Kotwal RS, 2016, JAMA SURG, V151, P15, DOI 10.1001/jamasurg.2015.3104; Kragh JF, 2009, ANN SURG, V249, P1, DOI 10.1097/SLA.0b013e31818842ba; Kuckelman J, 2018, J TRAUMA ACUTE CARE; Kwan I, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002245.pub2; Langan NR, 2014, JAMA SURG, V149, P904, DOI 10.1001/jamasurg.2014.940; Lerner EB, 2001, ACAD EMERG MED, V8, P758, DOI 10.1111/j.1553-2712.2001.tb00201.x; McKenney MG, 1996, J TRAUMA, V40, P607, DOI 10.1097/00005373-199604000-00015; Moore LJ, 2016, AM J SURG, V212, P1222, DOI 10.1016/j.amjsurg.2016.09.027; Moore LJ, 2015, J TRAUMA ACUTE CARE, V79, P523, DOI 10.1097/TA.0000000000000809; Pieper A, 2018, J TRAUMA ACUTE CARE, V84, P449, DOI 10.1097/TA.0000000000001794; Pommerening MJ, 2014, SURGERY, V156, P431, DOI 10.1016/j.surg.2014.04.019; Rasmussen TE, 2016, NEW ENGL J MED, V375, P1612, DOI 10.1056/NEJMp1607636; Roberts I, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI [10.3310/hta17100, 10.3310/HTA17100]; ROTONDO MF, 1993, J TRAUMA, V35, P375, DOI 10.1097/00005373-199309000-00008; Saito N, 2015, J TRAUMA ACUTE CARE, V78, P897, DOI 10.1097/TA.0000000000000614; Shakur H, 2017, LANCET, V389, P2105, DOI 10.1016/S0140-6736(17)30638-4; Spaite DW, 2017, JAMA SURG, V152, P360, DOI 10.1001/jamasurg.2016.4686; Sperry JL, 2018, NEW ENGL J MED, V379, P315, DOI 10.1056/NEJMoa1802345; Stinger HK, 2008, J TRAUMA, V64, pS79, DOI 10.1097/TA.0b013e318160a57b; Tran A, 2018, J TRAUMA ACUTE CARE, V84, P802, DOI 10.1097/TA.0000000000001816	49	34	36	2	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 21	2019	380	8					763	770		10.1056/NEJMra1609326	http://dx.doi.org/10.1056/NEJMra1609326			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM0PM	30786189				2023-01-03	WOS:000459149500009
J	Gackler, A; Rohn, H; Lisman, T; Benko, T; Witzke, O; Kribben, A; Saner, FH				Gaeckler, Anja; Rohn, Hana; Lisman, Ton; Benkoe, Tamas; Witzke, Oliver; Kribben, Andreas; Saner, Fuat H.			Evaluation of hemostasis in patients with end stage renal disease	PLOS ONE			English	Article							KIDNEY-DISEASE; PULMONARY-EMBOLISM; RISK; AGGREGOMETRY; ADHESION; FAILURE; POINT	An increased bleeding risk is reported for patients with end-stage renal disease. This study aims to analyze, whether bleeding risk can be assessed by global tests of hemostasis. Standard laboratory tests and an extended evaluation of hemostasis by rotational thromboelastometry, platelet function analyzer (PFA) and multiple electrode aggregometry as well as thrombin generation assays and measurement of fibrinolytic potential were performed in 20 patients on hemodialysis, 10 patients on peritoneal dialysis, 10 patients with chronic kidney disease stage G5 (CKD5) and in 10 healthy controls (HC). Hemoglobin was significantly lower in patients with end-stage renal disease versus HC (each p<0.01). Patients on peritoneal dialysis showed increased fibrinogen levels compared to HC (p<0.01), which were also reflected by FIBTEM results (each p<0.05). 41% of hemodialysis patients and 44% of CKD5 patients presented with prolonged PFA-ADP-test (p<0.05), while no patient on peritoneal dialysis and no HC offered this modification. Thrombin generating potential was significantly lower in patients on hemodialysis, while clot lysis time revealed a hypofibrinolytic state in patients on hemo- and peritoneal dialysis compared to HC (p<0.001). In conclusion, patients with end-stage renal disease have complex hemostatic changes with both hyper- and hypo coagulable features, which are dependent on use and type of dialysis. Hypercoagulable features include elevated fibrinogen levels and a hypofibrinolytic state, whereas hypocoagulable features include decreased thrombin generating capacity and platelet dysfunction. Our results may contribute to a more rational approach to hemostatic management in these patients.	[Gaeckler, Anja; Kribben, Andreas] Univ Duisburg Essen, Univ Hosp Essen, Dept Nephrol, Essen, Germany; [Rohn, Hana; Witzke, Oliver] Univ Duisburg Essen, Univ Hosp Essen, Dept Infect Dis, Essen, Germany; [Lisman, Ton] Univ Groningen, Univ Med Ctr Groningen, Dept Surg, Surg Res Lab, Groningen, Netherlands; [Lisman, Ton] Univ Groningen, Univ Med Ctr Groningen, Dept Surg, Sect Hepatobiliary Surg & Liver Transplantat, Groningen, Netherlands; [Benkoe, Tamas; Saner, Fuat H.] Univ Duisburg Essen, Univ Hosp Essen, Dept Gen Visceral & Transplant Surg, Essen, Germany	University of Duisburg Essen; University of Duisburg Essen; University of Groningen; University of Groningen; University of Duisburg Essen	Gackler, A (corresponding author), Univ Duisburg Essen, Univ Hosp Essen, Dept Nephrol, Essen, Germany.	anja.gaeckler@uk-essen.de	Saner, Fuat H/W-8024-2019	Lisman, Ton/0000-0002-3503-7140				Acedillo RR, 2013, ANN SURG, V258, P901, DOI 10.1097/SLA.0000000000000244; Anemia Work Group, 2012, KIDNEY INT, V2, P279, DOI [DOI 10.1038/kisup.2012.37, DOI 10.1093/NDT/GFT033.13]; Awidi A, 2009, PLATELETS, V20, P297, DOI 10.1080/09537100903006246; Bedreli S, 2017, LIVER INT, V37, P562, DOI 10.1111/liv.13254; Brophy DF, 2014, PERITON DIALYSIS INT, V34, P33, DOI 10.3747/pdi.2013.00036; Cheung KL, 2017, AM J KIDNEY DIS, V70, P182, DOI 10.1053/j.ajkd.2016.10.039; DELASERNA G, 1994, J FAM PRACTICE, V39, P468; Desch S, 2012, CLIN RES CARDIOL, V101, P117, DOI 10.1007/s00392-011-0372-6; GAARDER A., 1961, NATURE, V192, P531, DOI 10.1038/192531a0; Halimeh S, 2010, KLIN PADIATR, V222, P158, DOI 10.1055/s-0030-1249081; Hemker HC, 2002, PATHOPHYSIOL HAEMO T, V32, P249, DOI 10.1159/000073575; HOROWITZ HI, 1970, ARCH INTERN MED, V126, P823, DOI 10.1001/archinte.126.5.823; Jambor C, 2009, ANESTH ANALG, V109, P25, DOI 10.1213/ane.0b013e3181a27d10; Lisman T, 2017, SEMIN THROMB HEMOST, V43, P178, DOI 10.1055/s-0036-1585081; Lu HY, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882-018-0989-z; Lutz J, 2014, NEPHROL DIAL TRANSPL, V29, P29, DOI 10.1093/ndt/gft209; MARTIN W, 1985, J PHARMACOL EXP THER, V233, P679; Mohapatra A, 2018, INDIAN J NEPHROL, V28, P135, DOI 10.4103/ijn.IJN_104_17; Nieuwenhuijs-Moeke GJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200537; Ocak G, 2013, J THROMB HAEMOST, V11, P627, DOI 10.1111/jth.12141; Ocak G, 2012, J THROMB HAEMOST, V10, P2484, DOI 10.1111/j.1538-7836.2012.04921.x; Pavord S, 2011, BLOOD REV, V25, P271, DOI 10.1016/j.blre.2011.07.001; REMUZZI G, 1978, NEPHRON, V22, P347, DOI 10.1159/000181474; Shlipak MG, 2003, CIRCULATION, V107, P87, DOI 10.1161/01.CIR.0000042700.48769.59; Sibbing D, 2008, THROMB HAEMOSTASIS, V99, P121, DOI 10.1160/TH07-07-0478; Tanhehco YC, 2012, SEMIN DIALYSIS, V25, P539, DOI 10.1111/j.1525-139X.2012.01089.x; Wang IK, 2017, NEPHROL DIAL TRANSPL, V32, P1386, DOI 10.1093/ndt/gfw272; ZWAGINGA JJ, 1991, ARTERIOSCLER THROMB, V11, P733, DOI 10.1161/01.ATV.11.3.733; ZWAGINGA JJ, 1990, BLOOD, V75, P1498	29	25	26	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2019	14	2							e0212237	10.1371/journal.pone.0212237	http://dx.doi.org/10.1371/journal.pone.0212237			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM2OT	30785941	Green Submitted, Green Published, gold			2023-01-03	WOS:000459307000053
J	Murphy, C; Muscat, A; Ashley, D; Mukaro, V; West, L; Liao, Y; Chisanga, D; Shi, W; Collins, I; Baron-Hay, S; Patil, S; Lindeman, G; Khasraw, M				Murphy, Caitlin; Muscat, Andrea; Ashley, David; Mukaro, Violet; West, Linda; Liao, Yang; Chisanga, David; Shi, Wei; Collins, Ian; Baron-Hay, Sally; Patil, Sujata; Lindeman, Geoffrey; Khasraw, Mustafa			Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response	PLOS ONE			English	Article							HOMOLOGOUS RECOMBINATION DEFICIENCY; PREDICTS RESPONSE; SYSTEMIC THERAPY; SWI/SNF COMPLEX; CHEMOTHERAPY; EXPRESSION; EVOLUTION; TUMORS; MUTATIONS; REPAIR	Background This study evaluated the feasibility of achieving high response rates in stage II or III breast cancer by tailoring neoadjuvant therapy using clinical and histopathological features and the Oncotype DX Breast Recurrence Score. Genomic determinants of response and resistance were also explored. Patients and outcome measures Fifty-one patients were enrolled. The primary cohort comprised 40 patients: 15 human epidermal growth factor receptor type 2 (HER2)-amplified; 15 triple-negative (TNBC); and ten hormone receptor (HR)-positive, HER2-non-amplified tumours; with recurrence scores >= 25. Patients were treated with epirubicin and cyclophosphamide, followed by nab-paclitaxel, with the addition of trastuzumab if HER2-amplified. The primary endpoint was pathological complete response (pCR) in the breast. Pre- and post-treatment tumour samples underwent variant burden, gene and gene pathway, mutational signature profile and clonal evolution analyses. Results The pCR rates were: overall 55% (n = 22), HER2-amplified 80% (n = 12), triple-negative 46% (n = 7) and HR-positive, HER2-non-amplified 30% (n = 3). Grade 3 or 4 adverse events included febrile neutropenia (8%), neutropenia (18%), sensory neuropathy (5%), deranged transaminases (5%), fatigue (2%), diarrhoea (2%), and pneumothorax (2%). Molecular analyses demonstrated strong similarities between residual disease and matched primary tumour. ATM signalling pathway alterations and the presence of a COSMIC Signature 3 implied the majority of tumours contained some form of homologous repair deficiency. ATM pathway alterations were identified in the subset of TNBC patients who did not achieve pCR; Signature 3 was present in both pCR and non-pCR subgroups. Clonal evolution analyses demonstrated both persistence and emergence of chemoresistant clones. Conclusions This treatment regime resulted in a high rate of pCR, demonstrating that tailored neoadjuvant therapy using a genomic recurrence score is feasible and warrants further investigation. Molecular analysis revealed few commonalities between patients. For TNBC future clinical gains will require precision medicine, potentially using DNA sequencing to identify specific targets for individuals with resistant disease.	[Murphy, Caitlin; Ashley, David; Mukaro, Violet; West, Linda; Khasraw, Mustafa] Univ Hosp Geelong, Geelong, Vic, Australia; [Murphy, Caitlin; Muscat, Andrea; Ashley, David; Mukaro, Violet; Collins, Ian; Khasraw, Mustafa] Deakin Univ, Sch Med, Geelong, Vic, Australia; [Ashley, David] Duke Univ, Preston Robert Tisch Brain Tumor Ctr, Durham, NC USA; [West, Linda] Lake Imaging, Geelong, Vic, Australia; [Liao, Yang; Chisanga, David; Shi, Wei; Lindeman, Geoffrey] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia; [Collins, Ian] South West Hlth Care, Warrnambool, Vic, Australia; [Baron-Hay, Sally] Royal North Shore Hosp, St Leonards, NSW, Australia; [Baron-Hay, Sally] North Shore Private Hosp, St Leonards, NSW, Australia; [Patil, Sujata] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Khasraw, Mustafa] Univ Sydney, Natl Hlth & Med Res Council, Clin Trials Ctr, Sydney, NSW, Australia	Geelong Hospital; Deakin University; Duke University; Walter & Eliza Hall Institute; Royal North Shore Hospital; Memorial Sloan Kettering Cancer Center; University of Sydney	Khasraw, M (corresponding author), Univ Hosp Geelong, Geelong, Vic, Australia.; Khasraw, M (corresponding author), Deakin Univ, Sch Med, Geelong, Vic, Australia.; Khasraw, M (corresponding author), Univ Sydney, Natl Hlth & Med Res Council, Clin Trials Ctr, Sydney, NSW, Australia.	mustafa.khasraw@ctc.usyd.edu.au	Khasraw, Mustafa/ABH-5962-2020; Chisanga, David/AAB-1751-2019; Collins, Ian M/AAS-4527-2020	Khasraw, Mustafa/0000-0003-3249-9849; Chisanga, David/0000-0002-0421-3957; Collins, Ian M/0000-0001-6936-0942; Lindeman, Geoffrey/0000-0001-9386-2416; , Yang/0000-0002-9746-2839; Mukaro, Violet/0000-0002-3968-6551	Specialised Therapeutics Australia; National Medical Health and Research Council of Australia Centre of Research Excellence Grant [1040978]; Tuck Family Scholarship; Walter and Eliza Hall Institute Centenary Fellowship - CSL	Specialised Therapeutics Australia; National Medical Health and Research Council of Australia Centre of Research Excellence Grant; Tuck Family Scholarship; Walter and Eliza Hall Institute Centenary Fellowship - CSL	This study was funded by an unrestricted research grant from Specialised Therapeutics Australia, a National Medical Health and Research Council of Australia Centre of Research Excellence Grant (#1040978) and a Tuck Family Scholarship. Lake Imaging, Geelong, VIC, Australia provided support in the form of a salary for author LW. These funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.; We would like to thank Christoffer Flensburg and Christophe Lefevre for their help in clonality analysis. WS is supported by a Walter and Eliza Hall Institute Centenary Fellowship sponsored by CSL.	Awasthi P, 2015, J CELL SCI, V128, P4255, DOI 10.1242/jcs.169730; Balko JM, 2014, CANCER DISCOV, V4, P232, DOI 10.1158/2159-8290.CD-13-0286; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Castrellon AB, 2017, ONCOL REV, V11, DOI 10.4081/oncol.2017.324; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Davies H, 2017, NAT MED, V23, P517, DOI 10.1038/nm.4292; den Brok Wendie D, 2017, JCO Precis Oncol, V1, P1, DOI 10.1200/PO.16.00031; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Flensburg C., SUPERFREQ 2018; Geisler S, 2001, CANCER RES, V61, P2505; Gonzalez-Angulo AM, 2012, CLIN CANCER RES, V18, P1109, DOI 10.1158/1078-0432.CCR-11-2762; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Isakoff SJ, 2015, J CLIN ONCOL, V33, P1902, DOI 10.1200/JCO.2014.57.6660; Iwamoto T, 2011, J NATL CANCER I, V103, P264, DOI 10.1093/jnci/djq524; Jiang T, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002193; Jones RL, 2006, BRIT J CANCER, V94, P358, DOI 10.1038/sj.bjc.6602950; Katagiri A, 2012, MODERN PATHOL, V25, P282, DOI 10.1038/modpathol.2011.161; Khasraw M, 2012, EXPERT REV ANTICANC, V12, P1005, DOI [10.1586/ERA.12.62, 10.1586/era.12.62]; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Li H., 2013, ARXIV PREPRINT; Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214; Lu C, 2017, NAT GENET, V49, P178, DOI 10.1038/ng.3779; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Miao D, 2018, SCIENCE, V359, P801, DOI 10.1126/science.aan5951; Miller RE, 2016, MOL CANCER THER, V15, P1472, DOI 10.1158/1535-7163.MCT-15-0554; Nik-Zainal S, 2017, CLIN CANCER RES, V23, P2617, DOI 10.1158/1078-0432.CCR-16-2810; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Polak P, 2017, NAT GENET, V49, P1476, DOI 10.1038/ng.3934; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Robidoux A, 2010, CLIN BREAST CANCER, V10, P81, DOI 10.3816/CBC.2010.n.011; Rosenthal R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0893-4; Savas P, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002204; Sharma P, 2018, ANN ONCOL, V29, P654, DOI 10.1093/annonc/mdx821; Shi W, 2017, ANN ONCOL, V28, P128, DOI 10.1093/annonc/mdw434; Shi WLY, SUBREAD 2018; Sparano JA, 2018, NEW ENGL J MED, V379, P111, DOI 10.1056/NEJMoa1804710; Swanton C, 2015, CANCER DISCOV, V5, P704, DOI 10.1158/2159-8290.CD-15-0344; Taylor KN, 2018, RECENT PAT ANTI-CANC, V13, P145, DOI 10.2174/1574892813666171204094822; Telli ML, 2018, BREAST CANCER RES TR, V168, P625, DOI 10.1007/s10549-017-4624-7; Telli ML, 2016, CLIN CANCER RES, V22, P3764, DOI 10.1158/1078-0432.CCR-15-2477; Turner KM, 2017, NATURE, V543, P122, DOI 10.1038/nature21356; Stormo Gary D, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1110s43, 10.1002/0471250953.bi1201s43]; von Minckwitz G, 2012, J CLIN ONCOL, V30, P1796, DOI 10.1200/JCO.2011.38.8595; Williamson CT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13837; Yates LR, 2017, CANCER CELL, V32, P169, DOI 10.1016/j.ccell.2017.07.005; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Ye J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-134; Zhao EY, 2017, CLIN CANCER RES, V23, P7521, DOI 10.1158/1078-0432.CCR-17-1941	51	9	11	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2019	14	2							e0210891	10.1371/journal.pone.0210891	http://dx.doi.org/10.1371/journal.pone.0210891			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL5JX	30763338	Green Published, gold			2023-01-03	WOS:000458763900009
J	Li, XF; Rombouts, W; van der Gucht, J; de Vries, R; Dijksman, JA				Li, Xiufeng; Rombouts, Wolf; van der Gucht, Jasper; de Vries, Renko; Dijksman, Joshua A.			Mechanics of composite hydrogels approaching phase separation	PLOS ONE			English	Article							SECRETED PRODUCTION; TOUGH; GELATIN; GELS	For polymer-particle composites, limited thermodynamic compatibility of polymers and particles often leads to poor dispersal and agglomeration of the particles in the matrix, which negatively impacts the mechanics of composites. To study the impact of particle compatibility in polymer matrices on the mechanical properties of composites, we here study composite silica-protein based hydrogels. The polymer used is a previously studied telechelic protein-based polymer with end groups that form triple helices, and the particles are silica nanoparticles that only weakly associate with the polymer matrix. At 1mM protein polymer, up to 7% of silica nanoparticles can be embedded in the hydrogel. At higher concentrations the system phase separates. Oscillatory rheology shows that at high frequencies the particles strengthen the gels by acting as short-lived multivalent cross-links, while at low frequencies, the particles reduce the gel strength, presumably by sequestering part of the protein polymers in such a way that they can no longer contribute to the network strength. As is generally observed for polymer/particle composites, shear-induced polymer desorption from the particles leads to a viscous dissipation that strongly increases with increasing particle concentration. While linear rheological properties as function of particle concentration provide no signals for an approaching phase separation, this is very different for the non-linear rheology, especially fracture. Strain-at-break decreases rapidly with increasing particle concentration and vanishes as the phase boundary is approached, suggesting that the interfaces between regions of high and low particle densities in composites close to phase separation provide easy fracture planes.	[Li, Xiufeng; Rombouts, Wolf; van der Gucht, Jasper; de Vries, Renko; Dijksman, Joshua A.] Wageningen Univ & Res, Phys Chem & Soft Matter, Stippeneng 4, NL-6708WE Wageningen, Netherlands	Wageningen University & Research	Dijksman, JA (corresponding author), Wageningen Univ & Res, Phys Chem & Soft Matter, Stippeneng 4, NL-6708WE Wageningen, Netherlands.	joshua.dijksman@wur.nl	van der Gucht, Jasper/C-4639-2015	van der Gucht, Jasper/0000-0001-5525-8322; Li, Xiufeng/0000-0002-7615-4693	European Research Council [2015 CoG 682782]; Nederlandse Organisatie voor Wetenschappelijk Onderzoek, Unilever; TKI Agro-Food: Industrial Partnership Program [i41]	European Research Council(European Research Council (ERC)European Commission); Nederlandse Organisatie voor Wetenschappelijk Onderzoek, Unilever; TKI Agro-Food: Industrial Partnership Program	This work was supported by European Research Council (2015 CoG 682782, https://cordis.europa.eu/project/rcn/204138_en.html, JvdG) and Nederlandse Organisatie voor Wetenschappelijk Onderzoek, Unilever, TKI Agro-Food: Industrial Partnership Program i41 (https://www.nwo-i.nl/en/nwo-domain-science/research-programmes/ipp/nr-i41-hybrid-soft-materials-from-physical-mechanisms-to-designer-products/, JvdG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal SK, 2008, LANGMUIR, V24, P13148, DOI 10.1021/la8015518; Balazs AC, 2007, NAT MATER, V6, P94, DOI 10.1038/nmat1820; Dadsetan M, 2008, BIOMATERIALS, V29, P2193, DOI 10.1016/j.biomaterials.2008.01.006; ESHELBY JD, 1957, PROC R SOC LON SER-A, V241, P376, DOI 10.1098/rspa.1957.0133; Gerth M, 2014, MACROMOL RAPID COMM, V35, P2065, DOI 10.1002/marc.201400543; GUTH E, 1945, J APPL PHYS, V16, P20, DOI 10.1063/1.1707495; Hooper JB, 2006, MACROMOLECULES, V39, P5133, DOI 10.1021/ma060577m; Hribar KC, 2014, ADV FUNCT MATER, V24, P4922, DOI 10.1002/adfm.201400274; Juby KA, 2012, CARBOHYD POLYM, V89, P906, DOI 10.1016/j.carbpol.2012.04.033; Lee JY, 2002, MACROMOLECULES, V35, P4855, DOI 10.1021/ma0200266; Lemmers M, 2012, LANGMUIR, V28, P12311, DOI 10.1021/la301917e; Pimenta AFR, 2016, INT J PHARMACEUT, V515, P467, DOI 10.1016/j.ijpharm.2016.10.047; Qiao R, 2011, J POLYM SCI POL PHYS, V49, P740, DOI 10.1002/polb.22236; Silva CIF, 2011, BIOTECHNOL BIOENG, V108, P2517, DOI 10.1002/bit.23228; Skrzeszewska PJ, 2010, MACROMOLECULES, V43, P3542, DOI 10.1021/ma1000173; Skrzeszewska PJ, 2009, SOFT MATTER, V5, P2057, DOI 10.1039/b819967a; Smallwood HM, 1944, J APPL PHYS, V15, P758, DOI 10.1063/1.1707385; Tang C, 2014, INT J PHARMACEUT, V465, P427, DOI 10.1016/j.ijpharm.2014.02.039; Teng WQ, 2014, BIOMATERIALS, V35, P8916, DOI 10.1016/j.biomaterials.2014.07.013; Thompson RB, 2001, SCIENCE, V292, P2469, DOI 10.1126/science.1060585; Vulic K, 2012, J AM CHEM SOC, V134, P882, DOI 10.1021/ja210638x; Wang LY, 2014, SOFT MATTER, V10, P3850, DOI 10.1039/c4sm00206g; Wang Q, 2012, SOFT MATTER, V8, P6048, DOI 10.1039/c2sm07233e; Warren SC, 2007, NAT MATER, V6, P156, DOI 10.1038/nmat1819; Werten MWT, 2009, BIOMACROMOLECULES, V10, P1106, DOI 10.1021/bm801299u; Werten MWT, 2001, PROTEIN ENG, V14, P447, DOI 10.1093/protein/14.6.447; Yue K, 2015, BIOMATERIALS, V73, P254, DOI 10.1016/j.biomaterials.2015.08.045; Zhang YL, 2012, CHEM COMMUN, V48, P9305, DOI 10.1039/c2cc34745h; Zhu JM, 2011, EXPERT REV MED DEVIC, V8, P607, DOI [10.1586/ERD.11.27, 10.1586/erd.11.27]	29	8	8	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2019	14	1							e0211059	10.1371/journal.pone.0211059	http://dx.doi.org/10.1371/journal.pone.0211059			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ2YV	30682112	Green Submitted, gold, Green Published			2023-01-03	WOS:000457037500095
J	Frahm, N; Hecker, M; Zettl, UK				Frahm, Niklas; Hecker, Michael; Zettl, Uwe Klaus			Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: A single-center study	PLOS ONE			English	Article							HEALTH; PEOPLE; ASSOCIATION; LIFE; INFLAMMATION; DISABILITY; EDUCATION; FATIGUE	Background Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system. Given the chronic and heterogenous nature of the disease, treatment with various therapies is a frequent scenario in clinical practice. In persons with chronic morbidity such as MS patients, polypharmacy can give rise to considerable health problems. Objectives The aim of the present study was to examine the frequency of polypharmacy among relapsing-remitting (RR) MS patients as well as to analyse sociodemographic and clinical factors, which might be associated with polypharmacy (use of five or more medications). Differences in medication between MS patients with and without secondary illnesses (PwSI and Pw/oSI), between men and women and between patients with and without polypharmacy (PwP and Pw/oP) were examined. Methods For 145 RRMS outpatients, we prospectively collected data by means of anamnesis, patient records, clinical examination and a structured patient interview. This was followed by comparative analyses of various patient subgroups (PwP vs. Pw/oP, PwSI vs. Pw/oSI, men vs. women). Results The proportion of included MS patients with polypharmacy (use of >= 5 medications) was 30.3%. PwP were significantly older than Pw/oP (45.9 vs. 41.7 years), had a lower level of education and showed a significantly higher median EDSS score (3.0 vs. 2.0). Comorbidities (p<0.001; odds ratio [OR] = 6.293) and higher EDSS scores (p = 0.029; OR = 1.440) were associated with a higher risk of polypharmacy. The proportion of polypharmacy among PwSI was approximately four times higher than among Pw/oSI (46.8% vs. 11.8%). Particularly in the use of antihypertensives, gastrointestinal drugs and dietary supplements, there were differences between Pw/oP and PwP. Conclusion We found a high burden of polypharmacy in patients with RRMS. This particularly applies to more severely disabled MS patients who suffer from comorbidities.	[Frahm, Niklas; Hecker, Michael; Zettl, Uwe Klaus] Univ Rostock, Neuroimmunol Sect, Dept Neurol, Rostock, Germany	University of Rostock	Frahm, N (corresponding author), Univ Rostock, Neuroimmunol Sect, Dept Neurol, Rostock, Germany.	niklas-frahm@gmx.de		Frahm, Niklas/0000-0002-4655-774X; Hecker, Michael/0000-0001-7015-3094				Altenhoner T, 2014, GESUNDHEITSWESEN, V76, P19, DOI 10.1055/s-0033-1333729; Ayache SS, 2015, J NEUROL SCI, V358, P351, DOI 10.1016/j.jns.2015.09.360; Bazargan M, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0558-5; Beiske GAG, 2015, MULT SCLER INT, V2015, DOI 10.1155/2015/317859; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bjerrum L, 1997, EUR J CLIN PHARMACOL, V53, P7, DOI 10.1007/s002280050329; Brager R, 2005, NURSE PRACT, V30, P44, DOI 10.1097/00006205-200506000-00008; Broekmans T, 2011, MULT SCLER J, V17, P468, DOI 10.1177/1352458510391339; Browne P, 2014, NEUROLOGY, V83, P1022, DOI 10.1212/WNL.0000000000000768; Cakit BD, 2010, AM J PHYS MED REHAB, V89, P446, DOI 10.1097/PHM.0b013e3181d3e71f; Cattaneo D, 2007, CLIN REHABIL, V21, P771, DOI 10.1177/0269215507077602; Cree BAC, 2016, CURR OPIN NEUROL, V29, P263, DOI 10.1097/WCO.0000000000000332; Dargahi N, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7070078; Delcher A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141779; Dennison L, 2010, EXPERT REV NEUROTHER, V10, P1383, DOI [10.1586/ern.10.111, 10.1586/ERN.10.111]; DUQUETTE P, 1995, NEUROLOGY, V45, P1277; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Ellouzi I., 2018, PROCEEDINGS, V3, P3; Evans C, 2017, PHARMACOEPIDEM DR S, V26, P702, DOI 10.1002/pds.4207; Faries D, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-26; Fulton Maryann M, 2005, J Am Acad Nurse Pract, V17, P123, DOI 10.1111/j.1041-2972.2005.0020.x; Gupta S, 2014, CNS DRUGS, V28, P731, DOI 10.1007/s40263-014-0173-3; Guthrie B, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0322-7; Haider SI, 2008, CLIN THER, V30, P419, DOI 10.1016/j.clinthera.2008.02.010; Houtchens MK, 2017, MULT SCLER J, V23, P757, DOI 10.1177/1352458517701314; James T, 2018, HUM MOL GENET, V27, P912, DOI 10.1093/hmg/ddy001; Jelinek GA, 2015, NEUROL RES, V37, P662, DOI 10.1179/1743132815Y.0000000036; Jorgensen T, 2001, ANN PHARMACOTHER, V35, P1004, DOI 10.1345/aph.10351; Kawachi I, 2017, J NEUROL NEUROSUR PS, V88, P137, DOI 10.1136/jnnp-2016-313300; Koutsis G, 2016, MULT SCLER RELAT DIS, V9, P140, DOI 10.1016/j.msard.2016.07.009; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Laroni A, 2017, NEUROLOGY, V89, P2222, DOI 10.1212/WNL.0000000000004686; Lentjes MAH, 2018, P NUTR SOC, V78, P1; Linjakumpu T, 2002, J CLIN EPIDEMIOL, V55, P809, DOI 10.1016/S0895-4356(02)00411-0; Maher RL, 2014, EXPERT OPIN DRUG SAF, V13, P57, DOI 10.1517/14740338.2013.827660; Markowitz CE, 2013, AM J MANAG CARE, V19, pS294; Marrie RA, 2009, NEUROLOGY, V72, P117, DOI 10.1212/01.wnl.0000333252.78173.5f; MATHUR R, 2011, BRIT J GEN PRACT, V61; Murphy KL, 2017, MULTIPLE SCLEROSIS: PERSPECTIVES IN TREATMENT AND PATHOGENESIS, P53, DOI 10.15586/codon.multiplesclerosis.2017.ch4; O'Brien SK, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101154; O'Connor K, 2012, J NEUROL, V259, P637, DOI 10.1007/s00415-011-6226-3; Olafsson S, 2017, NPJ GENOM MED, V2, DOI 10.1038/s41525-017-0027-2; Onder G, 2012, J GERONTOL A-BIOL, V67, P698, DOI 10.1093/gerona/glr233; Patejdl R, 2017, AUTOIMMUN REV, V16, P925, DOI 10.1016/j.autrev.2017.07.004; Patejdl R, 2016, AUTOIMMUN REV, V15, P210, DOI 10.1016/j.autrev.2015.11.005; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; Payne RA, 2016, CLIN MED, V16, P465, DOI 10.7861/clinmedicine.16-5-465; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366; Reich DS, 2018, NEW ENGL J MED, V378, P169, DOI 10.1056/NEJMra1401483; Riccio P, 2015, ASN NEURO, V7, DOI 10.1177/1759091414568185; Richardson K, 2011, DRUG AGING, V28, P547, DOI 10.2165/11592000-000000000-00000; Sganga F, 2015, GERIATR GERONTOL INT, V15, P141, DOI 10.1111/ggi.12241; Solaro C, 2018, CNS DRUGS, V32, P117, DOI 10.1007/s40263-018-0489-5; Thelen JM, 2014, J PSYCHOSOM RES, V76, P400, DOI 10.1016/j.jpsychores.2014.02.013; van der Heide I, 2013, J HEALTH COMMUN, V18, P172, DOI 10.1080/10810730.2013.825668; Wingerchuk DM, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i3518; Zettl UK, 2018, EXPERT REV CLIN IMMU, V14, P137, DOI 10.1080/1744666X.2018.1426462	58	11	11	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2019	14	1							e0211120	10.1371/journal.pone.0211120	http://dx.doi.org/10.1371/journal.pone.0211120			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HI8IY	30677078	Green Published, Green Submitted, gold			2023-01-03	WOS:000456700400051
J	Brown, LB; Getahun, M; Ayieko, J; Kwarisiima, D; Owaraganise, A; Atukunda, M; Olilo, W; Clark, T; Bukusi, EA; Cohen, CR; Kamya, MR; Petersen, ML; Charlebois, ED; Havlir, DV; Camlin, CS				Brown, Lillian B.; Getahun, Monica; Ayieko, James; Kwarisiima, Dalsone; Owaraganise, Asiphas; Atukunda, Mucunguzi; Olilo, Winter; Clark, Tamara; Bukusi, Elizabeth A.; Cohen, Craig R.; Kamya, Moses R.; Petersen, Maya L.; Charlebois, Edwin D.; Havlir, Diane V.; Camlin, Carol S.			Factors predictive of successful retention in care among HIV-infected men in a universal test-and-treat setting in Uganda and Kenya: A mixed methods analysis	PLOS ONE			English	Article							ANTIRETROVIRAL TREATMENT OUTCOMES; GENDER-DIFFERENCES; TREATMENT PROGRAM; MASCULINITY; AFRICA; RISK; COHORT; SEX	Background Previous research indicates clinical outcomes among HIV-infected men in sub-Saharan Africa are sub-optimal. The SEARCH test and treat trial (NCT01864603) intervention included antiretroviral care delivery designed to address known barriers to HIV-care among men by decreasing clinic visit frequency and providing flexible, patient-centered care with retention support. We sought to understand facilitators and barriers to retention in care in this universal treatment setting through quantitative and qualitative data analysis. Methods We used a convergent mixed methods study design to evaluate retention in HIV care among adults (age > = 15) during the first year of the SEARCH (NCT01864603) test and treat trial. Cox proportional hazards regression was used to evaluate predictors of retention in care. Longitudinal qualitative data from n = 190 in-depth interviews with HIV-positive individuals and health care providers were analyzed to identify facilitators and barriers to HIV care engagement. Results There were 1,863 men and 3,820 women who linked to care following baseline testing. Retention in care was 89.7% (95% CI 87.0-91.8%) among men and 89.0% (86.8-90.9%) among women at one year. In both men and women older age was associated with higher rates of retention in care at one year. Additionally, among men higher CD4+ at ART initiation and decreased time between testing and ART initiation was associated with higher rates of retention. Maintaining physical health, a patient-centered treatment environment, supportive partnerships, few negative consequences to disclosure, and the ability to seek care in facilities outside of their community of residence were found to promote retention in care. Conclusions Features of the ART delivery system in the SEARCH intervention and social and structural advantages emerged as facilitators to retention in HIV care among men. Messaging around the health benefits of early ART start, decreasing logistical barriers to HIV care, support of flexible treatment environments, and accelerated linkage to care, are important to men's success in ART treatment programs. Men already benefit from increased social support following disclosure of their HIV-status. Future efforts to shift gender norms towards greater equity are a potential strategy to support high levels of engagement in care for both men and women.	[Brown, Lillian B.; Clark, Tamara; Havlir, Diane V.] Univ Calif San Francisco, Div HIV ID & Global Med, San Francisco, CA 94143 USA; [Brown, Lillian B.; Charlebois, Edwin D.; Camlin, Carol S.] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA; [Getahun, Monica; Cohen, Craig R.; Camlin, Carol S.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA; [Ayieko, James; Atukunda, Mucunguzi; Olilo, Winter; Bukusi, Elizabeth A.] Kenya Govt Med Res Ctr, Kisumu, Kenya; [Kwarisiima, Dalsone; Owaraganise, Asiphas; Kamya, Moses R.] Infect Dis Res Collaborat, Kampala, Uganda; [Kamya, Moses R.] Makerere Univ, Coll Hlth Sci, Kampala, Uganda; [Petersen, Maya L.] Univ Calif Berkeley, Sch Publ Hlth, Div Biostat, Berkeley, CA 94720 USA; [Petersen, Maya L.] Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kenya Medical Research Institute; Makerere University; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Brown, LB (corresponding author), Univ Calif San Francisco, Div HIV ID & Global Med, San Francisco, CA 94143 USA.; Brown, LB (corresponding author), Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA.	lillian.brown@ucsf.edu	Olilo, Winter/AAN-2778-2020	Brown, Lillian/0000-0003-1809-3762; Getahun, Monica/0000-0002-2116-2637; Cohen, Craig/0000-0001-8654-6634; Owaraganise, Asiphas/0000-0002-5594-0310	Division of AIDS, NIAID, of the National Institutes of Health [U01AI099959]; President's Emergency Plan for AIDS Relief; Bill and Melinda Gates Foundation; Gilead Sciences; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI099959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019105, P30MH062246] Funding Source: NIH RePORTER	Division of AIDS, NIAID, of the National Institutes of Health; President's Emergency Plan for AIDS Relief(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Gilead Sciences(Gilead Sciences); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Research reported in this manuscript was supported by Division of AIDS, NIAID, of the National Institutes of Health under award number U01AI099959 (DVH) and in part by the President's Emergency Plan for AIDS Relief, the Bill and Melinda Gates Foundation, and Gilead Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beckham SW, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.21106; Bor J, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001905; Boulle C, 2015, JAIDS-J ACQ IMM DEF, V69, P355, DOI 10.1097/QAI.0000000000000604; Brown LB, 2016, AIDS, V30, P2855, DOI 10.1097/QAD.0000000000001250; Camlin CS, 2016, AIDS CARE, V28, P67, DOI 10.1080/09540121.2016.1164806; Camlin CS, 2016, AIDS, V30, P495, DOI 10.1097/QAD.0000000000000931; Chamie G, 2016, LANCET HIV, V3, pE111, DOI 10.1016/S2352-3018(15)00251-9; Charmaz K., 2014, CONSTRUCTING GROUNDE, Vsecond; Connell RW, 2005, GENDER SOC, V19, P829, DOI 10.1177/0891243205278639; Cornell M, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001304; Creswell JW, 2021, CONCISE INTRO MIXED; Dovel K, 2015, AIDS, V29, P1123, DOI 10.1097/QAD.0000000000000655; Druyts E, 2013, AIDS, V27, P417, DOI 10.1097/QAD.0b013e328359b89b; Fleming PJ, 2016, AIDS, V30, P157, DOI 10.1097/QAD.0000000000000899; Geng EH, 2016, CLIN INFECT DIS, V62, P935, DOI 10.1093/cid/civ1004; Hawkins C, 2011, AIDS, V25, P1189, DOI 10.1097/QAD.0b013e3283471deb; Kahn J. G., 2016, 21 INT AIDS C DURB S; Kipp W, 2010, AIDS CARE, V22, P271, DOI 10.1080/09540120903193625; Kranzer K, 2010, JAIDS-J ACQ IMM DEF, V55, pE17, DOI 10.1097/QAI.0b013e3181f275fd; Kwarisiima D, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.5.21673; Maeri I, 2016, AIDS CARE, V28, P59, DOI 10.1080/09540121.2016.1168917; Marson KG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078900; Mburu G, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1061; Mosha F, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-38; Nyamhanga TM, 2013, TANZANIA GLOBAL HLTH, V6, P21812, DOI DOI 10.3402/GHA.V6I0.21812; Ochieng-Ooko V, 2010, B WORLD HEALTH ORGAN, V88, P681, DOI 10.2471/BLT.09.064329; Penot P, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.18646; Siu GE, 2013, SOC SCI MED, V89, P45, DOI 10.1016/j.socscimed.2013.04.025; Siu GE, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.3.17368; Skovdal M, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-13; Staveteig S., 2013, DEMOGRAPHIC PATTERNS; Takarinda KC, 2015, INT J INFECT DIS, V30, P98, DOI 10.1016/j.ijid.2014.11.009; Tsai AC, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001906; UNAIDS, 2015, AIDS NUMB 2015; Wringe A, 2009, AIDS CARE, V21, P632, DOI 10.1080/09540120802385629	35	21	21	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2019	14	1							e0210126	10.1371/journal.pone.0210126	http://dx.doi.org/10.1371/journal.pone.0210126			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HI4TC	30673744	Green Published, gold, Green Submitted			2023-01-03	WOS:000456442800032
J	Vinogradova, Y; Coupland, C; Hippisley-Cox, J				Vinogradova, Yana; Coupland, Carol; Hippisley-Cox, Julia			Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTMENOPAUSAL WOMEN	OBJECTIVE To assess the association between risk of venous thromboembolism and use of different types of hormone replacement therapy. DESIGN Two nested case-control studies. SETTING UK general practices contributing to the QResearch or Clinical Practice Research Datalink (CPRD) databases, and linked to hospital, mortality, and social deprivation data. PARTICIPANTS 80 396 women aged 40-79 with a primary diagnosis of venous thromboembolism between 1998 and 2017, matched by age, general practice, and index date to 391 494 female controls. MAIN OUTCOME MEASURES Venous thromboembolism recorded on general practice, mortality, or hospital records. Odds ratios were adjusted for demographics, smoking status, alcohol consumption, comorbidities, recent medical events, and other prescribed drugs. RESULTS Overall, 5795 (7.2%) women who had venous thromboembolism and 21 670 (5.5%) controls had been exposed to hormone replacement therapy within 90 days before the index date. Of these two groups, 4915 (85%) and 16 938 (78%) women used oral therapy, respectively, which was associated with a significantly increased risk of venous thromboembolism compared with no exposure (adjusted odds ratio 1.58, 95% confidence interval 1.52 to 1.64), for both oestrogen only preparations (1.40, 1.32 to 1.48) and combined preparations (1.73, 1.65 to 1.81). Estradiolhad a lower risk than conjugated equine oestrogen for oestrogen only preparations (0.85, 0.76 to 0.95) and combined preparations (0.83, 0.76 to 0.91). Compared with no exposure, conjugated equine oestrogen with medroxyprogesterone acetate had the highest risk (2.10, 1.92 to 2.31), and estradiol with dydrogesterone had the lowest risk (1.18, 0.98 to 1.42). Transdermal preparations were not associated with risk of venous thromboembolism, which was consistent for different regimens (overall adjusted odds ratio 0.93, 95% confidence interval 0.87 to 1.01). CONCLUSIONS In the present study, transdermal treatment was the safest type of hormone replacement therapy when risk of venous thromboembolism was assessed. Transdermal treatment appears to be underused, with the overwhelming preference still for oral preparations.	[Vinogradova, Yana; Coupland, Carol; Hippisley-Cox, Julia] Univ Nottingham, Div Primary Care, Nottingham NG2 7RD, England	University of Nottingham	Vinogradova, Y (corresponding author), Univ Nottingham, Div Primary Care, Nottingham NG2 7RD, England.	Yana.Vinogradova@nottingham.ac.uk	Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283; Vinogradova, Yana/0000-0002-3030-5257	NIHR	NIHR(National Institute for Health Research (NIHR))	We acknowledge the contribution of EMIS (Egton Medical Information Systems) practices who contribute to the QResearch database and EMIS, and the University of Nottingham for expertise in establishing, developing, and supporting the QResearch database. The hospital episode statistics data used in this analysis are re-used by permission from NHS Digital who retain the copyright. We thank the Office of National Statistics (ONS) for providing the mortality data. ONS and NHS Digital bear no responsibility for the analysis or interpretation of the data. QResearch acknowledges funding from the NIHR funded Nottingham Biomedical Research Centre. Mohammed Mustafa (Division of Population Medicine, School of Medicine, Cardiff University) contributed advice, in particular on the pharmacology of treatments and decisions made in the prescribing process, at an early stage of the study and we are grateful for his input.	Adomaityte J, 2008, THROMB HAEMOSTASIS, V99, P338, DOI 10.1160/TH07-07-0468; Altman DG, 1999, BRIT MED J, V319, P1492, DOI 10.1136/bmj.319.7223.1492; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Canonico M, 2007, CIRCULATION, V115, P840, DOI 10.1161/CIRCULATIONAHA.106.642280; Canonico M, 2015, MATURITAS, V82, P304, DOI 10.1016/j.maturitas.2015.06.040; Canonico M, 2010, ARTERIOSCL THROM VAS, V30, P340, DOI 10.1161/ATVBAHA.109.196022; DELIGNIERES B, 1986, J CLIN ENDOCR METAB, V62, P536, DOI 10.1210/jcem-62-3-536; Etminan M, 2004, PHARMACOTHERAPY, V24, P1105, DOI 10.1592/phco.24.13.1105.38083; Formoso G, 2016, COCHRANE DB SYST REV, V10; Gartlehner G, 2017, JAMA-J AM MED ASSOC, V318, P2234, DOI 10.1001/jama.2017.16952; Goldhaber SZ, 2010, J AM COLL CARDIOL, V56, P1, DOI 10.1016/j.jacc.2010.01.057; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Manson JE, 2013, JAMA-J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040; Marjoribanks J, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004143.pub5; Mohammed K, 2015, J CLIN ENDOCR METAB, V100, P4012, DOI 10.1210/jc.2015-2237; National Institute for Clinical Excellence, 2015, MEN DIAGN MAN NICE G; Oger E, 2003, ARTERIOSCL THROM VAS, V23, P1671, DOI 10.1161/01.ATV.0000087141.05044.1F; Ohira T, 2010, BRIT J HAEMATOL, V149, P606, DOI 10.1111/j.1365-2141.2010.08128.x; Renoux C, 2010, J THROMB HAEMOST, V8, P979, DOI 10.1111/j.1538-7836.2010.03839.x; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Royston P, 2004, STATA J, V4, P227, DOI 10.1177/1536867X0400400301; Scarabin PY, 2003, LANCET, V362, P428, DOI 10.1016/S0140-6736(03)14066-4; Smith NL, 2004, JAMA-J AM MED ASSOC, V292, P1581, DOI 10.1001/jama.292.13.1581; Stanczyk FZ, 2013, ENDOCR REV, V34, P171, DOI 10.1210/er.2012-1008; Sweetland S, 2012, J THROMB HAEMOST, V10, P2277, DOI 10.1111/j.1538-7836.2012.04919.x; Vinogradova Y, 2018, PROTOCOL ASSESS RISK	26	120	125	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 9	2019	364								k4810	10.1136/bmj.k4810	http://dx.doi.org/10.1136/bmj.k4810			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH5LZ	30626577	Green Published, hybrid			2023-01-03	WOS:000455769800007
J	Ruscetti, M; Leibold, J; Bott, MJ; Fennell, M; Kulick, A; Salgado, NR; Chen, CC; Ho, YJ; Sanchez-Rivera, FJ; Fencht, J; Baslan, T; Tian, S; Chen, HA; Romesser, PB; Poirier, JT; Rudin, CM; de Stanchina, E; Manchado, E; Sherr, CJ; Lowe, SW				Ruscetti, Marcus; Leibold, Josef; Bott, Matthew J.; Fennell, Myles; Kulick, Amanda; Salgado, Nelson R.; Chen, Chi-Chao; Ho, Yu-jui; Sanchez-Rivera, Francisco J.; Fencht, Judith; Baslan, Timour; Tian, Sha; Chen, Hsuan-An; Romesser, Paul B.; Poirier, John T.; Rudin, Charles M.; de Stanchina, Elisa; Manchado, Eusebio; Sherr, Charles J.; Lowe, Scott W.			NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination	SCIENCE			English	Article							SECRETORY PHENOTYPE; ANTITUMOR-ACTIVITY; T-CELL; SENESCENCE; INHIBITION; CANCER; EXPRESSION; P53; SURVEILLANCE; ACTIVATION	Molecularly targeted therapies aim to obstruct cell autonomous programs required for tumor growth. We show that mitogen-activated protein kinase (MARK) and cyclin-dependent kinase 4/6 inhibitors act in combination to suppress the proliferation of KRAS-mutant lung cancer cells while simultaneously provoking a natural killer (NK) cell surveillance program leading to tumor cell death. The drug combination, but neither agent alone, promotes retinoblastoma (RB) protein-mediated cellular senescence and activation of the irnmunomodulatory senescence-associated secretory phenotype (SASP). SASP components tumor necrosis factor-u and intercellular adhesion molecule-1 are required for NK cell surveillance of drug-treated tumor cells, which contributes to tumor regressions and prolonged survival in a KRAS-mutant lung cancer mouse model. Therefore, molecularly targeted agents capable of inducing senescence can produce tumor control through non-cell autonomous mechanisms involving NK cell surveillance.	[Ruscetti, Marcus; Leibold, Josef; Bott, Matthew J.; Fennell, Myles; Salgado, Nelson R.; Chen, Chi-Chao; Ho, Yu-jui; Sanchez-Rivera, Francisco J.; Baslan, Timour; Tian, Sha; Chen, Hsuan-An; Romesser, Paul B.; Manchado, Eusebio; Lowe, Scott W.] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, Sloan Kettering Inst, New York, NY 10065 USA; [Kulick, Amanda; Poirier, John T.; Rudin, Charles M.; de Stanchina, Elisa] Mem Sloan Kettering Canc Ctr, Dept Mol Pharmacol, Sloan Kettering Inst, New York, NY 10065 USA; [Fencht, Judith] Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, New York, NY 10065 USA; [Poirier, John T.; Rudin, Charles M.] Mem Sloan Kettering Canc Ctr, Immunol Program, New York, NY 10065 USA; [Sherr, Charles J.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Sherr, Charles J.; Lowe, Scott W.] St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; St Jude Children's Research Hospital	Lowe, SW (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, Sloan Kettering Inst, New York, NY 10065 USA.; Lowe, SW (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA.	lowes@mskcc.urg	Sánchez-Rivera, Francisco J./AAV-6985-2020; Rudin, Charles/R-2530-2019	Sánchez-Rivera, Francisco J./0000-0002-8466-8563; Rudin, Charles/0000-0001-5204-3465; Chen, Hsuan-An/0000-0002-8979-3670; Leibold, Josef/0000-0003-2336-1987; Bott, Matthew/0000-0003-0523-4028; Poirier, John/0000-0001-9795-5644; Ruscetti, Marcus/0000-0002-4394-2087; Salgado, Nelson/0000-0003-2056-341X; Ho, Yu-jui/0000-0002-7540-024X	Commonwealth Foundation for Cancer Research; National Cancer Institute [P01 CA129243-06, P30 CA008748-S5, U54 OD020355-01]; Center of Experimental Therapeutics of Memorial Sloan Kettering Cancer Center (MSKCC); MSKCC-Parker Institute for Cancer Immunotherapy pilot grant; MSKCC Translational Research Oncology Training Fellowship [NIH T32-CA160001]; American Cancer Society Postdoctoral Fellowship [129040-PF-16-115-01-TBG]; German Research Foundation (DFG); American Association for Thoracic Surgery-Andrew Morrow Research Scholarship; William C. and Joyce C. O'Neil Charitable Trust; Memorial Sloan Kettering Single Cell Sequencing Initiative; K12 Paul Calebresi Career Development Award for Clinical Oncology [K12 CA184746]; NIH grant [U54 OD020355-01]; Geoffrey Beene Cancer Research Center; Stand Up To Cancer grant from the American Association for Cancer Research; NATIONAL CANCER INSTITUTE [K12CA184746, P01CA129243, P30CA008748, T32CA160001] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [U54OD020355] Funding Source: NIH RePORTER	Commonwealth Foundation for Cancer Research; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center of Experimental Therapeutics of Memorial Sloan Kettering Cancer Center (MSKCC); MSKCC-Parker Institute for Cancer Immunotherapy pilot grant; MSKCC Translational Research Oncology Training Fellowship; American Cancer Society Postdoctoral Fellowship(American Cancer Society); German Research Foundation (DFG)(German Research Foundation (DFG)); American Association for Thoracic Surgery-Andrew Morrow Research Scholarship; William C. and Joyce C. O'Neil Charitable Trust; Memorial Sloan Kettering Single Cell Sequencing Initiative; K12 Paul Calebresi Career Development Award for Clinical Oncology; NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Geoffrey Beene Cancer Research Center; Stand Up To Cancer grant from the American Association for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank W. H. Goodwin and A. Goodwin and the Commonwealth Foundation for Cancer Research for research support. This work was supported by three grants from the National Cancer Institute (P01 CA129243-06, P30 CA008748-S5, and U54 OD020355-01), a grant from the Center of Experimental Therapeutics of Memorial Sloan Kettering Cancer Center (MSKCC), and an MSKCC-Parker Institute for Cancer Immunotherapy pilot grant. M.R. was supported by an MSKCC Translational Research Oncology Training Fellowship (NIH T32-CA160001) and an American Cancer Society Postdoctoral Fellowship (129040-PF-16-115-01-TBG). J.L. was supported by a fellowship of the German Research Foundation (DFG). M.J.B. was supported by an American Association for Thoracic Surgery-Andrew Morrow Research Scholarship. T.B. was supported by the William C. and Joyce C. O'Neil Charitable Trust and Memorial Sloan Kettering Single Cell Sequencing Initiative. F.J.S.-R. is an HHMI Hanna Gray Fellow and was partially supported by an MSKCC Translational Research Oncology Training Fellowship (NIH T32-CA160001). P.B.R. was supported in part by a K12 Paul Calebresi Career Development Award for Clinical Oncology (K12 CA184746). E.d.S. received support through a U54 OD020355-01 NIH grant and the Geoffrey Beene Cancer Research Center. C.M.R. was supported by a Stand Up To Cancer grant from the American Association for Cancer Research. S.W.L. is the Geoffrey Beene Chair of Cancer Biology. S.W.L. and C.J.S. are Howard Hughes Medical Institute investigators.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Childs BG, 2015, NAT MED, V21, P1424, DOI 10.1038/nm.4000; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; de Andrade LF, 2018, SCIENCE, V359, P1537, DOI 10.1126/science.aao0505; Deng JH, 2018, CANCER DISCOV, V8, P216, DOI 10.1158/2159-8290.CD-17-0915; Dimitrova N, 2016, CANCER DISCOV, V6, P188, DOI 10.1158/2159-8290.CD-15-0854; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Ebert PJR, 2016, IMMUNITY, V44, P609, DOI 10.1016/j.immuni.2016.01.024; Eggert T, 2016, CANCER CELL, V30, P533, DOI 10.1016/j.ccell.2016.09.003; Fridman AL, 2008, ONCOGENE, V27, P5975, DOI 10.1038/onc.2008.213; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gilmartin AG, 2011, CLIN CANCER RES, V17, P989, DOI 10.1158/1078-0432.CCR-10-2200; Goel S, 2017, NATURE, V548, P471, DOI 10.1038/nature23465; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600; Morvan MG, 2016, NAT REV CANCER, V16, P7, DOI 10.1038/nrc.2015.5; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Orjalo AV, 2009, P NATL ACAD SCI USA, V106, P17031, DOI 10.1073/pnas.0905299106; Poirier JT, 2015, ONCOGENE, V34, P5869, DOI 10.1038/onc.2015.38; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Sagiv A, 2016, AGING-US, V8, P328, DOI 10.18632/aging.100897; Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2015, NAT REV CANCER, V15, P397, DOI 10.1038/nrc3960; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Tasdemir N, 2016, CANCER DISCOV, V6, P612, DOI 10.1158/2159-8290.CD-16-0217; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529	41	143	144	8	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	2018	362	6421			SI		1416	+		10.1126/science.aas9090	http://dx.doi.org/10.1126/science.aas9090			50	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF0IS	30573629	Green Accepted			2023-01-03	WOS:000453845000062
J	Logie, CH; Khoshnood, K; Okumu, M; Rashid, SF; Senova, F; Meghari, H; Kipenda, CU				Logie, Carmen H.; Khoshnood, Kaveh; Okumu, Moses; Rashid, Sabina Faiz; Senova, Fidan; Meghari, Hamza; Kipenda, Claire Uwase			Self care interventions could advance sexual and reproductive health in humanitarian settings	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Logie, Carmen H.; Okumu, Moses] Univ Toronto, Factor Inwentash Fac Social Work, Toronto, ON, Canada; [Logie, Carmen H.] Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON, Canada; [Khoshnood, Kaveh] Yale Sch Publ Hlth, New Haven, CT USA; [Rashid, Sabina Faiz] BRAC Univ, James P Grant Sch Publ Hlth, Dhaka, Bangladesh; [Senova, Fidan] Cukurova Univ, Balcali Hosp, Fac Med, Adana, Turkey; [Meghari, Hamza] UCL, Inst Global Hlth, London, England; [Kipenda, Claire Uwase] Interaid Uganda, Kampala, Uganda	University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital; Yale University; Bangladesh Rural Advancement Committee BRAC; BRAC University; Cukurova University; University of London; University College London	Kipenda, CU (corresponding author), Interaid Uganda, Kampala, Uganda.	carmen.logie@utoronto.ca	Khoshnood, Kaveh/AAX-1402-2020; Okumu, Moses/AAI-7317-2021	Khoshnood, Kaveh/0000-0003-2795-0447; Meghari, Hamza/0000-0002-3571-1940; Rashid, Sabina Faiz/0000-0003-0916-2631				Blanchet K, 2017, LANCET, V390, P2287, DOI 10.1016/S0140-6736(16)30768-1; Casey SE, 2015, CONFL HEALTH, V9, DOI 10.1186/1752-1505-9-S1-S1; Chamla D, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25046; Donovan MeganK., 2018, GUTTMACHER POLICY RE, V21, P41; Gates G, 2011, MANY PEOPLE ARE LESB; Ghose T, 2013, QUAL HEALTH RES, V23, P495, DOI 10.1177/1049732312469463; Inter-Agency Working Group on Reproductive Health in Refugee Situations, 2011, MIN IN SERV PACK MIS; Johnson CC, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21594; Logie CH, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1270816; O'Laughlin Kelli N, 2013, Confl Health, V7, P2, DOI 10.1186/1752-1505-7-2; Singh NS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199300; Singh NS, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000682; Spiegel PB, 2014, AIDS, V28, P761, DOI 10.1097/QAD.0000000000000118; Spiegel PB., 2017, LANCET, V6736, P1, DOI [10.1016/S0140-6736(17)31278-3, DOI 10.1016/S0140-6736(17)31278-3]; UN Refugee Agency, 2018, GLOB TRENDS FORC DIS; UNHCR, 2019, UG COUNTR REF RESP P; Warren E, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008226; World Health Organization, 2015, HLTH WORK ROL PROV S; World health organization, 2018, ETH LEG HUM RIGHTS S	19	19	19	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	2019	365								l1083	10.1136/bmj.l1083	http://dx.doi.org/10.1136/bmj.l1083			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HS6TL	30936067	Green Published, hybrid			2023-01-03	WOS:000464004100002
J	Remme, M; Narasimhan, M; Wilson, D; Ali, M; Vijayasingham, L; Ghani, F; Allotey, P				Remme, Michelle; Narasimhan, Manjulaa; Wilson, David; Ali, Moazzam; Vijayasingham, Lavanya; Ghani, Fatima; Allotey, Pascale			Self care interventions for sexual and reproductive health and rights: costs, benefits, and financing	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SCREENING-PROGRAM; EXPANDING ACCESS; HIV; ACCEPTABILITY; WOMEN		[Remme, Michelle; Vijayasingham, Lavanya; Ghani, Fatima; Allotey, Pascale] United Nations Univ, Int Inst Global Hlth, Kuala Lumpur, Malaysia; [Narasimhan, Manjulaa; Ali, Moazzam] World Hlth Org, Dept Reprod Hlth & Res, Geneva, Switzerland; [Narasimhan, Manjulaa; Ali, Moazzam] World Hlth Org, UNDP UNFPA UNICEF WHO World Bank Special Programm, Geneva, Switzerland; [Wilson, David] World Bank, 1818 H St NW, Washington, DC 20433 USA	World Health Organization; The World Bank; United Nations Population Fund; World Health Organization; The World Bank	Remme, M (corresponding author), United Nations Univ, Int Inst Global Hlth, Kuala Lumpur, Malaysia.	michelle.remme@unu.edu		Ali, Moazzam/0000-0001-6949-8976; Narasimhan, Manjulaa/0000-0003-0598-6887; Remme, Michelle/0000-0003-4917-8531; Vijayasingham, Lavanya/0000-0002-4424-4491				Agha S, 2008, HEALTH POLICY PLANN, V23, P465, DOI 10.1093/heapol/czn035; [Anonymous], 2018, SELF CARE BETTER DAI; Blake DR, 2015, SEX TRANSM DIS, V42, P13, DOI 10.1097/OLQ.0000000000000221; Cambiano V, 2015, J INFECT DIS, V212, P570, DOI 10.1093/infdis/jiv040; Chapman S, 2012, SEX HEALTH, V9, P44, DOI 10.1071/SH10165; Childerhose JE, 2013, SOC SCI MED, V86, P1, DOI 10.1016/j.socscimed.2013.02.035; Cover J, 2017, CONTRACEPTION, V95, P306, DOI 10.1016/j.contraception.2016.10.007; Di Giorgio L, 2018, CONTRACEPTION, V98, P396, DOI 10.1016/j.contraception.2018.07.137; Di Giorgio L, 2018, CONTRACEPTION, V98, P389, DOI 10.1016/j.contraception.2018.05.018; Fajardo-Bernal L, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011317.pub2; Gilbert M, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2888; Grollman C, 2017, LANCET GLOB HEALTH, V5, pE104, DOI 10.1016/S2214-109X(16)30304-7; Gross T, 2014, J POLICY ANAL MANAG, V33, P70, DOI 10.1002/pam.21731; GROSSMAN M, 1972, J POLIT ECON, V80, P223, DOI 10.1086/259880; Gupta S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00077; Haghparast-Bidgoli H, 2015, INT J EQUITY HEALTH, V14, DOI 10.1186/s12939-015-0216-5; Haguenoer K, 2014, BRIT J CANCER, V111, P2187, DOI 10.1038/bjc.2014.510; Hanson K, 2001, HEALTH POLICY PLANN, V16, P125, DOI 10.1093/heapol/16.2.125; Huang W, 2011, SEX TRANSM DIS, V38, P815, DOI 10.1097/OLQ.0b013e31821b0f50; Jennings Larissa, 2017, J AIDS Clin Res, V8, DOI 10.4172/2155-6113.1000725; Jennings L, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-85; Johnson CC, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21594; Kuruvilla S, 2018, B WORLD HEALTH ORGAN, V96, P42, DOI 10.2471/BLT.17.198358; Li CL, 2017, REPROD SCI, V24, P731, DOI 10.1177/1933719116669055; Madzima TR, 2017, CAN FAM PHYSICIAN, V63, P597; Maheswaran H, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0577-7; Mangone ER, 2016, JMIR MHEALTH UHEALTH, V4, P299, DOI 10.2196/mhealth.4846; Murray M., 2017, WOMENS SELF CARE PRO; Narasimhan M, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l688; Nyqvist MB, 2018, AM ECON J-APPL ECON, V10, P287, DOI 10.1257/app.20160469; Panagioti M, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-356; Pearson WS, 2018, PREV MED, V115, P26, DOI 10.1016/j.ypmed.2018.08.007; Shidhaye R, 2016, HLTH CARE PLATFORM I, V4; Starrs AM, 2018, LANCET, V391, P2642, DOI 10.1016/S0140-6736(18)30293-9; Stevens DR, 2018, AIDS BEHAV, V22, P497, DOI 10.1007/s10461-017-1707-8; Trilla C, 2014, EUR J CONTRACEP REPR, V19, P259, DOI 10.3109/13625187.2014.913787; Trussell J, 2005, AUST NZ J OBSTET GYN, V45, P308, DOI 10.1111/j.1479-828X.2005.00417.x; van Valkengoed IGM, 2001, SEX TRANSM INFECT, V77, P276, DOI 10.1136/sti.77.4.276; Wulifan JK, 2016, BMC WOMENS HEALTH, V16, DOI 10.1186/s12905-015-0281-3; 2010, WORLD HLTH REP HLTH, P1	40	17	17	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	2019	365								l1228	10.1136/bmj.l1228	http://dx.doi.org/10.1136/bmj.l1228			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HS6TL	30936210	hybrid, Green Published			2023-01-03	WOS:000464004100004
J	Wang, LZ; Holland, L; Fong, R; Khokhar, S; Fox, AP; Xie, Z				Wang, Lingzhi; Holland, Lindsay; Fong, Robert; Khokhar, Suhail; Fox, Aaron P.; Xie, Zheng			A pilot study showing that repeated exposure to stress produces alterations in subsequent responses to anesthetics in rats	PLOS ONE			English	Article							MINIMUM ALVEOLAR CONCENTRATION; GENERAL-ANESTHESIA; PRENATAL STRESS; RECEPTOR EXPRESSION; ALTERS SENSITIVITY; RAPHE NUCLEI; MECHANISMS; ADAPTATION; MEMORY; SLEEP	The repeated use of a drug frequently leads to alterations in the response to that drug. We undertook this study to determine whether multiple exposures to the general anesthetic produced alterations in subsequent exposures to this anesthetic. For this study, adult male rats were anesthetized with 2.5% isoflurane for one hour. The rats were divided into 4 groups of 8 rats each. Groups 13 were transported between their homeroom and the anesthesia testing room and were handled in an identical manner weekly for a period of 12 weeks, but were anesthetized on different schedules. Group 1 was anesthetized weekly for 12 weeks, Group 2 on either a 3 or 4 week schedule and Group 3 was anesthetized a single time, at the end of the 12 week period. To receive anesthesia multiple times, animals were transported from their homeroom to the anesthesia location and handled repeatedly. We took into consideration of the frequency of anesthesia exposure and the stress involved. Rats in groups 2 and 3 were placed in the anesthesia chamber, with O-2 but with no anesthetic, every week when they were not scheduled to receive anesthesia. In Group 4, rats were not transported or handled in any way and stayed in the home room for a period of 12 weeks. Rats in this group were anesthetized once, at the very end of the study. Recovery of the rats righting reflex was used to assess the acceleration of recovery time from general anesthesia. Group 1 rats showed dramatically faster emergence from anesthesia after several rounds of anesthesia. Surprisingly, Groups 2 and 3 rats, treated in an identical manner as Group 1, but which were anesthetized on different schedules, also exhibited more rapid emergence from anesthesia, when compared to Group 4 rats, which were never handled or transported prior to a single anesthesia. These results suggest that the stress of transportation and handling altered responsiveness to anesthesia. Our results show that responsiveness to anesthetic agents can change over time outside of the normal developmental changes taking place in rats as they age.	[Wang, Lingzhi; Fong, Robert; Xie, Zheng] Univ Chicago, Dept Anesthesia & Crit Care, Box 428, Chicago, IL 60637 USA; [Wang, Lingzhi] Guangzhou Med Univ, Affiliated Hosp 2, Dept Anesthesia, Guangzhou, Guangdong, Peoples R China; [Holland, Lindsay] Univ Michigan, Coll Med, Ann Arbor, MI 48109 USA; [Khokhar, Suhail] Univ Illinois, Coll Med, Chicago, IL USA; [Fox, Aaron P.] Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Chicago; Guangzhou Medical University; University of Michigan System; University of Michigan; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago	Xie, Z (corresponding author), Univ Chicago, Dept Anesthesia & Crit Care, Box 428, Chicago, IL 60637 USA.	jxie@dacc.uchicago.edu		xie, zheng/0000-0001-8909-8339	NIH [RO-1GM-116119]; Medical Student Anesthesia Research Fellowship (MSARF); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM116119] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Student Anesthesia Research Fellowship (MSARF); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by a NIH grant (RO-1GM-116119) to Aaron Fox and Zheng Xie and by Medical Student Anesthesia Research Fellowship (MSARF) to Lindsay Holland and Suhail Khokhar. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allouche S, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00280; Baum A, 1999, ANNU REV PSYCHOL, V50, P137, DOI 10.1146/annurev.psych.50.1.137; Brown EN, 2010, NEW ENGL J MED, V363, P2638, DOI 10.1056/NEJMra0808281; Chemali JJ, 2015, BRIT J ANAESTH, V115, P58, DOI 10.1093/bja/aev112; Chen YC, 2008, J NEUROSCI, V28, P2903, DOI 10.1523/JNEUROSCI.0225-08.2008; Chen YC, 2016, J NEUROSCI, V36, P11295, DOI 10.1523/JNEUROSCI.2542-16.2016; Chetty S, 2014, MOL PSYCHIATR, V19, P1275, DOI 10.1038/mp.2013.190; CLANCY JJ, 1978, PHYSIOL BEHAV, V21, P457, DOI 10.1016/0031-9384(78)90109-9; Dang VC, 2012, BRIT J PHARMACOL, V165, P1704, DOI 10.1111/j.1476-5381.2011.01482.x; Davidson AJ, 2018, ANESTHESIOLOGY, V128, P840, DOI 10.1097/ALN.0000000000001972; de Kloet ER, 2005, NAT REV NEUROSCI, V6, P463, DOI 10.1038/nrn1683; Eger EI, 2001, ANESTH ANALG, V93, P947, DOI 10.1097/00000539-200110000-00029; EGER EI, 1965, ANESTHESIOLOGY, V26, P756, DOI 10.1097/00000542-196511000-00010; GAUMANN DM, 1992, BRIT J ANAESTH, V68, P81, DOI 10.1093/bja/68.1.81; GEINISMAN Y, 1995, PROG NEUROBIOL, V45, P223, DOI 10.1016/0301-0082(94)00047-L; Grasshoff C, 2005, CURR OPIN ANESTHESIO, V18, P386, DOI 10.1097/01.aco.0000174961.90135.dc; HAEFELY W, 1984, NEUROSCI LETT, V47, P201, DOI 10.1016/0304-3940(84)90514-7; Ivy AS, 2010, J NEUROSCI, V30, P13005, DOI 10.1523/JNEUROSCI.1784-10.2010; Iwasaki Masae, 2015, Acta Anaesthesiol Taiwan, V53, P99, DOI 10.1016/j.aat.2015.07.002; Jevtovic-Todorovic V, 2018, ANESTHESIOLOGY, V128, P832, DOI 10.1097/ALN.0000000000002047; Lakehayli S, 2016, NEUROSCIENCE, V330, P50, DOI 10.1016/j.neuroscience.2016.05.035; Lakehayli S, 2015, NEUROSCI LETT, V591, P187, DOI 10.1016/j.neulet.2015.02.015; Licata SC, 2008, PHARMACOL BIOCHEM BE, V90, P74, DOI 10.1016/j.pbb.2008.01.001; LOSS GE, 1989, ANESTH ANALG, V68, P359; Mashour GA, 2005, BEST PRACT RES-CLIN, V19, P349, DOI 10.1016/j.bpa.2005.01.004; McEwen BS, 2007, PHYSIOL REV, V87, P873, DOI 10.1152/physrev.00041.2006; McEwen BS, 2015, J ENDOCRINOL, V226, pT67, DOI 10.1530/JOE-15-0121; McEwen Bruce S, 2011, Cerebrum, V2011, P14; Narciso SP, 2003, INHAL TOXICOL, V15, P1133, DOI 10.1080/08958370390228592; Orliaguet G, 2001, ANESTHESIOLOGY, V95, P734, DOI 10.1097/00000542-200109000-00028; Orser BA, 2018, ANESTH ANALG, V126, P1393, DOI 10.1213/ANE.0000000000002833; Raper J, 2015, ANESTHESIOLOGY, V123, P1084, DOI 10.1097/ALN.0000000000000851; Said N, 2015, NEUROSCIENCE, V304, P279, DOI 10.1016/j.neuroscience.2015.07.029; Said N, 2015, INT J DEV NEUROSCI, V43, P92, DOI 10.1016/j.ijdevneu.2015.04.008; SMITH RA, 1979, ANESTHESIOLOGY, V50, P505, DOI 10.1097/00000542-197906000-00006; Solt K, 2007, CURR OPIN ANESTHESIO, V20, P300, DOI 10.1097/ACO.0b013e32816678a5; Stephenson R, 2012, J BIOL RHYTHM, V27, P490, DOI 10.1177/0748730412461247; SUTANTO W, 1994, LAB ANIM-UK, V28, P293, DOI 10.1258/002367794780745092; Ueno S, 1999, BRIT J PHARMACOL, V127, P377, DOI 10.1038/sj.bjp.0702563; Varlinskaya EI, 2010, PHARMACOL BIOCHEM BE, V96, P228, DOI 10.1016/j.pbb.2010.05.011; Wang Q, 2014, J NEUROPHYSIOL, V111, P1331, DOI 10.1152/jn.00792.2013; Williams JT, 2013, PHARMACOL REV, V65, P223, DOI 10.1124/pr.112.005942; Yuen EY, 2012, NEURON, V73, P962, DOI 10.1016/j.neuron.2011.12.033	43	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2019	14	3							e0214093	10.1371/journal.pone.0214093	http://dx.doi.org/10.1371/journal.pone.0214093			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ1KV	30908509	Green Submitted, Green Published, gold			2023-01-03	WOS:000462157600033
J	Jansen, MHE; Kessels, JPHM; Nelemans, PJ; Kouloubis, N; Arits, AHMM; van Pelt, HPA; Quaedvlieg, PJF; Essers, BAB; Steijlen, PM; Kelleners-Smeets, NWJ; Mosterd, K				Jansen, Maud H. E.; Kessels, Janneke P. H. M.; Nelemans, Patty J.; Kouloubis, Nina; Arits, Aimee H. M. M.; van Pelt, Han P. A.; Quaedvlieg, Patricia J. F.; Essers, Brigitte A. B.; Steijlen, Peter M.; Kelleners-Smeets, Nicole W. J.; Mosterd, Klara			Randomized Trial of Four Treatment Approaches for Actinic Keratosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; MALIGNANT-TRANSFORMATION; TREATMENT ALGORITHM; SOLAR KERATOSES; DOUBLE-BLIND; REAL-WORLD; CREAM; GUIDELINES; 5-PERCENT; CHEMOPREVENTION	BACKGROUND Actinic keratosis is the most frequent premalignant skin disease in the white population. In current guidelines, no clear recommendations are made about which treatment is preferred. METHODS We investigated the effectiveness of four frequently used field-directed treatments (for multiple lesions in a continuous area). Patients with a clinical diagnosis of five or more actinic keratosis lesions on the head, involving one continuous area of 25 to 100 cm(2), were enrolled at four Dutch hospitals. Patients were randomly assigned to treatment with 5% fluorouracil cream, 5% imiquimod cream, methyl aminolevulinate photodynamic therapy (MAL-PDT), or 0.015% ingenol mebutate gel. The primary outcome was the proportion of patients with a reduction of 75% or more in the number of actinic keratosis lesions from baseline to 12 months after the end of treatment. Both a modified intention-to-treat analysis and a per-protocol analysis were performed. RESULTS A total of 624 patients were included from November 2014 through March 2017. At 12 months after the end of treatment, the cumulative probability of remaining free from treatment failure was significantly higher among patients who received fluorouracil (74.7%; 95% confidence interval [CI], 66.8 to 81.0) than among those who received imiquimod (53.9%; 95% CI, 45.4 to 61.6), MAL-PDT (37.7%; 95% CI, 30.0 to 45.3), or ingenol mebutate (28.9%; 95% CI, 21.8 to 36.3). As compared with fluorouracil, the hazard ratio for treatment failure was 2.03 (95% CI, 1.36 to 3.04) with imiquimod, 2.73 (95% CI, 1.87 to 3.99) with MAL-PDT, and 3.33 (95% CI, 2.29 to 4.85) with ingenol mebutate (P <= 0.001 for all comparisons). No unexpected toxic effects were documented. CONCLUSIONS At 12 months after the end of treatment in patients with multiple actinic keratosis lesions on the head, 5% fluorouracil cream was the most effective of four field-directed treatments.	[Jansen, Maud H. E.; Kessels, Janneke P. H. M.; Kouloubis, Nina; Arits, Aimee H. M. M.; Steijlen, Peter M.; Kelleners-Smeets, Nicole W. J.; Mosterd, Klara] Maastricht Univ, Med Ctr, Dept Dermatol, P Debyelaan 25,POB 5800, NL-6202 AZ Maastricht, Netherlands; [Essers, Brigitte A. B.] Maastricht Univ, Med Ctr, Dept Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands; [Jansen, Maud H. E.; Kessels, Janneke P. H. M.; Arits, Aimee H. M. M.; Steijlen, Peter M.; Kelleners-Smeets, Nicole W. J.; Mosterd, Klara] Maastricht Univ, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands; [Nelemans, Patty J.] Maastricht Univ, Dept Epidemiol, Maastricht, Netherlands; [Kessels, Janneke P. H. M.; Quaedvlieg, Patricia J. F.] Zuyderland Med Ctr, Dept Dermatol, Heerlen, Netherlands; [Arits, Aimee H. M. M.; Steijlen, Peter M.] Catharina Hosp, Dept Dermatol, Eindhoven, Netherlands; [van Pelt, Han P. A.] VieCuri Med Ctr, Dept Dermatol, Venlo, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University; Maastricht University; Catharina Hospital; VieCuri Medical Center	Jansen, MHE (corresponding author), Maastricht Univ, Med Ctr, Dept Dermatol, P Debyelaan 25,POB 5800, NL-6202 AZ Maastricht, Netherlands.	maud.jansen@mumc.nl	Mosterd, Klara/AAB-1850-2020; Steijlen, Peter/X-2729-2019		Netherlands Organization for Health Research and Development (ZonMw) [80-83600-98-3054]	Netherlands Organization for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development)	Supported by a grant (80-83600-98-3054) from the Netherlands Organization for Health Research and Development (ZonMw), a governmental institution that finances research to improve health care in the Netherlands.	Ackerman AB, 2006, BRIT J DERMATOL, V155, P9, DOI 10.1111/j.1365-2133.2005.07121.x; [Anonymous], 2017, NED TIJDSCHR DERMATO; Criscione VD, 2009, CANCER-AM CANCER SOC, V115, P2523, DOI 10.1002/cncr.24284; de Berker D, 2017, BRIT J DERMATOL, V176, P20, DOI 10.1111/bjd.15107; Dinehart SM, 1997, CANCER, V79, P920, DOI 10.1002/(SICI)1097-0142(19970301)79:5<920::AID-CNCR8>3.0.CO;2-F; Dirschka T, 2017, J DERMATOL TREAT, V28, P431, DOI 10.1080/09546634.2016.1254328; Flohil SC, 2013, J INVEST DERMATOL, V133, P1971, DOI 10.1038/jid.2013.134; Frost C, 2000, J INVEST DERMATOL, V115, P273, DOI 10.1046/j.1523-1747.2000.00048.x; Glogau RG, 2000, J AM ACAD DERMATOL, V42, pS23, DOI 10.1067/mjd.2000.103339; Gupta AK, 2013, BRIT J DERMATOL, V169, P250, DOI 10.1111/bjd.12343; Gupta AK, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004415.pub2; Gupta AK, 2002, CUTIS, V70, P8; Kirby JS, 2017, JAMA DERMATOL, V153, P264, DOI 10.1001/jamadermatol.2016.4733; Lanoue J, 2016, CUTIS, V97, P415; Lebwohl M, 2004, J AM ACAD DERMATOL, V50, P714, DOI 10.1016/j.jaad.2003.12.010; MARKS R, 1988, LANCET, V1, P795, DOI 10.1016/s0140-6736(88)91658-3; Neugebauer R, 2018, J AM ACAD DERMATOL, V78, P710, DOI 10.1016/j.jaad.2017.12.042; OLSEN EA, 1991, J AM ACAD DERMATOL, V24, P738, DOI 10.1016/0190-9622(91)70113-G; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Pomerantz H, 2015, JAMA DERMATOL, V151, P952, DOI 10.1001/jamadermatol.2015.0502; Rothman KJ, 2012, MODERN EPIDEMIOLOGY; Siegel JA, 2017, BRIT J DERMATOL, V177, P350, DOI 10.1111/bjd.14852; Spencer James M, 2005, J Drugs Dermatol, V4, P296; Stockfleth E, 2006, EUR J DERMATOL, V16, P599, DOI 10.1684/ejd.2006.0017; Stockfleth E, 2008, EUR J DERMATOL, V18, P651, DOI 10.1684/ejd.2008.0514; Vegter S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096829; Weinstock MA, 2018, JAMA DERMATOL, V154, P167, DOI 10.1001/jamadermatol.2017.3631; Werner RN, 2015, J EUR ACAD DERMATOL, V29, P2069, DOI 10.1111/jdv.13180	28	92	92	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 7	2019	380	10					935	946		10.1056/NEJMoa1811850	http://dx.doi.org/10.1056/NEJMoa1811850			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN8QX	30855743	Green Published			2023-01-03	WOS:000460461500007
J	Feehley, T; Plunkett, CH; Bao, RY; Hong, SMC; Culleen, E; Belda-Ferre, P; Campbell, E; Aitoro, R; Nocerino, R; Paparo, L; Andrade, J; Antonopoulos, DA; Canani, RB; Nagler, CR				Feehley, Taylor; Plunkett, Catherine H.; Bao, Riyue; Hong, Sung Min Choi; Culleen, Elliot; Belda-Ferre, Pedro; Campbell, Evelyn; Aitoro, Rosita; Nocerino, Rita; Paparo, Lorella; Andrade, Jorge; Antonopoulos, Dionysios A.; Canani, Roberto Berni; Nagler, Cathryn R.			Healthy infants harbor intestinal bacteria that protect against food allergy	NATURE MEDICINE			English	Article							MICROBIOME; BUTYRATE; SENSITIZATION; HOMEOSTASIS; EXPRESSION; INDUCTION; PACKAGE; SHAPES; CELLS	There has been a striking generational increase in life-threatening food allergies in Westernized societies(1,2). One hypothesis to explain this rising prevalence is that twenty-first century lifestyle practices, including misuse of antibiotics, dietary changes, and higher rates of Caesarean birth and formula feeding have altered intestinal bacterial communities; early-life alterations may be particularly detrimental(3,4). To better understand how commensal bacteria regulate food allergy in humans, we colonized germ-free mice with feces from healthy or cow's milk allergic (CMA) infants(5). We found that germ-free mice colonized with bacteria from healthy, but not CMA, infants were protected against anaphylactic responses to a cow's milk allergen. Differences in bacterial composition separated the healthy and CMA populations in both the human donors and the colonized mice. Healthy and CMA colonized mice also exhibited unique transcriptome signatures in the ileal epithelium. Correlation of ileal bacteria with genes upregulated in the ileum of healthy or CMA colonized mice identified a clostridial species, Anaerostipes caccae, that protected against an allergic response to food. Our findings demonstrate that intestinal bacteria are critical for regulating allergic responses to dietary antigens and suggest that interventions that modulate bacterial communities may be therapeutically relevant for food allergy.	[Feehley, Taylor; Plunkett, Catherine H.; Hong, Sung Min Choi; Culleen, Elliot; Belda-Ferre, Pedro; Campbell, Evelyn; Nagler, Cathryn R.] Univ Chicago, Dept Pathol & Comm Immunol, Chicago, IL 60637 USA; [Bao, Riyue; Andrade, Jorge] Univ Chicago, Ctr Res Informat, Chicago, IL 60637 USA; [Bao, Riyue; Andrade, Jorge] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; [Aitoro, Rosita; Nocerino, Rita; Paparo, Lorella] Univ Naples Federico II, Sect Pediat, Dept Translat Med Sci, Naples, Italy; [Antonopoulos, Dionysios A.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Antonopoulos, Dionysios A.] Argonne Natl Lab, Biosci Div, 9700 S Cass Ave, Argonne, IL 60439 USA; [Canani, Roberto Berni] Univ Naples Federico II, European Lab Invest Food Induced Dis, Naples, Italy; [Canani, Roberto Berni] Univ Naples Federico II, CEINGE Adv Biotechnol, Naples, Italy	University of Chicago; University of Chicago; University of Chicago; University of Naples Federico II; University of Chicago; United States Department of Energy (DOE); Argonne National Laboratory; University of Naples Federico II; CEINGE Biotecnologie Avanzate; University of Naples Federico II	Nagler, CR (corresponding author), Univ Chicago, Dept Pathol & Comm Immunol, Chicago, IL 60637 USA.	cnagler@bsd.uchicago.edu	Belda-Ferre, Pedro/C-9825-2010; Nocerino, Rita/ABD-8087-2020; Antonopoulos, Dionysios/ABE-6212-2020; Canani, Roberto Berni/AAC-4810-2022; Paparo, Lorella/AAC-1720-2022; NOCERINO, RITA/AAC-1966-2022	Belda-Ferre, Pedro/0000-0001-6532-1161; Antonopoulos, Dionysios/0000-0002-2238-5031; Canani, Roberto Berni/0000-0002-5169-9574; Paparo, Lorella/0000-0002-5562-1408; NOCERINO, RITA/0000-0003-4681-546X	Sunshine Charitable Foundation; University of Chicago Institute for Translational Medicine [CTSA ULI TR000430]; National Institutes of Health (NIH) [AI134923, DK42086]; Italian Ministry of Health [PE-2011-02348447]; Biological Sciences Division at the University of Chicago; Institute for Translational Medicine/Clinical and Translational Award [NIH 5UL1TR002389-02]; University of Chicago Comprehensive Cancer Center Support Grant [NIH P30CA014599]; NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI134923, R01AI106302, T32AI007090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM109439] Funding Source: NIH RePORTER	Sunshine Charitable Foundation; University of Chicago Institute for Translational Medicine; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Italian Ministry of Health(Ministry of Health, Italy); Biological Sciences Division at the University of Chicago(University of Chicago); Institute for Translational Medicine/Clinical and Translational Award; University of Chicago Comprehensive Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the children and families for their participation in this study. We are grateful to D. Wesemann, E. Forbes-Blom, G. Nunez, M. Rothenberg, M. Alegre and J. Colson for discussion. We thank S. Wang, M. Bauer and A. Kemter for assistance with some experiments, M. Jarsulic for technical assistance with computing infrastructure, K. Hernandez for discussion of the statistical results and C. Weber for histopathological evaluation of all intestinal sections. Statistical consultation was also provided by M. Giurcanu of the University of Chicago Biostatistics Laboratory. We are grateful to B. Theriault and her staff at the University of Chicago Gnotobiotic Research Animal Facility for superb animal care and experimental support. This work was supported by the Sunshine Charitable Foundation (C.R.N.), a pilot award from the University of Chicago Institute for Translational Medicine (CTSA ULI TR000430, C.R.N.), National Institutes of Health (NIH) grants AI134923 (C.R.N.), DK42086 (D.A.A.) and an Italian Ministry of Health grant PE-2011-02348447 (R.B.C.). The Center for Research Informatics is funded by the Biological Sciences Division at the University of Chicago with additional support provided by the Institute for Translational Medicine/Clinical and Translational Award (NIH 5UL1TR002389-02), and the University of Chicago Comprehensive Cancer Center Support Grant (NIH P30CA014599). Bioinformatics analysis was performed on Gardner High-Performance Computing clusters at the Center for Research Informatics at the University of Chicago. A provisional US patent application (62/755,945) was filed on 5 November 2018.	Al-Dwairi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046716; Andrew S., 2016, FASTQC QUALITY CONTR; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Bashir MEH, 2004, J IMMUNOL, V172, P6978, DOI 10.4049/jimmunol.172.11.6978; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berger CN, 2017, CELL METAB, V26, P738, DOI 10.1016/j.cmet.2017.09.003; Blanton LV, 2016, SCIENCE, V351, DOI 10.1126/science.aad3311; Bray NL, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt0816-888d; Bunyavanich S, 2016, J ALLERGY CLIN IMMUN, V138, P1122, DOI 10.1016/j.jaci.2016.03.041; Byndloss MX, 2017, SCIENCE, V357, P570, DOI 10.1126/science.aam9949; Cahenzli J, 2013, CELL HOST MICROBE, V14, P559, DOI 10.1016/j.chom.2013.10.004; Canani RB, 2016, ISME J, V10, P742, DOI 10.1038/ismej.2015.151; Caporaso JG, 2012, ISME J, V6, P1621, DOI 10.1038/ismej.2012.8; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Caporaso JG, 2010, BIOINFORMATICS, V26, P266, DOI 10.1093/bioinformatics/btp636; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Donohoe DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046589; Donohoe DR, 2011, CELL METAB, V13, P517, DOI 10.1016/j.cmet.2011.02.018; Duncan SH, 2004, APPL ENVIRON MICROB, V70, P5810, DOI 10.1128/AEM.70.10.5810-5817.2004; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Ellis JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116587; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Honda K, 2016, NATURE, V535, P75, DOI 10.1038/nature18848; Iweala OI, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0616-7; Jiang LJ, 2017, MSYSTEMS, V2, DOI 10.1128/mSystems.00092-17; Kim YG, 2017, SCIENCE, V356, P312, DOI 10.1126/science.aag2029; Kurakawa T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126226; Kuznetsova A, 2017, J STAT SOFTW, V82, P1, DOI 10.18637/jss.v082.i13; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Liu X, 2010, ONCOGENE, V29, P442, DOI 10.1038/onc.2009.332; Miyoshi H, 2012, SCIENCE, V338, P108, DOI 10.1126/science.1223821; Mueller NT, 2015, TRENDS MOL MED, V21, P109, DOI 10.1016/j.molmed.2014.12.002; Nik AM, 2013, BIOTECHNIQUES, V55, P42, DOI 10.2144/000114055; Oksanen J., 2020, VEGAN COMMUNITY ECOL, DOI DOI 10.4135/9781412971874.N145; Ostroukhova M, 2012, AM J PHYSIOL-LUNG C, V302, pL300, DOI 10.1152/ajplung.00221.2011; Pabst O, 2012, MUCOSAL IMMUNOL, V5, P232, DOI 10.1038/mi.2012.4; Pinheiro JC, 2000, MIXED EFFECTS MODELS, P528, DOI DOI 10.1007/B98882; Planer JD, 2016, NATURE, V534, P263, DOI 10.1038/nature17940; Plunkett CH, 2017, J IMMUNOL, V198, P581, DOI 10.4049/jimmunol.1601266; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; ROELEN BAJ, 1994, DEV BIOL, V166, P716, DOI 10.1006/dbio.1994.1350; Schwiertz A, 2002, SYST APPL MICROBIOL, V25, P46, DOI 10.1078/0723-2020-00096; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Sicherer SH, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-0194; Soneson Charlotte, 2015, F1000Res, V4, P1521, DOI 10.12688/f1000research.7563.1; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; Thaiss CA, 2016, NATURE, V535, P65, DOI 10.1038/nature18847; Upadhyay V, 2012, NAT IMMUNOL, V13, P947, DOI 10.1038/ni.2403; Wesemann DR, 2016, IMMUNITY, V44, P728, DOI 10.1016/j.immuni.2016.02.002; Yanez AJ, 2003, J CELL PHYSIOL, V197, P189, DOI 10.1002/jcp.10337; Yano JM, 2015, CELL, V161, P264, DOI 10.1016/j.cell.2015.02.047; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang MF, 2001, IMMUNOL CELL BIOL, V79, P291, DOI 10.1046/j.1440-1711.2001.01013.x; Zhu Y, 2015, ONCOTARGET, V6, P21443, DOI 10.18632/oncotarget.4167	56	183	192	27	205	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2019	25	3					448	+		10.1038/s41591-018-0324-z	http://dx.doi.org/10.1038/s41591-018-0324-z			19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	HO1CO	30643289	Green Accepted			2023-01-03	WOS:000460643100023
J	Antico, M; Prinsen, P; Cellini, F; Fracassi, A; Isola, AA; Cobben, D; Fontanarosa, D				Antico, Maria; Prinsen, Peter; Cellini, Francesco; Fracassi, Alice; Isola, Alfonso A.; Cobben, David; Fontanarosa, Davide			Real-time adaptive planning method for radiotherapy treatment delivery for prostate cancer patients, based on a library of plans accounting for possible anatomy configuration changes	PLOS ONE			English	Article							MODULATED ARC THERAPY; IMAGE-GUIDED RADIOTHERAPY; INTRAFRACTION MOTION; RADIATION-THERAPY; BLADDER-CANCER; ROBOTIC COUCH; GLAND; IMRT; OPTIMIZATION; DEFORMATION	Background and purpose In prostate cancer treatment with external beam radiation therapy (EBRT), prostate motion and internal changes in tissue distribution can lead to a decrease in plan quality. In most currently used planning methods, the uncertainties due to prostate motion are compensated by irradiating a larger treatment volume. However, this could cause underdosage of the treatment volume and overdosage of the organs at risk (OARs). To reduce this problem, in this proof of principle study we developed and evaluated a novel adaptive planning method. The strategy proposed corrects the dose delivered by each beam according to the actual position of the target in order to produce a final dose distribution dosimetrically as similar as possible to the prescribed one. Material and methods Our adaptive planning method was tested on a phantom case and on a clinical case. For the first, a pilot study was performed on an in-silico pelvic phantom. A "library" of intensity modulated RT (IMRT) plans corresponding to possible positions of the prostate during a treatment fraction was generated at planning stage. Then a 3D random walk model was used to simulate possible displacements of the prostate during the treatment fraction. At treatment stage, at the end of each beam, based on the current position of the target, the beam from the library of plans, which could reproduce the best approximation of the prescribed dose distribution, was selected and delivered. In the clinical case, the same approach was used on two prostate cancer patients: for the first a tissue deformation was simulated in-silico and for the second a cone beam CT (CBCT) taken during the treatment was used to simulate an intra-fraction change. Then, dosimetric comparisons with the standard treatment plan and, for the second patient, also with an isocenter shift correction, were performed. Results For the phantom case, the plan generated using the adaptive planning method was able to meet all the dosimetric requirements and to correct for a misdosage of 13% of the dose prescription on the prostate. For the first clinical case, the standard planning method caused underdosage of the seminal vesicles, respectively by 5% and 4% of the prescribed dose, when the position changes for the target were correctly taken into account. The proposed adaptive planning method corrected any possible missed target coverage, reducing at the same time the dose on the OARs. For the second clinical case, both with the standard planning strategy and with the isocenter shift correction target coverage was significantly worsened (in particular uniformity) and some organs exceeded some toxicity objectives. While with our approach, the most uniform coverage for the target was produced and systematically the lowest toxicity values for the organs at risk were achieved. Conclusions In our proof of principle study, the adaptive planning method performed better than the standard planning and the isocenter shift methods for prostate EBRT. It improved the coverage of the treatment volumes and lowered the dose to the OARs. This planning method is particularly promising for hypofractionated IMRT treatments in which a higher precision and control on dose deposition are needed. Further studies will be performed to test more extensively the proposed adaptive planning method and to evaluate it at a full clinical level.	[Antico, Maria] Queensland Univ Technol, Sch Chem Phys & Mech Engn, Brisbane, Qld, Australia; [Antico, Maria; Fontanarosa, Davide] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia; [Antico, Maria] Delft Univ Technol, Delft, Netherlands; [Antico, Maria; Prinsen, Peter; Fracassi, Alice; Isola, Alfonso A.] Philips Res, Oncol Solut Dept, Eindhoven, Netherlands; [Cellini, Francesco] Univ Cattolica Sacro Cuore, Fdn Policlin A Gemelli, Dipartimento Diagnost Immagini Radioterapia Oncol, UOC Radioterapia Oncol,Ist Radiol,IRCCS, Rome, Italy; [Fracassi, Alice] Univ Roma Tor Vergata, Rome, Italy; [Cobben, David] Altnagelvin Hosp, North West Canc Ctr, Derry Londonderry, North Ireland; [Cobben, David] Univ Manchester, Div Canc Studies, Sch Med Sci, Fac Biol Med & Hlth, Manchester, Lancs, England; [Cobben, David] Christie NHS Fdn Trust, Clin Oncol, Manchester, Lancs, England; [Fontanarosa, Davide] Queensland Univ Technol, Sch Clin Sci, Gardens Point Campus, Brisbane, Qld, Australia	Queensland University of Technology (QUT); Queensland University of Technology (QUT); Delft University of Technology; Philips; Philips Research; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Rome Tor Vergata; University of Manchester; Christie NHS Foundation Trust; Queensland University of Technology (QUT)	Fontanarosa, D (corresponding author), Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia.; Fontanarosa, D (corresponding author), Queensland Univ Technol, Sch Clin Sci, Gardens Point Campus, Brisbane, Qld, Australia.	d3.fontanarosa@qut.edu.au	Cellini, Francesco/AAB-2994-2019	Cellini, Francesco/0000-0002-2145-2300; Antico, Maria/0000-0002-6314-7064; Fontanarosa, Davide/0000-0001-6986-3718				Adamson J, 2010, INT J RADIAT ONCOL, V78, P1563, DOI 10.1016/j.ijrobp.2009.09.027; Aherne NJ, 2009, RAD ONCOL BIOL, V75, DOI [10.1016/j.ijrobp.2009.07.684, DOI 10.1016/J.IJROBP.2009.07.684]; Baker M, 2015, ACTA ONCOL, V54, P1508, DOI 10.3109/0284186X.2015.1061208; Ballhausen H, 2013, PHYS MED BIOL, V58, P2413, DOI 10.1088/0031-9155/58/7/2413; Ballhausen H, 2014, INTRAFRACTION MOTION, V549, DOI [10.1088/0031-9155/60/2/549, DOI 10.1088/0031-9155/60/2/549]; Barrett A, 2009, PRACT RADIOTHER PLAN, P311; Bey P, 2000, INT J RADIAT ONCOL, V48, P513, DOI 10.1016/S0360-3016(00)00691-X; Bittner N, 2010, INT J RADIAT ONCOL, V77, P490, DOI 10.1016/j.ijrobp.2009.05.033; Boehmer D, 2006, RADIOTHER ONCOL, V79, P259, DOI 10.1016/j.radonc.2006.05.012; Bortfeld T, 1999, SEMIN RADIAT ONCOL, V9, P20, DOI 10.1016/S1053-4296(99)80052-6; Buzurovic I, 2011, IEEE ENG MED BIO, P2156, DOI 10.1109/IEMBS.2011.6090404; Byrne TE, 2005, MED DOSIM, V30, P155, DOI 10.1016/j.meddos.2005.03.005; Chen ML, 2008, MED PHYS, V35, P81, DOI 10.1118/1.2816107; Cheung P, 2005, INT J RADIAT ONCOL, V62, P418, DOI 10.1016/j.ijrobp.2004.09.051; Chiesa S, 2015, J APPL CLIN MED PHYS, V16, P35, DOI 10.1120/jacmp.v16i5.5525; Crehange G, 2012, RADIOTHER ONCOL, V103, P244, DOI 10.1016/j.radonc.2011.10.025; Dawson LA, 2000, INT J RADIAT ONCOL, V48, P319, DOI 10.1016/S0360-3016(00)00751-3; Dehnad H, 2003, RADIOTHER ONCOL, V67, P295, DOI 10.1016/S0167-8140(03)00078-1; Deurloo KEI, 2005, INT J RADIAT ONCOL, V61, P228, DOI 10.1016/j.ijrobp.2004.09.023; Drains O., 2002, P 3IMRT INSTRUCTIONS, P1, DOI [DOI 10.1515/9783110824469.X, 10.1515/9783110824469.X]; Fontanarosa D, Patent No. [WO2017005758 A1, 2017005758]; Foroudi F, 2011, INT J RADIAT ONCOL, V81, P765, DOI 10.1016/j.ijrobp.2010.06.061; Forthmann P., 2008, IEEE NSS MIC, P4157, DOI [DOI 10.1109/NSSMIC.2008.4774197, 10.1109/NSSMIC.2008.4774197]; Gill S, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-174; Gladwish A, 2014, RADIAT ONCOL, V9, DOI 10.1186/s13014-014-0262-y; Hardemark B, 2003, P3IMRT DIRECT MACHIN, P1; Kron T, 2010, RADIOTHER ONCOL, V95, P191, DOI 10.1016/j.radonc.2010.01.010; Kupelian PA, 2005, INT J RADIAT ONCOL, V62, P1291, DOI 10.1016/j.ijrobp.2005.01.005; Kupelian P, 2007, INT J RADIAT ONCOL, V67, P1088, DOI 10.1016/j.ijrobp.2006.10.026; Langen KM, 2008, INT J RADIAT ONCOL, V71, P1084, DOI 10.1016/j.ijrobp.2007.11.054; Litzenberg DW, 2006, INT J RADIAT ONCOL, V65, P548, DOI 10.1016/j.ijrobp.2005.12.033; Lof J, PINNACLE IMRT INVERS, P3; Macchia G, 2017, ONCOTARGETS THER, V10, P3755, DOI 10.2147/OTT.S113119; Mak D, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-139; Malone S, 2000, INT J RADIAT ONCOL, V48, P105, DOI 10.1016/S0360-3016(00)00603-9; McDonald F, 2013, CLIN ONCOL-UK, V25, P549, DOI 10.1016/j.clon.2013.06.001; McPartlin AJ, 2016, RADIOTHER ONCOL, V119, P371, DOI 10.1016/j.radonc.2016.04.014; Meijer GJ, 2012, RADIOTHER ONCOL, V105, P174, DOI 10.1016/j.radonc.2012.08.011; Mutanga TF, 2011, INT J RADIAT ONCOL, V81, P1160, DOI 10.1016/j.ijrobp.2010.09.013; Nichol AM, 2007, INT J RADIAT ONCOL, V67, P48, DOI 10.1016/j.ijrobp.2006.08.021; Nuver TT, 2007, INT J RADIAT ONCOL, V67, P1559, DOI 10.1016/j.ijrobp.2006.12.010; Padhani AR, 1999, INT J RADIAT ONCOL, V44, P525, DOI 10.1016/S0360-3016(99)00040-1; Palma DA, 2010, CANCER TREAT REV, V36, P393, DOI 10.1016/j.ctrv.2010.01.004; Pflugfelder D, 2008, Z MED PHYS, V18, P111, DOI 10.1016/j.zemedi.2007.12.001; Smith C., 2006, VERTEX VERTEX SYSTEM; Teoh M, 2011, BRIT J RADIOL, V84, P967, DOI 10.1259/bjr/22373346; Tuomikoski L, 2011, RADIOTHER ONCOL, V99, P61, DOI 10.1016/j.radonc.2011.02.011; van der Wielen GJ, 2008, INT J RADIAT ONCOL, V72, P1604, DOI 10.1016/j.ijrobp.2008.07.023; Vestergaard A, 2014, ACTA ONCOL, V53, P997, DOI 10.3109/0284186X.2014.928419; Webb S, 2003, BRIT J RADIOL, V76, P678, DOI 10.1259/bjr/65676879; Western C, 2015, CUREUS, V7, DOI 10.7759/cureus.280; Wong JR, 2005, INT J RADIAT ONCOL, V61, P561, DOI 10.1016/j.ijrobp.2004.06.010; Wu C, 2002, PHYS MED BIOL, V47, P3181, DOI 10.1088/0031-9155/47/17/309; Yan D, 1997, PHYS MED BIOL, V42, P123, DOI 10.1088/0031-9155/42/1/008; Zhang M, 2011, PHYS MED BIOL, V56, P4947, DOI 10.1088/0031-9155/56/15/019; Zhang SH, 2016, HELL J NUCL MED, V19, P223, DOI 10.1967/s002449910404	56	12	12	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2019	14	2							e0213002	10.1371/journal.pone.0213002	http://dx.doi.org/10.1371/journal.pone.0213002			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN7LS	30818345	Green Published, gold, Green Submitted			2023-01-03	WOS:000460371500065
J	Stockbridge, EL; Chhetri, S; Polcar, LE; Loethen, AD; Carney, CP				Stockbridge, Erica L.; Chhetri, Shlesma; Polcar, Leah E.; Loethen, Abiah D.; Carney, Caroline P.			Behavioral health conditions and potentially preventable diabetes-related hospitalizations in the United States: Findings from a national sample of commercial claims data	PLOS ONE			English	Article							SERIOUS MENTAL-ILLNESS; MEDICAL-CARE; SELF-MANAGEMENT; QUALITY; DISORDERS; PEOPLE; COMPLICATIONS; INTERVENTION; BARRIERS; STIGMA	Objective To characterize the relationship between potentially preventable hospitalizations (PPHs) for diabetes and behavioral health conditions in commercially insured working-age persons with diabetes in the United States. Research design and methods We retrospectively analyzed medical and pharmacy claims from services rendered between 2011 and 2013 for 229,039 adults with diabetes. Diabetes PPHs were identified using the Agency for Healthcare Research and Quality's Prevention Quality Indicators v6.0 logic. We used negative binomial-logit hurdle regression models to explore the adjusted relationships between diabetes PPHs and schizophrenia, bipolar, depression, anxiety, adjustment disorder, alcohol use disorder, and drug use disorder. Results A total of 4,521 diabetes PPHs were experienced by 3,246 of the persons in the sample. The 20.83% of persons with one or more behavioral health conditions experienced 43.62% (1,972/4,521; 95% CI 42.18%-45.07%) of all diabetes PPHs, and the 7.14% of persons with more than one diagnosed behavioral health condition experienced 24.77% (1,120/4,521; 95% CI 23.54%-26.05%) of all diabetes PPHs. After adjusting for sociodemographic and physical health covariates, patients with depression, schizophrenia, drug or alcohol use disorders, or multiple behavioral health conditions were at significantly increased risk of experiencing at least one diabetes PPH, while patients with depression, drug use disorder, or multiple behavioral health conditions were at significantly increased risk of experiencing recurring diabetes PPHs over time. Conclusions A number of behavioral health conditions are associated with diabetes PPHs, which are often preventable with timely, high-quality outpatient care. The results of this study will enable clinicians, payers, and policy-makers to better focus outpatient care interventions and resources within the population of persons with diabetes.	[Stockbridge, Erica L.; Chhetri, Shlesma] Univ North Texas, Sch Publ Hlth, Hlth Sci Ctr, Dept Hlth Behav & Hlth Syst, Ft Worth, TX 76107 USA; [Stockbridge, Erica L.; Polcar, Leah E.; Loethen, Abiah D.] Magellan Inc, Magellan Healthcare, Dept Adv Hlth Analyt & Solut, Scottsdale, AZ USA; [Carney, Caroline P.] Magellan Inc, Magellan Rx, Scottsdale, AZ USA	University of North Texas System; University of North Texas Denton	Stockbridge, EL (corresponding author), Univ North Texas, Sch Publ Hlth, Hlth Sci Ctr, Dept Hlth Behav & Hlth Syst, Ft Worth, TX 76107 USA.; Stockbridge, EL (corresponding author), Magellan Inc, Magellan Healthcare, Dept Adv Hlth Analyt & Solut, Scottsdale, AZ USA.	Erica.Stockbridge@unthsc.edu			Magellan Health, Inc.	Magellan Health, Inc.	ELS, LEP, ADL and CPC are current or former employees of or contractors with Magellan Health, Inc. a commercial managed care organization. Magellan Health, Inc., provided data access and salary support to ELS, LEP, ADL and CPC, but Magellan did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the authors are articulated in the "author contributions" section.	Aday L A, 1974, Health Serv Res, V9, P208; Agency for Healthcare Research and Quality, 2014, SELF MAN SUPP; Agency for Healthcare Research and Quality, 2017, PREV QUAL IND OV PRE; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; Armstrong C, 2017, AM FAM PHYSICIAN, V95, P40; Cahoon EK, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-37; Carrasquillo O, 2017, JAMA INTERN MED, V177, P948, DOI 10.1001/jamainternmed.2017.0926; Casagrande SS, 2012, DIABETES CARE, V35, P2243, DOI 10.2337/dc12-0257; Centers for Disease Control and Prevention, 2017, NAT DIAB STAT REP; Clark RE, 2009, MED CARE, V47, P545, DOI 10.1097/MLR.0b013e318190db45; Corrigan P, 2004, AM PSYCHOL, V59, P614, DOI 10.1037/0003-066X.59.7.614; Davydow DS, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009878; Davydow DS, 2016, MED CARE, V54, P90, DOI 10.1097/MLR.0000000000000448; Desai MM, 2002, AM J PSYCHIAT, V159, P1584, DOI 10.1176/appi.ajp.159.9.1584; Druss BG, 2012, MED CARE, V50, P428, DOI 10.1097/MLR.0b013e318245a528; Frayne SM, 2005, ARCH INTERN MED, V165, P2631, DOI 10.1001/archinte.165.22.2631; Freeman K, 2018, DIABETES EDUCATOR, V44, P395, DOI 10.1177/0145721718784262; Ghitza UE, 2013, SUBST ABUSE REHABIL, V4, P3, DOI 10.2147/SAR.S39982; Greaves CJ, 2007, BRIT J GEN PRACT, V57, P814; Heron Melonie, 2016, Natl Vital Stat Rep, V65, P1; Huang ES, 2007, DIABETES CARE, V30, P2478, DOI 10.2337/dc07-0499; Jones Andrew., 2007, APPL ECONOMETRICS HL; Kathol RG, 2010, PSYCHOSOM MED, V72, P511, DOI 10.1097/PSY.0b013e3181e2c4a0; Kilbourne AM, 2011, PSYCHIAT SERV, V62, P922, DOI 10.1176/ps.62.8.pss6208_0922; Kisely S, 2015, CAN J PSYCHIAT, V60, P497, DOI 10.1177/070674371506001105; Knaak Stephanie, 2017, Healthc Manage Forum, V30, P111, DOI 10.1177/0840470416679413; Lawrence D, 2000, ACTA PSYCHIAT SCAND, V101, P382, DOI 10.1034/j.1600-0447.2000.101005382.x; Leung G, 2011, PSYCHIAT SERV, V62, P659, DOI 10.1176/ps.62.6.pss6206_0659; Leung GY, 2011, AM J MANAG CARE, V17, P144; Leung Kit Sang, 2015, Prev Med Rep, V2, P379, DOI 10.1016/j.pmedr.2015.04.022; Li R, 2013, AM J MANAG CARE, V19, P421; Lin HC, 2011, CAN J PSYCHIAT, V56, P171, DOI 10.1177/070674371105600307; Mai Q, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-118; McBain H, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019400; McBain H, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011361.pub2; McGinty EE, 2015, SCHIZOPHR RES, V165, P227, DOI 10.1016/j.schres.2015.04.010; Mulligan K, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1744-5; Mulligan K, 2017, HEALTH EXPECT, V20, P1020, DOI 10.1111/hex.12543; National Committee for Quality Assurance (NCQA), 2016, HEDIS PERF MEAS; Optum Inc, 2014, CLINF DAT MART; Parks J., 2006, MORBIDITY MORTALITY; Pratt SI, 2013, PSYCHIATR REHABIL J, V36, P297, DOI 10.1037/prj0000022; Sajatovic M, 2017, PSYCHIAT SERV, V68, P883, DOI 10.1176/appi.ps.201600377; Sajatovic M, 2011, PSYCHIAT SERV, V62, P1001, DOI 10.1176/appi.ps.62.9.1001; Shrivastava SR, 2013, J DIABETES METAB DIS, V12, DOI 10.1186/2251-6581-12-14; van Boekel LC, 2013, DRUG ALCOHOL DEPEN, V131, P23, DOI 10.1016/j.drugalcdep.2013.02.018; World Health Organization, 2013, MENT HLTH ACT PLAN 2; Yang WY, 2018, DIABETES CARE, V41, P917, DOI 10.2337/dci18-0007; Yoon J, 2012, MED CARE, V50, P705, DOI 10.1097/MLR.0b013e31824e3379	49	5	5	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2019	14	2							e0212955	10.1371/journal.pone.0212955	http://dx.doi.org/10.1371/journal.pone.0212955			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HN7LS	30818377	gold, Green Published, Green Submitted			2023-01-03	WOS:000460371500061
J	Alghamdi, F; Alhussien, A; Alohali, M; Alatawi, A; Almusned, T; Fecteau, S; Habib, SS; Bashir, S				Alghamdi, Faisal; Alhussien, Ahmed; Alohali, Meshal; Alatawi, Abdullah; Almusned, Tariq; Fecteau, Shirley; Habib, Syed Shahid; Bashir, Shahid			Effect of transcranial direct current stimulation on the number of smoked cigarettes in tobacco smokers	PLOS ONE			English	Article							PREFRONTAL CORTEX MODULATION; MAGNETIC STIMULATION; CORTICAL STIMULATION; PLACEBO-RESPONSE; DOUBLE-BLIND; SMOKING; TDCS; SCHIZOPHRENIA; METAANALYSIS; ACTIVATION	Background Recent studies reported that transcranial direct current stimulation (tDCS) applied over the dorsolateral prefrontal cortex (DLPFC) reduced craving and cigarette smoking. We aimed to evaluate whether 3 sessions of tDCS over the DLPFC modulate cigarette smoking which is a critical factor in tobacco smokers. Methods In a double-blinded, sham-controlled, parallel experimental study, 22 participants who wished to quit smoking received tDCS with the cathodal over the right DLPFC and anodal over the left DLPFC based on the 10-20 EEG international system (F4, F3) at an intensity of 1.5 mA for 20 minutes during three consecutive days. For sham stimulation, the electrodes placement was the same as for the active stimulation. Results For the short time interval (8 days after the end of the tDCS regimen), the number of smoked cigarettes was reduced similarly in the active and sham groups (p < 0.001). Also, at the long time-interval (4 months after the end of the tDCS regimen) as compared to pre-tDCS, there was no significant difference in the number of smoked cigarettes in the active (p = 0.806) or the sham (p = 0.573) groups. Overall, there were no statistically significant differences between the active and sham tDCS groups on cigarette smoking. Conclusion These findings suggested that 3 sessions of tDCS over the right and left DLPFC may reduce number of smoked cigarettes for short-time period but might not be significantly more effective than sham to decrease cigarette smoking.	[Alghamdi, Faisal; Alhussien, Ahmed; Alohali, Meshal; Alatawi, Abdullah; Almusned, Tariq; Habib, Syed Shahid] King Saud Univ, Fac Med, Riyadh, Saudi Arabia; [Fecteau, Shirley] Laval Univ, Lab Canada Res Chair Cognit Neurosci, CERVO Brain Res Ctr, Sch Med, Quebec City, PQ, Canada; [Bashir, Shahid] King Fahad Specialist Hosp Dammam, Neurosci Ctr, Dammam, Saudi Arabia; [Bashir, Shahid] Harvard Med Sch, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02115 USA	King Saud University; Laval University; Harvard University; Harvard Medical School	Bashir, S (corresponding author), King Fahad Specialist Hosp Dammam, Neurosci Ctr, Dammam, Saudi Arabia.; Bashir, S (corresponding author), Harvard Med Sch, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02115 USA.	sbashir10@gmail.com	Habib, Syed/ABD-2283-2020; Alhussien, Ahmed/GRS-9857-2022; Bashir, Shahid/N-3031-2019	Habib, Syed/0000-0001-5944-8406; Bashir, Shahid/0000-0001-6286-6895; Alhussien, Ahmed/0000-0003-4754-0293				Ayo-Yusuf OA, 2014, NIGER J CLIN PRACT, V17, P174, DOI 10.4103/1119-3077.127542; Baker TB, 2004, ANNU REV PSYCHOL, V55, P463, DOI 10.1146/annurev.psych.55.090902.142054; Batista EK, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyv066; Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8; Bikson M, 2009, CLIN NEUROPHYSIOL, V120, P1033, DOI 10.1016/j.clinph.2009.03.018; Boggio PS, 2008, DRUG ALCOHOL DEPEN, V92, P55, DOI 10.1016/j.drugalcdep.2007.06.011; Boggio PS, 2009, NEUROSCI LETT, V463, P82, DOI 10.1016/j.neulet.2009.07.041; Brunoni AR, 2014, EXPERT REV MED DEVIC, V11, P383, DOI 10.1586/17434440.2014.911082; Cahill K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009329.pub2, 10.1002/14651858.CD006103.pub6]; Camprodon JA, 2007, DRUG ALCOHOL DEPEN, V86, P91, DOI 10.1016/j.drugalcdep.2006.06.002; Dollfus S, 2016, SCHIZOPHRENIA BULL, V42, P301, DOI 10.1093/schbul/sbv076; Eichhammer P, 2003, J CLIN PSYCHIAT, V64, P951, DOI 10.4088/JCP.v64n0815; Ekpu VU, 2015, TOB USE INSIGHTS, V8, P1, DOI 10.4137/TUI.S15628; Ellison-Loschmann L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181581; Engelmann JM, 2012, NEUROIMAGE, V60, P252, DOI 10.1016/j.neuroimage.2011.12.024; Fagerstrom K O, 1996, Tob Control, V5, P52, DOI 10.1136/tc.5.1.52; Falcone M, 2016, BRAIN STIMUL, V9, P191, DOI 10.1016/j.brs.2015.10.004; Fecteau S, 2014, DRUG ALCOHOL DEPEN, V140, P78, DOI 10.1016/j.drugalcdep.2014.03.036; Fraser Paige E, 2012, Front Psychiatry, V3, P79, DOI 10.3389/fpsyt.2012.00079; Fregni F, 2006, BIPOLAR DISORD, V8, P203, DOI 10.1111/j.1399-5618.2006.00291.x; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fregni F, 2008, J CLIN PSYCHIAT, V69, P32, DOI 10.4088/JCP.v69n0105; Fregni F, 2006, DEPRESS ANXIETY, V23, P482, DOI 10.1002/da.20201; Gallus S, 2015, PREV MED, V70, P76, DOI 10.1016/j.ypmed.2014.11.015; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14; George MS, 2001, ARCH GEN PSYCHIAT, V58, P345, DOI 10.1001/archpsyc.58.4.345; Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642; Hyland ME, 2011, PHILOS T R SOC B, V366, P1828, DOI 10.1098/rstb.2010.0391; Isa MM, 2014, INT J SCI RES PUBL, V4, P2250; Jansen JM, 2013, NEUROSCIENCE BIOBEHA; Kincses TZ, 2004, NEUROPSYCHOLOGIA, V42, P113, DOI 10.1016/S0028-3932(03)00124-6; Klauss J, 2014, INT J NEUROPSYCHOPH, V17, P1793, DOI 10.1017/S1461145714000984; Koks G, 2017, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-017-4590-3; LEEWAHNHEE, 2017, Epidemiology and Health, V39, P1, DOI 10.4178/epih.e2017026; Li J, 2015, ONCOTARGET; Mahapatra S, 2015, J CANCER RES THER, V11, P199, DOI 10.4103/0973-1482.143332; Mcbride D., 2006, NEUROPSYCHOPHARMACOL; Meron D, 2015, NEUROSCI BIOBEHAV R, V57, P46, DOI 10.1016/j.neubiorev.2015.07.012; Miller FG, 2006, J CLIN EPIDEMIOL, V59, P331, DOI 10.1016/j.jclinepi.2005.12.001; Moore RA, 2012, INT J ENV RES PUB HE, V9, P192, DOI 10.3390/ijerph9010192; Olbrich HM, 2006, AUST NZ J PSYCHIAT, V40, P171, DOI 10.1111/j.1440-1614.2006.01765.x; Pripfl J, 2014, BRAIN STIMUL, V7, P226, DOI 10.1016/j.brs.2013.11.003; Shahbabaie A, 2014, INT J NEUROPSYCHOPH, V17, P1591, DOI 10.1017/S1461145714000686; Stead LF, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008286.pub3; Uher R, 2005, BIOL PSYCHIAT, V58, P840, DOI 10.1016/j.biopsych.2005.05.043; WHO, 2017, TOBACCO; Wilson SJ, 2004, NAT NEUROSCI, V7, P211, DOI 10.1038/nn1200; Xu Jiansong, 2013, Front Psychiatry, V4, P112, DOI 10.3389/fpsyt.2013.00112; Zellweger JP, 2005, AM J HEALTH BEHAV, V29, P240, DOI 10.5993/AJHB.29.3.5; Zhao HC, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00685; Zwar NA, 2014, BMJ-BRIT MED J, P348	52	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2019	14	2							e0212312	10.1371/journal.pone.0212312	http://dx.doi.org/10.1371/journal.pone.0212312			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL5JX	30763404	gold, Green Published, Green Submitted			2023-01-03	WOS:000458763900066
J	Menditto, E; Miguel, AG; Juste, AM; Plou, BP; Pascual-Salcedo, MA; Orlando, V; Rubio, FG; Torres, AP				Menditto, Enrica; Gimeno Miguel, Antonio; Moreno Juste, Aida; Poblador Plou, Beatriz; Aza Pascual-Salcedo, Mercedes; Orlando, Valentina; Gonzalez Rubio, Francisca; Prados Torres, Alexandra			Patterns of multimorbidity and polypharmacy in young and adult population: Systematic associations among chronic diseases and drugs using factor analysis	PLOS ONE			English	Article							OLDER-ADULTS; INHIBITORS; PEOPLE; RISK; CARE	Objectives The objective was to identify the systematic associations among chronic diseases and drugs in the form of patterns and to describe and clinically interpret the constituted patterns with a focus on exploring the existence of potential drug-drug and drug-disease interactions and prescribing cascades. Methods This observational, cross-sectional study used the demographic and clinical information from electronic medical databases and the pharmacy billing records of all users of the public health system of the Spanish region of Aragon in 2015. An exploratory factor analysis was conducted based on the tetra-choric correlations among the diagnoses of chronic diseases and the dispensed drugs in 887,572 patients aged. 65 years. The analysis was stratified by age and sex. To name the constituted patterns, assess their clinical nature, and identify potential interactions among diseases and drugs, the associations found in each pattern were independently reviewed by two pharmacists and two doctors and tested against the literature and the information reported in the technical medicinal forms. Results Six multimorbidity-polypharmacy patterns were found in this large-scale population study, named as respiratory, mental health, cardiometabolic, endocrinological, osteometabolic, and mechanical-pain. The nature of the patterns in terms of diseases and drugs differed by sex and age and became more complex as age advanced. Conclusions The six clinically sound multimorbidity-polypharmacy patterns described in this non-elderly population confirmed the existence of systematic associations among chronic diseases and medications, and revealed some unexpected associations suggesting the prescribing cascade phenomenon as a potential underlying factor. These findings may help to broaden the focus and orient the early identification of potential interactions when caring for multimorbid patients at high risk of adverse health outcomes due to polypharmacy.	[Menditto, Enrica; Orlando, Valentina] Univ Naples Federico II, Ctr Pharmacoecon, CIRFF, Naples, Italy; [Menditto, Enrica; Gimeno Miguel, Antonio; Moreno Juste, Aida; Poblador Plou, Beatriz; Aza Pascual-Salcedo, Mercedes; Gonzalez Rubio, Francisca; Prados Torres, Alexandra] Miguel Servet Univ Hosp, Aragon Hlth Sci Inst IACS, IIS Aragon, REDISSEC ISCIII, Zaragoza, Spain; [Moreno Juste, Aida; Aza Pascual-Salcedo, Mercedes; Gonzalez Rubio, Francisca; Prados Torres, Alexandra] Aragon Hlth Serv SALUD, Zaragoza, Spain	University of Naples Federico II; Miguel Servet University Hospital	Menditto, E (corresponding author), Univ Naples Federico II, Ctr Pharmacoecon, CIRFF, Naples, Italy.; Menditto, E (corresponding author), Miguel Servet Univ Hosp, Aragon Hlth Sci Inst IACS, IIS Aragon, REDISSEC ISCIII, Zaragoza, Spain.	enrica.menditto@unina.it; sprados.iacs@aragon.es	Orlando, Valentina/AAD-1791-2019; Gimeno-Miguel, Antonio/AAC-9611-2019; Prados-Torres, Alexandra/P-5818-2017; Poblador-Plou, Beatriz/ABC-7915-2020; Aza-Pascual-Salcedo, Mercedes/AAY-6534-2021	Orlando, Valentina/0000-0002-8209-8878; Gimeno-Miguel, Antonio/0000-0002-5440-1710; Prados-Torres, Alexandra/0000-0002-5704-6056; Poblador-Plou, Beatriz/0000-0002-5119-5093; Aza-Pascual-Salcedo, Mercedes/0000-0002-8937-5559; menditto, enrica/0000-0001-8633-5650	Aragon Health Sciences Institute (IACS); IIS Aragon, Spain; University of Naples Federico II, Naples, Italy	Aragon Health Sciences Institute (IACS); IIS Aragon, Spain; University of Naples Federico II, Naples, Italy	This study was supported by a grant from the Aragon Health Sciences Institute (IACS) and IIS Aragon, Spain. English-language editing of the manuscript was provided by American Journal Experts (AJE) service and funded by the University of Naples Federico II, Naples, Italy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study was supported by a grant from the Aragon Health Sciences Institute (IACS) and IIS Aragon, Spain. English-language editing of the manuscript was provided by American Journal Experts (AJE) service.	Aguilar-palacio I, 2014, COMP RESULTADOS ENTR, V28, P41; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Bradley MC, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-72; Calderon-Larranaga A, 2016, INT J CARDIOL, V207, P310, DOI 10.1016/j.ijcard.2016.01.069; Calderon-Larranaga A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084967; Calderon-Larranaga A, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X659295; Collins AB, 2016, ASIA PAC J CLIN NUTR, V25, P221, DOI 10.6133/apjcn.2016.25.2.22; Committee for Medicinal Products for Human Use (CHMP), EUR MED AG FIND MED; de Abajo FJ, 1999, BRIT MED J, V319, P1106, DOI 10.1136/bmj.319.7217.1106; Madero AD, 2012, MED PALIATIVA, V19, P17, DOI 10.1016/j.medipa.2010.11.009; Dumbreck S, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h949; Holton AE, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0532-2; Loza Santamaria E., 2011, CONTRAS REUMATOL S2, V7, P40; Marengoni A, 2015, DRUG AGING, V32, P887, DOI 10.1007/s40266-015-0324-3; Martin J, 2018, BIOL PSYCHIAT; McIntosh J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195232; Merenda PF, 1997, MEAS EVAL COUNS DEV, V30, P156, DOI 10.1080/07481756.1997.12068936; Mino-Leon D, 2017, ARCH MED RES, V48, P121, DOI 10.1016/j.arcmed.2017.03.001; Nobili A, 2009, J CLIN PHARM THER, V34, P377, DOI 10.1111/j.1365-2710.2009.01021.x; Organization; WWH. WHO, 2015, CHRON RESP DIS CRDS; Papatheodoridis GV, 2005, WORLD J GASTROENTERO, V11, P3811; Prados-Torres A, 2018, INT J EPIDEMIOL; Prados-Torres A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032190; Putignano D, 2017, BMC WOMENS HEALTH, V17, DOI 10.1186/s12905-017-0424-9; Rickli A, 2018, BRIT J PHARMACOL, V175, P532, DOI 10.1111/bph.14105; Rochon PA, 1997, BMJ-BRIT MED J, V315, P1096, DOI 10.1136/bmj.315.7115.1096; Rochon PA, 2017, LANCET, V389, P1778, DOI 10.1016/S0140-6736(17)31188-1; Salisbury C, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X548929; Sanders G, 2011, COMP EFF REV; Scala D, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1411-9; Trifiro G, 2006, BRIT J CLIN PHARMACO, V62, P582, DOI 10.1111/j.1365-2125.2006.02687.x; Wallace E, 2014, MED CARE, V52, P751, DOI 10.1097/MLR.0000000000000171; Wang YP, 2014, J FORMOS MED ASSOC, V113, P155, DOI 10.1016/j.jfma.2012.04.003; Wilson M, 2015, J ROY COLL PHYS EDIN, V45, P108, DOI 10.4997/JRCPE.2015.204	34	24	24	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2019	14	2							e0210701	10.1371/journal.pone.0210701	http://dx.doi.org/10.1371/journal.pone.0210701			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK4EL	30726245	Green Published, gold			2023-01-03	WOS:000457874000026
J	Yeoh, YS; Koh, GCH; Tan, CS; Tu, TM; Singh, R; Chang, HM; De Silva, DA; Ng, YS; Ang, YH; Yap, P; Chew, E; Merchant, RA; Yeo, TT; Chou, N; Venketasubramanian, N; Lee, KE; Young, SH; Hoenig, H; Matchar, DB; Luo, N				Yeoh, Yen Shing; Koh, Gerald Choon-Huat; Tan, Chuen Seng; Tu, Tian Ming; Singh, Rajinder; Chang, Hui Meng; De Silva, Deidre A.; Ng, Yee Sien; Ang, Yan Hoon; Yap, Philip; Chew, Effie; Merchant, Reshma A.; Yeo, Tseng Tsai; Chou, Ning; Venketasubramanian, N.; Lee, Kim En; Young, Sherry H.; Hoenig, Helen; Matchar, David Bruce; Luo, Nan			Health-related quality of life loss associated with first-time stroke	PLOS ONE			English	Article							SELF-REPORT QUESTIONNAIRE; MINI-MENTAL-STATE; RHEUMATIC-DISEASES; POPULATION NORMS; EQ-5D; EUROQOL; VALIDATION; DISABILITY; RELIABILITY; PREVALENCE	Objectives This study aimed to quantify health-related quality of life (HRQoL) loss associated with first episode of stroke by comparing patient-reported HRQoL before and after stroke onset. The impact of stroke in local population was also evaluated by comparing the pre- and post-stroke HRQoL with that of the general population. Methods The HRQoL of stroke survivors was assessed with the EQ-5D-3L index score at recruitment, for recalled pre- stroke HRQoL, and at 3 and 12 month post-stroke. Change in HRQoL from pre- stroke to 3 and 12 month was self-reported by 285 and 238 patients, respectively. Mean EQ index score at each time point (baseline: 464 patients; 3 month post-stroke: 306 patients; 12 month post-stroke: 258 patients) was compared with published population norms for EQ-5D-3L. Results There was a significant decrease in HRQoL at 3 (0.25) and 12 month (0.09) post-stroke when compared to the retrospectively recalled patients' mean pre- stroke HRQoL level 0.87). The reduction at 3 month was associated with the reduction in all EQ-5D-3L health dimensions; reductions remaining at 12 month were limited to dimensions of mobility, self-care, usual activities, and anxiety/depression. Stroke patients had a lower mean EQ index than the general population by 0.07 points pre-stroke (0.87 vs. 0.94), 0.33 points at 3 month (0.61 vs. 0.94) and 0.18 points at 12 month (0.76 vs. 0.94) post-stroke. Conclusions Stroke has a substantial impact on HRQoL in Singapore, especially in the first three months post-stroke. Compared to the general population, stroke survivors have lower HRQoL even before stroke onset. This pre-stroke deficit in HRQoL should be taken into account when quantifying health burden of stroke or setting goals for stroke rehabilitation.	[Yeoh, Yen Shing; Koh, Gerald Choon-Huat; Tan, Chuen Seng; Luo, Nan] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore; [Tu, Tian Ming; Singh, Rajinder] Natl Neurosci Inst, Dept Neurol, Singapore, Singapore; [Chang, Hui Meng; De Silva, Deidre A.] Natl Neurosci Inst, Dept Neurol, Singapore Gen Hosp Campus, Singapore, Singapore; [Ng, Yee Sien] Singapore Gen Hosp, Dept Rehabil Med, Singapore, Singapore; [Ang, Yan Hoon; Yap, Philip] Khoo Teck Puat Hosp, Dept Geriatr Med, Singapore, Singapore; [Chew, Effie] Natl Univ Singapore Hosp, Dept Rehabil Med, Singapore, Singapore; [Merchant, Reshma A.] Natl Univ Singapore, Dept Med, Yong Loo Lin Sch Med, Singapore, Singapore; [Yeo, Tseng Tsai; Chou, Ning] Natl Univ Singapore Hosp, Dept Neurosurg, Singapore, Singapore; [Venketasubramanian, N.] Raffles Hosp, Raffles Neurosci Ctr, Singapore, Singapore; [Lee, Kim En] Farrer Pk Hosp, Farrer Pk Med Ctr, Singapore, Singapore; [Young, Sherry H.] Changi Gen Hosp, Dept Rehabil Med, Singapore, Singapore; [Hoenig, Helen] Durham Vet Affairs Med Ctr, Phys Med & Rehabil Serv, Durham, NC USA; [Hoenig, Helen] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA; [Matchar, David Bruce] Duke NUS Med Sch, Hlth Serv & Syst Res Programme, Singapore, Singapore; [Matchar, David Bruce] Duke Univ, Ctr Clin Hlth Policy Res, Med Ctr, Durham, NC USA	National University of Singapore; National Neuroscience Institute (NNI); National Neuroscience Institute (NNI); Singapore General Hospital; Singapore General Hospital; National University of Singapore; National University of Singapore; National University of Singapore; Raffles Hospital; Changi General Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University; National University of Singapore; Duke University	Luo, N (corresponding author), Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.	ephln@nus.edu.sg	Chou, Ning/B-5314-2011; Merchant, Reshma/ABD-4044-2020; Yeo, Tseng Tsai/U-8864-2017; Tu, Tian Ming/AAI-3949-2020; Venketasubramanian, Narayanaswamy/GPP-5948-2022; Tan, Chuen Seng/K-1078-2013; Merchant, Reshma Aziz/I-3033-2019	Tu, Tian Ming/0000-0002-7175-0357; Tan, Chuen Seng/0000-0002-6513-2309; Merchant, Reshma Aziz/0000-0002-9032-0184; Matchar, David/0000-0003-3020-2108; Ng, Yee-Sien/0000-0003-1377-5852; De Silva, Deidre Anne/0000-0002-7123-2381	Singapore Ministry of Health's National Medical Research Council under the Centre Grant Programme - Singapore Population Health Improvement Centre [NMRC/CG/C026/2017_NUHS]; Health Services Research Competitive Research Grant [HSRG/0006/2010]	Singapore Ministry of Health's National Medical Research Council under the Centre Grant Programme - Singapore Population Health Improvement Centre; Health Services Research Competitive Research Grant	This study was supported by the Singapore Ministry of Health's National Medical Research Council under the Centre Grant Programme - Singapore Population Health Improvement Centre (NMRC/CG/C026/2017_NUHS to GCHK) and Health Services Research Competitive Research Grant (HSRG/0006/2010 to GCHK). The funder did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdin E, 2015, QUAL LIFE RES, V24, P1545, DOI 10.1007/s11136-014-0859-5; Bonita R, 1997, STROKE, V28, P1898, DOI 10.1161/01.STR.28.10.1898; Bour A, 2010, J NEUROL, V257, P630, DOI 10.1007/s00415-009-5387-9; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Cameron CM, 2005, B WORLD HEALTH ORGAN, V83, P345; Cerniauskaite M, 2012, AM J PHYS MED REHAB, V91, pS39, DOI 10.1097/PHM.0b013e31823d4df7; Dorman PJ, 1997, STROKE, V28, P1876, DOI 10.1161/01.STR.28.10.1876; Dorman PJ, 1997, STROKE, V28, P1883, DOI 10.1161/01.STR.28.10.1883; Fang J, 2016, SCI REPORTS, V6; Fayers P.M., 2013, QUALITY LIFE ASSESSM; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gabbe BJ, 2007, J ORTHOP TRAUMA, V21, P223, DOI 10.1097/BOT.0b013e31803eb13c; Gokkaya NKO, 2005, INT J REHABIL RES, V28, P229, DOI 10.1097/00004356-200509000-00005; Golicki D, 2015, QUAL LIFE RES, V24, P1555, DOI 10.1007/s11136-014-0873-7; Hunger M, 2012, QUAL LIFE RES, V21, P1205, DOI 10.1007/s11136-011-0024-3; Luo N, 2003, ANN ACAD MED SINGAP, V32, P685; Luo N, 2003, QUAL LIFE RES, V12, P87, DOI 10.1023/A:1022063721237; Luo N, 2014, PHARMACOECONOMICS, V32, P495, DOI 10.1007/s40273-014-0142-1; Luo YH, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0246-0; Min KB, 2015, AGE AGEING, V44, P700, DOI 10.1093/ageing/afv060; Ministry of Health, 2011, NAT HLTH SURV 2010; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Ng TP, 2007, AM J GERIAT PSYCHIAT, V15, P130, DOI 10.1097/01.JGP.0000235710.17450.9a; Pinto EB, 2011, ARQ NEURO-PSIQUIAT, V69, P320, DOI 10.1590/S0004-282X2011000300010; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Sneeuw KCA, 1997, STROKE, V28, P1541, DOI 10.1161/01.STR.28.8.1541; Staquet M, 1992, QUAL LIFE RES, V1; StataCorp, 2019, STATA STAT SOFTWARE; Subramaniam M, 2014, PSYCHIAT RES, V215, P46, DOI 10.1016/j.psychres.2013.10.002; Watson WL, 2007, INJURY PREV, V13, P45, DOI 10.1136/ip.2005.010157; Wee HL, 2007, ANN ACAD MED SINGAP, V36, P403; Wilson R, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-68; WITYK RJ, 1994, STROKE, V25, P362, DOI 10.1161/01.STR.25.2.362; Xie JP, 2006, STROKE, V37, P2567, DOI 10.1161/01.STR.0000240506.34616.10	34	15	15	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2019	14	1							e0211493	10.1371/journal.pone.0211493	http://dx.doi.org/10.1371/journal.pone.0211493			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HJ3AL	30689666	Green Published, gold, Green Submitted			2023-01-03	WOS:000457041800036
J	Chard, AN; Trinies, V; Edmonds, CJ; Sogore, A; Freeman, MC				Chard, Anna N.; Trinies, Victoria; Edmonds, Caroline J.; Sogore, Assitan; Freeman, Matthew C.			The impact of water consumption on hydration and cognition among schoolchildren: Methods and results from a crossover trial in rural Mali	PLOS ONE			English	Article							HEAT-STRESS; VOLUNTARY DEHYDRATION; SANITATION PROGRAM; URINARY INDEXES; SCHOOL; EXERCISE; HYGIENE; PERFORMANCE	Adequate provision of safe water, basic sanitation, and hygiene (WASH) facilities and behavior change can reduce pupil absence and infectious disease. Increased drinking water quantity may also improve educational outcomes through the effect of hydration on attention, concentration, and short-term memory. A pilot study was conducted to adapt field measures of short-term cognitive performance and hydration, to evaluate levels of hydration, and to investigate the impact of providing supplementary drinking water on the cognitive performance of pupils attending water-scarce schools in rural Mali. Using a cross-over trial design, data were collected under normal school conditions (control condition) on one visit day; on the other, participants were given a bottle of water that was refilled throughout the day (water condition). Morning and afternoon hydration was assessed using specific gravity and urine color. Cognitive performance was evaluated using six paper-based tests. Three percent of pupils were dehydrated on the morning of each visit. The prevalence of dehydration increased in the afternoon, but was lower under the water condition. Although there was a trend indicating drinking water may improve cognitive test performance, as has been shown in studies in other settings, results were not statistically significant and were masked by a "practice effect."	[Chard, Anna N.; Trinies, Victoria; Freeman, Matthew C.] Emory Univ, Rollins Sch Publ Hlth, Dept Environm Hlth, Atlanta, GA 30322 USA; [Edmonds, Caroline J.] Univ East London, Sch Psychol, London, England; [Sogore, Assitan] Save Children Mali, Monitoring Evaluat & Learning Sect, Bamako, Mali	Emory University; Rollins School Public Health; University of East London; Save the Children	Freeman, MC (corresponding author), Emory Univ, Rollins Sch Publ Hlth, Dept Environm Hlth, Atlanta, GA 30322 USA.	matthew.freeman@emory.edu	Freeman, Matthew/ABE-6245-2020	Freeman, Matthew/0000-0002-1517-2572; Trinies, Victoria/0000-0002-7863-7509; Edmonds, Caroline/0000-0001-7971-0918	Emory University Research Committee; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES012870] Funding Source: NIH RePORTER	Emory University Research Committee; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Funding was provided by the Emory University Research Committee (http://www.urc.emory.edu/grants/urc/index.html). MCF received funding (grant number N/A). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armstrong LE, 2007, J AM COLL NUTR, V26, p575S, DOI 10.1080/07315724.2007.10719661; Armstrong LE, 2005, NUTR REV, V63, pS40, DOI 10.1111/j.1753-4887.2005.tb00153.x; Armstrong LE, 1998, INT J SPORT NUTR, V8, P345, DOI 10.1123/ijsn.8.4.345; ARMSTRONG LE, 1994, INT J SPORT NUTR, V4, P265, DOI 10.1123/ijsn.4.3.265; Baker LB, 2007, MED SCI SPORT EXER, V39, P976, DOI 10.1097/mss.0b013e3180471ff2; Bar-David Y, 2005, ACTA PAEDIATR, V94, P1667, DOI 10.1080/08035250500254670; Bar-David Y, 2009, J HUM NUTR DIET, V22, P455, DOI 10.1111/j.1365-277X.2009.00960.x; Benton D, 2009, APPETITE, V53, P143, DOI 10.1016/j.appet.2009.05.006; Bowen A, 2007, AM J TROP MED HYG, V76, P1166, DOI 10.4269/ajtmh.2007.76.1166; Cian C, 2001, INT J PSYCHOPHYSIOL, V42, P243, DOI 10.1016/S0167-8760(01)00142-8; Cian C, 2000, J PSYCHOPHYSIOL, V14, P29, DOI 10.1027//0269-8803.14.1.29; Edmonds CJ, 2009, APPETITE, V53, P469, DOI 10.1016/j.appet.2009.10.002; Edmonds CJ, 2009, APPETITE, V52, P776, DOI 10.1016/j.appet.2009.02.010; Fadda R, 2012, APPETITE, V59, P730, DOI 10.1016/j.appet.2012.07.005; Freeman MC, 2014, EPIDEMIOL INFECT, V142, P340, DOI 10.1017/S0950268813001118; Freeman MC, 2013, AM J TROP MED HYG, V89, P875, DOI 10.4269/ajtmh.13-0237; Freeman MC, 2012, TROP MED INT HEALTH, V17, P380, DOI 10.1111/j.1365-3156.2011.02927.x; GOPINATHAN PM, 1988, ARCH ENVIRON HEALTH, V43, P15, DOI 10.1080/00039896.1988.9934367; Grandjean AC, 2007, J AM COLL NUTR, V26, p549S, DOI 10.1080/07315724.2007.10719657; Kavouras SA, 2002, CURR OPIN CLIN NUTR, V5, P519, DOI 10.1097/00075197-200209000-00010; Rogers PJ, 2001, APPETITE, V36, P57, DOI 10.1006/appe.2000.0374; SHARMA VM, 1983, INT ARCH OCC ENV HEA, V52, P315, DOI 10.1007/BF02226897; Talaat M, 2011, EMERG INFECT DIS, V17, P619, DOI 10.3201/eid1704.101353; Trinies V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150071; UNICEF, 2013, UNICEF WATER SANITAT; Wong D L, 1988, Pediatr Nurs, V14, P9; WYON DP, 1979, SCAND J WORK ENV HEA, V5, P352, DOI 10.5271/sjweh.2646	27	12	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2019	14	1							e0210568	10.1371/journal.pone.0210568	http://dx.doi.org/10.1371/journal.pone.0210568			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH8WT	30653554	Green Submitted, Green Published, gold, Green Accepted			2023-01-03	WOS:000456015500052
J	Hsu, WH; Shen, YC; Shiao, YJ; Kuo, CH; Lu, CK; Lin, TY; Ku, WC; Lin, YL				Hsu, Wei-Hsiang; Shen, Yuh-Chiang; Shiao, Young-Ji; Kuo, Ching-Hua; Lu, Chung-Kuang; Lin, Tai-Yuan; Ku, Wei-Chi; Lin, Yun-Lian			Combined proteomic and metabolomic analyses of cerebrospinal fluid from mice with ischemic stroke reveals the effects of a Buyang Huanwu decoction in neurodegenerative disease	PLOS ONE			English	Article							ALZHEIMERS-DISEASE; MOUSE MODEL; BIOMARKER; PROTEIN; CSF; HYPOXANTHINE; MECHANISMS; XANTHINE; DEMENTIA; PLASMA	Ischemic stroke is one of the most common causes of death worldwide and is a major cause of acquired disability in adults. However, there is still a need for an effective drug for its treatment. Buyang Huanwu decoction (BHD), a traditional Chinese medicine (TCM) prescription, has long been used clinically to aid neurological recovery after stroke. To establish potential clinical indicators of BHD efficacy in stroke treatment and prognosis, we conducted a combined proteomic and metabolomic analysis of cerebrospinal fluid (CSF) samples in a mouse stroke model. CSF samples were obtained from male mice with acute ischemic stroke induced by middle cerebral ischemic/reperfusion (CI/R) injury, some of which were then treated with BHD. Label-free quantitative proteomics was conducted using nano-LC-MS/MS on an LTQ Orbitrap mass and metabolomic analysis was performed using nanoprobe NMR and UHPLC-QTOF-MS. The results showed that several proteins and metabolites were present at significantly different concentrations in the CSF samples from mice with CI/R alone and those treated with BHD. These belonged to pathways related to energy demand, inflammatory signaling, cytoskeletal regulation, Wnt signaling, and neuroprotection against neurodegenerative diseases. In conclusion, our in silico data suggest that BHD treatment is not only protective but can also ameliorate defects in pathways affected by neurological disorders. These data shed light on the mechanism whereby BHD may be effective in the treatment and prevention of stroke-related neurodegenerative disease.	[Hsu, Wei-Hsiang; Lin, Yun-Lian] China Med Univ, Dept Chinese Pharmaceut Sci & Chinese Med Resourc, Taichung, Taiwan; [Shen, Yuh-Chiang; Shiao, Young-Ji; Lu, Chung-Kuang] Minist Hlth & Welf, Natl Res Inst Chinese Med, Taipei, Taiwan; [Kuo, Ching-Hua; Lin, Yun-Lian] Natl Taiwan Univ, Dept Pharm, Taipei, Taiwan; [Lin, Tai-Yuan; Ku, Wei-Chi] Fu Jen Catholic Univ, Sch Med, Coll Med, New Taipei, Taiwan	China Medical University Taiwan; National Research Institute of Chinese Medicine; National Taiwan University; Fu Jen Catholic University	Lin, YL (corresponding author), China Med Univ, Dept Chinese Pharmaceut Sci & Chinese Med Resourc, Taichung, Taiwan.; Lin, YL (corresponding author), Natl Taiwan Univ, Dept Pharm, Taipei, Taiwan.; Ku, WC (corresponding author), Fu Jen Catholic Univ, Sch Med, Coll Med, New Taipei, Taiwan.	089052@mail.fju.edu.tw; yllin5212@gmail.com	Ku, Wei-Chi/F-1031-2010; Shiao, Young-Ji/AAA-9647-2022	Ku, Wei-Chi/0000-0001-8438-3210; Lin, Tai-Yuan/0000-0002-9958-5234	Ministry of Science and Technology of Taiwan [MOST 103-2320-B-039-055-MY3, 102-2320-B-030-012-MY2, 104-2320-B-039-055-MY3]	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by the grants from Ministry of Science and Technology of Taiwan (MOST 102-2320-B-039-055-MY3, 102-2320-B-030-012-MY2, and 103-2320-B-039-055-MY3).; This work was supported by the Ministry of Science and Technology of Taiwan (MOST 103-2320-B-039-055-MY3, 102-2320-B-030-012-MY2, and 104-2320-B-039-055-MY3). We thank the Mass Spectrometry Laboratory of Tzong Jwo Jang, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan, for the assistance on proteomics analyses. We are also grateful for Mr. Yen-Ming Chao assisting in <SUP>1</SUP>H-NMR analysis, Dr. Yu-Lun Kuo for the IPA analysis, and Professor Kuo-Tong Liu, Department of Chinese Martial Arts and Graduate Institute of Sport Coaching Science, Chinese Culture University, Taiwan, for his kindly providing BHD materials.	ALOM J, 1991, ANN NEUROL, V30, P735, DOI 10.1002/ana.410300518; [Anonymous], [No title captured]; Awasthi YC, 2004, FREE RADICAL BIO MED, V37, P607, DOI 10.1016/j.freeradbiomed.2004.05.033; Benjamin EJ, 2017, CIRCULATION, V135, pE146, DOI 10.1161/CIR.0000000000000485; Bruggink KA, 2015, J NEUROCHEM, V134, P1152, DOI 10.1111/jnc.13216; Chen HJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140823; Chen HJ, 2012, METABOLOMICS, V8, P974, DOI 10.1007/s11306-011-0394-0; Chen LH, 2011, CHINESE J ETHNOMEDIC, V15, P102; Cologna SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047845; Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591; Cruz T, 2014, METABOLITES, V4, P115, DOI 10.3390/metabo4010115; Cunningham R, 2013, J PROTEOME RES, V12, P719, DOI 10.1021/pr300785h; Czech C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031501; Dayon L, 2011, J PROTEOME RES, V10, P1043, DOI 10.1021/pr101123t; DEGRELL I, 1988, ARCH GERONTOL GERIAT, V7, P173, DOI 10.1016/0167-4943(88)90029-5; Dieks JK, 2013, J ALZHEIMERS DIS, V34, P387, DOI 10.3233/JAD-121810; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Fernandez-Lopez D, 2012, J NEUROSCI, V32, P9588, DOI 10.1523/JNEUROSCI.5977-11.2012; Hao CZ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/630124; Jellinger K, 2006, EUR J NEUROL, V13, pE1, DOI 10.1111/j.1468-1331.2006.00926.x; Kelly-Spratt KS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019721; Kim JY, 2014, CURR MED CHEM, V21, P2076, DOI 10.2174/0929867321666131228205146; Kimberly WT, 2013, STROKE, V44, P1389, DOI 10.1161/STROKEAHA.111.000397; Kominsky DJ, 2010, J IMMUNOL, V184, P4062, DOI 10.4049/jimmunol.0903002; Kulak NA, 2014, NAT METHODS, V11, P319, DOI [10.1038/NMETH.2834, 10.1038/nmeth.2834]; Lansberg MG, 2009, STROKE, V40, P2438, DOI 10.1161/STROKEAHA.109.552547; Liu Chuanzhen, 2003, J Tradit Chin Med, V23, P243; Liu Li, 2008, J Vis Exp, DOI 10.3791/960; Llano DA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182098; Luo L, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/4072658; MARTINEZ M, 1993, J NEURAL TRANSM-PARK, V6, P1, DOI 10.1007/BF02252617; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; Menzie J, 2014, AMINO ACIDS, V46, P31, DOI 10.1007/s00726-012-1382-z; Mi HY, 2016, NUCLEIC ACIDS RES, V44, pD336, DOI 10.1093/nar/gkv1194; Morimoto K., 1987, NO SHINKEI GEKA, V15, P25; NIKLASSON F, 1988, UPSALA J MED SCI, V93, P225, DOI 10.3109/03009738809178548; O'Brien RJ, 2011, ANNU REV NEUROSCI, V34, P185, DOI 10.1146/annurev-neuro-061010-113613; Pitteri SJ, 2011, CANCER RES, V71, P5090, DOI 10.1158/0008-5472.CAN-11-0568; Pla V, 2013, BRAIN PATHOL, V23, P274, DOI 10.1111/j.1750-3639.2012.00644.x; Pluta R, 2004, FOLIA NEUROPATHOL, V42, P181; Prestwich EG, 2013, CHEM RES TOXICOL, V26, P538, DOI 10.1021/tx300473n; Regeniter A, 2009, CLIN NEUROL NEUROSUR, V111, P313, DOI 10.1016/j.clineuro.2008.12.004; Sethi JK, 2010, BIOCHEM J, V427, P1, DOI 10.1042/BJ20091866; Shruster A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040843; Sjodin S, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0160-z; Smith JS, 2014, PROTEOMICS, V14, P1102, DOI 10.1002/pmic.201300241; Srivastava K, 2013, J CEREBR BLOOD F MET, V33, P1928, DOI 10.1038/jcbfm.2013.151; Stover JF, 1997, NEUROSCI LETT, V238, P25, DOI 10.1016/S0304-3940(97)00840-9; Talelli P, 2004, ARCH NEUROL-CHICAGO, V61, P983, DOI 10.1001/archneur.61.6.983-b; THOMPSON EJ, 2005, CSF PROTEINS BIOCH A; Voevodskaya O, 2016, NEUROLOGY, V86, P1754, DOI 10.1212/WNL.0000000000002672; Wang HW, 2011, J ETHNOPHARMACOL, V138, P22, DOI 10.1016/j.jep.2011.06.033; Wang WR, 2011, J ETHNOPHARMACOL, V137, P214, DOI 10.1016/j.jep.2011.05.008; Wang Y, 2013, MOL BIOSYST, V9, P431, DOI 10.1039/c2mb25224d; Watabe-Rudolph M, 2012, NEUROLOGY, V78, P569, DOI 10.1212/WNL.0b013e318247caa1; Xia JG, 2010, BIOINFORMATICS, V26, P2342, DOI 10.1093/bioinformatics/btq418; Yin GN, 2009, BRAIN RES, V1265, P158, DOI 10.1016/j.brainres.2009.01.058; Zenzmaier C, 2009, J NEUROCHEM, V110, P653, DOI 10.1111/j.1471-4159.2009.06158.x; Zhang QN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033722; Zhou JY, 2009, J PROTEOME RES, V8, P5387, DOI 10.1021/pr900564f	60	11	13	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2019	14	1							e0209184	10.1371/journal.pone.0209184	http://dx.doi.org/10.1371/journal.pone.0209184			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH6AH	30645580	Green Submitted, Green Published, gold			2023-01-03	WOS:000455810200007
J	Kompotiatis, P; Wiley, BM; Jentzer, JC; Kashani, KB				Kompotiatis, Panagiotis; Wiley, Brandon M.; Jentzer, Jacob C.; Kashani, Kianoush B.			Echocardiographic parameters of patients in the intensive care unit undergoing continuous renal replacement therapy	PLOS ONE			English	Article							ELECTRONIC SEARCH STRATEGIES; CRITICALLY-ILL PATIENTS; ACUTE KIDNEY INJURY; PULMONARY-HYPERTENSION; AMERICAN-SOCIETY; TRICUSPID REGURGITATION; EUROPEAN-ASSOCIATION; HEART-FAILURE; RECOMMENDATIONS; AKI	Main objectives Echocardiographic parameters have been used to predict outcomes for specific intensive care unit (ICU) populations. We sought to define echocardiographic parameters for ICU patients receiving continuous renal replacement therapy (CRRT). Design, setting, participants, and measurements This is a historical cohort study of consecutive ICU patients at Mayo Clinic (Rochester, Minnesota) who received CRRT from December 9, 2006, through November 13, 2015. Only patients with an echocardiographic examination within 7 days of CRRT initiation were considered. Results The study included 1,276 patients. Decreased left ventricular ejection fraction (LVEF; <= 45%) was noted in 361/1,120 (32%) and increased right ventricular systolic pressure (RVSP; >= 40 mm Hg) was noted in 529/798 (66%). Right ventricular systolic dysfunction was observed in 320/820 (39%). The most common valvular abnormality was tricuspid regurgitation (244/1,276 [19%]). Stratification of these parameters by ICU type (medical, surgical, cardiothoracic, cardiac) showed that most echocardiographic abnormalities were significantly more prevalent among cardiac ICU patients: LVEF <= 45% (67/105 [64%]), RVSP >= 40 mm Hg (63/79 [80%]) and tricuspid regurgitation (50/130 [38%]). We compared patients with acute kidney injury (AKI) vs end-stage renal disease and showed that decreased LVEF (284/921 [31%] vs 78/201 [39%]), was significantly less prevalent among patients with AKI, but increased RVSP was more prevalent (445/651 [68%] vs 84/147 [57%]) with AKI. Conclusions ICU patients who required CRRT had increased prevalence of pulmonary hypertension and right and left ventricular systolic dysfunction. Prediction of adverse outcomes with echocardiographic parameters in this patient population can lead to identification of modifiable risk factors.	[Kompotiatis, Panagiotis; Kashani, Kianoush B.] Mayo Clin, Dept Med, Div Nephrol & Hypertens, Rochester, MN 55905 USA; [Wiley, Brandon M.; Jentzer, Jacob C.] Mayo Clin, Dept Cardiovasc Med, Rochester, MN USA; [Kashani, Kianoush B.] Mayo Clin, Dept Med, Div Pulm & Crit Care Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Kashani, KB (corresponding author), Mayo Clin, Dept Med, Div Nephrol & Hypertens, Rochester, MN 55905 USA.; Kashani, KB (corresponding author), Mayo Clin, Dept Med, Div Pulm & Crit Care Med, Rochester, MN 55905 USA.	kashani.kianoush@mayo.edu	Wiley, Brandon M./AAG-6306-2020; Wiley, Brandon/Z-5879-2019	Wiley, Brandon/0000-0003-3651-7231; Kashani, Kianoush/0000-0003-2184-3683	CTSA Grant from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) [UL1 TR002377]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002377] Funding Source: NIH RePORTER	CTSA Grant from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This publication was made possible by CTSA Grant Number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). This study was not funded, and the grant is for the first author's training as part of the Clinical and Translational Science certificate program.	Alsara A, 2011, MAYO CLIN PROC, V86, P382, DOI 10.4065/mcp.2010.0802; Baumgartner H, 2009, J AM SOC ECHOCARDIOG, V22, P1, DOI 10.1016/j.echo.2008.11.029; Bellomo R, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0260-y; Bouchard J, 2015, CLIN J AM SOC NEPHRO, V10, P1324, DOI 10.2215/CJN.04360514; Chen KP, 2016, CLIN J AM SOC NEPHRO, V11, P602, DOI 10.2215/CJN.08080715; Etchecopar-Chevreuil C, 2008, INTENS CARE MED, V34, P250, DOI 10.1007/s00134-007-0929-z; Haji K, 2018, J CARDIOTHOR VASC AN, V32, P354, DOI 10.1053/j.jvca.2017.08.026; HARNETT JD, 1995, KIDNEY INT, V47, P884, DOI 10.1038/ki.1995.132; Herasevich V, 2010, MAYO CLIN PROC, V85, P247, DOI 10.4065/mcp.2009.0479; Hickson LJ, 2016, J AM COLL CARDIOL, V67, P1173, DOI 10.1016/j.jacc.2015.12.052; Hoste E, 2015, INTENS CARE MED, V41, P1411, DOI 10.1007/s00134-015-3934-7; Husain-Syed F, 2015, J AM COLL CARDIOL, V65, P2433, DOI 10.1016/j.jacc.2015.04.024; Jentzer JC, 2016, J INTENSIVE CARE MED, V31, P369, DOI 10.1177/0885066615583652; Jue J, 1992, J Am Soc Echocardiogr, V5, P613; Kanji HD, 2014, J CRIT CARE, V29, P700, DOI 10.1016/j.jcrc.2014.04.008; Kellum JA, 2015, J AM SOC NEPHROL, V26, P2231, DOI 10.1681/ASN.2014070724; Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789; Klein AL, 2013, J AM SOC ECHOCARDIOG, V26, P965, DOI 10.1016/j.echo.2013.06.023; Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005; Mehta RL, 2015, LANCET, V385, P2616, DOI 10.1016/S0140-6736(15)60126-X; Metcalfe W, 2002, QJM-INT J MED, V95, P579, DOI 10.1093/qjmed/95.9.579; Mutlak D, 2007, J AM SOC ECHOCARDIOG, V20, P405, DOI 10.1016/j.echo.2006.09.013; Nagueh SF, 2009, J AM SOC ECHOCARDIOG, V22, P107, DOI 10.1016/j.echo.2008.11.023; Ostermann M, 2016, BLOOD PURIFICAT, V42, P224, DOI 10.1159/000448506; Pulido JN, 2012, MAYO CLIN PROC, V87, P620, DOI 10.1016/j.mayocp.2012.01.018; Rabindranath K, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003773.pub3; Roberts MA, 2011, AM J KIDNEY DIS, V58, P64, DOI 10.1053/j.ajkd.2011.01.024; Rocco MV, 2012, AM J KIDNEY DIS, V60, P857, DOI 10.1053/j.ajkd.2012.07.005; Ronco C, 2012, J AM COLL CARDIOL, V60, P1031, DOI 10.1016/j.jacc.2012.01.077; Ronco C, 2008, INTENS CARE MED, V34, P2139, DOI 10.1007/s00134-008-1258-6; Rudski LG, 2010, J AM SOC ECHOCARDIOG, V23, P685, DOI 10.1016/j.echo.2010.05.010; SAGIE A, 1994, J AM COLL CARDIOL, V24, P446, DOI 10.1016/0735-1097(94)90302-6; Sanfilippo F, 2015, INTENS CARE MED, V41, P1004, DOI 10.1007/s00134-015-3748-7; Santosh S, 2019, NEPHROLOGY, V24, P74, DOI 10.1111/nep.13183; Schrier RW, 2008, CLIN J AM SOC NEPHRO, V3, P1232, DOI 10.2215/CJN.01960408; See KC, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0343-9; Singh B, 2012, MAYO CLIN PROC, V87, P817, DOI 10.1016/j.mayocp.2012.04.015; Stamm Jason A, 2011, Pulm Circ, V1, P95, DOI 10.4103/2045-8932.78104; Sturgess DJ, 2010, CRIT CARE, V14, DOI 10.1186/cc8931; Tang MY, 2018, AM J KIDNEY DIS, V72, P75, DOI 10.1053/j.ajkd.2017.11.018; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; Vallabhajosyula S, 2018, J INTENSIVE CARE MED, V33, P680, DOI 10.1177/0885066616684774; Vallabhajosyula S, 2018, SHOCK, V49, P144, DOI 10.1097/SHK.0000000000000952; Vallabhajosyula S, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0319-9; Villa G, 2015, CRIT CARE CLIN, V31, P839, DOI 10.1016/j.ccc.2015.06.015; Vinsonneau C, 2006, LANCET, V368, P379, DOI 10.1016/S0140-6736(06)69111-3; Wong BT, 2015, J CRIT CARE, V30, P975, DOI 10.1016/j.jcrc.2015.05.003; Zimmerman JE, 2013, CRIT CARE, V17, DOI 10.1186/cc12695; Zoghbi WA, 2003, J AM SOC ECHOCARDIOG, V16, P777, DOI 10.1016/S0894-7317(03)00335-3	49	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2019	14	1							e0209994	10.1371/journal.pone.0209994	http://dx.doi.org/10.1371/journal.pone.0209994			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH1MW	30633756	Green Published, Green Submitted, gold			2023-01-03	WOS:000455485100011
J	Wadhera, RK; Maddox, KEJ; Wasfy, JH; Haneuse, S; Shen, CY; Yeh, RW				Wadhera, Rishi K.; Maddox, Karen E. Joynt; Wasfy, Jason H.; Haneuse, Sebastien; Shen, Changyu; Yeh, Robert W.			Association of the Hospital Readmissions Reduction Program With Mortality Among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FALSE DISCOVERY RATE; RATES; PERFORMANCE; OUTCOMES; PENALTIES; QUALITY; TRENDS; CARE	IMPORTANCE The Hospital Readmissions Reduction Program (HRRP) has been associated with a reduction in readmission rates for heart failure (HF), acute myocardial infarction (AMI), and pneumonia. It is unclear whether the HRRP has been associated with change in patient mortality. OBJECTIVE To determine whether the HRRP was associated with a change in patient mortality. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study of hospitalizations for HF, AMI, and pneumonia among Medicare fee-for-service beneficiaries aged at least 65 years across 4 periods from April 1.2005, to March 31, 2015. Period 1 and period 2 occurred before the HRRP to establish baseline trends (April 2005-September 2007 and October 2007-March 2010). Period 3 and period 4 were after HRRP announcement (April 2010 to September 2012) and HRRP implementation (October 2012 to March 2015). EXPOSURES Announcement and implementation of the HRRP. MAIN OUTCOMES AND MEASURES Inverse probability-weighted mortality within 30 days of discharge following hospitalization for HF, AMI, and pneumonia, and stratified by whether there was an associated readmission. An additional end point was mortality within 45 days of initial hospital admission for target conditions. RESULTS The study cohort included 8.3 million hospitalizations for HF, AMI, and pneumonia, among which 7.9 million (mean age. 79.6 [8.7] years; 53.4% women) were alive at discharge. There were 3.2 million hospitalizations for HF, 1.8 million for AMI, and 3.0 million for pneumonia. There were 270 517 deaths within 30 days of discharge for HF, 128 088 for AMI, and 246 154 for pneumonia. Among patients with HF, 30-day postdischarge mortality increased before the announcement of the HRRP (0.27% increase from period 1 to period 2). Compared with this baseline trend, HRRP announcement (0.49% increase from period 2 to period 3; difference in change, 0.22%, P = .01) and implementation (0.52% increase from period 3 to period 4; difference in change, 0.25%, P = .001) were significantly associated with an increase in postdischarge mortality. Among patients with AMI, HRRP announcement was associated with a decline in postdischarge mortality (0.18% pre-HRRP increase vs 0.08% post-HRRP announcement decrease; difference in change, -0.26%; P = .01) and did not significantly change after HRRP implementation. Among patients with pneumonia, postdischarge mortality was stable before HRRP (0.04% increase from period 1 to period 2), but significantly increased after HRRP announcement (026% post-HRRP announcement increase; difference in change, 022%, P = .01) and implementation (0.44% post-HPPR implementation increase; difference in change, 0.40%, P < .001). The overall increase in mortality among patients with HF and pneumonia was mainly related to outcomes among patients who were not readmitted but died within 30 days of discharge. For all 3 conditions, HRRP implementation was not significantly associated with an increase in mortality within 45 days of admission, relative to pre-HRRP trends. CONCLUSIONS AND RELEVANCE Among Medicare beneficiaries, the HRRP was significantly associated with an increase in 30-day postdischarge mortality after hospitalization for HF and pneumonia, but not for AMI. Given the study design and the lack of significant association of the HRRP with mortality within 45 days of admission, further research is needed to understand whether the increase in 30-day postdischarge mortality is a result of the policy.	[Wadhera, Rishi K.; Shen, Changyu; Yeh, Robert W.] Beth Israel Deaconess Med, Richard A & Susan F Smith Ctr Outcomes Res Cardio, Boston, MA USA; [Wadhera, Rishi K.; Shen, Changyu; Yeh, Robert W.] Harvard Med Sch, Boston, MA USA; [Wadhera, Rishi K.] Harvard Med Sch, Heart & Vasc Ctr, Brigham & Womens Hosp, Boston, MA USA; [Maddox, Karen E. Joynt] Washington Univ, Sch Med, Dept Med, Div Cardiovasc, St Louis, MO 63110 USA; [Wasfy, Jason H.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA USA; [Haneuse, Sebastien] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Washington University (WUSTL); Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Shen, CY; Yeh, RW (corresponding author), Beth Israel Deaconess Med Ctr, Smith Ctr Outcomes Res Cardiol, 375 Longwood Ave, Boston, MA 02215 USA.	ryeh@bidmc.harvard.edu	Yeh, Robert/AAJ-3463-2020	Wadhera, Rishi/0000-0003-1089-3896	Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology	Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology	This work was supported by the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology.	Akintoye E, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006955; Benjamini Y, 2001, ANN STAT, V29, P1165; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boccuti C, AIMING FEWER HOSP TU; Bratzler DW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017401; Centers for Medicare and Medicaid Services, HOSP READM RED PROGR; Chatterjee P, 2018, JAMA CARDIOL, V3, P336, DOI 10.1001/jamacardio.2018.0218; D'Agostino RB, 2007, JAMA-J AM MED ASSOC, V297, P314, DOI 10.1001/jama.297.3.314; Dharmarajan K, 2017, JAMA-J AM MED ASSOC, V318, P270, DOI 10.1001/jama.2017.8444; Downing NS, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.2044; Figueroa JF, 2017, MED CARE, V55, P229, DOI 10.1097/MLR.0000000000000687; Fonarow GC, 2017, J AM COLL CARDIOL, V70, P1931, DOI 10.1016/j.jacc.2017.08.046; Gupta A, 2018, EUR J HEART FAIL, V20, P1169, DOI 10.1002/ejhf.1212; Gupta A, 2018, JAMA CARDIOL, V3, P44, DOI 10.1001/jamacardio.2017.4265; Ibrahim AM, 2018, JAMA INTERN MED, V178, P290, DOI 10.1001/jamainternmed.2017.6148; Joynt KE, 2013, NEW ENGL J MED, V368, P1175, DOI 10.1056/NEJMp1300122; Joynt KE, 2013, JAMA-J AM MED ASSOC, V309, P342, DOI 10.1001/jama.2012.94856; Keenan PS, 2008, CIRC-CARDIOVASC QUAL, V1, P29, DOI 10.1161/CIRCOUTCOMES.108.802686; Khera R, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.2777; Khera R, 2018, JACC-HEART FAIL, V6, P610, DOI 10.1016/j.jchf.2018.02.011; Krumholz HM, 2015, JAMA-J AM MED ASSOC, V314, P355, DOI 10.1001/jama.2015.8035; Krumholz HM, 2014, CIRCULATION, V130, P966, DOI 10.1161/CIRCULATIONAHA.113.007787; Krumholz HM, 2011, CIRC-CARDIOVASC QUAL, V4, P243, DOI 10.1161/CIRCOUTCOMES.110.957498; Krumholz HM, 2006, CIRCULATION, V113, P1683, DOI 10.1161/CIRCULATIONAHA.105.611186; Krumholz HM, 2006, CIRCULATION, V113, P1693, DOI 10.1161/CIRCULATIONAHA.105.611194; Lindenauer PK, 2012, JAMA-J AM MED ASSOC, V307, P1405, DOI 10.1001/jama.2012.384; Lindenauer PK, 2011, J HOSP MED, V6, P142, DOI 10.1002/jhm.890; Medicare Payment Advisory Commission, 2017, REP C MED PAYM POL; Medicare Payment Advisory Committee, 2018, REP C MED HLTH CAR D; Pandey A, 2017, JAMA CARDIOL, V2, P723, DOI 10.1001/jamacardio.2017.1143; Pandey A, 2016, JACC-HEART FAIL, V4, P935, DOI 10.1016/j.jchf.2016.07.003; Phadke A, 2016, J CARD FAIL, V22, P312, DOI 10.1016/j.cardfail.2015.12.005; Pope GC, 2004, HEALTH CARE FINANC R, V25, P119; Rothberg MB, 2014, ANN INTERN MED, V160, P380, DOI 10.7326/M13-1419; Teno JM, 2018, JAMA-J AM MED ASSOC, V320, P264, DOI 10.1001/jama.2018.8981; Thompson MP, 2017, HEALTH AFFAIR, V36, P893, DOI 10.1377/hlthaff.2016.1204; Wasfy JH, 2017, ANN INTERN MED, V166, P324, DOI 10.7326/M16-0185; Zuckerman RB, 2016, NEW ENGL J MED, V374, P1543, DOI 10.1056/NEJMsa1513024	38	202	206	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	2018	320	24					2542	2552		10.1001/jama.2018.19232	http://dx.doi.org/10.1001/jama.2018.19232			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG1EK	30575880	Green Published, Bronze			2023-01-03	WOS:000454693000015
J	Burton, LJ; Hawsawi, O; Sweeney, J; Bowen, N; Hudson, T; Odero-Marah, V				Burton, Liza J.; Hawsawi, Ohuod; Sweeney, Janae; Bowen, Nathan; Hudson, Tamaro; Odero-Marah, Valerie			CCAAT-displacement protein/cut homeobox transcription factor (CUX1) represses estrogen receptor-alpha (ER-alpha) in triple-negative breast cancer cells and can be antagonized by muscadine grape skin extract (MSKE)	PLOS ONE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CATHEPSIN-L; EXPRESSION; TAMOXIFEN; ISOFORM; NUCLEUS; SNAIL1; SIGNAL; PHASE; EGFR	Triple-Negative Breast Cancers (TNBCs) are the most difficult to treat subtype of breast cancer and are often associated with high nuclear expression of Snail and Cathepsin L (Cat L) protease. We have previously shown that Snail can increase Cat L expression/activity in prostate and breast cancer cells. This study investigated the role of CUX1 (a downstream substrate of Cat L) in TNBC. We showed that Cat L and CUX1 were highly expressed in TNBC patient tissue/cell lines, as compared to ER-positive samples, using cBioportal data and western blot/zymography analyses. Additionally, luciferase reporter and chromatin immunoprecipitation assays showed that CUX1 directly bound to estrogen receptor-alpha (ER-alpha) promoter in MDA-MB-468, a representative TNBC cell line, and that CUX1 siRNA could restore ER-alpha transcription and protein expression. Furthermore, Snail and CUX1 expression in various TNBC cell lines was inhibited by muscadine grape skin extract (MSKE, a natural grape product rich in anthocyanins) or Cat L inhibitor (Z-FY-CHO) leading to decreased cell invasion and migration. MSKE decreased cell viability and increased expression of apoptotic markers in MDA-MB-468 cells, with no effect on non-tumorigenic MCF10A cells. MSKE also decreased CUX1 binding to ER-alpha promoter and restored ER-a expression in TNBC cells, while both MSKE and CUX1 siRNA restored sensitivity to estradiol and 4-hydoxytamoxifen as shown by increased cell viability. Therefore, CUX1 activated by Snail-Cat L signaling may contribute to TNBC via ER-alpha repression, and may be a viable target for TNBC using natural products such as MSKE that targets cancer and not normal cells.	[Burton, Liza J.; Hawsawi, Ohuod; Sweeney, Janae; Bowen, Nathan; Odero-Marah, Valerie] Clark Atlanta Univ, Ctr Canc Res & Therapeut Dev, Dept Biol Sci, Atlanta, GA 30314 USA; [Hudson, Tamaro] Howard Univ, Dept Med, Washington, DC 20059 USA	Clark Atlanta University; Howard University	Odero-Marah, V (corresponding author), Clark Atlanta Univ, Ctr Canc Res & Therapeut Dev, Dept Biol Sci, Atlanta, GA 30314 USA.	voderomarah@cau.edu	Bowen, Nathan J./M-3202-2019	Bowen, Nathan J./0000-0002-1609-6698; Sweeney, Janae/0000-0002-5942-2158	National Institutes of Health [8 G12 MD007590, 2 P20 MD002285, 5F31CA200362-02]; NATIONAL CANCER INSTITUTE [F31CA200362] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [G12MD007590, P20MD002285] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This work was supported by National Institutes of Health grant 8 G12 MD007590, and 2 P20 MD002285 (to V.O.M), and 5F31CA200362-02 (to L.J.B). b). The funders had no role in design, data collection and analysis, decision to publish, or preparation of the manuscript.	Burton LJ, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00297-16; Burton LJ, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-97; Chen JQ, 2009, BBA-REV CANCER, V1796, P162, DOI 10.1016/j.bbcan.2009.06.003; Decensi A, 2003, J NATL CANCER I, V95, P779, DOI 10.1093/jnci/95.11.779; den Hollander P, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00250; Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293; Fan P, 2007, CANCER RES, V67, P1352, DOI 10.1158/0008-5472.CAN-06-1020; Geradts J, 2011, HUM PATHOL, V42, P1125, DOI 10.1016/j.humpath.2010.11.004; Gjerde J, 2012, BREAST CANCER RES TR, V134, P693, DOI 10.1007/s10549-012-2074-9; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Goulet B, 2006, BIOL CHEM, V387, P1285, DOI 10.1515/BC.2006.159; Grotsky DA, 2013, J CELL BIOL, V200, P187, DOI 10.1083/jcb.201204053; Hudson TS, 2007, CANCER RES, V67, P8396, DOI 10.1158/0008-5472.CAN-06-4069; Kedinger V, 2009, J BIOL CHEM, V284, P27701, DOI 10.1074/jbc.M109.031849; Kong EH, 2003, BIOCHEM SOC T, V31, P56, DOI 10.1042/BST0310056; Lazzeroni M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3233; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; McKeithen D, 2010, PROSTATE, V70, P982, DOI 10.1002/pros.21132; Paller CJ, 2015, PROSTATE, V75, P1518, DOI 10.1002/pros.23024; Santana-Davila R, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-42; Scherbakov AM, 2012, J CELL BIOCHEM, V113, P2147, DOI 10.1002/jcb.24087; Shanle EK, 2011, BIOCHEM PHARMACOL, V82, P1940, DOI 10.1016/j.bcp.2011.08.026; Smith BN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104987; Song RXD, 2010, J STEROID BIOCHEM, V118, P219, DOI 10.1016/j.jsbmb.2009.09.018; SOULE HD, 1990, CANCER RES, V50, P6075; Subik K, 2010, BREAST CANCER-BASIC, V4, P35; Sullivan S, 2009, INT J CANCER, V125, P54, DOI 10.1002/ijc.24275; Truscott M, 2003, MOL CELL BIOL, V23, P3013, DOI 10.1128/MCB.23.8.3013-3028.2003; Wilder C, 2011, ARCH BIOCHEM BIOPHYS, V516, P187; Wu YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078259	31	5	5	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2019	14	4							e0214844	10.1371/journal.pone.0214844	http://dx.doi.org/10.1371/journal.pone.0214844			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HS4YI	30964885	Green Published, Green Submitted, gold			2023-01-03	WOS:000463876300036
J	Mercer, MP; Singh, MK; Kanzaria, HK				Mercer, Mary P.; Singh, Malini K.; Kanzaria, Hemal K.			Reducing Emergency Department Length of Stay	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARE		[Mercer, Mary P.; Singh, Malini K.; Kanzaria, Hemal K.] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp & Trauma Ctr, Dept Emergency Med, 1001 Potrero Ave,Room 1E21, San Francisco, CA 94110 USA	University of California System; University of California San Francisco	Mercer, MP (corresponding author), Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp & Trauma Ctr, Dept Emergency Med, 1001 Potrero Ave,Room 1E21, San Francisco, CA 94110 USA.	mary.mercer@ucsf.edu			University of California San Francisco Department of Emergency Medicine; Zuckerberg San Francisco General Hospital	University of California San Francisco Department of Emergency Medicine; Zuckerberg San Francisco General Hospital	This work was supported by the University of California San Francisco Department of Emergency Medicine and the Zuckerberg San Francisco General Hospital and Trauma Center.	Chow JL, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014721; Dickson EW, 2009, ANN EMERG MED, V54, P504, DOI 10.1016/j.annemergmed.2009.03.024; Holden RJ, 2011, ANN EMERG MED, V57, P265, DOI 10.1016/j.annemergmed.2010.08.001; Kellermann AL, 2013, HEALTH AFFAIR, V32, P2069, DOI 10.1377/hlthaff.2013.0683; Le ST, 2014, JAMA INTERN MED, V174, P1847, DOI 10.1001/jamainternmed.2014.3431; Lukas CV, 2007, HEALTH CARE MANAGE R, V32, P309, DOI 10.1097/01.HMR.0000296785.29718.5d	6	17	17	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2019	321	14					1402	1403		10.1001/jama.2018.21812	http://dx.doi.org/10.1001/jama.2018.21812			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT5PG	30888416				2023-01-03	WOS:000464615200020
J	Filimao, DBC; Moon, TD; Senise, JF; Diaz, RS; Sidat, M; Castelo, A				Filimao, Dercio B. C.; Moon, Troy D.; Senise, Jorge F.; Diaz, Ricardo S.; Sidat, Mohsin; Castelo, Adauto			Individual factors associated with time to non-adherence to ART pick-up within HIV care and treatment services in three health facilities of Zambezia Province, Mozambique	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY INITIATION; SUB-SAHARAN AFRICA; ADHERENCE; DETERMINANTS; CHILDREN; PREDICTORS; RETENTION	Introduction Mozambique has made significant gains in addressing its HIV epidemic, yet adherence to visit schedules remains a challenge. HIV programmatic gains to date could be impaired if adherence and retention to ART remains low. We investigate individual factors associated with non-adherence to ART pick-up in Mozambique. Methods This was a retrospective cohort of patients initiating ART between January 2013 and June 2014. Non-adherence to ART pick-up was defined as a delay in pick-up. 15 days. Descriptive statistics were used to calculate socio-demographic and clinical characteristics. Adherence to ART pick-up was assessed using Kaplan Meier estimates. Cox proportional hazards model was used to determine factors associated with non-adherence. Results 1,413 participants were included (77% female). Median age was 30.4 years. 19% of patients remained adherent to ART pick-up during the evaluation period, while 81% of patients were non-adherent to ART pick-up. Probability of being non-adherent to ART pick-up by 166 days following initiation was 50%. In univariate analysis, being widowed was associated with higher adherence to ART pick-up than other marital status groups (p = 0.01). After adjusting, being >= 35 years (aHR: 0.843, 95% CI: 0.738-0.964, p = 0.012); receiving efavirenz (aHR: 0.932, 95% CI: 0.875-0.992, p = 0.026); and being urban (aHR: 0.754, 95% CI: 0.661-0.861, p < 0.0001) were associated with improved adherence. Non-participation in a Community ART Support Group (CASG) was associated with a 43% increased hazard of non-adherence to ART pick-up (aHR 1.431, 1.192-1.717, p < 0.0001) Conclusions Interventions should focus on the first 6 months following ARV initiation for improvements. Younger persons and widows are two target groups for better understanding facilitators and barriers to visit schedule adherence. Future strategies should explore the benefits of joining CASGs earlier in ones treatment course. Finally, greater efforts should be made to accelerate the scale-up of viral load capacity and HIV resistance monitoring.	[Filimao, Dercio B. C.] Prov Directorate Hlth, Quelimane, Zambezia Provin, Mozambique; [Filimao, Dercio B. C.; Moon, Troy D.] Vanderbilt Univ, Med Ctr, Vanderbilt Inst Global Hlth, Nashville, TN 37232 USA; [Filimao, Dercio B. C.; Senise, Jorge F.; Castelo, Adauto] Univ Fed Sao Paulo, Dept Med, Sao Paulo, Brazil; [Filimao, Dercio B. C.; Diaz, Ricardo S.] Univ Fed Sao Paulo, Retrovirol Lab, Sao Paulo, Brazil; [Sidat, Mohsin] Univ Eduardo Mondlane, Fac Med, Maputo, Mozambique	Vanderbilt University; Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP); Eduardo Mondlane University	Filimao, DBC (corresponding author), Prov Directorate Hlth, Quelimane, Zambezia Provin, Mozambique.; Filimao, DBC (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Inst Global Hlth, Nashville, TN 37232 USA.; Filimao, DBC (corresponding author), Univ Fed Sao Paulo, Dept Med, Sao Paulo, Brazil.; Filimao, DBC (corresponding author), Univ Fed Sao Paulo, Retrovirol Lab, Sao Paulo, Brazil.	derciobelo18@gmail.com	Sidat, Mohsin/AAS-1894-2021	Moon, Troy/0000-0002-1637-829X; Sidat, Mohsin/0000-0002-8378-2014	Fogarty International Center of the National Institutes for Health [D43 TW009745]; President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC) [NU2GGH002071]; FOGARTY INTERNATIONAL CENTER [D43TW009745] Funding Source: NIH RePORTER	Fogarty International Center of the National Institutes for Health; President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	This project has been supported by the Fogarty International Center of the National Institutes for Health under Award Number D43 TW009745 to TDM and by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC) under the terms of grant number NU2GGH002071. The findings and conclusions in this report are solely the responsibility of the author (s) and do not necessarily represent the office position of the National Institutes for Health or the U.S. Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alakija Kazeem Salami, 2010, J Int Assoc Physicians AIDS Care (Chic), V9, P191, DOI 10.1177/1545109710368722; Ammon N, 2018, PUBLIC HEALTH, V157, P20, DOI 10.1016/j.puhe.2017.12.010; [Anonymous], MOZ STEPP FAST TRACK; Audet CM, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0582-z; Audet CM, 2012, SAHARA J-J SOC ASP H, V9, P41, DOI 10.1080/17290376.2012.665257; Audet CM, 2010, BMC INT HEALTH HUM R, V10, DOI 10.1186/1472-698X-10-15; Bayham M, 2017, AM J TROP MED HYG, V96, P493, DOI 10.4269/ajtmh.16-0233; Beyene KA, 2009, PHARMACOEPIDEM DR S, V18, P1007, DOI 10.1002/pds.1814; Bezabhe WM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097353; Brinkhof MWG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005790; Carlucci JG, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1741-z; Charurat M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010584; Ciampa PJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039391; Cook RE, 2011, JAIDS-J ACQ IMM DEF, V56, pE104, DOI 10.1097/QAI.0b013e318207a535; da Silva M, 2015, AIDS BEHAV, V19, P666, DOI 10.1007/s10461-014-0874-0; Edwards LJ, 2015, INT J HEALTH POLICY, V4, P353, DOI 10.15171/ijhpm.2015.58; Enane LA, 2018, CURR OPIN HIV AIDS, V13, P212, DOI [10.1097/COH.0000000000000459, 10.1097/coh.0000000000000459]; Fonsah JY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170893; Gill CJ, 2005, AIDS, V19, P1243, DOI 10.1097/01.aids.0000180094.04652.3b; Gokarn Anant, 2012, J Assoc Physicians India, V60, P16; Groh K, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-650; Jamieson D, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20917; Jobarteh K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166444; Mannheimer S, 2002, CLIN INFECT DIS, V34, P1115, DOI 10.1086/339074; Mocumbi S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173243; Moon TD, 2011, INT J STD AIDS, V22, P621, DOI 10.1258/ijsa.2011.010442; Moon TD, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1250-5; Moon TD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109653; Moon TD, 2014, B WORLD HEALTH ORGAN, V92, P680, DOI 10.2471/BLT.13.129478; Moon Troy D, 2010, Retrovirology (Auckl), V3, P1; Mukui IN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167465; Nosyk B, 2015, AIDS, V29, P1681, DOI 10.1097/QAD.0000000000000746; Reliquet V, 2001, HIV Med, V2, P92, DOI 10.1046/j.1468-1293.2001.00066.x; Rose Elizabeth S, 2015, BMC Nutr, V1; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Shemwell SA, 2017, INT HEALTH, V9, P234, DOI 10.1093/inthealth/ihx020; Shepherd BE, 2013, AM J EPIDEMIOL, V178, P819, DOI 10.1093/aje/kwt030; Skovdal M, 2011, INT J HEALTH PLAN M, V26, P296, DOI 10.1002/hpm.1082; UNAIDS, 90 90 90 AMB TREATM; Uzochukwu BSC, 2009, HEALTH POLICY PLANN, V24, P189, DOI 10.1093/heapol/czp006; Vermund SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110116; Victor B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108654; Wakibi SN, 2011, AIDS RES THER, V8, DOI 10.1186/1742-6405-8-43	43	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2019	14	3							e0213804	10.1371/journal.pone.0213804	http://dx.doi.org/10.1371/journal.pone.0213804			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ1KV	30908522	Green Published, gold, Green Submitted			2023-01-03	WOS:000462157600020
J	Motzer, RJ; Penkov, K; Haanen, J; Rini, B; Albiges, L; Campbell, MT; Venugopal, B; Kollmannsberger, C; Negrier, S; Uemura, M; Lee, JL; Vasiliev, A; Miller, WH; Gurney, H; Schmidinger, M; Larkin, J; Atkins, MB; Bedke, J; Alekseev, B; Wang, J; Mariani, M; Robbins, PB; Chudnovsky, A; Fowst, C; Hariharan, S; Huang, B; di Pietro, A; Choueiri, TK				Motzer, Robert J.; Penkov, Konstantin; Haanen, John; Rini, Brian; Albiges, Laurence; Campbell, Matthew T.; Venugopal, Balaji; Kollmannsberger, Christian; Negrier, Sylvie; Uemura, Motohide; Lee, Jae L.; Vasiliev, Aleksandr; Miller, Wilson H., Jr.; Gurney, Howard; Schmidinger, Manuela; Larkin, James; Atkins, Michael B.; Bedke, Jens; Alekseev, Boris; Wang, Jing; Mariani, Mariangela; Robbins, Paul B.; Chudnovsky, Aleksander; Fowst, Camilla; Hariharan, Subramanian; Huang, Bo; di Pietro, Alessandra; Choueiri, Toni K.			Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERFERON-ALPHA; OPEN-LABEL; SYMPTOM INDEX; SORAFENIB; THERAPY; MULTICENTER; SURVIVAL	Background In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective responses in patients with advanced renal-cell carcinoma. This phase 3 trial involving previously untreated patients with advanced renal-cell carcinoma compared avelumab plus axitinib with the standard-of-care sunitinib. Methods We randomly assigned patients in a 1:1 ratio to receive avelumab (10 mg per kilogram of body weight) intravenously every 2 weeks plus axitinib (5 mg) orally twice daily or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The two independent primary end points were progression-free survival and overall survival among patients with programmed death ligand 1 (PD-L1)-positive tumors. A key secondary end point was progression-free survival in the overall population; other end points included objective response and safety. Results A total of 886 patients were assigned to receive avelumab plus axitinib (442 patients) or sunitinib (444 patients). Among the 560 patients with PD-L1-positive tumors (63.2%), the median progression-free survival was 13.8 months with avelumab plus axitinib, as compared with 7.2 months with sunitinib (hazard ratio for disease progression or death, 0.61; 95% confidence interval [CI], 0.47 to 0.79; P<0.001); in the overall population, the median progression-free survival was 13.8 months, as compared with 8.4 months (hazard ratio, 0.69; 95% CI, 0.56 to 0.84; P<0.001). Among the patients with PD-L1-positive tumors, the objective response rate was 55.2% with avelumab plus axitinib and 25.5% with sunitinib; at a median follow-up for overall survival of 11.6 months and 10.7 months in the two groups, 37 patients and 44 patients had died, respectively. Adverse events during treatment occurred in 99.5% of patients in the avelumab-plus-axitinib group and in 99.3% of patients in the sunitinib group; these events were grade 3 or higher in 71.2% and 71.5% of the patients in the respective groups. Conclusions Progression-free survival was significantly longer with avelumab plus axitinib than with sunitinib among patients who received these agents as first-line treatment for advanced renal-cell carcinoma.	[Motzer, Robert J.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA; [Hariharan, Subramanian] Pfizer, New York, NY USA; [Penkov, Konstantin] Private Med Inst Euromedserv, St Petersburg, Russia; [Vasiliev, Aleksandr] Nonstate Hlth Inst Rd Clin Hosp Russian Railways, St Petersburg, Russia; [Alekseev, Boris] Moscow Sci Res Oncol Inst, Moscow, Russia; [Haanen, John] Netherlands Canc Inst, Amsterdam, Netherlands; [Rini, Brian] Cleveland Clin, Cleveland, OH 44106 USA; [Albiges, Laurence] Inst Gustave Roussy, Villejuif, France; [Negrier, Sylvie] Univ Lyon, Ctr Leon Berard, Lyon, France; [Campbell, Matthew T.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Venugopal, Balaji] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland; [Larkin, James] Royal Marsden NHS Fdn Trust, London, England; [Kollmannsberger, Christian] British Columbia Canc Agcy, Vancouver, BC, Canada; [Miller, Wilson H., Jr.] McGill Univ, Lady Davis Inst, Montreal, PQ, Canada; [Miller, Wilson H., Jr.] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada; [Uemura, Motohide] Osaka Univ Hosp, Osaka, Japan; [Lee, Jae L.] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea; [Gurney, Howard] Macquarie Univ, Sydney, NSW, Australia; [Schmidinger, Manuela] Med Univ Vienna, Div Clin Oncol, Dept Med 1, Vienna, Austria; [Schmidinger, Manuela] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria; [Atkins, Michael B.] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA; [Bedke, Jens] Univ Tubingen, Dept Urol, Tubingen, Germany; [Wang, Jing; Chudnovsky, Aleksander] Pfizer, Cambridge, MA USA; [Choueiri, Toni K.] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA; [Choueiri, Toni K.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Mariani, Mariangela; di Pietro, Alessandra] Pfizer, Milan, Italy; [Fowst, Camilla] Pfizer Italia, Milan, Italy; [Robbins, Paul B.] Pfizer, San Diego, CA USA; [Huang, Bo] Pfizer, Groton, CT USA	Memorial Sloan Kettering Cancer Center; Pfizer; Russian Railroads; Netherlands Cancer Institute; Cleveland Clinic Foundation; UNICANCER; Gustave Roussy; UNICANCER; Centre Leon Berard; University of Texas System; UTMD Anderson Cancer Center; Beatson Oncology Centre; University of Glasgow; Royal Marsden NHS Foundation Trust; British Columbia Cancer Agency; Lady Davis Institute; McGill University; McGill University; Osaka University; University of Ulsan; Macquarie University; Medical University of Vienna; Medical University of Vienna; Eberhard Karls University of Tubingen; Pfizer; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Pfizer; Pfizer; Pfizer; Pfizer	Motzer, RJ (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.; Choueiri, TK (corresponding author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.	motzerr@mskcc.org; toni_choueiri@dfci.harvard.edu	Venugopal, Balaji/AAX-7846-2021; Gurney, Howard/ABF-6924-2020; Bedke, Jens/AAS-2837-2020; uemura, motohide/G-6101-2011; Choueiri, Toni/K-5238-2019; Haanen, John/AAD-8534-2022; Alekseev, Boris/O-1008-2017; Haanen, John/AAD-8578-2022	Gurney, Howard/0000-0003-0217-5261; Bedke, Jens/0000-0003-2778-3108; Choueiri, Toni/0000-0002-9201-3217; Haanen, John/0000-0001-5884-7704; Alekseev, Boris/0000-0002-3398-4128; Larkin, James/0000-0001-5569-9523; Miller, Wilson H./0000-0002-7408-1574	Pfizer; Merck (Darmstadt, Germany); Memorial Sloan Kettering Cancer Center Support Grant/Core Grant [P30 CA008748]; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Pfizer(Pfizer); Merck (Darmstadt, Germany)(Merck & Company); Memorial Sloan Kettering Cancer Center Support Grant/Core Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by Pfizer and an alliance between Pfizer and Merck (Darmstadt, Germany). The conduct of the trial at the Memorial Sloan Kettering Cancer Center was supported in part by Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748).	American Cancer Society, 2017, SURV RAT KIDN CANC S; [Anonymous], 2014, INL AX; [Anonymous], 2011, SUT SUN; [Anonymous], 2018, BAV AV INJ; Choueiri TK, 2018, LANCET ONCOL, V19, P451, DOI 10.1016/S1470-2045(18)30107-4; Choueiri TK, 2017, NEW ENGL J MED, V376, P354, DOI 10.1056/NEJMra1601333; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Escudier B, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.4511; Gulley JL, 2017, LANCET ONCOL, V18, P599, DOI 10.1016/S1470-2045(17)30240-1; Heng DYC, 2009, J CLIN ONCOL, V27, P5794, DOI 10.1200/JCO.2008.21.4809; Hutson TE, 2013, LANCET ONCOL, V14, P1287, DOI 10.1016/S1470-2045(13)70465-0; JENNISON C, 1984, CONTROL CLIN TRIALS, V5, P33, DOI 10.1016/0197-2456(84)90148-X; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kaufman HL, 2016, LANCET ONCOL, V17, P1374, DOI 10.1016/S1470-2045(16)30364-3; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Motzer RJ, 2002, J CLIN ONCOL, V20, P289, DOI 10.1200/JCO.2002.20.1.289; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Motzer RJ, 2013, NEW ENGL J MED, V369, P722, DOI 10.1056/NEJMoa1303989; Motzer RJ, 2013, LANCET ONCOL, V14, P552, DOI 10.1016/S1470-2045(13)70093-7; Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293; Nadal R, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.4566; National Comprehensive Cancer Network, 2018, NCCN GUID KIDN CANC; Patel MR, 2018, LANCET ONCOL, V19, P51, DOI 10.1016/S1470-2045(17)30900-2; Rao D, 2009, J PAIN SYMPTOM MANAG, V38, P291, DOI 10.1016/j.jpainsymman.2008.08.013; Rini BI, 2011, LANCET, V378, P1931, DOI 10.1016/S0140-6736(11)61613-9; Roland CL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007669; Rothrock NE, 2013, VALUE HEALTH, V16, P789, DOI 10.1016/j.jval.2013.04.015; Turajlic S, 2018, J EXP MED, V215, P2477, DOI 10.1084/jem.20181617; Vaishampayan N, 2018, ANN ONCOL S8, V29, pviii303; Yasuda S, 2013, CLIN EXP IMMUNOL, V172, P500, DOI 10.1111/cei.12069	32	1222	1250	6	60	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	2019	380	12					1103	1115		10.1056/NEJMoa1816047	http://dx.doi.org/10.1056/NEJMoa1816047			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP7VK	30779531	Bronze, Green Accepted			2023-01-03	WOS:000461898400006
J	Rini, BI; Plimack, ER; Stus, V; Gafanov, R; Hawkins, R; Nosov, D; Pouliot, F; Alekseev, B; Soulieres, D; Melichar, B; Vynnychenko, I; Kryzhanivska, A; Bondarenko, I; Azevedo, SJ; Borchiellini, D; Szczylik, C; Markus, M; McDermott, RS; Bedke, J; Tartas, S; Chang, YH; Tamada, S; Shou, Q; Perini, RF; Chen, M; Atkins, MB; Powles, T				Rini, Brian I.; Plimack, Elizabeth R.; Stus, Viktor; Gafanov, Rustem; Hawkins, Robert; Nosov, Dmitry; Pouliot, Frederic; Alekseev, Boris; Soulieres, Denis; Melichar, Bohuslav; Vynnychenko, Ihor; Kryzhanivska, Anna; Bondarenko, Igor; Azevedo, Sergio J.; Borchiellini, Delphine; Szczylik, Cezary; Markus, Maurice; McDermott, Raymond S.; Bedke, Jens; Tartas, Sophie; Chang, Yen-Hwa; Tamada, Satoshi; Shou, Qiong; Perini, Rodolfo F.; Chen, Mei; Atkins, Michael B.; Powles, Thomas		Keynote-426 Investigators	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLIND PHASE-III; OPEN-LABEL; SURVIVAL; SORAFENIB; PAZOPANIB; THERAPY	Background The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear. Methods In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients). The primary end points were overall survival and progression-free survival in the intention-to-treat population. The key secondary end point was the objective response rate. All reported results are from the protocol-specified first interim analysis. Results After a median follow-up of 12.8 months, the estimated percentage of patients who were alive at 12 months was 89.9% in the pembrolizumab-axitinib group and 78.3% in the sunitinib group (hazard ratio for death, 0.53; 95% confidence interval [CI], 0.38 to 0.74; P<0.0001). Median progression-free survival was 15.1 months in the pembrolizumab-axitinib group and 11.1 months in the sunitinib group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.57 to 0.84; P<0.001). The objective response rate was 59.3% (95% CI, 54.5 to 63.9) in the pembrolizumab-axitinib group and 35.7% (95% CI, 31.1 to 40.4) in the sunitinib group (P<0.001). The benefit of pembrolizumab plus axitinib was observed across the International Metastatic Renal Cell Carcinoma Database Consortium risk groups (i.e., favorable, intermediate, and poor risk) and regardless of programmed death ligand 1 expression. Grade 3 or higher adverse events of any cause occurred in 75.8% of patients in the pembrolizumab-axitinib group and in 70.6% in the sunitinib group. Conclusions Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression-free survival, as well as a higher objective response rate, than treatment with sunitinib.	[Rini, Brian I.] Cleveland Clin, Taussig Canc Inst, 9500 Euclid Ave,Desk CA60, Cleveland, OH 44195 USA; [Plimack, Elizabeth R.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Stus, Viktor] Minist Hlth Ukraine, Dnipropetrovsk Med Acad, Dnipro, Ukraine; [Bondarenko, Igor] Dnipropetrovsk Med Acad, Dnipro, Ukraine; [Vynnychenko, Ihor] Sumy State Univ, Sumy Reg Oncol Ctr, Sumy, Ukraine; [Kryzhanivska, Anna] Ivano Frankivsk Natl Med Univ, Ivano Frankivsk, Ukraine; [Gafanov, Rustem] Russian Sci Ctr Roentgen Radiol, Moscow, Russia; [Nosov, Dmitry] Cent Clin Hosp, Outpatient Clin, Moscow, Russia; [Alekseev, Boris] Hertzen Moscow Canc Res Inst, Moscow, Russia; [Hawkins, Robert] Christie NHS Fdn Trust, Manchester, Lancs, England; [Powles, Thomas] Barts Hlth NHS Trust, Barts Canc Inst, London, England; [Powles, Thomas] Royal Free NHS Trust, Barts Canc Inst, London, England; [Powles, Thomas] Queen Mary Univ London, London, England; [Pouliot, Frederic] Ctr Hosp Univ CHU Quebec, Quebec City, PQ, Canada; [Pouliot, Frederic] Univ Laval, Quebec City, PQ, Canada; [Soulieres, Denis] CHU Montreal, Montreal, PQ, Canada; [Melichar, Bohuslav] Palacky Univ, Med Sch & Teaching Hosp, Olomouc, Czech Republic; [Azevedo, Sergio J.] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil; [Borchiellini, Delphine] Univ Cote Azur, Ctr Antoine Lacassagne, Nice, France; [Tartas, Sophie] Hop Univ Lyon, Lyon, France; [Szczylik, Cezary] Mil Inst Med, Warsaw, Poland; [Markus, Maurice] Rocky Mt Canc Ctr, Colorado Springs, CO USA; [McDermott, Raymond S.] Adelaide & Meath Hosp, Dublin, Ireland; [McDermott, Raymond S.] Univ Coll Dublin, Dublin, Ireland; [Bedke, Jens] Eberhard Karls Univ Tubingen, Dept Urol, Tubingen, Germany; [Chang, Yen-Hwa] Taipei Vet Gen Hosp, Taipei, Taiwan; [Tamada, Satoshi] Osaka City Univ Hosp, Osaka, Japan; [Shou, Qiong] MSD China, Beijing, Peoples R China; [Perini, Rodolfo F.; Chen, Mei] Merck, Kenilworth, NJ USA; [Atkins, Michael B.] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA	Cleveland Clinic Foundation; Fox Chase Cancer Center; Dnipro State Medical University; Ministry of Health of Ukraine; Dnipro State Medical University; Ministry of Education & Science of Ukraine; Sumy State University; Ivano-Frankivsk National Medical University; Christie NHS Foundation Trust; Barts Health NHS Trust; University of London; Queen Mary University London; University of London; Queen Mary University London; University College London; University of London; Queen Mary University London; Laval University; Laval University; Universite de Montreal; Palacky University Olomouc; University Hospital Olomouc; UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; CHU Lyon; Military Institute of Aviation Medicine; Rocky Mountain Cancer Centers; Trinity College Dublin; University College Dublin; Eberhard Karls University of Tubingen; Taipei Veterans General Hospital; Osaka Metropolitan University; Merck & Company	Rini, BI (corresponding author), Cleveland Clin, Taussig Canc Inst, 9500 Euclid Ave,Desk CA60, Cleveland, OH 44195 USA.	rinib2@ccf.org	Vynnychenko, Ihor O/E-1684-2012; Kryzhanivska, Anna/ABG-4997-2020; Bondarenko, Igor/W-9412-2019; Bondarenko, Igor N/GQP-1497-2022; Kimura, Go/Y-7843-2018; de Azevedo, Sergio Jobim/P-5115-2015; Bedke, Jens/AAS-2837-2020; Gafanov, Rustem Ayratovich/P-3454-2017; Alekseev, Boris/O-1008-2017	Vynnychenko, Ihor O/0000-0002-2339-6509; Kryzhanivska, Anna/0000-0001-7720-7374; Bondarenko, Igor/0000-0002-7071-2471; Bondarenko, Igor N/0000-0002-7071-2471; Kimura, Go/0000-0003-0088-9324; Bedke, Jens/0000-0003-2778-3108; Alekseev, Boris/0000-0002-3398-4128; Gafanov, Rustem/0000-0002-7592-0392; Brugarolas, James/0000-0002-8575-499X; Pouliot, Frederic/0000-0002-6651-1079; OUDARD, Stephane/0000-0003-0893-285X; Szczylik, Cezary/0000-0002-2524-2810; McDermott, Ray/0000-0002-8952-4315	Merck Sharp Dohme	Merck Sharp Dohme(Merck & Company)	Supported by Merck Sharp & Dohme. Axitinib and sunitinib were provided by Pfizer.	[Anonymous], 2018, KEYTRUDA PEMBR INJ I; [Anonymous], 2018, INLYTA AX TABL OR AD; Atkins MB, 2018, LANCET ONCOL, V19, P405, DOI 10.1016/S1470-2045(18)30081-0; Choueiri TK, 2017, NEW ENGL J MED, V376, P354, DOI 10.1056/NEJMra1601333; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Escudier B, 2007, LANCET, V370, P2103, DOI 10.1016/S0140-6736(07)61904-7; Escudier B, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.4511; Escudier B, 2009, J CLIN ONCOL, V27, P1280, DOI 10.1200/JCO.2008.19.3342; Heng DYC, 2009, J CLIN ONCOL, V27, P5794, DOI 10.1200/JCO.2008.21.4809; Hutson TE, 2013, LANCET ONCOL, V14, P1287, DOI 10.1016/S1470-2045(13)70465-0; MCDERMOTT DF, 2018, J CLIN ONCOL S, V36; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Motzer RJ, 2018, EUR SOC MED ONC 2018; Motzer RJ, 2014, NEW ENGL J MED, V370, P1769, DOI 10.1056/NEJMc1400731; Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293; Noone A, 2017, SEER CANC STAT REV C; Rini BI, 2010, J CLIN ONCOL, V28, P2137, DOI 10.1200/JCO.2009.26.5561; SCHAG CC, 1984, J CLIN ONCOL, V2, P187, DOI 10.1200/JCO.1984.2.3.187; Sternberg CN, 2013, EUR J CANCER, V49, P1287, DOI 10.1016/j.ejca.2012.12.010; Tsimafeyeu I, 2017, CLIN GENITOURIN CANC, V15, pE1069, DOI 10.1016/j.clgc.2017.07.017	20	1554	1586	9	69	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	2019	380	12					1116	1127		10.1056/NEJMoa1816714	http://dx.doi.org/10.1056/NEJMoa1816714			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP7VK	30779529	Bronze			2023-01-03	WOS:000461898400007
J	Calvo-Lerma, J; Hulst, J; Boon, M; Colombo, C; Masip, E; Ruperto, M; Fornes-Ferrer, V; van der Wiel, E; Claes, I; Garriga, M; Roca, M; Crespo-Escobar, P; Bulfamante, A; Woodcock, S; Martinez-Barona, S; Andres, A; de Boeck, K; Ribes-Koninckx, C; Asensio-Grau, A; Asseiceira, I; Barreto, C; Martinez, AC; Heredia, A; Martins, T; Nobili, R; Pereira, L; Paz-Yepez, C; Valmarana, L; Valmarana, R; Walet, S				Calvo-Lerma, Joaquim; Hulst, Jessie; Boon, Mieke; Colombo, Carla; Masip, Etna; Ruperto, Mar; Fornes-Ferrer, Victoria; van der Wiel, Els; Claes, Ine; Garriga, Maria; Roca, Maria; Crespo-Escobar, Paula; Bulfamante, Anna; Woodcock, Sandra; Martinez-Barona, Sandra; Andres, Ana; de Boeck, Kris; Ribes-Koninckx, Carmen; Asensio-Grau, Andrea; Asseiceira, Ines; Barreto, Celeste; Canada Martinez, Antonio; Heredia, Ana; Martins, Tiago; Nobili, Rita; Pereira, Luisa; Paz-Yepez, Carolina; Valmarana, Lauretta; Valmarana, Rosella; Walet, Sylvia		MyCyFAPP Project	Clinical validation of an evidence-based method to adjust Pancreatic Enzyme Replacement Therapy through a prospective interventional study in paediatric patients with Cystic Fibrosis	PLOS ONE			English	Article							IN-VITRO; FAT; CHILDREN; PH; COEFFICIENT	Background A method to adjust Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis is not currently available. Objectives To assess the in vivo efficacy of a method to adjust the dose of enzymatic supplement in CF extrapolated from previous in vitro digestion studies (theoretical optimal dose, TOD). Secondly, to assess how individual patient characteristics influence the expected coefficient of fat absorption (CFA) and thus to identify an individual correction factor to improve TOD. Methods A prospective interventional study in 43 paediatric patients with CF from 5 European centres. They followed a 24h fixed diet with the theoretical optimal dose for each meal. Faecal collection was carried out between colorimetric markers in order to include all the faeces corresponding to the fixed diet. Beta regression models were applied to assess the associations of individual patient characteristics with the CFA. Results Median CFA was 90% (84, 94% 1st, 3rd Q.) with no significant differences among centres. Intestinal transit time was positively associated with CFA (p = 0.007), but no statistical associations were found with and age, gender, phenotype or BMI. Regression model showed no improvement of the in vitro predicted theoretical optimal dose when taking individual patient characteristics into account. Conclusion Strict adherence to the theoretical optimal dose of enzymatic supplement for a prescribed meal, led to median CFA levels at the clinical target of 90% with a low variability between patients. The proposed method can be considered as a first approach for an evidence-based method in PERT dosing based on food characteristics. Results have to be confirmed in free dietary settings.	[Calvo-Lerma, Joaquim; Masip, Etna; Fornes-Ferrer, Victoria; Roca, Maria; Crespo-Escobar, Paula; Martinez-Barona, Sandra; Ribes-Koninckx, Carmen] Inst Invest Sanitaria La Fe Valencia, Valencia, Spain; [Calvo-Lerma, Joaquim; Andres, Ana] Univ Politecn Valencia, Res Inst Food Engn Dev, Valencia, Spain; [Hulst, Jessie; van der Wiel, Els; Woodcock, Sandra] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Rotterdam, Netherlands; [Boon, Mieke; Claes, Ine; de Boeck, Kris] Univ Hosp Leuven, Pediat Pulmonol & Cyst Fibrosis Unit, Dept Pediat, Leuven, Belgium; [Colombo, Carla; Bulfamante, Anna] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, CF Ctr, Via Commenda 9, Milan, Italy; [Ruperto, Mar; Garriga, Maria] Hosp Univ Ramon & Cajal, Carretera Colmenar Viejo Km 9, Madrid, Spain; [Calvo-Lerma, Joaquim; Andres, Ana; Asensio-Grau, Andrea; Heredia, Ana; Paz-Yepez, Carolina] Univ Politecn Valencia, Valencia, Spain; [Asseiceira, Ines; Barreto, Celeste; Martins, Tiago; Pereira, Luisa] Ctr Hosp Lisboa Norte, Lisbon, Portugal; [Boon, Mieke; Claes, Ine; de Boeck, Kris] UZ Leuven, Leuven, Belgium; [Colombo, Carla; Bulfamante, Anna; Nobili, Rita; Valmarana, Lauretta; Valmarana, Rosella] Univ Milan, Milan, Italy; [Calvo-Lerma, Joaquim; Masip, Etna; Fornes-Ferrer, Victoria; Roca, Maria; Crespo-Escobar, Paula; Martinez-Barona, Sandra; Ribes-Koninckx, Carmen; Canada Martinez, Antonio] Inst Invest Sanitaria La Fe, Valencia, Spain; [Hulst, Jessie; van der Wiel, Els; Woodcock, Sandra; Walet, Sylvia] Erasmus MC Sophias Children, Rotterdam, Netherlands	Universitat Politecnica de Valencia; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; KU Leuven; University Hospital Leuven; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Hospital Universitario Ramon y Cajal; Universitat Politecnica de Valencia; Universidade de Lisboa; KU Leuven; University of Milan; Erasmus University Rotterdam; Erasmus MC	Calvo-Lerma, J (corresponding author), Inst Invest Sanitaria La Fe Valencia, Valencia, Spain.	joaquin_calvo@iislafe.es; ribes_-car@gva.es	del Mar Ruperto Lopez, María/AAT-5976-2020; Ribes-Koninckx, Maria Carmen/ABH-5577-2020; Grau, Ana M Andrés/C-9521-2016; Boon, Mieke/AAS-8943-2020; Calvo-Lerma, Joaquim/P-4605-2016; Llorens, María Roca/AAD-4676-2020; Heredia, Ana/C-7107-2016; Ruperto, Mar/AAA-4145-2019; Calvo-Lerma, Joaquim/AAB-2783-2020; Roca, Maria/AGD-5148-2022; Hulst, Jessie/AAI-8519-2021; Asensio-Grau, Andrea/AAB-4490-2020	del Mar Ruperto Lopez, María/0000-0002-8790-4007; Grau, Ana M Andrés/0000-0002-6132-3167; Boon, Mieke/0000-0001-8138-5405; Calvo-Lerma, Joaquim/0000-0001-7818-0652; Heredia, Ana/0000-0001-6629-9779; Calvo-Lerma, Joaquim/0000-0001-7818-0652; Roca, Maria/0000-0001-8157-2446; Pereira, Maria Luisa/0000-0001-7235-2484; Ribes-Koninckx, Carmen/0000-0002-0038-6324; Asensio-Grau, Andrea/0000-0001-9591-5534	European Union; Horizon 2020 Research and Innovation Framework Programme [PHC-26-2014, 643806]	European Union(European Commission); Horizon 2020 Research and Innovation Framework Programme	This work was fully funded by the European Union and the Horizon 2020 Research and Innovation Framework Programme (PHC-26-2014 call Self management of health and disease: citizen engagement and mHealth) under grant number 643806.	Borowitz D, 2005, J PEDIATR GASTR NUTR, V41, P273, DOI 10.1097/01.mpg.0000178439.64675.8d; Calvo-Leima J, 2017, J CYST FIBROS, V16, P510, DOI 10.1016/j.jcf.2017.03.005; Calvo-Lerma J., 2019, J ACAD NUTR DIET; Calvo-Lerma J, 2017, REV ESP ENFERM DIG, V109, P684, DOI 10.17235/reed.2017.4951/2017; Calvo-Lerma J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014931; De Boeck K., 2016, LANCET RESP MED, V2600, P1; Dorsey J, 2010, J PEDIATR GASTR NUTR, V50, P441, DOI 10.1097/MPG.0b013e3181b18308; Fang XX, 2016, FOOD RES INT, V88, P276, DOI 10.1016/j.foodres.2016.04.008; Gelfond D, 2013, DIGEST DIS SCI, V58, P2275, DOI 10.1007/s10620-012-2209-1; GOW R, 1981, LANCET, V2, P1071; HARRIES JT, 1979, ARCH DIS CHILD, V54, P19, DOI 10.1136/adc.54.1.19; Helbig A, 2012, FOOD HYDROCOLLOID, V28, P10, DOI 10.1016/j.foodhyd.2011.11.007; Humbert L, 2018, J LIPID RES, V59, P2202, DOI 10.1194/jlr.M084830; Hunter E.J., 2011, LIPIDS, V36, P655; Korpi-Steiner NL, 2009, CLIN CHIM ACTA, V400, P33, DOI 10.1016/j.cca.2008.10.001; KOUMANTAKIS G, 1987, CLIN CHEM, V33, P502; Li Y, 2011, FOOD CHEM, V126, P498, DOI 10.1016/j.foodchem.2010.11.027; MITCHELL EA, 1982, AUST PAEDIATR J, V18, P114; Proesmans M, 2003, EUR J PEDIATR, V162, P760, DOI 10.1007/s00431-003-1309-5; Riegler G, 2001, Tech Coloproctol, V5, P163, DOI 10.1007/s101510100019; Rivero-Marcotegui A, 1998, CLIN CHEM, V44, P1540; ROBINSON PJ, 1990, DIGEST DIS SCI, V35, P1299, DOI 10.1007/BF01536423; Schall JI, 2006, J PEDIATR GASTR NUTR, V43, P651, DOI 10.1097/01.mpg.0000234082.47884.d9; Turck D, 2016, CLIN NUTR, V35, P557, DOI 10.1016/j.clnu.2016.03.004; Vecht J, 2006, J CLIN GASTROENTEROL, V40, P721, DOI 10.1097/00004836-200609000-00012; Woestenenk JW, 2015, J PEDIATR GASTR NUTR, V61, P355, DOI 10.1097/MPG.0000000000000784; Wouthuyzen-Bakker M, 2011, J CYST FIBROS, V10, P150, DOI 10.1016/j.jcf.2011.03.008	27	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2019	14	3							e0213216	10.1371/journal.pone.0213216	http://dx.doi.org/10.1371/journal.pone.0213216			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO6JJ	30861039	Green Submitted, Green Published, gold			2023-01-03	WOS:000461035600024
J	Huang, YL; Li, S; Yue, HZ; Wang, MJ; Hu, QQ; Wang, HY; Li, T; Li, CG; Wu, H; Zhang, YB				Huang, Yuliang; Li, Sha; Yue, Haizhen; Wang, Meijiao; Hu, Qiaoqiao; Wang, Haiyang; Li, Tian; Li, Chenguang; Wu, Hao; Zhang, Yibao			Impact of nominal photon energies on normal tissue sparing in knowledge-based radiotherapy treatment planning for rectal cancer patients	PLOS ONE			English	Article							INTENSITY-MODULATED RADIOTHERAPY; DOSE DISTRIBUTIONS; BEAM ENERGY; IMRT; CAPECITABINE; TOXICITY; THERAPY; NUMBER	The interactive adjustment of the optimization objectives during the treatment planning process has made it difficult to evaluate the impact of beam quality exclusively in radiotherapy. Without consensus in the published results, the arbitrary selection of photon energies increased the probability of suboptimal plans. This work aims to evaluate the dosimetric impact of various photon energies on the sparing of normal tissues by applying a preconfigured knowledge-based planning (RapidPlan) model to various clinically available photon energies for rectal cancer patients, based on model-generated optimization objectives, which provide a comparison basis with less human interference. A RapidPlan model based on 81 historical VMAT plans for pre-surgical rectal cancer patients using 10MV flattened beam (10X) was used to generate patient-specific objectives for the automated optimization of other 20 patients using 6X, 8X, 10X (reference), 6MV flattening-filter-free (6F) and 1OF beams respectively on a TrueBeam accelerator. It was observed that flattened beams produced very comparable target dose coverage yet the conformity index using 6F and 1OF were clinically unacceptable (>1.29). Therefore, dose to organs-at-risk (OARs) and normal tissues were only evaluated for flattened beams. RapidPlan-generated objectives for 6X and 8X beams can achieve comparable target dose coverage as that of 10X, yet the dose to normal tissues increased monotonically with decreased energies. Differences were statistically significant except femoral heads. From the radiological perspective of view, higher beam energy is still preferable for deep seated tumors, even if multiple field entries such as VMAT technique can accumulate enough dose to the target using lower energies, as reported in the literature. In conclusion, RapidPlan model configured for flattened beams cannot optimize un-flattened beams before adjusting the target objectives, yet works for flattened beams of other energies. For the investigated 10X, 8X and 6X photons, higher energies provide better normal tissue sparing.	[Huang, Yuliang; Yue, Haizhen; Wang, Meijiao; Hu, Qiaoqiao; Wang, Haiyang; Li, Tian; Li, Chenguang; Wu, Hao; Zhang, Yibao] Peking Univ, Canc Hosp & Inst, Beijing Canc Hosp & Inst, Minist Educ Beijing,Dept Radiat Oncol,Key Lab Car, Beijing, Peoples R China; [Li, Sha] Peking Univ, Inst Med Humanities, Dept Med Phys, Beijing, Peoples R China	Peking University; Peking University	Wu, H; Zhang, YB (corresponding author), Peking Univ, Canc Hosp & Inst, Beijing Canc Hosp & Inst, Minist Educ Beijing,Dept Radiat Oncol,Key Lab Car, Beijing, Peoples R China.	13552661030@139.com; zhangyibao@pku.edu.cn		Zhang, Yibao/0000-0003-3658-0687	Beijing Natural Science Foundation [1184014, 7172048]; Capital's Funds for Health Improvement and Research [2018-4-1027]; National Natural Science Foundation of China [11505012]; Foundation of Science and Technology Department of Sichuan Province [2018HH0099]; Beijing Municipal Administration of Hospitals Incubating Program [PX2019042, PX2016060]; Beijing Municipal Administration of Hospitals' Youth Program [QML20171104]	Beijing Natural Science Foundation(Beijing Natural Science Foundation); Capital's Funds for Health Improvement and Research; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation of Science and Technology Department of Sichuan Province; Beijing Municipal Administration of Hospitals Incubating Program; Beijing Municipal Administration of Hospitals' Youth Program	This work was jointly supported by Beijing Natural Science Foundation (7172048), Capital's Funds for Health Improvement and Research (2018-4-1027), National Natural Science Foundation of China (11505012), Beijing Natural Science Foundation (1184014), Foundation of Science and Technology Department of Sichuan Province (2018HH0099), Beijing Municipal Administration of Hospitals Incubating Program (PX2019042 and PX2016060) and Beijing Municipal Administration of Hospitals' Youth Program (QML20171104).	BOICE JD, 1985, J NATL CANCER I, V74, P955; Cheung MR, 2007, INT J RADIAT ONCOL, V67, P1059, DOI 10.1016/j.ijrobp.2006.10.042; Griem ML, 1985, JAMA-J AM MED ASSOC, V254, P3108; Heemsbergen WD, 2005, INT J RADIAT ONCOL, V61, P1011, DOI 10.1016/j.ijrobp.2004.07.724; Hong TS, 2015, INT J RADIAT ONCOL, V93, P29, DOI 10.1016/j.ijrobp.2015.05.005; Jiang F, 2017, J APPL CLIN MED PHYS, V18, P9, DOI 10.1002/acm2.12038; LAUGHLIN JS, 1986, INT J RADIAT ONCOL, V12, P1551, DOI 10.1016/0360-3016(86)90277-4; Li JL, 2012, RADIOTHER ONCOL, V102, P4, DOI 10.1016/j.radonc.2011.07.030; Mattes MD, 2014, PRACT RADIAT ONCOL, V4, pE39, DOI 10.1016/j.prro.2013.03.001; Onal C, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130617; Ost P, 2011, INT J RADIAT ONCOL, V79, P920, DOI 10.1016/j.ijrobp.2010.04.025; Paddick I, 2000, J NEUROSURG, V93, P219, DOI 10.3171/jns.2000.93.supplement_3.0219; Pirzkall A, 2002, INT J RADIAT ONCOL, V53, P434, DOI 10.1016/S0360-3016(02)02750-5; Shiraishi S, 2016, MED PHYS, V43, P378, DOI 10.1118/1.4938583; Sun M, 2006, J APPL CLIN MED PHYS, V7, P43, DOI 10.1120/jacmp.v7i4.2263; Varian Medical Systems, 2015, ECL PHOT EL ALG REF; Welsh JS, 2007, TECHNOL CANCER RES T, V6, P147, DOI 10.1177/153303460700600212; Wu BB, 2011, INT J RADIAT ONCOL, V79, P1241, DOI 10.1016/j.ijrobp.2010.05.026; Wu H, 2016, J APPL CLIN MED PHYS, V17, P78, DOI 10.1120/jacmp.v17i6.6410; Wu H, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0684-9; Yadav G, 2017, REP PRACT ONCOL RADI, V22, P1, DOI 10.1016/j.rpor.2016.09.002; Yuan LL, 2012, MED PHYS, V39, P6868, DOI 10.1118/1.4757927	22	6	6	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2019	14	3							e0213271	10.1371/journal.pone.0213271	http://dx.doi.org/10.1371/journal.pone.0213271			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO1AY	30845263	Green Published, Green Submitted, gold			2023-01-03	WOS:000460638800062
J	Kajal, A; Singh, R				Kajal, Anu; Singh, Randhir			Coriandrum sativum seeds extract mitigate progression of diabetic nephropathy in experimental rats via AGEs inhibition	PLOS ONE			English	Article							GLYCATION END-PRODUCTS; OXIDATIVE STRESS; FUNCTIONAL FOOD; L.; COMPLICATIONS; HEPATOTOXICITY; ANTIOXIDANT	Inthe present study, we have demonstrated the phytochemical composition of petroleum ether extract of C. sativum (CPE) seeds by using chromatographic, spectroscopic as well spectrometric analysis. CPE was evaluated for its possible role in mitigation of diabetic nephropathy (DN) in Streptozotocin (STZ)-nicotinamide (NAD) induced type 2 diabetes model. Administration of CPE at doses of 100, 200, and 400 mg/kg for 45 days has produced significant attenuation of elevated biochemical parameters including serum glucose, lipid and creatinine levels. CPE has also reserved albuminuria and elevated creatinine clearance in treated diabetic rats. Advanced glycation end products (AGEs) formation in kidneys was also considerably reduced along with noteworthy increase in level of superoxide dismutase (SOD), glutathione (GSH), and decrease in lipid peroxidation in terms of thiobarbituric acid reactive species (TBARS). Molecular docking studies were also employed to reveal out the possible mechanism. In conclusion, using STZ-NAD model, we have successfully predicted that by assets of bioactive constituents CPE might inhibit the progression of DN. C. sativum may act as potential adjuvant for antidiabetic therapy and needs to be investigated further.	[Kajal, Anu; Singh, Randhir] MM Coll Pharm, Ambala, Haryana, India	Maharishi Markandeshwar University	Singh, R (corresponding author), MM Coll Pharm, Ambala, Haryana, India.	randhirsingh.dahiya@gmail.com	Singh, Randhir/AAF-6424-2020; Singh, Randhir/I-6538-2019	Singh, Randhir/0000-0003-0183-0797				[Anonymous], 2012, PROTOCOL EXCHANGE; Antonio MJC, 2010, J COMPUTTHEORNANOSCI, V7, P1; Ballali S, 2012, INT J FOOD SCI NUTR, V63, P51, DOI 10.3109/09637486.2011.637487; Bradberry J Chris, 2013, P T, V38, P681; Butterweck V, 2012, PLANTA MED, V78, P747, DOI 10.1055/s-0031-1298434; Celik S, 2002, PAK J BIOL SCI, V5, P881; Ceylan-Isik AF, 2008, CURR DIABETES REV, V4, P320, DOI 10.2174/157339908786241142; Deepa Balasubramaniam, 2011, Diabetologia Croatica, V40, P121; Eidi M, 2009, PHYTOTHER RES, V23, P404, DOI 10.1002/ptr.2642; Gray AM, 1999, BRIT J NUTR, V81, P203, DOI 10.1017/S0007114599000392; Hemalatha R, 2016, J FOOD SCI TECH MYS, V53, P1189, DOI 10.1007/s13197-015-2108-5; Kajal Anu, 2018, Journal of Dietary Supplements, V15, P482, DOI 10.1080/19390211.2017.1356419; Kishore L, 2017, J ENDOCRINOL THYROID, V2; Kishore L, 2017, J FOOD DRUG ANAL, V25, P576, DOI 10.1016/j.jfda.2016.08.009; Kishore L, 2016, RENAL FAILURE, V38, P1528, DOI 10.1080/0886022X.2016.1227920; Laribi B, 2015, FITOTERAPIA, V103, P9, DOI 10.1016/j.fitote.2015.03.012; Molitoris B.A., 2007, CECIL MED, V23rd; Moustafa AHA, 2014, TOXICOL IND HEALTH, V30, P621, DOI 10.1177/0748233712462470; Nadeem M, 2013, BRIT FOOD J, V115, P743, DOI 10.1108/00070701311331526; Nzali GH, 2012, ASIAN J BIOCH, V7, P194; OZBEK H, 2016, ACTA PHARM SCI, V54, P35, DOI DOI 10.23893/1307-2080.APS.0543; Patel D, 2012, EXCLI J, V11, P566; Peana AT, 2008, BOT MED CLIN PRACTIC; Perera Pathirage Kamal, 2012, Pharmacogn Rev, V6, P37, DOI 10.4103/0973-7847.95863; Prakash J., 2012, CLIN QUERIES NEPHROL, V0102, P115; Roberfroid MB, 1999, FOOD CHEM TOXICOL, V37, P1039, DOI 10.1016/S0278-6915(99)00080-0; Sahib NG, 2013, PHYTOTHER RES, V27, P1439, DOI 10.1002/ptr.4897; Samojlik I, 2010, J AGR FOOD CHEM, V58, P8848, DOI 10.1021/jf101645n; SENSI M, 1995, DIABETES RES CLIN PR, V28, P9, DOI 10.1016/0168-8227(94)01061-4; Singh R, 2014, PHARMACOL RES, V80, P21, DOI 10.1016/j.phrs.2013.12.005; Singh R, 2013, J ETHNOPHARMACOL, V150, P51, DOI 10.1016/j.jep.2013.08.051; Szkudelski T, 2012, EXP BIOL MED, V237, P481, DOI 10.1258/ebm.2012.011372; Toma MM, 2006, ACTA U LATVIENSIS BI, V710, P117; Trease G.E., 1989, PHARMACOGNOSY; Zhang CR, 2015, FOOD CHEM, V167, P24, DOI 10.1016/j.foodchem.2014.06.120	35	10	10	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2019	14	3							e0213147	10.1371/journal.pone.0213147	http://dx.doi.org/10.1371/journal.pone.0213147			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO1AY	30845182	Green Submitted, gold, Green Published			2023-01-03	WOS:000460638800038
J	Herrlinger, U; Tzaridis, T; Mack, F; Steinbach, JP; Schlegel, U; Sabel, M; Hau, P; Kortmann, RD; Krex, D; Grauer, O; Goldbrunner, R; Schnell, O; Bahr, O; Uhl, M; Seidel, C; Tabatabai, G; Kowalski, T; Ringel, F; Schmidt-Graf, F; Suchorska, B; Brehmer, S; Weyerbrock, A; Renovanz, M; Bullinger, L; Galldiks, N; Vajkoczy, P; Misch, M; Vatter, H; Stuplich, M; Schafer, N; Kebir, S; Weller, J; Schaub, C; Stummer, W; Tonn, JC; Simon, M; Keil, VC; Nelles, M; Urbach, H; Coenen, M; Wick, W; Weller, M; Fimmers, R; Schmid, M; Hattingen, E; Pietsch, T; Coch, C; Glas, M				Herrlinger, Ulrich; Tzaridis, Theophilos; Mack, Frederic; Steinbach, Joachim Peter; Schlegel, Uwe; Sabel, Michael; Hau, Peter; Kortmann, Rolf-Dieter; Krex, Dietmar; Grauer, Oliver; Goldbrunner, Roland; Schnell, Oliver; Baehr, Oliver; Uhl, Martin; Seidel, Clemens; Tabatabai, Ghazaleh; Kowalski, Thomas; Ringel, Florian; Schmidt-Graf, Friederike; Suchorska, Bogdana; Brehmer, Stefanie; Weyerbrock, Astrid; Renovanz, Miriam; Bullinger, Lars; Galldiks, Norbert; Vajkoczy, Peter; Misch, Martin; Vatter, Hartmut; Stuplich, Moritz; Schaefer, Niklas; Kebir, Sied; Weller, Johannes; Schaub, Christina; Stummer, Walter; Tonn, Joerg-Christian; Simon, Matthias; Keil, Vera C.; Nelles, Michael; Urbach, Horst; Coenen, Martin; Wick, Wolfgang; Weller, Michael; Fimmers, Rolf; Schmid, Matthias; Hattingen, Elke; Pietsch, Torsten; Coch, Christoph; Glas, Martin		German Canc Soc	Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial	LANCET			English	Article							RADIOTHERAPY; CHEMOTHERAPY; BEVACIZUMAB; CLASSIFICATION; SURVIVAL; GLIOMA; TUMORS	Background There is an urgent need for more effective therapies for glioblastoma. Data from a previous unrandomised phase 2 trial suggested that lomustine-temozolomide plus radiotherapy might be superior to temozolomide chemoradiotherapy in newly diagnosed glioblastoma with methylation of the MGMT promoter. In the CeTeG/NOA-09 trial, we aimed to further investigate the effect of lomustine-temozolomide therapy in the setting of a randomised phase 3 trial. Methods In this open-label, randomised, phase 3 trial, we enrolled patients from 17 German university hospitals who were aged 18-70 years, with newly diagnosed glioblastoma with methylated MGMT promoter, and a Karnofsky Performance Score of 70% and higher. Patients were randomly assigned (1:1) with a predefined SAS-generated randomisation list to standard temozolomide chemoradiotherapy (75 mg/m(2) per day concomitant to radiotherapy [59-60 Gy] followed by six courses of temozolomide 150-200 mg/m(2) per day on the first 5 days of the 4-week course) or to up to six courses of lomustine (100 mg/m(2) on day 1) plus temozolomide (100-200 mg/m(2) per day on days 2-6 of the 6-week course) in addition to radiotherapy (59-60 Gy). Because of the different schedules, patients and physicians were not masked to treatment groups. The primary endpoint was overall survival in the modified intention-to-treat population, comprising all randomly assigned patients who started their allocated chemotherapy. The prespecified test for overall survival differences was a log-rank test stratified for centre and recursive partitioning analysis class. The trial is registered with ClinicalTrials.gov, number NCT01149109. Findings Between June 17, 2011, and April 8, 2014, 141 patients were randomly assigned to the treatment groups; 129 patients (63 in the temozolomide and 66 in the lomustine-temozolomide group) constituted the modified intention-to-treat population. Median overall survival was improved from 31.4 months (95% CI 27.7-47.1) with temozolomide to 48.1 months (32.6 months-not assessable) with lomustine-temozolomide (hazard ratio [HR] 0.60, 95% CI 0.35-1.03; p=0.0492 for log-rank analysis). A significant overall survival difference between groups was also found in a secondary analysis of the intention-to-treat population (n=141, HR 0.60, 95% CI 0.35-1.03; p=0.0432 for log-rank analysis). Adverse events of grade 3 or higher were observed in 32 (51%) of 63 patients in the temozolomide group and 39 (59%) of 66 patients in the lomustine-temozolomide group. There were no treatment-related deaths. Interpretation Our results suggest that lomustine-temozolomide chemotherapy might improve survival compared with temozolomide standard therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter. The findings should be interpreted with caution, owing to the small size of the trial. Copyright (c) 2019 Elsevier Ltd. All rights reserved.	[Herrlinger, Ulrich; Tzaridis, Theophilos; Mack, Frederic; Stuplich, Moritz; Schaefer, Niklas; Kebir, Sied; Weller, Johannes; Schaub, Christina; Glas, Martin] Univ Hosp Bonn, Div Clin Neurooncol, Dept Neurol, Bonn, Germany; [Herrlinger, Ulrich; Tzaridis, Theophilos; Mack, Frederic; Stuplich, Moritz; Schaefer, Niklas; Kebir, Sied; Weller, Johannes; Schaub, Christina; Glas, Martin] Univ Hosp Bonn, Ctr Integrated Oncol, Bonn, Germany; [Vatter, Hartmut; Simon, Matthias] Univ Hosp Bonn, Dept Neurosurg, Bonn, Germany; [Keil, Vera C.; Nelles, Michael; Urbach, Horst; Hattingen, Elke] Univ Hosp Bonn, Dept Neuroradiol, Bonn, Germany; [Fimmers, Rolf; Schmid, Matthias] Univ Hosp Bonn, Inst Med Biometry Informat & Epidemiol, Bonn, Germany; [Pietsch, Torsten] Univ Hosp Bonn, Inst Neuropathol, Bonn, Germany; [Pietsch, Torsten] Univ Hosp Bonn, DGNN Brain Tumor Reference Ctr, Bonn, Germany; [Coenen, Martin; Coch, Christoph] Univ Hosp Bonn, Study Ctr Bonn, Bonn, Germany; [Steinbach, Joachim Peter; Baehr, Oliver] Goethe Univ Frankfurt, Dr Senckenberg Inst Neurooncol, Frankfurt, Germany; [Schlegel, Uwe; Kowalski, Thomas] Ruhr Univ Bochum, Dept Neurol, Univ Hosp Knappschaftskrankenhaus, Bochum, Germany; [Sabel, Michael] Univ Dusseldorf, Dept Neurosurg, Dusseldorf, Germany; [Hau, Peter; Uhl, Martin] Univ Hosp Regensburg, Dept Neurol, Regensburg, Germany; [Hau, Peter; Uhl, Martin] Univ Hosp Regensburg, Wilhelm Sander Neurooncol Unit, Regensburg, Germany; [Kortmann, Rolf-Dieter; Seidel, Clemens] Univ Leipzig, Dept Radiat Oncol, Leipzig, Germany; [Krex, Dietmar] Univ Dresden, Dept Neurosurg, Dresden, Germany; [Grauer, Oliver] Univ Munster, Dept Neurol, Munster, Germany; [Stummer, Walter] Univ Munster, Dept Neurosurg, Munster, Germany; [Goldbrunner, Roland] Univ Cologne, Dept Neurosurg, Cologne, Germany; [Galldiks, Norbert] Univ Cologne, Dept Neurol, Cologne, Germany; [Schnell, Oliver; Suchorska, Bogdana; Tonn, Joerg-Christian] Ludwig Maximillian Univ Munich, Dept Neurosurg, Munich, Germany; [Schnell, Oliver; Suchorska, Bogdana; Tonn, Joerg-Christian] Partner Site Munich, German Canc Consortium, Munich, Germany; [Tabatabai, Ghazaleh] Univ Tubingen, Interdisciplinary Div Neurooncol, Tubingen, Germany; [Ringel, Florian] Tech Univ Munich, Dept Neurosurg, Munich, Germany; [Schmidt-Graf, Friederike] Tech Univ Munich, Dept Neurol, Munich, Germany; [Brehmer, Stefanie] Univ Mannheim, Dept Neurosurg, Mannheim, Germany; [Schnell, Oliver; Weyerbrock, Astrid] Univ Freiburg, Dept Neurosurg, Freiburg, Germany; [Urbach, Horst] Univ Freiburg, Dept Neuroradiol, Freiburg, Germany; [Ringel, Florian; Renovanz, Miriam] Johannes Gutenberg Univ Mainz, Dept Neurosurg, Mainz, Germany; [Bullinger, Lars] Univ Ulm, Dept Internal Med, Ulm, Germany; [Vajkoczy, Peter; Misch, Martin] Charite, Dept Neurosurg, Berlin, Germany; [Wick, Wolfgang] Heidelberg Univ, Dept Neurol, Heidelberg, Germany; [Wick, Wolfgang] German Canc Res Ctr, Heidelberg, Germany; [Weller, Michael] Univ Hosp, Dept Neurol, Zurich, Switzerland; [Weller, Michael] Univ Zurich, Zurich, Switzerland; [Glas, Martin] Univ Duisburg Essen, Div Clin Neurooncol, Dept Neurol, Partner Site Essen,Univ Hosp Essen, Essen, Germany; [Glas, Martin] Univ Duisburg Essen, West German Canc Ctr, German Canc Consortium, Partner Site Essen,Univ Hosp Essen, Essen, Germany; [Galldiks, Norbert] Inst Neurosci & Med INM 3, Julich, Germany	University of Bonn; University of Bonn; University of Bonn; University of Bonn; University of Bonn; University of Bonn; University of Bonn; University of Bonn; Goethe University Frankfurt; Ruhr University Bochum; Heinrich Heine University Dusseldorf; University of Regensburg; University of Regensburg; Leipzig University; Technische Universitat Dresden; University of Munster; University of Munster; University of Cologne; University of Cologne; University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Eberhard Karls University of Tubingen; Technical University of Munich; Technical University of Munich; University of Mannheim; University of Freiburg; University of Freiburg; Johannes Gutenberg University of Mainz; Ulm University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Zurich; University Zurich Hospital; University of Zurich; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); University of Duisburg Essen	Herrlinger, U (corresponding author), Univ Bonn, Med Ctr, Div Clin Neurooncol, Dept Neurol, D-53105 Bonn, Germany.; Herrlinger, U (corresponding author), Univ Bonn, Med Ctr, Ctr Integrated Oncol, D-53105 Bonn, Germany.	ulrich.herrlinger@ukbonn.de	Wick, Wolfgang/AAA-2545-2020; Tonn, Joerg/AAK-8509-2021; Stummer, Walter/AAA-3319-2020; Galldiks, Norbert/AAG-6896-2019; Tabatabai, Ghazaleh/A-6365-2015; Coch, Christoph/AAW-5336-2021; Ringel, Florian/E-4933-2014; Bullinger, Lars/AAL-7965-2020; Renovanz, Mirjam/ABA-3535-2020; Stummer, Walter/AAF-9043-2019; Kebir, Sied/ABD-8792-2021; Keil, Vera/AAP-8695-2020; Weyerbrock, Astrid/AAI-1731-2020; Keil, Vera/AAD-6793-2020	Wick, Wolfgang/0000-0002-6171-634X; Galldiks, Norbert/0000-0002-2485-1796; Tabatabai, Ghazaleh/0000-0003-3702-923X; Kebir, Sied/0000-0002-0678-5852; Keil, Vera/0000-0001-8699-3506; Weyerbrock, Astrid/0000-0001-9060-4462; Weller, Michael/0000-0002-1748-174X; Bullinger, Lars/0000-0002-5890-5510; Hau, Peter/0000-0003-3894-5053; Tzaridis, Theophilos/0000-0001-9651-1144; Hattingen, Elke/0000-0002-8392-9004; Weller, Johannes/0000-0001-5818-5392; Misch, Martin/0000-0001-5283-5753; Schmid, Matthias/0000-0002-0788-0317; Tabatabai, Ghazaleh/0000-0002-3542-8782	German Federal Ministry of Education and Research	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF))	German Federal Ministry of Education and Research.	Barrie M, 2005, ANN ONCOL, V16, P1177, DOI 10.1093/annonc/mdi225; Cairncross G, 2013, J CLIN ONCOL, V31, P337, DOI 10.1200/JCO.2012.43.2674; Capper D, 2010, BRAIN PATHOL, V20, P245, DOI 10.1111/j.1750-3639.2009.00352.x; Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345; Dupont WD, 1997, CONTROL CLIN TRIALS, V18, P274, DOI 10.1016/S0197-2456(97)00074-3; Gilbert MR, 2013, J CLIN ONCOL, V31, P4085, DOI 10.1200/JCO.2013.49.6968; Glas M, 2009, J CLIN ONCOL, V27, P1257, DOI 10.1200/JCO.2008.19.2195; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Herrlinger U, 2006, J CLIN ONCOL, V24, P4412, DOI 10.1200/JCO.2006.06.9104; Herrlinger U, 2016, J CLIN ONCOL, V34, P1611, DOI 10.1200/JCO.2015.63.4691; Jakacki RI, 2016, NEURO-ONCOLOGY, V18, P1442, DOI 10.1093/neuonc/now038; KOHN KW, 1977, CANCER RES, V37, P1450; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Mikeska T, 2007, J MOL DIAGN, V9, P368, DOI 10.2353/jmoldx.2007.060167; Mirimanoff RO, 2006, J CLIN ONCOL, V24, P2563, DOI 10.1200/JCO.2005.04.5963; Peyre M, 2010, NEURO-ONCOLOGY, V12, P1078, DOI 10.1093/neuonc/noq055; PLOWMAN J, 1994, CANCER RES, V54, P3793; Quillien V, 2016, ONCOTARGET, V7, P61916, DOI 10.18632/oncotarget.11322; Quillien V, 2012, CANCER-AM CANCER SOC, V118, P4201, DOI 10.1002/cncr.27392; Quinn JA, 2009, J NEURO-ONCOL, V95, P393, DOI 10.1007/s11060-009-9937-x; Stuplich M, 2012, J CLIN ONCOL, V30, pE180, DOI 10.1200/JCO.2011.40.9565; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2017, JAMA-J AM MED ASSOC, V318, P2306, DOI 10.1001/jama.2017.18718; Stupp R, 2014, LANCET ONCOL, V15, P1100, DOI 10.1016/S1470-2045(14)70379-1; van den Bent MJ, 2017, LANCET, V390, P1645, DOI 10.1016/S0140-6736(17)31442-3; van den Bent MJ, 2013, J CLIN ONCOL, V31, P344, DOI 10.1200/JCO.2012.43.2229; Vlassenbroeck I, 2008, J MOL DIAGN, V10, P332, DOI 10.2353/jmoldx.2008.070169; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; Weller M, 2003, J CLIN ONCOL, V21, P3276, DOI 10.1200/JCO.2003.03.509; Weller M, 2017, LANCET ONCOL, V18, P1373, DOI 10.1016/S1470-2045(17)30517-X; Wen PY, 2010, J CLIN ONCOL, V28, P1963, DOI 10.1200/JCO.2009.26.3541; WHEELER GP, 1975, CANCER RES, V35, P2974; Wick W, 2017, NEW ENGL J MED, V377, P1954, DOI 10.1056/NEJMoa1707358	34	236	240	4	66	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 16	2019	393	10172					678	688		10.1016/S0140-6736(18)31791-4	http://dx.doi.org/10.1016/S0140-6736(18)31791-4			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL6AX	30782343	Green Accepted			2023-01-03	WOS:000458817300026
J	Sato, Y; Suzuki, K				Sato, Yousuke; Suzuki, Kentaroh			How do aerosols affect cloudiness?	SCIENCE			English	Editorial Material							SATELLITE DATA; PRECIPITATION; MODEL; GCM		[Sato, Yousuke] Nagoya Univ, Grad Sch Engn, Dept Appl Energy, Chikusa Ku, Furo Cho, Nagoya, Aichi, Japan; [Sato, Yousuke] RIKEN, Ctr Computat Sci, Chuo Ku, 7-1-26 Minatojima Minami Machi, Kobe, Hyogo, Japan; [Suzuki, Kentaroh] Univ Tokyo, Atmosphere & Ocean Res Inst, 5-1-5 Kashiwanoha, Kashiwa, Chiba, Japan	Nagoya University; RIKEN; University of Tokyo	Sato, Y (corresponding author), Nagoya Univ, Grad Sch Engn, Dept Appl Energy, Chikusa Ku, Furo Cho, Nagoya, Aichi, Japan.; Sato, Y (corresponding author), RIKEN, Ctr Computat Sci, Chuo Ku, 7-1-26 Minatojima Minami Machi, Kobe, Hyogo, Japan.	yousuke.sato@riken.jp	Sato, Yousuke/C-5416-2016; Suzuki, Kentaroh/C-3624-2011	Sato, Yousuke/0000-0002-6857-3783; Suzuki, Kentaroh/0000-0001-5315-2452	Research Institute for Applied Mechanics, Kyushu University; Institute for Space-Earth Environmental Research, Nagoya University; JAXA EarthCARE project; JAXA GCOM-C project; Integrated Research Program for Advancing Climate Models (TOUGOU program) of MEXT	Research Institute for Applied Mechanics, Kyushu University; Institute for Space-Earth Environmental Research, Nagoya University; JAXA EarthCARE project; JAXA GCOM-C project; Integrated Research Program for Advancing Climate Models (TOUGOU program) of MEXT	Y.S. is partly supported by the collaborative research program of the Research Institute for Applied Mechanics, Kyushu University, and by the joint research program of the Institute for Space-Earth Environmental Research, Nagoya University. K.S. is supported by the JAXA EarthCARE and GCOM-C projects and the Integrated Research Program for Advancing Climate Models (TOUGOU program) of MEXT.	ALBRECHT BA, 1989, SCIENCE, V245, P1227, DOI 10.1126/science.245.4923.1227; Chen YC, 2014, NAT GEOSCI, V7, P643, DOI [10.1038/ngeo2214, 10.1038/NGEO2214]; Kaufman YJ, 2005, P NATL ACAD SCI USA, V102, P11207, DOI 10.1073/pnas.0505191102; Kirtman B., 2013, IPCC 2013 CLIMATE CH, P953; Ma PL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05028-4; Matsui T, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006097; Michibata T, 2016, ATMOS CHEM PHYS, V16, P15413, DOI 10.5194/acp-16-15413-2016; Myhre G, 2007, ATMOS CHEM PHYS, V7, P3081, DOI 10.5194/acp-7-3081-2007; Nakajima T, 2001, GEOPHYS RES LETT, V28, P1171, DOI 10.1029/2000GL012186; Nakajima  T., 2009, STRUNGMANN FORUM REP, P597; Quaas J, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004317; Quaas J, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2007JD008962; Rosenfeld D, 2019, SCIENCE, V363, P599, DOI 10.1126/science.aav0566; Sato Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03379-6; Seifert A, 2015, J ADV MODEL EARTH SY, V7, P1918, DOI 10.1002/2015MS000489; Sekiguchi M, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003359; Stevens B, 2009, NATURE, V461, P607, DOI 10.1038/nature08281; Suzuki K, 2004, J ATMOS SCI, V61, P179, DOI 10.1175/1520-0469(2004)061<0179:ASOTAE>2.0.CO;2; Suzuki K, 2013, GEOPHYS RES LETT, V40, P4464, DOI 10.1002/grl.50874	19	17	18	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 8	2019	363	6427					580	+		10.1126/science.aaw3720	http://dx.doi.org/10.1126/science.aaw3720			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HK6SM	30733402				2023-01-03	WOS:000458114200024
J	Ingelse, SA; Juschten, J; Maas, MAW; Matute-Bello, G; Juffermans, NP; van Woensel, JBM; Bem, RA				Ingelse, Sarah A.; Juschten, Jenny; Maas, Martinus A. W.; Matute-Bello, Gustavo; Juffermans, Nicole P.; van Woensel, Job B. M.; Bem, Reinout A.			Fluid restriction reduces pulmonary edema in a model of acute lung injury in mechanically ventilated rats	PLOS ONE			English	Article							CRITICALLY-ILL CHILDREN; BALANCE; WATER; INFLAMMATION; MANAGEMENT; RESPONSES; OVERLOAD; REMOVAL	Experimental acute lung injury models are often used to increase our knowledge on the acute respiratory distress syndrome (ARDS), however, existing animal models often do not take into account the impact of specific fluid strategies on the development of lung injury. In contrast, the current literature strongly suggests that fluid management strategies have a significant impact on clinical outcome of patients with ARDS. Thus, it is important to characterize the role of fluid management strategies in experimental models of lung injury. In this study we investigated the effect of two different fluid strategies on commonly used outcome variables in a short-term model of acute lung injury, in relation to age. Infant (2-3 weeks) and adult (3-4 months) Wistar rats received intratracheal instillations of lipopolysaccharide and 24 hours later were mechanically ventilated for 6 hours. During mechanical ventilation, rats from both age groups were randomized to either a standard or conservative intravenous fluid strategy. We found that the hemodynamic response in infant and adult rats was similar in both fluid strategies. Lung wet-to-dry ratios were lower in adult, but not in infant rats receiving the conservative fluid strategy as compared to the standard fluid strategy. There were age-related differences in markers of alveolar capillary barrier disruption and alveolar fluid clearance, yet these were unaffected by fluid strategy. Finally, we found significantly higher IL-1 beta and TNF-alpha concentrations in the adult rats treated with the conservative as compared to the standard fluid regimen. In conclusion, the choice of fluid strategy in mechanically ventilated rats with experimental LPS-induced acute lung injury has a significant effect on pulmonary extravascular water, an important and well-recognized lung injury marker, and on the local pro-inflammatory cytokine profiles. We advocate the use of a more uniform, conservative, fluid strategy regimen in experimental models of acute lung injury.	[Ingelse, Sarah A.; van Woensel, Job B. M.; Bem, Reinout A.] Acad Med Ctr, Emma Childrens Hosp, Pediat Intens Care Unit, Amsterdam, Netherlands; [Ingelse, Sarah A.; Juschten, Jenny; Maas, Martinus A. W.; Juffermans, Nicole P.] Acad Med Ctr, LEICA, Amsterdam, Netherlands; [Juschten, Jenny; Juffermans, Nicole P.] Acad Med Ctr, Dept Intens Care, Amsterdam, Netherlands; [Juschten, Jenny] Vrije Univ Amsterdam Med Ctr, Dept Intens Care & Res VUmc Intens Care REVIVE, Amsterdam, Netherlands; [Matute-Bello, Gustavo] Univ Washington, Ctr Lung Biol, Div Pulm Crit Care & Sleep Med, Seattle, WA 98195 USA; [Matute-Bello, Gustavo] VA Puget Sound Healthcare Syst, Med Res Serv, Seattle, WA USA	Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Ingelse, SA (corresponding author), Acad Med Ctr, Emma Childrens Hosp, Pediat Intens Care Unit, Amsterdam, Netherlands.; Ingelse, SA (corresponding author), Acad Med Ctr, LEICA, Amsterdam, Netherlands.	s.a.ingelse@amc.uva.nl	A., Reinout/AAN-1411-2021	Bem, Reinout Alexander/0000-0002-9454-5321	Ammodo Foundation; Foundation of Pediatric Intensive Care (SKIC) in the Netherlands; NIH	Ammodo Foundation; Foundation of Pediatric Intensive Care (SKIC) in the Netherlands(Netherlands Government); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This research was supported by the Ammodo Foundation and the Foundation of Pediatric Intensive Care (SKIC) in the Netherlands. This publication was also funded in part by the NIH. The sponsors had no role in the design and execution of the research, the writing of the report or the decision to submit the manuscript for publication.	Alobaidi R, 2018, JAMA PEDIATR, V172, P257, DOI 10.1001/jamapediatrics.2017.4540; Aloia JF, 1998, J LAB CLIN MED, V132, P483, DOI 10.1016/S0022-2143(98)90126-3; Avila-Diaz M, 2006, PERITON DIALYSIS INT, V26, P574; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; CHAPPELL D, 2014, CRIT CARE, V18; Copland IB, 2004, AM J RESP CRIT CARE, V169, P739, DOI 10.1164/rccm.200310-1417OC; Diehl KH, 2001, J APPL TOXICOL, V21, P15, DOI 10.1002/jat.727; Flori HR, 2011, CRIT CARE RES PRACT, V2011, DOI 10.1155/2011/854142; Ingelse SA, 2017, PEDIATR CRIT CARE ME, V18, pE106, DOI 10.1097/PCC.0000000000001060; Ingelse SA, 2016, FRONT PEDIATR, V4, DOI 10.3389/fped.2016.00021; Ito Y, 2007, EXP LUNG RES, V33, P375, DOI 10.1080/01902140701634843; Katira BH, 2017, AM J RESP CRIT CARE, V196, P1411, DOI 10.1164/rccm.201611-2268OC; Kneyber MCJ, 2014, AM J RESP CRIT CARE, V190, P258, DOI 10.1164/rccm.201401-0168CP; Knoferl MW, 1999, J TRAUMA, V46, P23, DOI 10.1097/00005373-199901000-00005; Kornecki A, 2005, AM J RESP CRIT CARE, V171, P743, DOI 10.1164/rccm.200408-1053OC; Kuebler WM, 1999, J CLIN INVEST, V104, P495, DOI 10.1172/JCI6872; Mafia LDA, 2017, ANESTH ANALG, V125, P1364, DOI 10.1213/ANE.0000000000002348; Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008; Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST; Milos S, 2017, AM J PHYSIOL-LUNG C, V313, pL524, DOI 10.1152/ajplung.00055.2017; Nusmeier A, 2015, PEDIATR CRIT CARE ME, V16, pE28, DOI 10.1097/PCC.0000000000000312; R Core Team, 2021, R LANG ENV STAT COMP; Rosenberg Andrew L, 2009, J Intensive Care Med, V24, P35, DOI 10.1177/0885066608329850; Sakr Y, 2017, CRIT CARE MED, V45, P386, DOI 10.1097/CCM.0000000000002189; Schouten LRA, 2016, CRIT CARE MED, V44, pE1226, DOI [10.1097/CCM.0000000000002008, 10.1097/CCM.0000000000001388]; Schouten LR, 2016, CRIT CARE MED; Setzer F, 2013, CRIT CARE, V17, DOI 10.1186/cc12744; Sinitsky L, 2015, PEDIATR CRIT CARE ME, V16, P205, DOI 10.1097/PCC.0000000000000318; Valentine SL, 2012, CRIT CARE MED, V40, P2883, DOI 10.1097/CCM.0b013e31825bc54d; Weisberg JFS, 2011, R COMPANION APPL REG; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; Willson DF, 2013, PEDIATR CRIT CARE ME, V14, P666, DOI 10.1097/PCC.0b013e3182917cb5	32	6	7	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2019	14	1							e0210172	10.1371/journal.pone.0210172	http://dx.doi.org/10.1371/journal.pone.0210172			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH8WT	30653512	Green Published, gold, Green Submitted			2023-01-03	WOS:000456015500027
J	Garg, A; Gupta, A; Mishra, A; Singh, M; Yadav, S; Nityanand, S				Garg, Akanksha; Gupta, Anshul; Mishra, Ashish; Singh, Manoj; Yadav, Sanjeev; Nityanand, Soniya			Role of granulocyte transfusions in combating life-threatening infections in patients with severe neutropenia: Experience from a tertiary care centre in North India	PLOS ONE			English	Article							PEDIATRIC-PATIENTS; HEMATOLOGICAL MALIGNANCIES; STIMULATED DONORS; FUNGAL-INFECTIONS; G-CSF; EFFICACY; CHILDREN; THERAPY; CANCER; SAFETY	Bacterial and fungal infections still remain an important cause of mortality in patients with hematological malignancies and in recipients of hematopoietic stem cell transplants (HSCT) especially in developing countries like India. Granulocyte transfusions (GTX) from healthy donors may lead to early clearance of index infection and thus prevent mortality. The aim of the present study was to evaluate the efficacy of GTX in combating life-threatening infections and preventing mortality in patients of hematological disorders/recipients of HSCT with severe neutropenia. This study was a prospective, observational analysis of patients with different hematological disorders/recipients of HSCT, who received GTX from January 2014 to December 2017. All patients had an Absolute neutrophil Count (ANC) < 0.5 x 10(9)/L and a life threatening sepsis defined by presence of hemodynamic instability/impending septic shock/continuous high fever despite the use of the highest line of antimicrobials. A total of 143 granulocyte collections were done for 66 infectious episodes (IEs) in 60 patients. Multidrug resistant organisms (MDROs) were observed in 47/66 IEs (71.2%) and fungal infections were seen in 9/66 IEs (13.6%). Resolution of index infection after GTX was seen in 45/66 IEs (68.2%), and the 30 day overall survival (OS) was 67.7%. OS was significantly higher in patients who received GTX within 7 days of neutropenic sepsis (p = 0.01). Patients with MDROs who received early GTX therapy had a better OS as compared to those who received late GTX (p = 0.02). GTX were well tolerated and only 6 patients' developed mild features of transfusion related acute lung injury (TRALI) which was managed conservatively, and 1 patient demonstrated hypocalcemic tetany. GTX may be of particular relevance in countries like India, where the incidence of infections is very high in neutropenic patients and there is an increasing emergence of MDROs.	[Garg, Akanksha; Gupta, Anshul; Mishra, Ashish; Singh, Manoj; Yadav, Sanjeev; Nityanand, Soniya] Sanjay Gandhi Post Grad Inst Med Sci, Dept Hematol, Raebareli Rd, Lucknow, Uttar Pradesh, India	Sanjay Gandhi Postgraduate Institute of Medical Sciences	Nityanand, S (corresponding author), Sanjay Gandhi Post Grad Inst Med Sci, Dept Hematol, Raebareli Rd, Lucknow, Uttar Pradesh, India.	soniya_nityanand@yahoo.co.in	Garg, Akanksha/AAV-7278-2021; Garg, Akanksha/HIR-7947-2022					Al-Tanbal H, 2010, TRANSFUSION MED, V20, P160, DOI 10.1111/j.1365-3148.2009.00988.x; Ang AL, 2011, TRANSFUSION MED, V21, P13, DOI 10.1111/j.1365-3148.2010.01035.x; Atay D, 2011, J PEDIAT HEMATOL ONC, V33, pE220, DOI 10.1097/MPH.0b013e31821ffdf1; Cesaro S, 2003, SUPPORT CARE CANCER, V11, P101, DOI 10.1007/s00520-002-0394-8; Cherif H, 2013, SCAND J INFECT DIS, V45, P112, DOI 10.3109/00365548.2012.714906; Coburn B, 2013, ANTIMICROB AGENTS CH, V57, P1989, DOI 10.1128/AAC.00111-13; Diaz R, 2014, PEDIATR HEMAT ONCOL, V31, P425, DOI 10.3109/08880018.2013.868562; Dignani MC, 1997, LEUKEMIA, V11, P1621, DOI 10.1038/sj.leu.2400811; Dreniak A, 2009, HAEMATOLOGICA, V94, P1644, DOI [10.3324/haematol.2009.013680, DOI 10.3324/HAEMATOL.2009.013680]; Drewniak A, 2008, HAEMATOL-HEMATOL J, V93, P1058, DOI 10.3324/haematol.12489; Ecdc, 2013, SURV REP; Grigull L, 2006, SUPPORT CARE CANCER, V14, P910, DOI 10.1007/s00520-006-0041-x; Heim KF, 2011, TRANSFUSION, V51, P1154, DOI 10.1111/j.1537-2995.2010.02993.x; Illerhaus G, 2002, ANN HEMATOL, V81, P273, DOI 10.1007/s00277-002-0439-6; Kikuta A, 2006, VOX SANG, V91, P70, DOI 10.1111/j.1423-0410.2006.00776.x; Kim KH, 2011, CYTOTHERAPY, V13, P490, DOI 10.3109/14653249.2010.529889; Lee JJ, 2004, HAEMATOLOGICA, V89, P632; Lee JJ, 2001, LEUKEMIA, V15, P203, DOI 10.1038/sj.leu.2402007; Marfin AA, 2015, J INTENSIVE CARE MED, V30, P79, DOI 10.1177/0885066613498045; Massey E, 2012, TRANSFUSION MED, V22, P277, DOI 10.1111/j.1365-3148.2012.01152.x; Mikulska M, 2014, J INFECTION, V68, P321, DOI 10.1016/j.jinf.2013.12.006; Mousset S, 2005, ANN HEMATOL, V84, P734, DOI 10.1007/s00277-005-1055-z; Nikolajeva O, 2015, BONE MARROW TRANSPL, V50, P846, DOI 10.1038/bmt.2015.53; Ofran Y, 2007, VOX SANG, V93, P363, DOI 10.1111/j.1423-0410.2007.00971.x; Ozturkmen S, 2013, TRANSFUS APHER SCI, V48, P381, DOI 10.1016/j.transci.2013.04.022; Peters C, 1999, BRIT J HAEMATOL, V106, P689, DOI 10.1046/j.1365-2141.1999.01619.x; Price TH, 2000, BLOOD, V95, P3302, DOI 10.1182/blood.V95.11.3302.010k35_3302_3309; Price TH, 2015, BLOOD, V126, P2153, DOI 10.1182/blood-2015-05-645986; Quillen K, 2009, HAEMATOL-HEMATOL J, V94, P1661, DOI 10.3324/haematol.2009.010231; Rutella S, 2003, CYTOTHERAPY, V5, P19, DOI 10.1080/14653240310000047; Sachs UJ, 2003, TRANSFUSION, V43, P1683, DOI 10.1111/j.0041-1132.2003.00568.x; Sachs UJH, 2006, TRANSFUSION, V46, P1909, DOI 10.1111/j.1537-2995.2006.00996.x; Safdar A, 2004, CANCER, V101, P2859, DOI 10.1002/cncr.20710; Safdar A, 2014, ACTA HAEMATOL-BASEL, V131, P50, DOI 10.1159/000351174; Seidel MG, 2009, J PEDIAT HEMATOL ONC, V31, P166, DOI 10.1097/MPH.0b013e318196a6f9; Shankar K, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26740; Teofili L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159569; Thacker N, 2014, INDIAN J CANCER, V51, P442, DOI 10.4103/0019-509X.175310; Uppuluri R, 2017, INDIAN J HEMATOL BLO, V33, P207, DOI 10.1007/s12288-016-0727-2; Valentini CG, 2017, BIOL BLOOD MARROW TR, V23, P2034, DOI 10.1016/j.bbmt.2017.07.029; Vamvakas EC, 1996, J CLIN APHERESIS, V11, P1	41	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2018	13	12							e0209832	10.1371/journal.pone.0209832	http://dx.doi.org/10.1371/journal.pone.0209832			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF7KM	30589898	Green Published, Green Submitted, gold			2023-01-03	WOS:000454418200057
J	Hickl, J; Argyropoulou, A; Sakavitsi, ME; Halabalaki, M; Al-Ahmad, A; Hellwig, E; Aligiannis, N; Skaltsounis, AL; Wittmer, A; Vach, K; Karygianni, L				Hickl, Joachim; Argyropoulou, Aikaterini; Sakavitsi, Maria Eleni; Halabalaki, Maria; Al-Ahmad, Ali; Hellwig, Elmer; Aligiannis, Nektarios; Skaltsounis, Alexios Leandros; Wittmer, Annette; Vach, Kirstin; Karygianni, Lamprini			Mediterranean herb extracts inhibit microbial growth of representative oral microorganisms and biofilm formation of Streptococcus mutans	PLOS ONE			English	Article							LABDANE-TYPE DITERPENES; ESSENTIAL OILS; ROSMARINUS-OFFICINALIS; ANTIMICROBIAL ACTIVITY; ANTIBACTERIAL ACTIVITIES; HYDROALCOHOLIC EXTRACT; CHEMICAL-COMPOSITION; SUBSP ERIOCEPHALUS; PHENOLIC-COMPOUNDS; MASS-SPECTROMETRY	In light of the growing antibiotic resistance, the usage of plant-derived antimicrobial agents could serve as an effective alternative treatment against oral infections. The aim of this study was to investigate the antimicrobial and antibiofilm activity of Mediterranean herb extracts against representative oral microorganisms. The extraction procedures and the analysis of the obtained extracts were performed under established experimental conditions. The minimum inhibitory (MIC) and bactericidal (MBC) concentrations of the methanol extracts of Cistus creticus ssp. creticus, Cistus monspeliensis, Origanum vulgare, Rosmarinus officinalis, Salvia sclarea and Thymus longicaulis against eight typical oral bacteria and the fungus Candida albicans were determined. The antibiofilm activity against Streptococcus mutans was also quantified using the microtiter plate test. Overall, all tested extracts inhibited effectively the screened obligate anaerobic microorganisms and in concentrations >= 0.3 mg ml(-1) had moderate to high antibiofilm activity comparable to that of chlorhexidine (CHX) against S. mutans. In particular, R. officinalis (MIC: 0.08-5.00 mg ml(-1)) and S. sclarea (MIC: 0.08-2.50 mg ml(-1)) showed the highest antibacterial activity, while Cistusspp., R. officinalis and S. sclarea significantly inhibited S. mutans biofilm formation at 0.60, 1.25 and 2.50 mg ml(-1), respectively. Porphyromonas gingivalis and Parvimonas micra were high susceptible to O. vulgare (MIC = 0.30 mg ml(-1)), whereas T. longicaulis eradicated all oral bacteria (MBC: 0.15-2.50 mg ml(-1)). Nevertheless, C. albicans showed no sensitivity to the tested extracts. In conclusion, the tested plant extracts could serve as alternative natural antibacterial and antibiofilm components against oral infections.	[Hickl, Joachim; Al-Ahmad, Ali; Hellwig, Elmer; Karygianni, Lamprini] Univ Freiburg, Med Ctr, Dept Operat Dent & Periodontol, Fac Med, Freiburg, Germany; [Argyropoulou, Aikaterini; Sakavitsi, Maria Eleni; Halabalaki, Maria; Aligiannis, Nektarios; Skaltsounis, Alexios Leandros] Natl & Kapodistrian Univ Athens, Dept Pharmacognosy & Nat Prod Chem, Fac Pharm, Athens, Greece; [Wittmer, Annette] Univ Freiburg, Inst Med Microbiol & Hyg, Fac Med, Freiburg, Germany; [Vach, Kirstin] Univ Freiburg, Inst Med Biometry & Stat, Fac Med, Freiburg, Germany; [Vach, Kirstin] Univ Freiburg, Med Ctr, Freiburg, Germany; [Karygianni, Lamprini] Univ Zurich, Clin Prevent Dent Periodontol & Cariol, Ctr Dent Med, Zurich, Switzerland	University of Freiburg; National & Kapodistrian University of Athens; University of Freiburg; University of Freiburg; University of Freiburg; University of Zurich	Karygianni, L (corresponding author), Univ Freiburg, Med Ctr, Dept Operat Dent & Periodontol, Fac Med, Freiburg, Germany.; Karygianni, L (corresponding author), Univ Zurich, Clin Prevent Dent Periodontol & Cariol, Ctr Dent Med, Zurich, Switzerland.	lamprini.karygianni@zzm.uzh.ch	Sakavitsi, Maria Eleni/AAH-1514-2020; skaltsounis, alexios leandros/AAE-9617-2019; Halabalaki, Maria/AAD-2127-2020; Vach, Kirstin/GQP-0449-2022; Vach, Kirstin/AAI-4643-2020	Sakavitsi, Maria Eleni/0000-0002-7849-638X; Vach, Kirstin/0000-0001-9278-2203; Vach, Kirstin/0000-0001-9278-2203; ALIGIANNIS, NEKTARIOS/0000-0002-3335-8135	German Research Foundation (DFG) [AL 1179/2-1]	German Research Foundation (DFG)(German Research Foundation (DFG))	This study was supported in part by the German Research Foundation (DFG, AL 1179/2-1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.	Achour M, 2018, PHYTOCHEM ANALYSIS, V29, P87, DOI 10.1002/pca.2717; Agrawal Vineet, 2017, Journal of Dietary Supplements, V14, P229, DOI 10.1080/19390211.2016.1207004; Al-Ahmad A, 2008, ARCH ORAL BIOL, V53, P765, DOI 10.1016/j.archoralbio.2008.02.014; Anastasaki T, 1999, PLANTA MED, V65, P735, DOI 10.1055/s-1999-14095; Bardaji DKR, 2016, NAT PROD RES, V30, P1178, DOI 10.1080/14786419.2015.1043630; Borlinghaus J, 2014, MOLECULES, V19, P12591, DOI 10.3390/molecules190812591; Bouamama H, 2006, J ETHNOPHARMACOL, V104, P104, DOI 10.1016/j.jep.2005.08.062; Breen S, 2015, FRONT PLANT SCI, V6, DOI 10.3389/fpls.2015.00900; Chang SY, 2016, BIOCHEM BIOPH RES CO, V471, P282, DOI 10.1016/j.bbrc.2016.01.123; CHINOU I, 1994, PLANTA MED, V60, P34, DOI 10.1055/s-2006-959403; Chinsembu KC, 2016, ACTA TROP, V154, P6, DOI 10.1016/j.actatropica.2015.10.019; Chorianopoulos N, 2004, J AGR FOOD CHEM, V52, P8261, DOI 10.1021/jf049113i; CLSI, 2012, METHODS DILUTION ANT; CLSI, 2012, METH ANT SUSC TEST A, V32; Coccimiglio J, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1404505; Cui JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150595; De Martino L, 2009, MOLECULES, V14, P4614, DOI 10.3390/molecules14114614; Demetzos C, 1997, PLANTA MED, V63, P477, DOI 10.1055/s-2006-957742; Dewhirst FE, 2010, J BACTERIOL, V192, P5002, DOI 10.1128/JB.00542-10; Didry N, 1994, Pharm Acta Helv, V69, P25, DOI 10.1016/0031-6865(94)90027-2; Fernandez-Arroyo S, 2010, PHYTOCHEM ANALYSIS, V21, P307, DOI 10.1002/pca.1200; Fernandez-Ochoa A, 2017, J FUNCT FOODS, V33, P202, DOI 10.1016/j.jff.2017.03.046; Firuzi O, 2013, IRAN J PHARM RES, V12, P801; Freires IA, 2016, PHARM RES-DORDR, V33, P1311, DOI 10.1007/s11095-016-1905-5; Freires IA, 2015, MOLECULES, V20, P7329, DOI 10.3390/molecules20047329; German Institute for Standardization, 2007, 2077612006 ISO; Gortzi O, 2006, J FOOD PROTECT, V69, P2998, DOI 10.4315/0362-028X-69.12.2998; Gyawali R, 2014, FOOD CONTROL, V46, P412, DOI 10.1016/j.foodcont.2014.05.047; Hammer KA, 1999, J APPL MICROBIOL, V86, P985, DOI 10.1046/j.1365-2672.1999.00780.x; Hannig C, 2009, J DENT, V37, P560, DOI 10.1016/j.jdent.2009.03.017; Hernandez-Hernandez Elvia, 2014, ScientificWorldJournal, V2014, P641814, DOI 10.1155/2014/641814; Horner C, 2012, J ANTIMICROB CHEMOTH, V67, P2547, DOI 10.1093/jac/dks284; Hotwani Kavita, 2014, J Complement Integr Med, V11, P233, DOI 10.1515/jcim-2013-0015; Jenkinson HF, 2005, TRENDS MICROBIOL, V13, P589, DOI 10.1016/j.tim.2005.09.006; Jones D, 1991, MAINTENANCE MICROORG, P45; Justesen U, 2000, J CHROMATOGR A, V902, P369, DOI 10.1016/S0021-9673(00)00861-X; Karygianni L, 2016, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01529; Karygianni L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/839019; Kolenbrander PE, 2000, ANNU REV MICROBIOL, V54, P413, DOI 10.1146/annurev.micro.54.1.413; Kontogianni VG, 2013, FOOD CHEM, V136, P120, DOI 10.1016/j.foodchem.2012.07.091; Kuzma L, 2007, PHYTOMEDICINE, V14, P31, DOI 10.1016/j.phymed.2005.10.008; Lemstrova R, 2016, CANCER CHEMOTH PHARM, V78, P1101, DOI 10.1007/s00280-016-3058-y; Maggi F, 2016, BIOCHEM SYST ECOL, V66, P50, DOI 10.1016/j.bse.2016.02.030; Mahyari S, 2016, COMPLEMENT THER CLIN, V22, P93, DOI 10.1016/j.ctcp.2015.12.001; Martins N, 2015, FOOD CHEM, V170, P378, DOI 10.1016/j.foodchem.2014.08.096; Martins N, 2015, FOOD CHEM, V167, P131, DOI 10.1016/j.foodchem.2014.06.094; Martins N, 2014, FOOD CHEM, V158, P73, DOI 10.1016/j.foodchem.2014.02.099; Meyer B, 2010, J HOSP INFECT, V76, P200, DOI 10.1016/j.jhin.2010.05.020; Mikaili P, 2013, ANC SCI LIFE, V33, P131, DOI 10.4103/0257-7941.139059; Munita JM, 2015, CLIN INFECT DIS, V61, pS48, DOI 10.1093/cid/civ523; Nassiri-Asl M, 2009, PHYTOTHER RES, V23, P1197, DOI 10.1002/ptr.2761; Nawrocki KL, 2014, ANTIBIOTICS-BASEL, V3, P461, DOI 10.3390/antibiotics3040461; Oluwatuyi M, 2004, PHYTOCHEMISTRY, V65, P3249, DOI 10.1016/j.phytochem.2004.10.009; Page Malcolm G P, 2012, Handb Exp Pharmacol, P67, DOI 10.1007/978-3-642-28951-4_5; Pages JM, 2009, BBA-PROTEINS PROTEOM, V1794, P826, DOI 10.1016/j.bbapap.2008.12.011; Petiwala SM, 2015, CANCER LETT, V367, P93, DOI 10.1016/j.canlet.2015.07.005; Quave CL, 2008, J ETHNOPHARMACOL, V118, P418, DOI 10.1016/j.jep.2008.05.005; Sassi AB, 2008, PHARM BIOL, V45, P421; SCANNAPIECO FA, 1994, CRIT REV ORAL BIOL M, V5, P203, DOI 10.1177/10454411940050030201; Sender R, 2016, CELL, V164, P337, DOI 10.1016/j.cell.2016.01.013; Sharifzadeh A, 2016, AVICENNA J PHYTOMEDI, V6, P215; Stagos D, 2012, FOOD CHEM TOXICOL, V50, P4115, DOI 10.1016/j.fct.2012.08.033; Sulniute V, 2017, FOOD CHEM, V224, P37, DOI 10.1016/j.foodchem.2016.12.047; Taamalli A, 2015, PHYTOCHEM ANALYSIS, V26, P320, DOI 10.1002/pca.2566; Tiwari V, 2017, MICROB PATHOGENESIS, V110, P345, DOI 10.1016/j.micpath.2017.07.013; Tiwari V, 2015, FRONT MICROBIOL, V6, DOI [10.3389/fmicb.2015.00618, 10.3389/fmicb.2015.00429]; Tsai PJ, 2007, FOOD CHEM, V105, P311, DOI 10.1016/j.foodchem.2006.11.051; Tsimogiannis D, 2007, MOLECULES, V12, P593, DOI 10.3390/12030593; Walencka E, 2007, PLANTA MED, V73, P545, DOI 10.1055/s-2007-967179; Welin-Neilands J, 2007, APPL ENVIRON MICROB, V73, P5633, DOI 10.1128/AEM.01049-07; Wolf P, 2016, BRIT J DERMATOL, V174, P11, DOI 10.1111/bjd.14341	71	23	25	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2018	13	12							e0207574	10.1371/journal.pone.0207574	http://dx.doi.org/10.1371/journal.pone.0207574			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD9QX	30540782	gold, Green Published, Green Submitted			2023-01-03	WOS:000452898600023
J	Pluymaekers, NAHA; Dudink, EAMP; Luermans, JGLM; Meeder, JG; Lenderink, T; Widdershoven, J; Bucx, JJJ; Rienstra, M; Kamp, O; Van Opstal, JM; Alings, M; Oomen, A; Kirchhof, CJ; Van Dijk, VF; Ramanna, H; Liem, A; Dekker, LR; Essers, BAB; Tijssen, JGP; Van Gelder, IC; Crijns, HJGM				Pluymaekers, Nikki A. H. A.; Dudink, Elton A. M. P.; Luermans, Justin G. L. M.; Meeder, Joan G.; Lenderink, Timo; Widdershoven, Jos; Bucx, Jeroen J. J.; Rienstra, Michiel; Kamp, Otto; Van Opstal, Jurren M.; Alings, Marco; Oomen, Anton; Kirchhof, Charles J.; Van Dijk, Vincent F.; Ramanna, Hemanth; Liem, Anho; Dekker, Lukas R.; Essers, Brigitte A. B.; Tijssen, Jan G. P.; Van Gelder, Isabelle C.; Crijns, Harry J. G. M.		RACE 7 ACWAS Investigators	Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPONTANEOUS CONVERSION; TEMPORAL RELATIONSHIP; STROKE; ECHOCARDIOGRAPHY; ANTICOAGULATION; GUIDELINES; ABLATION; CATHETER; DESIGN; DEVICE	Background Patients with recent-onset atrial fibrillation commonly undergo immediate restoration of sinus rhythm by pharmacologic or electrical cardioversion. However, whether immediate restoration of sinus rhythm is necessary is not known, since atrial fibrillation often terminates spontaneously. Methods In a multicenter, randomized, open-label, noninferiority trial, we randomly assigned patients with hemodynamically stable, recent-onset (<36 hours), symptomatic atrial fibrillation in the emergency department to be treated with a wait-and-see approach (delayed-cardioversion group) or early cardioversion. The wait-and-see approach involved initial treatment with rate-control medication only and delayed cardioversion if the atrial fibrillation did not resolve within 48 hours. The primary end point was the presence of sinus rhythm at 4 weeks. Noninferiority would be shown if the lower limit of the 95% confidence interval for the between-group difference in the primary end point in percentage points was more than -10. Results The presence of sinus rhythm at 4 weeks occurred in 193 of 212 patients (91%) in the delayed-cardioversion group and in 202 of 215 (94%) in the early-cardioversion group (between-group difference, -2.9 percentage points; 95% confidence interval [CI], -8.2 to 2.2; P=0.005 for noninferiority). In the delayed-cardioversion group, conversion to sinus rhythm within 48 hours occurred spontaneously in 150 of 218 patients (69%) and after delayed cardioversion in 61 patients (28%). In the early-cardioversion group, conversion to sinus rhythm occurred spontaneously before the initiation of cardioversion in 36 of 219 patients (16%) and after cardioversion in 171 patients (78%). Among the patients who completed remote monitoring during 4 weeks of follow-up, a recurrence of atrial fibrillation occurred in 49 of 164 patients (30%) in the delayed-cardioversion group and in 50 of 171 (29%) in the early-cardioversion group. Within 4 weeks after randomization, cardiovascular complications occurred in 10 patients and 8 patients, respectively. Conclusions In patients presenting to the emergency department with recent-onset, symptomatic atrial fibrillation, a wait-and-see approach was noninferior to early cardioversion in achieving a return to sinus rhythm at 4 weeks. (Funded by the Netherlands Organization for Health Research and Development and others; RACE 7 ACWAS ClinicalTrials.gov number, NCT02248753.)	[Pluymaekers, Nikki A. H. A.; Dudink, Elton A. M. P.; Luermans, Justin G. L. M.; Crijns, Harry J. G. M.] Maastricht Univ, Med Ctr, Dept Cardiol, P Debyelaan 25, NL-6229 HX Maastricht, Netherlands; [Essers, Brigitte A. B.] Maastricht Univ, Med Ctr, Dept Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands; [Pluymaekers, Nikki A. H. A.; Dudink, Elton A. M. P.; Luermans, Justin G. L. M.; Crijns, Harry J. G. M.] Maastricht Univ, Med Ctr, Cardiovasc Res Inst Maastricht, Maastricht, Netherlands; [Meeder, Joan G.] VieCuri Med Ctr Noord Limburg, Venlo, Netherlands; [Lenderink, Timo] Zuyderland Med Ctr, Heerlen, Netherlands; [Widdershoven, Jos] Elisabeth TweeSteden Hosp, Tilburg, Netherlands; [Bucx, Jeroen J. J.] Diakonessen Hosp, Utrecht, Netherlands; [Rienstra, Michiel; Van Gelder, Isabelle C.] Univ Groningen, Groningen, Netherlands; [Kamp, Otto] VU Univ Med Ctr Amsterdam, Amsterdam, Netherlands; [Tijssen, Jan G. P.] Acad Med Ctr, Amsterdam, Netherlands; [Van Opstal, Jurren M.] Med Spectrum Twente, Enschede, Netherlands; [Alings, Marco] Amphia Hosp, Breda, Netherlands; [Oomen, Anton] Antonius Hosp, Sneek, Netherlands; [Kirchhof, Charles J.] Alrijne Hosp, Leiderdorp, Netherlands; [Van Dijk, Vincent F.] St Antonius Hosp, Nieuwegein, Netherlands; [Ramanna, Hemanth] Haga Teaching Hosp, The Hague, Netherlands; [Liem, Anho] St Franciscus Gasthuis, Rotterdam, Netherlands; [Dekker, Lukas R.] Catharina Hosp, Eindhoven, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University; VieCuri Medical Center; Elisabeth-TweeSteden Ziekenhuis (ETZ); Diakonessenhuis; University of Groningen; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Academic Medical Center Amsterdam; Medical Spectrum Twente; Amphia Hospital; St. Antonius Hospital Utrecht; Haga Hospital; Franciscus Gasthuis; Catharina Hospital	Crijns, HJGM (corresponding author), Maastricht Univ, Med Ctr, Dept Cardiol, P Debyelaan 25, NL-6229 HX Maastricht, Netherlands.	hjgm.crijns@mumc.nl	Dudink, Elton/AAC-9913-2019; Pluymaekers, Nikki/V-4252-2019	Pluymaekers, Nikki/0000-0002-9663-6315; kamp, otto/0000-0003-2707-2090; Meeder, Joan/0000-0003-3261-9361; Rienstra, Michiel/0000-0002-2581-070X; Dudink, Elton/0000-0003-4572-3969	Netherlands Organization for Health Research and Development-Health Care Efficiency Research Program [837002524]; Maastricht University Medical Center	Netherlands Organization for Health Research and Development-Health Care Efficiency Research Program; Maastricht University Medical Center	Supported by a grant (837002524) from the Netherlands Organization for Health Research and Development-Health Care Efficiency Research Program and by the Maastricht University Medical Center. Boehringer Ingelheim provided some of the remote monitoring devices.	Airaksinen KEJ, 2013, J AM COLL CARDIOL, V62, P1187, DOI 10.1016/j.jacc.2013.04.089; Brambatti M, 2014, CIRCULATION, V129, P2094, DOI 10.1161/CIRCULATIONAHA.113.007825; Calkins H, 2017, J ARRYTHM, V33, P369, DOI 10.1016/j.joa.2017.08.001; Camm AJ, 2010, EUROPACE, V12, P1360, DOI [10.1093/eurheartj/ehq278, 10.1093/europace/euq350]; Charitos EI, 2014, J AM COLL CARDIOL, V63, P2840, DOI 10.1016/j.jacc.2014.04.019; Coll-Vinent B, 2017, STROKE, V48, P1344, DOI 10.1161/STROKEAHA.116.014855; Cotter G, 1999, EUR HEART J, V20, P1833, DOI 10.1053/euhj.1999.1747; Crijns HJGM, 2012, BMC CARDIOVASC DISOR, V12, DOI 10.1186/1471-2261-12-85; Danias PG, 1998, J AM COLL CARDIOL, V31, P588, DOI 10.1016/S0735-1097(97)00534-2; Daoud EG, 2011, HEART RHYTHM, V8, P1416, DOI 10.1016/j.hrthm.2011.04.022; Decker WW, 2008, ANN EMERG MED, V52, P322, DOI 10.1016/j.annemergmed.2007.12.015; Doyle B, 2011, EMERG MED INT, V2011, DOI 10.1155/2011/545023; Elton D, 2017, AM HEART J, V183, P49, DOI 10.1016/j.ahj.2016.09.009; FARRINGTON CP, 1990, STAT MED, V9, P1447, DOI 10.1002/sim.4780091208; Geleris P, 2001, J Cardiol, V37, P103; January CT, 2014, CIRCULATION, V130, pE199, DOI [10.1161/CIR.0000000000000041, 10.1161/CIR.0000000000000142, 10.1016/j.jacc.2014.03.021, 10.1016/j.jacc.2014.03.022]; Kirchhof P, 2016, EUROPACE, V18, DOI [10.1093/europace/euw295, 10.5603/KP.2016.0172, 10.1016/j.rec.2016.11.033]; Klein AL, 2001, NEW ENGL J MED, V344, P1411, DOI 10.1056/NEJM200105103441901; Lindberg S, 2012, INTERN MED J, V42, P1195, DOI 10.1111/j.1445-5994.2011.02600.x; Lip GYH, 2014, AM J CARDIOL, V113, P480, DOI 10.1016/j.amjcard.2013.10.036; Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584; Little RJ, 2012, NEW ENGL J MED, V367, P1355, DOI 10.1056/NEJMsr1203730; Mauri L, 2017, NEW ENGL J MED, V377, P1357, DOI 10.1056/NEJMra1510063; Nieuwlaat R, 2008, EUR HEART J, V29, P915, DOI 10.1093/eurheartj/ehn101; Nuotio I, 2014, JAMA-J AM MED ASSOC, V312, P647, DOI 10.1001/jama.2014.3824; Pisters R, 2012, EUROPACE, V14, P1, DOI 10.1093/europace/eur310; Spertus J, 2011, CIRC-ARRHYTHMIA ELEC, V4, P15, DOI 10.1161/CIRCEP.110.958033; Tieleman RG, 2014, EUROPACE, V16, P1291, DOI 10.1093/europace/euu057; Van Gelder IC, 2010, NEW ENGL J MED, V362, P1363, DOI 10.1056/NEJMoa1001337; Verma A, 2015, NEW ENGL J MED, V372, P1812, DOI 10.1056/NEJMoa1408288	30	90	91	1	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 18	2019	380	16					1499	1508		10.1056/NEJMoa1900353	http://dx.doi.org/10.1056/NEJMoa1900353			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU3AO	30883054	Green Published, Bronze			2023-01-03	WOS:000465144100011
J	Barlati, S; Stefana, A; Bartoli, F; Bianconi, G; Bulgari, V; Candini, V; Carra, G; Cavalera, C; Clerici, M; Cricelli, M; Ferla, MT; Ferrari, C; Iozzino, L; Macis, A; Vita, A; de Girolamo, G; Bava, M; Conte, G; Micheletti, L; Negri, PV; Ornaghi, A; Turrina, C				Barlati, Stefano; Stefana, Alberto; Bartoli, Francesco; Bianconi, Giorgio; Bulgari, Viola; Candini, Valentina; Carra, Giuseppe; Cavalera, Cesare; Clerici, Massimo; Cricelli, Marta; Ferla, Maria Teresa; Ferrari, Clarissa; Iozzino, Laura; Macis, Ambra; Vita, Antonio; de Girolamo, Giovanni; Bava, Mattia; Conte, Giovanni; Micheletti, Luca; Negri, Paola Vittorina; Ornaghi, Alessandra; Turrina, Cesare		VIORMED-2 Grp	Violence risk and mental disorders (VIORMED-2): A prospective multicenter study in Italy	PLOS ONE			English	Article							PSYCHIATRIC RATING-SCALE; PERSONALITY-DISORDERS; PSYCHOMETRIC MEASURES; AGGRESSION; BEHAVIOR; PSYCHOSIS; PEOPLE; METAANALYSIS; VALIDATION; FACILITIES	Background The management of mentally ill offenders in the community is one of the great challenges imposed on community psychiatry. Aim The aim of this study was to analyze the association between sociodemographic, clinical, and psychosocial factors and violent behavior in a sample of outpatients with severe mental disorders. Method This was a prospective cohort study with a baseline cross-sectional design used to provide a detailed analysis of patients' profiles, followed by a longitudinal design to measure aggressive and violent behavior during a 1-year follow-up. Patients with severe mental disorders, with or without a history of violence, were enrolled in four Italian Departments of Mental Health and underwent a comprehensive multidimensional assessment. Results The sample included 247 outpatients, for a total of 126 cases and 121 controls. Compared to controls, patients with a history of violence had a greater frequency of lifetime domestic violence, a greater lifetime propensity to misuse substances, and a higher number of compulsory admissions. The forthnightly monitoring during the 1-year follow-up did show statistically significant differences in aggressive and violent behavior rates between the two groups. Verbal aggression was significantly associated with aggression against objects and physical aggression. Moreover, outpatients with an history of violence showed statistically significant higher MOAS scores compared to both residential patients with an history of violence, assessed in the first wave of this project, and all controls. Conclusions Patients with a history of violence had specific characteristics and showed a greater occurrence of additional community violence during a 1-year observation period. Our results may assist clinicians in implementing standardized methods of patient assessment and violence monitoring in outpatient mental health services and may prompt improved collaboration between different community services.	[Barlati, Stefano; Stefana, Alberto; Vita, Antonio] ASST Spedali Civili Brescia, Dept Mental Hlth & Addict Serv, Brescia, Italy; [Barlati, Stefano; Vita, Antonio] Univ Brescia, Dept Clin & Expt Sci, Brescia, Italy; [Bartoli, Francesco; Carra, Giuseppe; Clerici, Massimo] Univ Milano Bicocca, Dept Med & Surg, Monza, Italy; [Bianconi, Giorgio; Ferla, Maria Teresa; Vita, Antonio] ASST Ovest Milanese, Dept Mental Hlth, Milan, Italy; [Bulgari, Viola; Candini, Valentina; Cavalera, Cesare; Iozzino, Laura; de Girolamo, Giovanni] IRCCS Ist Ctr San Giovanni di Dio Fatebenefratell, Unit Epidemiol & Evaluat Psychiat, Brescia, Italy; [Cavalera, Cesare] Univ Cattolica Sacro Cuore, Dept Psychol, Milan, Italy; [Clerici, Massimo] San Gerardo Hosp Monza, Dept Mental Hlth, Monza, Italy; [Cricelli, Marta; Ferla, Maria Teresa] ASST Rhodense G Salvini Garbagnate, Dept Mental Hlth, Milan, Italy; [Ferrari, Clarissa; Macis, Ambra] IRCCS Ist Ctr San Giovanni di Dio Fatebenefratell, Unit Stat, Brescia, Italy	Hospital Spedali Civili Brescia; University of Brescia; University of Milano-Bicocca; Catholic University of the Sacred Heart	de Girolamo, G (corresponding author), IRCCS Ist Ctr San Giovanni di Dio Fatebenefratell, Unit Epidemiol & Evaluat Psychiat, Brescia, Italy.	gdegirolamo@fatebenefratelli.eu	Stefana, Alberto/C-5954-2016; de Girolamo, Giovanni/AFM-9128-2022; Carrà, Giuseppe/C-6091-2012; Macis, Ambra/AAC-2369-2020; ferrari, clarissa/ABA-8927-2020; IOZZINO, LAURA/I-8467-2018; Bartoli, Francesco/K-5755-2016; Bulgari, Viola/P-2312-2016; Macis, Ambra/GRS-5029-2022; Clerici, Massimo/U-3074-2019	Stefana, Alberto/0000-0002-4807-7184; de Girolamo, Giovanni/0000-0002-1611-8324; Carrà, Giuseppe/0000-0002-6877-6169; Macis, Ambra/0000-0003-0281-8570; ferrari, clarissa/0000-0002-4101-6872; IOZZINO, LAURA/0000-0002-3633-8316; Bartoli, Francesco/0000-0003-2612-4119; Bulgari, Viola/0000-0003-3956-1190; Clerici, Massimo/0000-0001-8769-6474; Vita, Antonio/0000-0002-3621-6394	Health Authority of Regione Lombardia, Italy [CUP E42I14000280002, 6848]	Health Authority of Regione Lombardia, Italy	The VIORMED-2 (Violence Risk and Mental Disorder 2) project was funded by the Health Authority of Regione Lombardia, Italy, grant CUP E42I14000280002 for "Disturbi mentali gravi e rischio di violenza: uno studio prospettico in Lombardia" with Decreto D.G. Salute N. 6848, date 16.7.2014.	Amore M, 2013, COMMUNITY MENT HLT J, V49, P451, DOI 10.1007/s10597-012-9530-1; Appelbaum PS, 2000, AM J PSYCHIAT, V157, P566, DOI 10.1176/appi.ajp.157.4.566; Barbui C, 2015, BRIT J PSYCHIAT, V206, P445, DOI 10.1192/bjp.bp.114.153817; BARRATT ES, 1965, PSYCHOL REP, V16, P547, DOI 10.2466/pr0.1965.16.2.547; BROWN GL, 1979, PSYCHIAT RES, V1, P131, DOI 10.1016/0165-1781(79)90053-2; Brucato G, 2018, NEUROPSYCHOPHARMACOL, V43, P264, DOI 10.1038/npp.2017.151; Bulgari V, 2018, AGGRESS VIOLENT BEH, V41, P119, DOI 10.1016/j.avb.2018.06.002; BUSS AH, 1957, J CONSULT PSYCHOL, V21, P343, DOI 10.1037/h0046900; Capuzzi E, 2019, INT J LAW PSYCHIAT, V62, P90, DOI 10.1016/j.ijlp.2018.11.003; Carli V, 2010, J AFFECT DISORDERS, V123, P116, DOI 10.1016/j.jad.2010.02.119; Catanesi R, 2007, PUGLIA BASILICATA RA, VI, P63; Chang WC, 2015, AUST NZ J PSYCHIAT, V49, P914, DOI 10.1177/0004867415603130; Coid JW, 2016, SCHIZOPHRENIA BULL, V42, P907, DOI 10.1093/schbul/sbw006; Coid JW, 2013, JAMA PSYCHIAT, V70, P465, DOI 10.1001/jamapsychiatry.2013.12; Dazzi F, 2016, J PSYCHIATR RES, V81, P140, DOI 10.1016/j.jpsychires.2016.07.001; de Girolamo G, 2007, EUR ARCH PSY CLIN N, V257, P83, DOI 10.1007/s00406-006-0695-x; de Girolamo G, 2016, J PSYCHIATR RES, V80, P5, DOI 10.1016/j.jpsychires.2016.05.010; De Luca V, 2018, INT J RISK RECOVER, V1; Dolan M, 2004, J FORENSIC PSYCHI PS, V15, P426, DOI 10.1080/14789940410001721048; Evans L, 2015, J CRIM PSYCHOL, V5, P1, DOI 10.1108/JCP-10-2014-0015; Ferracuti S, 2019, INT J LAW PSYCHIAT, V62, P45, DOI 10.1016/j.ijlp.2018.10.003; First M.B., 1994, USERS GUIDE SCID 5 P; Fond G, 2017, SCHIZOPHR RES, V182, P84, DOI 10.1016/j.schres.2016.10.023; Iozzino L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128536; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lievaart M, 2016, J CLIN PSYCHOL, V72, P263, DOI 10.1002/jclp.22253; Maffei C, 1997, J PERS DISORD, V11, P279, DOI 10.1521/pedi.1997.11.3.279; Margari F, 2005, INT J METH PSYCH RES, V14, P109, DOI 10.1002/mpr.22; Mauri MC, 2011, PROG NEURO-PSYCHOPH, V35, P1631, DOI 10.1016/j.pnpbp.2011.05.008; Montemagni C, 2015, J PSYCHOPATHOL-G PSI, V21, P287; Picardi A, 2014, J NERV MENT DIS, V202, P451, DOI 10.1097/NMD.0000000000000144; Pinna F, 2016, INT J LAW PSYCHIAT, V47, P122, DOI 10.1016/j.ijlp.2016.02.015; Preti A, 2009, PSYCHOL MED, V39, P485, DOI 10.1017/S0033291708003607; Ramsay J.O., 2005, FUNCTIONAL DATA ANAL, VSecond; Rueve Marie E, 2008, Psychiatry (Edgmont), V5, P34; Singh JP, 2014, BRIT J PSYCHIAT, V204, P180, DOI 10.1192/bjp.bp.113.131938; Spielberger C.D., 1985, ANGER HOSTILITY CARD, P5; Stuart Heather, 2003, World Psychiatry, V2, P121; Swanson JW, 2006, ARCH GEN PSYCHIAT, V63, P490, DOI 10.1001/archpsyc.63.5.490; van de Sande R, 2011, BRIT J PSYCHIAT, V199, P473, DOI 10.1192/bjp.bp.111.095141; van der Veeken FCA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160787; VENTURA J, 1993, INT J METH PSYCH RES, V3, P221; Williams J.B.W., 2002, STRUCTURED CLIN INTE; Witt K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055942	44	11	11	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2019	14	4							e0214924	10.1371/journal.pone.0214924	http://dx.doi.org/10.1371/journal.pone.0214924			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HT6TE	30990814	Green Published, gold, Green Submitted			2023-01-03	WOS:000464696100017
J	Wulandari, LPL; Ruddick, A; Guy, R; Kaldor, J				Wulandari, Luh Putu Lila; Ruddick, Abby; Guy, Rebecca; Kaldor, John			"Self-testing sounds more private, rather than going to the clinic and everybody will find out": Facilitators and barriers regarding HIV testing among men who purchase sex in Bali, Indonesia	PLOS ONE			English	Article							SEXUALLY-TRANSMITTED INFECTIONS; MALE CLIENTS; RISK BEHAVIORS; QUALITATIVE RESEARCH; DECISION-MAKING; HEALTH-CARE; CONDOM USE; GAY MEN; WORKERS; PREVALENCE	In many Asian countries, men who purchase sex account for the largest single network of people which often face elevated HIV risk in relation to the general population. However, high proportions of these men have never undertaken HIV testing. We assessed barriers to and facilitators of HIV testing among men who purchase sex in Indonesia, including the acceptability of HIV self-testing. A qualitative study was conducted during December 2016-January 2017 at fourteen sex-work venues and one voluntary HIV counselling and testing (VCT) clinic in Bali. Interviews were conducted with men who purchase sex exploring the men's views on HIV testing. Data were examined using thematic analysis. Twenty-nine men participated in the study. The themes that emerged regarding the barriers to HIV testing included fear of potential shame, embarrassment, and confidentiality breach in accessing HIV testing; fear of social exclusion if the test result was positive; self-treatment and prevention; the distance to a clinic; time constraints; and fear of an invasive testing method. Factors that were seen as facilitating a test were the convenience of time and place; the provision of speedy results; and privacy. Participants expressed interest in HIV self-testing and preferred it to clinic-based testing due to the privacy and confidentiality of the results. The findings support the introduction of an HIV self-testing strategy among this group to improve access to HIV testing.	[Wulandari, Luh Putu Lila; Guy, Rebecca; Kaldor, John] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia; [Wulandari, Luh Putu Lila] Udayana Univ, Fac Med, Dept Publ Hlth & Prevent Med, Denpasar, Bali, Indonesia	University of New South Wales Sydney; Kirby Institute; Universitas Udayana	Wulandari, LPL (corresponding author), Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.; Wulandari, LPL (corresponding author), Udayana Univ, Fac Med, Dept Publ Hlth & Prevent Med, Denpasar, Bali, Indonesia.	lwulandari@kirby.unsw.edu.au		Wulandari, Luh Putu Lila/0000-0002-3397-3648	Australia Awards Scholarships	Australia Awards Scholarships	Dr Luh Putu Lila Wulandari received an Australia Awards Scholarships administered by the Department of Foreign Affairs and Trade. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank the men who participated in this study, and the outreach workers of the Yayasan Kerti Praja who took part in recruiting participants. We also acknowledge the role of the UNSW Qualitative Research Network (QRN) Hub Services for their input in the article draft. Dr Luh Putu Lila Wulandari received an Australia Awards Scholarships administered by the Department of Foreign Affairs and Trade.	Abrams L.S., 2010, QUAL SOC WORK, V9, P536, DOI [10.1177/1473325010367821, DOI 10.1177/1473325010367821]; Alary M, 2003, SEX TRANSM INFECT, V79, P388, DOI 10.1136/sti.79.5.388; Baral S, 2012, LANCET INFECT DIS, V12, P538, DOI 10.1016/S1473-3099(12)70066-X; Bavinton BR, 2013, AIDS BEHAV, V17, P2084, DOI 10.1007/s10461-013-0450-z; Braun V., 2012, THEMATIC ANAL; Brown W, 2016, AIDS BEHAV, V20, P2000, DOI 10.1007/s10461-016-1309-x; Carballo-Dieguez A, 2012, AIDS BEHAV, V16, P1753, DOI 10.1007/s10461-012-0274-2; Chen Y, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003726; Choko AT, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2093-2; Choko AT, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21610; Choudhry V, 2015, GLOBAL HEALTH ACTION, V8, P1, DOI 10.3402/gha.v8.27249; Couture MC, 2008, SEX TRANSM DIS, V35, P849, DOI 10.1097/OLQ.0b013e318177ec5c; Cowan FM, 2005, JAIDS-J ACQ IMM DEF, V40, P371, DOI 10.1097/01.qai.0000162420.93243.ff; Darling KEA, 2012, SEX TRANSM INFECT, V88, P462, DOI 10.1136/sextrans-2012-050489; FAJANS P, 1995, SOC SCI MED, V41, P409, DOI 10.1016/0277-9536(94)00327-P; FAJANS P, 1994, AIDS CARE, V6, P459, DOI 10.1080/09540129408258661; Fang Y, 2019, AIDS CARE, V31, P193, DOI 10.1080/09540121.2018.1510100; Fleming PJ, 2017, AIDS BEHAV, V21, P2322, DOI 10.1007/s10461-016-1531-6; Flowers P, 2017, HIV MED, V18, P245, DOI 10.1111/hiv.12420; Given L, 2008, SAGE ENCY QUALITATIV; Harapan H., 2015, POLISH ANN MED, V22, P74, DOI DOI 10.1016/J.P0AMED.2015.05.003; Holloway I., 1997, BASIC CONCEPTS QUALI; Hor LB, 2005, INT J STD AIDS, V16, P170, DOI 10.1258/0956462053057567; Huang YY, 2012, GLOB PUBLIC HEALTH, V7, P509, DOI 10.1080/17441692.2012.657663; Indonesian Ministry of Health, 2014, INT BIOL BEHAV SURV; Indonesian Ministry of Health, 2017, EST JUML POP KUNC HI; Indonesian Ministry of Health, 2017, TREND REP CAS HIV AI; Jamil MS, 2017, LANCET HIV, V4, pE241, DOI 10.1016/S2352-3018(17)30023-1; Johnson CC, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21594; Jurgensen M, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-2; Kiene SM, 2015, J HEALTH PSYCHOL, V20, P173, DOI 10.1177/1359105313500685; Krause J, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-735; Lahuerta M, 2013, CULT HEALTH SEX, V15, P759, DOI 10.1080/13691058.2013.777474; Lau JTF, 2003, SEX TRANSM DIS, V30, P620, DOI 10.1097/01.OLQ.0000081393.94426.B4; Levitt H. M., 2016, APA HDB CLIN PSYCHOL, P335; Liamputtong D. E, 2005, QUALITATIVE RES METH, DOI [10.1016/j.ymeth.2005.03.001, DOI 10.1016/J.YMETH.2005.03.001]; Lowndes CM, 2000, AIDS, V14, P2523, DOI 10.1097/00002030-200011100-00015; Malta M, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-18; Maman S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174629; Marlin RW, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1226; Masters SH, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002166; Mays N, 2000, BMJ-BRIT MED J, V320, P50, DOI 10.1136/bmj.320.7226.50; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; McLaughlin MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071394; Medline A, 2014, C RETR OPP INF WASH; Merati T, 2005, AIDS CARE, V17, pS175, DOI 10.1080/09540120500119932; Milrod C, 2016, AM J MENS HEALTH, V10, P296, DOI 10.1177/1557988315623990; Mugo PM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170868; Nadol P, 2017, AIDS BEHAV, V21, P2381, DOI 10.1007/s10461-017-1751-4; Nguyen NT, 2009, AIDS BEHAV, V13, P881, DOI 10.1007/s10461-008-9463-4; Niccolai LM, 2012, AIDS CARE, V24, P665, DOI 10.1080/09540121.2011.630356; Njau B, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-838; Pai NP, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001414; Papworth E, 2013, AIDS S3, V16, P1; Perez GM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152653; QSR International Pty Ltd, 2015, NVIVO QUAL DAT AN SO; Rana MS, 2013, J CLIN DIAGN RES, V7, P112, DOI 10.7860/JCDR/2012/4391.2683; Reilly KH, 2012, SEX TRANSM DIS, V39, P750, DOI 10.1097/OLQ.0b013e31825f7af7; Sabido M, 2011, SEX TRANSM INFECT, V87, pA125, DOI 10.1136/sextrans-2011-050108.63; Santo MEGD, 2003, AIDS CARE, V15, P53, DOI 10.1080/0954012021000039752; Shaw SY, 2013, SEX TRANSM DIS, V40, P482, DOI 10.1097/OLQ.0b013e3182904a9a; Shaw SY, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S6-S4; Stevens DR, 2018, AIDS BEHAV, V22, P497, DOI 10.1007/s10461-017-1707-8; Stewart J, 2018, INT J STD AIDS, V29, P178, DOI 10.1177/0956462417721563; Tao J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102812; Tariq S, 2018, AIDS CARE, V30, P32, DOI 10.1080/09540121.2017.1349277; Thapa S, 2015, SYST REV, V4, DOI 10.1186/s13643-015-0130-3; Thirumurthy H, 2015, J INT AIDS SOC, V18, P22; Thirumurthy H, 2016, LANCET HIV, V3, pE266, DOI 10.1016/S2352-3018(16)00041-2; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; U.S. Food and Drug Administration, 2015, ORAQUICK IN HOM HIV; UNAIDS, 2014, AMB TREATM TARG WRIT; UNAIDS, 2018, UNAIDS DAT 2018; UNAIDS, 2013, HIV AS PAC; UNAIDS, 2016, IND NUMB PEOPL LIV H; Unemo M, 2017, NAT REV UROL, V14, P139, DOI 10.1038/nrurol.2016.268; United Nations, 2017, WORLD POPULATION PRO; VANHAASTRECHT HJA, 1993, GENITOURIN MED, V69, P251; Villarroel MA, 2013, SEX TRANSM INFECT, V89, pA242, DOI 10.1136/sextrans-2013-051184.0756; Wagner KD, 2015, AIDS BEHAV, V19, P987, DOI 10.1007/s10461-015-1001-6; Waluyo A, 2015, J ASSOC NURSE AIDS C, V26, P69, DOI 10.1016/j.jana.2014.03.001; WHO, 2015, CONSOLIDATED GUIDELI; WHO/UNICEF/UNAIDS, 2011, PROGR REP 2011 GLOB; Witzel TC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162713; Wray TB, 2018, AIDS PATIENT CARE ST, V32, P360, DOI 10.1089/apc.2018.0049; Wulandari LPL, 2018, 2018 AUSTR HIV AIDS; Wulandari LPL, 2018, AIDS CARE, V30, P1215, DOI 10.1080/09540121.2018.1453920; Yilmaz K, 2013, EUR J EDUC, V48, P311, DOI 10.1111/ejed.12014; Zander V, 2015, INT J ENV RES PUB HE, V12, P12043, DOI 10.3390/ijerph121012043	89	13	13	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2019	14	4							e0214987	10.1371/journal.pone.0214987	http://dx.doi.org/10.1371/journal.pone.0214987			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HS2MY	30958845	Green Published, Green Submitted, gold			2023-01-03	WOS:000463695900031
J	Eshete, MT; Baeumler, PI; Siebeck, M; Tesfaye, M; Wonde, D; Haileamlak, A; Michael, GG; Ayele, Y; Irnich, D				Eshete, Million Tesfaye; Baeumler, Petra I.; Siebeck, Matthias; Tesfaye, Markos; Wonde, Dereje; Haileamlak, Abraham; Michael, Girma G.; Ayele, Yemane; Irnich, Dominik			The views of patients, healthcare professionals and hospital officials on barriers to and facilitators of quality pain management in Ethiopian hospitals: A qualitative study	PLOS ONE			English	Article							ACUTE POSTOPERATIVE PAIN; DEVELOPING-COUNTRIES; SURGERY; ANESTHESIA; PERCEPTIONS; EXPERIENCES; ANALGESIA; INTENSITY; ATTITUDES; RELIEF	Background Postoperative pain remains a challenge in the developed world, but the consequences of inadequately treated postoperative pain are particularly severe in low-and middle-income countries' Since 2011, reports have drawn attention to the poor quality of postoperative pain management in Ethiopia; however, our multicenter qualitative study was the first to attempt to understand the factors that are barriers to and facilitators of quality pain managment in the country. To this aim, the study explored the perspectives of patients, healthcare professionals, and hospital officials. We expected that the results of this study would inform strategies to improve the provision of quality pain management in Ethiopia and perhaps even in other low-and middle-income countries. Methods This study used a qualitative, descriptive approach in which nine healthcare professionals, nine patients, and six hospital officials (i.e. executives in a managerial or leadership position in administration, nursing, or education) participated in face-to-face, semi-structured interviews. Thematic data analysis was conducted, and patterns were explained with the help of a theoretical framework. Findings The barriers identified ranged from healthcare professionals' lack of empathy to a positive social appraisal of patients' ability to cope with pain. They also included a lack of emphasis on pain and its management during early medical education, together with the absence of available resources. Enhancing the ability of healthcare professionals to create favorable rapport with patients and increasing the cultural competence of professionals are essential ingredients of future pain education interventions. Conclusions Barriers to and facilitators of postoperative pain management do not exist independently but are reciprocally linked. This finding calls for holistic and inclusive interventions targeting healthcare professionals, patients, and hospital officials. The current situation is unlikely to improve if only healthcare professionals are educated about pain physiology, pharmacology, and management. Patients should also be educated, and the hospital environment should be modified to provide high-quality postoperative pain management.	[Eshete, Million Tesfaye; Michael, Girma G.; Ayele, Yemane] Jimma Univ, Inst Hlth, Dept Anesthesiol, Fac Med, Jimma, Ethiopia; [Eshete, Million Tesfaye; Siebeck, Matthias] Ludwig Maximilians Univ Munchen, Ctr Int Hlth, Munich, Germany; [Baeumler, Petra I.; Irnich, Dominik] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Anaesthesiol, Multidisciplinary Pain Ctr, Munich, Germany; [Siebeck, Matthias] Hosp Univ Munich LMU, Dept Gen Visceral Vasc & Transplantat Surg, Munich, Germany; [Tesfaye, Markos] St Pauls Hosp, Millennium Med Coll, Dept Psychiat, Addis Ababa, Ethiopia; [Wonde, Dereje] Jimma Univ, Dept Sociol, Coll Social Sci & Humanity, Jimma, Ethiopia; [Haileamlak, Abraham] Jimma Univ, Inst Hlth, Dept Pediat & Child Hlth, Fac Med, Jimma, Ethiopia	Jimma University; University of Munich; University of Munich; University of Munich; Jimma University; Jimma University	Eshete, MT (corresponding author), Jimma Univ, Inst Hlth, Dept Anesthesiol, Fac Med, Jimma, Ethiopia.; Eshete, MT (corresponding author), Ludwig Maximilians Univ Munchen, Ctr Int Hlth, Munich, Germany.	mtesfaye1@gmail.com		Tesfaye, Markos/0000-0002-3351-701X	Jimma University; CIHLMU Center for International Health, Ludwig-Maximilians-Universitat, Munich, Germany	Jimma University; CIHLMU Center for International Health, Ludwig-Maximilians-Universitat, Munich, Germany	This study was supported by the Jimma University and CIHLMU Center for International Health, Ludwig-Maximilians-Universitat, Munich, Germany.	Al-Azawy M, 2015, APPL NURS RES, V28, P268, DOI 10.1016/j.apnr.2015.01.011; Alzghoul BI., 2015, MEDITERRANEAN J SOCI, V6, P60, DOI [10.5901/mjss.2015.v6n6s2p60, DOI 10.5901/MJSS.2015.V6N6S2P60]; [Anonymous], 2011, MANAGING ACUTE PAIN; [Anonymous], 1999, HDB PERSONALITY THEO, DOI DOI 10.1016/0749-5978(91)90022-L; Bandura A., 1999, ASIAN J SOC PSYCHOL, V2, P21, DOI DOI 10.1111/1467-839X.00024; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Brydon CW, 1996, ANAESTHESIA, V51, P279, DOI 10.1111/j.1365-2044.1996.tb13647.x; Burmeister E, 2012, AUST CRIT CARE, V25, P271, DOI 10.1016/j.aucc.2012.07.002; Carr Eloise, 2007, J Perioper Pract, V17, P200; Centers for Disease Control and Prevention FDRoEMoH Ethiopian Public Health Association, 2011, BAS EV PAIN MAN PRAC; Chao TE, 2012, WORLD J SURG, V36, P2545, DOI 10.1007/s00268-012-1729-3; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; Cleary J, 2013, ANN ONCOL, V24, P14, DOI 10.1093/annonc/mdt499; Crombie IK, 1998, PAIN, V76, P167, DOI 10.1016/S0304-3959(98)00038-4; Dehning S, 2012, BMC MED EDUC, V12, DOI 10.1186/1472-6920-12-34; DiCicco-Bloom B, 2006, MED EDUC, V40, P314, DOI 10.1111/j.1365-2929.2006.02418.x; Ethiopia CSAo, 2007, 2007 POP HOUS CENS 1; Ethiopian Publich Health Association FDRoEMoH, 2011, BAS EV PAIN MAN PRAC; Forero R, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2915-2; Fusch PI, 2015, QUAL REP, V20, P1408; Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3; Gordon Debra B, 2002, Pain Manag Nurs, V3, P116, DOI 10.1053/jpmn.2002.127570; Goucke CR, 2018, ANESTH ANALG, V126, P1283, DOI 10.1213/ANE.0000000000002736; Grimshaw J, 1995, J Eval Clin Pract, V1, P37, DOI 10.1111/j.1365-2753.1995.tb00006.x; Hadi MA, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016454; Hetmann F, 2015, ACTA ANAESTH SCAND, V59, P740, DOI 10.1111/aas.12532; Hodges SC, 2007, ANAESTHESIA, V62, P4, DOI 10.1111/j.1365-2044.2006.04907.x; Johnson AP, 2015, PAIN RES MANAG, V20, P255, DOI 10.1155/2015/297384; Joshi Girish P, 2005, Anesthesiol Clin North Am, V23, P21, DOI 10.1016/j.atc.2004.11.013; King NB, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001411; Lincoln YS, 1986, NEW DIRECTIONS EVALU, V30, P73, DOI [10.1002/ev.1427, 10.1002/(ISSN)1551-2371, DOI 10.1002/EV.1427]; Lundborg Christopher, 2015, J Pain Palliat Care Pharmacother, V29, P300, DOI 10.3109/15360288.2015.1065940; Martin JJ, 2020, ROUT INT HANDB, P280; Medrzycka-Dabrowska W, 2015, ADV CLIN EXP MED, V24, P905, DOI 10.17219/acem/26394; Murray AA, 2016, SOUTH AFR J ANAESTH, V22, P19, DOI 10.1080/22201181.2015.1115608; Nash R, 1999, J CLIN NURS, V8, P180, DOI 10.1046/j.1365-2702.1999.00228.x; Neergaard MA, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-52; Nyirigira G, 2018, CANADIAN J PAIN; Pain IAftSo, 2010, GUIDE PAIN MANAGEMEN; Rejeh N, 2008, INT NURS REV, V55, P468, DOI 10.1111/j.1466-7657.2008.00659.x; Rejeh N, 2009, SCAND J CARING SCI, V23, P274, DOI 10.1111/j.1471-6712.2008.00619.x; Sandelowski M, 2010, RES NURS HEALTH, V33, P77, DOI 10.1002/nur.20362; Shenton A. K., 2004, ED INFORM, V22, P63, DOI DOI 10.3233/EFI-2004-22201; Stephens J, 2003, RHEUMATOLOGY, V42, P40, DOI 10.1093/rheumatology/keg497; Tingle J, 1997, Br J Nurs, V6, P639; Weiser TG, 2016, B WORLD HEALTH ORGAN, V94, P201, DOI 10.2471/BLT.15.159293; Wilder-Smith OHG, 2002, PAIN, V97, P189, DOI 10.1016/S0304-3959(01)00430-4; WILDERSMITH CH, 1992, PAIN, V50, P257, DOI 10.1016/0304-3959(92)90029-B; Wilkinson Helen, 2017, Burn Res, V6, P18, DOI 10.1016/j.burn.2017.06.003; Woldehaimanot TE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102835; WOOD R, 1989, ACAD MANAGE REV, V14, P361, DOI 10.2307/258173; Zoega S, 2015, PAIN PRACT, V15, P236, DOI 10.1111/papr.12166	52	7	7	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2019	14	3							e0213644	10.1371/journal.pone.0213644	http://dx.doi.org/10.1371/journal.pone.0213644			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HO7YP	30870467	Green Submitted, Green Published, gold			2023-01-03	WOS:000461166300053
J	Guzman, IB; Cuesta, JG; Trelles, M; Jaweed, O; Cherestal, S; van Loenhout, JAF; Guha-Sapir, D				Guzman, Isabel Beltran; Cuesta, Julita Gil; Trelles, Miguel; Jaweed, Omar; Cherestal, Sophia; van Loenhout, Joris Adriaan Frank; Guha-Sapir, Debarati			Delays in arrival and treatment in emergency departments: Women, children and non-trauma consultations the most at risk in humanitarian settings	PLOS ONE			English	Article							HEALTH LITERACY; CARE-SEEKING; SYSTEMS; EDUCATION; BARRIERS; OUTCOMES; ACCESS; TIME; AGE	Introduction Delays in arrival and treatment at health facilities lead to negative health outcomes. Individual and external factors could be associated with these delays. This study aimed to assess common factors associated with arrival and treatment delays in the emergency departments (ED) of three hospitals in humanitarian settings. Methodology This was a cross-sectional study based on routine data collected from three MSF-supported hospitals in Afghanistan, Haiti and Sierra Leone. We calculated the proportion of consultations with delay in arrival (>24 hours) and in treatment (based on target time according to triage categories). We used a multinomial logistic regression model (MLR) to analyse the association between age, sex, hospital and diagnosis (trauma and non-trauma) with these delays. Results We included 95,025 consultations. Males represented 65.2%, Delay in arrival was present in 27.8% of cases and delay in treatment in 27.2%. The MLR showed higher risk of delay in arrival for females (OR 1.2, 95% CI 1.2-1.3), children <5 (OR 1.4, 95% CI 1.4-1.5), patients attending to Gondama (OR 30.0, 95% CI 25.6-35.3) and non-trauma cases (OR 4.7, 95% CI 4.4-4.8). A higher risk of delay in treatment was observed for females (OR 1.1, 95% CI 1.0-1.1), children < 5 (OR 2.0, 95% CI 1.9-2.1), patients attending to Martissant (OR 14.6, 95% CI 13.9-15.4) and non-trauma cases (OR 1.6, 95% CI 1.5-1.7). Conclusions Women, children <5 and non-trauma cases suffered most from delays. These delays could relate to educational and cultural barriers, and severity perception of the disease. Treatment delay could be due to insufficient resources with consequent overcrowding, and severity perception from medical staff for non-trauma patients. Extended community outreach, health promotion and support to community health workers could improve emergency care in humanitarian settings.	[Guzman, Isabel Beltran; van Loenhout, Joris Adriaan Frank; Guha-Sapir, Debarati] Catholic Univ Louvain, Inst Hlth & Soc, Ctr Res Epidemiol Disasters, Brussels, Belgium; [Guzman, Isabel Beltran] Medecins Sans Frontieres, Operat Ctr Geneva, Geneva, Switzerland; [Cuesta, Julita Gil; Trelles, Miguel] Medecins Sans Frontieres, Operat Ctr Brussels, Brussels, Belgium; [Jaweed, Omar] Medecins Sans Frontieres, Mission Afghanistan, Kunduz, Afghanistan; [Cherestal, Sophia] Medecins Sans Frontieres, Operat Ctr Brussels, Mission Haiti, Port Au Prince, Haiti	Universite Catholique Louvain; Doctors Without Borders; Doctors Without Borders	Guzman, IB (corresponding author), Catholic Univ Louvain, Inst Hlth & Soc, Ctr Res Epidemiol Disasters, Brussels, Belgium.; Guzman, IB (corresponding author), Medecins Sans Frontieres, Operat Ctr Geneva, Geneva, Switzerland.	kethze@hotmail.com	van Loenhout, Joris/AAV-2075-2020; Gil-Cuesta, Julita/AFV-5338-2022	van Loenhout, Joris/0000-0001-7810-7738; Gil-Cuesta, Julita/0000-0002-8291-9701				Alex  Jones, SIERRA LEONE FREE HL; Asplin BR, 2003, ANN EMERG MED, V42, P173, DOI 10.1067/mem.2003.302; Balagopal P, 2012, DIABETES EDUCATOR, V38, P822, DOI 10.1177/0145721712459890; Ball Chad G, 2013, J Trauma Manag Outcomes, V7, P11, DOI 10.1186/1752-2897-7-11; Boyle A, 2012, EMERG MED INT, V2012, P1; Brice JH, 2003, ANN EMERG MED, V41, P491, DOI 10.1067/mem.2003.115; Busia K, 2010, AFRICAN HLTH MONIT, P40; Byrne A, 2011, INT J GYNECOL OBSTET, V115, P127, DOI 10.1016/j.ijgo.2011.06.019; Calvello EJB, 2013, ACAD EMERG MED, V20, P1278, DOI 10.1111/acem.12266; Cha WC, 2011, PEDIATR EMERG CARE, V27, P1136, DOI 10.1097/PEC.0b013e31823ab90b; Corrarino JE, 2013, J MIDWIFERY WOM HEAL, V58, P257, DOI 10.1111/jmwh.12018; Crilly J, 2015, EMERG MED AUSTRALAS, V27, P216, DOI 10.1111/1742-6723.12399; Dalwai MK, 2013, PUBLIC HEALTH ACTION, V3, P43, DOI 10.5588/pha.12.0083; Dalwai M, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2016-000160; Davis JR, 2010, DISASTER MED PUBLIC, V4, P30, DOI 10.1017/S1935789300002391; De Cock D, 2014, SCAND J RHEUMATOL, V43, P1, DOI 10.3109/03009742.2013.805242; Diaz T, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-157; Essendi H, 2011, J URBAN HEALTH, V88, P356, DOI 10.1007/s11524-010-9481-1; Finlayson K, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001373; Frost A, 2016, GLOBALIZATION HEALTH, V12, DOI 10.1186/s12992-016-0212-6; Glenton C, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010414.pub2; Guttmann A, 2011, BMJ-BRIT MED J, P8; Jacobs B, 2012, HEALTH POLICY PLANN, V27, P288, DOI 10.1093/heapol/czr038; Johnson KD, 2011, ADV EMERG NURS J, V33, P39, DOI 10.1097/TME.0b013e318207e86a; Karlsen S, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-606; Kickbusch IS, 2001, HEALTH PROMOT INT, V16, P289, DOI 10.1093/heapro/16.3.289; Lindgren TG, 2011, RURAL REMOTE HEALTH, V11; McHugh M, 2013, CONSEQUENCES EMERGEN, P107, DOI [10.1007/978-1-4614-9512-3_5, DOI 10.1007/978-1-4614-9512-3_5]; Ministere De La Sante Publique Et De La Population, 2012, POL NAT SANT; Ministry of Public Health, 2005, ISL REP AFGH MIN PUB; Myer L, 2003, J MIDWIFERY WOM HEAL, V48, P268, DOI 10.1016/S1526-9523(02)00421-X; Newbrander W, 2014, GLOB PUBLIC HEALTH, V9, pS93, DOI 10.1080/17441692.2013.827735; Nguyen HL, 2010, CIRC-CARDIOVASC QUAL, V3, P82, DOI 10.1161/CIRCOUTCOMES.109.884361; Noorani Muhammad Muslim, 2014, Int Arch Med, V7, P41, DOI 10.1186/1755-7682-7-41; Nutbeam D, 2000, HEALTH PROMOT INT, V15, P259, DOI 10.1093/heapro/15.3.259; Peters DH, 2008, ANN NY ACAD SCI, V1136, P161, DOI 10.1196/annals.1425.011; Rassekh BM, 2014, HEALTH PSYCHOL BEHAV, V2, P359, DOI 10.1080/21642850.2014.896744; Read Jen'nan Ghazal, 2014, Qatar Med J, V2014, P98, DOI 10.5339/qmj.2014.16; Rukewe A, 2015, W INDIAN MED J, V64, P131, DOI 10.7727/wimj.2013.281; Rutebemberwa E, 2009, TROP MED INT HEALTH, V14, P472, DOI 10.1111/j.1365-3156.2009.02237.x; Fernandez IS, 2015, NEUROLOGY, V84, P2304, DOI 10.1212/WNL.0000000000001673; Sayah A, 2014, EMERG MED INT, V2014, DOI 10.1155/2014/981472; Schnippel K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119236; Scott K, 2014, HEALTH POLICY PLANN, V29, P292, DOI 10.1093/heapol/czt016; Sosnaud B, 2017, SOC PROBL, DOI DOI 10.1093/SOCPRO/SPX034/4553357; South African Triage Group. A division of the Emergency Medicine Society of South Africa, 2008, S AFR TRIAG SCAL SAT, P1; Talan DA, 2003, CLIN INFECT DIS, V37, P1481, DOI 10.1086/379331; Thankappan K R, 2013, Indian Heart J, V65, P504, DOI 10.1016/j.ihj.2013.08.023; Uleberg O, 2007, ACTA ANAESTH SCAND, V51, P1178, DOI 10.1111/j.1399-6576.2007.01414.x; UNESCO, 2017, GLOBAL ED MONITORING; Valluri S, 2015, J FAM ECON ISS, V36, P154, DOI 10.1007/s10834-014-9424-1	51	13	14	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2019	14	3							e0213362	10.1371/journal.pone.0213362	http://dx.doi.org/10.1371/journal.pone.0213362			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HN7LV	30835777	gold, Green Published, Green Submitted			2023-01-03	WOS:000460371800041
J	Saeterbakken, AH; Chaudhari, A; van den Tillaar, R; Andersen, V				Saeterbakken, Atle Hole; Chaudhari, Ajit; van den Tillaar, Roland; Andersen, Vidar			The effects of performing integrated compared to isolated core exercises	PLOS ONE			English	Article							TRUNK MUSCLE ACTIVATION; ELECTROMYOGRAPHIC ACTIVITY; STABILIZATION EXERCISES; ELASTIC RESISTANCE; LUMBAR SPINE; STABILITY; BALANCE; WEIGHT; BACK; INSTABILITY	Integrated exercises that mimic daily tasks are generally preferred for improving performance and the later stages of rehabilitation, but it is unknown whether integrated core exercises are better than isolated core exercises at improving muscle activation for hypertrophy. The aim of the study was to compare the electromyographic (EMG) activity in rectus abdominis, oblique externus, and erector spinae while performing three conditions of integrated core exercises (lunges) with three isolated core exercises (prone bridge, side bridge and back extension). The three conditions of lunges were: on a stable surface, unstable surface and with external resistance to the trunk using an elastic band. The external resistance was measured with a force cell and peaked at 75N. After one familiarization session, all exercises were performed in one experimental session in randomized order. The isolated core exercises were performed in 20 seconds and the time performing the five repetitions with lunges was matched (20 seconds). Significantly greater peak normalized EMG activity were observed in the isolated core exercises compared to the three integrated core exercises (P<0.001) with two exceptions. For the oblique externus, the isolated core exercise was only greater than the stable lunge. Lunges with elastic bands only demonstrated greater peak erector spinae activation compared the other lunge conditions. Comparing the mean EMG activity between the isolated and three integrated exercises, greater muscle activations were observed performing the isolated exercises (P<0.001). Unstable lunges did not increase the peak or mean core muscle activations. In conclusion, mean and peak EMG activity performing the isolated exercises were in general greater than the three condition of lunges. Based on these results, we recommend using isolated core exercises when the primary goal is to improve muscle activation and elicit hypertrophy, but integrated exercises once adequate initial hypertrophy is achieved.	[Saeterbakken, Atle Hole; Andersen, Vidar] Western Norway Univ, Fac Teacher Educ Culture & Sport, Dept Sport Food & Nat Sci, Sogndal, Sogn & Fjordane, Norway; [Chaudhari, Ajit] Ohio State Univ, Phys Therapy, Sch Hlth & Rehabil Sci, Columbus, OH 43210 USA; [van den Tillaar, Roland] Nord Univ, Dept Sport Sci & Phys Educ, Levanger, Norway	University System of Ohio; Ohio State University; Nord University	Saeterbakken, AH (corresponding author), Western Norway Univ, Fac Teacher Educ Culture & Sport, Dept Sport Food & Nat Sci, Sogndal, Sogn & Fjordane, Norway.	atle.saeterbakken@hvl.no	Chaudhari, Ajit/N-5831-2019; Chaudhari, Ajit M/E-2875-2011	Chaudhari, Ajit/0000-0001-5071-7147; Chaudhari, Ajit M/0000-0001-5071-7147				Alkner BA, 2000, MED SCI SPORT EXER, V32, P459, DOI 10.1097/00005768-200002000-00030; Andersen V, 2016, J STRENGTH COND RES, V30, P1196, DOI 10.1519/JSC.0000000000001240; Behm DG, 2010, APPL PHYSIOL NUTR ME, V35, P91, DOI 10.1139/H09-127; Behm DG, 2005, J STRENGTH COND RES, V19, P193; Bouillon LE, 2012, INT J SPORTS PHYS TH, V7, P595; Byrne JM, 2014, J STRENGTH COND RES, V28, P3049, DOI 10.1519/JSC.0000000000000510; Calatayud J, 2017, AM J PHYS MED REHAB, V96, P694, DOI 10.1097/PHM.0000000000000713; Calatayud J, 2017, MUSCULOSKEL SCI PRAC, V28, P54, DOI 10.1016/j.msksp.2017.01.011; Cholewicki J, 2002, CLIN BIOMECH, V17, P99, DOI 10.1016/S0268-0033(01)00118-8; Clark KM, 2003, J STRENGTH COND RES, V17, P475; Comerford MJ, 2001, MANUAL THER, V6, P3, DOI 10.1054/math.2000.0389; Comfort P, 2011, J STRENGTH COND RES, V25, P149, DOI 10.1519/JSC.0b013e3181fb412f; Cosio-Lima LM, 2003, J STRENGTH COND RES, V17, P721; Desai I, 2010, J ELECTROMYOGR KINES, V20, P1155, DOI 10.1016/j.jelekin.2010.08.003; Ekstrom RA, 2007, J ORTHOP SPORT PHYS, V37, P754, DOI 10.2519/jospt.2007.2471; Fenwick CMJ, 2009, J STRENGTH COND RES, V23, P350, DOI 10.1519/JSC.0b013e3181942019; Garcia-Vaquero MP, 2012, J ELECTROMYOGR KINES, V22, P398, DOI 10.1016/j.jelekin.2012.02.017; Gottschall JS, 2013, J STRENGTH COND RES, V27, P590, DOI 10.1519/JSC.0b013e31825c2cc7; Hamlyn N, 2007, J STRENGTH COND RES, V21, P1108; Jakobsen MD, 2013, HUM MOVEMENT SCI, V32, P65, DOI 10.1016/j.humov.2012.07.002; McBride JM, 2010, INT J SPORT PHYSIOL, V5, P177, DOI 10.1123/ijspp.5.2.177; McGill SM, 1998, PHYS THER, V78, P754, DOI 10.1093/ptj/78.7.754; McGill SM, 1999, ARCH PHYS MED REHAB, V80, P941, DOI 10.1016/S0003-9993(99)90087-4; Monfort-Panego M, 2009, J MANIP PHYSIOL THER, V32, P232, DOI 10.1016/j.jmpt.2009.02.007; Norwood JT, 2007, J STRENGTH COND RES, V21, P343, DOI 10.1519/R-17435.1; Notarnicola A, 2015, MLTJ-MUSCLE LIGAMENT, V5, P208, DOI 10.11138/mltj/2015.5.3.208; Nuzzo JL, 2008, J STRENGTH COND RES, V22, P95, DOI 10.1519/JSC.0b013e31815ef8cd; Oliver GD, 2010, CLIN J SPORT MED, V20, P452, DOI 10.1097/JSM.0b013e3181f7b0ef; Oliver GD, 2010, J STRENGTH COND RES, V24, P3069, DOI [10.1519/JSC.0b013e3181c865ce, 10.1519/JSC.0b013e3181d321da]; PANJABI MM, 1992, J SPINAL DISORD, V5, P383, DOI 10.1097/00002517-199212000-00001; Reed CA, 2012, SPORTS MED, V42, P697, DOI 10.2165/11633450-000000000-00000; ROBBINS S, 1994, BRIT J SPORT MED, V28, P117, DOI 10.1136/bjsm.28.2.117; Saeterbakken A, 2015, INT J SPORTS MED, V36, P900, DOI 10.1055/s-0034-1398646; Saeterbakken AH, 2014, J STRENGTH COND RES, V28, P3515, DOI 10.1519/JSC.0000000000000565; Saeterbakken AH, 2013, J STRENGTH COND RES, V27, P130, DOI 10.1519/JSC.0b013e3182541d43; Saeterbakken AH, 2011, J STRENGTH COND RES, V25, P712, DOI 10.1519/JSC.0b013e3181cc227e; Saeterbakken AH, 2012, EUR J APPL PHYSIOL, V112, P1671, DOI 10.1007/s00421-011-2141-7; Santana JC, 2007, J STRENGTH COND RES, V21, P1271; Smith BS, 2015, INT J SPORTS PHYS TH, V10, P69; Snarr RL, 2013, J HUM KINET, V39, P75, DOI 10.2478/hukin-2013-0070; Sundstrup E, 2012, INT J SPORTS PHYS TH, V7, P372; van den Tillaar R, 2018, J HUM KINET, V62, P43, DOI 10.1515/hukin-2017-0176; Vera-Garcia FJ, 2000, PHYS THER, V80, P564, DOI 10.1093/ptj/80.6.564; Wahl MJ, 2008, J STRENGTH COND RES, V22, P1360, DOI 10.1519/JSC.0b013e318175ca3c; Willardson JM, 2007, J STRENGTH COND RES, V21, P979; Willardson JM, 2009, INTJ SPORT PHYSIOL, V4, P97, DOI 10.1123/ijspp.4.1.97	46	8	8	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2019	14	2							e0212216	10.1371/journal.pone.0212216	http://dx.doi.org/10.1371/journal.pone.0212216			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM9LQ	30811444	Green Published, Green Submitted, gold			2023-01-03	WOS:000459806400061
J	Johansen, SL; Robakis, TK; Williams, KE; Rasgon, NL				Johansen, Sara L.; Robakis, Thalia K.; Williams, Katherine Ellie; Rasgon, Natalie L.			Management of perinatal depression with non-drug interventions	BMJ-BRITISH MEDICAL JOURNAL			English	Review							POSTTRAUMATIC-STRESS-DISORDER; TRANSCRANIAL MAGNETIC STIMULATION; BORDERLINE PERSONALITY-DISORDER; COGNITIVE-BEHAVIORAL THERAPY; OBSTRUCTIVE SLEEP-APNEA; MATERNAL MENTAL-HEALTH; POSTPARTUM DEPRESSION; INTERPERSONAL PSYCHOTHERAPY; POSTNATAL DEPRESSION; RISK-FACTORS	Perinatal depression is a common disorder that has been associated with serious risks to mother and child. Recently, screening for depression in pregnant and postpartum women has increased, as has the development of new psychotherapy and non-drug treatment modalities. Matching patients to treatments can be challenging, and although research into personalized treatment of major depression in the general population has increased, no published guidelines focus on personalized treatment approaches to perinatal depression. In particular, guidelines on non-drug treatments are lacking. This review summarizes the evidence on personalized non-drug treatment of perinatal depression, how to incorporate patients' preferences, novel treatments under investigation, and the potential role of biomarkers in matching patients to treatment. The review provides recommendations for future research in personalized care of perinatal depression.	[Johansen, Sara L.; Robakis, Thalia K.; Williams, Katherine Ellie; Rasgon, Natalie L.] Stanford Univ, Sch Med, Stanford, CA 94305 USA	Stanford University	Williams, KE (corresponding author), Stanford Univ, Sch Med, Stanford, CA 94305 USA.	elliew@stanford.edu	Rasgon, Natalie/ABH-9813-2020; Robakis, Thalia/AAQ-5277-2020	Robakis, Thalia/0000-0003-2919-2555				Abalovich M, 2007, J CLIN ENDOCR METAB, V92, pS1, DOI 10.1210/jc.2007-0141; Agostini F, 2015, MATERN CHILD HLTH J, V19, P1131, DOI 10.1007/s10995-014-1613-x; Akkaya C, 2007, PSYCHIAT CLIN NEUROS, V61, P698, DOI 10.1111/j.1440-1819.2007.01733.x; Amare AT, 2017, EPMA J, V8, P211, DOI 10.1007/s13167-017-0112-8; [Anonymous], 2016, RES EXP MOMS SLEEP T; Apter-Danon G, 2005, CLIN NEUROPSYCHIATR, V2, P302; Ashford MT, 2016, J AFFECT DISORDERS, V197, P134, DOI 10.1016/j.jad.2016.02.057; BaHammam AS, 2016, SLEEP BREATH, V20, P447, DOI 10.1007/s11325-015-1223-x; Battle CL, 2014, OBSTET MED, V7, P66, DOI 10.1177/1753495X13514402; Bifulco A, 2004, BRIT J PSYCHIAT, V184, pS31, DOI 10.1192/bjp.184.46.s31; Bloch M, 2005, J AFFECT DISORDERS, V88, P9, DOI 10.1016/j.jad.2005.04.007; Bloch M, 2003, COMPR PSYCHIAT, V44, P234, DOI 10.1016/S0010-440X(03)00034-8; Borak J, 1996, J SLEEP RES, V5, P123, DOI 10.1046/j.1365-2869.1996.d01-60.x; Brugha TS, 2000, PSYCHOL MED, V30, P1273, DOI 10.1017/S0033291799002937; Cassidy-Bushrow AE, 2012, J WOMENS HEALTH, V21, P1189, DOI 10.1089/jwh.2012.3528; Chisolm MS, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.h5918; Cohen MJ, 2017, PSYCHOTHERAPY, V54, P406, DOI 10.1037/pst0000151; Cohen NJ, 1999, INF MENTAL HLTH J, V20, P429, DOI 10.1002/(SICI)1097-0355(199924)20:4<429::AID-IMHJ5>3.0.CO;2-Q; Comasco E, 2011, PSYCHIAT GENET, V21, P19, DOI 10.1097/YPG.0b013e328341a3c1; Corral M, 2007, ARCH WOMEN MENT HLTH, V10, P221, DOI 10.1007/s00737-007-0200-1; Corwin EJ, 2003, J NUTR, V133, P4139, DOI 10.1093/jn/133.12.4139; Cox EQ, 2016, J CLIN PSYCHIAT, V77, P1189, DOI 10.4088/JCP.15r10174; Cuijpers P, 2008, J CLIN PSYCHOL, V64, P103, DOI 10.1002/jclp.20432; Cuijpers P, 2008, J CLIN PSYCHIAT, V69, P1675, DOI 10.4088/JCP.v69n1102; Curtis KM, 2016, MMWR RECOMM REP, V65, P3, DOI 10.15585/mmwr.rr6504a1; Dennis C, 2007, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD006116.PUB2; Dennis CL, 2006, BIRTH-ISS PERINAT C, V33, P323, DOI 10.1111/j.1523-536X.2006.00130.x; Dennis CL, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001690.pub2; Dennis CL, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-38; Dikmen-Yildiz P, 2017, MIDWIFERY, V55, P29, DOI 10.1016/j.midw.2017.09.001; Dimidjian S, 2017, J CONSULT CLIN PSYCH, V85, P26, DOI 10.1037/ccp0000151; Dimidjian S, 2015, ARCH WOMEN MENT HLTH, V18, P85, DOI 10.1007/s00737-014-0468-x; Dindo L, 2017, ARCH WOMEN MENT HLTH, V20, P757, DOI 10.1007/s00737-017-0769-y; Doornbos B, 2009, PROG NEURO-PSYCHOPH, V33, P1250, DOI 10.1016/j.pnpbp.2009.07.013; Douglas PS, 2013, J DEV BEHAV PEDIATR, V34, P497, DOI 10.1097/DBP.0b013e31829cafa6; Dubey N, 2017, MOL PSYCHIATR, V22, P1172, DOI 10.1038/mp.2016.229; Earls MF, 2010, PEDIATRICS, V126, P1032, DOI 10.1542/peds.2010-2348; Edwards C, 2015, J CLIN SLEEP MED, V11, P1029, DOI 10.5664/jcsm.5020; Figueiredo FP, 2015, J AFFECT DISORDERS, V172, P265, DOI 10.1016/j.jad.2014.10.016; Fisher J, 2012, B WORLD HEALTH ORGAN, V90, P139, DOI 10.2471/BLT.11.091850; Frank E, 2005, ARCH GEN PSYCHIAT, V62, P996, DOI 10.1001/archpsyc.62.9.996; Furuta M, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00591; Gahr M, 2012, PHARMACOPSYCHIATRY, V45, P79, DOI 10.1055/s-0031-1297936; Garcia KS, 2010, BRAIN STIMUL, V3, P36, DOI 10.1016/j.brs.2009.06.001; Garcia-Esteve L, 2008, ARCH WOMEN MENT HLTH, V11, P193, DOI 10.1007/s00737-008-0012-y; Gavin NI, 2005, OBSTET GYNECOL, V106, P1071, DOI 10.1097/01.AOG.0000183597.31630.db; Gelaye B, 2017, J AFFECT DISORDERS, V209, P195, DOI 10.1016/j.jad.2016.11.020; Giallo R, 2014, ARCH WOMEN MENT HLTH, V17, P115, DOI 10.1007/s00737-014-0411-1; Goddard E, 2015, BEHAV RES THER, V73, P1, DOI 10.1016/j.brat.2015.07.006; Goodman JH, 2009, BIRTH-ISS PERINAT C, V36, P60, DOI 10.1111/j.1523-536X.2008.00296.x; Gorwood P, 2010, BRIT J PSYCHIAT, V196, P139, DOI 10.1192/bjp.bp.109.067058; Grant KA, 2012, ARCH WOMEN MENT HLTH, V15, P297, DOI 10.1007/s00737-012-0292-0; Grote NK, 2016, J CLIN PSYCHIAT, V77, P1527, DOI 10.4088/JCP.15m10477; GUILOFF E, 1974, AM J OBSTET GYNECOL, V118, P42, DOI 10.1016/S0002-9378(16)33643-2; Guintivano J, 2014, MOL PSYCHIATR, V19, P560, DOI 10.1038/mp.2013.62; Gur EB, 2014, EUR J OBSTET GYN R B, V179, P110, DOI 10.1016/j.ejogrb.2014.05.017; HAMMARBACK S, 1988, ACTA OBSTET GYN SCAN, V67, P159, DOI 10.3109/00016348809004191; Heise AM, 2011, INT BREASTFEED J, V6, DOI 10.1186/1746-4358-6-6; Hellgren C, 2014, NEUROPSYCHOBIOLOGY, V69, P147, DOI 10.1159/000358838; Hiscock H, 2014, PEDIATRICS, V133, pE346, DOI 10.1542/peds.2013-1886; HOBFOLL SE, 1995, J CONSULT CLIN PSYCH, V63, P445, DOI 10.1037/0022-006X.63.3.445; Howard LM, 2014, LANCET, V384, P1775, DOI 10.1016/S0140-6736(14)61276-9; Howard M, 2006, ARCH WOMEN MENT HLTH, V9, P213, DOI 10.1007/s00737-006-0135-y; Hudson C, 2017, J AFFECT DISORDERS, V209, P169, DOI 10.1016/j.jad.2016.11.022; Huntley F, 2017, BJPSYCH OPEN, V3, P300, DOI 10.1192/bjpo.bp.117.005843; Hurlocker MC, 2018, J AFFECT DISORDERS, V229, P477, DOI 10.1016/j.jad.2017.12.076; Ikeda M, 2014, ATTACH HUM DEV, V16, P557, DOI 10.1080/14616734.2014.941884; Iliadis SI, 2017, J AFFECT DISORDERS, V207, P141, DOI 10.1016/j.jad.2016.09.030; Interian A, 2013, PSYCHIAT SERV, V64, P212, DOI 10.1176/appi.ps.201100136; Jonas W, 2013, GENES BRAIN BEHAV, V12, P681, DOI 10.1111/gbb.12069; Kim DR, 2011, J WOMENS HEALTH, V20, P255, DOI 10.1089/jwh.2010.2353; Klirova M, 2008, NEUROENDOCRINOL LETT, V29, P69; KUMAR R, 1995, J AFFECT DISORDERS, V33, P11, DOI 10.1016/0165-0327(94)00067-J; Kuo Wen-Hung, 2004, J Immigr Health, V6, P145, DOI 10.1023/B:JOIH.0000045252.10412.fa; Kwan BM, 2010, BEHAV RES THER, V48, P799, DOI 10.1016/j.brat.2010.04.003; Lau Ying, 2017, J Med Internet Res, V19, pe138, DOI 10.2196/jmir.6712; Lee DJ, 2016, DEPRESS ANXIETY, V33, P792, DOI 10.1002/da.22511; Leigh B, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-24; Lenze SN, 2017, J AFFECT DISORDERS, V210, P151, DOI 10.1016/j.jad.2016.12.029; Lin P, 2005, ANN BEHAV MED, V30, P164, DOI 10.1207/s15324796abm3002_9; Lydsdottir LB, 2014, J CLIN PSYCHIAT, V75, P393, DOI 10.4088/JCP.13m08646; Macfie J, 2009, CHILD DEV PERSPECT, V3, P66, DOI 10.1111/j.1750-8606.2008.00079.x; Mandelli L, 2016, J AFFECT DISORDERS, V204, P54, DOI 10.1016/j.jad.2016.06.025; Martini J, 2015, J AFFECT DISORDERS, V175, P385, DOI 10.1016/j.jad.2015.01.012; Marwood L, 2018, NEUROSCI BIOBEHAV R, V95, P61, DOI 10.1016/j.neubiorev.2018.09.022; Mehta D, 2014, PSYCHOL MED, V44, P2309, DOI 10.1017/S0033291713003231; Meltzer-Brody S, 2018, LANCET, V392, P1058, DOI 10.1016/S0140-6736(18)31551-4; Meltzer-Brody S, 2014, ARCH WOMEN MENT HLTH, V17, P107, DOI 10.1007/s00737-013-0390-7; Melville JL, 2010, OBSTET GYNECOL, V116, P1064, DOI 10.1097/AOG.0b013e3181f60b0a; Miniati M, 2014, ARCH WOMEN MENT HLTH, V17, P257, DOI 10.1007/s00737-014-0442-7; Molenaar NM, 2018, AUST NZ J PSYCHIAT, V52, P320, DOI 10.1177/0004867418762057; Murphy Pamela K, 2010, J Am Psychiatr Nurses Assoc, V16, P170, DOI 10.1177/1078390310370476; Newman Louise, 2008, Clin Child Psychol Psychiatry, V13, P505, DOI 10.1177/1359104508096766; O'Connor E, 2016, JAMA-J AM MED ASSOC, V315, P388, DOI 10.1001/jama.2015.18948; O'Mahen HA, 2013, J AFFECT DISORDERS, V150, P814, DOI 10.1016/j.jad.2013.03.005; O'Mahen HA, 2008, J WOMENS HEALTH, V17, P1301, DOI 10.1089/jwh.2007.0631; Oates M, 1996, INT REV PSYCHIATR, V8, P87, DOI 10.3109/09540269609037821; Okun ML, 2016, CURR PSYCHIAT REP, V18, DOI 10.1007/s11920-016-0705-2; Osborne LM, 2017, PSYCHONEUROENDOCRINO, V79, P116, DOI 10.1016/j.psyneuen.2017.02.012; Pagano HP, 2016, CONTRACEPTION, V94, P641, DOI 10.1016/j.contraception.2016.06.012; Pare-Miron V, 2016, WOMEN HEALTH ISS, V26, P190, DOI 10.1016/j.whi.2015.11.001; Pfeiffer PN, 2011, GEN HOSP PSYCHIAT, V33, P29, DOI 10.1016/j.genhosppsych.2010.10.002; Phillips J, 2010, AUST NZ J PSYCHIAT, V44, P280, DOI 10.3109/00048670903487225; Posmontier B, 2016, J MIDWIFERY WOM HEAL, V61, P456, DOI 10.1111/jmwh.12411; Prendes-Alvarez S, 2018, NEUROSCI LETT, V669, P10, DOI 10.1016/j.neulet.2016.09.049; Puckering C., 2010, COUNSELING PSYCHOL R, V25, P28; Putnam KT, 2017, LANCET PSYCHIAT, V4, P477, DOI 10.1016/S2215-0366(17)30136-0; Qadri MI, 2015, IRAN J MED SCI, V40, P73; Raisanen S, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004883; Rasmussen KG, 2011, J ECT, V27, P51, DOI 10.1097/YCT.0b013e3181da84c6; Ravitz P, 2011, J CLIN PSYCHOL, V67, P1129, DOI 10.1002/jclp.20850; Resick PA, 2002, J CONSULT CLIN PSYCH, V70, P867, DOI 10.1037//0022-006X.70.4.867; Rezaei Elham, 2014, Iran J Nurs Midwifery Res, V19, P508; Robakis TK, 2016, J AFFECT DISORDERS, V190, P623, DOI 10.1016/j.jad.2015.09.067; Sayar GH, 2014, ARCH WOMEN MENT HLTH, V17, P311, DOI 10.1007/s00737-013-0397-0; Schaffir J, 2016, EUR J CONTRACEP REPR, V21, P347, DOI 10.1080/13625187.2016.1217327; Schiller CE, 2013, PHYSIOL BEHAV, V119, P137, DOI 10.1016/j.physbeh.2013.06.009; Scholle Sarah Hudson, 2003, Matern Child Health J, V7, P95, DOI 10.1023/A:1023864810207; Scope A, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-321; Segebladh B, 2009, AM J OBSTET GYNECOL, V201, DOI 10.1016/j.ajog.2009.03.016; Sharkey KM, 2016, SLEEP HEALTH, V2, P225, DOI 10.1016/j.sleh.2016.05.002; Skovlund C, 2016, JAMA PSYCHIAT, V73, P1154, DOI 10.1001/jamapsychiatry.2016.2387; Smart J, 2007, J PAEDIATR CHILD H, V43, P293, DOI 10.1111/j.1440-1754.2007.01060.x; Sockol LE, 2018, J AFFECT DISORDERS, V232, P316, DOI 10.1016/j.jad.2018.01.018; Sockol LE, 2015, J AFFECT DISORDERS, V177, P7, DOI 10.1016/j.jad.2015.01.052; Sockol LE, 2013, CLIN PSYCHOL REV, V33, P1205, DOI 10.1016/j.cpr.2013.10.004; Sockol LE, 2011, CLIN PSYCHOL REV, V31, P839, DOI 10.1016/j.cpr.2011.03.009; Stein DJ, 2000, INT CLIN PSYCHOPHARM, V15, pS31, DOI 10.1097/00004850-200008002-00006; Strawbridge R, 2015, EUR NEUROPSYCHOPHARM, V25, P1532, DOI 10.1016/j.euroneuro.2015.06.007; Stremler R, 2006, SLEEP, V29, P1609, DOI 10.1093/sleep/29.12.1609; Stremler R, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1164; Strupp H.H., 1984, PSYCHOTHERAPY NEW KE; Swanson LM, 2018, ARCH WOMEN MENT HLTH, V21, P583, DOI 10.1007/s00737-018-0836-z; Swanson LM, 2013, BEHAV SLEEP MED, V11, P297, DOI 10.1080/15402002.2012.683902; Tani F, 2018, ACTA PAEDIATR, V107, P633, DOI 10.1111/apa.14162; Taylor DJ, 2014, INT REV PSYCHIATR, V26, P205, DOI 10.3109/09540261.2014.902808; Tezel A, 2006, PATIENT EDUC COUNS, V63, P64, DOI 10.1016/j.pec.2005.08.011; Tomfohr-Madsen LM, 2017, BEHAV SLEEP MED, V15, P377, DOI 10.1080/15402002.2016.1141769; Travis LA, 2001, PSYCHOTHERAPY, V38, P149, DOI 10.1037/0033-3204.38.2.149; Uguz F, 2009, J PSYCHOSOM OBST GYN, V30, P141, DOI 10.1080/01674820802545818; Watts BV, 2013, J CLIN PSYCHIAT, V74, pE541, DOI 10.4088/JCP.12r08225; Wenze SJ, 2018, J PSYCHIATR PRACT, V24, P158, DOI 10.1097/PRA.0000000000000299; Wirz-Justice A, 2011, J CLIN PSYCHIAT, V72, P986, DOI 10.4088/JCP.10m06188blu; Wisner KL, 2013, JAMA PSYCHIAT, V70, P490, DOI 10.1001/jamapsychiatry.2013.87; Wright TE, 2016, AM J OBSTET GYNECOL, V215, P539, DOI 10.1016/j.ajog.2016.06.038; Yanamadala J, 2017, IEEE ENG MED BIO, P1441, DOI 10.1109/EMBC.2017.8037105; Yildiz PD, 2017, J AFFECT DISORDERS, V208, P634, DOI 10.1016/j.jad.2016.10.009; Zayas LH, 2002, WOMEN HEALTH ISS, V12, P16, DOI 10.1016/S1049-3867(01)00138-4; Zhang DJ, 2009, ARCH WOMEN MENT HLTH, V12, P189, DOI 10.1007/s00737-009-0058-5; Zhang XL, 2014, J AFFECT DISORDERS, V165, P208, DOI 10.1016/j.jad.2014.04.049; Zhang XM, 2010, ARCH WOMEN MENT HLTH, V13, P369, DOI 10.1007/s00737-010-0163-5; 2015, OBSTET GYNECOL, V125, P1268, DOI DOI 10.1097/01.AOG.0000465192.34779.DC	152	10	10	2	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 25	2019	364								l322	10.1136/bmj.l322	http://dx.doi.org/10.1136/bmj.l322			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HN7RO	30803997	Bronze			2023-01-03	WOS:000460389500001
J	Stonington, S; Coffa, D				Stonington, Scott; Coffa, Diana			Case Studies in Social Medicine Structural Iatrogenesis - A 43-Year-Old Man with "Opioid Misuse"	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Stonington, Scott] Univ Michigan, Dept Anthropol, Ann Arbor, MI 48109 USA; [Stonington, Scott] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Stonington, Scott] Vet Adm Med Ctr, Ann Arbor, MI 48105 USA; [Coffa, Diana] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Stonington, S (corresponding author), Univ Michigan, Dept Anthropol, Ann Arbor, MI 48109 USA.; Stonington, S (corresponding author), Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.; Stonington, S (corresponding author), Vet Adm Med Ctr, Ann Arbor, MI 48105 USA.			Stonington, Scott/0000-0002-0472-3885				Berger Peter L., 1966, SOCIAL CONSTRUCTION; Bourgois P, 2017, ACAD MED, V92, P299, DOI 10.1097/ACM.0000000000001294; Farmer P., 2001, INFECT INEQUALITIES; Harper C, 2001, FAM PLANN PERSPECT, V33, P13, DOI 10.2307/2673737; Metzl JM, 2014, SOC SCI MED, V103, P126, DOI 10.1016/j.socscimed.2013.06.032	5	17	17	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 21	2019	380	8					701	704		10.1056/NEJMp1811473	http://dx.doi.org/10.1056/NEJMp1811473			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HM0PM	30786183				2023-01-03	WOS:000459149500001
J	Yang, B; Pan, CS; Li, Q; Yang, Z; Long, FX; Fan, JY; Wang, CS; Han, JY; Tang, DX				Yang, Bing; Pan, Chun-Shui; Li, Quan; Yang, Zhu; Long, Feng-Xi; Fan, Jing-Yu; Wang, Chuan-She; Han, Jing-Yan; Tang, Dong-Xin			Inhibitory effects of Chanling Gao on the proliferation and liver metastasis of transplanted colorectal cancer in nude mice	PLOS ONE			English	Article							EXPRESSION; HYPOXIA; GROWTH; INJURY; CXCR4	This study aimed to explore the efficacy and mechanism of Chanling Gao (CLG), a compound Chinese medicine, on colorectal cancer (CRC). A model of transplanted CRC was established in nude mice. The mice were treated 7 days after CRC transplantation with either Capecitabine or CLG for 3 weeks. On the 28th day after the operation, CRC growth and liver metastasis were assessed by morphology, the changes in the expression of HIF-1 alpha (hypoxia inducible factor-1 alpha), stromal cell-derived factor-1 alpha (SDF-1 alpha), CXCR4 (C-X-C chemokine receptor type 4), PI3K, and Akt in the transplanted tumor and SDF-1 alpha and CXCR4 in the liver were detected by Western blot and immunohistochemistry. The protein contents of vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP)-2, and collagen IV in the serum and transplanted tumor and SDF-1 alpha and CXCR4 in liver tissues were detected by enzyme-linked immunosorbent assay. In the Capecitabine and high dose CLG groups, the growth and liver metastasis of CRC were significantly inhibited, the protein levels of HIF-1 alpha, SDF-1 alpha, CXCR4, MMP-2, VEGF, PI3K, Akt, P-PI3K and P-Akt in the transplanted tumor were lower, while the content of collagen IV in the transplanted tumor was higher, than in Model group. A high dose of CLG inhibited the growth of transplanted tumor and liver metastasis of CRC in nude mice, probably by inhibiting the HIF-1 alpha/SDF-1 alpha-CXCR4/PI3K-Akt signaling pathway reducing the synthesis and release of VEGF and degradation of collagen IV.	[Yang, Bing; Yang, Zhu; Long, Feng-Xi; Tang, Dong-Xin] Guizhou Univ Tradit Chinese Med, Guiyang, Guizhou, Peoples R China; [Pan, Chun-Shui; Li, Quan; Fan, Jing-Yu; Wang, Chuan-She; Han, Jing-Yan] Peking Univ, Hlth Sci Ctr, Tasly Microcirculat Res Ctr, Beijing, Peoples R China; [Wang, Chuan-She; Han, Jing-Yan] Peking Univ, Sch Basic Med Sci, Dept Integrat Chinese & Western Med, Beijing, Peoples R China; [Tang, Dong-Xin] Guizhou Univ Tradit Chinese Med, Affiliated Hosp 1, Dept Oncol, Guiyang, Guizhou, Peoples R China	Guizhou University of Traditional Chinese Medicine; Peking University; Peking University; Guizhou University of Traditional Chinese Medicine	Tang, DX (corresponding author), Guizhou Univ Tradit Chinese Med, Guiyang, Guizhou, Peoples R China.; Han, JY (corresponding author), Peking Univ, Hlth Sci Ctr, Tasly Microcirculat Res Ctr, Beijing, Peoples R China.; Han, JY (corresponding author), Peking Univ, Sch Basic Med Sci, Dept Integrat Chinese & Western Med, Beijing, Peoples R China.; Tang, DX (corresponding author), Guizhou Univ Tradit Chinese Med, Affiliated Hosp 1, Dept Oncol, Guiyang, Guizhou, Peoples R China.	hanjingyan@bjmu.edu.cn; tangdongxin@sina.com	han, jingyan/HJG-6568-2022		National Natural Science Foundation of China [81460697, 81760814, 81860819]; Guizhou Province Traditional Chinese Medicine Modernization Project Foundation [SY-2014-3008-1]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guizhou Province Traditional Chinese Medicine Modernization Project Foundation	This work was supported in part by National Natural Science Foundation of China (grant number: 81460697 and 81760814 to DXT and 81860819 to BY) and by Guizhou Province Traditional Chinese Medicine Modernization Project Foundation (SY-2014-3008-1 to DXT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Balamurugan K, 2016, INT J CANCER, V138, P1058, DOI 10.1002/ijc.29519; Bing Y, 2016, LISHIZHEN MED MAT ME, V27, P1289; Canavese M, 2017, INT J CANCER, V140, P2183, DOI 10.1002/ijc.30567; Chatterjee S, 2014, ADV CANCER RES, V124, P31, DOI 10.1016/B978-0-12-411638-2.00002-1; Chen Q, 2013, ONCOL LETT, V6, P207, DOI 10.3892/ol.2013.1343; Cui YC, 2017, SCI REP-UK, V7, DOI 10.1038/srep44579; De Rosa M, 2016, THER ADV GASTROENTER, V9, P861, DOI 10.1177/1756283X16659790; Dongxin T, 2012, LISHIZHEN MED MAT ME, V23, P2213; Dongxin T, 2012, LISHIZHEN MED MAT ME, V23, P1452; Dongxin T, 2012, J MED REASERCH, V41, P79; Guo X, 2017, ONCOTARGET, V8, P80358, DOI 10.18632/oncotarget.18673; Guzman A, 2017, BIOMATERIALS, V115, P19, DOI 10.1016/j.biomaterials.2016.11.014; Hackl C, 2013, GUT, V62, P259, DOI 10.1136/gutjnl-2011-301585; Huang CY, 2010, J CELLULAR PHYSL, V221, P204; Iwai T, 2016, ONCOL REP, V36, P626, DOI 10.3892/or.2016.4902; Jianqiang C, 2016, CHINESE J PRACTICAL, V36, P858; Jones DT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044294; Kjersti F, 2004, EUR J CANCER, V40, P1593, DOI [10.1016/j.ejca.2004.02.023, DOI 10.1016/J.EJCA.2004.02.023]; Liang Z, 2007, BIOCHEM BIOPH RES CO, V359, P716, DOI 10.1016/j.bbrc.2007.05.182; Liao D, 2007, CANCER METAST REV, V26, P281, DOI 10.1007/s10555-007-9066-y; Maddirela DR, 2013, INT J ONCOL, V42, P1279, DOI 10.3892/ijo.2013.1806; Moench R, 2016, ONCOTARGET, V7, P68749, DOI 10.18632/oncotarget.11899; Mu HN, 2015, FREE RADICAL BIO MED, V85, P237, DOI 10.1016/j.freeradbiomed.2015.04.033; Murakami T, 2013, INT J CANCER, V132, P276, DOI 10.1002/ijc.27670; Nogawa M, 2005, CANCER LETT, V217, P243, DOI 10.1016/j.canlet.2004.07.010; Ottaiano A, 2005, CANCER IMMUNOL IMMUN, V54, P781, DOI 10.1007/s00262-004-0636-3; Pan F, 2013, MOL BIOL REP, V40, P4139, DOI 10.1007/s11033-012-2225-4; Prasad S, 2012, CLIN CANCER RES, V18, P4942, DOI 10.1158/1078-0432.CCR-11-2805; Rankin EB, 2008, CELL DEATH DIFFER, V15, P678, DOI 10.1038/cdd.2008.21; Romain B, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-58; Siegel R. L., 2018, CA-CANCER J CLIN, V60, P277; Stanisavljevic L, 2016, TUMOR BIOL, V37, P7441, DOI 10.1007/s13277-015-4591-8; Trudel D, 2010, HUM PATHOL, V41, P1694, DOI 10.1016/j.humpath.2010.05.001; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Veidal SS, 2011, FIBROGENESIS TISSUE, V4, DOI 10.1186/1755-1536-4-22; Wang GH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055298; Wang X, 2008, BIOCH BIOPHYSICAL RE; Wenqi H, 2016, CONTINUED MED ED, V30, P137; Yamada S, 2014, J SURG RES, V187, P107, DOI 10.1016/j.jss.2013.10.030	39	4	5	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2019	14	2							e0201504	10.1371/journal.pone.0201504	http://dx.doi.org/10.1371/journal.pone.0201504			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM2WC	30789971	Green Published, gold, Green Submitted			2023-01-03	WOS:000459330800002
J	Godwin, EM; Uglialoro, AD; Ali, A; Yearwood, L; Banerji, MA; Kral, JG				Godwin, Ellen M.; Uglialoro, Anthony D.; Ali, Andaleeb; Yearwood, Leah; Banerji, Mary Ann; Kral, John G.			A pilot study of metabolic fitness effects of weight-supported walking in women with obesity	PLOS ONE			English	Article							BODY POSITIVE-PRESSURE; PHYSICAL-ACTIVITY; GLYCEMIC CONTROL; RISK MARKERS; EXERCISE; APPETITE; TRIGLYCERIDES; OVERWEIGHT; RESPONSES; BEHAVIOR	Background This is an exploratory pilot study of novel technology enabling people with mobility disability to walk with minimal effort, in the "sedentary range". The study's premise is that impairment of the leading physical activity of daily living, walking, is a major contributor to a dysmetabolic state driving many prevalent "civilization diseases" associated with insulin resistance. Methods We explore within-subject changes in standard oral glucose tolerance (OGT) tests including metabotropic molecules after 22 twice-weekly, 30-minute bouts of weight-supported light-moderate physical activity in 16 non-diabetic obese, otherwise healthy, reproductive-age, volunteer women walking on an "anti-gravity" lower-body positive pressure (LBPP) treadmill. Results Subjects had reference base-line fasting plasma glucose and triglycerides (TG) but 2-hr OGT insulin levels of 467 +/- 276 pmol . liter(-1) (mean +/- S.D.) indicating nascent insulin resistance, compared to post-study 308 +/- 179 (p = 0.002). Fasting TG decreased from 0.80 +/- 0.30 mmol . liter(-1) to 0.71 0.25 (p = 0.03). Concomitantly plasma total ghrelin decreased from 69.6 +/- 41.6 pmol . liter(-1) to 56.0 +/- 41.3 (p = 0.008). There were no statistically significant changes in body weight or any correlations between weight change and cardiometabolic markers. However, there were robust positive correlations between changes among different classes of peptides including C-reactive protein-Interleukin 6, leptin-adiponectin, beta-endorphin oxytocin and orexin A (r(2) = 0.48-0.88). Conclusion We conclude that brief, low-dose physical activity, walking on an anti-gravity LBPP treadmill may improve cardiometabolic risk, exhibiting favorable changes in neuro-regulatory peptides without weight loss in people with problems walking.	[Godwin, Ellen M.] Long Isl Univ, Dept Phys Therapy, Brooklyn, NY USA; [Godwin, Ellen M.] Suny Downstate Med Ctr, Dept Orthoped Rehabil, Brooklyn, NY 11203 USA; [Uglialoro, Anthony D.; Kral, John G.] Suny Downstate Med Ctr, Dept Surg, Brooklyn, NY 11203 USA; [Ali, Andaleeb; Yearwood, Leah; Banerji, Mary Ann; Kral, John G.] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA; [Ali, Andaleeb] Providence Med Grp, Mobile, AL USA; [Yearwood, Leah] Cape Fear Valley Med Ctr, Fayetteville, NC USA	Long Island University-Brooklyn Campus; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Kral, JG (corresponding author), Suny Downstate Med Ctr, Dept Surg, Brooklyn, NY 11203 USA.; Kral, JG (corresponding author), Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA.	jkral@downstate.edu		KRAL, John/0000-0003-0842-664X				Afzal A, 2014, J AM SOC HYPERTENS, V8, P388, DOI 10.1016/j.jash.2014.03.004; Ainsworth BE, 2011, MED SCI SPORT EXER, V43, P1575, DOI 10.1249/MSS.0b013e31821ece12; Bailey DP, 2016, APPL PHYSIOL NUTR ME, V41, P324, DOI 10.1139/apnm-2015-0462; Baker PRA, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008366.pub3; Batacan RB, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/596367; Beaulieu K, 2018, PHYSIOL BEHAV, V192, P23, DOI 10.1016/j.physbeh.2017.12.032; BJORNTORP P, 1970, METABOLIS, V19, P631, DOI 10.1016/0026-0495(70)90020-X; Blevins JE, 2013, REV ENDOCR METAB DIS, V14, P311, DOI 10.1007/s11154-013-9260-x; Bos I, 2013, MED SCI SPORT EXER, V45, P439, DOI 10.1249/MSS.0b013e31827767fc; Brito JP, 2017, JAMA-J AM MED ASSOC, V317, P635, DOI 10.1001/jama.2016.20563; CarterNolan PL, 1996, J NATL MED ASSOC, V88, P558; Chastin SFM, 2015, OBESITY, V23, P1800, DOI 10.1002/oby.21180; Coplan JD, 2014, NEURAL PLAST, V2014, DOI 10.1155/2014/917981; Cutuk A, 2006, J APPL PHYSIOL, V101, P771, DOI 10.1152/japplphysiol.00644.2005; DeBoer LB, 2012, EXPERT REV NEUROTHER, V12, P1011, DOI 10.1586/ERN.12.73; Dohrn IM, 2018, CLIN EPIDEMIOL, V10, P179, DOI 10.2147/CLEP.S151613; Dulloo AG, 2018, EUR J CLIN NUTR, V72, P657, DOI 10.1038/s41430-018-0138-6; Duvivier BMFM, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00353; Eiken O, 1987, Acta Physiol Scand Suppl, V566, P1; Ellingsgaard H, 2011, NAT MED, V17, P1481, DOI 10.1038/nm.2513; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Figueroa MA, 2012, INT J APPL SCI TECHN, V2, P204; Francois ME, 2014, DIABETOLOGIA, V57, P1437, DOI 10.1007/s00125-014-3244-6; Freedhoff Y, 2016, LANCET, V388, P849, DOI 10.1016/S0140-6736(16)31338-1; Herisson FM, 2016, J NEUROENDOCRINOL, V28, DOI 10.1111/jne.12381; Herman AM, 2016, NATURE, V538, P253, DOI 10.1038/nature19789; Heymsfield SB, 2017, NEW ENGL J MED, V376, P1492, DOI 10.1056/NEJMc1701944; Inoue K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128720; Ito N, 2008, NEUROSCIENCE, V157, P720, DOI 10.1016/j.neuroscience.2008.09.042; Koehl M, 2008, FASEB J, V22, P2253, DOI 10.1096/fj.07-099101; KRAL JG, 1977, METABOLISM, V26, P1025, DOI 10.1016/0026-0495(77)90020-8; Kritchevsky SB, 2017, OBESITY, V25, P1199, DOI 10.1002/oby.21860; Larson-Meyer DE, 2012, J OBES, V2012, DOI 10.1155/2012/730409; Lee KY, 2016, ANN REHABIL MED-ARM, V40, P915, DOI 10.5535/arm.2016.40.5.915; Lin SX, 2011, METAB SYNDR RELAT D, V9, P35, DOI 10.1089/met.2010.0050; MacLean PS, 2015, OBESITY, V23, P7, DOI 10.1002/oby.20967; Malkova D, 2008, HORM METAB RES, V40, P410, DOI 10.1055/s-2008-1058100; MAYER J, 1967, SCIENCE, V156, P328, DOI 10.1126/science.156.3773.328; Mudaliar U, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002095; Nordestgaard BG, 2014, LANCET, V384, P626, DOI 10.1016/S0140-6736(14)61177-6; Pedersen BK, 2015, SCAND J MED SCI SPOR, V25, P1, DOI 10.1111/sms.12581; Perello M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059625; Pontzer H, 2016, CURR BIOL, V26, P410, DOI 10.1016/j.cub.2015.12.046; Poulimeneas D, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8090174; Proudler AJ, 1996, METABOLISM, V45, P328, DOI 10.1016/S0026-0495(96)90286-3; Rasgon NL, 2016, MOL PSYCHIATR, V21, P1648, DOI 10.1038/mp.2016.162; Riebe D., 2014, ACSMS GUIDELINES EXE, P161; Rifkind JM, 2014, NITRIC OXIDE-BIOL CH, V40, P117, DOI 10.1016/j.niox.2014.06.007; Rodriguez D, 2011, INT J GEN MED, V4, P549, DOI 10.2147/IJGM.S23094; Ropelle ER, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000465; Ross R, 2016, CONTEMP CLIN TRIALS, V47, P275, DOI 10.1016/j.cct.2016.02.001; Salciccioli LF, 2017, J STRENGTH COND RES, V31, pE69, DOI 10.1519/JSC.0000000000000562; Schwartz MW, 2017, ENDOCR REV, V38, P267, DOI 10.1210/er.2017-00111; Shook RP, 2015, AM J CLIN NUTR, V102, P1332, DOI 10.3945/ajcn.115.115360; Simonson S, 2011, CLIN KINESIOL, V65, P29; Solomon TPJ, 2013, J CLIN ENDOCR METAB, V98, P4176, DOI 10.1210/jc.2013-2232; Voulgari C, 2013, METABOLISM, V62, P609, DOI 10.1016/j.metabol.2012.09.005; Whybrow S, 2008, BRIT J NUTR, V100, P1109, DOI 10.1017/S0007114508968240; WILDMANN J, 1986, LIFE SCI, V38, P997, DOI 10.1016/0024-3205(86)90233-X; Zschucke E, 2015, PSYCHONEUROENDOCRINO, V51, P414, DOI 10.1016/j.psyneuen.2014.10.019	60	0	0	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2019	14	2							e0211529	10.1371/journal.pone.0211529	http://dx.doi.org/10.1371/journal.pone.0211529			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM2OT	30785891	Green Published, Green Submitted, gold			2023-01-03	WOS:000459307000029
J	Costello, SP; Hughes, PA; Waters, O; Bryant, RV; Vincent, AD; Blatchford, P; Katsikeros, R; Makanyanga, J; Campaniello, MA; Mavrangelos, C; Rosewarne, CP; Bickley, C; Peters, C; Schoeman, MN; Conlon, MA; Roberts-Thomson, IC; Andrews, JM				Costello, Samuel P.; Hughes, Patrick A.; Waters, Oliver; Bryant, Robert, V; Vincent, Andrew D.; Blatchford, Paul; Katsikeros, Rosa; Makanyanga, Jesica; Campaniello, Melissa A.; Mavrangelos, Chris; Rosewarne, Carly P.; Bickley, Chelsea; Peters, Cian; Schoeman, Mark N.; Conlon, Michael A.; Roberts-Thomson, Ian C.; Andrews, Jane M.			Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							METAANALYSIS; THERAPY; DISEASE	IMPORTANCE High-intensity, aerobically prepared fecal microbiota transplantation (FMT) has demonstrated efficacy in treating active ulcerative colitis (UC). FMT protocols involving anaerobic stool processing methods may enhance microbial viability and allow efficacy with a lower treatment intensity. OBJECTIVE To assess the efficacy of a short duration of FMT therapy to induce remission in UC using anaerobically prepared stool. DESIGN, SETTING, AND PARTICIPANTS A total of 73 adults with mild to moderately active UC were enrolled in a multicenter, randomized, double-blind clinical trial in 3 Australian tertiary referral centers between June 2013 and June 2016, with 12-month follow-up until June 2017. INTERVENTIONS Patients were randomized to receive either anaerobically prepared pooled donor FMT (n = 38) or autologous FMT (n = 35) via colonoscopy followed by 2 enemas over 7 days. Open-label therapy was offered to autologous FMT participants at 8 weeks and they were followed up for 12 months. MAIN OUTCOMES AND MEASURES The primary outcome was steroid-free remission of UC, defined as a total Mayo score of <= 2 with an endoscopic Mayo score of 1 or less at week 8. Total Mayo score ranges from 0 to 12 (0 = no disease and 12 = most severe disease). Steroid-free remission of UC was reassessed at 12 months. Secondary clinical outcomes included adverse events. RESULTS Among 73 patients who were randomized (mean age, 39 years; women, 33 [45%]), 69 (95%) completed the trial. The primary outcome was achieved in 12 of the 38 participants (32%) receiving pooled donor FMT compared with 3 of the 35 (9%) receiving autologous FMT (difference, 23%[95% CI, 4%-42%]; odds ratio, 5.0 [95% CI, 1.2-20.1]; P = .03). Five of the 12 participants (42%) who achieved the primary end point at week 8 following donor FMT maintained remission at 12 months. There were 3 serious adverse events in the donor FMT group and 2 in the autologous FMT group. CONCLUSIONS AND RELEVANCE In this preliminary study of adults with mild to moderate UC, 1-week treatment with anaerobically prepared donor FMT compared with autologous FMT resulted in a higher likelihood of remission at 8 weeks. Further research is needed to assess longer-term maintenance of remission and safety.	[Costello, Samuel P.; Hughes, Patrick A.; Bryant, Robert, V; Campaniello, Melissa A.; Mavrangelos, Chris; Schoeman, Mark N.; Roberts-Thomson, Ian C.; Andrews, Jane M.] Univ Adelaide, Adelaide Med Sch, Ctr Nutr & Gastrointestinal Dis, Adelaide, SA, Australia; [Costello, Samuel P.; Hughes, Patrick A.; Bryant, Robert, V; Campaniello, Melissa A.; Mavrangelos, Chris; Schoeman, Mark N.; Roberts-Thomson, Ian C.; Andrews, Jane M.] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia; [Costello, Samuel P.; Bryant, Robert, V; Peters, Cian; Schoeman, Mark N.; Andrews, Jane M.] Royal Adelaide Hosp, Dept Gastroenterol & Hepatol, Inflammatory Bowel Dis Serv, Adelaide, SA, Australia; [Costello, Samuel P.; Bryant, Robert, V; Katsikeros, Rosa; Roberts-Thomson, Ian C.] Queen Elizabeth Hosp, Dept Gastroenterol, Inflammatory Bowel Dis Serv, 28 Woodville Rd, Woodville, SA 5011, Australia; [Waters, Oliver; Makanyanga, Jesica] Fiona Stanley Hosp, Dept Gastroenterol, Murdoch, WA, Australia; [Vincent, Andrew D.] Univ Adelaide, Freemasons Fdn Ctr Mens Hlth, Adelaide Med Sch, Adelaide, SA, Australia; [Blatchford, Paul; Rosewarne, Carly P.; Bickley, Chelsea; Conlon, Michael A.] CSIRO Hlth & Biosecur, Adelaide, SA, Australia	University of Adelaide; South Australian Health & Medical Research Institute (SAHMRI); Royal Adelaide Hospital; University of Adelaide; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Costello, SP (corresponding author), Queen Elizabeth Hosp, Dept Gastroenterol, Inflammatory Bowel Dis Serv, 28 Woodville Rd, Woodville, SA 5011, Australia.	sam.costello@sa.gov.au	Hughes, Patrick Anthony/R-1283-2019	Hughes, Patrick Anthony/0000-0001-7324-3626; Rosewarne, Carly/0000-0002-5243-9846; Bryant, Robert/0000-0003-4229-3289; Costello, Samuel/0000-0002-2857-1812; Conlon, Michael/0000-0003-0338-3441	National Health and Medical Research Council; Gutsy Foundation	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Gutsy Foundation	This study was funded by the National Health and Medical Research Council and the Gutsy Foundation.	Borody T, 2012, AM J GASTROENTEROL, V107, pS665, DOI 10.14309/00000434-201210001-01644; Brinkworth GD, 2009, BRIT J NUTR, V101, P1493, DOI 10.1017/S0007114508094658; Cammarota G, 2015, ALIMENT PHARM THER, V41, P835, DOI 10.1111/apt.13144; Campaniello MA, 2017, BRAIN BEHAV IMMUN, V60, P319, DOI 10.1016/j.bbi.2016.11.015; Castano-Milla C, 2014, ALIMENT PHARM THER, V39, P645, DOI 10.1111/apt.12651; Chu ND, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170922; Costello SP, 2015, ALIMENT PHARM THER, V42, P1011, DOI 10.1111/apt.13366; Costello SP, 2015, AM J GASTROENTEROL, V110, P775, DOI 10.1038/ajg.2015.70; Costello SP, 2016, CLIN INFECT DIS, V62, P908, DOI 10.1093/cid/civ994; Hoie O, 2007, AM J GASTROENTEROL, V102, P1692, DOI 10.1111/j.1572-0241.2007.01265.x; Khan KJ, 2011, AM J GASTROENTEROL, V106, P661, DOI 10.1038/ajg.2011.72; Li YT, 2016, ALIMENT PHARM THER, V43, P445, DOI 10.1111/apt.13492; Mavrangelos C, 2018, GUT, V67, P397, DOI 10.1136/gutjnl-2017-314308; Moayyedi P, 2015, GASTROENTEROLOGY, V149, P102, DOI 10.1053/j.gastro.2015.04.001; Paramsothy S, 2017, LANCET, V389, P1218, DOI 10.1016/S0140-6736(17)30182-4; Parragi L, 2018, J CROHNS COLITIS, V12, P811, DOI 10.1093/ecco-jcc/jjy040; Rossen NG, 2015, GASTROENTEROLOGY, V149, P110, DOI 10.1053/j.gastro.2015.03.045; Rutgeerts P, 2005, NEW ENGL J MED, V353, P2462, DOI 10.1056/NEJMoa050516; Sheehan D, 2017, GASTROENTEROL CLIN N, V46, P143, DOI 10.1016/j.gtc.2016.09.011; TRUELOVE SC, 1955, BRIT MED J, V2, P1041, DOI 10.1136/bmj.2.4947.1041; Ungaro R, 2017, LANCET, V389, P1756, DOI 10.1016/S0140-6736(16)32126-2; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Walmsley RS, 1998, GUT, V43, P29, DOI 10.1136/gut.43.1.29	23	365	375	7	73	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	2019	321	2					156	164		10.1001/jama.2018.20046	http://dx.doi.org/10.1001/jama.2018.20046			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH3FZ	30644982	Bronze, Green Published			2023-01-03	WOS:000455606300014
J	Perdomo-Celis, F; Velilla, PA; Taborda, NA; Rugeles, MT				Perdomo-Celis, Federico; Velilla, Paula A.; Taborda, Natalia A.; Teresa Rugeles, Maria			An altered cytotoxic program of CD8(+) T-cells in HIV-infected patients despite HAART-induced viral suppression	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; GRANZYME-B; GASTROINTESTINAL MUCOSA; HIV-1-INFECTED PATIENTS; PERFORIN EXPRESSION; CD8+T LYMPHOCYTES; CD38 EXPRESSION; MEMORY SUBSETS; EFFECTOR	Despite the suppression of viral replication induced by the highly active anti-retroviral therapy (HAART), an increased immune activation and inflammatory state persists in HIV-infected patients, contributing to lower treatment response and immune reconstitution, and development of non-AIDS conditions. The chronic activation and inflammation affect the functionality and differentiation of CD8(+) T-cells, particularly reducing their cytotoxic capacity, which is critical in the control of HIV replication. Although previous studies have shown that HAART induce a partial immune reconstitution, its effect on CD8(+) T-cells cytotoxic function, as well as its relationship with the inflammatory state, is yet to be defined. Here, we characterized the functional profile of polyclonal and HIV-specific CD8(+) T-cells, based on the expression of cell activation and differentiation markers, in individuals chronically infected with HIV, under HAART. Compared with seronegative controls, CD8(+) T-cells from patients on HAART exhibited a low degranulation capacity (surface expression of CD107a), with consequent low secreted levels and high intracellular expression of granzyme B and perforin. This degranulation defect was particularly observed in those cells expressing the activation marker HLA-DR, which were further characterized as effector memory cells with high expression of CD57. The expression of CD107a, but not of granzyme B and perforin, in CD8(+) T-cells from HIV-infected patients on HAART reached levels similar to those in seronegative controls when the treatment duration was higher than 25 months. In addition, the expression of CD107a was negatively correlated with the expression of exhaustion markers on CD8(+) T-cells and the plasma inflammatory molecule sCD14. Thus, despite HAART-induced viral suppression, CD8(+) T-cells from HIV-infected patients have an alteration in their cytotoxic program. This defect is associated with the cellular activation, differentiation and exhaustion state, as well as with the inflammation levels, and can be partially recovered with a long and continuous treatment.	[Perdomo-Celis, Federico; Velilla, Paula A.; Taborda, Natalia A.; Teresa Rugeles, Maria] Univ Antioquia, UdeA, Grp Inmunovirol, Fac Med, Medellin, Colombia; [Taborda, Natalia A.] Corp Univ Remington, Grp Invest Biomed Uniremington, Programa Med, Fac Ciencias Salud, Medellin, Colombia	Universidad de Antioquia	Rugeles, MT (corresponding author), Univ Antioquia, UdeA, Grp Inmunovirol, Fac Med, Medellin, Colombia.	maria.rugeles@udea.edu.co		Taborda Vanegas, Natalia Andrea/0000-0001-6085-855X; Velilla, Paula A/0000-0003-0885-1320; Perdomo Celis, Federico/0000-0003-0119-8306; Rugeles, Maria T./0000-0001-7855-1409	Universidad de Antioquia, UdeA; COLCIENCIAS [111571249724, 111577757051]; Corporacion Universitaria Remington Uniremington [4000000063-16, 4000000121-17]	Universidad de Antioquia, UdeA; COLCIENCIAS(Departamento Administrativo de Ciencia, Tecnologia e Innovacion Colciencias); Corporacion Universitaria Remington Uniremington	This study was supported by Universidad de Antioquia, UdeA, COLCIENCIAS (Codes: 111571249724 and 111577757051, to MTR and PAV) (http://www.colciencias.gov.co) and Corporacion Universitaria Remington Uniremington (Codes: 4000000063-16 and 4000000121-17 to NAT) (http://www<SUP>.</SUP>uniremington.edu.co).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agata Y, 1996, INT IMMUNOL, V8, P765, DOI 10.1093/intimm/8.5.765; Agnellini P, 2007, P NATL ACAD SCI USA, V104, P4565, DOI 10.1073/pnas.0610335104; Taborda NA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136292; Appay V, 2002, J IMMUNOL, V169, P607, DOI 10.4049/jimmunol.169.1.607-a; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63; BERREBI G, 1987, P NATL ACAD SCI USA, V84, P1364, DOI 10.1073/pnas.84.5.1364; Betts MR, 2004, METHOD CELL BIOL, V75, P497; Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5; Blanco P, 2005, ARTHRITIS RHEUM, V52, P201, DOI 10.1002/art.20745; Cao LF, 2010, CYTOM PART A, V77A, P534, DOI 10.1002/cyto.a.20887; Cellerai C, 2010, J VIROL, V84, P3868, DOI 10.1128/JVI.02565-09; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Chan KS, 2007, J IMMUNOL METHODS, V325, P20, DOI 10.1016/j.jim.2007.05.011; Chatila T, 1989, J IMMUNOL, DOI [10.3847/2041-8205/817/1/L8, DOI 10.3847/2041-8205/817/1/L8]; Chattopadhyay PK, 2009, J LEUKOCYTE BIOL, V85, P88, DOI 10.1189/jlb.0208107; Chen G, 2001, BLOOD, V98, P156, DOI 10.1182/blood.V98.1.156; Cockerham LR, 2014, AIDS, V28, P1749, DOI 10.1097/QAD.0000000000000314; Croxford S, 2017, LANCET PUBLIC HEALTH, V2, pE35, DOI 10.1016/S2468-2667(16)30020-2; Cruz-Guilloty F, 2009, J EXP MED, V206, P51, DOI 10.1084/jem.20081242; Demers KR, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005805; DIANZANI U, 1994, J IMMUNOL, V153, P952; Gill J, 2010, CLIN INFECT DIS, V50, P1387, DOI 10.1086/652283; Grybko MJ, 2007, J LEUKOCYTE BIOL, V81, P509, DOI 10.1189/jlb.0206109; Haridas V, 2003, AIDS, V17, P2313, DOI 10.1097/00002030-200311070-00005; Heintel T, 2002, AIDS, V16, P1497, DOI 10.1097/00002030-200207260-00006; Helleberg M, 2015, J INFECT DIS, V211, P1726, DOI 10.1093/infdis/jiu669; Hersperger AR, 2008, CYTOM PART A, V73A, P1050, DOI 10.1002/cyto.a.20596; Hersperger AR, 2011, BLOOD, V117, P3799, DOI 10.1182/blood-2010-12-322727; Hersperger AR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000917; Hua S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101920; Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786; Kalokhe AS, 2015, J INFECT DIS, V211, P635, DOI 10.1093/infdis/jiu505; Kassahn D, 2009, CELL DEATH DIFFER, V16, P115, DOI 10.1038/cdd.2008.133; KESTENS L, 1992, AIDS, V6, P793, DOI 10.1097/00002030-199208000-00004; Kiniry BE, 2017, MUCOSAL IMMUNOL, V10, P1008, DOI 10.1038/mi.2016.100; Kiniry BE, 2018, J IMMUNOL, V200, P1876, DOI 10.4049/jimmunol.1701532; Kuerten S, 2008, AIDS RES HUM RETROV, V24, P62, DOI 10.1089/aid.2007.0125; Lancki DW, 1987, J IMMUNOL, DOI [10.1093/brain/awg057, DOI 10.1093/BRAIN/AWG057]; Larbi A, 2014, CYTOM PART A, V85A, P25, DOI 10.1002/cyto.a.22351; Leung V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077665; Makedonas G, 2009, J IMMUNOL, V182, P5560, DOI 10.4049/jimmunol.0803945; Mbitikon-Kobo FM, 2012, J IMMUNOL METHODS, V375, P252, DOI 10.1016/j.jim.2011.09.008; McBrien JB, 2018, EUR J IMMUNOL, V48, P898, DOI 10.1002/eji.201747172; McLane LM, 2013, J IMMUNOL, V190, P3207, DOI 10.4049/jimmunol.1201556; Migueles SA, 2008, IMMUNITY, V29, P1009, DOI 10.1016/j.immuni.2008.10.010; Oestreich KJ, 2008, J IMMUNOL, V181, P4832, DOI 10.4049/jimmunol.181.7.4832; Onlamoon N, 2012, CYTOM PART B-CLIN CY, V82B, P35, DOI 10.1002/cyto.b.20616; Pakker NG, 1999, AIDS, V13, P203, DOI 10.1097/00002030-199902040-00008; Pardo J, 2003, INT IMMUNOL, V15, P1441, DOI 10.1093/intimm/dxg141; Pearce EL, 2003, SCIENCE, V302, P1041, DOI 10.1126/science.1090148; Perdomo-Celis F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02502; Petrovas C, 2006, J EXP MED, V203, P2281, DOI 10.1084/jem.20061496; Pietersma FL, 2010, CLIN INFECT DIS, V50, P717, DOI 10.1086/650455; Resino S, 2004, CLIN INFECT DIS, V38, P412, DOI 10.1086/380793; Roberts ER, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006135; ROEDERER M, 1995, J CLIN INVEST, V95, P2061, DOI 10.1172/JCI117892; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sandler NG, 2011, J INFECT DIS, V203, P780, DOI 10.1093/infdis/jiq118; Serrano-Villar S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004078; Serrano-Villar S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085798; Shekhar K, 2014, P NATL ACAD SCI USA, DOI [10.1073/pnas, DOI 10.1073/PNAS]; Simonetta F, 2014, J VIROL, V88, P11861, DOI 10.1128/JVI.02013-14; Steel A, 2008, HIV MED, V9, P118, DOI 10.1111/j.1468-1293.2007.00528.x; Takata H, 2006, J IMMUNOL, V177, P4330, DOI 10.4049/jimmunol.177.7.4330; Tanko RF, 2018, CLIN IMMUNOL, V195, P127, DOI 10.1016/j.clim.2018.06.001; Tenca C, 2003, INT IMMUNOL, V15, P1105, DOI 10.1093/intimm/dxg111; Trabattoni D, 2004, AIDS, V18, P859, DOI 10.1097/00002030-200404090-00003; Trautmann L, 2006, NAT MED, V12, P1198, DOI 10.1038/nm1482; Trautmann L, 2012, BLOOD, V120, P3466, DOI 10.1182/blood-2012-04-422550; Tsegaye A, 2003, CLIN IMMUNOL, V109, P338, DOI 10.1016/j.clim.2003.08.008; Wada NI, 2015, AIDS, V29, P463, DOI 10.1097/QAD.0000000000000545; Wilson EMP, 2013, IMMUNOL REV, V254, P343, DOI 10.1111/imr.12064; Wolint P, 2004, J EXP MED, V199, P925, DOI 10.1084/jem.20031799; Zelinskyy G, 2005, J VIROL, V79, P10619, DOI 10.1128/JVI.79.16.10619-10626.2005; Zhang D, 2003, BLOOD, V101, P226, DOI 10.1182/blood-2002-03-0791	76	20	21	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2019	14	1							e0210540	10.1371/journal.pone.0210540	http://dx.doi.org/10.1371/journal.pone.0210540			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG9VK	30625227	Green Published, Green Submitted, gold			2023-01-03	WOS:000455359400095
J	Arabi, Y; Jawdat, D; Bouchama, A; Tamim, H; Tamimi, W; Al-Balwi, M; Al-Dorzi, HM; Sadat, M; Afesh, L; Abdullah, ML; Mashaqbeh, W; Sakhija, M; Hussein, MA; ElObeid, A; Al-Dawood, A				Arabi, Yaseen; Jawdat, Dunia; Bouchama, Abderrezak; Tamim, Hani; Tamimi, Waleed; Al-Balwi, Mohammed; Al-Dorzi, Hasan M.; Sadat, Musharaf; Afesh, Lara; Abdullah, Mashan L.; Mashaqbeh, Walid; Sakhija, Maram; Hussein, Mohamed A.; ElObeid, Adila; Al-Dawood, Abdulaziz			Permissive underfeeding, cytokine profiles and outcomes in critically ill patients	PLOS ONE			English	Article							ENTERAL NUTRITION; WEIGHT-LOSS; INFLAMMATION; STANDARD; EXERCISE; MARKERS; SEPSIS; ADULTS; MICE; DIET	Background During critical illness in humans, the effects of caloric restriction on the inflammatory response are not well understood. The aim of this study is to examine the associations of caloric restriction, inflammatory response profiles and outcomes in critically ill patients. Methods This is a sub-study of the PermiT trial (Permissive Underfeeding or Standard Enteral Feeding in Critically III Adults Trial- ISRCTN68144998). Serum samples were collected on study days 1, 3, 5, 7 and 14 and analyzed for a panel of 29 cytokines. We used principal component analysis to convert possibly correlated variables (cytokine levels) into a limited number of linearly uncorrelated variables (principal components). We constructed repeated measures mixed linear models to assess whether permissive underfeeding compared to standard feeding was associated with difference cytokine levels over time. Results A total of 72 critically ill patients were enrolled in this study (permissive underfeeding n = 36 and standard feeding n = 36). Principal component analysis identified 6 components that were responsible for 78% of the total variance. When adjusted to principal components, permissive underfeeding was not associated with 90-day mortality (adjusted odds ratio 1.75, 95% confidence interval 0.44, 6.95, p = 0.43) or with incident renal replacement therapy. The cytokines did not differ with time between permissive underfeeding and standard feeding groups. Conclusions The association of permissive underfeeding compared to standard feeding with mortality was not influenced by the inflammatory profile. Permissive underfeeding compared to standard feeding was not associated with differences in the serum levels of cytokines in critically ill patients.	[Arabi, Yaseen; Al-Dorzi, Hasan M.; Sadat, Musharaf; Afesh, Lara; Sakhija, Maram; Al-Dawood, Abdulaziz] King Saud bin Abdulaziz Univ Hlth Sci, King Abdullah Int Med Res Ctr, King Abdulaziz Med City, Intens Care Dept, Riyadh, Saudi Arabia; [Jawdat, Dunia; Mashaqbeh, Walid] King Saud bin Abdulaziz Univ Hlth Sci, King Abdulaziz Med City, King Abdullah Int Med Res Ctr, Cord Blood Bank, Riyadh, Saudi Arabia; [Bouchama, Abderrezak; Abdullah, Mashan L.] King Saud bin Abdulaziz Univ Hlth Sci, King Abdulaziz Med City, King Abdullah Int Med Res Ctr, Dept Expt Med, Riyadh, Saudi Arabia; [Tamim, Hani] Amer Univ Beirut, Med Ctr, Dept Internal Med, Beirut, Lebanon; [Tamimi, Waleed; Al-Balwi, Mohammed] King Saud bin Abdulaziz Univ Hlth Sci, King Abdullah Int Med Res Ctr, King Abdulaziz Med City, Dept Clin Lab, Riyadh, Saudi Arabia; [Hussein, Mohamed A.] King Saud bin Abdulaziz Univ Hlth Sci, King Abdullah Int Med Res Ctr, King Abdulaziz Med City, Dept Biostat & Bioinformat, Riyadh, Saudi Arabia; [ElObeid, Adila] King Saud bin Abdulaziz Univ Hlth Sci, King Abdullah Int Med Res Ctr, King Abdulaziz Med City, Dept Biobank, Riyadh, Saudi Arabia	King Abdulaziz Medical City; King Saud Bin Abdulaziz University for Health Sciences; King Abdulaziz Medical City - Riyadh; King Abdullah International Medical Research Center (KAIMRC); King Abdulaziz Medical City; King Saud Bin Abdulaziz University for Health Sciences; King Abdulaziz Medical City - Riyadh; King Abdullah International Medical Research Center (KAIMRC); King Abdulaziz Medical City; King Saud Bin Abdulaziz University for Health Sciences; King Abdulaziz Medical City - Riyadh; King Abdullah International Medical Research Center (KAIMRC); American University of Beirut; King Abdulaziz Medical City; King Saud Bin Abdulaziz University for Health Sciences; King Abdulaziz Medical City - Riyadh; King Abdullah International Medical Research Center (KAIMRC); King Abdulaziz Medical City; King Saud Bin Abdulaziz University for Health Sciences; King Abdulaziz Medical City - Riyadh; King Abdullah International Medical Research Center (KAIMRC); King Abdulaziz Medical City; King Saud Bin Abdulaziz University for Health Sciences; King Abdulaziz Medical City - Riyadh; King Abdullah International Medical Research Center (KAIMRC)	Arabi, Y (corresponding author), King Saud bin Abdulaziz Univ Hlth Sci, King Abdullah Int Med Res Ctr, King Abdulaziz Med City, Intens Care Dept, Riyadh, Saudi Arabia.	yaseenarabi@yahoo.com	Abdullah, Mashan L/E-7650-2019; Abdullah, Mashan/L-7606-2019; hussein, mohamed/GYU-6912-2022; Arabi, Yaseen/ABF-3316-2020	Abdullah, Mashan L/0000-0002-4628-1536; Abdullah, Mashan/0000-0002-4628-1536; Arabi, Yaseen/0000-0001-5735-6241; Al-Dorzi, Hasan M/0000-0002-3772-8949; Al Balwi, Mohammed/0000-0003-2910-0390; BOUCHAMA, abderrezak/0000-0003-3089-5936	King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia [AT 32-25 KACST]	King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia	The study was funded from King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia under Grant Number - AT 32-25 KACST to Y.A. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrishami R, 2010, DARU, V18, P103; Allingstrup MJ, 2017, INTENS CARE MED, V43, P1637, DOI 10.1007/s00134-017-4880-3; American Dietetic Association, 2000, MAN CLIN DIET, P1; Arabi YM, 2017, AM J RESP CRIT CARE, V195; Arabi YM, 2017, INTENS CARE MED, V43, P1239, DOI 10.1007/s00134-017-4711-6; Arabi YM, 2015, NEW ENGL J MED, V372, P2398, DOI 10.1056/NEJMoa1502826; Arabi YM, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-191; Bastarache JA, 2012, JPEN-PARENTER ENTER, V36, P732, DOI 10.1177/0148607111433054; Blanch L, 2017, INTENS CARE MED, V43, P557, DOI 10.1007/s00134-016-4583-1; Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783; Bruun JM, 2006, AM J PHYSIOL-ENDOC M, V290, pE961, DOI 10.1152/ajpendo.00506.2005; Casaer MP, 2017, INTENS CARE MED, V43, P1720, DOI 10.1007/s00134-017-4881-2; Darmon M, 2015, INTENS CARE MED, V41, P1132, DOI 10.1007/s00134-015-3801-6; Eckerwall GE, 2006, ANN SURG, V244, P959, DOI 10.1097/01.sla.0000246866.01930.58; Esposito K, 2003, JAMA-J AM MED ASSOC, V289, P1799, DOI 10.1001/jama.289.14.1799; Fjell CD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079207; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Goldberg RF, 2008, P NATL ACAD SCI USA, V105, P3551, DOI 10.1073/pnas.0712140105; Guzy C, 2009, EUR J NUTR, V48, P12, DOI 10.1007/s00394-008-0754-3; Lever J, 2017, NAT METHODS, V14, P641, DOI 10.1038/nmeth.4346; Marik PE, 2016, INTENS CARE MED, V42, P316, DOI 10.1007/s00134-015-4131-4; Matsuzaki J, 2001, J NUTR, V131, P2139, DOI 10.1093/jn/131.8.2139; Hermsdorff HHM, 2009, ENDOCRINE, V36, P445, DOI 10.1007/s12020-009-9248-1; Moller K, 2016, PROSTAG LEUKOTR ESS, V106, P39, DOI 10.1016/j.plefa.2015.12.001; Nicklas BJ, 2004, AM J CLIN NUTR, V79, P544; Nicolo M, 2016, JPEN-PARENTER ENTER, V40, P45, DOI 10.1177/0148607115583675; Nikolich-Zugich J, 2005, EXP GERONTOL, V40, P884, DOI 10.1016/j.exger.2005.06.007; Pene F, 2017, INTENS CARE MED, V43, P1154, DOI 10.1007/s00134-017-4840-y; Reignier J, 2018, LANCET, V391, P133, DOI [10.1016/S0140-6736(17)32146-3, 10.1016/s0140-6736(17)32146-3]; Rice TW, 2011, CRIT CARE MED, V39, P967, DOI 10.1097/CCM.0b013e31820a905a; Rimmele T, 2011, CRIT CARE, V15, DOI 10.1186/cc9411; Rugeles SJ, 2013, INDIAN J CRIT CARE M, V17, P343, DOI 10.4103/0972-5229.123438; Smith AR, 2011, J MED MICROBIOL, V60, P359, DOI 10.1099/jmm.0.026401-0; Starr ME, 2016, CRIT CARE MED, V44, pE509, DOI 10.1097/CCM.0000000000001475; Van Dyck L, 2018, NUTR CLIN PRACT, V33, P339, DOI 10.1002/ncp.10084; Weijs PJM, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0701-z; Zusman O, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1538-4	37	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2019	14	1							e0209669	10.1371/journal.pone.0209669	http://dx.doi.org/10.1371/journal.pone.0209669			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG5UW	30615631	Green Published, gold, Green Submitted			2023-01-03	WOS:000455045900024
J	Bohnert, ASB; Ilgen, MA				Bohnert, Amy S. B.; Ilgen, Mark A.			Understanding Links among Opioid Use, Overdose, and Suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							USE DISORDERS; NONCANCER PAIN; DRUG OVERDOSE; UNITED-STATES; PRESCRIBING PATTERNS; RISK; DEATHS; MORTALITY; ASSOCIATION; THERAPY		Univ Michigan, Dept Psychiat, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA; Univ Michigan, Injury Prevent Ctr, Ann Arbor, MI 48109 USA; Vet Affairs Ctr Clin Management Res, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Bohnert, ASB (corresponding author), Univ Michigan, 2800 Plymouth Rd,Bldg 16,Rm 227W, Ann Arbor, MI 48109 USA.	amybohne@med.umich.edu						Bohnert ASB, 2018, ADDICT BEHAV, V86, P66, DOI 10.1016/j.addbeh.2017.11.030; Bohnert ASB, 2016, DRUG ALCOHOL DEPEN, V163, P40, DOI 10.1016/j.drugalcdep.2016.03.018; Bohnert ASB, 2016, MED CARE, V54, P435, DOI 10.1097/MLR.0000000000000505; Bohnert ASB, 2013, INJURY PREV, V19, P326, DOI 10.1136/injuryprev-2012-040631; Bohnert ASB, 2012, AM J PSYCHIAT, V169, P64, DOI 10.1176/appi.ajp.2011.10101476; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Bohnert ASB, 2010, DRUG ALCOHOL DEPEN, V110, P183, DOI 10.1016/j.drugalcdep.2010.03.010; Bohnert KM, 2017, ADDICTION, V112, P1193, DOI 10.1111/add.13774; Brown GK, 2005, JAMA-J AM MED ASSOC, V294, P563, DOI 10.1001/jama.294.5.563; Butler SF, 2007, PAIN, V130, P144, DOI 10.1016/j.pain.2007.01.014; Case A, 2017, BROOKINGS PAP ECO AC, P397; Case A, 2015, P NATL ACAD SCI USA, V112, P15078, DOI 10.1073/pnas.1518393112; Centers for Disease Control and Prevention, 2018, WID RANG ONL DAT EP; Centers for Disease Control and Prevention. (, 2018, WEB BAS INJ STAT QUE; Cicero TJ, 2015, NEW ENGL J MED, V373, P1789, DOI 10.1056/NEJMc1505541; Coffin PO, 2016, ANN INTERN MED, V165, P245, DOI 10.7326/M15-2771; Coffin PO, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183354; Coffin PO, 2003, ADDICTION, V98, P739, DOI 10.1046/j.1360-0443.2003.00376.x; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Darke S, 2005, DRUG ALCOHOL DEPEN, V78, P177, DOI 10.1016/j.drugalcdep.2004.10.009; Darnall BD, 2018, JAMA INTERN MED, V178, P707, DOI 10.1001/jamainternmed.2017.8709; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMsa1406143, 10.1056/NEJMc1501822]; Degenhardt L, 2006, SUBST ABUSE TREAT PR, V1, DOI 10.1186/1747-597X-1-11; Demidenko MI, 2017, GEN HOSP PSYCHIAT, V47, P29, DOI 10.1016/j.genhosppsych.2017.04.011; Department of Health and Human Services Office of the Surgeon General National Action Alliance for Suicide Prevention, 2012, NAT STRAT SUIC PREV; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Elman I, 2013, PROG NEUROBIOL, V109, P1, DOI 10.1016/j.pneurobio.2013.06.003; Frank JW, 2017, ANN INTERN MED, V167, P181, DOI 10.7326/M17-0598; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Gibbons RD, 2007, AM J PSYCHIAT, V164, P1044, DOI 10.1176/appi.ajp.164.7.1044; Glanz JM, 2018, J GEN INTERN MED, V33, P1646, DOI 10.1007/s11606-017-4288-3; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Gray D, 2014, SUICIDE LIFE-THREAT, V44, P304, DOI 10.1111/sltb.12079; Grella CE, 2009, ADDICT BEHAV, V34, P498, DOI 10.1016/j.addbeh.2009.01.002; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Han B, 2015, JAMA-J AM MED ASSOC, V314, P1468, DOI 10.1001/jama.2015.11859; Ilgen MA, 2016, PAIN, V157, P1079, DOI 10.1097/j.pain.0000000000000484; Ilgen MA, 2013, JAMA PSYCHIAT, V70, P692, DOI 10.1001/jamapsychiatry.2013.908; Ilgen MA, 2010, SUICIDE LIFE-THREAT, V40, P597, DOI 10.1521/suli.2010.40.6.597; Ilgen MA, 2010, ARCH GEN PSYCHIAT, V67, P1152, DOI 10.1001/archgenpsychiatry.2010.129; Jones CM, 2015, AM J PREV MED, V49, P493, DOI 10.1016/j.amepre.2015.03.040; Jones CM, 2015, AM J PUBLIC HEALTH, V105, pE55, DOI 10.2105/AJPH.2015.302664; Kessler RC, 2017, INT J METH PSYCH RES, V26, DOI 10.1002/mpr.1575; Korthuis PT, 2017, ANN INTERN MED, V166, P268, DOI 10.7326/M16-2149; MOSCICKI EK, 1988, YALE J BIOL MED, V61, P259; Nugent SM, 2017, J GEN INTERN MED, V32, P1076, DOI 10.1007/s11606-017-4084-0; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Oliva EM, 2017, PSYCHOL SERV, V14, P34, DOI 10.1037/ser0000099; Oquendo MA, 2018, NEW ENGL J MED, V378, P1567, DOI 10.1056/NEJMp1801417; Park TW, 2016, J ADDICT MED, V10, P369, DOI 10.1097/ADM.0000000000000245; Park TW, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2698; Paulozzi LJ, 2011, J CLIN PSYCHIAT, V72, P589, DOI 10.4088/JCP.10com06560; Pfeiffer PN, 2009, DEPRESS ANXIETY, V26, P752, DOI 10.1002/da.20583; Ribeiro JD, 2015, DEPRESS ANXIETY, V32, P25, DOI 10.1002/da.22240; Richardson GA, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.2.e18; Rockett IRH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190200; Rockett IRH, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-35; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Ruhm C.J, 2018, 24188 NBER; Saez E, 2016, Q J ECON, V131, P519, DOI 10.1093/qje/qjw004; Simon GE, 2018, AM J PSYCHIAT, V175, P434, DOI [10.1176/appi.ajp.2017.17080844, 10.1176/appi.ajp.2018.17101167]; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS5; Turner BJ, 2015, J GEN INTERN MED, V30, P1081, DOI 10.1007/s11606-015-3199-4; Unick G, 2014, ADDICTION, V109, P1889, DOI 10.1111/add.12664; Volkow ND, 2014, NEW ENGL J MED, V370, P2063, DOI 10.1056/NEJMp1402780; Warner-Smith M, 2001, ADDICTION, V96, P1113, DOI 10.1046/j.1360-0443.2001.96811135.x; Wilcox HC, 2004, DRUG ALCOHOL DEPEN, V76, pS11, DOI 10.1016/j.drugalcdep.2004.08.003; Williams ACD, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007407.pub3	70	157	157	3	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 3	2019	380	1					71	79		10.1056/NEJMra1802148	http://dx.doi.org/10.1056/NEJMra1802148			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HG1PP	30601750	Bronze			2023-01-03	WOS:000454731200010
J	Shapiro, CL				Shapiro, Charles L.			Cancer Survivorship	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CLINICAL-PRACTICE GUIDELINE; COLORECTAL LIVER METASTASES; QUALITY-OF-LIFE; AMERICAN SOCIETY; CARE PLANS; LONG-TERM; MANAGEMENT; BREAST; RISK; IMPACT		[Shapiro, Charles L.] Icahn Sch Med Mt Sinai Uptown, New York, NY USA		Shapiro, CL (corresponding author), Icahn Sch Med, 1 Gustave L Levy Pl,Box 1079, New York, NY 10029 USA.	charles.shapiro@mssm.edu	shapiro, charles/P-3372-2017	shapiro, charles/0000-0002-7527-4984				Aaronson Neil K, 2014, EJC Suppl, V12, P54, DOI 10.1016/j.ejcsup.2014.03.005; Albers P, 2011, EUR UROL, V60, P304, DOI 10.1016/j.eururo.2011.05.038; [Anonymous], 2015, CAR US EX SUMM; Araujo RLC, 2015, ANN SURG ONCOL, V22, P3070, DOI 10.1245/s10434-014-4354-6; Armenian SH, 2017, J CLIN ONCOL, V35, P893, DOI 10.1200/JCO.2016.70.5400; Bernstein LJ, 2017, NEUROSCI BIOBEHAV R, V83, P417, DOI 10.1016/j.neubiorev.2017.10.028; Bluethmann SM, 2016, CANCER EPIDEM BIOMAR, V25, P1029, DOI 10.1158/1055-9965.EPI-16-0133; Bower JE, 2014, J CLIN ONCOL, V32, P1840, DOI 10.1200/JCO.2013.53.4495; Brydoy M, 2007, ACTA ONCOL, V46, P480, DOI 10.1080/02841860601166958; Burke S, 2017, CANCERS, V9, DOI 10.3390/cancers9050053; Carter J, 2018, J CLIN ONCOL, V36, P492, DOI 10.1200/JCO.2017.75.8995; Casco S, 2016, HORM CANCER-US, V7, P289, DOI 10.1007/s12672-016-0274-1; Chemaitilly W, 2014, CURR OPIN ENDOCRINOL, V21, P71, DOI 10.1097/MED.0000000000000029; Children's Oncology Group, 2013, LONG TERM FOLL UP GU; Chlebowski RT, 2016, J CLIN ONCOL, V34, P4238, DOI 10.1200/JCO.2016.69.4026; Conway A, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1407-6; Cupit-Link Margaret, 2018, Hematol Oncol Stem Cell Ther, V11, P129, DOI 10.1016/j.hemonc.2018.01.005; Davis MP, 2014, CANCER J, V20, P330, DOI 10.1097/PPO.0000000000000071; Denlinger CS, 2017, J NATL COMPR CANC NE, V15, P1140, DOI 10.6004/jnccn.2017.0146; Earle CC, 2004, CANCER, V101, P1712, DOI 10.1002/cncr.20560; El-Shami K, 2015, CA-CANCER J CLIN, V65, P427, DOI 10.3322/caac.21286; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Frobisher C, 2017, BRIT J CANCER, V117, P1723, DOI 10.1038/bjc.2017.347; Gilligan T, 2017, J CLIN ONCOL, V35, P3618, DOI 10.1200/JCO.2017.75.2311; Girgis A, 2013, J ONCOL PRACT, V9, P197, DOI 10.1200/JOP.2012.000690; Golant M, 2008, CANCER J, V14, P420, DOI 10.1097/PPO.0b013e31818d894a; Hahn EE, 2015, PSYCHO-ONCOLOGY, V24, P643, DOI 10.1002/pon.3623; Halpern MT, 2017, LANCET ONCOL, V18, pE51, DOI 10.1016/S1470-2045(16)30563-0; Halpern MT, 2015, J ONCOL PRACT, V11, pE19, DOI 10.1200/JOP.2014.001403; Henderson Tara O, 2014, Am Soc Clin Oncol Educ Book, pe423, DOI 10.14694/EdBook_AM.2014.34.e423; Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914; Hershman DL, 2011, BREAST CANCER RES TR, V126, P529, DOI 10.1007/s10549-010-1132-4; Hertoghe T, 2005, ANN NY ACAD SCI, V1057, P448, DOI 10.1196/annals.1322.035; Hewitt M, 2006, CANC PATIENT CANC SU, DOI DOI 10.17226/11613; Hodgson DC, 2016, J NATL CANC I, V108; Holland Jimmie C, 2007, J Natl Compr Canc Netw, V5, P3; Hunter MS, 2016, CLIMACTERIC, V19, P91, DOI 10.3109/13697137.2015.1125460; Hurria Arti, 2016, Am Soc Clin Oncol Educ Book, V35, pe516, DOI 10.14694/EDBK_156160; Inskip PD, 2016, INT J RADIAT ONCOL, V94, P800, DOI 10.1016/j.ijrobp.2015.11.046; Jaklitsch MT, 2012, J THORAC CARDIOV SUR, V144, P33, DOI 10.1016/j.jtcvs.2012.05.060; Jung B, 2016, J CANCER RES CLIN, V142, P465, DOI 10.1007/s00432-015-2059-2; Kim Y, 2016, PSYCHO-ONCOLOGY, V25, P266, DOI 10.1002/pon.3843; Lawrence RA, 2016, J GEN INTERN MED, V31, P1222, DOI 10.1007/s11606-016-3746-7; Ligibel JA, 2014, J CLIN ONCOL, V32, P3568, DOI 10.1200/JCO.2014.58.4680; LoConte NK, 2018, J CLIN ONCOL, V36, P83, DOI 10.1200/JCO.2017.76.1155; Loh KP, 2018, J ONCOL PRACT, V14, P85, DOI 10.1200/JOP.2017.026435; Lustberg MB, 2012, J CLIN ONCOL, V30, P3665, DOI 10.1200/JCO.2012.42.2097; Marino JL, 2014, MENOPAUSE, V21, P267, DOI 10.1097/GME.0b013e3182976f46; Mayer DK, 2015, CANCER-AM CANCER SOC, V121, P978, DOI 10.1002/cncr.28884; McCabe MS, 2013, J CLIN ONCOL, V31, P631, DOI 10.1200/JCO.2012.46.6854; McCarthy MC, 2013, CURR OPIN SUPPORT PA, V7, P289, DOI 10.1097/SPC.0b013e32836395e0; Nekhlyudov L, 2017, J CLIN ONCOL, V35, P1606, DOI 10.1200/JCO.2016.71.8478; Nekhlyudov L, 2017, LANCET ONCOL, V18, pE30, DOI 10.1016/S1470-2045(16)30570-8; Nyrop KA, 2016, SUPPORT CARE CANCER, V24, P2643, DOI 10.1007/s00520-015-3065-2; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Overholser L, 2017, MED CLIN N AM, V101, P1075, DOI 10.1016/j.mcna.2017.06.002; Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206; Phillips T, 2017, CURR TREAT OPTION ON, V18, DOI 10.1007/s11864-017-0451-7; Radivoyevitch T, 2016, LEUKEMIA, V30, P285, DOI 10.1038/leu.2015.258; Ramaswamy AT, 2016, CANCER-AM CANCER SOC, V122, P1247, DOI 10.1002/cncr.29851; Resnick MJ, 2015, J CLIN ONCOL, V33, P1078, DOI 10.1200/JCO.2014.60.2557; Robison LL, 2014, NAT REV CANCER, V14, P61, DOI 10.1038/nrc3634; Rubinstein EB, 2017, JAMA INTERN MED, V177, P1726, DOI 10.1001/jamainternmed.2017.4747; Runowicz CD, 2016, J CLIN ONCOL, V34, P611, DOI 10.1200/JCO.2015.64.3809; Salani R, 2011, AM J OBSTET GYNECOL, V204, P466, DOI 10.1016/j.ajog.2011.03.008; Schaapveld M, 2015, NEW ENGL J MED, V373, P2499, DOI 10.1056/NEJMoa1505949; Schwedhelm C, 2016, NUTR REV, V74, P737, DOI 10.1093/nutrit/nuw045; Shalom MM, 2011, J ONCOL PRACT, V7, P314, DOI 10.1200/JOP.2010.000208; Shanklin VE, 2018, EUR J CANCER CARE, V27, DOI 10.1111/ecc.12623; Shapiro CL, 2016, J ONCOL PRACT, V12, P145, DOI 10.1200/JOP.2015.009449; Shapiro CL, 2001, NEW ENGL J MED, V344, P1997, DOI 10.1056/NEJM200106283442607; Singh Gunjesh Kumar, 2017, World J Oncol, V8, P1, DOI 10.14740/wjon996w; Smith RA, 2017, CA-CANCER J CLIN, V67, P100, DOI 10.3322/caac.21392; Spetz Johan, 2018, Curr Treat Options Cardiovasc Med, V20, P31, DOI 10.1007/s11936-018-0627-x; Sun YL, 2017, SUPPORT CARE CANCER, V25, P709, DOI 10.1007/s00520-016-3446-1; Tomlinson JS, 2007, J CLIN ONCOL, V25, P4575, DOI 10.1200/JCO.2007.11.0833; van de Poll-Franse LV, 2017, ACTA ONCOL, V56, P134, DOI 10.1080/0284186X.2016.1266080; Vassilakopoulou M, 2016, CRIT REV ONCOL HEMAT, V97, P328, DOI 10.1016/j.critrevonc.2015.08.002; Waldron EA, 2013, PSYCHO-ONCOLOGY, V22, P1200, DOI 10.1002/pon.3118; Ward E, 2014, CA-CANCER J CLIN, V64, P83, DOI 10.3322/caac.21219; Woo J, 2017, CLIN GERIATR MED, V33, P305, DOI 10.1016/j.cger.2017.02.003; Xiao DY, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw145; Yi JC, 2017, MED CLIN N AM, V101, P1099, DOI 10.1016/j.mcna.2017.06.005	84	238	240	7	42	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 20	2018	379	25					2438	2450		10.1056/NEJMra1712502	http://dx.doi.org/10.1056/NEJMra1712502			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF0KI	30575480				2023-01-03	WOS:000453849400008
J	Chen, AX; Simpson, SQ; Pallin, DJ				Chen, Angela X.; Simpson, Steven Q.; Pallin, Daniel J.			Sepsis Guidelines	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SURVIVING SEPSIS; SEPTIC SHOCK; MORTALITY; CAMPAIGN; ANTIBIOTICS		[Chen, Angela X.; Simpson, Steven Q.] Univ Kansas, Div Pulm & Crit Care Med, Kansas City, KS 66160 USA; [Pallin, Daniel J.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Pallin, Daniel J.] Harvard Med Sch, Boston, MA 02115 USA	University of Kansas; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Chen, AX (corresponding author), Univ Kansas, Div Pulm & Crit Care Med, Kansas City, KS 66160 USA.		Simpson, Steven/GVT-5914-2022; Pallin, Daniel J/H-6382-2013	Pallin, Daniel J/0000-0002-8517-9702; Simpson, Steven/0000-0002-9166-2717				Allan John, 1816, Edinb Med Surg J, V12, P257; Eichacker PQ, 2006, NEW ENGL J MED, V355, P1640, DOI 10.1056/NEJMp068197; Farkas J, 2018, PETITION RETIRE SURV; Levy MM, 2018, CRIT CARE MED, V46, P997, DOI 10.1097/CCM.0000000000003119; Liu Vincent, 2013, Ann Am Thorac Soc, V10, P466, DOI 10.1513/AnnalsATS.201304-099OC; Liu VX, 2017, AM J RESP CRIT CARE, V196, P856, DOI 10.1164/rccm.201609-1848OC; Pruinelli L, 2018, CRIT CARE MED, V46, P500, DOI [10.1097/CCM.0000000000002949, 10.1097/ccm.0000000000002949]; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; Seymour CW, 2017, NEW ENGL J MED, V376, P2235, DOI 10.1056/NEJMoa1703058; Sprung CL, 2016, INTENS CARE MED, V42, P2024, DOI 10.1007/s00134-016-4604-0; Sterling SA, 2015, CRIT CARE MED, V43, P1907, DOI 10.1097/CCM.0000000000001142; Surviving Sepsis Campaign, 2018, **NON-TRADITIONAL**; Whiles BB, 2017, CRIT CARE MED, V45, P623, DOI 10.1097/CCM.0000000000002262	13	29	32	1	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 4	2019	380	14					1369	1371		10.1056/NEJMclde1815472	http://dx.doi.org/10.1056/NEJMclde1815472			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HR8DR	30943343				2023-01-03	WOS:000463386900015
J	Huang, L; Xi, Y; Peng, YF; Yang, Y; Huang, XD; Fu, YW; Tao, Q; Xiao, J; Yuan, TF; An, K; Zhao, H; Pu, ML; Xu, FQ; Xue, T; Luo, MM; So, WA; Ren, CR				Huang, Lu; Xi, Yue; Peng, Yanfang; Yang, Yan; Huang, Xiaodan; Fu, Yunwei; Tao, Qian; Xiao, Jia; Yuan, Tifei; An, Kai; Zhao, Huan; Pu, Mingliang; Xu, Fuqiang; Xue, Tian; Luo, Minmin; So, Kwok-Fai; Ren, Chaoran			A Visual Circuit Related to Habenula Underlies the Antidepressive Effects of Light Therapy	NEURON			English	Article							RETINAL GANGLION-CELLS; LATERAL GENICULATE-NUCLEUS; MAJOR DEPRESSIVE DISORDER; INTERGENICULATE LEAFLET; DOUBLE-BLIND; CONNECTIONS; EFFICACY; NEUROBIOLOGY; DYNAMICS; RHYTHMS	Light plays a pivotal role in the regulation of affective behaviors. However, the precise circuits that mediate the impact of light on depressive-like behaviors are not well understood. Here, we show that light influences depressive-like behaviors through a disynaptic circuit linking the retina and the lateral habenula (LHb). Specifically, M4-type melanopsin-expressing retinal ganglion cells (RGCs) innervate GABA neurons in the thalamic ventral lateral geniculate nucleus and intergeniculate leaflet (vLGN/IGL), which in turn inhibit CaMKII alpha neurons in the LHb. Specific activation of vLGN/IGL-projecting RGCs, activation of LHb-projecting vLGN/IGL neurons, or inhibition of postsynaptic LHb neurons is sufficient to decrease the depressive-like behaviors evoked by long-term exposure to aversive stimuli or chronic social defeat stress. Furthermore, we demonstrate that the antidepressive effects of light therapy require activation of the retina-vLGN/IGL-LHb pathway. These results reveal a dedicated retina-vLGN/IGL-LHb circuit that regulates depressive-like behaviors and provide a potential mechanistic explanation for light treatment of depression.	[Huang, Lu; Xi, Yue; Peng, Yanfang; Yang, Yan; Huang, Xiaodan; Fu, Yunwei; So, Kwok-Fai; Ren, Chaoran] Jinan Univ, CNS Regenerat Collaborat Joint Lab, Minist Educ, Guangdong Hongkong Macau Inst CNS Regenerat, Guangzhou 510632, Guangdong, Peoples R China; [Huang, Lu] Jinan Univ, Affiliated Hosp 1, Dept Neurol, Guangzhou 510632, Guangdong, Peoples R China; [Huang, Lu] Jinan Univ, Affiliated Hosp 1, Stroke Ctr, Guangzhou 510632, Guangdong, Peoples R China; [Tao, Qian] Jinan Univ, Sch Med, Psychol Dept, Guangzhou 510632, Guangdong, Peoples R China; [Xiao, Jia] Jinan Univ, Affiliated Hosp 1, Clin Med Res Inst, Guangzhou 510632, Guangdong, Peoples R China; [Yuan, Tifei] Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Shanghai 200030, Peoples R China; [An, Kai; Zhao, Huan; Xue, Tian] Univ Sci & Technol China, Div Life Sci & Med, Sch Life Sci,Hefei Natl Lab Phys Sci,Key Lab Brai, Chinese Acad Sci,Microscale Neurodegenerat Disord, Hefei 230026, Anhui, Peoples R China; [Pu, Mingliang] Peking Univ, Sch Basic Med Sci, Dept Anat, Beijing 100191, Peoples R China; [Xu, Fuqiang] Chinese Acad Sci, Ctr Excellence Brain Sci & Intelligent Technol, Wuhan Inst Phys & Math, State Key Lab Magnet Resonance & Atom & Mol Phys, Wuhan 430071, Hubei, Peoples R China; [Luo, Minmin] Natl Inst Biol Sci, Zhongguancun Life Sci Pk,7 Sci Pk Rd, Beijing 102206, Peoples R China; [So, Kwok-Fai; Ren, Chaoran] Guangzhou Regenerat Med & Hlth Guangdong Lab, Guangzhou 510530, Guangdong, Peoples R China; [So, Kwok-Fai] Univ Hong Kong, Dept Ophthalmol, Hong Kong, Peoples R China; [So, Kwok-Fai] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Hong Kong, Peoples R China; [So, Kwok-Fai; Ren, Chaoran] Nantong Univ, Coinnovat Ctr Neuroregenerat, Nantong 226001, Peoples R China	Jinan University; Jinan University; Jinan University; Jinan University; Jinan University; Shanghai Jiao Tong University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Peking University; Chinese Academy of Sciences; Wuhan Institute of Physics & Mathematics, CAS; National Institute of Biological Sciences, Beijing; Guangzhou Regenerative Medicine & Health Guangdong Laboratory (Bioisland Laboratory); University of Hong Kong; University of Hong Kong; Nantong University	Ren, CR (corresponding author), Jinan Univ, CNS Regenerat Collaborat Joint Lab, Minist Educ, Guangdong Hongkong Macau Inst CNS Regenerat, Guangzhou 510632, Guangdong, Peoples R China.; Ren, CR (corresponding author), Guangzhou Regenerat Med & Hlth Guangdong Lab, Guangzhou 510530, Guangdong, Peoples R China.; Ren, CR (corresponding author), Nantong Univ, Coinnovat Ctr Neuroregenerat, Nantong 226001, Peoples R China.	tchaoran@jnu.edu.cn	Ren, Chaoran/I-7904-2019; Xiao, Jia/GYU-9660-2022; xu, fuqiang/AAI-1571-2019; Zhao, Huan/AAG-8029-2021	So, Kwok-Fai/0000-0003-4039-4246; HUANG, Xiaodan/0000-0001-6222-7508; xu, fu qiang/0000-0002-4382-9797; Tao, Qian/0000-0002-9725-1871	National Natural Science Foundation of China [31771170, 31400942, 31571091]; National Program on Key Basic Research Project of China (973 Program) [2014CB542205, 2015CB351806]; Guangdong Special Support Program [2017TQ04R173]; Guangdong Natural Science Foundation [2014A030313387]; Pearl River S&T Nova Program of Guangzhou [201806010198]; Shenzhen Basic Research Grant [JCYJ20170412164259361]; Leading Talents of Guangdong (2013); Programme of Introducing Talents of Discipline to Universities [B14036]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Program on Key Basic Research Project of China (973 Program)(National Basic Research Program of China); Guangdong Special Support Program; Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Pearl River S&T Nova Program of Guangzhou; Shenzhen Basic Research Grant; Leading Talents of Guangdong (2013); Programme of Introducing Talents of Discipline to Universities(Ministry of Education, China - 111 Project)	We thank Dr. Wenbiao Gan and Dr. Gary Pickard for critical comments on the manuscript and Dr. Hailan Hu and Dr. Yihui Cui for advice concerning the firing pattern of LHb neurons. C.R. is supported by the National Natural Science Foundation of China (31771170 and 31400942), the National Program on Key Basic Research Project of China (973 Program, 2014CB542205), the Guangdong Special Support Program (2017TQ04R173), the Guangdong Natural Science Foundation (2014A030313387), the Pearl River S&T Nova Program of Guangzhou (201806010198), and Shenzhen Basic Research Grant JCYJ20170412164259361. M.P. is supported by the National Natural Science Foundation of China (31571091) and the National Program on Key Basic Research Project of China (973 Program, 2015CB351806). K.-F.S. is supported by funding from Leading Talents of Guangdong (2013) and the Programme of Introducing Talents of Discipline to Universities (B14036).	Aizawa H, 2012, J COMP NEUROL, V520, P4051, DOI 10.1002/cne.23167; Berton O, 2006, SCIENCE, V311, P864, DOI 10.1126/science.1120972; Boulos LJ, 2017, BIOL PSYCHIAT, V81, P296, DOI 10.1016/j.biopsych.2016.06.003; CRAGG BG, 1961, EXP NEUROL, V3, P388, DOI 10.1016/0014-4886(61)90013-9; Cruz-Martin A, 2014, NATURE, V507, P358, DOI 10.1038/nature12989; Cui YH, 2018, NATURE, V554, P323, DOI 10.1038/nature25752; DIAZ C, 1992, BRAIN BEHAV EVOLUT, V39, P312, DOI 10.1159/000114128; Dolzani SD, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0229-16.2016; Ecker JL, 2010, NEURON, V67, P49, DOI 10.1016/j.neuron.2010.05.023; Ely BA, 2016, HUM BRAIN MAPP, V37, P2369, DOI 10.1002/hbm.23179; Estevez ME, 2012, J NEUROSCI, V32, P13608, DOI 10.1523/JNEUROSCI.1422-12.2012; Fernandez DC, 2018, CELL, V175, P71, DOI 10.1016/j.cell.2018.08.004; Finlayson PG, 2010, INVEST OPHTH VIS SCI, V51, P3619, DOI 10.1167/iovs.09-4877; Golden RN, 2005, AM J PSYCHIAT, V162, P656, DOI 10.1176/appi.ajp.162.4.656; Golden SA, 2011, NAT PROTOC, V6, P1183, DOI 10.1038/nprot.2011.361; Gonzalez MMC, 2008, P NATL ACAD SCI USA, V105, P4898, DOI 10.1073/pnas.0703615105; Gunaydin LA, 2014, CELL, V157, P1535, DOI 10.1016/j.cell.2014.05.017; Hannibal J, 2017, J COMP NEUROL, V525, P1934, DOI 10.1002/cne.24181; Harrington ME, 1997, NEUROSCI BIOBEHAV R, V21, P705, DOI 10.1016/S0149-7634(96)00019-X; Hikosaka O, 2008, J NEUROSCI, V28, P11825, DOI 10.1523/JNEUROSCI.3463-08.2008; Jacinto LR, 2017, EXP NEUROL, V289, P46, DOI 10.1016/j.expneurol.2016.12.003; KEMALI M, 1980, EXP BRAIN RES, V38, P341; Kripke DF, 1998, J AFFECT DISORDERS, V49, P109, DOI 10.1016/S0165-0327(98)00005-6; Lam RW, 2016, JAMA PSYCHIAT, V73, P56, DOI 10.1001/jamapsychiatry.2015.2235; Lau BWM, 2011, CELL TRANSPLANT, V20, P871, DOI 10.3727/096368910X539065; Lawson RP, 2017, MOL PSYCHIATR, V22, P202, DOI 10.1038/mp.2016.81; Lecca S, 2016, NAT MED, V22, P254, DOI 10.1038/nm.4037; LeGates TA, 2014, NAT REV NEUROSCI, V15, P443, DOI 10.1038/nrn3743; Li K, 2013, SCIENCE, V341, P1016, DOI 10.1126/science.1240729; Lieverse R, 2011, ARCH GEN PSYCHIAT, V68, P61, DOI 10.1001/archgenpsychiatry.2010.183; Lowry CA, 2008, ANN NY ACAD SCI, V1148, P86, DOI 10.1196/annals.1410.004; Manji HK, 2001, NAT MED, V7, P541, DOI 10.1038/87865; Marburg O, 1944, J COMP NEUROL, V80, P211, DOI 10.1002/cne.900800205; Matsumoto M, 2007, NATURE, V447, P1111, DOI 10.1038/nature05860; Milosavljevic N, 2016, CURR BIOL, V26, P2358, DOI 10.1016/j.cub.2016.06.057; Monje FJ, 2011, J NEUROSCI, V31, P9075, DOI 10.1523/JNEUROSCI.1537-11.2011; Moore RY, 2000, J COMP NEUROL, V420, P398, DOI 10.1002/(SICI)1096-9861(20000508)420:3<398::AID-CNE9>3.0.CO;2-9; Nestler EJ, 2002, NEURON, V34, P13, DOI 10.1016/S0896-6273(02)00653-0; Oh SW, 2014, NATURE, V508, P207, DOI 10.1038/nature13186; Proulx CD, 2014, NAT NEUROSCI, V17, P1146, DOI 10.1038/nn.3779; Pulmanausahakul R, 2008, J VIROL, V82, P2330, DOI 10.1128/JVI.02327-07; Quattrochi LE, 2019, J COMP NEUROL, V527, P297, DOI 10.1002/cne.24556; Reifler AN, 2015, EXP EYE RES, V130, P17, DOI 10.1016/j.exer.2014.11.010; ROSENTHAL NE, 1984, ARCH GEN PSYCHIAT, V41, P72; Sit DK, 2018, AM J PSYCHIAT, V175, P131, DOI 10.1176/appi.ajp.2017.16101200; Tervo DGR, 2016, NEURON, V92, P372, DOI 10.1016/j.neuron.2016.09.021; Torrisi S, 2017, NEUROIMAGE, V147, P872, DOI 10.1016/j.neuroimage.2016.10.034; Tovote P, 2016, NATURE, V534, P206, DOI 10.1038/nature17996; Wang D., 2017, ELIFE, V6, P6; Wang Q, 2017, CURR BIOL, V27, P1791, DOI 10.1016/j.cub.2017.05.022; Weiss T, 2011, NEUROSCIENCE, V172, P74, DOI 10.1016/j.neuroscience.2010.10.047; Wilson Neil, 2002, Psychoanal Rev, V89, P557, DOI 10.1521/prev.89.4.557.17722; Wirz-Justice A, 2009, CHRONOTHERAPEUTICS A; Wirz-Justice A, 2011, J CLIN PSYCHIAT, V72, P986, DOI 10.4088/JCP.10m06188blu; Yadid G, 2008, PROG BRAIN RES, V172, P265, DOI 10.1016/S0079-6123(08)00913-8; Yang Y, 2018, NATURE, V554, P317, DOI 10.1038/nature25509; Zhao H, 2005, NEUROSCIENCE, V132, P519, DOI 10.1016/j.neuroscience.2005.01.012; Zingg B, 2017, NEURON, V93, P33, DOI 10.1016/j.neuron.2016.11.045	58	97	106	3	86	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	APR 3	2019	102	1					128	+		10.1016/j.neuron.2019.01.037	http://dx.doi.org/10.1016/j.neuron.2019.01.037			23	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HR7MH	30795900	Bronze			2023-01-03	WOS:000463337900016
J	Kumbhare, D				Kumbhare, Dinesh			An exercise intervention during acute hospitalization improved function and cognition at discharge in older adults	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Kumbhare, Dinesh] Univ Toronto, Toronto, ON, Canada	University of Toronto	Kumbhare, D (corresponding author), Univ Toronto, Toronto, ON, Canada.		Izquierdo, Mikel/O-8049-2019; Izquierdo, Mikel/A-4894-2010	Izquierdo, Mikel/0000-0002-1506-4272; Kumbhare, Dinesh/0000-0003-3889-7557					0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 19	2019	170	6					JC33	JC33		10.7326/ACPJ201903190-033	http://dx.doi.org/10.7326/ACPJ201903190-033			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP1ZR	30884503				2023-01-03	WOS:000461468300010
J	Evans, ML; Golubic, R				Evans, Mark L.; Golubic, Rajna			Technology to overcome clinical inertia in insulin therapy	LANCET			English	Editorial Material									[Evans, Mark L.] Univ Cambridge, MRC Inst Metab Sci, Wellcome Trust, Cambridge NIHR Biomed Campus, Cambridge CB20QQ, England; Univ Cambridge, Dept Med, Cambridge NIHR Biomed Campus, Cambridge CB20QQ, England	University of Cambridge; University of Cambridge	Evans, ML (corresponding author), Univ Cambridge, MRC Inst Metab Sci, Wellcome Trust, Cambridge NIHR Biomed Campus, Cambridge CB20QQ, England.	mle24@cam.ac.uk	Golubic, Rajna/GNH-4374-2022	Golubic, Rajna/0000-0003-0419-9582				Bally L, 2017, LANCET DIABETES ENDO, V5, P261, DOI 10.1016/S2213-8587(17)30001-3; Bergenstal RM, 2019, LANCET, V393, P1138, DOI 10.1016/S0140-6736(19)30368-X; Davidson MB, 2019, DIABETES THER, V10, P523, DOI 10.1007/s13300-019-0565-y; Donnelly R, 2015, PRACT DIABETES, V32, P247, DOI 10.1002/pdi.1966; Harris S, 2008, CAN FAM PHYSICIAN, V54, P550; Khunti K, 2017, PRIM CARE DIABETES, V11, P3, DOI 10.1016/j.pcd.2016.09.003; Selvin E, 2016, DIABETES CARE, V39, pE33, DOI 10.2337/dc15-2229	7	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 16	2019	393	10176					1078	1080		10.1016/S0140-6736(19)30416-7	http://dx.doi.org/10.1016/S0140-6736(19)30416-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HP1HF	30808513	Green Submitted			2023-01-03	WOS:000461416600007
J	Stevens, M; Neal, CR; Craciun, EC; Dronca, M; Harper, SJ; Oltean, S				Stevens, Megan; Neal, Christopher R.; Craciun, Elena C.; Dronca, Maria; Harper, Steven J.; Oltean, Sebastian			The natural drug DIAVIT is protective in a type II mouse model of diabetic nephropathy	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; NF-KAPPA-B; OXIDATIVE STRESS; VEGF; ANTIOXIDANT; OVEREXPRESSION; ANGIOGENESIS; ACTIVATION; VEGF(165)B; BLUEBERRY	There is evidence to suggest that abnormal angiogenesis, inflammation, and fibrosis drive diabetic nephropathy (DN). However, there is no specific treatment to counteract these processes. We aimed to determine whether DIAVIT, a natural Vaccinium myrtillus (blueberry) and Hippophae Rhamnoides (sea buckthorn) extract, is protective in a model of type II DN. Diabetic db/db mice were administered DIAVIT in their drinking water for 14 weeks. We assessed the functional, structural, and ultra-structural phenotype of three experimental groups (lean+vehicle, db/db+vehicle, db/db+DIAVIT). We also investigated the angiogenic and fibrotic pathways involved in the mechanism of action of DIAVIT. Diabetic db/db mice developed hyperglycaemia, albuminuria, and an increased glomerular water permeability; the latter two were prevented by DIAVIT. db/db mice developed fibrotic glomeruli, endothelial insult, and glomerular ultra-structural changes, which were not present in DIAVIT-treated mice. Vascular endothelial growth factor A (VEGF-A) splicing was altered in the db/db kidney cortex, increasing the pro-angiogenic VEGF-A(165) relative to the anti-angiogenic VEGF-A(165)b. This was partially prevented with DIAVIT treatment. Delphinidin, an anthocyanin abundant in DIAVIT, increased the VEGF-A(165)b expression relative to total VEGF-A165 in cultured podocytes through phosphorylation of the splice factor SRSF6. DIAVIT, in particular delphinidin, alters VEGF-A splicing in type II DN, rescuing the DN phenotype. This study highlights the therapeutic potential of natural drugs in DN through the manipulation of gene splicing and expression.	[Stevens, Megan; Oltean, Sebastian] Univ Exeter, Med Sch, Inst Biomed & Clin Sci, Exeter, Devon, England; [Stevens, Megan; Neal, Christopher R.; Harper, Steven J.; Oltean, Sebastian] Univ Bristol, Sch Physiol & Pharmacol, Bristol, Avon, England; [Stevens, Megan; Neal, Christopher R.; Harper, Steven J.; Oltean, Sebastian] Univ Bristol, Bristol Renal, Sch Clin Sci, Bristol, Avon, England; [Craciun, Elena C.] Univ Med & Pharm Iuliu Hatieganu Cluj Napoca, Sch Pharm, Dept Pharmaceut Biochem, Cluj Napoca, Romania; [Craciun, Elena C.] Univ Med & Pharm Iuliu Hatieganu Cluj Napoca, Clin Lab, Cluj Napoca, Romania; [Dronca, Maria] Univ Med & Pharm Iuliu Hatieganu Cluj Napoca, Sch Med, Dept Med Biochem, Cluj Napoca, Romania	University of Exeter; University of Bristol; University of Bristol; Iuliu Hatieganu University of Medicine & Pharmacy; Iuliu Hatieganu University of Medicine & Pharmacy; Iuliu Hatieganu University of Medicine & Pharmacy	Stevens, M; Oltean, S (corresponding author), Univ Exeter, Med Sch, Inst Biomed & Clin Sci, Exeter, Devon, England.; Stevens, M; Oltean, S (corresponding author), Univ Bristol, Sch Physiol & Pharmacol, Bristol, Avon, England.; Stevens, M; Oltean, S (corresponding author), Univ Bristol, Bristol Renal, Sch Clin Sci, Bristol, Avon, England.	m.stevens2@exeter.ac.uk; s.oltean@exeter.ac.uk	sTEVENS, Megan/GPT-0543-2022	Craciun, Elena Cristina/0000-0002-8192-1631; Oltean, Sebastian/0000-0001-7890-8439	British Heart Foundation [PG/15/53/31371]; Diabetes UK [17/0005668]; Richard Bright VEGF Research Trust; BHF [15/53/31371]; BBSRC [BB/J007293/2, BB/J007293/1, BB/P012035/1] Funding Source: UKRI	British Heart Foundation(British Heart Foundation); Diabetes UK(Diabetes UK); Richard Bright VEGF Research Trust; BHF(British Heart Foundation); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	Funding for this study was supported by grants from British Heart Foundation to SO (PG/15/53/31371), Diabetes UK to SO (17/0005668), and Richard Bright VEGF Research Trust to SO.; We would like to thank Simon Thorpe from the Faculty of Science Mass Spectrometry Centre, University of Sheffield, for his help in determining the chemical composition of the DIAVIT extract. Work on this paper was supported by grants from Diabetes UK (17/0005668) and BHF (15/53/31371) to SO.	Abbott CA, 2011, DIABETES CARE, V34, P2220, DOI 10.2337/dc11-1108; Amin EM, 2011, CANCER CELL, V20, P768, DOI 10.1016/j.ccr.2011.10.016; Bagchi D, 2004, BIOCHEMISTRY-MOSCOW+, V69, P75, DOI 10.1023/B:BIRY.0000016355.19999.93; Bates DO, 2002, CANCER RES, V62, P4123; Bharat D, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201700601; Bhatt SR, 2014, CLIN EXP HYPERTENS, V36, P367, DOI 10.3109/10641963.2014.943402; Bunea A, 2013, PHYTOCHEMISTRY, V95, P436, DOI 10.1016/j.phytochem.2013.06.018; Bunea A, 2011, NOT BOT HORTI AGROBO, V39, P70; Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039; Gammons MVR, 2013, INVEST OPHTH VIS SCI, V54, P5797, DOI 10.1167/iovs.13-11634; Gilbert RE, 1999, KIDNEY INT, V56, P1627, DOI 10.1046/j.1523-1755.1999.00721.x; Gilbertson DT, 2005, J AM SOC NEPHROL, V16, P3736, DOI 10.1681/ASN.2005010112; Gnudi L, 2016, TRENDS ENDOCRIN MET, V27, P820, DOI 10.1016/j.tem.2016.07.002; Juan-Mateu J, 2018, DIABETES, V67, P423, DOI 10.2337/db17-0736; Kang MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079823; Kawamura H, 2008, CANCER RES, V68, P4683, DOI 10.1158/0008-5472.CAN-07-6577; Keravis T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145291; Kim MH, 2017, ONCOL REP, V37, P777, DOI 10.3892/or.2016.5296; Kriz W, 2017, PEDIATR NEPHROL, V32, P405, DOI 10.1007/s00467-016-3358-9; Li J, 2012, J NUTR BIOCHEM, V23, P320, DOI 10.1016/j.jnutbio.2010.12.008; Liu HW, 2016, FOOD FUNCT, V7, P1941, DOI 10.1039/c6fo00078a; Ma W, 2014, J ETHNOPHARMACOL, V153, P840, DOI 10.1016/j.jep.2014.03.051; Maezawa Y, 2015, J DIABETES INVEST, V6, P3, DOI 10.1111/jdi.12255; Martini S, 2014, J AM SOC NEPHROL, V25, P2559, DOI 10.1681/ASN.2013080906; Mezzano S, 2004, NEPHROL DIAL TRANSPL, V19, P2505, DOI 10.1093/ndt/gfh207; Nair AR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111976; Nemes-Nagy E, 2008, ACTA PHYSIOL HUNG, V95, P383, DOI 10.1556/APhysiol.95.2008.4.5; Oltean S, 2015, J AM SOC NEPHROL, V26, P1889, DOI 10.1681/ASN.2014040350; Park CH, 2010, EUR J PHARMACOL, V640, P233, DOI 10.1016/j.ejphar.2010.04.028; Parving HH, 2008, NEW ENGL J MED, V358, P2433, DOI 10.1056/NEJMoa0708379; Qiu Y, 2010, J AM SOC NEPHROL, V21, P1498, DOI 10.1681/ASN.2009060617; Qiu Y, 2009, BIOCHEM SOC T, V37, P1207, DOI 10.1042/BST0371207; Salmon AHJ, 2006, J PHYSIOL-LONDON, V570, P141, DOI 10.1113/jphysiol.2005.099184; Schmid H, 2006, DIABETES, V55, P2993, DOI 10.2337/db06-0477; Schrijvers BF, 2004, KIDNEY INT, V65, P2003, DOI 10.1111/j.1523-1755.2004.00621.x; Stevens M, 2017, J PHYSIOL-LONDON, V595, P6281, DOI 10.1113/JP274481; Wen DH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082336; Zhou ZH, 2012, MOL CELL, V47, P422, DOI 10.1016/j.molcel.2012.05.014	38	5	5	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2019	14	3							e0212910	10.1371/journal.pone.0212910	http://dx.doi.org/10.1371/journal.pone.0212910			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO6OH	30865689	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000461048900046
J	Mueller, SM; Martin, S; Grunwald, M				Mueller, Stephanie Margarete; Martin, Sven; Grunwald, Martin			Self-touch: Contact durations and point of touch of spontaneous facial self-touches differ depending on cognitive and emotional load	PLOS ONE			English	Article							IRRELEVANT SOUND; WORKING-MEMORY; HAND MOVEMENTS; LEFT-EAR; BEHAVIOR; EEG; ANTICIPATION; DISTRACTION; ASYMMETRIES; SPEAKING	Every human being spontaneously touches its eyes, cheeks, chin and mouth manifold every day. These spontaneous facial self-touches (sFST) are elicited with little or no awareness and are distinct from gestures and instrumental acts. Self-touch frequency has been shown to be influenced by negative affect and attention distraction and may be involved in regulating emotion and working memory functions. Yet, even though self-touch research dates back several decades fundamental aspects, like the temporal progression of sFST or the effects of executing hand and touched face area, have not yet been analyzed. For the first time, the present study measured sFST temporal aspects to the millisecond using accelerometers and EMG. Spontaneous self-touch was triggered in sixty participants who completed a delayed memory task of complex haptic relief stimuli while listening to distracting aversive sounds. We found that while both hands were used equally often and with the same overall movement times and contact durations, significant effects occurred for face area in both frequency and contact durations. Ergo the point of touch seems to have some relevance of its own, independently of which hand is used to perform it. The results show that not only frequency but also the point of touch and contact durations are influenced by cognitive and emotional demands. We argue that investigating the fundamental characteristics of sFST will further the understanding of cognitive focusing and attentional mechanisms.	[Mueller, Stephanie Margarete; Martin, Sven; Grunwald, Martin] Univ Leipzig, Paul Flechsig Inst Brain Res, Hapt Res Lab, Leipzig, Germany	Leipzig University	Grunwald, M (corresponding author), Univ Leipzig, Paul Flechsig Inst Brain Res, Hapt Res Lab, Leipzig, Germany.	mgrun@medizin.uni-leipzig.de			DFG [623492]; German Research Foundation (DFG); University of Leipzig within the program of Open Access Publishing	DFG(German Research Foundation (DFG)); German Research Foundation (DFG)(German Research Foundation (DFG)); University of Leipzig within the program of Open Access Publishing	This work was supported by DFG grant 623492. We acknowledge support from the German Research Foundation (DFG) and University of Leipzig within the program of Open Access Publishing. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baddeley A.D., 1974, PSYCHOL LEARN MOTIV, V8, P47, DOI DOI 10.1016/S0079-7421(08)60452-1; BARROSO F, 1980, PERCEPT MOTOR SKILL, V50, P1083, DOI 10.2466/pms.1980.50.3c.1083; BARROSO F, 1986, J NONVERBAL BEHAV, V10, P51, DOI 10.1007/BF00987205; BARROSO F, 1978, J EXP PSYCHOL HUMAN, V4, P321, DOI 10.1037/0096-1523.4.2.321; BARROSO F, 1992, J PSYCHOLINGUIST RES, V21, P87, DOI 10.1007/BF01067989; Bitsios P, 2004, INT J PSYCHOPHYSIOL, V52, P87, DOI 10.1016/j.ijpsycho.2003.12.006; Bradley MM, 2000, PSYCHOPHYSIOLOGY, V37, P204, DOI 10.1111/1469-8986.3720204; Cobo J., 2017, JPRAS OPEN, V12, P9, DOI [10.1016/j.jpra.2017.01.005, DOI 10.1016/J.JPRA.2017.01.005]; Densing K, 2017, J MOTOR BEHAV, P1; EKMAN P, 1969, PSYCHIATR, V32, P88, DOI 10.1080/00332747.1969.11023575; EKMAN P, 1972, J COMMUN, V22, P353, DOI 10.1111/j.1460-2466.1972.tb00163.x; Ekman P., 1974, PSYCHOL DEPRESSION C, P203; FREEDMAN N, 1981, SEMIOTICA, V34, P225, DOI 10.1515/semi.1981.34.3-4.225; FREEDMAN N, 1972, J ABNORM PSYCHOL, V79, P239, DOI 10.1037/h0033162; Freedman N., 1972, STUDIES DYADIC COMMU, P153, DOI [10.1016/b978-0-08-015867-9.50012-5, DOI 10.1016/B978-0-08-015867-9.50012-5]; GOLDBERG S, 1986, J NONVERBAL BEHAV, V10, P65, DOI 10.1007/BF00987206; Grillon C, 1998, J PSYCHOPHYSIOL, V12, P329; Grunwald M, 2001, J CLIN EXP NEUROPSYC, V23, P520, DOI 10.1076/jcen.23.4.520.1229; Grunwald M, 2001, COGNITIVE BRAIN RES, V11, P33, DOI 10.1016/S0926-6410(00)00061-6; Grunwald M, 1999, NEUROSCI LETT, V260, P189, DOI 10.1016/S0304-3940(98)00990-2; Grunwald M, 2014, BRAIN RES, V1557, P111, DOI 10.1016/j.brainres.2014.02.002; Hadlington L, 2004, BRAIN COGNITION, V55, P545, DOI 10.1016/j.bandc.2004.04.001; Hadlington LJ, 2006, BRAIN COGNITION, V61, P159, DOI 10.1016/j.bandc.2005.11.006; HAMPSON E, 1984, CAN J PSYCHOL, V38, P102, DOI 10.1037/h0080787; HARRIGAN JA, 1987, PERS SOC PSYCHOL B, V13, P497, DOI 10.1177/0146167287134007; HARRIGAN JA, 1985, SOC SCI MED, V20, P1161, DOI 10.1016/0277-9536(85)90193-5; Holle H, 2012, P NATL ACAD SCI USA, V109, P19816, DOI 10.1073/pnas.1216160109; JOHANSSON RS, 1988, EXP BRAIN RES, V72, P204, DOI 10.1007/BF00248518; KIMURA D, 1973, NEUROPSYCHOLOGIA, V11, P45, DOI 10.1016/0028-3932(73)90063-8; Lausberg H, 2011, PSYCHOTHER WISS, V1, P41; LAVERGNE J, 1987, NEUROPSYCHOLOGIA, V25, P689, DOI 10.1016/0028-3932(87)90060-1; Leavens DA, 2001, AM J PRIMATOL, V55, P1, DOI 10.1002/ajp.1034; Little JS, 2010, BIOL PSYCHOL, V85, P62, DOI 10.1016/j.biopsycho.2010.05.004; Maier P, 1992, SPRECHWISSENSCHAFT P, P9; Novack MA, 2016, COGNITION, V146, P339, DOI 10.1016/j.cognition.2015.10.014; NOVAK CB, 1993, OTOLARYNG HEAD NECK, V109, P506, DOI 10.1177/019459989310900320; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Parmentier FBR, 2008, COGNITION, V109, P345, DOI 10.1016/j.cognition.2008.09.005; Ricker TJ, 2010, J EXP PSYCHOL LEARN, V36, P1355, DOI 10.1037/a0020356; ROGELS PLJM, 1990, PERCEPT MOTOR SKILL, V70, P1169; RUGGIERI V, 1982, PERCEPT MOTOR SKILL, V54, P1003, DOI 10.2466/pms.1982.54.3.1003; RUGGIERI V, 1982, PERCEPT MOTOR SKILL, V55, P695, DOI 10.2466/pms.1982.55.3.695; Shergill SS, 2001, J NEUROL NEUROSUR PS, V71, P688, DOI 10.1136/jnnp.71.5.688; Siemionow M, 2011, PLAST RECONSTR SURG, V127, P652, DOI 10.1097/PRS.0b013e3181fed6fd; Sorqvist P, 2010, BRAIN COGNITION, V74, P79, DOI 10.1016/j.bandc.2010.06.007; SOUSAPOZA JF, 1979, PERCEPT MOTOR SKILL, V48, P1323, DOI 10.2466/pms.1979.48.3c.1323; Troisi A, 2000, J NERV MENT DIS, V188, P13, DOI 10.1097/00005053-200001000-00003; ULRICH G, 1977, PHARMAKOPSYCH NEURO, V10, P176, DOI 10.1055/s-0028-1094537; ULRICH G, 1985, J AFFECT DISORDERS, V9, P63, DOI 10.1016/0165-0327(85)90011-4; Volosin M, 2014, INT J PSYCHOPHYSIOL, V92, P93, DOI 10.1016/j.ijpsycho.2014.03.003; Wilson-Pauwels L, 2002, CRANIAL NERVES HLTH	51	22	22	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2019	14	3							e0213677	10.1371/journal.pone.0213677	http://dx.doi.org/10.1371/journal.pone.0213677			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HO6JJ	30861049	Green Submitted, Green Published, gold			2023-01-03	WOS:000461035600052
J	Kong, SYJ; Wi, DH; Ro, YS; Shin, SD; Jeong, J; Kim, YJ; Kamgno, J; Alain, EMG; Hollong, B; Oh, YJ				Kong, So Yeon Joyce; Wi, Dae Han; Ro, Young Sun; Shin, Sang Do; Jeong, Joongsik; Kim, Yun Jeong; Kamgno, Joseph; Alain, Etoundi Mballa Georges; Hollong, Bonaventure; Oh, Young Jin			Changes in the healthcare utilization after establishment of emergency centre in Yaounde, Cameroon: A before and after cross-sectional survey analysis	PLOS ONE			English	Article							COUNTRIES	In effort to address the shortage of emergency medical care in Cameroon, the Yaounde Emergency Center (CURY) was established in June, 2015 in Yaounde, Cameroon. To evaluate its impact on the communities of Yaounde, we assessed the changes in utilizations of emergency medical care since the establishment of the CURY. In 2014 the first survey was conducted on randomly selected 619 households (3,201 individuals) living in six health districts of Yaounde. In 2017 the second quantitative survey was conducted on 622 households (3,472 individuals) using the same survey methods as the first survey. In both surveys, data on demographic information, socioeconomic status, and utilization of healthcare, including emergency care in the past year were collected on every member of the households via face-to-face interview. Data on two surveys were compared. Participants in the both surveys had similar age and gender distribution with mean age of 21-22 and 46% being male. In 2014 survey, healthcare utilization rates for emergency unit, outpatient, and hospitalization were 4.8%, 36.7%, and 10.0%, respectively. In 2017 survey, corresponding rates were 5.8%, 32.5%, and 9.2%%, respectively. The increase in the utilization of emergency unit between two surveys showed a marginal statistical significance (p = 0.08), while outpatient utilization showed statistically significant decrease from 2014 to 2017 survey (from 36.7% to 32.5%; p < 0.001). After the establishment of a dedicated emergency medical center in Yaounde, Cameroon, the utilization of emergency care was increased in the Yaounde community. Further studies are warranted to examine the direct effect of the establishment of the CURY on healthcare utilization in Yaounde.	[Kong, So Yeon Joyce; Ro, Young Sun; Shin, Sang Do; Oh, Young Jin] Seoul Natl Univ Hosp, Biomed Res Inst, Lab Emergency Med Serv, Seoul, South Korea; [Kong, So Yeon Joyce; Ro, Young Sun; Shin, Sang Do] Seoul Natl Univ Hosp, Dept Emergency Med, Seoul, South Korea; [Wi, Dae Han] Wonkwang Univ, Sch Med, Dept Emergency Med, Gyeonggi, South Korea; [Wi, Dae Han] Wonkwang Univ, Sanbon Hosp, Gyeonggi, South Korea; [Jeong, Joongsik] Korea Int Cooperat Agcy, Cameroon Off, Yaounde, Cameroon; [Jeong, Joongsik; Hollong, Bonaventure] Yaounde Emergency Ctr, Yaounde, Cameroon; [Kim, Yun Jeong] Kyungpook Natl Univ, Chilkok Hosp, Dept Emergency Med, Daegu, South Korea; [Kamgno, Joseph] Univ Yaounde I, Fac Med & Biomed Sci, Dept Publ Hlth, Yaounde, Cameroon; [Alain, Etoundi Mballa Georges] Minist Publ Hlth, Dis Control Epidem & Pandem, Yaounde, Cameroon	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Wonkwang University; Wonkwang University; Kyungpook National University; University of Yaounde I	Wi, DH (corresponding author), Wonkwang Univ, Sch Med, Dept Emergency Med, Gyeonggi, South Korea.; Wi, DH (corresponding author), Wonkwang Univ, Sanbon Hosp, Gyeonggi, South Korea.	great@wonkwang.ac.kr			Korea International Cooperation Agency (KOICA); Wonkwang university	Korea International Cooperation Agency (KOICA); Wonkwang university	This study was financially supported by the Korea International Cooperation Agency (KOICA). This paper was supported by Wonkwang university in 2017. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bonny A, 2017, INT J EPIDEMIOL, V46, P1230, DOI 10.1093/ije/dyx043; Burke Thomas F, 2014, BMJ Open, V4, pe006132, DOI 10.1136/bmjopen-2014-006132; Chang CY, 2016, EMERG MED J, V33, P794, DOI 10.1136/emermed-2016-205709; HARRIS D R, 1991, World Health Statistics Quarterly, V44, P107; HENDERSON RH, 1982, B WORLD HEALTH ORGAN, V60, P253; Hsia R, 2010, ANN EMERG MED, V56, P142, DOI 10.1016/j.annemergmed.2010.01.013; Juillard C, 2011, WORLD J SURG, V35, P1, DOI 10.1007/s00268-010-0825-5; KEJA K, 1988, World Health Statistics Quarterly, V41, P59; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Obermeyer Z, 2015, B WORLD HEALTH ORGAN, V93, P577, DOI 10.2471/BLT.14.148338; Razzak JA, 2002, B WORLD HEALTH ORGAN, V80, P900; Reynolds TA, 2013, ACAD EMERG MED, V20, P1246, DOI 10.1111/acem.12261; Reynolds TA, 2012, J PUBLIC HEALTH POL, V33, pS126, DOI 10.1057/jphp.2012.41; Ro YS, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014573; WHO, 2015, CAM WHO STAT PROF; World Bank, 2015, WORLD HLTH STAT 2015; World Health Organization, 2017, PREVALENCE OBESITY A; World Health Organization, 2015, WORLD HLTH STAT 2015	19	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2019	14	2							e0211777	10.1371/journal.pone.0211777	http://dx.doi.org/10.1371/journal.pone.0211777			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK7PK	30735533	Green Submitted, gold, Green Published			2023-01-03	WOS:000458181200027
J	Tanaka, M; Hashimoto, K				Tanaka, Mami; Hashimoto, Kenji			Impact of consuming green and yellow vegetables on the depressive symptoms of junior and senior high school students in Japan	PLOS ONE			English	Article							DIETARY PATTERNS; MENTAL-HEALTH; ACADEMIC-PERFORMANCE; BREAKFAST; MIDDLE; RISK; CONSUMPTION; DISORDERS; QUALITY; ADULTS	Adolescent depression is a significant public health concern. Although skipping breakfast is associated with depressive symptoms in adolescents, the effects of dietary patterns on their depressive symptoms remain unknown. Therefore, this study aims to determine whether dietary patterns are associated with depressive symptoms among junior and senior high school students in Japan. A total of 441 junior high school students and 417 senior high school students participated in this study. The Center for Epidemiologic Studies Depression scale (CES-D) was used to measure the participants' depressive symptoms. We surveyed the participants' breakfast consumption pattern, as well as their general dietary patterns (meat, fish, green and yellow vegetables, milk and dairy products, and fruits), using a self-report questionnaire. The results indicated that the senior high school students had a significantly higher CES-D score than the junior high school students. We found negative and significant partial correlations between regular consumption of breakfast and depressive symptoms, and between regular consumption of green and yellow vegetables and depressive symptoms in both junior and senior high school students, after controlling for age, sex, and sleep duration. Furthermore, a one-way analysis of covariance (ANCOVA) revealed that adolescents who consumed green and yellow vegetables every day (one or more times per day) had significantly lower depressive symptoms than those from the "Never/1-2 times a week" group. The findings of this study reveal that the regular consumption of green and yellow vegetables is associated with lower depressive symptoms in adolescents, that is, the consumption of green and yellow vegetables may be vital in the context of adolescents' mental health.	[Tanaka, Mami; Hashimoto, Kenji] Chiba Univ, Ctr Forens Mental Hlth, Chiba, Japan	Chiba University	Tanaka, M (corresponding author), Chiba Univ, Ctr Forens Mental Hlth, Chiba, Japan.	tanaka.mami@chiba-u.jp	Hashimoto, Kenji/I-5800-2015	Hashimoto, Kenji/0000-0002-8892-0439	Japan Society for the Promotion of Science (JSPS) KAKENHI [15K04112, 17H04243]; Strategic Research Program for Brain Sciences from Japan Agency for Medical Research and Development, AMED [JP17dm0107119]	Japan Society for the Promotion of Science (JSPS) KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Strategic Research Program for Brain Sciences from Japan Agency for Medical Research and Development, AMED(Japan Agency for Medical Research and Development (AMED))	This study was partly supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI (to MT, 15K04112, to KH, 17H04243), the Strategic Research Program for Brain Sciences from Japan Agency for Medical Research and Development, AMED (to KH, JP17dm0107119).	Akbaraly TN, 2009, BRIT J PSYCHIAT, V195, P408, DOI 10.1192/bjp.bp.108.058925; Avenevoli S, 2008, HDB DEPRESSION CHILD, P6, DOI [10.1176/ajp.153.6.836, DOI 10.1176/AJP.153.6.836]; Das JK, 2016, J ADOLESCENT HEALTH, V59, pS49, DOI 10.1016/j.jadohealth.2016.06.020; Finan PH, 2013, SLEEP MED REV, V17, P173, DOI 10.1016/j.smrv.2012.03.003; Frojd SA, 2008, J ADOLESCENCE, V31, P485, DOI 10.1016/j.adolescence.2007.08.006; Fujii A, 2016, JAPANESE J HLTH HUMA, V82, P217; Hines AR, 2006, ADOLESCENCE, V41, P597; Itani O, 2016, J CLIN PSYCHIAT, V77, pE860, DOI 10.4088/JCP.15m10044; Jacka FN, 2011, PSYCHOSOM MED, V73, P483, DOI 10.1097/PSY.0b013e318222831a; Jenni OG, 2008, HDB DEV COGNITIVE NE, V2, P807; La Greca AM, 2005, J CLIN CHILD ADOLESC, V34, P49, DOI 10.1207/s15374424jccp3401_5; Lai JS, 2014, AM J CLIN NUTR, V99, P181, DOI 10.3945/ajcn.113.069880; Li Y, 2017, PSYCHIAT RES, V253, P373, DOI 10.1016/j.psychres.2017.04.020; Lien L, 2007, PUBLIC HEALTH NUTR, V10, P422, DOI 10.1017/S1368980007258550; Lucas M, 2014, BRAIN BEHAV IMMUN, V36, P46, DOI 10.1016/j.bbi.2013.09.014; Marin O, 2016, NAT MED, V22, P1229, DOI 10.1038/nm.4225; National Institute of Mental Health, 2017, MENT HLTH INF STAT M; NOLENHOEKSEMA S, 1994, PSYCHOL BULL, V115, P424, DOI 10.1037/0033-2909.115.3.424; O'Sullivan TA, 2009, PUBLIC HEALTH NUTR, V12, P249, DOI 10.1017/S1368980008003935; Oellingrath IM, 2014, PUBLIC HEALTH NUTR, V17, P2554, DOI 10.1017/S1368980013002747; Paus T, 2008, NAT REV NEUROSCI, V9, P947, DOI 10.1038/nrn2513; Raaijmakers LGM, 2010, EUR J PUBLIC HEALTH, V20, P318, DOI 10.1093/eurpub/ckp191; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rahe C, 2014, EUR J NUTR, V53, P997, DOI 10.1007/s00394-014-0652-9; Sampasa-Kanyinga H, 2017, PUBLIC HEALTH, V145, P120, DOI 10.1016/j.puhe.2016.12.027; Sampasa-Kanyinga H, 2014, APPETITE, V79, P76, DOI 10.1016/j.appet.2014.04.007; Shaw ME, 1998, ADOLESCENCE, V33, P851; Shima S., 1985, CLIN PSYCHIATR, V27, P717, DOI DOI 10.11477/MF.1405203967; Smith AP, 1998, INT J FOOD SCI NUTR, V49, P397, DOI 10.3109/09637489809089415; Smith AP, 2003, NUTR NEUROSCI, V6, P59, DOI 10.1080/1028415021000042820; Smith AP, 2002, NUTR NEUROSCI, V5, P141, DOI 10.1080/10284150290018946; Tanaka H, 2002, PSYCHIAT CLIN NEUROS, V56, P235, DOI 10.1046/j.1440-1819.2002.00997.x; Thapar A, 2012, LANCET, V379, P1056, DOI 10.1016/S0140-6736(11)60871-4; Toyomaki A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181057; WEISSMAN MM, 1977, ARCH GEN PSYCHIAT, V34, P98; World Health Organization (WHO), 2017, MAT NEWB CHILD AD HL; Yao W, 2016, SCI REP-UK, V6, DOI 10.1038/srep30659; Yoshiike N, 2007, NUTR REV, V65, P149, DOI 10.1301/nr.2007.apr.149-154; Zhang JC, 2017, J NUTR BIOCHEM, V39, P134, DOI 10.1016/j.jnutbio.2016.10.004	39	4	5	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2019	14	2							e0211323	10.1371/journal.pone.0211323	http://dx.doi.org/10.1371/journal.pone.0211323			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HK5RX	30730901	Green Submitted, gold, Green Published			2023-01-03	WOS:000458026000020
J	Woodhams, EJ; Gilliam, M				Woodhams, Elisabeth J.; Gilliam, Melissa			Contraception	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							30 MU-G; HORMONAL CONTRACEPTION; EXTENDED USE; INTRAUTERINE-DEVICE; ULIPRISTAL ACETATE; ETHINYL ESTRADIOL; CYCLE CONTROL; RISK; EFFICACY; LEVONORGESTREL		[Woodhams, Elisabeth J.] Boston Med Ctr, Boston, MA 02118 USA; [Gilliam, Melissa] Univ Chicago, Chicago, IL 60637 USA	Boston Medical Center; University of Chicago	Woodhams, EJ (corresponding author), Boston Med Ctr, Boston, MA 02118 USA.			Woodhams, Elisabeth/0000-0003-3331-130X	American College of Physicians	American College of Physicians	American College of Physicians.	Ahrendt HJ, 2006, CONTRACEPTION, V74, P451, DOI 10.1016/j.contraception.2006.07.004; American College of Obstetricians and Gynecologists, 2017, CONTR CAR MEAS; American College of Obstetricians and Gynecologists Committee on Obstetric Practice, 2016, Obstet Gynecol, V128, pe32, DOI 10.1097/AOG.0000000000001587; [Anonymous], 2013, Obstet Gynecol, V121, P392, DOI 10.1097/01.AOG.0000426425.33845.b2; [Anonymous], 2011, Obstet Gynecol, V118, P184, DOI 10.1097/AOG.0b013e318227f05e; Arowojolu AO, 2012, COCHRANE DATABASE SY; Bahamondes L, 2015, HUM REPROD UPDATE, V21, P640, DOI 10.1093/humupd/dmv023; Barnhart KT, 2009, FERTIL STERIL, V91, P659, DOI 10.1016/j.fertnstert.2009.01.003; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; Castellano T, 2017, OBSTET GYNECOL SURV, V72, P663, DOI 10.1097/OGX.0000000000000503; Centers for Disease Control and Prevention, 2018, KEY STAT NAT SURV FA; Cibula D, 2010, HUM REPROD UPDATE, V16, P631, DOI 10.1093/humupd/dmq022; Committee on Gynecologic Practice, 2012, Obstet Gynecol, V120, P1239, DOI http://10.1097/AOG.0b013e318277c93b; Creinin MD, 2008, OBSTET GYNECOL, V111, P267, DOI 10.1097/01.AOG.0000298338.58511.d1; Curtis KM, 2016, MMWR RECOMM REP, V65, P3, DOI 10.15585/mmwr.rr6504a1; Cwiak C, 2018, CONTRACEPTIVE TECHNO; Dehlendorf C, 2017, CONTRACEPTION, V95, P452, DOI 10.1016/j.contraception.2016.12.010; Eisenberg DL, 2010, J GEN INTERN MED, V25, P291, DOI 10.1007/s11606-009-1215-2; Finer LB, 2016, NEW ENGL J MED, V374, P843, DOI 10.1056/NEJMsa1506575; Freeman EW, 2002, EUR J CONTRACEP REPR, V7, P27; FREEMAN EW, 2002, EUR J CONTRACEPT S3, V7, P42; Glasier AF, 2010, LANCET, V375, P555, DOI 10.1016/S0140-6736(10)60101-8; Graesslin O, 2008, EUR J CONTRACEP REPR, V13, P4, DOI 10.1080/13625180801942754; Grimes DA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006034.pub2; Grimes DA, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001327; Hanley GE, 2018, AM J OBSTET GYNECOL, V219, DOI 10.1016/j.ajog.2018.05.019; Harada T, 2011, FERTIL STERIL, V95, P1928, DOI 10.1016/j.fertnstert.2011.02.045; Hofmeyr GJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007043.pub2; Hubacher D, 2002, OBSTET GYNECOL SURV, V57, P120, DOI 10.1097/00006254-200202000-00024; Insurance Coverage of Contraceptives, 2018, GUTTM STAT POL BRIEF; Jamieson DJ, 2004, OBSTET GYNECOL, V103, P848, DOI 10.1097/01.AOG.0000123246.11511.e4; Jatlaoui TC, 2016, CONTRACEPTION, V94, P605, DOI 10.1016/j.contraception.2016.05.002; Jayakrishnan K, 2011, J Hum Reprod Sci, V4, P125, DOI 10.4103/0974-1208.92286; Jick SS, 2010, CONTRACEPTION, V81, P16, DOI 10.1016/j.contraception.2009.07.004; Jones RK, 2014, CONTRACEPTION, V90, P416, DOI 10.1016/j.contraception.2014.04.016; Lethaby AE, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002126.pub2; Lockhat FB, 2005, HUM REPROD, V20, P789, DOI 10.1093/humrep/deh650; Lohr PA, 2009, J WOMENS HEALTH, V18, P127, DOI 10.1089/jwh.2008.0809; Lopez LM, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003552.pub3; Lopez LM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006586.pub4; Marchbanks PA, 2002, NEW ENGL J MED, V346, P2025, DOI 10.1056/NEJMoa013202; Marchbanks PA, 2012, CONTRACEPTION, V85, P342, DOI 10.1016/j.contraception.2011.08.007; Marjoribanks J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003855.pub2; McNicholas C, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2017.01.036; Miller L, 2001, OBSTET GYNECOL, V98, P771, DOI 10.1016/S0029-7844(01)01555-1; Milsom I, 2006, HUM REPROD, V21, P2304, DOI 10.1093/humrep/del162; Morch LS, 2017, NEW ENGL J MED, V377, P2228, DOI 10.1056/NEJMoa1700732; Mueck AO, 2010, ENDOCR-RELAT CANCER, V17, pR263, DOI 10.1677/ERC-10-0076; Nelson A, 2018, CONTRACEPTIVE TECHNO; Raymond E, 2018, CONTRACEPTIVE TECHNO; Rosenberg MJ, 1997, CONTRACEPTION, V56, P17, DOI 10.1016/S0010-7824(97)00069-3; Schwartz JL, 2015, OBSTET GYNECOL, V125, P895, DOI 10.1097/AOG.0000000000000721; Shigesato M, 2018, CONTRACEPTION, V97, P264, DOI 10.1016/j.contraception.2017.10.009; Speroff L, 2011, POSTPARTUM PERIOD BR; Stewart FH, 2005, OBSTET GYNECOL, V105, P1389, DOI 10.1097/01.AOG.0000160430.61799.f6; Trussel J, 2018, CONTRACEPTIVE TECHNO; Trussell J., 2018, CONTRACEPTIVE TECHNO, V21st ed.; Trussell J, 2009, CONTRACEPTION, V79, P5, DOI 10.1016/j.contraception.2008.08.003; Warner L, 2018, CONTRACEPTIVE TECHNO; Wildemeersch D, 2007, MATURITAS, V57, P210, DOI 10.1016/j.maturitas.2006.12.004; Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855; Wu JP, 2014, CONTRACEPTION, V89, P495, DOI 10.1016/j.contraception.2014.02.011; Wu W, 2018, CONTRACEPTIVE TECHNO; Zieman M, 2002, FERTIL STERIL, V77, pS13	64	9	9	3	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 5	2019	170	3					ITC17	ITC31		10.7326/AITC201902050	http://dx.doi.org/10.7326/AITC201902050			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK2IZ	30716758				2023-01-03	WOS:000457735100001
J	Long, TE; Williams, CB				Long, Timothy E.; Williams, Christopher B.			Printing nanomaterials in shrinking gels Photopatterning of reactive sites in gels enables arbitrary patterning of nanoparticles	SCIENCE			English	Editorial Material									[Long, Timothy E.; Williams, Christopher B.] Virginia Tech, Dept Chem, Blacksburg, VA 24061 USA	Virginia Polytechnic Institute & State University	Long, TE (corresponding author), Virginia Tech, Dept Chem, Blacksburg, VA 24061 USA.	telong@vt.edu	Williams, Christopher/F-2472-2014	Williams, Christopher/0000-0002-0499-2444				Ali S, 2014, METHOD CELL BIOL, V121, P105, DOI 10.1016/B978-0-12-800281-0.00008-7; Fukuda K, 2017, ADV MATER, V29, DOI 10.1002/adma.201602736; Hu Q, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17391-1; Ma ZC, 2018, SMALL METHODS, V2, DOI 10.1002/smtd.201700413; Marino A, 2015, NANOSCALE, V7, P2841, DOI 10.1039/c4nr06500j; Oran D, 2018, SCIENCE, V362, P1281, DOI 10.1126/science.aau5119; Selimis A, 2015, MICROELECTRON ENG, V132, P83, DOI 10.1016/j.mee.2014.10.001; Skylar-Scott MA, 2016, ADV HEALTHC MATER, V5, P1233, DOI 10.1002/adhm.201600082; Tumbleston JR, 2015, SCIENCE, V347, P1349, DOI 10.1126/science.aaa2397; Zhang YL, 2010, NANO TODAY, V5, P435, DOI 10.1016/j.nantod.2010.08.007	10	6	6	6	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 14	2018	362	6420			SI		1244	1245		10.1126/science.aav5712	http://dx.doi.org/10.1126/science.aav5712			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HE0XV	30545873				2023-01-03	WOS:000452994400016
J	Al Thaher, Y; Yang, LR; Jones, SA; Perni, S; Prokopovich, P				Al Thaher, Yazan; Yang, Lirong; Jones, Steve A.; Perni, Stefano; Prokopovich, Polina			LbL-assembled gentamicin delivery system for PMMA bone cements to prolong antimicrobial activity	PLOS ONE			English	Article							PERIPROSTHETIC JOINT INFECTION; TOTAL HIP; RELEASE; ARTHROPLASTY; MULTILAYERS; COMBINATION; BIOFILMS; PROFILE	Introduction Antibiotic-loaded poly(methyl methacrylate) bone cements (ALBCs) are widely used in total joint replacement (TJR), for local delivery of antibiotics to provide prophylaxis against prosthetic joint infections (PJI). One of the shortcomings of the current generation of ALBCs is that the antibiotic release profile is characterized by a burst over the first few hours followed by a sharp decrease in rate for the following several days (often below minimum inhibitory concentration (MIC)), and, finally, exhaustion (after, typically, similar to 20 d). This profile means that the ALBCs provide only short-term antimicrobial action against bacterial strains involved PJI. Rationale The purpose of the present study was to develop an improved antibiotic delivery system for an ALBC. This system involved using a layer-by-layer technique to load the antibiotic (gentamicin sulphate) (GEN) on silica nanoparticles, which are then blended with the powder of the cement. Then, the powder was mixed with the liquid of the cement (NP-GEN cement). For controls, two GEN-loaded brands were used (Cemex Genta and Palacos R+G). Gentamicin release and a host of other relevant properties were determined for all the cements studied. Results Compared to control cement specimens, improved GEN release, longer antimicrobial activity (against clinically-relevant bacterial strains), and comparable setting time, cytocompatibility, compressive strength (both prior to and after aging in PBS at 37 degrees C for 30 d), 4-point bend strength and modulus, fracture toughness, and PBS uptake. Conclusions NP-GEN cement may have a role in preventing or treating PJI.	[Al Thaher, Yazan; Yang, Lirong; Perni, Stefano; Prokopovich, Polina] Cardiff Univ, Sch Pharm & Pharmaceut Sci, Cardiff, S Glam, Wales; [Jones, Steve A.] Univ Hosp Llandough, Cardiff, S Glam, Wales; [Jones, Steve A.] Vale Univ Hlth Board, Vale Of Glamorgan, Wales	Cardiff University	Prokopovich, P (corresponding author), Cardiff Univ, Sch Pharm & Pharmaceut Sci, Cardiff, S Glam, Wales.	prokopovichp@cf.ac.uk	Yang, Lirong/AAQ-7859-2021; Perni, Stefano/B-8158-2009	Prokopovich, Polina/0000-0002-5700-9570; Perni, Stefano/0000-0002-3101-0098; Al Thaher, Yazan/0000-0002-1643-6605	Philadelphia University (Amman, Jordan)	Philadelphia University (Amman, Jordan)	Funded by Philadelphia University (Amman, Jordan) to Yazan Al Thaher, Polina Prokopovich and Stefano Perni. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aggarwal VK, 2014, J KNEE SURG, V27, P399, DOI 10.1055/s-0033-1364102; Al Thaher Y, 2018, J COLLOID INTERF SCI, V526, P35, DOI 10.1016/j.jcis.2018.04.042; Al Thaher Y, 2017, ADV COLLOID INTERFAC, V249, P234, DOI 10.1016/j.cis.2017.04.017; Alotaibi HF, 2018, CURR OPIN COLLOID IN, V36, P130, DOI 10.1016/j.cocis.2018.02.008; Anagnostakos Konstantinos, 2017, J Bone Jt Infect, V2, P29, DOI 10.7150/jbji.16067; [Anonymous], 2017, UK NATL JOINT REGIST; Ariga K, 2011, ADV DRUG DELIVER REV, V63, P762, DOI 10.1016/j.addr.2011.03.016; Ayre WN, 2016, J BIOMED MATER RES B, V104, P1510, DOI 10.1002/jbm.b.33488; Barrett L, 2014, J ANTIMICROB CHEMOTH, V69, P25, DOI 10.1093/jac/dku250; Bechert T, 2000, NAT MED, V6, P1053, DOI 10.1038/79568; Brimmo O, 2016, J ARTHROPLASTY, V31, P461, DOI 10.1016/j.arth.2015.08.044; Buller LT, 2012, J ARTHROPLASTY, V27, P857, DOI 10.1016/j.arth.2012.01.003; Cenni E, 2002, J BIOMAT SCI-POLYM E, V13, P1283, DOI 10.1163/15685620260449697; Chang Y, 2013, BONE JOINT RES, V2, P220, DOI 10.1302/2046-3758.210.2000188; Chen A, 2014, J ORTHOP RES, V32, pS158, DOI 10.1002/jor.22561; Chuang HF, 2008, BIOMACROMOLECULES, V9, P1660, DOI 10.1021/bm800185h; Cobo J, 2011, PROSTHETIC JOINT INF; Deshmukh PK, 2013, J CONTROL RELEASE, V166, P294, DOI 10.1016/j.jconrel.2012.12.033; Farrar DF, 2001, BIOMATERIALS, V22, P3005, DOI 10.1016/S0142-9612(01)00047-3; Feng W, 2014, ACS APPL MATER INTER, V6, P8447, DOI 10.1021/am501337s; Gbejuade HO, 2015, ACTA ORTHOP, V86, P147, DOI 10.3109/17453674.2014.966290; Gentile P, 2015, NANOTECHNOLOGY, V26, DOI 10.1088/0957-4484/26/42/422001; GRANCHI D, 1995, BIOMATERIALS, V16, P1187, DOI 10.1016/0142-9612(95)93585-2; ISO, 2002, 58332002 ISO; ISO, 2000, 135862000 ISO; Kong LD, 2017, INT WOUND J, V14, P529, DOI 10.1111/iwj.12640; Kremers HM, 2016, J ARTHROPLASTY, V31, P1163, DOI 10.1016/j.arth.2015.12.010; Kurtz SM, 2009, CLIN ORTHOP RELAT R, V467, P2606, DOI 10.1007/s11999-009-0834-6; Letchmanan K, 2017, J MECH BEHAV BIOMED, V72, P163, DOI 10.1016/j.jmbbm.2017.05.003; Liddle AD, 2014, LANCET, V384, P1437, DOI 10.1016/S0140-6736(14)60419-0; Liu XW, 2015, INT J CLIN EXP MED, V8, P27, DOI 10.14257/ijsip.2015.8.11.04; Liu YJ, 2015, POLYM CHEM-UK, V6, P7514, DOI 10.1039/c5py01190f; Mah TFC, 2001, TRENDS MICROBIOL, V9, P34, DOI 10.1016/S0966-842X(00)01913-2; McConoughey SJ, 2014, FUTURE MICROBIOL, V9, P987, DOI [10.2217/FMB.14.64, 10.2217/fmb.14.64]; Minelli EB, 2015, J CHEMOTHERAPY, V27, P17, DOI 10.1179/1973947813Y.0000000157; Nottrott M, 2008, ACTA ORTHOP, V79, P826, DOI 10.1080/17453670810016920; Perni S, 2018, COLLOID SURFACE A, V541, P212, DOI 10.1016/j.colsurfa.2017.04.063; Perni S, 2015, INT J NANOMED, V10, P6317, DOI 10.2147/IJN.S86440; Perni S, 2014, RSC ADV, V4, P51904, DOI 10.1039/c4ra10023a; Pulido L, 2008, CLIN ORTHOP RELAT R, V466, P1710, DOI 10.1007/s11999-008-0209-4; Shen SC, 2016, MAT SCI ENG C-MATER, V58, P233, DOI 10.1016/j.msec.2015.08.011; Shuman EK, 2012, INFECT DIS CLIN N AM, V26, P165, DOI 10.1016/j.idc.2011.09.010; STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021-9797(68)90272-5; Strange S, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1213-8; Swearingen MC, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftv103; Tamanna T, 2015, J MATER SCI-MATER M, V26, DOI 10.1007/s10856-015-5444-0; Tande AJ, 2014, CLIN MICROBIOL REV, V27, P302, DOI 10.1128/CMR.00111-13; Tommasi G, 2016, TISSUE ENG PT A, V22, P862, DOI [10.1089/ten.tea.2016.0014, 10.1089/ten.TEA.2016.0014]; Webb JCJ, 2007, J BONE JOINT SURG BR, V89B, P851, DOI 10.1302/0301-620X.89B7.19148; Wendling A, 2016, BONE JOINT RES, V5, P26, DOI 10.1302/2046-3758.52.2000412; Wiegand I, 2008, NAT PROTOC, V3, P163, DOI 10.1038/nprot.2007.521; Wu K, 2016, J AM ACAD ORTHOP SUR, V24, P188, DOI 10.5435/JAAOS-D-15-00469; Yu T, 2010, COLLOID SURFACE B, V75, P363, DOI 10.1016/j.colsurfb.2009.09.012	53	12	12	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2018	13	12							e0207753	10.1371/journal.pone.0207753	http://dx.doi.org/10.1371/journal.pone.0207753			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE3IL	30543660	Green Submitted, gold, Green Published, Green Accepted			2023-01-03	WOS:000453247500009
J	Petrosyan, Y; Barnsley, JM; Kuluski, K; Liu, B; Wodchis, WP				Petrosyan, Yelena; Barnsley, Jan M.; Kuluski, Kerry; Liu, Barbara; Wodchis, Walter P.			Quality indicators for ambulatory care for older adults with diabetes and comorbid conditions: A Delphi study	PLOS ONE			English	Article							CLINICAL-PRACTICE GUIDELINES; HEALTH-CARE; MELLITUS; MULTIMORBIDITY	Background An increasing number of people are living with multiple chronic conditions and it is unclear which quality indicators should be used to guide care for this population. Objective To critically appraise and select the most appropriate set of quality indicators for ambulatory care for older adults with five selected disease combinations. Methods A two-round web-based Delphi process was used to critically appraise and select quality of care indicators for older adults with diabetes and comorbidities. A fifteen-member Canadian expert panel with broad geographical and clinical representation participated in this study. The panel evaluated process indicators for meaningfulness, potential for improvements in clinical practice, and overall value of inclusion, while outcome indicators were evaluated for importance, modifiability and overall value of inclusion. A 70% agreement threshold was required for high consensus, and 60-69% for moderate consensus as measured on a 5-point Likert type scale. Results Twenty high-consensus and nineteen medium-consensus process and outcome indicators were selected for assessing care for older adults with selected disease combinations, including 1) concordant (conditions with a common management plan), 2) discordant (conditions with unrelated management plans), and 3) both types. Panelists reached rapid consensus on quality indicators for care for older adults with concordant comorbid conditions, but not for those with discordant conditions. All selected indicators assess clinical aspects of care. The feedback from the panelists emphasized the importance of developing indicators related to patient-centred aspects of care, including patient self-management, education, patient-physician relationships, and patient's preferences. Conclusions The selected quality indicators are not intended to provide a comprehensive tool set for measuring quality of care for older adults with selected disease combinations. The recommended indicators address clinical aspects of care and can be used as a starting point for ambulatory care settings and development of additional quality indicators.	[Petrosyan, Yelena] Ottawa Hosp Res Inst, Clin Epidemiol, Ottawa, ON, Canada; [Barnsley, Jan M.; Kuluski, Kerry; Wodchis, Walter P.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Kuluski, Kerry] Sinai Hlth Syst, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada; [Liu, Barbara] Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Wodchis, Walter P.] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Wodchis, Walter P.] Toronto Rehabil Inst, Toronto, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto Rehabilitation Institute	Wodchis, WP (corresponding author), Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.; Wodchis, WP (corresponding author), Inst Clin Evaluat Sci, Toronto, ON, Canada.; Wodchis, WP (corresponding author), Toronto Rehabil Inst, Toronto, ON, Canada.	walter.wodchis@utoronto.ca		wodchis, walter/0000-0003-2494-7031	Canadian Institute for Health Research Community Based Primary Health Care Team Grant [TTF-128263]	Canadian Institute for Health Research Community Based Primary Health Care Team Grant	This work was supported by a research grant from a Canadian Institute for Health Research Community Based Primary Health Care Team Grant (#TTF-128263). There are no other sources of support. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2007, PRACTICAL ASSESSMENT, DOI [DOI 10.1576/T0AG.7.2.120.27071, DOI 10.7275/PDZ9-TH90]; Barkin RL, 2010, DRUG AGING, V27, P775, DOI 10.2165/11539430-000000000-00000; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Barnsley J, 2005, CAN FAM PHYSICIAN, V51, P701; Boulkedid R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020476; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Boyd CM, 2012, PUBLIC HLTH REV, V32, P451; Buchanan D., 2006, CAN J PSYCHIAT, V9, pS52; Campbell SM, 2003, BRIT MED J, V326, P816, DOI 10.1136/bmj.326.7393.816; Canadian Diabetes Association Expert Panel Committee, 2013, CAN J DIABETES, V37, pS168, DOI DOI 10.1016/J.JCJD.2013.01.009; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; Emslie-Smith A., 2003, BR J DIABETES VASC D, V3, P54, DOI [10.1177/14746514030030010901, DOI 10.1177/14746514030030010901]; Fortin M, 2005, ANN FAM MED, V3, P223, DOI 10.1370/afm.272; Fortin M, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-74; Giovannetti ER, 2013, AM J MANAG CARE, V19, pE359; GOODMAN CM, 1987, J ADV NURS, V12, P729, DOI 10.1111/j.1365-2648.1987.tb01376.x; Gruneir A, 2016, CAN J DIABETES, V40, P35, DOI 10.1016/j.jcjd.2015.09.002; Hutchings A, 2005, QUAL SAF HEALTH CARE, V14, P240, DOI 10.1136/qshc.2004.013227; Johnson JA, 2005, CAN J DIABETES, V29, P220; Kim J, 2015, BMJ OPEN DIAB RES CA, V3, DOI 10.1136/bmjdrc-2015-000133; Landeta J, 2006, TECHNOL FORECAST SOC, V73, P467, DOI 10.1016/j.techfore.2005.09.002; Laux G, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-14; Lugtenberg M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025987; Mainz J, 2003, INT J QUAL HEALTH C, V15, P523, DOI 10.1093/intqhc/mzg081; Martirosyan L, 2008, QUAL SAF HEALTH CARE, V17, P318, DOI 10.1136/qshc.2007.024224; McDonnell J., 2001, RANDUCLA APPROPRIATE; Mutasingwa DR, 2011, CAN FAM PHYSICIAN, V57, pE253; Normand SLT, 1998, INT J QUAL HEALTH C, V10, P247, DOI 10.1093/intqhc/10.3.247; Pefoyo AJK, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1733-2; Petrosyan Y, 2018, FAM PRACT, V35, P151, DOI 10.1093/fampra/cmx090; Petrosyan Y, 2017, SYST REV-LONDON, V6, DOI 10.1186/s13643-017-0530-7; Piette JD, 2006, DIABETES CARE, V29, P725, DOI 10.2337/diacare.29.03.06.dc05-2078; RTI International & Telligen. Accountable Care Organization, 2013, QUAL PERF STAND NARR; Ryan M, 2001, Health Technol Assess, V5, P1; Shekelle P, 2007, J AM GERIATR SOC, V55, pS312, DOI 10.1111/j.1532-5415.2007.01337.x; Tran CTT, 2003, CAN J CARDIOL, V19, P38; Young JM, 2014, COLORECTAL DIS, V16, P17, DOI 10.1111/codi.12399	37	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2018	13	12							e0208888	10.1371/journal.pone.0208888	http://dx.doi.org/10.1371/journal.pone.0208888			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HE3IL	30543672	gold, Green Published, Green Submitted			2023-01-03	WOS:000453247500050
J	Pirisinu, M; Blasco, P; Tian, XL; Sen, Y; Bode, AM; Liu, KD; Dong, ZG				Pirisinu, Marco; Blasco, Pilar; Tian, Xueli; Sen, Yang; Bode, Ann M.; Liu, Kangdong; Dong, Zigang			Analysis of hydrophobic and hydrophilic moments of short penetrating peptides for enhancing mitochondrial localization: prediction and validation	FASEB JOURNAL			English	Article						cell-penetrating peptides; molecular dynamics; drug delivery; specificity	CELLULAR UPTAKE; MEMBRANE INTERACTION; SECONDARY STRUCTURE; DRUG-DELIVERY; ACID; ANALOGS; MODELS	Pharmaceutical interest in targeting mitochondria is increasing because of their contribution in incurable diseases. However, the inner mitochondrial layer represents a major hurdle to overcome for most drugs. Penetrating peptides are a promising strategy for drug delivery, but the absence of standard principles and reliable prediction tools limits the design and discovery of sequences with improved organelle specificity. In our hypothesis, peptide local flexibility represents a valuable source to predict peptide performance. Here, a pool of short nonnatural peptides was designed with the same amino acid content but different positioning. Molecular dynamics and membrane-transfer simulations were used to generate the low-energy conformers in extra, intracellular, and membrane-inserted environments. The contributions of the hydrophobic and hydrophilic side chain-exposed surfaces revealed that the amino acid's relative position significantly affected the simulated peptide's dynamics. Based on the structural versatility, we predicted the peptides' behavior and the sequence with the most efficient membrane penetration and mitochondrial localization. The prediction and the improved performance of our peptides were experimentally confirmed and compared with a reported mitochondrial-targeting sequence. We demonstrated that an accurate understanding of the structural versatility is a valid aid for future works in designing sequences with improved mitochondrial targeting.-Pirisinu, M., Blasco, P., Tian, X., Sen, Y., Bode, A. M., Liu, K., Dong, Z. Analysis of hydrophobic and hydrophilic moments of short penetrating peptides for enhancing mitochondrial localization: prediction and validation.	[Pirisinu, Marco; Blasco, Pilar; Tian, Xueli; Sen, Yang; Liu, Kangdong; Dong, Zigang] China US Henan Hormel Canc Inst, Zhengzhou, Henan, Peoples R China; [Pirisinu, Marco; Blasco, Pilar; Bode, Ann M.; Dong, Zigang] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Tian, Xueli; Liu, Kangdong; Dong, Zigang] Zhengzhou Univ, Pathophysiol Dept, Sch Basic Med Sci, Zhengzhou, Henan, Peoples R China; [Liu, Kangdong; Dong, Zigang] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Henan, Peoples R China; [Liu, Kangdong; Dong, Zigang] Canc Chemoprevent Henan, Collaborat Innovat Ctr, Zhengzhou, Henan, Peoples R China	University of Minnesota System; Zhengzhou University; Zhengzhou University	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.; Liu, KD (corresponding author), Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, 127 Dongming Rd, Zhengzhou 450008, Henan, Peoples R China.	kdliu@zzu.edu.cn; zgdong@hi.umn.edu	Pirisinu, Marco/AAR-5399-2021	Pirisinu, Marco/0000-0002-7834-4386; Blasco Morales, Pilar/0000-0001-6703-5417	Key Program of Henan Province [161100510300]; National Natural Science Foundation of China [81572812, 81872335]	Key Program of Henan Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the Key Program of Henan Province (Grant 161100510300) and the National Natural Science Foundation of China (Grants 81572812 and 81872335). The authors declare no conflicts of interest.	Agemy L, 2011, P NATL ACAD SCI USA, V108, P17450, DOI 10.1073/pnas.1114518108; Bayrhuber M, 2008, P NATL ACAD SCI USA, V105, P15370, DOI 10.1073/pnas.0808115105; Bolhassani A, 2011, BBA-REV CANCER, V1816, P232, DOI 10.1016/j.bbcan.2011.07.006; Cabra V, 2006, BBA-PROTEINS PROTEOM, V1764, P1110, DOI 10.1016/j.bbapap.2006.04.002; Cerrato CP, 2015, FASEB J, V29, P4589, DOI 10.1096/fj.14-269225; Dimauro Ivan, 2012, BMC Res Notes, V5, P513, DOI 10.1186/1756-0500-5-513; Eiriksdottir E, 2010, BBA-BIOMEMBRANES, V1798, P1119, DOI 10.1016/j.bbamem.2010.03.005; FAUCHERE JL, 1988, INT J PEPT PROT RES, V32, P269; Fonseca SB, 2011, CHEM BIOL, V18, P445, DOI 10.1016/j.chembiol.2011.02.010; Gautam A, 2012, DATABASE-OXFORD, DOI 10.1093/database/bas015; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Guidotti G, 2017, TRENDS PHARMACOL SCI, V38, P406, DOI 10.1016/j.tips.2017.01.003; Gupta A, 2011, EUR BIOPHYS J BIOPHY, V40, P727, DOI 10.1007/s00249-011-0685-4; Herst PM, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00296; Horton KL, 2008, CHEM BIOL, V15, P375, DOI 10.1016/j.chembiol.2008.03.015; Horton KL, 2012, CHEMBIOCHEM, V13, P476, DOI 10.1002/cbic.201100415; Horton KL, 2009, J MED CHEM, V52, P3293, DOI 10.1021/jm900178n; Huang Y, 2014, PROTEIN CELL, V5, P194, DOI 10.1007/s13238-014-0028-1; Jobin ML, 2015, BBA-BIOMEMBRANES, V1848, P593, DOI 10.1016/j.bbamem.2014.11.013; Kelley SO, 2011, PHARM RES-DORDR, V28, P2808, DOI 10.1007/s11095-011-0530-6; Kovacs JM, 2006, BIOPOLYMERS, V84, P283, DOI 10.1002/bip.20417; Kristensen M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020185; Kuhlbrandt W, 2015, BMC BIOL, V13, DOI 10.1186/s12915-015-0201-x; Leopold P.L., 2016, LYSOSOMES BIOL DIS T, P383; Leung SSF, 2016, J CHEM INF MODEL, V56, P924, DOI 10.1021/acs.jcim.6b00005; Leung SSF, 2012, J CHEM INF MODEL, V52, P1621, DOI [10.1021/ci0120503t, 10.1021/ci200583t]; Mallick S, 2018, COLLOID SURFACE B, V161, P356, DOI 10.1016/j.colsurfb.2017.10.052; Marrache S, 2012, P NATL ACAD SCI USA, V109, P16288, DOI 10.1073/pnas.1210096109; Mellert K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052473; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Mueller J, 2008, BIOCONJUGATE CHEM, V19, P2363, DOI 10.1021/bc800194e; Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010; Oliver M, 2018, RSC ADV, V8, P14597, DOI 10.1039/c8ra02511h; Patterson MJ, 1996, MED MICROBIOLOGY; Pereira MP, 2011, J AM CHEM SOC, V133, P3260, DOI 10.1021/ja110246u; Rezgui R, 2016, BBA-BIOMEMBRANES, V1858, P1499, DOI 10.1016/j.bbamem.2016.03.023; Rink R, 2010, J PHARMACOL TOX MET, V61, P210, DOI 10.1016/j.vascn.2010.02.010; Rydberg HA, 2012, BIOCHEMISTRY-US, V51, P5531, DOI 10.1021/bi300454k; Sandberg M, 1998, J MED CHEM, V41, P2481, DOI 10.1021/jm9700575; Schmid S, 2017, BIOCONJUGATE CHEM, V28, P382, DOI 10.1021/acs.bioconjchem.6b00535; Schmidt N, 2010, FEBS LETT, V584, P1806, DOI 10.1016/j.febslet.2009.11.046; Smith LJ, 1996, FOLD DES, V1, pR95, DOI 10.1016/S1359-0278(96)00046-6; Soomets Ursel, 2005, V298, P241; Sun S, 2017, METHODS MOL BIOL, V1567, P1, DOI 10.1007/978-1-4939-6824-4_1; Verdurmen WPR, 2011, CHEM BIOL, V18, P1000, DOI 10.1016/j.chembiol.2011.06.006; Wang GS, 2009, NUCLEIC ACIDS RES, V37, pD933, DOI 10.1093/nar/gkn823; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Woldetsadik AD, 2017, FASEB J, V31, P2168, DOI 10.1096/fj.201601173R; Yamashita H, 2016, SCI REP-UK, V6, DOI 10.1038/srep33003; Zhao KS, 2004, J BIOL CHEM, V279, P34682, DOI 10.1074/jbc.M402999200; Zheng N, 2017, ACTA BIOMATER, V58, P146, DOI 10.1016/j.actbio.2017.05.001	52	2	2	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2019	33	7					7970	7984		10.1096/fj.201802748RR	http://dx.doi.org/10.1096/fj.201802748RR			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	IJ9SM	30917009	Bronze			2023-01-03	WOS:000476234700014
J	Clarke, PA; Roe, T; Swabey, K; Hobbs, SM; McAndrew, C; Tomlin, K; Westwood, I; Burke, R; van Montfort, R; Workman, P				Clarke, Paul A.; Roe, Toby; Swabey, Kate; Hobbs, Steve M.; McAndrew, Craig; Tomlin, Kathy; Westwood, Isaac; Burke, Rosemary; van Montfort, Robert; Workman, Paul			Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE INHIBITION; MUTATIONS CONFER RESISTANCE; MEK INHIBITION; ACQUIRED-RESISTANCE; ERK1/2 INHIBITOR; COMBINED BRAF; CLINICAL DEVELOPMENT; APOPTOTIC RESPONSE; TUMOR-GROWTH; PI3 KINASE	Genomic alterations in cancer cells result in vulnerabilities that clinicians can exploit using molecularly targeted drugs, guided by knowledge of the tumour genotype. However, the selective activity of these drugs exerts an evolutionary pressure on cancers that can result in the outgrowth of resistant clones. Use of rational drug combinations can overcome resistance to targeted drugs, but resistance may eventually develop to combinatorial therapies. We selected MAPK- and PI3K-pathway inhibition in colorectal cancer as a model system to dissect out mechanisms of resistance. We focused on these signalling pathways because they are frequently activated in colorectal tumours, have well-characterised mutations and are clinically relevant. By treating a panel of 47 human colorectal cancer cell lines with a combination of MEK- and PI3K-inhibitors, we observe a synergistic inhibition of growth in almost all cell lines. Cells with KRAS mutations are less sensitive to PI3K inhibition, but are particularly sensitive to the combined treatment. Colorectal cancer cell lines with inherent or acquired resistance to monotherapy do not show a synergistic response to the combination treatment. Cells that acquire resistance to an MEK-PI3K inhibitor combination treatment still respond to an ERK-PI3K inhibitor regimen, but subsequently also acquire resistance to this combination treatment. Importantly, the mechanisms of resistance to MEK and PI3K inhibitors observed, MEK1/2 mutation or loss of PTEN, are similar to those detected in the clinic. ERK inhibitors may have clinical utility in overcoming resistance to MEK inhibitor regimes; however, we find a recurrent active site mutation of ERK2 that drives resistance to ERK inhibitors in mono- or combined regimens, suggesting that resistance will remain a hurdle. Importantly, we find that the addition of low concentrations of the BCL2-family inhibitor navitoclax to the MEK-PI3K inhibitor regimen improves the synergistic interaction and blocks the acquisition of resistance.	[Clarke, Paul A.; Roe, Toby; Swabey, Kate; Hobbs, Steve M.; McAndrew, Craig; Tomlin, Kathy; Westwood, Isaac; Burke, Rosemary; van Montfort, Robert; Workman, Paul] Inst Canc Res, Canc Res UK Canc Therapeut Unit, London SM2 5NG, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Clarke, PA (corresponding author), Inst Canc Res, Canc Res UK Canc Therapeut Unit, London SM2 5NG, England.	paul.clarke@icr.ac.uk		Clarke, Paul/0000-0001-9342-1290	Cancer Research UK [C309/A11566, C368/A6743, A368/A7990]; Cancer Research UK; Kidani Memorial fund	Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK); Kidani Memorial fund	This work was supported by Cancer Research UK (grant numbers C309/A11566, C368/A6743, and A368/A7990). We acknowledge Cancer Research UK funding to the Cancer Research UK Unit at The Institute of Cancer Research. Paul Workman is a Cancer Research UK Life Fellow. We thank the Kidani Memorial fund for supporting KS. We thank Julian Blagg and Peter Sheldrake for synthesis of CCT245731, and Nicky Evans for editorial assistance.	Aronov AM, 2007, J MED CHEM, V50, P1280, DOI 10.1021/jm061381f; Bean GR, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003483; Blake JF, 2016, J MED CHEM, V59, P5650, DOI 10.1021/acs.jmedchem.6b00389; Chaikuad A, 2014, NAT CHEM BIOL, V10, P853, DOI [10.1038/NCHEMBIO.1629, 10.1038/nchembio.1629]; CHOU TC, 1983, TRENDS PHARMACOL SCI, V4, P450, DOI 10.1016/0165-6147(83)90490-X; Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; de Castro DG, 2013, CLIN PHARMACOL THER, V93, P252, DOI 10.1038/clpt.2012.237; Dreyling M, 2017, J CLIN ONCOL, V35, P3898, DOI 10.1200/JCO.2017.75.4648; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Faber AC, 2014, CANCER DISCOV, V4, P42, DOI 10.1158/2159-8290.CD-13-0315; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Garcia-Garcia C, 2015, CLIN CANCER RES, V21, P5499, DOI 10.1158/1078-0432.CCR-14-3091; Garraway LA, 2012, CANCER DISCOV, V2, P214, DOI 10.1158/2159-8290.CD-12-0012; Garrison Erik, 12073907 ARXIV; Germann UA, 2017, MOL CANCER THER, V16, P2351, DOI 10.1158/1535-7163.MCT-17-0456; Goetz EM, 2014, CANCER RES, V74, P7079, DOI 10.1158/0008-5472.CAN-14-2073; Guillard S, 2009, CELL CYCLE, V8, P443, DOI 10.4161/cc.8.3.7643; Haagensen EJ, 2012, BRIT J CANCER, V106, P1386, DOI 10.1038/bjc.2012.70; Hatzivassiliou G, 2012, MOL CANCER THER, V11, P1143, DOI 10.1158/1535-7163.MCT-11-1010; Hayakawa M, 2006, BIOORGAN MED CHEM, V14, P6847, DOI 10.1016/j.bmc.2006.06.046; Herrero A, 2015, CANCER CELL, V28, P170, DOI 10.1016/j.ccell.2015.07.001; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; Hoeflich KP, 2012, CANCER RES, V72, P210, DOI 10.1158/0008-5472.CAN-11-1515; Holford J, 1998, BRIT J CANCER, V77, P366, DOI 10.1038/bjc.1998.59; Jaiswal BS, 2018, CLIN CANCER RES, V24, P4044, DOI 10.1158/1078-0432.CCR-17-3674; Jha S, 2016, MOL CANCER THER, V15, P548, DOI 10.1158/1535-7163.MCT-15-0172; Johnson DB, 2014, J CLIN ONCOL, V32, P3697, DOI 10.1200/JCO.2014.57.3535; Jokinen E, 2015, THER ADV MED ONCOL, V7, P170, DOI 10.1177/1758834015571111; Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948; Kaserer T, 2018, CELL CHEM BIOL, V25, P1359, DOI 10.1016/j.chembiol.2018.07.013; Konieczkowski DJ, 2018, CANCER CELL, V33, P801, DOI 10.1016/j.ccell.2018.03.025; Kumar R, 2016, J PHARMACEUT BIOMED, V125, P140, DOI 10.1016/j.jpba.2016.03.036; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Mancini M, 2016, SEMIN CELL DEV BIOL, V50, P164, DOI 10.1016/j.semcdb.2015.09.018; Martinelli E, 2013, INT J CANCER, V133, P2089, DOI 10.1002/ijc.28236; Migliardi G, 2012, CLIN CANCER RES, V18, P2515, DOI 10.1158/1078-0432.CCR-11-2683; Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Oddo D, 2016, CANCER RES, V76, P4504, DOI 10.1158/0008-5472.CAN-16-0396; Petigny-Lechartier C, 2017, MOL CANCER THER, V16, P102, DOI 10.1158/1535-7163.MCT-16-0342; Raynaud FI, 2007, CANCER RES, V67, P5840, DOI 10.1158/0008-5472.CAN-06-4615; Raynaud FI, 2009, MOL CANCER THER, V8, P1725, DOI 10.1158/1535-7163.MCT-08-1200; Ren DC, 2010, SCIENCE, V330, P1390, DOI 10.1126/science.1190217; ROY S, 2010, J MOL SIGNAL, V5, DOI DOI 10.1186/1750-2187-5-10; Sale MJ, 2013, BIOCHEM J, V450, P285, DOI 10.1042/BJ20121212; Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Su YW, 2018, BIOCHEM PHARMACOL, V148, P13, DOI 10.1016/j.bcp.2017.11.022; Sullivan RJ, 2018, CANCER DISCOV, V8, P184, DOI 10.1158/2159-8290.CD-17-1119; Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631; Workman P, 2013, CURR OPIN PHARMACOL, V13, P486, DOI 10.1016/j.coph.2013.06.004; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang WS, 2008, NAT CELL BIOL, V10, P125, DOI 10.1038/ncb0208-125; Yap TA, 2012, ANNU REV PHARMACOL, V52, P549, DOI 10.1146/annurev-pharmtox-010611-134532; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhao YJ, 2014, NAT REV CLIN ONCOL, V11, P385, DOI 10.1038/nrclinonc.2014.83; Zunder ER, 2008, CANCER CELL, V14, P180, DOI 10.1016/j.ccr.2008.06.014	62	17	17	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					5076	5090		10.1038/s41388-019-0780-z	http://dx.doi.org/10.1038/s41388-019-0780-z			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30905967	Green Published, hybrid			2023-01-03	WOS:000472145900014
J	Nowacka-Woszuk, J; Grzemski, A; Sliwinska, M; Chmurzynska, A				Nowacka-Woszuk, Joanna; Grzemski, Adrian; Sliwinska, Magdalena; Chmurzynska, Agata			Hepatic DNA methylation and expression profiles under prenatal restricted diet in three generations of female rat fetuses	PLOS ONE			English	Article							CALORIC RESTRICTION; DEVELOPMENTAL ORIGINS; NUTRITION; HEALTH	The nutritional factors acting during early life can affect the development of the organism. It has been hypothesized that such programmed traits can be inherited by later generations. In this work, we present for the first time the effect of food deprivation in pregnant dams and its consequences for the transcription and DNA methylation profiles in the offspring of the next three generations. We used a 50% reduction in dietary intake during pregnancy in the rat and determined whether this altered the hepatic DNA methylation and transcription levels in female fetuses over three generations. Targeted next-generation sequencing (tNGS) was used in the first generation for 1748 genes associated with six selected biological processes. The selected cytosines were then studied by pyrosequencing in F1-F3. The transcript level of the selected genes was determined by the real-time PCR. The tNGS approach indicated 394 cytosines, in close proximity to 374 genes, with a statistically significant difference in methylation levels between the control and restricted groups. A gene clustering analysis revealed 23 molecular pathways to which the studied genes were assigned. Only seven cytosines were differently methylated to more than 10%, and so these sites were studied next using pyrosequencing. The observation from NGS was confirmed for only one cytosine located near the St6galnac5 gene, though this was with the opposite effect. A difference was also observed for the Usp30 gene, though in proximity to the cytosine selected from NGS. In F3, the differences were observed for the Oxct2b gene. We also found differences in methylation levels between generations for the Grb10 and St6galnac5 genes, but independently of the diet used. The transcript levels of selected genes (Usp30, Grb10, Pld1, St6galnac5, Oxct2b, Khk, and Acsl4) were not altered in F1, while changes were detected for Pld1 and Oxct2b in F2 and F3, respectively. Prenatal food deprivation did not induce broad changes in hepatic DNA methylation of the genes involved in lipid or carbohydrate metabolism, and did not result in alterations in their transcription. Thus, the hypothesis that transgenerational inheritance is induced by dietary restriction was not confirmed.	[Nowacka-Woszuk, Joanna; Grzemski, Adrian] Poznan Univ Life Sci, Dept Genet & Anim Breeding, Poznan, Poland; [Sliwinska, Magdalena; Chmurzynska, Agata] Poznan Univ Life Sci, Inst Human Nutr & Dietet, Poznan, Poland	Poznan University of Life Sciences; Poznan University of Life Sciences	Nowacka-Woszuk, J (corresponding author), Poznan Univ Life Sci, Dept Genet & Anim Breeding, Poznan, Poland.	joanna.nowacka-woszuk@up-poznan.pl		Chmurzynska, Agata/0000-0002-2045-0709; , Magdalena/0000-0003-0299-4937; Grzemski, Adrian/0000-0002-0873-9542; Nowacka-Woszuk, Joanna/0000-0002-1041-3576	National Science Centre (Poland) [2013/09/D/NZ2/02006]	National Science Centre (Poland)	All the analysis was funded by the National Science Centre (Poland), project no. 2013/09/D/NZ2/02006. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Araminaite V, 2014, TOHOKU J EXP MED, V234, P41, DOI 10.1620/tjem.234.41; Burdge GC, 2007, BRIT J NUTR, V97, P435, DOI 10.1017/S0007114507352392; Chmurzynska A, 2018, BIOCHIMIE, V152, P181, DOI 10.1016/j.biochi.2018.07.007; Chmurzynska A, 2010, NUTR REV, V68, P87, DOI 10.1111/j.1753-4887.2009.00265.x; Ekamper P, 2014, SOC SCI MED, V119, P232, DOI 10.1016/j.socscimed.2013.10.027; Ganguly A, 2014, J NUTR BIOCHEM, V25, P259, DOI 10.1016/j.jnutbio.2013.10.015; Hanafi MY, 2016, MOL CELL BIOCHEM, V412, P269, DOI 10.1007/s11010-015-2633-6; Hoile SP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021668; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Lagisz M, 2014, OBES REV, V15, P294, DOI 10.1111/obr.12138; Lee S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122115; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Nowacka-Woszuk J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193464; Nowacka-Woszuk J, 2017, BMC GENET, V18, DOI 10.1186/s12863-017-0544-0; Ogawa T, 2014, CONGENIT ANOM, V54, P195, DOI [10.1111/cga.12089, 10.1111/cga.12062]; Ponzio BF, 2012, LIFE SCI, V90, P571, DOI 10.1016/j.lfs.2012.01.017; Radford EJ, 2012, PLOS GENET, V8, P41, DOI 10.1371/journal.pgen.1002605; Ramirez-Lopez MT, 2016, FRONT BEHAV NEUROSCI, V10, DOI 10.3389/fnbeh.2016.00241; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; Schulz LC, 2010, P NATL ACAD SCI USA, V107, P16757, DOI 10.1073/pnas.1012911107; Tobi EW, 2015, INT J EPIDEMIOL, V44, P1211, DOI 10.1093/ije/dyv043; Wilson DF, 2017, J PHYSIOL-LONDON, V595, P7023, DOI 10.1113/JP273839	22	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2019	14	4							e0215471	10.1371/journal.pone.0215471	http://dx.doi.org/10.1371/journal.pone.0215471			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT6TE	30990843	gold, Green Published, Green Submitted			2023-01-03	WOS:000464696100047
J	Salehinejad, MA; Wischnewski, M; Nejati, V; Vicario, CM; Nitsche, MA				Salehinejad, Mohammad Ali; Wischnewski, Miles; Nejati, Vahid; Vicario, Carmelo M.; Nitsche, Michael A.			Transcranial direct current stimulation in attention-deficit hyperactivity disorder: A meta-analysis of neuropsychological deficits	PLOS ONE			English	Article							DORSOLATERAL PREFRONTAL CORTEX; NONINVASIVE BRAIN-STIMULATION; HUMAN MOTOR CORTEX; DEFICIT/HYPERACTIVITY DISORDER; WORKING-MEMORY; RESPONSE-INHIBITION; EXECUTIVE FUNCTIONS; MAJOR DEPRESSION; CHILDREN; ADHD	Transcranial direct current stimulation (tDCS) is a promising method for altering cortical excitability with clinical implications in neuropsychiatric diseases. Its application in neurodevelopmental disorders especially attention-deficit hyperactivity disorder (ADHD), is in early stage and promising but its effectiveness has not been systematically examined yet. We conducted a meta-analysis on the effectiveness of tDCS on the most studied neuropsychological symptoms of ADHD, which is the first reported meta-analysis of tDCS studies on ADHD. Data from 10 randomized controlled studies (including 11 separate experiments) targeting inhibitory control, and/or working memory (WM) in ADHD were included. Results show that overall tDCS significantly improved inhibitory control. Sub-analyses further show that dorsolateral prefrontal cortex (dlPFC) (but not right inferior frontal gyrus) tDCS and anodal (but not cathodal) tDCS significantly improved inhibitory control with a small effect size. Anodal dlPFC-tDCS had the largest significant effect on inhibitory control with a small-to-medium effect size. Additionally, a significant improving effect of tDCS on inhibitory control accuracy (but not response time) and WM speed (but not accuracy) were found. Overall, this meta-analysis supports a beneficial effect of tDCS on inhibitory control and WM in ADHD with a small-to-medium effect size. TDCS seems to be a promising method for improving neuropsychological and cognitive deficits in ADHD. However, there might be a dissociation between neuropsychological deficits and clinical symptoms of ADHD and therefore, the significance of this meta-analysis for clinical purposes is limited. Future studies should systematically evaluate the role of inter-individual factors (i.e., ADHD subtype, types of the deficit) and stimulation parameters (i.e., site, polarity, intensity, duration, repetition rate) on tDCS efficacy in ADHD population and examine whether benefits are long-term.	[Salehinejad, Mohammad Ali] Ruhr Univ Bochum, Int Grad Sch Neurosci, Bochum, Germany; [Salehinejad, Mohammad Ali; Vicario, Carmelo M.; Nitsche, Michael A.] Leibniz Res Ctr Working Environm & Human Factors, Dept Psychol & Neurosci, Dortmund, Germany; [Wischnewski, Miles] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands; [Nejati, Vahid] Shahid Beheshti Univ, Dept Psychol, Tehran, Iran; [Nejati, Vahid] Univ Regensburg, Dept Psychol, Regensburg, Germany; [Vicario, Carmelo M.] Univ Messina, Dept Sci Cognit Formaz & Studi Culturali, Messina, Italy; [Nitsche, Michael A.] Univ Med Hosp Bergmannsheil, Dept Neurol, Bochum, Germany	Ruhr University Bochum; Dortmund University of Technology; Leibniz Institut for Arbeitsforschung an der TU Dortmund (IFADO); Radboud University Nijmegen; Shahid Beheshti University; University of Regensburg; University of Messina; Ruhr University Bochum	Salehinejad, MA (corresponding author), Ruhr Univ Bochum, Int Grad Sch Neurosci, Bochum, Germany.; Salehinejad, MA (corresponding author), Leibniz Res Ctr Working Environm & Human Factors, Dept Psychol & Neurosci, Dortmund, Germany.	salehinejad@ifado.de	Salehinejad, Mohammad Ali/K-6273-2019; Salehinejad, Mohammad Ali/J-8662-2018; Wischnewski, Miles/AGY-3163-2022; VICARIO, CARMELO/AAR-2521-2021	Salehinejad, Mohammad Ali/0000-0003-1913-4677; Salehinejad, Mohammad Ali/0000-0003-1913-4677; Wischnewski, Miles/0000-0002-0056-6464; 	Open Access Fund of the Leibniz Association; National Organization of Science, Research & Technology, Iran [95000171]	Open Access Fund of the Leibniz Association; National Organization of Science, Research & Technology, Iran	Publication of this article was funded by the Open Access Fund of the Leibniz Association. MAS receives support from the National Organization of Science, Research & Technology, Deputy of Scholarship and Students Affairs, Iran, grant number: 95000171. The funder had no role in the study design, data collection, and analysis, decision to publish or preparation of the manuscript.; Publication of this article was funded by the Open Access Fund of the Leibniz Association.	Allenby C, 2018, BRAIN STIMUL, V11, P974, DOI 10.1016/j.brs.2018.04.016; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; Aron AR, 2006, J NEUROSCI, V26, P2424, DOI 10.1523/JNEUROSCI.4682-05.2006; Bandeira ID, 2016, J CHILD NEUROL, V31, P918, DOI 10.1177/0883073816630083; Bastani A, 2012, CLIN NEUROPHYSIOL, V123, P644, DOI 10.1016/j.clinph.2011.08.029; Batsikadze G, 2013, J PHYSIOL-LONDON, V591, P1987, DOI 10.1113/jphysiol.2012.249730; Bikson M, 2016, BRAIN STIMUL, V9, P641, DOI 10.1016/j.brs.2016.06.004; Boggio PS, 2006, J NEUROL SCI, V249, P31, DOI 10.1016/j.jns.2006.05.062; Breitling C, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00072; Brooks BL, 2010, CHILD NEUROPSYCHOL, V16, P80, DOI 10.1080/09297040903146966; Brunoni AR, 2014, BRAIN COGNITION, V86, P1, DOI 10.1016/j.bandc.2014.01.008; Brunoni AR, 2012, BRAIN STIMUL, V5, P175, DOI 10.1016/j.brs.2011.03.002; Bush G, 2005, BIOL PSYCHIAT, V57, P1273, DOI 10.1016/j.biopsych.2005.01.034; Cachoeira CT, 2017, PSYCHIAT RES, V247, P28, DOI 10.1016/j.psychres.2016.11.009; Cai WD, 2018, BIOL PSYCHIAT-COGN N, V3, P263, DOI 10.1016/j.bpsc.2017.10.005; Castellanos FX, 2012, TRENDS COGN SCI, V16, P17, DOI 10.1016/j.tics.2011.11.007; Castellanos FX, 2006, TRENDS COGN SCI, V10, P117, DOI 10.1016/j.tics.2006.01.011; Catala-Lopez F, 2015, SYST REV, V4, DOI 10.1186/s13643-015-0005-7; Cepeda NJ, 2000, J ABNORM CHILD PSYCH, V28, P213, DOI 10.1023/A:1005143419092; Christakou A, 2013, MOL PSYCHIATR, V18, P236, DOI 10.1038/mp.2011.185; Ciechanski P, 2016, PEDIATRIC BRAIN STIMULATION: MAPPING AND MODULATING THE DEVELOPING BRAIN, P85, DOI 10.1016/B978-0-12-802001-2.00005-9; Conners CK., 2000, MULTIHEALTH SYST INC, V29, P175, DOI DOI 10.1207/s15326942dn2901_9; Cortese S, 2016, J AM ACAD CHILD PSY, V55, P444, DOI 10.1016/j.jaac.2016.03.007; Cortese S, 2015, J AM ACAD CHILD PSY, V54, P164, DOI 10.1016/j.jaac.2014.12.010; Cosmo C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135371; Cosmo C, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00111; Daley D, 2014, J AM ACAD CHILD PSY, V53, P835, DOI 10.1016/j.jaac.2014.05.013; Datta Abhishek, 2012, Front Psychiatry, V3, P91, DOI 10.3389/fpsyt.2012.00091; Dedoncker J, 2016, J NEURAL TRANSM, V123, P1159, DOI 10.1007/s00702-016-1558-x; Dedoncker J, 2016, BRAIN STIMUL, V9, P501, DOI 10.1016/j.brs.2016.04.006; Depue BE, 2010, NEUROPSYCHOLOGIA, V48, P3909, DOI 10.1016/j.neuropsychologia.2010.09.013; Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750; El-Hagrassy MM, 2018, ADULT PEDIAT NEUROMO, P151, DOI DOI 10.1007/978-3-319-73266-4_12; Elliott R, 2003, BRIT MED BULL, V65, P49, DOI 10.1093/bmb/65.1.49; Fair DA, 2012, P NATL ACAD SCI USA, V109, P6769, DOI 10.1073/pnas.1115365109; Faraone Stephen V, 2006, MedGenMed, V8, P4; Filmer HL, 2014, TRENDS NEUROSCI, V37, P742, DOI 10.1016/j.tins.2014.08.003; Georgiou G., 2011, ENCY CHILD BEHAV DEV, P705, DOI [10.1007/978-0-387-79061-9_1267, DOI 10.1007/978-0-387-79061-9_1267]; Ghanavati E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40273-7; Ghanavati E, 2018, J COGN ENHANCE, V2, P88, DOI 10.1007/s41465-017-0059-7; Harty S, 2016, TRANSCRANIAL DIRECT, P103; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hill AT, 2016, BRAIN STIMUL, V9, P197, DOI 10.1016/j.brs.2015.10.006; Hoekzema E, 2014, HUM BRAIN MAPP, V35, P1261, DOI 10.1002/hbm.22250; Hoogman Martine, 2017, Lancet Psychiatry, V4, P310, DOI 10.1016/S2215-0366(17)30049-4; Hsu S, 2017, J AM ACAD CHILD PSY, V56, pS282, DOI 10.1016/j.jaac.2017.09.363; Hudec KL, 2015, RES DEV DISABIL, V45-46, P103, DOI 10.1016/j.ridd.2015.07.012; Jamil A, 2017, J PHYSIOL-LONDON, V595, P1273, DOI 10.1113/JP272738; Kalu UG, 2012, PSYCHOL MED, V42, P1791, DOI 10.1017/S0033291711003059; Kasper LJ, 2012, CLIN PSYCHOL REV, V32, P605, DOI 10.1016/j.cpr.2012.07.001; Kessels R P, 2000, Appl Neuropsychol, V7, P252, DOI 10.1207/S15324826AN0704_8; Kuo M.-F., 2016, TRANSCRANIAL DIRECT, P29, DOI [DOI 10.1007/978-3-319-33967-2_3, 10.1007/978-3-319-33967-2_3, DOI 10.4103/0253-7176.198937]; Kuo MF, 2012, CLIN EEG NEUROSCI, V43, P192, DOI 10.1177/1550059412444975; Langleben DD, 2001, NUCL MED COMMUN, V22, P1333, DOI 10.1097/00006231-200112000-00009; Larry H, 1985, STAT METHODS METAANA; Lefaucheur JP, 2017, CLIN NEUROPHYSIOL, V128, P56, DOI 10.1016/j.clinph.2016.10.087; Lefaucheur JP, 2016, NEUROPHYSIOL CLIN, V46, P319, DOI 10.1016/j.neucli.2016.10.002; Lei D, 2015, NEUROPSYCHOLOGY, V29, P874, DOI 10.1037/neu0000200; Marcos-Vidal L, 2018, HUM BRAIN MAPP, V39, P2442, DOI 10.1002/hbm.24013; McCarthy H, 2014, PSYCHOL MED, V44, P869, DOI 10.1017/S0033291713001037; Meron D, 2015, NEUROSCI BIOBEHAV R, V57, P46, DOI 10.1016/j.neubiorev.2015.07.012; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Moliadze V, 2015, BRAIN RES BULL, V119, P25, DOI 10.1016/j.brainresbull.2015.09.011; Molina BSG, 2009, J AM ACAD CHILD PSY, V48, P484, DOI 10.1097/CHI.0b013e31819c23d0; Monte-Silva K, 2013, BRAIN STIMUL, V6, P424, DOI 10.1016/j.brs.2012.04.011; Munz MT, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00307; Nejati V, 2017, NEUROL PSYCHIAT BR, V25, P15, DOI DOI 10.1016/J.NPBR; Nejati V, 2020, J ATTEN DISORD, V24, P1928, DOI 10.1177/1087054717730611; Nejati V, 2018, NEUROSCIENCE, V369, P109, DOI 10.1016/j.neuroscience.2017.10.042; Nigg JT, 2018, J AM ACAD CHILD PSY, V57, P175, DOI 10.1016/j.jaac.2017.12.013; Nigg JT, 2005, BIOL PSYCHIAT, V57, P1424, DOI 10.1016/j.biopsych.2004.11.011; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2003, CLIN NEUROPHYSIOL, V114, P600, DOI 10.1016/S1388-2457(02)00412-1; Nitsche MA, 2009, EXP NEUROL, V219, P14, DOI 10.1016/j.expneurol.2009.03.038; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Polania R, 2011, HUM BRAIN MAPP, V32, P1236, DOI 10.1002/hbm.21104; Prehn-Kristensen A, 2014, BRAIN STIMUL, V7, P793, DOI 10.1016/j.brs.2014.07.036; Price AR, 2015, BRAIN STIMUL, V8, P1093, DOI 10.1016/j.brs.2015.06.013; Roberts M, 2018, PSYCHON B REV, V25, P1423, DOI 10.3758/s13423-017-1407-4; Rosenberg M.S., 2000, METAWIN STAT SOFTWAR; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; Roy A, 2017, J ABNORM CHILD PSYCH, V45, P69, DOI 10.1007/s10802-016-0160-x; Rubia K, 2018, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00100; Rubio B, 2016, J CHILD NEUROL, V31, P784, DOI 10.1177/0883073815615672; Salehinejad MA, 2017, J AFFECT DISORDERS, V210, P241, DOI 10.1016/j.jad.2016.12.036; Samea F, 2019, NEUROSCI BIOBEHAV R, V100, P1, DOI 10.1016/j.neubiorev.2019.02.011; Seidman LJ, 2005, BIOL PSYCHIAT, V57, P1263, DOI 10.1016/j.biopsych.2004.11.019; Sergeant JA, 2003, NEUROSCI BIOBEHAV R, V27, P583, DOI 10.1016/j.neubiorev.2003.08.004; Shah-Basak PP, 2019, PRACTICAL GUIDE TRAN, P597; Shekhawat GS, 2016, NEUROREHAB NEURAL RE, V30, P349, DOI 10.1177/1545968315595286; Shiozawa P, 2014, INT J NEUROPSYCHOPH, V17, P1443, DOI 10.1017/S1461145714000418; Sibley MH, 2014, CLIN PSYCHOL REV, V34, P218, DOI 10.1016/j.cpr.2014.02.001; Soff C, 2017, J NEURAL TRANSM, V124, P133, DOI 10.1007/s00702-016-1646-y; Soltaninejad Z, 2019, J ATTEN DISORD, V23, P325, DOI 10.1177/1087054715618792; Sonuga-Barke EJS, 2005, BIOL PSYCHIAT, V57, P1231, DOI 10.1016/j.biopsych.2004.09.008; Sotnikova A, 2017, BRAIN TOPOGR, V30, P656, DOI 10.1007/s10548-017-0552-4; Stortelder Frans, 2010, J Am Acad Psychoanal Dyn Psychiatry, V38, P503, DOI 10.1521/jaap.2010.38.3.503; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; Vicario CM, 2019, NEUROSCI BIOBEHAV R, V96, P219, DOI 10.1016/j.neubiorev.2018.12.012; Vicario CM, 2019, NEUROTECHNOLOGY AND BRAIN STIMULATION IN PEDIATRIC PSYCHIATRIC AND NEURODEVELOPMENTAL DISORDERS, P217, DOI 10.1016/B978-0-12-812777-3.00009-X; Vicario CM, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00139; Vicario CM, 2010, COGN NEUROSCI-UK, V1, P144, DOI 10.1080/17588921003763969; Visser SN, 2014, J AM ACAD CHILD PSY, V53, P34, DOI 10.1016/j.jaac.2013.09.001; Willcutt EG, 2005, BIOL PSYCHIAT, V57, P1336, DOI 10.1016/j.biopsych.2005.02.006; Wischnewski M, 2019, CEREB CORTEX, V29, P2924, DOI 10.1093/cercor/bhy160; Woods A. J., 2016, TRANSCRANIAL DIRECT, P393, DOI [10.1007/978-3-319-33967-2_26, DOI 10.1007/978-3-319-33967-2_26]; Zhu YC, 2018, NEUROSCI BULL, V34, P566, DOI 10.1007/s12264-018-0214-x	109	55	58	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2019	14	4							e0215095	10.1371/journal.pone.0215095	http://dx.doi.org/10.1371/journal.pone.0215095			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT1UC	30978259	Green Published, gold, Green Submitted			2023-01-03	WOS:000464349000034
J	Soklaridis, S; McCann, M; Waller-Vintar, J; Johnson, A; Wiljer, D				Soklaridis, Sophie; McCann, Miriam; Waller-Vintar, Jacquelyn; Johnson, Andrew; Wiljer, David			Where is the family voice? Examining the relational dimensions of the family-healthcare professional and its perceived impact on patient care outcomes in mental health and addictions	PLOS ONE			English	Article							INFORMATION; INVOLVEMENT	Background We explored the relationship between family members and healthcare professionals (HCPs), specifically how family members can influence the course and outcome of patient care for youth. Exploring this under-researched area provided an opportunity to understand the tripartite relationship between the family, the youth experiencing mental health problems or substance use concerns and their HCP. Methods A qualitative research design was used to gain a full understanding of how family members experience relationships with HCPs. We interviewed 21 family members using semi-structure questions to explore the type of relationships formed between HCPs and family members throughout a patient's course of care, the family member's perceived role in the care of their youth accessing mental health or addiction services and the family member's awareness of formalized structures (i.e., hospital rules, policies) and resources that support family involvement. Results Within a relationship-centred framework, four themes, with various sub-themes emerged from the interviews: 1) The family member-HCP relationship regarding creating a positive impression, being an extension of the patient and the discovery of "pink flags"; 2) The family member-youth-HCP relationship regarding the receptivity of youth to family involvement and a youth's individual right to privacy; 3) The family member's relationship to self with regard to the situation being a family illness; and 4) The family member's relationship with friends, family and peers regarding the feelings of loneliness, stigma and shame and the lack of understanding about mental health problems and substance use. Conclusions Our study provided in-depth information about the importance of family involvement in the care and health outcomes of youth who are accessing mental health and addiction services. Family members experienced and conceptualized their relationships with HCPs, their youth, themselves and their friends and peers as active interactions that influenced the course and outcomes of care. Future studies are needed to collect the multiple perspectives of youth and HCPs alongside with the family perspectives.	[Soklaridis, Sophie; McCann, Miriam; Waller-Vintar, Jacquelyn; Johnson, Andrew] Ctr Addict & Mental Hlth, Toronto, ON, Canada; [Soklaridis, Sophie; Wiljer, David] Univ Toronto, Dept Psychiat, Fac Med, Toronto, ON, Canada; [Soklaridis, Sophie] Univ Toronto, Dept Family & Community Med, Fac Med, Toronto, ON, Canada; [Soklaridis, Sophie] Univ Hlth Network, Wilson Ctr Res Educ, Toronto, ON, Canada; [Soklaridis, Sophie] Univ Toronto, Toronto, ON, Canada; [Wiljer, David] Univ Hlth Network, Toronto, ON, Canada; [Wiljer, David] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Soklaridis, S (corresponding author), Ctr Addict & Mental Hlth, Toronto, ON, Canada.; Soklaridis, S (corresponding author), Univ Toronto, Dept Psychiat, Fac Med, Toronto, ON, Canada.; Soklaridis, S (corresponding author), Univ Toronto, Dept Family & Community Med, Fac Med, Toronto, ON, Canada.; Soklaridis, S (corresponding author), Univ Hlth Network, Wilson Ctr Res Educ, Toronto, ON, Canada.; Soklaridis, S (corresponding author), Univ Toronto, Toronto, ON, Canada.	sophie.soklaridis@camh.ca	Soklaridis, Sophie/ABG-2223-2020	Soklaridis, Sophie/0000-0001-5119-8473; Wiljer, David/0000-0002-2748-2658	Arnold P. Gold Foundation	Arnold P. Gold Foundation	This research project was made possible with a Mapping the Landscape, Journeying Together Grant from The Arnold P. Gold Foundation. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baker KM, 2016, SUBST USE MISUSE, V51, P489, DOI 10.3109/10826084.2015.1126737; Bauer M, 2011, J ADV NURS, V67, P1232, DOI 10.1111/j.1365-2648.2010.05575.x; Baxter B, 2010, EVAL PROGRAM PLANN, V33, P39, DOI 10.1016/j.evalprogplan.2009.05.011; Biswas A, 2015, MED TEACH, V37, P309, DOI 10.3109/0142159X.2014.960378; Bogart T, 1999, PSYCHIATR SERV, V50, P1321, DOI 10.1176/ps.50.10.1321; Bos AER, 2013, BASIC APPL SOC PSYCH, V35, P1, DOI 10.1080/01973533.2012.746147; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Burt R. S., 2005, BROKERAGE CLOSURE IN; Cleary M, 2005, AUST NZ J PSYCHIAT, V39, P507, DOI 10.1111/j.1440-1614.2005.01611.x; Dokken Deborah, 2006, Pediatr Nurs, V32, P562; Eassom E, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006108; Ferguson G, 2018, ACAD PSYCHIATR, V42, P329, DOI 10.1007/s40596-017-0878-y; Goffman E., 1959, PRESENTATION SELF EV, P259; Government Alberta, 2018, WHAT WE HEARD PART 2; Greenhalgh R, 2002, BRIT J GEN PRACT, V52, P395; Jubb Maureen, 2002, Int J Ment Health Nurs, V11, P47, DOI 10.1046/j.1440-0979.2002.00225.x; Kosovski JR, 2011, SUBST USE MISUSE, V46, P852, DOI 10.3109/10826084.2011.570610; Malterud K, 2016, QUAL HEALTH RES, V26, P1753, DOI 10.1177/1049732315617444; McGilton K, 2008, J APPL GERONTOL, V28, P723, DOI 10.1177%2F0733464809336088; McGinty EE, 2016, HEALTH AFFAIR, V35, P1121, DOI 10.1377/hlthaff.2016.0011; Moretz Julie Ginn, 2007, Pediatr Nurs, V33, P356; Nolan M., 2012, RELATIONSHIP CTR CAR; Rider EA, 2011, PEDIATR ANN, V40, P447, DOI 10.3928/00904481-20110815-08; Rolland JS, 2015, FAM SYST HEALTH, V33, P104, DOI 10.1037/fsh0000133; Rose LE, 2004, J NURS SCHOLARSHIP, V36, P39, DOI 10.1111/j.1547-5069.2004.04009.x; Ross AM, 2019, SOC PSYCH PSYCH EPID, V54, P11, DOI 10.1007/s00127-018-1608-9; Simpson EL, 2003, BRIT J PSYCHIAT, V183, P89, DOI 10.1192/bjp.183.2.89; Slade M, 2007, BRIT J PSYCHIAT, V190, P148, DOI 10.1192/bjp.bp.106.024935; Soklaridis S, 2016, J PATIENT EXP, V3, P130; Soklaridis S, 2017, J INTERPROF CARE, V31, P122, DOI 10.1080/13561820.2016.1233393; Velleman RDB, 2005, DRUG ALCOHOL REV, V24, P93, DOI 10.1080/09595230500167478	31	9	9	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2019	14	4							e0215071	10.1371/journal.pone.0215071	http://dx.doi.org/10.1371/journal.pone.0215071			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HT1UC	30978230	Green Published, Green Submitted, gold			2023-01-03	WOS:000464349000033
J	Germonpre, P; Van den Wyngaert, T				Germonpre, Paul; Van den Wyngaert, Tim			Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability	PLOS ONE			English	Article							PHASE-III TRIAL; OPEN-LABEL; DOCETAXEL; MULTICENTER; EXPRESSION; GEFITINIB; INSTITUTE; EFFICACY; THERAPY; TAILOR	Introduction Little data is available on patients with advanced non-squamous NSCLC treated with erlotinib specifically after failure of first-line pemetrexed-containing chemotherapy. We assessed the effectiveness, safety and tolerability of erlotinib in a real-world setting. Methods Prospective single-arm, open-label, multicenter, non-interventional study of erlotinib (150mg daily) in inoperable stage III/IV NSCLC after progression on first-line pemetrexed-containing chemotherapy without EGFR-mutation selection. Patients were followed according to routine practice and response assessment was performed using RECIST 1.1. The primary end point was progression-free survival (PFS). Secondary end points included best confirmed overall response rate (ORR), disease control rate (DCR), and overall survival (OS). Adverse events were recorded. An independent dataset was used to validate the results. Results In all, 59 patients were screened, 57 enrolled, and 54 (36 men; median age 65 years) included in the per-protocol analysis. Median PFS was 1.8 (95% CI 1.4-2.6) months, with 11% (95% CI 5-21%) alive and progression-free at 6 months. The ORR was 0.0% (97.5% CI 0.0-6.8%) and the DCR 34.6% (95% CI 21.9-49.0%). Median overall survival was 5.8 (95% CI 3.3-8.6) months with 28% (95% CI 17-42%) alive at one year. Rash occurred in 60.7% (95% CI 46.7-73.5%), with severe rash in 12.5% (95% CI 5.1-24.1%). Any grade diarrhea was observed in 42.8% (95% CI 29.7-56.8%), with grade 3 occurring in 7.1% (95% CI 1.9-17.2%). Erlotinib was stopped in 21.0% (95% CI 11.3-33.9%) of patients due to adverse events, which were treatment related in 7%. Conclusion Second-line erlotinib after pemetrexed treatment results in similar real-world outcomes as reported after non-pemetrexed containing first-line therapy. However, the overall duration of response in unselected patients remains limited and other effective treatments have in the meantime been introduced. No new safety signals were detected.	[Germonpre, Paul; Van den Wyngaert, Tim] Univ Antwerp, Fac Med & Hlth Sci, Antwerp, Belgium; [Germonpre, Paul] AZ Maria Middelares, Dept Pneumol, Ghent, Belgium; [Van den Wyngaert, Tim] Antwerp Univ Hosp, Dept Nucl Med, Edegem, Belgium	University of Antwerp; University of Antwerp	Van den Wyngaert, T (corresponding author), Univ Antwerp, Fac Med & Hlth Sci, Antwerp, Belgium.; Van den Wyngaert, T (corresponding author), Antwerp Univ Hosp, Dept Nucl Med, Edegem, Belgium.	tim.van.den.wyngaert@uza.be	Van den Wyngaert, Tim/C-7050-2017	Van den Wyngaert, Tim/0000-0002-0320-9075	Roche (Naamloze Vennootschap [NV]/Societe Anonyme [SA])	Roche (Naamloze Vennootschap [NV]/Societe Anonyme [SA])	This study was sponsored by Roche (Naamloze Vennootschap [NV]/Societe Anonyme [SA]). The analysis of the trial data and writing of the manuscript was performed by the academic authors. The sponsor approved the final version of the manuscript, but had no role in interpretation of the study results. TVdW received remuneration from NV Roche SA for statistical analysis for this project. PG has received honoraria from Roche NV/SA. No additional external funding received for this study.	Bezjak A, 2006, J CLIN ONCOL, V24, P3831, DOI 10.1200/JCO.2006.05.8073; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Ciuleanu T, 2012, LANCET ONCOL, V13, P300, DOI 10.1016/S1470-2045(11)70385-0; Clark GM, 2006, CLIN LUNG CANCER, V7, P389, DOI 10.3816/CLC.2006.n.022; COX DR, 1972, J R STAT SOC B, V34, P187; Crequit P, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0954-x; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; European Medicines Agency, 2017, TARC EPAR PROD INF 2; Garassino MC, 2013, LANCET ONCOL, V14, P981, DOI 10.1016/S1470-2045(13)70310-3; Green AK, 2015, ONCOLOGIST, V20, P464, DOI 10.1634/theoncologist.2014-0431; Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163; Hanna N, 2017, J CLIN ONCOL; Heigener DF, 2011, LUNG CANCER, V74, P274, DOI 10.1016/j.lungcan.2011.02.017; Hosmer DW, 1999, APPL SURVIVAL ANAL; Karampeazis A, 2013, CANCER-AM CANCER SOC, V119, P2754, DOI 10.1002/cncr.28132; Kawaguchi T, 2014, J CLIN ONCOL, V32, P1902, DOI 10.1200/JCO.2013.52.4694; Kim ES, 2008, LANCET, V372, P1809, DOI 10.1016/S0140-6736(08)61758-4; Malvezzi M, 2015, ANN ONCOL, V26, P779, DOI 10.1093/annonc/mdv001; Maruyama R, 2008, J CLIN ONCOL, V26, P4244, DOI 10.1200/JCO.2007.15.0185; Moro-Sibilot D, 2014, LUNG CANCER, V84, P315, DOI 10.1016/j.lungcan.2014.03.019; Natale RB, 2011, J CLIN ONCOL, V29, P1059, DOI 10.1200/JCO.2010.28.5981; National Cancer Institute National Institutes of Health, COMM TERM CRIT ADV E; National Comprehensive Cancer Network, NONSM CELL LUNG CANC; Park CK, 2018, ONCOLOGY-BASEL, V94, P373, DOI 10.1159/000486896; Reck M, 2010, J THORAC ONCOL, V5, P1616, DOI 10.1097/JTO.0b013e3181f1c7b0; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Scagliotti GV, 2012, J CLIN ONCOL, V30, P2070, DOI 10.1200/JCO.2011.39.2993; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Soria JC, 2015, LANCET ONCOL, V16, P897, DOI 10.1016/S1470-2045(15)00006-6; Thatcher N, 2009, ONCOLOGIST, V14, P840, DOI 10.1634/theoncologist.2009-0055; Weiss GJ, 2007, ANN ONCOL, V18, P453, DOI 10.1093/annonc/mdl454	31	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2019	14	4							e0215135	10.1371/journal.pone.0215135	http://dx.doi.org/10.1371/journal.pone.0215135			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HS8BQ	30973926	gold, Green Published, Green Submitted			2023-01-03	WOS:000464095000043
J	Vloothuis, JDM; Mulder, M; Nijland, RHM; Goedhart, QS; Konijnenbelt, M; Mulder, H; Hertogh, CMPM; van Tulder, M; van Wegen, EEH; Kwakkel, G				Vloothuis, Judith D. M.; Mulder, Marijn; Nijland, Rinske H. M.; Goedhart, Quirine S.; Konijnenbelt, Manin; Mulder, Henry; Hertogh, Cees M. P. M.; van Tulder, Maurits; van Wegen, Erwin E. H.; Kwakkel, Gert			Caregiver-mediated exercises with e-health support for early supported discharge after stroke (CARE4STROKE): A randomized controlled trial	PLOS ONE			English	Article							REHABILITATION; RECOVERY; ANXIETY; IMPACT; EXPERIENCES; PREVALENCE; CONSENSUS; SYMPTOMS	Background and purpose We designed an 8-week caregiver-mediated exercise program with e-health support after stroke (CARE4STROKE) in addition to usual care with the aim to improve functional outcome and to facilitate early supported discharge by increasing the intensity of task specific training. Methods An observer-blinded randomized controlled trial in which 66 stroke patient-caregiver couples were included during inpatient rehabilitation. Patients allocated to the CARE4STROKE program trained an additional amount of 150 minutes a week with a caregiver and were compared to a control group that received usual care alone. Primary outcomes: self-reported mobility domain of the Stroke Impact Scale 3.0 (SIS) and length of stay (LOS). Secondary outcomes: motor impairment, strength, walking ability, balance, mobility and (Extended) Activities of Daily Living of patients, caregiver strain of caregivers, and mood, self-efficacy, fatigue and quality of life of both patients and caregivers. Outcomes were assessed at baseline, 8 and 12 weeks after randomization. Results No significant between-group differences were found regarding SIS-mobility after 8 (beta 6.21, SD 5.16; P = 0.229) and 12 weeks (beta 0.14, SD 2.87; P = 0.961), and LOS (P = 0.818). Significant effects in favor of the intervention group were found for patient's anxiety (beta 2.01, SD 0.88; P = 0.023) and caregiver's depression (beta 2.33, SD 0.77; P = 0.003) post intervention. Decreased anxiety in patients remained significant at the 12-week follow-up (beta 1.01, SD 0.40; P = 0.009). Conclusions This proof-of concept trial did not find significant effects on both primary outcomes mobility and LOS as well as the secondary functional outcomes. Treatment contrast in terms of total exercise time may have been insufficient to achieve these effects. However, caregiver-mediated exercises showed a favorable impact on secondary outcome measures of mood for both patient and caregiver.	[Vloothuis, Judith D. M.; Nijland, Rinske H. M.; Konijnenbelt, Manin; Kwakkel, Gert] Reade, Amsterdam Rehabil Res Ctr, Amsterdam, Netherlands; [Vloothuis, Judith D. M.; Mulder, Marijn; Goedhart, Quirine S.; van Wegen, Erwin E. H.; Kwakkel, Gert] Vrije Univ Amsterdam, Amsterdam UMC, Dept Rehabil Med, Amsterdam Neurosci, Amsterdam, Netherlands; [Vloothuis, Judith D. M.; Mulder, Marijn; Goedhart, Quirine S.; van Wegen, Erwin E. H.; Kwakkel, Gert] Vrije Univ Amsterdam, Amsterdam UMC, Amsterdam Movement Sci, Amsterdam, Netherlands; [Mulder, Henry] AptaVivar, Hengelo, Netherlands; [Hertogh, Cees M. P. M.] Vrije Univ Amsterdam, Amsterdam UMC, Dept Gen Practice & Elderly Care Med, Amsterdam, Netherlands; [Hertogh, Cees M. P. M.] Vrije Univ Amsterdam, Amsterdam UMC, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [van Tulder, Maurits] Vrije Univ Amsterdam, Fac Sci, Dept Hlth Sci, Amsterdam, Netherlands; [van Tulder, Maurits] Vrije Univ Amsterdam, Fac Sci, Amsterdam Movement Sci, Amsterdam, Netherlands; [van Tulder, Maurits] Aarhus Univ Hosp, Dept Physiotherapy & Occupat Therapy, Aarhus, Denmark; [Kwakkel, Gert] Northwestern Univ, Dept Phys Therapy & Human Movement Sci, Evanston, IL USA	University of Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Aarhus University; Northwestern University	van Wegen, EEH (corresponding author), Vrije Univ Amsterdam, Amsterdam UMC, Dept Rehabil Med, Amsterdam Neurosci, Amsterdam, Netherlands.; van Wegen, EEH (corresponding author), Vrije Univ Amsterdam, Amsterdam UMC, Amsterdam Movement Sci, Amsterdam, Netherlands.	e.vanwegen@vumc.nl	Janson, Patrick/AAC-7581-2022; van Tulder, Maurits/AAB-9785-2022	van Tulder, Maurits/0000-0002-7589-8471; Kwakkel, Gert/0000-0002-4041-4043; van Wegen, Erwin/0000-0002-7920-9995	Netherlands Organization of Health Research and Development (ZonMW) [837001408, 606300098012]; AptaVivar; ZonMW [837001408, 606300098012]	Netherlands Organization of Health Research and Development (ZonMW)(Netherlands Organization for Health Research and Development); AptaVivar; ZonMW(Netherlands Organization for Health Research and Development)	This study was funded by the Netherlands Organization of Health Research and Development (ZonMW - www.zonmw.nl) grant number 837001408 (2013) and grant number 606300098012 (2015) Both grants were awarded to GK and EvW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. AptaVivar provided support in the form of salary for author HM, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of this author are articulated in the 'author contributions' section.; We would like to thank all participating patient-caregiver couples and the staff of all the participating centers involved in the CARE4STROKE program. In addition, we would like to thank ZonMW (grant number 837001408 and 606300098012) for providing financial support for this project.	Ahn C, 2010, J INVEST MED, V58, P277, DOI 10.2310/JIM.0b013e3181c9b2d4; [Anonymous], 1989, Stroke, V20, P1407; Bernhardt J, 2017, INT J STROKE, V12, P444, DOI 10.1177/1747493017711816; Beunder Carolina, 2015, Tijdschr Gerontol Geriatr, V46, P196, DOI 10.1007/s12439-015-0139-z; Bian ZX, 2011, ANN INTERN MED, V154, P290, DOI 10.7326/0003-4819-154-4-201102150-00016; Boyd Lara A, 2017, Int J Stroke, V12, P480, DOI 10.1177/1747493017714176; Brasel KJ, 2007, ARCH SURG-CHICAGO, V142, P461, DOI 10.1001/archsurg.142.5.461; Cumming TB, 2016, AM J GERIAT PSYCHIAT, V24, P154, DOI 10.1016/j.jagp.2015.06.003; Dobkin BH, 2017, STROKE, V48, P2329, DOI 10.1161/STROKEAHA.117.016620; Donnellan C, 2010, INT J GERIATR PSYCH, V25, P1288, DOI 10.1002/gps.2482; Duncan PW, 2003, ARCH PHYS MED REHAB, V84, P950, DOI 10.1016/S0003-9993(03)00035-2; Duncan PW, 2002, STROKE, V33, P2593, DOI 10.1161/01.STR.0000034395.06874.3E; Fearon P, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000443.pub3; Fisher RJ, 2011, STROKE, V42, P1392, DOI 10.1161/STROKEAHA.110.606285; Forster A, 2013, LANCET, V382, P2069, DOI 10.1016/S0140-6736(13)61603-7; Galvin R, 2011, STROKE, V42, P681, DOI 10.1161/STROKEAHA.110.594689; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Kruithof WJ, 2016, PATIENT EDUC COUNS, V99, P1632, DOI 10.1016/j.pec.2016.04.007; Kruithof WJ, 2015, CLIN REHABIL, V29, P1224, DOI 10.1177/0269215515570378; Kwakkel G, 2017, LANCET, V390, P538, DOI 10.1016/S0140-6736(17)31489-7; Langhorne P, 2017, HEALTH TECHNOL ASSES, V21, DOI 10.3310/hta21540; Langhorne P, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000443.pub4; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Lin KC, 2010, NEUROREHAB NEURAL RE, V24, P486, DOI 10.1177/1545968309356295; Lindley RI, 2017, LANCET, V390, P588, DOI [10.1016/S0140-6736(17)31447-2, 10.1016/s0140-6736(17)31447-2]; Loh AZ, 2017, J AM MED DIR ASSOC, V18, P111, DOI 10.1016/j.jamda.2016.08.014; Lohse KR, 2014, STROKE, V45, P2053, DOI 10.1161/STROKEAHA.114.004695; Luengo-Fernandez R, 2012, STROKE, V43, P3343, DOI 10.1161/STROKEAHA.112.667204; Lutz BJ, 2011, TOP STROKE REHABIL, V18, P786, DOI 10.1310/tsr1806-786; Otterman NM, 2012, STROKE, V43, P2395, DOI 10.1161/STROKEAHA.112.660092; Plant S, 2018, CLIN REHABIL, V32, P263, DOI 10.1177/0269215517719485; Saka O, 2009, STROKE, V40, P24, DOI 10.1161/STROKEAHA.108.518043; Smid DE, 2017, J AM MED DIR ASSOC, V18, P53, DOI 10.1016/j.jamda.2016.08.002; Tang WK, 2013, ARCH PHYS MED REHAB, V94, P2535, DOI 10.1016/j.apmr.2013.07.012; van de Port IGL, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2672; van de Port IGL, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-43; van den Berg M, 2016, STROKE, V47, P1885, DOI 10.1161/STROKEAHA.116.013431; Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987; Vloothuis J, 2018, DISABILITY REHABILIT; Vloothuis J, 2018, PHYSIOTHER RES INT, V23, DOI 10.1002/pri.1719; Vloothuis J, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0440-z; Vloothuis JDM, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011058.pub2; Walker MF, 2017, INT J STROKE, V12, P472, DOI 10.1177/1747493017711815; Winters C, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1592-x	45	25	25	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2019	14	4							e0214241	10.1371/journal.pone.0214241	http://dx.doi.org/10.1371/journal.pone.0214241			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HS2MY	30958833	Green Submitted, Green Published, gold			2023-01-03	WOS:000463695900009
J	Pell, CL; Adhikari, B; Thwin, MM; Kajeechiwa, L; Nosten, S; Nosten, FH; Sahan, KM; Smithuis, FM; Nguyen, TN; Hien, TT; Tripura, R; Peto, TJ; Sanann, N; Nguon, C; Pongvongsa, T; Phommasone, K; Mayxay, M; Mukaka, M; Peerawaranun, P; Kaehler, N; Cheah, PY; Day, NPJ; White, NJ; Dondorp, AM; von Seidlein, L				Pell, Christopher L.; Adhikari, Bipin; Thwin, May Myo; Kajeechiwa, Ladda; Nosten, Suphak; Nosten, Francois H.; Sahan, Kate M.; Smithuis, Frank M.; Thuy-Nhien Nguyen; Tran Tinh Hien; Tripura, Rupam; Peto, Thomas J.; Sanann, Nou; Nguon, Chea; Pongvongsa, Tiengkham; Phommasone, Koukeo; Mayxay, Mayfong; Mukaka, Mavuto; Peerawaranun, Pimnara; Kaehler, Nils; Cheah, Phaik Yeong; Day, Nicholas P. J.; White, Nicholas J.; Dondorp, Arjen M.; von Seidlein, Lorenz			Community engagement, social context and coverage of mass anti-malarial administration: Comparative findings from multi-site research in the Greater Mekong sub-Region	PLOS ONE			English	Article							PLASMODIUM-FALCIPARUM; ARTEMISININ RESISTANCE; DRUG ADMINISTRATIONS; VACCINE TRIAL; MALARIA; EPIDEMIOLOGY; ELIMINATION; INFECTIONS; PERCEPTIONS; DEVIANCE	Background Between 2013 and 2017, targeted malaria elimination (TME), a package of interventions that includes mass drug administration (MDA)-was piloted in communities with reservoirs of asymptomatic P. falciparum across the Greater Mekong sub-Region (GMS). Coverage in target communities is a key determinant of the effectiveness of MDA. Drawing on mixed methods research conducted alongside TME pilot studies, this article examines the impact of the community engagement, local social context and study design on MDA coverage. Methods and findings Qualitative and quantitative data were collected using questionnaire-based surveys, semistructured and in-depth interviews, focus group discussions, informal conversations, and observations of study activities. Over 1500 respondents were interviewed in Myanmar, Vietnam, Cambodia and Laos. Interview topics included attitudes to malaria and experiences of MDA. Overall coverage of mass anti-malarial administration was high, particularly participation in at least a single round (85%). Familiarity with and concern about malaria prompted participation in MDA; as did awareness of MDA and familiarity with the aim of eliminating malaria. Fear of adverse events and blood draws discouraged people. Hence, community engagement activities sought to address these concerns but their impact was mediated by the trust relationships that study staff could engender in communities. In contexts of weak healthcare infrastructure and (cash) poverty, communities valued the study's ancillary care and the financial compensation. However, coverage did not necessarily decrease in the absence of cash compensation. Community dynamics, affected by politics, village conformity, and household decision-making also affected coverage. Conclusions The experimental nature of TME presented particular challenges to achieving high coverage. Nonetheless, the findings reflect those from studies of MDA under implementation conditions and offer useful guidance for potential regional roll-out of MDA: it is key to understand target communities and provide appropriate information in tailored ways, using community engagement that engenders trust.	[Pell, Christopher L.] AIGHD, Amsterdam, Netherlands; [Pell, Christopher L.] Univ Amsterdam, Ctr Social Sci & Global Hlth, Amsterdam, Netherlands; [Adhikari, Bipin; Tripura, Rupam; Peto, Thomas J.; Sanann, Nou; Mukaka, Mavuto; Peerawaranun, Pimnara; Kaehler, Nils; Cheah, Phaik Yeong; Day, Nicholas P. J.; White, Nicholas J.; Dondorp, Arjen M.; von Seidlein, Lorenz] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand; [Adhikari, Bipin; Nosten, Francois H.; Tripura, Rupam; Peto, Thomas J.; Mayxay, Mayfong; Cheah, Phaik Yeong; Day, Nicholas P. J.; White, Nicholas J.; Dondorp, Arjen M.; von Seidlein, Lorenz] Univ Oxford, Nuffield Dept Med, Ctr Trop Med & Global Hlth, Oxford, England; [Thwin, May Myo; Kajeechiwa, Ladda; Nosten, Suphak; Nosten, Francois H.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Shoklo Malaria Res Unit, Mae Sot, Thailand; [Nosten, Francois H.] UPMC Univ Paris 06, UPMC, Sorbonne Univ, UMRS CR7, Paris, France; [Sahan, Kate M.; Cheah, Phaik Yeong] Univ Oxford, Ethox Ctr, Oxford, England; [Sahan, Kate M.; Cheah, Phaik Yeong] Univ Oxford, Li Ka Shing Ctr Hlth Informat & Discovery, Nuffield Dept Populat Hlth, Wellcome Ctr Eth & Humanities,Big Data Inst, Oxford, England; [Smithuis, Frank M.] Med Act Myanmar, Yangon, Myanmar; [Smithuis, Frank M.] Myanmar Oxford Clin Res Unit, Yangon, Myanmar; [Thuy-Nhien Nguyen; Tran Tinh Hien] Univ Oxford, Clin Res Unit, Wellcome Trust Asia Programme, Ho Chi Minh City, Vietnam; [Nguon, Chea] Natl Ctr Parasitol Entomol & Malaria Control, Phnom Penh, Cambodia; [Pongvongsa, Tiengkham] Savannakhet Prov Hlth Dept, Savannakhet, Savannakhet Pro, Laos; [Phommasone, Koukeo; Mayxay, Mayfong] Lao Oxford Mahosot Hosp, Wellcome Trust Res Unit LOMWRU, Microbiol Lab, Viangchan, Laos; [Mayxay, Mayfong] Univ Hlth Sci, Inst Res & Educ Dev, Viangchan, Laos	University of Amsterdam; Mahidol Oxford Tropical Medicine Research Unit (MORU); Mahidol University; University of Oxford; Mahidol Oxford Tropical Medicine Research Unit (MORU); Mahidol University; UDICE-French Research Universities; Sorbonne Universite; University of Oxford; University of Oxford; University of Oxford; National Center Parasitology, Entomology & Malaria Control	Pell, CL (corresponding author), AIGHD, Amsterdam, Netherlands.; Pell, CL (corresponding author), Univ Amsterdam, Ctr Social Sci & Global Hlth, Amsterdam, Netherlands.	c.l.pell@uva.nl	White, Nick/AAC-6527-2019; Nosten, Francois/AAC-5509-2019; Adhikari, Bipin/X-3110-2019	White, Nick/0000-0002-1897-1978; Nosten, Francois/0000-0002-7951-0745; Adhikari, Bipin/0000-0001-8981-3910; Cheah, Phaik Yeong/0000-0001-6327-3266; smithuis, frank/0000-0002-4704-9915; Pell, Christopher/0000-0001-9405-5851; Peto, Thomas/0000-0003-3197-9891	Bill and Melinda Gates Foundation [BMGF OPP1081420]; Wellcome Trust [101148/Z/13/Z]	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Wellcome Trust(Wellcome TrustEuropean Commission)	The TME pilots studies and the ancillary social science research is funded by the Bill and Melinda Gates Foundation (BMGF OPP1081420 - https://www.gatesfoundation.org/) (AD) and the Wellcome Trust (101148/Z/13/Z; https://wellcome.ac.uk/home) (AD, LvS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adhikari B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208912; Adhikari B, 2018, MALARIA J, V17, DOI 10.1186/s12936-017-2158-4; Adhikari B, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-2070-y; Adhikari B, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1366136; Adhikari B, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1593-y; Andriesse E, 2013, J CURR SE ASIAN AFF, V31, P3; Ashley EA, 2014, NEW ENGL J MED, V371, P411, DOI 10.1056/NEJMoa1314981; Atkinson JA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-225; Cheah PY, 2016, INT HEALTH, V8, P235, DOI 10.1093/inthealth/ihw027; Cheah PY, 2010, INT HEALTH, V2, P123, DOI 10.1016/j.inhe.2010.02.001; Chen I, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-2060-0; De Martin S, 2001, TROP MED INT HEALTH, V6, P442, DOI 10.1046/j.1365-3156.2001.00723.x; Durnez L, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-329; Emanuel EJ, 2004, J INFECT DIS, V189, P930, DOI 10.1086/381709; Geissler PW, 2006, TROP MED INT HEALTH, V11, P975, DOI 10.1111/j.1365-3156.2006.01682.x; Geissler PW, 2008, SOC SCI MED, V67, P696, DOI 10.1016/j.socscimed.2008.02.004; Gikonyo C, 2008, SOC SCI MED, V67, P708, DOI 10.1016/j.socscimed.2008.02.003; Grietens KP, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-23; Gryseels C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080343; Imwong M, 2017, LANCET INFECT DIS, V17, P491, DOI [10.1016/S1473-3099(17)30048-8, 10.1016/s1473-3099(17)30048-8]; Imwong M, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0906-x; International Monetary Fund, 2004, NAT GROWTH POV ER ST; Kaehler N, 2019, INT HEALTH, V11, P166, DOI 10.1093/inthealth/ihy079; Kajeechiwa Ladda, 2017, Wellcome Open Res, V2, P59, DOI 10.12688/wellcomeopenres.12051.1; Kajeechiwa L, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1528-7; Konig A, 2018, WELLCOME OPEN RES, V3; Landier J, 2018, LANCET, V391, P1916, DOI [10.1016/S0140-6736(18)30792-X, 10.1016/s0140-6736(18)30792-x]; Landier Jordi, 2017, Wellcome Open Res, V2, P81, DOI 10.12688/wellcomeopenres.12240.1; Lim R, 2016, LANCET, V388, P2990, DOI 10.1016/S0140-6736(16)32519-3; Lubell Y, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001704; Lwin KM, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0838-5; Lyttleton C, 2016, SOC SCI MED, V150, P144, DOI 10.1016/j.socscimed.2015.12.033; Maude RJ, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-385; Mbengue A, 2015, NATURE, V520, P683, DOI 10.1038/nature14412; Ribera JM, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1193-x; Munguambe K, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-344; Newby G, 2015, AM J TROP MED HYG, V93, P125, DOI 10.4269/ajtmh.14-0254; Nguon Chea, 2018, Glob Bioeth, V29, P16, DOI 10.1080/11287462.2017.1411762; Parker DM, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0921-y; Parker M, 2013, J BIOSOC SCI, V45, P517, DOI 10.1017/S0021932012000466; Parker M, 2011, HEALTH RES POLICY SY, V9, DOI 10.1186/1478-4505-9-3; Participants in the Community Engagement and Consent Workshop  Kilifi Kenya  March 2011, 2013, J Empir Res Hum Res Ethics, V8, P1, DOI 10.1525/jer.2013.8.4.1; Pell C, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1854-4; Peto TJ, 2018, T ROY SOC TROP MED H, V112, P264, DOI 10.1093/trstmh/try053; Peto TJ, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2202-z; Peto TJ, 2018, AM J TROP MED HYG, V98, P100, DOI 10.4269/ajtmh.17-0428; Peto TJ, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1284-8; Phommasone K, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1336-0; Pongvongsa T, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2541-9; Reynolds L, 2011, INT J HEALTH PLAN M, V26, P449, DOI 10.1002/hpm.1112; Sahan K, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1718-y; Schrempf M., 2010, MED SCI RELIG EXPLOR, V10, P157; Shafique M, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1129-5; SINGHANETRA-RENARD A, 1986, Southeast Asian Journal of Tropical Medicine and Public Health, V17, P396; Nguyen TN, 2018, LANCET INFECT DIS, V18, P565, DOI 10.1016/S1473-3099(18)30046-X; Nguyen TN, 2017, MALARIA J, V16, DOI 10.1186/s12936-016-1662-2; Tripura R, 2018, CLIN INFECT DIS, V67, P817, DOI 10.1093/cid/ciy196; Tripura R, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1703-5; Trung HD, 2005, TROP MED INT HEALTH, V10, P251, DOI 10.1111/j.1365-3156.2004.01378.x; von Seidlein L, 2015, EXPERT REV ANTI-INFE, V13, P715, DOI 10.1586/14787210.2015.1031744; WHO, 2016, GLOB PROGR EL LYMPH; WHO, 2010, PROGR CONT ART TOL M; WHO, STRAT MAL EL GREAT M; Wilkinson A, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0305; World Health Organization, 2018, ACC MAL EL GREAT MEK	65	25	25	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2019	14	3							e0214280	10.1371/journal.pone.0214280	http://dx.doi.org/10.1371/journal.pone.0214280			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HQ1KV	30908523	Green Published, gold, Green Submitted			2023-01-03	WOS:000462157600049
J	Ranieri, M; Di Mise, A; Difonzo, G; Centrone, M; Venneri, M; Pellegrino, T; Russo, A; Mastrodonato, M; Caponio, F; Valenti, G; Tamma, G				Ranieri, Marianna; Di Mise, Annarita; Difonzo, Graziana; Centrone, Mariangela; Venneri, Maria; Pellegrino, Tommaso; Russo, Annamaria; Mastrodonato, Maria; Caponio, Francesco; Valenti, Giovanna; Tamma, Grazia			Green olive leaf extract (OLE) provides cytoprotection in renal cells exposed to low doses of cadmium	PLOS ONE			English	Article							OXIDATIVE STRESS; ACTIN; GLUTATHIONYLATION; LEAVES; HYDROXYTYROSOL; CYTOTOXICITY; DAMAGE; BLOOD	Cadmium (Cd) is a heavy and highly toxic metal that contaminates air, food and water. Cadmium accumulates in several organs altering normal functions. The kidney is the major organ at risk of damage from chronic exposure to cadmium as a contaminant in food and water. This study aims to investigate the beneficial effects of OLE in renal collecting duct MCD4 cells exposed to a low dose cadmium (1 mu M). In MCD4 cells cadmium caused an increase in ROS production, as well as generation of lipid droplets and reduced cell viability. Moreover, cadmium exposure led to a remarkable increase in the frequency of micronuclei and DNA double-strand breaks, assessed using the alkaline comet assay. In addition, cadmium dramatically altered cell cytoskeleton architecture and caused S-glutathionylation of actin. Notably, all cadmium-induced cellular deregulations were prevented by co-treatment with OLE, possibly due to its antioxidant action and to the presence of bioactive phytocompounds. Indeed, OLE treatment attenuated Cd-induced actin S-glutathionylation, thereby stabilizing actin filaments. Taken together, these observations provide a novel insight into the biological action of OLE in renal cells and support the notion that OLE may serve as a potential adjuvant against cadmium-induced nephrotoxicity.	[Ranieri, Marianna; Di Mise, Annarita; Centrone, Mariangela; Venneri, Maria; Pellegrino, Tommaso; Russo, Annamaria; Valenti, Giovanna; Tamma, Grazia] Univ Bari Aldo Moro, Dept Biosci Biotechnol & Biopharmaceut, Bari, Italy; [Difonzo, Graziana; Caponio, Francesco] Univ Bari Aldo Moro, Dept Soil Plant & Food Sci, Bari, Italy; [Mastrodonato, Maria] Univ Bari Aldo Moro, Dept Biol, Bari, Italy; [Valenti, Giovanna; Tamma, Grazia] INBB, Bari, Italy; [Valenti, Giovanna] Univ Bari, Ctr Excellence Comparat Genom CEGBA, Bari, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Tamma, G (corresponding author), Univ Bari Aldo Moro, Dept Biosci Biotechnol & Biopharmaceut, Bari, Italy.; Tamma, G (corresponding author), INBB, Bari, Italy.	grazia.tamma@uniba.it	Difonzo, Graziana/AAF-6455-2019; Ranieri, Marianna/J-9421-2018; Venneri, Maria/AIB-6844-2022; Di Mise, Annarita/AAP-4176-2020; Russo, Annamaria/ABG-4681-2020	Ranieri, Marianna/0000-0003-3118-5813; Tamma, Grazia/0000-0002-8890-0278; Russo, Annamaria/0000-0002-4092-2558; Caponio, Francesco/0000-0002-0740-7677; DI MISE, Annarita/0000-0002-8132-4917; Venneri, Maria/0000-0002-1235-6157	Fondazione in rete per la Ricerca Agroalimentare - AGER 2 Project [2016-0105]; AGER 2 Project [2016-0105]	Fondazione in rete per la Ricerca Agroalimentare - AGER 2 Project; AGER 2 Project	This work has been funded by "Fondazione in rete per la Ricerca Agroalimentare - AGER 2 Project, grant no 2016-0105. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.r This work has been supported by AGER 2 Project, grant no 2016-0105.	Akesson A, 2014, ENVIRON HEALTH PERSP, V122, P431, DOI 10.1289/ehp.1307110; Almeer RS, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8487248; Apykhtina O. L., 2018, Experimental Oncology, V40, P194; Baldantoni D, 2016, ECOTOX ENVIRON SAFE, V123, P89, DOI 10.1016/j.ecoenv.2015.05.019; Boss A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8080513; Brzoska MM, 2016, CURR DRUG TARGETS, V17, P1350, DOI 10.2174/1389450116666150506114336; Caponio FD, 2018, FOOD RES INT; Cataldo I, 2017, CURR MED CHEM; Centrone M, 2017, CELL PHYSIOL BIOCHEM, V44, P515, DOI 10.1159/000485088; Chen X, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13050449; Cheurfa M, 2019, FOOD CHEM TOXICOL, V123, P98, DOI 10.1016/j.fct.2018.10.002; Choong G, 2013, TOXICOL APPL PHARM, V272, P423, DOI 10.1016/j.taap.2013.07.002; Dalle-Donne I, 2003, FREE RADICAL BIO MED, V34, P23, DOI 10.1016/S0891-5849(02)01182-6; de Bock M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057622; Delgado-Moreno LNR, 2017, INT J ENVIRON SCI TE, V14, P13; Difonzo G, 2018, FOOD RES INT, V108, P48, DOI 10.1016/j.foodres.2018.03.034; Difonzo G, 2017, J FUNCT FOODS, V31, P63, DOI 10.1016/j.jff.2017.01.039; El SN, 2009, NUTR REV, V67, P632, DOI 10.1111/j.1753-4887.2009.00248.x; Feoktistova Maria, 2016, Cold Spring Harb Protoc, V2016, DOI 10.1101/pdb.prot087379; Fiaschi T, 2006, J BIOL CHEM, V281, P22983, DOI 10.1074/jbc.M603040200; Gobrecht J, 2017, MUTAT RES-GEN TOX EN, V816, P12, DOI 10.1016/j.mrgentox.2017.03.001; Hallenbeck W H, 1986, Experientia Suppl, V50, P131; Imafidon CE, 2018, TOXICOL REP, V5, P324, DOI 10.1016/j.toxrep.2018.02.009; Iolascon A, 2007, NEPHRON PHYSIOL, V105, P33, DOI 10.1159/000098136; Jarup L, 2009, TOXICOL APPL PHARM, V238, P201, DOI 10.1016/j.taap.2009.04.020; Khemakhem I, 2018, FOOD SCI TECHNOL INT; Kim JG, 2018, J CELL PHYSIOL, V233, P6381, DOI 10.1002/jcp.26487; Kiziler AR, 2007, BIOL TRACE ELEM RES, V120, P82, DOI 10.1007/s12011-007-8020-8; Kovacs G, 2013, CELL CALCIUM, V54, P276, DOI 10.1016/j.ceca.2013.07.003; Lins PG, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e00805; Magrone T, 2018, ENDOCR METAB IMMUNE, V18, P85, DOI 10.2174/1871530317666171116110537; Mallya R, 2017, J CLIN DIAGN RES, V11, pCE1, DOI 10.7860/JCDR/2017/21796.9671; Marcos-Ramiro B, 2014, THROMB HAEMOSTASIS, V112, P1088, DOI 10.1160/TH14-04-0299; Martins LAM, 2014, CELL BIOCHEM BIOPHYS, V68, P247, DOI 10.1007/s12013-013-9703-8; Mieyal JJ, 2008, ANTIOXID REDOX SIGN, V10, P1941, DOI 10.1089/ars.2008.2089; Nordberg GF, 2009, TOXICOL APPL PHARM, V238, P192, DOI 10.1016/j.taap.2009.03.015; Olga Igorevna Kulikova TNF, 2016, BIOL MED, V8, P5; Pan SX, 2018, ENVIRON POLLUT, V235, P47, DOI 10.1016/j.envpol.2017.12.044; Planchart A, 2018, CURR ENV HLTH REP, V5, P110, DOI 10.1007/s40572-018-0182-3; Procino G, 2015, CELL PHYSIOL BIOCHEM, V35, P1070, DOI 10.1159/000373933; Rajakumar S, 2017, TOXICOL RES-UK, V6, P30, DOI 10.1039/c6tx00187d; Saibandith B, 2017, MOLECULES, V22, DOI 10.3390/molecules22071082; Sakai J, 2012, IMMUNITY, V37, P1037, DOI 10.1016/j.immuni.2012.08.017; Satarug S, 2018, J TRACE ELEM MED BIO, V46, P32, DOI 10.1016/j.jtemb.2017.11.008; SMITH TJ, 1976, AM REV RESPIR DIS, V114, P161; Soussi R., 2018, APPL PHYSL NUTR META; Sun S, 2014, J BIOMECH, V47, P3650, DOI 10.1016/j.jbiomech.2014.09.036; Takuma M, 2018, BIOSCI BIOTECH BIOCH, V82, P1101, DOI 10.1080/09168451.2018.1451741; Tamma G, 2005, J CELL SCI, V118, P3623, DOI 10.1242/jcs.02495; Tamma G, 2007, AM J PHYSIOL-CELL PH, V292, pC1476, DOI 10.1152/ajpcell.00375.2006; Tamma G, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1501847; Tamma G, 2016, ANTIOXID REDOX SIGN, V25, P147, DOI 10.1089/ars.2016.6656; Tamma G, 2014, J BIOL CHEM, V289, P27807, DOI 10.1074/jbc.M114.586024; Tesse A, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00030; Toteda G, 2018, FOOD FUNCT; Verma N, 2020, J DIET SUPPL, V17, P41, DOI 10.1080/19390211.2018.1481485; Wang Z, 1996, TOXICOL APPL PHARM, V139, P115, DOI 10.1006/taap.1996.0149; Wei TS, 2017, ONCOTARGET, V8, P44944, DOI 10.18632/oncotarget.16572; Wojciak-Stothard B, 2005, AM J PHYSIOL-LUNG C, V288, pL749, DOI 10.1152/ajplung.00361.2004; Wu LX, 2018, J BIOMED RES, V32, P371, DOI 10.7555/JBR.32.20170111; Xu Y, 2018, INT J MOL SCI, V19; Zanetti SR, 2014, BBA-MOL CELL BIOL L, V1841, P151, DOI 10.1016/j.bbalip.2013.09.014; Zou X, 2012, J NUTR BIOCHEM, V23, P994, DOI 10.1016/j.jnutbio.2011.05.006	63	25	26	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2019	14	3							e0214159	10.1371/journal.pone.0214159	http://dx.doi.org/10.1371/journal.pone.0214159			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP7SO	30897184	gold, Green Published, Green Submitted			2023-01-03	WOS:000461889700074
J	Jones, EA; Linas, BP; Truong, V; Burgess, JF; Lasser, KE				Jones, Eric A.; Linas, Benjamin P.; Ve Truong; Burgess, James F.; Lasser, Karen E.			Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program	PLOS ONE			English	Article							COST-EFFECTIVENESS; VIRUS-INFECTION; UNITED-STATES; SOFOSBUVIR; REGIMENS; PEOPLE; HEALTH; MODEL	Purpose Safety-net health systems, which serve a disproportionate share of patients at high risk for hepatitis C virus (HCV) infection, may use revenue generated by the federal drug discount pricing program, known as 340B, to support multidisciplinary care. Budgetary impacts of repealing the drug-pricing program are unknown. Our objective was to conduct a budgetary impact analysis of a multidisciplinary primary care-based HCV treatment program, with and without 340B support. Methods We conducted a budgetary impact analysis from the perspective of a large safety-net medical center in Boston, Massachusetts. Participants included 302 HCV-infected patients (mean age 45, 75% male, 53% white, 77% Medicaid) referred to the primary care-based HCV treatment program from 2015-2016. Main measures included costs and revenues associated with the treatment program. Our main outcomes were net cost with and without 340B Drug Pricing support. Results Total program costs were $942,770, while revenues totaled $1.2 million. With the 340B Drug Pricing Program the hospital received a net revenue of $930 per patient referred to the HCV treatment program. In the absence of the 340B program, the hospital would lose $370 per patient referred. Ninety-seven percent (68/70) of patients who initiated treatment in the program achieved a sustained virologic response (SVR) at a net cost of $4,150 each, among this patient subset. Conclusions The 340B Drug Pricing Program enabled a safety-net hospital to deliver effective primary care-based HCV treatment using a multidisciplinary care team. Efforts to sustain the 340B program could enable dissemination of similar HCV treatment models elsewhere.	[Jones, Eric A.; Burgess, James F.] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Linas, Benjamin P.; Lasser, Karen E.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Ve Truong; Lasser, Karen E.] Boston Med Ctr, Sect Gen Internal Med, Boston, MA 02118 USA	Boston University; Boston University; Boston Medical Center	Lasser, KE (corresponding author), Boston Univ, Sch Med, Boston, MA 02118 USA.; Lasser, KE (corresponding author), Boston Med Ctr, Sect Gen Internal Med, Boston, MA 02118 USA.	Karen.Lasser@bmc.org			National Institute on Drug Abuse (NIDA) [P30 DA040500-01]; Boston Providence Center for AIDS Research (CFAR) [P30AI042853]; "Center for Health Economics of Treatment Interventions for Substance use Disorder, HCV, and HIV"; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI042853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P30DA040500] Funding Source: NIH RePORTER	National Institute on Drug Abuse (NIDA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Boston Providence Center for AIDS Research (CFAR); "Center for Health Economics of Treatment Interventions for Substance use Disorder, HCV, and HIV"; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This research was funded by the National Institute on Drug Abuse (NIDA) (P30 DA040500-01-pilot grant, awarded to KEL), "Center for Health Economics of Treatment Interventions for Substance use Disorder, HCV, and HIV" and the Boston Providence Center for AIDS Research (CFAR) (P30AI042853 to KEL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Association for the Study of Liver Disease; Infectious Dis- eases Society of America, 2017, HCV GUID REC TEST MA; Arora S, 2011, NEW ENGL J MED, V364, P2199, DOI 10.1056/NEJMoa1009370; Assoumou SA, 2017, CLIN INFECT DIS, V9, DOI [10.1093/cid/ciw633, DOI 10.1093/CID/CIW633]; Boyer JL, 2003, HIV CLIN TRIALS, V4, P55; Chahal HS, 2016, JAMA INTERN MED, V176, P65, DOI 10.1001/jamainternmed.2015.6011; Chhatwal J, 2016, HEPATOLOGY, V64, P1442, DOI 10.1002/hep.28571; Chhatwal J, 2015, ANN INTERN MED, V162, P397, DOI 10.7326/M14-1336; Denniston MM, 2014, ANN INTERN MED, V160, P293, DOI 10.7326/M13-1133; Felt-Lisk S, 2002, HEALTH AFFAIR, V21, P277, DOI 10.1377/hlthaff.21.5.277; Grady BP, 2013, CLIN INFECT DIS, V57, pS105, DOI 10.1093/cid/cit301; Hellard M, 2014, HEPATOLOGY, V60, P1861, DOI 10.1002/hep.27403; Konerman MA, 2016, CLIN TRANSL GASTROEN, V7, DOI 10.1038/ctg.2016.50; Lasser KE, 2017, ANN FAM MED, V15, P258, DOI 10.1370/afm.2069; Leidner AJ, 2015, HEPATOLOGY, V61, P1860, DOI 10.1002/hep.27736; Linas BP, 2015, ANN INTERN MED, V162, P619, DOI 10.7326/M14-1313; Linas BP, 2017, COST EFFECTIVENESS C, V1; Liu S, 2016, MED DECIS MAKING, V1, P1; Mauskopf JA, 2007, VALUE HEALTH, V10, P336, DOI 10.1111/j.1524-4733.2007.00187.x; McGowan CE, 2012, LIVER INT, V32, P151, DOI 10.1111/j.1478-3231.2011.02706.x; Miller L, 2012, J NATL MED ASSOC, V104, P244, DOI 10.1016/S0027-9684(15)30161-9; Mitchell GK, 2008, MED J AUSTRALIA, V188, pS61; Mitruka K, 2014, MMWR-MORBID MORTAL W, V63, P393; Mulcahy AW, 2014, 340B PRESCRIPTION DR; National Institutes of Health, 2017, MICR SOURC INF; Neumann PJ, 2016, COST EFFECTIVENESS H; Page K, 2009, J INFECT DIS, V200, P1216, DOI 10.1086/605947; Razavi H, 2013, HEPATOLOGY, V57, P2164, DOI 10.1002/hep.26218; Sabouni D., 2010, PRIM CARE COMPANION, V12; Turner BJ, 2015, HEPATOLOGY, V62, P1388, DOI 10.1002/hep.28018; Wise M, 2008, HEPATOLOGY, V47, P1128, DOI 10.1002/hep.22165; Younossi ZM, 2015, HEPATOLOGY, V61, P1471, DOI 10.1002/hep.27757	31	7	7	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2019	14	3							e0213745	10.1371/journal.pone.0213745	http://dx.doi.org/10.1371/journal.pone.0213745			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO7YP	30870475	gold, Green Published, Green Submitted			2023-01-03	WOS:000461166300066
J	Gharbi, M; Drysdale, JH; Lishman, H; Goudie, R; Molokhia, M; Johnson, AP; Holmes, AH; Aylin, P				Gharbi, Myriam; Drysdale, Joseph H.; Lishman, Hannah; Goudie, Rosalind; Molokhia, Mariam; Johnson, Alan P.; Holmes, Alison H.; Aylin, Paul			Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all cause mortality: population based cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							METAANALYSIS; PROFILE; WOMEN; AGE	OBJECTIVE To evaluate the association between antibiotic treatment for urinary tract infection (UTI) and severe adverse outcomes in elderly patients in primary care. DESIGN Retrospective population based cohort study. SETTING Clinical Practice Research Datalink (2007-15) primary care records linked to hospital episode statistics and death records in England. PARTICIPANTS 157 264 adults aged 65 years or older presenting to a general practitioner with at least one diagnosis of suspected or confirmed lower UTI from November 2007 to May 2015. MAIN OUTCOME MEASURES Bloodstream infection, hospital admission, and all cause mortality within 60 days after the index UTI diagnosis. RESULTS Among 312 896 UTI episodes (157 264 unique patients), 7.2% (n=22 534) did not have a record of antibiotics being prescribed and 6.2% (n=19 292) showed a delay in antibiotic prescribing. 1539 episodes of bloodstream infection (0.5%) were recorded within 60 days after the initial UTI. The rate of bloodstream infection was significantly higher among those patients not prescribed an antibiotic (2.9%; n=647) and those recorded as revisiting the general practitioner within seven days of the initial consultation for an antibiotic prescription compared with those given a prescription for an antibiotic at the initial consultation (2.2% v 0.2%; P=0.001). After adjustment for covariates, patients were significantly more likely to experience a bloodstream infection in the deferred antibiotics group (adjusted odds ratio 7.12, 95% confidence interval 6.22 to 8.14) and no antibiotics group (8.08, 7.12 to 9.16) compared with the immediate antibiotics group. The number needed to harm (NNH) for occurrence of bloodstream infection was lower (greater risk) for the no antibiotics group (NNH=37) than for the deferred antibiotics group (NNH=51) compared with the immediate antibiotics group. The rate of hospital admissions was about double among cases with no antibiotics (27.0%) and deferred antibiotics (26.8%) compared with those prescribed immediate antibiotics (14.8%; P=0.001). The risk of all cause mortality was significantly higher with deferred antibiotics and no antibiotics than with immediate antibiotics at any time during the 60 days follow-up (adjusted hazard ratio 1.16, 95% confidence interval 1.06 to 1.27 and 2.18, 2.04 to 2.33, respectively). Men older than 85 years were particularly at risk for both bloodstream infection and 60 day all cause mortality. CONCLUSIONS In elderly patients with a diagnosis of UTI in primary care, no antibiotics and deferred antibiotics were associated with a significant increase in bloodstream infection and all cause mortality compared with immediate antibiotics. In the context of an increase of Escherichia coli bloodstream infections in England, early initiation of recommended first line antibiotics for UTI in the older population is advocated.	[Gharbi, Myriam; Lishman, Hannah; Goudie, Rosalind; Johnson, Alan P.; Holmes, Alison H.; Aylin, Paul] Imperial Coll London, Healthcare Associated Infect & Antimicrobial Resi, NIHR Hlth Protect Res Unit, London, England; [Gharbi, Myriam; Lishman, Hannah; Goudie, Rosalind; Aylin, Paul] Imperial Coll London, Dept Primary Care & Publ Hlth, London, England; [Drysdale, Joseph H.] St Georges Univ London, Sch Med, London, England; [Goudie, Rosalind] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England; [Molokhia, Mariam] Kings Coll London, Dept Primary Care & Publ Hlth Sci, London, England; [Johnson, Alan P.] Publ Hlth England, Healthcare Associated Infect & Antimicrobial Resi, Natl Infect Serv, London, England	Imperial College London; Imperial College London; St Georges University London; University of Oxford; University of London; King's College London; Public Health England	Aylin, P (corresponding author), Imperial Coll London, Healthcare Associated Infect & Antimicrobial Resi, NIHR Hlth Protect Res Unit, London, England.; Aylin, P (corresponding author), Imperial Coll London, Dept Primary Care & Publ Hlth, London, England.	p.aylin@imperial.ac.uk		Jones, Leah/0000-0002-0448-3471; Lishman, Hannah/0000-0003-2656-5352; Holmes, Alison/0000-0001-5554-5743; Gharbi, Myriam/0000-0002-8994-2816; Aylin, Paul/0000-0003-4589-1743	National Institute for Health Research Health Protection Research Unit (NIHR HPRU) [HPRU-2012-10 047]; Public Health England (PHE); National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London; NW London NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC); Imperial NIHR Biomedical Research Centre	National Institute for Health Research Health Protection Research Unit (NIHR HPRU); Public Health England (PHE); National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London; NW London NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC); Imperial NIHR Biomedical Research Centre(National Institute for Health Research (NIHR))	This work was supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) (grant No HPRU-2012-10 047) in Healthcare Associated Infections and Antimicrobial Resistance at Imperial College London in partnership with Public Health England (PHE), and the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London. The NIHR HPRU is also affiliated with the National Institute of Health Research (NIHR) Imperial Patient Safety Translational Research Centre. The Department of Primary Care and Public Health at Imperial College London is grateful for support from the NW London NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC) and the Imperial NIHR Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, NIHR, Department of Health, or Public Health England.	Abbo LM, 2014, ANTIBIOTICS-BASEL, V3, P174, DOI 10.3390/antibiotics3020174; Ahmed H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190521; Balinskaite V, 2019, CLIN INFECT DIS, V69, P227, DOI 10.1093/cid/ciy902; Bou-Antoun S, 2018, J ANTIMICROB CHEMOTH, V73, P2883, DOI 10.1093/jac/dky237; Brown KA, 2013, ANTIMICROB AGENTS CH, V57, P2326, DOI 10.1128/AAC.02176-12; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHISHOLM J, 1990, BRIT MED J, V300, P1092, DOI 10.1136/bmj.300.6732.1092; COVESMITH A, 2007, TRENDS UROL GYNECOL, V12, P31, DOI DOI 10.1002/TRE.33; Crellin E, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k341; Crnich CJ, 2017, J AM GERIATR SOC, V65, P1661, DOI 10.1111/jgs.14961; Deshpande A, 2013, J ANTIMICROB CHEMOTH, V68, P1951, DOI 10.1093/jac/dkt129; Duane S, 2016, ANTIBIOTICS-BASEL, V5, DOI 10.3390/antibiotics5030027; Falagas ME, 2009, J INFECTION, V58, P91, DOI 10.1016/j.jinf.2008.12.009; Gagyor I, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h6544; Herrett E, 2015, INT J EPIDEMIOL, V44, P827, DOI 10.1093/ije/dyv098; Knottnerus BJ, 2013, BMC FAM PRACT, V14, DOI 10.1186/1471-2296-14-71; Leydon GM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c279; Lim Vee Han, 2014, BMJ Qual Improv Rep, V3, DOI 10.1136/bmjquality.u203314.w1503; Linhares I, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-19; Little P, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c199; Little P, 2014, LANCET INFECT DIS, V14, P213, DOI 10.1016/S1473-3099(13)70294-9; Lutters M, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001535.pub2; Martin GS, 2006, CRIT CARE MED, V34, P15, DOI 10.1097/01.CCM.0000194535.82812.BA; McMurdo MET, 2000, AGE AGEING, V29, P297, DOI 10.1093/ageing/29.4.297; Mody L, 2014, JAMA-J AM MED ASSOC, V311, P844, DOI 10.1001/jama.2014.303; Morley GL, 2017, ARCH DIS CHILD ED PR; Nace DA, 2014, J AM MED DIR ASSOC, V15, P133, DOI 10.1016/j.jamda.2013.11.009; NHS_ England, 2016, QUAL PREM 2016 17 GU; NICE, 2015, CKS CLIN KNOWL SUMM; NICE, GUID UR TRACK INF LO, P34; PHE, 2017, MAN TREATM COMM INF, P150; PHE, 2014, MAN INF GUID PRIM CA, P61; PHE, 2018, ENGL SURV PROGR ANT, P147; PHE, 2016, ENGL SURV PROGR ANT, P181; Scottish Intercollegiate Guidelines Network. Scottish Intercollegiate Guidelines Network (SIGN), 2012, MAN SUSP BACT UR TRA; Spurling GKP, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004417.pub4; Tal S, 2005, J INFECTION, V50, P296, DOI 10.1016/j.jinf.2004.04.004; Wagenlehner FME, 2013, INT J UROL, V20, P963, DOI 10.1111/iju.12200; Williams T, 2012, THER ADV DRUG SAF, V3, P89, DOI 10.1177/2042098611435911; 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI DOI 10.1001/JAMA.2013.281053	40	81	82	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 27	2019	364								l525	10.1136/bmj.l525	http://dx.doi.org/10.1136/bmj.l525			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN7RW	30814048	Green Published, hybrid			2023-01-03	WOS:000460390400002
J	Le, TM; Morimoto, N; Mitsui, T; Notodihardjo, SC; Munisso, MC; Kakudo, N; Kusumoto, K				Tien Minh Le; Morimoto, Naoki; Mitsui, Toshihito; Notodihardjo, Sharon Claudia; Munisso, Maria Chiara; Kakudo, Natsuko; Kusumoto, Kenji			The sustained release of basic fibroblast growth factor accelerates angiogenesis and the engraftment of the inactivated dermis by high hydrostatic pressure	PLOS ONE			English	Article							COLLAGEN/GELATIN SCAFFOLD; CLINICAL-EFFICACY; BFGF; CELLS; PCR	We developed a novel skin regeneration therapy combining nevus tissue inactivated by high hydrostatic pressure (HHP) in the reconstruction of the dermis with a cultured epidermal autograft (CEA). The issue with this treatment is the unstable survival of CEA on the inactivated dermis. In this study, we applied collagen/gelatin sponge (CGS), which can sustain the release of basic fibroblast growth factor (bFGF), to the inactivated skin in order to accelerate angiogenesis. Murine skin grafts from C57BL6J/Jcl mice (8 mm in diameter) were prepared, inactivated by HHP and cryopreserved. One month later, the grafts were transplanted subcutaneously onto the back of other mice and covered by CGS impregnated with saline or bFGF. Grafts were harvested after one, two and eight weeks, at which point the engraftment was evaluated through the histology and angiogenesis-related gene expressions were determined by real-time polymerase chain reaction. Histological sections showed that the dermal cellular density and newly formed capillaries in the bFGF group were significantly higher than in the control group. The relative expression of FGF-2, PDGFA and VEGF-A genes in the bFGF group was significantly higher than in the control group at Week 1. This study suggested that the angiogenesis into grafts was accelerated, which might improve the engraftment of inactivated dermis in combination with the sustained release of bFGF by CGSs.	[Tien Minh Le; Morimoto, Naoki; Mitsui, Toshihito; Notodihardjo, Sharon Claudia; Munisso, Maria Chiara; Kakudo, Natsuko; Kusumoto, Kenji] Kansai Med Univ, Dept Plast & Reconstruct Surg, Hirakata, Osaka, Japan	Kansai Medical University	Morimoto, N (corresponding author), Kansai Med Univ, Dept Plast & Reconstruct Surg, Hirakata, Osaka, Japan.	morimotn@hirakata.kmu.ac.jp	Munisso, Maria Chiara/GXV-5409-2022	Morimoto, Naoki/0000-0002-0712-3172; Le, Tien Minh/0000-0003-4470-8433; Munisso, Maria Chiara/0000-0003-1616-4934	Practical Research for Innovative Cancer Control grant Agency for Medical Research and Development (AMED) [17ck0106304h0001];  [17H04360]	Practical Research for Innovative Cancer Control grant Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); 	This research was partially supported by Grants-in-Aid for Scientific Research (B) (17H04360) (https://kaken.nii.ac.jp/ja/index/) and partially supported by a Practical Research for Innovative Cancer Control grant (17ck0106304h0001) Agency for Medical Research and Development (AMED; http://www.amed.go.jp/en/); Dr. Naoki Morimoto. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.	Akita S, 2005, BURNS, V31, P855, DOI 10.1016/j.burns.2005.04.008; Ayvazyan A, 2011, J SURG RES, V171, pE247, DOI 10.1016/j.jss.2011.06.059; Badylak SE, 2008, SEMIN IMMUNOL, V20, P109, DOI 10.1016/j.smim.2007.11.003; Bao P, 2009, J SURG RES, V153, P347, DOI 10.1016/j.jss.2008.04.023; Crapo PM, 2011, BIOMATERIALS, V32, P3233, DOI 10.1016/j.biomaterials.2011.01.057; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Funamoto S, 2010, BIOMATERIALS, V31, P3590, DOI 10.1016/j.biomaterials.2010.01.073; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GOSPODAROWICZ D, 1974, NATURE, V249, P123, DOI 10.1038/249123a0; GREEN H, 1979, P NATL ACAD SCI USA, V76, P5665, DOI 10.1073/pnas.76.11.5665; Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039; Hashimoto Y, 2010, BIOMATERIALS, V31, P3941, DOI 10.1016/j.biomaterials.2010.01.122; HAYEK A, 1987, BIOCHEM BIOPH RES CO, V147, P876, DOI 10.1016/0006-291X(87)91011-4; Hiemer B, 2016, SCI REP-UK, V6, DOI 10.1038/srep33747; Ito R, 2013, TISSUE ENG PT A, V19, P1398, DOI [10.1089/ten.tea.2012.0375, 10.1089/ten.TEA.2012.0375]; Jinno C, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4567146; Jinno C, 2015, TISSUE ENG PART C-ME, V21, P1178, DOI [10.1089/ten.tec.2015.0054, 10.1089/ten.TEC.2015.0054]; Kanda N, 2014, J TISSUE ENG REGEN M, V8, P29, DOI 10.1002/term.1492; Kanda N, 2012, ANN PLAS SURG, V69, P569, DOI 10.1097/SAP.0b013e318222832f; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mahara A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/379607; Morimoto N, 2017, J BIOMED MATER RES B, V105, P2653, DOI 10.1002/jbm.b.33807; Morimoto N, 2017, J BIOMED MATER RES B, V105, P1091, DOI 10.1002/jbm.b.33631; Morimoto N, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/1320909; Morimoto N, 2015, CELLS TISSUES ORGANS, V201, P170, DOI 10.1159/000444048; Morimoto N, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/587247; Ogino S, 2018, J SURG RES, V221, P173, DOI 10.1016/j.jss.2017.08.051; Ohura T, 2011, WOUND REPAIR REGEN, V19, P542, DOI 10.1111/j.1524-475X.2011.00726.x; Liem PH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133979; Liem PH, 2013, J ARTIF ORGANS, V16, P332, DOI 10.1007/s10047-013-0708-2; Rivalain N, 2010, BIOTECHNOL ADV, V28, P659, DOI 10.1016/j.biotechadv.2010.04.001; Sakamoto M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186958; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Takemoto S, 2008, TISSUE ENG PT A, V14, P1629, DOI 10.1089/ten.tea.2007.0215; Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x; Turabelidze A, 2010, WOUND REPAIR REGEN, V18, P460, DOI 10.1111/j.1524-475X.2010.00611.x; Uchi H, 2009, EUR J DERMATOL, V19, P461, DOI 10.1684/ejd.2009.0750; Watt AJ, 2004, PLAST RECONSTR SURG, V113, P1968, DOI [10.1097/01.PRS.0000122209.10277.2A, 10.1097/01.prs.0000122209.10277.2a]; Weiss EM, 2010, J IMMUNOTOXICOL, V7, P194, DOI 10.3109/15476911003657414; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Wiles K, 2016, TISSUE ENG PART B-RE, V22, P208, DOI [10.1089/ten.teb.2015.0376, 10.1089/ten.TEB.2015.0376]	41	13	13	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2019	14	2							e0208658	10.1371/journal.pone.0208658	http://dx.doi.org/10.1371/journal.pone.0208658			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM2WC	30789932	gold, Green Published, Green Submitted			2023-01-03	WOS:000459330800005
J	Khuluza, F; Haefele-Abah, C				Khuluza, Felix; Haefele-Abah, Christine			The availability, prices and affordability of essential medicines in Malawi: A cross-sectional study	PLOS ONE			English	Article								Introduction The Malawian government recently introduced cost-covering consultation fees for self-referral patients in tertiary public hospitals. Previously, patients received medicines free of charge in government-owned health facilities, but must pay elsewhere. Before the government implements a payment policy in other areas of health care, it is important to investigate the prices, affordability and availability of essential medicines in Malawi. Methods Data on availability and prices of 50 essential medicines were collected in 44 health facilities in two major cities and two districts. These included 12 public facilities, 11 facilities of the Christian Health Association of Malawi (CHAM), nine retail pharmacies, eight wholesalers and four private clinics/hospitals. Price, availability and affordability were assessed based on the methodology developed by the World Health Organization and Health Action International, which compares local prices to international reference prices. Results and discussion The overall availability of medicines was 48.5% in public facilities, 71.1% in retail pharmacies, 62.9% in CHAM facilities and 57.5% in private clinics. The availability of essential medicines varied from 0% for ethosuximide to 100% for amoxicillin and cotrimoxazole tablets. Antibiotic formulations for adults were widely available, in contrast to the low availability of pediatric formulations. Several medicines for non-communicable diseases like sodium valproate, phenytoin, paraldehyde, captopril and simvastatin showed poor availability and affordability. The overall median price ratio compared to the international reference price was 1.11 for wholesalers, 2.54 in CHAM facilities, 2.70 in retail pharmacies, and 4.01 in private clinics, which is low compared to other countries. But nevertheless, for 18 out of 32 medicines assessed, the cost of one course exceeded the statutory minimum daily wage, making them unaffordable to a majority of the population. Therefore, continued provision of free public health care is still of critical importance for the foreseeable future until other financing mechanisms have been explored.	[Khuluza, Felix] Univ Malawi, Pharm Dept, Coll Med, Blantyre, Malawi; [Haefele-Abah, Christine] Eberhard Karls Univ Tuebingen, Pharmaceut Inst, Tubingen, Germany	University of Malawi; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Khuluza, F (corresponding author), Univ Malawi, Pharm Dept, Coll Med, Blantyre, Malawi.	fkhuluza@medcol.mw	Khuluza, Felix/HGC-0661-2022	Khuluza, Felix/0000-0002-8334-0160	German Medical Aid Organization action medeor e.V. Germany [7000129]; Consortium for Advanced Research Training in Africa (CARTA); Wellcome Trust (UK) [087547/Z/08/Z]; Carnegie Corporation of New York [B8606.R02]; Sida [54100029]; Deutsche Forschungsgemeinschaft; University of Tuebingen	German Medical Aid Organization action medeor e.V. Germany; Consortium for Advanced Research Training in Africa (CARTA); Wellcome Trust (UK)(Wellcome Trust); Carnegie Corporation of New York; Sida; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); University of Tuebingen	This study was financially supported by grant number 7000129 of the German Medical Aid Organization action medeor e.V. Germany. The contribution by FK was supported by the Consortium for Advanced Research Training in Africa (CARTA) during the draft of this manuscript. CARTA is jointly led by the African Population and Health Research Center and the University of the Witwatersrand and funded by the Wellcome Trust (UK) (Grant No. 087547/Z/08/Z), the Carnegie Corporation of New York (Grant No. B8606.R02) and Sida (Grant No. 54100029). We furthermore acknowledge support for open access publication by Deutsche Forschungsgemeinschaft and Open Access Publishing Fund of University of Tuebingen. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Abiiro GA, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-234; Alba S, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-163; [Anonymous], 2015, ESAPWP241; [Anonymous], 2018, BURD DIS MAL; Babar ZUD, 2013, PHARMACOECONOMICS, V31, P1063, DOI 10.1007/s40273-013-0095-9; Babigumira JB, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2530-7; Bazargani YT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087576; Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; Cameron A, 2012, EPILEPSIA, V53, P962, DOI 10.1111/j.1528-1167.2012.03446.x; Chinele J., 2016, UNREGULATED SALE DRU; Choi Y, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-266; Coates ARM, 2011, BRIT J PHARMACOL, V163, P184, DOI 10.1111/j.1476-5381.2011.01250.x; Ewen M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171284; Freye JE, 2014, INT DRUG PRICE INDIC; Government of Malawi, 2017, MAL GROWTH DEV STRAT, DOI [10.1093/heapol/czw050, DOI 10.1093/HEAPOL/CZW050]; Hamer J., 2016, ACHIEVING UNIVERSAL; Health Policy Project, 2016, HLTH FIN PROF MAL; Khuluza F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175399; Kumwenda K., 2018, K100 000 FINE SELLIN; Kwan P, 2004, EPILEPSIA, V45, P1141, DOI 10.1111/j.0013-9580.2004.12704.x; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Management Sciences for Health, 2012, MDS 3 MAN ACC MED HL; Manthalu G, 2016, HEALTH POLICY PLANN, V31, P1184, DOI 10.1093/heapol/czw050; Ministry of Health Malawi, 2015, INC MAL ESS MED LIST; Ministry of Health. National Medicine Policy, 2015, NAT MED POL PROM EQ; Ministry of Health-Malawi, 2012, NAT HLTH RES AG 2012; National Statistical Office ICF Macro., 2011, MAL DEM HLTH SURV 20; National Statistical Office Malawi ICF, 2017, MAL DEM HLTH SURV 20; National- Statistical- Office, 2018, SUMM PROJ POP GROWTH; Nkhulembe LG, 2017, MAL C TRAD UN PLEAS; Pisani E., 2015, ANTIMICROBIAL RESIST; Ravinetto RM, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i3618; Reserve- Bank- of- Malawi, 2017, RES BANK MAL EXCH RA; Sado E, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0572-3; Thomas SV, 2011, ANN INDIAN ACAD NEUR, V14, P158, DOI 10.4103/0972-2327.85873; United Nations Development Programme, 2016, SUST DEV GOALS; van Mourik MSM, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-25; WHO Health Action International, 2008, MEAS MED PRIC AV AFF, V2nd; Wong-Beringer A, 2009, PHARMACOTHERAPY, V29, P736, DOI 10.1592/phco.29.6.736; World Health Organization, 2015, WHO GLOBAL ACTION PL; World Health Organization, 2012, WHO REC PREV TREATM; World- Health-Organization, 2018, METH WCCFDS; Yin XX, 2013, J ANTIMICROB CHEMOTH, V68, P2445, DOI 10.1093/jac/dkt223; Zaheer Ud Din Babar MIMI, 2007, PLOS MED, DOI [10.1186/s12913-017-2530-7, DOI 10.1186/S12913-017-2530-7]	44	29	30	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2019	14	2							e0212125	10.1371/journal.pone.0212125	http://dx.doi.org/10.1371/journal.pone.0212125			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL0PE	30753219	Green Published, gold			2023-01-03	WOS:000458395600044
J	Limb, M				Limb, Matthew			How NHS investment in proton beam therapy is coming to fruition	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												limb@btinternet.com						Amos R, 2018, CLIN ONCOL-UK, V30, P280, DOI 10.1016/j.clon.2018.02.031; Crellin A, 2018, CLIN ONCOL-UK, V30, P277, DOI 10.1016/j.clon.2018.02.032; Gains J, 2016, NEUROONCOL S3, V18, P1, DOI [10.1093/neuonc/now070.34, DOI 10.1093/NEUONC/NOW070.34]; Indelicato DJ, 2014, ACTA ONCOL, V53, P1298, DOI 10.3109/0284186X.2014.957414; Wang DX, 2015, MED DEVICES-EVID RES, V8, P439, DOI 10.2147/MDER.S65594; Yock TI, 2016, LANCET ONCOL, V17, P287, DOI 10.1016/S1470-2045(15)00167-9; Zietman AL, 2018, CLIN ONCOL-UK, V30, P271, DOI 10.1016/j.clon.2017.11.002	7	5	5	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 11	2019	364								l313	10.1136/bmj.l313	http://dx.doi.org/10.1136/bmj.l313			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM0BG	30745321				2023-01-03	WOS:000459109500001
J	Sottas, O; Guidi, M; Thieffry, B; Schneider, M; Decosterd, L; Mueller, I; Genton, B; Csajka, C; Senn, N				Sottas, Oriane; Guidi, Monia; Thieffry, Benjamin; Schneider, Marie; Decosterd, Laurent; Mueller, Ivo; Genton, Blaise; Csajka, Chantal; Senn, Nicolas			Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: A pharmacological study alongside the randomized controlled trial	PLOS ONE			English	Article								Background The intermittent preventive treatment in infants (IPTi) trial that took place in Papua New Guinea showed an overall reduction of 29% of the risk of malaria when delivering single-dose sulfadoxine-pyrimethamine (SP) associated to 3 days of amodiaquine (AQ) every three months to children during the first year of life. The aim of the present study was to assess if the last two doses of AQ were truly administered as prescribed by the parents at home based on drug level measurement and PK modelling, which is a good proxy of medication adherence. It provides also important information to discuss the efficacy of the intervention and on feasibility of self-administered preventive malaria treatment. Methods and findings During the three-arm randomized double-blinded IPTi trial, each child was prescribed one dose of SP (day 0) and 3 doses of either AQ or artesunate (AS) at day 0, 1 & 2 adjusted to weight or placebo. Treatments were given at 3, 6, 9 and 12 months of age. The first day of treatment was delivered by nursing staff (initiation under directly observed treatment (DOT)) and the two last doses of AQ or AS by parents at home without supervision. For this cross-sectional study, 206 consecutive children already involved in the IPTi trial were enrolled over a 2-month period. At the time of the survey, allocation of the children to one of the three arms was not known. Blood samples for drug level measurement were collected from finger pricks one day after the planned last third dose intake. Only children allocated to the SP-AQ arm were included in the present analysis. Indeed, the half-life of AS is too short to assess if drugs were given on not. Because of the short half-life of AQ, desethyl-AQ (metabolite of AQ (DAQ)) measurements were used to investigate AQ medication adherence. Two PK (PK) models from previously published studies in paediatric populations were applied to the dataset using non-linear mixed effect modelling (NONMEM) to estimate the number of doses really given by the parents. The study nurse reported the administration time for the first AQ dose while it was estimated by the parents for the remaining two doses. Out of 206 children, 64 were in the SP-AQ arm. The adjusted dosing history for each individual was identified as the one with the lowest difference between observed and individual predicted concentrations estimated by the two PK models for all the possible adherence schemes. The median (range) blood concentration AQ in AQ arm was 9.3 ng/mL (0-1427.8 ng/mL), (Quartiles 1-3: 2.4 ng/mL -22.2 ng/mL). The median (range) for DAQ was 162.0 ng/mL (0712 ng/mL), (Quartiles 1-3: 80.4 ng/mL-267.7 ng/mL). Under the assumption of full adherence for all participants, a marked underprediction of concentrations was observed using both PK models. Our results suggest that only 39-50% of children received the three scheduled doses of AQ as prescribed, 33-37% two doses and 17-24% received only the first dose administered by the study nurse. Both models were highly congruent to classify adherence patterns. Conclusions Considering the IPTi intervention, our results seem to indicate that medication adherence is low in the ideal trial research setting and is likely to be even lower if given in day-to-day practice, questioning the real impact that this intervention might have. More generally, the estimation of the number of doses truly administered, a proxy measure of adherence and an assessment of the feasibility of the mode of administration, should be more thoroughly studied when discussing the efficacy of the interventions in trials investigating self-administered malaria preventive treatments.	[Sottas, Oriane; Schneider, Marie; Genton, Blaise; Senn, Nicolas] Dept Ambulatory Care & Community Med, Lausanne, Switzerland; [Guidi, Monia; Thieffry, Benjamin; Decosterd, Laurent; Csajka, Chantal] Lausanne Univ Hosp, Serv Clin Pharmacol, Lausanne, Switzerland; [Guidi, Monia; Schneider, Marie; Csajka, Chantal] Univ Lausanne, Univ Geneva, Sch Pharmaceut Sci, Clin Pharm Sci, Geneva, Switzerland; [Mueller, Ivo] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia; [Mueller, Ivo; Senn, Nicolas] PNG IMR, Madang, Papua N Guinea; [Genton, Blaise; Senn, Nicolas] Swiss Trop & Publ Hlth Inst, Basel, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva; University of Lausanne; Walter & Eliza Hall Institute; PNG Institute Of Medical Research; University of Basel; Swiss Tropical & Public Health Institute	Senn, N (corresponding author), Dept Ambulatory Care & Community Med, Lausanne, Switzerland.; Senn, N (corresponding author), PNG IMR, Madang, Papua N Guinea.; Senn, N (corresponding author), Swiss Trop & Publ Hlth Inst, Basel, Switzerland.	nicolas.senn@hospvd.ch	Decosterd, Laurent/E-8494-2019	Decosterd, Laurent/0000-0002-9840-1325; Guidi, Monia/0000-0002-6419-9317; Schneider, Marie Paule/0000-0002-7557-9278; Csajka, Chantal/0000-0002-0660-082X	PNG Institute of Medical Research from the Bill & Melinda Gates Foundation's Global Health Program [34678]; Department of Ambulatory Care and Community Medicine; PNG IMR	PNG Institute of Medical Research from the Bill & Melinda Gates Foundation's Global Health Program; Department of Ambulatory Care and Community Medicine; PNG IMR	This work was supported by a grant to the PNG Institute of Medical Research from the Bill & Melinda Gates Foundation's Global Health Program (Grant ID#34678), and internal funds from the PNG IMR and Department of Ambulatory Care and Community Medicine. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bell DJ, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-204; De Geest Sabina, 2003, Eur J Cardiovasc Nurs, V2, P323; Gosling RD, 2009, TROP MED INT HEALTH, V14, P1003, DOI 10.1111/j.1365-3156.2009.02303.x; Greenwood B, 2007, CLIN INFECT DIS, V45, P26, DOI 10.1086/518574; Hietala SF, 2007, J PHARMACOKINET PHAR, V34, P669, DOI 10.1007/s10928-007-9064-2; Lehmann A, 2014, INT J CLIN PHARM-NET, V36, P55, DOI 10.1007/s11096-013-9865-x; Minzi O, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-267; Morris CA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-263; Pell C, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-369; Schellenberg JRMA, 2010, AM J TROP MED HYG, V82, P772, DOI 10.4269/ajtmh.2010.09-0207; Senn N, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001195; SHEINER LB, 1981, J PHARMACOKINET BIOP, V9, P503, DOI 10.1007/BF01060893; Stepniewska K, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-200; Vrijens B, 2012, BRIT J CLIN PHARMACO, V73, P691, DOI 10.1111/j.1365-2125.2012.04167.x; World Health Organization (WHO), 2010, WHO POL REC INT PREV	15	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2019	14	2							e0210789	10.1371/journal.pone.0210789	http://dx.doi.org/10.1371/journal.pone.0210789			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK4EL	30726224	Green Accepted, Green Published, gold, Green Submitted			2023-01-03	WOS:000457874000031
J	Prinja, S; Bahuguna, P; Gupta, I; Chowdhury, S; Trivedi, M				Prinja, Shankar; Bahuguna, Pankaj; Gupta, Indrani; Chowdhury, Samik; Trivedi, Mayur			Role of insurance in determining utilization of healthcare and financial risk protection in India	PLOS ONE			English	Article							SECTOR; STATE	Background Universal health coverage has become a policy goal in most developing economies. We assess the association of health insurance (HI) schemes in general, and RSBY (National Health Insurance Scheme) in particular, on extent and pattern of healthcare utilization. Secondly, we assess the relationship of HI and RSBY on out-of-pocket (OOP) expenditures and financial risk protection (FRP). Methods A cross-sectional study was undertaken to interview 62335 individuals among 12,134 households in 8 districts of three states in India i.e. Gujarat, Haryana and Uttar Pradesh (UP). Data on socio-demographic characteristics, assets, education, occupation, consumption expenditure, illness in last 15 days or hospitalization during last 365 days, treatment sought and its OOP expenditure was collected. We computed catastrophic health expenditures (CHE) as indicator for FRP. Hospitalization rate, choice of care provider and CHE were regressed to assess their association with insurance status and type of insurance scheme, after adjusting for other covariates. Results Mean OOP expenditures for outpatient care among insured and uninsured were INR 961 (USD 16) and INR 840 (USD 14); and INR 32573 (USD 543) and INR 24788 (USD 413) for an episode of hospitalization respectively. The prevalence of CHE for hospitalization was 28% and 26% among the insured and uninsured population respectively. No significant association was observed in multivariate analysis between hospitalization rate, choice of care provider or CHE with insurance status or RSBY in particular. Conclusion Health insurance in its present form does not seem to provide requisite improvement in access to care or financial risk protection.	[Prinja, Shankar; Bahuguna, Pankaj] Post Grad Inst Med Educ & Res, Sch Publ Hlth, Chandigarh, India; [Gupta, Indrani; Chowdhury, Samik] Univ Delhi Enclave, Inst Econ Growth, Hlth Policy Res Unit, Delhi, India; [Trivedi, Mayur] Indian Inst Publ Hlth, Gandhinagar, Gujarat, India	Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; University of Delhi	Prinja, S (corresponding author), Post Grad Inst Med Educ & Res, Sch Publ Hlth, Chandigarh, India.	shankarprinja@gmail.com	Chowdhury, Samik/AAM-9819-2020; Trivedi, Mayur/AFU-4877-2022; Trivedi, Mayur/AHA-6256-2022	Trivedi, Mayur/0000-0002-4532-2340; Bahuguna, Pankaj/0000-0001-9952-6077	Indian Council of Social Science Research (ICSSR), New Delhi, India	Indian Council of Social Science Research (ICSSR), New Delhi, India	The study was funded by the Indian Council of Social Science Research (ICSSR), New Delhi, India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acharya A., 2012, IMPACT NATL HLTH INS; Aiyar A, 2013, RASHTRIYA SWASTHYA B; Amicus Advisory Private Limited, RASHTR SWASTHV BIM Y; Bergkvist S, 2014, WORLD BANK POLICY RE; Bhat R, 20060702 IND I MAN; Bhore Joseph, 1946, REPORT HLTH SURVEY D; Fan VY, 2012, INT J HEALTH CARE FI, V12, P189, DOI 10.1007/s10754-012-9110-5; GoI, 2013, STAT WIS PER CAP INC; GoI, 2014, KEY IND SOC CONS IND; Gupta I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166775; Hou X, 2011, HOSP PATTERNS RSBY P; Howe LD, 2012, INT J EPIDEMIOL, V41, P871, DOI 10.1093/ije/dys037; Indrani Gupta, 2017, Journal of Social and Economic Development, V19, P83, DOI 10.1007/s40847-017-0040-4; IRDAI, 2014, ANN REP 2013 14; IRDAI, 2017, ANN REP 2016 17; Katyal A, 2015, HEALTH POLICY PLANN, V30, pi23, DOI 10.1093/heapol/czu061; Krishnaswamy K, 2011, PERFORMANCE TRENDS P; La Forgia G, 2012, GOVT SPONSERED HLTH; MHFW, 2018, INF ED COMM IEC GUID; Ministry of Statistics and Programme Implementation (MOSPI), 2006, MORB HLTH CAR COND A; Nandi A, 2015, INDIAN J MED RES, V142, P383, DOI 10.4103/0971-5916.169194; Nandi A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066296; Narayana D., 2010, ECON POLIT WEEKLY, V45, P13; Palacios Robert, 2011, INDIAS HLTH INSURANC, P1; Philip NE, 2012, BMC P; Planning Commission Government of India, 2013, 12 5 YEAR PLAN 2012, VII; Planning Commission of India, 2011, HIGH LEV EXP GROUP R; Prinja S, 2019, INT J HEALTH PLAN M, V34, P277, DOI 10.1002/hpm.2628; Prinja S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170996; Prinja S, 2017, HEALTH POLICY PLANN, V32, P43, DOI 10.1093/heapol/czw097; Prinja S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137315; Prinja S, 2012, INDIAN J MED RES, V136, P421; Rao M, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004471; Reddy K.S., 2011, PUBLIC HLTH FDN INDI, V4, P1; RGI, 2013, SRS B SAMPL REG SYST; RGI, 2011, MAT MORT RAT B; Selvaraj Sakthivel, 2012, ECON POLIT WEEKLY, V47, P61; Sharma D, 2017, INDIAN J MED RES, V146, P759, DOI 10.4103/ijmr.IJMR_2003_15; Shoree S, 2014, EVALUATION RSBYS KEY; Sood N, 2014, BMJ, V13; United Nations, 2015, IND MDGS SUST FUT AL; Vellakkal S, 2009, MICROECONOMICS WORKI; Wagstaff A, 2003, HEALTH ECON, V12, P921, DOI 10.1002/hec.776	43	31	31	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2019	14	2							e0211793	10.1371/journal.pone.0211793	http://dx.doi.org/10.1371/journal.pone.0211793			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK2MO	30721253	Green Published, gold			2023-01-03	WOS:000457746300029
J	Xu, YC; Poggio, M; Jin, HY; Shi, Z; Forester, CM; Wang, Y; Stumpf, CR; Xue, LR; Devericks, E; So, L; Nguyen, HG; Griselin, A; Gordan, JD; Umetsu, SE; Reich, SH; Worland, ST; Asthana, S; Barna, M; Webster, KR; Cunningham, JT; Ruggero, D				Xu, Yichen; Poggio, Mauro; Jin, Hyun Yong; Shi, Zhen; Forester, Craig M.; Wang, Ying; Stumpf, Craig R.; Xue, Lingru; Devericks, Emily; So, Lomon; Nguyen, Hao G.; Griselin, Alice; Gordan, John D.; Umetsu, Sarah E.; Reich, Siegfried H.; Worland, Stephen T.; Asthana, Saurabh; Barna, Maria; Webster, Kevin R.; Cunningham, John T.; Ruggero, Davide			Translation control of the immune checkpoint in cancer and its therapeutic targeting	NATURE MEDICINE			English	Article							T-CELLS; HEPATOCELLULAR-CARCINOMA; READ ALIGNMENT; IN-VIVO; C-MYC; EXPRESSION; TUMOR; INITIATION; PHOSPHORYLATION; PD-L1	Cancer cells develop mechanisms to escape immunosurveillance, among which modulating the expression of immune suppressive messenger RNAs is most well-documented. However, how this is molecularly achieved remains largely unresolved. Here, we develop an in vivo mouse model of liver cancer to study oncogene cooperation in immunosurveillance. We show that MYC overexpression (MYCTg) synergizes with KRAS(G12D) to induce an aggressive liver tumor leading to metastasis formation and reduced mouse survival compared with KRAS(G12D) alone. Genome-wide ribosomal footprinting of MYCTg; KRAS(G12) tumors compared with KRAS(G12D) revealed potential alterations in translation of mRNAs, including programmed-death-ligand 1 (PD-L1). Further analysis revealed that PD-L1 translation is repressed in KRAS(G12D) tumors by functional, non-canonical upstream open reading frames in its 5' untranslated region, which is bypassed in MYCTg; KRAS(G12D) tumors to evade immune attack. We show that this mechanism of PD-L1 translational upregulation was effectively targeted by a potent, clinical compound that inhibits eIF4E phosphorylation, eFT508, which reverses the aggressive and metastatic characteristics of MYCTg; KRAS(G12D) tumors. Together, these studies reveal how immune-checkpoint proteins are manipulated by distinct oncogenes at the level of mRNA translation, which can be exploited for new immunotherapies.	[Xu, Yichen; Poggio, Mauro; Jin, Hyun Yong; Forester, Craig M.; Wang, Ying; Stumpf, Craig R.; Xue, Lingru; Devericks, Emily; So, Lomon; Nguyen, Hao G.; Griselin, Alice; Cunningham, John T.; Ruggero, Davide] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA; [Xu, Yichen; Poggio, Mauro; Jin, Hyun Yong; Forester, Craig M.; Wang, Ying; Stumpf, Craig R.; Xue, Lingru; Devericks, Emily; So, Lomon; Nguyen, Hao G.; Griselin, Alice; Gordan, John D.; Asthana, Saurabh; Cunningham, John T.; Ruggero, Davide] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Shi, Zhen; Barna, Maria] Stanford Univ, Dept Dev Biol, Stanford, CA 94305 USA; [Shi, Zhen; Barna, Maria] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Forester, Craig M.] Univ Calif San Francisco, Div Pediat Allergy Immunol & Bone Marrow Transpla, San Francisco, CA 94143 USA; [Wang, Ying] Nanjing Univ, Nanjing Adv Inst Life Sci, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing, Jiangsu, Peoples R China; [Stumpf, Craig R.; Reich, Siegfried H.; Worland, Stephen T.; Webster, Kevin R.] eFFECTOR Therapeut, San Diego, CA USA; [Umetsu, Sarah E.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Cunningham, John T.] Univ Cincinnati, Coll Med, Dept Canc Biol, Cincinnati, OH USA; [Ruggero, Davide] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Stanford University; Stanford University; University of California System; University of California San Francisco; Nanjing University; University of California System; University of California San Francisco; University System of Ohio; University of Cincinnati; University of California System; University of California San Francisco	Ruggero, D (corresponding author), Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA.; Ruggero, D (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.; Ruggero, D (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.	davide.ruggero@ucsf.edu	Forester, Craig/HCI-4174-2022; Cunningham, John T./AAS-5008-2021; Stumpf, Craig/B-8703-2014	Cunningham, John T./0000-0001-6490-4533; Stumpf, Craig/0000-0002-9946-8986; Worland, Stephen/0000-0001-8924-253X	Damon Runyon Postdoctoral Fellowship; AACR-Incyte Corporation Fellowship In Basic Cancer Research [17-40-46-JIN]; Life Science Foundation Postdoctoral Fellowship; Department of Defense Physician training award; Campini Foundation; Leukemia and Lymphoma Foundation; UCSF Department of Pediatrics K12 [5K12HDO72222-05]; American Cancer Society Postdoctoral Fellowship; Conquer Cancer Foundation Young Investigator Award; Pew Scholars Award; NIH [1R01HD086634, R01CA140456, R01CA154916, R01CA184624]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD072222, R01HD086634] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA184624, R01CA154916, R01CA140456] Funding Source: NIH RePORTER	Damon Runyon Postdoctoral Fellowship; AACR-Incyte Corporation Fellowship In Basic Cancer Research; Life Science Foundation Postdoctoral Fellowship; Department of Defense Physician training award; Campini Foundation; Leukemia and Lymphoma Foundation; UCSF Department of Pediatrics K12; American Cancer Society Postdoctoral Fellowship(American Cancer Society); Conquer Cancer Foundation Young Investigator Award; Pew Scholars Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank members of the Ruggero laboratory for discussion and critical reading of the manuscript. We thank C. Her for his help with the mouse HCC cell line generation protocol, D. Wang for the help with hydrodynamic transfection, and K. Fujii and D. Simsek for advice and technique assistance. We thank B. Tiano for the contribution in developing and characterizing the MYC transgenic mice. This work was supported by the Damon Runyon Postdoctoral Fellowship (Y.X.), AACR-Incyte Corporation Fellowship In Basic Cancer Research (grant no. 17-40-46-JIN) (H.Y.J), Life Science Foundation Postdoctoral Fellowship (S.Z.), Department of Defense Physician training award (H.G.N), the Campini Foundation, The Leukemia and Lymphoma Foundation Career Development Grant and UCSF Department of Pediatrics K12 (grant no. 5K12HDO72222-05) (C.M.F.), American Cancer Society Postdoctoral Fellowship and Conquer Cancer Foundation Young Investigator Award (J.D.G), Pew Scholars Award (M.B.), NIH grant no. 1R01HD086634 (M.B.), NIH grants (nos. R01CA140456, R01CA154916, and R01CA184624) (D.R.). M.B. is a New York Stem Cell Foundation Robertson Investigator. D.R. is a Leukemia and Lymphoma Society Scholar.	Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Butte MJ, 2007, IMMUNITY, V27, P111, DOI 10.1016/j.immuni.2007.05.016; Calkhoven CF, 2000, GENE DEV, V14, P1920; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Cerezo M, 2018, NAT MED, V24, P1877, DOI 10.1038/s41591-018-0217-1; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen Yunshun, 2016, F1000Res, V5, P1438, DOI 10.12688/f1000research.8987.2; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Fu JL, 2007, GASTROENTEROLOGY, V132, P2328, DOI 10.1053/j.gastro.2007.03.102; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Gao Q, 2007, J CLIN ONCOL, V25, P2586, DOI 10.1200/JCO.2006.09.4565; Gollwitzer ES, 2014, NAT MED, V20, P642, DOI 10.1038/nm.3568; Gordon SR, 2017, NATURE, V545, P495, DOI 10.1038/nature22396; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hart LS, 2012, J CLIN INVEST, V122, P4621, DOI 10.1172/JCI62973; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Herdy B, 2012, NAT IMMUNOL, V13, P543, DOI 10.1038/ni.2291; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Ingolia NT, 2009, SCIENCE, V324, P218, DOI 10.1126/science.1168978; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204; Kaposi-Novak P, 2009, CANCER RES, V69, P2775, DOI 10.1158/0008-5472.CAN-08-3357; Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294; Khan AR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6997; Kortlever RM, 2017, CELL, V171, P1301, DOI 10.1016/j.cell.2017.11.013; Kozak M, 1998, NUCLEIC ACIDS RES, V26, P4853, DOI 10.1093/nar/26.21.4853; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lau J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14572; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Liu X, 2016, SCI REP-UK, V6, DOI 10.1038/srep36722; Marquardt JU, 2014, J HEPATOL, V60, P346, DOI 10.1016/j.jhep.2013.10.014; Marzec M, 2008, P NATL ACAD SCI USA, V105, P20852, DOI 10.1073/pnas.0810958105; Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; MIYAZAKI J, 1989, GENE, V79, P269; O'Dell MR, 2012, CANCER RES, V72, P1557, DOI 10.1158/0008-5472.CAN-11-3596; Okada A, 1999, EXP NEUROL, V156, P394, DOI 10.1006/exnr.1999.7033; Palam LR, 2011, J BIOL CHEM, V286, P10939, DOI 10.1074/jbc.M110.216093; Pulko V, 2011, J IMMUNOL, V187, P5606, DOI 10.4049/jimmunol.1003976; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rees S, 1996, BIOTECHNIQUES, V20, P102; Reich SH, 2018, J MED CHEM, V61, P3516, DOI 10.1021/acs.jmedchem.7b01795; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Saha SK, 2014, NATURE, V513, P110, DOI 10.1038/nature13441; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Schlaeger C, 2008, HEPATOLOGY, V47, P511, DOI 10.1002/hep.22033; Sekine Y, 2015, SCIENCE, V348, P1027, DOI 10.1126/science.aaa6986; Sendoel A, 2017, NATURE, V541, P494, DOI 10.1038/nature21036; Shalapour S, 2015, NATURE, V521, P94, DOI 10.1038/nature14395; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Sidrauski C, 2015, ELIFE, V4, DOI 10.7554/eLife.05033; Starck SR, 2016, SCIENCE, V351, DOI 10.1126/science.aad3867; Stern-Ginossar N, 2012, SCIENCE, V338, P1088, DOI 10.1126/science.1227919; Stewart B, 2014, WORLD CANC REPORT 20; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Truitt ML, 2017, NAT REV CANCER, V17, P332, DOI 10.1038/nrc.2017.30; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058	69	117	120	1	76	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2019	25	2					301	+		10.1038/s41591-018-0321-2	http://dx.doi.org/10.1038/s41591-018-0321-2			18	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	HK3TW	30643286	Green Accepted			2023-01-03	WOS:000457842100028
J	Chua, KP; Fischer, MA; Linder, JA				Chua, Kao-Ping; Fischer, Michael A.; Linder, Jeffrey A.			Appropriateness of outpatient antibiotic prescribing among privately insured US patients: ICD-10-CM based cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UNITED-STATES; ADULTS; CARE	OBJECTIVE To assess the appropriateness of outpatient antibiotic prescribing for privately insured children and non-elderly adults in the US using a comprehensive classification scheme of diagnosis codes in ICD-10-CM (international classification of diseases-clinical modification, 10th revision), which replaced ICD-9-CM in the US on 1 October 2015. DESIGN Cross sectional study. SETTING MarketScan Commercial Claims and Encounters database, 2016. PARTICIPANTS 19.2 million enrollees aged 0-64 years. MAIN OUTCOME MEASURES A classification scheme was developed that determined whether each of the 91 738 ICD-10-CM diagnosis codes "always," "sometimes," or "never" justified antibiotics. For each antibiotic prescription fill, this scheme was used to classify all diagnosis codes in claims during a look back period that began three days before antibiotic prescription fills and ended on the day fills occurred. The main outcome was the proportion of fills in each of four mutually exclusive categories: "appropriate" (associated with at least one "always" code during the look back period, "potentially appropriate" (associated with at least one "sometimes" but no "always" codes), "inappropriate" (associated only with "never" codes), and "not associated with a recent diagnosis code" (no codes during the look back period). RESULTS The cohort (n=19 203 264) comprised 14 571 944 (75.9%) adult and 9 935 791 (51.7%) female enrollees. Among 15 455 834 outpatient antibiotic prescription fills by the cohort, the most common antibiotics were azithromycin (2 931 242, 19.0%), amoxicillin (2 818 939, 18.2%), and amoxicillinclavulanate (1 784 921, 11.6%). Among these 15 455 834 fills, 1 973 873 (12.8%) were appropriate, 5 487 003 (35.5%) were potentially appropriate, 3 592 183 (23.2%) were inappropriate, and 4 402 775 (28.5%) were not associated with a recent diagnosis code. Among the 3 592 183 inappropriate fills, 2 541 125 (70.7%) were written in office based settings, 222 804 (6.2%) in urgent care centers, and 168 396 (4.7%) in emergency departments. In 2016, 2 697 918 (14.1%) of the 19 203 264 enrollees filled at least one inappropriate antibiotic prescription, including 490 475 out of 4 631 320 children (10.6%) and 2 207 173 out of 14 571 944 adults (15.2%). CONCLUSIONS Among all outpatient antibiotic prescription fills by 19 203 264 privately insured US children and non-elderly adults in 2016, 23.2% were inappropriate, 35.5% were potentially appropriate, and 28.5% were not associated with a recent diagnosis code. Approximately 1 in 7 enrollees filled at least one inappropriate antibiotic prescription in 2016. The classification scheme could facilitate future efforts to comprehensively measure outpatient antibiotic appropriateness in the US, and it could be adapted for use in other countries that use ICD-10 codes.	[Chua, Kao-Ping] Univ Michigan, Sch Med, Dept Pediat Child Hlth Evaluat & Res, 300 N Ingalls St,SPC 5456 Room 6E18, Ann Arbor, MI 48109 USA; [Fischer, Michael A.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA; [Linder, Jeffrey A.] Northwestern Univ, Dept Med, Div Gen Internal Med & Geriatr, Feinberg Sch Med, Chicago, IL 60611 USA	University of Michigan System; University of Michigan; Harvard University; Brigham & Women's Hospital; Northwestern University; Feinberg School of Medicine	Chua, KP (corresponding author), Univ Michigan, Sch Med, Dept Pediat Child Hlth Evaluat & Res, 300 N Ingalls St,SPC 5456 Room 6E18, Ann Arbor, MI 48109 USA.	chuak@med.umich.edu	Linder, Jeffrey/AAF-3424-2021	Linder, Jeffrey/0000-0003-2217-184X; Chua, Kao-Ping/0000-0002-4081-272X	Agency for Healthcare Research and Quality [HHSP233201500020I, R01HS024930]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS024930] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	JAL and MAF are supported by a grant from the Agency for Healthcare Research and Quality (R01HS024930). JAL is supported by a contract from the Agency for Healthcare Research and Quality (HHSP233201500020I). The funding source played no role in the design of the study; the collection, analysis, and interpretation of the data; and the decision to approve publication of the finished manuscript.	Agency for Healthcare Research and Quality, 2018, BET CLIN CLASS SOFTW; Aizcorbe Ana, 2012, Stat J IAOS, V28, P43, DOI 10.3233/SJI-2012-0743; Barnett ML, 2017, JAMA INTERN MED, V177, P829, DOI 10.1001/jamainternmed.2017.0401; Barnett ML, 2014, JAMA-J AM MED ASSOC, V311, P2020, DOI 10.1001/jama.2013.286141; Barnett ML, 2014, JAMA INTERN MED, V174, P138, DOI 10.1001/jamainternmed.2013.11673; CDC, 2013, ANTIBIOTIC RESISTANC; Centers for Disease Control and Prevention, 2017, GET SMART KNOW ANT W; Chua KP, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-1809; Durkin MJ, 2018, J AM DENT ASSOC, V149, P372, DOI 10.1016/j.adaj.2017.11.034; Finkelstein JA, 2001, PEDIATRICS, V108, pU113; Fleming-Dutra KE, 2016, JAMA-J AM MED ASSOC, V315, P1864, DOI 10.1001/jama.2016.4151; Hansen LG, 2011, HLTH RES DATA REAL W; Havers FP, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0243; Hersh AL, 2011, PEDIATRICS, V128, P1053, DOI 10.1542/peds.2011-1337; Kaiser Family Foundation, 2018, HEALTH INSURANCE COV; Linder JA, 2014, JAMA INTERN MED, V174, P2029, DOI 10.1001/jamainternmed.2014.5225; Linder JA, 2010, AM J MANAG CARE, V16, pE311; Meeker D, 2016, JAMA-J AM MED ASSOC, V315, P562, DOI 10.1001/jama.2016.0275; Meeker D, 2014, JAMA INTERN MED, V174, P425, DOI 10.1001/jamainternmed.2013.14191; Mehrotra A, 2015, AM J MANAG CARE, V21, P294; Mundkur ML, 2018, CHANGES OUTPATIENT U, DOI [10.1007%2Fs40264-018-0697-4, DOI 10.1007/2FS40264-018-0697-4]; National Committee on Quality Assurance, 2016, HEALTHC EFF DAT INF; Olesen SW, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3155; Palms DL, 2018, JAMA INTERN MED, V178, P1267, DOI 10.1001/jamainternmed.2018.1632; Price L, 2018, J ANTIMICROB CHEMOTH, V73, P1464, DOI 10.1093/jac/dky076; Riedle BN, 2017, INFECT CONT HOSP EP, V38, P273, DOI 10.1017/ice.2016.269; Roth S, 2012, AM J MANAG CARE, V18, pE217; Shively NR, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.00337-18;e00337-18; Strauss JS, 2007, J AM ACAD DERMATOL, V56, P651, DOI 10.1016/j.jaad.2006.08.048	29	115	116	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 16	2019	364								k5092	10.1136/bmj.k5092	http://dx.doi.org/10.1136/bmj.k5092			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HI3YD	30651273	Green Published, hybrid			2023-01-03	WOS:000456386700015
J	Griffiths, GO; Cowan, RA; Grigor, KM; Uscinska, BM; Sydes, M; Russell, M				Griffiths, Gareth O.; Cowan, Richard A.; Grigor, Kenneth M.; Uscinska, Barbara M.; Sydes, Matthew; Russell, Martin			BA08: An open-label, single-arm, non-randomised, phase 2 trial of cisplatin, methotrexate and vinblastine (CMV) for pure squamous cell cancer of the urinary tract	PLOS ONE			English	Article							CARCINOMA; BLADDER	Background Pure squamous cell carcinoma (SCC) of the urinary tract is rare in the UK and has a poor prognosis compared with transitional cell carcinoma (TCC). Cisplatin based chemotherapy has been shown to be effective in TCC. Methods Patients with T3-T4, pelvic relapsed, nodal or metastatic SCC of the urinary tract were recruited into an open-label, single-arm, non-randomised, phase 2 trial evaluating the activity and safety of cisplatin, methotrexate and vinblastine (CMV) chemotherapy. CMV was given as three 21-day cycles of methotrexate 30mg/m(2) (day 1 & 8), vinblastine 4mg/m(2) (day 1 & 8) and cisplatin 100mg/m(2) (day 2). Results 38 patients were recruited. Overall response was 39% (95% CI 24%, 55%)-13% CR and 26% PR. Median OS was 7.8 months (95% CI 3.4, 12.6) with 39% 1-year survival. Toxicity was acceptable. Conclusion CMV is well tolerated and active in patients with pure SCC of the urinary tract.	[Griffiths, Gareth O.] Univ Southampton, Southampton Clin Trials Unit, Southampton, Hants, England; [Cowan, Richard A.] Christie Hosp, Manchester, Lancs, England; [Grigor, Kenneth M.] Western Gen Hosp, Dept Pathol, Edinburgh, Midlothian, Scotland; [Uscinska, Barbara M.; Sydes, Matthew] UCL, Med Res Council, Clin Trials Unit, London, England; [Russell, Martin] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland	University of Southampton; Christie NHS Foundation Trust; Christie Hospital; University of Edinburgh; Medical Research Council Clinical Trials Unit; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of London; University College London; University of Glasgow	Griffiths, GO (corresponding author), Univ Southampton, Southampton Clin Trials Unit, Southampton, Hants, England.	G.O.Griffiths@soton.ac.uk	Sydes, Matthew/C-3373-2008; Cowan, Richard/N-7633-2015	Sydes, Matthew/0000-0002-9323-1371; Russell, John/0000-0003-4594-4155; Cowan, Richard/0000-0001-9004-8136; Griffiths, Gareth/0000-0002-9579-8021	UK Medical Research Council; MRC at the MRC Clinical Trials Unit; MRC [MC_UU_12023/28] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC at the MRC Clinical Trials Unit(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The trial was funded by the UK Medical Research Council (www.mrc.ac.uk) which funded staff at the MRC Clinical Trial Unit. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript; The BA08 trial was developed on behalf of the MRC Working Party in Bladder Cancer (now the UK National Cancer Research Institute Bladder and Renal Cancer Clinical Studies Group). The trial was sponsored by the MRC at the MRC Clinical Trials Unit (formally the MRC Cancer Trials office). We thank all the participants, the doctors, UK National Institute for Health Research Clinical Research Network Cancer research nurses, and other members of the multidisciplinary teams and research teams who supported this trial at participating centres (Beatson Oncology Centre-13 patients, Christie Hospital-5 patients, Clatterbridge Hospital-4 patients, Middlesex Hospital-4 patients, Western General-2 patients, Weston Park-2 patients, Guys Hospital-2 patients, Newcastle General-1 patient, Queen Elizabeth-1 patient, Norwegian Radium Hospital-1 patient, Walsgrave Hospital-1 patient, North Staffordshire Hospital-1 patient, Oncology centre, Warsaw-1 patient).	Bogaerts J, 2015, EUR J CANCER, V51, P271, DOI 10.1016/j.ejca.2014.10.027; COSTELLO AJ, 1984, UROLOGY, V23, P234, DOI 10.1016/S0090-4295(84)90035-9; Griffiths G, 2011, J CLIN ONCOL, V29, P2171, DOI 10.1200/JCO.2010.32.3139; Guo CC, 2009, HUM PATHOL, V40, P1448, DOI 10.1016/j.humpath.2009.03.005; JOHNSON DE, 1976, J UROLOGY, V115, P542, DOI 10.1016/S0022-5347(17)59272-1; JONES MA, 1980, BRIT J UROL, V52, P511, DOI 10.1111/j.1464-410X.1980.tb03102.x; Mead GM, 1998, BRIT J CANCER, V78, P1067, DOI 10.1038/bjc.1998.629; National Institute for Health and Clinical Excellence (NICE) Guidance, 2015, BLADD CANC DIAGN MAN; QUILTY PM, 1986, INT J RADIAT ONCOL, V12, P861, DOI 10.1016/0360-3016(86)90377-9; Youssef R, 2012, BJU INT, V110, P961, DOI 10.1111/j.1464-410X.2012.10949.x	10	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2019	14	1							e0210785	10.1371/journal.pone.0210785	http://dx.doi.org/10.1371/journal.pone.0210785			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH6BK	30650143	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000455813300078
J	Nilson, F; Damsager, J; Lauritsen, J; Bonander, C				Nilson, Finn; Damsager, John; Lauritsen, Jens; Bonander, Carl			The effect of breed-specific dog legislation on hospital treated dog bites in Odense, Denmark-A time series intervention study	PLOS ONE			English	Article							EPIDEMIOLOGY; DEMOGRAPHY; INJURIES; CHILDREN	As dog bite injuries are a considerable problem in modern society, in order to reduce such injuries, breed-specific legislation has been introduced in a number of countries. Whilst many studies have shown a lack of effect with such legislation, the commonly used methodology is known to be flawed. Therefore, the aim of this study is to investigate the effect of the Danish breed-specific legislation on the number of dog bite injuries using more credible methods. A time series intervention method was used on a detailed dataset from Odense University Hospital, Denmark, regarding dog bite injuries presented to the emergency department. The results indicate that banning certain breeds has a highly limited effect on the overall levels of dog bite injuries, and that an enforcement of the usage of muzzle and leash in public places for these breeds also has a limited effect. Despite using more credible and sound methods, this study supports previous studies showing that breed-specific legislation seems to have no effect on dog bite injuries. In order to minimise dog bite injuries in the future, it would seem that other interventions or non-breed-specific legislation should be considered as the primary option.	[Nilson, Finn; Damsager, John] Karlstad Univ, Dept Environm & Life Sci, Karlstad, Sweden; [Nilson, Finn; Bonander, Carl] Karlstad Univ, Ctr Publ Safety, Karlstad, Sweden; [Lauritsen, Jens] Odense Univ Hosp, Dept Orthoped & Traumatol, Accid Anal Grp, Odense, Denmark; [Lauritsen, Jens] Univ Southern Denmark, Dept Clin Med, Odense, Denmark; [Bonander, Carl] Univ Gothenburg, Inst Med, Hlth Metr Unit, Gothenburg, Sweden	Karlstad University; Karlstad University; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; University of Gothenburg	Nilson, F (corresponding author), Karlstad Univ, Dept Environm & Life Sci, Karlstad, Sweden.; Nilson, F (corresponding author), Karlstad Univ, Ctr Publ Safety, Karlstad, Sweden.	finn.nilson@kau.se	; Nilson, Finn/H-2383-2017	Bonander, Carl/0000-0002-1189-9950; Nilson, Finn/0000-0002-6928-0683; Lauritsen, Jens/0000-0001-9281-8990				Abadie A, 2015, AM J POLIT SCI, V59, P495, DOI 10.1111/ajps.12116; Angrist JD, 2014, MASTERING METRICS PA; Beaver BV, 2001, J AM VET MED ASSOC, V218, P1732, DOI 10.2460/javma.2001.218.1732; Bonander C., 2016, ASSESSING EFFECTS SO; Box G. E. P., 2015, TIME SERIES ANAL FOR; Boyle P, 1991, CANC REGISTRATION PR, V95; Chapman S, 2000, BRIT MED J, V320, P1512, DOI 10.1136/bmj.320.7248.1512; Chiam SC, 2014, J PAEDIATR CHILD H, V50, P791, DOI 10.1111/jpc.12642; Collier S, 2006, J VET BEHAV, V1, P17, DOI 10.1016/j.jveb.2006.04.011; Cornelissen JMR, 2010, VET J, V186, P292, DOI 10.1016/j.tvjl.2009.10.001; D'Onise K, 2017, INJURY PREVENTION; Kimble RM, 2011, MED J AUSTRALIA, V195, P635, DOI 10.5694/mja11.11319; Klaassen B, 1996, INJURY, V27, P89, DOI 10.1016/0020-1383(96)83411-5; Mariti C., 2015, DOG BEHAV, V2, P25; NOMESCO, 1997, NOMESCO CLASS EXT CA; Overall KL, 2001, J AM VET MED ASSOC, V218, P1923, DOI 10.2460/javma.2001.218.1923; Ozanne-Smith J, 2001, Inj Prev, V7, P321, DOI 10.1136/ip.7.4.321; Patronek GJ, 2013, JAVMA-J AM VET MED A, V243, P1726, DOI 10.2460/javma.243.12.1726; Patronek GJ, 2010, JAVMA-J AM VET MED A, V237, P788, DOI 10.2460/javma.237.7.788; Raghavan M, 2012, INJURY PREVENTION; Roberts SE, 2003, BRIT MED J, V327, P771, DOI 10.1136/bmj.327.7418.771; Rosado B, 2007, J VET BEHAV, V2, P166, DOI 10.1016/j.jveb.2007.07.010; Rosado B, 2009, VET J, V179, P383, DOI 10.1016/j.tvjl.2008.02.002; Sacks J J, 1996, Inj Prev, V2, P52, DOI 10.1136/ip.2.1.52; Shuler CM, 2008, JAVMA-J AM VET MED A, V232, P542, DOI 10.2460/javma.232.4.542; Suilleabhain PO, 2015, VET J, V204, P357, DOI 10.1016/j.tvjl.2015.04.021; Villalbi JR, 2010, INJURY PREV, V16, DOI 10.1136/ip.2010.026997; Voith VL, 2009, J APPL ANIM WELF SCI, V12, P253, DOI 10.1080/10888700902956151; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x	29	10	10	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 26	2018	13	12							e0208393	10.1371/journal.pone.0208393	http://dx.doi.org/10.1371/journal.pone.0208393			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF7JV	30586418	Green Published, Green Submitted, gold			2023-01-03	WOS:000454416400018
J	Ding, XP; Mei, WL; Huang, SZ; Wang, H; Zhu, JH; Hu, W; Ding, ZH; Tie, WW; Peng, SQ; Dai, HF				Ding, Xupo; Mei, Wenli; Huang, Shengzhuo; Wang, Hui; Zhu, Jiahong; Hu, Wei; Ding, Zehong; Tie, Weiwei; Peng, Shiqing; Dai, Haofu			Genome survey sequencing for the characterization of genetic background of Dracaena cambodiana and its defense response during dragon's blood formation	PLOS ONE			English	Article							STEROIDAL SAPONINS; COCHINCHINENSIS; FLAVONOIDS; CINNABARI; EVOLUTION; FAMILIES; ENZYMES; DRACO; FLOW; SIZE	Dragon's blood collected from the genus Dracaena is used as a renowned traditional medicine in various cultures worldwide. However, the genetics of the genus Dracaena and the formation mechanism of dragon's blood remain poorly understood. Here, we generate the first draft genome reference assembly of an elite Chinese Dracaena species, Dracaena cambodiana, from next-generation sequencing data with 89.46x coverage. The reads were assembled into 2,640,704 contigs with an N50 length of 1.87 kb, and a 1.05 Gb assembly was finally assembled with 2,379,659 scaffolds. Furthermore, 97.75% of the 267,243 simple sequence repeats identified from these scaffolds were mononucleotide, dinucleotide, and trinucleotide repeats. Among all 53,700 predicted genes, 158 genes involved in cell wall and plant hormone synthesis and reactive oxygen species scavenging showed altered regulation during the formation of dragon's blood. This study provides a genomic characterization of D. cambodiana and improves understanding of the molecular mechanism of dragon's blood formation. This report represents the first genome-wide characterization of a Dracaena species in the Asparagaceae.	[Ding, Xupo; Mei, Wenli; Huang, Shengzhuo; Wang, Hui; Zhu, Jiahong; Hu, Wei; Ding, Zehong; Tie, Weiwei; Peng, Shiqing; Dai, Haofu] Chinese Acad Trop Agr Sci, Inst Trop Biosci & Biotechnol, Minist Agr & Rural Affairs, Key Lab Biol & Genet Resources Trop Crops, Haikou, Hainan, Peoples R China; [Ding, Xupo; Mei, Wenli; Huang, Shengzhuo; Wang, Hui; Dai, Haofu] Chinese Acad Trop Agr Sci, Inst Trop Biosci & Biotechnol, Hainan Key Lab Res & Dev Nat Prod Lifolk Med, Haikou, Hainan, Peoples R China	Chinese Academy of Tropical Agricultural Sciences; Ministry of Agriculture & Rural Affairs; Chinese Academy of Tropical Agricultural Sciences	Mei, WL; Peng, SQ; Dai, HF (corresponding author), Chinese Acad Trop Agr Sci, Inst Trop Biosci & Biotechnol, Minist Agr & Rural Affairs, Key Lab Biol & Genet Resources Trop Crops, Haikou, Hainan, Peoples R China.; Mei, WL; Dai, HF (corresponding author), Chinese Acad Trop Agr Sci, Inst Trop Biosci & Biotechnol, Hainan Key Lab Res & Dev Nat Prod Lifolk Med, Haikou, Hainan, Peoples R China.	meiwenli@itbb.org.cn; pengshiqing@itbb.org.cn; daihaofu@itbb.org.cn		Ding, Xupo/0000-0001-9195-7112	Central Public-interest Scientific Institution Basal Research Fund for Chinese Academy of Tropical Agricultural Sciences [1630052016002, 17CXTD-15]; National Natural Science Foundation of China [81803663]; Key Research and Development Project of Hainan Province [ZDYF2018226]; China Agriculture Research System [CARS-21]	Central Public-interest Scientific Institution Basal Research Fund for Chinese Academy of Tropical Agricultural Sciences; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research and Development Project of Hainan Province; China Agriculture Research System	This research was supported by the Central Public-interest Scientific Institution Basal Research Fund for Chinese Academy of Tropical Agricultural Sciences (1630052016002 and 17CXTD-15), www.catas.cn/; the National Natural Science Foundation of China (81803663), http://www.nsfc.gov.cn/; the Key Research and Development Project of Hainan Province (ZDYF2018226), www.dost.hainan.gov.cn/; and the China Agriculture Research System (CARS-21), http://www.moa.gov.cn/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This research was supported by the Central Public-interest Scientific Institution Basal Research Fund for Chinese Academy of Tropical Agricultural Sciences (1630052016002 and 17CXTD-15), the National Natural Science Foundation of China (81803663), the Key Research and Development Project of Hainan Province (ZDYF2018226) and the China Agriculture Research System (CARS-21). We are grateful to Biomarker Technologies Co., Ltd. (Beijing, China) and Beijing Genomics Institute (Shenzhen, China) for providing technical help.	Adelyna MAN, 2016, META GENE, V10, P67, DOI 10.1016/j.mgene.2016.10.005; Adolt R, 2004, TREES-STRUCT FUNCT, V18, P43, DOI 10.1007/s00468-003-0279-6; Ahuja I, 2012, TRENDS PLANT SCI, V17, P73, DOI 10.1016/j.tplants.2011.11.002; Aird D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-2-r18; Alazem M, 2015, MOL PLANT PATHOL, V16, P529, DOI 10.1111/mpp.12204; Aslam J, 2013, SAUDI J BIOL SCI, V20, P63, DOI 10.1016/j.sjbs.2012.11.005; Tapondjou LA, 2008, ARCH PHARM RES, V31, P653, DOI 10.1007/s12272-001-1208-3; Bao HXGDL, 2015, PLANT CELL ENVIRON, V38, P600, DOI 10.1111/pce.12419; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Ben Rejeb K, 2014, PLANT PHYSIOL BIOCH, V80, P278, DOI 10.1016/j.plaphy.2014.04.007; Blake JA, 2015, NUCLEIC ACIDS RES, V43, pD1049, DOI 10.1093/nar/gku1179; Blanco Enrique, 2007, Curr Protoc Bioinformatics, VChapter 4, DOI 10.1002/0471250953.bi0403s18; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Chen HQ, 2012, J ASIAN NAT PROD RES, V14, P436, DOI 10.1080/10286020.2012.668534; Chen W, 2017, MOL PLANT, V10, P899, DOI 10.1016/j.molp.2017.02.010; Choudhury FK, 2017, PLANT J, V90, P856, DOI 10.1111/tpj.13299; Cloonan N, 2008, NAT METHODS, V5, P613, DOI 10.1038/nmeth.1223; Cong Q, 2015, CELL REP, V10, P910, DOI 10.1016/j.celrep.2015.01.026; Deng WK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111988; Ding XP, 2015, FRONT PLANT SCI, V6, DOI 10.3389/fpls.2015.00830; Du HL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15324; Erb M, 2009, PLANT J, V59, P292, DOI 10.1111/j.1365-313X.2009.03868.x; Fan JY, 2014, MOLECULES, V19, P10650, DOI 10.3390/molecules190710650; Fischer Steve, 2011, Curr Protoc Bioinformatics, VChapter 6, DOI 10.1002/0471250953.bi0612s35; Gongora-Castillo E, 2012, METHOD ENZYMOL, V517, P139, DOI 10.1016/B978-0-12-404634-4.00007-3; Gonzalez AG, 2004, BIOCHEM SYST ECOL, V32, P179, DOI 10.1016/S0305-1978(03)00133-9; Goodwin S, 2016, NAT REV GENET, V17, P333, DOI 10.1038/nrg.2016.49; Gro?kinsky D.K., 2016, PLANT PATHOGEN RESIS, p131?154, DOI [10.1002/9781118867716.ch7, DOI 10.1002/9781118867716.CH7]; Gupta D, 2008, J ETHNOPHARMACOL, V115, P361, DOI 10.1016/j.jep.2007.10.018; Hall MR, 2017, NATURE, V544, P231, DOI 10.1038/nature22033; Hematy K, 2009, CURR OPIN PLANT BIOL, V12, P406, DOI 10.1016/j.pbi.2009.06.007; Herrera-Vasquez A, 2015, FRONT PLANT SCI, V6, DOI 10.3389/fpls.2015.00171; Hirakawa H, 2015, DNA RES, V22, P171, DOI 10.1093/dnares/dsv002; Huang SW, 2009, NAT GENET, V41, P1275, DOI 10.1038/ng.475; Jarvis DE, 2017, NATURE, V542, P307, DOI 10.1038/nature21370; Jiao Y, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-201; Jones JDG, 2006, NATURE, V444, P323, DOI 10.1038/nature05286; Jurka J, 2005, CYTOGENET GENOME RES, V110, P462, DOI 10.1159/000084979; Kajitani R, 2014, GENOME RES, V24, P1384, DOI 10.1101/gr.170720.113; Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092; Khan A, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1708-7; Kim NH, 2018, PLANT BIOTECHNOL J, V16, P1904, DOI 10.1111/pbi.12926; Kofler R, 2007, BIOINFORMATICS, V23, P1683, DOI 10.1093/bioinformatics/btm157; Kougan GB, 2010, J NAT PROD, V73, P1266, DOI 10.1021/np100153m; Kristensen DM, 2010, BIOINFORMATICS, V26, P1481, DOI 10.1093/bioinformatics/btq229; Kubicek CP, 2014, ANNU REV PHYTOPATHOL, V52, P427, DOI 10.1146/annurev-phyto-102313-045831; Kubituki K., 1998, FAMILIES GENERA VASC, V3, P125, DOI DOI 10.1007/S00122-011-1709-2; Kuo LY, 2017, NEW PHYTOL, V213, P1974, DOI 10.1111/nph.14291; Li RQ, 2008, BIOINFORMATICS, V24, P713, DOI 10.1093/bioinformatics/btn025; Lin BR, 2016, NEW PHYTOL, V209, P1159, DOI 10.1111/nph.13701; Lu M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147530; Luo Y, 2011, PLANTA MED, V77, P2053, DOI 10.1055/s-0031-1280086; Maldonado-Bonilla LD, 2008, EUR J PLANT PATHOL, V121, P439, DOI 10.1007/s10658-007-9262-1; Marcais G, 2011, BIOINFORMATICS, V27, P764, DOI 10.1093/bioinformatics/btr011; Mascher M, 2017, NATURE, V544, P426, DOI 10.1038/nature22043; Mei WL, 2013, B KOREAN CHEM SOC, V34, P1791, DOI 10.5012/bkcs.2013.34.6.1791; Ming R, 2015, NAT GENET, V47, P1435, DOI 10.1038/ng.3435; Nadezhdina N, 2015, FUNCT PLANT BIOL, V42, P1092, DOI 10.1071/FP15079; Price AL, 2005, BIOINFORMATICS, V21, pI351, DOI 10.1093/bioinformatics/bti1018; Qi JS, 2017, CURR OPIN PLANT BIOL, V38, P92, DOI 10.1016/j.pbi.2017.04.022; Schuman MC, 2016, ANNU REV ENTOMOL, V61, P373, DOI 10.1146/annurev-ento-010715-023851; Suda J, 2005, PLANT SYST EVOL, V252, P215, DOI 10.1007/s00606-004-0280-6; Sudhir Sharma, 2010, Agriculture and Biology Journal of North America, V1, P827, DOI 10.5251/abjna.2010.1.5.827.833; Tang CR, 2016, NAT PLANTS, V2, DOI [10.1038/NPLANTS.2016.73, 10.1038/nplants.2016.73]; Underwood W, 2012, FRONT PLANT SCI, V3, DOI 10.3389/fpls.2012.00085; van Bakel H, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-10-r102; Vesely P, 2012, ANN BOT-LONDON, V109, P65, DOI 10.1093/aob/mcr267; Wang XH, 2011, PLANT SCI, V180, P292, DOI 10.1016/j.plantsci.2010.09.007; Wu KL, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0087588, 10.1371/journal.pone.0103480, 10.1371/journal.pone.0110033, 10.1371/journal.pone.0103535, 10.1371/journal.pone.0099366, 10.1371/journal.pone.0091910, 10.1371/journal.pone.0103267, 10.1371/journal.pone.0113637, 10.1371/journal.pone.0096514, 10.1371/journal.pone.0095422, 10.1371/journal.pone.0095536, 10.1371/journal.pone.0105072, 10.1371/journal.pone.0107196, 10.1371/journal.pone.0087348, 10.1371/journal.pone.0093049]; Wuyun TN, 2018, MOL PLANT, V11, P429, DOI 10.1016/j.molp.2017.11.014; Xia EH, 2017, MOL PLANT, V10, P866, DOI 10.1016/j.molp.2017.04.002; Xu M, 2010, J NAT PROD, V73, P1524, DOI 10.1021/np100351p; Xu Z, 2007, NUCLEIC ACIDS RES, V35, pW265, DOI 10.1093/nar/gkm286; Yan L, 2015, MOL PLANT, V8, P922, DOI 10.1016/j.molp.2014.12.011; Yang JH, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-107; You J, 2014, PLANT PHYSIOL, V166, P2100, DOI 10.1104/pp.114.251116; Yu K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059831; Yuan Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03423-5; Zhang GH, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0104-3; Zhang N, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.00197; Zhong L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194863; Zhou W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069909; Zhu JH, 2017, J PLANT RES, P1, DOI [10.1007/s10265-016-0885-1, DOI 10.1007/S10265-016-0885-1]; Zhu JH, 2016, SCI REP-UK, V6, DOI 10.1038/srep38315	84	10	13	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2018	13	12							e0209258	10.1371/journal.pone.0209258	http://dx.doi.org/10.1371/journal.pone.0209258			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE3IQ	30550595	gold, Green Published, Green Submitted			2023-01-03	WOS:000453248000053
J	Pauly, V; Mendizabal, H; Gentile, S; Auquier, P; Boyer, L				Pauly, Vanessa; Mendizabal, Helene; Gentile, Stephanie; Auquier, Pascal; Boyer, Laurent			Predictive risk score for unplanned 30-day rehospitalizations in the French universal health care system based on a medico-administrative database	PLOS ONE			English	Article							HOSPITAL READMISSION; ELDERLY-PATIENTS; QUALITY; INSURANCE; FRANCE; ASSOCIATION; TRANSITIONS; REFORM; MODEL; TOOL	Background Reducing unplanned rehospitalizations is one of the priorities of health care policies in France and other Western countries. An easy-to-use algorithm for identifying patients at higher risk of rehospitalizations would help clinicians prioritize actions and care concerning discharge transitions. Our objective was to develop a predictive unplanned 30-day all-cause rehospitalization risk score based on the French hospital medico-administrative database. Methods This was a retrospective cohort study of all 2015 discharges from acute-care inpatient hospitalizations in a tertiary-care university center comprising four hospitals. The study endpoint was unplanned 30-day all-cause rehospitalization via emergency departments, and we collected sociodemographic, clinical, and hospital characteristics based on hospitalization database computed for reimbursement of fees. We derived a predictive rehospitalization risk score using a split-sample design and multivariate logistic regression, and we compared the discriminative properties with the LACE index risk-score. Result Our analysis included 118,650 hospitalizations, of which 4,127 (3.5%) led to rehospitalizations via emergency departments. Variables independently associated with rehospitalization were age, gender, state-funded medical assistance, as well as disease category and severity, Charlson comorbidity index, hospitalization via emergency departments, length of stay (LOS), and previous hospitalizations 6 months before. The predictive rehospitalization risk score yielded satisfactory discriminant properties (C statistic: 0.74) exceeding the LACE index (0.66). Conclusion Our findings indicate that the possibility of unplanned rehospitalization remains high for some patient characteristics, indicating that targeted interventions could be beneficial for patients at the greatest risk. We developed an easy-to-use predictive rehospitalization risk-score of unplanned 30-day all-cause rehospitalizations with satisfactory discriminant properties. Future works should, however, explore if other data from electronic medical records and other databases could improve the accuracy of our predictive rehospitalization risk score based on medico-administrative data.	[Pauly, Vanessa; Gentile, Stephanie; Auquier, Pascal; Boyer, Laurent] La Timone Med Univ, Aix Marseille Univ, Publ Hlth Chron Dis & Qual Life Res Unit, Blvd Jean Moulin, Marseille, France; [Pauly, Vanessa; Auquier, Pascal; Boyer, Laurent] La Concept Hosp, AP HM, Dept Publ Hlth, Serv Informat Med, Marseille, France; [Mendizabal, Helene; Gentile, Stephanie] La Concept Hosp, AP HM, Dept Publ Hlth, Cellule Evaluat Med, Marseille, France	UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Boyer, L (corresponding author), La Timone Med Univ, Aix Marseille Univ, Publ Hlth Chron Dis & Qual Life Res Unit, Blvd Jean Moulin, Marseille, France.; Boyer, L (corresponding author), La Concept Hosp, AP HM, Dept Publ Hlth, Serv Informat Med, Marseille, France.	laurent.boyer@ap-hm.fr	Boyer, Laurent/E-5728-2016	Boyer, Laurent/0000-0003-1229-6622				Aljishi M, 2014, NEW ZEAL MED J, V127, P42; Amarasingham R, 2010, MED CARE, V48, P981, DOI 10.1097/MLR.0b013e3181ef60d9; Andre JM, 2016, PUBLIC HEALTH REV, V37, DOI 10.1186/s40985-016-0017-4; ASHTON CM, 1995, ANN INTERN MED, V122, P415, DOI 10.7326/0003-4819-122-6-199503150-00003; Atete-Leblanc R, 2012, GYNECOL OBSTET FERTI, V40, P753, DOI 10.1016/j.gyobfe.2011.08.020; ATIH, MAN GHL VERS 11D; Balla U, 2008, MEDICINE, V87, P294, DOI 10.1097/MD.0b013e3181886f93; Ben-Chetrit E, 2012, ISR MED ASSOC J, V14, P752; Berchet C, 2012, PUBLIQUEPUBLIC  1115, P73; Bertakis KD, 2000, J FAM PRACTICE, V49, P147; Billings J, 2006, BRIT MED J, V333, P327, DOI 10.1136/bmj.38870.657917.AE; Bottle A, 2006, J ROY SOC MED, V99, P406, DOI 10.1258/jrsm.99.8.406; Boutwell AE, 2011, HEALTH AFFAIR, V30, P1272, DOI 10.1377/hlthaff.2011.0111; Caughey GE, 2017, MED J AUSTRALIA, V206, P170, DOI 10.5694/mja16.00671; Chen C, 2014, J HOSP MED, V9, P681, DOI 10.1002/jhm.2213; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Conroy S, 2012, AGE AGEING, V41, P702, DOI 10.1093/ageing/afs154; Conroy SP, 2011, AGE AGEING, V40, P436, DOI 10.1093/ageing/afr060; Crane SJ, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-338; Davidoff F, 2008, ANN INTERN MED, V149, P670, DOI 10.7326/0003-4819-149-9-200811040-00009; Dely C, 1983, PRESSE MED, V2012, pe1; Donze J, 2013, JAMA INTERN MED, V173, P632, DOI 10.1001/jamainternmed.2013.3023; Dourgnon P, 2009, QUESTIONS DECONOMIE; Francois P, 2001, REV EPIDEMIOL SANTE, V49, P183; Francois P, 2014, SANTE PUBLIQUE, V26, P189, DOI 10.3917/spub.138.0189; Friedman B, 2004, MED CARE RES REV, V61, P225, DOI 10.1177/1077558704263799; Garrison GM, 2016, J EVAL CLIN PRACT; Gonen M, 2007, ANAL RECEIVER OPERAT; Gusmano M, 2015, J HEALTH SERV RES PO, V20, P18, DOI 10.1177/1355819614551849; Gusmano MK, 2006, HEALTH AFFAIR, V25, P510, DOI 10.1377/hlthaff.25.2.510; Halfon P, 2006, MED CARE, V44, P972, DOI 10.1097/01.mlr.0000228002.43688.c2; Hansen LO, 2013, J HOSP MED, V8, P421, DOI 10.1002/jhm.2054; Hasan O, 2010, J GEN INTERN MED, V25, P211, DOI 10.1007/s11606-009-1196-1; Hernandez AF, 2010, JAMA-J AM MED ASSOC, V303, P1716, DOI 10.1001/jama.2010.533; Horwitz L, 2014, J HOSP MED, V9, P743, DOI 10.1002/jhm.2271; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jou HJ, 2014, TAIWAN J OBSTET GYNE, V53, P43, DOI 10.1016/j.tjog.2012.04.042; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515; Kates SL, 2015, ARCH ORTHOP TRAUM SU, V135, P329, DOI 10.1007/s00402-014-2141-2; Kossovsky MP, 2002, QUAL SAF HEALTH CARE, V11, P219, DOI 10.1136/qhc.11.3.219; Kripalani S, 2007, J HOSP MED, V2, P314, DOI 10.1002/jhm.228; Lam C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184253; Lasser KE, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2329; Leppin AL, 2014, JAMA INTERN MED, V174, P1095, DOI 10.1001/jamainternmed.2014.1608; Mesteig M, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-1; Meyer A, 2018, LANCET RESP MED; Moons KGM, 2002, J CLIN EPIDEMIOL, V55, P1054, DOI 10.1016/S0895-4356(02)00453-5; Morrissey EFR, 2003, CLIN DRUG INVEST, V23, P119, DOI 10.2165/00044011-200323020-00005; Muller CF, 1990, HLTH CARE GENDER; Nguyen OK, 2016, J HOSP MED, V11, P473, DOI 10.1002/jhm.2568; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rodwin VG, 2004, NEW ENGL J MED, V351, P2259, DOI 10.1056/NEJMp048210; Rodwin VG, 2003, AM J PUBLIC HEALTH, V93, P31, DOI 10.2105/AJPH.93.1.31; Schiltz NK, 2014, CLIN PEDIATR, V53, P845, DOI 10.1177/0009922814536924; Strom JB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180767; van Walraven Carl, 2012, Open Med, V6, pe80; van Walraven C, 2010, CAN MED ASSOC J, V182, P551, DOI 10.1503/cmaj.091117; WHO, 2010, ICD 10 VERS; Wong ELY, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-149; Woolhandler S, 2014, INT J HEALTH SERV, V44, P635, DOI 10.2190/HS.44.4.a	60	7	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2019	14	3							e0210714	10.1371/journal.pone.0210714	http://dx.doi.org/10.1371/journal.pone.0210714			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HO6JJ	30861004	Green Submitted, gold, Green Published			2023-01-03	WOS:000461035600006
J	Tremblay, G; McElroy, HJ; Westley, T; Meier, G; Misurski, D; Guo, M				Tremblay, Gabriel; McElroy, Heather J.; Westley, Tracy; Meier, Genevieve; Misurski, Derek; Guo, Matthew			Indirect treatment comparisons including network meta-analysis: Lenvatinib plus everolimus for the second-line treatment of advanced/metastatic renal cell carcinoma	PLOS ONE			English	Article							SORAFENIB; EFFICACY	Background In the absence of clinical trials providing direct efficacy results, this study compares different methods of indirect treatment comparison (ITC), and their respective impacts on efficacy estimates for lenvatinib (LEN) plus everolimus (EVE) combination therapy compared to other second-line treatments for advanced/metastatic renal cell carcinoma (a/mRCC). Methods Using EVE alone as the common comparator, the Bucher method for ITC compared LEN + EVE with cabozantinib (CAB), nivolumab (NIV), placebo (PBO) and axitinib (AXI). Hazard ratios (HR) for overall survival (OS) and progression-free survival (PFS) estimated the impact of applying three versions of the LEN+EVE trial data in separate ITCs. Last, to overcome exchangeability bias and potential violations to the proportional hazards assumption, a network meta-analysis using fractional polynomials was performed. Results Bucher ITCs demonstrated LEN + EVE superiority over EVE for PFS, indirect superiority to NIV, AXI, and PBO, and no difference to CAB. For OS, LEN + EVE was superior to EVE and indirectly superior to PBO, applying original HOPE 205 data. Using European Medicines Agency data, LEN + EVE was directly superior to EVE for OS. Fractional polynomial HRs for PFS and OS substantially overlapped with Bucher estimates, demonstrating LEN+EVE superiority over EVE, alone, NIV, and CAB. However, there were no statistically significant results as the credible intervals for HR crossed 1.0. Conclusions Comparing three Bucher ITCs, LEN + EVE demonstrated superior PFS when indirectly compared to NIV, AXI, and PBO, and mixed results for OS. While fractional polynomial modelling for PFS and OS failed to find statistically significant differences in LEN + EVE efficacy, the overall HR trends were comparable.	[Tremblay, Gabriel; Westley, Tracy] Purple Squirrel Econ, Dept Hlth Econ, New York, NY 10010 USA; [McElroy, Heather J.] Covance Pty Ltd, Dept Hlth Econ, Macquarie Pk, NSW, Australia; [Meier, Genevieve; Misurski, Derek; Guo, Matthew] Eisai Inc, Dept Oncol, Woodcliff Lake, NJ USA; [McElroy, Heather J.] Datalyt Pty Ltd, Dept Hlth Econ, Kingston, ACT, Australia	Eisai Co Ltd	Tremblay, G (corresponding author), Purple Squirrel Econ, Dept Hlth Econ, New York, NY 10010 USA.	gabrieltremblay@pshta.com			Eisai; Purple Squirrel Economics; Covance; Eisai Incorporated	Eisai(Eisai Co Ltd); Purple Squirrel Economics; Covance; Eisai Incorporated(Eisai Co Ltd)	This study was funded by Eisai. The funder Esai provided support in the form of salaries for authors GM, DM, and MG, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Purple Squirrel Economics provided support in the form of salaries for authors GTand TW but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Covance provided support in the form of salaries for author HM but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'Author Contributions' section.; We would like to thank Beth O'Leary, Carol Lee, Sophie Le Page and Michelle Hill from Covance Market Access Services for conducting the systematic literature review. The systematic literature review was funded by Eisai Incorporated, who had no bearing on the results. We would also like to thank Jaclyn Hearnden for her editorial assistance in preparing the manuscript.	Amit O, 2011, EUR J CANCER, V47, P1772, DOI 10.1016/j.ejca.2011.02.013; [Anonymous], 2017, KIDN CANC; [Anonymous], 2016, FDA ONC DRUGS ADV CO; [Anonymous], 2017, CANC STAT CTR KIDN R; [Anonymous], 2016, SUMM PROD CHAR KISPL; [Anonymous], 2017, SINGL TECHN APPR CAB; [Anonymous], 2016, SINGL TECHN APPR NIV; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Choueiri TK, 2015, NEW ENGL J MED, V373, P1814, DOI 10.1056/NEJMoa1510016; Escudier B, 2009, J CLIN ONCOL, V27, P3312, DOI 10.1200/JCO.2008.19.5511; Guyot P, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-9; Jansen JP, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-159; Jansen JP, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-61; Motzer RJ, 2016, ANN ONCOL, V27, P441, DOI 10.1093/annonc/mdv612; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Motzer RJ, 2015, LANCET ONCOL, V16, P1473, DOI 10.1016/S1470-2045(15)00290-9; Motzer RJ, 2013, LANCET ONCOL, V14, P552, DOI 10.1016/S1470-2045(13)70093-7; Muehlhausen W, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0362-x; Song FJ, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1147	20	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2019	14	3							e0212899	10.1371/journal.pone.0212899	http://dx.doi.org/10.1371/journal.pone.0212899			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN7LV	30835737	Green Submitted, Green Published, gold			2023-01-03	WOS:000460371800016
J	Leinonen, T; Solovieva, S; Husgafvel-Pursiainen, K; Laaksonen, M; Viikari-Juntura, E				Leinonen, Taina; Solovieva, Svetlana; Husgafvel-Pursiainen, Kirsti; Laaksonen, Mikko; Viikari-Juntura, Eira			Do individual and work-related factors differentiate work participation trajectories before and after vocational rehabilitation?	PLOS ONE			English	Article							EMPLOYMENT OUTCOMES; SICKNESS ABSENCE; SUPPORTED EMPLOYMENT; GENDER-DIFFERENCES; FOLLOW-UP; RETURN; PEOPLE; DISABILITY; SERVICES; PREDICTORS	Background Understanding diverse labor market trajectories around vocational rehabilitation provides important insight into potential effectiveness of rehabilitation efforts. We examined factors associated with work participation trajectories before and after vocational rehabilitation. Methods Using nationwide Finnish register data of 7180 vocational rehabilitees, we constructed latent trajectory groups of work participation two years before and two years after their rehabilitation episode starting in 2008-2010. We plotted changes in labor market statuses in these groups and examined other associated factors using multinomial logistic regression. Results We identified four trajectories based on work participation levels before and after vocational rehabilitation. The "High-Resumed" group (35.6%) typically returned to full duties. The "High-to-Negligible" group (20.7%) typically transitioned to full disability retirement or unemployment. Among the "Medium-Resumed" (25.5%) and "Longstanding Negligible" (18.3%) groups, work disability and unemployment were common before rehabilitation, but afterwards those assigned to the former group often returned to full or partial duties. Overall, older age, male gender, living in areas with lower employment rates, having lower education, being employed in the private sector, and having mental diagnoses were associated with the other three trajectories than the most favorable "High-Resumed" trajectory. Furthermore, certain industrial sectors, job exposures, and less common diagnoses further separated specific trajectories. Conclusions Work participation trajectories around vocational rehabilitation are diverse, only partly dependent on initial levels of work participation, and determined by various individual and work-related factors. Future nationwide studies should assess the effectiveness of vocational rehabilitation taking into consideration both individual and work-related factors.	[Leinonen, Taina; Solovieva, Svetlana; Husgafvel-Pursiainen, Kirsti; Viikari-Juntura, Eira] Finnish Inst Occupat Hlth, Helsinki, Finland; [Laaksonen, Mikko] Finnish Ctr Pens, Helsinki, Finland	Finnish Institute of Occupational Health	Leinonen, T (corresponding author), Finnish Inst Occupat Hlth, Helsinki, Finland.	taina.leinonen@ttl.fi			Academy of Finland [303534]	Academy of Finland(Academy of Finland)	This study was supported by the Academy of Finland (project number 303534 to Viikari-Juntura). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahlgren Asa, 2007, Work, V28, P343; Bekker MHJ, 2009, PSYCHOL HEALTH MED, V14, P405, DOI 10.1080/13548500903012830; Blackwell TL, 2003, REHABIL COUNS BULL, V46, P108, DOI 10.1177/00343552030460020501; Bolton BF, 2000, REHABIL COUNS BULL, V44, P10, DOI 10.1177/003435520004400103; Burke-Miller JK, 2006, COMMUNITY MENT HLT J, V42, P143, DOI 10.1007/s10597-005-9017-4; Burstrom B, 2011, DISABIL REHABIL, V33, P453, DOI 10.3109/09638288.2010.493596; Card D, 2018, J EUR ECON ASSOC, V16, P894, DOI 10.1093/jeea/jvx028; Chan JY, 2014, REHABIL COUNS BULL, V57, P209, DOI 10.1177/0034355213509855; Cook JA, 2006, J VOCAT REHABIL, V25, P71; Corbiere M, 2017, J NERV MENT DIS, V205, P275, DOI 10.1097/NMD.0000000000000612; Dean D, 2017, J HUM RESOUR, V52, P826, DOI 10.3368/jhr.52.3.0114-6111R1; Dutta A, 2008, J OCCUP REHABIL, V18, P326, DOI 10.1007/s10926-008-9154-z; Finnish Centre for Pensions, BACK WORK REH; Friberg IO, 2016, SCAND J PUBLIC HEALT, V44, P264, DOI 10.1177/1403494815618843; Gran JM, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2408-8; Jang Y, 2014, J OCCUP REHABIL, V24, P11, DOI 10.1007/s10926-013-9433-1; Jones BL, 2007, SOCIOL METHOD RES, V35, P542, DOI 10.1177/0049124106292364; Karasek R., 1990, HLTH WORK STRESS PRO; Kausto J, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001752; Kuoppala J, 2008, J REHABIL MED, V40, P796, DOI 10.2340/16501977-0270; Laaksonen M, 2015, J OCCUP REHABIL, V25, P471, DOI 10.1007/s10926-014-9554-1; Leinonen T, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019822; Leinonen T, 2018, ANN WORK EXPOS HEAL, V62, P438, DOI 10.1093/annweh/wxx107; Lindholdt L, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015661; Mann DR, 2017, J VOCAT REHABIL, V46, P159, DOI 10.3233/JVR-160852; Mastekaasa A, 2014, EUR SOCIOL REV, V30, P582, DOI 10.1093/esr/jcu059; Mastekaasa A, 2014, EUR J PUBLIC HEALTH, V24, P656, DOI 10.1093/eurpub/cku075; Michon H, 2005, SOC PSYCH PSYCH EPID, V40, P408, DOI 10.1007/s00127-005-0910-5; Nagin DS, 1999, PSYCHOL METHODS, V4, P139, DOI 10.1037/1082-989X.4.2.139; Organisation for Economic Co-operation and Development, 2008, SICKN DIS WORK BREAK, DOI [10.1787/9789264049826-en, DOI 10.1787/9789264049826-EN]; Oyeflaten I, 2014, J OCCUP REHABIL, V24, P199, DOI 10.1007/s10926-013-9466-5; Pedersen P, 2018, SCAND J PUBLIC HEALT, V46, P383, DOI 10.1177/1403494817722290; Rinaldo U, 2016, WORK, V55, P115, DOI 10.3233/WOR-162387; Saarnio L, 2017, TYOELAKEKUNTOUTUS VU; Solovieva S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108987; Solovieva S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048680; Suijkerbuijk YB, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011867.pub2; The Social Insurance Institution of Finland, VOC REH; Vaidya V, 2012, J WOMENS HEALTH, V21, P140, DOI 10.1089/jwh.2011.2876; van Vilsteren M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006955.pub3; Viikari-Juntura E, 2017, SCAND J WORK ENV HEA, V43, P447, DOI 10.5271/sjweh.3664; Wang YY, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003320; Wasiak R, 2007, J OCCUP REHABIL, V17, P766, DOI 10.1007/s10926-007-9101-4; Young AE, 2005, J OCCUP REHABIL, V15, P543, DOI 10.1007/s10926-005-8033-0; Young AE, 2016, J OCCUP REHABIL, V26, P434, DOI 10.1007/s10926-016-9675-9	45	6	6	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2019	14	2							e0212498	10.1371/journal.pone.0212498	http://dx.doi.org/10.1371/journal.pone.0212498			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HM2WC	30789938	gold, Green Published, Green Submitted			2023-01-03	WOS:000459330800030
J	Sereia, AL; de Oliveira, MT; Baranoski, A; Marques, LLM; Ribeiro, FM; Isolani, RG; de Medeiros, DC; Chierrito, D; Lazarin-Bidoia, D; Zielinski, AAF; Novello, CR; Nakamura, CV; Mantovani, MS; de Mello, JCP				Sereia, Ana Luiza; de Oliveira, Marcelo Tempesta; Baranoski, Adrivanio; Medeiros Marques, Leila Larisa; Ribeiro, Fabianne Martins; Isolani, Raquel Garcia; de Medeiros, Daniela Cristina; Chierrito, Danielly; Lazarin-Bidoia, Danielle; Ferreira Zielinski, Acacio Antonio; Novello, Claudio Roberto; Nakamura, Celso Vataru; Mantovani, Mario Sergio; Palazzo de Mello, Joao Carlos			In vitro evaluation of the protective effects of plant extracts against amyloid-beta peptide-induced toxicity in human neuroblastoma SH-SY5Y cells	PLOS ONE			English	Article							PHENYLPROPANOID-SUBSTITUTED FLAVAN-3-OLS; TRICHILIA-CATIGUA; ALZHEIMERS-DISEASE; SEMIPURIFIED EXTRACT; STRYPHNODENDRON-ADSTRINGENS; NATURAL-PRODUCTS; STEM BARK; EXPRESSION; TANNINS; DEATH	Alzheimer's disease (AD) is the most common form of dementia and has no cure. Therapeutic strategies focusing on the reduction of oxidative stress, modulation of amyloid-beta (A beta) toxicity and inhibition of tau protein hyperphosphorylation are warranted to avoid the development and progression of AD. The aim of this study was to screen the crude extracts (CEs) and ethyl-acetate fractions (EAFs) of Guazuma ulmifolia, Limonium brasiliense, Paullinia cupana, Poincianella pluviosa, Stryphnodendron adstringens and Trichilia catigua using preliminary in vitro bioassays (acetylcholinesterase inhibition, antioxidant activity and total polyphenol content) to select extracts/fractions and assess their protective effects against A beta(25-35) toxicity in SH-SY5Y cells. The effect of the EAF of S. adstringens on mitochondrial membrane potential, lipid peroxidation, superoxide production and mRNA expression of 10 genes related to AD was also evaluated and the electropherogram fingerprints of EAFs were established by capillary electrophoresis. Chemometric tools were used to correlate the in vitro activities of the samples with their potential to be evaluated against AD and to divide extracts/fractions into four clusters. Pretreatment with the EAFs grouped in cluster 1 (S. adstringens, P. pluviosa and L. brasiliense) protected SH-SY5Y cells from A beta(25-35)-induced toxicity. The EAF of S. adstringens at 15.62 mu g/mL was able completely to inhibit the mitochondrial depolarization (69%), superoxide production (49%) and A beta(25-35)-induced lipid peroxidation (35%). With respect to mRNA expression, the EAF of S. adstringens also prevented the MAPT mRNA overexpression (expression ratio of 2.387x) induced by A beta(25-35), which may be related to tau protein hyperphosphorylation. This is the first time that the neuroprotective effects of these fractions have been demonstrated and that the electropherogram fingerprints for the EAFs of G. ulmifolia, L. brasiliense, P. cupana, P. pluviosa and S. adstringens have been established. The study expands knowledge of the in vitro protective effects and quality control of the evaluated fractions.	[Sereia, Ana Luiza; de Oliveira, Marcelo Tempesta; Medeiros Marques, Leila Larisa; Ribeiro, Fabianne Martins; Isolani, Raquel Garcia; de Medeiros, Daniela Cristina; Chierrito, Danielly; Lazarin-Bidoia, Danielle; Nakamura, Celso Vataru; Palazzo de Mello, Joao Carlos] Univ Estadual Maringa, Dept Pharm, Programa Posgrad Ciencias Farmaceut, Maringa, Parana, Brazil; [Baranoski, Adrivanio; Mantovani, Mario Sergio] Univ Estadual Londrina, Dept Gen Biol, Programa Posgrad Genet & Biol Mol, Londrina, Parana, Brazil; [Ferreira Zielinski, Acacio Antonio] Univ Fed Santa Catarina, Dept Chem Engn & Food Engn, Florianopolis, SC, Brazil; [Novello, Claudio Roberto] Univ Tecnol Fed Parana, Acad Dept Chem & Biol, Francisco Beltrao, Parana, Brazil	Universidade Estadual de Maringa; Universidade Estadual de Londrina; Universidade Federal de Santa Catarina (UFSC); Universidade Tecnologica Federal do Parana	de Mello, JCP (corresponding author), Univ Estadual Maringa, Dept Pharm, Programa Posgrad Ciencias Farmaceut, Maringa, Parana, Brazil.	mello@uem.br	Zielinski, Acácio AF/N-4432-2013; Mello, Joao Carlos Palazzo de/B-9418-2013; Mantovani, Mário Sérgio/AAE-3456-2020; Bidoia, Danielle Lazarin/AAQ-2024-2020; de Oliveira, Marcelo Tempesta/N-1459-2013; Nakamura, Celso Vataru/AAA-5620-2019	Zielinski, Acácio AF/0000-0002-6184-9628; Mello, Joao Carlos Palazzo de/0000-0002-7532-3395; Mantovani, Mário Sérgio/0000-0001-5268-6508; de Oliveira, Marcelo Tempesta/0000-0002-1514-351X; Baranoski, Adrivanio/0000-0001-8808-9262	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Financiadora de Estudos e Projetos (FINEP); Complexo de Centrais de Apoio a Pesquisa (COMCAP/UEM); Fundacao Araucaria; Nacional de Ciencia e Tecnologia para Inovacao Farmaceutica (INCT_if)	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Financiadora de Estudos e Projetos (FINEP)(Financiadora de Inovacao e Pesquisa (Finep)); Complexo de Centrais de Apoio a Pesquisa (COMCAP/UEM); Fundacao Araucaria(Fundacao Araucaria de Apoio ao Desenvolvimento Cientifico e Tecnologico do Estado do Parana FAFundacao de Amparo a Pesquisa e Inovacoo Estado de Santa Catarina (FAPESC)); Nacional de Ciencia e Tecnologia para Inovacao Farmaceutica (INCT_if)	The authors are grateful to Brazilian agencies Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES - www.capes.gov.br), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq - www.cnpq.br), Financiadora de Estudos e Projetos (FINEP - www.finep.gov.br), Complexo de Centrais de Apoio a Pesquisa (COMCAP/UEM -www.comcap.uem.br), Fundacao Araucaria (www.fappr.pr.gov.br), and Instituto Nacional de Ciencia e Tecnologia para Inovacao Farmaceutica (INCT_if - http://inct.cnpq.br/web/inct-if) for their financial support and fellowships awarded to A. L. Sereia, M. T. de Oliveira, A. Baranoski, F. M. Ribeiro, R. G. Isolani, D. C. Medeiros, and D. Chierrito. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alam MN, 2013, SAUDI PHARM J, V21, P143, DOI 10.1016/j.jsps.2012.05.002; Ali SK, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-121; [Anonymous], 2010, FARMACOPEIA BRASILEI, V2, P671; Aranda PS, 2012, ELECTROPHORESIS, V33, P366, DOI 10.1002/elps.201100335; Atanasov AG, 2015, BIOTECHNOL ADV, V33, P1582, DOI 10.1016/j.biotechadv.2015.08.001; Bernardo J, 2018, J ETHNOPHARMACOL, V211, P247, DOI 10.1016/j.jep.2017.09.039; Blainski A, 2017, REV BRAS FARMACOGN, V27, P162, DOI 10.1016/j.bjp.2016.08.009; Blainski A, 2017, J ETHNOPHARMACOL, V198, P313, DOI 10.1016/j.jep.2017.01.013; Blainski A, 2013, MOLECULES, V18, P6852, DOI 10.3390/molecules18066852; Boasquivis PF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9241308; BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25; Bueno FG, 2014, FITOTERAPIA, V99, P252, DOI 10.1016/j.fitote.2014.10.007; Caleare AD, 2017, FITOTERAPIA, V118, P87, DOI 10.1016/j.fitote.2017.03.002; Calixto JT, 2016, SAUDI J BIOL SCI, V23, P434, DOI 10.1016/j.sjbs.2015.10.009; Campanini MZ, 2014, AAPS PHARMSCITECH, V15, P86, DOI 10.1208/s12249-013-0049-8; Castillo WO, 2016, NEUROTOXICOLOGY, V57, P291, DOI 10.1016/j.neuro.2016.10.013; Chen TF, 2013, FOOD CHEM TOXICOL, V62, P538, DOI 10.1016/j.fct.2013.09.015; Chen Y, 2010, ELECTROPHORESIS, V31, P1493, DOI 10.1002/elps.200900592; Costa MA, 2010, REGUL TOXICOL PHARM, V58, P330, DOI 10.1016/j.yrtph.2010.07.006; de Mello JCP, 1999, PHYTOCHEMISTRY, V51, P1105, DOI 10.1016/S0031-9422(98)00715-8; deMello JP, 1996, PHYTOCHEMISTRY, V42, P857, DOI 10.1016/0031-9422(95)00953-1; deMello JP, 1996, PHYTOCHEMISTRY, V41, P807, DOI 10.1016/0031-9422(95)00686-9; Dey A, 2017, BIOTECHNOL ADV, V35, P178, DOI 10.1016/j.biotechadv.2016.12.005; dos Santos EL, 2018, FREE RADICAL BIO MED, V128, pS66, DOI 10.1016/j.freeradbiomed.2018.10.136; Zielinski AAF, 2014, FOOD RES INT, V60, P246, DOI 10.1016/j.foodres.2013.09.010; Fujihara K, 2017, BIOORGAN MED CHEM, V25, P3377, DOI 10.1016/j.bmc.2017.04.023; Godinho J, 2018, BEHAV BRAIN RES, V337, P173, DOI 10.1016/j.bbr.2017.08.050; Hashimoto M, 2011, J NUTR BIOCHEM, V22, P22, DOI 10.1016/j.jnutbio.2009.11.005; Hwang YJ, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-310; Ishida K, 2006, J ANTIMICROB CHEMOTH, V58, P942, DOI 10.1093/jac/dkl377; Klein T, 2013, REV BRAS FARMACOGN, V23, P186, DOI 10.1590/S0102-695X2012005000147; Klein T, 2012, TALANTA, V88, P502, DOI 10.1016/j.talanta.2011.11.023; Lattanzio F, 2016, EXP TOXICOL PATHOL, V68, P271, DOI 10.1016/j.etp.2016.02.001; Lazarin-Bidoia D, 2013, FREE RADICAL BIO MED, V60, P17, DOI 10.1016/j.freeradbiomed.2013.01.008; Lee C, 2011, FOOD CHEM TOXICOL, V49, P1261, DOI 10.1016/j.fct.2011.03.005; Longhini R, 2013, J SEP SCI, V36, P1247, DOI 10.1002/jssc.201200911; Lopes GC, 2009, J BRAZIL CHEM SOC, V20, P1103, DOI 10.1590/S0103-50532009000600016; Lopes GC, 2008, BIOCHEM SYST ECOL, V36, P925, DOI 10.1016/j.bse.2008.10.004; Torma PDMR, 2017, FOOD CHEM, V222, P94, DOI 10.1016/j.foodchem.2016.12.006; Marquele FD, 2005, J PHARMACEUT BIOMED, V39, P455, DOI 10.1016/j.jpba.2005.04.004; Marques LLM, 2016, FOOD CHEM, V212, P703, DOI 10.1016/j.foodchem.2016.06.028; Montenegro JMF, 2017, PHYSIOL BEHAV, V173, P42, DOI 10.1016/j.physbeh.2017.01.034; Morais SM, 2017, S AFR J BOT, V110, P251, DOI 10.1016/j.sajb.2016.08.003; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Okimoto Y, 2000, FEBS LETT, V474, P137, DOI 10.1016/S0014-5793(00)01587-8; Omar SH, 2017, J NUTR BIOCHEM, V47, P1, DOI 10.1016/j.jnutbio.2017.02.016; Park SY, 2010, ARCH PHARM RES, V33, P1589, DOI 10.1007/s12272-010-1010-y; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Prince M., 2016, WORLD ALZHEIMERS REP; Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3; Resende FO, 2011, J BRAZIL CHEM SOC, V22, P2087, DOI 10.1590/S0103-50532011001100010; Rhee IK, 2001, J CHROMATOGR A, V915, P217, DOI 10.1016/S0021-9673(01)00624-0; Rodrigues MJ, 2019, S AFR J BOT, V120, P87, DOI 10.1016/j.sajb.2017.12.003; Ruchel JB, 2017, PHYSIOL BEHAV, V168, P11, DOI 10.1016/j.physbeh.2016.10.003; Ruijter JM, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp045; Ruijter JM, 2013, METHODS, V59, P32, DOI 10.1016/j.ymeth.2012.08.011; Seidl C, 2010, Z NATURFORSCH C, V65, P440; Sereia AL, 2017, PHYTOCHEM ANALYSIS, V28, P144, DOI 10.1002/pca.2653; Shakir Taner, 2013, Am J Neurodegener Dis, V2, P70; Shukla AK, 2012, EUR J MED CHEM, V54, P49, DOI 10.1016/j.ejmech.2012.04.034; Singleton VL, 1999, METHOD ENZYMOL, V299, P152; Sun WJ, 2009, NEUROSCI LETT, V450, P340, DOI 10.1016/j.neulet.2008.11.067; Wang HQ, 2010, BRAIN RES, V1360, P159, DOI 10.1016/j.brainres.2010.08.100; Yu HM, 2014, NEUROCHEM INT, V75, P89, DOI 10.1016/j.neuint.2014.06.001; Zeng KW, 2010, NEUROPHARMACOLOGY, V59, P542, DOI 10.1016/j.neuropharm.2010.07.020; Zhang L, 2010, NEUROCHEM INT, V57, P547, DOI 10.1016/j.neuint.2010.06.021	66	12	12	2	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2019	14	2							e0212089	10.1371/journal.pone.0212089	http://dx.doi.org/10.1371/journal.pone.0212089			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL5JX	30763379	Green Published, Green Submitted, gold			2023-01-03	WOS:000458763900040
J	Chen, F; Wang, L; Peng, G; Yan, N; Pan, XJ				Chen, Fei; Wang, Lan; Peng, Gang; Yan, Nan; Pan, Xiaojie			Development and evaluation of a 3-D virtual pronunciation tutor for children with autism spectrum disorders	PLOS ONE			English	Article							COMPUTER-ASSISTED-INSTRUCTION; HIGH-FUNCTIONING AUTISM; LANGUAGE DISORDERS; ANIMATED TUTOR; SPEECH; COMMUNICATION; PERCEPTION; VOCABULARY; INDIVIDUALS; ACQUISITION	The deficit in speech sound production in some children with autism spectrum disorder (ASD) adds to their communication barriers. The 3-D virtual environments have been implemented to improve their communication abilities. However, there were no previous studies on the use of a 3-D virtual pronunciation tutor designed specifically to train pronunciation for children with ASD. To fill this research gap, the current study developed and evaluated a 3D virtual tutor which served as a multimodal and real-data-driven speech production tutor to present both places and manners of Mandarin articulation. Using an eye-tracking technique (RED 5 Eye Tracker), Experiment 1 objectively investigated children's gauged attention distribution online while learning with our computer-assisted 3-D virtual tutor in comparison to a real human face (HF) tutor. Eye-tracking results indicated most participants showed more interests in the visual speech cues of the 3-D tutor, and paid some degree of absolute attention to the additional visual speech information of both articulatory movements and airflow changes. To further compare treatment outcomes, training performance was evaluated in Experiment 2 with the ASD learners divided into two groups, with one group learning from the HF tutor and the other from the 3-D tutor (HF group vs. 3-D group). Both groups showed improvement with the help of computer-based training in the post-intervention test based on the calculation of a 5-point Likert scale. However, the 3-D group showed much higher gains in producing Mandarin stop and affricate consonants, and apical vowels. We conclude that our 3-D virtual imitation intervention system provides an effective approach of audiovisual pronunciation training for children with ASD.	[Chen, Fei; Wang, Lan; Peng, Gang; Yan, Nan] Shenzhen Inst Adv Technol, CAS Key Lab Human Machine Intelligence Synergy Sy, Shenzhen, Peoples R China; [Chen, Fei; Peng, Gang] Hong Kong Polytech Univ, Dept Chinese & Bilingual Studies, Hong Kong, Peoples R China; [Pan, Xiaojie] Shenzhen Aixin Zhihui Rehabil Ctr Children Specia, Shenzhen, Peoples R China	Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS; Hong Kong Polytechnic University	Wang, L; Peng, G (corresponding author), Shenzhen Inst Adv Technol, CAS Key Lab Human Machine Intelligence Synergy Sy, Shenzhen, Peoples R China.; Peng, G (corresponding author), Hong Kong Polytech Univ, Dept Chinese & Bilingual Studies, Hong Kong, Peoples R China.	lan.wang@siat.ac.cn; gpeng@polyu.edu.hk	ARSLAN, Okan/AAA-3232-2020	CHEN, Fei/0000-0002-4500-2590; Peng, Gang/0000-0002-1465-1301	National Natural Science Foundation of China [NSFC: U1736202, 61771461, 11474300, NSFC: U1736203]; Shenzhen Fundamental Research Program [JCYJ20160429184226930, JCYJ20170413161611534]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Fundamental Research Program	This work was partly supported by grants from National Natural Science Foundation of China (NSFC: U1736202, 61771461, 11474300) (http://www.nsfc.gov.cn/), and Shenzhen Fundamental Research Program (JCYJ20160429184226930, JCYJ20170413161611534) (http://www.szsti.gov.cn/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was partly supported by grants from National Natural Science Foundation of China (NSFC: U1736203, 61771461, 11474300), and Shenzhen Fundamental Research Program: JCYJ20160429184226930; JCYJ20170413161611534. We sincerely thank all the child participants with ASD from Shenzhen Aixin Zhihui Rehabilitation Centre for Children with Special Needs, the TD children from Taoyuan Zhuoya Primary School, and their parents for their participation and cooperation. The authors have no conflict of interest regarding the contents of this manuscript.	Ali AZM, 2015, EDUC TECHNOL SOC, V18, P313; Association A.P., 2013, DIAGNOSTIC STAT MANU; Baltaxe C., 1977, J PEDIATR PSYCHOL, V2, P176, DOI [10.1093/jpepsy/2.4.176, DOI 10.1093/JPEPSY/2.4.176]; Baron-Cohen S, 1995, MINDBLINDNESS AN ESS; BARTAK L, 1975, BRIT J PSYCHIAT, V126, P127, DOI 10.1192/bjp.126.2.127; BARTOLUCCI G, 1976, J AUTISM CHILD SCHIZ, V6, P303, DOI 10.1007/BF01537908; Behrmann M, 2006, TRENDS COGN SCI, V10, P258, DOI 10.1016/j.tics.2006.05.001; Bellani M, 2011, EPIDEMIOL PSYCH SCI, V20, P235, DOI 10.1017/S2045796011000448; Bosseler, 2003, J DEV LEARNING DISOR, V7, P111; Bosseler A, 2003, J AUTISM DEV DISORD, V33, P653, DOI 10.1023/B:JADD.0000006002.82367.4f; BOUCHER J, 1976, J AUTISM CHILD SCHIZ, V6, P297, DOI 10.1007/BF01537907; Chen F, 2017, IEEE-ACM T AUDIO SPE, V25, P2399, DOI 10.1109/TASLP.2017.2755400; Chen F, 2016, INT CONF ACOUST SPEE, P6130, DOI 10.1109/ICASSP.2016.7472855; Chen KL, 2011, J AUTISM DEV DISORD, V41, P1658, DOI 10.1007/s10803-011-1201-5; Cleland J, 2010, INT J SPEECH-LANG PA, V12, P69, DOI 10.3109/17549500903469980; COLBY KM, 1973, J AUTISM CHILD SCHIZ, V3, P254, DOI 10.1007/BF01538283; Constantin A, 2017, COMPUT HUM BEHAV, V75, P404, DOI 10.1016/j.chb.2017.05.030; Ding, 2008, FRONT MED-PRC, V2, P344, DOI [10.1007/s11684-008-0065-3, DOI 10.1007/S11684-008-0065-3]; Eigsti IM, 2011, RES AUTISM SPECT DIS, V5, P681, DOI 10.1016/j.rasd.2010.09.001; Fu CP, 2010, RES AUTISM SPECT DIS, V4, P89, DOI 10.1016/j.rasd.2009.09.002; Fulton ML, 2013, J AUTISM DEV DISORD, V43, P2460, DOI 10.1007/s10803-013-1794-y; Gilliam J.E., 2006, GILLIAM AUTISM RATIN; Gillon G, 2017, FOLIA PHONIATR LOGO, V69, P8, DOI 10.1159/000479063; Goldstein H, 2002, J AUTISM DEV DISORD, V32, P373, DOI 10.1023/A:1020589821992; Haesen B, 2011, RES AUTISM SPECT DIS, V5, P701, DOI 10.1016/j.rasd.2010.11.006; Hamdan MN, 2015, 2015 INTERNATIONAL CONFERENCE ON SCIENCE IN INFORMATION TECHNOLOGY (ICSITECH), P58, DOI 10.1109/ICSITech.2015.7407777; Happe F, 2006, BRAIN COGNITION, V61, P25, DOI 10.1016/j.bandc.2006.03.004; HEIMANN M, 1995, J AUTISM DEV DISORD, V25, P459, DOI 10.1007/BF02178294; Holmqvist K., 2011, EYE TRACKING A COMPR; Hua Z, 2000, J CHILD LANG, V27, P3, DOI 10.1017/S030500099900402X; Iacoboni M, 2006, NAT REV NEUROSCI, V7, P942, DOI 10.1038/nrn2024; Jones W, 2008, ARCH GEN PSYCHIAT, V65, P946, DOI 10.1001/archpsyc.65.8.946; Kjelgaard MM, 2001, LANG COGNITIVE PROC, V16, P287, DOI 10.1080/01690960042000058; Klin A, 2009, NATURE, V459, P257, DOI 10.1038/nature07868; Koegel LK, 2000, J AUTISM DEV DISORD, V30, P383, DOI 10.1023/A:1005539220932; KOEGEL RL, 1988, J AUTISM DEV DISORD, V18, P525, DOI 10.1007/BF02211871; Koegel RL, 2009, J AUTISM DEV DISORD, V39, P1587, DOI 10.1007/s10803-009-0765-9; Lai MC, 2014, LANCET, V383, P896, DOI 10.1016/S0140-6736(13)61539-1; Liu XF, 2016, C HUM SYST INTERACT, P56, DOI 10.1109/HSI.2016.7529609; Liu XQ, 2013, 2013 IEEE INTERNATIONAL CONFERENCE ON INFORMATION AND AUTOMATION (ICIA), P191, DOI 10.1109/ICInfA.2013.6720294; Massaro D.W., 1998, PERCEIVING TALKING F; Massaro DW, 2006, AUTISM, V10, P495, DOI 10.1177/1362361306066599; Massaro DW, 2004, J SPEECH LANG HEAR R, V47, P304, DOI 10.1044/1092-4388(2004/025); McCleery JP, 2006, J COMMUN DISORD, V39, P217, DOI 10.1016/j.jcomdis.2005.12.002; Miller N, 2018, BEHAV INTERVENT, V33, P3, DOI 10.1002/bin.1507; Moore M, 2000, J AUTISM DEV DISORD, V30, P359, DOI 10.1023/A:1005535602064; Mori M, 2012, IEEE ROBOT AUTOM MAG, V19, P98, DOI 10.1109/MRA.2012.2192811; Naranjo CA, 2017, PROCEEDINGS OF THE 9TH INTERNATIONAL CONFERENCE ON EDUCATION TECHNOLOGY AND COMPUTERS (ICETC 2017), P41, DOI 10.1145/3175536.3175582; Navarra J, 2007, PSYCHOL RES-PSYCH FO, V71, P4, DOI 10.1007/s00426-005-0031-5; Nordgren PM, 2015, J INTERACT RES COM D, V6, P25, DOI 10.1558/jircd.v6i1.25; O'Connor K, 2012, NEUROSCI BIOBEHAV R, V36, P836, DOI 10.1016/j.neubiorev.2011.11.008; Paul R, 2005, J AUTISM DEV DISORD, V35, P861, DOI 10.1007/s10803-005-0031-8; Peng XL, 2018, INT J HUM-COMPUT ST, V109, P26, DOI 10.1016/j.ijhcs.2017.08.001; Prizant B.M., 2005, HDB AUTISM PERVASIVE, P925, DOI 10.1002/9780470939352.ch10; Rapin I, 2003, BRAIN DEV-JPN, V25, P166, DOI 10.1016/S0387-7604(02)00191-2; Rapin I, 2009, DEV NEUROPSYCHOL, V34, P66, DOI 10.1080/87565640802564648; Rathinavelu A, 2007, LECT NOTES COMPUT SC, V4554, P786; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; ROBINSON P, 1995, LANG LEARN, V45, P283, DOI 10.1111/j.1467-1770.1995.tb00441.x; Root JR, 2017, J AUTISM DEV DISORD, V47, P275, DOI 10.1007/s10803-016-2947-6; Schoen E, 2011, AUTISM RES, V4, P177, DOI 10.1002/aur.183; Schopler E., 2005, EXAMINERS MANUAL PSY, V3; Schopler E., 2002, CHILDHOOD AUTISM RAT; Seferoglu G, 2005, BRIT J EDUC TECHNOL, V36, P303, DOI 10.1111/j.1467-8535.2005.00459.x; Shriberg LD, 2011, J AUTISM DEV DISORD, V41, P405, DOI 10.1007/s10803-010-1117-5; Shriberg LD, 2001, J SPEECH LANG HEAR R, V44, P1097, DOI 10.1044/1092-4388(2001/087); Vashdi E., 2014, INT J CHILD HLTH HUM, V7, P198; Wan CY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025505; Wang WSY, 1978, LINGUISTICS 70S DIRE, V8, P63; Wang X., 2014, P 10 INT SEMINAR SPE, P449; Williams JHG, 2004, RES DEV DISABIL, V25, P559, DOI 10.1016/j.ridd.2004.01.008; Wolk L, 2000, J COMMUN DISORD, V33, P371, DOI 10.1016/S0021-9924(00)00021-6; Wolk L., 2013, SPEECH LANG HEARING, V16, P239, DOI [10.1179/2050572813Y.0000000020, DOI 10.1179/2050572813Y.0000000020]; Wolk L, 2016, SPEECH LANG HEARING, V19, P121, DOI 10.1080/2050571X.2015.1133488; Zhang D, 2014, 2014 9TH INTERNATIONAL SYMPOSIUM ON CHINESE SPOKEN LANGUAGE PROCESSING (ISCSLP), P299, DOI 10.1109/ISCSLP.2014.6936629; Zheng Z, IEEE INT C ROB AUT I; Zheng Z, 2015, PROCEEDINGS OF THE 17TH INTERNATIONAL CONFERENCE ON ADVANCED ROBOTICS (ICAR), P72, DOI 10.1109/ICAR.2015.7251436; Zhou Y, 2016, 10 INT S CHIN SPOK L	78	12	12	3	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2019	14	1							e0210858	10.1371/journal.pone.0210858	http://dx.doi.org/10.1371/journal.pone.0210858			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HJ3AL	30689645	gold, Green Published, Green Submitted			2023-01-03	WOS:000457041800012
J	Carrasco, JM; Gomez-Baceiredo, B; Navas, A; Krawczyk, M; Garcia, M; Centeno, C				Miguel Carrasco, Jose; Gomez-Baceiredo, Beatriz; Navas, Alejandro; Krawczyk, Marian; Garcia, Miriam; Centeno, Carlos			Social representation of palliative care in the Spanish printed media: A qualitative analysis	PLOS ONE			English	Article							COVERAGE; BARRIERS	Background Lack of social awareness is a major barrier to the development of palliative care. Mass media influences public opinion, and frequently deal with palliative care contributing to its image and public understanding. Aim To analyse how palliative care is portrayed in Spanish newspapers, as well as the contribution made by the press to its social representation. Design Based on criteria of scope and editorial plurality, four print newspapers were selected. Using the newspaper archive MyNews (www.mynews.es), articles published between 2009 and 2014 containing the words "palliative care" or "palliative medicine" were identified. Sociological discourse analysis was performed on the identified texts on two levels: a) contextual analysis, focusing on the message as a statement; b) interpretative analysis, considering the discourse as a social product. Results We examined 262 articles. Politician and healthcare professionals were the main representatives transmitting messages on palliative care. The discourses identified were characterised by: strong ideological and moral content focusing on social debate, strong ties linking palliative care and death and, to a lesser degree, as a healthcare service. The messages transmitted by representatives with direct experience in palliative care (professionals, patients and families) contributed the most to building a positive image of this healthcare practice. Overall, media reflect different interests in framing public understanding about palliative care. Conclusion The knowledge generated about how palliative care is reflected in the printed media may help to understand better one of the main barriers to its development not only in Spain, but also in other contexts.	[Miguel Carrasco, Jose; Centeno, Carlos] Univ Navarra, Inst Culture & Soc, ATLANTES Res Program, Pamplona, Spain; [Gomez-Baceiredo, Beatriz] Univ Navarra, Sch Commun, Journalism Projects Dept, Pamplona, Spain; [Navas, Alejandro] Univ Navarra, Sch Commun, Publ Commun Dept, Pamplona, Spain; [Krawczyk, Marian] Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC, Canada; [Krawczyk, Marian] Trinity Western Univ, Langley, BC, Canada; [Garcia, Miriam] Errea Comunicac, Pamplona, Spain; [Centeno, Carlos] Univ Navarra, Univ Navarra Clin, Pamplona, Spain; [Centeno, Carlos] Navarra Inst Hlth Res IdiSNA, Pamplona, Spain	University of Navarra; University of Navarra; University of Navarra; Trinity Western University; University of Navarra	Carrasco, JM (corresponding author), Univ Navarra, Inst Culture & Soc, ATLANTES Res Program, Pamplona, Spain.	jmcarrascog@unav.es	Centeno, Carlos/H-3430-2013; Krawczyk, Marian/AAC-1956-2019; Gomez, Beatriz/AAF-1391-2021; Carrasco, Jose Miguel/I-3482-2015	Centeno, Carlos/0000-0003-3395-7039; Gomez, Beatriz/0000-0001-5332-0698; Carrasco, Jose Miguel/0000-0002-3847-8312	Institute for Culture and Society (ICS) of the University Navarra	Institute for Culture and Society (ICS) of the University Navarra	Support for this work was received from the Institute for Culture and Society (ICS) of the University Navarra. The funder provided support in the form of salaries for authors [JMC, CC], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. One of the authors [MG] is employed by a commercial company [Errea Comunicacion], but the company did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Aguiar F, 2013, ADV APPL SOCIOLOGY, V3, P124; Akintola O, 2015, HEALTH RES POLICY SY, V13, DOI 10.1186/s12961-015-0051-6; Asociacion para la investigacion de medios de comunicacion, 2011, PRENS DIG VS PAP; Asociacion para la Investigacion de Medios de Comunicacion, 2014, EST GEN MED; Berger Peter L., 1966, SOCIAL CONSTRUCTION; Brown P, 2001, SOCIOL HEALTH ILL, V23, P747, DOI 10.1111/1467-9566.00274; Centeno C, 2016, PALLIATIVE MED, V30, P351, DOI 10.1177/0269216315598671; Conde F, 2009, CUADERNOS METODOLOGI, P43; Daw JR, 2013, HEALTH POLICY, V110, P67, DOI 10.1016/j.healthpol.2013.01.006; De Leon E, 2014, J MED INTERNET RES, V16, P119, DOI 10.2196/jmir.2837; Doblado R, 2006, DIRECTORIO RECURSOS; Duran M.A., 2004, REV ESP INVESTIG SOC, V106, P9; Gysels M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034188; Habermas J., 1981, HIST CRITICA OPINION; Husemann S, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1742-1; Khaw KT, 1999, BRIT MED J, V319, P1350, DOI 10.1136/bmj.319.7221.1350; Lupton D., 1999, HEALTH, V3, P259, DOI [10.177/136345939900300301, DOI 10.1177/136345939900300301]; Lynch T, 2010, PALLIATIVE MED, V24, P812, DOI 10.1177/0269216310368578; Lynch T, 2009, J PAIN SYMPTOM MANAG, V37, P305, DOI 10.1016/j.jpainsymman.2008.03.011; Lyons A C, 2000, J Health Psychol, V5, P349, DOI 10.1177/135910530000500307; McIlfatrick S, 2014, PALLIATIVE MED, V28, P273, DOI 10.1177/0269216313502372; McIlfatrick S, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-34; Carrasco JM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184806; Muszbek K, 2007, J PAIN SYMPTOM MANAG, V33, P605, DOI 10.1016/j.jpainsymman.2007.02.027; Naugle DA, 2014, J HEALTH COMMUN, V19, P190, DOI 10.1080/10810730.2014.918217; Oliver D, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4846; Peel E, 2014, SOCIOL HEALTH ILL, V36, P885, DOI 10.1111/1467-9566.12122; Ruiz J. R., 2009, FORUM QUALITATIVE SO, V10, P2; Strydom P, 2000, SOCIOLOGICAL DISCOUR; Taiwo R., 2007, PERSPECTIVES MEDIA D; Taylor S.J., 2016, INTRO QUALITATIVE RE, V4th; Van den Berg R, 2011, EUR J GEN PRACT, V17, P14, DOI 10.3109/13814788.2010.549224; van Dijk T. A., 1988, NEWS DISCOURSE; World Health Organization, 2013, EUR HLTH REP 2012 CH; World Health Organization, 2014, DEF PALL CAR, DOI [10.1186/1472-684X-13-34, DOI 10.1186/1472-684X-13-34]; World Palliative Care Alliance World Health Organization, 2014, GLOBAL ATLAS PALLIAT; Wurz A, 2013, J HEALTH COMMUN, V18, P1566, DOI 10.1080/10810730.2013.840698; 2013, WORLD MAL REP 2013, P1	39	7	7	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2019	14	1							e0211106	10.1371/journal.pone.0211106	http://dx.doi.org/10.1371/journal.pone.0211106			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HJ2YV	30682109	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000457037500101
J	Spitzer, SA; Vail, D; Tennakoon, L; Rajasingh, C; Spain, DA; Weiser, TG				Spitzer, Sarabeth A.; Vail, Daniel; Tennakoon, Lakshika; Rajasingh, Charlotte; Spain, David A.; Weiser, Thomas G.			Readmission risk and costs of firearm injuries in the United States, 2010-2015	PLOS ONE			English	Article							HOSPITALIZATIONS; VIOLENCE	Background In 2015 there were 36,252 firearm-related deaths and 84,997 nonfatal injuries in the United States. The longitudinal burden of these injuries through readmissions is currently underestimated. We aimed to determine the 6-month readmission risk and hospital costs for patients injured by firearms. Methods We used the Nationwide Readmission Database 2010-2015 to assess the frequency of readmissions at 6 months, and hospital costs associated with readmissions for patients with firearm-related injuries. We produced nationally representative estimates of readmission risks and costs. Results Of patients discharged following a firearm injury, 15.6% were readmitted within 6 months. The average annual cost of inpatient hospitalizations for firearm injury was over $911 million, 9.5% of which was due to readmissions. Medicare and Medicaid covered 45.2% of total costs for the 5 years, and uninsured patients were responsible for 20.1%. Conclusions From 2010-2015, the average total cost of hospitalization for firearm injuries per patient was $32,700, almost 10% of which was due to readmissions within 6 months. Government insurance programs and the uninsured shouldered most of this.	[Spitzer, Sarabeth A.; Vail, Daniel] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Tennakoon, Lakshika; Rajasingh, Charlotte; Spain, David A.; Weiser, Thomas G.] Stanford Div Gen Surg, Sect Trauma & Crit Care, Stanford, CA USA	Stanford University	Spitzer, SA (corresponding author), Stanford Univ, Sch Med, Stanford, CA 94305 USA.	spitzers@stanford.edu	Weiser, Thomas G/AAC-4609-2022	Weiser, Thomas G/0000-0002-3118-3888; Vail, Daniel/0000-0001-8769-2369	Stanford Medical Scholars Research Program	Stanford Medical Scholars Research Program	Sarabeth A. Spitzer was funded by the Stanford Medical Scholars Research Program for this work.	Agency for Healthcare Research and Quality, 2017, HEALTHC COSTS UT PRO; [Anonymous], 2013, INT CLASS DIS 9 REV; [Anonymous], 2017, NRD OV HEALTHC COST; [Anonymous], 2017, NRD DAT DOC HEALTHC; [Anonymous], 2017, HEALTHC COST UT PROJ; [Anonymous], BUR LAB STAT DAT HOS; Centers for Disease Control and Prevention, 2003, WEB BAS INJ STAT QUE; Clark DE OT, 2010, ICDPIC STATA MODULE; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Follman M., 2018, MOTHER JONES; Fowler KA, 2015, PREV MED, V79, P5, DOI 10.1016/j.ypmed.2015.06.002; Friedman B, 2004, MED CARE RES REV, V61, P225, DOI 10.1177/1077558704263799; Grinshteyn E, 2016, AM J MED, V129, P266, DOI 10.1016/j.amjmed.2015.10.025; Ponzer S, 1996, PUBLIC HEALTH, V110, P41, DOI 10.1016/S0033-3506(96)80034-5; Rattan R, 2018, ANN SURG, V267, P810, DOI 10.1097/SLA.0000000000002529; Salemi JL, 2015, FAM MED COMMUNITY HE, V3, P8, DOI 10.15212/FMCH.2015.0115; Smith M, 2018, INJURY PREV, V24, P332, DOI 10.1136/injuryprev-2017-042373; Spitzer SA, 2017, AM J PUBLIC HEALTH, V107, P770, DOI 10.2105/AJPH.2017.303684; Wintemute GJ, 2015, ANNU REV PUBL HEALTH, V36, P5, DOI 10.1146/annurev-publhealth-031914-122535; WINTEMUTE GJ, 1992, J TRAUMA, V33, P556, DOI 10.1097/00005373-199210000-00011; Yoon F, 201701 HCUP US AG HE	21	19	19	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2019	14	1							e0209896	10.1371/journal.pone.0209896	http://dx.doi.org/10.1371/journal.pone.0209896			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HI8IY	30677032	Green Submitted, gold, Green Published			2023-01-03	WOS:000456700400008
J	Hurley, R				Hurley, Richard			Legalise and regulate illicit drugs to reduce poverty, say campaigners	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Godlee F, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i6067; Horsfield N., 2018, PUNISHING POVERTY FA; International Drug Policy Consortium, 2018, TAK STOCK DEC DRUG P; United Nations Office on Drugs and Crime, 2009, POL DECL PLAN ACT IN	4	2	2	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 22	2019	364								l317	10.1136/bmj.l317	http://dx.doi.org/10.1136/bmj.l317			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ6NB	30670386				2023-01-03	WOS:000457306000016
J	Jablonowska, E; Siwak, E; Bociaga-Jasik, M; Gasiorowski, J; Kalinowska, A; Burkacka, EF; Wojcik-Cichy, K; Piatek, A; Cielniak, I; Horban, A				Jablonowska, Elzbieta; Siwak, Ewa; Bociaga-Jasik, Monika; Gasiorowski, Jacek; Kalinowska, Anna; Burkacka, Ewa Firlag; Wojcik-Cichy, Kamila; Piatek, Anna; Cielniak, Iwona; Horban, Andrzej			Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients	PLOS ONE			English	Article							REVERSE-TRANSCRIPTASE INHIBITORS; NUCLEOSIDE-SPARING REGIMEN; MYOCARDIAL-INFARCTION; PLUS RALTEGRAVIR; RENAL TOXICITY; DOUBLE-BLIND; HIV; EFFICACY; TENOFOVIR/EMTRICITABINE; SAFETY	Background Dual therapy based on dolutegravir and ritonavir-boosted darunavir (DTG/DRV/r) is a combination of well-known drugs with a high genetic barrier to HIV resistance. Method A retrospective analysis of all HIV-1 infected treatment-experienced patients who switched to DTG/DRV/r from May 2014 till March 2017 in 4 Polish centres-results of a 48-week treatment. Results The study group consisted of 59 men and 17 women. Median baseline parameters were: age-42.7 years, CD4 cells count-560.5 cells/mu l, CD4 cells nadir-150 cells/mu l, number of prior antiretroviral regimens-3. The introduction of dual therapy was primarily due to virologic failure (30 patients), adverse events on previous regimens (17 patients) and therapy simplification (27 patients). At week 48 the treatment was continued in 70/76 of patients and the median CD4 cells count increased from 560.5 to 641.0 cells/mu l. The therapy was discontinued in six patients (1 -virologic failure, 1 -decrease of estimated glomerular filtration rate (eGFR), 1 -myalgia, 3 -lost to follow-up). At week 48 six patients had detectable viremia, but only in one patient viremia was higher than 200 copies/ml. At week 48 the level of serum total cholesterol of the investigated subjects was statistically significantly higher than at the moment of dual therapy introduction (185.8 mg/dl vs. 174.8 mg/dl- p<0.05). However, in patients previously not treated with TDF, there were no changes in lipid parameters during therapy. Proteinuria was observed in 13.2% of patients before the switch to dual therapy and in 7.1% of patients at week 48. Conclusions The investigated dual therapy was effective and safe. The observed increase in lipid parameters only concerned the patients who had used a TDF-based regimen prior to analysed dual treatment.	[Jablonowska, Elzbieta; Wojcik-Cichy, Kamila] Med Univ Lodz, Dept Infect Dis & Hepatol, Lodz, Poland; [Siwak, Ewa; Burkacka, Ewa Firlag; Cielniak, Iwona; Horban, Andrzej] HIV Out Patient Clin, Hosp Infect Dis, Warsaw, Poland; [Bociaga-Jasik, Monika; Kalinowska, Anna; Piatek, Anna] Jagiellonian Univ, Coll Med, Dept Infect Dis, Krakow, Poland; [Gasiorowski, Jacek] Wroclaw Med Univ, Dept Infect Dis Hepatol & Acquired Immune Deficie, Wroclaw, Poland; [Horban, Andrzej] Med Univ Warsaw, Hosp Infect Dis, Warsaw, Poland	Medical University Lodz; Jagiellonian University; Collegium Medicum Jagiellonian University; Wroclaw Medical University; Medical University of Warsaw	Jablonowska, E (corresponding author), Med Univ Lodz, Dept Infect Dis & Hepatol, Lodz, Poland.	elajablonowska@gmail.com		Jablonowska, Elzbieta/0000-0002-7282-1225; Wojcik-Cichy, Kamila/0000-0003-2465-401X				[Anonymous], GUIDELINES USE ANTIR; Burgos J, 2012, J ANTIMICROB CHEMOTH, V67, P1453, DOI 10.1093/jac/dks057; Calza L, 2011, SCAND J INFECT DIS, V43, P656, DOI 10.3109/00365548.2011.572906; Capetti AF, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2755-4; Casado JL, 2016, AIDS, V30, P1423, DOI 10.1097/QAD.0000000000001067; Cottrell ML, 2013, CLIN PHARMACOKINET, V52, P981, DOI 10.1007/s40262-013-0093-2; Gallant JE, 2003, ANTIVIR THER, V8, P489; Gueler A, 2017, AIDS, V31, P427, DOI 10.1097/QAD.0000000000001335; Hoffmann C, 2017, HIV MED, V18, P56, DOI 10.1111/hiv.12468; Hughes CA, 2008, ANN PHARMACOTHER, V42, P387, DOI 10.1345/aph.1K522; Jablonowska E, 2017, J MED VIROL, V89, P2122, DOI 10.1002/jmv.24826; Kohler JJ, 2009, LAB INVEST, V89, P513, DOI 10.1038/labinvest.2009.14; Kozal MJ, 2012, HIV CLIN TRIALS, V13, P119, DOI 10.1310/hct1303-119; Lang S, 2010, ARCH INTERN MED, V170, P1228, DOI 10.1001/archinternmed.2010.197; Lepik KJ, 2018, AIDS, V32, P903, DOI 10.1097/QAD.0000000000001781; Levey AS, 2007, CLIN CHEM, V53, P766, DOI 10.1373/clinchem.2006.077180; Margolis AM, 2014, J MED TOXICOL, V10, P26, DOI 10.1007/s13181-013-0325-8; Mitra Shubhanker, 2014, J Assoc Physicians India, V62, P580; Montessori V, 2004, CAN MED ASSOC J, V170, P229; Penafiel J, 2017, J ANTIMICROB CHEMOTH, V72, P1752, DOI 10.1093/jac/dkx053; Raffi F, 2013, LANCET INFECT DIS, V13, P927, DOI 10.1016/S1473-3099(13)70257-3; Reynes J, 2013, AIDS RES HUM RETROV, V29, P256, DOI [10.1089/aid.2011.0275, 10.1089/AID.2011.0275]; Sabin CA, 2008, LANCET, V371, P1417, DOI 10.1016/S0140-6736(08)60423-7; Santos JR, 2015, CLIN INFECT DIS, V61, P403, DOI 10.1093/cid/civ296; Sterrantino G, 2015, INFECTION, V43, P339, DOI 10.1007/s15010-015-0764-z; Taiwo B, 2011, AIDS, V25, P2113, DOI 10.1097/QAD.0b013e32834bbaa9; Tremblay Cecile L, 2008, Ther Clin Risk Manag, V4, P759; Viani RM, 2015, PEDIATR INFECT DIS J, V34, P1207, DOI 10.1097/INF.0000000000000848	28	11	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2019	14	1							e0210476	10.1371/journal.pone.0210476	http://dx.doi.org/10.1371/journal.pone.0210476			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH8WT	30653541	gold, Green Published, Green Submitted			2023-01-03	WOS:000456015500041
J	Lacerda, MVG; Llanos-Cuentas, A; Krudsood, S; Lon, C; Saunders, DL; Mohammed, R; Yilma, D; Pereira, DB; Espino, FEJ; Mia, RZ; Chuquiyauri, R; Val, F; Casapia, M; Monteiro, WM; Brito, MAM; Costa, MRF; Buathong, N; Noedl, H; Diro, E; Getie, S; Wubie, KM; Abdissa, A; Zeynudin, A; Abebe, C; Tada, MS; Brand, F; Beck, HP; Angus, B; Duparc, S; Kleim, JP; Kellam, LM; Rousell, VM; Jones, SW; Hardaker, E; Mohamed, K; Clover, DD; Fletcher, K; Breton, JJ; Ugwuegbulam, CO; Green, JA; Koh, GCKW				Lacerda, M. V. G.; Llanos-Cuentas, A.; Krudsood, S.; Lon, C.; Saunders, D. L.; Mohammed, R.; Yilma, D.; Batista Pereira, D.; Espino, F. E. J.; Mia, R. Z.; Chuquiyauri, R.; Val, F.; Casapia, M.; Monteiro, W. M.; Brito, M. A. M.; Costa, M. R. F.; Buathong, N.; Noedl, H.; Diro, E.; Getie, S.; Wubie, K. M.; Abdissa, A.; Zeynudin, A.; Abebe, C.; Tada, M. S.; Brand, F.; Beck, H. -P.; Angus, B.; Duparc, S.; Kleim, J. -P.; Kellam, L. M.; Rousell, V. M.; Jones, S. W.; Hardaker, E.; Mohamed, K.; Clover, D. D.; Fletcher, K.; Breton, J. J.; Ugwuegbulam, C. O.; Green, J. A.; Koh, G. C. K. W.			Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ARTEMETHER-LUMEFANTRINE; RADICAL CURE; PRIMAQUINE; CHLOROQUINE; DEFICIENCY; RESISTANCE; VARIANTS; FAILURE; SOUTH	BACKGROUND Treatment of Plasmodium vivax malaria requires the clearing of asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared from the liver (a treatment termed "radical cure"). Tafenoquine is a single-dose 8-aminoquinoline that has recently been registered for the radical cure of P. vivax. METHODS This multicenter, double-blind, double-dummy, parallel group, randomized, placebocontrolled trial was conducted in Ethiopia, Peru, Brazil, Cambodia, Thailand, and the Philippines. We enrolled 522 patients with microscopically confirmed P. vivax infection (> 100 to < 100,000 parasites per microliter) and normal glucose-6-phosphate dehydrogenase (G6PD) activity (with normal activity defined as = 70% of the median value determined at each trial site among 36 healthy male volunteers who were otherwise not involved in the trial). All patients received a 3-day course of chloroquine (total dose of 1500 mg). In addition, patients were assigned to receive a single 300-mg dose of tafenoquine on day 1 or 2 (260 patients), placebo (133 patients), or a 15-mg dose of primaquine once daily for 14 days (129 patients). The primary outcome was the KaplanMeier estimated percentage of patients who were free from recurrence at 6 months, defined as P. vivax clearance without recurrent parasitemia. RESULTS In the intention-to-treat population, the percentage of patients who were free from recurrence at 6 months was 62.4% in the tafenoquine group (95% confidence interval [CI], 54.9 to 69.0), 27.7% in the placebo group (95% CI, 19.6 to 36.6), and 69.6% in the primaquine group (95% CI, 60.2 to 77.1). The hazard ratio for the risk of recurrence was 0.30 (95% CI, 0.22 to 0.40) with tafenoquine as compared with placebo (P< 0.001) and 0.26 (95% CI, 0.18 to 0.39) with primaquine as compared with placebo (P< 0.001). Tafenoquine was associated with asymptomatic declines in hemoglobin levels, which resolved without intervention. CONCLUSIONS Single-dose tafenoquine resulted in a significantly lower risk of P. vivax recurrence than placebo in patients with phenotypically normal G6PD activity.	[Lacerda, M. V. G.; Val, F.; Monteiro, W. M.; Brito, M. A. M.; Costa, M. R. F.] Fundacao Med Trop Dr Heitor Vieira Dourado, Manaus, Amazonas, Brazil; [Lacerda, M. V. G.] Fundacao Oswaldo Cruz, Manguinho, RJ, Brazil; [Batista Pereira, D.; Tada, M. S.] Ctr Pesquisa Med Trop Rondonia, Porto Velho, Brazil; [Llanos-Cuentas, A.; Chuquiyauri, R.; Casapia, M.] Univ Peruana Cayetano Heredia, Lima, Peru; [Krudsood, S.] Mahidol Univ, Bangkok, Thailand; [Lon, C.; Saunders, D. L.; Buathong, N.] Armed Forces Res Inst Med Sci, Bangkok, Thailand; [Mohammed, R.; Diro, E.; Getie, S.; Wubie, K. M.] Univ Gondar, Gondar, Ethiopia; [Yilma, D.; Abdissa, A.; Zeynudin, A.; Abebe, C.] Jimma Univ, Jimma, Ethiopia; [Espino, F. E. J.] Res Inst Trop Med, Manila, Philippines; [Mia, R. Z.] Rio Tuba Nickel Fdn Hosp, Palawan, Philippines; [Noedl, H.] Med Univ Vienna, Vienna, Austria; [Brand, F.; Beck, H. -P.] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Brand, F.; Beck, H. -P.] Univ Basel, Basel, Switzerland; [Duparc, S.] Med Malaria Venture, Geneva, Switzerland; [Angus, B.] Univ Oxford, Oxford, England; [Kleim, J. -P.; Kellam, L. M.; Rousell, V. M.; Jones, S. W.; Hardaker, E.; Mohamed, K.; Clover, D. D.; Fletcher, K.; Ugwuegbulam, C. O.; Green, J. A.; Koh, G. C. K. W.] GlaxoSmithKline, Stockley Pk West, Uxbridge UB11 1BT, Middx, England; [Breton, J. J.] GlaxoSmithKline, Collegeville, PA USA	Fundacao Oswaldo Cruz; Universidad Peruana Cayetano Heredia; Mahidol University; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); University of Gondar; Jimma University; Research Institute for Tropical Medicine - Philippines; Medical University of Vienna; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; University of Oxford; GlaxoSmithKline; GlaxoSmithKline	Koh, GCKW (corresponding author), GlaxoSmithKline, Stockley Pk West, Uxbridge UB11 1BT, Middx, England.	gavin.c.koh@gsk.com	Pereira, Dhelio Batista/F-9312-2017; Val, Fernando/GSJ-1036-2022; Duparc, Stephan/AAH-8758-2020; Yilma, Daniel/AAJ-2072-2021; Ejara, Ermias/HIU-0174-2022	Pereira, Dhelio Batista/0000-0002-7761-5498; Val, Fernando/0000-0001-9995-0249; Duparc, Stephan/0000-0002-9649-4847; Yilma, Daniel/0000-0001-6058-2696; Tada, Mauro/0000-0003-2470-8559; Chuquiyauri, Raul/0000-0003-4726-249X; Kasim, Ahmed Zeynudin/0000-0002-0552-1783; Llanos-Cuentas, Alejandro/0000-0002-7567-5534; Koh, Gavin/0000-0002-7336-1566; Casapia Morales, Wilfredo Martin/0000-0002-5972-0948; Abdissa, Alemseged/0000-0003-3798-5037	GlaxoSmithKline; Medicines for Malaria Venture; FOGARTY INTERNATIONAL CENTER [D43TW009343] Funding Source: NIH RePORTER	GlaxoSmithKline(GlaxoSmithKline); Medicines for Malaria Venture; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	Funded by GlaxoSmithKline and Medicines for Malaria Venture; DETECTIVE ClinicalTrials.gov number, NCT01376167.	Abreha T, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002299; Almeida ED, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-321; [Anonymous], COCHRANE DATABASE SY; Avula B, 2011, BIOMED CHROMATOGR, V25, P1010, DOI 10.1002/bmc.1557; Baird J Kevin, 2007, Curr Infect Dis Rep, V9, P39, DOI 10.1007/s11908-007-0021-4; Beck HP, 2016, J INFECT DIS, V213, P794, DOI 10.1093/infdis/jiv508; Bennett JW, 2013, NEW ENGL J MED, V369, P1381, DOI 10.1056/NEJMc1301936; DERN RJ, 1981, J LAB CLIN MED, V97, P750; Douglas NM, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002379; Friedrich DC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110691; Gaedigk A, 2008, CLIN PHARMACOL THER, V83, P234, DOI 10.1038/sj.clpt.6100406; Goncalves LA, 2014, MEM I OSWALDO CRUZ, V109, P534, DOI 10.1590/0074-0276130579; Green JA, 2016, ANTIMICROB AGENTS CH, V60, P7321, DOI 10.1128/AAC.01588-16; Howes RE, 2016, AM J TROP MED HYG, V95, P15, DOI 10.4269/ajtmh.16-0141; Howes RE, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001339; Ingram RJH, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-488; Koepfli C, 2009, J INFECT DIS, V199, P1074, DOI 10.1086/597303; Laosombat V, 2005, BLOOD CELL MOL DIS, V34, P191, DOI 10.1016/j.bcmd.2004.11.001; Llanos-Cuentas A, 2019, NEW ENGL J MED, V380, P229, DOI 10.1056/NEJMoa1802537; Llanos-Cuentas A, 2014, LANCET, V383, P1049, DOI 10.1016/S0140-6736(13)62568-4; Noori-Daloii MR, 2007, CLIN BIOCHEM, V40, P699, DOI 10.1016/j.clinbiochem.2007.02.008; Pereira EA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-355; Price RN, 2014, LANCET INFECT DIS, V14, P982, DOI 10.1016/S1473-3099(14)70855-2; Pybus BS, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-212; Silvino ACR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160172; Rochford R, 2013, P NATL ACAD SCI USA, V110, P17486, DOI 10.1073/pnas.1310402110; Rueangweerayut R, 2017, AM J TROP MED HYG, V97, P702, DOI 10.4269/ajtmh.16-0779; St Jean PL, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1145-5; Takeuchi R, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-308; Thomas D, 2016, ACTA TROP, V160, P35, DOI 10.1016/j.actatropica.2016.04.009; Thriemer K, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1784-1; White NJ, 2012, ADV PARASIT, V80, P113, DOI 10.1016/B978-0-12-397900-1.00002-5; WHO, 2016, MAL MICR STAND OP PR; WHO, 2015, GUID TREATM MAL, VThird; World Health Organization, 2016, TEST G6PD DEF SAF US; World Health Organization, 2015, CONTROL ELIMINATION; Yohannes AM, 2011, AM J TROP MED HYG, V84, P137, DOI 10.4269/ajtmh.2011.09-0723	37	124	127	1	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 17	2019	380	3					215	228		10.1056/NEJMoa1710775	http://dx.doi.org/10.1056/NEJMoa1710775			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH5YY	30650322	Green Accepted, Bronze, Green Published			2023-01-03	WOS:000455806200004
J	Dodd, SAS; Cave, NJ; Adolphe, JL; Shoveller, AK; Verbrugghe, A				Dodd, Sarah A. S.; Cave, Nick J.; Adolphe, Jennifer L.; Shoveller, Anna K.; Verbrugghe, Adronie			Plant-based (vegan) diets for pets: A survey of pet owner attitudes and feeding practices	PLOS ONE			English	Article							GREENHOUSE-GAS EMISSIONS; LIFE-STYLE; CONSCIENTIOUS OMNIVORES; VEGETARIAN DIETS; MEAT-EATERS; HEALTH; FOOD; CONSUMPTION; CATS; DOGS	People who avoid eating animals tend to share their homes with animal companions, and moral dilemma may arise when they are faced with feeding animal products to their omnivorous dogs and carnivorous cats. One option to alleviate this conflict is to feed pets a diet devoid of animal ingredients-a 'plant-based' or 'vegan' diet. The number of pet owners who avoid animal products, either in their own or in their pets' diet, is not currently known. The objective of this study was to estimate the number of meat-avoiding pet owners, identify concerns regarding conventional animal- and plant-based pet food, and estimate the number of pets fed a plant-based diet. A questionnaire was disseminated online to English-speaking pet owners (n = 3,673) to collect data regarding pet owner demographics, diet, pet type, pet diet, and concerns regarding pet foods. Results found that pet owners were more likely to be vegetarian (6.2%; 229/3,673) or vegan (5.8%; 212/3,673) than previously reported for members of the general population. With the exception of one dog owned by a vegetarian, vegans were the only pet owners who fed plant-based diets to their pets (1.6%; 59/3,673). Of the pet owners who did not currently feed plant-based diets but expressed interest in doing so, a large proportion (45%; 269/599) desired more information demonstrating the nutritional adequacy of plant-based diets. Amongst all pet owners, the concern most commonly reported regarding meat-based pet foods was for the welfare of farm animals (39%; 1,275/3,231). The most common concern regarding strictly plant-based pet foods was regarding the nutritional completeness of the diet (74%; 2,439/3,318). Amongst vegans, factors which predicted the feeding of plant-based diets to their pets were concern regarding the cost of plant-based diets, a lack of concern regarding plant-based diets being unnatural, and reporting no concern at all regarding plant-based diets for pets. Given these findings, further research is warranted to investigate plant-based nutrition for domestic dogs and cats.	[Dodd, Sarah A. S.; Verbrugghe, Adronie] Univ Guelph, Dept Clin Studies, Ontario Vet Coll, Guelph, ON, Canada; [Cave, Nick J.] Massey Univ, Sch Vet Sci, Palmerston North, New Zealand; [Adolphe, Jennifer L.] Petcurean Pet Nutr, Chilliwack, BC, Canada; [Shoveller, Anna K.] Univ Guelph, Dept Anim Biosci, Guelph, ON, Canada	University of Guelph; Massey University; University of Guelph	Verbrugghe, A (corresponding author), Univ Guelph, Dept Clin Studies, Ontario Vet Coll, Guelph, ON, Canada.	averbrug@uoguelph.ca	Cave, Nick/AAQ-9789-2021	Cave, Nick/0000-0002-6037-5942; Dodd, Sarah/0000-0002-8151-5844	Petcurean Pet Nutrition; Mitacs Accelerate program; Mitacs Accelerate award [IT10206]	Petcurean Pet Nutrition; Mitacs Accelerate program; Mitacs Accelerate award	One of the authors, Dr. Jennifer Adolphe, is employed by the commercial company Petcurean Pet Nutrition. Petcurean Pet Nutrition also provided financial support for the MSc stipend for the primary author, Dr. Sarah Dodd, in association with the Mitacs Accelerate program. The funder provided support in the form of salaries for Dr. Adolphe and partial support for Dr. Dodd, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Indeed, study design, data collection and analysis had all been performed prior to Dr. Adolphe's inclusion in the project and prior to Dr. Dodd's Mitacs Accelerate award (IT10206). The specific roles of these authors are articulated in the 'author contributions' section.	Agency FS, 2006, GUID VEG VEG LAB; Allen MW, 2000, J SOC PSYCHOL, V140, P405, DOI 10.1080/00224540009600481; [Anonymous], 2017, ASS AM FEED CONTROL; [Anonymous], 2014, BOO RIPENED HUMAN DE; [Anonymous], 2017, US WORLD POP CLOCK; Appleby PN, 2016, P NUTR SOC, V75, P287, DOI 10.1017/S0029665115004334; *AVMA, 2002, US PET OWN DEM SOURC; Bates B, 2009, NATL DIET NUTR SURVE; BAUDRY J, 2017, NUTRIENTS, V9, DOI DOI 10.3390/NU9091023; Beaton L., 2018, Petfood Industry, V60, P22; Bella F, 2017, INT J FOOD SCI NUTR, V68, P402, DOI 10.1080/09637486.2016.1261087; Berschneider HM, 2002, CLIN TECH SMALL AN P, V17, P1, DOI 10.1053/svms.2002.27782; Brown W. Y., 2009, RECENT ADV ANIM NUTR, V17, P137; Brown WY, 2009, BRIT J NUTR, V102, P1318, DOI 10.1017/S0007114509389254; Case L, 2008, J ANIM SCI, V86, P3245, DOI 10.2527/jas.2008-1147; Chambers L, 2018, NUTR BULL, V43, P46, DOI 10.1111/nbu.12305; Connolly KM, 2014, JAVMA-J AM VET MED A, V245, P669, DOI 10.2460/javma.245.6.669; Craig WJ, 2009, AM J CLIN NUTR, V89, pS1627, DOI 10.3945/ajcn.2009.26736N; Davey GK, 2003, PUBLIC HEALTH NUTR, V6, P259, DOI 10.1079/PHN2002430; de Boer J, 2011, ECOL ECON, V70, P1259, DOI 10.1016/j.ecolecon.2011.03.001; de Fomel-Thibaud P, 2007, J AM ANIM HOSP ASSOC, V43, P52, DOI 10.5326/0430052; DEFRA, 2007, REP QUEST DAT TABL F; Deng P, 2015, J ANIM SCI, V93, P823, DOI 10.2527/jas.2014-8520; Dillitzer N, 2011, BRIT J NUTR, V106, pS53, DOI 10.1017/S0007114511002765; European Pet Food Industry Federation (FEDIAF), 2017, NUTR GUID COMPL COMP; Fardet A, 2014, NUTR REV, V72, P741, DOI 10.1111/nure.12153; Filippi M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010847; Fox N, 2008, APPETITE, V50, P422, DOI 10.1016/j.appet.2007.09.007; GlobalData, 2017, TOP TRENDS PREP FOOD; Gosper EC, 2016, AUST VET J, V94, P12, DOI 10.1111/avj.12397; Graca J, 2015, APPETITE, V95, P113, DOI 10.1016/j.appet.2015.06.024; Graca J, 2015, APPETITE, V90, P80, DOI 10.1016/j.appet.2015.02.037; Gray CM, 2004, JAVMA-J AM VET MED A, V225, P1670, DOI 10.2460/javma.2004.225.1670; Health Navigator, 2017, VEG VEG; Hedenus F, 2014, CLIMATIC CHANGE, V124, P79, DOI 10.1007/s10584-014-1104-5; Henderson L, 2002, NATL DIET NUTR SURVE, V1; Herzog J.H., 1991, ANTHROZOOS, V4, P184, DOI DOI 10.2752/089279391787057170; Hill D., 2004, PET FOOD ASS CAN FAL; Hill RC, 2009, JAVMA-J AM VET MED A, V234, P347, DOI 10.2460/javma.234.3.347; Hoek AC, 2004, APPETITE, V42, P265, DOI 10.1016/j.appet.2003.12.003; Hutchinson D, 2012, JAVMA-J AM VET MED A, V241, P477, DOI 10.2460/javma.241.4.477; Janssen M, 2016, APPETITE, V105, P643, DOI 10.1016/j.appet.2016.06.039; Kanakubo K, 2015, JAVMA-J AM VET MED A, V247, P385, DOI 10.2460/javma.247.4.385; Kerschke-Risch P., 2015, Ernahrungs Umschau, V62, P98; Kienzle E., 2001, COMPENDIUM, V23, P81; Kivimaki H., 2013, CROSS SECTIONAL STUD; Knight A, 2016, ANIMALS, V6, DOI 10.3390/ani6090057; Kosonen H, 2005, SOZ PRAVENTIV MED, V50, P142, DOI 10.1007/s00038-005-3167-6; Lauten S. D., 2005, Journal of Veterinary Internal Medicine, V19, P476; Lawton R, 2009, HEALTH PSYCHOL, V28, P56, DOI 10.1037/a0013424; Lummis D., NATURAL ORGANIC ECO; Lund TB, 2016, ANTHROZOOS, V29, P89, DOI 10.1080/08927936.2015.1083192; Macdiarmid JI, 2016, APPETITE, V96, P487, DOI 10.1016/j.appet.2015.10.011; Maine IR, 2015, ACTA VET SCAND, V57, P1, DOI 10.1186/s13028-015-0097-z; Mangels AR, 2003, J AM DIET ASSOC, V103, P748, DOI 10.1053/jada.2003.50142; McDonald B, 2000, SOC ANIM, V8, P1, DOI 10.1163/156853000X00011; Meeker DL, 2015, J ANIM SCI, V93, P835, DOI 10.2527/jas.2014-8524; Mekonnen MM, 2012, ECOSYSTEMS, V15, P401, DOI 10.1007/s10021-011-9517-8; Michel KE, 2006, VET CLIN N AM-SMALL, V36, P1269, DOI 10.1016/j.cvsm.2006.08.003; Michel KE, 2008, JAVMA-J AM VET MED A, V233, P1699, DOI 10.2460/javma.233.11.1699; Morgan R., 2016, SLOW STEADY RISE VEG; Morgan SK, 2017, PEERJ, V5, DOI 10.7717/peerj.3031; Morris JG, 2002, NUTR RES REV, V15, P153, DOI 10.1079/NRR200238; Nath J, 2010, HEALTH SOCIOL REV, V19, P356, DOI 10.5172/hesr.2010.19.3.356; National Research Council, 2006, NUTR REQ DOGS CATS; Newport F, 2012, US 5 CONSIDER THEMSE; Okin GS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181301; Parr JM, 2014, VET CLIN N AM-SMALL, V44, P667, DOI 10.1016/j.cvsm.2014.03.006; Paul ES, 2000, ANTHROZOOS, V13, P194, DOI 10.2752/089279300786999699; PFI, 2015, PET FOOD TRENDS FOLL; Pimentel D, 2003, AM J CLIN NUTR, V78, p660S, DOI 10.1093/ajcn/78.3.660S; Preylo BD, 2008, ANTHROZOOS, V21, P387, DOI 10.2752/175303708X371654; Prunty J, 2013, ANTHROZOOS, V26, P265, DOI 10.2752/175303713X13636846944367; Radnitz C, 2015, APPETITE, V90, P31, DOI 10.1016/j.appet.2015.02.026; Rahaman S, 2000, COMPENDIUM CONTINUIN, V22, P70; Rajagopaul S, 2016, J SMALL ANIM PRACT, V57, P484, DOI 10.1111/jsap.12526; Remillard RL, 2008, TOP COMPANION ANIM M, V23, P137, DOI 10.1053/j.tcam.2008.04.006; Rothgerber H, 2015, APPETITE, V87, P251, DOI 10.1016/j.appet.2014.12.206; Rothgerber H, 2014, ANTHROZOOS, V27, P485, DOI 10.2752/089279314X14072268687844; Rothgerber H, 2015, APPETITE, V84, P196, DOI 10.1016/j.appet.2014.10.012; Rothgerber H, 2013, APPETITE, V68, P76, DOI 10.1016/j.appet.2013.04.012; Roudebush Philip, 1992, Vet Dermatol, V3, P23, DOI 10.1111/j.1365-3164.1992.tb00139.x; Scarborough P, 2014, CLIMATIC CHANGE, V125, P179, DOI 10.1007/s10584-014-1169-1; Semp P., 2014, THESIS VET U VIENNA; Spencer EH, 2007, J AM DIET ASSOC, V107, P72, DOI 10.1016/j.jada.2006.10.034; Stockman J, 2013, JAVMA-J AM VET MED A, V242, P1500, DOI 10.2460/javma.242.11.1500; Swanson KS, 2013, ADV NUTR, V4, P141, DOI 10.3945/an.112.003335; Sydney N, 2013, SURV 1202 AUSTR WHET; Taylor N, 2005, ANTHROZOOS, V18, P18, DOI 10.2752/089279305785594342; Verbrugghe A, 2011, VLAAMS DIERGEN TIJDS, V80, P61; Verbrugghe A, 2012, CRITICAL REV FOOD SC, V52, P203; Vinnari M, 2007, PUBLIC HEALTH NUTR, V12, P481; Vinnari M, 2009, PUBLIC HEALTH NUTR, V12, P481, DOI 10.1017/S1368980008002486; Wakefield LA, 2006, JAVMA-J AM VET MED A, V229, P70, DOI 10.2460/javma.229.1.70; Yeliosof O, 2018, J PEDIATR ENDOCR MET, V31, P91, DOI 10.1515/jpem-2017-0082; Yip CSC, 2013, INT J PUBLIC HEALTH, V58, P683, DOI 10.1007/s00038-013-0484-z	96	30	30	9	63	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2019	14	1							e0210806	10.1371/journal.pone.0210806	http://dx.doi.org/10.1371/journal.pone.0210806			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HH6AH	30645644	Green Published, gold, Green Submitted			2023-01-03	WOS:000455810200057
J	Conroy, T; Hammel, P; Hebbar, M; Ben Abdelghani, M; Wei, AC; Raoul, JL; Chone, L; Francois, E; Artru, P; Biagi, JJ; Lecomte, T; Assenat, E; Faroux, R; Ychou, M; Volet, J; Sauvanet, A; Breysacher, G; Di Fiore, F; Cripps, C; Kavan, P; Texereau, P; Bouhier-Leporrier, K; Khemissa-Akouz, F; Legoux, JL; Juzyna, B; Gourgou, S; O'Callaghan, CJ; Jouffroy-Zeller, C; Rat, P; Malka, D; Castan, F; Bachet, JB				Conroy, T.; Hammel, P.; Hebbar, M.; Ben Abdelghani, M.; Wei, A. C.; Raoul, J. -L.; Chone, L.; Francois, E.; Artru, P.; Biagi, J. J.; Lecomte, T.; Assenat, E.; Faroux, R.; Ychou, M.; Volet, J.; Sauvanet, A.; Breysacher, G.; Di Fiore, F.; Cripps, C.; Kavan, P.; Texereau, P.; Bouhier-Leporrier, K.; Khemissa-Akouz, F.; Legoux, J. -L.; Juzyna, B.; Gourgou, S.; O'Callaghan, C. J.; Jouffroy-Zeller, C.; Rat, P.; Malka, D.; Castan, F.; Bachet, J. -B.		Canadian Canc Trials Grp; Unicanc-GI-PRODIGE Grp	FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OPEN-LABEL; CHEMOTHERAPY; RESECTION; MULTICENTER; PHASE-3; TRIAL	BACKGROUND Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer. METHODS We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen (oxaliplatin [85 mg per square meter of body-surface area], irinotecan [180 mg per square meter, reduced to 150 mg per square meter after a protocol-specified safety analysis], leucovorin [400 mg per square meter], and fluorouracil [2400 mg per square meter] every 2 weeks) or gemcitabine (1000 mg per square meter on days 1, 8, and 15 every 4 weeks) for 24 weeks. The primary end point was disease-free survival. Secondary end points included overall survival and safety. RESULTS At a median follow-up of 33.6 months, the median disease-free survival was 21.6 months in the modified-FOLFIRINOX group and 12.8 months in the gemcitabine group (stratified hazard ratio for cancer-related event, second cancer, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.73; P<0.001). The disease-free survival rate at 3 years was 39.7% in the modified- FOLFIRINOX group and 21.4% in the gemcitabine group. The median overall survival was 54.4 months in the modified-FOLFIRINOX group and 35.0 months in the gemcitabine group (stratified hazard ratio for death, 0.64; 95% CI, 0.48 to 0.86; P = 0.003). The overall survival rate at 3 years was 63.4% in the modified-FOLFIRINOX group and 48.6% in the gemcitabine group. Adverse events of grade 3 or 4 occurred in 75.9% of the patients in the modified-FOLFIRINOX group and in 52.9% of those in the gemcitabine group. One patient in the gemcitabine group died from toxic effects (interstitial pneumonitis). CONCLUSIONS Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects.	[Conroy, T.] Inst Cancerol Lorraine, Nancy, France; [Conroy, T.] Univ Lorraine, Nancy, France; [Chone, L.] Ctr Hosp Univ, Nancy, France; [Hammel, P.; Sauvanet, A.] Hop Beaujon, Clichy, France; [Hammel, P.; Sauvanet, A.] Univ Paris VII, Clichy, France; [Hebbar, M.] Hop Huriez, Lille, France; [Ben Abdelghani, M.] Ctr Paul Strauss, Strasbourg, France; [Raoul, J. -L.] Inst Paoli Calmettes, Marseille, France; [Francois, E.] Ctr Antoine Lacassagne, Nice, France; [Artru, P.] Hop Jean Mermoz, Lyon, France; [Lecomte, T.] Hop Trousseau, Tours, France; [Assenat, E.] Ctr Hosp Univ St Eloi, Montpellier, France; [Ychou, M.; Gourgou, S.; Castan, F.] Univ Montpellier, Inst Canc Montpellier Val dAurelle, Montpellier, France; [Faroux, R.] Ctr Hosp Dept Vendee, La Roche Sur Yon, France; [Volet, J.] Ctr Hosp Univ Robert Debre, Reims, France; [Breysacher, G.] Hop Louis Pasteur, Colmar, France; [Di Fiore, F.] Normandie Univ, Rouen Univ Hosp, Rouen, France; [Texereau, P.] Hop Layne, Mt De Marsan, France; [Bouhier-Leporrier, K.] Ctr Hosp Univ Cote Nacre, Caen, France; [Khemissa-Akouz, F.] Hop St Jean, Perpignan, France; [Legoux, J. -L.] Ctr Hosp Reg, Orleans, France; [Juzyna, B.; Jouffroy-Zeller, C.] R&D Unicanc, Paris, France; [Bachet, J. -B.] Sorbonne Univ, Hop Univ Pitie Salpetriere, Assistance Publ Hop Paris, Paris, France; [Malka, D.] Univ Paris Saclay, Gustave Roussy, Villejuif, France; [Rat, P.] Ctr Hosp Univ, Dijon, France; [Wei, A. C.] Princess Margaret Canc Ctr, Toronto, ON, Canada; [Biagi, J. J.] Kingston Gen Hosp, Kingston, ON, Canada; [O'Callaghan, C. J.] Queens Univ, Canadian Canc Trials Grp, Kingston, ON, Canada; [Cripps, C.] Ottawa Hlth Res Inst, Ottawa, ON, Canada; [Kavan, P.] Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ, Canada	UNICANCER; Institut de cancerologie de Lorraine (ICL); Universite de Lorraine; CHU de Nancy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Universite de Lille - ISITE; CHU Lille; UNICANCER; Centre Paul Strauss; UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Centre Antoine Lacassagne; Universite de Franche-Comte; CHU Besancon; CHU Tours; Universite de Montpellier; CHU de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); CHD Vendee; CHU de Reims; CHU de Rouen; CHU de Caen NORMANDIE; Universite de Caen Normandie; Centre Hospitalier Annecy Genevois; Centre Hospitalier Regional d'Orleans; UNICANCER; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; CHU Dijon Bourgogne; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Queens University - Canada; Queens University - Canada; University of Ottawa; Ottawa Hospital Research Institute; McGill University	Conroy, T (corresponding author), Inst Cancerol Lorraine, Dept Med Oncol, 6 Ave Bourgogne,CS 30519, F-54519 Vandoeuvre Les Nancy, France.	t.conroy@nancy.unicancer.fr	Touchefeu, Yann/M-2969-2015; Conroy, Thierry/X-8127-2019; wibunsin, yasumin/AAE-5789-2019	Touchefeu, Yann/0000-0001-8421-3182; Wei, Alice Chia-Chi/0000-0002-2505-959X; Bennouna, Jaafar/0000-0002-5034-1108; Raoul, Jean-Luc/0000-0001-6305-8953; SAUVANET, alain/0000-0002-7436-5999; ghiringhelli, francois/0000-0002-5465-8305; DE LA FOUCHARDIERE, CHRISTELLE/0000-0003-2291-5693; LECOMTE, Thierry/0000-0001-5093-0212	R&D Unicancer (Chugai Pharmaceutical); French Ministry of Health [PHRC11-006]; Institut National du Cancer; French National League against Cancer; Canadian Cancer Society [704970]; Roche; Celgene; Sanofi; 7 Days in May	R&D Unicancer (Chugai Pharmaceutical); French Ministry of Health; Institut National du Cancer(Institut National du Cancer (INCA) France); French National League against Cancer; Canadian Cancer Society(Canadian Cancer Society (CCS)); Roche(Roche Holding); Celgene(Bristol-Myers SquibbCelgene Corporation); Sanofi; 7 Days in May	PRODIGE (Partenariat de Recherche en Oncologie Digestive) 24 was supported by R&D Unicancer (which received a grant from Chugai Pharmaceutical), by a Clinical Research Hospital Program grant (PHRC11-006) from the French Ministry of Health and the Institut National du Cancer, and by the French National League against Cancer. The Canadian Cancer Trials Group Pancreatic Adenocarcinoma (CCTG PA.6) part of the trial was supported by a Program Grant (704970) from the Canadian Cancer Society and by grants from 7 Days in May.; Dr. Conroy reports receiving travel support from Roche; Dr. Hammel, receiving grant support, consulting fees, and travel support from Celgene; Dr. Ben Abdelghani, receiving fees for providing expert testimony and travel support from Amgen, Bayer, Merck, Sanofi, and Ipsen; Dr. Wei, receiving consulting fees from Celgene, Shire, Ethicon, and Ipsen and travel support from Bayer; Dr. Raoul, receiving fees for serving on an advisory board from Bayer, Bristol-Myers Squibb, BTG, Ipsen, AstraZeneca, and Terumo Medical; Dr. Francois, receiving consulting fees and travel support from Roche, Merck, and Servier and personal fees from Amgen, Sanofi, Lilly, Novartis, and Bayer; Dr. Ychou, receiving grant support, paid to his institution, and fees for serving as a board member from Bayer, Servier, and Amgen, and grant support, paid to his institution, from Roche; Dr. Di Fiore, receiving fees for a meeting presentation from Celgene; Dr. Bouhier-Leporrier, receiving consulting fees and travel support from Ipsen and Novartis, fees for serving on a speakers' bureau from Amgen and MSD, and travel support from Bayer; Dr. Khemissa-Akouz, receiving personal fees from Sanofi and Ipsen and personal fees and travel support from Roche; Dr. Legoux, receiving consulting fees and travel support from Novartis, travel fees from Ipsen and Merck Serono, lecture fees and travel support from Servier, and grant support from Sanofi; Dr. Malka, receiving lecture fees and travel support from Amgen and Sanofi, lecture fees, consulting fees, and travel support from Bayer, Merck Serono, and Roche, consulting fees from Merck and Shire, and lecture fees and consulting fees from Servier and HalioDx; and Dr. Bachet, receiving consulting fees and lecture fees from Amgen, Bayer, Merck Serono, and Servier and lecture fees from Celgene, Roche, and Sanofi. No other potential conflict of interest relevant to this article was reported.	[Anonymous], 2009, COMMON TERMINOLOGY C; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Ducreux M, 2015, ANN ONCOL, V26, pV56, DOI 10.1093/annonc/mdv295; *EARL BREAST CANC, 1990, TREATM EARL BREAST C, V1; GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Khorana AA, 2016, J CLIN ONCOL, V34, P2541, DOI 10.1200/JCO.2016.67.5553; Mahaseth H, 2013, PANCREAS, V42, P1311, DOI 10.1097/MPA.0b013e31829e2006; Malvezzi M, 2018, ANN ONCOL, V29, P1016, DOI 10.1093/annonc/mdy033; Neoptolemos JP, 2017, LANCET, V389, P1011, DOI 10.1016/S0140-6736(16)32409-6; Neoptolemos JP, 2010, JAMA-J AM MED ASSOC, V304, P1073, DOI 10.1001/jama.2010.1275; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Oettle H, 2007, JAMA-J AM MED ASSOC, V297, P267, DOI 10.1001/jama.297.3.267; Oettle H, 2013, JAMA-J AM MED ASSOC, V310, P1473, DOI 10.1001/jama.2013.279201; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Reddy SK, 2007, ONCOLOGIST, V12, P654, DOI 10.1634/theoncologist.12-6-654; Sergeant G, 2013, WORLD J SURG, V37, P1782, DOI 10.1007/s00268-013-2064-z; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Sinn M, 2014, ANN ONCOL, V25, P1025, DOI 10.1093/annonc/mdu084; Sinn M, 2017, J CLIN ONCOL, V35, P3330, DOI 10.1200/JCO.2017.72.6463; Sobin LH, 2010, TNM CLASSIFICATION M; Uesaka K, 2016, LANCET, V388, P248, DOI 10.1016/S0140-6736(16)30583-9	23	1194	1219	13	87	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 20	2018	379	25					2395	2406		10.1056/NEJMoa1809775	http://dx.doi.org/10.1056/NEJMoa1809775			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF0KI	30575490	Bronze			2023-01-03	WOS:000453849400004
J	Tekelab, T; Chojenta, C; Smith, R; Loxton, D				Tekelab, Tesfalidet; Chojenta, Catherine; Smith, Roger; Loxton, Deborah			Factors affecting utilization of antenatal care in Ethiopia: A systematic review and meta-analysis	PLOS ONE			English	Review							SERVICE UTILIZATION; INSTITUTIONAL DELIVERY; DEVELOPING-COUNTRIES; PRENATAL-CARE; MASS-MEDIA; DETERMINANTS; COMMUNITY; WOMEN; SURVIVAL; DISTRICT	Background In the context of high maternal morbidity and mortality in Sub-Saharan Africa, less than 80% of pregnant women receive antenatal care services. According to a 2016 national report, only 62% of pregnant women in Ethiopia made at least one antenatal care visit. The aim of this review was to systematically and quantitatively summarize the factors affecting utilization of antenatal care in Ethiopia. Methods We searched PubMed, Medline, EMBASE, CINAHL, Google Scholar and Maternity and Infant Care database for studies that had been conducted in Ethiopia between 2002 and 2016. We summarized the studies on the use of antenatal care services quantitatively and qualitatively. A random-effects model was conducted to obtain the pooled estimates. Results A total of fifteen observational studies were included in this review. The pooled prevalence of utilization of antenatal care services in Ethiopia was 63.77% (95CI 53.84-75.54). The pooled odds ratio showed that a significant positive association was found between utilization of antenatal care and urban residence (OR = 1.92, 95% CI = 1.35-2.72), women's education (OR = 1.90, 95% CI = 1.52-2.37), husband's education (OR = 1.49, 95% CI = 1.321.69) and planned pregnancy (OR = 2.08, 95% CI = 1.45-2.98). Based on narrative synthesis exposure to mass media, family income and accessibility of the service were strongly associated with utilization of antenatal care. Conclusion The findings of this review found several modifiable factors such as empowering women through education and increasing their decision-making power, promoting family planning to prevent unplanned pregnancy, increasing awareness of women through mass media and making services more accessible would likely to increase utilization of antenatal care. Further research is needed on accessibility and availability of the service at the individual and community level to assess the predictors of antenatal care service utilization.	[Tekelab, Tesfalidet; Chojenta, Catherine; Loxton, Deborah] Univ Newcastle, Sch Med & Publ Hlth, Res Ctr Generat Hlth & Ageing, Newcastle, NSW, Australia; [Tekelab, Tesfalidet] Wollega Univ, Coll Med & Hlth Sci, Nekemte, Oromia Region, Ethiopia; [Smith, Roger] Univ Newcastle, Sch Med & Publ Hlth, Mothers & Babies Res Ctr, Newcastle, NSW, Australia	University of Newcastle; University of Newcastle	Tekelab, T (corresponding author), Univ Newcastle, Sch Med & Publ Hlth, Res Ctr Generat Hlth & Ageing, Newcastle, NSW, Australia.; Tekelab, T (corresponding author), Wollega Univ, Coll Med & Hlth Sci, Nekemte, Oromia Region, Ethiopia.	ttesfalove@gmail.com	Chojenta, Catherine L/B-2521-2008; Beyene, Tesfalidet Tekelab/H-4090-2019	Chojenta, Catherine L/0000-0002-2541-4491; Smith, Roger/0000-0003-4720-0280; Beyene, Dr Tesfalidet/0000-0003-0774-7708				Abosse Z, 2010, ETHIOP J HEALTH SCI, V20, P75; Abou-Zahr CL, 2003, ANTENATAL CARE DEV C; Acharya Dilaram, 2015, BMC Res Notes, V8, P345, DOI 10.1186/s13104-015-1312-8; Adamu Y M, 2002, J Obstet Gynaecol, V22, P600, DOI 10.1080/0144361021000020349; Adewuyi EO, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197324; Adhikari R, 2016, BMC WOMENS HEALTH, V16, DOI 10.1186/s12905-016-0305-7; Afulani PA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117996; Ali Abdel Aziem A, 2010, BMC Pregnancy Childbirth, V10, P67, DOI 10.1186/1471-2393-10-67; Amentie MA, 2015, GLOBAL J MED RES, V15; Amsalu Gashaw, 2015, BMC Research Notes, V8, P22, DOI 10.1186/s13104-014-0965-z; [Anonymous], 2006, STAND MAT NEON CAR; [Anonymous], 1996, MOTH BAB PACK IMPL S; Babalola S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-43; Bande IM, 2018, JTDH, V29, P1; Banke-Thomas OE, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1246-3; Bariagaber H., 2016, Studies on Ethno-Medicine, V10, P411; Bassani DG, 2009, INT PERSPECT SEX R H, V35, P15, DOI [10.1363/3501509, 10.1363/ifpp.35.015.09]; Bbaale E, 2011, AUSTRALAS MED J, V4, P516, DOI 10.4066/AMJ.2011.849; Bhutta ZA, 2008, LANCET, V372, P972, DOI 10.1016/S0140-6736(08)61407-5; Birmeta K, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-256; Bloom SS, 2001, DEMOGRAPHY, V38, P67, DOI 10.1353/dem.2001.0001; Boamah SA, 2016, J BIOSOC SCI, V48, P342, DOI 10.1017/S0021932015000218; Borenstein M, 2017, RES SYNTH METHODS, V8, P5, DOI 10.1002/jrsm.1230; Central Statistical Agency, 2014, ETH ICF INT ETH MIN; Ciceklioglu M, 2005, INT J QUAL HEALTH C, V17, P533, DOI 10.1093/intqhc/mzi076; CSA ICF, 2016, ETH DEM HLTH SURV; Dahiru T, 2015, PAN AFR MED J, V21, DOI 10.11604/pamj.2015.21.321.6527; Dibaba Y, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-50; Dutamo Z, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1047-1; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fagbamigbe AF, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0527-y; Fekede Bontu, 2007, Ethiop Med J, V45, P123; Finlayson K, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001373; Ghosh D, 2006, PROF GEOGR, V58, P278, DOI 10.1111/j.1467-9272.2006.00568.x; Girmaye M, 2016, ETHIOP J HEALTH SCI, V26, P369, DOI 10.4314/ejhs.v26i4.9; Gitonga E, 2017, ADV PUBLIC HLTH, V2017, DOI DOI 10.1155/2017/3685401; Graft-Johnson J, 2006, CONTINUUM CARE MATER; Gupta Shivam, 2014, PLoS One, V9, pe101893, DOI 10.1371/journal.pone.0101893; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; Jejeebhoy S., 1995, WOMENS ED AUTONOMY R; Jira C, 2005, ETHIOPIAN J HLTH SCI, V15; Kabir M, 2005, TROP DOCT, V35, P110, DOI 10.1258/0049475054036814; Kenya National Bureau of Statistics, 2015, KEN DEM HLTH SURV 20; Kinney MV, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000294; Lindtjorn B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169304; Marston C, 2003, POP STUD-J DEMOG, V57, P77, DOI 10.1080/0032472032000061749; Mbuagbaw LCE, 2011, MATERN CHILD HLTH J, V15, P1427, DOI 10.1007/s10995-010-0707-3; Melaku YA, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/s12884-014-0418-7; Mezmur M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184688; Ministry of Health Community Development Gender Elderly and Children (MoHCDGEC) Ministry of Health (MoH) National Bureau of Statistics (NBS) Office of the Chief Government Statistician (OCGS) and ICF, 2016, TANZ DEM HLTH SURV M; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; Moyer CA, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-40; Mustafa MH, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1128-1; Nisar N, 2003, J Pak Med Assoc, V53, P47; Nketiah-Amponsah E, 2013, AFR J ECON MANAG STU, V4, P58, DOI 10.1108/20400701311303159; Ntambue MLA, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-66; Oakley L, 2009, SYSTEMATIC REV EFFEC; Ochako R, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0168-2; Pallikadavath S, 2004, SOC SCI MED, V59, P1147, DOI 10.1016/j.socscimed.2003.11.045; Pell C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053747; Rashid M, 2014, J RES HEALTH SCI, V14, P187; Regassa N, 2011, AFR HEALTH SCI, V11, P390; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S0140-6736(06)69380-X; Rurangirwa AA, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1328-2; Saad-Haddad G, 2016, J GLOB HEALTH, V6, DOI [10.7189/Jogh.06.010404, 10.7189/jogh.06.010404]; Simkhada B, 2008, J ADV NURS, V61, P244, DOI 10.1111/j.1365-2648.2007.04532.x; Singh K, 2010, INFLUENCE WOMENS EMP; Tarekegn SM, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-161; Tekelab T., 2014, SCI TECHNOL ARTS RES, V3, P108, DOI [10.4314/star.v3i1.17, DOI 10.4314/STAR.V3I1.17]; Tewodros B, 2009, SW ETHIOPIA ETHIOP J, V19, P45; Tiruneh FN, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2670-9; Titaley CR, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-485; Tsegay Y, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-30; Tura G., 2009, ETHIOPIAN J HLTH SCI, V19; Tweheyo R, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-53; Uganda Bureau of Statistics (UBOS) ICF, 2017, UG DEM HLTH SURV 201; UN, 2015, MILL DEV GOALS REP 2, DOI DOI 10.18356/6CD11401-EN; UNICEF, 2017, GLOB DAT BAS MULT IN; van Eijk Anna M, 2006, Reprod Health, V3, P2, DOI 10.1186/1742-4755-3-2; Van Lerberghe W, 2005, WORLD HLTH REP 2005; Wells G.A., 2000, NEWCASTLE OTTAWA SCA; WHO, 2016, WHO TECH REP SER, V997, P1; Worku AG, 2013, BMC INT HEALTH HUM R, V13, DOI 10.1186/1472-698X-13-20; Zamawe COF, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0816-0; Zelalem Ayele Desalew, 2014, Int Sch Res Notices, V2014, P917058, DOI 10.1155/2014/917058; Zureick-Brown S, 2013, INT PERSPECT SEX R H, V39, P32, DOI 10.1363/3903213	87	66	66	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2019	14	4							e0214848	10.1371/journal.pone.0214848	http://dx.doi.org/10.1371/journal.pone.0214848			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HS8BQ	30973889	gold, Green Published, Green Submitted			2023-01-03	WOS:000464095000019
J	Wang, J; Sun, JW; Liu, LN; Flies, DB; Nie, XX; Toki, M; Zhang, JP; Song, C; Zarr, M; Zhou, X; Han, X; Archer, KA; O'Neill, T; Herbst, RS; Boto, AN; Sanmamed, MF; Langermann, S; Rimm, DL; Chen, LP				Wang, Jun; Sun, Jingwei; Liu, Linda N.; Flies, Dallas B.; Nie, Xinxin; Toki, Maria; Zhang, Jianping; Song, Chang; Zarr, Melissa; Zhou, Xu; Han, Xue; Archer, Kristina A.; O'Neill, Thomas; Herbst, Roy S.; Boto, Agedi N.; Sanmamed, Miguel F.; Langermann, Solomon; Rimm, David L.; Chen, Lieping			Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy	NATURE MEDICINE			English	Article							T-CELL-ACTIVATION; B7 FAMILY; MONOCLONAL-ANTIBODIES; ANTITUMOR IMMUNITY; OSTEOCLAST DIFFERENTIATION; QUANTITATIVE-ANALYSIS; PROTEIN EXPRESSION; PD-1; B7-H1; MOLECULE	Overexpression of the B7-H1 (PD-L1) molecule in the tumor microenvironment (TME) is a major immune evasion mechanism in some patients with cancer, and antibody blockade of the B7-H1/PD-1 interaction can normalize compromised immunity without excessive side-effects. Using a genome-scale T cell activity array, we identified Siglec-15 as a critical immune suppressor. While only expressed on some myeloid cells normally, Siglec-15 is broadly upregulated on human cancer cells and tumor-infiltrating myeloid cells, and its expression is mutually exclusive to B7-H1, partially due to its induction by macrophage colony-stimulating factor and downregulation by IFN-gamma. We demonstrate that Siglec-15 suppresses antigen-specific T cell responses in vitro and in vivo. Genetic ablation or antibody blockade of Siglec-15 amplifies anti-tumor immunity in the TME and inhibits tumor growth in some mouse models. Taken together, our results support Siglec-15 as a potential target for normalization cancer immunotherapy.	[Wang, Jun; Sun, Jingwei; Nie, Xinxin; Zhang, Jianping; Zhou, Xu; Han, Xue; Boto, Agedi N.; Sanmamed, Miguel F.; Chen, Lieping] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06510 USA; [Liu, Linda N.; Flies, Dallas B.; Song, Chang; Zarr, Melissa; Archer, Kristina A.; O'Neill, Thomas; Langermann, Solomon] NextCure Inc, Beltsville, MD USA; [Toki, Maria; Boto, Agedi N.; Rimm, David L.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Herbst, Roy S.; Rimm, David L.; Chen, Lieping] Yale Univ, Sch Med, Dept Med Med Oncol, New Haven, CT 06510 USA	Yale University; Yale University; Yale University	Chen, LP (corresponding author), Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06510 USA.; Chen, LP (corresponding author), Yale Univ, Sch Med, Dept Med Med Oncol, New Haven, CT 06510 USA.	lieping.chen@yale.edu	Nie, Xinxin/AAV-9668-2021; Toki, Maria/M-5582-2019; Liu, Linda/GVS-9417-2022; Zhou, Xu/AAI-9269-2020; F Sanmamed, Miguel/I-5572-2017	Toki, Maria/0000-0002-7074-7148; F Sanmamed, Miguel/0000-0002-7295-6074; Han, Xue/0000-0001-5016-2356; Wang, Jun/0000-0002-6346-2929; Rimm, David/0000-0001-5820-4397; Zhou, Xu/0000-0002-1692-6823	National Institutes of Health [P30 CA16359, P50 CA196530]; NextCure Inc.; United Technologies Corporation Endowed Chair; NATIONAL CANCER INSTITUTE [P50CA196530, P30CA016359] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NextCure Inc.; United Technologies Corporation Endowed Chair; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank B. Cadugan for editing the manuscript; other members in the laboratories of Yale and NextCure for helpful discussions and technical assistance; and D. Pardoll and J. Fu at Johns Hopkins University for the B16-GMCSF cell line. This research was supported partially by the National Institutes of Health grants nos. P30 CA16359 and P50 CA196530, sponsored research funding from NextCure Inc. and the United Technologies Corporation Endowed Chair.	Altan M., 2012, CLIN CANCER RES, V23, pE514; Angata T, 2007, GLYCOBIOLOGY, V17, P838, DOI 10.1093/glycob/cwm049; Bordeaux JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036559; Briard JG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03245-5; Brown JR, 2014, CLIN CANCER RES, V20, P5995, DOI 10.1158/1078-0432.CCR-14-1622; Camp RL, 2002, NAT MED, V8, P1323, DOI 10.1038/nm791; Chang LY, 2017, J PROTEOME RES, V16, P3929, DOI 10.1021/acs.jproteome.7b00625; Chapoval AI, 2001, NAT IMMUNOL, V2, P269, DOI 10.1038/85339; Chen H, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005112; Chen LP, 2015, J CLIN INVEST, V125, P3384, DOI 10.1172/JCI80011; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; CHEN LP, 1994, J EXP MED, V179, P523, DOI 10.1084/jem.179.2.523; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; De Henau O, 2016, NATURE, V539, P443, DOI 10.1038/nature20554; Dong HD, 1999, NAT MED, V5, P1365; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Flies DB, 2014, J CLIN INVEST, V124, P1966, DOI 10.1172/JCI74589; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Gangadhar TC, 2014, NAT REV CLIN ONCOL, V11, P91, DOI 10.1038/nrclinonc.2013.245; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Hamilton JA, 2008, NAT REV IMMUNOL, V8, P533, DOI 10.1038/nri2356; Hirano F, 2005, CANCER RES, V65, P1089; Hiruma Y, 2013, BONE, V53, P87, DOI 10.1016/j.bone.2012.11.036; Hiruma Y, 2011, BIOCHEM BIOPH RES CO, V409, P424, DOI 10.1016/j.bbrc.2011.05.015; Ishida-Kitagawa N, 2012, J BIOL CHEM, V287, P17493, DOI 10.1074/jbc.M111.324194; Kameda Y, 2013, J BONE MINER RES, V28, P2463, DOI 10.1002/jbmr.1989; Kim TK, 2018, TRENDS IMMUNOL, V39, P624, DOI 10.1016/j.it.2018.05.001; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Levine JH, 2015, CELL, V162, P184, DOI 10.1016/j.cell.2015.05.047; Lipson EJ, 2015, SEMIN ONCOL, V42, P587, DOI 10.1053/j.seminoncol.2015.05.013; McCabe A, 2005, JNCI-J NATL CANCER I, V97, P1808, DOI 10.1093/jnci/dji427; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Mittal D, 2014, CURR OPIN IMMUNOL, V27, P16, DOI 10.1016/j.coi.2014.01.004; Mosely SIS, 2017, CANCER IMMUNOL RES, V5, P29, DOI 10.1158/2326-6066.CIR-16-0114; Peper JK, 2014, J IMMUNOL METHODS, V405, P192, DOI 10.1016/j.jim.2014.01.012; Ricard C, 2016, SCI REP-UK, V6, DOI 10.1038/srep26381; Sanmamed MF, 2018, CELL, V175, P313, DOI 10.1016/j.cell.2018.09.035; Schalper KA, 2014, CLIN CANCER RES, V20, P2773, DOI 10.1158/1078-0432.CCR-13-2702; Shimizu T, 2015, BONE, V79, P65, DOI 10.1016/j.bone.2015.05.029; Sica GL, 2003, IMMUNITY, V18, P849, DOI 10.1016/S1074-7613(03)00152-3; Slansky JE, 2000, IMMUNITY, V13, P529, DOI 10.1016/S1074-7613(00)00052-2; Stuible M, 2014, J BIOL CHEM, V289, P6498, DOI 10.1074/jbc.M113.494542; Sznol M, 2013, CLIN CANCER RES, V19, P5542, DOI 10.1158/1078-0432.CCR-13-2234; Takamiya R, 2013, GLYCOBIOLOGY, V23, P178, DOI 10.1093/glycob/cws139; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Tsushima F, 2007, BLOOD, V110, P180, DOI 10.1182/blood-2006-11-060087; Wang J, 2019, CELL, V176, P334, DOI 10.1016/j.cell.2018.11.010; Yao S, 2011, IMMUNITY, V34, P729, DOI 10.1016/j.immuni.2011.03.014; Yao S, 2009, BLOOD, V113, P5811, DOI 10.1182/blood-2009-02-203141; Zhang Y, 2016, JAMA ONCOL, V2, P1403, DOI 10.1001/jamaoncol.2016.2450; Zhu YW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3043; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	56	282	302	19	216	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2019	25	4					656	+		10.1038/s41591-019-0374-x	http://dx.doi.org/10.1038/s41591-019-0374-x			25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	HR7OA	30833750	Green Accepted			2023-01-03	WOS:000463342800027
J	Dantas, LF; Marchesi, JF; Peres, IT; Hamacher, S; Bozza, FA; Neira, RAQ				Dantas, Leila F.; Marchesi, Janaina F.; Peres, Igor T.; Hamacher, Silvio; Bozza, Fernando A.; Quintano Neira, Ricardo A.			Public hospitalizations for stroke in Brazil from 2009 to 2016	PLOS ONE			English	Article							CASE-FATALITY RATES; MORTALITY; TRENDS; EPIDEMIOLOGY; OUTCOMES; DISEASE	Background Stroke is the third major cause of death in the world and the second in Brazil. The purpose of this work was to assess the stroke-related hospitalization, in-hospital mortality, and case fatality rates under the Brazilian Unified Health System (SUS) from 2009 to 2016. Methods We evaluated the hospital admissions for stroke and their associated outcomes using data from the Hospital Information available at the Informatics Department of SUS. We selected hospitalization registries according to stroke diagnosis codes from the International Statistical Classification of Diseases and Related Health Problems (ICD-10). We identified the association of age and sex with patient death through multiple logistic regression and calculated the rates of hospitalization, mortality and case-fatality per 100,000 inhabitants using age-adjustment methodology. Results We analyzed 1,113,599 stroke hospitalizations. From 2009 to 2016, the number of admissions increased from 131,122 to 146,950 and the absolute number of in-hospital deaths increased from 28,731 to 31,937. Younger age and male sex were significantly associated with patient survival. Our results showed that the annual age-adjusted hospitalization and in-hospital mortality rates decreased by 11.8% and 12.6%, respectively, but the case fatality rate increased for patients older than 70 years. Conclusions Although the age-adjusted hospitalization and in-hospital mortality rates declined, the total number of hospitalization and deaths have increased. It is expected a continuous increase over the next years of stroke admissions with the rapid aging of the Brazilian population. Efforts should be renewed targeting risk factors, access to hospital and rehabilitation in particular for the elderly population.	[Dantas, Leila F.; Marchesi, Janaina F.; Peres, Igor T.; Hamacher, Silvio; Quintano Neira, Ricardo A.] Pontifical Catolic Univ Rio De Janeiro, Dept Ind Engn, Rio De Janeiro, RJ, Brazil; [Bozza, Fernando A.] Oswaldo Cruz Fdn FIOCRUZ, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, RJ, Brazil; [Bozza, Fernando A.] DOr Inst Res & Educ, IDOR, Rio De Janeiro, RJ, Brazil	Pontificia Universidade Catolica do Rio de Janeiro; Fundacao Oswaldo Cruz; IDOR - Instituto D'Or de Ensino e Pesquisa	Bozza, FA (corresponding author), Oswaldo Cruz Fdn FIOCRUZ, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, RJ, Brazil.; Bozza, FA (corresponding author), DOr Inst Res & Educ, IDOR, Rio De Janeiro, RJ, Brazil.	bozza.fernando@gmail.com	Dantas, Leila Figueiredo/U-5407-2019; Bozza, Fernando A/A-2618-2013; hamacher, silvio/C-3325-2013; Marchesi, Janaina/AFL-9964-2022; Peres, Igor Tona/GWQ-6665-2022; Peres, Igor Tona/ABI-1502-2020; Marchesi, Janaina/AAH-2233-2022	Bozza, Fernando A/0000-0003-4878-0256; hamacher, silvio/0000-0002-3980-0342; Marchesi, Janaina/0000-0002-0262-5384; Peres, Igor/0000-0001-9863-4690	National Council for Scientific and Technological Development (CNPq) [306802/2015-5, 403863/2016-3, 140511/2018-0, 169049/2017-5]; Carlos Chagas Filho Foundation (FAPERJ) [E-26/201.959/2017]; Coordination for theImprovement of Higher Education Personnel (CAPES); Pontifical Catholic University of Rio de Janeiro; Philips Research; Brazilian National Council for Scientific and Technological Development (CNPq)	National Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Carlos Chagas Filho Foundation (FAPERJ)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); Coordination for theImprovement of Higher Education Personnel (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Pontifical Catholic University of Rio de Janeiro; Philips Research; Brazilian National Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by the National Council for Scientific and Technological Development (CNPq) http://cnpq.br/[grant numbers 306802/2015-5 and 403863/2016-3 to SH; 140511/2018-0 to RAQN; 169049/2017-5 to LED]; Carlos Chagas Filho Foundation (FAPERJ) http://www.faperj.br/. [grant number E-26/201.959/2017 to JFM]; the Coordination for theImprovement of Higher Education Personnel (CAPES) http://www.capes.gov.br/; and the Pontifical Catholic University of Rio de Janeiro http://www.puc-rio.br/english/.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.r The authors would like to thank Coordination for the Improvement of Higher Education Personnel (CAPES), the Pontifical Catholic University of Rio de Janeiro, Philips Research and the Brazilian National Council for Scientific and Technological Development (CNPq) for their financial support.	Adami F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152739; Ahmad O.B., 2001, GPE DISCUSS PAP SER, V9; Bejot Y, 2016, REV NEUROL-FRANCE, V172, P59, DOI 10.1016/j.neurol.2015.07.013; Bejot Y, 2016, PRESSE MED, V45, pE391, DOI 10.1016/j.lpm.2016.10.003; Cabral NL, 2009, J NEUROL NEUROSUR PS, V80, P749, DOI 10.1136/jnnp.2008.164475; CSIS, BRAZ SIST UN SAUD SU; de Santana Nathalia Matos, 2018, BMC Res Notes, V11, P735, DOI 10.1186/s13104-018-3842-3; Feigin VL, 2018, NEW ENGL J MED, V379, P2429, DOI 10.1056/NEJMoa1804492; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; de Carvalho JJF, 2011, STROKE, V42, P3341, DOI 10.1161/STROKEAHA.111.626523; Garritano CR, 2012, ARQ BRAS CARDIOL, V98, P519, DOI 10.1590/S0066-782X2012005000041; Goulart AC, 2010, INT J STROKE, V5, P284, DOI 10.1111/j.1747-4949.2010.00441.x; Hankey GJ, 2017, LANCET, V389, P641, DOI 10.1016/S0140-6736(16)30962-X; Iser BPM, 2016, DIABETOL METAB SYNDR, V8, DOI 10.1186/s13098-016-0185-x; Kamal N, 2015, CAN J NEUROL SCI, V42, P168, DOI 10.1017/cjn.2015.20; Lackland DT, 2014, STROKE, V45, P315, DOI 10.1161/01.str.0000437068.30550.cf; Lotufo PA, 2007, ARQ NEURO-PSIQUIAT, V65, P752, DOI 10.1590/S0004-282X2007000500004; Lotufo PA, 2015, SAO PAULO MED J, V133, P457, DOI 10.1590/1516-3180.2015.13360510; Malachias MVB, 2016, 7A DIRETRIZ BRASELLE; Malta DC, 2015, SCIELO PUBLIC HLTH, V20, P631; Mansur AD, 2016, ARQ BRAS CARDIOL, V107, P137, DOI 10.5935/abc.20160102; Marinho F, 2018, LANCET, V392, P760, DOI 10.1016/S0140-6736(18)31221-2; Massuda A, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000829; Minelli C, 2007, STROKE, V38, P2906, DOI 10.1161/STROKEAHA.107.484139; Monteiro CA, 2017, VIGITEL BRASIL 2006; O'Donnell MJ, 2016, LANCET, V388, P761, DOI 10.1016/S0140-6736(16)30506-2; Passos VMA, 2016, ARQ NEURO-PSIQUIAT, V74, P376, DOI 10.1590/0004-282X20160055; Picon RV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048255; Rolim CLRC, 2011, CAD SAUDE PUBLICA, V27, P2105; Sarfo FS, 2015, J NEUROL SCI, V357, P240, DOI 10.1016/j.jns.2015.07.043; Team RStudio, 2015, INT DEV R; Thrift AG, 2014, INT J STROKE, V9, P6, DOI 10.1111/ijs.12245; World Health Organization, 2007, INT CLASS DIS	33	10	11	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2019	14	3							e0213837	10.1371/journal.pone.0213837	http://dx.doi.org/10.1371/journal.pone.0213837			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP3JN	30889198	Green Published, Green Submitted, gold			2023-01-03	WOS:000461573000034
J	Mukthinuthalapati, VVPK; Akinyeye, S; Fricker, ZP; Syed, M; Orman, ES; Nephew, L; Vilar-Gomez, E; Slaven, J; Chalasani, N; Balakrishnan, M; Long, MT; Attar, BM; Ghabril, M				Mukthinuthalapati, V. V. Pavan Kedar; Akinyeye, Samuel; Fricker, Zachary P.; Syed, Moinuddin; Orman, Eric S.; Nephew, Lauren; Vilar-Gomez, Eduardo; Slaven, James; Chalasani, Naga; Balakrishnan, Maya; Long, Michelle T.; Attar, Bashar M.; Ghabril, Marwan			Early predictors of outcomes of hospitalization for cirrhosis and assessment of the impact of race and ethnicity at safety-net hospitals	PLOS ONE			English	Article							QUALITY-OF-CARE; HEPATOCELLULAR-CARCINOMA; IDENTIFIES PATIENTS; HIGH-RISK; VALIDATION; MORTALITY; DISPARITIES; SURVIVAL	Background Safety-net hospitals provide care for racially/ethnically diverse and disadvantaged urban populations. Their hospitalized patients with cirrhosis are relatively understudied and may be vulnerable to poor outcomes and racial/ethnic disparities. Aims To examine the outcomes of patients with cirrhosis hospitalized at regionally diverse safety-net hospitals and the impact of race/ethnicity. Methods A study of patients with cirrhosis hospitalized at 4 safety-net hospitals in 2012 was conducted. Demographic, clinical factors, and outcomes were compared between centers and racial/ethnic groups. Study endpoints included mortality and 30-day readmission. Results In 2012, 733 of 1,212 patients with cirrhosis were hospitalized for liver-related indications (median age 55 years, 65% male). The cohort was racially diverse (43% White, 25% black, 22% Hispanic, 3% Asian) with cirrhosis related to alcohol and viral hepatitis in 635 (87%) patients. Patients were hospitalized mainly for ascites (35%), hepatic encephalopathy (20%) and gastrointestinal bleeding (GIB) (17%). Fifty-four (7%) patients died during hospitalization and 145 (21%) survivors were readmitted within 30 days. Mortality rates ranged from 4 to 15% by center (p=.007) and from 3 to 10% by race/ethnicity (p=.03), but 30-day readmission rates were similar. Mortality was associated with Model for End-stage Liver Disease (MELD), acute-on-chronic liver failure, hepatocellular carcinoma, sodium and white blood cell count. Thirty-day readmission was associated with MELD and Charlson Comorbidity Index >4, with lower risk for GIB. We did not observe geographic or racial/ethnic differences in hospital outcomes in the risk-adjusted analysis. Conclusions Hospital mortality and 30-day readmission in patients with cirrhosis at safety-net hospitals are associated with disease severity and comorbidities, with lower readmissions in patients admitted for GIB. Despite geographic and racial/ethnic differences in hospital mortality, these factors were not independently associated with mortality.	[Mukthinuthalapati, V. V. Pavan Kedar; Orman, Eric S.; Nephew, Lauren; Vilar-Gomez, Eduardo; Chalasani, Naga; Ghabril, Marwan] Indiana Univ, Div Gastroenterol & Hepatol, Indianapolis, IN 46204 USA; [Mukthinuthalapati, V. V. Pavan Kedar; Syed, Moinuddin] Cook Cty Hlth & Hosp Syst, Dept Med, Chicago, IL USA; [Akinyeye, Samuel; Balakrishnan, Maya] Baylor Coll Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA; [Fricker, Zachary P.; Long, Michelle T.] Boston Univ, Sch Med, Gastroenterol Sect, Evans Dept Med, Boston, MA 02118 USA; [Slaven, James] Indiana Univ, Dept Biostat, Indianapolis, IN 46204 USA; [Attar, Bashar M.] Cook Cty Hlth & Hosp Syst, Dept Gastroenterol & Hepatol, Chicago, IL USA	Indiana University System; Indiana University-Purdue University Indianapolis; John H Stroger Junior Hospital Cook County; Baylor College of Medicine; Boston University; Indiana University System; Indiana University-Purdue University Indianapolis; John H Stroger Junior Hospital Cook County	Ghabril, M (corresponding author), Indiana Univ, Div Gastroenterol & Hepatol, Indianapolis, IN 46204 USA.	mghabril@iu.edu	Long, Michelle T/H-3801-2019; Mukthinuthalapati, Vijaya Venkatasubbaraya Pavan Kedar/AAV-4681-2021; Ghabril, Marwan/AAF-8661-2020; Orman, Eric/S-9191-2019; Nephew, Lauren/AAY-9123-2021	Mukthinuthalapati, Vijaya Venkatasubbaraya Pavan Kedar/0000-0003-3687-1927; Ghabril, Marwan/0000-0002-4784-3246; Nephew, Lauren/0000-0003-0837-0746; Balakrishnan, Maya/0000-0002-5196-7284	NIDDK NIH HHS [K23 DK109202] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK109202] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Bajaj JS, 2016, HEPATOLOGY, V64, P200, DOI 10.1002/hep.28414; Bajaj JS, 2014, HEPATOLOGY, V60, P250, DOI 10.1002/hep.27077; Berman K, 2011, CLIN GASTROENTEROL H, V9, P254, DOI 10.1016/j.cgh.2010.10.035; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Efron B, 1997, J AM STAT ASSOC, V92, P548, DOI 10.2307/2965703; Goldberg DS, 2013, PHARMACOEPIDEM DR S, V22, P103, DOI 10.1002/pds.3367; Harrell FE, 2001, REGRESSION MODELING, Vxxii; Hasnain-Wynia R, 2007, ARCH INTERN MED, V167, P1233, DOI 10.1001/archinte.167.12.1233; Kanwal F, 2017, AM J GASTROENTEROL, V112, P1287, DOI 10.1038/ajg.2017.175; McCormick PA, 2001, GUT, V49, P682, DOI 10.1136/gut.49.5.682; Mokdad AA, 2018, CANCER-AM CANCER SOC, V124, P743, DOI 10.1002/cncr.31066; Nehra MS, 2013, J CLIN GASTROENTEROL, V47, pE50, DOI 10.1097/MCG.0b013e3182688d2f; Nguyen GC, 2007, HEPATOLOGY, V45, P1282, DOI 10.1002/hep.21580; O'Leary JG, 2018, HEPATOLOGY, V67, P2367, DOI 10.1002/hep.29773; Orman ES, 2018, J HOSP MED, V13, P490, DOI 10.12788/jhm.2967; Robinson A, 2018, J RACIAL ETHN HEALTH, V5, P860, DOI 10.1007/s40615-017-0432-3; Ross JS, 2012, HEALTH AFFAIR, V31, P1739, DOI 10.1377/hlthaff.2011.1028; Schmidt ML, 2015, GASTROENTEROLOGY, V148, P967, DOI 10.1053/j.gastro.2015.01.032; Schomaker M, 2018, STAT MED, V37, P2252, DOI 10.1002/sim.7654; Sclair SN, 2016, DIGEST DIS SCI, V61, P2857, DOI 10.1007/s10620-016-4221-3; Singal AG, 2013, CLIN GASTROENTEROL H, V11, P1335, DOI 10.1016/j.cgh.2013.03.022; Singal AG, 2012, DIGEST DIS SCI, V57, P580, DOI 10.1007/s10620-011-1904-7; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Sutton J.P., 2016, CHARACTERISTICS SAFE; Tapper EB, 2015, HEPATOLOGY, V62, P584, DOI 10.1002/hep.27830; Turner BJ, 2015, HEPATOLOGY, V62, P1388, DOI 10.1002/hep.28018; Udompap P, 2015, CLIN GASTROENTEROL H, V13, P2031, DOI 10.1016/j.cgh.2015.08.015; Volk ML, 2012, AM J GASTROENTEROL, V107, P247, DOI 10.1038/ajg.2011.314; Werner RM, 2008, JAMA-J AM MED ASSOC, V299, P2180, DOI 10.1001/jama.299.18.2180; Westwood G, 2017, J HEPATOL, V67, P559, DOI 10.1016/j.jhep.2017.04.017; Wong RJ, 2018, AM J GASTROENTEROL, V113, P1329, DOI 10.1038/s41395-018-0033-8	32	10	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2019	14	3							e0211811	10.1371/journal.pone.0211811	http://dx.doi.org/10.1371/journal.pone.0211811			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN7LX	30840670	Green Published, Green Submitted, gold			2023-01-03	WOS:000460372100016
J	Luo, M; Yu, JJ; Zhu, SY; Huang, L; Chen, Y; Wei, SB				Luo, Mei; Yu, JiaJie; Zhu, ShuYi; Huang, Li; Chen, Yu; Wei, ShaoBin			Detoxification therapy of traditional Chinese medicine for genital tract high-risk human papillomavirus infection: A systematic review and meta-analysis	PLOS ONE			English	Review							CYTOLOGY; CANCER; CIN	Background Persistence of high-risk human papillomavirus (hr-HPV) infections is the most critical risk factor for cervical intraepithelial neoplasia (CIN) and cervical cancer (CC). Treatment of persistent oncogenic HPV-positive women after 12-24 months follow-up is still controversy. Detoxification therapy of Chinese medicine (DTCM) has been conducted recently. However, the conclusions are still unclear. We planned to conduct a systematic review and meta-analysis to explore DTCM in the treatment of persistent hr-HPV infections. Methods Nine electronic databases were systematically searched from their inception to 30 September 2018. Randomized controlled trials comparing DTCM with follow-up or placebo were included. Risk of bias was assessed by the Cochrane 'Risk of Bias' tool. Review Manager 5.3 was used for statistical analyses. Relative ratios (RR) and 95% confidence intervals were used for dichotomous data, and the mean difference (MD) was used for continuous data. We assessed the quality of trials by the GRADE. Results Seventeen RCTs from 2011 to 2018 with 1906 participants were included. The evidence showed that DTCM had a pooled efficacy difference in favor of increasing the HPV clearance rate compared to placebo groups (RR = 2.62, 95% CI 1.28 to 5.33, very low quality) and follow-up groups (RR = 1.88, 95% CI 1.60 to 2.22, low quality). The median HPV persistence tended to decline from 50% within six months to 41.5% at 12 months, and 31.5% at 24 months. A significantly increased regression rate of CIN was found in the DTCM compared with placebo groups (RR = 3.61, 95% CI 1.21 to 10.83, very low quality) and follow-up groups (RR = 1.79, 95% CI 1.31 to 2.45, very low quality). Additionally, we found DTCM have an impact on TNF-alpha (MD = 2.99, 95% CI 1.90 to 4.07; very low quality), IFN-alpha (MD = 3.47, 95% CI 2.42 to 4.52; very low quality), CD4+/CD8+ cells (MD = 0.21, 95% CI 0.05 to 0.37; very low quality) compared with follow up groups in some trials with small sample sizes. The major adverse events were genital mucosal irritation symptoms (10%, 5/50). Conclusions DTCM have favorable outcomes on improving the HPV clearance rate, increasing the regression rate of CIN, and impacting the proportion of some immune cells and cytokine levels. However, most of the evidence was of low quality. Any future high-quality trials and a more extended follow-up period of 24 months or more should be performed.	[Luo, Mei; Zhu, ShuYi; Huang, Li; Chen, Yu] Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China; [Luo, Mei] Hosp Chongqing Inst Tradit Chinese Med, Dept Gynecol, Chongqing, Peoples R China; [Yu, JiaJie] Sichuan Univ, West China Hosp, Chinese Evidence Based Med Ctr, Chengdu, Sichuan, Peoples R China; [Wei, ShaoBin] Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China	Chengdu University of Traditional Chinese Medicine; Sichuan University; Chengdu University of Traditional Chinese Medicine	Wei, SB (corresponding author), Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China.	weishaobin5620@163.com	jiajia, yu/AAP-4507-2020		National Natural Science Foundation of China [71704120, 81473722]; "Xinglin Scholars" Hospital Foundation of Chengdu University of Traditional Chinese Medicine [YYZX20180049]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); "Xinglin Scholars" Hospital Foundation of Chengdu University of Traditional Chinese Medicine	This work was supported by grant 81473722 from the National Natural Science Foundation of China (to SBW), grant 71704120 from the National Natural Science Foundation of China (to JJY), and grant YYZX20180049 from the "Xinglin Scholars" Hospital Foundation of Chengdu University of Traditional Chinese Medicine (to ML). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, GRADEPRO GDT 2014 CO; [Anonymous], 2016, OBSTET GYNECOL, V127, pE1, DOI DOI 10.1097/AOG.0000000000001263; Bulkmans NWJ, 2007, BRIT J CANCER, V96, P1419, DOI 10.1038/sj.bjc.6603653; Chen YL, 2016, MED FRONTIER, V10, P208; Chinese Society for Colposcopy and Cervical Pathology of China Healthy Birth Science Association CSCCP, 2017, CHIN J CLIN OBSTET G, V18, P190, DOI [10.13390/j.issn.1672-1861.2017.02.032, DOI 10.13390/J.ISSN.1672-1861.2017.02.032]; Demarco M, 2017, J LOW GENIT TRACT DI, V21, P261, DOI 10.1097/LGT.0000000000000343; Gao YH, 2014, JILIN J TRADITIONAL, V34, P716, DOI [10.13463/j.cnki.jlzyy.2014.07.023, DOI 10.13463/J.CNKI.JLZYY.2014.07.023]; Gravitt PE, 2011, J CLIN INVEST, V121, P4593, DOI 10.1172/JCI57149; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Hoffman SR, 2017, INT J CANCER, V141, P8, DOI 10.1002/ijc.30623; Huang WF, 2014, CHINA J PHARM EC, V4, P38; IRAC, 2012, MONOGRAPHS EVALUATIO, V100B, P255; [刘嵘 Liu Rong], 2018, [华中科技大学学报. 医学版, Acta Medicinae Universitatis Scientiae et Technologiae Huazhong], V47, P325; Lou JY, 2011, THESIS; Massad LS, 2013, OBSTET GYNECOL, V121, P829, DOI 10.1097/AOG.0b013e3182883a34; MEISELS A, 1976, ACTA CYTOL, V20, P505; Mollers M, 2013, VACCINE, V31, P394, DOI 10.1016/j.vaccine.2012.10.087; Montbriand MJ, 2004, ONCOL NURS FORUM REV, V31, P127, DOI [10.1188/04.ONF.E127-E146, DOI 10.1188/04.ONF.E127-E146]; PUROLA E, 1977, ACTA CYTOL, V21, P26; Qin X., 2017, ONCOLOGY PROGR, V15, P1439, DOI [10.11877/j.issn.1672-1535.2017.15.12.21, DOI 10.11877/J.ISSN.1672-1535.2017.15.12.21]; Shen JF, 2014, HLTH RES, V5, P572, DOI [10.3969/jissn.1674-6449.2014.05.038, DOI 10.3969/JISSN.1674-6449.2014.05.038]; Shen JJ, 2013, CHIN J CLIN OBSTET G, V6, P509; Tai YJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188203; Wang ShiZhuo, 2012, Journal of China Medical University, V41, P146; Wang XS, 2015, J HUNAN NORMAL U MED, V6, P82; Wen L., 2018, THESIS; Xia N., 2018, STUDY REMOTE SENSING; Xiao J, 2011, J GUANGDONG MED, V15, P2036; Xiao Jing, 2012, Zhongguo Zhong Xi Yi Jie He Za Zhi, V32, P1212; Xu CQ, 2017, MATERN CHILD HLTH J, V20, P4932, DOI [10.7620/zgfybj.j.issn.1001-4411.2017.20.13, DOI 10.7620/ZGFYBJ.J.ISSN.1001-4411.2017.20.13]; Xu YX, 2013, J LIAONING CHINESE M, V9, P1826, DOI [10.13192/j.issn.1000-1719.2013.09.038, DOI 10.13192/J.ISSN.1000-1719.2013.09.038]; Yan X., 2012, THESIS; Zhang H, 2013, J CAPITAL MED, V4, P37; Zhang J, 2012, J NEW CHINESE MED, V7, P94, DOI [10.13457/j.cnki.jncm.2012.07.115, DOI 10.13457/J.CNKI.JNCM.2012.07.115]; Zhang Qian, 2015, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V37, P534, DOI 10.3881/j.issn.1000-503X.2015.05.008; Zhao J, 2015, J PRACTICAL OBSTET G, V1, P45	36	5	6	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2019	14	3							e0213062	10.1371/journal.pone.0213062	http://dx.doi.org/10.1371/journal.pone.0213062			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN7LT	30822331	gold, Green Submitted, Green Published			2023-01-03	WOS:000460371600026
J	Hassan, AS; Bibby, DF; Mwaringa, SM; Agutu, CA; Ndirangu, KK; Sanders, EJ; Cane, PA; Mbisa, JL; Berkley, JA				Hassan, Amin S.; Bibby, David F.; Mwaringa, Shalton M.; Agutu, Clara A.; Ndirangu, Kennedy K.; Sanders, Eduard J.; Cane, Patricia A.; Mbisa, Jean L.; Berkley, James A.			Presence, persistence and effects of pre-treatment HIV-1 drug resistance variants detected using next generation sequencing: A Retrospective longitudinal study from rural coastal Kenya	PLOS ONE			English	Article							OLIGONUCLEOTIDE LIGATION ASSAY; ANTIRETROVIRAL-NAIVE ADULTS; TYPE-1; MUTATIONS; NEVIRAPINE; THERAPY; FAILURE; SURVEILLANCE; ADHERENCE; MULTIPLE	Background The epidemiology of HIV-1 drug resistance (HIVDR) determined by Sanger capillary sequencing, has been widely studied. However, much less is known about HIVDR detected using next generation sequencing (NGS) methods. We aimed to determine the presence, persistence and effect of pre-treatment HIVDR variants detected using NGS in HIV-1 infected antiretroviral treatment (ART) naive participants from rural Coastal Kenya. Methods In a retrospective longitudinal study, samples from HIV-1 infected participants collected prior [n = 2 time-points] and after [n = 1 time-point] ART initiation were considered. An ultra deep amplicon-based NGS assay, calling for nucleotide variants at >2.0% frequency of viral population, was used. Suspected virologic failure (sVF) was defined as a one-off HIV-1 viral load of >1000 copies/ml whilst on ART. Results Of the 50 eligible participants, 12 (24.0% [95% CI: 13.1-38.2]) had at least one detectable pre-treatment HIVDR variant against Protease Inhibitors (PIs, n = 6 [12%]), Nucleoside Reverse Transcriptase Inhibitors (NRTIs, n = 4 [8.0%]) and Non-NRTIs (n = 3 [6.0%]). Overall, 15 pre-treatment resistance variants were detected (frequency, range: 2.3-92.0%). A positive correlation was observed between mutation frequency and absolute load for NRTI and/or NNRTI variants (r = 0.761 [p = 0.028]), but not for PI variants (r = -0.117 [p = 0.803]). Participants with pre-treatment NRTI and/or NNRTI resistance had increased odds of sVF (OR = 6.0; 95% CI = 1.0-36.9; p = 0.054). Conclusions Using NGS, pre-treatment resistance variants were common, though observed PI variants were unlikely transmitted, but rather probably generated de novo. Even when detected from a low frequency, pre-treatment NRTI and/or NNRTI resistance variants may adversely affect treatment outcomes.	[Hassan, Amin S.; Mwaringa, Shalton M.; Agutu, Clara A.; Sanders, Eduard J.; Berkley, James A.] KEMRI Wellcome Trust Res Programme, Kilifi, Kenya; [Bibby, David F.; Cane, Patricia A.; Mbisa, Jean L.] Publ Hlth England, Virus Reference Dept, London, England; [Ndirangu, Kennedy K.] Kilifi Cty Hosp, Kilifi, Kenya; [Sanders, Eduard J.; Berkley, James A.] Univ Oxford, Ctr Trop Med & Global Hlth, Oxford, England	Public Health England; University of Oxford	Hassan, AS (corresponding author), KEMRI Wellcome Trust Res Programme, Kilifi, Kenya.	ahassan@kemri-wellcome.org		Hassan, Amin S./0000-0001-5296-4264; Bibby, David/0000-0002-8458-9662; Berkley, James/0000-0002-1236-849X; Mbisa, Jean/0000-0002-0348-9679	Wellcome Trust [WT089351MA, WT083579MA, 107752/Z/15/Z]; Ministry of Health through the Kilifi County government; International AIDS Vaccine Initiative (IAVI); Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative [DEL-15-006]; New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); UK government	Wellcome Trust(Wellcome TrustEuropean Commission); Ministry of Health through the Kilifi County government; International AIDS Vaccine Initiative (IAVI); Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative; New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); UK government	ASH and JAB were funded by Wellcome Trust fellowships (WT089351MA and WT083579MA respectively). SMM and CM were employees of the KEMRI/Wellcome Trust Research Programme. KKN was an employee at the Kilifi County Hospital, which receives support from Ministry of Health through the Kilifi County government. EJS was supported by the International AIDS Vaccine Initiative (IAVI). DFB, PAC and JLM were employed by Public Health England. ASH was also supported by the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative (grant #DEL-15-006). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (grant #107752/Z/15/Z) and the UK government. The employers and funding bodies played no part in the design, collection, analysis and interpretation of data and manuscript preparation.	[Anonymous], 2012, WHO GLOBAL STRATEGY; Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; Barbour JD, 2004, AIDS, V18, P1683, DOI 10.1097/01.aids.0000131391.91468.ff; Bennett DE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004724; Boender T. S., 2015, CLIN INFECT DIS; Boltz VF, 2011, P NATL ACAD SCI USA, V108, P9202, DOI 10.1073/pnas.1105688108; Buckton AJ, 2011, ANTIVIR THER, V16, P9, DOI 10.3851/IMP1687; Cai FP, 2007, NAT METHODS, V4, P123, DOI 10.1038/nmeth995; Cane P, 2011, METHODS MOL BIOL, V665, P123, DOI 10.1007/978-1-60761-817-1_8; Castro H, 2013, J INFECT DIS, V208, P1459, DOI 10.1093/infdis/jit345; Chung MH, 2014, JAIDS-J ACQ IMM DEF, V67, P246, DOI 10.1097/QAI.0000000000000312; Cunningham E., 2015, ENHANCED SURVE UNPUB; Cunningham E, 2017, J ANTIMICROB CHEMOTH, V72, P227, DOI 10.1093/jac/dkw404; Delport W, 2010, BIOINFORMATICS, V26, P2455, DOI 10.1093/bioinformatics/btq429; Dudley DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036494; Gill CJ, 2005, AIDS, V19, P1243, DOI 10.1097/01.aids.0000180094.04652.3b; Goodman DD, 2011, AIDS, V25, P325, DOI 10.1097/QAD.0b013e3283427dcb; Gunthard HF, 2014, JAMA-J AM MED ASSOC, V312, P410, DOI 10.1001/jama.2014.8722; Gupta RK, 2012, LANCET, V380, P1250, DOI 10.1016/S0140-6736(12)61038-1; Hamers RL, 2012, LANCET INFECT DIS, V12, P307, DOI 10.1016/S1473-3099(11)70255-9; Hassan AS, 2014, AIDS RES THER, V11, DOI 10.1186/1742-6405-11-9; Hassan AS, 2013, AIDS RES HUM RETROV, V29, P129, DOI [10.1089/aid.2012.0167, 10.1089/AID.2012.0167]; Hauser A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020357; Hue S, 2012, AIDS RES HUM RETROV, V28, P220, DOI 10.1089/aid.2011.0048; Jain V, 2011, J INFECT DIS, V203, P1174, DOI 10.1093/infdis/jiq167; Johnson JA, 2005, J INFECT DIS, V192, P16, DOI 10.1086/430741; (Kenya National AIDS and STI Control Programme (NASCOP), 2011, GUIDELINES ANTIRETRO, V4th; Lalonde MS, 2007, J CLIN MICROBIOL, V45, P2604, DOI 10.1128/JCM.00431-07; Li JZ, 2013, CLIN INFECT DIS, V56, P1667, DOI 10.1093/cid/cit125; Li JZ, 2012, AIDS, V26, P185, DOI 10.1097/QAD.0b013e32834e9d7d; Li JZ, 2011, JAMA-J AM MED ASSOC, V305, P1327, DOI 10.1001/jama.2011.375; Liu TF, 2006, CLIN INFECT DIS, V42, P1608, DOI 10.1086/503914; Lockman S, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001236; Palmer S, 2005, J CLIN MICROBIOL, V43, P406, DOI 10.1128/JCM.43.1.406-413.2005; Pham QD, 2014, AIDS, V28, P2751, DOI 10.1097/QAD.0000000000000494; Pineda-Pena AC, 2013, INFECT GENET EVOL, V19, P337, DOI 10.1016/j.meegid.2013.04.032; Schultz AK, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-265; Schuurman R, 1999, J CLIN MICROBIOL, V37, P2291, DOI 10.1128/JCM.37.7.2291-2296.1999; Simen BB, 2009, J INFECT DIS, V199, P693, DOI 10.1086/596736; Vandenbroucke I, 2011, BIOTECHNIQUES, V51, P167, DOI 10.2144/000113733; Vandenhende MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086771; Wittkop L, 2011, LANCET INFECT DIS, V11, P363, DOI 10.1016/S1473-3099(11)70032-9; World Health Organization, 2015, GUID START ANT THER; Zou XB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098740	44	13	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2019	14	2							e0210559	10.1371/journal.pone.0210559	http://dx.doi.org/10.1371/journal.pone.0210559			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL5IX	30759103	Green Published, gold, Green Submitted			2023-01-03	WOS:000458761300017
J	Varbanov, HP; Kuttler, F; Banfi, D; Turcatti, G; Dyson, PJ				Varbanov, Hristo P.; Kuttler, Fabien; Banfi, Damiano; Turcatti, Gerardo; Dyson, Paul J.			Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis	PLOS ONE			English	Article							IN-VITRO; DRUG; CISPLATIN; SPIRONOLACTONE; VORINOSTAT; AURANOFIN; COMPLEXES; RESPONSES; SYNERGY	Drug combinations are extensively used to treat cancer and are often selected according to complementary mechanisms. Here, we describe a cell-based high-throughput screening assay for identification of synergistic combinations between broadly applied platinum-based chemotherapeutics and drugs from a library composed of 1280 chemically and pharmacologically diverse (mostly FDA approved) compounds. The assay was performed on chemoresistant cell lines derived from lung (A549) and pancreatic (PANC-1) carcinoma, where platinum-based combination regimens are currently applied though with limited success. The synergistic combinations identified during the screening were validated by synergy quantification using the combination index method and via high content fluorescent microscopy analysis. New promising synergistic combinations discovered using this approach include compounds currently not used as anticancer drugs, such as cisplatin or carboplatin with hycanthone and cisplatin with spironolactone in pancreatic carcinoma, and carboplatin and deferoxamine in non-small cell lung cancer. Strong synergy between cisplatin or carboplatin and topotecan in PANC-1 cells, compared to A549 cells, suggests that this combination, currently used in lung cancer treatment regimens, could be applied to pancreatic carcinoma as well. Several drugs used to treat diseases other than cancer, including pyrvinium pamoate, auranofin, terfenadine and haloprogin, showed strong cytotoxicity on their own and synergistic interactions with platinum drugs. This study demonstrates that non-obvious drug combinations that would not be selected based on complementary mechanisms can be identified via high-throughput screening.	[Varbanov, Hristo P.; Dyson, Paul J.] Ecole Polytech Fed Lausanne, Inst Sci & Ingn Chim, Lausanne, Switzerland; [Kuttler, Fabien; Banfi, Damiano; Turcatti, Gerardo] Ecole Polytech Fed Lausanne, Biomol Screening Facil, Lausanne, Switzerland; [Varbanov, Hristo P.] Karl Franzens Univ Graz, Inst Chem, Graz, Austria	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Graz	Varbanov, HP; Dyson, PJ (corresponding author), Ecole Polytech Fed Lausanne, Inst Sci & Ingn Chim, Lausanne, Switzerland.; Varbanov, HP (corresponding author), Karl Franzens Univ Graz, Inst Chem, Graz, Austria.	hristo.varbanov@univie.ac.at; paul.dyson@epfl.ch	Varbanov, Hristo P./O-3973-2017; Dyson, Paul/AAB-9075-2019	Varbanov, Hristo P./0000-0003-4450-7332; Dyson, Paul/0000-0003-3117-3249; Kuttler, Fabien/0000-0003-2575-1989	Austrian Science Fund (FWF) [J3577-B13]; BSF-ACCESS screening platform at the EPFL	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); BSF-ACCESS screening platform at the EPFL	H.V. is indebted to the Austrian Science Fund (FWF) for the financial support (Schrodinger fellowship, Project number: J3577-B13). We acknowledge the Swiss National Center for Competence (NCCR) in Chemical Biology for providing access to the chemical libraries and screening facilities.; We acknowledge the BSF-ACCESS screening platform at the EPFL for support, in particular we are thankful to Julien Bortoli Chapalay for dispensing the PCL with the Echo acoustic liquid handler and to Antoine Gibelin for the quality control with LC-MS.	Adhireksan Z, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14860; Alekseev S, 2014, CHEM BIOL, V21, P398, DOI 10.1016/j.chembiol.2013.12.014; Apps MG, 2015, ENDOCR-RELAT CANCER, V22, pR219, DOI 10.1530/ERC-15-0237; Armstrong-Gordon E, 2018, J CANCER RES CLIN, V144, P1561, DOI 10.1007/s00432-018-2669-6; Bar J, 2016, NEOPLASIA, V18, P525, DOI 10.1016/j.neo.2016.07.004; Barnard C, 2017, JOHNSON MATTHEY TECH, V61, P52, DOI 10.1595/205651317X693624; Bots M, 2009, CLIN CANCER RES, V15, P3970, DOI 10.1158/1078-0432.CCR-08-2786; Bray F, GLOBOCAN 2012 V1 0; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Chan E, 2016, RADIOTHER ONCOL, V119, P312, DOI 10.1016/j.radonc.2016.04.013; Cheff DM, 2017, J MED CHEM, V60, P4517, DOI 10.1021/acs.jmedchem.6b01351; Chou T.-C., 2007, COMPUSYN SOFTWARE DR; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cosaert J, 2002, BRIT J CANCER, V87, P825, DOI 10.1038/sj.bjc.6600540; DeVita VT, 2012, NEW ENGL J MED, V366, P2207, DOI 10.1056/NEJMra1204479; Felth J, 2009, J NAT PROD, V72, P1969, DOI 10.1021/np900210m; Galanski M, 2005, CURR MED CHEM, V12, P2075, DOI 10.2174/0929867054637626; Greco WR, 1996, J NATL CANCER I, V88, P699, DOI 10.1093/jnci/88.11.699; Hall MD, 2014, CANCER RES, V74, P3913, DOI 10.1158/0008-5472.CAN-14-0247; Herdrich K, 2010, SELECTED SCHEDULES T; Jaramillo ML, 2008, CANCER BIOL THER, V7, P557, DOI 10.4161/cbt.7.4.5533; Jones TR, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-482; Jung YW, 2007, CHEM REV, V107, P1387, DOI 10.1021/cr068207j; Katzung, 2012, BASIC CLIN PHARMACOL; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Klauber N, 1996, CIRCULATION, V94, P2566, DOI 10.1161/01.CIR.94.10.2566; Michaelis M, 2015, SCI REP-UK, V5, DOI 10.1038/srep08202; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Muggia FM, 2015, J CLIN ONCOL, V33, P4219, DOI 10.1200/JCO.2015.60.7481; National Cancer Institute, UND CANC; Nosengo N, 2016, NATURE, V534, P314, DOI 10.1038/534314a; Nygren P, 2013, J CANCER RES CLIN, V139, P2133, DOI 10.1007/s00432-013-1539-5; O'Brien A, 2012, ANTICANCER RES, V32, P2679; Oun R, 2018, DALTON T, V47, P6645, DOI 10.1039/c8dt00838h; OuYang PY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079000; Pan CH, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2888-7; Petersen GH, 2016, J CONTROL RELEASE, V232, P255, DOI 10.1016/j.jconrel.2016.04.028; Pongrakhananon V, 2013, INTECH, P65, DOI [10.5772/55381, DOI 10.5772/55381]; Price P, 2008, TREATMENT OF CANC; Quaresma M, 2015, LANCET, V385, P1206, DOI 10.1016/S0140-6736(14)61396-9; Roder C, 2015, DRUGS R&D, V15, P13, DOI 10.1007/s40268-015-0083-y; Shahar OD, 2014, NUCLEIC ACIDS RES, V42, P5689, DOI 10.1093/nar/gku217; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Slingerland M, 2013, INVEST NEW DRUG, V31, P1087, DOI 10.1007/s10637-013-9984-1; Sternberg CN, 2009, J CLIN ONCOL, V27, P5431, DOI 10.1200/JCO.2008.20.1228; Sun YC, 2018, INT J ONCOL, V53, P1237, DOI 10.3892/ijo.2018.4447; Sweetman S., 2009, MARTINDALE COMPLETE, V36th; Taher MA, 2013, INT J SCI NAT, V4, P683; Traynor AM, 2009, J THORAC ONCOL, V4, P522, DOI 10.1097/JTO.0b013e3181952478; Varbanov HP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171052; Varghese E, 2014, CANCERS, V6, P2243, DOI 10.3390/cancers6042243; Webb JL, 1961, ENZYMES METABOL INH, V1, P66; Weinberg BA, 2015, ONCOLOGY-NY, V29, P809; Wermuth CG, 2004, J MED CHEM, V47, P1303, DOI 10.1021/jm030480f; Wheate NJ, 2010, DALTON T, V39, P8113, DOI 10.1039/c0dt00292e; WHO, CANC KEY FACTS; Yi YW, 2011, DNA REPAIR, V10, P1084, DOI 10.1016/j.dnarep.2011.09.008; Yosifov DY, 2011, CANCER CHEMOTH PHARM, V67, P13, DOI 10.1007/s00280-010-1273-5; Schneider NFZ, 2017, MOLECULES, V22, DOI 10.3390/molecules22111932; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	61	16	16	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2019	14	1							e0211268	10.1371/journal.pone.0211268	http://dx.doi.org/10.1371/journal.pone.0211268			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ3CE	30695050	gold, Green Published, Green Submitted			2023-01-03	WOS:000457046400022
J	Huh, G; Yoon, H; Choi, YJ; Shin, CM; Park, YS; Kim, N; Lee, DH; Kim, JS				Huh, Gunn; Yoon, Hyuk; Choi, Yoon Jin; Shin, Cheol Min; Park, Young Soo; Kim, Nayoung; Lee, Dong Ho; Kim, Joo Sung			Trends in emergency department visits and hospitalization rates for inflammatory bowel disease in the era of biologics	PLOS ONE			English	Article							ULCERATIVE-COLITIS; CROHNS-DISEASE; NATURAL-HISTORY; EPIDEMIOLOGY; METAANALYSIS; CHILDREN; SURGERY; KOREA; TIME	Background The use of biologics in inflammatory bowel disease (IBD) has increased recently. However, studies on whether the proportion of IBD patient visits to the emergency department (ED) has decreased are scarce. We investigated the trends in IBD-related ED visits and hospitalization rates. Methods Medical records of IBD-related visits to the ambulatory department (AD) and the ED of the Seoul National University Bundang Hospital in 2007, 2009, 2012, and 2014 were reviewed. Multiple-variable logistic regression analysis was used to identify significant risk factors for hospitalization. Results The proportion of IBD patients who visited ED was 12.3% in 2007, 9.7% in 2009, 8.3% in 2012, and 6.4% in 2014 (P = 0.002). The most common chief complaints were abdominal pain (66.9%) in Crohn's disease (CD) patients and hematochezia (36.5%) in ulcerative colitis (UC) patients. The hospitalization rate following ED visits was 47.2% in CD patients and 55.6% in UC patients (P = 0.100). Multiple-variable analysis showed that significant risk factors associated with hospitalization in CD were aggressive disease behavior (odds ratio[OR] 3.54, P = 0.017) and presence of steroid exposure (OR 2.35, P = 0.047). Elevated C-reactive protein (CRP) (>0.5 mg/dL) (OR 5.40, P = 0.016) was the only risk factor associated with hospitalization in UC. Conclusions The proportion of ED visits decreased from 2007 to 2014; there was no significant change in hospitalization rates. Disease behavior/presence of steroid exposure and elevated CRP were associated with hospitalization among CD and UC patients who visited the ED, respectively.	[Huh, Gunn; Kim, Nayoung; Lee, Dong Ho; Kim, Joo Sung] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea; [Yoon, Hyuk; Choi, Yoon Jin; Shin, Cheol Min; Park, Young Soo; Kim, Nayoung; Lee, Dong Ho] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Seongnam, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Yoon, H (corresponding author), Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Seongnam, South Korea.	bodnsoul@hanmail.net	Yoon, Hyuk/AAT-4978-2020	Yoon, Hyuk/0000-0002-2657-0349; Choi, Yoon Jin/0000-0002-1922-9388				Ananthakrishnan AN, 2010, AM J GASTROENTEROL, V105, P363, DOI 10.1038/ajg.2009.580; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cosnes J, 2011, GASTROENTEROLOGY, V140, P1785, DOI 10.1053/j.gastro.2011.01.055; Frolkis AD, 2013, GASTROENTEROLOGY, V145, P996, DOI 10.1053/j.gastro.2013.07.041; Gajendran M, 2016, DIGEST DIS SCI, V61, P389, DOI 10.1007/s10620-015-3895-2; Hou JK, 2009, AM J GASTROENTEROL, V104, P2100, DOI 10.1038/ajg.2009.190; Jung YS, 2017, DIGEST DIS SCI, V62, P2102, DOI 10.1007/s10620-017-4640-9; Kappelman MD, 2011, INFLAMM BOWEL DIS, V17, P62, DOI 10.1002/ibd.21371; Kappelman MD, 2008, GASTROENTEROLOGY, V135, P1907, DOI 10.1053/j.gastro.2008.09.012; Kim HJ, 2015, INFLAMM BOWEL DIS, V21, P623, DOI 10.1097/MIB.0000000000000313; Kim JW, 2018, J GASTROEN HEPATOL, V33, P847, DOI 10.1111/jgh.14027; Langholz E, 1996, SCAND J GASTROENTERO, V31, P260, DOI 10.3109/00365529609004876; Lichtenstein GR, 2004, AM J GASTROENTEROL, V99, P91, DOI 10.1046/j.1572-0241.2003.04010.x; Mao EJ, 2017, ALIMENT PHARM THER, V45, P3, DOI 10.1111/apt.13847; Ng SC, 2017, LANCET, V390, P2769, DOI 10.1016/S0140-6736(17)32448-0; Ng WK, 2016, INTEST RES, V14, P111, DOI 10.5217/ir.2016.14.2.111; Nugent Z, 2016, INFLAMM BOWEL DIS, V22, P2907, DOI 10.1097/MIB.0000000000000965; Park SH, 2007, INFLAMM BOWEL DIS, V13, P278, DOI 10.1002/ibd.20015; Reich KM, 2014, ALIMENT PHARM THER, V40, P629, DOI 10.1111/apt.12873; Silverberg MS, 2005, CAN J GASTROENTEROL, V19, p5A, DOI 10.1155/2005/269076; Yang SK, 2008, INFLAMM BOWEL DIS, V14, P542, DOI 10.1002/ibd.20310	21	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2019	14	1							e0210703	10.1371/journal.pone.0210703	http://dx.doi.org/10.1371/journal.pone.0210703			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH6BK	30650133	Green Published, Green Submitted, gold			2023-01-03	WOS:000455813300070
J	Muehlemann, N; Jouaneton, B; de Leotoing, L; Chale, JJ; Fernandes, J; Kagi, G; Sarikaya, H; Arnold, M				Muehlemann, Natalia; Jouaneton, Baptiste; de Leotoing, Lucie; Chale, Jean-Jacques; Fernandes, Jerome; Kagi, Georg; Sarikaya, Hakan; Arnold, Marcel			Hospital costs impact of post ischemic stroke dysphagia: Database analyses of hospital discharges in France and Switzerland	PLOS ONE			English	Article								Introduction Oropharyngeal dysphagia is frequent in hospitalized post-stroke patients and is associated with increased mortality and comorbidities. The aim of our analysis was to evaluate the impact of dysphagia on Length of Hospital Stay (LOS) and costs. The hospital perspective was used to assess costs. Methods Hospital discharge databases comparing hospital stays for ischemic stroke associated with dysphagia vs stroke without dysphagia in France and Switzerland were analyzed. The French Medical Information System Program (PMSI) database analysis focused on 62'297 stays for stroke in the public sector. 6'037 hospital stays for stroke were analyzed from the Swiss OFS (Office federal de la statistique: Statistique des couts par cas 2012) database. Diagnosis codes and listing of procedures were used to identify dysphagia in stroke patients. Results Patients with post-stroke dysphagia accounted for 8.4% of stroke hospital stays in Switzerland, which is consistent with recently reported prevalence of dysphagia at hospital discharge (Arnold et al, 2016). The French database analysis identified 4.2% stays with post-stroke dysphagia. We hypothesize that the difference between the Swiss and French datasets may be explained by the limitations of an analysis based on diagnosis and procedure coding. Patients with post-stroke dysphagia stayed longer at hospitals (LOS of 23.7 vs. 11.8 days in France and LOS of 14.9 vs. 8.9 days in Switzerland) compared with patients without post-stroke dysphagia. Post-stroke dysphagia was associated with about (sic)3'000 and CHF14'000 cost increase in France and Switzerland respectively. Discussion In this study post-stroke dysphagia was associated with increased LOS and higher hospital costs. It is difficult to isolate the impact of dysphagia in patients with multiple symptoms and disabilities impacting rehabilitation and recovery. After adjusting for confounding factors by matching stays according to age, sex and stroke complications, post-stroke dysphagia association with increased LOS and higher hospital costs was found to be independent of sensory or motor complications. Conclusion Post-stroke dysphagia is associated with increased length of hospital stay and higher hospital costs.	[Muehlemann, Natalia] Nestle Hlth Sci, Epalinges, Switzerland; [Jouaneton, Baptiste; de Leotoing, Lucie] HEVA, Lyon, France; [Chale, Jean-Jacques] Geneva Univ Hosp, Finance Dept, Geneva, Switzerland; [Fernandes, Jerome] Grp OC Sante, Montpellier, France; [Kagi, Georg] Kantonsspital St Gallen, Dept Neurol, St Gallen, Switzerland; [Sarikaya, Hakan; Arnold, Marcel] Univ Hosp Berne, Dept Neurol, Bern, Switzerland	University of Geneva; Kantonsspital St. Gallen; University of Bern; University Hospital of Bern	Muehlemann, N (corresponding author), Nestle Hlth Sci, Epalinges, Switzerland.	natalia.muehlemann@nestle.com		Muehlemann, Natalia/0000-0001-5167-904X	Nestle Health Science, Nestec S.A., Vevey, Switzerland; HEVA, Lyon, France	Nestle Health Science, Nestec S.A., Vevey, Switzerland(Nestle SA); HEVA, Lyon, France	This study was sponsored by Nestle Health Science, Nestec S.A., Vevey, Switzerland, through research contracts with HEVA, Lyon, France to L.L. HEVA was commissioned by Nestle Health Science to perform databases analysis and statistical analysis. In collaboration with coauthors, the funder was involved in study design, data interpretation, decision to publish and preparation of the manuscript. The funder was not involved in databases analysis and statistical analysis. All authors had full access to the data. All authors had final responsibility for the decision to submit for publication.	Arnold M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148424; Bonilha HS, 2014, DYSPHAGIA, V29, P545, DOI 10.1007/s00455-014-9543-8; Clave P, 2015, NAT REV GASTRO HEPAT, V12, P259, DOI 10.1038/nrgastro.2015.49; De Peretti C, 2012, BEH; Martino R, 2005, STROKE, V36, P2756, DOI 10.1161/01.STR.0000190056.76543.eb; NICE, 2008, NICE NATL CLIN GUIDE	6	15	15	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 10	2019	14	1							e0210313	10.1371/journal.pone.0210313	http://dx.doi.org/10.1371/journal.pone.0210313			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH1ME	30629665	Green Published, Green Submitted, gold			2023-01-03	WOS:000455483000073
J	Wada, T; Sameshima, A; Yonezawa, R; Morita, M; Sawakawa, K; Tsuneki, H; Sasaoka, T; Saito, S				Wada, Tsutomu; Sameshima, Azusa; Yonezawa, Rika; Morita, Mayuko; Sawakawa, Kanae; Tsuneki, Hiroshi; Sasaoka, Toshiyasu; Saito, Shigeru			Impact of central and peripheral estrogen treatment on anxiety and depression phenotypes in a mouse model of postmenopausal obesity	PLOS ONE			English	Article							GLUCOSE-METABOLISM; NEUROTROPHIC FACTOR; HIGH-FAT; ESTRADIOL; RECEPTOR; WOMEN; PERIMENOPAUSAL; EFFICACY; MECHANISMS; THERAPY	Obesity and diabetes increase the risk of depression, and the incidence of these conditions increases rapidly after menopause, but few animal models of postmenopausal obesity have been available. We developed a mouse model of postmenopausal obesity that exhibited anxiety and depressive phenotypes in behavioral tests. To examine the effect of estradiol (E2) in the model, we prepared 4 experimental groups: 1) control, sham-operated female C57BL/6 mice fed a regular diet; 2) OVX-HF, ovariectomized (OVX) mice fed a high-fat diet (HF); 3) E2-SC, OVX-HF mice administered subcutaneous (SC) E2 (50 mu g/kg/day); and 4) E2-ICV, OVX-HF mice administered intracerebroventricular (ICV) E2 (1 mu g/kg/day). OVX-HF mice exhibited anxiety phenotypes in the open field test, but not in the light-dark box test, and E2 treatment via both routes effectively ameliorated it. OVX-HF mice demonstrated depressive phenotypes in the tail suspension test and forced swim test. Both E2 treatments achieved significant improvement in the tail suspension test, but not in the forced swim test. Serum corticosterone levels did not differ among the groups. Hippocampal expression of glucocorticoid receptor mRNA and serotonin 1A receptor mRNA was significantly increased in OVX-HF mice and was decreased in E2-treated mice. The hypothalamic level of pro-brain-derived neurotrophic factor (proBDNF) protein was tended to decrease in OVX-HF mice, but neither E2 treatment increased it. Since this mouse model exhibited anxiety and depressive phenotypes in relatively short experimental periods without genetic manipulations, it would be useful for further exploring psychiatric phenotypes or screening of therapeutic candidates in postmenopausal obesity.	[Wada, Tsutomu; Morita, Mayuko; Sawakawa, Kanae; Tsuneki, Hiroshi; Sasaoka, Toshiyasu] Univ Toyama, Dept Clin Pharmacol, Toyama, Toyama, Japan; [Sameshima, Azusa; Yonezawa, Rika; Saito, Shigeru] Univ Toyama, Dept Obstet & Gynecol, Toyama, Toyama, Japan	University of Toyama; University of Toyama	Wada, T (corresponding author), Univ Toyama, Dept Clin Pharmacol, Toyama, Toyama, Japan.; Saito, S (corresponding author), Univ Toyama, Dept Obstet & Gynecol, Toyama, Toyama, Japan.	twada@pha.u-toyama.ac.jp; s30saito@med.u-toyama.ac.jp	Wada, Tsutomu/AAY-4450-2020	Wada, Tsutomu/0000-0001-5819-8556	JPSP KAKENHI [JP15K09410, JP25861480, JP15K15599]; Akaeda Medical Research Foundation	JPSP KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Akaeda Medical Research Foundation	This work was supported by JPSP KAKENHI Grants (Number JP15K09410 to T.W., JP25861480 to R.Y., and JP15K15599 to T.S.) and a research grant from Akaeda Medical Research Foundation (to R.Y.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali S, 2006, DIABETIC MED, V23, P1165, DOI 10.1111/j.1464-5491.2006.01943.x; Anacker C, 2011, PSYCHONEUROENDOCRINO, V36, P415, DOI 10.1016/j.psyneuen.2010.03.007; Arpels JC, 1996, J REPROD MED, V41, P633; BALL P, 1972, J CLIN ENDOCR METAB, V34, P736, DOI 10.1210/jcem-34-4-736; Benmansour S, 2014, INT J NEUROPSYCHOPH, V17, P765, DOI 10.1017/S146114571300165X; Berk M, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-74; Bethea CL, 2002, PSYCHONEUROENDOCRINO, V27, P431, DOI 10.1016/S0306-4530(01)00054-3; BRESLAU N, 1995, PSYCHIAT RES, V58, P1, DOI 10.1016/0165-1781(95)02765-O; Bromberger JT, 2003, AM J EPIDEMIOL, V158, P347, DOI 10.1093/aje/kwg155; Carpenter KM, 2000, AM J PUBLIC HEALTH, V90, P251, DOI 10.2105/AJPH.90.2.251; Cyranowski JM, 2000, ARCH GEN PSYCHIAT, V57, P21, DOI 10.1001/archpsyc.57.1.21; Dale E, 2015, BIOCHEM PHARMACOL, V95, P81, DOI 10.1016/j.bcp.2015.03.011; Duman RS, 1997, ARCH GEN PSYCHIAT, V54, P597; FEIGHNER JP, 1989, PSYCHOPATHOLOGY, V22, P21, DOI 10.1159/000284623; Galter D, 2000, J NEUROSCI RES, V61, P295, DOI 10.1002/1097-4547(20000801)61:3<295::AID-JNR7>3.0.CO;2-4; Galter D, 2000, MOL CELL NEUROSCI, V15, P446, DOI 10.1006/mcne.2000.0841; Gleason CE, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001833; Gruber CJ, 2002, NEW ENGL J MED, V346, P340, DOI 10.1056/NEJMra000471; Halbreich U, 1997, NEUROLOGY, V48, pS16, DOI 10.1212/WNL.48.5_Suppl_7.16S; Hassan AM, 2012, NUTR NEUROSCI, V26, P1; JACOBS BL, 1992, PHYSIOL REV, V72, P165, DOI 10.1152/physrev.1992.72.1.165; Jasienska G, 2005, WOMEN HEALTH ISS, V15, P145, DOI 10.1016/j.whi.2005.02.002; Keller MB, 2005, J CLIN PSYCHOPHARM, V25, P79, DOI 10.1097/01.jcp.0000150221.53877.d9; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kiss A, 2012, BEHAV BRAIN RES, V227, P100, DOI 10.1016/j.bbr.2011.10.047; KLAIBER EL, 1971, J CLIN ENDOCR METAB, V33, P630, DOI 10.1210/jcem-33-4-630; Levkovitz Y, 2011, J CLIN PSYCHIAT, V72, P509, DOI 10.4088/JCP.09m05949blu; Mayo-Wilson E, 2014, LANCET PSYCHIAT, V1, P368, DOI 10.1016/S2215-0366(14)70329-3; Meyer MR, 2011, ACTA PHYSIOL, V203, P259, DOI 10.1111/j.1748-1716.2010.02237.x; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Morrison MF, 2004, BIOL PSYCHIAT, V55, P406, DOI 10.1016/j.biopsych.2003.08.011; NEMEROFF CB, 1984, SCIENCE, V226, P1342, DOI 10.1126/science.6334362; Nestler EJ, 2002, NEURON, V34, P13, DOI 10.1016/S0896-6273(02)00653-0; NOMIKOS GG, 1988, NEUROPHARMACOLOGY, V27, P691, DOI 10.1016/0028-3908(88)90077-9; Ogren SO, 2008, BEHAV BRAIN RES, V195, P54, DOI 10.1016/j.bbr.2008.02.023; Onogi Y, 2017, DIABETES, V66, P1008, DOI 10.2337/db16-0881; Parks CL, 1998, P NATL ACAD SCI USA, V95, P10734, DOI 10.1073/pnas.95.18.10734; Resnick SM, 1997, NEUROLOGY, V49, P1491, DOI 10.1212/WNL.49.6.1491; Rubinow DR, 2015, DEPRESS ANXIETY, V32, P539, DOI 10.1002/da.22391; Rubinow DR, 1998, BIOL PSYCHIAT, V44, P839, DOI 10.1016/S0006-3223(98)00162-0; Sameshima A, 2015, J ENDOCRINOL, V227, P25, DOI 10.1530/JOE-15-0239; Schachter J, 2018, BRAIN BEHAV IMMUN, V69, P1, DOI 10.1016/j.bbi.2017.08.026; Seeman MV, 1997, AM J PSYCHIAT, V154, P1641, DOI 10.1176/ajp.154.12.1641; Sherwin BB, 2009, NAT REV ENDOCRINOL, V5, P620, DOI 10.1038/nrendo.2009.193; SLATER J, 1976, J COMP PHYSIOL PSYCH, V90, P755, DOI 10.1037/h0077248; Soares CD, 2001, ARCH GEN PSYCHIAT, V58, P529; Stahl SM, 2001, J CLIN PSYCHIAT, V62, P317, DOI 10.4088/JCP.v62n0501; Sumner BEH, 2007, NEUROSCI LETT, V417, P95, DOI 10.1016/j.neulet.2007.02.039; Toffol E, 2015, MENOPAUSE, V22, P564, DOI [10.1097/gme.0000000000000323, 10.1097/GME.0000000000000323]; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Tsuneki H, 2008, DIABETOLOGIA, V51, P657, DOI 10.1007/s00125-008-0929-8; Tsuneki H, 2016, ENDOCRINOLOGY, V157, P195, DOI 10.1210/en.2015-1488; Usher MG, 2010, J CLIN INVEST, V120, P3350, DOI 10.1172/JCI41080; Villa A, 2016, ENDOCR REV, V37, P372, DOI 10.1210/er.2016-1007; Wada T, 2017, J ENDOCRINOL, V235, P179, DOI 10.1530/JOE-17-0351; Wada T, 2010, AM J PHYSIOL-ENDOC M, V298, pE881, DOI 10.1152/ajpendo.00649.2009; Walf AA, 2005, NEUROPSYCHOPHARMACOL, V30, P1288, DOI 10.1038/sj.npp.1300708; Walf AA, 2008, STEROIDS, V73, P997, DOI 10.1016/j.steroids.2008.01.025; Wei Q, 2004, P NATL ACAD SCI USA, V101, P11851, DOI 10.1073/pnas.0402208101; Weiser MJ, 2010, BRAIN RES, V1336, P78, DOI 10.1016/j.brainres.2010.03.098; Woods Nancy Fugate, 2005, Am J Med, V118 Suppl 12B, P14; Yonezawa R, 2012, AM J PHYSIOL-ENDOC M, V303, pE445, DOI 10.1152/ajpendo.00638.2011	62	11	11	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2018	13	12							e0209859	10.1371/journal.pone.0209859	http://dx.doi.org/10.1371/journal.pone.0209859			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HF7KM	30589890	Green Submitted, Green Published, gold			2023-01-03	WOS:000454418200062
J	Johnson, RW; Ng, KWP; Dietz, AR; Hartman, ME; Baty, JD; Hasan, N; Zaidman, CM; Shoykhet, M				Johnson, Ryan W.; Ng, Kay W. P.; Dietz, Alexander R.; Hartman, Mary E.; Baty, Jack D.; Hasan, Nausheen; Zaidman, Craig M.; Shoykhet, Michael			Muscle atrophy in mechanically-ventilated critically ill children	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; ICU-ACQUIRED WEAKNESS; ELECTRICAL-IMPEDANCE MYOGRAPHY; RISK-FACTORS; METABOLIC-RESPONSE; POLYNEUROPATHY; DYSFUNCTION; ULTRASOUND; PARESIS; INJURY	Importance ICU-acquired muscle atrophy occurs commonly and worsens outcomes in adults. The incidence and severity of muscle atrophy in critically ill children are poorly characterized. Objective To determine incidence, severity and risk factors for muscle atrophy in critically ill children. Design, setting and participants A single-center, prospective cohort study of 34 children receiving invasive mechanical ventilation for >= 48 hours. Patients 1 week- 18 years old with respiratory failure and without preexisting neuromuscular disease or skeletal trauma were recruited from a tertiary Pediatric Intensive Care Unit (PICU) between June 2015 and May 2016. We used serial bedside ultrasound to assess thickness of the diaphragm, biceps brachii/brachialis, quadriceps femoris and tibialis anterior. Serial electrical impedance myography (EIM) was assessed in children >1 year old. Medical records were abstracted from an electronic database. Exposures Respiratory failure requiring endotracheal intubation for >= 48 hours. Main outcome and measures The primary outcome was percent change in muscle thickness. Secondary outcomes were changes in EIM-derived fat percentage and "quality". Results Of 34 enrolled patients, 30 completed >= 2 ultrasound assessments with a median interval of 6 (IQR 6-7) days. Mean age was 5.42 years, with 12 infants <1 year (40%) and 18 children >1 year old (60%). In the entire cohort, diaphragm thickness decreased 11.1% (95%CI, -19.7% to -2.52%) between the first two assessments or 2.2%/day. Quadriceps thickness decreased 8.62% (95%CI, -15.7% to -1.54%) or 1.5%/day. Biceps (-1.71%; 95%CI, -8.15% to 4.73%) and tibialis (0.52%; 95%CI, -5.81% to 3.40%) thicknesses did not change. Among the entire cohort, 47% (14/30) experienced diaphragm atrophy (defined a priorias >= 10% decrease in thickness). Eighty three percent of patients (25/30) experienced atrophy in >= 1 muscle group, and 47% (14/30)-in >= 2 muscle groups. On multivariate linear regression, increasing age and traumatic brain injury (TBI) were associated with greater muscle loss. EIM revealed increased fat percentage and decreased muscle "quality". Conclusions and relevance In children receiving invasive mechanical ventilation, diaphragm and other skeletal muscle atrophy is common and rapid. Increasing age and TBI may increase severity of limb muscle atrophy. Prospective studies are required to link muscle atrophy to functional outcomes in critically ill children.	[Johnson, Ryan W.; Hartman, Mary E.; Shoykhet, Michael] Washington Univ, Dept Pediat, Sch Med, St Louis, MO 63110 USA; [Ng, Kay W. P.; Dietz, Alexander R.; Zaidman, Craig M.] Washington Univ, Dept Neurol, Sch Med, St Louis, MO 63110 USA; [Ng, Kay W. P.] Natl Univ, Dept Med, Singapore, Singapore; [Dietz, Alexander R.] Blue Sky Neurol, Englewood, CO USA; [Baty, Jack D.] Washington Univ, Div Biostat, Sch Med, St Louis, MO 63110 USA; [Hasan, Nausheen] St Louis Childrens Hosp, St Louis, MO 63178 USA; [Shoykhet, Michael] Childrens Natl Med Ctr, Childrens Res Inst, Washington, DC 20010 USA	Washington University (WUSTL); Washington University (WUSTL); National University of Singapore; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Children's National Health System	Shoykhet, M (corresponding author), Washington Univ, Dept Pediat, Sch Med, St Louis, MO 63110 USA.; Shoykhet, M (corresponding author), Childrens Natl Med Ctr, Childrens Res Inst, Washington, DC 20010 USA.	mshoykhet@childrensnational.org		Shoykhet, Michael/0000-0001-5031-2377	Washington University [ICTS CTSA808]	Washington University	This work was supported by MS (Washington University ICTS CTSA808). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banwell BL, 2003, NEUROLOGY, V61, P1779, DOI 10.1212/01.WNL.0000098886.90030.67; Charrueau C, 2009, J NEUROTRAUM, V26, P1911, DOI 10.1089/neu.2008.0737; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; Corpeno R, 2014, J PHYSIOL-LONDON, V592, P3859, DOI 10.1113/jphysiol.2014.277962; Curley MAQ, 2006, PEDIATR CRIT CARE ME, V7, P107, DOI 10.1097/01.PCC.0000200955.40962.38; De Jonghe B, 2004, INTENS CARE MED, V30, P1117, DOI 10.1007/s00134-004-2174-z; De Jonghe B, 2002, JAMA-J AM MED ASSOC, V288, P2859, DOI 10.1001/jama.288.22.2859; de Letter MACJ, 2001, CRIT CARE MED, V29, P2281, DOI 10.1097/00003246-200112000-00008; Dejonghe B, 2009, CERAMICS-ART PERCEPT, P37; Demoule A, 2013, AM J RESP CRIT CARE, V188, P213, DOI 10.1164/rccm.201209-1668OC; Fan E, 2014, CRIT CARE MED, V42, P849, DOI 10.1097/CCM.0000000000000040; Field-Ridley A, 2016, PEDIATR CRIT CARE ME, V17, P53, DOI 10.1097/PCC.0000000000000538; Fukunaga T, 2001, ACTA PHYSIOL SCAND, V172, P249, DOI 10.1046/j.1365-201x.2001.00867.x; Garnacho-Montero J, 2005, CRIT CARE MED, V33, P349, DOI 10.1097/01.CCM.0000153521.41848.7E; Gerovasili V, 2009, CRIT CARE, V13, DOI 10.1186/cc8123; Glau CL, 2018, PEDIATR CRIT CARE ME, V19, P406, DOI 10.1097/PCC.0000000000001485; Goligher EC, 2018, AM J RESP CRIT CARE, V197, P204, DOI 10.1164/rccm.201703-0536OC; Gruther W, 2008, J REHABIL MED, V40, P185, DOI 10.2340/16501977-0139; Hermans G, 2014, AM J RESP CRIT CARE, V190, P410, DOI 10.1164/rccm.201312-2257OC; Hirose T, 2013, J CRIT CARE, V28, DOI 10.1016/j.jcrc.2013.02.010; Jaber S, 2011, AM J RESP CRIT CARE, V183, P364, DOI 10.1164/rccm.201004-0670OC; KANEHISA H, 1994, EUR J APPL PHYSIOL, V68, P148, DOI 10.1007/BF00244028; Khemani RG, 2017, CRIT CARE MED, V45, pE798, DOI 10.1097/CCM.0000000000002433; Koch S, 2011, J NEUROL NEUROSUR PS, V82, P287, DOI 10.1136/jnnp.2009.192997; Kress JP, 2014, NEW ENGL J MED, V370, P1626, DOI 10.1056/NEJMra1209390; LEIJTEN FSS, 1995, JAMA-J AM MED ASSOC, V274, P1221, DOI 10.1001/jama.274.15.1221; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; Lu ZH, 2016, RESP CARE, V61, P1316, DOI 10.4187/respcare.04746; Mtaweh H, 2014, PEDIATR CRIT CARE ME, V15, P242, DOI 10.1097/PCC.0000000000000041; Ng KW, 2018, MUSCLE NERVE; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Puthucheary ZA, 2013, JAMA-J AM MED ASSOC, V310, P1591, DOI 10.1001/jama.2013.278481; Rodriguez PO, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.04.010; Sanchez B, 2017, NEUROTHERAPEUTICS, V14, P107, DOI 10.1007/s13311-016-0491-x; Shahidi B, 2018, J NEUROTRAUM, V35, P398, DOI 10.1089/neu.2017.5172; Sharshar T, 2009, CRIT CARE MED, V37, P3047, DOI 10.1097/CCM.0b013e3181b027e9; Tarulli A, 2005, NEUROLOGY, V65, P451, DOI 10.1212/01.wnl.0000172338.95064.cb; Valla FV, 2017, PEDIATR CRIT CARE ME, V18, pE339, DOI 10.1097/PCC.0000000000001235; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wieske L, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0937-2; Wright DK, 2017, CEREB CORTEX, V27, P4503, DOI 10.1093/cercor/bhw254; Zaidman CM, 2015, MUSCLE NERVE, V52, P592, DOI 10.1002/mus.24611; Zaidman CM, 2014, MUSCLE NERVE, V50, P124, DOI 10.1002/mus.24117	44	35	38	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2018	13	12							e0207720	10.1371/journal.pone.0207720	http://dx.doi.org/10.1371/journal.pone.0207720			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE9NT	30566470	Green Published, gold, Green Submitted			2023-01-03	WOS:000453779300015
J	Gellad, WF; Ennis, M; Kuza, CC				Gellad, Walid F.; Ennis, Molly; Kuza, Courtney C.			A New Safe Harbor - Turning Drug Rebates into Discounts in Medicare Part D	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Gellad, Walid F.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA; [Gellad, Walid F.; Kuza, Courtney C.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA 15260 USA; [Ennis, Molly] Univ Pittsburgh, Sch Hlth Sci, Hlth Policy Inst, Pittsburgh, PA USA; [Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System	Gellad, WF (corresponding author), Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA.; Gellad, WF (corresponding author), Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA 15260 USA.; Gellad, WF (corresponding author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15213 USA.		Kuza, Courtney/V-4940-2019	Kuza, Courtney/0000-0001-9137-0928				Alston M, 2019, CHANGING REBATE GAME; Department of Health and Human Services, 2019, FACT SHEET TRUMP ADM; Doshi JA, 2018, HLTH AFFAIRS BLOG, DOI [10.1377/hblog20180724.734269/full/, DOI 10.1377/HBLOG20180724.734269/FULL/]; Dusetzina SB, 2017, JAMA INTERN MED, V177, P1185, DOI 10.1001/jamainternmed.2017.1885	4	6	6	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 2	2019	380	18					1688	1690		10.1056/NEJMp1902692	http://dx.doi.org/10.1056/NEJMp1902692			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX9ZK	30946552				2023-01-03	WOS:000467767800002
J	Neuman, MD; Bateman, BT; Wunsch, H				Neuman, Mark D.; Bateman, Brian T.; Wunsch, Hannah			Inappropriate opioid prescription after surgery	LANCET			English	Article							CHRONIC POSTSURGICAL PAIN; UNITED-STATES; PRESCRIBING PATTERNS; POSTOPERATIVE PAIN; RISK-FACTORS; ARTHROPLASTY EVIDENCE; NONMALIGNANT PAIN; NERVE BLOCKADE; NAIVE PATIENTS; ANALGESICS	Worldwide, the use of prescription opioid analgesics more than doubled between 2001 and 2013, with several countries, including the USA, Canada, and Australia, experiencing epidemics of opioid misuse and abuse over this period. In this context, excessive prescribing of opioids for pain treatment after surgery has been recognised as an important concern for public health and a potential contributor to patterns of opioid misuse and related harm. In the second paper in this Series we review the evolution of prescription opioid use for pain treatment after surgery in the USA, Canada, and other countries. We summarise evidence on the extent of opioid overprescribing after surgery and its potential association with subsequent opioid misuse, diversion, and the development of opioid use disorder. We discuss evidence on patient, physician, and system-level predictors of excessive prescribing after surgery, and summarise recent work on clinical and policy efforts to reduce such prescribing while ensuring adequate pain control.	[Neuman, Mark D.] Univ Penn, Dept Anesthesiol & Crit Care, Perelman Sch Med, Philadelphia, PA 19104 USA; [Neuman, Mark D.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; [Bateman, Brian T.] Brigham & Womens Hosp, Dept Anesthesia Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA; [Bateman, Brian T.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA; [Bateman, Brian T.] Harvard Med Sch, Boston, MA 02115 USA; [Wunsch, Hannah] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON, Canada; [Wunsch, Hannah] Sunnybrook Res Inst, Toronto, ON, Canada; [Wunsch, Hannah] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada; [Wunsch, Hannah] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto	Bateman, BT (corresponding author), Brigham & Womens Hosp, Boston, MA 02115 USA.	bbateman@bwh.harvard.edu			National Institute on Drug Abuse [R01 DA042299-01A1, R01 DA044293-01A1]; Canadian Institutes of Health Research (CIHR) [365432]; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA044293, R01DA042299] Funding Source: NIH RePORTER	National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	All authors received support from the National Institute on Drug Abuse (R01 DA042299-01A1 to MDN, BTB, and HW, and R01 DA044293-01A1 to BTB). HW received support from the Canadian Institutes of Health Research (CIHR grant number 365432). The study sponsors had no role in study design; the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the series for publication. We would like to thank Hance Clarke and Michael Ashburn who provided comments on an early draft of the manuscript. BTB confirms that he had full access to all the data in the study and had final responsibility for the decision to submit for publication.	Alam A, 2012, ARCH INTERN MED, V172, P425, DOI 10.1001/archinternmed.2011.1827; American Psychiatric Association, 2013, OP US DIS DIAGN STAT; Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; [Anonymous], 2017, FINANCIAL TIMES; [Anonymous], 2017, LANCET ONCOL, V18, P1285; [Anonymous], 2013, CBHSQ DATA REV; Antman KH, 2016, ACAD MED, V91, P1348, DOI 10.1097/ACM.0000000000001347; Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; Azam MA, 2017, CAN J PAIN, V1, P37, DOI 10.1080/24740527.2017.1325317; Baker DW, 2017, JAMA-J AM MED ASSOC, V317, P1117, DOI 10.1001/jama.2017.0935; Baker-White A, 2017, LOOK STATE LEGISLATI; Ballantyne JC, 2015, NEW ENGL J MED, V373, P2098, DOI 10.1056/NEJMp1507136; Bao YH, 2016, HEALTH AFFAIR, V35, P1045, DOI 10.1377/hlthaff.2015.1673; Barnett ML, 2017, NEW ENGL J MED, V376, P663, DOI 10.1056/NEJMsa1610524; Bateman BT, 2017, OBSTET GYNECOL, V130, P29, DOI 10.1097/AOG.0000000000002093; Bateman BT, 2016, JAMA INTERN MED, V176, P583, DOI 10.1001/jamainternmed.2016.0544; Bateman BT, 2016, AM J OBSTET GYNECOL, V215; Bates C, 2011, J UROLOGY, V185, P551, DOI 10.1016/j.juro.2010.09.088; Berterame S, 2016, LANCET, V387, P1644, DOI 10.1016/S0140-6736(16)00161-6; Bicket MC, 2017, JAMA SURG, V152, P1066, DOI 10.1001/jamasurg.2017.0831; Bounes V, 2016, AM J EMERG MED, V34, P1955, DOI 10.1016/j.ajem.2016.06.107; Brandal D, 2017, ANESTH ANALG, V125, P1784, DOI 10.1213/ANE.0000000000002510; Brat GA, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5790; Brummett CM, 2017, JAMA SURG, V152, DOI 10.1001/jamasurg.2017.0504; Callinan CE, 2017, J PAIN, V18, P360, DOI 10.1016/j.jpain.2016.11.001; Campbell JN, 1996, PAIN FORUM, V5, P85; Carr D, 2018, PUBLIC HLTH REP, V1; Chang AK, 2017, JAMA-J AM MED ASSOC, V318, P1661, DOI 10.1001/jama.2017.16190; Chen EY, 2018, JAMA SURG, V153, DOI 10.1001/jamasurg.2017.4859; Chiu AS, 2018, JAMA SURG, V153, P1012, DOI 10.1001/jamasurg.2018.2083; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; Clarke H, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1251; Davis CS, 2015, DRUG ALCOHOL DEPEN, V157, P112, DOI 10.1016/j.drugalcdep.2015.10.013; Delgado MK, 2018, J GEN INTERN MED, V33, P409, DOI 10.1007/s11606-017-4286-5; Devine CA, 2016, J BONE JOINT SURG AM, V98, DOI 10.2106/JBJS.15.01004; Deyo RA, 2017, J GEN INTERN MED, V32, P21, DOI 10.1007/s11606-016-3810-3; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Egan KL, 2018, ADDICT BEHAV, V86, P44, DOI 10.1016/j.addbeh.2018.03.029; Fischer B, 2012, PAIN PHYSICIAN, V15, pES191; Gawande AA, 2017, ANN SURG, V265, P693, DOI 10.1097/SLA.0000000000002133; Gerbershagen HJ, 2014, ANESTHESIOLOGY, V120, P1237, DOI 10.1097/ALN.0000000000000108; Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3; Geriatrics and Extended Care Strategic Healthcare Group National Pain Management Coordinating Committee Veterans Health Administration, 2000, PAIN 5 VIT SIGN TOOL; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Gomes Tara, 2011, Healthc Q, V14, P22; Gray J, 2015, AM J PUBLIC HEALTH, V105, pE89, DOI 10.2105/AJPH.2015.302689; Gray JA, 2012, ARCH INTERN MED, V172, P1186, DOI 10.1001/archinternmed.2012.2374; Guy GP, 2017, MMWR-MORBID MORTAL W, V66, P697, DOI 10.15585/mmwr.mm6626a4; Haddox JD, 1997, CLIN J PAIN, V13, P6; Haffajee RL, 2015, JAMA-J AM MED ASSOC, V313, P891, DOI 10.1001/jama.2014.18514; Hah J, 2022, JAMA SURG, DOI [10.1001/jamasurg.2017.4915, 10.1001/jamasurg.2022.1392]; Han B, 2017, ANN INTERN MED, V167, P293, DOI 10.7326/M17-0865; Hanna MN, 2019, AM J MED QUAL, V1; Harris K, 2013, JAMA DERMATOL; Hasak JM, 2018, J AM COLL SURGEONS, V226, P235, DOI 10.1016/j.jamcollsurg.2017.11.023; Helmerhorst GTT, 2017, BONE JOINT J, V99B, P856, DOI 10.1302/0301-620X.99B7.BJJ-2016-1350.R1; Hill MV, 2018, J AM COLL SURGEONS, V226, P996, DOI 10.1016/j.jamcollsurg.2017.10.012; Hill MV, 2018, ANN SURG, V267, P468, DOI 10.1097/SLA.0000000000002198; Hill MV, 2017, ANN SURG, V265, P709, DOI 10.1097/SLA.0000000000001993; Hooten WM, 2017, MAYO CLIN PROC, V92, P1822, DOI 10.1016/j.mayocp.2017.10.010; Howard R, 2018, JAMA SURG, V153, P285, DOI 10.1001/jamasurg.2017.4436; Howe CQ, 2014, GEN HOSP PSYCHIAT, V36, P99, DOI 10.1016/j.genhosppsych.2013.10.003; Huxtable CA, 2011, ANAESTH INTENS CARE, V39, P804, DOI 10.1177/0310057X1103900505; Inciardi JA, 2007, PAIN MED, V8, P171, DOI 10.1111/j.1526-4637.2006.00255.x; Inciardi James A, 2007, Law Enforc Exec Forum, V7, P127; Katz J, 2015, J PAIN RES, V8, P695, DOI 10.2147/JPR.S91924; Katz NP, 2013, AM J MANAG CARE, V19, P295; KEHLET H, 1994, BRIT J ANAESTH, V72, P375, DOI 10.1093/bja/72.4.375; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Krawczyk N, 2018, AM J PUBLIC HEALTH, V108, P666, DOI 10.2105/AJPH.2018.304341; Ladha KS, 2018, JAMA-J AM MED ASSOC, V320, P502, DOI 10.1001/jama.2018.6933; Ladha KS, 2016, ANESTHESIOLOGY, V124, P837, DOI 10.1097/ALN.0000000000001034; Ladha KS, 2016, ANESTHESIOLOGY, V124, P396, DOI 10.1097/ALN.0000000000000952; Larance B, 2018, DRUG ALCOHOL REV, V37, pS203, DOI 10.1111/dar.12617; Lavand'homme P, 2018, CURR OPIN ANESTHESIO, V31, P556, DOI 10.1097/ACO.0000000000000632; Lee JS, 2017, JAMA-J AM MED ASSOC, V317, P2013, DOI 10.1001/jama.2017.2827; Li RJ, 2018, JAMA OTOLARYNGOL, V144, P1060, DOI 10.1001/jamaoto.2018.1787; Liepert A., 2016, B AM COLL SURG, V101, P35; Lin HC, 2018, ADDICT BEHAV, V76, P348, DOI 10.1016/j.addbeh.2017.08.032; Lindenhovious ALC, 2009, J TRAUMA, V67, P160, DOI 10.1097/TA.0b013e31818c12ee; Macrae WA, 2008, BRIT J ANAESTH, V101, P77, DOI 10.1093/bja/aen099; Mars SG, 2014, INT J DRUG POLICY, V25, P257, DOI 10.1016/j.drugpo.2013.10.004; Maughan BC, 2016, DRUG ALCOHOL DEPEN, V168, P328, DOI 10.1016/j.drugalcdep.2016.08.016; MAX MB, 1990, ANN INTERN MED, V113, P885, DOI 10.7326/0003-4819-113-11-885; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; Michigan Opioid Prescribing Engagement Network, 2018, OP PRESCR REC SURG; Morden NE, 2014, MED CARE, V52, P852, DOI 10.1097/MLR.0000000000000183; Mosher HJ, 2018, J HOSP MED, V13, P243, DOI 10.12788/jhm.2930; Mudumbai SC, 2019, PAIN MED, V20, P1020, DOI 10.1093/pm/pny150; Mueller KG, 2017, ANESTH ANALG, V125, P1014, DOI 10.1213/ANE.0000000000002031; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Onishi E, 2017, J AM BOARD FAM MED, V30, P248, DOI 10.3122/jabfm.2017.02.160299; Paulozzi LJ, 2014, J AM BOARD FAM MED, V27, P329, DOI 10.3122/jabfm.2014.03.130290; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Pizzi LT, 2012, PHARMACOTHERAPY, V32, P502, DOI 10.1002/j.1875-9114.2012.01101.x; PORTENOY RK, 1986, PAIN, V25, P171, DOI 10.1016/0304-3959(86)90091-6; Portenoy RK, 1996, J LAW MED ETHICS, V24, P296, DOI 10.1111/j.1748-720X.1996.tb01871.x; PORTER J, 1980, NEW ENGL J MED, V302, P123; Prabhu M, 2017, OBSTET GYNECOL, V130, P42, DOI 10.1097/AOG.0000000000002094; Quinones S., 2016, DREAMLAND TRUE TALE; Rodgers J, 2012, J HAND SURG-AM, V37A, P645, DOI 10.1016/j.jhsa.2012.01.035; Rozet I, 2014, ANESTH ANALG, V119, P454, DOI 10.1213/ANE.0000000000000292; Schnell M, 2017, NBER WORKING PAPERS; Schoenfeld AJ, 2017, J BONE JOINT SURG AM, V99, P1247, DOI 10.2106/JBJS.16.01075; Schwenkglenks M, 2014, PAIN, V155, P1401, DOI 10.1016/j.pain.2014.04.021; Scully RE, 2018, JAMA SURG, V153, P37, DOI 10.1001/jamasurg.2017.3132; Sekhri S, 2018, ANN SURG, V268, P271, DOI 10.1097/SLA.0000000000002308; Shah A, 2017, J PAIN; Shah A, 2017, MMWR-MORBID MORTAL W, V66, P265, DOI 10.15585/mmwr.mm6610a1; Simanski CJP, 2014, PAIN MED, V15, P1222, DOI 10.1111/pme.12434; Sommer M, 2010, CLIN J PAIN, V26, P87, DOI 10.1097/AJP.0b013e3181b43d68; Steel Z, 2014, INT J EPIDEMIOL, V43, P476, DOI 10.1093/ije/dyu038; Sun EC, 2017, ANESTH ANALG, V125, P999, DOI 10.1213/ANE.0000000000001943; Sun EC, 2016, JAMA INTERN MED, V176, P1286, DOI 10.1001/jamainternmed.2016.3298; Theunissen M, 2012, CLIN J PAIN, V28, P819, DOI 10.1097/AJP.0b013e31824549d6; Thompson CA, 2017, AM J HEALTH-SYST PH, V74, P1924, DOI 10.2146/news170084; Truth Initiative, 2018, TRUTH OP; US Centers for Disease Control and Prevention National Center, 2017, RX AW; US Centers for Medicare and Medicaid Services, 2018, CMS ROADM ADDR OP EP; US National Institute on Drug Abuse, MIS PRESCR DRUGS; Volkow ND, 2011, JAMA-J AM MED ASSOC, V305, P1346, DOI 10.1001/jama.2011.369; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174; Ward EN, 2018, ANESTH ANALG, V127, P539, DOI 10.1213/ANE.0000000000003477; Webster PC, 2012, CAN MED ASSOC J, V184, pE345, DOI 10.1503/cmaj.109-4158; Winstock AR, 2014, INT J CLIN PRACT, V68, P1147, DOI 10.1111/ijcp.12429; Winstock A, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5599; Wu CL, 2011, LANCET, V377, P2215, DOI 10.1016/S0140-6736(11)60245-6; Wunsch H, 2016, JAMA-J AM MED ASSOC, V315, P1654, DOI 10.1001/jama.2016.0130; Yu SY, 2017, J GLOB ONCOL, V3, P583, DOI 10.1200/JGO.2016.005686; Zivin K, 2019, PAIN MED, V20, P103, DOI 10.1093/pm/pnx304	131	169	170	2	30	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 13	2019	393	10180					1547	1557		10.1016/S0140-6736(19)30428-3	http://dx.doi.org/10.1016/S0140-6736(19)30428-3			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HU0DA	30983590	Green Accepted			2023-01-03	WOS:000464940400031
J	Veasey, SC; Rosen, IM				Veasey, Sigrid C.; Rosen, Ilene M.			Obstructive Sleep Apnea in Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITIVE AIRWAY PRESSURE; BLOOD-PRESSURE; CARDIOVASCULAR EVENTS; AMERICAN ACADEMY; ORAL APPLIANCE; WEIGHT-LOSS; FOLLOW-UP; RISK; CPAP; ADHERENCE	Obstructive sleep apnea is common and is associated with daytime sleepiness and increased risks of motor vehicle accidents and cardiovascular disease. CPAP is considered first-line therapy for symptomatic or moderate-to-severe obstructive sleep apnea; mandibular-advancement devices and various surgical options are other approaches.	[Veasey, Sigrid C.; Rosen, Ilene M.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Veasey, SC (corresponding author), Univ Penn, Translat Res Lab, Rm 2115,125 S 31st St, Philadelphia, PA 19104 USA.	veasey@pennmedicine.upenn.edu						Andren A, 2013, SLEEP BREATH, V17, P705, DOI 10.1007/s11325-012-0746-7; [Anonymous], 2009, PLOS MED, V6, pS1; Barbe F, 2012, JAMA-J AM MED ASSOC, V307, P2161, DOI 10.1001/jama.2012.4366; BAYLISS DA, 1987, P NATL ACAD SCI USA, V84, P7788, DOI 10.1073/pnas.84.21.7788; Caples SM, 2010, SLEEP, V33, P1396, DOI 10.1093/sleep/33.10.1396; Chirinos JA, 2014, NEW ENGL J MED, V370, P2265, DOI 10.1056/NEJMoa1306187; Dempsey JA, 2010, PHYSIOL REV, V90, P47, DOI 10.1152/physrev.00043.2008; Dixon JB, 2012, JAMA-J AM MED ASSOC, V308, P1142, DOI 10.1001/2012.jama.11580; Drager LF, 2013, J AM COLL CARDIOL, V62, P569, DOI 10.1016/j.jacc.2013.05.045; Epstein LJ, 2009, J CLIN SLEEP MED, V5, P263; Faccenda JF, 2001, AM J RESP CRIT CARE, V163, P344, DOI 10.1164/ajrccm.163.2.2005037; Gami AS, 2013, J AM COLL CARDIOL, V62, P610, DOI 10.1016/j.jacc.2013.04.080; George CFP, 2001, THORAX, V56, P508, DOI 10.1136/thorax.56.7.508; Holmes TH, 2017, SLEEP MED, V37, P130, DOI 10.1016/j.sleep.2017.06.022; Hudgel DW, 2018, AM J RESP CRIT CARE, V198, pE70, DOI [10.1164/rccm.201807-1326ST, 10.1164/rccm.201807-1326st]; Kapur VK, 2017, J CLIN SLEEP MED, V13, P479, DOI 10.5664/jcsm.6506; Kushida CA, 2012, SLEEP, V35, P1593, DOI 10.5665/sleep.2226; Lettieri CJ, 2009, ANN INTERN MED, V151, P696, DOI 10.7326/0003-4819-151-10-200911170-00006; Lin TY, 2017, SLEEP MED, V36, P165, DOI 10.1016/j.sleep.2016.12.029; Liu PY, 2003, J CLIN ENDOCR METAB, V88, P3605, DOI 10.1210/jc.2003-030236; Martinez-Garcia MA, 2013, JAMA-J AM MED ASSOC, V310, P2407, DOI 10.1001/jama.2013.281250; McEvoy RD, 2016, NEW ENGL J MED, V375, P919, DOI 10.1056/NEJMoa1606599; Mehra R, 2006, AM J RESP CRIT CARE, V173, P910, DOI 10.1164/rccm.200509-1442OC; Myhill PC, 2012, J CLIN ENDOCR METAB, V97, P4212, DOI 10.1210/jc.2012-2107; Nadeem R, 2014, J CLIN SLEEP MED, V10, P475, DOI 10.5664/jcsm.3690; Ozcan KM, 2014, EUR ARCH OTO-RHINO-L, V271, P2937, DOI 10.1007/s00405-014-2962-1; Pepin JLD, 2018, J CLIN SLEEP MED, V14, P57, DOI 10.5664/jcsm.6880; Peppard PE, 2013, AM J EPIDEMIOL, V177, P1006, DOI 10.1093/aje/kws342; Peromaa-Haavisto P, 2017, SLEEP MED, V35, P85, DOI 10.1016/j.sleep.2016.12.017; Phillips CL, 2013, AM J RESP CRIT CARE, V187, P879, DOI 10.1164/rccm.201212-2223OC; Pliska BT, 2014, J CLIN SLEEP MED, V10, P1285, DOI 10.5664/jcsm.4278; Redline S, 2010, AM J RESP CRIT CARE, V182, P269, DOI 10.1164/rccm.200911-1746OC; Richards D, 2007, SLEEP, V30, P635, DOI 10.1093/sleep/30.5.635; Rosen IM, 2018, J CLIN SLEEP MED, V14, P2075, DOI 10.5664/jcsm.7540; Ruehland WR, 2009, SLEEP, V32, P150, DOI 10.1093/sleep/32.2.150; Sarbjit G, 2018, J AM HEART ASSOC, V7, pe286, DOI 10.1002/WENE.286; Shah N, 2009, CLIN CHEST MED, V30, P455, DOI 10.1016/j.ccm.2009.05.012; Siccoli MM, 2008, SLEEP, V31, P1551, DOI 10.1093/sleep/31.11.1551; Somers V K, 1992, Clin Auton Res, V2, P171, DOI 10.1007/BF01818958; Somers VK, 2008, CIRCULATION, V118, P1080, DOI 10.1161/CIRCULATIONAHA.107.189375; Stone KL, 2016, SLEEP, V39, P531, DOI 10.5665/sleep.5520; Taranto-Montemurro L, 2018, AM J RESPIR CRIT CAR; Tasali Esra, 2008, Proc Am Thorac Soc, V5, P207, DOI 10.1513/pats.200708-139MG; Tomfohr LM, 2011, SLEEP, V34, P121, DOI 10.1093/sleep/34.1.121; Turan O, 2018, CLIN RESPIR J, V12, P1003, DOI 10.1111/crj.12618; Wang LU, 2017, SLEEP MED, V36, P44, DOI 10.1016/j.sleep.2017.04.016; Woodson BT, 2018, OTOLARYNG HEAD NECK, V159, P194, DOI 10.1177/0194599818762383; Xie J, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.003162; Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080; Young T, 2005, J APPL PHYSIOL, V99, P1592, DOI 10.1152/japplphysiol.00587.2005; Young T, 2008, SLEEP, V31, P1071; Young Terry, 2009, WMJ, V108, P246	52	165	175	8	63	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 11	2019	380	15					1442	1449		10.1056/NEJMcp1816152	http://dx.doi.org/10.1056/NEJMcp1816152			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT5NG	30970189				2023-01-03	WOS:000464610000011
J	Byrne, JJ; Spong, CY				Byrne, John J.; Spong, Catherine Y.			"Is It Safe?" - The Many Unanswered Questions about Medications and Breast-Feeding	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Byrne, John J.; Spong, Catherine Y.] Univ Texas Southwestern Med Ctr Dallas, Dept Obstet & Gynecol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Byrne, JJ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Obstet & Gynecol, Dallas, TX 75390 USA.							Centers for Disease Control and Prevention, 2018, BREASTF REP CARD US; Morgan JL, 2018, PREGNANCY HYPERTENS, V11, P77, DOI 10.1016/j.preghy.2018.01.002; National Institute of Child Health and Human Development, 2018, TASK FORC RES SPEC P; Saha MR, 2015, INT BREASTFEED J, V10, DOI 10.1186/s13006-015-0053-6	4	20	21	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 4	2019	380	14					1296	1297		10.1056/NEJMp1817420	http://dx.doi.org/10.1056/NEJMp1817420			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HR8DR	30943334				2023-01-03	WOS:000463386900003
J	Hardon, A; Pell, C; Taqueban, E; Narasimhan, M				Hardon, Anita; Pell, Christopher; Taqueban, Efenita; Narasimhan, Manjulaa			Sexual and reproductive self care among women and girls: insights from ethnographic studies	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PHARMACEUTICALS		[Hardon, Anita; Pell, Christopher] Univ Amsterdam, Ctr Social Sci & Global Hlth, Amsterdam, Netherlands; [Hardon, Anita; Pell, Christopher] Amsterdam Inst Global Hlth & Dev, Amsterdam, Netherlands; [Taqueban, Efenita] Univ Philippines, Dept Anthropol, Quezon City, Philippines; [Narasimhan, Manjulaa] World Hlth Org, Reprod Hlth & Res, Geneva, Switzerland	University of Amsterdam; University of the Philippines System; University of the Philippines Diliman; World Health Organization	Hardon, A (corresponding author), Univ Amsterdam, Ctr Social Sci & Global Hlth, Amsterdam, Netherlands.; Hardon, A (corresponding author), Amsterdam Inst Global Hlth & Dev, Amsterdam, Netherlands.	a.p.hardon@uva.nl		Narasimhan, Manjulaa/0000-0003-0598-6887; Hardon, Anita/0000-0002-2761-5502				BLEDSOE CH, 1985, SOC SCI MED, V21, P275, DOI 10.1016/0277-9536(85)90101-7; Boonmongkon P, 2001, SOC SCI MED, V53, P1095, DOI 10.1016/S0277-9536(00)00404-4; Both R, 2015, REPROD HEALTH MATTER, V23, P58, DOI 10.1016/j.rhm.2015.06.005; Both R, 2013, SOCIOL COMPASS, V7, P751, DOI 10.1111/soc4.12066; Both R, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/s12905-014-0134-5; Chandra-Mouli V, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0293-6; Daoud F, 2016, ABORTION PILLS, TEST TUBE BABIES, AND SEX TOYS: EMERGING SEXUAL AND REPRODUCTIVE TECHNOLOGIES IN THE MIDDLE EAST AND NORTH AFRICA, P58; de Tolly KM, 2014, JMIR MHEALTH UHEALTH, V2, DOI 10.2196/mhealth.3165; De Zordo S, 2016, HIST CIENC SAUDE-MAN, V23, P19, DOI 10.1590/S0104-59702016000100003; HAAK H, 1988, LANCET, V2, P620; Handayani L, 2001, TRADITIONAL MED ASIA, P47; Hardon A., 2012, TECHNOLOGIES SEXUALI, P71; Hardon A, 2017, ANNU REV ANTHROPOL, V46, P117, DOI 10.1146/annurev-anthro-102116-041539; Hardon A, 2015, ANTHROPOL MED, V22, P49, DOI 10.1080/13648470.2015.1010114; Hardon A, 2014, ANTHROPOL MED, V21, P217, DOI 10.1080/13648470.2014.927417; Hardon A, 2008, J ETHNOBIOL ETHNOMED, V4, DOI 10.1186/1746-4269-4-16; Huber Machteld, 2011, BMJ, V343, pd4163, DOI 10.1136/bmj.d4163; Kleinman A., 1980, PATIENTS HEALERS CON, V3; Kumar A, 2011, SOC WORK PUBLIC HLTH, V26, P594, DOI 10.1080/19371918.2010.525144; Montgomery CM, 2010, CULT HEALTH SEX, V12, P649, DOI 10.1080/13691051003736261; Narasimhan M, 2018, LANCET GLOB HEALTH, V6, pE1058, DOI 10.1016/S2214-109X(18)30316-4; Petitet PH, 2018, GLOB PUBLIC HEALTH, V13, P692, DOI 10.1080/17441692.2017.1354228; Price A., 2014, LOW COST FEMININE HY; Shoveller J, 2007, PERSPECT SEX REPRO H, V39, P13, DOI 10.1363/3901307; Starrs AM, 2018, LANCET, V391, P2642, DOI 10.1016/S0140-6736(18)30293-9; Taqueban EMM, 2013, PHILIPP SOC SCI REV, V65; Van der Sijpt E., 2011, AMBIGUOUS AMBITIONS; van Eijk AM, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010290; Whyte SR, 2002, SOCIAL LIVES MED; World Health Organization, 2015, HLTH WORK ROL PROV S	30	8	8	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	2019	365								l1333	10.1136/bmj.l1333	http://dx.doi.org/10.1136/bmj.l1333			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HS6TL	30936060	Green Published, hybrid			2023-01-03	WOS:000464004100006
J	Poteet, E; Liu, DL; Liang, ZD; Van Buren, G; Chen, CY; Yao, QZ				Poteet, Ethan; Liu, Dongliang; Liang, Zhengdong; Van Buren, George; Chen, Changyi; Yao, Qizhi			Mesothelin and TGF-alpha predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib	PLOS ONE			English	Article							EPIDERMAL-GROWTH-FACTOR; FACTOR RECEPTOR INHIBITORS; MESENCHYMAL TRANSITION; PHASE-III; ANTITUMOR-ACTIVITY; GEFITINIB ZD1839; LUNG; GEMCITABINE; IRESSA; ERLOTINIB	Clinical trials of EGFR inhibitors in combination with gemcitabine for the treatment of pancreatic ductal adenocarcinoma (PDAC) have generated mixed results partially due to the poorly defined effectiveness of EGFR inhibitors in PDAC. Here, we studied a panel of PDAC cell lines to compare the IC50s of the EGFR inhibitors gefitinib and cetuximab. We found that gefitinib induced biphasic inhibition in over 50% of PDAC cells, with the initial growth inhibition occurring at nanomolar concentrations and a second growth inhibition occurring outside the clinical range. In contrast to gefitinib, cetuximab produced a single phase growth inhibition in a subset of PDAC cells. Using this sensitivity data, we screened for correlations between cell morphology proteins and EGFR ligands to EGFR inhibitor sensitivity, and found that mesothelin and the EGFR ligand TGF-alpha have a strong correlation to gefitinib and cetuximab sensitivity. Analysis of downstream signaling pathways indicated that plc-gamma 1 and c-myc were consistently inhibited by EGFR inhibitor treatment in sensitive cell lines. While an inconsistent additive effect was observed with either cetuximab or gefitinib in combination with gemcitabine, the cell pathway data indicated consistent ERK activation, leading us to pursue EGFR inhibitors in combination with trametinib, a MEK1/2 inhibitor. Both cetuximab and gefitinib in combination with trametinib produced an additive effect in all EGFR sensitive cell lines. Our results indicate that mesothelin and TGF-alpha can predict PDAC sensitivity to EGFR inhibitors and a combination of EGFR inhibitors with trametinib could be a novel effective treatment for PDAC.	[Poteet, Ethan; Liu, Dongliang; Liang, Zhengdong; Van Buren, George; Chen, Changyi; Yao, Qizhi] Baylor Coll Med, Michael E DeBakey Dept Surg, Div Surg Res, Houston, TX 77030 USA; [Yao, Qizhi] Michael E DeBakey VA Med Ctr, Ctr Translat Res Inflammatory Dis, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Yao, QZ (corresponding author), Baylor Coll Med, Michael E DeBakey Dept Surg, Div Surg Res, Houston, TX 77030 USA.; Yao, QZ (corresponding author), Michael E DeBakey VA Med Ctr, Ctr Translat Res Inflammatory Dis, Houston, TX 77030 USA.	qizhiyao@bcm.edu	Liu, Dongliang/AAP-6335-2021; Liu, Dongliang/AAM-9595-2021	Liu, Dongliang/0000-0001-5843-5451; Liu, Dongliang/0000-0001-5843-5451; Yao, Cathy/0000-0002-2267-0588	Michael E. DeBakey Department of Surgery Faculty Research Seed Grant from BCM; Dan Duncan Cancer Center Seed Fund from BCM; NIH [P30 AI036211, P30 CA125123, S10 RR024574, R01 CA183984]; Cytometry and Cell Sorting Core at Baylor College of Medicine; NATIONAL CANCER INSTITUTE [R01CA183984, P30CA125123] Funding Source: NIH RePORTER	Michael E. DeBakey Department of Surgery Faculty Research Seed Grant from BCM; Dan Duncan Cancer Center Seed Fund from BCM; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cytometry and Cell Sorting Core at Baylor College of Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This project was partially supported by Michael E. DeBakey Department of Surgery Faculty Research Seed Grant from BCM (PI: Poteet), Dan Duncan Cancer Center Seed Fund from BCM and NIH R01 CA183984 (PI: Yao). We gratefully acknowledge support from the Cytometry and Cell Sorting Core at Baylor College of Medicine with funding from the NIH (P30 AI036211, P30 CA125123, and S10 RR024574). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali S, 2005, MOL CANCER THER, V4, P1943, DOI 10.1158/1535-7163.MCT-05-0065; Argani P, 2001, CLIN CANCER RES, V7, P3862; Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Bharadwaj U, 2016, ONCOTARGET, V7, P26307, DOI 10.18632/oncotarget.8368; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Bill HM, 2004, MOL CELL BIOL, V24, P8586, DOI 10.1128/MCB.24.19.8586-8599.2004; Buck E, 2007, MOL CANCER THER, V6, P532, DOI 10.1158/1535-7163.MCT-06-0462; Buck E, 2006, MOL CANCER THER, V5, P2676, DOI 10.1158/1535-7163.MCT-06-0166; Chang AY, 2013, ANTI-CANCER DRUG, V24, P251, DOI 10.1097/CAD.0b013e32835ba289; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; Cohen MH, 2004, CLIN CANCER RES, V10, P1212, DOI 10.1158/1078-0432.CCR-03-0564; Conradt L, 2011, NEOPLASIA, V13, P1026, DOI 10.1593/neo.111016; De Cesare M, 2014, CLIN CANCER RES, V20, P995, DOI 10.1158/1078-0432.CCR-13-1684; Deer EL, 2010, PANCREAS, V39, P425, DOI 10.1097/MPA.0b013e3181c15963; Diep CH, 2011, CLIN CANCER RES, V17, P2744, DOI 10.1158/1078-0432.CCR-10-2214; Doody JF, 2007, MOL CANCER THER, V6, P2642, DOI 10.1158/1535-7163.MCT-06-0506; Frederick BA, 2007, MOL CANCER THER, V6, P1683, DOI 10.1158/1535-7163.MCT-07-0138; Hayes TK, 2016, CANCER CELL, V29, P75, DOI 10.1016/j.ccell.2015.11.011; Helfrich BA, 2006, CLIN CANCER RES, V12, P7117, DOI 10.1158/1078-0432.CCR-06-0760; Hotz B, 2012, GASTRIC CANCER, V15, P252, DOI 10.1007/s10120-011-0102-9; Kaneko O, 2009, J BIOL CHEM, V284, P3739, DOI 10.1074/jbc.M806776200; Ko AH, 2016, CLIN CANCER RES, V22, P61, DOI 10.1158/1078-0432.CCR-15-0979; Li M, 2008, MOL CANCER THER, V7, P286, DOI 10.1158/1535-7163.MCT-07-0483; Liston DR, 2017, CLIN CANCER RES, V23, P3489, DOI 10.1158/1078-0432.CCR-16-3083; Lo HW, 2006, BREAST CANCER RES TR, V95, P211, DOI 10.1007/s10549-005-9011-0; Miyabayashi K, 2013, CANCER RES, V73, P2221, DOI 10.1158/0008-5472.CAN-12-1453; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Morgan MA, 2008, CLIN CANCER RES, V14, P5142, DOI 10.1158/1078-0432.CCR-07-4072; Mukohara T, 2005, JNCI-J NATL CANCER I, V97, P1185, DOI 10.1093/jnci/dji238; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Oda K, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100014; Ono M, 2004, MOL CANCER THER, V3, P465; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Philip PA, 2010, J CLIN ONCOL, V28, P3605, DOI 10.1200/JCO.2009.25.7550; Pino MS, 2006, CANCER RES, V66, P3802, DOI 10.1158/0008-5472.CAN-05-3753; PLUNKETT W, 1995, SEMIN ONCOL, V22, P3; RAN W, 1986, P NATL ACAD SCI USA, V83, P8216, DOI 10.1073/pnas.83.21.8216; Rao TD, 2017, ACS CHEM BIOL, V12, P2085, DOI 10.1021/acschembio.7b00305; Seshacharyulu P, 2012, EXPERT OPIN THER TAR, V16, P15, DOI 10.1517/14728222.2011.648617; Sinn M, 2017, J CLIN ONCOL, V35, P3330, DOI 10.1200/JCO.2017.72.6463; Todorova MG, 2009, CELL SIGNAL, V21, P523, DOI 10.1016/j.cellsig.2008.12.005; Wakeling AE, 2002, CANCER RES, V62, P5749; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; Zhang S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068303	45	5	5	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2019	14	3							e0213294	10.1371/journal.pone.0213294	http://dx.doi.org/10.1371/journal.pone.0213294			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ7IR	30921351	Green Published, gold, Green Submitted			2023-01-03	WOS:000462594000015
J	[Anonymous]				[Anonymous]			Comparing the Effectiveness of Depression Treatments for Patients Undergoing Maintenance Hemodialysis	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 19	2019	170	6					JC25	JC25		10.7326/P19-0001	http://dx.doi.org/10.7326/P19-0001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP1ZR	30802906				2023-01-03	WOS:000461468300002
J	Jiang, Y; Sun, AH; Zhao, Y; Ying, WT; Sun, HC; Yang, XR; Xing, BC; Sun, W; Ren, LL; Hu, B; Li, CY; Zhang, L; Qin, GR; Zhang, MH; Chen, N; Zhang, ML; Huang, Y; Zhou, JN; Zhao, Y; Liu, MW; Zhu, XD; Qiu, Y; Sun, YJ; Huang, C; Yan, M; Wang, MC; Liu, W; Tian, F; Xu, HL; Zhou, J; Wu, ZY; Shi, TL; Zhu, WM; Qin, J; Xie, L; Fan, J; Qian, XH; He, FC; Zhu, YP; Wang, Y; Yang, D; Liu, WL; Liu, QM; Yang, XM; Zhen, B; Wu, ZY; Fan, J; Sun, HC; Qian, JY; Hong, T; Shen, L; Xing, BC; Yang, PY; Shen, HL; Zhang, LJ; Cheng, SJ; Cai, JQ; Zhao, XH; Sun, YL; Xiao, T; Mao, YS; Chen, XM; Wu, D; Chen, L; Dong, J; Deng, HT; Tan, MJ; Wu, ZX; Zhao, QC; Shen, ZY; Chen, XG; Gao, YH; Sun, W; Wang, T; Liu, SQ; Lin, L; Zi, J; Lou, XM; Zeng, R; Wu, Y; Cai, SJ; Jiang, B; Chen, AQ; Li, ZJ; Yang, FQ; Chen, XL; Sun, YN; Wang, QL; Zhang, Y; Wang, GS; Chen, ZC; Qin, WS; Li, ZS				Jiang, Ying; Sun, Aihua; Zhao, Yang; Ying, Wantao; Sun, Huichuan; Yang, Xinrong; Xing, Baocai; Sun, Wei; Ren, Liangliang; Hu, Bo; Li, Chaoying; Zhang, Li; Qin, Guangrong; Zhang, Menghuan; Chen, Ning; Zhang, Manli; Huang, Yin; Zhou, Jinan; Zhao, Yan; Liu, Mingwei; Zhu, Xiaodong; Qiu, Yang; Sun, Yanjun; Huang, Cheng; Yan, Meng; Wang, Mingchao; Liu, Wei; Tian, Fang; Xu, Huali; Zhou, Jian; Wu, Zhenyu; Shi, Tieliu; Zhu, Weimin; Qin, Jun; Xie, Lu; Fan, Jia; Qian, Xiaohong; He, Fuchu; Zhu, Yunping; Wang, Yi; Yang, Dong; Liu, Wanlin; Liu, Qiongming; Yang, Xiaoming; Zhen, Bei; Wu, Zhenyu; Fan, Jia; Sun, Huichuan; Qian, Juying; Hong, Tao; Shen, Lin; Xing, Baocai; Yang, Pengyuan; Shen, Huali; Zhang, Lijuan; Cheng, Shujun; Cai, Jianqiang; Zhao, Xiaohang; Sun, Yulin; Xiao, Ting; Mao, Yousheng; Chen, Xiangmei; Wu, Di; Chen, Lin; Dong, Jun; Deng, Haiteng; Tan, Minjia; Wu, Zhixing; Zhao, Qingchuan; Shen, Zhongyang; Chen, Xinguo; Gao, Youhe; Sun, Wei; Wang, Tong; Liu, Siqi; Lin, Liang; Zi, Jin; Lou, Xiaomin; Zeng, Rong; Wu, Yi; Cai, Sanjun; Jiang, Bo; Chen, Anqing; Li, Zijian; Yang, Fuquan; Chen, Xiulan; Sun, Yuna; Wang, Quanli; Zhang, Yi; Wang, Guangshun; Chen, Zhuchu; Qin, Weisong; Li, Zesong		Chinese Human Proteome Project C	Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma	NATURE			English	Article							GENOMIC CHARACTERIZATION; GENE; PATHWAY; CLASSIFICATION; FRACTIONATION; METASTASIS; ACTIVATION; ENRICHMENT; PREDICTION; MUTATIONS	Hepatocellular carcinoma is the third leading cause of deaths from cancer worldwide. Infection with the hepatitis B virus is one of the leading risk factors for developing hepatocellular carcinoma, particularly in East Asia(1). Although surgical treatment may be effective in the early stages, the five-year overall rate of survival after developing this cancer is only 50-70%(2). Here, using proteomic and phospho-proteomic profiling, we characterize 110 paired tumour and non-tumour tissues of clinical early-stage hepatocellular carcinoma related to hepatitis B virus infection. Our quantitative proteomic data highlight heterogeneity in early-stage hepatocellular carcinoma: we used this to stratify the cohort into the subtypes S-I, S-II and S-III, each of which has a different clinical outcome. S-III, which is characterized by disrupted cholesterol homeostasis, is associated with the lowest overall rate of survival and the greatest risk of a poor prognosis after first-line surgery. The knockdown of sterol O-acyltransferase 1 (SOAT1)-high expression of which is a signature specific to the S-III subtype-alters the distribution of cellular cholesterol, and effectively suppresses the proliferation and migration of hepatocellular carcinoma. Finally, on the basis of a patient-derived tumour xenograft mouse model of hepatocellular carcinoma, we found that treatment with avasimibe, an inhibitor of SOAT1, markedly reduced the size of tumours that had high levels of SOAT1 expression. The proteomic stratification of early-stage hepatocellular carcinoma presented in this study provides insight into the tumour biology of this cancer, and suggests opportunities for personalized therapies that target it.	[Jiang, Ying; Sun, Aihua; Zhao, Yang; Ying, Wantao; Sun, Wei; Ren, Liangliang; Li, Chaoying; Chen, Ning; Zhang, Manli; Huang, Yin; Zhou, Jinan; Zhao, Yan; Liu, Mingwei; Qiu, Yang; Sun, Yanjun; Yan, Meng; Wang, Mingchao; Tian, Fang; Xu, Huali; Wu, Zhenyu; Zhu, Weimin; Qin, Jun; Qian, Xiaohong; He, Fuchu; Zhu, Yunping; Wang, Yi; Yang, Dong; Liu, Wanlin; Liu, Qiongming; Yang, Xiaoming; Zhen, Bei; Wu, Zhenyu] Beijing Inst Life, State Key Lab Prote, Beijing Proteome Res Ctr, Natl Ctr Prot Sci Beijing, Beijing, Peoples R China; [Zhao, Yang; Qian, Xiaohong] Beijing Univ Technol, Coll Life Sci & Bioengn, Beijing, Peoples R China; [Sun, Huichuan; Yang, Xinrong; Hu, Bo; Zhu, Xiaodong; Zhou, Jian; Fan, Jia; Fan, Jia; Sun, Huichuan; Qian, Juying; Hong, Tao] Fudan Univ, Liver Canc Inst, Dept Liver Surg & Transplantat, Shanghai, Peoples R China; [Yang, Xinrong; Hu, Bo; Zhu, Xiaodong; Zhou, Jian; Fan, Jia; Fan, Jia; Sun, Huichuan; Qian, Juying; Hong, Tao] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China; [Xing, Baocai; Liu, Wei; Shen, Lin; Xing, Baocai] Peking Univ, Canc Hosp & Inst, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China; [Zhang, Li; Shi, Tieliu] East China Normal Univ, Sch Life Sci, Ctr Bioinformat & Computat Biol, Shanghai, Peoples R China; [Zhang, Li; Shi, Tieliu] East China Normal Univ, Inst Biomed Sci, Sch Life Sci, Shanghai, Peoples R China; [Qin, Guangrong; Zhang, Menghuan; Xie, Lu] Shanghai Acad Sci & Technol, Shanghai Ctr Bioinformat Technol, Shanghai, Peoples R China; [Yang, Pengyuan; Shen, Huali; Zhang, Lijuan] Fudan Univ, Shanghai Med Sch, Dept Chem, Shanghai, Peoples R China; [Yang, Pengyuan; Shen, Huali; Zhang, Lijuan] Fudan Univ, Inst Biomed Sci, Shanghai Med Sch, Shanghai, Peoples R China; [Cheng, Shujun; Cai, Jianqiang; Zhao, Xiaohang; Sun, Yulin; Xiao, Ting; Mao, Yousheng] Chinese Acad Med Sci & Peking Union Med, Canc Hosp, Beijing, Peoples R China; [Chen, Xiangmei; Wu, Di; Chen, Lin; Dong, Jun] Chinese Peoples Liberat Army, Gen Hosp, Beijing, Peoples R China; [Deng, Haiteng] Tsinghua Univ, Sch Life Sci, MOE Key Lab Bioinformat, Beijing, Peoples R China; [Tan, Minjia; Wu, Zhixing] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China; [Zhao, Qingchuan] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian, Shaanxi, Peoples R China; [Shen, Zhongyang; Chen, Xinguo] Chinese Peoples Armed Police Force, Gen Hosp, Beijing, Peoples R China; [Gao, Youhe; Sun, Wei] Chinese Acad Med Sci, Inst Basic Med Sci, Beijing, Peoples R China; [Wang, Tong] Jinan Univ, Coll Life Sci & Technol, Guangzhou, Guangdong, Peoples R China; [Liu, Siqi; Lin, Liang; Zi, Jin] BGI Shenzhen, Shenzhen, Peoples R China; [Lou, Xiaomin] Chinese Acad Sci, Beijing Inst Genom, Beijing, Peoples R China; [Zeng, Rong] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai, Peoples R China; [Cai, Sanjun] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China; [Jiang, Bo] Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China; [Li, Zijian] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai, Peoples R China; [Yang, Fuquan; Chen, Xiulan; Sun, Yuna] Peking Univ, Hosp 3, Beijing, Peoples R China; [Wang, Quanli] Chinese Acad Sci, Inst Biophys, Beijing, Peoples R China; [Zhang, Yi] Chinese Peoples Liberat Army, Hosp 307, Beijing, Peoples R China; [Wang, Guangshun] Capital Med Univ, Xuanwu Hosp, Beijing, Peoples R China; [Chen, Zhuchu] Tianjin Baodi Hosp, Tianjin, Peoples R China; [Qin, Weisong] Cent South Univ, Xiangya Hosp, Chinese Minist Hlth, Key Lab Canc Prote, Changsha, Hunan, Peoples R China; [Li, Zesong] Nanjing Mil Area Command, Nanjing Gen Hosp, Nanjing, Jiangsu, Peoples R China; Shenzhen Second Peoples Hosp, Shenzhen, Peoples R China	Beijing University of Technology; Fudan University; Fudan University; Peking University; East China Normal University; East China Normal University; Chinese Academy of Sciences; Fudan University; Fudan University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese People's Liberation Army General Hospital; Tsinghua University; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Air Force Military Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Jinan University; Beijing Genomics Institute (BGI); Chinese Academy of Sciences; Beijing Institute of Genomics, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Fudan University; Southern Medical University - China; Shanghai Jiao Tong University; Peking University; Chinese Academy of Sciences; Institute of Biophysics, CAS; Capital Medical University; Central South University; Nanjing General Hospital; Second People's Hospital of Shenzhen	Qian, XH; He, FC (corresponding author), Beijing Inst Life, State Key Lab Prote, Beijing Proteome Res Ctr, Natl Ctr Prot Sci Beijing, Beijing, Peoples R China.; Qian, XH (corresponding author), Beijing Univ Technol, Coll Life Sci & Bioengn, Beijing, Peoples R China.; Fan, J (corresponding author), Fudan Univ, Liver Canc Inst, Dept Liver Surg & Transplantat, Shanghai, Peoples R China.; Fan, J (corresponding author), Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China.	fan.jia@zs-hospital.sh.cn; qianxh1@163.com; hefc@nic.bmi.ac.cn	Tan, Minjia/C-4491-2014; Zhang, Li/X-7956-2019; Wang, Tong/A-2750-2011; dong, wang/T-9093-2019; Mao, Yousheng/T-7200-2018	Tan, Minjia/0000-0002-6784-9653; Wang, Tong/0000-0002-5980-3380; Xie, Lu/0000-0001-7541-2243; Zhang, Li/0000-0003-0665-8885; Sun, Hui-Chuan/0000-0003-3761-7058; QIN, GUANGRONG/0000-0001-8836-1246; Mao, Yousheng/0000-0003-1120-241X; Deng, Haiteng/0000-0001-9496-1280; Sun, Aihua/0000-0001-7931-6662; Yang, Xin-Rong/0000-0002-2716-9338; He, Fuchu/0000-0002-8571-2351; Zhao, Yang/0000-0003-1444-5927	Chinese Human Proteome Project; Chinese State Key Projects for Basic Research (973 Program) [2014CBA02001]; National Key R&D Program of China [2016YFC0902400, 2017YFC0906603, 2018YFA0507502, 2016YFF0101405, 2013ZX10002009, 2009ZX09503-002]; Program of International ST Cooperation [2014DFB30020,2014DFB30030, 2014DFB30010, 2009DFB33070, 2010DFA31260]; National Natural Science Foundation of China [81770581, 81570526, 81772551, 81802364, 8153077, 81672839, 81572823, 81772578, 81123001]; Beijing Science and Technology Project [Z161100002616036]; Shanghai 111 Project [B14019]; Innovation project [16CXZ027]	Chinese Human Proteome Project; Chinese State Key Projects for Basic Research (973 Program); National Key R&D Program of China; Program of International ST Cooperation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Science and Technology Project; Shanghai 111 Project; Innovation project	This work was supported by Chinese Human Proteome Project, and partially supported by Chinese State Key Projects for Basic Research (973 Program) (no. 2014CBA02001), National Key R&D Program of China (no. 2016YFC0902400, 2017YFC0906603, 2018YFA0507502, 2016YFF0101405, 2013ZX10002009 and 2009ZX09503-002), Program of International S&T Cooperation (no. 2014DFB30020,2014DFB30030, 2014DFB30010, 2009DFB33070 and 2010DFA31260), National Natural Science Foundation of China (no. 81770581, 81570526, 81772551, 81802364, 8153077, 81672839, 81572823, 81772578, 8153077 and 81123001), Innovation project (16CXZ027), Beijing Science and Technology Project (Z161100002616036) and Shanghai 111 Project (B14019). We acknowledge the assistance of Z. Jin and P. Zhang for the immune-related data analyses, and C. Chang for the method development and evaluation of the missing-value imputing analyses (National Center for Protein Sciences (Beijing)). We thank L. Shen, W. Xue and Z. Li (Cancer Hospital & Institute, Peking University) for their examination of tumour cellularity and immune-cell infiltration; and B. Zhen, L. Tang and Y. Wang (State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics) for scientific management.	Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Brunet JP, 2004, P NATL ACAD SCI USA, V101, P4164, DOI 10.1073/pnas.0308531101; Chiang DY, 2008, CANCER RES, V68, P6779, DOI 10.1158/0008-5472.CAN-08-0742; Coulouarn C, 2008, HEPATOLOGY, V47, P2059, DOI 10.1002/hep.22283; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2; Fraley C, 2002, J AM STAT ASSOC, V97, P611, DOI 10.1198/016214502760047131; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; HARTIGAN JA, 1985, ANN STAT, V13, P70, DOI 10.1214/aos/1176346577; Ho DWH, 2017, GUT, V66, P1496, DOI 10.1136/gutjnl-2016-312734; Hoshida Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015543; Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089; Hua X, 2013, AM J HUM GENET, V93, P439, DOI 10.1016/j.ajhg.2013.07.003; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kim PM, 2003, GENOME RES, V13, P1706, DOI 10.1101/gr.903503; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lachenmayer A, 2012, CLIN CANCER RES, V18, P4997, DOI 10.1158/1078-0432.CCR-11-2322; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li J, 2016, ONCOGENE, V35, P6378, DOI 10.1038/onc.2016.168; Li JW, 2013, BIOINFORMATICS, V29, P649, DOI 10.1093/bioinformatics/btt011; Llovet JM, 2015, NAT REV CLIN ONCOL, V12, P408, DOI [10.1038/nrclinonc.2015.103, 10.1038/nrclinonc.2015.121]; Ma J, 2019, NUCLEIC ACIDS RES, V47, pD1211, DOI 10.1093/nar/gky869; Mayakonda A, 2018, GENOME RES, V28, P1747, DOI 10.1101/gr.239244.118; Milacic Marija, 2012, Cancers (Basel), V4, P1180, DOI 10.3390/cancers4041180; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Pande G, 2000, CURR OPIN CELL BIOL, V12, P569, DOI 10.1016/S0955-0674(00)00133-2; Pascual-Montano A, 2006, IEEE T PATTERN ANAL, V28, P403, DOI 10.1109/TPAMI.2006.60; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; R Core Team, 2012, R LANG ENV STAT COMP; Rappsilber J, 2007, NAT PROTOC, V2, P1896, DOI 10.1038/nprot.2007.261; Ren LL, 2018, J PROTEOME RES, V17, P710, DOI 10.1021/acs.jproteome.7b00520; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Shimano H, 2017, NAT REV ENDOCRINOL, V13, P710, DOI 10.1038/nrendo.2017.91; Sia D, 2017, GASTROENTEROLOGY, V153, P812, DOI 10.1053/j.gastro.2017.06.007; Smyth GK., 2004, STAT APPL GENET MOL, V3, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Sohn BH, 2016, CLIN CANCER RES, V22, P1256, DOI 10.1158/1078-0432.CCR-15-1447; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Tornesello ML, 2013, GENOMICS, V102, P74, DOI 10.1016/j.ygeno.2013.04.001; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Vorkas PA, 2015, ANAL CHEM, V87, P4184, DOI 10.1021/ac503775m; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; Ye QH, 2016, CANCER CELL, V30, P444, DOI 10.1016/j.ccell.2016.07.017; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yue SH, 2014, CELL METAB, V19, P393, DOI 10.1016/j.cmet.2014.01.019; Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438; Zheng CH, 2017, CELL, V169, P1342, DOI 10.1016/j.cell.2017.05.035	64	376	408	55	756	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 14	2019	567	7747					257	+		10.1038/s41586-019-0987-8	http://dx.doi.org/10.1038/s41586-019-0987-8			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO7LD	30814741				2023-01-03	WOS:000461126600046
J	Komtenza, B; Satyanarayana, S; Takarinda, KC; Mukungunugwa, SH; Mugurungi, O; Chonzi, P; Sithole, N; Bvochora, T; Mushavi, A				Komtenza, Brian; Satyanarayana, Srinath; Takarinda, Kudakwashe C.; Mukungunugwa, Solomon H.; Mugurungi, Owen; Chonzi, Prosper; Sithole, Ngwarai; Bvochora, Talent; Mushavi, Angela			Identifying high or low risk of mother to child transmission of HIV: How Harare City, Zimbabwe is doing?	PLOS ONE			English	Article							PREVENTION; INFANTS	Background Despite high antiretroviral (ARV) treatment coverage among pregnant women for prevention of mother-to-child transmission (PMTCT) of Human Immunodeficiency Virus (HIV) in Zimbabwe, the MTCT rate is still high. Therefore in 2016, the country adopted World Health Organization recommendations of stratifying pregnant women into "High" or"Low" MTCT risk for subsequent provision of HIV exposed infant (HEI) with appropriate follow-up care according to risk status. Objective The study sought to ascertain, among pregnant women who delivered in clinics of Harare in August 2017: the extent to which high risk MTCT pregnancies were identified at time of delivery; and whether their newborns were initiated on appropriate ARV prophylaxis, cotrimoxazole prophylaxis, subjected to early HIV diagnostic testing and initiated on ARV treatment. Methods Cross-sectional study using review of records of routinely collected program data. Results Of the 1,786 pregnant women who delivered in the selected clinics, HIV status at the time of delivery was known for 1,756 (98%) of whom 197 (11%) were HIV seropositive. Only 19 (10%) could be classified as "high risk" for MTCT and the remaining 90% lacked adequate information to classify them into high or low risk for MTCT due to missing data. Of the 197 live births, only two (1%) infants had a nucleic-acid test (NAT) at birth and 32 (16%) infants had NAT at 6 weeks. Of all 197 infants, 183 (93%) were initiated on single ARV prophylaxis (Nevirapine), 15 (7%) infants' ARV prophylaxis status was not documented and one infant got dual ARV prophylaxis (Nevirapine+Zidovudine). Conclusion There was paucity of data requisite for MTCT risk stratification due to poor recording of data; "high risk" women were missed in the few circumstances where sufficient data were available. Thus "high risk" HEI are deprived of dual ARV prophylaxis and priority HIV NAT at birth and onwards which they require for PMTCT. Health workers need urgent training, mentorship and supportive supervision to master data management and perform MTCT risk stratification satisfactorily.	[Komtenza, Brian; Takarinda, Kudakwashe C.; Mukungunugwa, Solomon H.; Mugurungi, Owen; Sithole, Ngwarai; Mushavi, Angela] Govt Zimbabwe, AIDS & TB Unit, Minist Hlth & Child Care, Harare, Zimbabwe; [Satyanarayana, Srinath] Int Union TB & Lung Dis, Ctr Operat Res, Paris, France; [Chonzi, Prosper; Bvochora, Talent] City Harare Hlth Serv Dept, Harare, Zimbabwe		Komtenza, B (corresponding author), Govt Zimbabwe, AIDS & TB Unit, Minist Hlth & Child Care, Harare, Zimbabwe.	beekomtenza@gmail.com		Komtenza, Brian/0000-0002-7851-5237; Satyanarayana, Srinath/0000-0002-5420-2551	United Kingdom's Department for International Development (DFID); La Fondation Veuve Emile Metz-Tesch (Luxembourg); United States Agency for International Development (USAID) through Challenge TB; Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM); National AIDS Council Zimbabwe	United Kingdom's Department for International Development (DFID); La Fondation Veuve Emile Metz-Tesch (Luxembourg); United States Agency for International Development (USAID) through Challenge TB(United States Agency for International Development (USAID)); Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM); National AIDS Council Zimbabwe	This work was supported by United Kingdom's Department for International Development (DFID); La Fondation Veuve Emile Metz-Tesch (Luxembourg); the United States Agency for International Development (USAID) through Challenge TB; The Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) and the National AIDS Council Zimbabwe to BK.	Abrams EJ, 2017, PEDIATR INFECT DIS J, V36, P595, DOI [10.1097/inf.0000000000001507, 10.1097/INF.0000000000001507]; Dorward J, 2018, LANCET HIV, V5, pE8, DOI 10.1016/S2352-3018(17)30211-4; Fowler MG, 2014, JAIDS-J ACQ IMM DEF, V65, P366, DOI 10.1097/QAI.0000000000000052; Go Z, 2013, OP PLAN NAT TRANS OP; Newell ML, 2001, B WORLD HEALTH ORGAN, V79, P1138; Nielsen-Saines K, 2012, NEW ENGL J MED, V366, P2368, DOI 10.1056/NEJMoa1108275; Padian NS, 2011, LANCET, V378, P269, DOI 10.1016/S0140-6736(11)60877-5; The National Medicine and Therapeutics Policy Advisory Committee (NMTPAC) and The AIDS and TB Directorate Ministry of Health and Child Care (MOHCC) H, 2016, GUID ANT THER PREV T; UNAIDS, 2016, UNAIDS AIDS DAT 2016; UNAIDS, 2015, SUP FAST TRACK FRAM; WHO/UNAIDS, 2015, GLOB AIDS RESP PROGR; World Health Organization, 2015, GUID START ANT THER; World Health Organization, 2014, CRIT PROC VAL EL MOT	13	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2019	14	3							e0212848	10.1371/journal.pone.0212848	http://dx.doi.org/10.1371/journal.pone.0212848			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO6OH	30865646	Green Submitted, gold, Green Published			2023-01-03	WOS:000461048900042
J	Murray, LM; Knikou, M				Murray, Lynda M.; Knikou, Maria			Transspinal stimulation increases motoneuron output of multiple segments in human spinal cord injury	PLOS ONE			English	Article							LONG-TERM POTENTIATION; SYNAPTIC PLASTICITY; EPIDURAL STIMULATION; H-REFLEX; ELECTRICAL-STIMULATION; NATIONAL INSTITUTES; RESTORE COUGH; ACTIVATION; DEPRESSION; POLARIZATION	Targeted neuromodulation strategies that strengthen neuronal activity are in great need for restoring sensorimotor function after chronic spinal cord injury (SCI). In this study, we established changes in the motoneuron output of individuals with and without SCI after repeated noninvasive transspinal stimulation at rest over the thoracolumbar enlargement, the spinal location of leg motor circuits. Cases of motor incomplete and complete SCI were included to delineate potential differences when corticospinal motor drive is minimal. All 10 SCI and 10 healthy control subjects received daily monophasic transspinal stimuli of 1-ms duration at 0.2 Hz at right soleus transspinal evoked potential (TEP) subthreshold and suprathreshold intensities at rest. Before and two days after cessation of transspinal stimulation, we determined changes in TEP recruitment input-output curves, TEP amplitude at stimulation frequencies of 0.1, 0.125, 0.2, 0.33 and 1.0 Hz, and TEP postactivation depression upon transspinal paired stimuli at interstimulus intervals of 60, 100, 300, and 500 ms. TEPs were recorded at rest from bilateral ankle and knee flexor/extensor muscles. Repeated trans spinal stimulation increased the motoneuron output over multiple segments. In control and complete SCI subjects, motoneuron output increased for knee muscles, while in motor incomplete SCI subjects motoneuron output increased for both ankle and knee muscles. In control subjects, TEPs homosynaptic and postactivation depression were present at baseline, and were potentiated for the distal ankle or knee flexor muscles. TEPs homosynaptic and postactivation depression at baseline depended on the completeness of the SCI, with minimal changes observed after transspinal stimulation. These results indicate that repeated transspinal stimulation increases spinal motoneuron responsiveness of ankle and knee muscles in the injured human spinal cord, and thus can promote motor recovery. This noninvasive neuromodulation method is a promising modality for promoting functional neuroplasticity after SCI.	[Murray, Lynda M.; Knikou, Maria] CUNY Coll Staten Isl, Dept Phys Therapy, Klab4Recovery Res Lab, Staten Isl, NY 10314 USA; [Knikou, Maria] CUNY, Grad Ctr, PhD Program Biol & Collaborat Neurosci Program, New York, NY 10016 USA	City University of New York (CUNY) System; College of Staten Island (CUNY); City University of New York (CUNY) System	Knikou, M (corresponding author), CUNY Coll Staten Isl, Dept Phys Therapy, Klab4Recovery Res Lab, Staten Isl, NY 10314 USA.; Knikou, M (corresponding author), CUNY, Grad Ctr, PhD Program Biol & Collaborat Neurosci Program, New York, NY 10016 USA.	Maria.Knikou@csi.cuny.edu	, Lynda/E-3207-2015	, Lynda/0000-0001-7467-5607; Knikou, Maria/0000-0002-6277-236X	Craig H. Neilsen Foundation [339705]	Craig H. Neilsen Foundation	This research was supported by a grant from the Craig H. Neilsen Foundation [Grant No. 339705] awarded to Maria Knikou. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alam M, 2016, BRAIN RES, V1646, P25, DOI 10.1016/j.brainres.2016.05.039; Andrade-Talavera Y, 2016, CEREB CORTEX, V26, P3637, DOI 10.1093/cercor/bhw172; Angeli CA, 2018, NEW ENGL J MED, V379, P1244, DOI 10.1056/NEJMoa1803588; Angeli CA, 2014, BRAIN, V137, P1394, DOI 10.1093/brain/awu038; Aslan SC, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00565; Baptiste DC, 2006, J NEUROTRAUM, V23, P318, DOI 10.1089/neu.2006.23.318; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brinkworth RSA, 2007, J NEUROSCI METH, V162, P1, DOI 10.1016/j.jneumeth.2006.11.020; Cote MP, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00784; Courtine G, 2009, NAT NEUROSCI, V12, P1333, DOI 10.1038/nn.2401; Danner SM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147479; DENOORDHOUT AM, 1988, J NEUROL NEUROSUR PS, V51, P174, DOI 10.1136/jnnp.51.2.174; DiMarco AF, 2009, ARCH PHYS MED REHAB, V90, P717, DOI 10.1016/j.apmr.2008.11.013; DiMarco AF, 2009, ARCH PHYS MED REHAB, V90, P726, DOI 10.1016/j.apmr.2008.11.014; Dixon L, 2016, J NEUROPHYSIOL, V116, P904, DOI 10.1152/jn.00259.2016; Einhorn J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076940; ElBasiouny SM, 2007, J APPL PHYSIOL, V103, P1824, DOI 10.1152/japplphysiol.00362.2007; ELLAWAY PH, 1978, ELECTROEN CLIN NEURO, V45, P302, DOI 10.1016/0013-4694(78)90017-2; Estes SP, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00017; Gad PN, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00432; Galea JM, 2009, J NEUROPHYSIOL, V102, P294, DOI 10.1152/jn.00184.2009; Gerasimenko YP, 2015, J NEUROTRAUM, V32, P1968, DOI 10.1089/neu.2015.4008; Gill ML, 2018, NAT MED, V24, P1677, DOI 10.1038/s41591-018-0175-7; Gorodnichev R. M., 2012, Human Physiology, V38, P158, DOI 10.1134/S0362119712020065; Hammar I, 2002, EXP BRAIN RES, V145, P126, DOI 10.1007/s00221-002-1098-5; Harkema S, 2011, LANCET, V377, P1938, DOI 10.1016/S0140-6736(11)60547-3; Harkema SJ, 2018, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00083; Hofstoetter US, 2017, CURR PHARM DESIGN, V23, P1805, DOI 10.2174/1381612822666161214144655; Hofstoetter US, 2014, J SPINAL CORD MED, V37, P202, DOI 10.1179/2045772313Y.0000000149; HOUNSGAARD J, 1988, J PHYSIOL-LONDON, V405, P345, DOI 10.1113/jphysiol.1988.sp017336; HOUNSGAARD J, 1993, J PHYSIOL-LONDON, V468, P245, DOI 10.1113/jphysiol.1993.sp019769; Hultborn H, 2004, PROG BRAIN RES, V143, P77, DOI 10.1016/S0079-6123(03)43008-2; Hultborn H, 1996, EXP BRAIN RES, V108, P450; HULTBORN H, 1979, J PHYSIOL-LONDON, V297, P267, DOI 10.1113/jphysiol.1979.sp013039; Hunanyan AS, 2012, J NEUROPHYSIOL, V107, P3027, DOI 10.1152/jn.00015.2012; James ND, 2018, LANCET NEUROL, V17, P905, DOI 10.1016/S1474-4422(18)30287-4; Karunakaran KD, 2019, J NEUROTRAUM, V36, P2045, DOI 10.1089/neu.2018.6040; Kerchner GA, 2008, NAT REV NEUROSCI, V9, P813, DOI 10.1038/nrn2501; Klimstra M, 2008, EXP BRAIN RES, V186, P93, DOI 10.1007/s00221-007-1207-6; Knikou M, 2008, J NEUROSCI METH, V171, P1, DOI 10.1016/j.jneumeth.2008.02.012; Knikou M, 2018, J ELECTROMYOGR KINES, V43, P174, DOI 10.1016/j.jelekin.2018.10.005; Knikou M, 2017, NEURAL PLAST, V2017, DOI 10.1155/2017/6751810; Knikou M, 2015, J NEUROPHYSIOL, V114, P1486, DOI 10.1152/jn.00449.2015; Knikou M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102313; Knikou M, 2013, BIOELECTROMAGNETICS, V34, P630, DOI 10.1002/bem.21808; Knikou M, 2010, CLIN NEUROPHYSIOL, V121, P1655, DOI 10.1016/j.clinph.2010.01.039; Li YR, 2003, J NEUROPHYSIOL, V90, P857, DOI 10.1152/jn.00236.2003; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; Mallik A, 2005, J NEUROL NEUROSUR PS, V76, P23, DOI 10.1136/jnnp.2005.069138; Mendell LM, 2001, J PHYSIOL-LONDON, V533, P91, DOI 10.1111/j.1469-7793.2001.0091b.x; Minassian K, 2016, CNS NEUROSCI THER, V22, P262, DOI 10.1111/cns.12530; Molnar E, 2011, SEMIN CELL DEV BIOL, V22, P506, DOI 10.1016/j.semcdb.2011.07.017; Murray LM, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00050; Phillips AA, 2018, J NEUROTRAUM, V35, P446, DOI 10.1089/neu.2017.5082; Pierrot-Deseilligny E, 2000, NEUROPHYSIOL CLIN, V30, P67, DOI 10.1016/S0987-7053(00)00062-9; Raithatha R, 2016, NEUROREHABILITATION, V38, P15, DOI 10.3233/NRE-151291; Rath M, 2018, J NEUROTRAUM, V35, P2540, DOI 10.1089/neu.2017.5584; Rejc E, 2017, J NEUROTRAUM, V34, P1787, DOI 10.1089/neu.2016.4516; Rejc E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133998; Sayenko DG, 2015, J APPL PHYSIOL, V118, P1364, DOI 10.1152/japplphysiol.01128.2014; Smith AC, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/1216258; Volianskis A, 2015, BRAIN RES, V1621, P5, DOI 10.1016/j.brainres.2015.01.016; Yoon H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180697	64	13	13	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2019	14	3							e0213696	10.1371/journal.pone.0213696	http://dx.doi.org/10.1371/journal.pone.0213696			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO1AY	30845251	Green Published, gold			2023-01-03	WOS:000460638800107
J	Vonk, M; Wikkerink, S; Regan, K; Middleton, LE				Vonk, Matthew; Wikkerink, Spencer; Regan, Kayla; Middleton, Laura Elizabeth			Similar changes in executive function after moderate resistance training and loadless movement	PLOS ONE			English	Article							EXERCISE-INDUCED AROUSAL; MIDDLE-AGED ADULTS; COGNITIVE PERFORMANCE; INTENSITY	Growing evidence suggests that physical exercise may improve cognitive function in the short- and long-term. Aerobic exercise has been studied most extensively. Preliminary work suggests that resistance training also improves cognitive function, particularly executive function. Conversely, most studies found little dose-effect by intensity. Consequently, cognitive benefits may be elicited, at least in part, by the movement rather than the physical exertion of resistance training. The objective here was to examine and compare acute changes in executive function after resistance training and a loadless movement control among young, healthy adults. Twenty-two young healthy adults (mean age 23.4 years [2.4]; 50% female) completed three conditions, a baseline condition and two experimental conditions (moderate intensity resistance training, loadless movement control). Participants completed a computerized modified Stroop task with concurrent electroencephalography (EEG) before and 10, 20, 30, and 40min after each intervention. Outcomes (incongruent and congruent response time, accuracy, EEG P3 amplitude and latency) were analyzed using mixed linear regression models (factors: condition, time, condition* time). There was a main effect of time for Stroop response time (F-4,F-84 = 3.94, p = 0.006 and F-4,F-84 = 10.27, p< 0.0001 respectively) and incongruent and congruent P3 amplitude (F-4,F-76 = 4.40, p = 0.003 and F-4,F-76 = 5.09, p = 0.001 respectively). Post-hoc analyses indicated that both incongruent and congruent P3 amplitude were elevated at time points up to and including 40min after the interventions (compared to pre-intervention, p< 0.05). Both incongruent and congruent response times were faster at 10min post-intervention than pre-intervention (p< 0.04). There was no main effect of condition or interaction between condition and time for either outcome (p >= 0.53). Similar improvements in executive function were observed after loadless movement and resistance training, suggesting that movement is at least partially responsible for the benefits to executive function. Future research should continue to probe the influence of movement versus physical exertion in resistance training by including a movement and nonmovement control.	[Vonk, Matthew; Wikkerink, Spencer; Regan, Kayla; Middleton, Laura Elizabeth] Univ Waterloo, Dept Kinesiol, Waterloo, ON, Canada	University of Waterloo	Middleton, LE (corresponding author), Univ Waterloo, Dept Kinesiol, Waterloo, ON, Canada.	Laura.middleton@uwaterloo.ca	Middleton, Laura/ABG-8940-2021; Middleton, Laura/C-6024-2009	Middleton, Laura/0000-0001-8624-3123	Natural Sciences and Engineering Research Council (Canada) Discovery Award	Natural Sciences and Engineering Research Council (Canada) Discovery Award	LM received funding from a Natural Sciences and Engineering Research Council (Canada) Discovery Award.	Angevaren M, 2008, COCHRANE COLLAB; [Anonymous], 2007, AM COLL SPORT MED; [Anonymous], 2014, GLOB STRAT DIET PHYS; Baechle T, 2000, HUMAN KINETICS; Belanger S, 2010, NEUROPSYCHOLOGIA, V48, P581, DOI 10.1016/j.neuropsychologia.2009.10.021; BORG G, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P92; Brody H, 2000, J FAM PRACTICE, V49, P649; Byun KH, 2014, NEUROIMAGE, V98, P336, DOI 10.1016/j.neuroimage.2014.04.067; Canadian Society Of Exercise Physiology, 2016, PRESCR PHYS ACT PART; Cassilhas RC, 2007, MED SCI SPORT EXER, V39, P1401, DOI 10.1249/mss.0b013e318060111f; Chang YK, 2012, BRAIN RES, V1453, P87, DOI 10.1016/j.brainres.2012.02.068; Chang YK, 2014, J SCI MED SPORT, V17, P51, DOI 10.1016/j.jsams.2013.02.007; Chang YK, 2012, MED SCI SPORT EXER, V44, P1773, DOI 10.1249/MSS.0b013e3182574e0b; Chang YK, 2011, J SPORT EXERCISE PSY, V33, P866, DOI 10.1123/jsep.33.6.866; Chang YK, 2009, RES Q EXERCISE SPORT, V80, P78; Chang YK, 2009, PSYCHOL SPORT EXERC, V10, P19, DOI 10.1016/j.psychsport.2008.05.004; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Compumedics Neuroscan, 2015, CURR NEUR SUIT 7 0 1; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; Dunsky A, 2017, PLOS ONE, V12, P1; Harveson AT, 2016, RES Q EXERCISE SPORT, V1367, P1; Henckens MJAG, 2012, FRONT INTEGR NEUROSC, V6, DOI 10.3389/fnint.2012.00066; Hillman CH, 2003, INT J PSYCHOPHYSIOL, V48, P307, DOI 10.1016/S0167-8760(03)00080-1; Holroyd CB, 2015, PSYCHOL REV, V122, P54, DOI 10.1037/a0038339; Hommel B, 2002, PSYCHOL RES-PSYCH FO, V66, P215, DOI 10.1007/s00426-002-0096-3; Kamijo K, 2004, EUR J APPL PHYSIOL, V92, P305, DOI 10.1007/s00421-004-1097-2; Kamijo K, 2007, INT J PSYCHOPHYSIOL, V65, P114, DOI 10.1016/j.ijpsycho.2007.04.001; Kamijo K, 2009, J GERONTOL B-PSYCHOL, V64, P356, DOI 10.1093/geronb/gbp030; Kok A, 2001, PSYCHOPHYSIOLOGY, V38, P557, DOI 10.1017/S0048577201990559; Lakens D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00863; Lambourne K, 2010, BRAIN RES, V1341, P12, DOI 10.1016/j.brainres.2010.03.091; Lansbergen MM, 2008, CLIN NEUROPHYSIOL, V119, P2247, DOI 10.1016/j.clinph.2008.07.218; Liu-Ambrose T, 2010, ARCH INTERN MED, V170, P170, DOI 10.1001/archinternmed.2009.494; Luck S.J, 2005, MONOGR SOC RES CHILD, V78, P388; Luis G.Tassinary, 2013, PRINCIPLES COGNITIVE; McMorris T, 2011, PHYSIOL BEHAV, V102, P421, DOI 10.1016/j.physbeh.2010.12.007; Moretti DV, 2003, INT J PSYCHOPHYSIOL, V47, P199, DOI 10.1016/S0167-8760(02)00153-8; Nagamatsu LS, 2012, ARCH INTERN MED, V172, P666, DOI 10.1001/archinternmed.2012.379; Nashed JY, 2014, J NEUROSCI, V34, P1769, DOI 10.1523/JNEUROSCI.3063-13.2014; Nikolov I., 2015, REP SCHEME CALCULATO; Penner IK, 2012, CLIN NEUROPSYCHOL, V26, P1142, DOI 10.1080/13854046.2012.713513; Pontifex MB, 2009, MED SCI SPORT EXER, V41, P927, DOI 10.1249/MSS.0b013e3181907d69; Public Health Agency of Canada, 2014, PHYS ACT BEN, V54, P1; Rockwood K, 2007, ALZHEIMERS DEMENT, V3, pS38, DOI 10.1016/j.jalz.2007.01.003; Alves CRR, 2012, J SPORT EXERCISE PSY, V34, P539, DOI 10.1123/jsep.34.4.539; de Asteasu MLS, 2017, AGEING RES REV, V37, P117, DOI 10.1016/j.arr.2017.05.007; Smith PJ, 2010, PSYCHOSOM MED, V72, P239, DOI 10.1097/PSY.0b013e3181d14633; Tsai CL, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00023; Tsai CL, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00262; Wessinger C., 2009, ENCY NEUROSCIENCE, P1117	50	8	8	3	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2019	14	2							e0212122	10.1371/journal.pone.0212122	http://dx.doi.org/10.1371/journal.pone.0212122			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HM8DR	30794593	Green Submitted, gold, Green Published			2023-01-03	WOS:000459709100038
J	Berardi, L; Antonazzo, IC; Piccinni, C; Raschi, E; Forcesi, E; Fioritti, A; Berardi, D; De Ponti, F; Piazza, A; Poluzzi, E				Berardi, Lorenzo; Antonazzo, Ippazio Cosimo; Piccinni, Carlo; Raschi, Emanuel; Forcesi, Emanuele; Fioritti, Angelo; Berardi, Domenico; De Ponti, Fabrizio; Piazza, Antonella; Poluzzi, Elisabetta			Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres	PLOS ONE			English	Article							ORAL ANTIPSYCHOTICS; PALIPERIDONE PALMITATE; SCHIZOPHRENIA; DISCONTINUATION; RISPERIDONE; DEPOT; INJECTIONS; DRUGS; TIME; LIFE	Purpose This study aims to describe factors associated to treatment continuity and psychiatric relapses in patients treated with Long Acting Injectable antipsychotics (LAls) in Bologna Community Mental Health Centers (CMHCs). Methods New LAI treatments administered between July 1, 2010 and June 30, 2015 in CMHCs were selected. The cohort was followed-up for 6 months; predictors of continuity and psychiatric admissions were investigated by using logistic regression- and Cox- analysis respectively. Results Among the cohort of 1 070 patients, only 222 (21%) continued LAI treatment during the follow-up. LAI continuity was higher with first generation agents (OR: 1.71, 95%Cl 1.18-2.49) and in case of previous psychiatric hospitalizations (OR 2.00, 95%Cl 1.47-2.74). Incidence of psychiatric hospital admissions showed a sharp reduction in the follow-up compared with 6-month period before initiation (from 458 to 212), and was associated with previous psychiatric hospitalizations (HR 3.20, 95%Cl 2.22-4.59), immigration (HR 3.13, 95%Cl 1.28-7.69) and LAI discontinuation (HR 1.14, 95%Cl 1.01-1.97). Conclusions Psychiatric hospital admission before LAI initiation was the main predictor both of LAI continuity and hospitalization during the follow-up.	[Berardi, Lorenzo; Antonazzo, Ippazio Cosimo; Piccinni, Carlo; Raschi, Emanuel; Forcesi, Emanuele; De Ponti, Fabrizio; Poluzzi, Elisabetta] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy; [Berardi, Lorenzo] Univ Ferrara, Dept Biomed & Specialty Surg Sci, Clin Psychiat Div, Ferrara, Italy; [Fioritti, Angelo; Berardi, Domenico; Piazza, Antonella] Local Hlth Author Bologna, Dept Mental Hlth, Bologna, Italy; [Berardi, Domenico] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy	University of Bologna; University of Ferrara; University of Bologna	Poluzzi, E (corresponding author), Univ Bologna, Dept Med & Surg Sci, Bologna, Italy.	elisabetta.poluzzi@unibo.it	Piccinni, Carlo/J-1158-2018	Piccinni, Carlo/0000-0002-8648-8961; POLUZZI, ELISABETTA/0000-0002-7209-0426; Antonazzo, Ippazio Cosimo/0000-0001-8046-4574				Barnes TRE, 2009, BRIT J PSYCHIAT, V195, pS37, DOI 10.1192/bjp.195.52.s37; Brnabic AJM, 2011, INT J CLIN PRACT, V65, P945, DOI 10.1111/j.1742-1241.2011.02743.x; Buckley PF, 2009, SCHIZOPHRENIA BULL, V35, P383, DOI 10.1093/schbul/sbn135; Castillo EG, 2015, EVID-BASED MENT HEAL, V18, P36, DOI 10.1136/eb-2015-102086; Chou YH, 2015, CLIN PSYCHOPHARM NEU, V13, P121, DOI 10.9758/cpn.2015.13.2.121; Chwastiak LA, 2006, PSYCHIAT SERV, V57, P1102, DOI 10.1176/appi.ps.57.8.1102; Decuypere F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179049; Hsieh MH, 2017, J AFFECT DISORDERS, V218, P327, DOI 10.1016/j.jad.2017.04.074; Jones PB, 2006, ARCH GEN PSYCHIAT, V63, P1079, DOI 10.1001/archpsyc.63.10.1079; Kane JM, 2010, J CLIN PSYCHIAT, V71, P1115, DOI 10.4088/JCP.10r06264yel; Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688; Marcus SC, 2015, J MANAG CARE SPEC PH, V21, P754, DOI 10.18553/jmcp.2015.21.9.754; National Institute for Health and Care Excellence (NICE), PSYCH SCHIZ AD PREV; Palomares N, 2015, INT CLIN PSYCHOPHARM, V30, P338, DOI 10.1097/YIC.0000000000000095; Pandina GJ, 2010, J CLIN PSYCHOPHARM, V30, P235, DOI 10.1097/JCP.0b013e3181dd3103; Patel MX, 2010, J PSYCHOPHARMACOL, V24, P1483, DOI 10.1177/0269881109103133; Piccinni C, 2015, INT J PSYCHIAT MED, V49, P45, DOI 10.2190/PM.49.1.d; Rittmannsberger H, 2017, J CLIN PSYCHOPHARM, V37, P250, DOI 10.1097/JCP.0000000000000672; Rosenheck RA, 2011, NEW ENGL J MED, V364, P842, DOI 10.1056/NEJMoa1005987; Rucci P, 2015, EPIDEMIOL PSYCH SCI, V24, P342, DOI 10.1017/S2045796014000250; Sacchetti E., 2015, EVIDENCE BASED PSYCH, P27; Subotnik KL, 2015, JAMA PSYCHIAT, V72, P822, DOI 10.1001/jamapsychiatry.2015.0270; Suissa S, 2008, AM J EPIDEMIOL, V168, P329, DOI 10.1093/aje/kwn135; Verdoux H, 2017, ACTA PSYCHIAT SCAND, V135, P429, DOI 10.1111/acps.12722; Verdoux H, 2016, SCHIZOPHR RES, V178, P58, DOI 10.1016/j.schres.2016.09.014; Zhu BJ, 2008, PSYCHIAT SERV, V59, P315, DOI 10.1176/appi.ps.59.3.315	26	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 15	2019	14	2							e0211938	10.1371/journal.pone.0211938	http://dx.doi.org/10.1371/journal.pone.0211938			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HL5KT	30768607	Green Published, gold, Green Submitted			2023-01-03	WOS:000458766300015
J	Masaracchio, M; Kirker, K; States, R; Hanney, WJ; Liu, XL; Kolber, M				Masaracchio, Michael; Kirker, Kaitlin; States, Rebecca; Hanney, William J.; Liu, Xinliang; Kolber, Morey			Thoracic spine manipulation for the management of mechanical neck pain: A systematic review and meta-analysis	PLOS ONE			English	Review							RANDOMIZED CONTROLLED-TRIAL; LOW-BACK-PAIN; CERVICOTHORACIC MOTION SEGMENT; THRUST JOINT MANIPULATION; CLINICAL-PREDICTION RULE; IMMEDIATE CHANGES; CERVICAL RANGE; MANUAL THERAPY; COCHRANE BACK; SHOULDER PAIN	Objective To investigate the role of thoracic spine manipulation (TSM) on pain and disability in the management of mechanical neck pain (MNP). Data sources Electronic databases PubMed, CINAHL, Pedro, Embase, AMED, the Cochrane Library, and clinicaltrials.gov were searched in January 2018. Study selection Eligible studies were completed RCTs, written in English, had at least 2 groups with one group receiving TSM, had at least one measure of pain or disability, and included patients with MNP of any duration. The search identified 1717 potential articles, with 14 studies meeting inclusion criteria. Study appraisal and synthesis methods Methodological quality was evaluated independently by two authors using the guidelines published by the Cochrane Collaboration. Pooled analyses were analyzed using a random-effects model with inverse variance methods to calculate mean differences (MD) and 95% confidence intervals for pain (VAS 0-100mm, NPRS 0-10pts; 0 = no pain) and disability (NDI and NPQ 0-100%; 0 = no disability). Results Across the included studies, there was increased risk of bias for inadequate provider and participant blinding. The GRADE approach demonstrated an overall level of evidence ranging from very low to moderate. Meta-analysis that compared TSM to thoracic or cervical mobilization revealed a significant effect favoring the TSM group for pain (MD-13.63; 95% CI: -21.79, -5.46) and disability (MD -9.93; 95% CI: -14.38, -5.48). Meta-analysis that compared TSM to standard care revealed a significant effect favoring the TSM group for pain (MD -13.21; 95% CI: -21.87, -4.55) and disability (MD -11.36; 95% CI: -18.93, -3.78) at short-term follow-up, and a significant effect for disability (MD -4.75; 95% CI: -6.54, -2.95) at long-term follow-up. Meta-analysis that compared TSM to cervical spine manipulation revealed a non-significant effect (MD 3.43; 95% CI: -7.26, 14.11) for pain without a distinction between immediate and short-term follow-up. Limitations The greatest limitation in this systematic review was the heterogeneity among the studies making it difficult to assess the true clinical benefit, as well as the overall level of quality of evidence. Conclusions TSM has been shown to be more beneficial than thoracic mobilization, cervical mobilization, and standard care in the short-term, but no better than cervical manipulation or placebo thoracic spine manipulation to improve pain and disability.	[Masaracchio, Michael; Kirker, Kaitlin; States, Rebecca] Long Isl Univ, Dept Phys Therapy, Brooklyn, NY 11201 USA; [Hanney, William J.] Univ Cent Florida, Dept Hlth Profess, Orlando, FL 32816 USA; [Liu, Xinliang] Univ Cent Florida, Dept Hlth Management & Informat, Orlando, FL 32816 USA; [Kolber, Morey] Nova Southeastern Univ, Dept Phys Therapy, Ft Lauderdale, FL 33314 USA	Long Island University-Brooklyn Campus; State University System of Florida; University of Central Florida; State University System of Florida; University of Central Florida; Nova Southeastern University	Masaracchio, M (corresponding author), Long Isl Univ, Dept Phys Therapy, Brooklyn, NY 11201 USA.	michael.masaracchio@liu.edu	States, Rebecca A/A-4593-2008	States, Rebecca/0000-0002-9014-212X; Masaracchio, Michael/0000-0001-6851-2713				[Anonymous], 2011, **NON-TRADITIONAL**; Austin GP, 2002, MANUAL THER, V7, P168, DOI 10.1054/math.2002.0461; Bautista-Aguirre F, 2017, EUR J PHYS REHAB MED, V53, P333, DOI 10.23736/S1973-9087.17.04431-8; Bialosky JE, 2009, MANUAL THER, V14, P531, DOI 10.1016/j.math.2008.09.001; Blanpied Peter R, 2017, J Orthop Sports Phys Ther, V47, pA1, DOI 10.2519/jospt.2017.0302; Carnes D, 2010, MANUAL THER, V15, P2, DOI 10.1016/j.math.2009.02.003; Casanova-Mendez A, 2014, MANUAL THER, V19, P331, DOI 10.1016/j.math.2014.03.002; Cleland JA, 2005, MANUAL THER, V10, P127, DOI 10.1016/j.math.2004.08.005; Cleland JA, 2007, J MAN MANIP THER, V15, P143, DOI 10.1179/106698107790819828; Cleland JA, 2008, ARCH PHYS MED REHAB, V89, P69, DOI 10.1016/j.apmr.2007.08.126; Cleland JA, 2007, PHYS THER, V87, P431, DOI 10.2522/ptj.20060217; Cleland JA, 2007, PHYS THER, V87, P9, DOI 10.2522/ptj.20060155; Cleland JA, 2010, PHYS THER, V90, P1239, DOI 10.2522/ptj.20100123; Collins CK, 2017, J MAN MANIP THER, V25, P169, DOI 10.1080/10669817.2017.1358249; Collins CK, 2016, INT J SPORTS PHYS TH, V11, P1160; Cross KM, 2011, J ORTHOP SPORT PHYS, V41, P633, DOI 10.2519/jospt.2011.3670; Delitto A., 2015, NEXT C EXPOSITION; Delitto A., 2012, J ORTHOP SPORT PHYS, V42, pA1, DOI [10.2519/jospt.2012.42.4.A1, DOI 10.2519/jospt.2012.42.4.A1]; Dunning JR, 2012, J ORTHOP SPORT PHYS, V42, P5, DOI 10.2519/jospt.2012.3894; Fritz JM, 2007, SPINE, V32, pE793, DOI 10.1097/BRS.0b013e31815d001a; Fritz JM, 2007, MED CARE, V45, P973, DOI 10.1097/MLR.0b013e318070c6cd; Fritz JM, 2007, J ORTHOP SPORT PHYS, V37, P290, DOI 10.2519/jospt.2007.2498; Fritz JM, 2007, PHYS THER, V87, P513, DOI 10.2522/ptj.20060192; Fukui S, 1997, REGION ANESTH, V22, P332, DOI 10.1016/S1098-7339(97)80007-7; Furlan AD, 2015, SPINE, V40, P1660, DOI 10.1097/BRS.0000000000001061; Furlan AD, 2009, SPINE, V34, P1929, DOI 10.1097/BRS.0b013e3181b1c99f; Gonzalez-Iglesias J, 2009, MANUAL THER, V14, P306, DOI 10.1016/j.math.2008.04.006; Gonzalez-Iglesias J, 2009, J ORTHOP SPORT PHYS, V39, P20, DOI 10.2519/jospt.2009.2914; Groeneweg R, 2017, CHIROPR MAN THER, V25, DOI 10.1186/s12998-017-0141-3; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hoy DG, 2010, BEST PRACT RES CL RH, V24, P783, DOI 10.1016/j.berh.2011.01.019; Huisman PA, 2013, DISABIL REHABIL, V35, P1677, DOI 10.3109/09638288.2012.750689; Jette AM, 2006, PHYS THER, V86, P726, DOI 10.1093/ptj/86.5.726; Kelly AM, 2001, EMERG MED J, V18, P205, DOI 10.1136/emj.18.3.205; Khoja SS, 2015, INT J PHYS MED REHAB, V3, P1; Krauss J, 2008, J MAN MANIP THER, V16, P93, DOI 10.1179/106698108790818530; Lau HMC, 2011, MANUAL THER, V16, P141, DOI 10.1016/j.math.2010.08.003; Leaver AM, 2010, ARCH PHYS MED REHAB, V91, P1313, DOI 10.1016/j.apmr.2010.06.006; Lee KW, 2016, J PHYS THER SCI, V28, P175, DOI [10.1589/jpts.28.175, 10.1589/jpts.28.1569]; Lee MS, 2008, OSTEOPOROSIS INT, V19, P139, DOI 10.1007/s00198-007-0486-x; Martinez-Segura R, 2012, J ORTHOP SPORT PHYS, V42, P806, DOI 10.2519/jospt.2012.4151; Masaracchio M, 2016, INT J SPORTS PHYS TH, V11, P1135; Masaracchio M, 2013, J ORTHOP SPORT PHYS, V43, P118, DOI 10.2519/jospt.2013.4221; Mintken PE, 2008, J ORTHOP SPORT PHYS, V38, P465, DOI 10.2519/jospt.2008.2747; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Mokdad AH, 2018, JAMA-J AM MED ASSOC, V319, P1444, DOI 10.1001/jama.2018.0158; Norlander S, 1997, SCAND J REHABIL MED, V29, P167; Norlander S, 1998, SCAND J REHABIL MED, V30, P243; Norlander S, 1996, SCAND J REHABIL MED, V28, P183; Puentedura EJ, 2017, J MAN MANIP THER, V25, P74, DOI 10.1080/10669817.2016.1187902; Puentedura EJ, 2015, J MAN MANIP THER, V23, P154, DOI 10.1179/2042618615Y.0000000012; Puentedura EJ, 2012, J MAN MANIP THER, V20, P66, DOI 10.1179/2042618611Y.0000000022; Puentedura EJ, 2011, J ORTHOP SPORT PHYS, V41, P208, DOI 10.2519/jospt.2011.3640; Salom-Moreno J, 2014, J MANIP PHYSIOL THER, V37, P312, DOI 10.1016/j.jmpt.2014.03.003; Sedgwick P, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1342; Sillevis R, 2010, J MAN MANIP THER, V18, P181, DOI 10.1179/106698110X12804993427126; Sim J, 2006, CLIN J PAIN, V22, P820, DOI 10.1097/01.ajp.0000210937.58439.39; Stineman MG, 2012, AM J PHYS MED REHAB, V91, P126, DOI 10.1097/PHM.0b013e318241200d; Suvarnnato T, 2013, J PHYS THER SCI, V25, P865, DOI 10.1589/jpts.25.865; Wainner RS, 2007, J ORTHOP SPORT PHYS, V37, P658, DOI 10.2519/jospt.2007.0110; Young JL, 2014, J MAN MANIP THER, V22, P141, DOI 10.1179/2042618613Y.0000000043	63	22	22	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2019	14	2							e0211877	10.1371/journal.pone.0211877	http://dx.doi.org/10.1371/journal.pone.0211877			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL5IX	30759118	Green Published, gold, Green Submitted			2023-01-03	WOS:000458761300061
J	Abramson, A; Caffarel-Salvador, E; Khang, M; Dellal, D; Silverstein, D; Gao, Y; Frederiksen, MR; Vegge, A; Hubalek, F; Water, JJ; Friderichsen, AV; Fels, J; Kirk, RK; Cleveland, C; Collins, J; Tamang, S; Hayward, A; Landh, T; Buckley, ST; Roxhed, N; Rahbek, U; Langer, R; Traverso, G				Abramson, Alex; Caffarel-Salvador, Ester; Khang, Minsoo; Dellal, David; Silverstein, David; Gao, Yuan; Frederiksen, Morten Revsgaard; Vegge, Andreas; Hubalek, Frantisek; Water, Jorrit J.; Friderichsen, Anders V.; Fels, Johannes; Kirk, Rikke Kaae; Cleveland, Cody; Collins, Joy; Tamang, Siddartha; Hayward, Alison; Landh, Tomas; Buckley, Stephen T.; Roxhed, Niclas; Rahbek, Ulrik; Langer, Robert; Traverso, Giovanni			An ingestible self-orienting system for oral delivery of macromolecules	SCIENCE			English	Article							DRUG-DELIVERY; INSULIN; COMPLICATIONS; MICRONEEDLES; STOMACH; TABLETS	Biomacromolecules have transformed our capacity to effectively treat diseases; however, their rapid degradation and poor absorption in the gastrointestinal (GI) tract generally limit their administration to parenteral routes. An oral biologic delivery system must aid in both localization and permeation to achieve systemic drug uptake. Inspired by the leopard tortoise's ability to passively reorient, we developed an ingestible self-orienting millimeter-scale applicator (SOMA) that autonomously positions itself to engage with GI tissue. It then deploys milliposts fabricated from active pharmaceutical ingredients directly through the gastric mucosa while avoiding perforation. We conducted in vivo studies in rats and swine that support the applicator's safety and, using insulin as a model drug, demonstrated that the SOMA delivers active pharmaceutical ingredient plasma levels comparable to those achieved with subcutaneous millipost administration.	[Abramson, Alex; Caffarel-Salvador, Ester; Khang, Minsoo; Silverstein, David; Gao, Yuan; Cleveland, Cody; Collins, Joy; Tamang, Siddartha; Hayward, Alison; Roxhed, Niclas; Langer, Robert; Traverso, Giovanni] MIT, Dept Chem Engn, Cambridge, MA 02139 USA; [Abramson, Alex; Caffarel-Salvador, Ester; Khang, Minsoo; Silverstein, David; Gao, Yuan; Cleveland, Cody; Collins, Joy; Tamang, Siddartha; Hayward, Alison; Roxhed, Niclas; Langer, Robert; Traverso, Giovanni] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Caffarel-Salvador, Ester; Dellal, David; Langer, Robert] MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Frederiksen, Morten Revsgaard; Vegge, Andreas; Hubalek, Frantisek; Water, Jorrit J.; Friderichsen, Anders V.; Fels, Johannes; Kirk, Rikke Kaae; Cleveland, Cody; Landh, Tomas; Buckley, Stephen T.; Rahbek, Ulrik] Novo Nordisk AS, Global Res Technol, Global Drug Discovery & Device R&D, Copenhagen, Denmark; [Hayward, Alison] MIT, Div Comparat Med, Cambridge, MA 02139 USA; [Roxhed, Niclas] KTH Royal Inst Technol, Dept Micro & Nanosyst, Stockholm, Sweden; [Langer, Robert] MIT, Media Lab, Cambridge, MA 02139 USA; [Traverso, Giovanni] MIT, Dept Mech Engn, Cambridge, MA 02139 USA; [Traverso, Giovanni] Harvard Med Sch, Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Novo Nordisk; Massachusetts Institute of Technology (MIT); Royal Institute of Technology; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard Medical School	Langer, R; Traverso, G (corresponding author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.; Langer, R; Traverso, G (corresponding author), MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.; Langer, R (corresponding author), MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Langer, R (corresponding author), MIT, Media Lab, Cambridge, MA 02139 USA.; Traverso, G (corresponding author), MIT, Dept Mech Engn, Cambridge, MA 02139 USA.; Traverso, G (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA.	rlanger@mit.edu; ctraverso@bwh.harvard.edu	Traverso, Carlo Giovanni/ABC-9065-2020	Traverso, Carlo Giovanni/0000-0001-7851-4077; Cleveland, Cody/0000-0002-2973-8530; Roxhed, Niclas/0000-0002-7147-6730; Caffarel-Salvador, Ester/0000-0002-2844-7598; Dellal, David/0000-0001-9558-3517; Silverstein, David/0000-0002-8725-7444; Frederiksen, Morten Revsgaard/0000-0003-0000-4426; Water, Jorrit/0000-0001-5267-0637; Khang, Minsoo/0000-0003-1731-6258; Hubalek, Frantisek/0000-0003-3983-7900	Novo Nordisk grant; NIH [EB-000244]; NSF GRFP fellowship; Division of Gastroenterology, Brigham and Woman's Hospital; Viking Olaf Bjork scholarship trust; MIT UROP program; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000244, R37EB000244] Funding Source: NIH RePORTER	Novo Nordisk grant(Novo Nordisk); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF GRFP fellowship(National Science Foundation (NSF)NSF - Office of the Director (OD)); Division of Gastroenterology, Brigham and Woman's Hospital; Viking Olaf Bjork scholarship trust; MIT UROP program; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This work was funded in part by Novo Nordisk grant (R.L., G.T.); NIH grant EB-000244 (R.L., G.T.); NSF GRFP fellowship (A. A.); Division of Gastroenterology, Brigham and Woman's Hospital (G.T.); Viking Olaf Bjork scholarship trust (N.R.); and MIT UROP program (M.K., D.D., D.S.).	Aguirre TAS, 2016, ADV DRUG DELIVER REV, V106, P223, DOI 10.1016/j.addr.2016.02.004; AOYAGI N, 1992, J PHARM SCI, V81, P1170, DOI 10.1002/jps.2600811208; Banerjee A, 2018, P NATL ACAD SCI USA, V115, P7296, DOI 10.1073/pnas.1722338115; Banerjee A, 2017, J DRUG TARGET, V25, P608, DOI 10.1080/1061186X.2017.1300664; Bass DM, 2002, DRUG SAFETY, V25, P1021, DOI 10.2165/00002018-200225140-00004; BOLONDI L, 1985, GASTROENTEROLOGY, V89, P752, DOI 10.1016/0016-5085(85)90569-4; Brayden DJ, 2016, ADV DRUG DELIVER REV, V106, P193, DOI 10.1016/j.addr.2016.10.005; Caffarel-Salvador E, 2017, CURR OPIN PHARMACOL, V36, P8, DOI 10.1016/j.coph.2017.07.003; Calvert MJ, 2007, BRIT J GEN PRACT, V57, P455; Davies M, 2017, JAMA-J AM MED ASSOC, V318, P1460, DOI 10.1001/jama.2017.14752; Domokos G, 2008, P ROY SOC B-BIOL SCI, V275, P11, DOI 10.1098/rspb.2007.1188; Eisen GM, 2002, GASTROINTEST ENDOSC, V55, P784, DOI 10.1016/S0016-5107(02)70404-5; Fallowfield L, 2006, ANN ONCOL, V17, P205, DOI 10.1093/annonc/mdj044; Ferrua MJ, 2010, J FOOD SCI, V75, pR151, DOI 10.1111/j.1750-3841.2010.01748.x; Fox CB, 2016, ACS NANO, V10, P5873, DOI 10.1021/acsnano.6b00809; Glendorf T, 2008, BIOCHEMISTRY-US, V47, P4743, DOI 10.1021/bi800054z; Harrison GA, 1923, BRIT MED J, V1923, P1204, DOI 10.1136/bmj.2.3286.1204; Iddan G, 2000, NATURE, V405, P417, DOI 10.1038/35013140; Imran  M., 2017, U. S. Patent, Patent No. [9,844,655, 9844655]; Ortiz AJ, 2011, AM J ORTHOD DENTOFAC, V140, pE115, DOI 10.1016/j.ajodo.2011.02.021; Koetting MC, 2016, J CONTROL RELEASE, V221, P18, DOI 10.1016/j.jconrel.2015.11.023; Mathiowitz E, 1997, NATURE, V386, P410, DOI 10.1038/386410a0; McKenzie JE, 2004, J THERM BIOL, V29, P605, DOI 10.1016/j.jtherbio.2004.08.020; Mikiewicz D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172600; Moroz E, 2016, ADV DRUG DELIVER REV, V101, P108, DOI 10.1016/j.addr.2016.01.010; Ortiz C, 2004, ANAL BIOCHEM, V332, P245, DOI 10.1016/j.ab.2004.06.013; Podolsky DK, 1997, J GASTROENTEROL, V32, P122, DOI 10.1007/BF01213309; Prego Cecilia, 2005, Expert Opin Drug Deliv, V2, P843, DOI 10.1517/17425247.2.5.843; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Tortora GJ, 2008, PRINCIPLES ANATOMY P; Traverso G, 2015, J PHARM SCI-US, V104, P362, DOI 10.1002/jps.24182; Varkonyi PL, 2006, MATH INTELL, V28, P34, DOI 10.1007/BF02984701; Vazharov IP, 2012, J IMAB, V18, P273, DOI 10.5272/jimab.2012183.273; Vinther TN, 2013, PROTEIN SCI, V22, P296, DOI 10.1002/pro.2211; Wallace JL, 1996, FASEB J, V10, P731, DOI 10.1096/fasebj.10.7.8635690; Wang M, 2017, LAB CHIP, V17, P1373, DOI 10.1039/c7lc00016b	37	143	146	34	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 8	2019	363	6427					611	+		10.1126/science.aau2277	http://dx.doi.org/10.1126/science.aau2277			38	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK6SM	30733413	Green Accepted, Green Published			2023-01-03	WOS:000458114200044
J	Agarwal, A; Ioannidis, JPA				Agarwal, Arnav; Ioannidis, John P. A.			PREDIMED trial of Mediterranean diet: retracted, republished, still trusted?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							COMPOSITE END-POINTS; TOTAL MORTALITY; RISK		[Agarwal, Arnav] Univ Toronto, Dept Med, Toronto, ON, Canada; [Ioannidis, John P. A.] Stanford Univ, Stanford Prevent Res Ctr, Stanford, CA 94305 USA; [Ioannidis, John P. A.] Stanford Univ, Meta Res Innovat Ctr Stanford METRICS, Stanford, CA 94305 USA	University of Toronto; Stanford University; Stanford University	Ioannidis, JPA (corresponding author), Stanford Univ, Stanford Prevent Res Ctr, Stanford, CA 94305 USA.; Ioannidis, JPA (corresponding author), Stanford Univ, Meta Res Innovat Ctr Stanford METRICS, Stanford, CA 94305 USA.	jioannid@stanford.edu	Ioannidis, John P. A./G-9836-2011; Agarwal, Arnav/J-1553-2014	Agarwal, Arnav/0000-0002-0931-7851; Ioannidis, John P./0000-0003-3118-6859				Martinez-Gonzalez MA, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111226; Babio N, 2018, CAN MED ASSOC J, V190, pE808, DOI 10.1503/cmaj.180791; Barbour V., 2017, F1000RESEARCH, V6, DOI [10.12688/f1000research.13060.1, DOI 10.12688/F1000RESEARCH.13060.1]; Carlisle JB, 2017, ANAESTHESIA, V72, P944, DOI 10.1111/anae.13938; Diaz-Lopez A, 2018, DIABETES CARE, V41, P2260, DOI 10.2337/dc18-er10a; Ebrahim S, 2016, J CLIN EPIDEMIOL, V79, P130, DOI 10.1016/j.jclinepi.2016.05.016; Estruch R, 2018, NEW ENGL J MED, V378, DOI [10.1056/NEJMoa1800389, 10.1056/nejmoa1800389]; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Fanelli D, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12898; Ferreira-Gonzalez I, 2007, BRIT MED J, V334, P786, DOI 10.1136/bmj.39136.682083.AE; Guasch-Ferre M, 2017, NUTR METAB CARDIOVAS, V27, P624, DOI 10.1016/j.numecd.2017.05.004; Guasch-Ferre M, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-164; Henriquez-Sanchez P, 2016, EUR J NUTR, V55, P227, DOI 10.1007/s00394-015-0840-2; Hernandez-Alonso P, 2016, CLIN NUTR, V35, P496, DOI 10.1016/j.clnu.2015.03.016; Hooper L, 2015, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD011583.pub2, 10.1002/14651858.CD011737]; Ioannidis JPA, 2018, JAMA-J AM MED ASSOC, V319, P547, DOI 10.1001/jama.2017.18571; IOANNIDIS JPA, 2013, BMJ-BRIT MED J, V347, DOI DOI 10.1136/BMJ.F6698; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; Martinez-Gonzalez MA, 2018, JAMA INTERN MED, V178, P1730, DOI 10.1001/jamainternmed.2018.6456; Martinez-Gonzalez MA, 2018, JAMA-J AM MED ASSOC, V320, P2272, DOI 10.1001/jama.2018.16553; Martinez-Gonzalez MA, 2015, CLIN NUTR, V34, P859, DOI 10.1016/j.clnu.2014.09.006; Martinez-Gonzalez MA, 2014, AM J CLIN NUTR, V100, p320S, DOI 10.3945/ajcn.113.071431; Martinez-Gonzalez MA, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070823; Montori VM, 2005, BMJ-BRIT MED J, V330, P594, DOI 10.1136/bmj.330.7491.594; National Clinical Guideline Centre (UK), 2014, LIP MOD CARD RISK AS; Rees K, 2013, COCHRANE DB SYST REV; Salas-Salvado J, 2018, DIABETES CARE, V41, P2259, DOI 10.2337/dc18-er10; Toledo E, 2015, JAMA INTERN MED, V175, P1752, DOI 10.1001/jamainternmed.2015.4838	28	21	21	3	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 7	2019	364								l341	10.1136/bmj.l341	http://dx.doi.org/10.1136/bmj.l341			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL3MJ	30733217				2023-01-03	WOS:000458619400003
J	Stower, H				Stower, Hannah			Detecting opioid overdoses with smartphones	NATURE MEDICINE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2019	25	2					197	197		10.1038/s41591-019-0362-1	http://dx.doi.org/10.1038/s41591-019-0362-1			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	HK3TW	30728530	Bronze			2023-01-03	WOS:000457842100009
J	Montanier, N; Bernard, L; Lambert, C; Pereira, B; Desbiez, F; Terral, D; Abergel, A; Bohatier, J; Rosset, E; Schmidt, J; Sautou, V; Hadjadj, S; Batisse-Lignier, M; Tauveron, I; Maqdasy, S; Roche, B				Montanier, Nathanaelle; Bernard, Lise; Lambert, Celine; Pereira, Bruno; Desbiez, Francoise; Terral, Daniel; Abergel, Armand; Bohatier, Jerome; Rosset, Eugenio; Schmidt, Jeannot; Sautou, Valerie; Hadjadj, Samy; Batisse-Lignier, Marie; Tauveron, Igor; Maqdasy, Salwan; Roche, Beatrice			Prospective evaluation of a dynamic insulin infusion algorithm for non critically-ill diabetic patients: A before-after study	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; TIGHT GLYCEMIC CONTROL; GLUCOSE CONTROL; HOSPITALIZED-PATIENTS; HYPERGLYCEMIA; PROTOCOL; MORTALITY; MANAGEMENT; HYPOGLYCEMIA; ASSOCIATION	Introduction Insulin infusion is recommended during management of diabetic patients in critical care units to rapidly achieve glycaemic stability and reduce the mortality. The application of an easy-to-use standardized protocol, compatible with the workload is preferred. Glycaemic target must quickly be reached, therefore static algorithms should be replaced by dynamic ones. The dynamic algorithm seems closer to the physiological situation and appreciates insulin sensitivity. However, the protocol must meet both safety and efficiency requirements. Indeed, apprehension from hypoglycaemia is the main deadlock with the dynamic algorithms, thus their application remains limited. In contrary to the critical care units, to date, no prospective study evaluated a dynamic algorithm of insulin infusion in non-critically ill patients. Aim This study primarily aimed to evaluate the efficacy of a dynamic algorithm of intravenous insulin therapy in non-critically-ill patients, and addressed its safety and feasibility in different departments of our university hospital. Methods A "before-after" study was conducted in five hospital departments (endocrinology and four "non-expert" units) comparing a dynamic algorithm (during the "after" period-P2) to the static protocol (the "before" period-P1). Static protocol is based on determining insulin infusion according to an instant blood glycaemia (BG) level at a given time. In the dynamic algorithm, insulin infusion rate is determined according to the rate of change of the BG (the previous and actual BG under a specific insulin infusion rate). Additionally, two distinct glycaemic targets were defined according to the patients' profile: 100-180 mg/dl (5.5-10 mmol/l) for vigorous patients and 140-220 mg/dl (7.8-12.2 mmol/l) for frail ones. Different BG measurements for each patient were collected and recorded in a specific database (e-CRF) in order to analyse the rates of hypo- and hyperglycaemia. A satisfaction survey was also performed. A study approval was obtained from the institutional revision board before starting the study. Results Over 8 months, 72 and 66 patients during P1 and P2 were respectively included. The dynamic algorithm was more efficient, with reduced time to control hyperglycaemia (P1 vs P2:8.3 vs 5.3 hours; HR: 2.02 [1.27; 3.21]; p<0.01), increased the number of in-target BG measurements (P1 vs P2: 37.0% vs 41.8%; p<0.05), and reduced the glycaemic variability related to each patient (P1 vs P2, %CV: 40.9 vs 38.2; p<0.05, Index Correlation Class:0.30 vs 0.14; p<0.05). In patients after the first event of hypoglycemia after having started the infusion, new events were lower (P1 vs P2: 19.4 vs 11.4; p<0.001) thanks to an earlier reaction to hypoglycaemia (8.3% during P1 vs 44.3% during P2; p=0.004). With the dynamic algorithm, the percentage of recurrence of mild hypoglycaemia was significantly lower in frail patients (20.5% vs 10.2%; p<0.001), and in patients managed in the non-expert units (18 vs 7.1%, p<0.001). The % CV was significantly improved in frail patients (36.9%). Mean BG measurements for each patient/day were 5.5 +/- 1.1 during P1 and 6.0 +/- 1.6 during P2 (p=0.6). The threat from hypoglycaemia and the difficulty in using dynamic algorithm are barriers for nurses' adherence. Conclusions This dynamic algorithm for non-critically-ill patients is more efficient and safe than the static protocol, and adapted for frail patients and non-expert units.	[Montanier, Nathanaelle; Desbiez, Francoise; Batisse-Lignier, Marie; Tauveron, Igor; Maqdasy, Salwan; Roche, Beatrice] CHU Clermont Ferrand, Serv Endocrinol Diabetol & Malad Metab, Clermont Ferrand, France; [Bernard, Lise; Sautou, Valerie] CHU Clermont Ferrand, Pole Pharm, Clermont Ferrand, France; [Lambert, Celine; Pereira, Bruno] CHU Clermont Ferrand, DRCI, Clermont Ferrand, France; [Terral, Daniel] CHU Clermont Ferrand, Serv Pediat Gen, Clermont Ferrand, France; [Abergel, Armand] CHU Clermont Ferrand, Serv Med Digest, Clermont Ferrand, France; [Bohatier, Jerome] CHU Clermont Ferrand, Serv Court Sejour Geriatr, Riom, France; [Rosset, Eugenio] CHU Clermont Ferrand, Serv Chirurg Vasc, Clermont Ferrand, France; [Schmidt, Jeannot] CHU Clermont Ferrand, Pole Urgences, Clermont Ferrand, France; [Hadjadj, Samy] CHU Poitiers, Serv Med Interne Endocrinol & Malad Metab, Poitiers, France; [Batisse-Lignier, Marie; Tauveron, Igor; Maqdasy, Salwan] Univ Clermont Auvergne, Lab GReD, UMR, CNRS 6293,INSERM U1103, Clermont Ferrand, France	CHU Clermont Ferrand; CHU Clermont Ferrand; CHU Clermont Ferrand; CHU Clermont Ferrand; CHU Clermont Ferrand; CHU Clermont Ferrand; CHU Clermont Ferrand; CHU Clermont Ferrand; CHU Poitiers; Universite de Poitiers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Clermont Auvergne (UCA)	Maqdasy, S (corresponding author), CHU Clermont Ferrand, Serv Endocrinol Diabetol & Malad Metab, Clermont Ferrand, France.; Maqdasy, S (corresponding author), Univ Clermont Auvergne, Lab GReD, UMR, CNRS 6293,INSERM U1103, Clermont Ferrand, France.	smaqdasy@chu-clermontferrand.fr		SAUTOU, Valerie/0000-0002-3944-3752; MAQDASY, Salwan/0000-0001-5164-9879; Terral, Daniel/0000-0003-3706-6786				Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014; [Anonymous], 2009, ANN FR ANESTH, V28, P410, DOI DOI 10.1016/J.ANNFAR.2009.02.020; Balkin M, 2007, DIABETES-METAB RES, V23, P49, DOI 10.1002/dmrr.673; Bernard L, 2016, J EVAL CLIN PRACT, V22, P683, DOI 10.1111/jep.12517; Clement S, 2004, DIABETES CARE, V27, P553, DOI 10.2337/diacare.27.2.553; Clergeau A, 2017, DIABETES TECHNOL THE, V19, P115, DOI 10.1089/dia.2016.0314; DeSantis Anthony J, 2006, Endocr Pract, V12, P491; DHondt NJ, 2008, DIABETES SPECTRUM, V21, P255; Dickerson RN, 2012, NUTRITION, V28, P1008, DOI 10.1016/j.nut.2012.01.010; Egi M, 2016, INTENS CARE MED, V42, P562, DOI 10.1007/s00134-016-4216-8; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Furnary Anthony P, 2004, Endocr Pract, V10 Suppl 2, P21; Furnary AP, 2003, J THORAC CARDIOV SUR, V125, P1007, DOI 10.1067/mtc.2003.181; Goldberg PA, 2004, DIABETES CARE, V27, P461, DOI 10.2337/diacare.27.2.461; Kelly Janet L, 2014, Diabetes Spectr, V27, P218, DOI 10.2337/diaspect.27.3.218; Kelly JL, 2006, SEMIN THORAC CARDIOV, V18, P346, DOI 10.1053/j.semtcvs.2006.06.004; Krikorian A, 2010, CURR OPIN CLIN NUTR, V13, P198, DOI 10.1097/MCO.0b013e32833571db; Krinsley JS, 2008, CRIT CARE MED, V36, P3008, DOI 10.1097/CCM.0b013e31818b38d2; Krinsley JS, 2017, ENDOCR PRACT, V23, P318, DOI 10.4158/EP161532.OR; Krinsley JS, 2003, MAYO CLIN PROC, V78, P1471, DOI 10.4065/78.12.1471; Ku SY, 2005, JT COMM J QUAL PATIE, V31, P141, DOI 10.1016/S1553-7250(05)31019-1; Lien Lillian F, 2005, Endocr Pract, V11, P240; Malesker MA, 2007, AM J CRIT CARE, V16, P589; Marik PE, 2010, CHEST, V137, P544, DOI 10.1378/chest.09-1737; McAlister FA, 2005, DIABETES CARE, V28, P810, DOI 10.2337/diacare.28.4.810; McCreedy EM, 2018, J AM BOARD FAM MED, V31, P192, DOI 10.3122/jabfm.2018.02.170141; Meijering S, 2006, CRIT CARE, V10, DOI 10.1186/cc3981; Miller I, 2015, J CLIN ENDOCR METAB, V100, pE1428, DOI 10.1210/jc.2015-2312; Moghissi ES, 2009, DIABETES CARE, V32, P1119, DOI 10.2337/dc09-9029; Monnier L, 2017, DIABETES CARE, V40, P832, DOI 10.2337/dc16-1769; Murad MH, 2012, J CLIN ENDOCR METAB, V97, P49, DOI 10.1210/jc.2011-2100; Noordzij PG, 2007, EUR J ENDOCRINOL, V156, P137, DOI 10.1530/eje.1.02321; Papak J, 2012, AM J CARDIOL, V110, p24B, DOI 10.1016/j.amjcard.2012.08.034; Passarelli AJ, 2016, DIABETES TECHNOL THE, V18, P93, DOI 10.1089/dia.2015.0046; Preiser JC, 2009, INTENS CARE MED, V35, P1738, DOI 10.1007/s00134-009-1585-2; Rood E, 2005, J AM MED INFORM ASSN, V12, P172, DOI 10.1197/jamia.M1598; Smiley D, 2010, J HOSP MED, V5, P212, DOI 10.1002/jhm.646; Umpierrez G, 2015, DIABETES CARE, V38, P1665, DOI 10.2337/dc15-0303; Umpierrez GE, 2012, J CLIN ENDOCR METAB, V97, P16, DOI 10.1210/jc.2011-2098; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Wilson M, 2007, DIABETES CARE, V30, P1005, DOI 10.2337/dc06-1964	41	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2019	14	1							e0211425	10.1371/journal.pone.0211425	http://dx.doi.org/10.1371/journal.pone.0211425			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ3AL	30689675	gold, Green Published, Green Submitted			2023-01-03	WOS:000457041800035
J	Hofmeyr, GJ; Betran, AP; Singata-Madliki, M; Cormick, G; Munjanja, SP; Fawcus, S; Mose, S; Hall, D; Ciganda, A; Seuc, AH; Lawrie, TA; Bergel, E; Roberts, JM; von Dadelszen, P; Belizan, JM; Althabe, F; Sawchuck, D; Vidler, M; Allie, S; Anthony, J; Frank, K; de Greeff, A; Fawcus, S; Hofmeyr, J; Kovane, M; Kovane, P; Lawrie, T; Mshweshwe, N; Mqikela, V; Njikelana, P; Novikova, N; Oyebajo, A; Parker, C; Phuti, A; van Papendorp, E; Williams, X; Dannemann, T; Seuc, A; Magee, L; Donnay, F; Drebit, S; Roberts, J; Guzha, B; Makaza, E; Manyame, S; Munjanja, S; Tahuringana, E				Hofmeyr, G. Justus; Betran, Ana Pilar; Singata-Madliki, Mandisa; Cormick, Gabriela; Munjanja, Stephen P.; Fawcus, Susan; Mose, Simpiwe; Hall, David; Ciganda, Alvaro; Seuc, Armando H.; Lawrie, Theresa A.; Bergel, Eduardo; Roberts, James M.; von Dadelszen, Peter; Belizan, Jose M.; Althabe, Fernando; Sawchuck, Diane; Vidler, Marianne; Allie, Saadiqa; Anthony, John; Frank, Karlyn; de Greeff, Annmarie; Fawcus, Sue; Hofmeyr, Justus; Kovane, Mvuseleli; Kovane, Patience; Lawrie, Theresa; Mshweshwe, Nolundi; Mqikela, Velisa; Njikelana, Pamela; Novikova, Natalia; Oyebajo, Adegboyega; Parker, Catherine; Phuti, Angel; van Papendorp, Erika; Williams, Xoliswa; Dannemann, Tina; Seuc, Armando; Magee, Laura; Donnay, France; Drebit, Sharla; Roberts, Jim; Guzha, Bothwell; Makaza, Emilia; Manyame, Sarah; Munjanja, Stephen; Tahuringana, Eunice		Calcium Preeclampsia Study Grp	Prepregnancy and early pregnancy calcium supplementation among women at high risk of pre-eclampsia: a multicentre, double-blind, randomised, placebo-controlled trial	LANCET			English	Article							HYPERTENSIVE DISORDERS; VITAMIN-D; PREVENTION; HEALTH	Background Reducing deaths from hypertensive disorders of pregnancy is a global priority. Low dietary calcium might account for the high prevalence of pre-eclampsia and eclampsia in low-income countries. Calcium supplementation in the second half of pregnancy is known to reduce the serious consequences of pre-eclampsia; however, the effect of calcium supplementation during placentation is not known. We aimed to test the hypothesis that calcium supplementation before and in early pregnancy (up to 20 weeks' gestation) prevents the development of pre-eclampsia Methods We did a multicountry, parallel arm, double-blind, randomised, placebo-controlled trial in South Africa, Zimbabwe, and Argentina. Participants with previous pre-eclampsia and eclampsia received 500 mg calcium or placebo daily from enrolment prepregnancy until 20 weeks' gestation. Participants were parous women whose most recent pregnancy had been complicated by pre-eclampsia or eclampsia and who were intending to become pregnant. All participants received unblinded calcium 1.5 g daily after 20 weeks' gestation. The allocation sequence (1:1 ratio) used computer-generated random numbers in balanced blocks of variable size. The primary outcome was pre-eclampsia, defined as gestational hypertension and proteinuria. The trial is registered with the Pan-African Clinical Trials Registry, number PACTR201105000267371. The trial closed on Oct 31, 2017. Findings Between July 12, 2011, and Sept 8, 2016, we randomly allocated 1355 women to receive calcium or placebo; 331 of 678 participants in the calcium group versus 320 of 677 in the placebo group became pregnant, and 298 of 678 versus 283 of 677 had pregnancies beyond 20 weeks' gestation. Pre-eclampsia occurred in 69 (23%) of 296 participants in the calcium group versus 82 (29%) of 283 participants in the placebo group with pregnancies beyond 20 weeks' gestation (risk ratio [RR] 0.80, 95% CI 0.61-1.06; p=0.121). For participants with compliance of more than 80% from the last visit before pregnancy to 20 weeks' gestation, the pre-eclampsia risk was 30 (21%) of 144 versus 47 (32%) of 149 (RR 0.66, CI 0.44-0.98; p=0.037). There were no serious adverse effects of calcium reported. Interpretation Calcium supplementation that commenced before pregnancy until 20 weeks' gestation, compared with placebo, did not show a significant reduction in recurrent pre-eclampsia. As the trial was powered to detect a large effect size, we cannot rule out a small to moderate effect of this intervention. Funding The University of British Columbia, a grantee of the Bill & Melinda Gates Foundation; UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction, WHO; the Argentina Fund for Horizontal Cooperation of the Argentinean Ministry of Foreign Affairs; and the Centre for Intervention Science in Maternal and Child Health. Copyright (c) 2019 This is an Open Access article published under the CC BY 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.	[Hofmeyr, G. Justus; Singata-Madliki, Mandisa; Lawrie, Theresa A.] Univ Witwatersrand, Eastern Cape Dept Hlth, Effect Care Res Unit, East London, South Africa; [Hofmeyr, G. Justus; Singata-Madliki, Mandisa; Lawrie, Theresa A.] Univ Walter Sisulu, Eastern Cape Dept Hlth, Effect Care Res Unit, East London, South Africa; [Hofmeyr, G. Justus; Singata-Madliki, Mandisa; Lawrie, Theresa A.] Univ Ft Hare, Eastern Cape Dept Hlth, Effect Care Res Unit, East London, South Africa; [Betran, Ana Pilar; Seuc, Armando H.; Lawrie, Theresa A.] WHO, Dept Reprod Hlth & Res, Programme Res Dev & Res Training Human Reprod, HRP UNDP UNFPA UNICEF WHO World Bank Special, Geneva, Switzerland; [Cormick, Gabriela; Ciganda, Alvaro; Bergel, Eduardo; Belizan, Jose M.] Consejo Nacl Invest Cient & Tecn, Inst Clin Effectiveness & Hlth Policy IECS, Dept Mother & Child Hlth Res, Buenos Aires, DF, Argentina; [Cormick, Gabriela] Univ Cape Town, Fac Hlth Sci, Dept Human Biol, Cape Town, South Africa; [Fawcus, Susan] Univ Cape Town, Dept Obstet & Gynaecol, Cape Town, South Africa; [Munjanja, Stephen P.] Univ Zimbabwe, Harare, Zimbabwe; [Mose, Simpiwe] Univ Witwatersrand, Chris Hani Baragwanath Hosp, Dept Obstet & Gynaecol, Johannesburg, South Africa; [Hall, David] Stellenbosch Univ, Dept Obstet & Gynaecol, Cape Town, South Africa; [Hall, David] Tygerberg Hosp, Cape Town, South Africa; [Roberts, James M.] Univ Pittsburgh, Magee Womens Res Inst, Dept Obstet & Gynecol, Epidemiol & Clin & Translat Res, Pittsburgh, PA USA; [von Dadelszen, Peter] Kings Coll London, Sch Life Course Sci, Dept Women & Childrens Hlth, London, England	University of Witwatersrand; Walter Sisulu University; University of Fort Hare; World Health Organization; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Cape Town; University of Cape Town; University of Zimbabwe; University of Witwatersrand; Stellenbosch University; Tygerberg Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; University of London; King's College London	Lawrie, TA (corresponding author), WHO, Dept Reprod Hlth & Res, Geneva, Switzerland.	tess@lawrie.com	CORMICK, Gabriela/AAZ-7509-2021; Mose, Simpiwe/AAH-8713-2020; von Dadelszen, Peter/AAP-7480-2021; Roberts, James/AAI-3283-2020	CORMICK, Gabriela/0000-0001-7958-7358; Mose, Simpiwe/0000-0002-6625-616X; Roberts, James/0000-0002-2671-3207; Vidler, Marianne/0000-0002-7633-8812; Belizan, Jose/0000-0002-8412-3010; von Dadelszen, Peter/0000-0003-4136-3070	University of British Columbia of the Bill & Melinda Gates Foundation; UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction, WHO; Argentina Fund for Horizontal Cooperation of the Argentinean Ministry of Foreign Affairs; Centre for Intervention Science in Maternal and Child Health	University of British Columbia of the Bill & Melinda Gates Foundation; UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction, WHO; Argentina Fund for Horizontal Cooperation of the Argentinean Ministry of Foreign Affairs; Centre for Intervention Science in Maternal and Child Health	The University of British Columbia, a grantee of the Bill & Melinda Gates Foundation; UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction, WHO; the Argentina Fund for Horizontal Cooperation of the Argentinean Ministry of Foreign Affairs; and the Centre for Intervention Science in Maternal and Child Health.	Avenir, 2016, ONEHEALTH TOOL INT I; Bassaw B., 1998, Journal of Obstetrics and Gynaecology (Abingdon), V18, P123; BELIZAN JM, 1980, AM J CLIN NUTR, V33, P2202, DOI 10.1093/ajcn/33.10.2202; BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002; Cormick G, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1885-z; Crowther CA, 1999, AUST NZ J OBSTET GYN, V39, P12, DOI 10.1111/j.1479-828X.1999.tb03434.x; Dildy GA, 2007, SEMIN PERINATOL, V31, P135, DOI 10.1053/j.semperi.2007.03.005; HAMLIN RHJ, 1962, LANCET, V1, P864; Hofmeyr GJ, 2008, HYPERTENS PREGNANCY, V27, P299, DOI 10.1080/10641950701826802; Hofmeyr GJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001059.pub4; Hofmeyr GJ, PROTOCOL 11PRT 4028; Hofmeyr GJ, 2017, COCHRANE DB SYST REV, V9; Kassebaum NJ, 2014, LANCET, V384, P980, DOI 10.1016/S0140-6736(14)60696-6; Lawrie TA, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2220-0; Levine RJ, 1997, NEW ENGL J MED, V337, P69, DOI 10.1056/NEJM199707103370201; Li X., 2000, J XIAN MEDY, V21, P46; LOPEZJARAMILLO P, 1990, LANCET, V335, P293, DOI 10.1016/0140-6736(90)90112-I; MARYA RK, 1987, GYNECOL OBSTET INVES, V24, P38, DOI 10.1159/000298772; Medical Research Council, DIET ASS PHYS ACT ME; Merialdi M., 2005, FETAL MATERN MED REV, V16, P97, DOI [DOI 10.1017/S0965539505001506, 10.1017/s0965539505001506]; Newmark HL, 2004, AM J CLIN NUTR, V80, P264, DOI 10.1093/ajcn/80.2.264; Purwar M, 1996, J Obstet Gynaecol Res, V22, P425; Rumiris D, 2006, HYPERTENS PREGNANCY, V25, P241, DOI 10.1080/10641950600913016; Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X; Souza JP, 2013, LANCET, V381, P1747, DOI 10.1016/S0140-6736(13)60686-8; Villar J, 2006, AM J OBSTET GYNECOL, V194, P639, DOI 10.1016/j.ajog.2006.01.068; VILLAR J, 1987, OBSTET GYNECOL, V70, P317; Villar K., 2003, ECLAMPSIA PREECLAMPS, P189; World Health . Organization, 2013, GUID CALC SUPPL PREG	29	55	59	1	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 26	2019	393	10169					330	339		10.1016/S0140-6736(18)31818-X	http://dx.doi.org/10.1016/S0140-6736(18)31818-X			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HI9WK	30696573	Green Published, hybrid			2023-01-03	WOS:000456808200024
J	Goupy, F; Supiot, S; Pasquier, D; Latorzeff, I; Schick, U; Monpetit, E; Martinage, G; Herve, C; Le Proust, B; Castelli, J; de Crevoisier, R				Goupy, Flora; Supiot, Stephane; Pasquier, David; Latorzeff, Igor; Schick, Ulrike; Monpetit, Erik; Martinage, Geoffrey; Herve, Chloe; Le Proust, Bernadette; Castelli, Joel; de Crevoisier, Renaud			Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b): A multicentric retrospective analysis	PLOS ONE			English	Article							ADJUVANT ANDROGEN DEPRIVATION; EXTERNAL-BEAM RADIOTHERAPY; RATE BRACHYTHERAPY BOOST; PHASE-III TRIAL; RADIATION-THERAPY; RADICAL PROSTATECTOMY; RANDOMIZED-TRIAL; PROGNOSTIC-SIGNIFICANCE; DOSE-RESPONSE; INVASION	Objectives No study has reported clinical results of external-beam radiotherapy specifically for T3b prostate cancer. The possibility of escalating the dose to the involved seminal vesicles (ISV) while respecting the dose constraints in the organs at risk is thus so far not clearly demonstrated. The objective of the study was to analyze the dose distribution and the clinical outcome in a large series of patients who received IMRT for T3b prostate cancer. Materials and methods This retrospective analysis included all patients who received IMRT and androgen deprivation therapy for T3b prostate cancer, between 2008 and 2017, in six French institutions, with available MRI images and dosimetric data. Results A total of 276 T3b patients were included. The median follow-up was 26 months. The median (range) prescribed doses (Gy) to the prostate and to the ISV were 77 (70-80) and 76 (46-80), respectively. The dose constraint recommendations were exceeded in less than 12% of patients for the rectum and the bladder. The 5-year risks of biochemical and clinical recurrences and cancer-specific death were 24.8%, 21.7%, and 10.3%, respectively. The 5year risks of local, pelvic lymph node, and metastatic recurrences were 6.4%, 11.3%, and 15%, respectively. The number of involved lymph nodes (<= 2 or >= 3) on MRI was the only significant prognostic factor in clinical recurrence (HR 9.86) and death (HR 2.78). Grade. 2 acute and 5-year late toxicity rates were 13.2% and 12% for digestive toxicity, and 34% and 31.5% for urinary toxicity, respectively. The dose to the pelvic lymph node and the age were predictive of late digestive toxicity. Conclusion IMRT for T3b prostate cancer allows delivery of a curative dose in the ISV, with a moderate digestive toxicity but a higher urinary toxicity. Lymph node involvement increases the risk of recurrence and death.	[Goupy, Flora; Herve, Chloe; Castelli, Joel; de Crevoisier, Renaud] CLCC Eugene Marquis, Radiat Dept, Rennes, France; [Supiot, Stephane] CLCC Rene Gauducheau, Radiat Dept, Nantes, France; [Pasquier, David; Martinage, Geoffrey] CLCC Oscar Lambret, Radiat Dept, Lille, France; [Latorzeff, Igor] Clin Pasteur, Radiat Dept, Toulouse, France; [Schick, Ulrike] Univ Hosp Cavale Blanche, Radiat Dept, Brest, France; [Monpetit, Erik] Clin St Yves, Radiat Dept, Vannes, France; [Le Proust, Bernadette] CLCC Eugene Marquis, Med Imaging Dept, Rennes, France; [Castelli, Joel; de Crevoisier, Renaud] Univ Rennes 1, LTSI, Inserm U1099, Rennes, France	UNICANCER; Centre Eugene Marquis; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); UNICANCER; Centre Oscar Lambret; CHU Brest; UNICANCER; Centre Eugene Marquis; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes	de Crevoisier, R (corresponding author), CLCC Eugene Marquis, Radiat Dept, Rennes, France.; de Crevoisier, R (corresponding author), Univ Rennes 1, LTSI, Inserm U1099, Rennes, France.	r.de-crevoisier@rennes.unicancer.fr	de Crevoisier, Renaud/ABD-7321-2020; CASTELLI, joël/P-6142-2018; Supiot, Stéphane/M-1586-2015; Pasquier, David/O-8004-2014	CASTELLI, joël/0000-0001-6128-1836; Supiot, Stéphane/0000-0003-2094-1708; Pasquier, David/0000-0001-6019-7309				Abdollah F, 2018, EUR UROL, V74, P253, DOI 10.1016/j.eururo.2018.04.017; Amini A, 2016, J UROLOGY, V195, P1453, DOI 10.1016/j.juro.2015.11.005; Bastide C, 2012, BJU INT, V109, P525, DOI 10.1111/j.1464-410X.2011.10332.x; Beckendorf V, 2011, INT J RADIAT ONCOL, V80, P1056, DOI 10.1016/j.ijrobp.2010.03.049; Bolla M, 2009, NEW ENGL J MED, V360, P2516, DOI 10.1056/NEJMoa0810095; Brajtbord JS, 2011, BJU INT, V107, P1419, DOI 10.1111/j.1464-410X.2010.09599.x; Broughman JR, 2017, SEMIN RADIAT ONCOL, V27, P79, DOI 10.1016/j.semradonc.2016.08.006; Cahlon O, 2008, INT J RADIAT ONCOL, V71, P330, DOI 10.1016/j.ijrobp.2007.10.004; Cahlon O, 2008, SEMIN RADIAT ONCOL, V18, P48, DOI 10.1016/j.semradonc.2007.09.007; Cornud F, 2002, RADIOLOGY, V224, P203, DOI 10.1148/radiol.2241011001; D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969; Dayes IS, 2017, INT J RADIAT ONCOL, V99, P90, DOI 10.1016/j.ijrobp.2017.05.013; de Rooij M, 2016, EUR UROL, V70, P233, DOI 10.1016/j.eururo.2015.07.029; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Ennis RD, 2018, J CLIN ONCOL, V36, P1192, DOI 10.1200/JCO.2017.75.9134; Fiorino C, 2009, RADIOTHER ONCOL, V93, P153, DOI 10.1016/j.radonc.2009.08.004; Freedland SJ, 2004, CANCER-AM CANCER SOC, V100, P1633, DOI 10.1002/cncr.20122; Grivas N, 2018, EUR J RADIOL, V98, P107, DOI 10.1016/j.ejrad.2017.11.013; Hanks GE, 2003, J CLIN ONCOL, V21, P3972, DOI 10.1200/JCO.2003.11.023; Hoskin PJ, 2012, RADIOTHER ONCOL, V103, P217, DOI 10.1016/j.radonc.2012.01.007; Jang WS, 2017, ANN SURG ONCOL, V24, P1143, DOI 10.1245/s10434-016-5653-x; Koutrouvelis PG, 2003, RADIOTHER ONCOL, V67, P303, DOI 10.1016/S0167-8140(03)00079-3; Kristiansen A, 2017, PATHOLOGY, V49, P715, DOI 10.1016/j.pathol.2017.08.008; Lee HJ, 2016, INT J UROL, V23, P758, DOI 10.1111/iju.13144; Liang J, 2009, INT J RADIAT ONCOL, V73, P935, DOI 10.1016/j.ijrobp.2008.10.019; Lin CC, 2015, J NATL CANC I, V107; Marks LB, 2010, INT J RADIAT ONCOL, V76, pS10, DOI 10.1016/j.ijrobp.2009.07.1754; McMahon CJ, 2010, RADIOLOGY, V254, P31, DOI 10.1148/radiol.2541090361; Michalski JM, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2018.0039; Michalski JM, 2005, INT J RADIAT ONCOL, V62, P706, DOI 10.1016/j.ijrobp.2004.11.028; Mikel Hubanks J, 2014, UROL ONCOL, V32; Morlacco A, 2017, EUR UROL, V71, P701, DOI 10.1016/j.eururo.2016.08.015; Moschini M, 2017, BJU INT, V120, P69, DOI 10.1111/bju.13683; Pagano MJ, 2016, PROSTATE, V76, P226, DOI 10.1002/pros.23114; Peeters STH, 2006, J CLIN ONCOL, V24, P1990, DOI 10.1200/JCO.2005.05.2530; Pierorazio PM, 2011, J UROLOGY, V185, P1691, DOI 10.1016/j.juro.2010.12.059; Pollack A, 2002, INT J RADIAT ONCOL, V53, P1097, DOI 10.1016/S0360-3016(02)02829-8; Rades D, 2007, STRAHLENTHER ONKOL, V183, P398, DOI 10.1007/s00066-007-1643-z; Roach M, 2006, INT J RADIAT ONCOL, V65, P965, DOI 10.1016/j.ijrobp.2006.04.029; Rodda S, 2017, INT J RADIAT ONCOL, V98, P286, DOI 10.1016/j.ijrobp.2017.01.008; Rusthoven CG, 2014, INT J RADIAT ONCOL, V88, P1064, DOI 10.1016/j.ijrobp.2014.01.008; Ryu JK, 2002, INT J RADIAT ONCOL, V54, P1036, DOI 10.1016/S0360-3016(02)03006-7; Salembier C, 2018, RADIOTHER ONCOL, V127, P49, DOI 10.1016/j.radonc.2018.01.014; Salomon L, 2003, UROLOGY, V62, P304, DOI 10.1016/S0090-4295(03)00373-X; Secin FP, 2006, CANCER-AM CANCER SOC, V106, P2369, DOI 10.1002/cncr.21895; Seisen T, 2017, EUR UROL; Sheng Y, 2017, INT J RADIAT ONCOL, V98, P473, DOI 10.1016/j.ijrobp.2017.02.089; Siddiqui SA, 2011, BJU INT, V107, P383, DOI 10.1111/j.1464-410X.2010.09565.x; Sofer M, 2003, J UROLOGY, V169, P153, DOI 10.1016/S0022-5347(05)64057-8; Soylu FN, 2013, RADIOLOGY, V267, P797, DOI 10.1148/radiol.13121319; Spratt DE, 2013, INT J RADIAT ONCOL, V85, P686, DOI 10.1016/j.ijrobp.2012.05.023; Stone NN, 2012, BRACHYTHERAPY, V11, P334, DOI 10.1016/j.brachy.2011.12.008; Stone NN, 2018, BJU INT, V54; Swanson GP, 2008, J UROLOGY, V180, P2453, DOI 10.1016/j.juro.2008.08.037; Touijer KA, 2018, EUR UROL, V73, P890, DOI 10.1016/j.eururo.2017.09.027; Tsumura H, 2017, PROSTATE, V77, P1520, DOI 10.1002/pros.23430; van der Burgt M, 2015, RADIOTHER ONCOL, V117, P283, DOI 10.1016/j.radonc.2015.09.031; Van Hemelryk A, 2016, INT J RADIAT ONCOL, V96, P323, DOI 10.1016/j.ijrobp.2016.06.011; Zelefsky MJ, 2008, INT J RADIAT ONCOL, V70, P1124, DOI 10.1016/j.ijrobp.2007.11.044	59	10	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2019	14	1							e0210514	10.1371/journal.pone.0210514	http://dx.doi.org/10.1371/journal.pone.0210514			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ2YV	30682036	Green Published, gold, Green Submitted			2023-01-03	WOS:000457037500042
J	Agarwal, SD; Barnett, ML; Souza, J; Landon, BE				Agarwal, Sumit D.; Barnett, Michael L.; Souza, Jeffrey; Landon, Bruce E.			Adoption of Medicare's Transitional Care Management and Chronic Care Management Codes in Primary Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PAYMENT		[Agarwal, Sumit D.] Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, 75 Francis St, Boston, MA 02115 USA; [Barnett, Michael L.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA; [Souza, Jeffrey; Landon, Bruce E.] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Agarwal, SD (corresponding author), Brigham & Womens Hosp, Div Gen Internal Med, 1620 Tremont St, Boston, MA 02120 USA.	sagarwal14@bwh.harvard.edu	Barnett, Michael/ABA-4159-2021; Barnett, Michael/AAF-4017-2019	Barnett, Michael/0000-0002-4884-6609; Barnett, Michael/0000-0002-4884-6609	Health Resources and Services Administration (National Research Service Award for Primary Care) [T32-HP10251]; Ryoichi Sasakawa Fellowship Fund; National Institute on Aging of the National Institutes of Health [K23 AG058806-01]; NATIONAL INSTITUTE ON AGING [K23AG058806] Funding Source: NIH RePORTER	Health Resources and Services Administration (National Research Service Award for Primary Care); Ryoichi Sasakawa Fellowship Fund; National Institute on Aging of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This article was supported by grants from the Health Resources and Services Administration (National Research Service Award for Primary Care T32-HP10251), the Ryoichi Sasakawa Fellowship Fund, and the National Institute on Aging of the National Institutes of Health (K23 AG058806-01).	Basu S, 2015, ANN INTERN MED, V163, P580, DOI 10.7326/M14-2677; Bindman AB, 2013, NEW ENGL J MED, V368, P692, DOI 10.1056/NEJMp1214122; Burton R, 2017, MEDICARES EVOLVING A; Centers for Medicare & Medicaid Services, OV MED PHYS FEE SCHE; Centers for Medicare & Medicaid Services, PROGR GUID SPEC; Edwards ST, 2014, NEW ENGL J MED, V371, P2049, DOI 10.1056/NEJMp1410790	6	15	15	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	2018	320	24					2596	2597		10.1001/jama.2018.16116	http://dx.doi.org/10.1001/jama.2018.16116			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG1EK	30575868	Green Accepted, Bronze			2023-01-03	WOS:000454693000021
J	Liu, WW; Yuan, SW; Wei, FQ; Yang, J; Ma, J				Liu, Wenwei; Yuan, Suwei; Wei, Fengqin; Yang, Jing; Ma, Jin			Inappropriate admissions of the cardiology and orthopedics departments of a tertiary hospital in Shanghai, China	PLOS ONE			English	Article							APPROPRIATENESS; COST	Objectives Admission rates have increased in China, despite the fact that accessibility to primary care is improving. Hospital care could be cost-inefficient, and little is currently known about the appropriateness of admissions to tertiary hospitals in China. This study aims to measure the extent of inappropriate admissions in the cardiology and orthopedics departments of a tertiary hospital in Shanghai, to explore the factors associated with inappropriateness for each department, and to identify the causes of inappropriate admissions. Methods The records of inpatients discharged on randomly sampled two days each week during March 2013 to February 2014 from the two departments were extracted. Two reviewers were recruited to assess the records according to the Chinese version of the Appropriateness Evaluation Protocol (C-AEP). Demographic, socio-economic, and other admissions-related variables were collected. Logistic regression analysis was adopted to determine the associated factors of inappropriateness. Results 35.0% (N = 120) of the 343 admissions and 38.7% (N = 179) of the 463 admissions of the cardiology and orthopedics departments were not justified by the C-AEP, respectively. Age (OR = 0.717), self-pay (OR = 3.752), admission via outpatient sector (OR = 5.332), and readmission (OR = 2.501) were identified as factors affecting the appropriateness of admissions in the cardiology department. Age (OR = 0.930), self-pay (OR = 2.597), admission during 12:00-17:59 (OR = 3.211), and admission via outpatient sector (OR = 7.060) were determined to be associated with appropriateness of admission in the orthopedics department. The main reason for inappropriateness was premature admission for both departments. Conclusions The magnitude of inappropriate admissions was considerable in the departments. To improve appropriateness, the results suggest that further interventions should be focused on both external and internal factors.	[Liu, Wenwei] Shanghai Normal Univ, Coll Philosophy Law & Polit Sci, Shanghai, Peoples R China; [Yuan, Suwei; Wei, Fengqin; Ma, Jin] Shanghai Jiao Tong Univ, Sch Med, Sch Publ Hlth, Shanghai, Peoples R China; [Yuan, Suwei] Shanghai Jiao Tong Univ, China Hosp Dev Inst, Shanghai, Peoples R China; [Yang, Jing] Shanghai Rui Jin Hosp, Dept Med Adm, Shanghai, Peoples R China	Shanghai Normal University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Ma, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Sch Publ Hlth, Shanghai, Peoples R China.	majin@shsmu.edu.cn		Liu, Wenwei/0000-0002-5086-9033	National Natural Science Foundation of China [71273175]; Shanghai Normal University [A-7031-18-004021]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Normal University	This work was supported by National Natural Science Foundation of China [grant number 71273175 to JM], Shanghai Normal University [grant number A-7031-18-004021 to WL]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angelillo IF, 2000, PUBLIC HEALTH, V114, P9, DOI 10.1038/sj.ph.1900609; [Anonymous], 2010, CHIN HLTH STAT YB 20; Apolone G, 1997, EUR J PUBLIC HEALTH, V7, P34, DOI 10.1093/eurpub/7.1.34; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; Brabrand M, 2011, BMC HEALTH SERV RES, V11, P1; Brabrand M, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-152; Rodriguez FC, 2006, ARCH BRONCONEUMOL, V42, P440, DOI 10.1016/S1579-2129(06)60566-1; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chopard P, 1998, INT J EPIDEMIOL, V27, P513, DOI 10.1093/ije/27.3.513; ERMANN D, 1988, J HEALTH POLIT POLIC, V13, P683, DOI 10.1215/03616878-13-4-683; Frakt AB, 2011, MILBANK Q, V89, P90, DOI 10.1111/j.1468-0009.2011.00621.x; GERTMAN PM, 1981, MED CARE, V19, P855, DOI 10.1097/00005650-198108000-00005; Guangjun Y, 2013, CHINESE HOSP, P1; He L, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-34; Jepsen HK, 2013, DAN MED J, V60, P1; Khabiri R, 2015, GLOB J HLTH SCI, V7, P82; Langenbrunner JC, 2002, HOSP CHANGING EUROPE; Liu Q, 2011, LANCET, V377, P2064, DOI 10.1016/S0140-6736(11)60167-0; Liu WW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136498; Mannocci A, 2015, J MATERN-FETAL NEO M, V28, P1542, DOI 10.3109/14767058.2014.960833; National Health and Family Planning Commission of the People's Republic of China, 2015, CHIN HLTH STAT YB 20; Perneger TV, 1997, ARCH INTERN MED, V157, P1495, DOI 10.1001/archinte.157.13.1495; Pileggi C, 2004, PUBLIC HEALTH, V118, P284, DOI 10.1016/j.puhe.2003.06.002; Poppa G, 2012, ITALIAN J PUBLIC HLT, V6, P341; RESTUCCIA JD, 1995, INT J QUAL HEALTH C, V7, P253, DOI 10.1093/intqhc/7.3.253; Soria-Aledo V, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-361; Soria-Aledo V, 2009, AM J MED QUAL, V24, P321, DOI 10.1177/1062860609337252; SWEENEY GH, 1982, SOUTHERN ECON J, V48, P594, DOI 10.2307/1058653; Tamames S, 2007, BMC HEALTH SERV RES, V7, P1; [陶婧婧 Tao Jingjing], 2013, [上海交通大学学报. 医学版, Journal of Shanghai Jiaotong University .Medical Science], V33, P1146; Winickoff RN, 1991, MED CARE, P64; Zhan YQ, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-144; Zhang Y., 2014, CHIN HLTH SERV MANAG, V31, P678; Zhou XY, 2013, CHINESE HLTH QUALITY, V20, P33	34	3	3	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2018	13	12							e0208146	10.1371/journal.pone.0208146	http://dx.doi.org/10.1371/journal.pone.0208146			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HE9NT	30566422	Green Published, Green Submitted, gold			2023-01-03	WOS:000453779300024
J	Oliveira, MM; Marti, C; Ramlawi, M; Sarasin, FP; Grosgurin, O; Poletti, PA; Rouyer, F; Rutschmann, OT				Oliveira, Marta Morais; Marti, Christophe; Ramlawi, Majd; Sarasin, Francois P.; Grosgurin, Olivier; Poletti, Pierre-Alexandre; Rouyer, Frederic; Rutschmann, Olivier T.			Impact of a patient-flow physician coordinator on waiting times and length of stay in an emergency department: A before-after cohort study	PLOS ONE			English	Article							TEAM TRIAGE; THROUGHPUT	Objective Overcrowding is common in most emergency departments (ED). Despite the use of validated triage systems, some patients are at risk of delayed medical evaluation. The objective of this study was to assess the impact of a patient-flow physician coordinator (PFPC) on the proportion of patients offered medical evaluation within time limits imposed by the Swiss Emergency Triage Scale (SETS) and on patient flow within the emergency department of a teaching urban hospital. Methods In this before-after retrospective cohort study, we compared the proportions of patients who received their first medical contact within SETS-imposed time limits, mean waiting times before first medical consultation, mean length of stay, and number of patients who left with-out being seen by a physician, between two periods before and after introducing a PFPC. The PFPC was a senior physician charged with quickly assessing in the waiting area patients who could not immediately be seen and managing patient flow within the department. Results Before introducing the PFPC position, 33,605 patients were admitted, versus 36,288 after. Introducing a PFPC enabled the department to increase the proportion of patients seen within the SETS-imposed time limits from 60.1% to 69.0% (p <0.0001). Waiting times until first medical consultation were reduced on average by 27.7 minutes (95% confidence interval [95% CI]: 25.9-29.5, p < .0001). No significant differences were observed as to length of stay or number of patients who left without being seen between the two study periods. Conclusions Introducing a physician dedicated to managing patient flow enabled waiting times until first medical consultation to be reduced, yet had no significant benefit for patient flow within the ED, nor did it reduce the number of patients who left without being seen.	[Oliveira, Marta Morais] Geneva Sch Med, Geneva, Switzerland; [Marti, Christophe] Geneva Univ Hosp, Div Gen Internal Med, Dept Internal Med Rehabil & Geriatr, Geneva, Switzerland; [Marti, Christophe; Ramlawi, Majd; Sarasin, Francois P.; Grosgurin, Olivier; Poletti, Pierre-Alexandre; Rouyer, Frederic; Rutschmann, Olivier T.] Sch Med, Geneva, Switzerland; [Ramlawi, Majd; Sarasin, Francois P.; Grosgurin, Olivier; Poletti, Pierre-Alexandre; Rouyer, Frederic; Rutschmann, Olivier T.] Geneva Univ Hosp, Dept Community Primary Care & Emergency Med, Div Emergency Med, Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva; University of Geneva	Rutschmann, OT (corresponding author), Sch Med, Geneva, Switzerland.; Rutschmann, OT (corresponding author), Geneva Univ Hosp, Dept Community Primary Care & Emergency Med, Div Emergency Med, Geneva, Switzerland.	olivier.rutschmann@hcuge.ch	grosgurin, olivier/AAT-5605-2021	rouyer, frederic/0000-0002-5727-0859				Abdulwahid MA, 2016, EMERG MED J, V33, P504, DOI 10.1136/emermed-2014-204388; Begaz T, 2017, ANN EMERG MED, V69, P298, DOI 10.1016/j.annemergmed.2016.06.040; Burstrom L, 2016, UPSALA J MED SCI, V121, P38, DOI 10.3109/03009734.2015.1100223; Chan TC, 2005, ANN EMERG MED, V46, P491, DOI 10.1016/j.annemergmed.2005.06.013; Cheng I, 2013, BMC EMERG MED, V13, DOI 10.1186/1471-227X-13-17; Grant S, 1999, EMERGEN MED, V11, p72?7, DOI DOI 10.1046/J.1442-2026.1999.00017.X; Han JH, 2010, J EMERG MED, V39, P227, DOI 10.1016/j.jemermed.2008.10.006; Holroyd BR, 2007, ACAD EMERG MED, V14, P702, DOI 10.1197/j.aem.2007.04.018; Hoot NR, 2008, ANN EMERG MED, V52, P126, DOI 10.1016/j.annemergmed.2008.03.014; Lauks J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154372; Nestler DM, 2012, ACAD EMERG MED, V19, P1235, DOI 10.1111/acem.12010; Partovi SN, 2001, ACAD EMERG MED, V8, P990, DOI 10.1111/j.1553-2712.2001.tb01099.x; Rowe BH, 2011, ACAD EMERG MED, V18, P111, DOI 10.1111/j.1553-2712.2010.00984.x; Rutschmann OT, 2018, EUR J EMERG MED, V25, P264, DOI 10.1097/MEJ.0000000000000449; Rutschmann OT, 2006, J CLIN EPIDEMIOL, V59, P615, DOI 10.1016/j.jclinepi.2005.11.003; Subash F, 2004, EMERG MED J, V21, P542, DOI 10.1136/emj.2002.003665; Terris J, 2004, EMERG MED J, V21, P537, DOI 10.1136/emj.2002.003913; Travers JP, 2006, EUR J EMERG MED, V13, P342; van der Linden N, 2016, EUR J EMERG MED, V23, P337, DOI 10.1097/MEJ.0000000000000268; Veit-Rubin N, 2017, BJOG-INT J OBSTET GY, V124, P1867, DOI 10.1111/1471-0528.14535	20	10	10	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2018	13	12							e0209035	10.1371/journal.pone.0209035	http://dx.doi.org/10.1371/journal.pone.0209035			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE3IQ	30550579	gold, Green Published, Green Submitted			2023-01-03	WOS:000453248000039
J	Zhang, Y; Fu, B; Liu, CX; Yu, SY; Luo, TY; Zhang, L; Zhou, WJ; Yu, T				Zhang, Yu; Fu, Bao; Liu, Chengxi; Yu, Shouyang; Luo, Tianyuan; Zhang, Lin; Zhou, Wenjing; Yu, Tian			Activation of noradrenergic terminals in the reticular thalamus delays arousal from propofol anesthesia in mice	FASEB JOURNAL			English	Article						general anesthesia; thalamic reticular nucleus; adrenoceptor; locus coeruleus; DREADDs	LOCUS-COERULEUS; GLUTAMATERGIC TRANSMISSION; BASOLATERAL AMYGDALA; GABAERGIC INHIBITION; GENERAL-ANESTHESIA; SUBSTANTIA-NIGRA; MODULATION; NUCLEUS; NORADRENALINE; NEURONS	Electroencephalogram monitoring during propofol (PRO) anesthesia typically features low-frequency oscillations, which may be involved with thalamic reticular nucleus (TRN) modulation. TRN receives noradrenergic inputs from the locus coeruleus (LC). We hypothesized that specific noradrenergic connections in the TRN may contribute to the emergence from PRO anesthesia. Intranuclei norepinephrine (NE) injections (n = 10) and designer receptors exclusively activated by designer drugs (DREADDs) (n = 10) were used to investigate the role of noradrenergic inputs from the LC to the TRN during PRO anesthesia. Whole-cell recording in acute brain slice preparations was used to identify the type of adrenoceptor that regulates noradrenergic innervation in the TRN. An intracerebral injection of NE into the TRN delays arousal in mice recovering from PRO anesthesia (means +/- sd; 486.6 +/- 57.32 s for the NE injection group vs. 422.4 +/- 48.19 s for the control group; P = 0.0143) and increases the cortical-delta (0.1-4 Hz, 25.4 +/- 2.9 for the NE injection group vs. 21.0 +/- 1.7 for the control group; P = 0.0094) oscillation. An intra-TRN injection of NE also decreased the EC50 of PRO-induced unconsciousness (57.05 +/- 1.78 mg/kg for the NE injection group vs. 72.44 +/- 3.23 mg/kg for the control group; P = 0.0096). Moreover, the activation of LC-noradrenergic nerve terminals in the TRN using DREADDs increased the recovery time [466.1 +/- 44.57 s for the clozapine N-oxide (CNO) injection group vs. 426.1 +/- 38.75 s for the control group; P = 0.0033], decreased the EC50 of PRO-induced unconsciousness (64.77 +/- 3.40 mg/kg for the CNO injection group vs. 74.00 +/- 2.08 mg/kg for the control group; P = 0.0081), and increased the cortical-delta oscillation during PRO anesthesia (23.29 +/- 2.58 for the CNO injection group vs. 19.56 +/- 1.9 for the control group; P = 0.0213). In addition, whole-cell recording revealed that NE augmented the inhibitory postsynaptic currents in the TRN neurons via the alpha 1-adrenoceptor. Our data indicated that enhanced NE signaling at the noradrenergic terminals of the LC-TRN projection delays arousal from general anesthesia, which is likely mediated by the alpha 1-adrenoceptor activation. Our findings open a door for further understanding of the functions of various LC targets in both anesthesia and arousal.-Zhang, Y., Fu, B., Liu, C., Yu, S., Luo, T., Zhang, L., Zhou, W., Yu, T. Activation of noradrenergic terminals in the reticular thalamus delays arousal from propofol anesthesia in mice.	[Zhang, Yu] Zunyi Med Univ, Affiliated Hosp, Dept Anesthesiol, Zunyi, Guizhou, Peoples R China; [Fu, Bao] Zunyi Med Univ, Affiliated Hosp, Dept Crit Care Med, Zunyi, Guizhou, Peoples R China; [Zhang, Yu; Luo, Tianyuan; Zhang, Lin; Zhou, Wenjing; Yu, Tian] Zunyi Med Univ, Guizhou Key Lab Anesthesia & Organ Protect, Zunyi, Guizhou, Peoples R China; [Liu, Chengxi; Yu, Shouyang] Zunyi Med Univ, Guizhou Key Lab Brain Sci, Zunyi, Guizhou, Peoples R China	Zunyi Medical University; Zunyi Medical University; Zunyi Medical University; Zunyi Medical University	Yu, T (corresponding author), Zunyi Med Coll, Guizhou Key Lab Anesthesia & Organ Protect, Affiliated Hosp, 149 Dalian Rd, Zunyi 563000, Guizhou, Peoples R China.	dllyutian@163.com			National Natural Science Foundation of China (Beijing, China) [81760259, 81760206, 81571026]	National Natural Science Foundation of China (Beijing, China)(National Natural Science Foundation of China (NSFC))	The authors thank Prof. Daqing Ma (Imperial College London, London, United Kingdom) for critical comments during manuscript preparation and revision. The study is supported in part by the National Natural Science Foundation of China (Beijing, China) Grants 81760259 (to Y.Z.), 81760206 (to B.F.), and 81571026 (to T.Y.). The authors declare no conflicts of interest.	AKASU T, 1985, J PHYSIOL-LONDON, V361, P165, DOI 10.1113/jphysiol.1985.sp015639; Alkire MT, 2008, SCIENCE, V322, P876, DOI 10.1126/science.1149213; ANDREASEN M, 1991, J PHYSIOL-LONDON, V439, P649, DOI 10.1113/jphysiol.1991.sp018686; Bahraminasab A, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/10/103051; BICKFORD ME, 1994, J COMP NEUROL, V348, P481, DOI 10.1002/cne.903480402; Boly M, 2012, J NEUROSCI, V32, P7082, DOI 10.1523/JNEUROSCI.3769-11.2012; Chang AYW, 2001, HIPPOCAMPUS, V11, P783, DOI 10.1002/hipo.1094; CHEUN JE, 1992, NEUROSCIENCE, V51, P951, DOI 10.1016/0306-4522(92)90532-7; Chong W, 2004, J NEUROENDOCRINOL, V16, P450, DOI 10.1111/j.1365-2826.2004.01180.x; Crunelli V, 2014, REV NEUROSCIENCE, V25, P195, DOI 10.1515/revneuro-2013-0059; Dumont EC, 2004, J NEUROSCI, V24, P8198, DOI 10.1523/JNEUROSCI.0425-04.2004; DUNNE MJ, 1991, BRIT J PHARMACOL, V103, P1847, DOI 10.1111/j.1476-5381.1991.tb12340.x; Franks NP, 2008, NAT REV NEUROSCI, V9, P370, DOI 10.1038/nrn2372; Fu B, 2017, J NEUROCHEM, V140, P862, DOI 10.1111/jnc.13939; Fu B, 2016, NEUROCHEM RES, V41, P3181, DOI 10.1007/s11064-016-2042-6; GANDIA JA, 1993, BRAIN RES BULL, V32, P351, DOI 10.1016/0361-9230(93)90199-L; Gire DH, 2008, J NEUROPHYSIOL, V99, P2021, DOI 10.1152/jn.01324.2007; Gottschalk A, 2009, ANESTHESIOLOGY, V110, P996, DOI 10.1097/ALN.0b013e31819db923; Hirono M, 2006, J NEUROPHYSIOL, V95, P700, DOI 10.1152/jn.00711.2005; Jin YH, 2009, BRAIN RES, V1286, P75, DOI 10.1016/j.brainres.2009.06.058; KACHIDIAN P, 1990, NEUROSCI LETT, V109, P23, DOI 10.1016/0304-3940(90)90532-E; Kaneko K, 2008, NEUROSCIENCE, V157, P781, DOI 10.1016/j.neuroscience.2008.09.029; Kolmac CI, 1998, J COMP NEUROL, V396, P531; Kulik A, 1999, J NEUROSCI, V19, P8401; LaLumiere RT, 2003, J NEUROSCI, V23, P6754; Leenders AGM, 2005, PHARMACOL THERAPEUT, V105, P69, DOI 10.1016/j.pharmthera.2004.10.012; Leung LS, 2014, PROG NEUROBIOL, V122, P24, DOI 10.1016/j.pneurobio.2014.08.001; Lewis LD, 2015, ELIFE, V4, DOI 10.7554/eLife.08760; McCarren HS, 2013, JOVE-J VIS EXP, DOI 10.3791/51079; McCormick DA, 1997, ANNU REV NEUROSCI, V20, P185, DOI 10.1146/annurev.neuro.20.1.185; MCCORMICK DA, 1988, J NEUROPHYSIOL, V59, P978, DOI 10.1152/jn.1988.59.3.978; MCCORMICK DA, 1989, TRENDS NEUROSCI, V12, P215, DOI 10.1016/0166-2236(89)90125-2; Moncada D, 2011, P NATL ACAD SCI USA, V108, P12931, DOI 10.1073/pnas.1104495108; Murata Y, 1996, J BRAIN RES, V37, P15; Murphy M, 2011, SLEEP, V34, P283, DOI 10.1093/sleep/34.3.283; Ni KM, 2016, ELIFE, V5, DOI 10.7554/eLife.10382; PAPE HC, 1989, NATURE, V340, P715, DOI 10.1038/340715a0; PARE D, 1990, BRAIN RES, V535, P139, DOI 10.1016/0006-8993(90)91832-2; Paxinos G., 2001, MOUSE BRAIN STEREOTA, VSecond; Pinault D, 2004, BRAIN RES REV, V46, P1, DOI 10.1016/j.brainresrev.2004.04.008; Purdon PL, 2015, ANESTHESIOLOGY, V123, P937, DOI 10.1097/ALN.0000000000000841; Salgado H, 2011, CEREB CORTEX, V21, P212, DOI 10.1093/cercor/bhq081; Sara SJ, 2012, NEURON, V76, P130, DOI 10.1016/j.neuron.2012.09.011; Sloan TB, 1998, J CLIN NEUROPHYSIOL, V15, P217, DOI 10.1097/00004691-199805000-00005; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; Vazey EM, 2014, P NATL ACAD SCI USA, V111, P3859, DOI 10.1073/pnas.1310025111; Wakita M, 2013, EUR J PHARMACOL, V718, P63, DOI 10.1016/j.ejphar.2013.09.018; Ying SW, 2005, J NEUROPHYSIOL, V93, P1935, DOI 10.1152/jn.01058.2004; Zhao ZD, 2017, P NATL ACAD SCI USA, V114, P2042, DOI 10.1073/pnas.1616255114; Zhong HX, 2017, J CLIN INVEST, V127, P2295, DOI 10.1172/JCI91038	50	15	16	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2019	33	6					7252	7260		10.1096/fj.201802164RR	http://dx.doi.org/10.1096/fj.201802164RR			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	IJ7YD	30860868	Bronze			2023-01-03	WOS:000476114200048
J	Hiben, MG; de Haan, L; Spenkelink, B; Wesseling, S; Louisse, J; Vervoort, J; Rietjens, IMCM				Hiben, Mebrahtom Gebrelibanos; de Haan, Laura; Spenkelink, Bert; Wesseling, Sebas; Louisse, Jochem; Vervoort, Jacques; Rietjens, Ivonne M. C. M.			Effects of Maerua subcordata (Gilg) DeWolf on electrophile-responsive element (EpRE)-mediated gene expression in vitro	PLOS ONE			English	Article							NRF2/ARE PATHWAY; CANCER-CELLS; ISOTHIOCYANATES; PHYTOCHEMICALS; PREVENTION; ANNOTATION; ACTIVATION; EXTRACTION; INHIBITION; INDUCTION	Plant extracts and phytochemicals may prevent chronic diseases via activation of adaptive cellular stress response pathways including induction of antioxidant and phase II detoxifying enzymes. The regulatory regions of these inducible genes encode the electrophile-response element (EpRE). This study tested the EpRE induction ability of Maerua subcordata (fruit, leaf, root, seed) methanol extracts and selected candidate constituents thereof, identified by liquid chromatography coupled with multistage mass spectroscopy, employing an EpRE luciferase reporter gene assay using hepa-1c1c7 mouse hepatoma cells. A parallel Cytotox CALUX assay using human osteosarcoma U2OS cells was used to monitor any non-specific changes in luciferase activity or cytotoxicity. Results showed that fruit, root, and seed extracts were non-cytotoxic up to a concentration of 30 gram dry weight per litre but the leaf extract exhibited some cytotoxicity and that the leaf (despite some cytotoxicity), fruit, and seed extracts showed strong induction of EpRE mediated gene expression while induction by the root extract was minimal. Selected candidates included glucosinolates, isothiocyanates, and some biogenic amines. Subsequent studies showed that methyl-, ethyl-, isopropyl-, isobutyl-isothiocyanates, and sec-butyl thiocyanate as well as glucobrassicin induced concentration (1-100 mu M) dependent EpRE-mediated gene expression while the biogenic amines stachydrine and trigonelline acted as inhibitors of EpRE-mediated gene expression at 100 mu M. The identification of glucolepidiin, glucobrassicin, glucocapparin, stachydrine, and trigonelline in all extracts was confirmed using standards and based on multiple reaction monitoring; yet, glucobrassicin level in the root extract was negligible. In conclusion, this study provided a first report on EpRE mediated gene expression effects of M. subcordata; and despite detection of different glucosinolates in all extracts, those containing glucobrassicin particularly displayed high EpRE induction. Because EpRE inducers are cytoprotective and potential chemopreventive agents while inhibitors are suggested adjuvants of chemotherapy, results of this study imply that process manipulation of this plant may result in herbal preparations that may be used as chemopreventive agents or adjuvants of chemotherapies.	[Hiben, Mebrahtom Gebrelibanos; de Haan, Laura; Spenkelink, Bert; Wesseling, Sebas; Louisse, Jochem; Rietjens, Ivonne M. C. M.] Wageningen Univ, Div Toxicol, We Wageningen, Netherlands; [Hiben, Mebrahtom Gebrelibanos] Mekelle Univ, Sch Pharm, Dept Pharmacognosy, Coll Hlth Sci, Mekelle, Ethiopia; [Vervoort, Jacques] Wageningen Univ, Biochem Lab, We Wageningen, Netherlands	Wageningen University & Research; Mekelle University; Wageningen University & Research	Hiben, MG (corresponding author), Wageningen Univ, Div Toxicol, We Wageningen, Netherlands.; Hiben, MG (corresponding author), Mekelle Univ, Sch Pharm, Dept Pharmacognosy, Coll Hlth Sci, Mekelle, Ethiopia.	mebrahtomgs@yahoo.com		Louisse, Jochem/0000-0002-0517-2288	NUFFIC - the Netherlands Fellowship Programmes [NFP - PhD.15/0019, CF 09971]	NUFFIC - the Netherlands Fellowship Programmes	This work is part of a PhD project funded by NUFFIC - the Netherlands Fellowship Programmes, NFP - PhD.15/0019 Contract number CF 09971.	Abdo S, 2014, DIABETES, V63, P3483, DOI 10.2337/db13-1830; Angelino D, 2015, FRONT PLANT SCI, V6, DOI 10.3389/fpls.2015.00831; [Anonymous], AUSTIN J BIOORG ORG; Ares AM, 2016, J FOOD COMPOS ANAL, V46, P114, DOI 10.1016/j.jfca.2015.12.002; Arlt A, 2013, ONCOGENE, V32, P4825, DOI 10.1038/onc.2012.493; Atanasov AG, 2015, BIOTECHNOL ADV, V33, P1582, DOI 10.1016/j.biotechadv.2015.08.001; Auld DS, 2008, ACS CHEM BIOL, V3, P463, DOI 10.1021/cb8000793; Auld DS, 2004, ASSAY GUIDANCE MANUA, P917; Bianco G, 2012, J MASS SPECTROM, V47, P1160, DOI 10.1002/jms.2996; Blazevic I., 2014, AUSTIN J BIOORG ORG, V1, P4; Boeing H, 2012, EUR J NUTR, V51, P637, DOI 10.1007/s00394-012-0380-y; Boerboom AMJF, 2006, BIOCHEM PHARMACOL, V72, P217, DOI 10.1016/j.bcp.2006.04.002; Borek C., 2001, J NUTR, V131, p1010s; Bryan HK, 2013, BIOCHEM PHARMACOL, V85, P705, DOI 10.1016/j.bcp.2012.11.016; Cheruiyot K., 2013, J ETHNOBIOL TRADIT M, V120, P633; CHINI C, 1992, PLANTA MED, V58, P476, DOI 10.1055/s-2006-961522; Conforti F, 2011, FOOD SCI TECHNOL INT, V17, P87, DOI 10.1177/1082013210368583; DAXENBICHLER ME, 1991, PHYTOCHEMISTRY, V30, P2623, DOI 10.1016/0031-9422(91)85112-D; DELAVEAU P, 1973, PHYTOCHEMISTRY, V12, P2893, DOI 10.1016/0031-9422(73)80502-3; Dinkova-Kostova AT, 2012, TRENDS MOL MED, V18, P337, DOI 10.1016/j.molmed.2012.04.003; Doheny-Adams T, 2017, PLANT METHODS, V13, DOI 10.1186/s13007-017-0164-8; Eggler Aimee L, 2013, Recent Adv Phytochem, V43, P121; Fahey JW, 2001, PHYTOCHEMISTRY, V56, P5, DOI 10.1016/S0031-9422(00)00316-2; Freedman R., 2015, FAMINE FOODS CAPPARI; Gakuya DW, 2001, PHARM CLIN EVALUATIO; Giacoppo S, 2015, FITOTERAPIA, V106, P12, DOI 10.1016/j.fitote.2015.08.001; Gijsbers L, 2012, FOOD CHEM, V135, P1166, DOI 10.1016/j.foodchem.2012.05.073; Harder B, 2017, MOL CARCINOGEN, V56, P1493, DOI 10.1002/mc.22609; Ishida M, 2011, BREEDING SCI, V61, P208, DOI 10.1270/jsbbs.61.208; Joseph JA, 2009, J NUTR, V139, p1813S, DOI 10.3945/jn.109.108266; Kaigongi M., 2015, INT J ETHNOBIOL ETHN, V1, P1; Kaiser SJ, 2017, FITOTERAPIA, V119, P57, DOI 10.1016/j.fitote.2017.04.006; Keum YS, 2004, MUTAT RES-FUND MOL M, V555, P191, DOI 10.1016/j.mrfmmm.2004.05.024; KJAER A, 1963, PHYTOCHEMISTRY, V2, P29, DOI 10.1016/S0031-9422(00)88013-9; Krajka-Kuzniak V, 2017, PHARMACOL REP, V69, P393, DOI 10.1016/j.pharep.2016.12.011; Krajka-Kuzniak V, 2015, J PHYSIOL BIOCHEM, V71, P227, DOI 10.1007/s13105-015-0401-4; Kulisic-Bilusic T, 2012, FOOD CHEM, V132, P261, DOI 10.1016/j.foodchem.2011.10.074; Kumar H, 2014, NAT PROD REP, V31, P109, DOI 10.1039/c3np70065h; LOEWENTHAL R, 1991, J ETHNOPHARMACOL, V33, P227, DOI 10.1016/0378-8741(91)90081-N; LUNING B, 1992, BIOCHEM SYST ECOL, V20, P394, DOI 10.1016/0305-1978(92)90053-G; Maldini M, 2016, J MASS SPECTROM, V51, P716, DOI 10.1002/jms.3830; Matthiessen JN, 2005, PEST MANAG SCI, V61, P1043, DOI 10.1002/ps.1086; Mattson MP, 2006, TRENDS NEUROSCI, V29, P632, DOI 10.1016/j.tins.2006.09.001; McLean WFH, 1996, BIOCHEM SYST ECOL, V24, P427, DOI 10.1016/0305-1978(96)00044-0; Missler S.R., 2016, PLANTA MEDICA INT OP, V3, pe27; Mithen R, 2010, PHYTOCHEMISTRY, V71, P2074, DOI 10.1016/j.phytochem.2010.09.017; MORGAN WTW, 1981, ECON BOT, V35, P96, DOI 10.1007/BF02859220; Motahari P, 2015, DARU, V23, DOI 10.1186/s40199-015-0122-9; Murakami A, 2012, FOOD FUNCT, V3, P462, DOI 10.1039/c2fo10274a; Nagata N, 2017, DIABETES, V66, P1222, DOI 10.2337/db16-0662; Prinslool G, 2017, DRUG DISCOV TODAY, V22, P1187, DOI 10.1016/j.drudis.2017.05.002; Redovnikovic IR, 2008, PERIOD BIOL, V110, P297; Ridder L, 2013, ANAL CHEM, V85, P6033, DOI 10.1021/ac400861a; Ridder L, 2012, RAPID COMMUN MASS SP, V26, P2461, DOI 10.1002/rcm.6364; SAMUELSSON G, 1991, J ETHNOPHARMACOL, V35, P25, DOI 10.1016/0378-8741(91)90132-W; Smith Robert E, 2016, Diseases, V4, DOI 10.3390/diseases4040034; Son TG, 2008, NEUROMOL MED, V10, P236, DOI 10.1007/s12017-008-8037-y; Stefanson AL, 2014, NUTRIENTS, V6, P3777, DOI 10.3390/nu6093777; Sturm C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091890; Surh YJ, 2008, PLANTA MED, V74, P1526, DOI 10.1055/s-0028-1088302; Thorne N, 2010, CURR OPIN CHEM BIOL, V14, P315, DOI 10.1016/j.cbpa.2010.03.020; Tsuchida K, 2017, FREE RADICAL BIO MED, V103, P236, DOI 10.1016/j.freeradbiomed.2016.12.041; van der Linden SC, 2014, MUTAT RES-GEN TOX EN, V760, P23, DOI 10.1016/j.mrgentox.2013.09.009; Wagner AE, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/964539; Zhang YJ, 2015, MOLECULES, V20, P21138, DOI 10.3390/molecules201219753; Zhang YS, 2010, MOL NUTR FOOD RES, V54, P127, DOI 10.1002/mnfr.200900323; Zheng HZ, 2009, J ZHEJIANG UNIV-SC B, V10, P912, DOI 10.1631/jzus.B0920186	67	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2019	14	4							e0215155	10.1371/journal.pone.0215155	http://dx.doi.org/10.1371/journal.pone.0215155			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT4AF	30986264	Green Published, Green Submitted, gold			2023-01-03	WOS:000464503800022
J	Winter, SC; Dreibelbis, R; Dzombo, MN; Barchi, F				Winter, Samantha Cristine; Dreibelbis, Robert; Dzombo, Millicent Ningoma; Barchi, Francis			A mixed-methods study of women's sanitation utilization in informal settlements in Kenya	PLOS ONE			English	Article							WATER; HEALTH; HYGIENE; DISEASE; BURDEN; IMPACT; GENDER; SLUMS	While access to safe sanitation is a global issue, there are large disparities in access. Women living in informal settlements, in particular, are disproportionately affected by lack of access to sanitation. Without adequate sanitation, these women may resort to unsafe strategies to manage their sanitation needs, but limited research has focused specifically on this issue. Qualitative and quantitative data were collected from women in the Mathare informal settlement in Nairobi, Kenya in 2016. A latent class analysis (LCA) using the quantitative data yielded five distinct sanitation profiles (SP) among women in Mathare. In-depth interviews and sanitation walks with women added further detail about the characteristics of and motivations underlying each profile. Womens sanitation profiles in these settlements are complex. A majority of women in this study utilized an unsafe method of disposal at least once in a 24-hour period that increased their risk of direct exposure to waste and harmful pathogens.	[Winter, Samantha Cristine; Barchi, Francis] Rutgers State Univ, Edward J Bloustein Sch Planning & Publ Policy, New Brunswick, NJ 08901 USA; [Dreibelbis, Robert] London Sch Hyg & Trop Med, Dept Dis Control, London, England; [Dzombo, Millicent Ningoma] Univ Nairobi, Dept Sociol & Social Work, Nairobi, Kenya	Rutgers State University New Brunswick; University of London; London School of Hygiene & Tropical Medicine; University of Nairobi	Winter, SC (corresponding author), Rutgers State Univ, Edward J Bloustein Sch Planning & Publ Policy, New Brunswick, NJ 08901 USA.	winter.samantha@gmail.com		Winter, Samantha/0000-0001-6629-7642	National Security Education Program (NSEP); PEO International	National Security Education Program (NSEP); PEO International	The National Security Education Program (NSEP) and PEO International provided fellowship funding to specific researchers that made this project possible; however, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	African Population Health Research Center, 2002, POP HLTH DYN NAIR IN; [Anonymous], 2014, STAT SAN NAIR COUNT; [Anonymous], 2009, NEGL TROP DIS HIDD S; [Anonymous], 2010, INS IND WOM EXP SLUM; [Anonymous], 2017, EM PREP RESP CHOL KE; ArcGis Desktop, 2022, LOC ALL AN; Bartram J, 2005, LANCET, V365, P810, DOI 10.1016/S0140-6736(05)71007-2; Bartram J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000367; Bongartz P, 2016, SUSTAINABLE SANITATI; Bosch C., 2001, WATER SANITATION POV; Burt Z., 2016, GENDER EQUALITY SANI; Caruso BA, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14070755; Clasen T, 2014, TROP MED INT HEALTH, V19, P884, DOI 10.1111/tmi.12330; COHRE WaterAid SDC UN-HABITAT., 2008, SAN HUM RIGHTS IMP; Corbett JJ, 2015, J METHANE EMISSIONS, P1, DOI DOI 10.1155/2015/; Corburn J, 2016, HEALTH PROMOT INT, V31, P258, DOI 10.1093/heapro/dau100; Fisher J, 2008, P I CIVIL ENG-MUNIC, V161, P223, DOI 10.1680/muen.2008.161.4.223; Garn JV, 2017, INT J HYG ENVIR HEAL, V220, P329, DOI 10.1016/j.ijheh.2016.10.001; Gosling L., 2015, NOWHERE GO LACK SAFE; Gulyani S., 2006, INSIDE INFORMALITY P; Hirai M, 2016, J WATER SANIT HYG DE, V6, P151, DOI 10.2166/washdev.2016.128; Interagency Task Force on Gender and Water, 2006, GEND WAT SAN POL BRI; Isunju JB, 2011, PUBLIC HEALTH, V125, P368, DOI 10.1016/j.puhe.2011.03.008; Khanna T, 2016, GLOB PUBLIC HEALTH, V11, P1185, DOI 10.1080/17441692.2015.1062905; Khosla R, 2000, SOC CHANGE, V30, P192, DOI DOI 10.1177/004908570003000213; Kish L., 1965, SURVEY SAMPLING; Lundine J., 2012, CHILD YOUTH ENV, V22, P214, DOI [10.7721/chilyoutenvi.22.2.0214, DOI 10.7721/CHILYOUTENVI.22.2.0214]; Mahon T., 2010, Gender and Development, V18, P99, DOI 10.1080/13552071003600083; Massey K., 2011, INSECURITY SHAME EXP; Montgomery MA, 2007, ENVIRON SCI TECHNOL, V41, P17, DOI 10.1021/es072435t; Norstrom A, 2007, SWED WATER HOUSE REP, V21, P1; Pruss A, 2002, ENVIRON HEALTH PERSP, V110, P537, DOI 10.1289/ehp.02110537; Pruss-Ustun A., 2008, SAFER WATER BETTER H; Rheingans R, 2014, TROP MED INT HEALTH, V19, P2, DOI 10.1111/tmi.12220; Routray P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178042; Ruhiu J, 2009, STRATEGIC GUIDELINES; Sahoo KC, 2015, SOC SCI MED, V139, P80, DOI 10.1016/j.socscimed.2015.06.031; Schonlau, 2012, STATA ADO PACKAGE HO; Sclar ED, 2005, LANCET, V365, P901, DOI 10.1016/S0140-6736(05)71049-7; Tumwebaze IK, 2013, INT J ENVIRON HEAL R, V23, P191, DOI 10.1080/09603123.2012.713095; Unilever Domestos WaterAid (WSSCC) WSSCC, 2013, WE CANT WAIT REP SAN; United Nations Children Fund (UNICEF), 2007, WAT ENV SAN CHILDR W; WHO UNICEF, 2015, PROGR DRINK WAT SAN	43	6	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2019	14	3							e0214114	10.1371/journal.pone.0214114	http://dx.doi.org/10.1371/journal.pone.0214114			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP7SO	30897125	Green Published, Green Submitted, gold			2023-01-03	WOS:000461889700067
J	Aung, K				Aung, Koko			Guideline: Panel recommends maintaining SpO(2) at no higher than 96% in most acutely ill hospitalized patients	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							MANAGEMENT		[Aung, Koko] Paul L Foster Sch Med, El Paso, TX 79905 USA		Aung, K (corresponding author), Paul L Foster Sch Med, El Paso, TX 79905 USA.		Aung, KoKo/I-1236-2019	Aung, KoKo/0000-0002-3152-0610				Carvalho C R, 1998, Curr Opin Pulm Med, V4, P300, DOI 10.1097/00063198-199809000-00010; Chu DK, 2018, LANCET, V391, P1693, DOI 10.1016/S0140-6736(18)30479-3; KELLOGG RH, 1978, RESP PHYSIOL, V34, P1, DOI 10.1016/0034-5687(78)90046-4; O'Brien Jennifer, 2013, AANA J, V81, P205; O'Gara PT, 2013, CIRCULATION, V127, P529, DOI 10.1161/CIR.0b013e3182742c84; Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158; SASSOON CSH, 1987, AM REV RESPIR DIS, V135, P907, DOI 10.1164/arrd.1987.135.4.907	7	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 19	2019	170	6					JC26	JC26		10.7326/ACPJ201903190-026	http://dx.doi.org/10.7326/ACPJ201903190-026			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP1ZR	30884496				2023-01-03	WOS:000461468300003
J	Mao, WH; Huang, YY; Chen, W				Mao, Wenhui; Huang, Yunyu; Chen, Wen			An analysis on rational use and affordability of medicine after the implementation of National Essential Medicines Policy and Zero Mark-up Policy in Hangzhou, China	PLOS ONE			English	Article								Background The National Essential Medicine Policy and the Zero Mark-up Policy was introduced to improve the rational use and affordability of medicine. This study analyzed the changes of medicine use at different Health Care Institutions in Hangzhou city after the implementation of National Essential Medicine Policy and the Zero Mark-up Policy. Methods Facility based survey was conducted in 17 Health Care Institutions and 16406 outpatient prescriptions in 2011 and 2013 were collected. Average number of medicines, average number of antibiotics and average expenditure per prescription were analyzed. Comparisons between 2011 and 2013, among different levels of Health Care Institutions and age groups were conducted. Results The average number of medicines per prescription, use of antibiotics, intramuscular (IM) injections and intravenous (IV) injections decreased while the use of hormones increased. No significant change of the average medicine expenditure per prescription was observed. Disparities among different levels of Health Care Institutions and different age groups existed. Conclusion The problems of poly-pharmacy, overuse of antibiotics, intramuscular (IM) injections and intravenous (IV) injections and hormones still existed, however mitigated after the implementation of The National Essential Medicine Policy and the Zero Mark-up Policy.	[Mao, Wenhui; Huang, Yunyu; Chen, Wen] Fudan Univ, Sch Publ Hlth, Shanghai, Peoples R China; [Mao, Wenhui] Duke Univ, Duke Global Hlth Inst, Durham, NC USA	Fudan University; Duke University	Chen, W (corresponding author), Fudan Univ, Sch Publ Hlth, Shanghai, Peoples R China.	wenchen@fudan.edu.cn	Mao, Wenhui/T-3573-2019	Mao, Wenhui/0000-0001-9214-7787	Alliance for Health Policy and Systems Research (AHPSR), the World Health Organization [ATM2012-01-CHINA]	Alliance for Health Policy and Systems Research (AHPSR), the World Health Organization	This research was funded by Alliance for Health Policy and Systems Research (AHPSR), the World Health Organization (ATM2012-01-CHINA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chen MS, 2014, PHARMACOECONOMICS, V32, P245, DOI 10.1007/s40273-013-0068-z; China National Health Development Research Center of Ministry of Health of the People's of Republic of China, 2013, CHIN NAT HLTH ACC RE; Eggleston K, 2008, HEALTH ECON, V17, P149, DOI 10.1002/hec.1306; Health Department of Hangzhou, 2013, NOT 2013 WORK EMPH H; Health Department of Hangzhou, NOT OP IMPL NAT ESS; Hu Shanlian, 2013, J Med Econ, V16, P289, DOI 10.3111/13696998.2012.751176; Mao WH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117710; Mao WH, 2013, EXPERT REV PHARM OUT, V13, P693, DOI 10.1586/14737167.2013.856266; Ministry of Health Statistics Information Center of the People's of Republic of China, 2012, 2012 HLTH STAT YB; Napolitano F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082359; Napolitano F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084177; Pileggi C, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/413912; Rieckert A, 2018, BMC FAM PRACT, V19, DOI 10.1186/s12875-018-0789-3; Song Y, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0507-3; Tang JB, 1995, CHINA PHARM, V6, P5; Tang S, 2007, PHARM POLICIES CHINA; The Statistics Website of Hangzhou, 2015, 2014 HANGZH STAT YB; World Health Organization, EQ ACC ESS MED FRAM; World Health Organization, 2012, PURS RESP US MED SHA; World Health Organization, 1993, INVESTIGATE DRUG USE; World Health Organization, 2004, POLICY PERSPECTIVES, V3, P1; World Health Organization and OECD, 2014, MEAS PROGR UN HLTH C, DOI [10.1787/health_glance_ap-2014-en, DOI 10.1787/HEALTH_GLANCE_AP-2014-EN]; Yang L, 2013, B WORLD HEALTH ORGAN, V91, P184, DOI 10.2471/BLT.11.097998	23	10	10	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2019	14	3							e0213638	10.1371/journal.pone.0213638	http://dx.doi.org/10.1371/journal.pone.0213638			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO7YP	30870490	Green Published, gold, Green Submitted			2023-01-03	WOS:000461166300052
J	Cepeda, JA; Astemborski, J; Kirk, GD; Celentano, DD; Thomas, DL; Mehta, SH				Cepeda, Javier A.; Astemborski, Jacquie; Kirk, Gregory D.; Celentano, David D.; Thomas, David L.; Mehta, Shruti H.			Rising role of prescription drugs as a portal to injection drug use and associated mortality in Baltimore, Maryland	PLOS ONE			English	Article							HEROIN USE; TRANSITION; INITIATION; PREDICTORS; DISEASE; OPIOIDS; PEOPLE; COHORT	Introduction Prescription drug abuse is a major public health problem in rural and suburban areas of the United States, however its emergence in large urban settings with endemic injection drug use remains understudied. We examined temporal trends in injection drug use initiation and mortality among people who inject drugs (PWID) in Baltimore, Maryland. Methods Data were derived from the baseline assessment of PWID enrolled in a community-based cohort study with longitudinal follow-up for mortality assessment. PWID were recruited from 2005-2008 (N = 1,008) and 2015-2018 (N = 737). We compared characteristics by birth cohort (before/after 1980) and type of drug initiated (prescription opioids, prescription nonopioids, non-injection illicit drugs, or injection drugs). We calculated standardized mortality ratios (SMR) using the US general population as the reference. Results PWID born after 1980 were more likely to initiate drug use with prescription opioids and nonopioids and had higher levels of polysubstance prior to injection initiation, compared to individuals born before 1980. Overall mortality was high: 2.59 per 100 person-years (95% CI: 2.27-2.95 per 100 person-years). Compared to the US population, the highest SMRs were observed among participants between 40-44 years of age, with especially high mortality among women in this age group (SMR: 29.89, 95% CI: 15.24-44.54). Conclusions Mirroring national trends, the profile of PWID in Baltimore has changed with increased prescription drug abuse and high levels of polysubstance use among younger PWID. Interventions need to reach those using prescription drugs early after initiation of use in order to reduce transition to injecting. Urgent attention is warranted to address premature mortality, particularly among middle-aged and female PWID.	[Cepeda, Javier A.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Astemborski, Jacquie; Kirk, Gregory D.; Celentano, David D.; Mehta, Shruti H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Thomas, David L.] Johns Hopkins Sch Med, Div Infect Dis, Baltimore, MD USA	University of California System; University of California San Diego; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine	Cepeda, JA (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	jacepeda@ucsd.edu		Kirk, Gregory/0000-0002-7829-1405	National Institute on Drug Abuse [R01DA012568, R37DA013806, K01DA043421]; NATIONAL INSTITUTE ON DRUG ABUSE [K01DA043421, U01DA036297, R37DA013806, R01DA012568] Funding Source: NIH RePORTER	National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by grants from the National Institute on Drug Abuse (R01DA012568 [SHM], R37DA013806 [DLT], K01DA043421 [JAC]). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahman A, 2018, DRUG ALCOHOL DEPEN, V188, P274, DOI 10.1016/j.drugalcdep.2018.03.053; Baltimore City Heroin Treatment and Prevention Task Force, 2016, HER TREATM PREV TASK; Benson Jr JA, 1999, MARIJUANA MED ASSESS; Bluthenthal RN, 2017, DRUG ALCOHOL DEPENDE; Breslow NE, 1987, IARC SCI PUBL, V2; Bretteville-Jensen AL, 2017, ADDICTION; Carlson RG, 2016, DRUG ALCOHOL DEPEN, V160, P127, DOI 10.1016/j.drugalcdep.2015.12.026; Cerda M, 2015, J PEDIAT; Conrad C, 2015, MMWR-MORBID MORTAL W, V64, P443; Davis JM, 2017, AIDS BEHAV, V21, P1044, DOI 10.1007/s10461-016-1660-y; DESJARLAIS DC, 1992, BRIT J ADDICT, V87, P493; Drug Enforcement Agency, 2016, DEA ISS CARF WARN PO; Fuller CM, 2002, DRUG ALCOHOL DEPEN, V66, P189, DOI 10.1016/S0376-8716(01)00200-9; Gladden R.M., 2016, MMWR-MORBID MORTAL W, P65; Grau LE, 2007, AM J ADDICTION, V16, P166, DOI 10.1080/10550490701375293; Guarino H, 2018, ADDICTIVE BEHAV; Irwin A, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0153-2; Jones CM, 2015, MMWR-MORBID MORTAL W, V64, P719; Katz J, 2017, DRUG DEATHS AM ARE R; Katz J., 2017, 1 COUNT FENTANYL DEA; Kelley MS, 2004, SOC SCI MED, V58, P2083, DOI 10.1016/j.socscimed.2003.08.006; Lankenau SE, 2012, INT J DRUG POLICY, V23, P37, DOI 10.1016/j.drugpo.2011.05.014; Larney S, 2017, DRUG ALCOHOL DEPEN, V171, P39, DOI [10.1016/j.drugalcdep.2016.11.029, 10.1016/j.drugalcdep.2016.08.320]; Mars SG, 2014, INT J DRUG POLICY, V25, P257, DOI 10.1016/j.drugpo.2013.10.004; Maryland Department of Health and Mental Hygiene, 2017, DRUG ALC REL INT DEA; Mehta SH, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw121; Milloy MJS, 2012, AIDS, V26, P1049, DOI 10.1097/QAD.0b013e32835221cc; Murphy S. L., 2012, NATL VITAL STAT REP, V60, P4; Nambiar D, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0089-3; Novak SP, 2016, AM J PUBLIC HEALTH, V106, P298, DOI 10.2105/AJPH.2015.302972; Novak SP, 2011, J ADDICT DIS, V30, P248, DOI 10.1080/10550887.2011.581989; Peavy KM, 2012, J PSYCHOACTIVE DRUGS, V44, P259, DOI 10.1080/02791072.2012.704591; Peterson A. B., 2016, MMWR-MORBID MORTAL W, P65; Pollini RA, 2011, SUBST ABUSE REHABIL, V2, P173, DOI 10.2147/SAR.S24800; Roy E, 2003, J URBAN HEALTH, V80, P92, DOI 10.1093/jurban/jtg092; Roy E, 2007, DRUG-EDUC PREV POLIC, V14, P401, DOI 10.1080/09687630601111292; Sherman SG, 2005, J PSYCHOACTIVE DRUGS, V37, P437, DOI 10.1080/02791072.2005.10399817; Siegal HA, 2003, AM FAM PHYSICIAN, V67, P942; Stenbacka M, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-38; Sun J PD, 2018, C RETR OPP INF 2018; Tempalski B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064789; U.S. Census Bureau, 2010, PROF GEN POP HOUS CH; Vlahov D, 1991, NIDA Res Monogr, V109, P75; Wejnert C, 2016, MMWR-MORBID MORTAL W, P65; Werb D, 2017, PREVENTING INJECTION; Young AM, 2012, ADDICTION, V107, P587, DOI 10.1111/j.1360-0443.2011.03635.x; Zibbell JE, 2015, MMWR-MORBID MORTAL W, V64, P453	47	9	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2019	14	3							e0213357	10.1371/journal.pone.0213357	http://dx.doi.org/10.1371/journal.pone.0213357			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HN7LU	30830944	Green Published, gold, Green Submitted			2023-01-03	WOS:000460371700038
J	Song, DL; Jegatheesan, P; Nafday, S; Ahmad, KA; Nedrelow, J; Wearden, M; Nemerofsky, S; Pooley, S; Thompson, D; Vail, D; Cornejo, T; Cohen, Z; Govindaswami, B				Song, Dongli; Jegatheesan, Priya; Nafday, Suhas; Ahmad, Kaashif A.; Nedrelow, Jonathan; Wearden, Mary; Nemerofsky, Sheri; Pooley, Sunshine; Thompson, Diane; Vail, Daniel; Cornejo, Tania; Cohen, Zahava; Govindaswami, Balaji			Patterned frequency-modulated oral stimulation in preterm infants: A multicenter randomized controlled trial	PLOS ONE			English	Article							NONNUTRITIVE SUCKING; FEEDING PERFORMANCE; OROCUTANEOUS STIMULATION; PREMATURE-INFANTS; PACIFIER USE; DIFFICULTIES; TRANSITION; SWALLOW; INTERVENTIONS; COORDINATION	Objective To evaluate the effect of patterned, frequency-modulated oro-somatosensory stimulation on time to full oral feeds in preterm infants born 26-30 weeks gestation. Study design This is a multicenter randomized controlled trial. The experimental group (n = 109) received patterned, frequency-modulated oral stimulation via the NTrainer system through a pulsatile pacifier and the control group (n = 101) received a non-pulsatile pacifier. Intent-to-treat analysis (n = 210) was performed to compare the experimental and control groups and the outcomes were analyzed using generalized estimating equations. Time-to-event analyses for time to reach full oral feeds and length of hospital stay were conducted using Cox proportional hazards models. Results The experimental group had reduction in time to full oral feeds compared to the control group (-4.1 days, HR 1.37 (1.03, 1.82) p = 0.03). In the 29-30 weeks subgroup, infants in the experimental group had a significant reduction in time to discharge (-10 days, HR 1.87 (1.23, 2.84) p < 0.01). This difference was not observed in the 26-28 weeks subgroup. There was no difference in growth, mortality or morbidities between the two groups. Conclusions Patterned, frequency-modulated oro-somatosensory stimulation improves feeding development in premature infants and reduces their length of hospitalization. Trial registration ClinicalTrials.gov NCT01158391	[Song, Dongli; Jegatheesan, Priya; Pooley, Sunshine; Govindaswami, Balaji] Santa Clara Valley Med Ctr, Pediat Neonatol, San Jose, CA 95128 USA; [Song, Dongli; Jegatheesan, Priya; Pooley, Sunshine; Vail, Daniel; Govindaswami, Balaji] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Nafday, Suhas; Nemerofsky, Sheri] Albert Einstein Coll Med, Montefiore Weiler Div, Childrens Hosp, Pediat Neonatol, Bronx, NY 10467 USA; [Ahmad, Kaashif A.; Wearden, Mary] Nort Cent Baptist Hosp, Pediat Med Grp, San Antonio, TX USA; [Ahmad, Kaashif A.] Baylor Coll Med, Pediat Neonatol, San Antonio, TX USA; [Nedrelow, Jonathan] Cook Childrens Med Ctr, Pediat Neonatol, Ft Worth, TX USA; [Thompson, Diane] aVenture Consulting LLC, Leawood, KS USA; [Cornejo, Tania] Montefiore Med Ctr Weiler, Neonatol, Bronx, NY USA; [Cohen, Zahava] Montefiore Med Ctr Wakefield, Neonatol, Bronx, NY USA	Santa Clara Valley Medical Center; Stanford University; Yeshiva University; Albert Einstein College of Medicine; Baylor College of Medicine; Cook Children's Medical Center; Montefiore Medical Center	Song, DL (corresponding author), Santa Clara Valley Med Ctr, Pediat Neonatol, San Jose, CA 95128 USA.; Song, DL (corresponding author), Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.	dongli.song@hhs.sccgov.org	Govindaswami, Balaji/AAU-1168-2021	Vail, Daniel/0000-0001-8769-2369; Govindaswami, Balaji/0000-0002-8440-4226; Ahmad, Kaashif/0000-0002-5970-6791	Innara Health Inc., Olathe, Kansas, United States	Innara Health Inc., Olathe, Kansas, United States	This study was sponsored by Innara Health Inc., Olathe, Kansas, United States, http://www.innarahealth.com/. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials.	Adams-Chapman I, 2013, J PEDIATR-US, V163, P680, DOI 10.1016/j.jpeds.2013.03.006; ALS H, 1979, INFANTS BORN RISK BE, P173; Als Heidelise, 1998, Current Opinion in Pediatrics, V10, P138, DOI 10.1097/00008480-199804000-00004; Bache M, 2014, EARLY HUM DEV, V90, P125, DOI 10.1016/j.earlhumdev.2013.12.011; Bakewell-Sachs S, 2009, PEDIATRICS, V123, pE878, DOI 10.1542/peds.2008-2568; Barlow SM, 2008, J PERINATOL, V28, P541, DOI 10.1038/jp.2008.57; Barlow SM, 2014, J PERINATOL, V34, P213, DOI 10.1038/jp.2013.150; Barlow SM, 2014, J PERINATOL, V34, P136, DOI 10.1038/jp.2013.149; BARLOW SM, 1987, EXP NEUROL, V96, P253, DOI 10.1016/0014-4886(87)90044-6; Barlow Sm, 2014, J Neonatal Nurs, V20, P178; Barlow SM, 2009, CURR OPIN OTOLARYNGO; Barlow SM, 2009, CURR OPIN OTOLARYNGO, V17, P187, DOI 10.1097/MOO.0b013e32832b312a; Barlow Steven Michael, 2017, JMIR Res Protoc, V6, pe113, DOI 10.2196/resprot.7712; Bingham PM, 2010, ARCH DIS CHILD-FETAL, V95, pF194, DOI 10.1136/adc.2009.164186; Bingham PM, 2009, J CHILD NEUROL, V24, P743, DOI 10.1177/0883073808329530; Bingham PM, 2003, ARCH PEDIAT ADOL MED, V157, P72, DOI 10.1001/archpedi.157.10.1031; Boiron M, 2007, DEV MED CHILD NEUROL, V49, P439, DOI 10.1111/j.1469-8749.2007.00439.x; Bragelien R, 2007, ACTA PAEDIATR, V96, P1430, DOI 10.1111/j.1651-2227.2007.00448.x; Browne JV, 2011, CLIN PERINATOL, V38, P731, DOI 10.1016/j.clp.2011.08.004; Carlo WA, 2010, NEW ENGL J MED, V362, P1959, DOI 10.1056/NEJMoa0911781; Chorna OD, 2014, PEDIATRICS, V133, P462, DOI 10.1542/peds.2013-2547; Crapnell TL, 2015, J PEDIATR-US, V167, P1347, DOI 10.1016/j.jpeds.2015.09.022; da Costa SP, 2008, J PERINATOL, V28, P247, DOI 10.1038/sj.jp.7211924; da Costa SP, 2010, NEONATOLOGY, V98, P268, DOI 10.1159/000281106; Delaney AL, 2008, DEV DISABIL RES REV, V14, P105, DOI 10.1002/ddrr.16; Dodrill P, 2008, J PERINATOL, V28, P549, DOI 10.1038/jp.2008.56; Eichenwald EC, 2001, PEDIATRICS, V108, P928, DOI 10.1542/peds.108.4.928; Foster JP, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001071.pub3; Fucile S, 2005, DEV MED CHILD NEUROL, V47, P158, DOI 10.1017/S0012162205000290; Fucile S, 2018, BREASTFEED MED, V13, P473, DOI 10.1089/bfm.2018.0014; Fucile S, 2012, EARLY HUM DEV, V88, P345, DOI 10.1016/j.earlhumdev.2011.09.007; Fucile S, 2011, DEV MED CHILD NEUROL, V53, P829, DOI 10.1111/j.1469-8749.2011.04023.x; Gewolb IH, 2001, DEV MED CHILD NEUROL, V43, P22, DOI 10.1017/S0012162201000044; Gewolb IH, 2006, DEV MED CHILD NEUROL, V48, P595, DOI 10.1017/S0012162206001241; Gill N E, 1992, Scand J Caring Sci, V6, P3; Greene Z ODC, 2016, COCHRANE DB SYST REV, P74; Griffith T, 2017, ADV NEONAT CARE, V17, pE12, DOI 10.1097/ANC.0000000000000318; HACK M, 1985, EARLY HUM DEV, V11, P133, DOI 10.1016/0378-3782(85)90100-8; Hafstrom M, 2000, EARLY HUM DEV, V60, P13, DOI 10.1016/S0378-3782(00)00091-8; Harding C, 2014, INFANT BEHAV DEV, V37, P457, DOI 10.1016/j.infbeh.2014.05.002; Harding C, 2009, ARCH DIS CHILD, V94, P636, DOI 10.1136/adc.2008.144204; Hibbs AM, 2010, J PEDIATR-US, V156, P202, DOI 10.1016/j.jpeds.2009.08.049; Jadcherla SR, 2010, J PERINATOL, V30, P201, DOI 10.1038/jp.2009.149; Kaya V, 2017, J CLIN NURS, V26, P2055, DOI 10.1111/jocn.13617; Lau C, 2000, ACTA PAEDIATR, V89, P846, DOI 10.1080/080352500750043765; Lau C, 2012, ACTA PAEDIATR, V101, pe269, DOI 10.1111/j.1651-2227.2012.02662.x; Lau C, 2001, DYSPHAGIA, V16, P58, DOI 10.1007/s004550000043; Lau C, 2016, AM J CLIN NUTR, V103, p616S, DOI 10.3945/ajcn.115.109603; Lau C, 2015, ANN NUTR METAB, V66, P7, DOI 10.1159/000381361; Ludwig SM, 2007, NEWBORN INFANT NURS, V7, P155, DOI 10.1053/j.nainr.2007.06.007; Malas K, 2015, DEV MED CHILD NEUROL, V57, P872, DOI 10.1111/dmcn.12749; McCain G C, 1997, Neonatal Netw, V16, P43; McCain G C, 1995, J Pediatr Nurs, V10, P3, DOI 10.1016/S0882-5963(05)80093-4; McCain Gail C, 2003, Neonatal Netw, V22, P45; Medoff-Cooper B, 2009, J DEV BEHAV PEDIATR, V30, P16, DOI 10.1097/DBP.0b013e318196b0a8; Mizuno K, 2005, DEV MED CHILD NEUROL, V47, P299, DOI 10.1017/S0012162205000587; Mizuno K, 2003, J PEDIATR-US, V142, P36, DOI 10.1067/mpd.2003.mpd0312; Pagliaro CL, 2016, J PEDIAT-BRAZIL, V92, P7, DOI 10.1016/j.jped.2015.05.004; Patel AL, 2009, J PERINATOL, V29, P618, DOI 10.1038/jp.2009.55; Pickler RH, 1996, NURS RES, V45, P132, DOI 10.1097/00006199-199605000-00002; Pimenta HP, 2008, J PEDIAT-BRAZIL, V84, P423, DOI [10.2223/JPED.1839, 10.1590/S0021-75572008000600008]; Poore M, 2008, ACTA PAEDIATR, V97, P920, DOI 10.1111/j.1651-2227.2008.00825.x; Say B, 2018, BREASTFEED MED, V13, P433, DOI 10.1089/bfm.2018.0031; Simpson C, 2002, PEDIATRICS, V110, P517, DOI 10.1542/peds.110.3.517; Song DL, 2014, PEDIATR RES, V75, P85, DOI 10.1038/pr.2013.179; Stark AR, 2008, PEDIATRICS, V122, P1119, DOI 10.1542/peds.2008-2174; Tian X, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001310; Trulsson M, 2002, BEHAV BRAIN RES, V135, P27, DOI 10.1016/S0166-4328(02)00151-1; White-Traut RC, 2002, DEV MED CHILD NEUROL, V44, P91, DOI 10.1017/S0012162201001736; White-Traut Rosemary C, 2005, MCN Am J Matern Child Nurs, V30, P52; WOLFF PH, 1968, PEDIATRICS, V42, P943; Yildiz A, 2012, J CLIN NURS, V21, P644, DOI 10.1111/j.1365-2702.2010.03634.x; Yildiz A, 2011, J NURS SCHOLARSHIP, V43, P265, DOI 10.1111/j.1547-5069.2011.01410.x; Zhang YX, 2014, PEDIATR CRIT CARE ME, V15, P608, DOI 10.1097/PCC.0000000000000182; Zimmerman E, 2012, J PERINATOL, V32, P614, DOI 10.1038/jp.2011.177	75	12	13	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2019	14	2							e0212675	10.1371/journal.pone.0212675	http://dx.doi.org/10.1371/journal.pone.0212675			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HN7LS	30817764	gold, Green Published, Green Submitted			2023-01-03	WOS:000460371500028
J	Hernandez, G; Ospina-Tascon, GA; Damiani, LP; Estenssoro, E; Dubin, A; Hurtado, J; Friedman, G; Castro, R; Alegria, L; Teboul, JL; Cecconi, M; Ferri, G; Jibaja, M; Pairumani, R; Fernandez, P; Barahona, D; Granda-Luna, V; Cavalcanti, AB; Bakker, J				Hernandez, Glenn; Ospina-Tascon, Gustavo A.; Damiani, Lucas Petri; Estenssoro, Elisa; Dubin, Arnaldo; Hurtado, Javier; Friedman, Gilberto; Castro, Ricardo; Alegria, Leyla; Teboul, Jean-Louis; Cecconi, Maurizio; Ferri, Giorgio; Jibaja, Manuel; Pairumani, Ronald; Fernandez, Paula; Barahona, Diego; Granda-Luna, Vladimir; Cavalcanti, Alexandre Biasi; Bakker, Jan		ANDROMEDA-SHOCK Investigators Lat	Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock The ANDROMEDA-SHOCK Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAPILLARY REFILL TIME; INTENSIVE-CARE; SEPSIS; CONSENSUS; PRESSURE; THERAPY; SCORE	IMPORTANCE Abnormal peripheral perfusion after septic shock resuscitation has been associated with organ dysfunction and mortality. The potential role of the clinical assessment of peripheral perfusion as a target during resuscitation in early septic shock has not been established. OBJECTIVE To determine if a peripheral perfusion-targeted resuscitation during early septic shock in adults is more effective than a lactate level-targeted resuscitation for reducing mortality. DESIGN, SETTING, AND PARTICIPANTS Multicenter, randomized trial conducted at 28 intensive care units in 5 countries. Four-hundred twenty-four patients with septic shock were included between March 2017 and March 2018. The last date of follow-up was June 12, 2018. INTERVENTIONS Patients were randomized to a step-by-step resuscitation protocol aimed at either normalizing capillary refill time (n = 212) or normalizing or decreasing lactate levels at rates greater than 20% per 2 hours (n = 212), during an 8-hour intervention period. MAIN OUTCOMES AND MEASURES The primary outcomewas all-cause mortality at 28 days. Secondary outcomes were organ dysfunction at 72 hours after randomization, as assessed by Sequential Organ Failure Assessment (SOFA) score (range, 0 [best] to 24 [worst]); death within 90 days; mechanical ventilation-, renal replacement therapy-, and vasopressor-free days within 28 days; intensive care unit and hospital length of stay. RESULTS Among 424 patients randomized (mean age, 63 years; 226 [53%] women), 416 (98%) completed the trial. By day 28, 74 patients (34.9%) in the peripheral perfusion group and 92 patients (43.4%) in the lactate group had died (hazard ratio, 0.75 [95% CI, 0.55 to 1.02]; P = .06; risk difference, -8.5%[95% CI, -18.2% to 1.2%]). Peripheral perfusion-targeted resuscitation was associated with less organ dysfunction at 72 hours (mean SOFA score, 5.6 [SD, 4.3] vs 6.6 [SD, 4.7]; mean difference, -1.00 [95% CI, -1.97 to -0.02]; P = .045). There were no significant differences in the other 6 secondary outcomes. No protocol-related serious adverse reactions were confirmed. CONCLUSIONS AND RELEVANCE Among patients with septic shock, a resuscitation strategy targeting normalization of capillary refill time, compared with a strategy targeting serum lactate levels, did not reduce all-cause 28-day mortality. (c) 2019 American Medical Association. All rights reserved.	[Hernandez, Glenn; Castro, Ricardo; Alegria, Leyla; Bakker, Jan] Pontificia Univ Catolica Chile, Fac Med, Dept Med Intens, Ave Diagonal Paraguay 362, Santiago, Chile; [Ospina-Tascon, Gustavo A.] Univ ICESI, Dept Intens Care Med, Fdn Valle del Lili, Cali, Colombia; [Damiani, Lucas Petri; Cavalcanti, Alexandre Biasi] Univ Sao Paulo, Fac Med, HCor Res Inst, Hosp Coracao, Sao Paulo, Brazil; [Estenssoro, Elisa] Hosp Int Agudos San Martin La Plata, La Plata, Buenos Aires, Argentina; [Dubin, Arnaldo] Sanatorio Otamendi, Buenos Aires, DF, Argentina; [Dubin, Arnaldo] Univ Nacl La Plata, Fac Ciencias Med, Catedra Farmacol Aplicada, La Plata, Buenos Aires, Argentina; [Hurtado, Javier] Hosp Espanol ASSE, Intens Care Unit, Montevideo, Uruguay; [Hurtado, Javier] Sch Med Univ Republ, Dept Pathophysiol, Montevideo, Uruguay; [Friedman, Gilberto] Univ Fed Rio Grande do Sul, Sch Med, Dept Internal Med, Postgrad Program Pneumol Sci, Porto Alegre, RS, Brazil; [Teboul, Jean-Louis] Hop Univ Paris Sud, Hop Bicetre, Serv Reanimat Med, Paris, France; [Teboul, Jean-Louis] Univ Paris Sud, AP HP, Paris, France; [Cecconi, Maurizio] Humanitas Univ, Dept Biomed Sci, Humanitas Clin & Res Ctr, Milan, Italy; [Ferri, Giorgio; Pairumani, Ronald] Hosp Barros Luco, Unidad Cuidados Intens, Santiago, Chile; [Jibaja, Manuel] Univ Int Ecuador, Escuela Med, Hosp Eugenio Espejo, Unidad Cuidados Intens, Quito, Ecuador; [Fernandez, Paula] Hosp Guillermo Grant Benavente, Unidad Pacientes Crit, Concepcion, Chile; [Barahona, Diego] Univ Cent Ecuador, Hosp Gen Docente Calderon, Unidad Cuidados Intens, Quito, Ecuador; [Granda-Luna, Vladimir] Pontificia Univ Catolica Chile, Hosp San Francisco, Unidad Cuidados Intens, Quito, Ecuador; [Bakker, Jan] Erasmus MC Univ, Dept Intens Care Adults, Med Ctr, Rotterdam, Netherlands; [Bakker, Jan] NYU, Dept Pulm & Crit Care, New York, NY USA; [Bakker, Jan] Columbia Univ, Div Pulm Allergy & Crit Care Med, Med Ctr, New York, NY USA	Pontificia Universidad Catolica de Chile; Universidad ICESI; Hospital do Coracao - HCor; Universidade de Sao Paulo; National University of La Plata; Universidade Federal do Rio Grande do Sul; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Saclay; Humanitas University; Universidad de Chile; Universidad Central del Ecuador; Erasmus University Rotterdam; Erasmus MC; New York University; Columbia University	Hernandez, G (corresponding author), Pontificia Univ Catolica Chile, Fac Med, Dept Med Intens, Ave Diagonal Paraguay 362, Santiago, Chile.	glennguru@gmail.com	Tascón, Gustavo Adolfo Ospina/AAF-5200-2019; Cecconi, Maurizio/A-6241-2012; Bakker, Jan/A-4011-2009; Friedman, Gilberto/F-7208-2015; alegria, leyla/HDM-9456-2022; Friedman, Gilberto/F-7212-2015; Birri, Paolo Nahuel Rubatto/Y-7807-2019; Cecconi, Maurizio/HDN-8785-2022	Cecconi, Maurizio/0000-0002-4376-6538; Bakker, Jan/0000-0003-2236-7391; Friedman, Gilberto/0000-0001-9369-2488; alegria, leyla/0000-0002-0930-4452; Cecconi, Maurizio/0000-0002-4376-6538; Valenzuela Espinoza, Emilio Daniel/0000-0001-9758-3473; Garcia Aguilera, Maria Fernanda/0000-0002-5375-3474; Ospina-Tascon, Gustavo Adolfo/0000-0001-9370-3298; NIN, NICOLAS/0000-0001-6037-2357; Ornes Rodriguez, Antonio Miguel/0000-0002-2224-1599; Pozo, Mario O/0000-0002-0809-8087; Bustamante-Cristancho, Luis Alfonso/0000-0001-5587-810X				Ait-Oufella H, 2014, INTENS CARE MED, V40, P958, DOI 10.1007/s00134-014-3326-4; Alsma J, 2017, CHEST, V151, P1106, DOI 10.1016/j.chest.2016.11.035; Anderson B, 2008, AM J EMERG MED, V26, P62, DOI 10.1016/j.ajem.2007.06.026; Asfar P, 2014, NEW ENGL J MED, V370, P1583, DOI 10.1056/NEJMoa1312173; BROWN LH, 1994, AM J EMERG MED, V12, P46, DOI 10.1016/0735-6757(94)90196-1; Cecconi M, 2015, INTENS CARE MED, V41, P1529, DOI 10.1007/s00134-015-3850-x; Cecconi M, 2014, INTENS CARE MED, V40, P1795, DOI 10.1007/s00134-014-3525-z; Coopersmith CM, 2018, CRIT CARE MED, V46, P1334, DOI 10.1097/CCM.0000000000003225; Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754; Garcia-Alvarez M, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0503-3; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Hernández Glenn, 2018, Rev. bras. ter. intensiva, V30, P253, DOI [10.5935/0103-507x.20180041, 10.5935/0103-507X.20180041]; Hernandez G, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-018-0398-2; Hernandez G, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/s13613-014-0030-z; Hernandez G, 2012, J CRIT CARE, V27, P283, DOI 10.1016/j.jcrc.2011.05.024; Jansen TC, 2010, AM J RESP CRIT CARE, V182, P752, DOI 10.1164/rccm.200912-1918OC; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lara B, 2017, PLOS ONE, V12, DOI [10.1371/journal.pone.0188548, 10.1371/Journal.pone.0188548]; Levy MM, 2018, CRIT CARE MED, V46, P997, DOI 10.1097/CCM.0000000000003119; Lima A, 2014, CRIT CARE, V18, DOI 10.1186/cc13932; Lima A, 2009, CRIT CARE MED, V37, P934, DOI 10.1097/CCM.0b013e31819869db; Monnet X, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0216-7; Pickard A, 2011, ANESTH ANALG, V113, P120, DOI 10.1213/ANE.0b013e31821569f9; Pinsky MR, 2014, CRIT CARE RESUSC, V16, P245; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; SAAVEDRA JM, 1991, AM J DIS CHILD, V145, P296, DOI 10.1001/archpedi.1991.02160030064022; SCHRIGER DL, 1991, ANN EMERG MED, V20, P601, DOI 10.1016/S0196-0644(05)82375-3; Shankar-Hari M, 2016, JAMA-J AM MED ASSOC, V315, P775, DOI 10.1001/jama.2016.0289; Teboul JL, 2016, INTENS CARE MED, V42, P1350, DOI 10.1007/s00134-016-4375-7; van Genderen ME, 2015, AM J RESP CRIT CARE, V191, P477, DOI 10.1164/rccm.201408-1575LE; van Genderen ME, 2014, CRIT CARE, V18, DOI 10.1186/cc13905; van Genderen ME, 2012, CRIT CARE MED, V40, P2287, DOI 10.1097/CCM.0b013e31825333b2; Vincent JL, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1403-5; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751	34	289	306	3	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	2019	321	7					654	664		10.1001/jama.2019.0071	http://dx.doi.org/10.1001/jama.2019.0071			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL9MZ	30772908	Bronze, Green Published			2023-01-03	WOS:000459068300014
J	Humphreys, K; Saitz, R				Humphreys, Keith; Saitz, Richard			Should Physicians Recommend Replacing Opioids With Cannabis?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CHRONIC NONCANCER PAIN		[Humphreys, Keith] Vet Affairs Hlth Serv Res & Dev Ctr, Palo Alto, CA USA; [Humphreys, Keith] Stanford Univ, Palo Alto, CA 94304 USA; [Saitz, Richard] Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, 801 Massachusetts Ave,Fourth Floor, Boston, MA 02118 USA; [Saitz, Richard] Boston Med Ctr, Clin Addict Res & Educ Unit, Sect Gen Internal Med, Boston, MA USA; [Saitz, Richard] Boston Med Ctr, Grayken Ctr Addict, Boston, MA USA	Stanford University; Boston University; Boston Medical Center; Boston Medical Center	Saitz, R (corresponding author), Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, 801 Massachusetts Ave,Fourth Floor, Boston, MA 02118 USA.	richard.saitz@jamanetwork.org						Bonn-Miller MO, 2017, JAMA-J AM MED ASSOC, V318, P1708, DOI 10.1001/jama.2017.11909; Busse JW, 2018, JAMA-J AM MED ASSOC, V320, P2448, DOI 10.1001/jama.2018.18472; Campbell G, 2018, LANCET PUBLIC HEALTH, V3, pE469, DOI 10.1016/S2468-2667(18)30182-8; Campbell G, 2018, LANCET PUBLIC HEALTH, V3, pE341, DOI 10.1016/S2468-2667(18)30110-5; Caputi TL, 2018, J ADDICT MED, V12, P295, DOI 10.1097/ADM.0000000000000405; Hasin DS, 2015, JAMA PSYCHIAT, V72, P1235, DOI 10.1001/jamapsychiatry.2015.1858; Nader DA, 2018, AM J DRUG ALCOHOL AB, V44, P4, DOI 10.1080/00952990.2017.1306746; Nugent SM, 2017, ANN INTERN MED, V167, P319, DOI 10.7326/M17-0155	8	46	46	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	2019	321	7					639	640		10.1001/jama.2019.0077	http://dx.doi.org/10.1001/jama.2019.0077			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL9MZ	30707218				2023-01-03	WOS:000459068300007
J	Hellmuth, J; Rabinovici, GD; Miller, BL				Hellmuth, Joanna; Rabinovici, Gil D.; Miller, Bruce L.			The Rise of Pseudomedicine for Dementia and Brain Health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Hellmuth, Joanna; Rabinovici, Gil D.; Miller, Bruce L.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA USA	University of California System; University of California San Francisco	Hellmuth, J (corresponding author), 675 Nelson Rising Ln,Ste 190, San Francisco, CA 94158 USA.	Joanna.Hellmuth@ucsf.edu	Rabinovici, Gil/AAA-2495-2020	Miller, Bruce/0000-0002-2152-4220	NATIONAL INSTITUTE OF MENTAL HEALTH [K23MH114724] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG023481, P50AG023501, P01AG019724] Funding Source: NIH RePORTER; NIA NIH HHS [T32 AG023481, P50 AG023501, P01 AG019724] Funding Source: Medline; NIMH NIH HHS [K23 MH114724] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alzheimer's Association, 2018, FIGURES STAGE; [Anonymous], ALT TREATM; [Anonymous], 2018, ASS PRESS       0628; Elliot C., 2012, CHRONICLE HIGHER ED; Feynman R., 1974, CALTECH COMM; Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110; Schurks M, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5702	7	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	2019	321	6					543	544		10.1001/jama.2018.21560	http://dx.doi.org/10.1001/jama.2018.21560			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL1KO	30681701	Green Accepted			2023-01-03	WOS:000458456700011
J	Wei, YJJ; Chen, C; Sarayani, A; Winterstein, AG				Wei, Yu-Jung Jenny; Chen, Cheng; Sarayani, Amir; Winterstein, Almut G.			Performance of the Centers for Medicare & Medicaid Services' Opioid Overutilization Criteria for Classifying Opioid Use Disorder or Overdose	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Wei, Yu-Jung Jenny; Chen, Cheng; Sarayani, Amir; Winterstein, Almut G.] Univ Florida, Coll Pharm, Dept Pharmaceut Outcomes & Policy, 1225 Ctr Dr,Hlth Profess Nursing Pharm Bldg, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Wei, YJJ (corresponding author), Univ Florida, Coll Pharm, Dept Pharmaceut Outcomes & Policy, 1225 Ctr Dr,Hlth Profess Nursing Pharm Bldg, Gainesville, FL 32610 USA.	jenny.wei@cop.ufl.edu	winterstein, Almut/A-3017-2014; winterstein, almut/ABH-1838-2020	winterstein, Almut/0000-0002-6518-5961; Sarayani, Amir/0000-0003-2790-9938; Wei, YU-Jung Jenny/0000-0001-8861-6907	Mentored Research Scientist Award from the National Institute on Aging [K01AG054764]; NATIONAL INSTITUTE ON AGING [K01AG054764, P30AG028740] Funding Source: NIH RePORTER	Mentored Research Scientist Award from the National Institute on Aging; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This project had no direct funding. Dr Wei is supported in part by a Mentored Research Scientist Award (K01AG054764) from the National Institute on Aging.	[Anonymous], 2013, PRESCR DRUG OV DAT S; Centers for Medicare Medicaid Services, AN PROP OP OV CRIT M; Chavez-Valdez AL, 2017, COMMUNICATION; Franklin G, 2015, AM J PUBLIC HEALTH, V105, P463, DOI 10.2105/AJPH.2014.302367; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1	5	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	2019	321	6					609	611		10.1001/jama.2018.20404	http://dx.doi.org/10.1001/jama.2018.20404			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL1KO	30747958	Green Published			2023-01-03	WOS:000458456700024
J	Rub, MA				Rub, Malik Abdul			Aggregation and interfacial phenomenon of amphiphilic drug under the influence of pharmaceutical excipients (green/biocompatible gemini surfactant)	PLOS ONE			English	Article							SODIUM DODECYL-SULFATE; MIXED MICELLE FORMATION; NONIONIC SURFACTANTS; CATIONIC GEMINI; BINARY-MIXTURES; TETRADECYLTRIMETHYLAMMONIUM BROMIDE; IMIPRAMINE HYDROCHLORIDE; CONVENTIONAL SURFACTANTS; THERMODYNAMIC PARAMETERS; ASSOCIATION BEHAVIOR	In the current study, we have examined the interaction amongst an antidepressant drug amitriptyline hydrochloride (AMH) and ethane-1, 2-diyl bis(N,N-dimethyl-N-cetylammoniumacetoxy) dichloride (16-E2-16, a green gemini surfactant) through tensiometric and fluorimetric techniques in aqueous/electrolyte/urea solutions. Significant variations are observed in the various evaluated parameters in the present study. Gemini 16-E2-16 has outstanding surface properties along with a much lower cmc value, demonstrating very little toxicity as well as considerable antimicrobial activity. The cmc values of mixtures decrease through increase in mole fraction (alpha(1)) of 16-E2-16, which specifies the nonideality of the solution mixtures, along with demonstrating the occurrence of mixed micellization too. Negative beta(Rub) values signify on the whole attractive force of interaction between constituents of mixed micelles. Owing to the incidence of electrolyte NaCl (50 mmol.kg(-1)), lowering of the micelles' surface charge happens, resulting in aggregation taking place at lower concentration while the presence of urea (NH2CONH2) halts micellization taking place, which means the cmc value increases in the attendance of urea. The Delta G(m)degrees values for all systems were negative along with the presence of electrolyte/urea. The excess free energy (G(ex)) of studied mixed systems was also estimated and found to be negative for all the systems. Using the fluorescence quenching method, the micelle aggregation number (N-agg) was evaluated and it was found that the contribution of gemini surfactant was always more than that of the AMH and their value enhances in the existence of electrolyte while decreasing in the attendance of NH2CONH2 in the system. In addition, other fluorescence parameters such as micropolarity (I-1/I-3), dielectric constant (D-exp) as well as Stern-Volmer binding constants (K-sv) of mixed systems were evaluated and the results showed the synergistic performance of the AMH + 16-E2-16 mixtures. Along with tensiometric and fluorimetric techniques, FT-IR spectroscopy was also engaged to reveal the interaction among constituents.	[Rub, Malik Abdul] King Abdulaziz Univ, Fac Sci, Chem Dept, Jeddah, Saudi Arabia	King Abdulaziz University	Rub, MA (corresponding author), King Abdulaziz Univ, Fac Sci, Chem Dept, Jeddah, Saudi Arabia.	malikrub@gmail.com	Rub, Malik Abdul/H-6027-2012	Rub, Malik Abdul/0000-0002-4798-5308	Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah [130-059-D1434]; DSR	Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah; DSR	This work was funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, under grant No. (130-059-D1434). The authors, therefore, acknowledge with thanks DSR technical and financial support.	Al-Muhanna MK, 2015, J CHEM THERMODYN, V89, P112, DOI 10.1016/j.jct.2015.05.007; Ansari WH, 2013, SOFT MATTER, V9, P1478, DOI 10.1039/c2sm26926k; ASAKAWA T, 1995, LANGMUIR, V11, P2376, DOI 10.1021/la00007a010; Attwood D., 1983, SURFACTANT SYSTEMS T; Azum N, 2018, CHINESE J CHEM ENG, V26, P566, DOI 10.1016/j.cjche.2017.09.009; Azum N, 2017, J DISPER SCI TECHNOL, V38, P1785, DOI 10.1080/01932691.2017.1283510; Azum N, 2016, J SOLUTION CHEM, V45, P791, DOI 10.1007/s10953-016-0463-0; Azum N, 2017, J DISPER SCI TECHNOL, V38, P96, DOI 10.1080/01932691.2016.1144197; Bagheri A, 2017, RSC ADV, V7, P18151, DOI 10.1039/c6ra27382c; BRIGANTI G, 1991, J PHYS CHEM-US, V95, P8989, DOI 10.1021/j100175a103; Caetano W, 2000, J COLLOID INTERF SCI, V225, P69, DOI 10.1006/jcis.2000.6720; Camilleri P, 2000, CHEM COMMUN, P1253, DOI 10.1039/b001742f; Ruiz CC, 2011, J COLLOID INTERF SCI, V361, P178, DOI 10.1016/j.jcis.2011.05.019; Chattoraj D.K., 1984, ADSORPTION GIBBSUR; CLINT JH, 1975, J CHEM SOC FARAD T 1, V71, P1327, DOI 10.1039/f19757101327; Dai CL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102539; DLUHY RA, 1985, CAN J CHEM, V63, P1925, DOI 10.1139/v85-319; Dong B, 2007, LANGMUIR, V23, P4178, DOI 10.1021/la0633029; Fatma N, 2016, J MOL LIQ, V219, P959, DOI 10.1016/j.molliq.2016.04.038; Fatma N, 2015, COLLOID SURFACE A, V467, P9, DOI 10.1016/j.colsurfa.2014.11.010; Fatma N, 2013, J SURFACTANTS DETERG, V16, P609, DOI 10.1007/s11743-013-1448-2; Faustino CMC, 2014, IND ENG CHEM RES, V53, P10112, DOI 10.1021/ie5003735; Gaikar VG, 2008, J MOL LIQ, V138, P155, DOI 10.1016/j.molliq.2007.10.001; Haque ME, 1996, LANGMUIR, V12, P4084, DOI 10.1021/la9403587; HOLLAND PM, 1983, J PHYS CHEM-US, V87, P1984, DOI 10.1021/j100234a030; Hoque MA, 2017, J SOLUTION CHEM, V46, P682, DOI 10.1007/s10953-017-0594-y; ISRAELACHVILI JN, 1976, J CHEM SOC FARAD T 2, V72, P1525, DOI 10.1039/f29767201525; Jakubowska A, 2010, J COLLOID INTERF SCI, V346, P398, DOI 10.1016/j.jcis.2010.03.043; Jojart B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102114; KALYANASUNDARAM K, 1977, J AM CHEM SOC, V99, P2039, DOI 10.1021/ja00449a004; Khan F, 2018, J PHYS ORG CHEM, V31, DOI 10.1002/poc.3812; Khan F, 2016, J MOL LIQ, V222, P1020, DOI 10.1016/j.molliq.2016.07.104; Khan F, 2015, J DISPER SCI TECHNOL, V36, P83, DOI 10.1080/01932691.2013.852105; Kibbey TCG, 1997, ENVIRON SCI TECHNOL, V31, P1171, DOI 10.1021/es960681r; Kral'ova K, 2010, TENSIDE SURFACT DET, V47, P288, DOI 10.3139/113.110079; Kumar D, 2018, J MOL LIQ, V271, P254, DOI 10.1016/j.molliq.2018.08.147; Kumar D, 2018, J MOL LIQ, V250, P329, DOI 10.1016/j.molliq.2017.11.172; Kumar D, 2017, J MOL LIQ, V240, P253, DOI 10.1016/j.molliq.2017.05.088; Kumar D, 2017, J MOL LIQ, V238, P389, DOI 10.1016/j.molliq.2017.05.027; Kumar D, 2015, TENSIDE SURFACT DET, V52, P464, DOI 10.3139/113.110398; Lange KR, 1999, SURFACTANTS: A PRACTICAL HANDBOOK, P144; Mahajan RK, 2012, IND ENG CHEM RES, V51, P3338, DOI 10.1021/ie202463w; Menger FM, 2000, LANGMUIR, V16, P2062, DOI 10.1021/la9910576; MENGER FM, 1993, J AM CHEM SOC, V115, P10083, DOI 10.1021/ja00075a025; MENGER FM, 1991, J AM CHEM SOC, V113, P1451, DOI 10.1021/ja00004a077; Molla MR, 2017, J MOL LIQ, V238, P62, DOI 10.1016/j.molliq.2017.04.061; Motomura K, 1998, MIXED SURFACTANT SYS; MURANUSHI N, 1980, INT J PHARM, V4, P271; Myers D, 2006, SURFACTANT SCIENCE AND TECHNOLOGY, 3RD EDITION, P1; Olutas EB, 2012, J CHEM THERMODYN, V47, P144, DOI 10.1016/j.jct.2011.10.008; Patil SS, 2012, MOL PHARMACEUT, V9, P318, DOI 10.1021/mp200541r; Pietralik Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144373; Rao KS, 2011, J PHYS CHEM B, V115, P13847, DOI 10.1021/jp2076275; Rodriguez A, 2008, J PHYS CHEM B, V112, P11942, DOI 10.1021/jp802243f; Rohatgi-Mukherjee K.K., 1992, IND J CHEM, V31A, P500; ROSEN MJ, 1982, COLLOID SURFACE, V5, P159, DOI 10.1016/0166-6622(82)80071-1; Rosen MJ, 2004, SURFACTANTS INTERFAC, V3, DOI DOI 10.1002/0471670561.CH11; Rosen MJ, COLLOIDS SURF, V13, P201; Rub MA, 2018, J CHEM THERMODYN, V121, P199, DOI 10.1016/j.jct.2018.02.019; Rub MA, 2017, J CHEM ENG DATA, V62, P3216, DOI 10.1021/acs.jced.7b00298; Rub MA, 2017, J PHYS ORG CHEM, V30, DOI 10.1002/poc.3676; Rub MA, 2016, RUSS J PHYS CHEM B+, V10, P1007, DOI 10.1134/S1990793116060257; Rub MA, 2016, J CHEM THERMODYN, V96, P196, DOI 10.1016/j.jct.2016.01.001; Rub MA, 2015, TENSIDE SURFACT DET, V52, P236, DOI 10.3139/113.110371; Rub MA, 2014, J TAIWAN INST CHEM E, V45, P2068, DOI 10.1016/j.jtice.2014.04.024; Rub MA, 2014, J MOL LIQ, V194, P234, DOI 10.1016/j.molliq.2014.02.037; Rub MA, 2013, J MOL STRUCT, V1050, P35, DOI 10.1016/j.molstruc.2013.07.010; SCHOTT H, 1976, J PHARM SCI, V65, P975, DOI 10.1002/jps.2600650706; Schreier S, 2000, BBA-BIOMEMBRANES, V1508, P210, DOI 10.1016/S0304-4157(00)00012-5; Sugihara G., 2003, J OLEO SCI, V52, P449, DOI [10.5650/jos.52.449, DOI 10.5650/JOS.52.449]; Taboada P, 1999, J CHEM ENG DATA, V44, P820, DOI 10.1021/je990060o; Tanford C., 1980, HYDROPHOBIC EFFECT F; TURRO NJ, 1978, J AM CHEM SOC, V100, P5951, DOI 10.1021/ja00486a062; TURRO NJ, 1986, J PHYS CHEM-US, V90, P288, DOI 10.1021/j100274a017; UMEMURA J, 1981, J COLLOID INTERF SCI, V83, P558, DOI 10.1016/0021-9797(81)90350-7; Van Hamme JD, 2006, BIOTECHNOL ADV, V24, P604, DOI 10.1016/j.biotechadv.2006.08.001; WINNIK FM, 1993, CHEM REV, V93, P587, DOI 10.1021/cr00018a001; Xu DQ, 2016, J SURFACTANTS DETERG, V19, P91, DOI 10.1007/s11743-015-1752-0; YANG PW, 1986, J COLLOID INTERF SCI, V113, P218, DOI 10.1016/0021-9797(86)90222-5; ZANA R, 1993, NATURE, V362, P228, DOI 10.1038/362228a0; Zdziennicka A, 2017, J MOL LIQ, V243, P236, DOI 10.1016/j.molliq.2017.08.042; Zhinong G, 2008, J NAT SCI, V13, P227, DOI DOI 10.1007/S11859-008-0219-9; Zhou Q, 2003, LANGMUIR, V19, P4555, DOI 10.1021/la020789m	83	15	16	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2019	14	2							e0211077	10.1371/journal.pone.0211077	http://dx.doi.org/10.1371/journal.pone.0211077			30	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK4EL	30726255	Green Published, gold, Green Submitted			2023-01-03	WOS:000457874000051
J	Tan, TW; Shih, CD; Concha-Moore, KC; Diri, MM; Hu, B; Marrero, D; Zhou, W; Armstrong, DG				Tan, Tze-Woei; Shih, Chia-Ding; Concha-Moore, Kirsten C.; Diri, Muhanad M.; Hu, Bo; Marrero, David; Zhou, Wei; Armstrong, David G.			Disparities in outcomes of patients admitted with diabetic foot infections	PLOS ONE			English	Article							LOWER-EXTREMITY AMPUTATION; PERIPHERAL ARTERIAL-DISEASE; RACIAL DISPARITIES; RACE; VETERANS; REVASCULARIZATION; ISCHEMIA; ULCERS; RATES; PROGNOSIS	Objective The purpose of this study was to evaluate the disparities in the outcomes of White, African American (AA) and non-AA minority (Hispanics and Native Americans (NA)), patients admitted in the hospitals with diabetic foot infections (DFIs). Research design and methods The HCUP-Nationwide Inpatient Sample (2002 to 2015) was queried to identify patients who were admitted to the hospital for management of DFI using ICD-9 codes. Outcomes evaluated included minor and major amputations, open or endovascular revascularization, and hospital length of stay (LOS). Incidence for amputation and open or endovascular revascularization were evaluated over the study period. Multivariable regression analyses were performed to assess the association between race/ethnicity and outcomes. Results There were 150,701 admissions for DFI, including 98,361 Whites, 24,583 AAs, 24,472 Hispanics, and 1,654 Native Americans (NAs) in the study cohort. Overall, 45,278 (30%) underwent a minor amputation, 9,039 (6%) underwent a major amputation, 3,151 underwent an open bypass, and 8,689 had an endovascular procedure. There was a decreasing incidence in major amputations and an increasing incidence of minor amputations over the study period (P <.05). The risks for major amputation were significantly higher (all p<0.05) for AA (OR 1.4, 95%Cl 1.4,1.5), Hispanic (OR 1.3, 95%Cl 1.3,1.4), and NA (OR 1.5, 95%Cl 1.2,1.8) patients with DFIs compared to White patients. Hispanics (OR 1.3, 95%Cl 1.2,1.5) and AAs (OR 1.2, 95%Cl 1.1,1.4) were more likely to receive endovascular intervention or open bypass than Whites (all p<0.05). NA patients with DFI were less likely to receive a revascularization procedure (OR 0.6, 95%Cl 0.3, 0.9, p = 0.03) than Whites. The mean hospital length of stay (LOS) was significantly longer for AAs (9.2 days) and Hispanics (8.6 days) with DFIs compared to Whites (8.1 days, p<0.001). Conclusion Despite a consistent incidence reduction of amputation over the past decade, racial and ethnic minorities including African American, Hispanic, and Native American patients admitted to hospitals with DFIs have a consistently significantly higher risk of major amputation and longer hospital length of stay than their White counterparts. Native Americans were less likely to receive revascularization procedures compared to other minorities despite exhibiting an elevated risk of an amputation. Further study is required to address and limit racial and ethnic disparities and to further promote equity in the treatment and outcomes of these at-risk patients.	[Tan, Tze-Woei; Concha-Moore, Kirsten C.; Diri, Muhanad M.; Marrero, David; Zhou, Wei] Univ Arizona, Coll Med, Tucson, AZ 85721 USA; [Tan, Tze-Woei; Shih, Chia-Ding; Armstrong, David G.] SALSA, Los Angeles, CA 90012 USA; [Shih, Chia-Ding; Armstrong, David G.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90033 USA; [Hu, Bo] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA	University of Arizona; University of Southern California; Cleveland Clinic Foundation	Tan, TW (corresponding author), Univ Arizona, Coll Med, Tucson, AZ 85721 USA.; Tan, TW (corresponding author), SALSA, Los Angeles, CA 90012 USA.	ttan@surgery.arizona.edu	Tan, Tze-Woei/W-3871-2017; Shih, Chia-Ding/CAF-5495-2022	Tan, Tze-Woei/0000-0002-6658-9482; Shih, Chia-Ding/0000-0001-9203-1899	NIDDK NIH HHS [P30 DK111022] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APELQVIST J, 1993, J INTERN MED, V233, P485, DOI 10.1111/j.1365-2796.1993.tb01003.x; Armstrong DG, 2017, NEW ENGL J MED, V376, P2367, DOI 10.1056/NEJMra1615439; Arya S, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007425; Blumberg SN, 2014, J DIABETES, V6, P68, DOI 10.1111/1753-0407.12050; Boyko EJ, 1996, DIABETIC MED, V13, P967, DOI 10.1002/(SICI)1096-9136(199611)13:11<967::AID-DIA266>3.0.CO;2-K; Brennan MB, 2017, J DIABETES COMPLICAT, V31, P556, DOI 10.1016/j.jdiacomp.2016.11.020; Collins TC, 2002, MED CARE, V40, P106; Durazzo TS, 2013, JAMA SURG, V148, P617, DOI 10.1001/jamasurg.2013.1436; Durham CA, 2010, J VASC SURG, V52, P600, DOI 10.1016/j.jvs.2010.04.011; Eslami MH, 2007, J VASC SURG, V45, P55, DOI 10.1016/j.jvs.2006.09.044; Goodney PP, 2009, J VASC SURG, V50, P54, DOI 10.1016/j.jvs.2009.01.035; GUADAGNOLI E, 1995, ARCH SURG-CHICAGO, V130, P381; Henry AJ, 2011, J VASC SURG, V53, P330, DOI 10.1016/j.jvs.2010.08.077; Hinchliffe RJ, 2016, DIABETES-METAB RES, V32, P136, DOI 10.1002/dmrr.2705; Holman KH, 2011, J VASC SURG, V54, P420, DOI 10.1016/j.jvs.2011.02.035; Huber TS, 1999, J VASC SURG, V30, P417, DOI 10.1016/S0741-5214(99)70068-6; Lefebvre KM, 2015, VASC MED, V20, P51, DOI 10.1177/1358863X14565373; Lefebvre KM, 2011, CLIN ORTHOP RELAT R, V469, P1941, DOI 10.1007/s11999-011-1842-x; Lefebvre KM, 2009, J NATL MED ASSOC, V101, P649, DOI 10.1016/S0027-9684(15)30973-1; Li YF, 2012, DIABETES CARE, V35, P273, DOI 10.2337/dc11-1360; Margolis DJ, 2011, DATA POINTS PUBLICAT; Mebane EW, 1999, J AM GERIATR SOC, V47, P579, DOI 10.1111/j.1532-5415.1999.tb02573.x; MIROWSKY J, 1980, AM J SOCIOL, V86, P479, DOI 10.1086/227277; Mustapha JA, 2017, J RACIAL ETHN HLTH D; Ndosi M, 2018, DIABETIC MED, V35, P78, DOI 10.1111/dme.13537; Prompers L, 2007, DIABETOLOGIA, V50, P18, DOI 10.1007/s00125-006-0491-1; Robinson TE, 2016, DIABETIC MED, V33, P55, DOI 10.1111/dme.12807; Rowe VL, 2010, J VASC SURG, V51, p21S, DOI 10.1016/j.jvs.2009.09.066; Schofield CJ, 2009, DIABETIC MED, V26, P773, DOI 10.1111/j.1464-5491.2009.02770.x; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Singh N, 2005, JAMA-J AM MED ASSOC, V293, P217, DOI 10.1001/jama.293.2.217; Skrepnek GH, 2014, J VASC SURG, V60, P1255, DOI 10.1016/j.jvs.2014.04.071; Sohn MW, 2010, J FOOT ANKLE RES, V3, DOI 10.1186/1757-1146-3-27; Tseng CL, 2011, DIABETES CARE, V34, P1157, DOI 10.2337/dc10-1775; TUNIS SR, 1993, ARCH INTERN MED, V153, P991, DOI 10.1001/archinte.153.8.991; Uccioli L, 2010, DIABETES CARE, V33, P977, DOI 10.2337/dc09-0831	36	34	35	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2019	14	2							e0211481	10.1371/journal.pone.0211481	http://dx.doi.org/10.1371/journal.pone.0211481			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK2LY	30716108	Green Submitted, gold, Green Published			2023-01-03	WOS:000457744200026
J	Craig, S				Craig, Stephen			Hydrogels muscle their way into new territory	SCIENCE			English	Editorial Material									[Craig, Stephen] Duke Univ, Dept Chem, Durham, NC 27708 USA	Duke University	Craig, S (corresponding author), Duke Univ, Dept Chem, Durham, NC 27708 USA.	stephen.craig@duke.edu	Craig, Stephen L/D-3484-2011	Craig, Stephen L/0000-0002-8810-0369				Brown CL, 2015, CHEM SCI, V6, P2158, DOI 10.1039/c4sc01945h; Clough JM, 2015, TOP CURR CHEM, V369, P209, DOI 10.1007/128_2015_641; Gong JP, 2003, ADV MATER, V15, P1155, DOI 10.1002/adma.200304907; Hansen CJ, 2009, ADV MATER, V21, P4143, DOI 10.1002/adma.200900588; Li J, 2015, ACCOUNTS CHEM RES, V48, P2181, DOI 10.1021/acs.accounts.5b00184; Matsuda T, 2019, SCIENCE, V363, P504, DOI 10.1126/science.aau9533	6	7	8	1	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 1	2019	363	6426			SI		451	452		10.1126/science.aaw2242	http://dx.doi.org/10.1126/science.aaw2242			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HJ7WZ	30705169				2023-01-03	WOS:000457409400022
J	Matsuda, T; Kawakami, R; Namba, R; Nakajima, T; Gong, JP				Matsuda, Takahiro; Kawakami, Runa; Namba, Ryo; Nakajima, Tasuku; Gong, Jian Ping			Mechanoresponsive self-growing hydrogels inspired by muscle training	SCIENCE			English	Article							DOUBLE-NETWORK HYDROGELS; CROSS-LINKING; NATURAL RUBBER; POLYMER; ACID; MECHANOCHEMISTRY; MASTICATION; STRENGTH; GELS	Living tissues, such as muscle, autonomously grow and remodel themselves to adapt to their surrounding mechanical environment through metabolic processes. By contrast, typical synthetic materials cannot grow and reconstruct their structures once formed. We propose a strategy for developing "self-growing" polymeric materials that respond to repetitive mechanical stress through an effective-mechanochemical transduction. Robust double-network hydrogels provided with a sustained monomer supply undergo self-growth, and the materials are substantially strengthened under repetitive loading through a structural destruction-reconstruction process. This strategy also endows the hydrogels with tailored functions at desired positions by mechanical stamping. This work may pave the way for the development of self-growing gel materials for applications such as soft robots and intelligent devices.	[Matsuda, Takahiro; Kawakami, Runa; Namba, Ryo] Hokkaido Univ, Grad Sch Life Sci, Kita Ku, N21W11, Sapporo, Hokkaido 0010021, Japan; [Nakajima, Tasuku; Gong, Jian Ping] Hokkaido Univ, Fac Adv Life Sci, Kita Ku, N21W11, Sapporo, Hokkaido 0010021, Japan; [Nakajima, Tasuku; Gong, Jian Ping] Hokkaido Univ, Soft Matter GI CoRE, Kita Ku, N21W11, Sapporo, Hokkaido 0010021, Japan; [Nakajima, Tasuku; Gong, Jian Ping] Hokkaido Univ, Inst Chem React Design & Discovery, Kita Ku, N21W11, Sapporo, Hokkaido 0010021, Japan	Hokkaido University; Hokkaido University; Hokkaido University; Hokkaido University	Nakajima, T; Gong, JP (corresponding author), Hokkaido Univ, Fac Adv Life Sci, Kita Ku, N21W11, Sapporo, Hokkaido 0010021, Japan.; Nakajima, T; Gong, JP (corresponding author), Hokkaido Univ, Soft Matter GI CoRE, Kita Ku, N21W11, Sapporo, Hokkaido 0010021, Japan.; Nakajima, T; Gong, JP (corresponding author), Hokkaido Univ, Inst Chem React Design & Discovery, Kita Ku, N21W11, Sapporo, Hokkaido 0010021, Japan.	tasuku@sci.hokudai.ac.jp; gong@sci.hokudai.ac.jp	Gong, Jian Ping/B-7019-2009; Nakajima, Tasuku/E-5831-2017	Gong, Jian Ping/0000-0003-2228-2750; Nakajima, Tasuku/0000-0002-2235-3478; Matsuda, Takahiro/0000-0001-9681-8007	JSPS [JP17H06144, JP17J09290, JP17H04891]; ImPACT Program of the Council for Science, Technology and Innovation (Cabinet Office, Government of Japan)	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); ImPACT Program of the Council for Science, Technology and Innovation (Cabinet Office, Government of Japan)	This research was supported by JSPS KAKENHI grants JP17H06144, JP17J09290, and JP17H04891 and by the ImPACT Program of the Council for Science, Technology and Innovation (Cabinet Office, Government of Japan). The Institute for Chemical Reaction Design and Discovery (ICReDD) was established by the World Premier International Research Initiative (WPI), MEXT, Japan.	Agrawal A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2772; Ahmed S, 2014, POLYMER, V55, P914, DOI 10.1016/j.polymer.2013.12.066; Anderson T.L., 2017, FRACTURE MECH FUNDAM, DOI DOI 10.1201/9781315370293; ANGIER DJ, 1957, J POLYM SCI, V25, P1, DOI 10.1002/pol.1957.1202510801; ANGIER DJ, 1955, J POLYM SCI, V18, P129, DOI 10.1002/pol.1955.120188711; Baytekin HT, 2015, J AM CHEM SOC, V137, P1726, DOI 10.1021/ja507983x; Baytekin HT, 2012, ANGEW CHEM INT EDIT, V51, P3596, DOI 10.1002/anie.201108110; Beuermann S, 2006, MACROMOLECULES, V39, P509, DOI 10.1021/ma051187n; Carey BJ, 2011, ACS NANO, V5, P2715, DOI 10.1021/nn103104g; Chang BS, 2018, MATER HORIZ, V5, P416, DOI 10.1039/c8mh00032h; Coffey VG, 2007, SPORTS MED, V37, P737, DOI 10.2165/00007256-200737090-00001; Czerner M, 2015, PROC MAT SCI, V8, P287, DOI 10.1016/j.mspro.2015.04.075; Diaz DD, 2011, CHEM SOC REV, V40, P427, DOI 10.1039/c005401c; Ducrot E, 2014, SCIENCE, V344, P186, DOI 10.1126/science.1248494; Fitch KR, 2014, CHEM MATER, V26, P6771, DOI 10.1021/cm503253n; FLORY PJ, 1953, PRINCIPLES POLYM CHE, P432; Gay C, 1999, ANAL BIOCHEM, V273, P143, DOI 10.1006/abio.1999.4207; Ghatak A, 2000, J PHYS CHEM B, V104, P4018, DOI 10.1021/jp9942973; Gong JP, 2010, SOFT MATTER, V6, P2583, DOI 10.1039/b924290b; Gong JP, 2003, ADV MATER, V15, P1155, DOI 10.1002/adma.200304907; Hager MD, 2010, ADV MATER, V22, P5424, DOI 10.1002/adma.201003036; Imato K, 2015, ANGEW CHEM INT EDIT, V54, P6168, DOI 10.1002/anie.201412413; Jakobs RTM, 2013, ACS MACRO LETT, V2, P613, DOI 10.1021/mz400201c; Jockusch S, 2001, MACROMOLECULES, V34, P1619, DOI 10.1021/ma001836p; LAKE GJ, 1967, PROC R SOC LON SER-A, V300, P108, DOI 10.1098/rspa.1967.0160; Matsuda T, 2016, MACROMOLECULES, V49, P1865, DOI 10.1021/acs.macromol.5b02592; Michael P, 2015, ANGEW CHEM INT EDIT, V54, P13918, DOI 10.1002/anie.201505678; Moghadam F, 2015, CHEM COMMUN, V51, P13658, DOI 10.1039/c5cc04841a; Na YH, 2006, MACROMOLECULES, V39, P4641, DOI 10.1021/ma060568d; Naficy S, 2011, AUST J CHEM, V64, P1007, DOI 10.1071/CH11156; Nagamani C, 2016, J AM CHEM SOC, V138, P2540, DOI 10.1021/jacs.6b00097; Nakajima T, 2013, SOFT MATTER, V9, P1955, DOI 10.1039/c2sm27232f; Nakajima T, 2012, ADV FUNCT MATER, V22, P4426, DOI 10.1002/adfm.201200809; Patrick JF, 2016, NATURE, V540, P363, DOI 10.1038/nature21002; Phillips SM, 2004, NUTRITION, V20, P689, DOI 10.1016/j.nut.2004.04.009; Piermattei A, 2009, NAT CHEM, V1, P133, DOI [10.1038/NCHEM.167, 10.1038/nchem.167]; Ramirez ALB, 2013, NAT CHEM, V5, P757, DOI [10.1038/NCHEM.1720, 10.1038/nchem.1720]; Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721; Saitta AM, 1999, J CHEM PHYS, V111, P9434, DOI 10.1063/1.479855; SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R; Schoenfeld BJ, 2010, J STRENGTH COND RES, V24, P2857, DOI 10.1519/JSC.0b013e3181e840f3; Smalo HS, 2013, MOL PHYS, V111, P1563, DOI 10.1080/00268976.2013.811554; SOHMA J, 1989, PROG POLYM SCI, V14, P451, DOI 10.1016/0079-6700(89)90004-X; Tang T, 2015, RSC ADV, V5, P819, DOI 10.1039/c4ra13020k; Verstraeten F, 2016, CHEM COMMUN, V52, P8608, DOI 10.1039/c6cc04312g; Webber RE, 2007, MACROMOLECULES, V40, P2919, DOI 10.1021/ma062924y; Yoshida R, 2010, ADV MATER, V22, P3463, DOI 10.1002/adma.200904075; Yoshida Y, 2004, FREE RADICAL RES, V38, P375, DOI 10.1080/1071576042000191763; Zhang H, 2016, ANGEW CHEM INT EDIT, V55, P3040, DOI 10.1002/anie.201510171; Zhang MG, 2014, BIOMECH MODEL MECHAN, V13, P1, DOI 10.1007/s10237-013-0481-4	50	309	311	120	1125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 1	2019	363	6426			SI		504	+		10.1126/science.aau9533	http://dx.doi.org/10.1126/science.aau9533			32	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ7WZ	30705187				2023-01-03	WOS:000457409400044
J	Drak, D; Barratt, H; Templeton, DJ; O'Connor, CC; Gracey, DM				Drak, Douglas; Barratt, Hamish; Templeton, David J.; O'Connor, Catherine C.; Gracey, David M.			Renal function and risk factors for renal disease for patients receiving HIV pre-exposure prophylaxis at an inner metropolitan health service	PLOS ONE			English	Article							TENOFOVIR DISOPROXIL FUMARATE; KIDNEY-FUNCTION; MEN; EXPOSURE; ASSOCIATION; ADHERENCE	Background Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) significantly reduces the risk of HIV acquisition. TDF is a known nephrotoxin however, renal dysfunction from TDF is mostly reversible following discontinuation. Aims To describe the renal function, risk factors for renal disease and associated clinical testing practices in a cohort of PrEP patients. Methods A retrospective review was conducted of all PrEP patients commenced on TDF/FTC at an inner metropolitan sexual health clinic in Sydney, Australia between April 2016 and July 2017, with follow-up data obtained at 3-monthly intervals until 18 months. Results 525 patients met inclusion criteria. Patients were almost exclusively male and median age was 34 years (IQR: 28 to 42). At baseline, 1.5% had an estimated glomerular filtration rate (eGFR) < 70 mL/min/1.73m(2). A small significant drop in eGFR of -2.5 mL/min/1.73m(2) (p<0.05) occurred between PrEP commencement and the first follow-up period, followed by a progressive decline in eGFR of -0.38 mL/min/1.73m(2) per month (95% CI: -0.57 to -0.20; p<0.001). Renal impairment (eGFR < 70 mL/min/1.73m(2)) occurred in 6.5% of patients and persisted across consecutive follow-up periods in five (1.0%) patients. Patients aged. 40 years had a greater risk of renal impairment than younger patients (HR 3.9, 95% CI: 1.8 to 8.4; p<0.001), despite similar rates of eGFR decline (p = 0.19). PrEP was discontinued in two patients (0.4%) due to renal function concerns. Conclusion PrEP use led to an initial drop in eGFR and a more gradual progressive decline subsequently, but significant renal impairment remained uncommon up to 18 months of follow-up.	[Drak, Douglas; Barratt, Hamish] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Barratt, Hamish; Templeton, David J.; O'Connor, Catherine C.; Gracey, David M.] Univ Sydney, Cent Clin Sch, Sydney, NSW, Australia; [Templeton, David J.; O'Connor, Catherine C.] RPA Sexual Hlth, Sydney, NSW, Australia; [Templeton, David J.; O'Connor, Catherine C.] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia; [Gracey, David M.] Royal Prince Alfred Hosp, Renal Unit, Sydney, NSW, Australia	University of Sydney; University of Sydney; University of New South Wales Sydney; Kirby Institute; University of Sydney	Drak, D (corresponding author), Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia.	douglas.drak@sydney.edu.au		Templeton, David/0000-0003-2157-9587				Gandhi M, 2016, LANCET HIV, V3, pE521, DOI 10.1016/S2352-3018(16)30153-9; Glidden DV, 2016, CLIN INFECT DIS, V62, P1172, DOI 10.1093/cid/ciw022; Health N, 2016, PREEXP PROPH HIV ANT, P42; Kakar S, 2017, NEPHROLOGY, V22, P174, DOI 10.1111/nep.12844; Laprise C, 2013, CLIN INFECT DIS, V56, P567, DOI 10.1093/cid/cis937; Levy D, 2002, NEW ENGL J MED, V347, P1397, DOI 10.1056/NEJMoa020265; Marcus JL, 2016, JAIDS-J ACQ IMM DEF, V73, P540, DOI 10.1097/QAI.0000000000001129; McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2; Mocroft A, 2016, LANCET HIV, V3, pE23, DOI 10.1016/S2352-3018(15)00211-8; Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273; Mugwanya K, 2016, J INFECT DIS, V214, P1050, DOI 10.1093/infdis/jiw125; Mugwanya KK, 2016, JAIDS-J ACQ IMM DEF, V71, P374, DOI 10.1097/QAI.0000000000000868; Mugwanya KK, 2015, JAMA INTERN MED, V175, P246, DOI 10.1001/jamainternmed.2014.6786; Pendergraft WF, 2014, CLIN J AM SOC NEPHRO, V9, P1996, DOI 10.2215/CJN.00360114; Ricci Z, 2008, KIDNEY INT, V73, P538, DOI 10.1038/sj.ki.5002743; Solomon MM, 2014, AIDS, V28, P851, DOI 10.1097/QAD.0000000000000156; Suzuki S, 2017, AIDS PATIENT CARE ST, V31, P105, DOI 10.1089/apc.2016.0286; Tang EC, 2018, JAIDS-J ACQ IMM DEF, V77, P193, DOI 10.1097/QAI.0000000000001566; Wright E., 2018, J VIRUS ERAD, V2018, P143; Zablotska IB, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-017-5018-9; Zablotska IB, 2017, CURR HIV-AIDS REP, V14, P201, DOI 10.1007/s11904-017-0367-7	21	9	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2019	14	1							e0210106	10.1371/journal.pone.0210106	http://dx.doi.org/10.1371/journal.pone.0210106			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH8WT	30653509	Green Submitted, Green Published, gold			2023-01-03	WOS:000456015500026
J	Tamma, PD; Miller, MA; Cosgrove, SE				Tamma, Pranita D.; Miller, Melissa A.; Cosgrove, Sara E.			Rethinking How Antibiotics Are Prescribed Incorporating the 4 Moments of Antibiotic Decision Making Into Clinical Practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PREVALENCE		[Tamma, Pranita D.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21287 USA; [Miller, Melissa A.] Agcy Healthcare Res & Qual, Ctr Qual Improvement & Patient Safety, Rockville, MD USA; [Cosgrove, Sara E.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA	Johns Hopkins University; Agency for Healthcare Research & Quality; Johns Hopkins University	Tamma, PD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat, Div Pediat Infect Dis, 200 N Wolfe St,Ste 315, Baltimore, MD 21287 USA.	ptamma1@jhmi.edu		Miller, Melissa/0000-0003-4820-8946	Agency for Healthcare Research and Quality (AHRQ) [HHSP233201500020I/HHSP23337003T]	Agency for Healthcare Research and Quality (AHRQ)(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This work was supported by contract HHSP233201500020I/HHSP23337003T from the Agency for Healthcare Research and Quality (AHRQ).	[Anonymous], AHRQ SAF PROGR IMPR; Cai T, 2015, CLIN INFECT DIS, V61, P1655, DOI 10.1093/cid/civ696; Magill SS, 2014, JAMA-J AM MED ASSOC, V312, P1438, DOI 10.1001/jama.2014.12923; Marston HD, 2016, JAMA-J AM MED ASSOC, V316, P1193, DOI 10.1001/jama.2016.11764; Mohorek M, 2015, J SURG EDUC, V72, P402, DOI 10.1016/j.jsurg.2014.11.002; Olans RN, 2016, CLIN INFECT DIS, V62, P84, DOI 10.1093/cid/civ697; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Spellberg B, 2016, JAMA INTERN MED, V176, P1254, DOI 10.1001/jamainternmed.2016.3646; Tamma PD, 2017, CLIN INFECT DIS, V64, P537, DOI 10.1093/cid/ciw780; World Health Organization (WHO), WHO GUID HAND HYG HL	10	51	52	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	2019	321	2					139	140		10.1001/jama.2018.19509	http://dx.doi.org/10.1001/jama.2018.19509			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH3FZ	30589917				2023-01-03	WOS:000455606300006
J	Feucht, J; Sun, J; Eyquem, J; Ho, YJ; Zhao, ZG; Leibold, J; Dobrin, A; Cabriolu, A; Hamieh, M; Sadelain, M				Feucht, Judith; Sun, Jie; Eyquem, Justin; Ho, Yu-Jui; Zhao, Zeguo; Leibold, Josef; Dobrin, Anton; Cabriolu, Annalisa; Hamieh, Mohamad; Sadelain, Michel			Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency	NATURE MEDICINE			English	Article							CHIMERIC ANTIGEN RECEPTOR; CD8(+); CD19; ZETA; LYMPHOCYTES; GENERATION; EFFECTOR; DOMAINS; DESIGN	Chimeric antigen receptors (CARs) are synthetic receptors that target and reprogram T cells to acquire augmented antitumor properties(1). CD19-specific CARs that comprise CD28 and CD3 zeta signaling motifs(2) have induced remarkable responses in patients with refractory leukemia(3-5) and lymphoma(6) and were recently approved by the US Food and Drug Administration(7). These CARs program highly performing effector functions that mediate potent tumor elimination(4,8) despite the limited persistence they confer on T cells(3-6,8). Extending their functional persistence without compromising their potency should improve current CAR therapies. Strong T cell activation drives exhaustion(9,10), which may be accentuated by the redundancy of CD28 and CD3 zeta signaling(11,12) as well as the spatiotemporal constraints imparted by the structure of second-generation CARs(2). Thus, we hypothesized that calibrating the activation potential of CD28-based CARs would differentially reprogram T cell function and differentiation. Here, we show that CARs encoding a single immunoreceptor tyrosine-based activation motif direct T cells to different fates by balancing effector and memory programs, thereby yielding CAR designs with enhanced therapeutic profiles.	[Feucht, Judith; Sun, Jie; Eyquem, Justin; Zhao, Zeguo; Dobrin, Anton; Cabriolu, Annalisa; Hamieh, Mohamad; Sadelain, Michel] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Ctr Cell Engn, 1275 York Ave, New York, NY 10021 USA; [Feucht, Judith; Sun, Jie; Eyquem, Justin; Zhao, Zeguo; Dobrin, Anton; Cabriolu, Annalisa; Hamieh, Mohamad; Sadelain, Michel] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Immunol Program, 1275 York Ave, New York, NY 10021 USA; [Sun, Jie] Zhejiang Univ, Inst Hematol, Zhejing, Peoples R China; [Sun, Jie] Zhejiang Engn Lab Stem Cell & Immunotherapy, Zhejing, Peoples R China; [Ho, Yu-Jui; Leibold, Josef] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Zhejiang University; Memorial Sloan Kettering Cancer Center	Sadelain, M (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Ctr Cell Engn, 1275 York Ave, New York, NY 10021 USA.; Sadelain, M (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Immunol Program, 1275 York Ave, New York, NY 10021 USA.	m-sadelain@ski.mskcc.org	Eyquem, Justin/AAW-5753-2020; Hamieh, Mohamad/AAX-3056-2020	Ho, Yu-jui/0000-0002-7540-024X; Zhao, Zeguo/0000-0002-2901-5033; Leibold, Josef/0000-0003-2336-1987; Eyquem, Justin/0000-0001-8262-1190; Sun, Jie/0000-0002-5642-0560	NCI Cancer Center Support Grant [P30 CA08748]; Cycle for Survival; Marie-Josee and Henry R. Kravis Center for Molecular Oncology; Care-for-Rare Foundation; German Research Foundation (DFG); Edythe Griffinger Fellowship; Louis V. Gerstner Jr. Graduate School of Biomedical Sciences; Lake Road Foundation; Mr. William H. and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research; Lymphoma and Leukemia Society; MSKCC Support Grant/Core Grant [P30 CA008748]; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cycle for Survival; Marie-Josee and Henry R. Kravis Center for Molecular Oncology; Care-for-Rare Foundation; German Research Foundation (DFG)(German Research Foundation (DFG)); Edythe Griffinger Fellowship; Louis V. Gerstner Jr. Graduate School of Biomedical Sciences; Lake Road Foundation; Mr. William H. and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research; Lymphoma and Leukemia Society(Leukemia and Lymphoma Society); MSKCC Support Grant/Core Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank J. Mansilla-Soto, S. van der Stegen, F. Perna, and other Sadelain laboratory members (Memorial Sloan Kettering Cancer Center) for helpful and critical discussions and G. Gunset for excellent technical assistance. We thank the following Memorial Sloan Kettering Cancer Center (MSKCC) core facilities for the excellent support: SKI Flow Cytometry core facility; animal facility; bioinformatics core; and integrated genomics operation core, funded by the NCI Cancer Center Support Grant (P30 CA08748), Cycle for Survival, and the Marie-Josee and Henry R. Kravis Center for Molecular Oncology. We thank the Care-for-Rare Foundation (J.F.), the German Research Foundation (DFG) (J.F.), the Edythe Griffinger Fellowship (J.S.), and the Louis V. Gerstner Jr. Graduate School of Biomedical Sciences (A.D.) for their support. This work was in part supported by the Lake Road Foundation, the Mr. William H. and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research, the Lymphoma and Leukemia Society, and the MSKCC Support Grant/Core Grant (P30 CA008748).	Acuto O, 2003, NAT REV IMMUNOL, V3, P939, DOI 10.1038/nri1248; Bai AL, 2007, J IMMUNOL, V178, P7632, DOI 10.4049/jimmunol.178.12.7632; Brentjens RJ, 2007, CLIN CANCER RES, V13, P5426, DOI 10.1158/1078-0432.CCR-07-0674; Brentjens RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005930; Brentjens RJ, 2003, NAT MED, V9, P279, DOI 10.1038/nm827; Carlson CM, 2006, NATURE, V442, P299, DOI 10.1038/nature04882; Chae WJ, 2004, INT IMMUNOL, V16, P1225, DOI 10.1093/intimm/dxh120; Chang JT, 2014, NAT IMMUNOL, V15, P1104, DOI 10.1038/ni.3031; Daniels MA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00617; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Eyquem J, 2017, NATURE, V543, P113, DOI 10.1038/nature21405; Fraietta JA, 2018, NAT MED, V24, P563, DOI 10.1038/s41591-018-0010-1; Gade TPF, 2005, CANCER RES, V65, P9080, DOI 10.1158/0008-5472.CAN-05-0436; Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446; Ghosh A, 2013, J CLIN INVEST, V123, P2654, DOI 10.1172/JCI66301; Gong Michael C., 1999, Neoplasia (New York), V1, P123, DOI 10.1038/sj.neo.7900018; Ichii H, 2002, NAT IMMUNOL, V3, P558, DOI 10.1038/ni802; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; James JR, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aan1088; Kaech SM, 2012, NAT REV IMMUNOL, V12, P749, DOI 10.1038/nri3307; Kersh EN, 1998, SCIENCE, V281, P572, DOI 10.1126/science.281.5376.572; Kochenderfer JN, 2010, BLOOD, V116, P3875, DOI 10.1182/blood-2010-01-265041; Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3; Love PE, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002485; Maher J, 2002, NAT BIOTECHNOL, V20, P70, DOI 10.1038/nbt0102-70; Mukhopadhyay H, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003004; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; RIVIERE I, 1995, P NATL ACAD SCI USA, V92, P6733, DOI 10.1073/pnas.92.15.6733; Sadelain M, 2017, CELL, V171, P1471, DOI 10.1016/j.cell.2017.12.002; Sadelain M, 2017, NATURE, V545, P423, DOI 10.1038/nature22395; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; Sommermeyer D, 2016, LEUKEMIA, V30, P492, DOI 10.1038/leu.2015.247; van Oers NSC, 2000, NAT IMMUNOL, V1, P322, DOI 10.1038/79774; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Youngblood B, 2010, INT IMMUNOL, V22, P797, DOI 10.1093/intimm/dxq437; Yu BF, 2017, NAT IMMUNOL, V18, P573, DOI 10.1038/ni.3706; Zhao YB, 2009, J IMMUNOL, V183, P5563, DOI 10.4049/jimmunol.0900447; Zhao ZG, 2015, CANCER CELL, V28, P415, DOI 10.1016/j.ccell.2015.09.004; Zhou XY, 2012, J IMMUNOL, V189, P2722, DOI 10.4049/jimmunol.1201150	40	221	228	5	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2019	25	1					82	+		10.1038/s41591-018-0290-5	http://dx.doi.org/10.1038/s41591-018-0290-5			23	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	HG5OR	30559421	Green Accepted			2023-01-03	WOS:000455027700025
J	Champion, L; Economides, M; Chandler, C				Champion, Louise; Economides, Marcos; Chandler, Chris			The efficacy of a brief app-based mindfulness intervention on psychosocial outcomes in healthy adults: A pilot randomised controlled trial	PLOS ONE			English	Article							STRESS REDUCTION; MISSING DATA; GENDER-DIFFERENCES; SMARTPHONE APP; EFFECT SIZES; LIFE; SATISFACTION; RUMINATION; MIND; MEDITATION	Background Previous evidence suggests that mindfulness training may improve aspects of psychosocial well-being. Whilst mindfulness is traditionally taught in person, consumers are increasingly turning to mindfulness-based smartphone apps as an alternative delivery medium for training. Despite this growing trend, few studies have explored whether mindfulness delivered via a smartphone app can enhance psychosocial well-being within the general public. Methods The present pilot randomised controlled trial compared the impact of engaging with the self-guided mindfulness meditation (MM) app 'Headspace' (n = 38) for a period of 10 or 30 days, to a wait-list (WL) control (n = 36), using a cohort of adults from the general population. The Satisfaction with Life Scale, Perceived Stress Scale, and Wagnild Resilience Scale were administered online at baseline and after 10 and 30 days of the intervention. Results Twelve participants (MM n = 9, WL n = 3) were lost to follow-up for unknown reasons. Relative to the WL control, the MM app positively impacted self-reported satisfaction with life, stress, and resilience at day 10, with further improvements emerging at day 30 (Cohen's d = 0.57, 1.42, 0.63 respectively). The rate of improvement was largest at the 10-day assessment point, dropping moderately by day 30. Participants that rated the MM app as easy to engage with experienced the largest self-reported benefits. Moreover, the MM app was able to protect against an unexpected increase in perceived stress that emerged in the control group. Conclusions This pilot randomised controlled trial shows that self-reported improvements in psychosocial outcomes can be achieved at low cost through short-term engagement with a mindfulness-based smartphone app, and should be followed up with more substantive studies.	[Champion, Louise; Chandler, Chris] London Metropolitan Univ, Sch Social Sci, London, England; [Economides, Marcos] Headspace Inc, Los Angeles, CA 90404 USA	London Metropolitan University; University of Greenwich	Economides, M (corresponding author), Headspace Inc, Los Angeles, CA 90404 USA.	m_econ@outlook.com						Armijo-Olivo S, 2009, PHYS THER REV, V14, P36, DOI 10.1179/174328809X405928; Austin EJ, 1998, PERS INDIV DIFFER, V24, P421, DOI 10.1016/S0191-8869(97)00175-X; Baer RA, 2003, CLIN PSYCHOL-SCI PR, V10, P125, DOI 10.1093/clipsy/bpg015; Baer RA, 2012, J CLIN PSYCHOL, V68, P755, DOI 10.1002/jclp.21865; Bajaj B, 2016, PERS INDIV DIFFER, V93, P63, DOI 10.1016/j.paid.2015.09.005; Baraldi AN, 2010, J SCHOOL PSYCHOL, V48, P5, DOI 10.1016/j.jsp.2009.10.001; Beckman HB, 2012, ACAD MED, V87, P815, DOI 10.1097/ACM.0b013e318253d3b2; Bennike IH, 2017, J COGN ENHANCE, V1, P172, DOI 10.1007/s41465-017-0020-9; Blankers M, 2010, J MED INTERNET RES, V12, DOI 10.2196/jmir.1448; Bogosian A, 2015, MULT SCLER J, V21, P1184, DOI 10.1177/1352458515576261; Broderick PC, 1998, J EARLY ADOLESCENCE, V18, P173, DOI 10.1177/0272431698018002003; Brown KW, 2007, PSYCHOL INQ, V18, P211, DOI 10.1080/10478400701598298; Carmody J, 2008, J BEHAV MED, V31, P23, DOI 10.1007/s10865-007-9130-7; Carmody J, 2009, J CLIN PSYCHOL, V65, P627, DOI 10.1002/jclp.20555; Cavanagh K, 2018, MINDFULNESS, V9, P1191, DOI 10.1007/s12671-017-0856-1; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Crane RS, 2012, MINDFULNESS, V3, P76, DOI 10.1007/s12671-011-0073-2; Davidson RJ, 2015, AM PSYCHOL, V70, P581, DOI 10.1037/a0039512; Deyo M, 2009, EXPLORE-NY, V5, P265, DOI 10.1016/j.explore.2009.06.005; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Economides M, 2018, MINDFULNESS, V9, P1584, DOI 10.1007/s12671-018-0905-4; Enders CK, 2017, BEHAV RES THER, V98, P4, DOI 10.1016/j.brat.2016.11.008; Falkenstrom F, 2010, PERS INDIV DIFFER, V48, P305, DOI 10.1016/j.paid.2009.10.022; Folch-Fortuny A, 2015, CHEMOMETR INTELL LAB, V146, P77, DOI 10.1016/j.chemolab.2015.05.006; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Gotink RA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124344; Howells A, 2016, J HAPPINESS STUD, V17, P163, DOI 10.1007/s10902-014-9589-1; Jain S, 2007, ANN BEHAV MED, V33, P11, DOI 10.1207/s15324796abm3301_2; Jha AP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116889; Johnson DP, 2013, PERS INDIV DIFFER, V55, P367, DOI 10.1016/j.paid.2013.03.019; Johnson S, 2015, MINDFULNESS, V6, P88, DOI 10.1007/s12671-013-0234-6; Kabat-Zinn J, 2009, LIBR J; Keng SL, 2011, CLIN PSYCHOL REV, V31, P1041, DOI 10.1016/j.cpr.2011.04.006; Khoury B, 2015, J PSYCHOSOM RES, V78, P519, DOI 10.1016/j.jpsychores.2015.03.009; Killingsworth MA, 2010, SCIENCE, V330, P932, DOI 10.1126/science.1192439; Laurie J, 2016, INT J MED INFORM, V96, P38, DOI 10.1016/j.ijmedinf.2016.02.010; Lim D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118221; Lupien SJ, 2009, NAT REV NEUROSCI, V10, P434, DOI 10.1038/nrn2639; Ly KH, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-003440; Lyubomirsky S., 2008, THE HOW OF HAPPINESS; Lyubomirsky S, 2013, CURR DIR PSYCHOL SCI, V22, P57, DOI 10.1177/0963721412469809; Mahmood L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153923; Mak WWS, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.3746; Mani M, 2015, JMIR MHEALTH UHEALTH, V3, DOI 10.2196/mhealth.4328; Morgan D, 2003, PSYCHOTHER RES, V13, P123, DOI [10.1093/ptr/kpg004, 10.1080/713869628]; Morris SB, 2008, ORGAN RES METHODS, V11, P364, DOI 10.1177/1094428106291059; Nakagawa S, 2007, BIOL REV, V82, P591, DOI 10.1111/j.1469-185X.2007.00027.x; Nam SW, 2016, INT J MENT HEALTH AD, V14, P969, DOI 10.1007/s11469-016-9667-1; Parks AC, 2012, EMOTION, V12, P1222, DOI 10.1037/a0028587; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Plaza I, 2013, JMIR MHEALTH UHEALTH, V1, DOI 10.2196/mhealth.2733; Roeser RW, 2013, J EDUC PSYCHOL, V105, P787, DOI 10.1037/a0032093; Rojiani R, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00551; Santorelli S., 2014, MINDFULNESS BASED ST; Schueller SM, 2010, J POSIT PSYCHOL, V5, P192, DOI 10.1080/17439761003790948; Shapiro D H Jr, 1992, Int J Psychosom, V39, P62; Shapiro SL, 2008, J CLIN PSYCHOL, V64, P840, DOI 10.1002/jclp.20491; Sharma G., 2017, INT J APPL RES, V3, P749, DOI DOI 10.22271/ALLRESEARCH.2017.V3.I3I; Spijkerman MPJ, 2016, CLIN PSYCHOL REV, V45, P102, DOI 10.1016/j.cpr.2016.03.009; Stawarczyk D, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00363; Steinhubl SR, 2013, JAMA-J AM MED ASSOC, V310, P2395, DOI 10.1001/jama.2013.281078; Sterling M., 2011, J PHYSIOTHER; Sterling M, 2011, J PHYSIOTHER, V57, P259, DOI 10.1016/S1836-9553(11)70060-1; Teare MD, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-264; Unnebrink K, 2001, STAT MED, V20, P3931, DOI 10.1002/sim.1149; Van Dam NT, 2018, PERSPECT PSYCHOL SCI, V13, P36, DOI 10.1177/1745691617709589; van Emmerik AAP, 2017, MINDFULNESS, V6, P189; Wagnild G M, 1993, J Nurs Meas, V1, P165; Wen L, 2017, ACAD PSYCHIATR, V41, P646, DOI 10.1007/s40596-017-0768-3; Wylde CM, 2017, J PEDIATR NURS, V36, P205, DOI 10.1016/j.pedn.2017.06.008	70	57	58	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2018	13	12							e0209482	10.1371/journal.pone.0209482	http://dx.doi.org/10.1371/journal.pone.0209482			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HG0IO	30596696	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000454627200050
J	Dwyer, HC; Baranowski, DC; Mayer, PV; Gabriele, S				Dwyer, Heather C.; Baranowski, David C.; Mayer, Perry V.; Gabriele, Simona			LivRelief varicose veins cream in the treatment of chronic venous insufficiency of the lower limbs: A 6-week single arm pilot study	PLOS ONE			English	Article							QUALITY-OF-LIFE; NOTTINGHAM HEALTH PROFILE; CLINICAL SEVERITY SCORE; CEAP CLASSIFICATION; REVISION; RESPONSIVENESS; QUESTIONNAIRE; COMPRESSION; DISORDERS; ENJOYMENT	Background Chronic Venous Disease is characterized by morphological abnormalities of the venous system. Affected limbs are classified in increasing clinical severity with the Clinical Etiological Anatomical and Pathological system from C0 to C6. Limbs assessed at C3 through C6 meet the criteria of Chronic Venous Insufficiency. Chronic Venous Insufficiency of the Lower Limbs is a very common pathology affecting approximately similar to 40% of the world's population. This study observes the use of the LivRelief Varicose Vein Cream, a Natural Health Product that is licensed for sale by Health Canada, for use in the treatment of varicose veins. Methods An open label, single arm interventional, pilot study was conducted to determine the feasibility of recruitment and data collection in this population. To accomplish this, the cream was provided to all enrolled subjects. Subsequently, objective and subjective measures were performed at baseline and after 6 weeks of at-home use. Recruitment and data collection targets of at least 70% were established and the data collected at both timepoints were compared and analyzed using a paired t-test. Results were also reported as proportions where appropriate. Results A total of 32 subjects were enrolled. The pre-defined feasibility objectives for recruitment and data collection were met with the enrolment of 97% of all screened patients and the collection of 94% of all scheduled data. The most significant therapeutic improvement was seen in the results of the Venous Clinical Severity Score where 66% of the treated legs experienced a decrease in severity after 6 weeks of treatment. P values were <0.0001 and 0.0003 for the left and right leg, respectively. Conclusion It is feasible to recruit and collect data with the chosen outcome assessments within this population. Preliminary results suggest that the product could improve some of the clinical symptoms associated with the presence varicose veins. These results warrant further exploration in a longer, randomized and placebo-controlled study.	[Dwyer, Heather C.] Delivra Inc, Dept Res & Dev, Hamilton, ON, Canada; [Baranowski, David C.] Delivra Inc, Dept Res & Dev, Charlottetown, PE, Canada; [Mayer, Perry V.] Mayer Inst, Hamilton, ON, Canada; [Gabriele, Simona] McMaster Univ, Dept Med Sci, Hamilton, ON, Canada	McMaster University	Dwyer, HC (corresponding author), Delivra Inc, Dept Res & Dev, Hamilton, ON, Canada.	hdwyer@delivrainc.com		Dwyer, Heather/0000-0002-9446-4003	Atlantic Canada Opportunities Agency [201210]	Atlantic Canada Opportunities Agency	This work was partially supported by the Atlantic Canada Opportunities Agency (Grant number: 201210). Delivra Corp. provided support in the form of salaries for authors HCD and DCB but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Baro E, 2006, QUAL LIFE RES, V15, P575, DOI 10.1007/s11136-005-3691-0; Beebe-Dimmer JL, 2005, ANN EPIDEMIOL, V15, P175, DOI 10.1016/j.annepidem.2004.05.015; Belcaro G, 2015, ANGIOLOGY S1, V59, p7S; Belcaro G, 2015, INT J ANGIOL, V24, P268, DOI 10.1055/s-0035-1556060; Bourion-Bedes S, 2015, QUAL LIFE RES, V24, P287, DOI 10.1007/s11136-014-0772-y; Bozkurt K, 2017, CHRONIC VENOUS INSUF, P2; BSN Medical, 2018, VEN LEG ULC PREV MAN; Cesarone MR, 2005, ANGIOLOGY, V56, P1, DOI 10.1177/000331970505600101; Eberhardt RT, 2014, CIRCULATION, V130, P333, DOI 10.1161/CIRCULATIONAHA.113.006898; Eklof B, 2005, VASA-J VASCULAR DIS, V34, P157, DOI 10.1024/0301-1526.34.3.157; Eklof B, 2004, J VASC SURG, V40, P1248, DOI 10.1016/j.jvs.2004.09.027; Ely JW, 2006, J AM BOARD FAM MED, V19, P148, DOI 10.3122/jabfm.19.2.148; ENDICOTT J, 1993, PSYCHOPHARMACOL BULL, V29, P321; Garratt AM, 1996, QUAL LIFE RES, V5, P223, DOI 10.1007/BF00434744; Geest AJ van, 2003, MED ELASTIC COMPRESS; Gibson K, 2017, VASCULAR, V25, P149, DOI 10.1177/1708538116651014; Government of Canada, MON OR HORS CHESTN; Government of Canada, MON OR RUT; Government of Canada, MONOGRAPH TOPICAL WI; Hartung O, 2005, J VASC SURG, V42, P1138, DOI 10.1016/j.jvs.2005.08.012; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; Jin H., 2016, APPL RES COMPUTERS, P1; Kakkos SK, 2003, J VASC SURG, V38, P224, DOI 10.1016/S0741-5214(03)00323-9; Klem TMAL, 2009, EUR J VASC ENDOVASC, V37, P470, DOI 10.1016/j.ejvs.2008.11.036; Labropoulos N, 2009, J VASC SURG, V49, P704, DOI 10.1016/j.jvs.2008.10.014; Lattimer CR, 2014, PHLEBOLOGY, V29, P43, DOI 10.1258/phleb.2012.012080; Meissner MH, 2007, J VASC SURG, V46, p68S, DOI 10.1016/j.jvs.2007.08.048; Meissner MH, 2007, J VASC SURG, V46, p54S, DOI 10.1016/j.jvs.2007.08.038; Meissner MH, 2002, J VASC SURG, V36, P889, DOI 10.1067/mva.2002.128637; Mick E, 2008, J ATTEN DISORD, V11, P504, DOI 10.1177/1087054707308468; NNHPD, 2006, ARCH PROD LIC GUID D; Pascarella L, 2005, SEMIN VASC SURG, V18; Patel SK, 2018, VENOUS INSUFFICIENCY; Perrin M, 2011, EUR J VASC ENDOVASC, V41, P117, DOI 10.1016/j.ejvs.2010.09.025; Proebstle TM, 2018, J VASC SURG-VENOUS L, V6, P41, DOI 10.1016/j.jvsv.2017.07.007; Rabe E, 2013, PHLEBOLOGY, V28, P308, DOI 10.1177/0268355512471929; Rastel D, 2016, VASA, V45, P491, DOI 10.1024/0301-1526/a000576; Smith A, 2014, J ETHNOPHARMACOL, V158, P507, DOI 10.1016/j.jep.2014.06.037; Spence RK, 1996, J VASC SURG, V24, P783, DOI 10.1016/S0741-5214(96)70013-7; Suter A, 2006, ADV THER, V23, P179, DOI 10.1007/BF02850359; Uutela T, 2003, RHEUMATOLOGY, V42, P841, DOI 10.1093/rheumatology/keg229; Vasquez MA, 2010, PHLEBOLYMPHOLOGY, V17, P108; Vasquez MA, 2010, J VASC SURG, V52, P1387, DOI 10.1016/j.jvs.2010.06.161; Wyrwich K, 2009, INT CLIN PSYCHOPHARM, V24, P289, DOI 10.1097/YIC.0b013e32832d6bf4	44	1	1	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2018	13	12							e0208954	10.1371/journal.pone.0208954	http://dx.doi.org/10.1371/journal.pone.0208954			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG0IO	30596677	gold, Green Submitted, Green Published			2023-01-03	WOS:000454627200026
J	Murphy, PB; Piper, AJ; Hart, N				Murphy, Patrick B.; Piper, Amanda J.; Hart, Nicholas			Obesity hypoventilation syndrome: is less really more?	LANCET			English	Editorial Material							NONINVASIVE VENTILATION; SLEEP; CPAP; TRIAL		[Murphy, Patrick B.; Hart, Nicholas] St Thomas Hosp, Guys & St Thomas NHS Trust, Lane Fox Resp Serv, London SE1 7EH, England; [Murphy, Patrick B.; Hart, Nicholas] Royal Prince Alfred Hosp, Dept Resp & Sleep Med, Resp Failure Serv, Sydney, NSW, Australia; [Piper, Amanda J.] Guys & St Thomas NHS Fdn Trust, NIHR Biomed Res Ctr, London, England; [Piper, Amanda J.] Kings Coll London, London, England	Guy's & St Thomas' NHS Foundation Trust; University of Sydney; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Murphy, PB (corresponding author), St Thomas Hosp, Guys & St Thomas NHS Trust, Lane Fox Resp Serv, London SE1 7EH, England.; Murphy, PB (corresponding author), Royal Prince Alfred Hosp, Dept Resp & Sleep Med, Resp Failure Serv, Sydney, NSW, Australia.	patrick.murphy@gstt.nhs.uk	Piper, Amanda/AAM-7719-2020; Piper, Amanda J./H-8608-2019; Hart, Nicholas/O-7076-2015	Piper, Amanda J./0000-0003-3824-6172; Hart, Nicholas/0000-0002-6863-585X				Balachandran JS, 2014, SLEEP MED CLIN, V9, P341, DOI 10.1016/j.jsmc.2014.05.007; Berg G, 2001, CHEST, V120, P377, DOI 10.1378/chest.120.2.377; Corral J, 2018, THORAX, V73, P361, DOI 10.1136/thoraxjnl-2017-210642; Howard ME, 2017, THORAX, V72, P437, DOI 10.1136/thoraxjnl-2016-208559; Kohnlein T, 2014, LANCET RESP MED, V2, P698, DOI 10.1016/S2213-2600(14)70153-5; Mandal S, 2018, THORAX, V73, P62, DOI 10.1136/thoraxjnl-2016-209826; Masa JF, 2019, LANCET, V393, P1721, DOI 10.1016/S0140-6736(18)32978-7; Masa JF, 2016, THORAX, V71, P899, DOI 10.1136/thoraxjnl-2016-208501; Masa JF, 2016, CHEST, V150, P68, DOI 10.1016/j.chest.2016.02.647; Masa JF, 2015, AM J RESP CRIT CARE, V192, P86, DOI 10.1164/rccm.201410-1900OC; Murphy PB, 2017, JAMA-J AM MED ASSOC, V317, P2177, DOI 10.1001/jama.2017.4451; Orfanos S, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0391-9; Piper AJ, 2008, THORAX, V63, P395, DOI 10.1136/thx.2007.081315; SULLIVAN CE, 1983, AM REV RESPIR DIS, V128, P177, DOI 10.1164/arrd.1983.128.1.177	14	2	2	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 27	2019	393	10182					1674	1676		10.1016/S0140-6736(19)30248-X	http://dx.doi.org/10.1016/S0140-6736(19)30248-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HV8PQ	30935735				2023-01-03	WOS:000466244500007
J	Pachauri, A; Shah, P; Almroth, BC; Sevilla, NPM; Narasimhan, M				Pachauri, Ash; Shah, Prerna; Almroth, Bethanie C.; Sevilla, Norma P. M.; Narasimhan, Manjulaa			Safe and sustainable waste management of self care products	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HEPATITIS-C; HEALTH; HIV		[Pachauri, Ash] Ctr Human Progress, Ashburn, VA 20148 USA; [Shah, Prerna] POP Movement, G-1 Jangpura Extens, New Delhi, India; [Almroth, Bethanie C.] Univ Gothenburg, Dept Biol & Environm Sci, Gothenburg, Sweden; [Sevilla, Norma P. M.] Natl Polytech Inst, Interdisciplinary Ctr Res & Studies Environm & De, Mexico City, DF, Mexico; [Narasimhan, Manjulaa] World Hlth Org, UNDP UNFPA Unicef WHO World Bank Special Programm, Geneva, Switzerland	University of Gothenburg; Instituto Politecnico Nacional - Mexico; The World Bank; United Nations Population Fund; World Health Organization	Pachauri, A (corresponding author), Ctr Human Progress, Ashburn, VA 20148 USA.	ash.pachauri@gmail.com	Almroth, Bethanie Carney/Q-6411-2019	Almroth, Bethanie Carney/0000-0002-5037-4612; Narasimhan, Manjulaa/0000-0003-0598-6887				ABC News, 2017, ABC NEWS; American Academy of Family Physicians, 2003, MED WAST DISP NONM S; [Anonymous], 2017, LANCET PLANET HEALTH, V1, pE254, DOI 10.1016/S2542-5196(17)30121-3; [Anonymous], 2021, GROUPS NSWMC PLAST S; Barman A, 2017, J TEXTILE SCI ENG, V7, P308, DOI DOI 10.4172/2165-8064; CBS New York, 2013, 100 COND 1000 TAMP A; Chauhan Ankur, 2016, International Journal of Environment and Waste Management, V18, P120; Coffin PO, 2007, AIDS BEHAV, V11, P652, DOI 10.1007/s10461-006-9171-x; Cooper K-L, 2018, BBC NEWS; Cordina J, 2017, MCKINSEY HEALTHCARE; Crisp N, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3895; Ehiri J., 2002, ENV MANAGEMENT HLTH, V13, P55, DOI DOI 10.1108/09566160210417822; Good Trade, 2019, THES VEG COND BRANDS; Hanashi Y, 2011, JAPAN MED ASS J, V54, P271; Harhay MO, 2009, TROP MED INT HEALTH, V14, P1414, DOI 10.1111/j.1365-3156.2009.02386.x; Health and Safety Executive, 2019, RISK HEALTHC WORK; Health Improvement Scotland, 2021, SAFE MANAGEMENT WAST; Humboldt State University, 2019, BLOODB PATH LONG DO; Khan MS, 2018, HEALTH POLICY PLANN, V33, P215, DOI 10.1093/heapol/czx145; Lee BK, 2002, WASTE MANAGE, V22, P461, DOI 10.1016/S0956-053X(02)00006-5; LEVIN LS, 1983, ANNU REV PUBL HEALTH, V4, P181, DOI 10.1146/annurev.pu.04.050183.001145; Majumdar Anindo, 2015, Indian J Endocrinol Metab, V19, P420, DOI 10.4103/2230-8210.152792; Miyazaki M, 2007, WASTE MANAGE, V27, P130, DOI 10.1016/j.wasman.2005.12.018; Moin A, 2018, LANCET, V391, P834, DOI 10.1016/S0140-6736(18)30462-8; Muralidharan A., 2018, INS IND PAK; Neporent L, 2011, 7 FACTS CONDOMS; Nichols A, 2011, 1 WORLD SUSTAINABILI; Pareek S., 2014, THE BETTER INDIA; Pepin J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099677; Rauf MUA, 2013, J PAK MED ASSOC, V63, P798; Ripley K, 2018, REGIONAL FORUM PROMO; Rochester JR, 2015, ENVIRON HEALTH PERSP, V123, P643, DOI 10.1289/ehp.1408989; Shakeel S, 2015, BANGLADESH J MED SCI, V14, P376, DOI 10.3329/bjms.v14i4.25780; Siegle L, 2017, GUARDIAN; Stacey D, 2018, CAN CONDOMS BE RECYC; Transparency Market Research, SELF CAR MED DEV MAR; UNFPA, 2017, GREEN BLUE ENV FRIEN; UNFPA, 2013, SAF DISP MAN UN UNW; USAID, 2010, AIDS SUPP TECHN ASS; Wilson DC, 2006, HABITAT INT, V30, P797, DOI 10.1016/j.habitatint.2005.09.005; World Health Organization, 2018, MENSTR HYG DAY; World Health Organization, HLTH CAR SOL WAST; World Health Organization, 2018, SUST PROC HLTH CAR C; Ziraba AK, 2016, ARCH PUBLIC HEALTH, V74, DOI 10.1186/s13690-016-0166-4	44	6	6	2	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	2019	365								l1298	10.1136/bmj.l1298	http://dx.doi.org/10.1136/bmj.l1298			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HS6TL	30936055	hybrid, Green Published			2023-01-03	WOS:000464004100005
J	Kirpalani, H; Ratcliffe, SJ; Keszler, M; Davis, PG; Foglia, EE; te Pas, A; Fernando, M; Chaudhary, A; Localio, R; van Kaam, AH; Onland, W; Owen, LS; Schmolzer, GM; Katheria, A; Hummler, H; Lista, G; Abbasi, S; Klotz, D; Simma, B; Nadkarni, V; Poulain, FR; Donn, SM; Kim, HS; Park, WS; Cadet, C; Kong, JY; Smith, A; Guillen, U; Liley, HG; Hopper, AO; Tamura, M; LaLiberte, A; Hallinan, S; Mancini, T; White, D; Nuytenmans, D; Hal, L; dela Puerta, R; Huey, QB; Rajadurai, VS; StelzI, W; Narayen, I; Brouwer, E; Nicolau, Y; Rundquist, M; Lopez, J; Bates, S; Bastrenta, P; Castoldi, F; Cavigioli, F; Thio, M; Argus, B; Mills, B; Twitchell, E; Ishiguro, A; Sung, S; Ahn, SY; Shin, SH; Katheria, AC; Brown, M; Steen, J; Rich, W; Mendler, M; Essers, J; Zernickel, M; Kurfiss, A; Aziz, K; Cheung, PY; Van Os, S; Fray, C; Steinhorn, RH; Mirmiran, M; Pesavento, R; Hentschel, R; Young, T; Rhoades-Ryan, G; Mackley, A; Gray, K				Kirpalani, Haresh; Ratcliffe, Sarah J.; Keszler, Martin; Davis, Peter G.; Foglia, Elizabeth E.; te Pas, Arjan; Fernando, Melissa; Chaudhary, Aasma; Localio, Russell; van Kaam, Anton H.; Onland, Wes; Owen, Louise S.; Schmolzer, Georg M.; Katheria, Anup; Hummler, Helmut; Lista, Gianluca; Abbasi, Soraya; Klotz, Daniel; Simma, Burkhard; Nadkarni, Vinay; Poulain, Francis R.; Donn, Steven M.; Kim, Han-Suk; Park, Won Soon; Cadet, Claudia; Kong, Juin Yee; Smith, Alexandra; Guillen, Ursula; Liley, Helen G.; Hopper, Andrew O.; Tamura, Masanori; LaLiberte, A.; Hallinan, S.; Mancini, T.; White, D.; Nuytenmans, D.; Hal, L.; dela Puerta, R.; Huey, Q. B.; Rajadurai, V. S.; Stelz, W., I; Narayen, I.; Brouwer, E.; Nicolau, Y.; Rundquist, M.; Lopez, J.; Bates, S.; Bastrenta, P.; Castoldi, F.; Cavigioli, F.; Thio, M.; Argus, B.; Mills, B.; Twitchell, E.; Ishiguro, A.; Sung, S.; Ahn, S. Y.; Shin, S. H.; Katheria, A. C.; Brown, M.; Steen, J.; Rich, W.; Mendler, M.; Essers, J.; Zernickel, M.; Kurfiss, A.; Aziz, K.; Cheung, P. Y.; Van Os, S.; Fray, C.; Steinhorn, R. H.; Mirmiran, M.; Pesavento, R.; Hentschel, R.; Young, T.; Rhoades-Ryan, G.; Mackley, A.; Gray, K.		SAIL Site Investigators	Effect of Sustained Inflations vs Intermittent Positive Pressure Ventilation on Bronchopulmonary Dysplasia or Death Among Extremely Preterm Infants The SAIL Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INITIAL RESPIRATORY SUPPORT; NEONATAL RESUSCITATION 2015; BIRTH-WEIGHT INFANTS; LUNG-INFLATION; DELIVERY-ROOM; CARDIOPULMONARY-RESUSCITATION; CONSENT; TRANSITION; GUIDELINES; MANAGEMENT	IMPORTANCE Preterm infants must establish regular respirations at delivery. Sustained inflations may establish lung volume faster than short inflations. OBJECTIVE To determine whether a ventilation strategy including sustained inflations, compared with standard intermittent positive pressure ventilation, reduces bronchopulmonary dysplasia (BPD) or death at 36weeks' postmenstrual age without harm in extremely preterm infants. DESIGN, SETTING, AND PARTICIPANTS Unmasked, randomized clinical trial (August 2014 to September 2017, with follow-up to February 15, 2018) conducted in 18 neonatal intensive care units in 9 countries. Preterm infants 23 to 26 weeks' gestational age requiring resuscitation with inadequate respiratory effort or bradycardia were enrolled. Planned enrollment was 600 infants. The trial was stopped after enrolling 426 infants, following a prespecified review of adverse outcomes. INTERVENTIONS The experimental intervention was up to 2 sustained inflations at maximal peak pressure of 25 cm H2O for 15 seconds using a T-piece and mask (n = 215); standard resuscitation was intermittent positive pressure ventilation (n = 211). MAIN OUTCOME AND MEASURES The primary outcome was the rate of BPD or death at 36 weeks' postmenstrual age. There were 27 prespecified secondary efficacy outcomes and 7 safety outcomes, including death at less than 48 hours. RESULTS Among 460infants randomized (mean [SD] gestational age, 25.30 [0.97] weeks; 50.2% female), 426 infants (92.6%) completed the trial. In the sustained inflation group, 137 infants (63.7%) died or survived with BPD vs 125 infants (59.2%) in the standard resuscitation group (adjusted risk difference [aRD], 4.7%[95% CI, -3.8% to 13.1%]; P =.29). Death at less than 48 hours of age occurred in 16 infants (7.4%) in the sustained inflation group vs 3 infants (1.4%) in the standard resuscitation group (aRD, 5.6%[95% CI, 2.1% to 9.1%]; P =.002). Blinded adjudication detected an imbalance of rates of early death possibly attributable to resuscitation (sustained inflation: 11/16; standard resuscitation: 1/3). Of 27 secondary efficacy outcomes assessed by 36weeks' postmenstrual age, 26 showed no significant difference between groups. CONCLUSIONS AND RELEVANCE Among extremely preterm infants requiring resuscitation at birth, a ventilation strategy involving 2 sustained inflations, compared with standard intermittent positive pressure ventilation, did not reduce the risk of BPD or death at 36 weeks' postmenstrual age. These findings do not support the use of ventilation with sustained inflations among extremely preterm infants, although early termination of the trial limits definitive conclusions.	[Kirpalani, Haresh] Univ Penn, Childrens Hosp Philadelphia, Div Neonatol, Philadelphia, PA 19104 USA; [Ratcliffe, Sarah J.] Univ Virginia, Dept Publ Hlth Sci, Div Biostat, Charlottesville, VA USA; [Keszler, Martin] Brown Univ, Dept Pediat, Warren Alpert Med Sch, Women & Infants Hosp Rhode Isl, Providence, RI 02912 USA; [Davis, Peter G.] Royal Womens Hosp, Newborn Res Ctr, Melbourne, Vic, Australia; [Foglia, Elizabeth E.] Univ Penn, Dept Pediat, Childrens Hosp Philadelphia, Div Neonatol,Perelman Sch Med, Philadelphia, PA 19104 USA; [te Pas, Arjan; Narayen, I.; Brouwer, E.] Leiden Univ, Dept Pediat, Div Neonatol, Med Ctr, Leiden, Netherlands; [Ratcliffe, Sarah J.; Fernando, Melissa; Localio, Russell] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Chaudhary, Aasma] Hosp Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Div Neonatol, 3400 Spruce St, Philadelphia, PA 19104 USA; [van Kaam, Anton H.; Onland, Wes] Emma Childrens Hosp, Acad Med Ctr, Dept Neonatol, Amsterdam, Netherlands; [Davis, Peter G.; Owen, Louise S.; Thio, M.; Argus, B.; Mills, B.; Twitchell, E.] Royal Womens Hosp, Newborn Res Ctr, Melbourne, Vic, Australia; [Davis, Peter G.; Owen, Louise S.; Thio, M.; Argus, B.; Mills, B.; Twitchell, E.] Royal Womens Hosp, Neonatal Serv, Melbourne, Vic, Australia; [Owen, Louise S.] Univ Melbourne, Dept Obstet & Gynecol, Melbourne, Vic, Australia; [Davis, Peter G.; Owen, Louise S.; Thio, M.; Argus, B.; Mills, B.; Twitchell, E.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Schmolzer, Georg M.; Aziz, K.; Cheung, P. Y.; Van Os, S.; Fray, C.] Univ Alberta, Dept Pediat, Edmonton, AB, Canada; [Katheria, A. C.; Brown, M.; Steen, J.; Rich, W.] Sharp Mary Birch Hosp Women & Newborns, Dept Neonatol, San Diego, CA USA; [Hummler, Helmut] Sidra Med, Dept Pediat, Div Neonatol, Doha, Qatar; [Hummler, Helmut] Ulm Univ, Dept Pediat & Adolescent Med, Div Neonatol & Pediat Crit Care, Ulm, Germany; [Lista, Gianluca; Bastrenta, P.; Castoldi, F.; Cavigioli, F.] ASST FBF Sacco, Osped Bambini V Buzzi, NICU, Dept Pediat, Milan, Italy; [Abbasi, Soraya] Penn Hosp, Div Newborn Pediat, Philadelphia, PA 19107 USA; [Klotz, Daniel; Hentschel, R.] Univ Freiburg, Fac Med, Med Ctr, Ctr Pediat, Freiburg, Germany; [Simma, Burkhard] Landeskrankenhaus Feldkirch, Acad Teaching Hosp, Dept Pediat, Feldkirch, Austria; [Nadkarni, Vinay] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Poulain, Francis R.; Steinhorn, R. H.; Mirmiran, M.; Pesavento, R.] Univ Calif Davis, Dept Pediat, Div Neonatol, Sacramento, CA 95817 USA; [Donn, Steven M.; White, D.] Univ Michigan, CS Mott Childrens Hosp, Dept Pediat, Div Neonatal Perinatal Med,Michigan Med, Ann Arbor, MI 48109 USA; [Kim, Han-Suk; Shin, S. H.] Seoul Natl Univ, Childrens Hosp, Dept Pediat, Div Neonatol, Seoul, South Korea; [Park, Won Soon; Sung, S.; Ahn, S. Y.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, Seoul, South Korea; [Cadet, Claudia; White, D.; Young, T.; Rhoades-Ryan, G.] WakeMed Hlth & Hosp, Dept Neonatol, Raleigh, NC USA; [Kong, Juin Yee] KK Womens & Childrens Hosp, Dept Neonatol, Singapore, Singapore; [Smith, Alexandra; Kurfiss, A.] Tufts Med Ctr, Floating Hosp Children, Tufts Clin & Translat Res Inst, Dept Pediat, Boston, MA 02111 USA; [Guillen, Ursula] Christiana Care Hlth Syst, Newark, DE USA; [Liley, Helen G.; Bates, S.] Mater Mothers Hosp & Mater Res, Newborn Serv, South Brisbane, Qld, Australia; [Hopper, Andrew O.; Nicolau, Y.; Rundquist, M.; Lopez, J.] Loma Linda Univ, Dept Pediat, Div Neonatol, Loma Linda, CA 92350 USA; [Tamura, Masanori; Ishiguro, A.] Saitama Med Univ, Saitama Med Ctr, Dept Pediat, Kawagoe, Saitama, Japan; [Kirpalani, Haresh; Foglia, Elizabeth E.; Chaudhary, Aasma; Nadkarni, Vinay] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; [Kirpalani, Haresh; Foglia, Elizabeth E.; Chaudhary, Aasma; Nadkarni, Vinay] Childrens Hosp Philadelphia, Dept Anesthesiol, Philadelphia, PA 19104 USA; [Kirpalani, Haresh; Foglia, Elizabeth E.; Chaudhary, Aasma; Nadkarni, Vinay] Childrens Hosp Philadelphia, Dept Crit Care Med, Philadelphia, PA 19104 USA; [Kirpalani, Haresh; Foglia, Elizabeth E.; Chaudhary, Aasma; Abbasi, Soraya; Nadkarni, Vinay; Mancini, T.] Childrens Hosp Philadelphia, Div Newborn Pediat, Philadelphia, PA 19104 USA; [Kirpalani, Haresh; Foglia, Elizabeth E.; Chaudhary, Aasma; Nadkarni, Vinay] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA; [Keszler, Martin; LaLiberte, A.; Hallinan, S.] Brown Univ, Dept Pediat, Women & Infants Hosp Rhode Isl, Clin Coordinating Ctr,Warren Alpert Med Sch, Providence, RI 02912 USA; [Abbasi, Soraya; Mancini, T.] Penn Hosp, Philadelphia, PA 19107 USA; [van Kaam, Anton H.; Onland, Wes; Nuytenmans, D.] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Neonatol, Amsterdam, Netherlands; [Kong, Juin Yee; dela Puerta, R.; Huey, Q. B.; Rajadurai, V. S.] Singhealth, KK Womens & Childrens Hosp, Dept Neonatol, Singapore, Singapore; [Simma, Burkhard; Stelz, W., I] Landeskrankenhaus Feldkirch, Acad Teaching Hosp, Dept Pediat, Feldkirch, Austria; [Hummler, Helmut; Mendler, M.; Essers, J.; Zernickel, M.] Ulm Univ, Childrens Hosp, Ulm, Germany; [Guillen, Ursula; Mackley, A.; Gray, K.] Christiana Care, Newark, DE USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Virginia; Brown University; Women & Infants Hospital Rhode Island; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; University of Melbourne; Murdoch Children's Research Institute; University of Alberta; Sidra Medical & Research Center; Ulm University; University of Pennsylvania; Pennsylvania Medicine; University of Freiburg; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of California System; University of California Davis; University of Michigan System; University of Michigan; Seoul National University (SNU); Seoul National University Hospital; Sungkyunkwan University (SKKU); Samsung Medical Center; KK Women's & Children's Hospital; Floating Hospital For Children; Tufts Medical Center; Christiana Care Health System; Loma Linda University; Saitama Medical University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Brown University; Women & Infants Hospital Rhode Island; University of Pennsylvania; Pennsylvania Medicine; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; KK Women's & Children's Hospital; Ulm University; Christiana Care Health System	Kirpalani, H (corresponding author), Childrens Hosp Philadelphia, Div Neonatol, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	kirpalanih@email.chop.edu	Liley, Helen Gwendolin/C-5608-2011; pas, arjan te/AAA-9019-2020; Katheria, Anup/AAA-6834-2022; Katheria, Anup/K-2355-2013; Ratcliffe, Sarah J/GYR-1110-2022; ishiguro, akira/V-7004-2019; Klotz, Daniel/AAB-2585-2022; Schmölzer, Georg M/E-7883-2010; Hummler, Helmut/AAN-7297-2021	Liley, Helen Gwendolin/0000-0002-8249-9516; pas, arjan te/0000-0001-7831-8797; Katheria, Anup/0000-0001-9352-0934; Ratcliffe, Sarah J/0000-0002-6644-8284; ishiguro, akira/0000-0002-3896-5313; Klotz, Daniel/0000-0003-2347-3866; Schmölzer, Georg M/0000-0001-9798-2415; 	NICHD [1-U01-HD072906-01A1]	NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The trial was funded by the NICHD (grant 1-U01-HD072906-01A1). Fisher & Paykel Healthcare (Auckland, New Zealand) donated masks for the study at some sites.	Bruschettini M, 2017, COCHRANE DB SYST REV, V7; DAWES GS, 1966, P ROY SOC MED, V59, P508, DOI 10.1177/003591576605900613; DeMauro SB, 2014, PEDIATRICS, V134, pE1, DOI 10.1542/peds.2013-3720; El-Chimi MS, 2017, J MATERN-FETAL NEO M, V30, P1273, DOI 10.1080/14767058.2016.1210598; Finer NN, 2010, NEW ENGL J MED, V362, P1970, DOI 10.1056/NEJMoa0911783; Foglia EE, 2017, ARCH DIS CHILD-FETAL, V102, pF90, DOI 10.1136/archdischild-2016-310934; Foglia EE, 2016, CLIN PERINATOL, V43, P633, DOI 10.1016/j.clp.2016.07.002; Foglia EE, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0601-9; Harling AE, 2005, ARCH DIS CHILD-FETAL, V90, pF406, DOI 10.1136/adc.2004.059303; Jiravisitkul P, 2017, RESUSCITATION, V111, P68, DOI 10.1016/j.resuscitation.2016.12.003; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; Kramer MS, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e35; Lindner W, 2005, ACTA PAEDIATR, V94, P303, DOI 10.1080/08035250410023647; Lista G, 2015, PEDIATRICS, V135, pE457, DOI 10.1542/peds.2014-1692; Luta G, 1998, J Biopharm Stat, V8, P87; Mercadante D, 2016, J PERINATOL, V36, P443, DOI 10.1038/jp.2015.222; Morley CJ, 2008, NEW ENGL J MED, V358, P700, DOI 10.1056/NEJMoa072788; Neonatal Resuscitation Program (NRP); American Academy of Pediatrics and the American Heart Association, 2011, NEON RES TXB; Ngan AY, 2017, ARCH DIS CHILD-FETAL, V102, pF525, DOI 10.1136/archdischild-2016-312286; Norton EC, 2013, STATA J, V13, P492, DOI 10.1177/1536867X1301300304; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; Perlman JM, 2015, CIRCULATION, V132, pS204, DOI 10.1161/CIR.0000000000000276; Rich W, 2012, PEDIATRICS, V129, P480, DOI 10.1542/peds.2011-2121; Rich WD, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00056; Roehr CC, 2010, EUR J MED RES, V15, P493, DOI 10.1186/2047-783X-15-11-493; Sackett David L, 2004, ACP J Club, V140, pA11; Schmolzer GM, 2015, ARCH DIS CHILD-FETAL, V100, pF361, DOI 10.1136/archdischild-2014-306836; Schwaberger B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138964; SMITH CA, 1963, SCI AM, V209, P27, DOI 10.1038/scientificamerican1063-27; Sobotka KS, 2011, PEDIATR RES, V70, P56, DOI 10.1203/PDR.0b013e31821d06a1; Songstad NT, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-2092; Subramaniam P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001243.pub3; Pas ABT, 2007, PEDIATRICS, V120, P322, DOI 10.1542/peds.2007-0114; te Pas AB, 2009, PEDIATR RES, V65, P537, DOI 10.1203/PDR.0b013e31819da21b; van Vonderen JJ, 2014, J PEDIAT, V165, DOI 10.1016/j.jped5.2014.06.007; VYAS H, 1981, J PEDIATR-US, V99, P635, DOI 10.1016/S0022-3476(81)80279-X; Walsh Michele C, 2003, J Perinatol, V23, P451, DOI 10.1038/sj.jp.7210963; Wathen JK, PREDICTIVE PROBABILI; Wyckoff MH, 2015, CIRCULATION, V132, pS543, DOI 10.1161/CIR.0000000000000267; Wyllie J, 2015, RESUSCITATION, V95, P249, DOI 10.1016/j.resuscitation.2015.07.029	40	80	85	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2019	321	12					1165	1175		10.1001/jama.2019.1660	http://dx.doi.org/10.1001/jama.2019.1660			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR3XE	30912836	Green Published, Bronze			2023-01-03	WOS:000463074900012
J	Oktora, MP; Denig, P; Bos, JHJ; Schuiling-Veninga, CCM; Hak, E				Oktora, Monika P.; Denig, Petra; Bos, Jens H. J.; Schuiling-Veninga, Catharina C. M.; Hak, Eelko			Trends in polypharmacy and dispensed drugs among adults in the Netherlands as compared to the United States	PLOS ONE			English	Article							CLINICAL-PRACTICE; DATABASE IADB.NL; PRIMARY-CARE; PRESCRIPTION; POPULATION; GUIDELINES; HYPERTENSION; MANAGEMENT; OUTCOMES; PEOPLE	Background and purpose Polypharmacy is becoming increasingly common owing to the ageing population, which can pose problems for patients and society. We investigated the trends in polypharmacy and underlying drug groups among adults in the Netherlands from 1999 to 2014 stratified by age, and compared these with findings from the United States (US). Methods We conducted a repeated cross-sectional study using the Dutch IADB. nl prescription database. All patients aged 20 years and older in the period 1999 to 2014 were included. Polypharmacy was defined as the dispensing of five or more chronic drugs at the pharmacological subgroup level. Chi-square tests were applied to calculate the p-value for trends. Changes in prevalences were compared between the Netherlands and the US. Results The prevalence of polypharmacy increased from 3.1% to 8.0% (p-value for trend < 0.001) over 15 years, and increased in all age groups. The highest rates were observed in patients aged. 65 years, but the relative increase over time was higher in the younger age groups. Overall, large increases were observed for angiotensin-II inhibitors, statins and protonpump inhibitors. The relative increase in polypharmacy was larger in the Netherlands than in the US (ratio of polypharmacy prevalence 2.4 versus 1.8). The Netherlands showed larger relative increases for angiotensin-II inhibitors, statins, proton-pump inhibitors, biguanides and smaller relative increases for antidepressants, benzodiazepines and insulins. Conclusions Polypharmacy more than doubled from 1999 to 2014, and this increase was not limited to the elderly. The relative increase was larger in the Netherlands compared to the US, which was partly due to larger increases in several guideline-recommended preventive drugs.	[Oktora, Monika P.; Denig, Petra] Univ Groningen, UMCG, Dept Clin Pharm & Pharmacol, Groningen, Netherlands; [Bos, Jens H. J.; Schuiling-Veninga, Catharina C. M.; Hak, Eelko] Univ Groningen, Groningen Res Inst Pharm, Unit PharmacoTherapy Epidemiol & Econ, Groningen, Netherlands	University of Groningen; University of Groningen	Oktora, MP (corresponding author), Univ Groningen, UMCG, Dept Clin Pharm & Pharmacol, Groningen, Netherlands.	m.p.oktora@umcg.nl	Denig, Petra/L-9865-2014	Denig, Petra/0000-0002-7929-4739; Oktora, Monika/0000-0002-3116-787X				Abolhassani N, 2017, EUR J CLIN PHARMACOL, V73, P1187, DOI 10.1007/s00228-017-2288-1; Bauer S, 2014, DIABETIC MED, V31, P1078, DOI 10.1111/dme.12497; Berdot Sarah, 2009, BMC Geriatr, V9, P30, DOI 10.1186/1471-2318-9-30; Bonten MJM, 2006, BMJ-BRIT MED J, V332, P248, DOI 10.1136/bmj.332.7536.248; De Backer G, 2003, EUR J CARDIOV PREV R, V10, pS1, DOI 10.1097/01.hjr.0000087913.96265.e2; de Vries ST, 2014, DIABETES CARE, V37, P1312, DOI 10.2337/dc13-1861; European Centre for Disease Prevention and Control, 2017, ANT CONS DAT ESAC NE; Fijn R, 2000, BRIT J CLIN PHARMACO, V49, P254, DOI 10.1046/j.1365-2125.2000.00166.x; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; Gilbody S, 2005, QUAL SAF HEALTH CARE, V14, P246, DOI 10.1136/qshc.2004.012781; Haeseker MB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051860; Hajjar Emily R, 2007, Am J Geriatr Pharmacother, V5, P345, DOI 10.1016/j.amjopharm.2007.12.002; Herr M, 2017, EUR J CLIN PHARMACOL, V73, P1165, DOI 10.1007/s00228-017-2276-5; Hoeve C, 2015, THESIS; Hovstadius B, 2010, BMC CLIN PHARM, V10; Hovstadius B, 2013, HEALTH POLICY, V109, P166, DOI 10.1016/j.healthpol.2012.09.005; Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766; Koffeman AR, 2014, BRIT J GEN PRACT, V64, pE191, DOI 10.3399/bjgp14X677815; Maher RL, 2014, EXPERT OPIN DRUG SAF, V13, P57, DOI 10.1517/14740338.2013.827660; Moriarty F, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008656; Nederlands Huisartsen Genootschap (NHG), 2012, CARD RIS; Nederlands Huisartsen Genootschap (NHG) Nederlandse Vereniging voor Klinische Geriatrie (NVKG) Orde van Medisch Specialisten (OMS), MULT RICHTL POL BIJ; Nolte E, 2008, HEALTH AFFAIR, V27, P58, DOI 10.1377/hlthaff.27.1.58; Noordam R, 2015, EUR J CLIN PHARMACOL, V71, P369, DOI 10.1007/s00228-014-1803-x; Numans ME, 2013, HUISARTS WET, P26; oecd.org, DOES NETH COMP; Onoue H, 2018, J AM GERIATR SOC, V66, P2267, DOI 10.1111/jgs.15569; Organisation for Economic Co-operation and Development OECD, 2017, HLTH GLANC 2017 OECD, DOI [10.1787/health_glance-2017-en, DOI 10.1787/HEALTH_GLANCE-2017-EN]; Otten MH, 2015, ANN RHEUM DIS, V74, P1379, DOI 10.1136/annrheumdis-2013-204641; Passarelli MCG, 2005, DRUG AGING, V22, P767, DOI 10.2165/00002512-200522090-00005; Rogers S, 2009, DRUG AGING, V26, P951, DOI 10.2165/11316750-000000000-00000; Ruberu RP, 2012, CLIN GERIATR MED, V28, P187, DOI 10.1016/j.cger.2012.01.003; Schoen C, 2010, HEALTH AFFAIR, V29, P2323, DOI 10.1377/hlthaff.2010.0862; Schoenfeld AJ, 2016, JAMA INTERN MED, V176, P172, DOI 10.1001/jamainternmed.2015.7927; Scott IA, 2015, JAMA INTERN MED, V175, P827, DOI 10.1001/jamainternmed.2015.0324; Sediq R, 2018, CLIN EPIDEMIOL, V10, P981, DOI 10.2147/CLEP.S163037; Smulders YM, 2008, NETH J MED, V66, P169; Stichting Farmaceutische Kengetallen (SFK), 2018, PHARM WEEKBLAD, V12, P7; Stichting Farmaceutische Kengetallen (SFK), 2016, PHARM WEEKBL 27 28, V151, P1; Stichting Farmaceutische Kengetallen (SFK), 2014, FACTS FIG 2014 PHARM; Thomson Sarah, 2010, Issue Brief (Commonw Fund), V82, P1; van Buuren S, 2006, MED DECIS MAKING, V26, P145, DOI 10.1177/0272989X06286479; van der Linden M, 2009, BEHANDELING GASTRO O; van Dijk L, 2011, FAM PRACT, V28, P624, DOI 10.1093/fampra/cmr043; van Wyk JT, 2005, CURR MED RES OPIN, V21, P839, DOI 10.1185/030079905X46368; Visser ST, 2013, EXPERT REV PHARM OUT, V13, P285, DOI [10.1586/ERP.13.20, 10.1586/erp.13.20]; Wang YJ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00120; WHO, 2011, EURRC6114 WHO; WHOCC, 2015, WHO COLL CTR DRUG ST; Wielders CCH, 2012, EUR J PUBLIC HEALTH, V22, P150, DOI 10.1093/eurpub/ckq187; Zelko Erika, 2016, Mater Sociomed, V28, P129, DOI 10.5455/msm.2016.28.129-132; Zhang F, 2016, PHARMACOEPIDEM DR S, V25, P628, DOI 10.1002/pds.3947	52	34	35	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2019	14	3							e0214240	10.1371/journal.pone.0214240	http://dx.doi.org/10.1371/journal.pone.0214240			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HP9GF	30901377	Green Published, Green Submitted, gold			2023-01-03	WOS:000462000400044
J	Lee, HJ; Ko, HJ; Kim, SH; Jung, YJ				Lee, Hyo-Ji; Ko, Hyun-Jeong; Kim, Seung Hyun; Jung, Yu-Jin			Pasakbumin A controls the growth of Mycobacterium tuberculosis by enhancing the autophagy and production of antibacterial mediators in mouse macrophages	PLOS ONE			English	Article							EURYCOMA-LONGIFOLIA JACK; HOST-DIRECTED THERAPIES; CELL-DEATH; IMMUNITY; ANTIBIOTICS; METABOLISM; APOPTOSIS; BACTERIAL	Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis (Mtb) and remains a major health problem worldwide. Thus, identification of new and more effective drugs to treat emerging multidrug-resistant TB (MDR-TB) and to reduce the side effects of anti-TB drugs, such as liver toxicity and other detrimental changes, is urgently needed. In this study, to develop a novel candidate drug for effective TB treatment with few side effects in the host, we selected pasakbumin A isolated from Eurycoma longifolia (E. longifolia) Jack, which protected host cells against Mtb infection-induced death. Pasakbumin A significantly inhibited intracellular Mtb growth by inducing the autophagy via the ERK1/2-mediated signaling pathway in Mtb-infected macrophages. We further investigated whether pasakbumin A could be used as a potential adjuvant for TB treatment. Treatment with pasakbumin A and anti-TB drug rifampicin (RMP) potently suppressed intracellular Mtb killing by promoting autophagy as well as TNF-alpha production via the ERK1/2-and NF-KB-mediated signaling pathways in Mtb-infected cells. Our results suggest that pasakbumin A could be developed as a novel anti-TB drug or host-directed therapeutic (HDT) strategy to protect against host cell death and improve host defense mechanisms against Mtb infection in macrophages.	[Lee, Hyo-Ji; Jung, Yu-Jin] Kangwon Natl Univ, Dept Biol Sci, Chunchon, South Korea; [Lee, Hyo-Ji; Jung, Yu-Jin] Kangwon Natl Univ, Inst Life Sci, Chunchon, South Korea; [Ko, Hyun-Jeong] Kangwon Natl Univ, Coll Pharm, Chunchon, South Korea; [Kim, Seung Hyun] Yonsei Univ, Coll Pharm, Incheon, South Korea	Kangwon National University; Kangwon National University; Kangwon National University; Yonsei University	Jung, YJ (corresponding author), Kangwon Natl Univ, Dept Biol Sci, Chunchon, South Korea.; Jung, YJ (corresponding author), Kangwon Natl Univ, Inst Life Sci, Chunchon, South Korea.	yjjung@kangwon.ac.kr	Jung, Yu-Jin/GNH-4544-2022	Jung, Yu-Jin/0000-0002-4942-677X; Ko, Hyun-Jeong/0000-0002-3844-928X	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare of the Republic of Korea [HI15C0450]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [2017R1A6A3A11032251, 2018R1D1A1B07049097]	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare of the Republic of Korea; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology	This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), which is funded by the Ministry of Health & Welfare of the Republic of Korea (HI15C0450), and the Basic Science Research Program through the National Research Foundation of Korea (NRF), which is funded by the Ministry of Education, Science and Technology (2017R1A6A3A11032251, 2018R1D1A1B07049097).	Arbex MA, 2010, J BRAS PNEUMOL, V36, P626, DOI 10.1590/S1806-37132010000500016; Bhat R, 2010, FITOTERAPIA, V81, P669, DOI 10.1016/j.fitote.2010.04.006; Castillo EF, 2012, P NATL ACAD SCI USA, V109, pE3168, DOI 10.1073/pnas.1210500109; Cho JH, 2017, ONCOTARGET, V8, P24932, DOI 10.18632/oncotarget.15326; Domingo-Gonzalez R, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.TBTB2-0018-2016; Duan L, 2016, BIOCHEM BIOPH RES CO, V473, P1229, DOI 10.1016/j.bbrc.2016.04.045; Farouk AE, 2007, SAUDI MED J, V28, P1422; Forget EJ, 2006, EXPERT OPIN DRUG SAF, V5, P231, DOI 10.1517/14740338.5.2.231; Gupta A, 2012, IMMUNOBIOLOGY, V217, P363, DOI 10.1016/j.imbio.2011.07.008; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Harper Ian, 2010, Anthropol Med, V17, P201, DOI 10.1080/13648470.2010.493606; HAUSER WE, 1982, AM J MED, V72, P711, DOI 10.1016/0002-9343(82)90534-4; Hayat M., 2017, AUTOPHAGY CANC OTHER, P234; Hmama Z, 2015, IMMUNOL REV, V264, P220, DOI 10.1111/imr.12268; HSE National Drug Treatment Centre, 2016, CERV SMEAR GUID; Huang J, 2014, NAT REV MICROBIOL, V12, P101, DOI 10.1038/nrmicro3160; Jo EK, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00097; Kaufmann SHE, 2018, NAT REV DRUG DISCOV, V17, P35, DOI 10.1038/nrd.2017.162; Kim JJ, 2012, CELL HOST MICROBE, V11, P457, DOI 10.1016/j.chom.2012.03.008; Lee H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00924; Lee HJ, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00541; Lee HJ, 2015, MOL CELLS, V38, P26, DOI 10.14348/molcells.2015.2136; Lee YK, 2016, BMB REP, V49, P424, DOI 10.5483/BMBRep.2016.49.8.081; Nguyen L, 2016, ARCH TOXICOL, V90, P1585, DOI 10.1007/s00204-016-1727-6; MENZIES R, 1993, TUBERCLE LUNG DIS, V74, P32, DOI 10.1016/0962-8479(93)90066-7; Moraco AH, 2014, SEMIN IMMUNOL, V26, P497, DOI 10.1016/j.smim.2014.10.001; Mortaz E, 2015, J CLIN IMMUNOL, V35, P1, DOI 10.1007/s10875-014-0103-7; North RJ, 2004, ANNU REV IMMUNOL, V22, P599, DOI 10.1146/annurev.immunol.22.012703.104635; Park S, 2014, BIOORG MED CHEM LETT, V24, P3835, DOI 10.1016/j.bmcl.2014.06.058; Park WB, 2010, J INFECTION, V61, P323, DOI 10.1016/j.jinf.2010.07.009; Petrini B, 1999, INT J ANTIMICROB AG, V13, P93, DOI 10.1016/S0924-8579(99)00111-9; Pieters J, 2008, CELL HOST MICROBE, V3, P399, DOI 10.1016/j.chom.2008.05.006; Rehman SU, 2016, MOLECULES, V21, DOI 10.3390/molecules21030331; Romagnoli A, 2012, AUTOPHAGY, V8, P1357, DOI 10.4161/auto.20881; Ryter SW, 2013, MOL CELLS, V36, P7, DOI 10.1007/s10059-013-0140-8; Saraav I, 2014, IMMUNOL CELL BIOL, V92, P741, DOI 10.1038/icb.2014.52; Shi LB, 2005, P NATL ACAD SCI USA, V102, P15629, DOI 10.1073/pnas.0507850102; Shibutani ST, 2015, NAT IMMUNOL, V16, P1014, DOI 10.1038/ni.3273; Stephenson HN, 2016, CURR OPIN IMMUNOL, V38, P59, DOI 10.1016/j.coi.2015.11.004; Sulis G, 2016, NPJ PRIM CARE RESP M, V26, DOI 10.1038/npjpcrm.2016.78; Tee TT, 2007, ANTICANCER RES, V27, P3425; Tousif S, 2014, J BIOL CHEM, V289, P30190, DOI 10.1074/jbc.C114.598946; Wallis RS, 2015, NAT REV IMMUNOL, V15, P255, DOI 10.1038/nri3813; Yakar F, 2013, MULTIDISCIP RESP MED, V8, DOI 10.1186/2049-6958-8-13; Yuk JM, 2009, CELL HOST MICROBE, V6, P231, DOI 10.1016/j.chom.2009.08.004; Zumla A, 2016, LANCET INFECT DIS, V16, pE47, DOI 10.1016/S1473-3099(16)00078-5; Zumla A, 2015, LANCET GLOB HEALTH, V3, pE10, DOI 10.1016/S2214-109X(14)70361-4	47	13	13	3	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2019	14	3							e0199799	10.1371/journal.pone.0199799	http://dx.doi.org/10.1371/journal.pone.0199799			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO6OH	30865638	Green Published, Green Submitted, gold			2023-01-03	WOS:000461048900001
J	Ruetzler, K; Leung, S; Chmiela, M; Rivas, E; Szarpak, L; Khanna, S; Mao, G; Drake, RL; Sessler, DI; Turan, A				Ruetzler, Kurt; Leung, Steve; Chmiela, Mark; Rivas, Eva; Szarpak, Lukasz; Khanna, Sandeep; Mao, Guangmei; Drake, Richard L.; Sessler, Daniel I.; Turan, Alparslan			Regurgitation and pulmonary aspiration during cardio-pulmonary resuscitation (CPR) with a laryngeal tube: A pilot crossover human cadaver study	PLOS ONE			English	Article							ESOPHAGEAL-TRACHEAL COMBITUBE(TM); ADVANCED AIRWAY MANAGEMENT; HOSPITAL CARDIAC-ARREST; ENDOTRACHEAL INTUBATION; LIFE-SUPPORT; EUROPEAN RESUSCITATION; RETROSPECTIVE ANALYSIS; CHEST COMPRESSIONS; COUNCIL GUIDELINES; SURVIVAL	Background High-quality chest compressions are imperative for Cardio-Pulmonary-Resuscitation (CPR). International CPR guidelines advocate, that chest compressions should not be interrupted for ventilation once a patient's trachea is intubated or a supraglottic-airway-device positioned. Supraglottic-airway-devices offer limited protection against pulmonary aspiration. Simultaneous chest compressions and positive pressure ventilation both increase intrathoracic pressure and potentially enhances the risk of pulmonary aspiration. The hypothesis was, that regurgitation and pulmonary aspiration is more common during continuous versus interrupted chest compressions in human cadavers ventilated with a laryngeal tube airway. Methods Twenty suitable cadavers were included, and were positioned supine, the stomach was emptied, 500 ml of methylene-blue-solution instilled and laryngeal tube inserted. Cadavers were randomly assigned to: 1) continuous chest compressions; or, 2) interrupted chest compressions for ventilation breaths. After 14 minutes of the initial designated CPR strategy, pulmonary aspiration was assessed with a flexible bronchoscope. The methylene-blue-solution was replaced by 500 ml barium-sulfate radiopaque suspension. 14 minutes of CPR with the second designated ventilation strategy was performed. Pulmonary aspiration was then assessed with a conventional chest X-ray. Results Two cadavers were excluded for technical reasons, leaving 18 cadavers for statistical analysis. Pulmonary aspiration was observed in 9 (50%) cadavers with continuous chest compressions, and 7 (39%) with interrupted chest compressions (P = 0.75). Conclusion Our pilot study indicate, that incidence of pulmonary aspiration is generally high in patients undergoing CPR when a laryngeal tube is used for ventilation. Our study was not powered to identify potentially important differences in regurgitation or aspiration between ongoing vs. interrupted chest compression. Our results nonetheless suggest that interrupted chest compressions might better protect against pulmonary aspiration when a laryngeal tube is used for ventilation.	[Ruetzler, Kurt; Leung, Steve; Rivas, Eva; Khanna, Sandeep; Mao, Guangmei; Sessler, Daniel I.; Turan, Alparslan] Cleveland Clin, Inst Anesthesiol, Dept Outcomes Res, Cleveland, OH 44106 USA; [Ruetzler, Kurt; Chmiela, Mark; Khanna, Sandeep; Turan, Alparslan] Cleveland Clin, Dept Gen Anesthesiol, Inst Anesthesiol, Cleveland, OH 44106 USA; [Rivas, Eva] Hosp Clin Barcelona, Dept Anesthesiol, Barcelona, Spain; [Szarpak, Lukasz] Univ Warszaw, Dept Emergency Med, Warsaw, Poland; [Mao, Guangmei] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA; [Drake, Richard L.] Cleveland Clin, Lerner Coll Med, Dept Anat, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Barcelona; Hospital Clinic de Barcelona; University of Warsaw; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation	Ruetzler, K (corresponding author), Cleveland Clin, Inst Anesthesiol, Dept Outcomes Res, Cleveland, OH 44106 USA.; Ruetzler, K (corresponding author), Cleveland Clin, Dept Gen Anesthesiol, Inst Anesthesiol, Cleveland, OH 44106 USA.	kr@or.org	Rivas, Eva/AFU-7933-2022; Szarpak, Lukasz/N-5222-2018; Ruetzler, Kurt/P-7101-2019; Ruetzler, Kurt/W-2596-2017	Rivas, Eva/0000-0002-5816-998X; Szarpak, Lukasz/0000-0002-0973-5455; Ruetzler, Kurt/0000-0003-0467-1736; Ruetzler, Kurt/0000-0003-0467-1736	Research Program Committee of the Cleveland Clinic Foundation; Instituto Salud Carlos III [BA17/00032]	Research Program Committee of the Cleveland Clinic Foundation; Instituto Salud Carlos III(Instituto de Salud Carlos III)	This study project was funded by a grant by the Research Program Committee of the Cleveland Clinic Foundation and the Instituto Salud Carlos III (BA17/00032 to ER). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aufderheide Tom P, 2004, Crit Care Med, V32, pS345, DOI 10.1097/01.CCM.0000134335.46859.09; Beck-Schimmer B, 2011, EUR J ANAESTH, V28, P78, DOI 10.1097/EJA.0b013e32834205a8; Bein B, 2005, EUR J ANAESTH, V22, P341, DOI 10.1017/S026502150500058X; Benoit JL, 2015, RESUSCITATION, V93, P20, DOI 10.1016/j.resuscitation.2015.05.007; Berg RA, 2001, CIRCULATION, V104, P2465, DOI 10.1161/hc4501.098926; Bobrow BJ, 2009, ANN EMERG MED, V54, P656, DOI 10.1016/j.annemergmed.2009.06.011; Bollig G, 2006, RESUSCITATION, V71, P107, DOI 10.1016/j.resuscitation.2006.02.016; Deakin CD, 2010, RESUSCITATION, P81; Garza AG, 2009, CIRCULATION, V119, P2597, DOI 10.1161/CIRCULATIONAHA.108.815621; Genbrugge C, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0837-5; Goliasch G, 2013, EUR J EMERG MED, V20, P310, DOI 10.1097/MEJ.0b013e328358455e; Greif R, 2015, RESUSCITATION, V95, P288, DOI 10.1016/j.resuscitation.2015.07.032; Kellum MJ, 2006, AM J MED, V119, P335, DOI 10.1016/j.amjmed.2005.11.014; KNIGHT B H, 1975, Forensic Science, V6, P229, DOI 10.1016/0300-9432(75)90014-X; Link MS, 2015, CIRCULATION, V132, pS444, DOI 10.1161/CIR.0000000000000261; McCarthy JJ, 2018, CIRCULATION, V137, pE645, DOI 10.1161/CIR.0000000000000557; McClave Stephen A., 2002, Journal of Parenteral and Enteral Nutrition, V26, pS80, DOI 10.1177/014860710202600613; MENDELSON CL, 1946, AM J OBSTET GYNECOL, V52, P191; Mulcaster JT, 2003, ANESTHESIOLOGY, V98, P23, DOI 10.1097/00000542-200301000-00007; Nichol G, 2015, NEW ENGL J MED, V373, P2203, DOI 10.1056/NEJMoa1509139; Perbet S, 2011, AM J RESP CRIT CARE, V184, P1048, DOI 10.1164/rccm.201102-0331OC; Perkins GD, 2015, RESUSCITATION, V95, pE43, DOI 10.1016/j.resuscitation.2015.07.041; Piegeler T, 2016, RESUSCITATION, V105, P66, DOI 10.1016/j.resuscitation.2016.04.020; Piegeler T, 2016, RESUSCITATION, V102, P70, DOI 10.1016/j.resuscitation.2016.02.017; Rabitsch W, 2003, RESUSCITATION, V57, P27, DOI 10.1016/S0300-9572(02)00435-5; Radu RR, 2018, EUR J EMERG MED, V25, P362, DOI 10.1097/MEJ.0000000000000465; Schebesta K, 2012, ANESTHESIOLOGY, V116, P1204, DOI 10.1097/ALN.0b013e318254cf41; Soar J, 2015, RESUSCITATION, V95, P100, DOI 10.1016/j.resuscitation.2015.07.016; Stone BJ, 1998, RESUSCITATION, V38, P3, DOI 10.1016/S0300-9572(98)00068-9; Thoeni N, 2015, RESUSCITATION, V90, P42, DOI 10.1016/j.resuscitation.2015.02.010; Virkkunen I, 2007, ACTA ANAESTH SCAND, V51, P202, DOI 10.1111/j.1399-6576.2006.01229.x; Wang HE, 2018, JAMA-J AM MED ASSOC, V320, P769, DOI 10.1001/jama.2018.7044; Wenzel V, 2001, RESUSCITATION, V49, P123, DOI 10.1016/S0300-9572(00)00349-X; Yeung J, 2014, RESUSCITATION, V85, P898, DOI 10.1016/j.resuscitation.2014.02.018	34	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2019	14	2							e0212704	10.1371/journal.pone.0212704	http://dx.doi.org/10.1371/journal.pone.0212704			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM9LQ	30811470	gold, Green Submitted, Green Published			2023-01-03	WOS:000459806400085
J	Lee, SJ; Ha, KH; Lee, JH; Lee, H; Kim, DJ; Kim, HC				Lee, Su Jin; Ha, Kyoung Hwa; Lee, Jung Hyun; Lee, Hokyou; Kim, Dae Jung; Kim, Hyeon Chang			Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study	PLOS ONE			English	Article							HEALTH INSURANCE SERVICE; DPP-4 INHIBITORS; TYPE-2; ASSOCIATION; DATABASE; OUTCOMES; EVENTS	Aim To compare the risks of hospitalization for heart failure (HHF) associated with sulfonylurea (SU), dipeptidyl peptidase-4 inhibitor (DPP-4i), and thiazolidinedione (TZD) as add-on medications to metformin (MET) therapy using the data of Korean adults with type-2 diabetes from the Korean National Health Insurance database. Methods We identified 98,383 people who received SU (n = 42,683), DPP-4i (n = 50,310), or TZD (n = 5,390) added to initial treatment of MET monotherapy in patients with type-2 diabetes. The main outcome was the hospitalization for HHF. Hazard ratios for HHF by type of second-line glucose-lowering medication were estimated by Cox-proportional hazard models. Sex, age, duration of MET monotherapy, Charlson Comorbidity Index and additional comorbidities, and calendar year were controlled as potential confounders. Results The observed numbers (rate per 100,000 person-years) of HHF events were 1,129 (658) for MET+SU users, 710 (455) for MET+DPP-4i users, and 110 (570) for MET+TZD users. Compared to that for MET+SU users (reference group), the adjusted hazard ratios for HHF events were 0.76 (95% confidence interval 0.69-0.84) for MET+DPP-4i users and 0.96 (95% confidence interval 0.79-1.17) for MET+TZD users. Conclusion DPP-4i as an add-on therapy to MET may lower the risks of HHF compared with SU.	[Lee, Su Jin] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Lee, Su Jin; Lee, Jung Hyun; Lee, Hokyou; Kim, Hyeon Chang] Yonsei Univ, Coll Med, Dept Prevent Med, Seoul, South Korea; [Ha, Kyoung Hwa; Kim, Dae Jung] Ajou Univ, Sch Med, Dept Endocrinol & Metab, Suwon, South Korea; [Ha, Kyoung Hwa; Kim, Dae Jung] Ajou Univ, Sch Med, Cardiovasc & Metab Dis Etiol Res Ctr, Suwon, South Korea; [Kim, Hyeon Chang] Yonsei Univ, Coll Med, Cardiovasc & Metab Dis Etiol Res Ctr, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Ajou University; Ajou University; Yonsei University; Yonsei University Health System	Kim, HC (corresponding author), Yonsei Univ, Coll Med, Dept Prevent Med, Seoul, South Korea.; Kim, HC (corresponding author), Yonsei Univ, Coll Med, Cardiovasc & Metab Dis Etiol Res Ctr, Seoul, South Korea.	hckim@yuhs.ac	Kim, Dae Jung/AAJ-7518-2021; Kim, Hyeon Chang/F-8796-2019	Kim, Dae Jung/0000-0003-1025-2044; Kim, Hyeon Chang/0000-0001-7867-1240; Lee, Hokyou/0000-0002-5034-8422	Korea Health Technology R&D project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare, Republic of Korea [HI13C0715]; KHIDI; Ministry of Health and Welfare, Republic of Korea	Korea Health Technology R&D project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare, Republic of Korea; KHIDI; Ministry of Health and Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	This research was supported by a grant of the Korea Health Technology R&D project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (grant number: HI13C0715). KHIDI(https://www.khidi.or.kr/eps) the Ministry of Health and Welfare, Republic of Korea (http://www.mohw.go.kr/) The funder provided support in the form of salaries for authors DJ Kim, HC Kim. NO - The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amer Diabet Assoc, 2018, DIABETES CARE, V41, pS73, DOI 10.2337/dc18-S008; Chang YC, 2015, DIABETIC MED, V32, P1460, DOI 10.1111/dme.12800; Chene G, 1998, CONTROL CLIN TRIALS, V19, P233, DOI 10.1016/S0197-2456(97)00145-1; Fadini GP, 2015, EUR HEART J, V36, P2454, DOI 10.1093/eurheartj/ehv301; Fu AZ, 2016, DIABETES CARE, V39, P726, DOI 10.2337/dc15-0764; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Ha KH, 2017, DIABETIC MED, V34, P1235, DOI 10.1111/dme.13384; Kim YG, 2017, CIRC-HEART FAIL, V10, DOI 10.1161/CIRCHEARTFAILURE.117.003957; Ko SH, 2018, DIABETES METAB J, V42, P93, DOI 10.4093/dmj.2018.42.2.93; Komajda M, 2010, EUR HEART J, V31, P824, DOI 10.1093/eurheartj/ehp604; Maru S, 2005, DIABETES CARE, V28, P20, DOI 10.2337/diacare.28.1.20; McGuire DK, 2016, JAMA CARDIOL, V1, P126, DOI 10.1001/jamacardio.2016.0103; McMurray JJV, 2014, LANCET DIABETES ENDO, V2, P843, DOI 10.1016/S2213-8587(14)70031-2; Morgan CL, 2012, J CLIN ENDOCR METAB, V97, P4605, DOI 10.1210/jc.2012-3034; Packer M, 2018, DIABETES CARE, V41, P11, DOI 10.2337/dci17-0052; Rhee SY, 2017, KOREAN J INTERN MED, V32, P959, DOI 10.3904/kjim.2017.312; Scirica, 2015, CIRCULATION, V132, pE198, DOI 10.1161/CIR.0000000000000330; Seong SC, 2017, INT J EPIDEMIOL, V46, P799, DOI 10.1093/ije/dyw253; Singh S, 2007, DIABETES CARE, V30, P2148, DOI 10.2337/dc07-0141; Tella SH, 2015, EXPERT OPIN DRUG SAF, V14, P127, DOI 10.1517/14740338.2015.977863; Toh S, 2016, ANN INTERN MED, V164, P705, DOI 10.7326/M15-2568; Zannad F, 2015, LANCET, V385, P2067, DOI 10.1016/S0140-6736(14)62225-X	22	2	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2019	14	2							e0211959	10.1371/journal.pone.0211959	http://dx.doi.org/10.1371/journal.pone.0211959			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL0OI	30742667	Green Published, Green Submitted, gold			2023-01-03	WOS:000458393400035
J	Haddad, M; Prince, MS; Zarrouk, N; Tabben, M; Behm, DG; Chamari, K				Haddad, Monoem; Prince, Mohammad Shoaib; Zarrouk, Nidhal; Tabben, Montassar; Behm, David G.; Chamari, Karim			Dynamic stretching alone can impair slower velocity isokinetic performance of young male handball players for at least 24 hours	PLOS ONE			English	Article							VERTICAL JUMP PERFORMANCE; WARM-UP; STATIC STRETCH; SPRINT PERFORMANCE; FORCE-VELOCITY; MUSCLE DAMAGE; REACTION-TIME; JOINT-ANGLE; PEAK TORQUE; ACUTE BOUT	There are many adult studies reporting static stretch (SS)-induced deficits and dynamic stretch (DS) performance improvements shortly after the intervention. However, there is only a single study examining stretch-induced performance changes with youth at 24 hours' post-stretch. The objective of this study was to examine physiological responses of young trained athletes at 24-hours after experiencing SS or DS protocols. Eight young male, elite handball players (age: 16.1 +/- 5.1 years) were tested prior to-, 3-minutes and 24-hours following the three conditions (DS, SS, Control) in a randomized and counterbalanced order. Similar volumes of SS (2 repetitions of 75s for each leg) and DS (5 repetitions of 30s for each leg) involved one stretch each for the quadriceps and hamstrings. Tests included (i) two 4s maximal voluntary isometric contractions (MVC) at 60 degrees of knee flexion with 2-min rest, (ii) two maximal isokinetic contractions each at 60 degrees/sec and 300 degrees/sec with 1-min rest, and (iii) two drop jumps with 30-sec rest. To simulate a full warm-up, dynamic activity including 5 minutes of aerobic cycling (70 rpm; 1 kilopond), 4 submaximal isometric contractions and 4 drop jumps were instituted before the pre-tests and following the interventions. Two-way repeated measures ANOVAs revealed that 1) both the SS and control conditions exhibited knee extensor 60 degrees.s(-1) (SS:-10.3%; p = 0.04, Control: -8.7%; p = 0.07) and 300 degrees.s(-1) (SS: -12.9%; p = 0.005, Control: -16.3%; p = 0.02) isokinetic deficits at post-test, 2) DS impaired knee flexor 60 degrees.s(-1) isokinetic work and power-related measures at post-test (Work: -10.1%; p = 0.0006; Power: -19.1%; p = 0.08) and at 24-hours' post-test (Work: 9.9%; p = 0.023; Power: -9.6%; p = 0.01), 3) DS (12.07% and 10.47%) and SS (13.7% and 14.6%) enhanced knee flexor 300 degrees.s(-1) isokinetic force and power-related measures compared to control. In conclusion, testing-induced knee extensor isokinetic impairments were counterbalanced by DS, however the hip flexion DS could have produced minor muscle damage for at least 24-hours decreasing knee flexor forces and power at 60 degrees.s(-1).	[Haddad, Monoem; Prince, Mohammad Shoaib] Qatar Univ, Coll Arts & Sci, Sport Sci Program, Doha, Qatar; [Zarrouk, Nidhal] Aspetar Orthoped & Sports Med Hosp, Excellence Football Project, Natl Sports Med Programme, Doha, Qatar; [Tabben, Montassar] Aspetar Orthoped & Sports Med Hosp, ASPREV Dept, Doha, Qatar; [Behm, David G.] Mem Univ Newfoundland, Sch Human Kinet & Recreat, St John, NF, Canada; [Chamari, Karim] Qatar Orthopaed & Sports Med Hosp, Aspetar, AHP Res Ctr, Doha, Qatar	Qatar University; Aspetar Orthopaedic & Sports Medicine Hospital; Aspetar Orthopaedic & Sports Medicine Hospital; Memorial University Newfoundland; Aspetar Orthopaedic & Sports Medicine Hospital	Behm, DG (corresponding author), Mem Univ Newfoundland, Sch Human Kinet & Recreat, St John, NF, Canada.	dbehm@mun.ca	Behm, David George/I-6509-2019; Haddad, Monoem/D-4999-2014; CHAMARI, Karim/AAJ-7938-2021	Behm, David George/0000-0002-9406-6056; Haddad, Monoem/0000-0001-5989-1627; CHAMARI, Karim/0000-0001-9178-7678	Qatar University - University Grant [QUUG-CAS-DSSP-15\16-15]; Qatar National Library	Qatar University - University Grant; Qatar National Library(Qatar National Research Fund (QNRF))	This work was supported by Qatar University - University Grant QUUG-CAS-DSSP-15\16-15. The publication of this article was funded by the Qatar National Library.	Alter M.J., 1996, SCI FLEXIBILITY; Ayala F, 2014, J SPORT SCI, V32, P817, DOI 10.1080/02640414.2013.861606; Behm DG, 2007, EUR J APPL PHYSIOL, V101, P587, DOI 10.1007/s00421-007-0533-5; Behm DG, 2016, APPL PHYSIOL NUTR ME, V41, P1, DOI 10.1139/apnm-2015-0235; Behm DG, 2011, APPL PHYSIOL NUTR ME, V36, P790, DOI [10.1139/H11-107, 10.1139/h11-107]; Behm DG, 2011, EUR J APPL PHYSIOL, V111, P2633, DOI 10.1007/s00421-011-1879-2; Behm DG, 2016, EUR J APPL PHYSIOL, V116, P241, DOI 10.1007/s00421-015-3270-1; Behm DG, 2006, J SPORT SCI MED, V5, P33; Behm DG, 2004, MED SCI SPORT EXER, V36, P1397, DOI 10.1249/01.MSS.0000135788.23012.5F; Behm DG, 2004, CAN J APPL PHYSIOL, V29, P274, DOI 10.1139/h04-019; Behm DG, 2001, CAN J APPL PHYSIOL, V26, P261, DOI 10.1139/h01-017; Behm DG, 2001, J STRENGTH COND RES, V15, P255; Bishop D, 2003, SPORTS MED, V33, P439, DOI 10.2165/00007256-200333060-00005; Blazevich AJ, 2018, MED SCI SPORT EXER, V50, P1258, DOI 10.1249/MSS.0000000000001539; Bradley PS, 2007, J STRENGTH COND RES, V21, P223, DOI 10.1519/00124278-200702000-00040; BROOKS SV, 1995, J PHYSIOL-LONDON, V488, P459, DOI 10.1113/jphysiol.1995.sp020980; Chaouachi A, 2008, EUR J APPL PHYSIOL, V104, P515, DOI 10.1007/s00421-008-0799-2; Chaouachi A, 2010, J STRENGTH COND RES, V24, P2001, DOI 10.1519/JSC.0b013e3181aeb181; Cohen J., 2013, STAT POWER ANAL BEHA; Costa PB, 2014, MED SCI SPORT EXER, V46, P586, DOI 10.1249/MSS.0000000000000138; Costa PB, 2009, J STRENGTH COND RES, V23, P141, DOI 10.1519/JSC.0b013e31818eb052; Cramer JT, 2007, J ORTHOP SPORT PHYS, V37, P130, DOI 10.2519/jospt.2007.2389; Cramer JT, 2004, J STRENGTH COND RES, V18, P236, DOI 10.1519/00124278-200405000-00006; Curry BS, 2009, J STRENGTH COND RES, V23, P1811, DOI 10.1519/JSC.0b013e3181b73c2b; de Hoyo M, 2016, J SPORT SCI, V34, P1363, DOI 10.1080/02640414.2016.1150603; DEKONING FL, 1985, EUR J APPL PHYSIOL O, V54, P89, DOI 10.1007/BF00426305; Duncan M.J., 2006, J EXERC PHYSL, V9, P9; Faigenbaum AD, 2010, PEDIATR EXERC SCI, V22, P266, DOI 10.1123/pes.22.2.266; Falk B, 2006, EXERC SPORT SCI REV, V34, P107, DOI 10.1249/00003677-200607000-00004; Fletcher IM, 2007, J STRENGTH COND RES, V21, P784; Fletcher IM, 2010, EUR J APPL PHYSIOL, V109, P491, DOI 10.1007/s00421-010-1386-x; Fletcher IM, 2004, J STRENGTH COND RES, V18, P885; Fowles JR, 2000, J APPL PHYSIOL, V89, P1179, DOI 10.1152/jappl.2000.89.3.1179; Haddad M, 2014, J STRENGTH COND RES, V28, P140, DOI 10.1519/JSC.0b013e3182964836; Haghshenas R T-B I., 2014, INT J SPORT STUDIES, V4, P907; Halperin I, 2018, INT J SPORT PHYSIOL, V13, P127, DOI 10.1123/ijspp.2017-0322; Herda TJ, 2013, J SPORT SCI, V31, P479, DOI 10.1080/02640414.2012.736632; Hermens H. J., 1999, ROESSINGH RES DEV, V8, P13, DOI DOI 10.1016/S1050-6411(00)00027-4; Hough PA, 2009, J STRENGTH COND RES, V23, P507, DOI 10.1519/JSC.0b013e31818cc65d; Huijing PA, 1999, J BIOMECH, V32, P329, DOI 10.1016/S0021-9290(98)00186-9; INGEMANNHANSEN T, 1979, SCAND J REHABIL MED, V11, P85; Jaggers JR, 2008, J STRENGTH COND RES, V22, P1844, DOI 10.1519/JSC.0b013e3181854a3d; Janes WCI, 2016, APPL PHYSIOL NUTR ME, V41, P1052, DOI 10.1139/apnm-2016-0241; Kay AD, 2008, EUR J SPORT SCI, V8, P41, DOI 10.1080/17461390701855505; Kay AD, 2012, MED SCI SPORT EXER, V44, P154, DOI 10.1249/MSS.0b013e318225cb27; Kay AD, 2010, J APPL PHYSIOL, V108, P637, DOI 10.1152/japplphysiol.01135.2009; Kay AD, 2009, J APPL PHYSIOL, V106, P1249, DOI 10.1152/japplphysiol.91476.2008; Kirmizigil B, 2014, J STRENGTH COND RES, V28, P1263, DOI 10.1519/JSC.0000000000000268; Kokkonen J, 1998, RES Q EXERCISE SPORT, V69, P411, DOI 10.1080/02701367.1998.10607716; Mizuno T, 2013, INT J SPORTS MED, V34, P484, DOI 10.1055/s-0032-1327655; Morse CI, 2008, J PHYSIOL-LONDON, V586, P97, DOI 10.1113/jphysiol.2007.140434; Murphy JR, 2014, EUR J APPL PHYSIOL, V114, P825, DOI 10.1007/s00421-013-2809-2; Nelson AG, 2005, J SPORT SCI, V23, P449, DOI 10.1080/02640410410001730205; Nelson AG, 2001, RES Q EXERCISE SPORT, V72, P415, DOI 10.1080/02701367.2001.10608978; Nelson AG, 2001, RES Q EXERCISE SPORT, V72, P68, DOI 10.1080/02701367.2001.10608934; Papadopoulos G, 2005, ISOKINET EXERC SCI, V13, P285, DOI 10.3233/IES-2005-0216; Pearce AJ, 2009, EUR J APPL PHYSIOL, V105, P175, DOI 10.1007/s00421-008-0887-3; Perrier ET, 2011, J STRENGTH COND RES, V25, P1925, DOI 10.1519/JSC.0b013e3181e73959; PERRINE JJ, 1978, MED SCI SPORT EXER, V10, P159; PERRY J, 1981, CRIT REV BIOMED ENG, V7, P1; Power K, 2004, MED SCI SPORT EXER, V36, P1389, DOI 10.1249/01.MSS.0000135775.51937.53; Ratel S, 2006, SPORTS MED, V36, P1031, DOI 10.2165/00007256-200636120-00004; Reid JJ, 2016, PEDIAT EXERC SCI; Reid JC, 2018, EUR J APPL PHYSIOL, V118, P1427, DOI 10.1007/s00421-018-3874-3; SOLOMONOW M, 1990, Electromyography and Clinical Neurophysiology, V30, P141; Torres EM, 2008, J STRENGTH COND RES, V22, P1279, DOI 10.1519/JSC.0b013e31816eb501; Torres JB, 2009, BIOMED HUM KINET, V1, P52, DOI 10.2478/v10101-009-0013-y; Turki O, 2011, J STRENGTH COND RES, V25, P2453, DOI 10.1519/JSC.0b013e31822a5a79; Weir DE, 2005, EUR J APPL PHYSIOL, V93, P614, DOI 10.1007/s00421-004-1265-4; Winchester JB, 2009, RES Q EXERCISE SPORT, V80, P257, DOI 10.1080/02701367.2009.10599560; Yamaguchi T, 2005, J STRENGTH COND RES, V19, P677; Yamaguchi T, 2007, J STRENGTH COND RES, V21, P1238, DOI 10.1519/00124278-200711000-00044; Young WB, 2002, STRENGTH COND J, V24, P33, DOI 10.1519/1533-4295(2002)024<0033:SSSBUD>2.0.CO;2	73	3	3	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2019	14	1							e0210318	10.1371/journal.pone.0210318	http://dx.doi.org/10.1371/journal.pone.0210318			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HJ2YV	30682044	gold, Green Published, Green Submitted			2023-01-03	WOS:000457037500034
J	Stenehjem, DD; Hahn, AW; Gill, DM; Albertson, D; Gowrishankar, B; Merriman, J; Agarwal, AM; Thodima, V; Harrington, EB; Au, TH; Maughan, BL; Houldsworth, J; Pal, SK; Agarwal, N				Stenehjem, David D.; Hahn, Andrew W.; Gill, David M.; Albertson, Daniel; Gowrishankar, Banumathy; Merriman, Joseph; Agarwal, Archana M.; Thodima, Venkata; Harrington, Erik B.; Au, Trang H.; Maughan, Benjamin L.; Houldsworth, Jane; Pal, Sumanta K.; Agarwal, Neeraj			Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma	PLOS ONE			English	Article							BIOMARKERS; MUTATIONS; SUNITINIB	Background First-line treatment for metastatic renal cell carcinoma (mRCC) is rapidly changing. It currently includes VEGF targeted therapies (TT), multi-target tyrosine kinase inhibitors (TKIs), mTOR inhibitors, and immunotherapy. To optimize outcomes for individual patients, genomic markers of response to therapy are needed. Here, we aim to identify tumor-based genomic markers of response to VEGF TT to optimize treatment selection. Methods From an institutional database, primary tumor tissue was obtained from 79 patients with clear cell mRCC, and targeted sequencing was performed. Clinical outcomes were obtained retrospectively. Progression-free survival (PFS) on first-line VEGF TT was correlated to genomic alterations (GAs) using Kaplan-Meier methodology and Cox proportional hazard models. A composite model of significant GAs predicting PFS in the first-line setting was developed. Results Absence of VHL mutation was associated with inferior PFS on first-line VEGF TT. A trend for inferior PFS was observed with GAs in TP53 and FLT1 C/C variant. A composite model of these 3 GAs was associated with inferior PFS in a dose-dependent manner. Conclusion In mRCC, a composite model of TP53 mutation, wild type VHL, and FLT1 C/C variant strongly predicted PFS on first-line VEGF TT in a dose-dependent manner. These findings require external validation.	[Stenehjem, David D.] Univ Minnesota, Coll Pharm, Duluth, MN 55812 USA; [Hahn, Andrew W.; Gill, David M.; Merriman, Joseph; Maughan, Benjamin L.; Agarwal, Neeraj] Univ Utah, Dept Internal Med, Div Med Oncol, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Albertson, Daniel; Agarwal, Archana M.] Univ Utah, Dept Pathol, Salt Lake City, UT USA; [Albertson, Daniel; Agarwal, Archana M.] ARUP Labs, Salt Lake City, UT USA; [Gowrishankar, Banumathy; Thodima, Venkata; Houldsworth, Jane] Canc Genet Inc, Rutherford, NJ USA; [Harrington, Erik B.; Au, Trang H.] Univ Utah, Coll Pharm, PORC, Salt Lake City, UT 84112 USA; [Houldsworth, Jane] Mt Sinai Sch Med, Dept Pathol, New York, NY USA; [Pal, Sumanta K.] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA USA	University of Minnesota System; University of Minnesota Duluth; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; ARUP Laboratories; Utah System of Higher Education; University of Utah; Icahn School of Medicine at Mount Sinai; City of Hope	Agarwal, N (corresponding author), Univ Utah, Dept Internal Med, Div Med Oncol, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.	neeraj.agarwal@hci.utah.edu		Stenehjem, David/0000-0002-1831-285X	Pfizer; EMD Serono; Eisai	Pfizer(Pfizer); EMD Serono; Eisai(Eisai Co Ltd)	NA receives salary support from Pfizer, Exelixis, Merck, Argos, EMD Serono, and Eisai, and he receives research funding from Pfizer, EMD Serono, and Eisai. SKP receives salary support from Exelixis, BMS, GSK, Novartis, Pfizer, Astellas, and Genentech. BG, VT, and JH have received salary support from Cancer Genetics, Inc. The funders provided support in the form of salaries for authors NA, SKP, BG, VT, and JH, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Beuselinck B, 2016, BJU INT, V118, P890, DOI 10.1111/bju.13585; Beuselinck B, 2014, ACTA ONCOL, V53, P103, DOI 10.3109/0284186X.2013.770600; Carlo MI, 2017, KIDNEY CANCER, V1, P49, DOI 10.3233/KCA-160003; Che M, 2007, INT J RADIAT ONCOL, V69, P1117, DOI 10.1016/j.ijrobp.2007.04.070; Choueiri TK, 2008, J UROLOGY, V180, P860, DOI 10.1016/j.juro.2008.05.015; Choueiri TK, 2013, CLIN CANCER RES, V19, P5218, DOI 10.1158/1078-0432.CCR-13-0491; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Escudier B, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.4511; Heng DYC, 2009, J CLIN ONCOL, V27, P5794, DOI 10.1200/JCO.2008.21.4809; Ho TH, 2016, EUR UROL FOCUS, V2, P204, DOI 10.1016/j.euf.2015.11.007; Hsieh JJ, 2017, EUR UROL, V71, P405, DOI 10.1016/j.eururo.2016.10.007; Janzen NK, 2003, UROL CLIN N AM, V30, P843, DOI 10.1016/S0094-0143(03)00056-9; Ko JJ, 2015, LANCET ONCOL, V16, P293, DOI 10.1016/S1470-2045(14)71222-7; Lambrechts D, 2012, LANCET ONCOL, V13, P724, DOI 10.1016/S1470-2045(12)70231-0; Loo LWM, 2011, BREAST CANCER RES TR, V127, P297, DOI 10.1007/s10549-010-1297-x; McKay RR, 2018, J CLIN ONCOL, V36, P3615, DOI 10.1200/JCO.2018.79.0253; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; Olivier M, 2006, CLIN CANCER RES, V12, P1157, DOI 10.1158/1078-0432.CCR-05-1029; Pal SK, 2017, EUR UROL, V72, P557, DOI 10.1016/j.eururo.2017.03.046; Poeta ML, 2007, NEW ENGL J MED, V357, P2552, DOI 10.1056/NEJMoa073770; Ricketts CJ, 2018, CELL REP, V23, P313, DOI [10.1016/j.celrep.2018.03.075, 10.1016/j.celrep.2018.06.032]; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138	23	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2019	14	1							e0210415	10.1371/journal.pone.0210415	http://dx.doi.org/10.1371/journal.pone.0210415			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ2YV	30682039	Green Submitted, gold, Green Published			2023-01-03	WOS:000457037500035
J	Iacobucci, G				Iacobucci, Gareth			Sixty seconds on ... medical detection dogs	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Bomers MK, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7396; IACOBUCCI G, 2015, BMJ-BRIT MED J, V351, DOI DOI 10.1136/BMJ.H4691; Rooney NJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210092	3	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 22	2019	364								l302	10.1136/bmj.l302	http://dx.doi.org/10.1136/bmj.l302			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ6NB	30670381				2023-01-03	WOS:000457306000015
J	Krassovka, J; Borgschulze, A; Sahlender, B; Logters, T; Windolf, J; Grotheer, V				Krassovka, Julia; Borgschulze, Annika; Sahlender, Benita; Loegters, Tim; Windolf, Joachim; Grotheer, Vera			Blue light irradiation and its beneficial effect on Dupuytren's fibroblasts	PLOS ONE			English	Article							DISEASE; GROWTH; CONTRACTURE; DIFFERENTIATION; MYOFIBROBLAST; STIMULATION; CELLS; BETA	Dupuytren's contracture is a fibroproliferative disorder affecting the palmar fascia of the hand. Most affected are the ring fingers, and little fingers of middle-aged men. Symptomatic for this disease is the increased proliferation and differentiation of fibroblasts to myofibroblasts, which is accompanied by an elevated alpha-SMA expression. The present study evaluated the therapeutic benefit of blue light (lambda = 453 nm, 38 mW/cm(2), continuous radiance, spot size 10-12 cm(2)) as well as the molecular mechanism mediating this effect. It could be determined that blue light significantly diminished the induced alpha-SMA protein expression in both normal palmar fibroblasts and Duypuytren's fibroblasts. The beneficial effect mediated by this irradiance, radiant exposure and wavelength was associated with an elevated reactive oxygen species generation. Furthermore, the data underlines the potential usefulness of blue light irradiation as a promising therapy option for Dupuytren's disease, especially for relapse prevention, and may represent a useful strategy to treat further fibrotic diseases, such as keloids, hypertrophic scarring, and scleroderma.	[Krassovka, Julia; Borgschulze, Annika; Sahlender, Benita; Loegters, Tim; Windolf, Joachim; Grotheer, Vera] Heinrich Heine Univ Dusseldorf, Fac Med, Dept Trauma & Hand Surg, Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Grotheer, V (corresponding author), Heinrich Heine Univ Dusseldorf, Fac Med, Dept Trauma & Hand Surg, Dusseldorf, Germany.	vera.grotheer@med.uni-duesseldorf.de						Adamskaya N, 2011, INJURY, V42, P917, DOI 10.1016/j.injury.2010.03.023; Badalamente MA, 2000, J HAND SURG-AM, V25A, P629, DOI 10.1053/jhsu.2000.6918; Bisson MA, 2003, J HAND SURG-BRIT EUR, V28B, P351, DOI 10.1016/S0266-7681(03)00135-9; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Boulton M, 2004, PHOTOCH PHOTOBIO SCI, V3, P759, DOI 10.1039/b400108g; Feldman G, 2017, ISR MED ASSOC J, V19, P648; Fischer MR, 2013, EXP DERMATOL, V22, P558, DOI 10.1111/exd.12193; Gorgidze LA, 1998, BIOSCIENCE REP, V18, P215, DOI 10.1023/A:1020104914726; Gudmundsson KG, 2001, SCAND J RHEUMATOL, V30, P31; Jemec B, 1999, J HAND SURG-BRIT EUR, V24B, P511, DOI 10.1054/jhsb.1999.0251; KARU T, 1994, INT J RADIAT BIOL, V65, P691, DOI 10.1080/09553009414550811; Karu TI, 2005, PHOTOMED LASER SURG, V23, P355, DOI 10.1089/pho.2005.23.355; Krause C, 2011, FIBROGENESIS TISSUE, V4, DOI 10.1186/1755-1536-4-14; Losi A, 2007, PHOTOCHEM PHOTOBIOL, V83, P1283, DOI 10.1111/j.1751-1097.2007.00196.x; LUCK JV, 1959, J BONE JOINT SURG AM, V41, P635, DOI 10.2106/00004623-195941040-00008; Meek RMD, 2002, J HAND SURG-BRIT EUR, V27B, P270, DOI 10.1054/jhsb.2001.0742; Niemz MH, 2007, LASER TISSUE INTERAC; Ohara M, 2003, CANCER SCI, V94, P205, DOI 10.1111/j.1349-7006.2003.tb01420.x; Oplander C, 2011, J PHOTOCH PHOTOBIO B, V103, P118, DOI 10.1016/j.jphotobiol.2011.02.018; Pavelic SK, 2009, J PATHOL, V217, P524, DOI 10.1002/path.2483; Picardo NE, 2012, SURG-J R COLL SURG E, V10, P151, DOI 10.1016/j.surge.2012.01.004; Rayan GM, 2007, J BONE JOINT SURG AM, P89; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Shaw RB, 2007, PLAST RECONSTR SURG, V120, p44E, DOI 10.1097/01.prs.0000278455.63546.03; Shih B, 2010, NAT REV RHEUMATOL, V6, P715, DOI 10.1038/nrrheum.2010.180; Shnitkind Elaine, 2006, J Drugs Dermatol, V5, P605; Stromberg J, 2016, J HAND SURG-AM, V41, P873, DOI 10.1016/j.jhsa.2016.06.014; Taflinski L, 2014, EXP DERMATOL, V23, P240, DOI 10.1111/exd.12353; TOMASEK JJ, 1986, J HAND SURG-AM, V11A, P365, DOI 10.1016/S0363-5023(86)80143-5; Vaughan MB, 2000, EXP CELL RES, V257, P180, DOI 10.1006/excr.2000.4869; Wang YG, 2016, SCI REP-UK, V6, DOI 10.1038/srep33719; Wilutzky B, 1998, HISTOL HISTOPATHOL, V13, P67, DOI 10.14670/HH-13.67	32	10	11	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2019	14	1							e0209833	10.1371/journal.pone.0209833	http://dx.doi.org/10.1371/journal.pone.0209833			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH1MW	30633751	Green Published, gold, Green Submitted			2023-01-03	WOS:000455485100006
J	Lai, YL; Su, YC; Kao, CH; Liang, JA				Lai, Yo-Liang; Su, Yuan-Chih; Kao, Chia-Hung; Liang, Ji-An			Increased risk of varicella-zoster virus infection in patients with breast cancer after adjuvant radiotherapy: A population-based cohort study	PLOS ONE			English	Article							HERPES-ZOSTER; HODGKINS-DISEASE; WOMEN	Background/Purpose Limited evidence has been obtained on varicella-zoster virus (VZV) infection in patients with breast cancer as a complication related to adjuvant radiotherapy. We conducted a cohort study aimed to assess the risk of VZV infection in this patient setting. Materials and methods We used the National Health Insurance Research Database to identify 65,981 patients with breast cancer in Taiwan who underwent breast surgery between 2000 and 2011. After a 1:1 propensity score match was obtained between patients with and without radiotherapy, a competing risk regression model was constructed to estimate the hazard ratios and the incidence rate difference (IRD) of VZV infection in the patients with breast cancer receiving radiotherapy and those not receiving radiotherapy. Results After adjusting for covariates, the radiotherapy cohort showed a 1.51-fold higher risk (95% confidence interval = 1.06-5.16, p = 0.02, IRD = 4.98/10000 person-years) of subsequent VZV infection than the nonradiotherapy cohort. Furthermore, VZV infection risk was 3.85-fold higher among patients aged > 65 years who received radiotherapy than among those of the same age who did not receive radiotherapy (95% confidence interval = 1.1-13.4, p < 0.05, IRD = 11.09/10000 person-years). The risk increased with adjusted hazard ratio of 6.6 (95% confidence interval I = 1.51-28.8, p < 0.05, IRD = 32.01/10,000 person-years) and 7.08 (95% confidence interval = 1.64-30.5, p < 0.01, IRD = 35.72/10,000 person-years) in follow-up period less than 3 months and 3-5 months respectively. Conclusion Radiotherapy was associated with an increased risk of VZV infection among patients with breast cancer. The risk was significantly higher in older patient (>65 years old) and/or those who received chemotherapy. Regular clinical follow-up and additional serological testing in the first 5 months after radiotherapy are recommended.	[Lai, Yo-Liang; Liang, Ji-An] China Med Univ Hosp, Dept Radiat Oncol, Taichung, Taiwan; [Lai, Yo-Liang] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan; [Su, Yuan-Chih] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan; [Kao, Chia-Hung] China Med Univ Hosp, Dept Nucl Med, Taichung, Taiwan; [Kao, Chia-Hung] China Med Univ Hosp, PET Ctr, Taichung, Taiwan; [Liang, Ji-An] China Med Univ, Grad Inst Clin Med Sci, Coll Med, Taichung, Taiwan; [Kao, Chia-Hung] Asia Univ, Dept Bioinformat & Med Engn, Taichung, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Asia University Taiwan	Liang, JA (corresponding author), China Med Univ Hosp, Dept Radiat Oncol, Taichung, Taiwan.; Liang, JA (corresponding author), China Med Univ, Grad Inst Clin Med Sci, Coll Med, Taichung, Taiwan.	d4615@mail.cmuh.org.tw		Liang, Ji-An/0000-0002-4170-7155	Ministry of Health and Welfare, Taiwan [MOHW107-TDU-B-212-123004]; China Medical University Hospital [DMR-107-192]; Academia Sinica Stroke Biosignature Project [BM10701010021]; MOST Clinical Trial Consortium for Stroke [MOST 106-2321-B-039-005]; Tseng-Lien Lin Foundation, Taichung, Taiwan; Katsuzo and Kiyo Aoshima Memorial Funds, Japan	Ministry of Health and Welfare, Taiwan; China Medical University Hospital; Academia Sinica Stroke Biosignature Project; MOST Clinical Trial Consortium for Stroke; Tseng-Lien Lin Foundation, Taichung, Taiwan; Katsuzo and Kiyo Aoshima Memorial Funds, Japan	This work was supported by grants from the Ministry of Health and Welfare, Taiwan (MOHW107-TDU-B-212-123004); China Medical University Hospital (DMR-107-192); Academia Sinica Stroke Biosignature Project (BM10701010021); MOST Clinical Trial Consortium for Stroke (MOST 106-2321-B-039-005); Tseng-Lien Lin Foundation, Taichung, Taiwan; and Katsuzo and Kiyo Aoshima Memorial Funds, Japan. The funders played no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Cancer Society, 2015, BREAST CANC FACTS FI; Darby SC, 2013, NEW ENGL J MED, V368, P987, DOI 10.1056/NEJMoa1209825; Dunst Juergen, 2000, Strahlentherapie und Onkologie, V176, P513, DOI 10.1007/PL00002318; Early Breast Canc Trialists Collab, 2011, LANCET, V378, P1707, DOI 10.1016/S0140-6736(11)61629-2; Ferlay J, 2010, IARC CANCERBASE, V2; Guignard AP, 2014, INFECTION, V42, P729, DOI 10.1007/s15010-014-0645-x; GUINEE VF, 1985, CANCER-AM CANCER SOC, V56, P642, DOI 10.1002/1097-0142(19850801)56:3<642::AID-CNCR2820560334>3.0.CO;2-N; Jansen K, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-372; Kim ST, 2012, ONCOLOGY-BASEL, V82, P126, DOI 10.1159/000334739; Koo S, 2014, TRANSPL INFECT DIS, V16, P17, DOI 10.1111/tid.12149; Masci G, 2006, ONCOLOGY-BASEL, V71, P164, DOI 10.1159/000106065; McCrary ML, 1999, J AM ACAD DERMATOL, V41, P1, DOI 10.1016/S0190-9622(99)70398-1; McGale P, 2014, LANCET, V383, P2127, DOI 10.1016/S0140-6736(14)60488-8; Mueller NH, 2008, NEUROL CLIN, V26, P675, DOI 10.1016/j.ncl.2008.03.011; Ramirez-Fort MK, 2018, J CLIN VIROL, V98, P18, DOI 10.1016/j.jcv.2017.11.004; REBOUL F, 1978, CANCER, V41, P95, DOI 10.1002/1097-0142(197801)41:1<95::AID-CNCR2820410114>3.0.CO;2-Q; RUSTHOVEN JJ, 1988, ARCH INTERN MED, V148, P1561, DOI 10.1001/archinte.148.7.1561; SCHIMPFF SC, 1975, AM J MED, V59, P695, DOI 10.1016/0002-9343(75)90230-2; Whelan TJ, 2015, NEW ENGL J MED, V373, P307, DOI 10.1056/NEJMoa1415340	19	6	6	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2019	14	1							e0209365	10.1371/journal.pone.0209365	http://dx.doi.org/10.1371/journal.pone.0209365			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG9VK	30625182	Green Published, gold, Green Submitted			2023-01-03	WOS:000455359400036
J	Mahmoudi, S; Xu, L; Brunet, A				Mahmoudi, Salah; Xu, Lucy; Brunet, Anne			Turning back time with emerging rejuvenation strategies	NATURE CELL BIOLOGY			English	Review							HEMATOPOIETIC STEM-CELLS; EXTENDS LIFE-SPAN; NF-KAPPA-B; SENESCENT CELLS; IN-VIVO; SECRETORY PHENOTYPE; CALORIE RESTRICTION; CELLULAR SENESCENCE; DIETARY RESTRICTION; HIPPOCAMPAL NEUROGENESIS	Ageing is associated with the functional decline of all tissues and a striking increase in many diseases. Although ageing has long been considered a one-way street, strategies to delay and potentially even reverse the ageing process have recently been developed. Here, we review four emerging rejuvenation strategies-systemic factors, metabolic manipulations, senescent cell ablation and cellular reprogramming-and discuss their mechanisms of action, cellular targets, potential trade-offs and application to human ageing.	[Mahmoudi, Salah; Xu, Lucy; Brunet, Anne] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Xu, Lucy] Stanford Univ, Dept Biol, Stanford, CA 94305 USA; [Brunet, Anne] Stanford Univ, Glenn Labs Biol Aging, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Brunet, A (corresponding author), Stanford Univ, Dept Genet, Stanford, CA 94305 USA.; Brunet, A (corresponding author), Stanford Univ, Glenn Labs Biol Aging, Stanford, CA 94305 USA.	anne.brunet@stanford.edu		Xu, Lucy/0000-0001-6765-463X	Stanford Graduate Fellowship; NATIONAL INSTITUTE ON AGING [P01AG036695] Funding Source: NIH RePORTER	Stanford Graduate Fellowship(Stanford University); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We apologize to those colleagues whose work we could not cite owing to space limitations. We thank C. Kenyon, P. Singh, J. Vos, M. Quarta and A. Colville for helpful feedback on the manuscript. This work was supported by the Stanford Graduate Fellowship (L.X.) and a generous philanthropic gift from M. Barakett and T. Barakett.	Abad M, 2013, NATURE, V502, P340, DOI 10.1038/nature12586; Abbott A., 2017, NATURE NEWS; Baar MP, 2017, CELL, V169, P132, DOI 10.1016/j.cell.2017.02.031; Baht GS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8131; Baker DJ, 2016, NATURE, V530, P184, DOI 10.1038/nature16932; Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Banito A, 2009, GENE DEV, V23, P2134, DOI 10.1101/gad.1811609; Baruch K, 2014, SCIENCE, V346, P89, DOI 10.1126/science.1252945; Barzilai N, 2016, CELL METAB, V23, P1060, DOI 10.1016/j.cmet.2016.05.011; Beerman I, 2014, CELL STEM CELL, V15, P37, DOI 10.1016/j.stem.2014.04.016; Benayoun BA, 2015, NAT REV MOL CELL BIO, V16, P593, DOI 10.1038/nrm4048; de Jesus BB, 2012, EMBO MOL MED, V4, P691, DOI 10.1002/emmm.201200245; Bonkowski MS, 2016, NAT REV MOL CELL BIO, V17, P679, DOI 10.1038/nrm.2016.93; Brack AS, 2008, CELL STEM CELL, V2, P50, DOI 10.1016/j.stem.2007.10.006; Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090; Brady JJ, 2013, NAT CELL BIOL, V15, P1244, DOI 10.1038/ncb2835; Brandhorst S, 2015, CELL METAB, V22, P86, DOI 10.1016/j.cmet.2015.05.012; Burd CE, 2013, CELL, V152, P340, DOI 10.1016/j.cell.2012.12.010; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Sepulveda JC, 2014, STEM CELLS, V32, P1865, DOI 10.1002/stem.1654; Carrasco-Garcia E, 2015, AGING CELL, V14, P710, DOI 10.1111/acel.12343; Castellano JM, 2017, NATURE, V544, P488, DOI 10.1038/nature22067; Cerletti M, 2012, CELL STEM CELL, V10, P515, DOI 10.1016/j.stem.2012.04.002; Chandra T, 2012, MOL CELL, V47, P203, DOI 10.1016/j.molcel.2012.06.010; Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010; Chen C, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000559; Chen TT, 2011, AGING CELL, V10, P908, DOI 10.1111/j.1474-9726.2011.00722.x; Cheng CW, 2017, CELL, V168, P775, DOI 10.1016/j.cell.2017.01.040; Chiche A, 2017, CELL STEM CELL, V20, P407, DOI 10.1016/j.stem.2016.11.020; Childs BG, 2016, SCIENCE, V354, P472, DOI 10.1126/science.aaf6659; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Conboy IM, 2015, AGING-US, V7, P754, DOI 10.18632/aging.100819; Conboy MJ, 2013, AGING CELL, V12, P525, DOI 10.1111/acel.12065; Conti B, 2006, SCIENCE, V314, P825, DOI 10.1126/science.1132191; Copeland JM, 2009, CURR BIOL, V19, P1591, DOI 10.1016/j.cub.2009.08.016; de Cabo R, 2014, CELL, V157, P1515, DOI 10.1016/j.cell.2014.05.031; de Keizer PLJ, 2017, TRENDS MOL MED, V23, P6, DOI 10.1016/j.molmed.2016.11.006; Demaria M, 2014, DEV CELL, V31, P722, DOI 10.1016/j.devcel.2014.11.012; Demidenko ZN, 2009, CELL CYCLE, V8, P1888, DOI 10.4161/cc.8.12.8606; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Tran D, 2014, AGING CELL, V13, P669, DOI 10.1111/acel.12219; Edwards C, 2014, AGING-US, V6, P621, DOI 10.18632/aging.100683; Egerman MA, 2015, CELL METAB, V22, P164, DOI 10.1016/j.cmet.2015.05.010; Elabd C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5082; Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385; Fatt M, 2015, STEM CELL REP, V5, P988, DOI 10.1016/j.stemcr.2015.10.014; Fontana L, 2018, AGING CELL, V17, DOI 10.1111/acel.12746; Foran E, 2010, MOL CANCER RES, V8, P471, DOI 10.1158/1541-7786.MCR-09-0496; Franceschi C, 2000, ANN NY ACAD SCI, V908, P244; Freitas-Rodriguez S, 2016, ONCOTARGET, V7, P55951, DOI 10.18632/oncotarget.11096; Fuhrmann-Stroissnigg H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00314-z; Gandini S, 2014, CANCER PREV RES, V7, P867, DOI 10.1158/1940-6207.CAPR-13-0424; Garcia-Prat L, 2016, NATURE, V529, P37, DOI 10.1038/nature16187; Gasparini L, 2004, J NEUROCHEM, V91, P521, DOI 10.1111/j.1471-4159.2004.02743.x; Gems D, 2013, ANNU REV PHYSIOL, V75, P621, DOI 10.1146/annurev-physiol-030212-183712; Gewirtz DA, 2013, AUTOPHAGY, V9, P808, DOI 10.4161/auto.23922; Gocmez SS, 2016, NEUROBIOL LEARN MEM, V131, P131, DOI 10.1016/j.nlm.2016.03.022; Gonzalez-Navarro H, 2013, AGING CELL, V12, P102, DOI 10.1111/acel.12023; Hahn O, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1187-1; Hall BM, 2017, AGING-US, V9, P1867, DOI 10.18632/aging.101268; Han XJ, 2016, AGING CELL, V15, P416, DOI 10.1111/acel.12446; Hannum G, 2013, MOL CELL, V49, P359, DOI 10.1016/j.molcel.2012.10.016; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Hernandez-Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001; Hernandez-Segura A, 2017, CURR BIOL, V27, P2652, DOI 10.1016/j.cub.2017.07.033; Herranz N, 2015, NAT CELL BIOL, V17, P1205, DOI 10.1038/ncb3225; Ho TT, 2017, NATURE, V543, P205, DOI 10.1038/nature21388; Hodge DR, 2001, J BIOL CHEM, V276, P39508, DOI 10.1074/jbc.C100343200; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115; Hundal RS, 2002, J CLIN INVEST, V109, P1321, DOI 10.1172/JCI200214955; Iglesias-Bartolome R, 2012, CELL STEM CELL, V11, P401, DOI 10.1016/j.stem.2012.06.007; Imai S, 2014, TRENDS CELL BIOL, V24, P464, DOI 10.1016/j.tcb.2014.04.002; Ingram DK, 2017, AGEING RES REV, V39, P15, DOI 10.1016/j.arr.2017.05.008; Israel MA, 2012, NATURE, V482, P216, DOI 10.1038/nature10821; Jeon OH, 2017, NAT MED, V23, P775, DOI 10.1038/nm.4324; Jeyapalan JC, 2007, MECH AGEING DEV, V128, P36, DOI 10.1016/j.mad.2006.11.008; Johnson SC, 2013, NATURE, V493, P338, DOI 10.1038/nature11861; Jones JE, 2018, CELL REP, V22, P1522, DOI 10.1016/j.celrep.2018.01.044; Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612; Kapahi P, 2017, AGEING RES REV, V39, P3, DOI 10.1016/j.arr.2016.12.005; Katsimpardi L, 2014, SCIENCE, V344, P630, DOI 10.1126/science.1251141; Kennedy BK, 2014, CELL, V159, P708, DOI 10.1016/j.cell.2014.10.039; Kenyon CJ, 2010, NATURE, V464, P504, DOI 10.1038/nature08980; Kim CH, 2016, AGING CELL, V15, P1074, DOI 10.1111/acel.12513; Kim EN, 2018, AGING-US, V10, P83, DOI 10.18632/aging.101361; Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049; Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Lapasset L, 2011, GENE DEV, V25, P2248, DOI 10.1101/gad.173922.111; Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001; Lee J, 2012, CELL, V151, P547, DOI 10.1016/j.cell.2012.09.034; Lee SJ, 2009, CURR BIOL, V19, P715, DOI 10.1016/j.cub.2009.03.041; Leeman DS, 2018, SCIENCE, V359, P1277, DOI 10.1126/science.aag3048; Li H, 2009, NATURE, V460, P1136, DOI 10.1038/nature08290; Linehan E, 2015, EUR J MICROBIOL IMMU, V5, P14, DOI [10.1556/EuJMI-D-14-00035, 10.1556/EUJMI-D-14-00035]; Liu GH, 2011, NATURE, V472, P221, DOI 10.1038/nature09879; Liu ML, 2010, J BIOL CHEM, V285, P36387, DOI 10.1074/jbc.M110.169284; Liu XX, 2005, GENE DEV, V19, P2424, DOI 10.1101/gad.1352905; Liu Y, 2009, AGING CELL, V8, P439, DOI 10.1111/j.1474-9726.2009.00489.x; Lo Sardo V, 2017, NAT BIOTECHNOL, V35, P69, DOI 10.1038/nbt.3749; Loffredo FS, 2013, CELL, V153, P828, DOI 10.1016/j.cell.2013.04.015; Longo VD, 2015, AGING CELL, V14, P497, DOI 10.1111/acel.12338; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; Luo L, 2013, EXP GERONTOL, V48, P427, DOI 10.1016/j.exger.2013.02.009; Mahmoudi S, 2016, CELL, V167, P1672, DOI 10.1016/j.cell.2016.11.050; Mahmoudi S, 2012, CURR OPIN CELL BIOL, V24, P744, DOI 10.1016/j.ceb.2012.10.004; Mak SS, 2006, DEV BIOL, V291, P144, DOI 10.1016/j.ydbio.2005.12.025; Mannick JB, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009892; Martin-Montalvo A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3192; Matheu A, 2009, AGING CELL, V8, P152, DOI 10.1111/j.1474-9726.2009.00458.x; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; McShea A, 1997, AM J PATHOL, V150, P1933; Meidenbauer JJ, 2014, NUTR METAB, V11, DOI 10.1186/1743-7075-11-23; Mertens J, 2015, CELL STEM CELL, V17, P705, DOI 10.1016/j.stem.2015.09.001; Michaeli TF, 2015, AGING CELL, V14, P698, DOI 10.1111/acel.12286; Miller JD, 2013, CELL STEM CELL, V13, P691, DOI 10.1016/j.stem.2013.11.006; Mosteiro L, 2018, AGING CELL, V17, DOI 10.1111/acel.12711; Mosteiro L, 2016, SCIENCE, V354, DOI 10.1126/science.aaf4445; Munoz-Espin D, 2013, CELL, V155, P1104, DOI 10.1016/j.cell.2013.10.019; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Neff F, 2013, J CLIN INVEST, V123, P3272, DOI 10.1172/JCI67674; Nelson G, 2012, AGING CELL, V11, P345, DOI 10.1111/j.1474-9726.2012.00795.x; Newman JC, 2017, CELL METAB, V26, P547, DOI 10.1016/j.cmet.2017.08.004; Newman JC, 2017, ANNU REV NUTR, V37, P51, DOI 10.1146/annurev-nutr-071816-064916; Ocampo A, 2016, CELL, V167, P1719, DOI 10.1016/j.cell.2016.11.052; Ogrodnik M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15691; Ohnishi K, 2014, CELL, V156, P663, DOI 10.1016/j.cell.2014.01.005; Owusu-Ansah E, 2013, CELL, V155, P699, DOI 10.1016/j.cell.2013.09.021; Papp B, 2013, CELL, V152, P1324, DOI 10.1016/j.cell.2013.02.043; Passos JF, 2007, PLOS BIOL, V5, P1138, DOI 10.1371/journal.pbio.0050110; Passos JF, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.5; Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011; Poggioli T, 2016, CIRC RES, V118, P29, DOI 10.1161/CIRCRESAHA.115.307521; Polo JM, 2012, CELL, V151, P1617, DOI 10.1016/j.cell.2012.11.039; Poulos MG, 2017, J CLIN INVEST, V127, P4163, DOI 10.1172/JCI93940; Prigione A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027352; Rando TA, 2012, CELL, V148, P46, DOI 10.1016/j.cell.2012.01.003; Rebo J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13363; Rippe C, 2010, AGING CELL, V9, P304, DOI 10.1111/j.1474-9726.2010.00557.x; Ritschka B, 2017, GENE DEV, V31, P172, DOI 10.1101/gad.290635.116; Roberts MN, 2017, CELL METAB, V26, P539, DOI 10.1016/j.cmet.2017.08.005; Roos CM, 2016, AGING CELL, V15, P973, DOI 10.1111/acel.12458; Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030; Ruckh JM, 2012, CELL STEM CELL, V10, P96, DOI 10.1016/j.stem.2011.11.019; Schafer MJ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14532; Schoenwaelder SM, 2011, BLOOD, V118, P1663, DOI 10.1182/blood-2011-04-347849; Sharpless NE, 2015, NAT REV CANCER, V15, P397, DOI 10.1038/nrc3960; Shytikov D, 2014, BIORESEARCH OPEN ACC, V3, P226, DOI 10.1089/biores.2014.0043; Singh M, 2016, J FRALITY AGING, V5, P204, DOI 10.14283/jfa.2016.112; Sinha M, 2014, SCIENCE, V344, P649, DOI 10.1126/science.1251152; Smith LK, 2015, NAT MED, V21, P932, DOI 10.1038/nm.3898; Smith P, 2017, ELIFE, V6, DOI 10.7554/eLife.27014; Smith SC, 2015, CIRC RES, V117, P926, DOI 10.1161/CIRCRESAHA.115.307527; Soria-Valles C, 2015, NAT CELL BIOL, V17, P1004, DOI 10.1038/ncb3207; Sousa-Victor P, 2014, NATURE, V506, P316, DOI 10.1038/nature13013; Storer M, 2013, CELL, V155, P1119, DOI 10.1016/j.cell.2013.10.041; Strong R, 2008, AGING CELL, V7, P641, DOI 10.1111/j.1474-9726.2008.00414.x; Suhr S. T., 2010, PLOS ONE, V5, DOI DOI 10.1371/JOURNAL.PONE.0014095; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; Valdez G, 2010, P NATL ACAD SCI USA, V107, P14863, DOI 10.1073/pnas.1002220107; Valenzano DR, 2006, AGING CELL, V5, P275, DOI 10.1111/j.1474-9726.2006.00212.x; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005; Villanueva MT, 2017, NAT REV DRUG DISCOV, V16, P456, DOI 10.1038/nrd.2017.123; Villeda SA, 2014, NAT MED, V20, P659, DOI 10.1038/nm.3569; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357; Wan QL, 2013, EXP GERONTOL, V48, P499, DOI 10.1016/j.exger.2013.02.020; Wang R, 2017, AGING CELL, V16, P564, DOI 10.1111/acel.12587; Wei M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai8700; Wiley CD, 2017, AGING CELL, V16, P1043, DOI 10.1111/acel.12632; Wiley CD, 2016, CELL METAB, V23, P303, DOI 10.1016/j.cmet.2015.11.011; Wilson WH, 2010, LANCET ONCOL, V11, P1149, DOI 10.1016/S1470-2045(10)70261-8; Wu YS, 2015, NAT CELL BIOL, V17, P715, DOI 10.1038/ncb3172; Xu M, 2018, NAT MED, V24, P1246, DOI 10.1038/s41591-018-0092-9; Xu M, 2015, ELIFE, V4, DOI 10.7554/eLife.12997; Xu M, 2015, P NATL ACAD SCI USA, V112, pE6301, DOI 10.1073/pnas.1515386112; Yosef R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11190; Youm YH, 2013, CELL METAB, V18, P519, DOI 10.1016/j.cmet.2013.09.010; Yousef H, 2015, ONCOTARGET, V6, P11959, DOI 10.18632/oncotarget.3851; Zhang B, 2015, CELL REP, V11, P1414, DOI 10.1016/j.celrep.2015.04.066; Zhang G, 2013, NATURE, V497, P211, DOI 10.1038/nature12143; Zhang H, 2007, CELL DEATH DIFFER, V14, P943, DOI 10.1038/sj.cdd.4402081; Zhang YL, 2017, NATURE, V548, P52, DOI 10.1038/nature23282; Zhu Y, 2016, AGING CELL, V15, P428, DOI 10.1111/acel.12445; Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	188	73	72	1	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2019	21	1					32	43		10.1038/s41556-018-0206-0	http://dx.doi.org/10.1038/s41556-018-0206-0			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	HG1IY	30602763	Green Accepted			2023-01-03	WOS:000454708400006
J	Musa, KI; Keegan, TJ				Musa, Kamarul Imran; Keegan, Thomas J.			The change of Barthel Index scores from the time of discharge until 3-month post- discharge among acute stroke patients in Malaysia: A random intercept model	PLOS ONE			English	Article							MODIFIED RANKIN SCALE; ISCHEMIC-STROKE; FUNCTIONAL RECOVERY; OUTCOME MEASURES; RISK-FACTORS; AGE; IMPACT; REHABILITATION; DISABILITY; TELEPHONE	Background Acute stroke results in functional disability measurable using the well-known Barthel Index. The objectives of the study are to describe the change in the Barthel Index score and to model the prognostic factors for Barthel Index change from discharge up to 3 months post-discharge using the random intercept model among patients with acute first ever stroke in Kelantan, Malaysia. Methods A total 98 in-hospital first ever acute stroke patients were recruited, and their Barthel Index scores were measured at the time of discharge, at 1 month and 3 months post-discharge. The Barthel Index was scored through telephone interviews. We employed the random intercept model from linear mixed effect regression to model the change of Barthel Index scores during the three months intervals. The prognostic factors included in the model were acute stroke subtypes, age, sex and time of measurement (at discharge, at 1 month and at 3 month post-discharge). Results The crude mean Barthel Index scores showed an increased trend. The crude mean Barthel Index at the time of discharge, at 1-month post-discharge and 3 months post-discharge were 35.1 (SD = 39.4), 64.4 (SD = 39.5) and 68.8 (SD = 38.9) respectively. Over the same period, the adjusted mean Barthel Index scores estimated from the linear mixed effect model increased from 39.6 to 66.9 to 73.2. The adjusted mean Barthel Index scores decreased as the age increased, and haemorrhagic stroke patients had lower adjusted mean Barthel Index scores compared to the ischaemic stroke patients. Conclusion Overall, the crude and adjusted mean Barthel Index scores increase from the time of discharge up to 3-month post-discharge among acute stroke patients. Time after discharge, age and stroke subtypes are the significant prognostic factors for Barthel Index score changes over the period of 3 months.	[Musa, Kamarul Imran] Univ Sains Malaysia, Sch Med Sci, Dept Community Med, Kbg Kerian, Kelantan, Malaysia; [Keegan, Thomas J.] Univ Lancaster, CHICAS, Lancaster Med Sch, Lancaster, England	Universiti Sains Malaysia; Lancaster University	Musa, KI (corresponding author), Univ Sains Malaysia, Sch Med Sci, Dept Community Med, Kbg Kerian, Kelantan, Malaysia.	drkamarul@usm.my	Musa, Kamarul Imran/N-3198-2015	Musa, Kamarul Imran/0000-0002-3708-0628; Keegan, Thomas/0000-0003-3691-953X	Universiti Sains Malaysia (USM) Short-term Grant [304/PPSP/61312028]	Universiti Sains Malaysia (USM) Short-term Grant	This study and KIM were funded by Universiti Sains Malaysia (USM) Short-term Grant (304/PPSP/61312028). USM had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Saeed AH, 2016, DIABETES CARE, V39, P823, DOI 10.2337/dc15-0991; Asuzu D, 2015, NEUROCRIT CARE, V23, P172, DOI 10.1007/s12028-015-0154-5; Balu S, 2009, CURR MED RES OPIN, V25, P2765, DOI 10.1185/03007990903297741; Berge E, 2002, CEREBROVASC DIS, V13, P73, DOI 10.1159/000047752; Bruno A, 2010, STROKE, V41, P1048, DOI 10.1161/STROKEAHA.109.571562; Carr EC., 2001, J RES NURSING, V6, P511, DOI [DOI 10.1177/136140960100600107, 10.1177/136140960100600107]; Chindaprasirt Jarin, 2013, ISRN Neurol, V2013, P710681, DOI 10.1155/2013/710681; Cioncoloni D, 2012, NEUROREHABILITATION, V30, P315, DOI 10.3233/NRE-2012-0761; Coelho BP, 2014, NEUROSCI RES, V88, P67, DOI 10.1016/j.neures.2014.08.007; Corbetta M, 2015, NEURON, V85, P927, DOI 10.1016/j.neuron.2015.02.027; Della Pietra GL, 2011, STROKE, V42, P2077, DOI 10.1161/STROKEAHA.111.613521; Dhamoon MS, 2017, JAMA NEUROL, V74, P1439, DOI 10.1001/jamaneurol.2017.2802; Di Carlo A, 2006, J NEUROL SCI, V244, P143, DOI 10.1016/j.jns.2006.01.016; Diggle P., 2002, J R STAT SOC, DOI DOI 10.2307/2983303; Draca S, 2012, NEUROREHABILITATION, V30, P247, DOI 10.3233/NRE-2012-0752; Duffy L, 2013, STROKE, V44, P462, DOI 10.1161/STROKEAHA.112.678615; Ervasti J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017910; Fabiana NL, 2016, J CLIN NEUROSCI, V33, P269, DOI 10.1016/j.jocn.2016.04.013; Freundlieb N, 2015, RESTOR NEUROL NEUROS, V33, P221, DOI 10.3233/RNN-140454; Frontera JA, 2015, J NEUROL NEUROSUR PS, V86, P71, DOI 10.1136/jnnp-2013-307313; Go S., 2008, ALZHEIMERS DEMENT, V4, pT452; Gunathilake R, 2014, INT J STROKE, V9, pE36, DOI 10.1111/ijs.12347; Harrison JK, 2013, CLIN INTERV AGING, V8, P201, DOI 10.2147/CIA.S32405; Hartigan Irene, 2011, Appl Nurs Res, V24, pe1, DOI 10.1016/j.apnr.2009.11.002; Hoffmann T, 2010, TOP STROKE REHABIL, V17, P119, DOI 10.1310/tsr1702-119; Janssen PM, 2010, CEREBROVASC DIS, V29, P137, DOI 10.1159/000262309; Khan MS, 2012, INT NANO LETT, V2, DOI 10.1186/2228-5326-2-7; Kim JY, 2011, FOOD CHEM TOXICOL, V49, P2899, DOI 10.1016/j.fct.2011.08.001; Kim Y, 2018, MOL NEUROBIOL, V55, P7153, DOI 10.1007/s12035-018-0910-6; Knoflach M, 2012, NEUROLOGY, V78, P279, DOI 10.1212/WNL.0b013e31824367ab; Kong KH, 2014, NEUROREHABILITATION, V35, P221, DOI 10.3233/NRE-141110; KORNERBITENSKY N, 1995, AM J PHYS MED REHAB, V74, P9, DOI 10.1097/00002060-199501000-00003; Kwakkel G, 2013, INT J STROKE, V8, P25, DOI 10.1111/j.1747-4949.2012.00967.x; Li F, 2014, J NEUROL SCI, V341, P128, DOI 10.1016/j.jns.2014.04.021; Lindmark B, 1988, Scand J Rehabil Med Suppl, V21, P1; Lisabeth LD, 2014, STROKE, V45, P1096, DOI 10.1161/STROKEAHA.113.003912; McNaughton H, 2001, CLIN REHABIL, V15, P422, DOI 10.1191/026921501678310225; Nakao S, 2010, J MED INVESTIG, V57, P81, DOI 10.2152/jmi.57.81; O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3; Paci M, 2011, EUR J PHYS REHAB MED, V47, P19; Pinheiro J., NLME LINEAR NONLINEA; Quinn TJ, 2009, INT J STROKE, V4, P200, DOI 10.1111/j.1747-4949.2009.00271.x; Quinn TJ, 2011, STROKE, V42, P1146, DOI 10.1161/STROKEAHA.110.598540; Royston P, 1999, INT J EPIDEMIOL, V28, P964, DOI 10.1093/ije/28.5.964; Sangha H, 2005, INT J REHABIL RES, V28, P135, DOI 10.1097/00004356-200506000-00006; Sarker SJ, 2012, STROKE, V43, P1362, DOI 10.1161/STROKEAHA.111.645234; Sharrief AZ, 2017, J STROKE CEREBROVASC, V26, P2686, DOI 10.1016/j.jstrokecerebrovasdis.2017.06.039; Sohrabji F, 2013, NEUROCHEM INT, V63, P291, DOI 10.1016/j.neuint.2013.06.013; Tsang RCC, 2014, PHYSIOTHER THEOR PR, V30, P353, DOI 10.3109/09593985.2013.876563; Tveiten A, 2014, ACTA NEUROL SCAND, V129, P269, DOI 10.1111/ane.12185; van Almenkerk S, 2013, DISABIL REHABIL, V35, P1774, DOI 10.3109/09638288.2012.756941; Van Peppen RPS, 2004, CLIN REHABIL, V18, P833, DOI 10.1191/0269215504cr843oa; Volpato S, 2001, GERONTOLOGY, V47, P36, DOI 10.1159/000052768; von Vogelsang AC, 2015, WORLD NEUROSURG, V83, P1090, DOI 10.1016/j.wneu.2014.12.027; Wong ES, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-175	55	19	20	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2018	13	12							e0208594	10.1371/journal.pone.0208594	http://dx.doi.org/10.1371/journal.pone.0208594			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HF0HP	30571691	Green Published, Green Submitted, gold			2023-01-03	WOS:000453841700016
J	Rucinski, KB; Powers, KA; Schwartz, SR; Pence, BW; Chi, BH; Black, V; Rees, H; Pettifor, AE				Rucinski, Katherine B.; Powers, Kimberly A.; Schwartz, Sheree R.; Pence, Brian W.; Chi, Benjamin H.; Black, Vivian; Rees, Helen; Pettifor, Audrey E.			Longitudinal patterns of unmet need for contraception among women living with HIV on antiretroviral therapy in South Africa	PLOS ONE			English	Article							FAMILY-PLANNING-SERVICES; PREGNANCY INTENTIONS; POSITIVE WOMEN; CARE; FERTILITY; INTEGRATION; COHORT; KENYA	Objectives Fertility intentions and contraceptive use are often not assessed in the context of clinical HIV care, representing a possible programming gap if women's family planning needs change over time. We aimed to identify longitudinal patterns of unmet need for contraception over a 12-month period among women living with HIV taking antiretroviral therapy (ART). Study design 850 non-pregnant, HIV-positive women aged 18-35 on or initiating ART in Johannesburg, South Africa, were enrolled into a prospective cohort study in 2009-2010. Fertility intentions and contraceptive use were assessed during routine HIV care visits via an interviewer-administered questionnaire, and women were referred for on-site contraceptive counseling. We used group-based trajectory modeling to identify patterns of unmet need for contraception over 12 months, first in the entire population and then in a subset of recent ART initiators. Results In the full population we identified four patterns of unmet need for contraception over one year. Half of the enrolled women were predicted to have a consistently high probability of unmet need, 22.9% a consistently low probability, 16.7% a decreasing probability, and 10.4% an increasing probability over time. Contraceptive method discontinuation and rapidly changing fertility intentions were the primary drivers of changing (increasing or decreasing) unmet need over follow-up. Results were similar in recent ART initiators. Conclusions Half of women were estimated to have a high probability of unmet need that persisted over time, and more than a quarter were estimated to experience patterns of changing unmet need over 12 months. Family planning needs should be assessed more regularly in HIV-positive women to prevent unintended pregnancies and support safer conception among women trying to conceive.	[Rucinski, Katherine B.; Powers, Kimberly A.; Pence, Brian W.; Pettifor, Audrey E.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27515 USA; [Rucinski, Katherine B.; Schwartz, Sheree R.; Black, Vivian; Rees, Helen] Univ Witwatersrand, Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa; [Rucinski, Katherine B.; Schwartz, Sheree R.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; [Chi, Benjamin H.] Univ N Carolina, Sch Med, Dept Obstet & Gynecol, Chapel Hill, NC 27515 USA; [Black, Vivian] Univ Witwatersrand, Fac Hlth Sci, Clin Microbiol & Infect Dis, Johannesburg, South Africa	University of North Carolina; University of North Carolina Chapel Hill; University of Witwatersrand; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Witwatersrand	Rucinski, KB (corresponding author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27515 USA.; Rucinski, KB (corresponding author), Univ Witwatersrand, Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa.; Rucinski, KB (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA.	rucinski@jhu.edu		Pettifor, Audrey/0000-0002-3387-0817; Rucinski, Katherine/0000-0002-9858-5953; Rees, Helen/0000-0003-1442-6734	PEPFAR (President's Emergency Plan For AIDS Relief); United States Agency for International Development; United States Centers for Disease Control and Prevention (CDC) public health dissertation grant [R36 PS001584]; Society of Family Planning Research Fund [SFPRF11-T8]; NIH/NIAID [K24 AI120796, T32 AI102623]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P2CHD050924] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI102623, K24AI120796, P30AI050410] Funding Source: NIH RePORTER	PEPFAR (President's Emergency Plan For AIDS Relief); United States Agency for International Development(United States Agency for International Development (USAID)); United States Centers for Disease Control and Prevention (CDC) public health dissertation grant; Society of Family Planning Research Fund; NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research was conducted in clinics supported by PEPFAR (President's Emergency Plan For AIDS Relief) and the United States Agency for International Development. The original parent study received funding from the United States Centers for Disease Control and Prevention (CDC) public health dissertation grant R36 PS001584 to SRS. KBR was supported by an award through the Society of Family Planning Research Fund (SFPRF11-T8) and through NIH/NIAID T32 AI102623. BHC was supported through NIH/NIAID (K24 AI120796). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bachanas P, 2016, AIDS BEHAV, V20, P2110, DOI 10.1007/s10461-016-1349-2; Bradley SarahE.K., 2012, DHS ANAL STUDIES; Burgos-Soto J, 2014, JAIDS-J ACQ IMM DEF, V67, pE45, DOI 10.1097/QAI.0000000000000279; Chersich MF, 2017, SAMJ S AFR MED J, V107, P307, DOI 10.7196/SAMJ.2017.v107i4.12141; Cleland J, 2012, LANCET, V380, P149, DOI 10.1016/S0140-6736(12)60609-6; Cohen CR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172992; Cooper D, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1577-9; Cooper D, 2009, AIDS BEHAV, V13, pS38, DOI 10.1007/s10461-009-9550-1; Gray RH, 1998, LANCET, V351, P98, DOI 10.1016/S0140-6736(97)09381-1; Grossman D, 2013, AIDS, V27, pS77, DOI 10.1097/QAD.0000000000000035; Haberlen SA, 2017, STUD FAMILY PLANN, V48, P153, DOI 10.1111/sifp.12018; Haddad L, 2013, AIDS, V27, pS93, DOI 10.1097/QAD.0000000000000039; Haider TL, 2013, INT Q COMMUNITY HEAL, V33, P403, DOI 10.2190/IQ.33.4.g; Kaida A, 2008, AIDS CARE, V20, P21, DOI 10.1080/09540120701426540; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; Kosgei RJ, 2011, JAIDS-J ACQ IMM DEF, V58, pE121, DOI 10.1097/QAI.0b013e318237ca80; Loomba Foundation, 2015, GLOB WID REP 2015 GL; Lopez LM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010243.pub2; Machiyama K, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-016-0268-z; Maier M, 2009, AIDS BEHAV, V13, pS28, DOI 10.1007/s10461-008-9371-7; Marlow HM, 2014, HEALTH CARE WOMEN IN, V35, P175, DOI 10.1080/07399332.2013.815753; Mumford SL, 2016, FERTIL STERIL, V106, P1453, DOI 10.1016/j.fertnstert.2016.07.1067; Myer L, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000229; Nagin D.S., 2005, GROUP BASED MODELING; Nagin DS, 2010, ANNU REV CLIN PSYCHO, V6, P109, DOI 10.1146/annurev.clinpsy.121208.131413; Republic of South Africa Department of Health, 2014, S AFR NAT CONTR FERT; Republic of South Africa Department of Health, 2016, IMPL UN TEST TREAT S; Reynolds HW, 2008, SEX TRANSM INFECT, V84, pII49, DOI 10.1136/sti.2008.030049; Robinson JA, 2012, INFECT DIS OBSTET GY, V2012, DOI DOI 10.1155/2012/890160; Rocca CH, 2017, POP ASS AM ANN M CHI; Sarnquist CC, 2013, CURR HIV RES, V11, P160, DOI 10.2174/1570162X11311020008; Schwartz SR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036039; Schwartz SR, 2012, AIDS BEHAV, V16, P69, DOI 10.1007/s10461-011-9981-3; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; Shade SB, 2016, AIDS S1, V27, pS87; Singh S, 2012, ADDING IT COSTS BENE; Steiner RJ, 2016, J ACQUIR IMMUNE DEFI; Tang JH, 2016, INFECT DIS OBSTET GY; Todd CS, 2018, CONTRACEPTION; Tweya H, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1383724; Wilson KS, 2018, JAIDS-J ACQ IMM DEF, V78, P276, DOI 10.1097/QAI.0000000000001680; Yotebieng M, 2015, PAN AFR MED J, V20, DOI 10.11604/pamj.2015.20.235.5859; Zash R, 2018, NEW ENGL J MED, V379, P979, DOI 10.1056/NEJMc1807653	43	10	10	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2018	13	12							e0209114	10.1371/journal.pone.0209114	http://dx.doi.org/10.1371/journal.pone.0209114			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF0HP	30571702	Green Published, Green Submitted, gold			2023-01-03	WOS:000453841700038
J	Chen, SX; Sandford, S; Kirman, JR; Rehm, BHA				Chen, Shuxiong; Sandford, Sarah; Kirman, Joanna R.; Rehm, Bernd H. A.			Innovative antigen carrier system for the development of tuberculosis vaccines	FASEB JOURNAL			English	Article						polyester particle; particulate vaccine; bioengineering; Mycobacterium tuberculosis	PARTICLE-SIZE; POLYHYDROXYALKANOATE GRANULES; EFFICIENT PROTECTION; POLYESTER INCLUSIONS; BOVINE TUBERCULOSIS; IMMUNE-RESPONSE; DENDRITIC CELLS; T-CELLS; SURFACE; VACCINATION	A major obstacle to tuberculosis (TB)-subunit-vaccine development has been the induction of inadequate levels of protective immunity due to the limited breadth of antigen in vaccine preparations. In this study, immunogenic mycobacterial fusion peptides Ag85B-TB10.4 and Ag85B-TB10.4-Rv2660c were covalently displayed on the surface of self-assembled polyester particles. This study investigated whether polyester particles displaying mycobacterial antigens could provide augmented immunogenicity (i.e., offer an innovative vaccine formulation) when compared with free soluble antigens. Herein, polyester particle-based particulate vaccines were produced in an endotoxin-free Escherichia coli strain and emulsified with the adjuvant dimethyl dioctadecyl ammonium bromide. C57BL/6 mice were used to study the immunogenicity of formulated particulate vaccines. The result of humoral immunity showed the antibodies only interacted with target antigens and not with PhaC and the background proteins of the production host. The analysis of T helper 1 cellular immunity indicated that a relatively strong production of cellular immunity biomarkers, IFN-gamma and IL-17A cytokines, was induced by particulate vaccines when compared with the respective soluble controls. This study demonstrated that polyester particles have the potential to perform as a mycobacterial antigen-delivery agent to induce augmented antigen-specific immune responses in contrast to free soluble vaccines.-Chen, S., Sandford, S., Kirman, J. R., Rehm, B. H. A. Innovative antigen carrier system for the development of tuberculosis vaccines.	[Chen, Shuxiong] Massey Univ Manawatu, Inst Fundamental Sci, Palmerston North, New Zealand; [Sandford, Sarah; Kirman, Joanna R.] Univ Otago, Microbiol & Immunol Dept, Dunedin, New Zealand; [Rehm, Bernd H. A.] Griffith Univ, Ctr Cell Factories & Biopolymers, Griffith Inst Drug Discovery, Nathan Campus,Don Young Rd, Brisbane, Qld 4111, Australia	Massey University; University of Otago; Griffith University	Rehm, BHA (corresponding author), Griffith Univ, Ctr Cell Factories & Biopolymers, Griffith Inst Drug Discovery, Nathan Campus,Don Young Rd, Brisbane, Qld 4111, Australia.	b.rehm@griffith.edu.au	Chen, Shuxiong/ABE-3430-2020	Chen, Shuxiong/0000-0002-5275-0757; Kirman, Joanna/0000-0002-4802-7048; Sandford, Sarah/0000-0002-2901-4516	Massey University (Palmerston North, New Zealand); Griffith University (Brisbane, QLD, Australia)	Massey University (Palmerston North, New Zealand); Griffith University (Brisbane, QLD, Australia)	The authors thank research technician Michelle Wilson for the great support and advice with flow cytometry. The authors acknowledge the Manawatu Microscopy and Imaging Centre for preparation and development of transmission electron microscopic imaging. The authors are grateful to technicians at the University of Otago Department of Pathology for animal husbandry. Funding was provided by Massey University (Palmerston North, New Zealand) and Griffith University (Brisbane, QLD, Australia). The authors declare no conflicts of interest.	Aagaard C, 2011, NAT MED, V17, P189, DOI 10.1038/nm.2285; Amara AA, 2003, BIOCHEM J, V374, P413, DOI 10.1042/BJ20030431; Andersen P, 2005, NAT REV MICROBIOL, V3, P656, DOI 10.1038/nrmicro1211; Anderson L., 2018, GLOBAL TUBERCULOSIS; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bhatt K, 2015, CLIN VACCINE IMMUNOL, V22, P258, DOI 10.1128/CVI.00721-14; Billeskov R, 2007, J IMMUNOL, V179, P3973, DOI 10.4049/jimmunol.179.6.3973; Billeskov R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072185; Billeskov R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039909; Blatchford PA, 2012, BIOTECHNOL BIOENG, V109, P1101, DOI 10.1002/bit.24402; Burel JG, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.87499; Campisano A, 2008, J BIOTECHNOL, V133, P442, DOI 10.1016/j.jbiotec.2007.11.007; Chan J, 2014, SEMIN IMMUNOL, V26, P588, DOI 10.1016/j.smim.2014.10.005; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; Chen SX, 2018, ADV BIOSYST, V2, DOI 10.1002/adbi.201800118; Chen SX, 2014, APPL ENVIRON MICROB, V80, P2526, DOI 10.1128/AEM.04168-13; Chung CW, 2003, INT J BIOL MACROMOL, V32, P17, DOI 10.1016/S0141-8130(03)00020-5; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; De Temmerman ML, 2011, DRUG DISCOV TODAY, V16, P569, DOI 10.1016/j.drudis.2011.04.006; Deng YH, 2015, INFECT DIS-NOR, V47, P168, DOI 10.3109/00365548.2014.982167; Dey AK, 2014, EXPERT REV VACCINES, V13, P671, DOI 10.1586/14760584.2014.907528; Dietrich J, 2005, J IMMUNOL, V174, P6332, DOI 10.4049/jimmunol.174.10.6332; Fifis T, 2004, J IMMUNOL, V173, P3148, DOI 10.4049/jimmunol.173.5.3148; Foged C, 2005, INT J PHARMACEUT, V298, P315, DOI 10.1016/j.ijpharm.2005.03.035; Fox Christopher B, 2013, Ther Adv Vaccines, V1, P7, DOI 10.1177/2051013613480144; Geldenhuys H, 2015, VACCINE, V33, P3592, DOI 10.1016/j.vaccine.2015.05.036; Gonzalez-Miro M, 2018, ACS BIOMATER SCI ENG, V4, P3413, DOI 10.1021/acsbiomaterials.8b00579; Gonzalez-Miro M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20205-7; Grage K, 2009, BIOMACROMOLECULES, V10, P660, DOI 10.1021/bm801394s; Hazer B, 2007, APPL MICROBIOL BIOT, V74, P1, DOI 10.1007/s00253-006-0732-8; He H, 2015, EUR J CLIN MICROBIOL, V34, P1103, DOI 10.1007/s10096-015-2335-8; Hezayen FF, 2002, ARCH BIOCHEM BIOPHYS, V403, P284, DOI 10.1016/S0003-9861(02)00234-5; Honary S, 2013, TROP J PHARM RES, V12, P255, DOI 10.4314/tjpr.v12i2.19; Jacobs AJ, 2016, TUBERCULOSIS, V101, P102, DOI 10.1016/j.tube.2016.08.001; Jahns AC, 2012, MICROB BIOTECHNOL, V5, P188, DOI 10.1111/j.1751-7915.2011.00293.x; Katare YK, 2005, INT J PHARMACEUT, V301, P149, DOI 10.1016/j.ijpharm.2005.05.028; Kaufmann SHE, 2010, J INTERN MED, V267, P337, DOI 10.1111/j.1365-2796.2010.02216.x; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Lee JW, 2017, APPL ENVIRON MICROB, V83, DOI 10.1128/AEM.02289-16; Legat A, 2010, APPL MICROBIOL BIOT, V87, P1119, DOI 10.1007/s00253-010-2611-6; Lewinsohn DA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01262; Limbach LK, 2005, ENVIRON SCI TECHNOL, V39, P9370, DOI 10.1021/es051043o; Lindenstrom T, 2009, J IMMUNOL, V182, P8047, DOI 10.4049/jimmunol.0801592; Lopez-Sagaseta J, 2016, COMPUT STRUCT BIOTEC, V14, P58, DOI 10.1016/j.csbj.2015.11.001; Magalhaes PO, 2007, J PHARM PHARM SCI, V10, P388; Mottram PL, 2007, MOL PHARMACEUT, V4, P73, DOI 10.1021/mp060096p; Parlane NA, 2016, CLIN VACCINE IMMUNOL, V23, P19, DOI 10.1128/CVI.00462-15; Parlane NA, 2012, CLIN VACCINE IMMUNOL, V19, P37, DOI 10.1128/CVI.05505-11; Parlane NA, 2011, APPL ENVIRON MICROB, V77, P8516, DOI 10.1128/AEM.06420-11; Parlane NA, 2009, APPL ENVIRON MICROB, V75, P7739, DOI 10.1128/AEM.01965-09; Peters V, 2005, FEMS MICROBIOL LETT, V248, P93, DOI 10.1016/j.femsle.2005.05.027; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rehm BHA, 2007, CURR ISSUES MOL BIOL, V9, P41; Rehm BHA, 2017, CURR OPIN BIOTECH, V48, P42, DOI 10.1016/j.copbio.2017.03.018; Rehm BHA, 2003, BIOCHEM J, V376, P15, DOI 10.1042/BJ20031254; Rehm BHA, 2002, BBA-PROTEIN STRUCT M, V1594, P178, DOI 10.1016/S0167-4838(01)00299-0; Reyes PR, 2016, INT J MED MICROBIOL, V306, P624, DOI 10.1016/j.ijmm.2016.10.002; Rubio-Reyes P, 2017, MICROB BIOTECHNOL, V10, P1434, DOI 10.1111/1751-7915.12754; Sambrook Joseph, 1989, MOL CLONING LAB MANU; Snapper CM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00598; Steinmann B, 2010, APPL ENVIRON MICROB, V76, P5563, DOI 10.1128/AEM.00612-10; Thiele L, 2003, PHARM RES-DORDR, V20, P221, DOI 10.1023/A:1022271020390; Umemura M, 2016, IMMUN INFLAMM DIS, V4, P401, DOI 10.1002/iid3.121; Waters WR, 2012, VACCINE, V30, P2611, DOI 10.1016/j.vaccine.2012.02.018; Woodard R. W., 2012, VIABLE NONTOXIC GRAM; Zhang JY, 2018, MAT SCI ENG C-MATER, V86, P144, DOI 10.1016/j.msec.2017.12.035	66	13	13	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2019	33	6					7505	7518		10.1096/fj.201802501RR	http://dx.doi.org/10.1096/fj.201802501RR			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	IJ7YD	30870010	Bronze			2023-01-03	WOS:000476114200067
J	Tsuiki, S; Sasaki, R; Miyaguchi, S; Kojima, S; Saito, K; Inukai, Y; Masaki, M; Otsuru, N; Onishi, H				Tsuiki, Shota; Sasaki, Ryoki; Miyaguchi, Shota; Kojima, Sho; Saito, Kei; Inukai, Yasuto; Masaki, Mitsuhiro; Otsuru, Naofumi; Onishi, Hideaki			The effect of combined transcranial direct current stimulation and peripheral nerve electrical stimulation on corticospinal excitability	PLOS ONE			English	Article							HUMAN MOTOR CORTEX; MAGNETIC STIMULATION; CORTICOMOTOR EXCITABILITY; MODULATION; PLASTICITY; DC; VARIABILITY; MECHANISMS; PARAMETERS; TASK	Transcranial direct current stimulation (tDCS) and peripheral nerve electrical stimulation (PES) can change corticospinal excitability. tDCS can be used to non-invasively modulate the cerebral cortex's excitability by applying weak current to an electrode attached to the head, and the effect varies with the electrode's polarity. Previous studies have reported the effect of combined tDCS and PES on corticospinal excitability; when compared to single stimulation, combined stimulation increases cortical excitability. In contrast, another study reported that the effect of tDCS is attenuated by PES; hence, there is no consensus opinion on the effect on combined stimulation. Therefore, this study aimed to clarify the effect of combined tDCS and PES on corticospinal excitability. In Experiment 1, the combined stimulation of anodal tDCS and PES (anodal tDCS + PES) was performed, and in Experiment 2, a combined stimulation with PES, after cathodal tDCS (PES after cathodal tDCS), was performed using a homeostatic metaplasticity theoretical model. In Experiment 1, anodal tDCS produced a significant increase from baseline in motor-evoked potential (MEP) amplitude 10 min after stimulation, but no significant changes in MEP amplitude were observed with PES or the anodal tDCS + PES condition. Experiment 2 showed a significant decrease in MEP amplitude immediately after cathodal tDCS, and a significant increase in MEP amplitude 15 min after PES, but no significant change in MEP amplitude was observed with sequential PES following cathodal tDCS. In conclusion, our data indicate that PES with anodal tDCS suppressed the effect of tDCS. Also, PES after cathodal tDCS did not induce homeostatic metaplasticity and increase corticospinal excitability.	[Tsuiki, Shota; Sasaki, Ryoki] Niigata Univ Hlth & Welf, Grad Sch, Niigata, Japan; [Tsuiki, Shota; Sasaki, Ryoki; Miyaguchi, Shota; Kojima, Sho; Saito, Kei; Inukai, Yasuto; Masaki, Mitsuhiro; Otsuru, Naofumi; Onishi, Hideaki] Niigata Univ Hlth & Welf, Inst Human Movement & Med Sci, Niigata, Japan; [Tsuiki, Shota] Tochigi Med Assoc, Rehabil Ctr, Shiobara Hot Spring Hosp, Nasushiobara, Tochigi, Japan	Niigata University; Niigata University	Tsuiki, S (corresponding author), Niigata Univ Hlth & Welf, Grad Sch, Niigata, Japan.; Tsuiki, S (corresponding author), Niigata Univ Hlth & Welf, Inst Human Movement & Med Sci, Niigata, Japan.; Tsuiki, S (corresponding author), Tochigi Med Assoc, Rehabil Ctr, Shiobara Hot Spring Hosp, Nasushiobara, Tochigi, Japan.	hpm16007@nuhw.ac.jp		Sasaki, Ryoki/0000-0003-2758-0722	Japan Society for the Promotion of Science [16H03207]; Niigata University of Health and Welfare [H29F02]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Niigata University of Health and Welfare	This work was supported by a Grant-in-Aid for Scientific Research (B) 16H03207 from the Japan Society for the Promotion of Science and a Grant-in-Aid for Scientific Research of Graduate Students of Niigata University of Health and Welfare (H29F02). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrews RK, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-51; Antal A, 2007, EUR J NEUROSCI, V26, P2687, DOI 10.1111/j.1460-9568.2007.05896.x; BARKER AT, 1985, LANCET, V1, P1106; Bastani A, 2013, BRAIN STIMUL, V6, P932, DOI 10.1016/j.brs.2013.04.005; BINDMAN LJ, 1964, J PHYSIOL-LONDON, V172, P369, DOI 10.1113/jphysiol.1964.sp007425; Celnik P, 2009, STROKE, V40, P1764, DOI 10.1161/STROKEAHA.108.540500; Chipchase LS, 2011, ARCH PHYS MED REHAB, V92, P1423, DOI 10.1016/j.apmr.2011.01.011; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Hamdy S, 1998, NAT NEUROSCI, V1, P64, DOI 10.1038/264; Jeffery DT, 2007, EXP BRAIN RES, V182, P281, DOI 10.1007/s00221-007-1093-y; Kaelin-Lang A, 2002, J PHYSIOL-LONDON, V540, P623, DOI 10.1113/jphysiol.2001.012801; Kirimoto H, 2014, BRAIN STIMUL, V7, P836, DOI 10.1016/j.brs.2014.09.016; Kirimoto H, 2011, CLIN NEUROPHYSIOL, V122, P777, DOI 10.1016/j.clinph.2010.09.025; Lang N, 2004, BIOL PSYCHIAT, V56, P634, DOI 10.1016/j.biopsych.2004.07.017; Lefaucheur JP, 2009, NEUROPHYSIOL CLIN, V39, P1, DOI 10.1016/j.neucli.2008.11.001; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Lopez-Alonso V, 2014, BRAIN STIMUL, V7, P372, DOI 10.1016/j.brs.2014.02.004; Luft AR, 2002, EXP BRAIN RES, V142, P562, DOI 10.1007/s00221-001-0952-1; Miyaguchi S, 2013, BRAIN RES, V1529, P83, DOI 10.1016/j.brainres.2013.07.026; Monai H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11100; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; Nitsche MA, 2005, J PHYSIOL-LONDON, V568, P291, DOI 10.1113/jphysiol.2005.092429; Nitsche MA, 2007, J NEUROSCI, V27, P3807, DOI 10.1523/JNEUROSCI.5348-06.2007; Rizzo V, 2014, BRAIN STIMUL, V7, P113, DOI 10.1016/j.brs.2013.10.002; Rothwell JC, 1997, J NEUROSCI METH, V74, P113, DOI 10.1016/S0165-0270(97)02242-5; ROTHWELL JC, 1991, EXP PHYSIOL, V76, P159, DOI 10.1113/expphysiol.1991.sp003485; Sasaki R, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00146; Sasaki R, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00030; Schabrun SM, 2018, PAIN MED, V19, P608, DOI 10.1093/pm/pnx099; Schabrun SM, 2014, BRAIN STIMUL, V7, P451, DOI 10.1016/j.brs.2014.01.058; Schabrun SM, 2013, BRAIN STIMUL, V6, P624, DOI 10.1016/j.brs.2012.09.009; Schabrun SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051298; Siebner HR, 2010, CLIN NEUROPHYSIOL, V121, P461, DOI 10.1016/j.clinph.2009.12.009; Siebner HR, 2004, J NEUROSCI, V24, P3379, DOI 10.1523/JNEUROSCI.5316-03.2004; Stefan K, 2000, BRAIN, V123, P572, DOI 10.1093/brain/123.3.572; Uy J, 2003, J NEUROSCI METH, V127, P193, DOI 10.1016/S0165-0270(03)00142-0; Wiethoff S, 2014, BRAIN STIMUL, V7, P468, DOI 10.1016/j.brs.2014.02.003; Ziemann U, 2008, BRAIN STIMUL, V1, P60, DOI 10.1016/j.brs.2007.08.003	39	2	2	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2019	14	3							e0214592	10.1371/journal.pone.0214592	http://dx.doi.org/10.1371/journal.pone.0214592			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ9FO	30925178	Green Published, gold, Green Submitted			2023-01-03	WOS:000462732300023
J	Romley, J; Trish, E; Goldman, D; Buntin, MB; He, YL; Ginsburg, P				Romley, John; Trish, Erin; Goldman, Dana; Buntin, Melinda Beeuwkes; He, Yulei; Ginsburg, Paul			Geographic variation in the delivery of high-value inpatient care	PLOS ONE			English	Article							HOSPITAL COSTS; REGIONAL-VARIATIONS; HEALTH-CARE; PRODUCTIVITY GROWTH; MORTALITY; QUALITY; RATES; RISK	Objectives To measure value in the delivery of inpatient care and to quantify its variation across U.S. regions. Data sources / Study setting A random (20%) sample of 33,713 elderly fee-for-service Medicare beneficiaries treated in 2,232 hospitals for a heart attack in 2013. Study design We estimate a production function for inpatient care, defining output as stays with favorable patient outcomes in terms of survival and readmission. The regression model includes hospital inputs measured by treatment costs, as well as patient characteristics. Region-level effects in the production function are used to estimate the productivity and value of the care delivered by hospitals within regions. Data collection / Extraction methods Medicare claims and enrollment files, linked to the Dartmouth Atlas of Health Care and Inpatient Prospective Payment System Impact Files. Principal findings Hospitals in the hospital referral region at the 90th percentile of the value distribution delivered 54% more high-quality stays than hospitals at the 10th percentile could have delivered, after adjusting for treatment costs and patient severity. Conclusions Variation in the delivery of high-value inpatient care points to opportunities for better quality and lower costs.	[Romley, John; Goldman, Dana; Ginsburg, Paul] Univ Southern Calif, Price Sch Publ Policy, Los Angeles, CA 90089 USA; [Romley, John; Trish, Erin; Goldman, Dana] Univ Southern Calif, Sch Pharm, Los Angeles, CA 90089 USA; [Buntin, Melinda Beeuwkes] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA; [He, Yulei] Univ Maryland, Univ Coll, Adelphi, MD USA; [Ginsburg, Paul] Brookings Inst, Washington, DC 20036 USA	University of Southern California; University of Southern California; Vanderbilt University; University System of Maryland; University of Maryland University College; Brookings Institution	Romley, J (corresponding author), Univ Southern Calif, Price Sch Publ Policy, Los Angeles, CA 90089 USA.; Romley, J (corresponding author), Univ Southern Calif, Sch Pharm, Los Angeles, CA 90089 USA.	romley@healthpolicy.usc.edu	Goldman, Dana P/E-7667-2013	Goldman, Dana P/0000-0001-8498-6396; He, Yulei/0000-0002-8451-5452	Commonwealth Fund; National Institute on Aging	Commonwealth Fund; National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported by the Commonwealth Fund and the National Institute on Aging. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agency for Healthcare Quality and Research, 2008, GUID INP QUAL IND; [Anonymous], 2008, MODE PATIENT MIX ADJ; [Anonymous], HOSP VAL BAS PURCH; Bradley EH, 2005, MED CARE, V43, P282, DOI 10.1097/00005650-200503000-00011; Carey K, 1997, REV ECON STAT, V79, P443, DOI 10.1162/003465300556850; Centers for Medicare & Medicaid Services, WHAT AR VAL BAS PROG; Chandra A, 2007, J POLIT ECON, V115, P103, DOI 10.1086/512249; CMS, MEAS METH; CMS.gov, FY 16 IMP FIL; CONRAD RF, 1983, APPL ECON, V15, P341, DOI 10.1080/00036848300000005; COWING TG, 1983, SOUTHERN ECON J, V49, P637, DOI 10.2307/1058706; Curry LA, 2011, ANN INTERN MED, V154, P384, DOI 10.7326/0003-4819-154-6-201103150-00003; Dor A, 1996, J HEALTH ECON, V15, P1, DOI 10.1016/0167-6296(95)00029-1; Doyle JJ, 2011, AM ECON J-APPL ECON, V3, P221, DOI 10.1257/app.3.3.221; Dranove D, 1998, J HEALTH ECON, V17, P69, DOI 10.1016/S0167-6296(97)00013-1; Farsi M, 2008, HEALTH ECON, V17, P335, DOI 10.1002/hec.1268; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; FOURNIER GM, 1992, REV ECON STAT, V74, P627, DOI 10.2307/2109376; GAYNOR M, 1995, J HEALTH ECON, V14, P291, DOI 10.1016/0167-6296(95)00004-2; Gaynor MS, 2015, J APPL ECONOMET, V30, P398, DOI 10.1002/jae.2371; GRANNEMANN TW, 1986, J HEALTH ECON, V5, P107, DOI 10.1016/0167-6296(86)90001-9; Institute of Medicine, 2013, VARIATION HLTH CARE, DOI [10.17226/18393, DOI 10.17226/18393]; Jena AB, 2013, CIRCULATION, V128, P2754, DOI 10.1161/CIRCULATIONAHA.113.004074; MaCurdy T, 2009, REVISION MEDICARE WA; Markovitz AA, 2017, MED CARE RES REV, V74, P3, DOI 10.1177/1077558715619282; McKellar MR, 2017, HEALTH SERV RES, V52, P849, DOI 10.1111/1475-6773.12501; Medicare Payment Advisory Commission, 2012, REP C MED PAYM POL; Murphy S., 2013, DEATHS FINAL DATA 20; National Center for Health Statistics, NAT HOSP DISCH SURV; Olley GS, 1996, ECONOMETRICA, V64, P1263, DOI 10.2307/2171831; Porter ME, 2009, NEW ENGL J MED, V361, P109, DOI 10.1056/NEJMp0904131; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Romley JA, 2015, HEALTH AFFAIR, V34, P511, DOI 10.1377/hlthaff.2014.0587; Romley JA, 2011, ANN INTERN MED, V154, P160, DOI 10.7326/0003-4819-154-3-201102010-00005; Skinner J, 2016, JAMA-J AM MED ASSOC, V316, P497, DOI 10.1001/jama.2016.10158; Skinner J, 2015, REV ECON STAT, V97, P951, DOI 10.1162/REST_a_00535; Song YJ, 2010, NEW ENGL J MED, V363, P45, DOI 10.1056/NEJMsa0910881; StataCorp, STAT MULT MIX EFF RE; Tsai TC, 2013, NEW ENGL J MED, V369, P1134, DOI 10.1056/NEJMsa1303118; United States Census Bureau, AM COMMUNITY SURVEY; VITA MG, 1990, J HEALTH ECON, V9, P1, DOI 10.1016/0167-6296(90)90038-5; Volpp KG, 2007, JAMA-J AM MED ASSOC, V298, P984, DOI 10.1001/jama.298.9.984; Volpp KG, 2007, JAMA-J AM MED ASSOC, V298, P975, DOI 10.1001/jama.298.9.975; Welch HG, 2011, JAMA-J AM MED ASSOC, V305, P1113, DOI 10.1001/jama.2011.307; Wennberg JE., 1996, DARTMOUTH ATLAS HLTH, P15; Wooldridge J.M., 2002, ECONOMETRIC ANAL CRO; ZUCKERMAN S, 1994, J HEALTH ECON, V13, P255, DOI 10.1016/0167-6296(94)90027-2; Zuckerman S, 2010, NEW ENGLAND J MED	49	4	4	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2019	14	3							e0213647	10.1371/journal.pone.0213647	http://dx.doi.org/10.1371/journal.pone.0213647			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HQ1KV	30908492	Green Submitted, gold, Green Published			2023-01-03	WOS:000462157600013
J	Mehrotra, R; Cukor, D; Unruh, M; Rue, T; Heagerty, P; Cohen, SD; Dember, LM; Diaz-Linhart, Y; Dubovsky, A; Greene, T; Grote, N; Kutner, N; Trivedi, MH; Quinn, DK; ver Halen, N; Weisbord, SD; Young, BA; Kimmel, PL; Hedayati, SS				Mehrotra, Rajnish; Cukor, Daniel; Unruh, Mark; Rue, Tessa; Heagerty, Patrick; Cohen, Scott D.; Dember, Laura M.; Diaz-Linhart, Yaminette; Dubovsky, Amelia; Greene, Tom; Grote, Nancy; Kutner, Nancy; Trivedi, Madhukar H.; Quinn, Davin K.; ver Halen, Nisha; Weisbord, Steven D.; Young, Bessie A.; Kimmel, Paul L.; Hedayati, S. Susan			Comparative Efficacy of Therapies for Treatment of Depression for Patients Undergoing Maintenance Hemodialysis A Randomized Clinical Trial	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC KIDNEY-DISEASE; QUALITY-OF-LIFE; PRIMARY-CARE PATIENTS; COGNITIVE THERAPY; ANTIDEPRESSANT TREATMENT; DIALYSIS; SYMPTOMS; SERTRALINE; MORTALITY; MEDICATION	Background: Although depression is common among patients receiving maintenance hemodialysis, data on their acceptance of treatment and on the comparative efficacy of various therapies are limited. Objective: To determine the effect of an engagement interview on treatment acceptance (phase 1) and to compare the efficacy of cognitive behavioral therapy (CBT) versus sertraline (phase 2) for treating depression in patients receiving hemodialysis. Design: Multicenter, parallel-group, open-label, randomized controlled trial. (ClinicalTrials.gov: NCT02358343) Setting: 41 dialysis facilities in 3 U.S. metropolitan areas. Participants: Patients who had been receiving hemodialysis for at least 3 months and had a Beck Depression Inventory-II score of 15 or greater; 184 patients participated in phase 1, and 120 subsequently participated in phase 2. Intervention: Engagement interview versus control visit (phase 1) and 12 weeks of CBT delivered in the dialysis facility versus sertraline treatment (phase 2). Measurements: The primary outcome for phase 1 was the proportion of participants who started depression treatment within 28 days. For phase 2, the primary outcome was depressive symptoms measured by the Quick Inventory of Depressive Symptoms-Clinician-Rated (QIDS-C) at 12 weeks. Results: The proportion of participants who initiated treatment after the engagement or control visit did not differ (66% vs. 64%, respectively; P = 0.77; estimated risk difference, 2.1 [95% CI, -12.1 to 16.4]). Compared with CBT, sertraline treatment resulted in lower QIDS-C depression scores at 12 weeks (effect estimate, -1.84 [CI, -3.54 to -0.13]; P = 0.035). Adverse events were more frequent in the sertraline than the CBT group. Limitation: No randomized comparison was made with no treatment, and persistence of treatment effect was not assessed. Conclusion: An engagement interview with patients receiving maintenance hemodialysis had no effect on their acceptance of treatment for depression. After 12 weeks of treatment, depression scores were modestly better with sertraline treatment than with CBT.	[Mehrotra, Rajnish] Univ Washington, Kidney Res Inst, 325 Ninth Ave,Box 359606, Seattle, WA 98104 USA; [Mehrotra, Rajnish] Univ Washington, Harborview Med Ctr, 325 Ninth Ave,Box 359606, Seattle, WA 98104 USA; [Rue, Tessa] Univ Washington, Dept Biostat, 4333 Brooklyn Ave NE,Floor 15, Seattle, WA 98195 USA; [Heagerty, Patrick] Univ Washington, Dept Biostat, Box 357232, Seattle, WA 98195 USA; [Dubovsky, Amelia; Young, Bessie A.] Univ Washington, Seattle, WA 98195 USA; [Grote, Nancy] Univ Washington, Sch Social Work, 4101 15th Ave Northeast,103, Seattle, WA 98195 USA; [Cukor, Daniel; ver Halen, Nisha] SUNY, Downstate Med Ctr, Brooklyn, NY USA; [Unruh, Mark; Quinn, Davin K.] Univ New Mexico, Sch Med, MSC 10-5550,1 Univ New Mexico, Albuquerque, NM 87131 USA; [Cohen, Scott D.] George Washington Univ, Div Renal Dis & Hypertens, 2150 Penn Ave Northwest,Suite 3-438, Washington, DC 20037 USA; [Dember, Laura M.] Univ Penn, Renal Elect & Hypertens Div, 920 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA; [Diaz-Linhart, Yaminette] Boston Univ, Boston, MA 02215 USA; [Greene, Tom] Univ Utah, Dept Internal Med, 295 Chipeta Way, Salt Lake City, UT 84108 USA; [Greene, Tom] Univ Utah, Populat Hlth Sci, 295 Chipeta Way, Salt Lake City, UT 84108 USA; [Kutner, Nancy] Emory Univ, Sch Med, Dept Rehabil Med, 1441 Clifton Rd Northeast, Atlanta, GA 30322 USA; [Trivedi, Madhukar H.] Univ Texas Southwestern Dallas, Ctr Depress Res & Clin Care, Dept Psychiat, 6363 Forest Pk Rd,Suite BL13-100,MC 9119, Dallas, TX 75235 USA; [Hedayati, S. Susan] Univ Texas Southwestern Dallas, Div Nephrol, Dept Med, 5939 Harry Hines Blvd,HP5-.500,MC 8516, Dallas, TX 75390 USA; [Weisbord, Steven D.] Univ Pittsburgh, Pittsburgh, PA USA; [Weisbord, Steven D.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA; [Young, Bessie A.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA; [Kimmel, Paul L.] NIDDK, NIH, 6707 Democracy Blvd, Bethesda, MD 20892 USA	University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; SUNY Maritime College; University of New Mexico; George Washington University; University of Pennsylvania; Boston University; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Mehrotra, R (corresponding author), Univ Washington, Kidney Res Inst, 325 Ninth Ave,Box 359606, Seattle, WA 98104 USA.; Mehrotra, R (corresponding author), Univ Washington, Harborview Med Ctr, 325 Ninth Ave,Box 359606, Seattle, WA 98104 USA.	rmehrotr@uw.edu	Young, Lucky\\1234/GNH-2046-2022; Trivedi, Madhukar/A-9029-2013	Trivedi, Madhukar/0000-0002-2983-1110	Patient-Centered Outcomes Research Institute [CER-1310-07253]; Dialysis Clinic Inc. (Nashville, Tennessee); Kidney Research Institute at the University of Washington, Seattle; National Institute of Diabetes and Digestive and Kidney Diseases [R01DK085512]; Veterans Affairs Puget Sound Healthcare System	Patient-Centered Outcomes Research Institute(Patient-Centered Outcomes Research Institute - PCORI); Dialysis Clinic Inc. (Nashville, Tennessee); Kidney Research Institute at the University of Washington, Seattle; National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs Puget Sound Healthcare System	This trial was funded by contract CER-1310-07253 from the Patient-Centered Outcomes Research Institute. Additional support was provided by Dialysis Clinic Inc. (Nashville, Tennessee); the Kidney Research Institute at the University of Washington, Seattle; and grant R01DK085512 from the National Institute of Diabetes and Digestive and Kidney Diseases (to Dr. Hedayati). Dr. Young is supported in part by funding from the Veterans Affairs Puget Sound Healthcare System.	Arkowitz H., 2004, J COGN PSYCHOTHER, V18, P337, DOI [DOI 10.1891/JC0P.18.4.337.63998, https://doi.org/10.1891/jcop.18.4.337.63998]; Bell RA, 2011, ANN FAM MED, V9, P439, DOI 10.1370/afm.1277; Blumenfield M, 1997, INT J PSYCHIAT MED, V27, P71, DOI 10.2190/WQ33-M54T-XN7L-V8MX; Button KS, 2015, PSYCHOL MED, V45, P3269, DOI 10.1017/S0033291715001270; Cukor D, 2014, J AM SOC NEPHROL, V25, P196, DOI 10.1681/ASN.2012111134; Cukor D, 2009, KIDNEY INT, V75, P1223, DOI 10.1038/ki.2009.51; David D, 2008, J CLIN PSYCHOL, V64, P728, DOI 10.1002/jclp.20487; DeRubeis RJ, 2005, ARCH GEN PSYCHIAT, V62, P409, DOI 10.1001/archpsyc.62.4.409; DiMatteo MR, 2000, ARCH INTERN MED, V160, P2101, DOI 10.1001/archinte.160.14.2101; Dimidjian S, 2006, J CONSULT CLIN PSYCH, V74, P658, DOI 10.1037/0022-006X.74.4.658; Duarte PS, 2009, KIDNEY INT, V76, P414, DOI 10.1038/ki.2009.156; Epstein RM, 2010, J GEN INTERN MED, V25, P954, DOI 10.1007/s11606-010-1367-0; Flythe JE, 2018, CLIN J AM SOC NEPHRO, V13, P735, DOI 10.2215/CJN.10850917; Friedli K, 2017, CLIN J AM SOC NEPHRO, V12, P280, DOI 10.2215/CJN.02120216; Grote NK, 2007, SOC WORK, V52, P295, DOI 10.1093/sw/52.4.295; Hedayati SS, 2008, KIDNEY INT, V74, P930, DOI 10.1038/ki.2008.311; Hedayati SS, 2017, JAMA-J AM MED ASSOC, V318, P1876, DOI 10.1001/jama.2017.17131; Hedayati SS, 2016, CONTEMP CLIN TRIALS, V47, P1, DOI 10.1016/j.cct.2015.11.020; Hedayati SS, 2006, KIDNEY INT, V69, P1662, DOI 10.1038/sj.ki.5000308; Hedayati SS, 2005, AM J KIDNEY DIS, V46, P642, DOI 10.1053/j.ajkd.2005.07.002; Hegerl U, 2010, INT J NEUROPSYCHOPH, V13, P31, DOI 10.1017/S1461145709000224; Hettema J, 2005, ANNU REV CLIN PSYCHO, V1, P91, DOI 10.1146/annurev.clinpsy.1.102803.143833; Hosseini SH, 2012, IRAN J KIDNEY DIS, V6, P446; Jain N, 2013, CONTEMP CLIN TRIALS, V34, P136, DOI 10.1016/j.cct.2012.10.004; Jhamb M, 2011, BLOOD PURIFICAT, V31, P151, DOI 10.1159/000321855; Jhamb M, 2009, CLIN J AM SOC NEPHRO, V4, P1779, DOI 10.2215/CJN.00190109; Katon W, 2010, GEN HOSP PSYCHIAT, V32, P456, DOI 10.1016/j.genhosppsych.2010.04.001; Kimmel PL, 2000, KIDNEY INT, V57, P2093, DOI 10.1046/j.1523-1755.2000.00059.x; KIMMEL PL, 1995, J AM SOC NEPHROL, V5, P1826; Kirsch I, 2008, PLOS MED, V5, P260, DOI 10.1371/journal.pmed.0050045; Kravitz RL, 2013, JAMA-J AM MED ASSOC, V310, P1818, DOI 10.1001/jama.2013.280038; Kutner NG, 2002, NEPHROL DIAL TRANSPL, V17, P93, DOI 10.1093/ndt/17.1.93; Lacson E, 2012, NEPHROL DIAL TRANSPL, V27, P2921, DOI 10.1093/ndt/gfr778; Lopes AA, 2002, KIDNEY INT, V62, P199, DOI 10.1046/j.1523-1755.2002.00411.x; Palmer S, 2013, KIDNEY INT, V84, P179, DOI 10.1038/ki.2013.77; Palmer SC, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004541.pub3; Pena-Polanco JE, 2017, CLIN J AM SOC NEPHRO, V12, P298, DOI 10.2215/CJN.07720716; Qaseem A, 2016, ANN INTERN MED, V164, P350, DOI 10.7326/M15-2570; Rush AJ, 2005, NEUROPSYCHOPHARMACOL, V30, P405, DOI 10.1038/sj.npp.1300614; Rush AJ, 2003, BIOL PSYCHIAT, V54, P573, DOI 10.1016/S0006-3223(02)01866-8; Simon GE, 2004, JAMA-J AM MED ASSOC, V292, P935, DOI 10.1001/jama.292.8.935; Tamura MK, 2017, KIDNEY INT, V91, P948, DOI 10.1016/j.kint.2016.11.015; Taraz M, 2013, INT IMMUNOPHARMACOL, V17, P917, DOI 10.1016/j.intimp.2013.09.020; Thomas B, 2015, J AM SOC NEPHROL, V26, P2621, DOI 10.1681/ASN.2014101017; Unruh M, 2003, J AM SOC NEPHROL, V14, P2132, DOI 10.1097/01.ASN.0000076076.88336.B1; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; van Dijk S, 2013, J PSYCHOSOM RES, V74, P511, DOI 10.1016/j.jpsychores.2013.03.001; Weisbord SD, 2005, J AM SOC NEPHROL, V16, P2487, DOI 10.1681/ASN.2005020157; Weisbord SD, 2014, CLIN J AM SOC NEPHRO, V9, P1594, DOI 10.2215/CJN.00220114; Weisbord SD, 2013, CLIN J AM SOC NEPHRO, V8, P90, DOI 10.2215/CJN.04450512; Yazici AE, 2012, KLIN PSIKOFARMAKOL B, V22, P23, DOI 10.5455/bcp.20120215011558	51	46	46	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 19	2019	170	6					369	+		10.7326/M18-2229	http://dx.doi.org/10.7326/M18-2229			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HP1ZR	30802897				2023-01-03	WOS:000461468300014
J	Ohara, T				Ohara, Tadashi			Identification of the microbial diversity after fecal microbiota transplantation therapy for chronic intractable constipation using 16s rRNA amplicon sequencing	PLOS ONE			English	Article							CLOSTRIDIUM-DIFFICILE INFECTION; GUT MICROBIOTA; LARGE-INTESTINE; SP NOV.; TRANSIT; FROZEN; FECES	Background Fecal microbiota transplantation (FMT) is an effective therapeutic approach for the treatment of functional gastrointestinal disease by restoring gut microbiota; however, there is a lack of sufficient understanding regarding which microbial populations successfully colonize the recipient gut. This study characterized microbial composition and diversity in patients diagnosed with chronic constipation at 1 month and 1 year after FMT. Methods We explored the microbial diversity of pre- and posttransplant stool specimens from patients using 16S rRNA gene sequencing, followed by functional analysis. Results The results identified 22 species of microorganisms colonized in the recipients from the donors at 1 month after FMT. One-year follow-up of the patient identified the colonization of 18 species of microorganisms, resulting in identification of species in significant abundance, including Bacteroides fragilis and Hungatella hathewayi in the recipient at 1 month after FMT and Dialister succinatiphilus, Coprococcus catus, and Sutterella stercoricanis at 1 year after FMT. The majority of the colonized species belong to the phylum Firmicutes and carry genes related to polysaccharide metabolism and that enhance the energy-harvesting efficiency of the host. Conclusion These results suggest that FMT is effective for the treatment of chronic constipation through the restoration and colonization of donor microbiota in the recipient gut up to 1 year after FMT.	[Ohara, Tadashi] Fukushima Med Univ, Dept Intestinal Biosci & Med, Fukushima, Japan	Fukushima Medical University	Ohara, T (corresponding author), Fukushima Med Univ, Dept Intestinal Biosci & Med, Fukushima, Japan.	t-ohara@fmu.ac.jp		Ohara, Tadashi/0000-0002-7039-8144				Angelberger S, 2013, AM J GASTROENTEROL, V108, P1620, DOI 10.1038/ajg.2013.257; Aronesty E, 2011, COMMAND LINE TOOLS P; Barnes Danielle, 2017, Curr Gastroenterol Rep, V19, P10, DOI 10.1007/s11894-017-0548-y; Berer K, 2017, P NATL ACAD SCI USA, V114, P10719, DOI 10.1073/pnas.1711233114; Cammarota G, 2014, J CLIN GASTROENTEROL, V48, P693, DOI 10.1097/MCG.0000000000000046; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Dethlefsen L, 2008, PLOS BIOL, V6, P2383, DOI 10.1371/journal.pbio.0060280; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Fuentes S, 2014, ISME J, V8, P1621, DOI 10.1038/ismej.2014.13; Ge XL, 2016, ARCH MED RES, V47, P236, DOI 10.1016/j.arcmed.2016.06.005; Hamilton MJ, 2013, GUT MICROBES, V4, P125, DOI 10.4161/gmic.23571; Hisada T, 2015, ARCH MICROBIOL, V197, P919, DOI 10.1007/s00203-015-1125-0; Hosomi K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04511-0; Huang LS, 2018, SCI CHINA LIFE SCI, V61, P744, DOI 10.1007/s11427-017-9220-7; Kassam Z, 2013, AM J GASTROENTEROL, V108, P500, DOI 10.1038/ajg.2013.59; Kaur S, 2014, INT J SYST EVOL MICR, V64, P710, DOI 10.1099/ijs.0.056986-0; Khoruts A, 2010, J CLIN GASTROENTEROL, V44, P354, DOI 10.1097/MCG.0b013e3181c87e02; Landy J, 2011, ALIMENT PHARM THER, V34, P409, DOI 10.1111/j.1365-2036.2011.04737.x; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Lee CH, 2016, JAMA-J AM MED ASSOC, V315, P142, DOI 10.1001/jama.2015.18098; Lee STM, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0270-x; Li Ning, 2017, Zhonghua Wei Chang Wai Ke Za Zhi, V20, P40; Macfarlane GT, 2011, J CLIN GASTROENTEROL, V45, pS120, DOI 10.1097/MCG.0b013e31822fecfe; Manichanh C, 2012, NAT REV GASTRO HEPAT, V9, P599, DOI 10.1038/nrgastro.2012.152; MCNEIL NI, 1984, AM J CLIN NUTR, V39, P338, DOI 10.1093/ajcn/39.2.338; Miller PG, 2015, J IMMUNOL, V195, P4668, DOI 10.4049/jimmunol.1501664; Morgan BP, 2015, NAT REV DRUG DISCOV, V14, P857, DOI 10.1038/nrd4657; Morotomi M, 2008, INT J SYST EVOL MICR, V58, P2716, DOI 10.1099/ijs.0.2008/000810-0; Ohara T, 2018, CLIN CASE REP, V6, P2029, DOI 10.1002/ccr3.1798; Olesen SW, 2016, THESIS; Parks DH, 2014, BIOINFORMATICS, V30, P3123, DOI 10.1093/bioinformatics/btu494; Parthasarathy G, 2016, GASTROENTEROLOGY, V150, P367, DOI 10.1053/j.gastro.2015.10.005; R Core Team, 2021, R LANG ENV STAT COMP; Shahinas D, 2012, MBIO, V3, DOI 10.1128/mBio.00338-12; Takahashi S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105592; Tamura A, 2016, J NEUROGASTROENTEROL, V22, P677, DOI 10.5056/jnm15187; Tyson GW, 2004, NATURE, V428, P37, DOI 10.1038/nature02340; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Weingarden A, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0070-0; Weingarden AR, 2014, AM J PHYSIOL-GASTR L, V306, pG310, DOI 10.1152/ajpgi.00282.2013; Zhao Y, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2821-1	41	30	30	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2019	14	3							e0214085	10.1371/journal.pone.0214085	http://dx.doi.org/10.1371/journal.pone.0214085			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP3JN	30889205	Green Submitted, Green Published, gold			2023-01-03	WOS:000461573000048
J	Menon, S; Rossi, R; Kariisa, M; Acharya, SD; Zdraveska, N; Mahmood, S; Callens, S; Ndizeye, Z				Menon, Sonia; Rossi, Rodolfo; Kariisa, Mbabazi; Acharya, Sushama D.; Zdraveska, Natasha; Mahmood, Sultan; Callens, Steven; Ndizeye, Zacharie			Relationship between Highly Active Antiretroviral Therapy (HAART) and human papillomavirus type 16 (HPV 16) infection among women in Sub-Saharan Africa and public health implications: A systematic review	PLOS ONE			English	Review							BACTERIAL VAGINOSIS; HIGH-RISK; HIV; GENOTYPES; CANCERS; DISEASE	Invasive cervical cancer is the most prevalent cancer among women in Sub-Saharan Africa. In 2013, the World Health Organization (WHO) emitted recommendations to start Highly Active Antiretroviral Therapy (HAART) regardless of CD4 count. Although HAART has been shown to reduce the prevalence of high-risk human papillomavirus (HR-HPV) genotypes, it is unclear whether it confers a protective effect specifically for HPV 16. This review summarizes the existing evidence regarding the effect of HAART on HPV 16 infection, as this genotype may not be influenced by immunity level and explores its implications for Sub Saharan Africa. A comprehensive literature review was undertaken and quality assessment was carried out on the selected papers. Four cohort studies and three cross-sectional studies were identified for which the overall quality score assessment ranged from weak/moderate (Score of 1.8) to strong (Score of 3). The evidence yielded by our review was conflicting. Thus, the high heterogeneity between study populations and results did not allow us to draw any firm conclusions as to whether HAART has an impact on HPV 16 acquisition/prevalence. As only three studies were conducted in Africa, there are insufficient grounds for solid comparison between geographic regions. In light of inadequate data, HPV unvaccinated women on HAART should still receive more frequent follow-up.	[Menon, Sonia] Univ Ghent, ICRH, Ghent, Belgium; [Rossi, Rodolfo] Int Comm Red Cross, Primary Hlth Care Serv, Geneva, Switzerland; [Kariisa, Mbabazi] March Dimes Fdn, White Plains, NY USA; [Acharya, Sushama D.] CDC Fdn, Atlanta, GA USA; [Zdraveska, Natasha] Saints Cyril & Methodius Univ Alumni, Dept Clin Pharm, Fac Pharm, Skopje, North Macedonia; [Mahmood, Sultan] Massey Univ Alumni, Antwerp, Belgium; [Callens, Steven] Univ Hosp, Dept Internal Med & Infect Dis, Ghent, Belgium; [Ndizeye, Zacharie] Univ Burundi, Fac Med, Dept Community Med, Bujumbura, Burundi; [Ndizeye, Zacharie] Univ Antwerp, Fac Med & Hlth Sci, Global Hlth Inst, Antwerp, Belgium	Ghent University; Ghent University; Ghent University Hospital; University of Antwerp	Menon, S (corresponding author), Univ Ghent, ICRH, Ghent, Belgium.	soniasimonemenon@gmail.com	Ndizeye, Zacharie/A-4085-2019	Mahmood, Sultan/0000-0001-7585-9731; NDIZEYE, Zacharie/0000-0002-3235-9494				Altman DG, 2000, STAT MED, V19, P3275, DOI 10.1002/1097-0258(20001215)19:23<3275::AID-SIM626>3.3.CO;2-D; [Anonymous], M STRAT ADV GROUP EX; Blitz S, 2013, J INFECT DIS, V208, P454, DOI 10.1093/infdis/jit181; BMJ, CLIN EV WHAT IS GRAD; Boender TS, 2016, J INFECT DIS, V214, P873, DOI 10.1093/infdis/jiw219; Estill J, 2016, LANCET HIV, V3, pE132, DOI 10.1016/S2352-3018(16)00016-3; Firnhaber C, 2010, CANCER CAUSE CONTROL, V21, P433, DOI 10.1007/s10552-009-9475-z; Franceschi S, 2003, JAIDS-J ACQ IMM DEF, V34, P84, DOI 10.1097/00126334-200309010-00013; Gillet E, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-10; Globocan IARC, EST CANC INC MORT PR; Huchko MJ, 2014, INT J CANCER, V134, P740, DOI 10.1002/ijc.28401; Katki HA, 2013, J LOW GENIT TRACT DI, V17, pS78, DOI 10.1097/LGT.0b013e31828543c5; Kelly H, 2018, LANCET HIV, V5, pE45, DOI 10.1016/S2352-3018(17)30149-2; Kharsany Ayesha B M, 2016, Open AIDS J, V10, P34, DOI 10.2174/1874613601610010034; Konopnicki D, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18023; Lillo FB, 2006, J ANTIMICROB CHEMOTH, V57, P810, DOI 10.1093/jac/dkl073; Mane A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038731; McKenzie ND, 2010, GYNECOL ONCOL, V116, P572, DOI 10.1016/j.ygyno.2009.10.058; Menon S, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015123; Menon S, 2016, CLIN THER, V38, P2567, DOI 10.1016/j.clinthera.2016.10.005; Menon SS, 2016, INFECT AGENTS CANCER, V11, DOI 10.1186/s13027-016-0061-1; Moher D., 2010, PREFERRED REPORTING; Morris M, 2001, BRIT J OBSTET GYNAEC, V108, P439; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Rodriguez-Cerdeira C, 2012, ISRN Obstet Gynecol, V2012, P240190, DOI 10.5402/2012/240190; Ryu A, 2012, J GYNECOL ONCOL, V23, P217, DOI 10.3802/jgo.2012.23.4.217; Sahasrabuddhe VV, 2007, BRIT J CANCER, V96, P1480, DOI 10.1038/sj.bjc.6603737; Shrestha S, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-295; Stanley Margaret, 2010, Infect Agent Cancer, V5, P19, DOI 10.1186/1750-9378-5-19; Strickler HD, 2003, JNCI-J NATL CANCER I, V95, P1062, DOI 10.1093/jnci/95.14.1062; Strickler HD, 2008, INT J CANCER, V123, P1224, DOI 10.1002/ijc.23630; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; UNAIDS, 2013, GLOB REP KEN; van Aardt M C, 2016, SAMJ, S. Afr. med. j., V106, P617, DOI [10.7196/samj.2016.v106i6.10335, 10.7196/SAMJ.2016.v106i6.10335]; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wester C. William, 2009, HIV Therapy, V3, P501, DOI 10.2217/HIV.09.35; WHO, NEW WHO GUID PREV CO; WHO, ANT THER HIV INF AD; WHO Department of Immunization VaB World Health Organization, 2007, HUM PAP HPV VACC TEC; World Health Organization, GUID START ANT THER; World Health Organization, 2014, COMPR CERV CANC CONT, V2nd; Zeier MD, 2015, AIDS, V29, P59, DOI 10.1097/QAD.0000000000000512	42	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2019	14	3							e0213086	10.1371/journal.pone.0213086	http://dx.doi.org/10.1371/journal.pone.0213086			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO6HL	30856196	Green Published, gold, Green Submitted			2023-01-03	WOS:000461030300022
J	Wang, CH; Chang, WT; Huang, CH; Tsai, MS; Yu, PH; Wu, YW; Chen, WJ				Wang, Chih-Hung; Chang, Wei-Tien; Huang, Chien-Hua; Tsai, Min-Shan; Yu, Ping-Hsun; Wu, Yen-Wen; Chen, Wen-Jone			Factors associated with the decision to terminate resuscitation early for adult in-hospital cardiac arrest: Influence of family in an East Asian society	PLOS ONE			English	Article							LONG-TERM OUTCOMES; CARDIOPULMONARY-RESUSCITATION; DURATION; SURVIVAL; LIFE; CARE; UPDATE; HEART	Background We attempted to identify factors associated with physicians' decisions to terminate CPR and to explore the role of family in the decision-making process. Methods We conducted a retrospective observational study in a single center in Taiwan. Patients who experienced in-hospital cardiac arrest (IHCA) between 2006 and 2014 were screened for study inclusion. Multivariate survival analysis was conducted to identify independent variables associated with IHCA outcomes using the Cox proportional hazards model. Results A total of 1525 patients were included in the study. Family was present at the beginning of CPR during 722 (47.3%) resuscitation events. The median CPR duration was significantly shorter for patients with family present at the beginning of CPR than for those without family present (23.5 mins vs 30 min, p=0.01). Some factors were associated with shorter time to termination of CPR, including arrest in an intensive care unit, Charlson comorbidity index score greater than 2, age older than 79 years, baseline evidence of motor, cognitive, or functional deficits, and vasopressors in place at time of arrest. After adjusting for confounding effects, family presence was associated with shorter time to termination of CPR (hazard ratio, 1.25; 95% confidence interval, 1.06-1.46; p=0.008). Conclusion Clinicians' decisions concerning when to terminate CPR seemed to be based on outcome prognosticators. Family presence at the beginning of CPR was associated with shorter duration of CPR. Effective communication, along with outcome prediction tools, may avoid prolonged CPR efforts in an East Asian society.	[Wang, Chih-Hung; Chang, Wei-Tien; Huang, Chien-Hua; Tsai, Min-Shan; Chen, Wen-Jone] Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei, Taiwan; [Wang, Chih-Hung; Chang, Wei-Tien; Huang, Chien-Hua; Tsai, Min-Shan; Chen, Wen-Jone] Natl Taiwan Univ, Dept Emergency Med, Coll Med, Taipei, Taiwan; [Yu, Ping-Hsun] Taipei Hosp, Dept Emergency Med, Minist Hlth & Welf, New Taipei, Taiwan; [Wu, Yen-Wen] Far Eastern Mem Hosp, Dept Nucl Med, New Taipei, Taiwan; [Wu, Yen-Wen] Far Eastern Mem Hosp, Div Cardiol, Cardiovasc Med Ctr, New Taipei, Taiwan; [Wu, Yen-Wen] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan; [Chen, Wen-Jone] Natl Taiwan Univ Hosp, Div Cardiol, Dept Internal Med, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; Far Eastern Memorial Hospital; Far Eastern Memorial Hospital; National Yang Ming Chiao Tung University; National Taiwan University; National Taiwan University Hospital	Chen, WJ (corresponding author), Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei, Taiwan.; Chen, WJ (corresponding author), Natl Taiwan Univ, Dept Emergency Med, Coll Med, Taipei, Taiwan.; Chen, WJ (corresponding author), Natl Taiwan Univ Hosp, Div Cardiol, Dept Internal Med, Taipei, Taiwan.	wjchen1955@ntu.edu.tw	TSAI, MIN-SHAN/AHE-3825-2022	TSAI, MIN-SHAN/0000-0002-2862-7572; HUANG, CHIEN-HUA/0000-0003-2981-4537; WANG, CHIH-HUNG/0000-0003-0802-7825; CHEN, WEN-JONE/0000-0002-2098-5922; WU, YEN-WEN/0000-0003-1520-1166	National Taiwan University Hospital [108-S4091, 108-S4236 tp]	National Taiwan University Hospital(National Taiwan University)	This study was funded by the National Taiwan University Hospital (grant number 108-S4091 to Chih-Hung Wang and grant number 108-S4236 tp Dr Wen-Jone Chen). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adnet F, 2017, RESUSCITATION, V111, P74, DOI 10.1016/j.resuscitation.2016.11.024; Andrew E, 2017, RESUSCITATION, V110, P42, DOI 10.1016/j.resuscitation.2016.10.018; Apatira L, 2008, ANN INTERN MED, V149, P861, DOI 10.7326/0003-4819-149-12-200812160-00005; Barnato AE, 2009, J GEN INTERN MED, V24, P695, DOI 10.1007/s11606-009-0952-6; Benjamin EJ, 2017, CIRCULATION, V135, pE146, DOI 10.1161/CIR.0000000000000485; Bhardwaj A, 2017, RESUSCITATION, V111, P90, DOI 10.1016/j.resuscitation.2016.12.007; Bradley SM, 2017, RESUSCITATION, V113, P128, DOI 10.1016/j.resuscitation.2016.12.017; Cardoso LTQ, 2011, CRIT CARE, V15, DOI 10.1186/cc9975; Chan PS, 2013, NEW ENGL J MED, V368, P1019, DOI 10.1056/NEJMoa1200657; Chan PS, 2012, ARCH INTERN MED, V172, P947, DOI 10.1001/archinternmed.2012.2050; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen YS, 2008, LANCET, V372, P554, DOI 10.1016/S0140-6736(08)60958-7; Cheng SY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001573; Crippen D, 1999, CRIT CARE, V3, pR47, DOI 10.1186/cc354; Escutnaire J, 2018, RESUSCITATION, V131, P48, DOI 10.1016/j.resuscitation.2018.07.032; Goldberger ZD, 2015, CIRC-CARDIOVASC QUAL, V8, P226, DOI 10.1161/CIRCOUTCOMES.114.001272; Goldberger ZD, 2012, LANCET, V380, P1473, DOI 10.1016/S0140-6736(12)60862-9; Grunau B, 2016, RESUSCITATION, V101, P50, DOI 10.1016/j.resuscitation.2016.01.021; Harris D, 2009, RESUSCITATION, V80, P1275, DOI 10.1016/j.resuscitation.2009.07.008; Hastie T., 1990, GEN ADDITIVE MODELS, DOI DOI 10.1201/9780203753781; Hirlekar G, 2018, RESUSCITATION, V133, P118, DOI 10.1016/j.resuscitation.2018.10.006; Jabre P, 2013, NEW ENGL J MED, V368, P1008, DOI 10.1056/NEJMoa1203366; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Jones K, 2006, RESUSCITATION, V69, P235, DOI 10.1016/j.resuscitation.2005.07.023; Kang M, 2014, CLIN EXP EMERG MED, V1, P87, DOI 10.15441/ceem.14.010; Khan AM, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001044; Matsuyama T, 2017, RESUSCITATION, V113, P1, DOI 10.1016/j.resuscitation.2017.01.005; Rajan S, 2016, RESUSCITATION, V105, P45, DOI 10.1016/j.resuscitation.2016.05.004; Sharma RK, 2015, J CLIN ONCOL, V33, P3802, DOI 10.1200/JCO.2015.61.6458; van Walraven C, 2001, JAMA-J AM MED ASSOC, V285, P1602, DOI 10.1001/jama.285.12.1602; Wang CH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202938; Wang CH, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1058-7	32	5	5	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2019	14	3							e0213168	10.1371/journal.pone.0213168	http://dx.doi.org/10.1371/journal.pone.0213168			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO1AY	30845157	Green Published, gold, Green Submitted			2023-01-03	WOS:000460638800040
J	Favie, LMA; Groenendaal, F; van den Broek, MPH; Rademaker, CMA; de Haan, TR; van Straaten, HLM; Dijk, PH; van Heijst, A; Dudink, J; Dijkman, KP; Rijken, M; Zonnenberg, IA; Cools, F; Zecic, A; van der Lee, JH; Nuytemans, DHGM; van Bel, F; Egberts, TCG; Huitema, ADR; Brouwer, MJ; Mulder-de Tollenaer, SM; Jebbink-Akkerman, LJMG; Liem, D; Steiner, K; Simons, SHP; de Jonge, RCJ; Bos, AA; Sonnaert, M; Camfferman, FA				Favie, Laurent M. A.; Groenendaal, Floris; van den Broek, Marcel P. H.; Rademaker, Carin M. A.; de Haan, Timo R.; van Straaten, Henrica L. M.; Dijk, Peter H.; van Heijst, Arno; Dudink, Jeroen; Dijkman, Koen P.; Rijken, Monique; Zonnenberg, Inge A.; Cools, Filip; Zecic, Alexandra; van der Lee, Johanna H.; Nuytemans, Debbie H. G. M.; van Bel, Frank; Egberts, Toine C. G.; Huitema, Alwin D. R.; Brouwer, Mieke J.; Mulder-de Tollenaer, S. M.; Jebbink-Akkerman, L. J. M. Groot; Liem, Djien; Steiner, Katerina; Simons, Sinno H. P.; de Jonge, Rogier C. J.; Bos, Annelies A.; Sonnaert, Michel; Camfferman, Fleur Anne		PharmaCool Study Grp	Pharmacokinetics of morphine in encephalopathic neonates treated with therapeutic hypothermia	PLOS ONE			English	Article							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; POPULATION PHARMACOKINETICS; GENTAMICIN PHARMACOKINETICS; ASPHYXIATED NEWBORNS; DRUG-METABOLISM; INFANTS; PRETERM; GLUCURONIDATION; PHARMACODYNAMICS; SAFETY	Objective Morphine is a commonly used drug in encephalopathic neonates treated with therapeutic hypothermia after perinatal asphyxia. Pharmacokinetics and optimal dosing of morphine in this population are largely unknown. The objective of this study was to describe pharmacokinetics of morphine and its metabolites morphine-3-glucuronide and morphine-6-glucuronide in encephalopathic neonates treated with therapeutic hypothermia and to develop pharmacokinetics based dosing guidelines for this population. Study design Term and near-term encephalopathic neonates treated with therapeutic hypothermia and receiving morphine were included in two multicenter cohort studies between 2008-2010 (SHIVER) and 2010-2014 (PharmaCool). Data were collected during hypothermia and rewarming, including blood samples for quantification of morphine and its metabolites. Parental informed consent was obtained for all participants. Results 244 patients (GA mean (sd) 39.8 (1.6) weeks, BW mean (sd) 3,428 (613) g, male 61.5%) were included. Morphine clearance was reduced under hypothermia (33.5 degrees C) by 6.89%/degrees C (95% CI 5.37%/degrees C-8.41%/degrees C, p<0.001) and metabolite clearance by 4.91%/degrees C (95% CI 3.53%/degrees C-6.22%/degrees C, p<0.001) compared to normothermia (36.5 degrees C). Simulations showed that a loading dose of 50 mu g/kg followed by continuous infusion of 5 mu g/kg/h resulted in morphine plasma concentrations in the desired range (between 10 and 40 mu g/L) during hypothermia. Conclusions Clearance of morphine and its metabolites in neonates is affected by therapeutic hypothermia. The regimen suggested by the simulations will be sufficient in the majority of patients. However, due to the large interpatient variability a higher dose might be necessary in individual patients to achieve the desired effect.	[Favie, Laurent M. A.; van den Broek, Marcel P. H.; Rademaker, Carin M. A.; Egberts, Toine C. G.; Huitema, Alwin D. R.] Univ Med Ctr Utrecht, Dept Clin Pharm, Utrecht, Netherlands; [Favie, Laurent M. A.; Groenendaal, Floris; van Bel, Frank] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Neonatol, Utrecht, Netherlands; [Groenendaal, Floris; van Bel, Frank] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Utrecht, Netherlands; [van den Broek, Marcel P. H.] St Antonius Hosp, Dept Clin Pharm, Nieuwegein, Netherlands; [de Haan, Timo R.] Emma Childrens Hosp, Acad Med Ctr, Dept Neonatol, Amsterdam, Netherlands; [van Straaten, Henrica L. M.] Isala Clin, Dept Neonatol, Zwolle, Netherlands; [Dijk, Peter H.] Groningen Univ Med Ctr, Dept Neonatol, Groningen, Netherlands; [van Heijst, Arno] Radboud Univ Nijmegen, Med Ctr, Amalia Childrens Hosp, Dept Neonatol, Nijmegen, Netherlands; [van Heijst, Arno; Dudink, Jeroen] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Pediat, Div Neonatol, Rotterdam, Netherlands; [Dijkman, Koen P.] Maxima Med Ctr Veldhoven, Dept Neonatol, Veldhoven, Netherlands; [Rijken, Monique] Leiden Univ, Med Ctr, Dept Neonatol, Leiden, Netherlands; [Zonnenberg, Inge A.] Vrije Univ Amsterdam Med Ctr, Dept Neonatol, Amsterdam, Netherlands; [Cools, Filip] UZ Brussel Vrije Univ Brussel, Dept Neonatol, Brussels, Belgium; [Zecic, Alexandra] Univ Hosp Gent, Dept Neonatol, Ghent, Belgium; [van der Lee, Johanna H.] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Paediat Clin Res Off, Amsterdam, Netherlands; [Nuytemans, Debbie H. G. M.] PharmaCool Study, Amsterdam, Netherlands; [Egberts, Toine C. G.] Univ Utrecht, Fac Sci, Dept Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands; [Huitema, Alwin D. R.] Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Utrecht University; Utrecht University Medical Center; St. Antonius Hospital Utrecht; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Isala Clinics; University of Groningen; Radboud University Nijmegen; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Maxima Medical Center; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Ghent University; Ghent University Hospital; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Utrecht University; Netherlands Cancer Institute	Favie, LMA (corresponding author), Univ Med Ctr Utrecht, Dept Clin Pharm, Utrecht, Netherlands.; Favie, LMA (corresponding author), Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Neonatol, Utrecht, Netherlands.		de Jonge, R./M-9912-2014; Groenendaal, Floris/P-6872-2019; simons, sinno/AAC-7442-2019; Egberts, Toine/A-6625-2012	de Jonge, R./0000-0003-0595-1983; Groenendaal, Floris/0000-0002-9284-1637; Dudink, Jeroen/0000-0003-0446-3646; Cools, Filip/0000-0002-6581-7009; Egberts, Toine/0000-0003-1758-7779	Netherlands Organization for Health Research and Development (ZonMw) Priority Medicines for Children [40-41500-98-9002]	Netherlands Organization for Health Research and Development (ZonMw) Priority Medicines for Children	Funding for this study was received from the Netherlands Organization for Health Research and Development (ZonMw) Priority Medicines for Children (grant number: 40-41500-98-9002). The funder did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allegaert K, 2014, PEDIATR ANESTH, V24, P30, DOI 10.1111/pan.12176; Anand KJS, 2008, BRIT J ANAESTH, V101, P680, DOI 10.1093/bja/aen248; Attarian S, 2014, BRAIN SCI, V4, P321, DOI 10.3390/brainsci4020321; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Baarslag MA, 2017, EXPERT REV CLIN PHAR, V10, P111, DOI 10.1080/17512433.2017.1254040; Bijleveld YA, 2018, CLIN PHARMACOL THER, V103, P458, DOI 10.1002/cpt.748; Bijleveld YA, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.02311-17, 10.1128/aac.02311-17]; Bijleveld YA, 2016, BRIT J CLIN PHARMACO, V81, P1067, DOI 10.1111/bcp.12883; Bouwmeester NJ, 2004, BRIT J ANAESTH, V92, P208, DOI 10.1093/bja/aeh042; Bouwmeester NJ, 2003, BRIT J ANAESTH, V90, P642, DOI 10.1093/bja/aeg121; Brendel K, 2006, PHARM RES, V23, P2036, DOI 10.1007/s11095-006-9067-5; Capparelli EV, 2003, J CLIN PHARMACOL, V43, P133, DOI 10.1177/0091270002239821; CHAY PCW, 1992, CLIN PHARMACOL THER, V51, P334, DOI 10.1038/clpt.1992.30; Chhavi N, 2014, PEDIATR GASTROENTERO, V17, P162, DOI 10.5223/pghn.2014.17.3.162; Choudhary M, 2015, CLIN MED INSIGHTS-PE, V9, P1, DOI 10.4137/CMPed.S21426; Cook SF, 2016, CLIN PHARMACOKINET, V55, P1395, DOI 10.1007/s40262-016-0408-1; de Graaf J, 2013, PAIN, V154, P449, DOI 10.1016/j.pain.2012.12.006; de Graaf J, 2011, PAIN, V152, P1391, DOI 10.1016/j.pain.2011.02.017; De Gregori S, 2012, METAB BRAIN DIS, V27, P1, DOI 10.1007/s11011-011-9274-6; de Haan TR, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-45; de Wildt SN, 1999, CLIN PHARMACOKINET, V36, P439, DOI 10.2165/00003088-199936060-00005; Dosne AG, 2016, J PHARMACOKINET PHAR, V43, P583, DOI 10.1007/s10928-016-9487-8; Foulkes T, 2007, CHANNELS, V1, P154, DOI 10.4161/chan.4692; Frymoyer A, 2017, J CLIN PHARMACOL, V57, P64, DOI 10.1002/jcph.775; Frymoyer A, 2013, PHARMACOTHERAPY, V33, P718, DOI 10.1002/phar.1263; Groenendaal F, 2013, NEONATOLOGY, V104, P15, DOI 10.1159/000348823; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Kart T, 1997, PAEDIATR ANAESTH, V7, P93; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; Keizer RJ, 2013, CPT-PHARMACOMET SYST, V2, DOI 10.1038/psp.2013.24; Knibbe CAJ, 2009, CLIN PHARMACOKINET, V48, P371, DOI 10.2165/00003088-200948060-00003; Knosgaard KR, 2016, EUR J PHARM SCI, V92, P117, DOI 10.1016/j.ejps.2016.06.026; Krekels EHJ, 2014, CLIN PHARMACOKINET, V53, P553, DOI 10.1007/s40262-014-0135-4; Krekels EHJ, 2012, CURR DRUG METAB, V13, P728; Krekels EHJ, 2011, CLIN PHARMACOKINET, V50, P51, DOI 10.2165/11536750-000000000-00000; Muniraman H, 2017, EUR J PEDIATR, V176, P1295, DOI 10.1007/s00431-017-2956-2; OLKKOLA KT, 1988, CLIN PHARMACOL THER, V44, P128, DOI 10.1038/clpt.1988.127; Pacifici GM, 2016, CLINICS, V71, P474, DOI 10.6061/clinics/2016(08)11; Rao R, 2017, J PEDIATR-US, V183, P37, DOI 10.1016/j.jpeds.2016.11.019; Roka A, 2008, PEDIATRICS, V121, pE844, DOI 10.1542/peds.2007-1987; Rutkove SB, 2001, MUSCLE NERVE, V24, P867, DOI 10.1002/mus.1084.abs; Shah P, 2004, ARCH DIS CHILD-FETAL, V89, P152, DOI 10.1136/adc.2002.023093; Steinhorn R, 2015, J PEDIATR-US, V166, P1200, DOI 10.1016/j.jpeds.2015.02.012; Tarcan A, 2007, J MATERN-FETAL NEO M, V20, P407, DOI 10.1080/14767050701287459; Thoresen M, 2001, PEDIATR RES, V50, P405, DOI 10.1203/00006450-200109000-00017; van den Bosch GE, 2015, NEONATOLOGY, V108, P8, DOI 10.1159/000376566; van den Broek MPH, 2012, CLIN PHARMACOKINET, V51, P671, DOI 10.1007/s40262-012-0004-y; van den Broek MPH, 2015, NEONATOLOGY, V107, P150, DOI 10.1159/000368180; van den Broek MPH, 2013, ARCH DIS CHILD-FETAL, V98, pF341, DOI 10.1136/archdischild-2012-302678; van den Broek MPH, 2010, CLIN PHARMACOKINET, V49, P277, DOI 10.2165/11319360-000000000-00000; Van Donge T, 2018, EXPERT OPIN DRUG MET, V14, P287, DOI 10.1080/17425255.2018.1432595; Wang CG, 2013, CLIN DRUG INVEST, V33, P523, DOI 10.1007/s40261-013-0097-6; Zanelli S, 2011, J PERINATOL, V31, P377, DOI 10.1038/jp.2010.146; Zeilmaker GA, 2018, EXPERT OPIN DRUG MET, V14, P417, DOI 10.1080/17425255.2018.1461836; Zhou JQ, 2011, EXPERT OPIN DRUG MET, V7, P803, DOI 10.1517/17425255.2011.574127	55	15	16	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2019	14	2							e0211910	10.1371/journal.pone.0211910	http://dx.doi.org/10.1371/journal.pone.0211910			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL5JX	30763356	Green Published, Green Submitted, gold			2023-01-03	WOS:000458763900029
J	Pillai, N; Foster, N; Hanifa, Y; Ndlovu, N; Fielding, K; Churchyard, G; Chihota, V; Grant, AD; Vassall, A				Pillai, Natasha; Foster, Nicola; Hanifa, Yasmeen; Ndlovu, Nontobeko; Fielding, Katherine; Churchyard, Gavin; Chihota, Violet; Grant, Alison D.; Vassall, Anna			Patient costs incurred by people living with HIV/AIDS prior to ART initiation in primary healthcare facilities in Gauteng, South Africa	PLOS ONE			English	Article							ANTIRETROVIRAL TREATMENT; TUBERCULOSIS DIAGNOSIS; BARRIERS; THERAPY; ADHERENCE; ENABLERS; TIME	Purpose To quantify costs to patients of accessing HIV care prior to ART initiation. Materials and methods Using a cross-sectional study design, costs incurred by HIV-positive patients prior to ART initiation were estimated at urban primary healthcare facilities in South Africa. Costs included direct costs, indirect (productivity) costs, carer and coping costs (value of assets sold and money borrowed). The percentage of individual income spent on healthcare was calculated and compared by patient income tertiles and CD4 count strata. Results 289 patients (69% female, mean age 37 (SD: 10) years, median CD4 317 (IQR: 138-494) cells/mm(3)) were interviewed. The total mean monthly cost of pre-ART care was US$15.71. Indirect costs accounted for $2.59 (16.49%) of this when time was valued using the patient's reported income. The mean monthly patient costs were $31.61, $12.78, $12.65 and $11.93 for those with a CD4 count <100, 101-350, 351-500 and >500 cells/mm(3) respectively. The percentage of individual income spent on healthcare was 7.25% for those with a CD4 count <100 cells/mm(3) and 4.05% for those with a CD4 count >500 cells/mm(3). Conclusions Despite the provision of charge-free services at public clinics, care prior to ART initiation can be costly, particularly for the poor and unemployed. Our study adds to the growing body of evidence that highlights the need to consider policies to reduce the economic barriers to HIV service access, particularly for low income or unwell patient groups, such as improving access to disability grants.	[Pillai, Natasha; Vassall, Anna] London Sch Hyg & Trop Med, Social & Math Epidemiol, London, England; [Foster, Nicola] Univ Cape Town, Sch Publ Hlth & Family Med, Hlth Econ Unit, Cape Town, South Africa; [Hanifa, Yasmeen; Grant, Alison D.] London Sch Hyg & Trop Med, Dept Clin Res, London, England; [Ndlovu, Nontobeko; Churchyard, Gavin; Chihota, Violet] Aurum Inst, Johannesburg, South Africa; [Fielding, Katherine; Churchyard, Gavin] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England; [Fielding, Katherine; Churchyard, Gavin; Chihota, Violet; Grant, Alison D.] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa; [Grant, Alison D.] Univ KwaZulu Natal, Sch Nursing & Publ Hlth, Africa Hlth Res Inst, Durban, South Africa	University of London; London School of Hygiene & Tropical Medicine; University of Cape Town; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of Witwatersrand; Africa Health Research Institute; University of Kwazulu Natal	Vassall, A (corresponding author), London Sch Hyg & Trop Med, Social & Math Epidemiol, London, England.	Anna.Vassall@lshtm.ac.uk	Chihota, Violet/DWH-9372-2022; Foster, Nicola/AAA-9040-2020	Foster, Nicola/0000-0003-4630-6243; Chihota, Violet/0000-0003-1444-9266; Churchyard, Gavin/0000-0002-4269-3699; Vassall, Anna/0000-0002-2911-1375	Bill and Melinda Gates Foundation [OPP1034523]; Medical Research Council of South Africa; Public Health Enhancement Fund; MRC [MR/R010161/1] Funding Source: UKRI	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Medical Research Council of South Africa(South African Medical Research Council); Public Health Enhancement Fund; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This paper is part of the XPHACTOR study, funded by the Bill and Melinda Gates Foundation (Grant OPP1034523). In addition, NF is a PhD student, funded by the Medical Research Council of South Africa in terms of the National Health Scholars Programme from funds provided by the Public Health Enhancement Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aspler A, 2008, INT J TUBERC LUNG D, V12, P928; Ataguba JEO, 2012, HEALTH ECON POLICY L, V7, P309, DOI 10.1017/S1744133110000356; Badri M, 2006, PLOS MED, V3, P48, DOI 10.1371/journal.pmed.0030004; Bor J, 2012, HEALTH AFFAIR, V31, P1459, DOI 10.1377/hlthaff.2012.0407; C Arndt JDL, 2000, S AFRICAN J EC, V68, P857, DOI [10.1111/j.1813-6982.2000.tb01283.x, DOI 10.1111/J.1813-6982.2000.TB01283.X]; Churchyard GJ, 2015, LANCET GLOB HEALTH, V3, pE450, DOI 10.1016/S2214-109X(15)00100-X; Dahab M, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-63; Department of Labour Republic of South Africa, 2013, NON TRADITIONAL REF; Derek Yu AB, 2012, NON TRADITIONAL REF; du Toit E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096867; Foster N, 2015, SOC SCI MED, V130, P42, DOI 10.1016/j.socscimed.2015.01.046; Fox MP, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-8; Goudge J, 2007, SCAND J PUBLIC HEALT, V35, P181, DOI 10.1080/14034950701355551; Govender V, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0870-8; Hanifa Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181519; Hardon AP, 2007, AIDS CARE, V19, P658, DOI 10.1080/09540120701244943; Ingle SM, 2010, AIDS, V24, P2717, DOI 10.1097/QAD.0b013e32833fb71f; Kik SV, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-283; Mauch V, 2013, INT J TUBERC LUNG D, V17, P381, DOI 10.5588/ijtld.12.0368; Mauch V, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-43; Miller CM, 2010, TROP MED INT HEALTH, V15, P48, DOI 10.1111/j.1365-3156.2010.02514.x; Moshabela M, 2011, AIDS BEHAV, V15, P842, DOI 10.1007/s10461-010-9747-3; National Department of Health SA, 2015, NON TRADITIONAL REF; Onwujekwe O, 2010, TROP MED INT HEALTH, V15, P18, DOI 10.1111/j.1365-3156.2009.02418.x; Patcharanarumol W, 2012, SE ASIAN J TROP MED, V43, P1521; Peltzer K, 2011, AFR J TRADIT COMPLEM, V8, P337, DOI 10.4314/ajtcam.v8i4.1; Rosen S, 2008, AIDS, V22, pS131, DOI 10.1097/01.aids.0000327634.92844.91; Rosen S, 2007, SAMJ S AFR MED J, V97, P524; Russell S, 1996, HEALTH POLICY PLANN, V11, P219, DOI 10.1093/heapol/11.3.219; Sagbakken M, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-11; Shisana O, 2014, S AFRICAN NATL HIV P; Sinanovic E, 2003, INT J TUBERC LUNG D, V7, pS56; Statistics South Africa, 2014, NON TRADITIONAL REF; van Loggerenberg F, 2015, AIDS PATIENT CARE ST, V29, P299, DOI 10.1089/apc.2014.0293; Vassall A, 2010, INT J TUBERC LUNG D, V14, P604; WHO, 2015, IMM PRACT PRACT GUID, P91	37	9	9	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2019	14	2							e0210622	10.1371/journal.pone.0210622	http://dx.doi.org/10.1371/journal.pone.0210622			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HL0OI	30742623	gold, Green Accepted, Green Published, Green Submitted			2023-01-03	WOS:000458393400010
J	Thompson, S; Wiebe, N; Padwal, RS; Gyenes, G; Headley, SAE; Radhakrishnan, J; Graham, M				Thompson, Stephanie; Wiebe, Natasha; Padwal, Raj S.; Gyenes, Gabor; Headley, Samuel A. E.; Radhakrishnan, Jeyasundar; Graham, Michelle			The effect of exercise on blood pressure in chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials	PLOS ONE			English	Review							STAGE RENAL-DISEASE; AEROBIC EXERCISE; ARTERIAL STIFFNESS; LIFE-STYLE; ENDOTHELIAL DYSFUNCTION; RISK-FACTORS; HYPERTENSION; CKD; TIME; QUALITY	Background and objectives Management of hypertension in chronic kidney disease (CKD) remains a major challenge. We conducted a systematic review to assess whether exercise is an effective strategy for lowering blood pressure in this population. Design, setting, participants, and measurements We searched MEDLINE, EMBASE, the Cochrane Library, CINAHL and Web of Science for randomized controlled trials (RCTs) that examined the effect of exercise on blood pressure in adults with non-dialysis CKD, stages 3-5. Outcomes were non-ambulatory systolic blood pressure (primary), other blood pressure parameters, 24-hour ambulatory blood pressure, pulse-wave velocity, and flow-mediated dilatation. Results were summarized using random effects models. Results Twelve studies with 505 participants were included. Ten trials (335 participants) reporting non-ambulatory systolic blood pressure were meta-analysed. All included studies were a high risk of bias. Using the last available time point, exercise was not associated with an effect on systolic blood pressure (mean difference, MD -4.33 mmHg, 95% confidence interval, CI -9.04, 0.38). The MD after 12-16 and 24-26 weeks of exercise was significant (-4.93 mmHg, 95% CI -8.83, -1.03 and -10.94 mmHg, 95% CI -15.83, -6.05, respectively) but not at 48-52 weeks (1.07 mmHg, 95% CI -6.62, 8.77). Overall, exercise did not have an effect on 24-hour ambulatory blood pressure (-5.40 mmHg, 95% CI -12.67, 1.87) or after 48-52 weeks (-7.50 mmHg 95% CI -20.21, 5.21) while an effect was seen at 24 weeks (-18.00 mmHg, 95% CI -29.92, -6.08). Exercise did not have a significant effect on measures of arterial stiffness or endothelial function. Conclusion Limited evidence from shorter term studies suggests that exercise is a potential strategy to lower blood pressure in CKD. However, to recommend exercise for blood pressure control in this population, high quality, longer term studies specifically designed to evaluate hypertension are needed.	[Thompson, Stephanie; Wiebe, Natasha] Univ Alberta, Div Nephrol, Dept Med, Edmonton, AB, Canada; [Padwal, Raj S.] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Gyenes, Gabor; Graham, Michelle] Mackenzie Hlth Sci Ctr, Div Cardiol, Dept Med, Edmonton, AB, Canada; [Headley, Samuel A. E.] Springfield Coll, Dept Exercise Sci & Sport Studies, Springfield, MA USA; [Radhakrishnan, Jeyasundar] Innovat Phys Therapy Edmonton, Edmonton, AB, Canada	University of Alberta; University of Alberta; Springfield College	Thompson, S (corresponding author), Univ Alberta, Div Nephrol, Dept Med, Edmonton, AB, Canada.	th11@ualberta.ca	Wiebe, Natasha/V-7803-2019; Padwal, Raj/G-6903-2016	Wiebe, Natasha/0000-0002-5613-1582; Padwal, Raj/0000-0003-3541-2817; Thompson, Stephanie/0000-0003-3109-6837	University of Alberta, Department of Medicine	University of Alberta, Department of Medicine	This study was supported through funding from the University of Alberta, Department of Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal R, 2009, CLIN J AM SOC NEPHRO, V4, P830, DOI 10.2215/CJN.06201208; Aizawa K, 2008, OPEN CARDIOVASC MED, V2, P3, DOI 10.2174/1874192400802010003; Anderson AH, 2015, ANN INTERN MED, V162, P258, DOI 10.7326/M14-0488; Aoike DT, 2018, CLIN EXP NEPHROL, V22, P87, DOI 10.1007/s10157-017-1429-2; Aoike DT, 2015, INT UROL NEPHROL, V47, P359, DOI 10.1007/s11255-014-0894-8; Arora P, 2013, CAN MED ASSOC J, V185, pE417, DOI 10.1503/cmaj.120833; Ashor AW, 2015, SPORTS MED, V45, P279, DOI 10.1007/s40279-014-0272-9; Bakris GL, 2010, HYPERTENSION, V56, P824, DOI 10.1161/HYPERTENSIONAHA.110.156976; Barcellos FC, 2018, J HUM HYPERTENS, V32, P397, DOI 10.1038/s41371-018-0055-0; Baria F, 2014, NEPHROL DIAL TRANSPL, V29, P857, DOI 10.1093/ndt/gft529; Bassler D, 2010, JAMA-J AM MED ASSOC, V303, P1180, DOI 10.1001/jama.2010.310; Borenstein M., 2009, INTRO METAANALYSIS, DOI [10. 1002/9780470743386, DOI 10.1002/9780470743386]; Campbell N, 2017, KIDNEY INT REP, V2, P733, DOI [10.1111/jch.12948, 10.1016/j.ekir.2017.02.009]; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; Chiu YW, 2009, CLIN J AM SOC NEPHRO, V4, P1089, DOI 10.2215/CJN.00290109; Ciolac EG, 2012, AM J CARDIOVASC DIS, V2, P102; Cushman WC, J CLIN HYPERTENS GRE, V4, P393; Dickinson HO, 2006, J HYPERTENS, V24, P215, DOI 10.1097/01.hjh.0000199800.72563.26; Dimeo F, 2012, HYPERTENSION, V60, P653, DOI 10.1161/HYPERTENSIONAHA.112.197780; Downey RM, 2017, AM J PHYSIOL-RENAL, V312, pF917, DOI 10.1152/ajprenal.00603.2016; Drawz PE, 2018, J AM SOC NEPHROL, V29, P383, DOI 10.1681/ASN.2017070753; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ferrier KE, 2001, HYPERTENSION, V38, P222, DOI 10.1161/01.HYP.38.2.222; Green DJ, 2004, J PHYSIOL-LONDON, V561, P1, DOI 10.1113/jphysiol.2004.068197; Green DJ, 2009, EXERC SPORT SCI REV; Greenwood SA, 2015, AM J KIDNEY DIS, V65, P425, DOI 10.1053/j.ajkd.2014.07.015; Guimaraes GV, 2010, HYPERTENS RES, V33, P627, DOI 10.1038/hr.2010.42; Headley S, 2017, NEPHROLOGY, V22, P72, DOI 10.1111/nep.12730; Headley S, 2014, AM J KIDNEY DIS, V64, P222, DOI 10.1053/j.ajkd.2014.02.022; Headley S, 2012, MED SCI SPORT EXER, V44, P2392, DOI 10.1249/MSS.0b013e318268c70c; Heiwe S, 2014, AM J KIDNEY DIS, V64, P383, DOI 10.1053/j.ajkd.2014.03.020; Heiwe S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003236.pub2; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Howden EJ, 2015, CURR OPIN NEPHROL HY, V24, P480, DOI 10.1097/MNH.0000000000000165; Howden EJ, 2013, CLIN J AM SOC NEPHRO, V8, P1494, DOI 10.2215/CJN.10141012; Ikizler TA, 2018, J AM SOC NEPHROL, V29, P250, DOI 10.1681/ASN.2017010020; Khan YH, 2017, CLIN EXP NEPHROL, V21, P1011, DOI 10.1007/s10157-017-1397-6; Kiuchi MG, 2017, KIDNEY RES CLIN PRAC, V36, P264, DOI 10.23876/j.krcp.2017.36.3.264; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; Lee JH, 2018, DIABETOL METAB SYNDR, V10, DOI 10.1186/s13098-018-0316-7; Leehey DJ, 2016, AM J NEPHROL, V44, P54, DOI 10.1159/000447703; Leehey DJ, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-62; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lin AM, 2016, AM J PHYSIOL-RENAL, V310, pF1016, DOI 10.1152/ajprenal.00527.2015; Linden E, 2008, CLIN J AM SOC NEPHRO, V3, P691, DOI 10.2215/CJN.04291007; Liu S, 2012, MED SCI SPORT EXER, V44, P1644, DOI 10.1249/MSS.0b013e31825408fb; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Manios E, 2009, J HYPERTENS, V27, P2244, DOI 10.1097/HJH.0b013e328330a94f; Marcum ZA, 2011, CURR OPIN NEPHROL HY, V20, P449, DOI 10.1097/MNH.0b013e32834902ad; Moe SM, 2008, J AM SOC NEPHROL, V19, P213, DOI 10.1681/ASN.2007080854; Mojon A, 2013, CHRONOBIOL INT, V30, P145, DOI 10.3109/07420528.2012.703083; Moran AE, 2015, NEW ENGL J MED, V372, P447, DOI 10.1056/NEJMsa1406751; Mustata S, 2011, INT UROL NEPHROL, V43, P1133, DOI 10.1007/s11255-010-9823-7; Myers MG, 2016, J CLIN HYPERTENS, V18, P721, DOI 10.1111/jch.12820; Padilla J, 2011, PHYSIOLOGY, V26, P132, DOI 10.1152/physiol.00052.2010; Park J, 2013, J APPL PHYSIOL, V114, P538, DOI 10.1152/japplphysiol.01037.2012; Peters JL, 2008, J CLIN EPIDEMIOL, V61, P991, DOI 10.1016/j.jclinepi.2007.11.010; Plantinga LC, 2009, HYPERTENSION, V54, P47, DOI 10.1161/HYPERTENSIONAHA.109.129841; Ricardo AC, 2015, AM J KIDNEY DIS, V65, P412, DOI 10.1053/j.ajkd.2014.09.016; Rossi AP, 2014, CLIN J AM SOC NEPHRO, V9, P2052, DOI 10.2215/CJN.11791113; Sabbahi A, 2016, PROG CARDIOVASC DIS, V59, P226, DOI 10.1016/j.pcad.2016.09.006; Sarafidis PA, 2012, NEPHRON CLIN PRACT, V120, pC147, DOI 10.1159/000337571; Schaeffner ES, 2008, NEPHROL DIAL TRANSPL, V23, P1246, DOI 10.1093/ndt/gfm757; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Sheng KX, 2014, AM J NEPHROL, V40, P478, DOI 10.1159/000368722; Shi ZM, 2014, J PHYS THER SCI, V26, P1733, DOI 10.1589/jpts.26.1733; Stewart KJ, 2005, ARCH INTERN MED, V165, P756, DOI 10.1001/archinte.165.7.756; Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187; Tinken TM, 2008, J PHYSIOL-LONDON, V586, P5003, DOI 10.1113/jphysiol.2008.158014; Townsend RR, 2010, AM J HYPERTENS, V23, P282, DOI 10.1038/ajh.2009.240; Van Craenenbroeck AH, 2015, AM J KIDNEY DIS, V66, P285, DOI 10.1053/j.ajkd.2015.03.015; Whelton SP, 2002, ANN INTERN MED, V136, P493, DOI 10.7326/0003-4819-136-7-200204020-00006; Wiebe N, 2006, J CLIN EPIDEMIOL, V59, P342, DOI 10.1016/j.jclinepi.2005.08.017; Wyngaert KV, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203662; Young HML, 2018, NEPHROL DIAL TRANSPL, V33, P1436, DOI 10.1093/ndt/gfy045; Young JH, 2002, J AM SOC NEPHROL, V13, P2776, DOI 10.1097/01.ASN.0000031805.09178.37; Zoccali C, 2006, KIDNEY INT, V70, P26, DOI 10.1038/sj.ki.5000417	79	22	22	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2019	14	2							e0211032	10.1371/journal.pone.0211032	http://dx.doi.org/10.1371/journal.pone.0211032			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK4EL	30726242	gold, Green Published, Green Submitted			2023-01-03	WOS:000457874000046
J	Vanbutsele, G; Deliens, L; Cocquyt, V; Cohen, J; Pardon, K; Chambaere, K				Vanbutsele, Gaelle; Deliens, Luc; Cocquyt, Veronique; Cohen, Joachim; Pardon, Koen; Chambaere, Kenneth			Use and timing of referral to specialized palliative care services for people with cancer: A mortality follow-back study among treating physicians in Belgium	PLOS ONE			English	Article							OF-LIFE PRACTICES; SYMPTOM BURDEN; HEMATOLOGICAL MALIGNANCIES; PATIENT; INTEGRATION; OUTCOMES; HEALTH; EUTHANASIA; ENROLLMENT; BARRIERS	Background Referral to specialized palliative care services (SPCS) occurs often late in the illness trajectory but may differ across cancer types. We examined differences between cancer types in the use and timing of referral to specialized palliative care services (SPCS) and in the reasons for non-referral. Methods We conducted a population-based mortality follow-back survey among physicians who certified a representative sample of deaths in Flanders, Belgium. We focused only on sampled death cases of cancer (n = 2392). The questionnaire asked about the use of the existing types of SPCS and the timing of referral to these services. Results Response rate was 58% (1394/2392). Patients who died from breast, respiratory, head and neck, genitourinary or gastrointestinal cancer had higher chances of using SPCS compared to hematologic cancer patients. The most prevalent reason for non-referral was that regular care sufficiently addressed palliative and supportive care needs (51%). This differed significantly between cancer types ranging from 77,8% for breast cancer and 42.1% for hematologic cancer. A second prevalent reason for not using SPCS was that it was not meaningful (enough) (23.9%), particularly for hematologic malignancies (35,1%) and only in 5.3% for breast cancer. Conclusion Differences in referral across different types of cancer were found. Referral is more often delayed or not initiated for patients with hematologic cancer, possibly due to differences in illness trajectory. An influencing reason is that physicians perceive palliative care as not meaningful or not meaningful enough for these patients which may be linked to the uncertainty in the disease trajectory of hematologic malignancies.	[Vanbutsele, Gaelle; Deliens, Luc; Cohen, Joachim; Pardon, Koen; Chambaere, Kenneth] Vrije Univ Brussel, End Of Life Care Res Grp, Brussels, Belgium; [Vanbutsele, Gaelle; Deliens, Luc; Cohen, Joachim; Pardon, Koen; Chambaere, Kenneth] Univ Ghent, Brussels, Belgium; [Vanbutsele, Gaelle; Deliens, Luc; Chambaere, Kenneth] Univ Ghent, Dept Publ Hlth & Primary Care, Ghent, Belgium; [Cocquyt, Veronique] Ghent Univ Hosp, Dept Med Oncol, Ghent, Belgium	Vrije Universiteit Brussel; Ghent University; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital	Vanbutsele, G; Pardon, K; Chambaere, K (corresponding author), Vrije Univ Brussel, End Of Life Care Res Grp, Brussels, Belgium.; Vanbutsele, G; Pardon, K; Chambaere, K (corresponding author), Univ Ghent, Brussels, Belgium.; Vanbutsele, G; Chambaere, K (corresponding author), Univ Ghent, Dept Publ Hlth & Primary Care, Ghent, Belgium.	gaelle.vanbutsele@uzgent.be; koen.pardon@vub.be; Kenneth.chambaere@vub.be	Cohen, Joachim/B-6803-2008; Chambaere, Kenneth/ACV-2311-2022	Cohen, Joachim/0000-0002-7224-9476; Pardon, Koen/0000-0002-0571-709X; Vanbutsele, Gaelle/0000-0003-0284-8585	Flemish government agency for Innovation by Science and Technology (Agentschap voor Innovatie door Wetenschap en Technologie) (SBO IWT) [100036]; Research Foundation Flanders (Fonds Wetenschappelijk Onderzoek) (FWO) [G018012N]; Belgian society Kom Op Tegen Kanker; scientific fund Willy Gepts (UZ Brussel)	Flemish government agency for Innovation by Science and Technology (Agentschap voor Innovatie door Wetenschap en Technologie) (SBO IWT); Research Foundation Flanders (Fonds Wetenschappelijk Onderzoek) (FWO)(FWO); Belgian society Kom Op Tegen Kanker; scientific fund Willy Gepts (UZ Brussel)	This study is part of the 'Flanders Study to Improve End-of-Life Care and Evaluation Tools (FLIECE) project', a collaboration between the Vrije Universiteit Brussel, Ghent University, the Katholieke Universiteit Leuven, Belgium, and VU University Medical Centre Amsterdam, the Netherlands. This study is supported by a grant from the Flemish government agency for Innovation by Science and Technology (Agentschap voor Innovatie door Wetenschap en Technologie) (SBO IWT nr. 100036). The first author, Gaelle Vanbutsele, was funded by a grant from the Research Foundation Flanders (Fonds Wetenschappelijk Onderzoek) (FWO nr. G018012N), by the Belgian society Kom Op Tegen Kanker and by the scientific fund Willy Gepts (UZ Brussel). The funding sources had no role in the design and collection, analysis, and interpretation of data and in writing the manuscript.	Ahmed N, 2004, PALLIATIVE MED, V18, P525, DOI 10.1191/0269216304pm921oa; Ansell P, 2007, PALLIATIVE MED, V21, P487, DOI 10.1177/0269216307082020; Auret K, 2003, INTERN MED J, V33, P566, DOI 10.1111/j.1445-5994.2003.00490.x; Bakitas M, 2009, JAMA-J AM MED ASSOC, V302, P741, DOI 10.1001/jama.2009.1198; Bauman JR, 2014, J NATL COMPR CANC NE, V12, P1763, DOI 10.6004/jnccn.2014.0177; Beernaert K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137251; Beernaert K, 2014, PALLIATIVE MED, V28, P480, DOI 10.1177/0269216314522318; Beernaert K, 2013, RESP MED, V107, P1731, DOI 10.1016/j.rmed.2013.06.003; Bekelman JE, 2016, JAMA-J AM MED ASSOC, V315, P272, DOI 10.1001/jama.2015.18603; Bennett MI, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012576; Bilsen J, 2009, NEW ENGL J MED, V361, P1119, DOI 10.1056/NEJMc0904292; Brickner Leslea, 2004, J Palliat Med, V7, P411, DOI 10.1089/1096621041349518; Bruera E, 2010, J CLIN ONCOL, V28, P4013, DOI 10.1200/JCO.2010.29.5618; Burge F, 2002, PALLIATIVE MED, V16, P255, DOI 10.1191/0269216302pm550xx; Casarett D, 2006, J AM GERIATR SOC, V54, P472, DOI 10.1111/j.1532-5415.2005.00628.x; Chambaere K, 2015, NEW ENGL J MED, V372, P1179, DOI 10.1056/NEJMc1414527; Chambaere K, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-299; Cheung WY, 2009, SUPPORT CARE CANCER, V17, P1223, DOI 10.1007/s00520-009-0577-7; Cleeland CS, 2013, CANCER-AM CANCER SOC, V119, P4333, DOI 10.1002/cncr.28376; Costantini M, 1999, J PAIN SYMPTOM MANAG, V18, P243, DOI 10.1016/S0885-3924(99)00084-6; Deliens L, 2000, LANCET, V356, P1806, DOI 10.1016/S0140-6736(00)03233-5; Fadul N, 2007, J PALLIAT MED, V10, P1146, DOI 10.1089/jpm.2006.0259; Fadul NA, 2008, J PALLIAT MED, V11, P422, DOI 10.1089/jpm.2007.0184; Federale Evaluatiecel Palliatieve Zorg, 2014, EV PALL ZORG; Good PD, 2004, J PAIN SYMPTOM MANAG, V27, P310, DOI 10.1016/j.jpainsymman.2003.12.011; Howell DA, 2011, PALLIATIVE MED, V25, P630, DOI 10.1177/0269216310391692; Hui D, 2015, ONCOLOGIST, V20, P77, DOI 10.1634/theoncologist.2014-0312; Hui D, 2014, CANCER-AM CANCER SOC, V120, P1743, DOI 10.1002/cncr.28628; Hui D, 2012, ONCOLOGIST, V17, P1574, DOI 10.1634/theoncologist.2012-0192; Hui D, 2010, JAMA-J AM MED ASSOC, V303, P1054, DOI 10.1001/jama.2010.258; Hunt RW, 2002, PALLIATIVE MED, V16, P403, DOI 10.1191/0269216302pm571oa; Johnson C, 2011, J PALLIAT MED, V14, P429, DOI 10.1089/jpm.2010.0259; Kaasa S, 2015, PALLIATIVE CARE ONCO, P299; Kavalieratos D, 2016, JAMA-J AM MED ASSOC, V316, P2104, DOI 10.1001/jama.2016.16840; Kwon JH, 2013, J PALLIAT MED, V16, P148, DOI 10.1089/jpm.2012.0344; Lamont EB, 2002, CANCER, V94, P2733, DOI 10.1002/cncr.10530; LeBlanc TW, 2015, J ONCOL PRACT, V11, pE230, DOI 10.1200/JOP.2014.001859; Love AW, 2014, PROG PALLIAT CARE, V22, P9, DOI 10.1179/1743291X13Y.0000000055; Manitta V, 2011, J PAIN SYMPTOM MANAG, V42, P432, DOI 10.1016/j.jpainsymman.2010.12.008; Manitta VJ, 2010, J PALLIAT MED, V13, P1021, DOI 10.1089/jpm.2009.0267; McCaughan D, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0289-1; McCaughan D, 2018, BMJ SUPPORT PALLIAT, V8, P78, DOI 10.1136/bmjspcare-2016-001289; McGrath P, 2007, EUR J CANCER CARE, V16, P164, DOI 10.1111/j.1365-2354.2006.00745.x; McGrath Pam, 2002, Am J Hosp Palliat Care, V19, P103, DOI 10.1177/104990910201900208; Morita T, 2002, PALLIATIVE MED, V16, P185, DOI 10.1191/0269216302pm524oa; Pardon K, 2013, J CLIN ONCOL, V31, P1450, DOI 10.1200/JCO.2012.44.5916; Quill TE, 2013, NEW ENGL J MED, V368, P1173, DOI 10.1056/NEJMp1215620; Rehse B, 2003, PATIENT EDUC COUNS, V50, P179; Rosenwax LK, 2006, PALLIATIVE MED, V20, P439, DOI 10.1191/0269216306pm1146oa; Schmidt H, 2015, J PAIN SYMPTOM MANAG, V49, P118, DOI 10.1016/j.jpainsymman.2014.04.007; Sepulveda C, 2002, J PAIN SYMPTOM MANAG, V24, P91, DOI 10.1016/S0885-3924(02)00440-2; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Vanbutsele G, 2018, LANCET ONCOL, V19, P394, DOI 10.1016/S1470-2045(18)30060-3; Walshe C, 2008, SOC SCI MED, V67, P137, DOI 10.1016/j.socscimed.2008.03.027; Zimmermann C, 2016, LEUKEMIA RES, V48, P78, DOI 10.1016/j.leukres.2016.07.012; Zimmermann C, 2014, LANCET, V383, P1721, DOI 10.1016/S0140-6736(13)62416-2	56	10	10	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2019	14	1							e0210056	10.1371/journal.pone.0210056	http://dx.doi.org/10.1371/journal.pone.0210056			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH8WT	30653508	gold, Green Published, Green Submitted			2023-01-03	WOS:000456015500025
J	Dias, FJ; Fazan, VPS; Cury, DP; de Almeida, SRY; Borie, E; Fuentes, R; Coutinho-Netto, J; Watanabe, IS				Jose Dias, Fernando; Sassoli Fazan, Valeria Paula; Cury, Diego Pulzatto; Yokomizo de Almeida, Sonia Regina; Borie, Eduardo; Fuentes, Ramon; Coutinho-Netto, Joaquim; Watanabe, Ii-sei			Growth factors expression and ultrastructural morphology after application of low-level laser and natural latex protein on a sciatic nerve crush-type injury	PLOS ONE			English	Article							GENE-EXPRESSION; NEUROTROPHIC FACTOR; CORD FORMATION; REGENERATION; THERAPY; TISSUE; REPAIR; PROLIFERATION; CELLS; ANGIOGENESIS	The effects of low-level laser therapy (LLLT) and natural latex protein (F1, Hevea brasiliensis) were evaluated on crush-type injuries (15kg) to the sciatic nerve in the expressions of nerve growth factor (NGF) and vascular endothelium growth factor (VEGF) and ultrastructural morphology to associate with previous morphometric data using the same protocol of injury and treatment. Thirty-six male rats were allocated into six experimental groups (n = 6): 1-Control; 2-Exposed nerve; 3-Injured nerve; 4-LLLT (15J/cm(2), 780nm, 30mW, Continuous Wave) treated injured nerve; 5-F1 (0,1mg) treated injured nerve; and 6-LLLT&F1 treated injured nerve. Four or eight weeks after, sciatic nerve samples were processed for analysis. NGF expression were higher (p<0.05) four weeks after in all injured groups in comparison to Control (Med: 0.8; Q1:0; Q3:55.5% area). Among them, the Injured (Med:70.7; Q1:64.4; Q3:77.5% area) showed the highest expression, and F1 (Med: 17.3; Q1:14.1; Q3:21.7% area) had the lowest. At week 8, NGF expressions decreased in the injured groups. VEGF was expressed in all groups; its higher expression was observed in the injured groups 4 weeks after (Injured. Med: 29.5; F1. Med:17.7 and LLLT&F1. Med:19.4% area). At week 8, a general reduction of VEGF expression was noted, remaining higher in F1 (Med:35.1; Q1.30.6; Q3.39.6% area) and LLLT&F1 (Med:18.5; Q1:16; Q3:25% area). Ultrastructural morphology revealed improvements in the treated groups; 4 weeks after, the F1 group presented greater quantity and diameter of the nerve fibers uniformly distributed. Eight weeks after, the F1 and LLLT&F1 showed similar characteristics to the non-injured groups. In summary, these results and our previous studies indicated that F1 and LLLT may favorably influence the healing of nerve crush injury. Four weeks after nerve injury F1 group showed the best results suggesting recovery acceleration; at 8th week F1 and LLLT& F1 groups presented better features and higher vascularization that could be associated with VEGF maintenance.	[Jose Dias, Fernando; Borie, Eduardo; Fuentes, Ramon] Univ La Frontera, Dent Sch, CICO Res Ctr Dent Sci, Dept Integral Dent, Temuco, Chile; [Sassoli Fazan, Valeria Paula] Univ Sao Paulo, Dept Surg & Anat, Sch Med Ribeirao Preto, Ribeirao Preto, Brazil; [Cury, Diego Pulzatto; Yokomizo de Almeida, Sonia Regina; Watanabe, Ii-sei] Univ Sao Paulo, Inst Biomed Sci, Dept Anat, Sao Paulo, Brazil; [Coutinho-Netto, Joaquim] Univ Sao Paulo, Dept Pharmacol, Sch Med Ribeirao Preto, Ribeirao Preto, Brazil	Universidad de La Frontera; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo	Dias, FJ (corresponding author), Univ La Frontera, Dent Sch, CICO Res Ctr Dent Sci, Dept Integral Dent, Temuco, Chile.	fernando.dias@ufrontera.cl	Cury, Diego Pulzatto/N-9870-2015; Cury, Diego Pulzatto/AAS-5015-2021; Dias, Fernando Jose/AAP-7420-2020; Dias, Fernando Jose/D-8228-2014	Cury, Diego Pulzatto/0000-0002-8571-7144; Cury, Diego Pulzatto/0000-0002-8571-7144; Watanabe, Ii-sei/0000-0002-1000-1467; Dias, Fernando Jose/0000-0001-9945-9185	"DIUFRO - Direccion de Investigacion Universidad de La Frontera" [DI17-0115]; FAPESP - Sao Paulo Research Foundation (Brazil) [2014/07253-4]	"DIUFRO - Direccion de Investigacion Universidad de La Frontera"; FAPESP - Sao Paulo Research Foundation (Brazil)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This work was supported by "DIUFRO - Direccion de Investigacion Universidad de La Frontera", Project DI17-0115 to FJD, http://investigacion.ufro.cl/; FAPESP - Sao Paulo Research Foundation (Brazil) -Project 2014/07253-4 to FJD, http://www.fapesp.br/en/.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Gomes LEA, 2012, PHOTOMED LASER SURG, V30, P642, DOI 10.1089/pho.2012.3242; Acosta CMR, 2013, CNS NEUROL DISORD-DR, V12, P1242; Alberts B., 2010, MOL BIOL CELL; Alcantara CC, 2013, LASER SURG MED, V45, P246, DOI 10.1002/lsm.22129; Alves MM, 2017, ABCD-ARQ BRAS CIR DI, V30, P93, DOI 10.1590/0102-6720201700020004; Andrade TAM, 2011, BRAZ J MED BIOL RES, V44, P1036, DOI 10.1590/S0100-879X2011007500116; Araujo LA, 2018, BRAZ J BIOL, V78, P271, DOI 10.1590/1519-6984.06316; Balabanian Claudia A C A, 2006, J Oral Sci, V48, P201, DOI 10.2334/josnusd.48.201; Brassolatti P, 2018, J TISSUE VIABILITY, V27, P249, DOI 10.1016/j.jtv.2018.10.001; Chang CJ, 2009, TISSUE ENG PT A, V15, P547, DOI 10.1089/ten.tea.2007.0342; Chen XQ, 2018, FREE RADICAL BIO MED, V114, P52, DOI 10.1016/j.freeradbiomed.2017.10.341; Chiono V, 2009, INT REV NEUROBIOL, V87, P173, DOI 10.1016/S0074-7742(09)87009-8; Camara CND, 2011, ACTA CIR BRAS, V26, P12, DOI 10.1590/S0102-86502011000100004; Dias FJ, 2015, J NEUROL SCI, V349, P129, DOI 10.1016/j.jns.2014.12.043; Dias FJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/597863; Evans GRD, 2001, ANAT RECORD, V263, P396, DOI 10.1002/ar.1120; Felix SP, 2013, MICROSURG, V33, P468, DOI 10.1002/micr.22109; Ferguson TA, 2011, J TISSUE ENG, V2, DOI 10.1177/2041731411418392; Szezerbaty SKF, 2018, LASER MED SCI, V33, P315, DOI 10.1007/s10103-017-2375-7; Giacca M, 2012, GENE THER, V19, P622, DOI 10.1038/gt.2012.17; Guo H, 2016, NEURAL REGEN RES, V11, P174, DOI 10.4103/1673-5374.175067; Hashimoto T, 2002, EXP BRAIN RES, V146, P356, DOI 10.1007/s00221-002-1173-y; Hashmi JT, 2010, PM&R, V2, pS292, DOI 10.1016/j.pmrj.2010.10.013; Holmes K, 2007, CELL SIGNAL, V19, P2003, DOI 10.1016/j.cellsig.2007.05.013; Ishikawa N, 2007, J BIOMED MATER RES A, V83A, P33, DOI 10.1002/jbm.a.31126; Issa JPM, 2012, GERODONTOLOGY, V29, P258, DOI 10.1111/j.1741-2358.2011.00526.x; Jang CH, 2012, INT J PEDIATR OTORHI, V76, P1823, DOI 10.1016/j.ijporl.2012.09.009; Johnson-Weaver B, 2018, CURR OPIN PHARMACOL, V41, P89, DOI 10.1016/j.coph.2018.05.004; Kashyap MP, 2018, MOL NEUROBIOL, V55, P6939, DOI 10.1007/s12035-018-0885-3; Keefe KM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030548; Kim JR, 2013, TISSUE ENG PT A, V19, P2674, DOI [10.1089/ten.TEA.2012.0735, 10.1089/ten.tea.2012.0735]; Kim YS, 2013, BIOCHEM BIOPH RES CO, V431, P740, DOI 10.1016/j.bbrc.2013.01.045; Lecht S, 2010, VASC PHARMACOL, V53, P107, DOI 10.1016/j.vph.2010.04.005; Li BH, 2012, OR SURG OR MED OR PA, V113, pE26, DOI 10.1016/j.tripleo.2011.07.002; Li RJ, 2014, CELL BIOCHEM BIOPHYS, V68, P449, DOI 10.1007/s12013-013-9742-1; Lundborg G, 2003, J PERIPHER NERV SYST, V8, P209, DOI 10.1111/j.1085-9489.2003.03027.x; de Albornoz PM, 2011, BRIT MED BULL, V100, P73, DOI 10.1093/bmb/ldr005; Ziago EKM, 2017, LASER MED SCI, V32, P369, DOI 10.1007/s10103-016-2126-1; Medalha CC, 2012, LASER MED SCI, V27, P629, DOI 10.1007/s10103-011-1008-9; Meek MF, 2004, TISSUE ENG, V10, P1027, DOI 10.1089/ten.2004.10.1027; Meloni M, 2010, CIRC RES, V106, P1275, DOI 10.1161/CIRCRESAHA.109.210088; Mendonca RJ, 2010, PHYTOTHER RES, V24, P764, DOI 10.1002/ptr.3043; Mligiliche Nurru L., 2003, Anatomical Science International, V78, P156, DOI 10.1046/j.0022-7722.2003.00056.x; Mrue Fatima, 2004, Mat. Res., V7, P277, DOI 10.1590/S1516-14392004000200010; Ganga MVM, 2012, ACTA CIR BRAS, V27, P885, DOI 10.1590/S0102-86502012001200010; Muniz KL, 2015, MUSCLE NERVE, V52, P869, DOI 10.1002/mus.24602; Ohta M, 2018, INT J MOL MED, V42, P1484, DOI 10.3892/ijmm.2018.3714; Park J, 2010, J BIOMED MATER RES A, V93A, P1091, DOI 10.1002/jbm.a.32519; Park MJ, 2007, J BIOL CHEM, V282, P30485, DOI 10.1074/jbc.M701081200; Barreiros VCP, 2014, GROWTH FACTORS, V32, P164, DOI 10.3109/08977194.2014.952727; Pfister LA, 2007, J PERIPHER NERV SYST, V12, P65, DOI 10.1111/j.1529-8027.2007.00125.x; Rahbek UL, 2005, PFLUG ARCH EUR J PHY, V450, P355, DOI 10.1007/s00424-005-1436-0; Raimondo S, 2011, ANN ANAT, V193, P334, DOI 10.1016/j.aanat.2011.03.001; Raimondo S, 2009, INT REV NEUROBIOL, V87, P81, DOI 10.1016/S0074-7742(09)87005-0; Richner M, 2014, MOL NEUROBIOL, V50, P945, DOI 10.1007/s12035-014-8706-9; Rochkind S, 2016, PHOTOMED LASER SURG, V34, P585, DOI 10.1089/pho.2016.4206; Rochkind S, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/FOC.2009.26.2.E8; Rovak JM, 2004, J RECONSTR MICROSURG, V20, P53, DOI 10.1055/s-2004-818050; Sampaio RB, 2010, CURR EYE RES, V35, P56, DOI 10.3109/02713680903374216; Shen CC, 2011, INJURY, V42, P803, DOI 10.1016/j.injury.2011.02.005; Shibuya A, 2015, INHIBITORY IMMUNOREC, DOI [10.1007/978-4-431-55651-0_8, DOI 10.1007/978-4-431-55651-0_8]; Teixeira LD, 2012, CLIN EXP IMMUNOL, V168, P285, DOI 10.1111/j.1365-2249.2012.04582.x; Urzua U, 2012, HORM METAB RES, V44, P656, DOI 10.1055/s-0032-1304617; Wang WX, 2011, ACTA PHARMACOL SIN, V32, P1483, DOI 10.1038/aps.2011.141; Wang Y, 2018, INT J TUBERC LUNG D, V22, P1227, DOI 10.5588/ijtld.18.0027; Xiao L, 2013, HUM CELL, V26, P91, DOI 10.1007/s13577-013-0069-4; Yang CC, 2016, J TISSUE ENG REGEN M, V10, P120, DOI 10.1002/term.1714; Yang J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00978; Yazdani SO, 2012, J PHOTOCH PHOTOBIO B, V107, P9, DOI 10.1016/j.jphotobiol.2011.11.001; Yen P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027514; Zettler C, 1996, J NEUROSCI RES, V46, P581, DOI 10.1002/(SICI)1097-4547(19961201)46:5<581::AID-JNR7>3.0.CO;2-F; Zhao Juan, 2011, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V25, P107	72	10	11	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2019	14	1							e0210211	10.1371/journal.pone.0210211	http://dx.doi.org/10.1371/journal.pone.0210211			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG9VK	30625210	Green Published, gold, Green Submitted			2023-01-03	WOS:000455359400077
J	Bowden, J; Fenning, S; Marron, B; Macpherson, C; Boyce, S; Wardrope, V; Macmillan, KC; Johnston, L				Bowden, Jo; Fenning, Stephen; Marron, Brooke; Macpherson, Catriona; Boyce, Steinunn; Wardrope, Varrie; Macmillan, Karen Campbell; Johnston, Lucy			Best supportive care in advanced lung cancer-more than a label?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PALLIATIVE CARE; OUTCOMES; NEEDS		[Bowden, Jo; Fenning, Stephen; Macpherson, Catriona; Boyce, Steinunn] Queen Margaret Hosp, NHS Fife Specialist Palliat Care Serv, Dunfermline, Fife, Scotland; [Marron, Brooke; Macmillan, Karen Campbell; Johnston, Lucy] Edinburgh Napier Univ, Edinburgh, Midlothian, Scotland; [Marron, Brooke] Univ Glasgow, Glasgow, Lanark, Scotland	Edinburgh Napier University; University of Glasgow	Bowden, J (corresponding author), Queen Margaret Hosp, NHS Fife Specialist Palliat Care Serv, Dunfermline, Fife, Scotland.	joannabowden@nhs.net	campbell, karen/ABC-8720-2021	Fenning, Stephen/0000-0001-9297-7393; campbell, Karen/0000-0002-6104-9698				Adams D, 2018, BJA EDUC, V18, P89, DOI 10.1016/j.bjae.2017.12.002; Fife Health and Social Care Partnership, 2016, FIF HLTH SOC CAR PAR; Godlee F., 2015, BMJ-BRIT MED J, V350, ph1217, DOI DOI 10.1136/BMJ.H1217; Maguire R, 2013, EUR J ONCOL NURS, V17, P449, DOI 10.1016/j.ejon.2012.10.013; Mulley A, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j1401; NHS England, 2014, ACT PALL END LIF CAR; Partridge AH, 2014, J CLIN ONCOL, V32, P3330, DOI 10.1200/JCO.2013.54.8149; Public Health England, 2017, COST EFF COMM END LI; Salins N, 2016, INDIAN J PALLIAT CAR, V22, P252, DOI 10.4103/0973-1075.185028; Scottish Cancer Taskforce National Cancer Quality Steering Group, 2012, LUNG CANC CLIN QUAL; Scottish Government, 2016, NAT CLIN STRAT SCOTL; Scottish Government, 2015, STRAT FRAM ACT PALL; Scottish Government, TRANSF CAR TREATM; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; The Scottish Government, 2016, BEAT CANC AMB ACT; who, WHO DEF PALL CAR; Wilcock A, 2016, RESP MED, V114, P38, DOI 10.1016/j.rmed.2016.03.006; WISE J, 2017, BMJ-BRIT MED J, V356, DOI DOI 10.1136/BMJ.J370; Zafar SY, 2012, LANCET ONCOL, V13, pE77, DOI 10.1016/S1470-2045(11)70215-7	19	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 27	2018	363								k5017	10.1136/bmj.k5017	http://dx.doi.org/10.1136/bmj.k5017			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG1JM	30591556				2023-01-03	WOS:000454710000001
J	Leight, J; Sharma, V; Brown, W; Costica, L; Sule, FA; Nyqvist, MB				Leight, Jessica; Sharma, Vandana; Brown, Willa; Costica, Laura; Sule, Fatima Abdulaziz; Nyqvist, Martina Bjorkman			Associations between birth kit use and maternal and neonatal health outcomes in rural Jigawa state, Nigeria: A secondary analysis of data from a cluster randomized controlled trial	PLOS ONE			English	Article							CLEAN DELIVERY KIT; INTERVENTION; MORTALITY; IMPACT; DEATH; CARE	Background The burden of maternal and neonatal mortality remains persistently high in Nigeria. Sepsis contributes significantly to both maternal and newborn mortality, and safe delivery kits have long been promoted as a cost-effective intervention to ensure hygienic delivery practices and reduce sepsis. However, there is limited evidence on the effectiveness of home birth kit distribution by community health workers, and particularly the impact of this intervention on health outcomes. This paper reports a secondary analysis of data from a cluster randomized trial in rural northern Nigeria in which birth kits were distributed by community health workers to pregnant women in their homes, analyzing non-experimental variation in receipt and use of birth kits. More specifically, associations between pregnant women's baseline characteristics and receipt and use of birth kits, and associations between birth kit use, care utilization and maternal and newborn outcomes were assessed. Methods and findings Baseline, post-birth and endline data related to 3,317 births observed over a period of three years in 72 intervention communities in Jigawa state, Nigeria, were analyzed using hierarchical, logistic regression models. In total, 140 women received birth kits, and 72 women used the kits. There were no associations between baseline demographic characteristics, health history, and knowledge and attitudes and receipt of a kit, suggesting that community health workers did not systematically target the distribution of birth kits. However, women who used the kit reported reduced odds of past pregnancy complications (OR = 0.44, 95% CI: 0.19-1.00) as well as significantly higher odds of feeling generally healthy at baseline (OR = 2.00, 95% CI: 1.06-3.76), of exposure to radio media (OR = 1.97, 95% CI: 1.21-3.22), and of perceiving themselves as having a low-risk pregnancy (OR = 3.05, 95% CI: 1.39-6.68). While there were no significant associations between birth kit use and facility based delivery, skilled birth attendance or post-natal care, women who used a kit exhibited significantly lower odds of completing four or more ANC visits (adjusted OR = 0.39, 95% CI: 0.18-0.85) and significantly higher odds of reporting prolonged labor (adjusted OR = 4.75, 95% CI: 1.36-16.59), and post-partum bleeding (adjusted OR = 3.25, 95% CI: 1.11-9.52). Conclusions This evidence suggests that use of birth kits is low in a rural population characterized by minimal baseline utilization of maternal and neonatal health services, and the use of birth kits was not associated with reductions in maternal or neonatal morbidity. While further research is required to understand how the effectiveness of birth kits may be shaped by the mechanism through which women access and utilize the kits, our findings suggest that the provision of kits to women outside of the formal health system may be associated with increased risk of adverse outcomes.	[Leight, Jessica; Sule, Fatima Abdulaziz] Amer Univ, Econ Dept, Washington, DC 20016 USA; [Sharma, Vandana] Harvard TH Chan Sch Publ Hlth, Cambridge, MA USA; [Brown, Willa] MIT, Abdul Latif Jameel Poverty Act Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Costica, Laura] Planned Parenthood Federat Nigeria, Abuja, Nigeria; [Nyqvist, Martina Bjorkman] Stockholm Sch Econ, Stockholm, Sweden	American University; Harvard University; Harvard T.H. Chan School of Public Health; Massachusetts Institute of Technology (MIT); Stockholm School of Economics	Leight, J (corresponding author), Amer Univ, Econ Dept, Washington, DC 20016 USA.	leight@american.edu		Sule, Fatima Abdulaziz/0000-0001-8684-0630; Leight, Jessica/0000-0002-1691-9682	John D. and Catherine T. MacArthur Foundation; U.S. Agency for International Development [FY14-G11-6990, GHS-A-00-09-00015-00]	John D. and Catherine T. MacArthur Foundation; U.S. Agency for International Development(United States Agency for International Development (USAID))	The John D. and Catherine T. MacArthur Foundation (https://www.macfound.org/) provided the primary funding for this research in a grant awarded to MB, JL and VS. (No grant number was assigned.) The U.S. Agency for International Development provided secondary funding under Subgrant FY14-G11-6990 under cooperative agreement GHS-A-00-09-00015-00 (https://www.urc-chs.com/projects/translating-research-actiontraction-project); the principal investigator for the award was VS, and MB, JL and FAS were coinvestigators. The funders provided funding for all research activities and provided salary support for VS, FAS and LC. However, the funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011190; Akinyemi JO, 2012, BMC PEDIAT, V15; Aleman A, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0436-9; Balsara ZP, 2009, J PERINATOL, V29, P673, DOI 10.1038/jp.2009.80; Beun M, 2017, J HLTH POPULATION NU, V4, P367; Cameron A., 2010, HDB EMPIRICAL EC FIN, V3666, P1, DOI [10.1201/b10440-2, DOI 10.1201/B10440-2]; Colomar M, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0299-0; Darmstadt GL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009696; GARNER P, 1994, J TROP PEDIATRICS, V40, P24, DOI 10.1093/tropej/40.1.24; GREENLAND S, 1994, AM J EPIDEMIOL, V139, P747, DOI 10.1093/oxfordjournals.aje.a117069; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; Hundley VA, 2012, MIDWIFERY, V28, P204, DOI 10.1016/j.midw.2011.03.004; Jokhio AH, 2005, NEW ENGL J MED, V352, P2091, DOI 10.1056/NEJMsa042830; KAPOOR S K, 1991, Indian Journal of Pediatrics, V58, P341, DOI 10.1007/BF02754963; Khan K, 2007, LANCET, V367; Lawn JE, 2006, INT J EPIDEMIOL, V35, P706, DOI 10.1093/ije/dyl043; Leight J., 2016, AEA RCT REGISTRY; Meegan ME, 2001, LANCET, V358, P640, DOI 10.1016/S0140-6736(01)05787-7; Morrison J, 2015, ASIA-PAC J PUBLIC HE, V27, pNP1263, DOI 10.1177/1010539512458950; Mosha F, 2005, Tanzan Health Res Bull, V7, P185; Nigeria Demographic Health Survey, 2014, NIG DEM HLTH SURV; NPC (National Population Commission), 2006, POP HOUS CENS FED RE; Okeke E, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1688-8; Pagel C, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-151; PPFN, 2012, PPFN PROGR IMPL PLAN; PPFN, 2012, PPFN TRAIN MAN CORPS; Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X; Seward N, 2012, PLOS MED, P204; Seward N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136152; Sharma V, 2017, J HEALTH POPUL NUTR, V36, DOI 10.1186/s41043-017-0124-y; Sharma V, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1341-5; SHEINER LB, 1995, CLIN PHARMACOL THER, V57, P6, DOI 10.1016/0009-9236(95)90260-0; Simkhada B, 2008, J ADV NURS, V61, P244, DOI 10.1111/j.1365-2648.2007.04532.x; Tsu V., 2000, CLEAN HOME DELIVERY; UNICEF, 2009, STATE WORLDS CHILDRE; Wang P, 2016, TROP MED INT HEALTH, V21, P515, DOI 10.1111/tmi.12678; WHO,, 1994, ESSENTIAL NEWBORN CA; Winani S, 2007, J MIDWIFERY WOM HEAL, V52, P37, DOI 10.1016/j.jmwh.2006.09.004; Word Health Organization, 2018, INF YOUNG CHILD FEED; World Health Organization, 1998, CAR UMB CORD REV EV	41	2	2	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 26	2018	13	12							e0208885	10.1371/journal.pone.0208885	http://dx.doi.org/10.1371/journal.pone.0208885			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF7JV	30586441	Green Published, gold, Green Submitted			2023-01-03	WOS:000454416400043
J	Farooqi, MAM; Malhotra, N; Mukherjee, SD; Sanger, S; Dhesy-Thind, SK; Ellis, P; Leong, DP				Farooqi, Mohammed A. M.; Malhotra, Nikita; Mukherjee, Som D.; Sanger, Stephanie; Dhesy-Thind, Sukhbinder K.; Ellis, Peter; Leong, Darryl P.			Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials	PLOS ONE			English	Review							PREVIOUSLY TREATED PATIENTS; PHASE-II; PLUS SIMVASTATIN; DOUBLE-BLIND; PRAVASTATIN; BIAS; CHEMOTHERAPY; MULTICENTER; INHIBITION; CARCINOMA	Background Preclinical evidence suggests statins may have anti-tumor properties. Large observational studies are also consistent with improved survival and cancer-specific outcomes among cancer patients on statins. We sought to evaluate the randomized controlled trials of statins in addition to usual anti-cancer therapy. Methods A systematic search of MEDLINE, Embase, CINAHL, Cochrane Library, Web of Science, Papers First and Clinicaltrials. gov was performed from inception through to July 4, 2017 to identify randomized clinical trials that investigated statin therapy in cancer patients. Our primary outcome was overall survival and our secondary outcome was progression-free survival. We calculated summary hazard ratio's (HR) and 95% confidence intervals (CI) based on random-effects models using aggregate data. PROSPERO (CRD42017065503). Results Ten studies with 1,881 individuals were included with 1,572 deaths and a median follow-up of 23 months. All trials included patients with advanced (stage 3 or higher) disease. There was minimal between-study statistical heterogeneity (I-2 = 1.8%, for OS; I-2 = 0%, for PFS). The pooled HR for overall survival in patients randomized to statins plus standard anti-cancer therapy versus standard therapy alone was 0.94 (95% CI, 0.85 to 1.04). In the 9 studies that reported progression-free survival (1,798 participants), the pooled HR for statin plus standard therapy versus standard therapy alone was 0.97 (95% CI, 0.87 to 1.07). Conclusions In patients with advanced cancer and a prognosis < 2 years, the addition of statins to standard anti-cancer therapy does not appear to improve overall survival or progression-free survival. Future research should assess if cancer patients with better prognosis benefit from longer-term statin therapy.	[Farooqi, Mohammed A. M.; Malhotra, Nikita; Leong, Darryl P.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Farooqi, Mohammed A. M.; Leong, Darryl P.] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada; [Farooqi, Mohammed A. M.; Leong, Darryl P.] McMaster Univ, Hamilton Hlth Sci, Hamilton, ON, Canada; [Mukherjee, Som D.; Dhesy-Thind, Sukhbinder K.; Ellis, Peter] McMaster Univ, Div Med Oncol, Dept Oncol, Hamilton, ON, Canada; [Sanger, Stephanie] McMaster Univ, Hlth Sci Lib, Hamilton, ON, Canada	McMaster University; McMaster University; Population Health Research Institute; McMaster University; McMaster University; McMaster University	Leong, DP (corresponding author), McMaster Univ, Dept Med, Hamilton, ON, Canada.; Leong, DP (corresponding author), McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada.; Leong, DP (corresponding author), McMaster Univ, Hamilton Hlth Sci, Hamilton, ON, Canada.	darryl.leong@phri.ca	Sanger, Stephanie L/F-5828-2017	Sanger, Stephanie L/0000-0001-8456-5823; Leong, Darryl/0000-0002-1968-169X; Farooqi, Mohammed/0000-0001-5282-4034	Hamilton Health Sciences Strategic Research Initiative; Heart and Stroke Foundation of Canada; Canadian Institutes of Health Research	Hamilton Health Sciences Strategic Research Initiative; Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Dr. Darryl Leong is supported by the Hamilton Health Sciences Strategic Research Initiative, the Heart and Stroke Foundation of Canada, and the Canadian Institutes of Health Research.	Altwairgi AK, 2015, ONCOL REP, V33, P1019, DOI 10.3892/or.2015.3741; Baines AT, 2011, FUTURE MED CHEM, V3, P1787, DOI [10.4155/FMC.11.121, 10.4155/fmc.11.121]; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Chan KKW, 2003, CLIN CANCER RES, V9, P10; Clutterbuck RD, 1998, BRIT J HAEMATOL, V102, P522, DOI 10.1046/j.1365-2141.1998.00783.x; Collins R, 2016, LANCET, V388, P2532, DOI 10.1016/S0140-6736(16)31357-5; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; El-Hamamsy M, 2016, ONCOL RES, V24, P521, DOI 10.3727/096504016X14719078133528; Gbelcova H, 2008, INT J CANCER, V122, P1214, DOI 10.1002/ijc.23242; Georgescu EF, 2011, HEPATOL INT, V5, P423; Gizzo S, 2015, CURR DRUG TARGETS, V16, P1142, DOI 10.2174/1389450116666150330113239; Han JY, 2011, CLIN CANCER RES, V17, P1553, DOI 10.1158/1078-0432.CCR-10-2525; Higgins J.P.T, 2011, BMJ, V343; Hindler K, 2006, ONCOLOGIST, V11, P306, DOI 10.1634/theoncologist.11-3-306; Hong JY, 2014, CANCER CHEMOTH PHARM, V73, P125, DOI 10.1007/s00280-013-2328-1; Hus M, 2011, ANN HEMATOL, V90, P1161, DOI 10.1007/s00277-011-1276-2; Inano H, 1997, CARCINOGENESIS, V18, P1723, DOI 10.1093/carcin/18.9.1723; Jackevicius CA, 2002, JAMA-J AM MED ASSOC, V288, P462, DOI 10.1001/jama.288.4.462; Kawata S, 2001, BRIT J CANCER, V84, P886, DOI 10.1054/bjoc.2000.1716; Khanzada UK, 2006, ONCOGENE, V25, P877, DOI 10.1038/sj.onc.1209117; Kim ST, 2014, EUR J CANCER, V50, P2822, DOI 10.1016/j.ejca.2014.08.005; Konings IRHM, 2010, EUR J CANCER, V46, P3200, DOI 10.1016/j.ejca.2010.07.036; Lee Y, 2017, CANCER RES TREAT, V49, P1001, DOI 10.4143/crt.2016.546; Lim SH, 2015, BRIT J CANCER, V113, P1421, DOI 10.1038/bjc.2015.371; Lyman Gary H, 2005, BMC Med Res Methodol, V5, P14, DOI 10.1186/1471-2288-5-14; Mei ZB, 2017, INT J CANCER, V140, P1068, DOI 10.1002/ijc.30526; Mullen PJ, 2016, NAT REV CANCER, V16, P718, DOI 10.1038/nrc.2016.76; Narisawa T, 1996, TOHOKU J EXP MED, V180, P131, DOI 10.1620/tjem.180.131; Nielsen SF, 2012, NEW ENGL J MED, V367, P1792, DOI 10.1056/NEJMoa1201735; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Samura B, 2016, Georgian Med News, P56; Seckl MJ, 2017, J CLIN ONCOL, V35, P1506, DOI 10.1200/JCO.2016.69.7391; Suissa S, 2008, AM J EPIDEMIOL, V167, P492, DOI 10.1093/aje/kwm324; Thompson PD, 2016, J AM COLL CARDIOL, V67, P2395, DOI 10.1016/j.jacc.2016.02.071; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393; Wong WWL, 2001, CLIN CANCER RES, V7, P2067; Yusuf S, 2016, NEW ENGL J MED, V374, P2021, DOI 10.1056/NEJMoa1600176	40	38	40	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2018	13	12							e0209486	10.1371/journal.pone.0209486	http://dx.doi.org/10.1371/journal.pone.0209486			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF0HP	30571754	Green Submitted, gold, Green Published			2023-01-03	WOS:000453841700081
J	MacKellar, D; Maruyama, H; Rwabiyago, OE; Steiner, C; Cham, H; Msumi, O; Weber, R; Kundi, G; Suraratdecha, C; Mengistu, T; Byrd, J; Pals, S; Churi, E; Madevu-Matson, C; Kazaura, K; Morales, F; Rutachunzibwa, T; Justman, J; Rwebembera, A				MacKellar, Duncan; Maruyama, Haruka; Rwabiyago, Oscar Ernest; Steiner, Claire; Cham, Haddi; Msumi, Omari; Weber, Rachel; Kundi, Gerald; Suraratdecha, Chutima; Mengistu, Tewodaj; Byrd, Johnita; Pals, Sherri; Churi, Eliufoo; Madevu-Matson, Caitlin; Kazaura, Kokuhumbya; Morales, Fernando; Rutachunzibwa, Thomas; Justman, Jessica; Rwebembera, Anath			Implementing the package of CDC and WHO recommended linkage services: Methods, outcomes, and costs of the Bukoba Tanzania Combination Prevention Evaluation: Peer-delivered, linkage case management program, 2014-2017	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; HIV-INFECTION; PARTNER SERVICES; CARE; INTERVENTIONS; INITIATION; COMMUNITY; COUNTRIES; BARRIERS; CASCADE	Although several studies have evaluated one or more linkage services to improve early enrollment in HIV care in Tanzania, none have evaluated the package of linkage services recommended by the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). We describe the uptake of each component of the CDC/WHO recommended package of linkage services, and early enrollment in HIV care and antiretroviral therapy (ART) initiation among persons with HIV who participated in a peer-delivered, linkage case management (LCM) program implemented in Bukoba, Tanzania, October 2014-May 2017. Of 4206 participants (88% newly HIV diagnosed), most received recommended services including counseling on the importance of early enrollment in care and ART (100%); escort by foot or car to an HIV care and treatment clinic (CTC) (83%); treatment navigation at a CTC (94%); telephone support and appointment reminders (77% among clients with cellphones); and counseling on HIV-status disclosure and partner/family testing (77%), and on barriers to care (69%). During three periods with different ART-eligibility thresholds [CD4<350 (Oct 2014-Dec 2015, n = 2233), CD4 <= 500 (Jan 2016-Sept 2016, n = 1221), and Test & Start (Oct 2016-May 2017, n = 752)], 90%, 96%, and 97% of clients enrolled in HIV care, and 47%, 67%, and 86% of clients initiated ART, respectively, within three months of diagnosis. Of 463 LCM clients who participated in the last three months of the rollout of Test & Start, 91% initiated ART. Estimated per-client cost was $44 United States dollars (USD) for delivering LCM services in communities and facilities overall, and $18 USD for a facility-only model with task shifting. Well accepted by persons with HIV, peer-delivered LCM services recommended by CDC and WHO can achieve near universal early ART initiation in the Test & Start era at modest cost and should be considered for implementation in facilities and communities experiencing <90% early enrollment in ART care.	[MacKellar, Duncan; Cham, Haddi; Suraratdecha, Chutima; Mengistu, Tewodaj; Pals, Sherri] Ctr Dis Control & Prevent, Div Global HIV & TB, Natl Ctr Global Hlth, Atlanta, GA 30333 USA; [Maruyama, Haruka; Steiner, Claire; Msumi, Omari; Kundi, Gerald; Churi, Eliufoo; Morales, Fernando] Columbia Univ, ICAP, Dar Es Salaam, Tanzania; [Rwabiyago, Oscar Ernest; Kazaura, Kokuhumbya] Ctr Dis Control & Prevent, Dar Es Salaam, Tanzania; [Weber, Rachel] CTS Global Inc, Ctr Dis Control & Prevent, Dar Es Salaam, Tanzania; [Byrd, Johnita] ICF Int, Atlanta, GA USA; [Madevu-Matson, Caitlin; Justman, Jessica] Columbia Univ, ICAP, New York, NY USA; [Rutachunzibwa, Thomas] MoHCDGEC, Bukoba, Tanzania; [Rwebembera, Anath] MoHCDGEC, Natl AIDS Control Program, Dar Es Salaam, Tanzania	Centers for Disease Control & Prevention - USA; Columbia University	MacKellar, D (corresponding author), Ctr Dis Control & Prevent, Div Global HIV & TB, Natl Ctr Global Hlth, Atlanta, GA 30333 USA.	dym4@cdc.gov	Justman, Jessica/AAA-3572-2020	Mengistu, Tewodaj/0000-0003-3475-3599; MacKellar, Duncan/0000-0001-8217-9881	President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention [5UGPS001998]; ICF International	President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention; ICF International	This work was funded through the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (cooperative agreement 5UGPS001998). ICF International was contracted by the U.S. Centers for Disease Control and Prevention to provide data-management services only. Author Johnita Byrd is employed by ICF International. ICF International provided support in the form of salary for author JB, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.	Asiimwe S, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.5.21633; Auld AF, 2017, MMWR-MORBID MORTAL W, V66, P558, DOI 10.15585/mmwr.mm6621a3; Auld AF, 2015, MMWR-MORBID MORTAL W, V64, P1281, DOI 10.15585/mmwr.mm6446a2; Barnabas RV, 2014, LANCET HIV, V1, pE68, DOI 10.1016/S2352-3018(14)70024-4; Bassett IV, 2017, JAIDS-J ACQ IMM DEF, V74, P432, DOI [10.1097/QAI.0000000000001277, 10.1097/qai.0000000000001277]; Centers for Disease Control and Prevention Health Resources and Services Administration National Institutes of Health American Academy of HIV Medicine Association of Nurses in AIDS Care International Association of Providers of AIDS Care the National Minority AIDS Council Urban Coalition for HIV/AIDS Prevention Services, 2014, REC HIV PREV AD AD H, V2014; Cherutich P, 2017, LANCET HIV, V4, pE74, DOI 10.1016/S2352-3018(16)30214-4; Fagan JL, 2012, AIDS CARE, V24, P737, DOI 10.1080/09540121.2011.630360; Ford N, 2018, AIDS, V32, P17, DOI [10.1097/QAD.0000000000001671, 10.1097/qad.0000000000001671]; Genberg BL, 2016, AIDS BEHAV, V20, P2452, DOI 10.1007/s10461-016-1307-z; Govindasamy D, 2012, AIDS, V26, P2059, DOI 10.1097/QAD.0b013e3283578b9b; Hayes R, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002292; Henley C, 2013, SEX TRANSM DIS, V40, P909, DOI 10.1097/OLQ.0000000000000032; Hodgson I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111421; Iwuji CC, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002107; Kahabuka C, 2017, AIDS BEHAV, V21, P2551, DOI 10.1007/s10461-017-1750-5; Layer EH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104961; Little K, 2016, 11 INT C HIV TREATM; MacKellar D, 2018, MMWR-MORBID MORTAL W, V67, P663, DOI 10.15585/mmwr.mm6723a3; MacKellar DA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150086; Maheu-Giroux M, 2017, AIDS, V31, P1017, DOI 10.1097/QAD.0000000000001435; Mavegam BO, 2017, AIDS CARE, V29, P1198, DOI 10.1080/09540121.2017.1306637; Meehan SA, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2760-8; Ministry of Health Community Development Gender Elderly and Children, 2017, MAPP HIV SERV DEL ST, P24; National Bureau of Statistics United Republic of Tanzania, POP PROJ YEARS 2016; Nsigaye R, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-31; OANDA, 2014, HIST EXCH RAT; Ostermann J, 2015, AIDS CARE, V27, P59, DOI 10.1080/09540121.2015.1090534; Parker LA, 2015, TROP MED INT HEALTH, V20, P893, DOI 10.1111/tmi.12501; Reddy EA, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1804-8; Rosenberg NE, 2015, LANCET HIV, V2, pE483, DOI 10.1016/S2352-3018(15)00182-4; Sanga ES, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013733; Sharma M, 2015, NATURE, V528, pS77, DOI 10.1038/nature16044; Simmelink AM, 2014, MZIMA OPEN ADULT HLT; Tucker JD, 2017, EBIOMEDICINE, V17, P163, DOI 10.1016/j.ebiom.2017.01.036; UNAIDS, 2014, 90 90 90 AMBITIOUS T; United States President's Emergency Plan for AIDS Relief (PEPFAR), 2018, PEPFAR SOL PLATF; Ware NC, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20929; WHO, 2016, GUID HIV SELF TEST P; WHO (World Health Organization), 2016, PROGR REP 2016 PREV; World Health Organization, 2016, CONS GUID US ANT DRU; World Health Organization (WHO), 2017, GUIDELINES MANAGING; Wynberg E, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.18809	43	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2018	13	12							e0208919	10.1371/journal.pone.0208919	http://dx.doi.org/10.1371/journal.pone.0208919			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HE3IL	30543693	gold, Green Submitted, Green Published			2023-01-03	WOS:000453247500052
J	Makino, K; Lee, S; Bae, S; Jung, S; Shinkai, Y; Chiba, I; Shimada, H				Makino, Keitaro; Lee, Sangyoon; Bae, Seongryu; Jung, Songee; Shinkai, Yohei; Chiba, Ippei; Shimada, Hiroyuki			Pain characteristics and incidence of functional disability among community-dwelling older adults	PLOS ONE			English	Article							CHRONIC MUSCULOSKELETAL PAIN; PREVALENCE; IMPACT; RISK; ONSET	This study examined the association between pain characteristics and the incidence of functional disability among community-dwelling older adults. This prospective cohort study included 4,365 older adults (mean age 74.7 years, 53.5% female) living in community settings. Pain characteristics, including severity and duration of pain, were assessed in participants who also underwent monthly follow-up assessment of functional disability for 24 months based on the national long-term care insurance system. Among the 4,365 participants, 2,149 (48.7%) reported pain, regardless of severity and duration. Of the 2,149 participants with pain, 950 (44.2%) reported moderate to severe pain and 1,680 (78.2%) reported chronic pain. Based on the univariate analyses, participants with moderate (hazard ratio [95% confidence interval]: 1.48 [1.05-2.09]) or severe (2.84 [1.89-4.27]) pain and chronic pain (1.50 [1.15-1.95]) showed significantly higher risk of disability incidence than did those without pain. After adjusting for covariates, severe pain remained a significant predictor (hazard ratio [95% confidence interval]: 1.66 [1.05-2.62]), but moderate (1.00 [0.69-1.47]) and chronic pain (1.04 [0.77-1.40]) did not. Our results established that moderate to severe pain or chronic pain affects functional disability; in particular, severe pain was independently associated with the incidence of disability. Subjective complaints of pain do not always correspond to physical causes; however, simplified questions regarding pain characteristics could be useful predictors of functional disability in community-dwelling older people.	[Makino, Keitaro; Lee, Sangyoon; Bae, Seongryu; Jung, Songee; Shinkai, Yohei; Chiba, Ippei; Shimada, Hiroyuki] Natl Ctr Geriatr & Gerontol, Dept Prevent Gerontol, Ctr Gerontol & Social Sci, Obu, Aichi, Japan; [Bae, Seongryu; Jung, Songee] Japan Soc Promot Sci, Tokyo, Japan	National Center for Geriatrics & Gerontology; Japan Society for the Promotion of Science	Makino, K (corresponding author), Natl Ctr Geriatr & Gerontol, Dept Prevent Gerontol, Ctr Gerontol & Social Sci, Obu, Aichi, Japan.	kmakino@ncgg.go.jp	Makino, Keitaro/AHA-7480-2022	Makino, Keitaro/0000-0001-9252-8256; jung, songee/0000-0002-9086-8334	Strategic Basic Research Programs Redesigning Communities for Aged Society of the Japan Science and Technology Agency; Japanese Ministry of Health, Labour and Welfare (Project for Optimizing Long-Term Care) [B-3]	Strategic Basic Research Programs Redesigning Communities for Aged Society of the Japan Science and Technology Agency; Japanese Ministry of Health, Labour and Welfare (Project for Optimizing Long-Term Care)	This work was supported by the Strategic Basic Research Programs Redesigning Communities for Aged Society of the Japan Science and Technology Agency; and the Japanese Ministry of Health, Labour and Welfare (Project for Optimizing Long-Term Care) [grant number: B-3]. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alic Alma, 2011, Med Arh, V65, P102; Andrews JS, 2013, J AM GERIATR SOC, V61, P583, DOI 10.1111/jgs.12172; Doi T, 2015, J AM MED DIR ASSOC, V16, P1082, DOI 10.1016/j.jamda.2015.07.007; Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012; Eggermont LHP, 2014, J AM GERIATR SOC, V62, P1007, DOI 10.1111/jgs.12848; Gibson SJ, 2012, PAIN MED, V13, pS23, DOI 10.1111/j.1526-4637.2012.01349.x; Gill TK, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-0946-6; Goesling J, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0421-0; Kaiho Y, 2017, ANESTHESIOLOGY, V126, P688, DOI [10.1097/ALN.0000000000001540, 10.1097/aln.0000000000001540]; Knutson GA, 2002, J MANIP PHYSIOL THER, V25, P110; Landi F, 2009, J PAIN SYMPTOM MANAG, V38, P350, DOI 10.1016/j.jpainsymman.2008.10.005; Leveille SG, 2009, JAMA-J AM MED ASSOC, V302, P2214, DOI 10.1001/jama.2009.1738; Makizako H, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008462; McBeth J, 2010, EUR J PAIN, V14, P972, DOI 10.1016/j.ejpain.2010.03.005; McGreevy Kai, 2011, Eur J Pain Suppl, V5, P365; Murata S, 2017, EUR J PAIN, V21, P1717, DOI 10.1002/ejp.1083; Ojagbemi A, 2017, J GERONTOL A-BIOL, V72, P997, DOI 10.1093/gerona/glv188; Patel KV, 2013, PAIN, V154, P2649, DOI 10.1016/j.pain.2013.07.029; Thomas E, 2004, PAIN, V110, P361, DOI 10.1016/j.pain.2004.04.017; Tsutsui T, 2005, J AM GERIATR SOC, V53, P522, DOI 10.1111/j.1532-5415.2005.53175.x; Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]; Whitlock EL, 2017, JAMA INTERN MED, V177, P1146, DOI 10.1001/jamainternmed.2017.1622; Woo J, 2009, PUBLIC HEALTH, V123, P549, DOI 10.1016/j.puhe.2009.07.006; Yamada M, 2015, J AM MED DIR ASSOC, V16, pe1007, DOI DOI 10.1016/J; YESAVAGE JA, 1988, PSYCHOPHARMACOL BULL, V24, P709	25	16	16	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2019	14	4							e0215467	10.1371/journal.pone.0215467	http://dx.doi.org/10.1371/journal.pone.0215467			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HT4AF	30986257	Green Published, Green Submitted, gold			2023-01-03	WOS:000464503800046
J	Koch, D; Schuetz, P; Haubitz, S; Kutz, A; Mueller, B; Weber, H; Regez, K; Conca, A; Schuetz, P; Hausfater, P; Amin, D; Haubitz, S; Faessler, L; Grolimund, E; Kutz, A; Schild, U; Caldara, Z; Regez, K; Zhydkov, A; Kahles, T; Nedeltchev, K; von Felten, S; De Geest, S; Conca, A; Schaefer-Keller, P; Huber, A; Bargetzi, M; Buergi, U; Sauvin, G; Perrig-Chiello, P; Reutlinger, B; Koch, D; Weber, H; Mueller, B				Koch, Daniel; Schuetz, Philipp; Haubitz, Sebastian; Kutz, Alexander; Mueller, Beat; Weber, Helen; Regez, Katharina; Conca, Antoinette; Schuetz, Philipp; Hausfater, Pierre; Amin, Devendra; Haubitz, Sebastian; Faessler, Lukas; Grolimund, Eva; Kutz, Alexander; Schild, Ursula; Caldara, Zeljka; Regez, Katharina; Zhydkov, Andriy; Kahles, Timo; Nedeltchev, Krassen; von Felten, Stefanie; De Geest, Sabina; Conca, Antoinette; Schaefer-Keller, Petra; Huber, Andreas; Bargetzi, Mario; Buergi, Ulrich; Sauvin, Gabrielle; Perrig-Chiello, Pasqualina; Reutlinger, Barbara; Koch, Daniel; Weber, Helen; Mueller, Beat		Triage Study Grp	Improving the post-acute care discharge score (PACD) by adding patients' self-care abilities: A prospective cohort study	PLOS ONE			English	Article							PREDICTION; MODEL	Background Reducing delays in hospital discharge is important to improve transition processes and reduce health care costs. The recently proposed post-acute care discharge score focusing on the self-care abilities before hospital admission allows early identification of patients with a need for post-acute care. New limitations in self-care abilities identified during hospitalization may also indicate a risk. Our aim was to investigate whether the addition of the post-acute care discharge score and a validated self-care instrument would improve the prognostic accuracy to predict post-acute discharge needs in unselected medical inpatients. Methods We included consecutive adult medical and neurological inpatients. Logistic regression models with area under the receiver operating characteristic curve were calculated to study associations of post-acute discharge score and self-care index with post-acute discharge risk. We calculated joint regression models and reclassification statistics including the net reclassification index and integrated discrimination improvement to investigate whether merging the self-care index and the post-acute discharge score leads to better diagnostic accuracy. Results Out of 1342 medical and 402 neurological patients, 150 (11.18%) and 94 (23.38%) have reached the primary endpoint of being discharged to a post-acute care facility. Multivariate analysis showed that the self-care index is an outcome predictor (OR 0.897, 95%Cl 0.864-0.930). By combining the self-care index and the post-acute care discharge score discrimination for medical (from area under the curve 0.77 to 0.83) and neurological patients (from area under the curve 0.68 to 0.78) could be significantly improved. Reclassification statistics also showed significant improvements with regard to net reclassification index (14.2%, p<0.05) and integrated discrimination improvement (4.83%, p<0.05). Conclusions Incorporating an early assessment of patients' actual intrahospital self-care ability to the post-acute care discharge score led to an improved prognostic accuracy for identifying adult, medical and neurological patients at risk for discharge to a post-acute care facility.	[Koch, Daniel; Weber, Helen; Conca, Antoinette] Kantonsspital Aarau AG, Dept Clin Nursing Sci, Aarau, Switzerland; [Koch, Daniel; Schuetz, Philipp; Haubitz, Sebastian; Kutz, Alexander; Mueller, Beat; Regez, Katharina; Conca, Antoinette] Kantonsspital Aarau AG, Univ Dept Internal Med, Aarau, Switzerland; [Koch, Daniel; Schuetz, Philipp; Grolimund, Eva; Kutz, Alexander; Schild, Ursula; Caldara, Zeljka; Regez, Katharina; Zhydkov, Andriy; Bargetzi, Mario; Mueller, Beat] Kantonsspital Aarau, Univ Dept Internal Med, Aarau, Switzerland; [Hausfater, Pierre; Sauvin, Gabrielle] Grp Hosp Pitie Salpetriere, AP HP, Emergency Dept 1, Paris, France; [Amin, Devendra] Morton Plant Hosp, Dept Crit Care, Clearwater, FL USA; [Haubitz, Sebastian] Div Infect Dis, Aarau, Switzerland; [Haubitz, Sebastian] Kantonsspital Aarau, Hosp Epidemiol, Aarau, Switzerland; [Faessler, Lukas; Perrig-Chiello, Pasqualina] Univ Bern, Dept Psychol, Bern, Switzerland; [Kahles, Timo; Nedeltchev, Krassen] Kantonsspital Aarau, Dept Neurol, Aarau, Switzerland; [von Felten, Stefanie] Univ Hosp Basel, Clin Trial Unit, Basel, Switzerland; [De Geest, Sabina] Univ Basel, Inst Nursing Sci, Basel, Switzerland; [Conca, Antoinette; Reutlinger, Barbara; Weber, Helen] Kantonsspital Aarau, Dept Clin Nursing Sci, Aarau, Switzerland; [Schaefer-Keller, Petra] Univ Appl Sci & Arts Western Switzerland, Sch Hlth Sci Fribourg, HedS FR, HES SO, Fribourg, Switzerland; [Huber, Andreas] Kantonsspital Aarau, Dept Lab Med, Aarau, Switzerland; [Buergi, Ulrich] Kantonsspital Aarau, Emergency Dept, Aarau, Switzerland	Kantonsspital Aarau AG (KSA); Kantonsspital Aarau AG (KSA); Kantonsspital Aarau AG (KSA); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Kantonsspital Aarau AG (KSA); University of Bern; Kantonsspital Aarau AG (KSA); University of Basel; University of Basel; Kantonsspital Aarau AG (KSA); University of Applied Sciences & Arts Western Switzerland; Kantonsspital Aarau AG (KSA); Kantonsspital Aarau AG (KSA)	Conca, A (corresponding author), Kantonsspital Aarau AG, Dept Clin Nursing Sci, Aarau, Switzerland.; Conca, A (corresponding author), Kantonsspital Aarau AG, Univ Dept Internal Med, Aarau, Switzerland.	antoinette.conca@ksa.ch; beat.mueller@ksa.ch	schuetz, philipp/C-8475-2013; Mueller, Beat/G-2662-2012; von Felten, Stefanie/L-3514-2019	schuetz, philipp/0000-0001-6400-4949; von Felten, Stefanie/0000-0002-5264-6394; Koch, Daniel/0000-0002-4660-5924; De Geest, Sabina/0000-0001-6596-7237	Thermofisher; Swiss National Science Foundation (SNSF) [PP00P3_150531/1]; Swiss National Science Foundation [SNF 407440_167376]; Schweizerische Akademie der Medizinischen Wissenschaften (SAMW)	Thermofisher; Swiss National Science Foundation (SNSF)(Swiss National Science Foundation (SNSF)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Schweizerische Akademie der Medizinischen Wissenschaften (SAMW)	Thermofisher provided an unrestricted research grant for this study. PS is supported by the Swiss National Science Foundation (SNSF Professorship, PP00P3_150531/1); http://www.snf.ch/de/Seiten/default.aspx.BM is supported by the Swiss National Science Foundation (SNF 407440_167376). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. http://www.snf.ch/de/Seiten/default.aspx. This study was also supported by the Schweizerische Akademie der Medizinischen Wissenschaften (SAMW).	AlHilli MM, 2013, J AM COLL SURGEONS, V217, P507, DOI 10.1016/j.jamcollsurg.2013.04.036; Bartholomeyczik S, 2006, FOCUS; Campbell SE, 2005, AGE AGEING, V34, P467, DOI 10.1093/ageing/afi141; Conca A, 2015, PFLEGEWISSENSCHAFT, V11; Conca A, 2012, PFLEGEWISSENSCHAFT, V5, DOI [10.3936/1155, DOI 10.3936/1155]; Conca A, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2897-0; Costa AP, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-172; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Grosse-Schlarmann J, 2007, CMS EPA VERSCHIEDENE; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hauck K, 2011, MED CARE, V49, P1068, DOI 10.1097/MLR.0b013e31822efb09; Hendy P, 2012, CLIN MED, V12, P320, DOI 10.7861/clinmedicine.12-4-320; Holland DE, 2006, NURS RES, V55, P62, DOI 10.1097/00006199-200601000-00008; Hunstein D., 2015, ENTWICKLUNG TESTUNG; Jette DU, 2014, PHYS THER, V94, P1252, DOI 10.2522/ptj.20130359; Jupp BJ, 2011, GERIATR GERONTOL INT, V11, P8, DOI 10.1111/j.1447-0594.2010.00626.x; Kantonsspital Aarau AG, 2017, KSA GESCH 2014 2015; Liu SK, 2016, J AM GERIATR SOC, V64, P2095, DOI 10.1111/jgs.14345; Majeed MU, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-410; Schariatzadeh R, 2011, Praxis (Bern 1994), V100, P75, DOI 10.1024/1661-8157/a000410; Schuetz P., 2012, OPTIMIERTER PATIEN 4; Schuetz P, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1098-z; Schuetz P, 2013, BMC EMERG MED, V13, DOI 10.1186/1471-227X-13-12; Simonet ML, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-154; Sundstrom J, 2011, SCAND J PUBLIC HEALT, V39, P439, DOI 10.1177/1403494810396556; Tanaka M, 2008, ARCH GERONTOL GERIAT, V47, P1, DOI 10.1016/j.archger.2007.06.002	26	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2019	14	3							e0214194	10.1371/journal.pone.0214194	http://dx.doi.org/10.1371/journal.pone.0214194			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ7IR	30921356	Green Published, Green Submitted, gold			2023-01-03	WOS:000462594000038
J	Andersen, LW; Holmberg, MJ; Berg, KM; Donnino, MW; Granfeldt, A				Andersen, Lars W.; Holmberg, Mathias J.; Berg, Katherine M.; Donnino, Michael W.; Granfeldt, Asger			In-Hospital Cardiac Arrest A Review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ASSOCIATION GUIDELINES UPDATE; RESUSCITATION COUNCIL GUIDELINES; TARGETED TEMPERATURE MANAGEMENT; DECOMPRESSION CARDIOPULMONARY-RESUSCITATION; INITIAL NEUROLOGIC EXAMINATION; RANDOMIZED CONTROLLED-TRIAL; ENDOTRACHEAL INTUBATION; PREARREST PREDICTORS; TRACHEAL INTUBATION; INDUCED HYPOTHERMIA	IMPORTANCE In-hospital cardiac arrest is common and associated with a high mortality rate. Despite this, in-hospital cardiac arrest has received little attention compared with other high-risk cardiovascular conditions, such as stroke, myocardial infarction, and out-of-hospital cardiac arrest. OBSERVATIONS In-hospital cardiac arrest occurs in over 290 000 adults each year in the United States. Cohort data from the United States indicate that the mean age of patients with in-hospital cardiac arrest is 66 years, 58% are men, and the presenting rhythm is most often (81%) nonshockable (ie, asystole or pulseless electrical activity). The cause of the cardiac arrest is most often cardiac (50%-60%), followed by respiratory insufficiency (15%-40%). Efforts to prevent in-hospital cardiac arrest require both a system for identifying deteriorating patients and an appropriate interventional response (eg, rapid response teams). The key elements of treatment during cardiac arrest include chest compressions, ventilation, early defibrillation, when applicable, and immediate attention to potentially reversible causes, such as hyperkalemia or hypoxia. There is limited evidence to support more advanced treatments. Post-cardiac arrest care is focused on identification and treatment of the underlying cause, hemodynamic and respiratory support, and potentially employing neuroprotective strategies (eg, targeted temperature management). Although multiple individual factors are associated with outcomes (eg, age, initial rhythm, duration of the cardiac arrest), a multifaceted approach considering both potential for neurological recovery and ongoing multiorgan failure is warranted for prognostication and clinical decision-making in the post-cardiac arrest period. Withdrawal of care in the absence of definite prognostic signs both during and after cardiac arrest should be avoided. Hospitals are encouraged to participate in national quality-improvement initiatives. CONCLUSIONS AND RELEVANCE An estimated 290 000 in-hospital cardiac arrests occur each year in the United States. However, there is limited evidence to support clinical decision making. An increased awareness with regard to optimizing clinical care and new research might improve outcomes.	[Andersen, Lars W.; Holmberg, Mathias J.] Aarhus Univ, Dept Clin Med, Res Ctr Emergency Med, Palle Juul Jensens Blvd 99,Bygning J, DK-8200 Aarhus N, Denmark; [Andersen, Lars W.; Holmberg, Mathias J.; Berg, Katherine M.; Donnino, Michael W.] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Ctr Resuscitat Sci, Boston, MA 02215 USA; [Andersen, Lars W.] Randers Reg Hosp, Dept Intens Care Med, Randers, Denmark; [Berg, Katherine M.; Donnino, Michael W.] Beth Israel Deaconess Med Ctr, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02215 USA; [Granfeldt, Asger] Aarhus Univ Hosp, Dept Intens Care, Aarhus, Denmark	Aarhus University; Harvard University; Beth Israel Deaconess Medical Center; Aarhus University; Harvard University; Beth Israel Deaconess Medical Center; Aarhus University	Andersen, LW (corresponding author), Aarhus Univ, Dept Clin Med, Res Ctr Emergency Med, Palle Juul Jensens Blvd 99,Bygning J, DK-8200 Aarhus N, Denmark.	lwandersen@clin.au.dk	Holmberg, Mathias/GWQ-7813-2022	Granfeldt, Asger/0000-0002-7241-6131; Holmberg, Mathias Johan/0000-0001-5816-337X; Andersen, Lars Wiuff/0000-0001-5752-8082	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL127101, K23HL128814, R01HL136705] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL136705, K24 HL127101, K23 HL128814] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMSON NS, 1991, NEW ENGL J MED, V324, P1225; Anantharaman V, 2017, OPEN ACCESS EMERG M, V9, P9, DOI 10.2147/OAEM.S109339; Andersen LW, 2018, RESUSCITATION, V126, P72, DOI 10.1016/j.resuscitation.2018.02.021; Andersen LW, 2017, JAMA-J AM MED ASSOC, V317, P494, DOI 10.1001/jama.2016.20165; Andersen LW, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1577; Andersen LW, 2016, RESUSCITATION, V98, P112, DOI 10.1016/j.resuscitation.2015.08.016; Anderson ML, 2016, JAMA CARDIOL, V1, P37, DOI 10.1001/jamacardio.2015.0275; Annborn M, 2014, INTENS CARE MED, V40, P1210, DOI 10.1007/s00134-014-3375-8; Beitler JR, 2017, AM J RESP CRIT CARE, V195, P1198, DOI 10.1164/rccm.201609-1771OC; Benger JR, 2018, JAMA-J AM MED ASSOC, V320, P779, DOI 10.1001/jama.2018.11597; Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI 10.1161/CIR.0000000000000558; Berg KM, 2017, RESUSCITATION, V119, P18, DOI 10.1016/j.resuscitation.2017.07.024; Bergum D, 2015, RESUSCITATION, V97, P91, DOI 10.1016/j.resuscitation.2015.09.395; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bircher NG, 2019, ANESTHESIOLOGY, V130, P414, DOI 10.1097/ALN.0000000000002563; Bossaert LL, 2015, RESUSCITATION, V95, P302, DOI 10.1016/j.resuscitation.2015.07.033; Bradley SM, 2012, RESUSCITATION, V83, P1349, DOI 10.1016/j.resuscitation.2012.03.014; Brady WJ, 2011, RESUSCITATION, V82, P845, DOI 10.1016/j.resuscitation.2011.02.028; Bro-Jeppesen J, 2015, CRIT CARE MED, V43, P318, DOI 10.1097/CCM.0000000000000691; Callaway CW, 2015, CIRCULATION, V132, pS465, DOI 10.1161/CIR.0000000000000262; Chan PS, 2008, NEW ENGL J MED, V358, P9, DOI 10.1056/NEJMoa0706467; Chan PS, 2016, JAMA-J AM MED ASSOC, V316, P1375, DOI 10.1001/jama.2016.14380; Chan PS, 2013, NEW ENGL J MED, V368, P1019, DOI 10.1056/NEJMoa1200657; Chan PS, 2012, ARCH INTERN MED, V172, P947, DOI 10.1001/archinternmed.2012.2050; Chan PS, 2010, JAMA-J AM MED ASSOC, V304, P2129, DOI 10.1001/jama.2010.1576; COHEN TJ, 1993, NEW ENGL J MED, V329, P1918, DOI 10.1056/NEJM199312233292603; Coppler PJ, 2015, RESUSCITATION, V89, P86, DOI 10.1016/j.resuscitation.2015.01.020; DANARREST Steering Commitee, 2015, DANARREST REG HJERT; De Bruin ML, 2007, BRIT J CLIN PHARMACO, V63, P216, DOI 10.1111/j.1365-2125.2006.02722.x; Donnino MW, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3028; Eastwood GM, 2016, RESUSCITATION, V104, P83, DOI 10.1016/j.resuscitation.2016.03.023; Ebell MH, 2011, FAM PRACT, V28, P505, DOI 10.1093/fampra/cmr023; EBELL MH, 1992, J FAM PRACTICE, V34, P551; Galea S, 2007, AM J EPIDEMIOL, V166, P534, DOI 10.1093/aje/kwm102; Galhotra S, 2007, QUAL SAF HEALTH CARE, V16, P260, DOI 10.1136/qshc.2007.022210; Get With the Guidelines-Resuscitation Registry, 2014, GET GUID RES REG RES; Girotra S, 2012, NEW ENGL J MED, V367, P1912, DOI 10.1056/NEJMoa1109148; Goldberger ZD, 2012, LANCET, V380, P1473, DOI 10.1016/S0140-6736(12)60862-9; Harrison DA, 2014, RESUSCITATION, V85, P993, DOI 10.1016/j.resuscitation.2014.05.004; Hasselqvist-Ax I, 2015, NEW ENGL J MED, V372, P2307, DOI 10.1056/NEJMoa1405796; Holmberg M, 2018, AM HEART ASS RES SCI; Holmberg MJ, 2018, RESUSCITATION, V131, P91, DOI 10.1016/j.resuscitation.2018.07.029; Hu K, 2018, ANN EMERG MED, V71, P193, DOI 10.1016/j.annemergmed.2017.07.476; Itenov TS, 2018, LANCET RESP MED, V6, P183, DOI 10.1016/S2213-2600(18)30004-3; Jabre P, 2018, JAMA-J AM MED ASSOC, V319, P779, DOI 10.1001/jama.2018.0156; Joseph L, 2017, JAMA CARDIOL, V2, P976, DOI 10.1001/jamacardio.2017.2403; Koster RW, 2017, EUR HEART J, V38, P3006, DOI 10.1093/eurheartj/ehx318; Kronick SL, 2015, CIRCULATION, V132, pS397, DOI 10.1161/CIR.0000000000000258; Kudenchuk PJ, 1999, NEW ENGL J MED, V341, P871, DOI 10.1056/NEJM199909163411203; Larkin GL, 2010, RESUSCITATION, V81, P302, DOI 10.1016/j.resuscitation.2009.11.021; Laver S, 2004, INTENS CARE MED, V30, P2126, DOI 10.1007/s00134-004-2425-z; Legriel S, 2018, RESUSCITATION, V132, P147, DOI 10.1016/j.resuscitation.2018.08.004; Link MS, 2015, CIRCULATION, V132, pS444, DOI 10.1161/CIR.0000000000000261; LIPMAN J, 1993, ANAESTH INTENS CARE, V21, P192, DOI 10.1177/0310057X9302100210; Look X, 2018, AM J EMERG MED, V36, P66, DOI 10.1016/j.ajem.2017.07.017; Maharaj R, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0973-y; Mancini ME, 2015, CIRCULATION, V132, pS383, DOI 10.1161/CIR.0000000000000254; Mentzelopoulos SD, 2013, JAMA-J AM MED ASSOC, V310, P270, DOI 10.1001/jama.2013.7832; Mentzelopoulos SD, 2009, ARCH INTERN MED, V169, P15, DOI 10.1001/archinternmed.2008.509; Merchant RM, 2011, CRIT CARE MED, V39, P2401, DOI 10.1097/CCM.0b013e3182257459; Monsieurs KG, 2015, RESUSCITATION, V95, P1, DOI 10.1016/j.resuscitation.2015.07.038; Morrison LJ, 2013, CIRCULATION, V127, P1538, DOI 10.1161/CIR.0b013e31828b2770; Moskowitz A, 2018, RESUSCITATION, V124, P106, DOI 10.1016/j.resuscitation.2017.12.031; Mourvillier B, 2013, JAMA-J AM MED ASSOC, V310, P2174, DOI 10.1001/jama.2013.280506; Movahedi A, 2016, ACAD EMERG MED, V23, P448, DOI 10.1111/acem.12903; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; Neumar RW, 2015, CIRCULATION, V132, pS315, DOI 10.1161/CIR.0000000000000252; Nolan JP, 2014, RESUSCITATION, V85, P987, DOI 10.1016/j.resuscitation.2014.04.002; Overdyk H, 2016, PLOS ONE, V11, DOI 10.1371/journaLuune.0150214; Paiva EF, 2018, RESUSCITATION, V123, P1, DOI 10.1016/j.resuscitation.2017.12.003; PATRICK WD, 1995, AM J RESP CRIT CARE, V152, P519, DOI 10.1164/ajrccm.152.2.7633701; Paul M, 2016, INTENS CARE MED, V42, P1128, DOI 10.1007/s00134-016-4349-9; Perkins GD, 2018, NEW ENGL J MED, V379, P711, DOI 10.1056/NEJMoa1806842; Perman SM, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003638; Pittl U, 2013, CLIN RES CARDIOL, V102, P607, DOI 10.1007/s00392-013-0572-3; Radeschi G, 2017, RESUSCITATION, V119, P48, DOI 10.1016/j.resuscitation.2017.06.020; Roberts BW, 2018, CIRCULATION, V137, P2114, DOI 10.1161/CIRCULATIONAHA.117.032054; Roberts BW, 2013, CIRCULATION, V127, P2107, DOI 10.1161/CIRCULATIONAHA.112.000168; Rohlin O, 2018, RESUSCITATION, V132, P1, DOI 10.1016/j.resuscitation.2018.08.017; SACK JB, 1992, JAMA-J AM MED ASSOC, V267, P379; SACK JB, 1992, CIRCULATION, V86, P1692, DOI 10.1161/01.CIR.86.6.1692; Sandroni C, 2007, INTENS CARE MED, V33, P237, DOI 10.1007/s00134-006-0326-z; Sandroni C, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2060-7; Schluep M, 2018, RESUSCITATION, V132, P90, DOI 10.1016/j.resuscitation.2018.09.001; Sinha SS, 2016, CIRC-CARDIOVASC QUAL, V9, P749, DOI 10.1161/CIRCOUTCOMES.116.002916; Smith M E Beth, 2014, Ann Am Thorac Soc, V11, P1454, DOI 10.1513/AnnalsATS.201403-102OC; Soar J, 2015, RESUSCITATION, V95, pE71, DOI 10.1016/j.resuscitation.2015.07.042; Soar J, 2015, RESUSCITATION, V95, P100, DOI 10.1016/j.resuscitation.2015.07.016; Starks MA, 2018, AM HEART J, V204, P156, DOI 10.1016/j.ahj.2018.04.018; Stiell IG, 1996, JAMA-J AM MED ASSOC, V275, P1417, DOI 10.1001/jama.275.18.1417; STIELL IG, 1992, NEW ENGL J MED, V327, P1045, DOI 10.1056/NEJM199210083271502; Stiell IG, 2001, LANCET, V358, P105, DOI 10.1016/S0140-6736(01)05328-4; Thel MC, 1997, LANCET, V350, P1272, DOI 10.1016/S0140-6736(97)05048-4; Tirkkonen J, 2016, RESUSCITATION, V107, P19, DOI 10.1016/j.resuscitation.2016.07.007; Topjian AA, 2010, CRIT CARE MED, V38, P1254, DOI 10.1097/CCM.0b013e3181d8ca43; Tran S, 2016, RESUSCITATION, V107, P13, DOI 10.1016/j.resuscitation.2016.07.006; TUCKER KJ, 1994, J AM COLL CARDIOL, V24, P201, DOI 10.1016/0735-1097(94)90564-9; Vahedian-Azimi A, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1296-3; Velly L, 2018, LANCET NEUROL, V17, P317, DOI 10.1016/S1474-4422(18)30027-9; Wallace SK, 2013, CIRC-CARDIOVASC QUAL, V6, P148, DOI 10.1161/CIRCOUTCOMES.111.000041; Wallmuller C, 2012, RESUSCITATION, V83, P1206, DOI 10.1016/j.resuscitation.2012.05.001; Wang CH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202938; Wang HE, 2018, JAMA-J AM MED ASSOC, V320, P769, DOI 10.1001/jama.2018.7044; Weidman EK, 2010, RESUSCITATION, V81, P1556, DOI 10.1016/j.resuscitation.2010.05.021; Witten L, 2019, RESUSCITATION, V136, P93, DOI 10.1016/j.resuscitation.2019.01.031; Woodhouse SP, 1995, RESUSCITATION, V30, P243, DOI 10.1016/0300-9572(95)00890-X; Wu CS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191636; Youn CS, 2017, RESUSCITATION, V110, P120, DOI 10.1016/j.resuscitation.2016.10.024; Youn CS, 2015, RESUSCITATION, V94, P73, DOI 10.1016/j.resuscitation.2015.06.016; Zhang Q, 2017, CRIT CARE MED, V45, P1587, DOI 10.1097/CCM.0000000000002570	110	305	326	4	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2019	321	12					1200	1210		10.1001/jama.2019.1696	http://dx.doi.org/10.1001/jama.2019.1696			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR3XE	30912843	Green Submitted, Green Accepted			2023-01-03	WOS:000463074900016
J	Vihonen, H; Kuisma, M; Salo, A; Angerman, S; Pietilainen, K; Nurmi, J				Vihonen, Hanna; Kuisma, Markku; Salo, Ari; Angerman, Susanne; Pietilainen, Kirsi; Nurmi, Jouni			Mechanisms of early glucose regulation disturbance after out-of-hospital cardiopulmonary resuscitation: An explorative prospective study	PLOS ONE			English	Article							GLUCAGON-LIKE PEPTIDE-1; CRITICAL ILLNESS; CARDIAC-ARREST; BLOOD-GLUCOSE; INSULIN-SECRETION; PLASMA-GLUCOSE; STRESS; INCREASE; COUNCIL; CARE	Background Hyperglycemia is common and associated with increased mortality after out-of-hospital cardiac arrest (OHCA) and return of spontaneous circulation (ROSC). Mechanisms behind ultra-acute hyperglycemia are not well known. We performed an explorative study to describe the changes in glucose metabolism mediators during the prehospital postresuscitation phase. Methods We included patients who were successfully resuscitated from out-of-hospital cardiac arrest in two physician-staffed units. Insulin, glucagon, and glucagon-like peptide 1 (GLP-1) were measured in prehospital and hospital admission samples. Additionally, interleukin-6 (IL-6), cortisol, and HbA1c were measured at hospital admission. Results Thirty patients participated in the study. Of those, 28 cases (71% without diabetes) had sufficient data for analysis. The median time interval between prehospital samples and hospital admission samples was 96 minutes (IQR 85-119). At the time of ROSC, the patients were hyperglycemic (11.2 mmol/l, IQR 8.8-15.7), with insulin and glucagon concentrations varying considerably, although mostly corresponding to fasting levels (10.1 mU/l, IQR 4.2-25.2 and 141 ng/l, IQR 105-240, respectively). GLP-1 increased 2- to 8-fold with elevation of IL-6. The median glucose change from prehospital to hospital admission was -2.2 mmol/l (IQR -3.6 to -0.2). No significant correlations between the change in plasma glucose levels and the changes in insulin (r = 0.30, p = 0.13), glucagon (r = 0.29, p = 0.17), or GLP-1 levels (r = 0.32, p = 0.15) or with IL-6 (r = (-0.07), p = 0.75), cortisol (r = 0.13, p = 0.52) or HbA1c levels (r = 0.34, p = 0.08) were observed. However, in patients who did not receive exogenous epinephrine during resuscitation, changes in blood glucose correlated with changes in insulin (r = 0.59, p = 0.04) and glucagon (r = 0.65, p = 0.05) levels, demonstrating that lowering glucose values was associated with a simultaneous lowering of insulin and glucagon levels. Conclusions Hyperglycemia is common immediately after OHCA and cardiopulmonary resuscitation. No clear hormonal mechanisms were observed to be linked to changes in glucose levels during the postresuscitation phase in the whole cohort. However, in patients without exogenous epinephrine treatment, the correlations between glycemic and hormonal changes were more obvious. These results call for future studies examining the mechanisms of postresuscitation hyperglycemia and the metabolic effects of the global ischemic insult and medical treatment.	[Vihonen, Hanna] Paijat Hame Cent Hosp, Dept Emergency Med & Serv, Lahti, Finland; [Vihonen, Hanna; Kuisma, Markku; Salo, Ari; Angerman, Susanne; Nurmi, Jouni] Univ Helsinki, Dept Emergency Med & Serv, Helsinki, Finland; [Vihonen, Hanna; Kuisma, Markku; Salo, Ari; Angerman, Susanne; Pietilainen, Kirsi; Nurmi, Jouni] Helsinki Univ Hosp, Helsinki, Finland; [Pietilainen, Kirsi] Univ Helsinki, Obes Res Unit, Helsinki, Finland; [Pietilainen, Kirsi] Univ Helsinki, Abdominal Ctr, Endocrinol, Helsinki, Finland	Paijat Hame Central Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki	Vihonen, H (corresponding author), Paijat Hame Cent Hosp, Dept Emergency Med & Serv, Lahti, Finland.; Vihonen, H (corresponding author), Univ Helsinki, Dept Emergency Med & Serv, Helsinki, Finland.; Vihonen, H (corresponding author), Helsinki Univ Hosp, Helsinki, Finland.	hanna.vihonen@phsotey.fi	Pietiläinen, Kirsi/HJA-4960-2022	Kuisma, Markku/0000-0002-3057-6524; Pietilainen, Kirsi/0000-0002-8522-1288; Vihonen, Hanna/0000-0002-6060-408X	Academy of Finland [272376,266286, 314383]	Academy of Finland(Academy of Finland)	Funded by Academy of Finland, grant numbers: 272376,266286, and 314383 to KP. http://www.aka.fi.	Nguyen AT, 2014, DIABETES, V63, P471, DOI 10.2337/db13-0903; Arora S, 2014, CAN J EMERG MED, V16, P214, DOI 10.2310/8000.2013.131082; BARTON RN, 1985, BRIT MED BULL, V41, P218, DOI 10.1093/oxfordjournals.bmb.a072054; Bellomo R, 2015, BEST PRAC RES-CL ANA, V29, P471, DOI 10.1016/j.bpa.2015.10.003; Diebold S, 2018, DIABETES OBES METAB, V20, P2911, DOI 10.1111/dom.13472; Dungan KM, 2009, LANCET, V373, P1798, DOI 10.1016/S0140-6736(09)60553-5; Galiatsatos P, 2014, CRIT CARE MED, V42, P638, DOI 10.1097/CCM.0000000000000035; Kahles F, 2014, DIABETES, V63, P3221, DOI 10.2337/db14-0100; Krinsley JS, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0908-7; Lebherz C, 2017, AM J MED, V130, P833, DOI 10.1016/j.amjmed.2017.03.010; Lehrskov-Schmidt L, 2015, J CLIN ENDOCR METAB, V100, pE616, DOI 10.1210/jc.2014-4244; Llompart-Pou JA, 2012, NUTR HOSP, V27, P130, DOI [10.3305/nh.2012.27.1.5434, 10.1590/S0212-16112012000100015]; Marik P.E., 2013, CRIT CARE, V17, P1; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Meier JJ, 2004, DIABETES, V53, P654, DOI 10.2337/diabetes.53.3.654; Mesotten D, 2015, LANCET DIABETES ENDO, V3, P723, DOI 10.1016/S2213-8587(15)00223-5; Mizock BA, 2001, BEST PRACT RES CL EN, V15, P533, DOI 10.1053/beem.2001.0168; Nakamura M, 2012, CRIT CARE, V16, DOI 10.1186/cc11301; Nauck MA, 2002, J CLIN ENDOCR METAB, V87, P1239, DOI 10.1210/jc.87.3.1239; Nolan JP, 2015, RESUSCITATION, V95, P202, DOI 10.1016/j.resuscitation.2015.07.018; Nolan JP, 2008, RESUSCITATION, V79, P350, DOI 10.1016/j.resuscitation.2008.09.017; Nurmi J, 2012, DIABETES CARE, V35, P510, DOI 10.2337/dc11-1478; Nurmi J, 2011, ACAD EMERG MED, V18, P436, DOI 10.1111/j.1553-2712.2011.01020.x; Perl SH, 2018, DIABETES-METAB RES, V34, P1; Preiser JC, 2014, BRIT J ANAESTH, V113, P945, DOI 10.1093/bja/aeu187; Van den Berghe G, 1998, J CLIN ENDOCR METAB, V83, P1827, DOI 10.1210/jc.83.6.1827; Wiberg S, 2016, CIRCULATION, V134, P2115, DOI 10.1161/CIRCULATIONAHA.116.024088	27	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2019	14	3							e0214209	10.1371/journal.pone.0214209	http://dx.doi.org/10.1371/journal.pone.0214209			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ1KV	30908518	Green Published, Green Submitted, gold			2023-01-03	WOS:000462157600043
J	Kahan, S				Kahan, Scott			During weight-loss maintenance, energy expenditure was higher with lower-carbohydrate diets	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							MANAGEMENT; OBESITY		[Kahan, Scott] Johns Hopkins Bloomberg Sch Publ Hlth, Washington, DC USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Kahan, S (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Washington, DC USA.							Hall KD, 2018, BIORXIV, DOI [10.1101/476655, DOI 10.1101/476655]; Hall KD, 2018, MED CLIN N AM, V102, P183, DOI 10.1016/j.mcna.2017.08.012; Hall KD, 2017, GASTROENTEROLOGY, V152, P1718, DOI 10.1053/j.gastro.2017.01.052; Jensen MD, 2014, CIRCULATION, V129, pS102, DOI 10.1161/01.cir.0000437739.71477.ee	4	0	0	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 19	2019	170	6					JC31	JC31		10.7326/ACPJ201903190-031	http://dx.doi.org/10.7326/ACPJ201903190-031			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP1ZR	30884501				2023-01-03	WOS:000461468300008
J	Garcia-Otero, L; Lopez, M; Guitart-Mampel, M; Moren, C; Gonce, A; Esteve, C; Salazar, L; Gomez, O; Martinez, JM; Torres, B; Cesar, S; Garrabou, G; Crispi, F; Gratacos, E				Garcia-Otero, Laura; Lopez, Marta; Guitart-Mampel, Mariona; Moren, Constanza; Gonce, Anna; Esteve, Carol; Salazar, Laura; Gomez, Olga; Maria Martinez, Josep; Torres, Berta; Cesar, Sergi; Garrabou, Gloria; Crispi, Fatima; Gratacos, Eduard			Cardiac and mitochondrial function in HIV-uninfected fetuses exposed to antiretroviral treatment	PLOS ONE			English	Article							MYOCARDIAL TISSUE DOPPLER; INFECTED PREGNANT-WOMEN; REFERENCE RANGES; CHILDREN BORN; FETAL WEIGHT; DNA LEVELS; TOXICITY; NUCLEOSIDE; THERAPY; TRANSMISSION	Background Mitochondrial toxicity related to maternal combined antiretroviral treatment (cART) may have an impact on the heart of HIV-exposed uninfected (HEU) fetuses. Our objective was to evaluate fetal cardiovascular and mitochondrial biomarkers in HIV pregnancies. Methods Prospective cohort including 47 HIV-infected and 47 non HIV-infected pregnancies. Fetal echocardiography was performed at 26-32 weeks of pregnancy. Umbilical cord blood and placental tissue were collected to study mitochondrial DNA content (mtDNA) (ratio 12SrRNA/RNAseP) and mitochondrial function (cytochrome c oxidase, COX, enzymatic activity) normalized by mitochondrial content (citrate synthase, CS). Results HEU fetuses showed hypertrophic hearts (left myocardial wall thickness: HIV mean 3.21 mm (SD 0.81) vs. non-HIV 2.72 (0.42), p = 0.012), with signs of systolic and diastolic dysfunction (isovolumic relaxation time: HIV 52.2 ms (8.85) vs. non-HIV 42.5 ms (7.30); p<0.001). Cord blood mitochondrial content was significantly increased in HIV-exposed fetuses (CS activity: HIV 82.9 nmol/min. mg of protein (SD 40.5) vs. non-HIV 56.7 nmol/min. mg of protein (28.4); p = 0.007), with no differences in mtDNA content and COX activity. Both myocardial and mitochondrial mass parameters were significantly associated with zidovudine exposure. Conclusions HEU fetuses showed signs of increased myocardial and mitochondrial mass associated with maternal zidovudine treatment, suggesting a fetal adaptive response to cART toxicity.	[Garcia-Otero, Laura; Lopez, Marta; Gonce, Anna; Esteve, Carol; Salazar, Laura; Gomez, Olga; Maria Martinez, Josep; Crispi, Fatima; Gratacos, Eduard] Univ Barcelona, Hosp Clin,Fetal Fetal Med Res Ctr I D, BCNatal Barcelona Ctr Maternal Fetal & Neonatal M, ICGON,Inst Invest Biomed August Pi I Sunyer IDIBA, Barcelona, Spain; [Garcia-Otero, Laura; Lopez, Marta; Gonce, Anna; Esteve, Carol; Salazar, Laura; Gomez, Olga; Maria Martinez, Josep; Crispi, Fatima; Gratacos, Eduard] Univ Barcelona, Hosp St Joan de Deu,Fetal Fetal Med Res Ctr I D, BCNatal Barcelona Ctr Maternal Fetal & Neonatal M, ICGON,Inst Invest Biomed August Pi I Sunyer IDIBA, Barcelona, Spain; [Garcia-Otero, Laura; Lopez, Marta; Gonce, Anna; Esteve, Carol; Salazar, Laura; Gomez, Olga; Maria Martinez, Josep; Crispi, Fatima; Gratacos, Eduard] Ctr Biomed Res Rare Dis CIBER ER, Barcelona, Spain; [Guitart-Mampel, Mariona; Moren, Constanza; Garrabou, Gloria] Univ Barcelona, Fac Med & Hlth Sci, Hosp Clin Barcelona,Internal Med Serv, Muscle Res & Mitochondrial Funct Lab,Cellex IDIBA, Barcelona, Spain; [Guitart-Mampel, Mariona; Moren, Constanza; Garrabou, Gloria] CIBER ER, Barcelona, Spain; [Torres, Berta] FCRB, Hosp Clin, Infect Dis Dept, Barcelona, Spain; [Cesar, Sergi] Univ Barcelona, Hosp St Joan de Deu Barcelona, Dept Pediat Cardiol, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; University of Barcelona; Hospital Clinic de Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona	Lopez, M (corresponding author), Univ Barcelona, Hosp Clin,Fetal Fetal Med Res Ctr I D, BCNatal Barcelona Ctr Maternal Fetal & Neonatal M, ICGON,Inst Invest Biomed August Pi I Sunyer IDIBA, Barcelona, Spain.; Lopez, M (corresponding author), Univ Barcelona, Hosp St Joan de Deu,Fetal Fetal Med Res Ctr I D, BCNatal Barcelona Ctr Maternal Fetal & Neonatal M, ICGON,Inst Invest Biomed August Pi I Sunyer IDIBA, Barcelona, Spain.; Lopez, M (corresponding author), Ctr Biomed Res Rare Dis CIBER ER, Barcelona, Spain.	lopezro@clinic.cat	Cesar, Sergi/ABH-4429-2020; Morén, Constanza/AAB-6895-2021; Gratacos, Eduard/AAR-4939-2020	Morén, Constanza/0000-0001-6848-7407; Gratacos, Eduard/0000-0002-7405-7224; Garcia-Otero, Laura/0000-0003-2766-5048; Garrabou, Gloria/0000-0001-8973-9933; Gomez, O/0000-0003-4183-9876; CESAR, SERGI/0000-0002-2798-1756; LOPEZ, MARTA/0000-0003-1320-3088	Cerebra Foundation for the Brain Injured Child (Carmarthen, Wales, UK); Erasmus + Programme of the European Union [2013-0040]; Instituto de Salud Carios III [PI13/01738, PI14/00226, PI15/00130, PI15/00263, INT16/00168]; ISCIII-Subdireccion General de Evaluacion; Fondo Europeo de Desarrollo Regional (FEDER) "Otra manera de hacer Europa"; Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement de la Generalitat de Catalunya (2014 SGR) Spain [928, 2016FI_B01184]; European Social Funds; " la Caixa" Foundation (Spain)	Cerebra Foundation for the Brain Injured Child (Carmarthen, Wales, UK); Erasmus + Programme of the European Union; Instituto de Salud Carios III; ISCIII-Subdireccion General de Evaluacion; Fondo Europeo de Desarrollo Regional (FEDER) "Otra manera de hacer Europa"; Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement de la Generalitat de Catalunya (2014 SGR) Spain; European Social Funds(European Social Fund (ESF)); " la Caixa" Foundation (Spain)(La Caixa Foundation)	This study was supported by grants from Instituto de Salud Carios III (grants PI13/01738, PI14/00226, PI15/00130, PI15/00263 and INT16/00168) integrados en el Plan Nacional de I+D+I y cofinanciados por el ISCIII-Subdireccion General de Evaluacion y el Fondo Europeo de Desarrollo Regional (FEDER) "Otra manera de hacer Europa", the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement de la Generalitat de Catalunya (2014 SGR grant n degrees 928, 2016FI_B01184) Spain and European Social Funds, " la Caixa" Foundation (Spain), the Cerebra Foundation for the Brain Injured Child (Carmarthen, Wales, UK) and Erasmus + Programme of the European Union (Framework Agreement number: 2013-0040) [This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aldrovandi GM, 2009, PEDIATRICS, V124, pE1189, DOI 10.1542/peds.2008-2771; [Anonymous], 2017, FACT SHEET LATEST ST; Bainor A, 2011, ANAL BIOCHEM, V410, P310, DOI 10.1016/j.ab.2010.11.015; BARKER DJP, 1989, LANCET, V2, P577; Baschat AA, 2003, ULTRASOUND OBST GYN, V21, P124, DOI 10.1002/uog.20; Belenky A, 2004, CLIN CHIM ACTA, V340, P163, DOI 10.1016/j.cccn.2003.10.026; Casademont J, 2004, MED SCI MONITOR, V10, pCS49; CHAOUI R, 1994, FETAL DIAGN THER, V9, P92, DOI 10.1159/000263915; Comas M, 2011, ULTRASOUND OBST GYN, V37, P57, DOI 10.1002/uog.8870; Cossarizza A, 2003, CURR OPIN INFECT DIS, V16, P5, DOI 10.1097/00001432-200302000-00002; Cote HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035; Cote HCF, 2008, J INFECT DIS, V198, P851, DOI 10.1086/591253; Cruz-Martinez R, 2012, FETAL DIAGN THER, V32, P79, DOI 10.1159/000330798; Dadson K, 2017, CLIN SCI, V131, P1375, DOI 10.1042/CS20160170; De la Calle M, 2015, PRENATAL DIAG, V35, P453, DOI 10.1002/pd.4549; Desmonde S, 2016, CURR OPIN HIV AIDS, V11, P465, DOI 10.1097/COH.0000000000000300; Enns GM, 2017, CURR OPIN PEDIATR, V29, P541, DOI 10.1097/MOP.0000000000000535; Figueras F, 2008, EUR J OBSTET GYN R B, V136, P20, DOI 10.1016/j.ejogrb.2006.12.015; Garcia-Otero L, 2016, AIDS, V30, P1393, DOI 10.1097/QAD.0000000000001066; Gardiner HM, 2006, INT J CARDIOL, V113, P39, DOI 10.1016/j.ijcard.2005.10.029; Garrabou G, 2009, JAIDS-J ACQ IMM DEF, V52, P443, DOI 10.1097/QAI.0b013e3181bd564c; Germanakis I, 2012, FETAL DIAGN THER, V32, P65, DOI 10.1159/000330790; GESIDA/Spanish National AIDS study group, 2013, GUID HIV CONTR PREGN; Gomes Vania, 2015, BMC Res Notes, V8, P216, DOI 10.1186/s13104-015-1177-x; Guerra V, 2016, AIDS RES HUM RETROV, V32, P621, DOI [10.1089/aid.2015.0281, 10.1089/AID.2015.0281]; HADLOCK FP, 1984, RADIOLOGY, V150, P535, DOI 10.1148/radiology.150.2.6691115; HADLOCK FP, 1992, RADIOLOGY, V182, P501, DOI 10.1148/radiology.182.2.1732970; Hernandez S, 2012, AIDS, V26, P419, DOI 10.1097/QAD.0b013e32834f3232; Kakuda TN, 2000, CLIN THER, V22, P685, DOI 10.1016/S0149-2918(00)90004-3; Koczor CA, 2010, EXPERT OPIN DRUG MET, V6, P1493, DOI 10.1517/17425255.2010.526602; Kyeong KS, 2014, FETAL DIAGN THER, V36, P320, DOI 10.1159/000358591; Larsen S, 2012, J PHYSIOL-LONDON, V590, P3349, DOI 10.1113/jphysiol.2012.230185; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; Liotta G, 2015, INT J ENV RES PUB HE, V12, P13224, DOI 10.3390/ijerph121013224; Lipshultz SE, 2015, AIDS, V29, P91, DOI 10.1097/QAD.0000000000000499; Lipshultz SE, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18597; Lipshultz SE, 2012, EXPERT REV ANTI-INFE, V10, P661, DOI [10.1586/eri.12.53, 10.1586/ERI.12.53]; Little KM, 2017, PEDIATR INFECT DIS J, V36, P66, DOI 10.1097/INF.0000000000001355; Mannisto T, 2013, CIRCULATION, V127, P681, DOI 10.1161/CIRCULATIONAHA.112.128751; Mandelbrot L, 2001, JAMA-J AM MED ASSOC, V285, P2083, DOI 10.1001/jama.285.16.2083; Medja F, 2009, MITOCHONDRION, V9, P331, DOI 10.1016/j.mito.2009.05.001; Miro O, 2004, CLIN INFECT DIS, V39, P710, DOI 10.1086/423176; Mol BJ, 2016, LANCET, V387, P999, DOI 10.1016/S0140-6736(15)00070-7; Moren C, 2015, AIDS, V29, P5, DOI 10.1097/QAD.0000000000000486; Moretton MA, 2017, EXPERT OPIN PHARMACO, V18, P657, DOI 10.1080/14656566.2017.1316369; Noguera-Julian A, 2015, PEDIATR INFECT DIS J, V34, P1349, DOI 10.1097/INF.0000000000000894; Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, 2017, REC US ART PREGN HIV; Peng TY, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2016.10.007; Poirier MC, 2003, JAIDS-J ACQ IMM DEF, V33, P175, DOI 10.1097/00126334-200306010-00010; Ross AC, 2012, HIV MED, V13, P98, DOI 10.1111/j.1468-1293.2011.00945.x; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Rychik J, 2004, J AM SOC ECHOCARDIOG, V17, P803, DOI 10.1016/j.echo.2004.04.011; Shiramizu B, 2003, JAIDS-J ACQ IMM DEF, V32, P370, DOI 10.1097/00126334-200304010-00004; TEICHHOLZ LE, 1976, AM J CARDIOL, V37, P7, DOI 10.1016/0002-9149(76)90491-4; Wilkinson JD, 2013, AIDS, V27, P1099, DOI 10.1097/QAD.0b013e32835cf21c; World Health Organization, 2015, INT STAT CLASS DIS R	56	12	12	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2019	14	3							e0213279	10.1371/journal.pone.0213279	http://dx.doi.org/10.1371/journal.pone.0213279			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN7LU	30830946	gold, Green Published, Green Submitted			2023-01-03	WOS:000460371700032
J	Takakusagi, Y; Kawamura, H; Okamoto, M; Kaminuma, T; Kubo, N; Mizukami, T; Sato, H; Onishi, M; Ohtake, N; Sekihara, T; Nakano, T				Takakusagi, Yosuke; Kawamura, Hidemasa; Okamoto, Masahiko; Kaminuma, Takuya; Kubo, Nobuteru; Mizukami, Tatsuji; Sato, Hiro; Onishi, Masahiro; Ohtake, Nobuaki; Sekihara, Tetsuo; Nakano, Takashi			Long-term outcome of hypofractionated intensity-modulated radiotherapy using TomoTherapy for localized prostate cancer: A retrospective study	PLOS ONE			English	Article							RADIATION-DOSE RESPONSE; HELICAL TOMOTHERAPY; ALPHA/BETA RATIO; 5-YEAR OUTCOMES; NON-INFERIORITY; GY; FRACTIONATION; TOXICITY; THERAPY; RATES	Background Recently, the clinical outcome of prostate cancer treated by hypofractionated radiation therapy has been reported. However, there are few reports from Japan. In Hidaka Hospital, hypofractionated intensity-modulated radiotherapy (HIMRT) for prostate cancer was initiated in 2007. The purpose of this study is to analyze the long-term outcome. Methods Ninety-two patients with localized prostate cancer treated with HIMRT at Hidaka Hospital between 2007 and 2009 were retrospectively analyzed. HIMRT was delivered using TomoTherapy. The prescription dose was 66 Gy at 95% of the PTV in 22 fractions performed 3 days a week over 7 weeks in all patients. The overall survival rate, biochemical relapse-free rate, and acute and late toxicities were evaluated. Results The median follow-up duration was 78 (range 14-100) months. The median age at the start of the HIMRT was 72 (range 46-84) years. The disease characteristics were as follows: stage T1c, 45; T2a, 20; T2b, 5; T2c, 1; T3a, 13; T3b, 6; T4, 2; Gleason score 6, 13; 7, 44; 8, 20; 9, 15; 10, 0; pretreatment PSA <= 10 ng/mL, 42; 10 to <= 20, 27; and >20, 23. According to the D'Amico classification system, 10, 37, and 45 patients were classified as low-risk, intermediate-risk, and high-risk. The overall survival rate, the cause-specific survival rate, and the biochemical relapse-free rate at 5 years was 94.7%, 100% and 98.9%, respectively. Severe acute toxicity (grade 3 or more) was not observed. The late urinary toxicity was 52.2% in grade 0, 28.3% in grade 1, 19.6% in grade 2, and 2.2% in grade 3. The late rectal toxicity was 78.3% in grade 0, 7.6% in grade 1, 9.8% in grade 2, and 4.3% in grade 3. Conclusions The present study demonstrated that HIMRT using TomoTherapy for prostate cancer has a favorable outcome with tolerable toxicity.	[Takakusagi, Yosuke; Kawamura, Hidemasa; Okamoto, Masahiko; Kaminuma, Takuya; Kubo, Nobuteru; Mizukami, Tatsuji; Sato, Hiro; Onishi, Masahiro; Nakano, Takashi] Gunma Univ, Grad Sch Med, Dept Radiat Oncol, Showa Machi, Maebashi, Gunma, Japan; [Takakusagi, Yosuke; Kawamura, Hidemasa] Hidaka Hosp, Oncol Ctr, Nakao Machi, Takasaki, Gunma, Japan; [Ohtake, Nobuaki; Sekihara, Tetsuo] Hidaka Hosp, Dept Urol, Nakao Machi, Takasaki, Gunma, Japan	Gunma University	Kawamura, H (corresponding author), Gunma Univ, Grad Sch Med, Dept Radiat Oncol, Showa Machi, Maebashi, Gunma, Japan.; Kawamura, H (corresponding author), Hidaka Hosp, Oncol Ctr, Nakao Machi, Takasaki, Gunma, Japan.	kawa@gunma-u.ac.jp	Kaminuma, Takuya/ABG-1541-2021; Sato, Hiro/GWU-7659-2022	Kaminuma, Takuya/0000-0003-3527-5525; 				Akimoto T, 2004, INT J RADIAT ONCOL, V60, P1033, DOI 10.1016/j.ijrobp.2004.07.695; Akimoto T, 2004, INT J RADIAT ONCOL, V59, P372, DOI 10.1016/j.ijrobp.2003.10.033; Aluwini S, 2016, LANCET ONCOL, V17, P464, DOI 10.1016/S1470-2045(15)00567-7; Brenner DJ, 2004, INT J RADIAT ONCOL, V60, P1013, DOI 10.1016/j.ijrobp.2004.04.014; Brenner DJ, 2002, INT J RADIAT ONCOL, V52, P6; Brenner DJ, 1999, INT J RADIAT ONCOL, V43, P1095, DOI 10.1016/S0360-3016(98)00438-6; Catton CN, 2017, J CLIN ONCOL, V35, P1884, DOI 10.1200/JCO.2016.71.7397; D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969; D'Souza WD, 2001, INT J RADIAT ONCOL, V51, P1, DOI 10.1016/S0360-3016(01)01650-9; Dearnaley D, 2016, LANCET ONCOL, V17, P1047, DOI 10.1016/S1470-2045(16)30102-4; Fowler JF, 2005, ACTA ONCOL, V44, P265, DOI 10.1080/02841860410002824; Fowler JF, 2003, INT J RADIAT ONCOL, V56, P1093, DOI 10.1016/S0360-3016(03)00132-9; Hashimoto Y, 2018, INT J CLIN ONCOL, V23, P165, DOI 10.1007/s10147-017-1175-1; Haustermans K, 2000, INT J RADIAT ONCOL, V48, P303, DOI 10.1016/S0360-3016(00)00562-9; King CR, 2001, INT J RADIAT ONCOL, V51, P213, DOI 10.1016/S0360-3016(01)01651-0; Kong M, 2014, ONCOTARGETS THER, V7, P553, DOI 10.2147/OTT.S61465; Kupelian PA, 2000, INT J RADIAT ONCOL, V46, P567, DOI 10.1016/S0360-3016(99)00455-1; Kupelian PA, 2002, INT J RADIAT ONCOL, V53, P904, DOI 10.1016/S0360-3016(02)02836-5; Kupelian PA, 2001, INT J RADIAT ONCOL, V50, P621, DOI 10.1016/S0360-3016(01)01466-3; Lyons JA, 2000, UROLOGY, V55, P85, DOI 10.1016/S0090-4295(99)00380-5; Mackie TR, 2006, PHYS MED BIOL, V51, pR427, DOI 10.1088/0031-9155/51/13/R24; MACKIE TR, 1993, MED PHYS, V20, P1709, DOI 10.1118/1.596958; Pollack A, 2002, INT J RADIAT ONCOL, V53, P1097, DOI 10.1016/S0360-3016(02)02829-8; Sanfilippo NJ, 2014, AM J CLIN EXP UROL, V2, P286; Sanguineti G, 2006, INT J RADIAT ONCOL, V64, P151, DOI 10.1016/j.ijrobp.2005.06.026; Spyropoulou Despina, 2012, ISRN Oncol, V2012, P410892, DOI 10.5402/2012/410892; Takeda K, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-105; Tomita N, 2013, J RADIAT RES, V54, P919, DOI 10.1093/jrr/rrt025; Tucker SL, 2011, INT J RADIAT ONCOL, V81, P600, DOI 10.1016/j.ijrobp.2010.11.080; Zelefsky MJ, 2008, INT J RADIAT ONCOL, V70, P1124, DOI 10.1016/j.ijrobp.2007.11.044	30	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2019	14	2							e0211370	10.1371/journal.pone.0211370	http://dx.doi.org/10.1371/journal.pone.0211370			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM8EU	30807581	Green Published, Green Submitted, gold			2023-01-03	WOS:000459712100004
J	Huang, Q; Sun, D; Hussain, MZ; Liu, YG; Morozova-Roche, LA; Zhang, C				Huang, Qin; Sun, Dan; Hussain, Muhammad Zubair; Liu, Yonggang; Morozova-Roche, Ludmilla A.; Zhang, Ce			HEWL interacts with dissipated oleic acid micelles, and decreases oleic acid cytotoxicity	PLOS ONE			English	Article							FATTY-ACIDS; TRANSPORT; BRAIN; NEUROTOXICITY; PROTEINS	Senile plaques are well-known hallmarks of Alzheimer's Diseases (AD). However, drugs targeting tangles of the protein tau and plaques of beta-amyloid have no significant effect on disease progression, and the studies on the underlying mechanism of AD remain in high demand. Growing evidence supports the protective role of senile plaques in local inflammation driven by S100A9. We herein demonstrate that oleic acid (OA) micelles interact with hen egg white lysozyme (HEWL) and promote its amyloid formation. Consequently, SH-SY5Y cell line and mouse neural stem cells are rescued from OA toxicity by co-aggregation of OA and HEWL. Using atomic force microscopy in combination with fluorescence microscopy, we revealed that HEWL forms round-shaped aggregates in the presence of OA micelles instead of protofibrils of HEWL alone. These HEWL amyloids act as a sink for toxic OA micelles and their co-aggregate form large clumps, suggesting a protective function in amyloid and OA cytotoxicity.	[Huang, Qin; Liu, Yonggang] Chongqing Med Univ, Lab Stem Cell & Tissue Engn, Chongqing, Peoples R China; [Huang, Qin; Sun, Dan; Zhang, Ce] Northwest Univ, Inst Photon & Photon Technol, State Key Lab Cultivat Base Photoelect Technol &, Xian, Shaanxi, Peoples R China; [Hussain, Muhammad Zubair] Govt Emerson Coll, Dept Zool, Multan, Pakistan; [Hussain, Muhammad Zubair; Liu, Yonggang; Morozova-Roche, Ludmilla A.; Zhang, Ce] Umea Univ, Dept Med Biochem & Biophys, Umea, Sweden	Chongqing Medical University; Northwest University Xi'an; Umea University	Liu, YG (corresponding author), Chongqing Med Univ, Lab Stem Cell & Tissue Engn, Chongqing, Peoples R China.; Zhang, C (corresponding author), Northwest Univ, Inst Photon & Photon Technol, State Key Lab Cultivat Base Photoelect Technol &, Xian, Shaanxi, Peoples R China.; Liu, YG; Morozova-Roche, LA; Zhang, C (corresponding author), Umea Univ, Dept Med Biochem & Biophys, Umea, Sweden.	100418@cqmu.edu.cn; ludmilla.morozova-roche@umu.se; zhangce.univ@gmail.com	Morozova-Roche, Ludmilla A./AAU-9044-2021; Liu, Yong/GWQ-6163-2022	Zhang, Ce/0000-0003-1284-7279	Chongqing Basic and Frontier Research Program [cstc2015jcyjA10034]; Swedish Medical Research Council [2014-3241]; Insamlingsstiftelsen [FS 2.1.12-1605-14]; Biochemical Imaging Platform, Umea University	Chongqing Basic and Frontier Research Program; Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Insamlingsstiftelsen; Biochemical Imaging Platform, Umea University	This work was supported by the Chongqing Basic and Frontier Research Program. Project (cstc2015jcyjA10034), Swedish Medical Research Council (2014-3241 to L.A.M.-R.), Insamlingsstiftelsen (FS 2.1.12-1605-14 to L.A.M.-R.), Biochemical Imaging Platform, Umea University (to L.A.M.-R.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abedini A, 2009, PROTEIN ENG DES SEL, V22, P453, DOI 10.1093/protein/gzp036; Aisen PS, 1997, GERONTOLOGY, V43, P143; Behnan J, 2016, NEUROEPIGENETICS, V7, P6, DOI DOI 10.1016/j.nepig.2016.08.002; Calon F, 2004, NEURON, V43, P633, DOI 10.1016/j.neuron.2004.08.013; Cury-Boaventura MF, 2004, CLIN NUTR, V23, P721, DOI 10.1016/j.clnu.2003.12.004; Di Sabatino A, 2011, MUCOSAL IMMUNOL, V4, P574, DOI 10.1038/mi.2011.18; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Fontana A, 2013, BBA-PROTEINS PROTEOM, V1834, P1125, DOI 10.1016/j.bbapap.2013.02.041; Fraser PE, 2010, J NEUROCHEM, V61, P298; Golde TE, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt233; Grela A, 2016, CLIN CHEM LAB MED, V54, P197, DOI 10.1515/cclm-2015-0394; Grimm MOW, 2012, J NUTR BIOCHEM, V23, P1214, DOI 10.1016/j.jnutbio.2011.06.015; Guardia P, 2007, J MAGN MAGN MATER, V316, pE756, DOI 10.1016/j.jmmm.2007.03.085; Hamazaki K, 2013, PSYCHIAT RES, V210, P346, DOI 10.1016/j.psychres.2013.05.006; Hamilton JA, 1999, PROSTAG LEUKOTR ESS, V60, P291, DOI 10.1016/S0952-3278(99)80002-7; Hamilton LK, 2017, FATE FAT NEUTRAL LIP; Hussain MM, 2013, CLIN LIPIDOL, V8, P481, DOI [10.2217/CLP.13.40, 10.2217/clp.13.40]; Kamijima T, 2008, BIOCHEM BIOPH RES CO, V376, P211, DOI 10.1016/j.bbrc.2008.08.127; Ketones CSC, 2018, EDP SCI; Krajnak K, 2018, BIOORGANIC MED CHEM; LAI JCK, 1991, NEUROCHEM RES, V16, P795, DOI 10.1007/BF00965689; Lim GP, 2005, J NEUROSCIENCE OFFIC, P3032; Liskova K, 2010, J AGR FOOD CHEM, V58, P4421, DOI 10.1021/jf903901j; Liu J, 2016, DRUGS AGING, V33, P1; Liu RZ, 2010, INT J DEV BIOL, V54, P1229, DOI 10.1387/ijdb.092976rl; Ma BL, 2017, INT J BIOL MACROMOL, V98, P717, DOI 10.1016/j.ijbiomac.2017.01.128; Martin S, 2006, NAT REV MOL CELL BIO, V7, P373, DOI 10.1038/nrm1912; Martins DLT, 2006, CLIN SCI, P307, DOI DOI 10.1016/J.IJBIOMAC.2017.01.128; Mitchell RW, 2011, J NEUROCHEM, V117, P735, DOI 10.1111/j.1471-4159.2011.07245.x; Onur B, 2010, EUROPEAN J NEUROSCIE, V25, P1006; Pan YJ, 2015, MOL PHARMACEUT, V12, P4375, DOI 10.1021/acs.molpharmaceut.5b00580; Passingham RE, 2002, NAT REV NEUROSCI, V3, P606, DOI 10.1038/nrn893; PERLMUTTER LS, 1990, NEUROSCI LETT, V119, P32, DOI 10.1016/0304-3940(90)90748-X; Podtelezhnikov AA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029610; Reynolds LM, 2001, NEUROSCI LETT, V309, P193, DOI 10.1016/S0304-3940(01)02071-7; Riek R, 2016, NATURE, V539, P227, DOI 10.1038/nature20416; Schappe MS, 2018, IMMUNITY, V48, P59, DOI 10.1016/j.immuni.2017.11.026; Schneider SA, 2017, CURRENT DRUG; Schweiger M, 2012, J LIPID RES, V53, P2307, DOI 10.1194/jlr.M027409; Sebastien CD, 2010, TARGETED TRANSGENE E, V24, P1535; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Sipe JD, 2012, AMYLOID, V19, P167, DOI 10.3109/13506129.2012.734345; Snowden SG, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002266; Sporns O, 2005, PLOS COMPUT BIOL, V1, P245, DOI 10.1371/journal.pcbi.0010042; Svensson M, 2000, CONVERSION MIN PROTE, V97, P4375; Sykova Eva, 2013, Laser Ther, V22, P87, DOI 10.3136/islsm.22.87; Tan J, 1999, SCIENCE, V286, P2352, DOI 10.1126/science.286.5448.2352; Tarasoff-Conway JM, 2016, NAT REV NEUROL, V12, P248, DOI 10.1038/nrneurol.2016.36; Tugizov S, 2005, J VIROL, V79, P1099, DOI 10.1128/JVI.79.2.1099-1112.2005; van Dyck CH, 2018, BIOL PSYCHIAT, V83, P311, DOI 10.1016/j.biopsych.2017.08.010; Wilson DM, 1997, AM J PATHOL, V150, P2181; Yadav RS, 2014, MOL NEUROBIOL, V50, P168, DOI 10.1007/s12035-014-8661-5; Young SG, 2013, GENE DEV, V27, P459, DOI 10.1101/gad.209296.112; Zhang C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032953	54	2	2	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2019	14	2							e0212648	10.1371/journal.pone.0212648	http://dx.doi.org/10.1371/journal.pone.0212648			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM8DR	30794655	Green Published, Green Submitted, gold			2023-01-03	WOS:000459709100105
J	Synofzik, M; Puccio, H; Mochel, F; Schols, L				Synofzik, Matthis; Puccio, Helene; Mochel, Fanny; Schoels, Ludger			Autosomal Recessive Cerebellar Ataxias: Paving the Way toward Targeted Molecular Therapies	NEURON			English	Review							NIEMANN-PICK-DISEASE; ONSET METACHROMATIC LEUKODYSTROPHY; RECOMBINANT-HUMAN-ERYTHROPOIETIN; STEM-CELL TRANSPLANTATION; FRIEDREICHS-ATAXIA; OXIDATIVE STRESS; DNA-DAMAGE; SPINOCEREBELLAR ATAXIA; MITOCHONDRIAL-DNA; SPASTIC ATAXIA	Autosomal-recessive cerebellar ataxias (ARCAs) comprise a heterogeneous group of rare degenerative and metabolic genetic diseases that share the hallmark of progressive damage of the cerebellum and its associated tracts. This Review focuses on recent translational research in ARCAs and illustrates the steps from genetic characterization to preclinical and clinical trials. The emerging common pathways underlying ARCAs include three main clusters: mitochondrial dysfunction, impaired DNA repair, and complex lipid homeostasis. Novel ARCA treatments might target common hubs in pathogenesis by modulation of gene expression, stem cell transplantation, viral gene transfer, or interventions in faulty pathways. All these translational steps are addressed in current ARCA research, leading to the expectation that novel treatments for ARCAs will be reached in the next decade.	[Synofzik, Matthis; Schoels, Ludger] Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurodegenerat Dis, Hoppe Seyler Str 3, D-72076 Tubingen, Germany; [Synofzik, Matthis; Schoels, Ludger] Univ Tubingen, Ctr Neurol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany; [Synofzik, Matthis; Schoels, Ludger] German Ctr Neurodegenerat Dis DZNE, Tubingen, Germany; [Puccio, Helene] IGBMC, F-67404 Illkirch Graffenstaden, France; [Puccio, Helene] INSERM, U1258, F-67404 Illkirch Graffenstaden, France; [Puccio, Helene] CNRS, UMR7104, F-67404 Illkirch Graffenstaden, France; [Puccio, Helene] Univ Strasbourg, F-67000 Strasbourg, France; [Mochel, Fanny] UPMC Paris 6, Sorbonne Univ, UMRS 1127, F-75013 Paris, France; [Mochel, Fanny] Inserm 1127, F-75013 Paris, France; [Mochel, Fanny] CNRS, UMR7225, F-75013 Paris, France; [Mochel, Fanny] Inst Cerveau & Moelle Epiniere, F-75013 Paris, France; [Mochel, Fanny] La Pitie Salpetriere Univ Hosp, AP HP, Dept Genet, Paris, France; [Mochel, Fanny] La Pitie Salpetriere Univ Hosp, AP HP, Reference Ctr Adult Neurometabol Dis, Paris, France	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Schols, L (corresponding author), Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurodegenerat Dis, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.; Schols, L (corresponding author), Univ Tubingen, Ctr Neurol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.; Schols, L (corresponding author), German Ctr Neurodegenerat Dis DZNE, Tubingen, Germany.	ludger.schoels@uni-tuebingen.de	Schöls, Ludger/ABB-2482-2021; Puccio, Hélène/G-1717-2013	Schöls, Ludger/0000-0001-7774-5025; Puccio, Hélène/0000-0003-4711-2248; Synofzik, Matthis/0000-0002-2280-7273	European Union's Horizon 2020 research and innovation program under the ERA-NET Cofund action [643578, 779257]; BMBF [01GM1607]; DFG [SCHO754/5-2]; Else Kroner Fresenius Stiftung [2015_EKMS.018]	European Union's Horizon 2020 research and innovation program under the ERA-NET Cofund action; BMBF(Federal Ministry of Education & Research (BMBF)); DFG(German Research Foundation (DFG)); Else Kroner Fresenius Stiftung	This work was supported via the European Union's Horizon 2020 research and innovation program under the ERA-NET Cofund action No 643578 and funds to "Solve-RD'' (grant 779257) to M.S. and L.S. It was supported by the BMBF (01GM1607) under the frame of the E-Rare-3 network PREPARE (to M.S. and H.P.). The work of L.S. was supported by the DFG grant SCHO754/5-2. M.S. received additional support by the Else Kroner Fresenius Stiftung (2015_EKMS.018). We are grateful to Dr. Malco Rossi (Buenos Aires) for helping to identify calendar information when different ARCA genes have been identified.	Acquaviva F, 2008, CEREBELLUM, V7, P360, DOI 10.1007/s12311-008-0036-x; Adanyeguh IM, 2018, NEUROIMAGE-CLIN, V19, P858, DOI 10.1016/j.nicl.2018.06.011; Aggarwal A, 2018, TREMOR OTHER HYPERK, V8, DOI 10.7916/D841881D; Ala A, 2007, LANCET, V369, P397, DOI 10.1016/S0140-6736(07)60196-2; Anheim M, 2012, NEW ENGL J MED, V366, P636, DOI 10.1056/NEJMra1006610; Anttinen A, 2008, BRAIN, V131, P1979, DOI 10.1093/brain/awn126; Astudillo L, 2015, J INHERIT METAB DIS, V38, P65, DOI 10.1007/s10545-014-9736-1; Baldwin EJ, 2010, J NEUROL NEUROSUR PS, V81, P954, DOI 10.1136/jnnp.2008.161059; Bayot A, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-112; Benini M, 2017, CELL REP, V18, P2007, DOI 10.1016/j.celrep.2017.01.079; BERGINER VM, 1984, NEW ENGL J MED, V311, P1649, DOI 10.1056/NEJM198412273112601; Bhalla AD, 2016, ANN CLIN TRANSL NEUR, V3, P523, DOI 10.1002/acn3.322; Boesch S, 2014, MOVEMENT DISORD, V29, P935, DOI 10.1002/mds.25836; Bonifert T, 2014, BRAIN, V137, P2164, DOI 10.1093/brain/awu165; Boucher AA, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0313-y; Cachon-Gonzalez MB, 2018, CURR GENE THER, V18, P68, DOI 10.2174/1566523218666180404162622; Calap-Quintana P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132376; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Chandran V, 2017, ELIFE, V6, DOI 10.7554/eLife.30054; Chang JR, 2012, NEURODEGENER DIS, V9, P68, DOI 10.1159/000329999; Chen KC, 2016, ELIFE, V5, DOI 10.7554/eLife.20732; Chessa L, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/1750-1172-9-5; Choy KR, 2018, DEV DYNAM, V247, P33, DOI 10.1002/dvdy.24522; Clarke JTR, 2011, MOL GENET METAB, V102, P6, DOI 10.1016/j.ymgme.2010.09.004; Cohen S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02894-w; Colin F, 2013, J AM CHEM SOC, V135, P733, DOI 10.1021/ja308736e; Coutelier M, 2018, JAMA NEUROL, V75, P591, DOI 10.1001/jamaneurol.2017.5121; Coutinho P., 1993, GENEREVIEWS; Criscuolo C, 2015, J NEUROL, V262, P2755, DOI 10.1007/s00415-015-7911-4; Cullen JK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148213; Das BB, 2010, P NATL ACAD SCI USA, V107, P19790, DOI 10.1073/pnas.1009814107; Davidson CD, 2016, ANN CLIN TRANSL NEUR, V3, P366, DOI 10.1002/acn3.306; De Munter S, 2015, BRAIN PATHOL, V25, P663, DOI 10.1111/bpa.12290; Debs R, 2010, ARCH NEUROL-CHICAGO, V67, P126, DOI 10.1001/archneurol.2009.293; Desai R, 2017, BRAIN, V140, P1595, DOI 10.1093/brain/awx094; Dogan I, 2019, J NEUROL NEUROSUR PS, V90, P615, DOI 10.1136/jnnp-2018-318422; Duncan EJ, 2017, HUM MOL GENET, V26, P3130, DOI 10.1093/hmg/ddx197; Eaton JS, 2007, J CLIN INVEST, V117, P2723, DOI 10.1172/JCI31604; El Euch-Fayache G, 2014, BRAIN, V137, P402, DOI 10.1093/brain/awt339; Erwin GS, 2017, SCIENCE, V358, P1617, DOI 10.1126/science.aan6414; Fang EF, 2014, CELL, V157, P882, DOI 10.1016/j.cell.2014.03.026; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Ferreirinha F, 2004, J CLIN INVEST, V113, P231, DOI 10.1172/JCI200420138; Fogel BL, 2014, JAMA NEUROL, V71, P1237, DOI 10.1001/jamaneurol.2014.1944; Fuss JO, 2015, BBA-MOL CELL RES, V1853, P1253, DOI 10.1016/j.bbamcr.2015.01.018; Gabsi S, 2001, EUR J NEUROL, V8, P477, DOI 10.1046/j.1468-1331.2001.00273.x; Gagnon C, 2018, NEUROLOGY, V91, pE1307, DOI 10.1212/WNL.0000000000006290; Geberhiwot T, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0785-7; Gilmore EC, 2014, NEUROGENETICS, V15, P217, DOI 10.1007/s10048-014-0415-z; Girard M, 2012, P NATL ACAD SCI USA, V109, P1661, DOI 10.1073/pnas.1113166109; Grabczyk E, 2007, NUCLEIC ACIDS RES, V35, P5351, DOI 10.1093/nar/gkm589; Groeschel S, 2016, JAMA NEUROL, V73, P1133, DOI 10.1001/jamaneurol.2016.2067; Groh M, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004318; Guissart C, 2016, EUR J HUM GENET, V24, P1154, DOI 10.1038/ejhg.2015.259; Guleria A, 2016, DNA REPAIR, V39, P1, DOI 10.1016/j.dnarep.2015.12.009; Harlalka GV, 2013, BRAIN, V136, P3618, DOI 10.1093/brain/awt270; Haugen AC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000812; Herman D, 2006, NAT CHEM BIOL, V2, P551, DOI 10.1038/nchembio815; Hoch NC, 2017, NATURE, V541, P87, DOI 10.1038/nature20790; Inoue K, 1999, BIOCHEM BIOPH RES CO, V256, P198, DOI 10.1006/bbrc.1998.9497; Jackson TJ, 2016, DEV MED CHILD NEUROL, V58, P690, DOI 10.1111/dmcn.13052; Jeon SB, 2008, J IMMUNOL, V181, P8077, DOI 10.4049/jimmunol.181.11.8077; Jobling RK, 2015, BRAIN, V138, P1505, DOI 10.1093/brain/awv057; Khobta A, 2013, MECH AGEING DEV, V134, P253, DOI 10.1016/j.mad.2013.03.001; Koch SC, 2016, Q REV BIOPHYS, V49, DOI 10.1017/S0033583515000268; Kurian MA, 2013, INT REV NEUROBIOL, V110, P49, DOI 10.1016/B978-0-12-410502-7.00003-X; La P, 2013, J BIOL CHEM, V288, P12901, DOI 10.1074/jbc.M112.424499; Lagedrost SJ, 2011, AM HEART J, V161, P639, DOI 10.1016/j.ahj.2010.10.038; Lagier-Tourenne C, 2008, AM J HUM GENET, V82, P661, DOI 10.1016/j.ajhg.2007.12.024; LAMARCHE JB, 1980, CAN J NEUROL SCI, V7, P389, DOI 10.1017/S0317167100022927; Lamari F, 2015, J INHERIT METAB DIS, V38, P3, DOI 10.1007/s10545-014-9764-x; Langer Y, 2018, J MED GENET, V55, P599, DOI 10.1136/jmedgenet-2018-105330; Laugel V, 2013, MECH AGEING DEV, V134, P161, DOI 10.1016/j.mad.2013.02.006; Laule C, 2018, J NEUROIMAGING, V28, P252, DOI 10.1111/jon.12502; Lee J, 2014, J INHERIT METAB DIS, V37, P333, DOI 10.1007/s10545-013-9665-4; Li LD, 2018, NUCLEIC ACID THER, V28, P23, DOI 10.1089/nat.2017.0703; Li LD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10606; Libri V, 2014, LANCET, V384, P504, DOI 10.1016/S0140-6736(14)60382-2; Lynch DR, 2010, ARCH NEUROL-CHICAGO, V67, P941, DOI 10.1001/archneurol.2010.168; Maegawa GHB, 2007, J BIOL CHEM, V282, P9150, DOI 10.1074/jbc.M609304200; Maltecca F, 2015, J CLIN INVEST, V125, P263, DOI 10.1172/JCI74770; Martelli A, 2015, CELL METAB, V21, P311, DOI 10.1016/j.cmet.2015.01.010; Martelli A, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00130; Martin E, 2013, AM J HUM GENET, V92, P238, DOI 10.1016/j.ajhg.2012.11.021; Matzner U, 2005, HUM MOL GENET, V14, P1139, DOI 10.1093/hmg/ddi126; McMillan HJ, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-90; Meier T, 2012, J NEUROL, V259, P284, DOI 10.1007/s00415-011-6174-y; Menotta M, 2017, MOL CELL BIOCHEM, V12, P126, DOI DOI 10.1186/S13023-017-0669-2; Mignot C, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-173; Minnerop M, 2017, BRAIN, V140, P1561, DOI 10.1093/brain/awx095; Moreira M. C., 1993, GENEREVIEWS; Narita A, 2016, ANN CLIN TRANSL NEUR, V3, P200, DOI 10.1002/acn3.292; Nie SK, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0179-4; Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328; Ory DS, 2017, LANCET, V390, P1758, DOI 10.1016/S0140-6736(17)31465-4; Pandolfo M, 2014, ANN NEUROL, V76, P509, DOI 10.1002/ana.24248; Patel AY, 2011, BIOCHEM BIOPH RES CO, V405, P599, DOI 10.1016/j.bbrc.2011.01.075; Patron M, 2018, CELL RES, V28, P296, DOI 10.1038/cr.2018.17; Patterson MC, 2007, LANCET NEUROL, V6, P765, DOI 10.1016/S1474-4422(07)70194-1; Paupe V, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004253; Perdomini M, 2014, NAT MED, V20, P546, DOI 10.1038/nm.3510; Pfeffer G, 2015, NEUROLOGY, V84, P1174, DOI 10.1212/WNL.0000000000001369; Pierson TM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002325; Piguet F, 2018, MOL THER, V26, P1940, DOI 10.1016/j.ymthe.2018.05.006; Rauschka H, 2006, NEUROLOGY, V67, P859, DOI 10.1212/01.wnl.0000234129.97727.4d; Reczek D, 2007, CELL, V131, P770, DOI 10.1016/j.cell.2007.10.018; Reetz K, 2017, LANCET NEUROL, V16, P954, DOI 10.1016/S1474-4422(16)30287-3; Reetz K, 2015, LANCET NEUROL, V14, P174, DOI 10.1016/S1474-4422(14)70321-7; Renaud M, 2017, ANN NEUROL, V82, P892, DOI 10.1002/ana.25084; Rossi M, 2018, MOVEMENT DISORD, V33, P1056, DOI 10.1002/mds.27415; Rothblum-Oviatt C, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0543-7; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Rufini A, 2011, HUM MOL GENET, V20, P1253, DOI 10.1093/hmg/ddq566; Safdar A, 2016, CURR OPIN GENET DEV, V38, P127, DOI 10.1016/j.gde.2016.06.011; SALEN G, 1991, DEV NEUROSCI-BASEL, V13, P363, DOI 10.1159/000112186; Santoro A, 2018, HUM MOL GENET, V27, P992, DOI 10.1093/hmg/ddy016; Saveliev A, 2003, NATURE, V422, P909, DOI 10.1038/nature01596; Schmitz-Hubsch T, 2006, NEUROLOGY, V66, P1717, DOI 10.1212/01.wnl.0000219042.60538.92; Schmucker S, 2008, HUM MOL GENET, V17, P3521, DOI 10.1093/hmg/ddn244; Schols L, 2017, BRAIN, V140, P3112, DOI 10.1093/brain/awx273; Schulz JB, 2000, NEUROLOGY, V55, P1719, DOI 10.1212/WNL.55.11.1719; Schulz JB, 2009, NAT REV NEUROL, V5, P222, DOI 10.1038/nrneurol.2009.26; Sessa M, 2016, LANCET, V388, P476, DOI 10.1016/S0140-6736(16)30374-9; Shao YH, 2016, NEUROGENETICS, V17, P137, DOI 10.1007/s10048-016-0476-2; Sharma NK, 2014, DNA REPAIR, V13, P22, DOI 10.1016/j.dnarep.2013.11.002; Shen Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151026; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shimobayashi E, 2018, CURR NEUROPHARMACOL, V16, P151, DOI 10.2174/1570159X15666170529104000; Soragni E, 2016, EXPERT OPIN ORPHAN D, V4, P961, DOI 10.1080/21678707.2016.1215910; Soragni E, 2014, ANN NEUROL, V76, P489, DOI 10.1002/ana.24260; Stefely JA, 2016, MOL CELL, V63, P608, DOI 10.1016/j.molcel.2016.06.030; Stewart GS, 2007, P NATL ACAD SCI USA, V104, P16910, DOI 10.1073/pnas.0708408104; Sturm B, 2005, EUR J CLIN INVEST, V35, P711, DOI 10.1111/j.1365-2362.2005.01568.x; Sykora P, 2012, MECH AGEING DEV, V133, P169, DOI 10.1016/j.mad.2011.11.003; Sykora P, 2011, P NATL ACAD SCI USA, V108, P7437, DOI 10.1073/pnas.1100084108; Synofzik Matthis, 2018, Handb Clin Neurol, V155, P73, DOI 10.1016/B978-0-444-64189-2.00005-6; Synofzik M, 2017, MOVEMENT DISORD, V32, P332, DOI 10.1002/mds.26944; Synofzik M, 2016, BRAIN, V139, P1378, DOI 10.1093/brain/aww079; Synofzik M, 2015, J NEUROL, V262, P2557, DOI 10.1007/s00415-015-7889-y; Synofzik M, 2014, BRAIN, V137, P69, DOI 10.1093/brain/awt326; Synofzik M, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-41; Synofzik M, 2012, CEREBELLUM, V11, P1002, DOI 10.1007/s12311-012-0378-2; Tahbaz N, 2012, NUCLEIC ACIDS RES, V40, P3484, DOI 10.1093/nar/gkr1245; Takashima H, 2002, NAT GENET, V32, P267, DOI 10.1038/ng987; Tamarit J, 2016, FREE RADICAL BIO MED, V100, P138, DOI 10.1016/j.freeradbiomed.2016.06.007; Taylor AMR, 2004, DNA REPAIR, V3, P1219, DOI 10.1016/j.dnarep.2004.04.009; Tesson C, 2012, AM J HUM GENET, V91, P1051, DOI 10.1016/j.ajhg.2012.11.001; Valentin-Vega YA, 2012, BLOOD, V119, P1490, DOI 10.1182/blood-2011-08-373639; van Gassen KLI, 2012, BRAIN, V135, P2994, DOI 10.1093/brain/aws224; Vogtle FN, 2018, AM J HUM GENET, V102, P557, DOI 10.1016/j.ajhg.2018.02.014; Vyas PM, 2012, HUM MOL GENET, V21, P1230, DOI 10.1093/hmg/ddr554; Walkley SU, 2004, BBA-MOL CELL BIOL L, V1685, P48, DOI 10.1016/j.bbalip.2004.08.011; Wilke C, 2018, J NEUROL, V265, P1618, DOI 10.1007/s00415-018-8893-9; WINKELMAN MD, 1983, NEUROLOGY, V33, P994, DOI 10.1212/WNL.33.8.994; Wolf B, 2017, GENET MED, V19, P396, DOI 10.1038/gim.2016.135; Won JS, 2013, BRAIN RES, V1508, P44, DOI 10.1016/j.brainres.2013.02.024; Wraith JE, 2010, MOL GENET METAB, V99, P351, DOI 10.1016/j.ymgme.2009.12.006; Yahalom G, 2013, CLIN NEUROPHARMACOL, V36, P78, DOI 10.1097/WNF.0b013e318288076a; Zhao ZS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026991; Zolotov D, 2012, J CLIN APHERESIS, V27, P99, DOI 10.1002/jca.21200	160	40	40	2	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	FEB 20	2019	101	4					560	583		10.1016/j.neuron.2019.01.049	http://dx.doi.org/10.1016/j.neuron.2019.01.049			24	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HM0HD	30790538	Bronze			2023-01-03	WOS:000459127000008
J	Cook, R; Thomas, V; Martin, R				Cook, Rob; Thomas, Vaughan; Martin, Rosie		NIHR Dissemination Ctr	People with chronic obstructive pulmonary disease exacerbations prefer early discharge, then treatment at home	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material								The study Home treatment of COPD exacerbation selected by DECAF score: a non-inferiority, randomised controlled trial and economic evaluation	[Cook, Rob; Martin, Rosie] Bazian, Intelligence Unit Healthcare, London, England; [Thomas, Vaughan] Univ Southampton, Wessex Inst, Southampton, Hants, England	University of Southampton	Cook, R (corresponding author), Bazian, Intelligence Unit Healthcare, London, England.	rob.cook@bazian.com		Cook, Robert/0000-0002-2210-3989				Health and Social Care Information Centre, 2015, QUAL OUTC FRAM PREV; Jeppesen E, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003573.pub2; National Institute for Health and Care Excellence, 2018, CHRONIC OBSTRUCTIVE; NHS Digital, 2018, HOSP EP STAT 2017 18; NHS website, CHRON OBSTR PULM DIS; Stevenson R, 2007, THORAX, V62, P200	6	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 19	2019	364								k5339	10.1136/bmj.k5339	http://dx.doi.org/10.1136/bmj.k5339			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM8VT	30782586				2023-01-03	WOS:000459761700011
J	Murali, KM; Mullan, J; Roodenrys, S; Hassan, HC; Lambert, K; Lonergan, M				Murali, Karumathil M.; Mullan, Judy; Roodenrys, Steven; Hassan, Hicham C.; Lambert, Kelly; Lonergan, Maureen			Strategies to improve dietary, fluid, dialysis or medication adherence in patients with end stage kidney disease on dialysis: A systematic review and meta-analysis of randomized intervention trials	PLOS ONE			English	Review							BEHAVIORAL GROUP-APPROACH; HEMODIALYSIS-PATIENTS; EDUCATIONAL INTERVENTION; PHOSPHATE LEVELS; RENAL-DISEASE; MANAGEMENT; HYPERPHOSPHATEMIA; RESTRICTIONS; EFFICACY; OSTEODYSTROPHY	Background In patients with end stage kidney disease (ESKD) on dialysis, treatment non-adherence is common and results in poor health outcomes. However, the clinical benefits of interventions to improve adherence in dialysis patients are difficult to evaluate since trialled interventions and reported outcomes are highly diverse/heterogeneous. This review summarizes existing literature on randomized controlled trials (RCTs) evaluating adherence interventions in ESKD patients focusing on the intervention category, outcome efficacy and persistence of benefit beyond the intervention. Methods We performed electronic database searches in Medline, Embase & Cochrane CENTRAL upto 1 st July 2018 for RCTs evaluating interventions to improve diet, fluid, medication or dialysis adherence in ESKD patients. Study characteristics including category of interventions, outcomes, efficacy and follow-up were assessed. Meta-analysis was used to compute pooled estimates of the effects on the commonest reported outcome measures. Results From 1311 citations, we included 36 RCTs (13 cluster-randomized trials), recruiting a total of 3510 dialysis patients (mean age 55.1 +/- 5.8 years, males 58.1%). Overall risk of bias was 'high' for 24 and of 'some concern' for 12 studies. Most interventions (33 trials, 92%) addressed patient related factors, and included educational/cognitive (N = 11), behavioural /counselling (N = 4), psychological/affective (N = 4) interventions or a combination (N = 14) of the above. A majority of (28/36) RCTs showed improvement in some reported outcomes.Surrogate measures like changes in phosphate (N = 19) and inter-dialytic weight gain (N = 15) were the most common reported outcomes and both showed significant improvement in the meta-analysis. Sixteen trials reported follow-up (1-12 months) beyond intervention and the benefits waned or were absent in nine trials within 12 months post-intervention. Conclusions Interventions to improve treatment adherence result in modest short-term benefits in surrogate outcome measures in dialysis patients, but significant improvements in trial design and outcome reporting are warranted to identify strategies that would achieve meaningful and sustainable clinical benefits. Limitations Poor methodological quality of trials. Frequent use of surrogate outcomes measures. Low certainly of evidence.	[Murali, Karumathil M.; Hassan, Hicham C.; Lonergan, Maureen] Wollongong Hosp, Dept Nephrol, Wollongong, NSW, Australia; [Mullan, Judy; Lambert, Kelly] Univ Wollongong, CHRISP, Wollongong, NSW, Australia; [Roodenrys, Steven] Univ Wollongong, Sch Psychol, Wollongong, NSW, Australia	Wollongong Hospital; University of Wollongong; University of Wollongong	Murali, KM (corresponding author), Wollongong Hosp, Dept Nephrol, Wollongong, NSW, Australia.	karumathil.murali@health.nsw.gov.au	Mullan, Judy R/G-6642-2015; Hassan, Hicham Cheikh/AAH-2977-2019; Lambert, Kelly/A-3940-2015	Mullan, Judy R/0000-0003-3772-7986; Hassan, Hicham Cheikh/0000-0002-9198-6092; Lambert, Kelly/0000-0001-5935-7328				Ashurst ID, 2003, J RENAL NUTR, V13, P267, DOI 10.1053/S1051-2276(03)00116-X; Baraz S, 2010, J ADV NURS, V66, P60, DOI 10.1111/j.1365-2648.2009.05142.x; BRANTLEY PJ, 1990, HEALTH PSYCHOL, V9, P103, DOI 10.1037/0278-6133.9.1.103; Chen W, 2006, J RENAL NUTR, V16, P132, DOI 10.1053/j.jrn.2006.01.009; Cho MK, 2013, NURS HEALTH SCI, V15, P86, DOI 10.1111/nhs.12003; Cukor D, 2014, J AM SOC NEPHROL, V25, P196, DOI 10.1681/ASN.2012111134; CUMMINGS K M, 1981, Journal of Behavioral Medicine, V4, P111; De Bleser L, 2009, TRANSPL INT, V22, P780, DOI 10.1111/j.1432-2277.2009.00881.x; De Vries H, 1998, PSYCHOL HEALTH, V13, P369, DOI 10.1080/08870449808406757; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ford JC, 2004, J RENAL NUTR, V14, P36, DOI 10.1053/j.jrn.2003.09.008; FU R, 2013, AHRQ PUBLICATION; Ghimire S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144119; Griva K, 2018, AM J KIDNEY DIS, V71, P371, DOI 10.1053/j.ajkd.2017.09.014; Haq N, 2014, INT UROL NEPHROL, V46, P113, DOI 10.1007/s11255-013-0418-y; Hare J, 2014, NEPHROL DIAL TRANSPL, V29, P555, DOI 10.1093/ndt/gft477; Higgins J.P.T.S.J., 2016, REVISED TOOL ASSESSI; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; [Hou Yongmei 侯永梅], 2010, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V14, P5869; Howren MB, 2016, ANN BEHAV MED, V50, P167, DOI 10.1007/s12160-015-9741-0; Karavetian M, 2015, PATIENT EDUC COUNS, V98, P1116, DOI 10.1016/j.pec.2015.05.005; Karavetian M, 2014, NUTR REV, V72, P471, DOI 10.1111/nure.12115; Karavetian M, 2013, J RENAL CARE, V39, P19, DOI 10.1111/j.1755-6686.2012.00327.x; Kauric-Klein Z, 2012, NEPHROL NURS J, V39, P217; Lou LM, 2012, CLIN NEPHROL, V77, P476, DOI 10.5414/CN107218; Manera KE, 2017, PERITON DIALYSIS INT, V37, P639, DOI 10.3747/pdi.2017.00022; Matteson ML, 2013, OUTCOMES ASSESSMENT IN END - STAGE KIDNEY DISEASE - MEASUREMENTS AND APPLICATIONS IN CLINICAL PRACTICE, P138; Matteson ML, 2010, HEMODIAL INT, V14, P370, DOI 10.1111/j.1542-4758.2010.00462.x; Milazi Molly, 2017, JBI Database System Rev Implement Rep, V15, P971, DOI 10.11124/JBISRIR-2017-003360; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Molaison EF, 2003, PATIENT EDUC COUNS, V49, P5, DOI 10.1016/S0738-3991(02)00036-8; Morey B, 2008, NEPHRON CLIN PRACT, V109, pC173, DOI 10.1159/000145462; Murali KM, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0449-1; Neumann CL, 2013, TELEMED E-HEALTH, V19, P480, DOI 10.1089/tmj.2012.0188; Ogna VF, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/104892; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Pasyar N, 2015, COMPLEMENT THER MED, V23, P38, DOI 10.1016/j.ctim.2014.10.011; Reese PP, 2015, J RENAL NUTR, V25, P510, DOI 10.1053/j.jrn.2015.06.001; de Araujo LPR, 2010, REV ESC ENFERM USP, V44, P927, DOI 10.1590/S0080-62342010000400010; Sabat E, 2003, ADHERENCE LONG TERM; Saran R, 2003, KIDNEY INT, V64, P254, DOI 10.1046/j.1523-1755.2003.00064.x; Schunemann H, 2013, GRADE HDB; Sehgal AR, 2002, JAMA-J AM MED ASSOC, V287, P1961, DOI 10.1001/jama.287.15.1961; Sharp J, 2005, AM J KIDNEY DIS, V45, P1046, DOI 10.1053/j.ajkd.2005.02.032; Sherman RA, 2016, AM J KIDNEY DIS, V67, P182, DOI 10.1053/j.ajkd.2015.07.035; Shi YX, 2013, J CLIN NURS, V22, P1189, DOI 10.1111/jocn.12159; SKOUTAKIS VA, 1978, AM J HOSP PHARM, V35, P62, DOI 10.1093/ajhp/35.1.62; Sullivan C, 2009, JAMA-J AM MED ASSOC, V301, P629, DOI 10.1001/jama.2009.96; Tanner J L, 1998, J Ren Nutr, V8, P203, DOI 10.1016/S1051-2276(98)90019-X; Tong A, 2017, AM J KIDNEY DIS, V69, P97, DOI 10.1053/j.ajkd.2016.05.022; Tsay SL, 2003, J ADV NURS, V43, P370, DOI 10.1046/j.1365-2648.2003.02725.x; Welch JL, 2013, RES NURS HEALTH, V36, P284, DOI 10.1002/nur.21539; Wileman V, 2016, PSYCHOL HEALTH, V31, P100, DOI 10.1080/08870446.2015.1073729; Wileman V, 2014, ANN BEHAV MED, V48, P275, DOI 10.1007/s12160-014-9597-8; Wong FKY, 2010, INT J NURS STUD, V47, P268, DOI 10.1016/j.ijnurstu.2009.07.001; Yokum D, 2008, J RENAL NUTR, V18, P521, DOI 10.1053/j.jrn.2008.05.003	56	34	34	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2019	14	1							e0211479	10.1371/journal.pone.0211479	http://dx.doi.org/10.1371/journal.pone.0211479			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HJ3CE	30695068	Green Published, gold, Green Submitted			2023-01-03	WOS:000457046400037
J	Martinez-Valverde, S; Salinas-Escudero, G; Garcia-Delgado, C; Garduno-Espinosa, J; Moran-Barroso, VF; Granados-Garcia, V; Tiro-Sanchez, MT; Toledano-Toledano, F; Aldaz-Rodriguez, MV				Martinez-Valverde, Silvia; Salinas-Escudero, Guillermo; Garcia-Delgado, Constanza; Garduno-Espinosa, Juan; Moran-Barroso, Veronica F.; Granados-Garcia, Victor; Teresa Tiro-Sanchez, Ma.; Toledano-Toledano, Filiberto; Vanessa Aldaz-Rodriguez, Ma.			Out-of-pocket expenditures and care time for children with Down Syndrome: A single-hospital study in Mexico City	PLOS ONE			English	Article							HEALTH; ADOLESCENTS; COSTS; PROFILE; BURDEN	Aim To examine the burden of out-of-pocket household expenditures and time spent on care by families responsible for children with Down Syndrome (DS). Methods A cross-sectional analysis was performed after surveying families of children with DS. The children all received medical care at the Hospital Infantil de Mexico Federico Gomez (HIMFG), a National Institute of Health. Data were collected on out-of-pocket household expenditures for the medical care of these children. The percentage of such expenditure was calculated in relation to available household expenditure (after subtracting the cost of food/housing), and the percentage of households with catastrophic expenditure. Finally, the time spent on the care of the child was assessed. Results The socioeconomic analysis showed that 67% of the households with children with DS who received medical care in the HIMFG were within the lower four deciles (I-IV) of expenses, indicating a limited ability to pay for medical services. Yearly out-of-pocket expenditures for a child with DS represented 27% of the available household expenditure, which is equivalent to $ 464 for the United States dollars (USD). On average, 33% of families with DS children had catastrophic expenses, and 46% of the families had to borrow money to pay for medical expenses. The percentage of catastrophic expenditure was greater for a household with children aged five or older compared with households with younger children. The regression analysis revealed that the age of the child is the most significant factor determining the time spent on care. Conclusions Some Mexican families of children with DS incur substantial out-of-pocket expenditures, which constitute an economic burden for families of children who received medical care at the HIMFG.	[Martinez-Valverde, Silvia; Salinas-Escudero, Guillermo] Inst Nacl Salud, Hosp Infantil Mexico Federico Gomez, Ctr Estudios Econ & Sociales Salud, Mexico City, DF, Mexico; [Garcia-Delgado, Constanza; Moran-Barroso, Veronica F.] Inst Nacl Salud, Hosp Infantil Mexico Federico Gomez, Dept Genet, Mexico City, DF, Mexico; [Garduno-Espinosa, Juan] Inst Nacl Salud, Hosp Infantil Mexico Federico Gomez, Direcc Invest, Mexico City, DF, Mexico; [Granados-Garcia, Victor] Inst Mexicano Seguro Social, Unidad Invest Epidemiol & Serv Salud Area Envejec, Mexico City, DF, Mexico; [Teresa Tiro-Sanchez, Ma.] Inst Mexicano Seguro Social, Hosp Gen Zona 24, Serv Urgencias, Mexico City, DF, Mexico; [Toledano-Toledano, Filiberto] Inst Nacl Salud, Hosp Infantil Mexico Federico Gomez, Unidad Invest Med Basada Evidencias, Mexico City, DF, Mexico; [Vanessa Aldaz-Rodriguez, Ma.] Univ Nacl Autonoma Mexico, Programa Doctorado Adm & Sistemas Salud, Mexico City, DF, Mexico	Hospital Infantil de Mexico Federico Gomez; Hospital Infantil de Mexico Federico Gomez; Hospital Infantil de Mexico Federico Gomez; Instituto Mexicano del Seguro Social; Instituto Mexicano del Seguro Social; Hospital Infantil de Mexico Federico Gomez; Universidad Nacional Autonoma de Mexico	Granados-Garcia, V (corresponding author), Inst Mexicano Seguro Social, Unidad Invest Epidemiol & Serv Salud Area Envejec, Mexico City, DF, Mexico.	vic.granados@gmail.com	Granados-García, Víctor/AAR-5788-2020; Salinas, Guillermo/AGX-9751-2022; Espinosa, Juan Garduño/B-9867-2014; Toledano-Toledano, Filiberto/W-1886-2019	Granados-García, Víctor/0000-0002-9075-576X; Salinas, Guillermo/0000-0003-4573-4844; Espinosa, Juan Garduño/0000-0002-3000-4948; Toledano-Toledano, Filiberto/0000-0002-7126-5351; Martinez Valverde, Silvia/0000-0002-6467-291X	National Institute of Health in Mexico City [HIM/2009/004]	National Institute of Health in Mexico City	The authors did not receive additional payments for this manuscript. The editing and publishing fees were provided by federal funding assigned to project with registered number HIM/2009/004 conducted at Hospital Infantil de Mexico Federico Gomez (HIMFG), National Institute of Health in Mexico City.	Banco de Mexico, 2016, TIP DE CAMB; Besser LM, 2007, BIRTH DEFECTS RES A, V79, P765, DOI 10.1002/bdra.20404; Bonilla-Chacin M.E., 2013, MEXICAN SOCIAL PROTE; Boulet SL, 2008, J PEDIATR-US, V153, P241, DOI 10.1016/j.jpeds.2008.02.046; BRUST JD, 1992, PUBLIC HEALTH NURS, V9, P177, DOI 10.1111/j.1525-1446.1992.tb00097.x; Connel M, 2000, LIMITS MOTHERS CARIN; Cruz C, 2006, POLITICAS PUBLICAS S; Cruz Carlos, 2006, BIENESTAR POLITICA S, V2, P51; Dawson AL, 2014, BIRTH DEFECTS RES A, V100, P826, DOI 10.1002/bdra.23295; de Castro F, 2017, SALUD PUBLICA MEXICO, V59, P354, DOI 10.21149/8487; de Graaf G, 2015, AM J MED GENET A, V167, P756, DOI 10.1002/ajmg.a.37001; Diario oficial de la federacion, 2016, AC QUE SE EM REGL OP; Rodriguez-Ortega EE, 2012, SALUD PUBLICA MEXICO, V54, pS65, DOI 10.1590/S0036-36342012000700009; Flores-Ramirez F, 2015, ARCH MED RES, V46, P484, DOI 10.1016/j.arcmed.2015.08.001; Geelhoed EA, 2011, J PEDIATR-US, V159, P541, DOI 10.1016/j.jpeds.2011.06.007; Goudie A., 2010, CARING CHILDREN DISA; HOOK EB, 1981, NEW ENGL J MED, V305, P1410, DOI 10.1056/NEJM198112033052312; INEGI (Instituto Nacional de Estadstica y Geografa), 2015, ENCUESTA INTERCENSAL; Instituto Nacional de Estadistica y Geografia (INEGI), 2020, IND PREC CONS; Instituto Nacional de Estadistica y Geografia -INEGI, 2016, ENC NACL INGR GAST H; Kageleiry A, 2017, AM J MED GENET A, V173, P627, DOI 10.1002/ajmg.a.38050; Knaul FM, 2005, SALUD PUBLICA MEXICO, V47, P430; Kuhlthau K, 2005, MATERN CHILD HLTH J, V9, P207, DOI 10.1007/s10995-005-4870-x; McGrath RJ, 2011, J PEDIATR-US, V159, P535, DOI 10.1016/j.jpeds.2011.04.019; McPherson M, 1998, PEDIATRICS, V102, P137, DOI 10.1542/peds.102.1.137; Hernandez EN, 2013, B MED HOSP INFANT M, V70, P499; Presidencia de la Republica, 2011, SEG MED NUEV GEN; Roizen NJ, 2003, LANCET, V361, P1281, DOI 10.1016/S0140-6736(03)12987-X; Ruiz Herrera G., 2013, THESIS; Schieve LA, 2009, PEDIATRICS, V123, pE253, DOI 10.1542/peds.2008-1440; Secretaria de Salud, 2007, LIN TECN; Skotko BG, 2011, AM J MED GENET A, V155A, P2360, DOI 10.1002/ajmg.a.34235; Torres A., 2003, CALEIDOSCOPIO SALUD, P209; US Department of Education, 2018, CTR PAR INF RES OFF; Waitzman N., 1996, COST BIRTH DEFECTS E; World Health Organization, 2000, WORLD HLTH REP 2000; Xu K., 2005, DISTRIBUTION HLTH PA	37	2	2	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 10	2019	14	1							e0208076	10.1371/journal.pone.0208076	http://dx.doi.org/10.1371/journal.pone.0208076			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH1ME	30629602	gold, Green Submitted, Green Published			2023-01-03	WOS:000455483000010
J	Gregori, D; Giacovelli, G; Minto, C; Barbetta, B; Gualtieri, F; Azzolina, D; Vaghi, P; Rovati, LC				Gregori, Dario; Giacovelli, Giampaolo; Minto, Clara; Barbetta, Beatrice; Gualtieri, Francesca; Azzolina, Danila; Vaghi, Paola; Rovati, Lucio C.			Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis A Systematic Review and Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; VITAMIN-D SUPPLEMENTATION; CONTROLLED CLINICAL-TRIAL; STRUCTURE-MODIFYING DRUG; DOUBLE-BLIND; HYALURONIC-ACID; CHONDROITIN SULFATE; CARTILAGE VOLUME; SYMPTOMATIC OSTEOARTHRITIS; INTRAARTICULAR HYALURONAN	IMPORTANCE Even though osteoarthritis is a chronic and progressive disease, pharmacological agents are mainly studied over short-term periods, resulting in unclear recommendations for long-term disease management. OBJECTIVE To search, review, and analyze long-term (>= 12 months) outcomes (symptoms, joint structure) from randomized clinical trials (RCTs) of medications for knee osteoarthritis. DATA SOURCES AND STUDY SELECTION The databases of MEDLINE, Scopus, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials were searched until June 30, 2018 (MEDLINE alerts through August 31, 2018) for RCTs of patients with knee osteoarthritis that had treatment and follow-up lasting 1 year or longer. DATA EXTRACTION AND SYNTHESIS Data at baseline and at the longest available treatment and follow-up of 12 months' duration or longer (or the change from baseline) were extracted. A Bayesian random-effects network meta-analysis was performed. MAIN OUTCOMES AND MEASURES The primary outcome was the mean change from baseline in knee pain. Secondary outcomes were physical function and joint structure (the latter was measured radiologically as joint space narrowing). Standardized mean differences (SMDs) and mean differences with 95% credibility intervals (95% CrIs) were calculated. Findings were interpreted as associations when the 95% CrIs excluded the null value. RESULTS Forty-seven RCTs (22 037 patients; mean age range, mostly 55-70 years; and a higher mean proportion of women than men, around 70%) included the following medication categories: analgesics; antioxidants; bone-acting agents such as bisphosphonates and strontium ranelate; nonsteroidal anti-inflammatory drugs; intra-articular injection medications such as hyaluronic acid and corticosteroids; symptomatic slow-acting drugs in osteoarthritis such as glucosamine and chondroitin sulfate; and putative disease-modifying agents such as cindunistat and sprifermin. Thirty-one interventions were studied for pain, 13 for physical function, and 16 for joint structure. Trial duration ranged from 1 to 4 years. Associations with decreases in pain were found for the nonsteroidal anti-inflammatory drug celecoxib (SMD,-0.18 [95% CrI,-0.35 to -0.01]) and the symptomatic slow-acting drug in osteoarthritis glucosamine sulfate (SMD,-0.29 [95% CrI,-0.49 to -0.09]), but there was large uncertainty for all estimates vs placebo. The association with pain improvement remained significant only for glucosamine sulfate when data were analyzed using the mean difference on a scale from 0 to 100 and when trials at high risk of bias were excluded. Associations with improvement in joint space narrowing were found for glucosamine sulfate (SMD,-0.42 [95% CrI,-0.65 to -0.19]), chondroitin sulfate (SMD,-0.20 [95% CrI, -0.31 to -0.07]), and strontium ranelate (SMD,-0.20 [95% CrI,-0.36 to -0.05]). CONCLUSIONS AND RELEVANCE In this systematic review and network meta-analysis of studies of patients with knee osteoarthritis and at least 12 months of follow-up, there was uncertainty around the estimates of effect size for change in pain for all comparisons with placebo. Larger RCTs are needed to resolve the uncertainty around efficacy of medications for knee osteoarthritis.	[Gregori, Dario; Minto, Clara; Azzolina, Danila] Univ Padua, Dept Cardiac Thorac & Vasc Sci, Unit Biostat Epidemiol & Publ Hlth, Padua, Italy; [Giacovelli, Giampaolo; Barbetta, Beatrice; Vaghi, Paola] Rottapharm Biotech, Dept Biostat, Monza, Italy; [Gualtieri, Francesca] Rottapharm Biotech, Sci Informat & Lib Serv, Monza, Italy; [Rovati, Lucio C.] Rottapharm Biotech, Dept Clin Res, Monza, Italy; [Rovati, Lucio C.] Univ Milano Bicocca, Sch Med & Surg, Via Cadore 48, I-20900 Monza, Italy	University of Padua; Rottapharm; Rottapharm; Rottapharm; University of Milano-Bicocca	Rovati, LC (corresponding author), Univ Milano Bicocca, Sch Med & Surg, Via Cadore 48, I-20900 Monza, Italy.	lucio.rovati@unimib.it	Azzolina, Danila/M-5100-2019	Azzolina, Danila/0000-0002-8185-5742; Rovati, Lucio/0000-0002-3425-1583	BIRD 2016 DCTV from the University of Padova; Rottapharm Biotech	BIRD 2016 DCTV from the University of Padova; Rottapharm Biotech	This study was supported by grant BIRD 2016 DCTV from the University of Padova and by financial support from Rottapharm Biotech.	Abrams KR, 2005, STAT MED, V24, P3823, DOI 10.1002/sim.2423; Altman Roy D, 2009, Expert Rev Clin Pharmacol, V2, P359, DOI 10.1586/ecp.09.17; Arden NK, 2016, OSTEOARTHR CARTILAGE, V24, P1858, DOI 10.1016/j.joca.2016.05.020; Baker-LePain JC, 2012, BONE, V51, P197, DOI 10.1016/j.bone.2012.01.008; Bannuru RR, 2015, ANN INTERN MED, V162, P46, DOI 10.7326/M14-1231; Bannuru RR, 2009, ARTHRIT RHEUM-ARTHR, V61, P1704, DOI 10.1002/art.24925; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Bingham CO, 2006, ARTHRITIS RHEUM-US, V54, P3494, DOI 10.1002/art.22160; Bisicchia S, 2016, CLIN EXP RHEUMATOL, V34, P857; Brandt KD, 2005, ARTHRITIS RHEUM-US, V52, P2015, DOI 10.1002/art.21122; Brooks SP, 1998, J COMPUT GRAPH STAT, V7, P434, DOI 10.2307/1390675; Bruyere O, 2014, SEMIN ARTHRITIS RHEU, V44, P253, DOI 10.1016/j.semarthrit.2014.05.014; BUCKLANDWRIGHT JC, 1995, J RHEUMATOL, V22, P937; Cannon GW, 2000, ARTHRITIS RHEUM-US, V43, P978, DOI 10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0; Cohen J., 2013, STAT POWER ANAL BEHA; Curtis SP, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-58; da Costa BR, 2017, LANCET, V390, pE21, DOI 10.1016/S0140-6736(17)31744-0; Dahlberg LE, 2009, SCAND J RHEUMATOL, V38, P133, DOI 10.1080/03009740802419065; DeWan M, US patent, Patent No. 5,847,107; Dias S, 2010, STAT MED, V29, P932, DOI 10.1002/sim.3767; Dias S, 2013, MED DECIS MAKING, V33, P618, DOI 10.1177/0272989X13485157; Dias S, 2013, MED DECIS MAKING, V33, P607, DOI 10.1177/0272989X12458724; Dougados M, 1993, Osteoarthritis Cartilage, V1, P97, DOI 10.1016/S1063-4584(05)80024-X; Eriksen P, 2014, ARTHRIT CARE RES, V66, P1844, DOI 10.1002/acr.22376; Erturk C, 2016, KNEE SURG SPORT TR A, V24, P3653, DOI 10.1007/s00167-014-3398-2; Fernandes L, 2013, ANN RHEUM DIS, V72, P1125, DOI 10.1136/annrheumdis-2012-202745; Fransen M, 2015, ANN RHEUM DIS, V74, P851, DOI 10.1136/annrheumdis-2013-203954; Glass G. V., 1981, METAANALYSIS SOCIAL; Glyn-Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140-6736(14)60802-3; Gore M, 2012, PAIN PRACT, V12, P550, DOI 10.1111/j.1533-2500.2012.00532.x; Guner S, 2016, THER CLIN RISK MANAG, V12, P1693, DOI 10.2147/TCRM.S114707; Guyot P, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-9; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596; Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385; Jorgensen A, 2010, ANN RHEUM DIS, V69, P1097, DOI 10.1136/ard.2009.118042; Jubb RW, 2003, INT J CLIN PRACT, V57, P467; Juhl C, 2012, ARTHRITIS, DOI 10.1155/2012/136245; Kahan A, 2009, ARTHRITIS RHEUM-US, V60, P524, DOI 10.1002/art.24255; Karlsson J, 2002, RHEUMATOLOGY, V41, P1240, DOI 10.1093/rheumatology/41.11.1240; Karsdal MA, 2015, OSTEOARTHR CARTILAGE, V23, P532, DOI 10.1016/j.joca.2014.12.019; Kawasaki T, 2008, J BONE MINER METAB, V26, P279, DOI 10.1007/s00774-007-0813-5; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Kriegel W, 2001, INT J CLIN PRACT, V55, P510; Krzeski P, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2315; Lane NE, 2011, OSTEOARTHR CARTILAGE, V19, P478, DOI 10.1016/j.joca.2010.09.013; Laslett LL, 2012, ANN RHEUM DIS, V71, P1322, DOI 10.1136/annrheumdis-2011-200970; le Graverand MPH, 2013, ANN RHEUM DIS, V72, P187, DOI 10.1136/annrheumdis-2012-202239; Leighton R, 2014, OSTEOARTHR CARTILAGE, V22, P17, DOI 10.1016/j.joca.2013.10.009; LEQUESNE M, 1994, J RHEUMATOL, V21, P65; Listrat V, 1997, OSTEOARTHR CARTILAGE, V5, P153, DOI 10.1016/S1063-4584(97)80010-6; Lohmander LS, 2014, ARTHRITIS RHEUMATOL, V66, P1820, DOI 10.1002/art.38614; Lunn D., 2012, BUGS BOOK PRACTICAL, DOI DOI 10.1201/B13613; Mathieu P, 2002, PRESSE MED, V31, P1386; McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003; McAlindon T, 2013, JAMA-J AM MED ASSOC, V309, P155, DOI 10.1001/jama.2012.164487; McAlindon TE, 2017, JAMA-J AM MED ASSOC, V317, P1967, DOI 10.1001/jama.2017.5283; Michel BA, 2005, ARTHRITIS RHEUM-US, V52, P779, DOI 10.1002/art.20867; Mokdad AH, 2018, JAMA-J AM MED ASSOC, V319, P1444, DOI 10.1001/jama.2018.0158; Newberry SJ, TREATMENT OSTEOARTHR; Nissen SE, 2016, NEW ENGL J MED, V375, P2519, DOI 10.1056/NEJMoa1611593; NUESCH E, 2010, BRIT MED J, V341, DOI DOI 10.1136/BMJ.C3515; Ozturk C, 2006, RHEUMATOL INT, V26, P314, DOI 10.1007/s00296-005-0584-z; Pavelka K, 2002, ARCH INTERN MED, V162, P2113, DOI 10.1001/archinte.162.18.2113; Pavelka K, 2003, OSTEOARTHR CARTILAGE, V11, P730, DOI 10.1016/S1063-4584(03)00166-3; Pelletier JP, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1149-0; Pham T, 2004, ANN RHEUM DIS, V63, P1611, DOI 10.1136/ard.2003.019703; Raynauld JP, 2009, ANN RHEUM DIS, V68, P938, DOI 10.1136/ard.2008.088732; Raynauld JP, 2003, ARTHRITIS RHEUM, V48, P370, DOI 10.1002/art.10777; Reginster JY, 2015, OSTEOARTHR CARTILAGE, V23, P2086, DOI 10.1016/j.joca.2015.07.001; Reginster JY, 2013, ANN RHEUM DIS, V72, P179, DOI 10.1136/annrheumdis-2012-202231; Reginster JY, 2001, LANCET, V357, P251, DOI 10.1016/S0140-6736(00)03610-2; Reginster Y, 2007, ANN RHEUM DIS, V66, P945, DOI 10.1136/ard.2006.059162; RStudio Team, RSTUDIO INT DEV R; Saag K, 2000, ARCH FAM MED, V9, P1124, DOI 10.1001/archfami.9.10.1124; Salanti G, 2012, RES SYNTH METHODS, V3, P80, DOI 10.1002/jrsm.1037; Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016; Sawitzke AD, 2008, ARTHRITIS RHEUM, V58, P3183, DOI 10.1002/art.23973; Sawitzke AD, 2010, ANN RHEUM DIS, V69, P1459, DOI 10.1136/ard.2009.120469; Schwarzer G., 2015, METAANALYSIS R, P187; Scott DL, 2000, RHEUMATOLOGY, V39, P1095, DOI 10.1093/rheumatology/39.10.1095; Spector TD, 2005, ARTHRITIS RES THER, V7, pR625, DOI 10.1186/ar1716; Spiegelhalter DJ., 2004, BAYESIAN APPROACHES, V13; Towheed TE, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002946.pub2; Davalillo CAT, 2015, OPEN ACCESS RHEUMATO, V7, P9, DOI 10.2147/OARRR.S74553; Uebelhart D, 2004, OSTEOARTHR CARTILAGE, V12, P269, DOI 10.1016/j.joca.2004.01.004; van Valkenhoef G, 2012, RES SYNTH METHODS, V3, P285, DOI 10.1002/jrsm.1054; Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]; WILLIAMS HJ, 1993, ARTHRITIS RHEUM-US, V36, P1196, DOI 10.1002/art.1780360904; Wluka A, 2002, J RHEUMATOL, V29, P2585	90	136	150	18	63	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	2018	320	24					2564	2579		10.1001/jama.2018.19319	http://dx.doi.org/10.1001/jama.2018.19319			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG1EK	30575881	Green Published, Bronze			2023-01-03	WOS:000454693000017
J	Podolsky, SH; Herzberg, D; Greene, JA				Podolsky, Scott H.; Herzberg, David; Greene, Jeremy A.			Preying on Prescribers (and Their Patients) - Pharmaceutical Marketing, Iatrogenic Epidemics, and the Sackler Legacy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Podolsky, Scott H.] Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA 02115 USA; [Podolsky, Scott H.] Ctr Hist Med, Countway Med Lib, Boston, MA 02115 USA; [Herzberg, David] SUNY Buffalo, Dept Hist, Buffalo, NY 14260 USA; [Greene, Jeremy A.] Johns Hopkins Univ, Sch Med, Dept Hist Med, Baltimore, MD USA; [Greene, Jeremy A.] Johns Hopkins Univ, Sch Med, Ctr Med Humanities & Social Med, Baltimore, MD USA	Harvard University; Harvard Medical School; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Johns Hopkins University; Johns Hopkins University	Podolsky, SH (corresponding author), Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA 02115 USA.; Podolsky, SH (corresponding author), Ctr Hist Med, Countway Med Lib, Boston, MA 02115 USA.							Abraham Y., 2019, BOSTON GLOBE    0202; Greene JA, 2009, B HIST MED, V83, P331, DOI 10.1353/bhm.0.0218; Keefe PR, 2017, NEW YORKER, P34; PODOLSKY SH, 2015, ANT ER REF RES PURS, P1; Schwartz LM, 2019, JAMA-J AM MED ASSOC, V321, P80, DOI 10.1001/jama.2018.19320	5	6	6	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 9	2019	380	19					1785	1787		10.1056/NEJMp1902811	http://dx.doi.org/10.1056/NEJMp1902811			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX9ZZ	30969504				2023-01-03	WOS:000467769800001
J	Dusetzina, SB; Bach, PB				Dusetzina, Stacie B.; Bach, Peter B.			Prescription Drugs-List Price, Net Price, and the Rebate Caught in the Middle	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Dusetzina, Stacie B.] Vanderbilt Univ, Sch Med, Dept Hlth Policy, 2525 West End Ave,Ste 1203, Nashville, TN 37203 USA; [Dusetzina, Stacie B.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA; [Bach, Peter B.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA	Vanderbilt University; Vanderbilt University; Memorial Sloan Kettering Cancer Center	Dusetzina, SB (corresponding author), Vanderbilt Univ, Sch Med, Dept Hlth Policy, 2525 West End Ave,Ste 1203, Nashville, TN 37203 USA.	s.dusetzina@vanderbilt.edu						Bach PB, 2015, JAMA-J AM MED ASSOC, V314, P2503, DOI 10.1001/jama.2015.16843; 2017, JAMA INTERN MED, V177, P1185, DOI DOI 10.1001/JAMAINTERNMED.2017.1885	2	27	27	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	2019	321	16					1563	1564		10.1001/jama.2019.2445	http://dx.doi.org/10.1001/jama.2019.2445			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV7BZ	30840047				2023-01-03	WOS:000466137800007
J	Mehta, RS; Barlow, WE; Albain, KS; Vandenberg, TA; Dakhil, SR; Tirumali, NR; Lew, DL; Hayes, DF; Gralow, JR; Linden, HH; Livingston, RB; Hortobagyi, GN				Mehta, Rita S.; Barlow, William E.; Albain, Kathy S.; Vandenberg, Ted A.; Dakhil, Shaker R.; Tirumali, Nagendra R.; Lew, Danika L.; Hayes, Daniel F.; Gralow, Julie R.; Linden, Hannah H.; Livingston, Robert B.; Hortobagyi, Gabriel N.			Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							1ST-LINE TREATMENT; 500 MG; POSTMENOPAUSAL WOMEN; ENDOCRINE THERAPY; LETROZOLE; COMBINATION; BEVACIZUMAB; PALBOCICLIB	BACKGROUND We previously reported prolonged progression-free survival and marginally prolonged overall survival among postmenopausal patients with hormone receptor-positive metastatic breast cancer who had been randomly assigned to receive the aromatase inhibitor anastrozole plus the selective estrogen-receptor down-regulator fulvestrant, as compared with anastrozole alone, as first-line therapy. We now report final survival outcomes. METHODS We randomly assigned patients to receive either anastrozole or fulvestrant plus anastrozole. Randomization was stratified according to adjuvant tamoxifen use. Analysis of survival was performed by means of two-sided stratified log-rank tests and Cox regression. Efficacy and safety were compared between the two groups, both overall and in subgroups. RESULTS Of 707 patients who had undergone randomization, 694 had data available for analysis. The combination-therapy group had 247 deaths among 349 women (71%) and a median overall survival of 49.8 months, as compared with 261 deaths among 345 women (76%) and a median overall survival of 42.0 months in the anastrozole-alone group, a significant difference (hazard ratio for death, 0.82; 95% confidence interval (CIS, 0.69 to 0.98; P=0.03 by the log-rank test). In a subgroup analysis of the two strata, overall survival among women who had not received tamoxifen previously was longer with the combination therapy than with anastrozole alone (median, 52.2 months and 40.3 months, respectively; hazard ratio, 0.73; 95% CI, 0.58 to 0.92); among women who had received tamoxifen previously, overall survival was similar in the two groups (median, 48.2 months and 43.5 months, respectively; hazard ratio, 0.97; 95% CI, 0.74 to 1.27) (P=0.09 for interaction). The incidence of long-term toxic effects of grade 3 to 5 was similar in the two groups. Approximately 45% of the patients in the anastrozole-alone group crossed over to receive fulvestrant. CONCLUSIONS The addition of fulvestrant to anastrozole was associated with increased long-term survival as compared with anastrozole alone, despite substantial crossover to fulvestrant after progression during therapy with anastrozole alone. The results suggest that the benefit was particularly notable in patients without previous exposure to adjuvant endocrine therapy.	[Mehta, Rita S.] Univ Calif Irvine, Med Ctr, Chao Family Comprehens Canc Ctr, 101 City Dr,Bldg. 23, Orange, CA 92868 USA; [Barlow, William E.; Lew, Danika L.] Seattle Canc Care Alliance, SWOG Stat & Data Management Ctr, Seattle, WA USA; [Gralow, Julie R.; Linden, Hannah H.] Univ Washington, Med Ctr, Seattle, WA 98195 USA; [Albain, Kathy S.] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA; [Vandenberg, Ted A.] London Hlth Sci Ctr, London, ON, Canada; [Vandenberg, Ted A.] Natl Canc Inst, Canada Clin Trials Grp, London, ON, Canada; [Dakhil, Shaker R.] Wichita, Canc Ctr Kansas, Portland, OR USA; [Dakhil, Shaker R.] Wichita, Wichita Natl Canc Inst Community Oncol Res Progra, Portland, OR USA; [Tirumali, Nagendra R.] Kaiser Permanente NCORP, Portland, OR USA; [Hayes, Daniel F.] Univ Michigan, Ann Arbor, MI 48109 USA; [Livingston, Robert B.] Univ Arizona, Ctr Canc, Tucson, AZ USA; [Hortobagyi, Gabriel N.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	University of California System; University of California Irvine; Seattle Cancer Care Alliance; Southwest Oncology Group; University of Washington; University of Washington Seattle; Loyola University Chicago; London Health Sciences Centre; Queens University - Canada; Canadian Cancer Trials Group; Kaiser Permanente; University of Michigan System; University of Michigan; University of Arizona; University of Texas System; UTMD Anderson Cancer Center	Mehta, RS (corresponding author), Univ Calif Irvine, Med Ctr, Chao Family Comprehens Canc Ctr, 101 City Dr,Bldg. 23, Orange, CA 92868 USA.	rsmehta@uci.edu	Hayes, Daniel/ABE-1129-2020		National Cancer Institute; AstraZeneca; NATIONAL CANCER INSTITUTE [UG1CA233329, UG1CA189808, U10CA180888, P30CA016672, UG1CA233328, U10CA180863, UG1CA233160, P30CA062203, U10CA180819, UG1CA189952, UG1CA189953, U10CA180858, U10CA180801] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AstraZeneca(AstraZeneca); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by the National Cancer Institute and AstraZeneca; ClinicalTrials.gov number, NCT00075764.	Bergh J, 2012, J CLIN ONCOL, V30, P1919, DOI 10.1200/JCO.2011.38.1095; Di Leo A, 2018, BREAST, V38, P144, DOI 10.1016/j.breast.2017.12.016; Di Leo A, 2010, J CLIN ONCOL, V28, P4594, DOI 10.1200/JCO.2010.28.8415; Dickler MN, 2016, J CLIN ONCOL, V34, P2602, DOI 10.1200/JCO.2015.66.1595; Ellis MJ, 2015, J CLIN ONCOL, V33, P3781, DOI 10.1200/JCO.2015.61.5831; Finn RS, 2016, NEW ENGL J MED, V375, P1925, DOI 10.1056/NEJMoa1607303; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Goetz MP, 2017, J CLIN ONCOL, V35, P3638, DOI 10.1200/JCO.2017.75.6155; Hortobagyi GN, 2016, NEW ENGL J MED, V375, P1738, DOI 10.1056/NEJMoa1609709; Johnston SRD, 2013, LANCET ONCOL, V14, P989, DOI 10.1016/S1470-2045(13)70322-X; Martin M, 2015, J CLIN ONCOL, V33, P1045, DOI 10.1200/JCO.2014.57.2388; Mehta RS, 2012, NEW ENGL J MED, V367, P435, DOI 10.1056/NEJMoa1201622; Robertson JFR, 2016, LANCET, V388, P2997, DOI 10.1016/S0140-6736(16)32389-3; Slamon DJ, 2018, J CLIN ONCOL, V36, P2465, DOI 10.1200/JCO.2018.78.9909; Tripathy D, 2018, LANCET ONCOL, V19, P904, DOI 10.1016/S1470-2045(18)30292-4; Turner NC, 2018, NEW ENGL J MED, V379, P1926, DOI 10.1056/NEJMoa1810527	16	59	61	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 28	2019	380	13					1226	1234		10.1056/NEJMoa1811714	http://dx.doi.org/10.1056/NEJMoa1811714			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR6HX	30917258	Green Accepted, Bronze, Green Published			2023-01-03	WOS:000463251600007
J	Saetae, T; Pongpirul, K; Samransamruajkit, R				Saetae, Thansinee; Pongpirul, Krit; Samransamruajkit, Rujipat			Assessment of early goal-directed therapy guideline adherence: Balancing clinical importance and feasibility	PLOS ONE			English	Article							SURVIVING SEPSIS CAMPAIGN; SEPTIC SHOCK; MANAGEMENT; OUTCOMES; IMPLEMENTATION; RESUSCITATION; PROTOCOL	Background Assessing adherence to Early goal-directed therapy (EGDT) is challenging and might account for the negative findings and generalisability of the major trials to a real-life setting. This study was aimed (1) to extract key components of pediatric EGDT guidelines potentially becoming adherence criteria; (2) to classify adherence criteria into complete, clinically important, and feasible; and (3) to compare percent adherence to selected guidelines using the three approaches. Methods This study started with review of existing evidence to extract key components of pediatric EGDT guidelines. Modified Delphi method was then conducted in two rounds among national experts to identify feasible and/or clinically important criteria. Data from the national prospective multicenter study "Clinical Effectiveness of the Utilization of Bundled Care for Severe Sepsis and Septicemia Children" at King Chulalongkorn Memorial Hospital (KCMH) during 1 June 2012 and 28 February 2014 was used to compare percentage of adherence across the three approaches. Results Of 28 components extracted from the review, 10 were identified by the national experts through the Modified Delphi as feasible whereas 8 were identified as clinically important. Thirty-one severe sepsis patients (48.39% male, median age 3.4 years) were reviewed. Sepsis mortality was 9.7%, a significant reduction from 19% and 42% in 2010 and 2007, respectively. Based on the complete adherence criteria, the percent adherence varied from 60.71% to 89.29% (overall mean 76.84%), with lower adherence in the dead than the survived cases (73.81% vs 77.17%; p = 0.55). The percent adherence varied by criteria used: 69.35%, 76.84%, and 84.52% for clinical importance, complete, and feasibility criteria, respectively. Conclusion Adherence determination based on selected clinical importance alone might result in an incorrectly estimated clinical benefit of EGDT guidelines, especially in a resource-limited setting. Both clinical importance and feasibility should be integrated into the development of adherence assessment criteria.	[Saetae, Thansinee; Samransamruajkit, Rujipat] Chulalongkorn Univ, Dept Pediat, Fac Med, Bangkok, Thailand; [Pongpirul, Krit] Chulalongkorn Univ, Dept Prevent & Social Med, Fac Med, Bangkok, Thailand; [Pongpirul, Krit] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA	Chulalongkorn University; Chulalongkorn University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Pongpirul, K (corresponding author), Chulalongkorn Univ, Dept Prevent & Social Med, Fac Med, Bangkok, Thailand.; Pongpirul, K (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.	doctorkrit@gmail.com	Samransamruajkit, Rujipat/V-7046-2019; Pongpirul, Krit/H-4064-2019; Samransamruajkit, Rujipat/AFO-8542-2022	Pongpirul, Krit/0000-0003-3818-9761; 	National Research Council of Thailand	National Research Council of Thailand(National Research Council of Thailand (NRCT))	This study received funding support from the National Research Council of Thailand. The funding body did not involve in the study design, data collection, data analysis, data interpretation, or manuscript preparation.	Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Angus DC, 2015, INTENS CARE MED, V41, P1549, DOI 10.1007/s00134-015-3822-1; Carlbom DJ, 2007, CRIT CARE MED, V35, P2525, DOI 10.1097/01.ccm.0000298122.49245.d7; Crowe CA, 2010, AM J EMERG MED, V28, P689, DOI 10.1016/j.ajem.2009.03.007; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Dellinger RP, 2008, INTENS CARE MED, V34, P17, DOI 10.1007/s00134-007-0934-2; Jones AE, 2005, CRIT CARE MED, V33, P974, DOI [10.1097/01.CCM.0000162495.03291.C2, 10.1097/01.CCM.0000166872.78449.B1]; Jones AE, 2007, CHEST, V132, P425, DOI 10.1378/chest.07-0234; Kawasaki T, 2017, J INTENSIVE CARE, V5, DOI 10.1186/s40560-017-0240-1; Kortgen A, 2006, CRIT CARE MED, V34, P943, DOI 10.1097/01.CCM.0000206112.32673.D4; Micek ST, 2006, CRIT CARE MED, V34, P2707, DOI 10.1097/01.CCM.0000241151.25426.D7; Mikkelsen ME, 2010, CHEST, V138, P551, DOI 10.1378/chest.09-2210; Mouncey PR, 2015, NEW ENGL J MED, V372, P1301, DOI 10.1056/NEJMoa1500896; Nguyen HB, 2007, ACAD EMERG MED, V14, P1079, DOI 10.1111/j.1553-2712.2007.tb02392.x; O'Neill R, 2012, J EMERG MED, V42, P503, DOI 10.1016/j.jemermed.2011.03.024; Peake SL, 2014, NEW ENGL J MED, V371, P1496, DOI 10.1056/NEJMoa1404380; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Samransamruajkit R, 2014, INDIAN J CRIT CARE M, V18, P70, DOI 10.4103/0972-5229.126075; Sankar J, 2014, PEDIATR CRIT CARE ME, V15, pE157, DOI 10.1097/PCC.0000000000000073; Shapiro NI, 2006, CRIT CARE MED, V34, P1025, DOI 10.1097/01.CCM.0000206104.18647.A8; Trzeciak S, 2006, CHEST, V129, P225, DOI 10.1378/chest.129.2.225; Yealy DM, 2014, NEW ENGL J MED, V370, P1683, DOI 10.1056/NEJMoa1401602	22	2	2	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2019	14	3							e0213802	10.1371/journal.pone.0213802	http://dx.doi.org/10.1371/journal.pone.0213802			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO9WM	30875402	Green Published, gold, Green Submitted			2023-01-03	WOS:000461316400032
J	Jaffe, S				Jaffe, Susan			US lawmakers seek cuts in prescription drug prices	LANCET			English	Editorial Material																			0	1	1	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	2019	393	10175					975	976		10.1016/S0140-6736(19)30537-9	http://dx.doi.org/10.1016/S0140-6736(19)30537-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HO0OW	30860040				2023-01-03	WOS:000460604200014
J	Beitler, JR; Sarge, T; Banner-Goodspeed, VM; Gong, MN; Cook, D; Novack, V; Loring, SH; Talmor, D; Loring, S; Banner-Goodspeed, V; Fish, E; Jinadasa, S; Ritz, R; Previtera, J; Lee, L; Clarke, F; Piraino, T; Levitt, J; Vojnik, R; Park, P; Brierley, K; Haas, C; Weirauch, A; Fan, E; Matte, A; Harris, RS; Kone, M; Heard, S; Longtine, K; Lellouche, F; Bouchard, PA; Rubinson, L; McGrain, J; Griesdale, DEG; Foster, D; Oeckler, R; Amsbaugh, A; Jimenez, E; Danesh, V; Slutsky, AS; Hall, J; Hubmayr, RD; Rubenfeld, G; Schoenfeld, D				Beitler, Jeremy R.; Sarge, Todd; Banner-Goodspeed, Valerie M.; Gong, Michelle N.; Cook, Deborah; Novack, Victor; Loring, Stephen H.; Talmor, Daniel; Loring, Stephen; Banner-Goodspeed, Valerie; Fish, Emily; Jinadasa, Sayuri; Ritz, Ray; Previtera, Joseph; Lee, Lawrence; Clarke, France; Piraino, Tom; Levitt, Joseph; Vojnik, Rosemary; Park, Pauline; Brierley, Kristin; Haas, Carl; Weirauch, Andrew; Fan, Eddy; Matte, Andrea; Harris, R. Scott; Kone, Mamary; Heard, Stephen; Longtine, Karen; Lellouche, Francois; Bouchard, Pierre-Alexandre; Rubinson, Lewis; McGrain, Jennifer (Titus); Griesdale, Donald E. G.; Foster, Denise; Oeckler, Richard; Amsbaugh, Amy; Jimenez, Edgar; Danesh, Valerie; Slutsky, Arthur S.; Hall, Jesse; Hubmayr, Rolf D.; Rubenfeld, Gordon; Schoenfeld, David		EPVent-2 Study Grp	Effect of Titrating Positive End-Expiratory Pressure (PEEP) With an Esophageal Pressure-Guided Strategy vs an Empirical High PEEP-FIO2 Strategy on Death and Days Free From Mechanical Ventilation Among Patients With Acute Respiratory Distress Syndrome A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	48th Critical Care Congress of the Society-of-Critical-Care-Medicine	FEB 18, 2019	San Diego, CA	Soc Crit Care Med			ACUTE LUNG INJURY; TRANSPULMONARY PRESSURES; TIDAL VOLUMES; RECRUITMENT; MORTALITY; PULMONARY; SUBPHENOTYPES; MODEL; SIZE	IMPORTANCE Adjusting positive end-expiratory pressure (PEEP) to offset pleural pressure might attenuate lunginjury and improve patient outcomes inacute respiratory distress syndrome(ARDS). OBJECTIVE To determine whether PEEP titration guided by esophageal pressure (P-ES), an estimate of pleural pressure, was more effective than empirical high PEEP-fraction of inspired oxygen (FIO2) in moderate to severe ARDS. DESIGN, SETTING, AND PARTICIPANTS Phase 2 randomized clinical trial conducted at 14 hospitals in North America. Two hundred mechanically ventilated patients aged 16 years and older with moderate to severe ARDS (PaO2: FIO2 <= 200 mm Hg) were enrolled between October 31, 2012, and September 14, 2017; long-term follow-up was completed July 30, 2018. INTERVENTIONS Participants were randomized to P-ES-guided PEEP (n = 102) or empirical high PEEP-FIO2 (n = 98). All participants received low tidal volumes. MAIN OUTCOMES AND MEASURES The primary outcome was a ranked composite score incorporating death and days free from mechanical ventilation among survivors through day 28. Prespecified secondary outcomes included 28-day mortality, days free from mechanical ventilation among survivors, and need for rescue therapy. RESULTS Two hundred patients were enrolled (mean [SD] age, 56 [16] years; 46% female) and completed 28-day follow-up. The primary composite end point was not significantly different between treatment groups (probability of more favorable outcome with P-ES-guided PEEP: 49.6% [95% CI, 41.7% to 57.5%]; P = .92). At 28 days, 33 of 102 patients (32.4%) assigned to P-ES-guided PEEP and 30 of 98 patients (30.6%) assigned to empirical PEEP-FIO2 died (risk difference, 1.7%[95% CI, -11.1% to 14.6%]; P = .88). Days free from mechanical ventilation among survivors was not significantly different (median [interquartile range]: 22 [15-24] vs 21 [16.5-24] days; median difference, 0[95% CI, -1 to 2] days; P = .85). Patients assigned to P-ES-guided PEEP were significantly less likely to receive rescue therapy (4/102 [3.9%] vs 12/98 [12.2%]; risk difference, -8.3%[95% CI, -15.8% to -0.8%]; P = .04). None of the 7 other prespecified secondary clinical end points were significantly different. Adverse events included gross barotrauma, which occurred in 6 patients with P-ES-guided PEEP and 5 patients with empirical PEEP-FIO2. CONCLUSIONS AND RELEVANCE Amongpatients with moderate to severe ARDS, P-ES-guided PEEP, compared with empirical high PEEP-FIO2, resulted in no significant difference in death and days free from mechanical ventilation. These findings do not support P-ES-guided PEEP titration in ARDS.	[Sarge, Todd; Banner-Goodspeed, Valerie M.; Loring, Stephen H.; Talmor, Daniel] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, 330 Brookline Ave, Boston, MA 02215 USA; [Beitler, Jeremy R.] Columbia Univ Coll Phys & Surg, Ctr Acute Resp Failure, 630 W 168th St, New York, NY 10032 USA; [Beitler, Jeremy R.] Columbia Univ Coll Phys & Surg, Div Pulm Allergy & Crit Care Med, 630 W 168th St, New York, NY 10032 USA; [Gong, Michelle N.] Montefiore Med Ctr, Albert Einstein Coll Med, Div Crit Care Med, Bronx, NY 10467 USA; [Cook, Deborah] St Josephs Hosp, Dept Med, Hamilton, ON, Canada; [Cook, Deborah] McMaster Univ, Hamilton, ON, Canada; [Novack, Victor] Soroka Univ Med Ctr, Soroka Clin Res Ctr, Beer Sheva, Israel; [Sarge, Todd; Talmor, Daniel; Loring, Stephen; Banner-Goodspeed, Valerie; Fish, Emily; Jinadasa, Sayuri; Ritz, Ray; Previtera, Joseph] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Gong, Michelle N.; Lee, Lawrence] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA; [Beitler, Jeremy R.] Univ Calif San Diego, San Diego, CA 92103 USA; [Cook, Deborah; Clarke, France; Piraino, Tom] McMaster Univ, St Josephs Healthcare, Hamilton, ON, Canada; [Levitt, Joseph; Vojnik, Rosemary] Stanford Univ, Palo Alto, CA 94304 USA; [Park, Pauline; Brierley, Kristin; Haas, Carl; Weirauch, Andrew] Univ Michigan, Ann Arbor, MI 48109 USA; [Fan, Eddy; Matte, Andrea] Univ Toronto, Toronto Gen Hosp, Toronto, ON, Canada; [Harris, R. Scott; Kone, Mamary] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Heard, Stephen; Longtine, Karen] Univ Massachusetts, Worcester, MA 01605 USA; [Lellouche, Francois; Bouchard, Pierre-Alexandre] Univ Laval, Quebec City, PQ, Canada; [Rubinson, Lewis; McGrain, Jennifer (Titus)] Univ Maryland, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA; [Griesdale, Donald E. G.; Foster, Denise] Vancouver Gen Hosp, Vancouver, BC, Canada; [Oeckler, Richard; Amsbaugh, Amy] Mayo Clin, Rochester, MN USA; [Jimenez, Edgar; Danesh, Valerie] Orlando Hlth Inc, Orlando, FL USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Columbia University; Columbia University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; McGill University; McMaster University; McMaster University; Ben Gurion University; Soroka Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California San Diego; McMaster University; Stanford University; University of Michigan System; University of Michigan; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Harvard University; Massachusetts General Hospital; University of Massachusetts System; University of Massachusetts Worcester; Laval University; University System of Maryland; University of Maryland Baltimore; University of British Columbia; Mayo Clinic	Talmor, D (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, 330 Brookline Ave, Boston, MA 02215 USA.	dtalmor@bidmc.harvard.edu	Danesh, Valerie/AAZ-3014-2021; Lellouche, Francois/AAB-9014-2019; Slutsky, Arthur/M-3325-2019; Piraino, Thomas/AAB-8938-2019	Danesh, Valerie/0000-0002-2078-2578; Banner-Goodspeed, Valerie/0000-0002-7644-2521	US National Heart, Lung, and Blood Institute [UM1-HL108724]	US National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was funded by the US National Heart, Lung, and Blood Institute (grant UM1-HL108724).	Acion L, 2006, STAT MED, V25, P591, DOI 10.1002/sim.2256; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Beitler JR, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1153-9; Beitler JR, 2016, CRIT CARE MED, V44, P91, DOI 10.1097/CCM.0000000000001355; Bilek AM, 2003, J APPL PHYSIOL, V94, P770, DOI 10.1152/japplphysiol.00764.2002; Borges JB, 2014, CRIT CARE MED, V42, pE279, DOI 10.1097/CCM.0000000000000161; Briel M, 2010, JAMA-J AM MED ASSOC, V303, P865, DOI 10.1001/jama.2010.218; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Caironi P, 2010, AM J RESP CRIT CARE, V181, P578, DOI 10.1164/rccm.200905-0787OC; Calfee CS, 2014, LANCET RESP MED, V2, P611, DOI 10.1016/S2213-2600(14)70097-9; Cavalcanti AB, 2017, JAMA-J AM MED ASSOC, V318, P1335, DOI 10.1001/jama.2017.14171; Cornejo RA, 2013, AM J RESP CRIT CARE, V188, P440, DOI 10.1164/rccm.201207-1279OC; Famous KR, 2017, AM J RESP CRIT CARE, V195, P331, DOI 10.1164/rccm.201603-0645OC; Ferguson ND, 2013, NEW ENGL J MED, V368, P795, DOI 10.1056/NEJMoa1215554; Finkelstein DM, 1999, STAT MED, V18, P1341, DOI 10.1002/(SICI)1097-0258(19990615)18:11&lt;1341::AID-SIM129&gt;3.0.CO;2-7; Fish E, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006356; Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052; Gattinoni L, 1998, AM J RESP CRIT CARE, V158, P3, DOI 10.1164/ajrccm.158.1.9708031; Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103; HODGES JL, 1963, ANN MATH STAT, V34, P598, DOI 10.1214/aoms/1177704172; Huang DT, 2017, ANN AM THORAC SOC, V14, P124, DOI 10.1513/AnnalsATS.201608-629OT; Kassis EB, 2016, INTENS CARE MED, V42, P1206, DOI 10.1007/s00134-016-4403-7; Kraemer HC, 2006, STAT METHODS MED RES, V15, P525, DOI 10.1177/0962280206070650; LAIFOOK SJ, 1991, J APPL PHYSIOL, V70, P967, DOI 10.1152/jappl.1991.70.3.967; LIN DY, 1993, BIOMETRIKA, V80, P557, DOI 10.2307/2337177; Loring SH, 2010, J APPL PHYSIOL, V108, P515, DOI 10.1152/japplphysiol.00835.2009; Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637; Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646; Newcombe RG, 2006, STAT MED, V25, P559, DOI 10.1002/sim.2324; Oeckler RA, 2010, AM J PHYSIOL-LUNG C, V299, pL826, DOI 10.1152/ajplung.00217.2010; Pelosi P, 2001, AM J RESP CRIT CARE, V164, P122, DOI 10.1164/ajrccm.164.1.2007010; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Slutsky AS, 2013, NEW ENGL J MED, V369, P2126, DOI 10.1056/NEJMra1208707; Steinberg JM, 2004, AM J RESP CRIT CARE, V169, P57, DOI 10.1164/rccm.200304-544OC; Talmor D, 2006, CRIT CARE MED, V34, P1389, DOI 10.1097/01.CCM.0000215515.49001.A2; Talmor D, 2008, NEW ENGL J MED, V359, P2095, DOI 10.1056/NEJMoa0708638; Terragni P, 2017, INTENS CARE MED, V43, P142, DOI 10.1007/s00134-016-4589-8; Washko GR, 2006, J APPL PHYSIOL, V100, P753, DOI 10.1152/japplphysiol.00697.2005	40	152	161	5	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	2019	321	9					846	857		10.1001/jama.2019.0555	http://dx.doi.org/10.1001/jama.2019.0555			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	HN7EL	30776290	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000460351600015
J	Wang, JF; Soter, NA; Morrison, SA				Wang, Jason F.; Soter, Nicholas A.; Morrison, Simon A.			Whipped Cream-Viennese Ballet and Pop Surrealism Meet Dark Medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Wang, Jason F.] NYU, Sch Med, 550 First Ave, New York, NY 10016 USA; [Soter, Nicholas A.] NYU, Sch Med, Ronald O Perelman Dept Dermatol, New York, NY USA; [Morrison, Simon A.] Princeton Univ, Dept Mus, Princeton, NJ 08544 USA	New York University; New York University; Princeton University	Wang, JF (corresponding author), NYU, Sch Med, 550 First Ave, New York, NY 10016 USA.	jason.wang@nyumc.org		Soter, Nicholas/0000-0003-3518-3209					0	0	0	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	2019	321	7					630	631		10.1001/jama.2018.19502	http://dx.doi.org/10.1001/jama.2018.19502			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL9MZ	30778581				2023-01-03	WOS:000459068300001
J	Gashaye, KT; Tsegaye, AT; Shiferaw, G; Worku, AG; Abebe, SM				Gashaye, Kiros Terefe; Tsegaye, Adino Tesfahun; Shiferaw, Getachew; Worku, Abebaw Gebeyehu; Abebe, Solomon Mekonnen			Client satisfaction with existing labor and delivery care and associated factors among mothers who gave birth in university of Gondar teaching hospital; Northwest Ethiopia: Institution based cross-sectional study	PLOS ONE			English	Article							WOMENS SATISFACTION; CHILDBIRTH; EXPERIENCE; SERVICES; PAIN	Background There are many reasons for mothers not receiving modern obstetric care, being dissatisfied by health care deliveries is one of the major factors. There are limited studies about maternal satisfaction with labor and delivery care services in Ethiopia and particularly in the study area. Therefore, the aim of this study was to better understand client satisfaction on existing labor and delivery care service and associated factors among mothers who gave birth in the University of Gondar Teaching Hospital, Ethiopia. Methods This institution based cross-sectional study was conducted at the University of Gondar Referral Hospital. 593 mothers who gave birth between July and September 2016 were enrolled. Study participants were selected by systematic random sampling. A standardized, interviewer-administered questionnaire was used to collect data. Descriptive and summary statistics were performed. A linear regression model was fitted and variables having a P value of <= 0.05 in the multivariable model were considered statistically significant. Result Overall, 31.3% of mothers were satisfied by the existing labor and delivery care. Living in rural areas (-2.9%; 95% CI: -5.75,-0.12) and the presence of a co-morbidity (-3.2%; 95% CI:-5.70, -0.72) were the factor which have a negative influence on maternal satisfaction. On the other hand, travel time to reach to the hospital (hours) (0.79%; 95% CI: 0.07, 1.52), birth by episiotomy or assisted vaginal delivery (6.3%; 95%CI: 1.56, 11.04), and receiving cost-free maternal health services (6.66%; 95%CI: 3.31, 10.01) were the factors that had positive influence. Conclusion The level of satisfaction of laboring mothers with the labor and delivery care services was poor. Rural residency and chronic medical co-morbidity were negatively associated with level of satisfaction while travel time, mode of delivery, and payment free delivery service had a statistically significant positive influence on satisfaction.	[Gashaye, Kiros Terefe; Shiferaw, Getachew] Univ Gondar, Sch Med, Dept Obstet & Gynecol, Coll Med & Hlth Sci, Gondar, Ethiopia; [Tsegaye, Adino Tesfahun] Univ Gondar, Inst Publ Hlth, Dept Epidemiol & Biostat, Coll Med & Hlth Sci, Gondar, Ethiopia; [Worku, Abebaw Gebeyehu] Univ Gondar, Inst Publ Hlth, Dept Reprod Hlth, Coll Med & Hlth Sci, Gondar, Ethiopia; [Abebe, Solomon Mekonnen] Univ Gondar, Inst Publ Hlth, Dept Nutr, Coll Med & Hlth Sci, Gondar, Ethiopia	University of Gondar; University of Gondar; University of Gondar; University of Gondar	Tsegaye, AT (corresponding author), Univ Gondar, Inst Publ Hlth, Dept Epidemiol & Biostat, Coll Med & Hlth Sci, Gondar, Ethiopia.	atesfahun1@gmail.com		Worku, Abebaw Gebeyehu/0000-0002-1146-3399	University of Gondar	University of Gondar	We would like to thank the University of Gondar referral hospital's administrative bodies for their cooperation and permission to conduct the study. We are grateful to the University of Gondar for financial support as well as the data collectors who participated in this study for their commitment.	Amdemichael R, 2014, GYNECOLOGY OBSTET, V4, P1; Asefa A, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0024-9; Bazant ES, 2009, INT J QUAL HEALTH C, V21, P79, DOI 10.1093/intqhc/mzn058; Behruzi R, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-25; Bitew K, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/460767; Bohren MA, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001847; Bowser D, 2010, EXPLORING EVIDENCE D; Bruggemann Odalea M, 2007, Reprod Health, V4, P5, DOI 10.1186/1742-4755-4-5; Bruggemann OM, 2007, REPROD HLTH, V4; Cengiz E., 2010, J NAVAL SCI ENG, V6, P76; Central Statistical Agency, 2014, ETH MIN DEM HLTH SUR; Changole J, 2010, MALAWI MED J, V22, P5; Cunningham F, 2014, WILLIAMS OBSTET, V24; D'Ambruoso L, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-140; Declercq ER, 2014, J PERINAT EDUC, V23, P9, DOI 10.1891/1058-1243.23.1.9; Dewana Z, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0125-0; DOLIVEIRA AFPL, 2002, LANCET, V359, P1681; Dzomeku MV., 2011, INT J NURS MIDWIFERY, V3, P30, DOI DOI 10.5897/IJNM.9000029; Gil-Wey B, 2011, CAN J ANESTH, V58, P936, DOI 10.1007/s12630-011-9550-2; Goodman P, 2004, J ADV NURS, V46, P212, DOI 10.1111/j.1365-2648.2003.02981.x; Guest ML, 2009, RURAL REMOTE HEALTH, V9; Gungor I, 2007, WESTERN J NURS RES, V29, P213, DOI 10.1177/0193945906292538; Hodnett ED, 2002, AM J OBSTET GYNECOL, V186, pS160, DOI 10.1067/mob.2002.121141; Kigenyi O, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-162; Kumbani LC, 2012, REPROD HEALTH, V9, DOI 10.1186/1742-4755-9-30; Melese T, 2014, PAN AFR MED J, V17, DOI 10.11604/pamj.2014.17.76.3189; Mohammad K., 2014, INT J NURS MIDWIFERY, V6, P32, DOI [10.5897/ijnm2014.0127, DOI 10.5897/IJNM2014.0127]; Nketiah-Amponsah E., 2009, GLOBAL J HLTH SCI, V1, P50, DOI [10.5539/gjhs.v1n2p50, DOI 10.5539/GJHS.V1N2P50]; Pewitt AT, 2008, J PERINAT EDUC, V17, P42, DOI 10.1624/105812408X329593; Pitchforth E, 2010, SOC SCI MED, V71, P1739, DOI 10.1016/j.socscimed.2010.08.001; Redshaw M., 2010, DELIVERED CARE NATL; Roro Meselech Assegid, 2014, BMC Res Notes, V7, P556, DOI 10.1186/1756-0500-7-556; Rosen HE, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0728-4; Rudman A, 2007, WOMENS EVALUATION IN; Rudman A, 2007, WEMENS EVALUATION IN; Silal S.P., 2012, BMC HEALTH SERV RES, V12, P1; Sioma-Markowska U, 2015, NEUROENDOCRINOL LETT, V36, P447; Souza JP, 2014, BJOG-INT J OBSTET GY, V121, P1, DOI 10.1111/1471-0528.12735; Taghavi S., 2015, J ANAL RES CLIN MED, V3, P77; Tayelgn A, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-78; The White Ribbon Alliance for Safe Motherhood, 2013, ADV PROM RESP MAT CA; WHO, 2014, WORLD HLTH STAT; World Health Organization, 2015, STRATEGIES ENDING PR; World Health Organization, 2015, PREV EL DISR AB FAC; World Health Organization, 2005, RESP MAT CAR UN RIGH; Yohannes B., 2013, INT J SCI TECHNOL RE, V2, P74	46	17	17	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2019	14	2							e0210693	10.1371/journal.pone.0210693	http://dx.doi.org/10.1371/journal.pone.0210693			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HK4EL	30726297	gold, Green Published, Green Submitted			2023-01-03	WOS:000457874000024
J	Watson, H; Harrop, D; Walton, E; Young, A; Soltani, H				Watson, Helen; Harrop, Deborah; Walton, Elizabeth; Young, Andy; Soltani, Hora			A systematic review of ethnic minority women's experiences of perinatal mental health conditions and services in Europe	PLOS ONE			English	Review							POSTNATAL DEPRESSION; PSYCHOLOGICAL DISTRESS; LISTENING VISITS; MOTHERS; PREGNANCY; PSYCHOSIS; SUPPORT; PERIOD; CARE; UK	Background Women from ethnic minority groups are at greater risk of developing mental health problems. Poor perinatal mental health impacts on maternal morbidity and mortality and can have a devastating impact on child and family wellbeing. It is important to ensure that services are designed to meet the unique needs of women from diverse backgrounds. Aim The aim of the review was to explore ethnic minority women's experiences of perinatal mental ill health, help-seeking and perinatal mental health services in Europe. Data sources Searches included CINAHL, Maternity and Infant Care, MEDLINE and PsycINFO with no language or date restrictions. Additional literature was identified by searching reference lists of relevant studies. Design This was a mixed method systematic review. Study selection, appraisal and data extraction were conducted by two researchers independently. A convergent approach was adopted for the analysis and the data were synthesised thematically. Results The 15 eligible studies included women from a range of minority ethnic backgrounds and were all undertaken in the United Kingdom (UK). Seven overarching themes were identified; awareness and beliefs about mental health, isolation and seeking support, influence of culture, symptoms and coping strategies, accessing mental health services, experiences of mental health services and what women want. Conclusion Lack of awareness about mental ill health, cultural expectations, ongoing stigma, culturally insensitive and fragmented health services and interactions with culturally incompetent and dismissive health providers all impact on ethnic minority women's ability to receive adequate perinatal mental health support in the UK. Future research should focus on in-depth exploration of the experiences of these women across multiple European settings and interventions to reduce health inequalities among vulnerable mothers and families affected by perinatal mental ill health.	[Watson, Helen; Harrop, Deborah; Young, Andy; Soltani, Hora] Sheffield Hallam Univ, Fac Hlth & Wellbeing, Sheffield, S Yorkshire, England; [Walton, Elizabeth] Univ Sheffield, Acad Unit Primary Med Care, Sheffield, S Yorkshire, England	Sheffield Hallam University; University of Sheffield	Soltani, H (corresponding author), Sheffield Hallam Univ, Fac Hlth & Wellbeing, Sheffield, S Yorkshire, England.	h.soltani@shu.ac.uk		Walton, Elizabeth/0000-0003-0195-7886; Watson, Helen/0000-0002-5479-8527; Soltani, Hora/0000-0001-9611-6777	Sheffield Health and Social Care NHS Foundation Trust [Aa4344482]	Sheffield Health and Social Care NHS Foundation Trust	All authors received funding for this study from Sheffield Health and Social Care NHS Foundation Trust. Grant number Aa4344482. https//shsc uk/. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Almond P, 2011, J ADV NURS, V67, P2350, DOI 10.1111/j.1365-2648.2011.05669.x; Anderson FM, 2017, ARCH WOMEN MENT HLTH, V20, P449, DOI 10.1007/s00737-017-0723-z; Aromataris E, 2014, JOANN BRIGGS I REV M; Bentley P, 2008, CLIN MED, V8, P493, DOI 10.7861/clinmedicine.8-5-493; Bhui Kamaldeep, 2004, Transcult Psychiatry, V41, P307, DOI 10.1177/1363461504045642; Bolton HL, 1998, J PSYCHOSOM OBST GYN, V19, P202, DOI 10.3109/01674829809025698; Cantle F, 2010, ETHNICITY INEQUALITI, DOI [10.5042/eihsc.2010.0345, DOI 10.5042/EIHSC.2010.0345]; Carroll C, 2015, RES SYNTH METHODS, V6, P149, DOI 10.1002/jrsm.1128; Chew-Graham CA, 2009, BMC FAM PRACT, V10, DOI 10.1186/1471-2296-10-7; Clement S, 2015, PSYCHOL MED, V45, P11, DOI 10.1017/S0033291714000129; Cooke Sam, 2012, Community Pract, V85, P34; Cooper C, 2010, J AFFECT DISORDERS, V127, P96, DOI 10.1016/j.jad.2010.04.020; Cuijpers P, 2016, EU COMPASS ACTION ME; Currer C, 1994, INT J SOC PSYCHIAT, V30, P72; de Jonge A, 2001, J ADV NURS, V36, P49, DOI 10.1046/j.1365-2648.2001.01942.x; Dennis CL, 2006, BIRTH-ISS PERINAT C, V33, P323, DOI 10.1111/j.1523-536X.2006.00130.x; DH, 2011, NO HLTH MENT HLTH CR; Dogra N., 2005, ADV PSYCHIAT TREAT, V11, P159, DOI DOI 10.1192/APT.11.3.159; Edge D, 2005, SOC SCI MED, V61, P15, DOI 10.1016/j.socscimed.2004.11.047; Edge D, 2011, BRIT J GEN PRACT, V61, P256, DOI 10.3399/bjgp11X567063; Edwards E., 2005, J MENTAL HLTH, V14, P471, DOI [DOI 10.1080/09638230500271097, 10.1080/09638230500271097]; Gardner PL, 2014, MIDWIFERY, V30, P756, DOI 10.1016/j.midw.2013.08.001; General Medical Council, 2013, GOOD MED PRACTICE; George R.E., 2015, DIVERS EQUAL HLTH CA, V12, DOI [10.21767/2049-5471.100037, DOI 10.21767/2049-5471.100037]; Hall Pauline, 2006, Community Pract, V79, P256; Hanley J, 2006, MIDWIFERY, V22, P147, DOI 10.1016/j.midw.2005.08.004; Hanley Jane, 2007, Community Pract, V80, P34; Heron J, 2012, ARCH WOMEN MENT HLTH, V15, P155, DOI 10.1007/s00737-012-0267-1; HM Government and Department of Health, 2011, NO HLTH MENT HLTH CR; Howard LM, 2014, LANCET, DOI [10.1016/S01406736(14)61276-9, DOI 10.1016/S01406736(14)61276-9]; Howard LM, 2014, LANCET, V384, P1775, DOI 10.1016/S0140-6736(14)61276-9; Independent Mental Health Taskforce, 2016, 5 YEAR FORW VIEW MEN; Jarosinski JM, 2016, NURSING-RES REV, V6, P1, DOI 10.2147/NRR.S92203; Jones I, 2014, LANCET, V384, P1789, DOI 10.1016/S0140-6736(14)61278-2; Karlsen S, 2005, PSYCHOL MED, V35, P1795, DOI 10.1017/S0033291705005830; King L., 2012, BR J MIDWIFERY, V20, P396, DOI DOI 10.12968/BJ0M.2012.20.6.396; Kingston D, 2012, CHILD PSYCHIAT HUM D, V43, P683, DOI 10.1007/s10578-012-0291-4; Knight M, 2020, SAVING LIVES IMPROVI; Latif Z, 2014, BETTER HLTH BRIEFING; Lewin S, 2018, IMPLEMENT SCI, V13, DOI 10.1186/s13012-017-0688-3; Masood Y, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0263-5; McGrath L, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-341; McLeish J., 2005, BRIT J MIDWIFERY, V13, P782, DOI [DOI 10.12968/BJ0M.2005.13.12.20125, 10.12968/BJOM.2005.13.12.20125, DOI 10.12968/BJOM.2005.13.12.20125]; Megnin-Viggars O, 2015, ARCH WOMEN MENT HLTH, V18, P745, DOI 10.1007/s00737-015-0548-6; Memon A, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012337; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; National Institute for Health and Care Excellence (NICE), 2012, METH DEV NICE PUBL H, VThird; NHS England, 2013, REFR EQ DEL SYST NHS; NHS England, 2018, NHS ENGL FUND RES 20; NHS England, 2016, NATL MATERNITY REV B; NHS England, 2013, PUTT PAT 1; NICE, 2014, SICKL CELL DIS MAN A; Noor SZ, 2008, PUBLIC HEALTH NUTR, V11, P486, DOI 10.1017/S1368980007000912; Onozawa K, 2003, ARCH WOMEN MENT HLTH, V6, P551; Parvin A, 2004, FAM PRACT, V21, P254, DOI 10.1093/fampra/cmh307; Patel S, 2013, MIDWIFERY, V29, P682, DOI 10.1016/j.midw.2012.06.012; Pluye P, 2014, ANNU REV PUBL HEALTH, V35, P29, DOI 10.1146/annurev-publhealth-032013-182440; Prady SL, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0805-x; Raymond JE, 2009, MIDWIFERY, V25, P39, DOI 10.1016/j.midw.2007.01.005; Redshaw M, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-1029-9; Robertson E, 2003, PSYCHOL PSYCHOTHER-T, V76, P411, DOI 10.1348/147608303770584755; Sandelowski M, 2007, SOC SCI MED, V64, P236, DOI 10.1016/j.socscimed.2006.08.041; Sandelowski Margarete, 2006, Res Sch, V13, P29; Shakespeare J, 2003, BRIT J GEN PRACT, V53, P614; Shakespeare J, 2006, J REPROD INFANT PSYC, V24, P149, DOI 10.1080/02646830600643866; Slade P, 2010, BRIT J GEN PRACT, V60, DOI 10.3399/bjgp10X532611; Stanley N., 2006, PRIM HEALTH CARE RES, V7, P257, DOI [DOI 10.1191/1463423606PC2950A, 10.1191/1463423606pc295oa, DOI 10.1191/1463423606PC295OA]; Stein A, 2014, LANCET, V384, P1800, DOI 10.1016/S0140-6736(14)61277-0; Templeton L, 2003, ETHNIC HEALTH, V8, P207, DOI 10.1080/1355785032000136425; Thomas J, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-45; Turner KM, 2010, PATIENT EDUC COUNS, V78, P234, DOI 10.1016/j.pec.2009.05.022; Wallace S, 2016, AM J PUBLIC HEALTH, V106, P1294, DOI 10.2105/AJPH.2016.303121; WHO Maternal mental health, 2018, WHO MAT MENT HLTH; Williams CJ, 2016, MIDWIFERY, V35, P39, DOI 10.1016/j.midw.2016.01.015; Williams DR, 2016, HEALTH PSYCHOL, V35, P407, DOI 10.1037/hea0000242; Wittkowski A, 2011, J REPROD INFANT PSYC, V29, P480, DOI 10.1080/02646838.2011.639014	76	43	43	3	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2019	14	1							e0210587	10.1371/journal.pone.0210587	http://dx.doi.org/10.1371/journal.pone.0210587			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HJ3CE	30695019	Green Accepted, Green Published, Green Submitted, gold			2023-01-03	WOS:000457046400011
J	Pike, H				Pike, Harriet			GP workloads are made worse by shortages of common drugs	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		IACOBUCCI G, 2018, BMJ-BRIT MED J, V362, DOI DOI 10.1136/BMJ.K4040; IACOBUCCI G, 2017, BMJ-BRIT MED J, V359, DOI DOI 10.1136/BMJ.J5883; NHS England, SER SHORT PROT	3	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 21	2019	364								l315	10.1136/bmj.l315	http://dx.doi.org/10.1136/bmj.l315			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ6MM	30665920				2023-01-03	WOS:000457304100009
J	Czauderna, C; Palestino-Dominguez, M; Castven, D; Becker, D; Zanon-Rodriguez, L; Hajduk, J; Mahn, FL; Herr, M; Strand, D; Strand, S; Heilmann-Heimbach, S; Gomez-Quiroz, LE; Worns, MA; Galle, PR; Marquardt, JU				Czauderna, Carolin; Palestino-Dominguez, Mayrel; Castven, Darko; Becker, Diana; Zanon-Rodriguez, Luis; Hajduk, Jovana; Mahn, Friederike L.; Herr, Monika; Strand, Dennis; Strand, Susanne; Heilmann-Heimbach, Stefanie; Gomez-Quiroz, Luis E.; Woerns, Marcus A.; Galle, Peter R.; Marquardt, Jens U.			Ginkgo biloba induces different gene expression signatures and oncogenic pathways in malignant and non-malignant cells of the liver	PLOS ONE			English	Article							PHASE-II; EXTRACT; FIBROSIS; 5-FLUOROURACIL; DEREGULATION; PATHOGENESIS; INHIBITION; MECHANISMS; MICE; RAT	Ginkgo biloba (EGb761) is a widely used botanical drug. Several reports indicate that EGb761 confers preventive as well as anti-tumorigenic properties in a variety of tumors, including hepatocellular carcinoma (HCC). We here evaluate functional effects and molecular alterations induced by EGb761 in hepatoma cells and non-malignant hepatocytes. Hepatoma cell lines, primary human HCC cells and immortalized human hepatocytes (IH) were exposed to various concentrations (0-1000 mu g/ml) of EGb761. Apoptosis and proliferation were evaluated after 72h of EGb761 exposure. Response to oxidative stress, tumorigenic properties and molecular changes were further investigated. While anti-oxidant effects were detected in all cell lines, EGb761 promoted anti-proliferative and pro-apoptotic effects mainly in hepatoma cells. Consistently, EGb761 treatment caused a significant reduction in colony and sphere forming ability in hepatoma cells and no mentionable changes in IH. Transcriptomic changes involved oxidative stress response as well as key oncogenic pathways resembling Nrf2- and mTOR signaling pathway. Taken together, EGb761 induces differential effects in non-transformed and cancer cells. While treatment confers protective effects in non-malignant cells, EGb761 significantly impairs tumorigenic properties in cancer cells by affecting key oncogenic pathways. Results provide the rational for clinical testing of EGb761 in preventive and therapeutic strategies in human liver diseases.	[Czauderna, Carolin; Castven, Darko; Becker, Diana; Zanon-Rodriguez, Luis; Hajduk, Jovana; Mahn, Friederike L.; Herr, Monika; Strand, Dennis; Strand, Susanne; Woerns, Marcus A.; Galle, Peter R.; Marquardt, Jens U.] Johannes Gutenberg Univ Mainz, Dept Med 1, Mainz, Germany; [Czauderna, Carolin; Castven, Darko; Becker, Diana; Zanon-Rodriguez, Luis; Hajduk, Jovana; Mahn, Friederike L.; Herr, Monika; Marquardt, Jens U.] Lichtenberg Res Grp Mol Hepatocarcinogenesis, Mainz, Germany; [Palestino-Dominguez, Mayrel; Gomez-Quiroz, Luis E.] Univ Autonoma Metropolitana Iztapalapa, Div Ciencias Biol & Salud, Dept Ciencias Salud, Iztapalapa, Mexico; [Heilmann-Heimbach, Stefanie] Univ Bonn, Life & Brain Ctr, Inst Human Genet, Dept Genom, Bonn, Germany	Johannes Gutenberg University of Mainz; Universidad Autonoma Metropolitana - Mexico; University of Bonn	Marquardt, JU (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med 1, Mainz, Germany.; Marquardt, JU (corresponding author), Lichtenberg Res Grp Mol Hepatocarcinogenesis, Mainz, Germany.	marquarj@uni.mainz.de	Galle, Peter/ABE-2872-2021; Galle, Peter R/T-5292-2018	Galle, Peter/0000-0001-8294-0992; Galle, Peter R/0000-0001-8294-0992; Palestino Dominguez, Mayrel/0000-0002-1442-9719; Gomez-Quiroz, Luis Enrique/0000-0002-5704-5985	Dr. Willmar Schwabe GmBH; Transmed-Fellowship of the University of Mainz; Transmed Fellowship of the University of Mainz	Dr. Willmar Schwabe GmBH; Transmed-Fellowship of the University of Mainz; Transmed Fellowship of the University of Mainz	This project was financially supported by Dr. Willmar Schwabe GmBH. Dr. Wilmar Schwabe GmBH had no influence on the experimental design, results and content of the manuscript. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Dr. C. Czauderns is supported by a personal physician-scientist grant of the Transmed-Fellowship of the University of Mainz.; This project was supported by Dr. Willmar Schwabe GmBH. CC is supported by a Transmed Fellowship of the University of Mainz. We thank the FACS core facility of the Institute of Molecular Biology (IMB, Mainz, Germany) for providing excellent technical support.	Agha AM, 2001, J EXP CLIN CANC RES, V20, P39; Andersen JB, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001338; [Anonymous], 2003, Drugs R D, V4, P188; BASS DA, 1983, J IMMUNOL, V130, P1910; Bilanges B, 2007, ONCOGENE, V26, P5973, DOI 10.1038/sj.onc.1210431; Cai Z, 2016, PHYTOMEDICINE, V23, P1295, DOI 10.1016/j.phymed.2016.07.002; Alfredo SIC, 2018, PHARMACOL RES, V134, P92, DOI 10.1016/j.phrs.2018.06.013; Chao JCJ, 2004, WORLD J GASTROENTERO, V10, P37; Dias MC, 2008, CHEM-BIOL INTERACT, V173, P32, DOI 10.1016/j.cbi.2008.01.012; El Mesallamy Hala O, 2011, Cancer Cell Int, V11, P38, DOI 10.1186/1475-2867-11-38; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735; HAGUENAUER JP, 1986, PRESSE MED, V15, P1569; Hauns B, 2001, PHYTOTHER RES, V15, P34, DOI 10.1002/1099-1573(200102)15:1&lt;34::AID-PTR755&gt;3.0.CO;2-2; Hauns B, 1999, ARZNEIMITTEL-FORSCH, V49, P1030; Hectors SJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02706-z; Jeon YJ, 2015, CANCER SCI, V106, P413, DOI 10.1111/cas.12608; Jung IH, 2012, EXP MOL MED, V44, P311, DOI 10.3858/emm.2012.44.5.035; KIM M, 2016, IEICE ELECTRON EXPR, V13, DOI DOI 10.5620/EHT.E2016010; Kirstein MM, 2014, DIGEST DIS, V32, P545, DOI 10.1159/000360499; KLEIJNEN J, 1992, LANCET, V340, P1136, DOI 10.1016/0140-6736(92)93158-J; Koltermann A, 2009, J CELL MOL MED, V13, P2122, DOI 10.1111/j.1582-4934.2008.00561.x; Liu K, 2015, MED SCI MONIT BASIC, V21, P15, DOI 10.12659/MSMBR.893327; Liu SQ, 2015, ONCOL REP, V33, P2871, DOI 10.3892/or.2015.3923; Liu SQ, 2006, AM J CHINESE MED, V34, P99, DOI 10.1142/S0192415X06003679; Liu XP, 2007, LIFE SCI, V80, P1586, DOI 10.1016/j.lfs.2007.01.034; Lu G, 2006, BRAIN RES, V1090, P23, DOI 10.1016/j.brainres.2006.02.138; Lu Q, 2015, PHYTOMEDICINE, V22, P1071, DOI 10.1016/j.phymed.2015.08.010; Marquardt JU, 2012, BBA-MOL BASIS DIS, V1822, P942, DOI 10.1016/j.bbadis.2012.02.012; Marquardt JU, 2011, HEPATOLOGY, V54, P1031, DOI 10.1002/hep.24454; Matter MS, 2016, HEPATOLOGY, V63, P1888, DOI 10.1002/hep.28487; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Park YJ, 2016, FOOD CHEM TOXICOL, V87, P157, DOI 10.1016/j.fct.2015.12.007; Pelletier J, 2015, CANCER RES, V75, P250, DOI 10.1158/0008-5472.CAN-14-2789; PFEIFER AMA, 1993, P NATL ACAD SCI USA, V90, P5123, DOI 10.1073/pnas.90.11.5123; Qian Y, 2016, CLIN TRANSL ONCOL, V18, P521, DOI 10.1007/s12094-015-1399-3; Raggi C, 2014, HEPATOLOGY, V59, P2251, DOI 10.1002/hep.27026; Rider CV, 2014, TOXICOL PATHOL, V42, P830, DOI 10.1177/0192623313501235; Ruggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098; Sun BC, 2013, FRONT MED-PRC, V7, P242, DOI 10.1007/s11684-013-0256-4; Tsai JR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091331; Wang H, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-2014-7; Wang Wei-Wei, 2011, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, V25, P325; Wang YF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124812; Yao P, 2007, AM J CHINESE MED, V35, P643, DOI 10.1142/S0192415X07005132; Yao P, 2007, FOOD CHEM TOXICOL, V45, P1333, DOI 10.1016/j.fct.2007.01.016; Yuan GJ, 2007, PHYTOTHER RES, V21, P234, DOI 10.1002/ptr.2054	49	10	10	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 21	2018	13	12							e0209067	10.1371/journal.pone.0209067	http://dx.doi.org/10.1371/journal.pone.0209067			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF3QK	30576355	gold, Green Published, Green Submitted			2023-01-03	WOS:000454149400027
J	Smolle, C; Sendlhofer, G; Sandner-Kiesling, A; Herbert, MK; Jantscher, L; Pichler, B; Kamolz, LP; Brunner, G				Smolle, Christian; Sendlhofer, Gerald; Sandner-Kiesling, Andreas; Herbert, Michael K.; Jantscher, Lydia; Pichler, Bernd; Kamolz, Lars-Peter; Brunner, Gernot			Implementation and maintenance of a pain management quality assurance program at intensive care units: 360 degree feedback of physicians, nurses and patients	PLOS ONE			English	Article							POSTOPERATIVE PAIN; IMPROVEMENT; ALGORITHM	Background Pain management quality assurance programs (PMQP) have been successfully implemented in numerous hospitals across Europe. We aimed to evaluate the medium-term sustainability of a PMQP implemented at intensive care units (ICUs). Methods Two surveys, the first in 2012, immediately after introduction of the PMQP, and the second in 2015, were carried out amongst patients, physicians and nurses. Demographic parameters of all participants were assessed. Patients were asked after their pain levels during ICU stay. Staff members answered a questionnaire regarding familiarity with standards and processes of PMQP and self-perception of their knowledge as well as contentment with interdisciplinary communication. Results In total (2012/2015), 267 (125/142) patients, 113 (65/48) physicians and 510 (264/246) members of the nursing staff participated. Minimum and maximum pain levels of patients did not differ between both surveys. Patients' tolerance of pain 24 hours before the survey was better (p = 0.023), and vomiting occurred less often (p = 0.037) in 2015. Physicians' and nurses' contentment with the own knowledge about pharmacological pain treatment had increased from 2012 to 2015 (p = 0.002 and 0.004). Satisfaction with communication between nurses and physicians was better in 2015 (p<0.001 and p = 0.002). Familiarity with PMQP standards and processes remained stable in both collectives. Conclusion The implementation of our PMQP achieved a high standard of care, guarantying a high patient and staff member satisfaction. Continuous education, ongoing training, regular updates and implementation of feedback-loops ensure continuity, in some parameters even an increase in knowledge and competencies. This is mirrored in high patient and staff member satisfaction.	[Smolle, Christian; Sendlhofer, Gerald; Kamolz, Lars-Peter; Brunner, Gernot] Med Univ Graz, Dept Surg, Div Plast Aesthet & Reconstruct Surg, Res Unit Safety Hlth, Graz, Austria; [Smolle, Christian; Kamolz, Lars-Peter] Med Univ Graz, Dept Surg, Div Plast Aesthet & Reconstruct Surg, Graz, Austria; [Sendlhofer, Gerald; Jantscher, Lydia; Pichler, Bernd] Univ Hosp Graz, Execut Dept Qual & Risk Management, Graz, Austria; [Sandner-Kiesling, Andreas; Herbert, Michael K.] Med Univ Graz, Dept Anaesthesiol & Intens Care Med, Graz, Austria	Medical University of Graz; Medical University of Graz; Medical University of Graz	Sendlhofer, G (corresponding author), Med Univ Graz, Dept Surg, Div Plast Aesthet & Reconstruct Surg, Res Unit Safety Hlth, Graz, Austria.; Sendlhofer, G (corresponding author), Univ Hosp Graz, Execut Dept Qual & Risk Management, Graz, Austria.	gerald.sendlhofer@medunigraz.at		Sendlhofer, Gerald/0000-0002-6538-3116				Aguirre-Raya KA, 2016, BMC MED EDUC, V16, DOI 10.1186/s12909-016-0681-6; Ament Stephanie M C, 2015, BMJ Open, V5, pe008073, DOI 10.1136/bmjopen-2015-008073; Andersson V, 2017, SCAND J PAIN, V15, P22, DOI 10.1016/j.sjpain.2016.11.006; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Bohmer AB, 2012, SCHMERZ, V26, P425, DOI 10.1007/s00482-012-1205-x; Bohmer AB, 2012, SCHMERZ BERL GER, V26, P432; Cao XZ, 2017, J ANESTH, V31, P617, DOI 10.1007/s00540-017-2363-x; Cornet C, 2007, ANN FR ANESTH, V26, P292, DOI 10.1016/j.annfar.2006.12.008; Desbiens NA, 1996, CRIT CARE MED, V24, P1953, DOI 10.1097/00003246-199612000-00005; Diby M, 2008, J CRIT CARE, V23, P359, DOI 10.1016/j.jcrc.2007.11.005; Frykman M, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-218; Gerbershagen HJ, 2011, BRIT J ANAESTH, V107, P619, DOI 10.1093/bja/aer195; Lehmkuhl D, 2011, SCHMERZ, V25, P508, DOI 10.1007/s00482-011-1054-z; Macario A, 1999, ANESTH ANALG, V89, P652, DOI 10.1097/00000539-199909000-00022; Medrzycka-Dabrowska WA, 2016, ARCH MED SCI, V12, P808, DOI 10.5114/aoms.2015.54768; Olsen BF, 2015, HEART LUNG J CRIT CA, V42, P190; Olsen BF, 2016, J CRIT CARE, V36, P207, DOI 10.1016/j.jcrc.2016.07.011; Olsen BF, 2015, HEART LUNG, V44, P521, DOI 10.1016/j.hrtlng.2015.09.001; Sigakis MJG, 2015, CRIT CARE MED, V43, P2468, DOI 10.1097/CCM.0000000000001256; van Gulik L, 2017, PAIN RES MANAG, V2017, DOI 10.1155/2017/7187232; van Gulik L, 2010, EUR J ANAESTH, V27, P900, DOI 10.1097/EJA.0b013e32833d91c3; World Health Organization (WHO), WHOS CANC PAIN LADD; Wurm WE, 2015, FORTSCHR NEUROL PSYC, V83, P149, DOI 10.1055/s-0034-1399111	23	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2018	13	12							e0208527	10.1371/journal.pone.0208527	http://dx.doi.org/10.1371/journal.pone.0208527			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE9NT	30566446	Green Submitted, Green Published, gold			2023-01-03	WOS:000453779300046
J	Mourtada, R; Bottomley, C; Houben, F; Bashour, H; Campbell, OMR				Mourtada, Rima; Bottomley, Christian; Houben, Fiona; Bashour, Hyam; Campbell, Oona M. R.			A mixed methods analysis of factors affecting antenatal care content: A Syrian case study	PLOS ONE			English	Article							HEALTH-CARE; INCOME; ACCESS; PERCEPTIONS; QUALITY; LESSONS	Background Maternity care services provide critical interventions aimed at improving maternal and newborn health. In this study, we examined determinants of antenatal care (ANC) content in Syria, together with changes over time. Methods We analysed two national surveys conducted by the Central Bureau of Statistics in Damascus (PAPFAM 2001 and MICS 2006). Findings of this initial analysis led to a qualitative study on adequacy of antenatal care content in two Syrian governorates, Aleppo and Latakia in 2010, which in turn informed further quantitative analysis. The perspectives and practices of doctors, women, midwives and health officials were explored using in-depth interviews. A framework approach was used to analyse the data. Results The quantitative analysis demonstrated that women's education level, the type of health facility they attended and whether they had experienced health complications were important determinants of adequacy of ANC content received. The qualitative study revealed that additional factors related to supply side and demand side factors (e.g. organization of health services, doctors' selective prescription of ANC tests and women's selective uptake of those tests), influenced the quality of ANC and explained some regional differences between Aleppo and Latakia. Conclusions The percentage of women who received adequate ANC content was probably higher in Latakia than in Aleppo because women in Latakia were more educated, and because services were more available, accessible, and acceptable to them. Conclusions The percentage of women who received adequate ANC content was probably higher in Latakia than in Aleppo because women in Latakia were more educated, and because services were more available, accessible, and acceptable to them.	[Mourtada, Rima] Amer Univ Beirut, Dept Epidemiol & Populat Hlth, Fac Hlth Sci, Beirut, Lebanon; [Mourtada, Rima; Bottomley, Christian; Campbell, Oona M. R.] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London, England; [Houben, Fiona] Canterbury Christ Church Univ, Fac Hlth & Wellbeing, Canterbury, Kent, England; [Bashour, Hyam] Univ Damascus, Damascus, Syria	American University of Beirut; University of London; London School of Hygiene & Tropical Medicine; Canterbury Christ Church University	Mourtada, R (corresponding author), Amer Univ Beirut, Dept Epidemiol & Populat Hlth, Fac Hlth Sci, Beirut, Lebanon.; Mourtada, R (corresponding author), London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London, England.	rima.mourtada@yahoo.co.uk		Houben, Fiona/0000-0002-5630-3516; Mourtada, Rima/0000-0002-4009-3411; Bottomley, Christian/0000-0002-5241-8412	Wellcome Trust [074986/Z/04/Z]; MRC [MR/R010161/1] Funding Source: UKRI	Wellcome Trust(Wellcome TrustEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was made possible by funding from the Wellcome Trust (grant number 074986/Z/04/Z) (https://wellcome.ac.uk/home). The funder played no role in the collection, analysis or publication of data.	Akhan Suleyman Engin, 2003, Archives of Gynecology and Obstetrics, V268, P9; Al-Qutob R, 2008, HEALTH CARE WOMEN IN, V29, P539, DOI 10.1080/07399330801949657; [Anonymous], 2015, BBC; Balabanova D, 2006, ACCESS HLTH CARE TAK; Balabanova D, 2013, LANCET, V381, P2118, DOI 10.1016/S0140-6736(12)62000-5; Bashour H., 2008, Eastern Mediterranean Health Journal, V14, P595; Bashour H, 2005, REPROD HEALTH MATTER, V13, P147, DOI 10.1016/S0968-8080(05)25164-9; Benova L, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000779; Bhutta ZA, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-S1-S7; Carroli G, 2001, PAEDIATR PERINAT EP, V15, P1; DeJong J, 2017, BMJ GLOB HLTH, V2, P3, DOI [10.1136/bmjgh-2017-000302, DOI 10.1136/BMJGH-2017-000302]; DESAI S, 1994, POPUL DEV REV, V20, P115, DOI 10.2307/2137632; Finlayson K, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001373; Fisher I., 1997, PURCHASING POWER MON; Gabrysch S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-34; Ghebreyesus TA, 2017, LANCET GLOB HEALTH, V5, pE839, DOI 10.1016/S2214-109X(17)30295-4; Good CM., 1987, ETHNOMEDICAL SYSTEMS; Graham WJ, 1996, HEALTH POLICY PLANN, V11, P16, DOI 10.1093/heapol/11.1.16; Greene J. C., 1989, EDUC EVAL POLICY AN, V11, P255, DOI [DOI 10.3102/01623737011003255, 10.3102/01623737011003255]; Jacobs B, 2012, HEALTH POLICY PLANN, V27, P288, DOI 10.1093/heapol/czr038; Kherallah Mazen, 2012, Avicenna J Med, V2, P51; KROEGER A, 1983, SOC SCI MED, V17, P147, DOI 10.1016/0277-9536(83)90248-4; McIntyre D, 2009, HEALTH ECON POLICY L, V4, P179, DOI 10.1017/S1744133109004836; Montenegro H, 2011, J INTEGR CARE, V19, P5, DOI 10.1108/14769011111176707; Mounier-Jack S, 2017, HEALTH POLICY PLANN, V32, P6, DOI 10.1093/heapol/czx039; Nwaeze I L, 2013, Ann Ib Postgrad Med, V11, P22; Parrott FR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027917; Peters DH, 2008, ANN NY ACAD SCI, V1136, P161, DOI 10.1196/annals.1425.011; Powell-Jackson T, 2015, TROP MED INT HEALTH, V20, P230, DOI 10.1111/tmi.12414; Ritchie J., 1994, ANAL QUALITATIVE DAT, P173, DOI [DOI 10.4324/9780203413081_CHAPTER_9, 10.4324/9780203413081_chapter_9]; Rothman JK, 2008, MODERN EPIDEMIOLOGY, V3rd; Sachs JD, 2012, LANCET, V379, P2206, DOI 10.1016/S0140-6736(12)60685-0; Syrian Central Bureau of Statistics (SCBS), 2011, FAM HLTH SURV SYR AR; Syrian Central Bureau of Statistics (SCBS), 2011, STAT COLL SYR YEAR 2; Syrian Central Bureau of Statistics (SCBS), 1995, PAN AR PROJ CHILD HL; Teddlie Charles, 2006, RES SCH, V13, P12, DOI DOI 10.1177/2345678906293042; Turan JM, 2006, STUD FAMILY PLANN, V37, P49, DOI 10.1111/j.1728-4465.2006.00083.x; UN, 2022, WORLD POP PROSP; Villar J, 2004, SEMIN NEPHROL, V24, P607, DOI 10.1016/S0270-9295(04)00132-9; Villar J, 1997, ACTA OBSTET GYN SCAN, V76, P1, DOI 10.3109/00016349709047778; WHO, 2022, WHO RECOMMENDATIONS; World Health Organization, 2006, HLTH SYST PROF; World Health Organization (WHO), 2012, TRENDS MAT MORT 1990	43	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2019	14	3							e0214375	10.1371/journal.pone.0214375	http://dx.doi.org/10.1371/journal.pone.0214375			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HQ1KV	30908532	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000462157600058
J	Beynel, L; Davis, SW; Crowell, CA; Hilbig, SA; Lim, W; Nguyen, D; Palmer, H; Brito, A; Peterchev, AV; Luber, B; Lisanby, SH; Cabeza, R; Appelbaum, LG				Beynel, L.; Davis, S. W.; Crowell, C. A.; Hilbig, S. A.; Lim, W.; Nguyen, D.; Palmer, H.; Brito, A.; Peterchev, A. V.; Luber, B.; Lisanby, S. H.; Cabeza, R.; Appelbaum, L. G.			Online repetitive transcranial magnetic stimulation during working memory in younger and older adults: A randomized within-subject comparison	PLOS ONE			English	Article							POSTERIOR PARIETAL CORTEX; INTRACORTICAL INHIBITION; COGNITIVE PERFORMANCE; TASK-PERFORMANCE; STATE-DEPENDENCY; TMS; RTMS; MAINTENANCE; MANIPULATION; ENHANCEMENT	Working memory is the ability to perform mental operations on information that is stored in a flexible, limited capacity buffer. The ability to manipulate information in working memory is central to many aspects of human cognition, but also declines with healthy aging. Given the profound importance of such working memory manipulation abilities, there is a concerted effort towards developing approaches to improve them. The current study tested the capacity to enhance working memory manipulation with online repetitive transcranial magnetic stimulation in healthy young and older adults. Online high frequency (5Hz) repetitive transcranial magnetic stimulation was applied over the left dorsolateral prefrontal cortex to test the hypothesis that active repetitive transcranial magnetic stimulation would lead to significant improvements in memory recall accuracy compared to sham stimulation, and that these effects would be most pronounced in working memory manipulation conditions with the highest cognitive demand in both young and older adults. Repetitive transcranial magnetic stimulation was applied while participants were performing a delayed response alphabetization task with three individually-titrated levels of difficulty. The left dorsolateral prefrontal cortex was identified by combining electric field modeling to individualized functional magnetic resonance imaging activation maps and was targeted during the experiment using stereotactic neuronavigation with real-time robotic guidance, allowing optimal coil placement during the stimulation. As no accuracy differences were found between young and older adults, the results from both groups were collapsed. Subsequent analyses revealed that active stimulation significantly increased accuracy relative to sham stimulation, but only for the hardest condition. These results point towards further investigation of repetitive transcranial magnetic stimulation for memory enhancement focusing on high difficulty conditions as those most likely to exhibit benefits.	[Beynel, L.; Crowell, C. A.; Hilbig, S. A.; Lim, W.; Nguyen, D.; Palmer, H.; Brito, A.; Peterchev, A. V.; Appelbaum, L. G.] Duke Univ, Sch Med, Dept Psychiat & Behav Sci, Durham, NC 27708 USA; [Davis, S. W.] Duke Univ, Sch Med, Dept Neurol, Durham, NC USA; [Davis, S. W.; Crowell, C. A.; Cabeza, R.] Duke Univ, Ctr Cognit Neurosci, Durham, NC USA; [Peterchev, A. V.] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA; [Peterchev, A. V.] Duke Univ, Dept Elect & Comp Engn, Durham, NC USA; [Peterchev, A. V.] Duke Univ, Sch Med, Dept Neurosurg, Durham, NC USA; [Luber, B.; Lisanby, S. H.] NIMH, Bethesda, MD 20892 USA; [Cabeza, R.] Duke Univ, Dept Psychol & Neurosci, Durham, NC USA	Duke University; Duke University; Duke University; Duke University; Duke University; Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Duke University	Beynel, L (corresponding author), Duke Univ, Sch Med, Dept Psychiat & Behav Sci, Durham, NC 27708 USA.	lysianne.beynel@duke.edu	Lisanby, Sarah Hollingsworth/ABE-9003-2020; Peterchev, Angel V/I-1477-2019; Davis, Simon W/AAA-2660-2021; Beynel, Lysianne/ABF-2552-2020; Lisanby, Sarah Hollingsworth/T-3918-2019	Lisanby, Sarah Hollingsworth/0000-0003-2037-6470; Peterchev, Angel V/0000-0002-4385-065X; Davis, Simon W/0000-0002-5943-0756; Lisanby, Sarah Hollingsworth/0000-0003-2037-6470; Appelbaum, Lawrence/0000-0002-3184-6725; Beynel, Lysianne/0000-0001-8670-7178	National Institute of Aging [U01 AG050618]; Intramural Research Program of the National Institute of Mental Health; NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG050618] Funding Source: NIH RePORTER	National Institute of Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural Research Program of the National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was funded by grant U01 AG050618 from the National Institute of Aging (https://www.nia.nih.gov/) and in part by the Intramural Research Program of the National Institute of Mental Health (https://www.nimh.nih.gov/index.shtml). Authors who received the funding: SWD, SHL, BL, LGA and RC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abler B, 2005, BRAIN TOPOGR, V17, P193, DOI 10.1007/s10548-005-6028-y; AMASSIAN VE, 1989, ELECTROEN CLIN NEURO, V74, P458, DOI 10.1016/0168-5597(89)90036-1; Awiszus F, 2003, SUPPL CLIN NEUROPHYS, V56, P13; Baddeley A, 1998, CR ACAD SCI III-VIE, V321, P167, DOI 10.1016/S0764-4469(97)89817-4; Baddeley A, 2000, TRENDS COGN SCI, V4, P417, DOI 10.1016/S1364-6613(00)01538-2; Barr MS, 2013, BIOL PSYCHIAT, V73, P510, DOI 10.1016/j.biopsych.2012.08.020; Beynel L, 2014, BIOL PSYCHOL, V101, P9, DOI 10.1016/j.biopsycho.2014.05.011; Bungert A, 2016, CEREB CORTEX, V27, P5083, DOI [DOI 10.1093/CERCOR/BHW292, DOI 10.1093/cercor/bhw292]; Cabeza R, 2002, NEUROIMAGE, V17, P1394, DOI 10.1006/nimg.2002.1280; Cappell KA, 2010, CORTEX, V46, P462, DOI 10.1016/j.cortex.2009.11.009; Cattaneo Z, 2008, EUR J NEUROSCI, V28, P1924, DOI 10.1111/j.1460-9568.2008.06466.x; Chung SW, 2018, BRAIN STIMUL, V11, P566, DOI 10.1016/j.brs.2018.01.002; Edin F, 2009, P NATL ACAD SCI USA, V106, P13; Garcia-Perez MA, 1998, VISION RES, V38, P1861, DOI 10.1016/S0042-6989(97)00340-4; Glahn DC, 2002, NEUROIMAGE, V17, P201, DOI 10.1006/nimg.2002.1161; Goh JO, 2009, RESTOR NEUROL NEUROS, V27, P391, DOI 10.3233/RNN-2009-0493; Hamidi M, 2008, BRAIN RES, V1230, P202, DOI 10.1016/j.brainres.2008.07.008; Jonides J, 2006, NEUROSCIENCE, V139, P181, DOI 10.1016/j.neuroscience.2005.06.042; Jonides J, 1998, P NATL ACAD SCI USA, V95, P8410, DOI 10.1073/pnas.95.14.8410; Keel JC, 2001, CLIN NEUROPHYSIOL, V112, P720, DOI 10.1016/S1388-2457(00)00518-6; Kessels RPC, 2000, NEUROSCI LETT, V287, P68, DOI 10.1016/S0304-3940(00)01146-0; Kim SH, 2012, NEUROSCI RES, V74, P256, DOI 10.1016/j.neures.2012.08.008; Kirova AM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/748212; Klimesch W, 2003, EUR J NEUROSCI, V17, P1129, DOI 10.1046/j.1460-9568.2003.02517.x; Kossev AR, 2002, NEUROSCI LETT, V333, P83, DOI 10.1016/S0304-3940(02)00986-2; Li S, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00170; Luber B, 2008, CEREB CORTEX, V18, P2077, DOI 10.1093/cercor/bhm231; Luber B, 2007, BRAIN RES, V1128, P120, DOI 10.1016/j.brainres.2006.10.011; Luber B, 2014, NEUROIMAGE, V85, P961, DOI 10.1016/j.neuroimage.2013.06.007; Luber B, 2013, SLEEP, V36, P857, DOI 10.5665/sleep.2712; Manoach DS, 1997, NEUROREPORT, V8, P545, DOI 10.1097/00001756-199701200-00033; Martis B, 2003, CLIN NEUROPHYSIOL, V114, P1125, DOI 10.1016/S1388-2457(03)00046-4; Narayana S, 2014, NEUROIMAGE, V85, P971, DOI 10.1016/j.neuroimage.2013.07.024; PASCUALLEONE A, 1994, BRAIN, V117, P847, DOI 10.1093/brain/117.4.847; Peterchev AV, 2012, BRAIN STIMUL, V5, P435, DOI 10.1016/j.brs.2011.10.001; Plume A., 2014, SCI ENG ETHICS, V38, P16, DOI DOI 10.1016/J.TICS.2013.10.010; Ragert P, 2003, NEUROSCI LETT, V348, P105, DOI 10.1016/S0304-3940(03)00745-6; Sack AT, 2009, J COGNITIVE NEUROSCI, V21, P207, DOI 10.1162/jocn.2009.21126; Sheehan D.V., 2002, MINI INT NEUROPSYCHI; Silvanto J, 2007, EUR J NEUROSCI, V25, P1874, DOI 10.1111/j.1460-9568.2007.05440.x; Silvanto J, 2008, TRENDS COGN SCI, V12, P447, DOI 10.1016/j.tics.2008.09.004; Sole-Padulles C, 2006, CEREB CORTEX, V16, P1487, DOI 10.1093/cercor/bhj083; Thut G, 2011, CURR BIOL, V21, P1176, DOI 10.1016/j.cub.2011.05.049; Veltman DJ, 2003, NEUROIMAGE, V18, P247, DOI 10.1016/S1053-8119(02)00049-6; Viggiano MP, 2008, NEUROPSYCHOLOGIA, V46, P2725, DOI 10.1016/j.neuropsychologia.2008.05.004; Windhoff M, 2013, HUM BRAIN MAPP, V34, P923, DOI 10.1002/hbm.21479; Yamanaka K, 2010, CEREB CORTEX, V20, P1037, DOI 10.1093/cercor/bhp163; Yu ZY, 2006, BRAIN RES, V1099, P73, DOI 10.1016/j.brainres.2006.04.118	48	26	28	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2019	14	3							e0213707	10.1371/journal.pone.0213707	http://dx.doi.org/10.1371/journal.pone.0213707			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP9GF	30901345	Green Published, gold, Green Submitted			2023-01-03	WOS:000462000400017
J	Perrella, SL; Nancarrow, K; Trevenen, M; Murray, K; Geddes, DT; Simmer, KN				Perrella, Sharon Lisa; Nancarrow, Kathryn; Trevenen, Michelle; Murray, Kevin; Geddes, Donna Tracy; Simmer, Karen Norrie			Effect of vacuum-release teat versus standard teat use on feeding milestones and breastfeeding outcomes in very preterm infants: A randomized controlled trial	PLOS ONE			English	Article							BIRTH-WEIGHT INFANTS; INTENSIVE-CARE-UNIT; MILK	Background Breast milk is important to infant health, yet shorter breastfeeding duration is reported for preterm infants. Both breast and bottle feeds are given in the neonatal unit, with full oral feeding often the last milestone to be achieved prior to discharge home. Unlike standard bottle teats, a vacuum release teat requires the application of negative intra-oral pressure to release milk, and so may facilitate breastfeeding in preterm infants. The objective of this study was to determine the effect of vacuum release teat use on timing of achievement of the first full oral feed and on first completion of 24 h full oral feeds. Feeding method at discharge home, 2 weeks, 6 weeks and 12 weeks corrected gestational age were also examined. Methods A randomized controlled trial was completed with mothers of preterm infants born 24-33 weeks gestation in the neonatal unit of a tertiary women's hospital. Infants were randomized to one of two parallel groups using a vacuum release teat or standard teat for oral feeds when the mother was not available to breastfeed. Test weights were completed for all oral feeds. It was not possible to blind participants, care givers and outcome assessors to group assignment due to the nature of the study. Results The groups did not differ with regard to timing of achievement of first full oral feed or 24 h of full oral feeds. Significantly more infants in the vacuum release teat group were exclusively fed breast milk at discharge from hospital and breastfed at 3 months corrected gestational age. Conclusions Use of a vacuum release teat when the mother is not available to breastfeed may promote preterm breastfeeding skills, resulting in higher rates of exclusivity and longer breastfeeding duration.	[Perrella, Sharon Lisa; Geddes, Donna Tracy] Univ Western Australia, Fac Sci, Sch Mol Sci, Crawley, WA, Australia; [Nancarrow, Kathryn; Simmer, Karen Norrie] King Edward Mem Hosp, Neonatol Clin Care Unit, Subiaco, WA, Australia; [Trevenen, Michelle] Univ Western Australia, Sch Math & Stat, Fac Engn & Math Sci, Crawley, WA, Australia; [Murray, Kevin] Univ Western Australia, Sch Populat & Global Hlth, Fac Hlth & Med Sci, Crawley, WA, Australia; [Simmer, Karen Norrie] Univ Western Australia, Sch Paediat & Child Hlth, Fac Hlth & Med Sci, Ctr Neonatal Res & Educ, Crawley, WA, Australia	University of Western Australia; King Edward Memorial Hospital; University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia	Perrella, SL (corresponding author), Univ Western Australia, Fac Sci, Sch Mol Sci, Crawley, WA, Australia.	sharon.perrella@uwa.edu	; Geddes, Donna/H-9254-2014; Murray, Kevin/H-5503-2014	Simmer, Karen/0000-0003-4777-9069; Geddes, Donna/0000-0002-0431-7078; Trevenen, Michelle/0000-0002-0614-8319; Perrella, Sharon/0000-0002-7727-7767; Murray, Kevin/0000-0002-8856-6046	Medela AG (Switzerland); Channel 7 Telethon Trust	Medela AG (Switzerland); Channel 7 Telethon Trust	The salaries of SP and DG are paid by the University of Western Australia from an unrestricted research grant from Medela AG (Switzerland, https://www.medela.com/company), and the salary of KN was paid from an unrestricted research grant from Channel 7 Telethon Trust (https://www.telethon7.com). Medela AG and Channel 7 Telethon Trust had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amaizu N, 2008, ACTA PAEDIATR, V97, P61, DOI 10.1111/j.1651-2227.2007.00548.x; Australian Bureau of Statistics, 2018, SOC IND AR SEIFA IND; Belfort MB, 2016, J PEDIATR-US, V177, P133, DOI 10.1016/j.jpeds.2016.06.045; Bertoncelli N, 2012, INT J PEDIAT, V2012, DOI 10.1155/2012/896257; Bingham PM, 2009, J CHILD NEUROL, V24, P743, DOI 10.1177/0883073808329530; Casavant SG, 2015, ADV NEONAT CARE, V15, P421, DOI 10.1097/ANC.0000000000000234; Collins CT, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005252.pub4; Ericson J, 2018, MATERN CHILD NUTR, V14, DOI 10.1111/mcn.12618; Franca ECL, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-154; Freitas BAC, 2016, REV PAUL PEDIATR, V34, P189, DOI [10.1016/j.rpped.2015.10.00526614258, DOI 10.1016/J.RPPED.2015.10.00526614258, 10.1016/j, DOI 10.1016/J]; Geddes D, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030376; Geddes DT, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1574-3; Ikonen R, 2015, ADV NEONAT CARE, V15, P394, DOI 10.1097/ANC.0000000000000232; Jadcherla SR, 2010, J PERINATOL, V30, P201, DOI 10.1038/jp.2009.149; Lipchock SV, 2011, CLIN PERINATOL, V38, P627, DOI 10.1016/j.clp.2011.08.008; Maastrup R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108208; Maastrup R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089077; Mobbs EJ, 2016, ACTA PAEDIATR, V105, P24, DOI 10.1111/apa.13034; Niela-Vilen H, 2015, MATERN CHILD NUTR, V11, P712, DOI 10.1111/mcn.12108; Perrella SL, 2012, BREASTFEED MED, V7, P255, DOI 10.1089/bfm.2011.0118; Pickler RH, 2015, NURS RES PRACT, V2015, DOI 10.1155/2015/716828; Pinchevski-Kadir S, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111202; R Core Team, 2021, R LANG ENV STAT COMP; Simmer K, 2016, J PERINATOL, V36, P210, DOI 10.1038/jp.2015.184; Underwood MA, 2013, PEDIATR CLIN N AM, V60, P189, DOI 10.1016/j.pcl.2012.09.008; Vohr BR, 2007, PEDIATRICS, V120, pe953, DOI 10.1542/peds.2006-3227; Vohr BR, 2006, PEDIATRICS, V118, pE115, DOI 10.1542/peds.2005-2382	27	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2019	14	3							e0214091	10.1371/journal.pone.0214091	http://dx.doi.org/10.1371/journal.pone.0214091			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP9GF	30901356	Green Published, gold, Green Submitted			2023-01-03	WOS:000462000400036
J	Daliri, S; Hugtenburg, JG; ter Riet, G; van den Bemt, BJF; Buurman, BM; op Reimer, WJMS; Buul-Gast, MC; Karapinar-Carkit, F				Daliri, Sara; Hugtenburg, Jacqueline G.; ter Riet, Gerben; van den Bemt, Bart J. F.; Buurman, Bianca M.; op Reimer, Wilma J. M. Scholte; van Buul-Gast, Marie-Christine; Karapinar-Carkit, Fatma			The effect of a pharmacy-led transitional care program on medication-related problems post-discharge: A before-After prospective study	PLOS ONE			English	Article							DRUG-RELATED PROBLEMS; HOSPITAL READMISSIONS; COMMUNITY PHARMACISTS; PATIENT SAFETY; TEACH-BACK; INTERVENTION; DISCHARGE; DISCREPANCIES; RECONCILIATION; INFORMATION	Background Medication-related problems are common after hospitalization, for example when changes in patients' medication regimens are accompanied by insufficient patient education, poor information transfer between healthcare providers, and inadequate follow-up post-discharge. We investigated the effect of a pharmacy-led transitional care program on the occurrence of medication-related problems four weeks post-discharge. Methods A prospective multi-center before-after study was conducted in six departments in total of two hospitals and 50 community pharmacies in the Netherlands. We tested a pharmacy-led program incorporating (i) usual care (medication reconciliation at hospital admission and discharge) combined with, (ii) teach-back at hospital discharge, (iii) improved transfer of medication information to primary healthcare providers and (iv) post-discharge home visit by the patient's own community pharmacist, compared with usual care alone. The difference in medication-related problems four weeks post-discharge, measured by means of a validated telephone-interview protocol, was the primary outcome. Multiple logistic regression analysis was used, adjusting for potential confounders after multiple imputation to deal with missing data. Results We included 234 (January-April 2016) and 222 (July-November 2016) patients in the usual care and intervention group, respectively. Complete data on the primary outcome was available for 400 patients. The proportion of patients with any medication-related problem was 65.9% (211/400) in the usual care group compared to 52.4% (189/400) in the intervention group (p = 0.01). After multiple imputation, the proportion of patients with any medicationrelated problem remained lower in the intervention group (unadjusted odds ratio 0.57; 95% CI 0.38-0.86, adjusted odds ratio 0.50; 95% CI 0.31-0.79). Conclusions A pharmacy-led transitional care program reduced medication-related problems after discharge. Implementation research is needed to determine how best to embed these interventions in existing processes.	[Daliri, Sara; Buurman, Bianca M.; op Reimer, Wilma J. M. Scholte] Amsterdam Univ Appl Sci, Fac Hlth, Amsterdam, Netherlands; [Daliri, Sara; Karapinar-Carkit, Fatma] OLVG Hosp, Dept Clin Pharm, Amsterdam, Netherlands; [Daliri, Sara; Buurman, Bianca M.] Acad Med Ctr, Dept Internal Med, Sect Geriatr Med, Amsterdam, Netherlands; [Hugtenburg, Jacqueline G.] Vrije Univ Amsterdam, Med Ctr, Dept Clin Pharmacol & Pharm, Amsterdam, Netherlands; [Hugtenburg, Jacqueline G.] Community Pharm Westwijk, Amsterdam, Netherlands; [ter Riet, Gerben] Acad Med Ctr, Dept Gen Practice, Amsterdam, Netherlands; [van den Bemt, Bart J. F.] Sint Maartensklin, Dept Pharm, Nijmegen, Netherlands; [van den Bemt, Bart J. F.] Radboud Univ Nijmegen, Med Ctr, Dept Pharm, Nijmegen, Netherlands; [van den Bemt, Bart J. F.] Univ Med Ctr Maastricht, Dept Pharm, Maastricht, Netherlands; [op Reimer, Wilma J. M. Scholte] Acad Med Ctr, Dept Cardiol, Amsterdam, Netherlands; [van Buul-Gast, Marie-Christine] BovenIJ Hosp, Dept Hosp Pharm, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Sint Maartens Clinic; Radboud University Nijmegen; Maastricht University; Maastricht University Medical Centre (MUMC); University of Amsterdam; Academic Medical Center Amsterdam	Daliri, S (corresponding author), Amsterdam Univ Appl Sci, Fac Hlth, Amsterdam, Netherlands.; Daliri, S; Karapinar-Carkit, F (corresponding author), OLVG Hosp, Dept Clin Pharm, Amsterdam, Netherlands.; Daliri, S (corresponding author), Acad Med Ctr, Dept Internal Med, Sect Geriatr Med, Amsterdam, Netherlands.	s.daliri@hva.nl; f.karapinar@olvg.nl	Van den Bemt, Bart/Q-2740-2015; Riet, Gerben ter/A-6943-2011	Van den Bemt, Bart/0000-0002-8560-9514; Riet, Gerben ter/0000-0002-2231-7637; Daliri, Sara/0000-0003-3999-3444	Netherlands Organisation for Health Research and Development (ZonMw) [836044008]	Netherlands Organisation for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development)	F. Karapinar-Carkit received a research grant of 84 thousand euros from the Netherlands Organisation for Health Research and Development (ZonMw), grant no: 836044008: https://www.zonmw.nl/nl/.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad A, 2014, PATIENT PREFER ADHER, V8, P155, DOI 10.2147/PPA.S48357; Ahmad A, 2012, ARCH INTERN MED, V172, P1346, DOI 10.1001/archinternmed.2012.2816; Brown C, 2008, QUAL SAF HEALTH CARE, V17, P170, DOI 10.1136/qshc.2007.023655; Budnitz DS, 2006, JAMA-J AM MED ASSOC, V296, P1858, DOI 10.1001/jama.296.15.1858; Buurma H, 2008, J CLIN PHARM THER, V33, P17, DOI 10.1111/j.1365-2710.2008.00878.x; Cawthon C, 2012, J HEALTH COMMUN, V17, P312, DOI 10.1080/10810730.2012.712619; Coleman EA, 2005, ARCH INTERN MED, V165, P1842, DOI 10.1001/archinte.165.16.1842; Cua YM, 2008, ANN ACAD MED SINGAP, V37, P136; Eibergen L, 2018, RES SOC ADMIN PHARM, V14, P146, DOI 10.1016/j.sapharm.2017.01.006; El Morabet N, 2018, J AM GERIATR SOC, V66, P602, DOI 10.1111/jgs.15244; Ellitt GR, 2010, PHARM WORLD SCI, V32, P622, DOI 10.1007/s11096-010-9406-9; Ensing HT, 2017, J CLIN PHARM THER, V42, P170, DOI 10.1111/jcpt.12488; Farley TM, 2014, INT J CLIN PHARM-NET, V36, P430, DOI 10.1007/s11096-014-9917-x; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Garcia-Caballos M, 2010, AGE AGEING, V39, P430, DOI 10.1093/ageing/afq045; Grimmsmann T, 2007, EUR J CLIN PHARMACOL, V63, P783, DOI 10.1007/s00228-007-0325-1; Gyllensten H, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002574; Hawes EM, 2014, J PRIM CARE COMMUNIT, V5, P14, DOI 10.1177/2150131913502489; Hugtenburg JG, 2009, PHARM WORLD SCI, V31, P630, DOI 10.1007/s11096-009-9314-z; Joint Commission on the Accreditation of Healthcare Organizations, 2006, MED REC HDB; Karapinar-Carkit F, 2014, INT J CLIN PHARM-NET, V36, P807, DOI 10.1007/s11096-014-9965-2; Karapinar-Carkit F, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-39; Karapinar-Carkit F, 2009, ANN PHARMACOTHER, V43, P1001, DOI 10.1345/aph.1L597; Kattel S, 2020, J PATIENT SAF, V16, pE25, DOI 10.1097/PTS.0000000000000248; Kornburger C, 2013, J PEDIATR NURS, V28, P282, DOI 10.1016/j.pedn.2012.10.007; Koster ES, 2015, PHARMACOEPIDEM DR S, V24, P716, DOI 10.1002/pds.3803; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Kripalani S, 2012, ANN INTERN MED, V157, P1, DOI 10.7326/0003-4819-157-1-201207030-00003; Lehnbom EC, 2014, ANN PHARMACOTHER, V48, P1298, DOI 10.1177/1060028014543485; Luder HR, 2015, J AM PHARM ASSOC, V55, P246, DOI 10.1331/JAPhA.2015.14060; Mansah Martha, 2009, JBI Libr Syst Rev, V7, P1036; Naunton Mark, 2003, Journal of Pharmacy Practice and Research, V33, P176; Novak Christopher J, 2012, Consult Pharm, V27, P174, DOI 10.4140/TCP.n.2012.174; Paulino EI, 2004, PHARM WORLD SCI, V26, P353; Peter D, 2015, J NURS ADMIN, V45, P35, DOI 10.1097/NNA.0000000000000155; Ravn-Nielsen LV, 2018, JAMA INTERN MED, V178, P375, DOI 10.1001/jamainternmed.2017.8274; Roughead Elizabeth E, 2009, Aust New Zealand Health Policy, V6, P18, DOI 10.1186/1743-8462-6-18; Schillinger D, 2003, ARCH INTERN MED, V163, P83, DOI 10.1001/archinte.163.1.83; Schnipper JL, 2006, ARCH INTERN MED, V166, P565, DOI 10.1001/archinte.166.5.565; Schoonover H, 2014, J PATIENT SAF, V10, P186, DOI 10.1097/PTS.0000000000000067; Setter SM, 2009, AM J HEALTH-SYST PH, V66, P2027, DOI 10.2146/ajhp080582; Stuurman-Bieze AGG, 2005, PHARM WORLD SCI, V27, P376, DOI 10.1007/s11096-005-7112-9; Uitvlugt EB, 2015, INT J CLIN PHARM-NET, V37, P1206, DOI 10.1007/s11096-015-0187-z; Urbina O, 2015, THER CLIN RISK MANAG, V11, P9, DOI 10.2147/TCRM.S71749; van den Bemt PMLA, 2013, J AM GERIATR SOC, V61, P1262, DOI 10.1111/jgs.12380; Viktil KK, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001461; Weingart SN, 2005, ARCH INTERN MED, V165, P234, DOI 10.1001/archinte.165.2.234; Westberg SM, 2017, J PHARM TECHNOL, V33, P96, DOI 10.1177/8755122517698975; Willeboordse F, 2016, INT J CLIN PHARM-NET, V38, P380, DOI 10.1007/s11096-016-0258-9; Zhu JY, 2011, MED CARE, V49, P948, DOI 10.1097/MLR.0b013e31822047a8; Ziaeian B, 2012, J GEN INTERN MED, V27, P1513, DOI 10.1007/s11606-012-2168-4	51	36	37	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2019	14	3							e0213593	10.1371/journal.pone.0213593	http://dx.doi.org/10.1371/journal.pone.0213593			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO6JJ	30861042	gold, Green Published, Green Submitted			2023-01-03	WOS:000461035600045
J	Sado, J; Viana, KA; Correa-Faria, P; Costa, LR; Costa, PS				Sado-Filho, Joji; Viana, Karolline Alves; Correa-Faria, Patricia; Costa, Luciane Rezende; Costa, Paulo Sucasas			Randomized clinical trial on the efficacy of intranasal or oral ketamine-midazolam combinations compared to oral midazolam for outpatient pediatric sedation	PLOS ONE			English	Article							PROCEDURAL SEDATION; ADVERSE EVENTS; CHILDREN; ANALGESIA; PHARMACOKINETICS; MEDICATION	Purpose The optimal sedative regime that provides the greatest comfort and the lowest risk for procedural sedation in young children remains to be determined. The aim of this randomized, blinded, controlled, parallel-design trial was to evaluate the efficacy of intranasal ketamine and midazolam as the main component of the behavioral guidance approach for preschoolers during dental treatment. Materials and methods Children under seven years of age, with caries and non-cooperative behavior, were randomized into three groups: (KMIN) intranasal ketamine and midazolam; (KMO) oral ketamine and midazolam; or (MO) oral midazolam. The dental sedation appointments were video-taped, and the videos were analyzed using the Ohio State University Behavioral Rating Scale (OSUBRS) to determine the success of the sedation in each group. Intra-and postoperative adverse events were recorded. Data analysis involved descriptive statistics and non-parametric tests (P < 0.05, IBM SPSS). Results Participants were 84 children (28 per group; 43 boys), with a mean age of 3.1 years (SD 1.2). Children's baseline and the dental sedation session characteristics were balanced among groups. The success of the treatment as assessed by the dichotomous variable 'quiet behavior for at least 60% of the session length' was: KMIN 50.0% (n = 14; OR 2.10, 95% CI 0.71 to 6.30), KMO 46.4% (n = 13; OR 1.80, 95% CI 0.62 to 5.40), MO 32.1% (n = 9) (P = 0.360). Adverse events were minor, occurred in 37 of 84 children (44.0%), and did not differ among groups (P = 0.462). Conclusion All three regimens provided moderate dental sedation with minor adverse events, with marked variability in the behavior of children during dental treatment. The potential benefit of the ketamine-midazolam combination should be further investigated in studies with larger samples.	[Sado-Filho, Joji; Costa, Luciane Rezende] Univ Fed Goias, Fac Med, Hlth Sci Grad Program, Goiania, Go, Brazil; [Viana, Karolline Alves; Correa-Faria, Patricia; Costa, Luciane Rezende] Univ Fed Goias, Fac Odontol, Dent Grad Program, Goiania, Go, Brazil; [Costa, Luciane Rezende] Univ Fed Goias, Fac Odontol, Dept Oral Hlth, Goiania, Go, Brazil; [Costa, Paulo Sucasas] Univ Fed Goias, Fac Med, Dept Pediat, Goiania, Go, Brazil	Universidade Federal de Goias; Universidade Federal de Goias; Universidade Federal de Goias; Universidade Federal de Goias	Costa, LR (corresponding author), Univ Fed Goias, Fac Med, Hlth Sci Grad Program, Goiania, Go, Brazil.; Costa, LR (corresponding author), Univ Fed Goias, Fac Odontol, Dent Grad Program, Goiania, Go, Brazil.; Costa, LR (corresponding author), Univ Fed Goias, Fac Odontol, Dept Oral Hlth, Goiania, Go, Brazil.	lsucasas@ufg.br	Costa, Paulo S/L-5460-2016; Costa, Luciane Rezende/H-1732-2012	Costa, Paulo S/0000-0001-9370-9139; Costa, Luciane Rezende/0000-0001-7637-0049	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brasil [449950/2014-0]	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brasil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brasil, www.cnpq.br, Grant number: 449950/2014-0. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2017, Pediatr Dent, V39, P308; Bahetwar SK, 2011, J CLIN PEDIATR DENT, V35, P415, DOI 10.17796/jcpd.35.4.l43h3354705u2574; Buonsenso D, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-67; Cho HK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101259; Corcuera-Flores JR, 2016, MED ORAL PATOL ORAL, V21, pE579, DOI 10.4317/medoral.20981; Costa LR, 2012, J PEDIATR-US, V160, P807, DOI 10.1016/j.jpeds.2011.10.025; Cote Charles J, 2016, Pediatr Dent, V38, P13; Gomes HSD, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0838-4; Fallahinejad Ghajari Masoud, 2015, J Dent Res Dent Clin Dent Prospects, V9, P61, DOI 10.15171/joddd.2015.013; FELD LH, 1990, ANESTHESIOLOGY, V73, P831, DOI 10.1097/00000542-199011000-00006; Frankl SN., 1962, J DENT CHILD, V29, P150; Gomes HS, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1919-2; Goodwin M, 2015, BMC ORAL HEALTH, V15, DOI 10.1186/1472-6831-15-3; Green SM, 2016, BRIT J ANAESTH, V116, P449, DOI 10.1093/bja/aew048; Hartling L, 2016, ACAD EMERG MED, V23, P519, DOI 10.1111/acem.12938; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Johansson J, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-38; Kim HJ, 2017, J CLIN ANESTH, V38, P33, DOI 10.1016/j.jclinane.2017.01.014; Krauss B, 2006, LANCET, V367, P766, DOI 10.1016/S0140-6736(06)68230-5; Lochary Margaret E., 1993, Pediatric Dentistry, V15, P348; Lourenco-Matharu L, 2016, EUR ARCH PAEDIATR DE, V17, P157, DOI 10.1007/s40368-015-0205-9; Lourenco-Matharu L, 2010, BRIT DENT J, V209, DOI 10.1038/sj.bdj.2010.886; Lourenco-Matharu L, 2012, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858CD003877PUB4; MALLAMPATI SR, 1985, CAN ANAESTH SOC J, V32, P429, DOI 10.1007/BF03011357; Manoj M, 2017, J ANESTH, V31, P351, DOI 10.1007/s00540-017-2330-6; Mason KP, 2014, BRIT J ANAESTH, V113, P48, DOI 10.1093/bja/aeu387; Mason KP, 2012, BRIT J ANAESTH, V108, P13, DOI 10.1093/bja/aer407; Mataftsi A, 2017, BRIT J OPHTHALMOL, V101, P1423, DOI 10.1136/bjophthalmol-2016-309449; Miranda-Remijo D, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0743-2; Mitchual S, 2017, PEDIATR DENT, V39, P203; Moreira TA, 2013, INT J PAEDIATR DENT, V23, P207, DOI 10.1111/j.1365-263X.2012.01246.x; Moura LD, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/5248271; Musani IE, 2015, EUR ARCH PAEDIATR DE, V16, P417, DOI 10.1007/s40368-015-0187-7; Nelson Travis M, 2017, Anesth Prog, V64, P17, DOI 10.2344/anpr-63-03-01; Norderyd J, 2018, INT J PAEDIATR DENT, V28, P71, DOI 10.1111/ipd.12305; Poonai N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173253; Reed MD, 2001, J CLIN PHARMACOL, V41, P1359, DOI 10.1177/00912700122012832; Reynolds SL, 2017, ACAD EMERG MED, V24, P1430, DOI 10.1111/acem.13313; Roback MG, 2016, CURR OPIN ANESTHESIO, V29, pS21, DOI 10.1097/ACO.0000000000000316; Sahoo Sangeeta, 2013, Anesth Essays Res, V7, P221, DOI 10.4103/0259-1162.118967; Schrier L, 2017, BRIT J CLIN PHARMACO, V83, P721, DOI 10.1111/bcp.13163; van de Bunt JA, 2017, PEDIATR ANESTH, V27, P1091, DOI 10.1111/pan.13226; Williams MR, 2018, ANESTH ANALG, V126, P956, DOI 10.1213/ANE.0000000000002456; WILTON NCT, 1988, ANESTHESIOLOGY, V69, P972, DOI 10.1097/00000542-198812000-00032; Wolfe TR, 2010, PEDIATRICS, V126, P532, DOI 10.1542/peds.2010-0616	45	13	13	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2019	14	3							e0213074	10.1371/journal.pone.0213074	http://dx.doi.org/10.1371/journal.pone.0213074			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO6HL	30856181	gold, Green Published, Green Submitted			2023-01-03	WOS:000461030300021
J	Mohamed-Salem, R; Fernandez, CR; Nieto-Pelegrin, E; Conde-Valentin, B; Rumbero, A; Martinez-Quiles, N				Mohamed-Salem, Reda; Rodriguez Fernandez, Carmina; Nieto-Pelegrin, Elvira; Conde-Valentin, Beatriz; Rumbero, Angel; Martinez-Quiles, Narcisa			Aqueous extract of Hibiscus sabdariffa inhibits pedestal induction by enteropathogenic E. coli and promotes bacterial filamentation in vitro	PLOS ONE			English	Article							TIR RECEPTOR MOLECULE; ESCHERICHIA-COLI; ANTIMICROBIAL ACTIVITY; VIRULENCE FACTORS; L.; ATTACHMENT; RESISTANCE; CHILDREN; CELLS; FOOD	Diarrheic diseases account for the annual death of approximately 1.9 million children under the age of 5 years, and it is a major cause of work absenteeism in developed countries. As diarrheagenic bacteria, enteropathogenic Escherichia coli (EPEC) attach to cells in the small intestine, causing local disappearance of microvilli and inducing the formation of actin-rich pedestals that disrupt the intestinal barrier and help EPEC adhere to and infect intestinal cells. Antibiotics and other bioactive compounds can often be found by analyzing traditional medicines. Here a crude aqueous extract of Hibiscus sabdariffa, which typically grows in subtropical and tropical areas and is a popular medicinal tisane in many countries, was analyzed for antibacterial activity against EPEC. In standard microdilution assays, the extract showed a minimum inhibitory concentration of 6.5 mg/ml against EPEC growth. Time-kill kinetics assays demonstrated significant 24 h bactericidal activity at 25 mg/ml. The extract is able to impede pedestal induction. Not only did the extract inhibit preformed pedestals but it prevented pedestal induction as well. Remarkably, it also promoted the formation of EPEC filaments, as observed with other antibiotics. Our results in vitro support the potential of Hibiscus sabdariffa as an antimicrobial agent against EPEC.	[Mohamed-Salem, Reda; Rodriguez Fernandez, Carmina; Nieto-Pelegrin, Elvira; Conde-Valentin, Beatriz; Martinez-Quiles, Narcisa] Univ Complutense Madrid, Pharm Sch, Dept Microbiol & Parasitol, Madrid, Spain; [Conde-Valentin, Beatriz] Univ Complutense Madrid, Pharmaceut & Food Technol Dept, Madrid, Spain; [Rumbero, Angel] Univ Autonoma Madrid, Organ Chem Dept, Madrid, Spain; [Martinez-Quiles, Narcisa] Univ Complutense Madrid, Sch Med, Dept Immunol Ophthalmol & ENT, Madrid, Spain; [Martinez-Quiles, Narcisa] Gregorio Maranon Hlth Res Inst IiSGM, Madrid, Spain	Complutense University of Madrid; Complutense University of Madrid; Autonomous University of Madrid; Complutense University of Madrid	Martinez-Quiles, N (corresponding author), Univ Complutense Madrid, Pharm Sch, Dept Microbiol & Parasitol, Madrid, Spain.; Martinez-Quiles, N (corresponding author), Univ Complutense Madrid, Sch Med, Dept Immunol Ophthalmol & ENT, Madrid, Spain.; Martinez-Quiles, N (corresponding author), Gregorio Maranon Hlth Res Inst IiSGM, Madrid, Spain.	narcisa-quiles@med.ucm.es	Fernandez, Carmina Rodriguez/F-6797-2016	Fernandez, Carmina Rodriguez/0000-0002-4396-4016; Martinez Quiles, Narcisa/0000-0002-0366-6591; Nieto Pelegrin, Elvira/0000-0003-2755-2641	Instituto de Salud Carlos III FIS [PS09/0080]; Ministerio de Economia, y Empresa [SAF2017-82967-R]; FPI-MINECO [BES-2008-009174]; UCM; MEC-FPU [AP2010-0818]	Instituto de Salud Carlos III FIS(Instituto de Salud Carlos III); Ministerio de Economia, y Empresa; FPI-MINECO; UCM; MEC-FPU(Spanish Government)	This work was funded by grants to NM-Q Instituto de Salud Carlos III FIS PS09/0080 confounded by European Social Funds (FSE), Banco Santander-Universidad Complutense intramural grant for 970629 validated group, crowdfunding project precipita.es (FECYT) and by a Ministerio de Economia, y Empresa (SAF2017-82967-R) to NM-Q. RM-S was supported by a FPI-MINECO fellowship (BES-2008-009174), EN-P and BC-V were supported by a UCM predoctoral fellowship and a MEC-FPU Fellowship (AP2010-0818), respectively.	Ahmad I., 2006, MODERN PHYTOMEDICINE; Akim A, 2011, AFR J PHARM PHARMACO, V5, P957; Akinjogunla O J, 2009, AFR J BACTERIOL RES, V1, P034; Arenas-Hernandez Margarita M P, 2012, Curr Gastroenterol Rep, V14, P386, DOI 10.1007/s11894-012-0277-1; Bakhshi B, 2014, JUNDISHAPUR J MICROB, V7, DOI 10.5812/jjm.9924; Battle SE, 2014, INFECT IMMUN, V82, P3713, DOI 10.1128/IAI.01523-13; Bauab TM, 2012, INTECHOPEN; Bisi-Johnson M.A., 2012, ADV MED SCI-POLAND, V1, P1; Bonev B, 2008, J ANTIMICROB CHEMOTH, V61, P1295, DOI 10.1093/jac/dkn090; Buijs J, 2007, J ANTIMICROB CHEMOTH, V59, P926, DOI 10.1093/jac/dkm073; Cantarelli VV, 2006, CELL MICROBIOL, V8, P769, DOI 10.1111/j.1462-5822.2005.00664.x; Chao CY, 2009, FOODBORNE PATHOG DIS, V6, P201, DOI 10.1089/fpd.2008.0187; Da-Costa-Rocha I, 2014, FOOD CHEM, V165, P424, DOI 10.1016/j.foodchem.2014.05.002; Dean P, 2004, MOL MICROBIOL, V54, P665, DOI 10.1111/j.1365-2958.2004.04308.x; Diniz-Santos Daniel R., 2006, Braz J Infect Dis, V10, P217, DOI 10.1590/S1413-86702006000300011; ECHEVERRIA P, 1991, J INFECT DIS, V164, P550, DOI 10.1093/infdis/164.3.550; Ekwall V. S, 1990, TOXICITY TESTS MAMMA, P75; El-Rami F. E., 2012, ADV STUD BIOL, V4, P385; Fullerton M, 2011, J MED FOOD, V14, P950, DOI 10.1089/jmf.2010.0200; Gomez-Aldapa CA, 2018, J FOOD PROTECT, V81, P209, DOI 10.4315/0362-028X.JFP-17-053; Gonelimali FD, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01639; Gradelski E, 2001, INT J ANTIMICROB AG, V18, P43, DOI 10.1016/S0924-8579(01)00343-0; Gruenheid S, 2001, NAT CELL BIOL, V3, P856, DOI 10.1038/ncb0901-856; Harmidy K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027267; Hu J, 2015, CLIN MICROBIOL INFEC, V21, P729, DOI 10.1016/j.cmi.2015.01.015; Issam Alshami, 2014, Asian Pacific Journal of Tropical Disease, V4, P317, DOI 10.1016/S2222-1808(14)60581-8; Jabeur I, 2017, FOOD RES INT, V100, P717, DOI 10.1016/j.foodres.2017.07.073; Kaper JB, 2004, NAT REV MICROBIOL, V2, P123, DOI 10.1038/nrmicro818; Kenny B, 1999, MOL MICROBIOL, V31, P1229, DOI 10.1046/j.1365-2958.1999.01265.x; Kenny B, 2001, INFECT IMMUN, V69, P1444, DOI 10.1128/IAI.69.3.1444-1453.2001; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; KNUTTON S, 1989, INFECT IMMUN, V57, P1290, DOI 10.1128/IAI.57.4.1290-1298.1989; Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2; Makobe CK, 2012, J INFECT DEV COUNTR, V6, P598, DOI 10.3855/jidc.2082; Nataro JP, 1998, CLIN MICROBIOL REV, V11, P403; Nataro JP, 2006, EMERG INFECT DIS, V12, P696, DOI 10.3201/eid1204.060125; Nieto-Pelegrin E, 2014, CELL ADHES MIGR, V8, P404, DOI 10.4161/19336918.2014.969993; Nieto-Pelegrin E, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004022; Nieto-Pelegrin E, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-11; Rangel-Vargas E, 2018, J FOOD PROTECT, V81, P743, DOI 10.4315/0362-028X.JFP-17-258; Riaz G, 2018, BIOMED PHARMACOTHER, V102, P575, DOI 10.1016/j.biopha.2018.03.023; Roy S, 2013, INT J PHARM SCI RES, V4, P3004, DOI 10.13040/IJPSR.0975-8232.4(8).3004-12; Savoia D, 2012, FUTURE MICROBIOL, V7, P979, DOI [10.2217/FMB.12.68, 10.2217/fmb.12.68]; Sayago-Ayerdi SG, 2007, J AGR FOOD CHEM, V55, P7886, DOI 10.1021/jf070485b; Stradal TEB, 2017, CURR TOP MICROBIOL, V399, P175, DOI 10.1007/82_2016_35; Sudomova M., 2016, CES SLOV FARM, V65, P10; Tadesse DA, 2012, EMERG INFECT DIS, V18, P741, DOI 10.3201/eid1805.111153; TAYLOR J, 1970, P ROY SOC MED, V63, P1297, DOI 10.1177/003591577006301233; Torres A.G., 2016, ESCHERICHIA COLI AM	49	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2019	14	3							e0213580	10.1371/journal.pone.0213580	http://dx.doi.org/10.1371/journal.pone.0213580			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO1BT	30849110	Green Published, Green Submitted, gold			2023-01-03	WOS:000460640900045
J	Leong, C; Chateau, D; Dahl, M; Falk, J; Katz, A; Bugden, S; Raymond, C				Leong, Christine; Chateau, Dan; Dahl, Matthew; Falk, Jamie; Katz, Alan; Bugden, Shawn; Raymond, Colette			Prescription medication use during pregnancies that resulted in births and abortions (2001-2013): A retrospective population-based study in a Canadian population	PLOS ONE			English	Article							DRUG-USE; RISK	We aimed to describe medication use in pregnancies that resulted in births and abortions, as well as use after a pregnancy-related visit to characterize the receipt of medication after knowledge of pregnancy. Abortions included both spontaneous and induced abortions. Rates of medication use among women with a pregnancy outcome (2001-2013) were described using the Manitoba Population Research Data Repository at the Manitoba Centre for Health Policy. Use was determined as >= 1 prescription filled during pregnancies that resulted in births (livebirth/stillbirth) and abortions. Rates were calculated at any time during pregnancy and after a pregnancy-related visit. Rates were additionally characterized by risk in pregnancy using Briggs classification (2017). Of 174,848 birth pregnancies, overall 64.9% filled >= 1 prescription during pregnancy (a significant increase from 62.3% to 68.8% from 2001-2013, p<0.0001); 55.4% filled >= 1 prescription after a pregnancy-related visit. Of 71,967 abortions, 44.7% filled >= 1 prescription (a significant increase from 42.6% to 46.8% from 2001-2013, p<0.0001). Only 3.7% of birth pregnancies had at least one prescription for a contraindicated medication (according to Briggs classification), whereas 10.8% of abortions filled a prescription for a contraindicated medication. The most common drugs used in pregnancy were amoxicillin, doxylamine, codeine combinations, nitrofurantoin, cephalexin, salbutamol and ranitidine. Fewer women filled prescriptions for undesirable medications according to Briggs classification during pregnancy after a pregnancy-related visit.	[Leong, Christine; Falk, Jamie; Bugden, Shawn] Univ Manitoba, Rady Fac Hlth Sci, Coll Pharm, Winnipeg, MB, Canada; [Chateau, Dan; Dahl, Matthew; Katz, Alan; Raymond, Colette] Univ Manitoba, Dept Community Hlth Sci, Manitoba Ctr Hlth Policy, Winnipeg, MB, Canada	University of Manitoba; University of Manitoba	Leong, C (corresponding author), Univ Manitoba, Rady Fac Hlth Sci, Coll Pharm, Winnipeg, MB, Canada.	christine.leong@umanitoba.ca		Falk, Jamie/0000-0003-4029-320X; Leong, Christine/0000-0003-0033-6877; Katz, Alan/0000-0001-8280-7024	Canadian Network for Observational Drug Effects Studies (CNODES), a collaborating centre of the Drug Safety and Effectiveness Network - Canadian Institutes of Health Research; Manitoba Centre for Health Policy [2013-035, 2013/2014-35]	Canadian Network for Observational Drug Effects Studies (CNODES), a collaborating centre of the Drug Safety and Effectiveness Network - Canadian Institutes of Health Research; Manitoba Centre for Health Policy	Funding for this study was provided by the Canadian Network for Observational Drug Effects Studies (CNODES), a collaborating centre of the Drug Safety and Effectiveness Network funded by the Canadian Institutes of Health Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors acknowledge the Manitoba Centre for Health Policy for use of data contained in the Population Health Research Data Repository under project #2013-035 (HIPC#2013/2014-35). The results and conclusions are those of the authors and no official endorsement by the Manitoba Centre for Health Policy, Manitoba Health, Seniors and Active Living, or other data providers is intended or should be inferred. Data used in this study are from the Population Health Research Data Repository housed at the Manitoba Centre for Health Policy, University of Manitoba and were derived from data provided by Manitoba Health, Seniors and Active Living.	Andrade SE, 2004, AM J OBSTET GYNECOL, V191, P398, DOI 10.1016/j.ajog.2004.04.025; Berard A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093870; Bjorn Anne-Mette Bay, 2011, Clin Epidemiol, V3, P149, DOI 10.2147/CLEP.S17747; Canadian Institute for Health Information, IND AB; Colvin L, 2009, PHARMACOEPIDEM DR S, V18, P211, DOI 10.1002/pds.1705; Daw JR, 2012, CLIN THER, V34, P239, DOI 10.1016/j.clinthera.2011.11.025; Daw JR, 2011, PHARMACOEPIDEM DR S, V20, P895, DOI 10.1002/pds.2184; Engeland A, 2008, BRIT J CLIN PHARMACO, V65, P653, DOI 10.1111/j.1365-2125.2008.03102.x; Fantasia Heidi Collins, 2015, Nurs Womens Health, V19, P266, DOI 10.1111/1751-486X.12209; Food and Drug Administration Department of Health and Human Services, 2014, FED REGISTER, V233, P72063; Gagne JJ, 2008, EUR J CLIN PHARMACOL, V64, P1125, DOI 10.1007/s00228-008-0546-y; Gerald GB, 2017, DRUGS PREGNANCY LACT, V11th; Glover DD, 2003, AM J OBSTET GYNECOL, V188, P1039, DOI 10.1067/mob.2003.223; Haas DM, 2018, OBSTET GYNECOL, V131, P789, DOI 10.1097/AOG.0000000000002579; Heaman M, NATAL SERVICES OUTCO, V20; Lacroix I, 2000, LANCET, V356, P1735, DOI 10.1016/S0140-6736(00)03209-8; Law R, 2010, CAN FAM PHYSICIAN, V56, P239; Lee E, 2006, PHARMACOEPIDEM DR S, V15, P537, DOI 10.1002/pds.1241; Lin KJ, 2012, EPIDEMIOLOGY, V23, P699, DOI 10.1097/EDE.0b013e318258cb05; Margulis AV, 2015, PHARMACOEPIDEM DR S, V24, P335, DOI 10.1002/pds.3743; Mitchell AA, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.02.029; Palmsten K, 2015, OBSTET GYNECOL, V126, P465, DOI 10.1097/AOG.0000000000000982; ROOS LL, 1982, MED CARE, V20, P266, DOI 10.1097/00005650-198203000-00003; Roos LL, 1999, J CLIN EPIDEMIOL, V52, P39, DOI 10.1016/S0895-4356(98)00126-7; Smolina K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128312; Stephansson Olof, 2011, Clin Epidemiol, V3, P43, DOI 10.2147/CLEP.S16305; Thorpe PG, 2013, PHARMACOEPIDEM DR S, V22, P1013, DOI 10.1002/pds.3495; WHO Collaborating Centre for Drug Statistics Methodology, ATC DDD IND; Zomerdijk IM, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005602	29	8	9	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2019	14	3							e0211319	10.1371/journal.pone.0211319	http://dx.doi.org/10.1371/journal.pone.0211319			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN7LX	30840711	Green Submitted, Green Published, gold			2023-01-03	WOS:000460372100012
J	Calvo-Lerma, J; Fornes-Ferrer, V; Peinado, I; Heredia, A; Ribes-Koninckx, C; Andres, A				Calvo-Lerma, Joaquim; Fornes-Ferrer, Victoria; Peinado, Irene; Heredia, Ana; Ribes-Koninckx, Carmen; Andres, Ana			A first approach for an evidence-based in vitro digestion method to adjust pancreatic enzyme replacement therapy in cystic fibrosis	PLOS ONE			English	Article							NUTRITIONAL-STATUS; DAIRY MATRICES; PH; LIPOLYSIS; PROFILES; RELEASE; DIGESTIBILITY; INSUFFICIENCY; CHILDREN; OUTCOMES	Background Patients with cystic fibrosis have to take enzymatic supplements to allow for food digestion. However, an evidence-based method to adjust Pancreatic Enzyme Replacement Therapy (PERT) is inexistent, and lipid content of meals is used as a rough criterion. Objective In this study, an in vitro digestion model was set up to determine the theoretical optimal dose (TOD) of enzymatic supplement for a selection of foods, which is the dose that allows for maximum lipolysis extent. Methods A static in vitro digestion model was applied to simulate digestion of eight foods covering a wide range of lipid contents. First, the dose of the enzymatic supplement was fixed at 2000 lipase units per gram of fat (LU/g fat) using intestinal pH and bile salt concentration as variables. Second, intestinal pH and bile salt concentrations were fixed and the variable was the dose of the enzymatic supplement. Lipolysis extent was determined by measuring the free fatty acids released from initial triglycerides content of foods after digestion. Results in terms of percentage of lipolysis extent were fitted into a linear-mixed segmented model and the deducted equations were used to predict the TOD to reach 90% of lipolysis in every food. In addition, the effect of intestinal pH and bile salt concentration were investigated. Results The predictive equations obtained for the assessed foods showed that lipolysis was not only dependent on the dose of the enzyme supplement or the lipid content. Moreover, intestinal pH and bile salt concentration had significant effects on lipolysis. Therefore an evidence-based model can be developed taking into account these variables. Conclusions Depending on food characteristics, a specific TOD should be assigned to achieve an optimal digestion extent. This work represents a first step towards an evidence-based method for PERT dosing, which will be applied in an in vivo setting to validate its efficacy.	[Calvo-Lerma, Joaquim; Peinado, Irene; Heredia, Ana; Andres, Ana] Univ Politecn Valencia, Res Inst Food Engn Dev, Valencia, Spain; [Calvo-Lerma, Joaquim; Fornes-Ferrer, Victoria; Ribes-Koninckx, Carmen] Inst Invest Sanitaria La Fe Valencia, Valencia, Spain	Universitat Politecnica de Valencia	Calvo-Lerma, J (corresponding author), Univ Politecn Valencia, Res Inst Food Engn Dev, Valencia, Spain.; Calvo-Lerma, J (corresponding author), Inst Invest Sanitaria La Fe Valencia, Valencia, Spain.	joaquin_calvo@iislafe.es	Heredia, Ana/C-7107-2016; Ribes-Koninckx, Maria Carmen/ABH-5577-2020; Calvo-Lerma, Joaquim/P-4605-2016; Grau, Ana M Andrés/C-9521-2016; Calvo-Lerma, Joaquim/AAB-2783-2020	Heredia, Ana/0000-0001-6629-9779; Calvo-Lerma, Joaquim/0000-0001-7818-0652; Grau, Ana M Andrés/0000-0002-6132-3167; Calvo-Lerma, Joaquim/0000-0001-7818-0652; Ribes-Koninckx, Carmen/0000-0002-0038-6324	European Union [643806]	European Union(European Commission)	This work was fully funded by the European Union and the Horizon 2020 Research and Innovation Framework Programme (PHC-26-2014 call Self management of health and disease: citizen engagement and mHealth) under grant number 643806.	Aburub A, 2018, INT J PHARMACEUT, V544, P158, DOI 10.1016/j.ijpharm.2018.04.031; Aloulou A, 2008, ALIMENT PHARM THERAP, V27, P283, DOI 10.1111/j.1365-2036.2007.03563.x; Andree M., 1996, NEW ENGL J MED, V289, P1001; BLACKBERG L, 1979, J CLIN INVEST, V64, P1303, DOI 10.1172/JCI109586; Bornhorst GM, 2015, J FOOD SCI, V80, pR924, DOI 10.1111/1750-3841.12846; Borowitz D, 2005, J PEDIATR GASTR NUTR, V41, P273, DOI 10.1097/01.mpg.0000178439.64675.8d; Calvo-Leima J, 2017, J CYST FIBROS, V16, P510, DOI 10.1016/j.jcf.2017.03.005; Calvo-Lerma J, 2018, J FOOD SCI, V83, P2629, DOI 10.1111/1750-3841.14343; Calvo-Lerma J, 2017, REV ESP ENFERM DIG, V109, P684, DOI 10.17235/reed.2017.4951/2017; Calvo-Lerma J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014931; Carriere F, 2000, GASTROENTEROLOGY, V119, P949, DOI 10.1053/gast.2000.18140; COLOMBO C, 1988, SCAND J GASTROENTERO, V23, P151, DOI 10.3109/00365528809090237; Fang XX, 2016, FOOD RES INT, V88, P276, DOI 10.1016/j.foodres.2016.04.008; Farrell PM, 2008, J CYST FIBROS, V7, P450, DOI 10.1016/j.jcf.2008.03.007; Fieker A, 2011, CLIN EXP GASTROENTER, V4, P55, DOI 10.2147/CEG.S17634; Gelfond D, 2013, DIGEST DIS SCI, V58, P2275, DOI 10.1007/s10620-012-2209-1; Gonzalez- Bacerio J., 2010, REV COLOMBIANA DELEL, V12, P113; Helbig A, 2012, FOOD HYDROCOLLOID, V28, P10, DOI 10.1016/j.foodhyd.2011.11.007; Heneen WK, 2003, STARCH-STARKE, V55, P546, DOI 10.1002/star.200300187; Hu M, 2010, FOOD HYDROCOLLOID, V24, P719, DOI 10.1016/j.foodhyd.2010.03.010; Humbert L, 2018, J LIPID RES, V59, P2202, DOI 10.1194/jlr.M084830; Hunter JE, 2001, LIPIDS, V36, P655, DOI 10.1007/s11745-001-0770-0; Kim EHJ, 2008, FOOD BIOPHYS, V3, P229, DOI 10.1007/s11483-008-9066-7; Lamothe S, 2017, FOOD RES INT, V92, P138, DOI 10.1016/j.foodres.2016.12.026; Lamothe S, 2014, FOOD FUNCT, V5, P2621, DOI [10.1039/c4fo00203b, 10.1039/C4FO00203B]; Layer P, 2003, PANCREAS, V26, P1, DOI 10.1097/00006676-200301000-00001; Lesmes U, 2012, FOOD HYDROCOLLOID, V26, P221, DOI 10.1016/j.foodhyd.2011.05.011; Li Y, 2011, FOOD CHEM, V126, P498, DOI 10.1016/j.foodchem.2010.11.027; Mcclements DJ, 2009, CRIT REV FOOD SCI, V49, P48, DOI 10.1080/10408390701764245; Minekus M, 2014, FOOD FUNCT, V5, P1113, DOI 10.1039/c3fo60702j; Muggeo V.M.R., 2016, SEGMENTED MIXED MODE; Norman A. P., 1979, ARCH DIS CHILD, V54, P19; PRAZERES DMF, 1994, BIOPROCESS ENG, V10, P21, DOI 10.1007/BF00373531; RESMINI P, 1983, FOOD MICROSTRUCT, V2, P1; ROBINSON PJ, 1990, DIGEST DIS SCI, V35, P1299, DOI 10.1007/BF01536423; Rovner AJ, 2014, INFLAMM BOWEL DIS MO, V14, P65; Schall JI, 2006, J PEDIATR GASTR NUTR, V43, P651, DOI 10.1097/01.mpg.0000234082.47884.d9; Sikkens ECM, 2010, BEST PRACT RES CL GA, V24, P337, DOI 10.1016/j.bpg.2010.03.006; Turck D, 2016, CLIN NUTR, V35, P557, DOI 10.1016/j.clnu.2016.03.004; VERGER R, 1976, ANNU REV BIOPHYS BIO, V5, P77, DOI 10.1146/annurev.bb.05.060176.000453; Whitcomb DC, 2010, AM J GASTROENTEROL, V105, P2276, DOI 10.1038/ajg.2010.201; Ye XT, 2016, INT J BIOL MACROMOL, V84, P428, DOI 10.1016/j.ijbiomac.2015.12.054; Yen EH, 2013, J PEDIATR-US, V162, P530, DOI 10.1016/j.jpeds.2012.08.040; YOUNGBERG CA, 1987, DIGEST DIS SCI, V32, P472, DOI 10.1007/BF01296029; Zhu XQ, 2013, FOOD CHEM, V139, P398, DOI 10.1016/j.foodchem.2012.12.060	45	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2019	14	2							e0212459	10.1371/journal.pone.0212459	http://dx.doi.org/10.1371/journal.pone.0212459			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM8DR	30794618	Green Submitted, Green Published, gold			2023-01-03	WOS:000459709100071
J	Agudelo, M; Rodriguez, CA; Zuluaga, AF; Vesga, O				Agudelo, Maria; Rodriguez, Carlos A.; Zuluaga, Andres F.; Vesga, Omar			Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin	PLOS ONE			English	Article							THERAPEUTIC EQUIVALENCE; MEMBRANE DIPEPTIDASE; IN-VIVO; STABILITY; BIOEQUIVALENCE; SUBPOPULATIONS; IDENTIFICATION; SUBSTITUTION; ANTIBIOTICS; INFECTIONS	Background We demonstrated therapeutic nonequivalence of "bioequivalent" generics for meropenem, but there is no data with generics of other carbapenems. Methods One generic product of imipenem-cilastatin was compared with the innovator in terms of in vitro susceptibility testing, pharmaceutical equivalence, pharmacokinetic (PK) and pharmacodynamic (PD) equivalence in the neutropenic mouse thigh, lung and brain infection models. Both pharmaceutical forms were then subjected to analytical chemistry assays (LC/MS). Results and conclusion The generic product had 30% lower concentration of cilastatin compared with the innovator of imipenem-cilastatin. Regarding the active pharmaceutical ingredient (imipenem), we found no differences in MIC, MBC, concentration or potency or AUC, confirming equivalence in terms of in vitro activity. However, the generic failed therapeutic equivalence in all three animal models. Its E-max against S. aureus in the thigh model was consistently lower, killing from 0.1 to 7.3 million less microorganisms per gram in 24 hours than the innovator (P = 0.003). Against K. pneumoniae in the lung model, the generic exhibited a conspicuous Eagle effect fitting a Gaussian equation instead of the expected sigmoid curve of the Hill model. In the brain infection model with P. aeruginosa, the generic failed when bacterial growth was >4 log(10) CFU/g in 24 hours, but not if it was less than 2.5 log(10) CFU/g. These large differences in the PD profile cannot be explained by the lower concentration of cilastatin, and rather suggested a failure attributable to the imipenem constituent of the generic product. Analytical chemistry assays confirmed that, besides having 30% less cilastatin, the generic imipenem was more acidic, less stable, and exhibited four different degradation masses that were absent in the innovator.	[Agudelo, Maria; Rodriguez, Carlos A.; Zuluaga, Andres F.; Vesga, Omar] Univ Antioquia UdeA, Med Sch, GRIPE Grp Invest Problemas Enfermedades Infeccios, Medellin, Colombia; [Agudelo, Maria; Vesga, Omar] Hosp Univ San Vicente Fdn, Infect Dis Unit, Medellin, Colombia; [Rodriguez, Carlos A.; Zuluaga, Andres F.] Univ Antioquia UdeA, Med Sch, CIEMTO Ctr Informac Medicamentos & Tox, Medellin, Colombia	Universidad de Antioquia; Universidad de Antioquia	Vesga, O (corresponding author), Univ Antioquia UdeA, Med Sch, GRIPE Grp Invest Problemas Enfermedades Infeccios, Medellin, Colombia.; Vesga, O (corresponding author), Hosp Univ San Vicente Fdn, Infect Dis Unit, Medellin, Colombia.	omar.vesga@udea.edu.co	Zuluaga, Andres F./K-7366-2016; Rodriguez, Carlos A./P-8324-2019	Zuluaga, Andres F./0000-0001-5656-4153; Rodriguez, Carlos A./0000-0002-4042-4313	University of Antioquia's Research Committee (CODI); University of Antioquia's Sustainability Strategy 2012-2013; Fundacion Cientifica Rodrigo Vesga-Meneses	University of Antioquia's Research Committee (CODI); University of Antioquia's Sustainability Strategy 2012-2013; Fundacion Cientifica Rodrigo Vesga-Meneses	This project was financed by the University of Antioquia's Research Committee (CODI), the University of Antioquia's Sustainability Strategy 2012-2013, and Fundacion Cientifica Rodrigo Vesga-Meneses. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Agudelo M, 2014, ANTIMICROB AGENTS CH, V58, P1005, DOI 10.1128/AAC.00350-13; Agudelo M, 2012, ANTIMICROB AGENTS CH, V56, P2659, DOI 10.1128/AAC.06012-11; Agudelo M, 2015, INT J ANTIMICROB AG, V45, P161, DOI 10.1016/j.ijantimicag.2014.10.014; Alliance for Human Research Protection, 2005, FORM FDA COMM SAYS F; BENNETT JV, 1966, APPL MICROBIOL, V14, P170, DOI 10.1128/AEM.14.2.170-177.1966; Christopoulos A, 2001, J PHARMACOL EXP THER, V298, P1260; Cielecka-Piontek J, 2011, CURR PHARM ANAL, V7, P213, DOI 10.2174/157341211797457989; Clinical and Laboratory Standards Institute, 2012, PERF STAND ANT SUSC; Cummings JA, 2010, BIOCHEMISTRY-US, V49, P611, DOI 10.1021/bi901935y; EAGLE H, 1948, J EXP MED, V88, P99, DOI 10.1084/jem.88.1.99; Fujimura S, 2012, J INFECT CHEMOTHER, V18, P421, DOI 10.1007/s10156-012-0437-0; FUKASAWA M, 1992, ANTIMICROB AGENTS CH, V36, P1577, DOI 10.1128/AAC.36.7.1577; Generic Pharmaceutical Association, 2014, GEN DRUG SAV US 6 AN; Glantz SA., 2002, PRIMER BIOSTATISTICS, P230; Gonzalez JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141872; JACOBS RF, 1986, ANTIMICROB AGENTS CH, V29, P670, DOI 10.1128/AAC.29.4.670; Kera Y, 1999, COMP BIOCHEM PHYS B, V123, P53, DOI 10.1016/S0305-0491(99)00039-5; KEYNAN S, 1995, ANTIMICROB AGENTS CH, V39, P1629, DOI 10.1128/AAC.39.7.1629; Louie A, 2010, ANTIMICROB AGENTS CH, V54, P2638, DOI 10.1128/AAC.01721-09; Mastoraki E, 2008, J INFECTION, V56, P35, DOI 10.1016/j.jinf.2007.09.011; Merck, 2015, PRIM PROD MON IM CIL; Meredith PA, 2009, CURR MED RES OPIN, V25, P2179, DOI 10.1185/03007990903116867; Motulsky H., 2004, FITTING MODELS BIOL, P352, DOI 10.1002/pst.167; MYERS CM, 1984, ANTIMICROB AGENTS CH, V26, P78, DOI 10.1128/AAC.26.1.78; Neely MN, 2012, THER DRUG MONIT, V34, P467, DOI 10.1097/FTD.0b013e31825c4ba6; Papp-Wallace KM, 2011, ANTIMICROB AGENTS CH, V55, P4943, DOI 10.1128/AAC.00296-11; PATAMASUCON P, 1982, ANTIMICROB AGENTS CH, V21, P390, DOI 10.1128/AAC.21.3.390; Rawlings ND, 2012, NUCLEIC ACIDS RES, V40, pD343, DOI [10.1093/nar/gkr987, 10.1093/nar/gkt953]; Rodriguez CA, 2016, PLOS ONE, V11, DOI [10.1371/journal.pone.0155806, DOI 10.1371/journal.pone.0155806]; Rodriguez CA, 2017, INT J ANTIMICROB AG, V49, P189, DOI 10.1016/j.ijantimicag.2016.10.011; Rodriguez CA, 2015, ANTIMICROB AGENTS CH, V59, P53, DOI 10.1128/AAC.03633-14; Rodriguez CA, 2012, ANTIMICROB AGENTS CH, V56, P243, DOI 10.1128/AAC.05129-11; Rodriguez CA, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-153; Rodriguez CA, 2009, J INFECTION, V59, P277, DOI 10.1016/j.jinf.2009.08.005; Unites States Pharmacopoeia (USP), 2005, US PHARM MON DEV ANT, V27, P1110; Vesga O, 2010, ANTIMICROB AGENTS CH, V54, P3271, DOI 10.1128/AAC.01044-09; Wargo MJ, 2009, MICROBIOL-SGM, V155, P2411, DOI 10.1099/mic.0.028787-0; Winsor GL, 2011, NUCLEIC ACIDS RES, V39, pD596, DOI 10.1093/nar/gkq869; Xia M, 2009, J PHARMACEUT BIOMED, V49, P937, DOI 10.1016/j.jpba.2009.02.002; Zuluaga AF, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-55; Zuluaga Andres F, 2015, BMC Res Notes, V8, P546, DOI 10.1186/s13104-015-1507-z; Zuluaga AF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010744; Zuluaga Andres F, 2009, BMC Clin Pharmacol, V9, P1, DOI 10.1186/1472-6904-9-1	43	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2019	14	2							e0211096	10.1371/journal.pone.0211096	http://dx.doi.org/10.1371/journal.pone.0211096			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK4EL	30726248	Green Published, gold, Green Submitted			2023-01-03	WOS:000457874000052
J	Migueis, GD; da Silva, RH; Damasceno, GA; Neto, GG				Migueis, Graciela da Silva; da Silva, Rosa Helena; Damasceno Junior, Geraldo Alves; Guarim-Neto, Germano			Plants used by the rural community of Bananal, Mato Grosso, Brazil: Aspects of popular knowledge	PLOS ONE			English	Article							MART. EX HAYNE; MEDICINAL-PLANTS; ETHNOBOTANICAL SURVEY; STRYCHNOS-PSEUDOQUINA; HOME GARDENS; LAMIACEAE; DESERT; AREA	Studies in rural communities are important to maintain popular knowledge between generations, as well as to identify new species for pharmaceutical production. Thus, the objectives of this study were to determine which plant species the rural community of Bananal, Mato Grosso, Brazil, uses by calculating the levels of fidelity and concordance regarding species uses among residents and to determine if there is a relationship between the number of known useful plants and levels of education, age, and residence time. Ethnobotanical data was collected from residents of the community through semi-structured interviews in January/December/2016. Species diversity was calculated using Shannon-Wiener, Level of Fidelity (LF), Correction Factor, and the Percentage of Agreement regarding the Main Uses (AMU). Statistical tests were performed using generalized linear models (GLM) in the R environment. The plant use indications were grouped according to the International Classification of Diseases and Related Health Problems (ICD 10). We found 152 species belonging to 130 genera and 67 families. The most frequently used plant parts were leaves, and decoction was the most frequent preparation mode. Strychnos pseudoquina was the species with the highest amount of use indications. The diversity index was 4.5 nats/ind(-1). The body system with the most citations was the code XVIII of ICD 10, corresponding to the species: alfavaca, mentraste, terramicina, angelim, fedegoso. Medicinal species with AMU values higher than 25% were: Strychnos pseudoquina, Plectranthus barbatus, Citrus sinensis cv. pera, Cymbopogon citratus. There was a relationship between the number of useful plants and the residence time of the participants. The Bananal community revealed high species richness and the relationship of knowledge showed that the older the residents and the longer their residence time in the community, the more knowledge they acquired.	[Migueis, Graciela da Silva] Univ Fed Mato Grosso, Inst Ciencias Exatas & Nat, Rondonopolis, MG, Brazil; [da Silva, Rosa Helena; Damasceno Junior, Geraldo Alves] Univ Fed Mato Grosso do Sul, Inst Biociencias, Campo Grande, MS, Brazil; [Guarim-Neto, Germano] Univ Fed Mato Grosso, Inst Biociencias, Cuiaba, MG, Brazil	Universidade Federal de Mato Grosso; Universidade Federal de Mato Grosso do Sul; Universidade Federal de Mato Grosso	Migueis, GD (corresponding author), Univ Fed Mato Grosso, Inst Ciencias Exatas & Nat, Rondonopolis, MG, Brazil.	gmigueis@yahoo.com.br	Damasceno Junior, Geraldo/ABG-2834-2021	Migueis, Graciela/0000-0001-7287-6026; Silva, Rosa Helena/0000-0003-2691-9130	Foundation for Research Support of the State of Mato Grosso (FAPEMAT)	Foundation for Research Support of the State of Mato Grosso (FAPEMAT)(Fundacao de Amparo a Pesquisa do Estado de Mato Grosso (FAPEMAT))	The research obtained support from the Foundation for Research Support of the State of Mato Grosso (FAPEMAT).; The authors thank the Federal University of Mato Grosso (UFMT), to the course of Powders graduation in Biotechnology and Biodiversity of the Rede Pro-Centro-Oeste, the Foundation of support the Research of the State of Mato Grosso for (FAPEMAT) the offered support, to the Community Agent of Health for his disposition in accompanying the visits for the interviews and to the community's of the Bananal community residents for they share their knowledge.	Abbas Z, 2017, J ETHNOBIOL ETHNOMED, V13, DOI 10.1186/s13002-017-0172-9; Ahmad KS, 2017, J ETHNOBIOL ETHNOMED, V13, DOI 10.1186/s13002-017-0196-1; Amaral Cleomara Nunes do, 2008, Bol. Mus. Para. Emílio Goeldi. Ciênc. hum., V3, P329; Amorozo Maria Christina de Mello, 2002, Acta Bot. Bras., V16, P189, DOI 10.1590/S0102-33062002000200006; Andenberg AA, 2007, FAMILIES GENERA VASC, VVIII; Apostolides N.A., 2017, J ECOSYST ECOGRAPHY, V7, P10, DOI DOI 10.4172/2157-7625.1000245; Aziz MA, 2018, J ETHNOBIOL ETHNOMED, V14, DOI 10.1186/s13002-017-0204-5; Aziz MA, 2016, J ETHNOBIOL ETHNOMED, V12, DOI 10.1186/s13002-016-0126-7; Badke Marcio Rossato, 2011, Esc. Anna Nery, V15, P132; Bidak LM, 2015, GLOB ECOL CONSERV, V3, P433, DOI 10.1016/j.gecco.2015.02.001; Boff L, 2016, J APPL MICROBIOL, V121, P1519, DOI 10.1111/jam.13279; Boniface PK, 2017, J ETHNOPHARMACOL, V206, P193, DOI 10.1016/j.jep.2017.05.024; Bortolotto IM, 2017, REG ENVIRON CHANGE, V17, P1329, DOI 10.1007/s10113-016-1088-y; Bortolotto IM, 2015, J ETHNOBIOL ETHNOMED, V11, DOI 10.1186/s13002-015-0026-2; Bussmann RW, 2018, ECON BOT, V72, P357, DOI 10.1007/s12231-018-9420-8; Byg A, 2001, BIODIVERS CONSERV, V10, P951, DOI 10.1023/A:1016640713643; Camara-Leret R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085794; Chahad AM, 2015, J ALTERN COMPLEM MED, V21, P569, DOI 10.1089/acm.2014.0243; Conde BE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187599; Corrigan BM, 2011, S AFR J BOT, V77, P346, DOI 10.1016/j.sajb.2010.09.017; Bieski IGC, 2015, J ETHNOPHARMACOL, V173, P383, DOI 10.1016/j.jep.2015.07.025; Bieski IGC, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/272749; Costa M. C. C. D., 2006, Revista Brasileira de Plantas Medicinais, V8, P81; Culida de Oliveira T.A., 2007, REV ELETRONICA ENFER, V9, P93; da Costa IBC, 2017, B LATINOAM CARIBE PL, V16, P53; da Cunha SA, 2011, ACTA BOT BRAS, V25, P685, DOI 10.1590/S0102-33062011000300022; de Albuquerque UP, 2004, METODOS TECNICAS PES, P139; Dimech GS, 2013, SCI WORLD J, DOI 10.1155/2013/862763; dos Santos RT, 2012, QUIM NOVA, V35, P2229, DOI 10.1590/S0100-40422012001100025; Egea T, 2015, J ETHNOPHARMACOL, V175, P241, DOI 10.1016/j.jep.2015.08.053; Farias KD, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/1919474; Faruque MO, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00040; Freitas AVL, 2014, J GLOBAL BIOSCIENCES, V3, P749; FRIEDMAN J, 1986, J ETHNOPHARMACOL, V16, P275, DOI 10.1016/0378-8741(86)90094-2; Gonzalez JA, 2010, J ETHNOPHARMACOL, V131, P343, DOI 10.1016/j.jep.2010.07.022; Guarrera PM, 2015, ETHNOBIOL LETT, V6, P119, DOI 10.14237/ebl.6.1.2015.288; Jost X, 2016, J ETHNOBIOL ETHNOMED, V12, DOI 10.1186/s13002-016-0128-5; Kenicer G, 2005, ENDINB J BOT, V62, P195; Kiraithe MN, 2016, J ETHNOPHARMACOL, V178, P266, DOI 10.1016/j.jep.2015.12.013; Kulshrestha P., 2018, INT J ACAD RES DEV, V3, P52; Kunwar RM, 2018, J ETHNOBIOL ETHNOMED, V14, DOI 10.1186/s13002-018-0242-7; Lage PS, 2015, PARASITOL RES, V114, P4625, DOI 10.1007/s00436-015-4708-4; Lage PS, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/304354; Lautenschlager T, 2018, J ETHNOBIOL ETHNOMED, V14, DOI 10.1186/s13002-018-0238-3; Licata M, 2016, J ETHNOBIOL ETHNOMED, V12, DOI 10.1186/s13002-015-0074-7; Lima LMdeS, 2007, THESIS, DOI [10.11606/T.8.2007.tde-101020077-152602, DOI 10.11606/T.8.2007.TDE-101020077-152602]; Liporacci H.S.N, 2013, Rev. bras. plantas med., V15, P529, DOI 10.1590/S1516-05722013000400009; Liporacci Heitor S.N., 2017, Rodriguésia, V68, P1225, DOI 10.1590/2175-7860201768407; Lumpert M, 2017, J ETHNOBIOL ETHNOMED, V13, DOI 10.1186/s13002-017-0144-0; Maciel Márcia Regina Antunes, 2006, Bol. Mus. Para. Emílio Goeldi. Ciênc. hum., V1, P61; Martins JLR, 2015, FUND CLIN PHARMACOL, V29, P238, DOI 10.1111/fcp.12113; Mbunde MVN, 2017, J INTERCULT ETHNOPHA, V6, P84, DOI 10.5455/jice.20161222103956; Megersa M, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-68; MESSIAS M.C.T.B., 2015, Rev. bras. plantas med., V17, P76, DOI 10.1590/1983-084X/12_139; Meyer L., 2012, REV BRASILEIRA BIOCI, V10, P258; MONTELES R, 2007, REV BIOLOGIA CIENCIA, V7, P38; Moura Flávia de Barros Prado, 2007, Biota Neotrop., V7, P119, DOI 10.1590/S1676-06032007000300014; Murad W, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-77; Neto F.R.G, 2014, Rev. bras. plantas med., V16, P856, DOI 10.1590/1983-084X/11_207; NICOLETTI M, 1984, J NAT PROD, V47, P953, DOI 10.1021/np50036a007; Orsi PR, 2014, J ETHNOPHARMACOL, V151, P380, DOI 10.1016/j.jep.2013.10.056; Orsi PR, 2012, J ETHNOPHARMACOL, V143, P81, DOI 10.1016/j.jep.2012.06.001; Pasa Maria Corette, 2010, Interações (Campo Grande), V11, P195, DOI 10.1590/S1518-70122010000200008; Pasquini MW, 2018, ECON BOT, V72, P278, DOI 10.1007/s12231-018-9422-6; Pott A., 1994, PLANTAS PANTANAL; Prefeitura Municipal de Rondonopolis, 2010, PREF ROND MT AP PEQ; Premamalini P., 2017, INT J ADV HERBAL SCI, V3, P67, DOI [10.23953/cloud.ijahst.327, DOI 10.23953/CLOUD.IJAHST.327]; R Core Team, 2017, R LANG ENV STAT COMP; Ramos U.F., 2011, INFARMA, V24, P10; Randrianarivony TN, 2017, J ETHNOBIOL ETHNOMED, V13, DOI 10.1186/s13002-017-0147-x; Rankoana SA, 2015, AFRICAN J PHYS HLTH, V1, P773; Reyes-Garcia V, 2014, GLOBAL ENVIRON CHANG, V24, P223, DOI 10.1016/j.gloenvcha.2013.11.022; Ribeiro RV, 2017, J ETHNOPHARMACOL, V205, P69, DOI 10.1016/j.jep.2017.04.023; Rossato SC, 1999, ECON BOT, V53, P387, DOI 10.1007/BF02866716; Ruzza DAC, 2014, ENCICLOPEDIA BIOSFER, V10, P3332; Saraiva ME, 2015, J ETHNOPHARMACOL, V171, P141, DOI 10.1016/j.jep.2015.05.034; Sarandy MM, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9538351; Saravanan Kasilingam, 2017, INT J ADV HERBAL SCI, V3, P49, DOI [10.23953/cloud.ijahst. 315, DOI 10.23953/CLOUD.IJAHST.315]; Shaheen H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183956; Silva JS, 2012, REV CIENCIAS AGROAMB, V10, P9; Singh A, 2017, J ETHNOBIOL ETHNOMED, V13, DOI 10.1186/s13002-017-0178-3; Souza M, 2013, BIODIVERSIDADE, V12, P138; Stevens PF, 2017, BOT J LINN SOC, V181, P1; de Jesus NZT, 2009, REV BRAS FARMACOGN, V19, P130, DOI 10.1590/S0102-695X2009000100023; Tibiri A, 2015, J ALTERN COMPLEM MED, V21, P294, DOI 10.1089/acm.2014.0016; Tuasha N, 2018, J ETHNOBIOL ETHNOMED, V14, DOI 10.1186/s13002-018-0213-z; Umair M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177912; Veiga Junior VF, 2008, BRAZILIAN J PHARMACO, V18, P308, DOI [10.1590/S0102-695X2008000200027, DOI 10.1590/S0102-695X2008000200027]; Veiga VF, 2005, QUIM NOVA, V28, P519, DOI 10.1590/S0100-40422005000300026; Verma Raj Kumar, 2014, Asian Pacific Journal of Tropical Biomedicine, V4, pS460, DOI 10.12980/APJTB.4.2014C1067; VIEIRA L.S, 2015, Rev. bras. plantas med., V17, P1061, DOI 10.1590/1983-084X/15_009; Weckerle CS, 2006, ECON BOT, V60, P3, DOI 10.1663/0013-0001(2006)60[3:PKOTSI]2.0.CO;2; WHO, 2010, INT STAT CLASS DIS R; Wilson E.O., 1988, P3	94	8	8	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2019	14	1							e0210488	10.1371/journal.pone.0210488	http://dx.doi.org/10.1371/journal.pone.0210488			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ4PJ	30699133	Green Published, gold, Green Submitted			2023-01-03	WOS:000457155600036
J	Hui, WJ; Li, T; Liu, WD; Zhou, CY; Gao, F				Hui, Wenjia; Li, Ting; Liu, Weidong; Zhou, Chunyan; Gao, Feng			Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis	PLOS ONE			English	Article							OPEN-LABEL; EPIDEMIOLOGY; VANCOMYCIN; COLITIS; PATIENT; DONORS; FROZEN	Objectives Although systematic evaluation has confirmed the efficacy of fresh fecal microbiota transplantation (FMT) for treatment of recurrent and/or refractory and/or relapse C. difficile infection (RCDI), it lacks the support of well-designed randomized controlled trials (RCTs), and the latest guidelines do not optimize the management of FMT. In this paper, we focus on an in-depth study of fresh FMT and fecal infusion times to guide clinical practice. Methods We reviewed studies in PubMed, Medline, Embase, the Cochrane library and Cochrane Central written in English. The retrieval period was from the establishment of the databases to September 20th, 2018. The retrieval objects were published RCTs of RCDI treated by fresh FMT. The intervention group was fresh FMT group, while the control group included antibiotic therapy or placebo or frozen FMT or capsule. The primary and secondary outcomes were the clinical remission of diarrhea without relapse after 8-17 weeks and the occurrence of severe adverse events, respectively. Subgroup analysis analyzed the effect of single and multiple fecal infusions. Two authors independently completed the information extraction and assessed risk of bias and overall quality of the evidence. Results 8 randomized controlled trials met the inclusion criteria, involving 537 patients (273 in the fresh FMT group and 264 in the control group). The recurrence rate of clinical diarrhea in the fresh FMT group was 11.0% (30/273), which was significantly lower than the control group (24.6%, 65/264; P<0.05); the pooled relative risk (RR) was 0.38 (95%CI:0.16-0.87; I-2=67%; P=0.02) in the fresh FMT group, and the clinical heterogeneity was significant and random effects model was used; However, there was no significant difference neither for the effect of antibiotic treatment/frozen feces transplanted by enema (RR=1.07; 95%CI:0.64-1.80; I-2=0%; P=0.79) or capsule/frozen feces transplanted by colonoscopy (RR=0.42; 95%CI: 0.05-3.94; I-2=43%; P=0.45) compared with fresh FMT. The subgroup analysis showed that FMT by multiple infusions could effectively and significantly (RR=0.24; 95%CI:0.10-0.58; I-2=0%; P=0.001) improve the clinical diarrhea remission rate. Most mild to moderate adverse events caused by FMT were self-limited and could be quickly alleviated; no severe adverse events happened because of FMT. Conclusions Overall, the use of fresh feces for bacterial transplantation was the best efficiency for RCDI compared to antibiotic therapy or placebo. The fecal transmission method by enema was not ideal, but capsules or frozen feces transported by colonoscopy could be an alternative treatment compared to fresh FMT. For patients with severe RCDI, multiple fecal transplants can effectively improve their diarrhea remission rate. The focus of future research should be on how to standardize the production of capsules or frozen feces to better guide the clinical management of RCDI patients by FMT.	[Hui, Wenjia; Li, Ting; Liu, Weidong; Gao, Feng] Peoples Hosp Xin Jiang Uygur Autonomous Reg, Dept Gastroenterol, Urumqi, Xinjiang, Peoples R China; [Zhou, Chunyan] Nanchang Univ, State Key Lab Food Sci & Technol, Nanchang, Jiangxi, Peoples R China	Nanchang University	Gao, F (corresponding author), Peoples Hosp Xin Jiang Uygur Autonomous Reg, Dept Gastroenterol, Urumqi, Xinjiang, Peoples R China.	xjgf@sina.com		Hui, Wenjia/0000-0001-6055-1339; Liu, Weidong/0000-0003-3320-3958				Bang B, 2017, KOREAN J GASTROENTER, V69; Barbut F., 2015, ANNALES PHARMACEUTIQUES FRANCAISES, V73, P13, DOI 10.1016/j.pharma.2014.05.004; Brittnacher MJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158897; Broecker F, 2013, DIGESTION, V88, P243, DOI 10.1159/000355955; Camacho-Ortiz A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189768; Cammarota G, 2015, ALIMENT PHARM THER, V41, P835, DOI 10.1111/apt.13144; Cammarota G, 2014, J CLIN GASTROENTEROL, V48, P693, DOI 10.1097/MCG.0000000000000046; Chen B, 2017, J INFECTION, V74, pS120, DOI 10.1016/S0163-4453(17)30202-5; Cohen N, 2016, ISR MED ASS J, V18; Cohen SH, 2010, INFECT CONT HOSP EP, V31, P431, DOI 10.1086/651706; DerSimonian R, 2015, CONTEMP CLIN TRIALS, V45, P139, DOI 10.1016/j.cct.2015.09.002; Furuya-Kanamori L, 2017, J CLIN GASTROENTEROL, V51, P145, DOI 10.1097/MCG.0000000000000511; Garcia-Fernandez S, 2016, DIAGN MICR INFEC DIS, V86, P470, DOI 10.1016/j.diagmicrobio.2016.09.004; Garcia-Garcia-de-Paredes A, 2015, GASTROENT HEPAT-BARC, V38, P123, DOI 10.1016/j.gastrohep.2014.07.010; Gupta SB, 2016, CLIN INFECT DIS, V63, P730, DOI 10.1093/cid/ciw364; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hota SS, 2017, CLIN INFECT DIS, V64, P265, DOI 10.1093/cid/ciw731; Ianiro G, 2018, ALIMENT PHARM THER, V48, P152, DOI 10.1111/apt.14816; Jiang ZD, 2017, ALIMENT PHARM THER, V45, P899, DOI 10.1111/apt.13969; JPT H, 2011, COCHRANE HDB SYSTEMA, V2011; Juszczuk K, 2017, POSTEPY HIG MED DOSW, V71; Kao D, 2017, JAMA, V318; Kassam Z, 2014, CLIN LAB MED, V34, P787, DOI 10.1016/j.cll.2014.08.007; Kassam Z, 2013, AM J GASTROENTEROL, V108, P500, DOI 10.1038/ajg.2013.59; Kelly CP, 2008, NEW ENGL J MED, V359; Kelly CR, 2016, ANN INTERN MED, V165, P609, DOI 10.7326/M16-0271; Konturek PC, 2017, MED PRIN PRACT, V26, P182, DOI 10.1159/000455126; Lee CH, 2016, JAMA-J AM MED ASSOC, V315, P142, DOI 10.1001/jama.2015.18098; Li YT, 2016, ALIMENT PHARM THER, V43, P445, DOI 10.1111/apt.13492; Loke P, 2016, PEDIAT ALLERG IMM-UK, V27, P872, DOI 10.1111/pai.12619; McFarland LV, 2016, WORLD J GASTROENTERO, V22, P3078, DOI 10.3748/wjg.v22.i11.3078; McInnes MDF, 2018, JAMA-J AM MED ASSOC, V319, P388, DOI 10.1001/jama.2017.19163; Mendolia G, 2016, GASTROENTEROLOGY, V150, DOI [10.1016/S0016-5085(16)31855-8, DOI 10.1016/S0016-5085(16)31855-8]; Merlo G, 2016, J GASTROEN HEPATOL, V31, P1927, DOI 10.1111/jgh.13402; Moayyedi P, 2017, MED J AUST, V207; Nayak SU, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.02760-16; Ontario H Q, 2016, ONT HLTH TECHNOL ASS, V16; Pai N, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016698; Paramsothy S, 2017, LANCET, V389, P1218, DOI 10.1016/S0140-6736(17)30182-4; Quraishi MN, 2017, ALIMENT PHARM THER, V46, P479, DOI 10.1111/apt.14201; Reijnders D, 2016, CELL METAB, V24, P63, DOI [10.1016/j.cmet.2016.07.008, 10.1016/j.cmet.2016.06.016]; Rossen NG, 2015, GASTROENTEROLOGY, V149, P110, DOI 10.1053/j.gastro.2015.03.045; Rupnik M, 2009, NAT REV MICROBIOL, V7, P526, DOI 10.1038/nrmicro2164; Saeedi BJ, 2017, OBSTET GYNECOL, V129, P507, DOI 10.1097/AOG.0000000000001911; Seekatz AM, 2014, MBIO, V5, DOI 10.1128/mBio.00893-14; Seufferlein T, 2014, INTERNIST, V55, P455, DOI 10.1007/s00108-014-3483-0; Staley C, 2016, MBIO, V7, DOI 10.1128/mBio.01965-16; Tang GH, 2017, DIAGN MICR INFEC DIS, V88, P322, DOI 10.1016/j.diagmicrobio.2017.05.007; Tian HL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171308; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Vardakas KZ, 2012, INT J ANTIMICROB AG, V40, P1, DOI 10.1016/j.ijantimicag.2012.01.004; Wang SA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161174; Weingarden AR, 2014, AM J PHYSIOL-GASTR L, V306, pG310, DOI 10.1152/ajpgi.00282.2013; Wilson K, 1993, CLIN INFECT DIS S4, V16; Yamazaki Y, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1070-z; Youngster I, 2014, CLIN INFECT DIS, V58, P1515, DOI 10.1093/cid/ciu135; Zhang FM, 2018, PROTEIN CELL, V9, P462, DOI 10.1007/s13238-018-0541-8; Zimlichman E, 2013, JAMA INTERN MED, V173, P2039, DOI 10.1001/jamainternmed.2013.9763	59	68	70	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2019	14	1							e0210016	10.1371/journal.pone.0210016	http://dx.doi.org/10.1371/journal.pone.0210016			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HI4TC	30673716	gold, Green Submitted, Green Published			2023-01-03	WOS:000456442800027
J	Murphy, SM; McCollister, KE; Leff, JA; Yang, X; Jeng, PJ; Lee, JD; Nunes, EV; Novo, P; Rotrosen, J; Schackman, BR				Murphy, Sean M.; McCollister, Kathryn E.; Leff, Jared A.; Yang, Xuan; Jeng, Philip J.; Lee, Joshua D.; Nunes, Edward V.; Novo, Patricia; Rotrosen, John; Schackman, Bruce R.			Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-LIFE; ABUSE; DEPENDENCE; INFECTION; ADDICTION; PEOPLE	Background: Not enough evidence exists to compare buprenorphine-naloxone with extended-release naltrexone for treating opioid use disorder. Objective: To evaluate the cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone. Design: Cost-effectiveness analysis alongside a previously reported randomized clinical trial of 570 adults in 8 U.S. inpatient or residential treatment programs. Data Sources: Study instruments. Target Population: Adults with opioid use disorder. Time Horizon: 24-week intervention with an additional 12 weeks of observation. Perspective: Health care sector and societal. Interventions: Buprenorphine-naloxone and extended-release naltrexone. Outcome Measures: Incremental costs combined with incremental quality-adjusted life-years (QALYs) and incremental time abstinent from opioids. Results of Base-Case Analysis: Use of the health care sector perspective and a willingness-to-pay threshold of $100 000 per QALY showed buprenorphine-naloxone to be preferable to extended-release naltrexone in 97% of bootstrap replications at 24 weeks and in 85% at 36 weeks. Similar results were obtained with incremental time abstinent from opioids as an outcome and with use of the societal perspective. Results of Sensitivity Analysis: The base-case results were sensitive to the cost of the 2 treatments and the success of randomized treatment initiation. Limitation: Relatively short follow-up for a chronic condition, substantial missing data, no information on patient out-of-pocket and social service costs. Conclusion: Buprenorphine-naloxone is preferred to extended-release naltrexone as first-line treatment when both options are clinically appropriate and patients require detoxification before initiating extended-release naltrexone.	[Murphy, Sean M.; Leff, Jared A.; Jeng, Philip J.; Schackman, Bruce R.] Weill Cornell Med Coll, Dept Healthcare Policy & Res, 425 East 61st St,Suite 301, New York, NY 10065 USA; [McCollister, Kathryn E.; Yang, Xuan] Univ Miami, Miller Sch Med, Don Soffer Clin Res Ctr, 1120 Northwest 14th St,Suite 1019, Miami, FL 33136 USA; [Lee, Joshua D.; Novo, Patricia; Rotrosen, John] NYU, Sch Med, 227 East 30th St,Suite 712, New York, NY 10016 USA; [Nunes, Edward V.] Columbia Univ, Med Ctr, New York, NY USA; [Nunes, Edward V.] Columbia Univ, Dept Psychiat, 1051 Riverside Dr, New York, NY 10032 USA; [Novo, Patricia; Rotrosen, John] NYU, Dept Psychiat, Sch Med, One Pk Ave,8th Floor, New York, NY 10016 USA	Cornell University; University of Miami; New York University; Columbia University; Columbia University; New York University	Murphy, SM (corresponding author), Weill Cornell Med Coll, Dept Healthcare Policy & Res, 425 East 61st St,Suite 301, New York, NY 10065 USA.	smm2010@med.cornell.edu	Leff, Jared A./B-7631-2014	Leff, Jared A./0000-0001-6995-6009; Nunes, Edward/0000-0002-2055-3425; Lee, Joshua/0000-0003-3161-2950; Murphy, Sean M./0000-0001-9104-0670; Jeng, Philip/0000-0002-8336-5536	National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) [R01DA035808, P30DA040500]; NIDA National Drug Abuse Treatment Clinical Trials Network [U10DA013046, UG1/U10DA013035, UG1/U10DA013034, U10DA013045, UG1/U10DA013720, UG1/U10DA013732, UG1/U10DA013714, UG1/U10DA015831, U10DA015833, HHSN271201200017C, HHSN271201500065C];  [K24DA022412]; NATIONAL INSTITUTE ON DRUG ABUSE [P30DA040500, UG1DA013714, UG1DA013720, UG1DA013034, UG1DA015831, UG1DA013035, R01DA035808, UG1DA013732] Funding Source: NIH RePORTER	National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH); NIDA National Drug Abuse Treatment Clinical Trials Network; ; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	By grants R01DA035808 and P30DA040500 from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH); U10DA013046, UG1/U10DA013035, UG1/U10DA013034, U10DA013045, UG1/U10DA013720, UG1/U10DA013732, UG1/U10DA013714, UG1/U10DA015831, U10DA015833, HHSN271201200017C and HHSN271201500065C from the NIDA National Drug Abuse Treatment Clinical Trials Network; and K24DA022412 (to Dr. Nunes).	Birnbaum HG, 2011, PAIN MED, V12, P657, DOI 10.1111/j.1526-4637.2011.01075.x; Bisaga A, 2018, DRUG ALCOHOL DEPEN, V187, P171, DOI 10.1016/j.drugalcdep.2018.02.023; Bray JW, 2017, J SUBST ABUSE TREAT, V76, P88, DOI 10.1016/j.jsat.2017.01.019; Bureau of Labor Statistics, 2017, CONS PRIC IND; Bureau of Labor Statistics, 2017, OCC OUTL HDB; Council of Economic Advisers, 2017, UND COST OP CRIS; French M. T., 2003, DRUG ABUSE TREATMENT, V8th; French MT, 1997, J SUBST ABUSE TREAT, V14, P445, DOI 10.1016/S0740-5472(97)00132-3; Glick H.A., 2014, EC EVALUATION CLIN T; Gruber SA, 2007, NEUROPSYCHOL REV, V17, P299, DOI 10.1007/s11065-007-9041-y; Hagan H, 2011, J INFECT DIS, V204, P74, DOI 10.1093/infdis/jir196; Hess KL, 2017, ANN EPIDEMIOL, V27, P238, DOI 10.1016/j.annepidem.2017.02.003; IBM Watson Health, 2017, IBM MICR RED BOOK; Kampman K, 2015, J ADDICT MED, V9, P358, DOI 10.1097/ADM.0000000000000166; Lee JD, 2018, LANCET, V391, P309, DOI 10.1016/S0140-6736(17)32812-X; Lott DC, 2018, LANCET, V391, P283, DOI 10.1016/S0140-6736(17)32872-6; Manchikanti L, 2010, PAIN PHYSICIAN, V13, P401; Mark TL, 2001, DRUG ALCOHOL DEPEN, V61, P195, DOI 10.1016/S0376-8716(00)00162-9; McCollister KE, 2010, DRUG ALCOHOL DEPEN, V108, P98, DOI 10.1016/j.drugalcdep.2009.12.002; McCollister KE, 2018, AM J MANAG CARE, V24, P294; MOHER D, 2009, NEW ENGL J MED, V151, P264, DOI DOI 10.7326/0003-4819-151-4-200908180-00135; Murphy SM, 2017, ADDICTION, V112, P1440, DOI 10.1111/add.13807; Murphy SM, 2016, PHARMACOECONOMICS, V34, P863, DOI 10.1007/s40273-016-0400-5; Murphy SM, 2014, J CHILD ADOLESC MENT, V26, P35, DOI 10.2989/17280583.2013.849607; Neumann PJ, 2017, COST EFFECTIVENESS H, V2nd; Seaman SR, 2013, STAT METHODS MED RES, V22, P278, DOI 10.1177/0962280210395740; Sobell L. C., 1992, MEASURING ALCOHOL CO, P41, DOI [10.1007/978-1-4612-0357-5_3, 10.1007/978-1-4612-0357-5, DOI 10.1007/978-1-4612-0357-5_3]; Strada L, 2017, QUAL LIFE RES, V26, P3187, DOI 10.1007/s11136-017-1674-6; Sullivan M, 2017, AM J PSYCHIAT, V174, P459, DOI 10.1176/appi.ajp.2016.16050548; Tanum L, 2017, JAMA PSYCHIAT, V74, P1197, DOI 10.1001/jamapsychiatry.2017.3206; United States Department of Health and Human Services Office of Disease Prevention and Health Promotion, 2017, HLTH PEOPL 2020	31	33	33	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	2019	170	2					90	+		10.7326/M18-0227	http://dx.doi.org/10.7326/M18-0227			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HH3ZL	30557443	Green Accepted			2023-01-03	WOS:000455659100013
J	Landwehr, C; Richardson, J; Bint, L; Parsons, R; Sunderland, B; Czarniak, P				Landwehr, Caitlin; Richardson, Jennifer; Bint, Lewis; Parsons, Richard; Sunderland, Bruce; Czarniak, Petra			Cross-sectional survey of off-label and unlicensed prescribing for inpatients at a paediatric teaching hospital in Western Australia	PLOS ONE			English	Article							DRUG-USE; CHILDREN; PHARMACOLOGY; MEDICINES; WARDS	Objectives To evaluate the prevalence of off-label and unlicensed prescribing in inpatients at a major paediatric teaching hospital in Western Australia and to identify which drugs are commonly prescribed off-label or unlicensed, including factors influencing such prescribing. Methods A retrospective cross-sectional study was conducted in June, 2013. Patient and prescribing data were collected from 190 inpatient medication chart records which had been randomly selected from all admissions during the second week of February 2013. Drugs were categorised as licensed, off-label or unlicensed, according to their approved Australian registration product information (PI). All drugs were classified according to the Anatomical Therapeutic Chemical (ATC) code. Results There were 120 male and 70 female inpatients. The average age was 6.0 years (+/- 4.7). The study included 1160 prescribed drugs suitable for analysis. The number of drugs prescribed per patient ranged from 1 to 25 with an average of 6.1 (+/- 4.3). More than half (54%) were prescribed off-label. Oxycodone, clonidine, parecoxib and midazolam were always prescribed off-label. The most common off-label drugs were ondansetron (18.5%), fentanyl (12.9%), oxycodone (8.8%) and paracetamol (6.1%). Many ATC classifications included high off-label proportions especially the genitourinary system and sex hormones, respiratory system drugs, systemic hormonal preparations and alimentary tract and metabolism drugs. Conclusions This study highlights that prescribing of paediatric drugs needs to be better supported by existing and new evidence. Incentives should be established to foster the conduct of evidence-based studies in the paediatric population. The current level of off-label prescribing raises issues of unexpected toxicity and adverse drug effects in children that are in some cases severely ill.	[Landwehr, Caitlin; Richardson, Jennifer; Sunderland, Bruce; Czarniak, Petra] Curtin Univ, Sch Pharm & Biomed Sci, Perth, WA, Australia; [Bint, Lewis] Fiona Stanley Hosp, South Metropolitan Hlth Serv, Perth, WA, Australia; [Parsons, Richard] Curtin Univ, Sch Occupat Therapy Social Work & Speech Pathol, Perth, WA, Australia	Curtin University; Curtin University	Czarniak, P (corresponding author), Curtin Univ, Sch Pharm & Biomed Sci, Perth, WA, Australia.	P.Czarniak@curtin.edu.au						[Anonymous], 2016, AUSTR MED HDB; Ballard CDJ, 2013, J PAEDIATR CHILD H, V49, P38, DOI 10.1111/jpc.12065; Beggs Sean, 2009, Paediatr Drugs, V11, P38; Bucheler R, 2002, BRIT MED J, V324, P1311, DOI 10.1136/bmj.324.7349.1311; Choonara I, 2014, ARCH DIS CHILD, V99, P1143, DOI 10.1136/archdischild-2014-306853; Clinical Investigation of Medicinal Products in the Pediatric Population (E11), 2001, CLIN INV MED PROD PE; Conroy S, 1999, ARCH DIS CHILD-FETAL, V80, pF142, DOI 10.1136/fn.80.2.F142; Craig J S, 2001, Ir Med J, V94, P237; Czarniak P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120630; Davido B, 2016, INT J ANTIMICROB AG, V47, P490, DOI 10.1016/j.ijantimicag.2016.04.010; Di Paolo Ermindo R, 2006, Swiss Med Wkly, V136, P218; Dick A, 2003, ALIMENT PHARM THER, V17, P571, DOI 10.1046/j.1365-2036.2003.01441.x; eMIMS, 2013, EMIMS PRESCR INF; Hatala R, 1996, ANN INTERN MED, V124, P717, DOI 10.7326/0003-4819-124-8-199604150-00003; Hill P, 2005, ARCH DIS CHILD, V90, pI17, DOI 10.1136/adc.2004.058867; Hsien L, 2008, PHARM WORLD SCI, V30, P497, DOI 10.1007/s11096-008-9193-8; Joret-Descout P, 2015, INT J CLIN PHARM-NET, V37, P1222, DOI 10.1007/s11096-015-0191-3; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; Kemp C, 2005, PAEDIAT PHARMACOPEIA; Lee J, 2014, IEEE T IND ELECTRON, V61, P3786, DOI 10.1109/TIE.2013.2266079; Lenk C, 2009, EUR J PEDIATR, V168, P1473, DOI 10.1007/s00431-009-0956-6; Lindell-Osuagwu L, 2009, J CLIN PHARM THER, V34, P277, DOI 10.1111/j.1365-2710.2008.01005.x; Mason J, 2012, EUR J CLIN PHARMACOL, V68, P21, DOI 10.1007/s00228-011-1097-1; Palcevski G, 2012, EUR J CLIN PHARMACOL, V68, P1073, DOI 10.1007/s00228-012-1221-x; Pandolfini C, 2005, EUR J PEDIATR, V164, P552, DOI 10.1007/s00431-005-1698-8; Rossi S, 2012, AUSTR MED HDB 2012; Sansom L, AUSTR PHARM FORMULAR; Shah SS, 2007, ARCH PEDIAT ADOL MED, V161, P282, DOI 10.1001/archpedi.161.3.282; 't Jong GW, 2001, PEDIATRICS, V108, P1089, DOI 10.1542/peds.108.5.1089; Therapeutics Goods Administration (TGA), PRODUCT INFORMATION; Turner S, 1998, BRIT MED J, V316, P343, DOI 10.1136/bmj.316.7128.343; WHO Collaborating Centre for Drug Statistics Methodology, 2012, GUID ATC CLASS DDD A; World Health Organization, 2017, GLOB ANT RES SURV SY	33	10	10	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2019	14	1							e0210237	10.1371/journal.pone.0210237	http://dx.doi.org/10.1371/journal.pone.0210237			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG7HM	30620749	Green Published, Green Submitted, gold			2023-01-03	WOS:000455161300023
J	Green, MJ; Mahato, M				Green, Michael J.; Mahato, Mita			Graphic Medicine: The Best of 2018	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Green, Michael J.] Penn State Coll Med, Dept Humanities, 500 Univ Dr, Hershey, PA 17033 USA; [Green, Michael J.] Penn State Coll Med, Dept Med, Hershey, PA USA; [Mahato, Mita] Univ Puget Sound, Dept English, Tacoma, WA 98416 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Green, MJ (corresponding author), Penn State Coll Med, Dept Humanities, 500 Univ Dr, Hershey, PA 17033 USA.	mjg15@psu.edu						Forney Ellen. Marbles, 2018, ROCK STEADY BRILLIAN; Galloway M., 2018, SLIGHTLY PLURAL SHOR; Hamdy S, 2017, LISSA STORY MED PROM; Krosoczka J., 2018, HEY KIDDO; Lindsay Rachel, 2018, RX GRAPHIC MEMOIR; Open Door Clinic, MOST COSTL JOURN	6	0	0	2	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	2018	320	24					2510	2511		10.1001/jama.2018.18009	http://dx.doi.org/10.1001/jama.2018.18009			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG1EK	30575860				2023-01-03	WOS:000454693000001
J	Jussila, MP; Remes, T; Anttonen, J; Harila-Saari, A; Niinimaki, J; Pokka, T; Koskenkorva, P; Sutela, A; Toiviainen-Sale, S; Arikoski, P; Riikonen, P; Arola, M; Lahteenmaki, P; Sirkia, K; Rantala, H; Suo-Palosaari, M; Ojaniemi, M				Jussila, Miro-Pekka; Remes, Tiina; Anttonen, Julia; Harila-Saari, Arja; Niinimaki, Jaakko; Pokka, Tytti; Koskenkorva, Paivi; Sutela, Anna; Toiviainen-Sale, Sanna; Arikoski, Pekka; Riikonen, Pekka; Arola, Mikko; Lahteenmaki, Paivi; Sirkia, Kirsti; Rantala, Heikki; Suo-Palosaari, Maria; Ojaniemi, Marja			Late vertebral side effects in long-term survivors of irradiated childhood brain tumor	PLOS ONE			English	Article							BONE-MINERAL DENSITY; GROWTH-HORMONE; RADIATION-THERAPY; ADULT SURVIVORS; FRACTURES; ENDOCRINE; HEALTH; MASS	Purpose Long-term side effects of the treatments are common in survivors of irradiated pediatric brain tumors. Ionizing radiation in combination with surgery and chemotherapy during childhood may reduce vertebral height and bone mineral density (BMD), and cause growth failure. The aim of this study was to evaluate the late consequences of tumor treatments on vertebrae in survivors of childhood brain tumors. Methods 72 adult survivors (mean age 27.8 years, standard deviation 6.7) of irradiated childhood brain tumor were studied by spinal magnetic resonance imaging (MRI) for vertebral abnormalities from the national cohort of Finland. Patients were treated in five university hospitals in Finland between the years 1970 and 2008. Subject height and weight were measured and body mass index (BMI) was calculated. The morphology and height/ depth ratio of the vertebrae in the middle of the kyphotic thoracic curvature (Th8) and lumbar lordosis (L3) were examined. Vertebrae were analyzed by Genant's semiquantative (SQ) method and spinal deformity index (SDI) was calculated. BMD was measured by using dual X-ray absorptiometry. Results 4.2% (3/72) of the patients had undiagnosed asymptomatic vertebral fracture and 5.6% (4/72) of patients had radiation- induced decreased vertebral body height. Male patients had flatter vertebrae compared with females. Patient age at the time of irradiation, BMI and irradiation area correlated to vertebral morphology differentially in males and females. BMD had no association with the vertebral shape. Patients who had received craniospinal irradiation were shorter than the general population. Conclusion Childhood brain tumor survivors had a high number of vertebral abnormalities in young adulthood. Irradiation was associated with abnormal vertebral morphology and compromised final height. Male gender may predispose vertebrae to the side effects of irradiation.	[Jussila, Miro-Pekka; Niinimaki, Jaakko; Suo-Palosaari, Maria] Univ Oulu, Res Unit Med Imaging Phys & Technol, Fac Med, Oulu, Finland; [Jussila, Miro-Pekka; Niinimaki, Jaakko; Suo-Palosaari, Maria; Ojaniemi, Marja] Univ Oulu, Med Res Ctr, Oulu, Finland; [Remes, Tiina; Anttonen, Julia; Pokka, Tytti; Rantala, Heikki; Ojaniemi, Marja] Oulu Univ Hosp, Dept Pediat & Adolescence, Oulu, Finland; [Remes, Tiina; Anttonen, Julia; Pokka, Tytti; Rantala, Heikki; Ojaniemi, Marja] Oulu Univ Hosp, PEDEGO Res Unit, Oulu, Finland; [Remes, Tiina; Anttonen, Julia; Niinimaki, Jaakko; Pokka, Tytti; Rantala, Heikki; Suo-Palosaari, Maria; Ojaniemi, Marja] Univ Oulu, Oulu, Finland; [Harila-Saari, Arja] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden; [Niinimaki, Jaakko; Suo-Palosaari, Maria] Oulu Univ Hosp, Dept Diagnost Radiol, Oulu, Finland; [Koskenkorva, Paivi; Sutela, Anna] Kuopio Univ Hosp, Dept Clin Radiol, Kuopio, Finland; [Toiviainen-Sale, Sanna] Univ Helsinki, Dept Pediat Radiol, HUS Med Imaging Ctr, Radiol, Helsinki, Finland; [Toiviainen-Sale, Sanna] Helsinki Univ Hosp, Helsinki, Finland; [Arikoski, Pekka; Riikonen, Pekka] Kuopio Univ Hosp, Dept Pediat & Adolescence, Kuopio, Finland; [Arikoski, Pekka; Riikonen, Pekka] Univ Eastern Finland, Kuopio, Finland; [Arola, Mikko] Tampere Univ Hosp, Dept Pediat, Tampere, Finland; [Arola, Mikko] Univ Tampere, Fac Med & Life Sci, Tampere, Finland; [Lahteenmaki, Paivi] Turku Univ Hosp, Dept Pediat & Adolescent Med, Turku, Finland; [Lahteenmaki, Paivi] Turku Univ, Turku, Finland; [Sirkia, Kirsti] Helsinki Univ Hosp, Dept Pediat & Adolescence, Helsinki, Finland	University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Oulu; Uppsala University; University of Oulu; Kuopio University Hospital; University of Eastern Finland; Hyvinkaan Sairaala; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Kuopio University Hospital; University of Eastern Finland; University of Eastern Finland; Tampere University; Tampere University Hospital; Tampere University; University of Turku; University of Turku; University of Helsinki; Helsinki University Central Hospital	Ojaniemi, M (corresponding author), Univ Oulu, Med Res Ctr, Oulu, Finland.; Ojaniemi, M (corresponding author), Oulu Univ Hosp, Dept Pediat & Adolescence, Oulu, Finland.; Ojaniemi, M (corresponding author), Oulu Univ Hosp, PEDEGO Res Unit, Oulu, Finland.; Ojaniemi, M (corresponding author), Univ Oulu, Oulu, Finland.	marja.ojaniemei@oulu.fi	Harila-Saari, Arja/E-2124-2014; Remes, Tiina/CAG-3378-2022	Harila-Saari, Arja/0000-0003-2767-5828; Jussila, Miro-Pekka/0000-0002-4105-975X; Anttonen, Julia/0000-0002-4949-6997; Niinimaki, Jaakko/0000-0002-5591-3726; Remes, Tiina/0000-0003-4318-5343; Lahteenmaki, Paivi Maria/0000-0002-5500-9606	Special State Grants for Health Research in the Department of Pediatrics and Adolescence, Oulu University Hospital, Finland; Vare Foundation for Pediatric Cancer Research, Finland; Paivikki and Sakari Sohlberg Foundation, Finland; Arvo and Lea Ylppo Foundation, Finland; Foundation for Pediatric Research, Finland; Cancer Society of Finland; Thelma Makikyro Foundation, Finland; Cancer Foundation of Northern Finland; Alma and K. A. Snellman Foundation, Finland; Foundation of the Marta Donner Foundation, Finland	Special State Grants for Health Research in the Department of Pediatrics and Adolescence, Oulu University Hospital, Finland; Vare Foundation for Pediatric Cancer Research, Finland; Paivikki and Sakari Sohlberg Foundation, Finland; Arvo and Lea Ylppo Foundation, Finland; Foundation for Pediatric Research, Finland; Cancer Society of Finland; Thelma Makikyro Foundation, Finland; Cancer Foundation of Northern Finland; Alma and K. A. Snellman Foundation, Finland; Foundation of the Marta Donner Foundation, Finland	This work was supported by Special State Grants for Health Research in the Department of Pediatrics and Adolescence, Oulu University Hospital, Finland (http://www.ppshp.fi) (TR); Vare Foundation for Pediatric Cancer Research, Finland (http://vareensaatio.fi/) (M-PJ TR); the Paivikki and Sakari Sohlberg Foundation, Finland (http://www.pss-saatio.fi/english.htm) (TR); the Arvo and Lea Ylppo Foundation, Finland (http://www.alys.fi/) (TR); the Foundation for Pediatric Research, Finland (http://www.lastentautientutkimussaatio.fi/) (TR); the Cancer Society of Finland (https://www.cancersociety.fi/) (MO HR); the Thelma Makikyro Foundation, Finland (TR); the Cancer Foundation of Northern Finland (https://www.pohjois-suomensyopayhdistys.fi/) (TR); the Alma and K. A. Snellman Foundation, Finland (https://www.snellmansaatio.fi) (MO TR); and Foundation of the Marta Donner Foundation, Finland (TR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baxter NN, 2005, JAMA-J AM MED ASSOC, V294, P2587, DOI 10.1001/jama.294.20.2587; Briot K, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen-2014-000014; Brownstein CM, 2004, J CLIN ENDOCR METAB, V89, P4422, DOI 10.1210/jc.2004-0160; Carey Dennis E, 2015, Adolesc Med State Art Rev, V26, P291; Cohen LE, 2012, PEDIATR BLOOD CANCER, V58, P959, DOI 10.1002/pbc.23300; Davies JH, 2005, CLIN ENDOCRINOL, V63, P1, DOI 10.1111/j.1365-2265.2005.02263.x; Galloway TJ, 2012, AM J CLIN ONCOL-CANC, V35, P279, DOI 10.1097/COC.0b013e318210f533; GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915; Guglielmi G, 2008, EUR RADIOL, V18, P1484, DOI 10.1007/s00330-008-0899-8; Gurney JG, 2003, CANCER-AM CANCER SOC, V97, P663, DOI 10.1002/cncr.11095; Han JW, 2015, PEDIATR BLOOD CANCER, V62, P1838, DOI 10.1002/pbc.25581; Harindhanavudhi T, 2018, J INVEST MED, V66, P980, DOI 10.1136/jim-2018-000738; Hartley KA, 2008, INT J RADIAT ONCOL, V70, P1343, DOI 10.1016/j.ijrobp.2007.08.085; Hoorweg-Nijman JJG, 1999, CLIN ENDOCRINOL, V50, P237, DOI 10.1046/j.1365-2265.1999.00654.x; Hopewell JW, 2003, MED PEDIATR ONCOL, V41, P208, DOI 10.1002/mpo.10338; Il Yu J, 2015, RADIOTHER ONCOL, V114, P384, DOI 10.1016/j.radonc.2015.02.016; International Society for Clinical Densitometry, 2015, OFF POS 2015 AD PED; Janicka A, 2007, J CLIN ENDOCR METAB, V92, P143, DOI 10.1210/jc.2006-0794; Jaremko JL, 2015, PEDIATR RADIOL, V45, P593, DOI 10.1007/s00247-014-3210-y; Katz JR, 2001, ARCH DIS CHILD, V84, P436, DOI 10.1136/adc.84.5.436; Klein Gordon L, 2015, Osteoporos Sarcopenia, V1, P39, DOI 10.1016/j.afos.2015.07.008; Kumar R, 1988, Radiographics, V8, P455; Lai JS, 2007, CHILD NERV SYST, V23, P47, DOI 10.1007/s00381-006-0176-6; Laprie A, 2015, CANCER RADIOTHER, V19, P775, DOI 10.1016/j.canrad.2015.05.028; Lerner SE, 2004, J CLIN ENDOCR METAB, V89, P6100, DOI 10.1210/jc.2004-1515; Mitchell MJ, 1998, RADIOGRAPHICS, V18, P1125, DOI 10.1148/radiographics.18.5.9747611; Mitchell RM, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657-017-0363-y; Ng LW, 2018, INT J RAD ONCOL BIOL; Palermo A, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13060544; Pandya NA, 2001, ARCH DIS CHILD, V85, P492, DOI 10.1136/adc.85.6.492; Petraroli M, 2007, CHILD NERV SYST, V23, P59, DOI 10.1007/s00381-006-0175-7; Remes TM, 2018, ACTA ONCOL, V27, P1; Saari A, 2011, ANN MED, V43, P235, DOI 10.3109/07853890.2010.515603; Seo GH, 2018, J NEURO-ONCOL, V138, P55, DOI 10.1007/s11060-018-2765-0; SHALET SM, 1987, ARCH DIS CHILD, V62, P461, DOI 10.1136/adc.62.5.461; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; TESTER WJ, 1984, J CLIN ONCOL, V2, P762, DOI 10.1200/JCO.1984.2.7.762; van Niekerk G, 2018, CYTOKINE GROWTH FACT; Willey JS, 2011, CLIN REV BONE MINER, V9, P54, DOI 10.1007/s12018-011-9092-8	39	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 18	2018	13	12							e0209193	10.1371/journal.pone.0209193	http://dx.doi.org/10.1371/journal.pone.0209193			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE9MF	30562369	Green Published, gold			2023-01-03	WOS:000453774100042
J	Chagomerana, MB; Miller, WC; Tang, JH; Hoffman, IF; Harrington, BJ; DiPrete, B; Wallie, S; Jumbe, A; Limarzi, L; Hosseinipour, MC				Chagomerana, Maganizo B.; Miller, William C.; Tang, Jennifer H.; Hoffman, Irving F.; Harrington, Bryna J.; DiPrete, Bethany; Wallie, Shaphil; Jumbe, Allan; Limarzi, Laura; Hosseinipour, Mina C.			Prevalence of antiretroviral therapy treatment failure among HIV-infected pregnant women at first antenatal care: PMTCT Option B plus in Malawi	PLOS ONE			English	Article							DRUG-RESISTANCE; INITIATION; RETENTION; SUPPRESSION; VIREMIA; RISK; ART	Background In Malawi's PMTCT Option B+ program, HIV-infected pregnant women who are already receiving ART are continued on their current therapy regimen without testing for treatment failure at the first antenatal care (ANC) visit. HIV RNA screening at ANC may identify women with treatment failure and ensure that viral suppression is maintained throughout the pregnancy. Methods We conducted a cross-sectional study of HIV-infected pregnant women who had been receiving ART for at least 6 months at the first ANC visit under the PMTCT Option B+ program at Bwaila Hospital in Lilongwe, Malawi from June 2015 to December 2017. Poisson regression models with robust variance were used to investigate the predictors of ART treatment failure defined as viral load >= 1000 copies/ml. Results The median age of 864 women tested for ART failure was 31.1 years (interquartile range: 26.9-34.5). The prevalence of treatment failure was 7.6% (95% confidence interval (CI): 6.0-9.6). CD4 cell count (adjusted prevalence ratio (aPR) = 0.57; 95% CI: 0.50-0.65) was strongly associated with treatment failure. Conclusion The low prevalence of treatment failure among women presenting for their first ANC in urban Malawi demonstrates success of Option B+ in maintaining viral suppression and suggests progress towards the last 90% of the UNAIDS 90-90-90 targets. Women failing on ART should be identified early for adherence counseling and may require switching to an alternative ART regimen.	[Chagomerana, Maganizo B.; Tang, Jennifer H.; Hoffman, Irving F.; Harrington, Bryna J.; Wallie, Shaphil; Jumbe, Allan; Limarzi, Laura; Hosseinipour, Mina C.] UNC Project Malawi, Kamuzu Cent Hosp, Lilongwe, Malawi; [Miller, William C.] Ohio State Univ, Coll Publ Hlth, Div Epidemiol, Columbus, OH 43210 USA; [Tang, Jennifer H.] Univ North Carolina Chapel Hill, Dept Obstet & Gynecol, Chapel Hill, NC USA; [Hoffman, Irving F.; Hosseinipour, Mina C.] Univ North Carolina Chapel Hill, Dept Med, Chapel Hill, NC USA; [Harrington, Bryna J.; DiPrete, Bethany] Univ North Carolina Chapel Hill, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA	University System of Ohio; Ohio State University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Chagomerana, MB (corresponding author), UNC Project Malawi, Kamuzu Cent Hosp, Lilongwe, Malawi.	mchagomerana@unclilongwe.org	Miller, William C/H-4800-2014; Tang, Jennifer/K-9974-2017	Miller, William C/0000-0002-1934-7827; Tang, Jennifer/0000-0003-4238-2791	National Institutes of Health [P30 AI50410, R01 HD080485, F30 MH111370, T32 GM008719, R25 TW009340]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD080485] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [R25TW009340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI050410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F30MH111370] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by the National Institutes of Health (grant numbers P30 AI50410 (MBC), R01 HD080485 (MCH), F30 MH111370 (BJH), T32 GM008719 (BJH), and R25 TW009340 (BJH)). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by the National Institutes of Health (grant numbers P30 AI50410, R01 HD080485, F30 MH111370, T32 GM008719 and R25 TW009340). We would like to thank all "Option B+: ART Safety and Durability during First and Subsequent Pregnancies (S4)" study participants. Special thanks to the ever-enthusiastic S4 study team for their support.	Aziz N, 2013, BJOG-INT J OBSTET GY, V120, P1534, DOI 10.1111/1471-0528.12226; Babo YD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187694; Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21; Boerma RS, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.21140; Bulage L, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2428-3; Chimbwandria F, 2013, MMWR-MORBID MORTAL W, V62, P148; Evans DH, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19139; Gill MM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168671; Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9; Gupta-Wright A, 2018, URINE BASED SCREENIN; Haas AD, 2016, LANCET HIV, V3, pE175, DOI 10.1016/S2352-3018(16)00008-4; Hakim J, 2017, NEW ENGL J MED, V377, P233, DOI 10.1056/NEJMoa1615822; Hosseinipour M, 2017, JAIDS-J ACQ IMM DEF, V75, pS149, DOI 10.1097/qai.0000000000001368; Kityo C, 2016, AIDS RES HUM RETROV, V32, P628, DOI [10.1089/AID.2015.0215, 10.1089/aid.2015.0215]; Koss CA, 2017, JAIDS-J ACQ IMM DEF, V74, P279, DOI 10.1097/QAI.0000000000001228; Lesosky M, 2017, J INT AIDS SOC, V20, P26, DOI 10.1002/jia2.25000; Lyons FE, 2005, AIDS, V19, P63, DOI 10.1097/00002030-200501030-00007; Manasa J, 2016, AIDS RES HUM RETROV, V32, P763, DOI [10.1089/aid.2015.0225, 10.1089/AID.2015.0225]; MOH, 2016, INT HIV PROGR REP JA; Mutagoma M, 2016, ANTIVIR THER, V21, P247, DOI 10.3851/IMP2999; Myer L, 2017, HIV MED, V18, P80, DOI 10.1111/hiv.12397; Myer L, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002375; Myer L, 2017, CLIN INFECT DIS, V64, P422, DOI 10.1093/cid/ciw792; Onywera H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171124; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; Republic of Malawi MoH, 2014, MAL GUID CLIN MAN HI; Republic of Malawi MoH, 2016, MAL GUID CLIN MAN HI; Republic of Malawi MoH, 2010, INT HIV PROGR Q REP, P2010; Republic of Malawi MoH, 2017, INT HIV PROGR Q REP; Republic of Malawi MoH, 2016, INT HIV PROGR Q REP; Steegen K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166305; Sun GW, 1996, J CLIN EPIDEMIOL, V49, P907, DOI 10.1016/0895-4356(96)00025-X; Tenthani L, 2014, AIDS, V28, P589, DOI 10.1097/QAD.0000000000000143; UNAIDS, 2014, 90 90 90 AMB TREATM, P33; UNAIDS, 2014, THE GAP REP; Uy J, 2009, JAIDS-J ACQ IMM DEF, V51, P450, DOI 10.1097/QAI.0b013e3181acb630; Wadonda-Kabondo N, 2017, 9 INT AIDS SOC C HIV; World Health Organization, 2016, CONS GUID US ANT DRU; Zeh C, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000430; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	40	9	9	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2018	13	12							e0209052	10.1371/journal.pone.0209052	http://dx.doi.org/10.1371/journal.pone.0209052			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE3IL	30543685	Green Published, gold, Green Submitted			2023-01-03	WOS:000453247500067
J	Masa, JF; Mokhlesi, B; Benitez, I; de Terreros, FJG; Sanchez-Quiroga, MA; Romero, A; Caballero-Eraso, C; Teran-Santos, J; Alonso-Alvarez, ML; Troncoso, MF; Gonzalez, M; Lopez-Martin, S; Marin, JM; Marti, S; Diaz-Cambriles, T; Chiner, E; Egea, C; Barca, J; Vazquez-Polo, FJ; Negrin, MA; Martel-Escobar, M; Barbe, F; Corral, J; Fernandez, G; Ordax-Carbajo, E; Gonzalez-Mangado, N; Gomez-Garcia, T; Martinez-Martinez, MA; Ojeda-Castillejo, E; Padilla, DL; Carrizo, PJ; Gallego, B; Pallero, M; Romero, O; Ramon, MA; Arias, E; Munoz-Mendez, J; Senent, C; Sancho-Chust, JN; Soriano, NBN; Barrot, E; Benitez, JM; Sanchez-Gomez, J; Golpe, R; Santiago-Recuerda, A; Gomez, S; Bengoa, M				Masa, Juan F.; Mokhlesi, Babak; Benitez, Ivan; Gomez de Terreros, Francisco Javier; Angeles Sanchez-Quiroga, Maria; Romero, Auxiliadora; Caballero-Eraso, Candela; Teran-Santos, Joaquin; Luz Alonso-Alvarez, Maria; Troncoso, Maria F.; Gonzalez, Monica; Lopez-Martin, Soledad; Marin, Jose M.; Marti, Sergi; Diaz-Cambriles, Trinidad; Chiner, Eusebi; Egea, Carlos; Barca, Javier; Jose Vazquez-Polo, Francisco; Negrin, Miguel A.; Martel-Escobar, Maria; Barbe, Ferran; Corral, Jaime; Fernandez, Galo; Ordax-Carbajo, Estrella; Gonzalez-Mangado, Nicolas; Gomez-Garcia, Teresa; Martinez-Martinez, Maria-Angeles; Ojeda-Castillejo, Elena; Lopez Padilla, Daniel; Carrizo, PSantiago J.; Gallego, Begona; Pallero, Mercedes; Romero, Odile; Antonia Ramon, Maria; Arias, Eva; Munoz-Mendez, Jesus; Senent, Cristina; Sancho-Chust, Jose N.; Navarro Soriano, Nieves Belen; Barrot, Emilia; Benitez, Jose M.; Sanchez-Gomez, Jesus; Golpe, Rafael; Santiago-Recuerda, Ana; Gomez, Silvia; Bengoa, Monica		Spanish Sleep Network	Long-term clinical effectiveness of continuous positive airway pressure therapy versus non-invasive ventilation therapy in patients with obesity hypoventilation syndrome: a multicentre, open-label, randomised controlled trial	LANCET			English	Article							MECHANICAL VENTILATION; RESPIRATORY-FAILURE; PREVALENCE; ADHERENCE; EFFICACY; SUPPORT; IMPACT; CPAP	Background Obesity hypoventilation syndrome is commonly treated with continuous positive airway pressure or noninvasive ventilation during sleep. Non-invasive ventilation is more complex and costly than continuous positive airway pressure but might be advantageous because it provides ventilatory support. To date there have been no longterm trials comparing these treatment modalities. We therefore aimed to determine the long-term comparative effectiveness of both treatment modalities. Methods We did a multicentre, open-label, randomised controlled trial at 16 clinical sites in Spain. We included patients aged 15-80 years with untreated obesity hypoventilation syndrome and an apnoea-hypopnoea index of 30 or more events per h. We randomly assigned patients, using simple randomisation through an electronic database, to receive treatment with either non-invasive ventilation or continuous positive airway pressure. Both investigators and patients were aware of the treatment allocation. The research team was not involved in deciding hospital treatment, duration of treatment in the hospital, and adjustment of medications, as well as adjudicating cardiovascular events or cause of mortality. Treating clinicians from the routine care team were not aware of the treatment allocation. The primary outcome was the number of hospitalisation days per year. The analysis was done according to the intention-to-treat principle. This study is registered with ClinicalTrials. gov, number NCT01405976. Findings From May 4, 2009, to March 25, 2013, 100 patients were randomly assigned to the non-invasive ventilation group and 115 to the continuous positive airway pressure group, of which 97 patients in the non-invasive ventilation group and 107 in the continuous positive airway pressure group were included in the analysis. The median follow-up was 5.44 years (IQR 4.45-6.37) for all patients, 5.37 years (4.36-6.32) in the continuous positive airway pressure group, and 5.55 years (4.53-6.50) in the non-invasive ventilation group. The mean hospitalisation days per patient-year were 1.63 (SD 3.74) in the continuous positive airway pressure group and 1.44 (3.07) in the non-invasive ventilation group (adjusted rate ratio 0.78, 95% CI 0.34-1.77; p= 0.561). Adverse events were similar between both groups. Interpretation In stable patients with obesity hypoventilation syndrome and severe obstructive sleep apnoea, noninvasive ventilation and continuous positive airway pressure have similar long-term effectiveness. Given that continuous positive airway pressure has lower complexity and cost, continuous positive airway pressure might be the preferred first-line positive airway pressure treatment modality until more studies become available.	[Masa, Juan F.; Gomez de Terreros, Francisco Javier; Corral, Jaime] San Pedro de Alcantara Hosp, Resp Dept, Caceres 10004, Spain; [Mokhlesi, Babak] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Benitez, Ivan; Barbe, Ferran] Inst Recerca Biomed LLeida IRBLLEIDA, Resp Dept, Lleida, Spain; [Angeles Sanchez-Quiroga, Maria] Virgen del Puerto Hosp, Resp Dept, Plasencia, Caceres, Spain; [Masa, Juan F.; Benitez, Ivan; Gomez de Terreros, Francisco Javier; Angeles Sanchez-Quiroga, Maria; Romero, Auxiliadora; Caballero-Eraso, Candela; Teran-Santos, Joaquin; Luz Alonso-Alvarez, Maria; Troncoso, Maria F.; Marin, Jose M.; Marti, Sergi; Diaz-Cambriles, Trinidad; Egea, Carlos; Barbe, Ferran; Corral, Jaime] CIBER Enfermedades Resp CIBERES, Madrid, Spain; [Masa, Juan F.; Gomez de Terreros, Francisco Javier; Angeles Sanchez-Quiroga, Maria; Barca, Javier; Corral, Jaime] Inst Univ Invest Biosanitaria Extremadura INUBE, Caceres, Spain; [Romero, Auxiliadora; Caballero-Eraso, Candela] Univ Seville, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla IBiS, Unidad Medicoquirurg Enfermedades Resp, Seville, Spain; [Teran-Santos, Joaquin; Luz Alonso-Alvarez, Maria] Univ Hosp, Resp Dept, Burgos, Spain; [Troncoso, Maria F.] IIS Fdn Jimenez Diaz, Resp Dept, Madrid, Spain; [Gonzalez, Monica] Valdecilla Hosp, Resp Dept, Santander, Spain; [Lopez-Martin, Soledad] Gregorio Maranon Hosp, Resp Dept, Madrid, Spain; [Marin, Jose M.] Miguel Servet Hosp, Resp Dept, Zaragoza, Spain; [Marti, Sergi] ValldHebron Hosp, Resp Dept, Barcelona, Spain; [Diaz-Cambriles, Trinidad] Doce Octubre Hosp, Resp Dept, Madrid, Spain; [Chiner, Eusebi] San Juan Hosp, Resp Dept, Alicante, Spain; [Egea, Carlos] Alava Univ Hosp IRB, Resp Dept, Vitoria, Spain; [Barca, Javier] Extremadura Univ, Nursing Dept, Caceres, Spain; [Jose Vazquez-Polo, Francisco; Negrin, Miguel A.; Martel-Escobar, Maria] Las Palmas de Gran Canarias Univ Canary Isl, Dept Quantitat Methods, Las Palmas Gran Canaria, Las Palmas, Spain	University of Chicago; Institut de Recerca Biomedica - IRB Lleida; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; Fundacion Jimenez Diaz; Hospital Universitario Marques de Valdecilla (HUMV); General University Gregorio Maranon Hospital; Miguel Servet University Hospital; Hospital Universitario 12 de Octubre; Universidad de Extremadura	Masa, JF (corresponding author), San Pedro de Alcantara Hosp, Resp Dept, Caceres 10004, Spain.; Masa, JF (corresponding author), CIBER Enfermedades Resp CIBERES, Madrid, Spain.	fmasa@separ.es	GONZALEZ, MONICA/AAM-4033-2021; Sancho-Chust, Jose N./ABH-5025-2020; Romero, Odile/N-8109-2015; Vázquez-Polo, F.J./AAE-3635-2019; corral, jaime/S-1675-2019; Polo, Francisco José Vázquez/C-9730-2009; Barbé, Ferran/A-5988-2010; Chiner, Eusebi/AAM-5120-2020; Benítez, Iván David/AAI-9379-2020; Golpe, Rafael/AAA-4736-2019; Martel-Escobar, Maria/L-2013-2017	GONZALEZ, MONICA/0000-0003-1516-0181; Romero, Odile/0000-0002-0147-596X; corral, jaime/0000-0003-0353-0114; Polo, Francisco José Vázquez/0000-0002-0632-6138; Barbé, Ferran/0000-0002-2340-8928; Golpe, Rafael/0000-0002-3759-5322; Egea, Carlos/0000-0002-7618-7444; Martel-Escobar, Maria/0000-0002-7013-4747; BARCA DURAN, JAVIER/0000-0002-3532-8255; Ramon, Maria A/0000-0002-4856-8442; Munoz Mendez, Jesus/0000-0003-0363-0916; Marin Trigo, Jose Maria/0000-0001-9096-2294; Caballero-Eraso, Candela/0000-0002-6428-0027; Sancho-Chust, Jose N./0000-0002-3028-0715; Benitez, Ivan David/0000-0002-3558-5948; Troncoso, M Fernanda/0000-0003-4525-5499	Instituto de Salud Carlos III, Spanish Respiratory Foundation; Air Liquide Spain	Instituto de Salud Carlos III, Spanish Respiratory Foundation; Air Liquide Spain	Instituto de Salud Carlos III, Spanish Respiratory Foundation, and Air Liquide Spain.	BaHammam AS, 2015, SAUDI MED J, V36, P911, DOI 10.15537/smj.2015.8.11716; Basoglu OK, 2014, CLIN RESPIR J, V8, P167, DOI 10.1111/crj.12054; Berg G, 2001, CHEST, V120, P377, DOI 10.1378/chest.120.2.377; Berger KI, 2001, CHEST, V120, P1231, DOI 10.1378/chest.120.4.1231; Biring MS, 1999, AM J MED SCI, V318, P293, DOI 10.1097/00000441-199911000-00002; Borel JC, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0052006, 10.1371/journal.pone.0052004]; Borel JC, 2012, CHEST, V141, P692, DOI 10.1378/chest.10-2531; Bouloukaki I, 2018, J CLIN SLEEP MED, V14, P1539, DOI 10.5664/jcsm.7332; Carrillo A, 2012, AM J RESP CRIT CARE, V186, P1279, DOI 10.1164/rccm.201206-1101OC; Carter JR, 2016, AM J PHYSIOL-REG I, V310, pR602, DOI 10.1152/ajpregu.00516.2015; Castro-Anon O, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117808; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; de Lucas-Ramos P, 2004, RESP MED, V98, P961, DOI 10.1016/j.rmed.2004.03.014; Garcia-Rio F, 2013, ARCH BRONCONEUMOL, V49, P388, DOI 10.1016/j.arbres.2013.04.001; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Heinemann F, 2007, RESP MED, V101, P1229, DOI 10.1016/j.rmed.2006.10.027; Howard ME, 2017, THORAX, V72, P437, DOI 10.1136/thoraxjnl-2016-208559; Janssens JP, 2003, CHEST, V123, P67, DOI 10.1378/chest.123.1.67; Jennum P, 2011, THORAX, V66, P560, DOI 10.1136/thx.2010.143958; Kushida CA, 2008, J CLIN SLEEP MED, V4, P157; LEECH J, 1991, CHEST, V100, P1334, DOI 10.1378/chest.100.5.1334; Lopez-Jimenez MJ, 2016, ARCH BRONCONEUMOL, V52, P158, DOI 10.1016/j.arbres.2015.10.003; Macavei VM, 2013, J CLIN SLEEP MED, V9, P879, DOI 10.5664/jcsm.2986; MACGREGOR MI, 1970, JOHNS HOPKINS MED J, V126, P279; MAHLER DA, 1984, CHEST, V85, P751, DOI 10.1378/chest.85.6.751; Marik PE, 2016, OBES SCI PRACT, V2, P40, DOI 10.1002/osp4.27; Masa JF, 2004, AM J RESP CRIT CARE, V170, P1218, DOI 10.1164/rccm.200312-1787OC; Masa JF, 2001, CHEST, V119, P1102, DOI 10.1378/chest.119.4.1102; Masa JF, 2016, J CLIN SLEEP MED, V12, P1379, DOI 10.5664/jcsm.6194; Masa JF, 2016, THORAX, V71, P899, DOI 10.1136/thoraxjnl-2016-208501; Masa JF, 2015, AM J RESP CRIT CARE, V192, P86, DOI 10.1164/rccm.201410-1900OC; Masa JF, 2011, SLEEP BREATH, V15, P549, DOI 10.1007/s11325-010-0399-3; MILLER A, 1974, AM J MED, V56, P144, DOI 10.1016/0002-9343(74)90591-9; Mokhlesi Babak, 2008, Proc Am Thorac Soc, V5, P218, DOI 10.1513/pats.200708-122MG; Mokhlesi B, 2006, J CLIN SLEEP MED, V2, P57; Murphy PB, 2012, THORAX, V67, P727, DOI 10.1136/thoraxjnl-2011-201081; Nowbar S, 2004, AM J MED, V116, P1, DOI 10.1016/j.amjmed.2003.08.022; Castillejo EO, 2015, ARCH BRONCONEUMOL, V51, P61, DOI 10.1016/j.arbres.2014.02.015; Piper AJ, 2008, THORAX, V63, P395, DOI 10.1136/thx.2007.081315; Priou P, 2010, CHEST, V138, P84, DOI 10.1378/chest.09-2472; Ramirez-Molina VR, 2017, COPD, V14, P418, DOI 10.1080/15412555.2017.1317730; Rochester DF, 1998, HEART AND LUNG IN OBESITY, P109; Salord N, 2013, RESPIROLOGY, V18, P1135, DOI 10.1111/resp.12131; Trakada GP, 2010, SLEEP BREATH, V14, P381, DOI 10.1007/s11325-010-0360-5; Tsolaki V, 2011, RESPIRATION, V81, P402, DOI 10.1159/000317138; Weitzenblum E, 2002, Rev Pneumol Clin, V58, P83; Weitzenblum E, 1999, SLEEP MED REV, V3, P79, DOI 10.1016/S1087-0792(99)90015-1; Windisch W, 2008, EUR RESPIR J, V32, P1328, DOI 10.1183/09031936.00066407; ZWILLICH CW, 1975, AM J MED, V59, P343, DOI 10.1016/0002-9343(75)90392-7; 2012, RESPIROLOGY, V17, P1269, DOI DOI 10.1111/J.1440-1843.2012.02252.X; 2005, CHEST, V128, P587; 2007, J INTERN MED, V261, P375, DOI DOI 10.1111/J.1365-2796.2007.01765.X; 2001, CHEST, V120, P369	54	74	75	1	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 27	2019	393	10182					1721	1732		10.1016/S0140-6736(18)32978-7	http://dx.doi.org/10.1016/S0140-6736(18)32978-7			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV8PQ	30935737				2023-01-03	WOS:000466244500030
J	Griffiths, LJ; Cortina-Borja, M; Tingay, K; Bandyopadhyay, A; Akbari, A; DeStavola, BL; Bedford, H; Lyons, RA; Dezateux, C				Griffiths, Lucy J.; Cortina-Borja, Mario; Tingay, Karen; Bandyopadhyay, Amrita; Akbari, Ashley; DeStavola, Bianca L.; Bedford, Helen; Lyons, Ronan A.; Dezateux, Carol			Are active children and young people at increased risk of injuries resulting in hospital admission or accident and emergency department attendance? Analysis of linked cohort and electronic hospital records in Wales and Scotland	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; EXTREMITY INJURIES; SCHOOL RUGBY; AGED 6-12; HEALTH; BEHAVIORS; CONTACT	Introduction Children and young people (CYP) are encouraged to increase time spent being physically active, especially in moderate and vigorous intensity pursuits. However, there is limited evidence on the prospective association of activity levels with injuries resulting in use of hospital services. We examined the relationship between objectively-measured physical activity (PA) and subsequent injuries resulting in hospital admissions or accident and emergency department (A&E) attendances, using linked electronic hospital records (EHR) from a nationally representative prospective cohort of CYP in Wales and Scotland. Methods We analysed accelerometer-based estimates of moderate to vigorous (MVPA) and vigorous PA (VPA) from 1,585 (777 [46%] boys) seven-year-old Millennium Cohort Study members, living in Wales or Scotland, whose parents consented to linkage of cohort records to EHRs up until their 14th birthday. Negative binomial regression models adjusted by potential individual, household and area-level confounders, were fitted to estimate associations between average daily minutes of MVPA, and VPA (in 10-minute increments), and number of injury-related hospital admissions and/or A&E attendances from age nine to 14 years. Results CYP spent a median of 59.5 and 18.1 minutes in MVPA and VPA/day respectively, with boys significantly more active than girls; 47.3% of children experienced at least one injury-related admission or A&E attendance during the study period. Rates of injury-related hospital admission and/or A&E attendance were positively associated with MVPA and VPA in boys but not in girls: respective adjusted incidence rate ratios (95% CI) for boys: 1.09 (1.01, 1.17) and 1.16 (1.00, 1.34), and for girls: 0.94 (0.86, 1.03) and 0.85 (0.69, 1.04). Conclusion Boys but not girls who engage in more intense PA at age seven years are at higher risk of injury-related hospital admission or A&E attendance when aged nine to 14 years than their less active peers. This may reflect gender differences in the type and associated risks of activities undertaken. EHRs can make a useful contribution to injury surveillance and prevention if routinely augmented with information on context and setting of the injuries sustained. Injury prevention initiatives should not discourage engagement in PA and outdoor play given their over-riding health and social benefits.	[Griffiths, Lucy J.; Akbari, Ashley; Lyons, Ronan A.] Swansea Univ, Med Sch, Hlth Data Res UK, Swansea, W Glam, Wales; [Griffiths, Lucy J.; Bedford, Helen; Dezateux, Carol] UCL Great Ormond St Inst Child Hlth, Life Course Epidemiol & Biostat, London, England; [Cortina-Borja, Mario; DeStavola, Bianca L.] UCL Great Ormond St Inst Child Hlth, Clin Epidemiol Nutr & Biostat, London, England; [Tingay, Karen; Akbari, Ashley] Swansea Univ, Med Sch, Adm Data Res Ctr Wales, Swansea, W Glam, Wales; [Bandyopadhyay, Amrita; Lyons, Ronan A.] Swansea Univ, Med Sch, Natl Ctr Populat Hlth & Wellbeing Res, Swansea, W Glam, Wales; [Dezateux, Carol] Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Primary Care & Publ Hlth, London, England; [Dezateux, Carol] Queen Mary Univ London, Hlth Data Res UK London, London, England	Swansea University; University of London; University College London; University of London; University College London; Swansea University; Swansea University; University of London; Queen Mary University London; University of London; Queen Mary University London	Griffiths, LJ (corresponding author), Swansea Univ, Med Sch, Hlth Data Res UK, Swansea, W Glam, Wales.; Griffiths, LJ (corresponding author), UCL Great Ormond St Inst Child Hlth, Life Course Epidemiol & Biostat, London, England.	lucy.griffiths@swansea.ac.uk	Borja, Mario Cortina/A-3847-2009	Borja, Mario Cortina/0000-0003-0627-2624; Griffiths, Lucy/0000-0001-9230-624X; Dezateux, Carol/0000-0001-9787-6276; Akbari, Ashley/0000-0003-0814-0801	Wellcome Trust [087389/B/08/Z]; Health Data Research UK - UK Medical Research Council; Engineering and Physical Sciences Research Council; Economic and Social Research Council; National Institute for Health Research (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Public Health Agency (Northern Ireland); British Heart Foundation; Wellcome; Asthma UK Centre for Applied Research [AUK-AC-2012-01]; ESRC [ES/L007444/1]; Health and Social Care Research and Development Division (Welsh Government); Economic and Social Research Council [ES/L007444/1] Funding Source: researchfish; MRC [MR/M024881/1] Funding Source: UKRI	Wellcome Trust(Wellcome TrustEuropean Commission); Health Data Research UK - UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); National Institute for Health Research (England)(National Institute for Health Research (NIHR)); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Public Health Agency (Northern Ireland); British Heart Foundation(British Heart Foundation); Wellcome; Asthma UK Centre for Applied Research; ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Health and Social Care Research and Development Division (Welsh Government); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the Wellcome Trust (grant number 087389/B/08/Z) to RAL. LJG, CD, RAL and AA are supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, National Institute for Health Research (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome. RAL is also funded by the Asthma UK Centre for Applied Research (AUK-AC-2012-01). KT is supported by an ESRC award establishing the Administrative Data Research Centre Wales (ES/L007444/1). The Millennium Cohort Study [http://dx.doi.org/10.14301/llcs.v7i4.410] is funded by grants to the Centre for Longitudinal Studies at the Institute of Education from the Economic and Social Research Council and a consortium of government departments. This research benefited from funding awarded to the NIHR Great Ormond Street Hospital Biomedical Research Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.	Ball D.J., 2013, MANAGING RISK PLAY P, V2nd ed.; Brussoni M, 2015, INT J ENV RES PUB HE, V12, P6423, DOI 10.3390/ijerph120606423; Bull FC, 2010, PHYS ACT GUID UK REV; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; Connelly R, 2014, INT J EPIDEMIOL, V43, P1719, DOI 10.1093/ije/dyu001; Corder K, 2007, CURR OPIN CLIN NUTR, V10, P597, DOI 10.1097/MCO.0b013e328285d883; Department for Children Schools and Families, 2009, ACC PREV CYP PRIOR R; Ford DV, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-157; Gill T, 2018, PLAYING IT SAFE GLOB; Griffiths LJ, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002893; Hallal PC, 2012, LANCET, V380, P247, DOI 10.1016/S0140-6736(12)60646-1; Harmon Katherine J, 2018, Inj Epidemiol, V5, P23, DOI 10.1186/s40621-018-0152-0; Idler N, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1721-6; Janssen I, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-40; Jespersen E, 2015, SCAND J MED SCI SPOR, V25, P251, DOI 10.1111/sms.12177; Jones KH, 2014, J BIOMED INFORM, V50, P196, DOI 10.1016/j.jbi.2014.01.003; Kirk SFL, 2013, PUBLIC HEALTH NUTR, V16, P358, DOI 10.1017/S1368980012002728; Kirkwood G, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5337; Kwon S, 2012, INT J BEHAV NUTR PHY, V9, DOI 10.1186/1479-5868-9-68; Kyu HH, 2016, JAMA PEDIATR, V170, P267, DOI 10.1001/jamapediatrics.2015.4276; LAFLAMME L, 2010, J PEDIAT, DOI DOI 10.1155/2010/819687; Lyons R A, 1999, Inj Prev, V5, P129; Lyons RA, 2016, INJURY PREV, V22, P50, DOI 10.1136/injuryprev-2015-041814; Lyons RA, 2009, BMC MED INFORM DECIS, V9, DOI 10.1186/1472-6947-9-3; Lyons RA, 2010, INT J INJ CONTROL SA, V17, P145, DOI 10.1080/17457300903453104; Malina RM, 1996, RES Q EXERCISE SPORT, V67, pS48, DOI 10.1080/02701367.1996.10608853; Mattila V, 2004, EUR J EPIDEMIOL, V19, P437, DOI 10.1023/B:EJEP.0000027355.85493.cb; National Institute for Health and Care Excellence, 2010, UN INJ PREV STRAT 15; Nauta J, 2017, SCAND J MED SCI SPOR, V27, P93, DOI 10.1111/sms.12617; Nauta J, 2015, SPORTS MED, V45, P327, DOI 10.1007/s40279-014-0289-0; NHS Digital, SCCI0092 2062 COMM D; NHS Digital, EM CAR DAT SET ECDS; Petushek EJ, 2019, AM J SPORT MED, V47, P1744, DOI 10.1177/0363546518782460; Pollock AM, 2017, BRIT J SPORT MED, V51, P1113, DOI 10.1136/bjsports-2016-096996; Pollock AM, 2016, BRIT J SPORT MED, V50, P963, DOI 10.1136/bjsports-2016-096220; Pulsford RM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021822; Rich C, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002290; Rich C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085134; Rich C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067206; Smith D, 2015, INJURY, V46, P1131, DOI 10.1016/j.injury.2014.12.029; Spinks AB, 2006, INJURY PREV, V12, P390, DOI 10.1136/ip.2006.011502; Sugimoto D, 2012, J ATHL TRAINING, V47, P714, DOI 10.4085/1062-6050-47.6.10; Verhagen E, 2009, BRIT J SPORT MED, V43, P1031, DOI 10.1136/bjsm.2008.055483; World Health Organization, 2018, GLOB ACT PLAN PHYS A; World Health Organization, 2004, ICD 10 INT STAT CLAS	45	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 10	2019	14	4							e0213435	10.1371/journal.pone.0213435	http://dx.doi.org/10.1371/journal.pone.0213435			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HS6PA	30969971	gold, Green Published, Green Submitted			2023-01-03	WOS:000463992600008
J	Moyo, P; Zhao, XH; Thorpe, CT; Thorpe, JM; Sileanu, FE; Cashy, JP; Hale, JA; Mor, MK; Radomski, TR; Donohue, JM; Hausmann, LRM; Hanlon, JT; Good, CB; Fine, MJ; Gellad, WF				Moyo, Patience; Zhao, Xinhua; Thorpe, Carolyn T.; Thorpe, Joshua M.; Sileanu, Florentina E.; Cashy, John P.; Hale, Jennifer A.; Mor, Maria K.; Radomski, Thomas R.; Donohue, Julie M.; Hausmann, Leslie R. M.; Hanlon, Joseph T.; Good, Chester B.; Fine, Michael J.; Gellad, Walid F.			Dual Receipt of Prescription Opioids From the Department of Veterans Affairs and Medicare Part D and Prescription Opioid Overdose Death Among Veterans A Nested Case-Control Study	ANNALS OF INTERNAL MEDICINE			English	Article							UNITED-STATES; SYSTEM USE; HEALTH; RISK; CARE; ADJUSTMENT; MORTALITY; ENROLLEES; BENEFITS; IMPACT	Background: More than half of enrollees in the U.S. Department of Veterans Affairs (VA) are also covered by Medicare and can choose to receive their prescriptions from VA or from Medicare-participating providers. Such dual-system care may lead to unsafe opioid use if providers in these 2 systems do not coordinate care or if prescription use is not tracked between systems. Objective: To evaluate the association between dual-system opioid prescribing and death from prescription opioid overdose. Design: Nested case-control study. Setting: VA and Medicare Part D. Participants: Case and control patients were identified from all veterans enrolled in both VA and Part D who filled at least 1 opioid prescription from either system. The 215 case patients who died of a prescription opioid overdose in 2012 or 2013 were matched (up to 1: 4) with 833 living control patients on the basis of date of death (that is, index date), using age, sex, race/ethnicity, disability, enrollment in Medicaid or low-income subsidies, managed care enrollment, region and rurality of residence, and a medication-based measure of comorbid conditions. Measurements: The exposure was the source of opioid prescriptions within 6 months of the index date, categorized as VA only, Part D only, or VA and Part D (that is, dual use). The outcome was unintentional or undetermined-intent death from prescription opioid overdose, identified from the National Death Index. The association between this outcome and source of opioid prescriptions was estimated using conditional logistic regression with adjustment for age, marital status, prescription drug monitoring programs, and use of other medications. Results: Among case patients, the mean age was 57.3 years (SD, 9.1), 194 (90%) were male, and 181 (84%) were non-Hispanic white. Overall, 60 case patients (28%) and 117 control patients (14%) received dual opioid prescriptions. Dual users had significantly higher odds of death from prescription opioid overdose than those who received opioids from VA only (odds ratio [OR], 3.53 [95% CI, 2.17 to 5.75]; P < 0.001) or Part D only (OR, 1.83 [CI, 1.20 to 2.77]; P = 0.005). Limitation: Data are from 2012 to 2013 and cannot capture prescriptions obtained outside the VA or Medicare Part D systems. Conclusion: Among veterans enrolled in VA and Part D, dual use of opioid prescriptions was independently associated with death from prescription opioid overdose. This risk factor for fatal overdose among veterans underscores the importance of care coordination across health care systems to improve opioid prescribing safety. Primary Funding Source: U. S. Department of Veterans Affairs.	[Moyo, Patience] Brown Univ, Sch Publ Hlth, 121 South Main St,Box G-S121-6, Providence, RI 02912 USA; [Zhao, Xinhua; Sileanu, Florentina E.; Cashy, John P.; Hale, Jennifer A.; Mor, Maria K.; Hausmann, Leslie R. M.; Fine, Michael J.; Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr 151C,Bldg 30, Pittsburgh, PA 15240 USA; [Thorpe, Carolyn T.; Thorpe, Joshua M.; Radomski, Thomas R.; Donohue, Julie M.] VA Pittsburgh Healthcare Syst, Univ Dr 151C, Pittsburgh, PA 15240 USA; [Thorpe, Carolyn T.; Thorpe, Joshua M.] Univ N Carolina, Eshelman Sch Pharm, Div Pharmaceut Outcomes & Policy, 301 Pharm Lane, Chapel Hill, NC 27599 USA; [Mor, Maria K.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA; [Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Public Hlth Bldg,130 De Soto St, Pittsburgh, PA 15261 USA; [Radomski, Thomas R.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, 200 Lothrop St, Pittsburgh, PA 15213 USA; [Hausmann, Leslie R. M.; Good, Chester B.; Fine, Michael J.; Gellad, Walid F.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Hanlon, Joseph T.] Univ Pittsburgh, Hlth Policy Inst, Ctr Pharmaceut Policy & Prescribing, 311 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA; [Good, Chester B.] UPMC Hlth Plan, Ctr Value Based Pharmaceut Initiat, 600 Grant St, Pittsburgh, PA 15219 USA	Brown University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; University of North Carolina; University of North Carolina Chapel Hill; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gellad, WF (corresponding author), VA Pittsburgh Healthcare Syst, Univ Dr 151C, Pittsburgh, PA 15240 USA.	walid.gellad@va.gov		Hausmann, Leslie/0000-0002-3909-6009; Radomski, Thomas/0000-0002-7279-188X	VA Health Services Research Development [I01 HX001765-01]; VA Information Resource Center [SDR 02-237, 98-004]; Veterans Affairs [I01HX001765, I01HX002237] Funding Source: NIH RePORTER	VA Health Services Research Development(US Department of Veterans Affairs); VA Information Resource Center; Veterans Affairs(US Department of Veterans Affairs)	By grant I01 HX001765-01 from VA Health Services Research & Development. Support for VA-Centers for Medicare & Medicaid Services data is provided by VA, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource Center (project numbers SDR 02-237 and 98-004).	Bohnert ASB, 2012, AM J PSYCHIAT, V169, P64, DOI 10.1176/appi.ajp.2011.10101476; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Bohnert ASB, 2011, MED CARE, V49, P393, DOI 10.1097/MLR.0b013e318202aa27; Britton PC, 2010, DRUG ALCOHOL DEPEN, V107, P51, DOI 10.1016/j.drugalcdep.2009.09.005; Byrne MM, 2006, MED CARE, V44, P768, DOI 10.1097/01.mlr.0000218786.44722.14; Carico R, 2018, ANN INTERN MED, V169, P593, DOI 10.7326/M18-0852; Cowper DC, 2002, ANN EPIDEMIOL, V12, P462, DOI 10.1016/S1047-2797(01)00285-X; Department of Veterans Affairs, 2015, Fed Regist, V80, P66419; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Fink DS, 2018, ANN INTERN MED, V168, P783, DOI 10.7326/M17-3074; Gellad WF, 2018, AM J PUBLIC HEALTH, V108, P248, DOI [10.2105/ajph.2017.304174, 10.2105/AJPH.2017.304174]; Gellad WF, 2017, JAMA INTERN MED, V177, P611, DOI 10.1001/jamainternmed.2017.0147; Gellad WF, 2017, SUBST ABUS, V38, P22, DOI 10.1080/08897077.2016.1267071; Gellad WF, 2016, J GEN INTERN MED, V31, P153, DOI 10.1007/s11606-015-3492-2; Gellad WF, 2015, JAMA INTERN MED, V175, P26, DOI 10.1001/jamainternmed.2014.5405; Gomes T, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002396; Huang G., 2018, 2017 SURVEY VET ENRO; Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI 10.1001/jama.2013.272; Kabiri M, 2017, HEALTHCARE-J DEL SCI, V5, P105, DOI 10.1016/j.hjdsi.2016.11.001; Kizer KW, 2012, JAMA-J AM MED ASSOC, V307, P789, DOI 10.1001/jama.2012.196; Kupfer J, 2018, ANN INTERN MED, V169, P487, DOI 10.7326/M18-1539; Lin LWA, 2017, PAIN, V158, P833, DOI 10.1097/j.pain.0000000000000837; Minegishi T, 2018, J GEN INTERN MED, V33, P781, DOI 10.1007/s11606-018-4352-7; Morgan RO, 2009, AM J MANAG CARE, V15, pE1; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P897, DOI 10.15585/mmwr.mm6634a2; Oliva EM, 2017, PSYCHOL SERV, V14, P34, DOI 10.1037/ser0000099; Park TW, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2698; Passik Steven D, 2014, J Opioid Manag, V10, P263, DOI 10.5055/jom.2014.0214; Pizer SD, 2011, INQUIRY-J HEALTH CAR, V48, P109, DOI 10.5034/inquiryjrnl_48.02.02; Prescription Drug Abuse Policy System, 2016, PDMP REP AUTH US; Psaty BM, 1999, J AM GERIATR SOC, V47, P749, DOI 10.1111/j.1532-5415.1999.tb01603.x; Radomski TR, 2017, J GEN INTERN MED, V32, P967, DOI 10.1007/s11606-017-4064-4; Radomski TR, 2016, JAMA-J AM MED ASSOC, V316, P345, DOI 10.1001/jama.2016.5391; Radomski TR, 2016, J GEN INTERN MED, V31, P524, DOI 10.1007/s11606-016-3631-4; Robards J, 2012, MATURITAS, V73, P295, DOI 10.1016/j.maturitas.2012.08.007; Rosen AK, 2005, AM J MED QUAL, V20, P182, DOI 10.1177/1062860605275791; Ruhm CJ, 2018, ADDICTION, V113, P1339, DOI 10.1111/add.14144; Schneeweiss S, 2006, PHARMACOEPIDEM DR S, V15, P291, DOI 10.1002/pds.1200; Stroupe KT, 2013, AM J HEALTH-SYST PH, V70, P804, DOI 10.2146/ajhp120222; Suda KJ, 2017, J AM PHARM ASSOC, V57, P333, DOI 10.1016/j.japh.2017.02.018; Thorpe CT, 2018, HEALTH SERV RES, V53, P5375, DOI 10.1111/1475-6773.13055; Thorpe JM, 2017, ANN INTERN MED, V166, P157, DOI 10.7326/M16-0551; Trivedi AN, 2012, JAMA-J AM MED ASSOC, V308, P67, DOI 10.1001/jama.2012.7115; Warner M, 2013, ACAD FORENSIC PATHOL, V3, P231, DOI [DOI 10.23907/2013.029, 10.23907/2013.029]; Webster LR, 2011, PAIN MED, V12, pS26, DOI 10.1111/j.1526-4637.2011.01134.x; West AN, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1069-8; Wong ES, 2016, MED CARE RES REV, V73, P493, DOI 10.1177/1077558715617382; Zedler B, 2015, PAIN MED, V16, P1566, DOI 10.1111/pme.12777	48	18	18	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 2	2019	170	7					433	+		10.7326/M18-2574	http://dx.doi.org/10.7326/M18-2574			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HR3WA	30856660	Green Accepted			2023-01-03	WOS:000463070700002
J	Tegegn, HG; Erku, DA; Sebsibe, G; Gizaw, B; Seifu, D; Tigabe, M; Belachew, SA; Ayele, AA				Tegegn, Henok Getachew; Erku, Daniel Asfaw; Sebsibe, Girum; Gizaw, Biruktawit; Seifu, Dawit; Tigabe, Masho; Belachew, Sewunet Admasu; Ayele, Asnakew Achaw			Medication-related quality of life among Ethiopian elderly patients with polypharmacy: A cross-sectional study in an Ethiopia university hospital	PLOS ONE			English	Article							CONTROLLED-TRIAL; OLDER-PEOPLE; HEALTH; CARE; OUTPATIENTS; MANAGEMENT; ADHERENCE	Polypharmacy among older patients has been associated with a decline in their quality of life. We aimed to assess the medication-related quality of life (MRQOL) among older patients with polypharmacy at Gondar University Hospital, Gondar, Ethiopia. A prospective cross-sectional study was carried out among 150 elder patients who had visited the internal medicine ward and ambulatory ward of Gondar referral hospital from March 25 to May 15, 2017, using a validated scale, Medication-Related Quality of Life Scale version 1.0 (MRQoLS-v1.0). A total of 150 older patients with polypharmacy participated in the study with a mean age of 70.06 +/- 5.12, andtwo-thirds of the participants (67.3%) were female. The overall prevalence of poor quality of life due to polypharmacy in the current study was found to be three fourth (75.3%) of the participants. Regarding the severity of impairment in MRQoL, Univariate analysis revealed that frequency of hospital visits (COR = 1.34, 95% CI, 1.02-1.77) and medication number (COR = 1.94, 95% CI, 1.33, 2.8) had a statistically significant positive association with the likelihood of having a severe impairment.The multivariate analysis also showed that one unit increase in the number of hospital visits (AOR = 1.45, 95% CI, 1.040-2.024) and medications greater than 5 (AOR = 1.91, 95% CI, 1.29, 2.84) increases 1.45 and 1.91 times the likely hood of posing severe impairment of MRQoL, respectively. As far as poor MRQoL quality of life is concerned, multivariate analysis did not show any significant association between the poor MRQoL;and Sociodemographic and clinical data of patients. The poor QoL associated with medication was very high in this study. Deprescribing should be sought by the health care providers to optimize drug therapy and minimize the polypharmacy related poor quality of life.	[Tegegn, Henok Getachew; Erku, Daniel Asfaw; Sebsibe, Girum; Gizaw, Biruktawit; Seifu, Dawit; Tigabe, Masho; Belachew, Sewunet Admasu; Ayele, Asnakew Achaw] Univ Gondar, Dept Clin Pharm, Gondar, Amhara, Ethiopia	University of Gondar	Tegegn, HG (corresponding author), Univ Gondar, Dept Clin Pharm, Gondar, Amhara, Ethiopia.	heniget@gmail.com	Erku, Daniel/AAC-1508-2020; Tegegn, Henok Getachew/C-2469-2016	Erku, Daniel/0000-0002-8878-0317; Tegegn, Henok Getachew/0000-0003-0644-0958; Ayele, Asnakew/0000-0001-7837-7228; Admasu Belachew, Sewunet/0000-0002-1050-8188				Azpiazu Garrido M, 2003, ATEN PRIM, V31, P285; Bushardt RL, 2008, CLIN INTERV AGING, V3, P383, DOI 10.2147/CIA.S2468; Casado J, 2001, Aten Primaria, V28, P167; Chang YC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128356; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; Chew BH, 2015, QUAL LIFE RES, V24, P2723, DOI 10.1007/s11136-015-1006-7; Chumney Elinor C., 2006, Pharmacy Pract (Granada), V4, P103, DOI 10.4321/s1885-642x2006000300001; de Rivas B, 2008, QUAL LIFE RES, V17, P1229, DOI 10.1007/s11136-008-9397-3; Ferrer A, 2010, MED CLIN-BARCELONA, V134, P303, DOI 10.1016/j.medcli.2009.06.070; Hajjar Emily R, 2007, Am J Geriatr Pharmacother, V5, P345, DOI 10.1016/j.amjopharm.2007.12.002; Hanlon JT, 1996, AM J MED, V100, P428, DOI 10.1016/S0002-9343(97)89519-8; Henderson JA, 2006, J APPL GERONTOL, V25, p89S, DOI 10.1177/0733464805283035; HERRMAN H, 1993, QUAL LIFE RES, V2, P153; Holt EW, 2010, AGE AGEING, V39, P481, DOI 10.1093/ageing/afq040; Zamora-Sanchez JJ, 2012, ENFERM CLIN, V22, P239, DOI 10.1016/j.enfcli.2012.04.009; Jyrkka J, 2011, PHARMACOEPIDEM DR S, V20, P514, DOI 10.1002/pds.2116; Krska J, 2001, AGE AGEING, V30, P205, DOI 10.1093/ageing/30.3.205; Lalic S, 2016, EUR J CLIN PHARMACOL, V72, P1117, DOI 10.1007/s00228-016-2075-4; Machon M, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-016-0410-3; Makai P, 2014, SOC SCI MED, V102, P83, DOI 10.1016/j.socscimed.2013.11.050; Moen J, 2009, ANN PHARMACOTHER, V43, P1978, DOI 10.1345/aph.1M354; Montiel-Luque A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171320; National Institute of Mental Health, 2018, DEPRESSION; Ong GJ, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.321; Page AT, 2016, RES SOC ADMIN PHARM, V12, P438, DOI 10.1016/j.sapharm.2015.08.011; Page AT, 2016, MATURITAS, V91, P115, DOI 10.1016/j.maturitas.2016.06.006; Parekh N, 2017, THER ADV DRUG SAF, V8, P117, DOI 10.1177/2042098616682721; Patterson SM, 2014, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008165.pub3, 10.1002/14651858.CD008165.pub4]; Reeve E, 2014, BRIT J CLIN PHARMACO, V78, P738, DOI 10.1111/bcp.12386; Riker Gretchen I, 2012, Home Healthc Nurse, V30, P474, DOI 10.1097/NHH.0b013e31826502dd; Rosso AL, 2013, J AM GERIATR SOC, V61, P371, DOI 10.1111/jgs.12147; Saleh F, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-431; Shafie Asrul Akmal, 2013, Value Health Reg Issues, V2, P107, DOI 10.1016/j.vhri.2013.02.005; Shumaker S, 1995, INT ASSESSMENT HLTH; Taylor CT, 2003, AM J HEALTH-SYST PH, V60, P1123, DOI 10.1093/ajhp/60.11.1123; Tegegn HG, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020590; Tseng HM, 2016, QUAL LIFE RES, V25, P1295, DOI 10.1007/s11136-015-1177-2; Van der Weele GM, 2009, INT J GERIATR PSYCH, V24, P595, DOI 10.1002/gps.2162; Ware JE, 1998, J CLIN EPIDEMIOL, V51, P903, DOI 10.1016/S0895-4356(98)00081-X; Wiebe S, 2003, J CLIN EPIDEMIOL, V56, P52, DOI 10.1016/S0895-4356(02)00537-1	40	13	13	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2019	14	3							e0214191	10.1371/journal.pone.0214191	http://dx.doi.org/10.1371/journal.pone.0214191			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HQ7IR	30921379	Green Published, gold, Green Submitted			2023-01-03	WOS:000462594000037
J	Rodriguez-Garcia, CM; Ruiz-Ruiz, JC; Peraza-Echeverria, L; Peraza-Sanchez, SR; Torres-Tapia, LW; Perez-Brito, D; Tapia-Tussell, R; Herrera-Chale, FG; Segura-Campos, MR; Quijano-Ramayo, A; Ramon-Sierras, JM; Ortiz-Vazquez, E				Monica Rodriguez-Garcia, Cecilia; Carlos Ruiz-Ruiz, Jorge; Peraza-Echeverria, Leticia; Ruben Peraza-Sanchez, Sergio; Wiliunfo Torres-Tapia, Luis; Perez-Brito, Daisy; Tapia-Tussell, Raul; Gilberto Herrera-Chale, Francisco; Rubi Segura-Campos, Maira; Quijano-Ramayo, Andres; Manuel Ramon-Sierras, Jesus; Ortiz-Vazquez, Elizabeth			Antioxidant, antihypertensive, anti-hyperglycemic, and antimicrobial activity of aqueous extracts from twelve native plants of the Yucatan coast	PLOS ONE			English	Article							IN-VITRO; ANTIFUNGAL ACTIVITY; ALPHA-GLUCOSIDASE; MANILKARA-ZAPOTA; ANTIBACTERIAL; FLAVONOIDS; RESISTANCE; CHEMISTRY; AMYLASE	Looking for a biotechnical potential, aqueous extracts of leaves of 12 native species used in the Mayan traditional medicine of the coastal dune and mangrove of Yucatan (Mexico) were selected to evaluate their biological activities. Rhizophora mangle and Manilkara zapota showed the highest free radical scavenging activity (3.94 +/- 0.19 and 6.42 +/- 0.32 mu g/mL, respectively), and the highest antihypertensive activity was obtained from Solanum donianum (0.38 mu g/mL). The anti-hyperglycemic activity of these species was also tested; the highest activities were registered with R. mangle. The antimicrobial activity of Malvaviscus arboreus, S. donianum, M. zapota, and R. mangle at 10% (w/v) was positive against six human pathogenic bacteria and Bonellia macrocarpa against one pathogenic fungus. Solanum donianum, M. zapota, B. macrocarpa, and R. mangle were positive against two pathogenic plant fungi. These results show that the aqueous extracts of five native plants of the Yucatan coast have potential as antioxidants, ACE inhibitors, alpha-amylase and alpha-glucosidase inhibitors, and as antimicrobials, which make their exploration for utilization in the agricultural and pharmaceutical industries a possibility.	[Monica Rodriguez-Garcia, Cecilia; Peraza-Echeverria, Leticia; Ruben Peraza-Sanchez, Sergio; Wiliunfo Torres-Tapia, Luis; Gilberto Herrera-Chale, Francisco] Ctr Invest Cient Yucatan AC, Unidad Biotecnol, Merida, Yucatan, Mexico; [Carlos Ruiz-Ruiz, Jorge] Inst Tecnol Merida, Dept Ingn Quim Bioquim, Merida, Yucatan, Mexico; [Perez-Brito, Daisy; Tapia-Tussell, Raul; Quijano-Ramayo, Andres] Ctr Invest Cient Yucatan AC, GEMBIO, Merida, Yucatan, Mexico; [Rubi Segura-Campos, Maira] Univ Autonoma Yucatan, Fac Ingn Quim, Merida, Yucatan, Mexico; [Manuel Ramon-Sierras, Jesus; Ortiz-Vazquez, Elizabeth] Inst Tecnol Merida, Div Estudios Postgrad & Invest, Merida, Yucatan, Mexico; [Carlos Ruiz-Ruiz, Jorge] Univ Anahuac Mayab, Div Ciencias Salud, Escuela Nutr, Merida, Yucatan, Mexico; [Tapia-Tussell, Raul] Ctr Invest Cient Yucatan AC, Unidad Energia Renovable, Merida, Yucatan, Mexico; [Gilberto Herrera-Chale, Francisco] Inst Tecnol Super Progreso, Yucatan, Mexico	Centro de Investigacion Cientifica de Yucatan; Centro de Investigacion Cientifica de Yucatan; Universidad Autonoma de Yucatan; Centro de Investigacion Cientifica de Yucatan	Rodriguez-Garcia, CM (corresponding author), Ctr Invest Cient Yucatan AC, Unidad Biotecnol, Merida, Yucatan, Mexico.	koyi@cicy..mx	Ortiz-Vázquez, Elizabeth/GPJ-9528-2022; Segura-Campos, Maira Rubi/AAS-4880-2020; Perez-Brito, Daisy/F-7358-2019	Ortiz-Vázquez, Elizabeth/0000-0002-2881-2110; Perez-Brito, Daisy/0000-0003-2116-0065; Segura Campos, Maira Rubi/0000-0002-7664-6647; Ramon Sierra, Jesus Manuel/0000-0001-7773-190X; Rodriguez-Garcia, Cecilia Monica/0000-0002-4568-5125	National Council of Science and Technology of Mexico (Conacyt) [164458, 22650]	National Council of Science and Technology of Mexico (Conacyt)(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	The research was supported by the National Council of Science and Technology of Mexico (Conacyt, grant #164458) and a postdoctoral fellowship for Francisco G. Herrera (#22650).	Abu Osman M, 2011, INT J DRUG DEV RES, V3, P185; Ajith P. S., 2012, The Journal of Plant Protection Sciences, V4, P13; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andrade-Cetto A., 2015, PHARMACOLOGYONLINE, V1, P67; Bari MA, 2010, INT J AGRIC BIOL, V12, P386; Bautista F, 2015, ECOSIS RECUR AGROPEC, V2, P303; Castillo S, 1998, ACTA BOT MEX, V45, P55, DOI DOI 10.21829/ABM45.1998.812; Chanda SV, 2010, NAT SCI, V8, P260; CONAGUA, 2014, COORD GEN SERV MET N; Croft KD, 1998, ANN NY ACAD SCI, V854, P435, DOI 10.1111/j.1749-6632.1998.tb09922.x; Cruz S.M., 2015, INT J PHYTOCOSMET NA, V2, P12, DOI [10.15171/ijpni.2015.12, DOI 10.15171/IJPNI.2015.12]; Dewanto V, 2002, J AGR FOOD CHEM, V50, P3010, DOI 10.1021/jf0115589; DINESHKUMAR B., 2010, INT J ADV PHARM SCI, V1, P75, DOI DOI 10.1021/jf060617l; Duran-Garcia R, 2014, COSTA ESTADO YUCATAN, V2, P95; Espejel I., 1984, BIOTICA, V9, P183; Ferry DR, 1996, CLIN CANCER RES, V2, P659; Garcia-Sosa K, 2011, NAT PROD RES, V25, P1185, DOI 10.1080/14786419.2010.511215; George S, 2005, J AGR FOOD CHEM, V53, P1370, DOI 10.1021/jf048396b; HAYAKARI M, 1978, ANAL BIOCHEM, V84, P361, DOI 10.1016/0003-2697(78)90053-2; Indhumathi T., 2014, International Journal of Current Microbiology and Applied Sciences, V3, P939; Kaneria Mital, 2012, Asian Pacific Journal of Tropical Biomedicine, V2, pS1526; Kannan M., 2012, Journal of Pharmacy Research, V5, P2418; Kathiresan K, 2001, ADV MAR BIOL, V40, P81, DOI 10.1016/S0065-2881(01)40003-4; Kazeem MI, 2013, TROP J PHARM RES, V12, P719, DOI 10.4314/tjpr.v12i5.9; Kwon EK, 2010, J AGR FOOD CHEM, V58, P882, DOI 10.1021/jf903515f; Mahadev R, 2014, DON INT J PHARM SCI, V4, P507; Martin GJ, 1995, ETHNOBOTANY PEOPLE P, P96; Martinez JL, 2008, SCIENCE, V321, P365, DOI 10.1126/science.1159483; Meda A, 2005, FOOD CHEM, V91, P571, DOI 10.1016/j.foodchem.2004.10.006; Medina-Medrano JR, 2016, J CHEM BIOL PHYS SCI, V4, P1135; Mendez-Gonzalez M, 2012, FLORA MED MAYAS PENI; Monk BC, 2008, SCIENCE, V321, P367, DOI 10.1126/science.1159746; Montes de Oca N., 2001, Revista de Salud Animal, V23, P1; Nair R, 2008, INDIAN J PHARM SCI, V70, P390, DOI 10.4103/0250-474X.43012; Nair S.S., 2013, EUR J EXP BIOL, V3, P128; Pan YM, 2004, FOOD CHEM, V88, P347, DOI 10.1016/j.foodchem.2004.02.002; PARISH RC, 1992, DRUG SAFETY, V7, P14, DOI 10.2165/00002018-199207010-00004; Peraza-Echeverria L, 2008, AUSTRALAS PLANT PATH, V37, P460, DOI 10.1071/AP08042; Pérez Bueno Tania, 2011, Rev Cubana Plant Med, V16, P94; Rajeev Kumar, 2010, Der Pharmacia Lettre, V2, P273; Romero Gonzalez R. R, 2011, THESIS; Ruiz-Ruiz J. C., 2016, Journal of Plant Pathology and Microbiology, V7, P332; Russell PE, 2006, PLANT PATHOL, V55, P585, DOI 10.1111/j.1365-3059.2006.01440.x; Russell PE, 2005, J AGR SCI-CAMBRIDGE, V143, P11, DOI 10.1017/S0021859605004971; Sarker S.D., 2006, METHODS BIOTECHNOLOG, V20, P1; Sharififar F, 2009, FOOD CHEM, V112, P885, DOI 10.1016/j.foodchem.2008.06.064; Siddesha JM, 2011, NAT PROD RES, V25, P1931, DOI 10.1080/14786419.2010.497962; Stevenson DE, 2007, CELL MOL LIFE SCI, V64, P2900, DOI 10.1007/s00018-007-7237-1; Tapia-Tussell R, 2006, MOL BIOTECHNOL, V33, P67; Torres W, 2010, B SOC BOT MEX, V86, P37; Tsao R, 2010, NUTRIENTS, V2, P1231, DOI 10.3390/nu2121231; Vera-Ku M, 2015, INT J INDIGENOUS MED, V48, P1793; Yasunaka K, 2005, J ETHNOPHARMACOL, V97, P293, DOI 10.1016/j.jep.2004.11.014	54	18	18	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2019	14	3							e0213493	10.1371/journal.pone.0213493	http://dx.doi.org/10.1371/journal.pone.0213493			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ5PT	30917135	Green Published, Green Submitted, gold			2023-01-03	WOS:000462465800033
J	Tsujikawa, H; Tanaka, S; Matsukuma, Y; Kanai, H; Torisu, K; Nakano, T; Tsuruya, K; Kitazono, T				Tsujikawa, Hiroaki; Tanaka, Shigeru; Matsukuma, Yuta; Kanai, Hidetoshi; Torisu, Kumiko; Nakano, Toshiaki; Tsuruya, Kazuhiko; Kitazono, Takanari			Development of a risk prediction model for infection-related mortality in patients undergoing peritoneal dialysis	PLOS ONE			English	Article							RESIDUAL RENAL-FUNCTION; SERUM-ALBUMIN; LIPID-LEVELS; ASSOCIATION; SURVIVAL; OUTCOMES; PROTEIN; INFLAMMATION; NUTRITION; MODALITY	Background Assessment of infection-related mortality remains inadequate in patients undergoing peritoneal dialysis. This study was performed to develop a risk model for predicting the 2-year infection-related mortality risk in patients undergoing peritoneal dialysis. Methods The study cohort comprised 606 patients who started and continued peritoneal dialysis for 90 at least days and was drawn from the Fukuoka Peritoneal Dialysis Database Registry Study in Japan. The patients were registered from 1 January 2006 to 31 December 2016 and followed up until 31 December 2017. To generate a prediction rule, the score for each variable was weighted by the regression coefficients calculated using a Cox proportional hazard model adjusted by risk factors for infection-related mortality, including patient characteristics, comorbidities, and laboratory data. Results During the follow-up period (median, 2.2 years), 138 patients died; 58 of them of infectious disease. The final model for infection-related mortality comprises six factors: age, sex, serum albumin, serum creatinine, total cholesterol, and weekly renal Kt/V. The incidence of infection-related mortality increased linearly with increasing total risk score (P for trend < 0.001). Furthermore, the prediction model showed adequate discrimination (c-statistic = 0.79 [ 0.72-0.86]) and calibration (Hosmer-Lemeshow test, P = 0.47). Conclusion In this study, we developed a new model using clinical measures for predicting infection-related mortality in patients undergoing peritoneal dialysis.	[Tsujikawa, Hiroaki; Matsukuma, Yuta; Nakano, Toshiaki; Kitazono, Takanari] Kyushu Univ, Dept Med & Clin Sci, Fukuoka, Fukuoka, Japan; [Tanaka, Shigeru] Fukuoka Dent Coll, Fukuoka, Fukuoka, Japan; [Kanai, Hidetoshi] Kokura Mem Hosp, Fukuoka, Fukuoka, Japan; [Torisu, Kumiko; Tsuruya, Kazuhiko] Kyushu Univ, Dept Integrated Therapy Chron Kidney Dis, Fukuoka, Fukuoka, Japan; [Tsuruya, Kazuhiko] Nara Med Univ, Dept Nephrol, Nara, Japan	Kyushu University; Fukuoka Dental College (FDC); Kokura Memorial Hospital; Kyushu University; Nara Medical University	Nakano, T (corresponding author), Kyushu Univ, Dept Med & Clin Sci, Fukuoka, Fukuoka, Japan.	toshink@med.kyushu-u.ac.jp	Torisu, Kumiko/ABE-7626-2021					Cao XY, 2015, INT J MED SCI, V12, P354, DOI 10.7150/ijms.11694; Carrero JJ, 2007, AM J CLIN NUTR, V85, P695, DOI 10.1093/ajcn/85.3.695; Castrale C, 2010, NEPHROL DIAL TRANSPL, V25, P255, DOI 10.1093/ndt/gfp375; Chung SH, 2003, NEPHROL DIAL TRANSPL, V18, P590, DOI 10.1093/ndt/18.3.590; Collins Allan J, 2014, Am J Kidney Dis, V63, pA7, DOI 10.1053/j.ajkd.2013.11.001; den Hoedt CH, 2014, CLIN J AM SOC NEPHRO, V9, P318, DOI 10.2215/CJN.04470413; Eriguchi M, 2016, THER APHER DIAL, V20, P158, DOI 10.1111/1744-9987.12358; Foley RN, 2003, KIDNEY INT, V63, P1462, DOI 10.1046/j.1523-1755.2003.00860.x; Fouque D, 2008, KIDNEY INT, V73, P391, DOI 10.1038/sj.ki.5002585; Haapio M, 2017, KIDNEY INT REP, V2, P1176, DOI 10.1016/j.ekir.2017.06.019; Habib AN, 2006, NEPHROL DIAL TRANSPL, V21, P2881, DOI 10.1093/ndt/gfl272; Han SH, 2012, NAT REV NEPHROL, V8, P163, DOI 10.1038/nrneph.2012.12; Hemke AC, 2015, AM J NEPHROL, V42, P158, DOI 10.1159/000439181; Hemke AC, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-258; Johansson L, 2015, PERITON DIALYSIS INT, V35, P655, DOI 10.3747/pdi.2014.00343; Johnson DW, 2013, PERITON DIALYSIS INT, V33, P475, DOI 10.3747/pdi.2013.00191; Johnson DW, 2009, AM J KIDNEY DIS, V53, P290, DOI 10.1053/j.ajkd.2008.06.032; KESHAVIAH PR, 1994, J AM SOC NEPHROL, V4, P1475; Kitterer D, 2017, KIDNEY BLOOD PRESS R, V42, P276, DOI 10.1159/000477449; Landin M, 2017, SURG ENDOSC, V31, P917, DOI 10.1007/s00464-016-5055-y; Lee JE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185853; Liu YM, 2004, JAMA-J AM MED ASSOC, V291, P451, DOI 10.1001/jama.291.4.451; McCullough PA, 2010, AM J KIDNEY DIS, V55, pS1, DOI 10.1053/j.ajkd.2009.12.017; Mehrotra R, 2011, AM J KIDNEY DIS, V58, P418, DOI 10.1053/j.ajkd.2011.03.018; Moons KGM, 2002, J CLIN EPIDEMIOL, V55, P1054, DOI 10.1016/S0895-4356(02)00453-5; Nordio M, 2012, AM J KIDNEY DIS, V59, P819, DOI 10.1053/j.ajkd.2011.12.023; Obi Y, 2015, CURR OPIN CLIN NUTR, V18, P254, DOI 10.1097/MCO.0000000000000171; Park CH, 2017, J CLIN LIPIDOL, V11, P945, DOI 10.1016/j.jacl.2017.06.004; Park J, 2013, NEPHROL DIAL TRANSPL, V28, P2146, DOI 10.1093/ndt/gft213; Fontan MP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158696; Ribeiro SC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127453; Ros S, 2013, PERITON DIALYSIS INT, V33, P487, DOI 10.3747/pdi.2012.00243; Sarnak MJ, 2000, KIDNEY INT, V58, P1758, DOI 10.1111/j.1523-1755.2000.00337.x; SPIEGEL DM, 1994, AM J KIDNEY DIS, V23, P283, DOI 10.1016/S0272-6386(12)80985-1; Sullivan LM, 2004, STAT MED, V23, P1631, DOI 10.1002/sim.1742; Szeto CC, 1999, AM J KIDNEY DIS, V34, P1056, DOI 10.1016/S0272-6386(99)70011-9; Tsuruya K, 2017, RENAL REPLACEMENT TH, V3, DOI [10.1186/s41100-017-0126-7, DOI 10.1186/S41100-017-0126-7]; de Luijtgaarden MWM, 2016, NEPHROL DIAL TRANSPL, V31, P120, DOI 10.1093/ndt/gfv295; Wagner M, 2011, AM J KIDNEY DIS, V57, P894, DOI 10.1053/j.ajkd.2010.12.023; Wakasugi M, 2016, NEPHROL DIAL TRANSPL, V31, P1501, DOI 10.1093/ndt/gfw249; Wang AYM, 2005, AM J CLIN NUTR, V81, P79; Wang AYM, 2001, J AM SOC NEPHROL, V12, P2450, DOI 10.1681/ASN.V12112450; Yan XQ, 2017, KIDNEY BLOOD PRESS R, V42, P1225, DOI 10.1159/000485926; Yang X, 2013, DIABETES RES CLIN PR, V100, P354, DOI 10.1016/j.diabres.2013.03.030; Yu DH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20160-3; Yun T, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008421; Zhao C, 2014, EUR J CLIN INVEST, V44, P1095, DOI 10.1111/eci.12344	47	6	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2019	14	3							e0213922	10.1371/journal.pone.0213922	http://dx.doi.org/10.1371/journal.pone.0213922			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP6AW	30893369	Green Published, Green Submitted, gold			2023-01-03	WOS:000461765900060
J	van Schaik, L; Geertzen, JHB; Dijkstra, PU; Dekker, R				van Schaik, Loeke; Geertzen, Jan H. B.; Dijkstra, Pieter U.; Dekker, Rienk			Metabolic costs of activities of daily living in persons with a lower limb amputation: A systematic review and meta-analysis	PLOS ONE			English	Review							CONTROLLED PROSTHETIC KNEE; TO-STEP TRANSITION; QUALITY-OF-LIFE; ENERGY-EXPENDITURE; TRANSFEMORAL AMPUTEES; AEROBIC CAPACITY; WALKING ABILITY; HEART-RATE; OXYGEN-CONSUMPTION; OLDER-ADULTS	Objective To systematically review the literature on the metabolic costs of activities of daily living (ADL) in persons with a lower limb amputation (LLA). Data sources A literature search was undertaken in the Pubmed, Embase, CINAHL, CENTRAL, and Psy-cINFO databases using keywords and synonyms for LLA, metabolic costs, and ADL. The last search was performed on November 29 th, 2017. Study selection Studies were included if they met the following 2 criteria: participants were adults with a (unilateral or bilateral) LLA and metabolic costs were measured while participants performed a physical activity or ADL. Data extraction and synthesis Data of 1,912 participants from 61 studies were included in the systematic review and meta-analysis. The studies used different terms to describe metabolic costs. Participants were recruited in different settings, relatively healthy, with few comorbidities. Limited data were available on metabolic costs of other activities than walking with a prosthesis. A linear mixed model analysis was performed based on the means reported, with study as unit of analysis and test results of different groups and measurement conditions as repeated measures within the unit of analysis. Predictors entered in the analysis were e.g. level and reason of amputation, age, weight, and height. During walking, oxygen consumption (ml O-2/kg/min) and heart rate (beats/min) increased with a higher walking speed and a more proximal amputation. Additionally, oxygen consumption was determined by the interaction terms walking speed x amputation level and walking speed squared. Heart rate was determined by the interaction term walking speed squared. Conclusion During walking, oxygen consumption (ml O-2/kg/min) and heart rate (beats/min) increased with a higher walking speed and a more proximal amputation. Data on metabolic costs of other activities were limited. The poor quality of the studies and the relatively healthy participants limited generalizability of the results of the meta-analysis.	[van Schaik, Loeke; Geertzen, Jan H. B.; Dijkstra, Pieter U.; Dekker, Rienk] Univ Groningen, Univ Med Ctr Groningen, Dept Rehabil Med, Groningen, Netherlands; [Dijkstra, Pieter U.] Univ Groningen, Univ Med Ctr Groningen, Dept Oral & Maxillofacial Surg, Groningen, Netherlands	University of Groningen; University of Groningen	van Schaik, L (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Rehabil Med, Groningen, Netherlands.	L.van.Schaik@umcg.nl		van Schaik, Loeke/0000-0001-5288-1143				Ainsworth BE, 2011, MED SCI SPORT EXER, V43, P1575, DOI 10.1249/MSS.0b013e31821ece12; Andrysek J, 2017, DISABIL REHABIL-ASSI, V12, P378, DOI 10.3109/17483107.2016.1173730; Andrysek J, 2011, PROSTHET ORTHOT INT, V35, P163, DOI 10.1177/0309364611408495; Bell JC, 2014, CLIN ORTHOP RELAT R, V472, P3055, DOI 10.1007/s11999-014-3630-x; BOONSTRA AM, 1994, SCAND J REHABIL MED, V26, P217; Bussmann JBJ, 2004, EUR J APPL PHYSIOL, V91, P71, DOI 10.1007/s00421-003-0916-1; Bussmann JB, 2008, ARCH PHYS MED REHAB, V89, P430, DOI 10.1016/j.apmr.2007.11.012; Chin T, 2006, PROSTHET ORTHOT INT, V30, P73, DOI 10.1080/03093640500533414; Chin T, 2002, PROSTHET ORTHOT INT, V26, P44, DOI 10.1080/03093640208726620; Chin T, 2001, J REHABIL RES DEV, V38, P7; Chin T, 2006, AM J PHYS MED REHAB, V85, P992, DOI 10.1097/01.phm.0000247653.11780.0b; Cumming J, 2015, COCHRANE DATABASE SY, V2017; Datta D, 2005, CLIN REHABIL, V19, P398, DOI 10.1191/0269215505cr805oa; Delussu AS, 2016, EUR J PHYS REHAB MED, V52, P304; DUBOW LL, 1983, ARCH PHYS MED REHAB, V64, P255; Erjavec T, 2014, DISABIL REHABIL, V36, P1148, DOI 10.3109/09638288.2013.833307; Esposito ER, 2018, PROSTHET ORTHOT INT, V42, P214, DOI 10.1177/0309364617708649; Esposito ER, 2016, PROSTHET ORTHOT INT, V40, P311, DOI 10.1177/0309364614564021; Esposito ER, 2014, J REHABIL RES DEV, V51, P1287, DOI 10.1682/JRRD.2014.06.0141; Fleg JL, 2005, CIRCULATION, V112, P674, DOI 10.1161/CIRCULATIONAHA.105.545459; Fortington LV, 2013, PROSTHET ORTHOT INT, V37, P305, DOI 10.1177/0309364612469385; Fortington LV, 2012, J AM MED DIR ASSOC, V13, P319, DOI 10.1016/j.jamda.2010.12.097; GAILEY RS, 1994, PROSTHET ORTHOT INT, V18, P84; GAILEY RS, 1993, PROSTHET ORTHOT INT, V17, P95; GANGULI S, 1975, BIOMED ENG, V10, P52; GANGULI S, 1974, J APPL PHYSIOL, V36, P440, DOI 10.1152/jappl.1974.36.4.440; GANGULI S, 1973, ERGONOMICS, V16, P797, DOI 10.1080/00140137308924571; Gardinier ES, 2018, CLIN REHABIL, V32, P319, DOI 10.1177/0269215517723054; Genin JJ, 2008, EUR J APPL PHYSIOL, V103, P655, DOI 10.1007/s00421-008-0764-0; Gjovaag T, 2017, PROSTHET ORTHOT INT, V1, P1; Gjovaag T, 2014, PROSTHET ORTHOT INT, V38, P140, DOI 10.1177/0309364613490444; Goktepe AS, 2010, PROSTHET ORTHOT INT, V34, P31, DOI 10.3109/03093640903433928; Guirao L, 2017, PROSTHET ORTHOT INT, V41, P26, DOI 10.1177/0309364616633920; Hagberg K, 2007, DISABIL REHABIL, V29, P643, DOI 10.1080/09638280600902869; Hagberg K, 2011, PHYSIOTHER RES INT, V16, P92, DOI 10.1002/pri.477; Hamamura S, 2009, J INT MED RES, V37, P1921, DOI 10.1177/147323000903700630; Heller BW, 2000, CLIN REHABIL, V14, P518, DOI 10.1191/0269215500cr345oa; Hoffman MD, 1997, ARCH PHYS MED REHAB, V78, P385, DOI 10.1016/S0003-9993(97)90230-6; Houdijk H, 2009, GAIT POSTURE, V30, P35, DOI 10.1016/j.gaitpost.2009.02.009; HUANG CT, 1979, ARCH PHYS MED REHAB, V60, P18; ISAKOV E, 1985, SCAND J REHABIL MED, P108; JAEGERS SMHJ, 1993, ARCH PHYS MED REHAB, V74, P521, DOI 10.1016/0003-9993(93)90117-S; James U, 1973, Scand J Rehabil Med, V5, P71; Jarvis HL, 2017, ARCH PHYS MED REHAB, V98, P1389, DOI 10.1016/j.apmr.2016.09.134; Jones L, 1993, Disabil Rehabil, V15, P184; Kahle JT, 2016, TECHNOL INNOV, V18, P125, DOI 10.21300/18.2-3.2016.125; Kark L, 2011, INT J REHABIL RES, V34, P227, DOI 10.1097/MRR.0b013e328346e893; Kaufman KR, 2008, ARCH PHYS MED REHAB, V89, P1380, DOI 10.1016/j.apmr.2007.11.053; Kramer S, 2016, ARCH PHYS MED REHAB, V97, P619, DOI 10.1016/j.apmr.2015.11.007; Lacraz A, 2017, PROSTHET ORTHOT INT, V41, P258, DOI 10.1177/0309364616677649; Ladlow P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185731; Matsen SL, 2000, J BONE JOINT SURG AM, V82A, P1089, DOI 10.2106/00004623-200008000-00004; Mohanty R. K., 2012, Annals of Physical and Rehabilitation Medicine, V55, P252, DOI 10.1016/j.rehab.2012.02.006; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Mutlu Akmer, 2017, J Phys Ther Sci, V29, P629, DOI 10.1589/jpts.29.629; NOWROOZI F, 1983, ARCH PHYS MED REHAB, V64, P300; PAGLIARULO MA, 1979, PHYS THER, V59, P538, DOI 10.1093/ptj/59.5.538; Paysant J, 2006, J REHABIL RES DEV, V43, P153, DOI 10.1682/JRRD.2005.02.0043; PINZUR MS, 1992, ORTHOPEDICS, V15, P1033; Rommers GM, 1997, PROSTHET ORTHOT INT, V21, P92; Rowe DA, 2014, J PHYS ACT HEALTH, V11, P320, DOI 10.1123/jpah.2012-0056; Schmalz T, 2002, GAIT POSTURE, V16, P255, DOI 10.1016/S0966-6362(02)00008-5; Schnall BL, 2012, J REHABIL RES DEV, V49, P535, DOI 10.1682/JRRD.2011.04.0075; Seymour R, 2007, PROSTHET ORTHOT INT, V31, P51, DOI 10.1080/03093640600982255; Sokhangoei Y., 2013, EUR J EXP BIOL, V3, P173; Starholm IM, 2016, PROSTHET ORTHOT INT, V40, P336, DOI 10.1177/0309364615588344; Starholm IM, 2010, PROSTHET ORTHOT INT, V34, P184, DOI 10.3109/03093640903585016; Stickland MK, 2012, PULM MED, V2012, DOI 10.1155/2012/824091; Tekin L, 2009, PROSTHET ORTHOT INT, V33, P17, DOI 10.1080/03093640802482542; TORBURN L, 1995, J REHABIL RES DEV, V32, P111; Traballesi M, 2008, GAIT POSTURE, V27, P70, DOI 10.1016/j.gaitpost.2007.01.006; TRAUGH GH, 1975, ARCH PHYS MED REHAB, V56, P67; van Velzen JM, 2006, CLIN REHABIL, V20, P999, DOI 10.1177/0269215506070700; Vllasolli Teuta Osmani, 2015, Acta Inform Med, V23, P12, DOI 10.5455/aim.2015.23.12-17; Vllasolli Teuta Osmani, 2014, Ortop Traumatol Rehabil, V16, P419, DOI 10.5604/15093492.1119619; WATERS RL, 1976, J BONE JOINT SURG AM, V58, P42, DOI 10.2106/00004623-197658010-00007; Waters RL, 1999, GAIT POSTURE, V9, P207, DOI 10.1016/S0966-6362(99)00009-0; Weinert-Aplin RA, 2017, GAIT POSTURE, V51, P41, DOI 10.1016/j.gaitpost.2016.09.024; Wezenberg D, 2013, ARCH PHYS MED REHAB, V94, P1714, DOI 10.1016/j.apmr.2013.02.016; Wezenberg D, 2012, ARCH PHYS MED REHAB, V93, P1924, DOI 10.1016/j.apmr.2012.05.020; Wright DA, 2008, PROSTHET ORTHOT INT, V32, P57, DOI 10.1080/03093640701669108; Zeng Xiantao, 2015, J Evid Based Med, V8, P2, DOI 10.1111/jebm.12141	82	12	12	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2019	14	3							e0213256	10.1371/journal.pone.0213256	http://dx.doi.org/10.1371/journal.pone.0213256			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HP6AW	30893346	gold, Green Submitted, Green Published			2023-01-03	WOS:000461765900034
J	McEwen, SE; Donald, M; Jutzi, K; Allen, KA; Avery, L; Dawson, DR; Egan, M; Dittmann, K; Hunt, A; Hutter, J; Quant, S; Rios, J; Linkewich, E				McEwen, Sara E.; Donald, Michelle; Jutzi, Katelyn; Allen, Kay-Ann; Avery, Lisa; Dawson, Deirdre R.; Egan, Mary; Dittmann, Katherine; Hunt, Anne; Hutter, Jennifer; Quant, Sylvia; Rios, Jorge; Linkewich, Elizabeth			Implementing a function-based cognitive strategy intervention within inter-professional stroke rehabilitation teams: Changes in provider knowledge, self-efficacy and practice	PLOS ONE			English	Article							DECISION-MAKING; TO-ACTION; TRANSLATION; GUIDELINES; PERFORMANCE; PROGRAM; CARE	Background The Cognitive Orientation to daily Occupational Performance (CO-OP) approach is a complex rehabilitation intervention in which clients are taught to use problem-solving cognitive strategies to acquire personally-meaningful functional skills, and health care providers are required to shift control regarding treatment goals and intervention strategies to their clients. A multi-faceted, supported, knowledge translation (KT) initiative was targeted at the implementation of CO-OP in inpatient stroke rehabilitation teams at five freestanding rehabilitation hospitals. The study objective was to estimate changes in rehabilitation clinicians' knowledge, self-efficacy, and practice related to implementing CO-OP. Methods A single arm pre-post and 6-month follow up study was conducted. CO-OP KT consisted of a 2-day workshop, 4 months of implementation support, a consolidation session, and infrastructure support. In addition, a sustainability plan was implemented. Consistent with COOP principles, teams were given control over specific implementation goals and strategies. Multiple choice questions (MCQ) were used to assess knowledge. A self-efficacy questionnaire with 3 subscales (Promoting Cognitive Strategy Use, PCSU; Client-Focused Therapy, CFT; Top-Down Assessment and Treatment, TDAT) was developed for the study. Medical record audits were used to investigate practice change. Data analysis for knowledge and self-efficacy utilized mixed effects models. Medical record audits were analyzed with frequency counts and chi-squares. Results Sixty-five health care providers consisting mainly of occupational and physical therapists entered the study. Mixed effects models revealed intervention effects for MCQs, CFT, and PCSU at post intervention and follow-up, but no effect on TDAT. No charts showed any evidence of CO-OP use at baseline, compared to 8/40 (20%) post intervention. Post intervention there was a trend towards reduction in impairment goals and significantly more component goals were set (z = 2.7, p =.007).	[McEwen, Sara E.; Jutzi, Katelyn; Allen, Kay-Ann; Dittmann, Katherine; Hutter, Jennifer; Rios, Jorge] Sunnybrook Res Inst, St Johns Rehab Res Program, Toronto, ON, Canada; [McEwen, Sara E.; Quant, Sylvia] Univ Toronto, Dept Phys Therapy, Toronto, ON, Canada; [McEwen, Sara E.; Dawson, Deirdre R.; Hunt, Anne] Univ Toronto, Rehabil Sci Inst, Toronto, ON, Canada; [Donald, Michelle; Quant, Sylvia; Linkewich, Elizabeth] Sunnybrook Hlth Sci Ctr, North & East GTA Stroke Network, Toronto, ON, Canada; [Avery, Lisa] Avery Informat Serv Ltd, Orillia, ON, Canada; [Dawson, Deirdre R.; Hunt, Anne; Linkewich, Elizabeth] Univ Toronto, Dept & Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Dawson, Deirdre R.] Baycrest, Rotman Res Inst, Toronto, ON, Canada; [Egan, Mary] Univ Ottawa, Sch Rehabil Sci, Ottawa, ON, Canada; [Hunt, Anne] Holland Bloorview Kids Rehabil Hosp, Bloorview Res Inst, Toronto, ON, Canada; [Quant, Sylvia] Univ Toronto, Fac Med, Toronto, ON, Canada; [Linkewich, Elizabeth] Sunnybrook Res Inst, Practice Based Res, Toronto, ON, Canada; [Donald, Michelle] Cent Local Hlth Integrat Network, Markham, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University Toronto Affiliates; Baycrest; University of Ottawa; University of Toronto; University Toronto Affiliates; Holland Bloorview Kids Rehabilitation Hospital; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	McEwen, SE (corresponding author), Sunnybrook Res Inst, St Johns Rehab Res Program, Toronto, ON, Canada.; McEwen, SE (corresponding author), Univ Toronto, Dept Phys Therapy, Toronto, ON, Canada.; McEwen, SE (corresponding author), Univ Toronto, Rehabil Sci Inst, Toronto, ON, Canada.	sara.mcewen@sunnybrook.ca	; Dawson, Deirdre/I-8882-2014	Linkewich, Elizabeth/0000-0002-6327-3693; Dawson, Deirdre/0000-0001-7517-6121; Avery, Lisa/0000-0002-8431-5143; Allen, Kay-Ann/0000-0002-3815-1045	Canadian Institutes of Health Research, Partnerships for Health System Improvement [PHE-141799]; Sunnybrook Research Institute, D + H SRI Summer studentship Award	Canadian Institutes of Health Research, Partnerships for Health System Improvement(Canadian Institutes of Health Research (CIHR)); Sunnybrook Research Institute, D + H SRI Summer studentship Award	SM and EL were recipients of a Canadian Institutes of Health Research, Partnerships for Health System Improvement (PHE-141799) grant as co-principal investigators. DD, MD, ME, AH, and SQ were co-investigators on the same grant. JH is recipient of the Sunnybrook Research Institute, D + H SRI Summer studentship Award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. LA was paid, through the statistical analysis service she owns, Avery Information Services, to complete some of the data analysis. The funder provided support in the form of partial salaries for authors KA, LA (through Avery Information Services), KD, KJ, JH, and JR, but did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. This funding does not alter our adherence to PLOS ONE policies on sharing data and materials.	Armstrong MJ, 2017, STROKE VASC NEUROL, V2, P84, DOI 10.1136/svn-2017-000081; Bandura A., 2006, SELF EFFICACY BELIEF, V5, P307; Bobath B, 1977, Physiotherapy, V63, P310; Canadian Interprofessional Health Collaborative, 2010, NAT INT COMP FRAM; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Couet N, 2015, HEALTH EXPECT, V18, P542, DOI 10.1111/hex.12054; Dawson D., 2017, COGNITIVE ORIENTATIO; Egan M, 2019, DISABIL REHABIL; Eskes G, 2015, MOOD COGNITION FATIG; Graham ID, 2006, J CONTIN EDUC HEALTH, V26, P13, DOI 10.1002/chp.47; Grimshaw JM, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-50; Harter M, 2017, Z EVIDENZ FORTBILD Q, V123-124, P1, DOI 10.1016/j.zefq.2017.05.024; Hebert D, 2016, INT J STROKE, V11, P459, DOI 10.1177/1747493016643553; Hunt AW, 2015, QUAL HEALTH RES, V25, P1044, DOI 10.1177/1049732315588759; Instructors Group of NDTA, 2016, NDT BOB NEUR TREATM; Janzen S, 2016, CAN J NEUROL SCI, V43, P619, DOI 10.1017/cjn.2016.258; Kastner M, 2012, J CLIN EPIDEMIOL, V65, P1163, DOI 10.1016/j.jclinepi.2012.04.011; Kitson AL, 2009, J ADV NURS, V65, P217, DOI 10.1111/j.1365-2648.2008.04864.x; Laur C, 2015, J MULTIDISCIP HEALTH, V8, P463, DOI 10.2147/JMDH.S93103; Law M., 2014, CANADIAN OCCUPATIONA; Linkewich E, 2014, ARCH PHYS MED REHAB, V95, P95, DOI DOI 10.1016/J.APMR.2014.07.021; McEwen S, 2017, PHYSIOTHER CAN, V69, P193, DOI 10.3138/ptc.2016-13; McEwen S, 2015, NEUROREHAB NEURAL RE, V29, P526, DOI 10.1177/1545968314558602; McEwen SE, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0346-6; McEwen SE, 2010, NEUROPSYCHOL REHABIL, V20, P541, DOI 10.1080/09602011003638194; McEwen SE, 2009, BRAIN INJURY, V23, P1041, DOI 10.3109/02699050903421107; McEwen SE, 2017, COGNITIVE ORIENTATIO, V1st, P93; Meichenbaum D, 1977, COGNITIVE BEHAV MODI; Menon A, 2009, J REHABIL MED, V41, P1024, DOI 10.2340/16501977-0451; Miao M, 2015, DISABIL REHABIL, V37, P674, DOI 10.3109/09638288.2014.932444; Moore JE, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3220-9; Munce S, 2013, J CANCER EDUC, V28, P481, DOI 10.1007/s13187-013-0490-0; National Collaborating Centre for Methods and Tools, 2013, KNOWL TRANSL IN US S; Norton WE, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0655-z; Plant SE, 2016, CLIN REHABIL, V30, P921, DOI 10.1177/0269215516655856; Ploeg J, 2007, WORLDV EVID-BASED NU, V4, P210, DOI 10.1111/j.1741-6787.2007.00106.x; Polatajko H. J., 2004, ENABLING OCCUPATION; Polatajko HJ, 2012, AM J OCCUP THER, V66, P104, DOI 10.5014/ajot.2012.001784; Pollock A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001920.pub3; Prasad V, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-1; Scholl I, 2018, IMPLEMENT SCI, V13, DOI 10.1186/s13012-018-0731-z; Sharp S, 2014, STROKE S1, V45; Sibley KM, 2015, PHYS THER, V95, P579, DOI 10.2522/ptj.20130486; Skidmore E., 2017, COGNITIVE ORIENTATIO, P11; Skidmore ER, 2015, NEUROREHAB NEURAL RE, V29, P668, DOI 10.1177/1545968314562113; Skidmore ER, 2014, CLIN REHABIL, V28, P378, DOI 10.1177/0269215513502799; Skidmore ER, 2011, NEUROPSYCHOL REHABIL, V21, P208, DOI 10.1080/09602011.2011.552559; The CO- OP Academy, 2018, CO OP AC INF RES; Urquhart JR, 2014, OTJR-OCCUP PART HEAL, V34, P202, DOI 10.3928/15394492-20141006-05; van Bodegom-Vos L, 2017, BMJ QUAL SAF, V26, P495, DOI 10.1136/bmjqs-2016-005473; Winstein CJ, 2015, PROG BRAIN RES, V218, P331, DOI 10.1016/bs.pbr.2015.01.004	51	14	14	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2019	14	3							e0212988	10.1371/journal.pone.0212988	http://dx.doi.org/10.1371/journal.pone.0212988			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HO6HL	30856191	gold, Green Published, Green Submitted			2023-01-03	WOS:000461030300017
J	Min, HJ; Kim, HJ; Lee, DS; Choi, YY; Yoon, M; Lee, D; Cho, JY; Park, JS; Cho, YJ; Yoon, HI; Lee, JH; Lee, CT; Lee, YJ				Min, Hyun Ju; Kim, Hyung-Jun; Lee, Dong Seon; Choi, Yun Young; Yoon, Miae; Lee, Dayoon; Cho, Jun Yeun; Park, Jong Sun; Cho, Young-Jae; Yoon, Ho Il; Lee, Jae Ho; Lee, Choon-Taek; Lee, Yeon Joo			Intra-hospital transport of critically ill patients with rapid response team and risk factors for cardiopulmonary arrest: A retrospective cohort study	PLOS ONE			English	Article							SUDDEN CARDIAC DEATH; MYOCARDIAL-INFARCTION; RANDOMIZED-TRIAL; COMPLICATIONS; EVENTS	Introduction This study aimed to determine the occurrence rate and risk factors of cardiopulmonary arrest (CPA) during intra-hospital transport (IHT) among critically ill patients, accompanied by a rapid response team (RRT). Methods We performed a retrospective cohort study in a 1300-bed tertiary-care teaching hospital. Data of all admitted patients transported within the hospital and accompanied by the RRT from October 2012 to May 2016 were included. We compared patients with CPA (+) and patients without CPA (-) to identify risk factors for CPA during transport. Results Among 535 patients, CPA occurred in eight (1.5%) patients during IHT. There were no significant differences in age, sex, and comorbidities between groups. More patients in the CPA (+) group than in the CPA (-) group received manual ventilation during IHT (75% vs. 23.0%, p = 0.001). An increased risk of CPA (p<0.001) corresponded with a higher number of vasopressors used during IHT. In univariate logistic regression analysis, history of myocardial infarction (OR 10.7, 95% CI 2.4-50.5, p = 0.005), manual ventilation (OR 10.1, 95% CI 2.0-50.5, p = 0.005), and use of three or more vasopressors (OR 11.1, 95% CI 2.5-48.9, p = 0.001) were significantly associated with risk of CPA during RRT-led IHT. Conclusions Despite accompaniment by a specialized team such as the RRT, CPA can occur during IHT. History of myocardial infarction, manual ventilation with bag-valve mask, and the use of three or more vasopressors were independent risk factors of CPA during IHT of critically ill patients accompanied by the RRT.	[Min, Hyun Ju; Cho, Jun Yeun; Park, Jong Sun; Cho, Young-Jae; Yoon, Ho Il; Lee, Jae Ho; Lee, Choon-Taek; Lee, Yeon Joo] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Seongnam Si, Gyeonggi Do, South Korea; [Min, Hyun Ju; Lee, Dong Seon; Choi, Yun Young; Yoon, Miae; Lee, Dayoon] Seoul Natl Univ, Bundang Hosp, Dept Nursing, Seongnam, Gyeonggi Do, South Korea; [Kim, Hyung-Jun] Armed Forces Daegu Hosp, Dept Internal Med, Gyongsan, Gyeongsangbuk D, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Lee, YJ (corresponding author), Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Seongnam Si, Gyeonggi Do, South Korea.	yjlee1117@snubh.org	Cho, Young-Jae/D-5528-2012; Kim, Hyung-Jun/AAP-9020-2021	Cho, Young-Jae/0000-0001-6943-4462; Kim, Hyung-Jun/0000-0003-1984-8864				Adabag AS, 2008, JAMA-J AM MED ASSOC, V300, P2022, DOI 10.1001/jama.2008.553; Beckmann U, 2004, INTENS CARE MED, V30, P1579, DOI 10.1007/s00134-004-2177-9; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; Cairns JA, 1997, LANCET, V349, P675, DOI 10.1016/S0140-6736(96)08171-8; Damm C, 2005, ANN FR ANESTH, V24, P24, DOI 10.1016/j.annfar.2004.10.026; Dockery WK, 1999, CRIT CARE MED, V27, P802, DOI 10.1097/00003246-199904000-00040; Doring B L, 1999, J Neurosci Nurs, V31, P80; Fanara B, 2010, CRIT CARE, V14, DOI 10.1186/cc9018; Gillman L, 2006, EMERG MED J, V23, P858, DOI 10.1136/emj.2006.037697; HURST JM, 1989, J TRAUMA, V29, P1637, DOI 10.1097/00005373-198912000-00008; Jia L, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1183-y; Julian DG, 1997, LANCET, V349, P667, DOI 10.1016/S0140-6736(96)09145-3; Kim Y, 2017, CRIT CARE MED, V45, pE592, DOI 10.1097/CCM.0000000000002314; Knight Patrick H, 2015, Int J Crit Illn Inj Sci, V5, P256, DOI 10.4103/2229-5151.170840; Kue R, 2011, AM J CRIT CARE, V20, P153, DOI 10.4037/ajcc2011478; Lahner D, 2007, WIEN KLIN WOCHENSCHR, V119, P412, DOI 10.1007/s00508-007-0813-4; Lovell MA, 2001, ANAESTH INTENS CARE, V29, P400, DOI 10.1177/0310057X0102900412; McLenon Melissa, 2004, Dimens Crit Care Nurs, V23, P225, DOI 10.1097/00003465-200409000-00008; Papson JPN, 2007, ACAD EMERG MED, V14, P574, DOI 10.1197/j.aem.2007.02.034; Parmentier-Decrucq E, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-10; Peltola M, 2008, ANN MED, V40, P376, DOI 10.1080/07853890701884659; SINGER M, 1994, CHEST, V106, P1182, DOI 10.1378/chest.106.4.1182; Stearley H E, 1998, Am J Crit Care, V7, P282; TAYLOR JO, 1970, LANCET, V2, P1205; Warren J, 2004, CRIT CARE MED, V32, P256, DOI 10.1097/01.CCM.0000104917.39204.0A; WEG JG, 1989, CHEST, V96, P631, DOI 10.1378/chest.96.3.631; Zaman S, 2014, CIRCULATION, V129, P2426, DOI 10.1161/CIRCULATIONAHA.113.007497	27	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2019	14	3							e0213146	10.1371/journal.pone.0213146	http://dx.doi.org/10.1371/journal.pone.0213146			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN7LV	30835759	Green Published, gold, Green Submitted			2023-01-03	WOS:000460371800024
J	Khorana, AA; Tullio, K; Elson, P; Pennell, NA; Grobmyer, SR; Kalady, MF; Raymond, D; Abraham, J; Klein, EA; Walsh, RM; Monteleone, EE; Wei, W; Hobbs, B; Bolwell, BJ				Khorana, Alok A.; Tullio, Katherine; Elson, Paul; Pennell, Nathan A.; Grobmyer, Stephen R.; Kalady, Matthew F.; Raymond, Daniel; Abraham, Jame; Klein, Eric A.; Walsh, R. Matthew; Monteleone, Emily E.; Wei, Wei; Hobbs, Brian; Bolwell, Brian J.			Time to initial cancer treatment in the United States and association with survival over time: An observational study	PLOS ONE			English	Article							PRIOR AUTHORIZATION; ETHNIC DISPARITIES; DIAGNOSTIC DELAY; NECK-CANCER; NAVIGATION; SYMPTOMS; OUTCOMES; HEAD; CARE	Background Delays in time to treatment initiation (TTI) for new cancer diagnoses cause patient distress and may adversely affect outcomes. We investigated trends in TTI for common solid tumors treated with curative intent, determinants of increased TTI and association with overall survival. Methods and findings We utilized prospective data from the National Cancer Database for newly diagnosed United States patients with early-stage breast, prostate, lung, colorectal, renal and pancreas cancers from 2004-13. TTI was defined as days from diagnosis to first treatment (surgery, systemic or radiation therapy). Negative binomial regression and Cox proportional hazard models were used for analysis. The study population of 3,672,561 patients included breast (N = 1,368,024), prostate (N = 944,246), colorectal (N = 662,094), non-small cell lung (N = 363,863), renal (N = 262,915) and pancreas (N = 71,419) cancers. Median TTI increased from 21 to 29 days (P<0.001). Aside from year of diagnosis, determinants of increased TTI included care at academic center, race, education, prior history of cancer, transfer of facility, comorbidities and age. Increased TTI was associated with worsened survival for stages I and II breast, lung, renal and pancreas cancers, and stage I colorectal cancers, with hazard ratios ranging from 1.005 (95% confidence intervals [CI] 1.002-1.008) to 1.030 (95% CI 1.025-1.035) per week of increased TTI. Conclusions TTI has lengthened significantly and is associated with absolute increased risk of mortality ranging from 1.2-3.2% per week in curative settings such as early-stage breast, lung, renal and pancreas cancers. Studies of interventions to ease navigation and reduce barriers are warranted to diminish potential harm to patients.	[Khorana, Alok A.; Tullio, Katherine; Elson, Paul; Pennell, Nathan A.; Abraham, Jame; Monteleone, Emily E.; Wei, Wei; Hobbs, Brian; Bolwell, Brian J.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA; [Grobmyer, Stephen R.; Kalady, Matthew F.; Walsh, R. Matthew] Cleveland Clin, Digest Dis & Surg Inst, Cleveland, OH 44106 USA; [Raymond, Daniel] Cleveland Clin, Inst Heart & Vasc, Cleveland, OH 44106 USA; [Klein, Eric A.] Cleveland Clin, Glickman Urol & Kidney Inst, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Khorana, AA (corresponding author), Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.	Khorana@ccf.org	Pennell, Nathan/AAH-9303-2021	Pennell, Nathan/0000-0002-1458-0064; Klein, Eric A/0000-0002-1783-0698	Sondra and Stephen Hardis Chair in Oncology Research	Sondra and Stephen Hardis Chair in Oncology Research	Dr. Khorana acknowledges additional research support from the Sondra and Stephen Hardis Chair in Oncology Research.	Agarwal A, 2017, J ONCOL PRACT, V13, pE273, DOI 10.1200/JOP.2016.017756; Ayanian JZ, 2014, NEW ENGL J MED, V371, P2288, DOI 10.1056/NEJMsa1407273; Bilimoria KY, 2008, ANN SURG ONCOL, V15, P683, DOI 10.1245/s10434-007-9747-3; Bilimoria KY, 2011, ANN SURG, V253, P779, DOI 10.1097/SLA.0b013e318211cc0f; Bleicher RJ, 2016, JAMA ONCOL, V2, P330, DOI 10.1001/jamaoncol.2015.4508; Brazda A, 2010, ANN SURG ONCOL, V17, pS291, DOI 10.1245/s10434-010-1250-6; Comber H, 2005, Ir Med J, V98, P238; Dolly D, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00031; Freeman HP, 2004, CA-CANCER J CLIN, V54, P72, DOI 10.3322/canjclin.54.2.72; Freund KM, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju115; Gomez DR, 2015, RADIOTHER ONCOL, V115, P257, DOI 10.1016/j.radonc.2015.04.010; Hoffmann MS, 2016, J ONCOL PRACT, V12, pE257, DOI 10.1200/JOP.2015.007484; Holland JC, 2013, J NATL COMPR CANC NE, V11, P190, DOI 10.6004/jnccn.2013.0027; Kirkwood MK, 2018, J ONCOL PRACT, V14, P427, DOI 10.1200/JOP.18.00149; Kirkwood MK, 2015, J ONCOL PRACT, V11, P79, DOI 10.1200/JOP.2015.003772; Kozak VN, 2017, CLIN COLORECTAL CANC, V16, P366, DOI 10.1016/j.clcc.2017.03.020; Lin NU, 2018, J ONCOL PRACT, V14, P525, DOI 10.1200/JOP.18.00428; Miles A, 2017, PSYCHO-ONCOLOGY, V26, P29, DOI 10.1002/pon.4093; Murphy CT, 2015, CANCER-AM CANCER SOC, V121, P1204, DOI 10.1002/cncr.29191; Neal RD, 2015, BRIT J CANCER, V112, pS92, DOI 10.1038/bjc.2015.48; Niccolai JL, 2017, J ONCOL PRACT, V13, P45, DOI 10.1200/JOP.2016.012302; Posluszny DM, 2015, HEAD NECK-J SCI SPEC, V37, P1282, DOI 10.1002/hed.23760; Pruitt SL, 2013, CANCER CAUSE CONTROL, V24, P961, DOI 10.1007/s10552-013-0172-6; Robinson KM, 2012, QUAL LIFE RES, V21, P1519, DOI 10.1007/s11136-011-0077-3; Rocque GB, 2017, JAMA ONCOL, V3, P817, DOI 10.1001/jamaoncol.2016.6307; Sainsbury R, 1999, LANCET, V353, P1132; Samson P, 2015, ANN THORAC SURG, V99, P1906, DOI 10.1016/j.athoracsur.2015.02.022; Shah D, 2014, VALUE HEALTH, V17, pA418, DOI 10.1016/j.jval.2014.08.1019; Shavers VL, 2002, JNCI-J NATL CANCER I, V94, P334; Sohal DPS, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju011; Ward E, 2004, CA-CANCER J CLIN, V54, P78, DOI 10.3322/canjclin.54.2.78; Whitley EM, 2017, CANCER-AM CANCER SOC, V123, P312, DOI 10.1002/cncr.30316	32	111	110	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2019	14	3							e0213209	10.1371/journal.pone.0213209	http://dx.doi.org/10.1371/journal.pone.0213209			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN7LT	30822350	Green Published, gold, Green Submitted			2023-01-03	WOS:000460371600036
J	Lampert, A; Bruckner, T; Haefeli, WE; Seidling, HM				Lampert, Anette; Bruckner, Thomas; Haefeli, Walter E.; Seidling, Hanna M.			Improving eye-drop administration skills of patients - A multicenter parallel-group cluster-randomized controlled trial	PLOS ONE			English	Article							GLAUCOMA; ASTHMA; INSTILLATION; INFORMATION; TIMOLOL	Background Eye-drop administration errors occur in the majority of patients and increase the risk for treatment failure or systemic adverse events. While lacking knowledge is the principal error cause, most patients overestimate their skills and are unaware of often substantial knowledge gaps. Therefore, the impact of including motivational patient education on long-term eye-drop administration skills of patients was investigated. Methods This is a cluster-randomized controlled trial in German community pharmacies. Patient education in both groups comprised observation of the patient during eye-drop administration to identify individual errors, pharmaceutical counseling, and teach-back evaluation of the training. In the intervention group, motivational communication techniques were included to increase error awareness and readiness for patient education. In addition, intervention patients were trained on repeated errors until administration was performed correctly. In contrast, patients in the control group only received feedback on erroneous administration steps without another assessment and reinforced training. Results In total, 152 adult patients were eligible to the study and 91 patients (intervention group N = 46) agreed to participate in a 1-month, 6-month, and 12-month follow-up. Patient education significantly increased the proportion of patients correctly administering eye-drops from 6% (7 out of 56 intervention patients, 1 out of 82 control patients) at baseline to 35% (12 out of 30 intervention patients, 12 out of 39 control patients, p <= 0.001) at the 1-month follow-up, and 64% (11 out of 15 intervention patients, 17 out of 29 control patients, p <= 0.001) at the 6-month follow-up irrespective of group allocation. In some patients previously resolved errors recurred during follow-up visits. This emphasizes the need for periodical reevaluation of patient administration skills and the provision of prevention strategies besides education. Conclusion Patient education that included demonstration of administration skills and verbal and written counseling on observed errors improved eye-drop administration skills irrespective of the communication technique applied. Whereof, high drop-out rates limited the power to detect a difference between groups. In particular, periodic demonstration of administration skills seemed important for sustainable improvement of administration skills. However, further error prevention strategies such as additional education materials or support by a caregiver may be necessary in some patients.	[Lampert, Anette; Haefeli, Walter E.; Seidling, Hanna M.] Heidelberg Univ, Dept Clin Pharmacol & Pharmacoepidemiol, Heidelberg, Germany; [Lampert, Anette; Haefeli, Walter E.; Seidling, Hanna M.] Heidelberg Univ, Cooperat Unit Clin Pharm, Heidelberg, Germany; [Bruckner, Thomas] Heidelberg Univ, Inst Med Biometry & Informat, Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Seidling, HM (corresponding author), Heidelberg Univ, Dept Clin Pharmacol & Pharmacoepidemiol, Heidelberg, Germany.; Seidling, HM (corresponding author), Heidelberg Univ, Cooperat Unit Clin Pharm, Heidelberg, Germany.	hanna.seidling@med.uni-heidelberg.de	Haefeli, Walter Emil/AAJ-3024-2020	Haefeli, Walter Emil/0000-0003-0672-6876	Dr August and Anni Lesmueller foundation; Dr. August and Dr. Anni Lesmueller foundation	Dr August and Anni Lesmueller foundation; Dr. August and Dr. Anni Lesmueller foundation	AL received a personal scholarship from "Dr August and Anni Lesmueller foundation". The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank the Chamber of Pharmacists Baden-Wuerttemberg for its support and particularly all patients, pharmacists, and pharmacy technicians for participation in our study and their effort. AL received a personal scholarship from the "Dr. August and Dr. Anni Lesmueller foundation".	[Anonymous], 2009, AM J PHARM EDUC; Buetow S, 2009, ANN FAM MED, V7, P223, DOI 10.1370/afm.941; Busche S, 1997, KLIN MONATSBL AUGENH, V211, P257, DOI 10.1055/s-2008-1035132; Campbell MK, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5661; Carpenter DM, 2016, HEALTH COMMUN, V31, P1036, DOI 10.1080/10410236.2015.1020263; Connor AJ, 2011, EYE, V25, P466, DOI 10.1038/eye.2011.5; Dietlein TS, 2008, ACTA OPHTHALMOL, V86, P856, DOI 10.1111/j.1755-3768.2007.01155.x; Doak C, TEACHING PATIENTS LO; Feng A, 2016, CLIN OPHTHALMOL, V10, P1505, DOI 10.2147/OPTH.S108979; Flach Allan J, 2008, Trans Am Ophthalmol Soc, V106, P138; FRAUNFELDER FT, 1987, J OCUL PHARMACOL, V3, P177, DOI 10.1089/jop.1987.3.177; Friedman AJ, 2011, J CANCER EDUC, V26, P12, DOI 10.1007/s13187-010-0183-x; Gupta R, 2012, J GLAUCOMA, V21, P189, DOI 10.1097/IJG.0b013e31820bd2e1; Johnson A., 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003716; Lampert A, 2016, INT J QUAL HEALTH C, V28, P634, DOI 10.1093/intqhc/mzw077; Lampert A, 2014, PATIENT EDUC COUNS, V97, P434, DOI 10.1016/j.pec.2014.08.018; LOEWENSTEIN A, 1994, GRAEF ARCH CLIN EXP, V232, P680, DOI 10.1007/BF00171384; Mansour K, 2007, CORNEA, V26, P147, DOI 10.1097/01.ico.0000244877.30997.6a; Morales DR, 2016, BRIT J CLIN PHARMACO, V82, P814, DOI 10.1111/bcp.13006; Muir KW, 2010, SURV OPHTHALMOL, V55, P454, DOI 10.1016/j.survophthal.2010.03.005; NELSON JD, 1987, AM J OPHTHALMOL, V103, P333; Press VG, 2012, J GEN INTERN MED, V27, P1317, DOI 10.1007/s11606-012-2090-9; RIVERS PH, 1992, DRUG AGING, V2, P103, DOI 10.2165/00002512-199202020-00004; Sayner R, 2016, INT J PHARM PRACT, V24, P78, DOI 10.1111/ijpp.12215; SCHEIN OD, 1988, AM J OPHTHALMOL, V105, P361, DOI 10.1016/0002-9394(88)90298-X; Schulz M, 2001, J CLIN PHARMACOL, V41, P668, DOI 10.1177/00912700122010438; Schwartz GF, 2013, CURR MED RES OPIN, V29, P1515, DOI 10.1185/03007995.2013.833898; Solomon A, 2003, OPHTHALMOLOGY, V110, P796, DOI 10.1016/S0161-6420(02)01967-X; Stone JL, 2009, ARCH OPHTHALMOL-CHIC, V127, P732, DOI 10.1001/archophthalmol.2009.96; Tatham AJ, 2013, EYE, V27, P1293, DOI 10.1038/eye.2013.187; TEMPLETON WC, 1982, AM J OPHTHALMOL, V93, P723, DOI 10.1016/0002-9394(82)90467-6; WINFIELD AJ, 1990, BRIT J OPHTHALMOL, V74, P477, DOI 10.1136/bjo.74.8.477; ZIMMERMAN TJ, 1984, ARCH OPHTHALMOL-CHIC, V102, P551; ZIMMERMAN TJ, 1981, ANN OPHTHALMOL, V13, P683	34	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2019	14	2							e0212007	10.1371/journal.pone.0212007	http://dx.doi.org/10.1371/journal.pone.0212007			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HM2WC	30789934	Green Published, Green Submitted, gold			2023-01-03	WOS:000459330800017
J	Lexchin, J				Lexchin, Joel			Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study	PLOS ONE			English	Article								Background Patient groups represent the interest of their members when it comes to drug funding. Many patient groups receive grants from pharmaceutical companies that make products being considered for funding. This research examines whether there is an association between the positions that Canadian groups take about the products and conflicts of interest with the companies. Methods The Common Drug Review (CDR) and panCanadian Oncology Drug Review (pCODR) make recommendations to Canadian provincial and federal drug plans about funding particular drug-indications. Both utilize input from patient groups in making their recommendations. Patient group submissions are available from both organizations and these submissions contain statements about conflicts of interest. Views of the patient groups, with and without a conflict with the company making the drug under consideration and without any conflicts at all, were assessed and then compared with the recommendations from CDR and pCODR. Results There was a total of 222 reports for drug-indications. There were 372 submissions from 93 different patient groups. Groups declared a total of 1896 conflicts with drug companies in 324 (87.1%) individual submissions. There were 268 submissions where groups declared a conflict with the company making the product or said they had no conflict. Irrespective of whether there was a conflict, the views of patient groups about the drug-indications under consideration were the same. There was no statistically significant difference between views of patient groups and the recommendations from CDR and/or pCODR. Conclusions The large majority of patient groups making submissions about funding of particular drug-indications had conflicts with the companies making the products and their views about the products were almost always positive. This association between funding and views needs to be further investigated to determine if a true cause and effect exists.	[Lexchin, Joel] York Univ, Sch Hlth Policy & Management, Toronto, ON, Canada; [Lexchin, Joel] Univ Hlth Network, Emergency Dept, Toronto, ON, Canada; [Lexchin, Joel] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada	York University - Canada; University of Toronto; University Health Network Toronto; University of Toronto	Lexchin, J (corresponding author), York Univ, Sch Hlth Policy & Management, Toronto, ON, Canada.; Lexchin, J (corresponding author), Univ Hlth Network, Emergency Dept, Toronto, ON, Canada.; Lexchin, J (corresponding author), Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada.	jlexchin@yorku.ca						[Anonymous], 2014, CADTH COMM DRUG REV CADTH COMM DRUG REV; [Anonymous], 2016, PCODR EXP REV COMM T; Batt S, 2017, HLTH ADVOCACY INC PH; Berglas Sarah, 2016, Res Involv Engagem, V2, P21, DOI 10.1186/s40900-016-0036-9; Burton Bob, 2005, BMJ, V331, P1359, DOI 10.1136/bmj.331.7529.1359-b; CADTH, 2014, SUBS ENTR BIOL EM TR; CADTH(Canadian Agency forDrugs and Technologies in Health), 2017, INTR NEW PAT INP TEM; Claypool R., 2016, PATIENTS GROUPS BIG; Facey K, 2017, PATIENT INVOLV HEAL, P67; Goomansingh C., 2014, GLOBAL NEWS; Government of Ontario, 2018, HLTH SECT PAYM TRANS; Hughes David, 2013, Healthc Policy, V9, P52; Keizer B, 2010, PILOT STUDY POSITION; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; McCoy MS, 2017, NEW ENGL J MED, V376, P880, DOI 10.1056/NEJMsr1610625; Perehudoff SK, 2011, PATIENT CONSUMER VOI; Rose SL, 2017, JAMA INTERN MED, V177, P344, DOI 10.1001/jamainternmed.2016.8443; Rubenstein S., 2007, WALL STREET J; Weeks C., 2016, GLOBE MAIL	19	12	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 15	2019	14	2							e0212399	10.1371/journal.pone.0212399	http://dx.doi.org/10.1371/journal.pone.0212399			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL5KT	30768629	Green Published, gold, Green Submitted			2023-01-03	WOS:000458766300036
J	Keel, I; Schurch, R; Weiss, J; Zwahlen, M; Immer, FF; Bechir, M; Delalay, C; Delalay, C; Eckhart, F; Endermann, S; Fassler, E; Feiner, AS; Gasche, Y; Ghanfili, E; Lenherr, R; Moretti, D; Nebiker, M; Pfluger, M; Pilon, N; Re-Genscheit, S; Sauter, T; Sprachta, J; Tisljar, K				Keel, Isabelle; Schurch, Roger; Weiss, Julius; Zwahlen, Marcel; Immer, Franz F.; Bechir, Markus; Delalay, Corinne; Eckert, Philippe; Eckhart, Friedemann; Endermann, Susann; Fassler, Edith; Feiner, Adam-Scott; Gasche, Yvan; Ghanfili, Eva; Lenherr, Renato; Moretti, Diane; Nebiker, Mathias; Pfluger, Marc; Pilon, Nathalie; Re-Genscheit, Stefan; Sauter, Thomas; Sprachta, Jan; Tisljar, Kai		Com Natl Don d'Organes CNDO	Is there an association between consent rates in Swiss hospitals and critical care staffs' attitudes towards organ donation, their knowledge and confidence in the donation process?	PLOS ONE			English	Article							DONOR; DECISION; NEEDS; NONDONOR	This study investigated the critical care staff's attitude, knowledge and involvement with donation, skills and confidence with donation-related tasks and their association with consent rates at the hospital level. In 2015, we conducted a cross-sectional survey among critical care staff of hospitals involved in organ donation using an anonymous online questionnaire with a response rate of 56.4% (n = 2799). The hospital level consent rate was obtained from the Swiss Monitoring of Potential Donors database (2013-2015). For each hospital, we calculated a mean score for each predictor of interest of the Hospital Attitude Survey and investigated the association with hospital consent rates with generalized linear mixed-effect models. In univariable analysis, one score point increase in doctors' confidence resulted in a 66% (95% CI: 45%-80%) reduction in the odds to consent, and one score point increase in nurses' attitudes resulted in a 223% (95% CI: 84%-472%) increase in the odds to consent. After simultaneously adjusting for all major predictors found in the crude models, only levels of education of medical and nursing staff remained as significant predictors for hospital consent rates. In Switzerland, efforts are needed to increase consent rates for organ donation and should concentrate on continuous support as well as specific training of the hospital staff involved in the donation process.	[Keel, Isabelle; Weiss, Julius; Immer, Franz F.; Com Natl Don d'Organes CNDO] Swiss Natl Fdn Organ Donat & Transplantat, Bern, Switzerland; [Schurch, Roger] Univ Bern, CTU Bern, Dept Clin Res, Bern, Switzerland; [Schurch, Roger; Zwahlen, Marcel] Univ Bern, ISPM, Bern, Switzerland; [Bechir, Markus] Zentrum Innere Med ZIM Aarau, Aarau, Switzerland; [Delalay, Corinne; Gasche, Yvan; Moretti, Diane] Hop Univ Geneve, Geneva, Switzerland; [Eckert, Philippe; Feiner, Adam-Scott; Pilon, Nathalie] CHU Vaudois, Lausanne, Switzerland; [Eckhart, Friedemann] Kantonsspital Luzern, Luzern, Switzerland; [Endermann, Susann; Fassler, Edith] Kantonsspital St Gallen, St Gallen, Switzerland; [Ghanfili, Eva] Osped Reg Lugano Civico, Lugano, Switzerland; [Lenherr, Renato; Re-Genscheit, Stefan] Univ Spital Zurich, Zurich, Switzerland; [Nebiker, Mathias; Pfluger, Marc] Inselspital Bern, Bern, Switzerland; [Sauter, Thomas] Lindenhofspital Bern, Bern, Switzerland; [Sprachta, Jan; Tisljar, Kai] Univ Spital Basel, Basel, Switzerland	University of Bern; University of Bern; University of Geneva; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Lucerne Cantonal Hospital; University of Zurich; University Zurich Hospital; University of Basel	Immer, FF (corresponding author), Swiss Natl Fdn Organ Donat & Transplantat, Bern, Switzerland.	franz.immer@swisstransplant.org	Zwahlen, Marcel/AFF-8559-2022	Zwahlen, Marcel/0000-0002-6772-6346				[Anonymous], 2007, 810211 SR; Babaie Mohadese, 2015, Glob J Health Sci, V7, P129, DOI 10.5539/gjhs.v7n6p129; Balthasar A, 2009, AUSWERTUNGEN AUSGEWA; Beard T.R, 2020, INDEP REV; Bogh L, 2005, TRANSPL P, V37, P3256, DOI 10.1016/j.transproceed.2005.09.063; Czerwinski J, 2016, TRANSPL P, V48, P2429, DOI 10.1016/j.transproceed.2015.12.144; DuBois James M, 2006, Prog Transplant, V16, P65; Hulme W, 2016, ANAESTHESIA, V71, P1053, DOI 10.1111/anae.13535; Irving MJ, 2014, TRANSPL INT, V27, P617, DOI 10.1111/tri.12307; Irving MJ, 2012, NEPHROL DIAL TRANSPL, V27, P2526, DOI 10.1093/ndt/gfr683; Jacoby L, 2010, AM J CRIT CARE, V19, pE52, DOI 10.4037/ajcc2010396; Jacoby LH, 2005, DIMENS CRIT CARE NUR, V24, P183, DOI 10.1097/00003465-200507000-00009; Kosieradzki M, 2014, J TRANSPLANT, V2014, DOI 10.1155/2014/296912; Not I, 2016, SCHWEIZERISCHE ARZTE, V97, P52; Pelleriaux B, 2008, PROG TRANSPLANT, V18, P173; Zambudio AR, 2009, PROG TRANSPLANT, V19, P371; Rithalia Amber, 2009, BMJ, V338, pa3162, DOI 10.1136/bmj.a3162; Rodrigue JR, 2006, AM J TRANSPLANT, V6, P190, DOI 10.1111/j.1600-6143.2005.01130.x; Roels L, 2010, TRANSPL INT, V23, P842, DOI 10.1111/j.1432-2277.2010.01065.x; Schulz PJ, 2006, PATIENT EDUC COUNS, V64, P294, DOI 10.1016/j.pec.2006.03.009; Siminoff LA, 2002, J TRAUMA, V53, P754, DOI 10.1097/00005373-200210000-00023; Simpkin AL, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b991; Smudla A, 2012, ANN TRANSPL, V17, P93; Swisstransplant, SWISSPOD REP; Swisstransplant Comite National de Don d'Organes, INF MAT FACHP; Swisstransplant. Jahresbericht, 2014, ANN REPORT; Walchli-Bhend S, 2011, ORGANS TISSUES CELLS, V14, P25; Webb G, 2015, TRANSPLANTATION, V99, P1396, DOI 10.1097/TP.0000000000000504; Weiss J, 2017, SWISS MED WKLY, V147, DOI 10.4414/smw.2017.14401; Weiss J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106845; Weiss JH, 2014, SWISS MED WKLY, V144, DOI 10.4414/smw.2014.14045	31	4	4	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2019	14	2							e0211614	10.1371/journal.pone.0211614	http://dx.doi.org/10.1371/journal.pone.0211614			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK7PK	30735508	Green Submitted, gold, Green Accepted, Green Published			2023-01-03	WOS:000458181200023
J	Mose, KF; Bygum, A				Mose, Kristian Fredlov; Bygum, Anette			Chinese herbal remedy found to contain steroids and antifungals	LANCET			English	Editorial Material									[Mose, Kristian Fredlov; Bygum, Anette] Odense Univ Hosp, Dept Dermatol, DK-5000 Odense C, Denmark; [Mose, Kristian Fredlov; Bygum, Anette] Odense Univ Hosp, Allergy Ctr, DK-5000 Odense C, Denmark	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital	Mose, KF (corresponding author), Odense Univ Hosp, Dept Dermatol, DK-5000 Odense C, Denmark.; Mose, KF (corresponding author), Odense Univ Hosp, Allergy Ctr, DK-5000 Odense C, Denmark.	kristian.mose@rsyd.dk		Bygum, Anette/0000-0002-3004-0180					0	6	6	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 2	2019	393	10170					446	446		10.1016/S0140-6736(19)30116-3	http://dx.doi.org/10.1016/S0140-6736(19)30116-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HK1AM	30712902				2023-01-03	WOS:000457636900031
J	Roth, M; Fang, L; Stolz, D; Tamm, M				Roth, Michael; Fang, Lei; Stolz, Daiana; Tamm, Michael			Pelargonium sidoides radix extract EPs 7630 reduces rhinovirus infection through modulation of viral binding proteins on human bronchial epithelial cells	PLOS ONE			English	Article							RESPIRATORY-TRACT INFECTIONS; INDUCIBLE COSTIMULATOR LIGAND; CONTROLLED-TRIAL; ENTEROVIRUS 71; CHILDREN; EXPRESSION; EXACERBATIONS; RESPONSES; EFFICACY; ASTHMA	Bronchial epithelial cells are the first target cell for rhinovirus infection. The course of viral infections in patients with acute bronchitis, asthma and COPD can be improved by oral application of Pelargonium sidoides radix extract; however, the mechanism is not well understood. This study investigated the in vitro effect of Pelargonium sidoides radix extract (EPs 7630) on the expression of virus binding cell membrane and host defence supporting proteins on primary human bronchial epithelial cells (hBEC). Cells were isolated from patients with severe asthma (n = 6), moderate COPD (n = 6) and non-diseased controls (n = 6). Protein expression was determined by Western-blot and immunofluorescence. Rhinovirus infection was determined by immunofluorescence as well as by polymerase chain reaction. Cell survival was determined by manual cell count after live/death immunofluorescence staining. All parameters were determined over a period of 3 days. The results show that EPs 7630 concentration-dependently and significantly increased hBEC survival after rhinovirus infection. This effect was paralleled by decreased expression of the inducible co-stimulator (ICOS), its ligand ICOSL and cell surface calreticulin (C1qR). In contrast, EPs 7630 up-regulated the expression of the host defence supporting proteins beta-defensin-1 and SOCS-1, both in rhinovirus infected and un-infected hBEC. The expression of other virus interacting cell membrane proteins such as MyD88, TRL2/4 or ICAM-1 was not altered by EPs 7630. The results indicate that EPs 7630 may reduce rhinovirus infection of human primary BEC by down-regulating cell membrane docking proteins and up-regulating host defence proteins.	[Roth, Michael; Fang, Lei; Stolz, Daiana; Tamm, Michael] Univ Basel, Dept Biomed, Pulm Cell Res & Pneumol, Basel, Switzerland; [Roth, Michael; Fang, Lei; Stolz, Daiana; Tamm, Michael] Univ Basel, Dept Internal Med, Basel, Switzerland; [Roth, Michael; Fang, Lei; Stolz, Daiana; Tamm, Michael] Univ Hosp Basel, Dept Biomed, Pulm Cell Res & Pneumol, Basel, Switzerland; [Roth, Michael; Fang, Lei; Stolz, Daiana; Tamm, Michael] Univ Hosp Basel, Dept Internal Med, Basel, Switzerland	University of Basel; University of Basel; University of Basel; University of Basel	Roth, M (corresponding author), Univ Basel, Dept Biomed, Pulm Cell Res & Pneumol, Basel, Switzerland.	Michael.roth@usb.ch	Roth, Michael/H-8657-2019	Roth, Michael/0000-0002-8139-2821; Stolz, Daiana/0000-0003-0099-882X	Schwabe Pharma AG [CH-6403]	Schwabe Pharma AG	Prof. Tamm received an unrestricted Research grant of 46,957 Swiss Francs from Schwabe Pharma AG, Erlistrasse 2, CH-6403, Kussnacht am Rigi, Switzerland. The funder has no role in any of the study design, data collection and Analysis, decision to publish, or preparation of the manuscript.	Andresen E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021898; Bao YY, 2015, PHYTOMEDICINE, V22, P504, DOI 10.1016/j.phymed.2015.03.004; Bedke N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044580; Blumer T, 2017, J BIOL CHEM, V292, P17928, DOI 10.1074/jbc.M117.788877; Careddu D, 2018, INT J GEN MED, V11, P91, DOI 10.2147/IJGM.S154198; de Haij S, 2005, KIDNEY INT, V68, P2091, DOI 10.1111/j.1523-1755.2005.00665.x; Dowran Razieh, 2017, Gastroenterol Hepatol Bed Bench, V10, P272; Ezeakile M, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/153981; Gielen V, 2015, J ALLERGY CLIN IMMUN, V136, P177, DOI 10.1016/j.jaci.2014.11.039; Guani-Guerra E, 2011, ARCH MED RES, V42, P189, DOI 10.1016/j.arcmed.2011.04.003; Helfer M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087487; Hostettler KE, 2008, CLIN EXP ALLERGY, V38, P1309, DOI 10.1111/j.1365-2222.2008.03017.x; Hu DD, 2017, NEUROTOX RES, V31, P204, DOI 10.1007/s12640-016-9670-0; Humphreys IR, 2006, EUR J IMMUNOL, V36, P2928, DOI 10.1002/eji.200636155; Kajiwara Keiichi, 2009, Allergology International, V58, P573, DOI 10.2332/allergolint.09-OA-0113; Kalenik BM, 2018, VIRUS RES, V247, P10, DOI 10.1016/j.virusres.2018.01.008; Kamin W, 2010, INT J CLIN PHARM TH, V48, P184; Kamin W, 2018, CURR MED RES OPIN, V34, P475, DOI 10.1080/03007995.2017.1402754; Kamin W, 2012, PEDIATR INT, V54, P219, DOI 10.1111/j.1442-200X.2012.03598.x; Kuroki Y, 2007, CELL MICROBIOL, V9, P1871, DOI 10.1111/j.1462-5822.2007.00953.x; Lambers C, 2014, BIOCHEM PHARMACOL, V91, P400, DOI 10.1016/j.bcp.2014.07.026; Lee JJ, 2011, J PROTEOMICS, V74, P2018, DOI 10.1016/j.jprot.2011.05.022; Liao Jia-Yi, 2014, Zhongguo Dang Dai Er Ke Za Zhi, V16, P508; Liu W, 2008, IMMUNOL CELL BIOL, V86, P659, DOI 10.1038/icb.2008.45; Looi K, 2018, CLIN EXP ALLERGY, V48, P513, DOI 10.1111/cea.13097; Macaubas Claudia, 2003, Current Drug Targets - Inflammation and Allergy, V2, P175, DOI 10.2174/1568010033484304; Matthys H, 2013, RESP MED, V107, P691, DOI 10.1016/j.rmed.2013.02.011; Michaelis M, 2011, PHYTOMEDICINE, V18, P384, DOI 10.1016/j.phymed.2010.09.008; Mukhopadhyay S, 2014, RESPIROLOGY, V19, P508, DOI 10.1111/resp.12285; Nazzal D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.377; Obajemu AA, 2017, J IMMUNOL, V199, P3808, DOI 10.4049/jimmunol.1700807; Oliver BGG, 2008, THORAX, V63, P519, DOI 10.1136/thx.2007.081752; Patiroglu T, 2012, PHYTOMEDICINE, V19, P958, DOI 10.1016/j.phymed.2012.06.004; Qian XS, 2006, EUR J IMMUNOL, V36, P906, DOI 10.1002/eji.200535253; Ritchie AI, 2015, ANN AM THORAC SOC, V12, pS115, DOI 10.1513/AnnalsATS.201503-151AW; Roth M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188010; Sato J, 2016, ADV OTO-RHINO-LARYNG, V77, P59, DOI 10.1159/000441876; Shukla SD, 2017, INT J CHRONIC OBSTR, V12, P1413, DOI 10.2147/COPD.S138612; Shukla SD, 2017, RESP RES, V18, DOI 10.1186/s12931-016-0483-8; Stanciu LA, 2006, J INFECT DIS, V193, P404, DOI 10.1086/499275; Tahan F, 2013, PHYTOMEDICINE, V20, P148, DOI 10.1016/j.phymed.2012.09.022; Theisen LL, 2012, ANTIVIR RES, V94, P147, DOI 10.1016/j.antiviral.2012.03.006; Thibaut HJ, 2016, REV MED VIROL, V26, P21, DOI 10.1002/rmv.1856; Traub S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003520; Wickert LE, 2014, J LEUKOCYTE BIOL, V95, P951, DOI 10.1189/jlb.0713413; Wilkinson TMA, 2017, THORAX, V72, P919, DOI 10.1136/thoraxjnl-2016-209023; Wilson SS, 2013, J MOL BIOL, V425, P4965, DOI 10.1016/j.jmb.2013.09.038; Witte K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138075; Zhang GL, 2014, PHARMACEUTICALS-BASE, V7, P220, DOI 10.3390/ph7030220; Zheng XY, 2018, ARCH VIROL, V163, P845, DOI 10.1007/s00705-017-3700-y	50	22	25	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 1	2019	14	2							e0210702	10.1371/journal.pone.0210702	http://dx.doi.org/10.1371/journal.pone.0210702			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK2LM	30707726	Green Submitted, Green Published, gold			2023-01-03	WOS:000457742900012
J	Matiz, A; Crescentini, C; Fabbro, A; Budai, R; Bergamasco, M; Fabbro, F				Matiz, Alessio; Crescentini, Cristiano; Fabbro, Anastasia; Budai, Riccardo; Bergamasco, Massimo; Fabbro, Franco			Spontaneous eye movements during focused-attention mindfulness meditation	PLOS ONE			English	Article							MENTAL TIME-TRAVEL; INDEPENDENT COMPONENT ANALYSIS; WORKING-MEMORY; VISUAL-IMAGERY; WANDERING MIND; EXPERIENCE; THOUGHT; NETWORK; EEG; FLUCTUATIONS	Oculometric measures have been proven to be useful markers of mind-wandering during visual tasks such as reading. However, little is known about ocular activity during mindfulness meditation, a mental practice naturally involving mind-wandering episodes. In order to explore this issue, we extracted closed-eyes ocular movement measurements via a covert technique (EEG recordings) from expert meditators during two repetitions of a 7-minute mindfulness meditation session, focusing on the breath, and two repetitions of a 7-minute instructed mind-wandering task. Power spectral density was estimated on both the vertical and horizontal components of eye movements. The results show a significantly smaller average amplitude of eye movements in the delta band (1-4 Hz) during mindfulness meditation than instructed mind-wandering. Moreover, participants' meditation expertise correlated significantly with this average amplitude during both tasks, with more experienced meditators generally moving their eyes less than less experienced meditators. These findings suggest the potential use of this measure to detect mind-wandering episodes during mindfulness meditation and to assess meditation performance.	[Matiz, Alessio; Bergamasco, Massimo; Fabbro, Franco] Scuola Super Sant Anna, PERCRO Lab, Pisa, Italy; [Crescentini, Cristiano] Univ Udine, Commun Educ & Soc, Dept Languages & Literatures, Udine, Italy; [Fabbro, Anastasia] Univ Roma La Sapienza, Dept Psychol, Rome, Italy; [Fabbro, Anastasia; Fabbro, Franco] Univ Udine, Dept Med, Udine, Italy; [Budai, Riccardo] Univ Hosp S Maria Misericordia, Dept Neurosci, Udine, Italy	Scuola Superiore Sant'Anna; University of Udine; Sapienza University Rome; University of Udine; Hospital Santa Maria della Misericordia	Matiz, A (corresponding author), Scuola Super Sant Anna, PERCRO Lab, Pisa, Italy.	matiz.alessio@spes.uniud.it		CRESCENTINI, CRISTIANO/0000-0002-3154-3687; Matiz, Alessio/0000-0001-6785-3102	Scuola Superiore "Sant'Anna"	Scuola Superiore "Sant'Anna"	This work was supported by Scuola Superiore "Sant'Anna" (https://www.santannapisa.it/) Phd program to AM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANTROBUS JS, 1964, J ABNORM SOC PSYCH, V69, P244, DOI 10.1037/h0041846; BAHILL A T, 1975, Mathematical Biosciences, V24, P191, DOI 10.1016/0025-5564(75)90075-9; Baird B, 2012, PSYCHOL SCI, V23, P1117, DOI 10.1177/0956797612446024; Baird B, 2011, CONSCIOUS COGN, V20, P1604, DOI 10.1016/j.concog.2011.08.007; Bakeman R, 2005, BEHAV RES METHODS, V37, P379, DOI 10.3758/BF03192707; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Bhikkhu B, 1980, ANAPANASATI MINDFULN; Bixler R, 2016, USER MODEL USER-ADAP, V26, P33, DOI 10.1007/s11257-015-9167-1; Bloom HS, 2005, EVALUATION REV, V19, P547; Bonnet C, 2013, CLIN NEUROPHYSIOL, V124, P2216, DOI 10.1016/j.clinph.2013.05.002; Bortolussi M., 2015, INVESTIGATIONS PHENO, V81, P31, DOI [10.1007/978-3-319-14090-2_3, DOI 10.1007/978-3-319-14090-2_3]; Braboszcz C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170647; Brandmeyer T, 2018, EXP BRAIN RES, V236, P2519, DOI 10.1007/s00221-016-4811-5; BRANDT SA, 1989, P IEEE EMBS, V11, P278, DOI 10.1109/IEMBS.1989.95721; Brandt SA, 1997, J COGNITIVE NEUROSCI, V9, P27, DOI 10.1162/jocn.1997.9.1.27; Brefczynski-Lewis JA, 2007, P NATL ACAD SCI USA, V104, P11483, DOI 10.1073/pnas.0606552104; Brewer JA, 2011, P NATL ACAD SCI USA, V108, P20254, DOI 10.1073/pnas.1112029108; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Cahn BR, 2013, SOC COGN AFFECT NEUR, V8, P100, DOI 10.1093/scan/nss060; Cahn BR, 2010, COGN PROCESS, V11, P39, DOI 10.1007/s10339-009-0352-1; Cahn BR, 2009, INT J PSYCHOPHYSIOL, V72, P51, DOI 10.1016/j.ijpsycho.2008.03.013; Cahn BR, 2006, PSYCHOL BULL, V132, P180, DOI 10.1037/0033-2909.132.2.180; Campanella F, 2014, COMPR PSYCHIAT, V55, P1269, DOI 10.1016/j.comppsych.2014.03.009; Chaumon M, 2015, J NEUROSCI METH, V250, P47, DOI 10.1016/j.jneumeth.2015.02.025; Christoff K, 2016, NAT REV NEUROSCI, V17, P718, DOI 10.1038/nrn.2016.113; Corbetta M, 1998, NEURON, V21, P761, DOI 10.1016/S0896-6273(00)80593-0; Crescentini Cristiano, 2018, Int J MS Care, V20, P101, DOI 10.7224/1537-2073.2016-093; Crescentini C, 2016, COMPUT HUM BEHAV, V59, P304, DOI 10.1016/j.chb.2016.02.031; Crescentini C, 2015, J ADDICT DIS, V34, P75, DOI 10.1080/10550887.2014.991657; Crescentini C, 2014, CONSCIOUS COGN, V30, P266, DOI 10.1016/j.concog.2014.09.013; Davidson RJ, 2015, AM PSYCHOL, V70, P581, DOI 10.1037/a0039512; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Delorme A, 2007, NEUROIMAGE, V34, P1443, DOI 10.1016/j.neuroimage.2006.11.004; DEMENT W, 1957, J EXP PSYCHOL, V53, P339, DOI 10.1037/h0048189; Deng YQ, 2014, MINDFULNESS, V5, P124, DOI 10.1007/s12671-012-0157-7; DeRosario-Martinez H, 2015, PACKAGE PHIA VERSION; Dowiasch S, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00046; Ehrlichman H, 2007, BRAIN COGNITION, V64, P7, DOI 10.1016/j.bandc.2006.10.001; Ehrlichman H, 2012, CURR DIR PSYCHOL SCI, V21, P96, DOI 10.1177/0963721412436810; Fabbro F, 2016, RICERCHE PSICOLOGIA, V4, P457, DOI DOI 10.3280/RIP2016-004001; Fabbro F, 2014, WORLD FUTURES, V70, P386; Faber M, 2018, BEHAV RES METHODS, V50, P134, DOI 10.3758/s13428-017-0857-y; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Findlay JM, 1999, BEHAV BRAIN SCI, V22, P661, DOI 10.1017/S0140525X99002150; Forster S, 2009, COGNITION, V111, P345, DOI 10.1016/j.cognition.2009.02.006; Fourtassi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068560; Fox KCR, 2015, NEUROIMAGE, V111, P611, DOI 10.1016/j.neuroimage.2015.02.039; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hartmann M, 2014, CONSCIOUS COGN, V30, P201, DOI 10.1016/j.concog.2014.09.007; Hasenkamp W, 2012, NEUROIMAGE, V59, P750, DOI 10.1016/j.neuroimage.2011.07.008; Hassabis D, 2007, TRENDS COGN SCI, V11, P299, DOI 10.1016/j.tics.2007.05.001; HOLM S, 1979, SCAND J STAT, V6, P65; Johansson R, 2006, COGNITIVE SCI, V30, P1053, DOI 10.1207/s15516709cog0000_86; Kabat-Zinn J., 1990, FULL CATASTROPHE LIV; Kam JWY, 2011, J COGNITIVE NEUROSCI, V23, P460, DOI 10.1162/jocn.2010.21443; Kane MJ, 2007, PSYCHOL SCI, V18, P614, DOI 10.1111/j.1467-9280.2007.01948.x; Kaur Chamandeep, 2015, Adv Prev Med, V2015, P614723, DOI 10.1155/2015/614723; Nguyen KV, 2014, SCI STUD READ, V18, P274, DOI 10.1080/10888438.2013.876424; Killingsworth MA, 2010, SCIENCE, V330, P932, DOI 10.1126/science.1192439; Kruis A, 2016, PSYCHOPHYSIOLOGY, V53, P749, DOI 10.1111/psyp.12619; Kumari V, 2017, CONSCIOUS COGN, V48, P66, DOI 10.1016/j.concog.2016.10.008; Laeng B, 2002, COGNITIVE SCI, V26, P207, DOI 10.1016/S0364-0213(01)00065-9; Laeng B, 2014, COGNITION, V131, P263, DOI 10.1016/j.cognition.2014.01.003; Lakens D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00863; Lawrence MA, 2016, PACKAGE EZ VERSION 4; Lee TW, 1999, NEURAL COMPUT, V11, P417, DOI 10.1162/089976699300016719; Leigh RJ, 2004, BRAIN, V127, P460, DOI 10.1093/brain/awh035; Levinson DB, 2012, PSYCHOL SCI, V23, P375, DOI 10.1177/0956797611431465; Makeig S, 1996, ADV NEUR IN, V8, P145; Malinowski P, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00008; Manna A, 2010, BRAIN RES BULL, V82, P46, DOI 10.1016/j.brainresbull.2010.03.001; Martinez-Conde S, 2009, TRENDS NEUROSCI, V32, P463, DOI 10.1016/j.tins.2009.05.006; Mason MF, 2007, SCIENCE, V315, P393, DOI 10.1126/science.1131295; McVay JC, 2012, J EXP PSYCHOL GEN, V141, P302, DOI 10.1037/a0025250; Micic D, 2010, BRAIN COGNITION, V74, P210, DOI 10.1016/j.bandc.2010.07.014; Mooneyham BW, 2013, CAN J EXP PSYCHOL, V67, P11, DOI 10.1037/a0031569; Munoz DP, 1998, EXP BRAIN RES, V121, P391, DOI 10.1007/s002210050473; Ospina Maria B, 2007, Evid Rep Technol Assess (Full Rep), P1; Pace TWW, 2009, PSYCHONEUROENDOCRINO, V34, P87, DOI 10.1016/j.psyneuen.2008.08.011; R Core Team, 2021, R LANG ENV STAT COMP; Ramot M, 2011, NEUROIMAGE, V58, P213, DOI 10.1016/j.neuroimage.2011.06.015; Randall JG, 2014, PSYCHOL BULL, V140, P1411, DOI 10.1037/a0037428; Rayner K, 1998, PSYCHOL BULL, V124, P372, DOI 10.1037/0033-2909.124.3.372; Reichle ED, 2010, PSYCHOL SCI, V21, P1300, DOI 10.1177/0956797610378686; Renoult L, 2015, J COGNITIVE NEUROSCI, V27, P57, DOI 10.1162/jocn_a_00689; Rubin DC, 2003, MEM COGNITION, V31, P887, DOI 10.3758/BF03196443; Schacter DL, 2007, NATURE, V445, P27, DOI 10.1038/445027a; Schad DJ, 2012, COGNITION, V125, P179, DOI 10.1016/j.cognition.2012.07.004; Schooler JW, 2011, TRENDS COGN SCI, V15, P319, DOI 10.1016/j.tics.2011.05.006; Schooler JW, 2004, THINKING AND SEEING, P203; Seli P, 2016, TRENDS COGN SCI, V20, P605, DOI 10.1016/j.tics.2016.05.010; Seli P, 2015, PSYCHOL RES-PSYCH FO, V79, P750, DOI 10.1007/s00426-014-0617-x; Short EB, 2010, EVID-BASED COMPL ALT, V7, P121, DOI 10.1093/ecam/nem163; Signorell A., 2020, DESCTOOLS TOOLS DESC; Smallwood J, 2004, CONSCIOUS COGN, V13, P657, DOI 10.1016/j.concog.2004.06.003; Smallwood JM, 2003, CONSCIOUS COGN, V12, P452, DOI 10.1016/S1053-8100(03)00018-7; Smallwood J, 2008, MEM COGNITION, V36, P1144, DOI 10.3758/MC.36.6.1144; Smallwood J, 2008, J COGNITIVE NEUROSCI, V20, P458, DOI 10.1162/jocn.2008.20.3.458; Smallwood J, 2007, COGNITION EMOTION, V21, P816, DOI 10.1080/02699930600911531; Smallwood J, 2006, PSYCHOL BULL, V132, P946, DOI 10.1037/0033-2909.132.6.946; Smallwood J, 2011, CONSCIOUS COGN, V20, P1120, DOI 10.1016/j.concog.2010.12.017; Smallwood J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018298; Smallwood J, 2009, CONSCIOUS COGN, V18, P118, DOI 10.1016/j.concog.2008.11.004; Smilek D, 2010, PSYCHOL SCI, V21, P786, DOI 10.1177/0956797610368063; Soltanlou M, 2017, COGN AFFECT BEHAV NE, V17, P724, DOI 10.3758/s13415-017-0508-x; Song XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044423; Spivey MJ, 2001, PSYCHOL RES-PSYCH FO, V65, P235, DOI 10.1007/s004260100059; Stawarczyk D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00425; Stawarczyk D, 2011, ACTA PSYCHOL, V136, P370, DOI 10.1016/j.actpsy.2011.01.002; Suddendorf T, 2007, BEHAV BRAIN SCI, V30, P299, DOI 10.1017/S0140525X07001975; Suddendorf T, 2009, PHILOS T R SOC B, V364, P1317, DOI 10.1098/rstb.2008.0301; Tomasino B, 2013, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00346; Uzzaman S, 2011, CONSCIOUS COGN, V20, P1882, DOI 10.1016/j.concog.2011.09.010; WELCH PD, 1967, IEEE T ACOUST SPEECH, VAU15, P70, DOI 10.1109/TAU.1967.1161901; Wickham H., 2016, GGPLOT2 ELEGANT GRAP, DOI 10.1007/978-3-319-24277-4; Winkler I, 2014, J NEURAL ENG, V11, DOI 10.1088/1741-2560/11/3/035013; Winkler I, 2011, BEHAV BRAIN FUNCT, V7, DOI 10.1186/1744-9081-7-30	118	5	5	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2019	14	1							e0210862	10.1371/journal.pone.0210862	http://dx.doi.org/10.1371/journal.pone.0210862			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HI8IY	30677056	gold, Green Published			2023-01-03	WOS:000456700400028
J	Owora, AH; Carabin, H; Garwe, T; Anderson, MP				Owora, Arthur H.; Carabin, Helene; Garwe, Tabitha; Anderson, Michael P.			Are we validly assessing major depression disorder risk and associated factors among mothers of young children? A cross-sectional study involving home visitation programs	PLOS ONE			English	Article							CASE-FINDING INSTRUMENTS; MATERNAL DEPRESSION; POSTPARTUM DEPRESSION; UNITED-STATES; SCREENING TOOLS; MENTAL-HEALTH; MISCLASSIFICATION; SYMPTOMS; RELIABILITY; PREDICTORS	Failure to account for misclassification error accruing from imperfect case-finding instruments can produce biased estimates of suspected major depression disorder (MDD) risk factor associations. The objective of this study was to estimate the impact of misclassification error on the magnitude of measures of association between suspected risk factors and MDD assessed using the Center of Epidemiological Studies on Depression-Short Form during the prenatal and postnatal periods. Baseline data were collected from 520 mothers participating in two home visitation studies in Oklahoma City between 2010 and 2014. A Bayesian binomial latent class model was used to compare the prevalence proportion ratio (PPR) between suspected risk factors and MDD with and without adjustment for misclassification error and confounding by period of MDD symptom on-set. Adjustment for misclassification error and confounding by period of MDD on-set (prenatal vs postnatal) showed that the association between suspected risk factors and MDD is underestimated (-) and overestimated (+) differentially in different source populations of low-income mothers. The median bias in the magnitude of PPR estimates ranged between -.47 (95% Bayesian Credible Intervals [BCI]: -10.67, 1.90) for intimate partner violence to +.06 (95%BCI: -0.37, 0.47) for race/ethnicity among native-born US residents. Among recent Hispanic immigrants, bias ranged from -.77 (95%BCI: -15.31, 0.96) for history of childhood maltreatment to +.10 (95%BCI: -0.17, 0.39) for adequacy of family resources. Overall, the extent of bias on measures of association between maternal MDD and suspected risk factors is considerable without adjustment for misclassification error and is even higher for confounding by period of MDD assessment. Consideration of these biases in MDD prevention research is warranted.	[Owora, Arthur H.] Syracuse Univ, Dept Publ Hlth, Falk Coll, Syracuse, NY 13244 USA; [Carabin, Helene; Garwe, Tabitha; Anderson, Michael P.] Univ Oklahoma, Dept Biostat & Epidemiol, Hlth Sci Ctr, Oklahoma City, OK USA	Syracuse University; University of Oklahoma System; University of Oklahoma Health Sciences Center	Owora, AH (corresponding author), Syracuse Univ, Dept Publ Hlth, Falk Coll, Syracuse, NY 13244 USA.	ahowora@syr.edu	Owora, Arthur/X-3389-2019	Owora, Arthur/0000-0002-4580-7428	Administration of Children, Youth, and Families [90CA1764]; Health Resources and Services Administration [D89MC23154]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM104938] Funding Source: NIH RePORTER	Administration of Children, Youth, and Families; Health Resources and Services Administration(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by Administration of Children, Youth, and Families (grant number 90CA1764), Health Resources and Services Administration (grant number D89MC23154). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adirim T, 2013, PEDIATRICS, V132, pS59, DOI 10.1542/peds.2013-1021C; Ammerman RI, 2009, CHILD ABUSE NEGLECT, V33, P127, DOI 10.1016/j.chiabu.2008.09.005; Ammerman RT, 2010, AGGRESS VIOLENT BEH, V15, P191, DOI 10.1016/j.avb.2009.12.002; Beardslee WR, 1998, J AM ACAD CHILD PSY, V37, P1134, DOI 10.1097/00004583-199811000-00012; Beck CT, 1996, NURS RES, V45, P297, DOI 10.1097/00006199-199609000-00008; Beck CT, 2001, NURS RES, V50, P275, DOI 10.1097/00006199-200109000-00004; Beeghly Marjorie, 2003, Matern Child Health J, V7, P157, DOI 10.1023/A:1025132320321; BRENNER H, 1993, J CLIN EPIDEMIOL, V46, P1195, DOI 10.1016/0895-4356(93)90119-L; Bright JI, 1999, J CONSULT CLIN PSYCH, V67, P491, DOI 10.1037/0022-006X.67.4.491; Caronongan P, 2011, GS10F0050LHHSP233200; Chaffin M, 2012, CHILD MALTREATMENT, V17, P242, DOI 10.1177/1077559512457239; Chaudron LH, 2010, PEDIATRICS, V125, pE609, DOI 10.1542/peds.2008-3261; Chazan-Cohen R, 2007, INFANT MENT HEALTH J, V28, P151, DOI 10.1002/imhj.20127; Duggan AK, 2009, J CONSULT CLIN PSYCH, V77, P788, DOI 10.1037/a0015709; DUNST CJ, 1987, CHILD CARE HLTH DEV, V13, P111, DOI 10.1111/j.1365-2214.1987.tb00528.x; Ertel KA, 2011, J WOMENS HEALTH, V20, P1609, DOI 10.1089/jwh.2010.2657; FARR SL, 2011, PREV CHRONIC DIS, V8; Gaynes B. N., 2005, AGENCY HLTH RES QUAL, V119, P1, DOI DOI 10.1037/E439372005-001; Geweke J., 1992, BAYESIAN STAT, P169; Ghio L, 2015, J AFFECT DISORDERS, V175, P224, DOI 10.1016/j.jad.2015.01.014; Goodman SH, 2011, CLIN CHILD FAM PSYCH, V14, P1, DOI 10.1007/s10567-010-0080-1; HEIDELBERGER P, 1983, OPER RES, V31, P1109, DOI 10.1287/opre.31.6.1109; Ji SA, 2011, J PSYCHIATR RES, V45, P213, DOI 10.1016/j.jpsychires.2010.05.017; Jurek AM, 2005, INT J EPIDEMIOL, V34, P680, DOI 10.1093/ije/dyi060; Kernot J, 2015, ARCH WOMEN MENT HLTH, V18, P255, DOI 10.1007/s00737-014-0461-4; Kerr LK, 2001, WESTERN J MED, V175, P349, DOI 10.1136/ewjm.175.5.349; Kessler RC, 2013, ANNU REV PUBL HEALTH, V34, P119, DOI 10.1146/annurev-publhealth-031912-114409; Lancaster CA, 2010, AM J OBSTET GYNECOL, V202, P5, DOI 10.1016/j.ajog.2009.09.007; Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011; OHara MW, 1996, INT REV PSYCHIATR, V8, P37, DOI 10.3109/09540269609037816; Orr ST, 2002, AM J EPIDEMIOL, V156, P797, DOI 10.1093/aje/kwf131; Owora AH, 2018, PSYCHIAT RES, V261, P80, DOI 10.1016/j.psychres.2017.12.047; Owora AH, 2016, J AFFECT DISORDERS, V205, P335, DOI 10.1016/j.jad.2016.08.014; Owora AH, 2016, J AFFECT DISORDERS, V201, P185, DOI 10.1016/j.jad.2016.05.015; Pereira AT, 2014, J AFFECT DISORDERS, V166, P71, DOI 10.1016/j.jad.2014.04.008; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; Rubin D. B., 1992, STAT SCI, V7, P457, DOI DOI 10.1111/j.1469-8137.2011.03796.x; Savoca E., 2004, HLTH SERVICES OUTCOM, P175; SHROUT PE, 1989, J CLIN EPIDEMIOL, V42, P69, DOI 10.1016/0895-4356(89)90027-9; Simon GE, 2002, PSYCHOL MED, V32, P585, DOI 10.1017/S0033291702005457; Spijker J, 2002, BRIT J PSYCHIAT, V181, P208, DOI 10.1192/bjp.181.3.208; Stevens J, 2002, J COMMUNITY PSYCHOL, V30, P551, DOI 10.1002/jcop.10017; Stewart DE, 2003, POSTPARTUM DEPRESSIO; Straus Murray A, 2004, Violence Vict, V19, P507; Tandon SD, 2012, J AFFECT DISORDERS, V136, P155, DOI 10.1016/j.jad.2011.07.014; Tandon SD, 2005, MATERN CHILD HLTH J, V9, P273, DOI 10.1007/s10995-005-0012-8; Weiss R., 1974, DOING OTHERS, P17	48	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2019	14	1							e0209735	10.1371/journal.pone.0209735	http://dx.doi.org/10.1371/journal.pone.0209735			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HG5UW	30615650	Green Published, Green Submitted, gold			2023-01-03	WOS:000455045900028
J	Cao, J; Zhu, Z; Wang, H; Nichols, TC; Lui, GYL; Deng, SB; Rejto, PA; VanArsdale, T; Hardwick, JS; Weinrich, SL; Wei, P				Cao, Joan; Zhu, Zhou; Wang, Hui; Nichols, Timothy C.; Lui, Goldie Y. L.; Deng, Shibing; Rejto, Paul A.; VanArsdale, Todd; Hardwick, James S.; Weinrich, Scott L.; Wei, Ping			Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer	ONCOGENE			English	Article							DEPENDENT KINASE 4/6; BREAST-CANCER; EXPRESSION; ANGIOGENESIS; PHOSPHORYLATION; TRANSCRIPTION; REPLICATION; SENSITIVITY; DISRUPTION; RECEPTOR	The CDK4/6 inhibitor palbociclib reduces tumor growth by decreasing retinoblastoma (RB) protein phosphorylation and inducing cell cycle arrest at the G1/S phase transition. Palbociclib in combination with anti-hormonal therapy brings significant benefit to breast cancer patients. In this study, novel combination approaches and underlying molecular/cellular mechanisms for palbociclib were explored in squamous cell lung cancer (SqCLC), the second most common subtype of non-small cell lung cancer. While approximate 20% lung patients benefit from immunotherapy, most SqCLC patients who receive platinum-doublet chemotherapy as first-line treatment, which often includes a taxane, are still in need of more effective combination therapies. Our results demonstrated enhanced cytotoxicity and anti-tumor effect with palbociclib plus taxanes at clinically achievable doses in multiple SqCLC models with diverse cancer genetic backgrounds. Comprehensive gene expression analysis revealed a sustained disruption of pRB-E2F signaling by combination that was accompanied with enhanced regulation of pleiotropic biological effects. These included several novel mechanisms such as abrogation of G2/M and mitotic spindle assembly checkpoints, as well as impaired induction of hypoxia-inducible factor 1 alpha (HIF-1 alpha). The decrease in HIF-1 alpha modulated a couple key angiogenic and anti-angiogenic factors, resulting in an enhanced anti-angiogenic effect. This preclinical work suggests a new therapeutic opportunity for palbociclib in lung and other cancers currently treated with taxane based chemotherapy as standard of care.	[Cao, Joan; Zhu, Zhou; Rejto, Paul A.; Hardwick, James S.; Weinrich, Scott L.; Wei, Ping] Pfizer Inc, Oncol Translat Res, San Diego, CA 92121 USA; [Wang, Hui] Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; [Nichols, Timothy C.] Pfizer Inc, Drug Safety Res & Dev, San Diego, CA 92121 USA; [Lui, Goldie Y. L.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; [Deng, Shibing] Pfizer Inc, La Jolla Labs, Biostat, San Diego, CA 92121 USA; [VanArsdale, Todd] Pfizer Inc, Tumor Cell Biol Oncol Res & Dev, San Diego, CA 92121 USA	Pfizer; Novartis; Pfizer; Fred Hutchinson Cancer Center; Pfizer; Pfizer	Wei, P (corresponding author), Pfizer Inc, Oncol Translat Res, San Diego, CA 92121 USA.	ping.wei@pfizer.com	Lui, Goldie/J-7874-2019	Lui, Goldie/0000-0003-2741-6025				Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Bakker WJ, 2013, TRANSCR-AUSTIN, V4, P62, DOI 10.4161/trns.23680; Bertoli C, 2016, CELL REP, V15, P1412, DOI 10.1016/j.celrep.2016.04.036; Bocci G, 2013, ANGIOGENESIS, V16, P481, DOI 10.1007/s10456-013-9334-0; Bosco EE, 2007, J CLIN INVEST, V117, P218, DOI 10.1172/JCI28803; Bretz F., 2011, MULTIPLE COMP USING, DOI DOI 10.1201/9781420010909; Buck E, 2006, MOL CANCER THER, V5, P2676, DOI 10.1158/1535-7163.MCT-06-0166; Budde A, 2005, ONCOGENE, V24, P1802, DOI 10.1038/sj.onc.1208369; Dean JL, 2012, J BIOL CHEM, V287, P29075, DOI 10.1074/jbc.M112.365494; Deville JL, 2010, EXPERT OPIN THER TAR, V14, P1059, DOI 10.1517/14728222.2010.522328; Dhillon S, 2015, DRUGS, V75, P543, DOI 10.1007/s40265-015-0379-9; Dominguez-Brauer C, 2015, MOL CELL, V60, P524, DOI 10.1016/j.molcel.2015.11.006; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ertel A, 2010, CELL CYCLE, V9, P4153, DOI 10.4161/cc.9.20.13454; Escuin D, 2005, CANCER RES, V65, P9021, DOI 10.1158/0008-5472.CAN-04-4095; Ferrara R, 2016, EXPERT OPIN PHARMACO, V17, P1113, DOI 10.1517/14656566.2016.1157581; Flaherty KT, 2012, CLIN CANCER RES, V18, P568, DOI 10.1158/1078-0432.CCR-11-0509; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gabellini C, 2006, ONCOGENE, V25, P5326, DOI 10.1038/sj.onc.1209631; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Gong XQ, 2017, CANCER CELL, V32, P761, DOI 10.1016/j.ccell.2017.11.006; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Johnson J, 2016, ONCOGENE, V35, P4829, DOI 10.1038/onc.2016.32; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654; Kwong LN, 2012, NAT MED, V18, P1503, DOI 10.1038/nm.2941; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Manchado E, 2012, CELL DEATH DIFFER, V19, P369, DOI 10.1038/cdd.2011.197; Manning AL, 2012, NAT REV CANCER, V12, P220, DOI 10.1038/nrc3216; Newcomb EW, 2005, NEURO-ONCOLOGY, V7, P225, DOI 10.1215/S1152851704000997; O'Leary B, 2016, NAT REV CLIN ONCOL, V13, P417, DOI 10.1038/nrclinonc.2016.26; Oh E, 2016, SCI REP, V6, P1; Raspe E, 2017, EMBO MOL MED, V9, P1052, DOI 10.15252/emmm.201607084; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Schaal C, 2014, ADV CANCER RES, V121, P147, DOI 10.1016/B978-0-12-800249-0.00004-4; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Socinski MA, 2014, CURR ONCOL, V21, pE691, DOI 10.3747/co.21.1997; Spilker ME, 2017, CLIN CANCER RES, V23, P1080, DOI 10.1158/1078-0432.CCR-16-1164; Stetler-Stevenson WG, 2005, TRENDS MOL MED, V11, P97, DOI 10.1016/j.molmed.2005.01.007; Subramaniam D, 2012, MOL CANCER THER, V11, P1598, DOI 10.1158/1535-7163.MCT-12-0102; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Syed YY, 2017, DRUGS, V77, P799, DOI 10.1007/s40265-017-0742-0; Tse AN, 2007, CLIN CANCER RES, V13, P1955, DOI 10.1158/1078-0432.CCR-06-2793; VanArsdale T, 2015, CLIN CANCER RES, V21, P2905, DOI 10.1158/1078-0432.CCR-14-0816; Vernell R, 2003, J BIOL CHEM, V278, P46124, DOI 10.1074/jbc.M304930200; Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020; Weijts BGMW, 2012, EMBO J, V31, P3871, DOI 10.1038/emboj.2012.231; Witkiewicz AK, 2012, CLIN CANCER RES, V18, P5110, DOI 10.1158/1078-0432.CCR-12-0903; Zhang XH, 2013, CANCER BIOL THER, V14, P597, DOI 10.4161/cbt.24592	53	19	19	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4125	4141		10.1038/s41388-019-0708-7	http://dx.doi.org/10.1038/s41388-019-0708-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30700828				2023-01-03	WOS:000468740200011
J	Saito, A; Masugi, Y; Nakagawa, K; Obata, H; Nakazawa, K				Saito, Akira; Masugi, Yohei; Nakagawa, Kento; Obata, Hiroki; Nakazawa, Kimitaka			Repeatability of spinal reflexes of lower limb muscles evoked by transcutaneous spinal cord stimulation	PLOS ONE			English	Article							SOLEUS H-REFLEX; RELIABILITY; MODULATION; ACTIVATION; RESPONSES; DEPRESSION; STROKE	Transcutaneous electrical stimulation is a relatively new technique to evoke spinal reflexes in lower limb muscles. The advantage of this technique is that the spinal reflex responses can be obtained from multiple lower limb muscles simultaneously. However, repeatability of spinal reflexes evoked by transcutaneous spinal cord stimulation between days has not been evaluated. We aimed to examine repeatability of recruitment properties of the spinal reflexes evoked by transcutaneous spinal cord stimulation. Recruitment curves of the spinal reflexes evoked by transcutaneous spinal cord stimulation of 8 lower limb muscles (i.e., foot, lower leg, and thigh muscles) of 20 males were measured on two consecutive days. To confirm that responses were caused by activation of the sensory fiber, a double-pulse stimulation with 50 ms inter-pulse interval was delivered. Peak-to-peak amplitude of the first response was calculated for each muscle when no response was observed in the second response owing to post-activation depression. For comparison with the spinal reflexes evoked by transcutaneous spinal cord stimulation, the recruitment curves of the H-reflex amplitude of the soleus of 9 males were measured. Threshold intensity and maximal slope of the recruitment curves were calculated, and inter-day repeatability of the properties was quantified using intraclass correlation coefficients. For the spinal reflexes evoked by transcutaneous spinal cord stimulation, the intraclass correlation coefficient values of threshold intensity and maximal slope for each muscle ranged from 0.487 to 0.874 and from 0.471 to 0.964, respectively. Regarding the soleus H-reflex, the intraclass correlation coefficients of threshold intensity and maximal slope were 0.936 and 0.751, respectively. The present data showed that repeatability of the recruitment properties of the spinal reflexes evoked by transcutaneous spinal cord stimulation in the lower limb was moderate to high. Measurement of the spinal reflexes evoked by transcutaneous spinal cord stimulation would be useful for longitudinal neurophysiological studies.	[Saito, Akira; Masugi, Yohei; Nakagawa, Kento; Nakazawa, Kimitaka] Univ Tokyo, Grad Sch Arts & Sci, Meguro Ku, Tokyo, Japan; [Saito, Akira; Nakagawa, Kento] Japan Soc Promot Sci, Chiyoda Ku, Kojimachi, Tokyo, Japan; [Masugi, Yohei] Tokyo Int Univ, Inst Sports Med & Sci, Kawagoe, Saitama, Japan; [Obata, Hiroki] Kyushu Inst Technol, Inst Liberal Arts, Dept Humanities & Social Sci, Tobata Ku, Kitakyushu, Fukuoka, Japan	University of Tokyo; Japan Society for the Promotion of Science; Kyushu Institute of Technology	Saito, A (corresponding author), Univ Tokyo, Grad Sch Arts & Sci, Meguro Ku, Tokyo, Japan.; Saito, A (corresponding author), Japan Soc Promot Sci, Chiyoda Ku, Kojimachi, Tokyo, Japan.	a-saito@idaten.c.u-tokyo.ac.jp		Nakagawa, Kento/0000-0002-6203-6602; Masugi, Yohei/0000-0001-8156-8586	JSPS KAKENHI [JP17J02997]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by JSPS KAKENHI [grant number JP17J02997] to AS.	Aagaard P, 2002, J APPL PHYSIOL, V92, P2309, DOI 10.1152/japplphysiol.01185.2001; Andrews JC, 2015, NEUROSCI LETT, V589, P144, DOI 10.1016/j.neulet.2015.01.041; Bakhtiary AH, 2008, CLIN REHABIL, V22, P418, DOI 10.1177/0269215507084008; Bove M, 2003, J PHYSIOL-LONDON, V550, P617, DOI 10.1113/jphysiol.2003.043331; Burke D, 2016, CLIN NEUROPHYS PRACT, V1, P9, DOI 10.1016/j.cnp.2016.02.003; Courtine GG, 2007, J PHYSIOL-LONDON, V582, P1125, DOI 10.1113/jphysiol.2007.128447; Danner SM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147479; Danner SM, 2011, ARTIF ORGANS, V35, P257, DOI 10.1111/j.1525-1594.2011.01213.x; Doguet V, 2014, EUR J APPL PHYSIOL, V114, P2509, DOI 10.1007/s00421-014-2969-8; Dy CJ, 2010, J NEUROPHYSIOL, V103, P2808, DOI 10.1152/jn.00316.2009; Freyler K, 2014, GAIT POSTURE, V40, P291, DOI 10.1016/j.gaitpost.2014.04.186; Gerasimenko Y, 2015, ANN PHYS REHABIL MED, V58, P225, DOI 10.1016/j.rehab.2015.05.003; Holtermann A, 2007, EUR J APPL PHYSIOL, V101, P301, DOI 10.1007/s00421-007-0503-y; Jaberzadeh S, 2004, ARCH PHYS MED REHAB, V85, P1168, DOI 10.1016/j.apmr.2003.09.009; Lavrov I, 2006, J NEUROPHYSIOL, V96, P1699, DOI 10.1152/jn.00325.2006; Masugi Y, 2016, NEUROSCI LETT, V627, P100, DOI 10.1016/j.neulet.2016.05.047; Minassian K, 2007, MUSCLE NERVE, V35, P327, DOI 10.1002/mus.20700; Misiaszek JE, 2003, MUSCLE NERVE, V28, P144, DOI 10.1002/mus.10372; Mynark RG, 2005, CLIN NEUROPHYSIOL, V116, P1400, DOI 10.1016/j.clinph.2005.02.001; Nakagawa K, 2018, NEUROSCI LETT, V668, P55, DOI 10.1016/j.neulet.2018.01.015; Palmieri TM, 2002, INT J NEUROSCI, V112, P841, DOI 10.1080/00207450290025851; Pierrot-Deseilligny E, 2000, NEUROPHYSIOL CLIN, V30, P67, DOI 10.1016/S0987-7053(00)00062-9; Roy FD, 2012, EXP BRAIN RES, V223, P281, DOI 10.1007/s00221-012-3258-6; Sayenko DG, 2015, J APPL PHYSIOL, V118, P1364, DOI 10.1152/japplphysiol.01128.2014; Tokuno CD, 2012, EUR J APPL PHYSIOL, V112, P3259, DOI 10.1007/s00421-011-2302-8; Traversa R, 2000, CLIN NEUROPHYSIOL, V111, P1695, DOI 10.1016/S1388-2457(00)00373-4; Trimble MH, 1998, NEUROSCI LETT, V246, P186, DOI 10.1016/S0304-3940(98)00259-6; Versino M, 2007, MUSCLE NERVE, V36, P39, DOI 10.1002/mus.20775; Vincent W.J., 2012, STAT KINESIOLOGY, V4th ed.; Weir JP, 2005, J STRENGTH COND RES, V19, P231, DOI 10.1519/15184.1	30	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2019	14	4							e0214818	10.1371/journal.pone.0214818	http://dx.doi.org/10.1371/journal.pone.0214818			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR7EH	30947310	Green Published, Green Submitted, gold			2023-01-03	WOS:000463314500067
J	Narasimhan, M; de Iongh, A; Askew, I; Simpson, PJ				Narasimhan, Manjulaa; de Iongh, Anya; Askew, Ian; Simpson, Paul J.			It's time to recognise self care as an integral component of health systems	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Narasimhan, Manjulaa; Askew, Ian] World Hlth Org, Geneva, Switzerland; [de Iongh, Anya; Simpson, Paul J.] BMJ, London, England	World Health Organization	Simpson, PJ (corresponding author), BMJ, London, England.	psimpson@bmj.com		Narasimhan, Manjulaa/0000-0003-0598-6887; Simpson, Paul/0000-0002-5069-8588				Patel V, 2016, LANCET, V387, P1672, DOI 10.1016/S0140-6736(15)00390-6; Steverink Nardi, 2005, Eur J Ageing, V2, P235, DOI 10.1007/s10433-005-0012-y; Toksvig S., 2004, GUARDIAN	3	12	12	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	2019	365								l1403	10.1136/bmj.l1403	http://dx.doi.org/10.1136/bmj.l1403			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HS6TL	30936068	Green Published, hybrid			2023-01-03	WOS:000464004100007
J	Mutz, J; Vipulananthan, V; Carter, B; Hurlemann, R; Fu, CHY; Young, AH				Mutz, Julian; Vipulananthan, Vijeinika; Carter, Ben; Hurlemann, Rene; Fu, Cynthia H. Y.; Young, Allan H.			Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							TRANSCRANIAL MAGNETIC STIMULATION; STAR-ASTERISK-D; ELECTROCONVULSIVE-THERAPY; DOUBLE-BLIND; SEIZURE THERAPY; INCONSISTENCY; CONSISTENCY; REMISSION; DISORDER; OUTCOMES	OBJECTIVE To estimate the comparative clinical efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults. DESIGN Systematic review with pairwise and network meta-analysis. DATA SOURCES Electronic search of Embase, PubMed/Medline, and PsycINFO up to 8 May 2018, supplemented by manual searches of bibliographies of several reviews (published between 2009 and 2018) and included trials. ELIGIBILITY CRITERIA FOR SELECTING STUDIES Clinical trials with random allocation to electroconvulsive therapy (ECT), transcranial magnetic stimulation (repetitive (rTMS), accelerated, priming, deep, and synchronised), theta burst stimulation, magnetic seizure therapy, transcranial direct current stimulation (tDCS), or sham therapy. MAIN OUTCOME MEASURES Primary outcomes were response (efficacy) and all cause discontinuation (discontinuation of treatment for any reason) (acceptability), presented as odds ratios with 95% confidence intervals. Remission and continuous depression severity scores after treatment were also examined. RESULTS 113 trials (262 treatment arms) that randomised 6750 patients (mean age 47.9 years; 59% women) with major depressive disorder or bipolar depression met the inclusion criteria. The most studied treatment comparisons were high frequency left rTMS and tDCS versus sham therapy, whereas recent treatments remain understudied. The quality of the evidence was typically of low or unclear risk of bias (94 out of 113 trials, 83%) and the precision of summary estimates for treatment effect varied considerably. In network meta-analysis, 10 out of 18 treatment strategies were associated with higher response compared with sham therapy: bitemporal ECT (summary odds ratio 8.91, 95% confidence interval 2.57 to 30.91), high dose right unilateral ECT (7.27, 1.90 to 27.78), priming transcranial magnetic stimulation (6.02, 2.21 to 16.38), magnetic seizure therapy (5.55, 1.06 to 28.99), bilateral rTMS (4.92, 2.93 to 8.25), bilateral theta burst stimulation (4.44, 1.47 to 13.41), low frequency right rTMS (3.65, 2.13 to 6.24), intermittent theta burst stimulation (3.20, 1.45 to 7.08), high frequency left rTMS (3.17, 2.29 to 4.37), and tDCS (2.65, 1.55 to 4.55). Network meta-analytic estimates of active interventions contrasted with another active treatment indicated that bitemporal ECT and high dose right unilateral ECT were associated with increased response. All treatment strategies were at least as acceptable as sham therapy. CONCLUSIONS These findings provide evidence for the consideration of non-surgical brain stimulation techniques as alternative or add-on treatments for adults with major depressive episodes. These findings also highlight important research priorities in the specialty of brain stimulation, such as the need for further well designed randomised controlled trials comparing novel treatments, and sham controlled trials investigating magnetic seizure therapy.	[Mutz, Julian] Kings Coll London, Inst Psychiat Psychol & Neurosci, Social Genet & Dev Psychiat Ctr, London SE5 8AF, England; [Vipulananthan, Vijeinika; Young, Allan H.] South London & Maudsley Fdn NHS Trust, London, England; [Carter, Ben] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Biostat, London, England; [Hurlemann, Rene] Univ Bonn, Med Ctr, Dept Psychiat, Bonn, Germany; [Hurlemann, Rene] Univ Bonn, Med Ctr, Div Med Psychol, Bonn, Germany; [Fu, Cynthia H. Y.] Univ East London, Coll Appl Hlth & Communities, Sch Psychol, London, England; [Fu, Cynthia H. Y.; Young, Allan H.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol Med, Ctr Affect Disorders, London, England	University of London; King's College London; University of London; King's College London; University of Bonn; University of Bonn; University of East London; University of London; King's College London	Mutz, J (corresponding author), Kings Coll London, Inst Psychiat Psychol & Neurosci, Social Genet & Dev Psychiat Ctr, London SE5 8AF, England.	julian.mutz@gmail.com	Mutz, Julian/AAW-2775-2020; Fu, Cynthia H.Y./A-4165-2012; Hurlemann, Rene/AAL-5515-2020	Mutz, Julian/0000-0001-5308-1957; Fu, Cynthia H.Y./0000-0003-4313-3500; Hurlemann, Rene/0000-0003-2628-565X; Young, Allan/0000-0003-2291-6952; Carter, Ben/0000-0003-0318-8865	National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London	National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London(General Electric)	JM received funding from the German National Academic Foundation (Studienstifung des Deutschen Volkes) and a board grant from the International Master in Affective Neuroscience programme of Maastricht University and the University of Florence in support of this work, and current funding from the Biotechnology and Biological Sciences Research Council (BBSRC) and Eli Lilly outside of this work. AHY is funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health and Social Care. The funding bodies listed had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or in the decision to submit for publication.	Berlim MT, 2014, PSYCHOL MED, V44, P225, DOI 10.1017/S0033291713000512; Berlim MT, 2013, NEUROPSYCHOPHARMACOL, V38, P543, DOI 10.1038/npp.2012.237; Berlim MT, 2013, J PSYCHIATR RES, V47, P1, DOI 10.1016/j.jpsychires.2012.09.025; BRANDON S, 1984, BRIT MED J, V288, P22, DOI 10.1136/bmj.288.6410.22; Brunoni AR, 2017, JAMA PSYCHIAT, V74, P143, DOI 10.1001/jamapsychiatry.2016.3644; Brunoni AR, 2016, BRIT J PSYCHIAT, V208, P522, DOI 10.1192/bjp.bp.115.164715; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Chaimani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076654; Chen JJ, 2017, BEHAV BRAIN RES, V320, P30, DOI 10.1016/j.bbr.2016.11.028; Chen JJ, 2014, PSYCHIAT RES, V219, P51, DOI 10.1016/j.psychres.2014.05.010; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Fekadu A, 2009, J AFFECT DISORDERS, V116, P4, DOI 10.1016/j.jad.2008.10.014; Fitzgerald PB, 2018, DEPRESS ANXIETY, V35, P393, DOI 10.1002/da.22715; Furukawa TA, 2016, LANCET PSYCHIAT, V3, P1059, DOI 10.1016/S2215-0366(16)30307-8; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Heijnen WT, 2010, J CLIN PSYCHOPHARM, V30, P616, DOI 10.1097/JCP.0b013e3181ee0f5f; Higgins JPT, 2012, RES SYNTH METHODS, V3, P98, DOI 10.1002/jrsm.1044; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385; Jackson D, 2014, STAT MED, V33, P541, DOI 10.1002/sim.5957; Julian P.T.H., 2011, MANUAL COCHRANE REVI; Kalu UG, 2012, PSYCHOL MED, V42, P1791, DOI 10.1017/S0033291711003059; Kayser S, 2017, J ECT, V33, P167, DOI 10.1097/YCT.0000000000000425; Kayser S, 2011, J PSYCHIATR RES, V45, P569, DOI 10.1016/j.jpsychires.2010.09.008; Kellner CH, 2015, BRIT J PSYCHIAT, V206, P167, DOI 10.1192/bjp.206.2.167; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Khan A, 2017, WORLD PSYCHIATRY, V16, P181, DOI 10.1002/wps.20421; Kiebs M, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-023796; Kikuchi T, 2013, PSYCHIAT RES, V210, P127, DOI 10.1016/j.psychres.2013.05.007; Lepping P, 2014, ACTA PSYCHIAT SCAND, V130, P326, DOI 10.1111/acps.12276; Leucht S, 2016, EUR ARCH PSY CLIN N, V266, P477, DOI 10.1007/s00406-016-0715-4; Levkovitz Y, 2015, WORLD PSYCHIATRY, V14, P64, DOI 10.1002/wps.20199; Liu Y, 2016, LARYNGOSCOPE, V126, P951, DOI 10.1002/lary.25688; McCall WV, 2000, ARCH GEN PSYCHIAT, V57, P438, DOI 10.1001/archpsyc.57.5.438; Meron D, 2015, NEUROSCI BIOBEHAV R, V57, P46, DOI 10.1016/j.neubiorev.2015.07.012; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Murray CJL, 2015, LANCET, V386, P2145, DOI 10.1016/S0140-6736(15)61340-X; Mutz J, 2018, NEUROSCI BIOBEHAV R, V92, P291, DOI 10.1016/j.neubiorev.2018.05.015; Papakostas GI, 2008, J CLIN PSYCHIAT, V69, P1287, DOI 10.4088/JCP.v69n0812; Rush AJ, 2006, AM J PSYCHIAT, V163, P1905, DOI 10.1176/appi.ajp.163.11.1905; SACKEIM HA, 1993, NEW ENGL J MED, V328, P839, DOI 10.1056/NEJM199303253281204; Salanti G, 2012, RES SYNTH METHODS, V3, P80, DOI 10.1002/jrsm.1037; Schutter DJLG, 2009, PSYCHOL MED, V39, P65, DOI 10.1017/S0033291708003462; Schwarzer G, 2007, META R PACKAGE METAA, V7, P3; Scott J, 2016, BRIT J PSYCHIAT, V208, P208, DOI 10.1192/bjp.bp.115.169060; Serretti A, 2010, J CLIN PSYCHIAT, V71, P1259, DOI 10.4088/JCP.09r05346blu; Shiozawa P, 2014, INT J NEUROPSYCHOPH, V17, P1539, DOI 10.1017/S1461145714000807; Tavares DF, 2017, NEUROPSYCHOPHARMACOL, V42, P2593, DOI 10.1038/npp.2017.26; Trivedi MH, 2006, AM J PSYCHIAT, V163, P28, DOI 10.1176/appi.ajp.163.1.28; van Bronswijk S, 2019, PSYCHOL MED, V49, P366, DOI 10.1017/S003329171800199X; Velligan DI, 2009, J CLIN PSYCHIAT, V70, P6; White IR, 2012, RES SYNTH METHODS, V3, P111, DOI 10.1002/jrsm.1045; White IR, 2011, STATA J, V11, P255, DOI 10.1177/1536867X1101100206; White IR, 2009, STATA J, V9, P40, DOI 10.1177/1536867X0900900103	55	123	123	13	45	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 27	2019	364								l1079	10.1136/bmj.l1079	http://dx.doi.org/10.1136/bmj.l1079			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HR5WR	30917990	Green Published, Green Submitted, Green Accepted, hybrid			2023-01-03	WOS:000463218200002
J	Bergenstal, RM; Johnson, M; Passi, R; Bhargava, A; Young, N; Kruger, DF; Bashan, E; Bisgaier, SG; Isaman, DJM; Hodish, I				Bergenstal, Richard M.; Johnson, Mary; Passi, Rebecca; Bhargava, Anuj; Young, Natalie; Kruger, Davida F.; Bashan, Eran; Bisgaier, Stanley G.; Isaman, Deanna J. Marriott; Hodish, Israel			Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial	LANCET			English	Article							GLYCEMIC CONTROL; GLUCOSE READINGS; BASAL; HYPOGLYCEMIA; GLARGINE; SYSTEM; FREQUENCY; PEOPLE; ADULTS; ASSOCIATION	Background Insulin therapy is most effective if dosage titrations are done regularly and frequently, which is seldom practical for most clinicians, resulting in an insulin titration gap. The d-Nav Insulin Guidance System (Hygieia, Livonia, MI, USA) is a handheld device that is used to measure glucose, determine glucose patterns, and automatically determine the appropriate next insulin dose. We aimed to determine whether the combination of the d-Nav device and health-care professional support is superior to health-care professional support alone. Methods In this multicentre, randomised, controlled study, we recruited patients from three diabetes centres in the USA (in Detroit MI; Minneapolis, MN; and Des Moines IA). Patients were eligible if they were aged 21-70 years, diagnosed with type 2 diabetes with a glycated haemoglobin (HbA(1c)) concentration of 7.5% or higher (>= 58 mmol/mol) and 11% or lower (<= 97 mmol/mol), and had been using the same insulin regimen for the previous 3 months. Exclusion criteria included body-mass index of 45 kg/m (2) or higher; severe cardiac, hepatic, or renal impairment; and more than two severe hypoglycaemic events in the past year. Eligible participants were randomly assigned (1: 1), with randomisation blocked within each site, to either d-Nav and health-care professional support (intervention group) or health-care professional support alone (control group). Both groups were contacted seven times (three face-to-face and four phone visits) during 6 months of follow-up. The primary objective was to compare average change in HbA(1c) from baseline to 6 months. Safety was assessed by the frequency of hypoglycaemic events. The primary objective and safety were assessed in the intention-to-treat population. We used Student's t test to assess the primary outcome for statistical significance. This study was registered with ClinicalTrials. gov, number NCT02424500. Findings Between Feb 2, 2015, and March 17, 2017, 236 patients were screened for eligibility, of whom 181 (77%) were enrolled and randomly assigned to the intervention (n= 93) and control (n= 88) groups. At baseline, mean HbA(1c) was 8.7% (SD 0.8; 72 mmol/mol [SD 8.8]) in the intervention group and 8.5% (SD 0.8; 69 mmol/mol [SD 8.8]) in the control group. The mean decrease in HbA(1c) from baseline to 6 months was 1.0% (SD 1.0; 11 mmol/mol [SD 11]) in the intervention group, and 0.3% (SD 0.9; 3.3 mmol/mol [9.9]) in the control group (p< 0.0001). The frequency of hypoglycaemic events per month was similar between the groups (0.29 events per month [SD 0.48] in the intervention group vs 0.29 [SD 1.12] in the control group; p= 0.96). Interpretation The combination of automated insulin titration guidance with support from health-care professionals offers superior glycaemic control compared with support from health-care professionals alone. Such a solution facilitated safe and effective insulin titration in a large group of patients with type 2 diabetes, and now needs to be evaluated across large health-care systems to confirm these findings and study cost-effectiveness. Funding US National Institutes of Health, National Institute of Digestive and Kidney Diseases. Copyright (c) 2019 Elsevier Ltd. All rights reserved.	[Bergenstal, Richard M.; Johnson, Mary; Passi, Rebecca] Int Diabet Ctr, Minneapolis, MN 55416 USA; [Bhargava, Anuj; Young, Natalie] Iowa Diabet & Endocrinol Res Ctr, Des Moines, IA USA; [Kruger, Davida F.] Henry Ford Med Ctr, Endocrinol, Detroit, MI USA; [Bashan, Eran; Bisgaier, Stanley G.; Hodish, Israel] Hygieia Inc, Livonia, MI USA; [Isaman, Deanna J. Marriott] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA; [Hodish, Israel] Univ Michigan, Med Ctr, Dept Internal Med, Div Metab Endocrinol & Diabet, Ann Arbor, MI 48109 USA	International Diabetes Center; Henry Ford Health System; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Bergenstal, RM (corresponding author), Int Diabet Ctr, Minneapolis, MN 55416 USA.	richard.bergenstal@parknicollet.com			US National Institutes of Health, National Institute of Digestive and Kidney Diseases - US National Institute of Health's National Institute of Diabetes and Digestive and Kidney Diseases program [2R42DK085974-02A1]	US National Institutes of Health, National Institute of Digestive and Kidney Diseases - US National Institute of Health's National Institute of Diabetes and Digestive and Kidney Diseases program	US National Institutes of Health, National Institute of Digestive and Kidney Diseases.; This study was funded by the US National Institute of Health's National Institute of Diabetes and Digestive and Kidney Diseases program, award number 2R42DK085974-02A1. We thank the patients who participated in the study.	Akram K, 2006, J DIABETES COMPLICAT, V20, P402, DOI 10.1016/j.jdiacomp.2005.08.005; Amiel SA, 2017, DIABETES CARE, V40, P155, DOI 10.2337/dc16-2215; Bashan E, 2015, BMJ CASE REP, V2015; Bashan E, 2012, J DIABETES COMPLICAT, V26, P230, DOI 10.1016/j.jdiacomp.2012.03.012; Bashan E, 2011, DIABETES TECHNOL THE, V13, P85, DOI 10.1089/dia.2010.0112; Bastyr EJ, 2015, DIABETES TECHNOL THE, V17, P571, DOI 10.1089/dia.2014.0407; Bergenstal RM, 2008, DIABETES CARE, V31, P1305, DOI 10.2337/dc07-2137; Bergenstal RM, 2012, DIABETES TECHNOL THE, V14, P675, DOI 10.1089/dia.2011.0303; Bullard KM, 2018, MMWR-MORBID MORTAL W, V67, P359, DOI 10.15585/mmwr.mm6712a2; Buse JB, 2009, DIABETES CARE, V32, P1007, DOI 10.2337/dc08-2117; Carnethon MR, 2012, JAMA-J AM MED ASSOC, V308, P581, DOI 10.1001/jama.2012.9282; Davidson MB, 2009, DIABETES CARE, V32, P370, DOI 10.2337/dc08-2046; Donnelly R, 2015, PRACT DIABETES, V32, P247, DOI 10.1002/pdi.1966; Foerster V, 2016, CADTH ISSUES EMERGIN, P1; Grabner M, 2013, CLINICOECONOMIC OUTC, V5, P471, DOI 10.2147/CEOR.S46896; Harper R, 2016, J DIABETES COMPLICAT, V30, P1333, DOI 10.1016/j.jdiacomp.2016.05.017; Harper R, 2018, DIABETES TECHNOL THE, V12; Henderson JN, 2003, DIABETIC MED, V20, P1016, DOI 10.1046/j.1464-5491.2003.01072.x; Herman WH, 2005, DIABETES CARE, V28, P1568, DOI 10.2337/diacare.28.7.1568; Holman RR, 2007, NEW ENGL J MED, V357, P1716, DOI 10.1056/NEJMoa075392; Holman RR, 2009, NEW ENGL J MED, V361, P1736, DOI 10.1056/NEJMoa0905479; McQueen R Brett, 2011, Cost Eff Resour Alloc, V9, P13, DOI 10.1186/1478-7547-9-13; Mora P, 2017, DIABETES TECHNOL THE, V19, P715, DOI 10.1089/dia.2017.0206; Padman R, 2010, STUD HEALTH TECHNOL, V160, P262, DOI 10.3233/978-1-60750-588-4-262; Riddle MC, 2015, DIABETES OBES METAB, V17, P835, DOI 10.1111/dom.12472; Riddle MC, 2014, DIABETES CARE, V37, P2755, DOI 10.2337/dc14-0991; Rosenstock J, 2008, DIABETES CARE, V31, P20, DOI 10.2337/dc07-1122; Rosenthal ES, 2011, J DIABETES COMPLICAT, V25, P283, DOI 10.1016/j.jdiacomp.2011.01.002; Schutt M, 2006, EXP CLIN ENDOCR DIAB, V114, P384, DOI 10.1055/s-2006-924152; Selvin E, 2016, DIABETES CARE, V39, pE33, DOI 10.2337/dc15-2229; Thabit H, 2015, NEW ENGL J MED, V373, P2129, DOI 10.1056/NEJMoa1509351; U.S. Food and Drug Administration, 2018, MOB MED APPL; Wang C, 2015, DIABETIC MED, V32, P585, DOI 10.1111/dme.12694	33	21	21	2	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 16	2019	393	10176					1138	1148		10.1016/S0140-6736(19)30368-X	http://dx.doi.org/10.1016/S0140-6736(19)30368-X			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP1HF	30808512	Green Accepted			2023-01-03	WOS:000461416600032
J	Guinsburg, R				Guinsburg, Ruth			Improving care of critically ill newborns	SCIENCE			English	Editorial Material									[Guinsburg, Ruth] Univ Fed Sao Paulo, Escola Paulista Med, Div Neonatal Med, BR-01410020 Sao Paulo, SP, Brazil	Universidade Federal de Sao Paulo (UNIFESP)	Guinsburg, R (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Div Neonatal Med, BR-01410020 Sao Paulo, SP, Brazil.	ruth.guinsburg@unifesp.br	Guinsburg, Ruth/F-1984-2013	Guinsburg, Ruth/0000-0003-1967-9861				Akseer N, 2015, INT J GYNECOL OBSTET, V131, pS43, DOI 10.1016/j.ijgo.2015.03.017; Chung HU, 2019, SCIENCE, V363, P947, DOI 10.1126/science.aau0780; Haward Marlyse F, 2017, AJOB Empir Bioeth, V8, P243, DOI 10.1080/23294515.2017.1394399; Helenius K, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-1264; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; Mathews T. J., 2017, NCHS DATA BRIEF, V279; Pennaforte T, 2017, ARCH PEDIATRIE, V24, P146, DOI 10.1016/j.arcped.2016.11.002; Wang HD, 2016, LANCET, V388, P1725, DOI 10.1016/S0140-6736(16)31575-6	8	0	0	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 1	2019	363	6430					924	925		10.1126/science.aaw2085	http://dx.doi.org/10.1126/science.aaw2085			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HN5AG	30819947				2023-01-03	WOS:000460194200021
J	Chenoweth, L; Stein-Parbury, J; Lapkin, S; Wang, A; Liu, ZX; Williams, A				Chenoweth, Lynette; Stein-Parbury, Jane; Lapkin, Samuel; Wang, Alex; Liu, Zhixin; Williams, Anna			Effects of person-centered care at the organisational-level for people with dementia. A systematic review	PLOS ONE			English	Review							RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; NURSING-HOME; RESIDENTS; AGITATION; PERCEN	The aim of the systematic review was to determine the effectiveness of organizational-level person-centered care for people living with dementia in relation to their quality of life, mood, neuropsychiatric symptoms and function. ALOIS, the Cochrane Dementia and Cognitive Improvement Group Specialised Register databases, were searched up to June 2018 using the terms dementia OR cognitive impairment OR Alzheimer AND non-pharmacological AND personhood OR person-centered care. Reviewed studies included randomized controlled trials (RCTs), cluster-randomized trials (CRTs) and quasi-experimental studies that compared outcomes of person-centered care and usual (non-person-centered) care, for people with a diagnosis of dementia. The search yielded 12 eligible studies with a total of 2599 people living with dementia in long-term care homes, 600 receiving hospital care and 293 living in extra-care community housing. Random-effects models were used to pool adjusted risk ratios and standard mean differences from all studies; the findings were assessed followed the PRISMA guidelines and GRADE criteria. Statistical heterogeneity was assessed using the I-2 method and Chi(2)P value; studies with low statistical heterogeneity were analyzed using a random-effects model with restricted maximum likelihood estimation in R. Analyses of pre/post data within 12 months identified: a significant effect for quality of life (standardized mean difference (SMD) 0.16 and 95% CI 0.03 to 0.28; studies = 6; I-2 = 22%); non-significant effects for neuropsychiatric symptoms (SMD 0.06, 95% CI -0.08 to 0.19; studies = 4; I-2 = 0%) and well-being (SMD 0.15, 95% CI -0.15 to 0.45; studies = 4; I-2 = 77%); and no effects for agitation (SMD -0.05 (95% CI -0.17 to -0.07; studies 5; I-2 = 0%) and depression (SMD -0.06 and 95% CI -0.27 to 0.15, studies = 5; I-2 = 53%). The evidence from this review recommends implementation of person-centered care at the organizational-level to support the quality of life of people with living with dementia.	[Chenoweth, Lynette] Univ New South Wales Sydney, Fac Med, Ctr Hlth Brain Ageing CHeBA, Sydney, NSW, Australia; [Stein-Parbury, Jane; Wang, Alex] Univ Technol Sydney, Fac Hlth, Sydney, NSW, Australia; [Lapkin, Samuel] Univ Wollongong, Fac Sci Med & Hlth, Sch Nursing, South Western Sydney Campus, Wollongong, NSW, Australia; [Liu, Zhixin] Univ New South Wales Sydney, Stats Cent, Sydney, NSW, Australia; [Williams, Anna] Univ Notre Dame Sydney, Fac Med, Sch Nursing, Sydney, NSW, Australia	University of New South Wales Sydney; University of Technology Sydney; University of Wollongong; University of New South Wales Sydney; University of Notre Dame Australia	Chenoweth, L (corresponding author), Univ New South Wales Sydney, Fac Med, Ctr Hlth Brain Ageing CHeBA, Sydney, NSW, Australia.	l.chenoweth@unsw.edu.au		Lapkin, Samuel/0000-0002-1618-3812; Williams, Anna/0000-0003-0349-4248; Wang, Alex Yueping/0000-0002-3656-4284; Chenoweth, Lynette/0000-0002-1407-3804				ALOIS, 2011, COCHR DEM COGN IMPR; Alzheimer's Association, ALZH FACTS FIG 2013; Alzheimer's Disease International, 2014, DEM AS PAC REG; American Psychiatric Association, 2013, DIAGN STAT MAN DSM 5; Australian Health Ministers Advisory Council (AHMAC), 2015, NAT FRAM ACT DEM 201; Berry Lisa, 2009, Nurs Older People, V21, P3; *BRADF DEM GROUP, 2005, DCM 8 US MAN; Bradford Dementia Group and the Commission for Social Care Inspection in England, 2007, SHORT OBS FRAM INSP; Brooker D., 2016, PERSON CTR DEMENTIA; Brooker D, 2003, REV CLIN GERONTOL, V13, P215, DOI DOI 10.1017/S095925980400108X; Brooker DJ, 2011, AGING MENT HEALTH, V15, P1008, DOI 10.1080/13607863.2011.583628; Brownie S, 2013, CLIN INTERV AGING, V8, P1, DOI 10.2147/CIA.S38589; Burke C, 2016, CLIN GERONTOLOGIST, V39, P282, DOI 10.1080/07317115.2016.1172532; Chenoweth L, 2015, COCHRANE LIB, DOI [10.1002/14651858.CD011963, DOI 10.1002/14651858.CD011963]; Chenoweth L, 2015, INT PSYCHOGERIATR, V27, P2045, DOI 10.1017/S1041610215001350; Chenoweth L, 2014, INT PSYCHOGERIATR, V26, P1147, DOI 10.1017/S1041610214000398; Chenoweth L, 2009, LANCET NEUROL, V8, P317, DOI 10.1016/S1474-4422(09)70045-6; Cohen-Mansfield J, 1999, J Gerontol Nurs, V25, P42; Cohen-Mansfield J, 2012, J CLIN PSYCHIAT, V73, P478; Dewing J, 2008, INT J OLDER PEOPLE N, V3, P3, DOI 10.1111/j.1748-3743.2007.00103.x; Dichter MN, 2015, INT PSYCHOGERIATR, V27, P1875, DOI 10.1017/S1041610215000927; Doyle PJ, 2014, GERONTOLOGIST, V54, P952, DOI 10.1093/geront/gnt081; Effective Practice and Organisation of Care (EPOC)-Cochrane, 2015, EPOC RES REV AUTH, P1; Eriksen S, 2016, DEMENT GERIATR COGN, V42, P342, DOI 10.1159/000452404; Finnema E, 2005, INT J GERIATR PSYCH, V20, P330, DOI 10.1002/gps.1286; Fossey J, 2006, BMJ-BRIT MED J, V332, P756, DOI 10.1136/bmj.38782.575868.7C; Goldberg SE, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4132; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Jeon YH, 2015, J AM MED DIR ASSOC, V16, DOI 10.1016/j.jamda.2015.04.005; Kitson A, 2013, J ADV NURS, V69, P4, DOI 10.1111/j.1365-2648.2012.06064.x; Kitwood TM, 2007, DEMENTIA RECONSIDERE; Kogan AC, 2016, J AM GERIATR SOC, V64, pE1, DOI 10.1111/jgs.13873; Lawton MP, 1988, INT PSYCHOGERIATR, V10, P379; Li JX, 2017, BEHAV SLEEP MED, V15, P97, DOI 10.1080/15402002.2015.1104686; Love K, 2013, GENERATIONS, V37, P23; McCormack B., 2011, PERSON CTR NURSING T; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Moore Lucy, 2017, Scand J Caring Sci, V31, P662, DOI 10.1111/scs.12376; Morgan S, 2012, J HOLIST NURS, V30, P6, DOI 10.1177/0898010111412189; National Voices, 2017, PERS CENT CAR 2017; Olsson LE, 2013, J CLIN NURS, V22, P456, DOI 10.1111/jocn.12039; Peters JL, 2008, J EVAL CLIN PRACT, V14, P941, DOI 10.1111/j.1365-2753.2008.01010.x; Review Manager (RevMan), 2014, NON TRADITIONAL REF; Roen I, 2018, INT PSYCHOGERIATR, V30, P1279, DOI 10.1017/S1041610217002708; Rokstad AMM, 2013, DEMENT GERIATR COGN, V36, P340, DOI 10.1159/000354366; Rosvik J, 2013, REV CLIN GERONTOL, V23, P155, DOI 10.1017/S0959259813000014; Ryan R, 2016, GRADE QUALITY EVIDEN; Slater Lynne, 2006, Contemp Nurse, V23, P135; Sloane PD, 2004, J AM GERIATR SOC, V52, P1795, DOI 10.1111/j.1532-5415.2004.52501.x; van de Ven G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067325; World Health Organization, 2018, DEM PLAN WHO GUID; World Health Organization, 2015, INT STAT CLASS DIS R	53	33	35	3	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2019	14	2							e0212686	10.1371/journal.pone.0212686	http://dx.doi.org/10.1371/journal.pone.0212686			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HM8DR	30794651	gold, Green Published, Green Submitted			2023-01-03	WOS:000459709100114
J	Garnier, F; Couchoud, C; Landais, P; Moranne, O				Garnier, Fanny; Couchoud, Cecile; Landais, Paul; Moranne, Olivier			Increased incidence of acute kidney injury requiring dialysis in metropolitan France	PLOS ONE			English	Article							ACUTE-RENAL-FAILURE; CRITICALLY-ILL PATIENTS; UNITED-STATES; REPLACEMENT THERAPY; SEVERE SEPSIS; OUTCOMES; EPIDEMIOLOGY; MORTALITY; TRENDS; AKI	Background Acute kidney injury requiring dialysis (AKI-D) is associated with high mortality. Information about its epidemiology is nonetheless sparse in some countries. The objective of this study was to assess its epidemiology and prognosis in metropolitan France. Methods Using the French hospital discharge database, the study focused on adults hospitalized in metropolitan France between 2009 and 2014 and diagnosed with AKI-D according to the codes of the French common classification of medical procedures. Crude and standardized incidence rates (SIR) by gender and age were calculated. We explored the changes in patients' characteristics, modalities of renal replacement therapy (RRT), in-hospital care, and mortality, along with their determinants. Trends over time in the SIR for AKI-D, its principal diagnoses, and comorbidities were analyzed with joinpoint models. Results Between 2009 and 2014, the AKI-D SIR increased from 475 (95% CI, 468 to 482) to 512 per million population (95% CI, 505 to 519). AKI-D was twice as high in men as women. Median age was 68 years. Over the study period, the AKI-D SIR steadily increased in all age groups, particularly in the elderly. The most common comorbidities were cardio-cerebrovascular diseases (64.8%), pulmonary disease (42.2%), CKD (33.8%), and diabetes (26.0%); all of these except CKD increased significantly over time. In 2009, heart failure (17.2%), sepsis (17.0%), AKI (13.0%), digestive diseases (10.7%), and shock (6.6%) were the most frequent principal diagnoses, with a significant increase in heart failure and digestive diseases. The proportion of patients with at least one ICU stay and continuous RRT increased from 80.3% to 83.9% and from 56.9% to 61.8% (p<0.001), respectively. In-hospital mortality was high but stable (47%) and higher in patients with an ICU stay. Conclusions This is the first exhaustive study in metropolitan France of the SIR for AKI-D. It shows this SIR has increased significantly over 6 years, together with ICU care and continuous RRT. In-hospital mortality is high but stable.	[Garnier, Fanny; Moranne, Olivier] Nimes Univ Hosp, Nephrol Dialysis Apheresis Unit, Nimes, France; [Garnier, Fanny; Landais, Paul; Moranne, Olivier] Univ Montpellier, Lab Biostat Epidemiol Clin Res & Hlth Econ, UPRES EA2415, Montpellier, France; [Couchoud, Cecile] Biomed Agcy, REIN Registry, La Plaine St Denis, France	Universite de Montpellier; CHU de Nimes; Universite de Montpellier	Moranne, O (corresponding author), Nimes Univ Hosp, Nephrol Dialysis Apheresis Unit, Nimes, France.; Moranne, O (corresponding author), Univ Montpellier, Lab Biostat Epidemiol Clin Res & Hlth Econ, UPRES EA2415, Montpellier, France.	Olivier.moranne@chu-nimes.fr	moranne, olivier/AAA-3056-2019	moranne, olivier/0000-0002-3127-1415	French national society of nephrology dialys transplantation	French national society of nephrology dialys transplantation	The project benefits from a grant from French national society of nephrology dialys transplantation to FG, but funders did not play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afshinnia F, 2009, RENAL FAILURE, V31, P647, DOI 10.3109/08860220903151401; Agence Technique de l'Information Sur l'Hospitalisation, 2015, MAN GHM VERS DEF 11G; Ali T, 2007, J AM SOC NEPHROL, V18, P1292, DOI 10.1681/ASN.2006070756; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Bagshaw SM, 2008, NEPHROL DIAL TRANSPL, V23, P1203, DOI 10.1093/ndt/gfm744; Brown JR, 2016, AM J NEPHROL, V43, P261, DOI 10.1159/000445846; Carlson N, 2016, PLOS ONE, V11; Cole L, 2001, INTENS CARE MED, V27, P978, DOI 10.1007/s001340100963; Oliveira MAD, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0564-z; Dombrovskiy VY, 2007, CRIT CARE MED, V35, P1244, DOI 10.1097/01.CCM.0000261890.41311.E9; Gaudry S, 2016, NEW ENGL J MED, V375, P122, DOI 10.1056/NEJMoa1603017; Hoste E, 2015, INTENS CARE MED, V41, P1411, DOI 10.1007/s00134-015-3934-7; Hsu CY, 2007, KIDNEY INT, V72, P208, DOI 10.1038/sj.ki.5002297; Hsu CY, 2009, CLIN J AM SOC NEPHRO, V4, P891, DOI 10.2215/CJN.05571008; Hsu RK, 2016, CLIN J AM SOC NEPHRO, V11, P14, DOI 10.2215/CJN.04520415; Hsu RK, 2013, J AM SOC NEPHROL, V24, P37, DOI 10.1681/ASN.2012080800; Kashani K, 2017, KIDNEY INT, V92, P721, DOI 10.1016/j.kint.2017.03.020; Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.3.CO;2-Q; Kolhe NV, 2015, KIDNEY INT, V88, P1161, DOI 10.1038/ki.2015.234; Lameire NH, 2013, LANCET, V382, P170, DOI 10.1016/S0140-6736(13)60647-9; Landais P, 2014, HEALTH INFORM SER, P191, DOI 10.1007/978-2-8178-0478-1_9; Lassale M, 2014, 2014 ESRD INCIDENCE; Lauridsen MD, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1170-8; Lenihan CR, 2013, ANN THORAC SURG, V95, P20, DOI 10.1016/j.athoracsur.2012.05.131; Liangos O, 2006, CLIN J AM SOC NEPHRO, V1, P43, DOI 10.2215/CJN.00220605; Lo LJ, 2009, KIDNEY INT, V76, P893, DOI 10.1038/ki.2009.289; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Mavrakanas TA, 2017, CLIN J AM SOC NEPHRO, V12, P1624, DOI 10.2215/CJN.04020417; McAlister FA, 2004, CIRCULATION, V109, P1004, DOI 10.1161/01.CIR.0000116764.53225.A9; Mehta RL, 2015, LANCET, V385, P2616, DOI 10.1016/S0140-6736(15)60126-X; Quan H, 2008, HEALTH SERV RES, V43, P1424, DOI 10.1111/j.1475-6773.2007.00822.x; Rauf Anis Abdul, 2008, J Intensive Care Med, V23, P195, DOI 10.1177/0885066608315743; Ronco C, 2000, LANCET, V356, P26, DOI 10.1016/S0140-6736(00)02430-2; Ronco C, 2004, BLOOD PURIFICAT, V22, P164, DOI 10.1159/000074937; Sakhuja A, 2015, AM J RESP CRIT CARE, V192, P951, DOI 10.1164/rccm.201502-0329OC; Servillo G, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/108951; Siew ED, 2015, KIDNEY INT, V87, P46, DOI 10.1038/ki.2014.293; Susantitaphong P, 2013, CLIN J AM SOC NEPHRO, V8, P1482, DOI 10.2215/CJN.00710113; Thakar CV, 2009, CRIT CARE MED, V37, P2552, DOI 10.1097/CCM.0b013e3181a5906f; The Kidney Improving Global Outcomes (KDIGO) Working Group, 2012, KIDNEY INT S2, P193; Toft P, 2000, Ugeskr Laeger, V162, P2868; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; Waikar SS, 2006, J AM SOC NEPHROL, V17, P1143, DOI 10.1681/ASN.2005091017; Waikar SS, 2006, J AM SOC NEPHROL, V17, P1688, DOI 10.1681/ASN.2006010073; Wald R, 2015, AM J KIDNEY DIS, V65, P870, DOI 10.1053/j.ajkd.2014.10.017; Wonnacott A, 2014, CLIN J AM SOC NEPHRO, V9, P1007, DOI 10.2215/CJN.07920713; Zarbock A, 2016, JAMA-J AM MED ASSOC, V315, P2190, DOI 10.1001/jama.2016.5828	47	7	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2019	14	2							e0211541	10.1371/journal.pone.0211541	http://dx.doi.org/10.1371/journal.pone.0211541			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK5RX	30730975	Green Published, Green Submitted, gold			2023-01-03	WOS:000458026000034
J	Imaeda, T; Nakada, T; Abe, R; Oda, S				Imaeda, Taro; Nakada, Taka-aki; Abe, Ryuzo; Oda, Shigeto			Decreased total iron binding capacity upon intensive care unit admission predicts red blood cell transfusion in critically ill patients	PLOS ONE			English	Article							ANEMIA; ERYTHROPOIETIN; HEPCIDIN; SEPSIS; SERUM	Introduction Red blood cell (RBC) transfusion is associated with poor clinical outcome in critically ill patients. We investigated the predictive value of biomarkers on intensive care units (ICU) admission for RBC transfusion within 28 days. Methods Critically ill patients (n = 175) who admitted to our ICU with organ dysfunction and an expected stay of >= 48 hours, without hemorrhage, were prospectively studied (derivation cohort, n = 121; validation cohort, n = 54). Serum levels of 12 biomarkers (hemoglobin, creatinine, albumin, interleukin-6 [IL-6], erythropoietin, Fe, total iron binding capacity [TIBC], transferrin, ferritin, transferrin saturation, folate, and vitamin B12) were measured upon ICU admission, days 7, 14, 21 and 28. Results Among the 12 biomarkers measured upon ICU admission, levels of hemoglobin, albumin, IL-6, TIBC, transferrin and ferritin were statistically different between transfusion and non-transfusion group. Of 6 biomarkers, TIBC upon ICU admission had the highest area under the curve value (0.835 [95% confidence interval] = 0.765-0.906) for predicting RBC transfusion (cut-off value = 234.5 mu g/dL; sensitivity = 0.906, specificity = 0.632). This result was confirmed in validation cohort, whose sensitivity and specificity were 0.888 and 0.694, respectively. Measurement of these biomarkers every seven days revealed that albumin, TIBC and transferrin were statistically different between groups throughout hospitalization until 28 days. In validation cohort, patients in the transfusion group had significantly higher serum hepcidin levels than those in the non-transfusion group (P = 0.004). In addition, joint analysis across derivation and validation cohorts revealed that the serum IL-6 levels were higher in the transfusion group (P = 0.0014). Conclusion Decreased TIBC upon ICU admission has high predictive value for RBC transfusion unrelated to hemorrhage within 28 days.	[Imaeda, Taro; Nakada, Taka-aki; Abe, Ryuzo; Oda, Shigeto] Chiba Univ, Grad Sch Med, Dept Emergency & Crit Care Med, Chiba, Japan	Chiba University	Nakada, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Emergency & Crit Care Med, Chiba, Japan.	taka.nakada@chiba-u.jp			JSPS KAKENHI [JP15K15660]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by JSPS KAKENHI Grant Number JP15K15660 to SO (https://www.jsps.go.jp/english/e-grants/index.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by JSPS KAKENHI Grant Number JP15K15660.	[Anonymous], 1999, Crit Care Med, V27, P639; Astin R, 2014, EXTREME PHYSIOL MED, V3, DOI 10.1186/2046-7648-3-4; Corwin HL, 2004, CRIT CARE, V8, pS42, DOI 10.1186/cc2411; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Elliot JM, 2003, CRIT CARE, V7, pR35, DOI 10.1186/cc2185; ERSLEV AJ, 1991, NEW ENGL J MED, V324, P1339, DOI 10.1056/NEJM199105093241907; Fernandez R, 2010, ANESTHESIOLOGY, V112, P1211, DOI 10.1097/ALN.0b013e3181d74f87; Gambino R, 1997, CLIN CHEM, V43, P2408; Ganz T, 2011, ANNU REV MED, V62, P347, DOI 10.1146/annurev-med-050109-142444; Hayden SJ, 2012, AM J RESP CRIT CARE, V185, P1049, DOI 10.1164/rccm.201110-1915CI; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Heming N, 2011, CRIT CARE, V15, DOI 10.1186/cc9992; Holst LB, 2014, NEW ENGL J MED, V371, P1381, DOI 10.1056/NEJMoa1406617; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; Juffermans NP, 2011, SHOCK, V35, P355, DOI 10.1097/SHK.0b013e3182086094; Kasvosve I, 2002, CLIN CHEM LAB MED, V40, P1014, DOI 10.1515/CCLM.2002.176; Khorramian E, 2017, SHOCK, V48, P490, DOI 10.1097/SHK.0000000000000886; Lasocki S, 2011, ANESTHESIOLOGY, V114, P688, DOI 10.1097/ALN.0b013e3182065c57; Lasocki S, 2010, INTENS CARE MED, V36, P1044, DOI 10.1007/s00134-010-1794-8; Litton E, 2016, INTENSIVE CARE MED; Loftus TJ, 2018, AM J RESP CRIT CARE; Maynor L, 2007, ANN PHARMACOTHER, V41, P1476, DOI 10.1345/aph.1K187; Mukhopadhyay A, 2010, CRIT CARE, V14, DOI 10.1186/cc8859; Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945; Ramsay WNM, 1997, CLIN CHIM ACTA, V259, P25, DOI 10.1016/S0009-8981(96)06489-3; Retter A, 2013, BRIT J HAEMATOL, V160, P445, DOI 10.1111/bjh.12143; Rodriquez RM, 2001, J CRIT CARE, V16, P36, DOI 10.1053/jcrc.2001.21795; Salisbury AC, 2011, ARCH INTERN MED, V171, P1646, DOI 10.1001/archinternmed.2011.361; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Vincent JL, 2014, SHOCK, V41, P98, DOI 10.1097/SHK.0000000000000090; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809	32	2	3	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2019	14	1							e0210067	10.1371/journal.pone.0210067	http://dx.doi.org/10.1371/journal.pone.0210067			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HI4TC	30673726	Green Published, Green Submitted, gold			2023-01-03	WOS:000456442800030
J	Jones, MG; Rice, SM; Cotton, SM				Jones, Melanie G.; Rice, Simon M.; Cotton, Susan M.			Incorporating animal-assisted therapy in mental health treatments for adolescents: A systematic review of canine assisted psychotherapy	PLOS ONE			English	Review							CHILDREN; DOGS; INTERVENTIONS; DEPRESSION; DISORDERS; EFFICACY; YOUTH; ACCEPTABILITY; SUPPORT; UPDATE	Introduction As interest in Animal-Assisted Interventions (AAI) grows, there is increasing need to differentiate informal activities from formal and professionally directed therapies, including mental health focussed Canine-Assisted Psychotherapy (CAP). There have been no reviews focusing exclusively on CAP and the distinct developmental period of adolescence. The aims of this study were to identify the characteristics of CAP interventions, their impacts and their acceptability, tolerability and feasibility for adolescents with mental health disorders. Method A systematic review identified studies incorporating canines into mental health treatments for adolescents aged 10-19 years. Studies reporting qualitative or quantitative psychological or psychosocial outcomes were included. Results Seven studies were scrutinised. Intervention characteristics varied, including a range of formats, settings, locations, doses, and facilitators. Information on the role of the canines in sessions was sparse. CAP had a positive impact on primary diagnoses and symptomatology, conferring additional benefits to standard treatments for internalising disorders, post-traumatic stress disorder, and equivalent effects for anxiety, anger and externalising disorders. CAP was associated with positive impacts on secondary factors including increased engagement and socialisation behaviours, and reductions in disruptive behaviours within treatment sessions. Global functioning also improved. There was insufficient evidence that CAP improved factors associated with self-esteem, subjective wellbeing, or coping. Good attendance and retention rates indicated high levels of acceptability. Moderate to high tolerability was also indicated. Feasibility may be limited by additional training and logistical requirements. Recommendations We recommend the development of theoretically informed, standardised (manualised) intervention protocols that may subsequently form the basis of efficacy and effectiveness testing. Such protocols should clearly describe canine-participant-facilitator interactions via a formalised nomenclature; spontaneous (animal-led), adjunctive (facilitator-led), and experiential (participant-led). Conclusions There is emerging evidence to suggest that CAP improves the efficacy of mental health treatments in self-selected adolescent populations via reductions in primary symptomatology, and via secondary factors that improve therapeutic processes and quality, such as engagement and retention.	[Jones, Melanie G.; Rice, Simon M.; Cotton, Susan M.] Orygen Natl Ctr Excellence Youth Mental Hlth, Parkville, Vic, Australia; [Jones, Melanie G.; Rice, Simon M.; Cotton, Susan M.] Univ Melbourne, Parkville, Vic, Australia; [Jones, Melanie G.] Lead Way Inst, Boronia, Vic, Australia	Orygen, The National Centre of Excellence in Youth Mental Health; University of Melbourne	Jones, MG (corresponding author), Orygen Natl Ctr Excellence Youth Mental Hlth, Parkville, Vic, Australia.; Jones, MG (corresponding author), Univ Melbourne, Parkville, Vic, Australia.; Jones, MG (corresponding author), Lead Way Inst, Boronia, Vic, Australia.	melanie.jones@orygen.org.au	Rice, Simon/J-5656-2014	Rice, Simon/0000-0003-4045-8553; Cotton, Sue/0000-0002-9386-8348; Jones, Melanie/0000-0001-9192-9605				Anestis MD, 2014, J CLIN PSYCHOL, V70, P1115, DOI 10.1002/jclp.22113; Australian Government: National Health Medical Research Council (NHMRC), 2009, NHMRC ADD LEV EV GRA; Bauer MS, 1998, J CLIN PSYCHIAT, V59, P449, DOI 10.4088/JCP.v59n0902; Beck AM, 2003, AM BEHAV SCI, V47, P79, DOI 10.1177/0002764203255214; Becker JL, 2017, ANTHROZOOS, V30, P307, DOI 10.1080/08927936.2017.1311055; Beetz A, 2012, FRONT PSYCHOL, P3; Bert F, 2016, EUR J INTEGR MED, V8, P695, DOI 10.1016/j.eujim.2016.05.005; Brelsford VL, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14070669; Brooks S, 2011, EQ SPEC MENT HLTH LE; Calvo P, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00631; Chandler CK, 2012, ANIMAL ASSISTED THERAPY IN COUNSELING, 2ND EDITION, P1; Costello EJ, 2005, J AM ACAD CHILD PSY, V44, P972, DOI 10.1097/01.chi.0000172552.41596.6f; Davis TN, 2015, EDUC TRAIN AUTISM DE, V50, P316; Delta Society, 1996, STAND PRACT AN ASS A; Dietz TJ, 2012, J CHILD SEX ABUS, V21, P665, DOI 10.1080/10538712.2012.726700; [EAGALA Association EAGaL], 2012, FUND EAG MOD PRACT; Fine, 2015, HDB ANIMAL ASSISTED, P157, DOI DOI 10.3390/IJERPH16203997; Fine A., 2015, HDB ANIMAL ASSISTED; Fine A. H., 2015, HDB ANIMAL ASSISTED, V4th, P21, DOI DOI 10.1016/B978-0-12-801292-5.00003-1; Fine AH, HDB ANIMAL ASSISTED; Flay BR, 2005, PREV SCI, V6, P151, DOI 10.1007/s11121-005-5553-y; FOLSE EB, 1994, ANTHROZOOS, V7, P188, DOI 10.2752/089279394787001880; Garcia JA, 2002, J CONSULT CLIN PSYCH, V70, P439, DOI 10.1037//0022-006X.70.2.439; Gee NR, 2012, ANTHROZOOS, V25, P187, DOI 10.2752/175303712X13316289505387; Gee NR, 2010, ANTHROZOOS, V23, P173, DOI 10.2752/175303710X12682332910051; Germain SM, 2018, ANTHROZOOS, V31, P141, DOI 10.1080/08927936.2018.1434044; Glenk LM, 2017, ANIMALS-BASEL, V7, DOI 10.3390/ani7020007; Greenhalgh T, 1999, J ROY COLL PHYS LOND, V33, P36; Gueguen N, 2008, ANTHROZOOS, V21, P339, DOI 10.2752/175303708X371564; Hamama L, 2011, CHILD YOUTH SERV REV, V33, P1975, DOI 10.1016/j.childyouth.2011.05.021; Hanselman JL., 2001, J CHILD ADOLESCENT G, V11, P159, DOI 10.1023/A:1014802324267; Hart L.A., 2015, HDB ANIMAL ASSISTED, V4th ed., P53; Hartwig EK, 2017, J CREAT MENT HEALTH, V12, P468, DOI 10.1080/15401383.2017.1283281; HAVIGHURST RJ, 1956, SCHOOL REV, V64, P215, DOI 10.1086/442319; Hoagwood KE, 2017, APPL DEV SCI, V21, P1, DOI 10.1080/10888691.2015.1134267; Hunt MG, 2014, ANTHROZOOS, V27, P457, DOI 10.2752/175303714X14023922797959; IAHAIO, 2014, IAHAIO WHIT PAP; Jones MG, 2018, AUSTRALAS PSYCHIATRY, V26, P196, DOI 10.1177/1039856217749056; Julius H, INTEGRATIVE VIEW HUM; Julius H, 2013, ATTACHMENT PETS INTE, P35; Kamioka H, 2014, COMPLEMENT THER MED, V22, P371, DOI 10.1016/j.ctim.2013.12.016; Kendall E, 2015, EUR J PSYCHOTHER COU, V17, P57, DOI 10.1080/13642537.2014.996169; Kirby M., 2016, PRINCIPLES THEORY PR; Kohanov L., 2018, ABOUT EPONAQUEST; La Greca AM, 2005, J CLIN CHILD ADOLESC, V34, P49, DOI 10.1207/s15374424jccp3401_5; Lac V., 2017, HUMAN EQUINE RELATIO; Lange AM, 2007, J CREAT MENT HEALTH, V2, P17, DOI 10.1300/J456v02n02_03; Lawrence D., 2015, MENTAL HLTH CHILDREN; Lee PT, 2016, HEALTH SOC CARE COMM, V24, P225, DOI 10.1111/hsc.12201; Lentini JA, 2015, J CREAT MENT HEALTH, V10, P278, DOI 10.1080/15401383.2015.1023916; Lubbe C, 2013, S AFR J PSYCHOL, V43, P116, DOI 10.1177/0081246312474405; Maharaj N, 2016, J LOSS TRAUMA, V21, P335, DOI 10.1080/15325024.2015.1084857; Marr CA, 2000, ANTHROZOOS, V13, P43, DOI 10.2752/089279300786999950; Maujean A, 2015, ANTHROZOOS, V28, P23, DOI 10.2752/089279315X14129350721812; Merlin T, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-34; Mission-Australia, 2017, YOUTH MENT HLTH REP; Moher D, 2015, SYST REV-LONDON, V4, DOI [10.1186/2046-4053-4-1, 10.1186/s13643-015-0087-2]; Molaeb H, 2010, ADOLESCENT COMMUNITY; Nathans-Barel I, 2005, PSYCHOTHER PSYCHOSOM, V74, P31, DOI 10.1159/000082024; NHMRC, 2000, HDB SER PREP CLIN PR; NIH NHLaBI, 2018, NIH TOOL ASS QUAL PR; NIH NHLaBI, 2018, NIH TOOL ASS QUAL CO; Nimer J, 2007, ANTHROZOOS, V20, P225, DOI 10.2752/089279307X224773; Norton C., 2008, UNDERSTANDING IMPACT; Nurenberg JR, 2015, PSYCHIAT SERV, V66, P80, DOI 10.1176/appi.ps.201300524; O'Brien A, 2009, SOC PSYCH PSYCH EPID, V44, P558, DOI 10.1007/s00127-008-0476-0; O'Haire ME, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01121; O'Haire ME, 2013, J AUTISM DEV DISORD, V43, P1606, DOI 10.1007/s10803-012-1707-5; Olfson M, 2009, PSYCHIAT SERV, V60, P898, DOI 10.1176/appi.ps.60.7.898; Parish-Plass N., 2014, CHAYOT VCHEVRA, V50, P71; Parish-Plass N., 2013, ANIMAL ASSISTED PSYC; Park Bum Jin, 2010, Environmental Health and Preventive Medicine, V15, P18, DOI 10.1007/s12199-009-0086-9; Pearson A, 2005, INT J EVID-BASED HEA, V3, P207, DOI 10.1111/j.1479-6988.2005.00026.x; Pet-Partners, 2018, PET PARTN TERM 2018; Rabbitt SM, 2014, ANTHROZOOS, V27, P335, DOI 10.2752/175303714X13903827487881; Reichert E., 1994, FAMILY THERAPY, V2, P55; Reichert E., 1998, CHILD ADOLESCENT SOC, V15; Schneider MS, 2006, ANTHROZOOS, V19, P128, DOI 10.2752/089279306785593784; Schuck SEB, 2015, J ATTEN DISORD, V19, P125, DOI 10.1177/1087054713502080; Selby A, 2013, HEALTH PSYCHOL, V32, P418, DOI 10.1037/a0029188; Shambo L, 2013, MANUAL HEAL MODEL EQ; Signal T, 2017, APPL DEV SCI, V21, P81, DOI 10.1080/10888691.2016.1165098; Smith-Osborne A, 2010, CHILD ADOLESC SOC WO, V27, P291, DOI 10.1007/s10560-010-0201-1; Souter MA, 2007, ANTHROZOOS, V20, P167, DOI 10.2752/175303707X207954; Stefanini MC, 2015, COMPLEMENT THER CLIN, V21, P42, DOI 10.1016/j.ctcp.2015.01.001; Stefanini MC, 2016, EUR J INTEGR MED, V8, P81, DOI 10.1016/j.eujim.2016.03.001; Steinberg L, 2005, TRENDS COGN SCI, V9, P69, DOI 10.1016/j.tics.2004.12.005; Stern Cindy, 2013, Animals (Basel), V3, P127, DOI 10.3390/ani3010127; Szamoskozi, 2012, TRANSYLVANIAN J PSYH, V13, P1, DOI [DOI 10.2752/089279307X224773, 10.2752/089279307X224773]; VanFleet R., 2010, BRIT J PLAY THERAPY, V6, P4; Wesley MC, 2009, ANTHROZOOS, V22, P137, DOI 10.2752/175303709X434167; White JH, 2015, INTEGR CANCER THER, V14, P460, DOI 10.1177/1534735415580678; Wilson CC, 2003, AM BEHAV SCI, V47, P16, DOI 10.1177/0002764203255208; World Health Organization, 2014, REC AD; Zhou XY, 2015, WORLD PSYCHIATRY, V14, P207, DOI 10.1002/wps.20217; Zilcha-Mano S, 2017, CLIN CHILD PSYCHOL P, V22, P34, DOI 10.1177/1359104516671385; Zilcha-Mano S, 2011, ATTACH HUM DEV, V13, P541, DOI 10.1080/14616734.2011.608987	97	48	48	6	57	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2019	14	1							e0210761	10.1371/journal.pone.0210761	http://dx.doi.org/10.1371/journal.pone.0210761			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HH8WT	30653587	gold, Green Published			2023-01-03	WOS:000456015500068
J	Boehnke, KF; Clauw, DJ				Boehnke, Kevin F.; Clauw, Daniel J.			Brief Commentary: Cannabinoid Dosing for Chronic Pain Management	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Boehnke, Kevin F.; Clauw, Daniel J.] Univ Michigan, Med Sch, Ann Arbor, MI USA	University of Michigan System; University of Michigan	Boehnke, KF (corresponding author), 24 Frank Lloyd Wright Dr, Ann Arbor, MI 48106 USA.	kboehnke@med.umich.edu						Ballantyne JC, 2017, PAIN, V158, P2290, DOI 10.1097/j.pain.0000000000001043; MacCallum CA, 2018, EUR J INTERN MED, V49, P12, DOI 10.1016/j.ejim.2018.01.004; Malfait AM, 2000, P NATL ACAD SCI USA, V97, P9561, DOI 10.1073/pnas.160105897; Nugent SM, 2017, ANN INTERN MED, V167, P319, DOI 10.7326/M17-0155; Steigerwald S, 2018, J GEN INTERN MED, V33, P1426, DOI 10.1007/s11606-018-4480-0	5	10	10	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	2019	170	2					118	+		10.7326/M18-2972	http://dx.doi.org/10.7326/M18-2972			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH3ZL	30615778				2023-01-03	WOS:000455659100019
J	Lee, CH; Choi, SS; Lee, MK; Kim, JE; Chung, DI; Lee, M				Lee, Chung Hun; Choi, Sang Sik; Lee, Mi Kyoung; Kim, Jung Eun; Chung, Dong Ik; Lee, Mido			Electric stimulation-guided epidural analgesia for vaginal delivery: A randomized prospective study	PLOS ONE			English	Article							CONFIRMATION; ANESTHESIA; FAILURE; SPACE	Background The failure rate of epidural anesthesia using the loss of resistance technique is 13-23%. Objectives To investigate the efficacy of epidural electric stimulation-guided epidural analgesia in vaginal delivery. Study design An open label randomized prospective study. Methods Laboring women were randomized to two groups: epidural catheter insertion using only a loss of resistance technique or a loss of resistance technique with confirmation by electric stimulation. Catheters in both groups were initially tested with 3 ml of 1% lidocaine and those with any evidence of motor blockade were considered intrathecal. Sensory blockade and an 11 point numerical rating score for pain were assessed 30 minutes after administration of an epidural bolus of 10 ml of 0.22% ropivacaine with fentanyl. Successful epidural analgesia was defined as a decrease of 2 or more in the pain score and a bilateral L1-T10 sensory blockade. Results Thirty-one patients were randomized to each group. The first 20 patients in each group were enrolled in a pilot study and were also included in the final analysis. One patient in the electric stimulation group was excluded owing to dural puncture by the Tuohy needle. One patient in each group demonstrated motor blockade after test dose and were considered failures. The number (% (95% confidence interval)) of successful cases were 29 out of 30 (97% (85, 100%)) in the electric stimulation group and 24 out of 31 (77% (61, 89%)) in the loss of resistance group (P = 0.053). However, analysis of only patients with absence of motor blockade revealed that 29 out of 29 (100% (92, 100%)) patients in the electric stimulation group and 24 of 29 (80% (63, 91%)) patients in the loss of resistance group had adequate analgesia (P = 0.024). Conclusions Although limited by lack of blinding, small study size and inclusion of pilot study data, this study suggests epidural electric stimulation improves the success rate of subsequent labor analgesia.	[Lee, Chung Hun; Choi, Sang Sik; Lee, Mi Kyoung; Kim, Jung Eun; Chung, Dong Ik; Lee, Mido] Korea Univ, Med Ctr, Guro Hosp, Dept Anesthesiol & Pain Med, Seoul, South Korea	Korea University; Korea University Medicine (KU Medicine)	Choi, SS (corresponding author), Korea Univ, Med Ctr, Guro Hosp, Dept Anesthesiol & Pain Med, Seoul, South Korea.	clonidine@empal.com	Choi, Sangsik/HGD-4295-2022		Sewoon Medical Co., Ltd., Seoul, Korea	Sewoon Medical Co., Ltd., Seoul, Korea	The authors have no sources of funding to declare, however, the epidural catheter (RegionalStim (TM)) used in this study was provided by Sewoon Medical Co., Ltd., Seoul, Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funder only provided support in the form of research materials for authors [S. S. C.], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Agaram R, 2009, INT J OBSTET ANESTH, V18, P10, DOI 10.1016/j.ijoa.2007.10.008; Eappen S, 1998, INT J OBSTET ANESTH, V7, P220, DOI 10.1016/S0959-289X(98)80042-3; Gomar C, 2000, EUR J ANAESTH, V17, P542, DOI 10.1046/j.1365-2346.2000.00733.x; Goobie SM, 2003, ANESTH ANALG, V97, P984, DOI 10.1213/01.ANE.0000080609.05942.38; Grau T, 2002, J CLIN ANESTH, V14, P169, DOI 10.1016/S0952-8180(01)00378-6; Grau T, 2001, BRIT J ANAESTH, V86, P798, DOI 10.1093/bja/86.6.798; Hermanides J, 2012, BRIT J ANAESTH, V109, P144, DOI 10.1093/bja/aes214; Hislop H, 2014, PRINCIPLES MANUAL MU, P1; Jeong JS, 2012, KOREAN J ANESTHESIOL, V63, P238, DOI 10.4097/kjae.2012.63.3.238; Kinsella SM, 2008, ANAESTHESIA, V63, P822, DOI 10.1111/j.1365-2044.2008.05499.x; MICHAEL S, 1989, ANAESTHESIA, V44, P578, DOI 10.1111/j.1365-2044.1989.tb11446.x; Pan PH, 2004, INT J OBSTET ANESTH, V13, P227, DOI 10.1016/j.ijoa.2004.04.008; Silva M, 2010, LOCAL REG ANESTH, V3, P143, DOI 10.2147/LRA.S10237; Sutherland MA, 2009, REGION ANESTH PAIN M, V34, P575, DOI 10.1097/AAP.0b013e3181bfbe1e; Thangamuthu A, 2013, INT J OBSTET ANESTH, V22, P310, DOI 10.1016/j.ijoa.2013.04.013; Toledano RD, 2014, ANESTHESIOLOGY, V121, P9, DOI 10.1097/ALN.0000000000000239; Tsui BCH, 1998, CAN J ANAESTH, V45, P640, DOI 10.1007/BF03012093; Wantman A, 2006, ANAESTHESIA, V61, P370, DOI 10.1111/j.1365-2044.2006.04534.x	18	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2019	14	1							e0209967	10.1371/journal.pone.0209967	http://dx.doi.org/10.1371/journal.pone.0209967			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH1MW	30633755	Green Submitted, Green Published, gold			2023-01-03	WOS:000455485100010
J	Zhang, DH; Zhou, C; Wei, D; Ge, L; Li, Q				Zhang, Donghang; Zhou, Cheng; Wei, Dang; Ge, Long; Li, Qian			Dexamethasone added to local anesthetics in ultrasound-guided transversus abdominis plain (TAP) block for analgesia after abdominal surgery: A systematic review and meta-analysis of randomized controlled trials	PLOS ONE			English	Review							INGUINAL-HERNIA REPAIR; PLANE BLOCK; POSTOPERATIVE ANALGESIA; CLINICAL EFFECTIVENESS; ADDING DEXAMETHASONE; DOUBLE-BLIND; ROPIVACAINE; BUPIVACAINE; ADJUVANT; EFFICACY	Objective To evaluate the analgesic efficacy of dexamethasone added to local anesthetics in ultrasound-guided transversus abdominis plane (TAP) block for the patients after abdominal surgery. Methods PubMed, CENTRAL, EMBASE, Web of science were searched to identify eligible randomized controlled trials (RCTs) that compared dexamethasone added to local anesthetics in ultrasound-guided TAP block with control for postoperative analgesia in adult patients undergoing abdominal surgery. Primary outcomes included postoperative pain intensity, the time to the first request for additional analgesics, and opioid consumption over 24 h after surgery. Secondary outcome was the incidence of postoperative nausea and vomiting. Analysis was performed by RevMan 5.3 software and the quality of evidence was rated using GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach. Results Nine RCTs involving 575 patients were included. Compared to the control, dexamethasone added to local anesthetics in ultrasound-guided TAP block significantly decreased visual analogue scale (VAS) scores at rest at 4h (mean difference [MD] = -1.01; 95% confidence intervals [CI], -1.29 to -0.73; P<0.00001; moderate quality of evidence), 6h (MD = -1.21; 95% CI, -1.74 to-0.69; P<0.00001; low quality of evidence), and 12h after surgery (MD = -0.79; 95% CI, -0.97 to -0.60; P<0.00001; moderate quality of evidence). No difference was found at 2h (MD = -0.64; 95% CI, -1.35 to 0.08; P = 0.08; low quality of evidence) and 24 h (MD = -0.41; 95% CI, -0.91 to 0.09; P = 0.11; moderate quality of evidence) in VAS scores. The time to the first request for additional analgesics was prolonged in the dexamethasone group (MD = 3.08; 95% CI, 2.37 to 3.78; P<0.00001; moderate quality of evidence). Opioid consumption over 24 h after surgery was also reduced (MD = -5.42; 95% CI, -8.20 to -2.63; P = 0.0001; low quality of evidence). Meanwhile, the incidence of postoperative nausea and vomiting was significantly decreased in the dexamethasone group (risk ratios [RR] = 0.40; 95% CI, 0.28 to 0.58; P<0.00001; high quality of evidence). No complications were reported in all the included studies. Conclusions Dexamethasone added to local anesthetics in ultrasound-guided TAP block was a safe and effective strategy for postoperative analgesia in adult patients undergoing abdominal surgery.	[Zhang, Donghang; Li, Qian] Sichuan Univ, West China Hosp, Dept Anesthesiol, Chengdu, Sichuan, Peoples R China; [Zhou, Cheng] Sichuan Univ, West China Hosp, Translat Neurosci Ctr, Lab Anesthesia & Crit Care Med, Chengdu, Sichuan, Peoples R China; [Wei, Dang; Ge, Long] Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou, Gansu, Peoples R China	Sichuan University; Sichuan University; Lanzhou University	Zhang, DH; Li, Q (corresponding author), Sichuan Univ, West China Hosp, Dept Anesthesiol, Chengdu, Sichuan, Peoples R China.	zhangdhscu@163.com; hxliqian@foxmail.com	Ge, Long/G-8876-2017	Ge, Long/0000-0002-3555-1107				Abdallah FW, 2013, BRIT J ANAESTH, V111, P721, DOI 10.1093/bja/aet214; Akkaya A, 2014, EUR REV MED PHARMACO, V18, P717; Allcock E, 2010, PAIN MED, V11, P1426, DOI 10.1111/j.1526-4637.2010.00894.x; Ammar AS, 2012, SAUDI J ANAESTH, V6, P229, DOI 10.4103/1658-354X.101213; Belavy D, 2009, BRIT J ANAESTH, V103, P726, DOI 10.1093/bja/aep235; Bhatia N, 2014, J CLIN ANESTH, V26, P294, DOI 10.1016/j.jclinane.2013.11.023; Cao XZ, 2017, J ANESTH, V31, P617, DOI 10.1007/s00540-017-2363-x; Carlisle J, 2006, BMJ-BRIT MED J, V333; De Oliveira GS, 2014, ANESTH ANALG, V118, P454, DOI 10.1213/ANE.0000000000000066; Deshpande Jyoti P, 2017, Anesth Essays Res, V11, P499, DOI 10.4103/aer.AER_22_17; DEVOR M, 1985, PAIN, V22, P127, DOI 10.1016/0304-3959(85)90173-3; EI Sharnouby NM, 2015, AINS SHAMS J ANESTHE, V8, P194, DOI DOI 10.4103/1687-7934.156683; Foster CJ, TAP BLOCKS USING DEX; Fredrickson MJ, 2013, REGION ANESTH PAIN M, V38, P300, DOI 10.1097/AAP.0b013e318292c121; Golwala MP, 2009, J ANAESTHESIOL CLIN, V25, P285; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; HARRIS AL, 1982, LANCET, V1, P714; Hebbard P, 2007, ANAESTH INTENS CARE, V35, P616; Helander EM, 2017, INT ANESTHESIOL CLIN, V55, P51, DOI 10.1097/AIA.0000000000000165; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13; Huang SH, 2016, HEPATOB PANCREAT DIS, V15, P540, DOI 10.1016/S1499-3872(16)60086-3; Jakobsson J., 2015, F1000RESEARCH, V4; Jankovic Z, 2008, ANESTH ANALG, V107, P1758, DOI 10.1213/ane.0b013e3181853619; Johns N, 2012, COLORECTAL DIS, V14, pE635, DOI 10.1111/j.1463-1318.2012.03104.x; Kartalov Andrijan, 2015, Pril (Makedon Akad Nauk Umet Odd Med Nauki), V36, P35, DOI 10.1515/prilozi-2015-0076; Kehlet H, 1997, BRIT J ANAESTH, V78, P606, DOI 10.1093/bja/78.5.606; Kelly AM, 1998, ACAD EMERG MED, V5, P1086, DOI 10.1111/j.1553-2712.1998.tb02667.x; McCormack K, 1994, Drugs, V47 Suppl 5, P28, DOI 10.2165/00003495-199400475-00006; McCormack K., 1994, DRUGS S5, V47, P46, DOI DOI 10.2165/00003495-199400475-00006; McDonnell JG, 2007, ANESTH ANALG, V104, P193, DOI 10.1213/01.ane.0000250223.49963.0f; Melzack Ronald, 1999, J KATZ PAIN MEASUREM; Mirzai H, 2002, SPINE, V27, P343, DOI 10.1097/00007632-200202150-00003; Mishriky BM, 2012, CAN J ANESTH, V59, P766, DOI 10.1007/s12630-012-9729-1; Moeschler SM, 2013, J PAIN RES, V6, P493, DOI 10.2147/JPR.S45913; Movafegh A, 2006, ANESTH ANALG, V102, P263, DOI 10.1213/01.ane.0000189055.06729.0a; Peng K, 2016, MED PRIN PRACT, V25, P237, DOI 10.1159/000444688; PENNINGTON AJ, 1994, J NEUROENDOCRINOL, V6, P305, DOI 10.1111/j.1365-2826.1994.tb00587.x; RICH WM, 1980, GYNECOL ONCOL, V9, P193, DOI 10.1016/0090-8258(80)90027-X; Ripolles J, 2015, REV BRAS ANESTESIOL, V65, P255, DOI [10.1016/j.bjan.2013.10.014, 10.1016/j.bjane.2013.10.016]; Rozen WM, 2008, CLIN ANAT, V21, P325, DOI 10.1002/ca.20621; Sachdeva J, 2016, INDIAN J PAIN, V30, P181, DOI DOI 10.4103/0970-5333.198056; Sharma UB, 2018, INDIAN J ANAESTH, V62, P371, DOI [10.4103/ija.IJA_605_17, 10.4103/ija.IJA_210_18]; Shishido H, 2002, SPINE, V27, P581, DOI 10.1097/00007632-200203150-00005; Siddiqui MRS, 2011, J CLIN ANESTH, V23, P7, DOI 10.1016/j.jclinane.2010.05.008; Simpson D, 2005, DRUGS, V65, P2675, DOI 10.2165/00003495-200565180-00013; Souvik M, 2016, ANESTHESIOLOGY RES P, V2016; Sun N, 2016, CLIN J PAIN, V1; Von Korff M, 2008, CLIN J PAIN, V24, P521, DOI 10.1097/AJP.0b013e318169d03b; Waldron NH, 2013, BRIT J ANAESTH, V110, P191, DOI 10.1093/bja/aes431; Wang JJ, 2000, ANESTH ANALG, V91, P1404, DOI 10.1097/00000539-200012000-00019; Wang JJ, 2000, ANESTH ANALG, V91, P136, DOI 10.1097/00000539-200007000-00025; Wang PH, 2011, J HAND SURG-EUR VOL, V36E, P236, DOI 10.1177/1753193410390760; Wegner R, 2017, PAIN PHYSICIAN, V20, P413; Yu NZ, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-121	55	19	20	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2019	14	1							e0209646	10.1371/journal.pone.0209646	http://dx.doi.org/10.1371/journal.pone.0209646			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG7HM	30620730	Green Submitted, gold, Green Published			2023-01-03	WOS:000455161300007
J	Grottke, O; van Ryn, J; Zentai, C; Gan, GF; Honickel, M; Rossaint, R; ten Cate, H; Spronk, HMH				Grottke, Oliver; van Ryn, Joanne; Zentai, Christian; Gan, Guanfa; Honickel, Markus; Rossaint, Rolf; ten Cate, Hugo; Spronk, Henri M. H.			Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution	PLOS ONE			English	Article							DIRECT THROMBIN INHIBITOR; HYDROXYETHYL STARCH; PIG MODEL; COAGULOPATHY; COAGULATION; TRAUMA; PHARMACOKINETICS; PHARMACODYNAMICS; TOLERABILITY; MANAGEMENT	Background Idarucizumab is a humanized Fab fragment that specifically reverses dabigatran anticoagulation. In trauma, volume expanders are used for resuscitation to compensate for blood loss and hemorrhagic shock, but it is unknown whether volume expanders influence the binding of dabigatran to its antidote. Using a porcine dilutional coagulopathy model, this study investigated whether volume replacement strategies affect binding of dabigatran to idarucizumab. Methods Twenty-five male pigs were treated orally with dabigatran etexilate (30 mg/kg bid) for 3 days. The following day, animals were anesthetized, infused with dabigatran (total dose 0.645 mg/kg) to achieve supratherapeutic concentrations, and randomized 1:1:1:1:1 (n = 5 per group) to control (no hemodilution) or hemodilution where similar to 50% of blood volume was substituted with Ringer's solution, 6% hydroxyethyl starch 130/0.4, 6% hydroxyethyl starch 200/0.5 or 4% gelatin. Idarucizumab was then administered intravenously (30 mg/kg) and serial blood samples were taken for up to 24 hours to measure diluted thrombin time (corresponding with dabigatran activity), total dabigatran (bound to antidote and free drug) and a panel of coagulation parameters. Results Mean plasma dabigatran levels were 617 +/- 16 ng/mL after infusion and 600 +/- 114 ng/mL after similar to 50% hemodilution with no significant differences between groups. Following treatment with idarucizumab, plasma concentrations of unbound dabigatran decreased markedly, with similar reductions in all groups. Dabigatran-induced prolongation of coagulation parameters was rapidly reversed in all groups. Conclusion This study indicates that several volume expanders used for resuscitation in trauma do not interfere with the binding of idarucizumab to dabigatran.	[Grottke, Oliver; Zentai, Christian; Honickel, Markus; Rossaint, Rolf] RWTH Aachen Univ Hosp, Dept Anesthesiol, Aachen, Germany; [van Ryn, Joanne] Boehringer Ingelheim GmbH & Co KG, Dept CardioMetab Dis Res, Biberach, Germany; [Gan, Guanfa] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA; [ten Cate, Hugo; Spronk, Henri M. H.] Maastricht Univ, Med Ctr, Cardiovasc Res Inst Maastricht, Dept Internal Med,Lab Clin Thrombosis & Haemostas, Maastricht, Netherlands	RWTH Aachen University; RWTH Aachen University Hospital; Boehringer Ingelheim; Boehringer Ingelheim; Maastricht University	Grottke, O (corresponding author), RWTH Aachen Univ Hosp, Dept Anesthesiol, Aachen, Germany.	ogrottke@ukaachen.de	Cate, Hugo ten/AAM-4000-2021	Grottke, Oliver/0000-0002-0722-3122; Spronk, Henri/0000-0002-3858-334X	Boehringer Ingelheim, Biberach, Germany	Boehringer Ingelheim, Biberach, Germany(Boehringer Ingelheim)	This study was funded by Boehringer Ingelheim, Biberach, Germany. The study sponsor had no role in the collection or interpretation of data.	Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Coppola S, 2014, CURR OPIN CRIT CARE, V20, P444, DOI 10.1097/MCC.0000000000000115; Dickneite G, 2010, J TRAUMA, V68, P1151, DOI 10.1097/TA.0b013e3181b06364; European Medicines Agency, HYDR STARCH SOL INF; Glund S, 2015, THROMB HAEMOSTASIS, V113, P943, DOI 10.1160/TH14-12-1080; Grottke O, 2010, BRIT J ANAESTH, V105, P789, DOI 10.1093/bja/aeq263; Grottke O, 2015, J AM COLL CARDIOL, V66, P1518, DOI 10.1016/j.jacc.2015.07.051; Grottke O, 2011, BLOOD, V118, P1943, DOI 10.1182/blood-2011-03-343046; Grottke O, 2010, CRIT CARE, V14, DOI 10.1186/cc8960; Hartog CS, 2011, INTENS CARE MED, V37, P1725, DOI 10.1007/s00134-011-2385-z; Heidbuchel H, 2015, EUROPACE, V17, P1467, DOI 10.1093/europace/euv309; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; Pollack Jr CV, 2015, NEW ENGL J MED, V373, P511, DOI 10.1056/NEJMoa1502000; Rasmussen KC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004498; Rossaint R, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1265-x; Schiele F, 2013, BLOOD, V121, P3554, DOI 10.1182/blood-2012-11-468207; Schmohl M, 2017, THROMB HAEMOSTASIS, V117, P269, DOI 10.1160/TH16-05-0385; Schramko A, 2010, BRIT J ANAESTH, V104, P691, DOI 10.1093/bja/aeq084; Stangier J, 2008, CLIN PHARMACOKINET, V47, P285, DOI 10.2165/00003088-200847050-00001; Stangier J, 2007, BRIT J CLIN PHARMACO, V64, P292, DOI 10.1111/j.1365-2125.2007.02899.x; Stangier J, 2012, BLOOD COAGUL FIBRIN, V23, P138, DOI 10.1097/MBC.0b013e32834f1b0c; van Ryn J, 2014, CLIN LAB MED, V34, P479, DOI 10.1016/j.cll.2014.06.008; Weitz JI, 2012, CIRCULATION, V126, P2428, DOI 10.1161/CIRCULATIONAHA.112.123224; Wilkes MM, 2001, ANN THORAC SURG, V72, P527, DOI 10.1016/S0003-4975(01)02745-X	24	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2019	14	1							e0209350	10.1371/journal.pone.0209350	http://dx.doi.org/10.1371/journal.pone.0209350			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG5UW	30615630	Green Published, gold, Green Submitted			2023-01-03	WOS:000455045900021
J	Premji, S; McDonald, SW; Zaychkowsky, C; Zwicker, JD				Premji, Shainur; McDonald, Sheila W.; Zaychkowsky, Carol; Zwicker, Jennifer D.			Supporting healthy pregnancies: Examining variations in nutrition, weight management and substance abuse advice provision by prenatal care providers in Alberta, Canada. A study using the All Our Families cohort	PLOS ONE			English	Article							MARIJUANA USE; OBESE WOMEN; GAIN; OUTCOMES; BIRTH; INFORMATION; MIDWIFERY; PATIENT; TRENDS; VIEWS	Background Pregnancy is a critical time for fetal development, and education of women regarding healthy lifestyle choices is an important function for prenatal care providers, those that provide care to women during pregnancy. Within Canada, women choose to receive pregnancy care from one of a variety of publicly funded care providers. This study examines the association between the type of care provider(s) seen during pregnancy and the provision of advice related to nutrition, weight management and substance abuse. Methods Using data from the Alberta-based All Our Families prospective pregnancy cohort, we conducted bivariate and multivariate analyses to determine the likelihood of receiving advice related to nutrition, weight management, and substance abuse across provider (s) seen. Results Of 3341 women in our sample, 38% saw a single provider during pregnancy and 56% received care from multiple providers. Advice on nutrition was more likely to be provided across all providers, while weight management and substance abuse was less frequently and less consistently discussed. Relative to doctors in low-risk maternity clinics, midwives were most likely to provide nutrition (OR: 3.09, 95% CI: 1.19-8.01) and weight management (OR: 1.99, 95% CI: 1.13-3.50) advice to women. Conclusion Findings suggest that the type of prenatal advice received by women depends on the provider(s) seen during pregnancy. Substance abuse was least likely to be discussed across providers, suggesting important implications given recent cannabis legalization.	[Premji, Shainur; Zwicker, Jennifer D.] Univ Calgary, Sch Publ Policy, Calgary, AB, Canada; [Premji, Shainur; McDonald, Sheila W.] Univ Calgary, Cumming Sch Med, Calgary, AB, Canada; [Premji, Shainur; McDonald, Sheila W.; Zaychkowsky, Carol] Alberta Hlth Serv, Populat Publ & Indigenous Hlth, Calgary, AB, Canada; [Zwicker, Jennifer D.] Univ Calgary, Fac Kinesiol, Calgary, AB, Canada	University of Calgary; University of Calgary; Alberta Health Services (AHS); University of Calgary; University of Calgary	Premji, S; Zwicker, JD (corresponding author), Univ Calgary, Sch Publ Policy, Calgary, AB, Canada.; Premji, S (corresponding author), Univ Calgary, Cumming Sch Med, Calgary, AB, Canada.; Premji, S (corresponding author), Alberta Hlth Serv, Populat Publ & Indigenous Hlth, Calgary, AB, Canada.; Zwicker, JD (corresponding author), Univ Calgary, Fac Kinesiol, Calgary, AB, Canada.	Shainur.Premji2@ucalgary.ca; Zwicker1@ucalgary.ca	Premji, Shainur/J-2472-2018	Premji, Shainur/0000-0002-9951-5244	Secondary Analysis to Generate Evidence (SAGE) grant	Secondary Analysis to Generate Evidence (SAGE) grant	Funding was provided through a Secondary Analysis to Generate Evidence (SAGE) grant, administered by PolicyWise for Children and Families (SP, JDZ). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alberta Health Services, 2016, LOW RISK OBST OPT RE; ALEXANDER GR, 1995, FUTURE CHILD, V5, P103, DOI 10.2307/1602510; Bai J, 2008, AUST NZ J OBSTET GYN, V48, P454, DOI 10.1111/j.1479-828X.2008.00888.x; Begum F, 2012, J OBSTET GYNAECOL CA, V34, P637, DOI 10.1016/S1701-2163(16)35316-6; Brown QL, 2017, JAMA-J AM MED ASSOC, V317, P207, DOI 10.1001/jama.2016.17383; Day NL, 2011, NEUROTOXICOL TERATOL, V33, P129, DOI 10.1016/j.ntt.2010.07.006; Durand MA, 2010, HEALTH EXPECT, V13, P125, DOI 10.1111/j.1369-7625.2009.00544.x; Duthie EA, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-231; Eggertson L, 2013, CAN MED ASSOC J, V185, P1562, DOI 10.1503/cmaj.109-4653; Faucher MA, 2015, WOMEN BIRTH, V28, pE70, DOI 10.1016/j.wombi.2015.03.006; Fried PA, 2002, CANNABIS CANNABINOID, P269; Heslehurst N, 2013, MIDWIFERY, V29, P736, DOI 10.1016/j.midw.2012.07.007; Holton S, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1538-7; Jarlenski M, 2017, AM J OBSTET GYNECOL, V217, P705, DOI 10.1016/j.ajog.2017.08.015; Jarlenski M, 2016, WOMEN HEALTH ISS, V26, P452, DOI 10.1016/j.whi.2016.03.010; Klein MC, 2009, J OBSTET GYNAECOL CA, V31, P827, DOI 10.1016/S1701-2163(16)34301-8; Kuczkowski KM, 2007, CURR OPIN OBSTET GYN, V19, P578, DOI 10.1097/GCO.0b013e3282f1bf17; Macleod M, 2013, MATERN CHILD NUTR, V9, P467, DOI 10.1111/j.1740-8709.2011.00396.x; McDonald SD, 2012, J OBSTET GYNAECOL CA, V34, P129, DOI 10.1016/S1701-2163(16)35155-6; McDonald SW, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-S1-S2; McNeely J, 2018, ADDICT SCI CLIN PRAC, V13, DOI 10.1186/s13722-018-0110-8; Metcalfe A, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-62; O'Brien B, 2011, BIRTH-ISS PERINAT C, V38, P207, DOI 10.1111/j.1523-536X.2011.00482.x; O'Brien B, 2010, J OBSTET GYNAECOL CA, V32, P650, DOI 10.1016/S1701-2163(16)34568-6; Oga EA, 2018, MATERN CHILD HLTH J, V22, P1477, DOI 10.1007/s10995-018-2543-9; Ordean A, 2011, CAN FAM PHYSICIAN, V57, pE430; Phelan S, 2010, AM J OBSTET GYNECOL, V202, DOI [10.1016/j.ajog.2009.06.008, 10.1016/j.ajog.2010.06.051]; Porath A. J., 2018, CLEARING SMOKE CANNA; Public Health Agency of Canada, 2008, CAN PER HLTH REP; Rasmussen KM, 2009, CURR OPIN OBSTET GYN, V21, P521, DOI 10.1097/GCO.0b013e328332d24e; Schuurmans N, 1998, SOGC CLIN PRACTICE G, P1; Stengel MR, 2012, WOMEN HEALTH ISS, V22, pE535, DOI 10.1016/j.whi.2012.09.004; Stone R., 2015, HEAL JUSTICE, V3, DOI 10.1186/s40352-015-0015-5; Tough SC, 2017, INT J EPIDEMIOL, V46, P1389, DOI 10.1093/ije/dyw363; Vitner D, 2019, J MATERN-FETAL NEO M, V32, P2580, DOI [10.1080/14767058.2018.1440546, 10.1080/14767058.2018.1531121]; Whitaker KM, 2016, WOMEN HEALTH ISS, V26, P116, DOI 10.1016/j.whi.2015.10.007; Zelmer Jennifer, 2004, Healthc Q, V7, P21	37	5	5	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2019	14	1							e0210290	10.1371/journal.pone.0210290	http://dx.doi.org/10.1371/journal.pone.0210290			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HG5UW	30615660	Green Submitted, gold, Green Published			2023-01-03	WOS:000455045900058
J	Frasao, B; Costa, M; Silva, F; Rodrigues, B; Baltar, J; Araujo, J; Moreira, D; Torrezan, R; Conte, C				Frasao, Beatriz; Costa, Marion; Silva, Fabricio; Rodrigues, Bruna; Baltar, Jessica; Araujo, Jasmim; Moreira, Daniel; Torrezan, Renata; Conte-Junior, Carlos			Effect of pequi (Caryocar brasiliense) and jucara (Euterpe edulis) waste extract on oxidation process stability in broiler meat treated by UV-C	PLOS ONE			English	Article							FATTY-ACID-COMPOSITION; ANTIOXIDANT ACTIVITY; BIOACTIVE COMPOUNDS; PROTEIN OXIDATION; ROSEMARY EXTRACT; TROPICAL FRUITS; BIOGENIC-AMINES; SHELF-LIFE; CHICKEN; COLOR	The aim of this study was to determine the potential for waste extracts from the pequi (Caryocar brasiliense) and jucara (Euterpe edulis) to reduce oxidatiove processes in antibiotic-free broiler meat. The use of natural antioxidants extracted from fruit-processing wastes has been neglected. Although these residues contain high amounts of these bioactive compounds, they are often discarded by industry. Meat samples were exposed previously submitted to UV-C radiation at 1.161 mW / cm(2) for 10 minutes to accelerate the rancidity process. Pequi and jucara waste extracts were obtained by microwave-assisted extraction (MAE). A total of four conditions were tested using antibiotic-free broiler thighs and drumstick meat: BN - with no antioxidant (negative control), BP-with BHT (Butylated hydroxytoluene) (positive control), BE-with jucara extract, BC-with pequi extract. The color, pH, lipid and protein oxidation (days 0, 2, 4, 6, 8 and 10), antioxidant contents and activity (days 0 and 10), and proximal composition and fatty acid profile (day 0) were tested, followed by principal component analysis (PCA). Pequi waste extract presented the highest antioxidant content and activity. BE and BC treatments presented the highest total phenolic (TPC) and flavonoid (TFC) content, and BE presented the highest total monomeric anthocyanin content (TAC). TFC increased during storage in all treatments. The waste extracts of C. brasiliense presented the highest antioxidant activity against lipid oxidation in the antibiotic-free broiler meat. Moreover, both extracts presented high antioxidant activity against protein oxidation. Although the pequi peel extract had a better effect in terms of suppressing both types of oxidation, either this extract or the jussara waste extract could be used as a technological strategy to reduce the oxidative processes in antibiotic-free broiler meat for the poultry industry. Thus, waste extracts can be a potential technology to reduce the oxidative processes in antibiotic-free broiler meat.	[Frasao, Beatriz] Univ Fed Oeste Bahia, Multidisciplinary Ctr, Coll Vet Med, Barra Campus, Barra, BA, Brazil; [Costa, Marion] Univ Fed Bahia, Escola Med Vet & Zootecnia, Dept Prevent Vet Med & Anim Prod, Salvador, BA, Brazil; [Silva, Fabricio; Baltar, Jessica; Moreira, Daniel; Conte-Junior, Carlos] Univ Fed Rio de Janeiro, Chem Inst, Food Sci Programe, Rio De Janeiro, Brazil; [Rodrigues, Bruna; Araujo, Jasmim; Conte-Junior, Carlos] Univ Fed Fluminense, Fac Vet, Dept Food Technol, Rio De Janeiro, Brazil; [Torrezan, Renata] Brazilian Agr Res Corp, Embrapa Food Technol, Rio De Janeiro, Brazil; [Conte-Junior, Carlos] Oswaldo Cruz Fdn FIOCRUZ, Natl Inst Hlth Qual Control, Rio De Janeiro, Brazil; [Costa, Marion] Univ Fed Bahia, Dept Prevent Vet Med & Anim Prod, Salvador, BA, Brazil; [Conte-Junior, Carlos] Fluminense Fed Univ, Dept Food Technol, Niteroi, RJ, Brazil	Universidade Federal do Oeste da Bahia; Universidade Federal da Bahia; Universidade Federal do Rio de Janeiro; Universidade Federal Fluminense; Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA); Fundacao Oswaldo Cruz; Universidade Federal da Bahia; Universidade Federal Fluminense	Conte, C (corresponding author), Univ Fed Rio de Janeiro, Chem Inst, Food Sci Programe, Rio De Janeiro, Brazil.; Conte, C (corresponding author), Univ Fed Fluminense, Fac Vet, Dept Food Technol, Rio De Janeiro, Brazil.; Conte, C (corresponding author), Oswaldo Cruz Fdn FIOCRUZ, Natl Inst Hlth Qual Control, Rio De Janeiro, Brazil.; Conte, C (corresponding author), Fluminense Fed Univ, Dept Food Technol, Niteroi, RJ, Brazil.	carlosconte@id.uff.br	Conte-Junior, Carlos A./J-5815-2014; Costa, Marion/AAL-1269-2020; Silva, Fabricio/L-5502-2018	Conte-Junior, Carlos A./0000-0001-6133-5080; Costa, Marion/0000-0002-3003-6763; Silva, Fabricio/0000-0003-3248-1358	Coordination of Enhancement of People of a Superior Level [CAPES, Brazil] [125, CAPES/Embrapa 15/2014]; Research Foundation of the State of Rio de Janeiro [FAPERJ, Brazil] [E-26/201.185/2014]; National Council of Technological and Scientific Development [CNPq, Brazil] [311361/2013-7, 311422/2016-0, 439731/2016-0, 150200/2017-0]	Coordination of Enhancement of People of a Superior Level [CAPES, Brazil]; Research Foundation of the State of Rio de Janeiro [FAPERJ, Brazil]; National Council of Technological and Scientific Development [CNPq, Brazil](Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by the Coordination of Enhancement of People of a Superior Level [process no. 125, CAPES/Embrapa 15/2014, CAPES, Brazil], Research Foundation of the State of Rio de Janeiro [process no. E-26/201.185/2014, FAPERJ, Brazil], the National Council of Technological and Scientific Development [processes no. 311361/2013-7, 311422/2016-0, 439731/2016-0 and 150200/2017-0, CNPq, Brazil].	Ainsworth EA, 2007, NAT PROTOC, V2, P875, DOI 10.1038/nprot.2007.102; Amaral LFB, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-154; Andres AI, 2017, MEAT SCI, V129, P62, DOI 10.1016/j.meatsci.2017.02.013; AOAC, 2002, OFFICIAL METHODS ANA, Vfifteenth; Armenteros M, 2009, MEAT SCI, V83, P104, DOI 10.1016/j.meatsci.2009.04.007; Ascari J, 2010, B LATINOAM CARIBE PL, V9, P20; Azevedo-Meleiro CH, 2004, J FOOD COMPOS ANAL, V17, P385, DOI 10.1016/j.jfca.2004.02.004; Baptista A, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3753562; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boschetti E, 2016, ANIMAL, V10, P700, DOI 10.1017/S1751731115002712; Borges GDC, 2011, FOOD RES INT, V44, P2128, DOI 10.1016/j.foodres.2010.12.006; Chang CC, 2002, J FOOD DRUG ANAL, V10, P178; Cheynier V, 2005, AM J CLIN NUTR, V81, p223S, DOI 10.1093/ajcn/81.1.223S; Chin S. F., 1992, Journal of Food Composition and Analysis, V5, P185, DOI 10.1016/0889-1575(92)90037-K; Costa MP, 2017, J DAIRY SCI, V100, P157, DOI 10.3168/jds.2016-11315; da Cunha ALA, 2017, GRASAS ACEITES, V68, DOI 10.3989/gya.0442171; Dalziel CJ, 2015, FOOD CHEM, V179, P103, DOI 10.1016/j.foodchem.2015.01.118; De Alcantara A., 2015, J FOOD STUD, V4, P34, DOI [10.5296/jfs.v4i1.8362, DOI 10.5296/JFS.V4I1.8362]; Feng LF, 2016, INT J FOOD PROP, V19, P2338, DOI 10.1080/10942912.2015.1130053; Ferreira VCS, 2017, J FOOD SCI, V82, P622, DOI 10.1111/1750-3841.13640; Frasao B. da S., 2017, Journal of Agricultural Science (Toronto), V9, P178, DOI 10.5539/jas.v9n3p178; Frasao BS, 2017, THESIS; Fukada Y, 2016, J FOOD SCI TECH MYS, V53, P2476, DOI 10.1007/s13197-016-2233-9; Hwang KE, 2015, RADIAT PHYS CHEM, V106, P315, DOI 10.1016/j.radphyschem.2014.08.014; Incedayi B, 2006, FOOD SCI TECH-BRAZIL, V36, P171; Jayawardana BC, 2015, LWT-FOOD SCI TECHNOL, V64, P1204, DOI 10.1016/j.lwt.2015.07.028; Joseph P, 2012, J AGR FOOD CHEM, V60, P3196, DOI 10.1021/jf204188v; Karre L, 2013, MEAT SCI, V94, P220, DOI 10.1016/j.meatsci.2013.01.007; Kishino S, 2002, BIOSCI BIOTECH BIOCH, V66, P2283, DOI 10.1271/bbb.66.2283; Klangpetch W, 2016, INT FOOD RES J, V23, P700; Krishnan KR, 2014, INT J FOOD MICROBIOL, V171, P32, DOI 10.1016/j.ijfoodmicro.2013.11.011; Kumar Y, 2015, COMPR REV FOOD SCI F, V14, P796, DOI 10.1111/1541-4337.12156; Lazaro CA, 2014, POULTRY SCI, V93, P2304, DOI 10.3382/ps.2013-03642; Lee J, 2005, J AOAC INT, V88, P1269; Memon NN, 2011, FOOD CHEM, V126, P405, DOI 10.1016/j.foodchem.2010.10.107; Monteiro SS, 2015, INT FOOD RES J, V22, P1985; Moreira da SILVA PP, 2013, BRAZ J FOOD NUTR E, V24; Bicudo MOP, 2014, PLANT FOOD HUM NUTR, V69, P142, DOI 10.1007/s11130-014-0406-0; Ramana KV, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2163285; Ratter J. A., 2003, Edinburgh Journal of Botany, V60, P57, DOI 10.1017/S0960428603000064; Ribeiro DM, 2014, FOOD SCI TECH-BRAZIL, V34, P507, DOI [10.1590/1678-457x.6369, 10.1590/1678-457X.6369]; ROCHA L. B., 2015, Rev. bras. plantas med., V17, P592, DOI 10.1590/1983-084X/14_062; Roesler R, 2008, FOOD CHEM, V110, P711, DOI 10.1016/j.foodchem.2008.02.048; Roesler R, 2007, CIENCIA TECNOL ALIME, V27, P53, DOI 10.1590/S0101-20612007000100010; Rufino MDM, 2010, FOOD CHEM, V121, P996, DOI 10.1016/j.foodchem.2010.01.037; Sebranek JG, 2005, MEAT SCI, V69, P289, DOI 10.1016/j.meatsci.2004.07.010; Shao Y, 2014, ANAL METHODS-UK, V6, P170, DOI 10.1039/c3ay41279b; Sohaib M, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944-017-0426-5; Soladoye OP, 2015, COMPR REV FOOD SCI F, V14, P106, DOI 10.1111/1541-4337.12127; Zhang QQ, 2017, FOOD CONTROL, V78, P324, DOI 10.1016/j.foodcont.2017.02.054; Zhang WG, 2013, CRIT REV FOOD SCI, V53, P1191, DOI 10.1080/10408398.2011.577540; Zhuang H, 2016, LWT-FOOD SCI TECHNOL, V69, P233, DOI 10.1016/j.lwt.2016.01.054	52	9	9	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2018	13	12							e0208306	10.1371/journal.pone.0208306	http://dx.doi.org/10.1371/journal.pone.0208306			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF0HP	30571713	Green Submitted, gold, Green Published			2023-01-03	WOS:000453841700010
J	Wallentin, M				Wallentin, Mikkel			Sex differences in post-stroke aphasia rates are caused by age. A meta-analysis and database query	PLOS ONE			English	Article							ACUTE ISCHEMIC-STROKE; COGNITIVE IMPAIRMENT; NATURAL-HISTORY; HEART-DISEASE; RECOVERY; SEVERITY; LANGUAGE; BRAIN; REHABILITATION; DETERMINANTS	Background Studies have suggested that aphasia rates are different in men and women following stroke. One hypothesis says that men have more lateralized language function than women. Given unilateral stroke, this would lead to a prediction of men having higher aphasia rates than women. Another line of observations suggest that women are more severely affected by stroke, which could lead to a higher aphasia rate among women. An additional potential confounding variable could be age, given that women are typically older at the time of stroke. Methods & procedures This study consists of two parts. First, a meta-analysis of the available reports of aphasia rates in the two sexes was conducted. A comprehensive literature search yielded 25 studies with sufficient information about both aphasia and gender. These studies included a total of 48,362 stroke patients for which aphasia rates were calculated. Second, data were extracted from an American health database (with 1,967,038 stroke patients), in order to include age and stroke severity into a regression analysis of sex differences in aphasia rates. Outcomes & results Both analyses revealed significantly larger aphasia rates in women than in men (1 .1-1 .14 ratio). This speaks against the idea that men should be more lateralized in their language function. When age and stroke severity were included as covariates, sex failed to explain any aphasia rate sex difference above and beyond that which is explained by age differences at time of stroke.	[Wallentin, Mikkel] Aarhus Univ, Dept Linguist Cognit Sci & Semiot, Aarhus, Denmark; [Wallentin, Mikkel] Aarhus Univ Hosp, Ctr Functionally Integrat Neurosci, Aarhus, Denmark; [Wallentin, Mikkel] Aarhus Univ, Interacting Minds Ctr, Aarhus, Denmark	Aarhus University; Aarhus University; Aarhus University	Wallentin, M (corresponding author), Aarhus Univ, Dept Linguist Cognit Sci & Semiot, Aarhus, Denmark.; Wallentin, M (corresponding author), Aarhus Univ Hosp, Ctr Functionally Integrat Neurosci, Aarhus, Denmark.; Wallentin, M (corresponding author), Aarhus Univ, Interacting Minds Ctr, Aarhus, Denmark.	mikkel@cc.au.dk		Wallentin, Mikkel/0000-0002-5509-9621				Ali M, 2014, INT J STROKE, V9, P174, DOI 10.1111/ijs.12043; [Anonymous], 2017, Circulation, V136, pe196, DOI 10.1161/CIR.0000000000000530; Appelros P, 2010, ACTA NEUROL SCAND, V121, P359, DOI 10.1111/j.1600-0404.2009.01258.x; Appelros P, 2009, STROKE, V40, P1082, DOI 10.1161/STROKEAHA.108.540781; Baron-Cohen S, 2005, SCIENCE, V310, P819, DOI 10.1126/science.1115455; BASSO A, 1982, CORTEX, V18, P469, DOI 10.1016/S0010-9452(82)80044-0; Berglund A, 2017, MATURITAS, V99, P47, DOI 10.1016/j.maturitas.2017.02.007; Bersano A, 2009, INT J STROKE, V4, P443, DOI 10.1111/j.1747-4949.2009.00349.x; Bhatnagar SC, 2002, BRAIN LANG, V83, P353, DOI 10.1016/S0093-934X(02)00039-1; Bleses D, 2008, J CHILD LANG, V35, P651, DOI 10.1017/S0305000907008574; BOGOUSSLAVSKY J, 1988, STROKE, V19, P1083, DOI 10.1161/01.STR.19.9.1083; Brkic Ensala, 2009, Med Arh, V63, P197; BRUST JCM, 1976, STROKE, V7, P167, DOI 10.1161/01.STR.7.2.167; Candelise L, 2007, LANCET, V369, P299, DOI 10.1016/S0140-6736(07)60152-4; Chang TS, 2015, STROKE, V46, P2965, DOI 10.1161/STROKEAHA.115.010203; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Crinion JT, 2007, CURR OPIN NEUROL, V20, P667, DOI 10.1097/WCO.0b013e3282f1c6fa; Croquelois A, 2011, CEREBROVASC DIS, V31, P392, DOI 10.1159/000323217; DERENZI E, 1980, CORTEX, V16, P627, DOI 10.1016/S0010-9452(80)80010-4; Di Carlo A, 2003, STROKE, V34, P1114, DOI 10.1161/01.STR.0000068410.07397.D7; Dickey L, 2010, ARCH PHYS MED REHAB, V91, P196, DOI 10.1016/j.apmr.2009.09.020; El Hachioui H, 2012, J REHABIL MED, V44, P429, DOI 10.2340/16501977-0955; Ellis C, 2018, APHASIOLOGY, V32, P1075, DOI 10.1080/02687038.2017.1385052; Ellis C, 2016, TOP STROKE REHABIL, V23, P430, DOI 10.1080/10749357.2016.1150412; Engelter ST, 2006, STROKE, V37, P1379, DOI 10.1161/01.STR.0000221815.64093.8c; ESLINGER PJ, 1981, J NEUROL NEUROSUR PS, V44, P377, DOI 10.1136/jnnp.44.5.377; Fennis TFM, 2013, CEREBROVASC DIS, V35, P337, DOI 10.1159/000348696; Ferro JM, 1999, CEREBROVASC DIS, V9, P6, DOI 10.1159/000047571; Flowers HL, 2016, ARCH PHYS MED REHAB, V97, P2188, DOI 10.1016/j.apmr.2016.03.006; Flowers HL, 2013, J COMMUN DISORD, V46, P238, DOI 10.1016/j.jcomdis.2013.04.001; Fuh JL, 1996, STROKE, V27, P1338, DOI 10.1161/01.STR.27.8.1338; Gall S L, 2010, Neurology, V74, P975, DOI 10.1212/WNL.0b013e3181d5a48f; Gialanella B, 2013, EUR J PHYS REHAB MED, V49, P629; Gialanella B, 2011, DISABIL REHABIL, V33, P122, DOI 10.3109/09638288.2010.488712; Giaquinto S, 1999, ACTA NEUROL SCAND, V100, P202; Godefroy O, 2002, STROKE, V33, P702, DOI 10.1161/hs0302.103653; Goldstein LB, 1998, STROKE, V29, P1602, DOI 10.1161/01.STR.29.8.1602; Gonzalez-Fernandez M, 2011, ARCH PHYS MED REHAB, V92, P1809, DOI 10.1016/j.apmr.2011.05.026; HANTSON L, 1994, STROKE, V25, P2215, DOI 10.1161/01.STR.25.11.2215; Haselbach D, 2014, CEREBROVASC DIS EXTR, V4, P77, DOI 10.1159/000360218; Hausmann M, 2017, J NEUROSCI RES, V95, P40, DOI 10.1002/jnr.23857; HIER DB, 1994, BRAIN LANG, V47, P155, DOI 10.1006/brln.1994.1046; Hillis AE, 2002, APHASIOLOGY, V16, P885, DOI 10.1080/0268703; Hirnstein M, 2019, LATERALITY, V24, P204, DOI 10.1080/1357650X.2018.1497044; Hoffmann M, 2013, J STROKE CEREBROVASC, V22, P1385, DOI 10.1016/j.jstrokecerebrovasdis.2013.04.017; Inatomi Y, 2008, CEREBROVASC DIS, V25, P316, DOI 10.1159/000118376; Jerath NU, 2011, GENDER MED, V8, P312, DOI 10.1016/j.genm.2011.08.001; Jodzio K, 2005, NEUROPSYCHOL REHABIL, V15, P588, DOI 10.1080/09602010443000137; JONGBLOED L, 1986, STROKE, V17, P765, DOI 10.1161/01.STR.17.4.765; Kansaku K, 2001, NEUROSCI RES, V41, P333, DOI 10.1016/S0168-0102(01)00292-9; Kauhanen ML, 2000, CEREBROVASC DIS, V10, P455, DOI 10.1159/000016107; Kelly PJ, 2003, ARCH PHYS MED REHAB, V84, P968, DOI 10.1016/S0003-9993(03)00040-6; Kelly-Hayes Margaret, 2003, J Stroke Cerebrovasc Dis, V12, P119, DOI 10.1016/S1052-3057(03)00042-9; Kemper C, 2011, TOP STROKE REHABIL, V18, P172, DOI 10.1310/tsr1802-172; KERTESZ A, 1989, BRAIN LANG, V37, P401, DOI 10.1016/0093-934X(89)90027-8; KERTESZ A, 1981, BRAIN, V104, P117, DOI 10.1093/brain/104.1.117; Kremer C, 2013, CLIN NEUROL NEUROSUR, V115, P289, DOI 10.1016/j.clineuro.2012.05.019; KUNITZ SC, 1984, STROKE, V15, P740, DOI 10.1161/01.STR.15.4.740; Kuznetsova A, 2017, J STAT SOFTW, V82, P1, DOI 10.18637/jss.v082.i13; Kyrozis A, 2009, EUR J NEUROL, V16, P733, DOI 10.1111/j.1468-1331.2009.02580.x; Laska AC, 2001, J INTERN MED, V249, P413, DOI 10.1046/j.1365-2796.2001.00812.x; Law J, 2009, APHASIOLOGY, V23, P1266, DOI 10.1080/02687030802514953; Lazar RM, 2008, J NEUROL NEUROSUR PS, V79, P530, DOI 10.1136/jnnp.2007.122457; Lazar RM, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0797-z; Lesniak M, 2008, DEMENT GERIATR COGN, V26, P356, DOI 10.1159/000162262; LINDENSTROM E, 1991, CEREBROVASC DIS, V1, P103, DOI 10.1159/000108825; Lloyd-Jones D, 2010, CIRCULATION, V121, P948, DOI 10.1161/CIRCULATIONAHA.109.192666; Lubart E, 2005, ARCH GERONTOL GERIAT, V41, P95, DOI 10.1016/j.archger.2004.12.002; Maas MB, 2012, J STROKE CEREBROVASC, V21, P350, DOI 10.1016/j.jstrokecerebrovasdis.2010.09.009; Maehlum S, 1990, Tidsskr Nor Laegeforen, V110, P2657; Matsumoto N, 1973, STROKE, V4, P20, DOI 10.1161/01.STR.4.1.20; MCGLONE J, 1973, Cortex, V9, P313; Meyer BC, 2009, INT J STROKE, V4, P267, DOI 10.1111/j.1747-4949.2009.00294.x; MICELI G, 1981, ACTA NEUROL SCAND, V64, P370; Miller N, 2014, TOP STROKE REHABIL, V21, P52, DOI 10.1310/tsr2101-52; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; O'Malley KJ, 2005, HEALTH SERV RES, V40, P1620, DOI 10.1111/j.1475-6773.2005.00444.x; Ojala-Oksala J, 2012, STROKE, V43, P2931, DOI 10.1161/STROKEAHA.112.667618; Oliveira FF, 2009, ARQ NEURO-PSIQUIAT, V67, P849, DOI 10.1590/S0004-282X2009000500013; Paolucci S, 1996, EUR NEUROL, V36, P385, DOI 10.1159/000117298; Pedersen PM, 2004, CEREBROVASC DIS, V17, P35, DOI 10.1159/000073896; PEDERSEN PM, 1995, ANN NEUROL, V38, P659, DOI 10.1002/ana.410380416; PICKERSGILL MJ, 1983, J NEUROL NEUROSUR PS, V46, P130, DOI 10.1136/jnnp.46.2.130; PIZZAMIGLIO L, 1985, BRAIN LANG, V25, P213, DOI 10.1016/0093-934X(85)90081-1; Plowman E, 2012, J EVAL CLIN PRACT, V18, P689, DOI 10.1111/j.1365-2753.2011.01650.x; Reilly D, 2019, AM PSYCHOL, V74, P445, DOI 10.1037/amp0000356; Rohde A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194143; Roquer J, 2003, STROKE, V34, P1581, DOI 10.1161/01.STR.0000078562.82918.F6; Safaz I, 2016, INT J REHABIL RES, V39, P130, DOI 10.1097/MRR.0000000000000156; SARNO MT, 1985, J NERV MENT DIS, V173, P605, DOI 10.1097/00005053-198510000-00005; SCARPA M, 1987, CORTEX, V23, P331, DOI 10.1016/S0010-9452(87)80044-8; Schwartz HA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073791; SHAYWITZ BA, 1995, NATURE, V373, P607, DOI 10.1038/373607a0; Siirtola M, 1977, Scand J Soc Med Suppl, V14, P128; Sommer IEC, 2004, BRAIN, V127, P1845, DOI 10.1093/brain/awh207; STEGMAYR B, 1994, STROKE, V25, P1738, DOI 10.1161/01.STR.25.9.1738; Sturmer T, 2002, NEUROEPIDEMIOLOGY, V21, P8, DOI 10.1159/000048608; SUNDET K, 1988, SCAND J PSYCHOL, V29, P168, DOI 10.1111/j.1467-9450.1988.tb00788.x; Thommessen B, 2002, CEREBROVASC DIS, V13, P184, DOI 10.1159/000047773; Tilling K, 2001, STROKE, V32, P2867, DOI 10.1161/hs1201.099413; Troisi E, 2002, ACTA NEUROL SCAND, V105, P100, DOI 10.1034/j.1600-0404.2002.1o052.x; Tsouli S, 2009, NEUROEPIDEMIOLOGY, V33, P96, DOI 10.1159/000222091; Vidovic M, 2011, ACTA CLIN CROAT, V50, P491; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Vukovic V, 2009, COLLEGIUM ANTROPOL, V33, P977; WADE DT, 1984, ARCH PHYS MED REHAB, V65, P513; WADE DT, 1986, J NEUROL NEUROSUR PS, V49, P11, DOI 10.1136/jnnp.49.1.11; Wallentin M, 2009, TIDSSKRIFT SPROGFORS, V7, P1; Wallentin M, 2016, NEUROIMAGE-CLIN, V11, P239, DOI 10.1016/j.nicl.2016.02.002; Wallentin M, 2014, NEUROIMAGE, V101, P276, DOI 10.1016/j.neuroimage.2014.07.012; Wallentin M, 2009, BRAIN LANG, V108, P175, DOI 10.1016/j.bandl.2008.07.001; Wasserman JK, 2015, CAN J EMERG MED, V17, P624, DOI 10.1017/cem.2014.63; Watila MM, 2015, J NEUROL SCI, V352, P12, DOI 10.1016/j.jns.2015.03.020; Ween JE, 2000, NEUROREHAB NEURAL RE, V14, P229, DOI 10.1177/154596830001400309; Worrall LE, 2017, ARCH PHYS MED REHAB, V98, P235, DOI 10.1016/j.apmr.2016.06.020; Yuan SM, 2015, REV BRAS CIR CARDIOV, V30, P225, DOI 10.5935/1678-9741.20150022	116	15	16	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2018	13	12							e0209571	10.1371/journal.pone.0209571	http://dx.doi.org/10.1371/journal.pone.0209571			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HF0HP	30571747	Green Published, Green Submitted, gold			2023-01-03	WOS:000453841700086
J	Shoji, T; Inaba, M; Fukagawa, M; Ando, R; Emoto, M; Fujii, H; Fujimori, A; Fukui, M; Hase, H; Hashimoto, T; Hirakata, H; Honda, H; Hosoya, T; Ikari, Y; Inaguma, D; Inoue, T; Isaka, Y; Iseki, K; Ishimura, E; Itami, N; Ito, C; Kakuta, T; Kawai, T; Kawanishi, H; Kobayashi, S; Kumagai, J; Maekawa, K; Masakane, I; Minakuchi, J; Mitsuiki, K; Mizuguchi, T; Morimoto, S; Murohara, T; Nakatani, T; Negi, S; Nishi, S; Nishikawa, M; Ogawa, T; Ohta, K; Ohtake, T; Okamura, M; Okuno, S; Shigematsu, T; Sugimoto, T; Suzuki, M; Tahara, H; Takemoto, Y; Tanaka, K; Tominaga, Y; Tsubakihara, Y; Tsujimoto, Y; Tsuruya, K; Ueda, S; Watanabe, Y; Yamagata, K; Yamakawa, T; Yano, S; Yokoyama, K; Yorioka, N; Yoshiyama, M; Nishizawa, Y				Shoji, Tetsuo; Inaba, Masaaki; Fukagawa, Masafumi; Ando, Ryoichi; Emoto, Masanori; Fujii, Hisako; Fujimori, Akira; Fukui, Mitsuru; Hase, Hiroki; Hashimoto, Tetsuya; Hirakata, Hideki; Honda, Hirokazu; Hosoya, Tatsuo; Ikari, Yuji; Inaguma, Daijo; Inoue, Toru; Isaka, Yoshitaka; Iseki, Kunitoshi; Ishimura, Eiji; Itami, Noritomo; Ito, Chiharu; Kakuta, Toshitaka; Kawai, Toru; Kawanishi, Hideki; Kobayashi, Shuzo; Kumagai, Junko; Maekawa, Kiyoshi; Masakane, Ikuto; Minakuchi, Jun; Mitsuiki, Koji; Mizuguchi, Takashi; Morimoto, Satoshi; Murohara, Toyoaki; Nakatani, Tatsuya; Negi, Shigeo; Nishi, Shinichi; Nishikawa, Mitsushige; Ogawa, Tetsuya; Ohta, Kazumichi; Ohtake, Takayasu; Okamura, Mikio; Okuno, Senji; Shigematsu, Takashi; Sugimoto, Toshitsugu; Suzuki, Masashi; Tahara, Hideki; Takemoto, Yoshiaki; Tanaka, Kenji; Tominaga, Yoshihiro; Tsubakihara, Yoshiharu; Tsujimoto, Yoshihiro; Tsuruya, Kazuhiko; Ueda, Shinichiro; Watanabe, Yuzo; Yamagata, Kunihiro; Yamakawa, Tomoyuki; Yano, Shozo; Yokoyama, Keitaro; Yorioka, Noriaki; Yoshiyama, Minoru; Nishizawa, Yoshiki		J-DAVID Investigators	Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis The J-DAVID Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VITAMIN-D SUPPLEMENTATION; CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR-DISEASE; MORTALITY; SURVIVAL; ASSOCIATION; STATEMENT; CALCIUM; EVENTS; HEART	IMPORTANCE Patients with chronic kidney disease have impaired vitamin D activation and elevated cardiovascular risk. Observational studies in patients treated with hemodialysis showed that the use of active vitamin D sterols was associated with lower risk of all-cause mortality, regardless of parathyroid hormone levels. OBJECTIVE To determine whether vitamin D receptor activators reduce cardiovascular events and mortality in patients without secondary hyperparathyroidism undergoing hemodialysis. DESIGN, SETTING, AND PARTICIPANTS Randomized, open-label, blinded end point multicenter study of 1289 patients in 207 dialysis centers in Japan. The study included 976 patients receiving maintenance hemodialysis with serum intact parathyroid hormone levels less than or equal to 180 pg/mL. The first and last participants were enrolled on August 18, 2008, and January 26, 2011, respectively. The final date of follow-up was April 4, 2015. INTERVENTIONS Treatment with 0.5 mu g of oral alfacalcidol per day (intervention group; n = 495) vs treatment without vitamin D receptor activators (control group; n = 481). MAIN OUTCOMES AND MEASURES The primary outcome was a composite measure of fatal and nonfatal cardiovascular events, includingmyocardial infarctions, hospitalizations for congestive heart failure, stroke, aortic dissection/rupture, amputation of lower limb due to ischemia, and cardiac sudden death; coronary revascularization; and leg artery revascularization during 48 months of follow-up. The secondary outcomewas all-cause death. RESULTS Among 976 patients who were randomized from 108 dialysis centers, 964 patients were included in the intention-to-treat analysis (median age, 65 years; 386 women [40.0%]), and 944 (97.9%) completed the trial. During follow-up (median, 4.0 years), the primary composite outcome of cardiovascular events occurred in 103 of 488 patients (21.1%) in the intervention group and 85 of 476 patients (17.9%) in the control group (absolute difference, 3.25%[95% CI, -1.75% to 8.24%]; hazard ratio, 1.25 [95% CI, 0.94-1.67]; P =.13). There was no significant difference in the secondary outcome of all-cause mortality between the groups (18.2% vs 16.8%, respectively; hazard ratio, 1.12 [95% CI, 0.83-1.52]; P =.46). Of the 488 participants in the intervention group, 199 (40.8%) experienced serious adverse events that were classified as cardiovascular, 64 (13.1%) experienced adverse events classified as infection, and 22 (4.5%) experienced malignancy-related serious adverse events. Of 476 participants in the control group, 191 (40.1%) experienced cardiovascular-related serious adverse events, 63 (13.2%) experienced infection-related serious adverse events, and 21 (4.4%) experienced malignancy-related adverse events. CONCLUSIONS AND RELEVANCE Among patients without secondary hyperparathyroidism undergoing maintenance hemodialysis, oral alfacalcidol compared with usual care did not reduce the risk of a composite measure of select cardiovascular events. These findings do not support the use of vitamin D receptor activators for patients such as these.	[Shoji, Tetsuo] Osaka City Univ, Grad Sch Med, Dept Vasc Med, Osaka, Japan; [Shoji, Tetsuo; Inaba, Masaaki] Osaka City Univ, Grad Sch Med, Vasc Sci Ctr Translat Res, Osaka, Japan; [Inaba, Masaaki; Emoto, Masanori] Osaka City Univ, Grad Sch Med, Dept Metab Endocrinol & Mol Med, Osaka, Japan; [Fukagawa, Masafumi] Tokai Univ, Sch Med, Div Nephrol Endocrinol & Metab, Hiratsuka, Kanagawa, Japan; [Ando, Ryoichi] Musashino Red Cross Hosp, Dept Nephrol, Tokyo, Japan; [Fujii, Hisako] Osaka City Univ, Grad Sch Med, Dept Drug & Food Evaluat, Osaka, Japan; [Fujimori, Akira] Konan Hosp, Blood Purificat & Kidney Ctr, Nishiwaki, Hyogo, Japan; [Fukui, Mitsuru] Osaka City Univ, Grad Sch Med, Lab Stat, Osaka, Japan; [Hase, Hiroki] Toho Univ, Sch Med, Dept Nephrol, Tokyo, Japan; [Hashimoto, Tetsuya] Tojinkai Hosp, Dept Urol, Kyoto, Japan; [Hirakata, Hideki] Fukuoka Renal Clin, Div Nephrol, Fukuoka, Fukuoka, Japan; [Honda, Hirokazu] Showa Univ, Koto Toyosu Hosp, Dept Med, Div Nephrol, Tokyo, Japan; [Hosoya, Tatsuo] Jikei Univ, Sch Med, Dept Pathophysiol & Therapy & Chron Kidney Dis, Tokyo, Japan; [Ikari, Yuji] Tokai Univ, Sch Med, Dept Cardiol, Isehara, Kanagawa, Japan; [Inaguma, Daijo] Fujita Hlth Univ, Sch Med, Dept Nephrol, Toyoake, Aichi, Japan; [Inoue, Toru] Yuseikai Clin, Osaka, Japan; [Isaka, Yoshitaka] Osaka Univ, Grad Sch Med, Dept Nephrol, Osaka, Japan; [Iseki, Kunitoshi] Tomishiro Cent Hosp, Clin Res Support Ctr, Tomigusuku, Japan; [Ishimura, Eiji] Osaka City Univ, Grad Sch Med, Dept Nephrol, Osaka, Japan; [Itami, Noritomo] Itami Kidney Clin, Dept Nephrol, Hokkaido, Japan; [Ito, Chiharu] Haga Red Cross Hosp, Dept Internal Med, Ashikaga, Tochigi, Japan; [Kakuta, Toshitaka] Tokai Univ, Hachioji Hosp, Div Nephrol Endocrinol & Metab, Tokai, Ibaraki, Japan; [Kawai, Toru] Med Corp Chuou Naika Clin, Hiroshima, Japan; [Kawanishi, Hideki] Tsuchiya Gen Hosp, Dept Artificial Org, Hiroshima, Japan; [Kobayashi, Shuzo; Ohtake, Takayasu] Shonan Kamakura Gen Hosp, Dept Kidney Dis & Transplant Ctr, Kamakura, Kanagawa, Japan; [Kumagai, Junko] Akane Fdn Omachi Tsuchiya Clin, Hiroshima, Japan; [Maekawa, Kiyoshi] Fujiidera Shirasagi Clin, Hemodialysis, Osaka, Japan; [Masakane, Ikuto] Honcho Yabuki Clin, Nephrol, Yamagata, Japan; [Minakuchi, Jun] Kawashima Hosp, Dept Kidney Dis, Tokushima, Japan; [Mitsuiki, Koji] Japanese Red Cross Fukuoka Hosp, Nephrol & Dialysis Ctr, Fukuoka, Fukuoka, Japan; [Mizuguchi, Takashi] Kochi Takasu Hosp, Dept Hematol Dialysis & Diabet Mellitus, Kochi, Japan; [Morimoto, Satoshi] TokyoWomens Med Univ, Dept Med Endocrinol & Hypertens, Tokyo, Japan; [Murohara, Toyoaki] Nagoya Univ, Grad Sch Med, Dept Cardiol, Nagoya, Aichi, Japan; [Nakatani, Tatsuya; Takemoto, Yoshiaki] Osaka City Univ, Grad Sch Med, Dept Urol, Osaka, Japan; [Negi, Shigeo; Shigematsu, Takashi] Wakayama Med Univ, Dept Nephrol, Wakayama, Japan; [Nishi, Shinichi] Kobe Univ, Grad Sch Med, Div Nephrol & Kidney Ctr, Kobe, Hyogo, Japan; [Nishikawa, Mitsushige] Meisei Mem Hosp, Osaka, Japan; [Ogawa, Tetsuya] Tokyo Womens Med Univ, Dept Med, Med Ctr East, Tokyo, Japan; [Ohta, Kazumichi] Kochi Takasu Hosp, Dept Urol, Kochi, Japan; [Okamura, Mikio] Kayashima Ikuno Hosp, Dept Internal Med, Kadoma, Osaka, Japan; [Okuno, Senji] Shirasagi Hosp, Dept Internal Med, Kidney Ctr, Osaka, Japan; [Sugimoto, Toshitsugu] Shimane Univ, Fac Med, Dept Internal Med, Matsue, Shimane, Japan; [Suzuki, Masashi] Shinraku En Hosp, Dept Nephrol, Niigata, Japan; [Tahara, Hideki] Ikunoaiwa Hemodialysis Clin, Osaka, Japan; [Tanaka, Kenji] Suiyukai Clin, Dept Internal Med, Nara, Japan; [Tominaga, Yoshihiro] Nagoya 2nd Red Cross Hosp Japan, Dept Transplant & Endocrine Surg, Nagoya, Aichi, Japan; [Tsubakihara, Yoshiharu] Grad Sch Hlth Care Sci, Jikei Inst, Dept Safety Management Hlth Care Sci, Osaka, Japan; [Tsujimoto, Yoshihiro] Inoue Hosp, Dept Internal Med, Osaka, Japan; [Tsuruya, Kazuhiko] Nara Med Univ, Dept Nephrol, Nara, Japan; [Ueda, Shinichiro] Univ Ryukyus, Grad Sch Med, Dept Clin Pharmacol & Therapeut, Nishihara, Okinawa, Japan; [Watanabe, Yuzo] Kasugai Municipal Hosp, Kasugai, Aichi, Japan; [Yamagata, Kunihiro] Univ Tsukuba, Fac Med, Dept Nephrol, Tsukuba, Ibaraki, Japan; [Yamakawa, Tomoyuki] Shirasagi Hosp, Kidney Ctr, Osaka, Japan; [Yano, Shozo] Shimane Univ, Fac Med, Dept Lab Med, Matsue, Shimane, Japan; [Yokoyama, Keitaro] Jikei Univ, Sch Med, Dept Internal Med, Div Nephrol & Hypertens, Tokyo, Japan; [Yorioka, Noriaki] Hiroshima Kidney Org, Hiroshima, Japan; [Yoshiyama, Minoru] Osaka City Univ, Grad Sch Med, Dept Cardiovasc Med, Osaka, Japan; [Nishizawa, Yoshiki] Soryu Med Corp, Inoue Hosp, Hemodialysis Ctr, Osaka, Japan	Osaka Metropolitan University; Osaka Metropolitan University; Osaka Metropolitan University; Tokai University; Osaka Metropolitan University; Osaka Metropolitan University; Toho University; Showa University; Jikei University; Tokai University; Fujita Health University; Osaka University; Osaka Metropolitan University; Tokai University; Nagoya University; Osaka Metropolitan University; Wakayama Medical University; Kobe University; Tokyo Women's Medical University; Shimane University; Nara Medical University; University of the Ryukyus; University of Tsukuba; Shimane University; Jikei University; Osaka Metropolitan University	Shoji, T (corresponding author), Osaka City Univ, Grad Sch Med, Dept Vasc Med, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.	t-shoji@med.osaka-cu.ac.jp	Murohara, Toyoaki/M-4958-2014; Yano, Shozo/HJG-6965-2022; Tahara, Hidetoshi/G-7697-2019	Fujii, Hisako/0000-0002-7848-2404	Kidney Foundation, Japan	Kidney Foundation, Japan(Kidney Foundation, Japan)	This study was supported by a grant from The Kidney Foundation, Japan, which received donation from Chugai Pharmaceutical.	Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2; Bodyak N, 2007, P NATL ACAD SCI USA, V104, P16810, DOI 10.1073/pnas.0611202104; Egan BM, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003558; Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122; Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744-9987.12058; Fukagawa M, 2008, THER APHER DIAL, V12, P514, DOI 10.1111/j.1744-9987.2008.00648.x; Gaffney-Stomberg E, 2017, J BONE MINER RES, V32, P498, DOI 10.1002/jbmr.3008; Gutierrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130; Kendrick J, 2017, CLIN J AM SOC NEPHRO, V12, P1438, DOI 10.2215/CJN.01870217; Kovesdy CP, 2008, KIDNEY INT, V73, P1355, DOI 10.1038/ki.2008.35; Kumar V, 2017, J AM SOC NEPHROL, V28, P3100, DOI 10.1681/ASN.2017010003; Levin Adeera, 2017, Clin J Am Soc Nephrol, V12, P1447, DOI 10.2215/CJN.10791016; Li YC, 2002, J CLIN INVEST, V110, P229, DOI [10.1172/JCI200215219, 10.1172/JCI0215219]; Lim K, 2012, CIRCULATION, V125, P2243, DOI 10.1161/CIRCULATIONAHA.111.053405; Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414; Nakai S, 2008, THER APHER DIAL, V12, P428, DOI 10.1111/j.1744-9987.2008.00634.x; Naves-Diaz M, 2008, KIDNEY INT, V74, P1070, DOI 10.1038/ki.2008.343; Sarnak MJ, 2003, HYPERTENSION, V42, P1050, DOI 10.1161/01.HYP.0000102971.85504.7c; Scialla JJ, 2014, J AM SOC NEPHROL, V25, P349, DOI 10.1681/ASN.2013050465; Shoji T, 2004, NEPHROL DIAL TRANSPL, V19, P179, DOI 10.1093/ndt/gfg513; Shoji T., 2016, RENAL REPLACE THER, V2, P19, DOI [DOI 10.1186/S41100-016-0029-Z, 10.1186/s41100-016-0029-z]; Shoji T, 2015, THER APHER DIAL, V19, P235, DOI 10.1111/1744-9987.12274; Shoji T, 2011, CLIN J AM SOC NEPHRO, V6, P1112, DOI 10.2215/CJN.09961110; TABATA T, 1986, J CLIN ENDOCR METAB, V63, P1218, DOI 10.1210/jcem-63-5-1218; Taniguchi M, 2013, THER APHER DIAL, V17, P221, DOI 10.1111/1744-9987.12030; Teng M, 2005, J AM SOC NEPHROL, V16, P1115, DOI 10.1681/ASN.2004070573; Thadhani R, 2012, JAMA-J AM MED ASSOC, V307, P674, DOI 10.1001/jama.2012.120; Virdi AS, 1998, CELL MOL BIOL, V44, P1237; Wang AYM, 2014, J AM SOC NEPHROL, V25, P175, DOI 10.1681/ASN.2013010103; Wanner C, 2016, LANCET, V388, P276, DOI 10.1016/S0140-6736(16)30508-6	30	43	43	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	2018	320	22					2325	2334		10.1001/jama.2018.17749	http://dx.doi.org/10.1001/jama.2018.17749			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD9GV	30535217	Green Published, Bronze			2023-01-03	WOS:000452870700016
J	Liu, TW; Ng, SSM				Liu, Tai-Wa; Ng, Shamay S. M.			The reliability and validity of the Survey of Activities and Fear of Falling in the Elderly for assessing fear and activity avoidance among stroke survivors	PLOS ONE			English	Article							BALANCE CONFIDENCE; SENIORS	Introduction Activity restriction due to fear of falling is a common problem after a stroke. It can lead to deteriorated physical condition, restricted social participation and deprived quality of life. The Survey of Activities and Fear of Falling in the Elderly (SAFE) was developed to assess these difficulties, and its utility has been demonstrated among the older adults and older people with Parkinson's disease. This study aimed to expand those demonstrations to community-dwelling chronic stroke survivors using a Chinese translation of the instrument. Methods One hundred and eight elderly individuals with a history of stroke completed the Chinese version of the SAFE (SAFE-C). The internal consistency of their responses was assessed using Cronbach's alpha. Twenty of the same subjects were reassessed after a 1-week interval to assess the instrument's test-retest reliability. Structure validity was examined by exploratory factor analysis. Pearson correlation was used to establish the instrument's convergent validity with respect to the results from the Chinese version of the Activities-specific Balance Confidence Scale (ABC-C) and the Chinese version of the Lawton Instrumental Activities of Daily Living scale (IADL-C). Results The items of the SAFE-C demonstrated excellent internal consistency with a Cronbach's alphas of 0.90. The SAFE-C also had excellent test-retest reliability with an overall intra-class correlaton coefficient of 0.91. A 1-factor structure termed "fear avoidance circumstances" was identified and it was shown to be consistent with the original measure developed among community-living older people. The correlations between the SAFE-C and the ABC-C (r = -0.68) and the IADL-C (r = -0.57) confirmed the convergent validity. Conclusions Fear avoidance behavior is a homogeneous construct applicable to people with stroke-specific impairments alike. The SAFE-C is a reliable and valid instrument for measuring the level of fear avoidance behavior among community-dwelling stroke survivors. Stroke survivors with good functional mobility revealed a low level of fear and avoidance as measured by the SAFE-C.	[Liu, Tai-Wa; Ng, Shamay S. M.] Hong Kong Polytech Univ, Dept Rehabil Sci, Hung Hom, Hong Kong, Peoples R China; [Liu, Tai-Wa] Open Univ Hong Kong, Sch Nursing & Hlth Studies, Ho Man Tin, Hong Kong, Peoples R China	Hong Kong Polytechnic University; Hong Kong Metropolitan University	Ng, SSM (corresponding author), Hong Kong Polytech Univ, Dept Rehabil Sci, Hung Hom, Hong Kong, Peoples R China.	Shamay.Ng@polyu.edu.hk	NG, Sheung Mei Shamay/E-2731-2016	NG, Sheung Mei Shamay/0000-0003-1660-0548	General Research Fund [15101217]; Research Grants Council, Hong Kong	General Research Fund; Research Grants Council, Hong Kong(Hong Kong Research Grants Council)	This study was supported by the General Research Fund (reference number 15101217) from the Research Grants Council, Hong Kong to Dr. Shamay S. M. Ng and her team. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brouwer B, 2004, GERONTOLOGY, V50, P135, DOI 10.1159/000076771; Chou KL, 2005, AGING MENT HEALTH, V9, P255, DOI 10.1080/13607860500114035; Chu L. W., 1995, Hong Kong Medical Journal, V1, P207; Field A., 2005, METHODS; Fletcher PC, 2004, AGE AGEING, V33, P273, DOI 10.1093/ageing/afh077; Howland J, 1998, GERONTOLOGIST, V38, P549, DOI 10.1093/geront/38.5.549; KAISER HF, 1974, PSYCHOMETRIKA, V39, P31, DOI 10.1007/BF02291575; Kempen GIJM, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-170; Kline P., 2000, HDB PSYCHOL TESTING, V2nd; Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012; Lachman ME, 1998, J GERONTOL B-PSYCHOL, V53, pP43, DOI 10.1093/geronb/53B.1.P43; Li FZ, 2003, J GERONTOL B-PSYCHOL, V58, pP283, DOI 10.1093/geronb/58.5.P283; Liu TW, 2015, ARCH PHYS MED REHAB, V96, P1684, DOI 10.1016/j.apmr.2015.05.005; Mak MK, 2007, ARCH PHYS MED REHAB, V88, P496, DOI 10.1016/j.apmr.2007.01.018; Masoumeh Z, 2016, MIDDLE E J REHABIL H, V3; Myers AM, 1998, J GERONTOL A-BIOL, V53, pM287, DOI 10.1093/gerona/53A.4.M287; Ng SSM, 2011, DISABIL REHABIL, V33, P2291, DOI 10.3109/09638288.2011.568667; Nunnally J. C., 1978, PSYCHOMETRIC THEORY, V2nd; Tong AY, OTJR OCCUPATION PART; Ware J.E., 1993, SF 36 HLTH SURVEY MA, DOI 10.1097/00007632-200012150-00008; Wilson MMG, 2005, J GERONTOL A-BIOL, V60, P355, DOI 10.1093/gerona/60.3.355; Zijlstra GAR, 2009, J AM GERIATR SOC, V57, P2020, DOI 10.1111/j.1532-5415.2009.02489.x	22	4	4	5	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2019	14	4							e0214796	10.1371/journal.pone.0214796	http://dx.doi.org/10.1371/journal.pone.0214796			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HR1CY	30934022	gold, Green Published			2023-01-03	WOS:000462867000042
J	Cohen, R; Babushkin, F; Geller, K; Finn, T				Cohen, Regev; Babushkin, Frida; Geller, Keren; Finn, Talya			Characteristics of hospitalized adult patients with laboratory documented Influenza A, B and Respiratory Syncytial Virus - A single center retrospective observational study	PLOS ONE			English	Article							INFECTION; EPIDEMIOLOGY; POPULATION; MORBIDITY; MORTALITY; CHILDREN; SUBTYPE; DISEASE; ILLNESS	Introduction The epidemiology, clinical features and outcomes of hospitalized adult patients with Influenza A (FluA), Influenza B (FluB) and Respiratory Syncytial Virus (RSV) have not been thoroughly compared. The aim of this study was to describe the differences between these viruses during 3 winter seasons. Methods A retrospective observational study was conducted consisting of all the polymerase chain reaction (PCR)-based diagnoses of FluA, FluB and RSV among adults during 2015-2018, in one regional hospital. Epidemiology, clinical symptoms and outcome-related data were comparatively analyzed. Results Between November 2015 and April 2018, 759 patients were diagnosed with FluA, FluB or RSV. Study cohort included 539 adult patients (306 FluA, 148 FluB and 85 RSV). FluB was predominant during the winter of 2017-18. RSV caused 15.7% of hospitalizations with diagnosed viral infection and in comparison to influenza, had distinct epidemiological, clinical features and outcomes, including older age (74.2 vs 66.2, p = 0.001) and higher rates of comorbidities; complications including bacterial pneumonia (31 vs 18%, p = 0.02), mechanical ventilation (20 vs 7%, p = 0.001), and viral-related death (13 vs 6.6%, p = 0.04). FluA and FluB had similar epidemiology, clinical symptoms and outcomes, but vaccinated patients were less prone to be hospitalized with FluB as compared with FluA (3 vs 14%, p = 0.001). Paroxysmal atrial fibrillation and falls were common (8.7 and 8.5% respectively). Conclusions FluA and FluB had similar epidemiological, clinical features and contributed equally to hospitalization burden and complications. RSV had a major impact on hospitalizations, occurring among the more elderly and sick populations and causing significantly worse outcomes, when compared to influenza patients. Vaccination appeared as a protective factor against hospitalizations with FluB as compared with FluA.	[Cohen, Regev; Babushkin, Frida; Geller, Keren; Finn, Talya] Laniado Hosp, Sanz Med Ctr, Infect Dis Unit, Neytanya, Israel; [Cohen, Regev; Finn, Talya] Technion, Ruth & Bruce Rappaport Fac Med, Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Cohen, R (corresponding author), Laniado Hosp, Sanz Med Ctr, Infect Dis Unit, Neytanya, Israel.; Cohen, R (corresponding author), Technion, Ruth & Bruce Rappaport Fac Med, Haifa, Israel.	regevco@gmail.com		Cohen, Regev/0000-0001-7773-350X				Adlhoch C, 2018, EUROSURVEILLANCE, V23, P7, DOI 10.2807/1560-7917.ES.2018.23.13.18-00146; Anderson NW, 2016, DIAGN MICR INFEC DIS, V85, P367, DOI 10.1016/j.diagmicrobio.2016.02.025; [Anonymous], 2018, CONTROL ECFDPA INFLU; [Anonymous], 2018, CONTROL ICFD; Babcock HM, 2006, INFECT CONT HOSP EP, V27, P266, DOI 10.1086/501539; Beaute J, 2015, EPIDEMIOL INFECT, V143, P2950, DOI 10.1017/S0950268814003422; Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8; Bennett JE, 2015, MANDELL DOUGLAS BENN, Veighth, DOI DOI 10.1016/B978-1-4557-4801-3.00034-5; Branche AR, 2015, DRUG AGING, V32, P261, DOI 10.1007/s40266-015-0258-9; Caini S, 2018, INFLUENZA OTHER RESP, V12, P780, DOI 10.1111/irv.12575; Caram LB, 2009, J AM GERIATR SOC, V57, P482, DOI 10.1111/j.1532-5415.2008.02153.x; Chagvardieff A, 2018, MED MALADIES INFECT, V48, P180, DOI 10.1016/j.medmal.2017.11.007; Chang TY, 2016, HEART RHYTHM, V13, P1189, DOI 10.1016/j.hrthm.2016.01.026; Cohen JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139431; Dowell SF, 1996, J INFECT DIS, V174, P456, DOI 10.1093/infdis/174.3.456; Falsey AR, 2005, DRUG AGING, V22, P577, DOI 10.2165/00002512-200522070-00004; Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951; Flannery B, 2019, CLIN INFECT DIS, V68, P1798, DOI 10.1093/cid/ciy775; Glezen WP, 2013, AM J PUBLIC HEALTH, V103, pE43, DOI 10.2105/AJPH.2012.301137; Hall CB, 2001, CLIN INFECT DIS, V33, P792, DOI 10.1086/322657; Hong KW, 2015, JPN J INFECT DIS, V68, P20, DOI 10.7883/yoken.JJID.2013.466; Irving SA, 2012, INFLUENZA OTHER RESP, V6, P37, DOI 10.1111/j.1750-2659.2011.00263.x; Ivey KS, 2018, J AM COLL CARDIOL, V71, P1574, DOI 10.1016/j.jacc.2018.02.013; Jennings L, 2018, INFLUENZA OTHER RESP, V12, P383, DOI 10.1111/irv.12522; Kestler M, 2018, J HOSP INFECT, V100, P463, DOI 10.1016/j.jhin.2018.03.034; Kwong JC, 2018, NEW ENGL J MED, V378, P345, DOI 10.1056/NEJMoa1702090; Lee N, 2013, CLIN INFECT DIS, V57, P1069, DOI 10.1093/cid/cit471; Malosh RE, 2017, J CLIN VIROL, V96, P37, DOI 10.1016/j.jcv.2017.09.001; Moa AM, 2017, INFLUENZA OTHER RESP, V11, P102, DOI 10.1111/irv.12432; Mosnier A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136186; Pretorius MA, 2016, J CLIN VIROL, V75, P21, DOI 10.1016/j.jcv.2015.12.004; Puig-Barbera J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100497; Sharabi Sivan, 2018, Oncotarget, V9, P6623, DOI 10.18632/oncotarget.23601; Sharabi S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161195; Su S, 2014, CLIN INFECT DIS, V59, P252, DOI 10.1093/cid/ciu269; van de Sandt CE, 2015, FUTURE MICROBIOL, V10, P1447, DOI 10.2217/fmb.15.65; Volling C, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0665-2; Wang D, 2016, J MED VIROL, V88, P1334, DOI 10.1002/jmv.24480; Wie SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062685	39	23	23	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2019	14	3							e0214517	10.1371/journal.pone.0214517	http://dx.doi.org/10.1371/journal.pone.0214517			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HQ7IR	30921408	Green Published, gold, Green Submitted			2023-01-03	WOS:000462594000080
J	Madaras, L; Stonington, S; Seda, CH; Garcia, D; Zuroweste, E				Madaras, Laszlo; Stonington, Scott; Seda, Claire H.; Garcia, Deliana; Zuroweste, Ed			Social Distance and Mobility - A 39-Year-Old Pregnant Migrant Farmworker	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Madaras, Laszlo; Seda, Claire H.; Garcia, Deliana; Zuroweste, Ed] Migrant Clinicians Network, Austin, TX 78746 USA; [Madaras, Laszlo] Penn State Coll Med, Hershey, PA 17033 USA; [Stonington, Scott] Univ Michigan, Ann Arbor, MI 48109 USA; [Zuroweste, Ed] Johns Hopkins Sch Med, Baltimore, MD USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Michigan System; University of Michigan; Johns Hopkins University; Johns Hopkins Medicine	Madaras, L (corresponding author), Migrant Clinicians Network, Austin, TX 78746 USA.; Madaras, L (corresponding author), Penn State Coll Med, Hershey, PA 17033 USA.			Stonington, Scott/0000-0002-0472-3885				Durkheim E, 2014, DIVISION LABOR SOC; United Nations Department of Economic and Social Affairs Population Division, 2017, WORLD COUNT 258 MILL; Urry J, 2000, SOCIOLOGY SOC MOBILI	3	3	3	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	2019	380	12					1093	1096		10.1056/NEJMp1811501	http://dx.doi.org/10.1056/NEJMp1811501			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HP7VK	30893530				2023-01-03	WOS:000461898400003
J	Robertson, SA				Robertson, Sarah A.			Preventing Preeclampsia by Silencing Soluble Flt-1?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SFLT1		[Robertson, Sarah A.] Univ Adelaide, Robinson Res Inst, Adelaide, SA, Australia; [Robertson, Sarah A.] Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia	Robinson Research Institute; University of Adelaide; University of Adelaide	Robertson, SA (corresponding author), Univ Adelaide, Robinson Res Inst, Adelaide, SA, Australia.; Robertson, SA (corresponding author), Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia.		Robertson, Sarah A/C-8182-2009	Robertson, Sarah A/0000-0002-9967-0084				Charnock-Jones DS, 2016, J REPROD IMMUNOL, V114, P81, DOI 10.1016/j.jri.2015.07.004; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; Nakakita B, 2015, J OBSTET GYNAECOL RE, V41, P1661, DOI 10.1111/jog.12760; Redman CWG, 2010, AM J REPROD IMMUNOL, V63, P534, DOI 10.1111/j.1600-0897.2010.00831.x; Turanov A.A., 2018, NAT BIOTECHNOL	5	14	15	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 14	2019	380	11					1080	1082		10.1056/NEJMcibr1817501	http://dx.doi.org/10.1056/NEJMcibr1817501			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HO8NL	30865806				2023-01-03	WOS:000461210000016
J	Rollman, JE; Heyward, J; Olson, L; Lurie, P; Sharfstein, J; Alexander, GC				Rollman, Jeffrey Eric; Heyward, James; Olson, Lily; Lurie, Peter; Sharfstein, Joshua; Alexander, G. Caleb			Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								IMPORTANCE Transmucosal immediate-release fentanyls (TIRFs), indicated solely for breakthrough cancer pain in opioid-tolerant patients, are subject to a US Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategy (REMS) to prevent them from being prescribed inappropriately. OBJECTIVES To evaluate knowledge assessments of pharmacists, prescribers, and patients regarding appropriate TIRF use; to describe sponsor assessments, based on claims data, of whether the REMS program was meeting its goals; and to characterize how the FDA responded to REMS assessments. DESIGN, SETTING, AND PARTICIPANTS Qualitative analysis of 4877 pages of FDA documents obtained through a Freedom of Information Act request, including 6 annual REMS assessment reports (2012-2017), FDA evaluations of these reports, and FDA-sponsor correspondence about safety issues. EXPOSURE A REMS program to reduce the risk of adverse outcomes, including misuse, abuse, addiction, and overdose, arising from use of TIRFs. MAIN OUTCOMES AND MEASURES (1) Knowledge assessments of pharmacists, prescribers, and patients; (2) survey and claims-based prescribing assessments; (3) FDA and TIRF sponsor communications; (4) modifications to the REMS program; and (5) disenrollment of noncompliant prescribers. RESULTS Twelve months after initiation of the program, 24 of 302 pharmacists (7.9%), 35 of 302 prescribers (11.6%), and 5 of 192 patients (2.6%) incorrectly reported that TIRFs can be prescribed to opioid-nontolerant patients, with similar levels of misunderstanding maintained in the subsequent reports. At 60 months, product-specific analyses of claims data indicated that between 34.6% and 55.4% of patients prescribed TIRFs were opioid-nontolerant. In the 48-month survey, 106 of 310 prescribers (34.2%) reported prescribing TIRFs for opioid-tolerant patients with chronic, noncancer pain; at 60 months, 54 of 302 prescribers (18.4%) and 148 of 310 patients (47.7%) erroneously reported that TIRFs were FDA-approved for such use. Over the 60-month period examined, there were few substantive changes made to the REMS to address evidence of high rates of off-label TIRF use, and, although the REMS program had a noncompliance plan, there was no report of prescribers being disenrolled for inappropriate prescribing. CONCLUSIONS AND RELEVANCE In this review of FDA documents pertaining to the TIRF REMS, surveys of pharmacists, prescribers, and patients reflected generally high levels of knowledge regarding proper TIRF prescribing, yet some survey items as well as claims-based analyses indicated substantial rates of inappropriate TIRF use. Despite these findings, the FDA did not require substantive changes to the program. (c) 2019 American Medical Association. All rights reserved.	[Rollman, Jeffrey Eric; Heyward, James; Olson, Lily; Sharfstein, Joshua; Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Drug Safety & Effectiveness, Baltimore, MD 21205 USA; [Lurie, Peter] Ctr Sci Publ Interest, Washington, DC USA; [Sharfstein, Joshua] Johns Hopkins Bloomberg Sch Publ Hlth, Off Publ Hlth Practice & Training, Baltimore, MD 21205 USA; [Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St W6035, Baltimore, MD 21205 USA; [Alexander, G. Caleb] Johns Hopkins Med, Div Gen Internal Med, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine	Alexander, GC (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St W6035, Baltimore, MD 21205 USA.	galexan9@jhmi.edu						Ahmad F.B., 2018, PROVISIONAL DRUG OVE; [Anonymous], 2015, NON TRADITIONAL REF; Baumgaertner Emily, 2018, NY TIMES; National Institute on Drug Abuse, OV DEATH RAT; Office of Inspector General, 2013, FDA LACKS COMPR DAT; Substance Abuse and Mental Health Services Administration, 2017, KEY SUBST US MENT HL; Transmucosal Immediate Release Fentanyl Risk Evaluation and Mitigation Strategy, 2012, TRANSM IMM REL UNPUB; Transmucosal Immediate Release Fentanyl Risk Evaluation and Mitigation Strategy, 2012, TRANSM IMM REL UNPUB; Transmucosal Immediate Release Fentanyl Risk Evaluation and Mitigation Strategy, 2012, TRANSM IMM REL UNPUB, P64; Transmucosal Immediate Release Fentanyl Risk Evaluation and Mitigation Strategy Industry Group, 2013, TRANSM IMM REL UNPUB; US Food and Drug Administration, 2017, NON TRADITIONAL REF, P101; US Food and Drug Administration, 2018, QUEST ANSW MIT STRAT; US Food and Drug Administration, 2017, NON TRADITIONAL REF, P8; US Food and Drug Administration, 2015, NON TRADITIONAL REF, P3; US Food and Drug Administration, 2013, NON TRADITIONAL REF; US Food and Drug Administration, 2017, NON TRADITIONAL REF, P6; US Food and Drug Administration, 2017, NON TRADITIONAL REF, P7; US Food and Drug Administration Center for Drug Evaluation and Research, 2018, JOINT M DRUG SAF RIS; US Forest Service, 2016, NON TRADITIONAL REF, P1	19	30	30	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	2019	321	7					676	685		10.1001/jama.2019.0235	http://dx.doi.org/10.1001/jama.2019.0235			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL9MZ	30778596	Green Published, Bronze			2023-01-03	WOS:000459068300016
J	Wasir, R; Irawati, S; Makady, A; Postma, M; Goettsch, W; Buskens, E; Feenstra, T				Wasir, Riswandy; Irawati, Sylvi; Makady, Amr; Postma, Maarten; Goettsch, Wim; Buskens, Erik; Feenstra, Talitha			Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia	PLOS ONE			English	Article							QUALITATIVE RESEARCH; PERFORMANCE; FOCUS; CARE; PAY	Objectives This study aimed to define the problems of the current use of the e-Catalogue and the national formulary (NF)-two elements of medicine pricing and reimbursement policies in Indonesia for achieving universal health coverage (UHC)-by examining the knowledge and attitudes of stakeholders. Specifically, to investigate (1) the perceived challenges involved in the further implementation of the e-Catalogue and the NF, (2) reasons of prescribing medicines not listed in the NF, and (3) possible improvements in the acceptance and use of the e-Catalogue and the NF. Methods Semi-structured interviews were conducted with stakeholders (policymakers, healthcare providers, a pharmaceutical industry representative, and experienced patients) to collect the qualitative data. The data was analysed using directed content analysis, following the guidelines of the COnsolidated criteria for REporting Qualitative studies (COREQ) in reporting the findings. Results Interestingly, 20 of 45 participants decided to withdraw from the interview due to their lack of knowledge of the e-Catalogue and the NF. All 25 stakeholders who fully participated in this research were in favor of the e-Catalogue and the NF. However, interviewees identified a range of challenges. A major challenge was the lack of harmonization between the lists of medicines in the e-Catalogue and the NF. Several system and personal reasons for prescribing medicines not listed in the NF were identified. Important reasons were a lack of incentives for physicians as well as a lack of transparent and evidence-based methods of selection for the medicines to be listed in the NF. Conclusions The e-Catalogue and the NF have not been fully utilized for achieving UHC in Indonesia. Some possible improvements suggested were harmonization of medicines listed in the e-Catalogue and the NF, restructuring incentive programs for prescribing NF medicines, and increasing the transparency and evidence-based approach for selection of medicines listed in the e-Catalogue and the NF.	[Wasir, Riswandy; Buskens, Erik; Feenstra, Talitha] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands; [Wasir, Riswandy] Sekolah Tinggi Ilmu Farmasi Makassar, Makassar, Indonesia; [Wasir, Riswandy; Irawati, Sylvi; Postma, Maarten] Univ Groningen, Groningen Res Inst Pharm PharmacoTherapy Epidemio, Groningen, Netherlands; [Irawati, Sylvi] Univ Surabaya, Ctr Med Informat & Pharmaceut Care, Fac Pharm, Surabaya, Indonesia; [Irawati, Sylvi] Univ Surabaya, Dept Clin & Community Pharm, Fac Pharm, Surabaya, Indonesia; [Makady, Amr; Goettsch, Wim] Natl Hlth Care Inst, Diemen, Netherlands; [Makady, Amr; Goettsch, Wim] Univ Utrecht, Dept Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands; [Postma, Maarten] Univ Groningen, Dept Hlth Sci, Groningen, Netherlands; [Postma, Maarten] Univ Groningen, Dept Econ Econometr & Finance, Fac Econ & Business, Groningen, Netherlands; [Postma, Maarten] Univ Airlangga, Dept Pharmacol & Therapy, Fac Med, Surabaya, Indonesia; [Buskens, Erik] Univ Groningen, Fac Econ & Business, Dept Operat, Groningen, Netherlands; [Feenstra, Talitha] Dutch Natl Inst Publ Hlth & Environm, Bilthoven, Netherlands	University of Groningen; University of Groningen; Universitas Surabaya (UBAYA); Universitas Surabaya (UBAYA); Utrecht University; University of Groningen; University of Groningen; Airlangga University; University of Groningen	Wasir, R (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands.; Wasir, R (corresponding author), Sekolah Tinggi Ilmu Farmasi Makassar, Makassar, Indonesia.; Wasir, R (corresponding author), Univ Groningen, Groningen Res Inst Pharm PharmacoTherapy Epidemio, Groningen, Netherlands.	r.wasir@umcg.nl	Feenstra, Talitha/AAM-3234-2020; Irawati, Sylvi/GLQ-9438-2022	Feenstra, Talitha/0000-0002-5788-0454; Irawati, Sylvi/0000-0001-6278-9017; Postma, Maarten/0000-0002-6306-3653; buskens, erik/0000-0002-6463-1106; Wasir, Riswandy/0000-0001-6184-925X	DIKTI scholarship from the Ministry of Research, Technology and Higher Education; LPDP scholarship from the Ministry of Finance of the Republic Indonesia	DIKTI scholarship from the Ministry of Research, Technology and Higher Education(Ministry of Research and Technology of the Republic of Indonesia (RISTEK)); LPDP scholarship from the Ministry of Finance of the Republic Indonesia	This work was financially supported by DIKTI (to RW) and LPDP (to SI) scholarships from the Ministry of Research, Technology and Higher Education, and the Ministry of Finance of the Republic Indonesia, respectively. The DIKTI and LPDP had no direct role in research design, data collection, analysis and interpretation, or manuscript writing and publication.	Angelis A, 2018, EUR J HEALTH ECON, V19, P123, DOI 10.1007/s10198-017-0871-0; [Anonymous], 2013, MALAYSIA HEAL SYST R, V3, P103; [Anonymous], 2010, WOR HEALT REP; Ariati N., 2017, INTEGRITAS, V3, P231; Babar Z, 2017, PHARM POLICY COUNTRI; Bigdeli M, 2015, MED UNIVERSAL HLTH C; BPJS Kesehatan, 2014, PAND PRAKT PROL PROG; Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; Chalkidou K, 2013, LANCET, V382, pE48, DOI 10.1016/S0140-6736(13)62559-3; Diack A, 2010, ASSESSMENT GOVERNANC; Dirjen Binfar dan Alkes Kemenkes RI, 2015, IMPL FORM NAS DAL PE; Doran T, 2006, NEW ENGL J MED, V355, P375, DOI 10.1056/NEJMsa055505; Fahamnuaypol P., 2015, KINGDOM THAILAND HLT; Godman B, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00106; Gustafsson LL, 2011, BASIC CLIN PHARMACOL, V108, P224, DOI 10.1111/j.1742-7843.2011.00682.x; Hawkins L., 2011, WHO HAI PROJECT MED; Hidayat B, 2015, OUT POCKET PAYMENTS; Holloway KA., 2011, MISSION REPORT, P30; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Huskamp HA, 2003, NEW ENGL J MED, V349, P2224, DOI 10.1056/NEJMsa030954; Kemetrian Kesehatan Republik Indonesia, 2015, PED PEN FORM NAS; Kibuule D, 2017, INT J CLIN PRACT, V71, DOI 10.1111/ijcp.12918; Leach M, 2012, BRIT J GEN PRACT, V62, P293, DOI 10.3399/bjgp12X649061; Lembaga Kebijakan Pengadaan Barang dan Jasa Pemerintah (LKPP), 2018, KAT PROD OB 2018; Mashalla Y. J., 2016, Journal of Public Health and Epidemiology, V8, P127; MAYS N, 1995, BRIT MED J, V311, P182, DOI 10.1136/bmj.311.6998.182; Menteri Kesehatan Republik Indonesia, 2014, PER MENT KES REP IND, DOI [10.3389/fphar.2014.00106, DOI 10.3389/FPHAR.2014.00106]; Menteri Kesehatan Republik Indonesia, 2015, PED PEN FORM NAS; Ministry of Health Malaysia, 2012, MAL NAT MED POL; Nguyen TA, 2017, PHARM POLICY COUNTRI, P75; Rickwood S, 2013, IMS I HEALTHCARE INF, P5; Soonman Kwon, 2014, PHARM POLICY FINANCI; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Nguyen TA, 2015, HEALTH POLICY PLANN, V30, P267, DOI 10.1093/heapol/czt105; Wettermark B, 2009, APPL HEALTH ECON HEA, V7, P137, DOI 0.2165/11314810-000000000-00000; WHO, GLOB HLTH EXP DAT; Whyte P, 2013, ROLE HLTH TECHNOLOGY; Wirtz VJ, 2017, LANCET, V389, P403, DOI 10.1016/S0140-6736(16)31599-9; World Health Organization, 2016, BURN OPP CLEAN HOUS; World Health Organization, 2015, WHO GUID COUNTR PHAR; World Health Organization, WHO DEF EB 134 30	41	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2019	14	2							e0212328	10.1371/journal.pone.0212328	http://dx.doi.org/10.1371/journal.pone.0212328			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HL9KY	30779809	Green Submitted, Green Published, Green Accepted, gold			2023-01-03	WOS:000459062900047
J	van Westrhenen, N; Fritz, E; Vermeer, A; Boelen, P; Kleber, R				van Westrhenen, Nadine; Fritz, Elzette; Vermeer, Adri; Boelen, Paul; Kleber, Rolf			Creative arts in psychotherapy for traumatized children in South Africa: An evaluation study	PLOS ONE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; THERAPY PROGRAM; SUBSTANCE-ABUSE; SEXUAL-ABUSE; HEALTH-CARE; SYMPTOMS; GROWTH; ADOLESCENTS; DEPRESSION; ANXIETY	Aim To evaluate the feasibility and effect of a 10-session creative arts in psychotherapy group programme on posttraumatic stress symptoms, behavioural problems, and posttraumatic growth, in children who experienced a traumatic event. Design A multicentre non-randomized controlled trial with a treatment and a control condition conducted in South Africa (4 sites). Methods 125 children aged 7 to 13 years were assigned either to the treatment condition receiving creative arts in psychotherapy or a control condition with a low-level supportive programme without treatment. Attrition rates were 63.4% and in total 47 children completed the programme and questionnaires assessing posttraumatic stress, posttraumatic growth and behaviour problems both at baseline and follow-up; 23 in the treatment group and 24 in the control group. Adjusted mean differences were analysed using ANCOVA with bootstrapping. Results Results showed that both hyperarousal symptoms (d = 0.61) and avoidance symptoms (d = 0.41) decreased more in the treatment group compared to the control group. There was no significant effect of the intervention found for reported levels of behavioural problems and posttraumatic growth. Conclusion In spite of severe challenges implementing and executing this pioneering study in underprivileged areas of South Africa, support was found for creative arts in psychotherapy reducing hyperarousal and avoidance symptoms, but not for other symptoms. Valuable lessons were learned on feasibility of implementing this intervention in a developing context.	[van Westrhenen, Nadine; Boelen, Paul; Kleber, Rolf] Univ Utrecht, Dept Clin Psychol, Utrecht, Netherlands; [van Westrhenen, Nadine] Vrije Univ Amsterdam, Athena Inst, Amsterdam, Netherlands; [Fritz, Elzette] Univ Johannesburg, Dept Educ Psychol, Johannesburg, South Africa; [Vermeer, Adri] Univ Utrecht, Dept Educ & Pedag, Utrecht, Netherlands; [Boelen, Paul; Kleber, Rolf] Arq Psychotrauma Expert Grp, Diemen, Netherlands	Utrecht University; Vrije Universiteit Amsterdam; University of Johannesburg; Utrecht University; Arq Psychotrauma Expert Group	van Westrhenen, N (corresponding author), Univ Utrecht, Dept Clin Psychol, Utrecht, Netherlands.; van Westrhenen, N (corresponding author), Vrije Univ Amsterdam, Athena Inst, Amsterdam, Netherlands.	nadinevanwestrhenen@live.nl	Goldwasser, Dr Norman/F-6854-2019	Goldwasser, Dr Norman/0000-0002-8051-8330				Achenbach T.M., 2007, MULTICULTURAL SUPPLE; Achenbach T. M, 1991, BURLINGTON VT; Alisic E, 2008, J CLIN PSYCHIAT, V69, P1455, DOI 10.4088/JCP.v69n0913; Amaya-Jackson L., 1995, CHILD PTSD CHECKLIST; Bensimon M, 2008, ART PSYCHOTHER, V35, P34, DOI 10.1016/j.aip.2007.09.002; Boeije H, 2013, J MIX METHOD RES, V7, P347, DOI 10.1177/1558689813482756; Boyes ME, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046905; Bracken P, 2012, BRIT J PSYCHIAT, V201, P430, DOI 10.1192/bjp.bp.112.109447; Bruwer B, 2011, PSYCHIAT SERV, V62, P774, DOI 10.1176/ps.62.7.pss6207_0774; Calhoun L.G., 2006, HDB POSTTRAUMATIC GR; Campbell J., 2008, HERO 1000 FACES; Campbell-Hall V, 2010, TRANSCULT PSYCHIATRY, V47, P610, DOI 10.1177/1363461510383459; Cassidy S, 2014, ART PSYCHOTHER, V41, P353, DOI 10.1016/j.aip.2014.07.003; Clay Rebecca, 2009, Clin Child Psychol Psychiatry, V14, P411, DOI 10.1177/1359104509104049; Coholic D., 2009, TRAUMATOLOGY, V15, P64, DOI [10.1177/1534765609341590, DOI 10.1177/1534765609341590]; Dirik G, 2008, J CLIN PSYCHOL MED S, V15, P193, DOI 10.1007/s10880-008-9115-x; Eaton LG, 2007, ARTS PSYCHOTHERAPY, P34; Ehring T, 2014, CLIN PSYCHOL REV, V34, P645, DOI 10.1016/j.cpr.2014.10.004; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fincham DS, 2009, COMPR PSYCHIAT, V50, P193, DOI 10.1016/j.comppsych.2008.09.001; Gillies Donna, 2013, Evid Based Child Health, V8, P1004, DOI 10.1002/ebch.1916; Gladding ST, 2003, HANDBOOK OF ART THERAPY, P243; Halprin A., 2015, MOVING LIFE 5 DECADE; Heide FJ, 2016, EUROPEAN J PSYCHOTRA, V7, P28687, DOI DOI 10.3402/ejpt.v7.28687; Herman J., 1992, TRAUMA RECOVERY; Ho RTH, 2015, ART PSYCHOTHER, V46, P9, DOI 10.1016/j.aip.2015.09.004; Hogan S., 2009, INT J ART THERAPY, V14, P29, DOI [DOI 10.1080/17454830903006331, https://doi.org/10.1080/17454830903006331]; Jewkes RK, 2010, CHILD ABUSE NEGLECT, V34, P833, DOI 10.1016/j.chiabu.2010.05.002; Jiang J, 2016, ART PSYCHOTHER, V48, P62, DOI 10.1016/j.aip.2016.02.002; Kaminer D, 2013, PEACE CONFL, V19, P112, DOI 10.1037/a0032487; Kehle-Forbes SM, 2013, PSYCHOL TRAUMA-US, V5, P317, DOI 10.1037/a0030040; Killian B, 2016, SEXUAL ABUSE YOUNG C; Kilmer RP, 2009, J TRAUMA STRESS, V22, P248, DOI 10.1002/jts.20410; King G, 2004, CHILD ABUSE NEGLECT, V28, P683, DOI 10.1016/j.chiabu.2003.12.003; Kozlowska K., 2001, CLIN CHILD PSYCHOL P, V6, P49, DOI DOI 10.1177/1359104501006001006; Lev-Wiesel Rachel, 2007, Clin Child Psychol Psychiatry, V12, P65, DOI 10.1177/1359104507071056; Levine P.A., 2010, UNSPOKEN VOICE BODY; Lowe SR, 2013, J CONSULT CLIN PSYCH, V81, P877, DOI 10.1037/a0033252; Lyshak-Stelzer F, 2007, ART THER, V24, P163, DOI 10.1080/07421656.2007.10129474; Madu SN, 2001, ARCH SEX BEHAV, V30, P311, DOI 10.1023/A:1002704331364; Malchiodi C.A., 2015, CREATIVE INTERVENTIO, V2nd Ed; Malchiodi CA, 2013, EXPRESSIVE THERAPIES, DOI [10.1177/1359104507071056, DOI 10.1177/1359104507071056]; McNiff Shaun, 2004, ART HEALS CREATIVITY; Mudlaff, 2000, TERRIBLE THING HAPPE; Nickerson A, 2011, CLIN PSYCHOL REV, V31, P399, DOI 10.1016/j.cpr.2010.10.004; Pretorius G, 2010, S AFR J PSYCHOL, V40, P63, DOI 10.1177/008124631004000107; Quinlan R, 2016, ART PSYCHOTHER, V47, P72, DOI 10.1016/j.aip.2015.09.006; Saraceno B, 2007, LANCET, P370; Schnurr PP, 2007, JAMA-J AM MED ASSOC, P297; Schouten KA, 2015, TRAUMA VIOLENCE ABUS, V16, P220, DOI 10.1177/1524838014555032; Seedat M, 2009, LANCET, V374, P1011, DOI 10.1016/S0140-6736(09)60948-X; Seedat S, 2004, BRIT J PSYCHIAT, V184, P169, DOI 10.1192/bjp.184.2.169; Seedat S, 2009, SAMJ S AFR MED J, V99, P346; Silverman WK, 2008, J CLIN CHILD ADOLESC, V37, P156, DOI 10.1080/15374410701818293; Stuckey HL, 2010, AM J PUBLIC HEALTH, V100, P254, DOI 10.2105/AJPH.2008.156497; Suliman S, 2009, COMPR PSYCHIAT, V50, P121, DOI 10.1016/j.comppsych.2008.06.006; Tol WA, 2011, LANCET, P378; Tol WA, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-56; Tran US, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0979-2; Ugurlu N, 2016, VULNERABLE CHILD YOU, V11, P89, DOI 10.1080/17450128.2016.1181288; Van Westrhenen N, 2018, KNOWLEDGE MANAGEMENT; van Westrhenen N, 2017, ART PSYCHOTHER, V54, P128, DOI 10.1016/j.aip.2017.04.013; van Westrhenen N, 2014, ART PSYCHOTHER, V41, P527, DOI 10.1016/j.aip.2014.10.004; Yalom ID., 2008, THEORY PRACTICE GROU, V5	64	10	11	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2019	14	2							e0210857	10.1371/journal.pone.0210857	http://dx.doi.org/10.1371/journal.pone.0210857			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HL5IX	30759101	Green Published, Green Submitted, gold			2023-01-03	WOS:000458761300020
J	Stower, H				Stower, Hannah			Personalizing metabolic disease therapies	NATURE MEDICINE			English	Editorial Material																			0	0	0	2	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2019	25	2					197	197		10.1038/s41591-019-0365-y	http://dx.doi.org/10.1038/s41591-019-0365-y			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	HK3TW	30728533	Bronze			2023-01-03	WOS:000457842100008
J	Flint, LA; David, DJ; Smith, AK				Flint, Lynn A.; David, Daniel J.; Smith, Alexander K.			Rehabbed to Death	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Flint, Lynn A.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA; [David, Daniel J.] Univ Calif San Francisco, Sch Nursing, Dept Community Hlth Syst, San Francisco, CA 94143 USA; [David, Daniel J.; Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Flint, LA (corresponding author), Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA.		David, Daniel/AAF-4861-2019	David, Daniel/0000-0002-7545-8505				Huskamp HA, 2010, HEALTH AFFAIR, V29, P130, DOI 10.1377/hlthaff.2009.0523; Lage DE, 2018, ANN INTERN MED, V168, P748, DOI 10.7326/M17-2651; Smith AK, 2013, JAMA INTERN MED, V173, P1506, DOI 10.1001/jamainternmed.2013.8738; Wang SY, 2017, J AM GERIATR SOC, V65, P1406, DOI 10.1111/jgs.14891	4	33	33	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 31	2019	380	5					408	409		10.1056/NEJMp1809354	http://dx.doi.org/10.1056/NEJMp1809354			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HJ4HS	30699322				2023-01-03	WOS:000457135700002
J	Ayre, J; Bonner, C; Cvejic, E; McCaffery, K				Ayre, Julie; Bonner, Carissa; Cvejic, Erin; McCaffery, Kirsten			Randomized trial of planning tools to reduce unhealthy snacking: Implications for health literacy	PLOS ONE			English	Article							BRIEF PSYCHOLOGICAL INTERVENTION; PHYSICAL-ACTIVITY INTERVENTIONS; VOLITIONAL HELP SHEET; IMPLEMENTATION INTENTIONS; COGNITIVE IMPAIRMENT; SELF-EFFICACY; WEIGHT-LOSS; BEHAVIOR; CARE; IF	Objective Guidance to address health literacy often focuses on health education rather than tools to facilitate action, despite action being important for self-management. This study evaluated an online intervention informed by health literate design principles and behavior change theory to reduce unhealthy snacking. Methods 440 participants were recruited online and randomized to an intervention: 1) Health-literate action plan (guided implementation intention); 2) Standard action plan (self-guided implementation intention); 3) Education (healthy snacking fact-sheet). The primary outcome was self-reported unhealthy snacking. Follow-up was at 1 month. Results 373 participants (84.8%) completed follow-up. Half the sample had adequate health literacy (52%), and the other half had low (24%) or possibly low (25%) health literacy, as measured by Newest Vital Sign (NVS). At follow-up, lower health literacy was associated with more unhealthy snacks and there was no overall difference between intervention groups. However, participants with lower health literacy who used the health-literate action plan reported less unhealthy snacking compared to the standard action plan; the reverse was true for those with higher health literacy scores (b = 1.7, p = 0.03). People scoring 2 points below the mean NVS (M = 3.4, SD = 2.0) using the health-literate action plan reported eating 8 fewer serves of unhealthy snacks, whereas people scoring 2 points above the mean NVS reported eating 6 more serves of unhealthy snacks using the same tool. Conclusions These findings suggest that the universal precautions approach currently recommended for health information may be less effective for facilitating action than tailoring to health literacy level.	[Ayre, Julie; Bonner, Carissa; McCaffery, Kirsten] Univ Sydney, Sch Publ Hlth, Fac Med & Hlth, Sydney Hlth Literacy Lab, Sydney, NSW, Australia; [Cvejic, Erin] Univ Sydney, Sch Publ Hlth, Fac Med & Hlth, Sydney, NSW, Australia	University of Sydney; University of Sydney	McCaffery, K (corresponding author), Univ Sydney, Sch Publ Hlth, Fac Med & Hlth, Sydney Hlth Literacy Lab, Sydney, NSW, Australia.	Kirsten.mccaffery@sydney.edu.au	McCaffery, Kirsten/K-7945-2019; Ayre, Julie/ABA-5914-2020; Cvejic, Erin/P-2665-2016	McCaffery, Kirsten/0000-0003-2696-5006; Ayre, Julie/0000-0002-5279-5189; Cvejic, Erin/0000-0002-6043-6071	Australian Government Research Training Program (RTP) Scholarship	Australian Government Research Training Program (RTP) Scholarship(Australian GovernmentDepartment of Industry, Innovation and Science)	This research is supported by an Australian Government Research Training Program (RTP) Scholarship; We would like to thank Tessa Copp, University of Sydney, for her contribution to the content analysis of standard action plans. We would also like to acknowledge the CSIRO for their permission to use items from the discretionary foods components of the CSIRO diet score. This research is supported by an Australian Government Research Training Program (RTP) Scholarship	Adriaanse MA, 2011, APPETITE, V56, P183, DOI 10.1016/j.appet.2010.10.012; Al Sayah F, 2013, J GEN INTERN MED, V28, P444, DOI 10.1007/s11606-012-2241-z; Armitage CJ, 2008, HEALTH PSYCHOL, V27, P557, DOI 10.1037/0278-6133.27.5.557; Armitage CJ, 2017, PREV SCI, V18, P976, DOI 10.1007/s11121-017-0807-z; Armitage CJ, 2015, J PUBLIC HEALTH-UK, V37, P438, DOI 10.1093/pubmed/fdv054; Armitage CJ, 2015, J BEHAV MED, V38, P599, DOI 10.1007/s10865-015-9634-5; Armitage CJ, 2014, BEHAV THER, V45, P700, DOI 10.1016/j.beth.2014.04.001; Armitage CJ, 2010, PSYCHOL HEALTH, V25, P1129, DOI 10.1080/08870440903121638; Bailey SC, 2014, DIABETES EDUCATOR, V40, P581, DOI 10.1177/0145721714540220; Barry MM, 2013, J HEALTH COMMUN, V18, P1507, DOI 10.1080/10810730.2013.840699; Belanger-Gravel A, 2013, HEALTH PSYCHOL REV, V7, P23, DOI 10.1080/17437199.2011.560095; Berger I, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0745-9; Berkman Nancy D, 2011, Evid Rep Technol Assess (Full Rep), P1; Brega A.G., 2015, AHRQ HLTH LITERACY U, V2nd Edn; Cheng G, 2012, INTERN MED J, V42, P484, DOI 10.1111/j.1445-5994.2012.02758.x; Cohen J., 2013, STAT POWER ANAL BEHA; de Vries H, 2005, PATIENT EDUC COUNS, V56, P154, DOI 10.1016/j.pec.2004.01.002; Eggermont LHP, 2012, HEART, V98, P1334, DOI 10.1136/heartjnl-2012-301682; Gawrilow C, 2011, J SOC CLIN PSYCHOL, V30, P616, DOI 10.1521/jscp.2011.30.6.616; Gollwitzer P.M., 1990, HDB MOTIVATION COGNI, P53; Greaves CJ, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-119; Hagger MS, 2014, EXERC SPORT SCI REV, V42, P62, DOI 10.1249/JES.0000000000000008; Hall PA, 2012, J EXP SOC PSYCHOL, V48, P432, DOI 10.1016/j.jesp.2011.09.004; Hayes A. F., 2013, INTRO MEDIATION MODE; Healthdirect, 2018, SMART GOALS 2018; HECKHAUSEN H, 1987, MOTIV EMOTION, V11, P101, DOI 10.1007/BF00992338; Hendrie GA, 2017, NUTRIENTS, V9, DOI 10.3390/nu9010047; Kelly J.R., 2010, THEN MIRACLE OCCURS, P137, DOI DOI 10.1093/ACPROF:OSO/9780195377798.003.0008; Kim SH, 2016, WORLDV EVID-BASED NU, V13, P324, DOI 10.1111/wvn.12157; Lara J, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0177-3; Latham GP, 2013, NEW DEV GOAL SETTING, DOI [10.1111/j.1445-5994.2012.02758.x, DOI 10.1111/J.1445-5994.2012.02758.X]; McEwan D, 2016, HEALTH PSYCHOL REV, V10, P67, DOI 10.1080/17437199.2015.1104258; Meppelink CS, 2016, J HEALTH COMMUN, V21, P109, DOI 10.1080/10810730.2016.1193920; Michie S, 2009, HEALTH PSYCHOL, V28, P690, DOI 10.1037/a0016136; National Diabetes Services Scheme, 2016, HLTH SNACKS NAT DIAB; O'Brien N, 2015, HEALTH PSYCHOL REV, V9, P417, DOI 10.1080/17437199.2015.1012177; Office of Disease Prevention and Health Promotion, 2015, HLTH LIT ONL GUID SI; Olander Ellinor K, 2013, Int J Behav Nutr Phys Act, V10, P29, DOI 10.1186/1479-5868-10-29; Plain Language Action and Information Network, 2011, FED PLAIN LANG GUID; Prestwich A, 2005, PREDICTING HLTH BEHA; Schaffler J, 2018, J GEN INTERN MED, V33, P510, DOI 10.1007/s11606-017-4265-x; Schwarzer R, 2008, APPL PSYCHOL-INT REV, V57, P1, DOI 10.1111/j.1464-0597.2007.00325.x; Sheeran P, 2016, SOC PERSONAL PSYCHOL, V10, P503, DOI 10.1111/spc3.12265; Sheridan SL, 2011, J HEALTH COMMUN, V16, P30, DOI 10.1080/10810730.2011.604391; Sniehotta FF, 2005, PSYCHOL HEALTH, V20, P143, DOI 10.1080/08870440512331317670; Soureti A, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1773; Verhoeven AAC, 2014, PSYCHOL HEALTH, V29, P1476, DOI 10.1080/08870446.2014.950658; Verhoeven AAC, 2013, EUR J SOC PSYCHOL, V43, P344, DOI 10.1002/ejsp.1963; Verplanken B, 2003, J APPL SOC PSYCHOL, V33, P1313, DOI 10.1111/j.1559-1816.2003.tb01951.x; Vila I, 2017, BRIT J HEALTH PSYCH, V22, P281, DOI 10.1111/bjhp.12230; Webb TL, 2008, BRIT J SOC PSYCHOL, V47, P373, DOI 10.1348/014466607X267010; Webb TL, 2004, EUR J SOC PSYCHOL, V34, P407, DOI 10.1002/ejsp.205; Weiss BD, 2005, ANN FAM MED, V3, P514, DOI 10.1370/afm.405; Wilson EAH, 2009, PATIENT EDUC COUNS, V74, P318, DOI 10.1016/j.pec.2008.11.005	54	9	9	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2019	14	1							e0209863	10.1371/journal.pone.0209863	http://dx.doi.org/10.1371/journal.pone.0209863			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HH8WT	30653531	Green Submitted, Green Published, gold			2023-01-03	WOS:000456015500015
J	Smajla, D; Garcia-Ramos, A; Tomazin, K; Strojnik, V				Smajla, Darjan; Garcia-Ramos, Amador; Tomazin, Katja; Strojnik, Vojko			Selective effect of static stretching, concentric contractions, and a balance task on ankle force sense	PLOS ONE			English	Article							POSITION SENSE; MUSCLE STRENGTH; PEAK TORQUE; FATIGUE; KNEE; PREVENTION; INJURIES; KINESTHESIA; MOVEMENT; EXERCISE	Proper ankle motor control is critical for balance in the human body during functional activities such as standing, walking, and running. Different exercise modalities are often performed during the same training session where earlier activities may influence later ones. The purpose of the current study was to determine the acute effects of different exercise modalities on ankle force sense. Seventeen subjects performed four different intervention protocols (static stretching, balance task, concentric contractions, and control) in random order. Each session comprised measurements before and after the intervention protocol of the force sense of the ankle plantar flexors (PF) and dorsal flexors (DF) at 10% and 30% of maximal voluntary isometric contraction (MVC). Absolute errors (AE) were calculated separately for each force level and muscle group. An overall PF error (PF-SUM = PF at 10% MVC + PF at 30% MVC), DF error (DF-SUM = DF at 10% MVC + DF at 30% MVC) and ankle error (PF-DF-SUM = PF-SUM + DF-SUM) were also calculated. The main effect of time generally revealed that ankle force sense was significantly reduced after static stretching (PF-DF-SUM: Pre: 6.11 +/- 2.17 Nm, Post: 8.03 +/- 3.28 Nm; p < 0.05), but no significant differences were observed for the concentric contractions (PF-DF-SUM: Pre: 6.01 +/- 1.97 Nm, Post: 6.50 +/- 2.28 Nm) and the balance task (PF-DF-SUM: Pre: 5.25 +/- 1.97 Nm, Post: 5.50 +/- 1.26 Nm). The only significant interaction was observed for the PF-DF-SUM (F = 4.48, p = 0.008) due to greater error scores after stretching (+31.4%) compared to the concentric (+8.2%), balance (+4.8%), and control (-3.5%) conditions. Based on these results, static stretching should not be performed before activities that require a high ankle force sense such as balance, coordination, and precision tasks.	[Smajla, Darjan; Tomazin, Katja; Strojnik, Vojko] Univ Ljubljana, Fac Sport, Ljubljana, Slovenia; [Garcia-Ramos, Amador] Univ Granada, Fac Sport Sci, Dept Phys Educ & Sport, Granada, Spain; [Garcia-Ramos, Amador] Catholic Univ Most Holy Concepcion, Dept Sports Sci & Phys Conditioning, Fac Educ, CIEDE, Concepcion, Chile	University of Ljubljana; University of Granada; Universidad Catolica de la Santisima Concepcion	Smajla, D (corresponding author), Univ Ljubljana, Fac Sport, Ljubljana, Slovenia.	darjan.smajla@fsp.uni-lj.si	Ramos, Amador Garcia/S-6982-2016	Ramos, Amador Garcia/0000-0003-0608-8755; Smajla, Darjan/0000-0001-5441-8988	Javna Agencija za Raziskovalno Dejavnost RS (SI) [P5-0142]	Javna Agencija za Raziskovalno Dejavnost RS (SI)	This work was supported by Javna Agencija za Raziskovalno Dejavnost RS (SI) (P5-0142 to DS). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amako M, 2003, MIL MED, V168, P442, DOI 10.1093/milmed/168.6.442; Asslander L, 2014, J NEUROPHYSIOL, V111, P1852, DOI 10.1152/jn.00669.2013; Behm DG, 2016, APPL PHYSIOL NUTR ME, V41, P1, DOI 10.1139/apnm-2015-0235; Behm DG, 2004, MED SCI SPORT EXER, V36, P1397, DOI 10.1249/01.MSS.0000135788.23012.5F; Behm DG, 2001, CAN J APPL PHYSIOL, V26, P261, DOI 10.1139/h01-017; Bernardino S, 2014, EFFECTS DYNAMIC STRE, P586, DOI [10.1249/MSS.0000000000000138, DOI 10.1249/MSS.0000000000000138]; Billot M, 2010, EUR J APPL PHYSIOL, V109, P669, DOI 10.1007/s00421-010-1397-7; Bixler B, 1992, Fam Pract Res J, V12, P131; Bjorklund M, 2006, J ATHL TRAINING, V41, P270; Brindle TJ, 2010, SCAND J MED SCI SPOR, V20, P262, DOI 10.1111/j.1600-0838.2009.00887.x; Brockett C, 1997, BRAIN RES, V771, P251, DOI 10.1016/S0006-8993(97)00808-1; Brzycki M., 1993, J PHYS EDUC RECREAT, V64, P88, DOI [DOI 10.1080/07303084.1993.10606684, 10.1080/07303084.1993.10606684]; Chalmers GR, 2002, J GERONTOL A-BIOL, V57, pB321, DOI 10.1093/gerona/57.8.B321; COREN S, 1993, B PSYCHONOMIC SOC, V31, P1, DOI 10.3758/bf03334122; Costa PB, 2013, SCAND J MED SCI SPOR, V23, P38, DOI 10.1111/j.1600-0838.2011.01348.x; Costa PB, 2009, J SPORT MED PHYS FIT, V49, P401; Costa PB, 2009, INT J SPORTS MED, V30, P60, DOI 10.1055/s-2008-1038738; Costa PB, 2018, J SPORT MED PHYS FIT, V58, P957, DOI 10.23736/S0022-4707.17.07072-4; Docherty CL, 2008, J ORTHOP RES, V26, P1489, DOI 10.1002/jor.20682; EKSTRAND J, 1983, AM J SPORT MED, V11, P116, DOI 10.1177/036354658301100302; Fischer M, 2005, BRAIN RES, V1043, P163, DOI 10.1016/j.brainres.2005.02.059; Forestier N, 2002, MED SCI SPORT EXER, V34, P117, DOI 10.1097/00005768-200201000-00018; Garcia-Ramos A, 2017, EUR J SPORT SCI, V17, P690, DOI 10.1080/17461391.2017.1304999; Guissard N, 2006, EXERC SPORT SCI REV, V34, P154, DOI 10.1249/01.jes.0000240023.30373.eb; Hadala M, 2009, MED SCI SPORT EXER, V41, P1587, DOI 10.1249/MSS.0b013e31819c0de7; Hemmati L, 2016, ANN REHABIL MED-ARM, V40, P845, DOI 10.5535/arm.2016.40.5.845; Hopkins W, 2000, CALCULATIONS RELIABI; Hortobagyi T, 2004, ARTHRIT RHEUM-ARTHR, V51, P562, DOI 10.1002/art.20545; Kiers H, 2012, EUR J APPL PHYSIOL, V112, P1577, DOI 10.1007/s00421-011-2124-8; Lima BN, 2014, J SPORT SCI MED, V13, P564; Magnusson SP, 1996, J PHYSIOL-LONDON, V497, P291, DOI 10.1113/jphysiol.1996.sp021768; Marek SM, 2005, J ATHL TRAINING, V40, P94; Milani J, 2000, J EXERC PHYSL ONLINE, V3, P14; Okamura Y, 2004, EFFECT LOCAL GEN FAT, V20, P414, DOI [10.1016/j.arthro.2004.01.007, DOI 10.1016/J.ARTHRO.2004.01.007]; Proske U, 2006, MUSCLE NERVE, V34, P545, DOI 10.1002/mus.20627; Proske U, 2009, J PHYSIOL-LONDON, V587, P4139, DOI 10.1113/jphysiol.2009.175372; Ribeiro F., 2011, BIOMECHANICS APPL, DOI [10.5772/20335, DOI 10.5772/20335]; Ribeiro F, 2007, EUR J APPL PHYSIOL, V99, P379, DOI 10.1007/s00421-006-0357-8; Riemann BL, 2002, J ATHL TRAINING, V37, P71; Robbins S, 1998, SPORTS MED, V25, P63, DOI 10.2165/00007256-199825010-00005; Rosker J, 2010, SPORT SCI REV, V4, P165, DOI DOI 10.2478/V10237-011-0037-4; South M, 2007, PHYS THER SPORT, V8, P82, DOI 10.1016/j.ptsp.2006.12.001; Taube W, 2008, ACTA PHYSIOL, V193, P101, DOI 10.1111/j.1748-1716.2008.01850.x; Torres R, 2012, J HUM KINET, V34, P33, DOI 10.2478/v10078-012-0061-1; Trimble MH, 2001, INT J NEUROSCI, V106, P1, DOI 10.3109/00207450109149734; Tripp BL, 2006, CLIN BIOMECH, V21, P466, DOI 10.1016/j.clinbiomech.2005.12.015; van der Kooij H, 2011, J COMPUT NEUROSCI, V30, P759, DOI 10.1007/s10827-010-0291-y; van Dieen JH, 2015, J NEUROPHYSIOL, V114, P2967, DOI 10.1152/jn.00434.2015; Vuillerme N, 2008, GAIT POSTURE, V28, P521, DOI 10.1016/j.gaitpost.2008.03.005; Weir JP, 2005, J STRENGTH COND RES, V19, P231, DOI 10.1519/15184.1; Westlake KP, 2007, PHYS THER, V87, P1274, DOI 10.2522/ptj.20060263; WIKTORSSONMOLLER M, 1983, AM J SPORT MED, V11, P249, DOI 10.1177/036354658301100412	52	1	2	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2019	14	1							e0210881	10.1371/journal.pone.0210881	http://dx.doi.org/10.1371/journal.pone.0210881			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH8WT	30653585	Green Published, gold, Green Submitted			2023-01-03	WOS:000456015500109
J	Roubinian, NH; Murphy, EL; Mark, DG; Triulzi, DJ; Carson, JL; Lee, C; Kipnis, P; Kleinman, S; Liu, VX; Escobar, GJ				Roubinian, Nareg H.; Murphy, Edward L.; Mark, Dustin G.; Triulzi, Darrell J.; Carson, Jeffrey L.; Lee, Catherine; Kipnis, Patricia; Kleinman, Steven; Liu, Vincent X.; Escobar, Gabriel J.			Long-Term Outcomes Among Patients Discharged From the Hospital With Moderate Anemia A Retrospective Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							BLOOD-CELL TRANSFUSION; CLINICAL-PRACTICE GUIDELINE; CHRONIC HEART-FAILURE; RESTRICTIVE TRANSFUSION; LONGITUDINAL DATA; INTRAVENOUS IRON; ACQUIRED ANEMIA; MORTALITY; MANAGEMENT; IMPACT	Background: Randomized clinical trial findings support decreased red blood cell (RBC) transfusion and short-term tolerance of in-hospital anemia. However, long-term outcomes related to changes in transfusion practice have not been described. Objective: To describe the prevalence of anemia at and after hospital discharge and associated morbidity and mortality events. Design: Retrospective cohort study. Setting: Integrated health care delivery system with 21 hospitals serving 4 million members. Participants: 445 371 surviving adults who had 801 261 hospitalizations between January 2010 and December 2014. Measurements: Hemoglobin levels and RBC transfusion, rehospitalization, and mortality events within 6 months of hospital discharge. Generalized estimating equations were used to examine trends over time, accounting for correlated observations and patient-level covariates. Results: From 2010 to 2014, the prevalence of moderate anemia (hemoglobin levels between 7 and 10 g/dL) at hospital discharge increased from 20% to 25% (P < 0.001) and RBC transfusion declined by 28% (39.8 to 28.5 RBC units per 1000 patients; P < 0.001). The proportion of patients whose moderate anemia had resolved within 6 months of hospital discharge decreased from 42% to 34% (P < 0.001), and RBC transfusion and rehospitalization within 6 months of hospital discharge decreased from 19% to 17% and 37% to 33%, respectively (P < 0.001 for both). During this period, the adjusted 6-month mortality rate decreased from 16.1% to 15.6% (P = 0.004) in patients with moderate anemia, in parallel with that of all others. Limitation: Possible unmeasured confounding. Conclusion: Anemia after hospitalization increased in parallel with decreased RBC transfusion. This increase was not accompanied by a rise in subsequent RBC use, rehospitalization, or mortality within 6 months of hospital discharge. Longitudinal analyses support the safety of practice recommendations to limit RBC transfusion and tolerate anemia during and after hospitalization.	[Roubinian, Nareg H.; Mark, Dustin G.; Lee, Catherine; Liu, Vincent X.; Escobar, Gabriel J.] Kaiser Permanente Northern Calif, Div Res, 2000 Broadway, Oakland, CA 94612 USA; [Roubinian, Nareg H.; Murphy, Edward L.] Blood Syst Res Inst, San Francisco, CA USA; [Roubinian, Nareg H.; Murphy, Edward L.] Univ Calif San Francisco, 270 Masonic Ave, San Francisco, CA 94118 USA; [Triulzi, Darrell J.] Inst Transfus Med, 3636 Blvd Allies, Pittsburgh, PA 15213 USA; [Carson, Jeffrey L.] Rutgers Robert Wood Johnson Med Sch, 125 Paterson St, New Brunswick, NJ 08901 USA; [Kleinman, Steven] Univ British Columbia, 1281 Rockcrest Ave, Victoria, BC V9A 4W4, Canada; [Kipnis, Patricia] Kaiser Permanente Northern Calif, Div Res, 1800 Harrison St,7th Floor, Oakland, CA 94612 USA	Kaiser Permanente; Vitalant; Vitalant Research Institute; University of California System; University of California San Francisco; Institute for Transfusion Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of British Columbia; Kaiser Permanente	Roubinian, NH (corresponding author), Kaiser Permanente Northern Calif, Div Res, 2000 Broadway, Oakland, CA 94612 USA.	Nareg.H.Roubinian@kp.org; Catherine.lee@kp.org	Mark, Dustin George/AEB-1783-2022	Mark, Dustin George/0000-0002-5001-7228; Lee, Catherine/0000-0003-0008-9052; Roubinian, Nareg/0000-0002-1063-6155	National Heart, Lung, and Blood Institute (NHLBI) [R01HL126130]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL126130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R35GM128672] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	By grant R01HL126130 from the National Heart, Lung, and Blood Institute (NHLBI).	Anand I, 2004, CIRCULATION, V110, P149, DOI 10.1161/01.CIR.0000134279.79571.73; Anand IS, 2005, CIRCULATION, V112, P1121, DOI 10.1161/CIRCULATIONAHA.104.512988; BERNSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P2700; Bolger AP, 2006, J AM COLL CARDIOL, V48, P1225, DOI 10.1016/j.jacc.2006.07.015; Carson JL, 2016, JAMA-J AM MED ASSOC, V316, P2025, DOI 10.1001/jama.2016.9185; Carson JL, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002042.pub4; Carson JL, 2015, LANCET, V385, P1183, DOI 10.1016/S0140-6736(14)62286-8; Carson JL, 2011, NEW ENGL J MED, V365, P2453, DOI 10.1056/NEJMoa1012452; Carson JL, 1996, LANCET, V348, P1055, DOI 10.1016/S0140-6736(96)04330-9; Cassel CK, 2012, JAMA-J AM MED ASSOC, V307, P1801, DOI 10.1001/jama.2012.476; Chant C, 2006, CRIT CARE, V10, DOI 10.1186/cc5054; Culleton BF, 2006, BLOOD, V107, P3841, DOI 10.1182/blood-2005-10-4308; Dietrich W, 2014, EUR J ANAESTH, V31, P239, DOI 10.1097/EJA.0000000000000033; Escobar GJ, 2008, MED CARE, V46, P232, DOI 10.1097/MLR.0b013e3181589bb6; Escobar GJ, 2013, MED CARE, V51, P446, DOI 10.1097/MLR.0b013e3182881c8e; Ferraris VA, 2011, ANN THORAC SURG, V91, P944, DOI 10.1016/j.athoracsur.2010.11.078; Fischer MO, 2015, NEW ENGL J MED, V373, P191, DOI 10.1056/NEJMc1505810; Goodnough LT, 2013, LANCET, V381, P1791, DOI 10.1016/S0140-6736(13)60673-X; Goodnough LT, 2014, AM J HEMATOL, V89, P88, DOI 10.1002/ajh.23598; Goodnough LT, 2004, AM J MED, V116, P1, DOI 10.1016/j.amjmed.2003.12.007; Goodnough LT, 2001, NEW ENGL J MED, V345, P1272, DOI 10.1056/NEJM200110253451711; Hajjar LA, 2010, JAMA-J AM MED ASSOC, V304, P1559, DOI 10.1001/jama.2010.1446; Halpern SD, 2014, AM J RESP CRIT CARE, V190, P818, DOI 10.1164/rccm.201407-1317ST; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hicks LK, 2013, BLOOD, V122, P3879, DOI 10.1182/blood-2013-07-518423; Holst LB, 2015, NEW ENGL J MED, V372, P91, DOI 10.1056/NEJMc1413474; Jaffe MG, 2013, JAMA-J AM MED ASSOC, V310, P699, DOI 10.1001/jama.2013.108769; Kajimoto K, 2019, EUR HEART J-ACUTE CA, V8, P606, DOI 10.1177/2048872617730039; Khalafallah AA, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000998; Kipnis P, 2014, MED CARE, V52, P378, DOI 10.1097/MLR.0000000000000111; Koch CG, 2013, J HOSP MED, V8, P506, DOI 10.1002/jhm.2061; Krumholz HM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160492; Kwan JL, 2015, J HOSP MED, V10, P799, DOI 10.1002/jhm.2442; Liu V, 2015, AM J EMERG MED, V33, P1305, DOI 10.1016/j.ajem.2014.07.024; Liu VX, 2016, AM J RESP CRIT CARE, V193, P1264, DOI 10.1164/rccm.201507-1489OC; Mazer CD, 2018, NEW ENGL J MED, V379, P1224, DOI 10.1056/NEJMoa1808561; Mindell J, 2013, BRIT J HAEMATOL, V160, P368, DOI 10.1111/bjh.12121; Napolitano LM, 2009, J TRAUMA, V67, P1439, DOI 10.1097/TA.0b013e3181ba7074; Qaseem A, 2013, ANN INTERN MED, V159, P770, DOI 10.7326/0003-4819-159-11-201312030-00009; Retter A, 2013, BRIT J HAEMATOL, V160, P445, DOI 10.1111/bjh.12143; Roubinian NH, 2014, TRANSFUSION, V54, P2678, DOI 10.1111/trf.12825; Roubinian NH, 2014, JAMA INTERN MED, V174, P1405, DOI 10.1001/jamainternmed.2014.2889; Salisbury AC, 2011, ARCH INTERN MED, V171, P1646, DOI 10.1001/archinternmed.2011.361; Solomon MD, 2016, J AM COLL CARDIOL, V68, P666, DOI 10.1016/j.jacc.2016.03.607; Spahn DR, 2013, LANCET, V381, P1855, DOI 10.1016/S0140-6736(13)60808-9; Tavares MM, 2014, TRANSFUSION, V54, P2625, DOI 10.1111/trf.12552; Thakkar RN, 2016, TRANSFUSION, V56, P2212, DOI 10.1111/trf.13718; Thavendiranathan P, 2005, J GEN INTERN MED, V20, P520, DOI 10.1111/j.1525-1497.2005.0094.x; Toblli JE, 2007, J AM COLL CARDIOL, V50, P1657, DOI 10.1016/j.jacc.2007.07.029; Touloumis A, 2015, J STAT SOFTW, V64, P1; Vallet B, 2007, BEST PRACT RES-CLIN, V21, P173, DOI 10.1016/j.bpa.2007.02.003; Villanueva C, 2013, NEW ENGL J MED, V368, P11, DOI 10.1056/NEJMoa1211801; Volpp KG, 2012, JAMA-J AM MED ASSOC, V308, P1635, DOI 10.1001/jama.2012.13616; Wang JK, 2010, VOX SANG, V98, P2, DOI 10.1111/j.1423-0410.2009.01223.x; Wu WC, 2007, JAMA-J AM MED ASSOC, V297, P2481, DOI 10.1001/jama.297.22.2481; Yerrabothala S, 2014, TRANSFUSION, V54, P2640, DOI 10.1111/trf.12627; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734; Zou GY, 2013, STAT METHODS MED RES, V22, P661, DOI 10.1177/0962280211427759	58	31	31	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	2019	170	2					81	+		10.7326/M17-3253	http://dx.doi.org/10.7326/M17-3253			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH3ZL	30557414	Green Accepted			2023-01-03	WOS:000455659100012
J	Hashem, MM; Salama, MM; Mohammed, FF; Tohamy, AF; El Deeb, KS				Hashem, Mona M.; Salama, Maha M.; Mohammed, Faten F.; Tohamy, Adel F.; El Deeb, Kadriya S.			Metabolic profile and hepatoprotective effect of Aeschynomene elaphroxylon (Guill. & Perr.)	PLOS ONE			English	Article							CCL4-INDUCED LIVER-DAMAGE; ANTIOXIDANT ACTIVITIES; TRITERPENE SAPONINS; PHENOLIC CONTENTS; OXIDATIVE STRESS; EXTRACT; SERUM; MS; FLAVONOIDS; SEEDS	Liver diseases are life-threatening and need urgent medical treatments. Conventional treatment is expensive and toxic, so the urge for nutraceutical hepatoprotective agents is crucial. This study is considered the first metabolic profile of Aeschynomene elaphroxylon (Guill. & Perr.) extracts of; flowers, leaves & bark adopting UPLC-Orbitrap HRMS analysis to determine their bioactive metabolites, and it was designed to investigate the potential hepatoprotective activity of A. elaphroxylon flowers and bark extracts against CCl4-induced hepatic fibrosis in rats. Forty-nine compounds of various classes were detected in the three extracts, with triterpenoid saponins as the major detected metabolite. Flowers and bark extracts presented similar chemical profile while leaves extract was quite different. The antioxidant activities of the flowers, leaves & bark extracts were measured by in vitro assays as Fe+3 reducing antioxidant power and Oxygen radical absorbance capacity. It revealed that flowers and bark extracts had relatively high antioxidant activity as compared to leaves extract. Based on the metabolic profile and in vitro antioxidant activity, flowers and bark ethanolic extracts were chosen for alleviation of hepatotoxicity induced by CCl4 in rats. The hepato-protective activity was studied through measuring hepatotoxicity biomarkers in serum (ALT, AST, and Albumin). Liver tissues were examined histopathologically and their homogenates were used in determining the intracellular levels of oxidative stress biomarkers (MDA, GSH), inflammatory markers (TNF-alpha). Flowers and bark ethanolic extracts exerted a significant hepatoprotective effect through reduction in the activities of ALT, AST and Albumin, the tested extracts reduced oxidative stress by increasing GSH content and reducing the MDA level. Furthermore, the extracts decreased levels of pro-inflammatory TNF-alpha. Moreover, the present study revealed the potentiality of A. elaphroxylon in ameliorating the CCl4-induced hepatic fibrosis in rats. In this aspect, A. elaphroxylon can be used with other agents as a complementary drug.	[Hashem, Mona M.; Salama, Maha M.; El Deeb, Kadriya S.] Cairo Univ, Dept Pharmacognosy, Fac Pharm, Giza, Egypt; [Salama, Maha M.] British Univ Egypt, Dept Pharmacognosy, Fac Pharm, El Sherouk City, Egypt; [Mohammed, Faten F.] Cairo Univ, Dept Pathol, Fac Vet Med, Giza, Egypt; [Tohamy, Adel F.] Cairo Univ, Dept Toxicol & Forens Med, Fac Vet Med, Giza, Egypt; [Tohamy, Adel F.] Univ Vet Med Hannover, Inst Pharmacol Toxicol & Pharm, Hannover, Germany	Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); British University in Egypt; Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); Cairo University; University of Veterinary Medicine Hannover, Foundation	Hashem, MM (corresponding author), Cairo Univ, Dept Pharmacognosy, Fac Pharm, Giza, Egypt.	mona.hashem@pharma.cu.edu.eg	Mohammed, Faten/AHA-4407-2022; Afify, adel/AEY-4864-2022	Mohammed, Faten/0000-0003-0410-8118; Tohamy, Adel/0000-0001-7711-7432				Achika JI, 2016, BRIT J PHARM RES, V11, DOI 10.9734/BJPR/2016/23506; Achur RN, 2010, J NEUROIMMUNE PHARM, V5, P83, DOI 10.1007/s11481-009-9185-z; Alekhya C, 2013, INT J PHARM PHARM SC, V5, P386; [Anonymous], [No title captured]; Aruna C, 2012, INT J PHARM PHARM SC, V4, P1; Bharathi M. P., 2015, Journal of Pharmacy Research, V9, P21; Boll M, 2001, Z NATURFORSCH C, V56, P649; Burkill HM, 1994, USEFUL PLANTS W TROP, V2; Caamal-Fuentes E, 2013, NAT PROD COMMUN, V8, P1421; Caamal-Fuentes E, 2011, J ETHNOPHARMACOL, V135, P719, DOI 10.1016/j.jep.2011.04.004; Caamal-Fuentes EE, 2015, MOLECULES, V20, P13563, DOI 10.3390/molecules200813563; Chen SR, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0053662, 10.1371/journal.pone.0056380]; Chiu YJ, 2018, J FOOD DRUG ANAL, V26, P369, DOI 10.1016/j.jfda.2017.04.007; Clichici S, 2015, J MED FOOD, V18, P290, DOI 10.1089/jmf.2013.0179; Cuyckens F, 2004, J MASS SPECTROM, V39, P1, DOI 10.1002/jms.622; Davis BD, 2004, J AM SOC MASS SPECTR, V15, P1287, DOI 10.1016/j.jasms.2004.06.003; DOUMAS BT, 1971, CLIN CHIM ACTA, V31, P87, DOI 10.1016/0009-8981(71)90365-2; Dutta S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196411; ElSayed NH, 1997, ASIAN J CHEM, V9, P549; Ezejindu DN, 2013, INT J ENG SCI, V2, P54; Farag MA, 2015, ANAL BIOANAL CHEM, V407, P1937, DOI 10.1007/s00216-014-8432-1; Farag MA, 2013, PHYTOCHEMISTRY, V95, P177, DOI 10.1016/j.phytochem.2013.07.003; Ferreres F, 2004, J MASS SPECTROM, V39, P312, DOI 10.1002/jms.586; Ferreres F, 2012, FOOD CHEM, V134, P894, DOI 10.1016/j.foodchem.2012.02.201; Figueirinha A, 2008, FOOD CHEM, V110, P718, DOI 10.1016/j.foodchem.2008.02.045; Gu LW, 2003, J AGR FOOD CHEM, V51, P7513, DOI 10.1021/jf034815d; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Harish R, 2006, FOOD CHEM, V95, P180, DOI 10.1016/j.foodchem.2004.11.049; Hinson Jack A, 2010, Handb Exp Pharmacol, P369, DOI 10.1007/978-3-642-00663-0_12; Hong J, 2016, J MED FOOD, V19, P549, DOI 10.1089/jmf.2015.3604; Hossain MB, 2010, J AGR FOOD CHEM, V58, P10576, DOI 10.1021/jf102042g; Hua YS, 2012, J CHROMATOGR SCI, V50, P213, DOI 10.1093/chromsci/bmr049; Ignoato MC, 2012, QUIM NOVA, V35, P2241, DOI 10.1590/S0100-40422012001100028; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; JIANG Z, 1992, J HEPATOL, V16, P282, DOI 10.1016/S0168-8278(05)80658-0; Jin MC, 2007, J CHROMATOGR B, V846, P169, DOI 10.1016/j.jchromb.2006.08.043; KITAGAWA I, 1985, CHEM PHARM BULL, V33, P598; Koley TK, 2017, ARABIAN J CHEM; Li XC, 2009, MOLECULES, V14, P5349, DOI 10.3390/molecules14125349; Liang ZC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105146; Maatta KR, 2003, J AGR FOOD CHEM, V51, P6736, DOI 10.1021/jf0347517; Mahmoodzadeh Y, 2017, TOXICOL REP, V4, P455, DOI 10.1016/j.toxrep.2017.08.003; Murakami T, 2001, CHEM PHARM BULL, V49, P73, DOI 10.1248/cpb.49.73; Pandae PT KaV, 2011, PHARMACOLOGYONLINE, V3, P297; Poli Giuseppe, 2000, Molecular Aspects of Medicine, V21, P49, DOI 10.1016/S0098-2997(00)00004-2; Pollier J, 2011, J NAT PROD, V74, P1462, DOI 10.1021/np200218r; Prior RL, 2005, J AGR FOOD CHEM, V53, P4290, DOI 10.1021/jf0502698; Racanelli V, 2006, HEPATOLOGY, V43, pS54, DOI 10.1002/hep.21060; Radwan HA, 2015, RES J PHARM BIOL CHE, V6, P1061; Reeves HL, 2002, FRONT BIOSCI-LANDMRK, V7, pD808, DOI 10.2741/reeves; REITMAN S, 1957, AM J CLIN PATHOL, V28, P56, DOI 10.1093/ajcp/28.1.56; Rockenbach II, 2012, FOOD RES INT, V48, P848, DOI 10.1016/j.foodres.2012.07.001; Sadeghi H, 2016, AVICENNA J PHYTOMEDI, V6, P181; SHIRAIWA M, 1991, AGR BIOL CHEM TOKYO, V55, P911, DOI 10.1080/00021369.1991.10870686; Sinha K, 2013, ARCH TOXICOL, V87, P1157, DOI 10.1007/s00204-013-1034-4; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; Wu LL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101837; Xu Hui-Xian, 2013, Zhongguo Zhong Yao Za Zhi, V38, P2187; Xu RA, 2012, CELL MOL IMMUNOL, V9, P296, DOI 10.1038/cmi.2011.53; Xu Y, 2018, CHIN J NAT MEDICINES, V16, P271, DOI 10.1016/S1875-5364(18)30057-8; Yang Yoon Mee, 2015, Curr Pathobiol Rep, V3, P253; Zhang W, 2009, MOLECULES, V14, P2959, DOI 10.3390/molecules14082959; Zhao HF, 2008, FOOD CHEM, V107, P296, DOI 10.1016/j.foodchem.2007.08.018; Zheng YF, 2015, MOLECULES, V20, P6273, DOI 10.3390/molecules20046273; Zhu LJ, 2016, PHARMACOGN MAG, V12, P302, DOI 10.4103/0973-1296.192203	65	10	10	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 10	2019	14	1							e0210576	10.1371/journal.pone.0210576	http://dx.doi.org/10.1371/journal.pone.0210576			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH1ME	30629685	Green Published, gold			2023-01-03	WOS:000455483000111
J	MacDougall, L; Smolina, K; Otterstatter, M; Zhao, B; Chong, M; Godfrey, D; Mussavi-Rizi, A; Sutherland, J; Kuo, M; Kendall, P				MacDougall, Laura; Smolina, Kate; Otterstatter, Michael; Zhao, Bin; Chong, Mei; Godfrey, David; Mussavi-Rizi, Ali; Sutherland, Jenny; Kuo, Margot; Kendall, Perry			Development and characteristics of the Provincial Overdose Cohort in British Columbia, Canada	PLOS ONE			English	Article							OPIOID OVERDOSE; PUBLIC-HEALTH	Introduction British Columbia (BC), Canada declared a public health emergency in April 2016 for opioid overdose. Comprehensive data was needed to identify risk factors, inform interventions, and evaluate response actions. We describe the development of an overdose cohort, including linkage strategy, case definitions, and data governance model, and present the resulting characteristics, including data linkage yields and case overlap among data sources. Methods Overdose events from hospital admissions, physician visits, poison centre and ambulance calls, emergency department visits, and coroner's data were grouped into episodes if records were present in multiple sources. A minimum of five years of universal health care records (all prescription dispensations, fee-for-service physician billings, emergency department visits and hospitalizations) were appended for each individual. A 20% random sample of BC residents and a 1: 5 matched case-control set were generated. Consultation and prioritization ensured analysts worked to address questions to directly inform public health actions. Results 10,456 individuals suffered 14,292 overdoses from January 1, 2015 to Nov 30, 2016. Only 28% of overdose events were found in more than one dataset with the unique contribution of cases highest from ambulance records (32%). Compared with fatal overdoses, non-fatal events more often involved females, younger individuals (20 to 29 years) and those 60 or older. In 78% of illegal drug deaths, there was no associated ambulance response. In the year prior to first recorded overdose, 60% of individuals had at least one ED visit, 31% at least one hospital admission, 80% at least one physician visit, and 87% had filled at least one prescription in a community pharmacy. Conclusion While resource-intensive to establish, a linked cohort is useful for characterizing the full extent of the epidemic, defining sub-populations at risk, and patterns of contact with the health system. Overdose studies in other jurisdictions should consider the inclusion of multiple data sources.	[MacDougall, Laura; Smolina, Kate; Otterstatter, Michael; Zhao, Bin; Chong, Mei; Kuo, Margot] British Columbia Ctr Dis Control, Vancouver, BC, Canada; [Smolina, Kate; Otterstatter, Michael] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Godfrey, David] British Columbia Minist Hlth, Data Management & Stewardship Branch, Victoria, BC, Canada; [Mussavi-Rizi, Ali] Prov Hlth Serv Author, Performance Measurement & Reporting, Vancouver, BC, Canada; [Sutherland, Jenny; Kendall, Perry] British Columbia Minist Hlth, Off Prov Hlth Officer, Victoria, BC, Canada	University of British Columbia	MacDougall, L (corresponding author), British Columbia Ctr Dis Control, Vancouver, BC, Canada.	laura.macdougall@canada.ca		Otterstatter, Michael/0000-0001-5489-014X				[Anonymous], 2018, ILL DRUG OV DEATHS B; [Anonymous], 2017, DRUG ALCOHOL REV; [Anonymous], 2017, COMMUNICATION; Bahorik AL, 2017, SUBST ABUS, V19, P1; Boscarino JA, 2016, SUBST ABUSE REHABIL, V7, P131, DOI 10.2147/SAR.S108302; Canadian Institute for Health Information, 2016, DAT QUAL DOC NAT AMB; Drug Analysis Service, 2017, DRUG SIT SUMM REP CA; European Monitoring Centre for Drugs and Drug Addiction, 2018, STAT B 2018 OV DEATH; Formica SW, 2018, INT J DRUG POLICY, V54, P43, DOI 10.1016/j.drugpo.2018.01.001; Gladstone EJ, 2016, INJURY PREV, V22, P288, DOI 10.1136/injuryprev-2015-041604; Janjua NZ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150176; Leamon AW, 2017, ENHANCED EMERGENCY D; Office of the Provincial Health Officer of British Columbia, 2017, PREV PHARM OP ASS MO; Rasali D, 2016, PUBL HLTH ASS BRIT C; Rizi SAM, 2013, STUD HEALTH TECHNOL, V192, P861, DOI 10.3233/978-1-61499-289-9-861; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Wu LT, 2012, ANN EMERG MED, V60, P172, DOI 10.1016/j.annemergmed.2012.02.003	17	23	23	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 10	2019	14	1							e0210129	10.1371/journal.pone.0210129	http://dx.doi.org/10.1371/journal.pone.0210129			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH1ME	30629607	Green Submitted, Green Published, gold			2023-01-03	WOS:000455483000052
J	van Wijmen, MPS; Pasman, HRW; Twisk, JWR; Widdershoven, GAM; Onwuteaka-Philipsen, BD				van Wijmen, Matthijs P. S.; Pasman, H. Roeline W.; Twisk, Jos W. R.; Widdershoven, Guy A. M.; Onwuteaka-Philipsen, Bregje D.			Stability of end-of-life preferences in relation to health status and life-events: A cohort study with a 6-year follow-up among holders of an advance directive	PLOS ONE			English	Article							SUSTAINING TREATMENT; PATIENT PREFERENCES; PERSPECTIVE; CHOICES; CARE	Background Stating preferences about care beforehand using advance care planning and advance directives has become increasingly common in current medicine. There is still lack of clarity what happens over the course of time in relation to these preferences. We wanted to determine whether the preferences about end-of-life care of a person owning an advance directive stay stable after the experience of a life-event; how often advance directives are altered and discussed with family members and physicians over time. Design A longitudinal cohort study with a population consisting of people owning the most common advance directives in the Netherlands, with a follow-up of 6-years from 2005 until 2011. Respondents were recruited using two associations that provided the advance directives, Right to Die-NL (n = 4463) and the Dutch Patient Organisation (n = 1263). Each 1.5 year a questionnaire was sent. We analyzed the relationship between variables using generalized estimated equations. Results 96.9-98.1% of the respondents who had experienced a life-event had stable preferences. 89.9-93.7% of Right-to-Die-NL-members who had experienced a life-event didn't make any alterations in their advance directives. During the 6-year course of our study, a minority of both groups didn't discuss their advance directive with anyone (8.7-16.4%), while a majority didn't discuss it with physicians (ranging 58.1-95.1%). Factors related to health, such as deterioration in experienced health, increased the odds to discuss advance directives. Conclusion Our results largely dispute criticism concerning usability of advance directives due to lack of stability of preferences. Whereas a change in health status and the experience of other life-events were not related to instability in preferences, they did increase the odds of communication about advance directives. Because our results show that the possession of an advance directive does not necessarily result in frequent discussions between patients and caregivers, a more structured approach like advance care planning might be a solution.	[van Wijmen, Matthijs P. S.; Pasman, H. Roeline W.; Onwuteaka-Philipsen, Bregje D.] Vrije Univ Amsterdam, Med Ctr, Amsterdam Publ Hlth Res Inst, Dept Publ & Occupat Hlth, Amsterdam, Netherlands; [Twisk, Jos W. R.] Vrije Univ Amsterdam, Dept Epidemiol & Biostat, Med Ctr, Amsterdam, Netherlands; [Widdershoven, Guy A. M.] Vrije Univ Amsterdam, Amsterdam Publ Hlth Res Inst, Dept Med Humanities, Med Ctr, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	van Wijmen, MPS (corresponding author), Vrije Univ Amsterdam, Med Ctr, Amsterdam Publ Hlth Res Inst, Dept Publ & Occupat Hlth, Amsterdam, Netherlands.	m.vanwijmen@vumc.nl		van Wijmen, Matthijs/0000-0003-1173-4985; Onwuteaka-Philipsen, Bregje/0000-0002-9440-1248	Innovational Research Incentives Scheme VICI 2008 from the Netherlands Organisation for Scientific Research (NWO) [NWO VICI 916.96.628]; Pieter van Foreest Stichting, Right to Die-NL (NVVE); Nederlandse Patienten Vereniging (NPV)	Innovational Research Incentives Scheme VICI 2008 from the Netherlands Organisation for Scientific Research (NWO); Pieter van Foreest Stichting, Right to Die-NL (NVVE); Nederlandse Patienten Vereniging (NPV)	This study was funded by the Innovational Research Incentives Scheme VICI 2008 from the Netherlands Organisation for Scientific Research (NWO) (grant number: NWO VICI 916.96.628), Pieter van Foreest Stichting, Right to Die-NL (NVVE) and the Nederlandse Patienten Vereniging (NPV) (all received by BO). The NVVE and NPV helped with the collection of the data by providing the addresses of the respondents and preparing the sending of the questionnaires. The other funders had no role in the data collection. None of the funders had a role in study design, data analysis, decision to publish, or preparation of the manuscript.	Almack K, 2012, BMC PALLIAT CARE, V11, DOI 10.1186/1472-684X-11-15; Auriemma CL, 2014, JAMA INTERN MED, V174, P1085, DOI 10.1001/jamainternmed.2014.1183; Barrio-Cantalejo IM, 2013, J BIOETHIC INQ, V10, P103, DOI 10.1007/s11673-012-9417-4; Bischoff K, 2018, JAMA INTERN MED, V178, P48, DOI 10.1001/jamainternmed.2017.6313; Bolt EE, 2016, J AM GERIATR SOC, V64, P1628, DOI 10.1111/jgs.14208; Brinkman-Stoppelenburg A, 2014, PALLIATIVE MED, V28, P1000, DOI 10.1177/0269216314526272; Burchardi N, 2005, J NEUROL SCI, V237, P67, DOI 10.1016/j.jns.2005.05.013; Carmel S, 1999, SOC SCI MED, V49, P303, DOI 10.1016/S0277-9536(99)00121-5; DANIS M, 1994, ANN INTERN MED, V120, P567, DOI 10.7326/0003-4819-120-7-199404010-00006; de Beaufort I, 2005, NEW ENGL J MED, V352, P2373, DOI 10.1056/NEJMp058094; Ditto PH, 2006, MED DECIS MAKING, V26, P313, DOI 10.1177/0272989X06290494; Ditto PH, 2003, HEALTH PSYCHOL, V22, P605, DOI 10.1037/0278-6133.22.6.605; EMANUEL LL, 1994, ARCH INTERN MED, V154, P209, DOI 10.1001/archinte.1994.00420020131014; Evans N, 2014, PALLIATIVE MED, V28, P1206, DOI 10.1177/0269216314540017; EVERHART MA, 1990, CHEST, V97, P159, DOI 10.1378/chest.97.1.159; GANZINI L, 1994, AM J PSYCHIAT, V151, P1631; Janssen DJA, 2012, CHEST, V141, P1251, DOI 10.1378/chest.11-1472; Kohut N, 1997, J CLIN ETHIC, V8, P124; Lamers LM, 2005, NED TIJDSCHR GENEES, V149, P1574; McParland E, 2003, MT SINAI J MED, V70, P85; Ministerie van VolksgezondheidWen S, 2011, KENN OPV PUBL PROF M; Pruchno RA, 2008, J GERONTOL B-PSYCHOL, V63, pS81, DOI 10.1093/geronb/63.2.S81; van Wijmen MPS, 2015, J MED ETHICS, V41, P599, DOI 10.1136/medethics-2013-101544; van Wijmen MPS, 2014, PATIENT EDUC COUNS, V95, P393, DOI 10.1016/j.pec.2014.03.009; van Wijmen MPS, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-166; van Wijmen MPS, 2010, BIOETHICS, V24, P118, DOI 10.1111/j.1467-8519.2009.01788.x; Weissman JS, 1999, MED DECIS MAKING, V19, P16, DOI 10.1177/0272989X9901900103; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wittink MN, 2008, ARCH INTERN MED, V168, P2125, DOI 10.1001/archinte.168.19.2125	29	12	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 18	2018	13	12							e0209315	10.1371/journal.pone.0209315	http://dx.doi.org/10.1371/journal.pone.0209315			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HE9MF	30562403	Green Submitted, gold, Green Published			2023-01-03	WOS:000453774100048
J	Kumar, S; Sharma, C; Kaushik, SR; Kulshreshtha, A; Chaturvedi, S; Nanda, RK; Bhaskar, A; Chattopadhyay, D; Das, G; Dwivedi, VP				Kumar, Santosh; Sharma, Chetan; Kaushik, Sandeep Rai; Kulshreshtha, Ankur; Chaturvedi, Shivam; Nanda, Ranjan Kumar; Bhaskar, Ashima; Chattopadhyay, Debprasad; Das, Gobardhan; Dwivedi, Ved Prakash			The phytochemical bergenin as an adjunct immunotherapy for tuberculosis in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						Mycobacterium tuberculosis; immunotherapy; drug resistance; cytokine; T helper cells; infectious disease; adjunct therapy; bergenin; isoniazid; multidrug resistance; natural product; T cells; memory cells; immunity	CALMETTE-GUERIN VACCINE; CELL-DIFFERENTIATION; TGF-BETA; T-CELLS; BCG; INTERLEUKIN-12; T-HELPER-2; ACTIVATION; RESISTANCE; MOLECULES	The widespread availability and use of modern synthetic therapeutic agents have led to a massive decline in ethnomedical therapies. However, these synthetic agents often possess toxicity leading to various adverse effects. For instance, anti-tubercular treatment (ATT) is toxic, lengthy, and severely impairs host immunity, resulting in posttreatment vulnerability to reinfection and reactivation of tuberculosis (TB). Incomplete ATT enhances the risk for the generation of multidrug- or extensively drug-resistant (MDR or XDR, respectively) variants of Mycobacterium tuberculosis (M. tb), the TB-causing microbe. Therefore, a new therapeutic approach that minimizes these risks is urgently needed to combat this deadly disease and prevent future TB epidemics. Previously, we have shown that the phytochemical bergenin induces T helper 1 (Th1)- and Th17 cell-based protective immune responses and potently inhibits mycobacterial growth in a murine model of M. tb infection, suggesting bergenin as a potential adjunct agent to TB therapy. Here, we combined ATT therapy with bergenin and found that this combination reduces immune impairment and the length of treatment in mice. We observed that co-treatment with the anti-TB drug isoniazid and bergenin produces additive effects and significantly reduces bacterial loads compared with isoniazid treatment alone. The bergenin co-treatment also reduced isoniazid-induced immune impairment; promoted long-lasting, antigen-specific central memory T cell responses; and acted as a self-propelled vaccine. Of note, bergenin treatment significantly reduced the bacterial burden of a multidrug-resistant TB strain. These observations suggest that bergenin is a potent immunomodulatory agent that could be further explored as a potential adjunct to TB therapy.	[Kumar, Santosh; Sharma, Chetan; Kaushik, Sandeep Rai; Chaturvedi, Shivam; Nanda, Ranjan Kumar; Dwivedi, Ved Prakash] Int Ctr Genet Engn & Biotechnol, New Delhi 110067, India; [Kulshreshtha, Ankur] Inst Genom & Integrat Biol, New Delhi 110007, India; [Bhaskar, Ashima] Natl Inst Immunol, Signal Transduct Lab 1, New Delhi 110067, India; [Chattopadhyay, Debprasad] ID & BG Hosp, ICMR Virus Unit, Kolkata 700010, W Bengal, India; [Das, Gobardhan] Jawaharlal Nehru Univ, Special Ctr Mol Med, New Delhi 110067, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Indian Council of Medical Research (ICMR); ICMR - National Institute of Cholera & Enteric Diseases (NICED); ICMR - Virus Unit, Kolkata; Jawaharlal Nehru University, New Delhi	Das, G (corresponding author), Jawaharlal Nehru Univ, Special Ctr Mol Med, New Delhi 110067, India.; Dwivedi, VP (corresponding author), Aruna Asaf Ali Marg, New Delhi 110067, India.	das07@gmail.com; vedprakashbt@gmail.com	Nanda, Ranjan/ABD-3967-2021; KULSHRESHTHA, ANKUR/AFP-2527-2022	KULSHRESHTHA, ANKUR/0000-0001-5139-6744; Dwivedi, Ved Prakash/0000-0003-4321-2567; Sharma, Chetan/0000-0002-6446-8951; Kaushik, Sandeep Rai/0000-0002-3463-3522; BHASKAR, ASHIMA/0000-0002-7367-874X	International Centre for Genetic Engineering and Biotechnology (ICGEB, New Delhi, India)	International Centre for Genetic Engineering and Biotechnology (ICGEB, New Delhi, India)	We acknowledge the support of the DBT-supported Tuberculosis Aerosol Challenge Facility and Bio-experimentation Facility (Animal House) at the International Centre for Genetic Engineering and Biotechnology (ICGEB, New Delhi, India) and their staff in accomplishing this work.	Bhattacharya D, 2014, J BIOL CHEM, V289, P33404, DOI 10.1074/jbc.M114.600452; Bhattacharya D, 2014, J BIOL CHEM, V289, P16508, DOI 10.1074/jbc.M114.558098; Byrd TF, 2007, CURR NEUROL NEUROSCI, V7, P470, DOI 10.1007/s11910-007-0073-8; Cadena AM, 2016, MBIO, V7, DOI 10.1128/mBio.00342-16; Chatterjee S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002378; Chen WJ, 2010, J MOL CELL BIOL, V2, P30, DOI 10.1093/jmcb/mjp004; Cooper AM, 2007, CURR OPIN IMMUNOL, V19, P441, DOI 10.1016/j.coi.2007.07.004; Das J, 2009, J EXP MED, V206, P3157, DOI 10.1084/jem.20082286120409c; Davies J, 2010, MICROBIOL MOL BIOL R, V74, P417, DOI 10.1128/MMBR.00016-10; Duhen T, 2014, J IMMUNOL, V193, P120, DOI 10.4049/jimmunol.1302734; Dwivedi VP, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00149; Dwivedi VP, 2012, J BIOL CHEM, V287, P33656, DOI 10.1074/jbc.M112.375154; FINE PEM, 1989, REV INFECT DIS, V11, pS353; FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Gomez-Cansino R, 2017, AN ACAD BRAS CIENC, V89, P31, DOI 10.1590/0001-3765201720160298; Hickman SP, 2002, J IMMUNOL, V168, P4636, DOI 10.4049/jimmunol.168.9.4636; Jnawali HN, 2016, J NAT PROD, V79, P961, DOI 10.1021/acs.jnatprod.5b01033; Kernodle DS, 2010, CLIN INFECT DIS, V51, P177, DOI 10.1086/653533; Kursar M, 2007, J IMMUNOL, V178, P2661, DOI 10.4049/jimmunol.178.5.2661; Lee H, 2016, J IND MICROBIOL BIOT, V43, P205, DOI 10.1007/s10295-015-1709-3; Lienhardt C, 2002, EUR J IMMUNOL, V32, P1605, DOI 10.1002/1521-4141(200206)32:6<1605::AID-IMMU1605>3.0.CO;2-6; Mukherjee H, 2013, J ETHNOPHARMACOL, V149, P335, DOI 10.1016/j.jep.2013.06.045; Patel D. K., 2012, Asian Pacific Journal of Tropical Biomedicine, V2, pS165; Rahman MA, 2015, J BIOL CHEM, V290, P14407, DOI 10.1074/jbc.M115.653600; Rook GAW, 2007, CURR MOL MED, V7, P327; Santarlasci V, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00182; Schorey JS, 2003, CELL MICROBIOL, V5, P133, DOI 10.1046/j.1462-5822.2003.00263.x; Scott-Browne JP, 2007, J EXP MED, V204, P2159, DOI 10.1084/jem.20062105; Shafiani S, 2010, J EXP MED, V207, P1409, DOI 10.1084/jem.20091885; Singh DK, 2016, J INFECT DIS, V214, P1456, DOI 10.1093/infdis/jiw395; Stanford J L, 1990, Bull Int Union Tuberc Lung Dis, V65, P27; Sweeney KA, 2011, NAT MED, V17, P1261, DOI 10.1038/nm.2420; Tousif S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00739; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WHO, 2020, GLOBAL TUBERCULOSIS; Winslow GM, 2008, IMMUNOL REV, V225, P284, DOI 10.1111/j.1600-065X.2008.00693.x; World Health Organization, 2018, GLOBAL TUBERCULOSIS; World Health Organization, 2015, TUB VACC DEV; Yang L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021; Yoshimura A, 2010, J BIOCHEM, V147, P781, DOI 10.1093/jb/mvq043; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257	44	13	14	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2019	294	21					8555	8563		10.1074/jbc.RA119.008005	http://dx.doi.org/10.1074/jbc.RA119.008005			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	IC6UQ	30975902	Green Published, hybrid			2023-01-03	WOS:000471108200023
J	Al-Batran, SE; Homann, N; Pauligk, C; Goetze, TO; Meiler, J; Kasper, S; Kopp, HG; Mayer, F; Haag, GM; Luley, K; Lindig, U; Schmiegel, W; Pohl, M; Stoehlmacher, J; Folprecht, G; Probst, S; Prasnikar, N; Fischbach, W; Mahlberg, R; Trojan, J; Koenigsmann, M; Martens, UM; Thuss-Patience, P; Egger, M; Block, A; Heinemann, V; Illerhaus, G; Moehler, M; Schenk, M; Kullmann, F; Behringer, DM; Heike, M; Pink, D; Teschendorf, C; Lohr, C; Bernhard, H; Schuch, G; Rethwisch, V; von Weikersthal, LF; Hartmann, JT; Kneba, M; Daum, S; Schulmann, K; Weniger, J; Belle, S; Gaiser, T; Oduncu, FS; Guntner, M; Hozaeel, W; Reichart, A; Jager, E; Kraus, T; Monig, S; Bechstein, WO; Schuler, M; Schmalenberg, H; Hofheinz, RD				Al-Batran, Salah-Eddin; Homann, Nils; Pauligk, Claudia; Goetze, Thorsten O.; Meiler, Johannes; Kasper, Stefan; Kopp, Hans-Georg; Mayer, Frank; Haag, Georg Martin; Luley, Kim; Lindig, Udo; Schmiegel, Wolff; Pohl, Michael; Stoehlmacher, Jan; Folprecht, Gunnar; Probst, Stephan; Prasnikar, Nicole; Fischbach, Wolfgang; Mahlberg, Rolf; Trojan, Joerg; Koenigsmann, Michael; Martens, Uwe M.; Thuss-Patience, Peter; Egger, Matthias; Block, Andreas; Heinemann, Volker; Illerhaus, Gerald; Moehler, Markus; Schenk, Michael; Kullmann, Frank; Behringer, Dirk M.; Heike, Michael; Pink, Daniel; Teschendorf, Christian; Loehr, Carmen; Bernhard, Helga; Schuch, Gunter; Rethwisch, Volker; von Weikersthal, Ludwig Fischer; Hartmann, Joerg T.; Kneba, Michael; Daum, Severin; Schulmann, Karsten; Weniger, Joerg; Belle, Sebastian; Gaiser, Timo; Oduncu, Fuat S.; Guentner, Martina; Hozaeel, Wael; Reichart, Alexander; Jaeger, Elke; Kraus, Thomas; Moenig, Stefan; Bechstein, Wolf O.; Schuler, Martin; Schmalenberg, Harald; Hofheinz, Ralf D.		FLOT4-AIO Investigators	Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial	LANCET			English	Article							OPEN-LABEL; CANCER; MULTICENTER; CHEMORADIOTHERAPY; RESECTION; SURGERY; ESOPHAGEAL; REGRESSION; STOMACH	Background Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and docetaxel) as a perioperative therapy for patients with locally advanced, resectable tumours. Methods In this controlled, open-label, phase 2/3 trial, we randomly assigned 716 patients with histologically-confirmed advanced clinical stage cT2 or higher or nodal positive stage (cN+), or both, resectable tumours, with no evidence of distant metastases, via central interactive web-based-response system, to receive either three pre-operative and three postoperative 3-week cycles of 50 mg/m(2) epirubicin and 60 mg/m(2) cisplatin on day 1 plus either 200 mg/m(2) fluorouracil as continuous intravenous infusion or 1250 mg/m(2) capecitabine orally on days 1 to 21 (ECF/ECX; control group) or four preoperative and four postoperative 2-week cycles of 50 mg/m(2) docetaxel, 85 mg/m(2) oxaliplatin, 200 mg/m(2) leucovorin and 2600 mg/m(2) fluorouracil as 24-h infusion on day 1 (FLOT; experimental group). The primary outcome of the trial was overall survival (superiority) analysed in the intention-to-treat population. This trial is registered with ClinicalTrials. gov, number NCT01216644. Findings Between Aug 8, 2010, and Feb 10, 2015, 716 patients were randomly assigned to treatment in 38 German hospitals or with practice-based oncologists. 360 patients were assigned to ECF/ECX and 356 patients to FLOT. Overall survival was increased in the FLOT group compared with the ECF/ECX group (hazard ratio [HR] 0.77; 95% confidence interval [CI; 0.63 to 0.94]; median overall survival, 50 months [38.33 to not reached] vs 35 months [27.35 to 46.26]). The number of patients with related serious adverse events (including those occurring during hospital stay for surgery) was similar in the two groups (96 [27%] in the ECF/ECX group vs 97 [27%] in the FLOT group), as was the number of toxic deaths (two [<1%] in both groups). Hospitalisation for toxicity occurred in 94 patients (26%) in the ECF/ECX group and 89 patients (25%) in the FLOT group. Interpretation In locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma, perioperative FLOT improved overall survival compared with perioperative ECF/ECX. Copyright (C) 2019 Elsevier Ltd. All rights reserved.	[Al-Batran, Salah-Eddin; Pauligk, Claudia; Goetze, Thorsten O.] Krankenhaus NW Frankfurt, UCT Univ Canc Ctr, Inst Clin Canc Res, D-60488 Frankfurt, Germany; [Al-Batran, Salah-Eddin; Pauligk, Claudia; Goetze, Thorsten O.] Krankenhaus NW Frankfurt, IKF Klin Krebsforsch GmbH, Frankfurt, Germany; [Homann, Nils] Klinikum Wolfsburg, Wolfsburg, Germany; [Meiler, Johannes; Kasper, Stefan; Schuler, Martin] Univ Duisburg Essen, Dept Med Oncol, West German Canc Ctr, Essen, Germany; [Schuler, Martin] Partner Site Univ Hosp Essen, German Canc Consortium DKTK, Essen, Germany; [Kopp, Hans-Georg] RBCT, Stuttgart, Germany; [Mayer, Frank] Univ Klinikum Eberhard Karls Univ, Med Klin 2, Abt Onkol Hamatol Immunol Rheumatol Pneumol, Tubingen, Germany; [Haag, Georg Martin] Univ Klinikum Heidelberg, Natl Ctr Tumorerkrankungen, Abt Med Onkol, Heidelberg, Germany; [Luley, Kim] Univ Klinikum Schleswig Holstein, Klin Hamatol & Onkol, Lubeck, Germany; [Lindig, Udo] Univ Klinikum Jena, Klin Innere Med 2, Abt Hamatol & Onkol, Jena, Germany; [Schmiegel, Wolff; Pohl, Michael] Ruhr Univ Bochum, Dept Med, Univ Klinikum Knappschaftskrankenhaus Bochum GmbH, Bochum, Germany; [Schmiegel, Wolff] Ruhr Univ Bochum, Berufsgenossenschaftliches Univ Klinikum Bergmann, Dept Gastroenterol & Hepatol, Bochum, Germany; [Stoehlmacher, Jan; Folprecht, Gunnar] Univ Klinikum Carl Gustav Carus, Med Klin & Poliklin 1, Dresden, Germany; [Probst, Stephan] Klinikum Bielefeld, Klin Hamatol & Onkol, Bielefeld, Germany; [Prasnikar, Nicole] Asklepios Klin Barmbek, Hamatol Onkol & Palliat Med, Hamburg, Germany; [Fischbach, Wolfgang] Klinikum Aschaffenburg, Med Klin 2, Gastroenterol & Onkol, Aschaffenburg, Germany; [Mahlberg, Rolf] Klinikum Mutterhaus Borromaerinnen, Med Klin 1, Trier, Germany; [Trojan, Joerg] Goethe Univ, Univ Klinikum Frankfurt, Med Klin 1, Frankfurt, Germany; [Koenigsmann, Michael] Gesell Med Stat & Projektentwicklung, MediProjekt, Hannover, Germany; [Martens, Uwe M.] SLK Kliniken GmbH, Canc Ctr Heilbronn Franken, Klin Innere Med 3, Heilbronn, Germany; [Thuss-Patience, Peter] Charite Univ Med Berlin, Med Klin S Hamatol Onkol & Tumorimmunol, Berlin, Germany; [Daum, Severin] Charite Univ Med Berlin, Klin Gastroenterol Infektiol & Rheumatol, Berlin, Germany; [Egger, Matthias] Ortenau Klinikum Lahr, Med Klin, Gastroenterol & Onkol, Sekt Hamatol & Onkol, Lahr, Germany; [Block, Andreas] Univ Klinikum Hamburg Eppendorf, Med Klin & Poliklin Onkol Hamatol 2, UCCH, KMT,Sekt Pneumol, Hamburg, Germany; [Heinemann, Volker] Klinikum Univ Munchen, Med Klin & Poliklin 3, Campus Grosshadern, Munich, Germany; [Illerhaus, Gerald] Klinikum Stuttgart, Klin Hamatol Onkol & Palliat Med, Stuttgart, Germany; [Moehler, Markus] Johannes Gutenberg Univ Mainz, Med Klin & Poliklin 1, Mainz, Germany; [Schenk, Michael] Krankenhaus Barmherzige Bruder Regensburg, Klin Onkol & Hamatol, Regensburg, Germany; [Kullmann, Frank] Klinikum Weiden, Med Klin 1, Weiden, Germany; [Behringer, Dirk M.] Augusta Krankenanstalt Bochum, Klin Hamatol & Onkol, Bochum, Germany; [Heike, Michael] Klinikum Dortmund gGmbH, Med Klin, Gastroenterol Hamatol Onkol Endokrinol, Dortmund, Germany; [Pink, Daniel] Helios Klinikum Bad Saarow, Klin Hamatol Onkol & Palliat Med, Bad Saarow Pieskow, Germany; [Pink, Daniel] Univ Med Greifswald, Klin & Poliklin Innere Med C, Hamatol & Onkol & Transplantat Zentrum, Greifswald, Germany; [Teschendorf, Christian] St Josefs Hosp, Innere Med Klin, Dortmund, Germany; [Loehr, Carmen] Horst Schmidt Kliniken, Innere Med 2, Wiesbaden, Germany; [Bernhard, Helga] Klinikum Darmstadt, Med Klin 5, Hamatol & Onkol, Darmstadt, Germany; [Schuch, Gunter] HOPA, Hamburg, Germany; [Rethwisch, Volker] Klinikum Dortmund gGmbH, Med Klin, Gastroenterol Hamatol Onkol Endokrinol, Dortmund, Germany; [von Weikersthal, Ludwig Fischer] MVZ Gesundheitszentrum St Marien GmbH, Hamatol Internist Onkol, Amberg, Germany; [Hartmann, Joerg T.] Franziskus Hosp Bielefeld, Catholic Hosp Consortium Eastern Westphalia, Klin Innere Med Hamatol Internist Onkol Immunol 2, Bielefeld, Germany; [Kneba, Michael] Univ Clin Schleswig Holstein, Klin Innere Med Hamatol & Onkol 2, Campus Kiel, Kiel, Germany; [Schulmann, Karsten] MVZ Arnsberg, Praxis Hamatol & Onkol, Arnsberg, Germany; [Belle, Sebastian] Univ Med Mannheim, Med Klin 2, Mannheim, Germany; [Gaiser, Timo] Univ Med Mannheim, Inst Pathol, Mannheim, Germany; [Oduncu, Fuat S.] Klinikum Univ Munchen, Med Klin & Poliklin 3, Munich, Germany; [Guentner, Martina] Trium Anal Online, Munich, Germany; [Hozaeel, Wael] Marienhospital, MVZ Onkol GmbH, Hagen, Germany; [Reichart, Alexander; Jaeger, Elke] Krankenhaus NW Frankfurt, UCT Univ Canc Ctr, Klin Onkol & Hamatol, Frankfurt, Germany; [Kraus, Thomas] Krankenhaus NW Frankfurt, UCT Univ Canc Ctr, Klin Allgemein Viszeral & Minimal Invas Chirurg, Frankfurt, Germany; [Moenig, Stefan] Hop Univ Geneve, Serv Chirurg Viscerale, Geneva, Switzerland; [Bechstein, Wolf O.] Frankfurt Univ Hosp & Clin, Dept Gen & Visceral Surg, Frankfurt, Germany; [Schmalenberg, Harald] Univ Klinikum Jena, Klin Innere Med 2, Abt Hamatol & Internist Onkol, Jena, Germany; [Hofheinz, Ralf D.] Univ Med Mannheim, Tagestherapiezentrum ITM, Med Klin 3, Mannheim, Germany	Krankenhaus Nordwest; Krankenhaus Nordwest; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); Eberhard Karls University of Tubingen; University of Hamburg; University Medical Center Hamburg-Eppendorf; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Kiel; Schleswig Holstein University Hospital; Friedrich Schiller University of Jena; Ruhr University Bochum; Ruhr University Bochum; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Klinikum Stuttgart; Johannes Gutenberg University of Mainz; Klinikum Dortmund; Helios Kliniken; Greifswald Medical School; Klinikum Darmstadt; Klinikum Dortmund; University of Kiel; Schleswig Holstein University Hospital; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ruprecht Karls University Heidelberg; University of Munich; St. Marien Hospital; Krankenhaus Nordwest; Krankenhaus Nordwest; University of Geneva; Friedrich Schiller University of Jena; Ruprecht Karls University Heidelberg	Al-Batran, SE (corresponding author), Krankenhaus NW Frankfurt, UCT Univ Canc Ctr, Inst Clin Canc Res, D-60488 Frankfurt, Germany.	albatran@ikf-khnw.de	Pink, Daniel/A-1084-2014; Folprecht, Gunnar/F-8638-2011; Haag, Georg Martin/AAB-6323-2022; Kasper, Stefan/I-4521-2015; Schulmann, Karsten/N-2230-2016	Pink, Daniel/0000-0001-7243-7373; Folprecht, Gunnar/0000-0002-9321-9911; Kasper, Stefan/0000-0002-5947-8733; Kopp, Hans-Georg/0000-0002-0825-8888; Daum, Severin/0000-0003-0060-6013	German Cancer Aid (Deutsche Krebshilfe); Chugai; Stiftung Leben mit Krebs Foundation; Sanofi-Aventis	German Cancer Aid (Deutsche Krebshilfe)(Deutsche Krebshilfe); Chugai; Stiftung Leben mit Krebs Foundation; Sanofi-Aventis(Sanofi-Aventis)	The German Cancer Aid (Deutsche Krebshilfe), Sanofi-Aventis, Chugai, and Stiftung Leben mit Krebs Foundation.	Al-Batran SE, 2008, ANN ONCOL, V19, P1882, DOI 10.1093/annonc/mdn403; Al-Batran SE, 2017, JAMA ONCOL, V3, P1237, DOI 10.1001/jamaoncol.2017.0515; Al-Batran SE, 2016, LANCET ONCOL, V17, P1697, DOI 10.1016/S1470-2045(16)30531-9; Alderson D, 2017, LANCET ONCOL, V18, P1249, DOI 10.1016/S1470-2045(17)30447-3; Becker K, 2003, CANCER-AM CANCER SOC, V98, P1521, DOI 10.1002/cncr.11660; Cats A, 2018, LANCET ONCOL, V19, P616, DOI 10.1016/S1470-2045(18)30132-3; Cunningham D, 2017, LANCET ONCOL, V18, P357, DOI 10.1016/S1470-2045(17)30043-8; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; Ford HER, 2014, LANCET ONCOL, V15, P78, DOI 10.1016/S1470-2045(13)70549-7; Freidlin B, 2007, J CLIN ONCOL, V25, P5019, DOI 10.1200/JCO.2007.11.8711; Fuchs CS, 2017, J CLIN ONCOL, V35, P3671, DOI 10.1200/JCO.2017.74.2130; Homann N, 2012, INT J CANCER, V130, P1706, DOI 10.1002/ijc.26180; Low DE, 2019, ANN SURG, V269, P291, DOI 10.1097/SLA.0000000000002611; Macdonald JS, 2001, NEW ENGL J MED, V345, P725, DOI 10.1056/NEJMoa010187; Moehler M, 2011, Z GASTROENTEROL, V49, P461, DOI 10.1055/s-0031-1273201; Schulz C, 2015, INT J CANCER, V137, P678, DOI 10.1002/ijc.29403; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Siewert JR, 1998, BRIT J SURG, V85, P1457; Van Cutsem E, 2006, J CLIN ONCOL, V24, P4991, DOI 10.1200/JCO.2006.06.8429; van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088; Ychou M, 2011, J CLIN ONCOL, V29, P1715, DOI 10.1200/JCO.2010.33.0597; 2013, EUR J CANCER, V49, P835, DOI DOI 10.1016/J.EJCA.2012.09.025	22	874	913	5	99	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 11	2019	393	10184					1948	1957		10.1016/S0140-6736(18)32557-1	http://dx.doi.org/10.1016/S0140-6736(18)32557-1			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX9AE	30982686				2023-01-03	WOS:000467698100030
J	Jeon, MY; Kim, HS; Lim, TS; Han, DH; Kim, BK; Park, JY; Kim, DY; Ahn, SH; Choi, GH; Choi, JS; Han, KH; Kim, SU				Jeon, Mi Young; Kim, Hye Soo; Lim, Tae Seop; Han, Dai Hoon; Kim, Beom Kyung; Park, Jun Yong; Kim, Do Young; Ahn, Sang Hoon; Choi, Gi Hong; Choi, Jin Sub; Han, Kwang-Hyub; Kim, Seung Up			Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection	PLOS ONE			English	Article							CLINICAL-PRACTICE GUIDELINES; MANAGEMENT; SORAFENIB; CRITERIA; OUTCOMES; STAGE	Background/Aims It is important to identify patients who are refractory to transarterial chemoembolization (TACE), which is performed for the treatment of hepatocellular carcinoma (HCC). We investigated the predictors of poor treatment outcomes in patients with recurrent HCC treated who were treated with TACE after curative resection. Methods 428 patients with recurrent HCC after curative resection who were treated with TACE were enrolled. Results The median age of the study population was 59.2 years. On multivariate analysis, >= 2 TACE procedures within 6 months (hazard ratio [HR] = 1.898), and the des-gamma carboxyprothrombin level (HR = 1.000) independently predicted the progression to Barcelona Clinic Liver Cancer (BCLC) stage C in patients with BCLC stage 0-B HCC (both P<0.05). In addition, >= 2 and >= 3 TACE procedures within 6 months independently predicted mortality in the entire study population (HR = 1.863 and 1.620, respectively). The probability of progression to BCLC stage C in patients with BCLC stage 0-B HCC and the mortality rate in the entire study population were significantly higher in patients treated with >= 2 TACE within 6 months than in those who underwent fewer procedures (P= 0.002 and P<0.001, respectively). Conclusions More than 2 TACE procedures within 6 months might be associated with the refractoriness to TACE in patients with recurrent HCC after curative resection.	[Jeon, Mi Young; Kim, Hye Soo; Lim, Tae Seop; Kim, Beom Kyung; Park, Jun Yong; Kim, Do Young; Ahn, Sang Hoon; Han, Kwang-Hyub; Kim, Seung Up] Yonsei Univ, Coll Med, Inst Gastroenterol, Dept Internal Med, Seoul, South Korea; [Jeon, Mi Young; Lim, Tae Seop; Han, Dai Hoon; Kim, Beom Kyung; Park, Jun Yong; Kim, Do Young; Ahn, Sang Hoon; Choi, Gi Hong; Choi, Jin Sub; Han, Kwang-Hyub; Kim, Seung Up] Severance Hosp, Yonsei Liver Ctr, Seoul, South Korea; [Han, Dai Hoon; Choi, Gi Hong; Choi, Jin Sub] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Kim, SU (corresponding author), Yonsei Univ, Coll Med, Inst Gastroenterol, Dept Internal Med, Seoul, South Korea.; Kim, SU (corresponding author), Severance Hosp, Yonsei Liver Ctr, Seoul, South Korea.	ksukorea@yuhs.ac	Han, Dai Hoon/AAS-3726-2021	Han, Dai Hoon/0000-0003-2787-7876; LIM, TAE SEOP/0000-0002-4578-8685; Han, Kwang-Hyub/0000-0003-3960-6539; Kim, Beom Kyung/0000-0002-5363-2496; Kim, Seung Up/0000-0002-9658-8050; Ahn, Sang Hoon/0000-0002-3629-4624; Park, Jun Yong/0000-0001-6324-2224; Jeon, Mi Young/0000-0002-3980-4503; Choi, Gi Hong/0000-0002-1593-3773	Basic Science Research Program through the National Research Foundation of Korea - Ministry of Science, ICT & Future Planning [2016R1A1A1A05005138]	Basic Science Research Program through the National Research Foundation of Korea - Ministry of Science, ICT & Future Planning	This study was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning (2016R1A1A1A05005138). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI 10.1016/j.ejca.2011.12.021; Jeon MY, 2018, LIVER INT, V38, P1655, DOI 10.1111/liv.13731; Kim BK, 2015, J HEPATOL, V62, P1304, DOI 10.1016/j.jhep.2015.01.022; Kim BK, 2013, EUR J CANCER, V49, P826, DOI 10.1016/j.ejca.2012.08.022; Kim BK, 2012, LIVER INT, V32, P1120, DOI 10.1111/j.1478-3231.2012.02811.x; Kim HY, 2012, J GASTROEN HEPATOL, V27, P1051, DOI 10.1111/j.1440-1746.2011.06963.x; Kim JY, 2016, CLIN MOL HEPATOL, V22, P250, DOI 10.3350/cmh.2016.0015; Kim JH, 2017, CLIN MOL HEPATOL, V23, P42, DOI 10.3350/cmh.2016.0058; Korean Liver Cancer Study Group and National Cancer Center Korea, 2009, Korean J Hepatol, V15, P391, DOI 10.3350/kjhep.2009.15.3.391; Kudo M, 2014, LIVER CANCER, V3, P458, DOI 10.1159/000343875; Kudo M, 2014, ONCOLOGY-BASEL, V87, P22, DOI 10.1159/000368142; Kudo M, 2012, LIVER CANCER, V1, P62, DOI 10.1159/000342402; Kudo M, 2011, DIGEST DIS, V29, P339, DOI 10.1159/000327577; Lee JM, 2016, CLIN MOL HEPATOL, V22, P160, DOI 10.3350/cmh.2016.22.1.160; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Lo CM, 2002, HEPATOLOGY, V35, P1164, DOI 10.1053/jhep.2002.33156; Mitchell DG, 2015, HEPATOLOGY, V61, P1056, DOI 10.1002/hep.27304; Park Y, 2016, LIVER INT, V36, P100, DOI 10.1111/liv.12878; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Poon RTP, 2000, ANN SURG, V232, P10, DOI 10.1097/00000658-200007000-00003; Raoul JL, 2014, LIVER CANCER, V3, P119, DOI 10.1159/000343867; Rosen HR, 2017, HEPATOLOGY, V66, P1020, DOI 10.1002/hep.29361; Takayasu K, 2006, GASTROENTEROLOGY, V131, P461, DOI 10.1053/j.gastro.2006.05.021; Xu XC, 2018, INT J PHARMACEUT, V542, P153, DOI 10.1016/j.ijpharm.2018.03.018; Yamamoto Y, 2015, WORLD J GASTROENTERO, V21, P1207, DOI 10.3748/wjg.v21.i4.1207; Yu SJ, 2016, CLIN MOL HEPATOL, V22, P7, DOI 10.3350/cmh.2016.22.1.7; Yuen MF, 2000, HEPATOLOGY, V31, P330, DOI 10.1002/hep.510310211	29	4	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2019	14	4							e0214613	10.1371/journal.pone.0214613	http://dx.doi.org/10.1371/journal.pone.0214613			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR7EH	30947275	Green Published, gold, Green Submitted			2023-01-03	WOS:000463314500045
J	Hander, T; Fernandez-Fernandez, AD; Kumpf, RP; Willems, P; Schatowitz, H; Rombaut, D; Staes, A; Nolf, J; Pottie, R; Yao, PF; Goncalves, A; Pavie, B; Boller, T; Gevaert, K; Van Breusegem, F; Bartels, S; Stael, S				Hander, Tim; Fernandez-Fernandez, Alvaro D.; Kumpf, Robert P.; Willems, Patrick; Schatowitz, Hendrik; Rombaut, Debbie; Staes, An; Nolf, Jonah; Pottie, Robin; Yao, Panfeng; Goncalves, Amanda; Pavie, Benjamin; Boller, Thomas; Gevaert, Kris; Van Breusegem, Frank; Bartels, Sebastian; Stael, Simon			Damage on plants activates Ca2+-dependent metacaspases for release of immunomodulatory peptides	SCIENCE			English	Article							ELICITOR PEPTIDES; ARABIDOPSIS-THALIANA; ENDOGENOUS PEPTIDE; CRYSTAL-STRUCTURE; CELL-DEATH; RECEPTOR; SIGNAL; IMMUNITY; DEFENSE; CONTRIBUTES	Physical damage to cells leads to the release of immunomodulatory peptides to elicit a wound defense response in the surrounding tissue. In Arabidopsis thaliana, the plant elicitor peptide 1 (Pep1) is processed from its protein precursor, PRECURSOR OF PEP1 (PROPEP1). We demonstrate that upon damage, both at the tissue and single-cell levels, the cysteine protease METACASPASE4 (MC4) is instantly and spatiotemporally activated by binding high levels of Ca2+ and is necessary and sufficient for Pep1 maturation. Cytosol-localized PROPEP1 and MC4 react only after loss of plasma membrane integrity and prolonged extracellular Ca2+ entry. Our results reveal that a robust mechanism consisting of conserved molecular components links the intracellular and Ca2+-dependent activation of a specific cysteine protease with the maturation of damage-induced wound defense signals.	[Hander, Tim; Schatowitz, Hendrik; Boller, Thomas; Bartels, Sebastian] Univ Basel, Dept Environm Sci, Zurich Basel Plant Sci Ctr, CH-4056 Basel, Switzerland; [Fernandez-Fernandez, Alvaro D.; Kumpf, Robert P.; Willems, Patrick; Rombaut, Debbie; Nolf, Jonah; Pottie, Robin; Yao, Panfeng; Van Breusegem, Frank; Stael, Simon] Univ Ghent, Dept Plant Biotechnol & Bioinformat, B-9052 Ghent, Belgium; [Fernandez-Fernandez, Alvaro D.; Kumpf, Robert P.; Willems, Patrick; Rombaut, Debbie; Nolf, Jonah; Pottie, Robin; Yao, Panfeng; Van Breusegem, Frank; Stael, Simon] VIB UGent Ctr Plant Syst Biol, B-9052 Ghent, Belgium; [Willems, Patrick; Staes, An; Gevaert, Kris; Stael, Simon] Univ Ghent, Dept Biomol Med, B-9000 Ghent, Belgium; [Willems, Patrick; Staes, An; Gevaert, Kris; Stael, Simon] VIB UGent Ctr Med Biotechnol, B-9000 Ghent, Belgium; [Goncalves, Amanda; Pavie, Benjamin] VIB UGent Ctr Inflammat Res IRC, VIB BioImaging Core Gent, B-9052 Ghent, Belgium; [Bartels, Sebastian] Univ Freiburg, Univ Hosp Freiburg, Dept Med 2, Fac Med, D-79106 Freiburg, Germany	University of Basel; Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; University of Freiburg	Stael, S (corresponding author), Univ Ghent, Dept Plant Biotechnol & Bioinformat, B-9052 Ghent, Belgium.; Stael, S (corresponding author), VIB UGent Ctr Plant Syst Biol, B-9052 Ghent, Belgium.; Stael, S (corresponding author), Univ Ghent, Dept Biomol Med, B-9000 Ghent, Belgium.; Stael, S (corresponding author), VIB UGent Ctr Med Biotechnol, B-9000 Ghent, Belgium.	simon.stael@psb.vib-ugent.be	Gevaert, Kris/D-6489-2017; Stael, Simon/AAW-7948-2020; Van Breusegem, Frank/Y-2999-2019; Van Breusegem, Frank/AAJ-2647-2020; Boller, Thomas/G-3500-2012; Willems, Patrick/X-3986-2018; Fernandez-Fernandez, Alvaro Daniel/ABC-7187-2020; Gevaert, Kris/AAE-4212-2019	Gevaert, Kris/0000-0002-4237-0283; Stael, Simon/0000-0001-8322-0428; Van Breusegem, Frank/0000-0002-3147-0860; Boller, Thomas/0000-0001-6768-7503; Willems, Patrick/0000-0003-4667-2294; Gevaert, Kris/0000-0002-4237-0283; Fernandez Fernandez, Alvaro Daniel/0000-0003-4770-9757; Pavie, Benjamin/0000-0002-0249-3844; Pottie, Robin/0000-0003-2401-0994; Goncalves, Amanda Maffioletti Mac Cord/0000-0003-2748-3033; yao, panfeng/0000-0003-1291-3555	Swiss National Science Foundation [31003A_127563]; Research Foundation-Flanders [G.0C37.14N, FWO14/PDO/166]; Ghent University Special Research Fund [01J11311]; CLEM grant	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Research Foundation-Flanders(FWO); Ghent University Special Research Fund(Ghent University); CLEM grant	This work was supported by the Swiss National Science Foundation (grant 31003A_127563 to T.B.), the Research Foundation-Flanders (grant G.0C37.14N to K.G. and FWO14/PDO/166 to S.S.), the Ghent University Special Research Fund (grant 01J11311 to F.V.B.), and a CLEM grant from Minister Ingrid Lieten (Belgium) for the acquisition of the Zeiss LSM780 microscope.	Acosta-Maspons A, 2014, PLANTA, V239, P147, DOI 10.1007/s00425-013-1975-0; Bartels S, 2015, J EXP BOT, V66, P5183, DOI 10.1093/jxb/erv180; Bartels S, 2013, J EXP BOT, V64, P5309, DOI 10.1093/jxb/ert330; Behera S, 2018, PLANT CELL, V30, P2704, DOI 10.1105/tpc.18.00655; Beloshistov RE, 2018, NEW PHYTOL, V218, P1167, DOI 10.1111/nph.14568; Coll NS, 2010, SCIENCE, V330, P1393, DOI 10.1126/science.1194980; Costa A, 2017, J EXP BOT, V68, P3215, DOI 10.1093/jxb/erx162; Deutsch CA, 2018, SCIENCE, V361, P916, DOI 10.1126/science.aat3466; Fortin J, 2018, PLANT J, V96, P921, DOI 10.1111/tpj.14079; Ghorbani S, 2016, J EXP BOT, V67, P4877, DOI 10.1093/jxb/erw241; Heil M, 2014, FRONT PLANT SCI, V5, DOI 10.3389/fpls.2014.00578; Himschoot E, 2018, METHODS MOL BIOL, V1761, P115, DOI 10.1007/978-1-4939-7747-5_9; Huffaker A, 2006, P NATL ACAD SCI USA, V103, P10098, DOI 10.1073/pnas.0603727103; Huffaker A, 2013, P NATL ACAD SCI USA, V110, P5707, DOI 10.1073/pnas.1214668110; Klauser D, 2015, J EXP BOT, V66, P5327, DOI 10.1093/jxb/erv250; Kohler D, 2015, PLANT PHYSIOL, V167, P972, DOI 10.1104/pp.114.255562; Krol E, 2010, J BIOL CHEM, V285, P13471, DOI 10.1074/jbc.M109.097394; Liu C., 2017, BIORXIV, DOI [10.1101/140962, DOI 10.1101/140962]; Lori M, 2015, J EXP BOT, V66, P5315, DOI 10.1093/jxb/erv236; MCGURL B, 1992, SCIENCE, V255, P1570, DOI 10.1126/science.1549783; McLuskey K, 2012, P NATL ACAD SCI USA, V109, P7469, DOI 10.1073/pnas.1200885109; Minina EA, 2014, METHODS MOL BIOL, V1133, P237, DOI 10.1007/978-1-4939-0357-3_15; Pearce G, 2008, PEPTIDES, V29, P2083, DOI 10.1016/j.peptides.2008.08.019; Poncini L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185808; Razzell W, 2013, CURR BIOL, V23, P424, DOI 10.1016/j.cub.2013.01.058; Ross A, 2014, EMBO J, V33, P62, DOI 10.1002/embj.201284303; Schardon K, 2016, SCIENCE, V354, P1594, DOI 10.1126/science.aai8550; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Shannon EK, 2017, BIOPHYS J, V113, P1623, DOI 10.1016/j.bpj.2017.07.022; Stael S, 2012, J EXP BOT, V63, P1525, DOI 10.1093/jxb/err394; Stes E, 2014, J PROTEOME RES, V13, P3107, DOI 10.1021/pr4012443; Tang J, 2015, CELL RES, V25, P110, DOI 10.1038/cr.2014.161; Tintor N, 2013, P NATL ACAD SCI USA, V110, P6211, DOI 10.1073/pnas.1216780110; Toyota M, 2018, SCIENCE, V361, P1112, DOI 10.1126/science.aat7744; Tsiatsiani L, 2011, CELL DEATH DIFFER, V18, P1279, DOI 10.1038/cdd.2011.66; Tsiatsiani L, 2013, PLANT CELL, V25, P2831, DOI 10.1105/tpc.113.115287; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(00)00094-0; Venne AS, 2015, PROTEOMICS, V15, P2458, DOI 10.1002/pmic.201500014; Vercammen D, 2004, J BIOL CHEM, V279, P45329, DOI 10.1074/jbc.M406329200; Vercammen D, 2006, J MOL BIOL, V364, P625, DOI 10.1016/j.jmb.2006.09.010; Watanabe N, 2011, PLANT J, V66, P969, DOI 10.1111/j.1365-313X.2011.04554.x; Watanabe N, 2011, J BIOL CHEM, V286, P10027, DOI 10.1074/jbc.M110.194340; Wen S, 2013, FEBS LETT, V587, P2517, DOI 10.1016/j.febslet.2013.06.057; Willems P., 2018, BIORXIV, DOI [10.1101/415802, 10.1101/140962415802, DOI 10.1101/415802]; Willems P, 2017, MOL CELL PROTEOMICS, V16, P1064, DOI [10.1074/mcp.M116.066662, 10.1074/mcp.m116.066662]; Wong AHH, 2012, J BIOL CHEM, V287, P29251, DOI 10.1074/jbc.M112.381806; Wrzaczek M, 2015, EMBO J, V34, P55, DOI 10.15252/embj.201488582; Yamada K, 2016, EMBO J, V35, P46, DOI 10.15252/embj.201591807; Yamaguchi Y, 2010, PLANT CELL, V22, P508, DOI 10.1105/tpc.109.068874; Zhang HT, 2018, NEW PHYTOL, V218, P1106, DOI 10.1111/nph.14909	50	101	102	8	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 22	2019	363	6433					1301	+	eaar7486	10.1126/science.aar7486	http://dx.doi.org/10.1126/science.aar7486			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP9MD	30898901				2023-01-03	WOS:000462016400043
J	Shawe, J; Patel, D; Joy, M; Howden, B; Barrett, G; Stephenson, J				Shawe, Jill; Patel, Dilisha; Joy, Mark; Howden, Beth; Barrett, Geraldine; Stephenson, Judith			Preparation for fatherhood: A survey of men's preconception health knowledge and behaviour in England	PLOS ONE			English	Article							BODY-MASS INDEX; SEMEN QUALITY; LIFE-STYLE; DRUG-USE; REPRODUCTIVE HORMONES; UNINTENDED PREGNANCY; UNPLANNED PREGNANCY; PATERNAL SMOKING; BIRTH OUTCOMES; RISK-FACTORS	Methods A cross-sectional survey of men attending antenatal care with their partners at three London Maternity Units. We assessed level of pregnancy planning using the partner version of the London Measure of Unplanned Pregnancy (LMUP), preconception health behaviours, and whether they had sought information and health professional advice before conception. Main results We recruited 573 men (91% response rate). Mean age was 34 years, 86% were in employment or full time education and 66% had a degree. Half were overweight or obese, 16% were still smoking and 79% had consumed alcohol in the three months before conception. Of 250 men answering questions about medication, a third were taking medication with potentially adverse effects on male reproductive health, while 23% reported taking pre-pregnancy vitamins. 46.9% had looked at information about pregnancy from a variety of sources, including online, before their partner became pregnant. Assessed by the LMUP, 74% of pregnancies were planned. Male 'planners' were more likely than other men to reduce smoking, reduce alcohol consumption and to eat more healthily in preparation for pregnancy. However, 57% took no action to improve their health. Significance of the findings In a sample of relatively educated men accompanying their partners on an antenatal visit, nearly half had made at least one positive health behaviour change before pregnancy, but half were overweight or obese and a third were on medication that could impair male reproductive health. These findings, together with a high prevalence of alcohol consumption and smoking, indicate the need for greater paternal preconception health awareness and care. Innovative ways to promote positive messages about fatherhood, including medication review as part of preconception care, should be evaluated for impact on improving paternal reproductive health and pregnancy and neonatal outcomes.	[Shawe, Jill] Univ Plymouth, Inst Hlth & Community, Plymouth, Devon, England; [Shawe, Jill; Patel, Dilisha; Barrett, Geraldine; Stephenson, Judith] UCL, Inst Womens Hlth, London, England; [Joy, Mark] Univ Surrey, Sch Hlth Sci, Guildford, Surrey, England; [Howden, Beth] Univ Bristol, Bristol Med Sch, Bristol, Avon, England	University of Plymouth; University of London; University College London; University of Surrey; University of Bristol	Patel, D (corresponding author), UCL, Inst Womens Hlth, London, England.	dilisha.patel@ucl.ac.uk		Patel, Dilisha/0000-0002-3746-8171; SHAWE, JILL/0000-0002-2766-7302; Joy, Mark/0000-0002-4974-3724; Howden, Benjamin/0000-0003-0237-1473; Barrett, Geraldine/0000-0002-9738-1051	Policy Research Programme of the Department of Health [006/0068]	Policy Research Programme of the Department of Health	The study was funded by the Policy Research Programme of the Department of Health, http://www.prp-ccf.org.uk. The PRP Reference number for the project is 006/0068. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agricola E, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0156-6; Agricola E, 2014, BMC MED INFORM DECIS, V14, DOI 10.1186/1472-6947-14-33; Alio AP, 2012, AM J MENS HEALTH, V6, P427, DOI 10.1177/1557988312440718; Allstaff S, 2012, OBSTET GYNAECOL, V14, P25, DOI 10.1111/j.1744-4667.2011.00088.x; Amaral S, 2008, CURR DIABETES REV, V4, P46, DOI 10.2174/157339908783502398; Association BM, 2016, ALC PREGN PREV MAN F; Barrett G, 2004, J EPIDEMIOL COMMUN H, V58, P426, DOI 10.1136/jech.2003.014787; Barwell P, 2009, J PRIM HEALTH CARE, V1, P311, DOI 10.1071/HC09311; Bodin M, 2017, UPSALA J MED SCI, V122, P127, DOI 10.1080/03009734.2017.1316531; Bortolus R, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-016-1198-z; Brezina Paul R, 2012, J Reprod Infertil, V13, P3; Campbell F, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-491; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; Casey FE, 2016, AM J MENS HEALTH, V10, P59, DOI 10.1177/1557988314556670; Cheng D, 2009, CONTRACEPTION, V79, P194, DOI 10.1016/j.contraception.2008.09.009; Choi J, 2013, PREV MED, V56, P351, DOI 10.1016/j.ypmed.2013.02.021; Choiriyyah I, 2015, MATERN CHILD HLTH J, V19, P2358, DOI 10.1007/s10995-015-1753-7; Christiansen C, 2013, M DEV GLOBAL CONSENS; Craig JR, 2017, FERTIL STERIL, V107, DOI 10.1016/j.fertnstert.2017.02.115; Crijns I, 2012, EXPERT OPIN DRUG SAF, V11, P513, DOI 10.1517/14740338.2012.674109; D'Onofrio BM, 2014, AGE GAUGE OLDER FATH; D'Onofrio BM, 2014, JAMA PSYCHIAT, V71, P432, DOI 10.1001/jamapsychiatry.2013.4525; De Jonge CJ, 2006, SPERM CELL PRODUCTIO; Deng K, 2013, BIRTH DEFECTS RES A, V97, P210, DOI 10.1002/bdra.23128; Eisenberg ML, 2015, FERTIL STERIL, V103, P1271, DOI 10.1016/j.fertnstert.2015.02.010; Ekstrand M, 2007, EUR J CONTRACEP REPR, V12, P111, DOI 10.1080/13625180701201145; Engeland A, 2008, BRIT J CLIN PHARMACO, V65, P653, DOI 10.1111/j.1365-2125.2008.03102.x; Fleming TP, 2018, LANCET; Frey KA, 2012, J MENS HEALTH, V9, P25, DOI 10.1016/j.jomh.2011.11.001; Frey KA, 2008, AM J OBSTET GYNECOL, V199, pS389, DOI 10.1016/j.ajog.2008.10.024; Gavin L, 2014, MMWR RECOMM REP, V63, P1; Gluckman PD, 2009, NAT REV ENDOCRINOL, V5, P401, DOI 10.1038/nrendo.2009.102; Gynaecologists RCoO, 2015, RCOG REL ALC PREGN D; Hall JA, 2017, PATIENT-RELAT OUTCOM, V8, P43, DOI 10.2147/PROM.S122420; Hall JA, 2017, MATERN CHILD HLTH J, V21, P670, DOI 10.1007/s10995-016-2237-0; Hammiche F, 2012, HUM REPROD, V27, P2365, DOI 10.1093/humrep/des177; Hammiche F, 2011, HUM REPROD, V26, P2432, DOI 10.1093/humrep/der225; Hammoud AO, 2008, FERTIL STERIL, V90, P2222, DOI 10.1016/j.fertnstert.2007.10.011; Harvey S, WHY ARE MEN RETICENT; Hawkes S, 2013, LANCET, V381, P1783, DOI 10.1016/S0140-6736(13)60253-6; Health Do, 2016, HLTH RISKS ALC NEW G; HELLER CG, 1964, RECENT PROG HORM RES, V20, P545; Hogberg H, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3338-9; Hultman CM, 2011, MOL PSYCHIATR, V16, P1203, DOI 10.1038/mp.2010.121; Inskip HM, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b481; Jensen TK, 2006, OCCUP MED-OXFORD, V56, P544, DOI 10.1093/occmed/kql116; Jensen TK, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005462; Jensen TK, 2004, FERTIL STERIL, V82, P863, DOI 10.1016/j.fertnstert.2004.03.056; Kotelchuck M, 2017, MATERN CHILD HLTH J, V21, P2025, DOI 10.1007/s10995-017-2370-4; Kunzle R, 2003, FERTIL STERIL, V79, P287, DOI 10.1016/S0015-0282(02)04664-2; Lakha F, 2006, LANCET, V368, P1782, DOI 10.1016/S0140-6736(06)69737-7; Lassi ZS, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-S3-S7; Le Tortorec A, 2010, INT J ANDROL, V33, pE98, DOI 10.1111/j.1365-2605.2009.00973.x; Levine H, 2017, HUM REPROD UPDATE, V23, P646, DOI 10.1093/humupd/dmx022; Liu R., 2011, J ONCOLOGY, V2011; McCrory C, 2013, PAEDIATR PERINAT EP, V27, P208, DOI 10.1111/ppe.12027; McGrath JJ, 2014, JAMA PSYCHIAT, V71, P301, DOI 10.1001/jamapsychiatry.2013.4081; Merzenich H, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-24; Millsop JW, 2013, DERMATOL THER, V26, P337, DOI 10.1111/dth.12069; Misra DP, 2010, AM J OBSTET GYNECOL, V202, P99, DOI 10.1016/j.ajog.2009.11.031; Mitchell EW, 2012, MATERN CHILD HLTH J, V16, P31, DOI 10.1007/s10995-010-0663-y; Moos MK, 2010, J WOMENS HEALTH, V19, P561, DOI 10.1089/jwh.2009.1411; Moss JL, 2015, ARCH GYNECOL OBSTET, V291, P287, DOI 10.1007/s00404-014-3521-0; NICE, 2018, NICE GUID BEH CHANG; NICE, 2017, PREC ADV MAN; NICE, 2018, BRIT NAT FORM ON LIN; Ojukwu O, 2016, UPSALA J MED SCI, V121, P256, DOI 10.1080/03009734.2016.1215853; Povey AC, 2012, HUM REPROD, V27, P2799, DOI 10.1093/humrep/des183; Qin DD, 2007, ASIAN J ANDROL, V9, P827, DOI 10.1111/j.1745-7262.2007.00268.x; Robbins CL, 2018, J WOMENS HEALTH, V27, P430, DOI 10.1089/jwh.2017.6531; Sallmen M, 2006, EPIDEMIOLOGY, V17, P520, DOI 10.1097/01.ede.0000229953.76862.e5; Schirm E, 2004, PHARMACOEPIDEM DR S, V13, P609, DOI 10.1002/pds.959; Semet M, 2017, ANDROLOGY-US, V5, P640, DOI 10.1111/andr.12366; Sermondade N, 2012, REPROD BIOMED ONLINE, V24, P206, DOI 10.1016/j.rbmo.2011.10.014; Sharpe RM, 2010, PHILOS T R SOC B, V365, P1697, DOI 10.1098/rstb.2009.0206; Shawe J, 2015, EUR J CONTRACEP REPR, V20, P77, DOI 10.3109/13625187.2014.990088; Singh AK, 2014, TYPE 2 DIABETES MELL; Smith JL, 2011, SEX REPROD HEALTHC, V2, P37, DOI 10.1016/j.srhc.2010.10.002; Stephenson J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103085; Stern J, 2013, HUM REPROD, V28, P2450, DOI 10.1093/humrep/det279; Sternberg P, 2004, HEALTH PROMOT INT, V19, P389, DOI 10.1093/heapro/dah312; Svanes C, 2017, INT J EPIDEMIOL, V46, P235, DOI 10.1093/ije/dyw151; Trummer H, 2002, HUM REPROD, V17, P1554, DOI 10.1093/humrep/17.6.1554; van der Zee B, 2013, AM J OBSTET GYNECOL, V209, P11, DOI 10.1016/j.ajog.2013.01.009; Van Dijk Matthijs R, 2016, JMIR Mhealth Uhealth, V4, pe53, DOI 10.2196/mhealth.5197; van Dijk MR, 2017, REPROD BIOMED ONLINE, DOI [10.1016/j.rbmo.2017.06, DOI 10.1016/J.RBMO.2017.06]; Verbiest S, 2016, UPSALA J MED SCI, V121, P222, DOI 10.1080/03009734.2016.1204395; VINE MF, 1994, FERTIL STERIL, V61, P35; Wang YY, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003320; Warner JN, 2013, J AM BOARD FAM MED, V26, P196, DOI 10.3122/jabfm.2013.02.120143; Wellings K, 2013, LANCET, V382, P1807, DOI 10.1016/S0140-6736(13)62071-1; White A, 2011, STATE MENS HLTH EURO; Wright C, 2014, REPROD BIOMED ONLINE, V28, P684, DOI 10.1016/j.rbmo.2014.02.004; ZHANG J, 1992, INT J EPIDEMIOL, V21, P273, DOI 10.1093/ije/21.2.273	94	25	26	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2019	14	3							e0213897	10.1371/journal.pone.0213897	http://dx.doi.org/10.1371/journal.pone.0213897			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HP6AW	30893380	Green Published, Green Submitted, gold			2023-01-03	WOS:000461765900059
J	Stower, H				Stower, Hannah			Direct-to-stomach delivery	NATURE MEDICINE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2019	25	3					358	358		10.1038/s41591-019-0397-3	http://dx.doi.org/10.1038/s41591-019-0397-3			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	HO1CO	30842670	Bronze			2023-01-03	WOS:000460643100006
J	O'Leary, JD; Orser, BA				O'Leary, James D.; Orser, Beverley A.			Neurodevelopment after general anaesthesia in infants	LANCET			English	Editorial Material							AWAKE-REGIONAL ANESTHESIA; AGE; MULTICENTER; GAS		[O'Leary, James D.; Orser, Beverley A.] Univ Toronto, Dept Anaesthesia, Toronto, ON M5G 1E2, Canada	University of Toronto	O'Leary, JD (corresponding author), Univ Toronto, Dept Anaesthesia, Toronto, ON M5G 1E2, Canada.	james.oleary@utoronto.ca						Davidson AJ, 2018, ANESTHESIOLOGY, V128, P840, DOI 10.1097/ALN.0000000000001972; Davidson AJ, 2016, LANCET, V387, P239, DOI 10.1016/S0140-6736(15)00608-X; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Jevtovic-Todorovic V, 2018, ANESTHESIOLOGY, V128, P832, DOI 10.1097/ALN.0000000000002047; Kharasch ED, 2018, ANESTHESIOLOGY, V128, P693, DOI 10.1097/ALN.0000000000002122; Lin EP, 2017, NEUROTOXICOL TERATOL, V60, P117, DOI 10.1016/j.ntt.2016.10.008; McCann ME, 2019, LANCET, V393, P664, DOI 10.1016/S0140-6736(18)32485-1; Sun LS, 2016, JAMA-J AM MED ASSOC, V315, P2312, DOI 10.1001/jama.2016.6967; US Food and Drug Administration, 2017, DRUG SAF COMM APPR L; Warner DO, 2018, ANESTHESIOLOGY, V129, P89, DOI 10.1097/ALN.0000000000002232	10	4	4	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 16	2019	393	10172					614	615		10.1016/S0140-6736(18)32985-4	http://dx.doi.org/10.1016/S0140-6736(18)32985-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HL6AX	30782331				2023-01-03	WOS:000458817300006
J	Chen, KY; Ko, YC; Hsieh, MJ; Chiang, WC; Ma, MHM				Chen, Kuan-Yu; Ko, Ying-Chih; Hsieh, Ming-Ju; Chiang, Wen-Chu; Ma, Matthew Huei-Ming			Interventions to improve the quality of bystander cardiopulmonary resuscitation: A systematic review	PLOS ONE			English	Review							CHEST COMPRESSION DEPTH; DISPATCHER-ASSISTED CPR; ASSOCIATION GUIDELINES UPDATE; HOSPITAL CARDIAC-ARREST; BASIC LIFE-SUPPORT; FEEDBACK DEVICE; ONLY CPR; INSTRUCTIONS; RESCUER; TRIAL	Background Performing high-quality bystander cardiopulmonary resuscitation (CPR) improves the clinical outcomes of victims with sudden cardiac arrest. Thus far, no systematic review has been performed to identify interventions associated with improved bystander CPR quality. Methods We searched Ovid MEDLINE, Ovid EMBASE, EBSCO CI NAHL, Ovid Psyclnfo, Thomson Reuters SCI-EXPANDED, and the Cochrane Central Register of Controlled Trials to retrieve studies published from 1 January 1966 to 5 October 2018 associated with interventions that could improve the quality of bystander CPR. Data regarding participant characteristics, interventions, and design and outcomes of included studies were extracted. Results Of the initially identified 2,703 studies, 42 were included. Of these, 32 were randomized controlled trials. Participants included adults, high school students, and university students with non-medical professional majors. Interventions improving bystander CPR quality included telephone dispatcher-assisted CPR (DA-CPR) with simplified or more concrete instructions, compression-only CPR, and other on-scene interventions, such as four-hand CPR for elderly rescuers, kneel on opposite sides for two-person CPR, and CPR with heels for a tired rescuer. Devices providing real-time feedback and mobile devices containing CPR applications or software were also found to be beneficial in improving the quality of bystander CPR. However, using mobile devices for improving CPR quality or for assisting DA-CPR might cause rescuers to delay starting CPR. Conclusions To further improve the clinical outcomes of victims with cardiac arrest, these effective interventions may be included in the guidelines for bystander CPR.	[Chen, Kuan-Yu; Ma, Matthew Huei-Ming] Natl Taiwan Univ, Coll Med, Taipei, Taiwan; [Ko, Ying-Chih; Hsieh, Ming-Ju] Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei, Taiwan; [Chiang, Wen-Chu; Ma, Matthew Huei-Ming] Natl Taiwan Univ Hosp, Dept Emergency Med, Yun Lin Branch, Douliou City, Yun Lin County, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Ma, MHM (corresponding author), Natl Taiwan Univ, Coll Med, Taipei, Taiwan.; Hsieh, MJ (corresponding author), Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei, Taiwan.; Ma, MHM (corresponding author), Natl Taiwan Univ Hosp, Dept Emergency Med, Yun Lin Branch, Douliou City, Yun Lin County, Taiwan.	erdrmjhsieh@gmail.com; mattma.tw@gmail.com	CHEN, KUANYU/ADS-2415-2022; CHIANG, WEN-CHU/AAH-6057-2021	CHEN, KUANYU/0000-0003-0528-982X; CHIANG, WEN-CHU/0000-0001-8620-7982; HSIEH, MING-JU/0000-0003-3636-6250; MA, MATTHEW HUEI-MING/0000-0002-4388-9984	Taiwan Ministry of Science and Technology [MOST 105-2314-13-002-026, MOST 105-2314-B-002 -200 -MY3, MOST 107-2314-B-002 -001, MOST 106-2314-B-002-091]; National Taiwan University Hospital [108-09]	Taiwan Ministry of Science and Technology; National Taiwan University Hospital(National Taiwan University)	The article was supported by the Taiwan Ministry of Science and Technology (MOST 105-2314-13-002-026, MOST 105-2314-B-002 -200 -MY3, MOST 107-2314-B-002 -001 and MOST 106-2314-B-002-091) and National Taiwan University Hospital (108-09).	[Anonymous], 1966, J AMER MED ASSOC, V198, P372; Atkinson PRT, 1999, J TELEMED TELECARE, V5, P242, DOI 10.1258/1357633991933783; Atwood C, 2005, RESUSCITATION, V67, P75, DOI 10.1016/j.resuscitation.2005.03.021; Birkenes TS, 2014, RESUSCITATION, V85, P124, DOI 10.1016/j.resuscitation.2013.09.015; Birkenes TS, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-47; Birkenes TS, 2012, RESUSCITATION, V83, P494, DOI 10.1016/j.resuscitation.2011.09.021; Bohn A, 2011, RESUSCITATION, V82, P257, DOI 10.1016/j.resuscitation.2010.11.006; Bolle SR, 2009, ACTA ANAESTH SCAND, V53, P116, DOI 10.1111/j.1399-6576.2008.01779.x; Brown TB, 2008, RESUSCITATION, V76, P249, DOI 10.1016/j.resuscitation.2007.07.026; Buleon C, 2013, AM J EMERG MED, V31, P1457, DOI 10.1016/j.ajem.2013.07.029; Cabrini L, 2010, HEART LUNG VESSEL, V2, P279; Chavez DE, 2013, RESUSCITATION, V84, P979, DOI 10.1016/j.resuscitation.2012.12.010; Deeks JJ, 2009, COCHRANE HDB SYSTEMA, DOI [10.1253/circj.CJ-14-1258, DOI 10.1253/CIRCJ.CJ-14-1258]; Dias JA, 2007, RESUSCITATION, V72, P108, DOI 10.1016/j.resuscitation.2006.04.018; Eaton G, 2018, HEALTH INFORM J, V24, P14, DOI 10.1177/1460458216652645; Ghuysen A, 2011, RESUSCITATION, V82, P57, DOI 10.1016/j.resuscitation.2010.09.014; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Heidenreich JW, 2012, J EMERG MED, V42, P88, DOI 10.1016/j.jemermed.2010.05.019; Hurst V, 2007, RESUSCITATION, V73, P123, DOI 10.1016/j.resuscitation.2006.07.027; Jones A, 2015, RESUSCITATION, V90, P50, DOI 10.1016/j.resuscitation.2015.01.036; KELLERMANN AL, 1989, CIRCULATION, V80, P1231, DOI 10.1161/01.CIR.80.5.1231; Kim YH, 2015, J KOREAN MED SCI, V30, P1347, DOI 10.3346/jkms.2015.30.9.1347; Kramer-Johansen J, 2006, RESUSCITATION, V71, P283, DOI 10.1016/j.resuscitation.2006.05.011; Krikscionaitiene A, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0238-z; Kronick SL, 2015, CIRCULATION, V132, pS397, DOI 10.1161/CIR.0000000000000258; Lee JS, 2011, RESUSCITATION, V82, P64, DOI 10.1016/j.resuscitation.2010.09.467; Liu S, 2016, CAN J EMERG MED, V18, P461, DOI 10.1017/cem.2016.373; Liu YS, 2018, AM J EMERG MED, V36, P1980, DOI 10.1016/j.ajem.2018.02.034; Lopez-Gonzalez A, 2016, AM J EMERG MED, V34, P1845, DOI 10.1016/j.ajem.2016.06.058; Merchant RM, 2010, ANN EMERG MED, V55, P538, DOI 10.1016/j.annemergmed.2010.01.020; Mirza M, 2008, RESUSCITATION, V79, P97, DOI 10.1016/j.resuscitation.2008.05.012; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; Monsieurs KG, 2015, RESUSCITATION, V95, P1, DOI 10.1016/j.resuscitation.2015.07.038; Neset A, 2010, RESUSCITATION, V81, P887, DOI 10.1016/j.resuscitation.2010.03.028; Neumar RW, 2015, CIRCULATION, V132, pS315, DOI 10.1161/CIR.0000000000000252; Nikandish R, 2008, RESUSCITATION, V76, P256, DOI 10.1016/j.resuscitation.2007.07.032; Nishiyama C, 2010, RESUSCITATION, V81, P1152, DOI 10.1016/j.resuscitation.2010.05.008; Paal P, 2012, J EMERG MED, V43, P472, DOI 10.1016/j.jemermed.2011.09.011; Painter I, 2014, RESUSCITATION, V85, P1169, DOI 10.1016/j.resuscitation.2014.05.015; Park SO, 2013, EMERG MED J, V30, P658, DOI 10.1136/emermed-2012-201612; Perkins GD, 2015, RESUSCITATION, V95, pE43, DOI 10.1016/j.resuscitation.2015.07.041; Rasmussen SE, 2017, RESUSCITATION, V110, P74, DOI 10.1016/j.resuscitation.2016.09.009; Rea TD, 2001, CIRCULATION, V104, P2513, DOI 10.1161/hc4601.099468; Rodriguez SA, 2014, RESUSCITATION, V85, P119, DOI 10.1016/j.resuscitation.2013.09.003; Rossler B, 2013, RESUSCITATION, V84, P982, DOI 10.1016/j.resuscitation.2013.01.001; Sakai T, 2015, CIRC J, V79, P1052, DOI 10.1253/circj.CJ-14-1258; Scott G, 2018, PREHOSP DISASTER MED, V33, P399, DOI 10.1017/S1049023X18000602; Spelten O, 2016, EUR J ANAESTH, V33, P575, DOI 10.1097/EJA.0000000000000432; Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z; Stiell I, 2003, CIRCULATION, V108, P1939, DOI 10.1161/01.CIR.0000095028.95929.B0; Stiell IG, 2014, CIRCULATION, V130, P1962, DOI 10.1161/CIRCULATIONAHA.114.008671; Stipulante S, 2016, EUR J EMERG MED, V23, P418, DOI 10.1097/MEJ.0000000000000338; Torney H, 2016, IEEE T HUM-MACH SYST, V46, P749, DOI 10.1109/THMS.2016.2561267; Trenkamp RH, 2015, AM J EMERG MED, V33, P1449, DOI 10.1016/j.ajem.2015.06.070; Vadeboncoeur T, 2014, RESUSCITATION, V85, P182, DOI 10.1016/j.resuscitation.2013.10.002; van Tulder R, 2014, RESUSCITATION, V85, P112, DOI 10.1016/j.resuscitation.2013.08.010; VANHOEYWEGHEN RJ, 1993, RESUSCITATION, V26, P47, DOI 10.1016/0300-9572(93)90162-J; White AE, 2017, SINGAP MED J, V58, P438, DOI 10.11622/smedj.2017072; Williams JG, 2006, PREHOSP EMERG CARE, V10, P247, DOI 10.1080/10903120500541027; Woollard M, 2003, RESUSCITATION, V59, P123, DOI 10.1016/S0300-9572(03)00174-6; Wutzler A, 2018, MED KLIN-INTENSIVMED, V113, P124, DOI 10.1007/s00063-017-0278-9; Yang CW, 2008, RESUSCITATION, V78, P327, DOI 10.1016/j.resuscitation.2008.03.232; Yang CW, 2009, CRIT CARE MED, V37, P490, DOI 10.1097/CCM.0b013e31819573a5	63	26	26	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2019	14	2							e0211792	10.1371/journal.pone.0211792	http://dx.doi.org/10.1371/journal.pone.0211792			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL5IX	30759140	gold, Green Published, Green Submitted			2023-01-03	WOS:000458761300057
J	Steyaert, S; Holvoet, E; Nagler, E; Malfait, S; Van Biesen, W				Steyaert, Sanne; Holvoet, Els; Nagler, Evi; Malfait, Simon; Van Biesen, Wim			Reporting of "dialysis adequacy" as an outcome in randomised trials conducted in adults on haemodialysis	PLOS ONE			English	Article							QUALITY-OF-LIFE; CHRONIC KIDNEY-DISEASE; SINGLE-POOL KT/V; VARIABLE-VOLUME; UREMIC TOXINS; PROTEIN DIET; PATIENT; UREA; DIALYZERS; REMOVAL	Background Clinical trials are most informative for evidence-based decision-making when they consistently measure and report outcomes of relevance to stakeholders, especially patients, clinicians, and policy makers. However, sometimes terminology used is interpreted differently by different stakeholders, which might lead to confusion during shared decision making. The construct dialysis adequacy is frequently used, suggesting it is an important outcome both for health care professionals as for patients. Objective To assess the scope and consistency of the construct dialysis adequacy as reported in ran-domised controlled trials in hemodialysis, and evaluate whether these align to the insights and understanding of this construct by patients. Methods To assess scope and consistency of dialysis adequacy by professionals, we performed a systematic review searching the Cochrane Central Register of Controlled Trials (CENTRAL) up to July 2017. We identified all randomised controlled trails (RCT) including patients on hemodialysis and reporting dialysis adequacy, adequacy or adequacy of dialysis and extracted and classified all reported outcomes. To explore interpretation and meaning of the construct of adequacy by patients, we conducted 11 semi-structured interviews with HD patients using thematic analysis. Belgian registration number B670201731001. Findings From the 31 included trials, we extracted and classified 98 outcome measures defined by the authors as adequacy of dialysis, of which 94 (95%) were biochemical, 3 (3%) non-biochemical surrogate and 2 (2%) patient-relevant. The three most commonly reported measures were all biochemical. None of the studies defined adequacy of dialysis as a patient relevant outcome such as survival or quality of life. Patients had a substantially different understanding of the construct dialysis adequacy than the biochemical interpretation reported in the literature. Being alive, time spent while being on dialysis, fatigue and friendliness of staff were the most prominent themes that patients linked to the construct of dialysis adequacy. Conclusion Adequacy of dialysis as reported in the literature refers to biochemical outcome measures, most of which are not related with patient relevant outcomes. For patients, adequate dialysis is a dialysis that enables them to spend as much quality time in their life as possible.	[Steyaert, Sanne; Holvoet, Els; Nagler, Evi; Van Biesen, Wim] Ghent Univ Hosp, Div Renal, Dept Internal Med, Ghent, Belgium; [Malfait, Simon] Univ Ghent, Univ Ctr Nursing & Midwifery, Dept Publ Hlth, Fac Med & Hlth Sci, Ghent, Belgium	Ghent University; Ghent University Hospital; Ghent University	Van Biesen, W (corresponding author), Ghent Univ Hosp, Div Renal, Dept Internal Med, Ghent, Belgium.	wim.vanbiesen@ugent.be	Malfait, Simon/AAB-9895-2020	Van Biesen, Wim/0000-0002-4782-5224				Afaghi E., 2016, NEPHROUROL MON, V8, pe34993, DOI [10.5812/numonthly.34993, DOI 10.5812/NUMONTHLY.34993]; Ando H, 2014, COMPREHENSIVE PSYCHO, V3, P1, DOI [10.2466/03.CP.3.4, 10.2466/03.CP.3.4,03.CP.3.4]; Atherikul K, 1998, NEPHROL DIAL TRANSPL, V13, P745, DOI 10.1093/ndt/13.3.745; Basile C, 2011, NEPHROL DIAL TRANSPL, V26, P1296, DOI 10.1093/ndt/gfq543; BLACKMORE D, 1961, J CLIN PATHOL, V14, P455, DOI 10.1136/jcp.14.5.455; Chang CT, 2002, NEPHROL DIAL TRANSPL, V17, P1978, DOI 10.1093/ndt/17.11.1978; Chassin MR, 2010, NEW ENGL J MED, V363, P683, DOI 10.1056/NEJMsb1002320; Chow J, 2011, J REN CARE, V37, P85, DOI 10.1111/j.1755-6686.2011.00211.x; Cohen SD, 2013, SEMIN DIALYSIS, V26, P697, DOI 10.1111/sdi.12124; Couser WG, 2011, KIDNEY INT, V80, P1258, DOI 10.1038/ki.2011.368; Daugirdas J T, 1995, Adv Ren Replace Ther, V2, P295; Daugirdas J T, 1990, ASAIO Trans, V36, pM362; Daugirdas JT, 2008, SEMIN DIALYSIS, V21, P415, DOI 10.1111/j.1525-139X.2008.00482.x; Daugirdas JT, 2013, NEPHROL DIAL TRANSPL, V28, P2156, DOI 10.1093/ndt/gfs115; Daugirdas JT, 2013, KIDNEY INT, V83, P9, DOI 10.1038/ki.2012.365; DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205; DAUGIRDAS JT, 1993, AM J KIDNEY DIS, V22, P267, DOI 10.1016/S0272-6386(12)70317-7; DeOreo PB, 1997, AM J KIDNEY DIS, V30, P204, DOI 10.1016/S0272-6386(97)90053-6; Depner T, 1999, AM J KIDNEY DIS, V33, P142, DOI 10.1016/S0272-6386(99)70272-6; Depner T, 2004, KIDNEY INT, V65, P1386, DOI 10.1111/j.1523-1755.2004.00519.x; Dhondt A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128634; Duranton F, 2012, J AM SOC NEPHROL, V23, P1258, DOI 10.1681/ASN.2011121175; Eknoyan G, 2002, NEW ENGL J MED, V347, P2010, DOI 10.1056/NEJMoa021583; Eloot S, 2008, KIDNEY INT, V73, P765, DOI 10.1038/sj.ki.5002750; Eloot S, 2005, KIDNEY INT, V67, P1566, DOI 10.1111/j.1523-1755.2005.00238.x; Eloot S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076838; Evangelidis N, 2017, AM J KIDNEY DIS, V70, P464, DOI 10.1053/j.ajkd.2016.11.029; Figueras N, 2012, ELT J, V66, P477, DOI 10.1093/elt/ccs037; Flythe JE, 2013, KIDNEY INT, V83, P104, DOI 10.1038/ki.2012.346; Fritz BA, 2003, AM J KIDNEY DIS, V41, P1008, DOI 10.1016/S0272-6386(03)00198-7; Furuland H, 2005, J NEPHROL, V18, P80; Greene T, 2005, J AM SOC NEPHROL, V16, P3371, DOI 10.1681/ASN.2005030321; Gutzwiller JP, 2002, NEPHROL DIAL TRANSPL, V17, P1037, DOI 10.1093/ndt/17.6.1037; Hwang HS, 2012, SEMIN DIALYSIS, V25, P587, DOI 10.1111/j.1525-139X.2012.01054.x; Islam MS, 2016, AM J KIDNEY DIS, V68, P752, DOI 10.1053/j.ajkd.2016.05.013; Ito S, 2014, TOXINS, V6, P665, DOI 10.3390/toxins6020665; Kirkman DL, 2013, AM J NEPHROL, V38, P475, DOI 10.1159/000356340; Kloppenburg WD, 2004, NEPHROL DIAL TRANSPL, V19, P1212, DOI 10.1093/ndt/gfh044; Krieter DH, 2005, KIDNEY INT, V67, P349, DOI 10.1111/j.1523-1755.2005.00088.x; Lee MB, 2016, CLIN J AM SOC NEPHRO, V11, P1083, DOI 10.2215/CJN.13261215; Li HM, 2011, BLOOD PURIFICAT, V31, P33, DOI 10.1159/000321376; Liabeuf S, 2010, NEPHROL DIAL TRANSPL, V25, P1183, DOI 10.1093/ndt/gfp592; Locatelli F, 2000, NEPHROL DIAL TRANSPL, V15, P1399, DOI 10.1093/ndt/15.9.1399; Longtin Y, 2010, MAYO CLIN PROC, V85, P53, DOI 10.4065/mcp.2009.0248; LOWRIE EG, 1981, NEW ENGL J MED, V305, P1176, DOI 10.1056/NEJM198111123052003; Maarten Boers JRK, 2017, OMERACT HDB OMERACT; Mactier RA, 1997, NEPHROL DIAL TRANSPL, V12, P1182, DOI 10.1093/ndt/12.6.1182; Martins AM, 2015, J RENAL NUTR, V25, P321, DOI 10.1053/j.jrn.2014.10.007; McClellan WM, 2004, J AM SOC NEPHROL, V15, P754, DOI 10.1097/01.ASN.0000115701.51613.D7; Meert N, 2011, NEPHROL DIAL TRANSPL, V26, P2624, DOI 10.1093/ndt/gfq803; Morton RL, 2011, NEPHROL DIAL TRANSPL, V26, P4038, DOI 10.1093/ndt/gfr177; Nassar GM, 2014, SEMIN DIALYSIS, V27, P310, DOI 10.1111/sdi.12173; Palmer SC, 2011, AM J KIDNEY DIS, V58, P335, DOI 10.1053/j.ajkd.2011.06.006; Parker KP, 1997, J AM SOC NEPHROL, V8, P288; Pereira BJG, 1996, J AM SOC NEPHROL, V7, P861; Perl J, 2017, CLIN J AM SOC NEPHRO, V12, P839, DOI 10.2215/CJN.08460816; Pippias M, 2017, CLIN KIDNEY J, V10, P154, DOI 10.1093/ckj/sfw135; Power A, 2014, J VASC ACCESS, V15, P108, DOI 10.5301/jva.5000202; Powers KM, 2000, AM J KIDNEY DIS, V35, P266, DOI 10.1016/S0272-6386(00)70336-2; Richardson D, 2003, AM J KIDNEY DIS, V42, P551, DOI 10.1016/S0272-6386(03)00788-1; Rocha AD, 2014, HEMODIAL INT, V18, P467, DOI 10.1111/hdi.12113; Sangthawan PA, 2011, NEPHROLOGY, V6, P3, DOI [10.1046/j.1440-1797.2001.00022.x, DOI 10.1046/J.1440-1797.2001.00022.X]; Saunders B, 2018, QUAL QUANT, V52, P1893, DOI 10.1007/s11135-017-0574-8; Sehgal AR, 2002, JAMA-J AM MED ASSOC, V287, P1961, DOI 10.1001/jama.287.15.1961; STIGGELBOUT AM, 2012, BRIT MED J, V344; Tawney KW, 2000, AM J KIDNEY DIS, V36, P581, DOI 10.1053/ajkd.2000.16197; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Tong A, 2017, NEPHROL DIAL TRANSPL, V32, P1963, DOI 10.1093/ndt/gfx288; Tong A, 2017, AM J KIDNEY DIS, V69, P97, DOI 10.1053/j.ajkd.2016.05.022; Tong A, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0895-7; Urquhart-Secord R, 2016, AM J KIDNEY DIS, V68, P444, DOI 10.1053/j.ajkd.2016.02.037; Valderrabano F, 2001, AM J KIDNEY DIS, V38, P443, DOI 10.1053/ajkd.2001.26824; Vanholder R, 2015, KIDNEY INT, V88, P460, DOI 10.1038/ki.2015.155; Vanholder R, 2015, SEMIN DIALYSIS, V28, P114, DOI 10.1111/sdi.12331; Wang WJ, 2008, AM J KIDNEY DIS, V51, P796, DOI 10.1053/j.ajkd.2007.12.031	75	11	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2019	14	2							e0207045	10.1371/journal.pone.0207045	http://dx.doi.org/10.1371/journal.pone.0207045			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK2MO	30721242	Green Published, Green Submitted, gold			2023-01-03	WOS:000457746300001
J	Backman, C; Johnston, S; Oelke, ND; Burns, KK; Hughes, L; Gifford, W; Lacroix, J; Forster, AJ				Backman, Chantal; Johnston, Sharon; Oelke, Nelly D.; Burns, Katharina Kovacs; Hughes, Linda; Gifford, Wendy; Lacroix, Jeanie; Forster, Alan J.			Safe and effective person- and family-centered care practices during transitions from hospital to home-A web-based Delphi technique	PLOS ONE			English	Article							PATIENT SAFETY; INTERVENTIONS; INFORMATION	Background Research has shown that adverse events during care transitions from hospital to home can have a significant impact on patients' outcomes, leading to readmission, delayed healing or even death. Gaps exist in the ways of monitoring care during transition periods and there is a need to help organizations better implement and monitor safe person- and family-centered care. Value statements are a way to obtain narratives in lay terms about how well care, treatment and support is organized to meet the needs and preferences of patients/families. The purpose of this study was to identify the value statements that are perceived by decisio-nmakers and patients/families to best signify safe person- and family-centered care during transitions from hospital to home. Methods Between January and September 2017, a web-based Delphi was used to survey key stake-holders in acute care and home care organizations across Canada. Results Decision-makers (n = 22) and patients/families (n = 24) from five provinces participated in the Delphi. Following Round 1, 45 perceived value statements were identified. In Round 2, consensus was received on 33/45 (73.3%) by decision-makers, and 30/45 (66.7%) by patients/families. In Round 3, additional value statements reached consensus in the decision-makers' survey (3) and in the patients/families' survey (2). A total of 30 high priority value statements achieved consensus derived from both the decision-makers' and patients/families' perspectives. Conclusion This study was an important first step in identifying key consensus-based priority value statements for monitoring care transitions from the perspective of both decision-makers and patients/families. Future research is needed to test their usability and to determine whether these value statements are actually suggestive of safe person- and family-centered care transition interventions from hospital to home.	[Backman, Chantal; Gifford, Wendy] Univ Ottawa, Sch Nursing, Fac Hlth Sci, Ottawa, ON, Canada; [Backman, Chantal; Forster, Alan J.] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; [Backman, Chantal; Johnston, Sharon] Bruyere Res Inst, Ottawa, ON, Canada; [Johnston, Sharon; Forster, Alan J.] Univ Ottawa, Fac Med, Ottawa, ON, Canada; [Oelke, Nelly D.] Univ British Columbia, Sch Nursing, Fac Hlth & Social Dev, Kelowna, BC, Canada; [Burns, Katharina Kovacs; Hughes, Linda] Patients Patient Safety Canada, Edmonton, AB, Canada; [Burns, Katharina Kovacs] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada; [Lacroix, Jeanie] Canadian Inst Hlth Informat, Toronto, ON, Canada; [Backman, Chantal] Univ Ottawa, Fac Hlth Sci, Ottawa, ON, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of British Columbia; University of Alberta; Canadian Institute Health Information; University of Ottawa	Backman, C (corresponding author), Univ Ottawa, Sch Nursing, Fac Hlth Sci, Ottawa, ON, Canada.; Backman, C (corresponding author), Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.; Backman, C (corresponding author), Bruyere Res Inst, Ottawa, ON, Canada.; Backman, C (corresponding author), Univ Ottawa, Fac Hlth Sci, Ottawa, ON, Canada.	chantal.backman@uottawa.ca	Backman, Chantal/AAV-1661-2020; Kovacs Burns, Katharina/AAA-5993-2022	Backman, Chantal/0000-0001-7431-8159; Kovacs Burns, Katharina/0000-0002-6322-0778	Canadian Patient Safety Institute; Accreditation Canada; Canadian Home Care Association; Patients for Patient Safety Canada; Registered Nurses' Association of Ontario	Canadian Patient Safety Institute; Accreditation Canada; Canadian Home Care Association; Patients for Patient Safety Canada; Registered Nurses' Association of Ontario	We would like to thank the Canadian Patient Safety Institute, Accreditation Canada, the Canadian Home Care Association, Patients for Patient Safety Canada, and the Registered Nurses' Association of Ontario for financially supporting this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen J, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-346; ANDERSON RM, 1995, DIABETES CARE, V18, P943, DOI 10.2337/diacare.18.7.943; [Anonymous], 2010, DELPHI TECHNIQUE NUR; Backman C, 2017, SYST REV-LONDON, V6, DOI 10.1186/s13643-017-0554-z; Bate P, 2006, QUAL SAF HEALTH CARE, V15, P307, DOI 10.1136/qshc.2005.016527; Boivin A, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-24; Carman KL, 2013, HEALTH AFFAIR, V32, P223, DOI 10.1377/hlthaff.2012.1133; Charmel P, 2008, HEALTHC FINANC MANAG, pI; CIHI, 2013, PUBL ENG SUMM REP HL; Coleman EA, 2004, ANN INTERN MED, V141, P533, DOI 10.7326/0003-4819-141-7-200410050-00009; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Coleman K, 2009, HEALTH AFFAIR, V28, P75, DOI 10.1377/hlthaff.28.1.75; Dillman DA, 2009, TAILORED DESIGN METH, Vthird; Entwistle V A, 1998, J Health Serv Res Policy, V3, P100; Epstein R, 2010, HLTH AFF, V9, P1489; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Gerhardt Geoffrey, 2013, Medicare Medicaid Res Rev, V3, DOI 10.5600/mmrr.003.02.b01; Graham C., 2013, DEV MEASURES PEOPLES; Institute for Patient- and Family-Centered Care (IPFCC), WHAT IS PAT FAM CTR; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Laugaland K, 2012, WORK, V41, P2915, DOI 10.3233/WOR-2012-0544-2915; Li J, 2014, CLEV CLIN J MED, V81, P312, DOI 10.3949/ccjm.81a.13106; McMurray J, 2013, HEALTH INFORM J, V19, P218, DOI 10.1177/1460458212467547; Medicare C for Baltimore MS 7500 SB Usa M, 2016, READM RED PROGR; Naylor MD, 2010, SCALING BRING TRANSI, P103; Osborn R, 2012, J AMBUL CARE MANAG, V35, P118, DOI 10.1097/JAC.0b013e31824a579b; Parrish MM, 2009, PROF CASE MANAG, V14, P282, DOI 10.1097/NCM.0b013e3181c3d380; Redding D, 2013, J INTEGR CARE, V21, P315, DOI 10.1108/JICA-06-2013-0018; Registered Nurses' Association of Ontario (RNAO), 2015, CLIN BEST PRACT GUID; RNAO, 2014, CLIN BEST PRACT GUID; Wier LM, 2006, HEALTHCARE COST UTIL	31	5	5	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2019	14	1							e0211024	10.1371/journal.pone.0211024	http://dx.doi.org/10.1371/journal.pone.0211024			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HI2WF	30668588	Green Published, Green Submitted, gold			2023-01-03	WOS:000456306400027
J	Zhou, H; Wang, AQ; Huang, XN; Guo, SF; Yang, YN; Martin, K; Tian, XB; Josephs-Spaulding, J; Ma, CY; Scherpbier, RW; Wang, Y				Zhou, Hong; Wang, Anqi; Huang, Xiaona; Guo, Sufang; Yang, Yuning; Martin, Kathryn; Tian, Xiaobo; Josephs-Spaulding, Jonathan; Ma, Chuyang; Scherpbier, Robert W.; Wang, Yan			Quality antenatal care protects against low birth weight in 42 poor counties of Western China	PLOS ONE			English	Article							PRENATAL-CARE; SUPPLEMENTATION; PREGNANCY; MOTHERS	Limited data exist related to low birth weight (LBW) incidence and risk factors in Western China. This paper aims to assess LBW and its relationship with antenatal care (ANC) in the poor counties of Western China. A community-based study in rural Western China was conducted in 2011. A kernel distribution was used to estimate the adjusted LBW incidence, and associations between LBW and socio-demographic or maternal factors were examined using multilevel logistic regression. Among 8,964 participants, 65.7% were weighed at birth. Crude LBW incidence was 6.6% and the adjusted rate was 9.3%. The study revealed that risk factors of LBW are being female, raised within a minority group, and with a family income below the national poverty line. For maternal risk factors, LBW was positively associated with not attending at least five or eight ANC visits, not receiving any ANC during the first trimester, and not having access to assess certain ANC content (weight, blood pressure, blood test, urine test, B-scan ultrasound, and folic acid supplement). There is urgent need to promote quality ANC in poor and rural areas of Western China and to prioritize vulnerable women and children who will benefit from quality ANC.	[Zhou, Hong; Wang, Anqi; Wang, Yan] Peking Univ, Sch Publ Hlth, Dept Maternal & Child Hlth, Beijing, Peoples R China; [Zhou, Hong; Wang, Yan] Natl Human Genet Resources Ctr, Environm & Spatial Epidemiol Res Ctr, Beijing, Peoples R China; [Wang, Anqi] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Huang, Xiaona; Yang, Yuning; Martin, Kathryn; Tian, Xiaobo; Scherpbier, Robert W.] UNICEF China, Beijing, Peoples R China; [Guo, Sufang] UNICEF Reg Off South Asia, Leknath Marg, Kathmandu, Nepal; [Josephs-Spaulding, Jonathan] Christian Albrechts Univ Kiel, Inst Expt Med, Kiel, Germany; [Ma, Chuyang] Beijing Lu He Int Acad, Beijing, Peoples R China	Peking University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Kiel	Wang, Y (corresponding author), Peking Univ, Sch Publ Hlth, Dept Maternal & Child Hlth, Beijing, Peoples R China.; Wang, Y (corresponding author), Natl Human Genet Resources Ctr, Environm & Spatial Epidemiol Res Ctr, Beijing, Peoples R China.; Scherpbier, RW (corresponding author), UNICEF China, Beijing, Peoples R China.	rscherpbier@unicef.org; wangyan@bjmu.edu.cn	Josephs-Spaulding, Jonathan/T-7730-2019	Josephs-Spaulding, Jonathan/0000-0001-9828-0685	UNICEF China [YH702]	UNICEF China	This work was funded by a grant from UNICEF China (YH702 to YW); https://www.unicef.org/infobycountry/china.html.The funders participated the process of study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Balazs P, 2013, EUR J PUBLIC HEALTH, V23, P480, DOI 10.1093/eurpub/cks089; Bener Abdulbari, 2012, ISRN Obstet Gynecol, V2012, P540495; Bian YH, 2013, J BIOMED RES, V27, P14, DOI 10.7555/JBR.27.20120046; Borah Madhur, 2015, J Family Med Prim Care, V4, P380, DOI 10.4103/2249-4863.161326; da Fonseca CRB, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-255; Charnigo R, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-37; Chinese Nutrition Society, 2016, CHIN DIET GUID; Cui Hao, 2015, Zhonghua Yu Fang Yi Xue Za Zhi, V49, P161; Demelash H, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0677-y; Department of Household Surveys National Bureau of Statistics of China, 2016, POV MON REP RUR CHIN; Dijkhuizen MA, 2004, AM J CLIN NUTR, V80, P1299, DOI 10.1093/ajcn/80.5.1299; Division UNP, 2017, SEX RAT BIRTH REF MA; Keen CL, 2003, J NUTR, V133, p1597S, DOI 10.1093/jn/133.5.1597S; Khanal V, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-4; Khatun S, 2008, J BIOSOC SCI, V40, P321, DOI 10.1017/S0021932007002532; Kirkham C, 2005, AM FAM PHYSICIAN, V71, P1307; Lin Liangming, 2002, Zhonghua Yufang Yixue Zazhi, V36, P149; Pinzon-Rondon AM, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0541-0; Martinez-Mesa J, 2013, OSTEOPOROSIS INT, V24, P7, DOI 10.1007/s00198-012-2114-7; Matthews T J, 2013, Natl Vital Stat Rep, V62, P1; Nation Health and Family Planning Commission of the People's Republic of China, 2011, NAT BAS PUBL HLTH SE; National Bureau of Statistics, 2011, 2010 POP CENS PEOPL; National Bureau of Statistics of China, NAT DAT ANN 2010; National Health and Family Planning Commission of China, 2011, ADM HLTH CARE PREGN; Rao JM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21771-6; Servan-Mori E, 2016, HEALTH POLICY PLANN, V31, P444, DOI 10.1093/heapol/czv082; Shan XY, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-105; State Council of the People's Republic of China, 2009, OP CENTR COMM COMM P; Tang L, 2013, BIRTH-ISS PERINAT C, V40, P134, DOI 10.1111/birt.12038; UNICEF, MULT IND CLUST SURV; Van Kerm P, 2003, STATA J, V3, P148, DOI 10.1177/1536867X0300300204; Van Kerm P, 2012, STATA J, V12, P543, DOI 10.1177/1536867X1201200313; Wang YP, 2016, LANCET, V387, P273, DOI 10.1016/S0140-6736(15)00554-1; Waterland RA, 2004, NUTRITION, V20, P63, DOI 10.1016/j.nut.2003.09.011; WHO, 2022, WHO RECOMMENDATIONS; WHO, 2004, LOW BIRTHW COUNTR RE; WHO, 2018, GUIDELINES OPTIMAL F; World Health Organization, 2015, PREGN CHILDB POSTP N; Xiao PL, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0684-z; Ye F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134756; Zarrati M, 2013, ANN NUTR METAB, V63, P69, DOI 10.1159/000351869	42	20	22	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2019	14	1							e0210393	10.1371/journal.pone.0210393	http://dx.doi.org/10.1371/journal.pone.0210393			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH6BK	30650127	Green Submitted, gold, Green Published			2023-01-03	WOS:000455813300055
J	Enshaeifar, S; Zoha, A; Skillman, S; Markides, A; Acton, ST; Elsaleh, T; Kenny, M; Rostill, H; Nilforooshan, R; Barnaghi, P				Enshaeifar, Shirin; Zoha, Ahmed; Skillman, Severin; Markides, Andreas; Acton, Sahr Thomas; Elsaleh, Tarek; Kenny, Mark; Rostill, Helen; Nilforooshan, Ramin; Barnaghi, Payam			Machine learning methods for detecting urinary tract infection and analysing daily living activities in people with dementia	PLOS ONE			English	Article							EARLY WARNING SCORE; HOSPITAL ADMISSIONS; VALIDATION; ACTIGRAPHY; PREVALENCE; OUTCOMES; REASONS; EVENTS	Dementia is a neurological and cognitive condition that affects millions of people around the world. At any given time in the United Kingdom, 1 in 4 hospital beds are occupied by a person with dementia, while about 22% of these hospital admissions are due to preventable causes. In this paper we discuss using Internet of Things (IoT) technologies and in-home sensory devices in combination with machine learning techniques to monitor health and well-being of people with dementia. This will allow us to provide more effective and preventative care and reduce preventable hospital admissions. One of the unique aspects of this work is combining environmental data with physiological data collected via low cost in-home sensory devices to extract actionable information regarding the health and well-being of people with dementia in their own home environment. We have worked with clinicians to design our machine learning algorithms where we focused on developing solutions for real-world settings. In our solutions, we avoid generating too many alerts/alarms to prevent increasing the monitoring and support workload. We have designed an algorithm to detect Urinary Tract Infections (UTI) which is one of the top five reasons of hospital admissions for people with dementia (around 9% of hospital admissions for people with dementia in the UK). To develop the UTI detection algorithm, we have used a Non-negative Matrix Factorisation (NMF) technique to extract latent factors from raw observation and use them for clustering and identifying the possible UTI cases. In addition, we have designed an algorithm for detecting changes in activity patterns to identify early symptoms of cognitive decline or health decline in order to provide personalised and preventative care services. For this purpose, we have used an Isolation Forest (iForest) technique to create a holistic view of the daily activity patterns. This paper describes the algorithms and discusses the evaluation of the work using a large set of real-world data collected from a trial with people with dementia and their caregivers.	[Enshaeifar, Shirin; Zoha, Ahmed; Skillman, Severin; Markides, Andreas; Acton, Sahr Thomas; Elsaleh, Tarek; Barnaghi, Payam] Univ Surrey, CVSSP, Dept Elect & Elect Engn, Guildford, Surrey, England; [Kenny, Mark; Rostill, Helen; Nilforooshan, Ramin] Surrey & Borders Partnership NHS Fdn Trust, Leatherhead, Surrey, England	University of Surrey	Barnaghi, P (corresponding author), Univ Surrey, CVSSP, Dept Elect & Elect Engn, Guildford, Surrey, England.	p.barnaghi@surrey.ac.uk	Enshaeifar, Shirin/M-7783-2016; Elsaleh, Tarek/AAK-5803-2021; Barnaghi, Payam/ABE-9236-2020; Elsaleh, Tarek/X-1141-2019; Zoha, Ahmed/ABB-8933-2020	Enshaeifar, Shirin/0000-0001-6216-0622; Elsaleh, Tarek/0000-0002-9134-0232; Barnaghi, Payam/0000-0001-8591-9638; Zoha, Ahmed/0000-0001-7497-9336; Nilforooshan, Ramin/0000-0001-9801-183X	Office of Life Sciences at Department of Health UK [TS/N009894/1]	Office of Life Sciences at Department of Health UK	This project is supported by a grant from the Office of Life Sciences at Department of Health UK, grant number (TS/N009894/1) (PB). More information can be found here: (https://www.gov.uk/government/organisations/office-for-lifesciences). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrieu S, 2002, INT J GERIATR PSYCH, V17, P422, DOI 10.1002/gps.624; Bernardes C, 2018, ARCH GERONTOL GERIAT, V77, P150, DOI 10.1016/j.archger.2018.05.006; Berry R.B., 2012, RULES TERMINOL TECH, V176, P2012; Caljouw MAA, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-57; Carskadon MA, 2005, PRINCIPLES PRACTICE, P13, DOI DOI 10.1016/B0-72-160797-7/50009-4; Chernbumroong S, 2013, EXPERT SYST APPL, V40, P1662, DOI 10.1016/j.eswa.2012.09.004; Cook DJ, 2014, J INTELL INF SYST, V43, P503, DOI 10.1007/s10844-014-0341-4; Dawadi PN, 2013, TECHNOL HEALTH CARE, V21, P323, DOI 10.3233/THC-130734; de Souza L, 2003, SLEEP, V26, P81, DOI 10.1093/sleep/26.1.81; Demiris George, 2008, Technol Health Care, V16, P111; Enshaeifar S., 2018, IEEE T IND INFORM; Enshaeifar S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195605; Enshaeifar S, 2018, IEEE INTERNET COMPUT, V22, P8, DOI 10.1109/MIC.2018.112102418; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Gehrman P, 2002, J SLEEP RES, V11, P229, DOI 10.1046/j.1365-2869.2002.00306.x; Gerry S, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-019268; Hayes TL, 2010, IEEE ENG MED BIO, P2147, DOI 10.1109/IEMBS.2010.5628022; Hedner J, 2004, SLEEP, V27, P1560, DOI 10.1093/sleep/27.8.1560; Ibrisimovic MA, 2017, IFMBE PROC, V62, P289, DOI 10.1007/978-981-10-4166-2_43; Kaye JA, 2011, J GERONTOL B-PSYCHOL, V66, P180, DOI [10.1093/geronb/ghq095, 10.1093/geronb/gbq095]; Kim H, 2008, SIAM J MATRIX ANAL A, V30, P713, DOI 10.1137/07069239X; Kushida CA, 2005, SLEEP, V28, P499, DOI 10.1093/sleep/28.4.499; Leibovici L, 2000, IEEE T KNOWL DATA EN, V12, P517, DOI 10.1109/69.868905; Leys C, 2013, J EXP SOC PSYCHOL, V49, P764, DOI 10.1016/j.jesp.2013.03.013; Ligeza A., 2006, LOGICAL FDN RULE BAS, V11; Lymberopoulos D, 2011, UNIVERSAL ACCESS INF, V10, P125, DOI 10.1007/s10209-010-0197-5; Manevitz LM, 2002, J MACH LEARN RES, V2, P139, DOI 10.1162/15324430260185574; McCurry SM, 2006, AM J GERIAT PSYCHIAT, V14, P112, DOI 10.1097/01.JGP.0000192499.25940.da; Meister L, 2013, ACAD EMERG MED, V20, P632, DOI 10.1111/acem.12171; Morgan R, 1997, CLIN INTENSIVE CARE, V8, P100; Mukadam N, 2011, INT PSYCHOGERIATR, V23, P344, DOI 10.1017/S1041610210001717; Natalwala A, 2008, DEMENT GERIATR COGN, V26, P499, DOI 10.1159/000171044; National Audit Office, 2007, IMPR SERV SUPP PEOPL; Nicolle LE, 1997, INFECT DIS CLIN N AM, V11, P647, DOI 10.1016/S0891-5520(05)70378-0; Nourhashemi F, 2001, ALZ DIS ASSOC DIS, V15, P21, DOI 10.1097/00002093-200101000-00003; ORRELL M, 1995, PSYCHOL MED, V25, P373, DOI 10.1017/S0033291700036278; Rantz M. J., 2011, 2011 IEEE 13th International Conference on e-Health Networking, Applications and Services (Healthcom 2011), P142, DOI 10.1109/HEALTH.2011.6026731; Rao A, 2016, ARCH GERONTOL GERIAT, V66, P198, DOI 10.1016/j.archger.2016.06.008; ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7; Sadeh A, 2002, SLEEP MED REV, V6, P113, DOI 10.1053/smrv.2001.0182; Sampson EL, 2014, BRIT J PSYCHIAT, V205, P189, DOI 10.1192/bjp.bp.113.130948; Sampson EL, 2009, BRIT J PSYCHIAT, V195, P61, DOI 10.1192/bjp.bp.108.055335; Samy L, 2014, IEEE SENS J, V14, P2092, DOI 10.1109/JSEN.2013.2293917; Schmiemann G, 2010, DTSCH ARZTEBL INT, V107, P361, DOI 10.3238/arztebl.2010.0361; Skubic M, 2015, IEEE J TRANSL ENG HE, V3, DOI 10.1109/JTEHM.2015.2421499; Smith GB, 2013, RESUSCITATION, V84, P465, DOI 10.1016/j.resuscitation.2012.12.016; Smith L. J., 2003, MEASUREMENT SLEEP; Society A, 2018, COUNT COST CAR PEOPL; Subbe CP, 2001, QJM-MON J ASSOC PHYS, V94, P521, DOI 10.1093/qjmed/94.10.521; Tamura Toshiyo, 2007, Open Med Inform J, V1, P1, DOI 10.2174/1874431100701010001; Toot S, 2013, J AM MED DIR ASSOC, V14, P463, DOI 10.1016/j.jamda.2013.01.011; Tuppin P, 2009, DEMENT GERIATR COGN, V28, P225, DOI 10.1159/000238394; Urwyler P, 2017, SCI REP-UK, V7, DOI 10.1038/srep42084; Volicer L, 2001, AM J PSYCHIAT, V158, P704, DOI 10.1176/appi.ajp.158.5.704; Wang HY, 2010, IEEE INT C BIO BIO W, P405, DOI 10.1109/BIBMW.2010.5703836; Zhao Y, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-108	56	25	25	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2019	14	1							e0209909	10.1371/journal.pone.0209909	http://dx.doi.org/10.1371/journal.pone.0209909			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HH6AH	30645599	gold, Green Published, Green Accepted, Green Submitted			2023-01-03	WOS:000455810200015
J	Ivanova, MM; Changsila, E; Iaonou, C; Goker-Alpan, O				Ivanova, Margarita M.; Changsila, Erk; Iaonou, Chidima; Goker-Alpan, Ozlem			Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases	PLOS ONE			English	Article							LYSOSOMAL STORAGE DISORDERS; MAMMALIAN TARGET; GLUCOSYLCERAMIDE ACCUMULATION; RAPAMYCIN MTOR; CELLS; DEGRADATION; DYSFUNCTION; MOUSE; MANIFESTATIONS; REFORMATION	The major cellular clearance pathway for organelle and unwanted proteins is the autophagy-lysosome pathway (ALP). Lysosomes not only house proteolytic enzymes, but also traffic organelles, sense nutrients, and repair mitochondria. Mitophagy is initiated by damaged mitochondria, which is ultimately degraded by the ALP to compensate for ATP loss. While both systems are dynamic and respond to continuous cellular stressors, most studies are derived from animal models or cell based systems, which do not provide complete real time data about cellular processes involved in the progression of lysosomal storage diseases in patients. Gaucher and Fabry diseases are rare sphingolipid disorders due to the deficiency of the lysosomal enzymes; glucocerebrosidase and alpha-galactosidase A with resultant lysosomal dysfunction. Little is known about ALP pathology and mitochondrial function in patients with Gaucher and Fabry diseases, and the effects of enzyme replacement therapy (ERT). Studying blood mononuclear cells (PBMCs) from patients, we provide in vivo evidence, that regulation of ALP is defective. In PBMCs derived from Gaucher patients, we report a decreased number of autophagic vacuoles with increased cytoplasmic localization of LC3A/B, accompanied by lysosome accumulation. For both Gaucher and Fabry diseases, the level of the autophagy marker, Beclin1, was elevated and ubiquitin binding protein, SQSTM1/p62, was decreased. mTOR inhibition did not activate autophagy and led to ATP inhibition in PBMCs. Lysosomal abnormalities, independent of the type of the accumulated substrate suppress not only autophagy, but also mitochondrial function and mTOR signaling pathways. ERT partially restored ALP function, LC3-II accumulation and decreased LC3-I/LC3-II ratios. Levels of lysosomal (LAMP1), autophagy (LC3), and mitochondrial markers, (Tfam), normalized after ERT infusion. In conclusion, there is mTOR pathway dys-function in sphingolipidoses, as observed in both PBMCs derived from patients with Gaucher and Fabry diseases, which leads to impaired autophagy and mitochondrial stress. ERT partially improves ALP function.	[Ivanova, Margarita M.; Changsila, Erk; Iaonou, Chidima; Goker-Alpan, Ozlem] Lysosomal & Rare Disorders Res & Treatment Ctr, Fairfax, VA 22030 USA		Ivanova, MM; Goker-Alpan, O (corresponding author), Lysosomal & Rare Disorders Res & Treatment Ctr, Fairfax, VA 22030 USA.	mivanova@ldrtc.org; ogoker-alpan@ldrtc.org	Ivanova, Margarita/AAM-4510-2021	Ivanova, Margarita/0000-0002-6197-8606				Aflaki E, 2016, AGING CELL, V15, P77, DOI 10.1111/acel.12409; Awad O, 2015, HUM MOL GENET, V24, P5775, DOI 10.1093/hmg/ddv297; Babcock JT, 2013, J BIOL CHEM, V288, P15687, DOI 10.1074/jbc.M112.431056; Ballou Lisa M, 2008, J Chem Biol, V1, P27, DOI 10.1007/s12154-008-0003-5; Baris HN, 2014, PEDIATR ENDOCR REV P, V12, P72; Bauerly KA, 2006, BBA-GEN SUBJECTS, V1760, P1741, DOI 10.1016/j.bbagen.2006.07.009; Betz C, 2013, J CELL BIOL, V203, P563, DOI 10.1083/jcb.201306041; Campbell CT, 2012, BBA-GENE REGUL MECH, V1819, P921, DOI 10.1016/j.bbagrm.2012.03.002; Charrow J, 2015, AM J HEMATOL, V90, pS19, DOI 10.1002/ajh.24056; Chevrier M, 2010, AUTOPHAGY, V6, P589, DOI 10.4161/auto.6.5.11943; Chiang GG, 2005, J BIOL CHEM, V280, P25485, DOI 10.1074/jbc.M501707200; Collins Lucy M, 2017, F1000Res, V6, P1751, DOI 10.12688/f1000research.12090.1; Das AM, 2009, ADV CLIN CHEM, V49, P57, DOI 10.1016/S0065-2423(09)49003-6; de la Mata Mario, 2016, Diseases, V4, DOI 10.3390/diseases4040031; de la Mata M, 2015, SCI REP-UK, V5, DOI 10.1038/srep10903; Du TT, 2015, AUTOPHAGY, V11, P1803, DOI 10.1080/15548627.2015.1086055; Eng CM, 2001, NEW ENGL J MED, V345, P9, DOI 10.1056/NEJM200107053450102; Entingh AJ, 2001, ENDOCRINOLOGY, V142, P221, DOI 10.1210/en.142.1.221; Gegg ME, 2016, NEUROBIOL DIS, V90, P43, DOI 10.1016/j.nbd.2015.09.006; Germain DP, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-30; Goker-Alpan O, 2011, MOL GENET METAB, V104, P438, DOI 10.1016/j.ymgme.2011.08.004; Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220; Grabowski GA, 2008, LANCET, V372, P1263, DOI 10.1016/S0140-6736(08)61522-6; Hu YW, 2016, J CELL BIOCHEM, V117, P413, DOI 10.1002/jcb.25287; Ivanova MM, 2011, FASEB J, V25, P1402, DOI 10.1096/fj.10-169029; Jewell JL, 2013, NAT REV MOL CELL BIO, V14, P133, DOI 10.1038/nrm3522; Kim KH, 2014, NAT REV ENDOCRINOL, V10, P322, DOI 10.1038/nrendo.2014.35; Kinghorn KJ, 2016, J NEUROSCI, V36, P11654, DOI 10.1523/JNEUROSCI.4527-15.2016; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Komatsu M, 2010, FEBS LETT, V584, P1374, DOI 10.1016/j.febslet.2010.02.017; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Liebau MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063506; Limgala RP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168135; Lucke T, 2004, MOL GENET METAB, V82, P93, DOI 10.1016/j.ymgme.2004.01.011; MacDermot KD, 2001, J MED GENET, V38, P769, DOI 10.1136/jmg.38.11.769; Magalhaes J, 2016, HUM MOL GENET, V25, P3432, DOI 10.1093/hmg/ddw185; Marchesan D, 2012, J INHERIT METAB DIS, V35, P1107, DOI 10.1007/s10545-012-9472-3; Maxfield FR, 2005, NATURE, V438, P612, DOI 10.1038/nature04399; Mehta AB, 2009, INT J CLIN PHARM TH, V47, pS66; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Morita M, 2015, CELL CYCLE, V14, P473, DOI 10.4161/15384101.2014.991572; Nelson MP, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-20; Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232; Osellame LD, 2014, BRIT J PHARMACOL, V171, P1958, DOI 10.1111/bph.12453; Osellame LD, 2013, AUTOPHAGY, V9, P1633, DOI 10.4161/auto.25878; Osellame LD, 2013, CELL METAB, V17, P941, DOI 10.1016/j.cmet.2013.04.014; Pandey MK, 2017, NATURE, V543, P108, DOI 10.1038/nature21368; Pandey Manoj Kumar, 2013, Critical Reviews in Oncogenesis, V18, P197; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Parkinson-Lawrence EJ, 2010, PHYSIOLOGY, V25, P102, DOI 10.1152/physiol.00041.2009; Perrot A, 2002, HERZ, V27, P699, DOI 10.1007/s00059-002-2429-9; Platt FM, 2012, J CELL BIOL, V199, P723, DOI 10.1083/jcb.201208152; Plotegher N, 2017, TRENDS MOL MED, V23, P116, DOI 10.1016/j.molmed.2016.12.003; Puertollano Rosa, 2014, F1000Prime Rep, V6, P52, DOI 10.12703/P6-52; Raben N, 2009, METHOD ENZYMOL, V453, P417, DOI 10.1016/S0076-6879(08)04021-4; Radde BN, 2015, BIOCHEM J, V465, P49, DOI 10.1042/BJ20131608; Ramanathan A, 2009, P NATL ACAD SCI USA, V106, P22229, DOI 10.1073/pnas.0912074106; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Rozenfeld P, 2017, MOL GENET METAB, V122, P19, DOI 10.1016/j.ymgme.2017.09.004; Rusecka J, 2018, J APPL GENET, V59, P43, DOI 10.1007/s13353-017-0424-3; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarkar S, 2009, CELL DEATH DIFFER, V16, P46, DOI 10.1038/cdd.2008.110; Sawkar AR, 2006, CELL MOL LIFE SCI, V63, P1179, DOI 10.1007/s00018-005-5437-0; Scarpulla RC, 2008, ANN NY ACAD SCI, V1147, P321, DOI 10.1196/annals.1427.006; Schondorf DC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5028; Settembre C, 2008, AUTOPHAGY, V4, P113, DOI 10.4161/auto.5227; Settembre C, 2008, HUM MOL GENET, V17, P119, DOI 10.1093/hmg/ddm289; Settembre C, 2013, NAT REV MOL CELL BIO, V14, P283, DOI 10.1038/nrm3565; Slaats GG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29240-w; Squillaro T, 2017, J CELL PHYSIOL, V232, P3454, DOI 10.1002/jcp.25807; Sun Y, 2010, HUM MOL GENET, V19, P1088, DOI 10.1093/hmg/ddp580; Tabatabaian F, 2010, J BIOL CHEM, V285, P18991, DOI 10.1074/jbc.M110.111542; Tatti M, 2012, HUM MOL GENET, V21, P5159, DOI 10.1093/hmg/dds367; Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016; Welford RWD, 2018, HUM MOL GENET, V27, P3392, DOI 10.1093/hmg/ddy248; Wu YJ, 2018, MOL MED REP, V17, P8003, DOI 10.3892/mmr.2018.8831; Xu YH, 2014, HUM MOL GENET, V23, P3943, DOI 10.1093/hmg/ddu105; Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076; Zhang XJ, 2013, ACTA PHARMACOL SIN, V34, P595, DOI 10.1038/aps.2012.184; Zhou J, 2013, CELL RES, V23, P508, DOI 10.1038/cr.2013.11	80	33	34	4	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2019	14	1							e0210617	10.1371/journal.pone.0210617	http://dx.doi.org/10.1371/journal.pone.0210617			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH1MW	30633777	Green Submitted, Green Published, gold			2023-01-03	WOS:000455485100033
J	Hartley, P; Costello, P; Fenner, R; Gibbins, N; Quinn, E; Kuhn, I; Keevil, VL; Romero-Ortuno, R				Hartley, Peter; Costello, Patricia; Fenner, Rachel; Gibbins, Nathalie; Quinn, Edain; Kuhn, Isla; Keevil, Victoria L.; Romero-Ortuno, Roman			Change in skeletal muscle associated with unplanned hospital admissions in adult patients: A systematic review and meta-analysis	PLOS ONE			English	Review							OBSTRUCTIVE PULMONARY-DISEASE; ACUTE EXACERBATION; FUNCTIONAL DECLINE; GERIATRIC-PATIENTS; PHYSICAL-ACTIVITY; NUTRITIONAL SUPPORT; VASTUS LATERALIS; BODY-COMPOSITION; ELDERLY-PATIENTS; OLDER PATIENTS	Objectives The primary objective of the review was to describe change that occurs in skeletal muscle during periods of unplanned hospitalisation in adult patients. The secondary objective was to examine the relationship between both physical activity and inflammation with the change in skeletal muscle. A further objective was to investigate the effect of interventions on change in skeletal muscle during periods of unplanned hospitalisation. Design A systematic review and meta-analyses. Embase, MEDLINE, CINAHL, AMED, PEDro and the Cochrane Library were searched for studies that included any measures of skeletal muscle (excluding pulmonary function) at two time points during unplanned hospitalisation. Studies that were set in critical care, or included patients with acute or progressive neurological illness, were excluded. Results Our search returned 27,809 unique articles, of which 35 met the inclusion criteria. Meta-analyses of change between baseline and follow-up in random effects models suggested that grip strength had an average increase: standardised mean difference (SMD) = 0.10 (95% CI: 0.03; 0.16); knee extension strength had an average reduction: SMD = -0.24 (95% CI: -0.33; -0.14); and mid-arm muscle circumference had an average reduction: SMD = -0.17 (95% CI: -0.22; -0.11). Inflammation appeared to be associated with greater loss of muscle strength. There was inconclusive evidence that the level of physical activity affects change in skeletal muscle. In regard to the effect of interventions, only exercise interventions were consistently associated with improved skeletal muscle outcomes. Conclusions Adult patients who undergo an unplanned hospital admission may experience a small reduction in knee extension strength and mid-arm muscle mass. Prospective research is needed to clarify the contribution of confounding factors underlying the observations made in this review, with particular attention to levels of physical activity, and possible contributions from environmental factors and processes of hospital care.	[Hartley, Peter; Keevil, Victoria L.; Romero-Ortuno, Roman] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England; [Hartley, Peter; Costello, Patricia; Fenner, Rachel; Gibbins, Nathalie; Quinn, Edain] Cambridge Univ Hosp NHS Fdn Trust, Dept Physiotherapy, Cambridge, England; [Kuhn, Isla] Univ Cambridge, Med Lib, Cambridge, England; [Keevil, Victoria L.; Romero-Ortuno, Roman] Cambridge Univ Hosp NHS Fdn Trust, Dept Med Elderly, Cambridge, England; [Romero-Ortuno, Roman] St James Hosp, Discipline Med Gerontol, Trinity Coll Dublin, Mercers Inst Successful Ageing, Dublin, Ireland	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Trinity College Dublin	Hartley, P (corresponding author), Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England.; Hartley, P (corresponding author), Cambridge Univ Hosp NHS Fdn Trust, Dept Physiotherapy, Cambridge, England.	ph492@medschl.cam.ac.uk	Keevil, Victoria L/ABF-6256-2020; Romero-Ortuno, Roman/AAP-9221-2020; Keevil, Victoria L/AAE-9138-2019; Kuhn, Isla L/J-6753-2012	Romero-Ortuno, Roman/0000-0002-3882-7447; Keevil, Victoria L/0000-0001-6148-0640; Hartley, Peter/0000-0002-1033-5897	Dunhill Medical Trust [RTF115/0117]	Dunhill Medical Trust(Dunhill Medical Trust)	PH is supported by a research training fellowship from the Dunhill Medical Trust [grant number: RTF115/0117].	Abad A, 1986, J CLIN NUTR GASTROEN, V1, P1; Alley DE, 2010, J AM GERIATR SOC, V58, P2085, DOI 10.1111/j.1532-5415.2010.03144.x; Bautmans I, 2005, J GERONTOL A-BIOL, V60, P361, DOI 10.1093/gerona/60.3.361; Beyer I, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-292; Bloomfield SA, 1997, MED SCI SPORT EXER, V29, P197, DOI 10.1097/00005768-199702000-00006; Bodilsen AC, 2013, AM J PHYS MED REHAB, V92, P789, DOI 10.1097/PHM.0b013e31828cd2b6; Borenstein M, 2009, INTRO METAANALYSIS, P21, DOI DOI 10.1002/9780470743386.CH4; Borges RC, 2014, ARCH PHYS MED REHAB, V95, P1638, DOI 10.1016/j.apmr.2014.05.007; Brown CJ, 2009, J AM GERIATR SOC, V57, P1660, DOI 10.1111/j.1532-5415.2009.02393.x; Burtin C, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-46; Callahan Leigh Ann, 2009, Crit Care Med, V37, pS354, DOI 10.1097/CCM.0b013e3181b6e439; Chodos AH, 2015, J GEN INTERN MED, V30, P1765, DOI 10.1007/s11606-015-3395-2; Crul T, 2007, EUR J CLIN INVEST, V37, P897, DOI 10.1111/j.1365-2362.2007.01867.x; Crul T, 2010, CELL PHYSIOL BIOCHEM, V25, P491, DOI 10.1159/000303054; di Trifiletti AA, 2013, CLIN NUTR, V32, P527, DOI 10.1016/j.clnu.2012.11.011; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; English KL, 2010, CURR OPIN CLIN NUTR, V13, P34, DOI 10.1097/MCO.0b013e328333aa66; Farthing JP, 2009, J APPL PHYSIOL, V106, P830, DOI 10.1152/japplphysiol.91331.2008; Gupta R, 2001, PANCREATOLOGY, V1, P58, DOI 10.1159/000055793; Hartley P, 2017, AGE AGEING, V46, P559, DOI 10.1093/ageing/afx007; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2009, J R STAT SOC A STAT, V172, P137, DOI 10.1111/j.1467-985X.2008.00552.x; Humphreys J, 2002, NUTRITION, V18, P616, DOI 10.1016/S0899-9007(02)00756-6; Incalzi RA, 1996, J AM GERIATR SOC, V44, P166, DOI 10.1111/j.1532-5415.1996.tb02434.x; Jones J, 2017, J EVAL CLIN PRACT, V23, P1469, DOI 10.1111/jep.12833; Jose A, 2016, J PHYSIOTHER, V62, P96, DOI 10.1016/j.jphys.2016.02.014; Julian P.T.H., 2011, MANUAL COCHRANE REVI; Karlsen A, 2017, AM J PHYS MED REHAB, V96, pe78, DOI 10.1097/PHM.0000000000000671; Kitahara A, 2003, MED SCI SPORT EXER, V35, P1697, DOI 10.1249/01.MSS.0000089339.07610.5F; Klausen HH, 2017, MECH AGEING DEV, V164, P67, DOI 10.1016/j.mad.2017.04.005; Kortebein P, 2008, J GERONTOL A-BIOL, V63, P1076, DOI 10.1093/gerona/63.10.1076; Kortebein P, 2009, AM J PHYS MED REHAB, V88, P66, DOI 10.1097/PHM.0b013e3181838f70; Martin-Salvador A, 2016, MED CLIN-BARCELONA, V146, P301, DOI 10.1016/j.medcli.2015.11.009; Martin-Salvador A, 2015, ARCH BRONCONEUMOL, V51, P496, DOI 10.1016/j.arbres.2014.11.009; Matsuo H, 2017, GERIATR GERONTOL INT, V17, P1610, DOI 10.1111/ggi.12941; McCusker J, 2002, J GERONTOL A-BIOL, V57, pM569, DOI 10.1093/gerona/57.9.M569; Mesquita R, 2013, RESP CARE, V58, P2142, DOI 10.4187/respcare.02393; Mets Tony, 2004, Am J Geriatr Pharmacother, V2, P230, DOI 10.1016/j.amjopharm.2004.12.007; NIH National Heart Lung and Blood Institute, 2014, QUALITY ASSESSMENT T; Norheim KL, 2017, EXP GERONTOL, V99, P115, DOI 10.1016/j.exger.2017.10.006; Pedersen MM, 2013, J GERONTOL A-BIOL, V68, P331, DOI 10.1093/gerona/gls165; Pitta F, 2006, CHEST, V129, P536, DOI 10.1378/chest.129.3.536; POTTER J, 1995, AGE AGEING, V24, P131, DOI 10.1093/ageing/24.2.131; Rossi AP, 2016, EUR J CLIN NUTR, V70, P1439, DOI 10.1038/ejcn.2016.159; SaudnyUnterberger H, 1997, AM J RESP CRIT CARE, V156, P794, DOI 10.1164/ajrccm.156.3.9612102; Shepherd S, 2017, NEUROHOSPITALIST, V7, P41, DOI 10.1177/1941874416663279; SLOAN JP, 1992, J AM GERIATR SOC, V40, P1105, DOI 10.1111/j.1532-5415.1992.tb01798.x; Spruit MA, 2003, THORAX, V58, P752, DOI 10.1136/thorax.58.9.752; Torres-Sanchez I, 2017, COPD, V14, P37, DOI 10.1080/15412555.2016.1209476; Torres-Sanchez I, 2017, RESP CARE, V62, P209, DOI 10.4187/respcare.04597; Torres-Sanchez I, 2016, COPD, V13, P19, DOI 10.3109/15412555.2015.1043428; Troosters T, 2010, AM J RESP CRIT CARE, V181, P1072, DOI 10.1164/rccm.200908-1203OC; Unosson Mitra, 1995, Journal of Nutritional and Environmental Medicine (Abingdon), V5, P23, DOI 10.3109/13590849509008759; Van Ancum JM, 2017, EXP GERONTOL, V92, P34, DOI 10.1016/j.exger.2017.03.006; Vermeeren MAP, 2004, CLIN NUTR, V23, P1184, DOI 10.1016/j.clnu.2004.03.008; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Villumsen M, 2015, J AGING PHYS ACTIV, V23, P542, DOI 10.1123/japa.2014-0115; Wall BT, 2013, NUTR REV, V71, P195, DOI 10.1111/nure.12019; WEINSIER RL, 1979, AM J CLIN NUTR, V32, P418, DOI 10.1093/ajcn/32.2.418; Welch C, 2018, AGING DIS, V9, P151, DOI 10.14336/AD.2017.0315; Wieboldt J, 2012, J CYST FIBROS, V11, P209, DOI 10.1016/j.jcf.2011.12.001; Zisberg A, 2015, J AM GERIATR SOC, V63, P55, DOI 10.1111/jgs.13193	62	15	16	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 4	2019	14	1							e0210186	10.1371/journal.pone.0210186	http://dx.doi.org/10.1371/journal.pone.0210186			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HG4NS	30608987	gold, Green Published, Green Submitted			2023-01-03	WOS:000454952800052
J	Yaya, S; Ghose, B				Yaya, Sanni; Ghose, Bishwajit			Prevalence of unmet need for contraception and its association with unwanted pregnancy among married women in Angola	PLOS ONE			English	Article							TRENDS; BIRTH; COST; SAFE; AGE	Background Unmet need for contraception and unwanted pregnancy are recognised as significant barriers to promoting women's reproductive health and well-being. Currently there is no research evidence on these two crucial indicators of reproductive care in Angola. Therefore, we conducted this study with the objectives of exploring the current prevalence of unmet need for contraception and unintended pregnancy as well as their relationship among married women in Angola. Methods This study was based on cross-sectional data from Angola Demographic and Health Survey (DHS) conducted in 2015-16. Participants were 7,808 married women aged 15-49 years. Unwanted pregnancy was measured in terms of the mistimed and unintended conception for the last-born child. Unmet need for contraception included those who reported unmet need for spacing and limiting. Data were analysed using bivariate and multivariable techniques. Results The combined prevalence of mistimed and unwanted pregnancy was 38.3% (95%CI = 35.9-40.7), and that of unmet need for contraception for spacing and limiting was 51.7% (49.9-53.5). Among the 18 regions, Luanda had the highest prevalence of unmet need for contraception and of unwanted pregnancy with the prevalence being higher than more than one-third of the women. Multivariable analysis significantly revealed a significantly positive association between unmet need and unwanted pregnancy. In all the models, the odds of unwanted pregnancy were found to be as high as four times among women with unmet need compared with those had no unmet need. Compared to women who had no unmet need, those who had unmet need had respectively four (OR = 4.380; 95%CI = 3.690-5.198) and seven (OR = 6.951; 95%CI = 4.642-10.410) times higher odds of experiencing unwanted pregnancy. Conclusion This study concludes that the prevalence of unmet need for contraception and unwanted pregnancy are high with significant disparities across the regions. Women in the capital city had the highest prevalence of both unmet need for contraception and unwanted pregnancy. Although the data were cross-sectional and do not indicate causal relationships, the findings showed a strong positive association between unmet need for contraception and unwanted pregnancy. However, it is recommended to conduct further studies to replicate the findings and to explore the influence behavioural and cultural practices on unwanted pregnancy.	[Yaya, Sanni] Univ Parakou, Fac Med, Parakou, Benin; [Ghose, Bishwajit] Univ Dhaka, Inst Nutr & Food Sci, Dhaka, Bangladesh	University of Dhaka	Ghose, B (corresponding author), Univ Dhaka, Inst Nutr & Food Sci, Dhaka, Bangladesh.	brammaputram@gmail.com	Ghose, Bishwajit/L-8479-2015; Yaya, Sanni/C-1079-2019	Ghose, Bishwajit/0000-0003-4461-3821; Yaya, Sanni/0000-0002-4876-6043				Adhikari R, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-17; Alkema L, 2013, LANCET, V381, P1642, DOI 10.1016/S0140-6736(12)62204-1; Alum AC, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0089-5; Bishwajit G, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1379-4; Black AY, 2015, J OBSTET GYNAECOL CA, V37, P1086, DOI 10.1016/S1701-2163(16)30074-3; Curtis S, 2011, INT PERSPECT SEX R H, V37, P58, DOI 10.1363/3705811; Darroch JE, 2013, LANCET, V381, P1756, DOI 10.1016/S0140-6736(13)60597-8; Dastgiri Saeed, 2017, Mater Sociomed, V29, P58, DOI 10.5455/msm.2017.29.58-67; Exavery A, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-63; Haider Sadia, 2013, Glob Adv Health Med, V2, P94, DOI 10.7453/gahmj.2013.056; Horvath S, 2017, CURR PSYCHIAT REP, V19, DOI 10.1007/s11920-017-0832-4; Hurley KM, 2005, J AM DIET ASSOC, V105, P963, DOI 10.1016/j.jada.2005.03.007; Jackson E, 2011, THROMB RES, V127, pS35, DOI 10.1016/S0049-3848(11)70010-X; Joseph JG, 2009, AM J PUBLIC HEALTH, V99, P1053, DOI 10.2105/AJPH.2007.131425; Lothian JA, 2009, J PERINAT EDUC, V18, P48, DOI 10.1624/105812409X461225; Machiyama K, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-016-0268-z; Maier KM, 2002, CAN FAM PHYSICIAN, V48, P1199; Mccoy SI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105320; Melese T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0166287; Mezmur M, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2298-9; Nieto-Andrade B, 2017, GLOB HEALTH-SCI PRAC, V5, P75, DOI 10.9745/GHSP-D-16-00304; Prusty RK, 2014, J HEALTH POPUL NUTR, V32, P342; ROTHBERG AD, 1991, AM J OBSTET GYNECOL, V165, P403, DOI 10.1016/0002-9378(91)90103-X; Salazar M, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-26; Shah IH, 2012, REPROD HEALTH MATTER, V20, P169, DOI 10.1016/S0968-8080(12)39598-0; Skordis N, 2014, FERTILITY PREGNANCY; Srikanthan A, 2008, J OBSTET GYNAECOL CA, V30, P129, DOI 10.1016/S1701-2163(16)32736-0; Stephenson J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103085; Trussell J, 2007, CONTRACEPTION, V75, P168, DOI 10.1016/j.contraception.2006.11.009; Umar Abubakar Sadiq, 2016, Int J MCH AIDS, V5, P61; WHO, UNM NEED FAM PLANN; Yotebieng M, 2015, PAN AFR MED J, V20, DOI 10.11604/pamj.2015.20.235.5859	32	13	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2018	13	12							e0209801	10.1371/journal.pone.0209801	http://dx.doi.org/10.1371/journal.pone.0209801			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG0IO	30596733	Green Published, Green Submitted, gold			2023-01-03	WOS:000454627200089
J	Simon, F; Feuvret, L; Bresson, D; Guichard, JP; El Zein, S; Bernet, AL; Labidi, M; Calugaru, V; Froelich, S; Herman, P; Verillaud, B				Simon, Francois; Feuvret, Loic; Bresson, Damien; Guichard, Jean-Pierre; El Zein, Sophie; Bernet, Anne-Laure; Labidi, Moujahed; Calugaru, Valentin; Froelich, Sebastien; Herman, Philippe; Verillaud, Benjamin			Surgery and protontherapy in Grade I and II skull base chondrosarcoma: A comparative retrospective study	PLOS ONE			English	Article							NASAL-SEPTUM; ENDOSCOPIC RESECTION; SURGICAL-TREATMENT; RADIATION-THERAPY; PROTON THERAPY; CRANIAL BASE; FOLLOW-UP; CHORDOMAS; HEAD; RADIOSURGERY	Objective Skull base chondrosarcoma is a rare tumour usually treated by surgery and proton therapy. However, as mortality rate is very low and treatment complications are frequent, a less aggressive therapeutic strategy could be considered. The objective of this study was to compare the results of surgery only vs surgery and adjuvant proton therapy, in terms of survival and treatment adverse effects, based on a retrospective series. Methods Monocentric retrospective study at a tertiary care centre. All patients treated for a skull base grade I and II chondrosarcoma were included. We collected data concerning surgical and proton therapy treatment and up-to-date follow-up, including Common Terminology Criteria for Adverse Events (CTCAE) scores. Results 47 patients (23M/24F) were operated on between 2002 and 2015; mean age at diagnosis was 47 years-old (10-85). Petroclival and anterior skull base locations were found in 34 and 13 patients, respectively. Gross total resection was achieved in 17 cases (36%) and partial in 30 (64%). Adjuvant proton therapy (mean total dose 70 GyRBE, 1.8 GyRBE/day) was administered in 23 cases. Overall mean follow-up was 91 months (7-182). Of the patients treated by surgery only, 8 (34%) experienced residual tumour progression (mean delay 51 months) and 5 received second-line proton therapy. Adjuvant proton therapy was associated with a significantly lower rate of relapse (11%; p = 0.01). There was no significant difference in 10-year disease specific survival between patients initially treated with or without adjuvant proton therapy (100% vs 89.8%, p = 0.14). Difference in high-grade toxicity was not statistically significant between patients in both groups (25% (7) vs 11% (5), p = 0.10). The most frequent adverse effect of proton therapy was sensorineural hearing loss (39%). Conclusion Long-term disease specific survival was not significantly lower in patients without adjuvant proton therapy, but they experienced less adverse effects. We believe a surgery only strategy could be discussed, delaying as much as possible proton therapy in cases of relapse. Further prospective studies are needed to validate this more conservative strategy in skull base chondrosarcoma.	[Simon, Francois; Herman, Philippe; Verillaud, Benjamin] Hop Lariboisiere, AP HP, Dept Otorhinolaryngol, Paris, France; [Simon, Francois; Bresson, Damien; Guichard, Jean-Pierre; El Zein, Sophie; Bernet, Anne-Laure; Labidi, Moujahed; Froelich, Sebastien; Herman, Philippe; Verillaud, Benjamin] Paris Diderot Univ, Paris, France; [Feuvret, Loic] Hop La Pitie Salpetriere, AP HP, Dept Radiat Oncol, Paris, France; [Feuvret, Loic] Pierre & Marie Curie Univ, Paris, France; [Feuvret, Loic; Calugaru, Valentin] Ctr Univ, Inst Curie Ctr Protontherapie Orsay, Dept Radiat Oncol, Orsay, France; [Feuvret, Loic; Calugaru, Valentin] Ctr Univ, INSERM U61, Orsay, France; [Bresson, Damien; Bernet, Anne-Laure; Labidi, Moujahed; Froelich, Sebastien] Hop Lariboisiere, AP HP, Dept Neurosurg, Paris, France; [Guichard, Jean-Pierre] Hop Lariboisiere, AP HP, Dept Radiol, Paris, France; [El Zein, Sophie] Hop Lariboisiere, AP HP, Dept Pathol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	Simon, F (corresponding author), Hop Lariboisiere, AP HP, Dept Otorhinolaryngol, Paris, France.; Simon, F (corresponding author), Paris Diderot Univ, Paris, France.	fsimon05@gmail.com	Herman, Philippe/AAO-1376-2020; Verillaud, Benjamin/AAM-5105-2020; Calugaru, Valentin/AAG-9908-2020; SIMON, François/F-3880-2019; SIMON, François/L-8744-2019	SIMON, François/0000-0003-0082-538X; SIMON, François/0000-0003-0082-538X; Bresson, Damien/0000-0001-6250-8932; Labidi, Moujahed/0000-0002-7496-8327; CALUGARU, Valentin/0000-0002-7156-9750				Ahn PH, 2014, CANCER J, V20, P421, DOI 10.1097/PPO.0000000000000077; Alqudah M, 2016, J CRANIOFAC SURG, V27, P976, DOI 10.1097/SCS.0000000000002634; AMICHETTI M, 2012, RADIAT ONCOL, V7, DOI DOI 10.1186/1748-717X-7-; Amichetti M, 2010, NEUROSURG REV, V33, P155, DOI 10.1007/s10143-009-0235-z; Ares C, 2009, INT J RADIAT ONCOL, V75, P1111, DOI 10.1016/j.ijrobp.2008.12.055; Barnes L., 2005, PATHOLOGY GENETICS H; BERKMEN Y M, 1968, Clinical Radiology, V19, P327, DOI 10.1016/S0009-9260(68)80019-4; Bernstein KD, 2016, J SURG ONCOL, V114, P564, DOI 10.1002/jso.24368; Bloch O, 2013, NEUROSURG CLIN N AM, V24, P89, DOI 10.1016/j.nec.2012.08.002; Bloch OG, 2010, SKULL BASE-INTERD AP, V20, P149, DOI 10.1055/s-0029-1246218; Bloch OG, 2009, J CLIN NEUROSCI, V16, P1547, DOI 10.1016/j.jocn.2009.05.003; Boskos C, 2009, INT J RADIAT ONCOL, V75, P399, DOI 10.1016/j.ijrobp.2008.10.053; Brackmann DE, 2006, OTOL NEUROTOL, V27, P981, DOI 10.1097/01.mao.0000233812.48800.b4; Carlson ML, 2016, OTOL NEUROTOL, V37, P940, DOI 10.1097/MAO.0000000000001037; Carrau RL, 2004, AM J OTOLARYNG, V25, P274, DOI 10.1016/j.amjoto.2003.12.007; Coca-Pelaz A, 2014, EUR ARCH OTO-RHINO-L, V271, P2601, DOI 10.1007/s00405-013-2807-3; Coppit GL, 2002, OTOLARYNG HEAD NECK, V127, P569, DOI 10.1067/mhn.2002.128899; EVANS HL, 1977, CANCER-AM CANCER SOC, V40, P818, DOI 10.1002/1097-0142(197708)40:2<818::AID-CNCR2820400234>3.0.CO;2-B; Feuvret L, 2016, INT J RADIAT ONCOL, V95, P312, DOI 10.1016/j.ijrobp.2015.12.016; GAY E, 1995, NEUROSURGERY, V36, P887, DOI 10.1227/00006123-199505000-00001; Giger R, 2002, RHINOLOGY, V40, P96; Hasegawa T, 2007, J NEUROSURG, V107, P752, DOI 10.3171/JNS-07/10/0752; Health UDo Services H., 2009, COMMON TERMINOLOGY C; Holliday EB, 2014, INT J RADIAT ONCOL, V89, P292, DOI 10.1016/j.ijrobp.2014.02.029; Kainuma K, 2009, AURIS NASUS LARYNX, V36, P601, DOI 10.1016/j.anl.2008.12.006; Kano H, 2015, J NEUROSURG, V123, P1268, DOI 10.3171/2014.12.JNS132580; Khan MN, 2013, INT FORUM ALLERGY RH, V3, P670, DOI 10.1002/alr.21162; Knott PD, 2003, LARYNGOSCOPE, V113, P783, DOI 10.1097/00005537-200305000-00004; Koch BB, 2000, HEAD NECK-J SCI SPEC, V22, P408, DOI 10.1002/1097-0347(200007)22:4<408::AID-HED15>3.0.CO;2-H; Magnano M, 2015, EUR ARCH OTO-RHINO-L, V272, P765, DOI 10.1007/s00405-014-3419-2; Martin JJ, 2007, J NEUROSURG, V107, P758, DOI 10.3171/JNS-07/10/0758; McDonald MW, 2015, INT J RADIAT ONCOL, V91, P261, DOI 10.1016/j.ijrobp.2014.10.011; Moussazadeh N, 2015, J NEUROSURG, V122, P735, DOI 10.3171/2014.11.JNS14827; Nguyen QN, 2008, CURR ONCOL REP, V10, P338, DOI 10.1007/s11912-008-0052-5; Noel G, 2016, CHIN CLIN ONCOL, V5, DOI 10.21037/cco.2016.07.05; Oghalai JS, 2005, OTOL NEUROTOL, V26, P1052, DOI 10.1097/01.mao.0000185076.65822.f7; Potluri S, 2011, CLIN ONCOL-UK, V23, P199, DOI 10.1016/j.clon.2010.09.011; Raza SM, 2017, NEUROSURGERY, V81, P520, DOI 10.1093/neuros/nyx042; Samii A, 2009, NEUROSURG REV, V32, P67, DOI 10.1007/s10143-008-0170-4; Sbaihat A, 2013, ANN OTO RHINOL LARYN, V122, P763, DOI 10.1177/000348941312201206; Tzortzidis F, 2006, NEUROSURGERY, V58, P1090, DOI 10.1227/01.NEU.0000215892.65663.54; Van Gompel JJ, 2015, OTOLARYNG CLIN N AM, V48, P501, DOI 10.1016/j.otc.2015.02.009; Weber DC, 2016, NEURO-ONCOLOGY, V18, P236, DOI 10.1093/neuonc/nov154	43	12	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2018	13	12							e0208786	10.1371/journal.pone.0208786	http://dx.doi.org/10.1371/journal.pone.0208786			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE5TK	30557382	Green Published, Green Submitted, gold			2023-01-03	WOS:000453451000045
J	Kang, JC; Sun, W; Khare, P; Karimi, M; Wang, XL; Shen, Y; Ober, RJ; Ward, ES				Kang, Jeffrey C.; Sun, Wei; Khare, Priyanka; Karimi, Mostafa; Wang, Xiaoli; Shen, Yang; Ober, Raimund J.; Ward, E. Sally			Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy	NATURE BIOTECHNOLOGY			English	Article							IN-VIVO; BINDING; TRASTUZUMAB; FRAMEWORK; IMPROVES; SURFACE	We improve the potency of antibody-drug conjugates (ADCs) containing the human epidermal growth factor receptor 2 (HER2)-specific antibody pertuzumab by substantially reducing their affinity for HER2 at acidic endosomal pH relative to near neutral pH. These engineered pertuzumab variants show increased lysosomal delivery and cytotoxicity towards tumor cells expressing intermediate HER2 levels. In HER2(int) xenograft tumor models in mice, the variants show higher therapeutic efficacy than the parent ADC and a clinically approved HER2-specific ADC.	[Kang, Jeffrey C.; Sun, Wei; Khare, Priyanka; Wang, Xiaoli; Ober, Raimund J.; Ward, E. Sally] Texas A&M Univ, Hlth Sci Ctr, Dept Mol & Cellular Med, College Stn, TX 77843 USA; [Karimi, Mostafa; Shen, Yang] Texas A&M Univ, Dept Elect & Comp Engn, College Stn, TX USA; [Ober, Raimund J.] Texas A&M Univ, Dept Biomed Engn, College Stn, TX 77843 USA; [Ober, Raimund J.; Ward, E. Sally] Univ Southampton, Fac Med, Ctr Canc Immunol, Canc Sci Unit, Southampton, Hants, England; [Ward, E. Sally] Texas A&M Univ, Hlth Sci Ctr, Dept Microbial Pathogenesis & Immunol, Bryan, TX 77807 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; University of Southampton; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Ober, RJ; Ward, ES (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Dept Mol & Cellular Med, College Stn, TX 77843 USA.; Ober, RJ (corresponding author), Texas A&M Univ, Dept Biomed Engn, College Stn, TX 77843 USA.; Ober, RJ; Ward, ES (corresponding author), Univ Southampton, Fac Med, Ctr Canc Immunol, Canc Sci Unit, Southampton, Hants, England.; Ward, ES (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Dept Microbial Pathogenesis & Immunol, Bryan, TX 77807 USA.	raimund.ober@tamu.edu; sally.ward@tamu.edu	Shen, Yang/A-7939-2012; Karimi, Mostafa/K-8170-2019; Sun, Wei/AAJ-9828-2021; Khare, Priyanka/ABH-4730-2020	Shen, Yang/0000-0002-1703-7796; Sun, Wei/0000-0001-7661-4031; Ober, Raimund/0000-0002-1290-7430; Ward, E. Sally/0000-0003-3232-7238; khare, Priyanka/0000-0002-9445-5975; Karimi, Mostafa/0000-0002-8329-9612; Ward, E. Sally/0000-0002-9311-8571	Cancer Prevention and Research Institute of Texas (CPRIT) [RP140141]; National Institute of General Medical Sciences of the National Institutes of Health [R35GM124952]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R35GM124952] Funding Source: NIH RePORTER	Cancer Prevention and Research Institute of Texas (CPRIT); National Institute of General Medical Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank A. Gazdar, J. Minna and K. Huffman (Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center at Dallas) for the gift of HCC1954 cells. We are grateful to L. Dangott, C. Klemashevich and S. Shankar for help with LC-MS/MS. R. Li and J. Heimann recloned the genes encoding the anti-henegg lysozyme antibody (control) into the expression constructs used in this study. This work was supported in part by the Cancer Prevention and Research Institute of Texas (CPRIT; RP140141 to E.S.W.) and the National Institute of General Medical Sciences of the National Institutes of Health (R35GM124952 to Y.S.).	Austin CD, 2004, MOL BIOL CELL, V15, P5268, DOI 10.1091/mbc.E04-07-0591; Burris HA, 2011, J CLIN ONCOL, V29, P398, DOI 10.1200/JCO.2010.29.5865; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Chao J, 2010, IEEE T INF TECHNOL B, V14, P1075, DOI 10.1109/TITB.2010.2049024; Chaparro-Riggers J, 2012, J BIOL CHEM, V287, P11090, DOI 10.1074/jbc.M111.319764; Dalloneau E, 2016, ONCOTARGET, V7, P54415, DOI 10.18632/oncotarget.10074; de Goeij BECG, 2016, CURR OPIN IMMUNOL, V40, P14, DOI 10.1016/j.coi.2016.02.008; Devanaboyina SC, 2013, MABS-AUSTIN, V5, P851, DOI 10.4161/mabs.26389; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; Hinrichs MJM, 2015, AAPS J, V17, P1055, DOI 10.1208/s12248-015-9790-0; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; Igawa T, 2010, NAT BIOTECHNOL, V28, P1203, DOI 10.1038/nbt.1691; Karimi M, 2018, BIOINFORMATICS, V34, P811, DOI 10.1093/bioinformatics/bty564; Li GM, 2018, MOL CANCER THER, V17, P1441, DOI 10.1158/1535-7163.MCT-17-0296; Li JY, 2016, CANCER CELL, V29, P117, DOI 10.1016/j.ccell.2015.12.008; Li R, 2018, MOL CANCER THER, V17, P169, DOI 10.1158/1535-7163.MCT-17-0092; LoRusso PM, 2011, CLIN CANCER RES, V17, P6437, DOI 10.1158/1078-0432.CCR-11-0762; Lyon RP, 2015, NAT BIOTECHNOL, V33, P733, DOI 10.1038/nbt.3212; Ober RJ, 2002, ANAL BIOCHEM, V306, P228, DOI 10.1006/abio.2002.5716; Olsson MHM, 2011, J CHEM THEORY COMPUT, V7, P525, DOI 10.1021/ct100578z; Pyzik M, 2015, J IMMUNOL, V194, P4595, DOI 10.4049/jimmunol.1403014; Ram S, 2014, MABS-AUSTIN, V6, P1211, DOI 10.4161/mabs.29865; Sievers EL, 2013, ANNU REV MED, V64, P15, DOI 10.1146/annurev-med-050311-201823; Swiercz R, 2017, ONCOTARGET, V8, P3528, DOI 10.18632/oncotarget.13869; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Vaccaro C, 2005, NAT BIOTECHNOL, V23, P1283, DOI 10.1038/nbt1143; Ward ES, 2009, ADV IMMUNOL, V103, P77, DOI 10.1016/S0065-2776(09)03004-1; WARD ES, 1992, J MOL BIOL, V224, P885, DOI 10.1016/0022-2836(92)90455-S	29	38	41	1	60	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2019	37	5					523	+		10.1038/s41587-019-0073-7	http://dx.doi.org/10.1038/s41587-019-0073-7			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	HZ8MK	30936563	Green Accepted			2023-01-03	WOS:000469110000012
J	Shendure, J; Findlay, GM; Snyder, MW				Shendure, Jay; Findlay, Gregory M.; Snyder, Matthew W.			Genomic Medicine-Progress, Pitfalls, and Promise	CELL			English	Review							CELL-FREE DNA; NONINVASIVE PRENATAL-DIAGNOSIS; DE-NOVO MUTATIONS; COMPLEX TRAITS; LUNG-CANCER; PLASMA; ANEUPLOIDY; GENE; HERITABILITY; DISORDERS	In the wake of the Human Genome Project (HGP), strong expectations were set for the timeline and impact of genomics on medicine-an anticipated transformation in the diagnosis, treatment, and prevention of disease. In this Perspective, we take stock of the nascent field of genomic medicine. In what areas, if any, is genomics delivering on this promise, or is the path to success clear? Where are we falling short, and why? What have been the unanticipated developments? Overall, we argue that the optimism surrounding the transformational potential of genomics on medicine remains justified, albeit with a considerably different form and timescale than originally projected. We also argue that the field needs to pivot back to basics, as understanding the entirety of the genotype-to-phenotype equation is a likely prerequisite for delivering on the full potential of the human genome to advance the human condition.	[Shendure, Jay; Findlay, Gregory M.; Snyder, Matthew W.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; [Shendure, Jay] Howard Hughes Med Inst, Seattle, WA 98195 USA; [Shendure, Jay] Brotman Baty Inst Precis Med, Seattle, WA 98195 USA; [Snyder, Matthew W.] Bellwether Bio Inc, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute	Shendure, J (corresponding author), Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.; Shendure, J (corresponding author), Howard Hughes Med Inst, Seattle, WA 98195 USA.; Shendure, J (corresponding author), Brotman Baty Inst Precis Med, Seattle, WA 98195 USA.	shendure@uw.edu	Shendure, Jay/AAU-3684-2021; Findlay, Gregory/AAX-9029-2020	Findlay, Gregory/0000-0002-7767-8608; Snyder, Matthew/0000-0001-7433-4343	National Institutes of Health [5DP1HG007811]; NATIONAL CANCER INSTITUTE [F30CA213728] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [DP1HG007811] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007266] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the Shendure Lab and many colleagues for many useful discussions on these topics. We are greatly appreciative of the Illumina marketing department for their assistance with estimates of the number of individuals who have received genomic testing. This work was funded in part by grant 5DP1HG007811 from the National Institutes of Health. J.S. is an investigator of the Howard Hughes Medical Institute.	Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; [Anonymous], 2013, NAT GENET, DOI DOI 10.1038/NG.2797; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; BAIRD PA, 1988, AM J HUM GENET, V42, P677; Bernier R, 2014, CELL, V158, P263, DOI 10.1016/j.cell.2014.06.017; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Bianchi DW, 2014, NEW ENGL J MED, V370, P799, DOI 10.1056/NEJMoa1311037; Boyle EA, 2017, CELL, V169, P1177, DOI 10.1016/j.cell.2017.05.038; Burdett T, 2018, SPOT EMBL EBI NHGRI; Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z; Camunas-Soler J, 2018, CLIN CHEM, V64, P336, DOI 10.1373/clinchem.2017.278101; Chan KCA, 2017, NEW ENGL J MED, V377, P513, DOI [10.1056/NEJMoa1701717, 10.1056/nejmoa1701717]; Chan KCA, 2016, P NATL ACAD SCI USA, V113, pE8159, DOI 10.1073/pnas.1615800113; Chaudhary R, 2017, WORLD J CARDIOL, V9, P76, DOI 10.4330/wjc.v9.i2.76; Chiu RWK, 2008, P NATL ACAD SCI USA, V105, P20458, DOI 10.1073/pnas.0810641105; Choi M, 2009, P NATL ACAD SCI USA, V106, P19096, DOI 10.1073/pnas.0910672106; Chong JX, 2015, AM J HUM GENET, V97, P199, DOI 10.1016/j.ajhg.2015.06.009; Cohen JD, 2018, SCIENCE, V359, P926, DOI 10.1126/science.aar3247; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Couch FJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003212; Dar P, 2016, CLIN LAB MED, V36, P199, DOI 10.1016/j.cll.2016.01.015; deVos T, 2009, CLIN CHEM, V55, P1337, DOI 10.1373/clinchem.2008.115808; Dewey FE, 2017, NEW ENGL J MED, V377, P211, DOI 10.1056/NEJMoa1612790; Do R, 2013, NAT GENET, V45, P1345, DOI 10.1038/ng.2795; Dunbar CE, 2018, SCIENCE, V359, P175, DOI 10.1126/science.aan4672; Eldomery MK, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0412-6; Erlich Y, 2018, SCIENCE, V362, P690, DOI 10.1126/science.aau4832; Fan HC, 2008, P NATL ACAD SCI USA, V105, P16266, DOI 10.1073/pnas.0808319105; Fan HC, 2012, NATURE, V487, P320, DOI 10.1038/nature11251; Farnaes L, 2018, NPJ GENOM MED, V3, DOI 10.1038/s41525-018-0049-4; Findlay GM, 2018, NATURE, V562, P217, DOI 10.1038/s41586-018-0461-z; Finucane HK, 2015, NAT GENET, V47, P1228, DOI 10.1038/ng.3404; Fuchsberger C, 2016, NATURE, V536, P41, DOI 10.1038/nature18642; Gaj T, 2013, TRENDS BIOTECHNOL, V31, P397, DOI 10.1016/j.tibtech.2013.04.004; Gasperini M, 2019, CELL, V176, P377, DOI 10.1016/j.cell.2018.11.029; Gitlin J. M., 2013, CALCULATING EC IMPAC; Global Genomic Medicine Collaborative, 2018, IMPR IMPL GLOB GEN M; Gunderson KL, 2005, NAT GENET, V37, P549, DOI 10.1038/ng1547; Guo SC, 2017, NAT GENET, V49, P635, DOI 10.1038/ng.3805; Haque I. S., 2017, BIORXIV, DOI [10.1101/237578, DOI 10.1101/237578]; Herper M, 2018, FORBES; Hoischen A, 2010, NAT GENET, V42, P483, DOI 10.1038/ng.581; Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785; Hou Y, 2013, CELL, V155, P1492, DOI 10.1016/j.cell.2013.11.040; Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; Iossifov I, 2014, NATURE, V515, P216, DOI 10.1038/nature13908; Juneau K, 2014, FETAL DIAGN THER, V36, P282, DOI 10.1159/000367626; Kalia SS, 2017, GENET MED, V19, P249, DOI 10.1038/gim.2016.190; Khera AV, 2018, NAT GENET, V50, P1219, DOI 10.1038/s41588-018-0183-z; Kitzman JO, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004323; Kolata G, 2018, NY TIMES; Kumar A, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0160-4; LEON SA, 1977, CANCER RES, V37, P646; Litterman Nadia K, 2014, F1000Res, V3, P261, DOI 10.12688/f1000research.5564.1; Liu SY, 2018, CELL, V175, P347, DOI 10.1016/j.cell.2018.08.016; Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; MANDEL P, 1948, CR SOC BIOL, V142, P241; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; McCandless SE, 2004, AM J HUM GENET, V74, P121, DOI 10.1086/381053; Meng LY, 2017, JAMA PEDIATR, V171, DOI 10.1001/jamapediatrics.2017.3438; Motsinger-Reif AA, 2013, PHARMACOGENET GENOM, V23, P383, DOI 10.1097/FPC.0b013e32833d7b45; Mumbach MR, 2016, NAT METHODS, V13, P919, DOI 10.1038/nmeth.3999; Nelson MR, 2015, NAT GENET, V47, P856, DOI 10.1038/ng.3314; Ng SB, 2009, NATURE, V461, P272, DOI 10.1038/nature08250; Niemi MEK, 2018, NATURE, V562, P268, DOI 10.1038/s41586-018-0566-4; Norton ME, 2015, NEW ENGL J MED, V372, P1589, DOI 10.1056/NEJMoa1407349; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pasi KJ, 2017, NEW ENGL J MED, V377, P819, DOI [10.1056/NEJMoa1616569, 10.1056/NEJMoa1708483]; Perdigoto C, 2017, NAT REV GENET, V18, DOI 10.1038/nrg.2017.35; Radovich M, 2016, ONCOTARGET, V7, P56491, DOI 10.18632/oncotarget.10606; Ramsey BW, 2011, NEW ENGL J MED, V365, P1663, DOI 10.1056/NEJMoa1105185; Ribeil JA, 2017, NEW ENGL J MED, V376, P848, DOI 10.1056/NEJMoa1609677; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Russell R, 2018, POLYGENIC RISK SCORE; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Saunders CJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004041; Shendure J, 2005, SCIENCE, V309, P1728, DOI 10.1126/science.1117389; Shendure J, 2017, NATURE, V550, P345, DOI 10.1038/nature24286; Shendure J, 2012, NAT BIOTECHNOL, V30, P1084, DOI 10.1038/nbt.2421; Snyder MW, 2016, CELL, V164, P57, DOI 10.1016/j.cell.2015.11.050; Sparks AB, 2012, PRENATAL DIAG, V32, P3, DOI 10.1002/pd.2922; Srinivasan A, 2013, AM J HUM GENET, V92, P167, DOI 10.1016/j.ajhg.2012.12.006; Starita LM, 2017, AM J HUM GENET, V101, P315, DOI 10.1016/j.ajhg.2017.07.014; Stossel TP, 2008, CELL, V134, P903, DOI 10.1016/j.cell.2008.09.008; STROUN M, 1987, EUR J CANCER CLIN ON, V23, P707, DOI 10.1016/0277-5379(87)90266-5; Sun K, 2015, P NATL ACAD SCI USA, V112, pE5503, DOI 10.1073/pnas.1508736112; Tebas P, 2014, NEW ENGL J MED, V370, P901, DOI 10.1056/NEJMoa1300662; Topol Eric J, 2014, Cell, V157, P241, DOI 10.1016/j.cell.2014.02.012; Visscher PM, 2017, AM J HUM GENET, V101, P5, DOI 10.1016/j.ajhg.2017.06.005; Voight Benjamin F, 2012, Lancet, V380, P572, DOI 10.1016/S0140-6736(12)60312-2; Wapner RJ, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2014.11.041; Weiner DJ, 2017, NAT GENET, V49, P978, DOI 10.1038/ng.3863; Wheeler HE, 2015, J CLIN ONCOL, V33; Willig LK, 2015, LANCET RESP MED, V3, P377, DOI 10.1016/S2213-2600(15)00139-3; Wilson C, 2018, NEW SCI; Yang JA, 2010, NAT GENET, V42, P565, DOI 10.1038/ng.608; Yang YP, 2013, NEW ENGL J MED, V369, P1502, DOI 10.1056/NEJMoa1306555; Yuzuki D., 2015, SERACARE BLOG   1117; Zimmermann B, 2012, PRENATAL DIAG, V32, P1233, DOI 10.1002/pd.3993	105	62	64	2	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2019	177	1					45	57		10.1016/j.cell.2019.02.003	http://dx.doi.org/10.1016/j.cell.2019.02.003			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HP9SX	30901547	Green Accepted, Bronze			2023-01-03	WOS:000462034400012
J	Rubinstein, SM; de Zoete, A; van Middelkoop, M; Assendelft, WJJ; de Boer, MR; van Tulder, MW				Rubinstein, Sidney M.; de Zoete, Annemarie; van Middelkoop, Marienke; Assendelft, Willem J. J.; de Boer, Michiel R.; van Tulder, Maurits W.			Benefits and harms of spinal manipulative therapy for the treatment of chronic low back pain: systematic review and meta-analysis of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							FOLLOW-UP OUTCOMES; MANUAL THERAPY; CLINICAL-TRIAL; MEDICAL-CARE; COST-EFFECTIVENESS; TERM EFFECTIVENESS; CHIROPRACTIC CARE; MCKENZIE METHOD; NECK PAIN; PHYSIOTHERAPY	OBJECTIVE To assess the benefits and harms of spinal manipulative therapy (SMT) for the treatment of chronic low back pain. DESIGN Systematic review and meta-analysis of randomised controlled trials. DATA SOURCES Medline, PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, Physiotherapy Evidence Database (PEDro), Index to Chiropractic Literature, and trial registries up to 4 May 2018, including reference lists of eligible trials and related reviews. ELIGIBILITY CRITERIA FOR SELECTING STUDIES Randomised controlled trials examining the effect of spinal manipulation or mobilisation in adults (>= 18 years) with chronic low back pain with or without referred pain. Studies that exclusively examined sciatica were excluded, as was grey literature. No restrictions were applied to language or setting. REVIEW METHODS Two reviewers independently selected studies, extracted data, and assessed risk of bias and quality of the evidence. The effect of SMT was compared with recommended therapies, non-recommended therapies, sham (placebo) SMT, and SMT as an adjuvant therapy. Main outcomes were pain and back specific functional status, examined as mean differences and standardised mean differences (SMD), respectively. Outcomes were examined at 1, 6, and 12 months. Quality of evidence was assessed using GRADE. A random effects model was used and statistical heterogeneity explored. RESULTS 47 randomised controlled trials including a total of 9211 participants were identified, who were on average middle aged (35-60 years). Most trials compared SMT with recommended therapies. Moderate quality evidence suggested that SMT has similar effects to other recommended therapies for short term pain relief (mean difference -3.17, 95% confidence interval -7.85 to 1.51) and a small, clinically better improvement in function (SMD -0.25, 95% confidence interval -0.41 to -0.09). High quality evidence suggested that compared with non-recommended therapies SMT results in small, not clinically better effects for short term pain relief (mean difference -7.48, -11.50 to -3.47) and small to moderate clinically better improvement in function (SMD -0.41, -0.67 to -0.15). In general, these results were similar for the intermediate and long term outcomes as were the effects of SMT as an adjuvant therapy. Evidence for sham SMT was low to very low quality; therefore these effects should be considered uncertain. Statistical heterogeneity could not be explained. About half of the studies examined adverse and serious adverse events, but in most of these it was unclear how and whether these events were registered systematically. Most of the observed adverse events were musculoskeletal related, transient in nature, and of mild to moderate severity. One study with a low risk of selection bias and powered to examine risk (n=183) found no increased risk of an adverse event (relative risk 1.24, 95% confidence interval 0.85 to 1.81) or duration of the event (1.13, 0.59 to 2.18) compared with sham SMT. In one study, the Data Safety Monitoring Board judged one serious adverse event to be possibly related to SMT. CONCLUSION SMT produces similar effects to recommended therapies for chronic low back pain, whereas SMT seems to be better than non-recommended interventions for improvement in function in the short term. Clinicians should inform their patients of the potential risks of adverse events associated with SMT.	[Rubinstein, Sidney M.; de Zoete, Annemarie; de Boer, Michiel R.; van Tulder, Maurits W.] Vrije Univ Amsterdam, Fac Sci, Dept Hlth Sci, Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands; [van Middelkoop, Marienke] Erasmus MC, Dept Gen Practice, Rotterdam, Netherlands; [Assendelft, Willem J. J.] Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, Nijmegen, Netherlands; [van Tulder, Maurits W.] Aarhus Univ Hosp, Dept Physiotherapy & Occupat Therapy, Aarhus, Denmark	Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus MC; Radboud University Nijmegen; Aarhus University	Rubinstein, SM (corresponding author), Vrije Univ Amsterdam, Fac Sci, Dept Hlth Sci, Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.	s.m.rubinstein@vu.nl	de Zoete, Annemarie/J-3865-2014; Assendelft, W.J.J./H-8008-2014; van Tulder, Maurits/AAB-9785-2022	Assendelft, W.J.J./0000-0002-2966-3778; van Tulder, Maurits/0000-0002-7589-8471; de Boer, Michiel/0000-0001-9240-0199; de Zoete, Annemarie/0000-0002-1421-3862; Rubinstein, Sidney/0000-0002-4819-994X; van Middelkoop, Marienke/0000-0001-6926-0618				Airaksinen O, 2006, EUR SPINE J, V15, pS192, DOI 10.1007/s00586-006-1072-1; Andronis L, 2017, APPL HEALTH ECON HEA, V15, P173, DOI 10.1007/s40258-016-0268-8; Balthazard P, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-162; Bialosky JE, 2014, J PAIN, V15, P136, DOI 10.1016/j.jpain.2013.10.005; Bialosky JE, 2009, PHYS THERAPY, V89, P1292, DOI 10.2522/ptj.20090058; Bialosky JE, 2009, MANUAL THER, V14, P531, DOI 10.1016/j.math.2008.09.001; Bons SCS, 2017, NHG GUIDELINE ASPECI; Bronfort G, 1996, J Manipulative Physiol Ther, V19, P570; Bronfort G, 2011, SPINE J, V11, P585, DOI 10.1016/j.spinee.2011.01.036; Cecchi F, 2010, CLIN REHABIL, V24, P26, DOI 10.1177/0269215509342328; Chou R, 2016, AHRQ COMP EFFECTIVEN; Chown M, 2008, PHYSIOTHERAPY, V94, P21, DOI 10.1016/j.physio.2007.04.014; Cohen J., 1988, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; Cook C, 2013, MANUAL THER, V18, P191, DOI 10.1016/j.math.2012.08.005; Coronado RA, 2012, J ELECTROMYOGR KINES, V22, P752, DOI 10.1016/j.jelekin.2011.12.013; Currie SJ, 2016, J MANIP PHYSIOL THER, V39, P288, DOI 10.1016/j.jmpt.2016.02.011; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dima A, 2013, BRIT J GEN PRACT, V63, pE490, DOI 10.3399/bjgp13X669211; Dorron SL, 2016, CHIROPR MAN THER, V24, DOI 10.1186/s12998-016-0128-5; Dougherty PE, 2014, CHIROPR MAN THER, V22, DOI 10.1186/s12998-014-0041-8; EVANS DP, 1978, RHEUMATOL REHABIL, V17, P46, DOI 10.1093/rheumatology/17.1.46; Ferreira ML, 2007, PAIN, V131, P31, DOI 10.1016/j.pain.2006.12.008; Foster NE, PREVENTION TREATMENT; Franke H, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-286; Fryer G, 2017, INT J OSTEOPATH MED, V25, P30, DOI 10.1016/j.ijosm.2017.05.002; Furlan AD, 2009, SPINE, V34, P1929, DOI 10.1097/BRS.0b013e3181b1c99f; Ghroubi S., 2007, Annales de Readaptation et de Medecine Physique, V50, P570, DOI 10.1016/j.annrmp.2007.02.012; GIBSON T, 1985, LANCET, V1, P1258; GILBERT JR, 1985, BRIT MED J, V291, P791, DOI 10.1136/bmj.291.6498.791; Goldby LJ, 2006, SPINE, V31, P1083, DOI 10.1097/01.brs.0000216464.37504.64; Gudavalli MR, 2006, EUR SPINE J, V15, P1070, DOI 10.1007/s00586-005-0021-8; Haas M, 2014, SPINE J, V14, P1106, DOI 10.1016/j.spinee.2013.07.468; Hebert JJ, 2015, J MANIP PHYSIOL THER, V38, P677, DOI 10.1016/j.jmpt.2013.05.009; Hemmila HM, 2002, J MANIP PHYSIOL THER, V25, P99, DOI 10.1067/mmt.2002.122329; Hidalgo B, 2015, J MANIP PHYSIOL THER, V38, P365, DOI 10.1016/j.jmpt.2015.06.013; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Hondras MA, 2009, J MANIP PHYSIOL THER, V32, P330, DOI 10.1016/j.jmpt.2009.04.012; Hsieh CYJ, 2002, SPINE, V27, P1142, DOI 10.1097/00007632-200206010-00003; Hurwitz EL, 2002, SPINE, V27, P2193, DOI 10.1097/00007632-200210150-00002; Hurwitz EL, 2006, SPINE, V31, P611, DOI 10.1097/01.brs.0000202559.41193.b2; IntHout J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010247; Koes BW, 2010, EUR SPINE J, V19, P2075, DOI 10.1007/s00586-010-1502-y; KOES BW, 1992, SPINE, V17, P28, DOI 10.1097/00007632-199201000-00005; Krekoukias G, 2017, J MAN MANIP THER, V25, P66, DOI 10.1080/10669817.2016.1184435; Licciardone JC, 2003, SPINE, V28, P1355, DOI 10.1097/00007632-200307010-00002; Licciardone JC, 2013, ANN FAM MED, V11, P122, DOI 10.1370/afm.1468; Manca A, 2004, BMJ-BRIT MED J, V329, P1381, DOI 10.1136/bmj.38282.607859.AE; Castro-Sanchez AM, 2016, SPINE J, V16, P302, DOI 10.1016/j.spinee.2015.08.057; Michaleff ZA, 2012, J ELECTROMYOGR KINES, V22, P655, DOI 10.1016/j.jelekin.2012.02.011; Mohseni-Bandpei MA, 2006, PHYSIOTHERAPY, V92, P34, DOI 10.1016/j.physio.2005.05.005; Muller R, 2005, J MANIP PHYSIOL THER, V28, P3, DOI 10.1016/j.jmpt.2004.12.004; NICE guideline, 2016, LOW BACK PAIN SCI 16; Niemisto L, 2005, SPINE, V30, P1109, DOI 10.1097/01.brs.0000162569.00685.7b; Paatelma M, 2008, J REHABIL MED, V40, P858, DOI 10.2340/16501977-0262; Petersen T, 2011, SPINE, V36, P1999, DOI 10.1097/BRS.0b013e318201ee8e; POPE MH, 1994, SPINE, V19, P2571, DOI 10.1097/00007632-199411001-00013; Postacchini F, 1988, NEURO-ORTHOPEDICS, V6, P28; Qaseem A, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367; Randoll C, 2017, NEUROSCIENCE, V349, P220, DOI 10.1016/j.neuroscience.2017.03.006; Rasmussen J, 2008, JOINT BONE SPINE, V75, P708, DOI 10.1016/j.jbspin.2007.12.011; Rasmussen-Barr E, 2003, MANUAL THER, V8, P233, DOI 10.1016/S1356-689X(03)00053-5; Rubinstein SM, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008112.pub2; Rubinstein SM, 2014, J MANIP PHYSIOL THER, V37, P523, DOI 10.1016/j.jmpt.2014.07.007; Ruddock JK, 2016, J CHIROPR MED, V15, P165, DOI 10.1016/j.jcm.2016.04.014; Samir SM, 2016, INT J PHARMTECH RES, V9, P92; Sandoz R, 1969, ANN SWISS CHIRO ASS, V4, P47; Sarker KK, 2017, INT J PHARM BIO SCI, V7, P992; Savovic J, 2018, AM J EPIDEMIOL, V187, P1113, DOI 10.1093/aje/kwx344; Senna MK, 2011, SPINE, V36, P1427, DOI 10.1097/BRS.0b013e3181f5dfe0; Skillgate E, 2007, CLIN J PAIN, V23, P431, DOI 10.1097/AJP.0b013e31805593d8; Stochkendahl MJ, 2018, EUR SPINE J, V27, P60, DOI 10.1007/s00586-017-5099-2; Swait G, 2017, CHIROPR MAN THER, V25, DOI 10.1186/s12998-017-0168-5; Ulger O, 2017, J BACK MUSCULOSKELET, V30, P1303, DOI 10.3233/BMR-169673; Underwood M, 2004, BMJ-BRIT MED J, V329, P1377, DOI 10.1136/bmj.38282.669225AE; Verma Y, 2013, INT J PHYSIOTHER RES, V3, P48; Vismara L, 2012, MANUAL THER, V17, P451, DOI 10.1016/j.math.2012.05.002; Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2; Waagen GN, 1986, MANUAL MED, V2, P63; Walker BF, 2013, SPINE, V38, P2071, DOI 10.1097/01.brs.0000435032.73187.c7; Walker BF, 2013, SPINE, V38, P1723, DOI 10.1097/BRS.0b013e31829fefe4; Waqqar S, 2016, PAK J MED SCI, V32, P476, DOI 10.12669/pjms.322.9127; Wilkey A, 2008, J ALTERN COMPLEM MED, V14, P465, DOI 10.1089/acm.2007.0796; Wong AYL, 2015, SPINE, V40, P1329, DOI 10.1097/BRS.0000000000000981; Xia T, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1821-1; Xia T, 2016, SPINE, V41, pE702, DOI 10.1097/BRS.0000000000001373; Zaproudina N, 2009, COMPLEMENT THER MED, V17, P23, DOI 10.1016/j.ctim.2008.08.005	86	92	97	3	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 13	2019	364								l689	10.1136/bmj.l689	http://dx.doi.org/10.1136/bmj.l689			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP5VW	30867144	Green Published, hybrid			2023-01-03	WOS:000461751600001
J	Makwana, K; Gosai, N; Poe, A; Kondratov, RV				Makwana, Kuldeep; Gosai, Neha; Poe, Allan; Kondratov, Roman V.			Calorie restriction reprograms diurnal rhythms in protein translation to regulate metabolism	FASEB JOURNAL			English	Article						ACOTs; lipid metabolism; mRNA-sequencing	ACYL-COA THIOESTERASE; CIRCADIAN-RHYTHM; LIPID-METABOLISM; GENE-EXPRESSION; ENERGY-INTAKE; CELL-SIZE; LIVER; CLOCKS; CONSEQUENCES; DISRUPTION	Calorie restriction (CR) delays aging and affects the circadian clocks by reprogramming circadian rhythms in gene expression. To expand on the circadian mechanisms in CR, we assayed rhythms in the protein translation by analyzing polysome-associated mRNAs in the liver of mice fed ad libitum (AL) and CR diets. Global comparison of the diets revealed that <1% of transcripts were differentially abundant in the polysomes. In contrast, the large differential, up to 10%, was detected when CR and AL diets were compared at individual times throughout the day. Most transcripts that were rhythmic under AL lost their rhythms, and many new transcripts gained rhythms under CR. Only a small fraction of transcripts, including the circadian clock genes, were rhythmic under both diets. Thus, CR strongly reprograms translation. CR affected translation of enzymes regulating long-chain acetyl-coenzyme A (Acyl-CoA) metabolism. The expression of the Acyl-CoA thioesterase (ACOT) family was induced upon CR, leading to the increased transcriptional activity of peroxisome proliferator-activated receptor , the transcriptional factor regulated by the ACOT products. We propose that the differential translation induced by CR leads to a temporal partition and reprogramming of metabolic processes and provides a link between CR, lipid metabolism, and the circadian clock.Makwana, K., Gosai, N., Poe, A., Kondratov, R. V. Calorie restriction reprograms diurnal rhythms in protein translation to regulate metabolism.	[Makwana, Kuldeep; Gosai, Neha; Poe, Allan; Kondratov, Roman V.] Cleveland State Univ, Ctr Gene Regulat Hlth & Dis, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA	University System of Ohio; Cleveland State University	Kondratov, RV (corresponding author), Cleveland State Univ, Ctr Gene Regulat Hlth & Dis, 2121 Euclid Ave, Cleveland, OH 44115 USA.	r.kondratov@csuohio.edu	Makwana, Kuldeep/AAD-9386-2022	Makwana, Kuldeep/0000-0003-0890-8120; Kondratov, Roman/0000-0003-3449-745X	U.S. National Institues of Health, National Institute on Aging Grant [5RO1-AG039547]; NATIONAL INSTITUTE ON AGING [R01AG039547] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD025252] Funding Source: NIH RePORTER	U.S. National Institues of Health, National Institute on Aging Grant; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by U.S. National Institues of Health, National Institute on Aging Grant 5RO1-AG039547 (to R.V.K.), and internal support by the Gene Regulation in Health and Diseases Department at Cleveland State University (to R.V.K.). The authors declare no conflicts of interest.	Acosta-Rodriguez VA, 2017, CELL METAB, V26, P267, DOI 10.1016/j.cmet.2017.06.007; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Anderson RM, 2010, TRENDS ENDOCRIN MET, V21, P134, DOI 10.1016/j.tem.2009.11.005; Asher G, 2015, CELL, V161, P84, DOI 10.1016/j.cell.2015.03.015; Astafev AA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09289-9; Atger F, 2015, P NATL ACAD SCI USA, V112, pE6579, DOI 10.1073/pnas.1515308112; Barger JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120738; Bass J, 2012, NATURE, V491, P348, DOI 10.1038/nature11704; Brocker Chad, 2010, Hum Genomics, V4, P411; Bruss MD, 2010, AM J PHYSIOL-ENDOC M, V298, pE108, DOI 10.1152/ajpendo.00524.2009; Canto C, 2011, PHYSIOLOGY, V26, P214, DOI 10.1152/physiol.00010.2011; Hernandez-Rodas MC, 2015, INT J MOL SCI, V16, P25168, DOI 10.3390/ijms161025168; Chalasani N, 2012, HEPATOLOGY, V55, P2005, DOI 10.1002/hep.25762; Chasse H, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkw907; Chaudhari Amol, 2017, Nutr Healthy Aging, V4, P101, DOI 10.3233/NHA-160006; Chen SF, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1469-3; Chou SH, 2010, CARDIOVASC RES, V87, P751, DOI 10.1093/cvr/cvq095; DCOSTA AP, 1993, MECH AGEING DEV, V71, P59, DOI 10.1016/0047-6374(93)90035-P; Dermit M, 2017, MOL BIOSYST, V13, P2477, DOI 10.1039/c7mb00476a; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Ellis JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116587; Franklin MP, 2017, DIABETES, V66, P2112, DOI 10.2337/db16-1519; Froy O, 2013, AGEING RES REV, V12, P931, DOI 10.1016/j.arr.2013.09.002; Furuhashi M, 2008, NAT REV DRUG DISCOV, V7, P489, DOI 10.1038/nrd2589; Gachon F, 2011, P NATL ACAD SCI USA, V108, P4794, DOI 10.1073/pnas.1002862108; Heilbronn LK, 2003, AM J CLIN NUTR, V78, P361, DOI 10.1093/ajcn/78.3.361; Hsiao YS, 2004, J BIOL CHEM, V279, P31584, DOI 10.1074/jbc.M403484200; Hughes ME, 2010, J BIOL RHYTHM, V25, P372, DOI 10.1177/0748730410379711; Hunt MC, 2006, FASEB J, V20, P1855, DOI 10.1096/fj.06-6042com; Hunt MC, 2012, BBA-MOL BASIS DIS, V1822, P1397, DOI 10.1016/j.bbadis.2012.03.009; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Iwasaki S, 2017, TRENDS BIOCHEM SCI, V42, P612, DOI 10.1016/j.tibs.2017.05.004; Jouffe C, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001455; Jove M, 2014, AGING CELL, V13, P828, DOI 10.1111/acel.12241; Karunadharma PP, 2015, AGING CELL, V14, P547, DOI 10.1111/acel.12317; Katewa SD, 2016, CELL METAB, V23, P143, DOI 10.1016/j.cmet.2015.10.014; Ko CH, 2006, HUM MOL GENET, V15, pR271, DOI 10.1093/hmg/ddl207; Kulkarni SR, 2013, PHARM RES-DORDR, V30, P2221, DOI 10.1007/s11095-013-1138-9; Larson-Meyer DE, 2006, DIABETES CARE, V29, P1337, DOI 10.2337/dc05-2565; Lee C., 2016, F1000RESEARCH, P1; Li Min-Dian, 2012, Yale Journal of Biology and Medicine, V85, P387; Long YC, 2006, J CLIN INVEST, V116, P1776, DOI 10.1172/JCI29044; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maier T, 2009, FEBS LETT, V583, P3966, DOI 10.1016/j.febslet.2009.10.036; Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3; Manoogian ENC, 2017, AGEING RES REV, V39, P59, DOI 10.1016/j.arr.2016.12.006; Melamed D, 2007, METHOD ENZYMOL, V431, P177, DOI 10.1016/S0076-6879(07)31010-0; Miller BF, 2013, J GERONTOL A-BIOL, V68, P530, DOI 10.1093/gerona/gls219; Mitchell SJ, 2016, CELL METAB, V23, P1093, DOI 10.1016/j.cmet.2016.05.027; Moffat C, 2014, J LIPID RES, V55, P2458, DOI 10.1194/jlr.M046961; Park CY, 2017, BIOCHEM BIOPH RES CO, V490, P636, DOI 10.1016/j.bbrc.2017.06.090; PARVIN R, 1970, J BIOL CHEM, V245, P5773; Patel SA, 2016, SCI REP-UK, V6, DOI 10.1038/srep25970; Peek CB, 2013, SCIENCE, V342, P591, DOI 10.1126/science.1243417; Potter GDM, 2016, ENDOCR REV, V37, P584, DOI 10.1210/er.2016-1083; Rakhshandehroo M, 2010, PPAR RES, V2010, DOI 10.1155/2010/612089; Rhoads TW, 2018, CELL METAB, V27, P677, DOI 10.1016/j.cmet.2018.01.014; Sato S, 2017, CELL, V170, P664, DOI 10.1016/j.cell.2017.07.042; Savvidis C, 2012, MOL MED, V18, P1249, DOI 10.2119/molmed.2012.00077; Scheer FAJL, 2009, P NATL ACAD SCI USA, V106, P4453, DOI 10.1073/pnas.0808180106; Sinturel F, 2017, CELL, V169, P651, DOI 10.1016/j.cell.2017.04.015; Solanas G, 2017, CELL, V170, P678, DOI 10.1016/j.cell.2017.07.035; Swigonova Z, 2009, J MOL EVOL, V69, P176, DOI 10.1007/s00239-009-9263-0; Swindell WR, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-585; Tognini P, 2017, CELL METAB, V26, P523, DOI 10.1016/j.cmet.2017.08.015; van Eunen K, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003186; Weiss EP, 2006, AM J CLIN NUTR, V84, P1033	67	12	12	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2019	33	3					4473	4489		10.1096/fj.201802167R	http://dx.doi.org/10.1096/fj.201802167R			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HM9HS	30566374	Green Published, Bronze			2023-01-03	WOS:000459794800109
J	Heinzel, A; Marhold, M; Mayer, P; Schwarz, M; Tomasich, E; Lukas, A; Krainer, M; Perco, P				Heinzel, Andreas; Marhold, Maximilian; Mayer, Paul; Schwarz, Michael; Tomasich, Erwin; Lukas, Arno; Krainer, Michael; Perco, Paul			Synthetic lethality guiding selection of drug combinations in ovarian cancer	PLOS ONE			English	Article							1ST-LINE TREATMENT; PHASE-II; CHEMOTHERAPY; BEVACIZUMAB; CELLS; MULTICENTER; OLAPARIB; CYTOTOXICITY; TRASTUZUMAB; RESISTANCE	Background Synthetic lethality describes a relationship between two genes where single loss of either gene does not trigger significant impact on cell viability, but simultaneous loss of both gene functions results in lethality. Targeting synthetic lethal interactions with drug combinations promises increased efficacy in tumor therapy. Materials and methods We established a set of synthetic lethal interactions using publicly available data from yeast screens which were mapped to their respective human orthologs using information from orthology databases. This set of experimental synthetic lethal interactions was complemented by a set of predicted synthetic lethal interactions based on a set of protein metadata like e.g. molecular pathway assignment. Based on the combined set, we evaluated drug combinations used in late stage clinical development (clinical phase III and IV trials) or already in clinical use for ovarian cancer with respect to their effect on synthetic lethal interactions. We furthermore identified a set of drug combinations currently not being tested in late stage ovarian cancer clinical trials that however have impact on synthetic lethal interactions thus being worth of further investigations regarding their therapeutic potential in ovarian cancer. Results Twelve of the tested drug combinations addressed a synthetic lethal interaction with the anti-VEGF inhibitor bevacizumab in combination with paclitaxel being the most studied drug combination addressing the synthetic lethal pair between VEGFA and BCL2. The set of 84 predicted drug combinations for example holds the combination of the PARP inhibitor olaparib and paclitaxel, which showed efficacy in phase II clinical studies. Conclusion A set of drug combinations currently not tested in late stage ovarian cancer clinical trials was identified having impact on synthetic lethal interactions thus being worth of further investigations regarding their therapeutic potential in ovarian cancer.	[Heinzel, Andreas; Mayer, Paul; Lukas, Arno; Perco, Paul] Emergentec Biodev GmbH, Vienna, Austria; [Heinzel, Andreas] Med Univ Vienna, Dept Internal Med 3, Vienna, Austria; [Marhold, Maximilian; Schwarz, Michael; Tomasich, Erwin; Krainer, Michael] Med Univ Vienna, Dept Oncol, Div Internal Med 1, Vienna, Austria; [Perco, Paul] Med Univ Innsbruck, Dept Internal Med 4, Innsbruck, Austria	Emergentec Biodevelopment GmbH; Medical University of Vienna; Medical University of Vienna; Medical University of Innsbruck	Perco, P (corresponding author), Emergentec Biodev GmbH, Vienna, Austria.; Krainer, M (corresponding author), Med Univ Vienna, Dept Oncol, Div Internal Med 1, Vienna, Austria.; Perco, P (corresponding author), Med Univ Innsbruck, Dept Internal Med 4, Innsbruck, Austria.	michael.krainer@meduniwien.ac.at; paul.perco@emergentec.com	Perco, Paul/U-2489-2019; Marhold, Maximilian/AAF-4671-2021	Perco, Paul/0000-0003-2087-5691; Schwarz, Michael/0000-0002-2587-1385	European Community [279113]	European Community(European Commission)	The research leading to these results has received funding from the European Community's Seventh Framework Programme under grant agreement no. 279113 (OCTIPS).	Acland A, 2014, NUCLEIC ACIDS RES, V42, pD7, DOI 10.1093/nar/gkt1146; Altenhoff AM, 2011, NUCLEIC ACIDS RES, V39, pD289, DOI 10.1093/nar/gkq1238; Andorfer P, 2016, BMC SYST BIOL, V10, DOI 10.1186/s12918-016-0278-z; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Bronte G, 2016, THER ADV MED ONCOL, V8, P188, DOI 10.1177/1758834016630976; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Byrne AT, 2017, NAT REV CANCER, V17, P254, DOI 10.1038/nrc.2016.140; Candelaria M, 2007, ANN ONCOL, V18, P1529, DOI 10.1093/annonc/mdm204; Costanzo M, 2010, SCIENCE, V327, P425, DOI 10.1126/science.1180823; Dallinger C, 2016, J CLIN PHARMACOL, V56, P1387, DOI 10.1002/jcph.752; DeLuca TF, 2012, BIOINFORMATICS, V28, P715, DOI 10.1093/bioinformatics/bts006; DOBZHANSKY T, 1946, GENETICS, V31, P269; Dutta C, 2012, CANCER RES, V72, P4193, DOI 10.1158/0008-5472.CAN-11-4204; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fechete R., 2013, J COMPUT SCI SYST BI, V6, P73; Fechete R, 2011, MOL BIOSYST, V7, P200, DOI 10.1039/c0mb00082e; Forment JV, 2017, NAT CHEM BIOL, V13, P12, DOI [10.1038/NCHEMBIO.2226, 10.1038/nchembio.2226]; Fotopoulou C, 2014, ANN ONCOL, V25, P160, DOI 10.1093/annonc/mdt515; Fuh KC, 2015, GYNECOL ONCOL, V139, P413, DOI 10.1016/j.ygyno.2015.06.041; Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Hijaz M, 2016, GYNECOL ONCOL, V142, P323, DOI 10.1016/j.ygyno.2016.06.005; Hunter S, 2012, NUCLEIC ACIDS RES, V40, pD306, DOI 10.1093/nar/gkr948; Kanehisa M, 2014, NUCLEIC ACIDS RES, V42, pD199, DOI 10.1093/nar/gkt1076; Kemmer D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001440; Kersey PJ, 2014, NUCLEIC ACIDS RES, V42, pD546, DOI 10.1093/nar/gkt979; Kim G, 2015, CLIN CANCER RES, V21, P4257, DOI 10.1158/1078-0432.CCR-15-0887; Lee MJ, 2012, CELL, V149, P780, DOI 10.1016/j.cell.2012.03.031; Li YF, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00058; Liu N, 2011, INT IMMUNOPHARMACOL, V11, P212, DOI 10.1016/j.intimp.2010.11.021; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Meulendijks D, 2016, INVEST NEW DRUG, V34, P119, DOI 10.1007/s10637-015-0309-4; Nijman SMB, 2011, FEBS LETT, V585, P1, DOI 10.1016/j.febslet.2010.11.024; Oza AM, 2015, LANCET ONCOL, V16, P928, DOI 10.1016/S1470-2045(15)00086-8; Oza AM, 2015, LANCET ONCOL, V16, P87, DOI 10.1016/S1470-2045(14)71135-0; Papanikolaou V, 2015, CELL ONCOL, V38, P155, DOI 10.1007/s13402-014-0213-5; Plummer R, 2008, CLIN CANCER RES, V14, P7917, DOI 10.1158/1078-0432.CCR-08-1223; Remm M, 2001, J MOL BIOL, V314, P1041, DOI 10.1006/jmbi.2000.5197; Schwartzberg LS, 2014, CLIN BREAST CANCER, V14, P161, DOI 10.1016/j.clbc.2013.12.003; Sollner J, 2012, MOL BIOSYST, V8, P3197, DOI 10.1039/c2mb25256b; Sollner Johannes, 2008, Immunome Res, V4, P1, DOI 10.1186/1745-7580-4-1; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Wang YF, 2015, TARGET ONCOL, V10, P575, DOI 10.1007/s11523-015-0370-0; Yilmaz A, 2016, WSPOLCZESNA ONKOL, V20, P28, DOI 10.5114/wo.2016.58498; Zhang S, 2011, GYNECOL ONCOL, V121, P25, DOI [10.1038/nrc3144, DOI 10.1038/NRC3144]	47	12	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2019	14	1							e0210859	10.1371/journal.pone.0210859	http://dx.doi.org/10.1371/journal.pone.0210859			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ2YV	30682083	gold, Green Published, Green Submitted			2023-01-03	WOS:000457037500067
J	Llanos-Cuentas, A; Lacerda, MVG; Hien, TT; Velez, ID; Namaik-Iarp, C; Chu, CS; Villegas, MF; Val, F; Monteiro, WM; Brito, MAM; Costa, MRF; Chuquiyauri, R; Casapia, M; Nguyen, CH; Aruachan, S; Papwijitsil, R; Nosten, FH; Bancone, G; Angus, B; Duparc, S; Craig, G; Rousell, VM; Jones, SW; Hardaker, E; Clover, DD; Kendall, L; Mohamed, K; Koh, GCKW; Wilches, VM; Breton, JJ; Green, JA				Llanos-Cuentas, A.; Lacerda, M. V. G.; Hien, T. T.; Velez, I. D.; Namaik-Iarp, C.; Chu, C. S.; Villegas, M. F.; Val, F.; Monteiro, W. M.; Brito, M. A. M.; Costa, M. R. F.; Chuquiyauri, R.; Casapia, M.; Nguyen, C. H.; Aruachan, S.; Papwijitsil, R.; Nosten, F. H.; Bancone, G.; Angus, B.; Duparc, S.; Craig, G.; Rousell, V. M.; Jones, S. W.; Hardaker, E.; Clover, D. D.; Kendall, L.; Mohamed, K.; Koh, G. C. K. W.; Wilches, V. M.; Breton, J. J.; Green, J. A.			Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	66th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)	NOV 05-09, 2017	Baltimore, MD	Amer Soc Trop Med & Hyg			DOUBLE-BLIND; CHALLENGES; DEFICIENCY; VARIANTS; THERAPY; ANEMIA	BACKGROUND Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been associated with relapse prevention through the clearance of P. vivax parasitemia and hypnozoites, termed "radical cure." METHODS We performed a phase 3, prospective, double-blind, double-dummy, randomized, controlled trial to compare tafenoquine with primaquine in terms of safety and efficacy. The trial was conducted at seven hospitals or clinics in Peru, Brazil, Colombia, Vietnam, and Thailand and involved patients with normal glucose-6-phosphate dehydrogenase (G6PD) enzyme activity and female patients with moderate G6PD enzyme deficiency; all patients had confirmed P. vivax parasitemia. The patients were randomly assigned, in a 2: 1 ratio, to receive a single 300-mg dose of tafenoquine or 15 mg of primaquine once daily for 14 days (administered under supervision); all patients received a 3-day course of chloroquine and were followed for 180 days. The primary safety outcome was a protocol-defined decrease in the hemoglobin level (> 3.0 g per deciliter or = 30% from baseline or to a level of < 6.0 g per deciliter). Freedom from recurrence of P. vivax parasitemia at 6 months was the primary efficacy outcome in a planned patient-level meta-analysis of the current trial and another phase 3 trial of tafenoquine and primaquine (per-protocol populations), and an odds ratio for recurrence of 1.45 (tafenoquine vs. primaquine) was used as a noninferiority margin. RESULTS A protocol-defined decrease in the hemoglobin level occurred in 4 of 166 patients (2.4%; 95% confidence interval [CI], 0.9 to 6.0) in the tafenoquine group and in 1 of 85 patients (1.2%; 95% CI, 0.2 to 6.4) in the primaquine group, for a between-group difference of 1.2 percentage points (95% CI, -4.2 to 5.0). In the patient-level meta-analysis, the percentage of patients who were free from recurrence at 6 months was 67.0% (95% CI, 61.0 to 72.3) among the 426 patients in the tafenoquine group and 72.8% (95% CI, 65.6 to 78.8) among the 214 patients in the primaquine group. The efficacy of tafenoquine was not shown to be noninferior to that of primaquine (odds ratio for recurrence, 1.81; 95% CI, 0.82 to 3.96). CONCLUSIONS Among patients with normal G6PD enzyme activity, the decline in hemoglobin level with tafenoquine did not differ significantly from that with primaquine. Tafenoquine showed efficacy for the radical cure of P. vivax malaria, although tafenoquine was not shown to be noninferior to primaquine.	[Llanos-Cuentas, A.; Chuquiyauri, R.; Casapia, M.] Univ Peruana Cayetano Heredia, Lima, Peru; [Lacerda, M. V. G.; Val, F.; Monteiro, W. M.; Brito, M. A. M.; Costa, M. R. F.] Fundacao Med Trop Dr Heitor Vieira Dourado, Manaus, Amazonas, Brazil; [Lacerda, M. V. G.] Fundacao Oswaldo Cruz, Manguinho, RJ, Brazil; [Hien, T. T.; Nguyen, C. H.] Univ Oxford, Clin Res Unit, Ho Chi Minh City, Vietnam; [Velez, I. D.] Univ Antioquia, Medellin, Colombia; [Villegas, M. F.] Ctr Invest Clin SAS Cali, Cali, Colombia; [Aruachan, S.] IMAT Oncomed, Monteria, Colombia; [Namaik-Iarp, C.; Papwijitsil, R.] Umphang Hosp, Tak, Thailand; [Chu, C. S.; Nosten, F. H.; Bancone, G.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Shoklo Malaria Res Unit, Mae Sot, Thailand; [Chu, C. S.; Nosten, F. H.; Bancone, G.] Univ Oxford, Nuffield Dept Med, Ctr Trop Med & Global Hlth, Oxford, England; [Angus, B.] Univ Oxford, Nuffield Dept Med, Oxford Ctr Clin Trop Med, Oxford, England; [Craig, G.; Rousell, V. M.; Jones, S. W.; Hardaker, E.; Clover, D. D.; Mohamed, K.; Koh, G. C. K. W.; Green, J. A.] GlaxoSmithKline, Stockley Pk West, Uxbridge UB11 1BT, Middx, England; [Kendall, L.] GlaxoSmithKline, Stevenage, Herts, England; [Duparc, S.] Med Malaria Venture, Geneva, Switzerland; [Wilches, V. M.; Breton, J. J.] GlaxoSmithKline, Collegeville, PA USA	Universidad Peruana Cayetano Heredia; Fundacao Oswaldo Cruz; University of Oxford; Universidad de Antioquia; Mahidol Oxford Tropical Medicine Research Unit (MORU); Mahidol University; University of Oxford; University of Oxford; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Green, JA (corresponding author), GlaxoSmithKline, Stockley Pk West, Uxbridge UB11 1BT, Middx, England.	justin.a.green@gsk.com	Duparc, Stephan/AAH-8758-2020; Chu, Cindy S/E-3135-2014; Nosten, Francois/AAC-5509-2019; Val, Fernando/GSJ-1036-2022	Duparc, Stephan/0000-0002-9649-4847; Chu, Cindy S/0000-0001-9465-8214; Nosten, Francois/0000-0002-7951-0745; Val, Fernando/0000-0001-9995-0249; Chuquiyauri, Raul/0000-0003-4726-249X; Koh, Gavin/0000-0002-7336-1566; Kendall, Lindsay/0000-0003-2812-0154; Casapia Morales, Wilfredo Martin/0000-0002-5972-0948; Llanos-Cuentas, Alejandro/0000-0002-7567-5534; Bancone, Germana/0000-0003-4550-0431	GlaxoSmithKline; Medicines for Malaria Venture; FOGARTY INTERNATIONAL CENTER [D43TW009343] Funding Source: NIH RePORTER	GlaxoSmithKline(GlaxoSmithKline); Medicines for Malaria Venture; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	Funded by GlaxoSmithKline and Medicines for Malaria Venture; GATHER ClinicalTrials.gov number, NCT02216123.	[Anonymous], 2015, CONTR EL PLASM VIV M; [Anonymous], COCHRANE DATABASE SY; [Anonymous], 2016, MAL MICR STAND OP PR; [Anonymous], 2015, GUID TREATM MAL; Beck HP, 2016, J INFECT DIS, V213, P794, DOI 10.1093/infdis/jiv508; Bennett JW, 2013, NEW ENGL J MED, V369, P1381, DOI 10.1056/NEJMc1301936; Chu CS, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002224; DERN RJ, 1981, J LAB CLIN MED, V97, P750; Gaedigk A, 2008, CLIN PHARMACOL THER, V83, P234, DOI 10.1038/sj.clpt.6100406; Howes RE, 2016, AM J TROP MED HYG, V95, P15, DOI 10.4269/ajtmh.16-0141; Howes RE, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001339; Khantikul N, 2009, J HEALTH POPUL NUTR, V27, P4; Kim JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039645; Koepfli C, 2009, J INFECT DIS, V199, P1074, DOI 10.1086/597303; Lacerda MVG, 2019, NEW ENGL J MED, V380, P215, DOI 10.1056/NEJMoa1710775; Laosombat V, 2005, BLOOD CELL MOL DIS, V34, P191, DOI 10.1016/j.bcmd.2004.11.001; Leary KJ, 2009, AM J TROP MED HYG, V81, P356, DOI 10.4269/ajtmh.2009.81.356; Llanos-Cuentas A, 2014, LANCET, V383, P1049, DOI 10.1016/S0140-6736(13)62568-4; Lon C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093138; Maneeboonyang W, 2011, SE ASIAN J TROP MED, V42, P9; Mauri L, 2017, NEW ENGL J MED, V377, P1357, DOI 10.1056/NEJMra1510063; Noori-Daloii MR, 2007, CLIN BIOCHEM, V40, P699, DOI 10.1016/j.clinbiochem.2007.02.008; Pamba A, 2012, BLOOD, V120, P4123, DOI 10.1182/blood-2012-03-416032; Rochford R, 2013, P NATL ACAD SCI USA, V110, P17486, DOI 10.1073/pnas.1310402110; Rueangweerayut R, 2017, AM J TROP MED HYG, V97, P702, DOI 10.4269/ajtmh.16-0779; St Jean PL, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1145-5; Thriemer K, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1784-1; WOODRUFF AW, 1979, LANCET, V1, P1055	28	111	112	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 17	2019	380	3					229	241		10.1056/NEJMoa1802537	http://dx.doi.org/10.1056/NEJMoa1802537			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	HH5YY	30650326	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000455806200005
J	Veronese, S; Rabitti, E; Costantini, M; Valle, A; Higginson, I				Veronese, Simone; Rabitti, Elisa; Costantini, Massimo; Valle, Alessandro; Higginson, Irene			Translation and cognitive testing of the Italian Integrated Palliative Outcome Scale (IPOS) among patients and healthcare professionals	PLOS ONE			English	Article								Background Outcome measurement is fundamental to assess needs and priority of care in palliative care settings. The Integrated Palliative care Outcome Scale (IPOS) was developed from earlier versions of this tool. Its use is encouraged to ameliorate the assessment of individual outcomes in palliative care settings. This study aimed to translate and culturally adapt IPOS into Italian, and explore its face and content validity. Methods After forward-backward translation, a qualitative study explored the views of and cognitive processes used by respondents. We conducted individual semi structured interviews with 21 patients admitted to two palliative care services, from hospitals, hospices and the community, and focus groups with 12 professionals working in multidisciplinary palliative care teams and used thematic analysis. The results were integrated in a final audit, including the project team and the original POS developers, to refine the final format of the tool. Results We conducted 21 face to face cognitive interviews with patients, and 2 focus groups with 14 professionals. Patients and professionals felt content and format of IPOS appropriate and feasible, and not burdensome. Some layout problems were raised leading to adaptation. Main issues regarded: clarifying the meaning of choices and some cultural interpretation of some questions and response options and interpretation of some instructions. We proposed using some new terms as more appropriate and comprehensive in our context, such as replacing the term "family" with "dear ones". The items that appeared unchanged from the previously validated Italian POS were left unmodified to maintain coherence. Conclusions The Italian IPOS, in its four versions directed to patients or staff and with a recall period of 3 or 7 days, has face and content validity for use in clinical settings and is ready for further psychometric and clinimetric validation.	[Veronese, Simone; Valle, Alessandro] Fdn FARO Onlus, Turin, Italy; [Rabitti, Elisa] Azienda USL Reggio Emilia IRCCS, Psychooncol Unit, Reggio Emilia, Italy; [Costantini, Massimo] Azienda USL Reggio Emilia IRCCS, Sci Directorate, Reggio Emilia, Italy; [Higginson, Irene] Kings Coll London, Cicely Saunders Inst Palliat Care Policy & Rehabi, London, England	University of London; King's College London	Veronese, S (corresponding author), Fdn FARO Onlus, Turin, Italy.	simone.veronese@fondazionefaro.it	costantini, massimo/AAK-5388-2021; Veronese, Simone/GYD-2978-2022; Higginson, Irene Julie/C-7309-2012	costantini, massimo/0000-0002-5293-7079; Veronese, Simone/0000-0002-9555-7252; Higginson, Irene Julie/0000-0002-3687-1313	Fondazione FARO, Torino; IRCSS Reggio Emilia, Italy	Fondazione FARO, Torino; IRCSS Reggio Emilia, Italy	The study was UNFUNDED, the only obtained funds are the publication costs covered by the two main involved institutions: Fondazione FARO, Torino and IRCSS Reggio Emilia, Italy.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; Antunes B., 2012, PALLIATIVE CARE OUTC; Boland J, 2013, BMJ SUPPORT PALLIAT, V3, P2, DOI 10.1136/bmjspcare-2013-000446; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Costantini M, 2016, BMC PALLIAT CARE, V15, DOI 10.1186/s12904-016-0095-6; Gao W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165379; Hearn J, 1999, QUAL HEALTH CARE, V8, P219, DOI 10.1136/qshc.8.4.219; Higginson IJ, 1999, BRIT MED J, V318, P123, DOI 10.1136/bmj.318.7176.123; Kulis D, 2017, EORTC QUALITY LIFE G; Lee J, 2014, ASSESSMENT, V21, P227, DOI 10.1177/1073191112436671; Schildmann EK, 2016, PALLIATIVE MED, V30, P599, DOI 10.1177/0269216315608348; van Vliet LM, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0449-6; WHO, DEF PALL CAR	13	11	11	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 2	2019	14	1							e0208536	10.1371/journal.pone.0208536	http://dx.doi.org/10.1371/journal.pone.0208536			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG1BB	30601810	Green Submitted, Green Published, gold			2023-01-03	WOS:000454683200014
J	Edvardsen, A; Jarosch, I; Grongstad, A; Wiegand, L; Gloeckl, R; Kenn, K; Spruit, MA				Edvardsen, Anne; Jarosch, Inga; Grongstad, Anita; Wiegand, Laura; Gloeckl, Rainer; Kenn, Klaus; Spruit, Martijn A.			A randomized cross-over trial on the direct effects of oxygen supplementation therapy using different devices on cycle endurance in hypoxemic patients with Interstitial Lung Disease	PLOS ONE			English	Article							IDIOPATHIC PULMONARY-FIBROSIS; AMBULATORY OXYGEN; NASAL CANNULA; CONSERVATION DEVICE; PROGNOSTIC VALUE; EXERCISE; PERFORMANCE; STATEMENT; DIAGNOSIS; DYSPNEA	Background In patients with interstitial lung disease (ILD) a cardinal feature is exercise intolerance, often associated with significant dyspnea and severe hypoxemia. Supplemental oxygen therapy may be offered during exercise. The Oxymizer is a nasal cannula with an incorporated reservoir with the potential to deliver higher oxygen doses to the patient. Objective The primary aim was to investigate the effect of supplemental oxygen delivered via Oxymizer compared to a conventional nasal cannula (CNC) in patients with ILD during constant work rate tests (CWRT). Secondary aim was to evaluate effects on oxygen saturation (SpO(2)), dyspnea and heart rate at isotime. Methods In this randomized crossover study 24 ILD patients established on long-term oxygen treatment were included. Patients performed four cycling CWRT at 70% of their peak work rate; twice with the Oxymizer and twice with the CNC. Results Twenty-one patients finished all CWRTs (age 60 +/- 10.9 years, VC 55.4 +/- 23.0% predicted). Cycle endurance time was significantly higher while using the Oxymizer compared to CNC (718 +/- 485 vs. 680 +/- 579 seconds, p = 0.02), and SpO(2) at isotime was significantly higher while using the Oxymizer (85.5 +/- 6.7 vs. 82.8 +/- 7.2, p = 0.01). Fifteen of the 21 (71%) patients cycled longer with the Oxymizer. There were no significant differences for dyspnea and heart rate. Conclusions Supplemental oxygen provided by the Oxymizer significantly, but modestly, improved cycle endurance time and SpO(2) at isotime in ILD patients compared to CNC.	[Edvardsen, Anne; Grongstad, Anita] LHL Hosp Gardermoen, Dept Resp Physiol, Jessheim, Norway; [Jarosch, Inga; Gloeckl, Rainer; Kenn, Klaus] Schoen Klin Berchtesgadener Land, Dept Resp Med & Pulm Rehabil, Schoenau, Germany; [Wiegand, Laura] Philipps Univ Marburg, Dept Internal Med, Marburg, Germany; [Gloeckl, Rainer] Tech Univ Munich, Dept Prevent Rehabil & Sports Med, Munich, Germany; [Kenn, Klaus] Philipps Univ Marburg, Ctr Lung Res DZL, Dept Pulm Rehabil, Marburg, Germany; [Spruit, Martijn A.] Ctr Expertise Chron Organ Failure, CIRO, Dept Res & Educ, Horn, Netherlands; [Spruit, Martijn A.] Hasselt Univ, Fac Med & Life Sci, BIOMED Biomed Res Inst, REVAL Rehabil Res Ctr, Diepenbeek, Belgium; [Spruit, Martijn A.] Maastricht Univ, Med Ctr, NUTRIM Sch Nutr & Translat Res Metab, Dept Resp Med, Maastricht, Netherlands	Philipps University Marburg; Technical University of Munich; Philipps University Marburg; Hasselt University; Maastricht University; Maastricht University Medical Centre (MUMC)	Edvardsen, A (corresponding author), LHL Hosp Gardermoen, Dept Resp Physiol, Jessheim, Norway.	anne.edvardsen@lhl.no		Edvardsen, Anne/0000-0002-4230-8850				American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, 2002, AM J RESP CRIT CARE, V165, P277, DOI [10.1164/ajrccm.165.2.ats01, DOI 10.1164/AJRCCM.165.2.ATS01]; ARLATI S, 1988, CHEST, V93, P1165, DOI 10.1378/chest.93.6.1165; Booker AL, 2008, THORAX, V63, pA115; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; BYE PTP, 1982, AM REV RESPIR DIS, V126, P1005; CARTER R, 1986, CHEST, V89, P806, DOI 10.1378/chest.89.6.806; Casaburi Richard, 2005, COPD, V2, P131; Christensen CC, 2004, RESP MED, V98, P656, DOI 10.1016/j.rmed.2003.12.002; CLAIBORNE RA, 1987, AM REV RESPIR DIS, V136, P1095, DOI 10.1164/ajrccm/136.5.1095; COLLARD P, 1989, EUR RESPIR J, V2, P778; Dumont Cheryl Plate, 2002, Crit Care Nurse, V22, P41; EVANS TW, 1988, EUR RESPIR J, V1, P959; Flaherty KR, 2006, AM J RESP CRIT CARE, V174, P803, DOI 10.1164/rccm.200604-488OC; Frank RC, 2012, EUR RESPIR J, V40, P269, DOI 10.1183/09031936.00007712; Gloeckl R, 2014, RESPIRATION, V88, P399, DOI 10.1159/000368165; Gloeckl R, 2012, J HEART LUNG TRANSPL, V31, P934, DOI 10.1016/j.healun.2012.06.004; Hardinge M, 2015, THORAX, V70, P1, DOI 10.1136/thoraxjnl-2015-206865; HARRISEZE AO, 1994, AM J RESP CRIT CARE, V150, P1616, DOI 10.1164/ajrccm.150.6.7952624; Holland Anne E, 2010, Chron Respir Dis, V7, P101, DOI 10.1177/1479972309354689; Kenn K, 2013, RESPIRATION, V86, P89, DOI 10.1159/000354112; Lama VN, 2003, AM J RESP CRIT CARE, V168, P1084, DOI 10.1164/rccm.200302-219OC; Marti S, 2013, RESP CARE, V58, P1606, DOI 10.4187/respcare.02260; Miki K, 2003, RESP MED, V97, P482, DOI 10.1053/rmed.2002.1469; Nishiyama O, 2013, RESP MED, V107, P1241, DOI 10.1016/j.rmed.2013.05.015; Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL; Ross RM, 2003, AM J RESP CRIT CARE, V167, P1451, DOI 10.1164/ajrccm.167.10.950; Ryerson CJ, 2012, J PAIN SYMPTOM MANAG, V43, P771, DOI 10.1016/j.jpainsymman.2011.04.026; Sharp C, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011716.pub2; TIEP BL, 1984, AM REV RESPIR DIS, V130, P500; Visca D, 2011, EUR RESPIR J, V38, P987, DOI 10.1183/09031936.00190710	30	9	9	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 28	2018	13	12							e0209069	10.1371/journal.pone.0209069	http://dx.doi.org/10.1371/journal.pone.0209069			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG0GV	30592724	Green Submitted, Green Published, gold			2023-01-03	WOS:000454621900013
J	Jerez-Roig, J; Bosque-Prous, M; Gine-Garriga, M; Bagur-Calafat, C; de Souza, DLB; Teixido-Compano, E; Espelt, A				Jerez-Roig, Javier; Bosque-Prous, Marina; Gine-Garriga, Maria; Bagur-Calafat, Caritat; Bezerra de Souza, Dyego L.; Teixido-Compano, Ester; Espelt, Albert			Regional differences in the profile of disabled community-dwelling older adults: A European population-based cross-sectional study	PLOS ONE			English	Article							D SCALE; DISABILITY; HEALTH; DEPRESSION; PREVALENCE; SYMPTOMS; VERSION; GENDER; SHARE; LIFE	The main objective of this work was to estimate the prevalence of disability in European community-dwelling older adults, as well as to investigate differences in the profile of disabled older adults between European regions (Northern, Central, Eastern and Southern). A cross-sectional study based on wave 6 (2015) of the Survey of Health, Ageing and Retirement in Europe (SHARE) was conducted. Community-dwelling participants aged 65-84 were selected (n = 33,369). Disability was defined as presenting at least one functional limitation in basic activities of daily living (BADL). Sociodemographic, health services, lifestyle and health-related variables were analyzed. Statistical analysis was carried out through the Chi-square and ANOVA tests for bivariate analysis, and Poisson regression for multivariate analysis. Overall prevalence of disability was 13.8%: 9.4% in the Northern region, 13.1% in the Southern region, 13.6% in the Central region, and 16.6% in the Eastern region. Portugal, Poland, Estonia and Belgium showed the highest prevalence of BADL limitations, while Sweden, Denmark, Greece and Switzerland showed the lowest prevalence. Besides, disabled older adults from East Europe presented the most disadvantaged health profile, followed by the Southern region. On the other hand, disabled older adults living in the Northern region showed the most advantaged characteristics of most variables, except for smoking and polypharmacy.	[Jerez-Roig, Javier] Univ Vic, Univ Catalonia UVIC UCC, Res Grp Methodol Methods Models & Outcomes Hlth &, Fac Hlth Sci & Welf,Ctr Hlth & Social Care Res CE, Vic, Spain; [Jerez-Roig, Javier; Gine-Garriga, Maria] Ramon Llull Univ, Blanquerna Fac Psychol Educ & Sport Sci, Barcelona, Spain; [Jerez-Roig, Javier; Bezerra de Souza, Dyego L.] Univ Fed Rio Grande do Norte, Odontol Dept, Postgrad Program Collect Hlth, Natal, RN, Brazil; [Bosque-Prous, Marina] Univ Oberta Catalunya, Fac Hlth Sci, Barcelona, Spain; [Gine-Garriga, Maria] Glasgow Caledonian Univ, Sch Hlth & Life Sci, Glasgow, Lanark, Scotland; [Bagur-Calafat, Caritat] Univ Int Catalunya, Dept Physiotherapy, Sant Cugat Del Valles, Spain; [Bezerra de Souza, Dyego L.] Univ Fed Rio Grande do Norte, Dept Collect Hlth, Grad Program Collect Hlth, Natal, RN, Brazil; [Teixido-Compano, Ester; Espelt, Albert] Univ Vic, Fac Hlth Sci Manresa, Cent Univ Catalonia, Manresa, Spain	Universitat de Vic - Universitat Central de Catalunya (UVic-UCC); Universitat Ramon Llull; Universidade Federal do Rio Grande do Norte; UOC Universitat Oberta de Catalunya; Glasgow Caledonian University; Universitat Internacional de Catalunya (UIC); Universidade Federal do Rio Grande do Norte; Universitat de Vic - Universitat Central de Catalunya (UVic-UCC)	Bosque-Prous, M (corresponding author), Univ Oberta Catalunya, Fac Hlth Sci, Barcelona, Spain.	mbosquep@uoc.edu	Teixidó-Compañó, Ester/ABD-9912-2021; Jerez-Roig, Javier/V-6119-2018; Teixidó-Compañó, Ester/AAD-9055-2020; Bosque-Prous, Marina/AAE-1562-2020; Giné-Garriga, Maria/F-4089-2016; Giné-Garriga, Maria/AAF-9828-2019; Espelt, Albert/G-2281-2014; Bagur-Calafat, Caritat/R-7937-2017	Jerez-Roig, Javier/0000-0002-1968-4452; Teixidó-Compañó, Ester/0000-0002-0565-7023; Bosque-Prous, Marina/0000-0002-8830-8880; Giné-Garriga, Maria/0000-0003-4449-3524; Giné-Garriga, Maria/0000-0003-4449-3524; Espelt, Albert/0000-0002-8625-4356; Souza, Dyego L.B./0000-0001-8426-3120; Bagur-Calafat, Caritat/0000-0002-8637-5035				[Anonymous], 2011, WORLD REP DIS; de Lima ALB, 2018, CIENC SAUDE COLETIVA, V23, P2991, DOI 10.1590/1413-81232018239.20662016; Borrat-Besson CV, 2015, EVALUATION CASP 12 S; Castro-Costa E, 2008, INT J METH PSYCH RES, V17, P12, DOI 10.1002/mpr.236; Chatterji S, 2015, LANCET, V385, P563, DOI 10.1016/S0140-6736(14)61462-8; Crimmins EM, 2011, EUR J PUBLIC HEALTH, V21, P81, DOI 10.1093/eurpub/ckq022; Eikemo TA, 2008, SOCIOL HEALTH ILL, V30, P565, DOI 10.1111/j.1467-9566.2007.01073.x; Espelt A, 2017, ADICCIONES, V29, P105, DOI 10.20882/adicciones.823; Espelt A, 2010, J WOMENS HEALTH, V19, P927, DOI 10.1089/jwh.2009.1608; Green G, 2013, J URBAN HEALTH, V90, pS116, DOI 10.1007/s11524-012-9765-8; Hank K, 2011, J GERONTOL B-PSYCHOL, V66, P230, DOI 10.1093/geronb/gbq089; Hank K, 2010, AGEING SOC, V30, P1041, DOI 10.1017/S0144686X10000280; Hughes ME, 2004, RES AGING, V26, P655, DOI 10.1177/0164027504268574; Larraga L, 2006, INT J GERIATR PSYCH, V21, P1199, DOI 10.1002/gps.1642; Leonardi M, 2014, CLIN PSYCHOL PSYCHOT, V21, P193, DOI 10.1002/cpp.1856; Lunenfeld B, 2013, BEST PRACT RES CL OB, V27, P643, DOI 10.1016/j.bpobgyn.2013.02.005; Malter F, 2015, SHARE WAVE 5 INNOVAT, DOI [10.1002/wdev.204, DOI 10.1002/WDEV.204]; Ministry of Health and Social Protection, 2017, PRESS RELEASE; Perales J, 2014, INT PSYCHOGERIATR, V26, P1363, DOI 10.1017/S1041610214000520; Prince MJ, 1999, BRIT J PSYCHIAT, V174, P330, DOI 10.1192/bjp.174.4.330; Serrano-Alarcon M, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0673-0; UNESCO, 2013, INT STAND CLASS ED 2; Wahrendorf M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071893; Zunzunegui MV, 2006, AGING CLIN EXP RES, V18, P352, DOI 10.1007/BF03324830; Zunzunegui MV, 2011, GAC SANIT, V25, P12, DOI 10.1016/j.gaceta.2011.07.026	25	6	6	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2018	13	12							e0208946	10.1371/journal.pone.0208946	http://dx.doi.org/10.1371/journal.pone.0208946			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HD8CS	30533039	Green Published, gold, Green Submitted			2023-01-03	WOS:000452782500053
J	Okada, M; Ortiz, E; Corzo, G; Possani, LD				Okada, Masayoshi; Ortiz, Ernesto; Corzo, Gerardo; Possani, Lourival D.			Pore-forming spider venom peptides show cytotoxicity to hyperpolarized cancer cells expressing K+ channels: A lentiviral vector approach	PLOS ONE			English	Article							POTASSIUM CHANNELS; INCREASE; TUMORS	Recent studies demonstrated the upregulation of K+ channels in cancer cells. We have previously found that a pore-forming peptide LaFr26, purified from the venom of the Lachesana sp spider, was selectively incorporated into K+ channel expressing hyperpolarized cells. Therefore, it is expected that this peptide would have selective cytotoxicity to hyperpolarized cancer cells. Here we have tested whether LaFr26 and its related peptide, oxyopinin-2b, are selectively cytotoxic to K+ channel expressing cancer cells. These peptides were cytotoxic to the cells, of which resting membrane potential was hyperpolarized. The vulnerabilities of K+ channel-expressing cell lines correlated with their resting membrane potential. They were cytotoxic to lung cancer cell lines LX22 and BEN, which endogenously expressed K+ current. Contrastingly, these peptides were ineffective to glioblastoma cell lines, U87 and T98G, of which membrane potentials were depolarized. Peptides have a drawback, i.e. poor drug-delivery, that hinders their potential use as medicine. To overcome this drawback, we prepared lentiviral vectors that can express these pore-forming peptides and tested the cytotoxicity to K+ channel expressing cells. The transduction with these lentiviral vectors showed autotoxic activity to the channel expressing cells. Our study provides the basis for a new oncolytic viral therapy.	[Okada, Masayoshi] Kurashiki Univ Sci & Arts, Coll Life Sci, Dept Med Life Sci, Kurashiki, Okayama, Japan; [Ortiz, Ernesto; Corzo, Gerardo; Possani, Lourival D.] Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Med Mol & Bioproc, Cuernavaca, Morelos, Mexico	Universidad Nacional Autonoma de Mexico	Okada, M (corresponding author), Kurashiki Univ Sci & Arts, Coll Life Sci, Dept Med Life Sci, Kurashiki, Okayama, Japan.	mokada-tky@umin.ac.jp	Corzo, Gerardo/B-3778-2014; Okada, Masayoshi/ABE-9020-2020	Corzo, Gerardo/0000-0002-9513-1622; Okada, Masayoshi/0000-0001-8515-7143	JST; CONACyT, SICP; KAKENHI form JSPS [18K06830, 25460323]; Ryobi Memorial Foundation; Wesco Scientific Promotion Foundation	JST(Japan Science & Technology Agency (JST)); CONACyT, SICP; KAKENHI form JSPS; Ryobi Memorial Foundation; Wesco Scientific Promotion Foundation	This work was supported by Strategic International Research Cooperative Program between JST and CONACyT, SICP. M.O. was supported the KAKENHI (18K06830, 25460323) form JSPS, Ryobi Memorial Foundation, Wesco Scientific Promotion Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Belokoneva OS, 2003, BBA-BIOMEMBRANES, V1617, P22, DOI 10.1016/j.bbamem.2003.08.010; Bianchi L, 1998, CANCER RES, V58, P815; Bordey A, 1998, J NEUROPHYSIOL, V79, P2782, DOI 10.1152/jn.1998.79.5.2782; Brickley SG, 2001, NATURE, V409, P88, DOI 10.1038/35051086; Casucci M, 2011, J CANCER, V2, P378, DOI 10.7150/jca.2.378; Comes N, 2015, BBA-BIOMEMBRANES, V1848, P2477, DOI 10.1016/j.bbamem.2014.12.008; Corzo G, 2002, J BIOL CHEM, V277, P23627, DOI 10.1074/jbc.M200511200; Deshane J, 2003, J BIOL CHEM, V278, P4135, DOI 10.1074/jbc.M205662200; Garcia F, 2013, J ANTIBIOT, V66, P3, DOI 10.1038/ja.2012.87; Hockaday DC, 2005, J NUCL MED, V46, P580; Huang X, 2014, J CELL BIOL, V206, P151, DOI 10.1083/jcb.201404136; Jami S, 2018, TOXINS, V10, DOI 10.3390/toxins10010015; Knappskog S, 2007, J BIOTECHNOL, V128, P705, DOI 10.1016/j.jbiotec.2006.11.026; Kozlov SA, 2006, J BIOL CHEM, V281, P20983, DOI 10.1074/jbc.M602168200; Lawler SE, 2017, JAMA ONCOL, V3, P841, DOI 10.1001/jamaoncol.2016.2064; LeBeau AM, 2015, MOL CANCER THER, V14, P659, DOI 10.1158/1535-7163.MCT-14-0744; Liu HX, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0298-0; Miest TS, 2014, NAT REV MICROBIOL, V12, P23, DOI 10.1038/nrmicro3140; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Okada M, 2008, NEUROSCIENCE, V156, P289, DOI 10.1016/j.neuroscience.2008.07.038; Okada M, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0159-1; Okada M, 2015, BBA-GEN SUBJECTS, V1850, P657, DOI 10.1016/j.bbagen.2014.11.022; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Park CJ, 2005, J DENT RES, V84, P852, DOI 10.1177/154405910508400914; Piper SL, 2008, J BONE JOINT SURG AM, V90A, P986, DOI 10.2106/JBJS.G.01033; Santoni G, 2019, CANCERS, V11, DOI 10.3390/cancers11030322; Sun H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10339; Tan G, 2008, BIOCHEM BIOPH RES CO, V367, P743, DOI 10.1016/j.bbrc.2008.01.014; Voloshyna I, 2008, CANCER RES, V68, P1197, DOI 10.1158/0008-5472.CAN-07-5163; Yang M, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00185	30	14	15	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2019	14	4							e0215391	10.1371/journal.pone.0215391	http://dx.doi.org/10.1371/journal.pone.0215391			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT1UC	30978253	Green Published, gold, Green Submitted			2023-01-03	WOS:000464349000065
J	Siddique, A; Ebrahim, H; Mohyeldin, M; Qusa, M; Batarseh, Y; Fayyad, A; Tajmim, A; Nazzal, S; Kaddoumi, A; El Sayed, K				Siddique, Abu Bakar; Ebrahim, Hassan; Mohyeldin, Mohamed; Qusa, Mohammed; Batarseh, Yazan; Fayyad, Ahmed; Tajmim, Afsana; Nazzal, Sami; Kaddoumi, Amal; El Sayed, Khalid			Novel liquid-liquid extraction and self-emulsion methods for simplified isolation of extra-virgin olive oil phenolics with emphasis on (-)-oleocanthal and its oral anti-breast cancer activity	PLOS ONE			English	Article							IN-VITRO; INHIBITS PROLIFERATION; OLEOCANTHAL; OLEACEIN; ACTIVATION; EXPRESSION; OLEUROPEIN; COMPOUND	Epidemiological and clinical studies compellingly documented the ability of Mediterranean diet rich in extra-virgin olive oil (EVOO) to reduce breast and colon cancers incidence, cardiovascular diseases, and aging cognitive functions decline. (-)-Oleocanthal (OC) and other EVOO phenolics gain progressive research attention due to their documented biological effects against cancer, inflammations, and Alzheimer's disease. There is no simple, reliable, and cost-effective isolation protocol for EVOO phenolics, which hinder their therapeutic applications. This study develops novel methods to isolate OC and other EVOO phenolics. This includes the use of ultra-freezing to eliminate most EVOO fats and the successful water capacity to efficiently extract OC and EVOO phenolics as self-emulsified nano-emulsion. Subsequent resin entrapment and size exclusion chromatography afforded individual EVOO phenolics in high purity. OC in vitro and in vivo oral anti-breast cancer (BC) activities validated its lead candidacy. Effective isolation of EVOO phenolics provided in this study will facilitate future preclinical and clinical investigations and stimulate the therapeutic development of these important bioactive natural products.	[Siddique, Abu Bakar; Ebrahim, Hassan; Mohyeldin, Mohamed; Qusa, Mohammed; Batarseh, Yazan; Fayyad, Ahmed; Tajmim, Afsana; Nazzal, Sami; El Sayed, Khalid] Univ Louisiana Monroe, Coll Pharm, Sch Basic Pharmaceut & Toxicol Sci, Monroe, LA 71209 USA; [Kaddoumi, Amal] Auburn Univ, Harrison Sch Pharm, Dept Drug Discovery & Dev, Auburn, AL 36849 USA	University of Louisiana System; University of Louisiana Monroe; Auburn University System; Auburn University	El Sayed, K (corresponding author), Univ Louisiana Monroe, Coll Pharm, Sch Basic Pharmaceut & Toxicol Sci, Monroe, LA 71209 USA.	elsayed@ulm.edu	, Abu Bakar Siddique/W-8476-2019; Ebrahim, Hassan Y./F-2050-2017; Ebrahim, Hassan Y./ABF-8232-2021; Mohyeldin, Mohamed/AAA-5232-2019; Mohyeldin, Mohamed/K-5059-2017	, Abu Bakar Siddique/0000-0001-5424-9475; Ebrahim, Hassan Y./0000-0001-9057-4582; Tajmim, Afsana/0000-0003-4717-1141; El Sayed, Khalid/0000-0002-1456-4064; Mohyeldin, Mohamed/0000-0001-9052-7620	Louisiana Board of Regents [LEQSF(2017-20)-RD-B-07]; National Cancer Institute of the National Institutes of Health [R15CA167475]	Louisiana Board of Regents; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research reported in this publication was supported by the Louisiana Board of Regents, Award Number LEQSF(2017-20)-RD-B-07 and the National Cancer Institute of the National Institutes of Health under Award Number R15CA167475. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the study.	Adhami HR, 2015, FOOD CHEM, V170, P154, DOI 10.1016/j.foodchem.2014.08.079; Akl MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097622; Andrewes P, 2003, J AGR FOOD CHEM, V51, P1415, DOI 10.1021/jf026042j; Ayoub NM, 2017, EUR J PHARMACOL, V810, P100, DOI 10.1016/j.ejphar.2017.06.019; Beauchamp GK, 2005, NATURE, V437, P45, DOI 10.1038/437045a; Busnena BA, 2013, BIOORGAN MED CHEM, V21, P2117, DOI 10.1016/j.bmc.2012.12.050; Czerwinska M, 2012, FOOD CHEM, V131, P940, DOI 10.1016/j.foodchem.2011.09.082; Elnagar AY, 2011, PLANTA MED, V77, P1013, DOI 10.1055/s-0030-1270724; ElSayed K. A., 2018, PCT/ US 2017/043308 US, Patent No. [PCT/ US 2017/043308 US, 2017043308]; ElSayed K. A., 2018, Patent No. [WO 2018/017967, 2018017967]; Garcia A, 2016, FOOD CHEM, V197, P554, DOI 10.1016/j.foodchem.2015.10.131; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; Impellizzeri J, 2006, J AGR FOOD CHEM, V54, P3204, DOI 10.1021/jf052870b; Karkoula E, 2012, J AGR FOOD CHEM, V60, P11696, DOI 10.1021/jf3032765; Khanal P, 2011, CARCINOGENESIS, V32, P545, DOI 10.1093/carcin/bgr001; Khanfar MA, 2015, PHYTOTHER RES, V29, P1776, DOI 10.1002/ptr.5434; Kikuchi M, 2011, J NAT MED-TOKYO, V65, P237, DOI 10.1007/s11418-010-0476-8; Lopez-Biedma A, 2016, J FUNCT FOODS, V26, P36, DOI 10.1016/j.jff.2016.07.005; Menendez JA, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-80; Menendez JA, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-377; Monti MC, 2012, J NAT PROD, V75, P1584, DOI 10.1021/np300384h; Pang KL, 2018, NUTRIENTS, V10, DOI 10.3390/nu10050570; Parzonko A, 2013, PHYTOMEDICINE, V20, P1088, DOI 10.1016/j.phymed.2013.05.002; Pei TM, 2016, ONCOTARGET, V7, P43475, DOI 10.18632/oncotarget.9782; Perez-Jimenez F, 2007, MOL NUTR FOOD RES, V51, P1199, DOI 10.1002/mnfr.200790023; Pitt J, 2009, TOXICOL APPL PHARM, V240, P189, DOI 10.1016/j.taap.2009.07.018; Prinelli F, 2015, BRIT J NUTR, V113, P1003, DOI 10.1017/S0007114515000318; Qosa H, 2015, ACS CHEM NEUROSCI, V6, P1849, DOI 10.1021/acschemneuro.5b00190; Romero C, 2007, J AGR FOOD CHEM, V55, P680, DOI 10.1021/jf0630217; Scotece M, 2013, CURR MED CHEM, V20, P2467, DOI 10.2174/0929867311320190006; Scotece M, 2015, DRUG DISCOV TODAY, V20, P406, DOI 10.1016/j.drudis.2014.10.017; Sepporta MV, 2013, NUTR CANCER, V65, P1208, DOI 10.1080/01635581.2013.828089; Vougliannopoulou K, 2014, J NAT PROD, V77, P441, DOI 10.1021/np401010x; Vulcano I, 2015, FOOD CHEM, V169, P381, DOI 10.1016/j.foodchem.2014.08.007; Wen J, 2014, Chinese Patent, Patent No. [CN103483196 A, 103483196]	35	22	22	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2019	14	4							e0214798	10.1371/journal.pone.0214798	http://dx.doi.org/10.1371/journal.pone.0214798			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HS4YI	30964898	gold, Green Published, Green Submitted			2023-01-03	WOS:000463876300030
J	Duvetorp, A; Soderman, J; Assarsson, M; Skarstedt, M; Svensson, A; Seifert, O				Duvetorp, Albert; Soderman, Jan; Assarsson, Malin; Skarstedt, Marita; Svensson, Ake; Seifert, Oliver			Observational study on Swedish plaque psoriasis patients receiving narrowband-UVB treatment show decreased S100A8/A9 protein and gene expression levels in lesional psoriasis skin but no effect on S100A8/A9 protein levels in serum	PLOS ONE			English	Article							S100 PROTEINS; CALPROTECTIN S100A8/S100A9; CARDIOVASCULAR-DISEASE; DIFFERENTIATION; KERATINOCYTES; PHOTOTHERAPY; INFLAMMATION; ULTRAVIOLET; COMPLEX; PCR	S100A8 and S100A9 proteins are highly upregulated in patients with psoriasis and have been proposed as potential biomarkers for psoriasis. The present study was designed to analyze the effect of narrowband ultraviolet B therapy on these proteins. S100A8, S100A9 gene expression and S100A8/A9 heterocomplex protein levels were analyzed in lesional and non-lesional skin before and after narrowband-UVB treatment in patients with chronic plaque type psoriasis. In addition, disease severity was measured by psoriasis area and severity index (PASI) and serum protein levels of S100A8/A9 were repeatedly analyzed. Narrowband-UVB treatment significantly reduced S100A8, S100A9 gene expression and S100A8/A9 protein levels in lesional skin while serum levels showed no significant change. No correlation between PASI and serum S100A8/A9 protein levels was found. These results implicate a role of S100A8/A9 in the anti-inflammatory effect of narrowband-UVB. Serum S100A8/A9 levels do not respond to treatment suggesting that serum S100A8/A9 does not originate from psoriasis skin keratinocytes. Serum S100A8/A9 levels do not correlate with PASI questioning serum S100A8/A9 as a biomarker for psoriasis skin activity.	[Duvetorp, Albert; Svensson, Ake] Skane Univ Hosp, Dept Dermatol & Venereol, Div Endocrinol Skin Reprod Hlth & Ophthalmol, Malmo, Sweden; [Duvetorp, Albert; Soderman, Jan; Seifert, Oliver] Linkoping Univ, Dept Clin & Expt Med, Fac Med & Hlth Sci, Linkoping, Sweden; [Soderman, Jan; Skarstedt, Marita] Ryhov Cty Hosp, Div Med Diagnost, Lab Med, Jonkoping, Sweden; [Assarsson, Malin; Seifert, Oliver] Ryhov Cty Hosp, Div Med Hlth, Dept Dermatol & Venereol, Jonkoping, Sweden	Lund University; Skane University Hospital; Linkoping University	Duvetorp, A (corresponding author), Skane Univ Hosp, Dept Dermatol & Venereol, Div Endocrinol Skin Reprod Hlth & Ophthalmol, Malmo, Sweden.; Duvetorp, A (corresponding author), Linkoping Univ, Dept Clin & Expt Med, Fac Med & Hlth Sci, Linkoping, Sweden.	albert.duvetorp@skane.se	Seifert, Oliver/AAA-4212-2022; Duvetorp, Albert/AAD-6249-2019; Seifert, Oliver/ABA-6434-2020	Seifert, Oliver/0000-0002-2045-7142; Soderman, Jan/0000-0001-7505-7210	Futurum - Academy for Health and Care [657091, 416821, 383521]	Futurum - Academy for Health and Care	This study was funded by research grants (number 657091, 416821, 383521) from "Futurum - Academy for Health and Care". The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. http://plus.rjl.se/futurum.	Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; Aochi S, 2011, J AM ACAD DERMATOL, V64, P879, DOI 10.1016/j.jaad.2010.02.049; Batycka-Baran A, 2016, J PHOTOCH PHOTOBIO B, V161, P396, DOI 10.1016/j.jphotobiol.2016.05.023; Batycka-Baran A, 2015, J DERMATOL SCI, V79, P214, DOI 10.1016/j.jdermsci.2015.05.007; Benoit S, 2006, BRIT J DERMATOL, V155, P62, DOI 10.1111/j.1365-2133.2006.07198.x; Broome AM, 2003, J HISTOCHEM CYTOCHEM, V51, P675, DOI 10.1177/002215540305100513; Chimenti MS, 2016, J INT MED RES, V44, P33, DOI 10.1177/0300060515598900; Cotoi OS, 2014, ARTERIOSCL THROM VAS, V34, P202, DOI 10.1161/ATVBAHA.113.302432; Eckert RL, 2004, J INVEST DERMATOL, V123, P23, DOI 10.1111/j.0022-202X.2004.22719.x; Fagerhol MK, 2005, SCAND J CLIN LAB INV, V65, P211, DOI 10.1080/00365510510013587; Foell D, 2007, J LEUKOCYTE BIOL, V81, P28, DOI 10.1189/jlb.0306170; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; Grimbaldeston MA, 2003, J INVEST DERMATOL, V121, P1168, DOI 10.1046/j.1523-1747.2003.12561.x; Hansson C, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/696415; Hochberg M, 2007, BRIT J DERMATOL, V156, P289, DOI 10.1111/j.1365-2133.2006.07628.x; Hsu Kenneth, 2009, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V8, P290; Leach ST, 2007, SCAND J GASTROENTERO, V42, P1321, DOI 10.1080/00365520701416709; Lee Y, 2012, BIOCHEM BIOPH RES CO, V423, P647, DOI 10.1016/j.bbrc.2012.05.162; Lee YM, 2009, ARCH DERMATOL RES, V301, P523, DOI 10.1007/s00403-009-0960-8; Liu H, 2007, J HUAZHONG U SCI-MED, V27, P605, DOI 10.1007/s11596-007-0533-z; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lood C, 2016, ARTHRITIS RHEUMATOL, V68, P1970, DOI 10.1002/art.39656; Naik HB, 2015, ARTERIOSCL THROM VAS, V35, P2667, DOI 10.1161/ATVBAHA.115.306460; Park CC, 2009, ANN DERMATOL, V21, P35, DOI 10.5021/ad.2009.21.1.35; Perera C, 2010, IMMUNOL CELL BIOL, V88, P41, DOI 10.1038/icb.2009.88; Pruenster M, 2016, PHARMACOL THERAPEUT, V167, P120, DOI 10.1016/j.pharmthera.2016.07.015; Racz E, 2011, J INVEST DERMATOL, V131, P1547, DOI 10.1038/jid.2011.53; Schiopu A, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/828354; Schonthaler HB, 2013, IMMUNITY, V39, P1171, DOI 10.1016/j.immuni.2013.11.011; Sigurdardottir G, 2014, J AM ACAD DERMATOL, V70, P1067, DOI 10.1016/j.jaad.2013.12.044; Spuls PI, 2010, J INVEST DERMATOL, V130, P933, DOI 10.1038/jid.2009.391; Wilsmann-Theis D, 2016, J EUR ACAD DERMATOL, V30, P1165, DOI 10.1111/jdv.13269; Yui S, 2003, BIOL PHARM BULL, V26, P753	33	9	9	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2019	14	3							e0213344	10.1371/journal.pone.0213344	http://dx.doi.org/10.1371/journal.pone.0213344			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO6OH	30865695	Green Submitted, gold, Green Published			2023-01-03	WOS:000461048900062
J	Fuchs, Y				Fuchs, Yaron			The therapeutic promise of apoptosis	SCIENCE			English	Editorial Material							PROGRAMMED CELL-DEATH		[Fuchs, Yaron] Technion Israel Inst Technol, Lorry Lokey Interdisciplinary Ctr Life Sci & Engn, Dept Biol, Haifa, Israel	Technion Israel Institute of Technology	Fuchs, Y (corresponding author), Technion Israel Inst Technol, Lorry Lokey Interdisciplinary Ctr Life Sci & Engn, Dept Biol, Haifa, Israel.	yfuchs@technion.ac.il						Fuchs Y, 2015, NAT REV MOL CELL BIO, V16, P329, DOI 10.1038/nrm3999; Fuchs Y, 2013, SCIENCE, V341, P286, DOI 10.1126/science.1233029; Fuchs Y, 2011, CELL, V147, P742, DOI 10.1016/j.cell.2011.10.033; Koren E, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06941-4; Perez-Garijo A, 2013, ELIFE, V2, DOI 10.7554/eLife.01004; Soteriou D, 2018, NAT REV CANCER, V18, P186, DOI 10.1038/nrc.2017.122; Yosefzon Y, 2018, MOL CELL, V70, P573, DOI 10.1016/j.molcel.2018.04.019	7	5	5	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 8	2019	363	6431					1050	1051		10.1126/science.aaw3607	http://dx.doi.org/10.1126/science.aaw3607			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HO2MV	30846591				2023-01-03	WOS:000460750100030
J	Broadrup, RL; Mayack, C; Schick, SJ; Eppley, EJ; White, HK; Macherone, A				Broadrup, Robert L.; Mayack, Christopher; Schick, Sassicaia J.; Eppley, Elizabeth J.; White, Helen K.; Macherone, Anthony			Honey bee (Apis mellifera) exposomes and dysregulated metabolic pathways associated with Nosema ceranae infection	PLOS ONE			English	Article							PESTICIDE EXPOSURE; NEONICOTINOID PESTICIDE; NUTRITION; STRESS; MANIPULATION; REVEALS; HEALTH; GENE; KEGG	Honey bee (Apis mellifera) health has been severely impacted by multiple environmental stressors including parasitic infection, pesticide exposure, and poor nutrition. The decline in bee health is therefore a complex multifactorial problem which requires a holistic investigative approach. Within the exposome paradigm, the combined exposure to the environment, drugs, food, and individuals' internal biochemistry affects health in positive and negative ways. In the context of the exposome, honey bee hive infection with parasites such as Nosema ceranae is also a form of environmental exposure. In this study, we hypothesized that exposure to xenobiotic pesticides and other environmental chemicals increases susceptibility to N. ceranae infection upon incidental exposure to the parasite. We further queried whether these exposures could be linked to changes in conserved metabolic biological pathways. From 30 hives sampled across 10 sites, a total of 2,352 chemical features were found via gas chromatography-time of flight mass spectrometry (GC-TOF) in extracts of honey bees collected from each hive. Of these, 20 pesticides were identified and annotated, and found to be significantly associated with N. ceranae infection. We further determined that infected hives were linked to a greater number of xenobiotic exposures, and the relative concentration of the exposures were not linked to the presence of a N. ceranae infection. In the exposome profiles of the bees, we also found chemicals inherent to known biological metabolic pathways of Apis mellifera and identified 9 dysregulated pathways. These findings have led us to posit that for hives exposed to similar chemicals, those that incur multiple, simultaneous xenobiotic stressors have a greater incidence of infection with N. ceranae. Mechanistically, our results suggests the overwhelming nature of these exposures negatively affects the biological functioning of the bee, and could explain how the decline in bee populations is associated with pesticide exposures.	[Broadrup, Robert L.; White, Helen K.] Haverford Coll, Dept Chem, Haverford, PA 19041 USA; [Mayack, Christopher; Schick, Sassicaia J.; Eppley, Elizabeth J.] Swarthmore Coll, Dept Biol, Swarthmore, PA 19081 USA; [Mayack, Christopher] Sabanci Univ, Fac Engn & Nat Sci, Mol Biol Genet & Bioengn, Istanbul, Turkey; [Macherone, Anthony] Agilent Technol, Life Sci & Chem Anal Grp, Santa Clara, CA USA; [Macherone, Anthony] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Haverford College; Swarthmore College; Sabanci University; Agilent Technologies; Johns Hopkins University	Mayack, C (corresponding author), Swarthmore Coll, Dept Biol, Swarthmore, PA 19081 USA.; Mayack, C (corresponding author), Sabanci Univ, Fac Engn & Nat Sci, Mol Biol Genet & Bioengn, Istanbul, Turkey.	cmayack@sabanciuniv.edu	Mayack, Christopher/AAY-9174-2020	Mayack, Christopher/0000-0003-0213-2149	Agilent Technologies; Applications and Core Technology University Research [3937]	Agilent Technologies; Applications and Core Technology University Research	Agilent Technologies provided financial support to HW. The Applications and Core Technology University Research grant number is 3937. The website is https://www.agilent.com/en/resources/academia/grant-funding-support. Anthony Macherone is employed by Agilent Technologies. Agilent Technologies provided support in the form of salary for author AM and financial support to HW, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Alaux C, 2010, BIOL LETTERS, V6, P562, DOI 10.1098/rsbl.2009.0986; Alaux C, 2010, ENVIRON MICROBIOL, V12, P774, DOI 10.1111/j.1462-2920.2009.02123.x; Aliferis KA, 2012, J INSECT PHYSIOL, V58, P1349, DOI 10.1016/j.jinsphys.2012.07.010; Antunez K, 2009, ENVIRON MICROBIOL, P1; Berenbaum MR, 2015, CURR OPIN INSECT SCI, V10, P51, DOI 10.1016/j.cois.2015.03.005; BLUM MS, 1959, SCIENCE, V130, P452, DOI 10.1126/science.130.3373.452; Botias C, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-25; Brittain C, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2012.2767; Brodschneider R, 2010, APIDOLOGIE, V41, P278, DOI 10.1051/apido/2010012; Brown MJF, 2009, APIDOLOGIE, DOI [10.1051/apido/2008069, DOI 10.1051/APIDO/2008069]; Chen YP, 2009, J INVERTEBR PATHOL, V101, P204, DOI 10.1016/j.jip.2009.05.012; Christen V, 2017, ENVIRON POLLUT, V226, P48, DOI 10.1016/j.envpol.2017.04.003; Collison E, 2016, BIOL REV, V91, P1006, DOI 10.1111/brv.12206; Degrandi-Hoffman G, 2015, J ECON ENTOMOL, V108, P2518, DOI 10.1093/jee/tov251; Doublet V, 2015, ENVIRON MICROBIOL, V17, P969, DOI 10.1111/1462-2920.12426; Dussaubat C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037017; Garcia-Palencia P, 2010, J APICULT RES, V49, P278, DOI 10.3896/IBRA.1.49.3.08; Genersch E, 2010, APIDOLOGIE, V41, P332, DOI 10.1051/apido/2010014; Glavan Gordana, 2013, Acta Biologica Slovenica, V56, P11; Goblirsch M, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0058165, 10.1371/journal.pone.0069831]; Goulson D, 2015, SCIENCE, V347, DOI 10.1126/science.1255957; Hamiduzzaman MM, 2010, J INVERTEBR PATHOL, V105, P151, DOI 10.1016/j.jip.2010.06.001; Hein Lars, 2009, Open Ecology Journal, V2, P74, DOI 10.2174/1874213000902010074; Henry M, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2015.2110; Higes M, 2013, ENV MICROBIOL REP, V5, P17, DOI 10.1111/1758-2229.12024; Higes M, 2010, APIDOLOGIE, V41, P375, DOI 10.1051/apido/2010019; Jack CJ, 2016, J INSECT PHYSIOL, V87, P12, DOI 10.1016/j.jinsphys.2016.01.004; Johnson RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054092; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kanehisa M, 2016, NUCLEIC ACIDS RES, V44, pD457, DOI 10.1093/nar/gkv1070; Kaplan M, 2016, FOOD TECHNOL BIOTECH, V54, P497, DOI [10.17113/ftb.54.04.16.4635, 10.17113/ft b.54.04.16.4635]; Karacaoglu M., 2012, Asian Journal of Animal Sciences, V6, P42, DOI 10.3923/ajas.2012.42.46; Klein AM, 2007, P ROY SOC B-BIOL SCI, V274, P303, DOI 10.1098/rspb.2006.3721; Kremen C, 2007, ECOL LETT, V10, P299, DOI 10.1111/j.1461-0248.2007.01018.x; Kurze C, 2016, INSECT BIOCHEM MOLEC, V79, P42, DOI 10.1016/j.ibmb.2016.10.005; Leonhardt SD, 2010, BEHAV ECOL SOCIOBIOL, V64, P1415, DOI 10.1007/s00265-010-0956-6; Lewis KA, 2016, HUM ECOL RISK ASSESS, V22, P1050, DOI 10.1080/10807039.2015.1133242; Lorenz MW, 1999, J INSECT PHYSIOL, V45, P647, DOI 10.1016/S0022-1910(98)00158-9; Lorenz MW, 2001, J INSECT PHYSIOL, V47, P563, DOI 10.1016/S0022-1910(00)00133-5; Mao WF, 2017, P NATL ACAD SCI USA, V114, P2538, DOI 10.1073/pnas.1614864114; MARCIREAU C, 1990, ANTIMICROB AGENTS CH, V34, P989, DOI 10.1128/AAC.34.6.989; Martin-Hernandez R, 2012, ENVIRON MICROBIOL, V14, P2127, DOI 10.1111/j.1462-2920.2011.02645.x; Mayack C, 2015, INSECT MOL BIOL, V24, P662, DOI 10.1111/imb.12190; Mayack C, 2010, J INSECT PHYSIOL, V56, P1572, DOI 10.1016/j.jinsphys.2010.05.016; Mayack C, 2009, J INVERTEBR PATHOL, V100, P185, DOI 10.1016/j.jip.2008.12.001; Mullin CA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009754; Natsopoulou ME, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.1896; Pettis JS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070182; Pettis JS, 2012, NATURWISSENSCHAFTEN, V99, P153, DOI 10.1007/s00114-011-0881-1; Potter VR, 1943, J GEN PHYSIOL, V26, P391, DOI 10.1085/jgp.26.4.391; Potts SG, 2010, TRENDS ECOL EVOL, V25, P345, DOI 10.1016/j.tree.2010.01.007; Rappaport SM, 2010, SCIENCE, V330, P460, DOI 10.1126/science.1192603; Sahinler N, 2005, J APICULT RES, V44, P58; Sanchez-Bayo F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094482; Schmehl DR, 2014, J INSECT PHYSIOL, V71, P177, DOI 10.1016/j.jinsphys.2014.10.002; Simon-Delso N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103073; SVOBODA JA, 1986, LIPIDS, V21, P97, DOI 10.1007/BF02534310; Team R. D. C R Development Core Team R, 2019, R LANG ENV STAT COMP; Thompson GJ, 2007, J EXP ZOOL PART A, V307A, P600, DOI 10.1002/jez.415; Traynor KS, 2016, SCI REPORTS, V6, P16, DOI [10.1038/s41598-016-0019, DOI 10.1038/S41598-016-0019]; U.S. EPA, 2011, NAPHTH EM NEW ENGL; van der Zee R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131611; Vidau C, 2014, J INVERTEBR PATHOL, V121, P89, DOI 10.1016/j.jip.2014.07.002; Vidau C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021550; Wegener J, 2016, J INSECT PHYSIOL, V91-92, P1, DOI 10.1016/j.jinsphys.2016.06.004; Whitehorn PR, 2012, SCIENCE, V336, P351, DOI 10.1126/science.1215025; Wild CP, 2005, CANCER EPIDEM BIOMAR, V14, P1847, DOI 10.1158/1055-9965.EPI-05-0456	68	15	15	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2019	14	3							e0213249	10.1371/journal.pone.0213249	http://dx.doi.org/10.1371/journal.pone.0213249			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HO1AY	30845162	Green Accepted, Green Published, gold, Green Submitted			2023-01-03	WOS:000460638800056
J	Seo, J; Lee, JW; Kang, Y; Lee, E; Ahn, JM; Kim, DH; Kang, HS				Seo, Jiwoon; Lee, Joon Woo; Kang, Yusuhn; Lee, Eugene; Ahn, Joong Mo; Kim, Dong Hyun; Kang, Heung Sik			Evaluation of the responsiveness of outcome measures after spine injection: A retrospective study	PLOS ONE			English	Article							LOW-BACK-PAIN; EPIDURAL STEROID INJECTION; RATING-SCALE; SCORES; REDUCTION; AGREEMENT	Discrepancies in patients' responses to various outcome measures challenge clinicians' evaluation of treatment outcomes. Therefore, we aimed to 1) evaluate the concordance of outcome measures after spine injection, 2) determine the patient variables that lead to discordant responses, and 3) suggest practical outcome measure for spine injections with good responsiveness. From October 2014 to November 2014, 164 patients with neck or low back pain who visited our outpatient clinics and had spine injections on the previous visit were enrolled. We asked patients to report changes in their symptom in the form of outcome measures: numeric rating scale, Oswestry disability index, neck disability index, residual symptom percentage and global perceived effect. The responses were categorized into three groups according to the degree of change; not improved, minimally improved, and significantly improved. The concordances of these categorized answers were evaluated. When "significantly improved" was considered as true improvement, 46 (28%) of the 164 patients had discordant responses to the four measures. There was no significant patients' variable that affects discordance in the outcome measures. Good agreement was shown between the global perceived effect and residual symptom percentage, while the Oswestry disability index had poor agreement with the other measurements. The calculated numeric rating scale and residual symptom percentage also had low levels of agreement. However, patients with severe pre-treatment pain tended to have better agreement. In conclusion, this result suggest that the residual symptom percentage may be a more practical for clinicians and better represent patients' improvements after spine injection.	[Seo, Jiwoon; Lee, Joon Woo; Kang, Yusuhn; Lee, Eugene; Ahn, Joong Mo; Kang, Heung Sik] Seoul Natl Univ, Bundang Hosp, Dept Radiol, Seongnam Si, Gyeonggi Do, South Korea; [Kim, Dong Hyun] Seoul Natl Univ, Boramae Med Ctr, Dept Radiol, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital	Lee, JW (corresponding author), Seoul Natl Univ, Bundang Hosp, Dept Radiol, Seongnam Si, Gyeonggi Do, South Korea.	joonwoo2@gmail.com	Kang, Yusuhn/AAE-3405-2019	Kang, Yusuhn/0000-0003-1838-2564; Kim, Dong Hyun/0000-0002-3871-7002; Lee, Joon Woo/0000-0002-7106-5229	National Research Foundation of Korea [NRF-2016R1A2B4010992]; Seoul National University Bundang Hospital [02-2013-092]; NRF - Korea government (MSIP) [NRF-2016R1A2B4010992]; SNUBH Research Fund [02-2013-092]	National Research Foundation of Korea(National Research Foundation of Korea); Seoul National University Bundang Hospital; NRF - Korea government (MSIP); SNUBH Research Fund	Funded by National Research Foundation of Korea NRF-2016R1A2B4010992. Dr Joonwoo Lee. Seoul National University Bundang Hospital 02-2013-092. Dr Joonwoo Lee.; This work was supported by Mid-career Researcher Program through NRF grant funded by the Korea government (MSIP) (No. NRF-2016R1A2B4010992); the SNUBH Research Fund (grant no. 02-2013-092).	Cepeda MS, 2003, PAIN, V106, P439, DOI 10.1016/j.pain.2003.09.006; Chapman JR, 2011, SPINE, V36, pS54, DOI 10.1097/BRS.0b013e31822ef74d; Childs JD, 2005, SPINE, V30, P1331, DOI 10.1097/01.brs.0000164099.92112.29; Cohen SP, 2015, MAYO CLIN PROC, V90, P284, DOI 10.1016/j.mayocp.2014.09.008; Cormier S, 2016, PAIN, V157, P329, DOI 10.1097/j.pain.0000000000000379; Cushman D, 2015, PAIN MED, V16, P870, DOI 10.1111/pme.12669; Guyatt GH, 2002, J CLIN EPIDEMIOL, V55, P900, DOI 10.1016/S0895-4356(02)00435-3; Hooten WM, 2015, MAYO CLIN PROC, V90, P1699, DOI 10.1016/j.mayocp.2015.10.009; Kamper SJ, 2010, J CLIN EPIDEMIOL, V63, P760, DOI 10.1016/j.jclinepi.2009.09.009; Kim HJ, 2014, PAIN PRACT, V14, P405, DOI 10.1111/papr.12084; Ostelo RWJG, 2008, SPINE, V33, P90, DOI 10.1097/BRS.0b013e31815e3a10; Costa LOP, 2008, SPINE, V33, P2459, DOI 10.1097/BRS.0b013e3181849dbe; Shahgholi L, 2015, AM J NEURORADIOL, V36, P594, DOI 10.3174/ajnr.A4150; Theodore BR, 2012, PAIN MED, V13, P1131, DOI 10.1111/j.1526-4637.2012.01442.x; Tomkins-Lane CC, 2012, ARCH PHYS MED REHAB, V93, P2008, DOI 10.1016/j.apmr.2012.05.014	15	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2019	14	2							e0211763	10.1371/journal.pone.0211763	http://dx.doi.org/10.1371/journal.pone.0211763			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM9LQ	30811428	Green Published, Green Submitted, gold			2023-01-03	WOS:000459806400032
J	van den Akker, M; Vaes, B; Goderis, G; Van Pottelbergh, G; De Burghgraeve, T; Henrard, S				van den Akker, Marjan; Vaes, Bert; Goderis, Geert; Van Pottelbergh, Gijs; De Burghgraeve, Tine; Henrard, Severine			Trends in multimorbidity and polypharmacy in the Flemish-Belgian population between 2000 and 2015	PLOS ONE			English	Article							OLDER-ADULTS; HEALTH-CARE	Objectives The aim of this paper was to describe the time trends in the prevalence of multimorbidity and polypharmacy in Flanders (Belgium) between 2000 and 2015, while controlling for age and sex. Methods Data were available from Intego, a Flemish-Belgian general practice-based morbidity registration network. The practice population between 2000 and 2015 was used as the denominator, representing a mean of 159,946 people per year. Age and gender-standardised prevalence rates were used for the trends of multimorbidity and polypharmacy in the total population and for subgroups. Joinpoint regression analyses were used to analyse the time trends and breaks in trends, for the entire population as well as for specific age and sex groups. Results Overall, in 2015, 22.7% of the population had multimorbidity, while the overall prevalence of polypharmacy was 20%. Throughout the study period the standardised prevalence rate of multimorbidity rose for both sexes and in all age groups. The largest relative increase in multimorbidity was observed in the younger age groups (up to the age of 50 years). The prevalence of polypharmacy showed a significant increase between 2000 and 2015 for all age groups except the youngest (0-25 years). Conclusion For all adult age groups multimorbidity and polypharmacy are frequent, dynamic over time and increasing. This asks for both epidemiological and interventional studies to improve the management of the resulting complex care.	[van den Akker, Marjan] Maastricht Univ, Sch Caphri, Dept Family Med, Maastricht, Netherlands; [van den Akker, Marjan; Vaes, Bert; Goderis, Geert; Van Pottelbergh, Gijs; De Burghgraeve, Tine; Henrard, Severine] Univ Leuven, KU Leuven, Dept Publ Hlth & Primary Care, Leuven, Belgium; [Henrard, Severine] UCL, Louvain Drug Res Inst, Brussels, Belgium; [Henrard, Severine] UCL, Inst Hlth & Soc IRSS, Brussels, Belgium	Maastricht University; Maastricht University Medical Centre (MUMC); KU Leuven; Universite Catholique Louvain; Universite Catholique Louvain	van den Akker, M (corresponding author), Maastricht Univ, Sch Caphri, Dept Family Med, Maastricht, Netherlands.; van den Akker, M (corresponding author), Univ Leuven, KU Leuven, Dept Publ Hlth & Primary Care, Leuven, Belgium.	Marjan.vandenAkker@maastrichtuniversity.nl	Bert, Vaes/I-6850-2019; Henrard, Séverine/E-4816-2011	Bert, Vaes/0000-0001-5244-1930; Henrard, Séverine/0000-0002-0389-8093; Van Pottelbergh, gijs/0000-0002-4189-3517; van den Akker, Marjan/0000-0002-1022-8637; Goderis, Geert/0000-0001-5303-2290				Anderson E, 2016, CLIN TEACH, V13, P291, DOI 10.1111/tct.12485; Banerjee S, 2015, LANCET, V385, P587, DOI 10.1016/S0140-6736(14)61596-8; Barnett K, 2012, LANCET, V379; Bartholomeeusen S, 2005, FAM PRACT, V22, P442, DOI 10.1093/fampra/cmi054; Bleich SN, 2015, PREV CHRONIC DIS, V12, DOI 10.5888/pcd12.150275; Charlesworth CJ, 2015, J GERONTOL A-BIOL, V70, P989, DOI 10.1093/gerona/glv013; Chi WC, 2017, ANN FAM MED, V15, P546, DOI 10.1370/afm.2106; Divo MJ, 2014, EUR RESPIR J, V44, P1055, DOI 10.1183/09031936.00059814; ElmstOhl S., 2013, HLTH AGING CLIN CARE, V5, P1, DOI DOI 10.4137/HACCE.S11173; Feng X, 2018, POPUL HEALTH MANAG, V21, P123, DOI 10.1089/pop.2017.0065; Fortin Martin, 2004, Health Qual Life Outcomes, V2, P51, DOI 10.1186/1477-7525-2-51; Fortin M, 2012, ANN FAM MED, V10, P142, DOI 10.1370/afm.1337; Freid Virginia M, 2012, NCHS Data Brief, P1; Guthrie B, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0322-7; Hays R, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2727-9; Howard RL, 2007, BRIT J CLIN PHARMACO, V63, P136, DOI 10.1111/j.1365-2125.2006.02698.x; Huiskes VJB, 2017, BMC FAM PRACT, V18, DOI 10.1186/s12875-016-0577-x; Kim HJ, 2001, STAT MED, V20, P655, DOI 10.1002/sim.811; KNOTTNERUS JA, 1992, FAM PRACT, V9, P15, DOI 10.1093/fampra/9.1.15; Leppin AL, 2015, HEALTHCARE-BASEL, V3, P50, DOI 10.3390/healthcare3010050; Lewis Cliona, 2016, J Comorb, V6, P85, DOI 10.15256/joc.2016.6.87; Masnoon N, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0621-2; May C, 2009, BRIT MED J, V339, P485, DOI DOI 10.1177/1742395312463411; McPhail SM, 2016, RISK MANAG HEALTHC P, V9, P143, DOI 10.2147/RMHP.S97248; Meinow B, 2015, EUR J AGEING, V12, P285, DOI 10.1007/s10433-015-0351-2; Muth C, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0223-1; Nunes BP, 2016, ARCH GERONTOL GERIAT, V67, P130, DOI 10.1016/j.archger.2016.07.008; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; Roland M, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2510; Sinnott Carol, 2015, J Comorb, V5, P29, DOI 10.15256/joc.2015.5.51; Smith S., 2012, COCHRANE DATABASE SY; St Sauver JL, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006413; Team RC, 2014, R LANG ENV STAT COMP; Truyers C, 2014, BMC MED INFORM DECIS, V14, DOI 10.1186/1472-6947-14-48; Uijen Annemarie A, 2008, Eur J Gen Pract, V14 Suppl 1, P28, DOI 10.1080/13814780802436093; Vaes B, 2018, EUR J PUBLIC HEALTH, V28, P193, DOI 10.1093/eurpub/ckx106; van den Akker M, 2001, J CLIN EPIDEMIOL, V54, P675, DOI 10.1016/S0895-4356(00)00358-9; Van der Akker M, 1996, EUR J GEN PRACT, V2, P65, DOI 10.3109/13814789609162146; van Oostrom SH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160264; Xu XL, 2017, AGEING RES REV, V37, P53, DOI 10.1016/j.arr.2017.05.003	40	30	30	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2019	14	2							e0212046	10.1371/journal.pone.0212046	http://dx.doi.org/10.1371/journal.pone.0212046			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL0PE	30753214	Green Published, gold, Green Submitted			2023-01-03	WOS:000458395600040
J	Carter, A; Dattani, N; Hannan, SA				Carter, Alison; Dattani, Nikesh; Hannan, Saiful Alam			10-MINUTE CONSULTATION Chronic rhinosinusitis	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Carter, Alison; Hannan, Saiful Alam] Royal Natl Throat Nose & Ear Hosp, London, England; [Dattani, Nikesh] Millway Med Practice, London, England	University College London Hospitals NHS Foundation Trust; University of London; University College London	Carter, A (corresponding author), Royal Natl Throat Nose & Ear Hosp, London, England.	alicarter@doctors.org.uk						Ellegard Eva K, 2007, Clin Allergy Immunol, V19, P305; FOKKENS WJ, 2012, RHINOLOGY, V50, P1, DOI DOI 10.4193/RHINO12.000; Harvey R, 2007, COCHRANE DB SYST REV, V3; Hastan D, 2011, ALLERGY, V66, P1216, DOI 10.1111/j.1398-9995.2011.02646.x; Head K, 2016, COCHRANE DB SYST REV, V4; Hopkins C, 2016, COMMISSIONING GUIDE; Lasso A, 2017, CLIN OTOLARYNGOL, V42, P637, DOI 10.1111/coa.12787; Szefler SJ, 2001, J ALLERGY CLIN IMMUN, V108, pS26, DOI 10.1067/mai.2001.115563; Varghese M, 2010, CLIN EXP ALLERGY, V40, P381, DOI 10.1111/j.1365-2222.2009.03450.x	9	5	5	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 6	2019	364								l131	10.1136/bmj.l131	http://dx.doi.org/10.1136/bmj.l131			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL3LL	30728148				2023-01-03	WOS:000458616700002
J	Wilbur, J; Torondel, B; Hameed, S; Mahon, T; Kuper, H				Wilbur, Jane; Torondel, Belen; Hameed, Shaffa; Mahon, Therese; Kuper, Hannah			Systematic review of menstrual hygiene management requirements, its barriers and strategies for disabled people	PLOS ONE			English	Review							INTELLECTUAL DISABILITIES; WOMEN; PREVALENCE; AUTISM; ISSUES	Background One quarter of the global population is of menstruating age, yet menstruation is shrouded in discrimination and taboos. Disability also carries stigma, so disabled people may face layers of discrimination when they are menstruating. The objective of the review is to assess the menstrual hygiene requirements of disabled people, the barriers they face, and the available interventions to help them manage their menstruation hygienically and with dignity. Methods Eligible studies, gathered across all countries, were identified by conducting searches across four databases (MEDLINE, PubMed, EMBASE, Global Health) in May 2017, with alerts set on each database to highlight new titles added until April 2018. Eligible studies incorporated analyses relevant to menstruating disabled people and/or how their carers provide support during their menstrual cycle. Results The 22 studies included were published since 1976; the majority after 2010 (n = 12; 55%). One study was a quasi-experiment; all others were observational. Most studies (n = 15; 68%) were from high income countries and most (n = 17; 77%) focused on people with intellectual impairments, so the review findings focus on this group and their carers. Outcomes investigated include choice and preference of menstrual product, ability to manage menstrual hygiene and coping strategies applied. Barriers faced included a lack of standardised guidance for professional carers; a lack of menstruation training, information and support provided to people with intellectual impairments and their carers; a lack of understanding of severity of symptoms experienced by people with intellectual impairments, the high cost of menstrual products and lack of appropriate options for people with physical impairments. Few interventions were found, and strategies for menstrual hygiene management applied by carers of persons with intellectual impairments include limiting the disabled person's movements when menstruating and suppressing their menstruation. Conclusions Little evidence was identified on the requirements of disabled people and their carers in managing their menstruation, and only one intervention, but a range of barriers were identified. This gap in evidence is important, as the consequences of failing to meet menstrual hygiene needs of disabled people includes shame, social isolation, and even sterilisation. Systematic review registration PROSPERO CRD42018095497.	[Wilbur, Jane; Hameed, Shaffa; Kuper, Hannah] London Sch Hyg & Trop Med, Dept Clin Res, Int Ctr Evidence Disabil, London, England; [Torondel, Belen] London Sch Hyg & Trop Med, Dept Clin Res, Environm Hlth Grp, London, England; [Mahon, Therese] Wateraid, London, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Wilbur, J (corresponding author), London Sch Hyg & Trop Med, Dept Clin Res, Int Ctr Evidence Disabil, London, England.	jane.wilbur@lshtm.ac.uk		Wilbur, Jane/0000-0002-5329-1337; Hameed, Shaffa/0000-0003-2723-1709	Bill and Melinda Gates Foundation [OPP1159651]	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	Funding for this review was gratefully received from the Bill and Melinda Gates Foundation (https://www.gatesfoundation.org), Development Grant number OPP1159651, Global and Country-Level WSH Advocacy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altundag S, 2016, J CLIN NURS, V25, P1962, DOI 10.1111/jocn.13215; Amornkul PN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006470; [Anonymous], 2011, WORLD REP DIS; Banks LM, 2016, OXFORD DEV STUDIES, P1; Baydi H, 2008, J INT MED RES, V36, P268, DOI 10.1177/147323000803600208; Carnaby S, 2002, J INTELL DISABIL RES, V46, P120, DOI 10.1046/j.1365-2788.2002.00358.x; Castaneda X, 1996, SOC SCI MED, V42, P133, DOI 10.1016/0277-9536(95)00077-1; Cavill S., 2016, PUTTING HARDEST REAC; CHARLIFUE SW, 1992, PARAPLEGIA, V30, P192, DOI 10.1038/sc.1992.54; Chou YC, 2012, J INTELLECT DEV DIS, V37, P1, DOI 10.3109/13668250.2011.651615; Chou YC, 2009, J INTELLECT DEV DIS, V34, P36, DOI 10.1080/13668250802688322; Clark JP, 2003, PEER REV QUALITATIVE; Erik von Elm MDGA, 2007, ANN INTERN MED, P573; Garg S, 2001, SOCIOCULTURAL ASPECT; Hamilton A, 2011, J ADOLESCENT HEALTH, V49, P443, DOI 10.1016/j.jadohealth.2011.01.015; House S., 2012, MENSTRUAL HYGIENE MA; Ibralic I, 2010, RES DEV DISABIL, V31, P800, DOI 10.1016/j.ridd.2010.02.004; Jones H., 2014, DISABILITY MAKING CL; Juma M, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-84; Kerubo E, 2016, SEX TRANSM INFECT, V92, P251, DOI 10.1136/sextrans-2015-052371; Kirkham YA, 2013, J ADOLESCENT HEALTH, V53, P407, DOI 10.1016/j.jadohealth.2013.04.014; Kyrkou M, 2005, J INTELL DISABIL RES, V49, P770, DOI 10.1111/j.1365-2788.2005.00749.x; Lantman-de Valk HMJV, 2011, J INTELL DISABIL RES, V55, P434, DOI 10.1111/j.1365-2788.2011.01395.x; Lee J., 1993, MENARCHE HETERO SEXU; Lin LP, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-59; Lin LP, 2011, RES DEV DISABIL, V32, P824, DOI 10.1016/j.ridd.2010.10.015; Lobo RA, 2010, J CLIN ENDOCRINOLOGY, V95, pE1, DOI [10.1210/jcem.95.4.9998, DOI 10.1210/JCEM.95.4.9998]; Mason Lac C, 2007, J APPL RES INTELLECT, V21, P257; Mason L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079132; McMahon SA, 2011, BMC INT HEALTH HUM R, V11, DOI 10.1186/1472-698X-11-7; Moher D., 2009, BMJ-BRIT MED J, V6, DOI [DOI 10.1023/B:MEDI.0000005484.26741.79, 10.1371/journal.pmed1000097.]; Moore GF, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1258; Naeem K, 2015, WATERLINES, V34, P104; OHCHR, 2008, CONV RIGHTS PERS DIS; Patage D. P., 2015, International Journal of Medical Science and Public Health, V4, P964; Perrin JC, 1960, AM J DIS CHILD, P130; Phillips-Howard P, 2015, MENSTRUAL NEEDS ASS; Poornima Thapa, 2017, Waterlines, V36, P317, DOI 10.3362/1756-3488.17-00012; Ranganath P, 2004, INDIAN J HUM GENET, V10, P18; Roberts TA, 2002, PSYCHOL WOMEN QUART, V26, P131, DOI 10.1111/1471-6402.00051; Rodgers J, 2005, J INTELLECT DEV DIS, V30, P45, DOI 10.1080/13668250500033094; Sahin M, 2015, WATERLINES, V34, P3, DOI [10.3362/ 1756-3488.2015.001, DOI 10.3362/1756-3488.2015.001]; SHN Z, INT J COMMUNITY MED, V2915, P189; Stein MA, 1994, MOMMY HAS BLUE WHEEL; UN, SUST DEV GOAL 6 ENS; UNICEF University E, 2013, WASH SCH EMP GIRLS E; Van der Merwe J V, 1987, Obstet Gynecol Surv, V42, P489, DOI 10.1097/00006254-198708000-00003; W.H. Organization, 2017, PROGR DRINKING WATER; Wamoyi J, 2010, REPROD HEALTH, V7, DOI 10.1186/1742-4755-7-6; White S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155043; WHO UNICEF JMP, CONS DRAFT LONG LIST; Wilbur J., 2013, 336 WEDC INT C NAK K; Winkler I., 2015, CARDOZO J LAW GENDER; World Health Organization Department of Reproductive Health and Research; United Nations Population Fund (UNFPA), 2009, PROM SEX REPR HLTH P	54	31	31	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2019	14	2							e0210974	10.1371/journal.pone.0210974	http://dx.doi.org/10.1371/journal.pone.0210974			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HK4EL	30726254	Green Accepted, Green Published, Green Submitted, gold			2023-01-03	WOS:000457874000042
J	Biesheuvel-Leliefeld, KEM; Bosmans, JE; Dijkstra-Kersten, SMA; Smit, F; Bockting, CLH; van Schaik, DJF; van Marwijk, HWJ; van der Horst, HE				Biesheuvel-Leliefeld, Karolien E. M.; Bosmans, Judith E.; Dijkstra-Kersten, Sandra M. A.; Smit, Filip; Bockting, Claudi L. H.; van Schaik, Digna J. F.; van Marwijk, Harm W. J.; van der Horst, Henriette E.			A supported self-help for recurrent depression in primary care; An economic evaluation alongside a multi-center randomised controlled trial	PLOS ONE			English	Article							QUALITY-OF-LIFE; COST-EFFECTIVENESS; COGNITIVE THERAPY; SUBTHRESHOLD DEPRESSION; PREVENT DEPRESSION; MAJOR DEPRESSION; GLOBAL BURDEN; RELAPSE; DISABILITY; DISORDERS	Background Major depression is a prevalent mental disorder with a high risk of relapse or recurrence. Only few studies have focused on the cost-effectiveness of interventions aimed at the prevention of relapse or recurrence of depression in primary care. Aim To evaluate the cost-effectiveness of a supported Self-help Preventive Cognitive Therapy (S-PCT) added to treatment-as-usual (TAU) compared with TAU alone for patients with a history of depression, currently in remission. Methods An economic evaluation alongside a multi-center randomised controlled trial was performed (n = 248) over a 12-month follow-up. Outcomes included relapse or recurrence of depression and quality-adjusted-life-years (QALYs) based on the EuroQol-5D. Analyses were performed from both a societal and healthcare perspective. Missing data were imputed using multiple imputations. Uncertainty was estimated using bootstrapping and presented using the cost-effectiveness plane and the Cost-Effectiveness Acceptability Curve (CEAC). Cost estimates were adjusted for baseline costs. Results S-PCT statistically significantly decreased relapse or recurrence by 15% (95%Cl 3;28) compared to TAU. Mean total societal costs were (sic)2,114 higher (95%CI -112;4261). From a societal perspective, the ICER for relapse or recurrence was 13,515. At a Willingness To Pay (WTP) of 22,000 (sic)/recurrence prevented, the probability that S-PCT is cost-effective, in comparison with TAU, is 80%. The ICER for QALYs was 63,051. The CEA curve indicated that at a WTP of 30,000 (sic)/QALY gained, the probability that S-PCT is cost-effective compared to TAU is 21%. Conclusions Though ultimately depending on the WTP of decision makers, we expect that for both relapse or recurrence and QALYs, S-PCT cannot be considered cost-effective compared to TAU.	[Biesheuvel-Leliefeld, Karolien E. M.; Dijkstra-Kersten, Sandra M. A.; van der Horst, Henriette E.] Vrije Univ Amsterdam, Dept Gen Practice & Elderly Care Med, Inst Hlth & Care Res, Med Ctr, Amsterdam, Netherlands; [Biesheuvel-Leliefeld, Karolien E. M.; Dijkstra-Kersten, Sandra M. A.; van der Horst, Henriette E.] Vrije Univ Amsterdam, EMGO, Inst Hlth & Care Res, Med Ctr, Amsterdam, Netherlands; [Bosmans, Judith E.] Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Hlth Sci, Amsterdam, Netherlands; [Bosmans, Judith E.] Vrije Univ Amsterdam, Fac Earth & Life Sci, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Smit, Filip] Netherlands Inst Mental Hlth & Addict, Utrecht, Netherlands; [Smit, Filip] Vrije Univ Amsterdam, Dept Clin Psychol, Amsterdam, Netherlands; [Smit, Filip] Vrije Univ Amsterdam, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Smit, Filip] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [Smit, Filip] Vrije Univ Amsterdam, EMGO Inst Hlth & Care Res, Dept Epidemiol & Biostat, Med Ctr, Amsterdam, Netherlands; [Bockting, Claudi L. H.] Univ Utrecht, Dept Clin Psychol & Expt Psychopathol, Utrecht, Netherlands; [van Schaik, Digna J. F.] Vrije Univ Amsterdam, Dept Psychiat, Med Ctr, Amsterdam, Netherlands; [van Schaik, Digna J. F.] Vrije Univ Amsterdam, EMGO Inst Hlth & Care Res, Med Ctr, Amsterdam, Netherlands; [van Marwijk, Harm W. J.] Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [van Marwijk, Harm W. J.] NIHR Sch Primary Care Res, Manchester, Lancs, England	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Trimbos Institute; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Utrecht University; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of Manchester; University of Manchester	Biesheuvel-Leliefeld, KEM (corresponding author), Vrije Univ Amsterdam, Dept Gen Practice & Elderly Care Med, Inst Hlth & Care Res, Med Ctr, Amsterdam, Netherlands.; Biesheuvel-Leliefeld, KEM (corresponding author), Vrije Univ Amsterdam, EMGO, Inst Hlth & Care Res, Med Ctr, Amsterdam, Netherlands.	karolien.biesheuvel@gmail.com	Van Marwijk, Harm/K-6306-2013	Van Marwijk, Harm/0000-0001-6206-485X; Bosmans, Judith/0000-0002-1443-1026; van Schaik, Anneke/0000-0002-7169-9600	ZonMW, the Netherlands association for Health Research and Development; Department Disease management Chronical Illnesses [80-82310-97-11087, 171102002]	ZonMW, the Netherlands association for Health Research and Development; Department Disease management Chronical Illnesses	This research was funded by ZonMW, the Netherlands association for Health Research and Development, Department Disease management Chronical Illnesses, grant number: 80-82310-97-11087 or 171102002 to KBL. The funding source did not play any role in the collection, analysis, interpretation of the data, writing the manuscript or the decision to submit for publication.	[Anonymous], MEER EFFECT MET DEPR; Bakker Ingrid M, 2007, PLoS Clin Trials, V2, pe26, DOI 10.1371/journal.pctr.0020026; Beck A. T., 1979, COGNITIVE THERAPY DE; Berto Patrizia, 2000, J Ment Health Policy Econ, V3, P3, DOI 10.1002/1099-176X(200003)3:1<3::AID-MHP68>3.0.CO;2-H; Beshai S, 2011, CLIN PSYCHOL REV, V31, P1349, DOI 10.1016/j.cpr.2011.09.003; Biesheuvel-Leliefeld KEM, 2017, PSYCHOTHER PSYCHOSOM, V86, P220, DOI 10.1159/000472260; Biesheuvel-Leliefeld KEM, 2015, J AFFECT DISORDERS, V174, P400, DOI 10.1016/j.jad.2014.12.016; Biesheuvel-Leliefeld KEM, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-59; BLACK WC, 1990, MED DECIS MAKING, V10, P212, DOI 10.1177/0272989X9001000308; Bockting C. L, 2009, INGREDIENTS MOBILE P; Bockting CLH, 2009, J CLIN PSYCHIAT, V70, P1621, DOI 10.4088/JCP.08m04784blu; Bockting CLH, 2005, J CONSULT CLIN PSYCH, V73, P647, DOI 10.1037/0022-006X.73.4.647; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Burcusa SL, 2007, CLIN PSYCHOL REV, V27, P959, DOI 10.1016/j.cpr.2007.02.005; CAK. Centraal Administratie Kantoor, 2009, JAARV 2008, DOI [10.1136/bmj.b2393, DOI 10.1136/BMJ.B2393]; Conradi HJ, 2011, PSYCHOL MED, V41, P1165, DOI 10.1017/S0033291710001911; EFRON B, 1994, J AM STAT ASSOC, V89, P463, DOI 10.2307/2290846; Egede LE, 2007, GEN HOSP PSYCHIAT, V29, P409, DOI 10.1016/j.genhosppsych.2007.06.002; Fava M, 2006, J CLIN PSYCHIAT, V67, P1754, DOI 10.4088/JCP.v67n1113; Fenwick E, 2004, HEALTH ECON, V13, P405, DOI 10.1002/hec.903; First M., 1996, CLINICIAN VERSION SC; FRANK E, 1991, ARCH GEN PSYCHIAT, V48, P851, DOI 10.1001/archpsyc.1991.01810330075011; Greenberg PE, 2003, J CLIN PSYCHIAT, V64, P1465, DOI 10.4088/JCP.v64n1211; Greenberg PE, 2005, EXPERT OPIN PHARMACO, V6, P369, DOI 10.1517/14656566.6.3.369; Gunther OH, 2008, J AFFECT DISORDERS, V105, P81, DOI 10.1016/j.jad.2007.04.018; Hakkaart-van Roijen L, 2002, MANUAL TRIMBOS IMTA; Kok G, 2015, PSYCHOTHER PSYCHOSOM, V84, P90, DOI 10.1159/000369469; Kuyken W, 2015, LANCET, V386, P63, DOI 10.1016/S0140-6736(14)62222-4; Lamers LM, 2005, NED TIJDSCHR GENEES, V149, P1574; Lynch FL, 2005, ARCH GEN PSYCHIAT, V62, P1241, DOI 10.1001/archpsyc.62.11.1241; Mihalopoulos C, 2011, AUST NZ J PSYCHIAT, V45, P36, DOI 10.3109/00048674.2010.501024; National Institute for Health and Care Excellence (NICE), 2013, GUID METH TECHN APPR; National Institute for Health and Clinical Excellence, 2009, DEPR AD TREATM MAN D, P63; Oostenbrink J., 2004, GUIDELINE EC EVALUAT; Oostenbrink JB, 2002, STANDARDISATION COST, V7; ORMEL J, 1994, JAMA-J AM MED ASSOC, V272, P1741, DOI 10.1001/jama.272.22.1741; Ormel J, 2004, ARCH GEN PSYCHIAT, V61, P387, DOI 10.1001/archpsyc.61.4.387; Polder J, 2002, COST ILLNESS NETHERL; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Simon GE, 2002, MED CARE, V40, P941, DOI 10.1097/00005650-200210000-00011; Smit A, 2006, PSYCHOL MED, V36, P15, DOI 10.1017/S0033291705006318; Smit F, 2006, BRIT J PSYCHIAT, V188, P330, DOI 10.1192/bjp.188.4.330; Smit F, 2006, ARCH GEN PSYCHIAT, V63, P290, DOI 10.1001/archpsyc.63.3.290; Smit F, 2004, J AFFECT DISORDERS, V81, P241, DOI 10.1016/j.jad.2003.08.007; Spek V, 2008, PSYCHOL MED, V38, P635, DOI 10.1017/S0033291707002590; Stant AD, 2009, J MENT HEALTH POLICY, V12, P195; STERNE JAC, 2009, BMJ BRIT MED J, V0339; Ustun TB, 2004, BRIT J PSYCHIAT, V184, P386, DOI 10.1192/bjp.184.5.386; van den Berg M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022884; Vasiliadis HM, 2013, AM J GERIAT PSYCHIAT, V21, P536, DOI 10.1016/j.jagp.2012.12.016; Vittengl JR, 2007, J CONSULT CLIN PSYCH, V75, P475, DOI 10.1037/0022-006X.75.3.475; Vos T, 2004, ARCH GEN PSYCHIAT, V61, P1097, DOI 10.1001/archpsyc.61.11.1097; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Willan AR, 2004, HEALTH ECON, V13, P461, DOI 10.1002/hec.843; Willemse GRWM, 2004, BRIT J PSYCHIAT, V185, P416, DOI 10.1192/bjp.185.5.416	58	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2018	13	12							e0208570	10.1371/journal.pone.0208570	http://dx.doi.org/10.1371/journal.pone.0208570			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HE9NT	30566441	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000453779300048
J	Tornbom, K; Danielsson, A				Tornbom, Karin; Danielsson, Anna			Experiences of treadmill walking with non-immersive virtual reality after stroke or acquired brain injury - A qualitative study	PLOS ONE			English	Article							GAIT; SPEED; REHABILITATION; POSTSTROKE; MOBILITY; FEEDBACK; PROGRAM	Objectives It is well known that physical activity levels for persons after stroke or acquired brain injuries do not reach existing recommendations. Walking training is highly important since the ability to walk is considered to be a meaningful occupation for most people, and is often reduced after a brain injury. This suggests a need to innovate stroke rehabilitation, so that forms of walking training that are user-friendly and enjoyable can be provided. Method An interview study was carried out with persons after stroke (n = 8), or acquired brain injury (n = 2) at a rehabilitation unit at Sahlgrenska University Hospital. We used a semi-structured interview guide to investigate experiences and thoughts about walking on a treadmill with non-immersive virtual reality feedback. The contents were analyzed through an inductive approach, using qualitative content analysis. Results The virtual reality experience was perceived as enjoyable, exciting, and challenging. Participants stressed that the visual and auditory feedback increased their motivation to walk on a treadmill. However, for some participants, the virtual reality experience was too challenging, and extreme tiredness or fatigue were reported after the walking session. Conclusions Participants' thoughts and experiences indicated that the Virtual Reality walking system could serve as a complement to more traditional forms of walking training. Early after a brain injury, virtual reality could be a way to train the ability to handle individually adapted multisensory input while walking. Obvious benefits were that participants perceived it as engaging and exciting.	[Tornbom, Karin; Danielsson, Anna] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Res Grp Rehabil Med, Gothenburg, Sweden; [Tornbom, Karin] Univ Gothenburg, Ctr Person Ctr Care, Gothenburg, Sweden; [Danielsson, Anna] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Unit Physiotherapy,Dept Hlth & Rehabil, Gothenburg, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg	Tornbom, K (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Res Grp Rehabil Med, Gothenburg, Sweden.; Tornbom, K (corresponding author), Univ Gothenburg, Ctr Person Ctr Care, Gothenburg, Sweden.	karin.tombom@neuro.gu.se		Danielsson, Anna/0000-0002-6496-4066	John and Brit Wennerstrom foundation for Neurological Research; NorrbackaEugenia foundation [808-12]; Rune and Ulla Amlovs foundation for Neurological Research; Swedish Stroke association; Hjalmar Svensson foundation [HJSV2012056, HJSV 201354, HJSV20166034]; Swedish Stroke Centre West	John and Brit Wennerstrom foundation for Neurological Research; NorrbackaEugenia foundation; Rune and Ulla Amlovs foundation for Neurological Research; Swedish Stroke association; Hjalmar Svensson foundation; Swedish Stroke Centre West	This work was supported by: John and Brit Wennerstrom foundation for Neurological Research (A.D). The NorrbackaEugenia foundation, 808-12 (A.D). Rune and Ulla Amlovs foundation for Neurological Research (A.D). The Swedish Stroke association (A.D, K.T). Hjalmar Svensson foundation, HJSV2012056, HJSV 201354, HJSV20166034 (A. D). The Swedish Stroke Centre West (A.D, K.T). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamovich SV, 2009, NEUROREHABILITATION, V25, P29, DOI 10.3233/NRE-2009-0497; Aminov A, 2018, J NEUROENG REHABIL, V15, DOI 10.1186/s12984-018-0370-2; Baram Y, 2012, NEUROMODULATION, V15, P48, DOI 10.1111/j.1525-1403.2011.00412.x; Bergmann J., 2017, EUROPEAN J PHYS REHA; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Burdea GC, 2003, METHOD INFORM MED, V42, P519; Celinder D, 2012, SCAND J OCCUP THER, V19, P457, DOI 10.3109/11038128.2012.655307; Danielsson A, 2014, TURK WORLD C NEUR RE; Darekar A, 2015, J NEUROENG REHABIL, V12, DOI 10.1186/s12984-015-0035-3; FARROW S, 2004, TECHNOLOGY DISABILIT, V16, P69; Fini NA, 2017, PHYS THER, V97, P707, DOI 10.1093/ptj/pzx038; Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001; Gubrium JF, 2003, J GERONTOL B-PSYCHOL, V58, pS203, DOI 10.1093/geronb/58.4.S203; Harris-Love ML, 2004, NEUROREHAB NEURAL RE, V18, P154, DOI 10.1177/0888439004267678; Hurt CP, 1998, J MUSIC THER, V35, P228, DOI 10.1093/jmt/35.4.228; Khan F, 2016, J REHABIL MED, V48, P417, DOI 10.2340/16501977-2081; Kuys S, 2006, PHYSIOTHER RES INT, V11, P219, DOI 10.1002/pri.344; Kvale S., 2007, DOING INTERVIEWS; Lauber B, 2014, EUR J SPORT SCI, V14, P36, DOI 10.1080/17461391.2012.725104; Laver KE, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008349.pub2, 10.1002/14651858.CD008349.pub3, 10.1002/14651858.CD008349.pub4]; Lewek MD, 2012, PHYS THER, V92, P748, DOI 10.2522/ptj.20110206; Lledo LD, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00205; Mao Y, 2016, FRONTIERS PSYCHOL, V7; Mattlage AE, 2015, J NEUROL PHYS THER, V39, P166, DOI 10.1097/NPT.0000000000000092; Mirelman A, 2009, STROKE, V40, P169, DOI 10.1161/STROKEAHA.108.516328; Moreira MC, 2013, DISABIL REHABIL-ASSI, V8, P357, DOI 10.3109/17483107.2012.749428; Nascimento LR, 2015, J PHYSIOTHER, V61, P10, DOI 10.1016/j.jphys.2014.11.015; Nicholson S, 2013, INT J STROKE, V8, P357, DOI 10.1111/j.1747-4949.2012.00880.x; Nishiike S, 2013, J MED INVESTIG, V60, P236; Pallesen H, 2018, REHABIL RES PRACT, V2018, DOI 10.1155/2018/4318678; Pallesen H, 2014, DISABIL REHABIL, V36, P232, DOI 10.3109/09638288.2013.788217; Plummer P, 2013, ARCH PHYS MED REHAB, V94, P2565, DOI 10.1016/j.apmr.2013.08.002; Richards CL, 2018, PHYSIOTHER CAN, V70, P221, DOI 10.3138/ptc.2016-97; Shema SR, 2014, PHYS THER, V94, P1319, DOI 10.2522/ptj.20130305; Tornbom K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173463; Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987; Wingham J, 2015, CLIN REHABIL, V29, P295, DOI 10.1177/0269215514542638; Witte US, 1997, SCAND J REHABIL MED, V29, P161	39	11	12	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2018	13	12							e0209214	10.1371/journal.pone.0209214	http://dx.doi.org/10.1371/journal.pone.0209214			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HE3IQ	30550607	gold, Green Published, Green Submitted			2023-01-03	WOS:000453248000049
J	Real, D; Hoffmann, S; Leonardi, D; Salomon, C; Goycoolea, FM				Real, Daniel; Hoffmann, Stefan; Leonardi, Dario; Salomon, Claudio; Goycoolea, Francisco M.			Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations	PLOS ONE			English	Article							SPONTANEOUS EMULSIFICATION; ORAL BIOAVAILABILITY; HUMAN FASCIOLIASIS; NANOPARTICLES; ALBENDAZOLE; MICROPARTICLES; SOLUBILITY; DELIVERY; NANOCAPSULES; PRAZIQUANTEL	Triclabendazole is a poorly-water soluble (0.24 mu g/mL) compound classified into the Class I I/IV of the Biopharmaceutical Classification System. It is the drug of choice to treat fascioliasis, a neglected parasitic disease worldwide disseminated. Triclabendazole is registered as veterinary medicine and it is only available for human treatment as 250 mg tablets. Thus, the aim of this work was to develop novel drug delivery systems based on nanotechnology approaches. The chitosan-based nanocapsules and nanoemulsions of triclabendazole were fully characterized regarding their particle size distribution, polydispersity index and zeta potential, in-vitro release and stability in biological media. Cytotoxicity evaluation and cellular uptake studies using CaCo-2 cell line were also investigated. The results indicated an average hydrodynamic size around similar to 160 nm were found for unloaded nanoemulsions which were slightly increased up to-190 nm for loaded one. In contrast, the average hydrodynamic size of the nanocapsules increased from similar to 160 nm up to similar to 400 nm when loaded with triclabendazole. The stability studies upon 30 days storage at 4, 25 and 37 degrees C showed that average size of nanoemulsions was not modified with varying amounts of loaded TCBZ while an opposite result was seen in case of loaded nanocapsules. In addition, a slight reduction of zeta potential values over time was observed in both triclabendazole nanosystems. Release of TCBZ from nanoformulations over 6 h in simulated gastric fluid was 9 to 16-fold higher than with untreated TCBZ dispersion. In phosphate buffer saline solution there was no drug release for neither nanocapsules nor nanoemulsions. Cell viabilities studies indicated that at certain concentrations, drug encapsulation can lower its cytotoxic effects when compared to untreated drug. Confocal laser scanning microscopy study has shown that nanocapsules strongly interacted with Caco-2 cells in vitro which could increase the passage time of triclabendazole after oral administration. The results of this study constitute the first step towards the development of nanoformulations intended for the oral delivery of anti-parasitic drugs of enhanced bioavailability.	[Real, Daniel; Leonardi, Dario; Salomon, Claudio] Consejo Nacl Invest Cient & Tecn, Inst Quim Rosario, Rosario, Santa Fe, Argentina; [Real, Daniel; Leonardi, Dario; Salomon, Claudio] Univ Nacl Rosario, Dept Farm, Fac Cs Bioquim & Farmaceut, Rosario, Santa Fe, Argentina; [Hoffmann, Stefan; Goycoolea, Francisco M.] Westfalische Wilhelms Univ Munster, Inst Plant Biol & Biotechnol IBBP, Munster, Germany; [Hoffmann, Stefan; Goycoolea, Francisco M.] Univ Leeds, Sch Food Sci & Nutr, Leeds, W Yorkshire, England	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Rosario; University of Munster; University of Leeds	Salomon, C (corresponding author), Consejo Nacl Invest Cient & Tecn, Inst Quim Rosario, Rosario, Santa Fe, Argentina.; Salomon, C (corresponding author), Univ Nacl Rosario, Dept Farm, Fac Cs Bioquim & Farmaceut, Rosario, Santa Fe, Argentina.; Goycoolea, FM (corresponding author), Westfalische Wilhelms Univ Munster, Inst Plant Biol & Biotechnol IBBP, Munster, Germany.; Goycoolea, FM (corresponding author), Univ Leeds, Sch Food Sci & Nutr, Leeds, W Yorkshire, England.	csalomon@fbioyf.unr.edu.ar; f.m.goycoolea@leeds.ac.uk	Goycoolea, Francisco M./Q-5841-2017; Real, Daniel Andrés/AAW-5198-2021	Goycoolea, Francisco M./0000-0001-7949-5429; Real, Daniel Andrés/0000-0002-5189-680X; Hoffmann, Stefan/0000-0002-1959-1686; Salomon, Claudio/0000-0003-1599-790X	European Union's Seventh Framework Programme for research, technological development and demonstration [613931]; Deutsche Akademischer Austauschdienst (DAAD) Programme PROALAR [57134511]; Universidad Nacional de Rosario (Argentina); MINCyT (Argentina); CONICET (Argentina)	European Union's Seventh Framework Programme for research, technological development and demonstration; Deutsche Akademischer Austauschdienst (DAAD) Programme PROALAR; Universidad Nacional de Rosario (Argentina); MINCyT (Argentina); CONICET (Argentina)(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET))	This project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no613931. All authors are indebted to the funding by the Deutsche Akademischer Austauschdienst (DAAD) Programme PROALAR, project no 57134511. DR, DL, and CJS gratefully acknowledge the Universidad Nacional de Rosario (Argentina), MINCyT (Argentina) and CONICET (Argentina) for financial support. DR thanks CONICET (Argentina) for a Ph.D. fellowship.	Binnebose AM, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004173; Calvo P, 1997, COLLOID POLYM SCI, V275, P46, DOI 10.1007/s003960050050; Chua BY, 2012, MOL PHARMACEUT, V9, P81, DOI 10.1021/mp200264m; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; El-Feky GS, 2015, ANTIMICROB AGENTS CH, V59, P3501, DOI 10.1128/AAC.04875-14; Fairweather I, 2009, J HELMINTHOL, V83, P139, DOI 10.1017/S0022149X09321173; Garcia A, 2019, DRUG DELIV TRANSL RE, V9, P273, DOI 10.1007/s13346-018-0591-8; Goycoolea FM, 2012, COLLOID POLYM SCI, V290, P1423, DOI 10.1007/s00396-012-2669-z; Gu DY, 2017, EXPERT OPIN DRUG DEL, V14, P879, DOI 10.1080/17425247.2017.1245290; Hafner A, 2011, J MICROENCAPSUL, V28, P807, DOI 10.3109/02652048.2011.622053; Huang YB, 2014, ACTA PHARM SIN B, V4, P18, DOI 10.1016/j.apsb.2013.11.001; Jain S, 2015, DRUG DEV IND PHARM, V41, P875, DOI 10.3109/03639045.2014.971027; Paredes AJ, 2018, J PHARM PHARMACOL, V70, P51, DOI 10.1111/jphp.12834; Kaiser M, 2015, SCI REP-UK, V5, DOI 10.1038/srep10048; Kaiser M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141017; Kang BS, 2015, MATERIALS, V8, P486, DOI 10.3390/ma8020486; Keiser J, 2005, EXPERT OPIN INV DRUG, V14, P1513, DOI 10.1517/13543784.14.12.1513; Kohane DS, 2007, BIOTECHNOL BIOENG, V96, P203, DOI 10.1002/bit.21301; Lecaillon JB, 1998, BRIT J CLIN PHARMACO, V45, P601, DOI 10.1046/j.1365-2125.1998.00725.x; Liu Y, 2013, J BIOMED MATER RES B, V101B, P998, DOI 10.1002/jbm.b.32908; Lopez-Montilla JC, 2002, J DISPER SCI TECHNOL, V23, P219, DOI 10.1080/01932690208984202; Lozano MV, 2008, BIOMACROMOLECULES, V9, P2186, DOI 10.1021/bm800298u; Mas-Coma S, 2014, PARASITOLOGY, V141, P1918, DOI 10.1017/S0031182014000869; Mas-Coma S, 2009, ADV PARASIT, V69, P41, DOI 10.1016/S0065-308X(09)69002-3; MILLER CA, 1988, COLLOID SURFACE, V29, P89, DOI 10.1016/0166-6622(88)80173-2; Morgen M, 2012, PHARM RES-DORDR, V29, P427, DOI 10.1007/s11095-011-0558-7; Mourao SC, 2005, INT J PHARMACEUT, V295, P157, DOI 10.1016/j.ijpharm.2005.02.009; Omwenga EO, 2018, COLLOID SURFACE B, V164, P125, DOI 10.1016/j.colsurfb.2018.01.019; Piccirilli GN, 2014, DRUG DEV IND PHARM, V40, P1476, DOI 10.3109/03639045.2013.829486; PRICHARD RK, 1987, INT J PARASITOL, V17, P473, DOI 10.1016/0020-7519(87)90123-8; Qin XF, 2017, COLLOID SURFACE B, V149, P358, DOI 10.1016/j.colsurfb.2016.10.031; Real D, 2018, AAPS PHARMSCITECH, V19, P2311, DOI 10.1208/s12249-018-1057-5; Rial MS, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006119; Santander-Ortega MJ, 2011, COLLOID SURFACE B, V82, P571, DOI 10.1016/j.colsurfb.2010.10.019; Saokham P, 2018, MOLECULES, V23, DOI 10.3390/molecules23051161; Silva LD, 2018, DRUG DELIV TRANSL RE, V8, P1265, DOI 10.1007/s13346-018-0576-7; Smith J, 2004, PHARM RES-DORDR, V21, P43, DOI 10.1023/B:PHAM.0000012150.60180.e3; Solans C, 2016, CURR OPIN COLLOID IN, V22, P88, DOI 10.1016/j.cocis.2016.03.002; Sonvico F, 2006, INT J PHARMACEUT, V324, P67, DOI 10.1016/j.ijpharm.2006.06.036; Tsao NH, 2017, LANGMUIR, V33, P12960, DOI 10.1021/acs.langmuir.7b02954; Valenzano MC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133926; Villegas F, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001720; Vllasaliu D, 2010, INT J PHARMACEUT, V400, P183, DOI 10.1016/j.ijpharm.2010.08.020; Watts AB., 2016, AAPS ADV PHARM SCI, V22, DOI [10.1007/978-3-319-42609-9, DOI 10.1007/978-3-319-42609-9]; Williams HD, 2013, PHARMACOL REV, V65, P315, DOI 10.1124/pr.112.005660	45	23	24	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2018	13	12							e0207625	10.1371/journal.pone.0207625	http://dx.doi.org/10.1371/journal.pone.0207625			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD9QX	30540811	Green Submitted, Green Published, gold			2023-01-03	WOS:000452898600025
J	Foy, BD; Alout, H; Seaman, JA; Rao, S; Magalhaes, T; Wade, M; Parikh, S; Soma, DD; Sagna, AB; Fournet, F; Slater, HC; Bougma, R; Drabo, F; Diabate, A; Coulidiaty, AGV; Rouamba, N; Dabire, RK				Foy, Brian D.; Alout, Haoues; Seaman, Jonathan A.; Rao, Sangeeta; Magalhaes, Tereza; Wade, Martina; Parikh, Sunil; Soma, Dieudonne D.; Sagna, Andre B.; Fournet, Florence; Slater, Hannah C.; Bougma, Roland; Drabo, Francois; Diabate, Abdoulaye; Coulidiaty, A. Gafar V.; Rouamba, Noel; Dabire, Roch K.			Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial	LANCET			English	Article							PLASMODIUM-FALCIPARUM; TRANSMISSION; RESISTANCE	Background Ivermectin is widely used in mass drug administrations for controlling neglected parasitic diseases, and can be lethal to malaria vectors that bite treated humans. Therefore, it could be a new tool to reduce plasmodium transmission. We tested the hypothesis that frequently repeated mass administrations of ivermectin to village residents would reduce clinical malaria episodes in children and would be well tolerated with minimal harms. Methods We invited villages (clusters) in Burkina Faso to participate in a single-blind (outcomes assessor), parallel-assignment, two-arm, cluster-randomised trial over the 2015 rainy season. Villages were assigned (1: 1) by random draw to either the intervention group or the control group. In both groups, all eligible participants who consented to the treatment and were at least 90 cm in height received single oral doses of ivermectin (150-200 mu g/kg) and albendazole (400 mg), and those in the intervention group received five further doses of ivermectin alone at 3-week intervals thereafter over the 18-week treatment phase. The primary outcome was cumulative incidence of uncomplicated malaria episodes over 18 weeks (analysed on a cluster intention-to-treat basis) in an active case detection cohort of children aged 5 years or younger living in the study villages. This trial is registered with ClinicalTrials.gov, number NCT02509481. Findings Eight villages agreed to participate, and four were randomly assigned to each group. 2712 participants (1333 [49%] males and 1379 [51%] females; median age 15 years [IQR 6-34]), including 590 children aged 5 years or younger, provided consent and were enrolled between May 22 and July 20, 2015 (except for 77 participants enrolled after these dates because of unavailability before the first mass drug administration, travel into the village during the trial, or birth), with 1447 enrolled into the intervention group and 1265 into the control group. 330 (23%) participants in the intervention group and 233 (18%) in the control group met the exclusion criteria for mass drug administration. Most children in the active case detection cohort were not treated because of height restrictions. 14 (4%) children in the intervention group and 10 (4%) in the control group were lost to follow-up. Cumulative malaria incidence was reduced in the intervention group (648 episodes among 327 children; estimated mean 2.00 episodes per child) compared with the control group (647 episodes among 263 children; 2.49 episodes per child; risk difference -0.49 [95% CI -0.79 to -0.21], p=0.0009, adjusted for sex and clustering). The risk of adverse events among all participants did not differ between groups (45 events [3%] among 1447 participants in the intervention group vs 24 events [2%] among 1265 in the control group; risk ratio 1.63 [1.01 to 2.67]; risk difference 1.21 [0.04 to 2.38], p=0.060), and no adverse reactions were reported. Interpretation Frequently repeated mass administrations of ivermectin during the malaria transmission season can reduce malaria episodes among children without significantly increasing harms in the populace. Copyright (C) 2019 The Author(s). Published by Elsevier Ltd.	[Foy, Brian D.; Alout, Haoues; Seaman, Jonathan A.; Magalhaes, Tereza] Colorado State Univ, Arthropod Borne & Infect Dis Lab, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA; [Rao, Sangeeta] Colorado State Univ, Dept Clin Sci, Ft Collins, CO 80523 USA; [Wade, Martina; Parikh, Sunil] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA; [Soma, Dieudonne D.; Diabate, Abdoulaye; Rouamba, Noel; Dabire, Roch K.] Natl Ctr Sci & Technol Res, Inst Res Hlth Sci, Western Reg Direct, Bobo Dioulasso, Burkina Faso; [Soma, Dieudonne D.; Sagna, Andre B.; Fournet, Florence; Diabate, Abdoulaye; Dabire, Roch K.] Int Mixed Lab Vector Dis, Bobo Dioulasso, Burkina Faso; [Sagna, Andre B.; Fournet, Florence] Univ Montpellier, Inst Dev Infect Dis & Vectors Ecol Genet Evolut &, Natl Ctr Sci Res, Montpellier, France; [Slater, Hannah C.] Imperial Coll London, MRC Ctr Global Infect Dis Anal, Dept Infect Dis Epidemiol, London, England; [Bougma, Roland; Drabo, Francois] Minist Hlth, Natl Program Fight Neglected Trop Dis, Dept Dis Control, Ouagadougou, Burkina Faso; [Coulidiaty, A. Gafar V.] Ctr MURAZ, Dept Clin Res, Bobo Dioulasso, Burkina Faso	Colorado State University; Colorado State University; Yale University; Universite de Montpellier; Imperial College London; Centre Muraz	Foy, BD (corresponding author), Colorado State Univ, Arthropod Borne & Infect Dis Lab, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.	brian.foy@colostate.edu	Dabire, Roch Kounbobr/ABF-3525-2020; Sagna, André/AAY-6478-2021; Rao, Sangeeta/ABH-7983-2020; Magalhaes, Tereza/V-6632-2019; ALOUT, HAOUES/N-9556-2016	Rao, Sangeeta/0000-0002-9234-0082; DIABATE, Abdoulaye/0000-0002-9666-9395; ALOUT, HAOUES/0000-0001-7917-2697; SAGNA, Andre/0000-0001-8586-792X; COULIDIATY, Abdul Gafar Victoir/0000-0002-6050-8573	Bill & Melinda Gates Foundation; Bill & Melinda Gates Foundation [OPP1116536]; Laboratoire Mixte International sur les Maladies a Vecteurs micro-projets 2017; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER	Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); Laboratoire Mixte International sur les Maladies a Vecteurs micro-projets 2017; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Bill & Melinda Gates Foundation.; This study was funded by a Grand Challenges Explorations programme grant (number OPP1116536) from the Bill & Melinda Gates Foundation. Additional funding for testing human antibody responses to the Anopheles salivary gland antigen was provided by the Laboratoire Mixte International sur les Maladies a Vecteurs micro-projets 2017. We acknowledge the Burkina Faso Ministry of Health for donating drugs for use in this study. We thank the many people at the Institut de Recherche en Sciences de la Sante for study support, especially the clinical, parasitology, and entomology team members; and the administrative and institutional review board staff from Colorado State University. Finally, we sincerely thank the participants of the study and others in the Diebougou region for their kind support and hospitality.	Alout H, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-417; [Anonymous], CLIN GOV; Bhatt S, 2015, NATURE, V526, P207, DOI 10.1038/nature15535; Chaccour CJ, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0691-6; Chaccour CJ, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-153; da Cruz FP, 2012, J INFECT DIS, V205, P1278, DOI 10.1093/infdis/jis184; Dembele B, 2010, CLIN INFECT DIS, V51, P1229, DOI 10.1086/657063; Dondorp AM, 2010, NAT REV MICROBIOL, V8, P272, DOI 10.1038/nrmicro2331; Drakeley C, 2003, TROP MED INT HEALTH, V8, P767, DOI 10.1046/j.1365-3156.2003.01100.x; DUKE BOL, 1991, B WORLD HEALTH ORGAN, V69, P163; Foy BD, 2011, TRENDS PARASITOL, V27, P423, DOI 10.1016/j.pt.2011.05.007; Golding N, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0491-4; Govella NJ, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00199; Ismail MM, 1996, T ROY SOC TROP MED H, V90, P684, DOI 10.1016/S0035-9203(96)90437-X; Killeen GF, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-330; Kobylinski KC, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-381; Kobylinski KC, 2011, AM J TROP MED HYG, V85, P3, DOI 10.4269/ajtmh.2011.11-0160; LARIVIERE M, 1989, B SOC PATHOL EXOT, V82, P35; Mendes AM, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.02005-16; Mueller I, 2012, P NATL ACAD SCI USA, V109, P10030, DOI 10.1073/pnas.1200841109; Nasveld Peter, 2003, Southeast Asian Journal of Tropical Medicine and Public Health, V34, P552; Panchal M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.521; Rumisha SF, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.22682; Russell TL, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-56; Slater HC, 2014, J INFECT DIS, V210, P1972, DOI 10.1093/infdis/jiu351; Smit MR, 2018, LANCET INFECT DIS, V18, P615, DOI 10.1016/S1473-3099(18)30163-4; Sylla M, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-365; Tiono AB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086936; Toe KH, 2014, EMERG INFECT DIS, V20, P1691, DOI 10.3201/eid2010.140619; World Health Organization, 2011, ASS SAF PREV CHEM IN; World Health Organization, 2017, WORLD MALARIA REPORT, P160	31	61	62	3	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 13	2019	393	10180					1517	1526		10.1016/S0140-6736(18)32321-3	http://dx.doi.org/10.1016/S0140-6736(18)32321-3			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU0DA	30878222	Green Published, hybrid			2023-01-03	WOS:000464940400027
J	Saeterbakken, AH; Olsen, A; Behm, DG; Bardstu, HB; Andersen, V				Saeterbakken, Atle Hole; Olsen, Alexander; Behm, David George; Bardstu, Hilde Bremseth; Andersen, Vidar			The short- and long-term effects of resistance training with different stability requirements	PLOS ONE			English	Article							ELECTROMYOGRAPHIC ACTIVITY; MUSCLE-ACTIVITY; FORCE OUTPUT; UNSTABLE SURFACES; INSTABILITY; STRENGTH; BALANCE; PERFORMANCE; ACTIVATION; EXERCISES	The aim of this study was to assess the short- and long-term effects of resistance training (RT) with different stability requirements. Fifty-nine men underwent a 3-week familiarization period followed by a 7-week training period. During familiarization, all participants trained four sessions of squats with a Smith machine, free weights and free weights standing on a wobble board. After week-3, participants were randomized into a low (Smith machine), medium (Free-weight) or high (Wobble board) stability RT program, and Control group. All participants were tested pre-, after week-3 and post-intervention. Ten repetition maximum (10RM), rate of force development (RFD), electromyography (EMG) and maximum voluntary isometric contraction (MVIC) were tested in all three squat conditions in addition to countermovement jump (CMJ) on stable and unstable surfaces, and muscle thickness. After familiarization, greater 10RM loads (21.8-27.3%), MVIC (7.4-13.5%), RFD (29.7-43.8%) and CMJ (4.9-8.5%) were observed in all conditions. Between week 3 and 10, the Free-weight and Wobble board groups similarly improved 10RM in all conditions. Smith machine group demonstrated greater improvement in the trained exercise than the medium and high stability exercises. All training groups showed similar improvement in muscle thickness, RFD and MVIC. There was no CMJ improvement on the stable surface, but the Wobble board group demonstrated significantly greater improvement on the unstable surface. In conclusion, low, medium or high stability RT resulted in similar improvements in trained and non-trained testing conditions except for greater CMJ on the unstable surface in the Wobble group. Greater 10RM strength in trained than non-trained exercise was only observed in low stability group. Familiarization was associated with substantial improvements in 10RM and CMJ, with greater improvement associated with higher stability requirements. These findings suggest that high stability can increase strength, muscle thickness and explosive measurements similar to training with lower stability.	[Saeterbakken, Atle Hole; Olsen, Alexander; Bardstu, Hilde Bremseth; Andersen, Vidar] Western Norway Univ, Fac Educ Arts & Sports, Dept Sport Food & Nat Sciens, Sogndal, Sogn Og Fjordan, Norway; [Behm, David George] Mem Univ Newfoundland, Sch Human Kinet & Recreat, St John, NF, Canada	Memorial University Newfoundland	Saeterbakken, AH (corresponding author), Western Norway Univ, Fac Educ Arts & Sports, Dept Sport Food & Nat Sciens, Sogndal, Sogn Og Fjordan, Norway.	atle.saeterbakken@hvl.no	Behm, David George/I-6509-2019	Behm, David George/0000-0002-9406-6056				Andersen V, 2018, J STRENGTH COND RES, V32, P587, DOI 10.1519/JSC.0000000000001826; Andersen V, 2015, J STRENGTH COND RES, V29, P2932, DOI 10.1519/JSC.0000000000000950; Anderson K, 2005, CAN J APPL PHYSIOL, V30, P33, DOI 10.1139/h05-103; Anderson K, 2005, SPORTS MED, V35, P43, DOI 10.2165/00007256-200535010-00004; Anderson KG, 2004, J STRENGTH COND RES, V18, P637; Augustsson J, 1998, J ORTHOP SPORT PHYS, V27, P3, DOI 10.2519/jospt.1998.27.1.3; Behm D, 2012, INT J SPORTS PHYS TH, V7, P226; Behm DG, 2006, J STRENGTH COND RES, V20, P716; Behm DG, 2015, SPORTS MED, V45, P1645, DOI 10.1007/s40279-015-0384-x; BEHM DG, 1993, SPORTS MED, V15, P374, DOI 10.2165/00007256-199315060-00003; Behm DG, 2005, J STRENGTH COND RES, V19, P193; Behm DG, 2002, J STRENGTH COND RES, V16, P416; Bloomquist K, 2013, EUR J APPL PHYSIOL, V113, P2133, DOI 10.1007/s00421-013-2642-7; Burden A, 2010, J ELECTROMYOGR KINES, V20, P1023, DOI 10.1016/j.jelekin.2010.07.004; Campos GER, 2002, EUR J APPL PHYSIOL, V88, P50, DOI 10.1007/s00421-002-0681-6; Chulvi-Medrano I, 2012, INT J SPORTS PHYS TH, V7, P586; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cowley PM, 2007, INT J SPORTS MED, V28, P829, DOI 10.1055/s-2007-964893; Cressey EM, 2007, J STRENGTH COND RES, V21, P561, DOI 10.1519/R-19845.1; Drinkwater EJ, 2007, INT J SPORT PHYSIOL, V2, P400, DOI 10.1123/ijspp.2.4.400; Hermens HJ, 2000, J ELECTROMYOGR KINES, V10, P361, DOI 10.1016/S1050-6411(00)00027-4; Kean CO, 2006, J SPORT SCI MED, V5, P138; Kibele A, 2014, BMC SPORTS SCI MED R, V6, DOI 10.1186/2052-1847-6-30; Kibele A, 2009, J STRENGTH COND RES, V23, P2443, DOI 10.1519/JSC.0b013e3181bf0489; Marshall PWM, 2011, EUR J APPL PHYSIOL, V111, P3007, DOI 10.1007/s00421-011-1944-x; Mate-Munoz JL, 2014, J SPORT SCI MED, V13, P460; McBride JM, 2006, J STRENGTH COND RES, V20, P915; McBride JM, 2010, INT J SPORT PHYSIOL, V5, P177, DOI 10.1123/ijspp.5.2.177; Norwood JT, 2007, J STRENGTH COND RES, V21, P343, DOI 10.1519/R-17435.1; Prieske O, 2013, EUR J APPL PHYSIOL, V113, P2943, DOI 10.1007/s00421-013-2724-6; Rutherford OM, 1986, J SPORT SCI, V4, P101, DOI 10.1080/02640418608732105; RUTHERFORD OM, 1986, EUR J APPL PHYSIOL O, V55, P100, DOI 10.1007/BF00422902; Saeterbakken AH, 2013, J STRENGTH COND RES, V27, P1101, DOI 10.1519/JSC.0b013e3182606d3d; Saeterbakken AH, 2013, J STRENGTH COND RES, V27, P130, DOI 10.1519/JSC.0b013e3182541d43; Saeterbakken AH, 2011, J SPORT SCI, V29, P533, DOI 10.1080/02640414.2010.543916; Saeterbakken AH, 2016, EUR J APPL PHYSIOL, V116, P2247, DOI 10.1007/s00421-016-3470-3; SALE D, 1981, Canadian Journal of Applied Sport Sciences, V6, P87; Sparkes R, 2010, J STRENGTH COND RES, V24, P1931, DOI 10.1519/JSC.0b013e3181df7fe4; THORSTENSSON A, 1976, ACTA PHYSIOL SCAND, V96, P392, DOI 10.1111/j.1748-1716.1976.tb10207.x; Wahl MJ, 2008, J STRENGTH COND RES, V22, P1360, DOI 10.1519/JSC.0b013e318175ca3c	40	10	10	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2019	14	4							e0214302	10.1371/journal.pone.0214302	http://dx.doi.org/10.1371/journal.pone.0214302			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR1CY	30934001	Green Published, Green Submitted, gold			2023-01-03	WOS:000462867000013
J	Binswanger, IA				Binswanger, Ingrid A.			Opioid Use Disorder and Incarceration Hope for Ensuring the Continuity of Treatment	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								In my addiction medicine practice, patients with opioid use disorder (OUD) have asked me to help them discontinue use of buprenorphine or methadone before upcoming jail stays for pending	[Binswanger, Ingrid A.] Kaiser Permanente Colorado, Inst Hlth Res, Aurora, CO 80012 USA; [Binswanger, Ingrid A.] Univ Colorado, Sch Med, Colorado Permanente Med Grp, Aurora, CO 80045 USA; [Binswanger, Ingrid A.] Univ Colorado, Sch Med, Div Gen Internal Med, Aurora, CO 80045 USA	Kaiser Permanente; Permanente Medical Groups; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Binswanger, IA (corresponding author), Kaiser Permanente Colorado, Inst Hlth Res, Aurora, CO 80012 USA.; Binswanger, IA (corresponding author), Univ Colorado, Sch Med, Colorado Permanente Med Grp, Aurora, CO 80045 USA.; Binswanger, IA (corresponding author), Univ Colorado, Sch Med, Div Gen Internal Med, Aurora, CO 80045 USA.		Binswanger, Ingrid/X-4496-2019	Binswanger, Ingrid/0000-0001-8862-8078				Binswanger IA, 2007, NEW ENGL J MED, V356, P157, DOI 10.1056/NEJMsa064115; Freyer F., 2018, BOSTON GLOBE; Green TC, 2018, JAMA PSYCHIAT, V75, P405, DOI 10.1001/jamapsychiatry.2017.4614; Mitchell SG, 2009, J PSYCHOACTIVE DRUGS, V41, P145, DOI 10.1080/02791072.2009.10399907; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550	5	12	12	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 28	2019	380	13					1193	1195		10.1056/NEJMp1900069	http://dx.doi.org/10.1056/NEJMp1900069			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HR6HX	30811904				2023-01-03	WOS:000463251600002
J	Koester, KA; Johnson, MO; Wood, T; Fredericksen, R; Neilands, TB; Sauceda, J; Crane, HM; Mugavero, MJ; Christopoulos, KA				Koester, Kimberly A.; Johnson, Mallory O.; Wood, Troy; Fredericksen, Rob; Neilands, Torsten B.; Sauceda, John; Crane, Heidi M.; Mugavero, Michael J.; Christopoulos, Katerina A.			The influence of the 'good' patient ideal on engagement in HIV care	PLOS ONE			English	Article							HEALTH OUTCOMES; RETENTION; ACTIVATION; ADHERENCE; LINKAGE; PHYSICIANS; CONTINUUM; TRUST	Research on patient engagement in health care shows that better health outcomes and lower healthcare costs are observed among highly engaged patients. Similar to other illnesses, high levels of patient engagement in HIV care are considered essential to maintaining optimal health, and patients who are on treatment and retained in HIV care are known to have better health outcomes. In this article, we draw on focus group discussion data with patients living with HIV in order to explain tacit expectations associated with engagement in care. The main objective of our research was to elicit an explanatory model of engagement in HIV care from the patients' perspective. We conducted focus group discussions with a sample of two distinct types of patients: those who regularly attended medical appointments and those who did not. In total, we conducted six focus group discussions (n = 43) across in three cities in the US; these included two focus group discussions with a well-engaged and less-well-engaged group in each location. Both types of patients assigned a moral dimension to engagement in care, in that well-engaged patients were considered to be 'good' patients. Aspiring to become a 'good' patient provided a meaningful goal for some and deepened vulnerabilities among patients that struggled to achieve this status. More vulnerable patients may feel less secure in health care interactions and these feelings may be amplified if patients have an unreasonable impression of what constitutes a 'good' patient; thereby leading to disengagement in care. Our findings can inform the development of patient-centered, tailored messages to better serve patients struggling to stay engaged in HIV care.	[Koester, Kimberly A.; Johnson, Mallory O.; Wood, Troy; Neilands, Torsten B.; Sauceda, John; Christopoulos, Katerina A.] Univ Calif San Francisco, Dept Med, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA; [Fredericksen, Rob; Crane, Heidi M.] Univ Washington, Dept Med, Seattle, WA USA; [Mugavero, Michael J.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA	University of California System; University of California San Francisco; University of Washington; University of Washington Seattle; University of Alabama System; University of Alabama Birmingham	Koester, KA (corresponding author), Univ Calif San Francisco, Dept Med, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA.	Kimberly.koester@ucsf.edu			National Institutes of Health (NIH) [R01MH102198]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH102198, P30MH062246] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	The investigators (MOJ & KAC) have received grant funding (R01MH102198) from the National Institutes of Health (NIH) to conduct this study (Development and Validation of a Multidimensional Index of Engagement in HIV Care). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2016, DED V7 0 23; Ayres L, 2003, QUAL HEALTH RES, V13, P871, DOI 10.1177/1049732303013006008; Barello S, J PARTICIP MED, V6, pe9; Barello S, 2012, NURS RES PRACT, V2012, DOI 10.1155/2012/905934; Beach MC, 2006, J GEN INTERN MED, V21, P661, DOI 10.1111/j.1525-1497.2006.00399.x; Campbell C, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1139-x; Carman KL, 2013, HEALTH AFFAIR, V32, P223, DOI 10.1377/hlthaff.2012.1133; Castel AD, 2015, JAIDS-J ACQ IMM DEF, V69, pS44, DOI 10.1097/QAI.0000000000000575; Christopoulos KA, 2013, AIDS PATIENT CARE ST, V27, P223, DOI 10.1089/apc.2012.0418; Colasanti J, 2016, CLIN INFECT DIS, V62, P648, DOI 10.1093/cid/civ941; Creswell John W., 1994, RES DESIGN QUALITATI; Dawson-Rose C, 2016, J ASSOC NURSE AIDS C, V27, P574, DOI 10.1016/j.jana.2016.03.001; Dentzer S, 2013, HEALTH AFFAIR, V32, P202, DOI 10.1377/hlthaff.2013.0037; Entwistle V A, 1998, J Health Serv Res Policy, V3, P100; Flickinger TE, 2016, PATIENT EDUC COUNS, V99, P250, DOI 10.1016/j.pec.2015.08.020; Flickinger TE, 2013, JAIDS-J ACQ IMM DEF, V63, P362, DOI 10.1097/QAI.0b013e318295b86a; Flores D, 2016, INT J NURS STUD, V62, P126, DOI 10.1016/j.ijnurstu.2016.07.016; Forbat L, 2009, PATIENT EDUC COUNS, V74, P84, DOI 10.1016/j.pec.2008.07.055; Fredericksen RJ, 2015, AIDS CARE, V27, P1255, DOI 10.1080/09540121.2015.1050983; Frosch DL, 2012, HEALTH AFFAIR, V31, P1030, DOI 10.1377/hlthaff.2011.0576; Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243; Graham JL, 2015, AIDS PATIENT CARE ST, V29, P661, DOI 10.1089/apc.2015.0156; Greene J, 2015, HEALTH AFFAIR, V34, P431, DOI 10.1377/hlthaff.2014.0452; Greene J, 2012, J GEN INTERN MED, V27, P520, DOI 10.1007/s11606-011-1931-2; Higgins T, 2017, PATIENT EDUC COUNS, V100, P30, DOI 10.1016/j.pec.2016.09.002; Ibe C, 2017, PATIENT EDUC COUNS, V100, P1258, DOI 10.1016/j.pec.2016.12.016; Johnson MO, 2017, JMIR RES PROTOC, V6, DOI 10.2196/resprot.8520; Johnson MO, 2006, AIDS PATIENT CARE ST, V20, P258, DOI 10.1089/apc.2006.20.258; Kay ES, 2016, AIDS RES THER, V13, DOI 10.1186/s12981-016-0120-0; Lindlof T.R., 2002, QUALITATIVE COMMUNIC, V2nd ed.; Marshall R, 2013, J GEN INTERN MED, V28, P668, DOI 10.1007/s11606-012-2307-y; McCreaddie M, 2009, INT J NURS STUD, V46, P1079, DOI 10.1016/j.ijnurstu.2009.01.008; Mohta NS, 2016, PATIENT ENGAGEMENT S; Mugavero MJ, 2009, CLIN INFECT DIS, V48, P248, DOI 10.1086/595705; Nakagawa F, 2012, AIDS, V26, P335, DOI 10.1097/QAD.0b013e32834dcec9; Ondenge K, 2017, SEX TRANSM INFECT, V93, DOI 10.1136/sextrans-2016-052973; Ritchie J, 2003, QUALITATIVE RES PRAC, P219, DOI DOI 10.1186/1471-2288-13-117; Sheth AN, 2011, CLIN INFECT DIS, V52, P219, DOI 10.1093/cid/ciq043; Simon Wand GHJ, 1986, SEXUAL SCRIPTS PERMA, V15; Ulett KB, 2009, AIDS PATIENT CARE ST, V23, P41, DOI 10.1089/apc.2008.0132	40	9	9	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2019	14	3							e0214636	10.1371/journal.pone.0214636	http://dx.doi.org/10.1371/journal.pone.0214636			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HQ7IR	30921440	gold, Green Published, Green Submitted			2023-01-03	WOS:000462594000101
J	Maezawa, Y; Nakaminami, H; Takadama, S; Hayashi, M; Wajima, T; Nakase, K; Yamada, T; Ikoshi, H; Noguchi, N				Maezawa, Yuka; Nakaminami, Hidemasa; Takadama, Shunsuke; Hayashi, Minami; Wajima, Takeaki; Nakase, Keisuke; Yamada, Tetsuya; Ikoshi, Hideaki; Noguchi, Norihisa			Tokiinshi, a traditional Japanese medicine (Kampo), suppresses Panton-Valentine leukocidin production in the methicillin-resistant Staphylococcus aureus USA300 clone	PLOS ONE			English	Article							GENE; ANTIBIOTICS; EPIDERMIDIS; MICROBIOTA; PNEUMONIA; STRAIN; HOST	It is necessary to develop agents other than antimicrobials for the treatment of Staphylococcus aureus infections to prevent the emergence of antimicrobial-resistant strains. Particularly, anti-virulence agents against the Panton-Valentine leukocidin (PVL)-positive methicillin-resistant S. aureus (MRSA), USA300 clone, is desired due to its high pathogenicity. Here, we investigated the potential anti-virulence effect of Tokiinshi, which is a traditional Japanese medicine (Kampo) used for skin diseases, against the USA300 clone. A growth inhibition assay showed that a conventional dose (20 mg/ml) of Tokiinshi has bactericidal effects against the clinical USA300 clones. Notably, the growth inhibition effects of Tokiinshi against S. epidermidis strains, which are the major constituents of the skin microbiome, was a bacteriostatic effect. The data suggested that Tokiinshi is unlikely to affect skin flora of S. epidermidis. Furthermore, PVL production and the expression of its gene were significantly suppressed in the USA300 clone by a lower concentration (5 mg/ml) of Tokiinshi. This did not affect the number of viable bacteria. Moreover, Tokiinshi significantly suppressed the expression of the agrA gene, which regulates PVL gene expression. For the first time, our findings strongly suggest that Tokiinshi has the potential to attenuate the virulence of the USA300 clone by suppressing PVL production via agrA gene suppression.	[Maezawa, Yuka; Nakaminami, Hidemasa; Takadama, Shunsuke; Hayashi, Minami; Wajima, Takeaki; Nakase, Keisuke; Noguchi, Norihisa] Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Microbiol, Hachioji, Tokyo, Japan; [Yamada, Tetsuya; Ikoshi, Hideaki] Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Tradit Chinese Med, Hachioji, Tokyo, Japan	Tokyo University of Pharmacy & Life Sciences; Tokyo University of Pharmacy & Life Sciences	Nakaminami, H (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Microbiol, Hachioji, Tokyo, Japan.	nakami@toyaku.ac.jp	Nakase, Keisuke/AEP-0804-2022; Nakase, Keisuke/AAQ-2777-2020; Wajma, Takeaki/AAF-4743-2020	Wajma, Takeaki/0000-0001-9506-707X; Nakase, Keisuke/0000-0002-9205-3008; Nakaminami, Hidemasa/0000-0003-2889-8257	Japan Society for the Promotion of Science KAKENHI [JP18H00370]	Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Japan Society for the Promotion of Science KAKENHI Grant Number JP18H00370 (N.N). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Christensen GJM, 2014, BENEF MICROBES, V5, P201, DOI 10.3920/BM2012.0062; Dumitrescu O, 2008, CLIN MICROBIOL INFEC, V14, P384, DOI 10.1111/j.1469-0691.2007.01947.x; Genestier AL, 2005, J CLIN INVEST, V115, P3117, DOI 10.1172/JCI22684; Gillet Y, 2002, LANCET, V359, P753, DOI 10.1016/S0140-6736(02)07877-7; Guidos RJ, 2011, CLIN INFECT DIS, V52, pS397, DOI 10.1093/cid/cir153; Kaito C, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001267; Kaneko J, 2004, BIOSCI BIOTECH BIOCH, V68, P981, DOI 10.1271/bbb.68.981; Khodaverdian V, 2013, ANTIMICROB AGENTS CH, V57, P3645, DOI 10.1128/AAC.00269-13; Kong C, 2016, TOXINS, V8, DOI 10.3390/toxins8030072; Laborel-Preneron E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141067; Lai YP, 2010, J INVEST DERMATOL, V130, P2211, DOI 10.1038/jid.2010.123; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Miller LG, 2005, NEW ENGL J MED, V352, P1445, DOI 10.1056/NEJMoa042683; Morgun A, 2015, GUT, V64, P1732, DOI 10.1136/gutjnl-2014-308820; Nakaminami H, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00358-17; Nimmo GR, 2012, CLIN MICROBIOL INFEC, V18, P725, DOI 10.1111/j.1469-0691.2012.03822.x; Nose M, 1999, BIOL PHARM BULL, V22, P48, DOI 10.1248/bpb.22.48; Planet PJ, 2015, J INFECT DIS, V212, P1874, DOI 10.1093/infdis/jiv320; Sanford JA, 2013, SEMIN IMMUNOL, V25, P370, DOI 10.1016/j.smim.2013.09.005; Takadama S, 2018, Clin Microbiol Infect, V24, DOI 10.1016/j.cmi.2018.02.012; Takadama S, 2017, J INFECT CHEMOTHER, V23, P800, DOI 10.1016/j.jiac.2017.04.016; Tenover FC, 2009, J ANTIMICROB CHEMOTH, V64, P441, DOI 10.1093/jac/dkp241; Villaruz AE, 2009, J INFECT DIS, V200, P724, DOI 10.1086/604728; Wajima T, 2019, PHARMACOLOGY, V103, P221, DOI 10.1159/000496830; Wajima T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167335; Wang LQ, 2015, ACTA PHARM SIN B, V5, P310, DOI [10.1016//j.apsb.2015.05.005, 10.1016/j.apsb.2015.05.005]; Wang YH, 2014, APPL MICROBIOL BIOT, V98, P411, DOI 10.1007/s00253-013-5394-8; Yamada T, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1431-3; Yamamoto T, 2010, J INFECT CHEMOTHER, V16, P225, DOI 10.1007/s10156-010-0045-9	29	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2019	14	3							e0214470	10.1371/journal.pone.0214470	http://dx.doi.org/10.1371/journal.pone.0214470			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ7IR	30921402	Green Published, Green Submitted, gold			2023-01-03	WOS:000462594000075
J	Dolce, D; Neri, S; Grisotto, L; Campana, S; Ravenni, N; Miselli, F; Camera, E; Zavataro, L; Braggion, C; Fiscarelli, EV; Lucidi, V; Cariani, L; Girelli, D; Faelli, N; Colombo, C; Lucanto, C; Lombardo, M; Magazzu, G; Tosco, A; Raia, V; Manara, S; Pasolli, E; Armanini, F; Segata, N; Biggeri, A; Taccetti, G				Dolce, Daniela; Neri, Stella; Grisotto, Laura; Campana, Silvia; Ravenni, Novella; Miselli, Francesca; Camera, Erica; Zavataro, Lucia; Braggion, Cesare; Fiscarelli, Ersilia V.; Lucidi, Vincenzina; Cariani, Lisa; Girelli, Daniela; Faelli, Nadia; Colombo, Carla; Lucanto, Cristina; Lombardo, Mariangela; Magazzu, Giuseppe; Tosco, Antonella; Raia, Valeria; Manara, Serena; Pasolli, Edoardo; Armanini, Federica; Segata, Nicola; Biggeri, Annibale; Taccetti, Giovanni			Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: A randomized multicenter study	PLOS ONE			English	Article							PSEUDOMONAS-AERUGINOSA; MRSA; GUIDELINES; ASSOCIATION; INFECTIONS; EMERGENCE; DIAGNOSIS; CHILDREN; EFFICACY; CF	Background Few studies, based on a limited number of patients using non-uniform therapeutic protocols, have analyzed Methicillin-resistant Staphylococcus aureus (MRSA) eradication. Methods In a randomized multicenter trial conducted on patients with new-onset MRSA infection we evaluated the efficacy of an early eradication treatment (arm A) compared with an observational group (B). Arm A received oral rifampicin and trimethoprim/sulfamethoxazole (21 days). Patients' microbiological status, FEV1, BMI, pulmonary exacerbations and use of antibiotics were assessed. Results Sixty-one patients were randomized. Twenty-nine (47.5%) patients were assigned to active arm A and 32 (52.5%) patients to observational arm B. Twenty-nine (47.5%) patients, 10 patients in arm A and 19 in arm B, dropped out of the study. At 6 months MRSA was eradicated in 12 (63.2%) out of 19 patients in arm A while spontaneous clearance was observed in 5 (38.5%) out of 13 patients in arm B. A per-protocol analysis showed a 24.7% difference in the proportion of MRSA clearance between the two groups (z = 1.37, P(Z>z) = 0.08). Twenty-seven patients, 15 (78.9%) out of 19 in arm A and 12 (92.3%) out of 13 in arm B, were able to perform spirometry. The mean (+/- SD) FEV1 change from baseline was 7.13% (+/- 14.92) in arm A and -1.16% (+/- 5.25) in arm B (p = 0.08). In the same period the BMI change (mean +/- SD) from baseline was 0.54 (+/- 1.33) kg/m(2) in arm A and -0.38 (+/- 1.56) kg/m(2) in arm B (p = 0.08). At 6 months no statistically significant differences regarding the number of pulmonary exacerbations, days spent in hospital and use of antibiotics were observed between the two arms. Conclusions Although the statistical power of the study is limited, we found a 24.7% higher clearance of MRSA in the active arm than in the observational arm at 6 months. Patients in the active arm A also had favorable FEV1 and BMI tendencies.	[Dolce, Daniela; Neri, Stella; Campana, Silvia; Ravenni, Novella; Miselli, Francesca; Camera, Erica; Zavataro, Lucia; Braggion, Cesare; Taccetti, Giovanni] Univ Florence, Anna Meyer Childrens Univ Hosp, Cyst Fibrosis Ctr, Florence, Italy; [Neri, Stella; Miselli, Francesca] Univ Florence, Dept Hlth Sci, Florence, Italy; [Grisotto, Laura; Biggeri, Annibale] Univ Florence, Dept Stat Comp Sci & Applicat G Parenti, Florence, Italy; [Fiscarelli, Ersilia V.; Lucidi, Vincenzina] Childrens Hosp & Res Inst Bambino Gesu, Cyst Fibrosis Microbiol & Cyst Fibrosis Ctr, Rome, Italy; [Cariani, Lisa; Girelli, Daniela] Fdn IRCCS, Lab Cyst Fibrosis Microbiol, Ca Granda Osped Maggiore Policlin, Milan, Italy; [Faelli, Nadia; Colombo, Carla] Univ Milan, Cyst Fibrosis Ctr, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy; [Lucanto, Cristina; Lombardo, Mariangela; Magazzu, Giuseppe] Univ Messina, Cyst Fibrosis & Pediat Gastroenterol Unit, Messina, Italy; [Tosco, Antonella; Raia, Valeria] Univ Naples Federico II, Dept Translat Med Sci, Pediat Cyst Fibrosis Ctr, Naples, Italy; [Manara, Serena; Pasolli, Edoardo; Armanini, Federica; Segata, Nicola] Univ Trento, Ctr Integrat Biol, Trento, Italy	University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Florence; University of Florence; IRCCS Bambino Gesu; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Messina; University of Naples Federico II; University of Trento	Taccetti, G (corresponding author), Univ Florence, Anna Meyer Childrens Univ Hosp, Cyst Fibrosis Ctr, Florence, Italy.	giovanni.taccetti@meyer.it	Segata, Nicola/AAB-2980-2019; TOSCO, Antonella/U-7052-2017; Raia, Valeria/AAC-3029-2022; Manara, Serena/AAQ-7771-2020; Pasolli, Edoardo/K-5156-2016	TOSCO, Antonella/0000-0003-0470-6839; Manara, Serena/0000-0001-6371-528X; Pasolli, Edoardo/0000-0003-0799-3490; Dolce, Daniela/0000-0002-8317-9928; Lucidi, Vincenzina/0000-0003-3661-607X	Italian Cystic Fibrosis Research Foundation [20/2012]; Ministero della Salute, Italy [RF-2010-2316176]	Italian Cystic Fibrosis Research Foundation(Ministry of Health, ItalyItalian Cystic Fibrosis Research Foundation); Ministero della Salute, Italy(Ministry of Health, Italy)	This work was supported by the Italian Cystic Fibrosis Research Foundation, http://www.fibrosicisticaricerca.it/, Grant FFC# 20/2012 to GT with a contribution from: Delegazione FFC di Cecina, Delegazione FFC di Vittoria-Ragusa e Catania2, Delegazione FFC di Messina, Delegazione FFC di Lecce, and by the Ministero della Salute, Italy Grant RF-2010-2316176 to GT, http://www.salute.gov.it/.	Ahmed MI, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011581.pub3; AL-Tam Faroq, 2012, BMC Res Notes, V5, P642, DOI 10.1186/1756-0500-5-642; Ammerlaan HSM, 2009, CLIN INFECT DIS, V48, P922, DOI 10.1086/597291; Bell SC, 2017, THORAX, V72, P297, DOI 10.1136/thoraxjnl-2016-209605; Castellani C, 2018, J CYST FIBROS, V17, P153, DOI 10.1016/j.jcf.2018.02.006; Cocchi P, 2011, J CYST FIBROS, V10, P407, DOI 10.1016/j.jcf.2011.06.005; Cystic Fibrosis Foundation Patient Registry, CYST FIBR FDN PAT RE; Dasenbrook EC, 2008, AM J RESP CRIT CARE, V178, P814, DOI 10.1164/rccm.200802-327OC; Dasenbrook EC, 2010, JAMA-J AM MED ASSOC, V303, P2386, DOI 10.1001/jama.2010.791; European Cystic Fibrosis Patient Registry, EUR CYST FIBR PAT RE; Farrell PM, 2017, J PEDIATR-US, V181, pS4, DOI 10.1016/j.jpeds.2016.09.064; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; Gould FK, 2009, J ANTIMICROB CHEMOTH, V63, P849, DOI 10.1093/jac/dkp065; Gould IM, 2006, LANCET, V368, P824, DOI 10.1016/S0140-6736(06)69303-3; Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST; Grundmann H, 2006, LANCET, V368, P874, DOI 10.1016/S0140-6736(06)68853-3; Hirschhausen N, 2013, INT J MED MICROBIOL, V303, P685, DOI 10.1016/j.ijmm.2013.09.012; Hubert D, 2013, J CYST FIBROS, V12, P497, DOI 10.1016/j.jcf.2012.12.003; Kappler M, 2016, PEDIATR PULM, V51, P1010, DOI 10.1002/ppul.23519; Lelievre H, 1999, J CLIN MICROBIOL, V37, P3452; Lina G, 1999, CLIN INFECT DIS, V29, P1128, DOI 10.1086/313461; Lo DKH, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009650.pub4; Macfarlane M, 2007, J HOSP INFECT, V65, P231, DOI 10.1016/j.jhin.2006.10.011; Maliniak ML, 2016, J CYST FIBROS, V15, P350, DOI 10.1016/j.jcf.2015.10.014; Milheirico C, 2007, ANTIMICROB AGENTS CH, V51, P3374, DOI 10.1128/AAC.00275-07; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Muhlebach MS, 2011, J CYST FIBROS, V10, P201, DOI 10.1016/j.jcf.2011.02.004; Muhlebach MS, 2017, THORAX, V72, P318, DOI 10.1136/thoraxjnl-2016-208949; Solensky R, 2010, ANN ALLERG ASTHMA IM, V105, P259, DOI 10.1016/j.anai.2010.08.002; Solis A, 2003, PEDIATR PULM, V36, P189, DOI 10.1002/ppul.10231; Stevens DA, 2003, CLIN INFECT DIS, V37, pS225, DOI 10.1086/376525; Taccetti G, 2012, THORAX, V67, P853, DOI 10.1136/thoraxjnl-2011-200832; Talon D, 2002, INT J ANTIMICROB AG, V20, P174, DOI 10.1016/S0924-8579(02)00173-5; Tiddens HAWM, 2015, J CYST FIBROS, V14, P111, DOI 10.1016/j.jcf.2014.06.003; Treggiari MM, 2011, ARCH PEDIAT ADOL MED, V165, P847, DOI 10.1001/archpediatrics.2011.136; UK Cystic Fibrosis Trust Infection Control Group, 2004, PSEUD AER INF PEOPL; UK Cystic Fibrosis Trust Infection Control working Group, 2008, METH RES STAPH AUR M; Vallieres E, 2016, ERJ OPEN RES, V2; Yang L, 2011, P NATL ACAD SCI USA, V108, P7481, DOI 10.1073/pnas.1018249108; Zolfo M, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkw837	40	11	12	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2019	14	3							e0213497	10.1371/journal.pone.0213497	http://dx.doi.org/10.1371/journal.pone.0213497			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP9GF	30901344	Green Published, Green Submitted, gold			2023-01-03	WOS:000462000400008
J	Zhang, ZL; Wang, J; Liu, F; Yuan, L; Yuan, JL; Chen, LH; Zhong, NS; Lu, WJ				Zhang, Zili; Wang, Jian; Liu, Fei; Yuan, Liang; Yuan, Jili; Chen, Lianghua; Zhong, Nanshan; Lu, Wenju			Impacts of event-specific air quality improvements on total hospital admissions and reduced systemic inflammation in COPD patients	PLOS ONE			English	Article							C-REACTIVE PROTEIN; STEEL MILL; POLLUTION; DISEASE; ASSOCIATION; FIBRINOGEN; EXPOSURE; HEALTH; COAGULATION; POPULATION	There is limited evidence linking the impacts of reduced air pollution on hospital admissions. The potential biological mechanisms are still not completely understood. This study examined the effects of mitigated ambient pollution on hospital admissions and inflammatory biomarker levels in chronic obstructive pulmonary disease (COPD) COPD patients. Daily hospital admissions were compared over 51 days associated with the Asian Games period (Nov 1-Dec 21, 2010) with the identical calendar dates of baseline years (2004-2009 and 2011-2013). A three-year cohort study was conducted with 36 COPD patient participants. The daily particulate matter (PM10) decreased from 65.86 mu g/m(3) during the baseline period to 62.63 mu g/m(3) during the Asian Games period; the daily NO2 level decreased from 51.33 mu g/m(3) to 42.63 mu g/m(3). Between the baseline period and the Asian Games, daily hospital admissions from non-accidental diseases decreased from 116 to 93, respectively; respiratory diseases decreased from 20 to 17, respectively; and cardiovascular diseases decreased from 11 to 9 during the Asian Games period, respectively. No statistically significant reductions were seen in the remaining months of 2010 in Guangzhou, during the the Asian Games period in the control city, and two other control diseases. Furthermore, we identified significant improvement in CRP and fibrinogen by -20.4% and -15.4% from a pre-Asian game period to a during-Asian game period, respectively. For CRP, we found significant increases in NO2 at lag1-3 days after-Asian game period and significant increases in PM10 at lag1-2 days. Similar effects were also seen with fibrinogen. This discovery provides support for efforts to diminish air pollution and improve public health through human air pollutants intervention. Improved air pollution during the 2010 Asian games was correlated with decreases in biomarkers associated with systemic inflammation in COPD patient participants.	[Zhang, Zili; Wang, Jian; Liu, Fei; Yuan, Liang; Chen, Lianghua; Zhong, Nanshan; Lu, Wenju] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Dis, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China; [Wang, Jian] Univ Arizona, Dept Med, Div Translat & Regenerat Med, Tucson, AZ USA; [Yuan, Jili] Guangzhou Med Univ, Affiliated Hosp 1, Dept Pediat, Guangzhou, Guangdong, Peoples R China; [Lu, Wenju] Guangzhou Med Univ, Affiliated Hosp 1, Dept Lab Med, Guangzhou, Guangdong, Peoples R China	Guangzhou Medical University; State Key Laboratory of Respiratory Disease; University of Arizona; Guangzhou Medical University; Guangzhou Medical University	Lu, WJ (corresponding author), Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Dis, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China.; Lu, WJ (corresponding author), Guangzhou Med Univ, Affiliated Hosp 1, Dept Lab Med, Guangzhou, Guangdong, Peoples R China.	wlu92@yahoo.com			National Natural Science Foundation of China [81700043, 81520108001, 81770043]; 973 Key Scheme of China [2015CB553406]; Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme; Guangzhou Department of Education for Innovative Team [13C08]; Guangdong Natural Science Foundation [2016A030313593]; State Key Laboratory of Respiratory Disease Foundation [SKLRD-QN-201719]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 973 Key Scheme of China(National Basic Research Program of China); Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme; Guangzhou Department of Education for Innovative Team; Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); State Key Laboratory of Respiratory Disease Foundation	This work was supported by grants from National Natural Science Foundation of China (81700043, 81520108001, 81770043), the 973 Key Scheme of China (2015CB553406), Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2014, WLu), Guangzhou Department of Education for Innovative Team (13C08), and Guangdong Natural Science Foundation (2016A030313593), and State Key Laboratory of Respiratory Disease Foundation (SKLRD-QN-201719). The funding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.	Allen RW, 2011, AM J RESP CRIT CARE, V183, P1222, DOI 10.1164/rccm.201010-1572OC; Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8; Bubb MR, 2009, NEW ENGL J MED, V360, P2032, DOI 10.1056/NEJMc090375; Cao J, 2011, J HAZARD MATER, V186, P1594, DOI 10.1016/j.jhazmat.2010.12.036; Chen RJ, 2010, J HAZARD MATER, V181, P234, DOI 10.1016/j.jhazmat.2010.05.002; Chuang KJ, 2007, AM J RESP CRIT CARE, V176, P370, DOI 10.1164/rccm.200611-1627OC; Clancy L, 2002, LANCET, V360, P1210, DOI 10.1016/S0140-6736(02)11281-5; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; Delfino RJ, 2009, ENVIRON HEALTH PERSP, V117, P1232, DOI [10.1289/ehp.0800194, 10.1289/journla.ehp.0800194]; Dockery DW, 2007, NEW ENGL J MED, V356, P511, DOI 10.1056/NEJMe068274; Dockery Douglas W, 2013, Res Rep Health Eff Inst, P3; Dubowsky SD, 2006, ENVIRON HEALTH PERSP, V114, P992, DOI 10.1289/ehp.8469; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Gabay C, 1999, NEW ENGL J MED, V340, P1376; Gan WQ, 2004, THORAX, V59, P574, DOI 10.1136/thx.2003.019588; Gold DR, 2000, CIRCULATION, V101, P1267, DOI 10.1161/01.CIR.101.11.1267; Guo YM, 2010, SCI TOTAL ENVIRON, V409, P300, DOI 10.1016/j.scitotenv.2010.10.013; Guo YM, 2009, SCI TOTAL ENVIRON, V407, P4826, DOI 10.1016/j.scitotenv.2009.05.022; Heeringa J, 2006, J THROMB HAEMOST, V4, P1944, DOI 10.1111/j.1538-7836.2006.02115.x; Hilt B, 2002, OCCUP ENVIRON MED, V59, P9, DOI 10.1136/oem.59.1.9; Hoffmann B, 2009, ENVIRON HEALTH PERSP, V117, P1302, DOI 10.1289/ehp.0800362; Johansson C, 2009, ATMOS ENVIRON, V43, P4843, DOI 10.1016/j.atmosenv.2008.09.015; Kappelmayer J, 2004, CLIN CHEM LAB MED, V42, P475, DOI 10.1515/CCLM.2004.082; Lee SL, 2006, CLIN EXP ALLERGY, V36, P1138, DOI 10.1111/j.1365-2222.2006.02555.x; Li Yanli, 2012, Reviews on Environmental Health, V27, P133, DOI 10.1515/reveh-2012-0012; Li Y, 2010, SCI TOTAL ENVIRON, V408, P1226, DOI 10.1016/j.scitotenv.2009.11.035; Ling Sean H, 2009, Int J Chron Obstruct Pulmon Dis, V4, P233; Liu H, 2013, ATMOS ENVIRON, V76, P81, DOI 10.1016/j.atmosenv.2012.08.004; Lu WJ, 2016, COPD, V13, P203, DOI 10.3109/15412555.2015.1069807; Mancini GBJ, 2007, CHEST, V131, P950, DOI 10.1378/chest.06-2838; Mattoli S, 2001, ENVIRON HEALTH PERSP, V109, P553, DOI 10.2307/3454668; Mehta A J, 2012, Swiss Med Wkly, V142, pw13681, DOI 10.4414/smw.2012.13681; Miller KA, 2007, NEW ENGL J MED, V356, P447, DOI 10.1056/NEJMoa054409; Parker JD, 2008, EPIDEMIOLOGY, V19, P820, DOI 10.1097/EDE.0b013e3181883d5d; Peacock JL, 2011, THORAX, V66, P591, DOI 10.1136/thx.2010.155358; Peel Jennifer L, 2010, Res Rep Health Eff Inst, P3; Peters A, 2001, EUR HEART J, V22, P1198, DOI 10.1053/euhj.2000.2483; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; Rich DQ, 2015, ENVIRON HEALTH PERSP, V123, P880, DOI 10.1289/ehp.1408795; Riediker M, 2004, AM J RESP CRIT CARE, V169, P934, DOI 10.1164/rccm.200310-1463OC; Ruckerl R, 2006, AM J RESP CRIT CARE, V173, P432, DOI 10.1164/rccm.200507-1123OC; Rudez G, 2009, ENVIRON HEALTH PERSP, V117, P995, DOI 10.1289/ehp.0800437; Ruckerl R, 2007, ENVIRON HEALTH PERSP, V115, P1072, DOI 10.1289/ehp.10021; Schwarze PE, 2006, HUM EXP TOXICOL, V25, P559, DOI 10.1177/096032706072520; Sullivan JH, 2007, ENVIRON HEALTH-GLOB, V6, DOI 10.1186/1476-069X-6-3; Szalai AJ, 1999, CLIN CHEM LAB MED, V37, P265, DOI 10.1515/CCLM.1999.046; Teksam O, 2010, EUR J EMERG MED, V17, P192, DOI 10.1097/MEJ.0b013e328320ad48; van Eeden Stephan F, 2005, Proc Am Thorac Soc, V2, P61; Wu SW, 2010, ENVIRON HEALTH PERSP, V118, P87, DOI 10.1289/ehp.0900818; Yang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076759; Zhang ZL, 2016, ENVIRON SCI POLLUT R, V23, P6631, DOI 10.1007/s11356-015-5871-y; Zhang ZL, 2014, ENVIRON SCI POLLUT R, V21, P4236, DOI 10.1007/s11356-013-2374-6	53	4	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2019	14	3							e0208687	10.1371/journal.pone.0208687	http://dx.doi.org/10.1371/journal.pone.0208687			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP6AW	30893301	Green Submitted, Green Published, gold			2023-01-03	WOS:000461765900001
J	Zhu, WJ; Chernew, ME; Sherry, TB; Maestas, N				Zhu, Wenjia; Chernew, Michael E.; Sherry, Tisamarie B.; Maestas, Nicole			Initial Opioid Prescriptions among US Commercially Insured Patients, 2012-2017	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRESCRIBING PATTERNS; UNITED-STATES; NAIVE PATIENTS; CHRONIC PAIN; OVERDOSE; TRENDS; RISK	BACKGROUND The United States is undergoing a crippling opioid epidemic, spurred in part by overuse of prescription opioids by adults 25 to 64 years of age. Of concern are long-duration and high-dose initial prescriptions, which place the patients and their friends and relatives at heightened risk for long-term opioid use, misuse, overdose, and death. METHODS We estimated the incidence of initial opioid prescriptions in each month between July 2012 and December 2017 using administrative-claims data from across the United States (accessed through Blue Cross-Blue Shield [BCBS] Axis); monthly incidence was estimated as the percentage of enrollees who received an initial opioid prescription among those who had not used opioids (i.e., no opioid prescription or a diagnosis of opioid use disorder in the 6 months before a given month). We then estimated the percentage of enrollees initiating opioid therapy who received a long-duration or high-dose initial opioid prescription in each month during this period. We also calculated the number of providers who initiated opioid therapy in any patient who had not used opioids in each month and examined monthly trends in the duration and dose of initial opioid prescriptions in prescriber and patient subgroups. Our study sample included 63,817,512 enrollees who had not used opioids (mean, 15,897,673 per month). RESULTS The monthly incidence of initial opioid prescriptions among enrollees who had not used opioids declined by 54%, from 1.63% in July 2012 to 0.75% in December 2017. This decline was accompanied by a decreasing number of providers (from 114,043 in July 2012 to 80,462 in December 2017) who initiated opioid therapy in any patient who had not used opioids. Nonetheless, among the shrinking subgroup of physicians who initiated opioid therapy in such patients, high-risk prescribing (i.e., prescriptions for more than a 3-day supply or for a dose of 50 morphine milligram equivalents per day or higher) persisted at a monthly rate of 115,378 prescriptions per 15,897,673 enrollees who had not used opioids. CONCLUSIONS As the opioid crisis progressed between July 2012 and December 2017, many providers stopped initiating opioid therapy. Although the number of initial opioid prescriptions declined, a subgroup of providers continued to write high-risk initial opioid prescriptions. (Funded by the National Institute on Aging and a gift from Owen and Linda Robinson.)	[Zhu, Wenjia; Chernew, Michael E.; Maestas, Nicole] Harvard Med Sch, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA; [Sherry, Tisamarie B.] RAND, Boston, MA USA; [Sherry, Tisamarie B.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA	Harvard University; Harvard Medical School; RAND Corporation; Harvard University; Brigham & Women's Hospital	Maestas, N (corresponding author), Harvard Med Sch, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	maestas@hcp.med.harvard.edu			National Institute on Aging; NATIONAL INSTITUTE ON AGING [P01AG005842] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Funded by the National Institute on Aging and a gift from Owen and Linda Robinson.	[Anonymous], 2018, WHAT IS US OP EP; [Anonymous], 2016, CDC COMP BENZ DIAZ M; Axeen S, 2018, ANN EMERG MED, V71, P659, DOI 10.1016/j.annemergmed.2017.12.007; Barnett ML, 2017, NEW ENGL J MED, V376, P663, DOI 10.1056/NEJMsa1610524; Boudreau D, 2009, PHARMACOEPIDEM DR S, V18, P1166, DOI 10.1002/pds.1833; Brat GA, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5790; Cao S, 2018, JAMA DERMATOL, V154, P317, DOI 10.1001/jamadermatol.2017.5835; Centers for Disease Control and Prevention, 2019, CALC TOT DAIL DOS OP; Centers for Medicaid and Medicare Services, OP OR MORPH MILL EQ; Cicero TJ, 2014, JAMA PSYCHIAT, V71, P821, DOI 10.1001/jamapsychiatry.2014.366; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Deyo RA, 2017, J GEN INTERN MED, V32, P21, DOI 10.1007/s11606-016-3810-3; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI [10.1001/jama.2016.1464, 10.15585/mmwr.rr7103a1]; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Food and Drug Administration, NAT DRUG COD DAT FIL; Guy GP, 2017, MMWR-MORBID MORTAL W, V66, P697, DOI 10.15585/mmwr.mm6626a4; Han B, 2017, ANN INTERN MED, V167, P293, DOI 10.7326/M17-0865; Hedegaard Holly, 2017, NCHS Data Brief, P1; Jeffery MM, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k2833; Jena AB, 2016, JAMA INTERN MED, V176, P1294, DOI 10.1001/jamainternmed.2016.3284; Jena AB, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1393; Kuo YF, 2016, AM J MED, V129, DOI 10.1016/j.amjmed.2015.10.002; Levy B, 2015, AM J PREV MED, V49, P409, DOI 10.1016/j.amepre.2015.02.020; Miller M, 2015, JAMA INTERN MED, V175, P608, DOI 10.1001/jamainternmed.2014.8071; Morden NE, 2014, MED CARE, V52, P852, DOI 10.1097/MLR.0000000000000183; Office of the Inspector General, 2017, OP MED D; Pezalla EJ, 2017, J PAIN RES, V10, DOI 10.2147/JPR.S129553; Seth P, 2018, MMWR-MORBID MORTAL W, V67, P349, DOI 10.15585/mmwr.mm6712a1; Shah A, 2017, J PAIN, V18, P1374, DOI 10.1016/j.jpain.2017.06.010; Shah A, 2017, MMWR-MORBID MORTAL W, V66, P265, DOI 10.15585/mmwr.mm6610a1; Sherry TB, 2018, ANN INTERN MED, V169, P892, DOI 10.7326/M18-0644; Tehrani AB, 2018, ADDICT BEHAV, V76, P218, DOI 10.1016/j.addbeh.2017.08.005; Von Korff M, 2008, CLIN J PAIN, V24, P521, DOI 10.1097/AJP.0b013e318169d03b	33	99	99	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 14	2019	380	11					1043	1052		10.1056/NEJMsa1807069	http://dx.doi.org/10.1056/NEJMsa1807069			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HO8NL	30865798	Green Accepted, Bronze			2023-01-03	WOS:000461210000008
J	Alemkere, G; Tenna, A; Engidawork, E				Alemkere, Getachew; Tenna, Admasu; Engidawork, Ephrem			Antibiotic use practice and predictors of hospital outcome among patients with systemic bacterial infection: Identifying targets for antibiotic and health care resource stewardship	PLOS ONE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; EPIDEMIOLOGY; PROGRAM	Background Malpractice and excess use of antimicrobials have been associated with multiple costs, including the development of resistant bacteria, which has become a threat to the human health. The aim of this study, therefore, was to assess the antibiotic use practice and to identify predictors of hospital outcome to uncover targets for stewardship. Methods An Institution-based prospective observational study was performed from 9 April to 7 July 2014 in the internal medicine wards of Tikur Anbessa Specialized Hospital. Patients with suspected systemic bacterial infections during this period were strictly followed and data were abstracted using data abstraction format. Descriptive statistics and binary logistic regression were used for statistical analysis. Results About half of the attended patients had suspected systemic bacterial infections, in which pneumonia is the most common. Cephalosporins were the most widely prescribed class of drugs in all the wards. Initial antibiotics were empiric in almost all of the cases. About 28% of the ward and 59% of the ICU patients died during the in-hospital stay. The mean length of stay(LoS) was 18.5+12.2 in the wards and 8.9+4.9 days in the ICU. Whilst digestive disease (AOR = 6.94, 95% CI: 2.24, 21.49), different signs and symptoms of disease(AOR = 2.43, 95% CI: 1.30, 4.56), sepsis(AOR = 2.59, 95% CI: 1.12, 5.99) and vancomycin use(AOR = 2.60, 95% CI: 1.30, 5.21) were independent positive predictors, antibiotic days(> 10) (AOR = 0.37, 95% CI: 0.20, 0.70) was a negative predictor for mortality. On the other hand, hospital-acquired infection(AOR = 3.01, 95% CI: 1.05, 8.62), beyond the median antibiotic days (> 10) (AOR = 4.05, 95% CI: 1.96, 8.37) and agent days beyond 21 days (AOR = 2.18, 95% CI: 1.01-4.68) were independently associated with prolonged LoS. Conclusion Generally, this observation entails an appropriate infection management and antimicrobial use policy. Any future policy should better start by addressing cases like pneumonia, and sepsis and drugs like cephalosporins.	[Alemkere, Getachew; Engidawork, Ephrem] Addis Ababa Univ, Coll Hlth Sci, Sch Pharm, Dept Pharmacol & Clin Pharm, Addis Ababa, Ethiopia; [Tenna, Admasu] Addis Ababa Univ, Sch Med, Dept Internal Med, Addis Ababa, Ethiopia	Addis Ababa University; Addis Ababa University	Alemkere, G (corresponding author), Addis Ababa Univ, Coll Hlth Sci, Sch Pharm, Dept Pharmacol & Clin Pharm, Addis Ababa, Ethiopia.	getachewalemkere@gmail.com	Engidawork, Ephrem/K-7551-2019; Kolech, Getachew/W-3922-2019	Engidawork, Ephrem/0000-0002-9931-6421; Kolech, Getachew/0000-0002-8728-7600	Addis Ababa University	Addis Ababa University	Addis Ababa University is the source of the funding.	Alemkere Getachew, 2018, BMC Res Notes, V11, P675, DOI 10.1186/s13104-018-3782-y; [Anonymous], ETHIOP J HLTH DEV; Beedemariam G, 2018, PLOS ONE, V13, P1; Biadglegne F, 2010, ETHIOP J HEAL DEV, V23, P1498; Capellier G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041290; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Dellit TH, 2007, CLIN INFECT DIS, V44, P159, DOI 10.1086/510393; el Moussaoui R, 2006, BMJ-BRIT MED J, V332, P1355, DOI 10.1136/bmj.332.7554.1355; Endale Getachew, 2013, African Journal of Pharmacy and Pharmacology, V7, P2657; Eshetu S, 2018, ECON MICROBIOL, V14, P119; Fernandez J, 2012, HEPATOLOGY, V55, P1551, DOI 10.1002/hep.25532; Gaieski DF, 2013, CRIT CARE MED; Ghods Ali Asghar, 2014, Glob J Health Sci, V7, P82, DOI 10.5539/gjhs.v7n3p82; Gordon Stephen B, 2003, Malawi Med J, V15, P38; Gottlieb Thomas, 2011, Med J Aust, V194, P281; Gupta N, 2011, CLIN INFECT DIS, V53, P60, DOI 10.1093/cid/cir202; Hanberger H, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-513; Hill PC, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-2; Jenkins TC, 2013, INFECTION, V41, P135, DOI 10.1007/s15010-012-0362-2; Lee CR, 2013, INT J ENV RES PUB HE, V10, P4274, DOI 10.3390/ijerph10094274; Lye DC, 2012, CLIN MICROBIOL INFEC, V18, P502, DOI 10.1111/j.1469-0691.2011.03606.x; MacDougall C, 2005, CLIN MICROBIOL REV, V18, P638, DOI 10.1128/CMR.18.4.638-656.2005; Mauldin PD, 2010, ANTIMICROB AGENTS CH, V54, P109, DOI 10.1128/AAC.01041-09; McCabe C, 2009, ARCH INTERN MED, V169, P1525, DOI 10.1001/archinternmed.2009.259; Mettler J, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-21; Michaels K., 2012, HOSP PHARM, V47, P608, DOI [10.1310/hpj4708-608, DOI 10.1310/hpj4708-608]; Minejima E, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-252; Moore CL, 2011, ANTIMICROB AGENTS CH, V55, P4581, DOI 10.1128/AAC.00115-11; Roberts RR, 2009, CLIN INFECT DIS, V49, P1175, DOI 10.1086/605630; Sileshi A, 2016, BMC PHARMACOL TOXICO, V17, DOI 10.1186/s40360-016-0057-x; Suter-Widmer I, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-21; Usman M, 2011, GOMAL J MED SCI, V9, P18; van den Bosch CMA, 2015, CLIN INFECT DIS, V60, P281, DOI 10.1093/cid/ciu747; van Dijk CE, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0510-8; Yu VL, 2003, CLIN INFECT DIS, V37, P230, DOI 10.1086/377534; Zar HJ, 2013, THORAX, V68, P1052, DOI 10.1136/thoraxjnl-2013-204247; Zeleke B, 2015, AM J HEAL RES, V3, P333; Zeruesenay Desta, 2002, Ethiopian Journal of Health Development, V16, P183	38	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2019	14	2							e0212661	10.1371/journal.pone.0212661	http://dx.doi.org/10.1371/journal.pone.0212661			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM8DR	30794660	Green Published, Green Submitted, gold			2023-01-03	WOS:000459709100107
J	McCann, ME; de Graaff, JC; Dorris, L; Disma, N; Withington, D; Bell, G; Grobler, A; Stargatt, R; Hunt, RW; Sheppard, SJ; Marmor, J; Giribaldi, G; Bellinger, DC; Hartmann, PL; Hardy, P; Frawley, G; Izzo, F; Sternberg, BSV; Lynn, A; Wilton, N; Mueller, M; Polaner, DM; Absalom, AR; Szmuk, P; Morton, N; Berde, C; Soriano, S; Davidson, AJ; Arnup, SJ; Schuster, T; Lee, K; Sheppard, S; Ormond, GD; Hartmann, PL; Takagi, MJ; Malarbi, S; Doyle, M; Ragg, P; Backstrom, M; Costi, D; Knottenbelt, G; Montobbio, G; Mameli, L; Tuo, P; Prato, AP; Mattioli, G; Wolfler, A; Salvo, I; Sonzogni, V; Locatelli, BG; Khotcholava, M; van Gool, JTDG; Numan, SC; van Veldhuijzen, DJS; Kalkman, CJ; van Baar, AL; Steenis, LJP; Hagenaars, JHM; Hoekstra, FM; Volkers, M; Furue, K; Gaudreault, J; Young, V; Sethna, N; Kovatsis, P; Cravero, J; Ivanova, I; Hunyady, A; Verma, S; Thomas, J; Haret, D; Steiner, J; Kravitz, B; Surantham, S; Hays, S; Taenzer, A; Maxwell, L; Williams, RK; Adey, C; Pownall, J; Bagshaw, O; Chisakuta, A; Eissa, A; Stoddart, P; Davis, A; Myles, P; Wolf, A; McIntosh, N; Carlin, J; Leslie, K; de Lima, J; Hammer, G; Field, D; Gebski, V; Tibboel, D				McCann, Mary Ellen; de Graaff, Jurgen C.; Dorris, Liam; Disma, Nicola; Withington, Davinia; Bell, Graham; Grobler, Anneke; Stargatt, Robyn; Hunt, Rodney W.; Sheppard, Suzette J.; Marmor, Jacki; Giribaldi, Gaia; Bellinger, David C.; Hartmann, Penelope L.; Hardy, Pollyanna; Frawley, Geoff; Izzo, Francesca; Sternberg, Britta S. von Ungern; Lynn, Anne; Wilton, Niall; Mueller, Martin; Polaner, David M.; Absalom, Anthony R.; Szmuk, Peter; Morton, Neil; Berde, Charles; Soriano, Sulpicio; Davidson, Andrew J.; Arnup, Sarah J.; Schuster, Tibor; Lee, Katherine; Sheppard, Suzette; Ormond, Gillian D.; Hartmann, Penelope L.; Takagi, Michael J.; Malarbi, Stephanie; Doyle, Melissa; Ragg, Philip; Backstrom, Marie; Costi, David; Knottenbelt, Graham; Montobbio, Giovanni; Mameli, Leila; Tuo, Pietro; Prato, Alessio Pini; Mattioli, Girolamo; Wolfler, Andrea; Salvo, Ida; Sonzogni, Valter; Locatelli, Bruno Guido; Khotcholava, Magda; van Gool, Jose T. D. G.; Numan, Sandra C.; van Veldhuijzen, D. Judy S.; Kalkman, Cor J.; van Baar, Anneloes L.; Steenis, Leonie J. P.; Hagenaars, J. H. M.; Hoekstra, Frouckje M.; Volkers, Martin; Furue, Koto; Gaudreault, Josee; Young, Vanessa; Sethna, Navil; Kovatsis, Pete; Cravero, Joseph; Ivanova, Iskra; Hunyady, Agnes; Verma, Shilpa; Thomas, Joss; Haret, Denisa; Steiner, Jeffery; Kravitz, Brian; Surantham, Suresh; Hays, Stephen; Taenzer, Andreas; Maxwell, Lynne; Williams, Robert K.; Adey, Claire; Pownall, Jaycee; Bagshaw, Oliver; Chisakuta, Anthony; Eissa, Ayman; Stoddart, Peter; Davis, Annette; Myles, Paul; Wolf, Andy; McIntosh, Neil; Carlin, John; Leslie, Kate; de Lima, Jonathan; Hammer, Greg; Field, David; Gebski, Val; Tibboel, Dick		GAS Consortium	Neurodevelopmental outcome at 5 years of age after general anaesthesia or awake-regional anaesthesia in infancy (GAS): an international, multicentre, randomised, controlled equivalence trial	LANCET			English	Article							ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; SPINAL-ANESTHESIA; EARLY EXPOSURE; ACADEMIC-PERFORMANCE; BEHAVIORAL OUTCOMES; CHILDHOOD EXPOSURE; CELL-DEATH; SURGERY; COHORT; NEUROTOXICITY	Background In laboratory animals, exposure to most general anaesthetics leads to neurotoxicity manifested by neuronal cell death and abnormal behaviour and cognition. Some large human cohort studies have shown an association between general anaesthesia at a young age and subsequent neurodevelopmental deficits, but these studies are prone to bias. Others have found no evidence for an association. We aimed to establish whether general anaesthesia in early infancy affects neurodevelopmental outcomes. Methods In this international, assessor-masked, equivalence, randomised, controlled trial conducted at 28 hospitals in Australia, Italy, the USA, the UK, Canada, the Netherlands, and New Zealand, we recruited infants of less than 60 weeks' postmenstrual age who were born at more than 26 weeks' gestation and were undergoing inguinal herniorrhaphy, without previous exposure to general anaesthesia or risk factors for neurological injury. Patients were randomly assigned (1:1) by use of a web-based randomisation service to receive either awake-regional anaesthetic or sevoflurane-based general anaesthetic. Anaesthetists were aware of group allocation, but individuals administering the neurodevelopmental assessments were not. Parents were informed of their infants group allocation upon request, but were told to mask this information from assessors. The primary outcome measure was full-scale intelligence quotient (FSIQ) on the Wechsler Preschool and Primary Scale of Intelligence, third edition (WPPSI-III), at 5 years of age. The primary analysis was done on a per-protocol basis, adjusted for gestational age at birth and country, with multiple imputation used to account for missing data. An intention-to-treat analysis was also done. A difference in means of 5 points was predefined as the clinical equivalence margin. This completed trial is registered with ANZCTR, number ACTRN12606000441516, and ClinicalTrials.gov, number NCT00756600. Findings Between Feb 9, 2007, and Jan 31, 2013, 4023 infants were screened and 722 were randomly allocated: 363 (50%) to the awake-regional anaesthesia group and 359 (50%) to the general anaesthesia group. There were 74 protocol violations in the awake-regional anaesthesia group and two in the general anaesthesia group. Primary outcome data for the per-protocol analysis were obtained from 205 children in the awake-regional anaesthesia group and 242 in the general anaesthesia group. The median duration of general anaesthesia was 54 min (IQR 41-70). The mean FSIQ score was 99.08 (SD 18.35) in the awake-regional anaesthesia group and 98.97 (19.66) in the general anaesthesia group, with a difference in means (awake-regional anaesthesia minus general anaesthesia) of 0.23 (95% CI -2.59 to 3.06), providing strong evidence of equivalence. The results of the intention-to-treat analysis were similar to those of the per-protocol analysis. Interpretation Slightly less than 1 h of general anaesthesia in early infancy does not alter neurodevelopmental outcome at age 5 years compared with awake-regional anaesthesia in a predominantly male study population. Copyright (c) 2019 Elsevier Ltd. All rights reserved.	[McCann, Mary Ellen; Berde, Charles; Soriano, Sulpicio; Young, Vanessa; Sethna, Navil; Kovatsis, Pete; Cravero, Joseph] Boston Childrens Hosp, Dept Anesthesiol Crit Care & Pain Med, Boston, MA USA; [Marmor, Jacki; Bellinger, David C.] Boston Childrens Hosp, Dept Neurol, Boston, MA USA; [de Graaff, Jurgen C.] Erasmus MC, Dept Anaesthesiol, Rotterdam, Netherlands; [de Graaff, Jurgen C.] Univ Med Ctr Utrecht, Dept Anaesthesiol, Utrecht, Netherlands; [Dorris, Liam] Royal Hosp Children, Paediat Neurosci, Glasgow, Lanark, Scotland; [Bell, Graham; Morton, Neil] Royal Hosp Children, Dept Anaesthesia, Glasgow, Lanark, Scotland; [Dorris, Liam] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland; [Morton, Neil] Univ Glasgow, Acad Unit Anaesthesia Pain & Crit Care, Glasgow, Lanark, Scotland; [Disma, Nicola; Giribaldi, Gaia; Montobbio, Giovanni; Mameli, Leila; Tuo, Pietro] Ist Giannina Gaslini, Dept Anaesthesia, Genoa, Italy; [Withington, Davinia] Montreal Childrens Hosp, Dept Anaesthesia, Montreal, PQ, Canada; [Withington, Davinia] McGill Univ, Dept Anaesthesia, Montreal, PQ, Canada; [Grobler, Anneke] Murdoch Childrens Res Inst, Clin Epidemiol & Biostat Unit, Parkville, Vic, Australia; [Stargatt, Robyn] Murdoch Childrens Res Inst, Child Neuropsychol, Parkville, Vic, Australia; [Hunt, Rodney W.] Murdoch Childrens Res Inst, Neonatal Res Grp, Parkville, Vic, Australia; [Sheppard, Suzette J.; Hartmann, Penelope L.; Frawley, Geoff; Davidson, Andrew J.] Murdoch Childrens Res Inst, Anaesthesia & Pain Management Res Grp, Parkville, Vic 3052, Australia; [Grobler, Anneke; Hunt, Rodney W.; Frawley, Geoff; Davidson, Andrew J.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Stargatt, Robyn] La Trobe Univ, Sch Psychol Sci, Melbourne, Vic, Australia; [Hunt, Rodney W.] Royal Childrens Hosp, Dept Neonatal Med, Melbourne, Vic, Australia; [Frawley, Geoff; Davidson, Andrew J.] Royal Childrens Hosp, Dept Anaesthesia & Pain Management, Melbourne, Vic, Australia; [Hartmann, Penelope L.] Australian Catholic Univ, Sch Behav & Hlth Sci, Melbourne, Vic, Australia; [Hardy, Pollyanna] Univ Birmingham, Birmingham Clin Trials Unit, Birmingham, W Midlands, England; [Izzo, Francesca; Wolfler, Andrea; Salvo, Ida] Osped Pediat Vittore Buzzi, Dept Anaesthesiol & Paediat Intens Care, Milan, Italy; [Sternberg, Britta S. von Ungern] Univ Western Australia, Sch Med, Perth, WA, Australia; [Sternberg, Britta S. von Ungern] Perth Childrens Hosp, Dept Anaesthesia & Pain Management, Perth, WA, Australia; [Sternberg, Britta S. von Ungern] Telethon Kids Inst, Perth, WA, Australia; [Lynn, Anne] Univ Washington, Dept Anesthesiol & Pain Med & Pediat, Seattle, WA 98195 USA; [Lynn, Anne] Seattle Childrens Hosp, Dept Anaesthesia & Pain Med, Seattle, WA USA; [Wilton, Niall] Starship Childrens Hosp, Auckland Dist Hlth Board, Dept Paediat Anaesthesia & Operating Rooms, Auckland, New Zealand; [Mueller, Martin] Univ Iowa Hosp & Clin, Dept Anaesthesia, Iowa City, IA 52242 USA; [Polaner, David M.] Childrens Hosp Colorado, Dept Anaesthesiol, Denver, CO USA; [Polaner, David M.] Univ Colorado, Dept Anaesthesiol, Denver, CO 80202 USA; [Absalom, Anthony R.; Hagenaars, J. H. M.; Hoekstra, Frouckje M.; Volkers, Martin] Univ Groningen, Univ Med Ctr Groningen, Dept Anaesthesiol, Groningen, Netherlands; [Szmuk, Peter] Univ Texas Southwestern, Dept Anesthesiol & Pain Management, Dallas, TX USA; [Szmuk, Peter] Childrens Med Ctr Dallas, Dallas, TX USA; [Szmuk, Peter] Cleveland Clin, Dept Outcomes Res, Cleveland, OH 44106 USA; [Frawley, Geoff; Davidson, Andrew J.] Murdoch Childrens Res Inst, Dept Anaesthesia & Pain Management, Melbourne, Vic, Australia; [Frawley, Geoff; Davidson, Andrew J.] Royal Childrens Hosp, Melbourne, Vic, Australia; [Hunt, Rodney W.; Frawley, Geoff; Davidson, Andrew J.] Univ Melbourne, Melbourne, Vic, Australia; [Hardy, Pollyanna] Univ Oxford, Natl Perinatal Epidemiol Unit, Clin Trials Unit, Oxford, England; [Arnup, Sarah J.; Schuster, Tibor; Lee, Katherine] Murdoch Childrens Res Inst, Clin Epidemiol & Biostat Unit, Melbourne, Vic, Australia; [Hunt, Rodney W.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Stargatt, Robyn] Murdoch Childrens Res Inst, Child Neuropsychol, Melbourne, Vic, Australia; [Sheppard, Suzette; Ormond, Gillian D.; Hartmann, Penelope L.; Takagi, Michael J.; Malarbi, Stephanie; Doyle, Melissa] Murdoch Childrens Res Inst, Dept Anaesthesia & Pain Management, Melbourne, Vic, Australia; [Ragg, Philip] Royal Childrens Hosp, Dept Anaesthesia & Pain Management, Melbourne, Vic, Australia; [Backstrom, Marie] Monash Med Ctr, Dept Anaesthesia, Melbourne, Vic, Australia; [Costi, David] Womens & Childrens Hosp, Paediat Anaesthesia, Adelaide, SA, Australia; [Sternberg, Britta S. von Ungern] Princess Margaret Hosp Children, Dept Anaesthesia & Pain Management, Perth, WA, Australia; [Sternberg, Britta S. von Ungern] Univ Western Australia, Perth, WA, Australia; [Bell, Graham; Wilton, Niall; Knottenbelt, Graham] Starship Childrens Hosp, Dept Paediat Anaesthesia & Operating Rooms, Auckland, New Zealand; [Prato, Alessio Pini] Ist Giannina Gaslini, Dept Pediat Surg, Genoa, Italy; [Mattioli, Girolamo] DINOGMI Univ Genoa, Genoa, Italy; [Sonzogni, Valter; Locatelli, Bruno Guido; Khotcholava, Magda] Osped Papa Giovanni XXIII, Dept Anaesthesia, Bergamo, Italy; [de Graaff, Jurgen C.; van Gool, Jose T. D. G.; Numan, Sandra C.; van Veldhuijzen, D. Judy S.; Kalkman, Cor J.] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Anesthesiol, Utrecht, Netherlands; [van Baar, Anneloes L.; Steenis, Leonie J. P.] Univ Utrecht, Utrecht Ctr Child & Adolescent Studies, Utrecht, Netherlands; [Withington, Davinia] McGill Univ, Montreal, PQ, Canada; [Furue, Koto] Ctr Hosp Univ St Justine, Dept Anesthesie, Montreal, PQ, Canada; [Gaudreault, Josee] Montreal Childrens Hosp, Montreal, PQ, Canada; [Lynn, Anne; Ivanova, Iskra; Hunyady, Agnes; Verma, Shilpa] Univ Washington, Seattle Childrens Hosp, Dept Anesthesia & Pain Med, Seattle, WA 98195 USA; [Polaner, David M.] Childrens Hosp Colorado, Denver, CO USA; [Mueller, Martin; Thomas, Joss; Haret, Denisa] Univ Iowa Hosp, Dept Anesthesia, Iowa City, IA USA; [Szmuk, Peter; Steiner, Jeffery; Kravitz, Brian] Univ Texas Southwestern Med Ctr Dallas, Childrens Med Ctr Dallas, Dept Anesthesiol, Dallas, TX 75390 USA; [Szmuk, Peter; Steiner, Jeffery; Kravitz, Brian] Childrens Med Ctr Dallas, Dallas, TX USA; [Szmuk, Peter; Steiner, Jeffery; Kravitz, Brian] Outcome Res Consortium, Dallas, TX USA; [Surantham, Suresh] Northwestern Univ, Dept Pediat Anesthesiol, Ann & Robert H Lurie Childrens Hosp Chicago, Evanston, IL 60208 USA; [Hays, Stephen] Monroe Carell Jr Childrens Hosp Vanderbilt, Nashville, TN USA; [Taenzer, Andreas] Dartmouth Hitchcock Med Ctr, Dept Anesthesiol, Lebanon, NH 03766 USA; [Maxwell, Lynne] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Williams, Robert K.] Univ Vermont, Vermont Childrens Hosp, Coll Med, Anesthesia & Pediat, Burlington, VT 05405 USA; [Morton, Neil] Univ Glasgow, Glasgow, Lanark, Scotland; [Dorris, Liam; Adey, Claire] Royal Hosp Children, Paediat Neurosci Res Grp, Fraser Allander Unit, Glasgow, Lanark, Scotland; [Pownall, Jaycee] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland; [Bagshaw, Oliver] Birmingham Childrens Hosp, Dept Anaesthet, Birmingham, W Midlands, England; [Chisakuta, Anthony] Royal Belfast Hosp Sick Children, Dept Anaesthet, Belfast, Antrim, North Ireland; [Eissa, Ayman] Sheffield Childrens Hosp, Dept Anaesthet, Sheffield, S Yorkshire, England; [Stoddart, Peter] Bristol Royal Hosp Children, Bristol, Avon, England; [Davis, Annette] Alder Hey Childrens NHS Fdn Trust, Liverpool, Merseyside, England	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Erasmus University Rotterdam; Erasmus MC; Utrecht University; Utrecht University Medical Center; University of Glasgow; University of Glasgow; University of Genoa; IRCCS Istituto Giannina Gaslini; McGill University; McGill University; Murdoch Children's Research Institute; Murdoch Children's Research Institute; Murdoch Children's Research Institute; Murdoch Children's Research Institute; University of Melbourne; La Trobe University; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; Australian Catholic University; University of Birmingham; University of Western Australia; Telethon Kids Institute; University of Washington; University of Washington Seattle; Seattle Children's Hospital; Auckland District Health Board; Starship Children's Hospital; University of Iowa; Children's Hospital Colorado; University of Colorado System; University of Colorado Denver; University of Groningen; University of Texas System; University of Texas Southwestern Medical Center Dallas; Cleveland Clinic Foundation; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; University of Oxford; Murdoch Children's Research Institute; Murdoch Children's Research Institute; Murdoch Children's Research Institute; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Monash University; University of Western Australia; University of Western Australia; Starship Children's Hospital; University of Genoa; IRCCS Istituto Giannina Gaslini; ASST Papa Giovanni XXIII; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Utrecht University; McGill University; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; McGill University; Seattle Children's Hospital; University of Washington; University of Washington Seattle; Children's Hospital Colorado; University of Iowa; University of Texas System; University of Texas Southwestern Medical Center Dallas; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Vanderbilt University; Dartmouth College; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Vermont; University of Glasgow; University of Glasgow; University of Birmingham; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; Bristol Royal Hospital For Children; Alder Hey Children's NHS Foundation Trust	Davidson, AJ (corresponding author), Murdoch Childrens Res Inst, Anaesthesia & Pain Management Res Grp, Parkville, Vic 3052, Australia.	andrew.davidson@rch.org.au	Wolfler, Andrea/AAL-9453-2020; Pini Prato, Alessio/F-3145-2018; Kalkman, Cor/O-3215-2019; Disma, Nicola/AAA-8868-2020; von Ungern-Sternberg, Britta/CAG-9904-2022; Polaner, David M/AAX-2514-2021; Absalom, Anthony/GPG-1582-2022; van Baar, Anneloes/L-8236-2013; Dorris, Liam/AAK-2273-2021; Soriano, Sulpicio/K-3501-2019; Morton, Neil/AAE-6594-2020; De Graaff, Jurgen C/G-2298-2017; Carlin, John/AAG-4332-2020; Prato, Alessio Pini/O-1991-2019; Mattioli, Girolamo/AAA-8487-2020	Wolfler, Andrea/0000-0001-6389-3692; Pini Prato, Alessio/0000-0003-3080-7481; Kalkman, Cor/0000-0002-8372-6960; von Ungern-Sternberg, Britta/0000-0002-8043-8541; Polaner, David M/0000-0001-8716-6289; van Baar, Anneloes/0000-0002-3498-9019; Dorris, Liam/0000-0002-9502-3154; Morton, Neil/0000-0001-8848-7914; De Graaff, Jurgen C/0000-0002-2168-7900; Carlin, John/0000-0002-2694-9463; Prato, Alessio Pini/0000-0003-3080-7481; Mattioli, Girolamo/0000-0003-4355-1446; Disma, Nicola/0000-0002-2960-9333; Absalom, Anthony/0000-0001-7563-9157; Grobler, Anneke/0000-0002-7809-7688; Mueller, Martin/0000-0001-5102-4270; Hays, Stephen/0000-0003-2166-8811; Hunt, Rodney/0000-0002-2446-1739; Arnup, Sarah/0000-0002-9497-1902; Symonds, Joseph/0000-0002-2141-4216; Hartmann, Penelope/0000-0003-4706-4485; Suresh, Santhanam/0000-0002-2568-5830; Visser, Melissa/0000-0002-5313-3347; Takagi, Michael/0000-0003-2903-7598	US National Institutes of Health; US Food and Drug Administration; Thrasher Research Fund; Australian National Health and Medical Research Council; Health Technologies Assessment-National Institute for Health Research (UK); Australian and New Zealand College of Anaesthetists; Murdoch Children's Research Institute; Canadian Institutes of Health Research; Canadian Anesthesiologists Society; Pfizer Canada; Italian Ministry of Health; Fonds NutsOhra; UK Clinical Research Network; Perth Children's Hospital Foundation; Stan Perron Charitable Trust; Callahan Estate; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD090255, R01HD084566] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Food and Drug Administration; Thrasher Research Fund; Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Health Technologies Assessment-National Institute for Health Research (UK); Australian and New Zealand College of Anaesthetists; Murdoch Children's Research Institute; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Anesthesiologists Society; Pfizer Canada(Pfizer); Italian Ministry of Health(Ministry of Health, Italy); Fonds NutsOhra; UK Clinical Research Network; Perth Children's Hospital Foundation; Stan Perron Charitable Trust; Callahan Estate; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	US National Institutes of Health, US Food and Drug Administration, Thrasher Research Fund, Australian National Health and Medical Research Council, Health Technologies Assessment-National Institute for Health Research (UK), Australian and New Zealand College of Anaesthetists, Murdoch Children's Research Institute, Canadian Institutes of Health Research, Canadian Anesthesiologists Society, Pfizer Canada, Italian Ministry of Health, Fonds NutsOhra, UK Clinical Research Network, Perth Children's Hospital Foundation, the Stan Perron Charitable Trust, and the Callahan Estate.	Backeljauw B, 2015, PEDIATRICS, V136, pE1, DOI 10.1542/peds.2014-3526; Bartels DD, 2018, PEDIATR ANESTH, V28, P520, DOI 10.1111/pan.13391; Batty GD, 2006, BMJ-BRIT MED J, V332, P580, DOI 10.1136/bmj.38723.660637.AE; Bong CL, 2013, ANESTH ANALG, V117, P1419, DOI 10.1213/ANE.0b013e318299a7c2; Brambrink AM, 2012, ANN NEUROL, V72, P525, DOI 10.1002/ana.23652; Briner A, 2010, ANESTHESIOLOGY, V112, P546, DOI 10.1097/ALN.0b013e3181cd7942; Clausen NG, 2017, CLEFT PALATE-CRAN J, V54, P371, DOI 10.1597/15-185; Davidson A, PROTOCOL 09PRT 9078; Davidson A, 2016, EARLY HUM DEV, V102, P37, DOI 10.1016/j.earlhumdev.2016.09.006; Davidson AJ, 2018, ANESTHESIOLOGY, V128, P840, DOI 10.1097/ALN.0000000000001972; Davidson AJ, 2016, LANCET, V387, P239, DOI 10.1016/S0140-6736(15)00608-X; Davidson AJ, 2015, ANESTHESIOLOGY, V123, P38, DOI 10.1097/ALN.0000000000000709; de Heer IJ, 2017, ANAESTHESIA, V72, P57, DOI 10.1111/anae.13687; DiMaggio C, 2011, ANESTH ANALG, V113, P1143, DOI 10.1213/ANE.0b013e3182147f42; DiMaggio C, 2009, J NEUROSURG ANESTH, V21, P286, DOI 10.1097/ANA.0b013e3181a71f11; Disma N, 2018, PEDIATR ANESTH, V28, P758, DOI 10.1111/pan.13455; Disma N, 2018, J PEDIATR SURG, V53, P1643, DOI 10.1016/j.jpedsurg.2018.01.003; Flick RP, 2011, PEDIATRICS, V128, pE1053, DOI 10.1542/peds.2011-0351; Frawley G, 2015, ANESTHESIOLOGY, V123, P55, DOI 10.1097/ALN.0000000000000708; Glatz P, 2017, JAMA PEDIATR, V171, DOI 10.1001/jamapediatrics.2016.3470; Graham MR, 2016, ANESTHESIOLOGY, V125, P667, DOI 10.1097/ALN.0000000000001245; HINDLEY CB, 1978, J CHILD PSYCHOL PSYC, V19, P329, DOI 10.1111/j.1469-7610.1978.tb00480.x; Hu DQ, 2017, ANESTHESIOLOGY, V127, P227, DOI 10.1097/ALN.0000000000001735; Ing C, 2012, PEDIATRICS, V130, pE476, DOI 10.1542/peds.2011-3822; Istaphanous GK, 2013, ANESTH ANALG, V116, P845, DOI 10.1213/ANE.0b013e318281e988; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Ko WR, 2015, EUR J ANAESTH, V32, P303, DOI 10.1097/EJA.0000000000000130; Ko WR, 2014, PEDIATR ANESTH, V24, P741, DOI 10.1111/pan.12371; McCann ME, 2017, ANESTH ANALG, V125, P837, DOI 10.1213/ANE.0000000000001870; Montana MC, 2017, J PEDIATR-US, V181, P279, DOI 10.1016/j.jpeds.2016.10.049; O'Leary JD, 2016, ANESTHESIOLOGY; Paule MG, 2011, NEUROTOXICOL TERATOL, V33, P220, DOI 10.1016/j.ntt.2011.01.001; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; Raper J, 2015, ANESTHESIOLOGY, V123, P1084, DOI 10.1097/ALN.0000000000000851; Rappaport BA, 2015, NEW ENGL J MED, V372, P796, DOI 10.1056/NEJMp1414786; Sprung J, 2012, MAYO CLIN PROC, V87, P120, DOI 10.1016/j.mayocp.2011.11.008; Stratmann G, 2014, NEUROPSYCHOPHARMACOL, V39, P2275, DOI 10.1038/npp.2014.134; Stratmann G, 2010, ANESTH ANALG, V110, P431, DOI 10.1213/ane.0b013e3181af8015; Sun LS, 2016, JAMA-J AM MED ASSOC, V315, P2312, DOI 10.1001/jama.2016.6967; U. S. Food and Drug Administration, 2017, FDA DRUG SAF COMM FD; United States Food and Drug Administration, 2016, FDA DRUG SAF COMM FD; Vutskits L, 2017, CURR OPIN ANESTHESIO, V30, P337, DOI 10.1097/ACO.0000000000000461; Vutskits L, 2016, NAT REV NEUROSCI, V17, P705, DOI 10.1038/nrn.2016.128; Warner DO, 2018, ANESTHESIOLOGY, V129, P89, DOI 10.1097/ALN.0000000000002232; Wilder RT, 2009, ANESTHESIOLOGY, V110, P796, DOI 10.1097/01.anes.0000344728.34332.5d; Yahalom B, 2011, ANESTHESIOLOGY, V114, P1325, DOI 10.1097/ALN.0b013e31821b5729	46	271	285	11	57	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 16	2019	393	10172					664	677		10.1016/S0140-6736(18)32485-1	http://dx.doi.org/10.1016/S0140-6736(18)32485-1			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL6AX	30782342	Green Published, Green Accepted, Green Submitted, hybrid			2023-01-03	WOS:000458817300025
J	Sardh, E; Harper, P; Balwani, M; Stein, P; Rees, D; Bissell, DM; Desnick, R; Parker, C; Phillips, J; Bonkovsky, HL; Vassiliou, D; Penz, C; Chan-Daniels, A; He, QL; Querbes, W; Fitzgerald, K; Kim, JB; Garg, P; Vaishnaw, A; Simon, AR; Anderson, KE				Sardh, Eliane; Harper, Pauline; Balwani, Manisha; Stein, Penelope; Rees, David; Bissell, D. Montgomery; Desnick, Robert; Parker, Charles; Phillips, John; Bonkovsky, Herbert L.; Vassiliou, Daphne; Penz, Craig; Chan-Daniels, Amy; He, Qiuling; Querbes, William; Fitzgerald, Kevin; Kim, Jae B.; Garg, Pushkal; Vaishnaw, Akshay; Simon, Amy R.; Anderson, Karl E.			Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DELTA-AMINOLEVULINIC-ACID; GENOTYPE-PHENOTYPE CORRELATION; BIOCHEMICAL CHARACTERISTICS; LIVER-TRANSPLANTATION; CLINICAL MANAGEMENT; ACUTE ATTACKS; GENE; PORPHOBILINOGEN; RECOMMENDATIONS; PREVALENCE	BACKGROUND Induction of delta aminolevulinic acid synthase 1 (ALAS1) gene expression and accumulation of neurotoxic intermediates result in neurovisceral attacks and disease manifestations in patients with acute intermittent porphyria, a rare inherited disease of heme biosynthesis. Givosiran is an investigational RNA interference therapeutic agent that inhibits hepatic ALAS1 synthesis. METHODS We conducted a phase 1 trial of givosiran in patients with acute intermittent porphyria. In part A of the trial, patients without recent porphyria attacks (i.e., no attacks in the 6 months before baseline) were randomly assigned to receive a single subcutaneous injection of one of five ascending doses of givosiran (0.035, 0.10, 0.35, 1.0, or 2.5 mg per kilogram of body weight) or placebo. In part B, patients without recent attacks were randomly assigned to receive once-monthly injections of one of two doses of givosiran (0.35 or 1.0 mg per kilogram) or placebo (total of two injections 28 days apart). In part C, patients who had recurrent attacks were randomly assigned to receive injections of one of two doses of givosiran (2.5 or 5.0 mg per kilogram) or placebo once monthly (total of four injections) or once quarterly (total of two injections) during a 12-week period, starting on day 0. Safety, pharmacokinetic, pharmacodynamic, and exploratory efficacy outcomes were evaluated. RESULTS A total of 23 patients in parts A and B and 17 patients in part C underwent randomization. Common adverse events included nasopharyngitis, abdominal pain, and diarrhea. Serious adverse events occurred in 6 patients who received givosiran in parts A through C combined. In part C, all 6 patients who were assigned to receive once-monthly injections of givosiran had sustained reductions in ALAS1 messenger RNA (mRNA), delta aminolevulinic acid, and porphobilinogen levels to near normal. These reductions were associated with a 79% lower mean annualized attack rate than that observed with placebo (exploratory efficacy end point). CONCLUSIONS Once-monthly injections of givosiran in patients who had recurrent porphyria attacks resulted in mainly low-grade adverse events, reductions in induced ALAS1 mRNA levels, nearly normalized levels of the neurotoxic intermediates delta aminolevulinic acid and porphobilinogen, and a lower attack rate than that observed with placebo.	[Sardh, Eliane; Harper, Pauline; Vassiliou, Daphne] Karolinska Univ Hosp, Porphyria Ctr Sweden, Karolinska Inst, Stockholm, Sweden; [Balwani, Manisha; Desnick, Robert] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Stein, Penelope; Rees, David] Kings Coll Hosp London, London, England; [Bissell, D. Montgomery] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Parker, Charles; Phillips, John] Univ Utah, Salt Lake City, UT USA; [Bonkovsky, Herbert L.] Wake Forest Univ, Winston Salem, NC 27109 USA; [Penz, Craig; Chan-Daniels, Amy; He, Qiuling; Querbes, William; Fitzgerald, Kevin; Kim, Jae B.; Garg, Pushkal; Vaishnaw, Akshay; Simon, Amy R.] Alnylam Pharmaceut, Cambridge, MA USA; [Anderson, Karl E.] Univ Texas Med Branch, Galveston, TX 77555 USA	Karolinska Institutet; Karolinska University Hospital; Icahn School of Medicine at Mount Sinai; King's College Hospital NHS Foundation Trust; King's College Hospital; University of California System; University of California San Francisco; Utah System of Higher Education; University of Utah; Wake Forest University; University of Texas System; University of Texas Medical Branch Galveston	Sardh, E (corresponding author), Karolinska Univ Hosp, Ctr Inherited Metab Dis, L7 05, S-17176 Stockholm, Sweden.	eliane.sardh@ki.se	Sardh, Eliane/AFV-2232-2022; Bonkovsky, Herbert L./AAH-1892-2021; Rees, David/B-6789-2011	Sardh, Eliane/0000-0002-2366-2213; Bonkovsky, Herbert L./0000-0001-7387-3230; Rees, David/0000-0003-3647-1050; Anderson, Karl/0000-0002-6499-8573	Alnylam Pharmaceuticals	Alnylam Pharmaceuticals	Funded by Alnylam Pharmaceuticals	Anderson KE, 2005, ANN INTERN MED, V142, P439, DOI 10.7326/0003-4819-142-6-200503150-00010; Anderson KE, 2018, ONLINE METABOLIC MOL, V124; Andersson C, 2003, J INTERN MED, V254, P176, DOI 10.1046/j.1365-2796.2003.01172.x; Balwani M, 2017, HEPATOLOGY, V66, P1314, DOI 10.1002/hep.29313; Bissell DM, 2017, NEW ENGL J MED, V377, P862, DOI 10.1056/NEJMra1608634; Bissell DM, 2015, AM J MED, V128, P313, DOI 10.1016/j.amjmed.2014.10.026; Chan A, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.36; Chen B, 2016, HUM MUTAT, V37, P1215, DOI 10.1002/humu.23067; D'Avola D, 2016, J HEPATOL, V65, P776, DOI 10.1016/j.jhep.2016.05.012; Dowman JK, 2012, LIVER TRANSPLANT, V18, P195, DOI 10.1002/lt.22345; Floderus Y, 2006, CLIN CHEM, V52, P701, DOI 10.1373/clinchem.2005.058198; Fraunberg MVZ, 2005, MEDICINE, V84, P35, DOI 10.1097/01.md.0000152455.38510.af; Fraunberg MVZ, 2002, EUR J HUM GENET, V10, P649, DOI 10.1038/sj.ejhg.5200860; Gaskins AJ, 2014, OBSTET GYNECOL, V124, P23, DOI 10.1097/AOG.0000000000000343; Gouya L, 2018, INT LIV C PAR APR 11; Harper P, 2014, EXPERT OPIN ORPHAN D, V2, P349, DOI 10.1517/21678707.2014.891456; Kauppinen R, 2002, CLIN CHEM, V48, P1891; Marsden JT, 2015, JIMD REP, V22, P57, DOI 10.1007/8904_2015_411; Marsden JT, 2014, J CLIN PATHOL, V67, P60, DOI 10.1136/jclinpath-2012-201367; MONTEIRO HP, 1986, BIOCHIM BIOPHYS ACTA, V881, P100, DOI 10.1016/0304-4165(86)90102-9; MULLER WE, 1977, ANN NEUROL, V2, P340, DOI 10.1002/ana.410020415; Nordmann Y, 1997, J INTERN MED, V242, P213, DOI 10.1046/j.1365-2796.1997.00189.x; Pallet N, 2015, KIDNEY INT, V88, P386, DOI 10.1038/ki.2015.97; Pischik E, 2015, APPL CLIN GENET, V8, P201, DOI 10.2147/TACG.S48605; Puy H, 2010, LANCET, V375, P924, DOI 10.1016/S0140-6736(09)61925-5; Schmitt C, 2018, J INTERN MED, V284, P78, DOI 10.1111/joim.12750; Sehgal A, 2014, RNA, V20, P143, DOI 10.1261/rna.042507.113; Serrano-Mendioroz I, 2018, HUM GENE THER, V29, P480, DOI 10.1089/hum.2017.056; Simon A, 2018, PATIENT, V11, P527, DOI 10.1007/s40271-018-0319-3; Stein P, 2013, ANN CLIN BIOCHEM, V50, P217, DOI 10.1177/0004563212474555; Stein PE, 2017, BRIT J HAEMATOL, V176, P527, DOI 10.1111/bjh.14459; Tollanes MC, 2011, J INHERIT METAB DIS, V34, P217, DOI 10.1007/s10545-010-9231-2; Yasuda M, 2015, MOL MED, V21, P487, DOI 10.2119/molmed.2015.00099; Yasuda M, 2014, P NATL ACAD SCI USA, V111, P7777, DOI 10.1073/pnas.1406228111	34	139	144	2	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 7	2019	380	6					549	558		10.1056/NEJMoa1807838	http://dx.doi.org/10.1056/NEJMoa1807838			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK3YA	30726693	Green Published, Bronze			2023-01-03	WOS:000457854200008
J	Ke, C; Lau, E; Shah, BR; Stukel, TA; Ma, RC; So, WY; Kong, AP; Chow, E; Clarke, P; Goggins, W; Chan, JCN; Luk, A				Ke, Calvin; Lau, Eric; Shah, Baiju R.; Stukel, Therese A.; Ma, Ronald C.; So, Wing-Yee; Kong, Alice P.; Chow, Elaine; Clarke, Philip; Goggins, William; Chan, Juliana C. N.; Luk, Andrea			Excess Burden of Mental Illness and Hospitalization in Young-Onset Type 2 Diabetes A Population-Based Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							MULTIFACTORIAL INTERVENTION; CARDIOVASCULAR OUTCOMES; DEPRESSIVE SYMPTOMS; INTEGRATED CARE; FOLLOW-UP; MELLITUS; RISK; COMPLICATIONS; ASSOCIATION; MORTALITY	Background: Type 2 diabetes (T2D) increases hospitalization risk. Young-onset T2D (YOD) (defined as onset before age 40 years) is associated with excess morbidity and mortality, but its effect on hospitalizations is unknown. Objective: To determine hospitalization rates among persons with YOD and to examine the effect of age at onset on hospitalization risk. Design: Prospective cohort study. Setting: Hong Kong. Participants: Adults aged 20 to 75 years in population-based (2002 to 2014; n = 422 908) and registry-based (2000 to 2014; n = 20 886) T2D cohorts. Measurements: All-cause and cause-specific hospitalization rates. Negative binomial regression models estimated effect of age at onset on hospitalization rate and cumulative bed-days from onset to age 75 years for YOD. Results: Patients with YOD had the highest hospitalization rates by attained age. In the registry cohort, 36.8% of YOD bed-days before age 40 years were due to mental illness. The adjusted rate ratios showed increased hospitalization in YOD versus usual-onset T2D (onset at age >= 40 years) (all-cause, 1.8 [95% CI, 1.7 to 2.0]; renal, 6.7 [CI, 4.2 to 10.6]; diabetes, 3.7 [CI, 3.0 to 4.6]; cardiovascular, 2.1 [CI, 1.8 to 2.5]; infection, 1.7 [CI, 1.4 to 2.1]; P < 0.001 for all). Models estimated that intensified risk factor control in YOD (hemoglobin A(1c) level <6.2%, systolic blood pressure < 120 mm Hg, low-density lipoprotein cholesterol level < 2.0 mmol/L [<77.3 mg/dL], triglyceride level <1.3 mmol/L [<115.1 mg/dL], waist circumference of 85 cm [men] or 80 cm [women], and smoking cessation) was associated with a one-third reduction in cumulative bed-days from onset to age 75 years (97 to 65 bed-days). Limitation: Possible residual confounding. Conclusion: Adults with YOD have excess hospitalizations across their lifespan compared with persons with usual-onset T2D, including an unexpectedly large burden of mental illness in young adulthood. Efforts to prevent YOD and intensify cardio-metabolic risk factor control while focusing on mental health are urgently needed.	[Ke, Calvin; Lau, Eric; Goggins, William] Chinese Univ Hong Kong, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; [Ma, Ronald C.; So, Wing-Yee; Kong, Alice P.; Chow, Elaine; Chan, Juliana C. N.; Luk, Andrea] Chinese Univ Hong Kong, Prince Wales Hosp, Shatin, Dept Med & Therapeut, Lui Che Woo Clin Sci Bldg,9th Floor,Room 114025, Hong Kong, Peoples R China; [Ke, Calvin; Stukel, Therese A.] Univ Toronto, Toronto, ON, Canada; [Shah, Baiju R.] Univ Toronto, Inst Clin Evaluat Sci, Toronto, ON, Canada; [Shah, Baiju R.] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Stukel, Therese A.] Inst Clin Evaluat Sci, 2075 Bayview Ave,Suite G106, Toronto, ON M4N 3M5, Canada; [Clarke, Philip] Univ Oxford, Hlth Econ Res Ctr, Nuffield Dept Populat Hlth, Oxford, England	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Oxford	Chan, JCN (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Shatin, Dept Med & Therapeut, Lui Che Woo Clin Sci Bldg,9th Floor,Room 114025, Hong Kong, Peoples R China.	jchan@cuhk.edu.hk	Kong, Alice/P-3703-2015; Chan, Juliana/B-7918-2016; Chow, Elaine/HJB-2197-2022; Lau, Eric S.H./AGZ-2920-2022; Luk, Andrea/B-5766-2016; Ma, Ronald/C-2788-2009; Ke, Calvin/K-6231-2016	Kong, Alice/0000-0001-8927-6764; Chan, Juliana/0000-0003-1325-1194; Chow, Elaine/0000-0002-4147-3387; Ma, Ronald/0000-0002-1227-803X; Lau, Eric S.H./0000-0003-1581-5643; Ke, Calvin/0000-0002-9944-4976	Asia Diabetes Foundation; Canadian Institutes of Health Research Canada Graduate Scholarship; University of Toronto Clinician Investigator Program; Canadian Society of Endocrinology and Metabolism Dr. Fernand Labrie Fellowship Research Grant; Royal College of Physicians and Surgeons of Canada Detweiler Travelling Fellowship	Asia Diabetes Foundation; Canadian Institutes of Health Research Canada Graduate Scholarship(Canadian Institutes of Health Research (CIHR)); University of Toronto Clinician Investigator Program; Canadian Society of Endocrinology and Metabolism Dr. Fernand Labrie Fellowship Research Grant; Royal College of Physicians and Surgeons of Canada Detweiler Travelling Fellowship	By the Asia Diabetes Foundation. Dr. Ke is supported by the Canadian Institutes of Health Research Canada Graduate Scholarship and Michael Smith Foreign Study Supplements, the University of Toronto Clinician Investigator Program, the Canadian Society of Endocrinology and Metabolism Dr. Fernand Labrie Fellowship Research Grant, and the Royal College of Physicians and Surgeons of Canada Detweiler Travelling Fellowship.	Blixen CE, 2016, AM J HEALTH BEHAV, V40, P194, DOI 10.5993/AJHB.40.2.4; Chan JCN, 2017, LANCET DIABETES ENDO, V5, P927, DOI 10.1016/S2213-8587(17)30356-X; Chan JCN, 2014, AM J MED, V127, P616, DOI 10.1016/j.amjmed.2014.03.018; Chan JCN, 2014, JAMA INTERN MED, V174, P972, DOI 10.1001/jamainternmed.2014.655; Chan JCN, 2011, CURR CARDIOVASC RISK, V5, P230, DOI 10.1007/s12170-011-0172-6; Chan JCN, 2009, DIABETES CARE, V32, P227, DOI 10.2337/dc08-0435; Chan WB, 2004, DIABETIC MED, V21, P349, DOI 10.1111/j.1464-5491.2004.01158.x; Del Prato S, 2009, DIABETOLOGIA, V52, P1219, DOI 10.1007/s00125-009-1352-5; Food and Health Bureau, 2008, YOUR HLTH YOUR LIF H; Gde P, 2016, DIABETOLOGIA, V59, P2298, DOI 10.1007/s00125-016-4065-6; Golden SH, 2008, JAMA-J AM MED ASSOC, V299, P2751, DOI 10.1001/jama.299.23.2751; Katon WJ, 2010, NEW ENGL J MED, V363, P2611, DOI 10.1056/NEJMoa1003955; Kautzky-Willer A, 2016, ENDOCR REV, V37, P278, DOI 10.1210/er.2015-1137; Ke C, 2015, DIABETIC MED, V32, P487, DOI 10.1111/dme.12657; Laake JPS, 2014, DIABETES CARE, V37, P2186, DOI 10.2337/dc13-2522; Leung GM, 2007, HEALTH POLICY, V81, P93, DOI 10.1016/j.healthpol.2006.05.014; Lim LL, 2018, DIABETES CARE, V41, P1312, DOI 10.2337/dc17-2010; Lind M, 2008, DIABETES METAB SYND, V2, P282, DOI 10.1016/j.dsx.2008.04.006; Luk AOY, 2017, DIABETES-METAB RES, V33, DOI 10.1002/dmrr.2923; Luk AOY, 2014, DIABETES CARE, V37, P149, DOI 10.2337/dc13-1336; Luk AOY, 2013, DIABETES-METAB RES, V29, P384, DOI 10.1002/dmrr.2404; Mansur RB, 2018, ANN CLIN PSYCHIATRY, V30, P38; Marcellusi A, 2016, EUR J HEALTH ECON, V17, P139, DOI 10.1007/s10198-014-0660-y; McCoy RG, 2017, J GEN INTERN MED, V32, P1097, DOI 10.1007/s11606-017-4095-x; Nanayakkara N, 2018, J DIABETES COMPLICAT, V32, P279, DOI 10.1016/j.jdiacomp.2017.11.009; Pavkov ME, 2006, JAMA-J AM MED ASSOC, V296, P421, DOI 10.1001/jama.296.4.421; Perry BI, 2017, PSYCHIAT RES, V256, P102, DOI 10.1016/j.psychres.2017.06.027; PIWERNETZ K, 1993, DIABETIC MED, V10, P371, DOI 10.1111/j.1464-5491.1993.tb00083.x; Quan J, 2017, DIABETIC MED, V34, P902, DOI 10.1111/dme.13284; Ray KK, 2009, LANCET, V373, P1765, DOI 10.1016/S0140-6736(09)60697-8; Rhodes ET, 2012, DIABETIC MED, V29, P453, DOI 10.1111/j.1464-5491.2011.03542.x; Roussel R, 2018, DIABETES OBES METAB, V20, P238, DOI 10.1111/dom.13033; Sernyak MJ, 2002, AM J PSYCHIAT, V159, P561, DOI 10.1176/appi.ajp.159.4.561; Seshasai SRK, 2011, NEW ENGL J MED, V364, P829, DOI 10.1056/NEJMoa1008862; Snoek FJ, 2011, DIABETES CARE, V34, P601, DOI 10.2337/dc10-1552; Steinarsson AO, 2018, DIABETOLOGIA, V61, P599, DOI 10.1007/s00125-017-4532-8; Ting RZW, 2011, DIABETES CARE, V34, P1094, DOI 10.2337/dc10-1612; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Ueki K, 2017, LANCET DIABETES ENDO, V5, P951, DOI 10.1016/S2213-8587(17)30327-3; Working Group on Long-Term Fiscal Planning, 2014, REP WORK GROUP LONG; Xie FY, 2018, J DIABETES INVEST, V9, P998, DOI 10.1111/jdi.12830; Yeung Roseanne O, 2018, Clin Diabetes Endocrinol, V4, P5, DOI 10.1186/s40842-018-0055-6; Yeung RO, 2014, LANCET DIABETES ENDO, V2, P935, DOI 10.1016/S2213-8587(14)70137-8; Young-Hyman D, 2016, DIABETES CARE, V39, P2126, DOI 10.2337/dc16-2053; Zhang Y, 2017, DIABETIC MED, V34, P1701, DOI 10.1111/dme.13516; Zhang YY, 2015, J DIABETES, V7, P800, DOI 10.1111/1753-0407.12238; Zoungas S, 2014, DIABETOLOGIA, V57, P2465, DOI 10.1007/s00125-014-3369-7	47	38	38	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 5	2019	170	3					145	+		10.7326/M18-1900	http://dx.doi.org/10.7326/M18-1900			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HK2IZ	30641547				2023-01-03	WOS:000457735100002
J	Hou, JL; Pan, YW; Zhu, DS; Fan, YY; Feng, GW; Wei, YZ; Wang, H; Qin, K; Zhao, TC; Yang, Q; Zhu, Y; Che, YZ; Liu, YP; Cheng, JS; Kong, DL; Wang, PG; Shen, J; Zhao, Q				Hou, Jingli; Pan, Yiwa; Zhu, Dashuai; Fan, Yueyuan; Feng, Guowei; Wei, Yongzhen; Wang, He; Qin, Kang; Zhao, Tiechan; Yang, Qiang; Zhu, Yan; Che, Yongzhe; Liu, Yangping; Cheng, Jiansong; Kong, Deling; Wang, Peng George; Shen, Jie; Zhao, Qiang			Targeted delivery of nitric oxide via a 'bump-and-hole'-based enzyme-prodrug pair	NATURE CHEMICAL BIOLOGY			English	Article							NO; DIAZENIUMDIOLATE; BIOMATERIALS; ANGIOGENESIS; CHEMISTRY; INSIGHTS; RELEASE; ORIGIN; INJURY	The spatiotemporal generation of nitric oxide (NO), a versatile endogenous messenger, is precisely controlled. Despite its therapeutic potential for a wide range of diseases, NO-based therapies are limited clinically due to a lack of effective strategies for precisely delivering NO to a specific site. In the present study, we developed a novel NO delivery system via modification of an enzyme-prodrug pair of galactosidase-galactosyl-NONOate using a 'bump-and-hole' strategy. Precise delivery to targeted tissues was clearly demonstrated by an in vivo near-infrared imaging assay. The therapeutic potential was evaluated in both rat hindlimb ischemia and mouse acute kidney injury models. Targeted delivery of NO clearly enhanced its therapeutic efficacy in tissue repair and function recovery and abolished side effects due to the systemic release of NO. The developed protocol holds broad applicability in the targeted delivery of important gaseous signaling molecules and offers a potent tool for the investigation of relevant molecular mechanisms.	[Hou, Jingli; Fan, Yueyuan; Cheng, Jiansong; Shen, Jie] Nankai Univ, State Key Lab Med Chem Biol, Tianjin, Peoples R China; [Hou, Jingli; Fan, Yueyuan; Cheng, Jiansong; Shen, Jie] Nankai Univ, Coll Pharm, Tianjin, Peoples R China; [Hou, Jingli; Liu, Yangping] Tianjin Med Univ, Sch Pharm, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin, Peoples R China; [Pan, Yiwa; Wei, Yongzhen; Wang, He; Qin, Kang; Kong, Deling; Zhao, Qiang] Nankai Univ, Minist Educ, State key Lab Med Chem Biol, Key Lab Bioact Mat, Tianjin, Peoples R China; [Pan, Yiwa; Wei, Yongzhen; Wang, He; Qin, Kang; Kong, Deling; Zhao, Qiang] Nankai Univ, Coll Life Sci, Tianjin, Peoples R China; [Zhu, Dashuai; Che, Yongzhe] Nankai Univ, Sch Med, Tianjin, Peoples R China; [Feng, Guowei] Tianjin Med Univ, Dept Genitourinary Oncol, Canc Inst & Hosp, Natl Clin Res Ctr Canc,Key Lab Canc Prevent & The, Tianjin, Peoples R China; [Zhao, Tiechan; Zhu, Yan] Tianjin Univ Tradit Chinese Med, Ctr Res & Dev Chinese Med, Tianjin State Key Lab Modern Chinese Med, Tianjin, Peoples R China; [Yang, Qiang] Tianjin Hosp, Spine Dept, Tianjin, Peoples R China; [Wang, Peng George] Georgia State Univ, Dept Chem, Atlanta, GA 30303 USA; [Wang, Peng George] Georgia State Univ, Ctr Therapeut & Diagnost, Atlanta, GA 30303 USA; [Zhao, Qiang] Xuzhou Med Univ, Jiangsu Ctr Collaborat & Innovat Canc Biotherapy, Canc Inst, Xuzhou, Jiangsu, Peoples R China	Nankai University; Nankai University; Tianjin Medical University; Nankai University; Nankai University; Nankai University; Tianjin Medical University; Tianjin University of Traditional Chinese Medicine; University System of Georgia; Georgia State University; University System of Georgia; Georgia State University; Xuzhou Medical University	Cheng, JS; Shen, J (corresponding author), Nankai Univ, State Key Lab Med Chem Biol, Tianjin, Peoples R China.; Cheng, JS; Shen, J (corresponding author), Nankai Univ, Coll Pharm, Tianjin, Peoples R China.; Zhao, Q (corresponding author), Nankai Univ, Minist Educ, State key Lab Med Chem Biol, Key Lab Bioact Mat, Tianjin, Peoples R China.; Zhao, Q (corresponding author), Nankai Univ, Coll Life Sci, Tianjin, Peoples R China.; Zhao, Q (corresponding author), Xuzhou Med Univ, Jiangsu Ctr Collaborat & Innovat Canc Biotherapy, Canc Inst, Xuzhou, Jiangsu, Peoples R China.	jiansongcheng@nankai.edu.cn; jieshen@nankai.edu.cn; qiangzhao@nankai.edu.cn	Zhao, Qiang/AAQ-9688-2021; WANG, Peng/GSN-5263-2022; yang, qiang/GYJ-0971-2022; Zhu, Dashuai/AHB-8198-2022; Zhu, Yan/A-1548-2017	Zhu, Dashuai/0000-0002-4645-5786; Zhu, Yan/0000-0002-3197-7936; wang, he/0000-0002-7073-7521; Liu, Yangping/0000-0001-5455-3602	National Natural Science Foundation of China [81522023, 81830060, 81603064, 81871500, 91639113]; National Key R&D Program of China [2017YFC1103501]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China	We thank J. Xiao at Shanghai University for kindly donating eNOS-knockout mice. This study was supported by National Natural Science Foundation of China (Nos. 81522023 to Q.Z., 81830060 to D.K., 81603064 to J.H., 81871500 to Q.Z., and 91639113 to Q.Z.) and National Key R&D Program of China (2017YFC1103501 to D.K. and Q.Z.).	Baek SH, 2002, CIRCULATION, V105, P2779, DOI 10.1161/01.CIR.0000017432.19415.3E; Baud MGJ, 2016, J MED CHEM, V59, P1492, DOI 10.1021/acs.jmedchem.5b01135; Baud MGJ, 2014, SCIENCE, V346, P638, DOI 10.1126/science.1249830; BERG JD, 1988, APPL ENVIRON MICROB, V54, P2118, DOI 10.1128/AEM.54.8.2118-2122.1988; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Bolam DN, 2007, P NATL ACAD SCI USA, V104, P5336, DOI 10.1073/pnas.0607897104; Cai TB, 2004, ORG LETT, V6, P4203, DOI 10.1021/ol048397p; Cao RH, 2003, NAT MED, V9, P604, DOI 10.1038/nm848; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Chandrawati R, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201700385; Chandrawati R, 2017, ADV MATER, V29, DOI 10.1002/adma.201604932; Cheng H, 2005, J MED CHEM, V48, P645, DOI 10.1021/jm049693a; Chiazza F, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/804659; Cooke JP, 2003, ATHEROSCLEROSIS SUPP, V4, P53, DOI 10.1016/S1567-5688(03)00034-5; de Carvalho MP, 2016, CURR MED CHEM, V23, P23; Du W, 2017, BIOMATERIALS, V133, P70, DOI 10.1016/j.biomaterials.2017.04.030; Feng GW, 2016, J AM SOC NEPHROL, V27, P2357, DOI 10.1681/ASN.2015050578; Forstermann U, 2012, EUR HEART J, V33, P829, DOI 10.1093/eurheartj/ehr304; Hrabie JA, 2002, CHEM REV, V102, P1135, DOI 10.1021/cr000028t; Huber RE, 2003, BIOCHEMISTRY-US, V42, P1796, DOI 10.1021/bi0270642; Islam K, 2013, P NATL ACAD SCI USA, V110, P16778, DOI 10.1073/pnas.1216365110; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Kapadia MR, 2008, J VASC SURG, V47, P173, DOI 10.1016/j.jvs.2007.09.005; Kashiwagi S, 2005, J CLIN INVEST, V115, P1816, DOI 10.1172/JCI24015; Khambata RS, 2017, P NATL ACAD SCI USA, V114, pE550, DOI 10.1073/pnas.1613063114; Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57; LeBleu VS, 2013, NAT MED, V19, P1047, DOI 10.1038/nm.3218; Liu VWT, 2008, CARDIOVASC RES, V77, P19, DOI 10.1016/j.cardiores.2007.06.024; Liu YH, 2006, KIDNEY INT, V69, P213, DOI 10.1038/sj.ki.5000054; Lundberg JO, 2008, NAT REV DRUG DISCOV, V7, P156, DOI [10.1038/nrd2466, 10.1038/nrd2466-c2]; Lundberg JO, 2015, NAT REV DRUG DISCOV, V14, P623, DOI 10.1038/nrd4623; Mazzone M, 2008, NATURE, V453, P1194, DOI 10.1038/4531194a; Miller MR, 2007, BRIT J PHARMACOL, V151, P305, DOI 10.1038/sj.bjp.0707224; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nagano T, 2002, CHEM REV, V102, P1235, DOI 10.1021/cr010152s; NiculescuDuvaz I, 1997, ADV DRUG DELIVER REV, V26, P151, DOI 10.1016/S0169-409X(97)00032-X; Place ES, 2009, NAT MATER, V8, P457, DOI [10.1038/nmat2441, 10.1038/NMAT2441]; Portilla D, 2006, KIDNEY INT, V69, P2194, DOI 10.1038/sj.ki.5000433; Ramakrishnan B, 2002, J BIOL CHEM, V277, P20833, DOI 10.1074/jbc.M111183200; Ricles LM, 2016, BIOMATERIALS, V102, P9, DOI 10.1016/j.biomaterials.2016.06.011; Sabbisetti VS, 2014, J AM SOC NEPHROL, V25, P2177, DOI 10.1681/ASN.2013070758; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; SHINOBU LA, 1984, ACTA PHARMACOL TOX, V54, P189; SoRelle R, 1998, CIRCULATION, V98, P2365, DOI 10.1161/01.CIR.98.22.2365; Stadler B, 2017, ADV DRUG DELIVER REV, V118, P1, DOI 10.1016/j.addr.2017.10.006; Sun YBY, 2016, DIFFERENTIATION, V92, P102, DOI 10.1016/j.diff.2016.05.008; Uchida N, 2018, NAT CHEM BIOL, V14, P299, DOI [10.1038/NCHEMBIO.2555, 10.1038/nchembio.2555]; Vaziri ND, 2016, NAT REV NEPHROL, V12, P37, DOI 10.1038/nrneph.2015.180; Walther R, 2017, ADV DRUG DELIVER REV, V118, P65, DOI 10.1016/j.addr.2017.06.013; Wang ZH, 2015, J CONTROL RELEASE, V210, P179, DOI 10.1016/j.jconrel.2015.05.283; Wu XJ, 2001, TETRAHEDRON LETT, V42, P3779, DOI 10.1016/S0040-4039(01)00614-1; Yuen DA, 2012, J AM SOC NEPHROL, V23, P1810, DOI 10.1681/ASN.2011121170; Zhao Q, 2013, BIOMATERIALS, V34, P8450, DOI 10.1016/j.biomaterials.2013.07.045; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	55	53	54	5	175	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	FEB	2019	15	2					151	+		10.1038/s41589-018-0190-5	http://dx.doi.org/10.1038/s41589-018-0190-5			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HI1EU	30598545				2023-01-03	WOS:000456188100014
J	dos Santos, GL; da Silva, ESM; Desloovere, K; Russo, TL				dos Santos, Gabriela Lopes; Moreira da Silva, Erika Shirley; Desloovere, Kaat; Russo, Thiago Luiz			Effects of elastic tape on kinematic parameters during a functional task in chronic hemiparetic subjects: A randomized sham-controlled crossover trial	PLOS ONE			English	Article							HEMIPLEGIC SHOULDER PAIN; MINI-MENTAL-STATE; STROKE PATIENTS; UPPER-LIMB; KINESIO TAPE; EFFECT SIZE; MOVEMENT; DRINKING; MOTION; ELBOW	Background Approximately 50 to 70% of post-stroke subjects present a reduction in the upper limb (UL) function even during the chronic phase. An adjuvant technique widely used in neurorehabilitation is elastic taping applications. However, its efficacy in UL treatment for post-stroke subjects still requires further investigation. Objective To verify the effects of elastic tape (ET) used on the paretic shoulder in upper limb (UL) performance during a drinking task. Method A single-center randomized sham-controlled crossover trial randomized thirteen post-stroke subjects with mild to moderate UL impairment for group allocation to receive first Sham Tape (ST) or first Elastic Tape (ET), with one month of washout. Kinematic measures of a drinking task were taken before and after each intervention (elastic and sham tape), using Three-Dimensional Motion Analysis, and studied using feature analysis and Statistical Parametric Mapping. Outcome measures included spatiotemporal variables, scalar kinematic parameters (starting angles, range of motion-ROM, and endpoint angles) and time-normalized kinematic waveforms of trunk and UL joint angles (scapulothoracic, humerothoracic and elbow). Results Elastic tape provided common modifications throughout the task (shoulder more towards midline, reduced scapula protraction and trunk flexion) and important alterations at specific time-instants. At the end of the reaching phase, for both groups (ET and ST), the elastic tape increased elbow extension [ET: CI = 12.57 (6.90 to 18.17), p<0.001; ST: CI: 12.89 (6.79 to 18.98), p<0.001). At the end of transporting the glass to the mouth, patients who underwent the elastic tape intervention presented more shoulder elevation [ET: CI = 16.40 (4.28 to 28.52), p = 0.007; ST: CI: 15.13 (5.79 to 24.48), p = 0.002)]. Moreover, an increase of elbow extension at the end of transporting the glass to the table was observed for both groups [ET: CI = 8.13 (1.48 to 14.79), p = 0.014; ST: CI: 8.20 (4.03 to 12.38), p<0.001)]. However, no changes in the spatiotemporal parameters were observed for both groups during all the phases of the task (p>0.05). Conclusion The ET changed UL joint motions and posture during a drinking task in chronic hemiparetic subjects, which defines its role as an adjuvant therapy.	[dos Santos, Gabriela Lopes; Moreira da Silva, Erika Shirley; Russo, Thiago Luiz] Fed Univ Sao Carlos UFSCar, Dept Physiotherapy, Lab Neurol Physiotherapy Res, Sao Carlos, SP, Brazil; [dos Santos, Gabriela Lopes] Fac Alfredo Nasser UNIFAN, ICS, Aparecida De Goiania, Go, Brazil; [Desloovere, Kaat] Katholieke Univ Leuven, Dept Rehabil Sci, Fac Kinesiol & Rehabil Sci, Leuven, Belgium; [Desloovere, Kaat] Univ Hosp Pellenberg, Clin Mot Anal Lab, CERM, Pellenberg, Belgium	Universidade Federal de Sao Carlos; KU Leuven; KU Leuven; University Hospital Leuven	dos Santos, GL; Russo, TL (corresponding author), Fed Univ Sao Carlos UFSCar, Dept Physiotherapy, Lab Neurol Physiotherapy Res, Sao Carlos, SP, Brazil.; dos Santos, GL (corresponding author), Fac Alfredo Nasser UNIFAN, ICS, Aparecida De Goiania, Go, Brazil.	gabrielalsantos@hotmail.com; thiagoluizrusso@gmail.com	Russo, Thiago/B-7555-2012; Santos, Gabriela L Lopes dos/K-6023-2013; da Silva, Erika Shirley Moreira/T-2561-2019	Russo, Thiago/0000-0002-5483-3097; Lopes dos Santos, Gabriela/0000-0002-6230-999X; Silva, Erika Shirley/0000-0003-1485-275X	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP/CAPES) [2014/25845-6, 2015/21695-2]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [142923/2014-1]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP/CAPES); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This study (author: GLS) was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP/CAPES; grant numbers: 2014/25845-6 and 2015/21695-2), and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; grant number: 142923/2014-1).	Adler RJ., 2009, RANDOM FIELDS GEOMET; Alt Murphy M, 2011, NEUROREHAB NEURAL RE, V25, P71, DOI 10.1177/1545968310370748; Aprile I, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/636123; Bell A, 2013, TOP STROKE REHABIL, V20, P283, DOI 10.1310/tsr2003-283; Bravi R, 2016, INT J SPORTS MED, V37, P909, DOI 10.1055/s-0042-109777; Brucki SMD, 2003, ARQ NEURO-PSIQUIAT, V61, P777, DOI 10.1590/S0004-282X2003000500014; Buma F, 2013, RESTOR NEUROL NEUROS, V31, P707, DOI 10.3233/RNN-130332; Camerota F, 2014, DEV NEUROREHABIL, V17, P384, DOI 10.3109/17518423.2013.830152; CAPPOZZO A, 1995, CLIN BIOMECH, V10, P171, DOI 10.1016/0268-0033(95)91394-T; Cohen J., 2013, STAT POWER ANAL BEHA; dos Santos GL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170368; Faraone Stephen V, 2008, P T, V33, P700; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gamage SSHU, 2002, J BIOMECH, V35, P87, DOI 10.1016/S0021-9290(01)00160-9; Hatem SM, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00442; Huang YC, 2016, EUR J PHYS REHAB MED, V52, P774; Kalichman L, 2016, INT J REHABIL RES, V39, P272, DOI 10.1097/MRR.0000000000000167; Kandel E., 2000, PRINCIPLES NEURAL SC; Kim EB, 2015, J PHYS THER SCI, V27, P1455, DOI 10.1589/jpts.27.1455; Kim K, 2014, CLIN BIOMECH, V29, P248, DOI 10.1016/j.clinbiomech.2013.12.013; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Lee DH, 2015, J PHYS THER SCI, V27, P2101, DOI 10.1589/jpts.27.2101; Levine TR, 2002, HUM COMMUN RES, V28, P612, DOI 10.1111/j.1468-2958.2002.tb00828.x; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; Olejnik S, 2000, CONTEMP EDUC PSYCHOL, V25, P241, DOI 10.1006/ceps.2000.1040; Pamuk U, 2015, J BIOMECH, V48, P4262, DOI 10.1016/j.jbiomech.2015.10.036; Pandian JD, 2013, NEUROLOGY, V80, P528, DOI 10.1212/WNL.0b013e318281550e; Parker V M, 1986, Int Rehabil Med, V8, P69; Pataky TC, 2013, J BIOMECH, V46, P2394, DOI 10.1016/j.jbiomech.2013.07.031; Pillastrini P, 2016, DISABIL REHABIL, V38, P1603, DOI 10.3109/09638288.2015.1107631; Platz T, 2005, CLIN REHABIL, V19, P404, DOI 10.1191/0269215505cr832oa; Robertson JVG, 2012, EXP BRAIN RES, V218, P141, DOI 10.1007/s00221-012-3014-y; Roijezon U, 2015, MANUAL THER, V20, P368, DOI 10.1016/j.math.2015.01.008; Russo L, 2018, ASIAN J SPORTS MED; Santos GL, 2018, ARCH PHYS MED REHAB, V99, P501, DOI 10.1016/j.apmr.2017.08.479; Stoykov ME, 2015, J NEUROL PHYS THER, V39, P33, DOI 10.1097/NPT.0000000000000065; Van Herzeele M, 2013, INT J SPORTS MED, V34, P950, DOI 10.1055/s-0033-1334911; Wu G, 2005, J BIOMECH, V38, P981, DOI 10.1016/j.jbiomech.2004.05.042	39	3	4	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2019	14	1							e0211332	10.1371/journal.pone.0211332	http://dx.doi.org/10.1371/journal.pone.0211332			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HJ2YV	30682144	Green Published, gold, Green Submitted			2023-01-03	WOS:000457037500150
J	Schwimmer, JB; Ugalde-Nicalo, P; Welsh, JA; Angeles, JE; Cordero, M; Harlow, KE; Alazraki, A; Durelle, J; Knight-Scott, J; Newton, KP; Cleeton, R; Knott, C; Konomi, J; Middleton, MS; Travers, C; Sirlin, CB; Hernandez, A; Sekkarie, A; McCracken, C; Vos, MB				Schwimmer, Jeffrey B.; Ugalde-Nicalo, Patricia; Welsh, Jean A.; Angeles, Jorge E.; Cordero, Maria; Harlow, Kathryn E.; Alazraki, Adina; Durelle, Janis; Knight-Scott, Jack; Newton, Kimberly P.; Cleeton, Rebecca; Knott, Cynthia; Konomi, Juna; Middleton, Michael S.; Travers, Curtis; Sirlin, Claude B.; Hernandez, Albert; Sekkarie, Ahlia; McCracken, Courtney; Vos, Miriam B.			Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DE-NOVO LIPOGENESIS; PRACTICE GUIDELINE; CHILDREN; FRUCTOSE; ASSOCIATION; MANAGEMENT; STEATOSIS; DIAGNOSIS; FRACTION; ADULTS	IMPORTANCE Pediatric guidelines for the management of nonalcoholic fatty liver disease (NAFLD) recommend a healthy diet as treatment. Reduction of sugary foods and beverages is a plausible but unproven treatment. OBJECTIVE To determine the effects of a diet low in free sugars (those sugars added to foods and beverages and occurring naturally in fruit juices) in adolescent boys with NAFLD. DESIGN, SETTING, AND PARTICIPANTS An open-label, 8-week randomized clinical trial of adolescent boys aged 11 to 16 years with histologically diagnosed NAFLD and evidence of active disease (hepatic steatosis >10% and alanine aminotransferase level > 45 U/L) randomized 1: 1 to an intervention diet group or usual diet group at 2 US academic clinical research centers from August 2015 to July 2017; final date of follow-up was September 2017. INTERVENTIONS The intervention diet consisted of individualized menu planning and provision of study meals for the entire household to restrict free sugar intake to less than 3% of daily calories for 8 weeks. Twice-weekly telephone calls assessed diet adherence. Usual diet participants consumed their regular diet. MAIN OUTCOMES AND MEASURES The primary outcome was change in hepatic steatosis estimated by magnetic resonance imaging proton density fat fraction measurement between baseline and 8 weeks. The minimal clinically important difference was assumed to be 4%. There were 12 secondary outcomes, including change in alanine aminotransferase level and diet adherence. RESULTS Forty adolescent boys were randomly assigned to either the intervention diet group or the usual diet group (20 per group; mean [SD] age, 13.0 [1.9] years; most were Hispanic [95%]) and all completed the trial. The mean decrease in hepatic steatosis from baseline to week 8 was significantly greater for the intervention diet group (25% to 17%) vs the usual diet group (21% to 20%) and the adjusted week 8 mean difference was -6.23%(95% CI, -9.45% to -3.02%; P<.001). Of the 12 prespecified secondary outcomes, 7 were null and 5 were statistically significant including alanine aminotransferase level and diet adherence. The geometric mean decrease in alanine aminotransferase level from baseline to 8 weeks was significantly greater for the intervention diet group (103 U/L to 61 U/L) vs the usual diet group (82 U/L to 75 U/L) and the adjusted ratio of the geometric means at week 8 was 0.65 U/L (95% CI, 0.53 to 0.81 U/L; P<.001). Adherence to the diet was high in the intervention diet group (18 of 20 reported intake of <3% of calories from free sugar during the intervention). There were no adverse events related to participation in the study. CONCLUSIONS AND RELEVANCE In this study of adolescent boys with NAFLD, 8 weeks of provision of a diet low in free sugar content compared with usual diet resulted in significant improvement in hepatic steatosis. However, these findings should be considered preliminary and further research is required to assess long-term and clinical outcomes.	[Schwimmer, Jeffrey B.; Ugalde-Nicalo, Patricia; Angeles, Jorge E.; Harlow, Kathryn E.; Durelle, Janis; Newton, Kimberly P.] Univ Calif San Diego, Sch Med, Div Gastroenterol Hepatol & Nutr, Dept Pediat, La Jolla, CA 92093 USA; [Schwimmer, Jeffrey B.; Harlow, Kathryn E.; Newton, Kimberly P.] Rady Childrens Hosp San Diego, Dept Gastroenterol, San Diego, CA USA; [Welsh, Jean A.; Cordero, Maria; Cleeton, Rebecca; Konomi, Juna; Hernandez, Albert; Vos, Miriam B.] Emory Univ, Dept Pediat, Div Gastroenterol Hepatol & Nutr, Atlanta, GA 30322 USA; [Welsh, Jean A.; McCracken, Courtney; Vos, Miriam B.] Childrens Healthcare Atlanta, Atlanta, GA USA; [Welsh, Jean A.; Sekkarie, Ahlia; Vos, Miriam B.] Emory Univ, Nutr & Hlth Sci Program, Laney Grad Sch, Atlanta, GA 30322 USA; [Alazraki, Adina; Knight-Scott, Jack] Childrens Healthcare Atlanta, Dept Radiol, Atlanta, GA USA; [Knott, Cynthia] Univ Calif San Diego, Sch Med, Altman Clin & Translat Res Inst, La Jolla, CA 92093 USA; [Middleton, Michael S.; Sirlin, Claude B.] Univ Calif San Diego, Dept Radiol, Liver Imaging Grp, La Jolla, CA 92093 USA; [Travers, Curtis; McCracken, Courtney] Emory Univ, Dept Pediat, Pediat Biostat Core, Atlanta, GA 30322 USA	University of California System; University of California San Diego; Rady Childrens Hospital San Diego; Emory University; Children's Healthcare of Atlanta (CHOA); Emory University; Children's Healthcare of Atlanta (CHOA); University of California System; University of California San Diego; University of California System; University of California San Diego; Emory University	Vos, MB (corresponding author), Emory Univ, Dept Pediat, 1860 Haygood Dr, Atlanta, GA 30030 USA.	mvos@emory.edu	Sirlin, Claude/AAU-1376-2020	Sirlin, Claude/0000-0002-6639-9072; Alazraki, Adina/0000-0003-1094-282X; Schwimmer, Jeffrey/0000-0001-8538-2877	Nutrition Science Initiative; University of California, San Diego; Altman Clinical and Translational Research Institute; National Institutes of Health [UL1TR001442, UL1TR002378]; Children's Healthcare of Atlanta and Emory University's Children's Clinical and Translational Discovery Core; Children's Healthcare of Atlanta and Emory University Pediatric Biostatistics Core; Georgia Clinical and Translational Science Alliance; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002378, UL1TR001442] Funding Source: NIH RePORTER	Nutrition Science Initiative; University of California, San Diego(University of California System); Altman Clinical and Translational Research Institute; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Healthcare of Atlanta and Emory University's Children's Clinical and Translational Discovery Core; Children's Healthcare of Atlanta and Emory University Pediatric Biostatistics Core; Georgia Clinical and Translational Science Alliance; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This study was supported by foundational grant funding from the Nutrition Science Initiative (made possible by gifts from the Laura and John Arnold Foundation, Ambrose Monell Foundation, and individual donors); funding from the University of California, San Diego, Altman Clinical and Translational Research Institute; grants UL1TR001442 and UL1TR002378 from the National Institutes of Health; funding from the Children's Healthcare of Atlanta and Emory University's Children's Clinical and Translational Discovery Core; funding from the Children's Healthcare of Atlanta and Emory University Pediatric Biostatistics Core; and funding from the Georgia Clinical and Translational Science Alliance.	Anderson EL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140908; Arab JP, 2014, WORLD J GASTROENTERO, V20, P12182, DOI 10.3748/wjg.v20.i34.12182; Arsik I, 2018, CHILDREN-BASEL, V5, DOI 10.3390/children5060064; Beysen C, 2018, AM J PHYSIOL-ENDOC M, V315, pE126, DOI 10.1152/ajpendo.00470.2017; Brown RJ, 2010, INT J PEDIATR OBES, V5, P305, DOI 10.3109/17477160903497027; Brunt EM, 2011, HEPATOLOGY, V53, P810, DOI 10.1002/hep.24127; Carpenter J, 2007, DATA RANDOMIZED CONT; Chalasani N, 2012, GASTROENTEROLOGY, V142, P1592, DOI 10.1053/j.gastro.2012.04.001; Chiu S, 2018, CURR OPIN CLIN NUTR, V21, P277, DOI 10.1097/MCO.0000000000000469; Hedrick VE, 2018, NUTRIENTS, V10, DOI 10.3390/nu10010083; Jin R, 2014, NUTRIENTS, V6, P3187, DOI 10.3390/nu6083187; Lambert JE, 2014, GASTROENTEROLOGY, V146, P726, DOI 10.1053/j.gastro.2013.11.049; London School of Hygiene and Tropical Medicine, MISS DAT RAND CONTR; Loria P, 2010, DIGEST LIVER DIS, V42, P272, DOI 10.1016/j.dld.2010.01.021; Mackenzie T, 2006, ANN EPIDEMIOL, V16, P688, DOI 10.1016/j.annepidem.2005.11.009; McNaughton SA, 2008, DIABETES CARE, V31, P1343, DOI 10.2337/dc07-1946; Middleton MS, 2018, HEPATOLOGY, V67, P858, DOI 10.1002/hep.29596; Middleton MS, 2017, GASTROENTEROLOGY, V153, P753, DOI 10.1053/j.gastro.2017.06.005; Mueller NT, 2015, OBESITY, V23, P468, DOI 10.1002/oby.20950; Patel J, 2016, THER ADV GASTROENTER, V9, P692, DOI 10.1177/1756283X16656735; SAS Institute Inc, 2008, SAS STAT 9 2 US GUID; Schwimmer JB, 2005, PEDIATRICS, V115, pE561, DOI 10.1542/peds.2004-1832; Schwimmer JB, 2016, GASTROENTEROLOGY, V151, P1141, DOI 10.1053/j.gastro.2016.08.027; Schwimmer JB, 2015, HEPATOLOGY, V61, P1887, DOI 10.1002/hep.27666; Vos MB, 2017, CIRCULATION, V135, pE1017, DOI 10.1161/CIR.0000000000000439; Vos MB, 2017, J PEDIATR GASTR NUTR, V64, P319, DOI 10.1097/MPG.0000000000001482; Vos MB, 2013, HEPATOLOGY, V57, P2525, DOI 10.1002/hep.26299; Vuppalanchi R, 2014, CLIN GASTROENTEROL H, V12, P2121, DOI 10.1016/j.cgh.2014.05.010; Welsh JA, 2013, J PEDIATR-US, V162, P496, DOI 10.1016/j.jpeds.2012.08.043; World Health Organization, GUID SUG INT AD CHIL; Yokoo T, 2011, RADIOLOGY, V258, P749, DOI 10.1148/radiol.10100659	31	100	102	4	53	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	2019	321	3					256	265		10.1001/jama.2018.20579	http://dx.doi.org/10.1001/jama.2018.20579			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HI3JV	30667502	Green Published, Bronze			2023-01-03	WOS:000456347000017
J	Takahashi, YK; Stalnaker, TA; Marrero-Garcia, Y; Rada, RM; Schoenbaum, G				Takahashi, Yuji K.; Stalnaker, Thomas A.; Marrero-Garcia, Yasmin; Rada, Ray M.; Schoenbaum, Geoffrey			Expectancy-Related Changes in Dopaminergic Error Signals Are Impaired by Cocaine Self-Administration	NEURON			English	Article							LONG-TERM POTENTIATION; PREDICTION ERRORS; PREFRONTAL CORTEX; REWARD PREDICTION; DRUG-ADDICTION; INCENTIVE SENSITIZATION; AMPHETAMINE EXPOSURE; ORBITOFRONTAL CORTEX; MONETARY REWARD; NEURONS ENCODE	Addiction is a disorder of behavioral control and learning. While this may reflect pre-existing propensities, drug use also clearly contributes by causing changes in outcome processing in prefrontal and striatal regions. This altered processing is associated with behavioral deficits, including changes in learning. These areas provide critical input to midbrain dopamine neurons regarding expected outcomes, suggesting that effects on learning may result from changes in dopaminergic error signaling. Here, we show that dopamine neurons recorded in rats that had self-administered cocaine failed to suppress firing on omission of an expected reward and exhibited lower amplitude and imprecisely timed increases in firing to an unexpected reward. Learning also appeared to have less of an effect on rewardevoked and cue-evoked firing in the cocaine-experienced rats. Overall, the changes are consistent with reduced fidelity of input regarding the expected outcomes, such as their size, timing, and overall value, because of cocaine use.	[Takahashi, Yuji K.; Stalnaker, Thomas A.; Marrero-Garcia, Yasmin; Rada, Ray M.; Schoenbaum, Geoffrey] NIDA, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Schoenbaum, Geoffrey] Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA; [Schoenbaum, Geoffrey] Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA); University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine	Takahashi, YK; Schoenbaum, G (corresponding author), NIDA, Intramural Res Program, NIH, Baltimore, MD 21224 USA.; Schoenbaum, G (corresponding author), Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA.; Schoenbaum, G (corresponding author), Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.	yuji.takahashi@nih.gov; geoffrey.schoenbaum@nih.gov			Intramural Research Program at the National Institute on Drug Abuse; NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000587] Funding Source: NIH RePORTER	Intramural Research Program at the National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by the Intramural Research Program at the National Institute on Drug Abuse. The opinions expressed in this article are the authors' own and do not reflect the view of the NIH/DHHS.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; Argilli E, 2008, J NEUROSCI, V28, P9092, DOI 10.1523/JNEUROSCI.1001-08.2008; Asaad WF, 2011, J NEUROSCI, V31, P17772, DOI 10.1523/JNEUROSCI.3793-11.2011; Baker TE, 2011, ADDICT BIOL, V16, P458, DOI 10.1111/j.1369-1600.2010.00243.x; Borgland SL, 2004, J NEUROSCI, V24, P7482, DOI 10.1523/JNEUROSCI.1312-04.2004; Bromberg-Martin ES, 2010, J NEUROPHYSIOL, V104, P1068, DOI 10.1152/jn.00158.2010; Bromberg-Martin ES, 2009, NEURON, V63, P119, DOI 10.1016/j.neuron.2009.06.009; Bryden DW, 2011, J NEUROSCI, V31, P18266, DOI 10.1523/JNEUROSCI.4715-11.2011; Burke KA, 2006, LEARN MEMORY, V13, P416, DOI 10.1101/lm.216206; Burton AC, 2018, NEUROPSYCHOPHARMACOL, V43, P2350, DOI 10.1038/s41386-018-0058-0; Calu DJ, 2007, LEARN MEMORY, V14, P325, DOI 10.1101/lm.534807; Chang CY, 2017, CURR BIOL, V27, P3480, DOI 10.1016/j.cub.2017.09.049; Chang CY, 2016, NAT NEUROSCI, V19, P111, DOI 10.1038/nn.4191; Chen BT, 2013, NATURE, V496, P359, DOI 10.1038/nature12024; Cohen JY, 2012, NATURE, V482, P85, DOI 10.1038/nature10754; D'Ardenne K, 2008, SCIENCE, V319, P1264, DOI 10.1126/science.1150605; Ersche KD, 2016, SCIENCE, V352, P1468, DOI 10.1126/science.aaf3700; Fiorillo CD, 2008, NAT NEUROSCI, V11, P966, DOI 10.1038/nn.2159; George O, 2008, NEUROPSYCHOPHARMACOL, V33, P2474, DOI 10.1038/sj.npp.1301626; Goldstein RZ, 2007, AM J PSYCHIAT, V164, P43, DOI 10.1176/appi.ajp.164.1.43; Goldstein RZ, 2007, DRUG ALCOHOL DEPEN, V87, P233, DOI 10.1016/j.drugalcdep.2006.08.022; Goldstein RZ, 2009, TRENDS COGN SCI, V13, P372, DOI 10.1016/j.tics.2009.06.004; Groman SM, 2018, NEUROPSYCHOPHARMACOL, V43, P770, DOI 10.1038/npp.2017.159; Hollerman JR, 1998, NAT NEUROSCI, V1, P304, DOI 10.1038/1124; Horvitz JC, 1997, BRAIN RES, V759, P251, DOI 10.1016/S0006-8993(97)00265-5; Howard JD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04055-5; Hyman JM, 2017, NEURON, V95, P447, DOI 10.1016/j.neuron.2017.06.021; Jentsch JD, 2002, NEUROPSYCHOPHARMACOL, V26, P183, DOI 10.1016/S0893-133X(01)00355-4; Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483; Jo YS, 2016, CEREB CORTEX, V26, P4057, DOI 10.1093/cercor/bhv215; Jo YS, 2013, J NEUROSCI, V33, P8159, DOI 10.1523/JNEUROSCI.0118-13.2013; Joshua M, 2008, J NEUROSCI, V28, P11673, DOI 10.1523/JNEUROSCI.3839-08.2008; Keiflin R., 2017, BIORXIV, DOI [10.1101/232678, DOI 10.1101/232678]; Kobayashi S, 2008, J NEUROSCI, V28, P7837, DOI 10.1523/JNEUROSCI.1600-08.2008; Konova AB, 2012, EUR J NEUROSCI, V36, P2979, DOI 10.1111/j.1460-9568.2012.08211.x; Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442; Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0; Langdon AJ, 2018, CURR OPIN NEUROBIOL, V49, P1, DOI 10.1016/j.conb.2017.10.006; Lucantonio F, 2015, BIOL PSYCHIAT, V77, P912, DOI 10.1016/j.biopsych.2014.11.017; Lucantonio F, 2014, NAT NEUROSCI, V17, P1092, DOI 10.1038/nn.3763; Lucantonio F, 2014, NEUROPHARMACOLOGY, V76, P407, DOI 10.1016/j.neuropharm.2013.05.033; Lucantonio F, 2012, NAT NEUROSCI, V15, P358, DOI 10.1038/nn.3014; Matsumoto H, 2016, ELIFE, V5, DOI 10.7554/eLife.17328; Matsumoto M, 2007, NAT NEUROSCI, V10, P647, DOI 10.1038/nn1890; Matsumoto M, 2007, NATURE, V447, P1111, DOI 10.1038/nature05860; Matsumoto M, 2009, NATURE, V459, P837, DOI 10.1038/nature08028; Mendez IA, 2010, BEHAV NEUROSCI, V124, P470, DOI 10.1037/a0020458; MIRENOWICZ J, 1994, J NEUROPHYSIOL, V72, P1024, DOI 10.1152/jn.1994.72.2.1024; Moeller SJ, 2012, BRAIN, V135, P3481, DOI 10.1093/brain/aws252; Morris G, 2006, NAT NEUROSCI, V9, P1057, DOI 10.1038/nn1743; Nelson A, 2006, J NEUROSCI, V26, P3805, DOI 10.1523/JNEUROSCI.4305-05.2006; Oleson EB, 2012, J NEUROSCI, V32, P14804, DOI 10.1523/JNEUROSCI.3087-12.2012; Pan WX, 2005, J NEUROSCI, V25, P6235, DOI 10.1523/JNEUROSCI.1478-05.2005; Parvaz MA, 2015, J NEUROSCI, V35, P1872, DOI 10.1523/JNEUROSCI.2777-14.2015; Parvaz MA, 2012, PSYCHIAT RES-NEUROIM, V203, P75, DOI 10.1016/j.pscychresns.2012.01.001; Redish AD, 2004, SCIENCE, V306, P1944, DOI 10.1126/science.1102384; Rescorta RA, 1972, CLASSICAL CONDITION, P64; Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208; Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237; Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093; Roesch MR, 2007, NAT NEUROSCI, V10, P1615, DOI 10.1038/nn2013; Roesch MR, 2007, J NEUROSCI, V27, P245, DOI 10.1523/JNEUROSCI.4080-06.2007; Rutledge RB, 2009, J NEUROSCI, V29, P15104, DOI 10.1523/JNEUROSCI.3524-09.2009; Sadacca BF, 2016, ELIFE, V5, DOI 10.7554/eLife.13665; Schmitz JM, 2008, DRUG ALCOHOL DEPEN, V94, P142, DOI 10.1016/j.drugalcdep.2007.11.004; Schmitz JM, 2010, EXP CLIN PSYCHOPHARM, V18, P238, DOI 10.1037/a0019195; Schoenbaum G, 2005, CEREB CORTEX, V15, P1162, DOI 10.1093/cercor/bhh216; Schoenbaum G, 2008, BIOL PSYCHIAT, V63, P256, DOI 10.1016/j.biopsych.2007.06.003; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Sharnoff M, 2017, NASSER'S PEACE: EGYPT'S RESPONSE TO THE 1967 WAR WITH ISRAEL, P1, DOI 10.1038/nn.4538; Stalnaker TA, 2006, EUR J NEUROSCI, V24, P2643, DOI 10.1111/j.1460-9568.2006.05128.x; Steinberg EE, 2013, NAT NEUROSCI, V16, P966, DOI 10.1038/nn.3413; SUTTON RS, 1981, PSYCHOL REV, V88, P135, DOI 10.1037/0033-295X.88.2.135; Takahashi Y, 2008, FRONT NEUROSCI-SWITZ, V2, P86, DOI 10.3389/neuro.01.014.2008; Takahashi Y, 2007, FRONT INTEGR NEUROSC, V1, DOI 10.3389/neuro.07.011.2007; Takahashi YK, 2017, NEURON, V95, P1395, DOI 10.1016/j.neuron.2017.08.025; Takahashi YK, 2011, NAT NEUROSCI, V14, P1590, DOI 10.1038/nn.2957; Tanabe J, 2013, AM J PSYCHIAT, V170, P1356, DOI 10.1176/appi.ajp.2013.12091257; Terraneo A, 2016, EUR NEUROPSYCHOPHARM, V26, P37, DOI 10.1016/j.euroneuro.2015.11.011; Tian J, 2016, NEURON, V91, P1374, DOI 10.1016/j.neuron.2016.08.018; Tobler PN, 2003, J NEUROSCI, V23, P10402; Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077; Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318; Waelti P, 2001, NATURE, V412, P43, DOI 10.1038/35083500; Wied HM, 2013, PSYCHOPHARMACOLOGY, V229, P493, DOI 10.1007/s00213-013-3222-6; Willuhn I, 2014, NAT NEUROSCI, V17, P704, DOI 10.1038/nn.3694; Wunderlich K, 2012, NEURON, V75, P418, DOI 10.1016/j.neuron.2012.03.042; Wyvell CL, 2001, J NEUROSCI, V21, P7831, DOI 10.1523/JNEUROSCI.21-19-07831.2001	88	8	9	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	JAN 16	2019	101	2					294	+		10.1016/j.neuron.2018.11.025	http://dx.doi.org/10.1016/j.neuron.2018.11.025			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	HH6OT	30653935	Bronze, Green Accepted			2023-01-03	WOS:000455851600013
J	Cichowitz, C; Pellegrino, R; Motlhaoleng, K; Martinson, NA; Variava, E; Hoffmann, CJ				Cichowitz, Cody; Pellegrino, Rachael; Motlhaoleng, Katlego; Martinson, Neil A.; Variava, Ebrahim; Hoffmann, Christopher J.			Hospitalization and post-discharge care in South Africa: A critical event in the continuum of care	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; HEART-FAILURE; HIV; TRANSITION; MORTALITY; ADMISSION; METAANALYSIS; RETENTION; LINKAGE; TRENDS	Objectives The purpose of this prospective cohort study is to characterize the event of acute hospitalization for people living with and without HIV and describe its impact on the care continuum. This study describes care-seeking behavior prior to an index hospitalization, inpatient HIV testing and diagnosis, discharge instructions, and follow-up care for patients for patients being discharged from a single hospital in South Africa. Methods A convenience sample of adult patients was recruited from the medical wards of a tertiary care facility. Baseline information at the time of hospital admission, subsequent diagnoses, and discharge instructions were recorded. Participants were prospectively followed with phone calls for six months after hospital discharge. Descriptive analyses were performed. Results A total of 293 participants were enrolled in the study. Just under half (46%) of the participants were known to be living with HIV at the time of hospital admission. Most participants (97%) were given a referral for follow-up care; often that appointment was scheduled within two weeks of discharge (64%). Only 36% of participants returned to care within the first month, 50% returned after at least one month had elapsed, and 14% of participants did not return for any follow up. Conclusions Large discrepancies were found between the type of post-discharge follow-up care recommended by providers and what patients were able to achieve. The period of time following hospital discharge represents a key transition in care. Additional research is needed to characterize patients' risk following hospitalization and to develop patient-centered interventions.	[Cichowitz, Cody; Pellegrino, Rachael] Johns Hopkins Sch Med, Baltimore, MD USA; [Motlhaoleng, Katlego; Martinson, Neil A.; Variava, Ebrahim] Perinatal HIV Res Unit, Gauteng, South Africa; [Variava, Ebrahim] Tshepong Hosp, Dept Med, Klerksdorp, South Africa; [Hoffmann, Christopher J.] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Hoffmann, CJ (corresponding author), Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA.	choffmann@jhmi.edu	Variava, Ebrahim/AAO-5717-2020	Variava, Ebrahim/0000-0003-2888-789X; Cichowitz, Cody/0000-0002-9029-6508; Hoffmann, Christopher/0000-0002-9422-0519; Pellegrino, Rachael/0000-0002-7111-3040	National Institute of Allergy and Infectious Diseases (NIAID) [2U01-AI069924]; Johns Hopkins School of Medicine; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI094189] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Johns Hopkins School of Medicine(Johns Hopkins University); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was partially supported by National Institute of Allergy and Infectious Diseases (NIAID) grant 2U01-AI069924 and the Johns Hopkins School of Medicine; there was no additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akinkuotu A, 2011, INT J STD AIDS, V22, P465, DOI 10.1258/ijsa.2011.011021; Department of Health, 2013, S AFR ANT TREATM GUI; Fox MP, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002268; Fox MP, 2015, JAIDS-J ACQ IMM DEF, V69, P98, DOI 10.1097/QAI.0000000000000553; Govender K, 2017, PAN AFRICAN MED J, V26; Grimsrud A, 2017, J INT AIDS SOC, V20, P492; Holmes CB, 2015, CURR OPIN HIV AIDS, V10, P447, DOI 10.1097/COH.0000000000000194; Iwuji CC, 2017, PUBLIC HEALTH ACTION, V7, P243, DOI 10.5588/pha.17.0111; Jaffray J, 2018, THROMB RES, V163, P146, DOI 10.1016/j.thromres.2018.01.043; Kingery JR, 2017, INT J CARDIOL, V243, P311, DOI 10.1016/j.ijcard.2017.05.025; LaManna JB, 2016, DIABETES EDUCATOR, V42, P72, DOI 10.1177/0145721715620020; Lee JI, 2013, J HOSP MED, V8, P619, DOI 10.1002/jhm.2084; May CR, 2014, BMC HEALTH SERV RES, V14, P437; Meyer-Rath G, 2013, JAIDS-J ACQ IMM DEF, V62, P322, DOI 10.1097/QAI.0b013e31827e8785; Murphy RA, 2010, INT J TUBERC LUNG D, V14, P903; Nabayigga B, 2016, EUR J INTERN MED, V28, P25, DOI 10.1016/j.ejim.2015.12.011; Nabayigga B, 2016, EUR J INTERN MED, V27, P24, DOI 10.1016/j.ejim.2015.11.018; Neeman M, 2017, EUR J INTERN MED, V38, P30, DOI 10.1016/j.ejim.2016.11.004; Peck RN, 2016, J ACQ IMMUN DEF SYND, P1; Phillips A, 2015, NATURE, V528, pS68, DOI 10.1038/nature16046; Polinski JM, 2016, HEALTH AFFAIR, V35, P1222, DOI 10.1377/hlthaff.2015.0648; Reid A, 2005, JAIDS-J ACQ IMM DEF, V40, P53, DOI 10.1097/01.qai.0000174251.35398.72; Rosbach M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179916; Salas CM, 2015, AM J HEALTH-SYST PH, V72, pS43, DOI 10.2146/sp150012; Shah M, 2016, CLIN INFECT DIS, V62, P220, DOI 10.1093/cid/civ801; Sharma M, 2015, NATURE, V528, pS77, DOI 10.1038/nature16044; Tang N, 2014, J GEN INTERN MED, V29, P1513, DOI 10.1007/s11606-014-2942-6; Wajanga BM, 2014, INPATIENT MORTALITY, P1; Wandeler G, 2016, CURR OPIN HIV AIDS, V11, P492, DOI 10.1097/COH.0000000000000298; Yehia BR, 2013, AIDS, V27, P1529, DOI 10.1097/QAD.0b013e328360104e	30	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2018	13	12							e0208429	10.1371/journal.pone.0208429	http://dx.doi.org/10.1371/journal.pone.0208429			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE3IL	30543667	Green Published, gold, Green Submitted			2023-01-03	WOS:000453247500021
J	Akiyama, MJ; Norton, BL; Arnsten, JH; Agyemang, L; Heo, M; Litwin, AH				Akiyama, Matthew J.; Norton, Brianna L.; Arnsten, Julia H.; Agyemang, Linda; Heo, Moonseong; Litwin, Alain H.			Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy A Randomized Controlled Trial	ANNALS OF INTERNAL MEDICINE			English	Article							GENOTYPE 1; SOFOSBUVIR	Background: Many people who inject drugs (PWID) are denied treatment for hepatitis C virus (HCV) infection, even if they are receiving opioid agonist therapy (OAT). Research suggests that HCV in PWID may be treated effectively, but optimal models of care for promoting adherence and sustained virologic response (SVR) have not been evaluated in the direct-acting antiviral (DM) era. Objective: To determine whether directly observed therapy (DOT) and group treatment (GT) are more effective than self-administered individual treatment (SIT) in promoting adherence and achieving SVR among PWID receiving OAT. Design: Three-group, randomized controlled trial conducted from October 2013 to April 2017. (ClinicalTrials.gov: NCT01857245) Setting: Three OAT programs in Bronx, New York. Participants: Persons aged 18 years and older with genotype 1 HCV infection who were willing to receive HCV therapy on site in the OAT program. Of 190 persons screened, 158 were randomly assigned to a study group and 150 initiated treatment DOT (n = 51), GT (n = 48), and SIT (n = 51). Intervention: 2 intensive interventions (DOT and GT) and 1 control condition (SIT). Measurements: Primary: adherence, measured by using electronic blister packs. Secondary: HCV treatment completion and SVR 12 weeks after treatment completion. Results: Mean age was 51 years; 65% of participants had positive results on urine drug testing during the 6 months before treatment, and 75% reported ever injecting drugs. Overall adherence, estimated from mixed-effects models using the daily timeframe, was 78% (95% CI, 75% to 81%) and was greater among participants randomly assigned to DOT (86% [CI, 80% to 92%]) than those assigned to SIT (75% [CI, 70% to 81%]; difference, 11% [CI, 5% to 18%]; Bonferroni-corrected P = 0.001). No significant difference in adherence was observed between participants randomly assigned to GT (80% [CI, 74% to 86%]) and those assigned to SIT (difference, 4.7% [CI, -2% to 11%]; Bonferroni-corrected P = 0.29). The HCV treatment completion rate was 97%, with no differences among groups (P = 0.53). Overall SVR was 94% (CI, 89% to 97%); the SVR rate was 98% in the DOT group, 94% in the GT group, and 90% in the SIT group (P = 0.152). Limitation: These findings may not be generalizable to PWID not enrolled in OAT programs. Conclusion: All models of onsite HCV care delivered to PWID in OAT programs resulted in high SVR, despite ongoing drug use. Directly observed therapy was associated with greater adherence than SIT.	[Akiyama, Matthew J.; Norton, Brianna L.; Arnsten, Julia H.; Agyemang, Linda] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA; [Heo, Moonseong] Clemson Univ, Clemson, SC USA; [Litwin, Alain H.] Univ South Carolina, Sch Med Greenville, Columbia, SC 29208 USA; [Litwin, Alain H.] Prisma Hlth Upstate, Greenville, SC USA; [Litwin, Alain H.] Clemson Univ, Sch Hlth Res, Clemson, SC USA; [Litwin, Alain H.] Dept Med, 701 Grove Rd,5th Floor Support Tower, Greenville, SC 29605 USA; [Akiyama, Matthew J.; Norton, Brianna L.; Arnsten, Julia H.; Agyemang, Linda] 3300 Kossuth Ave, Bronx, NY 10467 USA; [Heo, Moonseong] 605 Grove Rd,Suite 205, Greenville, SC 29605 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Clemson University; University of South Carolina System; University of South Carolina Columbia; Greenville Health System; Clemson University	Litwin, AH (corresponding author), Dept Med, 701 Grove Rd,5th Floor Support Tower, Greenville, SC 29605 USA.	alain.litwin@prismahealth.org	Akiyama, Matthew Jiro/AAE-7230-2021	Heo, Moonseong/0000-0001-7711-1209; Akiyama, Matthew/0000-0003-4290-3083	National Institute on Drug Abuse [R01DA034086, K99DA043011];  [IN-337-1779]; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA034086, K99DA043011] Funding Source: NIH RePORTER	National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); ; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	By grants R01DA034086 and K99DA043011 from the National Institute on Drug Abuse. Gilead Sciences also provided support (grant IN-337-1779) for the research and supplied study medication, SOF/LDV.	Afdhal N, 2014, NEW ENGL J MED, V370, P1889, DOI 10.1056/NEJMoa1402454; Aghemo Alessio, 2017, Gastroenterology, V152, P1238, DOI 10.1053/j.gastro.2017.02.022; Akiyama MJ, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-2964-5; Alderks C.E., 2017, TRENDS USE METHADONE; American Association for the Study of Liver Disease; Infectious Dis- eases Society of America, 2017, HCV GUID REC TEST MA; Boyd J, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0159-9; Centers for Disease Control, HCV SURV REP 2015; Degenhardt L, 2017, LANCET GLOB HEALTH, V5, pE1192, DOI 10.1016/S2214-109X(17)30375-3; Information Mediary Corp, MED IC SMART LAB; Jacobson IM, 2011, NEW ENGL J MED, V364, P2405, DOI 10.1056/NEJMoa1012912; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lawitz E, 2013, NEW ENGL J MED, V368, P1878, DOI 10.1056/NEJMoa1214853; Litwin AH, 2011, INT C VIR HEP 2011 B; Osinusi A, 2013, JAMA-J AM MED ASSOC, V310, P804, DOI 10.1001/jama.2013.109309; Patel M, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx062; Strathdee SA, 2005, CLIN INFECT DIS, V40, pS304, DOI 10.1086/427445; van der Meer AJ, 2012, JAMA-J AM MED ASSOC, V308, P2584, DOI 10.1001/jama.2012.144878; Verna Elizabeth C, 2006, Clin Liver Dis, V10, P919; Zeuzem S, 2018, NEW ENGL J MED, V378, P354, DOI 10.1056/NEJMoa1702417; 2018, EXP THER MED, V15, P970, DOI DOI 10.3892/ETM.2017.5488; 2002, J GEN INTERN MED, V17, P377; 2017, INT J DRUG POLICY, V47, P202, DOI DOI 10.1016/J.DRUGPO.2017.05.025; 2017, J SUBST ABUSE TREAT, V75, P49, DOI DOI 10.1016/J.JSAT.2016.12.014; 2007, INT J DRUG POLICY, V18, P406, DOI DOI 10.1016/J.DRUGPO.2007.01.010; 1992, J SUBST ABUSE TREAT, V9, P199; 2005, J SUBST ABUSE TREAT, V28, P181, DOI DOI 10.1016/J.JSAT.2004.12.004; 2016, CLIN INFECT DIS, V63, P1405, DOI DOI 10.1093/CID/CIW580; 2014, JAMA INTERN MED, V174, P1974, DOI DOI 10.1001/JAMAINTERNMED.2014.5416; 2014, J ADDICT MED, V8, P249, DOI DOI 10.1097/ADM.0000000000000041; 2003, AM J MED, V114, P573, DOI DOI 10.1016/S0002-9343(03)00093-7; 2009, J VIRAL HEPATITUS, V16, P352, DOI DOI 10.1111/J.1365-2893.2009.01080.X; 2012, ANN INTERN MED, V156, P271, DOI DOI 10.7326/0003-4819-156-4-201202210-00004; 2004, ADDICTION, V99, P885, DOI DOI 10.1111/J.1360-0443.2004.00740.X; 2011, J HEPATOL, V55, P69, DOI DOI 10.1016/J.JHEP.2010.10.032; 2018, LIVER INT, V38, P1179, DOI DOI 10.1111/LIV.13650; 2018, HEPATOLOGY, V68, P827, DOI DOI 10.1002/HEP.29811; 2008, J COMMUNITY HLTH, V33, P126, DOI DOI 10.1007/S10900-007-9083-3; 2016, ANN INTERN MED, V165, P625, DOI DOI 10.7326/M16-0816; 2017, CLIN GASTROENTEROL H, V15, P421, DOI DOI 10.1016/J.CGH.2016.10.037; 2017, ANN INTERN MED, V167, P812, DOI DOI 10.7326/M17-1876; 2017, DRUG ALCOHOL DEPEN, V178, P106, DOI DOI 10.1016/J.DRUGALCDEP.2017.04.032; 2001, DRUG ALCOHOL DEPEND, V61, P211; 2010, J ADDICT MED, V4, P20, DOI DOI 10.1097/ADM.0B013E3181ADD3DE; 2003, J GEN INTERN MED, V18, P104; 2015, INT J DRUG POLICY, V26, P1014, DOI DOI 10.1016/J.DRUGPO.2015.08.008; 2012, J SUBST ABUSE TREAT, V43, P424, DOI DOI 10.1016/J.JSAT.2012.08.007; 2011, CLIN INFECT DIS, V53, P150, DOI DOI 10.1093/CID/CIR306; 2014, ADDICTION, V109, P2053, DOI DOI 10.1111/ADD.12682; 2018, LANCET GASTROENTEROL, V3, P153, DOI DOI 10.1016/S2468-1253(17)30404-1; 2008, ADDICTION, V103, P905, DOI DOI 10.1111/J.1360-0443.2008	50	74	74	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 7	2019	170	9					594	+		10.7326/M18-1715	http://dx.doi.org/10.7326/M18-1715			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW9KX	30959528	Green Accepted			2023-01-03	WOS:000467010800004
J	Walter-Nicolet, E; Courtois, E; Milesi, C; Ancel, PY; Beuchee, A; Tourneux, P; Benhammou, V; Carbajal, R; Durrmeyer, X				Walter-Nicolet, Elizabeth; Courtois, Emilie; Milesi, Christophe; Ancel, Pierre-Yves; Beuchee, Alain; Tourneux, Pierre; Benhammou, Valerie; Carbajal, Ricardo; Durrmeyer, Xavier			Premedication practices for delivery room intubations in premature infants in France: Results from the EPIPAGE 2 cohort study	PLOS ONE			English	Article							BLOOD-FLOW VELOCITY; TRACHEAL INTUBATION; ENDOTRACHEAL INTUBATION; NASOTRACHEAL INTUBATION; NEONATAL INTUBATIONS; CONTROLLED-TRIAL; PAIN MANAGEMENT; PRETERM INFANTS; PRESSURE; ATROPINE	Objectives To assess premedication practices before tracheal intubation of premature newborns in the delivery room (DR). Study design From the national population-based prospective EPIPAGE 2 cohort in 2011, we extracted all live born preterms intubated in the DR in level-3 centers, without subsequent circulatory resuscitation. Studied outcomes included the rate and type of premedication, infants' and maternities' characteristics and survival and major neonatal morbidities at discharge from hospital. Univariate and multivariate analysis were performed and a generalized estimating equation was used to identify factors associated with premedication use. Results Out of 1494 included neonates born in 65 maternities, 76 (5.1%) received a premedication. Midazolam was the most used drug accounting for 49% of the nine drugs regimens observed. Premedicated, as compared to non premedicated neonates, had a higher median [IQR] gestational age (30 [28-31] vs 28 [27-30] weeks, p<10(-3)), median birth weight (1391 [1037-1767] vs 1074 [840-1440] g, p<10(-3)) and median 1-minute Apgar score (8 [6-9] vs 6 [3-8], p<10(-3)). Using univariate analyses, premedication was significantly less frequent after maternal general anesthesia and during nighttime and survival without major morbidity was significantly higher among premedicated neonates (56/73 (81.4%) vs 870/1341 (69.3%), p = 0.028). Only 10 centers used premedication at least once and had characteristics comparable to the 55 other centers. In these 10 centers, premedication rates varied from 2% to 75%, and multivariate analysis identified gestational age and 1-minute Apgar score as independent factors associated with premedication use. Conclusion Premedication rate before tracheal intubation was only 5.1% in the DR of level-3 maternities for premature neonates below 34 weeks of gestation in France in 2011 and seemed to be mainly associated with centers' local policies.	[Walter-Nicolet, Elizabeth] St Joseph Hosp, Med & Neonatal Intens Care Unit, Paris, France; [Courtois, Emilie; Carbajal, Ricardo] Trousseau Hosp, AP HP, Paediat Emergency Dept, Paris, France; [Milesi, Christophe] Univ Hosp Arnaud de Villeneuve, Paediat & Neonatal Intens Care Unit, Montpellier, France; [Ancel, Pierre-Yves; Benhammou, Valerie; Carbajal, Ricardo; Durrmeyer, Xavier] INSERM, Sorbonne Paris Cite, U1153,Res Ctr, Epidemiol & Stat,Obstet Perinatal & Pediat Epidem, Paris, France; [Ancel, Pierre-Yves; Benhammou, Valerie; Carbajal, Ricardo] Paris Descartes Univ France, Paris, France; [Ancel, Pierre-Yves] Cochin Hotel Dieu Hosp, AP HP, URC CIC P1419, Paris, France; [Beuchee, Alain] Univ Hosp, Dept Pediat, Div Neonatol, Rennes, France; [Beuchee, Alain] Univ Hosp, Dept Pediat, CIC 1414, Rennes, France; [Beuchee, Alain] Univ Rennes 1, Inserm U1099, LTSI, Rennes, France; [Tourneux, Pierre] Univ Hosp, Neonatal & Paediat Intens Care Unit, Amiens, France; [Tourneux, Pierre] Picardie Jules Verne Univ, Med Univ, PeriTox UMI 01, Amiens, France; [Carbajal, Ricardo] Trousseau Hosp, AP HP, Paediat & Neonatal Intens Care Unit, Paris, France; [Durrmeyer, Xavier] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Neonatal Intens Care Unit, Creteil, France	Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Rennes; CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; Picardie Universites; Universite de Picardie Jules Verne (UPJV); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil	Walter-Nicolet, E (corresponding author), St Joseph Hosp, Med & Neonatal Intens Care Unit, Paris, France.	ewalter@hpsj.fr	Beuchée, Alain/AAB-7024-2021; Durrmeyer, Xavier/AAB-7519-2020; Tourneux, Pierre/AAX-3748-2021; christophe, Milési/AAO-6946-2021; Christophe, Milesi/AAN-7977-2021	Beuchée, Alain/0000-0003-0064-7085; Durrmeyer, Xavier/0000-0002-6303-7252; Walter-Nicolet, Elizabeth/0000-0002-5055-5501; Tourneux, Pierre/0000-0001-8069-4863; Christophe, Milesi/0000-0001-7714-5054	French Institute of Public Health Research/Institute of Public Health; French Health Ministry; National Institute of Health and Medical Research; National Institute of Cancer; National Solidarity Fund for Autonomy; National Research Agency through the French Equipex Program of Investments in the Future [ANR-11-EQPX-0038]; PremUp Foundation	French Institute of Public Health Research/Institute of Public Health; French Health Ministry; National Institute of Health and Medical Research(Institut National de la Sante et de la Recherche Medicale (Inserm)); National Institute of Cancer; National Solidarity Fund for Autonomy; National Research Agency through the French Equipex Program of Investments in the Future; PremUp Foundation	This study was supported by the French Institute of Public Health Research/Institute of Public Health and its partners the French Health Ministry, the National Institute of Health and Medical Research, the National Institute of Cancer, and the National Solidarity Fund for Autonomy; grant ANR-11-EQPX-0038 from the National Research Agency through the French Equipex Program of Investments in the Future; and the PremUp Foundation. The funders/sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.	Aly H, 2005, PEDIATRICS, V115, P1660, DOI 10.1542/peds.2004-2493; Ancel PY, 2015, JAMA PEDIATR, V169, P230, DOI 10.1001/jamapediatrics.2014.3351; Ancel PY, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-97; Attardi DM, 2000, ARCH DIS CHILD-FETAL, V83, pF161; Baleine J, 2014, EARLY HUM DEV, V90, P39, DOI 10.1016/j.earlhumdev.2013.10.007; Barois J, 2013, ACTA PAEDIATR, V102, pE534, DOI 10.1111/apa.12413; Barrington KJ, 2011, PAED CHILD HEALT-CAN, V16, P159, DOI 10.1093/pch/16.3.159; BELL MJ, 1978, ANN SURG, V187, P1, DOI 10.1097/00000658-197801000-00001; Bhutada A, 2000, ARCH DIS CHILD-FETAL, V82, pF34, DOI 10.1136/fn.82.1.F34; Bhutta AT, 2007, SEMIN PERINATOL, V31, P303, DOI 10.1053/j.semperi.2007.07.005; Bissuel M, 2013, ARCH PEDIATRIE, V20, P123, DOI 10.1016/j.arcped.2012.11.004; Carbajal R, 2007, SEMIN PERINATOL, V31, P309, DOI 10.1053/j.semperi.2007.07.006; Dong CX, 2013, TOXICOL LETT, V220, P53, DOI 10.1016/j.toxlet.2013.03.030; Durrmeyer X, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-120; Durrmeyer X, 2013, PEDIATR CRIT CARE ME, V14, pE169, DOI 10.1097/PCC.0b013e3182720616; Finer NN, 2010, NEW ENGL J MED, V362, P1970, DOI 10.1056/NEJMoa0911783; Foglia EE, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-0902; FRIESEN RH, 1987, ANESTH ANALG, V66, P874; Gole GA, 2005, ARCH OPHTHALMOL-CHIC, V123, P991, DOI 10.1001/archopht.123.7.991; Guedj R, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004086; Hatch LD, 2016, J PEDIATR-US, V168, P62, DOI 10.1016/j.jpeds.2015.09.077; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; KELLY MA, 1984, J PEDIATR-US, V105, P303, DOI 10.1016/S0022-3476(84)80137-7; Kumar P, 2010, PEDIATRICS, V125, P608, DOI 10.1542/peds.2009-2863; Le CN, 2014, J PERINATOL, V34, P458, DOI 10.1038/jp.2014.32; Leone TA, 2005, J PEDIATR-US, V146, P638, DOI 10.1016/j.jpeds.2005.01.029; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Mancuso A, 2010, J MATERN-FETAL NEO M, V23, P1114, DOI 10.3109/14767050903572158; Milesi C, 2018, ARCH DIS CHILD-FETAL, V103, pF221, DOI 10.1136/archdischild-2017-312808; Milesi C, 2010, ARCH DIS CHILD-FETAL, V95, pF263, DOI 10.1136/adc.2008.144758; MILLAR C, 1994, CAN J ANAESTH, V41, P281, DOI 10.1007/BF03009904; Muniraman HK, 2015, AM J PERINAT, V32, P821, DOI 10.1055/s-0034-1543987; Ng E, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002052.pub3; Norman E, 2011, J PEDIATR-US, V159, P893, DOI 10.1016/j.jpeds.2011.06.003; Oei J, 2002, J PAEDIATR CHILD H, V38, P146, DOI 10.1046/j.1440-1754.2002.00726.x; Olsen IE, 2010, PEDIATRICS, V125, pE214, DOI 10.1542/peds.2009-0913; Papoff P, 2008, PEDIATRICS, V121, P448, DOI 10.1542/peds.2007-3132; Porter FL, 1997, PEDIATRICS, V100, P626, DOI 10.1542/peds.100.4.626; Roberts KD, 2006, PEDIATRICS, V118, P1583, DOI 10.1542/peds.2006-0590; Sauer CW, 2016, J PEDIATR-US, V177, P108, DOI 10.1016/j.jpeds.2016.06.051; Simon L, 2004, CRIT CARE MED, V32, P565, DOI 10.1097/01.CCM.0000108883.58081.E3; Sweet DG, 2010, NEONATOLOGY, V97, P402, DOI 10.1159/000297773; van Alfen-van der Velden AAEM, 2006, BIOL NEONATE, V90, P197, DOI 10.1159/000093489; VANSTRAATEN HLM, 1992, DEV PHARMACOL THERAP, V19, P191, DOI 10.1159/000457484; Volpe JJ, 2009, LANCET NEUROL, V8, P110, DOI 10.1016/S1474-4422(08)70294-1; Walter-Nicolet E, 2007, ARCH PEDIATRIE, V14, P144, DOI 10.1016/j.arcped.2006.10.023; Walter-Nicolet E, 2014, ARCH PEDIATRIE, V21, P961, DOI 10.1016/j.arcped.2014.02.006; Welzing L, 2010, PEDIATR ANESTH, V20, P605, DOI 10.1111/j.1460-9592.2010.03330.x	48	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 10	2019	14	4							e0215150	10.1371/journal.pone.0215150	http://dx.doi.org/10.1371/journal.pone.0215150			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HS6PA	30970001	Green Published, Green Submitted, gold			2023-01-03	WOS:000463992600060
J	Ahuja, A; Ahuja, NK				Ahuja, Amisha; Ahuja, Nitin Kumar			Clinical Role-Play in Autonomous Sensory Meridian Response (ASMR) Videos Performance and Placebo in the Digital Era	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Ahuja, Amisha] Thomas Jefferson Univ, Dept Internal Med, Philadelphia, PA 19107 USA; [Ahuja, Nitin Kumar] Univ Penn, Div Gastroenterol, 3400 Civ Ctr Blvd,7 S Pavilion, Philadelphia, PA 19104 USA	Jefferson University; University of Pennsylvania	Ahuja, NK (corresponding author), Univ Penn, Div Gastroenterol, 3400 Civ Ctr Blvd,7 S Pavilion, Philadelphia, PA 19104 USA.	nitin.ahuja@uphs.upenn.edu						Barratt EL, 2017, PEERJ, V5, DOI 10.7717/peerj.3846; Beck J, ATLANTIC; Cash DK, 2018, PEERJ, V6, DOI 10.7717/peerj.5229; Kaptchuk TJ, 2015, NEW ENGL J MED, V373, P8, DOI 10.1056/NEJMp1504023; Kaptchuk TJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015591; Lochte BC, 2018, BIOIMPACTS, V8, P295, DOI 10.15171/bi.2018.32; Poerio GL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196645; Richard C., COMMUNICATION; Smith SD, 2017, SOC NEUROSCI-UK, V12, P361, DOI 10.1080/17470919.2016.1188851	9	4	4	1	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2019	321	14					1336	1337		10.1001/jama.2019.2302	http://dx.doi.org/10.1001/jama.2019.2302			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT5PG	30964507				2023-01-03	WOS:000464615200001
J	Lally, K				Lally, Kate			Having the Conversation I Encourage Others to Have	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Lally, Kate] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, 450 Brookline Ave,DA 2015, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute	Lally, K (corresponding author), Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, 450 Brookline Ave,DA 2015, Boston, MA 02215 USA.	kate_lally@DFCI.harvard.edu							0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2019	321	14					1353	1353		10.1001/jama.2019.3166	http://dx.doi.org/10.1001/jama.2019.3166			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT5PG	30964532				2023-01-03	WOS:000464615200011
J	Lee, JC; Chuang, KS; Liu, YWH; Lin, TY; Teng, YC; Wang, LW				Lee, Jia-Cheng; Chuang, Keh-Shih; Liu, Yen-Wan Hsueh; Lin, Tzung-Yi; Teng, Yi-Chiao; Wang, Ling-Wei			A comparison of dose distributions in gross tumor volume between boron neutron capture therapy alone and combined boron neutron capture therapy plus intensity modulation radiation therapy for head and neck cancer	PLOS ONE			English	Article							SIMULTANEOUS INTEGRATED BOOST; TREATMENT PLANNING SYSTEM; LOCALLY RECURRENT HEAD; DISEASE-CONTROL; BNCT; REIRRADIATION; VERIFICATION; EXPERIENCE; TRIAL; IMRT	Nine patients with recurrent head and neck (H&N) cancer received boron neutron capture therapy (BNCT) in one fraction at the Tsing-Hua Open pool reactor (THOR) utilizing the THORplan treatment planning system (TPS). The aims of the present study were to evaluate the use of intensity modulated radiation therapy (IMRT) of 45 Gy in 20 fractions to compensate for the dose heterogeneity in gross tumor volume observed with single-fraction BNCT with mean prescription dose 19 Gy (w), and to evaluate planning quality indices of simulated BNCT+IMRT versus single-fraction BNCT alone. All IMRT plans were generated using the Eclipse TPS which employs the analytical anisotropic algorithm. The conformity index for the gross tumor volume (GTV) was better for the BNCT+IMRT plan than for the BNCT-alone plan (p= 0.003). In addition, the BNCT+IMRT plan provided significantly better homogeneity in the GTV (p = 0.03). The cold spots in inhomogeneous dose distribution in the BNCT plan may be a key factor for H&N cancer recurrence. Our results suggest that single-fraction BNCT combined with compensated multi-fraction IMRT improves treatment homogeneity and conformity than single-fraction BNCT alone, especially for tumor volumes >100 cm(3), and possibly increases local tumor control.	[Lee, Jia-Cheng; Wang, Ling-Wei] Taipei Vet Gen Hosp, Dept Oncol, Taipei, Taiwan; [Lee, Jia-Cheng; Chuang, Keh-Shih] Natl Tsing Hua Univ, Dept Biomed Engn & Environm Sci, Hsinchu, Taiwan; [Liu, Yen-Wan Hsueh; Lin, Tzung-Yi; Teng, Yi-Chiao] Natl Tsing Hua Univ, Inst Nucl Engn & Sci, Hsinchu, Taiwan; [Wang, Ling-Wei] Natl Yang Ming Univ, Taipei, Taiwan	Taipei Veterans General Hospital; National Tsing Hua University; National Tsing Hua University; National Yang Ming Chiao Tung University	Wang, LW (corresponding author), Taipei Vet Gen Hosp, Dept Oncol, Taipei, Taiwan.; Wang, LW (corresponding author), Natl Yang Ming Univ, Taipei, Taiwan.	lwwang@vghtpe.gov.tw			Taipei Veterans General Hospital [V106A-016]	Taipei Veterans General Hospital(Taipei Veterans General Hospital)	The first authors are grateful for financial support provided by grants obtained from Taipei Veterans General Hospital (No: V106A-016, https://www.vghtpe.gov.tw/Index.action).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahlawat P, 2017, REP PRACT ONCOL RADI, V22, P331, DOI 10.1016/j.rpor.2017.05.001; Aly MMOM, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0452-2; Coderre JA, 1999, RADIAT RES, V151, P1, DOI 10.2307/3579742; Department of Health, 2014, TAIW CANC REG ANN RE; Dykstra C, 1996, RADIOTHER ONCOL, V41, P281, DOI 10.1016/S0167-8140(96)01847-6; Fogliata A, 2003, RADIOTHER ONCOL, V69, P267, DOI 10.1016/j.radonc.2003.10.003; ICRU, 1999, 50 ICRU, P62; ICRU I, 1993, 50 ICRU I; Kankaanranta L, 2007, INT J RADIAT ONCOL, V69, P475, DOI 10.1016/j.ijrobp.2007.03.039; Kawabata S, 2011, APPL RADIAT ISOTOPES, V69, P1796, DOI 10.1016/j.apradiso.2011.03.014; KONIJNENBERG MW, 1995, RADIAT RES, V142, P327, DOI 10.2307/3579142; Li HS, 2009, APPL RADIAT ISOTOPES, V67, pS122, DOI 10.1016/j.apradiso.2009.03.029; Lin T.L., 2004, THESIS; Lin TY, 2011, APPL RADIAT ISOTOPES, V69, P1878, DOI 10.1016/j.apradiso.2011.03.025; Liu YWH, 2015, APPL RADIAT ISOTOPES, V106, P121, DOI 10.1016/j.apradiso.2015.08.002; Margalit DN, 2016, ORAL ONCOL, V61, P19, DOI 10.1016/j.oraloncology.2016.07.012; Morgan-Fletcher S, 2001, 62 ICRU, pix+52; SHAW E, 1993, INT J RADIAT ONCOL, V27, P1231, DOI 10.1016/0360-3016(93)90548-A; Sulman EP, 2009, INT J RADIAT ONCOL, V73, P399, DOI 10.1016/j.ijrobp.2008.04.021; Suzuki M, 2006, INT J RADIAT ONCOL, P66; Wang LW, 2011, APPL RADIAT ISOTOPES, V69, P1803, DOI [10.1016/j.apradiso.2011.03.,008, 10.1016/j.apradiso.2011.03.008]; Wang LW, 2016, INT J RADIAT ONCOL, V95, P396, DOI 10.1016/j.ijrobp.2016.02.028; Wang LW, 2014, APPL RADIAT ISOTOPES, V88, P23, DOI 10.1016/j.apradiso.2013.11.134; Yu HT, 2011, APPL RADIAT ISOTOPES, V69, P1907, DOI 10.1016/j.apradiso.2011.02.041	24	5	5	2	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2019	14	4							e0210626	10.1371/journal.pone.0210626	http://dx.doi.org/10.1371/journal.pone.0210626			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR7EH	30947267	Green Submitted, gold, Green Published			2023-01-03	WOS:000463314500007
J	Valente, D; Palama, A; Malsert, J; Bolens, G; Gentaz, E				Valente, Dannyelle; Palama, Amaya; Malsert, Jennifer; Bolens, Guillemette; Gentaz, Edouard			Adults' visual recognition of actions simulations by finger gestures (ASFGs) produced by sighted and blind individuals	PLOS ONE			English	Article							PICTURE; CHILDREN	The present study examines the visual recognition of action simulations by finger gestures (ASFGs) produced by sighted and blind individuals. In ASFGs, fingers simulate legs to represent actions such as jumping, spinning, climbing, etc. The question is to determine whether the common motor experience of one's own body is sufficient to produce adequate ASFGs or whether the possibility to see gestures from others are also necessary to do it. Three experiments were carried out to address this question. Experiment 1 examined in 74 sighted adults the recognition of 18 types of ASFGs produced by 20 blindfolded sighted adults. Results showed that rates of correct recognition were globally very high, but varied with the type of ASFG. Experiment 2 studied in 91 other sighted adults the recognition of ASFGs produced by 10 early blind and 7 late blind adults. Results also showed a high level of recognition with a similar order of recognizability by type of ASFG. However, ASFGs produced by early blind individuals were more poorly recognized than those produced by late blind individuals. In order to match data of recognition obtained with the form that gestures are produced by individuals, two independant judges evaluated prototypical and atypical attributes of ASFG produced by blindfolded sighted, early blind and late blind individuals in Experiment 3. Results revealed the occurrence of more atypical attributes in ASFG produced by blind individuals: their ASFGs transpose more body movements from a characterviewpoint in less agreement with visual rules. The practical interest of the study relates to the relevance of including ASFGs as a new exploratory procedure in tactile devices which are more apt to convey action concepts to blind users/readers.	[Valente, Dannyelle; Palama, Amaya; Malsert, Jennifer; Gentaz, Edouard] Univ Geneva, Fac Psychol & Educ Sci, Geneva, Switzerland; [Valente, Dannyelle] Univ Lumiere Lyon, Dept Dev Psychol, Bron, France; [Bolens, Guillemette] Univ Geneva, Fac Humanities, Geneva, Switzerland	University of Geneva; Universite Lyon 2; University of Geneva	Valente, D (corresponding author), Univ Geneva, Fac Psychol & Educ Sci, Geneva, Switzerland.; Valente, D (corresponding author), Univ Lumiere Lyon, Dept Dev Psychol, Bron, France.	dannyelle.valente@univ-lyon2.fr		Palama, Amaya/0000-0002-9251-0520; Gentaz, Edouard/0000-0003-0574-5557; Valente, Dannyelle/0000-0003-2686-4379	Swiss National Science Foundation - SNF [100019_162688]	Swiss National Science Foundation - SNF(Swiss National Science Foundation (SNSF))	This study was supported by Swiss National Science Foundation - SNF (CH), http://www.snf.ch, research grant 100019_162688, awarded by Pr. Edouard Gentaz. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bara F, J VISUAL IMPAIRMENT; Barsalou LW, 2008, ANNU REV PSYCHOL, V59, P617, DOI 10.1146/annurev.psych.59.103006.093639; Barsalou LW, 2010, TOP COGN SCI, V2, P716, DOI 10.1111/j.1756-8765.2010.01115.x; BLASS T, 1974, PERCEPT MOTOR SKILL, V39, P279, DOI 10.2466/pms.1974.39.1.279; Bolens G., 2012, STYLE GESTURES EMBOD; Cuxac, 2000, LANGUE SIGNES FRANCA; Frame MJ, 2000, J VISUAL IMPAIR BLIN, V94, P155, DOI 10.1177/0145482X0009400304; Hainselin M., 2013, REV NEUROPSYCHOL, V5, P129, DOI DOI 10.3917/RNE.052.0129; HELLER MA, 1989, PERCEPTION, V18, P379, DOI 10.1068/p180379; Heller MA, 2014, PSYCHOL TOUCH BLINDN; Hostetter AB, 2008, PSYCHON B REV, V15, P495, DOI 10.3758/PBR.15.3.495; Howell D.C., 2010, STAT METHODS PSYCHOL, V7; Iverson JM, 1997, DEV PSYCHOL, V33, P453, DOI 10.1037/0012-1649.33.3.453; Iverson JM, 2001, DEVELOPMENTAL SCI, V4, P416, DOI 10.1111/1467-7687.00183; Iverson JM, 2000, J NONVERBAL BEHAV, V24, P105, DOI 10.1023/A:1006605912965; Kendon A., 2004, GESTURE VISIBLE ACTI, DOI DOI 10.1017/CBO9780511807572; KLATZKY RL, 1993, PERCEPT PSYCHOPHYS, V54, P170, DOI 10.3758/BF03211752; LEDERMAN SJ, 1990, PERCEPT PSYCHOPHYS, V47, P54, DOI 10.3758/BF03208164; Madan CR, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00507; McNeill D, 2016, WHY WE GESTURE: THE SURPRISING ROLE OF HAND MOVEMENTS IN COMMUNICATION, P1, DOI 10.1017/CBO9781316480526; McNeill D, 1992, MIND WHAT GESTURES R; ROSCH E, 1975, COGNITIVE PSYCHOL, V7, P573, DOI 10.1016/0010-0285(75)90024-9; Sharkey WF, 2000, J VISUAL IMPAIR BLIN, V94, P549, DOI 10.1177/0145482X0009400902; Theurel A, 2013, J EXP PSYCHOL-APPL, V19, P233, DOI 10.1037/a0034255; Theurel A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040251; Thompson LJ, 2006, EUR PSYCHOL, V11, P110, DOI 10.1027/1016-9040.11.2.110; Valente D, J EXPT PSYCHOL UNPUB; Valente D, RECONNAISSANCE ILLUS; Wilson M, 2002, PSYCHON B REV, V9, P625, DOI 10.3758/BF03196322	29	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2019	14	3							e0214371	10.1371/journal.pone.0214371	http://dx.doi.org/10.1371/journal.pone.0214371			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HQ7IR	30921397	Green Published, gold, Green Submitted			2023-01-03	WOS:000462594000061
J	Mouhid, L; de Cedron, MG; Garcia-Carrascosa, E; Reglero, G; Fornari, T; de Molina, AR				Mouhid, Lamia; Gomez de Cedron, Marta; Garcia-Carrascosa, Elena; Reglero, Guillermo; Fornari, Tiziana; Ramirez de Molina, Ana			Yarrow supercritical extract exerts antitumoral properties by targeting lipid metabolism in pancreatic cancer	PLOS ONE			English	Article							FATTY-ACID SYNTHASE; ELEMENT-BINDING PROTEIN-1; ENDOMETRIAL TUMOR-GROWTH; GENE-EXPRESSION; POOR-PROGNOSIS; CELL-PROLIFERATION; SUPPRESSOR CDC73; NATURAL-PRODUCTS; HLA-G; TRANSCRIPTION	Metabolic reprogramming is considered a hallmark of cancer. Currently, the altered lipid metabolism in cancer is a topic of interest due to the prominent role of lipids regulating the progression of various types of tumors. Lipids and lipid-derived molecules have been shown to activate growth regulatory pathways and to promote malignancy in pancreatic cancer. In a previous work, we have described the antitumoral properties of Yarrow (Achillea Millefolium) CO2 supercritical extract (Yarrow SFE) in pancreatic cancer. Herein, we aim to investigate the underlaying molecular mechanisms by which Yarrow SFE induces cytotoxicity in pancreatic cancer cells. Yarrow SFE downregulates SREBF1 and downstream molecular targets of this transcription factor, such as fatty acid synthase (FASN) and stearoyl-CoA desaturase (SCD). Importantly, we demonstrate the in vivo effect of Yarrow SFE diminishing the tumor growth in a xenograft mouse model of pancreatic cancer. Our data suggest that Yarrow SFE can be proposed as a complementary adjuvant or nutritional supplement in pancreatic cancer therapy.	[Mouhid, Lamia; Gomez de Cedron, Marta; Garcia-Carrascosa, Elena; Reglero, Guillermo; Ramirez de Molina, Ana] CEI UAM CSIC, IMDEA Food Inst, Mol Oncol & Nutr Genom Canc, Madrid, Spain; [Reglero, Guillermo; Fornari, Tiziana] CEI UAM CSIC, Inst Food Sci Res CIAL, Prod & Characterizat Novel Foods Dept, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UAM - Instituto de Investigacion en Ciencias de la Alimentacion (CIAL)	de Cedron, MG; de Molina, AR (corresponding author), CEI UAM CSIC, IMDEA Food Inst, Mol Oncol & Nutr Genom Canc, Madrid, Spain.	marta.gomezdecedro@imdea.org; ana.ramirez@imdea.org	de Molina, Ana Ramirez/AAA-3848-2019; Reglero, Guillermo/K-6658-2014; de Cedrón, Marta Gómez/M-7764-2014	Reglero, Guillermo/0000-0002-7730-3486; de Cedrón, Marta Gómez/0000-0002-0894-970X	Ministerio de Economia y Competitividad del Gobierno de Espana (MINECO, Plan Nacional I+D+i ) [AGL2013-48943-C2, AGL2016-76736-C3]; Gobierno regional de la Comunidad de Madrid (ALIBIRD-CM) [P2013/ABI-2728]; EU Structural Funds	Ministerio de Economia y Competitividad del Gobierno de Espana (MINECO, Plan Nacional I+D+i ); Gobierno regional de la Comunidad de Madrid (ALIBIRD-CM); EU Structural Funds	This work was supported by Ministerio de Economia y Competitividad del Gobierno de Espana (MINECO, Plan Nacional I+D+i AGL2013-48943-C2 and AGL2016-76736-C3), Gobierno regional de la Comunidad de Madrid (P2013/ABI-2728, ALIBIRD-CM) and EU Structural Funds. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Albrecht I, 2013, ANGIOGENESIS, V16, P795, DOI 10.1007/s10456-013-9356-7; Asanuma K, 2000, JPN J CANCER RES, V91, P1204, DOI 10.1111/j.1349-7006.2000.tb00906.x; Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Beloribi-Djefaflia S, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.49; Blum R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.38; Bowles TL, 2008, INT J CANCER, V123, P1950, DOI 10.1002/ijc.23723; Cao M, 2011, TISSUE ANTIGENS, V78, P120, DOI 10.1111/j.1399-0039.2011.01716.x; Choi KY, 2015, BIOCHEM BIOPH RES CO, V463, P673, DOI 10.1016/j.bbrc.2015.05.123; Choi WI, 2008, J BIOL CHEM, V283, P29341, DOI 10.1074/jbc.M802477200; Cragg GM, 2005, J ETHNOPHARMACOL, V100, P72, DOI 10.1016/j.jep.2005.05.011; Cruz PMR, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00119; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; Dang CV, 2010, CANCER RES, V70, P859, DOI 10.1158/0008-5472.CAN-09-3556; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Deisenroth C, 2011, J BIOL CHEM, V286, P28343, DOI 10.1074/jbc.M111.254227; Demoulin JB, 2004, J BIOL CHEM, V279, P35392, DOI 10.1074/jbc.M405924200; Dimberg J, 2011, ONCOL LETT, V2, P413, DOI 10.3892/ol.2011.280; Djidja MC, 2009, J PROTEOME RES, V8, P4876, DOI 10.1021/pr900522m; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Eberhard Y, 2011, ONCOTARGET, V2, P186; Eberle D, 2004, BIOCHIMIE, V86, P839, DOI 10.1016/j.biochi.2004.09.018; Falasca M, 2016, BBA-REV CANCER, V1865, P123, DOI 10.1016/j.bbcan.2016.01.001; Fan TWM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-41; Fleischmann M, 2000, BIOCHEM J, V349, P13, DOI 10.1042/bj3490013; Garcia-Risco MR, 2017, PLANT FOOD HUM NUTR, V72, P96, DOI 10.1007/s11130-016-0596-8; Gonzalez-Vallinas M, 2013, NUTR REV, V71, P585, DOI 10.1111/nure.12051; Gordon-Dseagu VL, 2017, EPIDEMIOL END RESULT; Griffiths B, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-3; Gunduz M, 2008, CANCER SCI, V99, P531, DOI 10.1111/j.1349-7006.2007.00708.x; Guo DL, 2014, CURR PHARM DESIGN, V20, P2619, DOI 10.2174/13816128113199990486; Hall WA, 2014, ONCOGENE, V33, P5450, DOI 10.1038/onc.2013.488; Hamada S, 2014, CELL SIGNAL, V26, P179, DOI 10.1016/j.cellsig.2013.11.003; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hansel Donna E, 2005, Int J Gastrointest Cancer, V35, P15, DOI 10.1385/IJGC:35:1:015; Harada T, 2008, ONCOGENE, V27, P1951, DOI 10.1038/sj.onc.1210832; Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Huang WC, 2012, MOL CANCER RES, V10, P133, DOI 10.1158/1541-7786.MCR-11-0206; Igal RA, 2010, CARCINOGENESIS, V31, P1509, DOI 10.1093/carcin/bgq131; Kammerer S, 2004, CANCER RES, V64, P8906, DOI 10.1158/0008-5472.CAN-04-1788; Kashimoto K, 2012, CANCER SCI, V103, P2021, DOI 10.1111/j.1349-7006.2012.02407.x; Kim RH, 2009, CANCER RES, V69, P700, DOI 10.1158/0008-5472.CAN-08-3157; Kirschner RD, 2010, CELL CYCLE, V9, P2177, DOI 10.4161/cc.9.11.11844; Kloth JN, 2008, J PATHOL, V215, P222, DOI 10.1002/path.2347; Kolla V, 2014, CANCER RES, V74, P652, DOI 10.1158/0008-5472.CAN-13-3056; Kotecha R, 2016, ONCOTARGET, V7, P52517, DOI 10.18632/oncotarget.9593; Kridel SJ, 2007, EXPERT OPIN INV DRUG, V16, P1817, DOI 10.1517/13543784.16.11.1817; Kuranami S, 2015, ANTICANCER RES, V35, P2410; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Li C, 2014, INT J MOL SCI, V15, P7124, DOI 10.3390/ijms15057124; Li J, 2016, ONCOGENE; Li JN, 2001, CANCER RES, V61, P1493; Li WH, 2012, CELL CYCLE, V11, P2348, DOI 10.4161/cc.20811; Lin L, 2014, ONCOL REP, V32, P2831, DOI 10.3892/or.2014.3521; Liu P, 2014, BMC PLANT BIOL, V14, DOI 10.1186/1471-2229-14-18; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Long XH, 2013, EXP THER MED, V5, P1048, DOI 10.3892/etm.2013.959; Lopez-Mateo I, 2012, CELL CYCLE, V11, P3887, DOI 10.4161/cc.22133; Ma LN, 2014, CANCER RES, V74, P1452, DOI 10.1158/0008-5472.CAN-13-2171; Macasek J, 2012, NUTR CANCER, V64, P946, DOI 10.1080/01635581.2012.716138; Maruya SI, 2005, ORAL ONCOL, V41, P580, DOI 10.1016/j.oraloncology.2005.01.002; MEDES G, 1953, CANCER RES, V13, P27; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Michaud DS, 2017, EPIDEMIOLOGY PANCREA, P471; Mouhid L, 2017, J ONCOL, V2017, DOI [10.1016/J.CELL.2011.02.013, DOI 10.1016/J.CELL.2011.02.013]; Mouhid L, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2322-6; Nazemalhosseini-Mojarad Ehsan, 2014, Gastroenterol Hepatol Bed Bench, V7, P79; Nie LY, 2013, ONCOL REP, V30, P1346, DOI 10.3892/or.2013.2575; Niu Zhe-Yu, 2015, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V37, P259, DOI 10.3881/j.issn.1000-503X.2015.03.002; Oh SY, 2003, J BIOL CHEM, V278, P28410, DOI 10.1074/jbc.M300553200; Ong CAJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju050; Ouyang L, 2014, CELL PROLIFERAT, V47, P506, DOI 10.1111/cpr.12143; Peck B, 2016, FEBS J, V283, P2767, DOI 10.1111/febs.13681; Phillips MM, 2013, CANCER RES TREAT, V45, P251, DOI 10.4143/crt.2013.45.4.251; Qiu FM, 2015, CANCER LETT, V364, P1, DOI 10.1016/j.canlet.2015.04.020; Rather MI, 2013, J BIOL CHEM, V288, P608, DOI 10.1074/jbc.M112.425736; Rozenblatt-Rosen O, 2009, P NATL ACAD SCI USA, V106, P755, DOI 10.1073/pnas.0812023106; Siqingaowa, 2017, BIOCHEM BIOPH RES CO, V488, P136, DOI 10.1016/j.bbrc.2017.05.023; Song L, 2016, TUMOR BIOL, V37, P2891, DOI 10.1007/s13277-015-4038-2; Subramani D, 2010, MOL CANCER, V9, P1, DOI [10.1186/1476-4598-9-1, DOI 10.1186/1476-4598-9-1]; Sullivan LB, 2016, NAT REV CANCER, V16, P680, DOI 10.1038/nrc.2016.85; Sun Y., 2015, INT J DISTRIB SENS N, V2015, P1; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Swierczynski J, 2014, WORLD J GASTROENTERO, V20, P2279, DOI 10.3748/wjg.v20.i9.2279; Tanaka M, 2016, CANCER RES, V76, P358, DOI 10.1158/0008-5472.CAN-15-1879; Turk CM, 2012, CANCER CELL INT, V12, DOI 10.1186/1475-2867-12-17; Uckun FM, 2011, BRIT J HAEMATOL, V153, P741, DOI 10.1111/j.1365-2141.2011.08671.x; Vargas T, 2015, ONCOTARGET, V6, P7348, DOI 10.18632/oncotarget.3130; Vazquez-Martin A, 2007, ONCOL REP, V18, P973; Walter K, 2009, CANCER EPIDEM BIOMAR, V18, P2380, DOI 10.1158/1055-9965.EPI-09-0144; Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003; Wu Xi, 2014, Advances in Biological Regulation, V54, P214, DOI 10.1016/j.jbior.2013.09.004; Xing Y, 2016, ONCOTARGET, V7, P30479, DOI 10.18632/oncotarget.8586; Xu YF, 2015, CURR MOL MED, V15, P360, DOI 10.2174/1566524015666150401102218; Yabushita S, 2013, PANCREAS, V42, P1034, DOI 10.1097/MPA.0b013e3182883624; Yan Wei-Hua, 2011, Endocrine Metabolic & Immune Disorders-Drug Targets, V11, P76; Yang Youyun, 2011, Int J Biochem Mol Biol, V2, P89; Yang ZG, 2015, INT J MED SCI, V12, P256, DOI 10.7150/ijms.10735; Yin T, 2011, INT J MOL SCI, V12, P1595, DOI 10.3390/ijms12031595; Yuan XP, 2015, MOL CELL BIOCHEM, V398, P55, DOI 10.1007/s11010-014-2204-2; Zecchin KG, 2011, LAB INVEST, V91, P232, DOI 10.1038/labinvest.2010.157; Zhang AH, 2013, EUR J MED CHEM, V63, P570, DOI 10.1016/j.ejmech.2012.12.062; Zhang ML, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-150; Zhang R, 2015, BMC VET RES, V11, P1, DOI [10.1186/S12917-014-0312-6, DOI 10.1186/S12917-014-0312-6]; Zhang YJ, 2015, MOLECULES, V20, P21138, DOI 10.3390/molecules201219753; Zhao R, 2012, LUNG CANCER, V76, P324, DOI 10.1016/j.lungcan.2011.11.019	108	9	9	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2019	14	3							e0214294	10.1371/journal.pone.0214294	http://dx.doi.org/10.1371/journal.pone.0214294			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ3IW	30913248	Green Submitted, Green Published, gold			2023-01-03	WOS:000462305600041
J	Vahabzadeh, M; Mohammadi, AB				Vahabzadeh, Maryam; Mohammadi, Ali Banagozar			Heroin body-packing and naloxone	LANCET			English	Editorial Material									[Vahabzadeh, Maryam] Mashhad Univ Med Sci, Med Toxicol Res Ctr, Mashhad, Iran; [Mohammadi, Ali Banagozar] Tabriz Univ Med Sci, Internal Med Dept, Fac Med, Tabriz, Iran	Mashhad University Medical Science; Tabriz University of Medical Science	Vahabzadeh, M (corresponding author), Mashhad Univ Med Sci, Med Toxicol Res Ctr, Mashhad, Iran.	vahabzadehm@mums.ac.ir	BanagozarMohammadi, Ali/C-3261-2017; Vahabzadeh, Maryam/I-1998-2019	BanagozarMohammadi, Ali/0000-0002-5255-5804; Vahabzadeh, Maryam/0000-0002-6234-1834					0	2	2	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 23	2019	393	10177					E35	E35		10.1016/S0140-6736(19)30502-1	http://dx.doi.org/10.1016/S0140-6736(19)30502-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HP9UL	30910307				2023-01-03	WOS:000462038400001
J	Kumbhare, D				Kumbhare, Dinesh			Review: Exercise rehabilitation improves outcomes by a small amount in chronic heart failure	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Kumbhare, Dinesh] Univ Toronto, Toronto, ON, Canada	University of Toronto	Kumbhare, D (corresponding author), Univ Toronto, Toronto, ON, Canada.			Kumbhare, Dinesh/0000-0003-3889-7557					0	0	0	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 19	2019	170	6					JC34	JC34		10.7326/ACPJ201903190-034	http://dx.doi.org/10.7326/ACPJ201903190-034			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP1ZR	30884504				2023-01-03	WOS:000461468300011
J	Maetens, A; Beernaert, K; Deliens, L; Gielen, B; Cohen, J				Maetens, Arno; Beernaert, Kim; Deliens, Luc; Gielen, Birgit; Cohen, Joachim			Who finds the road to palliative home care support? A nationwide analysis on the use of supportive measures for palliative home care using linked administrative databases	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; OLDER-ADULTS; LAST YEAR; LIFE; SERVICES; SURVIVAL; CANCER; DEATH; END; TRAJECTORIES	Background Many countries developed supportive measures for palliative home care, such as financial incentives or multidisciplinary palliative home care teams. For policy makers, it is important to evaluate the use of these national palliative home care supportive measures on a population level. Methods and findings Using routinely-collected data on all deaths in Belgium in 2012 (n = 107,847) we measured the use of four statutory supportive measures, specifically intended for patients who have obtained the legal palliative status, and three non-statutory supportive measures. Factors associated with uptake were analysed using multivariable logistic regression. Of all deaths of adult home-dwelling persons in Belgium (n = 87,007), 17.9 percent used at least one statutory supportive measure and 51.5 percent used at least one non-statutory supportive measure. In those who died of an illness indicative of palliative care needs 33.1 percent used at least one statutory supportive measure and 62.2 percent used at least one non-statutory supportive measure. Younger people and persons dying from cancer were more likely to use a statutory policy measure. Older people and persons dying from COPD were most likely to use a non-statutory policy measure. Women, non-single people, and those living in less urbanised areas were most likely to use any supportive measure. Conclusions Statutory supportive measures for palliative home care are underused, even in a subpopulation of persons with potential palliative care needs. Policy makers should stimulate an equitable uptake, and reducing the observed inequalities is an important focus for health care policy.	[Maetens, Arno; Beernaert, Kim; Deliens, Luc; Cohen, Joachim] Vrije Univ Brussel, Dept Family Med & Chron Care, End Of Life Care Res Grp, Brussels, Belgium; [Maetens, Arno; Beernaert, Kim; Deliens, Luc; Cohen, Joachim] Univ Ghent, Brussels, Belgium; [Deliens, Luc] Ghent Univ Hosp, Dept Publ Hlth & Primary Care, Ghent, Belgium; [Gielen, Birgit] Intermutualist Agcy IMA AIM, Brussels, Belgium	Vrije Universiteit Brussel; Ghent University; Ghent University; Ghent University Hospital	Maetens, A (corresponding author), Vrije Univ Brussel, Dept Family Med & Chron Care, End Of Life Care Res Grp, Brussels, Belgium.; Maetens, A (corresponding author), Univ Ghent, Brussels, Belgium.	arno.maetens@vub.be	Cohen, Joachim/B-6803-2008	Cohen, Joachim/0000-0002-7224-9476	Flemish government agency for Innovation by Science and Technology (Agentschap voor Innovatie door Wetenschap en Technologie; SBO IWT) [140009]	Flemish government agency for Innovation by Science and Technology (Agentschap voor Innovatie door Wetenschap en Technologie; SBO IWT)	This study is supported by a grant from the Flemish government agency for Innovation by Science and Technology (Agentschap voor Innovatie door Wetenschap en Technologie; SBO IWT nr. 140009).	Allen LA, 2008, JAMA-J AM MED ASSOC, V299, P2533, DOI 10.1001/jama.299.21.2533; Beccaro M, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-66; Beernaert K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137251; Brandt HE, 2006, J PAIN SYMPTOM MANAG, V32, P560, DOI 10.1016/j.jpainsymman.2006.06.006; Carpenter JG, 2017, GERIATR NURS, V38, P531, DOI 10.1016/j.gerinurse.2017.03.016; Clarke MG, 2009, EUR J INTERN MED, V20, P640, DOI 10.1016/j.ejim.2009.06.009; Cohen J., 2012, PUBLIC HLTH PERSPECT; Cohen J, 2010, HEALTH PLACE, V16, P784, DOI 10.1016/j.healthplace.2010.04.003; Coventry PA, 2005, AGE AGEING, V34, P218, DOI 10.1093/ageing/afi054; Davies E, 2004, PALLIATIVE CARE; Dempsey D, 2013, INT J PALLIAT NURS, V19, P227, DOI 10.12968/ijpn.2013.19.5.227; Emanuel EJ, 2002, ARCH INTERN MED, V162, P1722, DOI 10.1001/archinte.162.15.1722; European Commission, 2008, LONG TERM CAR EUR UN; Faes K, 2016, J PAIN SYMPTOM MANAG, V52, P588, DOI 10.1016/j.jpainsymman.2016.04.007; Field K, 2010, INTERN MED J, V40, P566, DOI 10.1111/j.1445-5994.2009.01984.x; Field MJ, 1997, APPROACHING DEATH IM; Gisquet E, 2016, J PUBLIC HEALTH-UK, V38, pE472, DOI 10.1093/pubmed/fdv167; Glare P, 2003, BRIT MED J, V327, P195, DOI 10.1136/bmj.327.7408.195; Gori C., 2015, LONG TERM CARE REFOR; Gysels M, 2008, J PAIN SYMPTOM MANAG, V36, P451, DOI 10.1016/j.jpainsymman.2007.11.008; Hanratty B, 2008, PALLIATIVE MED, V22, P248, DOI 10.1177/0269216307087140; Houttekier D, 2010, J PALLIAT MED, V13, P1461, DOI 10.1089/jpm.2010.0279; Jakobsson E, 2007, HEALTH POLICY, V82, P276, DOI 10.1016/j.healthpol.2006.10.003; Jutte DP, 2011, ANNU REV PUBL HEALTH, V32, P91, DOI 10.1146/annurev-publhealth-031210-100700; Keirse M, 2014, EVALUATIERAPPORT PAL; Koffman J, 2007, PALLIATIVE MED, V21, P145, DOI 10.1177/0269216306074639; Landers A, 2015, NPJ PRIM CARE RESP M, V25, DOI 10.1038/npjpcrm.2015.43; Lau F, 2007, J PALLIAT CARE, V23, P93, DOI 10.1177/082585970702300205; Maetens A, 2017, J PAIN SYMPTOM MANAG, V54, P523, DOI 10.1016/j.jpainsymman.2017.07.022; Maetens A, 2016, BMC PALLIAT CARE, V15, DOI 10.1186/s12904-016-0159-7; Moreels S, 2016, ZORG LEVENSEINDE VLA; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Murtagh FEM, 2004, CLIN MED, V4, P39, DOI 10.7861/clinmedicine.4-1-39; Pivodic L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084440; Rosenwax LK, 2005, PALLIATIVE MED, V19, P556, DOI 10.1191/0269216305pm1067oa; Solano JP, 2006, J PAIN SYMPTOM MANAG, V31, P58, DOI 10.1016/j.jpainsymman.2005.06.007; Stjernsward J, 2007, J PAIN SYMPTOM MANAG, V33, P486, DOI 10.1016/j.jpainsymman.2007.02.016; Teno J M, 2001, J Palliat Med, V4, P457, DOI 10.1089/109662101753381593; Walshe C, 2009, J PAIN SYMPTOM MANAG, V37, P884, DOI 10.1016/j.jpainsymman.2008.05.004; White N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161407; Willemse E, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1487-2; Woitha K, 2016, EUR J PUBLIC HEALTH, V26, P230, DOI 10.1093/eurpub/ckv201; World Health Organization, 2004, PALL CAR SOL FACTS	43	2	2	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2019	14	3							e0213731	10.1371/journal.pone.0213731	http://dx.doi.org/10.1371/journal.pone.0213731			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HO6JJ	30861057	gold, Green Published, Green Submitted			2023-01-03	WOS:000461035600056
J	Ekambi, GAE; Ebongue, CO; Penda, IC; Nga, EN; Mpondo, EM; Moukoko, CEE				Ekambi, Grace-Ange Elong; Ebongue, Cecile Okalla; Penda, Ida Calixte; Nga, Emmanuel Nnanga; Mpondo, Emmanuel Mpondo; Moukoko, Carole Else Eboumbou			Knowledge, practices and attitudes on antibiotics use in Cameroon: Self-medication and prescription survey among children, adolescents and adults in private pharmacies	PLOS ONE			English	Article							ANTIMICROBIAL RESISTANCE; UNIVERSITY-STUDENTS; PERCEPTIONS; COMMUNITY; BEHAVIOR; ANTIMALARIALS; BELIEFS	Benefits of antibiotics are threatened by the self-medication, people's lack of knowledge and inappropriate use of antibiotics, especially in developing countries. This study was designed to determine knowledge; attitudes and practices toward antibiotics use in an urban community, and evaluate the factors that are associated with antibiotic use. Between January and March 2015, a cross sectional and prospective study was conducted in all pharmacies within the Douala IV health district, Cameroon. Anonymous interviews including both open and closed ended questions were conducted in participants selected by convenience sampling Descriptive and logistic regression analysis were performed using StataSE11 software (version 11 SE) and R software (version 3.1.1) in data analysis. Overall 402 (33.7%) of 1,192 customers purchased antibiotics and of these, 47% bought antibiotics without a prescription. 60.7% of purchased antibiotics was for adult 'patients and around 60% of parents carried out self-medication on their children. The vast majority reported that all microbes can be treated with antibiotics (88.3%). The belief that antibiotics are appropriate for bacterial infections was more common among those with a higher level education (OR = 4.03, 95% CI: 1.89-8.57, p<0.0001) and among public/private servants (OR = 2.47, 95% CI: 1.21-5.08, p = 0.013). Physicians provide less explanations about antibiotics are and their potential side effects than the pharmacy auxiliaries (OR = 0.205, 95% CI = 0.09-0.46, p<0.0001), but more than pharmacists (OR = 3.692, 95% CI: 1.44-9.25, p = 0.005). Indications on antibiotics use were 7 times more given to customers with a prescription compared to those without a prescription (OR = 7.37, 95% CI = 2.13-25.43, p = 0.002). Adult male (OR = 2.32, 95% CI: 1.24-4.34, p = 0.009) and higher education (OR = 2.05, 95% CI: 1.08-3.89, p = 0.027) were significantly associated with self-medication. Misuse, little "practical knowledge" and high self-medication confirm the unsatisfactory prescription and dispensing practices of the antibiotics in our country. These results highlight the important of the development and implementation appropriate guidelines for the responsible use of antibiotics for health care providers and health education targeting community members themselves.	[Ekambi, Grace-Ange Elong; Nga, Emmanuel Nnanga; Mpondo, Emmanuel Mpondo] Univ Douala, Fac Med & Pharmaceut Sci, Dept Pharmaceut Sci, Douala, Cameroon; [Ebongue, Cecile Okalla; Moukoko, Carole Else Eboumbou] Univ Douala, Fac Med & Pharmaceut Sci, Dept Biol Sci, Douala, Cameroon; [Penda, Ida Calixte] Univ Douala, Fac Med & Pharmaceut Sci, Dept Clin Sci, Douala, Cameroon; [Moukoko, Carole Else Eboumbou] Ctr Pasteur Cameroon, Yaounde, Cameroon		Moukoko, CEE (corresponding author), Univ Douala, Fac Med & Pharmaceut Sci, Dept Biol Sci, Douala, Cameroon.; Moukoko, CEE (corresponding author), Ctr Pasteur Cameroon, Yaounde, Cameroon.	elsecarole@yahoo.fr		Penda, Calixte Ida/0000-0002-1070-2108	International Society for Health Research and Training (ISRT-Health), a local Lecturer network	International Society for Health Research and Training (ISRT-Health), a local Lecturer network	We are very grateful to the questionnaire respondents who agreed to participate in this study. We express our gratitude to the pharmacies for their support and cooperation during the survey. Thanks to Mr Eboumbou M., Dr Ayong L and T. Richter who reviewed and revised the manuscript for language editing. Statistical analysis and the interpretation of data were supported by International Society for Health Research and Training (ISRT-Health), a local Lecturer network.	Abbo LM, 2013, CLIN INFECT DIS, V57, P631, DOI 10.1093/cid/cit370; AduSarkodie YA, 1997, INT J STD AIDS, V8, P456, DOI 10.1258/0956462971920343; Ahmad A, 2014, ANN MED HEALTH SCI R, V4, P73, DOI 10.4103/2141-9248.138012; Akinlade K A, 2015, Afr J Med Med Sci, V44, P303; [Anonymous], 2012, EV THREAT ANT RES; Awad A, 2005, J PHARM PHARM SCI, V8, P326; Awad AI, 2007, ANN PHARMACOTHER, V41, P1249, DOI 10.1345/aph.1K068; Babatunde Kehinde M, 2016, Ghana Med J, V50, P233, DOI 10.4314/gmj.v50i4.6; Belkina T, 2014, J INFECT DEV COUNTR, V8, P424, DOI 10.3855/jidc.3866; Bianco A, 2013, J MED INTERNET RES, V15, P268, DOI 10.2196/jmir.2752; Bradley CP, 1996, BR J GEN PRACT, V46, P121; BRYANT BG, 1983, AM J HOSP PHARM, V40, P1669, DOI 10.1093/ajhp/40.10.1669; Cars O, 2001, LANCET, V357, P1851, DOI 10.1016/S0140-6736(00)04972-2; Centers for Disease Control and Prevention, 2015, NAT ACT PLAN COMB AN; Cochran WG, 1977, SAMPLING TECHNIQUES, V3rd; Cockburn J, 1997, BRIT MED J, V315, P520, DOI 10.1136/bmj.315.7107.520; Davey P, 2002, CLIN MICROBIOL INFEC, V8, P43, DOI 10.1046/j.1469-0691.8.s.2.6.x; Desaubiliaux AS, 2006, THESIS; Dyar OJ, 2013, MED MALADIES INFECT, V43, P423, DOI 10.1016/j.medmal.2013.07.010; Dyar OJ, 2014, J ANTIMICROB CHEMOTH, V69, P842, DOI 10.1093/jac/dkt440; El Zowalaty ME, 2016, INT J CLIN PHARM-NET, V38, P1261, DOI 10.1007/s11096-016-0362-x; Escourrou B., 2010, REV PRATICIEN, V60, P34; European Commission (EU). Communication from the Commission to the European Parliament and the Council, 2011, ACT PLAN RIS THREATS; Farah R, 2015, J INFECT PUBLIC HEAL, V8, P37, DOI 10.1016/j.jiph.2014.07.003; Gualano MR, 2015, PHARMACOEPIDEM DR S, V24, P2, DOI 10.1002/pds.3716; Harbarth S, 2005, EMERG INFECT DIS, V11, P794, DOI 10.3201/eid1106.050167; Haute autonte de Sante (HAS)/High Authority of Health, 2008, ANT THER STRAT PREV; Huang Y, 2013, BMC MED EDUC, V13, DOI 10.1186/1472-6920-13-163; Hughes Carmel M, 2003, Expert Opin Drug Saf, V2, P1; Hughes CM, 2001, DRUG SAFETY, V24, P1027, DOI 10.2165/00002018-200124140-00002; Hughes L, 2002, J CLIN PHARM THER, V27, P243, DOI 10.1046/j.1365-2710.2002.00416.x; Italia S, 2015, PHARMACOEPIDEM DR S, V24, P1133, DOI 10.1002/pds.3829; Jain S, 2011, IJPBA, V2, P831; James H, 2006, MED PRIN PRACT, V15, P270, DOI 10.1159/000092989; Jamison DT, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P1; Khan AKA, 2013, J CLIN DIAGN RES, V7, P1613, DOI 10.7860/JCDR/2013/6290.3230; Leekha S, 2011, MAYO CLIN PROC, V86, P156, DOI 10.4065/mcp.2010.0639; Masson E., 2008, CLIN THERAPEUTIC PHA; McNulty CAM, 2007, J ANTIMICROB CHEMOTH, V59, P727, DOI 10.1093/jac/dkl558; Minen MT, 2010, MICROB DRUG RESIST, V16, P285, DOI 10.1089/mdr.2010.0009; Mohanna Mabrook, 2010, Oman Med J, V25, P41, DOI 10.5001/omj.2010.10; Mumtaz Y, 2011, J LIAQUAT UNIV MED H, V10, P102; Napolitano F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084177; Njall Clotilde, 2013, Pan Afr Med J, V14, P140, DOI 10.11604/pamj.2013.14.140.1818; Nuermberger EL, 2004, CLIN INFECT DIS, V38, pS363, DOI 10.1086/382696; Ocan M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092323; Omolase CO, 2007, ANN IBADAN POSTGRADU, V5, P64, DOI [DOI 10.4314/AIPM.V5I2.64032, 10.4314/aipm.v5i2.64032]; Ouedraogo M, 1997, THESIS; Pileggi C, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/413912; Pottegard A, 2015, PEDIATR INFECT DIS J, V34, pE16, DOI 10.1097/INF.0000000000000519; Pouillard J., 2001, REPORT ADOPTED NATL; Scaioli G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122476; Shah SJ, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-74; Shehadeh M, 2012, SAUDI PHARM J, V20, P125, DOI 10.1016/j.jsps.2011.11.005; Suaifan GARY, 2012, AFR J PHARM PHARMACO, V6, P763, DOI 10.5897/AJPP12.080; Tandi TE, 2015, INT J EQUITY HEALTH, V14, DOI 10.1186/s12939-015-0172-0; Thriemer K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055495; Togoobaatar G, 2010, B WORLD HEALTH ORGAN, V88, P930, DOI 10.2471/BLT.10.079004; Viberg N, 2007, PHARM WORLD SCI, V29, P25, DOI 10.1007/s11096-005-4801-3; Viberg N, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-270; Wassa B., 2008, THESIS; World Health Organization, ROL PHARM SELF CAR S; World Health Organization, 2014, ANTIMICROBIAL RESIST; World Health Organization, 1998, ROL PHARM SELF CAR S; Wright EP, 2004, J ANTIMICROB CHEMOTH, V53, P550, DOI 10.1093/jac/dkh096; Wun YT, 2012, INT J CLIN PRACT, V66, P1197, DOI 10.1111/j.1742-1241.2012.03013.x; Yaba B., 2014, THESIS; Zucco R, 2018, INT J MED INFORM, V111, P131, DOI 10.1016/j.ijmedinf.2017.12.005	68	38	38	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2019	14	2							e0212875	10.1371/journal.pone.0212875	http://dx.doi.org/10.1371/journal.pone.0212875			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN7LS	30818373	gold, Green Submitted, Green Published			2023-01-03	WOS:000460371500050
J	Chen-Sankey, JC; Kong, G; Choi, K				Chen-Sankey, Julia Cen; Kong, Grace; Choi, Kelvin			Perceived ease of flavored e-cigarette use and e-cigarette use progression among youth never tobacco users	PLOS ONE			English	Article							HIGH-SCHOOL-STUDENTS; PRODUCT USE; UNITED-STATES; SUBSTANCE USE; ADOLESCENTS; MIDDLE; REASONS; PREFERENCES; EXPOSURE; SMOKING	Background There is an increased need to understand how e-cigarette flavors may contribute to e-cigarette uptake and use among youth. We examined the relationship between perceived ease of flavored e-cigarette use and e-cigarette use susceptibility and progression among a nationally representative sample of U.S. youth never tobacco users. Methods The wave 1 (2013-2014) and wave 2 (2014-2015) surveys of PATH Study were used. Youth never tobacco users (ages 12-17) who reported whether flavored e-cigarettes were easier to use than unflavored e-cigarettes at wave 1 (n = 6,983) were included in the study. Multivariable logistic regressions were used to examine the associations between perceived ease of using flavored e-cigarettes (wave 1) and e-cigarette use outcomes including e-cigarette use susceptibility (wave 1) and e-cigarette initiation and past-30-day use (wave 2). Results Overall, 21.2% of the sample perceived flavored e-cigarettes easier to use than unflavored e-cigarettes; and 28.9% of the sample were susceptible to using e-cigarettes at wave 1, and 7.5% and 2.0% initiated e-cigarettes and used e-cigarettes in the past 30 days at wave 2, respectively. Among those who perceived flavored e-cigarettes easier to use, 41.0% were susceptible to using e-cigarettes at wave 1, and 10.6% and 3.4% initiated and used e-cigarettes in the past 30 days at wave 2, respectively. Perceiving flavored e-cigarettes as easier to use than unflavored e-cigarettes at wave 1 was positively associated with e-cigarette use susceptibility at wave 1 (AOR = 1.43, CI = 1.21, 1.69), and e-cigarette initiation (AOR = 1.32, CI = 1.12, 1.67) and past-30-day use (AOR = 1.25, CI = 1.10, 2.47) at wave 2. Conclusions Perceiving flavored e-cigarettes as easier to use than unflavored e-cigarettes may lead to e-cigarette use progression among youth never tobacco users. Determining the factors (including e-cigarette marketing and specific e-cigarette flavors) that lead to perceived ease of using flavored e-cigarettes would inform efforts to prevent and curb youth e-cigarette use.	[Chen-Sankey, Julia Cen; Choi, Kelvin] Natl Inst Minor Hlth & Hlth Dispar, Div Intramural Res, Bethesda, MD 20892 USA; [Kong, Grace] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA	National Institutes of Health (NIH) - USA; NIH National Institute on Minority Health & Health Disparities (NIMHD); Yale University	Chen-Sankey, JC (corresponding author), Natl Inst Minor Hlth & Hlth Dispar, Div Intramural Res, Bethesda, MD 20892 USA.	Julia.Chen@nih.gov	Choi, Kelvin/U-1806-2019	Chen-Sankey, Julia/0000-0002-1797-5248	National Institute on Minority Health and Health Disparities Division of Intramural Research; Yale Tobacco Center of Regulatory Science [TCORS: P50DA036151]; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA036151] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [ZIAMD000006] Funding Source: NIH RePORTER	National Institute on Minority Health and Health Disparities Division of Intramural Research; Yale Tobacco Center of Regulatory Science; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	JCC and KC's efforts were supported by the National Institute on Minority Health and Health Disparities Division of Intramural Research. GK's efforts were partly supported by Yale Tobacco Center of Regulatory Science (TCORS: P50DA036151). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambrose BK, 2015, JAMA-J AM MED ASSOC, V314, P1871, DOI 10.1001/jama.2015.13802; Avena NM, 2008, NEUROSCI BIOBEHAV R, V32, P20, DOI 10.1016/j.neubiorev.2007.04.019; Bedoya L., 2008, GLOBAL APPRAISAL IND; Bold KW, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-1832; Centers for Disease Control and Prevention, 2014, SMOK CESS REP SURG G; Chen JC, 2018, TOB REGUL SCI, V4, P32, DOI 10.18001/TRS.4.4.4; Chen Julia Cen, 2017, Tob Regul Sci, V3, P68, DOI 10.18001/TRS.3.1.7; Conway KP, 2018, ADDICT BEHAV, V76, P208, DOI 10.1016/j.addbeh.2017.08.009; Cooper Maria, 2016, Tob Regul Sci, V2, P278; Courtemanche CJ, 2017, AM J PREV MED, V52, pE139, DOI 10.1016/j.amepre.2016.11.019; Dennis Matthew, 2006, AM INDIAN RHETORICS, P15; DESOR JA, 1987, PHYSIOL BEHAV, V39, P639, DOI 10.1016/0031-9384(87)90166-1; Fendrich M, 2003, DRUG ALCOHOL DEPEN, V70, P241, DOI 10.1016/S0376-8716(03)00010-3; Flay BR, 1999, NICOTINE TOB RES, P1; Garrison KA, 2018, DRUG ALCOHOL DEPEN, V186, P233, DOI 10.1016/j.drugalcdep.2018.01.026; Harrell M B, 2017, Prev Med Rep, V5, P33; Hoffman AC, 2016, TOB CONTROL, V25, pii32, DOI 10.1136/tobaccocontrol-2016-053192; Hoyle RH, 2002, PERS INDIV DIFFER, V32, P401, DOI 10.1016/S0191-8869(01)00032-0; Huh J, 2016, AM J PREV MED, V51, P513, DOI 10.1016/j.amepre.2016.04.004; Hyland A, 2017, TOB CONTROL, V26, P371, DOI 10.1136/tobaccocontrol-2016-052934; Jamal A, 2017, MMWR-MORBID MORTAL W, V66, P597, DOI 10.15585/mmwr.mm6623a1; Kim H, 2016, TOB CONTROL, V2016; Kong Grace, 2017, Tob Regul Sci, V3, P10, DOI 10.18001/TRS.3.1.2; Kong G, 2015, NICOTINE TOB RES, V17, P847, DOI 10.1093/ntr/ntu257; Krishnan-Sarin S, 2015, NICOTINE TOB RES, V17, P810, DOI 10.1093/ntr/ntu243; Kuiper NM, 2018, PREV CHRONIC DIS, V15, DOI 10.5888/pcd15.170576; Mantey DS, 2016, J ADOLESCENT HEALTH, V58, P686, DOI 10.1016/j.jadohealth.2016.03.003; Marynak K, 2018, MMWR-MORBID MORTAL W, V67, P294, DOI 10.15585/mmwr.mm6710a3; Morean ME, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0189015; National Center for Chronic Disease Prevention and Health Promotion, 2012, PREV TOB UYOUTH YO; Office of the Commissioner C for TP, PRESS ANN STAT FDA C; Pepper JK, 2017, J ADOLESCENT HEALTH, V61, P599, DOI 10.1016/j.jadohealth.2017.05.010; Pepper JK, 2014, INT J ENV RES PUB HE, V11, P10345, DOI 10.3390/ijerph111010345; Percy A, 2005, ADDICTION, V100, P189, DOI 10.1111/j.1360-0443.2004.00943.x; Pierce JP, 1996, HEALTH PSYCHOL, V15, P355, DOI 10.1037/0278-6133.15.5.355; Pisinger C, 2014, PREV MED, V69, P248, DOI 10.1016/j.ypmed.2014.10.009; ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P354, DOI 10.1177/109019817400200405; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Soneji S, 2017, JAMA PEDIATR, V171, P788, DOI 10.1001/jamapediatrics.2017.1488; Stanton CA, 2016, TOB CONTROL, V25, pii1, DOI 10.1136/tobaccocontrol-2016-053486; The U. S. Food and Drug Administration. Press Announcements- FDA, FTC TAKE ACTION CO M; Tsai J, 2018, MMWR-MORBID MORTAL W, V67, P196, DOI 10.15585/mmwr.mm6706a5; US Food and Drug Administration, 2018, STAT FDA COMM S GOTT; Villanti AC, 2017, AM J PREV MED, V53, P139, DOI 10.1016/j.amepre.2017.01.026; Warner KE, 2016, AM J PREV MED, V51, P179, DOI 10.1016/j.amepre.2015.12.004; Zhu SH, 2014, TOB CONTROL, V23, P3, DOI 10.1136/tobaccocontrol-2014-051670	46	20	21	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2019	14	2							e0212353	10.1371/journal.pone.0212353	http://dx.doi.org/10.1371/journal.pone.0212353			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HM9LQ	30811486	gold, Green Published, Green Submitted			2023-01-03	WOS:000459806400070
J	Canova, C; Anello, P; Amidei, CB; Parolin, V; Zanier, L; Simonato, L				Canova, Cristina; Anello, Paola; Amidei, Claudio Barbiellini; Parolin, Vito; Zanier, Loris; Simonato, Lorenzo			Use of healthcare services at the end of life in decedents compared to their surviving counterparts: A case-control study among adults born before 1946 in Friuli Venezia Giulia	PLOS ONE			English	Article							LONG-TERM-CARE; HOSPITAL UTILIZATION; OLDER-ADULTS; LAST YEARS; DEATH; POPULATION; CANCER; AGE; EXPENDITURE; TIME	Background There is a heterogeneous literature on healthcare utilization patterns at the end of life. The objective of this study is to examine the impact of closeness to death on the utilization of acute hospital-based healthcare services and some primary healthcare services and compare differences in gender, age groups and major causes of death disease specific mortality. Methods A matched case-control study, nested in a cohort of 411,812 subjects, linked to administrative databases was conducted. All subjects were residents in the Friuli Venezia Giulia Region (Italy), born before 1946, alive in January 2000 and were followed up to December 2014. Overall, 158,571 decedents/cases were matched by gender and year of birth to one control, alive at least one year after their matched case's death (index-date). Hospital admissions, emergency department visits, drug prescriptions, specialist visits and laboratory tests that occurred 365 days before death/index-date, have been evaluated. Odds Ratios (ORs) for healthcare utilization were estimated through conditional regression models, further adjusted for Charlson Comorbidity Index and stratified by gender, age groups and major causes of death. Results Decedents were significantly more likely of having at least one hospital admission (OR 7.0, 6.9-7.1), emergency department visit (OR 5.2, 5.1-5.3), drug prescription (OR 2.8, 2.7-2.9), specialist visit (OR 1.4, 1.4-1.4) and laboratory test (OR 2.7, 2.6-2.7) than their matched surviving counterparts. The ORs were generally lower in the oldest age group (95+) than in the youngest (55-74). Healthcare utilization did not vary by sex, but was higher in subjects who died of cancer. Conclusion Closeness to death appeared to be strongly associated with healthcare utilization in adult/elderly subjects. The risk seems to be greater among younger age groups than older ones, especially for acute based services. Reducing acute healthcare at the EOL represents an important issue to improve the quality of life in proximity to death.	[Canova, Cristina; Anello, Paola; Amidei, Claudio Barbiellini; Parolin, Vito; Simonato, Lorenzo] Univ Padua, Dept Cardiothoracovasc Sci & Publ Hlth, Padua, Italy; [Zanier, Loris] Friuli Venezia Giulia Reg, Hlth Directorate, Epidemiol Serv, Udine, Italy	University of Padua	Canova, C (corresponding author), Univ Padua, Dept Cardiothoracovasc Sci & Publ Hlth, Padua, Italy.	cristina.canova@unipd.it		Barbiellini Amidei, Claudio/0000-0002-7792-3781				Atella V, 2014, SOC SCI MED, V114, P10, DOI 10.1016/j.socscimed.2014.05.029; Bahler C, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0698-2; Bekelman JE, 2016, JAMA-J AM MED ASSOC, V315, P272, DOI 10.1001/jama.2015.18603; Bentur N, 2014, AM J HOSP PALLIAT ME, V31, P723, DOI 10.1177/1049909113499604; Bird Chloe E, 2002, J Palliat Med, V5, P705, DOI 10.1089/109662102320880525; Brameld KJ, 1998, J EPIDEMIOL COMMUN H, V52, P740, DOI 10.1136/jech.52.11.740; Brockmann H, 2002, SOC SCI MED, V55, P593, DOI 10.1016/S0277-9536(01)00190-3; Calver J, 2006, AUST NZ J PUBL HEAL, V30, P143, DOI 10.1111/j.1467-842X.2006.tb00107.x; Casotto V, 2017, J PAIN SYMPTOM MANAG, V54, P167, DOI 10.1016/j.jpainsymman.2017.04.004; Dagli Rushabh J, 2014, J Int Oral Health, V6, pi; DHoore W, 1996, J CLIN EPIDEMIOL, V49, P1429, DOI 10.1016/S0895-4356(96)00271-5; Dormont B, 2006, HEALTH ECON, V15, P947, DOI 10.1002/hec.1165; Forma L, 2017, EUR J PUBLIC HEALTH, V27, P665, DOI 10.1093/eurpub/ckw260; Forma L, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-14; Forma L, 2009, EUR J PUBLIC HEALTH, V19, P313, DOI 10.1093/eurpub/ckp028; Frogatt K, 2017, PALLIATIVE CARE SYST, P99; Gabriele S, DEMOGRAPHIC FACTORS, P33; Geue C, 2014, EUR J HEALTH ECON, V15, P885, DOI 10.1007/s10198-013-0543-7; Gill TM, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2361; Goldsbury DE, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1202-8; Goodridge D, 2008, RESP MED, V102, P885, DOI 10.1016/j.rmed.2008.01.007; Howard M, 2017, J PALLIAT MED, V20, P344, DOI 10.1089/jpm.2016.0283; Howdon D, 2018, J HEALTH ECON, V57, P60, DOI 10.1016/j.jhealeco.2017.11.001; Ishizaki T, 2017, GERIATR GERONTOL INT, V17, P737, DOI 10.1111/ggi.12777; Jacobzone S, 2003, GENEVA PAP R I-ISS P, V28, P254, DOI 10.1111/1468-0440.00222; Jakobsson E, 2007, HEALTH POLICY, V82, P276, DOI 10.1016/j.healthpol.2006.10.003; Kronman AC, 2008, J GEN INTERN MED, V23, P1330, DOI 10.1007/s11606-008-0638-5; Legramante JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165939; Levinsky NG, INFLUENCE AGE MEDICA, P7; Liddle R, CONSULTATION PAPER B, P56; Louis DZ, 2016, TUMORI J, V102, P614, DOI 10.5301/tj.5000544; Lyngaa T, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1124-1; Mariotto AB, 2013, J CLIN EPIDEMIOL, V66, P1376, DOI 10.1016/j.jclinepi.2013.07.002; Matthews RS, SAS PROGRAMS SELECT, P9; McGrail K, 2000, AGE AGEING, V29, P249, DOI 10.1093/ageing/29.3.249; Moore PV, 2017, SOC SCI MED, V184, P1, DOI 10.1016/j.socscimed.2017.04.038; Moorin R, 2012, J HEALTH SERV RES PO, V17, P197, DOI 10.1258/jhsrp.2012.011130; Pellizzari M, 2018, EUR J CANCER CARE, V27, DOI 10.1111/ecc.12742; Pot AM, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-139; Reeve E, 2018, EXPERT OPIN DRUG SAF, V17, P39, DOI 10.1080/14740338.2018.1397625; Rosenwax LK, 2011, HOSP EMERGENCY DEP U, V194, P4; Sampaio PYS, 2014, J CLIN GERONTOL GERI, V5, P82, DOI 10.1016/j.jcgg.2014.02.005; Seshamani M, 2004, HEALTH ECON, V13, P303, DOI 10.1002/hec.826; Tanuseputro P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121759; Tran B, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009410; Van den Block L, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-69; Westerhout EWMT, 2006, CESIFO ECON STUD, V52, P1, DOI 10.1093/cesifo/ifj001; Yang Z, 2003, J GERONTOL B-PSYCHOL, V58, pS2, DOI 10.1093/geronb/58.1.S2; Zweifel P, 1999, HEALTH ECON, V8, P485, DOI 10.1002/(SICI)1099-1050(199909)8:6<485::AID-HEC461>3.0.CO;2-4	49	4	4	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2019	14	2							e0212086	10.1371/journal.pone.0212086	http://dx.doi.org/10.1371/journal.pone.0212086			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HK5RX	30730965	Green Submitted, Green Published, gold			2023-01-03	WOS:000458026000096
J	Laas, E; Hamy, AS; Michel, AS; Panchbhaya, N; Faron, M; Lam, T; Carrez, S; Pierga, JY; Rouzier, R; Lerebours, F; Feron, JG; Reyal, F				Laas, Enora; Hamy, Anne-Sophie; Michel, Anne-Sophie; Panchbhaya, Nabilah; Faron, Matthieu; Lam, Thanh; Carrez, Sophie; Pierga, Jean-Yves; Rouzier, Roman; Lerebours, Florence; Feron, Jean-Guillaume; Reyal, Fabien			Impact of time to local recurrence on the occurrence of metastasis in breast cancer patients treated with neoadjuvant chemotherapy: A random forest survival approach	PLOS ONE			English	Article							SURGICAL ADJUVANT BREAST; TUMOR RECURRENCE; PREOPERATIVE CHEMOTHERAPY; LOCOREGIONAL RECURRENCES; PROGNOSTIC-SIGNIFICANCE; CONSERVATIVE SURGERY; DISTANT METASTASES; THERAPY; RECOMMENDATIONS; CARCINOMA	Background We studied the relationship between time to ipsilateral breast tumor recurrence (IBTR) and distant metastasis-free survival (DMFS) in patients with breast cancer treated by neoadjuvant chemotherapy (NAC). Methods Between 2002 and 2012, 1199 patients with primary breast cancer were treated with NAC. Clinical, radiological and pathological data were retrieved from medical records. Multivariate analysis was performed with the random survival forest (RSF) method, to evaluate the relationship between time to local recurrence and DMFS. Results Time to IBTR, local recurrence and molecular subtype were the factors most strongly associated with DMFS. In the total population, DMFS increased linearly with recurrence time, up to 50 months. For recurrences after 50 months, DMFS was similar for all times to recurrence. Considering molecular subtypes separately, the threshold was similar for the TNBC subtype (50 months), but appeared to occur later for the luminal and HER2-positive subtypes (75 months). Conclusion A threshold of 50 months seems to differentiate between early and late recurrences and could be used to guide the medical management of local breast tumour recurrences.	[Laas, Enora; Michel, Anne-Sophie; Panchbhaya, Nabilah; Carrez, Sophie; Rouzier, Roman; Feron, Jean-Guillaume; Reyal, Fabien] Inst Curie, Dept Surg, Paris, France; [Hamy, Anne-Sophie; Reyal, Fabien] PSL Res Univ, Translat Res Dept, Inst Curie, RT2Lab, Paris, France; [Hamy, Anne-Sophie; Reyal, Fabien] INSERM, Immun & Canc U932, Paris, France; [Faron, Matthieu] Inst Gustave Roussy, Dept Surg, Villejuif, France; [Lam, Thanh] Geneva Univ Hosp, Dept Obstet & Gynaecol, Geneva, Switzerland; [Pierga, Jean-Yves; Lerebours, Florence] Inst Curie, Dept Med Oncol, Paris, France; [Pierga, Jean-Yves] Paris Descartes Univ, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Gustave Roussy; University of Geneva; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Cite	Reyal, F (corresponding author), Inst Curie, Dept Surg, Paris, France.; Reyal, F (corresponding author), PSL Res Univ, Translat Res Dept, Inst Curie, RT2Lab, Paris, France.; Reyal, F (corresponding author), INSERM, Immun & Canc U932, Paris, France.	fabien.reyal@curie.fr			Roche France; ITMO-INSERM-AVIESAN cancer translational research grant; Roche* France	Roche France(Roche Holding); ITMO-INSERM-AVIESAN cancer translational research grant; Roche* France(Roche Holding)	This work was supported by Roche France: financial support for the construction of the Institut Curie neoadjuvant database (NEOREP), http://www.roche.fr, the funder had no role in study design, analysis, decision to publish, or preparation of the manuscript, the only role was for data collection; ITMO-INSERM-AVIESAN cancer translational research grant, https://www.aviesan.fr (ASH), the funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank Roche* France for financial support for the construction of the Institut Curie neoadjuvant database (NEOREP). The funding source had no role in data analysis and interpretation or in the writing of the manuscript.; AS Hamy was supported by an ITMO-INSERM-AVIESAN cancer translational research grant.	Anderson SJ, 2009, J CLIN ONCOL, V27, P2466, DOI 10.1200/JCO.2008.19.8424; Balaton AJ, 1999, ANN PATHOL, V19, P336; Baulies S, 2015, BRIT J CANCER, V113, P30, DOI 10.1038/bjc.2015.174; Bellera CA, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-20; Chen X, 2012, GENOMICS, V99, P323, DOI 10.1016/j.ygeno.2012.04.003; Datema FR, 2012, HEAD NECK-J SCI SPEC, V34, P50, DOI 10.1002/hed.21698; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; FISHER B, 1991, LANCET, V338, P327, DOI 10.1016/0140-6736(91)90475-5; Fisher B, 1997, J CLIN ONCOL, V15, P2483, DOI 10.1200/JCO.1997.15.7.2483; Fisher B, 1998, J CLIN ONCOL, V16, P2672, DOI 10.1200/JCO.1998.16.8.2672; Fortin A, 1999, J CLIN ONCOL, V17, P101, DOI 10.1200/JCO.1999.17.1.101; Fredriksson I, 2002, EUR J CANCER, V38, P1860, DOI 10.1016/S0959-8049(02)00219-8; Friedel G, 2013, ANTICANCER RES, V33, P1609; Ghadiani Mohammad Hassan, 2012, Arab J Nephrol Transplant, V5, P19; Gosset M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159888; Haffty BG, 1996, J CLIN ONCOL, V14, P52, DOI 10.1200/JCO.1996.14.1.52; Hamidi O, 2016, IRAN J PUBLIC HEALTH, V45, P27; Hsich E, 2011, CIRC-CARDIOVASC QUAL, V4, P39, DOI 10.1161/CIRCOUTCOMES.110.939371; Ishwaran H, 2008, ANN APPL STAT, V2, P841, DOI 10.1214/08-AOAS169; Karabicak I, 2011, CLIN TRANSPLANT, V25, pE264, DOI 10.1111/j.1399-0012.2011.01412.x; KURTZ JM, 1990, INT J RADIAT ONCOL, V18, P87, DOI 10.1016/0360-3016(90)90271-K; Lee JS, 2011, J BREAST CANCER, V14, P191, DOI 10.4048/jbc.2011.14.3.191; Mauri D, 2005, JNCI-J NATL CANCER I, V97, P188, DOI 10.1093/jnci/dji021; Mauriac L, 1999, ANN ONCOL, V10, P47, DOI 10.1023/A:1008337009350; Mieog JSD, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005002.pub2; Mogensen UB, 2012, J STAT SOFTW, V50, P1; Park S, 2012, BREAST, V21, P50, DOI 10.1016/j.breast.2011.07.008; Rouzier R, 2001, J CLIN ONCOL, V19, P3828, DOI 10.1200/JCO.2001.19.18.3828; Savignoni A, 2012, STAT MED, V31, P4444, DOI 10.1002/sim.5631; Touboul E, 1999, INT J RADIAT ONCOL, V43, P25, DOI 10.1016/S0360-3016(98)00365-4; van der Hage JA, 2001, J CLIN ONCOL, V19, P4224, DOI 10.1200/JCO.2001.19.22.4224; van der Sangen MJC, 2006, EJSO-EUR J SURG ONC, V32, P34, DOI 10.1016/j.ejso.2005.10.005; VERONESI U, 1995, J NATL CANCER I, V87, P19, DOI 10.1093/jnci/87.1.19; Voogd AC, 1999, CANCER-AM CANCER SOC, V85, P437, DOI 10.1002/(SICI)1097-0142(19990115)85:2<437::AID-CNCR23>3.0.CO;2-1; Wapnir IL, 2006, J CLIN ONCOL, V24, P2028, DOI 10.1200/JCO.2005.04.3273; WHELAN T, 1994, INT J RADIAT ONCOL, V30, P11, DOI 10.1016/0360-3016(94)90513-4; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Yin WJ, 2009, BREAST CANCER RES TR, V114, P527, DOI 10.1007/s10549-008-0022-5	38	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2019	14	1							e0208807	10.1371/journal.pone.0208807	http://dx.doi.org/10.1371/journal.pone.0208807			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HI4TC	30673703	gold, Green Submitted, Green Published			2023-01-03	WOS:000456442800010
J	Good, CB; Parekh, N; Fischer, K; Schuster, J; Manolis, C; Shrank, W				Good, Chester B.; Parekh, Natasha; Fischer, Kavita; Schuster, James; Manolis, Chronis; Shrank, William			Brief Commentary: Treating Pain-The Cannabis Conundrum	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Good, Chester B.] UPMC Hlth Plan, Ctr Value Based Pharm Initiat, 600 Grant St, Pittsburgh, PA 15219 USA; [Fischer, Kavita; Manolis, Chronis; Shrank, William] UPMC Hlth Plan, 600 Grant St,US Steel Bldg,Floor 55, Pittsburgh, PA 15219 USA; [Parekh, Natasha] Univ Pittsburgh, Div Gen Internal Med, 200 Lothrop St,Suite 933W, Pittsburgh, PA 15213 USA; [Fischer, Kavita; Schuster, James] Community Care Behav Hlth Org, 339 Sixth Ave,Suite 1300, Pittsburgh, PA 15222 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Good, CB (corresponding author), UPMC Hlth Plan, Ctr Value Based Pharm Initiat, 600 Grant St, Pittsburgh, PA 15219 USA.	goodcb2@upmc.edu						[Anonymous], 2018, GOVERNING; Commonwealth of Pennsylvania, 2018, WOLF ADM ANN TEMP RE; Newton D.E., 2013, MARIJUANA REFERENCE; Nugent SM, 2017, ANN INTERN MED, V167, P319, DOI 10.7326/M17-0155	4	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	2019	170	2					123	+		10.7326/M18-3237	http://dx.doi.org/10.7326/M18-3237			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH3ZL	30615783				2023-01-03	WOS:000455659100023
J	Welsford, M				Welsford, Michelle			Management of out-of-hospital cardiac arrest with laryngeal tube improved survival vs endotracheal intubation	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CARDIOPULMONARY-RESUSCITATION		[Welsford, Michelle] McMaster Univ, Div Emergency Med, Hamilton, ON, Canada	McMaster University	Welsford, M (corresponding author), McMaster Univ, Div Emergency Med, Hamilton, ON, Canada.		Welsford, Michelle/H-5535-2017	Welsford, Michelle/0000-0003-2682-641X				Benger JR, 2018, JAMA-J AM MED ASSOC, V320, P779, DOI 10.1001/jama.2018.11597; Kim SY, 2018, RESUSCITATION, V133, P187, DOI 10.1016/j.resuscitation.2018.08.032; Neumar RW, 2015, CIRCULATION, V132, pS315, DOI 10.1161/CIR.0000000000000252; Ruetzler K, 2011, RESUSCITATION, V82, P1060, DOI 10.1016/j.resuscitation.2011.03.027	4	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	2019	170	2					JC4	JC4		10.7326/ACPJC-2019-170-2-004	http://dx.doi.org/10.7326/ACPJC-2019-170-2-004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH3ZL	30641555				2023-01-03	WOS:000455659100004
J	Wall, C; Jankowski, T; Naruka, V; Mota, P				Wall, Christopher; Jankowski, Tania; Naruka, Vinci; Mota, Paula			Comparing the delay with different anticoagulants before elective electrical cardioversion for atrial fibrillation/flutter	PLOS ONE			English	Article							PREVENTION	Aims To assess the impact of the introduction of direct oral anticoagulants upon the outcomes from elective electrical cardioversion for atrial fibrillation. Methods This is a retrospective comparison of delay to elective cardioversion with different anticoagulants. The data was gathered from a large regional hospital from January 2013 to September 2017. There were 3 measured outcomes: 1) the time in weeks from referral to the date of attempted electrical cardioversion; 2) the proportion of patients who were successfully cardioverted; and 3) the proportion of patients who remained in sinus rhythm by the 12 week follow-up. Time-to-cardioversion was non-parametrically distributed so was analysed with Kruskal-Wallis testing and Mann-Whitney-U testing. Maintenance of sinus rhythm was analysed using z-testing. Results 1,374 patients were submitted to cardioversion. The referrals for cardioversion were either from primary care or from cardiologists. At the time of cardioversion, 789 cases were anticoagulated on warfarin (W), 215 on apixaban (A) and 370 on rivaroxaban (R). All 3 cohorts were initially compared independently using Kruskal-Wallis testing. This demonstrated a significant difference in the delay (measured in weeks) between the A and W group (A = 7, W = 9, P<0.00001); the R and W group (R = 7, W = 9, P<0.00001) and no difference between R and A (A = 7, R = 7, P = 0.92). As there was no difference between the A and R groups, they were combined to form the AR group. The AR group was compared to the W group using Mann-Whitney-U testing which demonstrated a significant delay between the groups (AR = 7, W = 9, P<0.00001). Excluding patients with prior or unknown attempts of cardioversion (n = 791), the W patients (n = 152) were less successful in achieving sinus rhythm at cardioversion than the AR (n = 431) group (W = 95% vs AR = 99% P = 0.04). However at 12 weeks, incidence of sinus rhythm was significantly different (W = 40% vs AR = 49% P = 0.049). These groups were compared by z testing. At 12 weeks' follow-up there was no statistical difference in rate of adverse consequences between the AR group and the W group, but the rate of adverse consequences was too low to draw further conclusions. Conclusion DOACs appear to significantly shorten the latency between the decision to cardiovert and the cardioversion procedure by at least 2 weeks compared to warfarin in a real-world setting. In this study, patients who had not previously been cardioverted who were anticoagulated with warfarin had a significantly lower probability of conversion to sinus rhythm and a significantly lower probability to remain in sinus rhythm at the 12 week follow-up compared to the combined apixaban and rivaroxaban group.	[Wall, Christopher; Jankowski, Tania; Naruka, Vinci; Mota, Paula] William Harvey Hosp, Dept Cardiol, Ashford, Kent, England		Wall, C (corresponding author), William Harvey Hosp, Dept Cardiol, Ashford, Kent, England.	christopher.wall12@nhs.net		Naruka, Vinci/0000-0002-9222-2684				Camm AJ, 2012, EUROPACE, V14, P1385, DOI [10.1093/europace/eus305, 10.1093/eurheartj/ehs253]; Cappato R, 2014, EUR HEART J, V35, P3346, DOI 10.1093/eurheartj/ehu367; Goette A, 2017, ARRHYTH ELECTROPHYSI, V6, P50, DOI 10.15420/aer.2017:3:2; Goette A, 2016, LANCET, V388, P1995, DOI 10.1016/S0140-6736(16)31474-X; Hohnloser SH, 2016, EUROPACE, V18, P184, DOI 10.1093/europace/euv294; Pampolini-Roberts O, 2014, HEART, P100; Patel MR, 2010, AM HEART J, V159, P340, DOI 10.1016/j.ahj.2009.11.025; Stellbrink C, 2004, CIRCULATION, V109, P997, DOI 10.1161/01.CIR.0000120509.64740.DC; Sulke N, 2007, HEART, V93, P29, DOI 10.1136/hrt.2006.099879	9	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2019	14	1							e0210170	10.1371/journal.pone.0210170	http://dx.doi.org/10.1371/journal.pone.0210170			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG1ZC	30605492	Green Published, Green Submitted, gold			2023-01-03	WOS:000454759900031
J	Floyd, EL; Queimado, L; Wang, J; Regens, JL; Johnson, DL				Floyd, Evan L.; Queimado, Lurdes; Wang, Jun; Regens, James L.; Johnson, David L.			Electronic cigarette power affects count concentration and particle size distribution of vaping aerosol	PLOS ONE			English	Article							MULTIPLE-PATH MODEL; RESPIRATORY-TRACT; PUFF TOPOGRAPHY; DEPOSITION; MAINSTREAM; PARAMETERS; SMOKE	Introduction Electronic cigarettes (EC) have evolved rapidly toward higher powered devices that produce more vaping aerosol and a more satisfying vaping experience. This research characterized the particle size distribution and estimated the mass concentration of vaping aerosols produced at power outputs spanning the operating range typical of second generation variable voltage EC devices. Methods EC aerosol was characterized from a single coil atomizer powered by a variable voltage EC battery at the minimum and maximum dial settings (3.3, 11.2 Watts, W), and a lab controlled power supply (3-11.9 W). Aerosol particle size distribution was measured by a Scanning Mobility Particle Sizer and Aerodynamic Particle Sizer, spanning 16 nm to 19.8 mu m. A mouth puff was simulated using a 100 mL glass syringe. Results Consistent with prior studies, sub-micron EC aerosol size distributions were bimodal, with peaks at 40 and 200 nm, however a previously unreported third mode was observed at approximately 1000 nm. The similar to 1000 nm mode accounted for 7-20x the aerosol mass of the smaller modes. Increasing atomizer power decreased count concentration of particles <600 nm but increased particle count >600 nm. Particle mass distribution shifted toward micron sized particles with increasing power and increased the respirable fraction of aerosol, likely due to increased coagulation and condensation around nano-sized particles. Conclusions Vaping power greatly affects EC aerosol count and mass distribution. Mouth puffed EC aerosol spans a much wider particle size range than previously reported, although the major portion of the mass is still well within the alveolar size range the larger particles will deposit within the oro-pharyngeal cavity at 2-3x greater efficiency than in alveoli. These observations have major clinical implications, as aerosol particle size distribution determines deposition sites along the respiratory tract. The results of this experiment stress the need for further research to inform the design, regulation and use of e-cigarette products.	[Floyd, Evan L.; Wang, Jun; Johnson, David L.] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Dept Occupat & Environm Hlth, Oklahoma City, OK 73104 USA; [Floyd, Evan L.; Queimado, Lurdes; Johnson, David L.] Oklahoma Tobacco Res Ctr, Oklahoma City, OK 73104 USA; [Queimado, Lurdes] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Otorhinolaryngol, Oklahoma City, OK 73190 USA; [Regens, James L.] Univ Oklahoma, OU Ctr Intelligence & Natl Secur, Oklahoma City, OK USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Floyd, EL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Dept Occupat & Environm Hlth, Oklahoma City, OK 73104 USA.; Floyd, EL (corresponding author), Oklahoma Tobacco Res Ctr, Oklahoma City, OK 73104 USA.	evan-floyd@ouhsc.edu	Queimado, Lurdes/L-7465-2013; Queimado, Lurdes/AAY-2545-2021	Queimado, Lurdes/0000-0002-1106-4873; Queimado, Lurdes/0000-0002-1106-4873; Floyd, Evan/0000-0002-0402-0565	Oklahoma Tobacco Research Center (OTRC) - Oklahoma Tobacco Settlement Endowment Trust [C1081507]	Oklahoma Tobacco Research Center (OTRC) - Oklahoma Tobacco Settlement Endowment Trust	This research was supported by an Advanced Development Grant from the Oklahoma Tobacco Research Center (OTRC), C1081507, which is funded by the Oklahoma Tobacco Settlement Endowment Trust.	Abrams DB, 2014, JAMA-J AM MED ASSOC, V311, P135, DOI 10.1001/jama.2013.285347; Administration FaD, 2014, DEEM TOB PROD BE SUB; ANJILVEL S, 1995, FUND APPL TOXICOL, V28, P41, DOI 10.1006/faat.1995.1144; Asgharian B, 2001, AEROSOL SCI TECH, V34, P332, DOI 10.1080/02786820119122; Bradford JA, 1936, IND ENG CHEM, V28, P836, DOI 10.1021/ie50319a020; BRAIN JD, 1979, AM REV RESPIR DIS, V120, P1325; Brown CJ, 2014, TOB CONTROL, V23, P4, DOI 10.1136/tobaccocontrol-2013-051476; CORESTA, 2015, NO 81 ROUT AN MACH E; Dickens C, 2009, J PHYS CONF SER, V151, DOI 10.1088/1742-6596/151/1/012019; Evans SE, 2014, TOB CONTROL, V23, P23, DOI 10.1136/tobaccocontrol-2013-051489; Fuoco FC, 2014, ENVIRON POLLUT, V184, P523, DOI 10.1016/j.envpol.2013.10.010; Herrington JS, 2015, J CHROMATOGR A, V1418, P192, DOI 10.1016/j.chroma.2015.09.034; HEYDER J, 1986, J AEROSOL SCI, V17, P811, DOI 10.1016/0021-8502(86)90035-2; Hinds W.C, 1999, AEROSOL TECHNOLOGY P; HINDS WC, 1978, AM IND HYG ASSOC J, V39, P48, DOI 10.1080/0002889778507712; Ingebrethsen BJ, 2012, INHAL TOXICOL, V24, P976, DOI 10.3109/08958378.2012.744781; Ingebrethsen BJ, 2011, AEROSOL SCI TECH, V45, P1422, DOI 10.1080/02786826.2011.596863; Ji EH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154447; Keith C.H., 1960, J COLL SCI IMP U TOK, V15, P340, DOI 10.1016/0095-8522(60)90037-4; Kosmider L, 2014, NICOTINE TOB RES; Laino T, 2012, J PHYS CHEM A, V116, P4602, DOI 10.1021/jp300997d; Laino T, 2011, J PHYS CHEM A, V115, P3592, DOI 10.1021/jp201078e; Londahl J, 2007, INHAL TOXICOL, V19, P109, DOI 10.1080/08958370601051677; Mikheev VB, 2016, NICOTINE TOB RES; NIST, NIST CHEM WEBBOOK, P69; Ogunwale MA, 2017, ACS OMEGA, V2, P1207, DOI 10.1021/acsomega.6b00489; Ohta K, 2011, BUNSEKI KAGAKU, V60, P791; Sahu SK, 2013, AEROSOL AIR QUAL RES, V13, P324, DOI 10.4209/aaqr.2012.02.0041; Schripp T, 2013, INDOOR AIR, V23, P25, DOI 10.1111/j.1600-0668.2012.00792.x; Sleiman M, 2016, ENVIRON SCI TECHNOL, V50, P9644, DOI 10.1021/acs.est.6b01741; SmokTech, 2017, Q BOX KIT; STAHLHOFEN W, 1980, AM IND HYG ASSOC J, V41, P385, DOI 10.1080/15298668091424933; Talih S, 2015, NICOTINE TOB RES, V17, P150, DOI 10.1093/ntr/ntu174; Uchiyama S, 2012, ANAL SCI INT J JAPAN, V29, P1219; Wagener TL, 2016, TOBACCO CONTROL; Zhang YP, 2013, NICOTINE TOB RES, V15, P501, DOI 10.1093/ntr/nts165; Zhao TK, 2016, ATMOS ENVIRON, V134, P61, DOI 10.1016/j.atmosenv.2016.03.027	37	60	61	2	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2018	13	12							e0210147	10.1371/journal.pone.0210147	http://dx.doi.org/10.1371/journal.pone.0210147			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG0IO	30596800	Green Published, Green Submitted, gold			2023-01-03	WOS:000454627200147
J	Yu, SB; Liao, QH; Zhou, YH; Hu, SX; Chen, Q; Luo, KW; Chen, ZH; Luo, L; Huang, W; Dai, BB; He, M; Liu, FF; Qiu, Q; Ren, LS; van Doorn, HR; Yu, HJ				Yu, Shuanbao; Liao, Qiaohong; Zhou, Yonghong; Hu, Shixiong; Chen, Qi; Luo, Kaiwei; Chen, Zhenhua; Luo, Li; Huang, Wei; Dai, Bingbing; He, Min; Liu, Fengfeng; Qiu, Qi; Ren, Lingshuang; van Doorn, H. Rogier; Yu, Hongjie			Population based hospitalization burden of laboratory-confirmed hand, foot and mouth disease caused by multiple enterovirus serotypes in Southern China	PLOS ONE			English	Article							COXSACKIEVIRUS A6; A10 INFECTIONS; 71 VACCINE; OUTBREAK; EPIDEMIOLOGY; CHILDREN; SURVEILLANCE; SINGAPORE; EFFICACY; FRANCE	Background Hand, foot and mouth disease (HFMD) is spread widely across Asia, and the hospitalization burden is currently not well understood. Here, we estimated serotype-specific and age-specific hospitalization rates of HFMD in Southern China. Methods We enrolled pediatric HFMD patients admitted to 3/3 county-level hospitals, and 3/23 township-level hospitals in Anhua county, Hunan (CN). Samples were collected to identify enterovirus serotypes by RT-PCRs between October 2013 and September 2016. Information on other eligible, but un-enrolled, patients were retrospectively collected from the same six hospitals. Monthly numbers of all-cause hospitalizations were collected from each of the 23 township-level hospitals to extrapolate hospitalizations associated with HFMD among these. Results During the three years, an estimated 3,236 pediatric patients were hospitalized with lab-confirmed HFMD, and among these only one case was severe. The mean hospitalization rate was 660 (95% Cl: 638-684) per 100,000 person-years for lab-confirmed HFMD, with higher rates among CV-A16 and CV-A6 associated HFMD (213 vs 209 per 100,000 person-years), and lower among EV-A71, CV-A10 and other enterovirus associated HFMD (134, 39 and 66 per 100,000 person-years respectively, p<0.001). Children aged 12-23 months had the high- est hospitalization rates (3,594/100,000 person-years), followed by those aged 24-35 months (1,828/100,000 person-years) and 6-11 months (1,572/100,000 person-years). Compared with other serotypes, CV-A6-associated hospitalizations were evident at younger ages. Conclusions Our study indicates a substantial hospitalization burden associated with non-severe HFMD in a rural county in southern China. Future mitigation policies should take into account the disease burden identified, and optimize interventions for HFMD.	[Yu, Shuanbao; Liao, Qiaohong; Luo, Li; Liu, Fengfeng; Yu, Hongjie] Chinese Ctr Dis Control & Prevent, Div Infect Dis, Key Lab Surveillance & Early Warning Infect Dis, Beijing, Peoples R China; [Liao, Qiaohong; Zhou, Yonghong; Qiu, Qi; Ren, Lingshuang; Yu, Hongjie] Fudan Univ, Sch Publ Hlth, Key Lab Publ Hlth Safety, Minist Educ, Shanghai, Peoples R China; [Hu, Shixiong; Luo, Kaiwei; Huang, Wei] Hunan Prov Ctr Dis Control & Prevent, Changsha, Hunan, Peoples R China; [Chen, Qi] Hubei Prov Ctr Dis Control & Prevent, Wuhan, Hubei, Peoples R China; [Chen, Zhenhua] Chengdu Ctr Dis Control & Prevent, Chengdu, Sichuan, Peoples R China; [Dai, Bingbing; He, Min] Anhua Cty Ctr Dis Control & Prevent, Anhua, Hunan, Peoples R China; [van Doorn, H. Rogier] Univ Oxford, Nuffield Dept Med, Oxford, England; [van Doorn, H. Rogier] Hosp Trop Dis, Oxford Univ Clin Res Unit, Ho Chi Minh City, Vietnam	Chinese Center for Disease Control & Prevention; Fudan University; University of Oxford	Yu, HJ (corresponding author), Chinese Ctr Dis Control & Prevent, Div Infect Dis, Key Lab Surveillance & Early Warning Infect Dis, Beijing, Peoples R China.; Yu, HJ (corresponding author), Fudan Univ, Sch Publ Hlth, Key Lab Publ Hlth Safety, Minist Educ, Shanghai, Peoples R China.	cfetpyhj@vip.sina.com	van Doorn, H. Rogier/H-3080-2019; Yu, Hongjie/GZK-5351-2022	van Doorn, H. Rogier/0000-0002-9807-1821; Qi, Chen/0000-0002-6190-0403; Zhou, Yonghong/0000-0002-1242-1764	National Science Fund for Distinguished Young Scholars [81525023]; National Natural Science Foundation of China [81473031]; Li Ka Shing Oxford Global Health Programme [B9RST00-B900.57]; TOTAL foundation [2015-099]; Chinese Preventive Medicine Association [20101801]	National Science Fund for Distinguished Young Scholars(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Li Ka Shing Oxford Global Health Programme; TOTAL foundation(Total SA); Chinese Preventive Medicine Association	This work was supported by grants from the National Science Fund for Distinguished Young Scholars (no. 81525023 to Hongjie Yu), the National Natural Science Foundation of China (no. 81473031 to Hongjie Yu), the Li Ka Shing Oxford Global Health Programme (no. B9RST00-B900.57 to Hongjie Yu), TOTAL foundation (no. 2015-099 to Hongjie Yu), and Chinese Preventive Medicine Association (no. 20101801 to Lidong Gao). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ang LW, 2009, ANN ACAD MED SINGAP, V38, P106; Blomqvist S, 2010, J CLIN VIROL, V48, P49, DOI 10.1016/j.jcv.2010.02.002; Caine EA, 2015, VIRUSES-BASEL, V7, P5919, DOI 10.3390/v7112916; Chan KP, 2003, EMERG INFECT DIS, V9, P78; Chan LG, 2000, CLIN INFECT DIS, V31, P678, DOI 10.1086/314032; Chen MY, 2017, J CLIN VIROL, V93, P20, DOI 10.1016/j.jcv.2017.05.011; Fujimoto T, 2002, MICROBIOL IMMUNOL, V46, P621, DOI 10.1111/j.1348-0421.2002.tb02743.x; Gao LD, 2018, CLIN INFECT DIS, V67, P1729, DOI 10.1093/cid/ciy341; Gu HY, 2014, PEDIATR INFECT DIS J, V33, P1302, DOI 10.1097/INF.0000000000000467; Han JF, 2014, J INFECTION, V69, P303, DOI 10.1016/j.jinf.2014.03.015; He SZ, 2017, EPIDEMIOL INFECT, V145, P1865, DOI 10.1017/S0950268817000309; Ho MT, 1999, NEW ENGL J MED, V341, P929, DOI 10.1056/NEJM199909233411301; Huang Y, 2015, J MED VIROL, V87, P1471, DOI 10.1002/jmv.24200; Kawado M, 2007, J EPIDEMIOL, V17, pS32, DOI 10.2188/jea.17.S32; Koh WM, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000442; Ku ZQ, 2014, VACCINE, V32, P4296, DOI 10.1016/j.vaccine.2014.06.025; Li RC, 2014, NEW ENGL J MED, V370, P829, DOI 10.1056/NEJMoa1303224; Liu DP, 2016, VACCINE, V34, P974, DOI 10.1016/j.vaccine.2015.12.026; Lu J, 2014, CLIN MICROBIOL INFEC, V20, pO442, DOI 10.1111/1469-0691.12468; Ma E, 2010, JPN J INFECT DIS, V63, P422; Mirand A, 2012, CLIN MICROBIOL INFEC, V18, pE110, DOI 10.1111/j.1469-0691.2012.03789.x; Mirand A, 2016, EMERG INFECT DIS, V22, P1884, DOI 10.3201/eid2211.160590; Montes M, 2013, EMERG INFECT DIS, V19; National Bureau of Statistics of China, NATL CENSUS CHINA 20; NikNadia NMN, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004562; Ooi MH, 2010, LANCET NEUROL, V9, P1097, DOI 10.1016/S1474-4422(10)70209-X; Reed C, 2009, EMERG INFECT DIS, V15, P2004, DOI 10.3201/eid1512.091413; Seiff A, 2012, LANCET, V380, P205, DOI 10.1016/S0140-6736(12)61200-8; Solomon T, 2010, LANCET INFECT DIS, V10, P778, DOI 10.1016/S1473-3099(10)70194-8; Sun YL, 2017, CLIN EPIDEMIOL, V9, P167, DOI 10.2147/CLEP.S106258; Van Tu P, 2007, EMERG INFECT DIS, V13, P1733, DOI 10.3201/eid1311.070632; Wang YR, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-539; Wu Y, 2010, INT J INFECT DIS, V14, pE1076, DOI 10.1016/j.ijid.2010.07.006; Xing WJ, 2014, LANCET INFECT DIS, V14, P308, DOI 10.1016/S1473-3099(13)70342-6; Xu MH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138514; Xu W, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-8; Yang B, 2017, EUROPEAN COMMUNICABL, V22; Yang BY, 2015, PEDIATR INFECT DIS J, V34, P1399, DOI 10.1097/INF.0000000000000900; Yang F, 2014, CLIN INFECT DIS, V59, P1504, DOI 10.1093/cid/ciu624; Zeng M, 2012, EPIDEMIOL INFECT, V140, P1122, DOI 10.1017/S0950268811001622; Zhang C, 2015, EMERG MICROBES INFEC, V4, DOI 10.1038/emi.2015.12; Zhu FC, 2013, LANCET, V381, P2024, DOI 10.1016/S0140-6736(13)61049-1; Zhu R, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-017-0003-z	43	3	3	6	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2018	13	12							e0203792	10.1371/journal.pone.0203792	http://dx.doi.org/10.1371/journal.pone.0203792			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE3IL	30543631	Green Published, Green Submitted, gold			2023-01-03	WOS:000453247500003
J	Franck, JA; Smeets, RJEM; Seelen, HAM				Franck, Johan Anton; Smeets, Rob Johannes Elise Marie; Seelen, Henk Alexander Maria			Changes in actual arm-hand use in stroke patients during and after clinical rehabilitation involving a well-defined arm-hand rehabilitation program: A prospective cohort study	PLOS ONE			English	Article							UPPER-LIMB ACTIVITY; UPPER EXTREMITY IMPAIRMENT; QUALITY-OF-LIFE; SUBACUTE STROKE; PHYSICAL-ACTIVITY; MOTOR RECOVERY; ACCELEROMETRY; MOVEMENT; PARTICIPATION; ASSOCIATION	Introduction Improvement of arm-hand function and arm-hand skill performance in stroke patients is reported by many authors. However, therapy content often is poorly described, data on actual arm-hand use are scarce, and, as follow-up time often is very short, little information on patients' mid-and long-term progression is available. Also, outcome data mainly stem from either a general patient group, unstratified for the severity of arm-hand impairment, or a very specific patient group. Objectives To investigate to what extent the rate of improvement or deterioration of actual arm-hand use differs between stroke patients with either a severely, moderately or mildly affected arm-hand, during and after rehabilitation involving a well-defined rehabilitation program. Methods Design: single-armed prospective cohort study. Outcome measure: affected arm-hand use during daily tasks (accelerometry), expressed as 'Intensity-of arm-hand-use' and 'Duration-of-arm-hand-use' during waking hours. Measurement dates: at admission, clinical discharge and 3, 6, 9, and 12 months post-discharge. Statistics: Two-way repeated measures ANOVAs. Results Seventy-six patients (63 males); mean age: 57.6 years (sd: 10.6); post-stroke time: 29.8 days (sd: 20.1) participated. Between baseline and 1-year follow-up, Intensity-of-arm-hand-use on the affected side increased by 51%, 114% and 14% (p < .000) in the mildly, moderately and severely affected patients, respectively. Similarly, Duration-of-arm-hand-use increased by 26%, 220% and 161% (p < .000). Regarding bimanual arm-hand use: Intensity-of-arm-hand-use increased by 44%, 74% and 30% (p <.000), whereas Duration-of-arm-hand-use increased by 10%, 22% and 16% (p < .000). Conclusion Stroke survivors with a severely, moderately or mildly affected arm-hand showed different, though (clinically) important, improvements in actual arm-hand use during the rehabilitation phase. Intensity-of-arm-hand-use and Duration-of-arm-hand-use significantly improved in both unimanual and bimanual tasks/skills. These improvements were maintained until at least 1 year post-discharge.	[Franck, Johan Anton] Adelante Rehabil Ctr, Dept Brain Injury Rehabil, Hoensbroek, Netherlands; [Franck, Johan Anton; Seelen, Henk Alexander Maria] Adelante Ctr Expertise Rehabil & Audiol, Hoensbroek, Netherlands; [Smeets, Rob Johannes Elise Marie; Seelen, Henk Alexander Maria] Maastricht Univ, Res Sch CAPHRI, Dept Rehabil Med, Maastricht, Netherlands	Maastricht University	Franck, JA (corresponding author), Adelante Rehabil Ctr, Dept Brain Injury Rehabil, Hoensbroek, Netherlands.; Franck, JA (corresponding author), Adelante Ctr Expertise Rehabil & Audiol, Hoensbroek, Netherlands.	h.franck@adelante-zorggroep.nl	Smeets, Rob JEM/D-1522-2011	Smeets, Rob JEM/0000-0002-9503-366X				[Anonymous], 2003, APPL LONGITUDINAL AN; Bailey RR, 2015, NEUROREHAB NEURAL RE, V29, P969, DOI 10.1177/1545968315583720; Barker RN, 2005, DISABIL REHABIL, V27, P1213, DOI 10.1080/09638280500075717; Block VAJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154335; Boomkamp-Koppen HGM, 2005, CLIN REHABIL, V19, P552, DOI 10.1191/0269215505cr846oa; Buma F, 2013, RESTOR NEUROL NEUROS, V31, P707, DOI 10.3233/RNN-130332; Cambridge_ Neurology_ ltd, 2008, ACT GUID GETT START; Canning CG, 2004, CLIN REHABIL, V18, P300, DOI 10.1191/0269215504cr715oa; Chen KY, 2005, MED SCI SPORT EXER, V37, pS490, DOI 10.1249/01.mss.0000185571.49104.82; Connell L, 2014, ARCH PHYS MED REHABI, V95; de Niet M, 2007, ARCH PHYS MED REHAB, V88, P1121, DOI 10.1016/j.apmr.2007.06.005; Doman CA, 2016, AM J OCCUP THER, V70, DOI 10.5014/ajot.2016.020891; Franceschini M, 2010, EUR J PHYS REHAB MED, V46, P389; Franck J.A., 2015, OPEN J OCCUP THER, V3, P10, DOI [10.15453/2168-6408.1164, DOI 10.15453/2168-6408.1164]; Frank J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175211; Gebruers N, 2008, CEREBROVASC DIS, V26, P533, DOI 10.1159/000160210; Gebruers N, 2010, ARCH PHYS MED REHAB, V91, P288, DOI 10.1016/j.apmr.2009.10.025; Guidetti S, 2014, J REHABIL MED, V46, P963, DOI 10.2340/16501977-1865; Hardwick DD, 2011, J NEUROL PHYS THER, V35, P18, DOI 10.1097/NPT.0b013e318208efa1; Hayward KS, 2016, BRAIN IMPAIR, P1; Jung SH, 2005, ARCH PHYS MED REHAB, V86, P1706, DOI 10.1016/j.apmr.2004.11.043; Kilbreath SL, 2005, AUSTR J PHYSIOTHERAP, V51; Kwakkel G, 2006, STROKE, V37, P2348, DOI 10.1161/01.STR.0000238594.91938.1e; Lang Catherine E, 2007, J Neurol Phys Ther, V31, P56; Lang Catherine E, 2007, J Neurol Phys Ther, V31, P3; Lang CE, 2013, J HAND THER, V26, P104, DOI 10.1016/j.jht.2012.06.005; Lee JY, 2018, PLOS ONE, V13; Lemmens RJM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118642; Lemmens RJM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096414; Lemmens RJM, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-21; Liao WW, 2012, CLIN REHABIL, V26, P111, DOI 10.1177/0269215511416383; Mallinson T, 2010, ARCH PHYS MED REHAB, V91, pS29, DOI 10.1016/j.apmr.2010.04.027; Mayo NE, 2002, ARCH PHYS MED REHAB, V83, P1035, DOI 10.1053/apmr.2002.33984; Michielsen ME, 2012, ARCH PHYS MED REHAB, V93, P1975, DOI 10.1016/j.apmr.2012.03.016; Mullick AA, 2015, RESTOR NEUROL NEUROS, V33, P389, DOI 10.3233/RNN-150510; Narai E, 2016, J GERIATR PHYS THER, V39, P171, DOI 10.1519/JPT.0000000000000067; Nichols-Larsen DS, 2005, STROKE, V36, P1480, DOI 10.1161/01.STR.0000170706.13595.4f; Noorkoiv M, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-144; Pollock A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010820.pub2; Prabhakaran S, 2008, NEUROREHAB NEURAL RE, V22, P64, DOI 10.1177/1545968307305302; Rand D, 2015, J STROKE CEREBROVASC, V24, P274, DOI 10.1016/j.jstrokecerebrovasdis.2014.07.039; Rand D, 2012, NEUROREHAB NEURAL RE, V26, P76, DOI 10.1177/1545968311408918; Rand D, 2010, AM J OCCUP THER, V64, P877, DOI 10.5014/ajot.2010.09043; Rauch A, 2008, EUR J PHYS REHAB MED, V44, P329; Reenen ETKV, 2009, DISABIL REHABIL, V31, P1338, DOI 10.1080/09638280902846855; Santello M., 2014, HUMAN HAND INSPIRATI, V1; Schaefer SY, 2013, NEUROREHAB NEURAL RE, V27, P602, DOI 10.1177/1545968313481279; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3-4.591; Sveen U, 1999, DISABIL REHABIL, V21, P372, DOI 10.1080/096382899297477; Taub E, 2006, Eura Medicophys, V42, P241; Taub E., 2013, NEUROL REHABIL, V19, P161; Thrane G, 2011, J REHABIL MED, V43, P299, DOI 10.2340/16501977-0676; Timmermans AA, 2014, J NEUROENG REHABIL, V31, P11; Tornbom K, 2017, J STROKE CEREBROVASC, V26, P57, DOI 10.1016/j.jstrokecerebrovasdis.2016.08.029; Urbin MA, 2015, ARCH PHYS MED REHAB, V96, P854, DOI 10.1016/j.apmr.2014.11.018; Uswatte G, 2005, ARCH PHYS MED REHAB, V86, P1498, DOI 10.1016/j.apmr.2005.01.010; Uswatte G, 2005, STROKE, V36, P2493, DOI 10.1161/01.STR.0000185928.90848.2e; Uswatte G, 2006, ARCH PHYS MED REHAB, V87, P1340, DOI 10.1016/j.apmr.2006.06.006; Uswatte G, 2006, NEUROREHABILITATION, V21, P147; van der Pas SC, 2011, ARCH PHYS MED REHAB, V92, P1437, DOI 10.1016/j.apmr.2011.02.021; Vanroy C, PLOS ONE, V9, P1; Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987; Vega-Gonzalez A, 2005, ARCH PHYS MED REHAB, V86, P541, DOI 10.1016/j.apmr.2004.04.049; Waddell KJ, 2017, NEUROREHAB NEURAL RE, V31, P290, DOI 10.1177/1545968316680493; White MJ, 2018, PUBLIC HEALTH NUTR, V21, P2866, DOI 10.1017/S1368980018001751; Winters C, 2015, NEUROREHAB NEURAL RE, V29, P614, DOI 10.1177/1545968314562115; Wolf T, 2013, DISABIL REHABIL, V35, P1143, DOI 10.3109/09638288.2012.720635; Wolfe CDA, 2000, BRIT MED BULL, V56, P275, DOI 10.1258/0007142001903120; World Health Organisation, 2001, ICF INT CLASFUNCT; Wyller TB, 1997, CLIN REHABIL, V11, P139, DOI 10.1177/026921559701100207	70	13	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2019	14	4							e0214651	10.1371/journal.pone.0214651	http://dx.doi.org/10.1371/journal.pone.0214651			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HR1CY	30934015	Green Published, gold, Green Submitted			2023-01-03	WOS:000462867000031
J	Mutua, MM; Achia, TNO; Manderson, L; Musenge, E				Mutua, Michael M.; Achia, Thomas N. O.; Manderson, Lenore; Musenge, Eustasius			Spatial and socio-economic correlates of effective contraception among women seeking post-abortion care in healthcare facilities in Kenya	PLOS ONE			English	Article							FAMILY-PLANNING-SERVICES; ABORTION SERVICES; PREGNANCY; ATTITUDES	Introduction Information, counseling, availability of contraceptives, and their adoption by post-abortion care (PAC) patients are central to the quality of PAC in healthcare facilities. Effective contraceptive adoption by these patients reduces the risks of unintended pregnancy and repeat abortion. Methods This study uses data from the Incidence and Magnitude of Unsafe Abortion Study of 2012 to assess the level and determinants of highly effective contraception among patients treated with complications from an unsafe abortion in healthcare facilities in Kenya. Highly effective contraception was defined as any method adopted by a PAC patient that reduces pregnancy rate by over 99%. Results Generally, contraceptive counseling was high among all PAC patients (90%). However, only 54% of them received a modern family planning method-45% a short-acting method and 9% a long-acting and permanent method. Adoption of highly effective contraception was determined by patient's previous exposure to unintended pregnancies, induced abortion and modern family planning (FP). Facility level factors associated with the uptake of highly effective contraceptives included: facility ownership, availability of evacuation procedure room, whether the facility had a specialized obstetric-gynecologist, a facility that also had maternity services and the number of FP methods available for PAC patients. Discussion and conclusion For better adoption of highly effective FP, counseling of PAC patients requires an understanding of the patient's past experience with contraception and their future fertility intentions and desires in order to meet their reproductive needs more specifically. Family planning integration with PAC can increase contraceptive uptake and improve the reproductive health of post-abortion care patients.	[Mutua, Michael M.] APHRC, Nairobi, Kenya; [Mutua, Michael M.; Achia, Thomas N. O.; Manderson, Lenore; Musenge, Eustasius] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa; [Achia, Thomas N. O.] Ctr Dis Control & Prevent, Nairobi, Kenya; [Manderson, Lenore] Brown Univ, IBES, Providence, RI 02912 USA	African Population & Health Research Centre; University of Witwatersrand; Brown University	Mutua, MM (corresponding author), APHRC, Nairobi, Kenya.; Mutua, MM (corresponding author), Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa.	mmutua@aphrc.org	Achia, Thomas N. O./I-3674-2013	Achia, Thomas N. O./0000-0002-0700-9468	Consortium for Advanced Research Training in Africa (CARTA); Consortium for Research on Unsafe Abortion in Africa; Wellcome Trust (UK) [087547/Z/08/Z]; Department for International Development (DfID) under the Development Partnerships in Higher Education (DelPHE); Carnegie Corporation of New York [B 8606]; Ford Foundation [1100-0399]; Google. Org [191994]; Sida [54100029]; John D. and Catherine T. MacArthur Foundation [10-95915-000-INP]	Consortium for Advanced Research Training in Africa (CARTA); Consortium for Research on Unsafe Abortion in Africa; Wellcome Trust (UK)(Wellcome Trust); Department for International Development (DfID) under the Development Partnerships in Higher Education (DelPHE); Carnegie Corporation of New York; Ford Foundation; Google. Org; Sida; John D. and Catherine T. MacArthur Foundation	Consortium for Advanced Research Training in Africa (CARTA) The study on which we draw is based on research funded by the Consortium for Research on Unsafe Abortion in Africa and its principal donors, the UK Department for International Development, and the Government of the Netherlands. MM's analysis and writing time was supported through funding from the Consortium for Advanced Research Training in Africa (CARTA), a jointly led consortium by the African Population and Health Research Center and the University of the Witwatersrand and is funded by the Wellcome Trust (UK) [Grant no. 087547/Z/08/Z], the Department for International Development (DfID) under the Development Partnerships in Higher Education (DelPHE), the Carnegie Corporation of New York [Grant no. B 8606], the Ford Foundation [Grant no. 1100-0399], Google. Org [Grant no. 191994], Sida [grant number 54100029] and John D. and Catherine T. MacArthur Foundation [Grant no. 10-95915-000-INP].	[Anonymous], 2011, FAMILY PLANNING GLOB; Bakibinga P, 2016, J RELIG HEALTH, V55, P192, DOI 10.1007/s10943-015-0030-9; Banerjee S, 2004, BIOMETRICS, V60, P268, DOI 10.1111/j.0006-341X.2004.00032.x; Banerjee S., 2014, HIERARCHICAL MODELIN, DOI DOI 10.1201/B17115; Banerjee SK, 2015, STUD FAMILY PLANN, V46, P387, DOI 10.1111/j.1728-4465.2015.00039.x; Basu S., 2016, INT STAT REV, V84, P159; Belitz C., 2015, SOFTWARE BAYESIAN IN; Benson J, 2018, GLOB PUBLIC HEALTH, V13, P35, DOI 10.1080/17441692.2016.1174280; BESAG J, 1991, ANN I STAT MATH, V43, P1, DOI 10.1007/BF00116466; Biney Adriana A E, 2011, Afr J Reprod Health, V15, P37; Boes S, 2006, ALLGEMEINES STAT ARC, P167, DOI [DOI 10.1007/S10182-006-0228-Y, 10.1007/s10182-006-0228-y]; Borges ALV, 2016, POSTABORTION CONTRAC, P32; Bradley EH, 2002, HEALTH SERV RES, V37, P1221, DOI 10.1111/1475-6773.01053; Center for Reproductive Rights, 2010, HARMS WAY IMP KEN RE; Curtis C, 2010, INT PERSPECT SEX R H, V36, P44, DOI 10.1363/ipsrh.36.044.10; Earnest A, 2007, INT J HEALTH GEOGR, V6, DOI 10.1186/1476-072X-6-54; Gemzell-Danielsson K, 2015, WOMENS HEALTH, V11, P779, DOI 10.2217/whe.15.72; HATCHER RA, 2007, CONTRACEPTIVE TECHNO; Juma PA, 2015, AFR HEALTH SCI, V15, P161, DOI 10.4314/ahs.v15i1.22; Keene M, 2015, CONTRACEPTION, V91, P398, DOI 10.1016/j.contraception.2014.10.011; Kenya National Bureau of Statistics (KNBS) and ICF Macro, 2014, KEN DEM HLTH SURV; Langer A, 1997, REPROD HEALTH MATTER, V5, P20; Lawson AB., 2013, BAYESIAN DIS MAPPING; Lawson AB, 1977, STAT METHODS SPAT EP, P363; Madden T, 2013, CONTRACEPTION, V88, P243, DOI 10.1016/j.contraception.2012.07.015; Marston C, 2003, INT FAM PLAN PERSPEC, V29, P6, DOI 10.2307/3180995; Mutombo N, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004643; Mutua MM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204240; Naanyu Violet, 2013, Afr J Reprod Health, V17, P44; National Coordinating Agency for Population and Development (NCAPD) [Kenya] Ministry of Medical Services (MOMS) [Kenya] Ministry of Public Health and Sanitation (MOPHS) [Kenya] Kenya National Bureau of Statistics (KNBS) [Kenya] ICF Macro, 2011, KEN SERV PROV ASS SU; Nguyen MH, 2007, REPROD HEALTH MATTER, V15, P172, DOI 10.1016/S0968-8080(07)29283-3; Nobili MP, 2007, PATIENT ED COUNS; Ohannessian A, 2016, J GYNECOL OBST BIO R, V45, P1568, DOI 10.1016/j.jgyn.2016.09.017; Olenick I, 2000, INT FAM PLAN PERSPEC, V26, P48, DOI 10.2307/2648294; Opollo VSA, 2017, IMP HIV AIDS SCAL UP; Osur J, 2013, GLOBAL HEALTH ACTION, V6, P1, DOI 10.3402/gha.v6i0.19649; Patel R, 2014, AIDS PATIENT CARE ST, V28, P418, DOI 10.1089/apc.2014.0046; Prata N, 2013, AFR J REPROD HLTH, V17; Roberts H, 2010, CONTRACEPTION, V82, P260, DOI 10.1016/j.contraception.2010.03.003; Schreiber CA, 2011, CONTRACEPTION, V84, P230, DOI 10.1016/j.contraception.2011.01.013; Schunmann C, 2006, HUM REPROD, V21, P2296, DOI 10.1093/humrep/del168; Secura GM, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.04.017; Sedgh G, 2016, LANCET, V388, P258, DOI 10.1016/S0140-6736(16)30380-4; Senlet P, 2001, INT FAM PLAN PERSPEC, V27, P90, DOI 10.2307/2673821; Solo J, 1999, STUD FAMILY PLANN, V30, P17, DOI 10.1111/j.1728-4465.1999.00017.x; Thompson KMJ, 2011, CONTRACEPTION, V83, P41, DOI 10.1016/j.contraception.2010.06.008; World Health Organization, 2013, UNS AB GLOB REG EST; World Health Organization, 2005, REP WHO TECHN CONS B; Zhu JL, 2009, EUR J CONTRACEP REPR, V14, P46, DOI 10.1080/13625180802512994	49	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2019	14	3							e0214049	10.1371/journal.pone.0214049	http://dx.doi.org/10.1371/journal.pone.0214049			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HQ5PT	30917161	Green Submitted, Green Published, gold			2023-01-03	WOS:000462465800048
J	Kumbhare, D				Kumbhare, Dinesh			Review: Extra physical therapy improves some outcomes by a small amount in acute or subacute health conditions	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Kumbhare, Dinesh] Univ Toronto, Toronto, ON, Canada	University of Toronto	Kumbhare, D (corresponding author), Univ Toronto, Toronto, ON, Canada.			Kumbhare, Dinesh/0000-0003-3889-7557				Brusco NK, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0822-3; McMillan LB, 2018, OSTEOPOROSIS INT, V29, P1379, DOI 10.1007/s00198-018-4446-4; SELIKSON S, 1988, J AM GERIATR SOC, V36, P707, DOI 10.1111/j.1532-5415.1988.tb07172.x; Surkan MJ, 2018, CAN J CARDIOL, V34, P881, DOI 10.1016/j.cjca.2018.04.033	4	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 19	2019	170	6					JC32	JC34		10.7326/ACPJ201903190-032	http://dx.doi.org/10.7326/ACPJ201903190-032			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP1ZR	30884502				2023-01-03	WOS:000461468300009
J	Pouwels, KB; Hopkins, S; Llewelyn, MJ; Walker, AS; McNulty, CAM; Robotham, JV				Pouwels, Koen B.; Hopkins, Susan; Llewelyn, Martin J.; Walker, Ann Sarah; McNulty, Cliodna A. M.; Robotham, Julie V.			Duration of antibiotic treatment for common infections in English primary care: cross sectional analysis and comparison with guidelines	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY-TRACT INFECTION; RISK; AMOXICILLIN; PHYSICIANS; RESISTANCE; PNEUMONIA	OBJECTIVE To evaluate the duration of prescriptions for antibiotic treatment for common infections in English primary care and to compare this with guideline recommendations. DESIGN Cross sectional study. SETTING General practices contributing to The Health Improvement Network database, 2013-15. PARTICIPANTS 931 015 consultations that resulted in an antibiotic prescription for one of several indications: acute sinusitis, acute sore throat, acute cough and bronchitis, pneumonia, acute exacerbation of chronic obstructive pulmonary disease (COPD), acute otitis media, acute cystitis, acute prostatitis, pyelonephritis, cellulitis, impetigo, scarlet fever, and gastroenteritis. MAIN OUTCOME MEASURES The main outcomes were the percentage of antibiotic prescriptions with a duration exceeding the guideline recommendation and the total number of days beyond the recommended duration for each indication. RESULTS The most common reasons for antibiotics being prescribed were acute cough and bronchitis (386 972, 41.6% of the included consultations), acute sore throat (239 231, 25.7%), acute otitis media (83 054, 8.9%), and acute sinusitis (76 683, 8.2%). Antibiotic treatments for upper respiratory tract indications and acute cough and bronchitis accounted for more than two thirds of the total prescriptions considered, and 80% or more of these treatment courses exceeded guideline recommendations. Notable exceptions were acute sinusitis, where only 9.6% (95% confidence interval 9.4% to 9.9%) of prescriptions exceeded seven days and acute sore throat where only 2.1% (2.0% to 2.1%) exceeded 10 days (recent guidance recommends five days). More than half of the antibiotic prescriptions were for longer than guidelines recommend for acute cystitis among females (54.6%, 54.1% to 55.0%). The percentage of antibiotic prescriptions exceeding the recommended duration was lower for most non-respiratory infections. For the 931 015 included consultations resulting in antibiotic prescriptions, about 1.3 million days were beyond the durations recommended by guidelines. CONCLUSION For most common infections treated in primary care, a substantial proportion of antibiotic prescriptions have durations exceeding those recommended in guidelines. Substantial reductions in antibiotic exposure can be accomplished by aligning antibiotic prescription durations with guidelines.	[Pouwels, Koen B.; Robotham, Julie V.] Publ Hlth England, Modelling & Econ Unit, Natl Infect Serv, London NW9 5EQ, England; [Pouwels, Koen B.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Global Hlth, Groningen, Netherlands; [Pouwels, Koen B.] Univ Oxford, Nuffield Dept Populat Hlth, Hlth Econ Res Ctr, Oxford, England; [Hopkins, Susan] Publ Hlth England, Healthcare Associated Infect & Antimicrobial Resi, Natl Infect Serv, London, England; [Hopkins, Susan] Royal Free London NHS Fdn Trust, Directorate Infect, London, England; [Hopkins, Susan; Walker, Ann Sarah; Robotham, Julie V.] Natl Inst Hlth Res, Hlth Protect Res Unit Healthcare Associated Infec, Oxford, England; [Llewelyn, Martin J.] Brighton & Sussex Med Sch, Dept Global Hlth & Infect, Brighton, E Sussex, England; [Llewelyn, Martin J.] Brighton & Sussex Univ Hosp NHS Trust, Dept Microbiol & Infect, Brighton, E Sussex, England; [Walker, Ann Sarah] Univ Oxford, Nuffield Dept Med, Oxford, England; [McNulty, Cliodna A. M.] Publ Hlth England, Gloucestershire Royal Hosp, Microbiol Dept, Primary Care Unit, Gloucester, England	Public Health England; University of Groningen; University of Oxford; Public Health England; University of London; University College London; Royal Free London NHS Foundation Trust; University of Brighton; University of Sussex; Brighton and Sussex University Hospitals NHS Trust; University of Brighton; University of Oxford; Gloucestershire Royal Hospital; Public Health England	Pouwels, KB (corresponding author), Publ Hlth England, Modelling & Econ Unit, Natl Infect Serv, London NW9 5EQ, England.; Pouwels, KB (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Global Hlth, Groningen, Netherlands.; Pouwels, KB (corresponding author), Univ Oxford, Nuffield Dept Populat Hlth, Hlth Econ Res Ctr, Oxford, England.	k.b.pouwels@gmail.com	Llewelyn, Martin/Y-1472-2019; Walker, Sarah/HDM-8717-2022; Llewelyn, Martin/A-7194-2011; Pouwels, Koen B./F-2081-2013	Llewelyn, Martin/0000-0002-6811-1124; Pouwels, Koen B./0000-0001-7097-8950; Robotham, Julie/0000-0003-2515-4084; Hopkins, Susan/0000-0001-5179-5702; McNulty, Cliodna Ann Miriam/0000-0003-4969-5360	National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford; NIHR Oxford Biomedical Research Centre; Public Health England (PHE) [HPRU-2012-10041]	National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford; NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Public Health England (PHE)	SH, ASW, and JV are supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with Public Health England (PHE) (HPRU-2012-10041). ASW is also supported by the NIHR Oxford Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, Department of Health, or PHE.	Alimi Y, 2017, J CLIN VIROL, V95, P26, DOI 10.1016/j.jcv.2017.07.019; Alp E, 2005, J ANTIMICROB CHEMOTH, V56, P441, DOI 10.1093/jac/dki213; Andersson DI, 2010, NAT REV MICROBIOL, V8, P260, DOI 10.1038/nrmicro2319; Blanquart F, 2018, J R SOC INTERFACE, V15, DOI 10.1098/rsif.2018.0040; Burgette LF, 2010, AM J EPIDEMIOL, V172, P1070, DOI 10.1093/aje/kwq260; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Chatterjee A, 2018, LANCET INFECT DIS, V18, pE368, DOI 10.1016/S1473-3099(18)30296-2; Costelloe C, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2096; Dawson-Hahn EE, 2017, FAM PRACT, V34, P511, DOI 10.1093/fampra/cmx037; Del Mar C, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j4170; Deshpande A, 2013, J ANTIMICROB CHEMOTH, V68, P1951, DOI 10.1093/jac/dkt129; Dolk FCK, 2018, J ANTIMICROB CHEMOTH, V73, P2, DOI 10.1093/jac/dkx504; Falcone M, 2019, CLIN MICROBIOL INFEC, V25, P562, DOI 10.1016/j.cmi.2018.07.028; Fisher H, 2018, LANCET INFECT DIS, V18, P957, DOI 10.1016/S1473-3099(18)30279-2; Fleming-Dutra KE, 2016, JAMA-J AM MED ASSOC, V315, P1864, DOI 10.1001/jama.2016.4151; Gillies M, 2015, CAN MED ASSOC J, V187, pE21, DOI 10.1503/cmaj.140848; Joshi Neha S, 2018, Hosp Pediatr, V8, P21, DOI 10.1542/hpeds.2017-0082; King LM, 2018, JAMA INTERN MED, V178, P992, DOI 10.1001/jamainternmed.2018.0407; Lawes T, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006596; Little P, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1606; Little P, 2013, LANCET INFECT DIS, V13, P123, DOI 10.1016/S1473-3099(12)70300-6; Livorsi D, 2016, J HOSP MED, V11, P174, DOI 10.1002/jhm.2495; Llewelyn MJ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3418; Llor C, 2018, FAM PRACT, V35, P228, DOI 10.1093/fampra/cmx126; Lott A, 2020, AM STAT, V74, P109, DOI 10.1080/00031305.2018.1473796; McNulty CAM, 2013, BRIT J GEN PRACT, V63, pE429, DOI 10.3399/bjgp13X669149; National Institute for Health and Care Excellence (NICE), UR TRACT INF LOW ANT; National Institute for Health and Care Excellence (NICE), SOR THROAT AC ANT PR; National Institute for Health and Care Excellence (NICE), SIN AC ANT PRESCR GU; National Institute for Health and Care Excellence (NICE), OT MED AC ANT PRESCR; National Institute for Health and Care Excellence (NICE), PYEL AC ANT PRESCR G; National Institute for Health and Care Excellence (NICE), PROST AC ANT PRESCR; Odenholt I, 2003, ANTIMICROB AGENTS CH, V47, P518, DOI 10.1128/AAC.47.2.518-523.2003; Olesen SW, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3155; Pouwels KB, 2018, J ANTIMICROB CHEMOTH, V73, P27, DOI 10.1093/jac/dkx501; Pouwels KB, 2018, J ANTIMICROB CHEMOTH, V73, P1700, DOI 10.1093/jac/dky031; Pouwels KB, 2018, J ANTIMICROB CHEMOTH, V73, P19, DOI 10.1093/jac/dkx502; Pouwels KB, 2017, J GLOB ANTIMICROB RE, V11, P71, DOI 10.1016/j.jgar.2017.07.013; Public Health England, UR TRACT INF DIAGN T; Public Health England, MAN COMM INF GUID PR; Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMc1207269; Riordan A, 2016, ARCH DIS CHILD, V101, P117, DOI 10.1136/archdischild-2015-309132; Saxena S, 2012, BRIT J GEN PRACT, V62, P340, DOI 10.3399/bjgp12X652166; Singer A, 2018, FAM PRACT, V35, P455, DOI 10.1093/fampra/cmx118; Smieszek T, 2018, J ANTIMICROB CHEMOTH, V73, P36, DOI 10.1093/jac/dkx500; Smith DRM, 2018, J ANTIMICROB CHEM S2, V73; Spellberg B, 2016, JAMA INTERN MED, V176, P1254, DOI 10.1001/jamainternmed.2016.3646; Stevens V, 2011, CLIN INFECT DIS, V53, P42, DOI 10.1093/cid/cir301; US Food & Drug Administration, SAF AL HUM MED PROD	49	42	42	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 27	2019	364								l440	10.1136/bmj.l440	http://dx.doi.org/10.1136/bmj.l440			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN7RW	30814052	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000460390400001
J	Seid, MA; Abdela, OA; Zeleke, EG				Seid, Mohammed Assen; Abdela, Ousman Abubeker; Zeleke, Ejigu Gebeye			Adherence to self-care recommendations and associated factors among adult heart failure patients. From the patients' point of view	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; CLINICAL CHARACTERISTICS; EUROPEAN-SOCIETY; DISEASE; GUIDELINES; BEHAVIORS; MORTALITY; DIAGNOSIS; KNOWLEDGE; UPDATE	Background Nowadays, heart failure (HF) related morbidity and mortality rate is increasing globally. Younger populations happen to be more affected by HF in sub- Saharan African than the western countries. Even though medications, low sodium diet, regular exercise, and weight monitoring are essential to control heart failure symptoms and its exacerbation, poor adherence to these self-care recommendations is contributing to an increased in hospitalization, morbidity, and mortality. Therefore, this study aimed to assess heart failure patients' adherence to self-care recommendations and its associated factors. Methods A hospital-based cross-sectional study was conducted on 310 adult heart failure patients attending Gondar University referral hospital from February to May 2017. The participants were selected by systematic random sampling technique. Data were collected through face to face interview and from the patients' medical records. The data were analyzed using SPSS version 20. A binary logistic regression model was used to check the effect of different factors on the patients' adherence level. Results Of 310 study participants only 22.3% (95% CI, 17.4%-26.8%) of heart failure patients reported good adherence to their self-care recommendations. Adherence to self-care recommendation was positively associated with being male in gender (AOR = 2.34, 95% CI: 1.18-4.62), good level of heart failure knowledge (AOR = 2.49, 95% CI: 1.276-4.856) and free from chronic comorbid diseases (AOR = 2.57, 95% CI: 1.28-5.14). Conclusion Overall, heart failure patients' adherence to self-care recommendations is poor and selective. Being male in gender, had no chronic comorbidity, and a good level of heart failure knowledge were positively associated with adherence to self-care recommendations. It is therefore strategic to plan improving heart failure patients' knowledge about heart failure signs, symptoms and its management approaches, to improve the patients' adherence level.	[Seid, Mohammed Assen; Abdela, Ousman Abubeker] Univ Gondar, Dept Clin Pharm, Gondar, Ethiopia; [Zeleke, Ejigu Gebeye] Univ Gondar, Inst Publ Hlth, Dept Epidemiol & Biostat, Gondar, Ethiopia	University of Gondar; University of Gondar	Seid, MA (corresponding author), Univ Gondar, Dept Clin Pharm, Gondar, Ethiopia.	hassenm100@gmail.com	Seid, Mohammed Assen/ABB-8713-2020	Seid, Mohammed Assen/0000-0002-5659-2493	University of Gondar	University of Gondar	This research work was part of a Master thesis, funded by the University of Gondar (http://www.uog.edu.et/en/) through the postgraduate students' research fund. MAS received the award. The funders had no role in study design, data collection, analysis, and decision to publish, or preparation of the manuscript. There was no additional external funding received for this study and all the funding support was received during this study.	AL-khadher MAA, AHMED WAM COMPLIANCE; [Anonymous], 2017, Circulation, V136, pe196, DOI 10.1161/CIR.0000000000000530; [Anonymous], 2015, J NAT SCI; Artinian NT, 2002, HEART LUNG, V31, P161, DOI 10.1067/mhl.2002.123672; Carlson B, 2001, HEART LUNG, V30, P351, DOI 10.1067/mhl.2001.118611; Chriss PM, 2004, HEART LUNG, V33, P345, DOI 10.1016/j.hrtlng.2004.03.004; da Conceicao AP, 2015, REV LAT-AM ENFERM, V23, P578, DOI 10.1590/0104-1169.0288.2591; Damasceno A, 2012, ARCH INTERN MED, V172, P1386, DOI 10.1001/archinternmed.2012.3310; Davidson Patricia M, 2003, Eur J Cardiovasc Nurs, V2, P255, DOI 10.1016/S1474-5151(03)00056-2; Dracup K, 2014, J CARDIOVASC NURS, V29, P423, DOI 10.1097/JCN.0b013e31829cbcf3; Evangelista LS, 2001, HEART LUNG, V30, P294, DOI 10.1067/mhl.2001.116011; Fitzgerald AA, 2011, J CARD FAIL, V17, P664, DOI 10.1016/j.cardfail.2011.04.011; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Jankowska-Polanska B, 2017, J ED HLTH SPORT, V7, P392; Jessup M, 2003, NEW ENGL J MED, V348, P2007, DOI 10.1056/NEJMra021498; Kato N, 2013, INT HEART J, V54, P228, DOI 10.1536/ihj.54.228; Kato N, 2009, HEART LUNG, V38, P398, DOI 10.1016/j.hrtlng.2008.11.002; Kraus S, 2016, SAMJ S AFR MED J, V106, P23, DOI [10.7196/SAMJ.2016.v106i1.10325, 10.7196/SAMJ.2016.V106I1.10325]; Lainscak M, 2011, EUR J HEART FAIL, V13, P115, DOI 10.1093/eurjhf/hfq219; Lee CS, 2009, INT J NURS STUD, V46, P1485, DOI 10.1016/j.ijnurstu.2009.04.004; Lee KS, 2016, EUROPEAN J CARDIOVAS; Lin CY, 2018, J CARDIOVASC NURS, V33, P536, DOI 10.1097/JCN.0000000000000488; Lin CY, 2018, J CARDIOVASC NURS, V33, P281, DOI 10.1097/JCN.0000000000000444; Marti Catherine N, 2013, Congest Heart Fail, V19, P16, DOI 10.1111/j.1751-7133.2012.00308.x; Matsuoka S, 2016, HLTH LITERACY IS IND; McMurray JJV, 2012, EUR HEART J, V33, P1787, DOI 10.1093/eurheartj/ehs104; Moser DK, 2015, J CARD FAIL, V21, P612, DOI 10.1016/j.cardfail.2015.04.004; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Murray MD, 2009, CLIN PHARMACOL THER, V85, P651, DOI 10.1038/clpt.2009.7; Murray MD, 2007, ANN INTERN MED, V146, P714, DOI 10.7326/0003-4819-146-10-200705150-00005; Nieuwenhuis MMW, 2012, AM J CARDIOL, V110, P392, DOI 10.1016/j.amjcard.2012.03.039; Nkomo VT, 2007, HEART, V93, P1510, DOI 10.1136/hrt.2007.118810; Ogah OS, 2015, CLIN RES CARDIOL, V104, P481, DOI 10.1007/s00392-015-0810-y; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Riegel B, 2016, J CARDIOVASC NURS, V31, P226, DOI 10.1097/JCN.0000000000000244; Riegel B, 2014, PATIENT PREFER ADHER, V8, P1, DOI 10.2147/PPA.S54520; Ruf V, 2009, CARDIOVASCULAR J AFR, V21, P86; Sabat E, 2003, ADHERENCE LONG TERM; Sedlar N, 2017, EUR J CARDIOVASC NUR, V16, P272, DOI 10.1177/1474515117691644; Sewagegn N., 2015, J PHARM CARE HLTH SY, V10, P2376; Shah D, 2015, RES REP CLIN CARDIOL, V6, P87, DOI 10.2147/RRCC.S50658; Sliwa K, 2008, LANCET, V371, P915, DOI 10.1016/S0140-6736(08)60417-1; Sun Ok Jong, 2015, [Korean Journal of Adult Nursing, 성인간호학회지], V27, P242, DOI 10.7475/kjan.2015.27.2.242; Tefera YG, 2017, VASC HEALTH RISK MAN, V13, P143, DOI 10.2147/VHRM.S131259; Unverzagt S, 2016, DTSCH ARZTEBL INT, V113, P423, DOI 10.3238/arztebl.2016.0423; van der Wal MHL, 2010, EUR HEART J, V31, P1486, DOI 10.1093/eurheartj/ehq091; van der Wal MHL, 2006, EUR HEART J, V27, P434, DOI 10.1093/eurheartj/ehi603; van der Wal MHL, 2005, EUR J HEART FAIL, V7, P5, DOI 10.1016/j.ejheart.2004.04.007; Vellone E, 2014, PATIENT EDUC COUNS, V94, P97, DOI 10.1016/j.pec.2013.09.014; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019; Yusuf S, 2014, NEW ENGL J MED, V371, P818, DOI 10.1056/NEJMoa1311890; Ziaeian B, 2016, NAT REV CARDIOL, V13, P368, DOI 10.1038/nrcardio.2016.25	52	42	41	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2019	14	2							e0211768	10.1371/journal.pone.0211768	http://dx.doi.org/10.1371/journal.pone.0211768			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK5RX	30730931	Green Published, gold, Green Submitted			2023-01-03	WOS:000458026000057
J	Alanazi, MA; Tully, MP; Lewis, PJ				Alanazi, Mahdi A.; Tully, Mary P.; Lewis, Penny J.			Prescribing errors by junior doctors- A comparison of errors with high risk medicines and non-high risk medicines	PLOS ONE			English	Article							IN-HOSPITAL INPATIENTS; ADVERSE DRUG EVENTS; MEDICATION ERRORS; PREVALENCE; WORKING; IMPACT	Introduction Prescribing errors in hospital are common. However, errors with high-risk-medicines (HRMs) have a greater propensity to cause harm compared to non-HRMs. We do not know if there are differences between the causes of errors with HRMs and non-HRMs but such knowledge might be useful in developing interventions to reduce errors and avoidable harm. Therefore, this study aims to compare and contrast junior doctors' prescribing errors with HRMs to non-HRMs to establish any differences. Methods A secondary analysis of fifty-nine interviews with foundation year doctors, obtained from three studies, was conducted. Using a Framework Analysis approach, through NVivo software, a detailed comparison was conducted between the unsafe acts, error-causing-conditions (ECCs), latent conditions, and types of errors related to prescribing errors with HRMs and non-HRMs. Results In relation to unsafe acts, violations were described in the data with non-HRMs only. Differences in ECCs of HRMs and non-HRMs were identified and related to the complexity of prescribing HRMs, especially dosage calculations. There were also differences in the circumstances of communication failures: with HRMs ineffective communication arose with exchanges with individuals outside the immediate medical team while with non-HRMs these failures occurred with exchanges within that team. Differences were identified with the latent conditions: with non-HRMs there was a reluctance to seek seniors help and with HRMs latent conditions related to the organisational system such as the inclusion of trade names in hospital formularies. Moreover, prescribing during the on-call period was particularly challenging especially with HRMs. Conclusion From this secondary analysis, differences in the nature and type of prescribing errors with HRMs and non-HRMs were identified, although further research is needed to investigate their prevalence. As errors with HRMs have the potential to cause great harm it may be appropriate to target limited resources towards interventions that tackle the underlying causes of such errors. Equally concerning, however, was the sense that doctors regard the prescribing of non-HRMs as 'safe'.	[Alanazi, Mahdi A.; Tully, Mary P.; Lewis, Penny J.] Univ Manchester, Fac Biol Med & Hlth, Sch Hlth Sci, Div Pharm & Optometry, Manchester, Lancs, England; [Alanazi, Mahdi A.] PSMMC, Pharmaceut Serv, Riyadh, Saudi Arabia	University of Manchester	Alanazi, MA; Lewis, PJ (corresponding author), Univ Manchester, Fac Biol Med & Hlth, Sch Hlth Sci, Div Pharm & Optometry, Manchester, Lancs, England.; Alanazi, MA (corresponding author), PSMMC, Pharmaceut Serv, Riyadh, Saudi Arabia.	ph.mahdi@yahoo.com; Penny.Lewis@manchester.ac.uk	Lewis, Penny/AAK-2928-2020	Lewis, Penny/0000-0002-3976-5807; Alanazi, Mahdi/0000-0002-7897-0483; Tully, Mary/0000-0003-2100-3983	Saudi Arabian Government	Saudi Arabian Government	The authors received no specific funding for this work. This study formed part of MA's PhD which was fully sponsored by the Saudi Arabian Government.	Alanazi MA, 2016, J CLIN PHARM THER, V41, P239, DOI 10.1111/jcpt.12389; [Anonymous], 2016, NVIVO QUAL DAT AN SO, DOI [10.1111/j.1365-2125.2012.04313.x, DOI 10.1111/J.1365-2125.2012.04313.X]; Ashcroft DM, 2015, DRUG SAFETY, V38, P833, DOI 10.1007/s40264-015-0320-x; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; Buckley MS, 2007, PEDIATR CRIT CARE ME, V8, P145, DOI 10.1097/01.PCC.0000257038.39434.04; Cheng Hui G, 2014, Shanghai Arch Psychiatry, V26, P371, DOI 10.11919/j.issn.1002-0829.214171; Classen DC, 2010, JT COMM J QUAL PATIE, V36, P12, DOI 10.1016/S1553-7250(10)36003-X; Coombes ID, 2009, QUAL SAF HEALTH CARE, V18, P478, DOI 10.1136/qshc.2007.025296; Coombes ID, 2008, MED J AUSTRALIA, V188, P89, DOI 10.5694/j.1326-5377.2008.tb01529.x; Dean B, 2002, QUAL SAF HEALTH CARE, V11, P340, DOI 10.1136/qhc.11.4.340; Dean B, 2000, QUAL HEALTH CARE, V9, P232, DOI 10.1136/qhc.9.4.232; Dean B, 2002, LANCET, V359, P1373, DOI 10.1016/S0140-6736(02)08350-2; Degnan BA, 2006, ANAESTHESIA, V61, P1155, DOI 10.1111/j.1365-2044.2006.04869.x; Doolan DM, 2017, MED RES ARCH, V5, DOI [10.18103/mra.v5i9.1526, DOI 10.18103/MRA.V5I9.1526]; Dornan T., 2009, DEPTH INVESTIGATION; Duncan EM, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-86; Elliott R, 2018, PREVALENCE EC BURDEN; Ferguson J, 2018, RES SOC ADMIN PHARM, V14, P241, DOI 10.1016/j.sapharm.2017.03.001; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Green J, 2007, AUST NZ J PUBL HEAL, V31, P545, DOI 10.1111/j.1753-6405.2007.00141.x; Hinds PS, 1997, QUAL HEALTH RES, V7, P408, DOI 10.1177/104973239700700306; Institute for Safe Medication Practices, 2014, ISMP LIST HIGH AL ME; Keyworth Chris, 2017, JMIR Hum Factors, V4, pe17, DOI 10.2196/humanfactors.7153; Kopp BJ, 2006, CRIT CARE MED, V34, P415, DOI 10.1097/01.CCM.0000198106.54306.D7; L ewis P, 2015, PHARMACOEPIDEM DR S, pO15, DOI [10.1002/pds.3812, DOI 10.1002/PDS.3812]; Lambert TW, 2003, BRIT MED J, V326, P194, DOI 10.1136/bmj.326.7382.194; Lawton R, 1998, SAFETY SCI, V28, P77, DOI 10.1016/S0925-7535(97)00073-8; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; Lederman R M, 2005, J Med Syst, V29, P33, DOI 10.1007/s10916-005-1102-2; Lewis PJ, 2014, BRIT J CLIN PHARMACO, V78, P310, DOI 10.1111/bcp.12332; Lewis PJ, 2009, J ROY SOC MED, V102, P481, DOI 10.1258/jrsm.2009.090150; Lewis PJ, 2009, DRUG SAFETY, V32, P379, DOI 10.2165/00002018-200932050-00002; McLellan L, 2016, J ANTIMICROB CHEMOTH, V71, P1415, DOI 10.1093/jac/dkv482; Moriarty HJ, 1999, WESTERN J NURS RES, V21, P143, DOI 10.1177/01939459922043794; National Patient Safety Agency, 2007, 4 NAT PAT SAF AG, V4, P1; NHS, 2008, RED HARM HIGH RISK M; Noble C, 2017, MED EDUC, V51, P442, DOI 10.1111/medu.13227; Parke John, 2006, Journal of Pharmacy Practice and Research, V36, P21; Patterson ES, 2004, IEEE T SYST MAN CY A, V34, P749, DOI 10.1109/TSMCA.2004.836807; Phipps DL, 2008, ERGONOMICS, V51, P1625, DOI 10.1080/00140130802331617; Reason J, 2000, BMJ-BRIT MED J, V320, P768, DOI 10.1136/bmj.320.7237.768; Reason J., 1990, HUMAN ERROR; Rew L, 2000, NURS OUTLOOK, V48, P223, DOI 10.1067/mno.2000.104901; Ritchie J., 2013, QUALITATIVE RES PRAC; Ross S, 2013, BMJ QUAL SAF, V22, P97, DOI 10.1136/bmjqs-2012-001175; Ryan C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0079802; Ryan C, 2013, BRIT J CLIN PHARMACO, V76, P980, DOI 10.1111/bcp.12154; Tully MP, 2012, BRIT J CLIN PHARMACO, V74, P668, DOI 10.1111/j.1365-2125.2012.04313.x; Tully MP, 2009, DRUG SAFETY, V32, P819, DOI 10.2165/11316560-000000000-00000; Tully MP, 2009, PHARM WORLD SCI, V31, P682, DOI 10.1007/s11096-009-9332-x	51	8	8	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2019	14	1							e0211270	10.1371/journal.pone.0211270	http://dx.doi.org/10.1371/journal.pone.0211270			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HJ6LR	30703104	Green Published, gold, Green Submitted			2023-01-03	WOS:000457301600034
J	Pugliese, M; Ramsay, T; Shamloul, R; Mallet, K; Zakutney, L; Corbett, D; Dukelow, S; Stotts, G; Shamy, M; Wilson, K; Guerinet, J; Dowlatshahi, D				Pugliese, Michael; Ramsay, Tim; Shamloul, Rany; Mallet, Karen; Zakutney, Lise; Corbett, Dale; Dukelow, Sean; Stotts, Grant; Shamy, Michel; Wilson, Kumanan; Guerinet, Julien; Dowlatshahi, Dar			RecoverNow: A mobile tablet-based therapy platform for early stroke rehabilitation	PLOS ONE			English	Article							POSTSTROKE DEPRESSION; CLINICAL-TRIALS; TELEREHABILITATION	Introduction Stroke survivors frequently experience a range of post-stroke deficits. Specialized stroke rehabilitation improves recovery, especially if it is started early post-stroke. However, resource limitations often preclude early rehabilitation. Mobile technologies may provide a platform for stroke survivors to begin recovery when they might not be able to otherwise. The study objective was to demonstrate the feasibility of RecoverNow, a tablet-based stroke recovery platform aimed at delivering speech and cognitive therapy. Methods We recruited a convenience sample of 30 acute stroke patients to use RecoverNow for up to 3 months. Allied health professionals assigned specific applications based on standard of care assessments. Participants were encouraged to take home the RecoverNow tablets upon discharge from acute care. The study team contacted participants to return for a follow-up interview 3 months after enrollment. The primary outcome of interest was feasibility, defined using 5 facets: recruitment rate, adherence rate, retention rate, the proportion of successful follow-up interventions, and protocol deviations. We tracked barriers to tablet-based care as a secondary outcome. Results We successfully recruited 30 of 62 eligible patients in 15 weeks (48% recruitment rate). Participants were non-adherent to tablet-based therapy inside and outside of acute care, using RecoverNow for a median of 12 minutes a day. Retention was high with 23 of 30 patients participating in follow-up interviews (77% retention rate) and all but 3 of the 23 interviews (87%) were successfully completed. Only 2 major protocol deviations occurred: one enrollment failure and one therapy protocol violation. Barriers to tablet-based care were frequently encountered by study participants with many expressing the assigned applications were either too easy or too difficult. Conclusions Acute stroke patients are interested in attempting tablet-based stroke rehabilitation and are easily recruited early post-stroke. However, tablet-based therapy may be challenging due to patient, device and system-related barriers. Reducing the frequency of common barriers will be essential to keeping patients engaged in tablet-based therapy.	[Pugliese, Michael; Ramsay, Tim; Wilson, Kumanan; Dowlatshahi, Dar] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada; [Ramsay, Tim; Shamloul, Rany; Mallet, Karen; Stotts, Grant; Shamy, Michel; Wilson, Kumanan; Guerinet, Julien; Dowlatshahi, Dar] Ottawa Hosp, Res Inst, Ottawa, ON, Canada; [Mallet, Karen; Zakutney, Lise; Stotts, Grant; Shamy, Michel; Dowlatshahi, Dar] Champlain Reg Stroke Network, Ottawa, ON, Canada; [Mallet, Karen; Zakutney, Lise; Stotts, Grant; Shamy, Michel; Wilson, Kumanan; Dowlatshahi, Dar] Ottawa Hosp, Ottawa, ON, Canada; [Mallet, Karen; Corbett, Dale; Dukelow, Sean; Dowlatshahi, Dar] Canadian Partnership Stroke Recovery, Ottawa, ON, Canada; [Corbett, Dale] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Corbett, Dale; Stotts, Grant; Dowlatshahi, Dar] Univ Ottawa, Brain & Mind Res Inst, Ottawa, ON, Canada; [Dukelow, Sean] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Calgary	Pugliese, M (corresponding author), Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada.	mpugl038@uottawa.ca		Pugliese, Michael/0000-0003-2794-1436; Dowlatshahi, Dar/0000-0003-1379-3612	Canadian Institutes of Health Research Canadian Graduate Scholarship Master's Award; University of Ottawa Ontario Graduate Scholarship; University of Ottawa Brain and Mind Research Institute; Canadian Partnership for Stroke Recovery; University of Ottawa Department of Medicine	Canadian Institutes of Health Research Canadian Graduate Scholarship Master's Award; University of Ottawa Ontario Graduate Scholarship; University of Ottawa Brain and Mind Research Institute; Canadian Partnership for Stroke Recovery; University of Ottawa Department of Medicine	This work was supported by a Canadian Institutes of Health Research Canadian Graduate Scholarship Master's Award (http://www.cihr-irsc.gc.ca/e/49440.html; M.P.), a University of Ottawa Ontario Graduate Scholarship (https://www.uottawa.ca/graduate-studies/students/awards/ontario-graduate-scholarship; M.P.), the University of Ottawa Brain and Mind Research Institute (https://www.uottawa.ca/brain/; D.D), the Canadian Partnership for Stroke Recovery (http://www.canadianstroke.ca/en/; D.D.), and the University of Ottawa Department of Medicine (https://med.uottawa.ca/en; D.D.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2007, MORBITY MORTAL WKLY, V56, P504; Banks JL, 2007, STROKE, V38, P1091, DOI 10.1161/01.STR.0000258355.23810.c6; Bernhardt J, 2004, STROKE, V35, P1005, DOI 10.1161/01.STR.0000120727.40792.40; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Burton LJ, 2015, PSYCHOL MED, V45, P29, DOI 10.1017/S0033291714000336; Carabeo CGG, 2014, SIMULAT GAMING, V45, P151, DOI 10.1177/1046878114531102; Choi YH, 2016, TELEMED E-HEALTH, V22, P434, DOI 10.1089/tmj.2015.0138; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, pS35, DOI 10.1016/S0003-9993(99)90101-6; Crotty M, 2014, J TELEMED TELECARE, V20, P370, DOI 10.1177/1357633X14552382; de Man-van Ginkel JM, 2012, NURS RES, V61, P333, DOI 10.1097/NNR.0b013e31825d9e9e; Des Roches CA, 2015, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.01015; Faltynek P, 2018, EVIDENCE BASED REV S; Heart and Stroke Foundation, 2014, TOG RIS TID ADV STRO; Hoover EL, 2014, SEMIN SPEECH LANG, V35, P25, DOI 10.1055/s-0033-1362990; Hussein N., 2018, EVIDENCE BASED REV S; Jang SH, 2016, SOMATOSENS MOT RES, V33, P124, DOI 10.1080/08990220.2016.1197117; Katalinic O, 2013, J TELEMED TELECARE, V19, P418, DOI 10.1177/1357633X13506513; Kizony R, 2016, J NEUROL PHYS THER, V40, P31, DOI 10.1097/NPT.0000000000000110; Krakauer JW, 2015, GETTING NEUROREHABIL, V26, P923, DOI [10.1177/1545968312440745.Getting, DOI 10.1177/1545968312440745.GETTING]; Kurland J, 2014, CLIN APHASIOLOGY C, V35, P51; Lavoie M, 2016, NEUROCASE, V22, P109, DOI 10.1080/13554794.2015.1051055; MAHONEY F I, 1965, Md State Med J, V14, P61; Mallet K, 2019, INT J STROKE, V14, P174, DOI 10.1177/1747493018790031; Mallet KH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167950; Meader N, 2014, J NEUROL NEUROSUR PS, V85, P198, DOI 10.1136/jnnp-2012-304194; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; NAKAYAMA H, 1994, ARCH PHYS MED REHAB, V75, P394, DOI 10.1016/0003-9993(94)90161-9; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; Pugliese M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191566; Quinn TJ, 2011, STROKE, V42, P1146, DOI 10.1161/STROKEAHA.110.598540; Rand D., 2013, 2013 International Conference on Virtual Rehabilitation (ICVR), P109, DOI 10.1109/ICVR.2013.6662068; Routhier S, 2016, APHASIOLOGY, V30, P269, DOI 10.1080/02687038.2014.973361; Salter K, 2018, EVIDENCE BASED REV S; Stark BC, 2018, NEUROPSYCHOL REHABIL, V28, P818, DOI 10.1080/09602011.2016.1146150; Swartz RH, 2016, INT J STROKE, V11, P509, DOI 10.1177/1747493016641968; White JH, 2015, DISABIL REHABIL, V37, P593, DOI 10.3109/09638288.2014.935876; Zhou X, 2018, TOP STROKE REHABIL, V25, P489, DOI 10.1080/10749357.2018.1482446	37	11	11	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2019	14	1							e0210725	10.1371/journal.pone.0210725	http://dx.doi.org/10.1371/journal.pone.0210725			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HJ2YV	30682076	Green Published, Green Submitted, gold			2023-01-03	WOS:000457037500056
J	Hilf, N; Kuttruff-Coqui, S; Frenzel, K; Bukur, V; Stevanovic, S; Gouttefangeas, C; Platten, M; Tabatabai, G; Dutoit, V; van der Burg, SH; Straten, PT; Martinez-Ricarte, F; Ponsati, B; Okada, H; Lassen, U; Admon, A; Ottensmeier, CH; Ulges, A; Kreiter, S; von Deimling, A; Skardelly, M; Migliorini, D; Kroep, JR; Idorn, M; Rodon, J; Piro, J; Poulsen, HS; Shraibman, B; McCann, K; Mendrzyk, R; Lower, M; Stieglbauer, M; Britten, CM; Capper, D; Welters, MJP; Sahuquillo, J; Kiesel, K; Derhovanessian, E; Rusch, E; Bunse, L; Song, C; Heesch, S; Wagner, C; Kemmer-Bruck, A; Ludwig, J; Castle, JC; Schoor, O; Tadmor, AD; Green, E; Fritsche, J; Meyer, M; Pawlowski, N; Dorner, S; Hoffgaard, F; Rossler, B; Maurer, D; Weinschenk, T; Reinhardt, C; Huber, C; Rammensee, HG; Singh-Jasuja, H; Sahin, U; Dietrich, PY; Wick, W				Hilf, Norbert; Kuttruff-Coqui, Sabrina; Frenzel, Katrin; Bukur, Valesca; Stevanovic, Stefan; Gouttefangeas, Cecile; Platten, Michael; Tabatabai, Ghazaleh; Dutoit, Valerie; van der Burg, Sjoerd H.; Straten, Per Thor; Martinez-Ricarte, Francisco; Ponsati, Berta; Okada, Hideho; Lassen, Ulrik; Admon, Arie; Ottensmeier, Christian H.; Ulges, Alexander; Kreiter, Sebastian; von Deimling, Andreas; Skardelly, Marco; Migliorini, Denis; Kroep, Judith R.; Idorn, Manja; Rodon, Jordi; Piro, Jordi; Poulsen, Hans S.; Shraibman, Bracha; McCann, Katy; Mendrzyk, Regina; Loewer, Martin; Stieglbauer, Monika; Britten, Cedrik M.; Capper, David; Welters, Marij J. P.; Sahuquillo, Juan; Kiesel, Katharina; Derhovanessian, Evelyna; Rusch, Elisa; Bunse, Lukas; Song, Colette; Heesch, Sandra; Wagner, Claudia; Kemmer-Bruck, Alexandra; Ludwig, Joerg; Castle, John C.; Schoor, Oliver; Tadmor, Arbel D.; Green, Edward; Fritsche, Jens; Meyer, Miriam; Pawlowski, Nina; Dorner, Sonja; Hoffgaard, Franziska; Roessler, Bernhard; Maurer, Dominik; Weinschenk, Toni; Reinhardt, Carsten; Huber, Christoph; Rammensee, Hans-Georg; Singh-Jasuja, Harpreet; Sahin, Ugur; Dietrich, Pierre-Yves; Wick, Wolfgang			Actively personalized vaccination trial for newly diagnosed glioblastoma	NATURE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; T-CELL RESPONSES; IMMUNE-RESPONSE; CANCER; MELANOMA; IDENTIFICATION; ANTIGENS; PATIENT; TEMOZOLOMIDE; MULTIFORME	Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors(1,2). For treatments using checkpoint inhibitors to be successful, a high mutational load and responses to neoepitopes are thought to be essential(3). There is limited intratumoural infiltration of immune cells(4) in glioblastoma and these tumours contain only 30-50 non-synonymous mutations(5). Exploitation of the full repertoire of tumour antigens-that is, both unmutated antigens and neoepitopes-may offer more effective immunotherapies, especially for tumours with a low mutational load. Here, in the phase I trial GAPVAC-101 of the Glioma Actively Personalized Vaccine Consortium (GAPVAC), we integrated highly individualized vaccinations with both types of tumour antigens into standard care to optimally exploit the limited target space for patients with newly diagnosed glioblastoma. Fifteen patients with glioblastomas positive for human leukocyte antigen (HLA)-A*02:01 or HLA-A* 24:02 were treated with a vaccine (APVAC1) derived from a premanufactured library of unmutated antigens followed by treatment with APVAC2, which preferentially targeted neoepitopes. Personalization was based on mutations and analyses of the transcriptomes and immunopeptidomes of the individual tumours. The GAPVAC approach was feasible and vaccines that had poly-ICLC (polyriboinosinic-polyribocytidylic acid-poly-L-lysine carboxymethylcellulose) and granulocyte-macrophage colony-stimulating factor as adjuvants displayed favourable safety and strong immunogenicity. Unmutated APVAC1 antigens elicited sustained responses of central memory CD8(+) T cells. APVAC2 induced predominantly CD4(+) T cell responses of T helper 1 type against predicted neoepitopes.	[Hilf, Norbert; Kuttruff-Coqui, Sabrina; Ulges, Alexander; Mendrzyk, Regina; Kiesel, Katharina; Song, Colette; Wagner, Claudia; Ludwig, Joerg; Schoor, Oliver; Fritsche, Jens; Meyer, Miriam; Pawlowski, Nina; Dorner, Sonja; Hoffgaard, Franziska; Roessler, Bernhard; Maurer, Dominik; Weinschenk, Toni; Reinhardt, Carsten; Singh-Jasuja, Harpreet] Immat Biotechnol GmbH, Tubingen, Germany; [Frenzel, Katrin; Bukur, Valesca; Kreiter, Sebastian; Loewer, Martin; Britten, Cedrik M.; Derhovanessian, Evelyna; Heesch, Sandra; Kemmer-Bruck, Alexandra; Castle, John C.; Huber, Christoph; Sahin, Ugur] BioNTech AG, Mainz, Germany; [Stevanovic, Stefan; Gouttefangeas, Cecile; Tabatabai, Ghazaleh; Stieglbauer, Monika; Rusch, Elisa; Rammensee, Hans-Georg] Eberhard Karls Univ Tubingen, Tubingen, Germany; [Stevanovic, Stefan; Gouttefangeas, Cecile; Tabatabai, Ghazaleh; Rammensee, Hans-Georg] German Canc Consortium DKTK, German Canc Res Ctr Partner Site Tubingen, Tubingen, Germany; [Gouttefangeas, Cecile; van der Burg, Sjoerd H.; Straten, Per Thor; Kreiter, Sebastian; Stieglbauer, Monika; Britten, Cedrik M.; Welters, Marij J. P.; Rusch, Elisa] CIMT CIP Assoc Canc Immunotherapy, Working Grp Canc Immunoguiding Program, Mainz, Germany; [Platten, Michael; von Deimling, Andreas; Capper, David; Bunse, Lukas; Wick, Wolfgang] Univ Hosp Heidelberg, Heidelberg, Germany; [Platten, Michael; von Deimling, Andreas; Capper, David; Bunse, Lukas; Green, Edward; Wick, Wolfgang] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany; [Platten, Michael; Green, Edward] Med Fac Mannheim, Mannheim, Germany; [Tabatabai, Ghazaleh; Skardelly, Marco] Univ Hosp Tubingen, Tubingen, Germany; [Dutoit, Valerie; Migliorini, Denis; Dietrich, Pierre-Yves] Geneva Univ Hosp, Geneva, Switzerland; [van der Burg, Sjoerd H.; Kroep, Judith R.; Welters, Marij J. P.] Leiden Univ, Med Ctr, Leiden, Netherlands; [Straten, Per Thor; Idorn, Manja] Univ Hosp Herlev, Dept Hematol, CCIT, Herlev, Denmark; [Straten, Per Thor; Idorn, Manja] Univ Copenhagen, Dept Immunol & Microbiol, Copenhagen, Denmark; [Martinez-Ricarte, Francisco; Rodon, Jordi; Sahuquillo, Juan] Vall dHebron Univ Hosp, Barcelona, Spain; [Ponsati, Berta; Piro, Jordi] BCN Peptides SA, Barcelona, Spain; [Okada, Hideho] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Okada, Hideho] Parker Inst Canc Immunotherapy, San Francisco, CA USA; [Lassen, Ulrik; Poulsen, Hans S.] Ringhospitalet, Copenhagen, Denmark; [Admon, Arie; Shraibman, Bracha] Technion Israel Inst Technol, Haifa, Israel; [Ottensmeier, Christian H.; McCann, Katy] Univ Southampton, Southampton, Hants, England; [Tadmor, Arbel D.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, TRON GmbH Translat Oncol, Mainz, Germany; [Rodon, Jordi] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Britten, Cedrik M.] GlaxoSmithKline, Oncol R&D, Stevenage, Herts, England; [Capper, David] Charite Univ Med Berlin, Berlin, Germany; [Castle, John C.] Agenus Inc, Lexington, KY USA	Immatics Biotechnologies GmbH; BioNTech SE; Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Geneva; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Copenhagen; Hospital Universitari Vall d'Hebron; University of California System; University of California San Francisco; Technion Israel Institute of Technology; University of Southampton; Johannes Gutenberg University of Mainz; University of Texas System; UTMD Anderson Cancer Center; GlaxoSmithKline; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Agenus Inc	Wick, W (corresponding author), Univ Hosp Heidelberg, Heidelberg, Germany.; Wick, W (corresponding author), German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany.	wolfgang.wick@med.uni-heidelberg.de	von Deimling, Andreas/F-7774-2013; Idorn, Manja/AAY-6260-2021; Ottensmeier, Christian/ABE-9056-2020; Tabatabai, Ghazaleh/A-6365-2015; Platten, Michael/F-2902-2013; Migliorini, Denis/Q-2699-2019; Martinez-Ricarte, Fran/AAI-6846-2020; Capper, David/I-8500-2014; Bunse, Lukas/L-2975-2016; Wick, Wolfgang/AAA-2545-2020; Martinez-Ricarte, Fran/J-4729-2017; Skardelly, Marco/AAF-8680-2021; Sahuquillo, Juan/B-3577-2008; Lassen, Ulrik/AAH-2799-2021; van der Burg, Sjoerd H/T-1875-2017	von Deimling, Andreas/0000-0002-5863-540X; Idorn, Manja/0000-0002-6769-9165; Ottensmeier, Christian/0000-0003-3619-1657; Tabatabai, Ghazaleh/0000-0003-3702-923X; Platten, Michael/0000-0002-4746-887X; Migliorini, Denis/0000-0003-0151-3222; Martinez-Ricarte, Fran/0000-0003-4567-0828; Capper, David/0000-0003-1945-497X; Bunse, Lukas/0000-0002-4490-7574; Wick, Wolfgang/0000-0002-6171-634X; Martinez-Ricarte, Fran/0000-0003-4567-0828; Sahuquillo, Juan/0000-0003-0713-5875; van der Burg, Sjoerd H/0000-0002-6556-0354; thor Straten, Per/0000-0002-4731-4969; Lassen, Ulrik/0000-0002-3865-4574; Admon, Arie/0000-0003-0504-3950; Wagner, Claudia/0000-0002-7311-2236; Kroep, Judith/0000-0003-2671-1903; Tabatabai, Ghazaleh/0000-0002-3542-8782	European Union [305061]; MRC [MR/P024351/1] Funding Source: UKRI	European Union(European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank all patients and their families for participating in this clinical trial; the Data Safety Monitoring Board (J. Rich, O. Chinot and C. Huber); S. Hess, M. Krauss (FGK) and S. Becker (spm<SUP>2</SUP>) for their contributions to trial management; I. Groskopf and M. Adis for technical support; T. Hillemann, M. Erdeljan and L. Alten for contributions to the revisions. A. Salazar (Oncovir) provided poly-ICLC. GAPVAC was supported by the European Union's FP7-HEALTH Research and Innovation funding program (number 305061). Further support information can be found in Supplementary Notes.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; BERTOLETTI A, 1993, J VIROL, V67, P2376, DOI 10.1128/JVI.67.4.2376-2380.1993; Bouffet E, 2016, J CLIN ONCOL, V34, P2206, DOI 10.1200/JCO.2016.66.6552; Britten CM, 2008, CANCER IMMUNOL IMMUN, V57, P289, DOI 10.1007/s00262-007-0378-0; Cohen CJ, 2007, CANCER RES, V67, P3898, DOI 10.1158/0008-5472.CAN-06-3986; Dutoit V, 2012, BRAIN, V135, P1042, DOI 10.1093/brain/aws042; Freudenmann LK, 2018, IMMUNOLOGY, V154, P331, DOI 10.1111/imm.12936; GRIMM EA, 1991, CANCER IMMUNOL IMMUN, V32, P391, DOI 10.1007/BF01741334; Hadrup SR, 2006, INT J CANCER, V119, P831, DOI 10.1002/ijc.21894; Hadrup SR, 2009, NAT METHODS, V6, P520, DOI 10.1038/nmeth.1345; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Johanns TM, 2016, CANCER DISCOV, V6, P1230, DOI 10.1158/2159-8290.CD-16-0575; Kalaora S, 2016, ONCOTARGET, V7, P5110, DOI 10.18632/oncotarget.6960; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202. Article published online before March 2002, 10.1101/gr.229202]; Kim Y, 2012, NUCLEIC ACIDS RES, V40, pW525, DOI 10.1093/nar/gks438; Kobayashi E, 2013, NAT MED, V19, P1542, DOI 10.1038/nm.3358; Koressaar T, 2007, BIOINFORMATICS, V23, P1289, DOI 10.1093/bioinformatics/btm091; Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lawson DH, 2015, J CLIN ONCOL, V33, P4066, DOI 10.1200/JCO.2015.62.0500; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Livingston BD, 1997, J IMMUNOL, V159, P1383; Loffler MW, 2016, J HEPATOL, V65, P849, DOI 10.1016/j.jhep.2016.06.027; Morse MA, 2011, CLIN CANCER RES, V17, P4844, DOI 10.1158/1078-0432.CCR-11-0891; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Okada H, 2011, J CLIN ONCOL, V29, P330, DOI 10.1200/JCO.2010.30.7744; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Platten M, 2016, CANCER IMMUNOL IMMUN, V65, P1269, DOI 10.1007/s00262-016-1874-x; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Rampling R, 2016, CLIN CANCER RES, V22, P4776, DOI 10.1158/1078-0432.CCR-16-0506; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Rodenko B, 2006, NAT PROTOC, V1, P1120, DOI 10.1038/nprot.2006.121; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Santegoets SJAM, 2015, CANCER IMMUNOL IMMUN, V64, P1271, DOI 10.1007/s00262-015-1729-x; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Shraibman B, 2018, MOL CELL PROTEOMICS, V17, P2132, DOI 10.1074/mcp.RA118.000792; Singh-Jasuja H, 2004, CANCER IMMUNOL IMMUN, V53, P187, DOI 10.1007/s00262-003-0480-x; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Stanke J, 2010, J IMMUNOL METHODS, V360, P56, DOI 10.1016/j.jim.2010.06.005; Straten PT, 2006, CANCER IMMUNOL IMMUN, V55, P495, DOI 10.1007/s00262-005-0023-8; Straten PT, 1999, J IMMUNOL, V163, P443; Stupp R, 2014, ANN ONCOL, V25, P93, DOI 10.1093/annonc/mdu050; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tran E, 2015, SCIENCE, V350, P1387, DOI 10.1126/science.aad1253; Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596; van der Burg SH, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002785; Walter S, 2003, J IMMUNOL, V171, P4974, DOI 10.4049/jimmunol.171.10.4974; Walter S, 2012, NAT MED, V18, P1254, DOI 10.1038/nm.2883; Weinschenk T, 2002, CANCER RES, V62, P5818; Weller M, 2017, LANCET ONCOL, V18, P1373, DOI 10.1016/S1470-2045(17)30517-X; Weller M, 2017, NAT REV NEUROL, V13, P363, DOI 10.1038/nrneurol.2017.64; Welters MJP, 2012, CANCER IMMUNOL IMMUN, V61, P967, DOI 10.1007/s00262-012-1282-9; Wen PY, 2010, J CLIN ONCOL, V28, P1963, DOI 10.1200/JCO.2009.26.3541; Widenmeyer M, 2012, INT J CANCER, V131, P140, DOI 10.1002/ijc.26365; Woroniecka K, 2018, CLIN CANCER RES, V24, P4175, DOI 10.1158/1078-0432.CCR-17-1846; Yadav M, 2014, NATURE, V515, P572, DOI 10.1038/nature14001; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	57	431	452	13	259	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 10	2019	565	7738					240	+		10.1038/s41586-018-0810-y	http://dx.doi.org/10.1038/s41586-018-0810-y			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG8EK	30568303	Green Submitted, Green Accepted			2023-01-03	WOS:000455231000048
J	Alegre, F; Ormonde, AR; Snider, KM; Woolard, K; Yu, AM; Wittenburg, LA				Alegre, Fernando; Ormonde, Amanda R.; Snider, Kellie M.; Woolard, Kevin; Yu, Ai-Ming; Wittenburg, Luke A.			A genetically engineered microRNA-34a prodrug demonstrates anti-tumor activity in a canine model of osteosarcoma	PLOS ONE			English	Article							RNA-DERIVED FRAGMENTS; COMPARATIVE ONCOLOGY; CANCER PROGRESSION; MIR-34A; EXPRESSION; CELLS; PROLIFERATION; INVASION; QUANTIFICATION; METASTASIS	Osteosarcoma (OSA) represents the most common primary bone tumor in humans and pet dogs. Little progress has been made with regard to viable treatment options in the past three decades and patients presenting with metastatic disease continue to have a poor prognosis. Recent mouse studies have suggested that microRNA-34a (miR-34a) may have anti-tumor activities in human OSA models. Due to the conservation of microRNA across species, we hypothesized that a bioengineered miR-34a prodrug (tRNA/miR-34a) would have similar effects in canine OSA, providing a valuable preclinical model for development of this therapeutic modality. Using a panel of canine OSA cell lines, we found that tRNA/miR-34a reduced viability, clonogenic growth, and migration and invasion while increasing tumor cell apoptosis. Furthermore, canine OSA cells successfully process the tRNA/miR-34a into mature miR-34a which reduces expression of target proteins such as platelet derived growth factor receptor alpha (PDGFR alpha), Notch1 and vascular endothelial growth factor (VEGF). Additionally, our subcutaneous OSA xenograft model demonstrated in vivo tumor growth delay, increased necrosis and apoptosis by tRNA/miR-34a, and decreased cellular proliferation ability. Taken together, these data support that this novel microRNA-based therapy may possess clinical utility in a spontaneously-occurring large animal model of OSA, which can then serve to inform the clinical development of this therapy for human OSA patients.	[Alegre, Fernando; Ormonde, Amanda R.; Snider, Kellie M.; Wittenburg, Luke A.] Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA; [Woolard, Kevin] Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA; [Yu, Ai-Ming] Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Alegre, F (corresponding author), Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA.	falegreguerra@ucdavis.edu		Yu, Aiming/0000-0003-1441-4012; Alegre, Fernando/0000-0003-1732-6309	University of California, Davis Medical Center Interdepartmental/Center Collaborative Research Seed Grant; National Institute of General Medical Sciences [R01GM133888]; National Institutes of Health; NATIONAL CANCER INSTITUTE [P30CA093373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM113888] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [K01OD026526] Funding Source: NIH RePORTER	University of California, Davis Medical Center Interdepartmental/Center Collaborative Research Seed Grant; National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part by grants from University of California, Davis Medical Center Interdepartmental/Center Collaborative Research Seed Grant [L.A. Wittenburg] and The National Institute of General Medical Sciences [R01GM133888; A.M. Yu], National Institutes of Health.	Agostini M, 2014, ONCOTARGET, V5, P872, DOI 10.18632/oncotarget.1825; Anderson P, 2014, FEBS LETT, V588, P4297, DOI 10.1016/j.febslet.2014.09.001; Angstadt AY, 2012, CANCER GENET-NY, V205, P572, DOI 10.1016/j.cancergen.2012.09.005; Brinkhof B, 2006, ANAL BIOCHEM, V356, P36, DOI 10.1016/j.ab.2006.06.001; Chandrasekaran KS, 2016, TUMOR BIOL, V37, P13155, DOI 10.1007/s13277-016-5261-1; Chen X, 2016, J CANCER, V7, P1057, DOI 10.7150/jca.15061; Cirera S, 2014, METHODS MOL BIOL, V1182, P73, DOI 10.1007/978-1-4939-1062-5_7; Fan Timothy M, 2015, Vet Sci, V2, P210, DOI 10.3390/vetsci2030210; Fenger JM, 2014, ILAR J, V55, P69, DOI 10.1093/ilar/ilu009; Fowles JS, 2017, VET COMP ONCOL, V15, P481, DOI 10.1111/vco.12192; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Goodarzi H, 2015, CELL, V161, P790, DOI 10.1016/j.cell.2015.02.053; Hayes J, 2014, TRENDS MOL MED, V20, P460, DOI 10.1016/j.molmed.2014.06.005; He CL, 2009, BIOCHEM BIOPH RES CO, V388, P35, DOI 10.1016/j.bbrc.2009.07.101; Ho PY, 2018, J PHARMACOL EXP THER, V365, P494, DOI 10.1124/jpet.118.247775; Ho PY, 2016, WIRES RNA, V7, P186, DOI 10.1002/wrna.1324; Huang BQ, 2017, CANCER RES, V77, P3194, DOI 10.1158/0008-5472.CAN-16-3146; Kim YH, 2017, ONCOTARGET, V8, P8726, DOI 10.18632/oncotarget.14429; Legare ME, 2011, J CANCER, V2, P262, DOI 10.7150/jca.2.262; Li C, 2016, NEOPLASMA, V63, P734, DOI 10.4149/neo_2016_510; Li XJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.270; Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008-5472.CAN-09-0529; Lopez CM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190086; Maeda J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043355; Marley K, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-15; Mirabello L, 2009, CANCER-AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121; Navarro F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132767; Paoloni M, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-625; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4; Rowell JL, 2011, TRENDS MOL MED, V17, P380, DOI 10.1016/j.molmed.2011.02.004; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Sahabi K, 2018, J VET SCI, V19, P162, DOI 10.4142/jvs.2018.19.2.162; Saito Y, 2015, J CLIN MED, V4, P1951, DOI 10.3390/jcm4111951; Salvatore V, 2017, ONCOTARGET, V8, P9608, DOI 10.18632/oncotarget.14155; Saraf AJ, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00004; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Selvarajah GT, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1281-3; Seo KW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042960; Shahi MH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131006; Shoeneman JK, 2012, CANCER RES, V72, P249, DOI 10.1158/0008-5472.CAN-11-2315; Slabakova E, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.495; Sun CX, 2018, CANCER LETT, V414, P16, DOI 10.1016/j.canlet.2017.10.031; Suzuki HI, 2015, ONCOGENE, V34, P3085, DOI 10.1038/onc.2014.254; Vail DM, 2000, CANCER INVEST, V18, P781, DOI 10.3109/07357900009012210; Varshney Jyotika, 2016, Vet Sci, V3, DOI 10.3390/vetsci3010003; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Vetter NS, 2017, MOL CANCER RES, V15, P953, DOI 10.1158/1541-7786.MCR-16-0372; Wang WP, 2015, J PHARMACOL EXP THER, V354, P131, DOI 10.1124/jpet.115.225631; Wang Y, 2015, AM J TRANSL RES, V7, P111; Wang Z, 2017, ONCOTARGET, V8, P111258, DOI 10.18632/oncotarget.22770; Wen J, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705761; Wu XY, 2013, INT J MED SCI, V10, P676, DOI 10.7150/ijms.5528; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yan K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033778; York D, 2017, VET COMP ONCOL, V15, P1087, DOI 10.1111/vco.12250; Zhang R, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0331-y; ZHAO Y, 2016, SCI REP UK, V6; Zhao Y, 2015, BIOCHEM PHARMACOL, V98, P602, DOI 10.1016/j.bcp.2015.10.015; Zou YG, 2017, MOL MED REP, V15, P1631, DOI 10.3892/mmr.2017.6187	59	10	10	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2018	13	12							e0209941	10.1371/journal.pone.0209941	http://dx.doi.org/10.1371/journal.pone.0209941			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG0IO	30596759	gold, Green Submitted, Green Published			2023-01-03	WOS:000454627200116
J	Yan, KK; Xue, ML; Ye, D; Yang, CJ; Chang, J; Jiang, MH; Zhao, MY; Zhang, HL; Fang, Y				Yan, Kangkang; Xue, Meiling; Ye, Dan; Yang, Caijun; Chang, Jie; Jiang, Minghuan; Zhao, Mingyue; Zhang, Hongli; Fang, Yu			Antibiotic prescribing practices in secondary and tertiary hospitals in Shaanxi province, western China, 2013-2015	PLOS ONE			English	Article							HEALTH; RESISTANCE; STEWARDSHIP; INFECTIONS	Introduction The irrational use of antibiotics is a major driver of antimicrobial resistance. This study aimed to explore how antibiotics were used in secondary and tertiary hospitals in Shaanxi Province, western China from 2013 to 2015. Method A retrospective study was conducted with a sample of 16 hospitals in Shaanxi Province (2 tertiary and 14 secondary hospitals; 8 public and 8 private hospitals) using a stratified random sampling method. All of the macro data from these hospitals from 2013 to 2015 were analyzed. All collected data were double-entered and analyzed using Excel 2007. Results The percentage of injectable antibiotic prescriptions was 26.6% of all of the antibiotic prescriptions in the secondary hospitals and 14.2% in the tertiary hospitals. Injectable antibiotic prescriptions in private tertiary hospitals (enter %) were more than two times that of public tertiary hospitals (enter %). In both tertiary and secondary hospitals, the percentage of antibiotic prescriptions for outpatients, emergency patients and inpatients were within the scope of the national standards, while the intensity of antibiotic use was higher than the national standard of 40 DDD/100 bed-days. The prophylactic antibiotic use rate in clean surgery was 40.4% in tertiary hospitals and 60.7% in secondary hospitals, which were both higher than the national standard of 30%. The preventive use rate of antibiotics in private tertiary hospitals (55.00%) was more than two times that of public tertiary hospitals (25.90%), and the rate was also higher in private secondary hospitals (61.50%) than in public secondary hospitals (59.70%). Conclusions Substantial antibiotic abuse occurred in the sample Chinese hospitals, especially in secondary hospitals. The government should continue to strengthen the administration of antimicrobial use in hospitals. At the same time, medical professional training and interventions for physicians should be conducted to fundamentally reduce the irrational use of antibiotics.	[Yan, Kangkang; Yang, Caijun; Chang, Jie; Jiang, Minghuan; Zhao, Mingyue; Fang, Yu] Xi An Jiao Tong Univ, Sch Pharm, Dept Pharm Adm & Clin Pharm, Xian, Shaanxi, Peoples R China; [Yan, Kangkang; Yang, Caijun; Chang, Jie; Jiang, Minghuan; Zhao, Mingyue; Fang, Yu] Xi An Jiao Tong Univ, Ctr Drug Safety & Policy Res, Xian, Shaanxi, Peoples R China; [Yan, Kangkang; Yang, Caijun; Chang, Jie; Jiang, Minghuan; Zhao, Mingyue; Fang, Yu] Shaanxi Ctr Hlth Reform & Dev Res, Xian, Shaanxi, Peoples R China; [Yan, Kangkang; Ye, Dan] Xian 3 Hosp, Dept Pharm, Xian, Shaanxi, Peoples R China; [Xue, Meiling] 521 Hosp Ordnance Ind, Dept Drug & Equipment, Xian, Shaanxi, Peoples R China; [Zhang, Hongli] Xian Cent Hosp, Dept Pharm, Xian, Shaanxi, Peoples R China	Xi'an Jiaotong University; Xi'an Jiaotong University	Fang, Y (corresponding author), Xi An Jiao Tong Univ, Sch Pharm, Dept Pharm Adm & Clin Pharm, Xian, Shaanxi, Peoples R China.; Fang, Y (corresponding author), Xi An Jiao Tong Univ, Ctr Drug Safety & Policy Res, Xian, Shaanxi, Peoples R China.; Fang, Y (corresponding author), Shaanxi Ctr Hlth Reform & Dev Res, Xian, Shaanxi, Peoples R China.	yufang@mail.xjtu.edu.cn	Chang, Jie/AAE-5797-2019	Chang, Jie/0000-0001-7296-8641	National Natural Science Foundation of China [71603199]; Central University Basic Research Fund [2015qngz05]; "Young Talent Support Plan" of Xi'an Jiaotong University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Central University Basic Research Fund; "Young Talent Support Plan" of Xi'an Jiaotong University	This study was financially supported by the National Natural Science Foundation of China (grant number 71603199 to KY), the Central University Basic Research Fund (2015qngz05 to YF), and the "Young Talent Support Plan" of Xi'an Jiaotong University to YF. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexiou VG, 2010, SURG INFECT, V11, P343, DOI 10.1089/sur.2009.023; [Anonymous], FULL TEXT G20 LEAD C; Arason VA, 2006, MICROB DRUG RESIST, V12, P169, DOI 10.1089/mdr.2006.12.169; Bao LD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118868; Baur D, 2017, LANCET INFECT DIS, V17, P990, DOI 10.1016/S1473-3099(17)30325-0; Bennett D, 2015, J IND ECON, V63, P371, DOI 10.1111/joie.12075; Cars Hakan, 1995, Scandinavian Journal of Primary Health Care, V13, P3, DOI 10.3109/02813439508996727; CDC, 2013, ANTIBIOTIC RESISTANC; Cosgrove SE, 2003, CLIN INFECT DIS, V36, P1433, DOI 10.1086/375081; Costelloe C, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2096; Currie J, 2011, J HEALTH ECON, V30, P933, DOI 10.1016/j.jhealeco.2011.05.009; Dar-Odeh NS, 2010, THER CLIN RISK MANAG, V6, P301; Dong LF, 2011, FAM PRACT, V28, P63, DOI 10.1093/fampra/cmq077; Fang Y, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g4233; Fridkin SK, 2015, EMERG INFECT DIS, V21, P1578, DOI 10.3201/eid2109.150512; GHEI P, 1995, HEALTH POLICY, V34, P73, DOI 10.1016/0168-8510(95)90068-3; Gutema G, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3107-9; Hiltunen T, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0039; Ma XD, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-2051-8; [毛小红 Mao Xiaohong], 2013, [中华医院感染学杂志, Chinese Journal of Nosocomiology], V23, P3739; Ministry of Health of the People's Republic of China, 2012, REG CLIN APPL ANT AG, P4; Napolitano F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079532; National Health and Family Planning Commission of the People's Republic of China, 2015, GUID PRINC CLIN APPL, P7; Naylor NR, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0364-8; Paterson DL, 2017, LANCET INFECT DIS, V17, P351, DOI 10.1016/S1473-3099(17)30053-1; Ran SP, 2016, CHINESE J INFECT CON, V15, P330; Shi W, 2014, CLIN MED J, V12, P21; Wang J, 2014, JAMA INTERN MED, V174, P1914, DOI 10.1001/jamainternmed.2014.5214; World Health Organization, 2014, MED J, V4, P237; World Health Organization, 2006, AN THER CHEM CLASS S; Xiao YH, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001556; Xiao YH, 2013, LANCET INFECT DIS, V13, P189, DOI 10.1016/S1473-3099(13)70011-2; Yao KH, 2008, VACCINE, V26, P4425, DOI 10.1016/j.vaccine.2008.06.052; Yezli S, 2012, INT J ANTIMICROB AG, V40, P389, DOI 10.1016/j.ijantimicag.2012.07.009	34	9	9	2	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2018	13	12							e0207229	10.1371/journal.pone.0207229	http://dx.doi.org/10.1371/journal.pone.0207229			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD9QX	30540753	Green Submitted, Green Published, gold			2023-01-03	WOS:000452898600010
J	Carrero, I; Liu, HC; Sikora, AG; Milosavljevic, A				Carrero, Ivenise; Liu, Hsuan-Chen; Sikora, Andrew G.; Milosavljevic, Aleksandar			Histoepigenetic analysis of HPV- and tobacco-associated head and neck cancer identifies both subtype-specific and common therapeutic targets despite divergent microenvironments	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; DNA METHYLATION DATA; HUMAN-PAPILLOMAVIRUS; GENE-EXPRESSION; POSITIVE HEAD; SURVIVAL; GENOME; EPIDEMIOLOGY; SIGNATURE; MUTATION	Although head and neck squamous cell carcinoma (HNSCC) has in the past been largely associated with tobacco use, human papillomavirus (HPV+) oropharynx cancer has in recent years emerged as the fastest growing type of HNSCC. Patients with HPV+ HNSCC have a better prognosis; however, the 5-year survival for both HPV+ and HPV- subtypes with recurrent or metastatic disease is poor. To gain insights into the tumor microenvironments of both HNSCC subtypes and identify potential therapeutic targets, we performed epigenomic deconvolution on 580 HNSCC samples from the TCGA dataset. Deconvolution revealed distinct molecular and histoepigenetic profiles of the two tumor subtypes, including their cellular composition, epigenomic profiles and gene expression for constituent cell types, and potential cancer cell-specific targets. Our analyses show that high abundance of both CD8 T-cells and B-cells explains better prognosis in HPV+ HNSCC. Deconvolution of gene expression profiles revealed higher expression of the immunotherapy target PD-1 in HPV+ immune cells compared to HPV- cells, suggesting that HPV+ tumors may preferentially benefit from PD-1 targeted therapy. Further analyses identified HPV+ and HPV- cancer cell surface proteins that can also serve as potential targets for therapy. Specifically, Wnt pathway receptor ROR2 is preferentially overexpressed in HPV+ subtypes, suggesting opportunities for development of targeted therapy based on HPV status. In summary, the comprehensive molecular and histoepigenetic analysis of tumor microenvironments by epigenomic deconvolution reveals potential novel biomarkers and targets for precision therapy of HNSCC.	[Carrero, Ivenise; Milosavljevic, Aleksandar] Baylor Coll Med, Mol & Human Genet Dept, Houston, TX 77030 USA; [Carrero, Ivenise; Milosavljevic, Aleksandar] Baylor Coll Med, Epigenome Ctr, Houston, TX 77030 USA; [Liu, Hsuan-Chen] Baylor Coll Med, Translat Biol & Mol Med Program, Houston, TX 77030 USA; [Liu, Hsuan-Chen; Sikora, Andrew G.] Baylor Coll Med, Dept Otolaryngol Head & Neck Surg, Houston, TX 77030 USA; [Milosavljevic, Aleksandar] Baylor Coll Med, Program Quantitat & Computat Biosci, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Milosavljevic, A (corresponding author), Baylor Coll Med, Mol & Human Genet Dept, Houston, TX 77030 USA.; Milosavljevic, A (corresponding author), Baylor Coll Med, Epigenome Ctr, Houston, TX 77030 USA.; Sikora, AG (corresponding author), Baylor Coll Med, Dept Otolaryngol Head & Neck Surg, Houston, TX 77030 USA.; Milosavljevic, A (corresponding author), Baylor Coll Med, Program Quantitat & Computat Biosci, Houston, TX 77030 USA.	Andrew.Sikora@bcm.edu; amilosav@bcm.edu		Liu, Hsuan-Chen/0000-0001-7857-0204	Common Fund of the National Institutes of Health (NIH) [5U54 DA036134]; Carolyn Weiss Law Foundation for Academic Excellence; Baylor College of Medicine Dan L. Duncan Cancer Center Pilot Grant; NATIONAL INSTITUTE ON DRUG ABUSE [U54DA036134] Funding Source: NIH RePORTER	Common Fund of the National Institutes of Health (NIH); Carolyn Weiss Law Foundation for Academic Excellence; Baylor College of Medicine Dan L. Duncan Cancer Center Pilot Grant; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by a grant from the Common Fund of the National Institutes of Health (NIH) (5U54 DA036134) (to A. M.), the Carolyn Weiss Law Foundation for Academic Excellence (to AS), and the Baylor College of Medicine Dan L. Duncan Cancer Center Pilot Grant (to AS).	Afghahi A, 2015, CANCER J, V21, P294, DOI 10.1097/PPO.0000000000000135; Ahmed S, 2015, BREAST CANCER-TOKYO, V22, P101, DOI 10.1007/s12282-015-0587-x; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Aran D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9971; Argiris A, 2009, CANCER-AM CANCER SOC, V115, P4504, DOI 10.1002/cncr.24528; Assenov Y, 2014, NAT METHODS, V11, P1138, DOI [10.1038/NMETH.3115, 10.1038/nmeth.3115]; Bausch-Fluck D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121314; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Becht E, 2016, ADV IMMUNOL, V130, P95, DOI 10.1016/bs.ai.2015.12.002; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Castiglioni P, 2005, EUR J IMMUNOL, V35, P1360, DOI 10.1002/eji.200425530; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Chen AX, 2016, INT J CLIN EXP PATHO, V9, P10981; Clements WM, 2002, CANCER RES, V62, P3503; Dalen AGD, 2003, INT J CANCER, V103, P768, DOI 10.1002/ijc.10903; Debey S, 2004, PHARMACOGENOMICS J, V4, P193, DOI 10.1038/sj.tpj.6500240; Esposti DD, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0419-z; Fakhry C, 2008, JNCI-J NATL CANCER I, V100, P261, DOI 10.1093/jnci/djn011; Ford CE, 2013, INT J CANCER, V133, P779, DOI 10.1002/ijc.27984; Forster MD, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00310; Ganguly KK, 2013, CELL ADHES MIGR, V7, P251, DOI 10.4161/cam.23840; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Gutman DA, 2013, J AM MED INFORM ASSN, V20, P1091, DOI 10.1136/amiajnl-2012-001469; Houseman EA, 2014, CANCER INFORM, V13, P53, DOI 10.4137/CIN.S13980; Houseman EA, 2014, BIOINFORMATICS, V30, P1431, DOI 10.1093/bioinformatics/btu029; Ishikawa N, 2007, CANCER RES, V67, P11601, DOI 10.1158/0008-5472.CAN-07-3243; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kamburov A, 2011, NUCLEIC ACIDS RES, V39, pD712, DOI 10.1093/nar/gkq1156; Knights Alexander J, 2012, Trends Cancer Res, V8, P61; Kong HK, 2012, J BIOL CHEM, V287, P38889, DOI 10.1074/jbc.M112.394270; Koshizuka K, 2018, ONCOTARGET, V9, P3663, DOI 10.18632/oncotarget.23194; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Li Y, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S5-S11; Litwin TR, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9080206; Lleras RA, 2013, CLIN CANCER RES, V19, P5444, DOI 10.1158/1078-0432.CCR-12-3280; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Mandal R, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89829; McCormack PL, 2008, DRUGS, V68, P487, DOI 10.2165/00003495-200868040-00009; McKaig RG, 1998, HEAD NECK-J SCI SPEC, V20, P250, DOI 10.1002/(SICI)1097-0347(199805)20:3<250::AID-HED11>3.0.CO;2-O; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mroz Edmund A, 2016, World J Otorhinolaryngol Head Neck Surg, V2, P60, DOI 10.1016/j.wjorl.2016.05.007; Nulton TJ, 2017, ONCOTARGET, V8, P17684, DOI 10.18632/oncotarget.15179; Onuchic V, 2016, CELL REP, V17, P2075, DOI 10.1016/j.celrep.2016.10.057; Orentas RJ, 2012, FRONT ONCOL, V2, DOI [10.3389/FONC.2012.00194/ABSTRACT, DOI 10.3389/FONC.2012.00194/ABSTRACT]; Organization WH, 2014, REV CANC MED WHO LIS, P1; Ragin CCR, 2007, J DENT RES, V86, P104, DOI 10.1177/154405910708600202; Riaz N, 2014, GENES DIS, V1, P75, DOI 10.1016/j.gendis.2014.07.002; Rieke DT, 2016, ONCOL RES TREAT, V39, P780, DOI 10.1159/000452432; Sakamoto T, 2017, ORAL ONCOL, V69, P15, DOI 10.1016/j.oraloncology.2017.03.019; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Seiwert TY, 2015, CLIN CANCER RES, V21, P632, DOI 10.1158/1078-0432.CCR-13-3310; Smith EM, 2008, ORAL ONCOL, V44, P133, DOI 10.1016/j.oraloncology.2007.01.010; Snell LM, 2017, TRENDS IMMUNOL, V38, P542, DOI 10.1016/j.it.2017.05.005; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tagliamonte M, 2014, HUM VACC IMMUNOTHER, V10, P3332, DOI 10.4161/21645515.2014.973317; Tong CCL, 2012, IMMUNOL RES, V54, P266, DOI 10.1007/s12026-012-8306-6; Voloshanenko O, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20641-5; Wang B, 2015, GENET MOL RES, V14, P17406, DOI 10.4238/2015.December.21.10; Wang JP, 2015, ONCOTARGET, V6, P18162, DOI 10.18632/oncotarget.4216; Yearley JH, 2017, CLIN CANCER RES, V23, P3158, DOI 10.1158/1078-0432.CCR-16-1761; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhang YX, 2016, CLIN CANCER RES, V22, P4735, DOI 10.1158/1078-0432.CCR-16-0323	62	17	17	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3551	3568		10.1038/s41388-018-0659-4	http://dx.doi.org/10.1038/s41388-018-0659-4			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30655605	Green Published, hybrid			2023-01-03	WOS:000467379600001
J	Spetz, J; Toretsky, C; Chapman, S; Phoenix, B; Tierney, M				Spetz, Joanne; Toretsky, Christopher; Chapman, Susan; Phoenix, Bethany; Tierney, Matthew			Nurse Practitioner and Physician Assistant Waivers to Prescribe Buprenorphine and State Scope of Practice Restrictions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Spetz, Joanne; Toretsky, Christopher] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, 3333 Calif St,Ste 265, San Francisco, CA 94118 USA; [Chapman, Susan] Univ Calif San Francisco, Dept Social & Behav Sci, San Francisco, CA 94143 USA; [Phoenix, Bethany; Tierney, Matthew] Univ Calif San Francisco, Dept Community Hlth Syst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Spetz, J (corresponding author), Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, 3333 Calif St,Ste 265, San Francisco, CA 94118 USA.	Joanne.Spetz@ucsf.edu		Spetz, Joanne/0000-0003-3112-5511	National Council of State Boards of Nursing's Center for Regulatory Excellence [R101026]	National Council of State Boards of Nursing's Center for Regulatory Excellence	This research was supported by the National Council of State Boards of Nursing's Center for Regulatory Excellence (grant R101026).	American Association of Physician Assistants, 6 KEY EL MOD PA PRAC; Andrilla CHA, 2020, MED CARE RES REV, V77, P208, DOI 10.1177/1077558718793070; Andrilla CHA, 2019, J RURAL HEALTH, V35, P108, DOI 10.1111/jrh.12307; Jones CM, 2015, AM J PUBLIC HEALTH, V105, pE55, DOI 10.2105/AJPH.2015.302664; Phillips SJ, 2018, NURSE PRACT, V43, P27, DOI 10.1097/01.NPR.0000527569.36428.ed	5	44	44	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2019	321	14					1407	1408		10.1001/jama.2019.0834	http://dx.doi.org/10.1001/jama.2019.0834			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT5PG	30964519	Green Published, Bronze			2023-01-03	WOS:000464615200022
J	Betjemann, JP; Josephson, SA; Lowenstein, DH; Guterman, EL				Betjemann, John P.; Josephson, S. Andrew; Lowenstein, Daniel H.; Guterman, Elan L.			Emergency Medical Services Protocols for Generalized Convulsive Status Epilepticus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							EVIDENCE-BASED GUIDELINES		[Betjemann, John P.; Josephson, S. Andrew; Lowenstein, Daniel H.; Guterman, Elan L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA	University of California System; University of California San Francisco	Betjemann, JP (corresponding author), UCSF, Dept Neurol, Zuckerberg San Francisco Gen Hosp, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	john.betjemann@ucsf.edu		Guterman, Elan/0000-0003-0817-3144				Alldredge BK, 2001, NEW ENGL J MED, V345, P631, DOI 10.1056/NEJMoa002141; Fishe JN, 2018, PREHOSP EMERG CARE, V22, P511, DOI 10.1080/10903127.2017.1413466; Glauser T, 2016, EPILEPSY CURR, V16, P48, DOI 10.5698/1535-7597-16.1.48; Martin-Gill C, 2016, PREHOSP EMERG CARE, V20, P175, DOI 10.3109/10903127.2015.1102995; Silbergleit R, 2012, NEW ENGL J MED, V366, P591, DOI 10.1056/NEJMoa1107494; Trinka E, 2015, EPILEPSIA, V56, P1515, DOI 10.1111/epi.13121	6	14	14	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2019	321	12					1216	1217		10.1001/jama.2019.0441	http://dx.doi.org/10.1001/jama.2019.0441			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR3XE	30912825	Green Published, Bronze			2023-01-03	WOS:000463074900019
J	Teufl, W; Miezal, M; Taetz, B; Frohlich, M; Bleser, G				Teufl, Wolfgang; Miezal, Markus; Taetz, Bertram; Froehlich, Michael; Bleser, Gabriele			Validity of inertial sensor based 3D joint kinematics of static and dynamic sport and physiotherapy specific movements	PLOS ONE			English	Article							SOFT-TISSUE ARTIFACT; MEASUREMENT UNITS; VERTICAL JUMP; MOTION; ACCURACY; MARKERS; WALKING; PERFORMANCE; CALIBRATION; AGREEMENT	3D joint kinematics can provide important information about the quality of movements. Optical motion capture systems (OMC) are considered the gold standard in motion analysis. However, in recent years, inertial measurement units (IMU) have become a promising alternative. The aim of this study was to validate IMU-based 3D joint kinematics of the lower extremities during different movements. Twenty-eight healthy subjects participated in this study. They performed bilateral squats (SQ), single-leg squats (SLS) and countermovement jumps (CMJ). The IMU kinematics was calculated using a recently-described sensor-fusion algorithm. A marker based OMC system served as a reference. Only the technical error based on algorithm performance was considered, incorporating OMC data for the calibration, initialization, and a biomechanical model. To evaluate the validity of IMU-based 3D joint kinematics, root mean squared error (RMSE), range of motion error (ROME), Bland-Altman (BA) analysis as well as the coefficient of multiple correlation (CMC) were calculated. The evaluation was twofold. First, the IMU data was compared to OMC data based on marker clusters; and, second based on skin markers attached to anatomical landmarks. The first evaluation revealed means for RMSE and ROME for all joints and tasks below 3 degrees. The more dynamic task, CMJ, revealed error measures approximately 1 degrees higher than the remaining tasks. Mean CMC values ranged from 0.77 to 1 over all joint angles and all tasks. The second evaluation showed an increase in the RMSE of 2.28 degrees-2.58 degrees on average for all joints and tasks. Hip flexion revealed the highest average RMSE in all tasks (4.87 degrees-8.27 degrees). The present study revealed a valid IMU-based approach for the measurement of 3D joint kinematics in functional movements of varying demands. The high validity of the results encourages further development and the extension of the present approach into clinical settings.	[Teufl, Wolfgang; Miezal, Markus; Taetz, Bertram; Bleser, Gabriele] Tech Univ Kaiserslautern, Dept Comp Sci, Kaiserslautern, Germany; [Teufl, Wolfgang; Froehlich, Michael] Tech Univ Kaiserslautern, Dept Sport Sci, Kaiserslautern, Germany	University of Kaiserslautern; University of Kaiserslautern	Teufl, W (corresponding author), Tech Univ Kaiserslautern, Dept Comp Sci, Kaiserslautern, Germany.; Teufl, W (corresponding author), Tech Univ Kaiserslautern, Dept Sport Sci, Kaiserslautern, Germany.	teufl@cs.uni-kl.de			Federal Ministry of Education and Research (BMBF) [16SV7115, 03IHS075B]; BMBF [16SV7115, 03IHS075B]	Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); BMBF(Federal Ministry of Education & Research (BMBF))	This work was performed by the interdisciplinary Junior Research Group wearHEALTH, funded by the Federal Ministry of Education and Research (BMBF), Grant numbers: 16SV7115 to GB, and 03IHS075B to GB. For more information, please visit the website www.wearhealth.org. The fundershad no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was performed by the Interdisciplinary Junior Research Group wearHEALTH, funded by the BMBF (16SV7115, 03IHS075B). For more information, please visit the website www.wearhealth.org.	Al-Amri M, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18030719; Angeloni C., 1993, J BIOMECH, V26; Baldon RD, 2015, AM J SPORT MED, V43, P1485, DOI 10.1177/0363546515574690; Barre A, 2015, J BIOMECH, V48, P1965, DOI 10.1016/j.jbiomech.2015.04.007; Bayford R, 2013, PHYSIOL MEAS, V34, DOI 10.1088/0967-3334/34/6/E01; Benoit DL, 2015, J BIOMECH, V48, P2124, DOI 10.1016/j.jbiomech.2015.02.050; Bergamini E, 2014, SENSORS-BASEL, V14, P18625, DOI 10.3390/s141018625; Bland JM, 2007, J BIOPHARM STAT, V17, P571, DOI 10.1080/10543400701329422; Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272; Bonnet V, 2017, J BIOMECH, V62, P148, DOI 10.1016/j.jbiomech.2017.04.033; Brauner T, 2014, ARCH PHYS MED REHAB, V95, P1946, DOI 10.1016/j.apmr.2014.06.003; Cappello A, 2005, IEEE T BIO-MED ENG, V52, P992, DOI 10.1109/TBME.2005.846728; Cockcroft J, 2016, COMPUT METHOD BIOMEC, V19, P1497, DOI 10.1080/10255842.2016.1157865; Cook G, 2014, INT J SPORTS PHYS TH, V9, P396; Cutti AG, 2010, MED BIOL ENG COMPUT, V48, P17, DOI 10.1007/s11517-009-0545-x; Davis KE, 2007, CLIN ORTHOP, V5; Dumas R, 2009, J BIOMECH, V42, P2214, DOI 10.1016/j.jbiomech.2009.06.006; Eie MK, 2013, J NUMBER THEORY, V133, P2475, DOI 10.1016/j.jnt.2013.01.010; Elvin NG, 2007, J APPL BIOMECH, V23, P180, DOI 10.1123/jab.23.3.180; Fasel Benedikt, 2018, IEEE J Biomed Health Inform, V22, P77, DOI 10.1109/JBHI.2017.2659758; Fasel B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181446; Ferrari A, 2010, GAIT POSTURE, V31, P540, DOI 10.1016/j.gaitpost.2010.02.009; Fiorentino NM, 2017, GAIT POSTURE, V55, P184, DOI 10.1016/j.gaitpost.2017.03.033; Forner-Cordero A, 2008, PHYSIOL MEAS, V29, pN21, DOI 10.1088/0967-3334/29/4/N01; Gathercole R, 2015, INT J SPORT PHYSIOL, V10, P84, DOI 10.1123/ijspp.2013-0413; Giavarina D, 2015, BIOCHEM MEDICA, V25, P141, DOI 10.11613/BM.2015.015; Kianifar R, 2017, IEEE J TRANSL ENG HE, V5, DOI 10.1109/JTEHM.2017.2736559; KLUGE F, 2017, SENSORS BASEL, V17, P57587, DOI DOI 10.3390/S17071522; Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012; Leardini A, 2005, GAIT POSTURE, V21, P212, DOI 10.1016/j.gaitpost.2004.05.002; Leardini A, 2007, GAIT POSTURE, V26, P560, DOI 10.1016/j.gaitpost.2006.12.018; Lebel K, 2017, BIOMED ENG ONLINE, V16, DOI 10.1186/s12938-017-0347-6; Manal K, 2002, GAIT POSTURE, V15, P10, DOI 10.1016/S0966-6362(01)00174-6; Manal K, 2000, GAIT POSTURE, V11, P38, DOI 10.1016/S0966-6362(99)00042-9; McGinnis RS, 2016, SPORTS ENG, V19, P21, DOI 10.1007/s12283-015-0185-3; McPherson AL, 2016, PHYS THER SPORT, V22, P54, DOI 10.1016/j.ptsp.2016.04.001; Menzel HJ, 2013, J STRENGTH COND RES, V27, P1370, DOI 10.1519/JSC.0b013e318265a3c8; Miezal Markus, 2017, 2017 IEEE International Conference on Robotics and Automation (ICRA), P3256, DOI 10.1109/ICRA.2017.7989371; Miezal M, 2016, SENSORS-BASEL, V16, DOI 10.3390/s16071132; Nuesch C, 2017, J BIOMECH, V57, P32, DOI 10.1016/j.jbiomech.2017.03.015; Peters A, 2010, GAIT POSTURE, V31, P1, DOI 10.1016/j.gaitpost.2009.09.004; Picerno P, 2017, GAIT POSTURE, V51, P239, DOI 10.1016/j.gaitpost.2016.11.008; Picerno P, 2011, J SPORT SCI, V29, P139, DOI 10.1080/02640414.2010.523089; Robert-Lachaine X, 2017, MED BIOL ENG COMPUT, V55, P609, DOI 10.1007/s11517-016-1537-2; Robert-Lachaine X, 2017, GAIT POSTURE, V54, P80, DOI 10.1016/j.gaitpost.2017.02.029; Setuain I, 2016, J SPORT SCI, V34, P843, DOI 10.1080/02640414.2015.1075057; Teufl W, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18071980; Thewlis D, 2013, J APPL BIOMECH, V29, P112, DOI 10.1123/jab.29.1.112; Weeks BK, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-207	49	45	47	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2019	14	2							e0213064	10.1371/journal.pone.0213064	http://dx.doi.org/10.1371/journal.pone.0213064			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN7LS	30817787	Green Published, gold, Green Submitted			2023-01-03	WOS:000460371500073
J	Tobe, RG; Islam, MT; Yoshimura, Y; Hossain, J				Tobe, Ruoyan Gai; Islam, Mohammad Tajul; Yoshimura, Yukie; Hossain, Jahangir			Strengthening the community support group to improve maternal and neonatal health seeking behaviors: A cluster-randomized controlled trial in Satkhira District, Bangladesh	PLOS ONE			English	Article							EMERGENCY OBSTETRIC CARE; RURAL BANGLADESH; NEWBORN HEALTH; SERVICES; INTERVENTIONS; STRATEGIES; FACILITIES; MORTALITY; SETTINGS; DELIVERY	Background Although achieved development goals on maternal and child health, in the era of Sustainable Development Goals (SDGs), Bangladesh still needs to promote skilled attendance at birth as well as a continuum of care for mothers and babies. How to implement effective interventions by strengthening the community health system also remains as a crucial policy issue. The objective of the proposed study is to evaluate the impact of a community-based intervention as part of a bilateral development aid project on utilization of maternal and neonatal care provided by skilled providers and qualified facilities. Methods A cluster randomized trial was conducted in Kalaroa Upazila of Satkhira District. Community Clinics (CCs) in the study setting were randomly allocated to either intervention or control. We recruited all eligible women covered by CC catchment areas who gave a birth during the past 12 months of data collection at the baseline and end-line surveys. In the intervention areas, three Community Support Groups (CSGs) were developed in each of the CC areas. The members of CSG were trained to identify pregnant women, educate community people on pregnancy related danger signs, and encourage them for utilization of skilled services in the community and health facilities. The primary outcomes were the utilization of services for antenatal care, delivery, postnatal care and sick newborns. Difference-in-Difference (DID) analysis was performed to identify the changes by the intervention with adjustment of cluster effects by generalized mixed effects regression models. Result The major indicators of the utilization of maternal and neonatal care among pregnant women with different wealth status showed significant improvement after the intervention. The impacts of the intervention were in particular significant among the women of 2nd and 3rd quintiles of household wealth status. The use of CCs increased after the intervention and private hospitals / clinics served as the major health providers. The study also identified increased practices of cesarean section. Conclusion The success of the intervention suggests a potential of the government efforts to strengthen the community support system for promotion of safe motherhood. The intervention helps to identify and remove existing and emerging barriers that lie between women and healthcare providers for safe motherhood and continuum of care.	[Tobe, Ruoyan Gai] Natl Ctr Child Hlth & Dev, Dept Hlth Policy, Tokyo, Japan; [Islam, Mohammad Tajul] Save Children Int, MaMoni HSS Project, Dhaka, Bangladesh; [Yoshimura, Yukie] JICA Bangladesh, SHASTO Project, Dhaka, Bangladesh; [Hossain, Jahangir] CARE Bangladesh, Dhaka, Bangladesh	National Center for Child Health & Development - Japan; Save the Children	Yoshimura, Y (corresponding author), JICA Bangladesh, SHASTO Project, Dhaka, Bangladesh.	yoshiboubd@gmail.com	Hossain, Jahangir/AAD-5492-2020	Hossain, Jahangir/0000-0001-7602-3581	Japan International Cooperation Agency; Japan International Cooperation Agency (JICA)	Japan International Cooperation Agency; Japan International Cooperation Agency (JICA)	This entire study was conducted with the financial support of Japan International Cooperation Agency.; Japan International Cooperation Agency (JICA) provided financial and technical supports to the field study.	Alam B, 2015, INT J GYNECOL OBSTET, V131, P63, DOI 10.1016/j.ijgo.2015.04.041; Anwar I, 2009, J HEALTH POPUL NUTR, V27, P139, DOI 10.3329/jhpn.v27i2.3327; Basu S, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001244; Bhutta ZA, 2005, PEDIATRICS, V115, P519, DOI 10.1542/peds.2004-1441; Bhutta ZA, 2014, LANCET, V384, P347, DOI 10.1016/S0140-6736(14)60792-3; Bullough C, 2005, BJOG-INT J OBSTET GY, V112, P1180, DOI 10.1111/j.1471-0528.2005.00718.x; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Chowdhury S, 2011, BJOG-INT J OBSTET GY, V118, P36, DOI 10.1111/j.1471-0528.2011.03111.x; Darmstadt GL, 2009, INT J GYNECOL OBSTET, V107, pS89, DOI 10.1016/j.ijgo.2009.07.010; Das S, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1069-7; Directorate General of Health Services, 2015, MAN IMPL 5S HOSP SET; El Arifeen S, 2014, LANCET, V384, P1366, DOI 10.1016/S0140-6736(14)60955-7; General Economics Division Planning Commission of Government of the People's Republic of Bangladesh, 2016, MAPP MIN TARG IMPL S; General Economics Division Planning Commission of Government of the People's Republic of Bangladesh UNDP Bangladesh, 2014, MILL DEV GOALS BANGL; Haider MR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181408; Hotchkiss DR, 2014, HEALTH POLICY PLANN, V29, pI12, DOI 10.1093/heapol/czt062; Hoxha I, 2017, BMJ OPEN, V7, DOI [10.1136/bmjopen-2016-013670, 10.1136/bmjopen-2017-016600]; Huq NL, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0520-5; Islam MT, 2015, RES REP NEONATOL, V5, P65, DOI 10.2147/RRN.S87122; Islam N, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-86; Japan International Cooperation Agency Bangladesh, 2012, NARS BANGL SAV LIV M; Kamiya Y, 2013, SOC SCI MED, V83, P34, DOI 10.1016/j.socscimed.2013.01.035; Karim RM, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1461-z; Khan MN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177579; Kibria Gulam Muhammed Al, 2017, Matern Health Neonatol Perinatol, V3, P7, DOI 10.1186/s40748-017-0046-0; Lassi ZS, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007754.pub3; Mbuagbaw L, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010994.pub2; National Institute of population research training (Bangladesh) Mitra and associates (firm) macro international. Institute for resource development, 2011, BANGL DEM HLTH SURV; Neuman M, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005982; Prost A, 2013, LANCET, V381, P1736, DOI 10.1016/S0140-6736(13)60685-6; Pulok MH, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0970-4; Rahman M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161647; Roy L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187238; Sarker BK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146161; Sarker Mohammad Abul Bashar, 2015, BMC Res Notes, V8, P590, DOI 10.1186/s13104-015-1374-7; Seward N, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002467; Shahjahan M, 2017, MIDWIFERY, V52, P42, DOI 10.1016/j.midw.2017.05.011; Sikder SS, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1405-2; Sustainable Development Goals, GOAL 3 ENS HLTH LIV; Taleb F, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0501-8; Tango T, 2016, BIOSTATISTICS, V17, P334, DOI 10.1093/biostatistics/kxv047; Tripathy P, 2016, LANCET GLOB HEALTH, V4, pE119, DOI 10.1016/S2214-109X(15)00287-9; Twisk J, 2018, CONT CLIN TRIAL COMM, V10, P80, DOI 10.1016/j.conctc.2018.03.008; Vieira C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047946; Yaya S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187303; Yaya S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171573	46	9	9	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2019	14	2							e0212847	10.1371/journal.pone.0212847	http://dx.doi.org/10.1371/journal.pone.0212847			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN7LS	30817784	Green Published, Green Submitted, gold			2023-01-03	WOS:000460371500046
J	Van Spall, HGC; Lee, SF; Xie, F; Oz, UE; Perez, R; Mitoff, PR; Maingi, M; Tjandrawidjaja, MC; Heffernan, M; Zia, MI; Porepa, L; Panju, M; Thabane, L; Graham, ID; Haynes, RB; Haughton, D; Simek, KD; Ko, DT; Connolly, SJ				Van Spall, Harriette G. C.; Lee, Shun Fu; Xie, Feng; Oz, Urun Erbas; Perez, Richard; Mitoff, Peter R.; Maingi, Manish; Tjandrawidjaja, Michael C.; Heffernan, Michael; Zia, Mohammad I.; Porepa, Liane; Panju, Mohamed; Thabane, Lehana; Graham, Ian D.; Haynes, R. Brian; Haughton, Dilys; Simek, Kim D.; Ko, Dennis T.; Connolly, Stuart J.			Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure The PACT-HF Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STEPPED WEDGE; 30-DAY READMISSION; SAMPLE-SIZE; ASSOCIATION; MANAGEMENT; KNOWLEDGE; DESIGNS; INDEX	IMPORTANCE Health care services that support the hospital-to-home transition can improve outcomes in patients with heart failure (HF). OBJECTIVE To test the effectiveness of the Patient-Centered Care Transitions in HF transitional care model in patients hospitalized for HF. DESIGN, SETTING, AND PARTICIPANTS Stepped-wedge cluster randomized trial of 2494 adults hospitalized for HF across 10 hospitals in Ontario, Canada, from February 2015 to March 2016, with follow-up until November 2016. INTERVENTIONS Hospitals were randomized to receive the intervention (n = 1104 patients), in which nurse-led self-care education, a structured hospital discharge summary, a family physician follow-up appointment less than 1 week after discharge, and, for high-risk patients, structured nurse home visits and heart function clinic care were provided to patients, or usual care (n = 1390 patients), in which transitional care was left to the discretion of clinicians. MAIN OUTCOMES AND MEASURES Primary outcomes were hierarchically ordered as composite all-cause readmission, emergency department (ED) visit, or death at 3 months; and composite all-cause readmission or ED visit at 30 days. Secondary outcomes were B-PREPARED score for discharge preparedness (range: 0[most prepared] to 22 [least prepared]); the 3-Item Care Transitions Measure (CTM-3) for quality of transition (range: 0[worst transition] to 100 [best transition]); the 5-level EQ-5D version (EQ-5D-5L) for quality of life (range: 0[dead] to 1 [full health]); and quality-adjusted life-years (QALY; range: 0[dead] to 0.5 [full health at 6 months]). RESULTS Among eligible patients, all 2494 (mean age, 77.7 years; 1258 [50.4%] women) completed the trial. There was no significant difference between the intervention and usual care groups in the first primary composite outcome (545 [49.4%] vs 698 [50.2%] events, respectively; hazard ratio [HR], 0.99 [95% CI, 0.83-1.19]) or in the second primary composite outcome (304 [27.5%] vs 408 [29.3%] events, respectively; HR, 0.93 [95% CI, 0.73-1.18]). There were significant differences between the intervention and usual care groups in the secondary outcomes of mean B-PREPARED score at 6 weeks (16.6 vs 13.9; difference, 2.65 [95% CI, 1.37-3.92]; P < .001); mean CTM-3 score at 6 weeks (76.5 vs 70.3; difference, 6.16 [95% CI, 0.90-11.43]; P = .02); and mean EQ-5D-5L score at 6 weeks (0.7 vs 0.7; difference, 0.06 [95% CI, 0.01 to 0.11]; P = .02) and 6 months (0.7 vs 0.6; difference, 0.06 [95% CI, 0.01-0.12]; P = .02). There was no significant difference in mean QALY between groups at 6 months (0.3 vs 0.3; difference, 0.00 [95% CI, -0.02 to 0.02]; P = .98). CONCLUSIONS AND RELEVANCE Among patients with HF in Ontario, Canada, implementation of a patient-centered transitional care model compared with usual care did not improve a composite of clinical outcomes. Whether this type of intervention could be effective in other health care systems or locations would require further research.	[Van Spall, Harriette G. C.; Panju, Mohamed; Connolly, Stuart J.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Van Spall, Harriette G. C.; Xie, Feng; Thabane, Lehana; Haynes, R. Brian] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Van Spall, Harriette G. C.; Lee, Shun Fu; Simek, Kim D.; Connolly, Stuart J.] Populat Hlth Res Inst, 20 Copeland Ave,David Braley Res Inst Bldg, Hamilton, ON L8L 0A3, Canada; [Xie, Feng] Ctr Hlth Econ & Policy Anal, Program Hlth Econ & Outcome Measures, Hamilton, ON, Canada; [Oz, Urun Erbas; Perez, Richard; Ko, Dennis T.] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Mitoff, Peter R.; Zia, Mohammad I.; Ko, Dennis T.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Mitoff, Peter R.] St Josephs Hlth Ctr, Dept Med, Toronto, ON, Canada; [Maingi, Manish] Trillium Hlth Partners, Cardiac Hlth Program, Mississauga, ON, Canada; [Tjandrawidjaja, Michael C.] William Osler Hlth Syst, Dept Med, Brampton, ON, Canada; [Heffernan, Michael] Halton Hlth Care Serv, Dept Med, Oakville, ON, Canada; [Zia, Mohammad I.] Michael Garron Hosp, Dept Med, Toronto, ON, Canada; [Porepa, Liane] Southlake Reg Hlth Ctr, Dept Med, Newmarket, ON, Canada; [Graham, Ian D.] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada; [Haughton, Dilys] Hamilton Niagara Haldimand Brant Community Care A, Hamilton, ON, Canada	McMaster University; McMaster University; Population Health Research Institute; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Joseph's Health Centre, Toronto; Western University (University of Western Ontario); University of Toronto; Trillium Health Partners; University of Toronto; Toronto East General Hospital; Southlake Regional Health Centre; University of Ottawa	Van Spall, HGC (corresponding author), Populat Hlth Res Inst, 20 Copeland Ave,David Braley Res Inst Bldg, Hamilton, ON L8L 0A3, Canada.	harriette.vanspall@phri.ca	Graham, Ian D./ABD-5259-2021	Graham, Ian D./0000-0002-3669-1216; Ko, Dennis/0000-0001-6840-8051; Van Spall, Harriette Gillian Christine/0000-0002-8370-4569	Canadian Institutes of Health Research [135917]; Ontario Ministry of Health and Long Term Care (MOHLTC) Health System Research Fund [6686]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Health and Long Term Care (MOHLTC) Health System Research Fund	This study was funded by peer-reviewed grants held by Dr Van Spall from the Canadian Institutes of Health Research (135917) and Ontario Ministry of Health and Long Term Care (MOHLTC) Health System Research Fund (6686), as well as in-kind support from the participating hospitals and Community Care Access Centers and from Roche Diagnostics.	Brown C.A., 2006, BMC MED RES METHODOL, V6, P54, DOI DOI 10.1186/1471-2288-6-54; Care Transitions Program, TOOLS RES; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Desai AS, 2012, CIRCULATION, V126, P501, DOI 10.1161/CIRCULATIONAHA.112.125435; Eccles M, 2003, QUAL SAF HEALTH CARE, V12, P47, DOI 10.1136/qhc.12.1.47; EuroQol Research Foundation, 2015, EQ 5D 5L USER GUIDE; Feltner C, 2014, ANN INTERN MED, V160, P774, DOI 10.7326/M14-0083; Graham ID, 2006, J CONTIN EDUC HEALTH, V26, P13, DOI 10.1002/chp.47; Harrison MB, 2007, INT J EVID-BASED HEA, V5, P92, DOI 10.1111/j.1479-6988.2007.00057.x; Health Quality Ontario Ministry of Health and Long-Term Care, 2015, QUAL BAS PROC CLIN H; Hemming K, 2016, J CLIN EPIDEMIOL, V69, P137, DOI 10.1016/j.jclinepi.2015.08.015; Hernandez AF, 2010, JAMA-J AM MED ASSOC, V303, P1716, DOI 10.1001/jama.2010.533; Hussey MA, 2007, CONTEMP CLIN TRIALS, V28, P182, DOI 10.1016/j.cct.2006.05.007; McClure NS, 2017, VALUE HEALTH, V20, P644, DOI 10.1016/j.jval.2016.11.015; Naylor MD, 2011, HEALTH AFFAIR, V30, P746, DOI 10.1377/hlthaff.2011.0041; Phelan D, 2009, IRISH J MED SCI, V178, P167, DOI 10.1007/s11845-009-0332-6; Roberts E, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h910; Shafie AA, 2018, HEART FAIL REV, V23, P131, DOI 10.1007/s10741-017-9661-0; Shanbhag D, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-017765; Smith LR, 2014, CONTEXTUAL FRAMEWORK, P8; Stukel TA, 2012, JAMA-J AM MED ASSOC, V307, P1037, DOI 10.1001/jama.2012.265; Van Spall HGC, 2007, JAMA-J AM MED ASSOC, V297, P1233, DOI 10.1001/jama.297.11.1233; Van Spall HGC, 2017, EUR J HEART FAIL, V19, P1427, DOI 10.1002/ejhf.765; Van Spall HGC, 2018, AM HEART J, V199, P75, DOI 10.1016/j.ahj.2017.12.013; van Walraven C, 2012, J EVAL CLIN PRACT, V18, P1211, DOI 10.1111/j.1365-2753.2011.01773.x; van Walraven C, 2010, CAN MED ASSOC J, V182, P551, DOI 10.1503/cmaj.091117; Whitehead SJ, 2010, BRIT MED BULL, V96, P5, DOI 10.1093/bmb/ldq033; Woertman W, 2013, J CLIN EPIDEMIOL, V66, P752, DOI 10.1016/j.jclinepi.2013.01.009; Wolfe A., 2001, POLICY POLITICS NURS, V2, P233, DOI DOI 10.1177/152715440100200312; World Health Organization (WHO) Regional Office for Europe, 2016, INTEGRATED CARE MODE; Yale New Haven Health Services Corporation/ Center for Outcomes Research and Evaluation, 2013, 2013 MEAS UPD SPEC R; Yancy CW, 2017, J AM COLL CARDIOL, V70, P776, DOI [10.1016/j.jacc.2017.04.025, 10.1161/CIR.0000000000000509]; Yazdan-Ashoori P, 2016, AM HEART J, V179, P51, DOI 10.1016/j.ahj.2016.06.007	34	96	97	14	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	2019	321	8					753	761		10.1001/jama.2019.0710	http://dx.doi.org/10.1001/jama.2019.0710			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN4ZE	30806695	Green Published, Bronze			2023-01-03	WOS:000460191400016
J	Orkibi, H; Feniger-Schaal, R				Orkibi, Hod; Feniger-Schaal, Rinat			Integrative systematic review of psychodrama psychotherapy research: Trends and methodological implications	PLOS ONE			English	Review							ARTICLE REPORTING STANDARDS; YOUTH VIOLENCE PREVENTION; CLINICAL-SIGNIFICANCE; MENTAL-HEALTH; APA PUBLICATIONS; OUTCOME RESEARCH; GROUP-THERAPY; PSYCHOLOGY; FIDELITY; MUSIC	Background Psychodrama is an experiential psychotherapy in which guided role-play is used to gain insights and work on personal and interpersonal problems and possible solutions. Despite the wealth of literature describing clinical work, psychodrama intervention research is relatively scarce compared to other psychotherapies and psychological interventions. Objective For this reason we implemented the integrative approach to systematic review that authorizes the combination of publications with diverse methodologies and all types of participants, interventions, comparisons, and outcomes. Our aim was to produce a comprehensive summary of psychodrama intervention research in the last decade that critically evaluates methodological issues to inform future studies. Methods We searched four major electronic databases (PsycINFO, PubMEd, Scopus by Elsevier, and Web of Science) for peer-reviewed articles on psychodrama interventions published in English between 1 January 2007 and 31 December 2017. The quality of qualitative and mixed methods studies was assessed on the basis of pre-established guidelines, and the risk of bias was assessed for all quantitative randomized control studies, consistent with the PRISMA protocol. Findings The database search and a hand search resulted in 31 psychodrama intervention publications. Overall, these studies examined the effects of psychodrama on more than 20 different outcomes and most studies had adult clients. The next largest group was adolescents, whereas only two studies involved children. Thus psychodrama intervention research in the last decade suggests there are promising results in all methodologies, and highlights the need to enhance methodological as well as reporting quality and to theorize and examine modality-specific mechanisms that lead to therapeutic change. Recommendations to improve methodology, transparency, and specificity in reporting future psychodrama and other psychotherapy research are discussed.	[Orkibi, Hod; Feniger-Schaal, Rinat] Univ Haifa, Fac Social Welf & Hlth Sci, Sch Creat Arts Therapies, Haifa, Israel	University of Haifa	Orkibi, H (corresponding author), Univ Haifa, Fac Social Welf & Hlth Sci, Sch Creat Arts Therapies, Haifa, Israel.	horkibi@univ.haifa.ac.il		Orkibi, Hod/0000-0003-1498-7953				Akinsola E. F., 2013, PSYCHOLOGY, V4, P246, DOI [DOI 10.4236/PSYCH.2013.43A037, 10.4236/psych.2013.43A037]; Alby F, 2017, RASSEGNA PSICOLOGIA, V34, P67; Ang KX, 2018, PALLIATIVE MED, V32, P500, DOI 10.1177/0269216317717369; Appelbaum M, 2018, AM PSYCHOL, V73, P3, DOI 10.1037/amp0000191; Aytemur ZA, 2012, TURK KLIN TIP BILIM, V32, P630, DOI 10.5336/medsci.2011-23965; Azoulay B, 2015, ART PSYCHOTHER, V42, P10, DOI 10.1016/j.aip.2014.12.012; Bilge A, 2017, J PSYCHIATR NURS, V8, P59, DOI 10.14744/phd.2017.08760; Biolcati R, 2017, RES PSYCHOTHER-PSYCH, V20, P201, DOI 10.4081/ripppo.2017.272; Buuren S.V., 2012, FLEXIBLE IMPUTATION; Chae SE, 2017, J COLL STUD PSYCH, V31, P59, DOI 10.1080/87568225.2016.1239512; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen L.M., 2011, ENCY CREATIVITY, V2nd ed., P9; Comer J. S., 2013, BERGIN GARFIELDS HDB, Vsixth, P21; Creswell J.W., 2003, RES DESIGN, Vsecond; Creswell J. W., 2018, DESIGNING CONDUCTING, V3rd; Dehnavi S, 2016, INT J MED RES HEALTH, V5, P243; Denton WH, 2009, J COUPLE RELATSH THE, V8, P226, DOI 10.1080/15332690903048820; Dogan T, 2010, ART PSYCHOTHER, V37, P112, DOI 10.1016/j.aip.2010.02.001; Elliott R, 2002, PSYCHOTHER RES, V12, P1, DOI 10.1080/713869614; Feniger-Schaal R, 2019, INTEGRATIVE SYSTEMAT; Ferguson CJ, 2009, PROF PSYCHOL-RES PR, V40, P532, DOI 10.1037/a0015808; Fox Jonathan, 1987, ESSENTIAL MORENO WRI; Frazier PA, 2004, J COUNS PSYCHOL, V51, P115, DOI 10.1037/0022-0167.51.1.115; Galvan J.L., 2006, WRITING LIT REV GUID; Gatta M, 2010, ART PSYCHOTHER, V37, P240, DOI 10.1016/j.aip.2010.04.010; Gokcakan Z., 2009, TURKISH JOURNAL OF P, V20, P1; Gonzalez AJ, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.01662; Gupta Sandeep K, 2011, Perspect Clin Res, V2, P109, DOI 10.4103/2229-3485.83221; Harkins L, 2011, INT J OFFENDER THER, V55, P546, DOI 10.1177/0306624X10370452; Hawker S, 2002, QUAL HEALTH RES, V12, P1284, DOI 10.1177/1049732302238251; Heppner PP., 2015, RES DESIGN COUNSELIN; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hildebrand MW, 2012, AM J PHYS MED REHAB, V91, P715, DOI 10.1097/PHM.0b013e31824ad462; Hogberg Goran, 2008, Clin Child Psychol Psychiatry, V13, P435; Holmes P, 2005, PSYCHODRAMA MORENO I; Hopia H, 2016, SCAND J CARING SCI, V30, P662, DOI 10.1111/scs.12327; Hug E, 1997, ART PSYCHOTHER, V24, P31, DOI 10.1016/S0197-4556(96)00046-9; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kahonen K, 2012, SCAND J PSYCHOL, V53, P523, DOI 10.1111/sjop.12020; Karabilgin OS, 2012, EUR J PSYCHOTHER COU, V14, P317, DOI 10.1080/13642537.2012.734529; Karatas Z, 2014, EGIT BILIM, V39, P117; Karatas Z, 2011, KURAM UYGUL EGIT BIL, V11, P609; Karatas Z, 2009, KURAM UYGULAMA EGI, V9, P1441; Kazdin A. E., 2011, SINGLE CASE RES DESI, V2nd; Kazdin A. E., 2014, QUANTITATIVE QUALITA, P87, DOI DOI 10.4324/9780203386071-6; Kazdin AE, 2009, PSYCHOTHER RES, V19, P418, DOI 10.1080/10503300802448899; KELLERMANN PF, 1987, SMALL GROUP BEHAV, V18, P459, DOI 10.1177/104649648701800402; Kellermann PF, 2000, FOCUS PSYCHODRAMA TH; Kipper DA, 2003, GROUP DYN-THEOR RES, V7, P13, DOI 10.1037/1089-2699.7.1.13; Kisbu-Sakarya Y, 2013, EDUC PSYCHOL MEAS, V73, P47, DOI 10.1177/0013164412450574; Konopik DA, 2013, SOC WORK, V58, P9, DOI 10.1093/sw/sws054; Kratochwill T. R., 2010, SINGLE CASE DESIGNS; Laird KT, 2017, CLIN PSYCHOL REV, V51, P142, DOI 10.1016/j.cpr.2016.11.001; Lambert MJ, 2009, PSYCHOTHER RES, V19, P493, DOI 10.1080/10503300902849483; Lee JH, 2016, J MUSIC THER, V53, P430, DOI 10.1093/jmt/thw012; Leung WC, 2001, POSTGRAD MED J, V77, P201, DOI 10.1136/pmj.77.905.201; Levitt HM, 2018, AM PSYCHOL, V73, P26, DOI 10.1037/amp0000151; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lutz W, 2014, QUANTITATIVE QUALITA, DOI [10.1080/10503307.2014.989290, DOI 10.1080/10503307.2014.989290]; McVea CS, 2011, PSYCHOTHER RES, V21, P416, DOI 10.1080/10503307.2011.577823; Menichetti J, 2016, EUR J CANCER CARE, V25, P903, DOI 10.1111/ecc.12412; Methley AM, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0579-0; Moreno JL, 1955, SOCIOMETRY, V18, P105, DOI 10.2307/2785848; Moreno J.L., 1946, PSYCHODRAMA, V1; MORENO JL, 1964, GROUP PSYCHOTHER PSY, V17, P149; Moreno JL, 1978, WHO SHALL SURVIVE FD; Munder T, 2018, PSYCHOTHER RES, V28, P347, DOI 10.1080/10503307.2017.1411628; Munn Z, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-017-0468-4; Oguzhanoglu NK, 2014, TURK PSIKIYATR DERG, V25, P75; Orkibi H, 2019, PSYCHOL AESTHET CREA, V13, P416, DOI 10.1037/aca0000193; Orkibi H, 2018, ART PSYCHOTHER, V59, P101, DOI 10.1016/j.aip.2018.04.004; Orkibi H, 2017, CLIN PSYCHOL PSYCHOT, V24, pO1455, DOI 10.1002/cpp.2103; Orkibi H, 2017, ART PSYCHOTHER, V55, P46, DOI 10.1016/j.aip.2017.04.001; Orkibi H, 2014, ART PSYCHOTHER, V41, P458, DOI 10.1016/j.aip.2014.08.006; Ozbas AA, 2016, PALLIAT SUPPORT CARE, V14, P393, DOI 10.1017/S1478951515001121; Robb SL, 2011, J HEALTH PSYCHOL, V16, P342, DOI 10.1177/1359105310374781; Ronk FR, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0895-5; Smokowski PR, 2009, RES SOCIAL WORK PRAC, V19, P165, DOI 10.1177/1049731508315989; Smokowski PR, 2009, SMALL GR RES, V40, P3, DOI 10.1177/1046496408326771; Sproesser E, 2010, PARKINSONISM RELAT D, V16, P298, DOI 10.1016/j.parkreldis.2009.08.008; Sullivan Gail M, 2012, J Grad Med Educ, V4, P279, DOI 10.4300/JGME-D-12-00156.1; Tarashoeva G., 2017, INT J PSYCHOTHER, V21, P55; Ten Have TR, 2008, PSYCHIAT ANN, V38, P772, DOI 10.3928/00485713-20081201-10; Terzioglu C, 2018, SEX DISABIL, V36, P87, DOI 10.1007/s11195-017-9514-8; Vural P, 2014, ART PSYCHOTHER, V41, P233, DOI 10.1016/j.aip.2014.02.004; Wampold BE, 2015, WORLD PSYCHIATRY, V14, P270, DOI 10.1002/wps.20238; Whittemore R, 2005, J ADV NURS, V52, P546, DOI 10.1111/j.1365-2648.2005.03621.x; Wieser M., 2007, PSYCHODRAMA ADV THEO, P271; Zhao K, 2016, INT J GERIATR PSYCH, V31, P1188, DOI 10.1002/gps.4494	89	43	48	3	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2019	14	2							e0212575	10.1371/journal.pone.0212575	http://dx.doi.org/10.1371/journal.pone.0212575			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HL9KY	30779787	Green Submitted, Green Published, gold			2023-01-03	WOS:000459062900066
J	Leischow, SJ				Leischow, Scott J.			Increasing Smoking Cessation in the United States Expanding the Availability of Over-the-Counter Medications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ADULTS		[Leischow, Scott J.] Arizona State Univ, Coll Hlth Solut, 425 N Fifth St, Phoenix, AZ 85004 USA	Arizona State University; Arizona State University-Downtown Phoenix	Leischow, SJ (corresponding author), Arizona State Univ, Coll Hlth Solut, 425 N Fifth St, Phoenix, AZ 85004 USA.	Scott.Leischow@asu.edu						Ali A, 2018, AM J PREV MED, V55, P253, DOI 10.1016/j.amepre.2018.04.021; Anthenelli RM, 2016, LANCET, V387, P2507, DOI 10.1016/S0140-6736(16)30272-0; Babb S, 2017, MMWR-MORBID MORTAL W, V65, P1457, DOI 10.15585/mmwr.mm6552a1; Cahill K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009329.pub2, 10.1002/14651858.CD006103.pub6]; Fiore MC, CLIN PRACTICE GUIDEL; Leischow SJ, 2004, AM J HEALTH BEHAV, V28, P291, DOI 10.5993/AJHB.28.4.1; Reed MB, 2005, CANCER EPIDEM BIOMAR, V14, P2131, DOI 10.1158/1055-9965.EPI-04-0919; Schlam TR, 2018, PSYCHOPHARMACOLOGY, V235, P2065, DOI 10.1007/s00213-018-4903-y; Stomberg C, 2013, HLTH IRVINE CALIF, V5, P1667, DOI [10.4236/health.2013.510225, DOI 10.4236/HEALTH.2013.510225]; Wang TW, 2018, MMWR-MORBID MORTAL W, V67, P1225, DOI 10.15585/mmwr.mm6744a2	10	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	2019	321	6					541	542		10.1001/jama.2018.21557	http://dx.doi.org/10.1001/jama.2018.21557			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL1KO	30653222				2023-01-03	WOS:000458456700010
J	Dribin, TE; Michelson, KA; Monuteaux, MC; Stack, AM; Farbman, KS; Schneider, LC; Neuman, MI				Dribin, Timothy E.; Michelson, Kenneth A.; Monuteaux, Michael C.; Stack, Anne M.; Farbman, Karen S.; Schneider, Lynda C.; Neuman, Mark I.			Identification of children with anaphylaxis at low risk of receiving acute inpatient therapies	PLOS ONE			English	Article							EMERGENCY-DEPARTMENT PATIENTS; REPEAT EPINEPHRINE TREATMENTS; BIPHASIC REACTIONS; ALLERGIC REACTIONS; CLINICAL PREDICTORS; MULTICENTER; SEVERITY; CARE	Objective Opportunity exists to reduce unnecessary hospitalizations for children with anaphylaxis given wide variation in admission rates across U.S. emergency departments (EDs). We sought to identify children hospitalized with anaphylaxis at low risk of receiving epinephrine and other acute inpatient therapies, as these patients may be candidates for ED discharge rather than inpatient hospitalization. Methods We conducted a single-center retrospective cohort study of children 1-21 years of age hospitalized with anaphylaxis from 2009 to 2016. Acute inpatient therapies included intramuscular (IM) or racemic epinephrine, bronchodilators, fluid boluses, vasopressors, non-invasive ventilation, or intubation. We derived age-specific (pre-verbal [<36 months] vs. verbal [>= 36 months]) prediction rules using recursive partitioning to identify children at low risk of receiving acute inpatient therapies. Results During the study period 665 children were hospitalized for anaphylaxis, of whom 108 (16.2%) received acute inpatient therapies. The prediction rule for patients < 36 months (no wheezing, no cardiac involvement [hypotension or wide pulse pressure]) had a sensitivity of 90.5% (CI 69.6-98.8%) and a negative predictive value of 98.3% (CI 94.1-99.8%) for identifying children at low risk of receipt of acute inpatient therapies during hospitalization. For children >= 36 months, the prediction rule (no wheezing, no cardiac involvement, presence of gastrointestinal symptoms) had a sensitivity of 90.8% (CI 82.7-96.0%) and a negative predictive value of 92.4% (CI 85.6-96.7%). Conclusions We derived age specific prediction rules for children hospitalized with anaphylaxis at low risk of receiving epinephrine and other acute inpatient therapies. These children may be candidates for ED discharge rather than inpatient hospitalization.	[Dribin, Timothy E.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Div Emergency Med, Cincinnati, OH 45221 USA; [Michelson, Kenneth A.; Monuteaux, Michael C.; Stack, Anne M.; Farbman, Karen S.; Neuman, Mark I.] Harvard Med Sch, Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Schneider, Lynda C.] Harvard Med Sch, Boston Childrens Hosp, Div Allergy & Immunol, Boston, MA USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Dribin, TE (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Div Emergency Med, Cincinnati, OH 45221 USA.	Timothy.Dribin@cchmc.org	Schneider, Lynda C/AAY-6545-2021	Schneider, Lynda C/0000-0002-5633-0178; Dribin, Tim/0000-0002-7483-1750	Boston Children's Hospital House Officer Award	Boston Children's Hospital House Officer Award	This work was supported by the Boston Children's Hospital House Officer Award to TED. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alba AC, 2017, JAMA-J AM MED ASSOC, V318, P1377, DOI 10.1001/jama.2017.12126; Alqurashi W, 2015, ANN ALLERG ASTHMA IM, V115, P217, DOI 10.1016/j.anai.2015.05.013; Banerji A, 2010, ALLERGY ASTHMA PROC, V31, P308, DOI 10.2500/aap.2010.31.3375; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Campbell RL, 2015, J ALLER CL IMM-PRACT, V3, P576, DOI 10.1016/j.jaip.2015.04.009; Campbell RL, 2014, ANN ALLERG ASTHMA IM, V113, P599, DOI 10.1016/j.anai.2014.10.007; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Collins GS, 2014, BMJ-BRIT MED J, V68, P134; DOUGLAS DM, 1994, J ALLERGY CLIN IMMUN, V93, P977, DOI 10.1016/S0091-6749(94)70044-3; Ellis, 2010, OPEN ALLERGY J, V3, P24, DOI [10.2174/1874838401003010024, DOI 10.2174/1874838401003010024]; Ellis AK, 2007, ANN ALLERG ASTHMA IM, V98, P64, DOI 10.1016/S1081-1206(10)60861-7; Farbman KS, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-4114; Gaeta TJ, 2007, ANN ALLERG ASTHMA IM, V98, P360, DOI 10.1016/S1081-1206(10)60883-6; Grunau BE, 2014, ANN EMERG MED, V63, P736, DOI 10.1016/j.annemergmed.2013.10.017; Ko BS, 2015, ANN ALLERG ASTHMA IM, V115, P312, DOI 10.1016/j.anai.2015.07.015; Lee JM, 2000, PEDIATRICS, V106, P762, DOI 10.1542/peds.106.4.762; Lee S, 2017, J ALLER CL IMM-PRACT, V5, P1295, DOI 10.1016/j.jaip.2017.07.020; Lee S, 2016, CURR OPIN ALLERGY CL, V16, P346, DOI 10.1097/ACI.0000000000000279; Lee S, 2015, J ALLER CL IMM-PRACT, V3, P408, DOI 10.1016/j.jaip.2014.12.010; Lee SG, 2014, J ALLER CL IMM-PRACT, V2, P281, DOI 10.1016/j.jaip.2014.01.012; Lieberman P, 2005, ANN ALLERG ASTHMA IM, V95, P217, DOI 10.1016/S1081-1206(10)61217-3; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126; Linden A., 2017, KFOLDCLASS STATA MOD; Manivannan V, 2009, ANN ALLERG ASTHMA IM, V103, P395, DOI 10.1016/S1081-1206(10)60358-4; Mehr S, 2009, CLIN EXP ALLERGY, V39, P1390, DOI 10.1111/j.1365-2222.2009.03276.x; Michelson KA, 2016, ACAD EMERG MED, V23, P623, DOI 10.1111/acem.12922; Motosue MS, 2017, J ALLERGY CLIN IMMUN; Motosue MS, 2017, J ALLERGY CLIN IMMUN, V5; Muraro A, 2007, ALLERGY, V62, P857, DOI 10.1111/j.1398-9995.2007.01421.x; Ralston M, 2006, PALS PROVIDER MANUAL; Rohacek M, 2014, ALLERGY, V69, P791, DOI 10.1111/all.12404; Rudders SA, 2010, PEDIATRICS, V125, pE711, DOI 10.1542/peds.2009-2832; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Simons FER, 2011, WORLD ALLERGY ORGAN, V4, P13, DOI 10.1097/WOX.0b013e318211496c; Soar J, 2008, RESUSCITATION, V77, P157, DOI 10.1016/j.resuscitation.2008.02.001; Tole JW, 2007, IMMUNOL ALLERGY CLIN, V27, P309, DOI 10.1016/j.iac.2007.03.011; Ye YM, 2015, ALLERGY ASTHMA IMMUN, V7, P22, DOI 10.4168/aair.2015.7.1.22	37	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2019	14	2							e0211949	10.1371/journal.pone.0211949	http://dx.doi.org/10.1371/journal.pone.0211949			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK5RX	30730977	Green Submitted, Green Published, gold			2023-01-03	WOS:000458026000077
J	Araujo, ACM; Almeida, EB; Rocha, CQ; Lima, AS; Silva, CR; Tangerina, MMP; Neto, JSL; Costa, LM				Araujo, Ana Cassia M.; Almeida, Eduardo B., Jr.; Rocha, Claudia Q.; Lima, Aldilene S.; Silva, Carolina R.; Tangerina, Marcelo M. P.; Lima Neto, Jose S.; Costa-Junior, Livio M.			Antiparasitic activities of hydroethanolic extracts of Ipomoea imperati (Vahl) Griseb. (Convolvulaceae)	PLOS ONE			English	Article							TANNIFEROUS PLANT-EXTRACTS; VITRO LARVAL MIGRATION; HAEMONCHUS-CONTORTUS; ANTHELMINTIC ACTIVITY; INFECTIVE LARVAE; EXSHEATHMENT; 3RD-STAGE; TANNINS	Ipomoea imperati is widely used in tropical areas to treat several pathological conditions. The effect of this plant against parasitic species has not been investigated even being used for this purpose in the Brazilian northeastern. This study aimed to evaluate the anthelmintic and acaricide potential of a hydroethanolic extract of I. imperati leaves and stolons. I. imperati leaves and stolons were crushed and subjected to maceration in ethanol 70% (v/v), after which the solvent was removed using a rotary evaporator. The chromatographic profile of the extract was obtained by UV Spectrum high-performance liquid chromatography and compounds were identified by liquid chromatography/electrospray ionization tandem mass spectrometry. Identification of the compounds present in the extract was achieved by comparing their retention times and UV spectra with data in the literature. Anthelmintic activity was evaluated by larval exsheathment inhibition assays using Haemonchus contortus larvae and five concentrations of each extract ranging from 0.07 to 1.2 mg/mL. Acaricide activity was evaluated via larval immersion of Rhipicephalus microplus in eight concentrations of each extract ranging from 5.0 to 25.0 mg/mL. Live and dead larvae were counted after 24 hours. The median inhibitory concentration (IC50) for H. contortus larvae and the median lethal concentration (LC50) for R. microplus larvae were calculated. Twelve compounds were observed in the hydroethanolic extract of leaves, with a predominance of the aglycone form of flavonoids and tannins. This extract was effective against H. contortus larvae, presenting an average inhibitory concentration of 0.22 mg/mL, but showed no activity toward R. microplus larvae. The stolon hydroethanolic extract presented 11 compounds, with phenolic acids and glycosylated flavonoids prevailing. This extract showed low activity on R. microplus and no effect on inhibiting H. contortus larval exsheathment at the concentrations tested. This study is the first to assess the anthelmintic and acaricidal activities of I. imperati. Data reported confirm promising potential of I. imperati leaves hydroethanolic extract against H. contortus. This effect could be due to its secondary compounds presents in this extract, such as procyanidin, kaempferol, isoquercitrin and rutin.	[Araujo, Ana Cassia M.] Univ Fed Maranhao, Ctr Ciencias Biol & Saude, Programa Posgrad Biodivers & Conservac, Sao Luis, Maranhao, Brazil; [Almeida, Eduardo B., Jr.] Univ Fed Maranhao, Dept Biol, Sao Luis, Maranhao, Brazil; [Rocha, Claudia Q.; Lima, Aldilene S.] Univ Fed Maranhao, Dept Quim, Sao Luis, Maranhao, Brazil; [Rocha, Claudia Q.; Silva, Carolina R.; Costa-Junior, Livio M.] Univ Fed Maranhao, Dept Patol, Sao Luis, Maranhao, Brazil; [Tangerina, Marcelo M. P.] Univ Estadual Paulista, Inst Biociencias, Lab Bioprospeccao Prod Nat, Sao Vicente, SP, Brazil; [Lima Neto, Jose S.] Univ Fed Piaui, Dept Farm, Lab Geoquim Organ, Teresina, Piaui, Brazil	Universidade Federal do Maranhao; Universidade Federal do Maranhao; Universidade Federal do Maranhao; Universidade Federal do Maranhao; Universidade de Sao Paulo; Universidade Estadual Paulista; Universidade Federal do Piaui	Almeida, EB (corresponding author), Univ Fed Maranhao, Dept Biol, Sao Luis, Maranhao, Brazil.; Costa, LM (corresponding author), Univ Fed Maranhao, Dept Patol, Sao Luis, Maranhao, Brazil.	ebaj25@yahoo.com.br; livio.martins@ufma.br	Rocha, Cláudia Quintino da/C-2320-2013; Tangerina, Marcelo M P Marucci Pereira/L-3580-2016; Costa-Junior, Livio M/H-7530-2012; Lima Neto, José de Sousa/E-6937-2015; Rocha e Silva, Carolina/HHN-8484-2022; Lima-Neto, José/T-3483-2019; Araujo, Ana Cássia Medeiros/AAD-7659-2019; Tangerina, Marcelo/AEF-1225-2022	Rocha, Cláudia Quintino da/0000-0002-3578-1869; Tangerina, Marcelo M P Marucci Pereira/0000-0002-4236-094X; Costa-Junior, Livio M/0000-0002-1475-049X; Lima Neto, José de Sousa/0000-0002-3933-6391; Rocha e Silva, Carolina/0000-0001-8667-1064	Financiadora de estudos e projetos by "FINEP Chamada Apoio Institucional" [03/2016]; Fundacao de Amparo a Pesquisa e ao Desenvolvimento cientifico e tecnologico do Maranhao (FAPEMA) by "IECT Biotecnologia"; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior CAPES (Coordination for the Improvement of High Higher Education Personnel, Brazil); FAPEMA; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico CNPq (National Council for Scientific and Technological Development)	Financiadora de estudos e projetos by "FINEP Chamada Apoio Institucional"; Fundacao de Amparo a Pesquisa e ao Desenvolvimento cientifico e tecnologico do Maranhao (FAPEMA) by "IECT Biotecnologia"; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior CAPES (Coordination for the Improvement of High Higher Education Personnel, Brazil); FAPEMA(Fundacao de Amparo a Pesquisa e Desenvolvimento Cientifico do Maranhao (FAPEMA)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico CNPq (National Council for Scientific and Technological Development)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	The study had financial support by Financiadora de estudos e projetos by "FINEP Chamada Apoio Institucional 03/2016" to LMCJ and Fundacao de Amparo a Pesquisa e ao Desenvolvimento cientifico e tecnologico do Maranhao (FAPEMA) by "IECT Biotecnologia" to LMCJ. The author CRS received scholarship from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior CAPES (Coordination for the Improvement of High Higher Education Personnel, Brazil). The authors ACMA and ASL received scholarship from FAPEMA. The author LMCJ received a fellowship from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico CNPq (National Council for Scientific and Technological Development). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akkari H, 2016, VET MED-CZECH, V61, P308, DOI 10.17221/169/2015-VETMED; Ali A, 2016, CIENC RURAL, V46, P1240, DOI 10.1590/0103-8478cr20151416; Alonso-Diaz MA, 2008, VET PARASITOL, V153, P313, DOI 10.1016/j.vetpar.2008.01.042; Alonso-Diaz MA, 2011, VET PARASITOL, V181, P360, DOI 10.1016/j.vetpar.2011.03.052; Athanasiadou S, 2007, ANIMAL, V1, P1392, DOI 10.1017/S1751731107000730; Austin DF, 1996, TAXON, V45, P3, DOI 10.2307/1222581; Azando EVB, 2011, VET PARASITOL, V180, P292, DOI 10.1016/j.vetpar.2011.03.010; Bahuaud D, 2006, PARASITOLOGY, V132, P545, DOI 10.1017/S0031182005009509; Barrau E, 2005, PARASITOLOGY, V131, P531, DOI 10.1017/S0031182005008024; Brito DRB, 2017, SEMIN-CIENC AGRAR, V38, P1963, DOI 10.5433/1679-0359.2017v38n4p1963; de Oliveira LMB, 2011, REV BRAS PARASITOL V, V20, P155, DOI 10.1590/S1984-29612011000200011; Brunet S, 2011, PARASITOL INT, V60, P419, DOI 10.1016/j.parint.2010.09.011; Cai CY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095931; Chougule MB, 2016, PROG DRUG RES, V71, P11, DOI 10.1007/978-3-319-26811-8_3; Costa Neto SV, 2000, B MUS PARA EMILIO GO, V16, P163; De Paula-Zurron ACB, 2010, REV BRAS FARMACOGN, V20, P180, DOI 10.1590/S0102-695X2010000200008; Dhembare A. J., 2015, Der Pharmacia Lettre, V7, P262; Dias DA, 2012, METABOLITES, V2, DOI 10.3390/metabo2020303; Soares AMD, 2015, REV BRAS PARASITOL V, V24, P396, DOI 10.1590/S1984-29612015072; Estrada-Pena A, 2013, AGRICULTURE-BASEL, V3, P221, DOI 10.3390/agriculture3020221; Felger Richard S., 2012, Journal of the Botanical Research Institute of Texas, V6, P459; Ferreira P. P. A., 2009, Revista Brasileira de Biociencias, V7, P440; Ghosh S, 2014, ASIAN J PHARM CLIN R, V7, P162; Grisi L, 2014, REV BRAS PARASITOL V, V23, P150, DOI 10.1590/S1984-29612014042; Hoste H, 2012, VET PARASITOL, V186, P18, DOI 10.1016/j.vetpar.2011.11.042; Jardim MAG., 2005, REV BRASILEIRA FARMA, V86, P117; Kamaraj C, 2010, PARASITOL RES, V106, P1071, DOI 10.1007/s00436-010-1750-0; Klafke GM, 2006, VET PARASITOL, V142, P386, DOI 10.1016/j.vetpar.2006.07.001; Klongsiriwet C, 2015, INT J PARASITOL-DRUG, V5, P127, DOI 10.1016/j.ijpddr.2015.06.001; Lasisi A. A., 2011, African Journal of Plant Science, V5, P469; Lonard RI, 1999, J COASTAL RES, V15, P645; Malakar C., 2015, ASIAN J PHARM CLIN R, V8, P60; Meira M, 2012, REV BRAS FARMACOGN, V22, P682, DOI 10.1590/S0102-695X2012005000025; Mengistu G, 2017, VET PARASITOL, V237, P110, DOI 10.1016/j.vetpar.2016.12.020; Minho Alessandro P, 2008, Rev Bras Parasitol Vet, V17 Suppl 1, P144; Miyahara MRM, 2011, REV BRAS FARMACOGN, V21, P978, DOI 10.1590/S0102-695X2011005000143; Moreno-Gonzalo J, 2013, VET PARASITOL, V197, P235, DOI 10.1016/j.vetpar.2013.05.010; O'Connor LJ, 2006, VET PARASITOL, V142, P1, DOI 10.1016/j.vetpar.2006.08.035; Oliveira AF, 2017, VET PARASITOL, V236, P121, DOI 10.1016/j.vetpar.2017.02.005; Paula ACB, 2003, BRAZ J MED BIOL RES, V36, P105, DOI 10.1590/S0100-879X2003000100014; Pavela R, 2016, RES VET SCI, V109, P1, DOI 10.1016/j.rvsc.2016.09.001; Qadir S, 2010, VET WORLD, V3, P515; Qamar M. F., 2011, Science International (Lahore), V23, P295; Quijada J, 2015, J AGR FOOD CHEM, V63, P6346, DOI 10.1021/acs.jafc.5b00831; Roeber F, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-153; SON-DE FERNEX E.V, 2012, EXPT PARASITOLOGY NE, V131, P413, DOI DOI 10.1016/J.EXPPARA.2012.05.010; Spiegler V, 2017, NAT PROD REP, V34, P627, DOI 10.1039/c6np00126b; Zaman MA, 2017, INT J AGRIC BIOL, V19, P957, DOI 10.17957/IJAB/15.0289; Zhang BY, 2015, CHEM PHARM BULL, V63, P255, DOI 10.1248/cpb.c14-00765; Zhou X, 2014, J PARASITOL, V100, P848, DOI 10.1645/14-556.1; Zia-Ul-Haq M, 2012, MOLECULES, V17, P13132, DOI 10.3390/molecules171113132	51	4	4	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2019	14	1							e0211372	10.1371/journal.pone.0211372	http://dx.doi.org/10.1371/journal.pone.0211372			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ2YV	30682142	Green Published, Green Submitted, gold			2023-01-03	WOS:000457037500157
J	Zelis, N; Mauritz, AN; Kuijpers, LIJ; Buijs, J; de Leeuw, PW; Stassen, PM				Zelis, Noortje; Mauritz, Arisja N.; Kuijpers, Lonne I. J.; Buijs, Jacqueline; de Leeuw, Peter W.; Stassen, Patricia M.			Short-term mortality in older medical emergency patients can be predicted using clinical intuition: A prospective study	PLOS ONE			English	Article							SELF-RATED HEALTH; MORBIDITY; ILLNESS; ADULTS	Background Older emergency department (ED) patients are at risk for adverse outcomes, however, it is hard to predict these. We aimed to assess the discriminatory value of clinical intuition, operationalized as disease perception, self-rated health and first clinical impression, including the 30-day surprise question (SQ: "Would I be surprised if this patient died in the next 30 days" of patients, nurses and physicians. Endpoints used to evaluate the discriminatory value of clinical intuition were short-term (30-day) mortality and other adverse outcomes (intensive/medium care admission, prolonged length of hospital stay, loss of independent living or 30-day readmission). Methods In this prospective, multicentre cohort study, older medical patients (>= 65 years), nurses and physicians filled in scores regarding severity of illness and their concerns (i.e. disease perception and clinical impression scores) immediately after arrival of the patient in the ED. In addition, patients filled in a self-rated health score and nurses and physicians answered the SQ. Area under the curves (AUCs) of receiver operating characteristics (ROCs) were calculated. Results The median age of the 602 included patients was 79 years and 86.7% were community dwelling. Within 30 days, 66 (11.0%) patients died and 263 (43.7%) patients met the composite endpoint. The severity of concern score of both nurses and physicians yielded the highest AUCs for 30-day mortality (for both 0.75; 95% CI 0.68-0.81). AUCs for the severity of illness score and SQ of nurses and physicians ranged from 0.71 to 0.74 while those for the disease perception and self-rated health of patients ranged from 0.64 to 0.69. The discriminatory value of the scores for the composite endpoint was lower (AUCs ranging from 0.60 to 0.67). We used scores that have not been previously validated which could influence their generalisability. Conclusion Clinical intuition,-disease perception, self-rated health and first clinical impression-documented at an early stage after arrival in the ED, is a useful clinical tool to predict mortality and other adverse outcomes in older ED patients. Highest discriminatory values were found for the nurses' and physicians' severity of concern score. Intuition may be helpful for the implementation of personalised medical care in the future.	[Zelis, Noortje; Kuijpers, Lonne I. J.; Buijs, Jacqueline; de Leeuw, Peter W.] Zuyderland Med Ctr, Dept Internal Med & Gastroenterol, Heerlen, Netherlands; [Zelis, Noortje; de Leeuw, Peter W.] Maastricht Univ, Maastricht Univ Med Ctr, CARIM Sch Cardiovasc Dis, Maastricht, Netherlands; [Mauritz, Arisja N.; de Leeuw, Peter W.; Stassen, Patricia M.] Maastricht Univ, Maastricht Univ Med Ctr, Sect Acute Med, Dept Internal Med,Div Gen Internal Med, Maastricht, Netherlands; [Stassen, Patricia M.] Maastricht Univ, Maastricht Univ Med Ctr, Sch CAPHRI, Maastricht, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC)	Zelis, N (corresponding author), Zuyderland Med Ctr, Dept Internal Med & Gastroenterol, Heerlen, Netherlands.; Zelis, N (corresponding author), Maastricht Univ, Maastricht Univ Med Ctr, CARIM Sch Cardiovasc Dis, Maastricht, Netherlands.	n.zelis@zuyderland.nl		Zelis, Noortje/0000-0003-0015-5240	Zuyderland MC	Zuyderland MC	Noortje Zelis was funded by Zuyderland MC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aminzadeh F, 2002, ANN EMERG MED, V39, P238, DOI 10.1067/mem.2002.121523; Bamia C, 2017, MATURITAS, V103, P37, DOI 10.1016/j.maturitas.2017.06.023; Beglinger B, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000374; Brabrand M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101739; Buurman BM, 2008, J GEN INTERN MED, V23, P1883, DOI 10.1007/s11606-008-0741-7; Carpenter CR, 2015, ACAD EMERG MED, V22, P1, DOI 10.1111/acem.12569; CHARLSON ME, 1986, J CHRON DIS, V39, P439, DOI 10.1016/0021-9681(86)90111-6; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cicchetti D.V., 1994, PSYCHOL ASSESSMENT, V6, P284, DOI 10.1037/1040-3590.6.4.284; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Downar J, 2017, CAN MED ASSOC J, V189, pE484, DOI 10.1503/cmaj.160775; Godard-Sebillotte C, 2016, QUAL LIFE RES, V25, P2335, DOI 10.1007/s11136-016-1252-3; Grossmann FF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106203; Hallgren Kevin A, 2012, Tutor Quant Methods Psychol, V8, P23; Hamano J, 2015, ONCOLOGIST, V20, P839, DOI 10.1634/theoncologist.2015-0015; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Rohacek M, 2015, INT J CLIN PRACT, V69, P710, DOI 10.1111/ijcp.12606; Samaras N, 2010, ANN EMERG MED, V56, P261, DOI 10.1016/j.annemergmed.2010.04.015; Simundic Ana-Maria, 2009, EJIFCC, V19, P203; Sinuff T, 2006, CRIT CARE MED, V34, P878, DOI 10.1097/01.CCM.0000201881.58644.41; van der Vegt AE, 2012, EUR J EMERG MED, V19, P373, DOI 10.1097/MEJ.0b013e32834def59; White N, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0907-4; *WHO, 2004, ICD 10 INT STAT CLAS, V2; Wong DD, 2007, EMERG MED AUSTRALAS, V19, P196, DOI 10.1111/j.1742-6723.2007.00924.x	24	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 2	2019	14	1							e0208741	10.1371/journal.pone.0208741	http://dx.doi.org/10.1371/journal.pone.0208741			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG1BB	30601815	Green Submitted, Green Published, gold			2023-01-03	WOS:000454683200021
J	van den Tempel, N; Naipal, KAT; Reams, A; van Gent, DC; Franckena, M; Boormans, JL; Kanaar, R				van den Tempel, Nathalie; Naipal, Kishan A. T.; Reams, Anja; van Gent, Dik C.; Franckena, Martine; Boormans, Joost L.; Kanaar, Roland			Ex vivo assays to predict enhanced chemosensitization by hyperthermia in urothelial cancer of the bladder	PLOS ONE			English	Article							HOMOLOGOUS RECOMBINATION; MITOMYCIN-C; CROSS-LINKS; CELL-LINES; REPAIR; CHEMOTHERAPY; CARCINOMA; CISPLATIN; THERAPY; FUTURE	Introduction Bladder cancer (urothelial carcinoma) is a common malignancy characterized by high recurrence rates and intense clinical follow-up, indicating the necessity for more effective therapies. Current treatment regimens include intra-vesical administration of mitomycin C (MMC) for non-muscle invasive disease and systemic cisplatin for muscle-invasive or metastatic disease. Hyperthermia, heating a tumor to 40-44 degrees C, enhances the efficacy of these chemotherapeutics by various modes of action, one of which is inhibition of DNA repair via homologous recombination. Here, we explore whether ex vivo assays on freshly obtained bladder tumors can be applied to predict the response towards hyperthermia. Material and methods The cytochrome C release assay (apoptosis) and the RAD51 focus formation assay (DNA repair) were first established in the bladder cancer cell lines RT112 and T24 as measurements for hyperthermia efficiency, and subsequently tested in freshly obtained bladder tumors (n = 59). Results Hyperthermia significantly increased the fraction of apoptotic cells after cisplatin or MMC treatment in both RT112 and T24 cells and in most of the bladder tumors (8/10). The RAD51 focus formation assay detected both morphological and numerical changes of RAD51 foci upon hyperthermia in the RT112 and T24 cell lines. In 64% of 37 analyzed primary bladder tumor samples, hyperthermia induced similar morphological changes in RAD51 foci. Conclusion The cytochrome C assay and the RAD51 focus formation assay are both feasible on freshly obtained bladder tumors, and could serve to predict the efficacy of hyperthermia together with cytotoxic agents, such as MMC or cisplatin.	[van den Tempel, Nathalie; Naipal, Kishan A. T.; Reams, Anja; van Gent, Dik C.; Kanaar, Roland] Erasmus Univ, Dept Mol Genet, Med Ctr, Rotterdam, Netherlands; [van Gent, Dik C.; Kanaar, Roland] Erasmus Univ, Oncode Inst, Dept Mol Genet, Med Ctr, Rotterdam, Netherlands; [Franckena, Martine] Erasmus MC Canc Inst, Dept Radiat Oncol, Rotterdam, Netherlands; [Boormans, Joost L.] Erasmus MC Canc Inst, Dept Urol, Rotterdam, Netherlands; [van den Tempel, Nathalie] Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; University of Groningen	Kanaar, R (corresponding author), Erasmus Univ, Dept Mol Genet, Med Ctr, Rotterdam, Netherlands.; Kanaar, R (corresponding author), Erasmus Univ, Oncode Inst, Dept Mol Genet, Med Ctr, Rotterdam, Netherlands.; Boormans, JL (corresponding author), Erasmus MC Canc Inst, Dept Urol, Rotterdam, Netherlands.	j.boormans@erasmusmc.nl; r.kanaar@erasmusmc.nl		van Gent, Dik C./0000-0003-1473-8148; Naipal, Kishan/0000-0001-8267-8218	European Community's Seventh Framework Programme (FP7/2007-2013) [HEALTH-F2-2010-259893]; Erasmus MC MRace grant; Dutch Cancer Society [DDHK 2013-6072, EMCR 2015-7846]; Netherlands Organisation for Scientific Research (NWO); Oncode Institute - Dutch Cancer Society	European Community's Seventh Framework Programme (FP7/2007-2013); Erasmus MC MRace grant; Dutch Cancer Society(KWF Kankerbestrijding); Netherlands Organisation for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Oncode Institute - Dutch Cancer Society	DCvG received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. HEALTH-F2-2010-259893 (https://ec.europa.eu/research/fp7/index_en.cfm).RK was supported by an Erasmus MC MRace grant (https://www.erasmusmc.nl/research/over-research/subsidies/subsidies/#). The Dutch Cancer Society awarded grants to MF (DDHK 2013-6072) and RK (EMCR 2015-7846) https://www.kwf.nl/pages/default.aspx.The work in RK's laboratory was funded by the gravitation program CancerGenomiCs.nl from the Netherlands Organisation for Scientific Research (NWO) and is part of the Oncode Institute, which is partly financed by the Dutch Cancer Society (https://www.oncode.nl/).The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Abdollah F, 2013, CANCER EPIDEMIOL, V37, P219, DOI 10.1016/j.canep.2013.02.002; Alabert C, 2009, EMBO J, V28, P1131, DOI 10.1038/emboj.2009.75; Alvarez-Berrios MP, 2013, INT J NANOMED, V8, P1003, DOI 10.2147/IJN.S38842; Arends TJH, 2016, EUR UROL, V69, P1046, DOI 10.1016/j.eururo.2016.01.006; Babjuk M, 2017, EUR UROL, V71, P447, DOI 10.1016/j.eururo.2016.05.041; BEDFORD P, 1987, CHEM-BIOL INTERACT, V61, P1, DOI 10.1016/0009-2797(87)90015-9; Burger M, 2013, EUR UROL, V63, P234, DOI 10.1016/j.eururo.2012.07.033; Dewhirst MW, 2016, INT J HYPERTHER, V32, P4, DOI 10.3109/02656736.2015.1091093; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Heijkoop ST, 2014, INT J HYPERTHER, V30, P6, DOI 10.3109/02656736.2013.844366; Issels RD, 2008, EUR J CANCER, V44, P2546, DOI 10.1016/j.ejca.2008.07.038; Jasin M, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012740; Karkoulis PK, 2016, TUMOR BIOL, V37, P6861, DOI 10.1007/s13277-015-4544-2; Knipscheer P, 2009, SCIENCE, V326, P1698, DOI 10.1126/science.1182372; Krawczyk PM, 2011, P NATL ACAD SCI USA, V108, P9851, DOI 10.1073/pnas.1101053108; Lammers RJM, 2011, EUR UROL, V60, P81, DOI 10.1016/j.eururo.2011.04.023; Landon CD, 2013, INT J HYPERTHER, V29, P528, DOI 10.3109/02656736.2013.790563; Long DT, 2011, SCIENCE, V333, P84, DOI 10.1126/science.1204258; Longo TA, 2016, INT J HYPERTHER, V32, P381, DOI 10.3109/02656736.2016.1157903; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Mutter RW, 2017, J PATHOL; Naipal KAT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126029; Naipal KAT, 2014, CLIN CANCER RES, V20, P4816, DOI 10.1158/1078-0432.CCR-14-0571; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Oei AL, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0462-0; Ploeg M, 2009, WORLD J UROL, V27, P289, DOI 10.1007/s00345-009-0383-3; Ploussard G, 2014, EUR UROL, V66, P361, DOI 10.1016/j.eururo.2013.09.050; Ploussard G, 2014, EUR UROL, V66, P120, DOI 10.1016/j.eururo.2014.02.038; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Semlow DR, 2016, CELL, V167, P498, DOI 10.1016/j.cell.2016.09.008; Steliarova-Foucher E, 2015, EUR J CANCER, V51, P1131, DOI 10.1016/j.ejca.2014.01.027; Tarsounas M, 2003, ONCOGENE, V22, P1115, DOI 10.1038/sj.onc.1206263; Tashiro S, 1996, ONCOGENE, V12, P2165; van den Tempel N, 2017, ONCOTARGET; van den Tempel N, 2016, INT J HYPERTHER, V32, P446, DOI 10.3109/02656736.2016.1157216; van der Heijden AG, 2004, EUR UROL, V46, P670, DOI 10.1016/j.eururo.2004.06.009; van der Heijden AG, 2016, INT J HYPERTHER, V32, P434, DOI 10.3109/02656736.2016.1155761; van Kessel KEM, 2015, NAT REV UROL, V12, P681, DOI 10.1038/nrurol.2015.231; van Valenberg H, 2016, INT J HYPERTHER, V32, P351, DOI 10.3109/02656736.2016.1140232; Vaughn JP, 1996, CANCER RES, V56, P4590; Volpe A, 2010, MINERVA UROL NEFROL, V62, P133; WALKER MC, 1987, J NATL CANCER I, V79, P213; Yang ZY, 2017, DNA REPAIR, V52, P1, DOI 10.1016/j.dnarep.2017.02.011	45	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2018	13	12							e0209101	10.1371/journal.pone.0209101	http://dx.doi.org/10.1371/journal.pone.0209101			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE3IQ	30550547	Green Published, Green Submitted, gold			2023-01-03	WOS:000453248000045
J	Lang, S; Herold, R; Kraft, A; Harth, V; Preisser, AM				Lang, Stephan; Herold, Robert; Kraft, Alexander; Harth, Volker; Preisser, Alexandra M.			Spiroergometric measurements under increased inspiratory oxygen concentration (FIO2)-Putting the Haldane transformation to the test	PLOS ONE			English	Article							EXERCISE PERFORMANCE; CONSUMPTION; HYPEROXIA	Spiroergometric measurements of persons who require oxygen insufflation due to illness can be performed under conditions of increased inspiratory oxygen concentration (FIO2). This increase in FIO2, however, often leads to errors in the calculation of oxygen consumption (VO2). These inconsistencies are due to the application of the Haldane Transformation (HT), an otherwise indispensable correction factor in the calculation of VO2 that becomes inaccurate at higher FIO2 concentrations. A possible solution to this problem could be the use of the Eschenbacher transformation' (ET) as an alternative correction factor. This study examines the concentration of FIO2 at which the HT and the ET are valid, providing plausible data of oxygen consumption corresponding to the wattage achieved during cycle ergometry. Ten healthy volunteers underwent spiroergometric testing under standard conditions (FIO2 = 20.9%), as well as at FIO2 = 40% and 80%. When compared with the predicted values of VO2, as calculated according to Wasserman et al. (2012), the data obtained show that both the HT and ET are valid under normal conditions and at an increased FIO2 of 40%. At FIO2 concentrations of 80%, however, the VO2 values provided by the HT begin to lose plausibility, whereas the ET continues to provide credible results. We conclude that the use of the ET in place of the HT in spiroergometric measurements with increased FIO2 allows a reliable evaluation of stress tests in patients requiring high doses of supplemental oxygen.	[Lang, Stephan; Herold, Robert; Kraft, Alexander; Harth, Volker; Preisser, Alexandra M.] Univ Med Ctr Hamburg Eppendorf, Inst Occupat & Maritime Med ZfAM, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Preisser, AM (corresponding author), Univ Med Ctr Hamburg Eppendorf, Inst Occupat & Maritime Med ZfAM, Hamburg, Germany.	a.preisser@uke.de	Harth, Volker/AGG-1586-2022	Harth, Volker/0000-0003-4308-223X; Preisser, Alexandra Marita/0000-0002-2957-3545	CareFusion Germany 234 GmbH Hochberg Germany; CareFusion	CareFusion Germany 234 GmbH Hochberg Germany; CareFusion	Sponsor: CareFusion Germany 234 GmbH Leibnizstrasse 7 97204 Hochberg Germany. CareFusion sponsored the Device for the FIO2-Testing [Vyntus CPX] and the additional material [Masks, Filter, Vyntus ECG, gas bottles].	Bland JM, 2010, INT J NURS STUD, V47, P931, DOI 10.1016/j.ijnurstu.2009.10.001; Consolazi CF, 1963, PHYSL MEASUREMENTS M; Eschenbacher H, 2016, HALDANE ESCHENBACHER; Haldane J.S., 1912, METHODS AIR ANAL; HARRISEZE AO, 1994, AM J RESP CRIT CARE, V150, P1616, DOI 10.1164/ajrccm.150.6.7952624; Hoppe J, 2009, ERRORS VO2 TESTING; Kleinberger G, 1988, METHODISCHE FRAGEN I; Kroidl R, 2014, SPIROERGOMETRIE TECH; Kuzma J.W., 1998, BASIC STAT HLTH SCI, V3rd; Lang S, 2017, ATEMWEG LUNGENKRANK, V43, P86, DOI DOI 10.5414/ATX02177; MARCUS CL, 1992, CHEST, V101, P52, DOI 10.1378/chest.101.1.52; Meyer F J, 2013, Pneumologie, V67, P16, DOI 10.1055/s-0032-1325901; PELTONEN JE, 1995, MED SCI SPORT EXER, V27, P573; Prieur F, 2002, EUR J APPL PHYSIOL, V88, P235, DOI 10.1007/s00421-002-0707-0; Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312; Rising R, 2015, NUTR METAB, V12, DOI 10.1186/s12986-015-0043-0; STANEK KA, 1979, J APPL PHYSIOL, V46, P1115, DOI 10.1152/jappl.1979.46.6.1115; Takala J, 1991, HANDBOOK OF GAS EXCH; Ulrich S, 2017, RESPIRATION, V93, P90, DOI 10.1159/000453620; Walsh ML, 1995, EUR J APPL PHYSIOL, V72, P71, DOI 10.1007/BF00964117; Wasserman K, 2012, PRINCIPLES EXERCISE, V5th; WELCH HG, 1981, J APPL PHYSIOL, V51, P725, DOI 10.1152/jappl.1981.51.3.725; WILMORE JH, 1973, J APPL PHYSIOL, V35, P85, DOI 10.1152/jappl.1973.35.1.85; WILSON BA, 1975, J APPL PHYSIOL, V39, P267, DOI 10.1152/jappl.1975.39.2.267	24	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2018	13	12							e0207648	10.1371/journal.pone.0207648	http://dx.doi.org/10.1371/journal.pone.0207648			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD9QX	30540773	Green Published, Green Submitted, gold			2023-01-03	WOS:000452898600028
J	Murphy, WJ; Longo, DL				Murphy, William J.; Longo, Dan L.			The Surprisingly Positive Association Between Obesity and Cancer Immunotherapy Efficacy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INFLAMMATION		[Murphy, William J.] Univ Calif Davis, Sch Med, Dept Dermatol, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Div Hematol Oncol, Dept Internal Med, Sacramento, CA 95817 USA; [Longo, Dan L.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA	University of California System; University of California Davis; University of California System; University of California Davis; Harvard University; Harvard Medical School	Murphy, WJ (corresponding author), Univ Calif Davis, Sch Med, 2921 Stockton Blvd,Ste 1614, Sacramento, CA 95817 USA.	wmjmurphy@ucdavis.edu	Longo, Dan L./F-6022-2011					Deng T, 2016, ANNU REV PATHOL-MECH, V11, P421, DOI 10.1146/annurev-pathol-012615-044359; Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057; Gibney GT, 2016, LANCET ONCOL, V17, pE542, DOI 10.1016/S1470-2045(16)30406-5; Hales CM, 2018, JAMA-J AM MED ASSOC, V319, P1723, DOI 10.1001/jama.2018.3060; McQuade JL, 2018, LANCET ONCOL, V19, P310, DOI 10.1016/S1470-2045(18)30078-0; Mirsoian A, 2014, J EXP MED, V211, P2373, DOI 10.1084/jem.20140116; Sanmamed MF, 2018, CELL, V175, P313, DOI 10.1016/j.cell.2018.09.035; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Wang ZM, 2019, NAT MED, V25, P141, DOI 10.1038/s41591-018-0221-5	9	50	51	2	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	2019	321	13					1247	1248		10.1001/jama.2019.0463	http://dx.doi.org/10.1001/jama.2019.0463			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR3XR	30882850				2023-01-03	WOS:000463076800007
J	Correa, S; Puertas, S; Gutierrez, L; Asin, L; de la Fuente, JM; Grazu, V; Betancor, L				Correa, Sonali; Puertas, Sara; Gutierrez, Lucia; Asin, Laura; Martinez de la Fuente, Jesus; Grazu, Valeria; Betancor, Lorena			Design of stable magnetic hybrid nanoparticles of Si-entrapped HRP	PLOS ONE			English	Article							HORSERADISH-PEROXIDASE; ENZYME; IMMOBILIZATION; STABILIZATION; ENCAPSULATION; BIOCATALYST; PROTEIN; POLYETHYLENEIMINE	Hybrid and composite nanoparticles represent an attractive material for enzyme integration due to possible synergic advantages of the structural builders in the properties of the nanobiocatalyst. In this study, we report the synthesis of a new stable hybrid nanobiocatalyst formed by biomimetic silica (Si) nanoparticles entrapping both Horseradish Peroxidase (HRP) (EC 1.11.1.7) and magnetic nanoparticles (MNPs). We have demonstrated that tailoring of the synthetic reagents and post immobilization treatments greatly impacted physical and biocatalytic properties such as an unprecedented similar to 280 times increase in the half-life time in thermal stability experiments. The optimized nanohybrid biocatalyst that showed superparamagnetic behaviour, was effective in the batch conversion of indole-3-acetic acid, a prodrug used in Direct Enzyme Prodrug Therapy (DEPT). Our system, that was not cytotoxic per se, showed enhanced cytotoxic activity in the presence of the prodrug towards HCT-116, a colorectal cancer cell line. The strategy developed proved to be effective in obtaining a stabilized nanobiocatalyst combining three different organic/inorganic materials with potential in DEPT and other biotechnological applications.	[Correa, Sonali; Betancor, Lorena] Univ ORT Uruguay, Lab Biotecnol, Montevideo, Uruguay; [Puertas, Sara] Nanoimmunotech SL, Zaragoza, Spain; [Gutierrez, Lucia] Univ Zaragoza, Inst Nanociencia Aragon, Campus Rio Ebro,Edificio I D, Zaragoza, Spain; [Gutierrez, Lucia; Martinez de la Fuente, Jesus; Grazu, Valeria] CSIC, ICMA, Zaragoza, Spain; [Gutierrez, Lucia; Asin, Laura; Martinez de la Fuente, Jesus; Grazu, Valeria] CIBER BBN, Ctr Invest Biomed Red Bioingn Biomat & Nanomed, Madrid, Spain	University ORT Uruguay; University of Zaragoza; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Quimica y Materiales de Aragon (CEQMA); CSIC - Instituto de Ciencia de Materiales de Aragon (ICMA); CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN	Betancor, L (corresponding author), Univ ORT Uruguay, Lab Biotecnol, Montevideo, Uruguay.; Grazu, V (corresponding author), CSIC, ICMA, Zaragoza, Spain.; Grazu, V (corresponding author), CIBER BBN, Ctr Invest Biomed Red Bioingn Biomat & Nanomed, Madrid, Spain.	vgrazu@unizar.es; betancor@ort.edu.uy	de la Fuente, Jesus M/L-8361-2016; Betancor, Lorena/AAO-6710-2021; Gutierrez, Lucia/A-4305-2008; ASIN, LAURA/H-7276-2017	de la Fuente, Jesus M/0000-0003-1081-8482; Betancor, Lorena/0000-0002-0569-0499; Gutierrez, Lucia/0000-0003-2366-3598; ASIN, LAURA/0000-0003-0641-3407	ANII [POS_NAC_2015_1_109910]	ANII	SC is funded by ANII (POS_NAC_2015_1_109910).	BAHULEKAR R, 1991, ENZYME MICROB TECH, V13, P858, DOI 10.1016/0141-0229(91)90101-F; Berne C, 2006, BIOMACROMOLECULES, V7, P2631, DOI 10.1021/bm060166d; Betancor L, 2008, TRENDS BIOTECHNOL, V26, P566, DOI 10.1016/j.tibtech.2008.06.009; Betancor L, 2006, CHEM COMMUN, P3640, DOI 10.1039/b604689d; Betancor L, 2010, BIOTECHNOL GENET ENG, V27, P95, DOI 10.1080/02648725.2010.10648146; Bolivar JM, 2013, GREEN PROCESS SYNTH, V2, P541, DOI 10.1515/gps-2013-0091; Cao SL, 2014, J MATER CHEM B, V2, P5522, DOI 10.1039/c4tb00584h; Cazaban D, 2017, CURR ORG CHEM, V21, P96, DOI 10.2174/1385272821666161108103040; Chiu YR, 2012, J NANOPART RES, V14, DOI 10.1007/s11051-012-0829-1; Consolati T, 2018, ACS APPL MATER INTER, V10, P6858, DOI 10.1021/acsami.7b16639; Cui JD, 2015, APPL BIOCHEM BIOTECH, V176, P999, DOI 10.1007/s12010-015-1624-0; Fejerskov B, 2017, ADV DRUG DELIVER REV, V118, P24, DOI 10.1016/j.addr.2017.04.013; Guisan JM, 2013, METHODS MOL BIOL, V1051, P1, DOI 10.1007/978-1-62703-550-7_1; HENLEY JP, 1985, ENZYME MICROB TECH, V7, P50, DOI 10.1016/0141-0229(85)90013-4; Hyde EDER, 2016, IND ENG CHEM RES, V55, P8891, DOI 10.1021/acs.iecr.6b01839; Jackson E, 2016, PROCESS BIOCHEM, DOI [10.1016/j.procbio.2016.03.002, DOI 10.1016/J.PROCBIO.2016.03.002]; Jackson E, 2015, LANGMUIR, V31, P3687, DOI 10.1021/la504978r; Jiang YJ, 2014, ENZYME MICROB TECH, V55, P1, DOI 10.1016/j.enzmictec.2013.11.005; Johnson GR, 2017, METHODS MOL BIOL, V1504, P61, DOI 10.1007/978-1-4939-6499-4_6; Karthikeyan S, 2016, ENVIRON SCI TECHNOL, V50, P11193, DOI 10.1021/acs.est.6b03044; Krainer FW, 2015, APPL MICROBIOL BIOT, V99, P1611, DOI 10.1007/s00253-014-6346-7; Lechner CC, 2015, MAR DRUGS, V13, P5297, DOI 10.3390/md13085297; Liu J, 2015, CHEM COMMUN, V51, P13731, DOI 10.1039/c5cc04590h; Liu RR, 2016, APPL BIOCHEM BIOTECH, V178, P1612, DOI 10.1007/s12010-015-1971-x; Loncar N, 2015, APPL MICROBIOL BIOT, V99, P3351, DOI 10.1007/s00253-015-6512-6; Lopez-Gallego F, 2007, ENZYME MICROB TECH, V40, P278, DOI 10.1016/j.enzmictec.2006.04.021; Lungu CN, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040555; Makizumi R, 2008, INT J CLIN EXP MED, V1, P117; Maximov V, 2009, J DRUG DELIV SCI TEC, V19, P311, DOI 10.1016/S1773-2247(09)50066-4; Nanayakkara S, 2014, ACS SUSTAIN CHEM ENG, V2, P1947, DOI 10.1021/sc500392k; Palomo JM, 2013, METHODS MOL BIOL, V1051, P255, DOI 10.1007/978-1-62703-550-7_17; Pavlovic M, 2018, J COLLOID INTERF SCI, V524, P114, DOI 10.1016/j.jcis.2018.04.007; Rakhi RB, 2016, SCI REP, V6, P1, DOI [10.1038/s41598-016-0001-8, DOI 10.1038/S41598-016-0001-8]; Tapias YAR, 2016, FOOD CHEM, V208, P252, DOI 10.1016/j.foodchem.2016.03.086; Ribeiro LMO, 2019, J POROUS MAT, V26, P77, DOI 10.1007/s10934-018-0615-2; Ritter DW, 2013, ENZYME MICROB TECH, V52, P279, DOI 10.1016/j.enzmictec.2013.01.004; Rodriguez F, 2004, BIOMACROMOLECULES, V5, P261, DOI 10.1021/bm034232c; Romero-Fernandez M, 2018, BIORESOURCE TECHNOL, V266, P249, DOI 10.1016/j.biortech.2018.06.070; Sahare P, 2016, NANOSCALE RES LETT, V11, DOI 10.1186/s11671-016-1605-4; Sahare P, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556-276X-9-409; Seo JH, 2007, TRANSDUCERS EUROSENS, DOI [10.1109/SENSOR.2007.4300488, DOI 10.1109/SENSOR.2007.4300488]; Sharma SK, 2017, ANAL BIOCHEM, V535, P1, DOI 10.1016/j.ab.2017.07.019; Sipponen MH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04715-6; Temocin Z, 2018, POLYM BULL, V75, P1843, DOI 10.1007/s00289-017-2129-5; Wang M, 2015, ACS NANO, V9, P10931, DOI 10.1021/acsnano.5b04073; Wu CZ, 2015, SOFT MATTER, V11, P972, DOI 10.1039/c4sm01746c; Zakharova GS, 2011, BIOCHEMISTRY-MOSCOW+, V76, P1391, DOI 10.1134/S0006297911130037; Zamora P, 2009, BIOELECTROCHEMISTRY, V76, P100, DOI 10.1016/j.bioelechem.2009.05.006; Zdarta J, 2018, CATALYSTS, V8, DOI 10.3390/catal8020092	49	6	6	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2019	14	4							e0214004	10.1371/journal.pone.0214004	http://dx.doi.org/10.1371/journal.pone.0214004			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR1CY	30933987	Green Published, gold			2023-01-03	WOS:000462867000009
J	Logtenberg, MEW; Jansen, JHM; Raaben, M; Toebes, M; Franke, K; Brandsma, AM; Matlung, HL; Fauster, A; Gomez-Eerland, R; Bakker, NAM; van der Schot, S; Marijt, KA; Verdoes, M; Haanen, JBAG; van den Berg, JH; Neefjes, J; van den Berg, TK; Brummelkamp, TR; Leusen, JHW; Scheeren, FA; Schumacher, TN				Logtenberg, Meike E. W.; Jansen, J. H. Marco; Raaben, Matthijs; Toebes, Mireille; Franke, Katka; Brandsma, Arianne M.; Matlung, Hanke L.; Fauster, Astrid; Gomez-Eerland, Raquel; Bakker, Noor A. M.; van der Schot, Simone; Marijt, Koen A.; Verdoes, Martijn; Haanen, John B. A. G.; van den Berg, Joost H.; Neefjes, Jacques; van den Berg, Timo K.; Brummelkamp, Thijn R.; Leusen, Jeanette H. W.; Scheeren, Ferenc A.; Schumacher, Ton N.			Glutaminyl cyclase is an enzymatic modifier of the CD47-SIRP alpha axis and a target for cancer immunotherapy	NATURE MEDICINE			English	Article							SIGNAL-REGULATORY PROTEIN; AMYLOID BETA-PEPTIDES; CD47 BLOCKADE; ANTIBODIES; CELLS; IDENTIFICATION; PHAGOCYTOSIS; INHIBITION; RITUXIMAB	Cancer cells can evade immune surveillance through the expression of inhibitory ligands that bind their cognate receptors on immune effector cells. Expression of programmed death ligand 1 in tumor microenvironments is a major immune checkpoint for tumor-specific T cell responses as it binds to programmed cell death protein-1 on activated and dysfunctional T cells(1). The activity of myeloid cells such as macrophages and neutrophils is likewise regulated by a balance between stimulatory and inhibitory signals. In particular, cell surface expression of the CD47 protein creates a 'don't eat me' signal on tumor cells by binding to SIRP alpha expressed on myeloid cells(2-5). Using a haploid genetic screen, we here identify glutaminyl-peptide cyclotransferase-like protein (QPCTL) as a major component of the CD47-SIRP alpha checkpoint. Biochemical analysis demonstrates that QPCTL is critical for pyroglutamate formation on CD47 at the SIRP alpha binding site shortly after biosynthesis. Genetic and pharmacological interference with QPCTL activity enhances antibody-dependent cellular phagocytosis and cellular cytotoxicity of tumor cells. Furthermore, interference with QPCTL expression leads to a major increase in neutrophil-mediated killing of tumor cells in vivo. These data identify QPCTL as a novel target to interfere with the CD47 pathway and thereby augment antibody therapy of cancer.	[Logtenberg, Meike E. W.; Toebes, Mireille; van der Schot, Simone; Schumacher, Ton N.] Netherlands Canc Inst, Oncode Inst, Div Mol Oncol & Immunol, Amsterdam, Netherlands; [Jansen, J. H. Marco; Brandsma, Arianne M.; Leusen, Jeanette H. W.] UMC Utrecht, Lab Translat Immunol, Utrecht, Netherlands; [Raaben, Matthijs; Fauster, Astrid; Brummelkamp, Thijn R.] Netherlands Canc Inst, Oncode Inst, Div Biochem, Amsterdam, Netherlands; [Franke, Katka; Matlung, Hanke L.; van den Berg, Timo K.] Sanquin Res, Landsteiner Lab, Dept Blood Cell Res, Amsterdam, Netherlands; [Franke, Katka; Matlung, Hanke L.; van den Berg, Timo K.] Univ Amsterdam, Med Ctr, Dept Mol Cell Biol, Amsterdam, Netherlands; [Gomez-Eerland, Raquel; Bakker, Noor A. M.; Haanen, John B. A. G.; van den Berg, Joost H.] Netherlands Canc Inst, Div Mol Oncol & Immunol, Amsterdam, Netherlands; [Marijt, Koen A.; Scheeren, Ferenc A.] Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands; [Verdoes, Martijn] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Dept Tumor Immunol, Nijmegen, Netherlands; [Verdoes, Martijn; Neefjes, Jacques; Schumacher, Ton N.] Inst Chem Immunol, Amsterdam, Netherlands; [Neefjes, Jacques] Leiden Univ, Med Ctr, Oncode Inst, Dept Cell & Chem Biol, Leiden, Netherlands	Netherlands Cancer Institute; Utrecht University; Utrecht University Medical Center; Netherlands Cancer Institute; University of Amsterdam; University of Amsterdam; Netherlands Cancer Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Radboud University Nijmegen; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Schumacher, TN (corresponding author), Netherlands Canc Inst, Oncode Inst, Div Mol Oncol & Immunol, Amsterdam, Netherlands.; Schumacher, TN (corresponding author), Inst Chem Immunol, Amsterdam, Netherlands.	t.schumacher@nki.nl	Neefjes, Jacques J.C./H-8780-2017; Haanen, John/AAD-8578-2022; Haanen, John/AAD-8534-2022; Verdoes, Martijn/AAD-5239-2022; , Jeanette/AAG-3736-2019; van den Berg, Timo K/AAC-2479-2022; Verdoes, Martijn/A-4911-2015; Schumacher, Ton/Y-2432-2019; Matlung, Hanke/ABH-5649-2020	Neefjes, Jacques J.C./0000-0001-6763-2211; Haanen, John/0000-0001-5884-7704; Verdoes, Martijn/0000-0001-8753-3528; Verdoes, Martijn/0000-0001-8753-3528; Schumacher, Ton/0000-0003-0517-8804; Brandsma, Arianne/0000-0002-7969-4046; Logtenberg, Meike/0000-0002-8981-1189; Leusen, Jeanette/0000-0003-4982-6914; Scheeren, Ferenc/0000-0002-8304-9023	European Research Council (ERC) advanced grant SENSIT; Institute for Chemical Immunology; ERC; Dutch Cancer Society/Koningin Wilhelmina Fonds kankerbestrijding (KWF) [10300]; KWF [NKI 2015-7609, 11537, UU 2015-7650]; Leiden University Medical Center fellowship; Errol McDowell Cancer Foundation; Netherlands Organization for Scientific Research (NWO) Vici Grant [016.Vici.170.033]; Cancer Genomics Center (CGC.nl); Ammodo KNAW Award 2015 for Biomedical Sciences	European Research Council (ERC) advanced grant SENSIT(European Research Council (ERC)); Institute for Chemical Immunology; ERC(European Research Council (ERC)European Commission); Dutch Cancer Society/Koningin Wilhelmina Fonds kankerbestrijding (KWF); KWF; Leiden University Medical Center fellowship; Errol McDowell Cancer Foundation; Netherlands Organization for Scientific Research (NWO) Vici Grant(Netherlands Organization for Scientific Research (NWO)); Cancer Genomics Center (CGC.nl); Ammodo KNAW Award 2015 for Biomedical Sciences	We thank R. Mezzadra, M. Wellenstein, C. Sun and members of the Schumacher, Brummelkamp, Scheeren, Leusen, van den Berg and Haanen laboratories for discussions, and O. van Tellingen, the Netherlands Cancer Institute-Antoni van Leeuwenhoek (NKI-AVL) Preclinical Intervention Unit and the NKI-AVL flow facility for technical support and input. This work was supported by European Research Council (ERC) advanced grant SENSIT (to T.N.S.), the Institute for Chemical Immunology (to T.N.S., J.N. and M.V.), ERC starting grant CHEMCHECK (to M.V.), Dutch Cancer Society/Koningin Wilhelmina Fonds kankerbestrijding (KWF) grant 10300 (to T.K.v.d.B.), KWF grant 11537 (to H.L.M.), a Leiden University Medical Center fellowship and the Errol McDowell Cancer Foundation (to F.A.S.), Netherlands Organization for Scientific Research (NWO) Vici Grant 016.Vici.170.033, KWF grant NKI 2015-7609, the Cancer Genomics Center (CGC.nl) and the Ammodo KNAW Award 2015 for Biomedical Sciences (to T.R.B.), and KWF grant UU 2015-7650 (to J.H.W.L.).	Advani R, 2018, NEW ENGL J MED, V379, P1711, DOI 10.1056/NEJMoa1807315; Ansell S, 2016, BLOOD, V128; Berkovits BD, 2015, NATURE, V522, P363, DOI 10.1038/nature14321; Blomen VA, 2015, SCIENCE, V350, P1092, DOI 10.1126/science.aac7557; Boross P, 2013, EMBO MOL MED, V5, P1213, DOI 10.1002/emmm.201201929; Bracke M, 2001, BLOOD, V97, P3478, DOI 10.1182/blood.V97.11.3478; Brandsma AM, 2015, CANCER IMMUNOL RES, V3, P1316, DOI 10.1158/2326-6066.CIR-15-0099-T; Brinkman EK, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku936; Brooke G, 2004, J IMMUNOL, V173, P2562, DOI 10.4049/jimmunol.173.4.2562; Carette JE, 2011, NATURE, V477, P340, DOI 10.1038/nature10348; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Chao MP, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001375; Chao MP, 2010, CELL, V142, P699, DOI 10.1016/j.cell.2010.07.044; Chen J, 2017, NATURE, V544, P493, DOI 10.1038/nature22076; Cynis H, 2008, J MOL BIOL, V379, P966, DOI 10.1016/j.jmb.2008.03.078; de Haij S, 2010, CANCER RES, V70, P3209, DOI 10.1158/0008-5472.CAN-09-4109; Gee MH, 2018, CELL, V172, P549, DOI 10.1016/j.cell.2017.11.043; Gong QY, 2018, ADV SCI, V5, DOI 10.1002/advs.201700664; Grizenkova J, 2012, P NATL ACAD SCI USA, V109, P13722, DOI 10.1073/pnas.1208917109; Hadrup SR, 2009, NAT METHODS, V6, P520, DOI 10.1038/nmeth.1345; Hatherley D, 2008, MOL CELL, V31, P266, DOI 10.1016/j.molcel.2008.05.026; Ho CCM, 2015, J BIOL CHEM, V290, P12650, DOI 10.1074/jbc.M115.648220; Hoffmann T, 2017, J PHARMACOL EXP THER, V362, P119, DOI 10.1124/jpet.117.240614; Huang KF, 2008, BIOCHEM J, V411, P181, DOI 10.1042/BJ20071073; Huang KF, 2005, P NATL ACAD SCI USA, V102, P13117, DOI 10.1073/pnas.0504184102; Ingram JR, 2017, P NATL ACAD SCI USA, V114, P10184, DOI 10.1073/pnas.1710776114; Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046; Jimenez-Sanchez M, 2015, NAT CHEM BIOL, V11, P347, DOI [10.1038/NCHEMBIO.1790, 10.1038/nchembio.1790]; KUIJPERS TW, 1991, BLOOD, V78, P1105; Lackner DH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10237; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Liu XJ, 2015, NAT MED, V21, P1209, DOI 10.1038/nm.3931; Lues Inge, 2015, Alzheimers Dement (N Y), V1, P182, DOI 10.1016/j.trci.2015.08.002; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Manguso RT, 2017, NATURE, V547, P413, DOI 10.1038/nature23270; Matlung HL, 2017, IMMUNOL REV, V276, P145, DOI 10.1111/imr.12527; Meyer S, 2016, MABS-AUSTIN, V8, P87, DOI 10.1080/19420862.2015.1106658; Morty RE, 2006, BIOCHEM J, V394, P635, DOI 10.1042/BJ20051593; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; Ring NG, 2017, P NATL ACAD SCI USA, V114, pE10578, DOI 10.1073/pnas.1710877114; Russo C, 2002, J NEUROCHEM, V82, P1480, DOI 10.1046/j.1471-4159.2002.01107.x; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; Scheltens P, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195-018-0431-6; Schilling S, 2003, J BIOL CHEM, V278, P49773, DOI 10.1074/jbc.M309077200; Schilling S, 2008, NAT MED, V14, P1106, DOI 10.1038/nm.1872; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Sockolosky JT, 2016, P NATL ACAD SCI USA, V113, pE2646, DOI 10.1073/pnas.1604268113; Stephan A, 2009, FEBS J, V276, P6522, DOI 10.1111/j.1742-4658.2009.07337.x; Tekirian TL, 1999, J NEUROCHEM, V73, P1584, DOI 10.1046/j.1471-4159.1999.0731584.x; Weiskopf K, 2017, EUR J CANCER, V76, P100, DOI 10.1016/j.ejca.2017.02.013; Weiskopf K, 2013, SCIENCE, V341, P88, DOI 10.1126/science.1238856; Willingham SB, 2012, P NATL ACAD SCI USA, V109, P6662, DOI 10.1073/pnas.1121623109; Zhao XW, 2011, P NATL ACAD SCI USA, V108, P18342, DOI 10.1073/pnas.1106550108; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	54	90	93	6	70	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2019	25	4					612	+		10.1038/s41591-019-0356-z	http://dx.doi.org/10.1038/s41591-019-0356-z			23	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	HR7OA	30833751	Green Accepted			2023-01-03	WOS:000463342800023
J	Bhandari, R; Pokhrel, KN; Gabrielle, N; Amatya, A				Bhandari, Rajan; Pokhrel, Khem Narayan; Gabrielle, Nguyen; Amatya, Archana			Long acting reversible contraception use and associated factors among married women of reproductive age in Nepal	PLOS ONE			English	Article								Modern contraceptives are highly effective and proven means of preventing unintended pregnancy and reducing maternal mortality. Social and economic characteristics are some of the key determinants of health and utilization family planning. However, studies examining the factors associated with utilization of long acting reversible contraception (LARC) are limited in Nepal. This study assessed the factors associated with utilization of LARC methods among married women of reproductive age in Nepal. Secondary data analysis was conducted using the 2016 Nepal Demographic and Health Survey (NDHS). A logistic regression model examined the association of socioeconomic, demographic, or fertility related characteristics with the use of LARCs among 9875 ever married women of reproductive age. The overall utilization rate of LARC in this study was 4.7%. Women in the age group of <25 years (AOR: 0.65, 95% CI: 0.45-0.92) and 25-35 years (AOR: 0.70, 95% CI: 0.56-0.89), having husbands with primary education (AOR:0.71; 95%CI: 0.64-0.84) and no education (AOR: 0.54; 95%CI: 0.38-0.73), belonging to Janajatis (AOR: 0.55; 95%CI: 0.42-0.71) and Newars (AOR: 0.29; 95%CI: 0.19-42), poor wealth quintile (AOR: 0.60; 95% CI: 0.45-0.86) had negative association with LARC use. On the other hand, women having their husband as a skilled worker (AOR: 1.49; 95%CI: 1.10-2), having two or less than two children (AOR: 1.46; 95% CI: 1.15-1.186), and having desire for children in future (AOR: 3.24; 95% CI: 2.29-4.57) had positive association with the use of LARC. In this study, younger women's age, low or no husband's education, from indigenous community such as Janajati and Newer, being in lowest wealth quintile negatively influenced the use of LARC. Conversely, women having her husband as skilled worker, parity less than two, and desire of having future children, positively influenced the use of LARC. The study highlights the need to reach women who were in the lower socioeconomic background to improve LARC use.	[Bhandari, Rajan] GHAN, Kathmandu, Nepal; [Pokhrel, Khem Narayan] Georgetown Univ, Inst Reprod Hlth, Airport Gate Area, Kathmandu, Nepal; [Gabrielle, Nguyen] Save Children, Washington, DC USA; [Amatya, Archana] Tribhuvan Univ, Dept Community Med & Publ Hlth, Inst Med, Kathmandu, Nepal	Save the Children; Tribhuvan University; Institute of Medicine (IoM) - Nepal	Bhandari, R (corresponding author), GHAN, Kathmandu, Nepal.	rjbhandari11@gmail.com	pokhrel, khem/AAT-6102-2021	pokhrel, khem/0000-0001-6956-1672				Abdisa B, 2017, ANAT PHYSL, V07, P2, DOI [10.4172/2161-0940.1000254, DOI 10.4172/2161-0940.1000254]; ACOG Committee, 2018, OBS GYNECOL, V131, P130; Azmoude E, 2017, WOOMENS HLTH B, V4; Bagade O., 2014, WORLD J PHARM PHARM, V3, P364; Baldwin MK, 2013, J ADOLESCENT HEALTH, V52, pS47, DOI 10.1016/j.jadohealth.2012.10.278; Biza N, 2017, LONG ACTING REVERSIB, V4, P469; Budihastuti UR, 2014, E JAVA APPL SOCIAL C, V1172, P313; Chandra-Mouli V, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-1; Dempsey AR, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2012.02.014; Desta SA., 2017, SCIENCE, V5, P428, DOI [10.11648/j.sjph.20170506.14, DOI 10.11648/J.SJPH.20170506.14]; Dockalova BLK, 2016, SUSTAINABLE DEV GOAL; Earsido A., 2015, J PREG CHILD HLTH, V2, P165; Frost JJ, 2008, PERSPECT SEX REPRO H, V40, P94, DOI 10.1363/4009408; Getinet S., 2014, GREENER J EPIDEMIOL, V2, P23, DOI [10.15580/GJEPH.2014.1.070514294, DOI 10.15580/GJEPH.2014.1.070514294]; Gudaynhe SW, 2014, GLOB J MED RES, V14; Gultie T, 2016, QUAL PRIM CARE, V24, P17; ICF International, 2012, MEASURE DHS, P41; Johnson OE, 2017, AFR J REPROD HEALTH, V21, P89, DOI 10.29063/ajrh2017/v21i3.8; Lotke PS, 2015, OBSTET GYN CLIN N AM, V42, P557, DOI 10.1016/j.ogc.2015.07.008; Manoj PDS, 2015, IEEE T COMPUT, V64, P3022, DOI 10.1109/TC.2015.2389827; Ministry of Health and Population, 2015, NAT FAM PLANN COST I, V39, P90; Ministry of Health and Population (MoHP), 2015, NEP HLTH SECT STRAT, P75; Ministry of Health Nepal; New ERA; and ICF, 2017, NEP DEM HLTH SURV 20; Ministry of Health (Nepal) New Era Macro International, 1996, NEP DEM HLTH SURV; Mishra MK, 2011, ETHNIC DISPARITIES C, V6, P14; Mustafa R, 2008, JCPSP-J COLL PHYSICI, V18, P542, DOI 09.2008/JCPSP.542545; Rose SB, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2011.06.102; Senarath U, 2009, ASIA-PAC J PUBLIC HE, V21, P137, DOI 10.1177/1010539509331590; Sharma SK, 2011, DEMOGR RES, V25, P837, DOI 10.4054/DemRes.2011.25.27; Melka AS, 2015, PAN AFR MED J, V21, DOI 10.11604/pamj.2015.21.246.5835; Tamang L, 2017, CONTRACEP REPROD MED, V2, DOI 10.1186/s40834-017-0040-y; Tekelab T., 2015, FAM MED MED SCI, V4, P158, DOI [10.4172/2327-4972.1000158, DOI 10.4172/2327-4972.1000158]; Tibaijuka L, 2017, BMC WOMENS HEALTH, V17, DOI 10.1186/s12905-017-0382-2; Townsend JW, 2007, CONTRACEPTION, V75, pS35, DOI 10.1016/j.contraception.2007.01.023; Wasti S P, 2017, Kathmandu Univ Med J (KUMJ), V15, P222; World Health Organisation, 2007, REP WHO TECHN CONS B, P34; World Health Organization, 2018, INT SOC BEH CHANG CO; Yalew Saleamlak Adbaru, 2015, BMC Res Notes, V8, P29, DOI 10.1186/s13104-015-0974-6	38	17	17	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2019	14	3							e0214590	10.1371/journal.pone.0214590	http://dx.doi.org/10.1371/journal.pone.0214590			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ7IR	30921403	gold, Green Published, Green Submitted			2023-01-03	WOS:000462594000092
J	Hsieh, CH; Lu, CH; Kuo, YY; Lin, GB; Chao, CY				Hsieh, Chih-Hsiung; Lu, Chueh-Hsuan; Kuo, Yu-Yi; Lin, Guan-Bo; Chao, Chih-Yu			The protective effect of non-invasive low intensity pulsed electric field and fucoidan in preventing oxidative stress-induced motor neuron death via ROCK/Akt pathway	PLOS ONE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; RHO-KINASE INHIBITOR; DOPAMINERGIC-NEURONS; ALZHEIMERS-DISEASE; PH CHANGES; IN-VITRO; FASUDIL; SURVIVAL; CELLS; MODEL	With the expansion of the aged population, it is predicted that neurodegenerative diseases (NDDs) will become a major threat to public health worldwide. However, existing therapies can control the symptoms of the diseases at best, rather than offering a fundamental cure. As for the complex pathogenesis, clinical and preclinical researches have indicated that oxidative stress, a central role in neuronal degeneration, is a possible therapeutic target in the development of novel remedies. In this study, the motor neuron-like cell line NSC-34 was employed as an experimental model in probing the effects induced by the combination of non-invasive low intensity pulsed electric field (LIPEF) and fucoidan on the H2O2-induced neuron damage. It was found that single treatment of the LIPEF could protect the NSC-34 cells from oxidative stress, and the protective effect was enhanced by combining the LIPEF and fucoidan. Notably, it was observed that single treatment of the LIPEF obviously suppressed the H2O2-enhanced expression of ROCK protein and increased the phosphorylation of Akt in the H2O2-treated NSC-34 cells. Moreover, the LIPEF can be easily modified to concentrate on a specific area. Accordingly, this technique can be used as an advanced remedy for ROCK inhibition without the drawback of drug metabolism. Therefore, we suggest the LIPEF would be a promising strategy as a treatment for motor neurodegeneration and warrant further probe into its potential in treating other neuronal degenerations.	[Hsieh, Chih-Hsiung; Lu, Chueh-Hsuan; Kuo, Yu-Yi; Lin, Guan-Bo; Chao, Chih-Yu] Natl Taiwan Univ, Dept Phys, Lab Med Phys & Biomed Engn, Taipei, Taiwan; [Hsieh, Chih-Hsiung; Lu, Chueh-Hsuan; Kuo, Yu-Yi; Lin, Guan-Bo; Chao, Chih-Yu] Natl Taiwan Univ, Coll Med, Biomed & Mol Imaging Ctr, Taipei, Taiwan; [Chao, Chih-Yu] Natl Taiwan Univ, Inst Appl Phys, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University	Chao, CY (corresponding author), Natl Taiwan Univ, Dept Phys, Lab Med Phys & Biomed Engn, Taipei, Taiwan.; Chao, CY (corresponding author), Natl Taiwan Univ, Coll Med, Biomed & Mol Imaging Ctr, Taipei, Taiwan.; Chao, CY (corresponding author), Natl Taiwan Univ, Inst Appl Phys, Taipei, Taiwan.	cychao@phys.ntu.edu.tw	Hsieh, Chih-Hsiung/AFI-4085-2022; Hsieh, Chih-Hsiung/GMX-1452-2022		Ministry of Science and Technology of the Republic of China [MOST 105-2112-M-002-006-MY3]; Ministry of Education of the Republic of China [MOE 107L880406]	Ministry of Science and Technology of the Republic of China(Ministry of Science and Technology, Taiwan); Ministry of Education of the Republic of China(Ministry of Education, Taiwan)	This work was supported by grants from Ministry of Science and Technology (MOST 105-2112-M-002-006-MY3 to CYC) and Ministry of Education (MOE 107L880406 to CYC) of the Republic of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aghajanian A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008045; Akinrinade Ibukun Dorcas, 2015, Pathophysiology, V22, P39, DOI 10.1016/j.pathophys.2014.12.001; Aoyama K, 2013, INT J MOL SCI, V14, P21021, DOI 10.3390/ijms141021021; Athukorala Y, 2006, CARBOHYD POLYM, V66, P184, DOI 10.1016/j.carbpol.2006.03.002; Bains JS, 1997, BRAIN RES REV, V25, P335, DOI 10.1016/S0165-0173(97)00045-3; Battaglia G, 2018, CURR OPIN PHARMACOL, V38, P65, DOI 10.1016/j.coph.2018.02.007; Bazaka K, 2013, ELECTRONICS-SWITZ, V2, P1, DOI 10.3390/electronics2010001; Berteau O, 2003, GLYCOBIOLOGY, V13, p29R, DOI 10.1093/glycob/cwg058; Bhonsle S, 2016, J VASC INTERV RADIOL, V27, P1913, DOI 10.1016/j.jvir.2016.07.012; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; Chen MH, 2013, EXPERT OPIN INV DRUG, V22, P537, DOI 10.1517/13543784.2013.778242; CHOI IY, 2015, NEUROLOGY S, V84; Conti A, 2014, BBA-MOL BASIS DIS, V1842, P99, DOI 10.1016/j.bbadis.2013.10.013; D'Amico E, 2013, FREE RADICAL BIO MED, V65, P509, DOI 10.1016/j.freeradbiomed.2013.06.029; Eruslanov E, 2010, METHODS MOL BIOL, V594, P57, DOI 10.1007/978-1-60761-411-1_4; Feng YB, 2016, J MED CHEM, V59, P2269, DOI 10.1021/acs.jmedchem.5b00683; Fish Raymond M, 2009, Eplasty, V9, pe44; Gandhi S, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/428010; Griffin Michelle, 2011, Eplasty, V11, pe34; Grys M, 2017, CELL MOL BIOL LETT, V22, DOI 10.1186/s11658-016-0030-0; Guo CY, 2013, NEURAL REGEN RES, V8, P2003, DOI 10.3969/j.issn.1673-5374.2013.21.009; Gupta V, 2013, J CONTROL RELEASE, V167, P189, DOI 10.1016/j.jconrel.2013.01.011; Hardiman O, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.71; Hemendinger RA, 2012, TOXICOL APPL PHARM, V258, P208, DOI 10.1016/j.taap.2011.10.022; Henderson BW, 2016, J NEUROCHEM, V138, P525, DOI 10.1111/jnc.13688; Hensel N, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00198; Herskowitz JH, 2013, J NEUROSCI, V33, P19086, DOI 10.1523/JNEUROSCI.2508-13.2013; Ho SY, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-230; Hsieh CH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201920; Hsieh CH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188885; Huang CQ, 2001, ANN BIOMED ENG, V29, P791, DOI 10.1114/1.1397793; Kim GH, 2015, EXP NEUROBIOL, V24, P325, DOI 10.5607/en.2015.24.4.325; Kim MH, 2008, IMMUNOL LETT, V115, P138, DOI 10.1016/j.imlet.2007.10.016; Koch JC, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.191; Koch JC, 2018, PHARMACOL THERAPEUT, V189, P1, DOI 10.1016/j.pharmthera.2018.03.008; KORCHAK HM, 1982, BIOCHEM BIOPH RES CO, V108, P1495, DOI 10.1016/S0006-291X(82)80076-4; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Lee SH, 2016, MOL NEUROBIOL, V53, P695, DOI 10.1007/s12035-014-9030-0; Li CM, 2011, FOOD CHEM TOXICOL, V49, P2090, DOI 10.1016/j.fct.2011.05.022; Li Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep17817; Liao DK, 2007, J CARDIOVASC PHARM, V50, P17, DOI 10.1097/FJC.0b013e318070d1bd; Lim SJ, 2014, FOOD HYDROCOLLOID, V42, P280, DOI 10.1016/j.foodhyd.2014.03.007; Lingor P, 2008, BRAIN, V131, P250, DOI 10.1093/brain/awm284; Liu ZW, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2525967; Lu CH, 2018, ONCOTARGETS THER, V11, P4723, DOI 10.2147/OTT.S166264; Luo DZ, 2009, EUR J PHARMACOL, V617, P33, DOI 10.1016/j.ejphar.2009.06.015; Maier O, 2013, NEUROCHEM INT, V62, P1029, DOI 10.1016/j.neuint.2013.03.008; Mehta P, 2018, MMWR-MORBID MORTAL W, V67, P216, DOI 10.15585/mmwr.mm6707a3; Mohamed LA, 2017, AAPS J, V19, P1600, DOI 10.1208/s12248-017-0120-6; Munoz Ana, 2016, J Gerontol A Biol Sci Med Sci, V71, P1254, DOI 10.1093/gerona/glv179; Niedzielska E, 2016, MOL NEUROBIOL, V53, P4094, DOI 10.1007/s12035-015-9337-5; Nuccitelli R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134364; Pasinelli P, 2006, NAT REV NEUROSCI, V7, P710, DOI 10.1038/nrn1971; Philips T, 2014, EXP NEUROL, V262, P111, DOI 10.1016/j.expneurol.2014.05.015; Rao RV, 2004, CURR OPIN CELL BIOL, V16, P653, DOI 10.1016/j.ceb.2004.09.012; Roser AE, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00094; Saal KA, 2017, BRAIN PATHOL, V27, P13, DOI 10.1111/bpa.12346; Scheuner D, 2008, ENDOCR REV, V29, P317, DOI 10.1210/er.2007-0039; Schmandke A, 2007, NEUROSCIENTIST, V13, P454, DOI 10.1177/1073858407303611; Shibuya M, 2005, J NEUROL SCI, V238, P31, DOI 10.1016/j.jns.2005.06.003; Song Y, 2013, CNS NEUROSCI THER, V19, P603, DOI 10.1111/cns.12116; Stankiewicz TR, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00314; Synytsya A, 2010, CARBOHYD POLYM, V81, P41, DOI 10.1016/j.carbpol.2010.01.052; Takata M, 2013, BRIT J PHARMACOL, V170, P341, DOI 10.1111/bph.12277; Tatenhorst L, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0310-y; Terao E, 2017, CURR EYE RES, V42, P738, DOI 10.1080/02713683.2016.1250276; Tonges L, 2012, BRAIN, V135, P3355, DOI 10.1093/brain/aws254; Tonges L, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00039; Torkaman G, 2014, ADV WOUND CARE, V3, P202, DOI 10.1089/wound.2012.0409; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Wang MD, 2014, J OCCUP ENVIRON MED, V56, P1235, DOI 10.1097/JOM.0000000000000323; Wijesekera LC, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-3; Xiao WD, 2014, INT J CLIN EXP PATHO, V7, P5564; Yao YY, 2017, MOLECULES, V22, DOI 10.3390/molecules22101766; Yonemori K, 1996, BONE, V19, P173, DOI 10.1016/8756-3282(96)00169-X; Zhang L, 2018, AGING DIS, V9, P590, DOI 10.14336/AD.2017.0831; Zhang X, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0251-9; Zhao M, 2009, SEMIN CELL DEV BIOL, V20, P674, DOI 10.1016/j.semcdb.2008.12.009; Zhou Y, 2003, SCIENCE, V302, P1215, DOI 10.1126/science.1090154	79	8	8	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2019	14	3							e0214100	10.1371/journal.pone.0214100	http://dx.doi.org/10.1371/journal.pone.0214100			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP3JN	30889218	gold, Green Submitted, Green Published			2023-01-03	WOS:000461573000049
J	Tornbom, K; Lundalv, J; Sunnerhagen, KS				Tornbom, Karin; Lundalv, Jorgen; Sunnerhagen, Katharina S.			Long-term participation 7-8 years after stroke: Experiences of people in working-age	PLOS ONE			English	Article							QUALITATIVE RESEARCH; POSTSTROKE FATIGUE; PHYSICAL-ACTIVITY; COMMUNITY; RETURN; SURVIVORS; BARRIERS; CONSEQUENCES; FACILITATORS; ADULTS	Objective To enhance the understanding of long-term participation in working-aged people 7-8 years after stroke. Methods This study had a qualitative design, using a thematic analysis methodology. Eleven individuals took part in an in depth interview 7-8 years after a first time stroke. They had received care at the Sahlgrenska University Hospital in Gothenburg, and were recruited as a heterogenic sample with respect to age, gender, stroke severity and subtype. Results From the participants' experiences four themes emerged: "Returning to work after stroke"; "Working life 7-8 years after stroke"; "Social life 7-8 years after stroke"; and "A state of reorientation in life". Quotes about experienced participation in everyday life were summarized and presented as "Participation after stroke narratives". Participants chose to emphasize on work- and social life when describing situations of successful participation. Being included in the wider community and having a sense of purpose, when interacting with others, were factors that these narratives had in common. Participants had gradually become accustomed to a somewhat altered life situation. Some consequences after stroke were still considered frustrating in social or work situations. However, the importance of these issues had reduced and were no longer problematized. Conclusions Participants felt content with their everyday life in general, which was a principal and positive result of this study. Reaching a stage of acceptance seemed to be a complex and continuous struggle, and an individual approach in long-term rehabilitation would be valuable to support this personal process. More knowledge about what factors that facilitate participation in people of working-age many years after stroke is needed, so that more people can reach a state of positive identity and participation.	[Tornbom, Karin; Sunnerhagen, Katharina S.] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Res Grp Rehabil Med,Sect Clin Neurosci, Gothenburg, Sweden; [Tornbom, Karin; Sunnerhagen, Katharina S.] Univ Gothenburg, Ctr Person Ctr Care GPCC, Gothenburg, Sweden; [Lundalv, Jorgen] Univ Gothenburg, Dept Social Work, Gothenburg, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg	Tornbom, K (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Res Grp Rehabil Med,Sect Clin Neurosci, Gothenburg, Sweden.; Tornbom, K (corresponding author), Univ Gothenburg, Ctr Person Ctr Care GPCC, Gothenburg, Sweden.	karin.tornbom@neuro.gu.se	Sunnerhagen, Katharina Stibrant/AAE-2405-2020	Sunnerhagen, Katharina Stibrant/0000-0002-5940-4400	Norrbacka Eugenia foundation [808-12]; Rune and Ulla Amlovs foundation for Neurological Research; Swedish Stroke association; Swedish science council [VR2012-3523 2017-00946]; Swedish Brain Foundation; Hjart-Lungfonden; FRF Foundation; Promobilia; Swedish state under Swedish government; ALF agreement [71980]	Norrbacka Eugenia foundation; Rune and Ulla Amlovs foundation for Neurological Research; Swedish Stroke association; Swedish science council; Swedish Brain Foundation; Hjart-Lungfonden; FRF Foundation; Promobilia; Swedish state under Swedish government; ALF agreement	This work was supported by the Norrbacka Eugenia foundation, 808-12 (KSS); Rune and Ulla Amlovs foundation for Neurological Research; The Swedish Stroke association (K.T); Swedish science council VR2012-3523 2017-00946; The Swedish Brain Foundation; Hjart-Lungfonden; FRF Foundation; Promobilia. The study was financed by grants from the Swedish state under Swedish government and the county councils, the ALF agreement 71980 (K.S.S.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alaszewski A, 2007, DISABIL REHABIL, V29, P1858, DOI 10.1080/09638280601143356; Arntzen C, 2015, DISABIL REHABIL, V37, P1626, DOI 10.3109/09638288.2014.972590; Bazeley P., 2013, QUALITATIVE DATA ANA; Beauchamp TL, 2013, PRINCIPAL BIOMEDICAL; Brannigan C, 2017, DISABIL REHABIL, V39, P211, DOI 10.3109/09638288.2016.1141242; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Chapman AL, 2015, J ROY COLL PHYS EDIN, V45, P201, DOI 10.4997/JRCPE.2015.305; Chin Y Y, 2018, Med J Malaysia, V73, P90; Daniel K, 2009, STROKE, V40, pE431, DOI [10.1161/STROKEAHA.108.535088, 10.1161/STROKEAHA.108.534487]; Danielsson A, 2012, STROKE RES TREAT, V2012, DOI 10.1155/2012/818513; de Graaf JA, 2018, DISABIL REHABIL, V40, P637, DOI 10.1080/09638288.2016.1271466; Duncan F, 2012, J PSYCHOSOM RES, V73, P18, DOI 10.1016/j.jpsychores.2012.04.001; Elf M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161942; Erikson A, 2016, J REHABIL MED, V48, P847, DOI 10.2340/16501977-2161; Fini NA, 2017, PHYS THER, V97, P707, DOI 10.1093/ptj/pzx038; Flinn NA, 2010, OCCUP THER INT, V17, P81, DOI 10.1002/oti.286; George Mary G, 2011, Ann Neurol, V70, P713, DOI 10.1002/ana.22539; Haggstrom A, 2008, J REHABIL MED, V40, P89, DOI 10.2340/16501977-0138; Hartke RJ, 2011, TOP STROKE REHABIL, V18, P341, DOI 10.1310/tsr1804-341; Horne J, 2014, CLIN REHABIL, V28, P1125, DOI 10.1177/0269215514534086; Jackson S, 2018, DISABIL REHABIL, V40, P414, DOI 10.1080/09638288.2016.1258437; Kralik D, 2004, J CLIN NURS, V13, P259, DOI 10.1046/j.1365-2702.2003.00826.x; Kuluski K, 2014, INT J QUAL STUD HEAL, V9, DOI 10.3402/qhw.v9.22252; Kutlubaev MA, 2015, INT J STROKE, V10, P280, DOI 10.1111/ijs.12428; Lawrence Maggie, 2010, Br J Nurs, V19, P241; Lindstrom B, 2009, J REHABIL MED, V41, P714, DOI 10.2340/16501977-0423; Lynch EB, 2008, J REHABIL MED, V40, P518, DOI 10.2340/16501977-0203; Maaijwee NAMM, 2014, NAT REV NEUROL, V10, P315, DOI 10.1038/nrneurol.2014.72; Mallinson T, 2010, ARCH PHYS MED REHAB, V91, pS29, DOI 10.1016/j.apmr.2010.04.027; Nicholson SL, 2017, J ROY COLL PHYS EDIN, V47, P231, DOI 10.4997/JRCPE.2017.304; Nicholson S, 2013, INT J STROKE, V8, P357, DOI 10.1111/j.1747-4949.2012.00880.x; Norlander A, 2018, BRAIN INJURY, V32, P858, DOI 10.1080/02699052.2018.1463561; Norlander A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149395; Oman M., 2017, STAT STROKE; Pallesen H, 2014, DISABIL REHABIL, V36, P232, DOI 10.3109/09638288.2013.788217; Palstam A, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021182; Patton MQ, 2015, QUALITATIVE RES EVAL, V4th; Persson HC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181006; Persson HC, 2012, BMC NEUROLOGY, V12, P1471; Priestley M, 2010, DISABIL SOC, V25, P731, DOI 10.1080/09687599.2010.505749; Reinholdsson M, 2018, NEUROLOGY, V91, pE146, DOI 10.1212/WNL.0000000000006354; Sadler E, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-011631; Sarre S, 2014, DISABIL REHABIL, V36, P716, DOI 10.3109/09638288.2013.814724; Smajlovic D, 2015, VASC HEALTH RISK MAN, V11, P157, DOI 10.2147/VHRM.S53203; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Wesali S, 2015, CLIN NEUROL NEUROSUR, V138, P52, DOI 10.1016/j.clineuro.2015.07.020; White JH, 2012, DISABIL REHABIL, V34, P1376, DOI 10.3109/09638288.2011.645111; Wood JP, 2010, CLIN REHABIL, V24, P1045, DOI 10.1177/0269215510375901; Woodman P, 2014, DISABIL REHABIL, V36, P2031, DOI 10.3109/09638288.2014.887796; Ytterberg C, 2017, J REHABIL MED, V49, P637, DOI 10.2340/16501977-2258	50	11	12	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2019	14	3							e0213447	10.1371/journal.pone.0213447	http://dx.doi.org/10.1371/journal.pone.0213447			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HO6OH	30865696	Green Published, Green Submitted, gold			2023-01-03	WOS:000461048900067
J	Hajek, P; Phillips-Waller, A; Przulj, D; Pesola, F; Smith, KM; Bisal, N; Li, JS; Parrott, S; Sasieni, P; Dawkins, L; Ross, L; Goniewicz, M; Wu, Q; McRobbie, HJ				Hajek, Peter; Phillips-Waller, Anna; Przulj, Dunja; Pesola, Francesca; Smith, Katie Myers; Bisal, Natalie; Li, Jinshuo; Parrott, Steve; Sasieni, Peter; Dawkins, Lynne; Ross, Louise; Goniewicz, Maciej; Wu, Qi; McRobbie, Hayden J.			A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SMOKING-CESSATION; WITHDRAWAL; RESOLUTION; NONSMOKER	BACKGROUND E-cigarettes are commonly used in attempts to stop smoking, but evidence is limited regarding their effectiveness as compared with that of nicotine products approved as smoking-cessation treatments. METHODS We randomly assigned adults attending U.K. National Health Service stop-smoking services to either nicotine-replacement products of their choice, including product combinations, provided for up to 3 months, or an e-cigarette starter pack (a second-generation refillable e-cigarette with one bottle of nicotine e-liquid [18 mg per milli-liter]), with a recommendation to purchase further e-liquids of the flavor and strength of their choice. Treatment included weekly behavioral support for at least 4 weeks. The primary outcome was sustained abstinence for 1 year, which was validated biochemically at the final visit. Participants who were lost to follow-up or did not provide biochemical validation were considered to not be abstinent. Secondary outcomes included participant-reported treatment usage and respiratory symptoms. RESULTS A total of 886 participants underwent randomization. The 1-year abstinence rate was 18.0% in the e-cigarette group, as compared with 9.9% in the nicotine-replacement group (relative risk, 1.83; 95% confidence interval [CI], 1.30 to 2.58; P<0.001). Among participants with 1-year abstinence, those in the e-cigarette group were more likely than those in the nicotine-replacement group to use their assigned product at 52 weeks (80% [63 of 79 participants] vs. 9% [4 of 44 participants]). Overall, throat or mouth irritation was reported more frequently in the e-cigarette group (65.3%, vs. 51.2% in the nicotine-replacement group) and nausea more frequently in the nicotine-replacement group (37.9%, vs. 31.3% in the e-cigarette group). The e-cigarette group reported greater declines in the incidence of cough and phlegm production from baseline to 52 weeks than did the nicotine-replacement group (relative risk for cough, 0.8; 95% CI, 0.6 to 0.9; relative risk for phlegm, 0.7; 95% CI, 0.6 to 0.9). There were no significant between-group differences in the incidence of wheezing or shortness of breath. CONCLUSIONS E-cigarettes were more effective for smoking cessation than nicotine-replacement therapy, when both products were accompanied by behavioral support.	[Hajek, Peter; Phillips-Waller, Anna; Przulj, Dunja; Smith, Katie Myers; Bisal, Natalie; McRobbie, Hayden J.] Queen Mary Univ London, London, England; [Pesola, Francesca; Sasieni, Peter] Kings Coll London, London, England; [Dawkins, Lynne] London South Bank Univ, London, England; [Li, Jinshuo; Parrott, Steve; Wu, Qi] Univ York, York, N Yorkshire, England; [Ross, Louise] Leicester City Council, Leicester, Leics, England; [Goniewicz, Maciej] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA	University of London; Queen Mary University London; University of London; King's College London; London South Bank University; University of York - UK	Przulj, D (corresponding author), Queen Mary Univ London, Hlth & Lifestyle Res Unit, 2 Stayners Rd, London E1 4AH, England.	d.przulj@qmul.ac.uk	Smith, Katie Elizabeth/GXH-2114-2022; Goniewicz, Maciej L/D-8986-2012; Goniewicz, Maciej Lukasz/Z-1604-2019; Li, Jinshuo/C-6827-2019; McRobbie, Hayden/B-4552-2018	Goniewicz, Maciej Lukasz/0000-0001-6748-3068; Li, Jinshuo/0000-0003-1496-7450; McRobbie, Hayden/0000-0002-7777-1845; Dawkins, Lynne/0000-0003-1236-009X; Sasieni, Peter/0000-0003-1509-8744; Bisal, Natalie/0000-0002-5938-0349; Parrott, Steven James/0000-0002-0165-1150	National Institute for Health Research and Cancer Research UK	National Institute for Health Research and Cancer Research UK	Funded by the National Institute for Health Research and Cancer Research UK	Bauld L, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13121175; Bullen C, 2010, TOB CONTROL, V19, P98, DOI 10.1136/tc.2009.031567; Bullen C, 2013, LANCET, V382, P1629, DOI 10.1016/S0140-6736(13)61842-5; Caponnetto P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066317; Farley AC, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006219.pub3; Ferguson J, 2005, ADDICTION, V100, P59, DOI 10.1111/j.1360-0443.2005.01028.x; HAJEK P, 1988, JAMA-J AM MED ASSOC, V260, P1593, DOI 10.1001/jama.260.11.1593; Hajek P, 2003, ADDICTION, V98, P1563, DOI 10.1046/j.1360-0443.2003.00497.x; HAJEK P, 1989, BRIT J ADDICT, V84, P591; Hajek P, 2015, J ADDICTION RES THER, V6, DOI [10.4172/2155-6105.1000244, DOI 10.4172/2155-6105.1000244]; Hajek P, 2018, PSYCHOPHARMACOLOGY, V235, P1083, DOI 10.1007/s00213-017-4826-z; Hajek P, 2015, ADDICTION, V110, P19, DOI 10.1111/add.12905; Halpern SD, 2018, NEW ENGL J MED, V378, P2302, DOI [10.1056/NEJMsa1715757, 10.1056/nejmsa1715757]; Hartmann-Boyce J, 2016, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD010216.pub4, 10.1002/14651858.CD010216.pub3]; McEwen A., 2006, MANUAL SMOKING CESSA; McNeill A, 2018, EVIDENCE REV E CIGAR; McRobbie H, 2004, NICOTINE TOB RES, V6, P655, DOI 10.1080/14622200410001734012; Miler J., 2016, J ADDICT RES THER, V7, P290, DOI [10.4172/2155-6105.1000290, DOI 10.4172/2155-6105.1000290]; Miler JA, 2018, MED HYPOTHESES, V118, P42, DOI 10.1016/j.mehy.2018.05.011; Miler JA, 2017, MED HYPOTHESES, V109, P17, DOI 10.1016/j.mehy.2017.09.006; National Academies of Sciences Engineering and Medicine, 2018, PUBL HLTH CONS E CIG; NHS Digital, 2016, STAT NHS STOP SMOK S; Royal College of Physicians, 2016, NIC SMOK TOB HARM RE; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub3; West R, 2005, ADDICTION, V100, P299, DOI 10.1111/j.1360-0443.2004.00995.x; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067	26	769	785	12	130	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 14	2019	380	7					629	637		10.1056/NEJMoa1808779	http://dx.doi.org/10.1056/NEJMoa1808779			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL3KE	30699054	Bronze, Green Accepted, Green Published			2023-01-03	WOS:000458612900006
J	Yajima, T; Arao, M; Yajima, K; Takahashi, H; Yasuda, K				Yajima, Takahiro; Arao, Maiko; Yajima, Kumiko; Takahashi, Hiroshi; Yasuda, Keigo			The associations of fat tissue and muscle mass indices with all-cause mortality in patients undergoing hemodialysis	PLOS ONE			English	Article							QUALITY-OF-LIFE; BODY-COMPOSITION; MAINTENANCE HEMODIALYSIS; ABDOMINAL FAT; INFLAMMATION; SARCOPENIA; CONSENSUS; SURVIVAL; DEPOSITION; MORBIDITY	Protein-energy wasting, which involves loss of fat and muscle mass, is prevalent and is associated with mortality in hemodialysis (HD) patients. We investigated the associations of fat tissue and muscle mass indices with all-cause mortality in HD patients. The study included 162 patients undergoing HD. The fat tissue index (FTI) and skeletal muscle mass index (SMI), which represent respective tissue masses normalized to height squared, were measured by bioimpedance analysis after dialysis. Patients were divided into the following four groups according to the medians of FTI and SMI values: group 1 (G1), lower FTI and lower SMI; G2, higher FTI and lower SMI; G3, lower FTI and higher SMI; and G4, higher FTI and higher SMI. The associations of the FTI, SMI, and body mass index (BMI) with all-cause mortality were evaluated. During a median follow-up of 2.5 years, 29 patients died. The 5-year survival rates were 48.6%, 76.1%, 95.7%, and 87.4% in the G1, G2, G3, and G4 groups, respectively (P = 0.0002). The adjusted hazard ratio values were 0.34 (95% confidence interval [CI] 0.10-0.95, P = 0.040) for G2 vs. G1, 0.13 (95%CI 0.01-0.69, P = 0.013) for G3 vs. G1, and 0.25 (95%CI 0.07-0.72, P = 0.0092) for G4 vs. G1, respectively. With regard to model discrimination, on adding both FTI and SMI to a model with established risk factors, the C-index increased significantly when compared with the value for a model with BMI (0.763 vs. 0.740, P = 0.016). Higher FTI and/or higher SMI values were independently associated with reduced risks of all-cause mortality in HD patients. Moreover, the combination of the FTI and SMI may more accurately predict all-cause mortality when compared with BMI. Therefore, these body composition indicators should be evaluated simultaneously in this population.	[Yajima, Takahiro; Arao, Maiko] Matsunami Gen Hosp, Dept Nephrol, Gifu, Japan; [Yajima, Kumiko; Yasuda, Keigo] Matsunami Gen Hosp, Dept Internal Med, Gifu, Japan; [Takahashi, Hiroshi] Fujita Hlth Univ, Sch Med, Div Med Stat, Toyoake, Aichi, Japan	Fujita Health University	Yajima, T (corresponding author), Matsunami Gen Hosp, Dept Nephrol, Gifu, Japan.	yajima5639@gmail.com						Abbott KC, 2004, KIDNEY INT, V65, P597, DOI 10.1111/j.1523-1755.2004.00385.x; Caetano C, 2016, J RENAL NUTR, V26, P81, DOI 10.1053/j.jrn.2015.10.005; Chen LK, 2014, J AM MED DIR ASSOC, V15, P95, DOI 10.1016/j.jamda.2013.11.025; Cordeiro AC, 2010, NEPHROL DIAL TRANSPL, V25, P562, DOI 10.1093/ndt/gfp492; Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034; de Gonzalez AB, 2010, NEW ENGL J MED, V363, P2211, DOI 10.1056/NEJMoa1000367; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Fouque D, 2008, KIDNEY INT, V73, P391, DOI 10.1038/sj.ki.5002585; Gotch FA, 2000, BLOOD PURIFICAT, V18, P276, DOI 10.1159/000014449; Honda H, 2007, AM J CLIN NUTR, V86, P633, DOI 10.1093/ajcn/86.3.633; Ikizler TA, 1999, KIDNEY INT, V55, P1945, DOI 10.1046/j.1523-1755.1999.00410.x; Johansen KL, 2015, CURR OPIN NEPHROL HY, V24, P268, DOI 10.1097/MNH.0000000000000120; Kalantar-Zadeh K, 2006, AM J CLIN NUTR, V83, P202; Kaysen GA, 2005, AM J CLIN NUTR, V82, P988, DOI 10.1093/ajcn/82.5.988; Kim JK, 2019, KOREAN J INTERN MED, V34, P599, DOI 10.3904/kjim.2017.083; Kittiskulnam P, 2017, KIDNEY INT, V92, P238, DOI 10.1016/j.kint.2017.01.024; Marcelli D, 2015, CLIN J AM SOC NEPHRO, V10, P1192, DOI 10.2215/CJN.08550814; McLaughlin T, 2011, J CLIN ENDOCR METAB, V96, pE1756, DOI 10.1210/jc.2011-0615; Morabia A, 1999, BRIT J NUTR, V82, P49, DOI 10.1017/S0007114599001117; Mulasi U, 2015, NUTR CLIN PRACT, V30, P180, DOI 10.1177/0884533614568155; Noori N, 2010, CLIN J AM SOC NEPHRO, V5, P2258, DOI 10.2215/CJN.02080310; Obi Y, 2015, CURR OPIN CLIN NUTR, V18, P254, DOI 10.1097/MCO.0000000000000171; Onofriescu M, 2014, AM J KIDNEY DIS, V64, P111, DOI 10.1053/j.ajkd.2014.01.420; Park J, 2014, PROG CARDIOVASC DIS, V56, P415, DOI 10.1016/j.pcad.2013.10.005; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Pou KM, 2007, CIRCULATION, V116, P1234, DOI 10.1161/CIRCULATIONAHA.107.710509; Rankinen T, 1999, INT J OBESITY, V23, P801, DOI 10.1038/sj.ijo.0800929; Romero-Corral A, 2007, EUR HEART J, V28, P2087, DOI 10.1093/eurheartj/ehm243; Rosenberger J, 2014, J RENAL NUTR, V24, P172, DOI 10.1053/j.jrn.2014.01.002; Samaras K, 2010, OBESITY, V18, P884, DOI 10.1038/oby.2009.443; Tangvoraphonkchai K, 2017, EUR J CLIN NUTR, V71, P169, DOI 10.1038/ejcn.2016.187; Wagenknecht LE, 2003, DIABETES, V52, P2490, DOI 10.2337/diabetes.52.10.2490; Whitlock G, 2009, LANCET, V373, P1083, DOI 10.1016/S0140-6736(09)60318-4; Yajima T, 2018, NUTRIENTS, V10, DOI 10.3390/nu10040480	34	22	22	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2019	14	2							e0211988	10.1371/journal.pone.0211988	http://dx.doi.org/10.1371/journal.pone.0211988			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL5IX	30759133	Green Published, gold, Green Submitted			2023-01-03	WOS:000458761300066
J	Stark, SM; Stark, CEL				Stark, Shauna M.; Stark, Craig E. L.			Excitatory/Inhibitory Imbalance in Anterior Lateral Occipital Complex Can Impair Hippocampal Mnemonic Discrimination	NEURON			English	Editorial Material									[Stark, Shauna M.; Stark, Craig E. L.] Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA	University of California System; University of California Irvine	Stark, CEL (corresponding author), Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA.	cestark@uci.edu						Barron HC, 2016, NEURON, V90, P191, DOI 10.1016/j.neuron.2016.02.031; EICHENBAUM H, 1994, BEHAV BRAIN SCI, V17, P449, DOI 10.1017/S0140525X00035391; Koolschijn RS, 2019, NEURON, V101, P528, DOI 10.1016/j.neuron.2018.11.042; Koutstaal W, 2006, PSYCHON B REV, V13, P84, DOI 10.3758/BF03193817; Kumaran D, 2007, J NEUROSCI, V27, P8517, DOI 10.1523/JNEUROSCI.1677-07.2007; Lacy JW, 2011, LEARN MEMORY, V18, P15, DOI [10.1101/lm.1971110, 10.1101/lm.1971111]; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; TREVES A, 1994, HIPPOCAMPUS, V4, P374, DOI 10.1002/hipo.450040319; Yassa MA, 2011, HIPPOCAMPUS, V21, P968, DOI 10.1002/hipo.20808	9	0	0	2	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	FEB 6	2019	101	3					360	362		10.1016/j.neuron.2019.01.020	http://dx.doi.org/10.1016/j.neuron.2019.01.020			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	HK3YY	30731057	Bronze			2023-01-03	WOS:000457856700005
J	Guo, QY; Ebihara, K; Shimodaira, T; Fujiwara, H; Toume, K; Dibwe, DF; Awale, S; Araki, R; Yabe, T; Matsumoto, K				Guo, Qing-Yun; Ebihara, Ken; Shimodaira, Takafumi; Fujiwara, Hironori; Toume, Kazufumi; Dibwe, Dya Fita; Awale, Suresh; Araki, Ryota; Yabe, Takeshi; Matsumoto, Kinzo			Kami-shoyo-san improves ASD-like behaviors caused by decreasing allopregnanolone biosynthesis in an SKF mouse model of autism	PLOS ONE			English	Article							ENDOGENOUS BRAIN ALLOPREGNANOLONE; GABA(A) RECEPTORS; EGR-1 EXPRESSION; ANIMAL-MODEL; FEAR MEMORY; MICE; MEDICINE; DEFICITS; STRESS; 5-ALPHA-DIHYDROPROGESTERONE	Dysfunctions in the GABAergic system are associated with the pathogenesis of autism spectrum disorder (ASD). However, the mechanisms by which GABAergic system dysfunctions induce the pathophysiology of ASD remain unclear. We previously demonstrated that a selective type I 5a-reductase inhibitor SKF105111 (SKF) induced ASD-like behaviors, such as impaired sociability-related performance and repetitive grooming behaviors, in male mice. Moreover, the effects of SKF were caused by a decrease in the endogenous levels of allopregnanolone (ALLO), a positive allosteric modulator of the GABA(A) receptor. In this study, we used SKF-treated male mice as a putative animal model of ASD and examined the effects of Kami-shoyo-san (KSS) as an experimental therapeutic strategy for ASD. KSS is a traditional Kampo formula consisting of 10 different crude drugs and has been used for the treatment of neuropsychiatric symptoms. KSS dose-dependently attenuated sociability deficits and suppressed an increase in grooming behaviors in SKF-treated mice without affecting ALLO content in the prefrontal cortex. The systemic administration of the dopamine D-1 receptor antagonist SCH23390 reversed the ameliorative effects of KSS. On the other hand, the dopamine D-2 receptor antagonist sulpiride and GABA(A) receptor antagonist bicuculline only attenuated the ameliorative effect of KSS on repetitive self-grooming behaviors. The present results indicate that KSS improves SKF-induced ASD-like behaviors by facilitating dopamine receptor-mediated mechanisms and partly by neurosteroid-independent GABA(A) receptor-mediated neurotransmission. Therefore, KSS is a potential candidate for the treatment of ASD.	[Guo, Qing-Yun; Ebihara, Ken; Shimodaira, Takafumi; Fujiwara, Hironori; Toume, Kazufumi; Dibwe, Dya Fita; Awale, Suresh; Matsumoto, Kinzo] Univ Toyama, Inst Nat Med, Toyama, Japan; [Araki, Ryota; Yabe, Takeshi] Setsunan Univ, Fac Pharmaceut Sci, Lab Funct Biomol & Chem Pharmacol, Osaka, Japan	University of Toyama; Setsunan University	Fujiwara, H (corresponding author), Univ Toyama, Inst Nat Med, Toyama, Japan.	arawijuf@inm.u-toyama.ac.jp	Awale, Suresh/G-1995-2012; Toume, Kazufumi/A-2632-2012; Dibwe, Dya Fita/M-6179-2018; GUO, QINGYUN/HCH-4738-2022	Awale, Suresh/0000-0002-5299-193X; Toume, Kazufumi/0000-0002-3315-145X; Dibwe, Dya Fita/0000-0003-3433-3834; Guo, Qingyun/0000-0002-4168-5021; Araki, Ryota/0000-0002-0881-9737	Ministry of Education, Culture, Sports, Science, and Technology (MEXT) [15K15269]; Kobayashi International Scholarship Foundation; Institute of Natural Medicine, University of Toyama; University of Toyama	Ministry of Education, Culture, Sports, Science, and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Kobayashi International Scholarship Foundation; Institute of Natural Medicine, University of Toyama; University of Toyama	This study was supported in part by a Grant-in-Aid for Challenging Exploratory Research from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) to KM (15K15269), 2014 and 2018 Grants-in-Aid from Kobayashi International Scholarship Foundation (KM and HF), and Grants-in-Aid for the 2016 and 2017 Cooperative Research Project I from the Institute of Natural Medicine, University of Toyama (RA and HF), and 2018 Director Leadership Expenses, University of Toyama to HF. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU; Buxbaum JD, 2013, NEUROSCIENCE OF AUTISM SPECTRUM DISORDERS, P113, DOI 10.1016/B978-0-12-391924-3.00008-9; Cellot G, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00070; Coghlan S, 2012, NEUROSCI BIOBEHAV R, V36, P2044, DOI 10.1016/j.neubiorev.2012.07.005; Dong E, 2001, P NATL ACAD SCI USA, V98, P2849, DOI 10.1073/pnas.051628598; Ebert DH, 2013, NATURE, V493, P327, DOI 10.1038/nature11860; Ebihara K, 2017, BEHAV BRAIN RES, V334, P6, DOI 10.1016/j.bbr.2017.07.019; Fujiwara H, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1710-7; Gepner B, 2009, NEUROSCI BIOBEHAV R, V33, P1227, DOI 10.1016/j.neubiorev.2009.06.006; Guidotti A, 2001, BRAIN RES REV, V37, P110, DOI 10.1016/S0165-0173(01)00129-1; Han S, 2014, NEURON, V81, P1282, DOI 10.1016/j.neuron.2014.01.016; Hara Y, 2016, AUTISM RES, V9, P926, DOI 10.1002/aur.1596; Hidaka T, 2013, J OBSTET GYNAECOL RE, V39, P223, DOI 10.1111/j.1447-0756.2012.01936.x; HOLT DA, 1990, J MED CHEM, V33, P943, DOI 10.1021/jm00165a010; Kim KC, 2016, BIOMOL THER, V24, P207, DOI 10.4062/biomolther.2016.061; Lee Y, 2018, MOL NEUROBIOL, V55, P5658, DOI 10.1007/s12035-017-0770-5; Matsumoto K, 2003, PHARMACOL BIOCHEM BE, V75, P831, DOI 10.1016/S0091-3057(03)00169-2; Matsumoto K, 2007, STRESS, V10, P3, DOI 10.1080/10253890701200997; Matsumoto K, 2012, NEUROSCI RES, V73, P257, DOI 10.1016/j.neures.2012.04.004; Mizowaki M, 2001, LIFE SCI, V69, P2167, DOI 10.1016/S0024-3205(01)01290-5; Mizuki D, 2014, J PHARMACOL SCI, V124, P457, DOI 10.1254/jphs.13252FP; Nguyen M, 2014, NEUROCHEM INT, V66, P15, DOI 10.1016/j.neuint.2014.01.002; Oblak A, 2009, AUTISM RES, V2, P205, DOI 10.1002/aur.88; Oblak AL, 2010, J NEUROCHEM, V114, P1414, DOI 10.1111/j.1471-4159.2010.06858.x; Okada R, 2015, NEUROSCIENCE, V299, P134, DOI 10.1016/j.neuroscience.2015.04.064; Okada R, 2014, NEUROCHEM RES, V39, P875, DOI 10.1007/s11064-014-1283-5; Ouchi H, 2013, BEHAV BRAIN RES, V238, P146, DOI 10.1016/j.bbr.2012.10.029; Park SW, 2007, PSYCHIAT CLIN NEUROS, V61, P401, DOI 10.1111/j.1440-1819.2007.01676.x; Puia G, 2003, NEUROPHARMACOLOGY, V44, P49, DOI 10.1016/S0028-3908(02)00341-6; Schule C, 2014, PROG NEUROBIOL, V113, P79, DOI 10.1016/j.pneurobio.2013.09.003; Silverman JL, 2010, NAT REV NEUROSCI, V11, P490, DOI 10.1038/nrn2851; STARR BS, 1986, NEUROPHARMACOLOGY, V25, P455, DOI 10.1016/0028-3908(86)90168-1; STARR BS, 1986, PHARMACOL BIOCHEM BE, V24, P837, DOI 10.1016/0091-3057(86)90421-1; Sugiyama K, 1996, NEUROSCI LETT, V216, P147, DOI 10.1016/S0304-3940(96)13000-7; Terauchi M, 2011, ARCH GYNECOL OBSTET, V284, P913, DOI 10.1007/s00404-010-1779-4; WACHTEL SR, 1992, PSYCHOPHARMACOLOGY, V109, P41, DOI 10.1007/BF02245478; Yoshimura A, 2018, OBSTET GYNECOL INT, V2018, DOI 10.1155/2018/9475919; Zager A, 2012, BEHAV BRAIN RES, V232, P30, DOI 10.1016/j.bbr.2012.03.036; Zoghbi HY, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a009886	39	10	10	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2019	14	1							e0211266	10.1371/journal.pone.0211266	http://dx.doi.org/10.1371/journal.pone.0211266			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HJ6LR	30703109	gold, Green Published, Green Submitted			2023-01-03	WOS:000457301600033
J	Michel, LL; Sommer, L; Silos, RG; Bermejo, JL; von Au, A; Seitz, J; Hennigs, A; Smetanay, K; Golatta, M; Heil, J; Schutz, F; Sohn, C; Schneeweiss, A; Marme, F				Michel, Laura L.; Sommer, Laura; Silos, Rosa Gonzalez; Bermejo, Justo Lorenzo; von Au, Alexandra; Seitz, Julia; Hennigs, Andre; Smetanay, Katharina; Golatta, Michael; Heil, Joerg; Schuetz, Florian; Sohn, Christof; Schneeweiss, Andreas; Marme, Frederik			Prediction of local recurrence risk after neoadjuvant chemotherapy in patients with primary breast cancer: Clinical utility of the MD Anderson Prognostic Index	PLOS ONE			English	Article							INTERNATIONAL EXPERT CONSENSUS; REGIONAL RECURRENCE; TUMOR RECURRENCE; PRIMARY THERAPY; CONSERVATION; HIGHLIGHTS; SURVIVAL	Background Locoregional recurrence after neoadjuvant chemotherapy for primary breast cancer is associated with poor prognosis. It is essential to identify patients at high risk of locoregional recurrence who may benefit from extended local therapy. Here, we examined the prediction accuracy and clinical applicability of the MD Anderson Prognostic Index (MDAPI). Methods Prospective clinical data from 456 patients treated between 2003 and 2011 was analyzed. The Kaplan-Meier method was used to examine the probabilities of locoregional recurrence, local recurrence and distant metastases according to individual prognosis score, stratified by type of surgery (breast conserving therapy or mastectomy). The possible confounding of the relationship between recurrence risk and MDAPI by established risk factors was accounted for in multiple survival regression models. To define the clinical utility of the MDAPI we analyzed its performance to predict locoregional recurrence censoring patients with prior or simultaneous distant metastases. Results Mastectomized patients (42% of the patients) presented with more advanced tumor stage, lower tumor grade, hormone-receptor positive disease and consequently lower pathological complete response rates. Only a few patients presented with high-risk scores (2,7% MDAPI >= 3). All patients with high-risk MDAPI score (MDAPI >= 3) who developed locoregional recurrence were simultaneously affected by distant metastases. Conclusion Our data do not support a clinical utility of the MDAPI to guide local therapy.	[Michel, Laura L.; Sommer, Laura; von Au, Alexandra; Seitz, Julia; Hennigs, Andre; Smetanay, Katharina; Golatta, Michael; Heil, Joerg; Schuetz, Florian; Sohn, Christof; Schneeweiss, Andreas; Marme, Frederik] Univ Hosp Heidelberg, Natl Ctr Tumor Dis, Heidelberg, Germany; [Michel, Laura L.; Sommer, Laura; von Au, Alexandra; Seitz, Julia; Hennigs, Andre; Smetanay, Katharina; Golatta, Michael; Heil, Joerg; Schuetz, Florian; Sohn, Christof; Schneeweiss, Andreas; Marme, Frederik] Univ Hosp Heidelberg, Dept Obstet & Gynecol, Heidelberg, Germany; [Silos, Rosa Gonzalez; Bermejo, Justo Lorenzo] Heidelberg Univ, Inst Med Biometry & Informat, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Michel, LL; Marme, F (corresponding author), Univ Hosp Heidelberg, Natl Ctr Tumor Dis, Heidelberg, Germany.; Michel, LL; Marme, F (corresponding author), Univ Hosp Heidelberg, Dept Obstet & Gynecol, Heidelberg, Germany.	Laura.michel@med.uni-heidelberg.de; Frederik.marme@med.uni-heidelberg.de	Heil, Joerg/M-4998-2017; Golatta, Michael/AAH-8735-2021; Schneeweiss, Andreas/HHS-4098-2022	Heil, Joerg/0000-0002-4684-9099; Golatta, Michael/0000-0002-2605-0060; 				Abe O, 2005, LANCET, V366, P2087; Akay CL, 2012, ANN SURG ONCOL, V19, P901, DOI 10.1245/s10434-011-2006-7; Chen AM, 2004, J CLIN ONCOL, V22, P2303, DOI 10.1200/JCO.2004.09.062; Chen AM, 2005, CANCER-AM CANCER SOC, V103, P689, DOI 10.1002/cncr.20815; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Hennigs A, 2016, BREAST CANCER RES TR, V160, P491, DOI 10.1007/s10549-016-4016-4; Huang EH, 2006, INT J RADIAT ONCOL, V66, P352, DOI 10.1016/j.ijrobp.2006.04.046; Ishitobi M, 2012, CANCER-AM CANCER SOC, V118, P4385, DOI 10.1002/cncr.27377; Kaufmann M, 2006, J CLIN ONCOL, V24, P1940, DOI 10.1200/JCO.2005.02.6187; Marme F, 2013, INT J CANCER, V133, P1006, DOI 10.1002/ijc.28094; Rouzier R, 2001, J CLIN ONCOL, V19, P3828, DOI 10.1200/JCO.2001.19.18.3828; Senkus E, 2015, ANN ONCOL, V26, pV8, DOI 10.1093/annonc/mdv298	13	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2019	14	1							e0211337	10.1371/journal.pone.0211337	http://dx.doi.org/10.1371/journal.pone.0211337			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ6LR	30703111	gold, Green Submitted, Green Published			2023-01-03	WOS:000457301600036
J	Cerritelli, F; van Dun, PLS; Esteves, JE; Consorti, G; Sciomachen, P; Lacorte, E; Vanacore, N; Marasco, ML; Maggiani, A; Cavallaro, A; Silvestri, D; Zurlo, J; Petracca, M; Fornari, M; Bersan, V; Lo Voi, G; Papa, L; Tamagnini, S; Filipazzi, R; Stirpe, T; Colonna, S; Gavazzi, A; Manzotti, A; Bergna, A; Marco, S; Franscini, F; Donnaquio, G; Parisi, A; Valente, M; Botti, E				Cerritelli, Francesco; van Dun, Patrick L. S.; Esteves, Jorge E.; Consorti, Giacomo; Sciomachen, Paola; Lacorte, Eleonora; Vanacore, Nicola; Marasco, Marcello Luca; Maggiani, Alberto; Cavallaro, Antonio; Silvestri, Dario; Zurlo, Joseph; Petracca, Marco; Fornari, Mauro; Bersan, Veronica; Lo Voi, Giacomo; Papa, Liria; Tamagnini, Sandro; Filipazzi, Roberta; Stirpe, Tatiana; Colonna, Saverio; Gavazzi, Alessandro; Manzotti, Andrea; Bergna, Andrea; Marco, Sbarbaro; Franscini, Federico; Donnaquio, Guglielmo; Parisi, Alessandro; Valente, Massimo; Botti, Emanuele		OPERA-IT Grp	The Italian Osteopathic Practitioners Estimates and RAtes (OPERA) study: A cross sectional survey	PLOS ONE			English	Article								The prevalence of osteopathic practitioners, their professional profile and features of their clinical practice, particularly where statutory regulation does not yet exist, are still significantly underreported. The Osteopathic Practitioners Estimates and RAtes (OPERA) project was developed as an European-based census dedicated to profiling the osteopathic profession across Europe. The present study aimed to describe the osteopathic practitioners and the profession in Italy. A voluntary, online based, closed-ended survey was distributed across Italy in the period between February and June 2017. An e-based campaign was set up to reach the Italian osteopathic professionals. Participants were asked to complete the forms by filling in the information regarding the demographics, working status and professional activities, education, consultation fees, patient complaints, treatment and management. The survey was completed by 4816 individuals. 196 people started the survey but did not finish, which corresponds to a 4% attrition rate. The majority of respondents were males (66.7%). The modal age group was 30-39 (40.0%). 73.8% of respondents had a previous academic degree, mainly in the fields of sports science (36.4%) and physiotherapy (25.3%). 25.6% declared not to have a previous academic degree. The majority of respondents declared to work alone (58.4%), while the remaining declared to work in association with other professionals. The osteopaths/citizens ratio was 8.0 osteopaths/100,000 citizens. The profile of osteopaths in Italy seems to be characterised by a self-employed young adult male working mostly as a sole practitioner, who has been trained as osteopath through a part-time curriculum and had a previous degree mostly in the fields of sports science or physiotherapy. These results provide important insights into the osteopathic profession in Italy. The varied professional educational backgrounds need to be considered with regard to the implementation of a professional licensing process and future pre-registration education in the country. The number of respondents is an estimate of the actual number of Italian osteopaths. Only the completion of the regulatory process and the creation of the mandatory official register will allow to know the number of Italy based osteopaths.	[Cerritelli, Francesco; Consorti, Giacomo] Fdn COME Collaborat, Clin Human Based Res Dept, Pescara, Italy; [van Dun, Patrick L. S.] Fdn COME Collaborat, Belgium Natl Ctr, Mechelen, Belgium; [Esteves, Jorge E.] Fdn COME Collaborat, Gulf Natl Ctr, Riyadh, Saudi Arabia; [Esteves, Jorge E.] Inst Piaget, Lisbon, Portugal; [Sciomachen, Paola] Registro Osteopati Italia, Milan, Italy; [Lacorte, Eleonora; Vanacore, Nicola] Natl Inst Hlth, Rome, Italy; [Marasco, Marcello Luca] ABEos, Laquila, Italy; [Maggiani, Alberto] AIMO, Saronno, Italy; [Cavallaro, Antonio] AISERCO, Palermo, Italy; [Silvestri, Dario] ASOMI, Turin, Italy; [Zurlo, Joseph; Petracca, Marco] CERDO, Rome, Italy; [Fornari, Mauro] CIO, Parma, Italy; [Bersan, Veronica] CSDOI, Verona, Italy; [Lo Voi, Giacomo] CSOT, Rome, Italy; [Papa, Liria] ICOM, Milan, Italy; [Tamagnini, Sandro] ICOMM, Rome, Italy; [Filipazzi, Roberta] IEMO, Genoa, Italy; [Stirpe, Tatiana] Meta Osteopatia, Rome, Italy; [Colonna, Saverio] OSCE, Bologna, Italy; [Gavazzi, Alessandro] SOFI, Rome, Italy; [Manzotti, Andrea; Bergna, Andrea] SOMA, Milan, Italy; [Marco, Sbarbaro] SSOI, Turin, Italy; [Franscini, Federico] APO, Turin, Italy; [Donnaquio, Guglielmo] Osteopatia Bambini, Imperia, Italy; [Parisi, Alessandro] SIOS, Imperia, Italy; [Valente, Massimo] Tuttosteopatia, Bisceglie, Italy; [Botti, Emanuele] Adv Osteopathy, Milan, Italy	Istituto Superiore di Sanita (ISS)	Cerritelli, F (corresponding author), Fdn COME Collaborat, Clin Human Based Res Dept, Pescara, Italy.	fcerritelli@comecollaboration.org	Vanacore, Nicola/ABC-7196-2021; Cerritelli, Francesco/AAJ-5003-2020; Cerritelli, Francesco/O-8416-2015	Lacorte, Eleonora/0000-0001-8530-9207; Consorti, Giacomo/0000-0003-3085-283X; Cerritelli, Francesco/0000-0002-2963-9620; Esteves, Jorge/0000-0001-9637-678X	Registro Osteopati d'Italia, ROI-2016	Registro Osteopati d'Italia, ROI-2016	This work was supported by the Registro Osteopati d'Italia, ROI-2016 (www.roi.it) to FC. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2013, OST OST MED GLOB VIE; Bennett C, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001069; Bleakley A, 2013, MED EDUC, V47, P59, DOI 10.1111/j.1365-2923.2012.04351.x; Burke SR, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-227; CEN// TC. Project Committee, 2015, OST HEALTHC PROV MAI; Drumare J.-E., 2012, RAP OSEOSTEO OST EXC; Dubois TCJ, 2012, OSTEOPATHIC TEACHING; Dyson B, 2014, IMPROVING GEN PRACTI; Eumetra Monterosa, 2017, OP IT SULL; European Parliament, NUTS CLASS NOM TERR; Fawkes C, 2010, STANDARDISED DATA CO; Forum for Osteopathic Regulation in Europe, 2018, REGULATION; General Osteopathic Council, 2012, OST OP SURV; Guo YM, 2016, AM J PUBLIC HEALTH, V106, P1422, DOI 10.2105/AJPH.2016.303198; ISTAT, 2018, POP RES GENN 2018; Jamison JR, 1991, AUST J OSTEOPATHY, V3, P24; KPMG, 2011, OST PRACT; Landurier G, 2018, OBSERVATOIRE SOCIOEC; Licciardone JC, 2011, J AM OSTEOPATH ASSOC, V111, P670; McDonnell A, 2006, BRIT MED J, V332, P109, DOI 10.1136/bmj.332.7533.109; McGrath MC, 2015, INT J OSTEOPATH MED, V18, P130, DOI 10.1016/j.ijosm.2015.01.004; Orrock P, 2009, INT J OSTEOPATH MED, V12, P14, DOI 10.1016/j.ijosm.2008.04.002; Orrock PJ, 2009, INT J OSTEOPATH MED, V12, P128, DOI 10.1016/j.ijosm.2009.06.001; Osteopathic International Alliance, 2014, SCOP PRACT; van Dun PLS, 2016, INT J OSTEOPATH MED, V20, P3, DOI 10.1016/j.ijosm.2016.01.003; Vaucher P, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023770; Vogel S, 2008, INT J OSTEOPATH MED, P153, DOI 10.1016/j.ijosm.2008.08.007; World Health Organization, 2010, BENCHM TRAIN TRAD CO	28	19	19	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2019	14	1							e0211353	10.1371/journal.pone.0211353	http://dx.doi.org/10.1371/journal.pone.0211353			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ2YV	30682169	Green Published, Green Submitted, gold			2023-01-03	WOS:000457037500154
J	Ballo, O; Tarazzit, I; Stratmann, J; Reinheimer, C; Hogardt, M; Wichelhaus, TA; Kempf, V; Serve, H; Finkelmeier, F; Brandts, C				Ballo, Olivier; Tarazzit, Ikram; Stratmann, Jan; Reinheimer, Claudia; Hogardt, Michael; Wichelhaus, Thomas A.; Kempf, Volkhard; Serve, Hubert; Finkelmeier, Fabian; Brandts, Christian			Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemotherapy	PLOS ONE			English	Article							BLOOD-STREAM INFECTIONS; HIGH-RISK PATIENTS; HEMATOLOGICAL MALIGNANCIES; KLEBSIELLA-PNEUMONIAE; ENTEROBACTERIACEAE; IMPACT; RECOMMENDATIONS; NEUTROPENIA; THERAPY; SOCIETY	Introduction The global spread of multidrug-resistant organisms (MDRO) complicates treatment and isolation measures in hospitals and has shown to increase mortality. Patients with disease- or therapy-related immunodeficiency are especially at risk for fatal infections caused by MDRO. The impact of MDRO colonization on the clinical course of AML patients undergoing intensive induction chemotherapy a potentially curative but highly toxic treatment option- has not been systematically studied. Materials & methods 312 AML patients undergoing intensive induction chemotherapy between 2007 and 2015 were examined for MDRO colonization. Patients with evidence for MDRO before or during the hospital stay of induction chemotherapy were defined as colonized, patients who never had a positive swab for MDRO were defined as noncolonized. Results Of 312 AML patients 90 were colonized and 130 were noncolonized. Colonized patients suffered from significantly more days with fever, spent more days on the intensive care unit and had a higher median C-reactive protein value during the hospital stay. These findings did not result in a prolonged length of hospital stay or an increased mortality rate for colonized patients. However, in a subgroup analysis, patients colonized with carbapenem-resistant enterobacteriaceae (CRE) had a significantly reduced 60- and 90-day, as well as 1- and 2-year survival rates when compared to noncolonized patients. Conclusion Our analysis highlights the importance of intensive MDRO screening especially in patients with febrile neutropenia since persisting fever can be a sign of MDRO-colonization. CRE-colonized patients require special surveillance, since they seem to be at risk for death.	[Ballo, Olivier; Tarazzit, Ikram; Stratmann, Jan; Serve, Hubert; Brandts, Christian] Goethe Univ Hosp, Dept Med, Hematol Oncol, Frankfurt, Germany; [Ballo, Olivier; Serve, Hubert; Finkelmeier, Fabian; Brandts, Christian] Goethe Univ Hosp, Univ Canc Ctr Frankfurt UCT, Frankfurt, Germany; [Reinheimer, Claudia; Hogardt, Michael; Wichelhaus, Thomas A.; Kempf, Volkhard] Goethe Univ Hosp, Inst Med Microbiol & Infect Control, Frankfurt, Germany; [Reinheimer, Claudia; Hogardt, Michael; Wichelhaus, Thomas A.; Kempf, Volkhard; Serve, Hubert] Goethe Univ Hosp, Univ Ctr Infect Dis, Frankfurt, Germany; [Finkelmeier, Fabian] Goethe Univ Frankfurt, Dept Med Gastroenterol Hepatol & Endocrinol, Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt	Ballo, O; Brandts, C (corresponding author), Goethe Univ Hosp, Dept Med, Hematol Oncol, Frankfurt, Germany.; Ballo, O; Brandts, C (corresponding author), Goethe Univ Hosp, Univ Canc Ctr Frankfurt UCT, Frankfurt, Germany.	olivier.ballo@kgu.de; brandts@em.uni-frankfurt.de						Ahn S, 2011, SUPPORT CARE CANCER, V19, P1151, DOI 10.1007/s00520-010-0928-4; Atallah E, 2007, BLOOD, V110, P3547, DOI 10.1182/blood-2007-06-095844; Chen CY, 2017, INT J ANTIMICROB AG, V49, P272, DOI 10.1016/j.ijantimicag.2016.11.009; Combariza JF, 2015, SUPPORT CARE CANCER, V23, P1009, DOI 10.1007/s00520-014-2454-2; Cornejo-Juarez P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035780; Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358; Doyle D, 2012, J CLIN MICROBIOL, V50, P3877, DOI 10.1128/JCM.02117-12; Fernandez HF, 2009, NEW ENGL J MED, V361, P1249, DOI 10.1056/NEJMoa0904544; Ford CD, 2015, INFECT CONT HOSP EP, V36, P47, DOI 10.1017/ice.2014.3; Freifeld AG, 2011, CLIN INFECT DIS, V52, pE56, DOI 10.1093/cid/cir073; Gudiol C, 2013, CLIN MICROBIOL INFEC, V19, P474, DOI 10.1111/j.1469-0691.2012.03879.x; Gudiol C, 2011, J ANTIMICROB CHEMOTH, V66, P657, DOI 10.1093/jac/dkq494; HIDDEMANN W, 1987, BLOOD, V69, P744; Higgins PG, 2010, J ANTIMICROB CHEMOTH, V65, P233, DOI 10.1093/jac/dkp428; Jaiswal SR, 2018, MEDITERR J HEMATOL I, V10, DOI 10.4084/MJHID.2018.025; Krug U, 2011, DTSCH ARZTEBL INT, V108, P863, DOI 10.3238/arztebl.2011.0863; Lehouritis P, 2015, SCI REP-UK, V5, DOI 10.1038/srep14554; Liss BJ, 2012, INFECTION, V40, P613, DOI 10.1007/s15010-012-0269-y; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Lye DC, 2012, CLIN MICROBIOL INFEC, V18, P502, DOI 10.1111/j.1469-0691.2011.03606.x; Magiorakos AP, 2012, CLIN MICROBIOL INFEC, V18, P268, DOI 10.1111/j.1469-0691.2011.03570.x; Mandelli F, 2009, J CLIN ONCOL, V27, P5397, DOI 10.1200/JCO.2008.20.6490; Marini BL, 2015, SUPPORT CARE CANCER, V23, P2287, DOI 10.1007/s00520-014-2582-8; Mellinghoff SC, 2018, ANN HEMATOL, V97, P197, DOI 10.1007/s00277-017-3196-2; Micozzi A, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2297-9; Neumann S, 2013, ANN HEMATOL, V92, P433, DOI 10.1007/s00277-013-1698-0; Satlin MJ, 2014, CLIN INFECT DIS, V58, P1274, DOI 10.1093/cid/ciu052; Scheich S, 2017, BIOL BLOOD MARROW TR, V23, P1455, DOI 10.1016/j.bbmt.2017.05.016; Sostarich AM, 2008, INFECTION, V36, P31, DOI 10.1007/s15010-007-6316-4; Temkin E, 2014, ANN NY ACAD SCI, V1323, P22, DOI 10.1111/nyas.12537; Trecarichi EM, 2016, AM J HEMATOL, V91, P1076, DOI 10.1002/ajh.24489; Vehreschild MJGT, 2014, J ANTIMICROB CHEMOTH, V69, P3387, DOI 10.1093/jac/dku305; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537; WIERNIK PH, 1989, SEMIN ONCOL, V16, P25	34	22	24	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2019	14	1							e0210991	10.1371/journal.pone.0210991	http://dx.doi.org/10.1371/journal.pone.0210991			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HI4TC	30673776	Green Published, gold, Green Submitted			2023-01-03	WOS:000456442800061
J	Fokialakis, N; Alexi, X; Aligiannis, N; Boulaka, A; Meligova, AK; Lambrinidis, G; Kalpoutzakis, E; Pratsinis, H; Cheilari, A; Mitsiou, DJ; Mitakou, S; Alexis, MN				Fokialakis, Nikolas; Alexi, Xanthippi; Aligiannis, Nektarios; Boulaka, Athina; Meligova, Aggeliki K.; Lambrinidis, George; Kalpoutzakis, Eleftherios; Pratsinis, Harris; Cheilari, Antigoni; Mitsiou, Dimitra J.; Mitakou, Sofia; Alexis, Michael N.			Biological evaluation of isoflavonoids from Genista halacsyi using estrogen-target cells: Activities of glucosides compared to aglycones	PLOS ONE			English	Article							RECEPTOR-BETA; OSTEOCLASTIC DIFFERENTIATION; FLAVONOID GLYCOSIDES; GENE-EXPRESSION; PHYTOESTROGENS; BINDING; PLASMA; ABSORPTION; ALPHA; PHARMACOKINETICS	The purpose of this study was to evaluate the response of estrogen target cells to a series of isoflavone glucosides and aglycones from Genista halacsyi Heldr. The methanolic extract of aerial parts of this plant was processed using fast centrifugal partition chromatography, resulting in isolation of four archetypal isoflavones (genistein, daidzein, isoprunetin, 8-C-beta-D-glucopyranosyl-genistein) and ten derivatives thereof. 7-O-beta-D-glucopyranosyl-genistein and 7,4'-di-O-beta-D-glucopyranosyl-genistein were among the most abundant constituents of the isolate. All fourteen, except genistein, displayed low binding affinity for estrogen receptors (ER). Models of binding to ER alpha could account for the low binding affinity of monoglucosides. Genistein and its glucosides displayed full efficacy in inducing alkaline phosphatase (AIkP) in Ishikawa cells, proliferation of MCF-7 cells and ER-dependent gene expression in reporter cells at low concentrations (around 0.3 mu M). IC1182,780 fully antagonized these effects. The AIkP-inducing efficacy of the fourteen isoflavonoids was more strongly correlated with their transcriptional efficacy through ER alpha. O-monoglucosides displayed higher area under the dose-response curve (AUC) of AIkP response relative to the AUC of ER alpha-transcriptional response compared to the respective aglycones. In addition, 7-O-beta-D-glucopyranosyl-genistein and 7,4-di-O-beta-D-glucopyranosyl-genistein displayed estradiol-like efficacy in promoting differentiation of MC3T3-E1 cells to osteoblasts, while genistein was not convincingly effective in this respect. Moreover, 7,4-di-O-beta-D-glucopyranosyl-genistein suppressed lipopolysaccharide-induced tumor necrosis factor mRNA expression in RAW 264.7 cells, while 7-O-beta-D-glucopyranosyl-genistein was not convincingly effective and genistein was ineffective. However, genistein and its O-glucosides were ineffective in inhibiting differentiation of RAW 264.7 cells to osteoclasts and in protecting glutamate-challenged HT22 hippocampal neurons from oxidative stress-induced cell death. These findings suggest that 7-O-beta-D-glucopyranosyl-genistein and 7,4-di-O-beta-D-glucopyranosyl-genistein display higher estrogen-like and/or anti-inflammatory activity compared to the aglycone. The possibility of using preparations rich in O-beta-D-glucopyranosides of genistein to substitute for low-dose estrogen in formulations for menopausal symptoms is discussed.	[Fokialakis, Nikolas; Aligiannis, Nektarios; Kalpoutzakis, Eleftherios; Cheilari, Antigoni; Mitakou, Sofia] Univ Athens, Fac Pharm, Dept Pharmacognosy & Nat Prod Chem, Athens, Greece; [Alexi, Xanthippi; Boulaka, Athina; Meligova, Aggeliki K.; Mitsiou, Dimitra J.; Alexis, Michael N.] Natl Hellen Res Fdn, Inst Biol Med Chem & Biotechnol, Mol Endocrinol Program, Athens, Greece; [Lambrinidis, George] Univ Athens, Fac Pharm, Div Pharmaceut Chem, Athens, Greece; [Pratsinis, Harris] NCSR Demokritos, Inst Biosci & Applicat, Lab Cell Proliferat & Ageing, Athens, Greece	National & Kapodistrian University of Athens; National Hellenic Research Foundation; National & Kapodistrian University of Athens; National Centre of Scientific Research "Demokritos"	Fokialakis, N (corresponding author), Univ Athens, Fac Pharm, Dept Pharmacognosy & Nat Prod Chem, Athens, Greece.; Alexis, MN (corresponding author), Natl Hellen Res Fdn, Inst Biol Med Chem & Biotechnol, Mol Endocrinol Program, Athens, Greece.	fokialakis@pharm.uoa.gr; mnalexis@eie.gr	Pratsinis, Harris/G-9861-2013; Fokialakis, Nikolas/AAD-1498-2020; Cheilari, Antigoni/A-7149-2019; Alexis, Michael N./AFM-1847-2022; Lambrinidis, George/AAD-2196-2020; Mitsiou, Dimitra/AEG-6575-2022	Pratsinis, Harris/0000-0001-7550-1975; Fokialakis, Nikolas/0000-0001-7028-1870; Cheilari, Antigoni/0000-0002-6180-821X; Alexis, Michael N./0000-0002-4243-7628; Lambrinidis, George/0000-0002-2820-9338; Mitsiou, Dimitra/0000-0001-8521-4216; ALIGIANNIS, NEKTARIOS/0000-0002-3335-8135	Thales 2011 project (European Social Fund) [MIS 375617]; Thales 2011 project (National Resources) [MIS 375617]	Thales 2011 project (European Social Fund); Thales 2011 project (National Resources)	This work was supported by Thales 2011 project MIS 375617 (SERMENCO; co-funded by the European Social Fund and National Resources) to SM and MNA.	Alexi X, 2009, J STEROID BIOCHEM, V117, P159, DOI 10.1016/j.jsbmb.2009.09.006; Amer DAM, 2012, J CELL PHYSIOL, V227, P3434, DOI 10.1002/jcp.24044; Aureli M, 2009, FEBS LETT, V583, P2469, DOI 10.1016/j.febslet.2009.06.048; Barnes S, 2011, FOOD FUNCT, V2, P235, DOI 10.1039/c1fo10025d; Bedell S, 2014, J STEROID BIOCHEM, V139, P225, DOI 10.1016/j.jsbmb.2012.12.004; Biasutto L, 2007, J MED CHEM, V50, P241, DOI 10.1021/jm060912x; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chang EC, 2006, ENDOCRINOLOGY, V147, P4831, DOI 10.1210/en.2006-0563; CHANG YC, 1994, J AGR FOOD CHEM, V42, P1869, DOI 10.1021/jf00045a007; Chanteranne B, 2008, CLIN INTERV AGING, V3, P711; Chiang SS, 2013, APPL MICROBIOL BIOT, V97, P1489, DOI 10.1007/s00253-012-4675-y; Cuetara BLV, 2006, IN VITRO CELL DEV-AN, V42, P182, DOI 10.1290/0510075.1; Deecher DC, 2005, J CELL BIOCHEM, V95, P302, DOI 10.1002/jcb.20413; Dietz BM, 2016, PHARMACOL REV, V68, P1026, DOI 10.1124/pr.115.010843; Fallahi-Sichani M, 2013, NAT CHEM BIOL, V9, P708, DOI [10.1038/NCHEMBIO.1337, 10.1038/nchembio.1337]; Fokialakis N, 2004, CHEM BIOL, V11, P397, DOI 10.1016/j.chembiol.2004.02.014; Fokialakis N, 2012, BIOORGAN MED CHEM, V20, P2962, DOI 10.1016/j.bmc.2012.03.012; Ghazanfarpour M, 2015, J OBSTET GYNAECOL, V35, P783, DOI 10.3109/01443615.2015.1011104; Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002; Gritzapis AD, 2003, BREAST CANCER RES TR, V80, P1, DOI 10.1023/A:1024462416640; Halabalaki M, 2006, PLANTA MED, V72, P488, DOI 10.1055/s-2005-916261; Harborne J. B., 1994, PHYTOCHEMICAL DICT L, P313; HARBORNE JB, 1999, HDB NATURAL FLAVONOI, V2, P1; He X, 2010, BIOCHEM BIOPH RES CO, V401, P356, DOI 10.1016/j.bbrc.2010.09.053; Hosoda K, 2008, DRUG METAB DISPOS, V36, P1485, DOI 10.1124/dmd.108.021006; Huang SG, 2012, ASSAY DRUG DEV TECHN, V10, P88, DOI 10.1089/adt.2011.0388; Izumi T, 2000, J NUTR, V130, P1695, DOI 10.1093/jn/130.7.1695; Ji GY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053101; Jiang QA, 2010, J MED CHEM, V53, P6153, DOI 10.1021/jm100610w; Jiang Y, 2013, FASEB J, V27, P4406, DOI 10.1096/fj.13-234617; Jimenez M, 1999, J AGR FOOD CHEM, V47, P56, DOI 10.1021/jf9805653; Jin JS, 2008, BIOL PHARM BULL, V31, P1621, DOI 10.1248/bpb.31.1621; Jung ME, 2005, J NEUROCHEM, V95, P745, DOI 10.1111/j.1471-4159.2005.03424.x; JURD L, 1972, PHYTOCHEMISTRY, V11, P2535, DOI 10.1016/S0031-9422(00)88532-5; Kang JS, 2005, BIOCHEM PHARMACOL, V71, P136, DOI 10.1016/j.bcp.2005.10.009; Kanno S, 2004, TOXICOLOGY, V196, P137, DOI 10.1016/j.tox.2003.12.002; Katsanou ES, 2007, J STEROID BIOCHEM, V104, P228, DOI 10.1016/j.jsbmb.2007.03.028; Kim JL, 2012, J CELL BIOCHEM, V113, P247, DOI 10.1002/jcb.23351; KINJO JE, 1987, CHEM PHARM BULL, V35, P4846; Kottra G, 2007, J PHARMACOL EXP THER, V322, P829, DOI 10.1124/jpet.107.124040; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lambrinidis G, 2006, ENVIRON CHEM LETT, V4, P159, DOI 10.1007/s10311-006-0065-y; Lee SH, 2014, INT J MOL SCI, V15, P10605, DOI 10.3390/ijms150610605; Maher P, 2007, BRAIN RES, V1173, P117, DOI 10.1016/j.brainres.2007.07.061; Manas ES, 2004, STRUCTURE, V12, P2197, DOI 10.1016/j.str.2004.09.015; MARKIEWICZ L, 1993, J STEROID BIOCHEM, V45, P399, DOI 10.1016/0960-0760(93)90009-L; Marston A, 2006, J CHROMATOGR A, V1112, P181, DOI 10.1016/j.chroma.2005.10.018; Maubach J, 2003, J CHROMATOGR B, V784, P137, DOI 10.1016/S1570-0232(02)00789-4; Morito K, 2001, BIOL PHARM BULL, V24, P351, DOI 10.1248/bpb.24.351; Mortensen A, 2009, MOL NUTR FOOD RES, V53, pS266, DOI 10.1002/mnfr.200800478; Murota K, 2000, ARCH BIOCHEM BIOPHYS, V384, P391, DOI 10.1006/abbi.2000.2123; Nemeth K, 2003, EUR J NUTR, V42, P29, DOI 10.1007/s00394-003-0397-3; Nettles KW, 2007, EMBO REP, V8, P563, DOI 10.1038/sj.embor.7400963; Panagiotidou E, 2014, J ENDOCRINOL, V220, P207, DOI 10.1530/JOE-13-0416; Pardo C, 2004, PLANT SYST EVOL, V244, P93, DOI 10.1007/s00606-003-0091-1; Park K, 2014, INT J MOL MED, V33, P178, DOI 10.3892/ijmm.2013.1557; Pfitscher A, 2008, J STEROID BIOCHEM, V112, P87, DOI 10.1016/j.jsbmb.2008.08.007; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Powell E, 2008, P NATL ACAD SCI USA, V105, P19012, DOI 10.1073/pnas.0807274105; QUARLES LD, 1992, J BONE MINER RES, V7, P683; Thai QD, 2016, PHYTOCHEMISTRY, V130, P170, DOI 10.1016/j.phytochem.2016.04.006; Rahn DD, 2014, OBSTET GYNECOL, V124, P1147, DOI 10.1097/AOG.0000000000000526; Richelle M, 2002, J NUTR, V132, P2587, DOI 10.1093/jn/132.9.2587; Rufer CE, 2008, AM J CLIN NUTR, V87, P1314, DOI 10.1093/ajcn/87.5.1314; Setchell KDR, 2002, AM J CLIN NUTR, V76, P447, DOI 10.1093/ajcn/76.2.447; Sherman W, 2006, J MED CHEM, V49, P534, DOI 10.1021/jm050540c; Skretas G, 2007, J AM CHEM SOC, V129, P8443, DOI 10.1021/ja067754j; Soukup ST, 2014, ANAL BIOANAL CHEM, V406, P6007, DOI 10.1007/s00216-014-8034-y; Srivastava S, 1999, J CLIN INVEST, V104, P503, DOI 10.1172/JCI7094; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Stuenkel CA, 2015, J CLIN ENDOCR METAB, V100, P3975, DOI 10.1210/jc.2015-2236; Sucontphunt A, 2011, J NAT MED-TOKYO, V65, P1, DOI 10.1007/s11418-010-0442-5; Tan Shirlee, 2001, Current Topics in Medicinal Chemistry, V1, P497, DOI 10.2174/1568026013394741; Tchourrachoua J, 2016, J STEROID BIOCHEM, V158, P138, DOI 10.1016/j.jsbmb.2015.12.015; THERON EJ, 1994, IN VITRO CELL DEV-AN, V30A, P115, DOI 10.1007/BF02631403; Villalonga-Barber C, 2011, BIOORGAN MED CHEM, V19, P339, DOI 10.1016/j.bmc.2010.11.018; WATANABE K, 1993, CHEM PHARM BULL, V41, P394, DOI 10.1248/cpb.41.394; WENKERT E, 1977, PHYTOCHEMISTRY, V16, P1811, DOI 10.1016/0031-9422(71)85095-1; Zhang DW, 2012, BIOCHIMIE, V94, P2514, DOI 10.1016/j.biochi.2012.06.033	79	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2019	14	1							e0210247	10.1371/journal.pone.0210247	http://dx.doi.org/10.1371/journal.pone.0210247			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG7HM	30620769	Green Published, Green Submitted, gold			2023-01-03	WOS:000455161300025
J	Huang, CW; Hwang, IH; Lee, YS; Hwang, SJ; Ko, SG; Chen, FP; Jang, BH				Huang, Ching-Wen; Hwang, I-Hsuan; Lee, Ye-seul; Hwang, Shinn-Jang; Ko, Seong-Gyu; Chen, Fang-Pey; Jang, Bo-Hyoung			Utilization patterns of traditional medicine in Taiwan and South Korea by using national health insurance data in 2011	PLOS ONE			English	Article								Background The growing popularity of traditional medicine (TM) is reflected in the increasing trend for its use worldwide. Many people are turning to use TM as a complementary or integrative treatment. The aim of this study is to present the first nationwide report describing the use of TM in two countries (South Korea and Taiwan). Materials and methods To present the TM utilization patterns between South Korea and Taiwan, we analyzed data from the National Health Insurance cohorts in each country, each of which has approximately one million inhabitants. Results In total, 261,478 (25.5%) of 1,025,340 people in South Korea and 260,529 (26.8%) of 970,866 people in Taiwan used TM services at least once under the National Health Insurance in 2011. Using multivariable logistic regression, TM users in South Korea were significantly more likely to be female, 61-80 years of age and individuals with a high income, and those in Taiwan were significantly more likely to be female, 21-40 years of age and individuals with a middle income. The two countries showed similar utilization patterns in visit seasons. People visited TM clinics more frequently than TM hospitals in both countries. The most common TM treatment in South Korea was acupuncture, whereas in Taiwan, various powdered Chinese herbal preparations were the most commonly used treatment. The most common diseases for people seeking TM services were musculoskeletal system and connective tissue diseases in South Korea and Symptoms, signs, and ill-defined conditions in Taiwan. Conclusion According to the National Health Insurance database, about one fourth of the NHI beneficiaries of South Korea and Taiwan had TM use in 2011. Different TM utilization patterns existed between South Korea and Taiwan, which might be due to the differences in insurance coverage between the two countries.	[Huang, Ching-Wen; Ko, Seong-Gyu; Jang, Bo-Hyoung] Kyung Hee Univ, Dept Prevent Med, Coll Korean Med, Seoul, South Korea; [Huang, Ching-Wen; Ko, Seong-Gyu] Kyung Hee Univ, Grad Sch, Dept Sci Korean Med, 26 Kyungheedae Ro, Seoul, South Korea; [Hwang, I-Hsuan] Cheng Hsin Gen Hosp, Ctr Qual Control, Taipei, Taiwan; [Lee, Ye-seul] Gachon Univ, Coll Korean Med, Dept Anat & Acupoint, Seongnam, South Korea; [Hwang, Shinn-Jang] Taipei Vet Gen Hosp, Dept Family Med, Taipei, Taiwan; [Hwang, Shinn-Jang] Natl Yang Ming Univ, Sch Med, Dept Family Med, Taipei, Taiwan; [Chen, Fang-Pey] Taipei Vet Gen Hosp, Ctr Tradit Med, Taipei, Taiwan; [Chen, Fang-Pey] Natl Yang Ming Univ, Sch Med, Inst Tradit Med, Taipei, Taiwan	Kyung Hee University; Kyung Hee University; Cheng Hsin General Hospital; Gachon University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University	Jang, BH (corresponding author), Kyung Hee Univ, Dept Prevent Med, Coll Korean Med, Seoul, South Korea.; Chen, FP (corresponding author), Taipei Vet Gen Hosp, Ctr Tradit Med, Taipei, Taiwan.; Chen, FP (corresponding author), Natl Yang Ming Univ, Sch Med, Inst Tradit Med, Taipei, Taiwan.	fpchen@vghtpe.gov.tw; bhjang@khu.ac.kr	Jang, Bo-Hyoung/ABF-2923-2020	Jang, Bo-Hyoung/0000-0002-2141-3483; Lee, Ye-Seul/0000-0001-6127-5401	Basic Science Research Program through the National Research Foundation of Korea [NRF-2018R1D1A1A02077145]	Basic Science Research Program through the National Research Foundation of Korea(National Research Foundation of Korea)	This work was supported by the Basic Science Research Program through the National Research Foundation of Korea. (No. NRF-2018R1D1A1A02077145).	Association of Korean Oriental Medicine Institute of Oriental Medicine Pusan National University School of Korean Medicine, 2012, YB TRAD KOR MED 2011; Chen FP, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-26; Hamsten A., 2014, CAN MED ASSOC J, V186, P9; Hsing AW, 2015, JAMA INTERN MED, V175, P1527, DOI 10.1001/jamainternmed.2015.3540; Huang TP, 2014, COMPLEMENT THER MED, V22, P500, DOI 10.1016/j.ctim.2014.04.002; Ishikawa H., 2014, JAP MED ASS J, V54, P192; Lai JN, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/891893; Leung SW, 2016, EVIDENCE BASED RES M; Lim B, 2013, INTEGR MED RES, V2, P81, DOI 10.1016/j.imr.2013.06.004; Ministry of Health and Welfare, 2011, STAT ANN REP MED CAR; Ministry of Health and Welfare, NHI W MED INP US TRA; Ministry of Health and Welfare, 2016, HEALTH AND NATIONAL; Ministry of Health and Welfare, 2016, 3 FOST DEV PLAN KOR; Park HL, 2012, EVID-BASED COMPL ALT, V2012, DOI [10.1155/2012/429103, DOI 10.1155/2012/429103]; Snadal Jon, 2014, Japan Med Assoc J, V57, P68; World Health Organization, 2016, ICD 11 BETA DRAFT JO; Yang PR, 2015, J ETHNOPHARMACOL, V169, P328, DOI 10.1016/j.jep.2015.04.046; Yang SH, 2001, INT IMMUNOPHARMACOL, V1, P1173, DOI 10.1016/S1567-5769(01)00051-0	18	19	19	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2018	13	12							e0208569	10.1371/journal.pone.0208569	http://dx.doi.org/10.1371/journal.pone.0208569			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF7KM	30589852	gold, Green Submitted, Green Published			2023-01-03	WOS:000454418200007
J	Hellberg, M; Hoglund, P; Svensson, P; Clyne, N				Hellberg, Matthias; Hoglund, Peter; Svensson, Philippa; Clyne, Naomi			Comparing effects of 4 months of two self-administered exercise training programs on physical performance in patients with chronic kidney disease: RENEXC - A randomized controlled trial	PLOS ONE			English	Article							GLOMERULAR-FILTRATION-RATE; AEROBIC EXERCISE; DIALYSIS; ASSOCIATION; CKD; PREDIALYSIS; MORTALITY; INJURIES; CAPACITY; BALANCE	Background Exercise training is recommended to patients with chronic kidney disease (CKD). However, the level of evidence is still low. This randomized controlled trial (RCT) compared two different and self-administered exercise training programs in a representative CKD population. Methods This single centre RCT included 151 non-dialysis dependent CKD patients, irrespective of age and comorbidity. Self-administered exercise training of 150 minutes per week was prescribed for 4 months and consisted of 60 minutes endurance training in combination with 90 minutes of either strength or balance training (strength versus balance group). Overall endurance (6-minute walk-test (6-MWT), stair climbing), muscular endurance (30-seconds sit-to-stand (30-STS), heel rises and toe lifts, handgrip (HGS) and isometric quadriceps (IQS) strength, balance (functional reach (FR) and Berg's balance scale (BBS)) and fine motor skills (Moberg's picking up test (MPUT)) were measured at baseline and after 4 months. Intention to treat analyses with mixed models was used. Results 53 women and 98 men, mean age 66 +/- 14: range 19 to 87 years, eGFR 20 +/- 7: range 8 to 48 ml/min/1.73m(2) participated. The strength group (n = 76) improved significantly in 6MWT, stair climbing, 30-STS, heel rises right and left, toe lifts right, IQS right and left, and MPUT with closed eyes with the right and left hand. The balance group (n = 75) improved significantly in heel rises right and left, IQS left, BBS and left-handed MPUT with open and closed eyes. A significant effect between the groups was found for IQS right. Conclusions Two different exercise training programs, consisting of endurance in combination with either strength or balance exercise training, improved or maintained overall endurance, muscular strength and endurance, balance and fine motor skills after 4 months of 150 minutes/week self-administered exercise training in a representative CKD population, regardless of age and comorbidity.	[Hellberg, Matthias; Svensson, Philippa; Clyne, Naomi] Lund Univ, Skane Univ Hosp, Inst Clin Sci, Dept Nephrol,Fac Med, Lund, Sweden; [Hoglund, Peter] Lund Univ, Skane Univ Hosp, Inst Lab Med, Dept Clin Chem & Pharmacol,Fac Med, Lund, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital	Hellberg, M (corresponding author), Lund Univ, Skane Univ Hosp, Inst Clin Sci, Dept Nephrol,Fac Med, Lund, Sweden.	MatthiasHellberg@gmx.de		Clyne, Naomi/0000-0001-5284-4406; Hellberg, Matthias/0000-0001-6248-1020	Birgit and Sven-Hakan Ohlsson's trust; Skane University Hospital trust; Skane regional funding; Kidney trust (Njurstiftelsen)	Birgit and Sven-Hakan Ohlsson's trust; Skane University Hospital trust; Skane regional funding; Kidney trust (Njurstiftelsen)	This work was supported by: 1. Birgit and Sven-Hakan Ohlsson's trust, NC; 2. Skane University Hospital trust, NC; 3. Skane regional funding, NC, MHG; 4. Kidney trust (Njurstiftelsen), NC. There are no grant numbers for any of the sponsors. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baria F, 2014, NEPHROL DIAL TRANSPL, V29, P857, DOI 10.1093/ndt/gft529; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Bowling CB, 2016, CLIN J AM SOC NEPHRO, V11, P1236, DOI 10.2215/CJN.11111015; CLYNE N, 1987, ACTA MED SCAND, V222, P183; Clyne N, 2016, NEPHROLOGY, V21, P1047, DOI 10.1111/nep.12706; Cook WL, 2006, CLIN J AM SOC NEPHRO, V1, P1197, DOI 10.2215/CJN.01650506; Davies SJ, 2002, NEPHROL DIAL TRANSPL, V17, P1085, DOI 10.1093/ndt/17.6.1085; Eidemak I, 1997, NEPHRON, V75, P36, DOI 10.1159/000189497; Fitts SS, 1999, NEPHRON, V82, P115, DOI 10.1159/000045386; Greenwood SA, 2012, NEPHROL DIAL TRANSPL, V27, P126, DOI 10.1093/ndt/gfs272; Grubb A, 2010, SCAND J CLIN LAB INV, V70, P65, DOI 10.3109/00365511003642535; Headley S, 2014, AM J KIDNEY DIS, V64, P222, DOI 10.1053/j.ajkd.2014.02.022; Heiwe S, 2001, NEPHRON, V88, P48, DOI 10.1159/000045959; Heiwe S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003236.pub2; Hellberg M, 2017, NEPHROLOGY, V22, P513, DOI 10.1111/nep.12810; Hellberg M, 2014, NEPHRON CLIN PRACT, V126, P116, DOI 10.1159/000358431; Hollmann vWS, 2009, GRUNDLAGEN KORPERLIC; Howden EJ, 2015, AM J KIDNEY DIS, V65, P583, DOI 10.1053/j.ajkd.2014.09.017; Kouidi E, 2004, Clin Nephrol, V61 Suppl 1, pS31; Manfredini F, 2017, J AM SOC NEPHROL, V28, P1259, DOI 10.1681/ASN.2016030378; Mustata S, 2011, INT UROL NEPHROL, V43, P1133, DOI 10.1007/s11255-010-9823-7; Roshanravan B, 2013, J AM SOC NEPHROL, V24, P822, DOI 10.1681/ASN.2012070702; Stack AG, 2005, AM J KIDNEY DIS, V45, P690, DOI 10.1053/j.ajkd.2004.12.013; Tentori F, 2010, NEPHROL DIAL TRANSPL, V25, P3050, DOI 10.1093/ndt/gfq138; Van Craenenbroeck EM, 2015, AM J PHYSIOL-HEART C, V309, pH1876, DOI 10.1152/ajpheart.00341.2015; Watson EL, 2015, AM J KIDNEY DIS, V66, P249, DOI 10.1053/j.ajkd.2014.10.019; Wen CP, 2012, LANCET, V380, P192, DOI 10.1016/S0140-6736(12)60954-4; Zhou YA, 2018, NEPHROL DIAL TRANSPL, V33, P342, DOI 10.1093/ndt/gfw466	28	6	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2018	13	12							e0207349	10.1371/journal.pone.0207349	http://dx.doi.org/10.1371/journal.pone.0207349			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF0HP	30571753	Green Published, gold, Green Submitted			2023-01-03	WOS:000453841700007
J	Chen, G; Zhang, YQ; Qadri, YJ; Serhan, CN; Ji, RR				Chen, Gang; Zhang, Yu-Qiu; Qadri, Yawar J.; Serhan, Charles N.; Ji, Ru-Rong			Microglia in Pain: Detrimental and Protective Roles in Pathogenesis and Resolution of Pain	NEURON			English	Review							PERIPHERAL-NERVE INJURY; ACTIVATED PROTEIN-KINASE; SPINAL-CORD MICROGLIA; P38 MAP KINASE; RESOLVING LIPID MEDIATORS; LONG-TERM POTENTIATION; RECEPTOR UP-REGULATION; TOLL-LIKE RECEPTORS; NEUROPATHIC PAIN; DORSAL-HORN	The previous decade has seen a rapid increase in microglial studies on pain, with a unique focus on microgliosis in the spinal cord after nerve injury and neuropathic pain. Numerous signaling molecules are altered in microglia and contribute to the pathogenesis of pain. Here, we discuss how microglial signaling regulates spinal cord synaptic plasticity in acute and chronic pain conditions with different degrees and variations of microgliosis. We highlight that microglial mediators such as pro- and anti-inflammatory cytokines are powerful neuromodulators that regulate synaptic transmission and pain via neuron-glial interactions. We also reveal an emerging role of microglia in the resolution of pain, in part via specialized pro-resolving mediators including resolvins, protectins, and maresins. We also discuss a possible role of microglia in chronic itch.	[Chen, Gang] Nantong Univ, Coinnovat Ctr Neuroregenerat, Key Lab Neuroregenerat Jiangsu, Nantong 226001, Jiangsu, Peoples R China; [Chen, Gang] Nantong Univ, Coinnovat Ctr Neuroregenerat, Minist Educ, Nantong 226001, Jiangsu, Peoples R China; [Zhang, Yu-Qiu] Fudan Univ, Collaborat Innovat Ctr Brain Sci, Inst Brain Sci, Inst Neurobiol, Shanghai 200032, Peoples R China; [Zhang, Yu-Qiu] Fudan Univ, Collaborat Innovat Ctr Brain Sci, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China; [Qadri, Yawar J.; Ji, Ru-Rong] Duke Univ, Med Ctr, Dept Anesthesiol, Ctr Translat Pain Med, Durham, NC 27710 USA; [Serhan, Charles N.] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Hale Transformat Med, Ctr Expt Therapeut & Reperfus Injury, 75 Francis St, Boston, MA 02115 USA; [Serhan, Charles N.] Harvard Med Sch, Boston, MA 02115 USA; [Ji, Ru-Rong] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Nantong University; Nantong University; Fudan University; Fudan University; Duke University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Duke University	Ji, RR (corresponding author), Duke Univ, Med Ctr, Dept Anesthesiol, Ctr Translat Pain Med, Durham, NC 27710 USA.; Ji, RR (corresponding author), Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA.	ru-rong.ji@duke.edu	Zhang, Yu-Qiu/AAS-2516-2020; Zhang, Yu-Qiu/CAF-6295-2022; Ji, Ru-Rong/L-7070-2017	Ji, Ru-Rong/0000-0002-9355-3688; Chen, Gang/0000-0003-3669-5687; Qadri, Yawar/0000-0003-2138-4018	National Key Research and Development Program of China [2017YFA0104704]; China Science Fund [31420103903]; NIH [P01GM095467, R01 NS87988, DE17794, DE22743, T32 GM08600]; Duke Health Scholars fund; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE022743, R01DE017794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008600, P01GM095467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS087988] Funding Source: NIH RePORTER	National Key Research and Development Program of China; China Science Fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Duke Health Scholars fund; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study is supported in part by The National Key Research and Development Program of China (2017YFA0104704 to G.C.), China Science Fund (31420103903 to Y.-Q.Z.), and NIH grants (R01 NS87988, DE17794, and DE22743 to R.-R.J.). Y.J.Q. is supported by NIH grant T32 GM08600 and the Duke Health Scholars fund. C.N.S. is supported by NIH grant P01GM095467.	Abbadie C, 2003, P NATL ACAD SCI USA, V100, P7947, DOI 10.1073/pnas.1331358100; Ajami B, 2018, NAT NEUROSCI, V21, P541, DOI 10.1038/s41593-018-0100-x; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Asatryan A, 2017, J BIOL CHEM, V292, P12390, DOI 10.1074/jbc.R117.783076; Bang SS, 2018, J CLIN INVEST, V128, P3568, DOI 10.1172/JCI99888; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Barragan-Iglesias P, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-29; Batti L, 2016, CELL REP, V15, P2608, DOI 10.1016/j.celrep.2016.05.039; Bazan NG, 2010, J LIPID RES, V51, P2018, DOI 10.1194/jlr.R001131; Beggs S, 2007, BRAIN BEHAV IMMUN, V21, P624, DOI 10.1016/j.bbi.2006.10.017; Berta T, 2016, J DENT RES, V95, P1124, DOI 10.1177/0022034516653604; Berta T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08865-3; Berta T, 2014, J CLIN INVEST, V124, P1173, DOI 10.1172/JCI72230; Biber K, 2011, EMBO J, V30, P1864, DOI 10.1038/emboj.2011.89; Bisicchia E, 2018, MOL NEUROBIOL, V55, P6894, DOI 10.1007/s12035-018-0889-z; Boumechache M, 2009, J BIOL CHEM, V284, P13446, DOI 10.1074/jbc.M901255200; Braz J, 2014, NEURON, V82, P522, DOI 10.1016/j.neuron.2014.01.018; Brown DD, 1944, ARCH NEURO PSYCHIATR, V51, P216; Burma NE, 2017, NAT MED, V23, P355, DOI 10.1038/nm.4281; Calvo M, 2011, GLIA, V59, P554, DOI 10.1002/glia.21124; Calvo M, 2010, J NEUROSCI, V30, P5437, DOI 10.1523/JNEUROSCI.5169-09.2010; Chamessian A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25110-7; Chen G, 2018, NEUROSCI BULL, V34, P98, DOI 10.1007/s12264-017-0145-y; Chen G, 2015, J CLIN INVEST, V125, P3226, DOI 10.1172/JCI80883; Chen G, 2014, BRAIN, V137, P2193, DOI 10.1093/brain/awu140; Chen ML, 2012, J PAIN, V13, P945, DOI 10.1016/j.jpain.2012.06.007; Chiang N, 2017, J IMMUNOL, V198, P842, DOI 10.4049/jimmunol.1601650; Chiang N, 2015, J EXP MED, V212, P1203, DOI 10.1084/jem.20150225; Chirila AM, 2014, P NATL ACAD SCI USA, V111, P8263, DOI 10.1073/pnas.1401013111; Clark AK, 2007, P NATL ACAD SCI USA, V104, P10655, DOI 10.1073/pnas.0610811104; Clark AK, 2015, J NEUROSCI, V35, P4552, DOI 10.1523/JNEUROSCI.2061-14.2015; Clark AK, 2012, EXP NEUROL, V234, P283, DOI 10.1016/j.expneurol.2011.09.012; Clark AK, 2011, CURR PHARM BIOTECHNO, V12, P1707; Clark AK, 2009, J NEUROSCI, V29, P6945, DOI 10.1523/JNEUROSCI.0828-09.2009; Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591; Corder G, 2017, NAT MED, V23, P164, DOI 10.1038/nm.4262; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; Coull JAM, 2003, NATURE, V424, P938, DOI 10.1038/nature01868; Crotti A, 2016, IMMUNITY, V44, P505, DOI 10.1016/j.immuni.2016.02.013; Cui Y, 2006, BRAIN RES, V1069, P235, DOI 10.1016/j.brainres.2005.11.066; Curtin CM, 2017, J HAND SURG-AM, V42, P166, DOI [10.1016/j.jhsa.2016.12.011, 10.1016/j.jhsa.2016.12,011]; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; De Biase LM, 2017, NEURON, V95, P341, DOI 10.1016/j.neuron.2017.06.020; Dominguez E, 2008, J NEUROCHEM, V107, P50, DOI 10.1111/j.1471-4159.2008.05566.x; Dong XT, 2018, NEURON, V98, P482, DOI 10.1016/j.neuron.2018.03.023; Duan B, 2018, NEUROSCI BULL, V34, P186, DOI 10.1007/s12264-017-0136-z; Duan B, 2014, CELL, V159, P1417, DOI 10.1016/j.cell.2014.11.003; Dukhinova M, 2018, METHODS MOL BIOL, V1745, P167, DOI 10.1007/978-1-4939-7680-5_10; Echeverry S, 2008, PAIN, V135, P37, DOI 10.1016/j.pain.2007.05.002; ERIKSSON NP, 1993, EXP BRAIN RES, V96, P19, DOI 10.1007/BF00230435; Erny D, 2015, NAT NEUROSCI, V18, P965, DOI 10.1038/nn.4030; Febinger HY, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0386-5; Ferrini F, 2013, NAT NEUROSCI, V16, P183, DOI 10.1038/nn.3295; Fu KY, 1999, BRAIN RES, V825, P59, DOI 10.1016/S0006-8993(99)01186-5; Fuger P, 2017, NAT NEUROSCI, V20, P1371, DOI 10.1038/nn.4631; Fukagawa H, 2013, J ANESTH, V27, P93, DOI 10.1007/s00540-012-1469-4; Furube E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20643-3; Galan-Arriero I, 2014, PAIN, V155, P2188, DOI 10.1016/j.pain.2014.08.030; Gao YJ, 2009, J NEUROSCI, V29, P4096, DOI 10.1523/JNEUROSCI.3623-08.2009; GILMORE SA, 1975, ANAT REC, V181, P799, DOI 10.1002/ar.1091810411; GILMORE SA, 1979, ANAT REC, V194, P369, DOI 10.1002/ar.1091940305; Gilroy DW, 2005, PROSTAG LEUKOTR ESS, V73, P203, DOI 10.1016/j.plefa.2005.05.007; Grace PM, 2018, EXP NEUROL, V304, P125, DOI 10.1016/j.expneurol.2018.03.005; Grace PM, 2016, P NATL ACAD SCI USA, V113, pE3441, DOI 10.1073/pnas.1602070113; Griffin RS, 2007, J NEUROSCI, V27, P8699, DOI 10.1523/JNEUROSCI.2018-07.2007; Gruber-Schoffnegger D, 2013, J NEUROSCI, V33, P6540, DOI 10.1523/JNEUROSCI.5087-12.2013; Gu N, 2016, CELL REP, V16, P605, DOI 10.1016/j.celrep.2016.06.018; Guan ZH, 2016, NAT NEUROSCI, V19, P94, DOI 10.1038/nn.4189; Gwak YS, 2012, EXP NEUROL, V234, P362, DOI 10.1016/j.expneurol.2011.10.010; Hains BC, 2006, J NEUROSCI, V26, P4308, DOI 10.1523/JNEUROSCI.0003-06.2006; Hald A, 2009, EUR J PAIN, V13, P138, DOI 10.1016/j.ejpain.2008.03.014; Han QJ, 2018, NEURON, V99, P449, DOI 10.1016/j.neuron.2018.06.039; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hansen RR, 2011, PAIN, V152, P1766, DOI 10.1016/j.pain.2011.03.024; Harrison JL, 2015, BRAIN BEHAV IMMUN, V47, P131, DOI 10.1016/j.bbi.2015.01.001; Harvey RJ, 2004, SCIENCE, V304, P884, DOI 10.1126/science.1094925; Hathway GJ, 2009, PAIN, V144, P110, DOI 10.1016/j.pain.2009.03.022; Heppner FL, 2015, NAT REV NEUROSCI, V16, P358, DOI 10.1038/nrn3880; Hildebrand ME, 2016, CELL REP, V17, P2753, DOI 10.1016/j.celrep.2016.11.024; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Honore P, 2000, NEUROSCIENCE, V98, P585, DOI 10.1016/S0306-4522(00)00110-X; Horvath RJ, 2010, NEUROSCIENCE, V169, P843, DOI 10.1016/j.neuroscience.2010.05.030; Hu LY, 2018, BRAIN BEHAV IMMUN, V68, P132, DOI 10.1016/j.bbi.2017.10.011; Hua XY, 2005, EUR J NEUROSCI, V22, P2431, DOI 10.1111/j.1460-9568.2005.04451.x; Hutchinson MR, 2010, BRAIN BEHAV IMMUN, V24, P83, DOI 10.1016/j.bbi.2009.08.004; Inoue K, 2018, NAT REV NEUROSCI, V19, P138, DOI 10.1038/nrn.2018.2; Ji RR, 2003, TRENDS NEUROSCI, V26, P696, DOI 10.1016/j.tins.2003.09.017; Ji RR, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-33; Ji RR, 2018, ANESTHESIOLOGY, V129, P343, DOI 10.1097/ALN.0000000000002130; Ji RR, 2014, NAT REV DRUG DISCOV, V13, P533, DOI 10.1038/nrd4334; Ji RR, 2013, PAIN, V154, pS10, DOI 10.1016/j.pain.2013.06.022; Ji RR, 2011, TRENDS NEUROSCI, V34, P599, DOI 10.1016/j.tins.2011.08.005; Ji RR, 2009, TRENDS PHARMACOL SCI, V30, P336, DOI 10.1016/j.tips.2009.04.002; Jin SX, 2003, J NEUROSCI, V23, P4017; Kambrun C, 2018, CELL REP, V22, P2886, DOI 10.1016/j.celrep.2018.02.068; Kanda H, 2013, GLIA, V61, P943, DOI 10.1002/glia.22487; Kantarci A, 2018, EXP NEUROL, V300, P111, DOI 10.1016/j.expneurol.2017.11.005; Katsura H, 2006, J NEUROSCI, V26, P8680, DOI 10.1523/JNEUROSCI.1771-06.2006; Kawasaki Y, 2008, J NEUROSCI, V28, P5189, DOI 10.1523/JNEUROSCI.3338-07.2008; Kawasaki Y, 2008, NAT MED, V14, P331, DOI 10.1038/nm1723; Kim D, 2010, P NATL ACAD SCI USA, V107, P14851, DOI 10.1073/pnas.1009926107; Kobayashi K, 2008, J NEUROSCI, V28, P2892, DOI 10.1523/JNEUROSCI.5589-07.2008; Kobayashi K, 2012, GLIA, V60, P1529, DOI 10.1002/glia.22373; Kobayashi K, 2011, NEUROSCI LETT, V504, P57, DOI 10.1016/j.neulet.2011.08.058; Kobayashi M, 2016, J NEUROSCI, V36, P11138, DOI 10.1523/JNEUROSCI.1238-16.2016; Kohno T, 2008, J NEUROSCI, V28, P4533, DOI 10.1523/JNEUROSCI.5349-07.2008; Krishnamoorthy S, 2012, AM J PATHOL, V180, P2018, DOI 10.1016/j.ajpath.2012.01.028; Kronschlager MT, 2016, SCIENCE, V354, P1144, DOI 10.1126/science.aah5715; LaMotte RH, 2014, NAT REV NEUROSCI, V15, P19, DOI 10.1038/nrn3641; Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012; Leduc-Pessah H, 2017, J NEUROSCI, V37, P10154, DOI 10.1523/JNEUROSCI.0852-17.2017; Li Y, 2014, J PAIN, V15, P712, DOI 10.1016/j.jpain.2014.04.001; Liu MJ, 2017, J PAIN RES, V10, P417, DOI 10.2147/JPR.S124326; Liu T, 2016, PAIN, V157, P806, DOI 10.1097/j.pain.0000000000000439; Liu T, 2013, PFLUG ARCH EUR J PHY, V465, P1671, DOI 10.1007/s00424-013-1284-2; Liu T, 2012, NEUROSCI BULL, V28, P131, DOI 10.1007/s12264-012-1219-5; Loggia ML, 2015, BRAIN, V138, P604, DOI 10.1093/brain/awu377; Lu Y, 2013, J CLIN INVEST, V123, P4050, DOI 10.1172/JCI70026; Luo C, 2014, TRENDS NEUROSCI, V37, P343, DOI 10.1016/j.tins.2014.04.002; Luo X, 2018, BRAIN BEHAV IMMUN, V72, P34, DOI 10.1016/j.bbi.2017.11.007; Mantyh PW, 1997, SCIENCE, V278, P275, DOI 10.1126/science.278.5336.275; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; Mao-Ying QL, 2012, MOL BRAIN, V5, DOI 10.1186/1756-6606-5-16; Marcheselli VL, 2010, PROSTAG LEUKOTR ESS, V82, P27, DOI 10.1016/j.plefa.2009.10.010; Martinez V, 2013, PAIN, V154, P1197, DOI 10.1016/j.pain.2013.03.028; Martini AC, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0540-8; Masuda T, 2015, J PHARMACOL SCI, V128, P216, DOI 10.1016/j.jphs.2015.08.002; Masuda T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4771; Masuda T, 2012, CELL REP, V1, P334, DOI 10.1016/j.celrep.2012.02.014; Mathys H, 2017, CELL REP, V21, P366, DOI 10.1016/j.celrep.2017.09.039; Matsushita K, 2014, ANESTHESIOLOGY, V120, P1491, DOI 10.1097/ALN.0000000000000190; McKelvey R, 2015, J NEUROSCI, V35, P457, DOI 10.1523/JNEUROSCI.2315-14.2015; McMahon SB, 2009, NEURON, V64, P46, DOI 10.1016/j.neuron.2009.09.033; Meng XW, 2017, NEUROSCI RES, V125, P37, DOI 10.1016/j.neures.2017.06.006; Miao XH, 2018, NEUROSCI BULL, V34, P42, DOI 10.1007/s12264-017-0124-3; Mogil JS, 2012, NAT REV NEUROSCI, V13, P859, DOI 10.1038/nrn3360; Moore KA, 2002, J NEUROSCI, V22, P6724, DOI 10.1523/jneurosci.22-15-06724.2002; Moss A, 2007, PAIN, V128, P215, DOI 10.1016/j.pain.2006.09.018; Mosser CA, 2017, PROG NEUROBIOL, V149-150, P1, DOI 10.1016/j.pneurobio.2017.01.002; Nicotra L, 2012, EXP NEUROL, V234, P316, DOI 10.1016/j.expneurol.2011.09.038; Nieto FR, 2015, ARTHRITIS RHEUMATOL, V67, P1668, DOI 10.1002/art.39082; Norris PC, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aan1471; Obata K, 2007, J NEUROCHEM, V102, P1569, DOI 10.1111/j.1471-4159.2007.04656.x; Ohira T, 2010, J BIOL CHEM, V285, P3451, DOI 10.1074/jbc.M109.044131; Okubo M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153375; Okubo M, 2010, GLIA, V58, P599, DOI 10.1002/glia.20948; Paige C, 2018, NEUROSCIENCE, V385, P133, DOI 10.1016/j.neuroscience.2018.06.012; Park CK, 2011, J NEUROSCI, V31, P15072, DOI 10.1523/JNEUROSCI.2443-11.2011; Peirs C, 2016, SCIENCE, V354, P578, DOI 10.1126/science.aaf8933; Peng JY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12029; Perez-Flores G, 2015, BIOCHEM BIOPH RES CO, V467, P484, DOI 10.1016/j.bbrc.2015.10.025; Peters CM, 2007, BRAIN RES, V1168, P46, DOI 10.1016/j.brainres.2007.06.066; Pevida M, 2014, CELL MOL NEUROBIOL, V34, P143, DOI 10.1007/s10571-013-9995-7; Raghavendra V, 2003, J PHARMACOL EXP THER, V306, P624, DOI 10.1124/jpet.103.052407; Ransohoff RM, 2016, SCIENCE, V353, P777, DOI 10.1126/science.aag2590; Rey C, 2016, BRAIN BEHAV IMMUN, V55, P249, DOI 10.1016/j.bbi.2015.12.013; Robinson CR, 2014, NEUROSCIENCE, V274, P308, DOI 10.1016/j.neuroscience.2014.05.051; Romero-Sandoval EA, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-25; Rothhammer V, 2018, NATURE, V557, P724, DOI 10.1038/s41586-018-0119-x; Salter MW, 2017, NAT MED, V23, P1018, DOI 10.1038/nm.4397; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Sandkuhler J, 2009, PHYSIOL REV, V89, P707, DOI 10.1152/physrev.00025.2008; Sandkuhler J, 2000, PAIN, V88, P113, DOI 10.1016/S0304-3959(00)00424-3; Sato KL, 2014, ANESTH ANALG, V118, P464, DOI 10.1213/ANE.0000000000000047; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2017, FASEB J, V31, P1273, DOI [10.1096/fj.201601222R, 10.1096/fj.201601222r]; Serhan CN, 2015, SEMIN IMMUNOL, V27, P200, DOI 10.1016/j.smim.2015.03.004; Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479; Serhan CN, 2012, FASEB J, V26, P1755, DOI 10.1096/fj.11-201442; Serhan CN, 2009, J EXP MED, V206, P15, DOI 10.1084/jem.20081880; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; Shan S, 2007, PAIN, V129, P64, DOI 10.1016/j.pain.2006.09.035; Shemer A, 2015, TRENDS IMMUNOL, V36, P614, DOI 10.1016/j.it.2015.08.003; Shen Y, 2015, NEUROBIOL DIS, V79, P100, DOI 10.1016/j.nbd.2015.04.012; Shi YQ, 2012, J NEUROSCI, V32, P10833, DOI 10.1523/JNEUROSCI.5628-11.2012; Shindou H, 2017, FASEB J, V31, P2973, DOI 10.1096/fj.201601183R; Sikandar S, 2018, BRAIN, V141, P1028, DOI 10.1093/brain/awy009; Sorge RE, 2011, J NEUROSCI, V31, P15450, DOI 10.1523/JNEUROSCI.3859-11.2011; Staniland AA, 2010, J NEUROCHEM, V114, P1143, DOI 10.1111/j.1471-4159.2010.06837.x; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Sumitani M, 2016, J PAIN PALLIAT CARE, V30, P31, DOI 10.3109/15360288.2014.1003674; Sumracki NM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038525; Sun YG, 2007, NATURE, V448, P700, DOI 10.1038/nature06029; Suter MR, 2007, NEURON GLIA BIOL, V3, P255, DOI 10.1017/S1740925X08000100; Suter MR, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-53; Svensson CI, 2007, J EXP MED, V204, P245, DOI 10.1084/jem.20061826; Svensson CI, 2003, J NEUROCHEM, V86, P1534, DOI 10.1046/j.1471-4159.2003.01969.x; Svensson CI, 2003, NEUROREPORT, V14, P1153, DOI 10.1097/00001756-200306110-00010; Tanga FY, 2005, P NATL ACAD SCI USA, V102, P5856, DOI 10.1073/pnas.0501634102; Tanga FY, 2004, NEUROCHEM INT, V45, P397, DOI 10.1016/j.neuint.2003.06.002; Tashima R, 2016, SCI REP-UK, V6, DOI 10.1038/srep23701; Tatsumi E, 2015, GLIA, V63, P216, DOI 10.1002/glia.22745; Taves S, 2016, BRAIN BEHAV IMMUN, V55, P70, DOI 10.1016/j.bbi.2015.10.006; Thacker MA, 2009, EUR J PAIN, V13, P263, DOI 10.1016/j.ejpain.2008.04.017; Thion MS, 2018, CELL, V172, P500, DOI 10.1016/j.cell.2017.11.042; Todd AJ, 2010, NAT REV NEUROSCI, V11, P823, DOI 10.1038/nrn2947; Tozaki-Saitoh H, 2008, J NEUROSCI, V28, P4949, DOI 10.1523/JNEUROSCI.0323-08.2008; Trang T, 2009, J NEUROSCI, V29, P3518, DOI 10.1523/JNEUROSCI.5714-08.2009; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Tsuda M, 2004, GLIA, V45, P89, DOI 10.1002/glia.10308; Tsuda M, 2005, TRENDS NEUROSCI, V28, P101, DOI 10.1016/j.tins.2004.12.002; Tsuda M, 2008, GLIA, V56, P50, DOI 10.1002/glia.20591; Tsuda M, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-28; Ulmann L, 2008, J NEUROSCI, V28, P11263, DOI 10.1523/JNEUROSCI.2308-08.2008; Vanelderen P, 2015, ANESTHESIOLOGY, V122, P399, DOI 10.1097/ALN.0000000000000508; Villa A, 2018, CELL REP, V23, P3501, DOI 10.1016/j.celrep.2018.05.048; Vit JP, 2006, PAIN, V120, P188, DOI 10.1016/j.pain.2005.10.033; Wang X, 2016, BRIT J PHARMACOL, V173, P856, DOI 10.1111/bph.13394; Watkins LR, 2009, TRENDS PHARMACOL SCI, V30, P581, DOI 10.1016/j.tips.2009.08.002; Wekerle H, 2018, NATURE, V557, P642, DOI 10.1038/d41586-018-05113-0; Wen YR, 2007, ANESTHESIOLOGY, V107, P312, DOI 10.1097/01.anes.0000270759.11086.e7; White FA, 2005, P NATL ACAD SCI USA, V102, P14092, DOI 10.1073/pnas.0503496102; Willemen HLDM, 2010, PAIN, V150, P550, DOI 10.1016/j.pain.2010.06.015; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Xie W, 2009, NEUROSCIENCE, V160, P847, DOI 10.1016/j.neuroscience.2009.03.016; Xu ZZ, 2013, ANN NEUROL, V74, P490, DOI 10.1002/ana.23928; Xu ZZ, 2013, J NEUROIMMUNE PHARM, V8, P37, DOI 10.1007/s11481-012-9394-8; Xu ZZ, 2010, NAT MED, V16, P592, DOI 10.1038/nm.2123; Yan XS, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0222-3; Yan XS, 2013, J BIOL CHEM, V288, P30544, DOI 10.1074/jbc.M113.495465; Yang Y, 2015, J NEUROSCI, V35, P7950, DOI 10.1523/JNEUROSCI.5250-14.2015; Yao Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep22839; Yosipovitch G, 2013, NEW ENGL J MED, V368, P1625, DOI 10.1056/NEJMcp1208814; Younger J, 2009, PAIN MED, V10, P663, DOI 10.1111/j.1526-4637.2009.00613.x; Zhan Y, 2014, NAT NEUROSCI, V17, P400, DOI 10.1038/nn.3641; Zhang J, 2007, J NEUROSCI, V27, P12396, DOI 10.1523/JNEUROSCI.3016-07.2007; Zhang RX, 2008, PAIN, V135, P232, DOI 10.1016/j.pain.2007.05.023; Zhao J, 2006, MOL CELL NEUROSCI, V31, P539, DOI 10.1016/j.mcn.2005.11.008; Zhao P, 2007, J NEUROSCI, V27, P2357, DOI 10.1523/JNEUROSCI.0138-07.2007; Zheng FY, 2011, NEUROSCIENCE, V176, P447, DOI 10.1016/j.neuroscience.2010.12.052; Zhou D, 2010, J NEUROSCI, V30, P8042, DOI 10.1523/JNEUROSCI.5377-09.2010; Zhuang ZY, 2007, BRAIN BEHAV IMMUN, V21, P642, DOI 10.1016/j.bbi.2006.11.003; Zhuang ZY, 2005, PAIN, V114, P149, DOI 10.1016/j.pain.2004.12.022	236	278	289	13	107	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	DEC 19	2018	100	6					1292	1311		10.1016/j.neuron.2018.11.009	http://dx.doi.org/10.1016/j.neuron.2018.11.009			20	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HF1JG	30571942	Green Accepted, Bronze			2023-01-03	WOS:000453922000008
